FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Peng, KY
   Horng, LY
   Sung, HC
   Huang, HC
   Wu, RT
AF Peng, Kang Yung
   Horng, Lin Yea
   Sung, Hui Ching
   Huang, Hui Chuan
   Wu, Rong Tsun
TI Antiosteoporotic Activity of Dioscorea alata L. cv. Phyto through
   Driving Mesenchymal Stem Cells Differentiation for Bone Formation
SO EVIDENCE BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID HORMONE REPLACEMENT THERAPY; TRABECULAR BONE; OSTEOBLAST
   DIFFERENTIATION; MINERAL DENSITY; STROMAL CELLS; IN VIVO; MARROW;
   OSTEOPOROSIS; MECHANISMS; ESTROGEN
AB The aim of this study was to evaluate the effect of an ethanol extract of the rhizomes of Dioscorea alata L. cv. Phyto, Dispo85E, on bone formation and to investigate the mechanisms involved. Our results showed that Dispo85E increased the activity of alkaline phosphatase (ALP) and bone nodule formation in primary bone marrow cultures. In addition, Dispo85E stimulated pluripotent C3H10T1/2 stem cells to differentiate into osteoblasts rather than adipocytes. Our in vivo data indicated that Dispo85E promotes osteoblastogenesis by increasing ALP activity and bone nodule formation in both intact and ovariectomized (OVX) mice. Microcomputed tomography (mu CT) analysis also showed that Dispo85E ameliorates the deterioration of trabecular bone mineral density (tBMD), trabecular bone volume/total volume (BV/TV), and trabecular bone number (Tb.N) in OVX mice. Our results suggested that Dispo85E is a botanical drug with a novel mechanism that drives the lineage specific differentiation of bone marrow stromal cells and is a candidate drug for osteoporosis therapy.
C1 [Peng, Kang Yung; Huang, Hui Chuan; Wu, Rong Tsun] Natl Yang Ming Univ, Sch Pharmaceut Sci, Inst Biopharmaceut Sci, Taipei 112, Taiwan.
   [Horng, Lin Yea; Sung, Hui Ching; Wu, Rong Tsun] Natl Yang Ming Univ, Res Ctr Drug Discovery, Taipei 112, Taiwan.
C3 National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung
   University
RP Wu, RT (通讯作者)，Natl Yang Ming Univ, Sch Pharmaceut Sci, Inst Biopharmaceut Sci, Taipei 112, Taiwan.
EM rtwu@ym.edu.tw
OI Peng, Kang Yung/0000 0002 5773 676X
FU Ministry of Economic, Republic of China (Taiwan)
   [93 EC 17 A 17 I1 0034]; Ministry of Education
FX The authors thank Grant in Aid (93 EC 17 A 17 I1 0034) from the Ministry
   of Economic, Republic of China (Taiwan) and a grant from the Ministry of
   Education, Aim for the Top University Plan. The authors also thank the
   Laboratory Animal Center, Chang Gung University for micro CT technical
   support and image analysis.
CR Aguila HL, 2005, IMMUNOL REV, V208, P7, DOI 10.1111/j.0105 2896.2005.00333.x
   Bäckesjö CM, 2006, J BONE MINER RES, V21, P993, DOI 10.1359/JBMR.060415
   BERESFORD JN, 1992, J CELL SCI, V102, P341
   Berg C, 2003, NAT REV DRUG DISCOV, V2, P257, DOI 10.1038/nrd1068
   Caplan AI, 2006, J CELL BIOCHEM, V98, P1076, DOI 10.1002/jcb.20886
   Clemons M, 2001, NEW ENGL J MED, V344, P276, DOI 10.1056/NEJM200101253440407
   Cui QJ, 2000, CONNECT TISSUE RES, V41, P45
   David V, 2007, ENDOCRINOLOGY, V148, P2553, DOI 10.1210/en.2006 1704
   Graham DY, 1999, ALIMENT PHARM THER, V13, P515
   Hale LV, 2000, CALCIFIED TISSUE INT, V67, P80, DOI 10.1007/s00223001101
   Hidaka S, 2006, EVID BASED COMPL ALT, V3, P339, DOI 10.1093/ecam/nel019
   Hill P A, 1998, Br J Orthod, V25, P101
   HO HY, 2011, EVID BASED COMPL ALT
   Hodsman A, 2006, CAN MED ASSOC J, V175, P48, DOI 10.1503/cmaj.060624
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Koch H, 2005, STEM CELLS DEV, V14, P621, DOI 10.1089/scd.2005.14.621
   Lacey JV, 2002, JAMA J AM MED ASSOC, V288, P334, DOI 10.1001/jama.288.3.334
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   MEUNIER P, 1984, CLIN ORTHOP RELAT R, V80, P147
   Miyawaki J, 2008, TOXICOL SCI, V102, P82, DOI 10.1093/toxsci/kfm296
   MUNDY GR, 1995, BONE, V17, pS71, DOI 10.1016/8756 3282(95)00182 D
   Naveiras O, 2009, NATURE, V460, P259, DOI 10.1038/nature08099
   Nelson HD, 2002, JAMA J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872
   Nuttall ME, 1998, J BONE MINER RES, V13, P371, DOI 10.1359/jbmr.1998.13.3.371
   Nuttall ME, 2000, BONE, V27, P177, DOI 10.1016/S8756 3282(00)00317 3
   Oskowitz AZ, 2008, P NATL ACAD SCI USA, V105, P18372, DOI 10.1073/pnas.0809807105
   OWEN M, 1988, CIBA F SYMP, V136, P42
   PARFITT AM, 1983, J CLIN INVEST, V72, P1396, DOI 10.1172/JCI111096
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Qu Q, 1998, BONE, V22, P201, DOI 10.1016/S8756 3282(97)00276 7
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rosen CJ, 2006, NAT CLIN PRACT RHEUM, V2, P35, DOI 10.1038/ncprheum0070
   Rosen CJ, 2004, BONE, V35, P1046, DOI 10.1016/j.bone.2004.07.008
   Sakai A, 1998, BONE, V23, P443, DOI 10.1016/S8756 3282(98)00121 5
   Stephenson J, 2003, JAMA J AM MED ASSOC, V289, P537, DOI 10.1001/jama.289.5.537
   TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092 8674(79)90317 9
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   WATANABE K, 1990, BIOCHEM BIOPH RES CO, V172, P1035, DOI 10.1016/0006 291X(90)91550 C
   Wimalawansa SJ, 2000, J CLIN DENSITOM, V3, P187, DOI 10.1385/JCD:3:2:187
   WRONSKI TJ, 1986, BONE, V7, P119, DOI 10.1016/8756 3282(86)90683 6
   Xie F, 2005, EVID BASED COMPL ALT, V2, P353, DOI 10.1093/ecam/neh101
   YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681
   Yin J, 2004, PLANTA MED, V70, P220, DOI 10.1055/s 2004 815538
   Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200
   Zhao HY, 2008, OSTEOPOROSIS INT, V19, P221, DOI 10.1007/s00198 007 0440 y
NR 46
TC 11
Z9 13
U1 0
U2 5
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741 427X
EI 1741 4288
J9 EVID BASED COMPL ALT
JI Evid. based Complement Altern. Med.
PY 2011
VL 2011
BP 1
EP 12
DI 10.1155/2011/712892
PG 12
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA 802SE
UT WOS:000293530500001
PM 21760825
OA Green Published, Green Submitted, hybrid
DA 2025 08 17
ER

PT J
AU Abraham, ST
AF Abraham, S. Thomas
TI A role for the Wnt3a/β catenin signaling pathway in the myogenic program
   of C2C12 cells
SO IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY ANIMAL
LA English
DT Article
DE C2C12 cells; Wnt signaling; beta Catenin; Skeletal muscle
   differentiation; Myotubes; IWR 1 endo; XAV939
ID MUSCLE REGENERATION; SKELETAL MUSCLE; DIFFERENTIATION; ACTIVATION;
   INHIBITION; EXPRESSION; TANKYRASES; DISEASE; FUSION; CANCER
AB The Wnt/beta catenin signaling pathway is a key regulator of embryonic development that was first identified in drosophila. More recent work has suggested a role for this pathway in mammalian, myogenesis but this process remains to be more completely elucidated. The current study was designed to investigate the role of the Wnt3a/beta catenin signaling module in C2C12 cell differentiation and myotube formation. Activation of the Wnt/beta catenin pathway in differentiating myoblasts, using lithium chloride supplementation, increased both the number and size of C2C12 myotubes. On the other hand, pharmacological inhibitors of Wnt/beta catenin signaling (IWR 1, XAV939) resulted in significant decreases in myotube length without affecting their numbers. In separate experiments, a neutralizing antibody to Wnt3a also reduced myotube length without affecting the number of myotubes formed during differentiation. Confocal imaging studies revealed that beta catenin was primarily localized in the cytoplasmic region of undifferentiated myoblasts and differentiation resulted in its enhanced expression in myotubes. Additionally, LiCl treatment resulted in enhanced expression of beta catenin in pre differentiating myoblast cultures. These data suggest that Wnt3a/beta catenin signaling plays a critical role in C2C12 cell differentiation and provides an appropriate model for elucidating its functions in more detail.
C1 [Abraham, S. Thomas] Campbell Univ, Dept Pharmaceut Sci, Coll Pharm & Hlth Sci, POB 1090, Buies Creek, NC 27506 USA.
C3 Campbell University
RP Abraham, ST (通讯作者)，Campbell Univ, Dept Pharmaceut Sci, Coll Pharm & Hlth Sci, POB 1090, Buies Creek, NC 27506 USA.
EM abraham@campbell.edu
FU Fayetteville State University Research Initiative for Scientific
   Enhancement Program; Campbell University Department of Pharmaceutical
   Science Research Fund
FX The technical assistance of Chanel Charles and Samantha Robbins is
   gratefully acknowledged, as well as the financial support of the
   following: Fayetteville State University Research Initiative for
   Scientific Enhancement Program and Campbell University Department of
   Pharmaceutical Science Research Fund.
CR Abraham ST, 2006, J CELL BIOCHEM, V97, P621, DOI 10.1002/jcb.20669
   Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657
   Brack AS, 2008, CELL STEM CELL, V2, P50, DOI 10.1016/j.stem.2007.10.006
   Busch AM, 2013, BMC CANCER, V13, DOI 10.1186/1471 2407 13 211
   Chargé SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003
   Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Constantin B, 1996, CELL CALCIUM, V19, P365, DOI 10.1016/S0143 4160(96)90109 8
   Goto S, 1999, ANAL BIOCHEM, V272, P135, DOI 10.1006/abio.1999.4163
   GUILD SB, 1992, BRIT J PHARMACOL, V106, P859, DOI 10.1111/j.1476 5381.1992.tb14425.x
   Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356
   Ishitani T, 2003, MOL CELL BIOL, V23, P131, DOI 10.1128/MCB.23.1.131 139.2003
   Kurth T, 1996, CELL TISSUE RES, V286, P1, DOI 10.1007/s004410050669
   Martin RM, 2005, CYTOM PART A, V67A, P45, DOI 10.1002/cyto.a.20172
   Nalesso G, 2011, J CELL BIOL, V193, P551, DOI 10.1083/jcb.201011051
   Narwal M, 2012, J MED CHEM, V55, P1360, DOI 10.1021/jm201510p
   Rao TP, 2010, CIRC RES, V106, P1798, DOI 10.1161/CIRCRESAHA.110.219840
   Rochat A, 2004, MOL BIOL CELL, V15, P4544, DOI 10.1091/mbc.E03 11 0816
   Sanders J, 1996, J CELL SCI, V109, P1113
   Schulte G, 2010, PHARMACOL REV, V62, P632, DOI 10.1124/pr.110.002931
   Scicchitano BM, 2002, MOL ENDOCRINOL, V16, P1407, DOI 10.1210/me.16.6.1407
   Takata H, 2007, DEV DYNAM, V236, P2800, DOI 10.1002/dvdy.21327
   Tanaka Shingo, 2011, J Mol Signal, V6, P12, DOI 10.1186/1750 2187 6 12
   von Maltzahn J, 2012, TRENDS CELL BIOL, V22, P602, DOI 10.1016/j.tcb.2012.07.008
   Yang YJ, 2011, MOL BIOL REP, V38, P2043, DOI 10.1007/s11033 010 0328 3
NR 25
TC 13
Z9 18
U1 3
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1071 2690
EI 1543 706X
J9 IN VITRO CELL DEV AN
JI In Vitro Cell. Dev. Biol. Anim.
PD OCT
PY 2016
VL 52
IS 9
BP 935
EP 941
DI 10.1007/s11626 016 0058 5
PG 7
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA EA5KE
UT WOS:000386658200005
PM 27251162
DA 2025 08 17
ER

PT J
AU Sen, S
   Lux, CJ
   Erber, R
AF Sen, Sinan
   Lux, Christopher J.
   Erber, Ralf
TI A Potential Role of Semaphorin 3A during Orthodontic Tooth Movement
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE tooth movement; mechanotransduction; neuronal guidance molecules;
   Semaphorins; bone remodeling
ID OSTEOBLAST DIFFERENTIATION; PERIODONTAL LIGAMENT; GENE EXPRESSION;
   OSTERIX; OSTEOGENESIS; COMPRESSION; FIBROBLASTS; HOMEOSTASIS; RECEPTORS;
   PROTEIN
AB Background: Induced tooth movement during orthodontic therapy requires mechano induced bone remodeling. Besides various cytokines and growth factors, neuronal guidance molecules gained attention for their roles in bone homeostasis and thus, potential roles during tooth movement. Several neuronal guidance molecules have been implicated in the regulation of bone remodeling. Amongst them, Semaphorin 3A is particular interesting as it concurrently induces osteoblast differentiation and disturbs osteoclast differentiation. Methods: Mechano regulation of Sema3A and its receptors PlexinA1 and Neuropilin (RT qPCR, WB) was evaluated by applying compressive and tension forces to primary human periodontal fibroblasts (hPDLF) and alveolar bone osteoblasts (hOB). The association of the transcription factor Osterix (SP7) and SEMA3A was studied by RT qPCR. Mechanisms involved in SEMA3A mediated osteoblast differentiation were assessed by Rac1GTPase pull downs, beta catenin expression analyses (RT qPCR) and nuclear translocation assays (IF). Osteogenic markers were analyzed by RT qPCR. Results: SEMA3A, PLXNA1 and NRP1 were differentially regulated by tension or compressive forces in hPDLF. Osterix (SP7) displayed the same pattern of regulation. Recombinant Sema3A induced the activation of Rac1GTPase, the nuclear translocation of beta catenin and the expression of osteogenic marker genes. Conclusion: Sema3A, its receptors and Osterix are regulated by mechanical forces in hPDLF. SEMA3A upregulation was associated with Osterix (SP7) modulation. Sema3A enhanced osteogenic marker gene expression in hOB might be dependent on a pathway involving Rac1GTPase and beta catenin. Thus, Semaphorin 3A might contribute to bone remodeling during induced tooth movement.
C1 [Sen, Sinan; Lux, Christopher J.; Erber, Ralf] Heidelberg Univ, Dept Orthodont & Dentofacial Orthopaed, Neuenheimer Feld 400, D 69120 Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg
RP Sen, S (通讯作者)，Heidelberg Univ, Dept Orthodont & Dentofacial Orthopaed, Neuenheimer Feld 400, D 69120 Heidelberg, Germany.
EM sinan.sen@med.uni heidelberg.de; christopher.lux@med.uni heidelberg.de;
   ralf.erber@med.uni heidelberg.de
RI ; Sen, Sinan/V 7915 2019
OI Lux, Christopher J./0000 0002 6995 5572; Sen, Sinan/0000 0001 5907 5398;
   
FU Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) [SE
   2692/1 1]
FX This research was funded by Deutsche Forschungsgemeinschaft (DFG, German
   Research Foundation) SE 2692/1 1 to Sinan Sen.
CR Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0
   Bellini Pereira SA, 2021, EUR J ORTHODONT, V43, P432, DOI 10.1093/ejo/cjaa054
   Bock JJ, 2011, J OROFAC ORTHOP, V72, P421, DOI 10.1007/s00056 011 0047 y
   Carmeliet P, 2003, NAT REV GENET, V4, P710, DOI 10.1038/nrg1158
   Diercke K, 2012, EUR J CELL BIOL, V91, P402, DOI 10.1016/j.ejcb.2011.12.005
   Diercke K, 2012, J OROFAC ORTHOP, V73, P397, DOI 10.1007/s00056 012 0095 y
   Diercke K, 2011, J BIOL CHEM, V286, P37651, DOI 10.1074/jbc.M110.166900
   Dirckx N, 2013, BIRTH DEFECTS RES C, V99, P170, DOI 10.1002/bdrc.21047
   Ehrlich PJ, 2002, OSTEOPOROSIS INT, V13, P688, DOI 10.1007/s001980200095
   Epstein JA, 2015, CELL METAB, V21, P163, DOI 10.1016/j.cmet.2014.12.015
   Fu X, 2017, J DENT RES, V96, P1451, DOI 10.1177/0022034517719749
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   HASEGAWA S, 1985, CALCIFIED TISSUE INT, V37, P431, DOI 10.1007/BF02553714
   Hassan B, 2017, HELIYON, V3, DOI 10.1016/j.heliyon.2017.e00430
   Hayashi M, 2019, CELL METAB, V29, P627, DOI 10.1016/j.cmet.2018.12.021
   Hayashi M, 2012, NATURE, V485, P69, DOI 10.1038/nature11000
   Irie N, 2009, J BIOL CHEM, V284, P14637, DOI 10.1074/jbc.M807598200
   KEYNES R, 1995, CELL, V83, P161, DOI 10.1016/0092 8674(95)90157 4
   Krishnan V, 2009, J DENT RES, V88, P597, DOI 10.1177/0022034509338914
   Kuchler Bopp S, 2018, J TISSUE ENG REGEN M, V12, pE2151, DOI 10.1002/term.2648
   Kumanogoh A, 2013, NAT REV IMMUNOL, V13, P802, DOI 10.1038/nri3545
   Li ZX, 2017, FRONT CELL NEUROSCI, V11, DOI [10.3389/fncel.2017.00040, 10.3389/fncel.2017.00042]
   Lin Y, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/8724503
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lotz EM, 2020, BONE, V134, DOI 10.1016/j.bone.2020.115260
   Luukko K, 2016, CELL ADHES MIGR, V10, P618, DOI 10.1080/19336918.2016.1216746
   Lux CJ, 2009, EUR J ORTHODONT, V31, P294, DOI 10.1093/ejo/cjn116
   Mediero A, 2015, J BONE MINER RES, V30, P837, DOI 10.1002/jbmr.2421
   Meikle MC, 2006, EUR J ORTHODONT, V28, P221, DOI 10.1093/ejo/cj1001
   Mundy GR, 2006, CELL, V126, P441, DOI 10.1016/j.cell.2006.07.015
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Padget RL, 2019, MECH DEVELOP, V156, P8, DOI 10.1016/j.mod.2019.02.002
   Park SY, 2013, GENE, V518, P368, DOI 10.1016/j.gene.2012.12.102
   Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806
   Rasband W.S., 1997, ImageJ
   Rodan GA, 1997, BONE, V20, P1, DOI 10.1016/S8756 3282(96)00318 3
   Sen S, 2015, J DENT RES, V94, P464, DOI 10.1177/0022034514567197
   Song YH, 2017, CELL REPROGRAM, V19, P324, DOI 10.1089/cell.2017.0020
   Spencer AY, 2009, J PERIODONTOL, V80, P1665, DOI 10.1902/jop.2009.090212
   Sun HL, 2009, CELLS TISSUES ORGANS, V190, P69, DOI 10.1159/000178020
   Takimoto A, 2015, DEVELOPMENT, V142, P787, DOI 10.1242/dev.116228
   Tamagnone L, 2004, EMBO REP, V5, P356, DOI 10.1038/sj.embor.7400114
   Tran TS, 2007, ANNU REV CELL DEV BI, V23, P263, DOI 10.1146/annurev.cellbio.22.010605.093554
   Verlinden L, 2016, MOL CELL ENDOCRINOL, V432, P76, DOI 10.1016/j.mce.2015.09.009
   Wishney M, 2017, AUST DENT J, V62, P86, DOI 10.1111/adj.12486
   Zhang M, 2017, IN VIVO, V31, P87, DOI 10.21873/invivo.11029
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
NR 47
TC 15
Z9 16
U1 0
U2 6
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD AUG
PY 2021
VL 22
IS 15
AR 8297
DI 10.3390/ijms22158297
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA TV6QY
UT WOS:000681846900001
PM 34361063
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Tian, S
   Li, YL
   Wang, J
   Dong, RC
   Wei, J
   Ma, Y
   Liu, YQ
AF Tian, Shuo
   Li, Yi Lin
   Wang, Jie
   Dong, Ren Chao
   Wei, Jun
   Ma, Yu
   Liu, Yan Qiu
TI Chinese Ecliptae herba (Eclipta prostrata (L.) L.) extract
   and its component wedelolactone enhances osteoblastogenesis of bone
   marrow mesenchymal stem cells via targeting METTL3 mediated m6A RNA
   methylation
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Ecliptae herba; Osteoblastogenesis; BMSC; N6 methyladenosine; METTL3
ID BREAST CANCER CELLS; PATHWAY; GROWTH
AB Ethnopharmacological relevance: Chinese Ecliptae herba (Eclipta prostrata (L.) L.) is an ethnomedicinal herb, which is used mainly to nourish kidney and thus strengthen bones according to traditional Chinese medicine theory. Pharmacological studies have supported the ethnomedicine use, showing that Ecliptae herba extract has an anti osteoporotic effect in vivo and promoted osteoblast proliferation and activity in vitro. However, the molecular mechanism of Ecliptae herba on osteoblast differentiation from bone marrow mesenchymal stem cells (BMSC), the progenitors of osteoblasts, is still unclear.Aim of the study: N6 methyladenosine (m6A) mRNA epigenetic modification may play a key role in promoting osteoblastic differentiation, and thus treating osteoporosis. This study sought to assess the mechanism through which Eclipate herba and its component wedelolactone influence m6A modification during the process of osteoblastogenesis from BMSC.Material and methods: The alkaline phosphatase (ALP) and Alizarin red S (ARS) staining were applied to deter mine osteoblastogenesis from BMSC. Western blot and quantitative real time PCR were performed. RNA sequencing analysis was used to determine the characteristics of m6A methylation. Stable knocking down of METTL3 using lentiviral based shRNA was performed. Results: Upon 9 d treatment of BMSC with ethyl acetate extract of Ecliptae herba (MHL), ALP activity and ossification level increased in comparison with osteogenic medium (OS) treated control. The expression of methyltransferase METTL3 and METTL14 was significantly increased, but WTAP expression had no change in response to MHL treatment. Knocking down of METTL3 resulted in a decrease in MHL induced ALP activity, ossification level as well as mRNA expression of Osterix and Osteocalcin, two bone formation related markers. The level of m6A increased when BMSC was treated with MHL for 9 d. RNA sequencing analysis indicated that MHL treatment altered mRNA m6A modification of genes associated with osteoblastogenesis. By kyoto encyclopedia of genes and genomes (KEGG) pathway analysis, HIF 1 alpha, PI3K/Akt, and Hippo signaling pathways were enriched and associated with m6A modification. The expression of m6A modified genes including HIF 1 alpha, VEGF A, and RASSF1, was upregulated by MHL, but the upregulation was reversed after METTL3 knockdown. Additionally, the enhanced expression of METTL3 was also observed after treatment with wedelolactone, a component from MHL.Conclusions: These results suggested a previously uncharacterized mechanism of MHL and wedelolactone on osteoblastogenesis, by which METTL3 mediated m6A methylation is involved and thus contributes to the enhancement of osteoblastogenesis.
C1 [Tian, Shuo; Li, Yi Lin; Wang, Jie; Dong, Ren Chao; Wei, Jun; Ma, Yu; Liu, Yan Qiu] Shandong Univ Tradit Chinese Med, Jinan, Peoples R China.
   [Liu, Yan Qiu] 4655 Univ Rd,Univ Sci Pk, Jinan, Shandong, Peoples R China.
C3 Shandong University of Traditional Chinese Medicine
RP Liu, YQ (通讯作者)，4655 Univ Rd,Univ Sci Pk, Jinan, Shandong, Peoples R China.
EM 838874432@qq.com; one79787776@163.com; wang062323@163.com;
   437436444@qq.com; 15098877105@163.com; m15134801606_x@163.com;
   60020218@sdutcm.edu.cn
OI Liu, Yanqiu/0000 0002 9248 3358; liu, Yan Qiu/0000 0002 1905 7168
FU National Natural Science Foundation of China [82074134]
FX Funding This work was supported by a grant from National Natural Science
   Foundation of China (82074134) .
CR Bertero A, 2018, NATURE, V555, P256, DOI 10.1038/nature25784
   Boriack Sjodin PA, 2018, NAT REV DRUG DISCOV, V17, P435, DOI 10.1038/nrd.2018.71
   Chen LS, 2022, ACTA PHARMACOL SIN, V43, P1311, DOI 10.1038/s41401 021 00756 8
   Chen XJ, 2020, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00911
   Cheng C, 2020, ANNU REV MED, V71, P277, DOI 10.1146/annurev med 052218 020620
   Deng X, 2018, INT IMMUNOPHARMACOL, V60, P41, DOI 10.1016/j.intimp.2018.04.037
   Dominissini D, 2013, NAT PROTOC, V8, P176, DOI 10.1038/nprot.2012.148
   Duan Y, 2023, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.1063899
   Feng L, 2019, J ETHNOPHARMACOL, V245, DOI 10.1016/j.jep.2019.112109
   Gao F, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02508 0
   Geula S, 2015, SCIENCE, V347, P1002, DOI 10.1126/science.1261417
   He MY, 2022, STEM CELL TRANSL MED, V11, P987, DOI 10.1093/stcltm/szac049
   Hu S.L., 1997, ACTA CHIN MED PHARM, V19997, P28
   Hutchings G., 2020, J CLIN MED
   Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161
   Khan AV, 2008, INDIAN J TRADIT KNOW, V7, P316
   Kim DI, 2008, NUTR RES, V28, P550, DOI 10.1016/j.nutres.2008.05.003
   Konar M, 2020, INT J BIOL MACROMOL, V150, P727, DOI 10.1016/j.ijbiomac.2020.02.113
   Krebsbach PH, 1999, CRIT REV ORAL BIOL M, V10, P165, DOI 10.1177/10454411990100020401
   Lee MK, 2009, PHYTOTHER RES, V23, P129, DOI 10.1002/ptr.2560
   Lee YJ, 2012, EUR J MED CHEM, V56, P361, DOI 10.1016/j.ejmech.2012.07.041
   Li B, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/2869572
   Li D, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051660
   Li Y, 2020, EUR J NUCL MED MOL I, V47, P768, DOI 10.1007/s00259 019 04535 w
   Lin J, 2017, BIOSCI TRENDS, V11, P496, DOI 10.5582/bst.2017.01216
   Lin SB, 2016, MOL CELL, V62, P335, DOI 10.1016/j.molcel.2016.03.021
   Liu YQ, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00375
   Liu YQ, 2014, J ETHNOPHARMACOL, V157, P206, DOI 10.1016/j.jep.2014.09.033
   Livneh I, 2020, NAT REV NEUROSCI, V21, P36, DOI 10.1038/s41583 019 0244 z
   Lukert B.P., 2020, J CLIN ENDOCR METAB, V105
   Meng ZP, 2016, GENE DEV, V30, P1, DOI 10.1101/gad.274027.115
   Mo XB, 2018, OSTEOPOROSIS INT, V29, P2029, DOI 10.1007/s00198 018 4573 y
   Nehybova T, 2015, J STEROID BIOCHEM, V152, P76, DOI 10.1016/j.jsbmb.2015.04.019
   Papaspyropoulos A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02786 5
   Peng J, 2022, CELL TISSUE RES, V388, P301, DOI 10.1007/s00441 022 03588 y
   Ping XL, 2014, CELL RES, V24, P177, DOI 10.1038/cr.2014.3
   Qiao YC, 2023, FRONT GENET, V13, DOI 10.3389/fgene.2022.1072948
   Qu JW, 2022, J HEMATOL ONCOL, V15, DOI 10.1186/s13045 022 01224 4
   Rauch A, 2019, NAT GENET, V51, P716, DOI 10.1038/s41588 019 0359 1
   Regan JN, 2014, P NATL ACAD SCI USA, V111, P8673, DOI 10.1073/pnas.1324290111
   Sorci M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0843 z
   Sun W, 2014, J HUAZHONG U SCI MED, V34, P114, DOI 10.1007/s11596 014 1241 0
   Sun ZY, 2021, AGING CELL, V20, DOI 10.1111/acel.13298
   Tian C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030551
   Timalsina D, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11111738
   Wagegg M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046483
   Wang C., 2022, BONE, V168
   Wang J, 2021, AGING US, V13, P21134, DOI 10.18632/aging.203377
   Wang X, 2016, NATURE, V534, P575, DOI 10.1038/nature18298
   Wu Y., 2018, NAT COMMUN
   Yan G, 2020, MOL THER NUCL ACIDS, V19, P421, DOI 10.1016/j.omtn.2019.12.001
   Yao YX, 2019, FASEB J, V33, P7529, DOI 10.1096/fj.201802644R
   Zaccara S, 2019, NAT REV MOL CELL BIO, V20, P608, DOI 10.1038/s41580 019 0168 5
   Zhang JF, 2010, MOL CELL ENDOCRINOL, V314, P70, DOI 10.1016/j.mce.2009.08.012
   Zhang ZG, 2013, MENOPAUSE, V20, P232, DOI 10.1097/gme.0b013e318265e7dd
NR 55
TC 24
Z9 25
U1 2
U2 13
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD AUG 10
PY 2023
VL 312
AR 116433
DI 10.1016/j.jep.2023.116433
EA APR 2023
PG 11
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA F6WN5
UT WOS:000983729200001
PM 37004744
DA 2025 08 17
ER

PT J
AU Mizuha, Y
   Yamamoto, H
   Sato, T
   Tsuji, M
   Masuda, M
   Uchida, M
   Sakai, K
   Taketani, Y
   Yasutomo, K
   Sasaki, H
   Takeda, E
AF Mizuha, Yoko
   Yamamoto, Hironori
   Sato, Tadatoshi
   Tsuji, Mitsuyoshi
   Masuda, Masashi
   Uchida, Masayuki
   Sakai, Kentaro
   Taketani, Yutaka
   Yasutomo, Koji
   Sasaki, Hajime
   Takeda, Eiji
TI Water extract of Cordyceps sinensis (WECS) inhibits the
   RANKL induced osteoclast differentiation
SO BIOFACTORS
LA English
DT Article
DE water extract of Cordyceps sinensis (WECS); osteoclast; differentiation;
   receptor activator of nuclear factor kappa B (NF kappa B) ligand
   (RANKL); nuclear factor kappa B (NF kappa B); inhibitor of the kappa B
   (I kappa B)
ID NF KAPPA B; HEPATIC ENERGY METABOLISM; MYCELIAL EXTRACT; ACTIVATION;
   TRANCE; FAMILY
AB It has been reported that Cordyceps sinensis, a traditional Chinese medicine, has various pharmacological effects. The aim of this study was to clarify the effect of water extract of Cordyceps sinensis (WECS) on osteoclast differentiation in vitro. In mouse bone marrow cells and monocyte/macrophage cell line RAW264.7, WECS dose dependently inhibited the receptor activator of nuclear factor kappaB(NF kappa B) ligand (RANKL) induced osteoclast differentiation by tartrate resistant acid phosphatase (TRAP) staining. In fact, cytotoxic effect was not observed in the RAW264.7 cells treated with WECS. Moreover, the mRNA expression of osteoclast related genes (calcitonin receptor, cathepsin K, matrix metalloprotease 9 and nuclear factor of activated T cells c1) was also inhibited by WECS. Investigation of inhibitory mechanism by using electrophoretic mobility shift assay (EMSA) and Western blot analysis revealed that WECS inhibited the activation of NF kappa B through the prevention of I kappa B alpha phosphorylation. In conclusion, the present results demonstrate for the first time that WECS is a potent inhibitor of the RANKL induced osteoclast differentiation through a mechanism involving the NF kappa B pathway.
C1 [Mizuha, Yoko; Yamamoto, Hironori; Sato, Tadatoshi; Tsuji, Mitsuyoshi; Masuda, Masashi; Taketani, Yutaka; Takeda, Eiji] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Clin Nutr, Tokushima 7708503, Japan.
   [Uchida, Masayuki; Sasaki, Hajime] Meiji Milk Prod Co, Nutr Sci Inst, Dept Nutr Res, Kanagawa, Japan.
   [Sakai, Kentaro] Hiroshima Univ, Fac Human Life Sci, Dept Nutr & Hlth Promot, Hiroshima, Japan.
   [Yasutomo, Koji] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Immunol & Parasitol, Tokushima 7708503, Japan.
C3 Tokushima University; Meiji Holdings Co., Ltd.; Hiroshima University;
   Tokushima University
RP Yamamoto, H (通讯作者)，Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Clin Nutr, 3 18 15 Kuramoto Cho, Tokushima 7708503, Japan.
EM yamamoto@nutr.med.tokushima u.ac.jp
RI Yamamoto, Hironori/E 3902 2015
OI Masuda, Masashi/0000 0003 3762 2770
CR Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bharti AC, 2004, J IMMUNOL, V172, P5940, DOI 10.4049/jimmunol.172.10.5940
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Buenz EJ, 2005, J ETHNOPHARMACOL, V96, P19, DOI 10.1016/j.jep.2004.09.029
   Chiba K, 2005, PHARMACOL THERAPEUT, V108, P308, DOI 10.1016/j.pharmthera.2005.05.002
   Colonna M, 2003, NAT REV IMMUNOL, V3, P445, DOI 10.1038/nri1106
   FUJITA T, 1994, J ANTIBIOT, V47, P208, DOI 10.7164/antibiotics.47.208
   Kim HG, 2006, EUR J PHARMACOL, V545, P192, DOI 10.1016/j.ejphar.2006.06.047
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Kuo CF, 2005, J MED MICROBIOL, V54, P795, DOI 10.1099/jmm.0.45704 0
   Manabe N, 1996, JPN J PHARMACOL, V70, P85, DOI 10.1254/jjp.70.85
   Manabe N, 2000, BRIT J NUTR, V83, P197, DOI 10.1017/S0007114500000258
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Sato T, 2006, J BONE MINER METAB, V24, P291, DOI 10.1007/s00774 006 0686 z
   Shevde NK, 2000, P NATL ACAD SCI USA, V97, P7829, DOI 10.1073/pnas.130200197
   Shevde NK, 2002, P NATL ACAD SCI USA, V99, P13487, DOI 10.1073/pnas.202471299
   Sun DX, 2003, J BONE MINER RES, V18, P1206, DOI 10.1359/jbmr.2003.18.7.1206
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   TSUNOO A, 1995, SCIENCE AND CULTIVATION OF EDIBLE FUNGI, VOLS 1 AND 2, P425
   Umezawa K, 2002, MOL CELLS, V14, P163
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wattel A, 2004, J CELL BIOCHEM, V92, P285, DOI 10.1002/jcb.20071
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097 2765(00)80232 4
   Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355
   Xing LP, 2002, J BONE MINER RES, V17, P1200, DOI 10.1359/jbmr.2002.17.7.1200
   Yamamoto H, 2005, BBA GENE STRUCT EXPR, V1732, P43, DOI 10.1016/j.bbaexp.2005.11.003
NR 27
TC 9
Z9 9
U1 0
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0951 6433
EI 1872 8081
J9 BIOFACTORS
JI Biofactors
PY 2007
VL 30
IS 2
BP 105
EP 116
DI 10.1002/biof.5520300204
PG 12
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 291MB
UT WOS:000255200400004
PM 18356582
DA 2025 08 17
ER

PT J
AU Zhou, K
   Hu, CH
   Zhou, ZG
   Huang, LF
   Liu, WL
   Sun, HY
AF Zhou, Kun
   Hu, Caihong
   Zhou, Zhigang
   Huang, Lifang
   Liu, Wenli
   Sun, Hanying
TI Fetal liver stromal cells promote hematopoietic cell expansion
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Sonic hedgehog; Wilt; Fetal liver; Aorta gonad mesonephros; Bone marrow;
   Stromal cells; Expansion
ID EMBRYONIC STEM CELLS; CYCLIN D1; EXPRESSION; DIFFERENTIATION;
   PROLIFERATION; TARGET; REGION; GENE; MYC
AB Future application of hematopoietic stem and progenitor cells (HSPCs) in clinical therapies largely depends on their Successful expansion in vitro. Fetal liver (FL) is a unique hematopoietic organ in which hematopoietic cells markedly expand in number, but the mechanisms involved remain unclear. Stromal cells (StroCs) have been suggested to provide a suitable cellular environment for in vitro expansion of HSPCs. In this study, murine StroCs derived from FL at E14.5, with a high level of Sonic hedgehog (Shh) and Writ expression, were found to have an increased ability to support the proliferation of HSPCs. This effect was inhibited by blocking Shh signaling. Supplementation with soluble Shh N promoted the proliferation of hematopoietic cells by activating Writ signaling. Our findings suggest that FL derived StroCs Support proliferation of HSPCs via Shh inducing an autocrine Wnt signaling loop. The use of FL derived StroCs and regulation of the Shh pathway might further enhance HPSC expansion. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Sun, Hanying] Huazhong Univ Sci & Technol, Dept Hematol, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China.
   [Zhou, Zhigang] Shanghai Jiao Tong Univ, Shanghai People Hosp 1, Shanghai 201620, Peoples R China.
C3 Huazhong University of Science & Technology; Shanghai Jiao Tong
   University
RP Sun, HY (通讯作者)，Huazhong Univ Sci & Technol, Dept Hematol, Tongji Hosp, Tongji Med Coll, 1095 Jie Fang Ave, Wuhan 430030, Hubei, Peoples R China.
EM shanhum@163.com
RI Zhou, Zhigang/AGW 2951 2022; liu, wenli/JRW 0517 2023; zhou,
   kun/KRP 1631 2024
FU National Natural Science Foundation [30570773]; Ministry of Education of
   China [20060487061, 200804870008]
FX We sincerely thank Prof. Axel R. Zander and Prof. Boris Fehse at
   University Medical Center Hamurg Eppendorf in Germany for critical
   review of the Manuscript. This work was supported by National Natural
   Science Foundation (No. 30570773) and Doctoral Fund of Ministry of
   Education of China (20060487061, 200804870008).
CR Baron MH, 2001, DIFFERENTIATION, V68, P175, DOI 10.1046/j.1432 0436.2001.680405.x
   Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282
   Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286
   Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302
   Duncan AW, 2005, NAT IMMUNOL, V6, P314, DOI 10.1038/ni1164
   Dzierzak E, 2008, NAT IMMUNOL, V9, P129, DOI 10.1038/ni1560
   Ema H, 2000, BLOOD, V95, P2284, DOI 10.1182/blood.V95.7.2284.007k14_2284_2288
   FRANCIS SA, 2002, INT J PHARM PRACT, V10, P1
   Harvey K, 2004, STEM CELLS, V22, P253, DOI 10.1634/stemcells.22 3 253
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   Kadereit S, 2002, STEM CELLS, V20, P573, DOI 10.1634/stemcells.20 6 573
   Keller G, 1999, EXP HEMATOL, V27, P777, DOI 10.1016/S0301 472X(99)00024 7
   Kumaravelu P, 2002, DEVELOPMENT, V129, P4891
   Lako M, 2001, MECH DEVELOP, V103, P49, DOI 10.1016/S0925 4773(01)00331 8
   Ledran MH, 2008, CELL STEM CELL, V3, P85, DOI 10.1016/j.stem.2008.06.001
   Martin MA, 2005, STEM CELLS DEV, V14, P493, DOI 10.1089/scd.2005.14.493
   Medvinsky A, 1996, CELL, V86, P897, DOI 10.1016/S0092 8674(00)80165 8
   MORRISON SJ, 1995, P NATL ACAD SCI USA, V92, P10302, DOI 10.1073/pnas.92.22.10302
   Murphy MJ, 2005, TRENDS CELL BIOL, V15, P128, DOI 10.1016/j.tcb.2005.01.008
   Nagao K, 2008, BIOCHEM BIOPH RES CO, V377, P205, DOI 10.1016/j.bbrc.2008.09.123
   Nikolova T, 2007, DIFFERENTIATION, V75, P100, DOI 10.1111/j.1432 0436.2006.00119.x
   Rebel VI, 1996, BLOOD, V87, P3500, DOI 10.1182/blood.V87.8.3500.bloodjournal8783500
   Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522
   Staal FJT, 2005, NAT REV IMMUNOL, V5, P21, DOI 10.1038/nri1529
   Tavian M, 1999, DEVELOPMENT, V126, P793
   Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884
   Trowbridge JJ, 2006, P NATL ACAD SCI USA, V103, P14134, DOI 10.1073/pnas.0604568103
   Whetton AD, 1998, CURR OPIN CELL BIOL, V10, P721, DOI 10.1016/S0955 0674(98)80113 0
   Wicking C, 1999, ONCOGENE, V18, P7844, DOI 10.1038/sj.onc.1203282
   Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611
   Wilson A, 2006, NAT REV IMMUNOL, V6, P93, DOI 10.1038/nri1779
NR 33
TC 4
Z9 8
U1 0
U2 8
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD SEP 25
PY 2009
VL 387
IS 3
BP 596
EP 601
DI 10.1016/j.bbrc.2009.07.071
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 485QE
UT WOS:000269137800034
PM 19619512
DA 2025 08 17
ER

PT J
AU Morse, L
   Teng, YD
   Pham, L
   Newton, K
   Yu, D
   Liao, WL
   Kohler, T
   Müller, R
   Graves, D
   Stashenko, P
   Battaglino, R
AF Morse, L.
   Teng, Y. D.
   Pham, L.
   Newton, K.
   Yu, D.
   Liao, W.  L.
   Kohler, T.
   Mueller, R.
   Graves, D.
   Stashenko, P.
   Battaglino, R.
TI Spinal cord injury causes rapid osteoclastic resorption and growth plate
   abnormalities in growing rats (SCI induced bone loss in growing rats)
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE bone; osteoclast; osteoporosis; rehabilitation medicine; spinal cord
   injury
ID ACUTE HEMATOGENOUS OSTEOMYELITIS; EXTERNAL URETHRAL SPHINCTER; CHRONIC
   CENTRAL PAIN; BLADDER DETRUSOR; MINERAL DENSITY; SYMPATHECTOMY;
   RECOVERY; CELLS; MODEL; COORDINATION
AB Spinal cord injury causes severe bone loss. We report osteoclast resorption with severe trabecular and cortical bone loss, decreased bone mineral apposition, and growth plate abnormalities in a rodent model of contusion spinal cord injury. These findings will help elucidate the mechanisms of osteoporosis following neurological trauma.
   Introduction Limited understanding of the mechanism(s) that underlie spinal cord injury (SCI) induced bone loss has led to few treatment options. As SCI induced osteoporosis carries significant morbidity and can worsen already profound disability, there is an urgency to advance knowledge regarding this pathophysiology.
   Methods A clinically relevant contusion model of experimental spinal cord injury was used to generate severe lower thoracic SCI by weight drop (10 g x 50 mm) in adolescent male Sprague Dawley rats. Body weight and gender matched naive (no surgery) rats served as controls. Bone microarchitecture was determined by micro computed tomographic imaging. Mature osteoclasts were identified by TRAP staining and bone apposition rate was determined by dynamic histomorphometry.
   Results At 10 days post injury we detected a marked 48% decrease in trabecular bone and a 35% decrease in cortical bone at the distal femoral metaphysis by micro CT. A 330% increase in the number of mature osteoclasts was detected at the growth plate in the injured animals that corresponded with cellular disorganization at the chondro osseous junction. Appositional growth studies demonstrated decreased new bone formation with a mineralization defect indicative of osteoblast dysfunction.
   Conclusions Contusion SCI results in a rapid bone loss that is the result of increased bone resorption and decreased bone formation.
C1 [Morse, L.; Teng, Y. D.; Liao, W.  L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA 02115 USA.
   [Morse, L.; Teng, Y. D.; Liao, W.  L.] Spaulding Rehabil Hosp, Boston, MA 02115 USA.
   [Teng, Y. D.; Newton, K.; Yu, D.] Harvard Univ, Sch Med, Dept Neurosurg, Boston, MA 02115 USA.
   [Teng, Y. D.; Newton, K.; Yu, D.] Brigham & Womens Hosp, Childrens Hosp, Boston, MA 02115 USA.
   [Teng, Y. D.; Newton, K.; Yu, D.; Liao, W.  L.] VA Boston Healthcare Syst, Div Spinal Cord Injury Res, Boston, MA USA.
   [Kohler, T.; Mueller, R.] ETH, Inst Biomech, Zurich, Switzerland.
   [Graves, D.] Boston Univ, Sch Dent Med, Boston, MA 02215 USA.
   [Pham, L.; Stashenko, P.; Battaglino, R.] Forsyth Inst, Dept Cytokine Biol, Boston, MA USA.
C3 Harvard University; Harvard Medical School; Harvard University; Harvard
   Medical School; Harvard University Medical Affiliates; Spaulding
   Rehabilitation Hospital; Harvard University; Harvard Medical School;
   Harvard University; Harvard University Medical Affiliates; Boston
   Children's Hospital; Brigham & Women's Hospital; Harvard University;
   Harvard University Medical Affiliates; US Department of Veterans
   Affairs; Veterans Health Administration (VHA); VA Boston Healthcare
   System; Swiss Federal Institutes of Technology Domain; ETH Zurich;
   Boston University; Harvard University; Harvard University Medical
   Affiliates; Forsyth Institute
RP Morse, L (通讯作者)，Harvard Univ, Sch Med, Dept Phys Med & Rehabil, 140 Fenway, Boston, MA 02115 USA.
EM lmorse4@partners.org
RI Muller, Ralph/A 1198 2008; Morse, Leslie/AAU 5608 2020; battaglino,
   ricardo/D 2892 2015; Müller, Ralph/A 1198 2008
OI Muller, Ralph/0000 0002 5811 7725; Yu, Dou/0000 0002 6636 9164; 
FU NIAMS NIH HHS [L30 AR063489] Funding Source: Medline; NICHD NIH HHS [K12
   HD001097 08, K12 HD001097] Funding Source: Medline; NIDCR NIH HHS
   [DE007378 18, R01 DE007378] Funding Source: Medline; NINDS NIH HHS [R21
   NS053935, R21NS53935] Funding Source: Medline
CR Adam C, 2000, EXP PHYSIOL, V85, P61, DOI 10.1111/j.1469 445X.2000.01930.x
   Aluisio FV, 1996, CLIN ORTHOP RELAT R, P239
   ANDERSEN EM, 1995, J AM GERIATR SOC, V43, P1030, DOI 10.1111/j.1532 5415.1995.tb05569.x
   Battaglino R, 2007, J CELL BIOCHEM, V100, P1387, DOI 10.1002/jcb.21131
   Battaglino R, 2004, J BONE MINER RES, V19, P1420, DOI 10.1359/JBMR.040606
   BIERINGSORENSEN F, 1990, EUR J CLIN INVEST, V20, P330, DOI 10.1111/j.1365 2362.1990.tb01865.x
   Chenu C., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P423
   Cherruau M, 1999, BONE, V25, P545, DOI 10.1016/S8756 3282(99)00211 2
   Cherruau M, 2003, J CELL PHYSIOL, V194, P341, DOI 10.1002/jcp.10209
   Choi H, 2005, J NEUROSCI, V25, P4550, DOI 10.1523/JNEUROSCI.5135 04.2005
   Cochran T P, 1988, J Spinal Disord, V1, P219
   Dauty M, 2000, BONE, V27, P305, DOI 10.1016/S8756 3282(00)00326 4
   de Bruin ED, 1999, ARCH PHYS MED REHAB, V80, P214, DOI 10.1016/S0003 9993(99)90124 7
   Demirel G, 1998, SPINAL CORD, V36, P822, DOI 10.1038/sj.sc.3100704
   Demulder A, 1998, CALCIFIED TISSUE INT, V63, P396, DOI 10.1007/s002239900547
   Dietz V, 2006, LANCET NEUROL, V5, P688, DOI 10.1016/S1474 4422(06)70522 1
   DUVALBEAUPERE G, 1983, PARAPLEGIA, V21, P339, DOI 10.1038/sc.1983.58
   Eser P., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P197
   Eser P, 2005, OSTEOPOROSIS INT, V16, P26, DOI 10.1007/s00198 004 1638 x
   Garland DE, 2004, J SPINAL CORD MED, V27, P202, DOI 10.1080/10790268.2004.11753748
   GARLAND DE, 1986, CLIN ORTHOP RELAT R, P237
   GIVRE S, 1989, Journal of Emergency Medicine, V7, P461, DOI 10.1016/0736 4679(89)90145 5
   HILL EL, 1991, NEUROSCIENCE, V44, P747, DOI 10.1016/0306 4522(91)90094 5
   HILL EL, 1991, CELL TISSUE RES, V264, P469, DOI 10.1007/BF00319037
   Hulsebosch CE, 2000, J NEUROTRAUM, V17, P1205, DOI 10.1089/neu.2000.17.1205
   Jiang SD, 2007, OSTEOPOROSIS INT, V18, P339, DOI 10.1007/s00198 006 0229 4
   Karsenty G, 2000, TRENDS ENDOCRIN MET, V11, P437, DOI 10.1016/S1043 2760(00)00322 2
   Kohler T, 2005, CALCIFIED TISSUE INT, V77, P281, DOI 10.1007/s00223 005 0039 2
   LEBLANC AD, 1990, J BONE MINER RES, V5, P843
   Lundberg P, 2002, MICROSC RES TECHNIQ, V58, P98, DOI 10.1002/jemt.10124
   Mills CD, 2001, J NEUROTRAUM, V18, P1091, DOI 10.1089/08977150152693773
   NOCKELS R, 1992, J NEUROTRAUM, V9, pS211
   Pikov V, 2002, J PHARMACOL EXP THER, V300, P421, DOI 10.1124/jpet.300.2.421
   Pikov V, 2001, J NEUROSCI, V21, P559, DOI 10.1523/JNEUROSCI.21 02 00559.2001
   Ruegsegger P, 1996, CALCIFIED TISSUE INT, V58, P24, DOI 10.1007/s002239900006
   Serre CM, 1999, BONE, V25, P623, DOI 10.1016/S8756 3282(99)00215 X
   Szollar SM, 1998, AM J PHYS MED REHAB, V77, P28, DOI 10.1097/00002060 199801000 00005
   TAKAHASHI H, 1990, J ORTHOP RES, V8, P393, DOI 10.1002/jor.1100080311
   Teng YD, 2002, P NATL ACAD SCI USA, V99, P3024, DOI 10.1073/pnas.052678899
   Thompson M K, 1999, J Assoc Acad Minor Phys, V10, P23
   VERHAS M, 1980, CALCIFIED TISSUE INT, V30, P83, DOI 10.1007/BF02408611
   Vico L, 2000, LANCET, V355, P1607, DOI 10.1016/S0140 6736(00)02217 0
   VILLANUEVA AR, 1977, AM J MED TECHNOL, V43, P536
   Warden SJ, 2002, OSTEOPOROSIS INT, V13, P586, DOI 10.1007/s001980200077
   WATSON FM, 1976, CLIN ORTHOP RELAT R, P296
   WILMET E, 1995, PARAPLEGIA, V33, P674, DOI 10.1038/sc.1995.141
NR 46
TC 51
Z9 54
U1 0
U2 6
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD MAY
PY 2008
VL 19
IS 5
BP 645
EP 652
DI 10.1007/s00198 007 0494 x
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 283GR
UT WOS:000254625200006
PM 17987335
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Braun, J
   Sieper, J
AF Braun, J.
   Sieper, J.
TI Treatment of rheumatoid arthritis and ankylosing spondylitis
SO CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
LA English
DT Article
DE Rheumatoid arthritis; ankylosing spondylitis; treatment; NSAIDs;
   biologics
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RANDOMIZED CONTROLLED TRIAL;
   LOW DOSE PREDNISOLONE; DOUBLE BLIND; RADIOGRAPHIC PROGRESSION; PLUS
   METHOTREXATE; CLINICAL TRIAL; MULTICENTER; THERAPY; INFLIXIMAB
AB The treatment of the two most frequent inflammatory rheumatic diseases rheumatoid arthritis (RA) and ankylosing spondylitis (AS) has some similarities but in total more differences. Thus, therapy with non steroidal anti inflammatory agents (NSAIDs), conventional disease modifying anti rheumatic drugs (DMARDs) and biologic agents has a different role in the management and different efficacy in AS and RA. This implies signs and symptoms, function, and structural damage. This is in part due to the different pathogenesis: (i) while the synovium is an important target in RA it is rather the bone in AS and (ii) while the pathology in RA is rather osteodestructive to cartilage and bone presenting with erosions, it is predominantly osteoproliferative in AS as indicated by a syndesmophytes and ankylosis. Biologic agents targeting tumor necrosis factor (TNF alpha) work clinically well in both diseases but, while they clearly inhibit structural damage in RA, they do not seem to have much influence on new bone formation in AS. DMARDs are efficacious in RA but less so in AS. NSAIDs are efficacious in both RA and AS, but they are considered first line of therapy in AS while they are rather adjunctive agents in RA. In AS, NSAIDs, potentially especially coxibs, may even prevent new bone formation due to their inhibitory effect on cyclooxygenase 2.
C1 [Sieper, J.] Charite, Dept Rheumatol, D 12200 Berlin, Germany.
   [Braun, J.] Rheumazentrum Ruhrgebiet, Herne, Germany.
C3 Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; Rheumazentrum Ruhrgebiet; Ruhr University
   Bochum
RP Sieper, J (通讯作者)，Charite, Dept Rheumatol, Campus Benjamin Franklin,Hindenburgdamn 30, D 12200 Berlin, Germany.
RI Braun, Juergen/E 8127 2013
CR Braun J, 2008, ARTHRITIS RHEUM US, V58, P73, DOI 10.1002/art.23144
   Braun J, 2006, ANN RHEUM DIS, V65, P1147, DOI 10.1136/ard.2006.052878
   Braun J, 2002, LANCET, V359, P1187, DOI 10.1016/S0140 6736(02)08215 6
   Braun J, 2009, CURR OPIN RHEUMATOL, V21, P324, DOI 10.1097/BOR.0b013e32832c6674
   Breedveld FC, 2006, ARTHRITIS RHEUM US, V54, P26, DOI 10.1002/art.21519
   Elyan M, 2008, CURR OPIN RHEUMATOL, V20, P282, DOI 10.1097/BOR.0b013e3282fa13c9
   Goekoop Ruiterman YPM, 2007, ANN INTERN MED, V146, P406, DOI 10.7326/0003 4819 146 6 200703200 00005
   Grigor C, 2004, LANCET, V364, P263, DOI 10.1016/S0140 6736(04)16676 2
   Heiberg MS, 2008, ARTHRIT RHEUM ARTHR, V59, P234, DOI 10.1002/art.23333
   Heiberg MS, 2005, ARTHRITIS RHEUM US, V52, P2506, DOI 10.1002/art.21209
   Klareskog L, 2004, LANCET, V363, P675, DOI 10.1016/S0140 6736(04)15640 7
   McGonagle D, 1998, ARTHRITIS RHEUM, V41, P694, DOI 10.1002/1529 0131(199804)41:4<694::AID ART17>3.0.CO;2 #
   Smolen JS, 2005, ARTHRITIS RHEUM, V52, P1020, DOI 10.1002/art.20982
   Song IH, 2008, ARTHRITIS RHEUM US, V58, P929, DOI 10.1002/art.23275
   Svensson B, 2005, ARTHRITIS RHEUM US, V52, P3360, DOI 10.1002/art.21298
   van der Heijde D, 2008, ARTHRITIS RHEUM US, V58, P3063, DOI 10.1002/art.23901
   Wanders A, 2005, ARTHRITIS RHEUM US, V52, P1756, DOI 10.1002/art.21054
   Wassenberg S, 2005, ARTHRITIS RHEUM US, V52, P3371, DOI 10.1002/art.21421
   Zochling J, 2006, ANN RHEUM DIS, V65, P442, DOI 10.1136/ard.2005.041137
   Zochling J, 2006, CLIN RHEUMATOL, V25, P794, DOI 10.1007/s10067 005 0132 y
NR 20
TC 14
Z9 15
U1 0
U2 0
PU CLINICAL & EXPER RHEUMATOLOGY
PI PISA
PA VIA SANTA MARIA 31, 56126 PISA, ITALY
SN 0392 856X
EI 1593 098X
J9 CLIN EXP RHEUMATOL
JI Clin. Exp. Rheumatol.
PD JUL AUG
PY 2009
VL 27
IS 4
SU 55
BP S146
EP S147
PG 2
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 507ZL
UT WOS:000270895600026
PM 19822062
DA 2025 08 17
ER

PT J
AU Binrayes, A
   Ge, C
   Mohamed, FF
   Franceschi, RT
AF Binrayes, A.
   Ge, C.
   Mohamed, F. F.
   Franceschi, R. T.
TI Role of Discoidin Domain Receptor 2 in Craniofacial Bone Regeneration
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE craniofacial biology; genetics; cell matrix interactions; collagen
   receptor; extracellular matrix; osteoblasts; cell differentiation
ID OSTEOBLAST DIFFERENTIATION; COLLAGEN FIBRILLOGENESIS; STEM CELLS;
   CAPACITY; FRACTURE; DEFECTS; SUTURES; OSTERIX; DDR2; SIZE
AB Bone loss caused by trauma, neoplasia, congenital defects, or periodontal disease is a major cause of disability and human suffering. Skeletal progenitor cell extracellular matrix interactions are critical for bone regeneration. Discoidin domain receptor 2 (DDR2), an understudied collagen receptor, plays an important role in skeletal development. Ddr2 loss of function mutations in humans and mice cause severe craniofacial and skeletal defects, including altered cranial shape, dwarfing, reduced trabecular and cortical bone, alveolar bone/periodontal defects, and altered dentition. However, the role of this collagen receptor in craniofacial regeneration has not been examined. To address this, calvarial subcritical size defects were generated in wild type (WT) and Ddr2 deficient mice. The complete bridging seen in WT controls at 4 wk postsurgery was not observed in Ddr2 deficient mice even after 12 wk. Quantitation of defect bone area by micro computed tomography also revealed a 50% reduction in new bone volume in Ddr2 deficient mice. Ddr2 expression during calvarial bone regeneration was measured using Ddr2 LacZ knock in mice. Expression was restricted to periosteal surfaces of uninjured calvarial bone and, after injury, was detected in select regions of the defect site by 3 d postsurgery and expanded during the healing process. The impaired bone healing associated with Ddr2 deficiency may be related to reduced osteoprogenitor or osteoblast cell proliferation and differentiation since knockdown/knockout of Ddr2 in a mesenchymal cell line and primary calvarial osteoblast cultures reduced osteoblast differentiation while Ddr2 overexpression was stimulatory. In conclusion, Ddr2 is required for cranial bone regeneration and may be a novel target for therapy.
C1 [Binrayes, A.; Ge, C.; Mohamed, F. F.; Franceschi, R. T.] Univ Michigan, Sch Dent, Dept Periodont, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.
   [Binrayes, A.; Ge, C.; Mohamed, F. F.; Franceschi, R. T.] Univ Michigan, Sch Dent, Dept Oral Med, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.
   [Binrayes, A.] King Saud Univ, Coll Dent, Dept Prosthet Dent Sci, Riyadh, Saudi Arabia.
   [Franceschi, R. T.] Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.
   [Franceschi, R. T.] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; King Saud University;
   University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan
RP Franceschi, RT (通讯作者)，Univ Michigan, Sch Dent, Dept Periodont, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.; Franceschi, RT (通讯作者)，Univ Michigan, Sch Dent, Dept Oral Med, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.
EM rennyf@umich.edu
RI Mohamed, Fatma/AAB 7728 2021; FRANCESCHI, RENNY/K 3533 2019; Binrayes,
   Abdulaziz/AAZ 9966 2021
OI , Abdulaziz Binrayes/0000 0003 1601 4901
FU National Institute of Dental and Craniofacial Research (NIDCR) [DE11723,
   DE29012]; Department of Defense [W81XWH2010571]; Michigan
   Musculoskeletal Health Core Center (National Institutes of Health/NIAMS)
   [P30 AR069620]; NIDCR [K12 DE023574]; King Saud University; Ministry of
   Higher Education and Scientific Research, Libyan Transitional
   Government; U.S. Department of Defense (DOD) [W81XWH2010571] Funding
   Source: U.S. Department of Defense (DOD); National Institute of
   Arthritis and Musculoskeletal and Skin Diseases [P30AR069620] Funding
   Source: NIH RePORTER; National Institute of Dental and Craniofacial
   Research [R01DE029465] Funding Source: NIH RePORTER
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: This work was
   supported by National Institute of Dental and Craniofacial Research
   (NIDCR) grants DE11723 and DE29012, Department of Defense Contract
   W81XWH2010571 (to R.T. Franceschi), the Michigan Musculoskeletal Health
   Core Center (National Institutes of Health/NIAMS P30 AR069620) and NIDCR
   Career Development Award K12 DE023574 (C. Ge; PI: S. Kapila), and
   scholarships from King Saud University (A. Binreyes) and the Ministry of
   Higher Education and Scientific Research, Libyan Transitional Government
   (F.F. Mohamed).
CR Bargal R, 2009, AM J HUM GENET, V84, P80, DOI 10.1016/j.ajhg.2008.12.004
   Bayer SVH, 2019, ELIFE, V8, DOI 10.7554/eLife.45508
   Behr B, 2010, BONE, V47, P281, DOI 10.1016/j.bone.2010.05.008
   Blissett AR, 2009, J MOL BIOL, V385, P902, DOI 10.1016/j.jmb.2008.10.060
   Bostrom MPG, 1999, ORTHOP CLIN N AM, V30, P647, DOI 10.1016/S0030 5898(05)70117 6
   Brunner M, 2013, INT REV CEL MOL BIO, V305, P1, DOI 10.1016/B978 0 12 407695 2.00001 9
   Clark AY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14000 9
   Cowan CM, 2004, NAT BIOTECHNOL, V22, P560, DOI 10.1038/nbt958
   Doro DH, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00956
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Ekholm E, 2002, AM J PATHOL, V160, P1779, DOI 10.1016/S0002 9440(10)61124 8
   Flynn LA, 2010, J MOL BIOL, V395, P533, DOI 10.1016/j.jmb.2009.10.073
   Ge C, 2018, J DENT RES, V97, P321, DOI 10.1177/0022034517738190
   Ge CX, 2016, J BONE MINER RES, V31, P2193, DOI 10.1002/jbmr.2893
   Ge CX, 2012, J BONE MINER RES, V27, P538, DOI 10.1002/jbmr.561
   Ge CX, 2009, J BIOL CHEM, V284, P32533, DOI 10.1074/jbc.M109.040980
   Itoh Y, 2018, CELL ADHES MIGR, V12, P378, DOI 10.1080/19336918.2018.1460011
   Kano K, 2008, MOL ENDOCRINOL, V22, P1866, DOI 10.1210/me.2007 0310
   Kim JB, 2007, BONE, V41, P39, DOI 10.1016/j.bone.2007.01.024
   Legate KR, 2009, GENE DEV, V23, P397, DOI 10.1101/gad.1758709
   Leitinger B, 2014, INT REV CEL MOL BIO, V310, P39, DOI 10.1016/B978 0 12 800180 6.00002 5
   Maruyama T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10526
   Mohamed FF, 2020, J DENT RES, V99, P214, DOI 10.1177/0022034519892563
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Park S, 2016, STEM CELLS DEV, V25, P1801, DOI 10.1089/scd.2016.0211
   Quarto N, 2010, J BONE MINER RES, V25, P1680, DOI 10.1359/jbmr.091116
   Reyes CD, 2004, J BIOMED MATER RES A, V69A, P591, DOI 10.1002/jbm.a.30034
   Shekaran A, 2014, BONE, V68, P131, DOI 10.1016/j.bone.2014.08.008
   Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097 2765(00)80004 0
   Valiathan RR, 2012, CANCER METAST REV, V31, P295, DOI 10.1007/s10555 012 9346 z
   Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097 2765(00)80003 9
   Wilk K, 2017, STEM CELL REP, V8, P933, DOI 10.1016/j.stemcr.2017.03.002
   Zhang Y, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005835
   Zhang Y, 2011, J BONE MINER RES, V26, P604, DOI 10.1002/jbmr.225
   Zhao H, 2015, NAT CELL BIOL, V17, P386, DOI 10.1038/ncb3139
   Zhao Z, 2007, J DENT RES, V86, P1207, DOI 10.1177/154405910708601213
NR 36
TC 12
Z9 14
U1 3
U2 10
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022 0345
EI 1544 0591
J9 J DENT RES
JI J. Dent. Res.
PD NOV
PY 2021
VL 100
IS 12
BP 1359
EP 1366
AR 00220345211007447
DI 10.1177/00220345211007447
EA APR 2021
PG 8
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA WK0TT
UT WOS:000681414500001
PM 33899571
OA Green Published
DA 2025 08 17
ER

PT J
AU Yu, LY
   Wang, XM
   Gao, XH
   Tong, J
   Zhang, JB
AF Yu, Liyin
   Wang, Xiangmiao
   Gao, Xiaohang
   Tong, Jie
   Zhang, Jianbao
TI The calcium transient characteristics induced by fluid shear stress
   affect the osteoblast proliferation
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE Shear stress; Proteomic; TCA cycle; Calcium transients; Mitochondrial
   calcium uptake
ID CELL PROLIFERATION; PYRUVATE DEHYDROGENASE; CHANNELS; CANCER
AB Ca2+ signaling is essential for bone metabolism. Fluid shear stress (FSS), which can induce a rapid release of calcium from endoplasmic reticulum (ER) to produce calcium transients, plays a significant role in osteoblast proliferation and differentiation. However, it is still unclear of how calcium transients induced by FSS activating a number of downstream signals which subsequently regulate cell functions. In this study, we performed a group of Ca2+ transients models, which were induced by FSS to investigate the effects of different magnitudes of Ca2+ transients in osteoblast proliferation. Further, we performed a global proteomic profile of MC3T3 E1 cells in different Ca2+ transients models stimulated by FSS. GO enrichment and KEGG pathway analysis revealed that the TCA cycle was activated in the proliferating process. The activation of TCA needed mitochondrial Ca2+ uptake which were influenced by the amplitude of Ca2+ transients induced by FSS. Our work elucidate that osteoblast proliferation induced by FSS was related to the magnitude of calcium transients, which further activated energetic metabolism signaling pathway. This work revealed further understanding the mechanism of osteoblast proliferation induced by mechanic loading and help us to design new methods for osteoporosis therapy.
C1 [Yu, Liyin; Wang, Xiangmiao; Gao, Xiaohang; Tong, Jie; Zhang, Jianbao] Xi An Jiao Tong Univ, Sch Life Sci & Technol, Minist Educ, Key Lab Biomed Informat Engn, Xian 710049, Shaanxi, Peoples R China.
C3 Xi'an Jiaotong University
RP Zhang, JB (通讯作者)，Xi An Jiao Tong Univ, Sch Life Sci & Technol, Minist Educ, Key Lab Biomed Informat Engn, Xian 710049, Shaanxi, Peoples R China.
EM zhangjb@mail.xjtu.edn.cn
FU National Natural Science Foundation of China [31670954]
FX We are very grateful to the stuff of PTM Biolabs (HangZhou) Co., Ltd.
   for their proteomics technical assistance, especially to Mr Fang zhang,
   and Dr. Xilong Wu. This work was supported by the National Natural
   Science Foundation of China (Project No. 31670954).
CR Arciuch VGA, 2012, ANTIOXID REDOX SIGN, V16, P1150, DOI 10.1089/ars.2011.4085
   Antigny F, 2014, CELL CALCIUM, V56, P513, DOI 10.1016/j.ceca.2014.10.014
   Basso N, 2002, BONE, V30, P347, DOI 10.1016/S8756 3282(01)00678 0
   Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035
   BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0
   Cantor JR, 2012, CANCER DISCOV, V2, P881, DOI 10.1158/2159 8290.CD 12 0345
   Capiod T, 2011, BIOCHIMIE, V93, P2075, DOI 10.1016/j.biochi.2011.07.015
   Chen RP, 2012, BMC MOL BIOL, V13, DOI 10.1186/1471 2199 13 31
   Clapham DE, 2007, CELL, V129, P220, DOI 10.1016/j.cell.2007.03.034
   CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092 8674(95)90408 5
   DANI JW, 1992, NEURON, V8, P429, DOI 10.1016/0896 6273(92)90271 E
   DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002
   Gingerich JL, 2005, DEV BIOL, V286, P427, DOI 10.1016/j.ydbio.2005.07.031
   Glaser T, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478 811X 11 12
   Grassian AR, 2011, GENE DEV, V25, P1716, DOI 10.1101/gad.16771811
   GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440
   Gurkan UA, 2008, ANN BIOMED ENG, V36, P1978, DOI 10.1007/s10439 008 9577 x
   Haizlip KM, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/468548
   Hu F., PLOS ONE, V9
   Jia XL, 2013, PFLUG ARCH EUR J PHY, V465, P221, DOI 10.1007/s00424 012 1182 z
   Kapur S, 2003, BONE, V32, P241, DOI 10.1016/S8756 3282(02)00979 1
   Liu XL, 2010, ACTA BIOCH BIOPH SIN, V42, P195, DOI 10.1093/abbs/gmq004
   Núñez L, 2006, J PHYSIOL LONDON, V571, P57, DOI 10.1113/jphysiol.2005.100586
   Patel MS, 2001, EXP MOL MED, V33, P191, DOI 10.1038/emm.2001.32
   Rajagopalan KN, 2015, CANCER METAB, V3, DOI 10.1186/s40170 015 0134 4
   Sun JQ, 2014, J BIOMECH, V47, P3903, DOI 10.1016/j.jbiomech.2014.10.003
   Terrand J, 2001, AM J PHYSIOL HEART C, V281, pH722, DOI 10.1152/ajpheart.2001.281.2.H722
   TUSCHIL A, 1992, J INVEST DERMATOL, V99, P294, DOI 10.1111/1523 1747.ep12616634
   Wei CL, 2009, NATURE, V457, P901, DOI 10.1038/nature07577
   Williams GSB, 2013, P NATL ACAD SCI USA, V110, P10479, DOI 10.1073/pnas.1300410110
   Yu Liyin, 2017, MOL MED REP, P7720
   Yu WL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089966
NR 32
TC 10
Z9 13
U1 0
U2 18
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0014 4827
EI 1090 2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD JAN 1
PY 2018
VL 362
IS 1
BP 51
EP 62
DI 10.1016/j.yexcr.2017.11.001
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA FT1KL
UT WOS:000422894500006
PM 29102602
DA 2025 08 17
ER

PT J
AU Aisha, MD
   Nor Ashikin, MNK
   Sharaniza, ABR
   Nawawi, H
   Froemming, GRA
AF Aisha, M. D.
   Nor Ashikin, M. N. K.
   Sharaniza, A. B. R.
   Nawawi, H.
   Froemming, G. R. A.
TI Orbital fluid shear stress promotes osteoblast metabolism, proliferation
   and alkaline phosphates activity in vitro
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE Normal Human Osteoblast cells; Mechanical loading; Orbital fluid shear
   stress; Cytoskeleton; Actin; tubulin; Anabolic stimulus;
   Osteoblastogenesis; Bone regeneration
ID OSTEOGENIC DIFFERENTIATION; MECHANICAL STRAIN; OSTEOCALCIN EXPRESSION;
   BONE; CELLS; COLLAGEN; STIMULATION; PROTEINS; HISTORY; OSTERIX
AB Prolonged disuse of the musculoskeletal system is associated with reduced mechanical loading and lack of anabolic stimulus. As a form of mechanical signal, the multidirectional orbital fluid shear stress transmits anabolic signal to bone forming cells in promoting cell differentiation, metabolism and proliferation. Signals are channeled through the cytoskeleton framework, directly modifying gene and protein expression. For that reason, we aimed to study the organization of Normal Human Osteoblast (NHOst) cytoskeleton with regards to orbital fluid shear (OFS) stress. Of special interest were the consequences of cytoskeletal reorganization on NHOst metabolism, proliferation, and osteogenic functional markers. Cells stimulated at 250 RPM in a shaking incubator resulted in the rearrangement of actin and tubulin fibers after 72 h. Orbital shear stress increased NHOst mitochondrial metabolism and proliferation, simultaneously preventing apoptosis. The ratio of RANKL/OPG was reduced, suggesting that orbital shear stress has the potential to inhibit osteoclastogenesis and osteoclast activity. Increase in ALP activity and OCN protein production suggests that stimulation retained osteoblast function. Shear stress possibly generated through actin seemed to hold an anabolic response as osteoblast metabolism and functional markers were enhanced. We hypothesize that by applying orbital shear stress with suitable magnitude and duration as a non drug anabolic treatment can help improve bone regeneration in prolonged disuse cases. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Aisha, M. D.; Nor Ashikin, M. N. K.; Froemming, G. R. A.] Univ Teknol MARA, Inst Med Mol Biotechnol, Sungai Buloh 47000, Selangor, Malaysia.
   [Aisha, M. D.; Nor Ashikin, M. N. K.; Froemming, G. R. A.] Univ Teknol MARA, Fac Med, Sungai Buloh 47000, Selangor, Malaysia.
   [Nawawi, H.] Univ Teknol MARA, Ctr Pathol Diagnost & Res Labs, Clin Training Ctr, Sungai Buloh 47000, Selangor, Malaysia.
   [Nor Ashikin, M. N. K.; Sharaniza, A. B. R.] Univ Teknol MARA, DDH, Shah Alam 40450, Selangor, Malaysia.
   [Nawawi, H.; Froemming, G. R. A.] Univ Teknol MARA, I PPerForM, Selayang 47000, Selangor, Malaysia.
C3 Universiti Teknologi MARA; Universiti Teknologi MARA; Universiti
   Teknologi MARA; Universiti Teknologi MARA
RP Froemming, GRA (通讯作者)，Univ Teknol MARA, Inst Med Mol Biotechnol, Fac Med, Sungai Buloh Campus,Jalan Hosp, Sungai Buloh 47000, Selangor, Malaysia.
EM gabriele@salam.uitm.edu.my
RI Nawawi, Hapizah/F 3617 2018; Froemming, Gabriele/C 3274 2013; Mohamed
   Noor Khan, Nor Ashikin/P 2055 2015; Nawawi, Hapizah/N 7446 2019;
   Nor Ashikin, Mohamed/P 2055 2015
OI Nawawi, Hapizah/0000 0003 4462 8484; Froemming,
   Gabriele/0000 0002 5931 1968; Mohamed Noor Khan, Nor
   Ashikin/0000 0002 1325 9236; Nawawi, M Ikhsan/0000 0002 1372 453X; 
FU Research Excellent Fund (DANA); University Teknologi MARA (UiTM)
   [600 RMI/ST/DANA 5/3 Dst (71/2011)]
FX We would also like to thank the staff of the Institute of Medical
   Molecular Biotechnology (IMMB), particularly Ms. Salina Othman for her
   excellent operating skills of the Leica Confocal Laser Scanning
   Microscope and Mrs. Norita Salim for her skillful molecular technical
   assistance. This study was funded by the Research Excellent Fund (DANA),
   University Teknologi MARA (UiTM). Grant code: 600 RMI/ST/DANA 5/3 Dst
   (71/2011).
CR Aisha MD, 2014, EXP CELL RES, V326, P46, DOI 10.1016/j.yexcr.2014.06.003
   Arnsdorf EJ, 2009, J CELL SCI, V122, P546, DOI 10.1242/jcs.036293
   David V, 2007, ENDOCRINOLOGY, V148, P2553, DOI 10.1210/en.2006 1704
   Douglas T, 2007, BIOMACROMOLECULES, V8, P1085, DOI 10.1021/bm0609644
   Eriksen EF, 2010, REV ENDOCR METAB DIS, V11, P219, DOI 10.1007/s11154 010 9153 1
   Fan DW, 2007, J CELL PHYSIOL, V211, P577, DOI 10.1002/jcp.21016
   Fritton SP, 2000, J BIOMECH, V33, P317, DOI 10.1016/S0021 9290(99)00210 9
   Guo Y, 2012, BIOMED ENG ONLINE, V11, DOI 10.1186/1475 925X 11 80
   Honda A, 2003, J APPL PHYSIOL, V95, P1032, DOI 10.1152/japplphysiol.00781.2002
   Ignatius A, 2005, BIOMATERIALS, V26, P311, DOI 10.1016/j.biomaterials.2004.02.045
   Jaalouk DE, 2009, NAT REV MOL CELL BIO, V10, P63, DOI 10.1038/nrm2597
   Jacobs CR, 1998, J BIOMECH, V31, P969, DOI 10.1016/S0021 9290(98)00114 6
   Kadow Romacker A, 2009, CELLS TISSUES ORGANS, V190, P61, DOI 10.1159/000178022
   Kamkin A., 2005, MECHANOBIOLOGY BONE
   Kaneuji T, 2011, BIOCHEM BIOPH RES CO, V408, P103, DOI 10.1016/j.bbrc.2011.03.128
   KANNUS P, 1994, J BONE MINER RES, V9, P423
   Kaspar D, 2000, J BIOMECH, V33, P45, DOI 10.1016/S0021 9290(99)00171 2
   Khatiwala CB, 2006, AM J PHYSIOL CELL PH, V290, pC1640, DOI 10.1152/ajpcell.00455.2005
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Kido S, 2009, BONE, V45, P1125, DOI 10.1016/j.bone.2009.07.087
   Kim CH, 2009, BMC MUSCULOSKEL DIS, V10, DOI 10.1186/1471 2474 10 109
   Kong HJ, 2005, NAT MATER, V4, P460, DOI 10.1038/nmat1392
   Kreja L, 2008, BIOCHEM BIOPH RES CO, V368, P582, DOI 10.1016/j.bbrc.2008.01.106
   LeBlanc A., 2000, Journal of Musculoskeletal & Neuronal Interactions, V1, P157
   Li X, 2012, CHINESE MED J PEKING, V125, P2568, DOI 10.3760/cma.j.issn.0366 6999.2012.14.031
   Lim KT, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/316803
   Liu L, 2012, CELL MOL BIOENG, V5, P427, DOI 10.1007/s12195 012 0244 9
   Lu HF, 2012, CHINESE MED J PEKING, V125, P4093, DOI 10.3760/cma.j.issn.0366 6999.2012.22.033
   Meazzini MC, 1998, J ORTHOP RES, V16, P170, DOI 10.1002/jor.1100160204
   Modlesky CM, 2004, J BONE MINER RES, V19, P48, DOI 10.1359/JBMR.0301208
   NEIDLINGERWILKE C, 1994, J ORTHOP RES, V12, P70, DOI 10.1002/jor.1100120109
   Prodanov L, 2010, BIOMATERIALS, V31, P7758, DOI 10.1016/j.biomaterials.2010.06.050
   Qi MC, 2008, INT J ORAL MAX SURG, V37, P453, DOI 10.1016/j.ijom.2007.12.008
   Reich KM, 1997, ENDOCRINOLOGY, V138, P1014, DOI 10.1210/en.138.3.1014
   Rosenberg N, 2002, CYTOTECHNOLOGY, V39, P125, DOI 10.1023/A:1023925230651
   Salin N, 2008, Med J Malaysia, V63 Suppl A, P67
   Sambandam Y, 2014, BONE, V61, P125, DOI 10.1016/j.bone.2014.01.004
   Simmons CA, 2004, J BIOMECH, V37, P1531, DOI 10.1016/j.jbiomech.2004.01.006
   Tanaka H, 2011, BIOCHEM BIOPH RES CO, V411, P690, DOI 10.1016/j.bbrc.2011.07.001
   Tanno M, 2003, BONE, V33, P475, DOI 10.1016/S8756 3282(03)00204 7
   Thompson WR, 2012, GENE, V503, P179, DOI 10.1016/j.gene.2012.04.076
   Tripuwabhrut P, 2013, ARCH ORAL BIOL, V58, P826, DOI 10.1016/j.archoralbio.2013.01.004
   Vandrovcová M, 2011, PHYSIOL RES, V60, P797, DOI 10.33549/physiolres.931994
   WEINREB M, 1990, J BONE MINER RES, V5, P831
NR 44
TC 30
Z9 41
U1 1
U2 22
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0014 4827
EI 1090 2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD SEP 10
PY 2015
VL 337
IS 1
BP 87
EP 93
DI 10.1016/j.yexcr.2015.07.002
PG 7
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA CP9BD
UT WOS:000360187800010
PM 26163894
DA 2025 08 17
ER

PT J
AU Kameo, Y
   Miya, Y
   Hayashi, M
   Nakashima, T
   Adachi, T
AF Kameo, Y.
   Miya, Y.
   Hayashi, M.
   Nakashima, T.
   Adachi, T.
TI In silico experiments of bone remodeling explore metabolic diseases and
   their drug treatment
SO SCIENCE ADVANCES
LA English
DT Article
ID POSTMENOPAUSAL WOMEN; MECHANISMS; MODEL; SCLEROSTIN; BIOLOGY;
   EXPRESSION; OSTEOCYTES; DENOSUMAB
AB Bone structure and function are maintained by well regulated bone metabolism and remodeling. Although the underlying molecular and cellular mechanisms are now being understood, physiological and pathological states of bone are still difficult to predict due to the complexity of intercellular signaling. We have now developed a novel in silico experimental platform, V Bone, to integratively explore bone remodeling by linking complex microscopic molecular/cellular interactions to macroscopic tissue/organ adaptations. Mechano biochemical couplings modeled in V Bone relate bone adaptation to mechanical loading and reproduce metabolic bone diseases such as osteoporosis and osteopetrosis. V Bone also enables in silico perturbation on a specific signaling molecule to observe bone metabolic dynamics over time. We also demonstrate that this platform provides a powerful way to predict in silico therapeutic effects of drugs against metabolic bone diseases. We anticipate that these in silico experiments will substantially accelerate research into bone metabolism and remodeling.
C1 [Kameo, Y.; Adachi, T.] Kyoto Univ, Inst Frontier Life & Med Sci, Dept Biosyst Sci, Kyoto, Japan.
   [Kameo, Y.; Miya, Y.; Adachi, T.] Kyoto Univ, Grad Sch Engn, Dept Micro Engn, Kyoto, Japan.
   [Kameo, Y.; Adachi, T.] Kyoto Univ, Grad Sch Biostudies, Dept Mammalian Regulatory Network, Kyoto, Japan.
   [Hayashi, M.; Nakashima, T.] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Cell Signaling, Tokyo, Japan.
   [Nakashima, T.; Adachi, T.] Japan Agcy Med Res & Dev, Core Res Evolut Sci & Technol, Tokyo, Japan.
C3 Kyoto University; Kyoto University; Kyoto University; Institute of
   Science Tokyo; Tokyo Medical & Dental University (TMDU); Japan Science &
   Technology Agency (JST)
RP Adachi, T (通讯作者)，Kyoto Univ, Inst Frontier Life & Med Sci, Dept Biosyst Sci, Kyoto, Japan.; Adachi, T (通讯作者)，Kyoto Univ, Grad Sch Engn, Dept Micro Engn, Kyoto, Japan.; Adachi, T (通讯作者)，Kyoto Univ, Grad Sch Biostudies, Dept Mammalian Regulatory Network, Kyoto, Japan.; Adachi, T (通讯作者)，Japan Agcy Med Res & Dev, Core Res Evolut Sci & Technol, Tokyo, Japan.
EM adachi@infront.kyoto u.ac.jp
RI Adachi, Taiji/P 8981 2016
OI Adachi, Taiji/0000 0001 5280 4156; Kameo, Yoshitaka/0000 0002 5193 9398
FU Advanced Research and Development Programs for Medical Innovation
   (AMED CREST); Japan Agency for Medical Research and Development (AMED)
   [JP19gm0810003]; Acceleration Program for Intractable Diseases Research
   Utilizing Disease Specific iPS cells from AMED [JP19bm0804006];
   Cross Ministerial Strategic Innovation Promotion Program (SIP) (3D
   Design & Additive Manufacturing) from Japan Science and Technology
   Agency (JST); VCAD System Research Program, RIKEN
FX This work was supported by Advanced Research and Development Programs
   for Medical Innovation (AMED CREST), Elucidation of Mechanobiological
   Mechanisms and their Application to the Development of Innovative
   Medical Instruments and Technologies from Japan Agency for Medical
   Research and Development (AMED) (JP19gm0810003), the Acceleration
   Program for Intractable Diseases Research Utilizing Disease Specific iPS
   cells from AMED (JP19bm0804006), Cross Ministerial Strategic Innovation
   Promotion Program (SIP) (3D Design & Additive Manufacturing) from Japan
   Science and Technology Agency (JST), and VCAD System Research Program,
   RIKEN.
CR Adachi T, 2001, J BIOMECH ENG T ASME, V123, P403, DOI 10.1115/1.1392315
   Adachi T, 2009, BIOCHEM BIOPH RES CO, V389, P495, DOI 10.1016/j.bbrc.2009.09.010
   Beno T, 2006, J BIOMECH, V39, P2378, DOI 10.1016/j.jbiomech.2005.08.005
   Bone HG, 2011, J CLIN ENDOCR METAB, V96, P972, DOI 10.1210/jc.2010 1502
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Canalis E, 2013, NAT REV ENDOCRINOL, V9, P575, DOI 10.1038/nrendo.2013.154
   Cowin SC, 2000, J BIOMECH ENG T ASME, V122, P553, DOI 10.1115/1.1324665
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Elefteriou F, 2008, ARCH BIOCHEM BIOPHYS, V473, P231, DOI 10.1016/j.abb.2008.03.016
   Florio M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11505
   Gerhard FA, 2009, PHILOS T R SOC A, V367, P2011, DOI 10.1098/rsta.2008.0297
   Hayashi M, 2012, NATURE, V485, P69, DOI 10.1038/nature11000
   HOLLISTER SJ, 1994, J BIOMECH, V27, P433, DOI 10.1016/0021 9290(94)90019 1
   Huiskes R, 2000, NATURE, V405, P704, DOI 10.1038/35015116
   Ishii M, 2009, NATURE, V458, P524, DOI 10.1038/nature07713
   JAWORSKI ZF, 1972, CALC TISS RES, V10, P103, DOI 10.1007/BF02012540
   Kawai M, 2011, NAT REV DRUG DISCOV, V10, P141, DOI 10.1038/nrd3299
   Kendler DL, 2010, J BONE MINER RES, V25, P72, DOI 10.1359/jbmr.090716
   Kim YK, 2017, BIOMECH MODEL MECHAN, V16, P1697, DOI 10.1007/s10237 017 0914 6
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   LeBlanc A. D., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P33
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Nakashima T, 2012, TRENDS ENDOCRIN MET, V23, P582, DOI 10.1016/j.tem.2012.05.005
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   OSHER S, 1988, J COMPUT PHYS, V79, P12, DOI 10.1016/0021 9991(88)90002 2
   PARFITT AM, 1994, J CELL BIOCHEM, V55, P273, DOI 10.1002/jcb.240550303
   Pastrama MI, 2018, BONE, V107, P208, DOI 10.1016/j.bone.2017.11.009
   Pivonka P, 2008, BONE, V43, P249, DOI 10.1016/j.bone.2008.03.025
   Plotkin LI, 2016, NAT REV ENDOCRINOL, V12, P593, DOI 10.1038/nrendo.2016.71
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Scheiner S, 2013, COMPUT METHOD APPL M, V254, P181, DOI 10.1016/j.cma.2012.10.015
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Spatz JM, 2015, J BIOL CHEM, V290, P16744, DOI 10.1074/jbc.M114.628313
   Stegen S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 04679 7
   Sutherland MK, 2004, BONE, V35, P828, DOI 10.1016/j.bone.2004.05.023
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Tsubota Ken ichi, 2004, Computer Methods in Biomechanics and Biomedical Engineering, V7, P187, DOI 10.1080/10255840410001729524
   Tsubota K, 2009, J BIOMECH, V42, P1088, DOI 10.1016/j.jbiomech.2009.02.030
   van der Meulen MCH, 2002, J BIOMECH, V35, P401, DOI 10.1016/S0021 9290(01)00184 1
   VANRIETBERGEN B, 1995, J BIOMECH, V28, P69, DOI 10.1016/0021 9290(95)80008 5
   WEINBAUM S, 1994, J BIOMECH, V27, P339, DOI 10.1016/0021 9290(94)90010 8
   Weivoda MM, 2014, CURR OSTEOPOROS REP, V12, P107, DOI 10.1007/s11914 014 0188 1
   Wijenayaka AR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025900
   Wolff J., 1870, ARCH PATHOLOGISCHE A, V50, P389
   Wolff J, 2010, CLIN ORTHOP RELAT R, V468, P1056, DOI 10.1007/s11999 010 1239 2
   Xiong JH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05244 y
NR 49
TC 43
Z9 44
U1 2
U2 30
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 2375 2548
J9 SCI ADV
JI Sci. Adv.
PD MAR
PY 2020
VL 6
IS 10
AR eaax0938
DI 10.1126/sciadv.aax0938
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA KT4RF
UT WOS:000519001400008
PM 32181336
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Francis, LK
   Alsayed, Y
   Leleu, X
   Jia, XY
   Singha, UK
   Anderson, J
   Timm, M
   Go, HN
   Lu, GW
   Huston, A
   Ehrlich, LA
   Dimmock, E
   Lentzsch, S
   Hideshima, T
   Roodman, GD
   Anderson, KC
   Ghobrial, IM
AF Francis, Lanie K.
   Alsayed, Yazan
   Leleu, Xavier
   Jia, Xiaoying
   Singha, Ujjal K.
   Anderson, Judith
   Timm, Michael
   Go, Hai N.
   Lu, Ganwei
   Huston, Alissa
   Ehrlich, Lori A.
   Dimmock, Elizabeth
   Lentzsch, Suzanne
   Hideshima, Teru
   Roodman, G. David
   Anderson, Kenneth C.
   Ghobrial, Irene M.
TI Combination mammalian target of rapamycin inhibitor rapamycin and HSP90
   inhibitor 17 allylamino 17 demethoxygeldanamycin has synergistic
   activity in multiple myeloma
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID CYCLIN D DYSREGULATION; IN VIVO; THERAPEUTIC IMPLICATIONS; OSTEOCLAST
   FORMATION; SIGNAL TRANSDUCTION; CANCER THERAPY; CELLS; PATHWAY;
   EXPRESSION; AKT
AB Purpose: The phosphatidylinositol 3 kinase/AKT/mammalian target of rapamycin (mTOR) pathway and the heat shock protein family are up regulated in multiple myeloma and are both regulators of the cyclin D/retinoblastoma pathway, a critical pathway in multiple myeloma. Inhibitors of mTOR and HSP90 protein have showed in vitro and in vivo single agent activity in multiple myeloma. Our objective was to determine the effects of the mTOR inhibitor rapamycin and the HSP90 inhibitor 17 allylamino 17 demethoxygeldanamycin (17 AAG) on multiple myeloma cells.
   Experimental Design: Multiple myeloma cell lines were incubated with rapamycin (0.1 100 nmol/L) and 17 AAG (100 600 nmol/L) alone and in combination.
   Results: In this study, we showed that the combination of rapamycin and 17 AAG synergistically inhibited proliferation, induced apoptosis and cell cycle arrest, induced cleavage of poly(ADPribose) polymerase and caspase 8/caspase 9, and dysregulated signaling in the phosphatidylinositol 3 kinase/AKT/mTOR and cyclin D1/retinoblastoma pathways. In addition, we showed that both 17 AAG and rapamycin inhibited angiogenesis and osteoclast formation, indicating that these agents target not only multiple myeloma cells but also the bone marrow microenvironment.
   Conclusions: These studies provide the basis for potential clinical evaluation of this combination for multiple myeloma patients.
C1 Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA.
   Univ Pittsburgh, Inst Canc, Dept Internal Med, Div Hematol Oncol, Pittsburgh, PA USA.
   Harvard Univ, Sch Med, Boston, MA USA.
   Mayo Clin, Coll Med, Rochester, MN USA.
C3 Harvard University; Harvard University Medical Affiliates; Dana Farber
   Cancer Institute; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Harvard University; Harvard Medical
   School; Mayo Clinic
RP Ghobrial, IM (通讯作者)，Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, 44 Binney St,Mayer 548A, Boston, MA 02115 USA.
EM irene_ghobrial@dfci.harvard.edu
RI LELEU, Xavier/ABP 5732 2022; Anderson, Kenneth/ACP 5073 2022
CR Barlogie B, 2001, SEMIN ONCOL, V28, P577
   Bergsagel PL, 2005, BLOOD, V106, P296, DOI 10.1182/blood 2005 01 0034
   Bergsagel PL, 2003, IMMUNOL REV, V194, P96, DOI 10.1034/j.1600 065X.2003.00052.x
   Chauhan D, 2003, INT J HEMATOL, V78, P114, DOI 10.1007/BF02983378
   Dancey JE, 2004, ANN ONCOL, V15, P233, DOI 10.1093/annonc/mdh932
   Dancey JE, 2002, HEMATOL ONCOL CLIN N, V16, P1101, DOI 10.1016/S0889 8588(02)00051 5
   Descamps G, 2004, J IMMUNOL, V173, P4953, DOI 10.4049/jimmunol.173.8.4953
   Frost P, 2004, BLOOD, V104, P4181, DOI 10.1182/blood 2004 03 1153
   Gera JF, 2004, J BIOL CHEM, V279, P2737, DOI 10.1074/jbc.M309999200
   Goetz MP, 2005, J CLIN ONCOL, V23, P1078, DOI 10.1200/JCO.2005.09.119
   Guba M, 2005, TRANSPL INT, V18, P89, DOI 10.1111/j.1432 2277.2004.00026.x
   Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202 128
   Helmbrecht K, 2000, CELL PROLIFERAT, V33, P341, DOI 10.1046/j.1365 2184.2000.00189.x
   Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091
   Hideshima T, 2002, NAT REV CANCER, V2, P927, DOI 10.1038/nrc952
   Hideshima T, 2004, BLOOD, V104, P607, DOI 10.1182/blood 2004 01 0037
   Hideshima T, 2006, BLOOD, V107, P4053, DOI 10.1182/blood 2005 08 3434
   Jagannath S, 2005, CANCER AM CANCER SOC, V103, P1195, DOI 10.1002/cncr.20888
   Kaur G, 2004, CLIN CANCER RES, V10, P4813, DOI 10.1158/1078 0432.CCR 03 0795
   Lee JW, 2004, BLOOD, V103, P2308, DOI 10.1182/blood 2003 06 1992
   Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433
   Maloney A, 2002, EXPERT OPIN BIOL TH, V2, P3, DOI 10.1517/14712598.2.1.3
   Maloney A, 2003, CURR CANCER DRUG TAR, V3, P331, DOI 10.2174/1568009033481822
   Menu E, 2004, BRIT J CANCER, V90, P1076, DOI 10.1038/sj.bjc.6601613
   Mitsiades CS, 2006, BLOOD, V107, P1092, DOI 10.1182/blood 2005 03 1158
   Mitsiades N, 2004, BLOOD, V104, p418A, DOI 10.1182/blood.V104.11.1496.1496
   Mitsiades N, 2002, BLOOD, V99, P4525, DOI 10.1182/blood.V99.12.4525
   Münster PN, 2001, CANCER RES, V61, P2945
   Oba Y, 2005, EXP HEMATOL, V33, P272, DOI 10.1016/j.exphem.2004.11.015
   Pene F, 2002, ONCOGENE, V21, P6587, DOI 10.1038/sj.onc.1205923
   Picard D, 2002, CELL MOL LIFE SCI, V59, P1640, DOI 10.1007/PL00012491
   Raje N, 2004, BLOOD, V104, P4188, DOI 10.1182/blood 2004 06 2281
   Rajkumar SV, 2001, BRIT J HAEMATOL, V113, P565, DOI 10.1046/j.1365 2141.2001.02690.x
   Richardson PG, 2005, BLOOD, V106, p109A
   Roodman GD, 2004, BLOOD CELL MOL DIS, V32, P290, DOI 10.1016/j.bcmd.2004.01.001
   Shi YJ, 2002, CANCER RES, V62, P5027
   Zhang J, 2003, ONCOGENE, V22, P6289, DOI 10.1038/sj.onc.1206718
NR 37
TC 83
Z9 92
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1078 0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD NOV 15
PY 2006
VL 12
IS 22
BP 6826
EP 6835
DI 10.1158/1078 0432.CCR 06 1331
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 108TY
UT WOS:000242263300030
PM 17121904
OA Bronze
DA 2025 08 17
ER

PT J
AU Higgs, JT
   Lee, JH
   Wang, H
   Ramani, VC
   Chanda, D
   Hardy, CY
   Sanderson, RD
   Ponnazhagan, S
AF Higgs, Jerome T.
   Lee, Joo Hyoung
   Wang, Hong
   Ramani, Vishnu C.
   Chanda, Diptiman
   Hardy, Cherlene Y.
   Sanderson, Ralph D.
   Ponnazhagan, Selvarangan
TI Mesenchymal stem cells expressing osteoprotegerin variants inhibit
   osteolysis in a murine model of multiple myeloma
SO BLOOD ADVANCES
LA English
DT Article
ID CANCER PATIENTS; RECEPTOR ACTIVATOR; POTENTIAL ROLE; STROMAL CELLS;
   BONE DISEASE; IN VITRO; LIGAND; TRAIL; OSTEONECROSIS; APOPTOSIS
AB The current treatment options for multiple myeloma (MM) osteolytic lesions are mainly combinations of chemotherapy and other small molecule inhibitors, but toxic side effects still remain a major concern. Studies have shown that osteoclast activity is enhanced in MM patients through increased expression of receptor activator of nuclear factor kappa B ligand (RANKL), triggering RANK signaling on osteoclast precursors, which results in aggressive bone resorption. Furthermore, osteoprotegerin (OPG), a decoy receptor for RANKL, and the osteogenic potential of mesenchymal stem cells (MSCs) are significantly decreased in myeloma patients with multiple bone lesions. Thus, the use of OPG as a therapeutic molecule would greatly decrease osteolytic damage and reduce morbidity. However, in addition to inhibiting osteoclast activation, OPG binds to tumor necrosis factor related apoptosis inducing ligand (TRAIL), thereby rendering the tumor cells resistant to TRAIL induced apoptosis and limiting the use of OPG for therapy. The present study developed a bone disseminated myeloma disease model in mouse and successfully tested a cell therapy approach using MSCs, genetically engineered to express OPG variants that retain the capacity to bind RANKL, but do not bind TRAIL. Our results of skeletal remodeling following this regenerative stem cell therapy with OPG variants indicated a significant protection against myeloma induced osteolytic bone damage in areas of major myeloma skeletal dissemination, suggesting the potential of this therapy for treating osteolytic damage in myeloma patients.
C1 [Higgs, Jerome T.; Lee, Joo Hyoung; Wang, Hong; Ramani, Vishnu C.; Chanda, Diptiman; Sanderson, Ralph D.; Ponnazhagan, Selvarangan] Univ Alabama Birmingham, Dept Pathol, 1825 Univ Blvd,SHEL 814, Birmingham, AL 35294 USA.
   [Hardy, Cherlene Y.] Univ Alabama Birmingham, Dept Radiat Oncol, Birmingham, AL USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Ponnazhagan, S (通讯作者)，Univ Alabama Birmingham, Dept Pathol, 1825 Univ Blvd,SHEL 814, Birmingham, AL 35294 USA.
EM pons@uab.edu
RI Lee, Joo/A 7713 2017
FU National Institutes of Health, National Cancer Institute [R01CA133737,
   R01CA184770, R01CA138340]; National Institute of Arthritis and
   Musculoskeletal and Skin Diseases [R01AR060948]
FX This work was supported by National Institutes of Health, National
   Cancer Institute grants R01CA133737 (S.P.), R01CA184770 (S.P.), and
   R01CA138340 (R.D.S.), and National Institute of Arthritis and
   Musculoskeletal and Skin Diseases grant R01AR060948 (S.P.).
CR Berenson James R, 2011, Curr Opin Support Palliat Care, V5, P233, DOI 10.1097/SPC.0b013e328349dc17
   Bosman MCJ, 2014, J BIOL CHEM, V289, P1071, DOI 10.1074/jbc.M113.491589
   Broek IV, 2008, CLIN EXP METASTAS, V25, P325, DOI 10.1007/s10585 007 9108 4
   Chanda D, 2010, J CELL BIOCHEM, V111, P249, DOI 10.1002/jcb.22701
   Chanda D, 2009, CLIN CANCER RES, V15, P7175, DOI 10.1158/1078 0432.CCR 09 1938
   Cho SW, 2009, MOL THER, V17, P1979, DOI 10.1038/mt.2009.153
   Conte PF, 1996, J CLIN ONCOL, V14, P2552, DOI 10.1200/JCO.1996.14.9.2552
   Corre J, 2007, LEUKEMIA, V21, P1079, DOI 10.1038/sj.leu.2404621
   Meirelles LDS, 2006, J CELL SCI, V119, P2204, DOI 10.1242/jcs.02932
   Farrugia AN, 2003, CANCER RES, V63, P5438
   Feige U, 2001, ANN RHEUM DIS, V60, pIII81
   Garderet L, 2007, LEUKEMIA LYMPHOMA, V48, P2032, DOI 10.1080/10428190701593644
   Gazitt Y, 1999, LEUKEMIA, V13, P1817, DOI 10.1038/sj.leu.2401501
   Giuliani N, 2001, BLOOD, V98, P3527, DOI 10.1182/blood.V98.13.3527
   Gunn WG, 2006, STEM CELLS, V24, P986, DOI 10.1634/stemcells.2005 0220
   Higgs JT, 2015, MOL CANCER RES, V13, P819, DOI 10.1158/1541 7786.MCR 14 0492
   Jöhrer K, 2004, CLIN CANCER RES, V10, P1901, DOI 10.1158/1078 0432.CCR 1053 03
   Khakoo AY, 2006, J EXP MED, V203, P1235, DOI 10.1084/jem.20051921
   Khotskaya YB, 2009, J BIOL CHEM, V284, P26085, DOI 10.1074/jbc.M109.018473
   Koç ON, 2000, J CLIN ONCOL, V18, P307, DOI 10.1200/JCO.2000.18.2.307
   Kumar S, 2008, GENE THER, V15, P711, DOI 10.1038/gt.2008.35
   Kyle RA, 2004, NEW ENGL J MED, V351, P1860, DOI 10.1056/NEJMra041875
   Kyle RA, 2004, CANCER AM CANCER SOC, V101, P2667, DOI 10.1002/cncr.20652
   Lincz LF, 2001, LEUKEMIA, V15, P1650, DOI 10.1038/sj.leu.2402251
   MCSHEEHY PMJ, 1986, ENDOCRINOLOGY, V119, P1654, DOI 10.1210/endo 119 4 1654
   Mitsiades CS, 2001, BLOOD, V98, P795, DOI 10.1182/blood.V98.3.795
   Molloy AP, 2009, INT J CANCER, V124, P326, DOI 10.1002/ijc.23939
   Ning H, 2008, LEUKEMIA, V22, P593, DOI 10.1038/sj.leu.2405090
   Oshita K, 2011, ARTHRITIS RHEUM US, V63, P1658, DOI 10.1002/art.30309
   Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442
   Pierce M, 1996, NEW ENGL J MED, V335, P384, DOI 10.1056/NEJM199608083350603
   Ponnazhagan S, 2004, CANCER RES, V64, P1781, DOI 10.1158/0008 5472.CAN 03 1786
   Pozzi S, 2011, ONCOLOGIST, V16, P651, DOI 10.1634/theoncologist.2010 0225
   Rabin N, 2007, LEUKEMIA, V21, P2181, DOI 10.1038/sj.leu.2404814
   Raje N, 2008, CLIN CANCER RES, V14, P2387, DOI 10.1158/1078 0432.CCR 07 1430
   Ramani VC, 2011, J BIOL CHEM, V286, P6490, DOI 10.1074/jbc.M110.183277
   Reagan MR, 2012, J BREAST CANCER, V15, P273, DOI 10.4048/jbc.2012.15.3.273
   Ren CC, 2008, STEM CELLS, V26, P2332, DOI 10.1634/stemcells.2008 0084
   Roodman GD, 2009, LEUKEMIA, V23, P435, DOI 10.1038/leu.2008.336
   Saad F, 2012, ANN ONCOL, V23, P1341, DOI 10.1093/annonc/mdr435
   SANDERSON RD, 1992, J IMMUNOL, V148, P3902
   Sezer O, 2003, BLOOD, V101, P2094, DOI 10.1182/blood 2002 09 2684
   Shane E, 2014, J BONE MINER RES, V29, P1, DOI 10.1002/jbmr.1998
   Standal T, 2002, BLOOD, V100, P3002, DOI 10.1182/blood 2002 04 1190
   Studeny M, 2004, JNCI J NATL CANCER I, V96, P1593, DOI 10.1093/jnci/djh299
   Suzuki K, 2013, JPN J CLIN ONCOL, V43, P116, DOI 10.1093/jjco/hys215
   Terpos E, 2003, BLOOD, V102, P1064, DOI 10.1182/blood 2003 02 0380
   Terpos E, 2013, J CLIN ONCOL, V31, P2347, DOI 10.1200/JCO.2012.47.7901
   Todoerti K, 2010, EXP HEMATOL, V38, P141, DOI 10.1016/j.exphem.2009.11.009
   Tropel P, 2004, EXP CELL RES, V295, P395, DOI 10.1016/j.yexcr.2003.12.030
   Vanderkerken K, 2003, CANCER RES, V63, P287
   Vescovi P, 2012, J ORAL PATHOL MED, V41, P214, DOI 10.1111/j.1600 0714.2011.01091.x
   Vitovski S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035830
   Waterman Gabriel N, 2011, J Bone Joint Surg Am, V93, pe106, DOI 10.2106/JBJS.J.00455
   Williams AR, 2011, CIRC RES, V109, P923, DOI 10.1161/CIRCRESAHA.111.243147
   Xu S, 2012, STEM CELLS, V30, P266, DOI 10.1002/stem.787
   Yaccoby S, 2010, LEUKEMIA LYMPHOMA, V51, P213, DOI 10.3109/10428190903503438
   Yang Y, 2010, CANCER RES, V70, P8329, DOI 10.1158/0008 5472.CAN 10 2179
   Yu R, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.19
NR 59
TC 11
Z9 12
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 2473 9529
EI 2473 9537
J9 BLOOD ADV
JI Blood Adv.
PD NOV 28
PY 2017
VL 1
IS 25
BP 2375
EP 2385
DI 10.1182/bloodadvances.2017007310
PG 11
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA FN9YB
UT WOS:000416397700009
PM 29296887
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Ascolani, G
   Skerry, TM
   Lacroix, D
   Dall'Ara, E
   Shuaib, A
AF Ascolani, Gianluca
   Skerry, Timothy M.
   Lacroix, Damien
   Dall'Ara, Enrico
   Shuaib, Aban
TI Revealing hidden information in osteoblast's mechanotransduction through
   analysis of time patterns of critical events
SO BMC BIOINFORMATICS
LA English
DT Article
DE Osteoblast mechanotransduction; Molecular network; Fluctuations;
   Subordination theory; Directing process; Waiting time distribution
ID MECHANICAL SIGNALS; LOW MAGNITUDE; SUBORDINATION; INHIBITORS; FREQUENCY;
   GLUTAMATE; PATHWAYS; MODEL
AB Background Mechanotransduction in bone cells plays a pivotal role in osteoblast differentiation and bone remodelling. Mechanotransduction provides the link between modulation of the extracellular matrix by mechanical load and intracellular activity. By controlling the balance between the intracellular and extracellular domains, mechanotransduction determines the optimum functionality of skeletal dynamics. Failure of this relationship was suggested to contribute to bone related diseases such as osteoporosis. Results A hybrid mechanical and agent based model (Mech ABM), simulating mechanotransduction in a single osteoblast under external mechanical perturbations, was utilised to simulate and examine modulation of the activation dynamics of molecules within mechanotransduction on the cellular response to mechanical stimulation. The number of molecules and their fluctuations have been analysed in terms of recurrences of critical events. A numerical approach has been developed to invert subordination processes and to extract the direction processes from the molecular signals in order to derive the distribution of recurring events. These predict that there are large fluctuations enclosing information hidden in the noise which is beyond the dynamic variations of molecular baselines. Moreover, studying the system under different mechanical load regimes and altered dynamics of feedback loops, illustrate that the waiting time distributions of each molecule are a signature of the system's state. Conclusions The behaviours of the molecular waiting times change with the changing of mechanical load regimes and altered dynamics of feedback loops, presenting the same variation of patterns for similar interacting molecules and identifying specific alterations for key molecules in mechanotransduction. This methodology could be used to provide a new tool to identify potent molecular candidates to modulate mechanotransduction, hence accelerate drug discovery towards therapeutic targets for bone mass upregulation.
C1 [Ascolani, Gianluca; Skerry, Timothy M.; Dall'Ara, Enrico; Shuaib, Aban] Univ Sheffield, Dept Oncol & Metab, Sheffield, S Yorkshire, England.
   [Ascolani, Gianluca; Lacroix, Damien; Dall'Ara, Enrico; Shuaib, Aban] Univ Sheffield, Insigneo Inst Silico Med, Sheffield, S Yorkshire, England.
   [Lacroix, Damien] Univ Sheffield, Dept Mech Engn, Sheffield, S Yorkshire, England.
C3 University of Sheffield; University of Sheffield; University of
   Sheffield
RP Shuaib, A (通讯作者)，Univ Sheffield, Dept Oncol & Metab, Sheffield, S Yorkshire, England.; Shuaib, A (通讯作者)，Univ Sheffield, Insigneo Inst Silico Med, Sheffield, S Yorkshire, England.
EM aban.shuaib@sheffield.ac.uk
RI Dall'Ara, Enrico/ABA 5046 2020; Lacroix, Damien/G 3230 2010
OI Shuaib, Aban/0000 0002 6137 8205; Lacroix, Damien/0000 0002 5482 6006;
   Dall'Ara, Enrico/0000 0003 1471 5077; 
FU Engineering and Physical Sciences Research Council (EPSRC)
   [EP/K03877X/1]; EPSRC [EP/K03877X/1] Funding Source: UKRI; Engineering
   and Physical Sciences Research Council [EP/K03877X/1] Funding Source:
   researchfish
FX This study was funded by the Engineering and Physical Sciences Research
   Council (EPSRC), Frontier Engineering Multiscale modelling of the
   skeleton: EP/K03877X/1. The funders did not participate in the design of
   the study and collection, analysis, and interpretation of data and in
   writing the manuscript.
CR Ali AM, 2019, COMPUT STRUCT BIOTEC, V17, P263, DOI 10.1016/j.csbj.2019.01.012
   Alonso J. L., 2016, TRANSPORT, V1, P7
   Arkin MR, 2014, CHEM BIOL, V21, P1102, DOI 10.1016/j.chembiol.2014.09.001
   Ascolani G, 2009, PHYSICA A, V388, P2727, DOI 10.1016/j.physa.2009.03.025
   Barreto S, 2013, BIOMATERIALS, V34, P6119, DOI 10.1016/j.biomaterials.2013.04.022
   Bartocci E, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004591
   Batra N, 2012, P NATL ACAD SCI USA, V109, P3359, DOI 10.1073/pnas.1115967109
   Bohara G, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01174
   Buo AM, 2014, FEBS LETT, V588, P1315, DOI 10.1016/j.febslet.2014.01.025
   Burge RT, 2001, VALUE HEALTH, V4, P67, DOI [10.1046/j.1524 4733.2001.40202 3.x, DOI 10.1046/J.1524 4733.2001.40202 3.X]
   Capulli M, 2014, ARCH BIOCHEM BIOPHYS, V561, P3, DOI 10.1016/j.abb.2014.05.003
   Charras G, 2018, CURR BIOL, V28, pR445, DOI 10.1016/j.cub.2018.02.003
   D'Antonio G, 2013, MATH BIOSCI ENG, V10, P75, DOI 10.3934/mbe.2013.10.75
   Dickman R, 1999, PHYS REV E, V60, pR2441, DOI 10.1103/PhysRevE.60.R2441
   Fisher J, 2007, NAT BIOTECHNOL, V25, P1239, DOI 10.1038/nbt1356
   Friedl P, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a029199
   Frith JE, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02486 0
   Fujioka A, 2006, J BIOL CHEM, V281, P8917, DOI 10.1074/jbc.M509344200
   Fullstone G, 2015, SCI REP UK, V5, DOI 10.1038/srep10649
   Gesty Palmer D, 2011, BRIT J PHARMACOL, V164, P59, DOI 10.1111/j.1476 5381.2011.01450.x
   Gesty Palmer D, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000071
   Glen CM, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/journal.pcbi.1006577
   Gorenflo R, 2011, EUR PHYS J SPEC TOP, V193, P119, DOI 10.1140/epjst/e2011 01386 2
   Grabowski F, 2019, J R SOC INTERFACE, V16, DOI 10.1098/rsif.2018.0792
   Harris AR, 2018, ANNU REV BIOPHYS, V47, P617, DOI 10.1146/annurev biophys 070816 033547
   HOLLAND JH, 1991, AM ECON REV, V81, P365
   Humphrey JD, 2014, NAT REV MOL CELL BIO, V15, P802, DOI 10.1038/nrm3896
   Hwang JH, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 03815 5
   Hwang JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135519
   Jiang JX, 2007, FRONT BIOSCI LANDMRK, V12, P1450, DOI 10.2741/2159
   Judex S, 2007, J BIOMECH, V40, P1333, DOI 10.1016/j.jbiomech.2006.05.014
   Jurchenko C, 2015, MOL CELL BIOL, V35, P2570, DOI 10.1128/MCB.00195 15
   Klann M, 2012, INT J MOL SCI, V13, P7798, DOI 10.3390/ijms13067798
   Klann MT, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752 0509 5 71
   Kochanczyk M, 2017, SCI REP UK, V7, DOI 10.1038/srep38244
   Legewie S, 2007, BIOPHYS J, V93, P2279, DOI 10.1529/biophysj.107.109132
   Li CX, 2017, NAT MATER, V16, P379, DOI [10.1038/NMAT4780, 10.1038/nmat4780]
   Li SN, 2018, EUR J ORTHODONT, V40, P537, DOI 10.1093/ejo/cjx099
   Lin XX, 2016, BIOMED MATER, V11, DOI 10.1088/1748 6041/11/1/014109
   Liu LY, 2014, J TISSUE ENG REGEN M, V8, P85, DOI 10.1002/term.1498
   Livne A, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4938
   Luo TZ, 2013, NAT MATER, V12, P1063, DOI [10.1038/nmat3772, 10.1038/NMAT3772]
   Magdevska L, 2018, BMC BIOINFORMATICS, V19, DOI 10.1186/s12859 018 2366 0
   Martino F, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00824
   Mitra T, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 31626 9
   Mogil RJ, 2016, JAMA ONCOL, V2, P908, DOI 10.1001/jamaoncol.2015.6557
   MONTROLL EW, 1965, J MATH PHYS, V6, P167, DOI 10.1063/1.1704269
   Muhamed Ismaeel, 2017, Bioengineering Basel, V4, DOI 10.3390/bioengineering4010012
   Mullen CA, 2013, J MECH BEHAV BIOMED, V28, P183, DOI 10.1016/j.jmbbm.2013.06.013
   Oh SH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188749
   Okamoto T, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112254
   Papachroni KK, 2009, TRENDS MOL MED, V15, P208, DOI 10.1016/j.molmed.2009.03.001
   Peng T, 2017, BMC SYST BIOL, V11, DOI 10.1186/s12918 017 0429 x
   Pogson M, 2006, BIOSYSTEMS, V85, P37, DOI 10.1016/j.biosystems.2006.02.004
   Pogson M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002367
   Purutçuoglu V, 2012, MATH PROBL ENG, V2012, DOI 10.1155/2012/752631
   Radhakrishnan K, 2009, IET SYST BIOL, V3, P329, DOI 10.1049/iet syb.2009.0010
   Rhodes DM, 2016, BIOSYSTEMS, V147, P21, DOI 10.1016/j.biosystems.2016.06.002
   Richmond P, 2010, BRIEF BIOINFORM, V11, P334, DOI 10.1093/bib/bbp073
   Rubin C, 2001, NATURE, V412, P603, DOI 10.1038/35088122
   Schneider GB, 2001, J DENT RES, V80, P1540, DOI 10.1177/00220345010800061201
   Shams H, 2017, ACS BIOMATER SCI ENG, V3, P2712, DOI 10.1021/acsbiomaterials.7b00117
   Shekaran A, 2014, BONE, V68, P131, DOI 10.1016/j.bone.2014.08.008
   Shuaib A, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 47958 z
   Shuaib A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156139
   Skerry T. M., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P166
   Skerry Tim, 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P401
   Skerry TM, 2001, CURR PHARM DESIGN, V7, P737, DOI 10.2174/1381612013397771
   Sokolov IM, 2005, CHAOS, V15, DOI 10.1063/1.1860472
   Vincent TL, 2013, CURR OPIN PHARMACOL, V13, P449, DOI 10.1016/j.coph.2013.01.010
   Wang N, 2017, J PHYS D APPL PHYS, V50, DOI 10.1088/1361 6463/aa6e18
   Yan YX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035709
   Yang C, 2014, NAT MATER, V13, P645, DOI [10.1038/NMAT3889, 10.1038/nmat3889]
   Yang JM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 07150 9
   Yap AS, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028761
   Yavropoulou MP, 2016, J MUSCULOSKEL NEURON, V16, P221
   Zarzycka B, 2016, DRUG DISCOV TODAY, V21, P48, DOI 10.1016/j.drudis.2015.09.011
NR 77
TC 3
Z9 3
U1 1
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471 2105
J9 BMC BIOINFORMATICS
JI BMC Bioinformatics
PD MAR 18
PY 2020
VL 21
IS 1
AR 114
DI 10.1186/s12859 020 3394 0
PG 19
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
GA KW6YI
UT WOS:000521328100006
PM 32183690
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Barbosa, JS
   Paz, FAA
   Braga, SS
AF Barbosa, Jessica S.
   Almeida Paz, Filipe A.
   Braga, Susana Santos
TI Bisphosphonates, Old Friends of Bones and New Trends in Clinics
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID IN VITRO EVALUATION; 1 PERCENT ALENDRONATE GEL; LOCAL DRUG DELIVERY;
   NITROGEN CONTAINING BISPHOSPHONATES; HIV 1 REVERSE TRANSCRIPTASE;
   RHEUMATOID ARTHRITIS; ZOLEDRONIC ACID; MEVALONATE PATHWAY; INTRAVENOUS
   BISPHOSPHONATE; OSTEOGENESIS IMPERFECTA
AB Bisphosphonates, used for a long time in osteoporosis management, are currently the target of intensive research, from pre formulation studies to more advanced stages of clinical practice. This review presents an overview of the contributions of this family of compounds to human health, starting with the chemistry and clinical uses of bisphosphonates. Following this, their pharmacology is described, highlighting administration borne handicaps and undesirable effects. The last three sections of the review describe the research efforts that seek to curb delivery related issues and expand bisphosphonate use. Innovative routes and strategies of administration, such as nano encapsulation for oral intake or injectable cements for local or in bone delivery are presented, as well as the latest results of case studies or preclinical studies proposing new therapeutic indications for the clinically approved bisphosphonates. Finally, a selection of anti infectious bisphosphonate new drug candidates is shown, with focus on the molecules reported in the last two decades.
C1 [Barbosa, Jessica S.; Almeida Paz, Filipe A.] Univ Aveiro, CICECO Aveiro Inst Mat, P 3810193 Aveiro, Portugal.
   [Barbosa, Jessica S.; Braga, Susana Santos] Univ Aveiro, LAQV Requimte, Dept Chem, P 3810193 Aveiro, Portugal.
C3 Universidade de Aveiro; Universidade de Aveiro
RP Braga, SS (通讯作者)，Univ Aveiro, LAQV Requimte, Dept Chem, P 3810193 Aveiro, Portugal.
EM sbraga@ua.pt
RI Barbosa, Jéssica/AAI 5044 2020; Braga, Susana/G 2383 2010; Paz,
   Filipe/F 3430 2010; Santos Braga, Susana/G 2383 2010
OI Almeida Paz, Filipe/0000 0003 2051 5645; Santos Braga,
   Susana/0000 0003 4460 970X
FU Foundation for Science and Technology/MCTES [FCT UID/QUI/00062/2019,
   UIDB/50006/2020, UIDB/50011/2020, UIDP/50011/2020]; FEDER; FCT
   [PD/BD/135104/2017]; University of Aveiro; Fundação para a Ciência e a
   Tecnologia [PD/BD/135104/2017] Funding Source: FCT
FX Thanks are due to the University of Aveiro and Foundation for Science
   and Technology/MCTES for the financial support for the QOPNA research
   Unit (FCT UID/QUI/00062/2019), to the associated laboratory
   LAQV REQUIMTE (project reference UIDB/50006/2020) and to CICECO Aveiro
   Institute of Materials (UIDB/50011/2020 & UIDP/50011/2020), through
   national founds and, where applicable, cofinanced by the FEDER, within
   the PT2020 Partnership Agreement, and to the Portuguese NMR Network. We
   also thank FCT for the Ph.D. grant No. PD/BD/135104/2017 to J.S.B.
CR Abtahi J, 2012, BONE, V50, P1148, DOI 10.1016/j.bone.2012.02.001
   Adler RA, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.1
   Ahlmark M, 1999, J MED CHEM, V42, P1473, DOI 10.1021/jm9810809
   AMJAD Z, 1987, LANGMUIR, V3, P1063, DOI 10.1021/la00078a032
   Andreeva OI, 2001, MOL BIOL+, V35, P717, DOI 10.1023/A:1012330521865
   Antoniazzi F, 2006, J PEDIATR US, V149, P174, DOI 10.1016/j.jpeds.2006.03.013
   Barbosa JS, 2020, MOLECULES, V25, DOI 10.3390/molecules25122821
   Baroncelli GI, 2014, HORM RES PAEDIAT, V82, P290, DOI 10.1159/000365889
   Biernacka J, 2013, ACTA POL PHARM, V70, P877
   Biggin A, 2017, CURR OSTEOPOROS REP, V15, P412, DOI 10.1007/s11914 017 0401 0
   BLACK DM, 2007, NEW ENGL J MED, V356, P1809, DOI DOI 10.1056/NEJMOA067312
   Bobyn JD, 2009, J BONE JOINT SURG AM, V91A, P23, DOI 10.2106/JBJS.I.00518
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Boskey AL., 2006, Dynamics of Bone and Cartilage Metabolism, VSecond, P201
   Breuil V, 2006, JOINT BONE SPINE, V73, P349, DOI 10.1016/j.jbspin.2005.10.019
   Buhaescu I, 2007, CLIN BIOCHEM, V40, P575, DOI 10.1016/j.clinbiochem.2007.03.016
   Cantatore FP, 1999, J RHEUMATOL, V26, P2318
   Carroll MF, 2003, AM FAM PHYSICIAN, V67, P1959
   Chai ECC, 2013, CLIN GENET, V83, P527, DOI 10.1111/cge.12136
   Coleman R, 2015, LANCET, V386, P1353, DOI 10.1016/S0140 6736(15)60908 4
   Coppens I, 1996, EXP PARASITOL, V82, P76, DOI 10.1006/expr.1996.0011
   Cormier Daire V, 2003, J MED GENET, V40, P195, DOI 10.1136/jmg.40.3.195
   Corral Gudino Luis, 2017, Cochrane Database Syst Rev, V12, pCD004956, DOI 10.1002/14651858.CD004956.pub3
   Cremers S, 2011, BONE, V49, P42, DOI 10.1016/j.bone.2011.01.014
   De Geeter F, 2007, CLIN NUCL MED, V32, P32, DOI 10.1097/01.rlu.0000249545.85131.5f
   deGroen PC, 1996, NEW ENGL J MED, V335, P1016, DOI 10.1056/NEJM199610033351403
   Deshpande P. B., 2008, U.S. Patent, Patent No. 7439385
   DEVOGELAER JP, 1987, SKELETAL RADIOL, V16, P360, DOI 10.1007/BF00350961
   DIAERESISINEN JVS, 2002, CURR MED CHEM, V9, P1201
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Ezra A, 2000, ADV DRUG DELIVER REV, V42, P175, DOI 10.1016/S0169 409X(00)00061 2
   Ezra A, 2000, J MED CHEM, V43, P3641, DOI 10.1021/jm980645y
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   FLEISCH H, 1969, SCIENCE, V165, P1262, DOI 10.1126/science.165.3899.1262
   FLEISCH HA, 1970, EUR J CLIN INVEST, V1, P12, DOI 10.1111/j.1365 2362.1970.tb00591.x
   FLEISH H, 1961, AM J PHYSIOL, V200, P1296, DOI 10.1152/ajplegacy.1961.200.6.1296
   Frith JC, 2001, ARTHRITIS RHEUM, V44, P2201, DOI 10.1002/1529 0131(200109)44:9<2201::AID ART374>3.0.CO;2 E
   Fu SH, 2017, J BONE JOINT SURG AM, V99, P938, DOI 10.2106/JBJS.16.00385
   Gabelli SB, 2006, PROTEINS, V62, P80, DOI 10.1002/prot.20754
   Gao Y, 2009, BONE, V44, P225, DOI 10.1016/j.bone.2008.10.054
   Ghosh S, 2004, J MED CHEM, V47, P175, DOI 10.1021/jm030084x
   Gluz E, 2013, POLYMER, V54, P565, DOI 10.1016/j.polymer.2012.11.071
   Goldring SR, 2008, RHEUM DIS CLIN N AM, V34, P561, DOI 10.1016/j.rdc.2008.07.001
   Green J, 2010, BMJ BRIT MED J, V341, DOI 10.1136/bmj.c4444
   GRUSPACINGDIAER.A, 2019, NAT METAB, V1, P236, DOI DOI 10.1038/s42255 018 0016 5
   Guo RT, 2007, P NATL ACAD SCI USA, V104, P10022, DOI 10.1073/pnas.0702254104
   Hamdan A, 2005, EUR RADIOL, V15, P840, DOI 10.1007/s00330 004 2560 5
   Han HK, 2012, EUR J PHARM SCI, V46, P500, DOI 10.1016/j.ejps.2012.04.002
   Henrotin Y, 2012, OSTEOPOROSIS INT, V23, pS847, DOI 10.1007/s00198 012 2162 z
   Hernlund E., 2013, ARCH OSTEOPOROS, V8, P1, DOI DOI 10.1007/S11657 013 0136 1
   Hirabayashi H, 2001, J CONTROL RELEASE, V70, P183, DOI 10.1016/S0168 3659(00)00355 2
   Holroyd C, 2008, BEST PRACT RES CL EN, V22, P671, DOI 10.1016/j.beem.2008.06.001
   Hosny KM, 2013, EXPERT OPIN DRUG DEL, V10, P741, DOI 10.1517/17425247.2013.799136
   Houghton TJ, 2008, J MED CHEM, V51, P6955, DOI 10.1021/jm801007z
   Houshmand B, 2007, J PERIODONTAL RES, V42, P119, DOI 10.1111/j.1600 0765.2006.00923.x
   HYLDSTRUP L, 1993, CALCIFIED TISSUE INT, V53, P297, DOI 10.1007/BF01351831
   Iida A, 2013, J HUM GENET, V58, P391, DOI 10.1038/jhg.2013.25
   Ilyas Z, 2019, CURR OPIN ENDOCRINOL, V26, P335, DOI 10.1097/MED.0000000000000501
   Jornada DH, 2016, MOLECULES, V21, DOI 10.3390/molecules21010042
   Kang Ho, 2017, J Bone Metab, V24, P97
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Kempfle JS, 2018, BIOCONJUGATE CHEM, V29, P1240, DOI 10.1021/acs.bioconjchem.8b00022
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Khan Masood A, 2003, Rev Urol, V5, P204
   Khan SA, 1997, J BONE MINER RES, V12, P1700, DOI 10.1359/jbmr.1997.12.10.1700
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Khwaja A, 2015, FRONT PEDIATR, V3, DOI 10.3389/fped.2015.00048
   Kieczykowski GR, 1995, J ORG CHEM, V60, P8310, DOI 10.1021/jo00130a036
   KING HL, 1977, BIOCHEMISTRY US, V16, P3815, DOI 10.1021/bi00636a015
   KLEIN G, 1988, BIOCHEMISTRY US, V27, P1897, DOI 10.1021/bi00406a015
   König D, 2018, NUTRIENTS, V10, DOI 10.3390/nu10010097
   KOPONEN HM, 1990, PHARMACOL TOXICOL, V66, P294
   Koren R, 2018, ARCH ENDOCRIN METAB, V62, P125, DOI 10.20945/2359 3997000000016
   Lacbay CM, 2014, J MED CHEM, V57, P7435, DOI 10.1021/jm501010f
   Lewis LES, 2010, INDIAN J PEDIATR, V77, P567, DOI 10.1007/s12098 010 0043 z
   Leyland Jones B, 2004, EJC SUPPL, V2, P9, DOI 10.1016/j.ejcsup.2004.01.003
   Lifshitz Liron Kovalevski Ishai, 2006, U.S. Patent, Patent No. [20060128960 A1, 20060128960]
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   Ling Y, 2005, J MED CHEM, V48, P3130, DOI 10.1021/jm040132t
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Macherey S, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006250.pub2
   Maines E, 2012, J BONE MINER METAB, V30, P434, DOI 10.1007/s00774 011 0331 3
   Mallik S, 2016, SUPPORT CARE CANCER, V24, P1771, DOI 10.1007/s00520 015 2962 8
   Malwal SR, 2019, J MED CHEM, V62, P2564, DOI 10.1021/acs.jmedchem.8b01878
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   Maricic, 2006, FUTURE RHEUMATOL, V1, P541
   Martin MB, 2002, J MED CHEM, V45, P2904, DOI 10.1021/jm0102809
   Martin MB, 2001, J MED CHEM, V44, P909, DOI 10.1021/jm0002578
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Marx Robert E, 2014, Int J Oral Maxillofac Implants, V29, pe247, DOI 10.11607/jomi.te61
   Matuszewski L, 2013, INT ORTHOP, V37, P1187, DOI 10.1007/s00264 013 1855 z
   McCadden L, 2018, J LARYNGOL OTOL, V132, P372, DOI 10.1017/S0022215118000324
   Merlotti D, 2007, J BONE MINER RES, V22, P1510, DOI 10.1359/JBMR.070704
   Mhaskar R, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD003188.pub3, 10.1002/14651858.CD003188.pub4]
   Migianu E, 2004, TETRAHEDRON LETT, V45, P4511, DOI 10.1016/j.tetlet.2004.04.047
   Mitchell DY, 2001, PHARMACEUT RES, V18, P166, DOI 10.1023/A:1011024200280
   Mönkkönen H, 2006, BRIT J PHARMACOL, V147, P437, DOI 10.1038/sj.bjp.0706628
   Monteil M, 2005, TETRAHEDRON, V61, P7528, DOI 10.1016/j.tet.2005.05.053
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Neogi T, 2018, ANN RHEUM DIS, V77, P92, DOI 10.1136/annrheumdis 2017 211811
   Niederkohr RD, 2013, CLIN NUCL MED, V38, P655, DOI 10.1097/RLU.0b013e3182952c18
   Niemi R, 1999, J MED CHEM, V42, P5053, DOI 10.1021/jm991109o
   Niemi R, 1998, INT J PHARM, V174, P111, DOI 10.1016/S0378 5173(98)00250 6
   Niemi R, 2000, EUR J PHARM SCI, V11, P173, DOI 10.1016/S0928 0987(00)00099 3
   Nishii T, 2013, CLIN RHEUMATOL, V32, P1759, DOI 10.1007/s10067 013 2338 8
   O'Carrigan B, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003474.pub4
   Odén A, 2013, CALCIFIED TISSUE INT, V92, P42, DOI 10.1007/s00223 012 9666 6
   OFFEL JV, 2005, CURR RHEUMATOL REV, V1, P125, DOI DOI 10.2174/1573397054023119
   Ohishi T, 2018, THER CLIN RISK MANAG, V14, P729, DOI 10.2147/TCRM.S149236
   Panagiotakou A, 2020, METABOLISM, V110, DOI 10.1016/j.metabol.2020.154264
   Papapoulos SE, 2006, BONE, V38, P613, DOI 10.1016/j.bone.2006.01.141
   Park YE, 2019, CALCIFIED TISSUE INT, V105, P497, DOI 10.1007/s00223 019 00590 5
   Peter B, 2006, J BIOMED MATER RES A, V76A, P133, DOI 10.1002/jbm.a.30456
   Petroianu GA, 2011, PHARMAZIE, V66, P804, DOI 10.1691/ph.2011.1053
   Piper PK, 2009, CLIN INTERV AGING, V4, P289
   POLGA JP, 1981, CLIN NUCL MED, V6, P416, DOI 10.1097/00003072 198109000 00009
   Porfírio Elisângela, 2016, Rev. bras. geriatr. gerontol., V19, P153
   Powell D, 2012, QJM INT J MED, V105, P965, DOI 10.1093/qjmed/hcs112
   Pozzi S, 2011, ONCOLOGIST, V16, P651, DOI 10.1634/theoncologist.2010 0225
   Pradeep AR, 2013, J PERIODONTOL, V84, P307, DOI 10.1902/jop.2012.110729
   Pradeep AR, 2012, J PERIODONTOL, V83, P1322, DOI 10.1902/jop.2012.110292
   Ralston S.H., 2013, Medicine, V41, P581, DOI [10.1016/j.mpmed.2013.07.007, DOI 10.1016/J.MPMED.2013.07.007]
   Ralston SH, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115465
   Ralston SH, 2020, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00924
   Ravn P, 1996, BONE, V19, P527, DOI 10.1016/S8756 3282(96)00229 3
   Reddy GT, 2005, DRUG DELIV, V12, P217, DOI 10.1080/10717540590952663
   Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010
   Reid IR, 2020, OSTEOPOROSIS INT, V31, P827, DOI 10.1007/s00198 019 05259 1
   Reid IR, 2011, BONE, V49, P89, DOI 10.1016/j.bone.2010.09.002
   REID IR, 1994, J CLIN ENDOCR METAB, V79, P1595, DOI 10.1210/jc.79.6.1595
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Rogers MJ, 2020, BONE, V139, DOI 10.1016/j.bone.2020.115493
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Rudnick Glick S, 2015, PROC SPIE, V9550, DOI 10.1117/12.2186765
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Sakkers R, 2004, LANCET, V363, P1427, DOI 10.1016/S0140 6736(04)16101 1
   Sanjad SA, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00240
   Sato M, 1999, J MED CHEM, V42, P1, DOI 10.1021/jm980344o
   Sedghizadeh PP, 2017, J MED CHEM, V60, P2326, DOI 10.1021/acs.jmedchem.6b01615
   Seibel Markus J, 2005, Clin Biochem Rev, V26, P97
   Seist R, 2020, FRONT MOL NEUROSCI, V13, DOI 10.3389/fnmol.2020.00087
   Semler O, 2011, HORM RES PAEDIAT, V76, P321, DOI 10.1159/000331128
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   Senthilkumar U.P., 2008, Patent, Patent No. [2008035131 A1, 2008035131, WO2008035131A1]
   Sharma A, 2012, J PERIODONTOL, V83, P11, DOI 10.1902/jop.2011.110091
   Sharma A, 2012, J PERIODONTOL, V83, P19, DOI 10.1902/jop.2011.110206
   Shi CG, 2016, AM J THER, V23, pe894, DOI 10.1097/MJT.0000000000000236
   Shmeeda H, 2013, J CONTROL RELEASE, V167, P265, DOI 10.1016/j.jconrel.2013.02.003
   Siris ES, 1997, J BONE MINER RES, V12, P691, DOI 10.1359/jbmr.1997.12.4.691
   Skjodt MK, 2019, BRIT J CLIN PHARMACO, V85, P1063, DOI 10.1111/bcp.13759
   Song YC, 2008, BIOORGAN MED CHEM, V16, P8959, DOI 10.1016/j.bmc.2008.08.047
   Srisubut S, 2007, ORAL SURG ORAL MED O, V104, pE11, DOI 10.1016/j.tripleo.2007.04.022
   STORM T, 1990, NEW ENGL J MED, V322, P1265, DOI 10.1056/NEJM199005033221803
   Tada M, 2017, RHEUMATOL INT, V37, P999, DOI 10.1007/s00296 017 3720 7
   Taguchi A, 2019, J BONE MINER METAB, V37, P886, DOI 10.1007/s00774 019 00990 5
   Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109 004 0612 6
   Tammireddy, 2009, WO Patent, Patent No. [2009034580 A1, 2009034580]
   Tanvetyanon T, 2006, ANN ONCOL, V17, P897, DOI 10.1093/annonc/mdj105
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Terpos E, 2013, BLOOD, V121, P3325, DOI 10.1182/blood 2012 10 435750
   Torstrick FB, 2014, CURR OSTEOPOROS REP, V12, P33, DOI 10.1007/s11914 014 0191 6
   Tyler K, 1999, AM J MED GENET, V83, P47, DOI 10.1002/(SICI)1096 8628(19990305)83:1<47::AID AJMG9>3.0.CO;2 5
   Urbina JA, 1999, J BIOL CHEM, V274, P33609, DOI 10.1074/jbc.274.47.33609
   Vachal P, 2006, J MED CHEM, V49, P3060, DOI 10.1021/jm060398v
   Van Acker HH, 2016, PHARMACOL THERAPEUT, V158, P24, DOI 10.1016/j.pharmthera.2015.11.008
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   Van den Wyngaert T, 2016, EUR J NUCL MED MOL I, V43, P1723, DOI 10.1007/s00259 016 3415 4
   Van Offel JF, 2001, CLIN EXP RHEUMATOL, V19, P13
   VANBEEK E, 1994, J BONE MINER RES, V9, P1875, DOI 10.1002/jbmr.5650091206
   Vaysbrot EE, 2018, OSTEOARTHR CARTILAGE, V26, P154, DOI 10.1016/j.joca.2017.11.013
   Verron E, 2014, ACTA BIOMATER, V10, P4887, DOI 10.1016/j.actbio.2014.07.012
   Verron E, 2010, BIOMATERIALS, V31, P7776, DOI 10.1016/j.biomaterials.2010.06.047
   Viguet Carrin S, 2006, OSTEOPOROSIS INT, V17, P319, DOI 10.1007/s00198 005 2035 9
   Walsh DA, 2010, RHEUMATOLOGY, V49, P1852, DOI 10.1093/rheumatology/keq188
   Ward LM, 2011, J CLIN ENDOCR METAB, V96, P355, DOI 10.1210/jc.2010 0636
   Wat WZM, 2014, THER CLIN RISK MANAG, V10, P977, DOI 10.2147/TCRM.S58367
   Watts NB, 2020, BONE, V134, DOI 10.1016/j.bone.2020.115222
   Weiss HM, 2008, DRUG METAB DISPOS, V36, P2043, DOI 10.1124/dmd.108.021071
   Widler L, 2002, J MED CHEM, V45, P3721, DOI 10.1021/jm020819i
   Wright NC, 2014, J BONE MINER RES, V29, P2520, DOI 10.1002/jbmr.2269
   Xing RL, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064 016 3359 y
NR 181
TC 55
Z9 61
U1 0
U2 27
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022 2623
EI 1520 4804
J9 J MED CHEM
JI J. Med. Chem.
PD FEB 11
PY 2021
VL 64
IS 3
BP 1260
EP 1282
DI 10.1021/acs.jmedchem.0c01292
EA FEB 2021
PG 23
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA QJ5PU
UT WOS:000619743200002
PM 33522236
DA 2025 08 17
ER

PT J
AU Wang, H
   Liu, J
   Tao, S
   Chai, GH
   Wang, JW
   Hu, FQ
   Yuan, H
AF Wang, Hua
   Liu, Jun
   Tao, Shan
   Chai, Guihong
   Wang, Jianwei
   Hu, Fu Qiang
   Yuan, Hong
TI Tetracycline grafted PLGA nanoparticles as bone targeting drug delivery
   system
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE poly(lactic co glycolic acid); simvastatin; tetracycline; osteoporosis;
   bone targeting; nanoparticles
ID BLOCK COPOLYMER MICELLES; OSTEOBLAST DIFFERENTIATION; MINERAL DENSITY;
   IN VITRO; SIMVASTATIN; ACID; RESOLUTION; RELEASE; CARRIER
AB Purpose: Nanoparticles (NPs) that target bone tissue were developed using poly(lactic co glycolic acid) (PLGA) copolymers and tetracycline (TC) based bone targeting moieties. These NPs are expected to enable the transport of drugs, such as simvastatin (SIM), for the treatment of osteoporosis.
   Methods: The molecular structures of TC PLGA were validated by H 1 NMR, and the SIM loaded NPs were prepared using the solvent emulsification method. The surface properties, cytotoxicity, cellular uptake, cell mineralization, bone targeting potential, and animal pharmacodynamics of the TC PLGA NPs were evaluated and compared to those of PLGA NPs.
   Results: It was confirmed that the average particle size of the NPs was approximately 220 nm. In phosphate buffered saline (PBS, pH 7.4), the SIM loaded NPs exhibited a cumulative release of up to 80% within 72 hours. An in vitro cell evaluation indicated that the NPs had an excellent cellular uptake capacity and showed great biocompatibility with MC3T3 E1 cells, thereby reducing the cytotoxic effects of SIM. The cell mineralization assay showed that the SIM loaded NPs induced osteogenic differentiation and mineralized nodule formation in MC3T3 E1 cells, thereby achieving the same effect as SIM. Preliminary findings from in vitro and in vivo bone affinity assays indicated that the TC PLGA NPs may display increased bone targeting efficiency compared to PLGA NPs lacking a TC moiety. The use of SIM loaded TC PLGA NPs in treating osteoporosis was tested through animal pharmacodynamics analyses performed in ovariectomized rats, and the results suggested that the SIM loaded TC PLGA NPs can improve the curative effects of SIM on the recovery of bone mineral density compared to either SIM loaded PLGA NPs or SIM alone.
   Conclusion: Bone targeting NPs, which were based on the conjugation of TC to PLGA copolymers, have the ability to target bone. These NPs may be developed as a delivery system for hydrophobic drugs, and they are expected to improve the curative effects of drugs, reduce the administered drug doses, and reduce side effects in other organs.
C1 [Wang, Hua] Zhejiang Univ, Ctr Anal & Measurement, Hangzhou 310058, Zhejiang, Peoples R China.
   [Liu, Jun; Tao, Shan; Chai, Guihong; Hu, Fu Qiang; Yuan, Hong] Zhejiang Univ, Coll Pharmaceut Sci, Hangzhou 310058, Zhejiang, Peoples R China.
   [Wang, Jianwei] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Hangzhou 310009, Zhejiang, Peoples R China.
C3 Zhejiang University; Zhejiang University; Zhejiang University
RP Yuan, H (通讯作者)，Zhejiang Univ, Coll Pharmaceut Sci, 866 Yuhangtang Rd, Hangzhou 310058, Zhejiang, Peoples R China.
EM wangjianwei_i@sina.com; yuanhong70@zju.edu.cn
OI Chai, Guihong/0000 0002 9728 2643
CR BLUM CB, 1994, AM J CARDIOL, V73, pD3, DOI 10.1016/0002 9149(94)90626 2
   Danhier F, 2012, J CONTROL RELEASE, V161, P505, DOI 10.1016/j.jconrel.2012.01.043
   De Jong WH, 2008, INT J NANOMED, V3, P133, DOI 10.2147/ijn.s596
   Fu YC, 2014, ACTA BIOMATER, V10, P4583, DOI 10.1016/j.actbio.2014.07.015
   Gaucher A, 2001, TETRAHEDRON ASYMMETR, V12, P2571, DOI 10.1016/S0957 4166(01)00435 9
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Guyton JR, 2006, AM J CARDIOL, V97, p95C, DOI 10.1016/j.amjcard.2005.12.016
   Hans ML, 2002, CURR OPIN SOLID ST M, V6, P319, DOI 10.1016/S1359 0286(02)00117 1
   Ho ML, 2008, J CONTROL RELEASE, V128, P142, DOI 10.1016/j.jconrel.2008.02.012
   Ho MH, 2011, J ORTHOP RES, V29, P1504, DOI 10.1002/jor.21421
   Ito T, 2013, J PHARM PHARMACOL, V65, P494, DOI 10.1111/jphp.12008
   Kataoka K, 2001, ADV DRUG DELIVER REV, V47, P113, DOI 10.1016/S0169 409X(00)00124 1
   KWON GS, 1995, ADV DRUG DELIVER REV, V16, P295, DOI 10.1016/0169 409X(95)00031 2
   Maeda T, 2004, J CELL BIOCHEM, V92, P458, DOI 10.1002/jcb.20074
   Maeda T, 2001, BIOCHEM BIOPH RES CO, V280, P874, DOI 10.1006/bbrc.2000.4232
   Mazaleyrat JP, 1998, TETRAHEDRON ASYMMETR, V9, P2701, DOI 10.1016/S0957 4166(98)00253 5
   Montagnani A, 2003, BONE, V32, P427, DOI 10.1016/S8756 3282(03)00034 6
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Nath SD, 2013, INT J PHARMACEUT, V443, P87, DOI 10.1016/j.ijpharm.2012.12.037
   Park JB, 2012, J SURG RES, V174, P278, DOI 10.1016/j.jss.2010.12.029
   PERRIN DD, 1965, NATURE, V208, P787, DOI 10.1038/208787a0
   Shekunov BY, 2006, PHARM RES DORDR, V23, P196, DOI 10.1007/s11095 005 8635 4
   Skoglund B, 2002, J BONE MINER RES, V17, P2004, DOI 10.1359/jbmr.2002.17.11.2004
   Tikiz C, 2005, CLIN RHEUMATOL, V24, P447, DOI 10.1007/s10067 004 1053 x
   Tiwari R, 2011, INT J PHARMACEUT, V415, P232, DOI 10.1016/j.ijpharm.2011.05.044
   Wang CZ, 2014, J COLLOID INTERF SCI, V432, P190, DOI 10.1016/j.jcis.2014.06.037
   Wang G, 2008, EXPERT OPIN DRUG DEL, V5, P499, DOI 10.1517/17425247.5.5.499 
   Wang JW, 2007, OSTEOPOROSIS INT, V18, P1641, DOI 10.1007/s00198 007 0412 2
   Waynforth H B., 1980, Experimental and the surgical technique in the rat, V2nd
   Wong HL, 2007, ADV DRUG DELIVER REV, V59, P491, DOI 10.1016/j.addr.2007.04.008
   Yang F, 2011, ORAL SURG ORAL MED O, V111, P551, DOI 10.1016/j.tripleo.2010.06.018
NR 31
TC 81
Z9 87
U1 0
U2 77
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178 2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2015
VL 10
BP 5671
EP 5685
DI 10.2147/IJN.S88798
PG 15
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Pharmacology & Pharmacy
GA CR2CU
UT WOS:000361133300001
PM 26388691
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Yamagishi, S
   Nakamura, K
   Matsui, T
   Takeuchi, M
AF Yamagishi, S
   Nakamura, K
   Matsui, T
   Takeuchi, M
TI Minodronate, a nitrogen containing bisphosphonate, is a promising remedy
   for treating patients with diabetic retinopathy
SO MEDICAL HYPOTHESES
LA English
DT Article
ID GLYCATION END PRODUCTS; ENDOTHELIAL GROWTH FACTOR; MELANOMA GROWTH;
   AGES; RECEPTOR; RAGE
AB In diabetes mellitus, the formation and accumulation of advanced glycation end products (AGEs) progress. There is a growing body of evidence to show that AGEs their receptor (RAGE) interactions are involved in the development and progression of diabetic retinopathy. Bisphosphonates are potent inhibitors of bone resorption and are widely used drugs for the treatment of osteoporosis and osteotytic bone metastasis. Recently, farnesyl pyrophosphate synthase has been shown as a molecular target of nitrogen containing bisphosphonates, and inhibition of posttranslational prenylation of small molecular weight G proteins is likely involved in their anti resorptive activity on osteoclasts. NADPH oxidase derived reactive oxygen species (ROS) generation is required for the AGE RAGE signaling in vascular wall cells, and small G protein Rac is a critical component of vascular NADPH oxidase complex. These observations let us to speculate that minodronate, a newly developed nitrogen  containing bisphosphonate, might be a promising remedy for treating patients with diabetic retinopathy by inhibiting the AGE RAGE signaling pathways through suppression of ROS generation via inhibition of Rac prenylation. In this paper, we like to propose the possible ways of testing our hypotheses: (1) Does treatment with minodronate decrease the risk for the development and progression of diabetic retinopathy in osteoporotic patients? (2) If the answer is yes, is this beneficial effect of minodronate superior to that of other nitrogen noncontaining bisphosphonates with equihypolipidernic properties? (3) Does minodronate treatment suppress NADPH oxidase mediated ROS generation in retinas of diabetic animals? (4) Does treatment with pyridoxamine, a post Amadori inhibitor of AGE formation, attenuate these beneficial effects of minodronate on diabetic retinopathy? These clinical and animal studies could clarify whether the use of minodronate is of benefit in patients with AGE RAGE related disorders such as diabetic retinopathy, even in the absence of osteoporosis. (c) 2005 Elsevier Ltd. All rights reserved.
C1 Kurume Univ, Sch Med, Dept Internal Med, Kurume, Fukuoka 8300011, Japan.
   Kurume Univ, Sch Med, Dept Internal Med, Kurume, Fukuoka 8300011, Japan.
   Hokuriku Univ, Fac Pharmaceut Sci, Dept Pathophysiol Sci, Kanazawa, Ishikawa 92011, Japan.
C3 Kurume University; Kurume University; Hokuriku University
RP Kurume Univ, Sch Med, Dept Internal Med, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan.
EM shoichi@med.kurume u.ac.jp
OI Matsui, Takanori/0000 0001 9506 7571
CR Abe R, 2004, J INVEST DERMATOL, V122, P461, DOI 10.1046/j.0022 202X.2004.22218.x
   Bierhaus A, 1998, CARDIOVASC RES, V37, P586, DOI 10.1016/S0008 6363(97)00233 2
   Brown DL, 1999, J CLIN PHARMACOL, V39, P651, DOI 10.1177/00912709922008272
   Okamoto T, 2002, FASEB J, V16, P1928, DOI 10.1096/fj.02 0030fje
   Okamoto T, 2002, BIOCHEM BIOPH RES CO, V297, P419, DOI 10.1016/S0006 291X(02)02218 0
   Onorato JM, 2000, J BIOL CHEM, V275, P21177, DOI 10.1074/jbc.M003263200
   Schmidt A M, 2000, Curr Atheroscler Rep, V2, P430, DOI 10.1007/s11883 000 0082 4
   Takeuchi M, 2004, INT J CLIN PHARM RES, V24, P95
   Takeuchi M, 2004, MED HYPOTHESES, V63, P449, DOI 10.1016/j.mehy.2004.02.042
   Takeuchi M, 2004, MED HYPOTHESES, V63, P453, DOI 10.1016/j.mehy.2004.03.005
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   VLASSARA H, 1994, LAB INVEST, V70, P138
   Wautier MP, 2001, AM J PHYSIOL ENDOC M, V280, pE685, DOI 10.1152/ajpendo.2001.280.5.E685
   Yamagishi S, 2005, CURR PHARM DESIGN, V11, P2279, DOI 10.2174/1381612054367300
   Yamagishi S, 2004, AM J PATHOL, V165, P1865, DOI 10.1016/S0002 9440(10)63239 7
   Yamagishi S, 2004, DRUG EXP CLIN RES, V30, P169
   Yamagishi S, 2003, INT J CLIN PHARM RES, V23, P129
   Yamagishi S, 2002, BIOCHEM BIOPH RES CO, V290, P973, DOI 10.1006/bbrc.2001.6312
   YAMAGISHI S, 2005, INT J PHARMACEUT, V1, P203
   Yamagishi S, 2005, CURR DIABETES REV, V1, P93, DOI 10.2174/1573399052952631
   Ylitalo R, 1998, PHARMACOL TOXICOL, V83, P125, DOI 10.1111/j.1600 0773.1998.tb01455.x
NR 21
TC 11
Z9 11
U1 0
U2 2
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306 9877
EI 1532 2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PY 2006
VL 66
IS 2
BP 273
EP 275
DI 10.1016/j.mehy.2005.08.042
PG 3
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 002WS
UT WOS:000234643400008
PM 16216433
DA 2025 08 17
ER

PT J
AU Hu, HM
   Wang, XD
   Huang, YS
   He, BR
   Zhu, JW
   Sun, K
   Deng, CY
   Guo, YS
   Hao, DJ
   Jian, B
AF Hu, Huimin
   Wang, Xiaodong
   Huang, Yansheng
   He, Baorong
   Zhu, Jinwen
   Sun, Kai
   Deng, Chaoyang
   Guo, Yunshan
   Hao, Dingjun
   Jian, Bin
TI Obacunone inhibits RANKL/M CSF mediated osteoclastogenesis by
   suppressing integrin  FAK Src signaling
SO CYTOKINE
LA English
DT Article
DE Obacunone; Osteoclast differentiation; Integrin; FAK Src; Osteoporosis
ID C SRC; ADHESION KINASE; BONE MARROW; P38 MAPK; EXPRESSION; OSTEOPOROSIS;
   CELLS; DIFFERENTIATION; PREVENTION; PATHWAY
AB Disrupted osteoblastogenesis or aberrant activation of osteoclastogenesis usually results in the break of bone homeostasis thus causing bone associated diseases like osteoporosis. Obacunone, as a natural compound present in citrus fruits, has been demonstrated for various biological activities including anti cancer and anti inflammatory properties. However, the role of obacunone in regulating osteoclastogenesis has not been eluci dated so far. Here, using in vitro cell models of RANKL (Receptor activator of nuclear factor kB ligand) and M CSF (Macrophage colony stimulating factor) induced osteoclastogenesis, we showed that obacunone inhibited oste oclast differentiation in RAW264.7 cells and bone marrow macrophages (BMMs), as evidenced by obacunone dose dependent reduction in numbers of osteoclasts and downregulated expressions of osteoclastogenesis associated key genes. The anti osteoclastic properties of obacunone were associated with downregulated ex pressions of Integrin alpha 1 and attenuated activation of Focal adhesion kinase (FAK) and Steroid receptor coac tivator (Src) signaling. Functional Integrin alpha 1 blockade or FAK Src inhibition suppressed RANKL/M CSF induced osteoclastogenesis, while Integrin alpha 1 overexpression or FAK/Src activation partially attenuated obacunone's effects on suppressing RANKL/M CSF induced osteoclast differentiation. Furthermore, in vivo administration of obacunone displayed super therapeutic effects in attenuating ovariectomy induced bone loss in mice, as indi cated by decreases in serum biomarkers of bone turnover, restoring of femur fracture maximum force, and reversing of the worsened bone related parameters in ovariectomized animals. Taken together, these findings demonstrate that obacunone has pharmacological activities to suppress osteoclast differentiation through modulating the Integrin FAK Src pathway, and suggest that obacunone is a therapeutic candidate for the treatment and prevention of bone diseases such as osteoporosis.
C1 [Hu, Huimin; Wang, Xiaodong; Huang, Yansheng; He, Baorong; Zhu, Jinwen; Sun, Kai; Deng, Chaoyang; Guo, Yunshan; Hao, Dingjun] Honghui Hosp, Dept Spine Surg, 555 Youyi East Rd, Xian 710054, Shaanxi, Peoples R China.
   [Jian, Bin] Honghui Hosp, Dept Tradit Chinese Med & West Med, 555 Youyi East Rd, Xian 710054, Shaanxi, Peoples R China.
RP Hao, DJ (通讯作者)，Honghui Hosp, Dept Spine Surg, 555 Youyi East Rd, Xian 710054, Shaanxi, Peoples R China.; Jian, B (通讯作者)，Honghui Hosp, Dept Tradit Chinese Med & West Med, 555 Youyi East Rd, Xian 710054, Shaanxi, Peoples R China.
EM dochaodingjun@outlook.com; jiabin939@sina.com
RI zhu, Jinwen/P 2181 2019; Sun, Kai/ABI 2598 2020; Wang,
   Shaoxin/JKH 8763 2023
CR An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Barczyk M, 2010, CELL TISSUE RES, V339, P269, DOI 10.1007/s00441 009 0834 6
   Boyce Brendan, 2011, Clin Investig (Lond), V1, P1695
   Boyer B, 2002, ONCOGENE, V21, P2347, DOI 10.1038/sj.onc.1205298
   Brunton VG, 2008, CURR OPIN PHARMACOL, V8, P427, DOI 10.1016/j.coph.2008.06.012
   Cafiero C, 2018, NEPHROL DIAL TRANSPL, V33, P65, DOI 10.1093/ndt/gfx222
   Carina V, 2020, CALCIFIED TISSUE INT, V107, P301, DOI 10.1007/s00223 020 00724 0
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Cho ES, 2012, MOL CELLS, V33, P173, DOI 10.1007/s10059 012 2240 z
   de Vries TJ, 2009, MOL CANCER RES, V7, P476, DOI 10.1158/1541 7786.MCR 08 0219
   Ekholm E, 2002, AM J PATHOL, V160, P1779, DOI 10.1016/S0002 9440(10)61124 8
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Gao Y, 2018, J CELL BIOCHEM, V119, P837, DOI 10.1002/jcb.26248
   Gendron S, 2008, IMMUNOLOGY, V125, P359, DOI 10.1111/j.1365 2567.2008.02858.x
   Geoghegan IP, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 41095 3
   Guan JL, 2010, IUBMB LIFE, V62, P268, DOI 10.1002/iub.303
   Gyori DS, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00507
   HORNE WC, 1992, J CELL BIOL, V119, P1003, DOI 10.1083/jcb.119.4.1003
   Kim J, 2014, BIOCHIMIE, V105, P36, DOI 10.1016/j.biochi.2014.06.002
   Kim M, 2021, MOL MED REP, V24, DOI 10.3892/mmr.2021.12248
   Kong LB, 2020, J CELL MOL MED, V24, P3271, DOI 10.1111/jcmm.15052
   Lee SY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080873
   Lu X, 2016, TROP J PHARM RES, V15, P299, DOI 10.4314/tjpr.v15i2.11
   Luo XP, 2020, PHARM BIOL, V58, P886, DOI 10.1080/13880209.2020.1812673
   Luo XP, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00497
   Muñoz M, 2020, CLIN OBSTET GYNECOL, V63, P770, DOI 10.1097/GRF.0000000000000572
   Murphy JM, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 44098 2
   Murthy KNC, 2015, TOXICOLOGY, V329, P88, DOI 10.1016/j.tox.2015.01.008
   Myoui A, 2003, CANCER RES, V63, P5028
   Nakamura I, 2007, J BONE MINER METAB, V25, P337, DOI 10.1007/s00774 007 0773 9
   Nakayamada S, 2003, J BIOL CHEM, V278, P45368, DOI 10.1074/jbc.M308786200
   Panaroni C, 2014, CURR OSTEOPOROS REP, V12, P22, DOI 10.1007/s11914 014 0190 7
   Park EJ, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.588066
   Park K.R., 2021, Int. J. Mol. Sci., V22
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Riquelme MA, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.567844
   Srivastava M, 2002, CLIN GERIATR MED, V18, P529, DOI 10.1016/S0749 0690(02)00022 8
   Srouji S, 2012, HUM GENE THER, V23, P167, DOI 10.1089/hum.2011.059
   Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0
   Tanaka Yoshiya, 2005, Current Drug Targets   Inflammation and Allergy, V4, P325, DOI 10.2174/1568010054022015
   Voisin M, 2015, ANAT REC, V298, P1548, DOI 10.1002/ar.23173
   Xiong WC, 2003, FRONT BIOSCI LANDMRK, V8, pD1219, DOI 10.2741/1117
   Yahara Y, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.622035
   Yokota Kazuhiro, 2017, Nihon Rinsho Meneki Gakkai Kaishi, V40, P367, DOI 10.2177/jsci.40.367
   Zhang LY, 2012, ONCOL LETT, V3, P395, DOI 10.3892/ol.2011.487
NR 45
TC 4
Z9 4
U1 2
U2 9
PU ACADEMIC PRESS LTD  ELSEVIER SCIENCE LTD
PI LONDON
PA 24 28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043 4666
EI 1096 0023
J9 CYTOKINE
JI Cytokine
PD APR
PY 2023
VL 164
AR 156134
DI 10.1016/j.cyto.2023.156134
EA FEB 2023
PG 12
WC Biochemistry & Molecular Biology; Cell Biology; Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Immunology
GA 9I5WI
UT WOS:000939580000001
PM 36804257
DA 2025 08 17
ER

PT J
AU Krasnova, O
   Neganova, I
AF Krasnova, O.
   Neganova, I.
TI Assembling the Puzzle Pieces. Insights for in Vitro Bone Remodeling
SO STEM CELL REVIEWS AND REPORTS
LA English
DT Article
DE Bone remodeling; Osteoporosis; Bone tissue engineering; Bone matrix;
   Mesenchymal stem cells; Induced pluripotent stem cells
ID TRANSCRIPTION FACTOR PU.1; MESENCHYMAL STEM CELLS; NF KAPPA B;
   COLONY STIMULATING FACTOR; OSTEOBLAST LINEAGE CELLS; FUNCTIONAL
   GAP JUNCTIONS; OSTEOGENIC DIFFERENTIATION; OSTEOCYTE APOPTOSIS;
   GENE EXPRESSION; RECEPTOR ACTIVATOR
AB As a highly dynamic organ, bone changes during throughout a person's life. This process is referred to as 'bone remodeling' and it involves two stages   a well balanced osteoclastic bone resorption and an osteoblastic bone formation. Under normal physiological conditions bone remodeling is highly regulated that ensures tight coupling between bone formation and resorption, and its disruption results in a bone metabolic disorder, most commonly osteoporosis. Though osteoporosis is one of the most prevalent skeletal ailments that affect women and men aged over 40 of all races and ethnicities, currently there are few, if any safe and effective therapeutic interventions available. Developing state of the art cellular systems for bone remodeling and osteoporosis can provide important insights into the cellular and molecular mechanisms involved in skeletal homeostasis and advise better therapies for patients. This review describes osteoblastogenesis and osteoclastogenesis as two vital processes for producing mature, active bone cells in the context of interactions between cells and the bone matrix. In addition, it considers current approaches in bone tissue engineering, pointing out cell sources, core factors and matrices used in scientific practice for modeling bone diseases and testing drugs. Finally, it focuses on the challenges that bone regenerative medicine is currently facing.
C1 [Krasnova, O.; Neganova, I.] Russian Acad Sci, Inst Cytol, St Petersburg, Russia.
C3 Russian Academy of Sciences; St. Petersburg Scientific Centre of the
   Russian Academy of Sciences; Institute of Cytology RAS
RP Neganova, I (通讯作者)，Russian Acad Sci, Inst Cytol, St Petersburg, Russia.
EM irina.neganova@incras.ru
RI ; Neganova, Irina/HDN 1880 2022
OI Krasnova, Olga/0000 0003 0315 7735; Neganova, Irina/0000 0001 5712 2170
FU Ministry of Science and Higher Education of the Russian Federation
   [075 15 2021 1075]
FX This work was supported by Ministry of Science and Higher Education of
   the Russian Federation (Agreement No. 075 15 2021 1075 dated
   09/28/2021).
CR Aasebo E, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115665
   Aguirre JI, 2006, J BONE MINER RES, V21, P605, DOI 10.1359/JBMR.060107
   Ahmadi A, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287 022 03204 4
   Akiva A, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202010524
   Al Bari AA, 2020, FASEB BIOADV, V2, P668, DOI 10.1096/fba.2020 00058
   Al Dujaili SA, 2011, J CELL BIOCHEM, V112, P2412, DOI 10.1002/jcb.23164
   Alfaro D, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020310
   Almeida AR, 2020, J BIOMED MATER RES A, V108, P851, DOI 10.1002/jbm.a.36863
   Amarasekara DS, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22062851
   Amirazad H, 2022, J BIOL ENG, V16, DOI 10.1186/s13036 021 00282 5
   Andersen TL, 2013, AM J PATHOL, V183, P235, DOI 10.1016/j.ajpath.2013.03.006
   Andrzejewska A, 2019, STEM CELLS, V37, P855, DOI 10.1002/stem.3016
   Aquino Martínez R, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0713 0
   Arnsdorf EJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005388
   Arnsdorf EJ, 2009, J CELL SCI, V122, P546, DOI 10.1242/jcs.036293
   Arthur A, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.598612
   Ashley JW, 2015, J CELL BIOCHEM, V116, P2598, DOI 10.1002/jcb.25205
   Mora Roldan GA, 2021, CELLS BASEL, V10, DOI 10.3390/cells10112858
   Barrow AD, 2011, J CLIN INVEST, V121, P3505, DOI 10.1172/JCI45913
   Batra N, 2012, P NATL ACAD SCI USA, V109, P3359, DOI 10.1073/pnas.1115967109
   Bernhardt A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22147316
   Bessy T, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.645496
   Blair HC, 2017, TISSUE ENG PART B RE, V23, P268, DOI [10.1089/ten.teb.2016.0454, 10.1089/ten.TEB.2016.0454]
   Blair HC, 2009, LAB INVEST, V89, P1007, DOI 10.1038/labinvest.2009.58
   Blangy A, 2020, J CELL SCI, V133, DOI 10.1242/jcs.244798
   Bolamperti S, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00219 8
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Borciani G, 2020, ACTA BIOMATER, V108, P22, DOI 10.1016/j.actbio.2020.03.043
   Buenzli PR, 2015, BONE, V75, P144, DOI 10.1016/j.bone.2015.02.016
   Burger EH, 1999, FASEB J, V13, pS101, DOI 10.1096/fasebj.13.9001.s101
   Byun MR, 2014, CELL DEATH DIFFER, V21, P854, DOI 10.1038/cdd.2014.8
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504
   Cardoso L, 2009, J BONE MINER RES, V24, P597, DOI 10.1359/JBMR.081210
   Carey HA, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0011 1
   Chang YC, 2020, FRONT MOL BIOSCI, V6, DOI 10.3389/fmolb.2019.00157
   Chen H, 2015, MED MOL MORPHOL, V48, P61, DOI 10.1007/s00795 015 0099 y
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   Chen SS, 2022, BIOACT MATER, V18, P15, DOI 10.1016/j.bioactmat.2022.01.048
   Cheng BX, 2001, J BONE MINER RES, V16, P249, DOI 10.1359/jbmr.2001.16.2.249
   Cheung WY, 2016, J BONE MINER RES, V31, P890, DOI 10.1002/jbmr.2740
   Choi JUA, 2022, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.770143
   Colnot C, 2009, J BONE MINER RES, V24, P274, DOI 10.1359/JBMR.081003
   Dai R, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00433
   Dallas SL, 2002, J BIOL CHEM, V277, P21352, DOI 10.1074/jbc.M111663200
   Davis HM, 2017, AGING CELL, V16, P551, DOI 10.1111/acel.12586
   De Pieri A, 2021, NPJ REGEN MED, V6, DOI 10.1038/s41536 021 00133 3
   de Villiers TJ, 2022, CLIMACTERIC, V25, P1, DOI 10.1080/13697137.2021.1965408
   De Witte TM, 2018, REGEN BIOMATER, V5, P197, DOI 10.1093/rb/rby013
   Del Fattore Andrea, 2012, Front Biosci (Elite Ed), V4, P2302
   Delaisse JM, 2020, BONE, V141, DOI [10.1016/j/bone.2020.115628, 10.1016/j.bone.2020.115628]
   Delaisse Jean Marie, 2014, Bonekey Rep, V3, P561, DOI 10.1038/bonekey.2014.56
   Domnina A.P., 2022, Transl Med, V9, P41, DOI [10.18705/2311 4495 2022 9 4 41 61, DOI 10.18705/2311 4495 2022 9 4 41 61]
   Dou C, 2016, SCI REP UK, V6, DOI 10.1038/srep21499
   Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511
   Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137
   Dupuis V, 2021, WORLD J STEM CELLS, V13, P1094, DOI 10.4252/wjsc.v13.i8.1094
   Evans CH, 2007, J ORTHOP RES, V25, P556, DOI 10.1002/jor.20386
   Fatehullah A, 2016, NAT CELL BIOL, V18, P246, DOI 10.1038/ncb3312
   Feng W, 2019, J ORAL BIOSCI, V61, P16, DOI 10.1016/j.job.2019.01.001
   Franz Odendaal TA, 2006, DEV DYNAM, V235, P176, DOI 10.1002/dvdy.20603
   FROST H M, 1965, Henry Ford Hosp Med Bull, V13, P161
   FULLER K, 1995, J CELL SCI, V108, P2221
   Furuya M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02541 w
   Galindo M, 2005, J BIOL CHEM, V280, P20274, DOI 10.1074/jbc.M413665200
   Gangenahalli GU, 2005, STEM CELLS DEV, V14, P140, DOI 10.1089/scd.2005.14.140
   Gao MM, 2018, EUR CELLS MATER, V36, P1, DOI 10.22203/eCM.v036a01
   Gordon JAR, 2007, BONE, V41, P462, DOI 10.1016/j.bone.2007.04.191
   Grosso A, 2017, FRONT BIOENG BIOTECH, V5, DOI 10.3389/fbioe.2017.00068
   GRZESIK WJ, 1994, J BONE MINER RES, V9, P487, DOI 10.1002/jbmr.5650090408
   Guillot PV, 2008, DIFFERENTIATION, V76, P946, DOI 10.1111/j.1432 0436.2008.00279.x
   Gultian KA, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 12143 2
   Håkelien AM, 2014, STEM CELLS, V32, P2780, DOI 10.1002/stem.1759
   Halloran D, 2020, J DEV BIOL, V8, DOI 10.3390/jdb8030019
   Haraguchi Y, 2012, NAT PROTOC, V7, P850, DOI 10.1038/nprot.2012.027
   Hardy E, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00047
   Hayman AR, 2008, AUTOIMMUNITY, V41, P218, DOI 10.1080/08916930701694667
   Hikita A, 2006, J BIOL CHEM, V281, P36846, DOI 10.1074/jbc.M606656200
   Hirao M, 2007, J BONE MINER METAB, V25, P266, DOI 10.1007/s00774 007 0765 9
   Holmbeck K, 2005, J CELL SCI, V118, P147, DOI 10.1242/jcs.01581
   Hong HX, 2013, BIOCHEM BIOPH RES CO, V440, P545, DOI 10.1016/j.bbrc.2013.09.098
   Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955
   Hu JA, 2010, TISSUE ENG PT A, V16, P3507, DOI [10.1089/ten.tea.2010.0097, 10.1089/ten.TEA.2010.0097]
   Hua R, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.892229
   Huang S, 2021, BIOL REV, V96, P357, DOI 10.1111/brv.12659
   Hwang JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135519
   Iordachescu A, 2021, NPJ MICROGRAVITY, V7, DOI 10.1038/s41526 021 00146 8
   Iwasaki H, 2005, BLOOD, V106, P1590, DOI 10.1182/blood 2005 03 0860
   Jeon OH, 2016, SCI REP UK, V6, DOI 10.1038/srep26761
   Jilka RL, 2003, MED PEDIATR ONCOL, V41, P182, DOI 10.1002/mpo.10334
   Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793
   Jilka RL, 2013, J GERONTOL A BIOL, V68, P1209, DOI 10.1093/gerona/glt046
   Ortuño MJ, 2013, BONE, V52, P548, DOI 10.1016/j.bone.2012.11.007
   Jung Y, 2006, BONE, V38, P497, DOI 10.1016/j.bone.2005.10.003
   Kamioka H, 2001, BONE, V28, P145, DOI 10.1016/S8756 3282(00)00421 X
   Kaneshita Y, 2007, ORTHOD WAVES, V66, P122, DOI 10.1016/j.odw.2007.09.003
   Kang HM, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600691
   Kang HM, 2014, ACTA BIOMATER, V10, P4961, DOI 10.1016/j.actbio.2014.08.010
   Kawai S, 2019, NAT BIOMED ENG, V3, P558, DOI 10.1038/s41551 019 0410 7
   Kenkre JS, 2018, ANN CLIN BIOCHEM, V55, P308, DOI 10.1177/0004563218759371
   Kennedy OD, 2012, BONE, V50, P1115, DOI 10.1016/j.bone.2012.01.025
   Khademhosseini A, 2020, Embryonic stem cells as a cell source for tissue engineering, P467, DOI [10.1016/B978 0 12 818422 6.00027 7, DOI 10.1016/B978 0 12 818422 6.00027 7]
   Khosla S, 2010, J CLIN ENDOCR METAB, V95, P3, DOI 10.1210/jc.2009 1740
   Kim BH, 2017, MOL CELLS, V40, P752, DOI 10.14348/molcells.2017.0098
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kim KM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092427
   Kimura H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003174
   Kitahama S, 2000, BONE, V27, P61, DOI 10.1016/S8756 3282(00)00292 1
   KLEINNULEND J, 1995, FASEB J, V9, P441, DOI 10.1096/fasebj.9.5.7896017
   Koizumi K, 2009, J IMMUNOL, V183, P7825, DOI 10.4049/jimmunol.0803627
   Kostina D, 2022, CELLS BASEL, V11, DOI 10.3390/cells11213356
   Kreja L, 2010, J CELL BIOCHEM, V109, P347, DOI 10.1002/jcb.22406
   Kurosawa H, 2007, J BIOSCI BIOENG, V103, P389, DOI 10.1263/jbb.103.389
   Kwon OH, 2005, BIOCHEM BIOPH RES CO, V335, P437, DOI 10.1016/j.bbrc.2005.07.092
   Langenbach F, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt328
   Lassen NE, 2017, J BONE MINER RES, V32, P1395, DOI 10.1002/jbmr.3091
   Lau KHW, 2013, AM J PHYSIOL ENDOC M, V305, pE271, DOI 10.1152/ajpendo.00092.2013
   Lawal RA, 2017, J BONE MINER RES, V32, P1320, DOI 10.1002/jbmr.3106
   Lee D, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0562 5
   Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783 8792.2000
   Lee MN, 2018, EXP MOL MED, V50, DOI 10.1038/s12276 018 0170 6
   Lesnyak OM, 2018, TRAVMATOL ORTOP ROSS, V24, P155, DOI 10.21823/2311 2905 2018 24 1 155 168
   Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566
   Liang B, 2022, CELL MOL BIOL LETT, V27, DOI 10.1186/s11658 022 00371 3
   Lim WF, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt222
   Liu F, 1997, EXP CELL RES, V232, P97, DOI 10.1006/excr.1997.3501
   Liu H, 2017, INT J ONCOL, V50, P631, DOI 10.3892/ijo.2016.3815
   Liu Y, 2003, J BIOL CHEM, V278, P20603, DOI 10.1074/jbc.M212093200
   Lloyd SA, 2014, J BONE MINER RES, V29, P1118, DOI 10.1002/jbmr.2113
   Lobov Arseniy, 2022, Biological Communications, V67, P32, DOI 10.21638/spbu03.2022.104
   Lotinun S, 2013, J CLIN INVEST, V123, P666, DOI 10.1172/JCI64840
   Ma YFL, 2001, ENDOCRINOLOGY, V142, P4047, DOI 10.1210/en.142.9.4047
   Maeda K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225525
   Maeda K, 2012, NAT MED, V18, P405, DOI 10.1038/nm.2653
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Mansoorifar A, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202006796
   Matic I, 2016, STEM CELLS, V34, P2930, DOI 10.1002/stem.2474
   Mazzoni E, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.610570
   McNamara LM, 2009, ANAT REC, V292, P355, DOI 10.1002/ar.20869
   Mejía Salazar JR, 2020, SENSORS BASEL, V20, DOI 10.3390/s20071951
   Miao DS, 2002, J HISTOCHEM CYTOCHEM, V50, P333, DOI 10.1177/002215540205000305
   Miszkiewicz JJ, 2019, ANAT REC, V302, P1934, DOI 10.1002/ar.24224
   Miyamoto T, 2000, BLOOD, V96, P4335, DOI 10.1182/blood.V96.13.4335.h8004335_4335_4343
   Moriishi T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040143
   Mossadegh Keller N, 2013, NATURE, V497, P239, DOI 10.1038/nature12026
   Mullen CA, 2013, J MECH BEHAV BIOMED, V28, P183, DOI 10.1016/j.jmbbm.2013.06.013
   Murakami S, 1997, ENDOCRINOLOGY, V138, P1972, DOI 10.1210/en.138.5.1972
   Na WJ, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222212391
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nakashima T, 2000, BIOCHEM BIOPH RES CO, V275, P768, DOI 10.1006/bbrc.2000.3379
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Nedeva IR, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.641162
   Nistala H, 2010, J CELL BIOL, V190, P1107, DOI 10.1083/jcb.201003089
   Noble BS, 2003, AM J PHYSIOL CELL PH, V284, pC934, DOI 10.1152/ajpcell.00234.2002
   Okawa H, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/6240794
   Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934
   Orwoll ES, 2013, J BONE MINER RES, V28, P1243, DOI 10.1002/jbmr.1948
   Owen R, 2018, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00134
   Ozasa R, 2018, J BIOMED MATER RES A, V106, P360, DOI 10.1002/jbm.a.36238
   Paiva KBS, 2017, PROG MOL BIOL TRANSL, V148, P203, DOI 10.1016/bs.pmbts.2017.05.001
   PALUMBO C, 1990, ACTA ANAT, V137, P350
   Park D., 2013, OSTEOPOROSIS, P127
   Park Y, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abd6495
   Paschos NK, 2015, J TISSUE ENG REGEN M, V9, P488, DOI 10.1002/term.1870
   Patel C, 2022, CURR PROTOC, V2, DOI 10.1002/cpz1.400
   Pederson L, 2008, P NATL ACAD SCI USA, V105, P20764, DOI 10.1073/pnas.0805133106
   Pfeiffenberger M, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9070748
   Phillips MD, 2014, STEM CELL TRANSL MED, V3, P867, DOI 10.5966/sctm.2013 0154
   Plotkin LI, 2005, AM J PHYSIOL CELL PH, V289, pC633, DOI 10.1152/ajpcell.00278.2004
   Plotkin LI, 2013, BONE, V52, P157, DOI 10.1016/j.bone.2012.09.030
   Prideaux M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036786
   Quint P, 2013, J BIOL CHEM, V288, P5398, DOI 10.1074/jbc.M112.413583
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Rashki Kemmak Asma, 2020, Med J Islam Repub Iran, V34, P154, DOI 10.34171/mjiri.34.154
   Riquelme MA, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21031146
   Roelofsen T, 2008, J CELL BIOCHEM, V105, P1128, DOI 10.1002/jcb.21915
   Rössler U, 2021, J BONE MINER RES, V36, P1621, DOI 10.1002/jbmr.4322
   Roscher Anne, 2016, Bone Rep, V5, P214, DOI 10.1016/j.bonr.2016.07.002
   Rozenberg S, 2020, MATURITAS, V138, P14, DOI 10.1016/j.maturitas.2020.05.004
   Ru JY, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 03059 8
   Rutkovskiy A, 2016, MED SCI MONIT BASIC, V22, P95, DOI 10.12659/MSMBR.901142
   Salvagiotto G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017829
   Sapir Koren R, 2014, OSTEOPOROSIS INT, V25, P2685, DOI 10.1007/s00198 014 2808 0
   Sarrazin S, 2011, SEMIN IMMUNOL, V23, P326, DOI 10.1016/j.smim.2011.08.011
   Sarrazin S, 2009, CELL, V138, P300, DOI 10.1016/j.cell.2009.04.057
   Scarfì S, 2016, WORLD J STEM CELLS, V8, P1, DOI 10.4252/wjsc.v8.i1.1
   Shackelford LC, 2004, J APPL PHYSIOL, V97, P119, DOI 10.1152/japplphysiol.00741.2003
   Shanks G., 2019, OBSTET GYNAECOLOGY R, V29, P201, DOI [10.1016/j.ogrm.2019.04.001, DOI 10.1016/J.OGRM.2019.04.001]
   Sharma SM, 2007, J BIOL CHEM, V282, P15921, DOI 10.1074/jbc.M609723200
   Siller Jackson AJ, 2008, J BIOL CHEM, V283, P26374, DOI 10.1074/jbc.M803136200
   Singh VK, 2015, FRONT CELL DEV BIOL, V3, DOI 10.3389/fcell.2015.00002
   Sobacchi C, 2017, FRONT BIOENG BIOTECH, V5, DOI 10.3389/fbioe.2017.00032
   Soe K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207717
   Soe K, 2021, SEMIN CELL DEV BIOL, V112, P8, DOI 10.1016/j.semcdb.2020.05.016
   Song LG, 2012, J BONE MINER RES, V27, P2344, DOI 10.1002/jbmr.1694
   Staines KA, 2019, BMC MUSCULOSKEL DIS, V20, DOI 10.1186/s12891 019 2731 9
   Staines KA, 2017, J CELL PHYSIOL, V232, P3006, DOI 10.1002/jcp.25999
   Staines KA, 2016, J CELL PHYSIOL, V231, P1392, DOI 10.1002/jcp.25282
   Sucur A, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075 017 1337 6
   Sun CH, 2016, J BONE MINER RES, V31, P2227, DOI 10.1002/jbmr.2908
   Sundaram K, 2007, EXP CELL RES, V313, P168, DOI 10.1016/j.yexcr.2006.10.001
   Supronowicz P, 2011, TISSUE ENG PT A, V17, P789, DOI 10.1089/ten.TEA.2010.0357
   Takeshita S, 2013, J CLIN INVEST, V123, P3914, DOI 10.1172/JCI69493
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Tariverdian T, 2019, WOODH PUBL SER BIOM, P189, DOI 10.1016/B978 0 08 102563 5.00010 1
   Teti Anna, 2011, Curr Osteoporos Rep, V9, P264, DOI 10.1007/s11914 011 0078 8
   Thi MM, 2013, P NATL ACAD SCI USA, V110, P21012, DOI 10.1073/pnas.1321210110
   Thomas DM, 2004, J CELL BIOL, V167, P925, DOI 10.1083/jcb.200409187
   Tomkinson A, 1997, J CLIN ENDOCR METAB, V82, P3128, DOI 10.1210/jc.82.9.3128
   Torreggiani E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075204
   Tresguerres FGF, 2020, ANN ANAT, V227, DOI 10.1016/j.aanat.2019.151422
   Truesdell SL, 2020, JOVE J VIS EXP, DOI 10.3791/61076
   Twine NA, 2014, BONE, V67, P23, DOI 10.1016/j.bone.2014.06.027
   Uda Y, 2017, CURR OSTEOPOROS REP, V15, P318, DOI 10.1007/s11914 017 0373 0
   Udagawa N, 1999, BONE, V25, P517, DOI 10.1016/S8756 3282(99)00210 0
   Vahidi G, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115663
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   Verborgt O, 2002, J BONE MINER RES, V17, P907, DOI 10.1359/jbmr.2002.17.5.907
   Vrahnas C., 2015, Current Molecular Biology Reports, V1, P148, DOI DOI 10.1007/S40610 015 0024 0
   Wang RN, 2014, GENES DIS, V1, P87, DOI 10.1016/j.gendis.2014.07.005
   Wee NKY, 2021, CURR OSTEOPOROS REP, V19, P604, DOI 10.1007/s11914 021 00708 5
   WeinEmail M.N., 2017, CURRENT MOL BIOL REP, V3, P79, DOI DOI 10.1007/S40610 017 0062 X
   Weinstein RS, 2000, J CLIN ENDOCR METAB, V85, P2907, DOI 10.1210/jc.85.8.2907
   Werner SL, 2020, JBMR PLUS, V4, DOI 10.1002/jbm4.10080
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
   Wu H, 2014, GENOME BIOL, V15, DOI 10.1186/gb 2014 15 3 r52
   Wu HP, 2009, J BONE MINER RES, V24, P871, DOI [10.1359/JBMR.081239, 10.1359/jbmr.081239]
   Wu Q, 2017, CELL PHYSIOL BIOCHEM, V41, P1360, DOI 10.1159/000465455
   Xian LL, 2012, NAT MED, V18, P1095, DOI 10.1038/nm.2793
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Xu X, 2018, BONE RES, V6, DOI 10.1038/s41413 017 0005 4
   Yagi M, 2007, J BONE MINER RES, V22, P992, DOI 10.1359/JBMR.070401
   Yahara Y, 2022, DEVELOPMENT, V149, DOI 10.1242/dev.199908
   Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092 8674(04)00344 7
   Yang XR, 2021, FRONT MATER, V7, DOI 10.3389/fmats.2020.610558
   Yao ZQ, 2008, J BIOL CHEM, V283, P9917, DOI 10.1074/jbc.M706415200
   Yellowley CE, 2000, J BONE MINER RES, V15, P209, DOI 10.1359/jbmr.2000.15.2.209
   Yi S, 2020, BMB REP, V53, P646, DOI 10.5483/BMBRep.2020.53.12.199
   Youngstrom DW, 2016, BONE, V91, P64, DOI 10.1016/j.bone.2016.07.006
   Yourek G, 2010, REGEN MED, V5, P713, DOI 10.2217/RME.10.60
   Yu HY, 2011, ANGLE ORTHOD, V81, P100, DOI 10.2319/050210 238.1
   Yu J, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115474
   Yu SB, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007583
   Yu XF, 2003, J BONE MINER RES, V18, P1404, DOI 10.1359/jbmr.2003.18.8.1404
   ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373
   Zhang J, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.716907
   Zhang KQ, 2006, MOL CELL BIOL, V26, P4539, DOI 10.1128/MCB.02120 05
   Zhang N, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.812094
   Zhang YL, 2015, NANOSCALE, V7, P19207, DOI 10.1039/c5nr05421d
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
   Zheng ZR, 2022, REACT FUNCT POLYM, V171, DOI 10.1016/j.reactfunctpolym.2021.105151
   Zhong ZD, 2012, P NATL ACAD SCI USA, V109, pE2197, DOI 10.1073/pnas.1120407109
   Zhu H, 2019, BIOMATERIALS, V196, P31, DOI 10.1016/j.biomaterials.2018.02.009
   Zhu LX, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaw6143
   Zohar R, 1998, EUR J ORAL SCI, V106, P401, DOI 10.1111/j.1600 0722.1998.tb02206.x
   Zou LJ, 2013, SCI REP UK, V3, DOI 10.1038/srep02243
   Zou SS, 2014, J ORTHOP SURG RES, V9, DOI 10.1186/s13018 014 0102 7
   Zujur D, 2020, REGEN THER, V14, P19, DOI 10.1016/j.reth.2019.12.010
NR 258
TC 11
Z9 12
U1 6
U2 16
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2629 3269
EI 2629 3277
J9 STEM CELL REV REP
JI Stem Cell Rev. Rep.
PD AUG
PY 2023
VL 19
IS 6
BP 1635
EP 1658
DI 10.1007/s12015 023 10558 6
EA MAY 2023
PG 24
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA N4FI6
UT WOS:000992674100001
PM 37204634
DA 2025 08 17
ER

PT J
AU Zeng, DF
   Liu, T
   Zhang, Y
   Chang, C
   Zhang, X
   Kong, PY
AF Zeng Dong Feng
   Liu Ting
   Zhang Yong
   Chang Cheng
   Zhang Xi
   Kong Pei Yan
TI The TPO/c MPL Pathway in the Bone Marrow may Protect Leukemia Cells from
   Chemotherapy in AML Patients
SO PATHOLOGY & ONCOLOGY RESEARCH
LA English
DT Article
DE Thrombopoietin; c MPL; Acute myeloid leukemia; Chemotherapy resistance;
   Relapse
ID HEMATOPOIETIC STEM CELLS; PROGENITOR CELLS; MESSENGER RNA;
   THROMBOPOIETIN; NICHE; RECEPTOR; PROLIFERATION; EXPRESSION; RESISTANCE
AB Accumulating evidence indicates that the interaction of human LSCs (leukemic stem cells) with the hematopoietic microenvironment, mediated by the thrombopoietin (TPO)/c MPL pathway, may be an underlying mechanism for resistance to cell cycle dependent cytotoxic chemotherapy. However, the role of TPO/c MPL signaling in AML (acute myelogenous leukemia) chemotherapy resistance hasn't been fully understood. The c MPL and TPO levels in different AML samples were measured by flow cytometry and ELISA. We also assessed the TPO levels in the osteoblasts derived from bone mesenchymal stem cells (BMSCs). The survival rate of an AML cell line that had been co cultured with different BMSC derived osteoblasts was measured to determine the IC50 of an AML chemotherapy drug daunorubicin (DNR). The levels of TPO/c MPL in the initial and relapse AML patients were significantly higher than that in the control (P < 0.05). The osteoblasts derived from AML patients' BMSCs secreted more TPO than the osteoblasts derived from normal control BMSCs (P < 0.05). A strong positive correlation between the TPO level and c MPL expression was found in the bone marrow mononuclear cells of the relapse AML patients. More importantly, the IC50 of DNR in the HEL + AML derived osteoblasts was the highest among all co culture systems. High level of TPO/c MPL signaling may protect LSCs from chemotherapy in AML. The effects of inhibition of the TPO/c MPL pathway on enhancing the chemotherapy sensitivity of AML cells, and on their downstream effector molecules that direct the interactions between patient derived blasts and leukemia repopulating cells need to be further studied.
C1 [Zeng Dong Feng; Chang Cheng; Zhang Xi; Kong Pei Yan] Third Mil Med Univ, Xinqiao Hosp, Dept Hematol, Chongqing 400037, Peoples R China.
   [Liu Ting] Third Mil Med Univ, Daping Hosp, Dept Ophtalmol, Chongqing 400042, Peoples R China.
   [Zhang Yong] Chengdu Gen Hosp Chengdu Mil Reg, Dept Hematol, Chengdu 610000, Peoples R China.
C3 Army Medical University; Army Medical University
RP Kong, PY (通讯作者)，Third Mil Med Univ, Xinqiao Hosp, Dept Hematol, Chongqing 400037, Peoples R China.
EM kongpeiyanpp1312@hotmail.com
FU Military Natural Science foundation of China [06 MB238]; Natural Science
   fund of Chongqing [2009BB5151]; National Natural Science Foundation of
   China [81000195]
FX The study was funded by grants from Military Natural Science foundation
   of China (06 MB238), Natural Science fund of Chongqing (2009BB5151) and
   National Natural Science Foundation of China (81000195).
CR Adams GB, 2006, NAT IMMUNOL, V7, P333, DOI 10.1038/ni1331
   Arai F, 2009, ANN NY ACAD SCI, V1176, P36, DOI 10.1111/j.1749 6632.2009.04561.x
   Blanco TM, 2010, BIOMATERIALS, V31, P2243, DOI 10.1016/j.biomaterials.2009.11.094
   Corazza F, 2006, BLOOD, V107, P2525, DOI 10.1182/blood 2005 06 2552
   Fox N, 2002, J CLIN INVEST, V110, P389, DOI 10.1172/JCI200215430
   Guo Y, 1999, Zhonghua Xue Ye Xue Za Zhi, V20, P120
   Ishikawa F, 2007, NAT BIOTECHNOL, V25, P1315, DOI 10.1038/nbt1350
   Jawad M, 2010, LEUKEMIA, V24, P74, DOI 10.1038/leu.2009.199
   Kaushansky K, 2005, J CLIN INVEST, V115, P3339, DOI 10.1172/JCI26674
   Ku H, 1996, BLOOD, V87, P4544, DOI 10.1182/blood.V87.11.4544.bloodjournal87114544
   Lane SW, 2011, BLOOD, V118, P2849, DOI 10.1182/blood 2011 03 345165
   Lane SW, 2009, BLOOD, V114, P1150, DOI 10.1182/blood 2009 01 202606
   Li LH, 2005, ANNU REV CELL DEV BI, V21, P605, DOI 10.1146/annurev.cellbio.21.012704.131525
   Matsumura IKY, 2005, BLOOD, V86, P703
   Nervi B, 2009, BLOOD, V113, P6206, DOI 10.1182/blood 2008 06 162123
   Parmar A, 2011, CANCER RES, V71, P4696, DOI 10.1158/0008 5472.CAN 10 4136
   Saito Y, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000349
   Schröder JK, 2000, LEUKEMIA RES, V24, P401, DOI 10.1016/S0145 2126(99)00201 5
   She MR, 2012, CANCER LETT, V318, P173, DOI 10.1016/j.canlet.2011.12.017
   Sitnicka E, 1996, BLOOD, V87, P4998, DOI 10.1182/blood.V87.12.4998.bloodjournal87124998
   Wetzler M, 1997, J CLIN ONCOL, V15, P2262, DOI 10.1200/JCO.1997.15.6.2262
   Wilson A, 2009, CURR OPIN GENET DEV, V19, P461, DOI 10.1016/j.gde.2009.08.005
   Wu Yong Xia, 2010, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V18, P671
   Yoshihara H, 2007, CELL STEM CELL, V1, P685, DOI 10.1016/j.stem.2007.10.020
   Zeng ZH, 2009, BLOOD, V113, P6215, DOI 10.1182/blood 2008 05 158311
NR 25
TC 21
Z9 27
U1 0
U2 6
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1219 4956
EI 1532 2807
J9 PATHOL ONCOL RES
JI Pathol. Oncol. Res.
PD APR
PY 2014
VL 20
IS 2
BP 309
EP 317
DI 10.1007/s12253 013 9696 z
PG 9
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pathology
GA AE8WJ
UT WOS:000334283400012
PM 24085601
DA 2025 08 17
ER

PT J
AU Wang, J
   Stern, PH
AF Wang, Jun
   Stern, Paula H.
TI Sex Specific Effects of Estrogen and Androgen on Gene Expression in
   Human Monocyte Derived Osteoclasts
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE GENDER; OSTEOCLAST; GENE; ESTROGEN; ANDROGEN
ID NECROSIS FACTOR ALPHA; BONE MINERAL DENSITY; IN VITRO;
   SIGNAL TRANSDUCTION; ADHESION MOLECULES; PROMOTES APOPTOSIS;
   GENDER DIFFERENCES; FAS LIGAND; DIFFERENTIATION; OSTEOPOROSIS
AB Estrogen and androgen are both critical for the maintenance of bone, but the target cells, mechanisms, and responses could be sex specific. To compare sex specific actions of estrogen and androgen on osteoclasts, human peripheral blood mononuclear precursor cells from adult Caucasian males (n = 3) and females (n = 3) were differentiated into osteoclasts and then treated for 24 h with 17 beta estradiol (10 nM) or testosterone ( 10 nM). Gene expression was studied with a custom designed qPCR based array containing 94 target genes related to bone and hormone action. In untreated osteoclasts, 4 genes showed significant gender differences. 17 beta estradiol significantly affected 12 genes in osteoclasts from females and 6 genes in osteoclasts from males. Fifteen of the 18 17 beta estradiol responsive genes were different in the cells from the two sexes; 2 genes affected by 17 beta estradiol in both sexes were regulated oppositely in the two sexes. Testosterone significantly affected 6 genes in osteoclasts from females and 2 genes in osteoclasts from males; all except one were different in the two sexes. 17 beta estradiol and testosterone largely affected different genes, suggesting that conversion of testosterone to 17 beta estradiol had a limited role in the responses. The findings indicate that although osteoclasts from both sexes respond to 17 beta estradiol and testosterone, the effects of both 17 beta estradiol and testosterone differ in the two sexes, highlighting the importance of considering gender in the design of therapy. J. Cell. Biochem. 112: 3714 3721, 2011. (C) 2011 Wiley Periodicals, Inc.
C1 [Wang, Jun; Stern, Paula H.] Northwestern Univ, Dept Mol Pharmacol & Biol Chem, Feinberg Sch Med, Chicago, IL 60611 USA.
C3 Northwestern University; Feinberg School of Medicine
RP Stern, PH (通讯作者)，Northwestern Univ, Dept Mol Pharmacol & Biol Chem, Feinberg Sch Med, 303 E Chicago Ave, Chicago, IL 60611 USA.
EM p stern@northwestern.edu
OI Wang, Jun/0000 0002 2678 2456
FU Northwestern University Institute for Women's Health Research
FX We thank Dr. Peter Kopp, Dr. Eugene Silinsky, and Dr. Teresa Woodruff
   for their insightful comments and suggestions on the manuscript. This
   study was supported by a Pioneer Award from the Northwestern University
   Institute for Women's Health Research.
CR Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858
   Balga R, 2006, BONE, V39, P325, DOI 10.1016/j.bone.2006.02.056
   Bashir A, 2005, STEROIDS, V70, P847, DOI 10.1016/j.steroids.2005.04.011
   Binder NB, 2009, NAT MED, V15, P417, DOI 10.1038/nm.1945
   Bloemen V, 2010, J CELL PHYSIOL, V222, P565, DOI 10.1002/jcp.21971
   Chen M, 2007, PRINCIPLES OF CLINICAL PHARMACOLOGY, 2ND EDITION, P325, DOI 10.1016/B978 012369417 1/50061 4
   Choi JY, 2005, CALCIFIED TISSUE INT, V77, P152, DOI 10.1007/s00223 004 0264 0
   DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144
   Duma D, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001077
   Ebeling PR, 2010, CURR OPIN ENDOCRINOL, V17, P284, DOI 10.1097/MED.0b013e328339658c
   Ekholm E, 2002, AM J PATHOL, V160, P1779, DOI 10.1016/S0002 9440(10)61124 8
   Erben RG, 2003, ENDOCRINOLOGY, V144, P40, DOI 10.1210/en.2002 220513
   Franconi F, 2007, PHARMACOL RES, V55, P81, DOI 10.1016/j.phrs.2006.11.001
   Frenkel B, 2010, J CELL PHYSIOL, V224, P305, DOI 10.1002/jcp.22159
   Garcia Palacios V, 2007, BONE, V40, P316, DOI 10.1016/j.bone.2006.08.004
   GRIMES R, 1993, GENOMICS, V15, P421, DOI 10.1006/geno.1993.1079
   Helleman J, 2008, CLIN CANCER RES, V14, P5555, DOI 10.1158/1078 0432.CCR 08 0555
   Henriksen K, 2005, AM J PATHOL, V167, P1341, DOI 10.1016/S0002 9440(10)61221 7
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4367, DOI 10.1210/en.140.9.4367
   Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096 1132
   Ichikawa S, 2010, J BONE MINER RES, V25, P1821, DOI 10.1002/jbmr.62
   Ikeda F, 2008, J BONE MINER RES, V23, P907, DOI 10.1359/JBMR.080211
   Kanazawa K, 2005, J BONE MINER RES, V20, P840, DOI 10.1359/JBMR.041225
   Karsdal MA, 2003, J BIOL CHEM, V278, P44975, DOI 10.1074/jbc.M303905200
   Khosla S, 2010, J CLIN ENDOCR METAB, V95, P3, DOI 10.1210/jc.2009 1740
   Kim N, 2002, J EXP MED, V195, P201, DOI 10.1084/jem.20011681
   Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275
   Krum SA, 2008, EMBO J, V27, P535, DOI 10.1038/sj.emboj.7601984
   KURACHI T, 1993, BIOCHIM BIOPHYS ACTA, V1178, P259, DOI 10.1016/0167 4889(93)90202 Z
   Lee HJ, 2007, BONE, V41, P979, DOI 10.1016/j.bone.2007.08.034
   Li WF, 2010, HUM GENET, V127, P249, DOI 10.1007/s00439 009 0773 z
   Metcalfe PD, 2008, AM J PHYSIOL ENDOC M, V294, pE435, DOI 10.1152/ajpendo.00704.2006
   Michael H, 2005, J BONE MINER RES, V20, P2224, DOI 10.1359/JBMR.050803
   MORISHIMA A, 1995, J CLIN ENDOCR METAB, V80, P3689, DOI 10.1210/jc.80.12.3689
   Mühlenbeck F, 1998, J BIOL CHEM, V273, P33091, DOI 10.1074/jbc.273.49.33091
   Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Nicks Kristy M, 2010, Curr Osteoporos Rep, V8, P60, DOI 10.1007/s11914 010 0014 3
   Okada Y, 2002, ENDOCR J, V49, P483, DOI 10.1507/endocrj.49.483
   Pederson L, 1999, P NATL ACAD SCI USA, V96, P505, DOI 10.1073/pnas.96.2.505
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Richards JB, 2009, ANN INTERN MED, V151, P528, DOI 10.7326/0003 4819 151 8 200910200 00006
   Saintier D, 2006, J STEROID BIOCHEM, V99, P165, DOI 10.1016/j.jsbmb.2006.01.009
   SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604
   Sugatani T, 2003, J BIOL CHEM, V278, P5001, DOI 10.1074/jbc.M209299200
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tiedemann K, 2009, J BIOL CHEM, V284, P33662, DOI 10.1074/jbc.M109.010785
   Young BA, 1998, BIOCHEM BIOPH RES CO, V251, P320, DOI 10.1006/bbrc.1998.9475
   Young M. F., 2006, Journal of Musculoskeletal & Neuronal Interactions, V6, P364
   Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685
   Zhang X, 2002, METHOD FIND EXP CLIN, V24, P125, DOI 10.1358/mf.2002.24.3.802295
NR 51
TC 22
Z9 27
U1 0
U2 5
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD DEC
PY 2011
VL 112
IS 12
BP 3714
EP 3721
DI 10.1002/jcb.23297
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 851YV
UT WOS:000297309600026
PM 21815190
DA 2025 08 17
ER

PT J
AU Zhuo, MC
   Song, ZF
AF Zhuo, Mengchuan
   Song, Zhoufeng
TI A network pharmacology based investigation on the underlying mechanism
   of Huqian Wan against osteoporosis
SO TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH
LA English
DT Article
DE Huqian Wan; Osteoporosis; Network pharmacology; Molecular docking;
   osteoclast
AB Purpose: To investigate the underlying molecular mechanism of Huqian Wan (HQW) in the treatment of osteoporosis (OP) using a network pharmacology based strategy. Methods: The bioactive components and their targets of HQW, as well as OP related targets were identified using public databases, and online predictive tools. Functional enrichment analyses were performed using Metascape platform. Network construction and analysis were conducted using Cytoscape software, while molecular docking was performed to analyze molecular binding affinities using AutoDock software. Results: A database retrieval identification of HQW contained 128 active components and 482 targets, 85 of which overlapped with OP related genes and were considered potential targets for HQW treatment of OP. Protein interaction analysis revealed five key targets, including AKT1, IL6, VEGFA, IL1B, and CASP3. Functional annotation and pathways enrichment analyses showed that the 85 targets were significantly enriched in interleukin related signal pathways, inflammatory response, and cell proliferation. Moreover, network topology analysis showed that quercetin, kaempferol, nobiletin, tetradecanoic acid, and palmitic acid are the most important 5 active components. Sankey diagram illustrated the herb component target connections in osteoclast differentiation and demonstrated that PPARG was the most affected target. Molecular docking revealed the potential binding pose and affinity between PPARG and active compounds. Conclusion: This systemic characterization of the active components and molecular mechanisms of HQW's treatment of OP will drive subsequent mechanistic and clinical research, and provide a new approach to understanding the mechanism of complex traditional Chinese medicine (TCM).
C1 [Zhuo, Mengchuan] 906th Hosp Joint Logist Support Force Chinese Peop, Dept Orthoped, 377 Zhongshan East Rd, Ningbo 315040, Zhejiang, Peoples R China.
   [Song, Zhoufeng] Zhejiang Chinese Med Univ, Affiliated Hosp 1, Zhejiang Prov Hosp Chinese Med, Dept Orthoped, 54 Youdian Rd, Hangzhou 310006, Zhejiang, Peoples R China.
C3 Zhejiang Chinese Medical University
RP Song, ZF (通讯作者)，Zhejiang Chinese Med Univ, Affiliated Hosp 1, Zhejiang Prov Hosp Chinese Med, Dept Orthoped, 54 Youdian Rd, Hangzhou 310006, Zhejiang, Peoples R China.
EM szfzjtcm@163.com
FU Medical and Health Science and Technology Program of Zhejiang Province,
   China [2021KY825]; Traditional Chinese Medicine Science and Technology
   Plan of Zhejiang Province, China [2021ZB091]
FX This work was supported by Medical and Health Science and Technology
   Program of Zhejiang Province, China (no. 2021KY825) , and Traditional
   Chinese Medicine Science and Technology Plan of Zhejiang Province, China
   (no. 2021ZB091) .
CR Chen P, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889 016 3712 7
   Cho K, 2008, BONE, V42, P53, DOI 10.1016/j.bone.2007.09.051
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Hou PW, 2022, EVID BASED COMPL ALT, V2022, DOI 10.1155/2022/5367494
   Huang YY, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/6080597
   Jia Y, 2022, BIOENGINEERED, V13, P5581, DOI 10.1080/21655979.2022.2038941
   Jin W, STUDY PROTECTIVE EFF, V16
   Li N, 2021, EUR J MED RES, V26, DOI 10.1186/s40001 021 00610 x
   Ma YG, 2021, SCI TOTAL ENVIRON, V750, DOI 10.1016/j.scitotenv.2020.141638
   Qin XY, 2021, J ETHNOPHARMACOL, V270, DOI 10.1016/j.jep.2021.113815
   Sheng B, 2021, EXP MOL PATHOL, V118, DOI 10.1016/j.yexmp.2020.104570
   Wang NN, 2019, J ETHNOPHARMACOL, V241, DOI 10.1016/j.jep.2019.111977
   Wang TT, 2019, CURR DRUG TARGETS, V20, P1, DOI 10.2174/1389450119666180405094046
   Wang YB, 2019, INT J NANOMED, V14, P7839, DOI 10.2147/IJN.S213724
   Xiao P, 2008, J BONE MINER RES, V23, P644, DOI 10.1359/JBMR.080105
   Zeng Q, 2019, J BONE MINER RES, V34, P1789, DOI 10.1002/jbmr.3757
   Zhao J, 2019, MOL MED REP, V20, P5197, DOI 10.3892/mmr.2019.10747
   Zhu NQ, 2020, COMPUT BIOL CHEM, V85, DOI 10.1016/j.compbiolchem.2020.107240
NR 18
TC 0
Z9 0
U1 2
U2 17
PU PHARMACOTHERAPY GROUP
PI BENIN CITY
PA UNIV BENIN, FACULTY PHARMACY, BENIN CITY, 00000, NIGERIA
SN 1596 5996
J9 TROP J PHARM RES
JI Trop. J. Pharm. Res.
PD MAR
PY 2023
VL 22
IS 3
BP 579
EP 587
DI 10.4314/tjpr.v22i3.15
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA D4DN5
UT WOS:000968252900014
OA gold
DA 2025 08 17
ER

PT J
AU Parfitt, M
   Qiu, SJ
   Palnitkar, S
   Rao, DS
AF Parfitt, Michael
   Qiu, Shijing
   Palnitkar, Saroj
   Rao, D. Sudhaker
TI Abnormal Bone Remodeling in Patients With Spontaneous Painful Vertebral
   Fracture
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE OSTEOPOROSIS; OSTEOCLAST; OSTEOBLAST; BONE FORMATION; APOPTOSIS
ID HORMONE REPLACEMENT THERAPY; ILIAC TRABECULAR BONE; POSTMENOPAUSAL
   OSTEOPOROSIS; CANCELLOUS BONE; HISTOMORPHOMETRIC DATA; BIOCHEMICAL
   MARKERS; CELLULAR MECHANISMS; OSTEOCYTE APOPTOSIS; WOMEN; AGE
AB The application of tetracycline based iliac bone histomorphometry to the study of the pathogenesis of osteoporosis has given conflicting results. Accordingly, we performed this procedure in 78 postmenopausal white women with one or more vertebral fractures identified according to rigorous criteria that excluded other causes of vertebral deformity and 66 healthy postmenopausal white women recruited from the same geographic region; the groups did not differ in age or weight. In each subject, measurements were made separately on the cancellous (Cn), endocortical (Ec), and intracortical (Ct) subdivisions of the endosteal envelope. In the fracture patients, osteoblast surface was reduced substantially on each subdivision, most markedly on the Cn surface, where about 25% of the deficit was in cuboidal (type II) osteoblasts, suggesting impaired recruitment; the remaining 75% of the deficit was in intermediate (type III) cells, suggesting earlier transition from type III to type IV (flat) cells. On the Ec and Ct surfaces, the deficit was exclusively in type III cells. Mean bone formation rate was reduced by about 18% on the Cn but not on the Ec or Ct surfaces. The deficit was more significant in subjects matched for Cn BV/TV when adjusted for the inverse regression on osteocyte density and after logarithmic transformation. The difference in bone formation rate resulted from a corresponding reduction in wall thickness without a change in activation frequency. The frequency distribution of bone formation rate was more skewed to the left in the fracture patients than in the controls. Osteoclast surface was significantly lower on each subdivision. The variation in osteoblast surface, bone formation rate, and osteoclast surface was significantly greater in the fracture patients than in the controls, with more abnormally low and abnormally high values. The data suggest the following conclusions: (1) The histologic heterogeneity of postmenopausal osteoporosis is reaffirmed; (2) the different subdivisions of the endosteal envelope, although in continuity, behave differently in health and disease; (3) a combination of defective osteoblast recruitment and premature osteoblast apoptosis would account for the deficit in type II and III cells and the reductions in wall thickness and bone formation rate on the Cn surface and the previously reported osteocyte deficiency in Cn bone; (4) premature disaggregation of multinuclear to mononuclear resorbing cells could account for the osteoclast deficit; and (5) some patients with vertebral fracture have one or another disorder of bone remodeling that at present cannot be identified by noninvasive means. (c) 2011 American Society for Bone and Mineral Research.
C1 [Parfitt, Michael] Univ Arkansas Med Sci, Div Endocrinol, Little Rock, AR 72205 USA.
   [Parfitt, Michael] Univ Arkansas Med Sci, Ctr Osteoporosis & Metab Bone Dis, Little Rock, AR 72205 USA.
   [Qiu, Shijing; Palnitkar, Saroj; Rao, D. Sudhaker] Henry Ford Hosp, Bone & Mineral Res Lab, Detroit, MI 48202 USA.
C3 University of Arkansas System; University of Arkansas Medical Sciences;
   University of Arkansas System; University of Arkansas Medical Sciences;
   Henry Ford Health System; Henry Ford Hospital
RP Parfitt, M (通讯作者)，Univ Arkansas Med Sci, Div Endocrinol, 4301 W Markham,Slot 587, Little Rock, AR 72205 USA.
EM emparfitt@yahoo.com
RI Rao, Sudhaker/ABG 8204 2021
CR Almeida M, 2007, J BIOL CHEM, V282, P27285, DOI 10.1074/jbc.M702810200
   Altman DG., 1991, PRACTICAL STAT MED R
   [Anonymous], OSTEOPOROSIS
   Arlot M E, 1990, Osteoporos Int, V1, P41, DOI 10.1007/BF01880415
   Bell KL, 2001, ANAT REC, V264, P378, DOI 10.1002/ar.10014
   BROWN MEA, 1993, BONE, V14, P473, DOI 10.1016/8756 3282(93)90182 A
   Ciarelli TE, 2003, BONE, V32, P311, DOI 10.1016/S8756 3282(02)00975 4
   COHENSOLAL ME, 1991, J BONE MINER RES, V6, P1331
   Donovan MA, 2005, J CLIN ENDOCR METAB, V90, P3331, DOI 10.1210/jc.2004 2042
   EASTELL R, 1988, J CLIN ENDOCR METAB, V67, P741, DOI 10.1210/jcem 67 4 741
   ERIKSEN EF, 1990, J BONE MINER RES, V5, P311, DOI 10.1002/jbmr.5650050402
   ERIKSEN EF, 1986, ENDOCR REV, V7, P379, DOI 10.1210/edrv 7 4 379
   Eriksen EF, 1999, J BONE MINER RES, V14, P1217, DOI 10.1359/jbmr.1999.14.7.1217
   ERIKSEN EF, 1984, METAB BONE DIS RELAT, V5, P235, DOI 10.1016/0221 8747(84)90065 1
   Flora L., 1981, BONE HISTOMORPHOMETR, P389
   FOLDES J, 1991, J BONE MINER RES, V6, P759
   FOLDES J, 1990, J BONE MINER RES, V5, P1063
   Frost HM, 1997, BONE, V20, P385, DOI 10.1016/S8756 3282(97)00019 7
   Han ZH, 1997, J BONE MINER RES, V12, P498, DOI 10.1359/jbmr.1997.12.4.498
   HATTNER RS, VITAMIN D BIOCH CHEM, P377
   Heaney RP, 2003, BONE, V33, P457, DOI 10.1016/S8756 3282(03)00236 9
   Jilka RL, 2007, J BONE MINER RES, V22, P1492, DOI 10.1359/JBMR.070518
   JONES SJ, 1974, CALC TISS RES, V14, P309, DOI 10.1007/BF02060305
   KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802
   KIMMEL DB, 1990, BONE MINER, V11, P217, DOI 10.1016/0169 6009(90)90061 J
   Kleerekoper M, 1991, Osteoporos Int, V1, P155, DOI 10.1007/BF01625446
   KLEEREKOPER M, 1994, J BONE MINER RES, V9, P1267
   KLEEREKOPER M, 1984, OSTEOPOROSIS, P103
   Kotowicz M A, 1990, Osteoporos Int, V1, P14, DOI 10.1007/BF01880411
   Lean JM, 2003, J CLIN INVEST, V112, P915, DOI 10.1172/JCI200318859
   Manolagas SC, 1998, ANN NY ACAD SCI, V840, P194, DOI 10.1111/j.1749 6632.1998.tb09563.x
   Marie PJ, 1999, HISTOL HISTOPATHOL, V14, P525, DOI 10.14670/HH 14.525
   Meunier P., 1981, OSTEOPOROSIS RECENT, P293
   Mullender MG, 2005, CALCIFIED TISSUE INT, V77, P291, DOI 10.1007/s00223 005 0043 6
   OTT SM, 1993, J BONE MINER RES, V8, P443
   Parfitt A.M., 1987, Osteoporosis, P301
   Parfitt A.M., 1986, Current concepts of bone fragility, P167
   PARFITT AM, 1983, J CLIN INVEST, V72, P1396, DOI 10.1172/JCI111096
   PARFITT AM, 1995, J BONE MINER RES, V10, P466
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   PARFITT AM, 1985, BONE, V6, P211, DOI 10.1016/8756 3282(85)90003 1
   Parfitt AM, 2003, CURR OPIN NEPHROL HY, V12, P387, DOI 10.1097/00041552 200307000 00007
   Parfitt AM, 1997, J BONE MINER RES, V12, P1864, DOI 10.1359/jbmr.1997.12.11.1864
   PARFITT AM, 1987, J BONE MINER RES, V2, P427
   PARFITT AM, 1991, CALCIFIED TISSUE INT, V48, P74, DOI 10.1007/BF02555869
   Parfitt AM., 1990, BONE, V1, P351
   PARFITT AM, 1989, CLIN DISORDERS BONE, P7
   PARFITT AM, 1984, MINERAL METABOLISM R, V4, P3
   PARFITT AM, 1982, SPINE, P775
   QIU MC, 1983, CLIN DISORDERS BONE, P209
   Qiu S, 2006, J BONE MINER RES, V21, pS267
   Qiu SJ, 2003, J BONE MINER RES, V18, P1657, DOI 10.1359/jbmr.2003.18.9.1657
   QUI S, 2002, BONE, V31, P709
   Rao D.S., 1983, Bone histomorphometry: Techniques and interpretation, P3
   Rauch F, 2002, BONE, V31, P85, DOI 10.1016/S8756 3282(02)00814 1
   RECKER RR, 2001, OSTEOPOROSIS, P59
   SEDLIN ED, 1963, MED B, V11, P217
   SOKAL RR, 1981, BIOMETRY
   VILLANUEVA A, 1966, J LAB CLIN MED, V68, P598
   VILLANUEVA A. R., 1966, CLIN ORTHOP RELATED RES, V49, P135
   VILLANUEVA AR, 1986, STAIN TECHNOL, V61, P83, DOI 10.3109/10520298609110713
   VILLANUEVA AR, 1983, HDB BONE MORPHOMETRY, P191
   Weinstein RS, 2000, J BONE MINER RES, V15, P621, DOI 10.1359/jbmr.2000.15.4.621
   Weinstein RS, 2003, OSTEOPOROSIS INT, V14, P814, DOI 10.1007/s00198 003 1434 z
   WEINSTEIN RS, 1983, NUTRITION MIDDLE LAT, P211
   WHYTE MP, 1982, AM J MED, V72, P192
NR 66
TC 13
Z9 14
U1 0
U2 3
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD MAR
PY 2011
VL 26
IS 3
BP 475
EP 485
DI 10.1002/jbmr.239
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 727UG
UT WOS:000287827600007
PM 20814971
OA Bronze
DA 2025 08 17
ER

PT J
AU Wadhwa, R
   Kumar, M
   Paudel, YN
   Iqbal, R
   Kothari, P
   Trivedi, R
   Vohora, D
AF Wadhwa, Ravisha
   Kumar, Manoj
   Paudel, Yam Nath
   Iqbal, Ramsha
   Kothari, Priyanka
   Trivedi, Ritu
   Vohora, Divya
TI Effect of escitalopram and carbidopa on bone markers in Wistar rats: a
   preliminary experimental study
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE Escitalopram; Carbidopa; Alkaline phosphatase; RANKL; Sclerostin
ID SEROTONIN; 5 HYDROXYTRYPTOPHAN; OSTEOPROTEGERIN; INHIBITION; SCLEROSTIN;
   RESORPTION; DENSITY; PATHWAY; LRP5; MICE
AB In view of the opposite effects of gut and brain serotonin in bone, the key role of Wnt /catenin pathway in osteoblastic proliferation and the controversial bony effects of selective serotonin reuptake inhibitors antidepressants, the present study investigated the effects of escitalopram alone and in combination with carbidopa (to block gut derived serotonin) on markers of bone turnover and Wnt signaling and micro CT in male Wistar rats. Escitalopram (2.0mg/kg, p.o.) and carbidopa (10mg/kg, p.o.) were administered daily for 40days following which indicators of reduced (dickkopf 1, sclerostin), and increased (alkaline phosphatase) bone formation and bone resorption markers (receptor activator of nuclear factor B ligand, tartrate resistant acid phosphatase 5b) were determined. Our results indicated that escitalopram adversely affected bone as indicated by reduced bone formation and enhanced bone resorption. Further, the effects of escitalopram on bone formation were possibly mediated through gut serotonin while the mechanisms responsible for effects on resorption seem unrelated to gut serotonin. The promising effects of carbidopa on bone formation, as observed in our study, open up exciting possibilities for this drug requiring further investigations.
C1 [Wadhwa, Ravisha; Paudel, Yam Nath; Vohora, Divya] Jamia Hamdard, Sch Pharmaceut Educ & Res, Dept Pharmacol, New Delhi 110062, India.
   [Kumar, Manoj; Iqbal, Ramsha; Vohora, Divya] Jamia Hamdard, Sch Pharmaceut Educ & Res, Dept Pharmacol, Pharmaceut Med, New Delhi 110062, India.
   [Kothari, Priyanka; Trivedi, Ritu] Cent Drug Res Inst, CSIR, Endocrinol Div, Lucknow 226031, Uttar Pradesh, India.
C3 Jamia Hamdard University; Jamia Hamdard University; Council of
   Scientific & Industrial Research (CSIR)   India; CSIR   Central Drug
   Research Institute (CDRI)
RP Vohora, D (通讯作者)，Jamia Hamdard, Sch Pharmaceut Educ & Res, Dept Pharmacol, New Delhi 110062, India.; Vohora, D (通讯作者)，Jamia Hamdard, Sch Pharmaceut Educ & Res, Dept Pharmacol, Pharmaceut Med, New Delhi 110062, India.
EM dvohra@jamiahamdard.ac.in
RI ; Kothari, Priyanka/AAE 3770 2021; Paudel, Yam/L 2908 2019; Vohora,
   Divya/H 4245 2019
OI Vohora, Divya/0000 0003 1852 9191; Trivedi, Ritu/0000 0002 9524 2541; 
FU AICTE (GPAT)
FX This work was carried out in UGC SAP assisted Neurobehavioral
   Pharmacology Laboratory. We thank M. Raj for helping in arranging
   carbidopa sample from Shodhana Laboratories, Hyderabad. Special thanks
   to Dr. Bibhu Prasad Panda, for permission to work in Pharmaceutical
   Biotechnology Laboratory (Jamia Hamdard). The work was supported by
   fellowship from AICTE (GPAT).
CR Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Battaglino R, 2007, J CELL BIOCHEM, V100, P1387, DOI 10.1002/jcb.21131
   Bourke CH, 2013, PSYCHOPHARMACOLOGY, V228, P231, DOI 10.1007/s00213 013 3030 z
   Diem SJ, 2014, J CLIN ENDOCR METAB, V99, pE1732, DOI 10.1210/jc.2014 2288
   Dubnov Raz G, 2012, EARLY HUM DEV, V88, P191, DOI 10.1016/j.earlhumdev.2011.08.005
   Ducy P, 2010, J CELL BIOL, V191, P7, DOI 10.1083/jcb.201006123
   GARFINKEL PE, 1977, ARCH GEN PSYCHIAT, V34, P735
   Gaudio A, 2010, J CLIN ENDOCR METAB, V95, P2248, DOI 10.1210/jc.2010 0067
   Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848
   Goltzman D, 2011, J BONE MINER RES, V26, P1997, DOI 10.1002/jbmr.462
   GOODWIN GM, 1985, BRIT J PHARMACOL, V84, P743, DOI 10.1111/j.1476 5381.1985.tb16157.x
   Gustafsson BI, 2006, J CELL BIOCHEM, V98, P139, DOI 10.1002/jcb.20734
   Halleen JM, 2000, J BONE MINER RES, V15, P1337, DOI 10.1359/jbmr.2000.15.7.1337
   Hampson G, 2013, BONE, V56, P42, DOI 10.1016/j.bone.2013.05.010
   Inose H, 2011, J BONE MINER RES, V26, P2002, DOI 10.1002/jbmr.439
   Kaiser M, 2008, EUR J HAEMATOL, V80, P490, DOI 10.1111/j.1600 0609.2008.01065.x
   Kostenuik PJ, 2005, CURR OPIN PHARMACOL, V5, P618, DOI 10.1016/j.coph.2005.06.005
   Lee DJ, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.20
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Ominsky MS, 2008, J BONE MINER RES, V23, P672, DOI 10.1359/JBMR.080109
   Radaei F, 2013, BRAIN DISORD THER, V2, P2
   Smarius LJCA, 2008, J PSYCHOPHARMACOL, V22, P426, DOI 10.1177/0269881107082025
   TENNISWOOD M, 1976, CAN J BIOCHEM CELL B, V54, P350, DOI 10.1139/o76 051
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Yadav VK, 2010, NAT MED, V16, P308, DOI 10.1038/nm.2098
   Yadav VK, 2009, CELL, V138, P976, DOI 10.1016/j.cell.2009.06.051
   Yadav VK, 2008, CELL, V135, P825, DOI 10.1016/j.cell.2008.09.059
   Yamada J, 1999, EUR J PHARMACOL, V383, P49, DOI 10.1016/S0014 2999(99)00580 4
   Zhang W, 2012, CURR OSTEOPOROS REP, V10, P93, DOI 10.1007/s11914 011 0086 8
NR 29
TC 2
Z9 3
U1 0
U2 0
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3 8 1 NISHI KANDA, CHIYODA KU, TOKYO, 101 0065,
   JAPAN
SN 0914 8779
EI 1435 5604
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD JAN
PY 2019
VL 37
IS 1
BP 36
EP 42
DI 10.1007/s00774 018 0908 1
PG 7
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA HO0KV
UT WOS:000460593200006
PM 29380075
DA 2025 08 17
ER

PT J
AU Hall, CL
   Kang, SN
   MacDougald, OA
   Keller, ET
AF Hall, CL
   Kang, SN
   MacDougald, OA
   Keller, ET
TI Role of Wnts in prostate cancer bone metastases
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE prostate cancer; DKK; metastasis; Wnt; osteoblast; bone
ID HEPATOCYTE GROWTH FACTOR; RECEPTOR RELATED PROTEIN 5; MESENCHYMAL
   STEM CELLS; BETA CATENIN; OSTEOBLAST DIFFERENTIATION; C MET; OSTEOGENIC
   DIFFERENTIATION; NUCLEAR TRANSLOCATION; PROMOTES OSTEOGENESIS; INHIBITS
   APOPTOSIS
AB Prostate cancer (CaP) is unique among all cancers in that when it metastasizes to bone, it typically forms osteoblastic lesions (characterized by increased bone production). CaP cells produce many factors, including Wnts that are implicated in tumor induced osteoblastic activity. In this prospectus, we describe our research on Wnt and the CaP bone phenotype. Wnts are cysteine rich glycoproteins that mediate bone development in the embryo and promote bone production in the adult. Wnts have been shown to have autocrine tumor effects, such as enhancing proliferation and protecting against apoptosis. In addition, we have recently identified that CaP produced Wnts act in a paracrine fashion to induce osteoblastic activity in CaP bone metastases. In addition to Wnts, CaP cells express the soluble Wnt inhibitor dickkopf 1 (DKK 1). If appears that DKK 1 production Occurs early in the development of skeletal metastases, which results in masking of osteogenic Wnts, thus favoring osteolysis at the metastatic site. As metastases progress, DKK 1 expression decreases allowing for unmasking of Wnt's osteoblastic activity and ultimately resulting in osteosclerosis at the metastatic site. We believe that DKK 1 is one of the switches that transitions the CaP bone metastasis activity from osteolytic to osteoblastic. Wnt/DKK 1 activity fits a model of CaP induced bone remodeling occurring in, a continuum composed of an osteolytic phase, mediated by receptor activator of NFkB ligand (RANKL), parathyroid hormone related protein (PTHRP) and DKK 1; a transitional phase, where environmental alterations promote expression of osteoblastic factors (Wnts) and decreases osteolytic factors (i.e., DKK 1); and an osteoblastic phase, in which tumor growth associated hypoxia results in production of vascular endothelial growth factor and endothelin 1, which have osteoblastic activity. This model suggests that targeting both osteolytic activity and osteoblastic activity will provide efficacy for therapy of CaP bone metastases.
C1 Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA.
   Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan
RP RM 5304 CCGCB,1300 E Med Ctr Dr, Ann Arbor, MI 48109 USA.
EM etkeller@umich.edu
RI ; MacDougald, Ormond/HTL 2168 2023; Keller, Evan/M 1446 2016
OI Hall, Christopher/0000 0003 1421 1733; MacDougald,
   Ormond/0000 0001 6907 7960; 
FU NCI NIH HHS [P01 CA093900, R01 CA071672] Funding Source: Medline;
   National Cancer Institute [P01CA093900] Funding Source: NIH RePORTER
CR ABRAMS HL, 1950, CANCER, V3, P74, DOI 10.1002/1097 0142(1950)3:1<74::AID CNCR2820030111>3.0.CO;2 7
   Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960
   Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Bodine PVN, 2004, MOL ENDOCRINOL, V18, P1222, DOI 10.1210/me.2003 0498
   Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284
   Boyce BF, 1999, ENDOCR RELAT CANCER, V6, P333, DOI 10.1677/erc.0.0060333
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002 9440(10)65204 2
   Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87
   Cheng SL, 2003, J BIOL CHEM, V278, P45969, DOI 10.1074/jbc.M306972200
   Chirgwin J. M., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P308
   Church VL, 2002, INT J DEV BIOL, V46, P927
   Corey E, 2003, CLIN CANCER RES, V9, P295
   Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627
   Cronauer MV, 2005, INT J ONCOL, V26, P1033
   Dai JL, 2005, CANCER RES, V65, P8274, DOI 10.1158/0008 5472.CAN 05 1891
   Dai JL, 2004, CANCER RES, V64, P994, DOI 10.1158/0008 5472.CAN 03 1382
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   de Boer J, 2004, BONE, V34, P818, DOI 10.1016/j.bone.2004.01.016
   Derfoul A, 2004, DIFFERENTIATION, V72, P209, DOI 10.1111/j.1432 0436.2004.07205003.x
   Farr GH, 2000, J CELL BIOL, V148, P691, DOI 10.1083/jcb.148.4.691
   Fizazi K, 2003, CLIN CANCER RES, V9, P2587
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Giles RH, 2003, BBA REV CANCER, V1653, P1, DOI 10.1016/S0304 419X(03)00005 2
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Grotewold L, 2002, EMBO J, V21, P966, DOI 10.1093/emboj/21.5.966
   Guise Theresa A., 2000, Cancer, V88, P2892, DOI 10.1002/1097 0142(20000615)88:12+<2892::AID CNCR2>3.0.CO;2 Y
   Hall CL, 2005, CANCER RES, V65, P7554, DOI 10.1158/0008 5472.CAN 05 1317
   Hall CL, 2004, PROSTATE, V59, P167, DOI 10.1002/pros.20009
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839
   Herynk MH, 2003, CLIN EXP METASTAS, V20, P291, DOI 10.1023/A:1024024218529
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564
   HUGUET EL, 1994, CANCER RES, V54, P2615
   HUMPHREY PA, 1995, AM J PATHOL, V147, P386
   Hwang SG, 2004, J BIOL CHEM, V279, P26597, DOI 10.1074/jbc.M401401200
   Jackson A, 2005, BONE, V36, P585, DOI 10.1016/j.bone.2005.01.007
   Jeon MJ, 2003, J BIOL CHEM, V278, P23270, DOI 10.1074/jbc.M211610200
   Jiang W, 1999, CRIT REV ONCOL HEMAT, V29, P209, DOI 10.1016/S1040 8428(98)00019 5
   Johnson M. L., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P135
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   Keller ET, 2001, CANCER METAST REV, V20, P333, DOI 10.1023/A:1015599831232
   Kennell JA, 2005, J BIOL CHEM, V280, P24004, DOI 10.1074/jbc.M501080200
   Kikuchi A, 2000, BIOCHEM BIOPH RES CO, V268, P243, DOI 10.1006/bbrc.1999.1860
   Koeneman KS, 1999, PROSTATE, V39, P246
   Kühl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/S0168 9525(00)02028 X
   Kuhnert F, 2004, P NATL ACAD SCI USA, V101, P266, DOI 10.1073/pnas.2536800100
   LEJEUNE S, 1995, CLIN CANCER RES, V1, P215
   Lévy L, 2002, J BIOL CHEM, V277, P42386, DOI 10.1074/jbc.M207418200
   Li JN, 2005, GASTROENTEROLOGY, V128, P1907, DOI 10.1053/j.gastro.2005.02.067
   Li XF, 2005, NAT GENET, V37, P945, DOI 10.1038/ng1614
   Lin DL, 2001, PROSTATE, V47, P212, DOI 10.1002/pros.1065
   Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528
   Longo KA, 2002, J BIOL CHEM, V277, P38239, DOI 10.1074/jbc.M206402200
   Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108
   Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756
   Monga SPS, 2002, CANCER RES, V62, P2064
   Morony S, 2001, CANCER RES, V61, P4432
   Mukhopadhyay M, 2001, DEV CELL, V1, P423, DOI 10.1016/S1534 5807(01)00041 7
   Mulholland DJ, 2002, J BIOL CHEM, V277, P17933, DOI 10.1074/jbc.M200135200
   Müller T, 2002, EXP CELL RES, V280, P119, DOI 10.1006/excr.2002.5630
   Mundy GR, 1997, CANCER AM CANCER SOC, V80, P1546, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1546::AID CNCR4>3.3.CO;2 R
   Nelson JB, 2003, J UROLOGY, V169, P1143, DOI 10.1097/01.ju.0000042162.08938.27
   Nuttall ME, 2004, CURR OPIN PHARMACOL, V4, P290, DOI 10.1016/j.coph.2004.03.002
   Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124
   PISTERS LL, 1995, J UROLOGY, V154, P293, DOI 10.1016/S0022 5347(01)67297 5
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Rubin J, 2004, PROSTATE, V58, P41, DOI 10.1002/pros.10299
   Schneider A, 2005, ENDOCRINOLOGY, V146, P1727, DOI 10.1210/en.2004 1211
   Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   van der Horst G, 2005, J BONE MINER RES, V20, P1867, DOI 10.1359/JBMR.050614
   Van Wesenbeeck L, 2003, AM J HUM GENET, V72, P763, DOI 10.1086/368277
   vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092 8674(00)81925 X
   Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534 5807(03)00266 1
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002 9440(10)65297 2
   Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611
   YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087
   Yang Yingzi, 2003, Birth Defects Research, V69, P305, DOI 10.1002/bdrc.10026
   Zechner D, 2003, DEV BIOL, V258, P406, DOI 10.1016/S0012 1606(03)00123 4
   Zhang J, 2003, CANCER RES, V63, P7883
   Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685
NR 92
TC 141
Z9 164
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD MAR 1
PY 2006
VL 97
IS 4
BP 661
EP 672
DI 10.1002/jcb.20735
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 021BV
UT WOS:000235958500002
PM 16447163
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Jin, C
   Zheng, JW
   Yang, QC
   Jia, YW
   Li, HB
   Liu, XW
   Xu, YJ
   Chen, ZL
   He, L
AF Jin, Cong
   Zheng, Jiewen
   Yang, Qichang
   Jia, Yewei
   Li, Haibo
   Liu, Xuewen
   Xu, Yangjun
   Chen, Zhuolin
   He, Lei
TI Morusin Inhibits RANKL induced Osteoclastogenesis and Ovariectomized
   Osteoporosis
SO COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING
LA English
DT Article
DE Postmenopausal osteoporosis; morusin; moraceae; osteoclastogenesis;
   osteoclasts; RANKL
ID NF KAPPA B; BONE RESORPTION; DIFFERENTIATION; ACTIVATION; FUSION;
   APOPTOSIS; RECEPTOR; AKT; CSF
AB Background Postmenopausal osteoporosis (PMOP) is a classic type of osteoporosis that has gradually become a significant health problem worldwide. There is an urgent need for a safe alternative therapeutic agent considering the poor therapeutic strategies currently available for this disease. The roots and bark of the Morus australis tree (Moraceae) are used to make a traditional Chinese medicine known as "Morusin", and accumulating evidence has demonstrated its multiple activities, such as anti inflammatory and anti tumor effects.Objective In this study, we aim to explore the effect of Morusin on mouse osteoclasts and its mechanism.Methods In this study, we explored the inhibitory effects of Morusin on murine osteoclasts in vitro and its mechanism, and the protective effect of Morusin on an ovariectomy (OVX) induced osteoporosis model in vivo.Results The results showed that Morusin prevented OVX induced bone loss and dramatically decreased RANKL induced osteoclastogenesis. Morusin interfered with RANKL activated NF kappa B, MAPK, and PI3K/AKT signaling pathways. The expression of three master factors that control osteoclast differentiation, c Fos, NFATc1, and c Jun, was reduced by Morusin treatment. Collectively, in vitro results indicated that Morusin has a protective effect on OVX induced bone loss in a mouse model.Conclusion Our data provide encouraging evidence that Morusin may be an effective treatment for PMOP.
C1 [Jin, Cong; Zheng, Jiewen; Yang, Qichang; Jia, Yewei; Li, Haibo; Liu, Xuewen; Xu, Yangjun; Chen, Zhuolin; He, Lei] Shaoxing Peoples Hosp, Dept Orthopaed, Shaoxing 312000, Zhejiang, Peoples R China.
   [Zheng, Jiewen; Xu, Yangjun] Shaoxing Univ, Sch Med, Shaoxing 312000, Zhejiang, Peoples R China.
   [Yang, Qichang; Liu, Xuewen] Wenzhou Med Univ, Affiliated Hosp & Yuying Childrens Hosp 2, Wenzhou 325000, Zhejiang, Peoples R China.
   [Chen, Zhuolin] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Orthopaed, Sch Med, Hangzhou 310000, Zhejiang, Peoples R China.
C3 Shaoxing University; Wenzhou Medical University; Zhejiang University
RP He, L (通讯作者)，Shaoxing Peoples Hosp, Dept Orthopaed, Shaoxing 312000, Zhejiang, Peoples R China.
EM helei1981@163.com
FU Zhejiang Basic Public Welfare Research Project [LGF20H060011]
FX This study was supported by the Zhejiang Basic Public Welfare Research
   Project (Grant no. LGF20H060011).
CR Aki S, 2003, YONSEI MED J, V44, P961, DOI 10.3349/ymj.2003.44.6.961
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Bonetti B, 1999, AM J PATHOL, V155, P1433, DOI 10.1016/S0002 9440(10)65456 9
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen M, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02239 3
   Chiu YC, 2009, J IMMUNOL, V183, P2785, DOI 10.4049/jimmunol.0802826
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   GENANT HK, 1989, AM J OBSTET GYNECOL, V161, P1842, DOI 10.1016/S0002 9378(89)80004 3
   Jia YW, 2020, DRUG DES DEV THER, V14, P1227, DOI 10.2147/DDDT.S244462
   Jia YW, 2019, J CELL PHYSIOL, V234, P7498, DOI 10.1002/jcp.27511
   KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169 6009(91)90124 I
   Khan M, 2017, ENDOCRIN METAB CLIN, V46, P181, DOI 10.1016/j.ecl.2016.09.009
   Kim HK, 2006, J NUTR, V136, P409, DOI 10.1093/jn/136.2.409
   Kim Jung Ha, 2016, Chonnam Med J, V52, P12, DOI 10.4068/cmj.2016.52.1.12
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Lamothe B, 2007, BIOCHEM BIOPH RES CO, V359, P1044, DOI 10.1016/j.bbrc.2007.06.017
   Lee K, 2016, INT J BIOL SCI, V12, P235, DOI 10.7150/ijbs.13814
   Lee MS, 2009, J IMMUNOL, V183, P3390, DOI 10.4049/jimmunol.0804314
   Li HY, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046 015 0252 4
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   Lin B, 2017, BIOORG MED CHEM LETT, V27, P2389, DOI 10.1016/j.bmcl.2017.04.018
   Ljusberg J, 2005, J BIOL CHEM, V280, P28370, DOI 10.1074/jbc.M502469200
   Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605
   Ross FP, 2006, ANN NY ACAD SCI, V1068, P110, DOI 10.1196/annals.1346.014
   Sanz L, 2000, EMBO J, V19, P1576, DOI 10.1093/emboj/19.7.1576
   Seeman E, 2003, OSTEOPOROSIS INT, V14, pS2, DOI 10.1007/s00198 002 1340 9
   Soysa NS, 2009, BIOCHEM BIOPH RES CO, V378, P1, DOI 10.1016/j.bbrc.2008.10.146
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Vochyánová Z, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182464
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wagner EF, 2010, ANN RHEUM DIS, V69, P86, DOI 10.1136/ard.2009.119396
   Walsh MC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004064
   Wang F, 2017, ONCOTARGET, V8, P57187, DOI 10.18632/oncotarget.19231
   Wang L, 2013, MOL CELL BIOCHEM, V379, P7, DOI 10.1007/s11010 013 1621 y
   Werner HJ, 1996, MED ENG PHYS, V18, P601, DOI 10.1016/1350 4533(96)00012 4
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   Yamanaka Y, 2013, J ORTHOP RES, V31, P67, DOI 10.1002/jor.22200
   Zhao KX, 2019, FASEB J, V33, P9100, DOI 10.1096/fj.201802575RR
   Zhao QX, 2010, INT J BIOCHEM CELL B, V42, P576, DOI 10.1016/j.biocel.2009.12.018
NR 45
TC 5
Z9 6
U1 1
U2 11
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1386 2073
EI 1875 5402
J9 COMB CHEM HIGH T SCR
JI Comb. Chem. High Throughput Screen
PY 2024
VL 27
IS 9
BP 1358
EP 1370
DI 10.2174/0113862073252310230925062415
PG 13
WC Biochemical Research Methods; Chemistry, Applied; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy
GA RD0J1
UT WOS:001225612100005
PM 37807416
DA 2025 08 17
ER

PT J
AU Kim, HKW
   Oxendine, I
   Kamiya, N
AF Kim, Harry K. W.
   Oxendine, Ila
   Kamiya, Nobuhiro
TI High concentration of BMP2 reduces cell proliferation and increases
   apoptosis via DKK1 and SOST in human primary periosteal cells
SO BONE
LA English
DT Article
DE High concentration BMP2; Wnt; SOST; DKK1; Periosteum; Proliferation
ID BONE MORPHOGENETIC PROTEIN 2; INTERBODY FUSION; FRACTURES; OSTEOPOROSIS;
   SCLEROSTIN; RESORPTION; REGULATOR; NONUNIONS; RHBMP 2; LESSONS
AB BMP2, a well known osteoinductive agent approved by FDA, is currently being used for various off label orthopedic applications. Recently, concerns about its efficacy for off label use, concentration, and complications have emerged. Interestingly, there is an extremely large discrepancy in BMP2 concentration between clinical use (i.e. 1.5 mg/ml) and in vitro studies (50 300 ng/ml). The purpose of this study was to determine the effects of a relatively high concentration of BMP2 on cell proliferation and apoptosis using human primary periosteal cells as BMP2 is generally applied around the periosteum in orthopedic surgeries. We isolated periosteal cells from three independent patients. The cell proliferation assessed by MIT activity was significantly reduced by a high concentration of BMP2 (similar to 2000 ng/ml), while such a reduction was not observed by using a low concentration of BMP2 (similar to 200 ng/ml). The cell apoptosis assessed by caspase activity was significantly increased by high concentration BMP2, while such an increase was not observed by low concentration BMP2. We found that Wnt signaling activity was significantly reduced by high concentration BMP2 along with a dramatic increase in DKK1 and SOST, key inhibitors of Wnt signaling in bone. The addition of Dial or SOST protein to the primary periosteal cells reduced MIT activity and significantly increased caspase activity. Silencing the DKK1 or SOST expression using the siRNA technique normalized cell proliferation and apoptosis in the periosteum derived cells when exposed to a high concentration BMP2. Taken together, these results suggest that a high concentration BMP2 decreases human periosteal cell proliferation and induces apoptosis via the activation of Wnt inhibitors DKK1 and SOST. This study provides new insights to the effects of high BMP2 concentration on human periosteal cells and brings out the possibility of multiple effects of current BMP2 therapy on various skeletal tissues. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Kim, Harry K. W.; Oxendine, Ila; Kamiya, Nobuhiro] Texas Scottish Rite Hosp Children, Ctr Excellence Hip Disorders, Dallas, TX 75219 USA.
   [Kim, Harry K. W.; Kamiya, Nobuhiro] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
C3 Texas Scottish Rite Hospital for Children; University of Texas System;
   University of Texas Southwestern Medical Center
RP Kamiya, N (通讯作者)，Texas Scottish Rite Hosp Children, 2222 Welborn St, Dallas, TX 75219 USA.
EM Nobby.Kamiya@tsrh.org
RI ; Kim, Harry/AAE 1892 2020
OI Kim, Harry/0000 0002 0330 4777; 
FU Intramural Research Program of Texas Scottish Rite Hospital for Children
FX This work was supported by the Intramural Research Program of Texas
   Scottish Rite Hospital for Children (N. K.). Thanks Cindy Daniel for the
   IRB paperwork (Study ID: STU 012011 181) for this study. Authors' roles:
   IO performed the experiments and gathered the data. NK designed the
   experiments, reviewed data, and wrote the manuscript. HK provided the
   clinical input, reviewed data, and edited the manuscript.
CR Allen MR, 2004, BONE, V35, P1003, DOI 10.1016/j.bone.2004.07.014
   Aro HT, 2011, J BONE JOINT SURG AM
   Baron R, 2006, CURR TOP DEV BIOL, V76, P103, DOI 10.1016/S0070 2153(06)76004 5
   Bodine PVN, 2008, CELL RES, V18, P248, DOI 10.1038/cr.2008.13
   Carragee EJ, 2011, SPINE J, V11, P511, DOI 10.1016/j.spinee.2011.02.013
   Carragee EJ, 2011, SPINE J, V11, P471, DOI 10.1016/j.spinee.2011.04.023
   David L, 2009, CYTOKINE GROWTH F R, V20, P203, DOI 10.1016/j.cytogfr.2009.05.001
   Dmitriev AE, 2011, SPINE J, V11, P500, DOI 10.1016/j.spinee.2011.05.002
   FDA, 2002, INFUSE BONE GRAFT LT
   Garrison KR, 2007, HEALTH TECHNOL ASSES, V11, P1
   Garrison KR, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006950.pub2
   Gupta MC, 2005, CYTOKINE GROWTH F R, V16, P347, DOI 10.1016/j.cytogfr.2005.02.004
   Joseph V, 2007, SPINE, V32, P2885, DOI 10.1097/BRS.0b013e31815b7596
   Kamiya N, 2002, J BONE MINER RES, V17, P1832, DOI 10.1359/jbmr.2002.17.10.1832
   Kamiya N, 2008, DEVELOPMENT, V135, P3801, DOI 10.1242/dev.025825
   Kamiya Nobuhiro, 2012, Curr Mol Pharmacol, V5, P153
   Kamiya N, 2011, BIOCHEM BIOPH RES CO, V414, P326, DOI 10.1016/j.bbrc.2011.09.060
   Kamiya N, 2010, J BONE MINER RES, V25, P200, DOI 10.1359/jbmr.090806
   Khosla S, 2008, J CLIN INVEST, V118, P421, DOI 10.1172/JCI33612
   Lee KB., 2012, J Orthop Res
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   LUYTEN FP, 1989, J BIOL CHEM, V264, P13377
   MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092 8674(92)90627 O
   Mindea SA, 2009, SPINE, V34, P1480, DOI 10.1097/BRS.0b013e3181a396a1
   Mroz TE, 2010, SPINE, V35, pS86, DOI 10.1097/BRS.0b013e3181d81ef2
   Pradhan BB, 2006, SPINE, V31, pE277, DOI 10.1097/01.brs.0000216442.12092.01
   Rihn JA, 2009, EUR SPINE J, V18, P1629, DOI 10.1007/s00586 009 1046 1
   SAMPATH TK, 1981, P NATL ACAD SCI BIOL, V78, P7599, DOI 10.1073/pnas.78.12.7599
   Schmitt JM, 1999, J ORTHOPAED RES, V17, P269, DOI 10.1002/jor.1100170217
   Seeherman HJ, 2010, J BONE JOINT SURG AM, V92A, P411, DOI 10.2106/JBJS.H.01732
   Shields LBE, 2006, SPINE, V31, P542, DOI 10.1097/01.brs.0000201424.27509.72
   Starman JS, 2012, J TRAUMA ACUTE CARE, V72, P676, DOI 10.1097/TA.0b013e318232cf5a
   Steven Gitelis M, 2008, AAOS NOW, V2
   Tumialan LM, 2007, SPINE J, V7, P509, DOI 10.1016/j.spinee.2007.03.005
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   Valentin Opran A, 2002, CLIN ORTHOP RELAT R, P110
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   White AP, 2007, INT ORTHOP, V31, P735, DOI 10.1007/s00264 007 0422 x
   Williams BJ, 2011, SPINE, V36, P1685, DOI 10.1097/BRS.0b013e318216d825
   Woo EJ, CLIN ORTHOP RELAT RE
   Woo EJ, 2012, SPINE J, V12, P894, DOI 10.1016/j.spinee.2012.09.052
   Woo EJ, 2012, J ORAL MAXIL SURG, V70, P765, DOI 10.1016/j.joms.2011.09.008
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   WOZNEY JM, 1992, MOL REPROD DEV, V32, P160, DOI 10.1002/mrd.1080320212
   Wu DT, 2005, J AM SOC NEPHROL, V16, P3211, DOI 10.1681/ASN.2004121055
   Zara JN, 2011, TISSUE ENG PT A, V17, P1389, DOI [10.1089/ten.TEA.2010.0555, 10.1089/ten.tea.2010.0555]
   Zhang C, 2008, P NATL ACAD SCI USA, V105, P6936, DOI 10.1073/pnas.0710831105
NR 47
TC 46
Z9 56
U1 0
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAY
PY 2013
VL 54
IS 1
BP 141
EP 150
DI 10.1016/j.bone.2013.01.031
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 115VK
UT WOS:000316839800019
PM 23360788
DA 2025 08 17
ER

PT J
AU Cai, C
   Liu, CY
   Zhao, LM
   Liu, H
   Li, WJ
   Guan, HF
   Zhao, LB
   Xiao, J
AF Cai, Cong
   Liu, Changyu
   Zhao, Liming
   Liu, Hui
   Li, Weijin
   Guan, Hanfeng
   Zhao, Libo
   Xiao, Jun
TI Effects of Taxifolin on Osteoclastogenesis in vitro and in
   vivo
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE taxifolin; osteoclast; osteoporosis; RANK; NF kappa B
ID KAPPA B ACTIVATION; OXIDATIVE STRESS; BONE; DIFFERENTIATION; CELLS;
   INHIBITION; FLAVONOIDS; APOPTOSIS; PATHWAY; DIHYDROQUERCETIN
AB Osteoporosis is a highly prevalent disease which has been a major public health problem and considered to be associated with chronic low grade systemic inflammation and oxidative damage. Taxifolin is a natural flavonoid and possesses many pharmacological activities including antioxidant and anti inflammatory. Because flavonoids have been confirmed to fight osteoporosis and promote bone health, the aim of this study was to investigate the effects of taxifolin on the formation and function of osteoclast. In this study, we examined the effects of taxifolin on osteoclast using both in vitro and in vivo studies. Taxifolin suppressed the activation of nuclear factor kappa B, C Fos and mitogen activated protein kinase, and also decreased osteoclast specific genes expression, including Trap, Mmp 9, Cathepsin K, C Fos, Nfatc1, and Rank. Taxifolin also prevented reactive oxygen species (ROS) production following RANKL stimulation. In addition, taxifolin alleviated ovariectomized induced bone loss by repressing osteoclast activity and decreasing serum levels of tumor necrosis factor alpha, interleukin 1 beta, interleukin 6 and receptor activator of nuclear factor kappa B ligand (RANKL) in vivo. Our results indicated that taxifolin inhibits osteoclastogenesis via regulation of modulation of several RANKL signaling pathways. Therefore, taxifolin may be considered as a potential alternative therapeutic agent for treating osteoclast related diseases.
C1 [Cai, Cong; Liu, Changyu; Zhao, Liming; Liu, Hui; Li, Weijin; Guan, Hanfeng; Zhao, Libo; Xiao, Jun] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Orthopaed Surg, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
C3 Huazhong University of Science & Technology
RP Zhao, LB; Xiao, J (通讯作者)，Huazhong Univ Sci & Technol, Tongji Hosp, Dept Orthopaed Surg, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
EM zhaolibo@hust.edu.cn; xiaojun301@sina.com
RI Zhao, Libo/G 2421 2010; cai, cong/MTA 9728 2025; 刘, 长玉/IXN 1731 2023
FU National Natural Science Foundation of China [81572200]
FX This study was supported in part by National Natural Science Foundation
   of China (No. 81572200).
CR Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bijak Michal, 2017, Pol Merkur Lekarski, V42, P34
   Brincat S D, 2014, Minerva Ginecol, V66, P391
   Chen YW, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060833
   Dok Go H, 2003, BRAIN RES, V965, P130, DOI 10.1016/S0006 8993(02)04150 1
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Galochkina AV, 2016, ARCH VIROL, V161, P929, DOI 10.1007/s00705 016 2749 3
   Guan HF, 2015, FASEB J, V29, P1092, DOI 10.1096/fj.14 262055
   Guan HF, 2013, J PATHOL, V229, P775, DOI 10.1002/path.4164
   Guo HP, 2015, TOXICOL APPL PHARM, V287, P168, DOI 10.1016/j.taap.2015.06.002
   Jefferson WN, 2002, J CHROMATOGR B, V777, P179, DOI 10.1016/S1570 0232(02)00493 2
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Kim A, 2017, BRAIN RES BULL, V134, P63, DOI 10.1016/j.brainresbull.2017.07.008
   Kim HJ, 2006, FREE RADICAL BIO MED, V40, P1483, DOI 10.1016/j.freeradbiomed.2005.10.066
   Kuang HX, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071546
   Lee B, 2010, J IMMUNOL, V185, P5926, DOI 10.4049/jimmunol.1001591
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Manigandan K, 2015, BIOCHIMIE, V119, P103, DOI 10.1016/j.biochi.2015.10.014
   Mundy GR, 2007, NUTR REV, V65, pS147, DOI [10.1111/j.1753 4887.2007.tb00353.x, 10.1301/nr.2007.dec.S147 S151]
   Novack DV, 2011, CELL RES, V21, P169, DOI 10.1038/cr.2010.159
   Salaritabar A, 2017, WORLD J GASTROENTERO, V23, P5097, DOI 10.3748/wjg.v23.i28.5097
   Sasaki H, 2009, J MED INVESTIG, V56, P33, DOI 10.2152/jmi.56.33
   Satue M, 2013, BIOCHEM PHARMACOL, V86, P1476, DOI 10.1016/j.bcp.2013.09.009
   Sun X, 2014, FOOD CHEM TOXICOL, V63, P221, DOI 10.1016/j.fct.2013.11.013
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Wang YH, 2006, J BIOMED SCI, V13, P127, DOI 10.1007/s11373 005 9031 0
   Wang YJ, 2017, BIOCHEM BIOPH RES CO, V490, P36, DOI 10.1016/j.bbrc.2017.06.002
   Weaver Connie M., 2012, Journal of Nutrition in Gerontology and Geriatrics, V31, P239, DOI 10.1080/21551197.2012.698220
   Welch AA, 2014, CURR OSTEOPOROS REP, V12, P205, DOI 10.1007/s11914 014 0212 5
   Winkel Shirley B, 2001, PLANT PHYSIOL, V126, P485, DOI 10.1104/pp.126.2.485
   Xie XB, 2017, MOL VIS, V23, P520
   Zhao LB, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00928
   Zhao LM, 2018, BONE, V110, P177, DOI 10.1016/j.bone.2018.01.035
   Zhao MY, 2015, INT IMMUNOPHARMACOL, V28, P938, DOI 10.1016/j.intimp.2015.04.032
NR 34
TC 59
Z9 62
U1 1
U2 25
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD NOV 12
PY 2018
VL 9
AR 1286
DI 10.3389/fphar.2018.01286
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA GZ9YK
UT WOS:000449859200001
PM 30483128
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Brown, JE
   Wood, SL
   Confavreux, C
   Abe, M
   Weilbaecher, K
   Hadji, P
   Johnson, RW
   Rhoades, JA
   Edwards, CM
   Croucher, P
   Juarez, P
   El Badri, S
   Ariaspinilla, G
   D'Oronzo, S
   Guise, TA
   Van Poznak, C
AF Brown, J. E.
   Wood, S. L.
   Confavreux, C.
   Abe, M.
   Weilbaecher, K.
   Hadji, P.
   Johnson, R. W.
   Rhoades, J. A.
   Edwards, C. M.
   Croucher, P., I
   Juarez, P.
   El Badri, S.
   Ariaspinilla, G.
   D'Oronzo, S.
   Guise, T. A.
   Van Poznak, C.
TI Management of bone metastasis and cancer treatment induced bone loss
   during the COVID 19 pandemic: An international perspective and
   recommendations
SO JOURNAL OF BONE ONCOLOGY
LA English
DT Article
DE COVID 19; Bone metastasis; Bisphosphonates; Zoledronic acid; Denosumab;
   Bone health
ID BREAST CANCER; ZOLEDRONIC ACID; CARE ONTARIO; TARGETED THERAPIES;
   AMERICAN SOCIETY; MODIFYING AGENTS; BISPHOSPHONATES; GUIDELINE;
   FRACTURES; DENOSUMAB
AB Optimum management of patients with cancer during the COVID 19 pandemic has proved extremely challenging. Patients, clinicians and hospital authorities have had to balance the risks to patients of attending hospital, many of whom are especially vulnerable, with the risks of delaying or modifying cancer treatment. Those whose care has been significantly impacted include patients suffering from the effects of cancer on bone, where delivering the usual standard of care for bone support has often not been possible and clinicians have been forced to seek alternative options for adequate management. At a virtual meeting of the Cancer and Bone Society in July 2020, an expert group shared experiences and solutions to this challenge, following which a questionnaire was sent internationally to the symposium's participants, to explore the issues faced and solutions offered. 70 respondents, from 9 countries (majority USA, 39%, followed by UK, 19%) included 50 clinicians, spread across a diverse range of specialties (but with a high proportion, 64%, of medical oncologists) and 20 who classified themselves as non clinical (solely lab based). Spread of clinician specialty across tumour types was breast (65%), prostate (27%), followed by renal, myeloma and melanoma. Analysis showed that management of metastatic bone disease in all solid tumour types and myeloma, adjuvant bisphosphonate breast cancer therapy and cancer treatment induced bone loss, was substantially impacted. Respondents reported delays to routine CT scans (58%), standard bone scans (48%) and MRI scans (46%), though emergency scans were less affected. Delays in palliative radiotherapy for bone pain were reported by 31% of respondents with treatments often involving only a single dose without fractionation. Delays to, or cancellation of, prophylactic surgery for bone pain were reported by 35% of respondents. Access to treatments with intravenous bisphosphonates and subcutaneous deno sumab was a major problem, mitigated by provision of drug administration at home or in a local clinic, reduced frequency of administration or switching to oral bisphosphonates taken at home. The question naire also revealed damaging delays or complete stopping of both clinical and laboratory research. In addition to an analysis of the questionnaire, this paper presents a rationale and recommendations for adaptation of the normal guidelines for protection of bone health during the pandemic. (c) 2021 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY NC ND license (http://creativecommons.org/licenses/by nc nd/4.0/).
C1 [Brown, J. E.; Wood, S. L.] Univ Sheffield, Acad Unit Clin Oncol, Dept Oncol & Metab, Sheffield, S Yorkshire, England.
   [Brown, J. E.; El Badri, S.; Ariaspinilla, G.] Sheffield Teaching Hosp NHS Fdn Trust, Directorate Oncol, Sheffield, S Yorkshire, England.
   [Confavreux, C.] Univ Lyon, Hosp Civils Lyon, Dept Rheumatol South, Lyon, France.
   [Confavreux, C.] Univ Lyon, INSERM, UMR 1033, Lyon, France.
   [Abe, M.] Tokushima Univ, Dept Hematol Endocrinol & Metab, Grad Sch, Tokushima, Japan.
   [Weilbaecher, K.] Washington Univ, Div Oncol, St Louis, MO USA.
   [Hadji, P.] Krankenhaus NW Frankfurt, Dept Bone Oncol Endocrinol & Reprod Med, Frankfurt, Germany.
   [Johnson, R. W.; Rhoades, J. A.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA.
   [Rhoades, J. A.] Tennessee Valley Healthcare Syst, Dept Vet Affairs, Nashville, TN USA.
   [Edwards, C. M.] Nuffield Dept Surg Sci, Oxford, England.
   [Croucher, P., I] Garvan Inst Med Res, Bone Biol, Darlinghurst, NSW, Australia.
   [Juarez, P.] Ctr Sci Res & Higher Educ, Biomed Innovat Dept, Ensenada, Baja California, Mexico.
   [D'Oronzo, S.] Univ Bari Aldo Moro, Dept Biomed Sci & Clin Oncol, Bari, Italy.
   [Guise, T. A.] MD Anderson Canc Ctr, Houston, TX USA.
   [Van Poznak, C.] Univ Michigan, Ann Arbor, MI 48109 USA.
C3 University of Sheffield; University of Sheffield; CHU Lyon; Universite
   Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Tokushima University; Washington University (WUSTL);
   Krankenhaus Nordwest; Vanderbilt University; US Department of Veterans
   Affairs; Veterans Health Administration (VHA); VA Tennessee Valley
   Healthcare System; University of Oxford; Garvan Institute of Medical
   Research; Universita degli Studi di Bari Aldo Moro; University of Texas
   System; UTMD Anderson Cancer Center; University of Michigan System;
   University of Michigan
RP Brown, JE (通讯作者)，Sheffield Teaching Hosp NHS Fdn Trust, Directorate Oncol, Sheffield, S Yorkshire, England.; Brown, JE (通讯作者)，Univ Sheffield, Acad Unit Clin Oncol, Dept Oncol & Metab, Weston Pk Hosp, Sheffield, S Yorkshire, England.
EM j.e.brown@sheffield.ac.uk
RI ; D'Oronzo, Stella/AAA 9784 2019; Confavreux, Cyrille/HTT 0045 2023;
   Edwards, Claire/D 7114 2011; Rhoades, Julie/LNU 1104 2024; Johnson,
   Rachelle/AFL 3690 2022
OI Arias Pinilla, Gustavo/0000 0002 0137 8377; Edwards,
   Claire/0000 0002 1257 5659; 
CR ALMAGHLOUTH NK, 2020, J MED VIROL
   Amadori D, 2013, LANCET ONCOL, V14, P663, DOI 10.1016/S1470 2045(13)70174 8
   Anastasilakis AD, 2017, J BONE MINER RES, V32, P1291, DOI 10.1002/jbmr.3110
   Anderson K, 2018, J ONCOL PRACT, V14, P266, DOI 10.1200/JOP.17.00013
   Barwick BG, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01121
   Body J J, ANN ONCOL, V202, P165
   Brown JE, 2007, CLIN CANCER RES, V13, P5406, DOI 10.1158/1078 0432.CCR 07 0247
   Brown JE, 2020, J BONE ONCOL, V25, DOI 10.1016/j.jbo.2020.100311
   Clemons M, 2021, EUR J CANCER, V142, P132, DOI 10.1016/j.ejca.2020.08.019
   Coleman R, 2020, BONE, V140, DOI 10.1016/j.bone.2020.115570
   Coleman RE, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572 020 00216 3
   Dhesy Thind S, 2017, J CLIN ONCOL, V35, P2062, DOI 10.1200/JCO.2016.70.7257
   Grávalos C, 2016, CLIN TRANSL ONCOL, V18, P1243, DOI 10.1007/s12094 016 1590 1
   Grossmann, 2018, UROL ONCOL
   Himelstein AL, 2017, JAMA J AM MED ASSOC, V317, P48, DOI 10.1001/jama.2016.19425
   Hortobagyi GN, 2017, JAMA ONCOL, V3, P906, DOI 10.1001/jamaoncol.2016.6316
   Kan C, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101674
   Ng TL, 2021, SUPPORT CARE CANCER, V29, P925, DOI 10.1007/s00520 020 05556 0
   Roelofs AJ, 2010, CURR PHARM DESIGN, V16, P2950
   Saylor PJ, 2020, J CLIN ONCOL, V38, P1736, DOI 10.1200/JCO.19.03148
   Shapiro CL, 2019, J CLIN ONCOL, V37, P2916, DOI 10.1200/JCO.19.01696
   Shapiro CL, 2017, J CLIN ONCOL, V35, P3949, DOI 10.1200/JCO.2017.73.7437
   Skolarus TA, 2014, CURR OPIN UROL, V24, P601, DOI 10.1097/MOU.0000000000000101
   Song Y, 2020, ONCOL RES TREAT, V43, P96, DOI 10.1159/000505376
   Sousa S, 2018, CALCIFIED TISSUE INT, V102, P227, DOI 10.1007/s00223 017 0353 5
   Van Poznak C, 2017, J CLIN ONCOL, V35, P3978, DOI 10.1200/JCO.2017.75.4614
   Wilkinson E, 2021, LANCET ONCOL
   Yang M, 2020, SUPPORT CARE CANCER, V28, P2533, DOI 10.1007/s00520 020 05355 7
NR 28
TC 11
Z9 11
U1 0
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 2212 1374
J9 J BONE ONCOL
JI J. Bone Oncol.
PD AUG
PY 2021
VL 29
AR 100375
DI 10.1016/j.jbo.2021.100375
EA JUN 2021
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA UD6LH
UT WOS:000687316200005
PM 34131559
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Raivola, J
   Dini, A
   Salokas, K
   Karvonen, H
   Niininen, W
   Piki, E
   Varjosalo, M
   Ungureanu, D
AF Raivola, Juuli
   Dini, Alice
   Salokas, Kari
   Karvonen, Hanna
   Niininen, Wilhelmiina
   Piki, Emilia
   Varjosalo, Markku
   Ungureanu, Daniela
TI New insights into the molecular mechanisms of ROR1, ROR2, and PTK7
   signaling from the proteomics and pharmacological modulation of ROR1
   interactome
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Article
DE Receptor pseudokinases; Kinase inhibitors; GZD824; Wnt signaling; ROR1;
   ROR2; PTK7; TSA; CETSA
ID WNT5A INDUCES ROR1; COMPLEX; BINDING; PROTEIN; ACTIVATION; PROGRESSION;
   CHEMOTAXIS; KINDLIN 3; SURVIVAL; CELLS
AB ROR1, ROR2, and PTK7 are Wnt ligand binding members of the receptor tyrosine kinase family. Despite their lack of catalytic activity, these receptors regulate skeletal, cardiorespiratory, and neurological development during embryonic and fetal stages. However, their overexpression in adult tissue is strongly connected to tumor development and metastasis, suggesting a strong pharmacological potential for these molecules. Wnt5a ligand can activate these receptors, but lead to divergent signaling and functional outcomes through mechanisms that remain largely unknown. Here, we developed a cellular model by stably expressing ROR1, ROR2, and PTK7 in BaF3 cells that allowed us to readily investigate side by side their signaling capability and functional outcome. We applied proteomic profiling to BaF3 clones and identified distinctive roles for ROR1, ROR2, and PTK7 pseudokinases in modulating the expression of proteins involved in cytoskeleton dynamics, apoptotic, and metabolic signaling. Functionally, we show that ROR1 expression enhances cell survival and Wnt mediated cell proliferation, while ROR2 and PTK7 expression is linked to cell migration. We also demonstrate that the distal C terminal regions of ROR1 and ROR2 are required for receptors stability and downstream signaling. To probe the pharmacological modulation of ROR1 oncogenic signaling, we used affinity purification coupled to mass spectrometry (AP MS) and proximity dependent biotin identification (BioID) to map its interactome before and after binding of GZD824, a small molecule inhibitor previously shown to bind to the ROR1 pseudokinase domain. Our findings bring new insight into the molecular mechanisms of ROR1, ROR2, and PTK7, and highlight the therapeutic potential of targeting ROR1 with small molecule inhibitors binding to its vestigial ATP binding site.
C1 [Raivola, Juuli; Dini, Alice; Piki, Emilia; Ungureanu, Daniela] Univ Helsinki, Fac Med, Appl Tumor Genom Res Program, Helsinki 00014, Finland.
   [Salokas, Kari; Varjosalo, Markku] Univ Helsinki, Inst Biotechnol, HiLife, Helsinki 00014, Finland.
   [Karvonen, Hanna; Niininen, Wilhelmiina; Ungureanu, Daniela] Tampere Univ, Fac Med & Hlth Technol, Tampere 33014, Finland.
   [Karvonen, Hanna; Ungureanu, Daniela] Columbia Univ, Herbert Irving Comprehens Canc Ctr, Irving Med Ctr, New York, NY 10032 USA.
C3 University of Helsinki; University of Helsinki; Tampere University;
   Columbia University; NewYork Presbyterian Hospital
RP Ungureanu, D (通讯作者)，Univ Helsinki, Fac Med, Appl Tumor Genom Res Program, Helsinki 00014, Finland.; Ungureanu, D (通讯作者)，Tampere Univ, Fac Med & Hlth Technol, Tampere 33014, Finland.; Ungureanu, D (通讯作者)，Columbia Univ, Herbert Irving Comprehens Canc Ctr, Irving Med Ctr, New York, NY 10032 USA.
EM daniela.ungureanu@helsinki.fi
RI Varjosalo, Markku/K 6424 2015
OI Varjosalo, Markku/0000 0002 1340 9732; Piki, Emilia/0000 0001 6662 0518;
   Dini, Alice/0000 0002 2720 4551; Salokas, Kari/0000 0002 4471 6698;
   Ungureanu, Daniela/0000 0002 9314 4972; Karvonen,
   Hanna/0000 0002 7815 0709
FU University of Helsinki including Helsinki University Central Hospital
FX Open Access funding provided by University of Helsinki including
   Helsinki University Central Hospital.
CR Ahsan A, 2013, J BIOL CHEM, V288, P26879, DOI 10.1074/jbc.M113.492280
   Akbarzadeh S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001873
   Andreeva A, 2014, DEV CELL, V29, P20, DOI 10.1016/j.devcel.2014.02.008
   Bainbridge TW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102695
   BENJAMINI Y, 1995, J ROY STAT SOC B, V57, P289, DOI 10.1111/j.2517 6161.1995.tb02031.x
   Bentayeb H, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046 019 1440 4
   Bicocca VT, 2012, CANCER CELL, V22, P656, DOI 10.1016/j.ccr.2012.08.027
   Bioconductor CoreTeam, 2015, MUS MUS ANN PACK MUS, DOI [10.18129/B9.bioc.Mus.musculus.https://bioconductor.org/packages/Mus.musculus, DOI 10.18129/B9.BIOC.MUS.MUSCULUS.HTTPS://BIOCONDUCTOR.ORG/PACKAGES/MUS.MUSCULUS]
   Castro MV, 2022, CRIT REV ONCOL HEMAT, V170, DOI 10.1016/j.critrevonc.2022.103595
   Chen D, 2007, ONCOGENE, V26, P5029, DOI 10.1038/sj.onc.1210327
   Cheng ZL, 2019, ONCOL REP, V41, P3189, DOI 10.3892/or.2019.7113
   Choi MY, 2018, CELL STEM CELL, V22, P951, DOI 10.1016/j.stem.2018.05.018
   Choi MY, 2015, CL LYMPH MYELOM LEUK, V15, pS167, DOI 10.1016/j.clml.2015.02.010
   Cui B, 2016, BLOOD, V128, P2931, DOI 10.1182/blood 2016 04 712562
   Cui NP, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.699889
   Curto J, 2018, MOL ONCOL, V12, P611, DOI 10.1002/1878 0261.12184
   Damelin M, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aag2611
   Daneshmanesh AH, 2012, LEUKEMIA, V26, P1348, DOI 10.1038/leu.2011.362
   Djaafri I, 2014, ONCOTARGET, V5, P8970, DOI 10.18632/oncotarget.2125
   Frenquelli M, 2020, LEUKEMIA, V34, P257, DOI 10.1038/s41375 019 0486 9
   Gentile A, 2014, INT J CANCER, V135, P2305, DOI 10.1002/ijc.28879
   González Casimiro CM, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9010086
   Grote Steffi, 2017, Bioconductor
   Guyon A, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00065
   Harada Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20236074
   Hasan MK, 2017, LEUKEMIA, V31, P2615, DOI 10.1038/leu.2017.133
   Hasan MK, 2019, NPJ BREAST CANCER, V5, DOI 10.1038/s41523 019 0131 9
   Hellmann I, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02490
   Hobbs S, 1998, BIOCHEM BIOPH RES CO, V252, P368, DOI 10.1006/bbrc.1998.9646
   Hsiao BY, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22042037
   Jiang GH, 2012, LEUKEMIA RES, V36, P1347, DOI 10.1016/j.leukres.2012.07.004
   Johnson M, 2009, CELL SIGNAL, V21, P1471, DOI 10.1016/j.cellsig.2009.02.023
   Karvonen H, 2019, ONCOGENE, V38, P3288, DOI 10.1038/s41388 018 0670 9
   Karvonen H, 2018, FEBS LETT, V592, P434, DOI 10.1002/1873 3468.12966
   Knight JDR, 2017, NAT METHODS, V14, P645, DOI 10.1038/nmeth.4330
   Kung JE, 2019, NAT REV DRUG DISCOV, V18, P500, DOI 10.1038/s41573 019 0018 3
   Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011
   Liu XA, 2020, NAT PROTOC, V15, P3182, DOI 10.1038/s41596 020 0365 x
   Liu XN, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03523 2
   Lu XW, 2004, NATURE, V430, P93, DOI 10.1038/nature02677
   Mataraza JM, 2003, J BIOL CHEM, V278, P41237, DOI 10.1074/jbc.M304838200
   Menck K, 2021, CELLS BASEL, V10, DOI 10.3390/cells10010142
   Molina DM, 2013, SCIENCE, V341, P84, DOI 10.1126/science.1233606
   Murphy JM, 2014, BIOCHEM J, V457, P323, DOI 10.1042/BJ20131174
   Qu J, 2015, SCI REP UK, V5, DOI 10.1038/srep18491
   Rajalingam K, 2005, NAT CELL BIOL, V7, P837, DOI 10.1038/ncb1283
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Rodor J, 2016, RNA, V22, P1411, DOI 10.1261/rna.057158.116
   Salokas K., 2021, BIORXIV, DOI [10.1101/2021.09.17.460748, DOI 10.1101/2021.09.17.460748]
   Sayols, 2020, RRVGO BIOCONDUCTOR P
   Sheetz JB, 2020, MOL CELL, V79, P390, DOI 10.1016/j.molcel.2020.06.018
   Sossey Alaoui K, 2014, FASEB J, V28, P2260, DOI 10.1096/fj.13 244004
   Uruno T, 2003, BIOCHEM J, V371, P485, DOI 10.1042/BJ20021791
   Varjosalo M, 2013, NAT METHODS, V10, P307, DOI [10.1038/nmeth.2400, 10.1038/NMETH.2400]
   Wan QY, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392 020 00233 4
   Witte F, 2010, FASEB J, V24, P2417, DOI 10.1096/fj.09 150615
   Xu N, 2020, J CELL BIOCHEM, V121, P231, DOI 10.1002/jcb.29136
   Yamaguchi T, 2012, CANCER CELL, V21, P348, DOI 10.1016/j.ccr.2012.02.008
   Ye W, 2017, ONCOTARGET, V8, P87002, DOI 10.18632/oncotarget.10881
   Yu J, 2017, LEUKEMIA, V31, P2608, DOI 10.1038/leu.2017.132
   Yu J, 2016, J CLIN INVEST, V126, P585, DOI 10.1172/JCI83535
   Zhang Q, 2019, J IMMUNOL, V203, P2043, DOI 10.4049/jimmunol.1801327
   Zhao YW, 2015, CELL REP, V13, P1407, DOI 10.1016/j.celrep.2015.10.011
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09234 6
NR 64
TC 11
Z9 11
U1 2
U2 19
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420 682X
EI 1420 9071
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD MAY
PY 2022
VL 79
IS 5
AR 276
DI 10.1007/s00018 022 04301 6
PG 16
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 0Y2YU
UT WOS:000790260400002
PM 35504983
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Scholten, DJ II
   Timmer, CM
   Peacock, JD
   Pelle, DW
   Williams, BO
   Steensma, MR
AF Scholten, Donald J., II
   Timmer, Christine M.
   Peacock, Jacqueline D.
   Pelle, Dominic W.
   Williams, Bart O.
   Steensma, Matthew R.
TI Down Regulation of Wnt Signaling Mitigates Hypoxia Induced
   Chemoresistance in Human Osteosarcoma Cells
SO PLOS ONE
LA English
DT Article
ID INDUCIBLE FACTOR 1 ALPHA; BETA CATENIN; TUMOR HYPOXIA; CANCER; HIF 1;
   EXPRESSION; PATHWAYS; OVEREXPRESSION; INACTIVATION; METASTASIS
AB Osteosarcoma (OS) is the most common type of solid bone cancer and remains the second leading cause of cancer related death for children and young adults. Hypoxia is an element intrinsic to most solid tumor microenvironments, including that of OS, and is associated with resistance to therapy, poor survival, and a malignant phenotype. Cells respond to hypoxia through alterations in gene expression, mediated most notably through the hypoxia inducible factor (HIF) class of transcription factors. Here we investigate hypoxia induced changes in the Wnt/beta catenin signaling pathway, a key signaling cascade involved in OS pathogenesis. We show that hypoxia results in increased expression and signaling activation of HIF proteins in human osteosarcoma cells. Wnt/beta catenin signaling is down regulated by hypoxia in human OS cells, as demonstrated by decreased active beta catenin protein levels and axin2 mRNA expression (p<0.05). This down regulation appears to rely on both HIF independent and HIF dependent mechanisms, with HIF 1 alpha standing out as an important regulator. Finally, we show that hypoxia results in resistance of human OS cells to doxorubicin mediated toxicity (6 13 fold increase, p<0.01). These hypoxic OS cells can be sensitized to doxorubicin treatment by further inhibition of the Wnt/bcatenin signaling pathway (p<0.05). These data support the conclusion that Wnt/b catenin signaling is down regulated in human OS cells under hypoxia and that this signaling alteration may represent a viable target to combat chemoresistant OS subpopulations in a hypoxic niche.
C1 [Scholten, Donald J., II; Timmer, Christine M.; Pelle, Dominic W.; Steensma, Matthew R.] Michigan State Univ, Coll Human Med, Grand Rapids, MI 49503 USA.
   [Scholten, Donald J., II; Peacock, Jacqueline D.; Pelle, Dominic W.; Williams, Bart O.; Steensma, Matthew R.] Van Andel Res Inst, Grand Rapids, MI USA.
   [Pelle, Dominic W.; Steensma, Matthew R.] Spectrum Hlth Syst, Helen DeVos Childens Hosp, Grand Rapids, MI USA.
C3 Michigan State University; Michigan State University College of Human
   Medicine; Van Andel Institute; Van Andel Research Institute
RP Steensma, MR (通讯作者)，Michigan State Univ, Coll Human Med, Grand Rapids, MI 49503 USA.
EM matt.steensma@vai.org
RI Steensma, Matt/K 6281 2014; Williams, Bart/A 3539 2013
OI Williams, Bart/0000 0002 5261 5301
FU Van Andel Research Institute and Spectrum Health
FX The authors thank the Van Andel Research Institute and Spectrum Health
   for financial support of this work. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Adamski J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065304
   Agani F, 2013, CURR CANCER DRUG TAR, V13, P245, DOI 10.2174/1568009611313030003
   Anninga JK, 2011, EUR J CANCER, V47, P2431, DOI 10.1016/j.ejca.2011.05.030
   [Anonymous], ONCOIMMUNOLOGY
   Bertout JA, 2008, NAT REV CANCER, V8, P967, DOI 10.1038/nrc2540
   Bielack S, 2009, ANN ONCOL, V20, P137, DOI 10.1093/annonc/mdp154
   Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367
   Cai YP, 2010, J PATHOL, V220, P24, DOI 10.1002/path.2628
   Cai Y, 2014, J CELL BIOCHEM, V115, P625, DOI 10.1002/jcb.24708
   Chan DA, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002394
   Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137
   Chen DF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065940
   Chen DF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052948
   Chen D, 2013, TUMOR BIOL, V34, P1895, DOI 10.1007/s13277 013 0733 z
   Deng ZM, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/496193
   Du XL, 2014, BMC CANCER, V14, DOI 10.1186/1471 2407 14 450
   El Naggar A, 2012, PEDIATR BLOOD CANCER, V59, P1215, DOI 10.1002/pbc.24191
   Enomoto M, 2009, ONCOGENE, V28, P3197, DOI 10.1038/onc.2009.175
   Flores RJ, 2012, BMC SYST BIOL, V6, DOI 10.1186/1752 0509 6 50
   Genetos DC, 2010, J CELL BIOCHEM, V110, P457, DOI 10.1002/jcb.22559
   Goda N, 2003, MOL CELL BIOL, V23, P359, DOI 10.1128/MCB.23.1.359 369.2003
   Guo Y, 2008, CLIN ORTHOP RELAT R, V466, P2039, DOI 10.1007/s11999 008 0344 y
   Höckel M, 2001, JNCI J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266
   Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356
   Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172 1183.2002
   Kaidi A, 2007, NAT CELL BIOL, V9, P210, DOI 10.1038/ncb1534
   Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041
   Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183
   Knowles HJ, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 372
   Kuijjer ML, 2013, INT J CANCER, V133, P2512, DOI 10.1002/ijc.28124
   Kumar N, 2009, NUCLEIC ACIDS RES, V37, P3321, DOI 10.1093/nar/gkp196
   Kwon J, 2004, P NATL ACAD SCI USA, V101, P16419, DOI 10.1073/pnas.0407396101
   Liao D, 2007, CANCER METAST REV, V26, P281, DOI 10.1007/s10555 007 9066 y
   Lin Carol H., 2013, Sarcoma, V2013, P147541, DOI 10.1155/2013/147541
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lu X, 2010, CLIN CANCER RES, V16, P5928, DOI 10.1158/1078 0432.CCR 10 1360
   Ma YM, 2013, BIOCHEM BIOPH RES CO, V431, P274, DOI 10.1016/j.bbrc.2012.12.118
   Martin SK, 2011, LEUKEMIA, V25, P1533, DOI 10.1038/leu.2011.122
   Mazumdar J, 2009, J CELL MOL MED, V13, P4319, DOI 10.1111/j.1582 4934.2009.00963.x
   Michaylira CZ, 2006, CANCER BIOL THER, V5, P476, DOI 10.4161/cbt.5.5.2749
   Mizukami Y, 2007, CLIN CANCER RES, V13, P5670, DOI 10.1158/1078 0432.CCR 07 0111
   Mohseny AB, 2011, LAB INVEST, V91, P1195, DOI 10.1038/labinvest.2011.72
   Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427
   Onnis B, 2009, J CELL MOL MED, V13, P2780, DOI 10.1111/j.1582 4934.2009.00876.x
   R Development Core Team, 2014, R LANG ENV STAT COMP
   Rubin EM, 2010, MOL CANCER THER, V9, P731, DOI 10.1158/1535 7163.MCT 09 0147
   Siclari VA, 2010, J ORTHOP SURG RES, V5, DOI 10.1186/1749 799X 5 78
   Staal FJT, 2002, EMBO REP, V3, P63, DOI 10.1093/embo reports/kvf002
   Tormos KV, 2010, J CELL MOL MED, V14, P795, DOI 10.1111/j.1582 4934.2010.01031.x
   Turner DC, 2014, CLIN CANCER RES, V20, P2783, DOI 10.1158/1078 0432.CCR 13 2364
   Vaupel P, 2007, CANCER METAST REV, V26, P225, DOI 10.1007/s10555 007 9055 1
   Wang DP, 2011, CANCER SCI, V102, P1322, DOI 10.1111/j.1349 7006.2011.01950.x
   Wilson Edell KA, 2014, BREAST CANCER RES TR, V144, P287, DOI 10.1007/s10549 014 2877 y
   Yang QC, 2007, JPN J CLIN ONCOL, V37, P127, DOI 10.1093/jjco/hyl137
NR 54
TC 33
Z9 39
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD OCT 27
PY 2014
VL 9
IS 10
AR e111431
DI 10.1371/journal.pone.0111431
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA AZ1JF
UT WOS:000347994900071
PM 25347326
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Song, CH
   Yan, QQ
   Ma, YJ
   Li, P
   Yang, Y
   Wang, YH
   Li, WJ
   Wan, XY
   Li, YB
   Zhu, RY
   Liu, HX
   Zhang, ZG
AF Song, Changheng
   Yan, Qiqi
   Ma, Yujie
   Li, Pei
   Yang, Ying
   Wang, Yuhan
   Li, Wenjie
   Wan, Xinyu
   Li, Yubo
   Zhu, Ruyuan
   Liu, Haixia
   Zhang, Zhiguo
TI Modified Zuo Gui Wan Ameliorates Ovariectomy Induced Osteoporosis in
   Rats by Regulating the SCFA GPR41 p38MAPK Signaling Pathway
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Article
DE osteoporosis; short chain fatty acids; SCFA GPR41 p38MAPK signaling
   pathway; osteoclasts; modified Zuo Gui Wan
ID OSTEOCLASTOGENESIS; EXPRESSION; NFATC1; P38
AB Objective: Modified Zuo Gui Wan (MZGW) was a combination of Zuo Gui Wan and red yeast rice used for treating osteoporosis (OP), but its mechanism remains unclear. We aimed to validate the anti OP effect of MZGW and explore its underlying mechanism. Methods: An ovariectomy (OVX) rat model in vivo and a RANKL induced osteoclasts (OCs) model in vitro were established. Key active ingredients in MZGW high dose (MZGW H) group were detected by UPLC MS/MS. Micro CT scans and histomorphology analysis were performed in OVX rats. 16S rRNA gene sequencing was performed to investigate the relationship between the anti OP effect of MZGW H and intestinal flora. CCK 8 assay was applied to examine the optimal concentration of Modified Zuo Gui Wan drug serum (MZGW DS) on osteoclasts. The qRT PCR and Western blotting were utilized to explore the potential anti OP pathway of MZGW, namely the SCFA GPR41 p38MAPK signaling pathway. GPR41 was knocked down to further reverse to verify whether the pathway was the key pathway for MZGW DS to exert its inhibitory effect on osteoclasts. Results: The three main blood components, Ferulic acid, L Ascorbic acid and Riboflavin, were examined mainly by UPLC MS/MS. 16S rRNA gene sequencing showed that MZGW H changed the metabolism of SCFAs. In vivo studies verified that MZGW H ameliorated microstructure damage, improved histological changes and reduced TRAP, BALP, and BGP in OVX rats by regulating the SCFA GPR41 p38MAPK signaling pathway. CCK 8 revealed that 5% MZGW DS group was the most optimal concentration of MZGW DS to inhibit osteoclast differentiation. In vitro, MZGW DS was better than peripheral blood concentration of SCFAs in inhibiting osteoclasts. After the knockout of GPR41, MZGW DS could not inhibit the expression of osteoclast related protein (CTSK and NFATc1) via SCFA GPR41 p38MAPK signaling pathway. Conclusion: MZGW H effectively ameliorates OVX induced osteoporosis partially achieved by increasing SCFAs metabolism and modulating the SCFA GPR41 p38MAPK signaling pathway.
C1 [Song, Changheng; Yan, Qiqi; Li, Pei; Yang, Ying; Wang, Yuhan; Li, Wenjie; Wan, Xinyu; Li, Yubo; Zhu, Ruyuan; Liu, Haixia; Zhang, Zhiguo] China Acad Chinese Med Sci, Inst Basic Theory Chinese Med, 16 DongzhimenNei Nanxiaojie St, Beijing 100700, Peoples R China.
   [Song, Changheng] China Acad Chinese Med Sci, Guanganmen Hosp, Dept Endocrinol, Beijing, Peoples R China.
   [Ma, Yujie] Guangzhou Univ Chinese Med, Sci & Technol Innovat Ctr, Guangzhou, Peoples R China.
C3 Institute of Basic Theory for Chinese Medicine, CACMS; China Academy of
   Chinese Medical Sciences; China Academy of Chinese Medical Sciences;
   Guang'anmen Hospital, CACMS; Guangzhou University of Chinese Medicine
RP Liu, HX; Zhang, ZG (通讯作者)，China Acad Chinese Med Sci, Inst Basic Theory Chinese Med, 16 DongzhimenNei Nanxiaojie St, Beijing 100700, Peoples R China.
EM lhx8866_7@163.com; zzgtcm@163.com
RI Li, Yubo/MFH 4301 2025; Ma, Yujie/JFB 3837 2023
OI Li, Yubo/0000 0003 0944 1446; 
FU National Natural Science Foundation of China [82074297]; CACMS
   Innovation Fund [CI2021A00107]
FX Funding This work was supported by the National Natural Science
   Foundation of China (grant number: 82074297) , CACMS Innovation Fund
   (grant number: CI2021A00107) .
CR Ai TY, 2024, J AGR FOOD CHEM, V72, P7969, DOI 10.1021/acs.jafc.4c00281
   Carbone AM, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23105803
   Charles JF, 2015, CLIN IMMUNOL, V159, P163, DOI 10.1016/j.clim.2015.03.019
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Dong YH, 2019, FOOD FUNCT, V10, P3880, DOI [10.1039/c9fo00583h, 10.1039/C9FO00583H]
   Huang FR, 2024, PROBIOTICS ANTIMICRO, V16, P383, DOI 10.1007/s12602 023 10057 7
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Kang MR, 2014, MAR DRUGS, V12, P5643, DOI 10.3390/md12115643
   Kobayashi M, 2017, BIOCHEM BIOPH RES CO, V486, P499, DOI 10.1016/j.bbrc.2017.03.071
   Lee CG, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221910642
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Lee YD, 2020, EXP MOL MED, V52, P514, DOI 10.1038/s12276 020 0406 0
   Li B, 2020, BIOMED PHARMACOTHER, V132, DOI 10.1016/j.biopha.2020.110923
   Li WX, 2018, J TRADIT CHIN MED, V38, P33
   Li YL, 2020, GYNECOL ENDOCRINOL, V36, P997, DOI 10.1080/09513590.2020.1785420
   Liang QL, 2023, BIOMATERIALS, V302, DOI 10.1016/j.biomaterials.2023.122331
   Liu FX, 2018, BIOMED PHARMACOTHER, V103, P1052, DOI 10.1016/j.biopha.2018.04.102
   Lucas S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02490 4
   Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200
   Shen GY, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.878963
   Sun MM, 2017, J GASTROENTEROL, V52, P1, DOI 10.1007/s00535 016 1242 9
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Ticinesi A, 2025, OSTEOPOROSIS INT, V36, P167, DOI 10.1007/s00198 024 07320 0
   Vila AV, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aap8914
   Villa I, 2017, J TRANSL MED, V15, DOI 10.1186/s12967 017 1233 5
   Wallimann A, 2021, EUR CELLS MATER, V40, P454, DOI 10.22203/eCM.v041a29
   Wang Y, 2023, BIOACT MATER, V25, P13, DOI 10.1016/j.bioactmat.2023.01.009
   Wu B, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/7231827
   Wu YL, 2022, MILITARY MED RES, V9, DOI 10.1186/s40779 022 00404 0
   Xu JK, 2009, CYTOKINE GROWTH F R, V20, P7, DOI 10.1016/j.cytogfr.2008.11.007
   Xu YE, 2018, PHYTOMEDICINE, V51, P68, DOI 10.1016/j.phymed.2018.09.235
   Yang H, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.599760
   Yang KL, 2024, ARTHRITIS RHEUMATOL, V76, P647, DOI 10.1002/art.42765
   Zaiss MM, 2019, J CLIN INVEST, V129, P3018, DOI 10.1172/JCI128521
   Zhang HY, 2022, FRONT NUTR, V9, DOI 10.3389/fnut.2022.860086
   Zhang YW, 2022, J ORTHOP TRANSL, V37, P46, DOI 10.1016/j.jot.2022.08.003
   Zhang ZG, 2017, NUTRIENTS, V9, DOI 10.3390/nu9101146
   Zhou HY, 2023, NUTRIENTS, V15, DOI 10.3390/nu15040973
NR 38
TC 0
Z9 0
U1 3
U2 3
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177 8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2024
VL 18
BP 6359
EP 6377
DI 10.2147/DDDT.S482965
PG 19
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA Q3F6O
UT WOS:001383587800001
PM 39741920
OA gold
DA 2025 08 17
ER

PT J
AU Allori, AC
   Sailon, AM
   Pan, JH
   Warren, SM
AF Allori, Alexander C.
   Sailon, Alexander M.
   Pan, Jenny H.
   Warren, Stephen M.
TI Biological basis of bone formation, remodeling, and repair   Part III:
   Biomechanical forces
SO TISSUE ENGINEERING PART B REVIEWS
LA English
DT Article
ID MANDIBULAR DISTRACTION OSTEOGENESIS; MARROW STROMAL OSTEOBLASTS;
   IN VITRO MICRODISTRACTION; MESSENGER RNA EXPRESSION;
   FINITE ELEMENT ANALYSIS; MESENCHYMAL STEM CELLS; FLOW PERFUSION CULTURE;
   INDUCED FLUID FLOW; MECHANICAL STRAIN; OSTEOPROGENITOR CELLS
AB While it has been long appreciated that biomechanical forces are involved in bone remodeling and repair, the actual mechanism by which a physical force is translated to the corresponding intracellular signal has largely remained a mystery. To date, most biomechanical research has concentrated upon the effect on bone morphology and architecture, and. it is only recently that the complex cellular and molecular pathways involved in this process (called mechanotransduction) are being described. In this paper, we review the current understanding of bone mechanobiology and highlight the implications for clinical medicine and tissue engineering research.
C1 [Allori, Alexander C.; Sailon, Alexander M.; Pan, Jenny H.; Warren, Stephen M.] NYU, Inst Reconstruct Plast Surg, Med Ctr, New York, NY 10016 USA.
C3 New York University
RP Warren, SM (通讯作者)，NYU, Inst Reconstruct Plast Surg, Med Ctr, 560 1st Ave,TH 169, New York, NY 10016 USA.
EM stephen.warren.md@gmail.com
RI Allori, Alexander/S 5509 2019
OI Allori, Alexander/0000 0003 3334 9877
FU Lyndon Peer Research Fellowship; Plastic Surgery Educational Foundation
   (PSEF); American Society of Maxillofacial Surgery (ASMS); CMF; PSEF
   Basic Science Research; Alpha Omega Alpha (AOmegaA) Carolyn L. Kuckein
   Research Fellowship; Association of Academic Plastic Surgeons (AAPS)
   Academic Scholar Award
FX This work was graciously supported in part by the 2007 Lyndon Peer
   Research Fellowship, administered by the Plastic Surgery Educational
   Foundation (PSEF); the 2007 Bernd Spiessl Research Award, administered
   by the American Society of Maxillofacial Surgery (ASMS) through the
   Courtesy of Synthes CMF; the 2007 PSEF Basic Science Research Grant (to
   A.C.A.) the 2008 Alpha Omega Alpha (A Omega A) Carolyn L. Kuckein
   Research Fellowship (to A.M.S.) and the 2008 Association of Academic
   Plastic Surgeons (AAPS) Academic Scholar Award (to S.M.W.).
CR AARDEN EM, 1994, J CELL BIOCHEM, V55, P287, DOI 10.1002/jcb.240550304
   Adams DJ, 1997, J BIOMECH, V30, P671, DOI 10.1016/S0021 9290(97)00004 3
   Aguirre JI, 2006, J BONE MINER RES, V21, P605, DOI 10.1359/JBMR.060107
   Amir LR, 2007, J HISTOCHEM CYTOCHEM, V55, P1095, DOI 10.1369/jhc.6A7162.2007
   Armstrong VJ, 2007, J BIOL CHEM, V282, P20715, DOI 10.1074/jbc.M703224200
   Askari M, 2006, PLAST RECONSTR SURG, V117, P449, DOI 10.1097/01.prs.0000197085.72380.e3
   BEAUPRE GS, 1990, J ORTHOP RES, V8, P662, DOI 10.1002/jor.1100080507
   BEAUPRE GS, 1990, J ORTHOP RES, V8, P651, DOI 10.1002/jor.1100080506
   Beno T, 2006, J BIOMECH, V39, P2378, DOI 10.1016/j.jbiomech.2005.08.005
   Bhatt KA, 2007, J SURG RES, V143, P329, DOI 10.1016/j.jss.2007.01.023
   Botchwey EA, 2001, J BIOMED MATER RES, V55, P242
   Bruder SP, 1997, J CELL BIOCHEM, V64, P278, DOI 10.1002/(SICI)1097 4644(199702)64:2<278::AID JCB11>3.0.CO;2 F
   BURGER EH, 1995, J NUTR, V125, pS2020, DOI 10.1093/jn/125.suppl_7.2020S
   Burr DB, 2002, BONE, V30, P781, DOI 10.1016/S8756 3282(02)00707 X
   Carter DR, 1998, CLIN ORTHOP RELAT R, pS41
   Cartmell SH, 2003, TISSUE ENG, V9, P1197, DOI 10.1089/10763270360728107
   Cavanagh Peter R, 2005, Gravit Space Biol Bull, V18, P39
   CHALFIE M, 1993, J NEUROBIOL, V24, P1433, DOI 10.1002/neu.480241013
   Chen Xu yi, 2007, Zhonghua Yi Xue Za Zhi, V87, P1160
   COWIN SC, 1985, J BIOMECH, V18, P665, DOI 10.1016/0021 9290(85)90022 3
   COWIN SC, 1991, J BIOMECH ENG T ASME, V113, P191, DOI 10.1115/1.2891234
   Dehority W, 1999, AM J PHYSIOL ENDOC M, V276, pE62
   Dvir T, 2006, TISSUE ENG, V12, P2843, DOI 10.1089/ten.2006.12.2843
   Fritton SP, 2000, J BIOMECH, V33, P317, DOI 10.1016/S0021 9290(99)00210 9
   FROST HM, 1983, CLIN ORTHOP RELAT R, P286
   Fuller B., 1961, PORTFOLIO ARTNEWS AN, V4, P112
   Gabbay JS, 2006, TISSUE ENG, V12, P3055, DOI 10.1089/ten.2006.12.3055
   Han YF, 2004, P NATL ACAD SCI USA, V101, P16689, DOI 10.1073/pnas.0407429101
   HAYNESWORTH SE, 1992, BONE, V13, P81, DOI 10.1016/8756 3282(92)90364 3
   HILLSLEY MV, 1994, BIOTECHNOL BIOENG, V43, P573, DOI 10.1002/bit.260430706
   Holtorf HL, 2005, J BIOMED MATER RES A, V72A, P326, DOI 10.1002/jbm.a.30251
   Hsieh YF, 2002, J ORTHOP RES, V20, P764, DOI 10.1016/S0736 0266(01)00161 9
   Hughes Fulford M, 2006, J CELL BIOCHEM, V99, P435, DOI 10.1002/jcb.20883
   Huiskes R, 1992, Chir Organi Mov, V77, P121
   HUISKES R, 1987, J BIOMECH, V20, P1135, DOI 10.1016/0021 9290(87)90030 3
   Huiskes R, 1997, ST HEAL T, V40, P33
   Ingber D, 1999, FASEB J, V13, pS3
   Ingber D E, 2004, Mech Chem Biosyst, V1, P53
   Ingber DE, 2003, J CELL SCI, V116, P1397, DOI 10.1242/jcs.00360
   Ingber DE, 2003, J CELL SCI, V116, P1157, DOI 10.1242/jcs.00359
   Ingber DE, 2006, FASEB J, V20, P811, DOI 10.1096/fj.05 5424rev
   Ishijima M, 2007, J ENDOCRINOL, V193, P235, DOI 10.1677/joe.1.06704
   Ishijima M, 2006, EXP CELL RES, V312, P3075, DOI 10.1016/j.yexcr.2006.06.003
   ISSEKUTZ B, 1966, J APPL PHYSIOL, V21, P1013, DOI 10.1152/jappl.1966.21.3.1013
   Iwamoto Jun, 2005, Keio Journal of Medicine, V54, P55, DOI 10.2302/kjm.54.55
   KARAHARJUSUVANTO T, 1992, INT J ORAL MAX SURG, V21, P118, DOI 10.1016/S0901 5027(05)80547 8
   KleinNulend J, 1997, J BONE MINER RES, V12, P45, DOI 10.1359/jbmr.1997.12.1.45
   Kostenuik PJ, 1999, J BONE MINER RES, V14, P21, DOI 10.1359/jbmr.1999.14.1.21
   Kostenuik PJ, 1997, AM J PHYSIOL ENDOC M, V273, pE1133
   Kotsis F, 2007, PFLUG ARCH EUR J PHY, V453, P819, DOI 10.1007/s00424 006 0168 0
   Kung C, 2005, NATURE, V436, P647, DOI 10.1038/nature03896
   Kwon RY, 2007, J BIOMECH, V40, P3162, DOI 10.1016/j.jbiomech.2007.04.003
   Loboa EG, 2005, J ORTHOP RES, V23, P663, DOI 10.1016/j.orthres.2004.09.010
   Loboa EG, 2004, BONE, V34, P336, DOI 10.1016/j.bone.2003.10.012
   Malone AMD, 2007, P NATL ACAD SCI USA, V104, P13325, DOI 10.1073/pnas.0700636104
   Manfredini P, 1999, J BIOMECH, V32, P135, DOI 10.1016/S0021 9290(98)00162 6
   McCarthy ID, 2005, ANN BIOMED ENG, V33, P95, DOI 10.1007/s10439 005 8967 6
   MULLENDER MG, 1994, J BIOMECH, V27, P1389, DOI 10.1016/0021 9290(94)90049 3
   Nauli SM, 2008, CIRCULATION, V117, P1161, DOI 10.1161/CIRCULATIONAHA.107.710111
   Oganov V S, 2004, J Gravit Physiol, V11, pP143
   OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304
   Peter SJ, 1998, J CELL BIOCHEM, V71, P55, DOI 10.1002/(SICI)1097 4644(19981001)71:1<55::AID JCB6>3.0.CO;2 0
   Rowe NM, 1999, ANN PLAS SURG, V42, P470, DOI 10.1097/00000637 199905000 00002
   Rubin C, 2002, J BONE MINER RES, V17, P349, DOI 10.1359/jbmr.2002.17.2.349
   Rubin C, 2001, NATURE, V412, P603, DOI 10.1038/35088122
   Rubin C, 2002, BONE, V30, P445, DOI 10.1016/S8756 3282(01)00689 5
   Schwarz R P, 1992, J Tissue Cult Methods, V14, P51, DOI 10.1007/BF01404744
   Sekulic SR, 2005, MED HYPOTHESES, V64, P221, DOI 10.1016/j.mehy.2004.08.012
   Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092 8674(00)00046 5
   Sikavitsas VI, 2003, P NATL ACAD SCI USA, V100, P14683, DOI 10.1073/pnas.2434367100
   Sikavitsas VI, 2001, BIOMATERIALS, V22, P2581, DOI 10.1016/S0142 9612(01)00002 3
   Sikavitsas VI, 2002, J BIOMED MATER RES, V62, P136, DOI 10.1002/jbm.10150
   Smalt R, 1997, ADV EXP MED BIOL, V433, P311
   Smalt R, 1997, AM J PHYSIOL ENDOC M, V273, pE751, DOI 10.1152/ajpendo.1997.273.4.E751
   Smit TH, 2002, J BIOMECH, V35, P829, DOI 10.1016/S0021 9290(02)00021 0
   Sorkin AM, 2004, AM J PHYSIOL CELL PH, V287, pC1527, DOI 10.1152/ajpcell.00059.2004
   Steck R, 2003, J THEOR BIOL, V220, P249, DOI 10.1006/jtbi.2003.3163
   Stevens HY, 2003, METH MOLEC MED, V80, P381
   Sumanasinghe RD, 2006, TISSUE ENG, V12, P3459, DOI 10.1089/ten.2006.12.3459
   Swan CC, 2003, J BIOMECH ENG T ASME, V125, P25, DOI 10.1115/1.1535191
   Tate MLK, 1998, AM J MED SCI, V316, P189, DOI 10.1097/00000441 199809000 00007
   Tate MLK, 2000, J BIOMECH, V33, P247, DOI 10.1016/S0021 9290(99)00143 8
   Thi MM, 2003, AM J PHYSIOL CELL PH, V284, pC389, DOI 10.1152/ajpcell.00052.2002
   TORRANCE AG, 1994, CALCIFIED TISSUE INT, V54, P241, DOI 10.1007/BF00301686
   van den Dolder J, 2003, J BIOMED MATER RES A, V64A, P235, DOI 10.1002/jbm.a.10365
   Wang LY, 2004, BONE, V34, P499, DOI 10.1016/j.bone.2003.11.022
   Wang LY, 1999, J BIOMECH, V32, P663, DOI 10.1016/S0021 9290(99)00059 7
   Warren SM, 2001, PLAST RECONSTR SURG, V107, P441, DOI 10.1097/00006534 200102000 00021
   WEINANS H, 1992, J BIOMECH, V25, P1425, DOI 10.1016/0021 9290(92)90056 7
   WEINANS H, 1995, J BIOMECH, V28, P739, DOI 10.1016/0021 9290(94)00122 K
   WEINBAUM S, 1994, J BIOMECH, V27, P339, DOI 10.1016/0021 9290(94)90010 8
   Weinbaum S, 2001, BIORHEOLOGY, V38, P119
   WHALEN RT, 1988, J BIOMECH, V21, P825, DOI 10.1016/0021 9290(88)90015 2
   Wolff J., 1986, GESETZ TRANSFORMATIO
   Xiao ZS, 2006, J BIOL CHEM, V281, P30884, DOI 10.1074/jbc.M604772200
   You LD, 2001, J BIOMECH, V34, P1375, DOI 10.1016/S0021 9290(01)00107 5
   Ziambaras K, 1998, J BONE MINER RES, V13, P218, DOI 10.1359/jbmr.1998.13.2.218
NR 97
TC 53
Z9 62
U1 0
U2 18
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3368
EI 1937 3376
J9 TISSUE ENG PART B RE
JI Tissue Eng. Part B Rev.
PD SEP
PY 2008
VL 14
IS 3
BP 285
EP 293
DI 10.1089/ten.teb.2008.0084
PG 9
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Engineering;
   Materials Science
GA 354AU
UT WOS:000259612100007
PM 18707225
DA 2025 08 17
ER

PT J
AU Sun, CX
   Chen, X
   Yang, SP
   Jin, C
   Ding, K
   Chen, C
AF Sun, Chuanxin
   Chen, Xia
   Yang, Shangpo
   Jin, Can
   Ding, Kan
   Chen, Chang
TI LBP1C 2 from Lycium barbarum alleviated age related bone
   loss by targeting BMPRIA/BMPRII/Noggin
SO CARBOHYDRATE POLYMERS
LA English
DT Article
DE Lycium barbarum ( L; barbarum ); Polysaccharide; LBP1C 2; Aging; Bone
   loss; BMP signaling
ID FRUITS; L.
AB Age related bone loss is unavoidable and effective safe drugs are in great need. The fruit of Lycium barbarum was recorded to strengthen bones in the "Ben Cao Gang Mu (Compendium of Materia Medica)". However, there lacks scientific explanation. Herein, we investigated L. barbarum water extract (LBE), L. barbarum polysaccharides (LBP) and the homogeneous polysaccharide LBP1C 2 on the bone loss in adult mouse, aging mouse and ovariectomized mouse models. LBE, LBP and LBP1C 2 all markedly increased bone mass and bone strength in these models and promoted osteoblast proliferation, differentiation and ossification. Mechanistic studies showed that LBP1C 2 binds directly to the BMP receptors (BMPRIA and BMPRII) and noggin, activates the phosphorylation of Smad and disrupts the interaction between noggin and BMPs. Our results clearly elucidate the mechanism, the critical component and the direct targets of L. barbarum and provide potentially safe natural products and new drug candidate against age related bone loss.
C1 [Sun, Chuanxin; Yang, Shangpo; Chen, Chang] Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China.
   [Chen, Xia; Jin, Can; Ding, Kan] Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, State Key Lab Drug Res, Shanghai, Peoples R China.
   [Ding, Kan; Chen, Chang] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
   [Chen, Chang] Beijing Inst Brain Disorders, Beijing 100069, Peoples R China.
   [Ding, Kan] Chinese Acad Sci, Zhongshan Inst Drug Discovery, Shanghai Inst Mat Med, Zhongshan 528400, Guangdong, Peoples R China.
C3 Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese
   Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Chinese
   Academy of Sciences; University of Chinese Academy of Sciences, CAS;
   Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS
RP Ding, K; Chen, C (通讯作者)，Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
EM dingkan@simm.ac.cn; changchen@ibp.ac.cn
RI Ding, Kan/AAT 2124 2020; Chen, Chang/ITD 0049 2023; Jin,
   Can/ABG 8174 2020; Chen, Xiao Dong/ADG 8612 2022; Ding,
   Kan/AGG 3302 2022
OI Ding, Kan/0000 0002 8140 9259; chen, chang/0000 0003 1008 1062
FU Ningxia Key Research and Development Program Grant [2016BZ05]; Regional
   Key Projects of Science and Technology Service Network Plan of the
   Chinese Academy of Sciences (CAS  STS plan) [KFJ STS QYZD 181]; National
   Key Research and Development Program of China [2017YFA0504000,
   2022YFA1303802]; Strategic Priority Research Program of the Chinese
   Academy of Sciences [XDB39000000]; National Natural Science Foundation
   of China  Key program project [91849203]; High level Innovative Research
   Institute [2021B0909050003]
FX This work was supported by the Ningxia Key Research and Development
   Program Grant (Grant No. 2016BZ05), Regional Key Projects of Science and
   Technology Service Network Plan of the Chinese Academy of Sciences (CAS
    STS plan, Grant No. KFJ STS QYZD 181), National Key Research and
   Development Program of China (Grant No. 2017YFA0504000, 2022YFA1303802),
   Strategic Priority Research Program of the Chinese Academy of Sciences
   (Grant No. XDB39000000) and National Natural Science Foundation of China
    Key program project (Grant No. 91849203), High level Innovative
   Research Institute (Grant No. 2021B0909050003). We thank Prof. Jian Luo
   (Institute of Biomedical Sciences and School of Life Sciences, East
   China Normal University) for very helpful discussion.
CR Amagase H, 2009, NUTR RES, V29, P19, DOI 10.1016/j.nutres.2008.11.005
   Bouvard B, 2021, JOINT BONE SPINE, V88, DOI 10.1016/j.jbspin.2021.105135
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Chang RCC, 2008, CELL MOL NEUROBIOL, V28, P643, DOI 10.1007/s10571 007 9181 x
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Ishikawa H, 2007, ACTA ORTHOP, V78, P285, DOI 10.1080/17453670710013816
   James AW, 2016, TISSUE ENG PART B RE, V22, P284, DOI [10.1089/ten.TEB.2015.0357, 10.1089/ten.teb.2015.0357]
   Li JM, 2017, CANCER RES, V77, P6253, DOI 10.1158/0008 5472.CAN 17 0484
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Meng J, 2020, FASEB J, V34, P11460, DOI 10.1096/fj.202000136R
   Meng J, 2017, REDOX BIOL, V11, P365, DOI 10.1016/j.redox.2016.12.026
   Poynton AR, 2002, SPINE, V27, pS40, DOI 10.1097/00007632 200208151 00010
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Sun P, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz0368
   Ulbricht Catherine, 2015, Journal of Dietary Supplements, V12, P184, DOI 10.3109/19390211.2014.904128
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Yoon BH, 2014, J BONE MINER RES, V29, P1950, DOI 10.1002/jbmr.2238
   Zhang HY, 2019, J CELL BIOCHEM, V120, P5018, DOI 10.1002/jcb.27777
   Zhou LS, 2018, CARBOHYD POLYM, V201, P65, DOI 10.1016/j.carbpol.2018.08.050
   Zhou LS, 2018, CARBOHYD POLYM, V195, P643, DOI 10.1016/j.carbpol.2018.05.022
   Zhou LS, 2018, INT J BIOL MACROMOL, V108, P47, DOI 10.1016/j.ijbiomac.2017.11.111
NR 23
TC 25
Z9 32
U1 7
U2 108
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 0144 8617
EI 1879 1344
J9 CARBOHYD POLYM
JI Carbohydr. Polym.
PD JUN 15
PY 2023
VL 310
AR 120725
DI 10.1016/j.carbpol.2023.120725
EA FEB 2023
PG 12
WC Chemistry, Applied; Chemistry, Organic; Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Polymer Science
GA 9W2YR
UT WOS:000948946000001
PM 36925250
DA 2025 08 17
ER

PT J
AU Jiang, ZC
   Pan, YX
   Wang, JH
   Li, JY
   Yang, HZ
   Guo, Q
   Liang, SL
   Chen, SJ
   Hu, YH
   Wang, L
AF Jiang, Zichao
   Pan, Yixiao
   Wang, Jiahao
   Li, Jingyi
   Yang, Haoze
   Guo, Qi
   Liang, Shuailong
   Chen, Sijie
   Hu, Yihe
   Wang, Long
TI Bone  targeted ICG/Cyt c@ZZF 8 nanoparticles based on the zeolitic
   imidazolate framework 8: a new synergistic photodynamic and protein
   therapy for bone metastasis
SO BIOMATERIALS SCIENCE
LA English
DT Article
ID CYTOCHROME C; HYPOXIC TUMOR; BISPHOSPHONATES; MECHANISMS; INDUCTION;
   ACID
AB Bone metastasis (BM) is a solid tumor confined to narrow bone marrow cavities with a relatively poor blood supply and hypoxic environment, making conventional anticancer treatments difficult. In our study, we fabricated nanoparticles (NPs) based on zeolitic imidazolate framework 8 (ZIF 8) loaded with indocyanine green (ICG, a photodynamic agent) and cytochrome c (Cyt c, an anticancer protein) with a surface modified by zoledronate (ZOL, a bone targeting moiety) and a polyvinyl pyrrolidone (PVP) coating to increase their stability. The ICG/Cyt c@ZZF 8 NPs were expected to have synergistic antitumor therapy and bone protection efficiency. The in vitro and in vivo experiments showed the bone targeted and pH sensitive ability of ICG/Cyt c@ZZF 8 NPs, which could be engulfed by tumor cells and release the cargos. Upon 780 nm laser irradiation, ICG produces cytotoxic reactive oxygen species (ROS, O 1(2)) that directly kill tumor cells, and Cyt c with catalase like activity can induce programmed cell death and decompose H2O2 to O 2, thus enhancing the PDT efficiency. The ZOL can further inhibit bone resorption. The ICG/Cyt c@ZZF 8 NPs showed improved antitumor and bone protection efficiency in a mouse model of BM. This study demonstrated a potential mode for the synergetic therapy of orthopedic diseases.
C1 [Jiang, Zichao; Pan, Yixiao; Wang, Jiahao; Li, Jingyi; Guo, Qi; Liang, Shuailong; Wang, Long] Cent South Univ, Xiangya Hosp, Dept Orthoped, Changsha, Peoples R China.
   [Jiang, Zichao; Pan, Yixiao; Wang, Jiahao; Li, Jingyi; Guo, Qi; Liang, Shuailong; Wang, Long] Cent South Univ, Univ Hunan Engn Res Ctr Biomed Met & Ceram Implan, Xiangya Hosp, Changsha, Peoples R China.
   [Jiang, Zichao; Pan, Yixiao; Wang, Jiahao; Li, Jingyi; Guo, Qi; Liang, Shuailong; Hu, Yihe; Wang, Long] Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha, Peoples R China.
   [Yang, Haoze] Cent South Univ, Xiangya Hosp 2, Dept Cardiol, Changsha, Peoples R China.
   [Chen, Sijie] Cent South Univ, Xiangya Hosp 2, Dept Ultrasound Diag, Changsha, Peoples R China.
   [Hu, Yihe] Sch Med, Affiliated Hosp 1, Dept Orthoped, Hangzhou, Zhejiang, Peoples R China.
   [Wang, Long] Cent South Univ, Xiangya Hosp, Hunan Key Laboratary Aging Biol, Changsha, Peoples R China.
C3 Central South University; Central South University; Central South
   University; Central South University; Central South University; Central
   South University
RP Wang, L (通讯作者)，Cent South Univ, Xiangya Hosp, Dept Orthoped, Changsha, Peoples R China.; Wang, L (通讯作者)，Cent South Univ, Univ Hunan Engn Res Ctr Biomed Met & Ceram Implan, Xiangya Hosp, Changsha, Peoples R China.; Hu, YH; Wang, L (通讯作者)，Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha, Peoples R China.; Hu, YH (通讯作者)，Sch Med, Affiliated Hosp 1, Dept Orthoped, Hangzhou, Zhejiang, Peoples R China.; Wang, L (通讯作者)，Cent South Univ, Xiangya Hosp, Hunan Key Laboratary Aging Biol, Changsha, Peoples R China.
EM huyh1964@163.com; dr_wanglong@csu.edu.cn
RI ; Guo, Qi/U 5576 2019
OI Li, Jingyi/0000 0003 0445 1303; Wang, Long/0000 0002 2733 7370
FU National Natural Science Foundation of China [81873988]; Key Research
   and Development Program of Hunan Province of China [2021SK2005];
   Fundamental Research Funds for the Central Universities of Central South
   University [1053320190897, 1053320191463]
FX This study was supported by the National Natural Science Foundation of
   China project (Grant No. 81873988), the Key Research and Development
   Program of Hunan Province of China (Grant No. 2021SK2005), and the
   Fundamental Research Funds for the Central Universities of Central South
   University (Grant No. 1053320190897, 1053320191463).
CR Ali SM, 2001, J CLIN ONCOL, V19, P3434, DOI 10.1200/JCO.2001.19.14.3434
   Alsaiari SK, 2018, J AM CHEM SOC, V140, P143, DOI 10.1021/jacs.7b11754
   Bischin C, 2011, FREE RADICAL RES, V45, P439, DOI 10.3109/10715762.2010.540575
   Celli JP, 2010, CHEM REV, V110, P2795, DOI 10.1021/cr900300p
   Chapartegui Arias A, 2019, ACS OMEGA, V4, P17090, DOI 10.1021/acsomega.9b01051
   Chen HC, 2015, J AM CHEM SOC, V137, P1539, DOI 10.1021/ja511420n
   Chen TT, 2018, J AM CHEM SOC, V140, P9912, DOI 10.1021/jacs.8b04457
   Cheng L, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201800685
   Chindamo G, 2020, NANOMATERIALS BASEL, V10, DOI 10.3390/nano10050875
   Chung CH, 2020, BIOMATERIALS, V257, DOI 10.1016/j.biomaterials.2020.120227
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Ding L, 2020, ACS APPL MATER INTER, V12, P36906, DOI 10.1021/acsami.0c09657
   Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071
   Fang C, 2020, THERANOSTICS, V10, P7671, DOI 10.7150/thno.45079
   Fardjahromi MA, 2022, MATER TODAY CHEM, V23, DOI 10.1016/j.mtchem.2021.100670
   Farrell Kristen B, 2018, Bone Rep, V9, P47, DOI 10.1016/j.bonr.2018.06.007
   Fornetti J, 2018, J BONE MINER RES, V33, P2099, DOI 10.1002/jbmr.3618
   Gu Z, 2011, CHEM SOC REV, V40, P3638, DOI 10.1039/c0cs00227e
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   Ibrahim A, 2003, CLIN CANCER RES, V9, P2394
   Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706
   Jiang ZC, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 70659 x
   Kaneti YV, 2017, ADV MATER, V29, DOI 10.1002/adma.201700213
   Kuchuk I, 2013, J BONE ONCOL, V2, P137, DOI 10.1016/j.jbo.2013.09.001
   Kwiatkowski S, 2018, BIOMED PHARMACOTHER, V106, P1098, DOI 10.1016/j.biopha.2018.07.049
   Lan Y, 2020, NANOSCALE, V12, P7875, DOI 10.1039/c9nr10453d
   LANDSMAN MLJ, 1976, J APPL PHYSIOL, V40, P575, DOI 10.1152/jappl.1976.40.4.575
   Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299
   Lian XZ, 2017, CHEM SOC REV, V46, P3386, DOI 10.1039/c7cs00058h
   Liang H, 2017, NANOTECHNOLOGY, V28, DOI 10.1088/1361 6528/aa8d9c
   Michaelson MD, 2005, J CLIN ONCOL, V23, P8219, DOI 10.1200/JCO.2005.02.9579
   Ni KY, 2020, ACS CENTRAL SCI, V6, P861, DOI 10.1021/acscentsci.0c00397
   Niu CC, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 06122 1
   Pang YC, 2020, NANO LETT, V20, P829, DOI 10.1021/acs.nanolett.9b02916
   Schwetz BA, 2001, JAMA J AM MED ASSOC, V286, P1569, DOI 10.1001/jama.286.13.1569 a
   Shyngys M, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.603608
   Song XJ, 2018, NANO LETT, V18, P6360, DOI 10.1021/acs.nanolett.8b02720
   Srinivasan S, 2016, ONCOGENE, V35, P1585, DOI 10.1038/onc.2015.227
   Tomásková N, 2021, INT J BIOL MACROMOL, V174, P413, DOI 10.1016/j.ijbiomac.2021.01.189
   Tong F, 2020, ACS APPL MATER INTER, V12, P34630, DOI 10.1021/acsami.0c08992
   Vasconcelos IB, 2012, RSC ADV, V2, P9437, DOI 10.1039/c2ra21087h
   Wang ZH, 2011, ORG BIOMOL CHEM, V9, P4766, DOI 10.1039/c1ob05552f
   Wu MX, 2017, ADV MATER, V29, DOI 10.1002/adma.201606134
   Yan JQ, 2020, ANAL CHEM, V92, P11453, DOI 10.1021/acs.analchem.0c02599
   Yang GB, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01050 0
   Yin V, 2017, J AM CHEM SOC, V139, P15701, DOI 10.1021/jacs.7b07106
   Yu Q, 2019, CHEM SCI, V10, P9091, DOI 10.1039/c9sc03161h
   Zhang L, 2018, ACS NANO, V12, P10201, DOI 10.1021/acsnano.8b05200
   Zhao YW, 2020, ACS APPL MATER INTER, V12, P23697, DOI 10.1021/acsami.0c04363
   Zheng DW, 2016, ACS NANO, V10, P8715, DOI 10.1021/acsnano.6b04156
   Zhu HM, 2020, BIOMATER SCI UK, V8, P3844, DOI 10.1039/d0bm00533a
NR 51
TC 20
Z9 20
U1 4
U2 69
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2047 4830
EI 2047 4849
J9 BIOMATER SCI UK
JI Biomater. Sci.
PD MAY 4
PY 2022
VL 10
IS 9
BP 2345
EP 2357
DI 10.1039/d2bm00185c
EA MAR 2022
PG 13
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA 0Y4TW
UT WOS:000778501900001
PM 35383343
DA 2025 08 17
ER

PT J
AU Prowse, PDH
   Elliott, CG
   Hutter, J
   Hamilton, DW
AF Prowse, Paul D. H.
   Elliott, Christopher G.
   Hutter, Jeff
   Hamilton, Douglas W.
TI Inhibition of Rac and ROCK Signalling Influence Osteoblast Adhesion,
   Differentiation and Mineralization on Titanium Topographies
SO PLOS ONE
LA English
DT Article
ID MESENCHYMAL STEM CELLS; ACTIN STRESS FIBERS; DENTAL IMPLANTS;
   CYTOSKELETAL ORGANIZATION; NANOSCALE TOPOGRAPHY; SURFACE ENERGY; RHO
   GTPASES; ACTIVATION; EXPRESSION; KINASE
AB Reducing the time required for initial integration of bone contacting implants with host tissues would be of great clinical significance. Changes in osteoblast adhesion formation and reorganization of the F actin cytoskeleton in response to altered topography are known to be upstream of osteoblast differentiation, and these processes are regulated by the Rho GTPases. Rac and RhoA (through Rho Kinase (ROCK)). Using pharmacological inhibitors, we tested how inhibition of Rac and ROCK influenced osteoblast adhesion, differentiation and mineralization on PT (Pre treated) and SLA (sandblasted large grit, acid etched) topographies. Inhibition of ROCK, but not Rac, significantly reduced adhesion number and size on PT, with adhesion size consistent with focal complexes. After 1 day, ROCK, but not Rac inhibition increased osteocalcin mRNA levels on SLA and PT, with levels further increasing at 7 days post seeding. ROCK inhibition also significantly increased bone sialoprotein expression at 7 days, but not BMP 2 levels. Rac inhibition significantly reduced BMP 2 mRNA levels. ROCK inhibition increased nuclear translocation of Runx2 independent of surface roughness. Mineralization of osteoblast cultures was greater on SLA than on PT, but was increased by ROCK inhibition and attenuated by Rac inhibition on both topographies. In conclusion, inhibition of ROCK signalling significantly increases osteoblast differentiation and biomineralization in a topographic dependent manner, and its pharmacological inhibition could represent a new therapeutic to speed bone formation around implanted metals and in regenerative medicine applications.
C1 [Prowse, Paul D. H.; Hamilton, Douglas W.] Univ Western Ontario, Dept Anat, Grad Program Biomed Engn, London, ON, Canada.
   [Elliott, Christopher G.; Hamilton, Douglas W.] Univ Western Ontario, Dept Cell Biol, Grad Program Biomed Engn, London, ON, Canada.
   [Hutter, Jeff] Univ Western Ontario, Dept Phys & Astron, London, ON, Canada.
   [Hamilton, Douglas W.] Univ Western Ontario, Div Oral Biol, Schulich Sch Med & Dent, London, ON, Canada.
C3 Western University (University of Western Ontario); Western University
   (University of Western Ontario); Western University (University of
   Western Ontario); Western University (University of Western Ontario)
RP Hamilton, DW (通讯作者)，Univ Western Ontario, Dept Anat, Grad Program Biomed Engn, London, ON, Canada.
EM dhamil2@uwo.ca
RI ; Hamilton, Douglas/L 8932 2015
OI Hutter, Jeffrey/0009 0000 6152 3284; Hamilton,
   Douglas/0000 0002 9798 5197
FU Canadian Foundation for Innovation Leaders Opportunity Fund [18742];
   Natural Sciences and Engineering Research Council of Canada
   [355615 2009]; Ontario Ministry of Research and Innovation Early
   Researcher Award; Joint Motion Program(JuMP)   A CIHR Training Program
   in Musculoskeletal Health Research and Leadership
FX This work was funded by the Canadian Foundation for Innovation Leaders
   Opportunity Fund(Grant no: 18742) and the Natural Sciences and
   Engineering Research Council of Canada(Grant Number: 355615 2009) to
   DWH. DWH is a recipient of the Ontario Ministry of Research and
   Innovation Early Researcher Award. This work was also supported by the
   Joint Motion Program(JuMP)   A CIHR Training Program in Musculoskeletal
   Health Research and Leadership. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Alves RDAM, 2010, J PROTEOME RES, V9, P4688, DOI 10.1021/pr100400d
   Anselme K, 2004, BIO MED MATER ENG, V14, P545
   Bächle M, 2004, CLIN ORAL IMPLAN RES, V15, P683, DOI 10.1111/j.1600 0501.2004.01054.x
   BELLOWS CG, 1986, CALCIFIED TISSUE INT, V38, P143, DOI 10.1007/BF02556874
   Berenjeno IM, 2008, CLIN TRANSL ONCOL, V10, P726, DOI 10.1007/s12094 008 0279 5
   Biggs MJP, 2008, J R SOC INTERFACE, V5, P1231, DOI 10.1098/rsif.2008.0035
   Biggs MJP, 2007, J MATER SCI MATER M, V18, P399, DOI 10.1007/s10856 006 0705 6
   Biggs MJP, 2009, J BIOMED MATER RES A, V91A, P195, DOI 10.1002/jbm.a.32196
   Biggs MJP, 2009, BIOMATERIALS, V30, P5094, DOI 10.1016/j.biomaterials.2009.05.049
   Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264 6021:3480241
   Bornstein MM, 2008, CLIN ORAL IMPLAN RES, V19, P1034, DOI 10.1111/j.1600 0501.2008.01573.x
   Bornstein MM, 2005, CLIN ORAL IMPLAN RES, V16, P631, DOI 10.1111/j.1600 0501.2005.01209.x
   Chen NX, 2010, AM J PHYSIOL RENAL, V299, pF674, DOI 10.1152/ajprenal.00730.2009
   de Vicente JC, 2006, INT J ORAL MAX SURG, V35, P1047, DOI 10.1016/j.ijom.2006.06.008
   Elias BC, 2010, CELL ADHES MIGR, V4, P419, DOI 10.4161/cam.4.3.12043
   Galli C, 2012, ACTA BIOMATER, V8, P2963, DOI 10.1016/j.actbio.2012.04.043
   Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101
   Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509
   Hamamura K., 2012, Connective tissue research
   Hamilton DW, 2006, CALCIFIED TISSUE INT, V78, P314, DOI 10.1007/s00223 005 0238 x
   Hamilton DW, 2007, BIOMATERIALS, V28, P1806, DOI 10.1016/j.biomaterials.2006.11.041
   Harmey D, 2004, J BONE MINER RES, V19, P661, DOI 10.1359/JBMR.040105
   Higuchi C, 2009, J BONE MINER METAB, V27, P158, DOI 10.1007/s00774 009 0037 y
   Javed F, 2011, IMPLANT DENT, V20, P40, DOI 10.1097/ID.0b013e31820867da
   Javed F, 2010, J DENT, V38, P612, DOI 10.1016/j.jdent.2010.05.013
   Jung UW, 2008, J PERIODONTOL, V79, P1857, DOI [10.1902/jop.2008.070632, 10.1902/jop.2008.070632 ]
   Kanazawa I, 2010, ENDOCR J, V57, P415, DOI 10.1507/endocrj.K09E 328
   Kanazawa I, 2009, AM J PHYSIOL ENDOC M, V296, pE139, DOI 10.1152/ajpendo.90677.2008
   Khatiwala CB, 2009, J BONE MINER RES, V24, P886, DOI [10.1359/jbmr.081240, 10.1359/JBMR.081240]
   Koh RU, 2010, IMPLANT DENT, V19, P98, DOI 10.1097/ID.0b013e3181d47eaf
   Lai HC, 2010, J BIOMED MATER RES A, V93A, P289, DOI 10.1002/jbm.a.32542
   Lamers E, 2010, EUR CELLS MATER, V20, P329
   Le Guéhennec L, 2007, DENT MATER, V23, P844, DOI 10.1016/j.dental.2006.06.025
   Lethaus B, 2011, INT J ORAL MAX IMPL, V26, P887
   Massaro C, 2002, J MATER SCI MATER M, V13, P535, DOI 10.1023/A:1015170625506
   McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534 5807(04)00075 9
   McMurray RJ, 2011, NAT MATER, V10, P637, DOI [10.1038/NMAT3058, 10.1038/nmat3058]
   Miron RJ, 2010, BIOMATERIALS, V31, P449, DOI 10.1016/j.biomaterials.2009.09.075
   Neto PT, 2004, QUINTESSENCE INT, V35, P717
   NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092 8674(95)90370 4
   Olivares Navarrete R, 2011, BIOMATERIALS, V32, P6399, DOI 10.1016/j.biomaterials.2011.05.036
   PARR GR, 1985, J PROSTHET DENT, V54, P410, DOI 10.1016/0022 3913(85)90562 1
   Passeri G, 2010, CLIN ORAL IMPLAN RES, V21, P756, DOI 10.1111/j.1600 0501.2009.01906.x
   Qu J, 1996, Oral Dis, V2, P102
   RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092 8674(92)90163 7
   Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960 9822(99)80286 3
   Rupp F, 2006, J BIOMED MATER RES A, V76A, P323, DOI 10.1002/jbm.a.30518
   Schwarz F, 2007, J PERIODONTOL, V78, P2171, DOI 10.1902/jop.2007.070157
   Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247
   Wang GY, 2004, J BIOL CHEM, V279, P13205, DOI 10.1074/jbc.M311427200
   Wennerberg A, 2010, INT J ORAL MAX IMPL, V25, P63
   Wieland M, 2005, BIOMATERIALS, V26, P1119, DOI 10.1016/j.biomaterials.2004.04.020
   Wieland M, 2001, INT J ORAL MAX IMPL, V16, P163
   Yamanouchi K., 1997, J BONE MINER METAB, V15, P23, DOI [DOI 10.1007/BF02439451, 10.1007/BF02439451]
   Yoshikawa H, 2009, CLIN ORTHOP RELAT R, V467, P3087, DOI 10.1007/s11999 009 0976 6
   Zhao G, 2007, BIOMATERIALS, V28, P2821, DOI 10.1016/j.biomaterials.2007.02.024
   Zimmerman AW, 2004, J CELL SCI, V117, P2841, DOI 10.1242/jcs.01139
   Zinger O, 2005, BIOMATERIALS, V26, P1837, DOI 10.1016/j.biomaterials.2004.06.035
NR 58
TC 39
Z9 44
U1 0
U2 29
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD MAR 7
PY 2013
VL 8
IS 3
AR e58898
DI 10.1371/journal.pone.0058898
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 136BN
UT WOS:000318334500131
PM 23505566
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Li, X
   Li, Y
   Jin, W
   Zheng, Y
   Rong, C
   Lyu, H
   Shen, H
AF Li, X.
   Li, Y.
   Jin, W.
   Zheng, Y.
   Rong, C.
   Lyu, H.
   Shen, H.
TI Investigation of strontium accumulation on ovariectomized Sprague Dawley
   rat tibia by micro PIXE
SO NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH SECTION B BEAM
   INTERACTIONS WITH MATERIALS AND ATOMS
LA English
DT Article; Proceedings Paper
CT 21st International Conference on Ion Beam Analysis (IBA)
CY JUN 23 28, 2013
CL Amer Vacuum Soc, Pacific NW Chapter, Seattle, WA
HO Amer Vacuum Soc, Pacific NW Chapter
DE Micro PIXE; Strontium ranelate; Strontium chloride; Osteoporosis
ID BONE MINERALIZATION DENSITY; SENSING RECEPTOR CAR; OSTEOBLAST
   DIFFERENTIATION; PARATHYROID HORMONE; FLUORIDE TREATMENT; CELL
   REPLICATION; SODIUM FLUORIDE; CANCELLOUS BONE; CORTICAL BONE; ILIAC
   CREST
AB Strontium ranelate is a newly developed drug effective in osteoporosis treatment by depressing bone resorption and maintaining bone formation. Strontium accumulation and distribution are determined in bones of rat after strontium ranelate administration by using micro PIXE. The investigated rats are divided into four groups: (A) control, (B) ovariectomized, (C) ovariectomized followed with strontium chloride, (D) ovariectomized followed with strontium ranelate. It was found that strontium ranelate would result in increasing trabecular volume and decreasing bone resorption to treat osteoporosis. There are similar contours of calcium and strontium in two dimensional images, while the strontium is not evenly distributed in the bone. It supports the conclusion that strontium has an affinity for bone and it is capable of replacing calcium atoms as a part of the strontium mechanism in the osteoporosis treatment. The results related to biochemistry are also discussed. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Li, X.; Li, Y.; Zheng, Y.; Rong, C.; Lyu, H.; Shen, H.] Fudan Univ, Inst Modern Phys, Shanghai 200433, Peoples R China.
   [Jin, W.] Fudan Univ, Inst Radiat Med, Shanghai 200032, Peoples R China.
C3 Fudan University; Chinese Academy of Sciences; Fudan University
RP Shen, H (通讯作者)，Fudan Univ, Inst Modern Phys, 220 Handan Rd, Shanghai 200433, Peoples R China.
EM haoshen@fudan.edu.cn
CR Aaseth J, 2012, J TRACE ELEM MED BIO, V26, P149, DOI 10.1016/j.jtemb.2012.03.017
   Ammann P, 2004, J BONE MINER RES, V19, P2012, DOI 10.1359/JBMR.040906
   Ammann P, 2007, J BONE MINER RES, V22, P1419, DOI 10.1359/jbmr.070607
   Aranyosiova M, 2011, SURF INTERFACE ANAL, V43, P306, DOI 10.1002/sia.3458
   Bain SD, 2009, OSTEOPOROSIS INT, V20, P1417, DOI 10.1007/s00198 008 0815 8
   Barbara A, 2004, METABOLISM, V53, P532, DOI 10.1016/j.metabol.2003.10.022
   Bärenholdt O, 2009, BONE, V45, P200, DOI 10.1016/j.bone.2009.04.196
   Baron R, 2002, EUR J PHARMACOL, V450, P11, DOI 10.1016/S0014 2999(02)02040 X
   Blake GM, 2007, J CLIN DENSITOM, V10, P259, DOI 10.1016/j.jocd.2007.03.102
   Boivin G, 1996, J BONE MINER RES, V11, P1302
   Bonnelye E, 2008, BONE, V42, P129, DOI 10.1016/j.bone.2007.08.043
   Braux J, 2011, ACTA BIOMATER, V7, P2593, DOI 10.1016/j.actbio.2011.02.013
   Brennan TC, 2009, BRIT J PHARMACOL, V157, P1291, DOI 10.1111/j.1476 5381.2009.00305.x
   Buehler J, 2001, BONE, V29, P176, DOI 10.1016/S8756 3282(01)00484 7
   Campana SE, 1997, CAN J FISH AQUAT SCI, V54, P2068, DOI 10.1139/cjfas 54 9 2068
   Campbell JL, 1999, NUCL INSTRUM METH B, V150, P260, DOI 10.1016/S0168 583X(98)01067 2
   Canalis E, 1996, BONE, V18, P517, DOI 10.1016/8756 3282(96)00080 4
   Caudrillier A, 2010, MOL PHARMACOL, V78, P569, DOI 10.1124/mol.109.063347
   Caverzasio J, 2008, BONE, V42, P1131, DOI 10.1016/j.bone.2008.02.010
   CHANG GY, 1993, RAD PROTECT B, V6
   Chattopadhyay N, 2007, BIOCHEM PHARMACOL, V74, P438, DOI 10.1016/j.bcp.2007.04.020
   Choudhary S, 2007, J BONE MINER RES, V22, P1002, DOI 10.1359/JBMR.070321
   Dahl SG, 2001, BONE, V28, P446, DOI 10.1016/S8756 3282(01)00419 7
   Farlay D, 2005, J BONE MINER RES, V20, P1569, DOI 10.1359/JBMR.050405
   Fonseca JE, 2008, RHEUMATOLOGY, V47, P17, DOI 10.1093/rheumatology/ken165
   FRATZL P, 1994, J BONE MINER RES, V9, P1541
   Fratzl P, 1996, J BONE MINER RES, V11, P248
   Gallacher SJ, 2010, CALCIFIED TISSUE INT, V87, P469, DOI 10.1007/s00223 010 9420 x
   GRIME GW, 1995, NUCL INSTRUM METH B, V104, P107, DOI 10.1016/0168 583X(95)00401 7
   Halden NM, 1996, NUCL INSTRUM METH B, V109, P592, DOI 10.1016/0168 583X(95)00975 2
   Hamdy NAT, 2009, RHEUMATOLOGY, V48, pIV9, DOI 10.1093/rheumatology/kep274
   [黄国涛 Huang Guotao], 2008, [中国组织工程研究与临床康复, Journal of Clinical Rehabilitative Tissue Engineering Research], V12, P9113
   Kendler DL, 2009, OSTEOPOROSIS INT, V20, P1101, DOI 10.1007/s00198 009 0886 1
   Li CH, 2010, J BONE MINER RES, V25, P968, DOI 10.1359/jbmr.091038
   LIKINS RC, 1959, ARCH BIOCHEM BIOPHYS, V83, P472, DOI 10.1016/0003 9861(59)90055 4
   MACDONALD NS, 1951, J BIOL CHEM, V188, P137
   Marie P.M., 1981, P U MISS 19 ANN C TR, P193
   Marie PJ, 2007, BONE, V40, pS5, DOI 10.1016/j.bone.2007.02.003
   MARIE PJ, 1993, J BONE MINER RES, V8, P607
   Marie PJ, 2003, OSTEOPOROSIS INT, V14, pS9, DOI 10.1007/s00198 002 1344 5
   MARIE PJ, 1986, METABOLISM, V35, P547, DOI 10.1016/0026 0495(86)90013 2
   MATSUMOTO A, 1988, ARCH TOXICOL, V62, P240, DOI 10.1007/BF00570150
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   Misof BM, 2003, J CLIN ENDOCR METAB, V88, P1150, DOI 10.1210/jc.2002 021988
   Morris JA, 2005, X RAY SPECTROM, V34, P301, DOI 10.1002/xrs.819
   PARFITT AM, 1984, CALCIFIED TISSUE INT, V36, pS123, DOI 10.1007/BF02406145
   PECK WA, 1993, AM J MED, V94, P646
   Pemmer B, 2011, J SYNCHROTRON RADIAT, V18, P835, DOI 10.1107/S090904951103038X
   Roschger P, 2008, BONE, V42, P456, DOI 10.1016/j.bone.2007.10.021
   Roschger P, 1997, BONE, V20, P393, DOI 10.1016/S8756 3282(97)00018 5
   Roschger P, 2001, BONE, V29, P185, DOI 10.1016/S8756 3282(01)00485 9
   Saquet M, 2002, NUCL INSTRUM METH B, V189, P196, DOI 10.1016/S0168 583X(01)01041 2
   SCHROEDER HA, 1972, J CHRON DIS, V25, P491, DOI 10.1016/0021 9681(72)90150 6
   SU Y, 1992, J BONE MINER RES, V7, pS306
   Takahashi N, 2003, J BONE MINER RES, V18, P1082, DOI 10.1359/jbmr.2003.18.6.1082
   Takaoka S, 2010, HORM METAB RES, V42, P627, DOI 10.1055/s 0030 1255091
   Valenta A, 2005, BONE, V37, P87, DOI 10.1016/j.bone.2005.03.013
   Yang L., 2004, Chinese Journal of Osteoporosis, V10, P384, DOI [10.3969/j.issn.1006 7108.2004.03.041, DOI 10.3969/J.ISSN.1006 7108.2004.03.041]
   Zheng Y, 2009, NUCL INSTRUM METH B, V267, P2128, DOI 10.1016/j.nimb.2009.03.066
   Zhong L, 2007, NUCL INSTRUM METH B, V260, P109, DOI 10.1016/j.nimb.2007.01.283
   Zhu LL, 2007, BIOCHEM BIOPH RES CO, V355, P307, DOI 10.1016/j.bbrc.2007.01.120
   Zoehrer R, 2006, J BONE MINER RES, V21, P1106, DOI 10.1359/JBMR.060401
NR 62
TC 4
Z9 4
U1 0
U2 10
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168 583X
EI 1872 9584
J9 NUCL INSTRUM METH B
JI Nucl. Instrum. Methods Phys. Res. Sect. B Beam Interact. Mater. Atoms
PD AUG 1
PY 2014
VL 332
BP 321
EP 325
DI 10.1016/j.nimb.2014.02.087
PG 5
WC Instruments & Instrumentation; Nuclear Science & Technology; Physics,
   Atomic, Molecular & Chemical; Physics, Nuclear
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Instruments & Instrumentation; Nuclear Science & Technology; Physics
GA AL4UV
UT WOS:000339131200071
DA 2025 08 17
ER

PT J
AU Zhang, JW
   Wang, Y
   Guo, J
   Zhang, NH
   He, J
   Zhou, ZK
   Wu, F
AF Zhang, Junwei
   Wang, Yao
   Guo, Jing
   Zhang, Nihui
   He, Jing
   Zhou, Zongke
   Wu, Fang
TI Direct Reprogramming of Mouse Fibroblasts to Osteoblast like Cells Using
   Runx2/Dlx5 Factors on Engineered Stiff Hydrogels
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE direct reprogramming; mechanicalmicroenvironment; reprogramming
   efficiency; transcriptionalfactors; cell therapy
ID STEM CELLS; GENERATION; MICROENVIRONMENTS; METABOLISM; MECHANISMS;
   CONVERSION; DELIVERY
AB Direct reprogramming of somatic cells into functional cells still faces major limitations in terms of efficiency and achieving functional maturity of the reprogramed cells. While different approaches have been developed commonly based on exploiting biochemical signals, introducing appropriate mechanical cues that stimulate the reprogramming process is rarely reported. In this study, collagen coated polyacrylamide (PAM) hydrogels with stiffness close to that of collagenous bone (40 kPa) were adopted to augment the direct reprogramming process of mouse fibroblasts to osteoblastic like cells. The results suggested that culturing cells on a hydrogel substrate enhanced the overexpression of osteogenic transcription factors using nonviral vectors and improved the yield of osteoblast like cells. Particularly, a synergistic effect on achieving osteogenic functionality has been observed for the mechanical cues and overexpression of transcriptional factors, leading to enhanced osteogenic transformation and production of bone mineral matrix. Animal experiments suggested that reprogramed cells generated on matrix hydrogels accelerated bone regeneration and stimulated ectopic osteogenesis. Mechanism analysis suggested the critical involvement of actomyosin contraction and mechanical signal mediated pathways like the RhoA ROCK pathway, leading to a synergistic effect on the key transcriptional processes, including chromatin remodeling, nuclear translocation, and epigenetic transition. This study provides insights into the mechanical cue enhanced direct reprogramming and cell therapy.
C1 [Zhang, Junwei; Wang, Yao; Guo, Jing; Zhang, Nihui; He, Jing; Wu, Fang] Sichuan Univ, Natl Engn Res Ctr Biomat, Chengdu 610064, Peoples R China.
   [Zhou, Zongke] Sichuan Univ, West China Hosp, Orthoped Res Inst, Chengdu 610041, Sichuan, Peoples R China.
   [Zhou, Zongke] Sichuan Univ, Dept Orthoped, West China Hosp, Chengdu 610041, Sichuan, Peoples R China.
C3 Sichuan University; Sichuan University; Sichuan University
RP He, J; Wu, F (通讯作者)，Sichuan Univ, Natl Engn Res Ctr Biomat, Chengdu 610064, Peoples R China.; Zhou, ZK (通讯作者)，Sichuan Univ, West China Hosp, Orthoped Res Inst, Chengdu 610041, Sichuan, Peoples R China.; Zhou, ZK (通讯作者)，Sichuan Univ, Dept Orthoped, West China Hosp, Chengdu 610041, Sichuan, Peoples R China.
EM jinghe30@scu.edu.cn; zhouzongke@scu.edu.cn; fwu@scu.edu.cn
RI Wu, Fang/D 7264 2011; He, Jing/JTT 9706 2023
OI Zhou, Zongke/0000 0002 9037 4756; Wu, Fang/0000 0001 5268 9098; 
FU National Natural Science Foundation of China [31971257, 32271397,
   82172394, 81671826]; National Natural Science Foundation of China
   [2022NSFSC0360]; Natural Science Foundation of Sichuan Province
FX This work was supported by the National Natural Science Foundation of
   China (nos. 31971257, 32271397, 82172394, and 81671826) and the Natural
   Science Foundation of Sichuan Province (no. 2022NSFSC0360).
CR Brusatin G, 2018, NAT MATER, V17, P1063, DOI 10.1038/s41563 018 0180 8
   Caiazzo M, 2016, NAT MATER, V15, P344, DOI [10.1038/NMAT4536, 10.1038/nmat4536]
   Cao X, 2013, ADV FUNCT MATER, V23, P5403, DOI 10.1002/adfm.201203646
   Chaudhuri O, 2020, NATURE, V584, P535, DOI 10.1038/s41586 020 2612 2
   Cherry ABC, 2012, CELL, V148, P1110, DOI 10.1016/j.cell.2012.02.031
   Dehnavi SS, 2022, ADV MATER, V34, DOI 10.1002/adma.202108757
   Dekker J, 2016, CELL, V164, P1110, DOI 10.1016/j.cell.2016.02.007
   Downing TL, 2013, NAT MATER, V12, P1154, DOI [10.1038/NMAT3777, 10.1038/nmat3777]
   Doyle AD, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9720
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Fang J, 2020, ACS NANO, V14, P1296, DOI 10.1021/acsnano.9b04837
   Foldvari M, 2016, J CONTROL RELEASE, V240, P165, DOI 10.1016/j.jconrel.2015.12.012
   Fu JD, 2013, STEM CELL REP, V1, P235, DOI 10.1016/j.stemcr.2013.07.005
   Gu W, 2016, CELL STEM CELL, V19, P476, DOI 10.1016/j.stem.2016.08.008
   Hajj KA, 2017, NAT REV MATER, V2, DOI 10.1038/natrevmats.2017.56
   Killaars AR, 2019, ADV SCI, V6, DOI 10.1002/advs.201801483
   Kim YJ, 2014, CELL STEM CELL, V15, P497, DOI 10.1016/j.stem.2014.07.013
   Lu ZY, 2021, BIOMATERIALS, V269, DOI 10.1016/j.biomaterials.2021.120668
   Ma KY, 2014, MOL CELL BIOCHEM, V389, P209, DOI 10.1007/s11010 013 1942 x
   Ma YF, 2018, ADV MATER, V30, DOI 10.1002/adma.201705911
   Macri Pellizzeri L, 2018, J TISSUE ENG REGEN M, V12, P1012, DOI 10.1002/term.2586
   Madl CM, 2018, ANNU REV BIOMED ENG, V20, P21, DOI 10.1146/annurev bioeng 062117 120954
   Maharana S, 2016, NUCLEIC ACIDS RES, V44, P5148, DOI 10.1093/nar/gkw131
   Mahmood SR, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 25596 2
   Mammoto A, 2012, J CELL SCI, V125, P3061, DOI 10.1242/jcs.093005
   Mattiassi S, 2021, BIOMATER SCI UK, V9, P5175, DOI 10.1039/d1bm00400j
   Mertens J, 2016, NAT REV NEUROSCI, V17, P424, DOI 10.1038/nrn.2016.46
   Meshorer E, 2006, NAT REV MOL CELL BIO, V7, P540, DOI 10.1038/nrm1938
   Park EJ, 2023, CELL STEM CELL, V30, P335, DOI 10.1016/j.stem.2023.03.001
   Polo JM, 2012, CELL, V151, P1617, DOI 10.1016/j.cell.2012.11.039
   Roy B, 2018, P NATL ACAD SCI USA, V115, pE4741, DOI 10.1073/pnas.1714770115
   Sancho Martinez I, 2013, NATURE, V493, P310, DOI 10.1038/493310b
   Sekiya S, 2011, NATURE, V475, P390, DOI 10.1038/nature10263
   Shi Y, 2017, NAT REV DRUG DISCOV, V16, P115, DOI 10.1038/nrd.2016.245
   Sia JR, 2016, BIOMATERIALS, V92, P36, DOI 10.1016/j.biomaterials.2016.03.033
   Srivastava D, 2016, CELL, V166, P1386, DOI 10.1016/j.cell.2016.08.055
   Stone NR, 2019, CELL STEM CELL, V25, P87, DOI 10.1016/j.stem.2019.06.012
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Théry M, 2006, CELL MOTIL CYTOSKEL, V63, P341, DOI 10.1002/cm.20126
   Wu J, 2016, CELL, V166, P1371, DOI 10.1016/j.cell.2016.08.008
   Xu J, 2015, CELL STEM CELL, V16, P119, DOI 10.1016/j.stem.2015.01.013
   Xu XB, 2018, ACS NANO, V12, P4503, DOI 10.1021/acsnano.8b00763
   Xu ZR, 2022, ACTA BIOMATER, V152, P255, DOI 10.1016/j.actbio.2022.08.049
   Yin H, 2014, NAT REV GENET, V15, P541, DOI 10.1038/nrg3763
   Zhang JF, 2019, INT J ORAL SCI, V11, DOI 10.1038/s41368 019 0046 1
   Zhou ZX, 2017, ADV DRUG DELIVER REV, V115, P115, DOI 10.1016/j.addr.2017.07.021
NR 46
TC 4
Z9 4
U1 2
U2 26
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944 8244
EI 1944 8252
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD DEC 16
PY 2023
VL 15
IS 51
BP 59209
EP 59223
DI 10.1021/acsami.3c14777
PG 15
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA DQ2K9
UT WOS:001133456300001
PM 38102996
DA 2025 08 17
ER

PT J
AU Wang, CP
   Li, L
   Zhang, S
   Yan, Y
   Huang, Q
   Cai, XP
   Xiao, JR
   Cheng, YY
AF Wang, Changping
   Li, Lin
   Zhang, Song
   Yan, Yang
   Huang, Quan
   Cai, Xiaopan
   Xiao, Jianru
   Cheng, Yiyun
TI Carrier Free Platinum Nanomedicine for Targeted Cancer Therapy
SO SMALL
LA English
DT Article
DE bone targeting; carrier&#8208; free nanomedicine; multifunctional
   nanoparticles; targeted cancer therapy
ID DRUG DELIVERY SYSTEMS; CLINICAL TRANSLATION; NANOPARTICLES; COMBINATION;
   CHEMOTHERAPY; CONJUGATE; NANODRUG; PRODRUG
AB Numerous nanomedicines have been developed to improve the efficiency and safety of conventional anticancer drugs; however, the complexities in carrier materials and functional integration make it challenging to promote these candidates for clinical translation. In this study, a facile method to prepare carrier free anticancer nanodrug with inherent bone targeting and osteoclastogenesis inhibition capabilities is reported. Phytic acid, a naturally occurring and nontoxic product, is reacted with cisplatin to form uniform nanoparticles of different sizes. The prepared nanoparticles possess high drug loading and pH responsive drug release behaviors. Phytic acid in the nanomedicine ensures high bone targeting and osteoclastogenesis inhibition, and the released platinum drugs triggered by tumor extracellular acidity eradicate tumor cells. The nanomedicine around 100 nm shows high anticancer activity and much reduced side effects in a subcutaneous breast cancer model when compared with cisplatin. In addition, it shows high accumulation at osteolytic lesions, and efficiently inhibits tumor growth and tumor associated osteolysis in a bone metastatic breast cancer model. Here, a facile and efficient strategy to prepare carrier free nanomedicines with high anticancer drug loading, inherent bone targeting, and osteoclast inhibitory activities for cancer therapy is provided.
C1 [Wang, Changping; Zhang, Song; Cheng, Yiyun] South China Univ Technol, Sch Mol Sci & Engn, South China Adv Inst Soft Matter Sci & Technol, Guangzhou 510640, Peoples R China.
   [Li, Lin; Huang, Quan; Cai, Xiaopan; Xiao, Jianru] Second Mil Med Univ, Changzheng Hosp, Dept Orthoped Oncol, Shanghai 200003, Peoples R China.
   [Yan, Yang; Cheng, Yiyun] East China Normal Univ, Sch Life Sci, Shanghai Key Lab Regulatory Biol, Shanghai 200241, Peoples R China.
C3 South China University of Technology; Naval Medical University; East
   China Normal University
RP Cheng, YY (通讯作者)，South China Univ Technol, Sch Mol Sci & Engn, South China Adv Inst Soft Matter Sci & Technol, Guangzhou 510640, Peoples R China.; Xiao, JR (通讯作者)，Second Mil Med Univ, Changzheng Hosp, Dept Orthoped Oncol, Shanghai 200003, Peoples R China.; Cheng, YY (通讯作者)，East China Normal Univ, Sch Life Sci, Shanghai Key Lab Regulatory Biol, Shanghai 200241, Peoples R China.
EM jianruxiao83@163.com; yycheng@mail.ustc.edu.cn
RI Cheng, Jessica Yi Yun/MSZ 1589 2025; Wang, Changping/JSK 6142 2023
OI Wang, Changping/0000 0002 9330 2379; xiao, jianru/0000 0003 1547 851X
FU National Natural Science Foundation of China [21725402, 81871470,
   81971735, 82001949]; Shanghai Municipal Science and Technology
   Commission [188014580]; Guangdong Innovative and Entrepreneurial
   Research Team Program [2016ZT06C322]
FX C.W. and L.L. contributed equally to this work. This work was supported
   by the National Natural Science Foundation of China (21725402, 81871470,
   81971735, 82001949), the Shanghai Municipal Science and Technology
   Commission (188014580), and the Guangdong Innovative and Entrepreneurial
   Research Team Program (2016ZT06C322). All animal experiments were
   approved by the animal experimentation ethics committee of ECNU.
CR Abbas M, 2017, ADV MATER, V29, DOI 10.1002/adma.201605021
   Allen TM, 2013, ADV DRUG DELIVER REV, V65, P36, DOI 10.1016/j.addr.2012.09.037
   Brehm MA, 2019, BIOCHEM PHARMACOL, V163, P206, DOI 10.1016/j.bcp.2019.02.024
   Chen Q, 2016, ADV MATER, V28, P10557, DOI 10.1002/adma.201600038
   Chen SZ, 2018, SCI CHINA LIFE SCI, V61, P371, DOI 10.1007/s11427 018 9293 2
   Cheng L, 2020, ADV MATER, V32, DOI 10.1002/adma.201902333
   Chu CC, 2019, ANGEW CHEM INT EDIT, V58, P269, DOI 10.1002/anie.201812482
   Arriero MD, 2012, CELL PHYSIOL BIOCHEM, V30, P974, DOI 10.1159/000341474
   Ekladious I, 2019, NAT REV DRUG DISCOV, V18, P273, DOI 10.1038/s41573 018 0005 0
   Feng CH, 2017, SOLID STATE COMMUN, V266, P34, DOI 10.1016/j.ssc.2017.08.016
   Fu LH, 2019, ADV MATER, V31, DOI 10.1002/adma.201808325
   Gao X, 2021, BIOMATERIALS, V265, DOI 10.1016/j.biomaterials.2020.120404
   Gu M, 2009, CANCER RES, V69, P9465, DOI 10.1158/0008 5472.CAN 09 2805
   Guo Y, 2017, ACS APPL MATER INTER, V9, P43508, DOI 10.1021/acsami.7b14755
   Hou YQ, 2017, ACS APPL MATER INTER, V9, P17757, DOI 10.1021/acsami.7b03686
   Hua S, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00790
   Huang P, 2014, J AM CHEM SOC, V136, P11748, DOI 10.1021/ja505212y
   Jang HL, 2016, NANOMEDICINE UK, V11, P1495, DOI 10.2217/nnm 2016 0133
   Ke WD, 2019, ACS NANO, V13, P2357, DOI 10.1021/acsnano.8b09082
   Li SK, 2018, J AM CHEM SOC, V140, P10794, DOI 10.1021/jacs.8b04912
   Li TY, 2020, ANGEW CHEM INT EDIT, V59, P2700, DOI 10.1002/anie.201914453
   Li Y, 2017, J CONTROL RELEASE, V258, P95, DOI 10.1016/j.jconrel.2017.05.011
   Liang C, 2016, CHEM SOC REV, V45, P6250, DOI 10.1039/c6cs00458j
   Liu XL, 2019, ADV MATER, V31, DOI [10.1002/adma.201804922, 10.19386/j.cnki.jxnyxb.2019.12.01]
   Lv J, 2019, BIOMATERIALS, V218, DOI 10.1016/j.biomaterials.2019.119358
   Min YZ, 2015, CHEM REV, V115, P11147, DOI 10.1021/acs.chemrev.5b00116
   Mou Q, 2016, J CONTROL RELEASE, V230, P34, DOI 10.1016/j.jconrel.2016.03.037
   Mura S, 2013, NAT MATER, V12, P991, DOI [10.1038/NMAT3776, 10.1038/nmat3776]
   Shen SH, 2017, INT J NANOMED, V12, P4085, DOI 10.2147/IJN.S132780
   Shim MK, 2019, J CONTROL RELEASE, V294, P376, DOI 10.1016/j.jconrel.2018.11.032
   Tan YF, 2018, J CONTROL RELEASE, V284, P39, DOI 10.1016/j.jconrel.2018.06.014
   van der Meel R, 2019, NAT NANOTECHNOL, V14, P1007, DOI 10.1038/s41565 019 0567 y
   Wang CP, 2018, NANO LETT, V18, P7045, DOI 10.1021/acs.nanolett.8b03015
   Wang DL, 2017, J AM CHEM SOC, V139, P14021, DOI 10.1021/jacs.7b08303
   Wang H, 2016, BIOMATER SCI UK, V4, P375, DOI 10.1039/c5bm00532a
   Wang JJ, 2019, SCI CHINA LIFE SCI, V62, P1392, DOI 10.1007/s11427 019 9824 0
   Wang Y, 2016, BIOCONJUGATE CHEM, V27, P2722, DOI 10.1021/acs.bioconjchem.6b00503
   Wang YT, 2018, BIOMATERIALS, V183, P10, DOI 10.1016/j.biomaterials.2018.08.033
   Wang YT, 2017, BIOMATERIALS, V114, P97, DOI 10.1016/j.biomaterials.2016.11.010
   Wen Y, 2017, NANOSCALE, V9, P14347, DOI 10.1039/c7nr03129g
   Wu CW, 2018, BIOMATER SCI UK, V6, P2261, DOI 10.1039/c8bm00437d
   Xiu Y, 2014, J CLIN INVEST, V124, P297, DOI 10.1172/JCI66947
   Xue XD, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 06093 5
   Yan Y, 2019, ACS APPL MATER INTER, V11, P160, DOI 10.1021/acsami.8b15827
   Yang K, 2016, ADV DRUG DELIVER REV, V105, P228, DOI 10.1016/j.addr.2016.05.015
   Ye SY, 2018, ADV MATER, V30, DOI 10.1002/adma.201801216
   Zhang CY, 2019, ACS APPL MATER INTER, V11, P9872, DOI 10.1021/acsami.8b22336
   Zhang H, 2018, ACS NANO, V12, P8266, DOI 10.1021/acsnano.8b03529
   Zhang PF, 2018, J AM CHEM SOC, V140, P14980, DOI 10.1021/jacs.8b09396
   Zhang ZH, 2017, ACS APPL MATER INTER, V9, P29505, DOI 10.1021/acsami.7b07565
   Zhao H, 2019, ACS NANO, V13, P6647, DOI 10.1021/acsnano.9b00972
   Zhao LY, 2020, ANGEW CHEM INT EDIT, V59, P3793, DOI 10.1002/anie.201909825
   Zhou ZJ, 2019, BIOMATERIALS, V203, P63, DOI 10.1016/j.biomaterials.2019.02.023
   Zhou ZJ, 2019, BIOMATERIALS, V194, P130, DOI 10.1016/j.biomaterials.2018.12.024
   Zhu YX, 2018, J AM CHEM SOC, V140, P4062, DOI 10.1021/jacs.7b13672
NR 55
TC 34
Z9 37
U1 6
U2 135
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1613 6810
EI 1613 6829
J9 SMALL
JI Small
PD DEC
PY 2020
VL 16
IS 49
AR 2004829
DI 10.1002/smll.202004829
EA NOV 2020
PG 7
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA PE8BP
UT WOS:000589946200001
PM 33205610
DA 2025 08 17
ER

PT J
AU Shimizu, H
   Nakagami, H
   Tsukamoto, I
   Morita, S
   Kunugiza, Y
   Tomita, T
   Yoshikawa, H
   Kaneda, Y
   Ogihara, T
   Morishita, R
AF Shimizu, H.
   Nakagami, H.
   Tsukamoto, I.
   Morita, S.
   Kunugiza, Y.
   Tomita, T.
   Yoshikawa, H.
   Kaneda, Y.
   Ogihara, T.
   Morishita, R.
TI NFκB decoy oligodeoxynucleotides ameliorates osteoporosis through
   inhibition of activation and differentiation of osteoclasts
SO GENE THERAPY
LA English
DT Article
DE transcriptional factors; NF kappa B decoy; osteoclast; osteoblast;
   osteoporosis
ID TUMOR NECROSIS FACTOR; FACTOR ALPHA; RHEUMATOID ARTHRITIS;
   ENDOTHELIAL CELLS; BONE; RESORPTION; INTERLEUKIN 1; INDUCTION; CYTOKINE;
   LIGAND
AB The transcription factor, nuclear factor kappa B (NF kappa B), is believed to play a pivotal role in osteoclast formation. In this study, we focused on NF kappa B decoy oligodeoxynucleotides (ODN) as a new therapeutic strategy to attenuate osteoporosis. Tartrate resistant acid phosphatase (TRAP) positive multinuclear osteoclasts formed in mononuclear cells including osteoclast precursors from neonatal rabbit bone marrow were increased in the presence of 1,25 dihydroxyvitamin D3, whereas transfection of NF kappa B decoy ODN decreased the number of TRAP positive cells and attenuated RANKL and M CSF induced osteoclast formation. NF kappa B decoy ODN also inhibited the activity of osteoclasts, as assessed by pit formation. In rat overiectomized model of estrogen deficiency, continuous administration of NF kappa B decoy ODN attenuated the increase of TRAP activity, accompanied by a significant increase in calcium concentration in tibia and femur and decrease in urinary deoxypyridinoline. In additional osteoporosis model using vitamin C deficient rat, inhibition of NF kappa B by decoy ODN dramatically improved the bone length, weight, density as assessed by dual energy X ray absorptiometry. Overall, inhibition of NF kappa B by decoy strategy prevented osteoporosis through the inhibition of bone resorption. Targeting of NF kappa B might be potential therapy in various bone metabolic diseases.
C1 Osaka Univ, Grad Sch Med, Div Clin Gene Therapy, Suita, Osaka 5650871, Japan.
   Osaka Univ, Grad Sch Med, Dept Geriatr Med, Osaka, Japan.
   Osaka Univ, Grad Sch Med, Div Gene Therapy Sci, Osaka, Japan.
   Nara Womens Univ, Dept Food Sci & Nutr, Nara 630, Japan.
   Osaka Dent Univ, Dept Oral & Maxillofacial Surg, Osaka, Japan.
   Osaka Univ, Grad Sch Med, Dept Orthopaed Surg, Osaka, Japan.
C3 University of Osaka; University of Osaka; University of Osaka; Nara
   Womens University; University of Osaka
RP Morishita, R (通讯作者)，Osaka Univ, Grad Sch Med, Div Clin Gene Therapy, 2 2 Yamadaoka, Suita, Osaka 5650871, Japan.
EM morishit@cgt.med.osaka u.ac.jp
RI ; Nakagami, Hironori/GLU 0570 2022
OI Nakagami, Hironori/0000 0003 4494 3601; 
CR AREND WP, 1995, ARTHRITIS RHEUM, V38, P151, DOI 10.1002/art.1780380202
   Bergman I, 1970, Clin Chim Acta, V27, P347, DOI 10.1016/0009 8981(70)90355 4
   ELLIOTT MJ, 1993, ARTHRITIS RHEUM, V36, P1681, DOI 10.1002/art.23362
   Feldmann M, 1997, ADV IMMUNOL, V64, P283, DOI 10.1016/S0065 2776(08)60891 3
   GITELMAN HJ, 1968, AM J PHYSIOL, V215, P483, DOI 10.1152/ajplegacy.1968.215.2.483
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Jimi E, 1999, EXP CELL RES, V247, P84, DOI 10.1006/excr.1998.4320
   Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Nakagami H, 2001, HYPERTENSION, V37, P581, DOI 10.1161/01.HYP.37.2.581
   Nakagami H, 2001, DIABETES, V50, P1472, DOI 10.2337/diabetes.50.6.1472
   Penolazzi L, 2003, BIOCHEM PHARMACOL, V66, P1189, DOI 10.1016/S0006 2952(03)00470 2
   PIGUET PF, 1992, SPRINGER SEMIN IMMUN, V13, P345
   SHIMIZU H, 1989, BONE MINER, V6, P261, DOI 10.1016/0169 6009(89)90033 0
   SHIMIZU H, 1990, J BONE MINER RES, V5, P411, DOI 10.1002/jbmr.5650050415
   SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66
   SUDA T, 1995, BONE S2, V17, P87
   Sugimoto M, 1998, J BONE MINER RES, V13, P271, DOI 10.1359/jbmr.1998.13.2.271
   Tomita T, 2000, RHEUMATOLOGY, V39, P749, DOI 10.1093/rheumatology/39.7.749
   UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260
   VANDERPLUIJM G, 1991, ENDOCRINOLOGY, V129, P1596
   Venken K, 2005, BONE, V36, P663, DOI 10.1016/j.bone.2005.01.003
   WALTER K, 1974, METHOD ENZYMAT AN, P856
   Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   2000, SO MED J, V94, P569
NR 29
TC 29
Z9 38
U1 1
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0969 7128
EI 1476 5462
J9 GENE THER
JI Gene Ther.
PD JUN
PY 2006
VL 13
IS 12
BP 933
EP 941
DI 10.1038/sj.gt.3302711
PG 9
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Research & Experimental Medicine
GA 049TW
UT WOS:000238041000001
PM 16511526
DA 2025 08 17
ER

PT J
AU Weitzmann, MN
AF Weitzmann, M. Neale
TI Bone and the Immune System
SO TOXICOLOGIC PATHOLOGY
LA English
DT Article
DE bone; immunoskeletal interface; T cell; B cell; RANKL; osteoprotegerin;
   osteoimmunology
ID TUMOR NECROSIS FACTOR; ANTIRETROVIRAL THERAPY INITIATION; ESTROGEN
   DEFICIENCY INCREASES; HIV INFECTED PATIENTS; T CELL PROLIFERATION;
   MINERAL DENSITY; TNF ALPHA; OSTEOPROTEGERIN LIGAND; PARATHYROID HORMONE;
   MOUSE MODEL
AB Osteoporosis increases fracture risk, a cause of crippling morbidity and mortality. The immunoskeletal interface (ISI) is a centralization of cell and cytokine effectors shared between skeletal and immune systems. Consequently, the immune system mediates powerful effects on bone turnover. Physiologically, B cells secrete osteoprotegerin (OPG), a potent anti osteoclastogenic factor that preserves bone mass. However, activated T cells and B cells secrete pro osteoclastogenic factors including receptor activator of Nuclear factor kappaB (NF kB) ligand (RANKL), Interleukin (IL) 17A, and tumor necrosis factor (TNF)  promoting bone loss in inflammatory states such as rheumatoid arthritis. Recently, ISI disruption has been linked to osteoporosis in human immunodeficiency virus (HIV) infection/acquired immunodeficiency syndrome (AIDS), where elevated B cell RANKL and diminished OPG drive bone resorption. HIV antiretroviral therapy paradoxically intensifies bone loss during disease reversal, as immune reconstitution produces osteoclastogenic cytokines. Interestingly, in estrogen deficiency, activated T cells secrete RANKL, TNF, and IL 17A that amplify bone resorption and contribute to postmenopausal osteoporosis. T cell produced TNF and IL 17A further contribute to bone loss in hyperparathyroidism, while T cell production of the anabolic Wingless integration site (Wnt) ligand, Wnt10b, promotes bone formation in response to anabolic parathyroid hormone and the immunomodulatory costimulation inhibitor cytotoxic T lymphocyte associated protein 4 IgG (abatacept). These findings provide a window into the workings of the ISI and suggest novel targets for future therapeutic interventions to reduce fracture risk.
C1 [Weitzmann, M. Neale] Atlanta VA Med Ctr, Dept Vet Affairs, Decatur, GA USA.
   [Weitzmann, M. Neale] Emory Univ, Sch Med, Dept Med, Div Endocrinol & Metab & Lipids, 101 Woodruff Circle,1305 WMB, Atlanta, GA 30322 USA.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Atlanta VA Health Care System; Atlanta VA Medical Center; Emory
   University
RP Weitzmann, MN (通讯作者)，Emory Univ, Sch Med, Dept Med, Div Endocrinol & Metab & Lipids, 101 Woodruff Circle,1305 WMB, Atlanta, GA 30322 USA.
EM mweitzm@emory.edu
FU Biomedical Laboratory Research and Development Service of the VA Office
   of Research and Development [5I01BX000105]; National Institutes of
   Health (the National Institute of Arthritis and Musculoskeletal and Skin
   Diseases) [AR056090, AR059364, AR068157, AR070091]; National Institutes
   of Health (the National Institute on Aging) [AG040013]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: Biomedical
   Laboratory Research and Development Service of the VA Office of Research
   and Development (5I01BX000105) and from the National Institutes of
   Health (the National Institute of Arthritis and Musculoskeletal and Skin
   Diseases [grant numbers AR056090, AR059364, AR068157, and AR070091] and
   the National Institute on Aging [grant number AG040013]).
CR Almeida M, 2007, J BIOL CHEM, V282, P27285, DOI 10.1074/jbc.M702810200
   Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Bass E, 2007, ANN EPIDEMIOL, V17, P514, DOI 10.1016/j.annepidem.2006.12.004
   Bedi B, 2012, P NATL ACAD SCI USA, V109, pE725, DOI 10.1073/pnas.1120735109
   Bedi B, 2010, ANN NY ACAD SCI, V1192, P215, DOI 10.1111/j.1749 6632.2009.05216.x
   Bodine PVN, 2006, REV ENDOCR METAB DIS, V7, P33, DOI 10.1007/s11154 006 9002 4
   Britton RA, 2014, J CELL PHYSIOL, V229, P1822, DOI 10.1002/jcp.24636
   Brown TT, 2006, AIDS, V20, P2165, DOI 10.1097/QAD.0b013e32801022eb
   Brown TT, 2009, JAIDS J ACQ IMM DEF, V51, P554, DOI 10.1097/QAI.0b013e3181adce44
   Bruera D, 2003, AIDS, V17, P1917, DOI 10.1097/00002030 200309050 00010
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   BURING K, 1975, CLIN ORTHOP RELAT R, P293
   Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066
   Cenci S, 2003, P NATL ACAD SCI USA, V100, P10405, DOI 10.1073/pnas.1533207100
   Chan HLY, 2016, LANCET GASTROENTEROL, V1, P185, DOI 10.1016/S2468 1253(16)30024 3
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   D'Amelio P, 2008, BONE, V43, P92, DOI 10.1016/j.bone.2008.02.017
   DeSelm CJ, 2012, J CELL BIOCHEM, V113, P2895, DOI 10.1002/jcb.24165
   Eghbali Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215
   Eisman JA, 2012, J BONE MINER RES, V27, P2039, DOI 10.1002/jbmr.1698
   Ernst B, 1999, IMMUNITY, V11, P173, DOI 10.1016/S1074 7613(00)80092 8
   Feldmann M, 1996, CELL, V85, P307, DOI 10.1016/S0092 8674(00)81109 5
   Fuller K, 2002, ENDOCRINOLOGY, V143, P1108, DOI 10.1210/en.143.3.1108
   Gao Y, 2008, CELL METAB, V8, P132, DOI 10.1016/j.cmet.2008.07.001
   Gibellini D, 2010, NEW MICROBIOL, V33, P109
   Grant PM, 2013, CLIN INFECT DIS, V57, P1483, DOI 10.1093/cid/cit538
   Grassi F, 2007, P NATL ACAD SCI USA, V104, P15087, DOI 10.1073/pnas.0703610104
   Grigsby IF, 2010, BIOCHEM BIOPH RES CO, V394, P48, DOI 10.1016/j.bbrc.2010.02.080
   Grigsby IF, 2010, BIOCHEM BIOPH RES CO, V391, P1324, DOI 10.1016/j.bbrc.2009.12.039
   Güerri Fernandez R, 2013, J BONE MINER RES, V28, P1259, DOI 10.1002/jbmr.1874
   Hofbauer LC, 1999, BONE, V25, P255, DOI 10.1016/S8756 3282(99)00162 3
   Hory BG, 2000, J ENDOCRINOL INVEST, V23, P273, DOI 10.1007/BF03343723
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Kates SL, 2007, INJURY, V38, P17, DOI 10.1016/j.injury.2007.08.007
   Kimble RB, 1996, J BIOL CHEM, V271, P28890, DOI 10.1074/jbc.271.46.28890
   KITAZAWA R, 1994, J CLIN INVEST, V94, P2397, DOI 10.1172/JCI117606
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Kotake S, 2001, ARTHRITIS RHEUM, V44, P1003, DOI 10.1002/1529 0131(200105)44:5<1003::AID ANR179>3.3.CO;2 R
   Kuek A, 2007, POSTGRAD MED J, V83, P251, DOI 10.1136/pgmj.2006.052688
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Lee SK, 2006, J BONE MINER RES, V21, P695, DOI 10.1359/JBMR.060117
   Lee SK, 2006, J BONE MINER RES, V21, P1704, DOI 10.1359/JBMR.060726
   Lewis JR, 2006, INJURY, V37, P698, DOI 10.1016/j.injury.2006.04.121
   Li JY, 2016, J CLIN INVEST, V126, P2049, DOI 10.1172/JCI86062
   Li P, 2003, SPRINGER SEMIN IMMUN, V25, P19, DOI 10.1007/s00281 003 0125 3
   Li Y, 2007, BLOOD, V109, P3839, DOI 10.1182/blood 2006 07 037994
   Li Y, 2007, J CELL BIOCHEM, V100, P1370, DOI 10.1002/jcb.21121
   Lindberg MK, 2006, BONE, V38, P85, DOI 10.1016/j.bone.2005.07.027
   McComsey GA, 2010, CLIN INFECT DIS, V51, P937, DOI 10.1086/656412
   McCoy KD, 1999, IMMUNOL CELL BIOL, V77, P1, DOI 10.1046/j.1440 1711.1999.00795.x
   Miyaura C, 1997, P NATL ACAD SCI USA, V94, P9360, DOI 10.1073/pnas.94.17.9360
   Ofotokun I, 2016, AIDS, V30, P405, DOI 10.1097/QAD.0000000000000918
   Ofotokun I, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9282
   Ohlsson C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092368
   Onal M, 2012, J BIOL CHEM, V287, P29851, DOI 10.1074/jbc.M112.377945
   PACIFICI R, 1991, P NATL ACAD SCI USA, V88, P5134, DOI 10.1073/pnas.88.12.5134
   Pacifici R, 2013, ENDOCRINE, V44, P576, DOI 10.1007/s12020 013 9960 8
   Pacifici R, 2010, BONE, V47, P461, DOI 10.1016/j.bone.2010.04.611
   Piso RJ, 2011, JAIDS J ACQ IMM DEF, V56, P320, DOI 10.1097/QAI.0b013e31820cf010
   Prieto Alhambra D, 2014, JAIDS J ACQ IMM DEF, V66, P90, DOI 10.1097/QAI.0000000000000112
   Prior J, 2007, OSTEOPOROSIS INT, V18, P1345, DOI 10.1007/s00198 007 0428 7
   Reid W, 2001, P NATL ACAD SCI USA, V98, P9271, DOI 10.1073/pnas.161290298
   Roser Page S, 2014, ARTHRITIS RHEUMATOL, V66, P990, DOI 10.1002/art.38319
   Ryan MR, 2005, P NATL ACAD SCI USA, V102, P16735, DOI 10.1073/pnas.0505168102
   Sass DA, 1997, J BONE MINER RES, V12, P479, DOI 10.1359/jbmr.1997.12.3.479
   Sayegh MH, 1999, J CLIN INVEST, V103, P1223, DOI 10.1172/JCI6952
   Sharma A, 2015, JAIDS J ACQ IMM DEF, V70, P54, DOI 10.1097/QAI.0000000000000674
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Sjögren K, 2012, J BONE MINER RES, V27, P1357, DOI 10.1002/jbmr.1588
   Surh CD, 2000, J EXP MED, V192, pF9, DOI 10.1084/jem.192.4.F9
   Tawfeek H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012290
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Terauchi M, 2009, CELL METAB, V10, P229, DOI 10.1016/j.cmet.2009.07.010
   Titanji K, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004497
   Triant VA, 2008, J CLIN ENDOCR METAB, V93, P3499, DOI 10.1210/jc.2008 0828
   Tsuda E, 1997, BIOCHEM BIOPH RES CO, V234, P137, DOI 10.1006/bbrc.1997.6603
   Tyagi AM, 2014, J BONE MINER RES, V29, P1981, DOI 10.1002/jbmr.2228
   Tyagi AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044552
   Unnanuntana A, 2010, J BONE JOINT SURG AM, V92A, P743, DOI 10.2106/JBJS.I.00919
   Vikulina T, 2010, P NATL ACAD SCI USA, V107, P13848, DOI 10.1073/pnas.1003020107
   WALKER DG, 1975, SCIENCE, V190, P784, DOI 10.1126/science.1105786
   WALKER DG, 1972, ENDOCRINOLOGY, V91, P916, DOI 10.1210/endo 91 4 916
   Wang MWH, 2004, J CLIN INVEST, V114, P206, DOI 10.1172/JCI200415797
   Weitzmann MN, 2017, CURR OSTEOPOROS REP, V15, P135, DOI 10.1007/s11914 017 0359 y
   Weitzmann MN, 2016, NAT REV ENDOCRINOL, V12, P518, DOI 10.1038/nrendo.2016.91
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Weitzmann MN, 2002, J CLIN INVEST, V110, P1643, DOI 10.1172/JCI200215687
   Wohl D, 2016, JAIDS J ACQ IMM DEF, V72, P58, DOI 10.1097/QAI.0000000000000940
   Womack JA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017217
   Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075
   Young B, 2011, CLIN INFECT DIS, V52, P1061, DOI 10.1093/cid/ciq242
   Yun TJ, 1998, J IMMUNOL, V161, P6113
   Zha YY, 2006, NAT IMMUNOL, V7, P1166, DOI 10.1038/ni1394
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
NR 95
TC 152
Z9 187
U1 2
U2 12
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0192 6233
EI 1533 1601
J9 TOXICOL PATHOL
JI Toxicol. Pathol.
PD OCT
PY 2017
VL 45
IS 7
BP 911
EP 924
DI 10.1177/0192623317735316
PG 14
WC Pathology; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pathology; Toxicology
GA FN4YJ
UT WOS:000416012600017
PM 29046115
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Tamplen, M
   Trapp, K
   Nishimura, I
   Armin, B
   Steinberg, M
   Beumer, J
   Abemayor, E
   Nabili, V
AF Tamplen, Matthew
   Trapp, Kelley
   Nishimura, Ichiro
   Armin, Bob
   Steinberg, Michael
   Beumer, John
   Abemayor, Elliot
   Nabili, Vishad
TI Standardized Analysis of Mandibular Osteoradionecrosis in a Rat Model
SO OTOLARYNGOLOGY HEAD AND NECK SURGERY
LA English
DT Article; Proceedings Paper
CT Annual Meeting of the
   American Academy of Otolaryngology Head and Neck Surgery Foundation and 
   OTO EXPO
CY SEP 25 29, 2010
CL Boston, MA
SP Amer Acad Otolaryngol Head & Neck Surg Fdn, UMDNJ New Jersey Med Sch
DE osteoradionecrosis; animal model; mandible; irradiation
ID HYPERBARIC OXYGEN THERAPY; IRRADIATION; BONE; MANAGEMENT; TRIAL;
   RADIONECROSIS; SURGERY; JAW
AB Objective. To develop a rat model of mandibular osteoradionecrosis (ORN) that uses novel micro computed tomography bone volume analysis and detailed histology to provide a more effective, quantifiable, and standardized way to study ORN in vivo.
   Study Design. Animal model.
   Setting. Academic medical center.
   Subjects and Methods. Modifications to our previously published rat model of mandibular ORN were done to develop an ideal protocol consisting of 10 rats (6 experimental and 4 controls) with their left middle mandibular molar removed 7 days after either 20 Gy high dose rate brachytherapy or sham irradiation. Rats were sacrificed 21 days after extraction for landmark defined bone volume and histologic analysis.
   Results. A standardized method of quantification was achieved in all samples. The radiated group (XRT) had a mean bone volume/total volume (BV/TV) of 13.8% compared to 65.9% for controls (P < .001). There were increases in osteoclasts and fibrosis, decreases in osteoblasts, and less bone in radiated samples with a mean (SD) of 5.91 (3.77) osteoclasts/high powered field (HPF) and 4.00 (1.83) osteoblasts/HPF in XRT samples compared to 1.08 (1.08) osteoclasts/HPF and 22.49 (6.00) osteoblasts/HPF for controls (P <. 001).
   Conclusion. Our updated model continues to be clinically analogous to human mandibular ORN and improves the radiologic and histologic analysis of bony defects, providing a method for quantification of bone loss. Further cell specific staining, including immunohistochemistry, can be used with this model to study potential cellular mechanisms of mandibular ORN and test any future therapeutic options.
C1 [Tamplen, Matthew; Trapp, Kelley; Armin, Bob; Abemayor, Elliot; Nabili, Vishad] Univ Calif Los Angeles, Div Head & Neck Surg, David Geffen Sch Med, Los Angeles, CA 90024 USA.
   [Nishimura, Ichiro; Beumer, John] Univ Calif Los Angeles, Sch Dent, Weintraub Ctr Reconstruct Biotechnol, Los Angeles, CA 90024 USA.
   [Steinberg, Michael] Univ Calif Los Angeles, Dept Radiat Oncol, David Geffen Sch Med, Los Angeles, CA 90024 USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of California System; University of
   California Los Angeles; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA
RP Tamplen, M (通讯作者)，Univ Calif Los Angeles, Div Head & Neck Surg, David Geffen Sch Med, 10833 Le Conte Ave,CHS 62 132, Los Angeles, CA 90024 USA.
EM Mtamplen@mednet.ucla.edu
CR Annane D, 2004, J CLIN ONCOL, V22, P4893, DOI 10.1200/JCO.2004.09.006
   Arnold M, 1998, RADIOTHER ONCOL, V48, P259, DOI 10.1016/S0167 8140(98)00039 5
   BEUMER J, 1972, J PROSTHET DENT, V27, P640, DOI 10.1016/0022 3913(72)90311 3
   BEUMER J, 1983, HEAD NECK SURG, V6, P581, DOI 10.1002/hed.2890060107
   COHEN M, 2010, AM J OTOLARYNGO 0817
   David L A, 2001, J Can Dent Assoc, V67, P384
   Delanian S, 2005, HEAD NECK J SCI SPEC, V27, P114, DOI 10.1002/hed.20121
   Delanian S, 2004, RADIOTHER ONCOL, V73, P119, DOI 10.1016/j.radonc.2004.08.021
   Fenner M, 2010, J CRANIO MAXILL SURG, V38, P47, DOI 10.1016/j.jcms.2009.07.011
   FRANDSEN ASGER M., 1962, ACTA ODONTOL SCAND, V20, P307
   GUGLIELMOTTI MB, 1986, J ORAL MAXIL SURG, V44, P972, DOI 10.1016/S0278 2391(86)80051 9
   HARRIS M, 1992, BRIT J ORAL MAX SURG, V30, P313, DOI 10.1016/0266 4356(92)90181 H
   HORN Y, 1979, INT J ORAL MAXILLOF, V8, P457, DOI 10.1016/S0300 9785(79)80085 X
   HUEBSCH RF, 1952, ORAL SURG ORAL MED O, V5, P864, DOI 10.1016/0030 4220(52)90316 2
   Hutchinson IL, 1996, CURR RAD ONCOL, V2, P144
   JACOBSSON M, 1985, INT J RADIAT ONCOL, V11, P1963, DOI 10.1016/0360 3016(85)90278 0
   Kurihashi Takeo, 2002, Odontology, V90, P35, DOI 10.1007/s102660200005
   London SD, 1998, LARYNGOSCOPE, V108, P1291, DOI 10.1097/00005537 199809000 00005
   Maier A, 2000, BRIT J ORAL MAX SURG, V38, P173, DOI 10.1054/bjom.1999.0285
   MARX RE, 1987, ORAL SURG ORAL MED O, V64, P379, DOI 10.1016/0030 4220(87)90136 8
   MARX RE, 1983, J ORAL MAXIL SURG, V41, P283, DOI 10.1016/0278 2391(83)90294 X
   MARX RE, 1985, J AM DENT ASSOC, V111, P49, DOI 10.14219/jada.archive.1985.0074
   MCKENZIE MR, 1993, ORAL ONCOL, V29B, P201, DOI 10.1016/0964 1955(93)90023 8
   MERKESTEYN JPR, 1995, ORAL SURG ORAL MED O, V80, P12
   MEYER I, 1970, J ORAL SURG, V28, P17
   MOUNSEY RA, 1993, LARYNGOSCOPE, V103, P605
   Myers R A, 1990, NCI Monogr, P151
   Niehoff P, 2008, J CRANIO MAXILL SURG, V36, P203, DOI 10.1016/j.jcms.2008.01.003
   Suh JD, 2010, OTOLARYNG HEAD NECK, V142, P586, DOI 10.1016/j.otohns.2009.12.008
NR 29
TC 27
Z9 30
U1 1
U2 8
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0194 5998
J9 OTOLARYNG HEAD NECK
JI Otolaryngol. Head Neck Surg.
PD SEP
PY 2011
VL 145
IS 3
BP 404
EP 410
DI 10.1177/0194599811400576
PG 7
WC Otorhinolaryngology; Surgery
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Otorhinolaryngology; Surgery
GA 814OY
UT WOS:000294467700008
PM 21493310
DA 2025 08 17
ER

PT J
AU Cutini, PH
   Rauschemberger, MB
   Sandoval, MJ
   Massheimer, VL
AF Cutini, Pablo H.
   Rauschemberger, Maria B.
   Sandoval, Marisa J.
   Massheimer, Virginia L.
TI Vascular action of bisphosphonates: In vitro effect of alendronate on
   the regulation of cellular events involved in vessel pathogenesis
SO JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
LA English
DT Article
DE Nitric oxide; Alendronate; Endothelial monocyte adhesion; Platelet
   adhesion and aggregation; Vascular calcification; Osteogenic markers
ID NITRIC OXIDE; CARDIOVASCULAR DISEASE; ALKALINE PHOSPHATASE; BONE LOSS;
   OSTEOPOROSIS; EXPRESSION; CALCIFICATION; PROGESTERONE; CELLS;
   TESTOSTERONE
AB In this work we investigate whether, despite the procalcific action of alendronate on bone, the drug would be able to regulate in vitro the main cellular events that take part in atherosclerotic lesion generation. Using endothelial cell cultures we showed that Alendronate (1 50 mu M) acutely enhances nitric oxide production (10 30 min). This stimulatory action of the bisphosphonate involves the participation of MAPK signaling transduction pathway. Under inflammatory stress, the drug reduces monocytes and platelets interactions with endothelial cells induced by lipopolysaccharide. Indeed the bisphophonate exhibits a significant inhibition of endothelial dependent platelet aggregation. The molecular mechanism of alendronate (ALN) on leukocyte adhesion depends on the regulation of the expression of cell adhesion related genes (VCAM 1; ICAM 1); meanwhile the antiplatelet activity is associated with the effect of the drug on nitric oxide production. On vascular smooth muscle cells, the drug exhibits ability to decrease osteogenic transdifferentiation and extracellular matrix mineralization. When vascular smooth muscle cells were cultured in osteogenic medium for 21 days, they exhibited an upregulation of calcification markers (RUNX2 and TNAP), high alkaline phosphatase activity and a great amount of mineralization nodules. ALN treatment significantly down regulates mRNA levels of osteoblasts markers; diminishes alkaline phosphatase activity and reduces the extracellular calcium deposition. The effect of ALN on vascular cells differs from its own bone action. On calvarial osteoblasts ALN induces cell proliferation, enhances alkaline phosphatase activity, and increases mineralization, but does not affect nitric oxide synthesis. Our results support the hypothesis that ALN is an active drug at vascular level that regulates key processes involved in vascular pathogenesis through a direct action on vessel cells. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Cutini, Pablo H.; Rauschemberger, Maria B.; Sandoval, Marisa J.; Massheimer, Virginia L.] UNS, Inst Ciencias Biol Biomed INBIOSUR, Consejo Nacl Invest Cient & Tecn CONICET, Dept Biol Bioquim & Farm, San Juan 670,B8000ICN, Bahia Blanca, Buenos Aires, Argentina.
C3 National University of the South; Consejo Nacional de Investigaciones
   Cientificas y Tecnicas (CONICET)
RP Massheimer, VL (通讯作者)，Univ Nacl Sur, Catedra Bioquim Clin 2, Dept Biol Bioquim & Farm, San Juan 670,B8000ICN, Bahia Blanca, Buenos Aires, Argentina.
EM pcutini@uns.edu.ar; mbrausch@criba.edu.ar; msandova@criba.edu.ar;
   massheim@uns.edu.ar
FU SGCyT, Universidad Nacional del Sur, Bahia Blanca, Argentina [PGI
   24/B203]; Consejo Nacional de Investigaciones Cientificas y Tecnicas
   (CONICET) [PIP D 4061]
FX The authors would like to thank Graciela Santillan, PhD from
   Departamento de Biologia, Bioquimica y Farmacia, Universidad Nacional
   del Sur, Bahia Blanca, Argentina, for kindly providing calvaria cells.
   This research was supported by grants from the SGCyT, Universidad
   Nacional del Sur, Bahia Blanca, Argentina (PGI 24/B203); Consejo
   Nacional de Investigaciones Cientificas y Tecnicas (CONICET, Argentina,
   PIP D 4061).
CR Rauschemberger MB, 2011, MOL CELL ENDOCRINOL, V339, P136, DOI 10.1016/j.mce.2011.04.009
   Bellido T, 2011, BONE, V49, P50, DOI 10.1016/j.bone.2010.08.008
   Boström KI, 2011, CIRC RES, V109, P564, DOI 10.1161/CIRCRESAHA.110.234278
   Campelo AE, 2012, STEROIDS, V77, P1033, DOI 10.1016/j.steroids.2012.05.008
   Campelo AE, 2012, J ENDOCRINOL, V213, P77, DOI 10.1530/JOE 11 0441
   Chistiakov DA, 2015, ACTA PHYSIOL, V214, P33, DOI 10.1111/apha.12466
   Cutini PH, 2012, J STEROID BIOCHEM, V132, P322, DOI 10.1016/j.jsbmb.2012.08.001
   Cutini PH, 2014, J ENDOCRINOL, V220, P179, DOI 10.1530/JOE 13 0263
   Cutini PH, 2010, STEROIDS, V75, P355, DOI 10.1016/j.steroids.2010.01.017
   D'Elía NL, 2013, BBA GEN SUBJECTS, V1830, P5014, DOI 10.1016/j.bbagen.2013.07.020
   Dombrecht EJ, 2007, CLIN EXP RHEUMATOL, V25, P817
   Duckles SP, 2010, PFLUG ARCH EUR J PHY, V459, P841, DOI 10.1007/s00424 010 0797 1
   Epstein H, 2007, J CONTROL RELEASE, V117, P322, DOI 10.1016/j.jconrel.2006.10.030
   Förstermann U, 2010, PFLUG ARCH EUR J PHY, V459, P923, DOI 10.1007/s00424 010 0808 2
   Fu LJ, 2008, BONE, V43, P40, DOI 10.1016/j.bone.2008.03.008
   Haynes MP, 2002, VASC PHARMACOL, V38, P99, DOI 10.1016/S0306 3623(02)00133 7
   Kanno Y, 2008, CARDIOVASC RES, V77, P221, DOI 10.1093/cvr/cvm049
   Li QL, 2016, J INVEST DERMATOL, V136, P275, DOI 10.1038/JID.2015.377
   Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353
   Lomashvili KA, 2008, KIDNEY INT, V73, P1024, DOI 10.1038/ki.2008.26
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Makkonen N, 1999, EUR J PHARM SCI, V8, P109, DOI 10.1016/S0928 0987(98)00065 7
   Mawardi H.H., 2013, PRIMER METABOLIC BON, P929
   McFarlane SI, 2004, ENDOCRINE, V23, P1, DOI 10.1385/ENDO:23:1:01
   Mendiberri J, 2006, INT J BIOCHEM CELL B, V38, P288, DOI 10.1016/j.biocel.2005.09.012
   Misso G, 2012, CANCER BIOL THER, V13, P1491, DOI 10.4161/cbt.22274
   Mori K, 1998, FEBS LETT, V433, P19, DOI 10.1016/S0014 5793(98)00870 9
   Okamoto M, 2014, J TRANSPLANT, V2014, DOI 10.1155/2014/269613
   Park ES, 2012, MOL CELL ENDOCRINOL, V362, P165, DOI 10.1016/j.mce.2012.06.005
   Plotkin LI, 2006, BONE, V39, P443, DOI 10.1016/j.bone.2006.02.060
   Price PA, 2001, ARTERIOSCL THROM VAS, V21, P817, DOI 10.1161/01.ATV.21.5.817
   Pugliese G, 2015, ATHEROSCLEROSIS, V238, P220, DOI 10.1016/j.atherosclerosis.2014.12.011
   Reid IR, 2015, NAT REV ENDOCRINOL, V11, P418, DOI 10.1038/nrendo.2015.71
   Ribeiro V, 2014, J CELL MOL MED, V18, P27, DOI 10.1111/jcmm.12154
   Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207
   Sandoval MJ, 2010, BRIT J NUTR, V104, P171, DOI 10.1017/S0007114510000413
   Santos LL, 2012, CLIN MED INSIGHTS EN, V5, P47, DOI 10.4137/CMED.S10007
   Silva RO, 2014, NITRIC OXIDE BIOL CH, V40, P22, DOI 10.1016/j.niox.2014.05.002
   Simoncini T, 2004, ENDOCRINOLOGY, V145, P5745, DOI 10.1210/en.2004 0510
   Sittig HB, 2012, ONKOLOGIE, V35, P380, DOI 10.1159/000338947
   Tankó LB, 2005, J BONE MINER RES, V20, P1912, DOI 10.1359/JBMR.050711
   Toledo Piza AR, 2013, CELL PROLIFERAT, V46, P97, DOI 10.1111/cpr.12003
   Viale Bouroncle S, 2014, ARCH ORAL BIOL, V59, P1249, DOI 10.1016/j.archoralbio.2014.07.013
   von der Recke P, 1999, AM J MED, V106, P273, DOI 10.1016/S0002 9343(99)00028 5
   Wimalawansa SJ, 2007, ANN NY ACAD SCI, V1117, P283, DOI 10.1196/annals.1402.066
   Wimalawansa SJ, 2010, ANN NY ACAD SCI, V1192, P391, DOI 10.1111/j.1749 6632.2009.05230.x
   Wu L, 2009, EUR J PHARMACOL, V602, P124, DOI 10.1016/j.ejphar.2008.10.043
   Zwolak P, 2013, ANTICANCER RES, V33, P2981
NR 48
TC 24
Z9 26
U1 0
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0022 2828
EI 1095 8584
J9 J MOL CELL CARDIOL
JI J. Mol. Cell. Cardiol.
PD NOV
PY 2016
VL 100
BP 83
EP 92
DI 10.1016/j.yjmcc.2016.08.017
PG 10
WC Cardiac & Cardiovascular Systems; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cardiovascular System & Cardiology; Cell Biology
GA EF4IH
UT WOS:000390288500010
PM 27705747
OA Green Published
DA 2025 08 17
ER

PT J
AU Rucci, N
   Recchia, I
   Angelucci, A
   Alamanou, M
   Del Fattore, A
   Fortunati, D
   Susa, M
   Fabbro, D
   Bologna, M
   Teti, A
AF Rucci, Nadia
   Recchia, Irene
   Angelucci, Adriano
   Alamanou, Marina
   Del Fattore, Andrea
   Fortunati, Dario
   Susa, Mira
   Fabbro, Doriano
   Bologna, Mauro
   Teti, Anna
TI Inhibition of protein kinase c src reduces the incidence of breast
   cancer metastases and increases survival in mice: Implications for
   therapy
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article
ID TYROSINE KINASE; BONE METASTASES; IN VITRO; EXPRESSION; CELLS;
   CHEMOTHERAPY; CARCINOMA; DISEASE; MODEL
AB Src is a proto oncogene, belonging to the nonreceptor protein kinases family, which plays a prominent role in carcinogenesis. In this study, we tested the hypothesis that c Src could promote breast cancer metastasis acting on several cell types and that pharmacological disruption of its kinase activity could be beneficial for the treatment of metastases. Female BALB/c nu/nu mice were subjected to intracardiac injection of the human breast cancer cells MDA MB 231 (MDA 231), which induced prominent bone and visceral metastases. These were pharmacologically reduced by treatment with the c Src inhibitor [7 {4 [2 (2 methoxy ethylamino ethoxy] phenyl} 5 (3 methoxy phenyl) 7H pyrrolo[2,3 d]pyrimidin 4 ylamine] CGP76030 (100 mg/kg/day p.o.), resulting in decreased morbidity and lethality. Metastases were more severe in mice injected with MDA 231 cells stably transfected with wild type c Src (MDA 231 Src(WT)), whereas transfection in injected cells of a c Src kinase dead dominant negative construct (MDA231 Src(DN)) resulted in reduced morbidity, lethality, and incidence of metastases similar to the mice treated with the inhibitor. An analogous beneficial effect of c Src inhibition was observed in subcutaneous and intratibial implanted tumors. In vitro, c Src suppression reduced MDA 231 cell aggressiveness. It also impaired osteoclast bone resorption both directly and by reducing expression by osteoblasts of the osteoclastogenic cytokines interleukin 1 beta and interleukin 6, whereas parathyroid hormone related peptide was not implicated. c Src was also modestly but consistently involved in the enhancement of endothelial cell proliferation in vitro and angiogenesis in vivo. In conclusion, we propose that c Src disruption affects the metastatic process and thus is a therapeutic target for the treatment of breast cancer.
C1 Univ Aquila, Dept Expt Med, I 67100 Laquila, Italy.
   Univ Aquila, Dept Surg, I 67100 Laquila, Italy.
   Univ Aquila, Dept Bas & Appl Biol, I 67100 Laquila, Italy.
   Novartis Pharm Res, Therapeut Area Arthritis & Bone Metab, Basel, Switzerland.
C3 University of L'Aquila; University of L'Aquila; University of L'Aquila;
   Novartis
RP Teti, A (通讯作者)，Univ Aquila, Dept Expt Med, Via Vetoio Coppito 2, I 67100 Laquila, Italy.
EM teti@univaq.it
RI ; Angelucci, Adriano/B 7134 2013; Del Fattore, Andrea/H 4409 2015
OI BOLOGNA, Mauro/0000 0002 6306 6897; Angelucci,
   Adriano/0000 0002 8755 1889; Teti, Anna Maria/0000 0002 5887 4419;
   Rucci, Nadia/0000 0002 1371 8252; Del Fattore,
   Andrea/0000 0003 3848 412X
CR ALBINI A, 1987, CANCER RES, V47, P3239
   ARGUELLO F, 1988, CANCER RES, V48, P6876
   Blumenschein GR, 1997, CLIN CANCER RES, V3, P2633
   Brown MT, 1996, BBA REV CANCER, V1287, P121, DOI 10.1016/0304 419X(96)00003 0
   Caselli G, 1997, J BONE MINER RES, V12, P972, DOI 10.1359/jbmr.1997.12.6.972
   CIFUENTES N, 1979, J SURG ONCOL, V11, P193, DOI 10.1002/jso.2930110303
   COLEMAN RE, 1987, BRIT J CANCER, V55, P61, DOI 10.1038/bjc.1987.13
   Dehm SM, 2004, BIOCHEM CELL BIOL, V82, P263, DOI 10.1139/o03 077
   ELTE JWF, 1986, EUR J CANCER CLIN ON, V22, P493, DOI 10.1016/0277 5379(86)90117 3
   Greenberg PAC, 1996, J CLIN ONCOL, V14, P2197, DOI 10.1200/JCO.1996.14.8.2197
   Guise Theresa A, 2004, Cancer Treat Res, V118, P197
   Hannon RA, 2005, BONE, V36, pS135
   HENDERSON BE, 1993, SCIENCE, V259, P633, DOI 10.1126/science.8381558
   HENNIPMAN A, 1989, CANCER RES, V49, P516
   Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001
   James JJ, 2003, BRIT J CANCER, V89, P660, DOI 10.1038/sj.bjc.6601198
   Marr HS, 1997, ENDOTHELIUM NEW YORK, V5, P209, DOI 10.3109/10623329709053399
   Marzia M, 2000, J CELL BIOL, V151, P311, DOI 10.1083/jcb.151.2.311
   Missbach M, 2000, BIOORG MED CHEM LETT, V10, P945, DOI 10.1016/S0960 894X(00)00131 1
   Missbach M, 1999, BONE, V24, P437, DOI 10.1016/S8756 3282(99)00020 4
   Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200
   Myoui A, 2003, CANCER RES, V63, P5028
   OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773
   Perez M, 2001, EUR J CANCER, V37, P629, DOI 10.1016/S0959 8049(00)00436 6
   Recchi I, 2003, EUR J CANCER, V39, P1927, DOI 10.1016/S0959 8049(03)00394 0
   Recchia I, 2004, BONE, V34, P65, DOI 10.1016/j.bone.2003.06.004
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Rucci N, 2004, BONE, V34, P697, DOI 10.1016/j.bone.2003.07.012
   Solovey A, 1997, NEW ENGL J MED, V337, P1584, DOI 10.1056/NEJM199711273372203
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   Susa M, 2005, CANC DRUG DISC DEV, P71
   UNG O, 1995, J CLIN ONCOL, V13, P435, DOI 10.1200/JCO.1995.13.2.435
   Verbeek BS, 1996, J PATHOL, V180, P383, DOI 10.1002/(SICI)1096 9896(199612)180:4<383::AID PATH686>3.0.CO;2 N
   Yezhelyev MV, 2004, CLIN CANCER RES, V10, P8028, DOI 10.1158/1078 0432.CCR 04 0621
   Yoneda T, 2005, BIOCHEM BIOPH RES CO, V328, P679, DOI 10.1016/j.bbrc.2004.11.070
   Yoneda T, 1997, J CLIN INVEST, V99, P2509, DOI 10.1172/JCI119435
NR 36
TC 108
Z9 121
U1 0
U2 5
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3995 USA
SN 0022 3565
EI 1521 0103
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD JUL
PY 2006
VL 318
IS 1
BP 161
EP 172
DI 10.1124/jpet.106.102004
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 055GB
UT WOS:000238437000019
PM 16627750
DA 2025 08 17
ER

PT J
AU Häussling, V
   Aspera Werz, RH
   Rinderknecht, H
   Springer, F
   Arnscheidt, C
   Menger, MM
   Histing, T
   Nussler, AK
   Ehnert, S
AF Haeussling, Victor
   Aspera Werz, Romina H.
   Rinderknecht, Helen
   Springer, Fabian
   Arnscheidt, Christian
   Menger, Maximilian M.
   Histing, Tina
   Nussler, Andreas K.
   Ehnert, Sabrina
TI 3D Environment Is Required In Vitro to Demonstrate Altered Bone
   Metabolism Characteristic for Type 2 Diabetics
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE diabetes mellitus; bone metabolism; cryogel; scaffold; 3D coculture;
   osteoblast; osteoclast
AB A large British study, with almost 3000 patients, identified diabetes as main risk factor for delayed and nonunion fracture healing, the treatment of which causes large costs for the health system. In the past years, much progress has been made to treat common complications in diabetics. However, there is still a lack of advanced strategies to treat diabetic bone diseases. To develop such therapeutic strategies, mechanisms leading to massive bone alterations in diabetics have to be well understood. We herein describe an in vitro model displaying bone metabolism frequently observed in diabetics. The model is based on osteoblastic SaOS 2 cells, which in direct coculture, stimulate THP 1 cells to form osteoclasts. While in conventional 2D cocultures formation of mineralized matrix is decreased under pre /diabetic conditions, formation of mineralized matrix is increased in 3D cocultures. Furthermore, we demonstrate a matrix stability of the 3D carrier that is decreased under pre /diabetic conditions, resembling the in vivo situation in type 2 diabetics. In summary, our results show that a 3D environment is required in this in vitro model to mimic alterations in bone metabolism characteristic for pre /diabetes. The ability to measure both osteoblast and osteoclast function, and their effect on mineralization and stability of the 3D carrier offers the possibility to use this model also for other purposes, e.g., drug screenings.
C1 [Haeussling, Victor; Aspera Werz, Romina H.; Rinderknecht, Helen; Arnscheidt, Christian; Menger, Maximilian M.; Histing, Tina; Nussler, Andreas K.; Ehnert, Sabrina] Univ Tubingen, Siegfried Weller Res Inst, Dept Trauma & Reconstruct Surg, BG Trauma Ctr Tubingen, Schnarrenbergstr 95, D 72076 Tubingen, Germany.
   [Springer, Fabian] Univ Tubingen, Dept Diagnost & Intervent Radiol, Hoppe Seyler Str 3, D 72076 Tubingen, Germany.
   [Springer, Fabian] BG Trauma Ctr Tubingen, Dept Radiol, Schnarrenbergstr 95, D 72076 Tubingen, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University of
   Tubingen; Eberhard Karls University Hospital
RP Nussler, AK (通讯作者)，Univ Tubingen, Siegfried Weller Res Inst, Dept Trauma & Reconstruct Surg, BG Trauma Ctr Tubingen, Schnarrenbergstr 95, D 72076 Tubingen, Germany.
EM victor.haeussling@student.uni tuebingen.de; rominaaspera@hotmail.com;
   helen.rinderknecht@student.uni tuebingen.de;
   fabian.springer@med.uni tuebingen.de; carnscheidt@bgu tuebingen.de;
   mmenger@bgu tuebingen.de; thisting@bgu tuebingen.de;
   andreas.nuessler@gmail.com; sabrina.ehnert@med.uni tuebingen.de
RI Ehnert, Sabrina/AAE 8163 2019; Menger, Maximilian M/HHZ 8483 2022
OI Ehnert, Sabrina/0000 0003 4347 1702; Rinderknecht,
   Helen/0000 0002 9311 0131; Aspera Werz, Romina/0000 0002 5160 2111
FU Ministerium fur Landlichen Raum und Verbraucherschutz Baden Wurttemberg
   [14 (34) 8402.43]; German Research Foundation [DFG EH 471/2]
FX This work was partially supported by the "Ministerium fur Landlichen
   Raum und Verbraucherschutz Baden Wurttemberg" (14 (34) 8402.43) and the
   German Research Foundation (DFG EH 471/2).
CR Bernhardt A, 2017, EUR CELLS MATER, V33, P28, DOI 10.22203/eCM.v033a03
   Böcker W, 2008, J CELL MOL MED, V12, P1347, DOI [10.1111/j.1582 4934.2008.0299.x, 10.1111/j.1582 4934.2008.00299.x]
   Catalfamo DL, 2013, ORAL DIS, V19, P303, DOI 10.1111/odi.12002
   Chen GB, 2015, ACS APPL MATER INTER, V7, P15790, DOI 10.1021/acsami.5b02662
   Costantini S, 2019, WORLD J DIABETES, V10, P421, DOI 10.4239/wjd.v10.i8.421
   Crotti TN, 2011, J CELL PHYSIOL, V226, P3413, DOI 10.1002/jcp.22699
   Cunha JS, 2014, CELL TISSUE RES, V358, P249, DOI 10.1007/s00441 014 1913 x
   Ehnert S., 2020, SciMedicine Journal, V2, P157, DOI [10.28991/SciMedJ 2020 0203 6, DOI 10.28991/SCIMEDJ 2020 0203 6]
   Ehnert S, 2020, ARCH TOXICOL, V94, P3937, DOI 10.1007/s00204 020 02906 z
   Ehnert S, 2015, EXP CELL RES, V332, P247, DOI 10.1016/j.yexcr.2014.12.011
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Freude T, 2012, J MOL MED, V90, P1257, DOI 10.1007/s00109 012 0948 2
   Griffith LG, 2006, NAT REV MOL CELL BIO, V7, P211, DOI 10.1038/nrm1858
   Häussling V, 2019, BIOENGINEERING BASEL, V6, DOI 10.3390/bioengineering6030067
   Hernandez RK, 2012, ACTA ORTHOP, V83, P653, DOI 10.3109/17453674.2012.747054
   Hygum K, 2017, EUR J ENDOCRINOL, V176, pR137, DOI 10.1530/EJE 16 0652
   Kähm K, 2018, DIABETES CARE, V41, P971, DOI 10.2337/dc17 1763
   Kastelic V, 2009, J FORENSIC SCI, V54, P551, DOI 10.1111/j.1556 4029.2009.01007.x
   Kopesky P, 2014, BIOL OPEN, V3, P767, DOI 10.1242/bio.20148128
   Kostenuik PJ, 2001, CURR PHARM DESIGN, V7, P613, DOI 10.2174/1381612013397807
   Lauterbach S, 2010, J WOUND CARE, V19, P333, DOI 10.12968/jowc.2010.19.8.77711
   Lotz EM, 2020, BONE, V134, DOI 10.1016/j.bone.2020.115260
   Pandit V, 2013, TISSUE ENG PT A, V19, P2452, DOI [10.1089/ten.TEA.2012.0644, 10.1089/ten.tea.2012.0644]
   Picke AK, 2019, ENDOCR CONNECT, V8, pR55, DOI 10.1530/EC 18 0456
   Prasad RB, 2019, J INTERN MED, V285, P40, DOI 10.1111/joim.12859
   Pscherer S., 2017, J FUNCT MORPHOL KIN, V2, DOI [10.3390/jfmk2040041, DOI 10.3390/JFMK2040041]
   Pscherer S, 2012, PRIM CARE DIABETES, V6, P241, DOI 10.1016/j.pcd.2012.02.004
   Retzepi M, 2010, CLIN ORAL IMPLAN RES, V21, P673, DOI 10.1111/j.1600 0501.2010.01923.x
   Rinker TE, 2014, INTEGR BIOL UK, V6, P324, DOI [10.1039/c3ib40194d, 10.1039/c3b40194d]
   Rucci N, 2016, MATRIX BIOL, V52 54, P176, DOI 10.1016/j.matbio.2016.02.009
   Ruoss M, 2020, METHOD PROTOCOL, V3, DOI 10.3390/mps3010001
   Sassi F, 2018, BMC ENDOCR DISORD, V18, DOI 10.1186/s12902 018 0283 x
   Shapira L, 2009, CLIN ORAL IMPLAN RES, V20, P50, DOI 10.1111/j.1600 0501.2008.01594.x
   Sreekumar V, 2017, ARCH TOXICOL, V91, P1353, DOI 10.1007/s00204 016 1796 6
   Vestergaard P, 2007, OSTEOPOROSIS INT, V18, P427, DOI 10.1007/s00198 006 0253 4
   Vestergaard P, 2005, DIABETOLOGIA, V48, P1292, DOI 10.1007/s00125 005 1786 3
   Weng WD, 2020, BIOENGINEERING BASEL, V7, DOI 10.3390/bioengineering7020052
   Wittrant Y, 2008, BONE, V42, P1122, DOI 10.1016/j.bone.2008.02.006
   Xu J, 2015, MOL MED REP, V11, P865, DOI 10.3892/mmr.2014.2807
   Yang JS, 2019, MOL MED REP, V20, P5084, DOI 10.3892/mmr.2019.10790
   Yang L, 2020, DIABETES METAB SYNDR, V13, P545, DOI 10.2147/DMSO.S239892
   Zhang Y, 2018, ACS APPL MATER INTER, V10, P36652, DOI 10.1021/acsami.8b10992
   Zhao W, 2014, MAT SCI ENG C MATER, V40, P316, DOI 10.1016/j.msec.2014.03.048
NR 43
TC 6
Z9 6
U1 0
U2 12
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAR
PY 2021
VL 22
IS 6
AR 2925
DI 10.3390/ijms22062925
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA RV3CV
UT WOS:000645716200001
PM 33805833
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Huo, L
   Wang, L
   Yang, ZY
   Li, PY
   Geng, DC
   Xu, YZ
AF Huo, Lei
   Wang, Lei
   Yang, Zhaoyao
   Li, Pingyuan
   Geng, Dechun
   Xu, Yaozeng
TI Prednisolone induces osteoporosis like phenotypes via focal adhesion
   signaling pathway in zebrafish larvae
SO BIOLOGY OPEN
LA English
DT Article
DE Zebrafish; GIOP; Focal adhesion signaling pathway; itga10; itgbl1
ID GLUCOCORTICOID INDUCED OSTEOPOROSIS; EXTRACELLULAR MATRIX; IN VITRO;
   INDUCED APOPTOSIS; BONE TISSUE; OSTEOBLASTS; MECHANISMS; RECEPTOR;
   OSTEOCYTES; DIFFERENTIATION
AB Patients taking glucocorticoid or glucocorticoid like drugs for an extended period of time may develop osteoporosis, termed glucocorticoid induced osteoporosis (GIOP). GIOP is the most common form of secondary osteoporosis, but the mechanism underlying its development is unclear. In the present study, we used prednisolone to treat zebrafish larvae to investigate GIOP. Our RNA deep sequencing (RNA seq) results show that prednisolone affects genes known to act in the extracellular region. Therefore the extracellular region, extracellular matrix, and collagen trimer might be involved in glucocorticoid induced osteoporosis. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis revealed that the focal adhesion signaling pathway is the most enriched signaling pathway in terms of differentially expressed genes (DEGs). In this pathway, integrin subunit alpha 10 (itga10) and integrin subunit beta like 1 (itgbl1), genes encoding two adapter proteins, were down regulated in the prednisolone treated larvae. Further experiments showed that prednisolone contributes to GIOP by down regulating itga10 and itgbl1.
C1 [Huo, Lei; Wang, Lei; Yang, Zhaoyao; Li, Pingyuan; Geng, Dechun; Xu, Yaozeng] Soochow Univ, Affiliated Hosp 1, Dept Orthoped, 188 Shi Zi Rd, Suzhou 215006, Peoples R China.
   [Huo, Lei; Wang, Lei; Yang, Zhaoyao; Li, Pingyuan] Suzhou Sci & Technol Town Hosp, Dept Orthoped, 1 Lijiang Rd, Suzhou 215010, Peoples R China.
C3 Soochow University   China
RP Geng, DC; Xu, YZ (通讯作者)，Soochow Univ, Affiliated Hosp 1, Dept Orthoped, 188 Shi Zi Rd, Suzhou 215006, Peoples R China.
EM dechungeng1234@163.com; xuyaozeng21@163.com
RI ; Geng, Dechun/LMO 1733 2024
OI Xu, Yaozeng/0000 0002 0424 4884; 
FU Nature Science Foundation of Jiangsu Province [BK2011303]; Key Project
   of Science and Technology Development Fund of Nanjing Medical University
   [2015NJMUZD084]; Nature Science Foundation of Suzhou City [SYSD2015266]
FX This work was supported by grants from the Nature Science Foundation of
   Jiangsu Province (BK2011303) to D.G., the Key Project of Science and
   Technology Development Fund of Nanjing Medical University
   (2015NJMUZD084) and the Nature Science Foundation of Suzhou City
   (SYSD2015266) to L.H.
CR Abu EO, 2000, J CLIN ENDOCR METAB, V85, P883, DOI 10.1210/jc.85.2.883
   ADINOFF AD, 1983, NEW ENGL J MED, V309, P265, DOI 10.1056/NEJM198308043090502
   Barrett Ruth, 2006, Biotechnology Journal, V1, P651, DOI 10.1002/biot.200600043
   Binkley Neil, 2005, Curr Rheumatol Rep, V7, P61, DOI 10.1007/s11926 005 0010 2
   Boden SD, 1997, ENDOCRINOLOGY, V138, P2820, DOI 10.1210/en.138.7.2820
   BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415
   Camper L, 1998, J BIOL CHEM, V273, P20383, DOI 10.1074/jbc.273.32.20383
   Chang NN, 2013, CELL RES, V23, P465, DOI 10.1038/cr.2013.45
   Conradie MM, 2007, J ENDOCRINOL, V195, P229, DOI 10.1677/JOE 07 0217
   de Vrieze E, 2014, OSTEOPOROSIS INT, V25, P567, DOI 10.1007/s00198 013 2441 3
   Diehl AD, 2007, BIOINFORMATICS, V23, P913, DOI 10.1093/bioinformatics/btm029
   Elshal MF, 2013, AFR J TRADIT COMPLEM, V10, P267, DOI 10.4314/ajtcam.v10i5.8
   Ferreira AM, 2012, ACTA BIOMATER, V8, P3191, DOI 10.1016/j.actbio.2012.06.014
   Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066
   Giuliani N, 1998, BONE, V22, P455, DOI 10.1016/S8756 3282(98)00033 7
   Harris MA, 2008, NUCLEIC ACIDS RES, V36, pD440, DOI 10.1093/nar/gkm883
   HUGHES AL, 1992, MOL BIOL EVOL, V9, P216
   Kadmiel M, 2013, TRENDS PHARMACOL SCI, V34, P518, DOI 10.1016/j.tips.2013.07.003
   Kanehisa M, 2008, NUCLEIC ACIDS RES, V36, pD480, DOI 10.1093/nar/gkm882
   Lieschke GJ, 2007, NAT REV GENET, V8, P353, DOI 10.1038/nrg2091
   Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033
   MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953
   Metzker ML, 2010, NAT REV GENET, V11, P31, DOI 10.1038/nrg2626
   Naganawa T, 2008, J CELL BIOCHEM, V103, P1975, DOI 10.1002/jcb.21589
   Nagarajan N, 2010, METHODS MOL BIOL, V673, P1, DOI 10.1007/978 1 60761 842 3_1
   Ohnaka K, 2005, BIOCHEM BIOPH RES CO, V329, P177, DOI 10.1016/j.bbrc.2005.01.117
   Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702
   Pasqualetti S, 2015, INT J EXP PATHOL, V96, P11, DOI 10.1111/iep.12106
   Qiang YW, 2009, BLOOD, V113, P4319, DOI 10.1182/blood 2008 08 174300
   Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092 8674(00)81183 6
   Reid IR, 1997, EUR J ENDOCRINOL, V137, P209, DOI 10.1530/eje.0.1370209
   Revollo JR, 2009, ANN NY ACAD SCI, V1179, P167, DOI 10.1111/j.1749 6632.2009.04986.x
   Robles E, 2006, NAT NEUROSCI, V9, P1274, DOI 10.1038/nn1762
   Sato AY, 2015, BONE, V73, P60, DOI 10.1016/j.bone.2014.12.012
   Seibel MJ, 2013, LANCET DIABETES ENDO, V1, P59, DOI 10.1016/S2213 8587(13)70045 7
   Sroga GE, 2012, CURR OSTEOPOROS REP, V10, P141, DOI 10.1007/s11914 012 0103 6
   Straub RH, 2016, RHEUMATOLOGY, V55, P6, DOI 10.1093/rheumatology/kew348
   Viguet Carrin S, 2006, OSTEOPOROSIS INT, V17, P319, DOI 10.1007/s00198 005 2035 9
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Witten PE, 2001, J MORPHOL, V250, P197, DOI 10.1002/jmor.1065
   Yao W, 2016, OSTEOPOROSIS INT, V27, P283, DOI 10.1007/s00198 015 3308 6
   Yao W, 2008, ARTHRITIS RHEUM, V58, P1674, DOI 10.1002/art.23454
   Yun SI, 2009, J BONE MINER METAB, V27, P140, DOI 10.1007/s00774 008 0019 5
NR 43
TC 24
Z9 28
U1 0
U2 15
PU COMPANY BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND
SN 2046 6390
J9 BIOL OPEN
JI Biol. Open
PD JUL
PY 2018
VL 7
IS 7
AR bio029405
DI 10.1242/bio.029405
PG 10
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA GP1QX
UT WOS:000440592700004
PM 30012552
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Li, XT
   Li, ZL
   Li, PL
   Wang, FY
   Zhang, XY
   Wang, YX
   Zhao, ZD
   Yin, BF
   Hao, RC
   Mao, N
   Xia, WR
   Ding, L
   Zhu, H
AF Li, Xiao Tong
   Li, Zhi Ling
   Li, Pei Lin
   Wang, Fei Yan
   Zhang, Xiao Yu
   Wang, Yu Xing
   Zhao, Zhi Dong
   Yin, Bo Feng
   Hao, Rui Cong
   Mao, Ning
   Xia, Wen Rong
   Ding, Li
   Zhu, Heng
TI TNFAIP3 Derived from Skeletal Stem Cells Alleviated Rat Osteoarthritis
   by Inhibiting the Necroptosis of Subchondral Osteoblasts
SO STEM CELLS
LA English
DT Article
DE cellular therapy; osteoblast; skeleton; tissue specific stem cells
ID CARTILAGE; BONE; IDENTIFICATION; HIP
AB Recent investigations have shown that the necroptosis of tissue cells in joints is important in the development of osteoarthritis (OA). This study aimed to investigate the potential effects of exogenous skeletal stem cells (SSCs) on the necroptosis of subchondral osteoblasts in OA. Human SSCs and subchondral osteoblasts isolated from human tibia plateaus were used for Western blotting, real time PCR, RNA sequencing, gene editing, and necroptosis detection assays. In addition, the rat anterior cruciate ligament transection OA model was used to evaluate the effects of SSCs on osteoblast necroptosis in vivo. The micro CT and pathological data showed that intra articular injections of SSCs significantly improved the microarchitecture of subchondral trabecular bones in OA rats. Additionally, SSCs inhibited the necroptosis of subchondral osteoblasts in OA rats and necroptotic cell models. The results of bulk RNA sequencing of SSCs stimulated or not by tumor necrosis factor alpha suggested a correlation of SSCs derived tumor necrosis factor alpha induced protein 3 (TNFAIP3) and cell necroptosis. Furthermore, TNFAIP3 derived from SSCs contributed to the inhibition of the subchondral osteoblast necroptosis in vivo and in vitro. Moreover, the intra articular injections of TNFAIP3 overexpressing SSCs further improved the subchondral trabecular bone remodeling of OA rats. Thus, we report that TNFAIP3 from SSCs contributed to the suppression of the subchondral osteoblast necroptosis, which suggests that necroptotic subchondral osteoblasts in joints may be possible targets to treat OA by stem cell therapy.
   Graphical Abstract
C1 [Li, Xiao Tong; Li, Zhi Ling; Li, Pei Lin; Wang, Fei Yan; Zhang, Xiao Yu; Wang, Yu Xing; Zhao, Zhi Dong; Yin, Bo Feng; Hao, Rui Cong; Zhu, Heng] Beijing Inst Radiat Med, Dept Stem Cells & Regenerat Med, Beijing 100850, Peoples R China.
   [Li, Xiao Tong; Li, Zhi Ling; Li, Pei Lin; Wang, Fei Yan; Zhang, Xiao Yu; Yin, Bo Feng; Hao, Rui Cong; Zhu, Heng] Beijing Inst Radiat Med, Beijing Key Lab Radiobiol, Beijing 100850, Peoples R China.
   [Wang, Fei Yan; Hao, Rui Cong; Zhu, Heng] Anhui Med Univ, Basic Med Coll, Hefei 230032, Peoples R China.
   [Zhang, Xiao Yu; Zhu, Heng] Hebei Univ, Sch Life Sci, Baoding 071002, Peoples R China.
   [Wang, Yu Xing; Zhao, Zhi Dong; Mao, Ning] Peoples Liberat Army Gen Hosp, Beijing 100853, Peoples R China.
   [Mao, Ning] Beijing Inst Basic Med Sci, Beijing 100850, Peoples R China.
   [Xia, Wen Rong] PLA, Acad Mil Med Sci, Rd Taiping 27, Beijing 100850, Peoples R China.
   [Ding, Li] PLA, Air Force Med Ctr, Rd Fucheng 30, Beijing 100142, Peoples R China.
   [Zhu, Heng] Beijing Inst Radiat Med, Rd Taiping 27, Beijing 100850, Peoples R China.
C3 Academy of Military Medical Sciences   China; Anhui Medical University;
   Hebei University; Chinese People's Liberation Army General Hospital;
   Academy of Military Medical Sciences   China; Institute of Basic Medical
   Sciences (IBMS); Academy of Military Medical Sciences   China
RP Xia, WR (通讯作者)，PLA, Acad Mil Med Sci, Rd Taiping 27, Beijing 100850, Peoples R China.; Ding, L (通讯作者)，PLA, Air Force Med Ctr, Rd Fucheng 30, Beijing 100142, Peoples R China.; Zhu, H (通讯作者)，Beijing Inst Radiat Med, Rd Taiping 27, Beijing 100850, Peoples R China.
EM xiawenrong@sina.com; dingli7578@163.com; zhudingdingabc@163.com
RI zhu, dingdingabc/AAZ 7892 2020; Wang, Yuxing/F 3195 2017; li,
   peilin/R 4460 2019; Zhang, Xiaoyu/GZN 0054 2022
OI Zhu, Heng/0000 0002 8408 3821; 
FU National Natural Sciences Grants China [82172388, 82372373, 81871771];
   National Key R&D Program of China [2022YFA1104100, 2022YFA1103500];
   Beijing Natural Sciences Foundation [7222123, L212065]
FX This work was supported by the National Natural Sciences Grants China
   (grant nos. 82172388, 82372373, 81871771), National Key R&D Program of
   China (grant nos. 2022YFA1104100, 2022YFA1103500), and the Beijing
   Natural Sciences Foundation (grant no. 7222123, L212065).
CR Ahn J, 2018, CANCER CELL, V33, P862, DOI 10.1016/j.ccell.2018.03.027
   Ambrosi TH, 2021, NATURE, V597, P256, DOI 10.1038/s41586 021 03795 7
   Armaka M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 02935 4
   Bernabei I, 2023, NAT REV RHEUMATOL, V19, P10, DOI 10.1038/s41584 022 00875 4
   Bez M, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3128
   Chan CKF, 2018, CELL, V175, P43, DOI 10.1016/j.cell.2018.07.029
   Chan CKF, 2015, CELL, V160, P285, DOI 10.1016/j.cell.2014.12.002
   Chen Y, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.34
   Conaghan PG, 2019, NAT REV RHEUMATOL, V15, P355, DOI 10.1038/s41584 019 0221 y
   Cui HW, 2016, SCI REP UK, V6, DOI 10.1038/srep33803
   Cui HW, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150805
   Cui Z, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00229 6
   Dai X, 2020, INT ENDOD J, V53, P1204, DOI 10.1111/iej.13323
   De Lorenzo G, 2018, TRENDS IMMUNOL, V39, P937, DOI 10.1016/j.it.2018.09.006
   Eccleston A, 2023, NAT REV DRUG DISCOV, V22, P96, DOI 10.1038/d41573 022 00215 x
   Frank D, 2019, CELL DEATH DIFFER, V26, P99, DOI 10.1038/s41418 018 0212 6
   Goldring SR, 2016, NAT REV RHEUMATOL, V12, P632, DOI 10.1038/nrrheum.2016.148
   He B, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.790613
   He F, 2022, J BONE MINER RES, V37, P1044, DOI 10.1002/jbmr.4542
   He J, 2021, CELL RES, V31, P742, DOI 10.1038/s41422 021 00467 z
   Hu WH, 2021, ANN RHEUM DIS, V80, P413, DOI 10.1136/annrheumdis 2020 218089
   Jeffery EC, 2022, CELL STEM CELL, V29, P1547, DOI 10.1016/j.stem.2022.10.002
   Jeon J, 2020, ANN RHEUM DIS, V79, P1635, DOI 10.1136/annrheumdis 2020 217904
   Jones IA, 2019, NAT REV RHEUMATOL, V15, P77, DOI 10.1038/s41584 018 0123 4
   Katz JN, 2021, JAMA J AM MED ASSOC, V325, P568, DOI 10.1001/jama.2020.22171
   Li X, 2020, STEM CELL TRANSL MED, V9, P261, DOI 10.1002/sctm.19 0300
   Liang JW, 2021, STEM CELL TRANSL MED, V10, P1217, DOI 10.1002/sctm.20 0536
   Liu D, 2020, CELL METAB, V31, P726, DOI 10.1016/j.cmet.2020.03.007
   Lyons TJ, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471 2474 7 52
   MAROUDAS A, 1968, Journal of Bone and Joint Surgery British Volume, V50B, P166
   Maruyama T, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abb4416
   Menon S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 24801 6
   Newton K, 2021, SCIENCE, V374, P1076, DOI 10.1126/science.abi5934
   Onizawa M, 2015, NAT IMMUNOL, V16, P618, DOI 10.1038/ni.3172
   Pan J, 2009, J ORTHOP RES, V27, P1347, DOI 10.1002/jor.20883
   Polykratis A, 2019, NAT CELL BIOL, V21, P731, DOI 10.1038/s41556 019 0324 3
   Rhoads JP, 2017, NAT REV RHEUMATOL, V13, P313, DOI 10.1038/nrrheum.2017.54
   Riegger J, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1930 5
   Rosenberg JH, 2017, MOL CELL BIOCHEM, V436, P59, DOI 10.1007/s11010 017 3078 x
   Sharma L, 2021, NEW ENGL J MED, V384, P51, DOI 10.1056/NEJMcp1903768
   Shu HS, 2021, CELL STEM CELL, V28, P2122, DOI 10.1016/j.stem.2021.08.010
   Vandenabeele P, 2023, NAT REV MOL CELL BIO, V24, P312, DOI 10.1038/s41580 022 00564 w
   Wang KT, 2019, AM J SPORT MED, V47, P2200, DOI 10.1177/0363546519854219
   Worthley DL, 2015, CELL, V160, P269, DOI 10.1016/j.cell.2014.11.042
   Yan K, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12778
   Yan X, 2021, ADV MATER, V33, DOI 10.1002/adma.202104758
   Yang Y, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1413 8
   Yao Q, 2023, SIGNAL TRANSDUCT TAR, V8, DOI 10.1038/s41392 023 01330 w
   Yin BF, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287 022 02911 2
   Yun HM, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23158297
   Zammit NW, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.811525
   Zhang C, 2017, OSTEOARTHR CARTILAGE, V25, P1324, DOI 10.1016/j.joca.2017.03.018
   Zhang T, 2022, TOXICOLOGY, V476, DOI 10.1016/j.tox.2022.153244
   Zhu H, 2015, BIOMATERIALS, V53, P688, DOI 10.1016/j.biomaterials.2015.03.005
   Zhu H, 2010, NAT PROTOC, V5, P550, DOI 10.1038/nprot.2009.238
   Zhu JJ, 2022, SCI ADV, V8, DOI 10.1126/sciadv.abk0011
NR 56
TC 5
Z9 6
U1 0
U2 12
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1066 5099
EI 1549 4918
J9 STEM CELLS
JI Stem Cells
PD APR 15
PY 2024
VL 42
IS 4
BP 360
EP 373
DI 10.1093/stmcls/sxad097
EA JAN 2024
PG 14
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA NR6P1
UT WOS:001140114800001
PM 38153253
DA 2025 08 17
ER

PT J
AU Kim, HJ
   Park, M
   Han, YM
   Kwon, BM
   Kim, SH
AF Kim, Hye Joo
   Park, Mikyung
   Han, Young Min
   Kwon, Byoung Mog
   Kim, Seong Hwan
TI Butamben derivatives enhance BMP 2 stimulated commitment of C2C12 cells
   into osteoblasts with induction of voltage gated potassium channel
   expression
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Drug repositioning; Butamben; Osteoblastogenesis; Bone morphogenetic
   protein; Voltage gated potassium channel
ID ROOT GANGLION NEURONS; BONE; DIFFERENTIATION; AMINOBENZOATE; ACTIVATION;
   MOLECULES; ESTERS; P38
AB As the primary step for 'drug repositioning', we evaluated the effect of 2000 drugs and drug candidates on the commitment of bi potential mesenchymal precursor C2C12 cells into osteoblasts in the presence of bone morphogenetic protein (BMP) 2 and found that butamben enhanced BMP 2 stimulated induction of alkaline phosphatase, a biomarker of osteoblastogenesis. Investigating the underlying mechanism of its anabolic actions, we found anabolic action of its derivative (compound 4) relies on BMP 2 signaling and mRNA induction of BMPs and voltage gated potassium channels. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Han, Young Min; Kwon, Byoung Mog] Univ Sci Technol, Korea Res Inst Biosci Biotechnol, Lab Chem Biol Genom, Taejon 305806, South Korea.
   [Kim, Hye Joo; Park, Mikyung; Kim, Seong Hwan] Korea Res Inst Chem Technol, Pharmacol Res Ctr, Lab Chem Genom, Taejon 305600, South Korea.
   [Kim, Hye Joo] Seoul Natl Univ, Dept Chem, Seoul 151742, South Korea.
C3 Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea
   Research Institute of Chemical Technology (KRICT); Seoul National
   University (SNU)
RP Kwon, BM (通讯作者)，Univ Sci Technol, Korea Res Inst Biosci Biotechnol, Lab Chem Biol Genom, 111 Gwahangno, Taejon 305806, South Korea.
EM kwonbm@kribb.re.kr; hwan@krict.re.kr
RI Kim, Seong/AAA 6086 2021; Park, Joohyun/KAL 8175 2024
FU National Research Foundation (NRF); Korean Ministry of Education,
   Science, and Technology (MEST) [20100002073]
FX This work was supported by a National Research Foundation (NRF) grant
   (for 'Chemical Genomics Research') funded by the National RD Program of
   the Korean Ministry of Education, Science, and Technology (MEST), No.
   20100002073.
CR Ashburn TT, 2004, NAT REV DRUG DISCOV, V3, P673, DOI 10.1038/nrd1468
   Beekwilder JP, 2003, J PHARMACOL EXP THER, V304, P531, DOI 10.1124/jpet.102.042135
   Bessa PC, 2009, PROTEIN EXPRES PURIF, V63, P89, DOI 10.1016/j.pep.2008.09.014
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen D, 1997, CALCIFIED TISSUE INT, V60, P283, DOI 10.1007/s002239900230
   Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623 200308000 00017
   Ebisawa T, 1999, J CELL SCI, V112, P3519
   Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997
   Garrett IR, 2007, CURR TOP DEV BIOL, V78, P127, DOI 10.1016/S0070 2153(06)78004 8
   HAINING CG, 1960, J PHARM PHARMACOL, V12, P641, DOI 10.1111/j.2042 7158.1960.tb12724.x
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Harvey N, 2010, NAT REV RHEUMATOL, V6, P99, DOI 10.1038/nrrheum.2009.260
   Kawai M, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471 2474 7 62
   Kim HJ, 2010, AMINO ACIDS, V39, P1217, DOI 10.1007/s00726 010 0557 8
   KORSTEN HHM, 1991, ANESTHESIOLOGY, V75, P950, DOI 10.1097/00000542 199112000 00005
   Li JZ, 2003, GENE THER, V10, P1735, DOI 10.1038/sj.gt.3302075
   Mucke H. A. M., 2010, INSIGHT PHARM REPORT
   Nakamura Y, 2005, J BONE MINER METAB, V23, P426, DOI 10.1007/s00774 005 0624 5
   Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872
   Nöth U, 2003, EXP CELL RES, V291, P201, DOI 10.1016/S0014 4827(03)00386 0
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   SEKI H, 1988, J PHARM SCI, V77, P855, DOI 10.1002/jps.2600771009
   Sellarajah S, 2004, J MED CHEM, V47, P5515, DOI 10.1021/jm049922t
   Shulman M, 1998, REGION ANESTH PAIN M, V23, P395, DOI 10.1016/S1098 7339(98)90014 1
   Valentin Opran A, 2002, CLIN ORTHOP RELAT R, P110
   Winkelman DLB, 2005, J PHARMACOL EXP THER, V314, P1177, DOI 10.1124/jpet.105.087759
   Yamachika E, 2009, J BIOMED MATER RES A, V88A, P599, DOI 10.1002/jbm.a.31833
   Yeh LCC, 2002, J CELL BIOCHEM, V87, P292, DOI 10.1002/jcb.10315
   Young KA, 2006, AM J PHYSIOL LUNG C, V290, pL841, DOI 10.1152/ajplung.00158.2005
NR 29
TC 4
Z9 4
U1 0
U2 4
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960 894X
EI 1464 3405
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD DEC 15
PY 2011
VL 21
IS 24
BP 7363
EP 7366
DI 10.1016/j.bmcl.2011.10.020
PG 4
WC Chemistry, Medicinal; Chemistry, Organic
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Chemistry
GA 849UK
UT WOS:000297150600025
PM 22041064
DA 2025 08 17
ER

PT J
AU Kim, CJ
   Shin, SH
   Kim, BJ
   Kim, CH
   Kim, JH
   Kang, HM
   Park, BS
   Kim, IR
AF Kim, Chang Ju
   Shin, Sang Hun
   Kim, Bok Joo
   Kim, Chul Hoon
   Kim, Jung Han
   Kang, Hae Mi
   Park, Bong Soo
   Kim, In Ryoung
TI The Effects of Kaempferol Inhibited Autophagy on Osteoclast Formation
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE bone remodeling; osteoporosis; bisphosphonate related osteonecrosis of
   the jaw (BRONJ); osteoclast differentiation; autophagy; flavonoids
ID BISPHOSPHONATE RELATED OSTEONECROSIS; BONE RESORPTION; IN VITRO; C FOS;
   TERMINAL DIFFERENTIATION; ANTIOXIDANT ACTIVITY; SIGNALING PATHWAY;
   DOWN REGULATION; FLAVONOIDS; CELLS
AB Kaempferol, a flavonoid compound, is derived from the rhizome of Kaempferia galanga L., which is used in traditional medicine in Asia. Autophagy has pleiotropic functions that are involved in cell growth, survival, nutrient supply under starvation, defense against pathogens, and antigen presentation. There are many studies dealing with the inhibitory effects of natural flavonoids in bone resorption. However, no studies have explained the relationship between the autophagic and inhibitory processes of osteoclastogenesis by natural flavonoids. The present study was undertaken to investigate the inhibitory effects of osteoclastogenesis through the autophagy inhibition process stimulated by kaempferol in murin macrophage (RAW 264.7) cells. The cytotoxic effect of Kaempferol was investigated by MTT assay. The osteoclast differentiation and autophagic process were confirmed via tartrate resistant acid phosphatase (TRAP) staining, pit formation assay, western blot, and real time PCR. Kaempferol controlled the expression of autophagy related factors and in particular, it strongly inhibited the expression of p62/SQSTM1. In the western blot and real time PCR analysis, when autophagy was suppressed with the application of 3 Methyladenine (3 MA) only, osteoclast and apoptosis related factors were not significantly affected. However, we found that after cells were treated with kaempferol, these factors inhibited autophagy and activated apoptosis. Therefore, we presume that kaempferol inhibited autophagy activated apoptosis by degradation of p62/SQSTM1. Further study of the p62/SQSTM1 gene as a target in the autophagy mechanism, may help to delineate the potential role of kaempferol in the treatment of bone metabolism disorders.
C1 [Kim, Chang Ju; Shin, Sang Hun] Pusan Natl Univ, Dept Oral & Maxillofacial Surg, Dent Hosp, 20 Geumo Ro, Yangsan Si 50612, Gyeongsangnam D, South Korea.
   [Kim, Bok Joo; Kim, Chul Hoon; Kim, Jung Han] Dong A Univ, Dept Oral & Maxillofacial Surg, Med Ctr, 26 Daesingongwon Ro, Busan 49201, South Korea.
   [Kang, Hae Mi; Park, Bong Soo] Pusan Natl Univ, Sch Dent, PLUS Project BK21, 49 Mulguem Eup, Yangsan Si 50612, Gyeongsangnam D, South Korea.
   [Kang, Hae Mi; Park, Bong Soo; Kim, In Ryoung] Pusan Natl Univ, Sch Dent, Dept Oral Anat, 49 Mulguem Eup, Yangsan Si 50612, Gyeongsangnam D, South Korea.
C3 Pusan National University; Dong A University; Pusan National University;
   Pusan National University
RP Kim, IR (通讯作者)，Pusan Natl Univ, Sch Dent, Dept Oral Anat, 49 Mulguem Eup, Yangsan Si 50612, Gyeongsangnam D, South Korea.
EM changju75@hanmail.net; ssh8080@pusan.ac.kr; samehope@naver.com;
   bbp2000@hanmail.net; noenemyguy@hanmail.net; khaemi90@naver.com;
   parkbs@pusan.ac.kr; biowool@pusan.ac.kr
RI kim, Inryoung/AGF 2385 2022; Kim, Chang Gon/IAP 6721 2023; Kim,
   In Ryoung/AGF 2385 2022; Kim, Chang/H 4759 2011
OI kim, Inryoung/0000 0003 0232 0385; gim, jeonghan/0000 0002 3469 6136;
   KIM, BOKJOO/0000 0002 7482 8738; 
FU National Research Foundation of Korea (NRF)   Korea government
   [NRF 2017R1C1B5018034]
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korea government (No. NRF 2017R1C1B5018034).
CR Amic D, 2007, CURR MED CHEM, V14, P827, DOI 10.2174/092986707780090954
   Arai A, 2012, J CELL SCI, V125, P2910, DOI 10.1242/jcs.099986
   Ariyoshi W, 2005, J BIOL CHEM, V280, P18967, DOI 10.1074/jbc.M412740200
   Asai K, 2014, CELL BIOCHEM FUNCT, V32, P401, DOI 10.1002/cbf.3028
   Bitto A, 2010, CURR MED CHEM, V17, P3007, DOI 10.2174/092986710791959738
   Bloemen V, 2010, J CELL PHYSIOL, V222, P565, DOI 10.1002/jcp.21971
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen EH, 2005, SCIENCE, V308, P369, DOI 10.1126/science.1104799
   Córdoba A, 2015, ADV HEALTHC MATER, V4, P540, DOI 10.1002/adhm.201400587
   Fleming A, 2011, NAT CHEM BIOL, V7, P9, DOI 10.1038/NCHEMBIO.500
   Galleano M, 2012, ANN NY ACAD SCI, V1259, P87, DOI 10.1111/j.1749 6632.2012.06511.x
   García Mediavilla V, 2007, EUR J PHARMACOL, V557, P221, DOI 10.1016/j.ejphar.2006.11.014
   Gatica D, 2015, CIRC RES, V116, P456, DOI 10.1161/CIRCRESAHA.114.303788
   Guo AJ, 2012, CHIN MED UK, V7, DOI 10.1186/1749 8546 7 10
   Ha SW, 2014, ACS NANO, V8, P5898, DOI 10.1021/nn5009879
   Hippert MM, 2006, CANCER RES, V66, P9349, DOI 10.1158/0008 5472.CAN 06 1597
   Hocking LJ, 2012, J BONE MINER RES, V27, P1439, DOI 10.1002/jbmr.1668
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Huang H, 2006, BIOCHEM BIOPH RES CO, V351, P99, DOI 10.1016/j.bbrc.2006.10.011
   Huang LF, 2008, J ETHNOPHARMACOL, V120, P123, DOI 10.1016/j.jep.2008.07.045
   Huang WW, 2013, INT J ONCOL, V42, P2069, DOI 10.3892/ijo.2013.1909
   Huang X, 2016, MOL MED REP, V13, P613, DOI 10.3892/mmr.2015.4627
   Ikeda Kyoji, 2014, J Bone Metab, V21, P163, DOI 10.11005/jbm.2014.21.3.163
   Jin ZX, 2014, CELL METAB, V20, P483, DOI 10.1016/j.cmet.2014.07.011
   Kim H, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/596496
   Kim MH, 2008, FOOD CHEM TOXICOL, V46, P3375, DOI 10.1016/j.fct.2008.08.016
   Kumar S., 2013, SCI WORLD J, DOI 10.1155/2013/16275024470791
   Lazarovici TS, 2010, J ORAL MAXIL SURG, V68, P790, DOI 10.1016/j.joms.2009.09.017
   Lee WS, 2014, INFLAMMATION, V37, P1221, DOI 10.1007/s10753 014 9849 6
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Liu F, 2013, J BONE MINER RES, V28, P2414, DOI 10.1002/jbmr.1971
   Maynard AA, 2010, AM J PHYSIOL GASTR L, V299, pG614, DOI 10.1152/ajpgi.00076.2010
   Middleton E, 2000, PHARMACOL REV, V52, P673
   Miyake M, 2003, BIOSCI BIOTECH BIOCH, V67, P1199, DOI 10.1271/bbb.67.1199
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Noh EM, 2009, RHEUMATOLOGY, V48, P45, DOI 10.1093/rheumatology/ken417
   Oberley TD, 2008, J HISTOCHEM CYTOCHEM, V56, P615, DOI 10.1369/jhc.2008.950873
   Oikawa T, 2013, CELL MOL LIFE SCI, V70, P3341, DOI 10.1007/s00018 012 1238 4
   Pang JL, 2006, BIOCHEM PHARMACOL, V71, P818, DOI 10.1016/j.bcp.2005.12.023
   PARFITT AM, 1987, CLIN OBSTET GYNECOL, V30, P789, DOI 10.1097/00003081 198712000 00004
   Pichardo SEC, 2016, J CRANIO MAXILL SURG, V44, P1216, DOI 10.1016/j.jcms.2016.06.016
   Prouillet C, 2004, BIOCHEM PHARMACOL, V67, P1307, DOI 10.1016/j.bcp.2003.11.009
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rezk BM, 2002, BIOCHEM BIOPH RES CO, V295, P9, DOI 10.1016/S0006 291X(02)00618 6
   Ross JA, 2002, ANNU REV NUTR, V22, P19, DOI 10.1146/annurev.nutr.22.111401.144957
   Ryter Stefan W, 2014, Int J Cell Biol, V2014, P502676, DOI 10.1155/2014/502676
   Sharan K, 2009, CURR MED CHEM, V16, P1138, DOI 10.2174/092986709787581806
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2009, NAT REV RHEUMATOL, V5, P667, DOI 10.1038/nrrheum.2009.217
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   THOMSON BM, 1987, J IMMUNOL, V138, P775
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Wattel A, 2004, J CELL BIOCHEM, V92, P285, DOI 10.1002/jcb.20071
   Wattel A, 2003, BIOCHEM PHARMACOL, V65, P35, DOI 10.1016/S0006 2952(02)01445 4
   Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007 1102
   Yamaguchi M, 2007, MOL CELL BIOCHEM, V303, P83, DOI 10.1007/s11010 007 9458 x
   Zhao Y, 2012, J CELL PHYSIOL, V227, P639, DOI 10.1002/jcp.22768
NR 57
TC 78
Z9 91
U1 0
U2 28
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JAN
PY 2018
VL 19
IS 1
AR 125
DI 10.3390/ijms19010125
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA FV2OI
UT WOS:000424407200122
PM 29301320
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Corrigan, MA
   Johnson, GP
   Stavenschi, E
   Riffault, M
   Labour, MN
   Hoey, DA
AF Corrigan, Michele A.
   Johnson, Gillian P.
   Stavenschi, Elena
   Riffault, Mathieu
   Labour, Marie Noelle
   Hoey, David A.
TI TRPV4 mediates oscillatory fluid shear mechanotransduction in
   mesenchymal stem cells in part via the primary cilium
SO SCIENTIFIC REPORTS
LA English
DT Article
ID OSTEOGENIC DIFFERENTIATION; BONE; FLOW; TRPV4; OSTEOPONTIN; ACTIVATION;
   CHANNELS; PROLIFERATION; INFLAMMATION; OSTEOPOROSIS
AB Skeletal homeostasis requires the continued replenishment of the bone forming osteoblast from a mesenchymal stem cell (MSC) population, a process that has been shown to be mechanically regulated. However, the mechanisms by which a biophysical stimulus can induce a change in biochemical signaling, mechanotransduction, is poorly understood. As a precursor to loading induced bone formation, deciphering the molecular mechanisms of MSC osteogenesis is a critical step in developing novel anabolic therapies. Therefore, in this study we characterize the expression of the mechanosensitive calcium channel Transient Receptor Potential subfamily V member 4 (TRPV4) in MSCs and demonstrate that TRPV4 localizes to areas of high strain, specifically the primary cilium. We demonstrate that TRPV4 is required for MSC mechanotransduction, mediating oscillatory fluid shear induced calcium signaling and early osteogenic gene expression. Furthermore, we demonstrate that TRPV4 can be activated pharmacologically eliciting a response that mirrors that seen with mechanical stimulation. Lastly, we show that TRPV4 localization to the primary cilium is functionally significant, with MSCs with defective primary cilia exhibiting an inhibited osteogenic response to TRPV4 activation. Collectively, this data demonstrates a novel mechanism of stem cell mechanotransduction, which can be targeted therapeutically, and further highlights the critical role of the primary cilium in MSC biology.
C1 [Corrigan, Michele A.; Johnson, Gillian P.; Stavenschi, Elena; Riffault, Mathieu; Labour, Marie Noelle; Hoey, David A.] Trinity Coll Dublin, Trinity Biomed Sci Inst, Trinity Ctr Bioengn, Dublin 2, Ireland.
   [Corrigan, Michele A.; Johnson, Gillian P.; Stavenschi, Elena; Riffault, Mathieu; Labour, Marie Noelle; Hoey, David A.] Trinity Coll Dublin, Sch Engn, Dept Mech & Mfg Engn, Dublin 2, Ireland.
   [Corrigan, Michele A.; Johnson, Gillian P.; Stavenschi, Elena; Labour, Marie Noelle; Hoey, David A.] Univ Limerick, Dept Mech Aeronaut & Biomed Engn, Limerick, Ireland.
   [Riffault, Mathieu; Hoey, David A.] Trinity Coll Dublin, Adv Mat & Bioengn Res Ctr, Dublin 2, Ireland.
   [Riffault, Mathieu; Hoey, David A.] RCSI, Dublin 2, Ireland.
C3 Trinity College Dublin; Trinity College Dublin; University of Limerick;
   Trinity College Dublin; Royal College of Surgeons   Ireland
RP Hoey, DA (通讯作者)，Trinity Coll Dublin, Trinity Biomed Sci Inst, Trinity Ctr Bioengn, Dublin 2, Ireland.; Hoey, DA (通讯作者)，Trinity Coll Dublin, Sch Engn, Dept Mech & Mfg Engn, Dublin 2, Ireland.; Hoey, DA (通讯作者)，Univ Limerick, Dept Mech Aeronaut & Biomed Engn, Limerick, Ireland.; Hoey, DA (通讯作者)，Trinity Coll Dublin, Adv Mat & Bioengn Res Ctr, Dublin 2, Ireland.; Hoey, DA (通讯作者)，RCSI, Dublin 2, Ireland.
EM dahoey@tcd.ie
RI Hoey, David/X 9231 2019; Hoey, David/G 3301 2013
OI Stavenschi Toth, Elena/0000 0002 7329 7082; Riffault,
   Mathieu/0000 0002 1689 8199; Labour, Marie Noelle/0000 0001 5517 302X;
   Hoey, David/0000 0001 5898 0409
FU European Research Council (ERC) [336882]; Science Foundation Ireland ERC
   [SFI 13/ERC/L2864]; European Research Council (ERC) [336882] Funding
   Source: European Research Council (ERC)
FX The study was supported by a European Research Council (ERC) Starting
   Grant (#336882) and a Science Foundation Ireland ERC Support Grant SFI
   13/ERC/L2864 (to D.A.H.).
CR Bancroft GN, 2002, P NATL ACAD SCI USA, V99, P12600, DOI 10.1073/pnas.202296599
   Battle C, 2015, P NATL ACAD SCI USA, V112, P1410, DOI 10.1073/pnas.1421845112
   Chen J. C., 2015, FASEB J
   Downs ME, 2014, COMPUT METHOD BIOMEC, V17, P2, DOI 10.1080/10255842.2011.653784
   Espinha LC, 2014, CYTOSKELETON, V71, P435, DOI 10.1002/cm.21183
   Forwood MR, 1996, J BONE MINER RES, V11, P1688
   Giachelli CM, 2000, MATRIX BIOL, V19, P615, DOI 10.1016/S0945 053X(00)00108 6
   Haycraft CJ, 2007, DEVELOPMENT, V134, P307, DOI 10.1242/dev.02732
   Hills CE, 2012, EXP DIABETES RES, DOI 10.1155/2012/936518
   Höger U, 2008, NEUROSCI RES, V62, P278, DOI 10.1016/j.neures.2008.09.006
   Hoey DA, 2012, STEM CELLS, V30, P2561, DOI 10.1002/stem.1235
   Hoey David A, 2012, Front Endocrinol (Lausanne), V3, P75, DOI 10.3389/fendo.2012.00075
   Hoey DA, 2012, J BIOMECH, V45, P17, DOI 10.1016/j.jbiomech.2011.08.008
   Hu KZ, 2017, BIOMED PHARMACOTHER, V91, P841, DOI 10.1016/j.biopha.2017.04.094
   Irianto J, 2014, J BIOMECH, V47, P579, DOI 10.1016/j.jbiomech.2013.11.040
   Kahles F, 2014, MOL METAB, V3, P384, DOI 10.1016/j.molmet.2014.03.004
   Kang SS, 2012, EXP MOL MED, V44, P707, DOI 10.3858/emm.2012.44.12.080
   Knight MN, 2013, ADV WOUND CARE, V2, P306, DOI 10.1089/wound.2012.0420
   Kötttgen M, 2008, J CELL BIOL, V182, P437, DOI 10.1083/jcb.200805124
   Komm BS, 2015, EXPERT REV CLIN PHAR, V8, P769, DOI 10.1586/17512433.2015.1099432
   Kwon RY, 2010, FASEB J, V24, P2859, DOI 10.1096/fj.09 148007
   Labour MN, 2016, SCI REP UK, V6, DOI 10.1038/srep35542
   Lee Eun Ung, 2015, Biomater Res, V19, P1
   Lee Kristen L, 2015, Cilia, V4, P7, DOI 10.1186/s13630 015 0016 y
   Li YJ, 2004, J ORTHOP RES, V22, P1283, DOI 10.1016/j.orthres.2004.04.002
   Lund SA, 2009, J CELL COMMUN SIGNAL, V3, P311, DOI 10.1007/s12079 009 0068 0
   Luo N, 2014, P NATL ACAD SCI USA, V111, P12871, DOI 10.1073/pnas.1323292111
   Pino AM, 2012, BIOL RES, V45, P279, DOI 10.4067/S0716 97602012000300009
   Matthews BD, 2010, INTEGR BIOL UK, V2, P435, DOI 10.1039/c0ib00034e
   McMurray RJ, 2015, J TISSUE ENG REGEN M, V9, P528, DOI 10.1002/term.1957
   Metzger TA, 2015, J BIOMECH ENG T ASME, V137, DOI 10.1115/1.4028985
   Mizoguchi F, 2008, J CELL PHYSIOL, V216, P47, DOI 10.1002/jcp.21374
   Nilius B, 2011, GENOME BIOL, V12, DOI 10.1186/gb 2011 12 3 218
   O'Conor CJ, 2014, P NATL ACAD SCI USA, V111, P1316, DOI 10.1073/pnas.1319569111
   O'Conor CJ, 2013, ANN RHEUM DIS, V72, P300, DOI 10.1136/annrheumdis 2012 202272
   Phan MN, 2009, ARTHRITIS RHEUM US, V60, P3028, DOI 10.1002/art.24799
   Pisani P, 2016, WORLD J ORTHOP, V7, P171, DOI 10.5312/wjo.v7.i3.171
   Pochynyuk O, 2013, PFLUG ARCH EUR J PHY, V465, P177, DOI 10.1007/s00424 012 1190 z
   Riddle RC, 2006, AM J PHYSIOL CELL PH, V290, pC776, DOI 10.1152/ajpcell.00082.2005
   Riehl B. D., 2015, J R SOC INTERFACE, V12
   Ross TD, 2013, CURR OPIN CELL BIOL, V25, P613, DOI 10.1016/j.ceb.2013.05.006
   Rydholm S, 2010, AM J PHYSIOL RENAL, V298, pF1096, DOI 10.1152/ajprenal.00657.2009
   Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140 6736(06)68891 0
   Satir P, 2010, J CELL SCI, V123, P499, DOI 10.1242/jcs.050377
   Scaglione S, 2008, J BIOMED MATER RES A, V86A, P411, DOI 10.1002/jbm.a.31607
   Sonam S, 2016, SCI REP UK, V6, DOI 10.1038/srep20415
   Stavenschi E, 2017, J BIOMECH, V55, P99, DOI 10.1016/j.jbiomech.2017.02.002
   Suzuki T, 2013, BONE, V54, P172, DOI 10.1016/j.bone.2013.01.001
   Tada M, 2014, EUR J NEUROSCI, V39, P1720, DOI 10.1111/ejn.12476
   Takao D, 2017, DEV GROWTH DIFFER, V59, P415, DOI 10.1111/dgd.12360
   Thodeti CK, 2009, CIRC RES, V104, P1123, DOI 10.1161/CIRCRESAHA.108.192930
   Turner CH, 1998, BONE, V23, P399, DOI 10.1016/S8756 3282(98)00118 5
   Tzima E, 2001, EMBO J, V20, P4639, DOI 10.1093/emboj/20.17.4639
   Vaughan T. J., 2014, BIOMECH MODEL MECHAN
   Veronesi F, 2011, CRIT REV EUKAR GENE, V21, P363, DOI 10.1615/CritRevEukarGeneExpr.v21.i4.60
   Wen L, 2012, BIOCHEM BIOPH RES CO, V424, P439, DOI 10.1016/j.bbrc.2012.06.128
   Whitfield JF, 2008, CELL SIGNAL, V20, P1019, DOI 10.1016/j.cellsig.2007.12.001
   You J, 2001, J BIOL CHEM, V276, P13365, DOI 10.1074/jbc.M009846200
   Yourek G, 2010, REGEN MED, V5, P713, DOI 10.2217/RME.10.60
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
NR 60
TC 87
Z9 100
U1 2
U2 25
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD FEB 28
PY 2018
VL 8
AR 3824
DI 10.1038/s41598 018 22174 3
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA FX7IM
UT WOS:000426262400077
PM 29491434
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kang, HL
   Guo, Q
   Dong, YM
   Peng, RP
   Song, KH
   Wang, J
   Liu, HY
   Zhu, MP
   Zhao, HJ
   Guan, HF
   Li, F
AF Kang, Honglei
   Guo, Qian
   Dong, Yimin
   Peng, Renpeng
   Song, Kehan
   Wang, Jia
   Liu, Haiyang
   Zhu, Meipeng
   Zhao, Hongjian
   Guan, Hanfeng
   Li, Feng
TI Inhibition of MAT2A suppresses osteoclastogenesis and prevents
   ovariectomy induced bone loss
SO FASEB JOURNAL
LA English
DT Article
DE bone remodeling; MAT2A; osteoclast; osteoporosis; RANKL
ID NF KAPPA B; DIFFERENTIATION; METHIONINE; IMMUNE; MASS
AB Methionine adenosyltransferase II alpha (MAT2A) is the key enzyme to transform methionine and adenosine triphosphate (ATP) to S adenosylmethionine (SAM), a general methyl group donor in vitro. MAT2A has been reported to participate in the NF kappa B pathway and maintain the methylated modification, which also affects osteoclastogenesis. In this study, we found the expression of MAT2A was increased upon RANKL stimulation. Pharmacological inhibition of MAT2A by its selective inhibitor AG 270 or genetic silencing by MAT2A shRNA suppressed osteoclast formation and function in vitro. In vivo treatment with the inhibitor AG 270 also prevented OVX induced bone loss. Further study revealed that the inhibition of MAT2A affected osteoclast differentiation mainly by suppressing crucial transcription factors and reactive oxygen species induced by RANKL. A quasi targeted metabolomics assay performed by LC MS/MS indicated that SAM was reduced by MAT2A knockdown, and the administration of SAM partly rescued the effects of MAT2A inhibition on osteoclastogenesis. These findings revealed that MAT2A is crucial for osteoclastogenesis and might be a potential target for the treatment of osteoporosis attributed to osteoclast dysfunction.
C1 [Kang, Honglei; Guo, Qian; Dong, Yimin; Peng, Renpeng; Song, Kehan; Wang, Jia; Liu, Haiyang; Zhu, Meipeng; Zhao, Hongjian; Guan, Hanfeng; Li, Feng] Huazhong Univ Sci & Technol, Dept Orthoped, Tongji Med Coll, Tongji Hosp, 1095 Jiefang Ave, Wuhan 430030, Peoples R China.
C3 Huazhong University of Science & Technology
RP Guan, HF; Li, F (通讯作者)，Huazhong Univ Sci & Technol, Dept Orthoped, Tongji Med Coll, Tongji Hosp, 1095 Jiefang Ave, Wuhan 430030, Peoples R China.
EM hguan@hust.edu.cn; lifengmd@hust.edu.cn
OI Li, Feng/0000 0002 7961 3728
FU National Natural Science Foundation of China (NSFC) [82072500,
   81874024]; Key Research and Development Program of Hubei Province
   [2020BCB049]; Wuhan Huanghe Talent Program [HHYC 201601]
FX National Natural Science Foundation of China (NSFC), Grant/Award Number:
   82072500 and 81874024; Key Research and Development Program of Hubei
   Province, Grant/Award Number: 2020BCB049; Wuhan Huanghe Talent Program,
   Grant/Award Number: HHYC 201601
CR Abato JE, 2022, NUTR NEUROSCI, V25, P558, DOI 10.1080/1028415X.2020.1769412
   Agidigbi TS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143576
   Anselmino N, 2020, ANTIOXID REDOX SIGN, V32, P1243, DOI 10.1089/ars.2019.7879
   Astleford K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197080
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Da WCL, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.675385
   Gao X, 2019, NATURE, V572, P397, DOI 10.1038/s41586 019 1437 3
   Goettsch C, 2013, J CLIN INVEST, V123, P4731, DOI 10.1172/JCI67603
   Hiruma Y, 2009, BLOOD, V113, P4894, DOI 10.1182/blood 2008 08 173948
   Huh YJ, 2006, CELL DEATH DIFFER, V13, P1138, DOI 10.1038/sj.cdd.4401793
   Hyeon S, 2013, FREE RADICAL BIO MED, V65, P789, DOI 10.1016/j.freeradbiomed.2013.08.005
   Ishii M, 2009, NATURE, V458, P524, DOI 10.1038/nature07713
   Ivashkiv LB, 2015, NAT MED, V21, P212, DOI 10.1038/nm.3815
   Jacome Galarza CE, 2019, NATURE, V568, P541, DOI 10.1038/s41586 019 1105 7
   Kanzaki H, 2016, REDOX BIOL, V8, P186, DOI 10.1016/j.redox.2016.01.006
   Koga T, 2005, NAT MED, V11, P880, DOI 10.1038/nm1270
   Krzeszinski JY, 2015, CLIN EXP METASTAS, V32, P245
   Kurotaki D, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115471
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Li D, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051660
   Luo P, 2015, ANAL CHEM, V87, P5050, DOI 10.1021/acs.analchem.5b00615
   McDonald MM, 2021, CELL, V184, P1330, DOI 10.1016/j.cell.2021.02.002
   Morgan MJ, 2011, CELL RES, V21, P103, DOI 10.1038/cr.2010.178
   Muñoz J, 2020, NUTRIENTS, V12, DOI 10.3390/nu12102999
   Nishikawa K, 2015, NAT MED, V21, P281, DOI 10.1038/nm.3774
   Okamoto K, 2017, PHYSIOL REV, V97, P1295, DOI 10.1152/physrev.00036.2016
   Park Min KH, 2019, SEMIN IMMUNOPATHOL, V41, P565, DOI 10.1007/s00281 019 00757 0
   Roscher Anne, 2016, Bone Rep, V5, P214, DOI 10.1016/j.bonr.2016.07.002
   Song C, 2018, FASEB J, V32, P3215, DOI 10.1096/fj.201600825RRR
   Sun XW, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101309
   Villanueva JA, 2004, HEPATOLOGY, V39, P1303, DOI 10.1002/hep.20168
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Walsh MC, 2015, IMMUNOL REV, V266, P72, DOI 10.1111/imr.12302
   Wang ZX, 2019, NAT MED, V25, P825, DOI 10.1038/s41591 019 0423 5
   Yang HB, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7973
   Yang HP, 2003, J BIOL CHEM, V278, P50887, DOI 10.1074/jbc.M307600200
NR 36
TC 8
Z9 8
U1 2
U2 26
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD FEB
PY 2022
VL 36
IS 2
AR e22167
DI 10.1096/fj.202101205RR
PG 17
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA YO5NJ
UT WOS:000747987800034
PM 35064691
OA hybrid
DA 2025 08 17
ER

PT J
AU Mikami, Y
   Suzuki, S
   Ishii, Y
   Watanabe, N
   Takahashi, T
   Isokawa, K
   Honda, MJ
AF Mikami, Yoshikazu
   Suzuki, Shinnosuke
   Ishii, Yumiko
   Watanabe, Nobukazu
   Takahashi, Tomihisa
   Isokawa, Keitaro
   Honda, Masaki J.
TI The p75 neurotrophin receptor regulates MC3T3 E1 osteoblastic
   differentiation
SO DIFFERENTIATION
LA English
DT Article
DE MC3T3 E1 Cells; Osteoblast; Osteogenic differentiation; p75(NTR); Trk
ID MESENCHYMAL STEM CELLS; NERVE GROWTH FACTOR; TRANSCRIPTION FACTOR;
   STROMAL CELLS; IN VITRO; APOPTOSIS; EXPRESSION; DISRUPTION; INDUCTION;
   OSTERIX
AB While the role of p75(NTR) signaling in the regulation of nerve related cell growth and survival has been well documented, its actions in osteoblasts are poorly understood. In this study, we examined the effects of p75(NTR) on osteoblast proliferation and differentiation using the MC3T3 E1 pre osteoblast cell line. Proliferation and osteogenic differentiation were significantly enhanced in p75(NTR) overexpressing MC3T3 E1 cells (p75GFP E1). In addition, expression of osteoblast specific osteocalcin (OCN), bone sialoprotein (BSP), and osterix mRNA, ALP activity, and mineralization capacity were dramatically enhanced in p75GFP E1 cells, compared to wild MC3T3 E1 cells (GFP E1). To determine the binding partner of p75(NTR) in p75GFP E1 cells during osteogenic differentiation, we examined the expression of trkA, trkB, and trkC that are known binding partners of p75(NTR), as well as NgR. Pharmacological inhibition of trk tyrosine kinase with the K252a inhibitor resulted in marked reduction in the level of ALPase under osteogenic conditions. The deletion of the GDI binding domain in the p75(NTR) GFP construct had no effect on mineralization. Taken together, our studies demonstrated that p75(NTR) signaling through the trk tyrosine kinase pathway affects osteoblast functions by targeting osteoblast proliferation and differentiation.
C1 [Mikami, Yoshikazu; Suzuki, Shinnosuke; Takahashi, Tomihisa; Isokawa, Keitaro; Honda, Masaki J.] Nihon Univ, Sch Dent, Dept Anat, Tokyo 1018310, Japan.
   [Mikami, Yoshikazu; Takahashi, Tomihisa; Isokawa, Keitaro; Honda, Masaki J.] Nihon Univ, Sch Dent, Dent Res Ctr, Tokyo 1018310, Japan.
   [Ishii, Yumiko] Univ Tokyo, Inst Med Sci, FACS Core Lab, Tokyo 1088639, Japan.
   [Watanabe, Nobukazu] Univ Tokyo, Inst Med Sci, Lab Diagnost Med, Tokyo 1088639, Japan.
C3 Nihon University; Nihon University; University of Tokyo; University of
   Tokyo
RP Honda, MJ (通讯作者)，Nihon Univ, Sch Dent, Dept Anat, 1 8 13 Kanda Surugadai, Tokyo 1018310, Japan.
EM mikami t@dent.nihon ua.c.jp; suzuki sn@ri.ncgm.go.jp;
   yumii@ims.u tokyo.ac.jp; nwatanab@ims.u tokyo.ac.jp;
   takahashi tm@dent.nihon u.ac.jp; isokawa.keitaro@nihon u.ac.jp;
   honda.masaki@nihon u.ac.jp
OI Isokawa, Keitaro/0000 0002 7955 7252
FU Grants in Aid for Scientific Research [24390447, 22791778] Funding
   Source: KAKEN
CR Al Halabiah H, 2005, GENE EXPR PATTERNS, V5, P561, DOI 10.1016/j.modgep.2004.10.010
   Alexander D, 2009, CELL PHYSIOL BIOCHEM, V24, P283, DOI 10.1159/000233253
   Asai K, 2006, LIVER INT, V26, P595, DOI 10.1111/j.1478 3231.2006.01267.x
   BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896 6273(89)90040 8
   Barker PA, 2004, NEURON, V42, P529, DOI 10.1016/j.neuron.2004.04.001
   BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896 6273(94)90470 7
   Barry FP, 2004, INT J BIOCHEM CELL B, V36, P568, DOI 10.1016/j.biocel.2003.11.001
   Botchkarev VA, 2000, FASEB J, V14, P1931, DOI 10.1096/fj.99 0930com
   Caddick J, 2006, GLIA, V54, P840, DOI 10.1002/glia.20421
   Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078
   Dechant G, 2001, CELL TISSUE RES, V305, P229, DOI 10.1007/s004410100378
   DIMARCO E, 1993, J BIOL CHEM, V268, P22838
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   FRIEDENSTEIN AJ, 1974, TRANSPLANTATION, V17, P331, DOI 10.1097/00007890 197404000 00001
   Fu HH, 2007, J BIOMED MATER RES A, V83A, P770, DOI 10.1002/jbm.a.31356
   Huang W, 2007, FRONT BIOSCI LANDMRK, V12, P3068, DOI 10.2741/2296
   Igarashi M, 2004, J MOL HISTOL, V35, P3, DOI 10.1023/B:HIJO.0000020883.33256.fe
   Jackson L, 2007, J POSTGRAD MED, V53, P121
   Jones EA, 2002, ARTHRITIS RHEUM US, V46, P3349, DOI 10.1002/art.10696
   Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959 4388(00)00092 1
   KOIZUMI S, 1988, J NEUROSCI, V8, P715
   Komori T, 2002, J CELL BIOCHEM, V87, P1, DOI 10.1002/jcb.10276
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Lambiase A, 1998, INVEST OPHTH VIS SCI, V39, P1272
   Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140 6736(04)16104 7
   Lee FS, 2001, CURR OPIN NEUROBIOL, V11, P281, DOI 10.1016/S0959 4388(00)00209 9
   Majdan M, 1997, J NEUROSCI, V17, P6988
   Mischel PS, 2001, J BIOL CHEM, V276, P11294, DOI 10.1074/jbc.M005132200
   Mogi M, 2000, LIFE SCI, V67, P1197, DOI 10.1016/S0024 3205(00)00705 0
   NAKANISHI T, 1994, BIOCHEM BIOPH RES CO, V203, P1268, DOI 10.1006/bbrc.1994.2319
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nalbandian A, 2005, DIFFERENTIATION, V73, P385, DOI 10.1111/j.1432 0436.2005.00040.x
   Okumura T, 2003, ONCOGENE, V22, P4017, DOI 10.1038/sj.onc.1206525
   Patapoutian A, 2001, CURR OPIN NEUROBIOL, V11, P272, DOI 10.1016/S0959 4388(00)00208 7
   Pinski J, 2002, CANCER RES, V62, P986
   Pittenger MF, 2004, CIRC RES, V95, P9, DOI 10.1161/01.RES.0000135902.99383.6f
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Poloni A, 2009, CYTOTHERAPY, V11, P153, DOI 10.1080/14653240802582125
   POWER MJ, 1991, CRIT REV CL LAB SCI, V28, P287, DOI 10.3109/10408369109106867
   Quirici N, 2002, EXP HEMATOL, V30, P783, DOI 10.1016/S0301 472X(02)00812 3
   RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899
   Raouf A, 2000, ONCOGENE, V19, P6455, DOI 10.1038/sj.onc.1204037
   Rolf HJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002064
   Roux PP, 2002, PROG NEUROBIOL, V67, P203, DOI 10.1016/S0301 0082(02)00016 3
   Roux PP, 2002, J BIOL CHEM, V277, P49473, DOI 10.1074/jbc.M203428200
   Roux PP, 2001, J BIOL CHEM, V276, P23097, DOI 10.1074/jbc.M011520200
   Serafeim Adamantios, 2001, Current Opinion in Pharmacology, V1, P398, DOI 10.1016/S1471 4892(01)00069 8
   Shao ZH, 2005, NEURON, V45, P353, DOI 10.1016/j.neuron.2004.12.050
   Stepp MA, 2005, OCUL SURF, V3, P15, DOI 10.1016/S1542 0124(12)70119 2
   Teng KK, 2004, CELL MOL LIFE SCI, V61, P35, DOI 10.1007/s00018 003 3099 3
   Touhami A, 2002, INVEST OPHTH VIS SCI, V43, P987
   Wong ST, 2002, NAT NEUROSCI, V5, P1302, DOI 10.1038/nn975
   Yamamoto N, 2007, J DERMATOL SCI, V48, P43, DOI 10.1016/j.jdermsci.2007.05.015
   Yamashita T, 1999, NEURON, V24, P585, DOI 10.1016/S0896 6273(00)81114 9
   Zampieri N, 2006, BIOCHEM SOC T, V34, P607, DOI 10.1042/BST0340607
NR 56
TC 22
Z9 27
U1 3
U2 26
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0301 4681
EI 1432 0436
J9 DIFFERENTIATION
JI Differentiation
PD DEC
PY 2012
VL 84
IS 5
BP 392
EP 399
DI 10.1016/j.diff.2012.07.001
PG 8
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA 049CQ
UT WOS:000311960000006
PM 22906707
DA 2025 08 17
ER

PT J
AU Lenz, A
   Bennett, M
   Skelton, WP
   Vesely, DL
AF Lenz, Anne
   Bennett, Meghan
   Skelton, William P.
   Vesely, David L.
TI Vessel Dilator and C Type Natriuretic Peptide Enhance the Proliferation
   of Human Osteoblasts
SO PEDIATRIC RESEARCH
LA English
DT Article
ID PROSTATE CANCER CELLS; PROTEIN KINASE II; ENDOCHONDRAL OSSIFICATION;
   RECEPTOR B; DWARFISM; ATRIAL; CGMP; CNP; ACTIVATION; PATHWAY
AB C natriuretic peptide (CNP) has been shown to regulate proliferation of mouse and rat osteoblasts. Genetic deletion of CNP results in dwarfism. Overexposure of CNP has been associated with arachnodactyly of hands and feet with a very long hallux bilaterally in a 14 y old girl. CNP effects on bone growth involve inhibition of MEK 1 and ERK 1/2 kinases mediated via the intracellular messenger cGMP. Vessel dilator is another natriuretic peptide synthesized by the atrial natriuretic peptide gene whose biologic half life is 12 times longer than CNP. Vessel dilator's biologic effects on proliferating cells are mediated via inhibiting MEK 1/2 and ERK 1/2 kinases via cGMP. Vessel dilator has never been studied on osteoblasts. CNP at 10 (nanomolar) nM (p = 0.02) and vessel dilator at 10 nM, 1 nM, 100 (picomolar) pM, and 10 pM (p <= 0.01) in dose response studies enhanced human osteoblasts' proliferation. This first study of human osteoblasts would suggest that vessel dilator with a much longer biologic half life and with osteoblast stimulatory effects at lower concentrations than CNP may have therapeutic potential in human achondroplasia, short stature, and osteoporosis. Vessel dilator stimulates osteoblast proliferation whereas most current therapies of osteoporosis target osteoclasts. (Pediatr Res 68: 405 408, 2010)
C1 [Bennett, Meghan; Skelton, William P.; Vesely, David L.] Univ S Florida, Dept Internal Med, Sch Med, James A Haley Vet Med Ctr, Tampa, FL 33612 USA.
   [Lenz, Anne] Univ S Florida, Dept Pediat, Sch Med, James A Haley Vet Med Ctr, Tampa, FL 33612 USA.
   [Vesely, David L.] Univ S Florida, Dept Mol Pharmacol & Physiol, Sch Med, James A Haley Vet Med Ctr, Tampa, FL 33612 USA.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   James A. Haley Veterans Hospital; State University System of Florida;
   University of South Florida; State University System of Florida;
   University of South Florida; US Department of Veterans Affairs; Veterans
   Health Administration (VHA); James A. Haley Veterans Hospital; State
   University System of Florida; University of South Florida; US Department
   of Veterans Affairs; Veterans Health Administration (VHA); James A.
   Haley Veterans Hospital
RP Vesely, DL (通讯作者)，James A Haley Vet Med Ctr 151, Dept Internal Med, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.
EM david.vesely@va.gov
RI Vesely, David/A 7807 2009
FU Department of Veterans Affairs
FX Supported, in part, by a Merit Review grant from the Department of
   Veterans Affairs [to D.L.V.].
CR Ackerman BH, 1997, J PHARMACOL EXP THER, V282, P603
   [Anonymous], [No title captured]
   Bocciardi R, 2007, HUM MUTAT, V28, P724, DOI 10.1002/humu.20511
   BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665
   Chusho H, 2001, P NATL ACAD SCI USA, V98, P4016, DOI 10.1073/pnas.071389098
   CORY AH, 1991, CANCER COMMUN, V3, P207, DOI 10.3727/095535491820873191
   Daggubati S, 1997, CARDIOVASC RES, V36, P246, DOI 10.1016/S0008 6363(97)00164 8
   HAGIWARA H, 1994, J BIOL CHEM, V269, P10729
   Hagiwara H, 1996, AM J PHYSIOL CELL PH, V270, pC1311, DOI 10.1152/ajpcell.1996.270.5.C1311
   HARRIS SA, 1995, J BONE MINER RES, V10, P178
   Kalra PR, 2001, EUR HEART J, V22, P997, DOI 10.1053/euhj.2000.2395
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Mericq V, 2000, PEDIATR RES, V47, P189, DOI 10.1203/00006450 200002000 00007
   Miyazawa T, 2002, ENDOCRINOLOGY, V143, P3604, DOI 10.1210/en.2002 220307
   Murakami S, 2004, GENE DEV, V18, P290, DOI 10.1101/gad.1179104
   NAKAO K, 1986, EUR J CLIN PHARMACOL, V31, P101, DOI 10.1007/BF00870995
   Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191
   Ozasa A, 2005, BONE, V36, P1056, DOI 10.1016/j.bone.2005.03.006
   Pfeifer A, 1996, SCIENCE, V274, P2082, DOI 10.1126/science.274.5295.2082
   RUBIN JE, 2009, KELLYS TXB RHEUMATOL, P71
   Suda M, 1996, BIOCHEM BIOPH RES CO, V223, P1, DOI 10.1006/bbrc.1996.0836
   Sun Y., 2007, J CANC MOL, V3, P113
   Sun Y, 2007, ANTICANCER RES, V27, P1387
   Sun Y, 2006, ANTICANCER RES, V26, P3217
   Tamura N, 2004, P NATL ACAD SCI USA, V101, P17300, DOI 10.1073/pnas.0407894101
   Teixeira CC, 2008, DEV BIOL, V319, P171, DOI 10.1016/j.ydbio.2008.04.031
   Tsuji T, 2005, J BIOL CHEM, V280, P14288, DOI 10.1074/jbc.C500024200
   Vesely DL, 2003, AM J PHYSIOL RENAL, V285, pF167, DOI 10.1152/ajprenal.00259.2002
   VESELY DL, 1994, CIRCULATION, V90, P1129, DOI 10.1161/01.CIR.90.3.1129
   YANDLE TG, 1986, LIFE SCI, V38, P1827, DOI 10.1016/0024 3205(86)90137 2
   Yasoda A, 2004, NAT MED, V10, P80, DOI 10.1038/nm971
   Yasoda A, 1998, J BIOL CHEM, V273, P11695, DOI 10.1074/jbc.273.19.11695
   Yoder AR, 2008, PEPTIDES, V29, P1575, DOI 10.1016/j.peptides.2008.04.020
NR 33
TC 12
Z9 15
U1 0
U2 4
PU INT PEDIATRIC RESEARCH FOUNDATION, INC
PI BALTIMORE
PA 351 W CAMDEN ST, BALTIMORE, MD 21201 2436 USA
SN 0031 3998
J9 PEDIATR RES
JI Pediatr. Res.
PD NOV
PY 2010
VL 68
IS 5
BP 405
EP 408
PG 4
WC Pediatrics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pediatrics
GA 670GR
UT WOS:000283409700007
PM 20613683
OA Bronze
DA 2025 08 17
ER

PT J
AU Tal, N
   Rudnick Glick, S
   Margel, S
AF Tal, Nimrod
   Rudnick Glick, Safra
   Margel, Shlomo
TI Novel bisphosphonates near infrared fluorescent and non fluorescent
   nanoparticles of narrow size distribution for bone targeting
SO POLYMER
LA English
DT Article
DE Bisphosphonates; Calcium targeting; Nanoparticles
ID DRUG DELIVERY; POLYMERIZATION; OSTEOPOROSIS; MECHANISMS; RELEASE; ACID)
AB Bisphosphonates (BPs) are a group of organophosphorus compounds which are used in the treatment of various bone related diseases. BPs possess a high affinity to the calcium in bone and thus can be used for bone targeting. Nanoparticles (NPs) are being developed as in vivo targeted drug delivery systems. In this article, we report the synthesis and characterization of a new bisphosphonate vinylic monomer MAGlu  BP (methacrylate glutamate bisphosphonate) prepared by interacting methacryloyl chloride with gGlu BP. Non fluorescent crosslinked bisphosphonate NPs of narrow size distribution were then prepared by dispersion co polymerization of MA Glu BP with a vinylic monomer containing primary amino group, N (3 aminopropyl) methacrylamide (APMA) and a crosslinker vinylic monomer, tetra ethylene glycol diacrylate (TTEGDA). Near infra red (NIR) fluorescent crosslinked bisphosphonate NPs were then prepared by covalent conjugation of the NIR dye Cy 7 to the primary amino groups belonging to the APMA monomeric units of the non fluorescent bisphosphonate NPs. The affinity of the poly(MA Glu BP) NPs to calcium was illustrated by interacting the NIR fluorescent poly(MA Glu BP) NPs with hydroxyapatite. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Tal, Nimrod; Rudnick Glick, Safra; Margel, Shlomo] Bar Ilan Univ, Inst Nanotechnol & Adv Mat, Dept Chem, IL 52900 Ramat Gan, Israel.
C3 Bar Ilan University
RP Margel, S (通讯作者)，Bar Ilan Univ, Inst Nanotechnol & Adv Mat, Dept Chem, IL 52900 Ramat Gan, Israel.
EM nimrodxtal@gmail.com; safrar@gmail.com; shlomo.margel@biu.ac.il
RI Rudnick Glick, Safra/AAS 6529 2021
OI Rudnick Glick, Safra/0000 0001 6082 3779
CR Amiot CL, 2008, SENSORS BASEL, V8, P3082, DOI 10.3390/s8053082
   Askinadze N, 2013, POLYMER, V54, P2926, DOI 10.1016/j.polymer.2013.04.030
   Chmielewska E., 2016, Open Pharm. Sci. J, P56, DOI DOI 10.2174/1874844901603010056
   Clézardin P, 2011, BONE, V49, P66, DOI 10.1016/j.bone.2010.11.017
   Dash S, 2010, ACTA POL PHARM, V67, P217
   De Jong WH, 2008, INT J NANOMED, V3, P133, DOI 10.2147/ijn.s596
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Eastell R, 2011, BONE, V49, P82, DOI 10.1016/j.bone.2011.02.011
   Guenin E, 2004, EUR J ORG CHEM, V2004, P2983
   KULKARNI RK, 1961, J POLYM SCI, V54, P491, DOI 10.1002/pol.1961.1205416014
   Labhasetwar V, 1997, ADV DRUG DELIVER REV, V24, P63, DOI 10.1016/S0169 409X(96)00483 8
   Liu YD, 2015, CARBOHYD POLYM, V117, P312, DOI 10.1016/j.carbpol.2014.09.074
   Mahapatro A, 2011, J NANOBIOTECHNOL, V9, DOI 10.1186/1477 3155 9 55
   Miller PD, 2011, BONE, V49, P77, DOI 10.1016/j.bone.2010.12.024
   Owens G, 2007, AM J MANAG CARE, V13, pS290
   Reid IR, 2011, BONE, V49, P89, DOI 10.1016/j.bone.2010.09.002
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Rudnick Glick S, 2016, J NANOBIOTECHNOL, V14, DOI 10.1186/s12951 016 0233 6
   Rudnick  Glick S., 2014, JSM NANOTECHNOL NANO, V2, P1022
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Wang W, 2011, BIOMACROMOLECULES, V12, P2466, DOI 10.1021/bm200668n
   Xu QY, 2000, TETRAHEDRON ASYMMETR, V11, P2309, DOI 10.1016/S0957 4166(00)00193 2
NR 23
TC 3
Z9 3
U1 0
U2 21
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0032 3861
EI 1873 2291
J9 POLYMER
JI Polymer
PD DEC 6
PY 2017
VL 132
BP 188
EP 192
DI 10.1016/j.polymer.2017.11.003
PG 5
WC Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Polymer Science
GA FN5JD
UT WOS:000416042500021
DA 2025 08 17
ER

PT J
AU Yang, N
   Zhang, X
   Li, LF
   Xu, TT
   Li, MH
   Zhao, Q
   Yu, JL
   Wang, J
   Liu, ZH
AF Yang, Nan
   Zhang, Xiao
   Li, Lingfeng
   Xu, Tongtong
   Li, Meihui
   Zhao, Qi
   Yu, Jinling
   Wang, Jue
   Liu, Zhihui
TI Ginsenoside Rc Promotes Bone Formation in Ovariectomy Induced
   Osteoporosis In Vivo and Osteogenic Differentiation In Vitro
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE bone formation; ginsenoside Rc; osteoporosis; Wnt signaling pathway
ID PANAX GINSENG; MC3T3 E1 CELLS; WNT; ACTIVATION; MINERALIZATION;
   PATHWAYS; CATENIN; KINASE; PROLIFERATION; STIMULATION
AB Ginsenoside Rc is one of the active components used in traditional Chinese medicine. We aim to explore how ginsenoside Rc can be used in the treatment of osteoporosis. Micro CT demonstrated that the treatment of ovariectomized (OVX) mice with ginsenoside Rc significantly inhibited the decrease in bone mineral density, bone volumetric fraction, and trabecular number, and the increase in trabecular separation. Histological staining, qRT PCR, and Western blot demonstrated that ginsenoside Rc enhances the microstructure of trabecular bone, and promotes the expression of bone formation related genes. Alkaline phosphatase (ALP) staining, Alizarin Red staining, qRT PCR, and Western blotting demonstrated that ginsenoside Rc dose dependently promoted the osteogenic differentiation of MC3T3 E1 cells. A ginsenoside Rc induced increase in the expression of beta catenin, p GSK 3 beta, collagen 1, ALP, and RUNX 2 family transcription factor 2 was significantly attenuated upon 10 mu M XAV 939 treatment, while the decrease in the expression of GSK 3 beta and p beta catenin was significantly enhanced. Ginsenoside Rc promotes bone formation in ovariectomy induced osteoporosis in vivo and promotes osteogenic differentiation in vitro via the Wnt/beta catenin signaling pathway.
C1 [Yang, Nan; Zhang, Xiao; Li, Lingfeng; Xu, Tongtong; Li, Meihui; Zhao, Qi; Yu, Jinling; Wang, Jue; Liu, Zhihui] Jilin Univ, Dept Stomatol, Changchun 130000, Peoples R China.
C3 Jilin University
RP Liu, ZH (通讯作者)，Jilin Univ, Dept Stomatol, Changchun 130000, Peoples R China.
EM yangnan19@mails.jlu.edu.cn; xiaozhang19@mails.jlu.edu.cn;
   lilf19@mails.jlu.edu.cn; xtt19@mails.jlu.edu.cn;
   limh19@mails.jlu.edu.cn; zhaoqi20@mails.jlu.edu.cn;
   yujl20@mails.jlu.edu.cn; wangjue19@mails.jlu.edu.cn; liu_zh@jlu.edu.cn
RI Mei Hui, Li/JHU 9181 2023; 志辉, 刘/HRC 8063 2023
OI Yang, Nan/0000 0003 2731 6366; Liu, Zhihui/0000 0001 8650 9104
FU Jilin University [101832020DJX087]; Science and Technology Research
   Project of Jilin Provincial Department of Education [JJKH20211212KJ];
   Jilin Provincial Development and Reform Commission [2021C043 2]; Jilin
   Provincial Department of Finance Science and Technology Project jcsz
   [2021893 9]
FX This research was funded by Jilin University 2020 Doctoral
   Interdisciplinary Research Funding Program, grant number
   101832020DJX087; 2021 Science and Technology Research Project of Jilin
   Provincial Department of Education, grant number JJKH20211212KJ; Jilin
   Provincial Department of Finance Science and Technology Project jcsz
   grant number 2021893 9; Jilin Provincial Development and Reform
   Commission 2021 Industrial Technology Research and Development Project
   grant number 2021C043 2.
CR [Anonymous], 2016, J Midwifery Womens Health, V61, P289, DOI 10.1111/jmwh.12460
   Banu J, 2012, NUTR REV, V70, P22, DOI 10.1111/j.1753 4887.2011.00451.x
   Chu Y, 2013, J CHROMATOGR B, V919, P75, DOI 10.1016/j.jchromb.2012.12.022
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Cosman F, 2000, OSTEOPOROSIS INT, V11, P271, DOI 10.1007/s001980050292
   Edwards MH, 2012, NAT REV ENDOCRINOL, V8, P512, DOI 10.1038/nrendo.2012.131
   Ettinger B, 2018, MENOPAUSE, V25, P1191, DOI 10.1097/GME.0000000000001216
   Fitzpatrick Lorraine A., 2006, Arq Bras Endocrinol Metab, V50, P705, DOI 10.1590/S0004 27302006000400016
   Fu BW, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01394
   Gordon MD, 2006, J BIOL CHEM, V281, P22429, DOI 10.1074/jbc.R600015200
   Gregory CA, 2005, ANN NY ACAD SCI, V1049, P97, DOI 10.1196/annals.1334.010
   Guicheux J, 2003, J BONE MINER RES, V18, P2060, DOI 10.1359/jbmr.2003.18.11.2060
   HIURA K, 1991, ENDOCRINOLOGY, V128, P1630, DOI 10.1210/endo 128 3 1630
   Hua Y, 2018, J BIOL CHEM, V293, P19710, DOI 10.1074/jbc.RA118.004434
   Huang Q, 2014, BONE, V66, P306, DOI 10.1016/j.bone.2014.06.010
   Hwang YH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030912
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   Kestler HA, 2008, PHILOS T R SOC B, V363, P1333, DOI 10.1098/rstb.2007.2251
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kieslinger M, 2005, DEV CELL, V9, P757, DOI 10.1016/j.devcel.2005.10.009
   Kim DY, 2012, FITOTERAPIA, V83, P215, DOI 10.1016/j.fitote.2011.10.017
   Kim DY, 2011, BMB REP, V44, P659, DOI 10.5483/BMBRep.2011.44.10.659
   Kim DY, 2011, INT J MOL MED, V28, P753, DOI 10.3892/ijmm.2011.750
   Kodama H.A., 1981, J ORAL BIOL, V23, P899, DOI DOI 10.2330/JORALBIOSCI1965.23.899
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Lee HY, 2015, J FUNCT FOODS, V13, P192, DOI 10.1016/j.jff.2014.12.039
   Lee JH, 2014, EUR J PHARMACOL, V724, P145, DOI 10.1016/j.ejphar.2013.12.035
   Lee MS, 2010, J ETHNOPHARMACOL, V127, P771, DOI 10.1016/j.jep.2009.11.022
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Lerner UH, 2015, J INTERN MED, V277, P630, DOI 10.1111/joim.12368
   Lu YY, 2017, NAT MED, V23, P1331, DOI 10.1038/nm.4424
   [Luo Zhijun 罗志军], 2013, [中国组织工程研究, Chinese Journal of Tissue Engineering Research], V17, P5799
   Maeda K, 2013, J MOL MED, V91, P15, DOI 10.1007/s00109 012 0974 0
   Oh YR, 2017, MOL MED REP, V16, P2907, DOI 10.3892/mmr.2017.6943
   Papapoulos S, 2008, NAT CLIN PRACT ENDOC, V4, P514, DOI 10.1038/ncpendmet0941
   Pochampally RR, 2005, GENE THER, V12, P1119, DOI 10.1038/sj.gt.3302514
   Price MA, 2006, GENE DEV, V20, P399, DOI 10.1101/gad.1394306
   Rauch F, 2004, LANCET, V363, P1377, DOI 10.1016/S0140 6736(04)16051 0
   Sakkers R, 2004, LANCET, V363, P1427, DOI 10.1016/S0140 6736(04)16101 1
   Schilling T, 2014, J STEROID BIOCHEM, V139, P252, DOI 10.1016/j.jsbmb.2012.12.006
   Serigano K, 2010, J ORTHOP RES, V28, P1267, DOI 10.1002/jor.21147
   Shi YC, 2007, BONE, V41, P87, DOI 10.1016/j.bone.2007.04.174
   Shin BK, 2015, J GINSENG RES, V39, P287, DOI 10.1016/j.jgr.2014.12.005
   Taurin S, 2006, J BIOL CHEM, V281, P9971, DOI 10.1074/jbc.M508778200
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   THOMPSON DD, 1995, BONE, V17, pS125, DOI 10.1016/8756 3282(95)00285 L
   Tomkinson A, 1997, J CLIN ENDOCR METAB, V82, P3128, DOI 10.1210/jc.82.9.3128
   Wagner Eric R, 2011, Curr Mol Pharmacol, V4, P14
   Wan Y, 2021, J GINSENG RES, V45, P617, DOI 10.1016/j.jgr.2021.03.001
   Wang Y, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/4206392
   Yu FY, 2020, STEM CELLS, V38, P1020, DOI 10.1002/stem.3192
   Yu T, 2017, J GINSENG RES, V41, P127, DOI 10.1016/j.jgr.2016.02.001
   Yu T, 2016, AM J CHINESE MED, V44, P595, DOI 10.1142/S0192415X16500336
   Zhao ZR, 2005, MOL THER, V12, P247, DOI 10.1016/j.ymthe.2005.03.009
   ZHOU HY, 1995, CALCIFIED TISSUE INT, V56, P403, DOI 10.1007/BF00301610
   Zhou W, 2018, J GINSENG RES, V42, P199, DOI 10.1016/j.jgr.2017.03.004
NR 56
TC 23
Z9 26
U1 6
U2 57
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUN
PY 2022
VL 23
IS 11
AR 6187
DI 10.3390/ijms23116187
PG 22
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 1Z3JQ
UT WOS:000808725100001
PM 35682866
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Mahatma, MM
   Jayasuriya, RL
   Hughes, D
   Hoggard, N
   Buckley, SC
   Gordon, A
   Hamer, AJ
   Tomouk, MW
   Kerry, RM
   Eastell, R
   Wilkinson, JM
AF Mahatma, Mohit M.
   Jayasuriya, Raveen L.
   Hughes, David
   Hoggard, Nigel
   Buckley, Simon C.
   Gordon, Andrew
   Hamer, Andrew J.
   Tomouk, Mohammed W.
   Kerry, Robert M.
   Eastell, Richard
   Wilkinson, Jeremy M.
TI Effect of denosumab on osteolytic lesion activity after total hip
   arthroplasty: a single centre, randomised, double blind,
   placebo controlled, proof of concept trial
SO LANCET RHEUMATOLOGY
LA English
DT Article
ID STRUCTURAL DAMAGE; BONE TURNOVER; TISSUE; RANKL; FIBROBLASTS; FRACTURES;
   INTERFACE; ARTHRITIS; MEMBRANE
AB Background Osteolysis causes recurrent pain and disability after total hip arthroplasty. We investigated the effect of the human monoclonal antibody denosumab on osteolytic lesion activity in patients undergoing revision total hip arthroplasty surgery to show the biological proof of concept for a non surgical treatment for the disease.
   Methods We did a phase 2, randomised, double blind, placebo controlled, proof of concept superiority trial at Sheffield Teaching Hospitals, Sheffield, UK. Eligible patients aged 30 years or older and scheduled for revision surgery for symptomatic, radiographically confirmed osteolysis were randomly allocated (1:1) to subcutaneous denosumab (60 mg single dose) or placebo by an independent pharmacist using a random number table. The primary outcome was the between group difference in osteoclast number per mm of bone surface of biopsies taken from the osteolytic membrane bone interface at surgery 8 weeks later, measured by quantitative histomorphometry in all patients who underwent revision surgery. Adverse events were analysed in all randomly assigned participants. This trial is registered with the EU Clinical Trials Register (EudraCT 2011 000541 20).
   Findings Between Dec 12, 2012, and June 24, 2018, 51 patients were assessed for eligibility, of whom 24 were randomly assigned to study treatment. Two patients had their revision surgery cancelled for unrelated reasons, leaving 22 patients (ten in the denosumab group) for analysis of the primary outcome. There were 83% fewer osteoclasts at the osteolysis membrane bone interface in the denosumab versus the placebo group (median 0.05 per mm [IQR 0.11] vs 0.30 mm [0.40], p=0.011). No deaths or treatment related serious adverse events occurred. Seven adverse events, including one severe adverse event, occurred in four (36%) of 11 patients in the denosumab group. In the placebo group ten adverse events, including three severe adverse events, occurred in five (38%) of 13 patients.
   Interpretation To our knowledge, this is the first clinical trial of an investigational drug for osteolysis that shows tissue specific biological efficacy. These results justify the need for future trials that target earlier stage disease to test for clinical efficacy in reducing the need for revision surgery. Copyright (C) 2021 Elsevier Ltd. All rights reserved.
C1 [Mahatma, Mohit M.; Jayasuriya, Raveen L.; Eastell, Richard; Wilkinson, Jeremy M.] Univ Sheffield, Dept Oncol & Metab, Sheffield S10 2RX, S Yorkshire, England.
   [Eastell, Richard; Wilkinson, Jeremy M.] Univ Sheffield, Mellanby Ctr Musculoskeletal Res, Sheffield, S Yorkshire, England.
   [Hoggard, Nigel] Univ Sheffield, Dept Infect Immun & Cardiovasc Dis, Sheffield, S Yorkshire, England.
   [Hughes, David; Buckley, Simon C.; Gordon, Andrew; Hamer, Andrew J.; Tomouk, Mohammed W.; Kerry, Robert M.] Sheffield Teaching Hosp NHS Fdn Trust, Sheffield, S Yorkshire, England.
C3 University of Sheffield; University of Sheffield; University of
   Sheffield; University of Sheffield
RP Wilkinson, JM (通讯作者)，Univ Sheffield, Dept Oncol & Metab, Sheffield S10 2RX, S Yorkshire, England.
EM j.m.wilkinson@sheffield.ac.uk
RI Eastell, Richard/G 5851 2011
OI Mahatma, Mohit/0000 0003 2121 2574
FU Amgen
FX This study was funded by Amgen. Denosumab and placebo were provided by
   Amgen free of charge. We thank all the participants in our trial. We
   thank Angela Green, the study research nurse at Sheffield Teaching
   Hospitals NHS Foundation Trust, for managing the participant study
   visits and doing study related procedures; Orla Gallagher, histology
   technician, for biopsy processing and making the immunohistochemistry
   measurements; Maggie Glover, histology technician, for
   immunohistochemistry staining; and Fatma Gossiel, bone biochemistry
   technician, for assisting with the biochemical marker measurements.
CR [Anonymous], 2004, T ORS
   Aspenberg P, 2011, BONE, V48, P225, DOI 10.1016/j.bone.2010.09.024
   Bone HG, 2017, LANCET DIABETES ENDO, V5, P513, DOI 10.1016/S2213 8587(17)30138 9
   Bone HG, 2011, J CLIN ENDOCR METAB, V96, P972, DOI 10.1210/jc.2010 1502
   Cohen SB, 2008, ARTHRITIS RHEUM, V58, P1299, DOI 10.1002/art.23417
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   DANTONIO J, 1993, CLIN ORTHOP RELAT R, P133
   DANTONIO JA, 1989, CLIN ORTHOP RELAT R, P126
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Evans JT, 2019, LANCET, V393, P647, DOI 10.1016/S0140 6736(18)31665 9
   GOLDRING SR, 1983, J BONE JOINT SURG AM, V65, P575, DOI 10.2106/00004623 198365050 00001
   Goodman SB, 2020, EXPERT REV MED DEVIC, V17, P41, DOI 10.1080/17434440.2020.1702024
   Granchi D, 2006, J BONE JOINT SURG AM, V88A, P1501, DOI 10.2106/JBJS.E.01038
   HARRIS WH, 1969, J BONE JOINT SURG AM, VA 51, P737, DOI 10.2106/00004623 196951040 00012
   Haynes DR, 2001, J BONE JOINT SURG BR, V83B, P902, DOI 10.1302/0301 620X.83B6.10905
   Horiki M, 2004, J BONE MINER METAB, V22, P346, DOI 10.1007/s00774 003 0493 8
   Mandelin J, 2003, J BONE JOINT SURG BR, V85B, P1196, DOI 10.1302/0301 620X.85B8.13311
   National Joint Registry, 2019, 16 ANN REP
   Reid IR, 2010, J BONE MINER RES, V25, P2256, DOI 10.1002/jbmr.149
   Ren WP, 2006, J ORTHOP RES, V24, P1575, DOI 10.1002/jor.20190
   Sabokbar A, 2005, J ORTHOP RES, V23, P511, DOI 10.1016/j.orthres.2004.10.006
   Sakai H, 2002, ANN RHEUM DIS, V61, P103, DOI 10.1136/ard.61.2.103
   Takeuchi T, 2016, ANN RHEUM DIS, V75, P983, DOI 10.1136/annrheumdis 2015 208052
   Tsutsumi R, 2008, J ORTHOP RES, V26, P1340, DOI 10.1002/jor.20620
   Valleala H, 2012, CLIN EXP RHEUMATOL, V30, P114
   Weber M, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/8987104
   Yue J, 2017, ARTHRIT CARE RES, V69, P1156, DOI 10.1002/acr.23133
NR 27
TC 4
Z9 4
U1 1
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2665 9913
J9 LANCET RHEUMATOL
JI Lancet Rheumatol.
PD MAR
PY 2021
VL 3
IS 3
BP E195
EP E203
DI 10.1016/S2665 9913(20)30394 5
EA FEB 2021
PG 9
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA RC2OI
UT WOS:000632643600007
PM 38279382
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Gao, L
   Deng, HJ
   Zhao, HB
   Hirbe, A
   Harding, J
   Ratner, L
   Weilbaecher, K
AF Gao, L
   Deng, HJ
   Zhao, HB
   Hirbe, A
   Harding, J
   Ratner, L
   Weilbaecher, K
TI HTLV 1 Tax transgenic mice develop spontaneous osteolytic bone
   metastases prevented by osteoclast inhibition
SO BLOOD
LA English
DT Article
ID T CELL LEUKEMIA; VIRUS TYPE I; HORMONE RELATED PROTEIN; BREAST CANCER
   CELLS; MULTIPLE MYELOMA; PROSTATE CANCER; ZOLEDRONIC ACID; TUMOR CELLS;
   SKELETAL COMPLICATIONS; GENE EXPRESSION
AB One in 20 carriers of human T cell leukemia virus type 1 (HTLV 1) will develop adult T cell leukemia/lymphoma (ATL), a disease frequently associated with hypercalcemia, bone destruction, and a fatal course refractory to current therapies. Overexpression of the HTLV 1 encoded Tax oncoprotein under the human granzyme B promoter causes large granular lymphocytic leukemia/lymphomas in mice. We found that Tax(+) mice spontaneously developed hypercalcemia, high frequency osteolytic bone metastases, and enhanced osteoclast activity. We evaluated Tax tumors for the production of osteoclast activating factors. Purification of Tax(+) tumor cells and nonmalignant tumor infiltrating lymphocytes demonstrated that each of these populations expressed transcripts for distinct osteoclast activating factors. We then evaluated the effect of osteoclast inhibition on tumor formation. Mice doubly transgenic for Tax and the osteoclast inhibitory factor, osteoprotegerin, were protected from osteolytic bone disease and developed fewer soft tissue tumors. Likewise, osteoclast inhibition with bone targeted zoledronic acid protected Tax(+) mice from bone and soft tissue tumors and prolonged survival. Tax(+) mice represent the first animal model of high penetrance spontaneous osteolytic bone metastasis and underscore the critical role of nonmalignant host cells recruited by tumor cells in the process of cancer progression and metastasis.
C1 Washington Univ, Sch Med, Dept Med, Div Oncol, St Louis, MO 63110 USA.
   Washington Univ, Sch Med, Dept Cellular Biol & Physiol, Div Oncol, St Louis, MO 63110 USA.
   Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.
C3 Washington University (WUSTL); Washington University (WUSTL); Washington
   University (WUSTL)
RP Weilbaecher, K (通讯作者)，Washington Univ, Sch Med, Dept Med, Div Oncol, 660 S Euclid Ave,Box 8069, St Louis, MO 63110 USA.
EM kweilbae@im.wustl.edu
RI ; Zhao, Haibo/ABG 9729 2021
OI Ratner, Lee/0000 0003 2744 7294; ZHAO, HAIBO/0000 0003 0836 7555; Gao,
   Ling/0000 0001 7320 1442
CR Anzai S, 2002, J DERMATOL, V29, P644, DOI 10.1111/j.1346 8138.2002.tb00195.x
   ARGUELLO F, 1988, CANCER RES, V48, P6876
   Azran Inbal, 2004, Retrovirology, V1, P20
   Berenson JR, 1998, J CLIN ONCOL, V16, P593, DOI 10.1200/JCO.1998.16.2.593
   Bex F, 1998, METHODS, V16, P83, DOI 10.1006/meth.1998.0646
   Cheng YY, 2004, CALCIFIED TISSUE INT, V75, P71, DOI 10.1007/s00223 004 0120 2
   Choong PFM, 2003, CLIN ORTHOP RELAT R, pS19, DOI 10.1097/01.blo.0000093839.72468.da
   Croucher PI, 2003, J BONE MINER RES, V18, P482, DOI 10.1359/jbmr.2003.18.3.482
   Diel IJ, 1996, JNCI J NATL CANCER I, V88, P1652, DOI 10.1093/jnci/88.22.1652
   FRANCHINI G, 1995, BAILLIERE CLIN HAEM, V8, P131, DOI 10.1016/S0950 3536(05)80235 5
   Gallwitz WE, 2002, J CLIN INVEST, V110, P1559, DOI 10.1172/JCI200211936
   Gober HJ, 2003, J EXP MED, V197, P163, DOI 10.1084/jem.20021500
   Grisolano JL, 2003, P NATL ACAD SCI USA, V100, P9506, DOI 10.1073/pnas.1531730100
   GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057
   Grossman WJ, 1996, J ACQ IMMUN DEF SYND, V13, pS162, DOI 10.1097/00042560 199600001 00025
   Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947
   Hortobagyi GN, 1996, NEW ENGL J MED, V335, P1785, DOI 10.1056/NEJM199612123352401
   Imada K, 1996, JPN J CANCER RES, V87, P887, DOI 10.1111/j.1349 7006.1996.tb02116.x
   ISHIBASHI K, 1991, BLOOD, V77, P2451
   IWAKURA Y, 1991, SCIENCE, V253, P1026, DOI 10.1126/science.1887217
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Kehn K, 2005, ONCOGENE, V24, P525, DOI 10.1038/sj.onc.1208105
   Kitazawa R, 2002, BIOCHEM BIOPH RES CO, V290, P650, DOI 10.1006/bbrc.2001.6251
   Klezovitch O, 2004, CANCER CELL, V6, P185, DOI 10.1016/j.ccr.2004.07.008
   KORBER B, 1991, J VIROL, V65, P5471, DOI 10.1128/JVI.65.10.5471 5476.1991
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Lane NE, 2005, J BONE MINER RES, V20, P58, DOI 10.1359/JBMR.041017
   Lipton A, 2000, CANCER, V88, P1082, DOI 10.1002/(SICI)1097 0142(20000301)88:5<1082::AID CNCR20>3.0.CO;2 Z
   Liu YX, 2002, LEUKEMIA RES, V26, P561, DOI 10.1016/S0145 2126(01)00169 2
   Mahieux R, 2000, AIDS RES HUM RETROV, V16, P1677, DOI 10.1089/08892220050193137
   Mariani S, 2005, LEUKEMIA, V19, P664, DOI 10.1038/sj.leu.2403693
   Mitra Kaushik S, 2004, BLOOD, V104, P3305, DOI 10.1182/blood 2004 01 0266
   Mitra Kaushik S, 2004, BLOOD, V104, P802, DOI 10.1182/blood 2003 11 3967
   MORI N, 1994, BLOOD, V84, P2904
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nicot C, 2000, BLOOD, V96, P275, DOI 10.1182/blood.V96.1.275.013k43_275_281
   Nosaka K, 2002, BLOOD, V99, P634, DOI 10.1182/blood.V99.2.634
   OHUCHIDA T, 1985, SKELETAL RADIOL, V14, P194, DOI 10.1007/BF00355562
   Okada Y, 2004, J BONE MINER RES, V19, P1105, DOI 10.1359/JBMR.040314
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Pise Masison CA, 2005, FRONT BIOSCI LANDMRK, V10, P919, DOI 10.2741/1586
   Portis T, 2001, J VIROL, V75, P2185, DOI 10.1128/JVI.75.5.2185 2193.2001
   Powles T, 2002, J CLIN ONCOL, V20, P3219, DOI 10.1200/JCO.2002.11.080
   RADL J, 1988, AM J PATHOL, V132, P593
   Ratner L, 2004, FRONT BIOSCI LANDMRK, V9, P2852, DOI 10.2741/1442
   Reszka Alfred A, 2003, Curr Rheumatol Rep, V5, P65, DOI 10.1007/s11926 003 0085 6
   Rischer M, 2004, BRIT J HAEMATOL, V126, P583, DOI 10.1111/j.1365 2141.2004.05077.x
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Roodman GD, 1997, CANCER, V80, P1557, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1557::AID CNCR5>3.3.CO;2 K
   Rosol TJ, 2003, CANCER AM CANCER SOC, V97, P748, DOI 10.1002/cncr.11150
   RUDDLE NH, 1993, VIROLOGY, V197, P196, DOI 10.1006/viro.1993.1580
   Saad F, 2002, SEMIN ONCOL, V29, P19, DOI 10.1053/sonc.2002.37418
   Saggioro D, 1997, J ACQ IMMUN DEF SYND, V14, P272, DOI 10.1097/00042560 199703010 00012
   Santini D, 2003, ANN ONCOL, V14, P1468, DOI 10.1093/annonc/mdg401
   Shuh M, 2000, J VIROL, V74, P11394, DOI 10.1128/JVI.74.23.11394 11397.2000
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Sohara Y, 2005, CANCER RES, V65, P1129, DOI 10.1158/0008 5472.CAN 04 2853
   Thompson K, 2004, J BONE MINER RES, V19, P278, DOI 10.1359/JBMR.0301230
   Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15
   UDAGAWA N, 1989, ENDOCRINOLOGY, V125, P1805, DOI 10.1210/endo 125 4 1805
   WANO Y, 1987, J CLIN INVEST, V80, P911, DOI 10.1172/JCI113152
   WATANABE T, 1990, J EXP MED, V172, P759, DOI 10.1084/jem.172.3.759
   WEBER J, 1989, T ROY SOC TROP MED H, V83, P729, DOI 10.1016/0035 9203(89)90310 6
   Wilhelm M, 2003, BLOOD, V102, P200, DOI 10.1182/blood 2002 12 3665
   Winter SF, 2003, PROSTATE CANCER P D, V6, P204, DOI 10.1038/sj.pcan.4500655
   Yamano Y, 2002, BLOOD, V99, P88, DOI 10.1182/blood.V99.1.88
   Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523
   Yoneda Toshiyuki, 2000, Cancer, V88, P2979, DOI 10.1002/1097 0142(20000615)88:12+<2979::AID CNCR13>3.0.CO;2 U
   Yu JS, 2003, CANCER RES, V63, P6170
NR 70
TC 60
Z9 71
U1 0
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0006 4971
EI 1528 0020
J9 BLOOD
JI Blood
PD DEC 15
PY 2005
VL 106
IS 13
BP 4294
EP 4302
DI 10.1182/blood 2005 04 1730
PG 9
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA 993AU
UT WOS:000233925900046
PM 16118323
OA Green Published
DA 2025 08 17
ER

PT J
AU Chlebek, C
   Moore, JA
   Ross, FP
   van der Meulen, MCH
AF Chlebek, Carolyn
   Moore, Jacob A.
   Ross, F. Patrick
   van der Meulen, Marjolein C. H.
TI Molecular Identification of Spatially Distinct Anabolic Responses to
   Mechanical Loading in Murine Cortical Bone
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE BIOMECHANICS; MOLECULAR PATHWAYS REMODELING; CELL; TISSUE
   SIGNALING TRANSCRIPTION FACTORS; OSTEOPOROSIS; PRECLINICAL STUDIES
ID POSTMENOPAUSAL WOMEN; TIBIAL COMPRESSION; CANCELLOUS BONE; III COLLAGEN;
   RNA SEQ; OSTEOCYTE; GENE; EXPRESSION; PROTEIN; CELLS
AB Osteoporosis affects over 200 million women worldwide, one third of whom are predicted to suffer from an osteoporotic fracture in their lifetime. The most promising anabolic drugs involve administration of expensive antibodies. Because mechanical loading stimulates bone formation, our current data, using a mouse model, replicates the anabolic effects of loading in humans and may identify novel pathways amenable to oral treatment. Murine tibial compression produces axially varying deformations along the cortical bone, inducing highest strains at the mid diaphysis and lowest at the metaphyseal shell. To test the hypothesis that load induced transcriptomic responses at different axial locations of cortical bone would vary as a function of strain magnitude, we loaded the left tibias of 10 week old female C57Bl/6 mice in vivo in compression, with contralateral limbs as controls. Animals were euthanized at 1, 3, or 24 hours post loading or loaded for 1 week (n = 4 5/group). Bone marrow and cancellous bone were removed, cortical bone was segmented into the metaphyseal shell, proximal diaphysis, and mid diaphysis, and load induced differential gene expression and enriched biological processes were examined for the three segments. At each time point, the mid diaphysis (highest strain) had the greatest transcriptomic response. Similarly, biological processes regulating bone formation and turnover increased earlier and to the greatest extent at the mid diaphysis. Higher strain induced greater levels of osteoblast and osteocyte genes, whereas expression was lower in osteoclasts. Among the top differentially expressed genes at 24 hours post loading, 17 had known functions in bone biology, of which 12 were present only in osteoblasts, 3 exclusively in osteoclasts, and 2 were present in both cell types. Based on these results, we conclude that murine tibial loading induces spatially unique transcriptomic responses correlating with strain magnitude in cortical bone. (c) 2022 American Society for Bone and Mineral Research (ASBMR).
C1 [Chlebek, Carolyn; van der Meulen, Marjolein C. H.] Cornell Univ, Meinig Sch Biomed Engn, 121D Weill Hall, Ithaca, NY 14853 USA.
   [Moore, Jacob A.] Cornell Univ, Coll Agr & Life Sci, Ithaca, NY 14853 USA.
   [Ross, F. Patrick] FPR Sci Consulting, Amherst, MA USA.
   [van der Meulen, Marjolein C. H.] Hosp Special Surg, New York, NY 10021 USA.
C3 Cornell University; Cornell University
RP van der Meulen, MCH (通讯作者)，Cornell Univ, Meinig Sch Biomed Engn, 121D Weill Hall, Ithaca, NY 14853 USA.
EM mcv3@cornell.edu
RI van der Meulen, Marjolein/D 1549 2010
FU NSF [1636012]; NSF GRFP [DGE 1650441]; GAANN [P200A150273 J];
   Directorate For Engineering; Div Of Civil, Mechanical, & Manufact Inn
   [1636012] Funding Source: National Science Foundation
FX Funding was provided by NSF grant no. 1636012, NSF GRFP (DGE 1650441),
   and GAANN P200A150273 J. The sponsors had no role in the writing or
   submission of the manuscript.
CR Armstrong VJ, 2007, J BIOL CHEM, V282, P20715, DOI 10.1074/jbc.M703224200
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Aubin JE, 1998, BIOCHEM CELL BIOL, V76, P899, DOI 10.1139/bcb 76 6 899
   Ayturk U, 2019, CURR OSTEOPOROS REP, V17, P178, DOI 10.1007/s11914 019 00517 x
   Birkhold AI, 2017, CALCIFIED TISSUE INT, V100, P255, DOI 10.1007/s00223 016 0217 4
   Canelón SP, 2019, CALCIFIED TISSUE INT, V105, P660, DOI 10.1007/s00223 019 00603 3
   Carbon S, 2021, NUCLEIC ACIDS RES, V49, pD325, DOI 10.1093/nar/gkaa1113
   Chan WL., 2018, PLOS GENET, V14, P1
   Chermside Scabbo CJ, 2020, J BONE MINER RES, V35, P1751, DOI 10.1002/jbmr.4031
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Croft D, 2014, NUCLEIC ACIDS RES, V42, pD472, DOI [10.1093/nar/gkt1102, 10.1093/nar/gkz1031]
   Deng WW, 2015, INT J BIOCHEM CELL B, V65, P32, DOI 10.1016/j.biocel.2015.05.019
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Dowrey T., 2017, PHYSIOL BEHAV, V176, P139
   Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511
   Feng JQ, 2003, J DENT RES, V82, P776, DOI 10.1177/154405910308201003
   Fritton JC, 2005, BONE, V36, P1030, DOI 10.1016/j.bone.2005.02.013
   Fujita K, 2012, NAT MED, V18, P589, DOI 10.1038/nm.2659
   Fujiwara T, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.86330
   Galea GL, 2017, GENE, V599, P36, DOI 10.1016/j.gene.2016.11.006
   Galea GL, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00052
   Gennari L, 2016, EXPERT OPIN PHARMACO, V17, P1141, DOI 10.1080/14656566.2016.1176147
   GERSTENFELD LC, 1987, DEV BIOL, V122, P49, DOI 10.1016/0012 1606(87)90331 9
   Ghosh M., 2021, SCI REP UK, V11, P1
   Greenblatt MB, 2019, J BONE MINER RES, V34, P1207, DOI 10.1002/jbmr.3802
   Guo DY, 2010, PROTEOMICS, V10, P3688, DOI 10.1002/pmic.201000306
   Holguin N, 2016, J BONE MINER RES, V31, P2215, DOI 10.1002/jbmr.2900
   Huang J, 2017, JBMR PLUS, V1, P86, DOI 10.1002/jbm4.10015
   Inoue D, 2004, J BIOL CHEM, V279, P49795, DOI 10.1074/jbc.M404096200
   Javaheri B, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax8301
   JONES HH, 1977, J BONE JOINT SURG AM, V59, P204, DOI 10.2106/00004623 197759020 00012
   Kelly NH, 2016, BONE, V86, P22, DOI 10.1016/j.bone.2016.02.007
   Kelly NH, 2014, BONE, V68, P1, DOI 10.1016/j.bone.2014.07.022
   Kimura H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003174
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Lemma S, 2016, INT J BIOCHEM CELL B, V79, P168, DOI 10.1016/j.biocel.2016.08.034
   Lewis KJ, 2017, P NATL ACAD SCI USA, V114, P11775, DOI 10.1073/pnas.1707863114
   Li Z, 2014, BBA GEN SUBJECTS, V1840, P2112, DOI 10.1016/j.bbagen.2014.03.008
   Looker AC, 2017, OSTEOPOROSIS INT, V28, P1979, DOI 10.1007/s00198 017 3996 1
   LOVE MI, 2014, GENOME BIOL, V15, DOI DOI 10.1186/S13059 014 0550 8
   Lv X, 2021, ELIFE, V10, DOI 10.7554/eLife.70324
   Lynch ME, 2011, BONE, V49, P439, DOI 10.1016/j.bone.2011.05.017
   Lynch ME, 2010, J APPL PHYSIOL, V109, P685, DOI 10.1152/japplphysiol.00210.2010
   Maehata Y, 2007, MATRIX BIOL, V26, P371, DOI 10.1016/j.matbio.2007.01.005
   Main RP, 2020, J ORTHOP RES, V38, P233, DOI 10.1002/jor.24466
   Main RP, 2014, J EXP BIOL, V217, P1775, DOI 10.1242/jeb.085522
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   MARK MP, 1987, J BONE MINER RES, V2, P337, DOI 10.1002/jbmr.5650020411
   Martyn St James M, 2010, J BONE MINER METAB, V28, P251, DOI 10.1007/s00774 009 0139 6
   Matsuoka K, 2018, J BONE MINER RES, V33, P1500, DOI 10.1002/jbmr.3436
   Mattson AM, 2019, J BIOL CHEM, V294, P11772, DOI 10.1074/jbc.RA119.007660
   Maurice SB, 2014, OSTEOPOROSIS INT, V25, P1975, DOI 10.1007/s00198 014 2700 y
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Miller PD, 2016, JAMA J AM MED ASSOC, V316, P722, DOI 10.1001/jama.2016.11136
   MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252
   Morse A, 2018, J BONE MINER RES, V33, P486, DOI 10.1002/jbmr.3330
   Nampei A, 2004, J BONE MINER METAB, V22, P176, DOI 10.1007/s00774 003 0468 9
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Patel TK, 2014, J BIOMECH, V47, P451, DOI 10.1016/j.jbiomech.2013.10.052
   Razi H, 2015, ACTA BIOMATER, V13, P301, DOI 10.1016/j.actbio.2014.11.021
   Robinson JA, 2006, J BIOL CHEM, V281, P31720, DOI 10.1074/jbc.M602308200
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Robling AG, 2020, ANNU REV PHYSIOL, V82, P485, DOI 10.1146/annurev physiol 021119 034332
   Rubin MR, 2003, CLIN GERIATR MED, V19, P415, DOI 10.1016/S0749 0690(02)00074 5
   San Cheong V, 2020, ACTA BIOMATER, V116, P302, DOI 10.1016/j.actbio.2020.09.011
   Schmidt K, 2005, J CELL BIOL, V168, P899, DOI 10.1083/jcb.200408013
   Shi Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 02171 2
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Takeshita S, 2013, J CLIN INVEST, V123, P3914, DOI 10.1172/JCI69493
   Tandonnet S, 2017, GENOM DATA, V11, P9, DOI 10.1016/j.gdata.2016.11.002
   Troy KL, 2020, J BONE MINER RES, V35, P1300, DOI 10.1002/jbmr.3999
   van Dijk FS, 2020, AM J HUM GENET, V107, P989, DOI 10.1016/j.ajhg.2020.09.009
   Volk SW, 2014, CALCIFIED TISSUE INT, V94, P621, DOI 10.1007/s00223 014 9843 x
   Wei JW, 2015, CELL, V161, P1576, DOI 10.1016/j.cell.2015.05.029
   Westbroek I, 2002, J BONE MINER RES, V17, P845, DOI 10.1359/jbmr.2002.17.5.845
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
   Winters Stone KM, 2006, BONE, V39, P1203, DOI 10.1016/j.bone.2006.06.005
   Yan Y, 2009, J CELL SCI, V122, P3566, DOI 10.1242/jcs.051904
   Zaman G, 2010, BONE, V46, P628, DOI 10.1016/j.bone.2009.10.021
   Zhang W, 2021, J BONE MINER RES, V36, P2017, DOI 10.1002/jbmr.4394
   Zhao XF, 2016, SCI REP UK, V6, DOI 10.1038/srep19296
NR 84
TC 10
Z9 13
U1 2
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD NOV
PY 2022
VL 37
IS 11
BP 2277
EP 2287
DI 10.1002/jbmr.4686
EA SEP 2022
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 6S6LX
UT WOS:000854610900001
PM 36054133
DA 2025 08 17
ER

PT J
AU Zhou, WY
   Hao, MZ
   Du, XL
   Chen, KX
   Wang, GW
   Yang, JL
AF Zhou, Wenya
   Hao, Mengze
   Du, Xiaoling
   Chen, Kexin
   Wang, Guowen
   Yang, Jilong
TI Advances in Targeted Therapy for Osteosarcoma
SO DISCOVERY MEDICINE
LA English
DT Article
ID HIGH GRADE OSTEOSARCOMA; CELL INVASION; TUMOR SUPPRESSOR; PROMOTES
   APOPTOSIS; PROTEIN EXPRESSION; UP REGULATION; MIGRATION; GENE;
   PROLIFERATION; PATHWAY
AB Osteosarcoma is an aggressive cancer in skeletal system with unknown molecular mechanisms of etiology and pathogenesis, therefore it remains a challenge for current therapeutic strategies to effectively treat osteosarcoma. The aim of this review is to give an overview of the molecular and mechanistic changes identified in recent years which might be new targets for the treatment of osteosarcoma. These molecules play important roles in different biological and pathological programs of osteosarcoma, including the altered oncogenes and tumor suppressor genes, molecules involved in tumor cell migration and invasion, angiogenesis, apoptosis and proliferation, miRNAs, and molecules involved in osteoclast function and multidrug resistance. Further research on these molecules in osteosarcoma will provide new insights into the target therapy for osteosarcoma.
C1 [Zhou, Wenya; Hao, Mengze; Wang, Guowen; Yang, Jilong] Tianjin Med Univ Canc Hosp & Inst, Dept Bone & Soft Tissue Tumor, Tianjin 300060, Peoples R China.
   [Zhou, Wenya; Hao, Mengze; Wang, Guowen; Yang, Jilong] Tianjin Med Univ Canc Hosp & Inst, Natl Clin Res Ctr Canc, Tianjin 300060, Peoples R China.
   [Du, Xiaoling] Tianjin Med Univ, Dept Diagnost, Tianjin 300060, Peoples R China.
   [Chen, Kexin] Tianjin Med Univ Canc Hosp & Inst, Dept Epidemiol & Biostat, Tianjin 300060, Peoples R China.
C3 Tianjin Medical University; Tianjin Medical University; Tianjin Medical
   University; Tianjin Medical University
RP Yang, JL (通讯作者)，Tianjin Med Univ Canc Hosp & Inst, Dept Bone & Soft Tissue Tumor, Tianjin 300060, Peoples R China.
EM yangjilong@tjmuch.com
RI Chen, Kexin/ISV 0772 2023; Yang, Jilong/ADB 8853 2022; wang,
   guowen/MGU 8324 2025
OI Chen, Kexin/0000 0003 4248 7681; 
FU National Nature Science Foundation of China [81372872, 81320108022];
   University Cancer Foundation via the Sister Institution Network Fund
   (SINF); Program for Changjiang Scholars and Innovative Research Team in
   University (PCSIRT) in China [IRT1076]; National Key Scientific and
   Technological Project [2011ZX09307 001 04]
FX This work was partly supported by the National Nature Science Foundation
   of China (81372872 to J.Y. and 81320108022 to K. C.), funds from the
   University Cancer Foundation via the Sister Institution Network Fund
   (SINF) (to J.Y. and W.Z.), the Program for Changjiang Scholars and
   Innovative Research Team in University (PCSIRT) in China (IRT1076) (to
   J.Y. and K. C.), and the National Key Scientific and Technological
   Project (2011ZX09307 001 04) (to K. C.).
CR Adamski J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065304
   Akiyama T, 2008, MOL CANCER THER, V7, P3461, DOI 10.1158/1535 7163.MCT 08 0530
   Aqeilan RI, 2007, P NATL ACAD SCI USA, V104, P3949, DOI 10.1073/pnas.0609783104
   Bid HK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035513
   Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776
   Bjornland K, 2005, J SURG RES, V127, P151, DOI 10.1016/j.jss.2004.12.016
   Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399
   Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655
   Chen J, 2013, MOL CELL BIOCHEM, V384, P269, DOI 10.1007/s11010 013 1807 3
   Chen K, 2012, INT ORTHOP, V36, P2107, DOI 10.1007/s00264 012 1626 2
   Chung AS, 2011, ANNU REV CELL DEV BI, V27, P563, DOI 10.1146/annurev cellbio 092910 154002
   Fromigué O, 2008, J BIOL CHEM, V283, P30549, DOI 10.1074/jbc.M801436200
   Fromigue O, 2011, J BONE MINER RES, V26, P1533, DOI 10.1002/jbmr.343
   Fuchs Nicola, 1993, Current Opinion in Oncology, V5, P667, DOI 10.1097/00001622 199307000 00009
   Fujiwara Okada Y, 2013, BRIT J CANCER, V108, P836, DOI 10.1038/bjc.2012.579
   Gao Y, 2014, BIOCHEM BIOPHYS RES
   Gobin B, 2014, CANCER LETT, V344, P291, DOI 10.1016/j.canlet.2013.11.017
   Han G, 2012, ONCOL RES, V20, P149, DOI 10.3727/096504012X13522227232237
   Hellwinkel OJC, 2005, J GENE MED, V7, P407, DOI 10.1002/jgm.684
   Huang J, 2012, CANCER RES, V72, P230, DOI 10.1158/0008 5472.CAN 11 2001
   Ji F, 2013, BONE, V56, P220, DOI 10.1016/j.bone.2013.05.020
   Jia M, 2014, FEBS LETT
   Jiang ZH, 2014, ONCOL REP, V31, P1249, DOI 10.3892/or.2014.2986
   Jin J, 2013, ASIAN PAC J CANCER P, V14, P3681, DOI 10.7314/APJCP.2013.14.6.3681
   Kim SM, 2012, J ORTHOP RES, V30, P1040, DOI 10.1002/jor.22025
   Kuijjer ML, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755 8794 7 4
   Kurek KC, 2010, CANCER RES, V70, P5577, DOI 10.1158/0008 5472.CAN 09 4602
   Lenos K, 2012, CANCER RES, V72, P4074, DOI 10.1158/0008 5472.CAN 12 0215
   Li GD, 2012, CELL PHYSIOL BIOCHEM, V30, P1481, DOI 10.1159/000343336
   Lin F, 2011, MED ONCOL, V28, P649, DOI 10.1007/s12032 010 9493 4
   Liotta L A, 1990, Semin Cancer Biol, V1, P99
   Liu WN, 2012, ONCOL RES, V20, P319, DOI 10.3727/096504013X13644751511888
   Liu XZ, 2011, J ORTHOP RES, V29, P1259, DOI 10.1002/jor.21403
   Mao JH, 2012, ONCOL LETT, V4, P1125, DOI 10.3892/ol.2012.863
   Martin J. W., 2011, Sarcoma, V2011, P282745, DOI 10.1155/2011/282745
   Nakase M, 2005, MOL CANCER THER, V4, P625, DOI 10.1158/1535 7163.MCT 04 0196
   Ohba T, 2014, J BONE MINER RES
   Onishi Y, 2012, INT J ONCOL, V40, P1839, DOI 10.3892/ijo.2012.1400
   Ottaviani G, 2009, CANCER TREAT RES, V152, P3, DOI 10.1007/978 1 4419 0284 9_1
   Pignochino Y, 2013, CLIN CANCER RES, V19, P2117, DOI 10.1158/1078 0432.CCR 12 2293
   Ryu K, 2010, J ORTHOP RES, V28, P971, DOI 10.1002/jor.21088
   Sadikovic B, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 202
   Schuetze S, 2010, J CLIN ONCOL, V28
   Song B, 2010, MOL CANCER, V9, DOI 10.1186/1476 4598 9 96
   Sueyoshi T, 2012, CANCER LETT, V316, P23, DOI 10.1016/j.canlet.2011.10.013
   TOGUCHIDA J, 1989, NATURE, V338, P156, DOI 10.1038/338156a0
   Tugues S, 2011, MOL ASPECTS MED, V32, P88, DOI 10.1016/j.mam.2011.04.004
   UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004
   Wan XL, 2005, CANCER RES, V65, P2406, DOI 10.1158/0008 5472.CAN 04 3135
   Wang B, 2012, ACTA BIOCH BIOPH SIN, V44, P685, DOI 10.1093/abbs/gms053
   Wang J, 2014, TUMOUR BIOL
   Wang Y, 2013, MOL CELL BIOCHEM, V384, P105, DOI 10.1007/s11010 013 1786 4
   Wu Qiang, 2005, Ai Zheng, V24, P531
   Xu H, 2013, CELL BIOCHEM BIOPHYS
   Xu X, 2013, INT J ONCOL, V43, P1578, DOI 10.3892/ijo.2013.2067
   Yang JL, 2013, BMC MED GENOMICS, V6, DOI 10.1186/1755 8794 6 56
   Yang JL, 2011, CANCER AM CANCER SOC, V117, P4925, DOI 10.1002/cncr.26116
   Yang JL, 2010, CANCER LETT, V291, P31, DOI 10.1016/j.canlet.2009.09.018
   Yang JL, 2010, TECHNOL CANCER RES T, V9, P161, DOI 10.1177/153303461000900205
   Yang QC, 2006, J EXP CLIN CANC RES, V25, P593
   Zhang AL, 2014, CANCER CELL INT, V14, DOI 10.1186/1475 2867 14 15
   Zhou QA, 2010, MED ONCOL, V27, P1239, DOI 10.1007/s12032 009 9365 y
   Zhou Y, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/1756 9966 33 12
   Zhu JW, 2013, TUMOR BIOL, V34, P1097, DOI 10.1007/s13277 013 0651 0
NR 64
TC 152
Z9 160
U1 0
U2 27
PU DISCOVERY MEDICINE
PI TIMONIUM
PA 10 GERARD AVE, STE 201, TIMONIUM, MD 21093 USA
SN 1539 6509
EI 1944 7930
J9 DISCOV MED
JI Discov. Med.
PD JUN
PY 2014
VL 17
IS 96
BP 301
EP 307
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA AK8SF
UT WOS:000338697600001
PM 24979249
DA 2025 08 17
ER

PT J
AU Maïmoun, L
   Simar, D
   Caillaud, C
   Coste, O
   Barbotte, E
   Peruchon, E
   Rossi, M
   Mariano Goulart, D
AF Maimoun, L.
   Simar, D.
   Caillaud, C.
   Coste, O.
   Barbotte, E.
   Peruchon, E.
   Rossi, M.
   Mariano Goulart, D.
TI Response of calciotropic hormones and bone turnover to brisk walking
   according to age and fitness level
SO JOURNAL OF SCIENCE AND MEDICINE IN SPORT
LA English
DT Article
DE Exercise; Calcium; Parathyroid hormone; Bone remodelling
ID PARATHYROID HORMONE; RESISTANCE EXERCISE; PHYSICAL ACTIVITY; MINERAL
   DENSITY; CALCIUM; MARKERS; MEN; METABOLISM; STRENGTH; OSTEOCALCIN
AB Ageing is associated with a gradual bone loss and physical activity has been suggested as practical strategy for a non pharmacological prevention of osteoporosis. However, until now, the specific mechanism by which physical activity affects bone tissue is not thoroughly understood. The aim of this study was to evaluate the effect of strenuous exercise on bone metabolism as a function of age and fitness level. Eighteen physically highly active elderly participants (mean age 71.7 +/  7.3 years, HAcEI group), 18 moderately active elderly participants (mean age 71.9 +/  8.6 years, ModEl group) and 9 young physically active participants (mean age 25.8 +/  2.3 years, AcYo) participated in this study. Concentrations of plasma ionised calcium (iCa), serum parathyroid hormone (iPTH), 25 hydroxy vitamin D [25(OH)D], and 1,25 dihydroxy vitamin D3 [1,25(OH)(2)D3] as well as the bone biochemical markets type I collagen C telopeptide (CTX) for bone resorption and osteocalcin (OC) and bone alkaline phosphatase (B ALP) for bone formation, were analyzed before and after a maximal incremental exercise test. In all groups, iCa decreased significantly (p < 0.05 for ModEl and AcYo and p < 0.001 for HAcEl) while iPTH increased significantly (p<0.01 for ModEl and HAcEI and p<0.001 for AcYo) after exercise. The levels of 1,25(OH)(2)D3, OC and CTX remained unchanged, while 25(OH)D decreased only in HAcEl group while B ALP increased in ModEl group. In conclusion, strenuous exercise disturbed calcium homeostasis, mainly the iCa/iPTH equilibrium independently of gender, age or fitness level of the participants while no immediate effect on bone turnover was observed. (C) 2008 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.
C1 [Maimoun, L.] CHU Montpellier, Hop Lapeyronie, Nucl Med Serv, F 34000 Montpellier, France.
   [Maimoun, L.] GRISMO, Montpellier, France.
   [Maimoun, L.; Coste, O.] DRDJS, Montpellier, France.
   [Simar, D.] Univ New S Wales, Fac Med, Sch Med Sci, Sydney, NSW, Australia.
   [Caillaud, C.] Univ Sydney, Fac Hlth Sci, Sydney, NSW 2006, Australia.
   [Barbotte, E.] CHU Montpellier, Dept Med Informat, F 34000 Montpellier, France.
   [Peruchon, E.] INSERM, Montpellier, France.
C3 Universite de Montpellier; CHU de Montpellier; University of New South
   Wales Sydney; University of Sydney; Universite de Montpellier; CHU de
   Montpellier; Universite de Montpellier; Institut National de la Sante et
   de la Recherche Medicale (Inserm)
RP Maïmoun, L (通讯作者)，CHU Montpellier, Hop Lapeyronie, Nucl Med Serv, F 34000 Montpellier, France.
EM laurent.maimoun@laposte.net
RI caillaud, corinne/AAJ 7414 2020
OI Simar, David/0000 0002 3862 1932; Mariano Goulart,
   Denis/0000 0001 7044 2961
CR Ashizawa N, 1997, J APPL PHYSIOL, V83, P1159, DOI 10.1152/jappl.1997.83.4.1159
   BLUM JW, 1978, J CLIN INVEST, V61, P1113, DOI 10.1172/JCI109026
   Bouassida A, 2003, EUR J APPL PHYSIOL, V88, P339, DOI 10.1007/s00421 002 0721 2
   Chow JWM, 1998, AM J PHYSIOL ENDOC M, V274, pE146, DOI 10.1152/ajpendo.1998.274.1.E146
   Ehrnborg C, 2003, J CLIN ENDOCR METAB, V88, P394, DOI 10.1210/jc.2002 020037
   Frost HM, 1999, J BONE MINER METAB, V17, P90, DOI 10.1007/s007740050070
   Guillemant J, 2004, CALCIFIED TISSUE INT, V74, P407, DOI 10.1007/s00223 003 0070 0
   Kraemer WJ, 1998, EUR J APPL PHYSIOL O, V78, P69, DOI 10.1007/s004210050389
   KRISTOFFERSSON A, 1995, INT J SPORTS MED, V16, P145, DOI 10.1055/s 2007 972982
   Lamberts SWJ, 1997, SCIENCE, V278, P419, DOI 10.1126/science.278.5337.419
   Lopez I, 2002, J BONE MINER RES, V17, P1691, DOI 10.1359/jbmr.2002.17.9.1691
   Maïmoun L, 2006, INT J SPORTS MED, V27, P105, DOI 10.1055/s 2005 837621
   Maïmoun L, 2005, BRIT J SPORT MED, V39, P497, DOI 10.1136/bjsm.2004.013151
   Malatesta D, 2003, J APPL PHYSIOL, V95, P2248, DOI 10.1152/japplphysiol.01106.2002
   MENKES A, 1993, J APPL PHYSIOL, V74, P2478, DOI 10.1152/jappl.1993.74.5.2478
   Nguyen TV, 2000, J BONE MINER RES, V15, P322, DOI 10.1359/jbmr.2000.15.2.322
   NISHIYAMA S, 1988, CALCIFIED TISSUE INT, V43, P150, DOI 10.1007/BF02571312
   Paterson DH, 1999, MED SCI SPORT EXER, V31, P1813, DOI 10.1097/00005768 199912000 00018
   RIGGS BL, 1983, AM J MED, V75, P899, DOI 10.1016/0002 9343(83)90860 4
   Rong H, 1997, SCAND J MED SCI SPOR, V7, P152
   Ryan AS, 2004, SCAND J MED SCI SPOR, V14, P16, DOI 10.1111/j.1600 0838.2003.00328.x
   SALVESEN H, 1994, CALCIFIED TISSUE INT, V54, P256, DOI 10.1007/BF00295947
   Simar D, 2004, EXP GERONTOL, V39, P1467, DOI 10.1016/j.exger.2004.08.002
   Theiler R, 1999, ARCH PHYS MED REHAB, V80, P485, DOI 10.1016/S0003 9993(99)90186 7
   VIRTANEN P, 1993, J APPL PHYSIOL, V75, P1272, DOI 10.1152/jappl.1993.75.3.1272
   VOORRIPS LE, 1991, MED SCI SPORT EXER, V23, P974, DOI 10.1249/00005768 199108000 00015
   Wallace JD, 2000, J CLIN ENDOCR METAB, V85, P124, DOI 10.1210/jc.85.1.124
   Welsh L, 1997, INT J SPORTS MED, V18, P247, DOI 10.1055/s 2007 972628
   Whipple TJ, 2004, INT J SPORTS MED, V25, P496, DOI 10.1055/s 2004 820942
   Zittermann A, 2002, EUR J NUTR, V41, P189, DOI 10.1007/s00394 002 0375 1
NR 30
TC 22
Z9 24
U1 0
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1440 2440
EI 1878 1861
J9 J SCI MED SPORT
JI J. Sci. Med. Sport
PD JUL
PY 2009
VL 12
IS 4
BP 463
EP 467
DI 10.1016/j.jsams.2008.05.004
PG 5
WC Sport Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Sport Sciences
GA 477TS
UT WOS:000268542400010
PM 18768364
DA 2025 08 17
ER

PT J
AU Kim, JY
   Cheon, YH
   Oh, HM
   Rho, MC
   Erkhembaatar, M
   Kim, MS
   Lee, CH
   Kim, JJ
   Choi, MK
   Yoon, KH
   Lee, MS
   Oh, J
AF Kim, Ju Young
   Cheon, Yoon Hee
   Oh, Hyun Mee
   Rho, Mun Chual
   Erkhembaatar, Munkhsoyol
   Kim, Min Seuk
   Lee, Chang Hoon
   Kim, Jeong Joong
   Choi, Min Kyu
   Yoon, Kwon Ha
   Lee, Myeung Su
   Oh, Jaemin
TI Oleanolic acid acetate inhibits osteoclast differentiation by
   downregulating PLCγ2 Ca<SUP>2+</SUP> NFATc1 signaling, and suppresses
   bone loss in mice
SO BONE
LA English
DT Article
DE Osteoclast; Oleanolic acid acetate; PLC gamma 2; Calcium oscillation;
   NFATc1
ID SPONTANEOUSLY HYPERTENSIVE RATS; PHOSPHOLIPASE C GAMMA; ANGULARIS SEED
   COATS; HOT WATER EXTRACT; VIGNA ANGULARIS; RECEPTOR ACTIVATOR;
   DIABETIC RATS; IMMUNE SYSTEM; CELLS; OSTEOIMMUNOLOGY
AB Owing to their potential pharmacological activities in human disease, natural plant derived compounds have recently become the focus of increased research interest. In this study, we first isolated oleanolic acid acetate (OAA), a triterpenoid compound, from Vigna angularis (azuki bean) to discover anti bone resorptive agents. Many studies have identified and described the various medicinal effects of V. angularis extract. However, the pharmacological effect of OAA derived V. angularis extract, particularly the effect on osteoclastogenesis, is not known. Therefore, we investigated the effect and mechanism of OAA in receptor activator of nuclear factor KB ligand (RANKL) induced osteodastogenesis. OAA inhibited RANKL induced osteoclast differentiation in bone marrow macrophages (BMMs) without any evidence of cytotoxicity. Interestingly, OAA significantly inhibited Btk phosphorylation, phospholipase C gamma 2 (PLC gamma 2) phosphorylation, calcium ion (Ca2+) oscillation, and nuclear factor of activated T cell cl (NFATc1) expression in RANKL stimulated BMMs, but did not affect RANKL induced mitogen activated protein kinase. OAA also inhibited the bone resorbing activity of mature osteoclasts. Furthermore, mice treated with QAA demonstrated marked attenuation of lipopolysaccharide induced bone erosion based on micro comPuted tomography and histologic analysis of femurs. Taken together, the results suggested that OAA inhibited RANKL mediated osteoclastogenesis via PLC gamma 2 Ca2+ NFATc1 signaling in vitro and suppressed inflammatory bone loss in vivo. (C) 2013 Published by Elsevier Inc.
C1 [Kim, Ju Young; Yoon, Kwon Ha; Lee, Myeung Su; Oh, Jaemin] Wonkwang Univ, Imaging Sci Based Lung & Bone Dis Res Ctr, Iksan 570749, Jeonbuk, South Korea.
   [Cheon, Yoon Hee; Kim, Jeong Joong; Choi, Min Kyu; Oh, Jaemin] Wonkwang Univ, Sch Med, Dept Anat, Iksan 570749, Jeonbuk, South Korea.
   [Oh, Hyun Mee; Rho, Mun Chual] Korea Res Inst Biosci & Biotechnol, Biomat Res Inst, Bioind Proc Res Ctr, Jeongeup 580185, Jeonbuk, South Korea.
   [Erkhembaatar, Munkhsoyol; Kim, Min Seuk] Wonkwang Univ, Sch Dent, Dept Oral Physiol, Iksan 570749, Jeonbuk, South Korea.
   [Kim, Min Seuk; Lee, Chang Hoon; Kim, Jeong Joong; Lee, Myeung Su; Oh, Jaemin] Wonkwang Univ, Inst Skeletal Dis, Iksan 570749, Jeonbuk, South Korea.
   [Lee, Chang Hoon; Lee, Myeung Su] Wonkwang Univ, Div Rheumatol, Dept Internal Med, Iksan 570749, Jeonbuk, South Korea.
   [Yoon, Kwon Ha] Wonkwang Univ, Sch Med, Dept Radiol, Iksan 570749, Jeonbuk, South Korea.
C3 Wonkwang University; Wonkwang University; Korea Research Institute of
   Bioscience & Biotechnology (KRIBB); Wonkwang University; Wonkwang
   University; Wonkwang University; Wonkwang University
RP Lee, MS (通讯作者)，Wonkwang Univ, Sch Med, Dept Internal Med, Div Rheumatol, 344 2 Sinyong Dong, Iksan 570749, Jeonbuk, South Korea.
EM ckhlms@wku.ac.kr; jmoh@wku.ac.kr
RI Lee, Sang Hoon/ABH 6210 2020
OI Kim, Ju Young/0000 0002 4493 0264; Erkhembaatar,
   Munkhsoyol/0009 0006 0855 9636
FU Korean Health Technology R&D Project, Ministry of Health & Welfare,
   Republic of Korea [A111649, A120152]
FX This study was supported by a grant from the Korean Health Technology
   R&D Project, Ministry of Health & Welfare, Republic of Korea (A111649)
   (A120152).
CR Bharti AC, 2004, J IMMUNOL, V172, P5940, DOI 10.4049/jimmunol.172.10.5940
   Bian Q, 2012, MENOPAUSE, V19, P225, DOI 10.1097/gme.0b013e3182272ef1
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Choi SW, 2012, FEBS LETT, V586, P263, DOI 10.1016/j.febslet.2011.12.033
   Cremasco V, 2008, ARTHRITIS RHEUM US, V58, P2712, DOI 10.1002/art.23757
   Eriksen EF, 2010, REV ENDOCR METAB DIS, V11, P219, DOI 10.1007/s11154 010 9153 1
   Faccio R, 2010, ANN NY ACAD SCI, V1192, P124, DOI 10.1111/j.1749 6632.2009.05217.x
   Giner Larza EM, 2001, EUR J PHARMACOL, V428, P137, DOI 10.1016/S0014 2999(01)01290 0
   Graham DB, 2007, J CLIN INVEST, V117, P3445, DOI 10.1172/JCI32729
   Itoh T, 2004, BIOSCI BIOTECH BIOCH, V68, P2421, DOI 10.1271/bbb.68.2421
   Itoh T, 2012, PHYTOTHER RES, V26, P1003, DOI 10.1002/ptr.3660
   Jakus Z, 2009, J EXP MED, V206, P577, DOI 10.1084/jem.20081859
   Ji QS, 1997, P NATL ACAD SCI USA, V94, P2999, DOI 10.1073/pnas.94.7.2999
   Kawai A, 2007, MICROBIOL IMMUNOL, V51, P1071, DOI 10.1111/j.1348 0421.2007.tb04002.x
   Kertész Z, 2012, EUR J CLIN INVEST, V42, P49, DOI 10.1111/j.1365 2362.2011.02556.x
   Kim K, 2005, J BIOL CHEM, V280, P35209, DOI 10.1074/jbc.M505815200
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Kwak HB, 2010, BONE, V46, P724, DOI 10.1016/j.bone.2009.10.042
   Lee JY, 2010, BIOL PHARM BULL, V33, P230, DOI 10.1248/bpb.33.230
   Leibbrandt A, 2008, ANN NY ACAD SCI, V1143, P123, DOI 10.1196/annals.1443.016
   Li JX, 2005, PLANTA MED, V71, P673, DOI 10.1055/s 2005 871275
   Li YJ, 2007, J ETHNOPHARMACOL, V113, P191, DOI 10.1016/j.jep.2007.04.020
   Lorenzo J, 2008, ENDOCR REV, V29, P403, DOI 10.1210/er.2007 0038
   Mao DL, 2006, J CLIN INVEST, V116, P2869, DOI 10.1172/JCI28775
   Morrison D. K., 2012, Cold Spring Harb, Perspect. Biol., P1
   Mukai Y, 2011, J NUTR BIOCHEM, V22, P16, DOI 10.1016/j.jnutbio.2009.11.004
   Patterson RL, 2005, TRENDS BIOCHEM SCI, V30, P688, DOI 10.1016/j.tibs.2005.10.005
   Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153
   Rauner M, 2007, INT ARCH ALLERGY IMM, V143, P31, DOI 10.1159/000098223
   Sato S, 2005, J NUTR BIOCHEM, V16, P547, DOI 10.1016/j.jnutbio.2005.02.003
   Sato S, 2008, CLIN EXP PHARMACOL P, V35, P43, DOI 10.1111/j.1440 1681.2007.04743.x
   Shinohara M, 2008, CELL, V132, P794, DOI 10.1016/j.cell.2007.12.037
   Shirane M, 2001, DEVELOPMENT, V128, P5173
   Suda K, 2002, J CELL PHYSIOL, V190, P101, DOI 10.1002/jcp.10041
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105 2896.2005.00327.x
   Walsh MC, 2006, ANNU REV IMMUNOL, V24, P33, DOI 10.1146/annurev.immunol.24.021605.090646
   Wang DM, 2000, IMMUNITY, V13, P25, DOI 10.1016/S1074 7613(00)00005 4
   Wu X, 2012, J BONE MINER RES, V27, P1298, DOI 10.1002/jbmr.1576
   Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257
NR 41
TC 53
Z9 57
U1 1
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAR
PY 2014
VL 60
BP 104
EP 111
DI 10.1016/j.bone.2013.12.013
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AB8RH
UT WOS:000332057200013
PM 24361669
DA 2025 08 17
ER

PT J
AU Lau, CPY
   Fung, CSH
   Wong, KC
   Wang, YH
   Huang, L
   Tsui, SKW
   Lee, OK
   Kumta, SM
AF Lau, Carol P. Y.
   Fung, Cathy S. H.
   Wong, Kwok Chuen
   Wang, Yu Hsuan
   Huang, Lin
   Tsui, Stephen K. W.
   Lee, Oscar K.
   Kumta, Shekhar M.
TI Simvastatin Possesses Antitumor and Differentiation Promoting Properties
   That Affect Stromal Cells in Giant Cell Tumor of Bone
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE Giant Cell Tumor of Bone; Simvastatin; Vitamin D receptor pathway;
   Osteogenic differentiation; Cell apoptosis
ID INHIBITS OSTEOCLAST DIFFERENTIATION; MESSENGER RNA EXPRESSION; VITAMIN D
   DEFICIENCY; REDUCTASE INHIBITOR; HUMAN OSTEOBLASTS; COA REDUCTASE;
   PATHWAY; STATINS; PRENYLATION; METABOLISM
AB Giant cell tumor of bone (GCTB) is a locally aggressive destructive bone lesion. The management of pulmonary metastasis and local recurrence after the surgical treatment of GCTB remains a challenge. Pathologically, stromal cells in GCTB are known as primary neoplastic cells and are recognized as incompletely differentiated preosteoblasts. Therefore, inducing GCTB stromal cells to differentiate into cells with a mature osteoblastic phenotype may stop tumor growth and recurrence. In this study, we aimed to investigate how simvastatin, a clinically approved and commonly used statin that has been known to promote the maturation of cells of the osteogenic lineage, affects GCTB stromal cells. We found that simvastatin effectively inhibited cell viability by suppressing proliferation and by inducing apoptosis in GCTB stromal cells. Moreover, simvastatin treatment upregulated the expression of genes related to osteogenic maturation, such as runt related transcription factor 2, osteopontin, and osteocalcin, and increased the mineralization of the extracellular matrix in GCTB stromal cells. Ingenuity pathway analysis was used to discover that the vitamin D receptor pathway was involved in the simvastatin induced osteogenic differentiation of GCTB stromal cells by upregulating the 1,25 dihydroxyvitamin D metabolism. Taken together, this in vitro study demonstrates the antitumor and differentiation promoting effects of simvastatin on GCTB stromal cells and suggests the possibility of using simvastatin as an adjuvant therapy for GCTB. These findings support further clinical investigation of the efficacy of using simvastatin as an adjuvant therapy for GCTB to reduce recurrence and distant metastasis after surgical treatment. (c) 2019 Orthopedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res
C1 [Lau, Carol P. Y.; Wong, Kwok Chuen; Wang, Yu Hsuan; Lee, Oscar K.; Kumta, Shekhar M.] Chinese Univ Hong Kong, Dept Orthopaed & Traumatol, Hong Kong, Peoples R China.
   [Lau, Carol P. Y.; Wang, Yu Hsuan; Lee, Oscar K.] Chinese Univ Hong Kong, Inst Tissue Engn & Regenerat Med, Hong Kong, Peoples R China.
   [Lau, Carol P. Y.; Kumta, Shekhar M.] Chinese Univ Hong Kong, Prince Wales Hosp, Sir Yue Kong Pao Canc Ctr, Hong Kong, Peoples R China.
   [Fung, Cathy S. H.; Tsui, Stephen K. W.] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Peoples R China.
   [Huang, Lin] Chinese Univ Hong Kong, Dept Surg, Hong Kong, Peoples R China.
   [Lee, Oscar K.] Chinese Univ Hong Kong, Prince Wales Hosp, Li Ka Shing Inst Hlth Sci, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong; Chinese University of Hong Kong;
   Chinese University of Hong Kong; Prince of Wales Hospital; Chinese
   University of Hong Kong; Chinese University of Hong Kong; Chinese
   University of Hong Kong; Prince of Wales Hospital
RP Lee, OK; Kumta, SM (通讯作者)，Chinese Univ Hong Kong, Dept Orthopaed & Traumatol, Hong Kong, Peoples R China.; Lee, OK (通讯作者)，Chinese Univ Hong Kong, Inst Tissue Engn & Regenerat Med, Hong Kong, Peoples R China.; Kumta, SM (通讯作者)，Chinese Univ Hong Kong, Prince Wales Hosp, Sir Yue Kong Pao Canc Ctr, Hong Kong, Peoples R China.; Lee, OK (通讯作者)，Chinese Univ Hong Kong, Prince Wales Hosp, Li Ka Shing Inst Hlth Sci, Hong Kong, Peoples R China.
EM oscar.lee@cuhk.edu.hk; kumta@cuhk.edu.hk
RI Lee, Oscar/MEK 9750 2025; Tsui, Stephen Kwok Wing/E 4385 2015; Tsui,
   Stephen/E 4385 2015; FUNG, Sin Hang/GSI 7607 2022; Lau,
   Carol/G 2577 2017; Kumta, Shekhar/K 1080 2013; Wang,
   Yu Hsuan/IAN 2109 2023
OI Tsui, Stephen Kwok Wing/0000 0003 0686 4259; Lau,
   Carol/0000 0002 9240 092X; Kumta, Shekhar/0000 0001 5507 9674; 
FU CUHK Research Committee Funding [2014.1.046]
FX This study was supported by CUHK Research Committee Funding (Direct
   Grants) to Professor Shekhar Madhukar Kumta (Reference no. 2014.1.046).
CR Ahn KS, 2008, INT J CANCER, V123, P1733, DOI 10.1002/ijc.23745
   Alizadeh J, 2017, SCI REP UK, V7, DOI 10.1038/srep44841
   Anderson PH, 2007, J STEROID BIOCHEM, V103, P601, DOI 10.1016/j.jsbmb.2006.12.084
   Atkins GJ, 2007, BONE, V40, P1517, DOI 10.1016/j.bone.2007.02.024
   Atkins GJ, 2002, BONE, V31, P448, DOI 10.1016/S8756 3282(02)00858 X
   Bioquest ATT Inc, 2019, QUEST GRAPH 4 PAR LO
   Branstetter DG, 2012, CLIN CANCER RES, V18, P4415, DOI 10.1158/1078 0432.CCR 12 0578
   Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092 8674(00)80213 5
   Chen PY, 2010, NUTR RES, V30, P191, DOI 10.1016/j.nutres.2010.03.004
   Sandoval Usme MC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087769
   Denoyelle C, 2001, CARCINOGENESIS, V22, P1139, DOI 10.1093/carcin/22.8.1139
   Fulcher J, 2015, LANCET, V385, P1397, DOI 10.1016/S0140 6736(14)61368 4
   García Ruiz C, 2012, ANTI CANCER AGENT ME, V12, P303, DOI 10.2174/187152012800228715
   Gniadecki R, 2004, BIOCHEM BIOPH RES CO, V320, P165, DOI 10.1016/j.bbrc.2004.05.145
   Gundavda MK, 2019, MED HYPOTHESES, V123, P67, DOI 10.1016/j.mehy.2018.12.010
   Herrero Martin G, 2008, FEBS LETT, V582, P2589, DOI 10.1016/j.febslet.2008.06.034
   Horas K, 2017, CANCER INVEST, V35, P562, DOI 10.1080/07357907.2017.1351985
   Horiguchi A, 2004, CLIN CANCER RES, V10, P8648, DOI 10.1158/1078 0432.CCR 04 1568
   HOWARD GA, 1981, J BIOL CHEM, V256, P7738
   Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]
   Klenke FM, 2011, CLIN ORTHOP RELAT R, V469, P591, DOI 10.1007/s11999 010 1501 7
   Kozai M, 2013, ENDOCRINOLOGY, V154, P609, DOI 10.1210/en.2012 1647
   Krämer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703
   Lau CPY, 2013, CONNECT TISSUE RES, V54, P439, DOI 10.3109/03008207.2013.848202
   Lau CPY, 2011, J ORTHOP RES, V29, P403, DOI 10.1002/jor.21249
   Liede A, 2018, J BONE ONCOL, V12, P96, DOI 10.1016/j.jbo.2018.07.003
   Maeda T, 2001, BIOCHEM BIOPH RES CO, V280, P874, DOI 10.1006/bbrc.2000.4232
   Mak IWY, 2014, J BONE JOINT SURG AM, V96A, DOI 10.2106/JBJS.M.01332
   MCQUILLAN DJ, 1995, BONE, V16, P415
   Miller T, 2011, DIGEST LIVER DIS, V43, P395, DOI 10.1016/j.dld.2011.01.010
   Moon HJ, 2011, EXP MOL MED, V43, P605, DOI 10.3858/emm.2011.43.11.067
   Muheremu A, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477 7819 12 261
   Niu XH, 2015, ARCH PATHOL LAB MED, V139, P1149, DOI 10.5858/arpa.2014 0432 OA
   Pertea M, 2015, NAT BIOTECHNOL, V33, P290, DOI 10.1038/nbt.3122
   ROBINSON D, 1994, J CELL BIOCHEM, V55, P300, DOI 10.1002/jcb.240550305
   Sassano A, 2008, CANCER LETT, V260, P11, DOI 10.1016/j.canlet.2007.11.036
   Shi MM, 2019, CANCER MANAG RES, V11, P669, DOI 10.2147/CMAR.S187316
   Sivaprasad U, 2006, MOL CANCER THER, V5, P2310, DOI 10.1158/1535 7163.MCT 06 0175
   Sterck L., Calculate and draw custom Venn diagrams
   Sun LP, 2005, J BIOL CHEM, V280, P26483, DOI 10.1074/jbc.M504041200
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI [10.1093/nar/gky1131, 10.1093/nar/gkac1000]
   Tai IC, 2015, INT J NANOMED, V10, P5881, DOI 10.2147/IJN.S84273
   Trapnell C, 2013, NAT BIOTECHNOL, V31, P46, DOI 10.1038/nbt.2450
   Wu YP, 2015, J BIOMED NANOTECHNOL, V11, P1247, DOI 10.1166/jbn.2015.2068
   Wülling M, 2001, J CANCER RES CLIN, V127, P467, DOI 10.1007/s004320100234
   Xu LL, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0716 x
   Yamashita M, 2010, REGUL PEPTIDES, V162, P99, DOI 10.1016/j.regpep.2010.03.003
   Yu XP, 2008, INT J ONCOL, V33, P555, DOI 10.3892/ijo_00000040
   Zheng MH, 2001, HISTOL HISTOPATHOL, V16, P297, DOI 10.14670/HH 16.297
NR 49
TC 14
Z9 15
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
EI 1554 527X
J9 J ORTHOP RES
JI J. Orthop. Res.
PD FEB
PY 2020
VL 38
IS 2
BP 297
EP 310
DI 10.1002/jor.24456
EA SEP 2019
PG 14
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA KD1TK
UT WOS:000485414600001
PM 31471919
OA Bronze
DA 2025 08 17
ER

PT J
AU Malizia, AP
   Vioreanu, MH
   Doran, PP
   Powderly, WG
AF Malizia, Andrea P.
   Vioreanu, Mihai H.
   Doran, Peter P.
   Powderly, William G.
TI HIV1 protease inhibitors selectively induce inflammatory chemokine
   expression in primary human osteoblasts
SO ANTIVIRAL RESEARCH
LA English
DT Article
DE HAART; osteoblasts; inflammation; MCP 1; IL 8; nelfinavir; ritonavir
ID FAT; OSTEOPENIA; BONE; MEN
AB HIV infected patients are at increased risk of decreased bone mineral density. Several studies have implicated antiretroviral therapy as a contributor to the decreased bone mineral density seen in treated HIV 1 patients. Whilst the exact molecular mechanisms underlying decreased bone density remain to be elucidated, inflammation has been postulated to be an important pathogenomic mechanism. In this study, we have explored primary human osteoblast gene expression in response to protease inhibitors (PIs), by oligonucleotide microarray analysis. A list of dysregulated genes, correlated with the inflammatory response, increased significantly after NFV and RTV exposure. Analysis of gene and protein expression determined a selectively increase of the pro inflammatory cytokines monocyte chemoattractant protein (MCP) 1 and interleukin 8 (IL 8) following exposure to a pharmacological concentration of NFV and RTV. These data suggested that generation of local inflammatory cascades may contribute to the development of decreased bone mineral density in highly active antiretroviral therapy (HAART) treated HIV patients. (c) 2006 Elsevier B.V. All rights reserved.
C1 Univ Coll Dublin, Sch Med & Med Sci, Gen Clin Res Unit, Dublin 2, Ireland.
   Mater Misericordiae Univ Hosp, Dublin Mol Med Ctr, Dublin, Ireland.
   Mater Misericordiae Univ Hosp, Natl Spinal Injuries Unit, Dublin, Ireland.
C3 University College Dublin; University College Dublin; Trinity College
   Dublin; Mater Misericordiae University Hospital; University College
   Dublin; Mater Misericordiae University Hospital
RP Doran, PP (通讯作者)，Univ Coll Dublin, Sch Med & Med Sci, Gen Clin Res Unit, Dublin 2, Ireland.
EM pdoran@mater.ie
OI P. Malizia, Andrea/0000 0003 0913 1309; Doran,
   Peter/0000 0003 2064 5335; Powderly, William/0000 0001 7808 3086
CR BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97
   BENBARUCH A, 1995, J BIOL CHEM, V270, P11703, DOI 10.1074/jbc.270.20.11703
   Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185
   Carr A, 2001, AIDS, V15, P703, DOI 10.1097/00002030 200104130 00005
   DOUGLAS AH, 2003, GENOME BIOL, V4, pP4
   Duval X, 2004, HIV MED, V5, P307, DOI 10.1111/j.1468 1293.2004.00226.x
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Graves DT, 1999, HISTOL HISTOPATHOL, V14, P1347, DOI 10.14670/HH 14.1347
   Jain RG, 2002, J BIOL CHEM, V277, P19247, DOI 10.1074/jbc.C200069200
   Kieran NE, 2003, KIDNEY INT, V64, P480, DOI 10.1046/j.1523 1755.2003.00106.x
   Lawal A, 2001, AIDS, V15, P278, DOI 10.1097/00002030 200101260 00022
   Liu YZ, 2005, J BIOL CHEM, V280, P29011, DOI 10.1074/jbc.M501164200
   MALIZIA AP, 2007, AIDS RES HUM RETROV, V23, P135
   McDermott AY, 2001, AM J CLIN NUTR, V74, P679
   Rothe L, 1998, ENDOCRINOLOGY, V139, P4353, DOI 10.1210/en.139.10.4353
   Safrin S, 1999, AIDS, V13, P2493, DOI 10.1097/00002030 199912240 00002
   Sozzani S, 1996, INT J CLIN LAB RES, V26, P69, DOI 10.1007/BF02592349
   Tebas P, 2000, AIDS, V14, pF63, DOI 10.1097/00002030 200003100 00005
   Walsh CA, 2000, INT J EXP PATHOL, V81, P159
   YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233
   ZWAHLEN R, 1993, INT REV EXP PATHOL, V34, P27
NR 21
TC 19
Z9 19
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0166 3542
EI 1872 9096
J9 ANTIVIR RES
JI Antiviral Res.
PD APR
PY 2007
VL 74
IS 1
BP 72
EP 76
DI 10.1016/j.antiviral.2006.12.003
PG 5
WC Pharmacology & Pharmacy; Virology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Virology
GA 155YJ
UT WOS:000245614400010
PM 17240460
DA 2025 08 17
ER

PT J
AU Niu, YJ
   Xia, CJ
   Ai, X
   Xu, WM
   Lin, XT
   Zhu, YQ
   Zhu, HY
   Zeng, X
   Cao, ZL
   Zhou, W
   Huang, H
   Shi, XL
AF Niu, Yi jun
   Xia, Cheng jie
   Ai, Xin
   Xu, Wei ming
   Lin, Xiao tong
   Zhu, Ying qi
   Zhu, Hai yan
   Zeng, Xian
   Cao, Zhong lian
   Zhou, Wei
   Huang, Hai
   Shi, Xun long
TI Sequential activation of ERα AMPKα signaling by the flavonoid baicalin
   down regulates viral HNF dependent HBV replication
SO ACTA PHARMACOLOGICA SINICA
LA English
DT Article
DE antiviral flavonoid; baicalin; hepatocyte nuclear factor; hepatitis B
   virus; ER alpha; AMPK alpha
ID CHRONIC HEPATITIS B; BREAST CANCER; EXPRESSION; OSTEOBLASTS; AUTOPHAGY;
   THERAPY; TARGET; ROLES
AB Baicalin (BA), a natural component found in many traditional Chinese medicines, exerts protective effects against several viruses. Although our previous studies have revealed that the anti hepatitis B virus (anti HBV) activity of BA depends on hepatocyte nuclear factor (HNF) signaling, the specific mechanisms remain unclear. The present study explored the potential signaling mechanisms involved in BA mediated HBV suppression. Transcriptomic analysis suggested that BA significantly modulates the estrogen receptor (ER) and AMPK signaling pathways in HepG2 cells. The ER alpha (ER alpha) binding affinity of BA and its estrogen like agonist activity were subsequently verified through molecular docking assays, BA ER alpha affinity detection experiments, ER alpha luciferase reporter gene assays, and qRT PCR. ER alpha knockdown (shRNA) and AMPK inhibition (Compound C and doxorubicin [Dox]) experiments revealed that the sequential activation of the ER alpha LKB1 AMPK HNF signaling axis is essential for the anti HBV effects of BA. This study indicates that BA may trigger the ER alpha AMPK alpha HNF pathway to inhibit HBV replication, providing insights into its potential protective mechanisms against other viruses.
C1 [Niu, Yi jun; Xia, Cheng jie; Ai, Xin; Xu, Wei ming; Lin, Xiao tong; Zhu, Ying qi; Zhu, Hai yan; Zeng, Xian; Cao, Zhong lian; Huang, Hai; Shi, Xun long] Fudan Univ, Sch Pharm, Dept Biol Med, Shanghai 201023, Peoples R China.
   [Niu, Yi jun; Xia, Cheng jie; Ai, Xin; Xu, Wei ming; Lin, Xiao tong; Zhu, Ying qi; Zhu, Hai yan; Zeng, Xian; Cao, Zhong lian; Huang, Hai; Shi, Xun long] Fudan Univ, Shanghai Engn Res Ctr Immunotherapeut, Sch Pharm, Shanghai 201203, Peoples R China.
   [Zhou, Wei] Fudan Univ, Dept Chem, Shanghai 201203, Peoples R China.
C3 Fudan University; Fudan University; Fudan University
RP Shi, XL (通讯作者)，Fudan Univ, Sch Pharm, Dept Biol Med, Shanghai 201023, Peoples R China.; Shi, XL (通讯作者)，Fudan Univ, Shanghai Engn Res Ctr Immunotherapeut, Sch Pharm, Shanghai 201203, Peoples R China.
EM xunlongshi@fudan.edu.cn
RI Ai, Xin/O 9012 2018; zhu, xueqiong/U 1320 2019; Zeng,
   Xian/AAL 8713 2020; shi, xunlong/AAF 9803 2020
FU National Key Research and Development Program of China [2023YFC3503400];
   National Nature Science Foundation of China [82074097]; Key Program of
   National Nature Science Foundation of China [82030113]; Shanghai Science
   and Technology Funds [17ZR1401700]; Shanghai Municipal Health Commission
   Project [201740200]; Shanghai Engineering Research Center of
   Immunotherapeutics [19DZ2251400]
FX This work was supported by grants from the National Key Research and
   Development Program of China (No. 2023YFC3503400), the National Nature
   Science Foundation of China (No. 82074097), the Key Program of National
   Nature Science Foundation of China (No. 82030113), Shanghai Science and
   Technology Funds (No. 17ZR1401700), Shanghai Municipal Health Commission
   Project (No. 201740200), and Shanghai Engineering Research Center of
   Immunotherapeutics (No. 19DZ2251400).
CR ALMOG Y, 1992, ANTIVIR RES, V19, P285, DOI 10.1016/0166 3542(92)90010 3
   Baig S, 2009, JCPSP J COLL PHYSICI, V19, P598, DOI 09.2009/JCPSP.598600
   Burki T, 2024, LANCET INFECT DIS, V24, pe362, DOI 10.1016/S1473 3099(24)00307 4
   Dinda B, 2017, EUR J MED CHEM, V131, P68, DOI 10.1016/j.ejmech.2017.03.004
   Fogarty S, 2016, MOL CANCER RES, V14, P683, DOI 10.1158/1541 7786.MCR 15 0479
   Girault I, 2003, CLIN CANCER RES, V9, P1259
   Gnoni A, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031044
   Guo AJY, 2011, J BIOL CHEM, V286, P27882, DOI 10.1074/jbc.M111.236281
   Habashy HO, 2010, BREAST CANCER RES TR, V120, P603, DOI 10.1007/s10549 009 0419 9
   Hsu SK, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22179453
   Huang H, 2017, TOXICOL APPL PHARM, V323, P36, DOI 10.1016/j.taap.2017.03.016
   Kang J, 2018, EUR J PHARMACOL, V820, P235, DOI 10.1016/j.ejphar.2017.12.038
   Kaur M, 2015, J PHARM PHARM SCI, V18, P132, DOI 10.18433/J3P31K
   Kim DH, 2016, WORLD J GASTROENTERO, V22, P7017, DOI 10.3748/wjg.v22.i31.7017
   Kim JB, 1998, P NATL ACAD SCI USA, V95, P4333, DOI 10.1073/pnas.95.8.4333
   Leclerc I, 2001, DIABETES, V50, P1515, DOI 10.2337/diabetes.50.7.1515
   Lee Hye Rim, 2012, Lab Anim Res, V28, P71, DOI 10.5625/lar.2012.28.2.71
   Li Y, 2011, CELL METAB, V13, P376, DOI 10.1016/j.cmet.2011.03.009
   Li ZS, 2016, AM J TRANSL RES, V8, P142
   Lipovka Y, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20150074
   Medina JJM, 2017, J INORG BIOCHEM, V166, P150, DOI 10.1016/j.jinorgbio.2016.11.005
   Montenegro Landívar MF, 2021, SCI TOTAL ENVIRON, V801, DOI 10.1016/j.scitotenv.2021.149719
   Osborne CK, 2004, BRIT J CANCER, V90, pS2, DOI 10.1038/sj.bjc.6601629
   Paterni I, 2014, STEROIDS, V90, P13, DOI 10.1016/j.steroids.2014.06.012
   Pol S, 2012, J VIRAL HEPATITIS, V19, P377, DOI 10.1111/j.1365 2893.2012.01602.x
   Prossnitz ER, 2008, TRENDS PHARMACOL SCI, V29, P116, DOI 10.1016/j.tips.2008.01.001
   Puranik NV, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 43768 5
   Shi XL, 2013, CRIT CARE, V17, DOI 10.1186/cc13171
   Stecher C, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.698603
   Sureram S, 2024, INT J BIOL MACROMOL, V273, DOI 10.1016/j.ijbiomac.2024.133059
   ter Borg MJ, 2006, HEPATOLOGY, V44, P721, DOI 10.1002/hep.21302
   Tripathi DN, 2013, P NATL ACAD SCI USA, V110, pE2950, DOI 10.1073/pnas.1307736110
   Tzeng HT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039179
   Wang SC, 2022, INT J BIOL SCI, V18, P4669, DOI 10.7150/ijbs.74676
   Wang SH, 2012, GASTROENTEROLOGY, V142, P989, DOI 10.1053/j.gastro.2011.12.045
   Wang ZZ, 2022, RSC ADV, V12, P8737, DOI 10.1039/d1ra07553e
   Wani A, 2021, AUTOPHAGY, V17, P3813, DOI 10.1080/15548627.2021.1872187
   Xia CJ, 2020, TOXICOL APPL PHARM, V403, DOI 10.1016/j.taap.2020.115131
   Xie N, 2016, AUTOPHAGY, V12, P1507, DOI 10.1080/15548627.2016.1191857
   Xu ML, 2016, CHEM BIOL INTERACT, V259, P295, DOI 10.1016/j.cbi.2016.03.025
   Zhang KQ, 2011, CARDIOVASC RES, V89, P426, DOI 10.1093/cvr/cvq296
   Zhu HY, 2015, ANTIVIR RES, V113, P62, DOI 10.1016/j.antiviral.2014.11.003
   Zhuang Y, 2020, AGING US, V12, P11754, DOI 10.18632/aging.103341
   Zurli V, 2020, SCI SIGNAL, V13, DOI 10.1126/scisignal.aaz1965
NR 44
TC 3
Z9 3
U1 3
U2 6
PU NATURE PUBL GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1671 4083
EI 1745 7254
J9 ACTA PHARMACOL SIN
JI Acta Pharmacol. Sin.
PD MAR
PY 2025
VL 46
IS 3
BP 653
EP 661
DI 10.1038/s41401 024 01408 3
EA OCT 2024
PG 9
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA X8H3Y
UT WOS:001344987400001
PM 39478159
OA hybrid
DA 2025 08 17
ER

PT J
AU Kalyan, S
   Chandrasekaran, V
   Quabius, ES
   Lindhorst, TK
   Kabelitz, D
AF Kalyan, Shirin
   Chandrasekaran, Vijayanand
   Quabius, Elgar S.
   Lindhorst, Thisbe K.
   Kabelitz, Dieter
TI Neutrophil uptake of nitrogen bisphosphonates leads to the suppression
   of human peripheral blood γδ T cells
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Article
DE Nitrogen bisphosphonates; Osteoporosis therapy; Adverse drug effects;
   gamma delta T cells; Cancer therapy
ID HYDROGEN PEROXIDE; ZOLEDRONIC ACID; CANCER PATIENTS; IMMUNOTHERAPY;
   INTERLEUKIN 2; RECOGNITION; ACTIVATION; MECHANISMS; IMMUNOSUPPRESSION;
   MYELOPEROXIDASE
AB Nitrogen bisphosphonates (n BP), such as zoledronate, are the main class of drugs used for the prevention of osteoporotic fractures and the management of cancer associated bone disease. However, long term or high dose use has been associated with certain adverse drug effects, such as osteonecrosis of the jaw and the loss of peripheral of blood V gamma 9V delta 2 T cells, which appear to be linked to drug induced immune dysfunction. In this report we show that neutrophils present in human peripheral blood readily take up zoledronate, and this phenomenon is associated with the potent immune suppression of human peripheral blood V gamma 9V delta 2 T cells. Furthermore, we found this zoledronate mediated inhibition by neutrophils could be overcome to fully reconstitute V gamma 9V delta 2 T cell proliferation by concomitantly targeting neutrophil derived hydrogen peroxide, serine proteases, and arginase I activity. These findings will enable the development of targeted strategies to mitigate some of the adverse effects of n BP treatment on immune homeostasis and to improve the success of immunotherapy trials based on harnessing the anticancer potential of peripheral blood gamma delta T cells in the context of n BP treatment.
C1 [Kalyan, Shirin; Quabius, Elgar S.; Kabelitz, Dieter] Univ Kiel, Inst Immunol, D 24105 Kiel, Germany.
   [Chandrasekaran, Vijayanand; Lindhorst, Thisbe K.] Univ Kiel, Otto Diels Inst Organ Chem, D 24105 Kiel, Germany.
   [Quabius, Elgar S.] Univ Hosp Schleswig Holstein, Dept Otorhinolaryngol Head & Neck Surg, Kiel, Germany.
C3 University of Kiel; University of Kiel; University of Kiel; Schleswig
   Holstein University Hospital
RP Kalyan, S (通讯作者)，Univ Kiel, Inst Immunol, Arnold Heller Str 3,Haus 17, D 24105 Kiel, Germany.
EM kalyan@immunologie.uni kiel.de; kabelitz@immunologie.uni kiel.de
RI Kalyan, Shirin/E 2130 2011; Kabelitz, Dieter/A 2757 2010
OI Kalyan, Shirin/0000 0002 7332 2225; 
FU Alexander von Humboldt Foundation of Germany; Faculty of Medicine Grant
   from Christian Albrechts University of Kiel; Deutsche
   Forschungsgemeinschaft [Ka 502/10 2]
FX SK was supported by a Fellowship from the Alexander von Humboldt
   Foundation of Germany and a Faculty of Medicine Grant from
   Christian Albrechts University of Kiel. DK acknowledges grant support
   from the Deutsche Forschungsgemeinschaft (Ka 502/10 2 and
   "Inflammation at Interfaces" Cluster of Excellence). We would like to
   thank Hilke Clasen (Department of Immunology) for technical assistance,
   and Dr. Millan Patel (University of British Columbia) for review of the
   manuscript.
CR Bouet Toussaint F, 2008, CANCER IMMUNOL IMMUN, V57, P531, DOI 10.1007/s00262 007 0391 3
   Cabillic F, 2010, CANCER IMMUNOL IMMUN, V59, P1611, DOI 10.1007/s00262 010 0887 0
   CONSTANT P, 1994, SCIENCE, V264, P267, DOI 10.1126/science.8146660
   Davey MS, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002040
   ELHAG A, 1986, J IMMUNOL, V136, P3420
   ELHAG A, 1987, J IMMUNOL, V139, P2406
   Harly C, 2012, BLOOD, V120, P2269, DOI 10.1182/blood 2012 05 430470
   Kabelitz Dieter, 2008, Recent Pat Antiinfect Drug Discov, V3, P1, DOI 10.2174/157489108783413218
   Kalyan S, 2011, CURR MED CHEM, V18, P5206, DOI 10.2174/092986711798184280
   Kalyan S, 2013, J BONE MINER RES, V28, P728, DOI 10.1002/jbmr.1769
   Kalyan S, 2013, CELL MOL IMMUNOL, V10, P21, DOI 10.1038/cmi.2012.44
   Kashemirov BA, 2008, BIOCONJUGATE CHEM, V19, P2308, DOI 10.1021/bc800369c
   Kobayashi H, 2011, CANCER IMMUNOL IMMUN, V60, P1075, DOI 10.1007/s00262 011 1021 7
   Kondo M, 2008, CYTOTHERAPY, V10, P842, DOI 10.1080/14653240802419328
   Korkmaz B, 2010, PHARMACOL REV, V62, P726, DOI 10.1124/pr.110.002733
   Kuiper JWP, 2012, BRIT J PHARMACOL, V165, P532, DOI 10.1111/j.1476 5381.2011.01592.x
   Kunzmann V, 1999, NEW ENGL J MED, V340, P737, DOI 10.1056/NEJM199903043400914
   Lang JM, 2011, CANCER IMMUNOL IMMUN, V60, P1447, DOI 10.1007/s00262 011 1049 8
   Mattarollo SR, 2007, CANCER IMMUNOL IMMUN, V56, P1285, DOI 10.1007/s00262 007 0279 2
   Meraviglia S, 2010, CLIN EXP IMMUNOL, V161, P290, DOI 10.1111/j.1365 2249.2010.04167.x
   Miyagawa F, 2001, J IMMUNOL, V166, P5508, DOI 10.4049/jimmunol.166.9.5508
   Morita CT, 2007, IMMUNOL REV, V215, P59, DOI 10.1111/j.1600 065X.2006.00479.x
   Munder M, 2006, BLOOD, V108, P1627, DOI 10.1182/blood 2006 11 010389
   Nolan T, 2006, NAT PROTOC, V1, P1559, DOI 10.1038/nprot.2006.236
   PATTERSON DA, 1988, ARCH SURG CHICAGO, V123, P300
   Pham CTN, 2008, INT J BIOCHEM CELL B, V40, P1317, DOI 10.1016/j.biocel.2007.11.008
   Pillay J, 2012, J CLIN INVEST, V122, P327, DOI 10.1172/JCI57990
   Poccia F, 2009, AIDS, V23, P555, DOI 10.1097/QAD.0b013e3283244619
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Roelofs AJ, 2009, BRIT J HAEMATOL, V144, P245, DOI 10.1111/j.1365 2141.2008.07435.x
   Rotondo R, 2011, J LEUKOCYTE BIOL, V89, P721, DOI 10.1189/jlb.1109737
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Sippel TR, 2011, CLIN CANCER RES, V17, P6992, DOI 10.1158/1078 0432.CCR 11 1107
   Wang H, 2003, J IMMUNOL, V170, P3696, DOI 10.4049/jimmunol.170.7.3696
   Welton JL, 2013, J BONE MINER RES, V28, P464, DOI 10.1002/jbmr.1797
   Wimalawansa SJ, 2008, EXPERT OPIN DRUG SAF, V7, P491, DOI 10.1517/14740338.7.4.491 
   Zmijewski JW, 2009, AM J RESP CRIT CARE, V179, P694, DOI 10.1164/rccm.200806 851OC
NR 37
TC 55
Z9 61
U1 0
U2 9
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420 682X
EI 1420 9071
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD JUN
PY 2014
VL 71
IS 12
BP 2335
EP 2346
DI 10.1007/s00018 013 1495 x
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA AH8SJ
UT WOS:000336408200011
PM 24162933
OA Green Published
DA 2025 08 17
ER

PT J
AU Yan, B
   Zhou, H
   Chu, JP
   Cao, XP
AF Yan, Bo
   Zhou, Hong
   Chu, Jinpu
   Cao, Xuanping
TI Suppression of puerarin on polymethylmethacrylate induced lesion of
   peri implant by inhibiting NF κB activation in vitro and in
   vivo
SO PATHOLOGY RESEARCH AND PRACTICE
LA English
DT Article
DE Lesion of peri implant; NF kappa B signaling; Osteoclastogenesis;
   Polymethylmethacrylate; Puerarin
ID OSTEOCLAST FORMATION; RECEPTOR ACTIVATOR; INTERFACE TISSUE; BONE LOSS;
   LIGAND; DIFFERENTIATION; OSTEOPROTEGERIN; INFLAMMATION; EXPRESSION;
   OSTEOLYSIS
AB Puerarin (PR), a natural isoflavone isolated from Chinese traditional plant pueraria lobata, has attracted considerable attention due to its important biological and pharmacological activities. However, its effects on lesion of peri implant and related mechanism of action are still not clear, which require further investigation. In this study, we evaluated the effects of PR on polymethylmethacrylate (PMMA) induced lesion of peri implant in vitro and in vivo, and explored its possible mechanism of action. Our results indicated that PR could inhibit PMMA induced osteoclastogenesis in RAW264.7 cells with a dose dependent manner in vitro and effectively down regulate mRNA and protein expressions of matrix metalloprotein 9 (MMP 9), tumor necrosis factor (TNF) alpha, interleukin (IL) 6, and receptor activator of nuclear factor (NF) kappa B (RANK), primarily via the suppression of NF kappa B signaling. Furthermore, we found that PMMA induction could directly cause the phosphorylation of I kappa B and significantly promote the nuclear translocation of p65 in RAW264.7 cells. In other words, PR was able to dose dependently attenuate the PMMA induced nuclear translocation of p65 in RAW264.7 cells. In vivo, PR was observed to attenuate PMMA induced osteoclastogenesis, osteolysis, mRNA expressions of receptor activator of nuclear factor (NF) kappa B ligand (RANKL) and RANK, as well as protein levels of MMP 9, TNF alpha, IL 6, and p65 in a murine calvarial osteolysis model. These findings suggested that PR might be a potential therapeutic drug to lesion of peri implant, and provided new insights for understanding its possible mechanism.
C1 [Yan, Bo] Zhengzhou Univ, Affiliated Hosp 1, Dept Oral Radiol, 1 East Jianshe Rd, Zhengzhou 450052, Henan, Peoples R China.
   [Zhou, Hong] Zhengzhou Univ, Affiliated Hosp 1, Dept Dent Implant, 1 East Jianshe Rd, Zhengzhou 450052, Henan, Peoples R China.
   [Chu, Jinpu] Zhengzhou Univ, Affiliated Hosp 1, Sch Stomatol, 1 East Jianshe Rd, Zhengzhou 450052, Henan, Peoples R China.
   [Cao, Xuanping] Zhengzhou Univ, Affiliated Hosp 1, Dept Oral Surg, 1 East Jianshe Rd, Zhengzhou 450052, Henan, Peoples R China.
C3 Zhengzhou University; Zhengzhou University; Zhengzhou University;
   Zhengzhou University
RP Cao, XP (通讯作者)，Zhengzhou Univ, Affiliated Hosp 1, Dept Oral Surg, 1 East Jianshe Rd, Zhengzhou 450052, Henan, Peoples R China.
EM caoxp1962@163.com
CR Clohisy JC, 2002, J ORTHOPAED RES, V20, P174, DOI 10.1016/S0736 0266(01)00088 2
   Cong X, 2017, THERIOGENOLOGY, V88, P215, DOI 10.1016/j.theriogenology.2016.09.033
   Darowish M, 2009, BONE, V45, P661, DOI 10.1016/j.bone.2009.06.004
   Deng HF, 2018, BIOMED PHARMACOTHER, V104, P261, DOI 10.1016/j.biopha.2018.05.038
   Figuero E, 2014, PERIODONTOL 2000, V66, P255, DOI 10.1111/prd.12049
   Franco GCN, 2011, EXP CELL RES, V317, P1454, DOI 10.1016/j.yexcr.2011.03.014
   Goodman SB, 2010, BIOMATERIALS, V31, P5045, DOI 10.1016/j.biomaterials.2010.03.046
   Hayden MS, 2012, GENE DEV, V26, P203, DOI 10.1101/gad.183434.111
   Haynes DR, 2001, J BONE JOINT SURG BR, V83B, P902, DOI 10.1302/0301 620X.83B6.10905
   Holt G, 2007, CLIN ORTHOP RELAT R, P240, DOI 10.1097/BLO.0b013e31804b4147
   Hu WZ, 2011, PHARMACOL REP, V63, P781, DOI 10.1016/S1734 1140(11)70590 4
   Jiang C, 2015, BIOCHIMIE, V111, P107, DOI 10.1016/j.biochi.2015.02.002
   Keyler DE, 2002, J ALTERN COMPLEM MED, V8, P175, DOI 10.1089/107555302317371460
   Kitaura H, 2005, J CLIN INVEST, V115, P3418, DOI 10.1172/JCI26132
   Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651
   Li XL, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 14906 8
   Lindhe J, 2008, J CLIN PERIODONTOL, V35, P282, DOI 10.1111/j.1600 051X.2008.01283.x
   Mandelin J, 2005, J RHEUMATOL, V32, P713
   Mandelin J, 2003, J BONE JOINT SURG BR, V85B, P1196, DOI 10.1302/0301 620X.85B8.13311
   Peng XC, 2008, BIOCHEM BIOPH RES CO, V377, P532, DOI 10.1016/j.bbrc.2008.10.026
   Qu C, 2015, FASEB J, V29, P1269, DOI 10.1096/fj.14 264804
   Sabokbar A, 1998, ARCH ORTHOP TRAUM SU, V117, P136, DOI 10.1007/s004020050213
   Soysa NS, 2009, BIOCHEM BIOPH RES CO, V378, P1, DOI 10.1016/j.bbrc.2008.10.146
   Taki N, 2007, BONE, V40, P1276, DOI 10.1016/j.bone.2006.12.053
   Wang W, 1997, J PATHOL, V182, P92
   Wang Y, 2014, PHYTOMEDICINE, V21, P1032, DOI 10.1016/j.phymed.2014.04.012
   Yang XJ, 2010, BASIC CLIN PHARMACOL, V107, P637, DOI 10.1111/j.1742 7843.2010.00548.x
   Yu ZL, 2006, CANCER LETT, V238, P53, DOI 10.1016/j.canlet.2005.06.022
   Yuan SY, 2016, CHIN J NAT MEDICINES, V14, P265, DOI 10.1016/S1875 5364(16)30026 7
   Zhang H, 2008, ACTA ORTHOP, V79, P281, DOI 10.1080/17453670710015166
   Zhang Y, 2016, BIOL PHARM BULL, V39, P2028, DOI 10.1248/bpb.b16 00522
NR 31
TC 2
Z9 4
U1 0
U2 15
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0344 0338
J9 PATHOL RES PRACT
JI Pathol. Res. Pract.
PY 2019
VL 215
IS 6
AR 152372
DI 10.1016/j.prp.2019.03.001
PG 8
WC Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pathology
GA IV2KT
UT WOS:000484106800008
PM 30853175
DA 2025 08 17
ER

PT J
AU Shrivats, AR
   McDermott, MC
   Klimak, M
   Averick, SE
   Pan, HC
   Matyjaszewski, K
   Mishina, Y
   Hollinger, JO
AF Shrivats, Arun R.
   McDermott, Michael C.
   Klimak, Molly
   Averick, Saadyah E.
   Pan, Haichun
   Matyjaszewski, Krzysztof
   Mishina, Yuji
   Hollinger, Jeffrey O.
TI Nanogel Mediated RNAi Against Runx2 and Osx Inhibits Osteogenic
   Differentiation in Constitutively Active BMPR1A Osteoblasts
SO ACS BIOMATERIALS SCIENCE & ENGINEERING
LA English
DT Article
DE atom transfer radical polymerization; gene delivery; siRNA; bone
   morphogenetic protein; heterotopic ossification; fibrodysplasia
   ossificans progressiva
ID HETEROTOPIC OSSIFICATION; TRANSCRIPTION FACTOR; SIRNA DELIVERY; OSTERIX;
   EXPRESSION; MINERALIZATION; RUNX2/CBFA1; POLYMERS; GENE
AB Trauma induced heterotopic ossification (HO) and fibrodysplasia ossificans progressiva (FOP) are acquired and genetic variants of pathological bone formation occurring in soft tissues. Conventional treatment modalities target the inflammatory processes preceding bone formation. We investigated the development of a prophylaxis for heterotopic bone formation by addressing the biological basis for HO   dysregulation in the bone morphogenetic protein (BMP) signaling pathway. We previously reported the synthesis of cationic nanogel nanostructured polymers (NSPs) for efficient delivery of short interfering ribonucleic acids (siRNAs) and targeted gene silencing. Results suggested that nanogel:siRNA weight ratios of 1:1 and 5:1 silenced Runx2 and Osx gene expression in primary mouse osteoblasts with a constitutively active (ca) BMP Receptor 1A (BMPR1A) by the Q233D mutation. Repeated RNAi treatments over 14 days significantly inhibited alkaline phosphatase activity in caBMPR1A osteoblasts. Hydroxyapatite (HA) deposition was diminished over 28 days in culture, though complete suppression of HA deposition was not achieved. Outcome data suggested minimal cytotoxicity of nanogel based RNAi therapeutics, and the multistage disruption of BMP induced bone formation processes. This RNAi based approach to impeding osteoblastic differentiation and subsequent bone formation may form the basis of a clinical therapy for heterotopic bone formation.
C1 [Shrivats, Arun R.; McDermott, Michael C.; Klimak, Molly; Hollinger, Jeffrey O.] Carnegie Mellon Univ, Dept Biomed Engn, 700 Technol Dr, Pittsburgh, PA 15219 USA.
   [Averick, Saadyah E.; Matyjaszewski, Krzysztof] Carnegie Mellon Univ, Dept Chem, Pittsburgh, PA 15213 USA.
   [Pan, Haichun; Mishina, Yuji] Univ Michigan, Sch Dent, Ann Arbor, MI 48109 USA.
C3 Carnegie Mellon University; Carnegie Mellon University; University of
   Michigan System; University of Michigan
RP Hollinger, JO (通讯作者)，Carnegie Mellon Univ, Dept Biomed Engn, 700 Technol Dr, Pittsburgh, PA 15219 USA.
EM jhollinge@andrew.cmu.edu
RI Matyjaszewski, Krzysztof/A 2508 2008; Averick, Saadyah/A 9999 2015
OI Matyjaszewski, Krzysztof/0000 0003 1960 3402; Klimak,
   Molly/0000 0003 4673 9540; McDermott, Michael/0000 0001 5628 3378;
   Averick, Saadyah/0000 0003 4775 2317
FU Department of Defense [W81XWH1120073]; Defense Medical Research and
   Development Program; National Institutes of Health [R01DE020843]; 
   [DMR 1501324]; Direct For Mathematical & Physical Scien; Division Of
   Materials Research [1501324] Funding Source: National Science
   Foundation; U.S. Department of Defense (DOD) [W81XWH1120073] Funding
   Source: U.S. Department of Defense (DOD)
FX The authors gratefully acknowledge DMR 1501324 and Department of Defense
   Grant W81XWH1120073, which was awarded by the Defense Medical Research
   and Development Program, for funding. Y.M. and K.M. are supported by the
   National Institutes of Health (R01DE020843).
CR Agarwal S, 2012, MATER TODAY, V15, P388, DOI 10.1016/S1369 7021(12)70165 7
   Averick SE, 2012, BIOMACROMOLECULES, V13, P3445, DOI 10.1021/bm301166s
   Bikkavilli Rama Kamesh, 2009, Commun Integr Biol, V2, P46
   Chao ST, 2007, ORTHOPEDICS, V30, P457, DOI 10.3928/01477447 20070601 18
   Chen D, 2004, FRONT BIOSCI LANDMRK, V9, P349, DOI 10.2741/1090
   CONNOR JM, 1982, J BONE JOINT SURG BR, V64, P76, DOI 10.1302/0301 620X.64B1.7068725
   Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097 4652(200009)184:3<341::AID JCP8>3.3.CO;2 Q
   Eliyahu H, 2005, MOLECULES, V10, P34, DOI 10.3390/10010034
   Forsberg JA, 2009, J BONE JOINT SURG AM, V91A, P1084, DOI 10.2106/JBJS.H.00792
   Franceschi RT, 2003, CONNECT TISSUE RES, V44, P109, DOI 10.1080/03008200390152188
   Gannon FH, 1997, HUM PATHOL, V28, P339, DOI 10.1016/S0046 8177(97)90133 7
   GARLAND DE, 1991, CLIN ORTHOP RELAT R, P13
   Healy W L, 1990, J Arthroplasty, V5, P369, DOI 10.1016/S0883 5403(08)80097 6
   Hsu EW, 2014, J BIOMED NANOTECHNOL, V10, P1130, DOI 10.1166/jbn.2014.1823
   Kamiya N, 2008, DEVELOPMENT, V135, P3801, DOI 10.1242/dev.025825
   Kan LX, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/309287
   Kaplan FS, 2010, J BONE JOINT SURG AM, V92A, P686, DOI 10.2106/JBJS.I.00705
   Komatsu Y, 2013, J BONE MINER RES, V28, P1422, DOI 10.1002/jbmr.1857
   Komori T, 2002, J CELL BIOCHEM, V87, P1, DOI 10.1002/jcb.10276
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Lavery K, 2008, J BIOL CHEM, V283, P20948, DOI 10.1074/jbc.M800850200
   Lin L, 2006, BIOCHEM BIOPH RES CO, V349, P564, DOI 10.1016/j.bbrc.2006.08.089
   Matsubara T, 2008, J BIOL CHEM, V283, P29119, DOI 10.1074/jbc.M801774200
   Matyjaszewski K, 2001, CHEM REV, V101, P2921, DOI 10.1021/cr940534g
   Matyjaszewski K, 2014, J AM CHEM SOC, V136, P6513, DOI 10.1021/ja408069v
   Matyjaszewski K, 2012, MACROMOLECULES, V45, P4015, DOI 10.1021/ma3001719
   Mishra S, 2012, INTEGR BIOL UK, V4, P1498, DOI 10.1039/c2ib20200j
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nishio Y, 2006, GENE, V372, P62, DOI 10.1016/j.gene.2005.12.022
   Otto F, 2002, HUM MUTAT, V19, P209, DOI 10.1002/humu.10043
   Parkinson J R, 1982, Hip, P211
   Prince M, 2001, J CELL BIOCHEM, V80, P424, DOI 10.1002/1097 4644(20010301)80:3<424::AID JCB160>3.0.CO;2 6
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Ryoo HM, 2006, GENE, V366, P51, DOI 10.1016/j.gene.2005.10.011
   Shore EM, 2006, NAT GENET, V38, P525, DOI 10.1038/ng1783
   Shrivats A. R., 2013, BIOMIMETICS STEM CEL
   Shrivats Arun R., 2015, Bioengineering Basel, V2, P160, DOI 10.3390/bioengineering2030160
   Shrivats AR, 2015, CLIN ORTHOP RELAT R, V473, P2139, DOI 10.1007/s11999 014 4073 0
   Shrivats AR, 2014, PRINCIPLES OF TISSUE ENGINEERING, 4TH EDITION, P1201, DOI 10.1016/B978 0 12 398358 9.00055 0
   Smith R, 1998, CLIN ORTHOP RELAT R, P7
   Tam Yuen Yi C, 2013, Pharmaceutics, V5, P498, DOI 10.3390/pharmaceutics5030498
   Tsionos I, 2004, J BONE JOINT SURG BR, V86B, P396, DOI 10.1302/0301 620X.86B3.14480
   Ulsamer A, 2008, J BIOL CHEM, V283, P3816, DOI 10.1074/jbc.M704724200
   Wan C, 2014, DRUG DELIV TRANSL RE, V4, P74, DOI 10.1007/s13346 013 0161 z
   Wang J, 2010, AAPS J, V12, P492, DOI 10.1208/s12248 010 9210 4
   Whelton A., 1999, Am J Med, V106, p13S, DOI [10.1016/S0002 9343(99)00113 8, DOI 10.1016/S0002 9343(99)00113 8]
   Yamauchi Y, 1999, DEV BIOL, V212, P191, DOI 10.1006/dbio.1999.9323
NR 47
TC 12
Z9 14
U1 1
U2 17
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2373 9878
J9 ACS BIOMATER SCI ENG
JI ACS Biomater. Sci. Eng.
PD NOV
PY 2015
VL 1
IS 11
BP 1139
EP 1150
DI 10.1021/acsbiomaterials.5b00294
PG 12
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA DC6RY
UT WOS:000369348500011
PM 26985455
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Ishizuka, Y
   Moriwaki, S
   Kawahara Hanaoka, M
   Uemura, Y
   Serizawa, I
   Miyauchi, M
   Shibata, S
   Kanaya, T
   Takata, T
   Taniguchi, N
   Niida, S
AF Ishizuka, Yasuyuki
   Moriwaki, Sawako
   Kawahara Hanaoka, Miyuki
   Uemura, Yasunori
   Serizawa, Isao
   Miyauchi, Mutsumi
   Shibata, Shunichi
   Kanaya, Toshimichi
   Takata, Takashi
   Taniguchi, Naoyuki
   Niida, Shumpei
TI Treatment with anti γ glutamyl transpeptidase antibody attenuates
   osteolysis in collagen induced arthritis mice
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE antibody therapy; arthritis; y glutamyl transpeptidase; osteoclast;
   osteolysis
ID OSTEOCLAST LIKE CELLS; RHEUMATOID ARTHRITIS; BONE DESTRUCTION; OXIDATIVE
   STRESS; EXPRESSION; POPULATIONS; INFLIXIMAB; MECHANISM; ACTIVATOR; MODEL
AB The effectiveness of a new antibody treatment on arthritis associated osteolysis was studied by using CIA mice. GGT, a newly identified bone resorbing factor, was upregulated in arthritic joints. We generated monoclonal antibodies against GGT and injected them into CIA mice. Mice treated with antibodies showed a reduction in osteoclast number and bone erosion.
   Introduction: gamma Glutamyl transpeptidase (GGT) acts as a bone resorbing factor that stimulates osteoclast formation. GGT expression has been detected in active lymphocytes that accumulate at inflammation sites, such as rheumatoid arthritis (RA). We hypothesize that GGT is an effective target for suppression of arthritis related osteoclastogenesis and joint destruction. Here, we describe the therapeutic effect of neutralizing antibodies against GGT on joint destruction using a collagen induced arthritis (CIA) mouse model.
   Materials and Methods: GGT expression in the synovium of RA patients and CIA mice was determined by immunohistochemistry and RT PCR. Monoclonal antibodies were generated against recombinant human GGT (GGT mAbs) using BALB/c mice. Antibody treatment was performed by intraperitoneal injections of GGT mAbs into CIA mice. Effects of antibody treatment on arthritis and bone erosion were evaluated by incidence score, arthritis score, and histopathological observations. The role of GGT in osteoclast development was examined by using the established osteoclastogenic culture system.
   Results: GGT expression was significantly upregulated in inflamed synovium. Immunohistochemistry revealed that GGT was present in lymphocytes, plasma cells, and macrophages, as well as capillaries. Injection of GGT mAbs significantly decreased the number of osteoclasts and attenuated the severity of joint destruction in CIA mice. In vitro examination showed that GGT enhanced RANKL dependent osteoclast formation. GGT stimulated the expression of RANKL in osteoblasts and its receptor RANK in osteoclast precursors, respectively.
   Conclusions: This study indicates that inflamed synovial tissue derived GGT acts as a risk factor for joint destruction and that the antibody mediated inhibition of GGT significantly decreases osteoclast number and bone erosion in CIA mice. GGT antagonists might be novel therapeutic agents for attenuating joint destruction in RA patients.
C1 Appl Cell Biotechnol, Yokohama, Kanagawa, Japan.
   Natl Ctr Geriat & Gerontol, Res Inst, Dept Bone & Joint Dis, Aichi, Japan.
   Ishida Dent Orthodont Clin, Hiroshima, Japan.
   Kirin Brewery Co Ltd, Pharmaceut Res Labs, Takasaki, Gunma, Japan.
   Hiroshima Univ, Grad Sch Biomed Sci, Dept Oral & Maxillofacial Pathobiol, Hiroshima, Japan.
   Jikei Univ, Sch Med, Dept Biochem, Tokyo, Japan.
   Osaka Univ, Sch Med, Dept Biochem, Osaka, Japan.
   Kitayama Labes Co, Ina Bio Ctr, Nagano, Japan.
C3 National Center for Geriatrics & Gerontology; Kirin Brewery Company
   Limited; Hiroshima University; Jikei University; University of Osaka
RP Ishizuka, Y (通讯作者)，Appl Cell Biotechnol, Yokohama, Kanagawa, Japan.
RI Miyauchi, Mutsumi/G 5268 2019; Taniguchi, Naoyuki/I 4182 2014
OI Taniguchi, Naoyuki/0000 0001 5889 5968
CR Bratcher JM, 2006, EXPERT OPIN DRUG SAF, V5, P9, DOI 10.1517/14740338.5.1.9
   Carlisle ML, 2003, INT IMMUNOL, V15, P17, DOI 10.1093/intimm/dxg010
   Feldmann M, 2003, NAT MED, V9, P1245, DOI 10.1038/nm939
   Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397
   GOLDRING SR, 2002, CURR RHEUMATOL REP, V2, P226
   GRISK O, 1993, BIOL CHEM H S, V374, P287, DOI 10.1515/bchm3.1993.374.1 6.287
   Hanigan MH, 1996, J HISTOCHEM CYTOCHEM, V44, P1101, DOI 10.1177/44.10.8813074
   Hiramatsu K, 2007, ENDOCRINOLOGY, V148, P2708, DOI 10.1210/en.2007 0215
   HOLMDAHL R, 1986, ARTHRITIS RHEUM US, V29, P400, DOI 10.1002/art.1780290314
   IKEDA Y, 1995, P NATL ACAD SCI USA, V92, P126, DOI 10.1073/pnas.92.1.126
   Ishizuka Y, 1999, BBA MOL CELL RES, V1450, P92, DOI 10.1016/S0167 4889(99)00039 7
   Kamijo S, 2006, BIOCHEM BIOPH RES CO, V347, P124, DOI 10.1016/j.bbrc.2006.06.098
   Karp DR, 1999, INT IMMUNOL, V11, P1791, DOI 10.1093/intimm/11.11.1791
   Katagiri M, 2006, J BONE MINER RES, V21, P219, DOI 10.1359/JBMR.051025
   Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110
   Lawrence BP, 2000, EUR J IMMUNOL, V30, P1902
   LIEBERMAN MW, 1995, AM J PATHOL, V147, P1175
   MAPP PI, 1995, BRIT MED BULL, V51, P419, DOI 10.1093/oxfordjournals.bmb.a072970
   Miyauchi M, 2001, HISTOCHEM CELL BIOL, V116, P57
   Mochizuki A, 2006, J IMMUNOL, V177, P4360, DOI 10.4049/jimmunol.177.7.4360
   Niida S, 2004, J BIOL CHEM, V279, P5752, DOI 10.1074/jbc.M311905200
   NOVOGRODSKY A, 1976, P NATL ACAD SCI USA, V73, P2414, DOI 10.1073/pnas.73.7.2414
   Shomer NH, 2003, INFECT IMMUN, V71, P3572, DOI 10.1128/IAI.71.6.3572 3577.2003
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Straub RH, 2006, ARTHRITIS RHEUM US, V54, P1778, DOI 10.1002/art.21826
   Suzuki Y, 1998, J RHEUMATOL, V25, P1154
   Suzuki Y, 2001, RHEUMATOLOGY, V40, P673, DOI 10.1093/rheumatology/40.6.673
   Tak PP, 2000, IMMUNOL TODAY, V21, P78, DOI 10.1016/S0167 5699(99)01552 2
   Takayanagi H, 2005, J PERIODONTAL RES, V40, P287, DOI 10.1111/j.1600 0765.2005.00814.x
   Takayanagi H, 1997, BIOCHEM BIOPH RES CO, V240, P279, DOI 10.1006/bbrc.1997.7404
   Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   Udagawa N, 1997, J EXP MED, V185, P1005, DOI 10.1084/jem.185.6.1005
   Udagawa N, 2002, ARTHRITIS RES, V4, P281, DOI 10.1186/ar431
NR 34
TC 20
Z9 21
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD DEC
PY 2007
VL 22
IS 12
BP 1933
EP 1942
DI 10.1359/JBMR.070726
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 236HA
UT WOS:000251292400014
PM 17680722
DA 2025 08 17
ER

PT J
AU Knowles, HJ
   Vasilyeva, A
   Sheth, M
   Pattinson, O
   May, J
   Rumney, RMH
   Hulley, PA
   Richards, DB
   Carugo, D
   Evans, ND
   Stride, E
AF Knowles, Helen J.
   Vasilyeva, Alexandra
   Sheth, Mihir
   Pattinson, Oliver
   May, Jonathan
   Rumney, Robin M. H.
   Hulley, Philippa A.
   Richards, Duncan B.
   Carugo, Dario
   Evans, Nicholas D.
   Stride, Eleanor
TI Use of oxygen loaded nanobubbles to improve tissue oxygenation:
   Bone relevant mechanisms of action and effects on osteoclast
   differentiation
SO BIOMATERIALS
LA English
DT Article
DE Nanobubble; Oxygen; Monocyte; Osteoclast; Osteoclastogenesis; Fusion
ID HYPOXIA; RESORPTION; DELIVERY
AB Gas loaded nanobubbles have potential as a method of oxygen delivery to increase tumour oxygenation and therapeutically alleviate tumour hypoxia. However, the mechanism(s) whereby oxygen loaded nanobubbles increase tumour oxygenation are unknown; with their calculated oxygen carrying capacity being insufficient to explain this effect. Intra tumoural hypoxia is a prime therapeutic target, at least partly due to hypoxia dependent stimulation of the formation and function of bone resorbing osteoclasts which establish metastatic cells in bone. This study aims to investigate potential mechanism(s) of oxygen delivery and in particular the possible use of oxygen loaded nanobubbles in preventing bone metastasis via effects on osteoclasts. Lecithin based nanobubbles preferentially interacted with phagocytic cells (monocytes, osteoclasts) via a combination of lipid transfer, clathrin dependent endocytosis and phagocytosis. This interaction caused general suppression of osteoclast differentiation via inhibition of cell fusion. Additionally, repeat exposure to oxygen loaded nanobubbles inhibited osteoclast formation to a greater extent than nitrogen loaded nanobubbles. This gas dependent effect was driven by differential effects on the fusion of mononuclear precursor cells to form pre osteoclasts, partly due to elevated potentiation of RANKL induced ROS by nitrogen loaded nanobubbles. Our findings suggest that oxygen loaded nanobubbles could represent a promising therapeutic strategy for cancer therapy; reducing osteoclast formation and therefore bone metastasis via preferential interaction with monocytes/macrophages within the tumour and bone microenvironment, in addition to known effects of directly improving tumour oxygenation.
C1 [Knowles, Helen J.; Vasilyeva, Alexandra; Sheth, Mihir; Hulley, Philippa A.; Richards, Duncan B.; Carugo, Dario; Stride, Eleanor] Univ Oxford, Bot Inst Musculoskeletal Sci, Nuffield Dept Orthopaed Rheumatol & Musculoskeleta, Oxford, England.
   [Vasilyeva, Alexandra; Sheth, Mihir; Stride, Eleanor] Univ Oxford, Inst Biomed Engn, Dept Engn Sci, Oxford, England.
   [Pattinson, Oliver; May, Jonathan; Evans, Nicholas D.] Univ Southampton, Southampton Gen Hosp, Bone & Joint Res Grp, Human Dev & Hlth,Fac Med, Southampton, England.
   [Rumney, Robin M. H.] Univ Portsmouth, Sch Pharm & Biomed Sci, Portsmouth, England.
   [Stride, Eleanor] Univ Oxford, Bot Res Ctr, Nuffield Orthopaed Ctr, Oxford OX3 7LD, England.
C3 University of Oxford; University of Oxford; University of Southampton;
   University of Portsmouth; University of Oxford; Nuffield Orthopaedic
   Centre
RP Stride, E (通讯作者)，Univ Oxford, Bot Res Ctr, Nuffield Orthopaed Ctr, Oxford OX3 7LD, England.
EM eleanor.stride@eng.ox.ac.uk
RI Rumney, Robin/H 6805 2019; Knowles, Helen/F 3857 2018; Hulley,
   Philippa/A 8538 2011; May, Jonathan/AAA 1894 2020; May,
   Jonathan/T 4546 2017
OI Rumney, Robin Mark Howard/0000 0002 4266 5962; Knowles,
   Helen/0000 0002 9575 6067; Hulley, Philippa/0000 0002 4994 2264; Sheth,
   Mihir/0000 0001 5605 4671; May, Jonathan/0000 0003 1651 130X; Evans,
   Nicholas/0000 0002 3255 4388
FU UK  SPINE [R52853/CN023]; EPSRC [EP/R013624/1, EP/R013594/1]; National
   Institute for Health and Care Research (NIHR) Oxford Biomedical Research
   Centre (BRC)
FX This work was supported by funding from UK  SPINE (R52853/CN023) , the
   EPSRC (EP/R013624/1, EP/R013594/1) and the National Institute for Health
   and Care Research (NIHR) Oxford Biomedical Research Centre (BRC) . We
   also gratefully acknowledge the support of Gilberto Sayao da Silva whose
   donation to the University funded Mihir Sheth ' s salary. Many thanks to
   Dr Christoffer Lagerholm and Dr Emma Morris for technical assistance
   with confocal microscopy.
CR Agidigbi TS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143576
   Arnett TR, 2003, J CELL PHYSIOL, V196, P2, DOI 10.1002/jcp.10321
   Bhandari PN, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 08988 7
   BRIGHTON CT, 1972, J BONE JOINT SURG AM, VA 54, P323, DOI 10.2106/00004623 197254020 00010
   Bui BP, 2022, CANCERS, V14, DOI 10.3390/cancers14246054
   Carugo D, 2017, BIOMATERIALS, V113, P105, DOI 10.1016/j.biomaterials.2016.10.034
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Dou C, 2018, J BONE MINER RES, V33, P899, DOI 10.1002/jbmr.3364
   Eisenbrey JR, 2015, INT J PHARMACEUT, V478, P361, DOI 10.1016/j.ijpharm.2014.11.023
   Feshitan JA, 2014, BIOMATERIALS, V35, P2600, DOI 10.1016/j.biomaterials.2013.12.070
   Fournier L, 2023, BIOMATERIALS, V294, DOI 10.1016/j.biomaterials.2023.122025
   Fujikawa Y, 1996, ENDOCRINOLOGY, V137, P4058, DOI 10.1210/en.137.9.4058
   Gombodorj N, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23126838
   Gratton SEA, 2008, P NATL ACAD SCI USA, V105, P11613, DOI 10.1073/pnas.0801763105
   Gulino GR, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/964838
   Hiraga T, 2007, CANCER RES, V67, P4157, DOI 10.1158/0008 5472.CAN 06 2355
   Hiraga T, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113523
   Huang TB, 2023, ISCIENCE, V26, DOI 10.1016/j.isci.2023.106682
   Huang XY, 2022, INT J MOL MED, V50, DOI 10.3892/ijmm.2022.5197
   Hulley PA, 2020, JBMR PLUS, V4, DOI 10.1002/jbm4.10370
   Hulley PA, 2017, J PATHOL, V242, P322, DOI 10.1002/path.4906
   Jeganathan S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104498
   Kang JH, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2712 9
   Kelly C, 2011, J DRUG DELIV, V2011, DOI 10.1155/2011/727241
   Khan MS, 2019, CANCERS, V11, DOI 10.3390/cancers11101464
   Khan MS, 2018, ARTIF CELL NANOMED B, V46, pS318, DOI 10.1080/21691401.2018.1492420
   Kheir JN, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003679
   Kim HS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01527 y
   King DG, 2024, J DIET SUPPL, V21, P167, DOI 10.1080/19390211.2023.2203738
   Knowles H.J., 2022, Bone Cancer: Bone Sarcomas and Bone Metastases   from Bench to Bedside, V3rd
   Knowles HJ, 2015, HYPOXIA, V3, P73, DOI 10.2147/HP.S95960
   Knowles HJ, 2009, J PATHOL, V218, P256, DOI 10.1002/path.2534
   KOFOED H, 1986, INJURY, V17, P391, DOI 10.1016/0020 1383(86)90078 1
   Mahjour A, 2019, J CELL BIOCHEM, V120, P15546, DOI 10.1002/jcb.28821
   Maurer P, 2006, INT J ORAL MAX SURG, V35, P231, DOI 10.1016/j.ijom.2005.07.016
   Maurizi A, 2018, CANCERS, V10, DOI 10.3390/cancers10070218
   McDonald MM, 2021, CELL, V184, P1940, DOI 10.1016/j.cell.2021.03.010
   Muzylak M, 2006, CALCIFIED TISSUE INT, V79, P301, DOI 10.1007/s00223 006 0082 7
   Neale SD, 2000, J ARTHROPLASTY, V15, P654, DOI 10.1054/arth.2000.6622
   Ottaviano L, 2010, GENE CHROMOSOME CANC, V49, P40, DOI 10.1002/gcc.20717
   Owen J., 2021, Nano Select, P1
   Owen J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168088
   Pierrevelcin M, 2020, CELLS BASEL, V9, DOI 10.3390/cells9091998
   Quinn JMW, 1998, ENDOCRINOLOGY, V139, P4424, DOI 10.1210/endo.139.10.6331
   Reynaud C, 2017, CANCER RES, V77, P268, DOI 10.1158/0008 5472.CAN 15 2621
   Richter RP, 2005, BIOPHYS J, V89, P3372, DOI 10.1529/biophysj.105.064337
   Sabi EM, 2022, INFLAMMOPHARMACOLOGY, V30, P737, DOI 10.1007/s10787 022 00974 4
   Sahay G, 2010, J CONTROL RELEASE, V145, P182, DOI 10.1016/j.jconrel.2010.01.036
   Schito L, 2016, TRENDS CANCER, V2, P758, DOI 10.1016/j.trecan.2016.10.016
   Song RY, 2018, ACS APPL MATER INTER, V10, P36805, DOI 10.1021/acsami.8b15293
   Taheem DK, 2020, TISSUE ENG PART B RE, V26, P105, DOI [10.1089/ten.teb.2019.0283, 10.1089/ten.TEB.2019.0283]
   Takemori T, 2018, ONCOL REP, V40, P2079, DOI 10.3892/or.2018.6608
   Takito J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186629
   Torres M, 2021, MEMBRANES BASEL, V11, DOI 10.3390/membranes11120919
   Utting JC, 2010, CELL BIOCHEM FUNCT, V28, P374, DOI 10.1002/cbf.1660
   Verma SK, 2018, J BIOL CHEM, V293, P254, DOI 10.1074/jbc.M117.809681
   Wang YJ, 2022, PHARMACOL THERAPEUT, V240, DOI 10.1016/j.pharmthera.2022.108303
   Zhuang Y, 2023, MEDCOMM, V4, DOI 10.1002/mco2.203
NR 58
TC 11
Z9 12
U1 10
U2 33
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD MAR
PY 2024
VL 305
AR 122448
DI 10.1016/j.biomaterials.2023.122448
EA JAN 2024
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA HT4U6
UT WOS:001161754100001
PM 38218121
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Samarpita, S
   Rasool, M
AF Samarpita, Snigdha
   Rasool, Mahaboobkhan
TI Cyanidin attenuates IL 17A cytokine signaling mediated monocyte
   migration and differentiation into mature osteoclasts in rheumatoid
   arthritis
SO CYTOKINE
LA English
DT Article
DE Cyanidin; Interleukin 17A; Monocyte migration; Osteoclastogenesis;
   Rheumatoid arthritis
ID RANKL
AB Interleukin (IL) 17A signaling pathway plays a critical role in the initiation and progression of rheumatoid arthritis (RA) and represents a viable target for RA therapy. Cyanidin, a flavonoid compound, is a novel inhibitor of IL 17A/IL 17RA (receptor subunit A) interaction in several inflammatory diseases. However, the therapeutic efficacy of cyanidin on IL 17A cytokine signaling induced monocyte migration and fibroblast like synoviocytes (FLS) released RANKL mediated osteoclastogenesis in RA has not yet been deciphered. In the present study, cyanidin impeded IL 17A induced migration of monocytes isolated from adjuvant induced arthritic (AA) rats. At the molecular level, cyanidin blocked the activation of p38MAPK signaling in response to IL 17A. Importantly, cyanidin downregulated IL 17A induced expression of HSP27, CXCR4, and CCR7 in AA monocytes via modulating IL 17/p38 MAPK signaling axis. Alternatively, cyanidin significantly suppressed the formation of matured osteoclasts and bone resorption in a coculture system consisting of IL 17 treated AA FLS and rat bone marrowderived monocytes/macrophages. Further, cyanidin significantly inhibited the expression of RANKL and increased the expression of OPG in AA FLS via blunted activation of IL 17A/STAT 3 signaling cascade. Interestingly, cyanidin impaired IL 17A induced overexpression of IL 17RA. Taken together, our study proposes a novel therapeutic function of cyanidin towards targeted inhibition of IL 17A/IL 17RA signaling mediated disease severity and bone erosion in RA.
C1 [Samarpita, Snigdha; Rasool, Mahaboobkhan] Vellore Inst Technol VIT, Sch Bio Sci & Technol, Immunopathol Lab, SMV 240, Vellore 632014, Tamil Nadu, India.
C3 Vellore Institute of Technology (VIT); VIT Vellore
RP Rasool, M (通讯作者)，Vellore Inst Technol VIT, Sch Bio Sci & Technol, Immunopathol Lab, SMV 240, Vellore 632014, Tamil Nadu, India.
EM rasool.m@vit.ac.in
RI Rasool, Mahaboobkhan/KOC 4395 2024
OI Rasool, Mahaboobkhan/0000 0003 4980 5355
FU Science and Engineering Research Board (SERB) , Department of Science
   and Technology, Government of India, New Delhi [EMR/2017/000523]
FX This work was supported by the Science and Engineering Research Board
   (SERB) , Department of Science and Technology, Government of India, New
   Delhi (File no. EMR/2017/000523) .
CR [Anonymous], 2012, ARTH RES THER
   Arefieva TI, 2005, CYTOKINE, V31, P439, DOI 10.1016/j.cyto.2005.06.016
   Cecchinato V, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02118
   Cheng JW, 2018, J CELL PHYSIOL, V233, P2502, DOI 10.1002/jcp.26126
   Di Fede O, 2016, ORAL DIS, V22, P543, DOI 10.1111/odi.12490
   Elmesmari A, 2016, RHEUMATOLOGY, V55, P2056, DOI 10.1093/rheumatology/kew272
   Fischer JAA, 2015, ARTHRITIS RHEUMATOL, V67, P51, DOI 10.1002/art.38896
   Ganesan R, 2019, J CELL BIOCHEM, V120, P1878, DOI 10.1002/jcb.27502
   Genovese MC, 2013, ANN RHEUM DIS, V72, P863, DOI 10.1136/annrheumdis 2012 201601
   Graham John M, 2002, ScientificWorldJournal, V2, P1540
   Jin W, 2013, EMERG MICROBES INFEC, V2, DOI 10.1038/emi.2013.58
   Katschke KJ, 2001, ARTHRITIS RHEUM, V44, P1022, DOI 10.1002/1529 0131(200105)44:5<1022::AID ANR181>3.0.CO;2 N
   Kellner H, 2013, THER ADV MUSCULOSKEL, V5, P141, DOI 10.1177/1759720X13485328
   Kylmaoja E., HELIYON, V1
   Li J, 2015, SCI REP UK, V5, DOI 10.1038/srep17605
   Liu CN, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aaf8823
   McHugh J, 2019, NAT REV RHEUMATOL, V15, P576, DOI 10.1038/s41584 019 0296 5
   Monin L, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028522
   Mooring SR, 2014, HETEROCYCL COMMUN, V20, P149, DOI 10.1515/hc 2014 0041
   Park JK, 2013, RHEUMATOLOGY, V52, P1529, DOI 10.1093/rheumatology/ket184
   Robert M, 2019, FRONT MED LAUSANNE, V5, DOI 10.3389/fmed.2018.00364
   Samarpita S, 2020, TOXICOL APPL PHARM, V391, DOI 10.1016/j.taap.2020.114917
   Shahrara S, 2010, J IMMUNOL, V184, P4479, DOI 10.4049/jimmunol.0901942
   Shahrara S, 2009, J IMMUNOL, V182, P3884, DOI 10.4049/jimmunol.0802246
   Tang XY, 2016, ONCOTARGET, V7, P8590, DOI 10.18632/oncotarget.6535
   Williams B, 2018, J HYPERTENS, V36, P2284, DOI [10.1097/HJH.0000000000001961, 10.1097/HJH.0000000000002026]
   Xu SQ, 2012, RHEUMATOL INT, V32, P3397, DOI 10.1007/s00296 011 2175 5
   Yoon BR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109775
NR 28
TC 19
Z9 20
U1 0
U2 19
PU ACADEMIC PRESS LTD  ELSEVIER SCIENCE LTD
PI LONDON
PA 24 28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043 4666
EI 1096 0023
J9 CYTOKINE
JI Cytokine
PD JUN
PY 2021
VL 142
AR 155502
DI 10.1016/j.cyto.2021.155502
EA APR 2021
PG 13
WC Biochemistry & Molecular Biology; Cell Biology; Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Immunology
GA RL7NT
UT WOS:000639155700011
PM 33810944
DA 2025 08 17
ER

PT J
AU Viglietti, AIP
   Gentilini, MV
   Benitez, PCA
   Giambartolomei, GH
   Delpino, MV
AF Pesce Viglietti, Ayelen Ivana
   Virginia Gentilini, Maria
   Arriola Benitez, Paula Constanza
   Hernan Giambartolomei, Guillermo
   Victoria Delpino, Maria
TI B. abortus Modulates Osteoblast Function Through the
   Induction of Autophagy
SO FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
LA English
DT Article
DE Brucella; bone; osteoblast; autophagy; osteoblast activity
ID BONE; OSTEOPONTIN; DIFFERENTIATION; EXPRESSION; DESTRUCTION; OSTERIX;
   CBFA1
AB Osteoarticular brucellosis is the most common localization of human active disease. Osteoblasts are specialized mesenchymal derived cells involved in bone formation and are considered as professional mineralizing cells. Autophagy has been involved in osteoblast metabolism. The present study demonstrates that Brucella abortus infection induces the activation of the autophagic pathway in osteoblast cells. Autophagy was revealed by upregulation of LC3II/LC3I ratio and Beclin 1 expression as well as inhibition of p62 expression in infected cells. Induction of autophagy was also corroborated by using the pharmacological inhibitors wortmannin, a PI 3 kinase inhibitor, and leupeptin plus E64 (inhibitors of lysosomal proteases). Autophagy induction create a microenvironment that modifies osteoblast metabolism by the inhibition of the deposition of organic and mineral matrix, the induction of matrix metalloproteinase (MMP) 2, osteopontin, and RANKL secretion leading to bone loss. Accordingly, autophagy is also involved in the down modulation of the master transcription factor in bone formation osterix during B. abortus infection. Taking together our results indicate that B. abortus induces the activation of autophagy pathway in osteoblast cells and this activation is involved in the modulation of osteoblast function and bone formation.
C1 [Pesce Viglietti, Ayelen Ivana; Virginia Gentilini, Maria; Arriola Benitez, Paula Constanza; Hernan Giambartolomei, Guillermo; Victoria Delpino, Maria] Univ Buenos Aires, Consejo Nacl Invest Cient & Tecn, Inst Inmunol Genet & Metab INIGEM, Buenos Aires, DF, Argentina.
C3 Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET);
   University of Buenos Aires
RP Delpino, MV (通讯作者)，Univ Buenos Aires, Consejo Nacl Invest Cient & Tecn, Inst Inmunol Genet & Metab INIGEM, Buenos Aires, DF, Argentina.
EM mdelpino@ffyb.uba.ar
RI ; Delpino, Victoria/ITV 4318 2023
OI Delpino, M. Victoria/0000 0003 2077 8509; 
FU Agencia Nacional of Promocion Cientifica y Tecnologica (ANPCYT,
   Argentina) [PICT 2014 1111, PICT 2015 0316]; Consejo Nacional de
   Investigaciones cientificas y tecnicas (CONICET) [PIP 2015 2017 0200]
FX This work was supported by grants PICT 2014 1111 and PICT 2015 0316 from
   Agencia Nacional of Promocion Cientifica y Tecnologica (ANPCYT,
   Argentina), by grant PIP 2015 2017 0200 from Consejo Nacional de
   Investigaciones cientificas y tecnicas (CONICET).
CR Aydin M, 2005, NUCL MED COMMUN, V26, P639, DOI 10.1097/01.mnm.0000167651.52724.68
   Carlinfante G, 2003, CLIN EXP METASTAS, V20, P437, DOI 10.1023/A:1025419708343
   Celil AB, 2005, J CELL BIOCHEM, V95, P518, DOI 10.1002/jcb.20429
   Celli J, 2015, CELL MICROBIOL, V17, P951, DOI 10.1111/cmi.12452
   Claro T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018748
   Colmenero JD, 2008, CLIN INFECT DIS, V46, P426, DOI 10.1086/525266
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   He CC, 2010, CURR OPIN CELL BIOL, V22, P140, DOI 10.1016/j.ceb.2010.01.001
   He LQ, 2013, ACTA PHARMACOL SIN, V34, P605, DOI 10.1038/aps.2012.188
   HIBBS MS, 1985, J BIOL CHEM, V260, P2493
   Hocking LJ, 2012, J BONE MINER RES, V27, P1439, DOI 10.1002/jbmr.1668
   Jiang PD, 2014, CELL RES, V24, P69, DOI 10.1038/cr.2013.161
   Kido J, 2001, J PERIODONTAL RES, V36, P328, DOI 10.1034/j.1600 0765.2001.360509.x
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Kusuyama J, 2017, MOL BIOL CELL, V28, P1326, DOI 10.1091/mbc.E16 10 0716
   Lee MH, 2003, BIOCHEM BIOPH RES CO, V309, P689, DOI 10.1016/j.bbrc.2003.08.058
   Lippai M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/832704
   Liu F, 2013, J BONE MINER RES, V28, P2414, DOI 10.1002/jbmr.1971
   Madkour M M., 2001, InMadkour's Brucellosis, P74, DOI DOI 10.1007/978 3 642 59533 2_83258712
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nollet M, 2014, AUTOPHAGY, V10, P1965, DOI 10.4161/auto.36182
   Ohshima S, 2002, ARTHRITIS RHEUM, V46, P1094, DOI 10.1002/art.10143
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Ozeki N, 2016, EXP CELL RES, V347, P24, DOI 10.1016/j.yexcr.2016.07.002
   Pappas G, 2005, NEW ENGL J MED, V352, P2325, DOI 10.1056/NEJMra050570
   Pierrefite Carle V, 2015, AGEING RES REV, V24, P206, DOI 10.1016/j.arr.2015.08.004
   Rittig MG, 2003, J LEUKOCYTE BIOL, V74, P1045, DOI 10.1189/jlb.0103015
   Scian R, 2012, INFECT IMMUN, V80, P2333, DOI 10.1128/IAI.00208 12
   Scian R, 2011, INFECT IMMUN, V79, P192, DOI 10.1128/IAI.00934 10
   Shapiro SD, 1999, THROMB HAEMOSTASIS, V82, P846
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Starr T, 2012, CELL HOST MICROBE, V11, P33, DOI 10.1016/j.chom.2011.12.002
   Suda T, 2001, Novartis Found Symp, V232, P235
   Takayanagi H, 2010, ADV EXP MED BIOL, V658, P61, DOI 10.1007/978 1 4419 1050 9_7
   Tullberg Reinert H, 1999, HISTOCHEM CELL BIOL, V112, P271, DOI 10.1007/s004180050447
   Walker B, 2014, CURR REV MUSCULOSKE, V7, P208, DOI 10.1007/s12178 014 9224 0
   Weng YM, 2018, EUR REV MED PHARMACO, V22, P1224, DOI 10.26355/eurrev_201803_14462
   Young E. J., 1989, Brucellosis: clinical and laboratory aspects., P97
NR 39
TC 11
Z9 12
U1 0
U2 9
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2235 2988
J9 FRONT CELL INFECT MI
JI Front. Cell. Infect. Microbiol.
PD DEC 4
PY 2018
VL 8
AR 425
DI 10.3389/fcimb.2018.00425
PG 11
WC Immunology; Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Microbiology
GA HC8UU
UT WOS:000452080900001
PM 30564561
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Hirata, S
   Kitamura, C
   Fukushima, H
   Nakamichi, I
   Abiko, Y
   Terashita, M
   Jimi, E
AF Hirata, Shizu
   Kitamura, Chiaki
   Fukushima, Hidefumi
   Nakamichi, Ikuo
   Abiko, Yoshimitsu
   Terashita, Masamichi
   Jimi, Eijiro
TI Low Level Laser Irradiation Enhances BMP Induced Osteoblast
   Differentiation by Stimulating the BMP/Smad Signaling Pathway
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE LOW LEVEL LASER; OSTEOBLASTS; BMP; SMAD PHOSPHORYLATION
ID BONE MORPHOGENETIC PROTEIN 2; RAT CALVARIAL CELLS; NODULE FORMATION;
   GENE EXPRESSION; PROMOTES PROLIFERATION; THERAPY; INHIBITION; DENTISTRY;
   CULTURE; ARREST
AB Low level laser irradiation (LLLI) has been shown to induce bone formation and osteoblast differentiation both in vivo and in vitro. However, the molecular mechanism by which LW stimulates osteoblast differentiation is still unclear. The aim of the present study was to examine whether Ga Al As laser irradiation could enhance BMP2 induced alkaline phosphatase (ALP) activity in C2C12 cells. Laser irradiation at 0.5W for 20 min enhanced BMP2 induced ALP activity. Laser treatment alone did not affect ALP activity. To exclude the effect of pH or temperature changes during irradiation, we shortened the exposure time to 2 min, with various levels of laser power. At 2.5W, irradiation stimulated BMP2 induced ALP activity but not cell proliferation, whereas 1 or SW laser power did not induce any significant effects. Irradiation stimulated BMP2 induced phosphorylation of Smad1/5/8 and BMP2 expression, but had no effect on the expression of inhibitory Smads 6 and 7, BMP4, or insulin like growth factor I. Laser irradiation enhanced Smad induced Id1 reporter activity as well as expression of bone morphogenetic protein (BMP) induced transcription factors such as Id1, Osterix, and Runx2. Laser irradiation also stimulated BMP induced expressions of type 1 collagen, osteonectin, and osteocalcin mRNA, markers of osteoblasts. This enhancement of BMP2 induced ALP activity and Smad phosphorylation by laser irradiation was also observed in primary osteoblasts. These results suggest that LLLI accelerates the differentiation of BMP induced osteoblasts by stimulating the BMP/Smad signaling pathway. J. Cell. Biochem. 111: 1445 1452, 2010. (C) 2010 Wiley Liss, Inc.
C1 [Hirata, Shizu; Fukushima, Hidefumi; Jimi, Eijiro] Kyushu Dent Coll, Dept Biosci, Div Mol Signaling & Biochem, Kokurakita Ku, Fukuoka 8038580, Japan.
   [Hirata, Shizu; Kitamura, Chiaki] Kyushu Dent Coll, Dept Cariol & Periodontol, Div Pulp Biol Operat Dent & Endodont, Kokurakita Ku, Fukuoka 8038580, Japan.
   [Kitamura, Chiaki; Jimi, Eijiro] Kyushu Dent Coll, Oral Biol Res Ctr, Kokurakita Ku, Fukuoka 8038580, Japan.
   [Nakamichi, Ikuo] Kyushu Dent Coll, Dept Hlth Promot, Div Gen Internal Med, Kokurakita Ku, Fukuoka 8038580, Japan.
   [Abiko, Yoshimitsu] Nihon Univ, Sch Dent Matsudo, Dept Biochem & Mol Biol, Chiba 2718587, Japan.
   [Terashita, Masamichi] Kyushu Dent Coll, Dept Clin Commun Practice, Div Comprehens Dent, Kokurakita Ku, Fukuoka 8038580, Japan.
C3 Kyushu Dental University; Kyushu Dental University; Kyushu Dental
   University; Kyushu Dental University; Nihon University; Kyushu Dental
   University
RP Jimi, E (通讯作者)，Kyushu Dent Coll, Dept Biosci, Div Mol Signaling & Biochem, Kokurakita Ku, 2 6 1 Manazuru, Fukuoka 8038580, Japan.
EM ejimi@kyu dent.ac.jp
FU Kyushu Dental College; Kyuchiren Grants
FX Grant sponsor: Kyushu Dental College Internal Grants; Grant sponsor:
   Kyuchiren Grants.
CR ANDERS JJ, 1993, LASER SURG MED, V13, P72, DOI 10.1002/lsm.1900130113
   Aubin J E, 2001, Rev Endocr Metab Disord, V2, P81, DOI 10.1023/A:1010011209064
   BARUSHKA O, 1995, BONE, V16, P47, DOI 10.1016/S8756 3282(94)00006 9
   Conlan MJ, 1996, J CLIN PERIODONTOL, V23, P492, DOI 10.1111/j.1600 051X.1996.tb00580.x
   de Almeida JM, 2008, J PERIODONTOL, V79, P1081, DOI [10.1902/jop.2008.070456, 10.1902/jop.2008.070456 ]
   De Felice E, 2010, PHLEBOLOGY, V25, P11, DOI 10.1258/phleb.2009.009036
   Fukuhara E, 2006, CALCIFIED TISSUE INT, V79, P443, DOI 10.1007/s00223 006 0072 9
   Gavish L, 2006, LASER SURG MED, V38, P779, DOI 10.1002/lsm.20383
   Hamajima S, 2003, LASER MED SCI, V18, P78, DOI 10.1007/s10103 003 0255 9
   HONMURA A, 1992, LASER SURG MED, V12, P441, DOI 10.1002/lsm.1900120414
   Jimi E, 2010, JPN DENT SCI REV, V46, P33, DOI 10.1016/j.jdsr.2009.10.003
   KARU TI, 1990, PHOTOCHEM PHOTOBIOL, V52, P1089, DOI 10.1111/j.1751 1097.1990.tb08450.x
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Katagiri T, 2002, GENES CELLS, V7, P949, DOI 10.1046/j.1365 2443.2002.00573.x
   Katagiri Takenobu, 2008, P121
   Khadra M, 2005, BIOMATERIALS, V26, P3503, DOI 10.1016/j.biomaterials.2004.09.033
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Kusumoto K, 2002, J INT MED RES, V30, P251, DOI 10.1177/147323000203000305
   Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783 8792.2000
   Massagué J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705
   Matsui Satoshi, 2008, J Oral Sci, V50, P75, DOI 10.2334/josnusd.50.75
   Mckay WF, 2007, INT ORTHOP, V31, P729, DOI 10.1007/s00264 007 0418 6
   MESTER E, 1985, LASER SURG MED, V5, P31, DOI 10.1002/lsm.1900050105
   Moshkovska T, 2005, POSTGRAD MED J, V81, P436, DOI 10.1136/pgmj.2004.027755
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Ninomiya T, 2007, BONE, V40, P140, DOI 10.1016/j.bone.2006.07.026
   Ozawa Y, 1998, BONE, V22, P347, DOI 10.1016/S8756 3282(97)00294 9
   ROCHKIND S, 1986, ACTA NEUROCHIR, V83, P125, DOI 10.1007/BF01402391
   Ross Gerry, 2008, General Dentistry, V56, P629
   Schubert MM, 2007, SUPPORT CARE CANCER, V15, P1145, DOI 10.1007/s00520 007 0238 7
   SHIMIZU N, 1995, J DENT RES, V74, P1382, DOI 10.1177/00220345950740071001
   Shimizu N, 2007, LASER SURG MED, V39, P551, DOI 10.1002/lsm.20521
   Stein A, 2005, PHOTOMED LASER SURG, V23, P161, DOI 10.1089/pho.2005.23.161
   Stein E, 2008, WIEN KLIN WOCHENSCHR, V120, P112, DOI 10.1007/s00508 008 0932 6
   Tuby H, 2007, LASER SURG MED, V39, P373, DOI 10.1002/lsm.20492
   Ueda Y, 2003, J CLIN LASER MED SUR, V21, P271, DOI 10.1089/104454703322564479
   Vaidya R, 2008, J SPINAL DISORD TECH, V21, P557, DOI 10.1097/BSD.0b013e31815ea897
   WALKER J, 1983, NEUROSCI LETT, V43, P339, DOI 10.1016/0304 3940(83)90211 2
   Walsh LJ, 1997, AUST DENT J, V42, P302, DOI 10.1111/j.1834 7819.1997.tb00134.x
NR 39
TC 64
Z9 70
U1 0
U2 21
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD DEC 15
PY 2010
VL 111
IS 6
BP 1445
EP 1452
DI 10.1002/jcb.22872
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 707QI
UT WOS:000286300700007
PM 20830741
DA 2025 08 17
ER

PT J
AU Jeong, BC
   Kim, HJ
   Bae, IH
   Lee, KN
   Lee, KY
   Oh, WM
   Kim, SH
   Kang, IC
   Lee, SE
   Koh, GY
   Kim, KK
   Koh, JT
AF Jeong, Byung Chul
   Kim, Hyun Joo
   Bae, In Ho
   Lee, Kkot Nim
   Lee, Kwang Youl
   Oh, Won Mann
   Kim, Sun Hun
   Kang, In Chol
   Lee, Shee Eun
   Koh, Gou Young
   Kim, Kyung Keun
   Koh, Jeong Tae
TI COMP Ang1, a chimeric form of Angiopoietin 1, enhances BMP2 induced
   osteoblast differentiation and bone formation
SO BONE
LA English
DT Article
DE COMP Ang1; Tie2; Bone morphogenetic protein; Bone formation;
   Angiogenesis
ID GENE THERAPY; SIGNAL TRANSDUCTION; VEGF; ANGIOGENESIS; KINASE; BMP 2;
   P38; EXPRESSION; PATHWAY; VARIANT
AB Introduction: Angiogenesis is closely associated with bone formation, especially endochondral ossification. Angiopoietin 1 (Ang1) is a specific growth factor functioning to generate a stable and matured vasculature through the Tie2 receptor/PI3K/AKT pathway. Recently cartilage oligomeric matrix protein (COMP) Ang1, an Ang1 variant which is more potent than native Ang1 in phosphorylating Tie2 receptor and AKT, was developed. This study was designed to examine the effects of angiogenic COMP Ang1 on BMP2 induced osteoblast differentiation and bone formation.
   Methods: Expression of endogenous Ang 1 and its binding receptor Tie 2 mRNA was examined in osteoblast like cells and primary mouse calvarial cells by RT PCR analysis, and was also monitored during osteoblast differentiation induced by BMP 2 and/or ascorbic acid and beta glycerophosphate. Effects of COMP Ang 1 on osteoblast differentiation and mineralization were evaluated by alkaline phosphatase (ALP) activity and osteocalcin (OC) production, and Alizarin red stain. For a molecular mechanism, Western blot and OG2 and 6xOSE promoter assays were done. For in vivo evaluation, adenoviral (Ad) vectors containing COMP Ang 1 or BMP 2 gene were administered into thigh muscle of mice, and after 2 weeks bone formation was analyzed by micro computed tomography and histology. Angiogenic event of COMP Ang1 was confirmed by immunofluorescence analysis with anti CD31 antibody.
   Results: Expression of Tie2 receptor was significantly increased in the course of osteoblast differentiation. Treatment or overexpression of COMP Ang1 enhanced BMP2 induced ALP activity, OC production, and mineral deposition in a dose dependent manner. In addition, COMP Ang1 synergistically increased OG2 and 6xOSE promoter activities of BMP2, and sustained p38, Smad and AKT phosphorylation of BMP2. Notably, in vivo intramuscular injection of COMP Ang1 dose dependently enhanced BMP2 induced ectopic bone formation with increases in CD31 reactivity.
   Conclusions: These results suggest that COMP Ang1 synergistically enhanced osteoblast differentiation and bone formation through potentiating BMP2 signaling pathways and angiogenesis. Combination of BMP2 and COMP Ang1 should be clinically useful for therapeutic application to fracture and destructive bone diseases. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Koh, Jeong Tae] Chonnam Natl Univ, Sch Dent, Dept Pharmacol & Dent Therapeut, Dent Sci Res Inst, Kwangju 500757, South Korea.
   [Jeong, Byung Chul; Kim, Hyun Joo; Bae, In Ho; Lee, Kkot Nim; Oh, Won Mann; Kim, Sun Hun; Kang, In Chol; Lee, Shee Eun; Koh, Jeong Tae] Chonnam Natl Univ, Sch Dent, Project BK21, Kwangju 500757, South Korea.
   [Lee, Kwang Youl] Chonnam Natl Univ, Coll Pharm, Kwangju 500757, South Korea.
   [Lee, Kwang Youl] Chonnam Natl Univ, Res Inst Drug Dev, Kwangju 500757, South Korea.
   [Koh, Gou Young] Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.
   [Kim, Kyung Keun] Chonnam Natl Univ, Sch Med, Med Res Ctr Gene Regulat, Kwangju 501190, South Korea.
C3 Chonnam National University; Chonnam National University; Chonnam
   National University; Chonnam National University; Korea Advanced
   Institute of Science & Technology (KAIST); Chonnam National University
RP Koh, JT (通讯作者)，Chonnam Natl Univ, Sch Dent, Dept Pharmacol & Dent Therapeut, Dent Sci Res Inst, 300 Yongbong Dong, Kwangju 500757, South Korea.
EM jtkoh@chonnam.ac.kr
RI Koh, Gou/C 1615 2011
FU Korea Healthcare Technology RD Project; Ministry for Health, Welfare &
   Family Affairs, Republic of Korea [A080709]; Brain Korea 21 project
FX This study was supported by a grant of the Korea Healthcare Technology
   R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of
   Korea (A080709). In Ho Bae and Kkot Nim Lee were supported by the second
   stage of Brain Korea 21 project.
CR Asahara T, 1998, CIRC RES, V83, P233, DOI 10.1161/01.RES.83.3.233
   Carmeliet P, 2000, NAT MED, V6, P1102, DOI 10.1038/80430
   Chen D, 2004, FRONT BIOSCI LANDMRK, V9, P349, DOI 10.2741/1090
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Chen D, 1998, J CELL BIOL, V142, P295, DOI 10.1083/jcb.142.1.295
   Cho CH, 2006, P NATL ACAD SCI USA, V103, P4946, DOI 10.1073/pnas.0506352103
   Cho CH, 2004, P NATL ACAD SCI USA, V101, P5547, DOI 10.1073/pnas.0307574101
   Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467
   Ghosh Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200
   Guicheux J, 2003, J BONE MINER RES, V18, P2060, DOI 10.1359/jbmr.2003.18.11.2060
   Isner JM, 1999, J CLIN INVEST, V103, P1231, DOI 10.1172/JCI6889
   IWAMA A, 1993, BIOCHEM BIOPH RES CO, V195, P301, DOI 10.1006/bbrc.1993.2045
   Jeong BC, 2009, J BIOL CHEM, V284, P14211, DOI 10.1074/jbc.M808345200
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24
   Kim KT, 2005, J BIOL CHEM, V280, P20126, DOI 10.1074/jbc.M500292200
   Kozawa O, 2002, J CELL BIOCHEM, V84, P583, DOI 10.1002/jcb.10056.abs
   Lee HJ, 2008, J RADIAT RES, V49, P313, DOI 10.1269/jrr.07064
   Moutsatsos IK, 2001, MOL THER, V3, P449, DOI 10.1006/mthe.2001.0291
   Peng HR, 2005, J BONE MINER RES, V20, P2017, DOI 10.1359/JBMR.050708
   Peng HR, 2002, J CLIN INVEST, V110, P751, DOI 10.1172/JCI200215153
   Puleo DA, 1997, J CELL PHYSIOL, V173, P93, DOI 10.1002/(SICI)1097 4652(199710)173:1<93::AID JCP11>3.0.CO;2 O
   Schliemann C, 2006, HAEMATOLOGICA, V91, P1203
   Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F
   Sonobe J, 2004, HUM GENE THER, V15, P659, DOI 10.1089/1043034041361208
   Sugimori K, 2005, J BONE MINER METAB, V23, P411, DOI 10.1007/s00774 005 0622 7
   Suzuki T, 2007, BIOCHEM BIOPH RES CO, V362, P1019, DOI 10.1016/j.bbrc.2007.08.099
   Tang CH, 2008, EUR J PHARMACOL, V579, P40, DOI 10.1016/j.ejphar.2007.10.013
   Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   Young BH, 2002, CLIN ORTHOP RELAT R, pS243, DOI 10.1097/01.blo.0000031984.92980.5d
NR 31
TC 55
Z9 58
U1 0
U2 19
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD FEB
PY 2010
VL 46
IS 2
BP 479
EP 486
DI 10.1016/j.bone.2009.09.019
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 557XG
UT WOS:000274702800033
PM 19782780
DA 2025 08 17
ER

PT J
AU Bae, S
   Lee, MJ
   Mun, SH
   Giannopoulou, EG
   Yong Gonzalez, V
   Cross, JR
   Murata, K
   Giguère, V
   van der Meulen, M
   Park Min, KH
AF Bae, Seyeon
   Lee, Min Joon
   Mun, Se Hwan
   Giannopoulou, Eugenia G.
   Yong Gonzalez, Vladimir
   Cross, Justin R.
   Murata, Koichi
   Giguere, Vincent
   van der Meulen, Marjolein
   Park Min, Kyung Hyun
TI MYC dependent oxidative metabolism regulates osteoclastogenesis via
   nuclear receptor ERRα
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID ESTROGEN RELATED RECEPTORS; C MYC; BONE RESORPTION; MITOCHONDRIAL
   BIOGENESIS; DIFFERENTIATION; ACTIVATION; ORPHAN; INFLAMMATION; CELLS;
   MICE
AB Osteoporosis is a metabolic bone disorder associated with compromised bone strength and an increased risk of fracture. Inhibition of the differentiation of bone resorbing osteoclasts is an effective strategy for the treatment of osteoporosis. Prior work by our laboratory and others has shown that MYC promotes osteoclastogenesis in vitro, but the underlying mechanisms are not well understood. In addition, the in vivo importance of osteoclast expressed MYC in physiological and pathological bone loss is not known. Here, we have demonstrated that deletion of Myc in osteoclasts increases bone mass and protects mice from ovariectomy induced (OVX induced) osteoporosis. Transcriptomic analysis revealed that MYC drives metabolic reprogramming during osteoclast differentiation and functions as a metabolic switch to an oxidative state. We identified a role for MYC action in the transcriptional induction of estrogen receptor related receptor alpha (ERR alpha), a nuclear receptor that cooperates with the transcription factor nuclear factor of activated T cells, c1 (NFATc1) to drive osteoclastogenesis. Accordingly, pharmacological inhibition of ERRa attenuated OVX induced bone loss in mice. Our findings highlight a MYC/ERR alpha pathway that contributes to physiological and pathological bone loss by integrating the MYC/ERR alpha axis to drive metabolic reprogramming during osteoclast differentiation.
C1 [Bae, Seyeon; Lee, Min Joon; Mun, Se Hwan; Giannopoulou, Eugenia G.; Murata, Koichi; Park Min, Kyung Hyun] Hosp Special Surg, David Z Rosensweig Genom Res Ctr, Arthrit & Tissue Degenerat Program, 535 E 70th St, New York, NY 10021 USA.
   [Giannopoulou, Eugenia G.] CUNY, New York City Coll Technol, Biol Sci Dept, Brooklyn, NY 11210 USA.
   [Yong Gonzalez, Vladimir; Cross, Justin R.] Mem Sloan Kettering Canc Ctr, Donald B & Catherine C Marron Canc Metab Ctr, 1275 York Ave, New York, NY 10021 USA.
   [Giguere, Vincent] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ, Canada.
   [Giguere, Vincent] McGill Univ, Dept Biochem, Montreal, PQ, Canada.
   [Giguere, Vincent] McGill Univ, Dept Med, Montreal, PQ, Canada.
   [Giguere, Vincent] McGill Univ, Dept Oncol, Montreal, PQ, Canada.
   [van der Meulen, Marjolein] Cornell Univ, Sibley Sch Mech & Aerosp Engn, Ithaca, NY 14853 USA.
   [van der Meulen, Marjolein] Hosp Special Surg, Musculoskeletal Integr Program, 535 E 70th St, New York, NY 10021 USA.
   [Park Min, Kyung Hyun] Weill Cornell Med Coll, Dept Med, New York, NY USA.
C3 City University of New York (CUNY) System; Memorial Sloan Kettering
   Cancer Center; McGill University; McGill University; McGill University;
   McGill University; Cornell University; Cornell University; Weill Cornell
   Medicine
RP Park Min, KH (通讯作者)，535 East 70th St, New York, NY 10021 USA.
EM ParkminK@hss.edu
RI van der Meulen, Marjolein/D 1549 2010; Murata, Koichi/HLH 5882 2023;
   Giannopoulou, Evgenia/K 9576 2019; van der Meulen, Marjolein Christine
   Hermance/D 1549 2010
OI Giguere, Vincent/0000 0001 9567 3694; Murata,
   Koichi/0000 0002 7896 3937; Lee, Min Joon/0000 0003 2722 8526; van der
   Meulen, Marjolein Christine Hermance/0000 0001 6637 9808
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases
   (NIAMS), NIH [R00AR061430, R01AR069562]; Grants in Aid for Scientific
   Research [17H06816] Funding Source: KAKEN
FX We thank Lionel B. Ivashkiv, Steven Goldring (Hospital for Special
   Surgery, New York, NY), Matthew B. Greenblatt (Weill Cornell Medical
   College, New York, NY) for helpful discussions and critical review of
   the manuscript and Jae Hyuck Shim and Yeon Suk Yang (University of
   Massachusetts Medical School) for micro CT analysis and helpful
   discussions. This study was supported by the National Institute of
   Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH
   (R00AR061430 and R01AR069562). The contents of this manuscript are
   solely the responsibility of the authors and do not necessarily
   represent the official views of the NIH.
CR Aliprantis AO, 2008, J CLIN INVEST, V118, P3775, DOI 10.1172/JCI35711
   Battaglino R, 2002, J BONE MINER RES, V17, P763, DOI 10.1359/jbmr.2002.17.5.763
   Baudino TA, 2002, GENE DEV, V16, P2530, DOI 10.1101/gad.1024602
   Bonnelye E, 2013, J BONE MINER RES, V28, P225, DOI 10.1002/jbmr.1836
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Busch BB, 2004, J MED CHEM, V47, P5593, DOI 10.1021/jm049334f
   Carnesecchi J, 2016, MOL CELL ENDOCRINOL, V432, P47, DOI 10.1016/j.mce.2015.07.019
   Charles JF, 2012, J CLIN INVEST, V122, P4592, DOI 10.1172/JCI60920
   Charles JF, 2012, BONE, V51, P902, DOI 10.1016/j.bone.2012.08.113
   Chen BJ, 2014, INT J BIOL SCI, V10, P1084, DOI 10.7150/ijbs.10190
   Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960
   Dang CV, 2011, COLD SH Q B, V76, P369, DOI 10.1101/sqb.2011.76.011296
   Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003
   ENGLEN MD, 1995, J IMMUNOL METHODS, V184, P281, DOI 10.1016/0022 1759(95)00136 X
   Gallopin M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077503
   Huss JM, 2015, BBA MOL BASIS DIS, V1852, P1912, DOI 10.1016/j.bbadis.2015.06.016
   Ikeda K, 2016, J BIOCHEM, V159, P1, DOI 10.1093/jb/mvv112
   Indo Y, 2013, J BONE MINER RES, V28, P2392, DOI 10.1002/jbmr.1976
   Ishii K, 2009, NAT MED, V15, P259, DOI 10.1038/nm.1910
   Jin ZX, 2014, CELL METAB, V20, P483, DOI 10.1016/j.cmet.2014.07.011
   Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026
   Lorenzo J, 2008, ENDOCR REV, V29, P403, DOI 10.1210/er.2007 0038
   Nie ZQ, 2012, CELL, V151, P68, DOI 10.1016/j.cell.2012.08.033
   Nishikawa K, 2015, NAT MED, V21, P281, DOI 10.1038/nm.3774
   Novack DV, 2003, J EXP MED, V198, P771, DOI 10.1084/jem.20030116
   Parfitt A M., J Bone Miner Res
   Park Min KH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6418
   Pello OM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045399
   Rahl PB, 2010, CELL, V141, P432, DOI 10.1016/j.cell.2010.03.030
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Rosen CJ, 2005, NEW ENGL J MED, V353, P595, DOI 10.1056/NEJMcp043801
   Shim JH, 2013, J CLIN INVEST, V123, P4010, DOI 10.1172/JCI69443
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Teyssier C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007942
   Vaira S, 2008, P NATL ACAD SCI USA, V105, P3897, DOI 10.1073/pnas.0708576105
   Villena JA, 2008, TRENDS ENDOCRIN MET, V19, P269, DOI 10.1016/j.tem.2008.07.005
   Wan YH, 2010, TRENDS ENDOCRIN MET, V21, P722, DOI 10.1016/j.tem.2010.08.006
   Wang RN, 2011, IMMUNITY, V35, P871, DOI 10.1016/j.immuni.2011.09.021
   Wei W, 2016, CELL METAB, V23, P479, DOI 10.1016/j.cmet.2015.12.010
   Wei W, 2010, CELL METAB, V11, P503, DOI 10.1016/j.cmet.2010.04.015
   Yang C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015383
   Yuk JM, 2015, IMMUNITY, V43, P80, DOI 10.1016/j.immuni.2015.07.003
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zeng R, 2015, J BONE MINER RES, V30, P2287, DOI 10.1002/jbmr.2584
NR 46
TC 10
Z9 10
U1 0
U2 10
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021 9738
EI 1558 8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD JUN 30
PY 2017
VL 127
IS 7
BP 2555
EP 2568
DI 10.1172/JCI89935
PG 14
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA EZ2RM
UT WOS:000404557400016
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Vanhara, P
   Lincová, E
   Kozubík, A
   Jurdic, P
   Soucek, K
   Smarda, J
AF Vanhara, Petr
   Lincova, Eva
   Kozubik, Alois
   Jurdic, Pierre
   Soucek, Karel
   Smarda, Jan
TI Growth/differentiation factor 15 inhibits differentiation into
   osteoclasts A novel factor involved in control of osteoclast
   differentiation
SO DIFFERENTIATION
LA English
DT Article
DE GDF 15; Osteoclast; LNCaP; RAW264.7; Prostate cancer
ID NF KAPPA B; PROSTATE CANCER CELLS; CARBONIC ANHYDRASE II; TGF BETA
   SUPERFAMILY; DRUG ACTIVATED GENE; VITAMIN D; TUMOR MICROENVIRONMENT;
   RECEPTOR ACTIVATOR; BONE METASTASIS; CATHEPSIN K
AB Survival and capability of cancer cells to form metastases fundamentally depend on interactions with their microenvironment. Secondary tumors originating from prostate carcinomas affect remodeling of bone tissue and can induce both osteolytic and osteocondensing lesions. However, particular molecular mechanisms responsible for selective homing and activity of cancer cells in bone microenvironment have not been clarified yet. Growth/differentiationfactor 15 (GDF 15), a distant member of the TGF beta protein family, has recently been associated with many human cancers, including prostate.
   We show that both pure GDF 15 and the GDF 15 containing growth medium of 1,25(OH)(2) vitamin D 3 treated prostate adenocarcinoma LNCaP cells suppress formation of mature osteoclasts differentiated from RAW264.7 macrophages and bone marrow precursors by M CSF/RANKL in a dose dependent manner. GDF 15 inhibits expression of c Fos and activity of NF kappa B by delayed degradation of I kappa B. Moreover, GDF 15 inhibits expression of carbonic anhydrase II and cathepsin K, key osteoclast enzymes, and induces changes in SMAD and p38 signaling.
   The lack of functional osteoclasts can contribute to accumulation of bone matrix by reduction of bone resorption. These results unveil new role of GDF 15 in modulation of osteoclast differentiation and possibly in therapy of bone metastases. (C) 2009 International Society of Differentiation. Published by Elsevier Ltd. All rights reserved.
C1 [Lincova, Eva; Kozubik, Alois; Soucek, Karel] Acad Sci Czech Republ, Inst Biophys, Dept Cytokinet, CZ 61265 Brno, Czech Republic.
   [Vanhara, Petr; Lincova, Eva; Kozubik, Alois; Smarda, Jan] Masaryk Univ, Fac Sci, Dept Expt Biol, CZ 61137 Brno, Czech Republic.
   [Jurdic, Pierre] Univ Lyon, ENS, CNRS, IGFL,UCBL, F 69364 Lyon, France.
C3 Czech Academy of Sciences; Institute of Biophysics of the Czech Academy
   of Sciences; Masaryk University Brno; CHU Lyon; Centre National de la
   Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de
   LYON); Universite Claude Bernard Lyon 1
RP Soucek, K (通讯作者)，Acad Sci Czech Republ, Inst Biophys, Dept Cytokinet, Kralovopolska 135, CZ 61265 Brno, Czech Republic.
EM ksoucek@ibp.cz; smarda@sci.muni.cz
RI Soucek, Karel/B 3621 2008; Slabakova, Eva/H 1908 2014; Kozubík,
   Alois/H 1954 2014; Vanhara, Petr/G 5363 2011
OI Soucek, Karel/0000 0001 7283 8150; Slabakova, Eva/0000 0002 2416 4064;
   Vanhara, Petr/0000 0002 7470 177X; 
FU Czech Science Foundation [301/06/0036, 301/09/1115, 204/08/H054,
   204/07/0834, 310/07/0961]; Ministry of Education, Youth and Sports of
   the Czech Republic [MSM0021622415]; Academy of Sciences of the Czech
   Republic [AV0Z50040507, AV0Z50040702]; Ministry of Health of the Czech
   Republic [IGA9875 4]
FX We thank Johana Maresova Iva Liskova and Jaromira Netikova for technical
   assistance, Petr Krontorad (Centre for Biomedical Image Analysis,
   Faculty of Informatics, Masaryk University) for image analysis of bone
   resorption and Sabina. Sevcikova (Faculty of Medicine, Masaryk
   University) for critical reading of the manuscript. This work was
   supported by grants 301/06/0036, 301/09/1115, 204/08/H054 of the Czech
   Science Foundation, MSM0021622415 of Ministry of Education, Youth and
   Sports of the Czech Republic and grants 204/07/0834, 310/07/0961 of the
   Czech Science Foundation and AV0Z50040507, AV0Z50040702 of the Grant
   Agency of Academy of Sciences of the Czech Republic and IGA9875 4 of
   Ministry of Health of the Czech Republic.
CR Aliprantis AO, 2008, J CLIN INVEST, V118, P3775, DOI 10.1172/JCI35711
   Baek SJ, 2006, PROG LIPID RES, V45, P1, DOI 10.1016/j.plipres.2005.10.001
   Bauskin AR, 2006, CANCER RES, V66, P4983, DOI 10.1158/0008 5472.CAN 05 4067
   Beer TM, 2006, ANTICANCER RES, V26, P2647
   Blouin S, 2008, BRIT J CANCER, V98, P809, DOI 10.1038/sj.bjc.6604238
   Blutt SE, 2000, ENDOCRINOLOGY, V141, P10, DOI 10.1210/en.141.1.10
   Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Boyle GM, 2009, J INVEST DERMATOL, V129, P383, DOI 10.1038/jid.2008.270
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bronisz A, 2006, MOL BIOL CELL, V17, P3897, DOI 10.1091/mbc.E06 05 0470
   Brown DA, 2006, CLIN CANCER RES, V12, P89, DOI 10.1158/1078 0432.CCR 05 1331
   Buijs JT, 2007, AM J PATHOL, V171, P1047, DOI 10.2353/ajpath.2007.070168
   Cappellen D, 2002, J BIOL CHEM, V277, P21971, DOI 10.1074/jbc.M200434200
   CHEN YL, 2007, J PHARM EXP THER
   Cher ML, 2006, AM J PATHOL, V168, P1405, DOI 10.2353/ajpath.2006.050874
   Chiao JW, 2000, BRIT J CANCER, V83, P360, DOI 10.1054/bjoc.2000.1261
   Chung LWK, 2006, CLIN GENITOURIN CANC, V5, P162, DOI 10.3816/CGC.2006.n.034
   Chung LWK, 2005, J UROLOGY, V173, P10, DOI 10.1097/01.ju.0000141582.15218.10
   Clezardin P, 2007, CLIN EXP METASTAS, V24, P599, DOI 10.1007/s10585 007 9112 8
   Crotti TN, 2008, J CELL PHYSIOL, V215, P636, DOI 10.1002/jcp.21344
   Dai JL, 2008, CANCER RES, V68, P5785, DOI 10.1158/0008 5472.CAN 07 6541
   David JP, 2001, J CELL PHYSIOL, V188, P89, DOI 10.1002/jcp.1099
   Destaing O, 2003, MOL BIOL CELL, V14, P407, DOI 10.1091/mbc.E02 07 0389
   Emami KH, 2007, CANCER LETT, V253, P170, DOI 10.1016/j.canlet.2006.12.040
   Fujisaki K, 2007, LIFE SCI, V80, P1311, DOI 10.1016/j.lfs.2006.12.037
   Futakuchi M, 2009, CANCER SCI, V100, P71, DOI 10.1111/j.1349 7006.2008.01012.x
   Garimella R, 2008, J HISTOCHEM CYTOCHEM, V56, P569, DOI 10.1369/jhc.2008.950394
   Gingery A, 2008, EXP CELL RES, V314, P2725, DOI 10.1016/j.yexcr.2008.06.006
   Goltzman D, 1997, CANCER, V80, P1581, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1581::AID CNCR8>3.0.CO;2 N
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Guise TA, 2003, CLIN ORTHOP RELAT R, pS32, DOI 10.1097/01.blo.0000093055.96273.69
   HATTERSLEY G, 1991, J BONE MINER RES, V6, P165
   Hofbauer LC, 1998, BIOCHEM BIOPH RES CO, V250, P776, DOI 10.1006/bbrc.1998.9394
   Holen I, 2002, CANCER RES, V62, P1619
   HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809
   Hotokezaka H, 2002, J BIOL CHEM, V277, P47366, DOI 10.1074/jbc.M208284200
   Hu R, 2007, MOL CELL BIOL, V27, P4018, DOI 10.1128/MCB.01839 06
   Idris A, 2008, BIOCHEM BIOPH RES CO, V371, P94, DOI 10.1016/j.bbrc.2008.04.014
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Inoue H, 2005, CANCER LETT, V223, P121, DOI 10.1016/j.canlet.2004.09.053
   Ishii J, 2008, J CELL BIOCHEM, V105, P896, DOI 10.1002/jcb.21886
   Jemal A, 2008, CA CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Johnen H, 2007, NAT MED, V13, P1333, DOI 10.1038/nm1677
   KAIGHN ME, 1979, INVEST UROL, V17, P16
   Kaneko H, 2000, BONE, V27, P479, DOI 10.1016/S8756 3282(00)00358 6
   Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621
   Kawada M, 2008, ANTICANCER RES, V28, P721
   Kim KK, 2008, CARCINOGENESIS, V29, P704, DOI 10.1093/carcin/bgn031
   Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535 7163.MCT 07 0234
   Koeneman KS, 1999, PROSTATE, V39, P246
   Kondo T, 2004, J BONE MINER RES, V19, P1411, DOI 10.1359/JBMR.040604
   Kubota K, 2002, J BONE MINER RES, V17, P257, DOI 10.1359/jbmr.2002.17.2.257
   Lambert JR, 2006, J CELL PHYSIOL, V208, P566, DOI 10.1002/jcp.20692
   Levy C, 2006, TRENDS MOL MED, V12, P406, DOI 10.1016/j.molmed.2006.07.008
   Li NX, 2000, METHOD ENZYMOL, V319, P273
   Liao JH, 2006, CANCER METAST REV, V25, P559, DOI 10.1007/s10555 006 9033 z
   Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528
   Massagué J, 2008, MOL CELL, V29, P149, DOI 10.1016/j.molcel.2008.01.006
   Massey HM, 2001, BONE, V28, P577, DOI 10.1016/S8756 3282(01)00432 X
   Morrissey C, 2007, J CELL BIOCHEM, V101, P873, DOI 10.1002/jcb.21214
   Newman D, 2003, MOL PHARMACOL, V63, P557, DOI 10.1124/mol.63.3.557
   Noorali S, 2007, DIFFERENTIATION, V75, P325, DOI 10.1111/j.1432 0436.2006.00142.x
   Pang M, 2007, GENE, V403, P151, DOI 10.1016/j.gene.2007.08.007
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Polek TC, 2003, ENDOCRINOLOGY, V144, P50, DOI 10.1210/en.2001 210109
   Rao A, 2002, J NUTR, V132, P3191, DOI 10.1093/jn/131.10.3191
   RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092 8674(78)90101 0
   Roudier MP, 2003, HUM PATHOL, V34, P646, DOI 10.1016/S0046 8177(03)00190 4
   Roudier MP, 2003, CLIN EXP METASTAS, V20, P171, DOI 10.1023/A:1022627421000
   Selander KS, 2007, CANCER EPIDEM BIOMAR, V16, P532, DOI 10.1158/1055 9965.EPI 06 0841
   Sevcíková S, 2002, CELL MOL LIFE SCI, V59, P1690, DOI 10.1007/PL00012497
   Sharma SM, 2007, J BIOL CHEM, V282, P15921, DOI 10.1074/jbc.M609723200
   Smith MR, 2008, UROL ONCOL SEMIN ORI, V26, P420, DOI 10.1016/j.urolonc.2007.11.004
   Stephan C, 2006, PROSTATE, V66, P651, DOI 10.1002/pros.20381
   Stewart LV, 2005, PROSTATE, V64, P9, DOI 10.1002/pros.20212
   Stewart LV, 2004, EXP BIOL MED, V229, P277, DOI 10.1177/153537020422900401
   Strelau J, 2008, CANCER LETT, V270, P30, DOI 10.1016/j.canlet.2008.04.042
   Sung SY, 2007, CURR PROB CANCER, V31, P36, DOI 10.1016/j.currproblcancer.2006.12.002
   Swanson C, 2006, ENDOCRINOLOGY, V147, P3613, DOI 10.1210/en.2005 0717
   Van Huyen JPD, 2008, J AM SOC NEPHROL, V19, P1965, DOI 10.1681/ASN.2007070781
   WAKCHOURE S, 2009, PROSTATE
   Wei S, 2008, PATHOL RES PRACT, V204, P695, DOI 10.1016/j.prp.2008.07.002
   Wilson LC, 2003, INT J CANCER, V105, P747, DOI 10.1002/ijc.11173
   Yang H, 2003, MOL CANCER THER, V2, P1023
   ZHANG L, 2008, ORAL ONCOL
   Zimmers TA, 2006, J SURG RES, V130, P45, DOI 10.1016/j.jss.2005.07.036
NR 87
TC 39
Z9 45
U1 0
U2 16
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0301 4681
EI 1432 0436
J9 DIFFERENTIATION
JI Differentiation
PD NOV
PY 2009
VL 78
IS 4
BP 213
EP 222
DI 10.1016/j.diff.2009.07.008
PG 10
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA 555RU
UT WOS:000274532600003
PM 19695766
DA 2025 08 17
ER

PT J
AU Chiminazzo, A
   Borsato, G
   Favero, A
   Fabbro, C
   McKenna, CE
   Dalle Carbonare, LG
   Valenti, MT
   Fabris, F
   Scarso, A
AF Chiminazzo, Andrea
   Borsato, Giuseppe
   Favero, Alessia
   Fabbro, Chiara
   McKenna, Charles E.
   Dalle Carbonare, Luca Giuseppe
   Valenti, Maria Teresa
   Fabris, Fabrizio
   Scarso, Alessandro
TI Diketopyrrolopyrrole Bis Phosphonate Conjugate: A New Fluorescent Probe
   for In Vitro Bone Imaging
SO CHEMISTRY A EUROPEAN JOURNAL
LA English
DT Article
DE click chemistry; fluorescent probes; imaging agents; nitrogen
   heterocycles; phosphonates
ID NEAR INFRARED FLUORESCENT; EFFICIENT SYNTHESIS; CLICK CHEMISTRY;
   1,3 DIPOLAR CYCLOADDITIONS; TRIAZOLE BISPHOSPHONATES; ESTIMATE
   SOLUBILITY; DRUG DISCOVERY; DIAZO TRANSFER; TURN ON; AZIDE
AB The synthesis of a conjugate molecule between an unusual red fluorescent diketopyrrolopyrrole (DPP) unit and a bis phosphonate (BP) precursor by a click chemistry strategy to target bone tissue and monitor the interaction is reported. After thorough investigation, conjugation through a triazole unit between a gamma azido rather than a beta azido BP and an alkyne functionalized DPP fluorophore group turned out to be the winning strategy. Visualization of the DPP BP conjugate on osteoclasts and specific antiresorption activity were successfully demonstrated.
C1 [Chiminazzo, Andrea; Borsato, Giuseppe; Fabris, Fabrizio; Scarso, Alessandro] Univ Ca Foscari Venezia, Dipartimento Sci Mol & Nanosistemi, Via Torino 155, I 30172 Venice, VE, Italy.
   [Favero, Alessia] Univ Parma, Dipartimento Sci Chim Vita & Sostenibilita Ambien, Parma, Italy.
   [Fabbro, Chiara] Imperial Coll London, Dept Chem, Wood Lane, London W12 0BZ, England.
   [McKenna, Charles E.] Univ Southern Calif, Dept Chem, Los Angeles, CA 90089 USA.
   [Dalle Carbonare, Luca Giuseppe; Valenti, Maria Teresa] Univ Verona, Dipartimento Med, Verona, Italy.
C3 Universita Ca Foscari Venezia; University of Parma; Imperial College
   London; University of Southern California; University of Verona
RP Scarso, A (通讯作者)，Univ Ca Foscari Venezia, Dipartimento Sci Mol & Nanosistemi, Via Torino 155, I 30172 Venice, VE, Italy.
EM alesca@unive.it
RI Carbonare, Luca/E 5720 2011; Scarso, Alessandro/B 8197 2014; Fabbro,
   Chiara/H 5316 2011; Valenti, Maria/F 4712 2011
OI Fabbro, Chiara/0000 0002 7665 7880; Scarso,
   Alessandro/0000 0001 6114 9181; Dalle Carbonare,
   Luca/0000 0003 3263 6671; Favero, Alessia/0000 0002 1106 9818
FU Universita Ca' Foscari
FX The authors gratefully acknowledge Universita Ca' Foscari for support.
CR Alper PB, 1996, TETRAHEDRON LETT, V37, P6029, DOI 10.1016/0040 4039(96)01307 X
   Artyushin OI, 2009, SYNTHESIS STUTTGART, P3579, DOI 10.1055/s 0029 1216982
   Avdeef A, 2002, CELL MOL LIFE SCI, V59, P1681, DOI 10.1007/PL00012496
   Beninatto R, 2013, DYES PIGMENTS, V96, P679, DOI 10.1016/j.dyepig.2012.11.011
   Bergan K., 2009, J AM CHEM SOC, V131, P5153
   Bortolini O, 2011, TETRAHEDRON, V67, P5635, DOI 10.1016/j.tet.2011.05.098
   Cai Y, 2018, ORG CHEM FRONT, V5, P98, DOI 10.1039/c7qo00755h
   Cao Y, 2017, J MATER CHEM B, V5, P5479, DOI 10.1039/c7tb01264k
   Chamberlain BT, 2011, J ORG CHEM, V76, P5132, DOI 10.1021/jo200045a
   Chandran D, 2013, MACROMOL RES, V21, P272, DOI 10.1007/s13233 013 1141 3
   Chen XL, 2013, TETRAHEDRON, V69, P4047, DOI 10.1016/j.tet.2013.03.078
   Chiminazzo A, 2017, HELV CHIM ACTA, V100, DOI 10.1002/hlca.201700104
   Colonna G, 2007, DYES PIGMENTS, V75, P125, DOI 10.1016/j.dyepig.2006.05.024
   Deng L, 2011, J ORG CHEM, V76, P9294, DOI 10.1021/jo201487m
   Diez Gonzalez S., 2008, ANGEW CHEM, V120, P9013, DOI DOI 10.1002/ANGE.200803289
   Díez González S, 2008, ANGEW CHEM INT EDIT, V47, P8881, DOI 10.1002/anie.200803289
   Díez González S, 2008, CHEM COMMUN, P4747, DOI 10.1039/b806806b
   Ferrer Casal M, 2013, SYNTHESIS STUTTGART, V45, P2397, DOI 10.1055/s 0033 1338498
   Fischer G.M., 2007, ANGEW CHEMIE, V119, P3824
   Fischer GM, 2007, ANGEW CHEM INT EDIT, V46, P3750, DOI 10.1002/anie.200604763
   Fischer N, 2012, J ORG CHEM, V77, P1760, DOI 10.1021/jo202264r
   Ftouni H, 2013, DYES PIGMENTS, V97, P77, DOI 10.1016/j.dyepig.2012.11.028
   Gao JB, 2013, BBA GEN SUBJECTS, V1830, P3635, DOI 10.1016/j.bbagen.2013.02.011
   Goddard Borger ED, 2007, ORG LETT, V9, P3797, DOI 10.1021/ol701581g
   Gourves JP, 1998, PHOSPHORUS SULFUR, V132, P219, DOI 10.1080/10426509808036988
   Grzybowski M, 2015, ADV OPT MATER, V3, P280, DOI 10.1002/adom.201400559
   Hagiwara H, 2009, SYNLETT, P643, DOI 10.1055/s 0028 1087926
   Hyun H., 2014, ANGEW CHEM, V126, P10844, DOI DOI 10.1002/ANGE.201404930
   Hyun H, 2014, ANGEW CHEM INT EDIT, V53, P10668, DOI 10.1002/anie.201404930
   IQBAL A, 1988, B SOC CHIM BELG, V97, P615
   Iqbal A, 1983, U.S. Pat, Patent No. [US4415685A, 4415685]
   Jeong YH, 2012, CHEM ASIAN J, V7, P1562, DOI 10.1002/asia.201101038
   Johansson H, 2012, EUR J ORG CHEM, V2012, P4267, DOI 10.1002/ejoc.201200496
   Kashemirov BA, 2008, BIOCONJUGATE CHEM, V19, P2308, DOI 10.1021/bc800369c
   Kaur M, 2015, CHEM SOC REV, V44, P58, DOI 10.1039/c4cs00248b
   Kaur M, 2014, DYES PIGMENTS, V100, P118, DOI 10.1016/j.dyepig.2013.09.001
   Kaur M, 2014, SENSOR ACTUAT B CHEM, V190, P542, DOI 10.1016/j.snb.2013.09.006
   KHARE AB, 1991, SYNTHESIS STUTTGART, P405
   Kowada T, 2011, J AM CHEM SOC, V133, P17772, DOI 10.1021/ja2064582
   Kozloff KM, 2010, J BONE MINER RES, V25, P1748, DOI 10.1002/jbmr.66
   Lartia R, 2011, ORG LETT, V13, P5672, DOI 10.1021/ol202397e
   Li YN, 2013, ENERG ENVIRON SCI, V6, P1684, DOI 10.1039/c3ee00015j
   Liang PP, 2017, NANOSCALE, V9, P18890, DOI 10.1039/c7nr07204j
   LIBSON K, 1980, J AM CHEM SOC, V102, P2476, DOI 10.1021/ja00527a066
   Link AJ, 2007, NAT PROTOC, V2, P1879, DOI 10.1038/nprot.2007.268
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169 409X(00)00129 0
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169 409X(96)00423 1
   Liu SY, 2015, PHOSPHORUS SULFUR, V190, P1735, DOI 10.1080/10426507.2015.1012200
   Luak S., 2009, J MOL STRUCT, V919, P239
   Makarov MV, 2014, RUSS CHEM B+, V63, P2388, DOI 10.1007/s11172 014 0752 y
   Matthiesen RA, 2018, BIOORGAN MED CHEM, V26, P376, DOI 10.1016/j.bmc.2017.10.023
   Meckel M, 2013, NUCL MED BIOL, V40, P823, DOI 10.1016/j.nucmedbio.2013.04.012
   Mishra A, 2015, J ORG CHEM, V80, P4869, DOI 10.1021/acs.joc.5b00179
   Mizuguchi J, 2006, DYES PIGMENTS, V68, P47, DOI 10.1016/j.dyepig.2005.01.001
   Nielsen CB, 2013, ADV MATER, V25, P1859, DOI 10.1002/adma.201201795
   Qiu L, 2011, MOLECULES, V16, P6165, DOI 10.3390/molecules16086165
   Qu Y, 2010, ORG LETT, V12, P3320, DOI 10.1021/ol101081m
   Raju MVR, 2013, MACROMOLECULES, V46, P6731, DOI 10.1021/ma401485b
   Raju MVR, 2013, ORG LETT, V15, P1274, DOI 10.1021/ol400221h
   Rochat A. C., 1983, Eur. Pat. Appl, Patent No. 94911
   Rostovtsev VV, 2002, ANGEW CHEM INT EDIT, V41, P2596, DOI 10.1002/1521 3773(20020715)41:14<2596::AID ANIE2596>3.0.CO;2 4
   Rudnick Glick S, 2016, J NANOBIOTECHNOL, V14, DOI 10.1186/s12951 016 0233 6
   Rudnick Glick S, 2015, J NANOBIOTECHNOL, V13, DOI 10.1186/s12951 015 0126 0
   Russell RGG, 2007, BONE, V40, pS21, DOI 10.1016/j.bone.2007.03.002
   Schutting S, 2013, ANAL CHEM, V85, P3271, DOI 10.1021/ac303595v
   Sharpless K.B., 2002, Angew. Chem., V114, P2708, DOI DOI 10.1002/1521 3757(20020715)114:14<2708::AID ANGE2708>3.0.CO;2 0
   Shou KQ, 2018, CHEM SCI, V9, P3105, DOI 10.1039/c8sc00206a
   Sminia TJ, 2012, SYNLETT, P2643, DOI 10.1055/s 0032 1317445
   Speers AE, 2003, J AM CHEM SOC, V125, P4686, DOI 10.1021/ja034490h
   Sun ST, 2016, BIOCONJUGATE CHEM, V27, P329, DOI 10.1021/acs.bioconjchem.5b00369
   Sun ST, 2011, PHOSPHORUS SULFUR, V186, P970, DOI 10.1080/10426507.2010.526674
   Tal N, 2017, POLYMER, V132, P188, DOI 10.1016/j.polymer.2017.11.003
   Tornoe CW, 2002, J ORG CHEM, V67, P3057, DOI 10.1021/jo011148j
   Turhanen PA, 2014, J ORG CHEM, V79, P6330, DOI 10.1021/jo500831r
   Velázquez HD, 2014, ORG BIOMOL CHEM, V12, P9350, DOI 10.1039/c4ob01350f
   Wiemer AJ, 2008, BIOORGAN MED CHEM, V16, P3652, DOI 10.1016/j.bmc.2008.02.016
   Wiktorowski S, 2014, CHEM COMMUN, V50, P4755, DOI 10.1039/c4cc01014k
   Wills VS, 2015, ACS MED CHEM LETT, V6, P1195, DOI 10.1021/acsmedchemlett.5b00334
   Winckler W, 1996, PHOSPHORUS SULFUR, V112, P137, DOI 10.1080/10426509608046357
   Yamagata T, 2010, TETRAHEDRON LETT, V51, P1596, DOI 10.1016/j.tetlet.2010.01.069
   ZALOOM J, 1981, J ORG CHEM, V46, P5173, DOI 10.1021/jo00338a022
   Zambounis J. S., 1995, [No title captured], Patent No. [EP0648770, 0648770]
   Zhang GJ, 2013, ANALYST, V138, P6163, DOI 10.1039/c3an00873h
   Zhang YH, 2009, J AM CHEM SOC, V131, P5153, DOI 10.1021/ja808285e
   Zhou X, 2014, BIOORGAN MED CHEM, V22, P2791, DOI 10.1016/j.bmc.2014.03.014
   Zhou X, 2013, BIOORG MED CHEM LETT, V23, P764, DOI 10.1016/j.bmcl.2012.11.089
NR 86
TC 20
Z9 23
U1 1
U2 58
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 0947 6539
EI 1521 3765
J9 CHEM EUR J
JI Chem. Eur. J.
PD MAR 7
PY 2019
VL 25
IS 14
BP 3617
EP 3626
DI 10.1002/chem.201805436
PG 10
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Chemistry
GA HO1SW
UT WOS:000460692100026
PM 30600841
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Sun, XH
   Zhu, KD
   Feng, CC
   Zhu, J
   Chen, SS
   Tang, WK
   Wang, ZF
   Xiao, L
   Li, H
   Geng, DC
   Wang, ZR
AF Sun, Xiaohong
   Zhu, Keda
   Feng, Chengcheng
   Zhu, Jie
   Chen, Shuangshuang
   Tang, Wenkai
   Wang, Zhifang
   Xiao, Long
   Li, Hong
   Geng, Dechun
   Wang, Zhirong
TI Paeoniflorin Ameliorates Hyperprolactinemia Induced Inhibition of
   Osteoblastogenesis by Suppressing the NF κB Signaling Pathway
SO INTERNATIONAL JOURNAL OF ENDOCRINOLOGY
LA English
DT Article
ID ANIT INDUCED CHOLESTASIS; BONE MINERAL DENSITY; PROLACTIN; PREGNANCY;
   LACTATION; OSTEOPOROSIS; PREVALENCE; TURNOVER; ESTROGEN; BLOCKING
AB Hyperprolactinemia is a common endocrine disease in women of reproductive age. Research has shown that patients with hyperprolactinemia often have decreased bone mineral density and an increased risk of fractures. However, there is still a lack of effective treatments. Paeoniflorin, one of the primary bioactive components in peony, is widely used in traditional Chinese medicine. Research has shown that paeoniflorin promotes osteoblast differentiation. However, whether paeoniflorin plays a role in hyperprolactinemia induced osteoblastogenesis inhibition is not yet clear. In this study, we investigated the effect of paeoniflorin on prolactin (PRL) mediated inhibition of osteoblast function. Our results showed that prolactin significantly reduced the expression of alkaline phosphatase (ALP), Osterix, and runt related transcription factor 2 (RUNX2) in MC3T3 E1 cells cultured in an osteoblast differentiation medium, suggesting that prolactin inhibited osteoblast function. After treatment with paeoniflorin (PF), the expression of these osteoblast markers was upregulated. In addition, our findings proved that paeoniflorin increased the absorbance values of ALP positive cells and the areas of alizarin red S (ARS) deposition compared to those in the prolactin group, suggesting that paeoniflorin reversed the PRL induced reduction in osteoblast differentiation. The PRL induced activation of nuclear factor kappa B (NF kappa B) was significantly reversed by paeoniflorin, indicating that paeoniflorin promoted osteoblast function by inhibiting the NF kappa B signaling pathway. In summary, these results showed that paeoniflorin alleviated the inhibitory effect of prolactin on osteoblastogenesis by suppressing the NF kappa B signaling pathway.
C1 [Sun, Xiaohong; Feng, Chengcheng; Zhu, Jie; Chen, Shuangshuang; Tang, Wenkai; Wang, Zhifang; Xiao, Long; Wang, Zhirong] Nanjing Univ Chinese Med, Ctr Lab, Zhangjiagang TCM Hosp, Zhangjiagang 215600, Peoples R China.
   [Sun, Xiaohong; Zhu, Keda; Feng, Chengcheng; Chen, Shuangshuang; Li, Hong] Nanjing Univ Chinese Med, Dept Endocrinol, Zhangjiagang TCM Hosp, Zhangjiagang 215600, Peoples R China.
   [Zhu, Jie; Tang, Wenkai; Xiao, Long; Wang, Zhirong] Nanjing Univ Chinese Med, Dept Orthoped, Zhangjiagang TCM Hosp, Zhangjiagang 215600, Peoples R China.
   [Xiao, Long; Geng, Dechun] Soochow Univ, Dept Orthoped, Affiliated Hosp 1, Suzhou 215006, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese
   Medicine; Nanjing University of Chinese Medicine; Soochow University  
   China
RP Xiao, L; Wang, ZR (通讯作者)，Nanjing Univ Chinese Med, Ctr Lab, Zhangjiagang TCM Hosp, Zhangjiagang 215600, Peoples R China.; Li, H (通讯作者)，Nanjing Univ Chinese Med, Dept Endocrinol, Zhangjiagang TCM Hosp, Zhangjiagang 215600, Peoples R China.; Xiao, L; Wang, ZR (通讯作者)，Nanjing Univ Chinese Med, Dept Orthoped, Zhangjiagang TCM Hosp, Zhangjiagang 215600, Peoples R China.; Xiao, L; Geng, DC (通讯作者)，Soochow Univ, Dept Orthoped, Affiliated Hosp 1, Suzhou 215006, Peoples R China.
EM zjgzy065@njucm.edu.cn; zjgzy066@njucm.edu.cn; zjgzy056@njucm.edu.cn;
   zjgzy055@njucm.edu.cn; zjgzy064@njucm.edu.cn; zjgzy062@njucm.edu.cn;
   zjgzy058@njucm.edu.cn; zjgfy_spine_xl@njucm.edu.cn;
   zjgzyy_lihong@njucm.edu.cn; szgengdc@163.com;
   zjgfy_spine_wzr@njucm.edu.cn
RI chen, shuangshuang/KGK 6684 2024; chen, shuang shuang/KGK 6684 2024;
   Zhirong, Wang/AAR 5563 2021; luo, xiaomin/HNS 7206 2023; Geng,
   Dechun/LMO 1733 2024
OI chen, shuang shuang/0009 0009 6549 1449; 
FU National Natural Science Foundation of China [82074473, 82104892];
   Natural Science Foundation of Jiangsu province [BK20180001, BK20191201,
   BE2020666]; Jiangsu Province "333 Project" research project
   [BRA2020129]; Elderly Health Research Project of Jiangsu Province
   [LK2021043, LR2021024]; Key Disciplines in Suzhou [SZXK202120]; Suzhou
   Science and Technology Development Plan Project [SYSD2017008,
   SYSD2019007, SYSD2020009, SYSD2021175, SKY2021001, SKJY2021002]; Suzhou
   Health Personnel Training Project [GSWS2019074, GSWS2020103];
   Zhangjiagang Health Personnel Training Project [ZJGWSRC2020002];
   Zhangjiagang Health System Youth Science and Technology Project
   [ZJGQNKJ201804, ZJGQNKJ201807, ZJGQNKJ202010, ZJGQNKJ202031,
   ZJGQNKJ202110, ZJGQNKJ202133, ZKS2007, ZKS2121, ZKS2126, ZKS2129,
   ZKS2030]
FX The authors greatly acknowledge the financial support from the National
   Natural Science Foundation of China (82074473 and 82104892), the Natural
   Science Foundation of Jiangsu province (BK20180001, BK20191201, and
   BE2020666), Jiangsu Province "333 Project" research project
   (BRA2020129), the Elderly Health Research Project of Jiangsu Province
   (LK2021043 and LR2021024), Key Disciplines in Suzhou (SZXK202120),
   Suzhou Science and Technology Development Plan Project (SYSD2017008,
   SYSD2019007, SYSD2020009, SYSD2021175, SKY2021001, and SKJY2021002), the
   Suzhou Health Personnel Training Project (GSWS2019074 and GSWS2020103),
   the Zhangjiagang Health Personnel Training Project (ZJGWSRC2020002), and
   the Zhangjiagang Health System Youth Science and Technology Project
   (ZJGQNKJ201804, ZJGQNKJ201807, ZJGQNKJ202010, ZJGQNKJ202031,
   ZJGQNKJ202110, ZJGQNKJ202133, ZKS2007, ZKS2121, ZKS2126, ZKS2129, and
   ZKS2030).
CR Amnattanakul S, 2005, CAN J PHYSIOL PHARM, V83, P595, DOI 10.1139/Y05 045
   Bezerra F, 2004, AM J CLIN NUTR, V80, P1322, DOI 10.1093/ajcn/80.5.1322
   Canul Medina G, 2019, J PHYSIOL SCI, V69, P825, DOI 10.1007/s12576 019 00714 4
   Charoenphandhu N, 2008, CAN J PHYSIOL PHARM, V86, P240, DOI [10.1139/Y08 037, 10.1139/y08 037]
   Chen Z, 2015, PHYTOTHER RES, V29, P1768, DOI 10.1002/ptr.5431
   Coss D, 2000, AM J PHYSIOL ENDOC M, V279, pE1216, DOI 10.1152/ajpendo.2000.279.6.E1216
   di Filippo L, 2020, PITUITARY, V23, P314, DOI 10.1007/s11102 020 01041 3
   Galdiero M, 2012, J ENDOCRINOL INVEST, V35, P782, DOI 10.1007/BF03345805
   Haddad PM, 2004, DRUGS, V64, P2291, DOI 10.2165/00003495 200464200 00003
   He YQ, 2018, CHEM BIOL INTERACT, V291, P128, DOI 10.1016/j.cbi.2018.06.015
   Honjo S, 2001, AM J OBSTET GYNECOL, V185, P246, DOI 10.1067/mob.2001.113910
   Jung DU, 2006, J CLIN PSYCHIAT, V67, P1391, DOI 10.4088/JCP.v67n0909
   Kovacs CS, 2016, PHYSIOL REV, V96, P449, DOI 10.1152/physrev.00027.2015
   Kyvernitakis I, 2018, OSTEOPOROSIS INT, V29, P135, DOI 10.1007/s00198 017 4239 1
   Li H, 2017, INFLAMMATION, V40, P2042, DOI 10.1007/s10753 017 0644 z
   Liu GW, 2017, BIOCHEM BIOPH RES CO, V491, P388, DOI 10.1016/j.bbrc.2017.07.091
   Mazziotti G, 2018, ENDOCR REV, V39, P440, DOI 10.1210/er.2018 00005
   Montejo AL, 2016, REV PSIQUIATR SALUD, V9, P158, DOI 10.1016/j.rpsm.2015.11.003
   Naliato ECO, 2005, J ENDOCRINOL INVEST, V28, P12, DOI 10.1007/BF03345523
   Ni J, 2016, J PERIODONTAL RES, V51, P257, DOI 10.1111/jre.12305
   Noris E, 2015, METHODS MOL BIOL, V1236, P61, DOI 10.1007/978 1 4939 1743 3_6
   Ochoa Amaya JE, 2010, NEUROIMMUNOMODULAT, V17, P386, DOI 10.1159/000292063
   Olausson H, 2008, AM J CLIN NUTR, V88, P1032
   Olavarría VH, 2010, J IMMUNOL, V185, P3873, DOI 10.4049/jimmunol.0902306
   Suarez ALP, 2015, ADV EXP MED BIOL, V846, P243, DOI 10.1007/978 3 319 12114 7_11
   Puntheeranurak S, 2006, CAN J PHYSIOL PHARM, V84, P993, DOI 10.1139/Y06 047
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rivero Segura NA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176910
   Seriwatanachai D, 2008, BONE, V42, P535, DOI 10.1016/j.bone.2007.11.008
   Seriwatanachai D, 2009, J CELL BIOCHEM, V107, P677, DOI 10.1002/jcb.22161
   Song SL, 2017, PHYTOMEDICINE, V34, P115, DOI 10.1016/j.phymed.2017.08.010
   Tao Y, 2016, EXP THER MED, V11, P263, DOI 10.3892/etm.2015.2902
   WANG C, 1982, ENDOCRINOLOGY, V110, P1085, DOI 10.1210/endo 110 4 1085
   WANG C, 1980, MOL CELL ENDOCRINOL, V20, P135, DOI 10.1016/0303 7207(80)90077 5
   Wang C, 2013, INFLAMM RES, V62, P1035, DOI 10.1007/s00011 013 0662 8
   Wang JT, 2018, GENE, V676, P29, DOI 10.1016/j.gene.2018.06.068
   Wang Y., 2018, ONCOTARGET, V9, P7372, DOI 10.18632/oncotarget.23677
   Wang YM, 2018, BIOCHEM BIOPH RES CO, V498, P981, DOI 10.1016/j.bbrc.2018.03.093
   Wu XX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 017 0151 z
   Xu WZ, 2020, J PERIODONTOL, V91, P683, DOI 10.1002/JPER.18 0710
   Yu HY, 2007, PHARMACOL BIOCHEM BE, V88, P131, DOI 10.1016/j.pbb.2007.07.013
   Zhang MH, 2013, PLANTA MED, V79, P1319, DOI 10.1055/s 0033 1350649
   Zhao YL, 2013, FOOD CHEM TOXICOL, V58, P242, DOI 10.1016/j.fct.2013.04.030
   Zheng L, 2019, FASEB J, V33, P7667, DOI 10.1096/fj.201802364RR
   Zhou YX, 2020, BIOMED PHARMACOTHER, V130, DOI 10.1016/j.biopha.2020.110505
NR 45
TC 3
Z9 4
U1 0
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1687 8337
EI 1687 8345
J9 INT J ENDOCRINOL
JI Int. J. Endocrinol.
PD APR 15
PY 2022
VL 2022
AR 4572033
DI 10.1155/2022/4572033
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 1V6GK
UT WOS:000806185500001
PM 35465073
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Allard, L
   Demoncheaux, N
   Machuca Gayet, I
   Georgess, D
   Coury Lucas, F
   Jurdic, P
   Bacchetta, J
AF Allard, Lise
   Demoncheaux, Nathalie
   Machuca Gayet, Irma
   Georgess, Dan
   Coury Lucas, Fabienne
   Jurdic, Pierre
   Bacchetta, Justine
TI Biphasic Effects of Vitamin D and FGF23 on Human Osteoclast Biology
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Bone resorption; Differentiation; FGF23; Human; Osteoclast; Vitamin D
ID GROWTH FACTOR 23; BONE; MATRIX; FIBROBLAST GROWTH FACTOR 23;
   DIFFERENTIATION; DEGRADATION; METABOLISM; PHOSPHATE; PROTEIN; TARGET
AB Vitamin D and FGF23 play a major role in calcium/phosphate balance. Vitamin D may control bone resorption but the potential role of FGF23 has never been evaluated. The objective of this study was therefore to compare the effects of vitamin D and FGF23 on osteoclast differentiation and activity in human monocyte derived osteoclasts. Human monocytes, purified from blood of healthy donors, were incubated with M CSF and RANKL to obtain mature multinucleated osteoclasts (MNC). Experiments were carried out to assess the effects of FGF23 as compared to native vitamin D (25 D) and active vitamin D (1,25 D) on osteoclast differentiation and on bone resorbing osteoclast activity. Additional experiments with the pan fibroblast growth factor receptor inhibitor (FGFR i) were performed. Phosphorylation Akt and Erk pathways were analyzed by Western blot analyses. Both 1,25 D and FGF23, to a lesser extent, significantly inhibited osteoclastogenesis at early stages; when adding FGFR i, osteoclast formation was restored. Biochemical experiments showed an activation of the Akt and Erk pathways under FGF23 treatment. In contrast, in terms of activity, 1,25 D had no effect on resorption, whereas FGF23 slightly but significantly increased bone resorption; 25 D had no effects on either differentiation or on activity. These data show that 1,25 D inhibits osteoclastogenesis without regulating osteoclast mediated bone resorption activity; FGF23 has biphasic effects on osteoclast physiology, inhibiting osteoclast formation while stimulating slightly osteoclast activity. These results may be of importance and taken into account in chronic kidney disease when therapies modulating FGF23 are available.
C1 [Allard, Lise; Demoncheaux, Nathalie; Machuca Gayet, Irma; Georgess, Dan; Coury Lucas, Fabienne; Jurdic, Pierre; Bacchetta, Justine] Univ Lyon, Inst Genom Fonct Lyon, ENS UMR 5242, Lyon, France.
   [Allard, Lise] CHU Angers, Pole Femme Mere Enfant, Serv Pediat, F 49003 Angers, France.
   [Machuca Gayet, Irma; Coury Lucas, Fabienne] INSERM 1033, F 69008 Lyon, France.
   [Bacchetta, Justine] Hop Femme Mere Enfant, Hosp Civils Lyon, Serv Nephrol & Rhumatol Pediat, Ctr Reference Malad Renales Rares, F 69677 Bron, France.
C3 CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole
   Normale Superieure de Lyon (ENS de LYON); Universite Claude Bernard Lyon
   1; CNRS   National Institute for Biology (INSB); Universite d'Angers;
   Centre Hospitalier Universitaire d'Angers; Institut National de la Sante
   et de la Recherche Medicale (Inserm); Universite Claude Bernard Lyon 1;
   CHU Lyon
RP Bacchetta, J (通讯作者)，Univ Lyon, Inst Genom Fonct Lyon, ENS UMR 5242, Lyon, France.
EM justine.bacchetta@chu lyon.fr
RI Georgess, Dan/AAC 6280 2020; Coury, Fabienne/MSW 4864 2025; Bacchetta,
   Justine/B 3842 2016
OI Georgess, Dan/0000 0003 3075 4527; Allard, Lise/0000 0003 1741 0607;
   Machuca  Gayet, irma/0000 0002 3010 9774; coury,
   fabienne/0000 0002 9175 8620; Bacchetta, Justine/0000 0002 0578 2529
FU French Society of Pediatric Endocrinology and Diabetology; Amgen;
   Sandoz; la Fondation du Rein/Prix Jeune Chercheur
FX Lise Allard received an educational grant from the French Society of
   Pediatric Endocrinology and Diabetology for her master research project.
   A financial support was provided by Amgen, Sandoz and by la Fondation du
   Rein/Prix Jeune Chercheur 2013 (JB) for reagents and experiments. The
   authors would like to acknowledge Marlene Mazzorana, PhD, for her
   skillful technical help for the purification of monocytes and cell
   cultures.
CR Bacchetta J, 2013, J BONE MINER RES, V28, P46, DOI 10.1002/jbmr.1740
   Bacchetta J, 2012, AM J KIDNEY DIS, V59, P152, DOI 10.1053/j.ajkd.2011.08.035
   Ben Dov IZ, 2007, J CLIN INVEST, V117, P4003, DOI 10.1172/JCI32409
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Cappariello A, 2014, ARCH BIOCHEM BIOPHYS, V558, P70, DOI 10.1016/j.abb.2014.06.017
   Chen IP, 2011, HUM MOL GENET, V20, P948, DOI 10.1093/hmg/ddq541
   Farrow EG, 2009, J AM SOC NEPHROL, V20, P955, DOI 10.1681/ASN.2008070783
   Faul C, 2011, J CLIN INVEST, V121, P4393, DOI 10.1172/JCI46122
   FugierVivier I, 1997, J EXP MED, V186, P813, DOI 10.1084/jem.186.6.813
   Gattineni J, 2014, AM J PHYSIOL RENAL, V306, pF351, DOI 10.1152/ajprenal.00232.2013
   Gutiérrez OM, 2008, NEW ENGL J MED, V359, P584, DOI 10.1056/NEJMoa0706130
   Harre U, 2012, J CLIN INVEST, V122, P1791, DOI 10.1172/JCI60975
   Hayashibara T, 2007, J BONE MINER RES, V22, P1743, DOI 10.1359/JBMR.070709
   Hollberg K, 2008, BONE, V42, P1111, DOI 10.1016/j.bone.2008.01.019
   Hu LJ, 2013, BIOCHEM BIOPH RES CO, V430, P901, DOI 10.1016/j.bbrc.2012.12.056
   Itonaga I, 1999, BIOCHEM BIOPH RES CO, V264, P590, DOI 10.1006/bbrc.1999.1545
   Kogawa M, 2010, J STEROID BIOCHEM, V121, P277, DOI 10.1016/j.jsbmb.2010.03.048
   Kogawa M, 2010, ENDOCRINOLOGY, V151, P4613, DOI 10.1210/en.2010 0334
   Kurosu H, 2009, MOL CELL ENDOCRINOL, V299, P72, DOI 10.1016/j.mce.2008.10.052
   Pereira RC, 2009, BONE, V45, P1161, DOI 10.1016/j.bone.2009.08.008
   Razzaque MS, 2009, AM J PHYSIOL RENAL, V296, pF470, DOI 10.1152/ajprenal.90538.2008
   Rivollier A, 2004, BLOOD, V104, P4029, DOI 10.1182/blood 2004 01 0041
   Sakai S, 2009, J BONE MINER METAB, V27, P643, DOI 10.1007/s00774 009 0084 4
   Shalhoub V, 2012, J CLIN INVEST, V122, P2543, DOI 10.1172/JCI61405
   Sitara D, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000154
   Takasu H, 2006, J CLIN INVEST, V116, P528, DOI 10.1172/JCI24742
   Vincent C, 2009, J BONE MINER RES, V24, P1434, DOI [10.1359/JBMR.090305, 10.1359/jbmr.090305]
   Wang H, 2008, J BONE MINER RES, V23, P939, DOI 10.1359/JBMR.080220
   Wang N, 2014, FASEB J, V28, P2249, DOI 10.1096/fj.13 243626
   Wesseling Perry K, 2009, J CLIN ENDOCR METAB, V94, P511, DOI 10.1210/jc.2008 0326
   Wolf M, 2011, J AM SOC NEPHROL, V22, P956, DOI 10.1681/ASN.2010080894
   Yamazaki Y, 2008, J BONE MINER RES, V23, P1509, DOI 10.1359/JBMR.080417
   Yoshiko Y, 2007, BONE, V40, P1565, DOI 10.1016/j.bone.2007.01.017
NR 33
TC 36
Z9 38
U1 0
U2 11
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD JUL
PY 2015
VL 97
IS 1
BP 69
EP 79
DI 10.1007/s00223 015 0013 6
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CK0AR
UT WOS:000355866600009
PM 25987164
DA 2025 08 17
ER

PT J
AU Morse, LR
   Xu, Y
   Solomon, B
   Boyle, L
   Yoganathan, S
   Stashenko, P
   Battaglino, RA
AF Morse, Leslie R.
   Xu, Yan
   Solomon, Bethlehem
   Boyle, Lara
   Yoganathan, Subbiah
   Stashenko, Philip
   Battaglino, Ricardo A.
TI Severe Spinal Cord Injury Causes Immediate Multi cellular Dysfunction at
   the Chondro Osseous Junction
SO TRANSLATIONAL STROKE RESEARCH
LA English
DT Article
DE Rehabilitation medicine; Spinal cord injury; Osteoporosis; Osteoblast;
   Chondrocyte
ID BONE MINERAL DENSITY; GROWTH PLATE; ARTICULAR CARTILAGE; OSTEOPOROSIS;
   FRACTURES; KNEE; RATS; METABOLISM; EXPRESSION; MANAGEMENT
AB Spinal cord injury is associated with rapid bone loss and arrested long bone growth due to mechanisms that are poorly understood. In this study, we sought to determine the effects of severe T10 contusion spinal cord injury on the sublesional bone microenvironment in adolescent rats. A severe lower thoracic (vertebral T10) spinal cord injury was generated by weight drop (10 gx50 mm). Severely injured and body weight matched uninjured male Sprague Dawley rats were studied. At 3 and 5 days post injury, we performed histological analysis of the distal femoral metaphysis, TUNEL assay, immunohistochemistry, real time PCR, and western blot analysis compared to uninjured controls. We observed severe hindlimb functional deficits typical of this model. We detected uncoupled remodeling with increased osteoclast activity in the absence of osteoblast activity. We detected osteoblast, osteocyte, and chondrocyte apoptosis with suppressed osteoblast and chondrocyte proliferation and growth plate arrest due to spinal cord injury. We also detected altered gene expression in both whole bone extracts and bone marrow monocytes following spinal cord injury. We conclude that spinal cord injury results in altered gene expression of key regulators of osteoblast and chondrocyte activity. This leads to premature cellular apoptosis, suppressed cellular proliferation, growth plate arrest, and uncoupled bone remodeling in sublesional bone with unopposed osteoclastic resorption.
C1 [Morse, Leslie R.] Harvard Univ, Dept PMR, Sch Med, Forsyth Inst, Boston, MA 02118 USA.
   [Morse, Leslie R.] Spaulding Harvard Spinal Cord Injury Model Syst, Spaulding Rehabil Hosp, Boston, MA USA.
   [Morse, Leslie R.; Xu, Yan; Solomon, Bethlehem; Boyle, Lara; Yoganathan, Subbiah; Stashenko, Philip; Battaglino, Ricardo A.] Forsyth Inst, Dept Cytokine Biol, Boston, MA USA.
   [Morse, Leslie R.] Harvard Univ, Dept Phys Med & Rehabil, Sch Med, Boston, MA 02118 USA.
   [Stashenko, Philip; Battaglino, Ricardo A.] Harvard Univ, Dept Oral Med Infect & Immun, Sch Dent Med, Boston, MA 02118 USA.
   [Xu, Yan] Kunming Med Univ, Dept Med Microbiol & Immunol, Kunming, Yunnan, Peoples R China.
C3 Harvard University; Harvard University Medical Affiliates; Forsyth
   Institute; Harvard School of Dental Medicine; Harvard Medical School;
   Harvard University; Harvard Medical School; Harvard University Medical
   Affiliates; Spaulding Rehabilitation Hospital; Harvard University;
   Harvard University Medical Affiliates; Forsyth Institute; Harvard
   University; Harvard Medical School; Harvard University; Harvard School
   of Dental Medicine; Kunming Medical University
RP Morse, LR (通讯作者)，Harvard Univ, Dept PMR, Sch Med, Forsyth Inst, 140 Fenway, Boston, MA 02118 USA.
EM lmorse4@partners.org
RI ; battaglino, ricardo/D 2892 2015; Morse, Leslie/AAU 5608 2020
OI Solomon, Bethlehem/0000 0001 6448 9595; 
FU NIH/NICHD [K12HD001097 08]
FX Grant sponsor: NIH/NICHD Grant number K12HD001097 08 (L.M.)
CR ARO H, 1985, ACTA ORTHOP SCAND, V56, P228
   Basso N, 2006, BONE, V39, P807, DOI 10.1016/j.bone.2006.04.014
   CAMPBELL J, 1975, CLIN ORTHOP RELAT R, P114
   Dauty M, 2000, BONE, V27, P305, DOI 10.1016/S8756 3282(00)00326 4
   Demirel G, 1998, SPINAL CORD, V36, P822, DOI 10.1038/sj.sc.3100704
   DUVALBEAUPERE G, 1983, PARAPLEGIA, V21, P339, DOI 10.1038/sc.1983.58
   Eser P., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P197
   Garland DE, 2004, J SPINAL CORD MED, V27, P202, DOI 10.1080/10790268.2004.11753748
   GARLAND DE, 1992, J ORTHOPAED RES, V10, P371, DOI 10.1002/jor.1100100309
   GARLAND DE, 1986, CLIN ORTHOP RELAT R, P237
   GULLICKSON GLENN, 1950, ARCH PHYS MED, V31, P392
   Hecht JT, 2004, J ORTHOP RES, V22, P759, DOI 10.1016/j.orthres.2003.11.010
   Jepsen KJ, 2008, J BONE MINER RES, V23, P1204, DOI 10.1359/JBMR.080317
   Kocina P, 1997, SPORTS MED, V23, P48, DOI 10.2165/00007256 199723010 00005
   Kogianni G, 2008, J BONE MINER RES, V23, P915, DOI 10.1359/JBMR.080207
   MCMASTER WC, 1975, CLIN ORTHOP RELAT R, P44
   MONTUFARSOLIS D, 1992, J APPL PHYSIOL, V73, pS19, DOI 10.1152/jappl.1992.73.2.S19
   Moriyama H, 2008, OSTEOARTHR CARTILAGE, V16, P392, DOI 10.1016/j.joca.2007.07.002
   Moriyama H, 2009, SPINAL CORD, V47, P218, DOI 10.1038/sc.2008.96
   Morse L, 2008, OSTEOPOROSIS INT, V19, P645, DOI 10.1007/s00198 007 0494 x
   Morse LR, 2009, OSTEOPOROSIS INT, V20, P385, DOI 10.1007/s00198 008 0671 6
   Morse LR, 2009, PM&R, V1, P240, DOI 10.1016/j.pmrj.2008.10.008
   NOTTAGE WM, 1981, CLIN ORTHOP RELAT R, P65
   RING PA, 1957, LANCET, V2, P980
   Roberts D, 1998, J CLIN ENDOCR METAB, V83, P415, DOI 10.1210/jc.83.2.415
   Szollar SM, 1998, AM J PHYS MED REHAB, V77, P28, DOI 10.1097/00002060 199801000 00005
   Szollar SM, 1997, SPINAL CORD, V35, P223, DOI 10.1038/sj.sc.3100401
   UEBELHART D, 1994, SCAND J REHABIL MED, V26, P197
   Van Der Eerden BCJ, 2000, J BONE MINER RES, V15, P1045, DOI 10.1359/jbmr.2000.15.6.1045
   Vashishth D, 2000, BONE, V26, P375, DOI 10.1016/S8756 3282(00)00236 2
   Verborgt O, 2000, J BONE MINER RES, V15, P60, DOI 10.1359/jbmr.2000.15.1.60
   WILMET E, 1995, PARAPLEGIA, V33, P674, DOI 10.1038/sc.1995.141
NR 32
TC 17
Z9 21
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1868 4483
EI 1868 601X
J9 TRANSL STROKE RES
JI Transl. Stroke Res.
PD DEC
PY 2011
VL 2
IS 4
SI SI
BP 643
EP 650
DI 10.1007/s12975 011 0118 9
PG 8
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology
GA 943YJ
UT WOS:000304163700021
PM 22368723
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Kwon, SM
   Kim, S
   Song, NJ
   Chang, SH
   Hwang, YJ
   Yang, DK
   Hong, JW
   Park, WJ
   Park, KW
AF Kwon, So Mi
   Kim, Suji
   Song, No Joon
   Chang, Seo Hyuk
   Hwang, Yu Jin
   Yang, Dong Kwon
   Hong, Joung Woo
   Park, Woo Jin
   Park, Kye Won
TI Antiadipogenic and proosteogenic effects of luteolin, a major dietary
   flavone, are mediated by the induction of DnaJ (Hsp40) Homolog,
   Subfamily B, Member 1
SO JOURNAL OF NUTRITIONAL BIOCHEMISTRY
LA English
DT Article
DE Luteolin; Dnajb1; Heat shock protein; Adipocyte differentiation;
   Osteoblast differentiation
ID MESENCHYMAL STEM CELLS; OSTEOBLAST DIFFERENTIATION; PPAR GAMMA;
   ADIPOCYTE DIFFERENTIATION; SIGNALING PATHWAY; BONE HEALTH; MARROW;
   OBESITY; FAT; OSTEOPOROSIS
AB Luteolin (3,4,5,7 tetrahydroxyflavones), a major dietary flavone, regulates a variety of biological effects including cancer progression, insulin resistance and inflammation. However, its exact actions on adipogenesis and osteogenesis and the underlying molecular mechanisms are yet to be clarified. In this study, we show that luteolin suppresses lipid accumulation but increases osteoblast differentiation. In mechanism studies, luteolin increases the expression of the heat shock proteins (Hsp) 40 (Dnajb1) and Hsp90 (Hsp90b1), but not those of other heat shock proteins including Hsp20, Hsp27, Hsp47, Hsp70, Hsp72, and Hsp90, and another type of Hsp40 (Dnaja1). Silencing Dnajb1 by using small interfering RNAs (siRNAs), but not against Hsp90b, recapitulates the effects of luteolin in adipocyte and osteoblast differentiation. Consistently, the forced expression of Dnajb1 decreases the lipid accumulation and stimulates alkaline phosphatase (ALPL) activity. The antiadipogenic and proosteogenic effects of luteolin are significantly blunted in Dnajb1=deficient cells, further suggesting that Dnajb1 is, at least in part, required for luteolin's dual actions in adipogenesis and osteogenesis. Together, our data implicate luteolin as an ingredient and Dnajb1 as a molecular target for the development of functional foods and drugs in metabolic and bone related diseases. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Kwon, So Mi; Kim, Suji; Song, No Joon; Chang, Seo Hyuk; Park, Kye Won] Sungkyunkwan Univ, Dept Food Sci & Biotechnol, Suwon 16419, South Korea.
   [Hwang, Yu Jin] RDA, Natl Acad Agr Sci, Dept Agrofood Resources, Wanju Gun 55365, Jeollabuk Do, South Korea.
   [Yang, Dong Kwon; Park, Woo Jin] Gwangju Inst Sci & Technol, Coll Life Sci, Gwangju 61005, South Korea.
   [Hong, Joung Woo] Kyung Hee Univ, Grad Sch East West Med Sci, Yongin 17104, South Korea.
C3 Sungkyunkwan University (SKKU); Rural Development Administration (RDA),
   Republic of Korea; Gwangju Institute of Science & Technology (GIST);
   Kyung Hee University
RP Park, KW (通讯作者)，Sungkyunkwan Univ, Dept Food Sci & Biotechnol, Suwon 440746, South Korea.
EM kwpark@skku.edu
RI Kim, Yoo min/AAZ 6413 2020; Hong, Joung Woo/AAG 1173 2021
OI Hong, Joung Woo/0000 0001 6511 7881; Park, Kye Won/0000 0003 2771 249X
FU Basic Science Research Program through National Research Foundation of
   Korea (NRF)   Ministry of Education, Science and Technology
   [NRF 2011 0014302, NRF 2013R1A1A2060447]
FX This study was supported by the Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Education, Science and Technology (NRF 2011 0014302,
   NRF 2013R1A1A2060447).
CR BERESFORD JN, 1989, CLIN ORTHOP RELAT R, P270
   BERESFORD JN, 1992, J CELL SCI, V102, P341
   Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19 3 180
   Botolin S, 2007, ENDOCRINOLOGY, V148, P198, DOI 10.1210/en.2006 1006
   Chen D, 2014, BIOCHEM BIOPH RES CO, V443, P326, DOI 10.1016/j.bbrc.2013.11.122
   Chen JR, 2014, J BONE MINER RES, V29, P1043, DOI 10.1002/jbmr.2034
   Chen XW, 2014, J BONE MINER RES, V29, P1041, DOI 10.1002/jbmr.2234
   Choi EM, 2007, CELL BIOL INT, V31, P870, DOI 10.1016/j.cellbi.2007.01.038
   Choi SS, 2014, BMB REP, V47, P599, DOI 10.5483/BMBRep.2014.47.11.174
   Desarzens S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094127
   Fatokun AA, 2015, NAT PROD RES, V29, P1127, DOI 10.1080/14786419.2014.980252
   Fu J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049194
   Habich C, 2015, HORM MOL BIOL CLIN I, V21, P117, DOI 10.1515/hmbci 2014 0040
   Halade GV, 2010, J NUTR BIOCHEM, V21, P1162, DOI 10.1016/j.jnutbio.2009.10.002
   Hansen RK, 1997, BIOCHEM BIOPH RES CO, V239, P851, DOI 10.1006/bbrc.1997.7572
   Hong JW, 2010, EXP MOL MED, V42, P12, DOI 10.3858/emm.2010.42.1.007
   Jang WS, 2015, FOOD FUNCT, V6, P265, DOI 10.1039/c4fo00836g
   Jia ZQ, 2015, J NUTR BIOCHEM, V26, P293, DOI 10.1016/j.jnutbio.2014.11.008
   Jung SR, 2013, NUTR RES, V33, P162, DOI 10.1016/j.nutres.2012.11.006
   Kang H, 2015, BMB REP, V48, P319, DOI 10.5483/BMBRep.2015.48.6.206
   Kim JA, 2015, CARCINOGENESIS, V36, P696, DOI 10.1093/carcin/bgv045
   Kim MJ, 2014, J MED FOOD, V17, P772, DOI 10.1089/jmf.2013.3056
   López Lázaro M, 2009, MINI REV MED CHEM, V9, P31, DOI 10.2174/138955709787001712
   Nash LA, 2015, MOL NUTR FOOD RES, V59, P443, DOI 10.1002/mnfr.201400592
   Nelson Dooley C, 2005, CURR MED CHEM, V12, P2215, DOI 10.2174/0929867054864886
   Ohtsuka K, 2000, INT J HYPERTHER, V16, P231, DOI 10.1080/026567300285259
   Pandurangan AK, 2014, ASIAN PAC J CANCER P, V15, P5501, DOI 10.7314/APJCP.2014.15.14.5501
   Park HS, 2009, BIOFACTORS, V35, P373, DOI 10.1002/biof.38
   Park KW, 2008, MOL ENDOCRINOL, V22, P2038, DOI 10.1210/me.2007 0454
   Park KW, 2009, MOL CELL BIOL, V29, P3905, DOI 10.1128/MCB.00002 09
   Park KW, 2008, CELL METAB, V8, P454, DOI 10.1016/j.cmet.2008.11.001
   Patil S, 2014, CELLS TISSUES ORGANS, V199, P81, DOI 10.1159/000362226
   Peng SL, 2013, BONE, V55, P230, DOI 10.1016/j.bone.2013.02.012
   Rosen CJ, 2006, NAT CLIN PRACT RHEUM, V2, P35, DOI 10.1038/ncprheum0070
   Seelinger G, 2008, PLANTA MED, V74, P1667, DOI 10.1055/s 0028 1088314
   Sharma AK, 2011, BRIT J NUTR, V106, P1713, DOI 10.1017/S000711451100225X
   Shen CL, 2013, AM J CLIN NUTR, V98, p1694S, DOI 10.3945/ajcn.113.058255
   Song NJ, 2013, J LIPID RES, V54, P1385, DOI 10.1194/jlr.M035576
   Tontonoz P, 2008, ANNU REV BIOCHEM, V77, P289, DOI 10.1146/annurev.biochem.77.061307.091829
   Tuorkey M.J., 2015, EUR J CANC PREV
   Wang S, 2014, J NUTR BIOCHEM, V25, P1, DOI 10.1016/j.jnutbio.2013.09.001
   Weaver Connie M., 2012, Journal of Nutrition in Gerontology and Geriatrics, V31, P239, DOI 10.1080/21551197.2012.698220
   Xiao Na, 2014, Planta Med, V80, P993, DOI 10.1055/s 0034 1382864
   Yamaguchi M, 2013, CELL TISSUE RES, V354, P743, DOI 10.1007/s00441 013 1707 6
   Yoon HY, 2011, EUR J PHARMACOL, V664, P54, DOI 10.1016/j.ejphar.2011.04.047
NR 45
TC 21
Z9 22
U1 2
U2 30
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0955 2863
EI 1873 4847
J9 J NUTR BIOCHEM
JI J. Nutr. Biochem.
PD APR
PY 2016
VL 30
BP 24
EP 32
DI 10.1016/j.jnutbio.2015.11.013
PG 9
WC Biochemistry & Molecular Biology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Nutrition & Dietetics
GA DJ6TY
UT WOS:000374347300003
PM 27012618
DA 2025 08 17
ER

PT J
AU Wei, LH
   Chen, WW
   Huang, LK
   Wang, H
   Su, YG
   Liang, JM
   Lian, HY
   Xu, JK
   Zhao, JM
   Liu, Q
AF Wei, Linhua
   Chen, Weiwei
   Huang, Linke
   Wang, Hui
   Su, Yuangang
   Liang, Jiamin
   Lian, Haoyu
   Xu, Jiake
   Zhao, Jinmin
   Liu, Qian
TI Alpinetin ameliorates bone loss in LPS induced inflammation osteolysis
   via ROS mediated P38/PI3K signaling pathway
SO PHARMACOLOGICAL RESEARCH
LA English
DT Article
DE Alpinetin; Inflammation; ROS; Osteolysis
ID RAW 264.7 CELLS; OSTEOCLAST DIFFERENTIATION
AB Background and objective: Bone loss occurs in several inflammatory diseases because of chronic persistent inflammation that activates osteoclasts (OCs) to increase bone resorption. Currently available antiresorptive drugs have severe side effects or contraindications. Herein, we explored the effects and mechanism of Alpinetin (Alp) on receptor activator of nuclear factor kappa B ligand (RANKL) mediated OCs differentiation, function, and in inflammatory osteolysis of mice.
   Method: Primary mouse bone marrow derived macrophages (BMMs) induced by RANKL and macrophage colony stimulating factor (M CSF) were utilized to test the impact of Alp on OCs differentiation, function, and intracellular reactive oxygen species (ROS) production, respectively. Expression of oxidant stress relevant factors and OCs specific genes were assessed via real time quantitative PCR. Further, oxidative stress related factors, NF kappa B, MAPK, PI3K/AKT/GSK3 beta, and NFATc1 pathways were examined via Western blot. Finally, LPS induced mouse calvarial osteolysis was used to investigate the effect of Alp on inflammatory osteolysis in vivo.
   Result: Alp suppressed OCs differentiation and resorption function, and down regulated the ROS production. Alp inhibited IL 1 beta, TNF alpha and osteoclast specific gene transcription. It also blocked the gene and protein expression of Nox1 and Keap1, but enhanced Nrf2, CAT, and HO 1 protein levels. Additionally, Alp suppressed the phosphorylation of PI3K and P38, and restrained the expression of osteoclast specific gene Nfatc1 and its auto amplification, hence minimizing LPS induced osteolysis in mice.
   Conclusion: Alp is a novel candidate or therapeutics for the osteoclast associated inflammatory osteolytic ailment.
C1 [Wei, Linhua; Chen, Weiwei; Huang, Linke; Wang, Hui; Su, Yuangang; Liang, Jiamin; Lian, Haoyu; Zhao, Jinmin; Liu, Qian] Guangxi Med Univ, Affiliated Hosp 1, Guangxi Key Lab Regenerat Med, Orthopaed Dept, Nanning 530021, Guangxi, Peoples R China.
   [Wei, Linhua] Guangxi Med Univ, Peoples Hosp Nanning 4, Affiliated Infect Dis Hosp, Dept Orthopaed, Nanning, Guangxi, Peoples R China.
   [Chen, Weiwei; Su, Yuangang; Liang, Jiamin; Lian, Haoyu; Zhao, Jinmin] Guangxi Med Univ, Collaborat Innovat Ctr Regenerat Med & Med BioRes, Nanning 530021, Guangxi, Peoples R China.
   [Huang, Linke] Guangxi Med Univ, Affiliated Hosp 2, Dept Orthopaed, Nanning 530007, Guangxi, Peoples R China.
   [Xu, Jiake] Univ Western Australia, Sch Biomed Sci, Perth, WA 6009, Australia.
C3 Guangxi Medical University; Guangxi Medical University; Guangxi Medical
   University; Guangxi Medical University; University of Western Australia
RP Zhao, JM; Liu, Q (通讯作者)，Guangxi Med Univ, Affiliated Hosp 1, Guangxi Key Lab Regenerat Med, Orthopaed Dept, Nanning 530021, Guangxi, Peoples R China.
EM zhaojinmin@126.com; liuqian@gxmu.edu.cn
RI zhao, jin/LBH 0351 2024; Su, Yuangang/KKU 6952 2024; Lian,
   Haoyu/W 3317 2017
OI Xu, Jiake/0000 0003 2021 8309; 
FU National Natural Science Foun dation of China [81960405]; Guangxi
   Science and Technology Base and Talent Special Project
   [GuikeAD19254003]; Guangxi Natural Science Foundation [2022GXNSFBA35492]
FX Acknowledgments This research was supported by the National Natural
   Science Foun dation of China (Grant No. 81960405) , Guangxi Science and
   Technology Base and Talent Special Project (Grant No. GuikeAD19254003) ,
   and Guangxi Natural Science Foundation (Grant No. 2022GXNSFBA35492) .
CR Barcena ML, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.758767
   Bellavia D, 2021, TRENDS ENDOCRIN MET, V32, P76, DOI 10.1016/j.tem.2020.11.007
   Bhatt AP, 2010, BLOOD, V115, P4455, DOI 10.1182/blood 2009 10 251082
   Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   Cauley JA, 2016, J BONE MINER RES, V31, P2129, DOI 10.1002/jbmr.2905
   Chen K, 2019, THERANOSTICS, V9, P1634, DOI 10.7150/thno.30206
   Cho E, 2019, MOLECULES, V24, DOI 10.3390/molecules24183346
   Domazetovic V, 2017, CLIN CASES MINER BON, V14, P209, DOI 10.11138/ccmbm/2017.14.1.209
   Gan XQ, 2018, J PHYSIOL BIOCHEM, V74, P395, DOI 10.1007/s13105 018 0627 z
   Gao Y, 2020, INFLAMMATION, V43, P1742, DOI 10.1007/s10753 020 01248 3
   Huo MX, 2012, INT IMMUNOPHARMACOL, V12, P241, DOI 10.1016/j.intimp.2011.11.017
   Jing XZ, 2019, J CELL PHYSIOL, V234, P10123, DOI 10.1002/jcp.27678
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kohara Y, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082745
   Kwak SC, 2020, NUTRIENTS, V12, DOI 10.3390/nu12103164
   Kwon M, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17081292
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Lee MY, 2012, INFLAMMATION, V35, P746, DOI 10.1007/s10753 011 9370 0
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Lee SH, 2014, INT J MOL SCI, V15, P10605, DOI 10.3390/ijms150610605
   Liu L, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/6661534
   Lu JW, 2020, J CELL MOL MED, V24, P10444, DOI 10.1111/jcmm.15657
   Luo J, 2016, NAT MED, V22, P539, DOI 10.1038/nm.4076
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Nakano S, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 40974 z
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   Park Min KH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6418
   Place DE, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 020 20807 8
   Ramesh P, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.779638
   Rucci N, 2019, METHODS MOL BIOL, V1914, P3, DOI 10.1007/978 1 4939 8997 3_1
   Shapouri Moghaddam A, 2018, J CELL PHYSIOL, V233, P6425, DOI 10.1002/jcp.26429
   Tabatabaei Malazy O, 2017, DARU, V25, DOI 10.1186/s40199 017 0167 z
   Tao HQ, 2020, ACTA BIOCH BIOPH SIN, V52, P1055, DOI 10.1093/abbs/gmaa098
   Udagawa N, 2021, J BONE MINER METAB, V39, P19, DOI 10.1007/s00774 020 01162 6
   Wang W, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00696
   Wu D, 2020, INT IMMUNOPHARMACOL, V89, DOI 10.1016/j.intimp.2020.107073
   Wu YX, 2016, BIOMED PHARMACOTHER, V82, P399, DOI 10.1016/j.biopha.2016.05.008
   Xiao DL, 2020, J CELL BIOCHEM, V121, P4542, DOI 10.1002/jcb.29677
   Yang WL, 2018, J CELL PHYSIOL, V233, P4606, DOI 10.1002/jcp.26372
   Yang W, 2020, CANCERS, V12, DOI 10.3390/cancers12051329
   Yao Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.664871
   Yu Dongdong, 2019, Nan Fang Yi Ke Da Xue Xue Bao, V39, P672, DOI 10.12122/j.issn.1673 4254.2019.06.07
   Yu J, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115474
   Zhang JX, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/4350965
   Zhang ND, 2016, J ETHNOPHARMACOL, V189, P61, DOI 10.1016/j.jep.2016.05.025
   Zhang T, 2020, J CELL MOL MED, V24, P8430, DOI 10.1111/jcmm.15371
   Zhou Z, 2008, J BONE MINER RES, V23, P1084, DOI 10.1359/JBMR.080234
NR 47
TC 61
Z9 64
U1 2
U2 33
PU ACADEMIC PRESS LTD  ELSEVIER SCIENCE LTD
PI LONDON
PA 24 28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043 6618
EI 1096 1186
J9 PHARMACOL RES
JI Pharmacol. Res.
PD OCT
PY 2022
VL 184
AR 106400
DI 10.1016/j.phrs.2022.106400
EA AUG 2022
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 4U8IX
UT WOS:000859032200002
PM 35988868
DA 2025 08 17
ER

PT J
AU Li, JH
   Li, YM
   Peng, XC
   Li, B
   Yuan, XW
   Chen, YS
AF Li, Juehong
   Li, Yamin
   Peng, Xiaochun
   Li, Bin
   Yuan, Xiangwei
   Chen, Yunsu
TI Emodin attenuates titanium particle induced osteolysis and
   RANKL mediated osteoclastogenesis through the suppression of IKK
   phosphorylation
SO MOLECULAR IMMUNOLOGY
LA English
DT Article
DE Peri implant osteolysis; Titanium particles; Emodin; Osteoclastogenesis;
   NF kappa B pathway
ID NF KAPPA B; WEAR DEBRIS; INFLAMMATORY RESPONSES; RECEPTOR ACTIVATOR;
   KNEE ARTHROPLASTY; HIP ARTHROPLASTY; GENE EXPRESSION; BONE RESORPTION;
   IN VITRO; DIFFERENTIATION
AB Aseptic loosening due to wear particles is a serious challenge for orthopedic surgeons, sabotaging the long term success of total joint arthroplasty. The existing treatments for aseptic loosening are still far from satisfactory, necessitating more aggressive drug exploration. Here, we examined the effect of emodin on titanium particle induced osteolysis and further investigated its underlying mechanism in vivo and in vitro. Thirty two C57BL/6 mice were randomly assigned into four groups: the Sham group (sham operation with vehicle injection), Vehicle group (titanium particle treatment with vehicle injections), Low group (titanium particle treatment with injections of 10 mg/kg/day emodin) and High group (titanium particle treatment with injections of 50 mg/kg/day emodin). Micro CT scanning and histological analysis revealed that after emodin injections, the inflammatory response and bone destruction were markedly ameliorated. TRAP staining showed that osteoclast numbers were also dramatically reduced. Throughout the in vitro culture period, emodin significantly decreased the bone resorption area, number of osteoclasts and formation of F actin rings. Mechanistic studies suggested that reduced NF kappa B signaling might be mediating the inhibitory effects of emodin. Collectively, our findings suggest that emodin, a natural product extracted from Rheum palmatum, may be developed as a promising candidate for the treatment of wear particle induced osteolysis and subsequent aseptic loosening.
C1 [Li, Juehong; Li, Yamin; Peng, Xiaochun; Li, Bin; Yuan, Xiangwei; Chen, Yunsu] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Orthopaed Surg, Orthopaed Dept, 7th Floor,6 Bldg,600 Yuhan Rd, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University
RP Chen, YS (通讯作者)，Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Orthopaed Surg, Orthopaed Dept, 7th Floor,6 Bldg,600 Yuhan Rd, Shanghai, Peoples R China.
EM yschen2016@hotmail.com
RI peng, xiaochun/HJI 4832 2023
CR Abu Amer Y, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2170
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   BOWLER WA, 1992, AM J MED, V92, P249, DOI 10.1016/0002 9343(92)90072 J
   Bozic KJ, 2009, J BONE JOINT SURG AM, V91A, P128, DOI 10.2106/JBJS.H.00155
   Chen X, 2017, ENVIRON TOXICOL PHAR, V54, P162, DOI 10.1016/j.etap.2017.07.007
   Ding Y, 2008, EUR J PHARMACOL, V590, P377, DOI 10.1016/j.ejphar.2008.06.044
   Fritz EA, 2005, J ORTHOP RES, V23, P1249, DOI 10.1016/j.orthres.2005.03.013
   Gannon SC, 2013, J CELL PHYSIOL, V228, P1098, DOI 10.1002/jcp.24259
   Goodman SB, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2013.0962
   Hirakawa K, 1996, J BIOMED MATER RES, V31, P257, DOI 10.1002/(SICI)1097 4636(199606)31:2<257::AID JBM13>3.0.CO;2 I
   Holding CA, 2006, BIOMATERIALS, V27, P5212, DOI 10.1016/j.biomaterials.2006.05.054
   Hu XY, 2017, ACTA BIOMATER, V48, P479, DOI 10.1016/j.actbio.2016.11.022
   Hulley PA, 2017, J PATHOL, V242, P322, DOI 10.1002/path.4906
   Hwang JK, 2013, RHEUMATOLOGY, V52, P1583, DOI 10.1093/rheumatology/ket178
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Jiang C, 2015, BIOCHIMIE, V111, P107, DOI 10.1016/j.biochi.2015.02.002
   Jing YW, 2006, FREE RADICAL BIO MED, V40, P2183, DOI 10.1016/j.freeradbiomed.2006.02.016
   Kauther MD, 2013, BIOMATERIALS, V34, P2911, DOI 10.1016/j.biomaterials.2013.01.034
   Kim JY, 2014, J BONE MINER RES, V29, P1541, DOI 10.1002/jbmr.2183
   Kurtz SM, 2009, CLIN ORTHOP RELAT R, V467, P2606, DOI 10.1007/s11999 009 0834 6
   Lee SU, 2008, INT IMMUNOPHARMACOL, V8, P741, DOI 10.1016/j.intimp.2008.01.027
   Li YM, 2017, MOL IMMUNOL, V85, P27, DOI 10.1016/j.molimm.2017.02.003
   Lin TH, 2014, ACTA BIOMATER, V10, P3747, DOI 10.1016/j.actbio.2014.04.034
   Liu XQ, 2014, BIOMATERIALS, V35, P5721, DOI 10.1016/j.biomaterials.2014.04.006
   Lu SY, 2014, EXP CELL RES, V328, P32, DOI 10.1016/j.yexcr.2014.08.018
   Mandal CC, 2009, ENDOCRINOLOGY, V150, P4989, DOI 10.1210/en.2009 0026
   Mbalaviele G, 2017, J CLIN INVEST, V127, P2030, DOI 10.1172/JCI93356
   Meng GQ, 2010, BRIT J PHARMACOL, V161, P1628, DOI 10.1111/j.1476 5381.2010.00993.x
   O'Halloran M, 2014, AUST DENT J, V59, P516, DOI 10.1111/adj.12217
   Ong KL, 2006, CLIN ORTHOP RELAT R, P22, DOI 10.1097/01.blo.0000214439.95268.59
   Otero JE, 2010, J BONE MINER RES, V25, P1282, DOI 10.1002/jbmr.4
   Patel A, 2015, BONE JOINT J, V97B, P1076, DOI 10.1302/0301 620X.97B8.35170
   Ping ZC, 2017, ACTA BIOMATER, V62, P362, DOI 10.1016/j.actbio.2017.08.046
   Pioletti DP, 2004, BIOMATERIALS, V25, P5803, DOI 10.1016/j.biomaterials.2004.01.053
   Ren WP, 2003, BIOMATERIALS, V24, P4819, DOI 10.1016/S0142 9612(03)00384 3
   Sawyer A, 2003, BIOTECH HISTOCHEM, V78, P271, DOI 10.1080/10520290310001646668
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Tas SW, 2009, CURR GENE THER, V9, P160, DOI 10.2174/156652309788488569
   Vives V, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7218
   von Knoch M, 2004, J ORTHOP RES, V22, P237, DOI 10.1016/j.orthres.2003.08.013
   Wu CL, 2015, BIOCHEM PHARMACOL, V93, P59, DOI 10.1016/j.bcp.2014.10.019
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yang F, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472 6882 14 74
   Yasui T, 2011, ANN NY ACAD SCI, V1240, P7, DOI 10.1111/j.1749 6632.2011.06245.x
NR 44
TC 22
Z9 22
U1 1
U2 28
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0161 5890
J9 MOL IMMUNOL
JI Mol. Immunol.
PD APR
PY 2018
VL 96
BP 8
EP 18
DI 10.1016/j.molimm.2018.02.008
PG 11
WC Biochemistry & Molecular Biology; Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Immunology
GA GD6VX
UT WOS:000430647700002
PM 29455094
DA 2025 08 17
ER

PT J
AU Hattersley, G
   Dean, T
   Corbin, BA
   Bahar, H
   Gardella, TJ
AF Hattersley, Gary
   Dean, Thomas
   Corbin, Braden A.
   Bahar, Hila
   Gardella, Thomas J.
TI Binding Selectivity of Abaloparatide for PTH Type 1 Receptor
   Conformations and Effects on Downstream Signaling
SO ENDOCRINOLOGY
LA English
DT Article
ID PARATHYROID HORMONE PTH; (PTH)/PTH RELATED PROTEIN RECEPTOR; ERK1/2
   ACTIVATION; LIGAND BINDING; BIASED AGONISM; OSTEOPOROSIS; MECHANISMS;
   PATHWAYS; STATES; CAMP
AB The PTH receptor type 1 (PTHR1) mediates the actions of two endogenous polypeptide ligands, PTH and PTHrP, and thereby plays key roles in bone biology. Based on its capacity to stimulate bone formation, the peptide fragment PTH (1 34) is currently in use as therapy for osteoporosis. Abaloparatide (ABL) is a novel synthetic analog of human PTHrP (1 34) that holds promise as a new osteoporosis therapy, as studies in animals suggest that it can stimulate bone formation with less of the accompanying bone resorption and hypercalcemic effects that can occur with PTH (1 34). Recent studies in vitro suggest that certain PTH or PTHrP ligand analogs can distinguish between two high affinity PTHR1 conformations, R 0 and RG, and that efficient binding to R 0 results in prolonged signaling responses in cells and prolonged calcemic responses in animals, whereas selective binding to RG results in more transient responses. As intermittent PTH ligand action is known to favor the bone formation response, whereas continuous ligand action favors the net bone resorption/calcemic response, we hypothesized that ABL binds more selectively to the RG vs the R 0 PTHR1 conformation than does PTH (1 34), and thus induces more transient signaling responses in cells. We show that ABL indeed binds with greater selectivity to the RG conformation than does PTH (1 34), and as a result of this RG bias, ABL mediates more transient cAMP responses in PTHR1 expressing cells. The findings provide a plausible mechanism (ie, transient signaling via RG selective binding) that can help account for the favorable anabolic effects that ABL has on bone.
C1 [Hattersley, Gary; Bahar, Hila] Radius Hlth Inc, Waltham, MA 02451 USA.
   [Dean, Thomas; Corbin, Braden A.; Gardella, Thomas J.] Massachusetts Gen Hosp, Endocrine Unit, Thier 10,50 Blossom St, Boston, MA 02114 USA.
   Harvard Univ, Sch Med, Boston, MA 02114 USA.
C3 Radius Health, Inc.; Harvard University; Harvard University Medical
   Affiliates; Massachusetts General Hospital; Harvard University; Harvard
   Medical School
RP Gardella, TJ (通讯作者)，Massachusetts Gen Hosp, Endocrine Unit, Thier 10,50 Blossom St, Boston, MA 02114 USA.
EM gardella@helix.mgh.harvard.edu
FU National Institutes of Health [DK 11794, AR066261]
FX This work was supported by the National Institutes of Health Grants
   DK 11794 (PO1) and AR066261 (P30).
CR Baron R, 2012, J CLIN ENDOCR METAB, V97, P311, DOI 10.1210/jc.2011 2332
   Binkowski BF, 2011, ACS CHEM BIOL, V6, P1193, DOI 10.1021/cb200248h
   Culler M, 2001, J BONE MINER RES  S1, V16, pM460
   Cupp ME, 2013, J PHARMACOL EXP THER, V345, P404, DOI 10.1124/jpet.112.199752
   Dean T, 2006, MOL ENDOCRINOL, V20, P931, DOI 10.1210/me.2005 0349
   Dean T, 2008, MOL ENDOCRINOL, V22, P156, DOI 10.1210/me.2007 0274
   Dong J., 2001, PEPTIDES WAVE FUTURE, P668
   Doyle N, 2013, J BONE MINER RES, V28
   Feinstein TN, 2011, NAT CHEM BIOL, V7, P278, DOI 10.1038/nchembio.545
   Ferrandon S, 2009, NAT CHEM BIOL, V5, P734, DOI 10.1038/nchembio.206
   Gesty Palmer D, 2006, J BIOL CHEM, V281, P10856, DOI 10.1074/jbc.M513380200
   Gesty Palmer D, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000071
   Gidon A, 2014, NAT CHEM BIOL, V10, P707, DOI [10.1038/nchembio.1589, 10.1038/NCHEMBIO.1589]
   Hoare SRJ, 2003, PEPTIDES, V24, P1881, DOI 10.1016/j.peptides.2003.09.002
   Hoare SRJ, 1999, J PHARMACOL EXP THER, V289, P1323
   Hothersall JD, 2016, DRUG DISCOV TODAY, V21, P90, DOI 10.1016/j.drudis.2015.07.015
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Leder BZ, 2015, J CLIN ENDOCR METAB, V100, P697, DOI 10.1210/jc.2014 3718
   Luttrell LM, 2014, MOL ENDOCRINOL
   Maeda A, 2013, P NATL ACAD SCI USA, V110, P5864, DOI 10.1073/pnas.1301674110
   Okazaki M, 2008, J BONE MINER RES, V23
   Pioszak AA, 2009, J BIOL CHEM, V284, P28382, DOI 10.1074/jbc.M109.022905
   Reiter E, 2012, ANNU REV PHARMACOL, V52, P179, DOI 10.1146/annurev.pharmtox.010909.105800
   Rey A, 2006, J BIOL CHEM, V281, P38181, DOI 10.1074/jbc.M606762200
   Vilardaga JP, 2012, TRENDS PHARMACOL SCI, V33, P423, DOI 10.1016/j.tips.2012.05.004
   Vilardaga JP, 2011, CELL MOL LIFE SCI, V68, P1, DOI 10.1007/s00018 010 0465 9
   Wisler JW, 2014, CURR OPIN CELL BIOL, V27, P18, DOI 10.1016/j.ceb.2013.10.008
   Xiong JH, 2012, J BONE MINER RES, V27, P499, DOI 10.1002/jbmr.1547
NR 28
TC 226
Z9 247
U1 0
U2 26
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0013 7227
EI 1945 7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD JAN
PY 2016
VL 157
IS 1
BP 141
EP 149
DI 10.1210/en.2015 1726
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA DD5KM
UT WOS:000369962600020
PM 26562265
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Zeng, Y
   Baugh, E
   Akyalcin, S
   Letra, A
AF Zeng, Y.
   Baugh, E.
   Akyalcin, S.
   Letra, A.
TI Functional Effects of WNT10A Rare Variants Associated with Tooth
   Agenesis
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE gene function; hypodontia; oligodontia; wnt; tooth development; tooth
   agenesis
ID DENTAL AGENESIS; STEM CELLS; MUTATIONS; MICE; PAX9; DIFFERENTIATION;
   ROLES; TEETH; RUNX2; BONE
AB Mutations in WNT10A have frequently been reported as etiologic for tooth agenesis (TA). However, the effects of WNT10A variation on gene/protein function and contribution to TA phenotypes remain poorly understood. Here, we performed bioinformatic and functional characterization analysis of WNT10A variants. In silico prediction of variant function was performed with VIPUR for all WNT10A missense variants reported in the Exome Aggregation Consortium database. Functional characterization experiments were then performed for selected WNT10A variants previously associated with TA. Expression vectors for wild type and mutant WNT10A were made and transfected into stem cells from human exfoliated deciduous teeth (SHED) for evaluation of gene/protein function, WNT signaling activity, and effects on expression of relevant genes. While 75% of WNT10A variants were predicted neutral, most of the TA associated variants received deleterious scores by potentially destabilizing or preventing the disulfide bond formation required for proper protein function. WNT signaling was significantly decreased with 8 of 13 variants tested, whereas wild type like activity was retained with 4 of 13 variants. WNT10A mutant cells (T357I, R360C, and R379C mutants) showed reduced or impaired binding affinity to FZD5, suggesting a potential mechanism for the decreased WNT signaling. Mutant cells also had decreased WNT10A protein expression in comparison to wild type cells. mRNA expression of PAX9, MSX1, AXIN2, and RUNX2 (known tooth development genes) was perturbed in mutant cells and quite significantly for PAX9 and RUNX2. Transcriptome analysis of wild type and T357I mutant cells identified 36 differentially expressed genes (26 downregulated, 10 upregulated) involved in skeletal system development and morphogenesis and pattern specification. WNT10A variants deemed pathogenic for TA likely affect protein folding and/or stabilization, leading to decreased WNT signaling and concomitant dysregulated expression of relevant genes. These findings may allow for improved interpretation of TA phenotypes upon clinical diagnosis while providing important insights toward the development of future tooth replacement therapies.
C1 [Zeng, Y.; Letra, A.] Univ Texas Hlth Sci Ctr Houston, Sch Dent, Ctr Craniofacial Res, Houston, TX 77030 USA.
   [Zeng, Y.; Letra, A.] Univ Texas Hlth Sci Ctr Houston, Sch Dent, Dept Diagnost & Biomed Sci, Houston, TX 77030 USA.
   [Baugh, E.] NYU, Dept Biol, New York, NY 10003 USA.
   [Akyalcin, S.] Tufts Univ, Sch Dent Med, Dept Orthodont, Houston, TX USA.
   [Letra, A.] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Pediat Res Ctr, Houston, TX 77030 USA.
C3 University of Texas System; University of Texas Health Science Center
   Houston; University of Texas System; University of Texas Health Science
   Center Houston; New York University; University of Texas System;
   University of Texas Health Science Center Houston
RP Letra, A (通讯作者)，Univ Texas Hlth Sci Ctr Houston, Sch Dent, Ctr Craniofacial Res, Dept Diagnost & Biomed Sci, 1941 East Rd,BBSB Room 4210, Houston, TX 77054 USA.
EM ariadne.m.letra@uth.tmc.edu
RI Letra, Ariadne/Q 7007 2019; Akyalcin, Sercan/LFU 0715 2024
OI Letra, Ariadne/0000 0002 7197 6735
CR Agostino M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174168
   Arzoo PS, 2014, AM J MED GENET A, V164, P353, DOI 10.1002/ajmg.a.36243
   Baugh EH, 2016, NUCLEIC ACIDS RES, V44, P2501, DOI 10.1093/nar/gkw120
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Bermudez O, 2010, AM J PHYSIOL CELL PH, V299, pC189, DOI 10.1152/ajpcell.00347.2009
   Christians JK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056260
   D'Souza RN, 1999, DEVELOPMENT, V126, P2911
   Dinckan N, 2018, J DENT RES, V97, P49, DOI 10.1177/0022034517724149
   Du RQ, 2018, HUM GENET, V137, P689, DOI 10.1007/s00439 018 1907 y
   Fournier BP, 2018, J DENT RES, V97, P1306, DOI 10.1177/0022034518777460
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   GORLIN RJ, 1990, SYNDROMES HEAD NECK
   Grejtakova D, 2018, J GENET, V97, P1169, DOI 10.1007/s12041 018 1011 z
   Hu XL, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1278 x
   James MJ, 2006, J BONE MINER RES, V21, P1034, DOI 10.1359/JBMR.060413
   Jia SH, 2017, DEVELOPMENT, V144, P3819, DOI 10.1242/dev.157750
   Kim TK, 2010, ANAL BIOANAL CHEM, V397, P3173, DOI 10.1007/s00216 010 3821 6
   Letra A, 2014, J DENT RES, V93, P651, DOI 10.1177/0022034514534444
   Liu F, 2010, J DENT RES, V89, P318, DOI 10.1177/0022034510363373
   Magruder S, 2018, ORTHOD CRANIOFAC RES, V21, P258, DOI 10.1111/ocr.12248
   Miura M, 2003, P NATL ACAD SCI USA, V100, P5807, DOI 10.1073/pnas.0937635100
   Mostowska A, 2003, EUR J ORAL SCI, V111, P365, DOI 10.1034/j.1600 0722.2003.00069.x
   Nakatomi M, 2010, DEV BIOL, V340, P438, DOI 10.1016/j.ydbio.2010.01.031
   Numakura C, 2010, AM J MED GENET A, V152A, P2355, DOI 10.1002/ajmg.a.33556
   Peters H, 1998, GENE DEV, V12, P2735, DOI 10.1101/gad.12.17.2735
   Polder BJ, 2004, COMMUNITY DENT ORAL, V32, P217, DOI 10.1111/j.1600 0528.2004.00158.x
   Posey JE, 2017, NEW ENGL J MED, V376, P21, DOI 10.1056/NEJMoa1516767
   Sakai VT, 2010, J DENT RES, V89, P791, DOI 10.1177/0022034510368647
   Song SJ, 2014, HUM GENET, V133, P117, DOI 10.1007/s00439 013 1360 x
   Thesleff I, 1996, ANAT REC, V245, P151
   van den Boogaard MJ, 2012, J MED GENET, V49, P327, DOI 10.1136/jmedgenet 2012 100750
   Voloshanenko O, 2017, FASEB J, V31, P4832, DOI 10.1096/fj.201700144R
   Williams MA, 2018, GENES BASEL, V9, DOI 10.3390/genes9050255
   Williams MA, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 21368 z
   Xu MG, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15397
   Xue JF, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7156
   Yamashiro T, 2007, DIFFERENTIATION, V75, P452, DOI 10.1111/j.1432 0436.2006.00150.x
   Yang J, 2015, MOL GENET GENOM MED, V3, P40, DOI 10.1002/mgg3.111
   Yin W, 2015, J DENT RES, V94, P878, DOI 10.1177/0022034515583999
   Yuan QP, 2017, MOL GENET GENOM MED, V5, P730, DOI 10.1002/mgg3.332
   Zhang ZC, 2016, STEM CELLS, V34, P1576, DOI 10.1002/stem.2334
NR 41
TC 21
Z9 25
U1 0
U2 17
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022 0345
EI 1544 0591
J9 J DENT RES
JI J. Dent. Res.
PD MAR
PY 2021
VL 100
IS 3
BP 302
EP 309
DI 10.1177/0022034520962728
PG 8
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA QK8ZW
UT WOS:000620669200011
PM 33034246
DA 2025 08 17
ER

PT J
AU Alexander, KA
   Chang, MK
   Maylin, ER
   Kohler, T
   Müller, R
   Wu, AC
   Van Rooijen, N
   Sweet, MJ
   Hume, DA
   Raggatt, LJ
   Pettit, AR
AF Alexander, Kylie A.
   Chang, Ming K.
   Maylin, Erin R.
   Kohler, Thomas
   Mueller, Ralph
   Wu, Andy C.
   Van Rooijen, Nico
   Sweet, Matthew J.
   Hume, David A.
   Raggatt, Liza J.
   Pettit, Allison R.
TI Osteal Macrophages Promote In Vivo Intramembranous Bone Healing in a
   Mouse Tibial Injury Model
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE MACROPHAGE; OSTEOBLAST; OSTEOCLAST; OSTEOMAC; BONE FORMATION
ID COLONY STIMULATING FACTOR; MONONUCLEAR PHAGOCYTE SYSTEM; CRUCIAL ROLE;
   REPAIR; PHOSPHATASE; EXPRESSION; RECEPTOR; OSTEOCLASTOGENESIS;
   OSTEOPROTEGERIN; IDENTIFICATION
AB Bone lining tissues contain a population of resident macrophages termed osteomacs that interact with osteoblasts in vivo and control mineralization in vitro. The role of osteomacs in bone repair was investigated using a mouse tibial bone injury model that heals primarily through intramembranous ossification and progresses through all major phases of stabilized fracture repair. Immunohistochemical studies revealed that at least two macrophage populations, F4/80(+)Mac 2( /low)TRACP( ) osteomacs and F4/80(+)Mac 2(hi)TRACP( ) inflammatory macrophages, were present within the bone injury site and persisted throughout the healing time course. In vivo depletion of osteomacs/macrophages (either using the Mafia transgenic mouse model or clodronate liposome delivery) or osteoclasts (recombinant osteoprotegerin treatment) established that osteomacs were required for deposition of collagen type 1(+) (CT1(+)) matrix and bone mineralization in the tibial injury model, as assessed by quantitative immunohistology and micro computed tomography. Conversely, administration of the macrophage growth factor colony stimulating factor 1 (CSF 1) increased the number of osteomacs/macrophages at the injury site significantly with a concurrent increase in new CT1(+) matrix deposition and enhanced mineralization. This study establishes osteomacs as participants in intramembranous bone healing and as targets for primary anabolic bone therapies. (C) 2011 American Society for Bone and Mineral Research.
C1 [Alexander, Kylie A.; Maylin, Erin R.; Raggatt, Liza J.; Pettit, Allison R.] Univ Queensland, UQ Ctr Clin Res, Herston, Qld 4029, Australia.
   [Alexander, Kylie A.; Sweet, Matthew J.; Hume, David A.; Raggatt, Liza J.; Pettit, Allison R.] Univ Queensland, Inst Mol Biosci, St Lucia, Qld, Australia.
   [Chang, Ming K.; Mueller, Ralph] ETH, Inst Biomech, Zurich, Switzerland.
   [Kohler, Thomas] B Cube AG, Schlieren, Switzerland.
   [Wu, Andy C.] Griffith Univ, Sch Med Sci, Southport, Qld 4215, Australia.
   [Van Rooijen, Nico] Vrije Univ Amsterdam, Dept Mol Cell Biol, Amsterdam, Netherlands.
   [Hume, David A.] Univ Edinburgh, Roslin Inst, Roslin, Midlothian, Scotland.
   [Hume, David A.] Univ Edinburgh, Royal Dick Sch Vet Studies, Roslin, Midlothian, Scotland.
   [Sweet, Matthew J.] Univ Queensland, Australian Infect Dis Res Ctr, Brisbane, Qld 4072, Australia.
C3 University of Queensland; University of Queensland; Swiss Federal
   Institutes of Technology Domain; ETH Zurich; Griffith University;
   Griffith University   Gold Coast Campus; Vrije Universiteit Amsterdam;
   University of Edinburgh; UK Research & Innovation (UKRI); Biotechnology
   and Biological Sciences Research Council (BBSRC); Roslin Institute;
   University of Edinburgh; University of Queensland
RP Raggatt, LJ (通讯作者)，Univ Queensland, UQ Ctr Clin Res, Royal Brisbane & Womens Hosp, Bldg 71 918, Herston, Qld 4029, Australia.
EM l.raggat@uq.edu.au; a.pettit@uq.edu.au
RI Sweet, Matthew/F 2229 2011; Müller, Ralph/A 1198 2008; Raggatt,
   Liza Jane/S 4530 2016; Pettit, Allison/O 4462 2019; Muller,
   Ralph/A 1198 2008; Alexander, Kylie/P 2666 2016; Van Rooijen,
   Nico/Z 1578 2019; Hume, David/C 7695 2013
OI Sweet, Matthew/0000 0002 0406 8139; Alexander,
   Kylie/0000 0001 5772 0277; Wu, Andy C/0000 0002 0864 4447; Muller,
   Ralph/0000 0002 5811 7725; Hume, David/0000 0002 2615 1478; Pettit,
   Allison/0000 0003 4707 7892; 
FU NHMRC [455941, 631484, 409914, 519 744]
FX We thank Professor Don Cohen for the Mafia mice, as well as the
   Institute for Molecular Bioscience and Herston Medical Research Center
   animal houses for their technical assistance. This work was supported by
   NHMRC project grants (455941 and 631484) to ARP and LJR, an NHMRC Dora
   Lush Postgraduate Scholarship (409914) to KAA, and a NHMRC CDA award
   (519 744) to ARP.
CR ANDREW JG, 1994, ACTA ORTHOP SCAND, V65, P462, DOI 10.3109/17453679408995493
   Arron JR, 2000, NATURE, V408, P535, DOI 10.1038/35046196
   Blumer MJF, 2008, J ANAT, V213, P431, DOI 10.1111/j.1469 7580.2008.00958.x
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Burnett SH, 2004, J LEUKOCYTE BIOL, V75, P612, DOI 10.1189/jlb.0903442
   Campbell TM, 2003, CALCIFIED TISSUE INT, V73, P49, DOI 10.1007/s00223 002 2120 4
   Champagne CM, 2002, BONE, V30, P26, DOI 10.1016/S8756 3282(01)00638 X
   Chang MK, 2008, J IMMUNOL, V181, P1232, DOI 10.4049/jimmunol.181.2.1232
   Chitu V, 2006, CURR OPIN IMMUNOL, V18, P39, DOI 10.1016/j.coi.2005.11.006
   Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111
   Dempster DW., 2006, Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism
   EINHORN TA, 1995, J BONE MINER RES, V10, P1272
   Frost H. M., 1963, BONE REMODELING DYNA
   Geissmann F, 2010, NAT REV IMMUNOL, V10, P453, DOI 10.1038/nri2784
   Gerstenfeld LC, 2003, J CELL BIOCHEM, V88, P873, DOI 10.1002/jcb.10435
   Gerstenfeld LC, 2009, J BONE MINER RES, V24, P196, DOI 10.1359/JBMR.081113
   Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978
   Gröngröft I, 2009, J BIOMECH, V42, P2089, DOI 10.1016/j.jbiomech.2009.06.004
   Halleen JM, 2000, J BONE MINER RES, V15, P1337, DOI 10.1359/jbmr.2000.15.7.1337
   Hankemeier S, 2001, J ORTHOP RES, V19, P531, DOI 10.1016/S0736 0266(00)00044 9
   Henderson NC, 2009, IMMUNOL REV, V230, P160, DOI 10.1111/j.1600 065X.2009.00794.x
   HUME DA, 1984, J CELL SCI, V66, P189
   Hume DA, 2006, CURR OPIN IMMUNOL, V18, P49, DOI 10.1016/j.coi.2005.11.008
   Ishida K, 2010, TISSUE ENG PT A, V16, P3271, DOI 10.1089/ten.tea.2009.0268
   Jacquin C, 2006, J BONE MINER RES, V21, P67, DOI 10.1359/JBMR.051007
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Layne JE, 1999, MED SCI SPORT EXER, V31, P25, DOI 10.1097/00005768 199901000 00006
   Lean JM, 2000, BONE, V27, P29, DOI 10.1016/S8756 3282(00)00306 9
   Lin HS, 2008, SCIENCE, V320, P807, DOI 10.1126/science.1154370
   LINDSAY R, 1995, AM J MED, V98, pS9, DOI 10.1016/S0002 9343(05)80038 5
   MARKS SC, 1976, J HERED, V67, P11, DOI 10.1093/oxfordjournals.jhered.a108657
   Martin TJ, 2005, TRENDS MOL MED, V11, P76, DOI 10.1016/j.molmed.2004.12.004
   McDonald MM, 2008, BONE, V43, P653, DOI 10.1016/j.bone.2008.05.019
   Middleton ET, 2010, J BONE MINER RES, V25, P455, DOI 10.1359/jbmr.090821
   Mizoguchi T, 2009, J CELL BIOL, V184, P541, DOI 10.1083/jcb.200806139
   Nahrendorf M, 2007, J EXP MED, V204, P3037, DOI 10.1084/jem.20070885
   NIIDA S, 1994, J BONE MINER RES, V9, P873
   Okazaki T, 2005, J IMMUNOL, V174, P7531, DOI 10.4049/jimmunol.174.12.7531
   Pettit AR, 2008, BONE, V43, P976, DOI 10.1016/j.bone.2008.08.128
   RAGGATT L, 2009, J BONE MINER RES S1, V24
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Ritter MR, 2006, J CLIN INVEST, V116, P3266, DOI 10.1172/JCI29683
   Roggin KK, 2000, J SURG RES, V90, P166, DOI 10.1006/jsre.2000.5879
   Ruegsegger P, 1996, CALCIFIED TISSUE INT, V58, P24, DOI 10.1007/s002239900006
   Sarahrudi K, 2009, J ORTHOP RES, V27, P36, DOI 10.1002/jor.20680
   Sasmono RT, 2003, BLOOD, V101, P1155, DOI 10.1182/blood 2002 02 0569
   Seeman E, 2010, NAT MED, V16, P264, DOI 10.1038/nm0310 264
   Selander KS, 1996, MOL PHARMACOL, V50, P1127
   Shioi A, 2002, CIRC RES, V91, P9, DOI 10.1161/01.RES.0000026421.61398.F2
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Toben D, 2011, J BONE MINER RES, V26, P113, DOI 10.1002/jbmr.185
   Ulrich Vinther M, 2005, CALCIFIED TISSUE INT, V76, P280, DOI 10.1007/s00223 004 0126 9
   van Lent PLEM, 2004, ARTHRITIS RHEUM, V50, P103, DOI 10.1002/art.11422
   Van Wesenbeeck L, 2002, P NATL ACAD SCI USA, V99, P14303, DOI 10.1073/pnas.202332999
   VANROOIJEN N, 1994, J IMMUNOL METHODS, V174, P83
   WAHL SM, 1990, ANN NY ACAD SCI, V593, P188, DOI 10.1111/j.1749 6632.1990.tb16111.x
   WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828
   Wu CKA, 2009, J BIOMED MATER RES A, V91A, P845, DOI 10.1002/jbm.a.32238
   Xing ZQ, 2010, DIS MODEL MECH, V3, P451, DOI 10.1242/dmm.003186
NR 60
TC 377
Z9 429
U1 2
U2 58
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUL
PY 2011
VL 26
IS 7
BP 1517
EP 1532
DI 10.1002/jbmr.354
PG 16
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 783DJ
UT WOS:000292061400014
PM 21305607
OA Bronze
DA 2025 08 17
ER

PT J
AU Neumann, S
   Eliseeva, E
   Boutin, A
   Barnaeva, E
   Ferrer, M
   Southall, N
   Kim, D
   Hu, X
   Morgan, SJ
   Marugan, JJ
   Gershengorn, MC
AF Neumann, Susanne
   Eliseeva, Elena
   Boutin, Alisa
   Barnaeva, Elena
   Ferrer, Marc
   Southall, Noel
   Kim, David
   Hu, Xin
   Morgan, Sarah J.
   Marugan, Juan J.
   Gershengorn, Marvin C.
TI Discovery of a Positive Allosteric Modulator of the Thyrotropin
   Receptor: Potentiation of Thyrotropin Mediated Preosteoblast
   Differentiation In Vitro
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article
ID THYROID STIMULATING HORMONE; PROTEIN COUPLED RECEPTORS;
   PARATHYROID HORMONE; BIASED AGONISM; DRUG DISCOVERY; BONE LOSS; TSH;
   LIGANDS; FAMILY; CELLS
AB Recently, we showed that TSH enhanced differentiation of a human preosteoblast like cell model involved a beta arrestin 1 (beta Arr 1) mediated pathway. To study this pathway in more detail, we sought to discover a small molecule ligand that was functionally selective toward human TSH receptor (TSHR) activation of beta Arr 1. High throughput screening using a cell line stably expressing mutated TSHRs and mutated beta Arr 1 (DiscoverX1 cells) led to the discovery of agonists that stimulated translocation of beta Arr 1 to the TSHR, but did not activate Gs mediated signaling pathways, i.e., cAMP production. D3 beta Arr (NCGC00379308) was selected. In Discover X1 cells, D3 beta Arr stimulated beta Arr 1 translocation with a 5.1 fold greater efficacy than TSH and therefore potentiated the effect of TSH in stimulating beta Arr 1 translocation. In human U2OS TSHR cells expressing wild type TSHRs, which is a model of human preosteoblast like cells, TSH upregulated the osteoblast specific genes osteopontin (OPN) and alkaline phosphatase (ALPL). D3 beta Arr alone had only a weak effect to upregulate these bone markers, but D3 beta Arr potentiated TSH induced upregulation of ALPL and OPN mRNA levels 1.6 fold and 5.5 fold, respectively, at the maximum dose of ligands. Furthermore, the positive allosteric modulator effect of D3 beta Arr resulted in an increase of TSH induced secretion of OPN protein. In summary, we have discovered the first small molecule positive allosteric modulator of TSHR. As D3 beta Arr potentiates the effect of TSH to enhance differentiation of a human preosteoblast in an in vitro model, it will allow a novel experimental approach for probing the role of TSH induced beta Arr 1 signaling in osteoblast differentiation.
C1 [Neumann, Susanne; Eliseeva, Elena; Boutin, Alisa; Morgan, Sarah J.; Gershengorn, Marvin C.] NIDDK, Lab Endocrinol & Receptor Biol, NIH, Bethesda, MD 20892 USA.
   [Barnaeva, Elena; Ferrer, Marc; Southall, Noel; Kim, David; Hu, Xin; Marugan, Juan J.] Natl Ctr Adv Translat Sci, Div Preclin Innovat, NIH, Rockville, MD USA.
C3 National Institutes of Health (NIH)   USA; NIH National Institute of
   Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of
   Health (NIH)   USA; NIH National Center for Advancing Translational
   Sciences (NCATS)
RP Neumann, S (通讯作者)，NIDDK, 50 South Dr,Bldg 50,Rm 4130, Bethesda, MD 20892 USA.
EM susannen@intra.niddk.nih.gov
RI Southall, Noel/H 8991 2012; Neumann, Susanne/GPK 6035 2022
OI Southall, Noel/0000 0003 4500 880X; 
FU Intramural Research Program of the National Institutes of Health
   National Institute of Diabetes and Digestive and Kidney Diseases [Z01
   DK011006]; National Center for Advancing Translational Sciences
FX This research was supported by the Intramural Research Program of the
   National Institutes of Health National Institute of Diabetes and
   Digestive and Kidney Diseases [Grant Z01 DK011006] and the National
   Center for Advancing Translational Sciences.
CR Abe E, 2003, CELL, V115, P151, DOI 10.1016/S0092 8674(03)00771 2
   Abe E, 2007, ANN NY ACAD SCI, V1116, P383, DOI 10.1196/annals.1402.062
   Baliram R, 2011, P NATL ACAD SCI USA, V108, P16277, DOI 10.1073/pnas.1110286108
   Boutin A, 2016, ENDOCRINOLOGY, V157, P2173, DOI 10.1210/en.2015 2040
   Boutin A, 2014, FASEB J, V28, P3446, DOI 10.1096/fj.14 251124
   Burford NT, 2011, BIOCHEM PHARMACOL, V81, P691, DOI 10.1016/j.bcp.2010.12.012
   Conn PJ, 2009, NAT REV DRUG DISCOV, V8, P41, DOI 10.1038/nrd2760
   Coopman K, 2010, J PHARMACOL EXP THER, V334, P795, DOI 10.1124/jpet.110.166009
   Gentry PR, 2015, J BIOL CHEM, V290, P19478, DOI 10.1074/jbc.R115.662759
   Gesty Palmer D, 2011, BRIT J PHARMACOL, V164, P59, DOI 10.1111/j.1476 5381.2011.01450.x
   Gesty Palmer D, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000071
   Giusti Massimo, 2007, Hormones (Athens), V6, P304
   Harrington PE, 2007, CURR MED CHEM, V14, P3027, DOI 10.2174/092986707782794096
   Huang XP, 2015, NATURE, V527, P477, DOI 10.1038/nature15699
   Inglese J, 2006, P NATL ACAD SCI USA, V103, P11473, DOI 10.1073/pnas.0604348103
   Karga H, 2010, J BONE MINER METAB, V28, P35, DOI 10.1007/s00774 009 0098 y
   Kleinau G, 2011, J BIOL CHEM, V286, P25859, DOI 10.1074/jbc.M110.196980
   Langmead CJ, 2008, BRIT J PHARMACOL, V154, P1104, DOI 10.1038/bjp.2008.152
   Latif R, 2009, ENDOCRIN METAB CLIN, V38, P319, DOI 10.1016/j.ecl.2009.01.006
   Laugwitz KL, 1996, P NATL ACAD SCI USA, V93, P116, DOI 10.1073/pnas.93.1.116
   Leader A, 2014, J CLIN ENDOCR METAB, V99, P2665, DOI 10.1210/jc.2013 2474
   Martin TJ, 2009, CRIT REV EUKAR GENE, V19, P73, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.40
   Mazziotti G, 2005, J BONE MINER RES, V20, P480, DOI 10.1359/JBMR.041126
   MOSEKILDE L, 1991, ENDOCRINOLOGY, V129, P421, DOI 10.1210/endo 129 1 421
   Neumann S, 2011, J CLIN ENDOCR METAB, V96, P548, DOI 10.1210/jc.2010 1935
   O'Brien JA, 2003, MOL PHARMACOL, V64, P731, DOI 10.1124/mol.64.3.731
   Qin L, 2004, TRENDS ENDOCRIN MET, V15, P60, DOI 10.1016/j.tem.2004.01.006
   Quoyer J, 2010, J BIOL CHEM, V285, P1989, DOI 10.1074/jbc.M109.067207
   Rankovic Z, 2016, BIOORG MED CHEM LETT, V26, P241, DOI 10.1016/j.bmcl.2015.12.024
   Rominger DH, 2014, CURR OPIN PHARMACOL, V16, P108, DOI 10.1016/j.coph.2014.04.002
   Salvatori L, 2009, J CELL PHYSIOL, V220, P35, DOI 10.1002/jcp.21724
   Sampath TK, 2007, J BONE MINER RES, V22, P849, DOI 10.1359/JBMR.070302
   Siddiqui JA, 2016, PHYSIOLOGY, V31, P233, DOI 10.1152/physiol.00061.2014
   Southall N.T., 2009, HDB DRUG SCREENING, P442
   Sun L, 2008, P NATL ACAD SCI USA, V105, P4289, DOI 10.1073/pnas.0712395105
   Williams GR, 2011, ANN ENDOCRINOL PARIS, V72, P68, DOI 10.1016/j.ando.2011.03.006
   Wisler JW, 2014, CURR OPIN CELL BIOL, V27, P18, DOI 10.1016/j.ceb.2013.10.008
   Wood M, 2016, MOL PHARMACOL, V89, P303, DOI 10.1124/mol.115.100172
   Wootten D, 2013, NAT REV DRUG DISCOV, V12, P630, DOI 10.1038/nrd4052
NR 39
TC 17
Z9 19
U1 0
U2 3
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3995 USA
SN 0022 3565
EI 1521 0103
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD JAN 1
PY 2018
VL 364
IS 1
BP 38
EP 45
DI 10.1124/jpet.117.244095
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA FS9BH
UT WOS:000422708500005
PM 29089368
DA 2025 08 17
ER

PT J
AU Lombardi, MS
   Gilliéron, C
   Berkelaar, M
   Gabay, C
AF Lombardi, Maria Stella
   Gillieron, Corine
   Berkelaar, Majoska
   Gabay, Cem
TI Salt inducible kinases (SIK) inhibition reduces RANKL induced
   osteoclastogenesis
SO PLOS ONE
LA English
DT Article
ID NF KAPPA B; RECEPTOR ACTIVATOR; PROTEIN KINASE; BONE RESORPTION; C FOS;
   DIFFERENTIATION; EXPRESSION; PATHWAYS; LIGAND; TLR
AB Osteoclasts are large multinucleated cells responsible for bone resorption. Excessive inflammatory activation of osteoclasts leads to bony erosions, which are the hallmark of several diseases such as rheumatoid arthritis (RA). Salt inducible kinases (SIK) constitute a subfamily of kinases comprising three members (SIK1, 2, and  3). Inhibition of SIK kinase activity induces an anti inflammatory phenotype in macrophages. Since osteoclasts originate from precursors of macrophage origin, we hypothesized a role of SIK in osteoclastogenesis. We analyzed SIK1, 2 and  3 expression and function in osteoclast differentiation using the mouse macrophage cell line RAW264.7 and bone marrow derived macrophages (BMM). We show that all three SIK are expressed in fully differentiated osteoclasts and that in BMM derived osteoclasts there is an increased expression of SIK1 and SIK3 proteins. Interestingly, the pan SIK inhibitor HG 9 91 01 significantly inhibited osteoclastogenesis by dose dependently reducing osteoclast differentiation markers (i. e. CathepsinK, MMP 9 and TRAP) and bone resorbing activity. Analysis of the signaling pathways activated by RANKL in RAW cells showed that SIK inhibitors did not affect RANKL induced ERK1/2, JNK, p38 or NF .B activation, but induced a significant downregulation in c Fos and NFATc1 protein levels, the two main transcription factors involved in the regulation of osteoclast specific genes. Moreover, SIK inhibition partially increased the proteasome mediated degradation of c Fos. SIK2 and SIK3 knockout RAW cells were generated by the CRISPR/Cas9 approach. SIK2 KO and, to a lesser extent, SIK3 KO recapitulated the effect of SIK small molecule inhibitor, thus confirming the specificity of the effect of SIK inhibition on the reduction of osteoclastogenesis.
   Overall, our results support the notion that the SIK signaling pathway plays a significant role among the check points controlling osteoclastogenesis. SIK kinase inhibitors could thus represent a potential novel therapy to prevent bone erosions.
C1 [Lombardi, Maria Stella; Gillieron, Corine; Berkelaar, Majoska; Gabay, Cem] Univ Hosp Geneva, Div Rheumatol, Dept Internal Med Specialties, Geneva, Switzerland.
   [Lombardi, Maria Stella; Gillieron, Corine; Berkelaar, Majoska; Gabay, Cem] Univ Geneva, Dept Pathol & Immunol, Sch Med, Geneva, Switzerland.
   [Lombardi, Maria Stella] GSK Consumer Healthcare, Dept Preclin Dev, Nyon, Switzerland.
C3 University of Geneva; University of Geneva
RP Lombardi, MS; Gabay, C (通讯作者)，Univ Hosp Geneva, Div Rheumatol, Dept Internal Med Specialties, Geneva, Switzerland.; Lombardi, MS; Gabay, C (通讯作者)，Univ Geneva, Dept Pathol & Immunol, Sch Med, Geneva, Switzerland.; Lombardi, MS (通讯作者)，GSK Consumer Healthcare, Dept Preclin Dev, Nyon, Switzerland.
EM maria stella.x.lombardi@gsk.com; cem.gabay@houge.ch
RI Gabay, Cem/LJM 4539 2024
FU Rheumasearch Foundation; Institute of Arthritis Research (iAR); Swiss
   National Science Foundation (SNF) [310030_172674]; Swiss National
   Science Foundation (SNF) [310030_172674] Funding Source: Swiss National
   Science Foundation (SNF)
FX This work was supported by the Rheumasearch Foundation (grant to M.S.
   Lombardi) and by the Institute of Arthritis Research (iAR) and the Swiss
   National Science Foundation (SNF grant number 310030_172674) to C.
   Gabay.
CR Adamopoulos IE, 2015, NAT REV RHEUMATOL, V11, P189, DOI 10.1038/nrrheum.2014.198
   Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bagnis Claude, 2009, V515, P151, DOI 10.1007/978 1 59745 559 6_10
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   BURGER EH, 1982, J EXP MED, V156, P1604, DOI 10.1084/jem.156.6.1604
   Clark K, 2014, BIOCHEM SOC T, V42, P11, DOI 10.1042/BST20130124
   Clark K, 2012, P NATL ACAD SCI USA, V109, P16986, DOI 10.1073/pnas.1215450109
   Darling NJ, 2017, BIOCHEM J, V474, P521, DOI 10.1042/BCJ20160646
   Fu Q, 2002, J BIOL CHEM, V277, P48868, DOI 10.1074/jbc.M208494200
   Granholm S, 2007, J ENDOCRINOL, V195, P415, DOI 10.1677/JOE 07 0338
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Han KY, 2007, BIOCHEM PHARMACOL, V74, P911, DOI 10.1016/j.bcp.2007.06.044
   Ito Y, 2005, BONE, V37, P842, DOI 10.1016/j.bone.2005.04.030
   Katoh Y, 2004, MOL CELL ENDOCRINOL, V217, P109, DOI 10.1016/j.mce.2003.10.016
   Kim JH, 2010, J BIOL CHEM, V285, P5224, DOI 10.1074/jbc.M109.042812
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Li X, 2015, SHOCK VIB, V2015, DOI 10.1155/2015/431476
   Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110
   Lombardi MS, 2016, J LEUKOCYTE BIOL, V99, P711, DOI 10.1189/jlb.2A0715 307R
   Lubberts E, 2002, ARTHRITIS RHEUM, V46, P3055, DOI 10.1002/art.10607
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Ozanne J, 2015, BIOCHEM J, V465, P271, DOI 10.1042/BJ20141165
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Phan TCA, 2004, HISTOL HISTOPATHOL, V19, P1325, DOI 10.14670/HH 19.1325
   Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047
   Sasagawa S, 2012, DEVELOPMENT, V139, P1153, DOI 10.1242/dev.072652
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Vaira S, 2008, J CLIN INVEST, V118, P2088, DOI 10.1172/JCI33392
   van der Linden AM, 2007, EMBO J, V26, P358, DOI 10.1038/sj.emboj.7601479
   Walkinshaw DR, 2013, J BIOL CHEM, V288, P9345, DOI 10.1074/jbc.M113.456996
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Wei S, 2001, ENDOCRINOLOGY, V142, P1290, DOI 10.1210/en.142.3.1290
   Xie ZL, 2006, J BIOL CHEM, V281, P6366, DOI 10.1074/jbc.M511178200
NR 36
TC 23
Z9 26
U1 2
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD OCT 3
PY 2017
VL 12
IS 10
AR e0185426
DI 10.1371/journal.pone.0185426
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA FI6UJ
UT WOS:000412131900017
PM 28973003
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Han, SY
   Kim, YK
AF Han, Sang Yong
   Kim, Yun Kyung
TI Berberine Suppresses RANKL Induced Osteoclast Differentiation by
   Inhibiting c Fos and NFATc1 Expression
SO AMERICAN JOURNAL OF CHINESE MEDICINE
LA English
DT Article
DE Berberine; Osteoclast Differentiation; Bone Loss; c Fos; NFATc1
ID NF KAPPA B; TUMOR NECROSIS FACTOR; MICROPHTHALMIA TRANSCRIPTION FACTOR;
   RECEPTOR ACTIVATOR; BONE RESORPTION; SIGNAL TRANSDUCTION;
   NUCLEAR FACTOR; IN VIVO; M CSF; PATHWAY
AB Osteoporosis is a common disorder of bone remodeling, marked by excessive osteoclast formation. Recent studies indicated that berberine (BBR) is a potential natural drug for the treatment of various bone diseases. However, it still needs to be further studied for the treatment of osteoporosis. The current study investigated the inhibitory effects of BBR on receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclast differentiation in vitro and in vivo. Cell based assays were performed using osteoclasts generated in cultures of murine bone marrow derived macrophages (BMMs) treated with RANKL and M CSF. The effects of BBR on in vivo lipopolysaccharide (LPS) mediated bone loss were evaluated using ICR mice. BBR significantly inhibited TRAP positive osteoclast formation induced by RANKL. BBR also inhibited RANKL induced Akt, p38 and ERK phosphorylation and I kappa B degradation, and suppressed RANKL induced expression of c Fos and nuclear factor of activated T cells c1 (NFATc1), which is a key transcription factors for osteoclast formation. BBR reduced the mRNA levels of osteoclast markers, including TRAP, osteoclast associated receptor (OSCAR), cathepsin K, and ATPase H+ transporting V0 subunit d2 (ATP6v0d2). Moreover, BBR prevented LPS mediated bone loss in vivo. We suggest BBR as a natural compound that can be a potential therapeutic agent for osteoclast related bone diseases.
C1 [Han, Sang Yong; Kim, Yun Kyung] Wonkwang Univ, Wonkwang Oriental Med Res Inst, Coll Pharm, Dept Herbal Med, Iksan, Jeonbuk, South Korea.
C3 Wonkwang University
RP Kim, YK (通讯作者)，Wonkwang Univ, Dept Herbal Med, Coll Pharm, 460 Iksan Daero, Iksan, Jeonbuk, South Korea.
EM hestia@wonkwang.ac.kr
FU National Research Foundation of Korea (NRF)   Korea government (MOE)
   [NRF 2016R1A6A3A11933612]
FX This research was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korea government (MOE,
   NRF 2016R1A6A3A11933612).
CR AbuAmer Y, 1997, J CLIN INVEST, V100, P1557, DOI 10.1172/JCI119679
   Anis KV, 2001, J PHARM PHARMACOL, V53, P763, DOI 10.1211/0022357011775901
   Armstrong AP, 2002, J BIOL CHEM, V277, P44347, DOI 10.1074/jbc.M202009200
   Clarke B, 2008, CLIN J AM SOC NEPHRO, V3, pS131, DOI 10.2215/CJN.04151206
   Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905
   Deal C, 2009, NAT CLIN PRACT RHEUM, V5, P20, DOI 10.1038/ncprheum0977
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120
   Grabowski P, 2015, ENDOCR DEV, V28, P33, DOI 10.1159/000380991
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Harvey N, 2010, NAT REV RHEUMATOL, V6, P99, DOI 10.1038/nrrheum.2009.260
   He YZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024780
   Hienz SA, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/615486
   Hu JP, 2008, EUR J PHARMACOL, V580, P70, DOI 10.1016/j.ejphar.2007.11.013
   Hu JP, 2000, ORAL DIS, V6, P297, DOI 10.1111/j.1601 0825.2000.tb00142.x
   Huang H, 2006, CELL DEATH DIFFER, V13, P1879, DOI 10.1038/sj.cdd.4401882
   Hwang JM, 2006, ARCH TOXICOL, V80, P62, DOI 10.1007/s00204 005 0014 8
   ISHIHARA Y, 1991, J PERIODONTAL RES, V26, P155, DOI 10.1111/j.1600 0765.1991.tb01639.x
   Islam S, 2007, BIOCHEM BIOPH RES CO, V360, P346, DOI 10.1016/j.bbrc.2007.06.023
   Jeong HW, 2009, AM J PHYSIOL ENDOC M, V296, pE955, DOI 10.1152/ajpendo.90599.2008
   Jin Y, 2016, EXPERT OPIN THER PAT, V26, P229, DOI 10.1517/13543776.2016.1118060
   Kim Jung Ha, 2016, Chonnam Med J, V52, P12, DOI 10.4068/cmj.2016.52.1.12
   Kim K, 2005, J BIOL CHEM, V280, P35209, DOI 10.1074/jbc.M505815200
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kobayashi Y, 2005, J BIOL CHEM, V280, P11395, DOI 10.1074/jbc.M411189200
   KUO CL, 1995, CANCER LETT, V93, P193, DOI 10.1016/0304 3835(95)03809 B
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee K, 2016, INT J BIOL SCI, V12, P235, DOI 10.7150/ijbs.13814
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Li HY, 1999, BIOL PHARM BULL, V22, P391, DOI 10.1248/bpb.22.391
   Mansky KC, 2002, J BIOL CHEM, V277, P11077, DOI 10.1074/jbc.M111696200
   Mantena SK, 2006, MOL CANCER THER, V5, P296, DOI 10.1158/1535 7163.MCT 05 0448
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Mörmann M, 2008, MOL IMMUNOL, V45, P3330, DOI 10.1016/j.molimm.2008.04.022
   Motyckova G, 2001, P NATL ACAD SCI USA, V98, P5798, DOI 10.1073/pnas.091479298
   Oh Y, 2017, INT J MED SCI, V14, P729, DOI 10.7150/ijms.19616
   ORCEL P, 1993, AM J PHYSIOL, V264, pE391, DOI 10.1152/ajpendo.1993.264.3.E391
   Park KH, 2017, AM J CHINESE MED, V45, P1725, DOI 10.1142/S0192415X17500938
   REDDY SV, 1995, J BONE MINER RES, V10, P601
   Rho TW, 2017, AM J CHINESE MED, V45, P283, DOI [10.1142/S0192415X17500185, 10.1142/s0192415x17500185]
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Ross FP, 2006, ANN NY ACAD SCI, V1068, P110, DOI 10.1196/annals.1346.014
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Tanaka Yoshiya, 2005, Current Drug Targets   Inflammation and Allergy, V4, P325, DOI 10.2174/1568010054022015
   Tang J, 2009, J ETHNOPHARMACOL, V126, P5, DOI 10.1016/j.jep.2009.08.009
   Wei Peng, 2009, Zhong Xi Yi Jie He Xue Bao, V7, P342, DOI 10.3736/jcim20090408
   Zhang H, 2017, INT IMMUNOPHARMACOL, V52, P93, DOI 10.1016/j.intimp.2017.08.032
   Zhou L, 2015, INT J MOL SCI, V16, P27087, DOI 10.3390/ijms161125998
NR 49
TC 41
Z9 51
U1 0
U2 17
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0192 415X
EI 1793 6853
J9 AM J CHINESE MED
JI Am. J. Chin. Med.
PY 2019
VL 47
IS 2
BP 439
EP 455
DI 10.1142/S0192415X19500228
PG 17
WC Integrative & Complementary Medicine; Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine; General & Internal Medicine
GA HQ6FF
UT WOS:000462507300010
PM 30827151
DA 2025 08 17
ER

PT J
AU Abdullah, AR
   Hapidin, H
   Abdullah, H
AF Abdullah, Amira Raudhah
   Hapidin, Hermizi
   Abdullah, Hasmah
TI The Role of Semipurified Fractions Isolated from Quercus
   infectoria on Bone Metabolism by Using hFOB 1.19 Human Fetal
   Osteoblast Cell Model
SO EVIDENCE BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID IN VITRO; POSTMENOPAUSAL WOMEN; MINERAL DENSITY; BISPHOSPHONATES;
   OSTEOPONTIN; EXTRACT; GALLS; ACID; DIFFERENTIATION; PROLIFERATION
AB Background. Quercus infectoria (QI) is a plant used in traditional medicines in Asia. The plant was reported to contain various active phytochemical compounds that have potential to stimulate bone formation. However, the precise mechanism of the stimulation effect of QI on osteoblast has not been elucidated. The present study was carried out to isolate QI semipurified fractions from aqueous QI extract and to delineate the molecular mechanism of QI semipurified fraction that enhanced bone formation by using hFOB1.19 human fetal osteoblast cell model. Methods. Isolation of QI semipurified fractions was established by means of column chromatography and thin layer chromatography. Established QI semipurified fractions were identified using Liquid Chromatography Mass Spectrometry (LC MS). Cells were treated with derived QI semipurified fractions and investigated for mineralization deposition and protein expression level of BMP 2, Runx2, and OPN by ELISA followed gene expression analysis of BMP 2 and Runx2 by RT PCR. Results. Column chromatography isolation and purification yield Fractions A, B, and C. LC MS analysis reveals the presence of polyphenols in each fraction. Results show that QI semipurified fractions increased the activity and upregulated the gene expression of BMP 2 and Runx2 at day 1, day 3, and day 7. OPN activity increased in cells treated with QI semipurified fractions at day 1 and day 3. Meanwhile, at day 7, expression of OPN decreased in activity. Furthermore, the study showed that combination of Fractions A, B, and C with osteoporotic drug (pamidronate) further increased the activity and upregulated the gene expression of BMP 2 and Runx2. Conclusions. These findings demonstrated that polyphenols from semipurified fractions of QI enhanced bone formation through expression of the investigated bone related marker that is its potential role when combined with readily available osteoporotic drug.
C1 [Abdullah, Amira Raudhah; Hapidin, Hermizi] Univ Sains Malaysia, Sch Hlth Sci, Biomed Programme, Kubang Kerian 16150, Kelantan, Malaysia.
   [Abdullah, Hasmah] Univ Sains Malaysia, Sch Hlth Sci, Environm & Occupat Hlth Programme, Kubang Kerian 16150, Kelantan, Malaysia.
C3 Universiti Sains Malaysia; Universiti Sains Malaysia
RP Hapidin, H (通讯作者)，Univ Sains Malaysia, Sch Hlth Sci, Biomed Programme, Kubang Kerian 16150, Kelantan, Malaysia.
EM hermizi@usm.my
RI Hapidin, Hermizi/E 1692 2012; abdullah, hasmah/B 2604 2018
OI Hapidin, Hermizi/0000 0002 9427 1332; Abdullah, Amira
   Raudhah/0000 0003 2170 7948
FU Ministry of Higher Education, Malaysia under the Fundamental Research
   Grant Scheme (FRGS) [203/PPSK/6171169]
FX The authors were grateful to the Ministry of Higher Education, Malaysia,
   for funding this work under the Fundamental Research Grant Scheme
   (FRGS), Grant no. 203/PPSK/6171169, and School of Health Sciences and
   School of Dental Sciences, Universiti Sains Malaysia (USM), for
   providing the research facility.
CR Abdelgadir AA, 2011, ENVIRON HEALTH INSIG, V5, P1, DOI 10.4137/EHI.S6292
   Abdullah Amira Raudhah, 2017, P MIN PROL HUM FOET, P79
   Aroonrerk N, 2009, J HEALTH RES, V23, P16
   Avery VM, 2010, COMPREHENSIVE NATURAL PRODUCTS II: CHEMISTRY AND BIOLOGY, VOL 3: DEVELOPMENT & MODIFICATION OF BIOACTIVITY, P177
   Basri D. F., 2005, Indian Journal of Pharmacology, V37, P26
   Chen Q, 2014, STEM CELLS, V32, P327, DOI 10.1002/stem.1567
   Chusri S, 2009, J APPL MICROBIOL, V106, P89, DOI 10.1111/j.1365 2672.2008.03979.x
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Faried A, 2007, INT J ONCOL, V30, P605
   Fleisch H, 2003, EUR SPINE J, V12, pS142, DOI 10.1007/s00586 003 0622 z
   Hapidin H., 2012, OPEN J ENDOCRINE MET, V02, P10
   Hapidin H, 2015, MALAYS J MED SCI, V22, P12
   Huang WB, 2004, BONE, V34, P799, DOI 10.1016/j.bone.2003.11.027
   Hwang JK, 2000, PLANTA MED, V66, P273, DOI 10.1055/s 2000 8569
   Jin P, 2015, YONSEI MED J, V56, P760, DOI 10.3349/ymj.2015.56.3.760
   Johnston CC, 2000, ARCH INTERN MED, V160, P3444, DOI 10.1001/archinte.160.22.3444
   Kamba AS, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/215097
   Kaur G, 2004, J ETHNOPHARMACOL, V90, P285, DOI 10.1016/j.jep.2003.10.009
   Kaur G, 2008, CHEM BIOL INTERACT, V171, P272, DOI 10.1016/j.cbi.2007.10.002
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Kharwadkar N, 2017, BONE JOINT RES, V6, P144, DOI 10.1302/2046 3758.63.BJR 2016 0125.R1
   Landete JM, 2011, FOOD RES INT, V44, P1150, DOI 10.1016/j.foodres.2011.04.027
   Lee MH, 2003, BIOCHEM BIOPH RES CO, V309, P689, DOI 10.1016/j.bbrc.2003.08.058
   Liang WN, 2012, INT J MOL MED, V30, P889, DOI 10.3892/ijmm.2012.1079
   LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302
   Matsubara T, 2008, J BIOL CHEM, V283, P29119, DOI 10.1074/jbc.M801774200
   Miki Y, 2009, J STEROID BIOCHEM, V113, P281, DOI 10.1016/j.jsbmb.2009.01.010
   Neve A, 2011, CELL TISSUE RES, V343, P289, DOI 10.1007/s00441 010 1086 1
   Papachroni KK, 2009, TRENDS MOL MED, V15, P208, DOI 10.1016/j.molmed.2009.03.001
   Passeri G, 2010, CLIN ORAL IMPLAN RES, V21, P756, DOI 10.1111/j.1600 0501.2009.01906.x
   Ponader S, 2008, COLLOID SURFACE B, V64, P275, DOI 10.1016/j.colsurfb.2008.02.002
   Qin LP, 2008, J ETHNOPHARMACOL, V118, P271, DOI 10.1016/j.jep.2008.04.009
   REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473
   Rina R., 2011, HLTH ENV J, V2, P13
   Rodriguez JES, 2009, J BONE MINER RES, V24, P1917, DOI [10.1359/JBMR.090507, 10.1359/jbmr.090507]
   Rosen CJ, 2001, J CLIN ENDOCR METAB, V86, P957, DOI 10.1210/jc.86.3.957
   Sambrook PN, 2009, NAT CLIN PRACT RHEUM, V5, P6, DOI 10.1038/ncprheum0960
   Samuelsson G., 1992, Drugs of Natural Origin. A Textbook of Pharmacognosy, V4th, P86
   Schmid R., 1995, Taxon, V44, P469, DOI [10.1002/j.1996 8175.1995.tb04959.x, DOI 10.1002/J.1996 8175.1995.TB04959.X, 10.2307/1223435, DOI 10.2307/1223435]
   Shahid M, 2012, DYES PIGMENTS, V95, P53, DOI 10.1016/j.dyepig.2012.03.029
   Shen CL, 2008, OSTEOPOROSIS INT, V19, P979, DOI 10.1007/s00198 007 0527 5
   Titorencu I, 2012, MOL CRYST LIQ CRYST, V555, P208, DOI 10.1080/15421406.2012.635540
   Umachigi SP, 2008, TROP J PHARM RES, V7, P913
   Wanachewin O, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472 6882 12 71
   Wang Q, 2009, J NUTR BIOCHEM, V20, P369, DOI 10.1016/j.jnutbio.2008.04.007
   Xiong JH, 2012, J BONE MINER RES, V27, P499, DOI 10.1002/jbmr.1547
   Yadav DK, 2012, J MOL MODEL, V18, P2513, DOI 10.1007/s00894 011 1265 3
   Yamaguchi M, 2001, BIOL PHARM BULL, V24, P1437, DOI 10.1248/bpb.24.1437
   Yoshikawa M, 2007, CHEM PHARM BULL, V55, P428, DOI 10.1248/cpb.55.428
   Zhao J, 2008, BIOCHEM BIOPH RES CO, V369, P444, DOI 10.1016/j.bbrc.2008.02.054
NR 51
TC 11
Z9 11
U1 0
U2 8
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741 427X
EI 1741 4288
J9 EVID BASED COMPL ALT
JI Evid. based Complement Altern. Med.
PY 2018
VL 2018
AR 5319528
DI 10.1155/2018/5319528
PG 13
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA GH4FF
UT WOS:000433358000001
PM 29861772
OA Green Published, hybrid, Green Submitted
DA 2025 08 17
ER

PT J
AU Fitter, S
   Dewar, AL
   Kostakis, P
   To, LB
   Hughes, TP
   Roberts, MM
   Lynch, K
   Vernon Roberts, B
   Zannettino, ACW
AF Fitter, Stephen
   Dewar, Andrea L.
   Kostakis, Panagiota
   To, L. Bik
   Hughes, Timothy P.
   Roberts, Marion M.
   Lynch, Kevin
   Vernon Roberts, Barrie
   Zannettino, Andrew C. W.
TI Long term imatinib therapy promotes bone formation in CML patients
SO BLOOD
LA English
DT Article
ID STEM CELL DIFFERENTIATION; COLONY STIMULATING FACTOR; CHRONIC
   MYELOID LEUKEMIA; GROWTH FACTOR RECEPTOR; ILIAC CREST; IN VITRO;
   OSTEOBLAST DIFFERENTIATION; MINERAL DENSITY; C ABL; INTERFERON
AB Imatinib inhibits tyrosine kinases important in osteoclast (c Fms) and osteoblast (platelet derived growth factor receptor [PDGF R], c Abl)function, suggesting that long term therapy may alter bone homeostasis. To investigate this question, we measured the trabecular bone volume (TBV) in iliac crest bone biopsies taken from chronic myeloid leukemia (CML) patients at diagnosis and again after 2 to 4 years of imatinib therapy. Half the patients (8 of 17) showed a substantive increase in TBV (> 2 fold), after imatinib therapy, with the TBV in the posttreatment biopsy typically surpassing the normal upper limit for the patient's age group. Imatinib treated patients exhibited reduced serum calcium and phosphate levels with hypophosphatemia evident in 53% (9 of 17) of patients. In vitro, imatinib suppressed osteoblast proliferation and stimulated osteogenic gene expression and mineralized matrix production by inhibiting PDGF receptor function. In PDGF stimulated cultures, imatinib dose dependently inhibited activation of Akt and Crk L. Using pharmacologic inhibitors, inhibition of P13 kinase/Akt activation promoted mineral formation, suggesting a possible molecular mechanism for the imatinib mediated increase in TBV in vivo. Further investigation is required to determine whether the increase in TBV associated with imatinib therapy may represent a novel therapeutic avenue for the treatment of diseases that are characterized by generalized bone loss.
C1 [Fitter, Stephen; Dewar, Andrea L.; Kostakis, Panagiota; To, L. Bik; Hughes, Timothy P.; Roberts, Marion M.] Inst Med & Vet Sci, Myeloma & Mesenchymal Res Grp, Bone & Canc Res Labs, Div Haematol,Hauson Inst, Adelaide, SA 5000, Australia.
   [Lynch, Kevin] Novartis Pharmaceut, Med Oncol, Sydney, NSW, Australia.
   [Vernon Roberts, Barrie] Inst Med & Vet Sci, Adelaide Ctr Spinal Res, Hauson Inst, Adelaide, SA 5000, Australia.
C3 Institute Medical & Veterinary Science Australia; Novartis; NOVARTIS
   AUSTRALIA; Institute Medical & Veterinary Science Australia
RP Zannettino, ACW (通讯作者)，Inst Med & Vet Sci, Myeloma & Mesenchymal Res Grp, Bone & Canc Res Labs, Div Haematol,Hauson Inst, GPO box 14, Adelaide, SA 5000, Australia.
EM andrew.zannettino@imvs.sa.gov.au
RI ; Hughes, Tim/AAO 9975 2021
OI Zannettino, Andrew/0000 0002 6646 6167; Hughes,
   Timothy/0000 0002 0910 3730; Fitter, Stephen/0000 0003 1663 6807; 
CR Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200
   [Anonymous], MARROW STROMAL CELL
   Aouadi M, 2006, DIABETES, V55, P281, DOI 10.2337/diabetes.55.02.06.db05 0963
   Apperley JF, 2002, NEW ENGL J MED, V347, P481, DOI 10.1056/NEJMoa020150
   Artemenko Y, 2005, J CELL PHYSIOL, V204, P646, DOI 10.1002/jcp.20314
   Avnet S, 2007, INT J ONCOL, V30, P469
   Baccarani M, 2006, BLOOD, V108, P1809, DOI 10.1182/blood 2006 02 005686
   BECK JS, 1960, J PATHOL BACTERIOL, V80, P391, DOI 10.1002/path.1700800223
   Berman E, 2006, NEW ENGL J MED, V354, P2006, DOI 10.1056/NEJMoa051140
   Bost F, 2005, BIOCHIMIE, V87, P51, DOI 10.1016/j.biochi.2004.10.018
   Chaudhary LR, 2004, BONE, V34, P402, DOI 10.1016/j.bone.2003.11.014
   Debiais F, 2004, EXP CELL RES, V297, P235, DOI 10.1016/j.yexcr.2004.03.032
   Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461
   Dewar AL, 2005, BLOOD, V105, P3127, DOI 10.1182/blood 2004 10 3967
   Dewar AL, 2006, BLOOD, V107, P4334, DOI 10.1182/blood 2005 09 3568
   Felsenberg D, 2005, CLIN THER, V27, P1, DOI 10.1016/j.clinthera.2004.12.020
   FRYDECKA I, 1984, Folia Haematologica (Leipzig), V111, P610
   Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138
   Fukuyama R, 2004, BIOCHEM BIOPH RES CO, V315, P636, DOI 10.1016/j.bbrc.2004.01.104
   GARNER A, 1966, J PATHOL BACTERIOL, V91, P545, DOI 10.1002/path.1700910231
   Ghosh Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200
   Grey A, 2006, NEW ENGL J MED, V355, P2494, DOI 10.1056/NEJMc062388
   GRIGORIADIS AE, 1990, DEV BIOL, V142, P313, DOI 10.1016/0012 1606(90)90352 J
   GRIGORIADIS AE, 1988, J CELL BIOL, V106, P2139, DOI 10.1083/jcb.106.6.2139
   Gronthos S, 1999, J BONE MINER RES, V14, P47, DOI 10.1359/jbmr.1999.14.1.47
   HOCK JM, 1994, ENDOCRINOLOGY, V134, P1423, DOI 10.1210/en.134.3.1423
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645
   Kauppila M, 2000, CLIN LAB HAEMATOL, V22, P15, DOI 10.1046/j.1365 2257.2000.00269.x
   Koellensperger E, 2006, STEM CELLS, V24, P1218, DOI 10.1634/stemcells.2005 0020
   Kratchmarova I, 2005, SCIENCE, V308, P1472, DOI 10.1126/science.1107627
   Kubota K, 2002, J BONE MINER RES, V17, P257, DOI 10.1359/jbmr.2002.17.2.257
   le Coutre P, 2004, CANCER CHEMOTH PHARM, V53, P313, DOI 10.1007/s00280 003 0741 6
   Li BJ, 2000, NAT GENET, V24, P304, DOI 10.1038/73542
   LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022 1759(94)90236 4
   MELSEN F, 1978, ACTA PATH MICRO IM A, V86, P70
   MELSEN F, 1978, ACTA PATH MICRO IM A, V86, P63
   Mitlak BH, 1996, J BONE MINER RES, V11, P238
   MOORE RJ, 1989, J CLIN PATHOL, V42, P213, DOI 10.1136/jcp.42.2.213
   MOORE RJ, 1989, J CLIN PATHOL, V42, P814, DOI 10.1136/jcp.42.8.814
   Nadal E, 2001, LEUKEMIA LYMPHOMA, V41, P203, DOI 10.3109/10428190109057972
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   NASH TJ, 1994, BONE, V15, P203, DOI 10.1016/8756 3282(94)90709 9
   Pérez Castrillón JL, 2003, REV NEUROLOGIA, V36, P901, DOI 10.33588/rn.3610.2002555
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Plattner R, 2004, MOL CELL BIOL, V24, P2573, DOI 10.1128/mcb.24.6.2573 2583.2004
   Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400
   REVELL PA, 1986, PATHOLOGY BONE, P87
   Sattler M, 1996, ONCOGENE, V12, P839
   Solís Herruzo JA, 2000, J HEPATOL, V33, P812, DOI 10.1016/S0168 8278(00)80314 1
   Summers SA, 1999, J BIOL CHEM, V274, P23858, DOI 10.1074/jbc.274.34.23858
   TANAKA S, 1993, J CLIN INVEST, V91, P257, DOI 10.1172/JCI116179
   THIELE J, 1989, PATHOL RES PRACT, V184, P591, DOI 10.1016/S0344 0338(89)80164 5
   Viñals F, 2002, FEBS LETT, V510, P99, DOI 10.1016/S0014 5793(01)03236 7
   YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681
   YAMAGUCHI A, 1991, CALCIFIED TISSUE INT, V49, P221, DOI 10.1007/BF02556122
NR 56
TC 135
Z9 142
U1 0
U2 7
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006 4971
J9 BLOOD
JI Blood
PD MAR 1
PY 2008
VL 111
IS 5
BP 2538
EP 2547
DI 10.1182/blood 2007 07 104281
PG 10
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA 269SX
UT WOS:000253671600017
PM 18042796
OA Bronze
DA 2025 08 17
ER

PT J
AU Gabet, Y
   Kohavi, D
   Voide, R
   Mueller, TL
   Müller, R
   Bab, I
AF Gabet, Yankel
   Kohavi, David
   Voide, Romain
   Mueller, Thomas L.
   Mueller, Ralph
   Bab, Itai
TI Endosseous Implant Anchorage Is Critically Dependent on
   Mechanostructural Determinants of Pen Implant Bone Trabeculae
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE ENDOSSEOUS IMPLANTS; ORCHIECTOMY INDUCED TRABECULAR BONE LOSS;
   IMAGE GUIDED FAILURE ASSESSMENT; PARATHYROID HORMONE; PERI IMPLANT BONE
ID PARATHYROID HORMONE 1 34; OSTEOPENIC OVARIECTOMIZED RATS; TITANIUM
   DENTAL IMPLANTS; FIBROBLAST GROWTH FACTOR; MINERAL DENSITY;
   HISTOMORPHOMETRIC EVALUATION; NONDESTRUCTIVE EVALUATION; SEQUENTIAL
   TREATMENT; SURFACE TREATMENTS; CORTICAL BONE
AB Low bone mass is highly prevalent among patients receiving endosseous implants. In turn, the implantation prognosis in low density skeletal sites is poor. However, little is known about the mechanostructural determinants of implant anchorage. Using metabolic manipulations that lead to low bone density and to its rescue, we show here that anchorage is critically dependent on the pen implant bone (PIB). Titanium implants were inserted horizontally into the proximal tibial metaphysis of adult rats 6 weeks after orchiectomy (ORX) or sham ORX. Systemic intermittent administration of human parathyroid hormone (1 34) [iahPTH(1 34)] or vehicle commenced immediately thereafter for 6 weeks. The bone implant apparatus was then subjected to image guided failure assessment, which assesses biomechanical properties and microstructural deformation concomitantly. Anchorage failure occurred mainly in PIB trabeculae, 0.5 to 1.0 mm away from the implant. Mechanically, the anchorage performed poorly in ORX induced low density bone, attributable mainly to decreased trabecular number. iahPTH(1 34) rescued the PIB density and implant mechanical function by augmenting trabecular thickness (Tb.Th). However, implant biomechanical properties in low density bone were relatively insensitive to implant surface treatment that affected only the osseointegration (%bone implant contact). These results support a model wherein anchorage failure involves buckling of the weakest trabecular struts followed by sequential failure of the stronger trabeculae. Treatment with iahPTH(1 34) induced thicker struts, which were able to delay and even prevent failure of individual elements, thus implicating trabecular thickness as a prime target for enhancing implant anchorage by systemic bone anabolic therapy. (C) 2010 American Society for Bone and Mineral Research.
C1 [Gabet, Yankel; Bab, Itai] Hebrew Univ Jerusalem, Bone Lab, Hadassah Fac Dent Med, Inst Dent Sci, IL 91120 Jerusalem, Israel.
   [Kohavi, David] Hebrew Univ Jerusalem, Oral Implant Ctr, Hadassah Fac Dent Med, IL 91120 Jerusalem, Israel.
   [Voide, Romain; Mueller, Thomas L.; Mueller, Ralph] Swiss Fed Inst Technol, Inst Biomech, Zurich, Switzerland.
C3 Hebrew University of Jerusalem; Hebrew University of Jerusalem; Swiss
   Federal Institutes of Technology Domain; ETH Zurich
RP Bab, I (通讯作者)，Hebrew Univ Jerusalem, Bone Lab, Hadassah Fac Dent Med, Inst Dent Sci, POB 12272, IL 91120 Jerusalem, Israel.
EM babi@cc.huji.ac.il
RI ; Mueller, Thomas/B 7089 2009; Müller, Ralph/A 1198 2008; Muller,
   Ralph/A 1198 2008; Gabet, Yankel/I 6244 2019
OI Gabet, Yankel/0000 0002 7494 0631; Muller, Ralph/0000 0002 5811 7725; 
FU Julius Oppenheimer Fund; Swiss National Science Foundation [PP 104317/1]
FX This work was supported by a grant from the Julius Oppenheimer Fund (to
   IB and DK) and by the professorship in bioengineering from the Swiss
   National Science Foundation (Grant No. PP 104317/1).
CR Alexander JM, 2001, J BONE MINER RES, V16, P1665, DOI 10.1359/jbmr.2001.16.9.1665
   Alkhiary YM, 2005, J BONE JOINT SURG AM, V87A, P731, DOI 10.2106/JBJS.D.02115
   Bauer TW, 1999, SKELETAL RADIOL, V28, P423, DOI 10.1007/s002560050541
   Bowers K T, 1992, Int J Oral Maxillofac Implants, V7, P302
   BROZ JJ, 1993, J BIOMECH ENG T ASME, V115, P447, DOI 10.1115/1.2895510
   BUSER D, 1991, J BIOMED MATER RES, V25, P889, DOI 10.1002/jbm.820250708
   Davies John E, 2003, J Dent Educ, V67, P932
   Dayer R, 2006, J BONE MINER RES, V21, P258, DOI 10.1359/JBMR.051009
   Dayer R, 2007, J BONE MINER RES, V22, P1526, DOI 10.1359/JBMR.070610
   ERICSSON I, 1994, CLIN ORAL IMPLAN RES, V5, P202, DOI 10.1034/j.1600 0501.1994.050402.x
   Esposito M, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003815.pub2
   Finkelstein JS, 2009, J CLIN ENDOCR METAB, V94, P2495, DOI 10.1210/jc.2009 0154
   Fox J, 2006, CALCIFIED TISSUE INT, V79, P262, DOI 10.1007/s00223 006 0108 1
   Friedl G, 2009, J BONE JOINT SURG AM, V91A, P274, DOI 10.2106/JBJS.G.01193
   Fukushima T, 2000, JPN J PHARMACOL, V82, P240, DOI 10.1254/jjp.82.240
   Gabet Y, 2005, OSTEOPOROSIS INT, V16, P1436, DOI 10.1007/s00198 005 1876 6
   Gabet Y, 2004, BONE, V35, P65, DOI 10.1016/j.bone.2004.03.025
   Gabet Y, 2008, J BONE MINER RES, V23, P48, DOI 10.1359/JBMR.070901
   Gabet Y, 2006, BONE, V39, P276, DOI 10.1016/j.bone.2006.02.004
   Gasser JA, 2005, J BONE MINER METAB, V23, P90, DOI 10.1007/BF03026331
   Giavaresi G, 2003, BIOMATERIALS, V24, P1583, DOI 10.1016/S0142 9612(02)00548 3
   Gittens SA, 2004, J PHARM PHARM SCI, V7, P27
   Grassi S, 2006, J PERIODONTOL, V77, P1736, DOI 10.1902/jop.2006.050325
   Grizon F, 2002, J DENT, V30, P195, DOI 10.1016/S0300 5712(02)00018 0
   Guo XE, 2002, BONE, V30, P404, DOI 10.1016/S8756 3282(01)00673 1
   Hallgren C, 2001, J BIOMED MATER RES, V57, P485, DOI 10.1002/1097 4636(20011215)57:4<485::AID JBM1194>3.0.CO;2 1
   Hildebrand T, 1999, J BONE MINER RES, V14, P1167, DOI 10.1359/jbmr.1999.14.7.1167
   IWAMOTO M, 1994, J BIOL CHEM, V269, P17245
   Iwaniec UT, 2002, ENDOCRINOLOGY, V143, P2515, DOI 10.1210/en.143.7.2515
   JAFFIN RA, 1991, J PERIODONTOL, V62, P2, DOI 10.1902/jop.1991.62.1.2
   Keller JC, 2004, INT J ORAL MAX IMPL, V19, P687
   KIMMEL DB, 1993, ENDOCRINOLOGY, V132, P1577, DOI 10.1210/en.132.4.1577
   Lane NE, 2003, J BONE MINER RES, V18, P2105, DOI 10.1359/jbmr.2003.18.12.2105
   Le Guéhennec L, 2007, DENT MATER, V23, P844, DOI 10.1016/j.dental.2006.06.025
   LINDER L, 1988, J BONE JOINT SURG BR, V70, P550, DOI 10.1302/0301 620X.70B4.3403596
   LIU CC, 1991, J BONE MINER RES, V6, P1071
   Martinez H, 2001, CLIN ORAL IMPLAN RES, V12, P423, DOI 10.1034/j.1600 0501.2001.120501.x
   Meraw SJ, 1999, J PERIODONTOL, V70, P1228, DOI 10.1902/jop.1999.70.10.1228
   Miyauchi A, 2008, J BONE MINER METAB, V26, P624, DOI 10.1007/s00774 008 0871 3
   Mori H, 1997, J ORAL MAXIL SURG, V55, P351, DOI 10.1016/S0278 2391(97)90124 5
   Muller R, 1997, ST HEAL T, V40, P61
   Muller R, 1998, Technol Health Care, V6, P433
   Nakajima A, 2002, J BONE MINER RES, V17, P2038, DOI 10.1359/jbmr.2002.17.11.2038
   Nazarian A, 2005, J BIOMED MATER RES B, V73B, P400, DOI 10.1002/jbm.b.30232
   Nazarian A, 2004, J BIOMECH, V37, P55, DOI 10.1016/S0021 9290(03)00254 9
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Okimoto N, 1998, BONE, V22, P523, DOI 10.1016/S8756 3282(98)00024 6
   Orwoll E, 2003, J BONE MINER RES, V18, P9, DOI 10.1359/jbmr.2003.18.1.9
   Park YS, 2005, CLIN ORAL IMPLAN RES, V16, P156, DOI 10.1111/j.1600 0501.2004.01083.x
   Peng ZQ, 1999, J BONE MINER RES, V14, P616, DOI 10.1359/jbmr.1999.14.4.616
   Ruegsegger P, 1996, CALCIFIED TISSUE INT, V58, P24, DOI 10.1007/s002239900006
   SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180
   Shirota T, 2003, J ORAL MAXIL SURG, V61, P471, DOI 10.1053/joms.2003.50093
   Silva MJ, 1997, BONE, V21, P191, DOI 10.1016/S8756 3282(97)00100 2
   Solomon DH, 2009, CURR OPIN RHEUMATOL, V21, P363, DOI 10.1097/BOR.0b013e32832ca433
   Stewart AF, 2000, J BONE MINER RES, V15, P1517, DOI 10.1359/jbmr.2000.15.8.1517
   Takano Y, 1996, J BONE MINER RES, V11, P169
   Terry Canale S., 2003, CAMPBELLS OPERATIVE, V10th
   Trisi P, 1999, INT J ORAL MAX IMPL, V14, P689
   Wennerberg A, 1996, J BIOMED MATER RES, V30, P251, DOI 10.1002/(SICI)1097 4636(199602)30:2<251::AID JBM16>3.0.CO;2 P
   WONG M, 1995, J BIOMED MATER RES, V29, P1567, DOI 10.1002/jbm.820291213
   WRONSKI TJ, 1993, ENDOCRINOLOGY, V132, P823, DOI 10.1210/en.132.2.823
   Yamazaki M, 1999, ORAL SURG ORAL MED O, V87, P411, DOI 10.1016/S1079 2104(99)70239 8
   Yao W, 2005, OSTEOPOROSIS INT, V16, P1939, DOI 10.1007/s00198 005 1969 2
NR 64
TC 64
Z9 70
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD MAR
PY 2010
VL 25
IS 3
BP 575
EP 583
DI 10.1359/jbmr.090808
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 584QP
UT WOS:000276767700019
PM 19653813
DA 2025 08 17
ER

PT J
AU Lietman, SA
   Levine, MA
AF Lietman, Steven A.
   Levine, Michael A.
TI Fibrous Dysplasia
SO PEDIATRIC ENDOCRINOLOGY REVIEWS PER
LA English
DT Article
DE McCune Albright syndrome; GNAS; bisphosphonates; denosumab;
   Wnt/beta catenin pathway; gsp mutation
AB Fibrous dysplasia is a developmental abnormality of bone that is characterized by a highly disorganized mixture of immature fibrous tissue and fragments of immature trabecular bone. Fibrous dysplasia may arise as a single, discrete (monostotic) lesion or can occur with a more widespread distribution with multiple lesions that affect many bones (oligo  or polyostotic). Fibrous dysplasia is usually an isolated skeletal finding but can sometimes occur as a component of a multisystem developmental disorder known as McCune Albright syndrome (MAS) that is also associated with endocrine hyperfunction (e.g. precocious puberty) and cafe au lait cutaneous macules. The identification of activating mutations in GNAS in a subset of human GH secreting pituitary tumors and autonomously functioning human thyroid tumors provided the initial basis for understanding the molecular pathophysiology of McCune Albright syndrome and fibrous dysplasia. These observations led to the concept that activating mutations of the GNAS gene convert it into a putative oncogene referred to as gsp (Gsa or Gas). The classic radiographic feature of fibrous dysplasia is a hazy, radiolucent, or ground glass, pattern resulting from the defective mineralization of immature dysplastic bone; it is usually strikingly different from the radiographic appearance of normal bone, calcified cartilage, or soft tissue. The surgical approach to fibrous dysplasia should in general be conservative. Recent research suggests that the Wnt/beta catenin pathway may play a role in fibrous dysplasia as patients with activating GNAS mutations specifically showed that Gas mutations activated Wnt/beta catenin signaling. Thus inhibition of beta catenin signaling or silencing GNAS alleles that encode constitutively active Gsa molecules in fibrous dysplasia and McCune Albright syndrome offer potential therapeutic promise and deserve further study. In summary fibrous dysplasia is a developmental abnormality of bone with a known molecular etiology; Further knowledge about the molecular pathology of fibrous dysplasia may lead to improved conservative therapies in the near future.
C1 [Lietman, Steven A.] Cleveland Clin, Musculoskeletal Tumor Ctr, Main Campus Mail Code A41,9500 Euclid Ave, Cleveland, OH 44195 USA.
   [Levine, Michael A.] Childrens Hosp Philadelphia, Div Endocrinol & Diabet, Philadelphia, PA 19104 USA.
   [Levine, Michael A.] Childrens Hosp Philadelphia, Ctr Bone Hlth, Philadelphia, PA 19104 USA.
   [Levine, Michael A.] Univ Penn, Pediat & Med, Perelman Sch Med, Philadelphia, PA 19104 USA.
C3 Cleveland Clinic Foundation; University of Pennsylvania; Pennsylvania
   Medicine; Childrens Hospital of Philadelphia; University of
   Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia;
   University of Pennsylvania
RP Lietman, SA (通讯作者)，Cleveland Clin, Musculoskeletal Tumor Ctr, Main Campus Mail Code A41,9500 Euclid Ave, Cleveland, OH 44195 USA.
EM LIETMAS@ccf.org
RI ; Levine, Michael/JED 8261 2023
OI Levine, Michael/0000 0003 0036 7809; 
CR Akintoye SO, 2006, J CLIN ENDOCR METAB, V91, P2960, DOI 10.1210/jc.2005 2661
   Amit M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025179
   Ashcroft AJ, 2003, IMMUNITY, V19, P849, DOI 10.1016/S1074 7613(03)00326 1
   Bastepe M, 2004, P NATL ACAD SCI USA, V101, P14794, DOI 10.1073/pnas.0405091101
   Bhattacharyya N, 2012, J BONE MINER RES, V27, P1132, DOI 10.1002/jbmr.1546
   Bianco P, 1998, J CLIN INVEST, V101, P1737, DOI 10.1172/JCI2361
   Boyce AM, 2012, J BONE MINER RES, V27, P1462, DOI 10.1002/jbmr.1603
   CANDELIERE GA, 1995, NEW ENGL J MED, V332, P1546, DOI 10.1056/NEJM199506083322304
   Candeliere GA, 1997, BONE, V21, P201, DOI 10.1016/S8756 3282(97)00107 5
   Chanson Philippe, 2007, Pediatr Endocrinol Rev, V4 Suppl 4, P453
   Chao K, 2008, J NEUROSURG, V109, P889, DOI 10.3171/JNS/2008/109/11/0889
   Chapurlat RD, 1997, J BONE MINER RES, V12, P1746, DOI 10.1359/jbmr.1997.12.10.1746
   Collins MT, 2006, J BONE MINER RES, V21, pP99, DOI 10.1359/JBMR.06S219
   Collins MT, 2001, J BONE MINER RES, V16, P806, DOI 10.1359/jbmr.2001.16.5.806
   DiCaprio MR, 2005, J BONE JOINT SURG AM, V87A, P1848, DOI 10.2106/JBJS.D.02942
   Drezner MK, 1999, J BONE MINER RES, V14, P2, DOI 10.1359/jbmr.1999.14.1.2
   ECONS MJ, 1994, BONE MINER, V24, P17, DOI 10.1016/S0169 6009(08)80127 4
   ECONS MJ, 1994, NEW ENGL J MED, V330, P1679, DOI 10.1056/NEJM199406093302310
   Germain Lee EL, 2002, BIOCHEM BIOPH RES CO, V296, P67, DOI 10.1016/S0006 291X(02)00833 1
   Hannon TS, 2003, J PEDIATR US, V142, P532, DOI 10.1067/mpd.2003.153
   HAPPLE R, 1986, CLIN GENET, V29, P321
   Idowu BD, 2007, HISTOPATHOLOGY, V50, P691, DOI 10.1111/j.1365 2559.2007.02676.x
   Imel EA, 2007, J BONE MINER RES, V22, P520, DOI 10.1359/JBMR.070107
   Ippolito E, 2003, J PEDIATR ORTHOP B, V12, P155, DOI 10.1097/00009957 200305000 00001
   JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100
   Karadag A, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh059
   KEHLENBACH RH, 1994, NATURE, V372, P804
   KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1
   Kochar IP, INDIAN PEDIATR, V47, P633
   Kumar D, 1997, AM J MED GENET, V70, P107, DOI 10.1002/(SICI)1096 8628(19970516)70:2<107::AID AJMG1>3.0.CO;2 V
   Kuznetsov SA, 2008, J BONE MINER RES, V23, P1731, DOI 10.1359/JBMR.080609
   Kuznetsov SA, 2008, BIOMATERIALS, V29, P4211, DOI 10.1016/j.biomaterials.2008.07.013
   Lala Roberto, 2007, Pediatr Endocrinol Rev, V4 Suppl 4, P423
   LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0
   Lane JM, 2001, CLIN ORTHOP RELAT R, P6
   Liang Q, 2011, J MOL DIAGN, V13, P137, DOI 10.1016/j.jmoldx.2010.10.003
   Lietman SA, 2005, J BONE JOINT SURG AM, V87A, P2489, DOI 10.2106/JBJS.E.00160
   Linglart AS, 2006, ENDOCRINOLOGY, V147, P2253, DOI 10.1210/en.2005 1487
   Liu B, 2003, J ORAL PATHOL MED, V32, P367, DOI 10.1034/j.1600 0714.2003.00126.x
   Liu J, 2003, J CLIN ENDOCR METAB, V88, P4336, DOI 10.1210/jc.2003 030393
   LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665
   MALCHOFF CD, 1994, J CLIN ENDOCR METAB, V78, P803, DOI 10.1210/jc.78.3.803
   Mandrioli S, 1998, Minerva Stomatol, V47, P37
   Mariot V, 2011, BONE, V48, P312, DOI 10.1016/j.bone.2010.09.032
   Mazabraud A, 1967, Presse Med, V75, P2223
   McCune DJ, 1937, AM J DIS CHILD, V54, P806, DOI 10.1001/archpedi.1937.01980040110009
   Michienzi S, 2007, HUM MOL GENET, V16, P1921, DOI 10.1093/hmg/ddm139
   Motomura T, 1998, J BONE MINER RES, V13, P1084, DOI 10.1359/jbmr.1998.13.7.1084
   Murdock Deborah G, 2002, Methods Mol Biol, V208, P145
   ORUM H, 1993, NUCLEIC ACIDS RES, V21, P5332, DOI 10.1093/nar/21.23.5332
   Pfeilschifter J, 1998, MED KLIN, V93, P352, DOI 10.1007/BF03044679
   Piersanti S, 2010, J BONE MINER RES, V25, P1103, DOI 10.1359/jbmr.091036
   Plotkin H, 2003, J CLIN ENDOCR METAB, V88, P4569, DOI 10.1210/jc.2003 030050
   Regard JB, 2011, P NATL ACAD SCI USA, V108, P20101, DOI 10.1073/pnas.1114656108
   Riminucci M, 1999, J BONE MINER RES, V14, P1987, DOI 10.1359/jbmr.1999.14.11.1987
   Riminucci M, 1997, AM J PATHOL, V151, P1587
   Riminucci M, 2003, J CLIN INVEST, V112, P683, DOI 10.1172/JC120031899
   ROODMAN GD, 1992, J CLIN INVEST, V89, P46, DOI 10.1172/JCI115584
   Sakamoto A, 2005, J BONE MINER RES, V20, P663, DOI 10.1359/JBMR.041210
   SHENKER A, 1994, J CLIN ENDOCR METAB, V79, P750, DOI 10.1210/jc.79.3.750
   Sundaram M., 2006, J BONE MINER RES, P28
   Wold LE, 1990, Atlas of Orthopedic Pathology
   YABUT SM, 1988, CLIN ORTHOP RELAT R, P281
   ZUNG A, 1995, J CLIN ENDOCR METAB, V80, P3576, DOI 10.1210/jc.80.12.3576
NR 64
TC 15
Z9 16
U1 0
U2 3
PU MEDICAL MEDIA
PI NETANYA
PA PO BOX 8214, NETANYA, 4250543, ISRAEL
SN 1565 4753
J9 PEDIATR ENDOCR REV P
JI Pediatr. Endocrinol. Rev. PER
PD JUN
PY 2013
VL 10
SU 2
BP 389
EP 396
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA VK4GX
UT WOS:000695858400006
PM 23858622
DA 2025 08 17
ER

PT J
AU Mattheos, N
   Caldwell, P
   Petcu, EB
   Ivanovski, S
   Reher, P
AF Mattheos, Nikos
   Caldwell, Patrick
   Petcu, Eugen B.
   Ivanovski, Saso
   Reher, Peter
TI Dental Implant Placement with Bone Augmentation in a Patient Who
   Received Intravenous Bisphosphonate Treatment for Osteoporosis
SO JOURNAL OF THE CANADIAN DENTAL ASSOCIATION
LA English
DT Article
ID ORAL BISPHOSPHONATES; ZOLEDRONIC ACID; RISK FACTORS; OSTEONECROSIS; JAW;
   CANCER; ALENDRONATE; PREVENTION; EXPERIENCE; THERAPY
AB Intravenous (IV) administration of bisphosphonates has been considered an absolute contraindication for placement of dental implants, because of the increased risk of bisphosphonate related osteonecrosis of the jaw (BRONJ). However, the evidence regarding this association originates from patients being treated for various forms of metastatic cancer. In the case reported here, a patient received a dental implant while undergoing IV treatment with zoledronic acid for osteoporosis. The authors discuss the current evidence regarding the risks of dental procedures in patients receiving IV bisphosphonates for this indication. They also evaluate important risk factors and the decision making pathway in such cases. On the basis of existing evidence, receipt of a single IV infusion of zoledronic acid for the treatment of osteoporosis does not appear to be an absolute contraindication to implant placement.
   Bisphosphonates reduce or even suppress osteoclast function and can therefore be used to treat various disorders that cause abnormal bone resorption. In the 1980's, bisphosphonates administered by the intravenous (IV) route were initially used for the treatment of malignancies affecting the bone tissue, such as multiple myeloma and bone metastases of breast and prostate cancer.(1,2) However, the relatively recent introduction of IV bisphosphonates for the treatment and prevention of osteoporosis has expanded the application of these medications to a significant proportion of the adult population. (3) Loss of osseointegrated implants in association with bisphosphonate therapy was reported as early as 1995.(4) Not surprisingly, early studies focused on positive outcomes from the use of these drugs in conjunction with implant therapy, such as increasing the contact between bone and implant.(5,6) The possibility of a connection between use of bisphosphonates for cancer therapy and osteonecrosis of the jaw bones was first raised in 2003.(7) Further studies in cancer patients confirmed the association between IV treatment with bisphosphonates and the condition later described as bisphosphonate related osteonecrosis of the jaw (BRONJ).(8 10) However, this association appears less clear where bisphosphonates are used for treatment or prevention of osteoporosis. Treatment of osteopenia and osteoporosis involves a much lower cumulative dosage than is the case for cancer therapy. Typically, the required dosage has been achieved by systemic oral administration, but IV administration is increasingly the treatment of choice.(11,12)
   Numerous papers in the dental literature have examined the risks of invasive dental procedures in patients being treated with oral bisphosphonates and have concluded that dental procedures are not contraindicated for such patients,(13) the evidence being stronger for treatment of less than 5 years' duration.(14) In the case of IV administration, the few papers that have discussed this subject have usually considered this form of therapy to be an absolute contraindication for dental procedures, especially elective surgery(15,16) such as dental implants. However, this conclusion is based on published research for patients with cancer and does not differentiate on the basis of purpose of treatment, type of medication, cumulative dose or duration of treatment.
   The current manuscript describes a patient who was receiving treatment with IV bisphosphonates for osteoporosis and who was a candidate for dental implant placement and reviews the underlying evidence to support decision making and treatment planning in similar cases.
C1 [Mattheos, Nikos] Univ Hong Kong, Fac Dent, Hong Kong, Hong Kong, Peoples R China.
   [Petcu, Eugen B.; Ivanovski, Saso; Reher, Peter] Griffith Univ, Sch Dent & Oral Hlth, Gold Coast, Qld, Australia.
C3 University of Hong Kong; Griffith University; Griffith University   Gold
   Coast Campus
RP Mattheos, N (通讯作者)，Univ Hong Kong, Fac Dent, HKU, Prince Philip Dent Hosp, Block A,4 F,34 Hosp Rd, Hong Kong, Hong Kong, Peoples R China.
EM nikos@mattheos.net
RI Petcu, Eugen/C 3824 2011; Ivanovski, Saso/I 1835 2016; Mattheos,
   Nikos/C 8614 2011
OI Petcu, Eugen/0000 0001 5726 729X; Mattheos, Nikos/0000 0001 7358 7496;
   Reher, Peter/0000 0002 4444 125X
CR Assael LA, 2009, J ORAL MAXIL SURG, V67, P35, DOI 10.1016/j.joms.2009.01.003
   Bamias A, 2005, J CLIN ONCOL, V23, P8580, DOI 10.1200/JCO.2005.02.8670
   Bell BM, 2008, J ORAL MAXIL SURG, V66, P1022, DOI 10.1016/j.joms.2007.12.040
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Carmagnola D, 2008, ORAL SURG ORAL MED O, V106, pE10, DOI 10.1016/j.tripleo.2008.07.011
   Carmona R, 2009, PATIENT PREFER ADHER, V3, P189
   Dimopoulos MA, 2006, HAEMATOL HEMATOL J, V91, P968
   Fleisher KE, 2010, ORAL SURG ORAL MED O, V110, P509, DOI 10.1016/j.tripleo.2010.04.023
   Heikkinen JE, 1997, J BONE MINER RES, V12, P103, DOI 10.1359/jbmr.1997.12.1.103
   Hoff AO, 2008, J BONE MINER RES, V23, P826, DOI [10.1359/JBMR.080205, 10.1359/jbmr.080205]
   Hubner RA, 2005, HOSP MED, V66, P414
   Huja SS, 2011, ANGLE ORTHOD, V81, P363, DOI 10.2319/070710 384.1
   Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941
   Madrid C, 2009, CLIN ORAL IMPLAN RES, V20, P87, DOI 10.1111/j.1600 0501.2009.01772.x
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Marx RE, 2007, J ORAL MAXIL SURG, V65, P2397, DOI 10.1016/j.joms.2007.08.003
   Meraw SJ, 1999, J PERIODONTOL, V70, P1228, DOI 10.1902/jop.1999.70.10.1228
   Meraw SJ, 1999, J PERIODONTOL, V70, P151, DOI 10.1902/jop.1999.70.2.151
   Serra MPM, 2008, MED ORAL PATOL ORAL, V13, pE755
   Montefusco V, 2008, LEUKEMIA LYMPHOMA, V49, P2156, DOI 10.1080/10428190802483778
   Narongroeknawin P, 2010, SPEC CARE DENT, V30, P77, DOI 10.1111/j.1754 4505.2009.00128.x
   Ngamphaiboon N, 2011, CLIN BREAST CANCER, V11, P252, DOI 10.1016/j.clbc.2011.02.001
   Nicolatou Galitis O, 2011, ORAL SURG ORAL MED O, V112, P195, DOI 10.1016/j.tripleo.2011.02.037
   Pirih Flavia Q, 2009, J Mich Dent Assoc, V91, P38
   Ripamonti CI, 2009, ANN ONCOL, V20, P137, DOI 10.1093/annonc/mdn526
   Ruggiero SL, 2006, ORAL SURG ORAL MED O, V102, P433, DOI 10.1016/j.tripleo.2006.06.004
   Ruggiero SL, 2009, AUST ENDOD J, V35, P119, DOI 10.1111/j.1747 4477.2009.00213.x
   Scully Crispian, 2006, Implant Dent, V15, P212, DOI 10.1097/01.id.0000236120.22719.02
   SHANE E, 1982, AM J MED, V72, P939, DOI 10.1016/0002 9343(82)90855 5
   Shannon J, 2011, J AM GERIATR SOC, V59, P2350, DOI 10.1111/j.1532 5415.2011.03713.x
   Starck W J, 1995, Int J Oral Maxillofac Implants, V10, P74
   Tong ACK, 2010, ORAL SURG ORAL MED O, V109, P238, DOI 10.1016/j.tripleo.2009.08.044
   Torres J, 2009, ORAL SURG ORAL MED O, V107, P387, DOI 10.1016/j.tripleo.2008.11.024
NR 33
TC 9
Z9 10
U1 0
U2 18
PU CANADIAN DENTAL ASSOC
PI OTTAWA
PA 1815 ALTA VISTA DRIVE, OTTAWA, ON K1G 3Y6, CANADA
SN 1488 2159
J9 J CAN DENT ASSOC
JI J. Can. Dent. Assoc.
PD MAR 20
PY 2013
VL 79
AR d2
PG 10
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 163GP
UT WOS:000320324300001
PM 23763726
DA 2025 08 17
ER

PT J
AU Deng, XH
   Lin, BF
   Wang, F
   Xu, PC
   Wang, NN
AF Deng, Xuehui
   Lin, Bingfeng
   Wang, Fang
   Xu, Pingcui
   Wang, Nani
TI Mangiferin attenuates osteoporosis by inhibiting osteoblastic
   ferroptosis through Keap1/Nrf2/SLC7A11/GPX4 pathway
SO PHYTOMEDICINE
LA English
DT Article
DE Osteoporosis; Mangiferin; Ferroptosis; SLC7A11; GPX4; Osteoblast
ID OXIDATIVE STRESS
AB Background: Ferroptosis is a crucial contributor to impaired osteoblast function in osteoporosis. Mangiferin, a xanthonoid glucoside isolated from mangoes, exhibits anti osteoporosis effects. However, its potential mechanism is not fully understood.
   Purpose: This study explores the potencies of mangiferin on osteoblastic ferroptosis and deciphers its direct target in the context of solute carrier family 7 member 11 (SLC7A11)/glutathione peroxidases 4 (GPX4) pathway.
   Methods: In vivo models include bilateral ovariectomy induced osteoporosis mice, iron dextran induced ironoverloaded mice, and nuclear factor erythroid 2 related factor 2 (Nrf2) knockout mice. Mice are orally administrated mangiferin (10, 50 or 100 mg.kg( 1).d( 1)) for 12 weeks. In vitro osteoblast models include iron dextran induced iron overloaded cells, erastin induced ferroptosis cells, and gene knockout cells. RNA sequencing is applied for investigating the underlying mechanisms. The direct target of mangiferin is studied using a cellular thermal shift assay, silico docking, and surface plasmon resonance.
   Results: Mangiferin promotes bone formation and inhibits ferroptosis in vivo models (osteoporosis mice, ironoverloaded mice) and in vitro models (ferroptosis osteoblast, iron overloaded osteoblasts). Mechanismly, mangiferin directly binds to the kelch like ECH associated protein 1 (Keap1) and activates the downstream Nrf2/SLC7A11/GPX4 pathway in both the in vivo and in vitro models. Mangiferin failed to restore the osteoporosis and ferroptosis in Nrf2 knockout mice. Silencing Nrf2, SLC7A11 or GPX4 abolished the anti ferroptosis effect of mangiferin in erastin induced cells. Addition of the ferroptosis agonist RSL 3 also blocked the protective effects of mangiferin on iron overloaded cells. Furthermore, mangiferin had better effects on osteogenesis than the ferroptosis inhibitor (ferrostatin 1) and the Nrf2 agonists (sulforaphane, dimethyl fumarate, and bardoxolone).
   Conclusions: We identify for the first time mangiferin as a ferroptosis inhibitor and a direct Keap1 conjugator that promotes bone formation and alleviates osteoporosis. This work also provides a potentially practical pharmacological approach for treating ferroptosis driven diseases.
C1 [Deng, Xuehui; Wang, Fang; Wang, Nani] Zhejiang Chinese Med Univ, Sch Pharm, Hangzhou 311402, Zhejiang, Peoples R China.
   [Lin, Bingfeng; Xu, Pingcui; Wang, Nani] Zhejiang Acad Tradit Chinese Med, Dept Med, Hangzhou 310007, Zhejiang, Peoples R China.
   [Wang, Nani] Zhejiang Acad Tradit Chinese Med, Dept Med, 132 Tianmushan Rd, Hangzhou 310007, Zhejiang, Peoples R China.
C3 Zhejiang Chinese Medical University
RP Wang, NN (通讯作者)，Zhejiang Acad Tradit Chinese Med, Dept Med, 132 Tianmushan Rd, Hangzhou 310007, Zhejiang, Peoples R China.
EM wnn8511@163.com
OI Wang, Nani/0000 0003 0748 0222
FU National Natural Science Foundation of China [82374012, 81973447];
   Zhejiang Provincial Natural Science Foundation of China [LY21H280001,
   2021C03047]; Zhejiang Provincial Medicine Foundation [2021ZQ018,
   2022ZX002, 2021ZYY28, GZY ZJ KJ 23006]
FX This work was supported by the National Natural Science Foundation of
   China [grant number 82374012, 81973447] ; Zhejiang Provincial Natural
   Science Foundation of China [grant number LY21H280001, 2021C03047] ;
   Zhejiang Provincial Medicine Foundation [grant number 2021ZQ018,
   2022ZX002, 2021ZYY28, GZY ZJ KJ 23006] .
CR Andreu GP, 2005, PHARMACOL RES, V51, P427, DOI 10.1016/j.phrs.2004.11.002
   Bertolini F, 2007, J PHARM SCI US, V96, P2931, DOI 10.1002/jps.20881
   Deardorff WJ, 2022, JAMA INTERN MED, V182, P33, DOI 10.1001/jamainternmed.2021.6745
   Ding LZ, 2018, INT J MOL MED, V41, P2517, DOI 10.3892/ijmm.2018.3506
   Dodson M, 2019, REDOX BIOL, V23, DOI 10.1016/j.redox.2019.101107
   Dong H, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 04307 1
   Dong XR, 2022, ACUPUNCT HERB MED, V2, P130, DOI 10.1097/HM9.0000000000000031
   du Sert NP, 2020, J CEREBR BLOOD F MET, V40, P1769, DOI [10.1186/s12917 020 02451 y, 10.1371/journal.pbio.3000410, 10.1177/0271678X20943823]
   Feng ST, 2019, PHARMACOL RES, V146, DOI 10.1016/j.phrs.2019.104336
   Gan L, 2022, EUR J PHARMACOL, V927, DOI 10.1016/j.ejphar.2022.174954
   Gao J, 2018, CELL DEATH DIFFER, V25, P229, DOI 10.1038/cdd.2017.144
   Gao ZH, 2022, EXP GERONTOL, V165, DOI 10.1016/j.exger.2022.111836
   Geng QH, 2019, INT J BIOL SCI, V15, P58, DOI 10.7150/ijbs.25783
   Giacomino CM, 2019, J ENDODONT, V45, P51, DOI 10.1016/j.joen.2018.08.007
   Hu YX, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.986384
   Jain AD, 2015, EUR J MED CHEM, V103, P252, DOI 10.1016/j.ejmech.2015.08.049
   Jayasuriya R, 2021, PHYTOMEDICINE, V92, DOI 10.1016/j.phymed.2021.153755
   Jeney V, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00077
   Kato I, 2000, INT J VITAM NUTR RES, V70, P119, DOI 10.1024/0300 9831.70.3.119
   Kim C, 2012, J WOMENS HEALTH, V21, P872, DOI 10.1089/jwh.2012.3549
   Koppula P, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 29905 1
   Koppula P, 2021, PROTEIN CELL, V12, P599, DOI 10.1007/s13238 020 00789 5
   Liu CT, 2023, ADV SCI, V10, DOI 10.1002/advs.202301136
   Park MW, 2021, REDOX BIOL, V41, DOI 10.1016/j.redox.2021.101947
   Piwowar A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072510
   Popovic Z, 2021, PLANTS BASEL, V10, DOI 10.3390/plants10010140
   Ramesh P, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.779638
   Samadarsi R, 2020, INT J BIOL MACROMOL, V151, P36, DOI 10.1016/j.ijbiomac.2020.02.112
   Song JN, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104845
   Song SS, 2022, PHARMACOL THERAPEUT, V237, DOI 10.1016/j.pharmthera.2022.108168
   Sykiotis GP, 2021, ANTIOXIDANTS BASEL, V10, DOI 10.3390/antiox10060828
   Szandruk M, 2018, INFLAMMOPHARMACOLOGY, V26, P571, DOI 10.1007/s10787 017 0337 0
   Tang DL, 2020, CURR BIOL, V30, pR1292, DOI 10.1016/j.cub.2020.09.068
   Wang X, 2022, ACTA PHARM SIN B, V12, P708, DOI 10.1016/j.apsb.2021.10.005
   Wang YL, 2022, CELL DEATH DIFFER, V29, P1982, DOI 10.1038/s41418 022 00990 5
   Xia G, 2017, BIOCHEM BIOPH RES CO, V491, P807, DOI 10.1016/j.bbrc.2017.06.184
   Xu PC, 2022, FREE RADICAL BIO MED, V193, P720, DOI 10.1016/j.freeradbiomed.2022.11.013
   Xu YX, 2021, PHYTOMEDICINE, V85, DOI 10.1016/j.phymed.2021.153485
   Yamamoto M, 2018, PHYSIOL REV, V98, P1169, DOI 10.1152/physrev.00023.2017
   Yang YQ, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00198 w
   Yuan L, 2022, CELL DEATH DIFFER, V29, P1513, DOI 10.1038/s41418 022 00939 8
   Zhao J, 2014, INT J MOL MED, V33, P1348, DOI 10.3892/ijmm.2014.1696
   Zhu RJ, 2022, STEM CELLS INT, V2022, DOI 10.1155/2022/9359429
NR 43
TC 28
Z9 30
U1 18
U2 55
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0944 7113
EI 1618 095X
J9 PHYTOMEDICINE
JI Phytomedicine
PD FEB
PY 2024
VL 124
AR 155282
DI 10.1016/j.phymed.2023.155282
EA JAN 2024
PG 14
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA GR4O5
UT WOS:001154387700001
PM 38176266
DA 2025 08 17
ER

PT J
AU Qi, J
   Chi, LQ
   Wang, J
   Sumanasinghe, R
   Wall, M
   Tsuzaki, M
   Banes, AJ
AF Qi, Jie
   Chi, Liqun
   Wang, Jian
   Sumanasinghe, Ruwan
   Wall, Michelle
   Tsuzaki, Mari
   Banes, Albert J.
TI Modulation of collagen gel compaction by extracellular ATP is MAPK and
   NF κB pathways dependent
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE ATP; Collagen gel; P2 receptor; bone; NF kappa B; MAPK; Prestress
ID ACTIVATED PROTEIN KINASE; LIGHT CHAIN KINASE; LATTICE CONTRACTION;
   ADENINE NUCLEOTIDES; FLUID SHEAR; IN VITRO; BIOARTIFICIAL TENDONS; WOUND
   CONTRACTION; GENE EXPRESSION; GROWTH FACTOR
AB Understanding the mechanisms that regulate mechanosensitivity in osteoblasts is important for controlling bone homeostasis and the development of new drugs to combat bone loss. It is believed that prestress or force generation (the tensile stress within the cell body) plays an important role in regulating cellular mechanosensitivity. In the present study, a three dimensional (3D) collagen culture was used to monitor the change in prestress of the osteoblast like cells. Collagen hydrogel compaction has been used as an indicator of the change in the degree of cell prestress. Previous results in this model demonstrated that extracellular ATP reduced the mechanosensitivity of osteoblasts by reducing cellular prestress. To elucidate the potential mechanisms involved in this process, the signaling pathways downstream of P2 purinoceptors involved in regulating the compaction of type I collagen gels were investigated. By using specific inhibitors to these signaling pathways, we found that ATP induced reduction in collagen gel compaction rate is dependent on mitogen activated protein kinase (MAKP) and NF kappa B pathways. However, blocking protein kinase C with GF109203X did not change the compaction kinetics in the presence of ATP gamma S. Moreover, blocking cyclic AMP (cAMP), phosphatidylinositol 3 kinase (PI3K), calmodulin (CaM) or L type voltage sensitive calcium channels did not affect ATP's ability to reduce Collagen gel compaction. The results from the present and previous studies indicate that extracellular ATP may act as a negative feedback modulator in the mechanotransduction system since mechanical stimuli increase ATP release from stimulated cells. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Qi, Jie; Chi, Liqun; Wang, Jian; Sumanasinghe, Ruwan; Wall, Michelle; Tsuzaki, Mari; Banes, Albert J.] Flexcell Int Corp, Hillsborough, NC 27278 USA.
   [Qi, Jie; Banes, Albert J.] Joint Dept Biomed Engn N Carolina Chapel Hill, Raleigh, NC USA.
   [Qi, Jie; Banes, Albert J.] N Carolina State Univ, Raleigh, NC 27695 USA.
   [Banes, Albert J.] Univ N Carolina, Chapel Hill, NC 27599 USA.
C3 North Carolina State University; University of North Carolina;
   University of North Carolina Chapel Hill
RP Qi, J (通讯作者)，Flexcell Int Corp, 437 Dimmocks Mill Rd,Suite 28, Hillsborough, NC 27278 USA.
EM jie@flexcellint.com
FU Flexcell International Corporation
FX Disclosure: Dr. Albert J. Banes is the president of Flexcell
   International Corporation and receives compensation as such.
CR Alenghat FJ, 2004, EXP CELL RES, V301, P23, DOI 10.1016/j.yexcr.2004.08.003
   Archambault J, 2002, J ORTHOPAED RES, V20, P36, DOI 10.1016/S0736 0266(01)00075 4
   BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.iy.12.040194.001041
   Bando H, 2006, EXP EYE RES, V82, P529, DOI 10.1016/j.exer.2005.08.014
   Banes AJ, 1995, BIOCHEM CELL BIOL, V73, P349, DOI 10.1139/o95 043
   Biswas G, 2003, J CELL BIOL, V161, P507, DOI 10.1083/jcb.200211104
   Bowler WB, 2001, BONE, V28, P507, DOI 10.1016/S8756 3282(01)00430 6
   Burnstock G, 2007, CELL MOL LIFE SCI, V64, P1471, DOI 10.1007/s00018 007 6497 0
   CAMPBELL CG, 1993, J BIOL CHEM, V268, P15399
   Carlson MA, 2004, WOUND REPAIR REGEN, V12, P134, DOI 10.1111/j.1067 1927.2004.012208.x
   Cerovac Z, 1999, NEUROCHEM INT, V34, P337, DOI 10.1016/S0197 0186(99)00018 2
   Chen CS, 1999, OSTEOARTHR CARTILAGE, V7, P81, DOI 10.1053/joca.1998.0164
   CHEN JK, 1993, J CELL PHYSIOL, V155, P8, DOI 10.1002/jcp.1041550103
   Communi D, 2000, CELL SIGNAL, V12, P351, DOI 10.1016/S0898 6568(00)00083 8
   Dignass AU, 1998, EUR J CLIN INVEST, V28, P554
   DUCY F, 1996, NATURE, V382, P448
   EHRLICH HP, 1991, J CELL PHYSIOL, V146, P1, DOI 10.1002/jcp.1041460102
   EHRLICH HP, 1986, J CELL SCI, V82, P281
   Elfervig MK, 2001, OSTEOARTHR CARTILAGE, V9, P518, DOI 10.1053/joca.2000.0435
   Erb L, 2006, PFLUG ARCH EUR J PHY, V452, P552, DOI 10.1007/s00424 006 0069 2
   Feng CL, 2004, J IMMUNOL, V173, P7539, DOI 10.4049/jimmunol.173.12.7539
   Ferrari D, 1997, J CELL BIOL, V139, P1635, DOI 10.1083/jcb.139.7.1635
   Ferri N, 2003, J BIOL CHEM, V278, P19757, DOI 10.1074/jbc.M212714200
   FROST HM, 1987, ANAT RECORD, V219, P1, DOI 10.1002/ar.1092190104
   FROST HM, 1992, J BONE MINER RES, V7, P253
   Fung Y C., 1993, Biomechanics: Mechanical Properties of Living Tissues, V2
   Garvin J, 2003, TISSUE ENG, V9, P967, DOI 10.1089/107632703322495619
   Gerstenfeld LC, 1999, J BONE MINER RES, V14, P850, DOI 10.1359/jbmr.1999.14.6.850
   Giannone G, 2006, TRENDS CELL BIOL, V16, P213, DOI 10.1016/j.tcb.2006.02.005
   GIETZEN K, 1982, BIOCHEM J, V207, P637, DOI 10.1042/bj2070637
   Graff RD, 2000, ARTHRITIS RHEUM US, V43, P1571, DOI 10.1002/1529 0131(200007)43:7<1571::AID ANR22>3.0.CO;2 L
   Grinnell F, 2000, TRENDS CELL BIOL, V10, P362, DOI 10.1016/S0962 8924(00)01802 X
   Grinnell F, 1999, J BIOL CHEM, V274, P918, DOI 10.1074/jbc.274.2.918
   GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401
   Gross TS, 2005, J BONE MINER RES, V20, P250, DOI 10.1359/JBMR.041004
   Ingber DE, 2003, J CELL SCI, V116, P1397, DOI 10.1242/jcs.00360
   Ingber DE, 2006, FASEB J, V20, P811, DOI 10.1096/fj.05 5424rev
   Jeng JH, 2006, BRIT J PHARMACOL, V147, P188, DOI 10.1038/sj.bjp.0706462
   Kagami S, 2001, EXP CELL RES, V268, P274, DOI 10.1006/excr.2001.5279
   KIRKPATRICK KA, 1992, GEN PHARMACOL VASC S, V23, P1045, DOI 10.1016/0306 3623(92)90284 Q
   Lee YJ, 2005, AM J PHYSIOL CELL PH, V289, pC1268, DOI 10.1152/ajpcell.00002.2005
   Levinson H, 2004, WOUND REPAIR REGEN, V12, P505, DOI 10.1111/j.1067 1927.2004.012502.x
   Liu DW, 2008, BONE, V42, P644, DOI 10.1016/j.bone.2007.09.058
   Lova P, 2003, J BIOL CHEM, V278, P131, DOI 10.1074/jbc.M204821200
   LUTHJE J, 1989, KLIN WOCHENSCHR, V67, P317, DOI 10.1007/BF01741386
   Maaser K, 2002, BRIT J CANCER, V86, P636, DOI 10.1038/sj.bjc.6600100
   Malone AMD, 2007, P NATL ACAD SCI USA, V104, P13325, DOI 10.1073/pnas.0700636104
   Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076
   Nauli SM, 2008, CIRCULATION, V117, P1161, DOI 10.1161/CIRCULATIONAHA.107.710111
   Ohsawa K, 2007, GLIA, V55, P604, DOI 10.1002/glia.20489
   Ostrom RS, 2000, J BIOL CHEM, V275, P11735, DOI 10.1074/jbc.275.16.11735
   PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585
   Parast MM, 2000, J CELL BIOL, V150, P643, DOI 10.1083/jcb.150.3.643
   Perkins ND, 2006, CELL DEATH DIFFER, V13, P759, DOI 10.1038/sj.cdd.4401838
   PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529
   PODRASKY E, 1997, AM J PHYSIOL HEART C, V273, pH2380
   Qi J, 2007, J APPL PHYSIOL, V102, P1152, DOI 10.1152/japplphysiol.00535.2006
   Qi J, 2006, TISSUE ENG, V12, P2913, DOI 10.1089/ten.2006.12.2913
   Qi J, 2006, J APPL PHYSIOL, V101, P189, DOI 10.1152/japplphysiol.01128.2005
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   SCAMPS F, 1992, J GEN PHYSIOL, V100, P675, DOI 10.1085/jgp.100.4.675
   Shimegi S, 1996, CALCIFIED TISSUE INT, V58, P109, DOI 10.1007/BF02529732
   Short SM, 2000, J BIOL CHEM, V275, P12970, DOI 10.1074/jbc.275.17.12970
   Stein GS, 1997, MOL BIOL REP, V24, P185, DOI 10.1023/A:1006803615430
   SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191
   Sumiyoshi K, 2003, BRIT J DERMATOL, V149, P464, DOI 10.1046/j.1365 2133.2003.05490.x
   TOULLEC D, 1991, J BIOL CHEM, V266, P15771
   TRANQUILLO RT, 1992, CYTOTECHNOLOGY, V10, P225, DOI 10.1007/BF00146673
   Triggle DJ, 2007, BIOCHEM PHARMACOL, V74, P1, DOI 10.1016/j.bcp.2007.01.016
   Tsuzaki M, 2003, J CELL BIOCHEM, V89, P556, DOI 10.1002/jcb.10534
   Tzima E, 2005, NATURE, V437, P426, DOI 10.1038/nature03952
   WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161
   Wang ZQ, 2008, J BIOL CHEM, V283, P21011, DOI 10.1074/jbc.M802229200
   Wen LT, 2003, BRIT J PHARMACOL, V140, P1009, DOI 10.1038/sj.bjp.0705523
   Wu S, 2007, J BIOL CHEM, V282, P33698, DOI 10.1074/jbc.M702991200
   Xu JH, 1998, J CELL BIOL, V140, P709, DOI 10.1083/jcb.140.3.709
   YAMADA M, 1992, CIRC RES, V70, P477, DOI 10.1161/01.RES.70.3.477
   Yamazaki S, 2003, J CELL BIOCHEM, V90, P812, DOI 10.1002/jcb.10681
   Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116
   Zhu C, 2000, ANNU REV BIOMED ENG, V2, P189, DOI 10.1146/annurev.bioeng.2.1.189
NR 80
TC 11
Z9 16
U1 0
U2 5
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0014 4827
J9 EXP CELL RES
JI Exp. Cell Res.
PD JUL 1
PY 2009
VL 315
IS 11
BP 1990
EP 2000
DI 10.1016/j.yexcr.2009.02.012
PG 11
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA 454BG
UT WOS:000266656000019
PM 19245806
DA 2025 08 17
ER

PT J
AU Rizzoli, R
AF Rizzoli, R.
TI Osteoporosis: non hormonal treatment
SO CLIMACTERIC
LA English
DT Article; Proceedings Paper
CT 7th Workshop of the International Menopause Society
CY FEB, 2007
CL Budapest, HUNGARY
SP Int Menopause Soc
DE osteoporosis; non hormonal treatment; bone formation stimulating agents;
   bisphosphonates; antiresorptive agents; denosumab; strontium ranelate
ID VITAMIN D SUPPLEMENTATION; POSTMENOPAUSAL WOMEN; VERTEBRAL FRACTURES;
   NONVERTEBRAL FRACTURES; RISK; ALENDRONATE; RISEDRONATE; METAANALYSIS;
   EFFICACY; CALCIUM
AB Significant progress has been achieved in osteoporosis treatment, in terms of agents with novel mechanisms of action, of new schedules of administration, and of long term treatment safety demonstration.
   Alendronate, ibandronate, intranasal calcitonin, parathyroid hormones, raloxifene, risedronate, hormone replacement therapy, strontium ranelate and zoledronate decrease the risk of vertebral fracture. Alendronate, risedronate, strontium ranelate and zoledronate reduce the risk of hip fracture in women with osteoporosis, hormone replacement therapy in postmenopausal women, and calcium and vitamin D in institutionalized patients.
   In two meta analyses, the combination of calcium and vitamin D was able to reduce the risk of falling, and hip fracture risk was decreased (> 700 IU/day). Two subsequently published large trials were unable to detect any antifracture effect. PTH(1 84) reduces the risk of new vertebral fracture. There is no indication that combining PTH with a bone resorption inhibitor has any additional benefit to either drug alone. Strontium ranelate is a new agent for the treatment of osteoporosis, with antifracture efficacy whatever the severity of osteoporosis. An extension of the phase 3 trials up to 5 years has shown sustained antifracture efficacy. The humanized monoclonal antibody to the receptor activator of nuclear factor kappa B ligand (RANKL) denosumab causes a rapid, high magnitude, dose dependent inhibition of bone resorption. Spine, hip and forearm bone mineral density increased, to an extent slightly higher than with the weekly administration of 70 mg alendronate.
C1 Univ Hosp, WHO, Collaborat Ctr Osteoporosis Prevent, Dept Rehabil & Geriat,Div Bone Dis, CH 1211 Geneva 14, Switzerland.
C3 World Health Organization; University of Geneva
RP Rizzoli, R (通讯作者)，Univ Hosp, WHO, Collaborat Ctr Osteoporosis Prevent, Dept Rehabil & Geriat,Div Bone Dis, CH 1211 Geneva 14, Switzerland.
CR Bischoff Ferrari HA, 2004, JAMA J AM MED ASSOC, V291, P1999, DOI 10.1001/jama.291.16.1999
   Bischoff Ferrari HA, 2005, JAMA J AM MED ASSOC, V293, P2257, DOI 10.1001/jama.293.18.2257
   Black DM, 2006, JAMA J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
   Black DM, 2005, NEW ENGL J MED, V353, P555, DOI 10.1056/NEJMoa050336
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Boonen S, 2006, J BONE MINER RES, V21, pS60
   Boonen S, 2004, J AM GERIATR SOC, V52, P1832, DOI 10.1111/j.1532 5415.2004.52506.x
   Boonen S, 2005, OSTEOPOROSIS INT, V16, P1291, DOI 10.1007/s00198 005 1945 x
   Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325
   Delmas PD, 2003, BONE, V33, P522, DOI 10.1016/S8756 3282(03)00241 2
   Delmas PD, 2006, ARTHRITIS RHEUM US, V54, P1838, DOI 10.1002/art.21918
   Grant AM, 2005, LANCET, V365, P1621, DOI 10.1016/S0140 6736(05)63013 9
   Jackson RD, 2006, NEW ENGL J MED, V354, P669, DOI 10.1056/NEJMoa055218
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   Reginster JY, 2006, OSTEOPOROSIS INT, V17, pS11
   Reginster JY, 2006, ANN RHEUM DIS, V65, P654, DOI 10.1136/ard.2005.044958
   Reginster JY, 2005, J CLIN ENDOCR METAB, V90, P2816, DOI 10.1210/jc.2004 1774
   Rosen CJ, 2005, J BONE MINER RES, V20, P141, DOI 10.1359/jbmr.2005.20.1.141
   Roux C, 2004, CURR MED RES OPIN, V20, P433, DOI 10.1185/030079903125003125
   Silverman SL, 2006, J BONE MINER RES, V21, pS173
   Silverman SL, 2007, OSTEOPOROSIS INT, V18, P25, DOI 10.1007/s00198 006 0274 z
   Solomon DH, 2004, AM J MED, V117, P919, DOI 10.1016/j.amjmed.2004.06.040
NR 23
TC 7
Z9 8
U1 0
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1369 7137
EI 1473 0804
J9 CLIMACTERIC
JI Climacteric
PD OCT
PY 2007
VL 10
SU 2
BP 74
EP 78
DI 10.1080/13697130701600815
PG 5
WC Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Obstetrics & Gynecology
GA 221MA
UT WOS:000250230800014
PM 17882678
DA 2025 08 17
ER

PT J
AU Zhang, Y
   Li, XH
   Peng, P
   Qiu, ZH
   Di, CX
   Chen, XF
   Wang, NN
   Chen, F
   He, YW
   Liu, ZB
   Zhao, F
   Zhu, DL
   Dong, SS
   Hu, SY
   Yang, Z
   Li, YP
   Guo, Y
   Yang, TL
AF Zhang, Yan
   Li, Xin Hao
   Peng, Pai
   Qiu, Zi Han
   Di, Chen Xi
   Chen, Xiao Feng
   Wang, Nai Ning
   Chen, Fei
   He, Yin Wei
   Liu, Zhong Bo
   Zhao, Fan
   Zhu, Dong Li
   Dong, Shan Shan
   Hu, Shou Ye
   Yang, Zhi
   Li, Yi Ping
   Guo, Yan
   Yang, Tie Lin
TI RUNX2 Phase Separation Mediates Long Range Regulation Between
   Osteoporosis Susceptibility Variant and XCR1 to Promote
   Osteoblast Differentiation
SO ADVANCED SCIENCE
LA English
DT Article
DE GWAS; osteoporosis; phase separation; RUNX2; XCR1
ID CHROMATIN; ORGANIZATION; PREDICTION
AB GWASs have identified many loci associated with osteoporosis, but the underlying genetic regulatory mechanisms and the potential drug target need to be explored. Here, a new regulatory mechanism is found that a GWAS intergenic SNP (rs4683184) functions as an enhancer to influence the binding affinity of transcription factor RUNX2, whose phase separation can mediate the long range chromatin interaction between enhancer and target gene XCR1 (a member of the GPCR family), leading to changes of XCR1 expression and osteoblast differentiation. Bone targeting AAV of Xcr1 can improve bone formation in osteoporosis mice, suggesting that XCR1 can be a new susceptibility gene for osteoporosis. This study is the first to link non coding SNP with phase separation, providing a new insight into long range chromatin regulation mechanisms with susceptibility to complex diseases, and finding a potential target for the development of osteoporosis drugs and corresponding translational research.
C1 [Zhang, Yan; Li, Xin Hao; Peng, Pai; Qiu, Zi Han; Di, Chen Xi; Chen, Xiao Feng; Wang, Nai Ning; Chen, Fei; He, Yin Wei; Zhao, Fan; Zhu, Dong Li; Dong, Shan Shan; Guo, Yan; Yang, Tie Lin] Xi An Jiao Tong Univ, Key Lab Biol Multiom & Dis Shaanxi Prov Higher Edu, Sch Life Sci & Technol, Key Lab Biomed Informat Engn,Minist Educ, Xian 710049, Shaanxi, Peoples R China.
   [Zhang, Yan; Li, Xin Hao; Peng, Pai; Qiu, Zi Han; Di, Chen Xi; Chen, Xiao Feng; Wang, Nai Ning; Chen, Fei; He, Yin Wei; Zhao, Fan; Zhu, Dong Li; Dong, Shan Shan; Guo, Yan; Yang, Tie Lin] Xi An Jiao Tong Univ, Biomed Informat & Genom Ctr, Sch Life Sci & Technol, Xian 710049, Shaanxi, Peoples R China.
   [Wang, Nai Ning; Yang, Tie Lin] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Orthoped, Xian 710061, Shaanxi, Peoples R China.
   [Liu, Zhong Bo] Xi'an Jiaotong Univ, Coll Stomatol, Key Lab Shaanxi Prov Craniofacial Precis Med Res, Xian 710049, Shaanxi, Peoples R China.
   [Hu, Shou Ye; Yang, Zhi] Xi An Jiao Tong Univ, Honghui Hosp, Dept Joint Surg, Xian 710054, Shaanxi, Peoples R China.
   [Li, Yi Ping] Tulane Univ, Sch Med, Dept Pathol & Lab Med, Div Cellular & Mol Med, New Orleans, LA 70112 USA.
C3 Xi'an Jiaotong University; Xi'an Jiaotong University; Xi'an Jiaotong
   University; Xi'an Jiaotong University; Xi'an Jiaotong University; Tulane
   University
RP Guo, Y; Yang, TL (通讯作者)，Xi An Jiao Tong Univ, Key Lab Biol Multiom & Dis Shaanxi Prov Higher Edu, Sch Life Sci & Technol, Key Lab Biomed Informat Engn,Minist Educ, Xian 710049, Shaanxi, Peoples R China.; Guo, Y; Yang, TL (通讯作者)，Xi An Jiao Tong Univ, Biomed Informat & Genom Ctr, Sch Life Sci & Technol, Xian 710049, Shaanxi, Peoples R China.; Yang, TL (通讯作者)，Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Orthoped, Xian 710061, Shaanxi, Peoples R China.
EM guoyan253@xjtu.edu.cn; yangtielin@xjtu.edu.cn
RI Zhang, Yan/MTF 5312 2025; Chen, Xiao Feng/AAN 8808 2020; Yang,
   Tie Lin/G 8365 2014; Li, YiPing/ICL 4465 2023
OI Chen, Xiao Feng/0000 0002 5886 6427; Zhang, Yan/0000 0001 6213 4416; 
FU National Natural Science Foundation of China; Science Fund for
   Distinguished Young Scholars of Shaanxi Province [2021JC 02]; Innovation
   Capability Support Program of Shaanxi Province [2022TD 44]; China
   Postdoctoral Science Foundation [2021M692582]; Fundamental Research
   Funds for the Central Universities [xtr052022013, xzy012022032]; 
   [32300486];  [82170896];  [32170616]
FX This work was supported by the National Natural Science Foundation of
   China (32300486, 82170896, and 32170616), the Science Fund for
   Distinguished Young Scholars of Shaanxi Province (2021JC 02), the
   Innovation Capability Support Program of Shaanxi Province (2022TD 44),
   the China Postdoctoral Science Foundation (2021M692582), the Fundamental
   Research Funds for the Central Universities (xtr052022013,
   xzy012022032). The authors would like to thank the participants and the
   organizers of the Genotype Tissue Expression (GTEx) project. BioRender
   was used to create the working model. The authors would also like to
   thank the Instrumental Analysis Center of Xi'an Jiaotong University for
   sharing the platform of laboratory apparatus and facilities.
CR Ahn JH, 2021, NATURE, V595, P591, DOI 10.1038/s41586 021 03662 5
   Bailey TL, 2015, NUCLEIC ACIDS RES, V43, pW39, DOI 10.1093/nar/gkv416
   Basu S, 2020, CELL, V181, P1062, DOI 10.1016/j.cell.2020.04.018
   Chaumeil J, 2013, JOVE J VIS EXP, DOI 10.3791/50087
   Chen F, 2024, GENES DIS, V11, P546, DOI 10.1016/j.gendis.2023.03.024
   Chen XF, 2024, CELL GENOM, V4, DOI 10.1016/j.xgen.2024.100501
   Chen XF, 2018, AM J HUM GENET, V102, P776, DOI 10.1016/j.ajhg.2018.03.001
   Deczkowska A, 2021, NAT MED, V27, P1043, DOI 10.1038/s41591 021 01344 3
   Domenjo Vila E, 2023, CELL REP, V42, DOI 10.1016/j.celrep.2023.112123
   Ensrud Kristine E, 2021, JAMA, V325, P96, DOI 10.1001/jama.2020.2923
   Fox JC, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aat4128
   Gibson BA, 2019, CELL, V179, P470, DOI 10.1016/j.cell.2019.08.037
   Gomathi K, 2020, LIFE SCI, V245, DOI 10.1016/j.lfs.2020.117389
   He JN, 2024, CELL, V187, DOI 10.1016/j.cell.2024.03.023
   Hershberg EA, 2021, NAT METHODS, V18, P937, DOI 10.1038/s41592 021 01187 3
   Hnisz D, 2017, CELL, V169, P13, DOI 10.1016/j.cell.2017.02.007
   Ji DY, 2024, MOL CELL, V84, DOI 10.1016/j.molcel.2023.11.020
   Kalinkovich A, 2021, PHARMACOL RES, V171, DOI 10.1016/j.phrs.2021.105794
   Kim S, 2019, MOL CELL, V76, P306, DOI 10.1016/j.molcel.2019.08.010
   Kim WJ, 2020, EXP MOL MED, V52, P1178, DOI 10.1038/s12276 020 0471 4
   Lancaster AK, 2014, BIOINFORMATICS, V30, P2501, DOI 10.1093/bioinformatics/btu310
   Lee WC, 2017, ENDOCR REV, V38, P255, DOI 10.1210/er.2017 00064
   Li CW, 2020, NAT REV GENET, V21, P255, DOI 10.1038/s41576 019 0205 4
   Li M, 2020, J CLIN ENDOCR METAB, V105, DOI 10.1210/clinem/dgz270
   Linding R, 2003, STRUCTURE, V11, P1453, DOI 10.1016/j.str.2003.10.002
   Ling XR, 2022, CELL REGEN, V11, DOI 10.1186/s13619 022 00145 4
   Liu XY, 2021, GENOME BIOL, V22, DOI 10.1186/s13059 021 02455 3
   Luo J, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0059 6
   Maurya S, 2022, CANCER GENE THER, V29, P1305, DOI 10.1038/s41417 021 00413 6
   Mora A, 2016, BRIEF BIOINFORM, V17, P980, DOI 10.1093/bib/bbv097
   Morris JA, 2019, NAT GENET, V51, P258, DOI 10.1038/s41588 018 0302 x
   Mullin BH, 2020, GENOME BIOL, V21, DOI 10.1186/s13059 020 01997 2
   Nelson MR, 2015, NAT GENET, V47, P856, DOI 10.1038/ng.3314
   Peng K, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471 2105 7 208
   Sabari BR, 2018, SCIENCE, V361, DOI 10.1126/science.aar3958
   Salhotra A, 2020, NAT REV MOL CELL BIO, V21, P696, DOI 10.1038/s41580 020 00279 w
   Stadhouders R, 2019, NATURE, V569, P345, DOI 10.1038/s41586 019 1182 7
   Thynn HN, 2020, J INVEST DERMATOL, V140, P348, DOI 10.1016/j.jid.2019.06.147
   Ulianov SV, 2021, NUCLEIC ACIDS RES, V49, P10524, DOI 10.1093/nar/gkab249
   WANG K, 2010, NUCLEIC ACIDS RES, V38, DOI DOI 10.1093/NAR/GKQ603
   Wang NN, 2023, AM J HUM GENET, V110, P625, DOI 10.1016/j.ajhg.2023.02.012
   Wang T, 2015, BIOCHEM BIOPH RES CO, V464, P635, DOI 10.1016/j.bbrc.2015.06.175
   Xing YH, 2024, NAT BIOTECHNOL, V42, DOI 10.1038/s41587 023 01737 4
   Yang DH, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392 020 00435 w
   Yang Jian, 2011, Am J Hum Genet, V88, P76, DOI 10.1016/j.ajhg.2010.11.011
   Yang JH, 2024, NAT REV MOL CELL BIO, V25, P574, DOI 10.1038/s41580 024 00710 6
   Yang TL, 2020, NAT REV ENDOCRINOL, V16, P91, DOI 10.1038/s41574 019 0282 7
   Yang YS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10809 6
   Zhu XW, 2021, BONE RES, V9, DOI 10.1038/s41413 021 00143 3
NR 49
TC 0
Z9 0
U1 13
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
EI 2198 3844
J9 ADV SCI
JI Adv. Sci.
PD FEB
PY 2025
VL 12
IS 6
DI 10.1002/advs.202413561
EA DEC 2024
PG 14
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA W2B2S
UT WOS:001380354300001
PM 39704037
OA gold
DA 2025 08 17
ER

PT J
AU Jobke, B
   Burghardt, AJ
   Muche, B
   Hahn, M
   Semler, J
   Amling, M
   Majumdar, S
   Busse, B
AF Jobke, Bjoern
   Burghardt, Andrew J.
   Muche, Burkhard
   Hahn, Michael
   Semler, Jutta
   Amling, Michael
   Majumdar, Sharmila
   Busse, Bjoern
TI Trabecular Reorganization in Consecutive Iliac Crest Biopsies when
   Switching from Bisphosphonate to Strontium Ranelate Treatment
SO PLOS ONE
LA English
DT Article
ID BONE MINERAL DENSITY; MICRO COMPUTED TOMOGRAPHY; POSTMENOPAUSAL WOMEN;
   CANCELLOUS BONE; NONVERTEBRAL FRACTURES; ALKALINE PHOSPHATASE;
   PARATHYROID HORMONE; VERTEBRAL FRACTURE; OSTEOPOROSIS; HISTOMORPHOMETRY
AB Background: Several agents are available to treat osteoporosis while addressing patient specific medical needs. Individuals' residual risk to severe fracture may require changes in treatment strategy. Data at osseous cellular and microstructural levels due to a therapy switch between agents with different modes of action are rare. Our study on a series of five consecutively taken bone biopsies from an osteoporotic individual over a six year period analyzes changes in cellular characteristics, bone microstructure and mineralization caused by a therapy switch from an antiresorptive (bisphosphonate) to a dual action bone agent (strontium ranelate).
   Methodology/Principal Findings: Biopsies were progressively taken from the iliac crest of a female patient. Four biopsies were taken during bisphosphonate therapy and one biopsy was taken after one year of strontium ranelate (SR) treatment. Furthermore, serum bone markers and dual x ray absorptiometry measurements were acquired. Undecalcified histology was used to assess osteoid parameters and bone turnover. Structural indices and degree of mineralization were determined using microcomputed tomography, quantitative backscattered electron imaging, and combined energy dispersive x ray/mu x ray fluorescence microanalysis.
   Conclusions/Significance: Microstructural data revealed a notable increase in bone volume fraction after one year of SR treatment compared to the bisphosphonate treatment period. Indices of connectivity density, structure model index and trabecular bone pattern factor were predominantly enhanced indicating that the architectural transformation from trabecular rods to plates was responsible for the bone volume increase and less due to changes in trabecular thickness and number. Administration of SR following bisphosphonates led to a maintained mineralization profile with an uptake of strontium on the bone surface level. Reactivated osteoclasts designed tunneling, hook like intratrabecular resorption sites. The appearance of tunneling resorption lacunae and the formation of both mini modeling units and osteon like structures within increased plate like cancellous bone mass provides additional information on the mechanisms of strontium ranelate following bisphosphonate treatment, which may deserve special attention when monitoring a treatment switch.
C1 [Jobke, Bjoern; Burghardt, Andrew J.; Majumdar, Sharmila] Univ Calif San Francisco, Dept Radiol, Musculoskeletal Quantitat Imaging Res Grp, San Francisco, CA 94143 USA.
   [Jobke, Bjoern] Helios Klinikum Berlin Buch, Inst Radiol, Berlin, Germany.
   [Muche, Burkhard; Semler, Jutta] Immanuel Hosp Berlin Wannsee, Dept Bone Metab & Osteol, Berlin, Germany.
   [Hahn, Michael; Amling, Michael; Busse, Bjoern] Univ Med Ctr Hamburg Eppendorf, Dept Osteol & Biomech, Hamburg, Germany.
   [Busse, Bjoern] Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Berkeley, CA 94720 USA.
C3 University of California System; University of California San Francisco;
   Helios Kliniken; University of Hamburg; University Medical Center
   Hamburg Eppendorf; United States Department of Energy (DOE); Lawrence
   Berkeley National Laboratory; University of California System;
   University of California Berkeley
RP Jobke, B (通讯作者)，Univ Calif San Francisco, Dept Radiol, Musculoskeletal Quantitat Imaging Res Grp, San Francisco, CA 94143 USA.
EM b.busse@uke.uni hamburg.de
RI ; Busse, Björn/AAC 4033 2020; Bloch, Michael/O 7845 2017; Burghardt,
   Andrew/ABF 2691 2020
OI Burghardt, Andrew/0000 0002 6343 4944; Muche,
   Burkhard/0000 0003 4104 5080; Busse, Bjorn/0000 0002 3099 8073
CR AMLING M, 1994, KIDNEY INT, V46, P733, DOI 10.1038/ki.1994.328
   Amling M, 1996, J BONE MINER RES, V11, P36, DOI 10.1002/jbmr.5650110107
   Bilezikian JP, 2009, AM J MED, V122, P14, DOI 10.1016/j.amjmed.2008.12.003
   Bjeoumikhov A, 2005, X RAY SPECTROM, V34, P493, DOI 10.1002/xrs.872
   Blake GM, 2007, J CLIN DENSITOM, V10, P34, DOI 10.1016/j.jocd.2006.10.004
   Blake GM, 2005, J BONE MINER RES, V20, P1901, DOI 10.1359/JBMR.050810
   Boivin G, 2010, OSTEOPOROSIS INT, V21, P667, DOI 10.1007/s00198 009 1005 z
   Bromage Timothy G., 2003, Anatomical Record, V274B, P157, DOI 10.1002/ar.b.10031
   Burghardt AJ, 2008, CALCIFIED TISSUE INT, V83, P129, DOI 10.1007/s00223 008 9158 x
   Burghardt AJ, 2007, ANN BIOMED ENG, V35, P1678, DOI 10.1007/s10439 007 9344 4
   Busse B, 2010, ACTA BIOMATER, V6, P4513, DOI 10.1016/j.actbio.2010.07.019
   Busse B, 2010, AGING CELL, V9, P1065, DOI 10.1111/j.1474 9726.2010.00633.x
   Busse B, 2010, J BIOMED MATER RES A, V92A, P1440, DOI 10.1002/jbm.a.32432
   Busse B, 2009, BONE, V45, P1034, DOI 10.1016/j.bone.2009.08.002
   Chavassieux PM, 1997, J CLIN INVEST, V100, P1475, DOI 10.1172/JCI119668
   Ding M, 2000, BONE, V26, P291, DOI 10.1016/S8756 3282(99)00281 1
   Dos Reis LM, 2007, J BONE MINER METAB, V25, P400, DOI 10.1007/s00774 007 0778 4
   Doube M, 2011, P ROYAL SCI B
   Doube M, 2010, BONE, V47, P1076, DOI 10.1016/j.bone.2010.08.023
   DVO, 2011, OSTEOLOGIE, V20, P55
   Ensrud KE, 2008, J BONE MINER RES, V23, P112, DOI 10.1359/JBMR.070904
   Eriksen EF, 2002, BONE, V31, P620, DOI 10.1016/S8756 3282(02)00869 4
   Eriksen EF, 2007, J BONE MINER RES, V22, P1, DOI 10.1359/JBMR.060910
   Frost H M, 1983, Henry Ford Hosp Med J, V31, P3
   Garnero P, 2001, CLIN CHEM, V47, P694
   Garnero P, 1999, BONE, V24, P603, DOI 10.1016/S8756 3282(99)00087 3
   Glorieux FH, 2000, BONE, V26, P103, DOI 10.1016/S8756 3282(99)00257 4
   GOMEZ B, 1995, CLIN CHEM, V41, P1560
   HAHN M, 1992, BONE, V13, P327, DOI 10.1016/8756 3282(92)90078 B
   HAHN M, 1991, VIRCHOWS ARCH A, V418, P1, DOI 10.1007/BF01600238
   Hauge EM, 2001, BONE, V28, P556, DOI 10.1016/S8756 3282(01)00424 0
   Hildebrand TOR, 1997, Comput Methods Biomech Biomed Engin, V1, P15, DOI 10.1080/01495739708936692
   Iki M, 2004, OSTEOPOROSIS INT, V15, P981, DOI 10.1007/s00198 004 1634 1
   Jee W. S. S., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P232
   Jobke B, 2006, THESIS U MED CTR HAM
   Jobke B, 2011, TERIPARATIDE BISPHOS, P1
   KUFAHL RH, 1990, J BIOMECH, V23, P171, DOI 10.1016/0021 9290(90)90350 C
   Laib A, 2001, OSTEOPOROSIS INT, V12, P936, DOI 10.1007/s001980170022
   Li CH, 2010, J BONE MINER RES, V25, P968, DOI 10.1359/jbmr.091038
   Liao J, 2010, BONE, V47, P882, DOI 10.1016/j.bone.2010.08.005
   Lips P, 2001, ENDOCR REV, V22, P477, DOI 10.1210/er.22.4.477
   Liu XWS, 2006, J BONE MINER RES, V21, P1608, DOI 10.1359/JBMR.060716
   Ma YFL, 2006, J BONE MINER RES, V21, P855, DOI 10.1359/JBMR.060314
   Marx RE, 2007, J ORAL MAXIL SURG, V65, P2397, DOI 10.1016/j.joms.2007.08.003
   Meunier PJ, 2009, OSTEOPOROSIS INT, V20, P1663, DOI 10.1007/s00198 008 0825 6
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   Middleton ET, 2010, J BONE MINER RES, V25, P455, DOI 10.1359/jbmr.090821
   Mulder L, 2004, ACTA RADIOL, V45, P769, DOI 10.1080/02841850410008171
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Nielsen SP, 1999, J CLIN DENSITOM, V2, P371, DOI 10.1016/S1094 6950(06)60402 2
   ODGAARD A, 1993, BONE, V14, P173, DOI 10.1016/8756 3282(93)90245 6
   PARFITT AM, 1988, CALCIFIED TISSUE INT, V42, P284, DOI 10.1007/BF02556360
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Patel V, 2003, J ORTHOP RES, V21, P6, DOI 10.1016/S0736 0266(02)00093 1
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Reginster JY, 2008, ARTHRITIS RHEUM US, V58, P1687, DOI 10.1002/art.23461
   Reginster JY, 2005, J CLIN ENDOCR METAB, V90, P2816, DOI 10.1210/jc.2004 1774
   Roschger P, 1998, BONE, V23, P319, DOI 10.1016/S8756 3282(98)00112 4
   Roschger P, 2008, BONE, V42, P456, DOI 10.1016/j.bone.2007.10.021
   SATO K, 1981, CALCIFIED TISSUE INT, V33, P459, DOI 10.1007/BF02409474
   Schafer AL, 2010, OSTEOPOROSIS INT, V21, P439, DOI 10.1007/s00198 009 0974 2
   SCHNITZLER CM, 1990, BONE MINER, V10, P183, DOI 10.1016/0169 6009(90)90261 D
   Sebba AI, 2004, CURR MED RES OPIN, V20, P2031, DOI 10.1185/030079904X16768
   Seitz S, 2010, OSTEOPOROSIS INT, V21, P119, DOI 10.1007/s00198 009 0933 y
   SKEDROS JG, 1993, J BIOMED MATER RES, V27, P57, DOI 10.1002/jbm.820270108
   Stauber M, 2006, BONE, V38, P475, DOI 10.1016/j.bone.2005.09.019
   Thomsen JS, 2005, J MICROSC OXFORD, V218, P171, DOI 10.1111/j.1365 2818.2005.01469.x
   Torgerson DJ, 2001, JAMA J AM MED ASSOC, V285, P2891, DOI 10.1001/jama.285.22.2891
   VEDI S, 1982, METAB BONE DIS RELAT, V4, P231, DOI 10.1016/0221 8747(82)90032 7
   Watts NB, 2001, OSTEOPOROSIS INT, V12, P279, DOI 10.1007/s001980170117
   Won YY, 2003, YONSEI MED J, V44, P811, DOI 10.3349/ymj.2003.44.5.811
   WOODS CG, 1972, J PATHOL, V107, P137, DOI 10.1002/path.1711070210
   Zikan V, 2009, BONE, V44, P634, DOI 10.1016/j.bone.2008.12.013
NR 73
TC 17
Z9 18
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD AUG 16
PY 2011
VL 6
IS 8
AR e23638
DI 10.1371/journal.pone.0023638
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 810KZ
UT WOS:000294125500038
PM 21858188
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Schreuder, WH
   Meijer, EB
   Cleven, AHG
   Edelenbos, E
   Klop, C
   Schreurs, R
   de Jong, RT
   van Maarle, MC
   Horsthuis, RBG
   de Lange, J
   van den Berg, H
AF Schreuder, Willem H.
   Meijer, Ethan B.
   Cleven, Arjen H. G.
   Edelenbos, Esther
   Klop, Cornelis
   Schreurs, Ruud
   de Jong, Renate T.
   van Maarle, Merel C.
   Horsthuis, Roy B. G.
   de Lange, Jan
   van den Berg, Henk
TI Efficacy and Toxicity of Calcitonin Treatment in Children with
   Cherubism: A Single Center Cohort Study
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE Therapeutics calcitonin; Diseases and disorders of/related to
   bone cherubism; Molecular pathways development; Dental biology; Cells of
   bone osteoclasts
ID GIANT CELL GRANULOMA; DENOSUMAB TREATMENT; SH3BP2 CHERUBISM; THERAPY;
   LESIONS; NFATC1; GENE; JAWS; BISPHOSPHONATES; INFLAMMATION
AB Cherubism is a rare autosomal dominant disease characterized by expansile osteolytic jawbone lesions. The effect and safety of off label calcitonin treatment during the progressive phase of the disease are not well described. In this retrospective study, we present data on the radiological response and adverse effects of subcutaneously administered calcitonin in a cohort of nine cherubism children (three female, six male). Two of the nine patients underwent two separate treatment courses with a significant off treatment interval in between; therefore, a total of 11 treatment courses with a mean duration of 17.9 months (range <1 to 35, SD 10.8) were studied. To measure the response, the cumulative volume of cherubism lesions was calculated from available three dimensional imaging. The primary outcome was the change in the volume of lesions during calcitonin treatment and only assessed for the eight treatment courses with a minimal duration of 6 months. A statistically significant reduction in the mean cumulative volume of lesions was seen regardless of treatment duration. Average volume reduction was highest in the first half year of treatment, with a gradual, ongoing reduction thereafter. For the secondary outcome, the change in the cumulative volume of lesions after treatment cessation was assessed for the seven treatment courses with follow up imaging available. After six of these seven treatment courses, the cumulative volume increased again but remained undoubtedly smaller than the initial volume at the start of therapy. Adverse effects were assessed for all 11 treatment courses and occurred in 73% of them. Most adverse effects were mild and low grade, with the most severe being one grade 3 symptomatic hypocalcemia requiring hospitalization and early treatment termination. Calcitonin treatment seems effective and tolerable in treating actively progressing cherubism in children. However, further research is required to better understand the pharmacological treatment of cherubism, including also other drugs, dosing, and protocols.(c) 2023 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
C1 [Schreuder, Willem H.; Meijer, Ethan B.; Klop, Cornelis; Schreurs, Ruud; de Lange, Jan] Amsterdam Univ Med Ctr Locat AMC, Dept Oral & Maxillofacial Surg, Amsterdam, Netherlands.
   [Schreuder, Willem H.; Meijer, Ethan B.; Klop, Cornelis; Schreurs, Ruud; de Lange, Jan] Univ Amsterdam, Acad Ctr Dent Amsterdam, Amsterdam, Netherlands.
   [Schreuder, Willem H.] Antoni van Leeuwenhoek Netherlands Canc Ctr, Dept Head & Neck Surg & Oncol, Amsterdam, Netherlands.
   [Cleven, Arjen H. G.] Univ Med Ctr Groningen, Dept Pathol, Groningen, Netherlands.
   [Edelenbos, Esther; van den Berg, Henk] Univ Amsterdam, Amsterdam Univ Med Ctr Locat AMC, Dept Pediat Oncol, Amsterdam, Netherlands.
   [de Jong, Renate T.] Amsterdam UMC Locat Vrije Univ Amsterdam, Dept Internal Med, Endocrine Sect, Amsterdam, Netherlands.
   [van Maarle, Merel C.] Univ Amsterdam, Dept Clin Genet, Amsterdam UMC, Amsterdam, Netherlands.
   [Horsthuis, Roy B. G.] Almelo & Med Spectrum Twente, Ziekenhuisgroep Twente, Dept Oral & Maxillofacial Surg, Enschede, Netherlands.
   [Schreuder, Willem H.] Univ Amsterdam, Dept Oral & Maxillofacial Surg, Med Ctr, Meibergdreef 9, NL 1105 AZ Amsterdam, Netherlands.
C3 University of Amsterdam; Vrije Universiteit Amsterdam; Academic Center
   for Dentistry Amsterdam; University of Groningen; University of
   Amsterdam; University of Amsterdam; Medical Spectrum Twente; University
   of Amsterdam
RP Schreuder, WH (通讯作者)，Univ Amsterdam, Dept Oral & Maxillofacial Surg, Med Ctr, Meibergdreef 9, NL 1105 AZ Amsterdam, Netherlands.
EM w.h.schreuder@amsterdamumc.nl
RI ; Schreurs, Ruud/P 6769 2015; Schreurs, Ruud/KBA 7274 2024
OI /0000 0002 7639 5999; de Jongh, Renate/0000 0001 8414 3938; Schreurs,
   Ruud/0000 0003 2429 2071; 
CR Aliprantis AO, 2008, J CLIN INVEST, V118, P3775, DOI 10.1172/JCI35711
   Amaral FR, 2010, J ORAL PATHOL MED, V39, P269, DOI 10.1111/j.1600 0714.2009.00855.x
   Baroncelli GI, 2014, HORM RES PAEDIAT, V82, P290, DOI 10.1159/000365889
   Beaman FD, 2004, AM J ROENTGENOL, V182, P1051, DOI 10.2214/ajr.182.4.1821051
   BIANCHI SD, 1987, SKELETAL RADIOL, V16, P6, DOI 10.1007/BF00349920
   Boyce AM, 2012, J BONE MINER RES, V27, P1462, DOI 10.1002/jbmr.1603
   Bradley D, 2021, J ORAL MAXIL SURG, V79, P598, DOI 10.1016/j.joms.2020.10.001
   Chrcanovic BR, 2021, INT J ORAL MAX SURG, V50, P43, DOI 10.1016/j.ijom.2020.05.021
   De Lange J, 2007, ORAL SURG ORAL MED O, V104, P603, DOI 10.1016/j.tripleo.2007.04.003
   de Lange J, 2007, J ORAL MAXIL SURG, V65, P1665, DOI 10.1016/j.joms.2006.06.266
   Droma EB, 2020, J ORAL MAXIL SURG, V78, P2226, DOI 10.1016/j.joms.2020.06.016
   Duarte AP, 2011, ONCOL LETT, V2, P571, DOI 10.3892/ol.2011.274
   Dunnion S, 2020, PEDIATR RADIOL, V50, P877, DOI 10.1007/s00247 020 04651 y
   Eiden S, 2017, ROFO FORTSCHR RONTG, V189, P675, DOI 10.1055/s 0043 105074
   El Naggar AK, 2017, WHO CLASSIFICATION H
   Etoz Osman A, 2011, Eur J Dent, V5, P486
   European Medicines Agency, 2013, SCI CONCL GROUNDS VA
   Fernandes Gomes M., 2011, ISRN DENT, V2011
   Greenwood TJ, 2015, RADIOGRAPHICS, V35, P1539, DOI 10.1148/rg.2015140267
   HARRIS M, 1993, BRIT J ORAL MAX SURG, V31, P89, DOI 10.1016/0266 4356(93)90168 V
   Hart W, 2000, Ned Tijdschr Geneeskd, V144, P34
   Hero M, 2013, BONE, V52, P347, DOI 10.1016/j.bone.2012.10.003
   Horst Sikorska W, 1996, Przegl Lek, V53, P9
   Hoyer Kuhn H, 2014, J CLIN ENDOCR METAB, V99, P3954, DOI 10.1210/jc.2014 3072
   Itonaga I, 2003, J ORAL PATHOL MED, V32, P224, DOI 10.1034/j.1600 0714.2003.00069.x
   Kadlub N, 2015, J BONE MINER RES, V30, P878, DOI 10.1002/jbmr.2431
   Kawamura H, 2020, J PEDIATR ENDOCR MET, V33, P963, DOI 10.1515/jpem 2019 0581
   Kömerik N, 2014, HEAD NECK PATHOL, V8, P164, DOI 10.1007/s12105 013 0489 1
   Kugushev AY., 2018, MOJ TUMOR RES, V1, P75
   Lannon DA, 2001, BRIT J PLAST SURG, V54, P708, DOI 10.1054/bjps.2001.3701
   Lietman SA, 2008, BIOCHEM BIOPH RES CO, V371, P644, DOI 10.1016/j.bbrc.2008.04.080
   Liles SI, 2023, CLEFT PALATE CRAN J, V60, P1665, DOI 10.1177/10556656221113891
   Lima Gde M., 2010, JOMR J ORAL MAXIL RE, V1
   Liu B, 2003, J ORAL PATHOL MED, V32, P367, DOI 10.1034/j.1600 0714.2003.00126.x
   Mangion J, 1999, AM J HUM GENET, V65, P151, DOI 10.1086/302454
   Mazhar Heena, 2018, Ann Maxillofac Surg, V8, P373, DOI 10.4103/ams.ams_177_17
   McMahon Mark S, 2009, HSS J, V5, P159, DOI 10.1007/s11420 009 9115 x
   Motamedi MHK, 1998, J ORAL MAXIL SURG, V56, P1336, DOI 10.1016/S0278 2391(98)90618 8
   Mukai T, 2014, J BONE MINER RES, V29, P2618, DOI 10.1002/jbmr.2295
   Novack DV, 2007, CELL, V128, P15, DOI 10.1016/j.cell.2006.12.019
   Pagnini T, 2011, CLIN EXP RHEUMATOL, V29, P147
   Papadaki ME, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750 1172 7 S1 S6
   Pinheiro Lucas R., 2013, Braz. Dent. J., V24, P74
   PONTIROLI AE, 1991, J ENDOCRINOL INVEST, V14, P47, DOI 10.1007/BF03350260
   Raposo Amaral CE, 2007, ANN PLAS SURG, V58, P645, DOI 10.1097/01.sap.0000248141.36904.19
   Redfors M, 2013, DENTOMAXILLOFAC RAD, V42, DOI 10.1259/dmfr.20130034
   Reichenberger EJ, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750 1172 7 S1 S5
   Ricalde P, 2019, J ORAL MAXIL SURG, V77, DOI 10.1016/j.joms.2019.02.021
   Schreuder WH, 2021, BONE, V149, DOI 10.1016/j.bone.2021.115935
   Schreuder WH, 2017, J CRANIO MAXILL SURG, V45, P232, DOI 10.1016/j.jcms.2016.11.011
   Stefanelli S, 2018, INSIGHTS IMAGING, V9, P571, DOI 10.1007/s13244 018 0623 4
   Tiziani V, 1999, AM J HUM GENET, V65, P158, DOI 10.1086/302456
   Ueki Y, 2001, NAT GENET, V28, P125, DOI 10.1038/88832
   Ueki Y, 2007, CELL, V128, P71, DOI 10.1016/j.cell.2006.10.047
   Upfill Brown A, 2019, JBMR PLUS, V3, DOI 10.1002/jbm4.10210
   Wang DX, 2023, TRANSL PEDIATR, V12, P470, DOI 10.21037/tp 22 276
   Yoshitaka T, 2014, CELL REP, V8, P1752, DOI 10.1016/j.celrep.2014.08.023
NR 57
TC 1
Z9 1
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD DEC
PY 2023
VL 38
IS 12
BP 1822
EP 1833
DI 10.1002/jbmr.4922
EA NOV 2023
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA IN5X3
UT WOS:001098056000001
PM 37823782
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Kambrath, AV
   Williams, JN
   Sankar, U
AF Kambrath, Anuradha Valiya
   Williams, Justin N.
   Sankar, Uma
TI An Improved Methodology to Evaluate Cell and Molecular Signals in the
   Reparative Callus During Fracture Healing
SO JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
LA English
DT Article
DE bone matrix; cartilage; chondrocytes; cryosection; fluorescence
   microscopy; fracture callus; immunofluorescence labeling; osteoblasts;
   safranin O; fast green
ID INDIAN HEDGEHOG; OSTEOBLAST
AB Approximately 5% to 10% of all bone fractures do not heal completely, contributing to significant patient suffering and medical costs. Even in healthy individuals, fracture healing is associated with significant downtime and loss of productivity. However, no pharmacological treatments are currently available to promote efficient bone healing. A better understanding of the underlying molecular mechanisms is crucial for developing novel therapies to hasten healing. The early reparative callus that forms around the site of bone injury is a fragile tissue consisting of shifting cell populations held together by loose connective tissue. The delicate callus is challenging to section and is vulnerable to disintegration during the harsh steps of immunostaining, namely, decalcification, deparaffinization, and antigen retrieval. Here, we describe an improved methodology for processing early stage fracture calluses and immunofluorescence labeling of the sections to visualize the temporal (timing) and spatial (location) patterns of cellular and molecular events that regulate bone healing. This method has a short turnaround time from sample collection to microscopy as it does not require lengthy decalcification. It preserves the structural integrity of the fragile callus as the method does not entail deparaffinization or harsh methods of antigen retrieval. Our method can be adapted for high throughput screening of drugs that promote efficacious bone healing:
C1 [Kambrath, Anuradha Valiya; Williams, Justin N.; Sankar, Uma] Indiana Univ Sch Med, Dept Anat Cell Biol & Physiol, 635 Barnhill Dr,MS 5035, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University Bloomington
RP Sankar, U (通讯作者)，Indiana Univ Sch Med, Dept Anat Cell Biol & Physiol, 635 Barnhill Dr,MS 5035, Indianapolis, IN 46202 USA.
EM usankar@iupui.edu
RI Sankar, Uma/AHE 2383 2022
OI Williams, Justin/0000 0003 2341 2596
FU Department of Defense (DoD) United States Army Medical Research and
   Materiel Command; National Institute of Arthritis and Musculoskeletal
   and Skin Diseases of the National Institutes of Health (NIH)
   [R01AR068332]; Comprehensive Musculoskeletal T32 Training Program from
   NIAMS/NIH [AR065971]; Department of Defense (DoD) Congressionally
   Directed Medical Research Program [PR121604]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: Research
   reported in this publication was supported by the Department of Defense
   (DoD) United States Army Medical Research and Materiel Command and
   Congressionally Directed Medical Research Program under Award Number
   PR121604, and the National Institute of Arthritis and Musculoskeletal
   and Skin Diseases of the National Institutes of Health (NIH) under Award
   Number R01AR068332 (both to U.S.). J.N.W. is supported through a
   Comprehensive Musculoskeletal T32 Training Program from NIAMS/NIH
   (AR065971). The content is solely the responsibility of the authors and
   does not necessarily represent the official views of the DoD or the NIH.
CR Ai Aql ZS, 2008, J DENT RES, V87, P107, DOI 10.1177/154405910808700215
   Akkiraju H, 2016, J HISTOCHEM CYTOCHEM, V64, P168, DOI 10.1369/0022155415626765
   Doherty L, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223846
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   Gerstenfeld LC, 2006, J HISTOCHEM CYTOCHEM, V54, P1215, DOI 10.1369/jhc.6A6959.2006
   Grcevic D, 2012, STEM CELLS, V30, P187, DOI 10.1002/stem.780
   Hilton MJ, 2005, DEVELOPMENT, V132, P4339, DOI 10.1242/dev.02025
   Kawamoto T, 2003, ARCH HISTOL CYTOL, V66, P123, DOI 10.1679/aohc.66.123
   Le AX, 2001, J ORTHOPAED RES, V19, P78, DOI 10.1016/S0736 0266(00)00006 1
   Long FX, 2004, DEVELOPMENT, V131, P1309, DOI 10.1242/dev.01006
   Matthews BG, 2014, J BONE MINER RES, V29, P1283, DOI 10.1002/jbmr.2140
   Murakami S, 2000, CALCIFIED TISSUE INT, V66, P272, DOI 10.1007/PL00005843
   Ono N, 2014, DEV CELL, V29, P330, DOI 10.1016/j.devcel.2014.03.014
   Schindeler A, 2008, SEMIN CELL DEV BIOL, V19, P459, DOI 10.1016/j.semcdb.2008.07.004
   St Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072
   Tevlin R, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aag2809
   Williams JN, 2018, JOVE J VIS EXP, DOI 10.3791/58122
   Williams JN, 2018, J BONE MINER RES, V33, P930, DOI 10.1002/jbmr.3379
NR 18
TC 7
Z9 7
U1 0
U2 5
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0022 1554
EI 1551 5044
J9 J HISTOCHEM CYTOCHEM
JI J. Histochem. Cytochem.
PD MAR
PY 2020
VL 68
IS 3
BP 199
EP 208
AR 0022155419900915
DI 10.1369/0022155419900915
EA JAN 2020
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA KP0KO
UT WOS:000507204500001
PM 31928129
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Aida, Y
   Kurihara, H
   Kato, K
AF Aida, Yusuke
   Kurihara, Hidemi
   Kato, Koichi
TI Wnt3a promotes differentiation of human bone marrow derived mesenchymal
   stem cells into cementoblast like cells
SO IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY ANIMAL
LA English
DT Article
DE Cementoblast; Wnt/ss catenin signaling; Mesenchymal stem cell;
   Periodontium; Regenerative medicine
ID PERIODONTAL LIGAMENT CELLS; DENTAL FOLLICLE CELLS; OSTEOBLASTIC
   DIFFERENTIATION; CEMENTUM FORMATION; SIGNALING PATHWAY; BETA CATENIN;
   REGENERATION; EXPRESSION; ACTIVATION; TRANSPLANTATION
AB Cementum is a calcified, avascular connective tissue that laminates the root of a tooth and plays a pivotal role in the development, homeostasis, and regeneration of a periodontal tissue. As a potential treatment for periodontal tissue defects in the patient with chronic periodontitis, much attention has been paid to tissue engineering combined with mesenchymal stem cells for regenerating periodontal tissues including cementum. However, limited information is available for the molecular factors that have impacts on the differentiation of mesenchymal stem cells into cementoblasts. Here, we focus on the effect of Wnt3a as a potential inducer and tested the effect of this protein in vitro using human bone marrow derived mesenchymal stem cells. It was found that, when cells were cultured in an osteogenic medium containing Wnt3a, cementoblast specific genes, such as cementum protein 1 and cementum attachment protein, as well as bone related genes were significantly upregulated. These results suggest that Wnt3a promotes differentiation of the cells into cementoblast like cells. Further experiments were carried out using inhibitors to gain deeper insights into molecular mechanisms underlying the observed differentiation. As a result, we conclude that Wnt3a triggered differentiation into cementoblast like cells is the consequence of the activation of the canonical Wnt signaling pathway with possible involvement of the non canonical pathway.
C1 [Aida, Yusuke; Kato, Koichi] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Biomat, Minami Ku, 1 2 3 Kasumi, Hiroshima 7348553, Japan.
   [Aida, Yusuke; Kurihara, Hidemi] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Periodontal Med, Minami Ku, 1 2 3 Kasumi, Hiroshima 7348553, Japan.
   [Aida, Yusuke] Univ Fukui, Div Dent & Oral Surg, Dept Sensory & Locomotor Med, Fac Med Sci, 23 3 Matsuokashimoaizuki, Eiheiji, Fukui 9101193, Japan.
C3 Hiroshima University; Hiroshima University; University of Fukui
RP Kato, K (通讯作者)，Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Biomat, Minami Ku, 1 2 3 Kasumi, Hiroshima 7348553, Japan.
EM kokato@hiroshima u.ac.jp
RI ; Kato, Koichi/G 5704 2019; Kurihara, Hidemi/G 5730 2019
OI Kato, Koichi/0000 0002 0587 3527; 
FU Strategic Promotion of Innovative Research and Development
   (S Innovation) program, Japan Science and Technology Agency
FX The part of this study was supported by Strategic Promotion of
   Innovative Research and Development (S Innovation) program, Japan
   Science and Technology Agency, FY2012. The authors thank Dr. Takashi
   Takata, Department of Oral and Maxillofacial Pathobiology, Graduate
   School of Biomedical & Health Sciences, Hiroshima University, for the
   cementoblast cell line and Dr. Sigeki Suzuki, Department of Biological
   Endodontics, Graduate School of Biomedical & Health Sciences, Hiroshima
   University, for the DSPP specific primers.
CR Alvarez Pérez MA, 2006, BONE, V38, P409, DOI 10.1016/j.bone.2005.09.009
   Arzate H, 2015, PERIODONTOL 2000, V67, P211, DOI 10.1111/prd.12062
   Bikkavilli RK, 2008, J CELL SCI, V121, P3598, DOI 10.1242/jcs.032854
   Carmona Rodríguez B, 2007, BIOCHEM BIOPH RES CO, V358, P763, DOI 10.1016/j.bbrc.2007.04.204
   Caverzasio J, 2007, ENDOCRINOLOGY, V148, P5323, DOI 10.1210/en.2007 0520
   Choi H, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 08607 5
   Choi H, 2014, TISSUE ENG PT A, V20, P410, DOI [10.1089/ten.tea.2013.0132, 10.1089/ten.TEA.2013.0132]
   Paula Silva FWG, 2010, CALCIFIED TISSUE INT, V87, P144, DOI 10.1007/s00223 010 9368 x
   Han PP, 2015, J BONE MINER RES, V30, P1160, DOI 10.1002/jbmr.2445
   Han PP, 2012, BIOMATERIALS, V33, P6370, DOI 10.1016/j.biomaterials.2012.05.061
   Hoz L, 2012, CELL BIOL INT, V36, P129, DOI 10.1042/CBI20110168
   Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564
   Hu L, 2018, ORAL DIS, V24, P696, DOI 10.1111/odi.12703
   Jung HS, 2011, J MOL HISTOL, V42, P227, DOI 10.1007/s10735 011 9327 5
   Kawaguchi H, 2004, J PERIODONTOL, V75, P1281, DOI 10.1902/jop.2004.75.9.1281
   Kim TH, 2011, BIOCHEM BIOPH RES CO, V412, P549, DOI 10.1016/j.bbrc.2011.07.116
   Kitagawa M, 2006, BONE, V39, P1035, DOI 10.1016/j.bone.2006.05.022
   Koch S, 2017, DIFFERENTIATION, V97, P1, DOI 10.1016/j.diff.2017.08.003
   Komaki M, 2012, J CELL PHYSIOL, V227, P649, DOI 10.1002/jcp.22770
   Komiya Yuko, 2008, Organogenesis, V4, P68
   Li SG, 2016, MOL MED REP, V14, P4975, DOI 10.3892/mmr.2016.5909
   Liu N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093364
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Matyas JJ, 2017, CELL TRANSPLANT, V26, P1472, DOI 10.1177/0963689717721214
   Miao C, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0697 9
   Mitsiadis TA, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00357
   Naujok Ortwin, 2014, BMC Res Notes, V7, P273, DOI 10.1186/1756 0500 7 273
   Nemoto E, 2016, J PERIODONTAL RES, V51, P164, DOI 10.1111/jre.12294
   Nemoto E, 2009, BONE, V44, P805, DOI 10.1016/j.bone.2008.12.029
   Norgaard R, 2006, ANN NY ACAD SCI, V1067, P443, DOI 10.1196/annals.1354.063
   Qiu WM, 2011, BIOCHEM BIOPH RES CO, V413, P98, DOI 10.1016/j.bbrc.2011.08.061
   Sakisaka Y, 2015, EXP CELL RES, V336, P85, DOI 10.1016/j.yexcr.2015.06.013
   Shang FQ, 2017, THERANOSTICS, V7, P4370, DOI 10.7150/thno.19888
   Sonoyama W, 2007, J DENT RES, V86, P594, DOI 10.1177/154405910708600703
   Takewaki M, 2017, J DENT RES, V96, P984, DOI 10.1177/0022034517708770
   Yun MS, 2005, J CELL SCI, V118, P313, DOI 10.1242/jcs.01601
   Zhang R, 2013, INT J BIOL SCI, V9, P228, DOI 10.7150/ijbs.5476
   Zhang Y, 2014, CELL TISSUE RES, V358, P633, DOI 10.1007/s00441 014 2010 x
NR 39
TC 14
Z9 14
U1 0
U2 16
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1071 2690
EI 1543 706X
J9 IN VITRO CELL DEV AN
JI In Vitro Cell. Dev. Biol. Anim.
PD JUN
PY 2018
VL 54
IS 6
BP 468
EP 476
DI 10.1007/s11626 018 0265 3
PG 9
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA GJ2US
UT WOS:000435129700009
PM 29785536
DA 2025 08 17
ER

PT J
AU Golu, MV
   Pascanu, I
   Toganel, C
   Petrovan, C
   Cosarca, A
   Temistocle, DLB
   Ormenisan, A
AF Golu, Mihai Vlad
   Pascanu, Ionela
   Toganel, Cornelia
   Petrovan, Cecilia
   Cosarca, Adina
   Temistocle, Despina Luciana Bereczki
   Ormenisan, Alina
TI What Do Prescribers of Bone Modifying Agents Know about
   Medication Related Osteonecrosis of the Jaw? Is Current Prevention
   Enough?
SO APPLIED SCIENCES BASEL
LA English
DT Article
DE osteonecrosis of the jaw; medication related osteonecrosis of the jaw;
   bisphosphonate related osteonecrosis of the jaw; dentistry; oral health;
   multidisciplinary approach
ID SURGEONS POSITION PAPER; AMERICAN ASSOCIATION
AB Osteonecrosis of the jaw represents interference by external and internal factors in the natural bone remodeling system. Numerous bone remodeling agents (BMAs), such as bisphosphonates, denosumab, and tyrosine kinase inhibitors, can lead to medication related osteonecrosis of the jaw (MRONJ). This is a serious condition that ocurs as a side effect of treatment in patients with osteoporosis or malignancies. Antiresorptive drugs are medications that target osteoclasts with the aim of preventing bone resorption and are used to treat osteoporosis, osteopenia, and a variety of other conditions, such as Paget's disease. They are also used in cancer patients with active bone metastases where antiresorptive treatment is used for the prevention of skeletal complications. Poor dental health, infections, and especially dental surgery are the primary causes of MRONJ, while other risk factors, such as smoking, alcohol abuse, and diabetes mellitus, can also influence its development. Prevention is the key component of management, and thus awareness of the risk factors among prescribers is very important. The aim of our study was to evaluate current knowledge about MRONJ among BMA prescribers in an academic hospital and their awareness about oral health and dental check ups. By using a custom designed questionnaire addressed to general and internal medical practitioners, endocrinologists, rheumatologists, and oncologists as an instrument for collecting data, we tried to identify trends in BMA prescription among different specialists and their recommended preventative measures, with the aim of creating new strategies to prevent the occurrence of MRONJ. The survey revealed a low awareness among physicians of the potential risk factors and underlined the need for a concerted effort to improve patient management. In this sense, a multidisciplinary team approach that includes the patient, the drug prescriber, the dentist, and the oral surgeon could significantly improve the quality of life of patients with MRONJ.
C1 [Golu, Mihai Vlad; Pascanu, Ionela; Toganel, Cornelia; Petrovan, Cecilia; Cosarca, Adina; Temistocle, Despina Luciana Bereczki; Ormenisan, Alina] George Emil Palade Univ Med Pharm Sci & Tehnol Ta, Dept Oral & Maxillofacial Surg, 38 Gheorghe Marinescu St, Targu Mures 540142, Romania.
   [Golu, Mihai Vlad; Temistocle, Despina Luciana Bereczki] George Emil Palade Univ Med Pharm Sci & Technol T, IOSUD Doctoral Sch, Targu Mures 540142, Romania.
C3 George Emil Palade University of Medicine, Pharmacy, Science, &
   Technology of Targu Mures
RP Temistocle, DLB (通讯作者)，George Emil Palade Univ Med Pharm Sci & Tehnol Ta, Dept Oral & Maxillofacial Surg, 38 Gheorghe Marinescu St, Targu Mures 540142, Romania.; Temistocle, DLB (通讯作者)，George Emil Palade Univ Med Pharm Sci & Technol T, IOSUD Doctoral Sch, Targu Mures 540142, Romania.
EM despina.bereczki temistocle@unafst.ro
RI ; Golu, Mihai Vlad/AAC 4619 2020; Ormenisan, Alina/LQL 2664 2024;
   Pascanu, Maria/AAY 4174 2020; Bereczki Temistocle, Despina
   Luciana/HKP 1037 2023; Adina, Cosarca/IXW 5359 2023
OI ormenisan, alina/0000 0002 1218 4201; Bereczki Temistocle, Despina
   Luciana/0009 0001 4018 6749; Golu, Mihai Vlad/0000 0001 8776 2654
CR Bermúdez Bejarano EB, 2017, MED ORAL PATOL ORAL, V22, pE43, DOI 10.4317/medoral.21477
   de Sales Lima Marco Vinicius, 2018, J Oral Maxillofac Res, V9, pe5, DOI 10.5037/jomr.2018.9405
   Golu Mihai Vlad, 2023, Med Pharm Rep, V96, P323, DOI 10.15386/mpr 2502
   Kim YH, 2014, J KOR ASSOC ORAL MAX, V40, P206, DOI 10.5125/jkaoms.2014.40.5.206
   Okuyama K, 2021, J DENT SCI, V16, P885, DOI 10.1016/j.jds.2020.12.007
   Ottesen C, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e03795
   Owosho AA, 2016, J CRANIO MAXILL SURG, V44, P265, DOI 10.1016/j.jcms.2015.12.005
   Ruggiero SL, 2022, J ORAL MAXIL SURG, V80, P920, DOI 10.1016/j.joms.2022.02.008
   Ruggiero SL, 2009, J ORAL MAXIL SURG, V67, P2, DOI 10.1016/j.joms.2009.01.009
   Vallina C, 2019, MED ORAL PATOL ORAL, V24, pE326, DOI 10.4317/medoral.22858
NR 10
TC 0
Z9 0
U1 6
U2 17
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
EI 2076 3417
J9 APPL SCI BASEL
JI Appl. Sci. Basel
PD SEP
PY 2022
VL 12
IS 18
AR 9224
DI 10.3390/app12189224
PG 10
WC Chemistry, Multidisciplinary; Engineering, Multidisciplinary; Materials
   Science, Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Engineering; Materials Science; Physics
GA 4S3VP
UT WOS:000857372900001
OA gold
DA 2025 08 17
ER

PT J
AU Yu, X
   Wu, Q
   Ren, ZR
   Chen, B
   Wang, DS
   Yuan, T
   Ding, H
   Wang, Y
   Yuan, GD
   Wang, YX
   Zhang, L
   Zhao, JN
   Sun, ZY
AF Yu, Xin
   Wu, Qi
   Ren, Zhengrong
   Chen, Bin
   Wang, Dongsheng
   Yuan, Tao
   Ding, Hao
   Wang, Yang
   Yuan, Guodong
   Wang, Yuxiang
   Zhang, Lei
   Zhao, Jianning
   Sun, Zhongyang
TI Kaempferol attenuates wear particle induced inflammatory osteolysis via
   JNK and p38 MAPK signaling pathways
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Periprosthetic osteolysis; Kaempferol; Inflammation; Osteoclastogenesis;
   JNK; p38 MAPK
ID DEGRADATION PRODUCTS; DOWN REGULATION; IN VIVO; OSTEOCLASTOGENESIS;
   ACTIVATION; INHIBITION; FLAVONOIDS; QUERCETIN; INDUCTION; METAL
AB Ethnopharmacological relevance: Wear particle induced inflammatory osteoclast activation is a master contributor to periprosthetic osteolysis, which can cause pathological bone loss and destruction. Hence, inhibiting inflammation and osteoclastogenesis is an important strategy for preventing wear particle induced osteolysis. To date, there are no FDA approved non surgical pharmacotherapies for arresting periprosthetic osteolysis. Kaempferol (KAE), a natural flavonol abundant in many traditional Chinese herbal medicines, has been shown to have protective effects against inflammatory bone diseases such as rheumatoid arthritis, but no previous study has evaluated the effects of KAE on wear particle induced osteolysis. Aim of the study: The study aimed to investigate the effects of KAE on wear particle induced inflammatory osteolysis and osteoclast activation, and further explore the underlying mechanisms. Materials and methods: TiAl6V4 metal particles (TiPs) were retrieved from the prosthesis of patients who underwent revision hip arthroplasty due to aseptic loosening. A mouse calvarial osteolysis model was used to investigate the effects of KAE on wear particle induced inflammatory osteolysis in vivo. Primary bone marrowderived macrophages (BMMs) were used to explore the effects of KAE on osteoclast differentiation and boneresorbing activity as well as the underlying mechanisms in vitro. Results: In the present study, we found that KAE alleviated wear particle induced inflammatory bone loss in vivo and inhibited osteoclast differentiation and function in vitro. Furthermore, we revealed that KAE exerted antiosteoclastogenic effects by downregulating JNK and p38 MAPK signaling as well as the downstream NFATc1 expression. Conclusions: KAE is an alternative therapeutic agent for preventing and treating periprosthetic osteolysis and aseptic loosening.
C1 [Yu, Xin; Wu, Qi; Chen, Bin; Wang, Dongsheng; Yuan, Tao; Ding, Hao; Wang, Yang; Yuan, Guodong; Wang, Yuxiang; Zhang, Lei; Zhao, Jianning; Sun, Zhongyang] Nanjing Univ, Affiliated Jinling Hosp, Med Sch, Dept Orthoped, Nanjing 210093, Peoples R China.
   [Wu, Qi] Tsinghua Univ, Beijing Tsinghua Changgung Hosp, Sch Clin Med, Dept Vasc Surg, Beijing 102218, Peoples R China.
   [Ren, Zhengrong] Nanjing Univ, Sch Life Sci, State Key Lab Pharmaceut Biotechnol, Nanjing 210023, Peoples R China.
   [Sun, Zhongyang] Anhui Med Univ, Air Force Hosp Eastern Theater, Dept Orthoped, Nanjing 210002, Peoples R China.
C3 Nanjing University; Tsinghua University; Nanjing University; Anhui
   Medical University
RP Zhang, L; Zhao, JN; Sun, ZY (通讯作者)，Nanjing Univ, Affiliated Jinling Hosp, Med Sch, Dept Orthoped, Nanjing 210093, Peoples R China.
EM leizhang1987md@163.com; zhaojianning.0207@163.com; szylpxt@163.com
RI Wang, Yuyan/GQZ 8255 2022; 袁, 国栋/GRY 2814 2022; Ren,
   Zhengrong/NHP 6891 2025; Yu, Xin/JDW 8736 2023; Sun,
   Zhongyang/AAW 4093 2021; 吴, 琪/JBS 8638 2023; Chen, Bin/AAA 5877 2021
OI Ren, Zhengrong/0009 0006 0325 6441; Sun, Zhongyang/0000 0002 6558 2174;
   Yu, Xin/0000 0002 8173 1555; 
FU National Natural Science Foundation of China [81972044, CKJ18J019];
   Logistics Research Project of PLA [CKJ20J024, CKJ21J033, BK20221555];
   Foundation Research Project of Jiangsu Province [21XLS18]; Research
   subject of CMC Logistic Support~Department;  [81600694]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 81600694 and 81972044) , the Logistics Research Project
   of PLA (Grant No. CKJ18J019, CKJ20J024, and CKJ21J033) , the Foundation
   Research Project of Jiangsu Province (Grant No. BK20221555) and Research
   subject of CMC Logistic Support & nbsp;Department (Grant No. 21XLS18).
   We also thank Figdraw (www.fi gdraw.com) for the assistance in creating
   the graphical representation in Fig. 9.
CR Aa LX, 2020, ACTA PHARMACOL SIN, V41, P73, DOI 10.1038/s41401 019 0279 8
   Adhikary S, 2018, NUTRITION, V53, P64, DOI 10.1016/j.nut.2017.12.003
   Alam W, 2020, MOLECULES, V25, DOI 10.3390/molecules25184073
   ALSAFFAR N, 1995, ANN RHEUM DIS, V54, P201, DOI 10.1136/ard.54.3.201
   Bangar SP, 2023, CRIT REV FOOD SCI, V63, P9580, DOI 10.1080/10408398.2022.2067121
   Bellavia D, 2021, TRENDS ENDOCRIN MET, V32, P76, DOI 10.1016/j.tem.2020.11.007
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen YQ, 2020, CLIN TRANSL MED, V10, DOI 10.1002/ctm2.240
   Cong YH, 2023, FRONT IMMUNOL, V14, DOI 10.3389/fimmu.2023.1122057
   Dai QG, 2018, JOVE J VIS EXP, DOI 10.3791/56468
   Devi KP, 2015, PHARMACOL RES, V99, P1, DOI 10.1016/j.phrs.2015.05.002
   Ding Y, 2012, BIOMED MATER, V7, DOI 10.1088/1748 6041/7/4/045019
   Dong J, 2022, BIOMATERIALS, V288, DOI 10.1016/j.biomaterials.2022.121742
   Doorn PF, 1998, J BIOMED MATER RES, V42, P103, DOI 10.1002/(SICI)1097 4636(199810)42:1<103::AID JBM13>3.3.CO;2 D
   Goodman SB, 2022, CURR OSTEOPOROS REP, V20, P43, DOI 10.1007/s11914 022 00720 3
   Goodman SB, 2019, J CLIN MED, V8, DOI 10.3390/jcm8122091
   Guan YQ, 2023, PHYTOMEDICINE, V108, DOI 10.1016/j.phymed.2022.154246
   Hodges NA, 2021, BIOMATERIALS, V278, DOI 10.1016/j.biomaterials.2021.121127
   Hong GJ, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.392
   Huang XJ, 2018, MOL MED REP, V18, P2697, DOI 10.3892/mmr.2018.9280
   Jiang H, 2018, JOVE J VIS EXP, DOI 10.3791/56276
   Kang H, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.339
   Ke DS, 2019, FASEB J, V33, P11082, DOI 10.1096/fj.201802597RR
   Kim CJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010125
   Kim H, 2013, CELL METAB, V17, P249, DOI 10.1016/j.cmet.2013.01.002
   Lee CJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0433 0
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Lee WS, 2014, INFLAMMATION, V37, P1221, DOI 10.1007/s10753 014 9849 6
   Li YP, 2020, J IMMUNOL RES, V2020, DOI 10.1155/2020/2462039
   Li YY, 2019, J BONE MINER RES, V34, P1938, DOI 10.1002/jbmr.3810
   Liang MM, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1594 1
   Lin F, 2015, INT IMMUNOPHARMACOL, V28, P859, DOI 10.1016/j.intimp.2015.03.044
   Luo H, 2012, FOOD CHEM, V130, P321, DOI 10.1016/j.foodchem.2011.07.045
   Martiniakova M, 2022, NUTRIENTS, V14, DOI 10.3390/nu14030523
   Mediero A, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003393
   Milosev I, 2009, J BIOMED MATER RES A, V91A, P1100, DOI 10.1002/jbm.a.32301
   Miyanishi K, 2003, J BONE MINER RES, V18, P1573, DOI 10.1359/jbmr.2003.18.9.1573
   Nine MJ, 2014, MATERIALS, V7, P980, DOI 10.3390/ma7020980
   Nowak B, 2017, PHARMACOL REP, V69, P1113, DOI 10.1016/j.pharep.2017.05.002
   Pan DM, 2018, INT IMMUNOPHARMACOL, V55, P174, DOI 10.1016/j.intimp.2017.12.011
   Pang JL, 2006, BIOCHEM PHARMACOL, V71, P818, DOI 10.1016/j.bcp.2005.12.023
   Park Min KH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6418
   Rajendran P, 2014, EUR J MED CHEM, V86, P103, DOI 10.1016/j.ejmech.2014.08.011
   Shin SA, 2020, MOLECULES, V25, DOI 10.3390/molecules25245932
   Sun YX, 2023, PHYTOTHER RES, V37, P2290, DOI 10.1002/ptr.7740
   Tevlin R, 2014, JOVE J VIS EXP, DOI 10.3791/52056
   Tian HW, 2021, EXP EYE RES, V208, DOI 10.1016/j.exer.2021.108627
   Tipping WJ, 2017, CHEM SCI, V8, P5606, DOI 10.1039/c7sc01837a
   Trivedi R, 2008, MOL CELL ENDOCRINOL, V289, P85, DOI 10.1016/j.mce.2008.02.027
   Wang WG, 2014, INT J MOL SCI, V15, P21913, DOI 10.3390/ijms151221913
   Wang ZH, 2017, ACTA BIOMATER, V48, P489, DOI 10.1016/j.actbio.2016.11.020
   Wang ZH, 2015, AUTOPHAGY, V11, P2358, DOI 10.1080/15548627.2015.1106779
   Wattel A, 2003, BIOCHEM PHARMACOL, V65, P35, DOI 10.1016/S0006 2952(02)01445 4
   Wong SK, 2019, DRUG DES DEV THER, V13, P3497, DOI 10.2147/DDDT.S227738
   Wu QJ, 2023, BIOMED PHARMACOTHER, V157, DOI 10.1016/j.biopha.2022.114087
   Wu YL, 2022, J NANOBIOTECHNOL, V20, DOI 10.1186/s12951 022 01320 0
   Xie BC, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.739326
   Xiong LB, 2019, THERANOSTICS, V9, P7140, DOI 10.7150/thno.35988
   Xu XH, 2017, BRAZ J MED BIOL RES, V50, DOI [10.1590/1414 431x20165396, 10.1590/1414 431X20165396]
   Yoon HY, 2013, INT J MOL MED, V32, P971, DOI 10.3892/ijmm.2013.1468
   Zhai ZJ, 2014, BIOMATERIALS, V35, P6299, DOI 10.1016/j.biomaterials.2014.04.044
   Zhang L, 2020, INT J NANOMED, V15, P6705, DOI 10.2147/IJN.S248848
   Zhang L, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00352
   Zhang LW, 2020, THERANOSTICS, V10, P6638, DOI 10.7150/thno.44793
   Zhao JN, 2023, J CONTROL RELEASE, V353, P1068, DOI 10.1016/j.jconrel.2022.12.041
   Zhuang ZL, 2017, MED SCI MONITOR, V23, DOI 10.12659/MSM.902491
NR 66
TC 25
Z9 26
U1 2
U2 13
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD JAN 10
PY 2024
VL 318
AR 117019
DI 10.1016/j.jep.2023.117019
EA AUG 2023
PN B
PG 14
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA Q5JE8
UT WOS:001057874300001
PM 37574017
DA 2025 08 17
ER

PT J
AU Marra, M
   Santini, D
   Tonini, G
   Meo, G
   Zappavigna, S
   Facchini, G
   Morabito, A
   Abbruzzese, A
   Cartenì, G
   Budillon, A
   Caraglia, M
AF Marra, M.
   Santini, D.
   Tonini, G.
   Meo, G.
   Zappavigna, S.
   Facchini, G.
   Morabito, A.
   Abbruzzese, A.
   Carteni, G.
   Budillon, A.
   Caraglia, M.
TI Molecular and preclinical models enhancing anti tumour activity of
   zoledronic acid
SO EJC SUPPLEMENTS
LA English
DT Article; Proceedings Paper
CT 10th National GOIM Congress
CY JUN 22 25, 2008
CL Naples, ITALY
SP GOIM
DE Aminobisphosphonates; Zoledronic acid; Clinical activity;
   Farnesyltransferase inhibitors; Prostate cancer; Breast cancer;
   Docetaxel; Cyr61; Microarray; Invasion
ID REFRACTORY PROSTATE CANCER; NITROGEN CONTAINING BISPHOSPHONATES;
   DRUG DELIVERY STRATEGIES; CELL CULTURES AICC; IN VITRO; TECHNOLOGICAL
   PLATFORMS; ITALIAN ASSOCIATION; BONE RESORPTION; BREAST; DOCETAXEL
AB Zoledronic acid (ZOL) is an aminobisphosphonate able to inhibit the prenylation of intracellular proteins through the inhibition of farnesylpyrophosphate synthase. Prenylation. is essential for the maintenance of the activation of components of signal transduction pathways regulating apoptosis and proliferation such as Ras and Ras related proteins. ZOL has demonstrated a direct anti tumour effect in vitro and in preclinical models, and its ability in preventing skeletal related events is proven in patients with bone metastases from different origins. Clinical evidence on its direct anti proliferative effects is emerging. We describe several strategies in order to improve the anti tumour activity of ZOL. In detail, we illustrate new combinations between ZOL and cytotoxic drugs or other biological agents such as the farnesyltransferase inhibitor tipifarnib focusing on the sequence of administration of these drugs. Moreover, the efforts to find new molecular targets of ZOL through the use of technological platforms such as DNA microarrays are described. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Marra, M.; Meo, G.; Zappavigna, S.; Abbruzzese, A.; Caraglia, M.] Univ Naples Federico 2, Dept Biochem & Biophys, I 80138 Naples, Italy.
   [Marra, M.; Meo, G.; Zappavigna, S.; Caraglia, M.] Natl Canc Inst Fdn G Pascale, Expt Pharmacol Unit, Naples, Italy.
   [Facchini, G.] Natl Canc Inst Fdn G Pascale, Urogenital Canc Unit, Naples, Italy.
   [Morabito, A.] Natl Canc Inst Fdn G Pascale, Clin Trial Unit, Naples, Italy.
   [Carteni, G.] Azienda Osped Rilievo Nazl Cardarelli, Div Oncol, Naples, Italy.
   [Santini, D.; Tonini, G.] Univ Campus Biomed, Rome, Italy.
C3 University of Naples Federico II; IRCCS Fondazione Pascale; IRCCS
   Fondazione Pascale; IRCCS Fondazione Pascale; Antonio Cardarelli
   Hospital; University Campus Bio Medico   Rome Italy
RP Caraglia, M (通讯作者)，Univ Naples Federico 2, Dept Biochem & Biophys, Via Costantinopoli 16, I 80138 Naples, Italy.
EM michele.caraglia@alice.it
RI GIACOMO, CARTENI/K 5810 2016; FACCHINI, GAETANO/P 4491 2015; Budillon,
   Alfredo/K 4763 2016; Morabito, Alessandro/J 4814 2018; Morabito,
   A./J 4814 2018; Facchini, Gaetano/P 4491 2015; Caraglia,
   Michele/AFY 9729 2022; Caraglia, Michele/N 5670 2015; Carteni,
   Giacomo/K 5810 2016
OI FACCHINI, GAETANO/0000 0002 7430 001X; Morabito,
   Alessandro/0000 0002 1319 9608; Budillon, Alfredo/0000 0002 6330 6053;
   Caraglia, Michele/0000 0003 2408 6091; Carteni,
   Giacomo/0000 0003 1441 6376
CR Bellahcène A, 2007, ENDOTHELIUM J ENDOTH, V14, P123, DOI 10.1080/10623320701347187
   Benford HL, 2001, BONE, V28, P465, DOI 10.1016/S8756 3282(01)00412 4
   Boissier S, 2000, CANCER RES, V60, P2949
   Bonjean Karine, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P106
   Caraglia M, 2006, ENDOCR RELAT CANCER, V13, P7, DOI 10.1677/erc.1.01094
   Caraglia M, 2004, ONCOGENE, V23, P6900, DOI 10.1038/sj.onc.1207814
   Caraglia M, 2008, EXPERT OPIN BIOL TH, V8, P1031, DOI [10.1517/14712598.8.7.1031, 10.1517/14712598.8.7.1031 ]
   Caraglia M, 2008, EXPERT OPIN BIOL TH, V8, P845, DOI 10.1517/14712598.8.6.845 
   Caraglia M, 2007, J CELL PHYSIOL, V211, P533, DOI 10.1002/jcp.20960
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   Corey E, 2003, CLIN CANCER RES, V9, P295
   Croucher PI, 2003, J BONE MINER RES, V18, P482, DOI 10.1359/jbmr.2003.18.3.482
   Facchini G, 2007, J EXP CLIN CANC RES, V26, P307
   Ferretti G, 2005, ONCOLOGY BASEL, V69, P35, DOI 10.1159/000087286
   Fleisch H, 2002, BREAST CANCER RES, V4, P30, DOI 10.1186/bcr414
   Fournier P, 2002, CANCER RES, V62, P6538
   Fromigue O, 2000, J BONE MINER RES, V15, P2211, DOI 10.1359/jbmr.2000.15.11.2211
   Green JR, 2003, CANCER, V97, P840, DOI 10.1002/cncr.11128
   Green JR, 2002, DRUG DEVELOP RES, V55, P210, DOI 10.1002/ddr.10071
   HO LH, ONCOGENE        0114
   Kattan JG, 2008, INVEST NEW DRUG, V26, P75, DOI 10.1007/s10637 007 9074 3
   Lee MV, 2001, CANCER RES, V61, P2602
   LIPTON A, 2004, 7 WORKSH BISPH LAB P
   Lipton Allan, 2004, J Support Oncol, V2, P205
   Mönkkönen H, 2006, BRIT J PHARMACOL, V147, P437, DOI 10.1038/sj.bjp.0706628
   MONKKONEN H, LIFE SCI, V81, P1166
   Morgan TM, 2008, PROSTATE, V68, P861, DOI 10.1002/pros.20752
   Neville Webbe HL, 2006, TUMOR BIOL, V27, P92, DOI 10.1159/000092489
   *NOV PHARM CORP, 2005, ZOM ZOL AC INJ PACK
   Pandha H, 2006, J UROLOGY, V176, P2255, DOI 10.1016/j.juro.2006.07.053
   PICKERING LM, 2003, P AN M AM SOC CLIN, V22, P863
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Russell R.G. G., 2006, ANN NY ACAD SCI, V1068, P367
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   Santini D, 2006, NAT CLIN PRACT ONCOL, V3, P325, DOI 10.1038/ncponc0520
   Sato K, 2005, INT J CANCER, V116, P94, DOI 10.1002/ijc.20987
   Senaratne SG, 2002, BRIT J CANCER, V86, P1479, DOI 10.1038/sj.bjc.6600297
   Sewing L, 2008, APOPTOSIS, V13, P782, DOI 10.1007/s10495 008 0211 z
   Skerjanec A, 2003, J CLIN PHARMACOL, V43, P154, DOI 10.1177/0091270002239824
   SOMA MR, 1992, TOXICOL LETT, V64 5, P1, DOI 10.1016/0378 4274(92)90167 I
   Stenbeck G, 2002, SEMIN CELL DEV BIOL, V13, P285, DOI 10.1016/S1084952102000587
   TAS F, MED ONCOL       0119
   Ullén A, 2005, ACTA ONCOL, V44, P644, DOI 10.1080/02841860510029617
   van Beek E, 1999, J BONE MINER RES, V14, P722, DOI 10.1359/jbmr.1999.14.5.722
   VANBEEK E, 1994, J BONE MINER RES, V9, P1875, DOI 10.1002/jbmr.5650091206
   Vordos D, 2004, BJU INT, V94, P524, DOI 10.1111/j.1464 4096.2004.04919.x
   WINTER MC, CANC TREAT REV  0416
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
NR 48
TC 9
Z9 9
U1 0
U2 1
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1359 6349
EI 1878 1217
J9 EJC SUPPL
JI EJC Suppl.
PD OCT
PY 2008
VL 6
IS 14
BP 79
EP 85
DI 10.1016/j.ejcsup.2008.06.023
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Oncology
GA 384JL
UT WOS:000261741000017
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Zhao, HY
   Cai, WS
   Li, S
   Da, ZK
   Sun, HX
   Ma, L
   Lin, YX
   Zhi, DB
AF Zhao, Hongyu
   Cai, Weisong
   Li, Shuai
   Da, Zuke
   Sun, Hanxue
   Ma, Liang
   Lin, Yaoxin
   Zhi, Debao
TI Establishment and characterization of xenograft models of human
   neuroblastoma bone metastasis
SO CHILDS NERVOUS SYSTEM
LA English
DT Article
DE Neuroblastoma; Bone metastasis; Osteolytic response; Animal model
ID CXCR4 EXPRESSION; PLASMA LEVELS; MECHANISMS; TUMOR; INVASION; BIOLOGY;
   GROWTH; CELLS; SURVIVAL; LIGAND
AB Objects To improve the therapy of advanced neuroblastoma (NB), it is critical to develop animal models that mimic NB bone metastases. Unlike the human disease, NB xenograft models rarely metastasize spontaneously to bone from the orthotopic site of primary tumor growth.
   Methods Single cell suspensions of SY5Y, KCNR NB cells were injected directly into the femur of nude mice. Radiological and histological analyses and immunohistochemistry analyses were performed to characterize these osseous NB models. SY5Y and KCNR result in osteolytic responses.
   Results We have detected osteoprotegerin, receptor activator of nuclear factor kappa B ligand, parathyroid hormone related protein, and endothelin 1, proteins associated with bone growth and osteolysis, and C X C chemokine receptor type 4 (CXCR4) involved in tumor growth and tumor cell migration in the NB cells grown in the bone.
   Conclusions These animal models can be used to study biological interactions, pathways, and potential therapeutic targets and also to evaluate new agents for treatment and prevention of NB bone metastasis.
C1 [Zhao, Hongyu; Li, Shuai; Da, Zuke; Ma, Liang; Lin, Yaoxin; Zhi, Debao] China Med Univ, Shengjing Hosp, Dept Neurosurg, Shenyang, Peoples R China.
   [Cai, Weisong] China Med Univ, Shengjing Hosp, Dept Oncol, Shenyang, Peoples R China.
   [Sun, Hanxue] China Med Univ, Shengjing Hosp, Dept Pathol, Shenyang, Peoples R China.
C3 China Medical University; China Medical University; China Medical
   University
RP Zhao, HY (通讯作者)，China Med Univ, Shengjing Hosp, Dept Neurosurg, Shenyang, Peoples R China.
EM zhaocmu1974@yahoo.com.cn
RI Linden, Rafael/F 2275 2011
FU National Natural Science Foundation from China National Science
   Foundation Committee [81172410]
FX This work was supported by National Natural Science Foundation grant
   from China National Science Foundation Committee (project code
   81172410).
CR Ara T, 2006, CANCER METAST REV, V25, P645, DOI 10.1007/s10555 006 9028 9
   Bilir A, 2010, J NEURO ONCOL, V100, P385, DOI 10.1007/s11060 010 0209 6
   Carlisle AJ, 2009, MOL CANCER, V8, DOI 10.1186/1476 4598 8 126
   Dickey A, 2011, J NEURO ONCOL, V104, P145, DOI 10.1007/s11060 010 0491 3
   DuBois SG, 1999, J PEDIAT HEMATOL ONC, V21, P181, DOI 10.1097/00043426 199905000 00005
   Feng CZ, 2012, J BIOL CHEM, V287, P22730, DOI 10.1074/jbc.M111.338590
   Granchi D, 2006, INT J CANCER, V119, P146, DOI 10.1002/ijc.21783
   Granchi D, 2011, BONE, V48, P152, DOI 10.1016/j.bone.2010.06.028
   Hua YQ, 2012, CANCER AM CANCER SOC, V118, P5140, DOI 10.1002/cncr.27496
   Ishola TA, 2007, SURG ONCOL, V16, P149, DOI 10.1016/j.suronc.2007.09.005
   Kroesen M, 2012, IMMUNOTHERAPY UK, V4, P163, DOI [10.2217/IMT.11.169, 10.2217/imt.11.169]
   Li W, 2012, BRAIN RES BULL, V88, P501, DOI 10.1016/j.brainresbull.2012.05.002
   Ma M, 2011, CANCER LETT, V312, P1, DOI 10.1016/j.canlet.2011.06.028
   Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140 6736(07)60983 0
   Matthay KK, 2012, CLIN CANCER RES, V18, P2740, DOI 10.1158/1078 0432.CCR 11 1939
   Meier R, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001016
   Owens C, 2012, CRIT REV CL LAB SCI, V49, P85, DOI 10.3109/10408363.2012.683483
   Park JR, 2008, PEDIATR CLIN N AM, V55, P97, DOI 10.1016/j.pcl.2007.10.014
   Patel LR, 2011, FUTURE ONCOL, V7, P1285, DOI [10.2217/fon.11.112, 10.2217/FON.11.112]
   Peng HJ, 2007, CANCER RES, V67, P9346, DOI 10.1158/0008 5472.CAN 06 4508
   Poretti A, 2012, DEV MED CHILD NEUROL, V54, P297, DOI 10.1111/j.1469 8749.2011.04174.x
   Roodman GD, 2004, NEW ENGL J MED, V351, P195
   Sartelet H, 2012, IN VIVO, V26, P19
   Sharp SE, 2011, SEMIN NUCL MED, V41, P345, DOI 10.1053/j.semnuclmed.2011.05.001
   Sohara Y, 2005, CANCER LETT, V228, P203, DOI 10.1016/j.canlet.2005.01.059
   Sohara Y, 2003, CANCER RES, V63, P3026
   Sorrentino S, 2012, J PEDIAT HEMATOL ONC, V34, P154, DOI [10.1097/MPH.0b013e31821d80be, 10.1097/MPH.0b013e3182281dc3]
   Sun WL, 2012, ONCOTARGETS THER, V5, P21, DOI 10.2147/OTT.S14578
   Suva LJ, 2011, NAT REV ENDOCRINOL, V7, P208, DOI 10.1038/nrendo.2010.227
   van Golen CM, 2006, CANCER RES, V66, P6570, DOI 10.1158/0008 5472.CAN 05 1448
   Yang SB, 2012, ONCOL REP, V28, P186, DOI 10.3892/or.2012.1765
   Zhang LB, 2007, NEOPLASIA, V9, P36, DOI 10.1593/neo.06670
NR 32
TC 5
Z9 6
U1 0
U2 14
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0256 7040
J9 CHILD NERV SYST
JI Childs Nerv. Syst.
PD DEC
PY 2012
VL 28
IS 12
BP 2047
EP 2054
DI 10.1007/s00381 012 1909 3
PG 8
WC Clinical Neurology; Pediatrics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology; Pediatrics; Surgery
GA 038UQ
UT WOS:000311200000008
PM 22983667
DA 2025 08 17
ER

PT J
AU Chen, CY
   Li, RM
   Yang, T
   Ma, LY
   Zhou, S
   Li, M
   Zhou, Y
   Cui, YM
AF Chen, Chaoyang
   Li, Ruoming
   Yang, Ting
   Ma, Lingyun
   Zhou, Shuang
   Li, Min
   Zhou, Ying
   Cui, Yimin
TI Denosumab Versus Zoledronic Acid in the Prevention of Skeletal related
   Events in Vulnerable Cancer Patients: A Meta analysis of Randomized,
   Controlled Trials
SO CLINICAL THERAPEUTICS
LA English
DT Article
DE cancer; denosumab; meta analysis; monoclonal antibodies; multiple
   myeloma; zoledronic acid
ID METASTATIC BONE DISEASE; MULTIPLE MYELOMA; DOUBLE BLIND;
   MONOCLONAL ANTIBODY; AMERICAN SOCIETY; MODIFYING AGENTS; TARGETED
   AGENTS; BREAST CANCER; OSTEONECROSIS; PLACEBO
AB Purpose: Bone metastases from solid tumors and multiple myeloma (MM) represent an important source of morbidity. The present meta analysis was performed with the purpose of comparing the efficacy and tolerability of denosumab versus zoledronic acid (ZA) in the prevention of skeletal related events (SREs) in patients with bone metastases secondary to solid tumors or bone lesions in multiple myeloma.
   Methods: We searched PubMed, PubMed Central, EMBASE, the Cochrane Library, and ClinicalTrials. gov for relevant studies published until April 23, 2020. We included randomized, controlled trials that investigated the efficacy and tolerability of denosumab 120 mg SC versus ZA 4 mg IV, given every 4 weeks, in patients with bone lesions in multiple myeloma or bone metastases secondary to advanced solid tumors. Two reviewers independently identified studies, assessed the risk for bias, and extracted the data. Times to event outcomes were analyzed using hazard ratios (HRs) and 95% CIs. We analyzed tolerability outcomes using risk ratios (RRs) and 95% CIs, with a fixed effects model.
   Findings: Four randomized, controlled trials (7379 patients) were identified as suitable for analysis. The pooled data indicated that denosumab was more favorable than ZA in delaying the time to first on study SRE (HR = 0.86; 95% CI, 0.80 0.93; P = 0.0001) as well as the time to first and subsequent on study SREs (HR = 0.83; 95% CI, 0.76 0.90; P < 0.0001); however, the results on overall survival and disease progression were similar between the 2 drugs. Additionally, denosumab was associated with lower risks for bone pain (risk ratio [RR] = 0.88; 95% CI, 0.80 0.97; P = 0.01), osteonecrosis of the jaw (RR = 0.75; 95% CI, 0.61 0.93; P = 0.007), and acute phase reactions (RR = 0.47; 95% CI, 0.40 0.56; P < 0.00001). (C) 2020 The Authors. Published by Elsevier Inc.
C1 [Chen, Chaoyang; Li, Ruoming; Yang, Ting; Ma, Lingyun; Zhou, Shuang; Li, Min; Zhou, Ying; Cui, Yimin] Peking Univ, Dept Pharm, Hosp 1, 8 Xishiku St, Beijing 100034, Peoples R China.
   [Chen, Chaoyang; Li, Ruoming; Zhou, Shuang; Li, Min; Zhou, Ying; Cui, Yimin] Peking Univ, Sch Pharmaceut Sci, Dept Pharm Adm & Clin Pharm, Hlth Sci Ctr, Beijing, Peoples R China.
C3 Peking University; Peking University
RP Zhou, Y; Cui, YM (通讯作者)，Peking Univ, Dept Pharm, Hosp 1, 8 Xishiku St, Beijing 100034, Peoples R China.
EM zhouying0321@126.com; cui.pharm@pkufh.com
RI cui, yimin/JCE 0464 2023; Li, Menggang/O 7886 2018; ZHOU,
   Ying/ABI 6583 2022
OI Cui, Yi Min/0000 0002 4186 1005
FU Scientific Research Seed Fund of Peking University First Hospital in
   China [2018SF038]
FX This project was supported in part by Scientific Research Seed Fund of
   Peking University First Hospital in China grant 2018SF038 (C.Y.C.).
CR Anderson K, 2018, J CLIN ONCOL, V36, P812, DOI 10.1200/JCO.2017.76.6402
   [Anonymous], 2018, XGEVA DENOSUMAB INJE
   [Anonymous], 2018, ZOMETA ZOLEDRONIC AC
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Body JJ, 2019, J BONE ONCOL, V14, DOI 10.1016/j.jbo.2018.100212
   Body JJ, 2015, EUR J CANCER, V51, P1812, DOI 10.1016/j.ejca.2015.05.016
   Chen FX, 2016, ONCOL RES TREAT, V39, P453, DOI 10.1159/000447372
   Coleman R, 2014, ANN ONCOL, V25, P124, DOI 10.1093/annonc/mdu103
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Corso A, 2005, CANCER, V104, P118, DOI 10.1002/cncr.21104
   Costa L, 2008, SUPPORT CARE CANCER, V16, P879, DOI 10.1007/s00520 008 0418 0
   Diel I, 2020, SUPPORT CARE CANCER, V28, P5223, DOI 10.1007/s00520 020 05357 5
   Ding Y, 2017, ORTHOP SURG, V9, P284, DOI 10.1111/os.12338
   Egloff Juras C, 2018, J ORAL PATHOL MED, V47, P66, DOI 10.1111/jop.12646
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Gralow JR, 2013, J NATL COMPR CANC NE, V11, pS1
   Henry D, 2014, SUPPORT CARE CANCER, V22, P679, DOI 10.1007/s00520 013 2022 1
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Hussain A, 2019, CRIT REV ONCOL HEMAT, V139, P108, DOI 10.1016/j.critrevonc.2019.04.020
   Imatoh T, 2019, J CLIN PHARM THER, V44, P788, DOI 10.1111/jcpt.13004
   Imura Y, 2020, ONCOL LETT, V19, P717, DOI 10.3892/ol.2019.11142
   Kajizono M, 2015, BIOL PHARM BULL, V38, P1850, DOI 10.1248/bpb.b15 00385
   Kotán EV, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen 2018 025600
   Kyle RA, 2003, MAYO CLIN PROC, V78, P21, DOI 10.4065/78.1.21
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Liberati A, 2009, ANN INTERN MED, V151, pW65, DOI [10.1371/journal.pmed.1000100, 10.7326/0003 4819 151 4 200908180 00136]
   Limones A, 2020, MED ORAL PATOL ORAL, V25, pE326, DOI 10.4317/medoral.23324
   Lipton A, 2010, AM J CLIN ONCOL CANC, V33, pS1, DOI 10.1097/COC.0b013e3181deb9e5
   Macedo F, 2017, ONCOL REV, V11, P43, DOI 10.4081/oncol.2017.321
   Menshawy A, 2018, SUPPORT CARE CANCER, V26, P1029, DOI 10.1007/s00520 018 4060 1
   Moher D, 2010, INT J SURG, V8, P336, DOI [10.1371/journal.pmed.1000097, 10.1186/2046 4053 4 1, 10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535, 10.1136/bmj.b2700, 10.1016/j.ijsu.2010.07.299, 10.1136/bmj.i4086]
   Otto S, 2013, J CRANIO MAXILL SURG, V41, P694, DOI 10.1016/j.jcms.2013.05.038
   Vieira CMP, 2019, CANCER MANAG RES, V11, P37, DOI 10.2147/CMAR.S174731
   Raje N, 2016, BLOOD CANCER J, V6, DOI 10.1038/bcj.2015.96
   Raje N, 2018, LANCET ONCOL, V19, P370, DOI 10.1016/S1470 2045(18)30072 X
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Rosen LS, 2003, J CLIN ONCOL, V21, P3150, DOI 10.1200/JCO.2003.04.105
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Saylor PJ, 2020, J CLIN ONCOL, V38, P1736, DOI 10.1200/JCO.19.03148
   Smith Matthew R, 2005, Cancer Treat Rev, V31 Suppl 3, P19, DOI 10.1016/j.ctrv.2005.09.004
   Stopeck A, 2020, J MED ECON, V23, P37, DOI 10.1080/13696998.2019.1651122
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Terpos E, 2015, HAEMATOLOGICA, V100, P1254, DOI 10.3324/haematol.2014.117176
   Van Poznak C, 2017, J CLIN ONCOL, V35, P3978, DOI 10.1200/JCO.2017.75.4614
   Wang W, 2008, CLIN PHARMACOL THER, V84, P548, DOI 10.1038/clpt.2008.170
   Wang ZY, 2015, ONCOLOGIST, V20, P440, DOI 10.1634/theoncologist.2014 0328
   Yong M, 2011, BREAST CANCER RES TR, V129, P495, DOI 10.1007/s10549 011 1475 5
   Zhang ZC, 2017, J BONE ONCOL, V9, P21, DOI 10.1016/j.jbo.2017.09.003
   Zheng GZ, 2017, EUR J CANCER CARE, V26, DOI 10.1111/ecc.12541
NR 51
TC 8
Z9 8
U1 0
U2 3
PU ELSEVIER
PI BRIDGEWATER
PA 685 ROUTE 202 206, BRIDGEWATER, NJ 08807 USA
SN 0149 2918
EI 1879 114X
J9 CLIN THER
JI Clin. Ther.
PD AUG
PY 2020
VL 42
IS 8
BP 1494
EP +
DI 10.1016/j.clinthera.2020.05.019
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA NU1JG
UT WOS:000573396700010
PM 32718784
OA hybrid
DA 2025 08 17
ER

PT J
AU Kim, SH
   Lee, JW
   Choi, KG
   Chung, HW
   Lee, HW
AF Kim, Sook Hui
   Lee, Jin Wha
   Choi, Kyoung Gyu
   Chung, Hye Won
   Lee, Hyang Woon
TI A 6 month longitudinal study of bone mineral density with antiepileptic
   drug monotherapy
SO EPILEPSY & BEHAVIOR
LA English
DT Article
DE antiepileptic drugs; bone mineral density; bone metabolism; bone
   formation; bone resorption; carbamazepine
ID TERM ANTICONVULSANT THERAPY; EPILEPTIC PATIENTS; VITAMIN D;
   CARBAMAZEPINE; TURNOVER; CALCIUM; METABOLISM; VALPROATE; ADULTS; WOMEN
AB Antiepileptic drugs (AEDs) can affect bone metabolism, but the exact mechanisms or differences in individual drugs are still unknown. The purpose of this study was to prospectively investigate the alterations in bone mineral density (BMD) and markers of bone metabolism induced by different AEDs in Koreans with epilepsy. Subjects included 33 drug naive, newly diagnosed patients with epilepsy aged between 18 and 50. BNID at right calcaneus and various markers for bone metabolism were measured before and after 6 months of AED monotherapy including carbamazepine, valproic acid, and lamotrigine. Carbamazepine caused a significant decrease in BMD, which was accompanied by a decrease in the level of vitamin D (25 OHD3). BNID and vitamin D were not affected by 6 months of valproic acid or lamotrigine therapy. Interestingly, valproic acid and lamotrigine, but not carbamazepine, significantly increased osteocalcin, a marker of bone formation. All AEDs almost doubled the parathyroid hormone level, whereas urinary Pyrilinks, a marker of bone resorption, was not affected by those AEDs. These findings suggest that carbamazepine, a hepatic enzyme inducing drug, decreases BMD. (c) 2006 Elsevier Inc. All rights reserved.
C1 Ewha Womans Univ, Coll Med, Dept Neurol, Seoul 120750, South Korea.
   Ewha Womans Univ, Coll Med, Med Res Inst, Seoul 120750, South Korea.
   Ewha Womans Univ, Coll Med, Dept Obstet & Gynecol, Seoul 120750, South Korea.
C3 Ewha Womans University; Ewha Womans University; Ewha Womans University
RP Lee, HW (通讯作者)，Ewha Womans Univ, Coll Med, Dept Neurol, Seoul 120750, South Korea.
EM leeh@ewha.ac.kr
CR Andress DL, 2002, ARCH NEUROL CHICAGO, V59, P781, DOI 10.1001/archneur.59.5.781
   Barrett Connor E, 2005, J BONE MINER RES, V20, P185, DOI 10.1359/JBMR.041007
   BOGLIUN G, 1986, ACTA NEUROL SCAND, V74, P284
   BOUILLON R, 1975, J CLIN ENDOCR METAB, V41, P1130, DOI 10.1210/jcem 41 6 1130
   Brämswig S, 2003, CALCIFIED TISSUE INT, V73, P356, DOI 10.1007/s00223 002 0018 9
   CHRISTIANSEN C, 1983, ACTA NEUROL SCAND, V67, P21
   CHUNG SJ, 1994, BRAIN DEV JPN, V16, P382, DOI 10.1016/0387 7604(94)90125 2
   DAVIE MWJ, 1983, Q J MED, V52, P79
   Drezner MK, 2004, EPILEPSY BEHAV, V5, pS41, DOI 10.1016/j.yebeh.2003.11.028
   Feldkamp J, 2000, EXP CLIN ENDOCR DIAB, V108, P37
   Fitzpatrick LA, 2004, EPILEPSY BEHAV, V5, pS3, DOI 10.1016/j.yebeh.2003.11.026
   GOUGH H, 1986, Q J MED, V59, P569
   Guo CY, 2001, EPILEPSIA, V42, P1141, DOI 10.1046/j.1528 1157.2001.416800.x
   HAHN TJ, 1972, NEW ENGL J MED, V287, P900, DOI 10.1056/NEJM197211022871803
   HOIKKA V, 1981, ACTA NEUROL SCAND, V64, P122
   HOIKKA V, 1984, ACTA NEUROL SCAND, V70, P77
   KRUSE K, 1987, J PEDIATR US, V111, P57, DOI 10.1016/S0022 3476(87)80342 6
   Kumandas S, 2006, J PEDIATR ENDOCR MET, V19, P529
   OHARE JA, 1980, ACTA NEUROL SCAND, V62, P282
   Pack AM, 2001, CNS DRUGS, V15, P633, DOI 10.2165/00023210 200115080 00006
   Pack AM, 2003, EPILEPSY BEHAV, V4, P169, DOI 10.1016/S1525 5050(03)00036 2
   Pack AM, 2005, ANN NEUROL, V57, P252, DOI 10.1002/ana.20378
   Pedrera JD, 2000, EUR J CLIN INVEST, V30, P895, DOI 10.1046/j.1365 2362.2000.00731.x
   PENTO JT, 1973, ENDOCRINOLOGY, V92, P330, DOI 10.1210/endo 92 1 330
   Pluskiewicz W, 1997, ULTRASOUND MED BIOL, V23, P553, DOI 10.1016/S0301 5629(97)00036 7
   Pothiwala P, 2006, J WOMENS HEALTH, V15, P709, DOI 10.1089/jwh.2006.15.709
   Sato Y, 2001, NEUROLOGY, V57, P445, DOI 10.1212/WNL.57.3.445
   Sheth RD, 2004, LANCET NEUROL, V3, P516, DOI 10.1016/S1474 4422(04)00848 8
   SHETH RD, 1995, J PEDIATR US, V127, P256, DOI 10.1016/S0022 3476(95)70304 7
   SKILLEN AW, 1976, CLIN CHIM ACTA, V72, P245, DOI 10.1016/0009 8981(76)90080 2
   STAMP TCB, 1972, BRIT MED J, V4, P9, DOI 10.1136/bmj.4.5831.9
   Stephen LJ, 1999, SEIZURE EUR J EPILEP, V8, P339, DOI 10.1053/seiz.1999.0301
   TJELLESEN L, 1983, ACTA NEUROL SCAND, V68, P424, DOI 10.1111/j.1600 0404.1983.tb04854.x
   VALIMAKI MJ, 1994, J BONE MINER RES, V9, P631
   VERNILLO AT, 1990, BONE, V11, P309, DOI 10.1016/8756 3282(90)90085 D
   Verrotti A, 2002, EPILEPSIA, V43, P1488, DOI 10.1046/j.1528 1157.2002.13002.x
   Verrotti A, 2000, ANN NEUROL, V47, P385, DOI 10.1002/1531 8249(200003)47:3<385::AID ANA18>3.0.CO;2 W
   VOGEL JM, 1988, BONE MINER, V5, P35, DOI 10.1016/0169 6009(88)90005 0
   WEINSTEIN RS, 1984, J CLIN ENDOCR METAB, V58, P1003, DOI 10.1210/jcem 58 6 1003
NR 39
TC 107
Z9 113
U1 0
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 1525 5050
EI 1525 5069
J9 EPILEPSY BEHAV
JI Epilepsy Behav.
PD MAR
PY 2007
VL 10
IS 2
BP 291
EP 295
DI 10.1016/j.yebeh.2006.11.007
PG 5
WC Behavioral Sciences; Clinical Neurology; Psychiatry
WE Science Citation Index Expanded (SCI EXPANDED)
SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry
GA 156WR
UT WOS:000245681100013
PM 17224308
DA 2025 08 17
ER

PT J
AU De Vita, A
   Vanni, S
   Miserocchi, G
   Fausti, V
   Pieri, F
   Spadazzi, C
   Cocchi, C
   Liverani, C
   Calabrese, C
   Casadei, R
   Recine, F
   Gurrieri, L
   Bongiovanni, A
   Ibrahim, T
   Mercatali, L
AF De Vita, Alessandro
   Vanni, Silvia
   Miserocchi, Giacomo
   Fausti, Valentina
   Pieri, Federica
   Spadazzi, Chiara
   Cocchi, Claudia
   Liverani, Chiara
   Calabrese, Chiara
   Casadei, Roberto
   Recine, Federica
   Gurrieri, Lorena
   Bongiovanni, Alberto
   Ibrahim, Toni
   Mercatali, Laura
TI A Rationale for the Activity of Bone Target Therapy and Tyrosine Kinase
   Inhibitor Combination in Giant Cell Tumor of Bone and Desmoplastic
   Fibroma: Translational Evidences
SO BIOMEDICINES
LA English
DT Article
DE bone sarcoma; giant cell tumor of bone; desmoplastic fibroma; primary
   culture; 3D scaffold; gene expression profiling; denosumab; lenvatinib;
   zebrafish
ID DENOSUMAB; EXPRESSION; VEGF
AB Giant cell tumor of bone (GCTB) and desmoplastic fibroma (DF) are bone sarcomas with intermediate malignant behavior and unpredictable prognosis. These locally aggressive neoplasms exhibit a predilection for the long bone or mandible of young adults, causing a severe bone resorption. In particular, the tumor stromal cells of these lesions are responsible for the recruiting of multinucleated giant cells which ultimately lead to bone disruption. In this regard, the underlying pathological mechanism of osteoclastogenesis processes in GCTB and DF is still poorly understood. Although current therapeutic strategy involves surgery, radiotherapy and chemotherapy, the benefit of the latter is still debated. Thus, in order to shed light on these poorly investigated diseases, we focused on the molecular biology of GCTB and DF. The expression of bone vicious cycle  and neoangiogenesis related genes was investigated. Moreover, combining patient derived primary cultures with 2D and 3D culture platforms, we investigated the role of denosumab and levantinib in these diseases. The results showed the upregulation of RANK L, RANK, OPN, CXCR4, RUNX2 and FLT1 and the downregulation of OPG and CXCL12 genes, underlining their involvement and promising role in these neoplasms. Furthermore, in vitro analyses provided evidence for suggesting the combination of denosumab and lenvatinib as a promising therapeutic strategy in GCTB and DF compared to monoregimen chemotherapy. Furthermore, in vivo zebrafish analyses corroborated the obtained data. Finally, the clinical observation of retrospectively enrolled patients confirmed the usefulness of the reported results. In conclusion, here we report for the first time a molecular and pharmacological investigation of GCTB and DF combining the use of translational and clinical data. Taken together, these results represent a starting point for further analyses aimed at improving GCTB and DF management.
C1 [De Vita, Alessandro; Vanni, Silvia; Miserocchi, Giacomo; Fausti, Valentina; Spadazzi, Chiara; Cocchi, Claudia; Liverani, Chiara; Calabrese, Chiara; Gurrieri, Lorena; Bongiovanni, Alberto; Mercatali, Laura] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amado, Osteoncol & Rare Tumors Ctr, I 47014 Meldola, Italy.
   [Pieri, Federica] Morgagni Pierantoni Hosp, Pathol Unit, I 47121 Forli, Italy.
   [Casadei, Roberto] Morgagni Pierantoni Hosp, Orthoped Unit, I 47121 Forli, Italy.
   [Recine, Federica] Azienda Osped San Giovanni Addolorata, Med Oncol Unit, I 00184 Rome, Italy.
   [Ibrahim, Toni] IRCCS Ist Ortoped Rizzoli, Osteoncol Bone & Soft Tissue Sarcomas & Innovat T, I 40136 Bologna, Italy.
RP Vanni, S (通讯作者)，IRCCS Ist Romagnolo Studio Tumori IRST Dino Amado, Osteoncol & Rare Tumors Ctr, I 47014 Meldola, Italy.
EM alessandro.devita@irst.emr.it; silvia.vanni@irst.emr.it;
   giacomo.miserocchi@irst.emr.it; valentina.fausti@irst.emr.it;
   federica.pieri@auslromagna.it; chiara.spadazzi@irst.emr.it;
   claudia.cocchi@irst.emr.it; chiara.liverani@irst.emr.it;
   chiara.calabrese@irst.emr.it; roberto.casadei@auslromagna.it;
   federica.recine@irst.emr.it; lorena.gurrieri@irst.emr.it;
   alberto.bongiovanni@irst.emr.it; toni.ibrahim@ior.it;
   laura.mercatali@irst.emr.it
RI ; Miserocchi, Giacomo/AAA 7159 2021; Fausti, Valentina/AAA 6071 2021;
   Gurrieri, Lorena/AAC 2832 2019; Vanni, Silvia/AAA 7149 2021; Liverani,
   Chiara/K 3913 2016; Mercatali, Laura/J 9154 2016; Spadazzi,
   Chiara/AAB 5917 2021; De Vita, Alessandro/K 1534 2016; Bongiovanni,
   Alberto/J 9802 2018; Ibrahim, Toni/IQR 9219 2023; Cocchi,
   Claudia/AAB 8902 2021
OI Bongiovanni, Alberto/0000 0002 3845 4687; Fausti,
   Valentina/0000 0003 0432 1445; Liverani, Chiara/0000 0002 4279 1926;
   Cocchi, Claudia/0000 0002 7736 9039; Vanni, Silvia/0000 0003 1192 7322;
   De Vita, Alessandro/0000 0002 1677 5797; Gurrieri,
   Lorena/0000 0001 8935 8794; Calabrese, Chiara/0000 0002 3543 6918;
   Calabrese, Chiara/0000 0003 3388 2217
CR Agrawal AC, 2021, CUREUS J MED SCIENCE, V13, DOI 10.7759/cureus.16150
   Balke M, 2008, J CANCER RES CLIN, V134, P969, DOI 10.1007/s00432 008 0370 x
   Bianchi ME, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02109
   Bohm P, 1996, CANCER, V78, P1011, DOI 10.1002/(SICI)1097 0142(19960901)78:5<1011::AID CNCR11>3.0.CO;2 5
   Boss DS, 2012, BRIT J CANCER, V106, P1598, DOI 10.1038/bjc.2012.154
   BRIDGE JA, 1990, CANCER AM CANCER SOC, V65, P2697, DOI 10.1002/1097 0142(19900615)65:12<2697::AID CNCR2820651217>3.0.CO;2 3
   CAMPANACCI M, 1987, J BONE JOINT SURG AM, V69A, P106, DOI 10.2106/00004623 198769010 00018
   Chawla S, 2013, LANCET ONCOL, V14, P901, DOI 10.1016/S1470 2045(13)70277 8
   De Vita A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222111564
   De Vita A, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046 021 01963 1
   De Vita A, 2018, JOVE J VIS EXP, DOI 10.3791/56767
   ENNEKING WF, 1986, CLIN ORTHOP RELAT R, P9
   Errani C, 2010, CANCER TREAT REV, V36, P1, DOI 10.1016/j.ctrv.2009.09.002
   Evans S, 2014, J BONE ONCOL, V3, P77, DOI 10.1016/j.jbo.2014.08.001
   Gamberi G, 1998, J ORTHOP RES, V16, P1, DOI 10.1002/jor.1100160102
   Gaspar N, 2021, LANCET ONCOL, V22, P1312, DOI 10.1016/S1470 2045(21)00387 9
   Hao ZL, 2020, ONCOLOGIST, V25, pE302, DOI 10.1634/theoncologist.2019 0407
   He YF, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 04161 1
   Ishizaka T, 2021, J ORTHOP SCI, V26, P306, DOI 10.1016/j.jos.2018.07.011
   Jaffe H.L., 1959, Academic Medicine, V34, P72, DOI 10.1097/00001888 195901000 00023
   JAFFE HL, 1953, ANN ROY COLL SURG, V13, P343
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   Kumta SM, 2003, LIFE SCI, V73, P1427, DOI 10.1016/S0024 3205(03)00434 X
   Lipplaa A, 2019, CURR OPIN ONCOL, V31, P329, DOI 10.1097/CCO.0000000000000529
   Liverani C, 2014, BONE, V66, P214, DOI 10.1016/j.bone.2014.06.017
   Lucas David R, 2012, Surg Pathol Clin, V5, P183, DOI 10.1016/j.path.2011.07.012
   Lucasti Christopher, 2021, J Spine Surg, V7, P208, DOI 10.21037/jss 20 652
   Mercatali L, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081655
   Miserocchi G, 2021, CANCER BIOL MED, V18, P502, DOI 10.20892/j.issn.2095 3941.2020.0482
   Nag H L, 2003, J Orthop Surg (Hong Kong), V11, P90
   Nakano K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030739
   Nedopil Alexander, 2013, Open Orthop J, V8, P40, DOI 10.2174/1874325001307010040
   Puri A, 2007, J PEDIATR ORTHOPED, V27, P635, DOI 10.1097/BPO.0b013e3181425629
   Raikwar NS, 2013, EXP CELL RES, V319, P2578, DOI 10.1016/j.yexcr.2013.07.005
   Ramírez González MA, 2020, INT J SURG CASE REP, V77, P560, DOI 10.1016/j.ijscr.2020.11.112
   Raskin KA, 2013, J AM ACAD ORTHOP SUR, V21, P118, DOI 10.5435/JAAOS 21 02 118
   Roitman PD, 2017, HUM PATHOL, V63, P89, DOI 10.1016/j.humpath.2017.02.008
   Rutkowski P, 2018, EJSO EUR J SURG ONC, V44, P1384, DOI 10.1016/j.ejso.2018.03.020
   SANFILIPPO NJ, 1995, SOUTHERN MED J, V88, P1267, DOI 10.1097/00007611 199512000 00016
   Singh VA, 2020, J ORTHOP SURG HONG K, V28, DOI 10.1177/2309499020979750
   Taylor RM, 2012, LAB INVEST, V92, P1398, DOI 10.1038/labinvest.2012.108
   Thomas D, 2010, LANCET ONCOL, V11, P275, DOI 10.1016/S1470 2045(10)70010 3
   Traub F, 2016, EUR J CANCER, V59, P1, DOI 10.1016/j.ejca.2016.01.006
   van der Heijden L, 2014, ONCOLOGIST, V19, P550, DOI 10.1634/theoncologist.2013 0432
   WHO Classification of Tumours, 2020, SOFT TISS BON TUM
   Woods TR, 2015, HEAD NECK PATHOL, V9, P196, DOI 10.1007/s12105 014 0561 5
   Xgeva INN Denosumab European Medicines Agency, 2011, ASS REP XGEVA INT NO
   Yayan J, 2020, CANCER CONTROL, V27, DOI 10.1177/1073274820934822
   Yoshimatsu Y, 2021, HUM CELL, V34, P1899, DOI 10.1007/s13577 021 00579 z
   Zhao HL, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0391 6
NR 50
TC 39
Z9 39
U1 1
U2 16
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
EI 2227 9059
J9 BIOMEDICINES
JI Biomedicines
PD FEB
PY 2022
VL 10
IS 2
AR 372
DI 10.3390/biomedicines10020372
PG 17
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA ZL9XR
UT WOS:000764022400001
PM 35203581
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Cha, S
   Wang, JY
   Lee, SM
   Tan, Z
   Zhao, Q
   Bai, D
AF Cha, Sa
   Wang, Jiangyue
   Lee, Sueng Min
   Tan, Zhen
   Zhao, Qing
   Bai, Ding
TI Clock modified mesenchymal stromal cells therapy rescues molecular
   circadian oscillation and age related bone loss via miR142 3p/Bmal1/YAP
   signaling axis
SO CELL DEATH DISCOVERY
LA English
DT Article
ID STEM CELLS; GENE EXPRESSION; MARROW; PROLIFERATION; BMAL1; ARCHITECTURE;
   METABOLISM; CULTURE; LIGHT; WEB
AB Age related bone loss and disease strongly affect the quality of life of the elderly population. Cellular circadian rhythms have been reported to regulate bone aging, and micro RNAs (miRNAs) play crucial posttranscriptional regulatory roles in the peripheral clock network. Proliferation capability, osteogenic lineage commitment, senescence associated secreted phenotype (SASP) and circadian oscillation of clock genes under osteogenic condition were assessed in bone marrow mesenchymal stromal cells (BMSCs) from young adult and aged adult mice. miRNAs targeting the core clock gene brain and muscle arntl like protein 1 (Bmal1) were screened and verified in young and old BMSCs with RT qPCR and Western Blot analysis. ChIP seq and RNA seq datasets were mined to define the downstream mechanism and gain  and loss of function genetic experiments were performed to confirm the hypothesis. To compare the therapeutic effect of these clock engineered BMSCs, SASP and osteogenic capability of Bmal1 overexpressing and miR 142 3p inhibited BMSCs were investigated in vitro and transplanted into bone defects and femur cavities of aged mice. Aged BMSCs displayed an abolished circadian rhythm, impaired self renewal capability and decreased osteoblast differentiation. miR 142 3p was elevated with aging, which downregulated Bmal1 and diminished the osteogenic potential of BMSCs. In addition, Bmal1 inhibited YAP expression to promote BMSCs osteogenesis, which was independent from the activation of Hippo signaling pathway. Overexpression of Bmal1 or inhibition of miR 142 3p rescued the molecular temporal rhythm and osteoblast differentiation ex vivo. Cell based circadian therapy showed improved bone formation and higher turnover levels in vivo. This study demonstrates that transcriptional and post transcriptional level clock modified BMSCs rescued circadian oscillation and age related bone loss via miR 142 3p/Bmal1/YAP signaling axis. These data provide promising clinical prospects of circadian mediated stromal cell based therapy and bone tissue regeneration.
C1 [Cha, Sa; Wang, Jiangyue; Lee, Sueng Min; Tan, Zhen; Zhao, Qing; Bai, Ding] Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu, Peoples R China.
   [Cha, Sa; Wang, Jiangyue; Lee, Sueng Min; Tan, Zhen; Zhao, Qing; Bai, Ding] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Chengdu, Peoples R China.
C3 Sichuan University; Sichuan University
RP Zhao, Q; Bai, D (通讯作者)，Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu, Peoples R China.; Zhao, Q; Bai, D (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Chengdu, Peoples R China.
EM fanfan_qing@163.com; baiding@scu.edu.cn
OI Bai, Ding/0000 0002 5058 4329; Cha, Sa/0000 0003 4126 8620
FU National Natural Science Foundation of China [81870745, 82071146]
FX The work was support by National Natural Science Foundation of China
   (grant number 81870745 and 82071146).
CR Alvarez Saavedra M, 2011, HUM MOL GENET, V20, P731, DOI 10.1093/hmg/ddq519
   Ambrosi TH, 2017, CELL STEM CELL, V20, P771, DOI 10.1016/j.stem.2017.02.009
   Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092 8674(00)81199 X
   Bergman RJ, 1996, J BONE MINER RES, V11, P568
   Chen RM, 2013, CURR BIOL, V23, P1959, DOI 10.1016/j.cub.2013.08.005
   Chen YJ, 2012, ARCH MED SCI, V8, P30, DOI 10.5114/aoms.2012.27277
   Cheng HYM, 2007, NEURON, V54, P813, DOI 10.1016/j.neuron.2007.05.017
   Curtis AM, 2015, P NATL ACAD SCI USA, V112, P7231, DOI 10.1073/pnas.1501327112
   Dierickx P, 2018, EMBO REP, V19, P18, DOI 10.15252/embr.201745130
   EGRISE D, 1992, BONE, V13, P355, DOI 10.1016/8756 3282(92)90451 2
   Farr JN, 2016, J BONE MINER RES, V31, P1920, DOI 10.1002/jbmr.2892
   Gerhart Hines Z, 2015, ENDOCR REV, V36, P289, DOI 10.1210/er.2015 1007
   Green CB, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a030692
   Hassan N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183359
   Hastings MH, 2003, NAT REV NEUROSCI, V4, P649, DOI 10.1038/nrn1177
   Hirano A, 2013, CELL, V152, P1106, DOI 10.1016/j.cell.2013.01.054
   Hoyle NP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal2774
   Huang S, 2015, J ORTHOP TRANSL, V3, P26, DOI 10.1016/j.jot.2014.07.005
   Kegelman CD, 2020, CURR OSTEOPOROS REP, V18, P526, DOI 10.1007/s11914 020 00605 3
   Koike N, 2012, SCIENCE, V338, P349, DOI 10.1126/science.1226339
   Kondratov RV, 2006, GENE DEV, V20, P1868, DOI 10.1101/gad.1432206
   Koronowski KB, 2019, CELL, V177, P1448, DOI 10.1016/j.cell.2019.04.025
   Lee KH, 2013, MOL BIOL CELL, V24, P2248, DOI 10.1091/mbc.E12 12 0849
   Li F, 2010, BONE, V47, P546, DOI 10.1016/j.bone.2010.05.040
   Lin FW, 2013, CELL BIOCHEM FUNCT, V31, P166, DOI 10.1002/cbf.2871
   Liu W, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10771
   Menet JS, 2012, ELIFE, V1, DOI 10.7554/eLife.00011
   Mengatto CM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015848
   Nehlin JO, 2019, BONE, V123, P265, DOI 10.1016/j.bone.2019.03.041
   Pan JX, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0018 7
   Parasram K, 2018, STEM CELL REP, V11, P1287, DOI 10.1016/j.stemcr.2018.10.010
   Partch CL, 2014, TRENDS CELL BIOL, V24, P90, DOI 10.1016/j.tcb.2013.07.002
   Rogers EH, 2018, BIOGERONTOLOGY, V19, P497, DOI 10.1007/s10522 018 9772 6
   Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246
   Schibler U, 2002, CELL, V111, P919, DOI 10.1016/S0092 8674(02)01225 4
   Seo E, 2013, CELL REP, V3, P2075, DOI 10.1016/j.celrep.2013.05.029
   Sivaraj KK, 2020, ELIFE, V9, DOI 10.7554/eLife.50770
   Suchacki KJ, 2016, CURR OPIN PHARMACOL, V28, P50, DOI 10.1016/j.coph.2016.03.001
   Sutton GM, 2010, FASEB J, V24, P862, DOI 10.1096/fj.09 142000
   Takarada T, 2017, J BONE MINER RES, V32, P872, DOI 10.1002/jbmr.3053
   Takarada T, 2012, J BIOL CHEM, V287, P36081, DOI 10.1074/jbc.M112.408963
   Yan J, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000193
   Zhang R, 2014, P NATL ACAD SCI USA, V111, P16219, DOI 10.1073/pnas.1408886111
   Zheng CX, 2019, INT J ORAL SCI, V11, DOI 10.1038/s41368 019 0060 3
   Zhou W, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578 020 00508 x
   Zhuo HY, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/3407821
NR 46
TC 20
Z9 26
U1 2
U2 28
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
EI 2058 7716
J9 CELL DEATH DISCOV
JI Cell Death Discov.
PD MAR 12
PY 2022
VL 8
IS 1
AR 111
DI 10.1038/s41420 022 00908 7
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA ZR7CL
UT WOS:000767936200002
PM 35279674
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kilickap, S
   Ozdamar, Y
   Altundag, MK
   Dizdar, O
AF Kilickap, Saadettin
   Ozdamar, Yasemin
   Altundag, M. Kadri
   Dizdar, Omer
TI A case report: zoledronic acid induced anterior uveitis
SO MEDICAL ONCOLOGY
LA English
DT Article
DE zoledronic acid; cancer; uveitis; side effect; pathogenesis
ID BONE METASTASES; BREAST CANCER; BISPHOSPHONATES; PAMIDRONATE; THERAPY
AB Background Bisphosphonates prevent bone loss by binding on active sites of bone remodeling and inhibiting osteoclast mediated bone resorption. Zoledronic acid is recommended for patients with bone metastases from breast, prostate, and lung cancers. Objective To report a case of anterior uveitis after the infusion of zoledronic acid. Case Summary A breast cancer patient with bone metastasis was admitted with pain, visual loss, hyperemia, and periorbital swelling in her right eye 24 h after the first dose of zoledronic acid. Biomicroscopic anterior segment examination of the right eye showed corneal keratic precipitates, ciliary injection, and moderate amount of cells in anterior chamber. With the diagnosis of right anterior uveitis, topical prednisolone acetate (1%) was started, and her symptoms completely resolved within 1 week. Use of the Naranjo probability scale indicated a probable relationship between uveitis and zoledronic acid therapy in our patient. Discussion Uveitis is a rare complication of zoledronic acid. The mechanism is unclear. Proinflammatory cytokines such as TNF alpha and IL 6 may also play a role in pathogenesis of zoledronic acid related uveitis. Conclusion Zoledronic acid may be associated with inflammatory eye diseases and result in serious ocular damage.
C1 [Kilickap, Saadettin; Altundag, M. Kadri; Dizdar, Omer] Hacettepe Univ, Inst Oncol, Dept Oncol, TR 06100 Ankara, Turkey.
   [Ozdamar, Yasemin] Ankara Ulucanlar Eye Res Hosp, Dept Retina, Ankara, Turkey.
C3 Hacettepe University; Ankara Ulucanlar Eye Training & Research Hospital
RP Kilickap, S (通讯作者)，Hacettepe Univ, Inst Oncol, Dept Oncol, TR 06100 Ankara, Turkey.
EM skilickap@yahoo.com
RI Kilickap, Saadettin/AAP 3732 2021; Özdamar Erol, Yasemin/JXX 4915 2024
OI Kilickap, Saadettin/0000 0003 1637 7390
CR Benderson D, 2006, CLIN LYMPHOMA MYELOM, V7, P145, DOI 10.3816/CLM.2006.n.053
   Body JJ, 2004, SEMIN NEPHROL, V24, P48, DOI 10.1053/j.semnephrol.2003.08.015
   Curnow SJ, 2006, CURR OPIN OPHTHALMOL, V17, P532, DOI 10.1097/ICU.0b013e32801094b5
   Dicuonzo G, 2003, J INTERF CYTOK RES, V23, P649, DOI 10.1089/107999003322558782
   Durnian JM, 2005, EYE, V19, P221, DOI 10.1038/sj.eye.6701461
   El Saghir NS, 2005, BMC CANCER, V5, DOI 10.1186/1471 2407 5 156
   Fraunfelder FW, 2003, NEW ENGL J MED, V348, P1187, DOI 10.1056/NEJM200303203481225
   GHOSE K, 1994, AUST NZ J MED, V24, P320, DOI 10.1111/j.1445 5994.1994.tb02186.x
   Gilhotra JS, 2006, BRIT J OPHTHALMOL, V90, P798, DOI 10.1136/bjo.2006.092189
   Green JR, 2003, CANCER, V97, P840, DOI 10.1002/cncr.11128
   Malik AR, 2002, BRIT J OPHTHALMOL, V86, P1443, DOI 10.1136/bjo.86.12.1443
   Michaelson MD, 2005, J CLIN ONCOL, V23, P8219, DOI 10.1200/JCO.2005.02.9579
   NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154
   Ooi KGJ, 2006, CLIN MED RES, V4, P294, DOI 10.3121/cmr.4.4.294
   Rey J, 2000, JOINT BONE SPINE, V67, P337
   Salmen Siham, 2002, Invest. clín, V43, P49
   Wardley A, 2005, BRIT J CANCER, V92, P1869, DOI 10.1038/sj.bjc.6602551
NR 17
TC 22
Z9 25
U1 0
U2 6
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1357 0560
J9 MED ONCOL
JI Med. Oncol.
PD JUN
PY 2008
VL 25
IS 2
BP 238
EP 240
DI 10.1007/s12032 007 9006 2
PG 3
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 303GJ
UT WOS:000256028700019
PM 18488162
DA 2025 08 17
ER

PT J
AU Moore, ER
   Zhu, YX
   Ryu, HS
   Jacobs, CR
AF Moore, Emily R.
   Zhu, Ya Xing
   Ryu, Han Seul
   Jacobs, Christopher R.
TI Periosteal progenitors contribute to load induced bone formation in
   adult mice and require primary cilia to sense mechanical stimulation
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Primary cilium; Periosteal progenitors; Osteoblasts;
   Osteochondroprogenitors; Mechanotransduction; Bone regeneration; Prx1
ID MESENCHYMAL STEM CELLS; GROWTH FACTOR BETA; ANTIRESORPTIVE DRUGS;
   GENE EXPRESSION; IN VIVO; MARROW; DIFFERENTIATION; OSTEOCYTES;
   PROLIFERATION; OSTEOBLASTS
AB Background: The fully developed adult skeleton adapts to mechanical forces by generating more bone, usually at the periosteal surface. Progenitor cells in the periosteum are believed to differentiate into bone forming osteoblasts that contribute to load induced adult bone formation, but in vivo evidence does not yet exist. Furthermore, the mechanism by which periosteal progenitors might sense physical loading and trigger differentiation is unknown. We propose that periosteal osteochondroprogenitors (OCPs) directly sense mechanical load and differentiate into bone forming osteoblasts via their primary cilia, mechanosensory organelles known to be involved in osteogenic differentiation.
   Methods: We generated a diphtheria toxin ablation mouse model and performed ulnar loading and dynamic histomorphometry to quantify the contribution of periosteal OCPs in adult bone formation in vivo. We also generated a primary cilium knockout model and isolated periosteal cells to study the role of the cilium in periosteal OCP mechanosensing in vitro. Experimental groups were compared using one way analysis of variance or student's t test, and sample size was determined to achieve a minimum power of 80%.
   Results: Mice without periosteal OCPs had severely attenuated mechanically induced bone formation and lacked the mineralization necessary for daily skeletal maintenance. Our in vitro results demonstrate that OCPs in the periosteum uniquely sense fluid shear and exhibit changes in osteogenic markers consistent with osteoblast differentiation; however, this response is essentially lost when the primary cilium is absent.
   Conclusions: Combined, our data show that periosteal progenitors are a mechanosensitive cell source that significantly contribute to adult skeletal maintenance. More importantly, an OCP population persists in the adult skeleton and these cells, as well as their cilia, are promising targets for bone regeneration strategies.
C1 [Moore, Emily R.; Zhu, Ya Xing; Ryu, Han Seul; Jacobs, Christopher R.] Columbia Univ, Dept Biomed Engn, 500 W 120th St, New York, NY 10027 USA.
C3 Columbia University
RP Moore, ER (通讯作者)，Columbia Univ, Dept Biomed Engn, 500 W 120th St, New York, NY 10027 USA.
EM erm17@case.edu
RI Moore, Emily/K 1459 2019
OI Ryu, Han Seul/0000 0001 9938 4902; Moore, Emily R./0000 0001 5141 0550
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases at
   the National Institutes of Health [R01 AR062177]; National Institutes of
   Health [T32 AR59038, S10OD020056]
FX This work was supported by National Institute of Arthritis and
   Musculoskeletal and Skin Diseases at the National Institutes of Health
   grant R01 AR062177, National Institutes of Health training grant
   T32 AR59038, and National Institutes of Health award S10OD020056.
CR Arnsdorf EJ, 2009, TISSUE ENG PT A, V15, P2637, DOI 10.1089/ten.TEA.2008.0244
   Arnsdorf EJ, 2009, J CELL SCI, V122, P546, DOI 10.1242/jcs.036293
   Bakker AD, 2014, J DENT RES, V93, P394, DOI 10.1177/0022034514522485
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Besschetnova TY, 2010, CURR BIOL, V20, P182, DOI 10.1016/j.cub.2009.11.072
   Birkhold AI, 2016, SCI REP UK, V6, DOI 10.1038/srep23480
   BONEWALD LF, 1990, CLIN ORTHOP RELAT R, P261
   Brady RT, 2015, BIOCHEM BIOPH RES CO, V459, P118, DOI 10.1016/j.bbrc.2015.02.080
   Castro Silva II, 2012, CLIN ORAL IMPLAN RES, V23, P1238, DOI 10.1111/j.1600 0501.2011.02287.x
   Chen JC, 2016, FASEB J, V30, P1504, DOI 10.1096/fj.15 276402
   Clement CA, 2013, CELL REP, V3, P1806, DOI 10.1016/j.celrep.2013.05.020
   Colnot C, 2009, J BONE MINER RES, V24, P274, DOI 10.1359/JBMR.081003
   Crane JL, 2013, BONE RES, V1, DOI 10.4248/BR201302007
   De Bari C, 2006, ARTHRITIS RHEUM, V54, P1209, DOI 10.1002/art.21753
   de Lageneste OD, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03124 z
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Ding L, 2013, NATURE, V495, P231, DOI 10.1038/nature11885
   Ferretti Concetta, 2014, World J Stem Cells, V6, P266, DOI 10.4252/wjsc.v6.i3.266
   Greenbaum A, 2013, NATURE, V495, P227, DOI 10.1038/nature11926
   Heino TJ, 2004, EXP CELL RES, V294, P458, DOI 10.1016/j.yexcr.2003.11.016
   Hoey DA, 2012, STEM CELLS, V30, P2561, DOI 10.1002/stem.1235
   Hoey DA, 2011, BIOCHEM BIOPH RES CO, V412, P182, DOI 10.1016/j.bbrc.2011.07.072
   Javaheri B, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 25084 6
   Jilka RL, 2013, J GERONTOL A BIOL, V68, P1209, DOI 10.1093/gerona/glt046
   Kanno T, 2005, J ORAL MAXIL SURG, V63, P499, DOI 10.1016/j.joms.2004.07.023
   Kawanami A, 2009, BIOCHEM BIOPH RES CO, V386, P477, DOI 10.1016/j.bbrc.2009.06.059
   Kfoury Y, 2015, CELL STEM CELL, V16, P239, DOI 10.1016/j.stem.2015.02.019
   KLEINNULEND J, 1995, J CELL PHYSIOL, V163, P115, DOI 10.1002/jcp.1041630113
   KOSHIHARA Y, 1994, MECH AGEING DEV, V74, P89, DOI 10.1016/0047 6374(94)90101 5
   Lee KL, 2014, FASEB J, V28, P1157, DOI 10.1096/fj.13 240432
   Li Y, 2012, J BONE MINER RES, V27, P1263, DOI 10.1002/jbmr.1574
   Lim SM, 2005, BIOTECHNOL LETT, V27, P607, DOI 10.1007/s10529 005 3625 5
   Lindbaek L, 2015, CILIA S1, V4, P17
   Malone AMD, 2007, P NATL ACAD SCI USA, V104, P13325, DOI 10.1073/pnas.0700636104
   Matic I, 2016, STEM CELLS, V34, P2930, DOI 10.1002/stem.2474
   Meakin LB, 2014, J BONE MINER RES, V29, P1859, DOI 10.1002/jbmr.2222
   MILLER SC, 1989, SCANNING MICROSCOPY, V3, P953
   Moore Emily R, 2018, J Mol Biochem, V7, P48
   Moore ER, 2018, J ORTHOP RES, V36, P533, DOI 10.1002/jor.23732
   Mulvihill BM, 2010, CLIN BIOMECH, V25, P491, DOI 10.1016/j.clinbiomech.2010.01.006
   Murao H, 2013, J BONE MINER METAB, V31, P390, DOI 10.1007/s00774 013 0429 x
   Ota S, 2017, BREAST CANCER TOKYO, V24, P601, DOI 10.1007/s12282 016 0746 8
   Ouyang ZF, 2014, BONE, V58, P136, DOI 10.1016/j.bone.2013.10.016
   RAABCULLEN DM, 1994, CALCIFIED TISSUE INT, V55, P473, DOI 10.1007/BF00298562
   Razi H, 2015, J BONE MINER RES, V30, P1864, DOI 10.1002/jbmr.2528
   Sanchez Gurmaches J, 2015, STEM CELL REP, V4, P541, DOI 10.1016/j.stemcr.2015.02.008
   Saris DBF, 1999, J ORTHOPAED RES, V17, P668, DOI 10.1002/jor.1100170508
   Schaffler MB, 2014, CALCIFIED TISSUE INT, V94, P5, DOI 10.1007/s00223 013 9790 y
   Sheng Matilda H C, 2014, J Bone Metab, V21, P41, DOI 10.11005/jbm.2014.21.1.41
   Soleimani M, 2009, NAT PROTOC, V4, P102, DOI 10.1038/nprot.2008.221
   Spasic M, 2017, EUR CELLS MATER, V33, P158, DOI 10.22203/eCM.v033a12
   Stenderup K, 2003, BONE, V33, P919, DOI 10.1016/j.bone.2003.07.005
   Sun Y, 1996, Chin Med Sci J, V11, P209
   Teixeira MZ, 2012, HOMEOPATHY, V101, P231, DOI 10.1016/j.homp.2012.07.001
   Temiyasathit S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033368
   Thompson WR, 2012, GENE, V503, P179, DOI 10.1016/j.gene.2012.04.076
   TURNER CH, 1995, J BONE MINER RES, V10, P1544
   Yukata K, 2014, BONE, V62, P79, DOI 10.1016/j.bone.2014.02.002
NR 58
TC 53
Z9 60
U1 0
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1757 6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD JUL 11
PY 2018
VL 9
AR 190
DI 10.1186/s13287 018 0930 1
PG 15
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA GM6BZ
UT WOS:000438243100005
PM 29996901
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wang, L
   Foster, BL
   Kram, V
   Nociti, FH
   Zerfas, PM
   Tran, AB
   Young, MF
   Somerman, MJ
AF Wang, L.
   Foster, B. L.
   Kram, V.
   Nociti, F. H., Jr.
   Zerfas, P. M.
   Tran, A. B.
   Young, M. F.
   Somerman, M. J.
TI Fibromodulin and Biglycan Modulate Periodontium through TGFβ/BMP
   Signaling
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE extracellular matrix; periodontal ligament; proteoglycan; tooth root;
   mineralization; signal transduction
ID LEUCINE RICH PROTEOGLYCANS; ABNORMAL COLLAGEN FIBRILS; DEFICIENT MICE;
   EXTRACELLULAR MATRIX; IMMUNOHISTOCHEMICAL LOCALIZATION; CANCELLOUS BONE;
   LIGAMENT CELLS; NULL MICE; CEMENTUM; DECORIN
AB A full understanding of the key regulators controlling periodontal development and homeostasis is necessary for the design of improved periodontal regenerative therapies. Small leucine rich proteoglycans (SLRPs) are extracellular matrix molecules suggested to regulate collagen organization and cell signaling. Mice with double deficiency of 2 SLRPs, fibromodulin and biglycan (dKO), acquire skeletal abnormalities, but their roles in regulating the periodontium remain undefined and were the focus of our studies. Transmission electron microscopy studies showed abnormal collagen fibrils in the periodontal ligament (PDL) and altered remodeling of alveolar bone in dKO mice. Immunohistochemistry (IHC) revealed increased staining of SLRPs (asporin, lumican, and decorin) and dentin matrix protein 1 (DMP1, a mechanosensory/osteocyte marker), while osteoblast markers, bone sialoprotein and osteopontin, remained unchanged. Disruption of homeostasis was further evidenced by increased expression of receptor activator of nuclear factor kappa B ligand (RANKL) and elevated numbers of osteoclasts, especially noted around the alveolar bone of molars (buccal side) and incisors. Polymerase chain reaction (PCR) array revealed hyperactive transforming growth factors beta/bone morphogenetic protein (TGF beta/BMP) signaling in dKO PDL tissues, which was further confirmed by elevated expression of phosphorylated Smad5 (p Smad5) by IHC in dKO PDL. These studies highlight the importance of SLRPs in maintaining periodontal homeostasis through regulation of TGF beta/BMP signaling, matrix turnover, and collagen organization.
C1 [Wang, L.; Foster, B. L.; Nociti, F. H., Jr.; Tran, A. B.; Somerman, M. J.] Natl Inst Arthrit & Musculoskeletal & Skin Dis N, NIH, Bethesda, MD 20892 USA.
   [Kram, V.; Young, M. F.] NIDCR, NIH, Bethesda, MD USA.
   [Nociti, F. H., Jr.] Univ Estadual Campinas, Piracicaba Dent Sch, Dept Prosthodont & Periodont, Piracicaba, Brazil.
   [Zerfas, P. M.] NIH, Div Vet Resources, Off Res Serv, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH)   USA; NIH National Institute of
   Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes
   of Health (NIH)   USA; NIH National Institute of Dental & Craniofacial
   Research (NIDCR); Universidade Estadual de Campinas; National Institutes
   of Health (NIH)   USA; NIH Office of Research Services (ORS)
RP Wang, L (通讯作者)，Natl Inst Arthrit & Musculoskeletal & Skin Dis N, NIH, Bethesda, MD 20892 USA.
EM le.wang@nih.gov
RI ; Foster, Brian/AAV 4336 2020; Nociti, Francisco/G 4907 2015
OI Young, Marian F/0000 0003 0929 8854; Nociti,
   Francisco/0000 0001 6809 8866; 
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases
   (NIAMS); National Institute of Dental and Craniofacial Research (NIDCR)
   (Bethesda, MD, USA)
FX This research was supported by the Intramural Research Programs of the
   National Institute of Arthritis and Musculoskeletal and Skin Diseases
   (NIAMS) (MJS) and the National Institute of Dental and Craniofacial
   Research (NIDCR) (MFY) (Bethesda, MD, USA). The authors thank Drs. Min
   Ao, Brendan Lopez, and Kanako Nagatomo for their contributions to this
   research. The authors declare no potential conflicts of interest with
   respect to the authorship and/or publication of this article.
CR Ababneh KT, 1999, J PERIODONTAL RES, V34, P87, DOI 10.1111/j.1600 0765.1999.tb02227.x
   Ameye L, 2002, FASEB J, V16, DOI 10.1096/fj.01 0848com
   BERKOVITZ BKB, 1990, EUR J ORTHODONT, V12, P51, DOI 10.1093/ejo/12.1.51
   Bi YM, 2007, NAT MED, V13, P1219, DOI 10.1038/nm1630
   Cabello Verrugio C, 2007, J BIOL CHEM, V282, P18842, DOI 10.1074/jbc.M700243200
   Chen SJ, 2013, FEBS J, V280, P2120, DOI 10.1111/febs.12136
   Chen XD, 2004, FASEB J, V18, P948, DOI 10.1096/fj.03 0899com
   Chen XD, 2002, J BONE MINER RES, V17, P331, DOI 10.1359/jbmr.2002.17.2.331
   Chiu R, 2012, ARCH ORAL BIOL, V57, P177, DOI 10.1016/j.archoralbio.2011.08.011
   Embree MC, 2010, AM J PATHOL, V176, P812, DOI 10.2353/ajpath.2010.090450
   Foster BL, 2013, J DENT RES, V92, P166, DOI 10.1177/0022034512469026
   Foster BL, 2012, INT J ORAL SCI, V4, P119, DOI 10.1038/ijos.2012.57
   Geng YQ, 2006, MATRIX BIOL, V25, P484, DOI 10.1016/j.matbio.2006.08.259
   Gluhak Heinrich J, 2003, J BONE MINER RES, V18, P807, DOI 10.1359/jbmr.2003.18.5.807
   Goldberg M, 2006, J HISTOCHEM CYTOCHEM, V54, P525, DOI 10.1369/jhc.5A6650.2005
   HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527
   Hildebrand T, 1999, J BONE MINER RES, V14, P1167, DOI 10.1359/jbmr.1999.14.7.1167
   Ho SP, 2010, BIOMATERIALS, V31, P6635, DOI 10.1016/j.biomaterials.2010.05.024
   Jepsen KJ, 2002, J BIOL CHEM, V277, P35532, DOI 10.1074/jbc.M205398200
   Kajikawa T, 2014, J DENT RES, V93, P400, DOI 10.1177/0022034513520549
   Kalamajski S, 2010, MATRIX BIOL, V29, P248, DOI 10.1016/j.matbio.2010.01.001
   Leong NL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035980
   Marchesan JT, 2011, ARCH ORAL BIOL, V56, P933, DOI 10.1016/j.archoralbio.2011.03.003
   Matheson S, 2005, J PERIODONTAL RES, V40, P312, DOI 10.1111/j.1600 0765.2005.00800.x
   Matias MA, 2003, J PERIODONTAL RES, V38, P502, DOI 10.1034/j.1600 0765.2003.00682.x
   Meikle MC, 2006, EUR J ORTHODONT, V28, P221, DOI 10.1093/ejo/cj1001
   Moreno M, 2005, EMBO J, V24, P1397, DOI 10.1038/sj.emboj.7600615
   Muller R, 1996, Technol Health Care, V4, P113
   Niethamer TK, 2012, MOL GENET METAB, V107, P748, DOI 10.1016/j.ymgme.2012.10.011
   Robling AG, 2009, CRIT REV EUKAR GENE, V19, P319, DOI 10.1615/CritRevEukarGeneExpr.v19.i4.50
   Santra M, 2002, J BIOL CHEM, V277, P35671, DOI 10.1074/jbc.M205317200
   Schaefer L, 2010, CELL TISSUE RES, V339, P237, DOI 10.1007/s00441 009 0821 y
   Svensson L, 1999, J BIOL CHEM, V274, P9636, DOI 10.1074/jbc.274.14.9636
   Wu B, 2013, J MOL HISTOL, V44, P423, DOI 10.1007/s10735 013 9497 4
   Xu TS, 1998, NAT GENET, V20, P78, DOI 10.1038/1746
NR 35
TC 33
Z9 37
U1 1
U2 21
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022 0345
EI 1544 0591
J9 J DENT RES
JI J. Dent. Res.
PD AUG
PY 2014
VL 93
IS 8
BP 780
EP 787
DI 10.1177/0022034514541126
PG 8
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA AL7OX
UT WOS:000339325200009
PM 24966230
OA Green Published
DA 2025 08 17
ER

PT J
AU Niu, CC
   Lin, SS
   Yuan, LJ
   Chen, LH
   Yang, CY
   Chung, AN
   Lu, ML
   Tsai, TT
   Lai, PL
   Chen, WJ
AF Niu, Chi Chien
   Lin, Song Shu
   Yuan, Li Jen
   Chen, Lih Huei
   Yang, Chuen Yung
   Chung, An Ni
   Lu, Meng Ling
   Tsai, Tsung Ting
   Lai, Po Liang
   Chen, Wen Jer
TI Correlation of blood bone turnover biomarkers and Wnt signaling
   antagonists with AS, DISH, OPLL, and OYL
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
DE Wnt inhibitor; OPLL; OYL; AS; DISH
ID POSTERIOR LONGITUDINAL LIGAMENT; IDIOPATHIC SKELETAL HYPEROSTOSIS;
   ANKYLOSING SPONDYLITIS; MINERAL DENSITY; BIOCHEMICAL MARKERS;
   SERUM LEVELS; OSSIFICATION; SPINE; DICKKOPF 1; PROTEINS
AB Background: Wnt signaling plays an important role in development and maintenance of many organs and tissues. The most studied secreted Wnt inhibitors are sclerostin (SOST), Dickkopf related protein 1 (DKK 1), and secreted frizzled related protein 1 (SFRP 1) which play important roles in bone turnover. The present study investigated the relationship between serum Wnt inhibitors and diseases with excessive ossification structures, such as ossification of posterior longitudinal ligament (OPLL), ankylosing spondylitis (AS), diffuse idiopathic skeletal hyperostosis (DISH), and ossification of yellow ligament (OYL).
   Methods: Twenty five patients with AS, DISH, OPLL, or OYL were recruited in this study. Fasting peripheral blood samples were collected from all patients and nine controls. Various biomarkers of bone turnover including osteocalcin (OSC), osteoprotegerin (OPG), SFRP 1, DKK 1, and SOST were investigated.
   Results: Our data showed that serum levels of OSC were higher, but Dkk 1 levels were lower in AS, DISH, OPLL, and OYL patients than those in the controls. Serum levels of SFRP 1 were significantly higher in DISH patients than those in the controls. Serum levels of SOST were significantly higher in DISH and OPLL patients than both levels in the controls. Serum levels of OPG were lower in AS patients than those in the controls. Serum levels of OSC were higher in the OPLL patients than those in the AS patients. Serum levels of DKK 1, SFRP 1, SOST, and OPG were not significantly different between the different disease groups.
   Conclusions: In this exploratory study, both OSC and DKK 1 levels are correlated with the clinical conditions associated with excessive ossification, indicating that blood OSC and DKK 1 levels may serve as diagnostic biomarkers for AS, DISH, OPLL, and OYL. These findings may also help discover potential drug therapies for management of these diseases in the future.
C1 [Niu, Chi Chien; Lin, Song Shu; Yuan, Li Jen; Chen, Lih Huei; Yang, Chuen Yung; Chung, An Ni; Lu, Meng Ling; Tsai, Tsung Ting; Lai, Po Liang; Chen, Wen Jer] Chang Gung Mem Hosp, Dept Orthopaed, Linkou, Taiwan.
   [Niu, Chi Chien; Yuan, Li Jen; Chen, Lih Huei; Lu, Meng Ling; Tsai, Tsung Ting; Lai, Po Liang; Chen, Wen Jer] Chang Gung Univ, Coll Med, Taoyuan, Taiwan.
   [Niu, Chi Chien; Yuan, Li Jen; Chen, Lih Huei; Lu, Meng Ling; Tsai, Tsung Ting; Lai, Po Liang; Chen, Wen Jer] Chang Gung Mem Hosp, Bone & Joint Res Ctr, Linkou, Taiwan.
   [Yuan, Li Jen] Chang Gung Mem Hosp, Dept Orthopaed, Taoyuan, Taiwan.
   [Niu, Chi Chien] Chang Gung Mem Hosp, Dept Orthopaed Surg, 5 Fu Hsing St 333, Taoyuan, Taiwan.
C3 Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial
   Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital
RP Niu, CC (通讯作者)，Chang Gung Mem Hosp, Dept Orthopaed, Linkou, Taiwan.; Niu, CC (通讯作者)，Chang Gung Univ, Coll Med, Taoyuan, Taiwan.; Niu, CC (通讯作者)，Chang Gung Mem Hosp, Bone & Joint Res Ctr, Linkou, Taiwan.; Niu, CC (通讯作者)，Chang Gung Mem Hosp, Dept Orthopaed Surg, 5 Fu Hsing St 333, Taoyuan, Taiwan.
EM niuchien@adm.cgmh.org.tw
RI Niu, Chi Chien/AAT 4229 2021
FU Chang Gung Memorial Hospital, Linkou, Taiwan, Republic of China [CMRPG
   3C1591]
FX This research was supported by grants from Chang Gung Memorial Hospital
   (CMRPG 3C1591), Linkou, Taiwan, Republic of China.
CR Aeberli D, 2011, JOINT BONE SPINE, V78, P422, DOI 10.1016/j.jbspin.2011.02.015
   Athanasios DA, 2010, CLIN ENDOCRINOL OXF, V72, P752
   Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180
   Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286
   Chavez A, 1998, ANN RHEUM DIS, V57, P429
   Chen CH, 2010, CLIN RHEUMATOL, V29, P1155, DOI 10.1007/s10067 010 1543 y
   Chiba N, 2015, J PHARMACOL SCI, V127, P467, DOI 10.1016/j.jphs.2015.03.008
   Daoussis D, 2011, SEMIN ARTHRITIS RHEU, V41, P170, DOI 10.1016/j.semarthrit.2011.01.006
   Daoussis D, 2010, ARTHRITIS RHEUM US, V62, P150, DOI 10.1002/art.27231
   De Keyser F, 1998, RHEUM DIS CLIN N AM, V24, P785, DOI 10.1016/S0889 857X(05)70042 9
   DEVOGELAER JP, 1992, ARTHRITIS RHEUM, V35, P1062, DOI 10.1002/art.1780350911
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Epstein NE, 1999, J SPINAL DISORD, V12, P250
   Franck H, 2004, J RHEUMATOL, V31, P2236
   Gladman D, 2002, ED REV MANUAL RHEUMA, P1
   Gladman DD, 1998, RHEUM DIS CLIN N AM, V24, P829, DOI 10.1016/S0889 857X(05)70044 2
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Ishihara C, 2000, SPINAL CORD, V38, P211, DOI 10.1038/sj.sc.3100989
   Jones SE, 2002, BIOESSAYS, V24, P811, DOI 10.1002/bies.10136
   Kashii M, 2016, J BONE MINER METAB, V34, P315, DOI 10.1007/s00774 015 0671 5
   Kawabori M, 2009, SPINE, V34, pE709, DOI 10.1097/BRS.0b013e3181aa26a4
   Kawaguchi H., 2006, OPLL: Ossification of the posterior longitudinal ligament, V2nd, P37
   Khedr EM, 2009, RHEUMATOL INT, V29, P1031, DOI 10.1007/s00296 009 0841 7
   Kobayashi Shu, 2007, Mod Rheumatol, V17, P418, DOI 10.1007/s10165 007 0599 2
   Kwon SR, 2012, RHEUMATOL INT, V32, P2523, DOI 10.1007/s00296 011 1981 0
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Mader R, 2008, J RHEUMATOL, V35, P377
   Maeda K, 2013, J MOL MED, V91, P15, DOI 10.1007/s00109 012 0974 0
   Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756
   Matsui H, 1996, CALCIFIED TISSUE INT, V59, P397, DOI 10.1007/s002239900146
   Muñoz Ortego J, 2014, J BONE MINER RES, V29, P1770, DOI 10.1002/jbmr.2217
   Nakajima M, 2014, NAT GENET, V46, P1012, DOI 10.1038/ng.3045
   Pascal Mousselard H, 1998, SPINE, V23, P1607, DOI 10.1097/00007632 199807150 00019
   Rawadi G, 2005, EXPERT OPIN THER TAR, V9, P1063, DOI 10.1517/14728222.9.5.1063
   RESNICK D, 1978, AM J ROENTGENOL, V131, P1049, DOI 10.2214/ajr.131.6.1049
   Schett G, 2008, NAT CLIN PRACT RHEUM, V4, P473, DOI 10.1038/ncprheum0881
   Senolt L, 2012, ANN RHEUM DIS, V71, P71, DOI 10.1136/annrheumdis 2011 200357
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Sohn S, 2013, CALCIFIED TISSUE INT, V92, P28, DOI 10.1007/s00223 012 9662 x
   Sugimori K, 2003, SPINE, V28, P378, DOI 10.1097/00007632 200302150 00013
   Taguchi T, 2006, OPLL OSSIFICATION PO, P33
   Taylan A, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471 2474 13 191
   Uderhardt S, 2010, ANN RHEUM DIS, V69, P592, DOI 10.1136/ard.2008.102046
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Yoshimura N, 2014, OSTEOPOROSIS INT, V25, P1089, DOI 10.1007/s00198 013 2489 0
NR 45
TC 43
Z9 45
U1 0
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471 2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD FEB 2
PY 2017
VL 18
AR 61
DI 10.1186/s12891 017 1425 4
PG 8
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA EM3HH
UT WOS:000395204600004
PM 28153008
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Riffel, RM
   Goebel, A
   Rachner, TD
AF Riffel, Romy M.
   Goebel, Andy
   Rachner, Tilman D.
TI Bone Metastases: From Mechanisms to Treatment
SO SEMINARS IN ONCOLOGY NURSING
LA English
DT Article
DE Bone metastasis; Cancer; Mechanisms; Osteolytic; Sclerotic; Individual
   treatment
ID PROSTATE CANCER METASTASIS; HORMONE RELATED PROTEIN; BREAST CANCER;
   SKELETAL COMPLICATIONS; DOUBLE BLIND; CELLS; DENOSUMAB; BISPHOSPHONATES;
   DISEASE; HEALTH
AB Objectives: Bone metastases are of high clinical relevance because they are a frequent complication of most types of common cancers, such as breast and prostate. The metastatic process is complex, requiring the com pletion of several different steps to allow successful dissemination and homing. In addition, preparation of the metastatic niche changes the constant cycle of bone matrix formation and degradation, leading to the clinical phenotypes of lytic and sclerotic lesions. We review our current knowledge on this topic and briefly explain the current treatment landscape of bone metastasis.Data Sources: These include PubMed, international guidelines, and clinician experience.Conclusion: Bone metastases remain a clinical challenge that negatively impacts patients prognosis and qual ity of life. A comprehensive understanding of the complex molecular mechanisms that results in bone metas tasis is the basis for successful treatment of affected patients. The disruption of bone matrix metabolism is already recognized as the prerequisite for metastasis formation, but many open questions remain that need to be addressed in future research to establish individually tailored treatment approaches. Implications for Nursing Practice: Patient centered therapy of bone metastases requires suitable pharmacolog ical options, and importantly a holistic approach in care delivery across the multidisciplinary team. Nurses provide the cornerstone of the multidisciplinary team and provide the closest and the most frequent contact to the patient and their families to provide timely intervention. Nurses require a basic understanding of the complex physiology of metastasis to inform practice.(c) 2022 Elsevier Inc. All rights reserved.
C1 [Riffel, Romy M.; Goebel, Andy; Rachner, Tilman D.] Tech Univ Dresden, Dept Med 3, Div Endocrinol Diabet & Bone Dis, Dresden, Germany.
   [Riffel, Romy M.; Goebel, Andy; Rachner, Tilman D.] Tech Univ Dresden, Ctr Hlth Aging, Dresden, Germany.
   [Rachner, Tilman D.] Tech Univ Dresden, Dept Med 3, Div Endocrinol Diabet & Bone Dis, Med Ctr, Fetscherstr 74, D 01307 Dresden, Germany.
C3 Technische Universitat Dresden; Technische Universitat Dresden;
   Technische Universitat Dresden
RP Rachner, TD (通讯作者)，Tech Univ Dresden, Dept Med 3, Div Endocrinol Diabet & Bone Dis, Med Ctr, Fetscherstr 74, D 01307 Dresden, Germany.
EM tilman.rachner@uniklinikum dresden.de
FU Deutsche Forschungsgemeinschaft; DFG priority program [SPP 2084];
   Deutsche Krebshilfe
FX The work was funded by the Deutsche Forschungsgemeinschaft to AG, and to
   TDR as part of the DFG priority program (SPP 2084) mBONE and by the
   Deutsche Krebshilfe to RMR, AG and TDR as part of the Mildred Scheel
   Early Career Center.
CR Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220
   Ban JZ, 2021, CELLS BASEL, V10, DOI 10.3390/cells10112944
   Benford HL, 2001, BONE, V28, P465, DOI 10.1016/S8756 3282(01)00412 4
   Berruti A, 1996, BRIT J CANCER, V73, P1581, DOI 10.1038/bjc.1996.298
   Body JJ, 2015, EUR J CANCER, V51, P1812, DOI 10.1016/j.ejca.2015.05.016
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Braun S, 2005, NEW ENGL J MED, V353, P793, DOI 10.1056/NEJMoa050434
   Breuksch I, 2016, J BONE ONCOL, V5, P143, DOI 10.1016/j.jbo.2016.06.004
   Cher ML, 2006, AM J PATHOL, V168, P1405, DOI 10.2353/ajpath.2006.050874
   Clézardin P, 2021, PHYSIOL REV, V101, P797, DOI 10.1152/physrev.00012.2019
   Clezardin Philippe, 2013, Bonekey Rep, V2, P267, DOI 10.1038/bonekey.2013.1
   Coleman R, 2014, ANN ONCOL, V25, P124, DOI 10.1093/annonc/mdu103
   Coleman R, 2012, JNCI J NATL CANCER I, V104, P1059, DOI 10.1093/jnci/djs263
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Coleman RE, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572 020 00216 3
   Costa L, 2008, SUPPORT CARE CANCER, V16, P879, DOI 10.1007/s00520 008 0418 0
   Croucher PI, 2016, NAT REV CANCER, V16, P373, DOI 10.1038/nrc.2016.44
   D'Oronzo S, 2019, J BONE ONCOL, V15, DOI 10.1016/j.jbo.2018.10.004
   Drabsch Y, 2011, J MAMMARY GLAND BIOL, V16, P97, DOI 10.1007/s10911 011 9217 1
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Fornetti J, 2018, J BONE MINER RES, V33, P2099, DOI 10.1002/jbmr.3618
   Ghajar CM, 2013, NAT CELL BIOL, V15, P807, DOI 10.1038/ncb2767
   Gnant M, 2015, LANCET, V386, P433, DOI 10.1016/S0140 6736(15)60995 3
   Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947
   Gurung P, 2015, AM J PATHOL, V185, P17, DOI 10.1016/j.ajpath.2014.08.025
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4367, DOI 10.1210/en.140.9.4367
   Hofbauer LC, 2014, LANCET DIABETES ENDO, V2, P500, DOI 10.1016/S2213 8587(13)70203 1
   Hofbauer LC, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2842
   Hortobagyi GN, 1996, NEW ENGL J MED, V335, P1785, DOI 10.1056/NEJM199612123352401
   Ibrahim T, 2010, CANCER AM CANCER SOC, V116, P1406, DOI 10.1002/cncr.24896
   Itzstein Cecile, 2011, Small GTPases, V2, P117
   Iwamura M, 1996, UROLOGY, V48, P317, DOI 10.1016/S0090 4295(96)00182 3
   Jacobs C, 2014, CURR OPIN SUPPORT PA, V8, P420, DOI 10.1097/SPC.0000000000000084
   Joeckel E, 2014, MOL CANCER, V13, DOI 10.1186/1476 4598 13 42
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186
   Kelly T, 2005, CANCER RES, V65, P5778, DOI 10.1158/0008 5472.CAN 05 0749
   Koeneman KS, 1999, PROSTATE, V39, P246
   Krog BL, 2018, ADV EXP MED BIOL, V1092, P209, DOI 10.1007/978 3 319 95294 9_11
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Lawson MA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9983
   Lehr JE, 1998, J NATL CANCER I, V90, P118, DOI 10.1093/jnci/90.2.118
   Lin SC, 2018, CURR OSTEOPOROS REP, V16, P642, DOI 10.1007/s11914 018 0480 6
   Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Luzzi KJ, 1998, AM J PATHOL, V153, P865, DOI 10.1016/S0002 9440(10)65628 3
   Lynch CC, 2005, CANCER CELL, V7, P485, DOI 10.1016/j.ccr.2005.04.013
   Macedo F, 2017, ONCOL REV, V11, P43, DOI 10.4081/oncol.2017.321
   Migliorati CA, 2011, NAT REV ENDOCRINOL, V7, P34, DOI 10.1038/nrendo.2010.195
   Miller PD, 2011, THER ADV MUSCULOSKEL, V3, P271, DOI 10.1177/1759720X11424220
   Ming J, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01283
   Mishra A, 2011, CANCER MICROENVIRON, V4, P221, DOI 10.1007/s12307 011 0083 6
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Mundy GR, 1997, CANCER AM CANCER SOC, V80, P1546, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1546::AID CNCR4>3.3.CO;2 R
   Nakamura K, 2018, CANCER CELL, V33, P634, DOI 10.1016/j.ccell.2018.02.007
   NELSON JB, 1995, NAT MED, V1, P944, DOI 10.1038/nm0995 944
   PAGET S, 1989, CANCER METAST REV, V8, P98
   Pang XC, 2019, PHARMACOL RES, V144, P235, DOI 10.1016/j.phrs.2019.04.030
   Panigrahy D, 2012, J CLIN INVEST, V122, P178, DOI 10.1172/JCI58128
   Pazolli E, 2009, CANCER RES, V69, P1230, DOI 10.1158/0008 5472.CAN 08 2970
   Phan TG, 2020, NAT REV CANCER, V20, P398, DOI 10.1038/s41568 020 0263 0
   Pilleron S, 2021, INT J CANCER, V148, P601, DOI 10.1002/ijc.33232
   Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620
   Rachner TD, 2012, PHARMACOL THERAPEUT, V134, P338, DOI 10.1016/j.pharmthera.2012.02.005
   Ribas A, 2015, CANCER DISCOV, V5, P915, DOI 10.1158/2159 8290.CD 15 0563
   Roberts E, 2013, PROSTATE CANCER, V2013, DOI 10.1155/2013/418340
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Shane E, 2014, J BONE MINER RES, V29, P1, DOI 10.1002/jbmr.1998
   Shi JJ, 2015, NATURE, V526, P660, DOI 10.1038/nature15514
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Swanson KM, 2006, CURR CANCER DRUG TAR, V6, P15, DOI 10.2174/156800906775471743
   Taddei ML, 2012, J PATHOL, V226, P380, DOI 10.1002/path.3000
   Tulotta C, 2019, CLIN CANCER RES, V25, P2769, DOI 10.1158/1078 0432.CCR 18 2202
   von Moos R, 2019, CANCER TREAT REV, V76, P57, DOI 10.1016/j.ctrv.2019.05.003
   von Moos R, 2016, SUPPORT CARE CANCER, V24, P1327, DOI 10.1007/s00520 015 2908 1
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   WHO, 2013, WORLD MALARIA REPORT 2013, P1
   Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523
   Zekri J, 2014, J BONE ONCOL, V3, P25, DOI 10.1016/j.jbo.2013.12.001
   Zhang XHF, 2013, CELL, V154, P1060, DOI 10.1016/j.cell.2013.07.036
   Zhu MH, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 11913 7
NR 86
TC 9
Z9 10
U1 2
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0749 2081
EI 1878 3449
J9 SEMIN ONCOL NURS
JI Semin. Oncol. Nurs.
PD APR
PY 2022
VL 38
IS 2
SI SI
AR 151277
DI 10.1016/j.soncn.2022.151277
PG 6
WC Oncology; Nursing
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Oncology; Nursing
GA 1T8OK
UT WOS:000804985000006
PM 35474145
DA 2025 08 17
ER

PT J
AU Zandi, M
   Dehghan, A
   Amini, P
   Doulati, S
   Rezaeian, L
AF Zandi, Mohammad
   Dehghan, Arash
   Amini, Payam
   Doulati, Shideh
   Rezaeian, Leila
TI Evaluation of the effect of teriparatide therapy on mandibular fracture
   healing in rats with medication related osteonecrosis of the jaw
SO CLINICAL ORAL INVESTIGATIONS
LA English
DT Article
DE Teriparatide; Mandibular fracture; Osteonecrosis; Healing; Rat
ID BISPHOSPHONATE RELATED OSTEONECROSIS; PARATHYROID HORMONE; SAFETY;
   INHIBITION; MECHANISMS; RESECTION; MODEL; DRUG
AB Objective The aim of this study was to evaluate the effect of teriparatide therapy on mandibular fracture healing in rats with medication related osteonecrosis of the jaw (MRONJ). Materials and methods To induce MRONJ, a total of 120 rats received intravenous zoledronate 0.06 mg/kg once a week for 6 weeks and their right mandibular first molar was extracted. Eighty of 94 rats with MRONJ were randomly selected and underwent unilateral mandibular osteotomy to replicate a fracture. After surgery, the rats were randomly assigned to T (teriparatide treated) and C (control) groups. Group T (n = 40) received subcutaneous injection of 2 mu g/kg/day teriparatide and group C (n = 40) received the same volume of normal saline until sacrifice. Four and 8 weeks after surgery, 20 rats in each group were sacrificed. Fracture healing was scored using a histological grading system (1 to 10). Results In group C, at 4 weeks and 8 weeks post fracture, fibrous and cartilaginous tissues and scant bone formation at the fracture site and lacunae without osteocyte in adjacent mandibular bone were seen. In group T, substantial amounts of new trabecular bone rimmed by osteoblasts and some areas of remodeled mature bone were seen. After 8 weeks, extensive replacement of trabecular bone with mature bone occurred. Except between C4 and C8 groups, the healing score was significantly different between all subgroups. Conclusion Teriparatide therapy successfully improved mandibular fracture healing in rats with MRONJ. However, this study was limited by the use of an animal model whose anatomy, physiology, and drug metabolism might be different from humans.
C1 [Zandi, Mohammad] Hamadan Univ Med Sci, Fac Dent, Dept Oral & Maxillofacial Surg, Shahid Fahmideh St, Hamadan, Iran.
   [Zandi, Mohammad] Hamadan Univ Med Sci, Dent Res Ctr, Hamadan, Iran.
   [Dehghan, Arash] Hamadan Univ Med Sci, Dept Pathol, Hamadan, Iran.
   [Amini, Payam] ACECR, Royan Inst Reprod Biomed, Reprod Epidemiol Res Ctr, Dept Epidemiol & Reprod Hlth, Tehran, Iran.
   [Doulati, Shideh; Rezaeian, Leila] Hamadan Univ Med Sci, Dept Oral & Maxillofacial Surg, Hamadan, Iran.
C3 Hamadan University of Medical Sciences; Hamadan University of Medical
   Sciences; Hamadan University of Medical Sciences; Academic Center for
   Education, Culture & Research (ACECR); Hamadan University of Medical
   Sciences
RP Zandi, M (通讯作者)，Hamadan Univ Med Sci, Fac Dent, Dept Oral & Maxillofacial Surg, Shahid Fahmideh St, Hamadan, Iran.; Zandi, M (通讯作者)，Hamadan Univ Med Sci, Dent Res Ctr, Hamadan, Iran.
EM zandi88m@yahoo.com
RI Zandi, Mohammad/L 1368 2018; Amini, Payam/K 5164 2019; Dehghan,
   Arash/P 9666 2017
OI Zandi, Mohammad/0000 0003 1238 186X; Amini, Payam/0000 0001 8675 0045; 
FU Hamadan University of Medical Sciences [9507134134]
FX The study was funded by the vice chancellor for Research and Technology,
   Hamadan University of Medical Sciences (no. 9507134134).
CR Andrews EB, 2012, J BONE MINER RES, V27, P2429, DOI 10.1002/jbmr.1768
   Barba Recreo P, 2014, J CRANIO MAXILL SURG, V42, P744, DOI 10.1016/j.jcms.2013.11.005
   Bukata Susan V, 2010, Curr Osteoporos Rep, V8, P28, DOI 10.1007/s11914 010 0006 3
   Caldroney S, 2017, INT J ORAL MAX SURG, V46, P871, DOI 10.1016/j.ijom.2017.01.023
   Collinge C, 2016, INJURY, V47, pS36, DOI 10.1016/S0020 1383(16)30009 2
   Corrado A, 2010, CLIN EXP RHEUMATOL, V28, P873
   Curi MM, 2007, J ORAL MAXIL SURG, V65, P349, DOI 10.1016/j.joms.2005.12.051
   Dayisoylu EH, 2014, OR SURG OR MED OR PA, V117, P329, DOI 10.1016/j.oooo.2013.11.490
   Edwards BJ, 2013, J BONE JOINT SURG AM, V95A, P297, DOI 10.2106/JBJS.K.01181
   Eli Lilly and Co, 2002, US PACK INS FORT TER
   Jowett A, 2015, INT J SURG CASE REP, V10, P162, DOI 10.1016/j.ijscr.2015.02.049
   Kakehashi H, 2015, INT J ORAL MAX SURG, V44, P1558, DOI 10.1016/j.ijom.2015.07.018
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kim KM, 2014, OSTEOPOROSIS INT, V25, P1625, DOI 10.1007/s00198 014 2622 8
   Kim Youngwoo, 2015, Bone Rep, V3, P11, DOI 10.1016/j.bonr.2015.04.003
   Komatsubara S, 2005, BONE, V36, P678, DOI 10.1016/j.bone.2005.02.002
   Kuroshima S, 2014, OSTEOPOROSIS INT, V25, P1141, DOI 10.1007/s00198 013 2570 8
   Kwon YD, 2012, OSTEOPOROSIS INT, V23, P2721, DOI 10.1007/s00198 011 1882 9
   Landesberg R, 2008, J ORAL MAXIL SURG, V66, P839, DOI 10.1016/j.joms.2008.01.026
   Lee Cameron Y S, 2007, J Oral Implantol, V33, P371, DOI 10.1563/1548 1336(2007)33[371:UOPPIT]2.0.CO;2
   Lewiecki EM, 2011, DRUGS, V71, P791, DOI 10.2165/11585470 000000000 00000
   Li CY, 2001, J BONE MINER RES, V16, P429, DOI 10.1359/jbmr.2001.16.3.429
   Maahs MP, 2011, HEAD NECK J SCI SPEC, V33, P199, DOI 10.1002/hed.21422
   McLeod NMH, 2011, BRIT J ORAL MAX SURG, V49, P335, DOI 10.1016/j.bjoms.2010.08.005
   Meganck JA, 2013, BONE, V56, P204, DOI 10.1016/j.bone.2013.06.003
   Mognetti B, 2011, CALCIFIED TISSUE INT, V89, P163, DOI 10.1007/s00223 011 9503 3
   Munns CFJ, 2004, J BONE MINER RES, V19, P1779, DOI 10.1359/JBMR.040814
   Nakajima A, 2002, J BONE MINER RES, V17, P2038, DOI 10.1359/jbmr.2002.17.11.2038
   Perry AC, 2003, CLIN ORTHOP RELAT R, P95, DOI 10.1097/01.blo.0000087322.60612.14
   Pietrogrande L, 2013, INJURY, V44, pS54, DOI 10.1016/S0020 1383(13)70013 5
   Rozental TD, 2009, J HAND SURG AM, V34A, P595, DOI 10.1016/j.jhsa.2008.12.011
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Russell RGG, 2007, ANN NY ACAD SCI, V1117, P209, DOI 10.1196/annals.1402.089
   Tashjian AH, 2006, J BONE MINER RES, V21, P354, DOI 10.1359/JBMR.051023
   Tu PH, 2012, J CLIN NEUROSCI, V19, P532, DOI 10.1016/j.jocn.2011.04.048
   Vahle JL, 2002, TOXICOL PATHOL, V30, P312, DOI 10.1080/01926230252929882
   Vescovi P, 2007, BRIT J ORAL MAX SURG, V45, P628, DOI 10.1016/j.bjoms.2007.03.016
   Wongchuensoontorn C, 2009, J ORAL MAXIL SURG, V67, P1311, DOI 10.1016/j.joms.2008.12.030
   Yao M, 2016, INT J SURG CASE REP, V21, P151, DOI 10.1016/j.ijscr.2016.02.028
   Zandi M, 2016, J CRANIOMAXILLOFAC S, V44, P261
   Zandi M, 2018, INJURY, V49, P1746, DOI 10.1016/j.injury.2018.07.006
   Zandi M, 2017, J CRANIO MAXILL SURG, V45, P157, DOI 10.1016/j.jcms.2016.10.015
NR 42
TC 8
Z9 11
U1 0
U2 7
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 1432 6981
EI 1436 3771
J9 CLIN ORAL INVEST
JI Clin. Oral Investig.
PD NOV
PY 2019
VL 23
IS 11
BP 3987
EP 3993
DI 10.1007/s00784 019 02830 2
PG 7
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA JF7JA
UT WOS:000491561300007
PM 30715621
DA 2025 08 17
ER

PT J
AU Kurtova, AV
   Heinlein, M
   Haas, S
   Velten, L
   Dijkgraaf, GJP
   Storm, EE
   Kljavin, NM
   Boumahdi, S
   Himmels, P
   Herault, A
   Mancini, A
   Koeppen, H
   Dail, M
   Yan, QX
   Zhang, JH
   Koch, U
   Radtke, F
   Modrusan, Z
   Metcalfe, C
   Piskol, R
   de Sauvage, FJ
AF Kurtova, Antonina, V
   Heinlein, Melanie
   Haas, Simon
   Velten, Lars
   Dijkgraaf, Gerrit J. P.
   Storm, Elaine E.
   Kljavin, Noelyn M.
   Boumahdi, Soufiane
   Himmels, Patricia
   Herault, Aurelie
   Mancini, Andrew
   Koeppen, Hartmut
   Dail, Monique
   Yan, Qingxiang
   Zhang, Jianhuan
   Koch, Ute
   Radtke, Freddy
   Modrusan, Zora
   Metcalfe, Ciara
   Piskol, Robert
   de Sauvage, Frederic J.
TI Disruption of stem cell niche confined R spondin 3 expression leads to
   impaired hematopoiesis
SO BLOOD ADVANCES
LA English
DT Article
ID BETA CATENIN; WNT/BETA CATENIN; WNT PATHWAY; LGR5; RECEPTORS; MOUSE;
   DIFFERENTIATION; ACTIVATION; ZONATION; LIGANDS
AB Self renewal and differentiation of stem and progenitor cells are tightly regulated to ensure tissue homeostasis. This regulation is enabled both remotely by systemic circulating cues, such as cytokines and hormones, and locally by various niche confined factors. R spondin 3 (RSPO3) is one of the most potent enhancers of Wnt signaling, and its expression is usually restricted to the stem cell niche where it provides localized enhancement of Wnt signaling to regulate stem cell expansion and differentiation. Disruption of this niche confined expression can disturb proper tissue organization and lead to cancers. Here, we investigate the consequences of disrupting the niche restricted expression of RSPO3 in various tissues, including the hematopoietic system. We show that normal Rspo3 expression is confined to the perivascular niche in the bone marrow. Induction of increased systemic levels of circulating RSPO3 outside of the niche results in prominent loss of early B cell progenitors and anemia but surprisingly has no effect on hematopoietic stem cells. Using molecular, pharmacologic, and genetic approaches, we show that these RSPO3 induced hematopoietic phenotypes are Wnt and RSPO3 dependent and mediated through noncanonical Wnt signaling. Our study highlights a distinct role for a Wnt/RSPO3 signaling axis in the regulation of hematopoiesis, as well as possible challenges related to therapeutic use of RSPOs for regenerative medicine.
C1 [Kurtova, Antonina, V; Heinlein, Melanie; Dijkgraaf, Gerrit J. P.; Storm, Elaine E.; Kljavin, Noelyn M.; Boumahdi, Soufiane; Himmels, Patricia; Herault, Aurelie; Mancini, Andrew; de Sauvage, Frederic J.] Genentech Inc, Mol Oncol, San Francisco, CA 94080 USA.
   [Haas, Simon] HISTEM gGmbH, Heidelberg, Germany.
   [Haas, Simon] Deutsch Krebsforschungszentrum DKFZ, Div Stem Cells & Canc, Heidelberg, Germany.
   [Haas, Simon] DKFZ ZMBH Alliance, Heidelberg, Germany.
   [Haas, Simon] Charite Univ Med Berlin, Berlin Inst Hlth BIH, Berlin, Germany.
   [Haas, Simon] Berlin Inst Med Syst Biol, Max Delbruck Ctr Mol Med Helmholtz Assoc, Berlin, Germany.
   [Haas, Simon] Charite, Berlin, Germany.
   [Velten, Lars] Barcelona Inst Sci & Technol, Ctr Genom Regulat CRG, Barcelona, Spain.
   [Velten, Lars] Univ Pompeau Fabra UPF, Barcelona, Spain.
   [Koeppen, Hartmut] Genentech Inc, Res Pathol, MS37,1 DNA Way, San Francisco, CA 94080 USA.
   [Dail, Monique] Genentech Inc, Oncol Biomarker Dev, San Francisco, CA USA.
   [Yan, Qingxiang] Hoffmann La Roche, Biometr Dept, Mississauga, ON, Canada.
   [Zhang, Jianhuan] Genentech Inc, Biochem & Cellular Pharmacol, San Francisco, CA USA.
   [Koch, Ute; Radtke, Freddy] Ecole Polytech Fed Lausanne, Swiss Inst Expt Canc Res, Lausanne, Switzerland.
   [Modrusan, Zora] Genentech Inc, Mol Biol, San Francisco, CA 94080 USA.
   [Metcalfe, Ciara] Genentech Inc, Discovery Oncol, San Francisco, CA 94080 USA.
   [Piskol, Robert] Genentech Inc, Oncol Bioinformat, San Francisco, CA 94080 USA.
C3 Roche Holding; Genentech; Roche Holding USA; Helmholtz Association;
   German Cancer Research Center (DKFZ); Helmholtz Association; German
   Cancer Research Center (DKFZ); Humboldt University of Berlin; Free
   University of Berlin; Charite Universitatsmedizin Berlin; Berlin
   Institute of Health; Helmholtz Association; Max Delbruck Center for
   Molecular Medicine; Free University of Berlin; Humboldt University of
   Berlin; Charite Universitatsmedizin Berlin; Barcelona Institute of
   Science & Technology; Pompeu Fabra University; Centre de Regulacio
   Genomica (CRG); Roche Holding; Roche Holding USA; Genentech; Roche
   Holding; Genentech; Roche Holding USA; Roche Holding; Roche Holding USA;
   Genentech; Swiss Institute Experimental Cancer Research; Swiss Federal
   Institutes of Technology Domain; Ecole Polytechnique Federale de
   Lausanne; Roche Holding; Roche Holding USA; Genentech; Roche Holding;
   Roche Holding USA; Genentech; Roche Holding; Roche Holding USA;
   Genentech
RP de Sauvage, FJ (通讯作者)，Genentech Inc, Mol Oncol, San Francisco, CA 94080 USA.
EM desauvage.fred@gene.com
RI Kurtova, Antonina/H 6546 2015; Radtke, Freddy/Q 3198 2017; Velten,
   Lars/Z 5952 2019; de Sauvage, Frederic/ABE 8400 2020
OI Himmels, Patricia/0000 0001 6210 7688; Velten, Lars/0000 0002 1233 5874;
   Haas, Simon/0000 0001 9227 2051; 
CR Ashman LK, 2000, LEUKEMIA LYMPHOMA, V37, P233, DOI 10.3109/10428190009057652
   Baccin C, 2020, NAT CELL BIOL, V22, P38, DOI 10.1038/s41556 019 0439 6
   Beumer J, 2021, NAT REV MOL CELL BIO, V22, P39, DOI 10.1038/s41580 020 0278 0
   Bhagat TD, 2017, CANCER RES, V77, P4846, DOI 10.1158/0008 5472.CAN 17 0282
   Carmon KS, 2011, P NATL ACAD SCI USA, V108, P11452, DOI 10.1073/pnas.1106083108
   Cobas M, 2004, J EXP MED, V199, P221, DOI 10.1084/jem.20031615
   Coletta PL, 2004, BLOOD, V103, P1050, DOI 10.1182/blood 2003 03 0707
   Comazzetto S, 2021, DEV CELL, V56, P1848, DOI 10.1016/j.devcel.2021.05.018
   Crane GM, 2017, NAT REV IMMUNOL, V17, P573, DOI 10.1038/nri.2017.53
   de Lau W, 2014, GENE DEV, V28, P305, DOI 10.1101/gad.235473.113
   de Lau W, 2011, NATURE, V476, P293, DOI 10.1038/nature10337
   Florian MC, 2013, NATURE, V503, P392, DOI 10.1038/nature12631
   Glinka A, 2011, EMBO REP, V12, P1055, DOI 10.1038/embor.2011.175
   Greicius G, 2018, P NATL ACAD SCI USA, V115, pE3173, DOI 10.1073/pnas.1713510115
   Hao HX, 2012, NATURE, V485, P195, DOI 10.1038/nature11019
   Harnack C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 12349 5
   Heng TSP, 2008, NAT IMMUNOL, V9, P1091, DOI 10.1038/ni1008 1091
   Hilkens J, 2017, GUT, V66, P1095, DOI 10.1136/gutjnl 2016 311606
   Inukai S, 2017, CURR OPIN GENET DEV, V43, P110, DOI 10.1016/j.gde.2017.02.007
   Jeannet G, 2008, BLOOD, V111, P142, DOI 10.1182/blood 2007 07 102558
   Kim KA, 2005, SCIENCE, V309, P1256, DOI 10.1126/science.1112521
   Kirstetter P, 2006, NAT IMMUNOL, V7, P1048, DOI 10.1038/ni1381
   Koch S, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006502
   Koch U, 2008, BLOOD, V111, P160, DOI 10.1182/blood 2007 07 099754
   Lambert SA, 2018, CELL, V175, P598, DOI 10.1016/j.cell.2018.09.045
   Lambert SA, 2018, CELL, V172, P650, DOI 10.1016/j.cell.2018.01.029
   Lane SW, 2010, BLOOD, V115, P3489, DOI 10.1182/blood 2009 11 251728
   Lau T, 2013, CANCER RES, V73, P3132, DOI 10.1158/0008 5472.CAN 12 4562
   Lebensohn AM, 2018, ELIFE, V7, DOI 10.7554/eLife.33126
   Liang HL, 2003, CANCER CELL, V4, P349, DOI 10.1016/S1535 6108(03)00268 X
   Lin XL, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2001833118
   Longerich T, 2019, GUT, V68, P1287, DOI 10.1136/gutjnl 2018 317632
   Luis TC, 2011, CELL STEM CELL, V9, P345, DOI 10.1016/j.stem.2011.07.017
   Masala E, 2012, LEUKEMIA RES, V36, P1290, DOI 10.1016/j.leukres.2012.05.023
   McCarthy N, 2020, NAT CELL BIOL, V22, P1033, DOI 10.1038/s41556 020 0567 z
   Nemeth MJ, 2007, P NATL ACAD SCI USA, V104, P15436, DOI 10.1073/pnas.0704747104
   Park S, 2018, J BIOL CHEM, V293, P9759, DOI 10.1074/jbc.RA118.002743
   Park S, 2017, J CLIN ONCOL, V35, P1591, DOI 10.1200/JCO.2016.71.3271
   Pinho S, 2019, NAT REV MOL CELL BIO, V20, P303, DOI 10.1038/s41580 019 0103 9
   Planas Paz L, 2016, NAT CELL BIOL, V18, P1260, DOI 10.1038/ncb3428
   Planas Paz L, 2016, NAT CELL BIOL, V18, P467, DOI 10.1038/ncb3337
   Repsold L, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/9405617
   Rocha AS, 2015, CELL REP, V13, P1757, DOI 10.1016/j.celrep.2015.10.049
   Scheller M, 2006, NAT IMMUNOL, V7, P1037, DOI 10.1038/ni1387
   Scholz B, 2016, DEV CELL, V36, P79, DOI 10.1016/j.devcel.2015.12.015
   Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282
   Shaikh LH, 2015, J CLIN ENDOCR METAB, V100, pE836, DOI 10.1210/jc.2015 1734
   Sigal M, 2017, NATURE, V548, P451, DOI 10.1038/nature23642
   Skaria T, 2018, MOL MED, V24, DOI 10.1186/s10020 018 0048 z
   Stoddart A, 2017, BLOOD, V129, P2959, DOI 10.1182/blood 2016 08 736454
   Storm EE, 2016, NATURE, V529, P97, DOI 10.1038/nature16466
   Sugimura R, 2012, CELL, V150, P351, DOI 10.1016/j.cell.2012.05.041
   Tanaka Y, 1998, P ASSOC AM PHYSICIAN, V110, P118
   Tikhonova AN, 2020, CELL STEM CELL, V27, P19, DOI 10.1016/j.stem.2020.06.013
   Tikhonova AN, 2019, NATURE, V572, pE6, DOI 10.1038/s41586 019 1394 x
   Tikhonova AN, 2019, NATURE, V569, P222, DOI 10.1038/s41586 019 1104 8
   Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048
   Vidal V, 2016, GENE DEV, V30, P1389, DOI 10.1101/gad.277756.116
   Wang JH, 2010, BLOOD, V115, P3481, DOI 10.1182/blood 2009 11 251835
   Weinberg OK, 2019, SEMIN HEMATOL, V56, P15, DOI 10.1053/j.seminhematol.2018.05.015
   Wojchowski DM, 2010, CURR OPIN HEMATOL, V17, P169, DOI 10.1097/MOH.0b013e328338008b
   Yan KS, 2017, NATURE, V545, P238, DOI 10.1038/nature22313
   Zebisch M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3787
   Zhang JH, 2014, ANAL BIOCHEM, V463, P61, DOI 10.1016/j.ab.2014.06.024
   Zhang ZJ, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 70912 3
   Zhou BO, 2014, CELL STEM CELL, V15, P154, DOI 10.1016/j.stem.2014.06.008
NR 66
TC 5
Z9 6
U1 0
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2473 9529
EI 2473 9537
J9 BLOOD ADV
JI Blood Adv.
PD FEB 28
PY 2023
VL 7
IS 4
BP 491
EP 507
DI 10.1182/bloodadvances.2022007714
EA FEB 2023
PG 17
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA 9W2HQ
UT WOS:000948901000001
PM 35914228
OA Green Published, gold, Green Accepted
DA 2025 08 17
ER

PT J
AU Lin, HM
   Zhang, W
   Xu, YS
   You, ZX
   Zheng, ML
   Liu, ZT
   Li, CX
AF Lin, Haiming
   Zhang, Wei
   Xu, Yashi
   You, Zexing
   Zheng, Minlin
   Liu, Zhentao
   Li, Chaoxiong
TI 4D label free quantitative proteomics analysis to screen potential drug
   targets of Jiangu Granules treatment for postmenopausal osteoporotic
   rats
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE 4D label free quantitative proteomics; postmenopausal osteoporotic; OVX
   rats; Jiangu granules; osteoblast differentiation
ID OSTEOBLAST DIFFERENTIATION; BONE FORMATION; LOCALIZATION
AB Background: Postmenopausal osteoporosis (PMOP) is a disease with a high prevalence in postmenopausal women and is characterized by an imbalance in bone metabolism, reduced bone mass, and increased risk of fracture due to estrogen deficiency. Jiangu granules (JG) is a compound prescription used in traditional Chinese medicine to treat PMOP. However, its definitive mechanism in PMOP is unclear. This study used a 4D label free quantitative proteomics method to explore the potential therapeutic mechanism of JG in an ovariectomy (OVX) rats' model.Materials and methods: A rat model of PMOP was established by removing the ovaries bilaterally. Nine 3 month old specific pathogen free female SD rats. The nine rats were randomly divided into 3 groups (n = 3 in each group): the sham operated group (J), the ovariectomy group (NC), and the JG treatment (ZY) group. Proteins extracted from the bone tissue of the lumbar spine (L3, L4) of three groups of rats were analyzed by 4D label free quantitative proteomics, and proteins differentially expressed after JG treatment and proteins differentially expressed after de ovulation were intersected to identify proteins associated with the mechanism of PMOP by JG treatment.Result: There were 104 up regulated and 153 down regulated differentially expressed proteins (DEPs) in the J group vs. NC group, 107 up regulated and 113 down regulated DEPs in the J group vs. ZY group, and 15 up regulated and 32 down regulated DEPs in the NC group vs. ZY group. Six potential target proteins for JG regulation of osteoblast differentiation in OVX rats were identified by taking intersections of differential proteins in the J group vs. NC group and NC group vs. ZY group.Conclusion: JG may exert therapeutic effects by modulating the expression levels of target proteins associated with osteoblast differentiation to enhance osteoblast differentiation in OVX rats. These results further uncovered the target proteins and specific mechanisms of JG in treating PMOP, providing an experimental basis for the clinical application of JG in treating PMOP.
C1 [Lin, Haiming; Zhang, Wei; Zheng, Minlin; Liu, Zhentao] Fujian Univ Tradit Chinese Med, Coll Integrated Chinese & Western Med, Fuzhou, Peoples R China.
   [Xu, Yashi; You, Zexing] Fujian Univ Tradit Chinese Med, Coll Pharm, Fuzhou, Peoples R China.
   [Li, Chaoxiong] Xiamen Univ, Fuzhou Hosp 2, Dept Orthoped, Fuzhou, Peoples R China.
   [Li, Chaoxiong] Fujian Med Univ, Clin Med Coll 3, Fuzhou, Peoples R China.
   [Li, Chaoxiong] Fujian Prov Clin Med Res Ctr First Aid & Rehabil O, Fuzhou, Peoples R China.
C3 Fujian University of Traditional Chinese Medicine; Fujian University of
   Traditional Chinese Medicine; Xiamen University; Fujian Medical
   University
RP Li, CX (通讯作者)，Xiamen Univ, Fuzhou Hosp 2, Dept Orthoped, Fuzhou, Peoples R China.; Li, CX (通讯作者)，Fujian Med Univ, Clin Med Coll 3, Fuzhou, Peoples R China.; Li, CX (通讯作者)，Fujian Prov Clin Med Res Ctr First Aid & Rehabil O, Fuzhou, Peoples R China.
EM lichaox0591aone@126.com
RI Zhang, Wei/AAG 9913 2019
FU Natural Science Foundation of Fujian Province; Open project of the
   scientific research platform of Fujian University of Traditional Chinese
   Medicine [2020J011187, 2019J01720];  [X2019011]
FX This study was jointly supported by the Natural Science Foundation of
   Fujian Province (2020J011187, 2019J01720), the Open project of the
   scientific research platform of Fujian University of Traditional Chinese
   Medicine (X2019011 Fujian Key Laboratory of Integrative Medicine on
   Geriatrics).
CR Anastasilakis AD, 2020, EXPERT OPIN PHARMACO, V21, P477, DOI 10.1080/14656566.2020.1717468
   Anupama DS, 2020, INT J ORTHOP TRAUMA, V39, DOI 10.1016/j.ijotn.2020.100796
   Bidwell JP, 2013, CURR OSTEOPOROS REP, V11, P117, DOI 10.1007/s11914 013 0139 2
   Cox J, 2014, MOL CELL PROTEOMICS, V13, P2513, DOI 10.1074/mcp.M113.031591
   de la Cruz López KG, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01143
   Doherty JR, 2013, J CLIN INVEST, V123, P3685, DOI 10.1172/JCI69741
   Flores R, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00566
   Forostyak S, 2013, BIOCHIMIE, V95, P2257, DOI 10.1016/j.biochi.2013.08.004
   Galperin MY, 2015, NUCLEIC ACIDS RES, V43, pD261, DOI 10.1093/nar/gku1223
   Gautvik KM, 2020, J BONE MINER RES, V35, P1065, DOI 10.1002/jbmr.3974
   Gimble JM, 2012, CLIN BIOCHEM, V45, P874, DOI 10.1016/j.clinbiochem.2012.03.006
   Heidemann J, 2014, INFLAMM RES, V63, P513, DOI 10.1007/s00011 014 0732 6
   Heinrich M, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.953205
   Heinrich M, 2020, J ETHNOPHARMACOL, V246, DOI 10.1016/j.jep.2019.112230
   Horton P, 2007, NUCLEIC ACIDS RES, V35, pW585, DOI 10.1093/nar/gkm259
   Huang YM, 2017, MOL MED REP, V16, P8420, DOI 10.3892/mmr.2017.7645
   Ishida M, 2018, ENDOCRINOLOGY, V159, P3775, DOI 10.1210/en.2018 00639
   Kanehisa M, 2016, NUCLEIC ACIDS RES, V44, pD457, DOI 10.1093/nar/gkv1070
   Kataoka Y, 2020, ARCH OSTEOPOROS, V15, DOI 10.1007/s11657 020 0697 8
   Kim HJ, 2020, BIOCHEM BIOPH RES CO, V524, P1044, DOI 10.1016/j.bbrc.2020.02.054
   Kou JQ, 2020, J CELL BIOCHEM, V121, P1216, DOI 10.1002/jcb.29355
   Li Dong tao, 2011, Zhong Xi Yi Jie He Xue Bao, V9, P1326
   Maeda SS, 2014, ARQ BRAS ENDOCRINOL, V58, P162, DOI 10.1590/0004 2730000003039
   Marie PJ, 2013, NAT REV ENDOCRINOL, V9, P288, DOI 10.1038/nrendo.2013.4
   Meier F, 2018, MOL CELL PROTEOMICS, V17, P2534, DOI 10.1074/mcp.TIR118.000900
   PECK WA, 1993, AM J MED, V94, P646
   Rivera D, 2014, J ETHNOPHARMACOL, V152, P393, DOI 10.1016/j.jep.2013.12.022
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Schiller C, 2013, HUM IMMUNOL, V74, P412, DOI 10.1016/j.humimm.2012.11.026
   Shen LY, 2022, CURR OSTEOPOROS REP, V20, P53, DOI 10.1007/s11914 022 00721 2
   Sun P, 2022, BIOMED PHARMACOTHER, V150, DOI 10.1016/j.biopha.2022.112975
   Tao HQ, 2021, PHARMACOL RES, V174, DOI 10.1016/j.phrs.2021.105967
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Valvona CJ, 2016, BRAIN PATHOL, V26, P3, DOI 10.1111/bpa.12299
   Wang Xin xiang, 2010, Zhong Xi Yi Jie He Xue Bao, V8, P1119
   Wu Yin Sheng, 2010, Zhongguo Zhong Xi Yi Jie He Za Zhi, V30, P966
   Wu Y, 2017, MOL CELL ENDOCRINOL, V452, P84, DOI 10.1016/j.mce.2017.05.017
   Xie BC, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.697442
   Yang J., 2019, J OSTEOPOROS, V25, P1067
   Yang L, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/6641838
   Yu CS, 2004, PROTEIN SCI, V13, P1402, DOI 10.1110/ps.03479604
   Zaw JJT, 2018, AGEING RES REV, V48, P79, DOI 10.1016/j.arr.2018.10.005
   Zhang C., 2020, J OSTEOPOROS, V26, P497
   Zhang Z., 2018, EFFECT JIANGU GRANUL, V28, P26
   Zhong Hang, 2017, Sichuan Da Xue Xue Bao Yi Xue Ban, V48, P862
   Zhou F., 2022, J REHABILITATION, V32, P224
NR 46
TC 14
Z9 15
U1 2
U2 28
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD NOV 1
PY 2022
VL 13
AR 1052922
DI 10.3389/fphar.2022.1052922
PG 16
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 6H2IA
UT WOS:000885269100001
PM 36386173
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Ferrando, M
   Wan, XH
   Meiss, R
   Yang, J
   De Siervi, A
   Navone, N
   Vazquez, E
AF Ferrando, Mercedes
   Wan, Xinhai
   Meiss, Roberto
   Yang, Jun
   De Siervi, Adriana
   Navone, Nora
   Vazquez, Elba
TI Heme Oxygenase 1 (HO 1) Expression in Prostate Cancer Cells Modulates
   the Oxidative Response in Bone Cells
SO PLOS ONE
LA English
DT Article
ID OSTEOBLAST DIFFERENTIATION; UP REGULATION; BETA CATENIN;
   OSTEOCLASTOGENESIS; STRESS; ACTIVATION; GROWTH
AB Prostate cancer (PCa) is a leading cause of death among males. It is currently estimated that inflammatory responses are linked to 15 20% of all deaths from cancer worldwide. PCa is dominated by complications arising from metastasis to the bone where the tumor cells interact with the bone microenvironment impairing the balance between bone formation and degradation. However, the molecular nature of this interaction is not completely understood. Heme oxygenase 1 (HO 1) counteracts oxidative damage and inflammation. Previous studies from our laboratory showed that HO 1 is implicated in PCa, demonstrating that endogenous HO 1 inhibits bone derived prostate cancer cells proliferation, invasion and migration and decreases tumor growth and angiogenesis in vivo. The aim of this work was to analyze the impact of HO 1 modulated PCa cells on osteoblasts proliferation in vitro and on bone remodeling in vivo. Using a co culture system of PC3 cells with primary mice osteoblasts (PMOs), we demonstrated that HO 1 pharmacological induction (hemin treatment) abrogated the diminution of PMOs proliferation induced by PCa cells and decreased the expression of osteoclast modulating factors in osteoblasts. No changes were detected in the expression of genes involved in osteoblasts differentiation. However, co culture of hemin pre treated PC3 cells (PC3 Hem) with PMOs provoked an oxidative status and activated FoxO signaling in osteoblasts. The percentage of active osteoblasts positive for HO 1 increased in calvarias explants co cultured with PC3 Hem cells. Nuclear HO 1 expression was detected in tumors generated by in vivo bone injection of HO 1 stable transfected PC3 (PC3HO 1) cells in the femur of SCID mice. These results suggest that HO 1 has the potential to modify the bone microenvironment impacting on PCa bone metastasis.
C1 [Ferrando, Mercedes; De Siervi, Adriana; Vazquez, Elba] Univ Buenos Aires, Dept Biol Chem, Sch Sci, IQUIBICEN CONICET, Buenos Aires, DF, Argentina.
   [Wan, Xinhai; Yang, Jun; Navone, Nora] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA.
   [Meiss, Roberto] Natl Acad Med Buenos Aires, Inst Oncol Studies, Dept Pathol, Buenos Aires, DF, Argentina.
C3 University of Buenos Aires; University of Texas System; UTMD Anderson
   Cancer Center; Buenos Aires National Academy of Medicine
RP Vazquez, E (通讯作者)，Univ Buenos Aires, Dept Biol Chem, Sch Sci, IQUIBICEN CONICET, Buenos Aires, DF, Argentina.
EM elba@qb.fcen.uba.ar
RI ; Vazquez, Elba/D 5134 2019; De Siervi, Adriana/AAC 7177 2020; Yao,
   Jun/JAC 5608 2023
OI De Siervi, Adriana/0000 0002 1524 8063; Vazquez,
   Elba/0000 0002 0460 0236; 
FU University of Buenos Aires, Argentina; UBACyT [20020100100179]; ANPCYT
   [PICT RAICES 2010 0431]; CONICET; UICC International Cancer Technology
   Transfer Fellowship
FX This work was supported by grants from the University of Buenos Aires,
   Argentina, UBACyT (20020100100179) and ANPCYT (PICT RAICES 2010 0431).
   M. F. held fellowships from CONICET and UICC International Cancer
   Technology Transfer Fellowship. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Almeida M, 2007, J BIOL CHEM, V282, P27298, DOI 10.1074/jbc.M702811200
   Almeida M, 2011, BONE, V49, P319, DOI 10.1016/j.bone.2011.05.023
   Bai XC, 2004, BIOCHEM BIOPH RES CO, V314, P197, DOI 10.1016/j.bbrc.2003.12.073
   Barbagallo I, 2010, J BONE MINER METAB, V28, P276, DOI 10.1007/s00774 009 0134 y
   Battisti V, 2011, BIOMED PHARMACOTHER, V65, P516, DOI 10.1016/j.biopha.2011.06.003
   Clérigues V, 2012, BIOCHEM PHARMACOL, V83, P395, DOI 10.1016/j.bcp.2011.11.024
   Darash Yahana M, 2004, FASEB J, V18, P1240, DOI 10.1096/fj.03 0935fje
   De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090
   Elguero B, 2012, NEOPLASIA, V14, P1043, DOI 10.1593/neo.121358
   Feller L, 2011, CANCER CELL INT, V11, DOI 10.1186/1475 2867 11 24
   Ferrando M, 2011, ANGIOGENESIS, V14, P467, DOI 10.1007/s10456 011 9230 4
   Fizazi K, 2003, CLIN CANCER RES, V9, P2587
   Freshney RI., 1994, Culture of animal cells : A manual of basic technique, V3rd
   Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264 6021:3490629
   Glass DA, 2007, ENDOCRINOLOGY, V148, P2630, DOI 10.1210/en.2006 1372
   Goldring SR, 2002, J RHEUMATOL, V29, P44
   Graves DT, 2011, J DENT RES, V90, P143, DOI 10.1177/0022034510385236
   Grochot Przeczek A, 2012, CLIN SCI, V122, P93, DOI 10.1042/CS20110147
   Gueron G, 2009, MOL CANCER RES, V7, P1745, DOI 10.1158/1541 7786.MCR 08 0325
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Kido J, 1997, J CELL BIOCHEM, V67, P248
   Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Lahusen T, 2003, MOL CARCINOGEN, V36, P183, DOI 10.1002/mc.10114
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Lin TH, 2010, J CELL PHYSIOL, V222, P757, DOI 10.1002/jcp.22008
   Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528
   Martinez J, 1996, J CELL BIOCHEM, V61, P18, DOI 10.1002/(SICI)1097 4644(19960401)61:1<18::AID JCB3>3.0.CO;2 5
   Pratap J, 2003, CANCER RES, V63, P5357
   Sacca P, 2007, BRIT J CANCER, V97, P1683, DOI 10.1038/sj.bjc.6604081
   Sakai E, 2013, J PHARMACOL SCI, V121, P288, DOI 10.1254/jphs.12243FP
   Vanella L, 2010, BONE, V46, P236, DOI 10.1016/j.bone.2009.10.012
   Wauquier F, 2009, TRENDS MOL MED, V15, P468, DOI 10.1016/j.molmed.2009.08.004
   Yang J, 2001, CANCER RES, V61, P5652
   Zwerina J, 2005, FASEB J, V19, P2011, DOI 10.1096/fj.05 4278fje
NR 37
TC 19
Z9 20
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD NOV 4
PY 2013
VL 8
IS 11
AR e80315
DI 10.1371/journal.pone.0080315
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 245ZC
UT WOS:000326503400153
PM 24224047
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU von Moos, R
   Lewis, K
   Massey, L
   Marongiu, A
   Rider, A
   Seesaghur, A
AF von Moos, Roger
   Lewis, Katie
   Massey, Lucy
   Marongiu, Andrea
   Rider, Alex
   Seesaghur, Anouchka
TI Initiation of bone targeted agents in patients with bone metastases and
   breast or castrate resistant prostate cancer actively treated in routine
   clinical practice in Europe
SO BONE
LA English
DT Article
DE Bone metastases; Bone pain; Bone targeted agents; Breast cancer;
   Prostate cancer
ID SKELETAL RELATED EVENTS; QUALITY OF LIFE; ZOLEDRONIC ACID; SOLID TUMORS;
   DOUBLE BLIND; HEALTH; DENOSUMAB
AB Background: Guidelines recommend starting bone targeted agents (BTA), such as zoledronic acid and denosumab, as soon as bone metastases (BMs) are definitively diagnosed in all patients with breast cancer (BC) or castration resistant prostate cancer (CRPC) whether they are symptomatic or not.
   Methods: Data were analyzed from 1364 patients with BC and 1161 patients with CRPC who had BMs and were receiving anti cancer therapy in hospitals across six European countries (Belgium, France, Germany, Italy, Spain and the UK). The 731 physicians (medical oncologists or urologists) provided insights in the decision making factors driving their management of bone health for these patients, and the patient medical records indicated how these decisions were reflected in routine clinical practice.
   Results: Within three months of a BM diagnosis, 74% of BC and 51% of CRPC patients had initiated treatment with a BTA. Around 12% of BC and 23% of CRPC patients did not receive a BTA following BM diagnosis. Irrespective of the tumour type (BC or CRPC), most physicians prescribed either denosumab or zoledronic acid as first BTA therapy. Physicians reported bone pain as a major decision making factor to initiate a BTA. The presence of bone complications at BM diagnosis and bone pain at BM diagnosis were found to be significant predictive factors for a BTA initiation, irrespective of tumour type.
   Conclusions: Despite European Society for Medical Oncology (ESMO) guidance on bone protection irrespective of symptomatic disease, not all patients with BMs received a BTA following a BM diagnosis. This suggests that clinical judgements and patients' communication of their pain to their physicians contributed to the decision to prescribe bone protection therapy in cancer patients.
C1 [von Moos, Roger] Kantonsspital Graubunden, Loestr 170, CH 7000 Chur, Switzerland.
   [Lewis, Katie; Massey, Lucy; Rider, Alex] Adelphi Real World, Bollington, England.
   [Marongiu, Andrea; Seesaghur, Anouchka] Amgen Ltd, Ctr Observat Res, Uxbridge, Middx, England.
C3 Kantonsspital Graubunden; Adelphi Group Ltd; Amgen; Amgen Limited
RP von Moos, R (通讯作者)，Kantonsspital Graubunden, Loestr 170, CH 7000 Chur, Switzerland.
EM roger.vonmoos@ksgr.ch
RI von Moos, Roger/AAG 4570 2020; Seesaghur, Anouchka/AAX 1816 2020
CR Alzahrani M, 2021, SUPPORT CARE CANCER, V29, P6903, DOI 10.1007/s00520 021 06238 1
   Anderson P, 2008, CURR MED RES OPIN, V24, P3063, DOI [10.1185/03007990802457040, 10.1185/03007990802457040 ]
   Body JJ, 2019, J BONE ONCOL, V14, DOI 10.1016/j.jbo.2018.100212
   Body JJ, 2017, CRIT REV ONCOL HEMAT, V115, P67, DOI 10.1016/j.critrevonc.2017.04.008
   Body JJ, 2016, EUR J HEALTH ECON, V17, P711, DOI 10.1007/s10198 015 0716 7
   Brown JE, 2021, J BONE ONCOL, V29, DOI 10.1016/j.jbo.2021.100375
   Butler AM, 2018, PHARMACOEPIDEM DR S, V27, P229, DOI 10.1002/pds.4360
   Cardoso F, 2017, ANN ONCOL, V28, P16, DOI 10.1093/annonc/mdw544
   Cathomas R, 2014, UROL INT, V92, P377, DOI 10.1159/000358258
   Coleman R, 2020, ANN ONCOL, V31, P1650, DOI 10.1016/j.annonc.2020.07.019
   Coleman R, 2014, ANN ONCOL, V25, P124, DOI 10.1093/annonc/mdu103
   Cornford P, 2021, EUR UROL, V79, P263, DOI 10.1016/j.eururo.2020.09.046
   Costa L, 2008, SUPPORT CARE CANCER, V16, P879, DOI 10.1007/s00520 008 0418 0
   Drudge Coates L, 2020, SUPPORT CARE CANCER, V28, P4019, DOI 10.1007/s00520 020 05440 x
   Drudge Coates L, 2018, CLIN GENITOURIN CANC, V16, pE411, DOI 10.1016/j.clgc.2017.09.015
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Freedland SJ, 2012, UROLOGY, V80, P293, DOI 10.1016/j.urology.2012.04.007
   Gallicchio R, 2019, TUMORI J, V105, P367, DOI 10.1177/0300891619851376
   Hagiwara May, 2014, J Med Econ, V17, P223, DOI 10.3111/13696998.2014.890937
   Hagiwara M, 2014, SUPPORT CARE CANCER, V22, P103, DOI 10.1007/s00520 013 1951 z
   Hechmati G, 2013, J Med Econ, V16, P691, DOI 10.3111/13696998.2013.779921
   Hoefeler H, 2014, J BONE ONCOL, V3, P40, DOI 10.1016/j.jbo.2014.04.001
   Klaassen Z, 2017, CANCER AM CANCER SOC, V123, P1528, DOI 10.1002/cncr.30505
   Link H, 2020, SUPPORT CARE CANCER, V28, P2175, DOI 10.1007/s00520 019 05018 2
   Major Pierre P, 2005, Support Cancer Ther, V2, P234, DOI 10.3816/SCT.2005.n.017
   Mark M, 2020, J BONE ONCOL, V21, DOI 10.1016/j.jbo.2019.100273
   McGrath LJ, 2018, CLIN EPIDEMIOL, V10, P1349, DOI 10.2147/CLEP.S175063
   Nicolatou Galitis O, 2019, OR SURG OR MED OR PA, V127, P117, DOI 10.1016/j.oooo.2018.09.008
   Otto S, 2018, CANCER TREAT REV, V69, P177, DOI 10.1016/j.ctrv.2018.06.007
   Pereira J, 2016, J MED ECON, V19, P611, DOI 10.3111/13696998.2016.1150852
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Schröder J, 2017, EUR J CANCER, V79, P139, DOI 10.1016/j.ejca.2017.03.031
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Tablazon IL, 2019, CANCER AM CANCER SOC, V125, P4003, DOI 10.1002/cncr.32414
   von Moos R, 2018, J BONE ONCOL, V11, P1, DOI 10.1016/j.jbo.2017.11.004
   von Moos R, 2019, CANCER TREAT REV, V76, P57, DOI 10.1016/j.ctrv.2019.05.003
   von Moos R, 2013, SUPPORT CARE CANCER, V21, P3497, DOI 10.1007/s00520 013 1932 2
   Weinfurt KP, 2005, ANN ONCOL, V16, P579, DOI 10.1093/annonc/mdi122
   Weinfurt KP, 2004, MED CARE, V42, P164, DOI 10.1097/01.mlr.0000108746.69256.45
   Zhang HW, 2018, J BONE ONCOL, V11, P38, DOI 10.1016/j.jbo.2018.01.004
NR 40
TC 8
Z9 8
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JAN
PY 2022
VL 154
AR 116243
DI 10.1016/j.bone.2021.116243
EA NOV 2021
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA XC6RP
UT WOS:000722138500001
PM 34757213
OA hybrid
DA 2025 08 17
ER

PT J
AU Weivoda, MM
   Hohl, RJ
AF Weivoda, Megan M.
   Hohl, Raymond J.
TI Effects of Farnesyl Pyrophosphate Accumulation on Calvarial Osteoblast
   Differentiation
SO ENDOCRINOLOGY
LA English
DT Article
ID NITROGEN CONTAINING BISPHOSPHONATES; COA REDUCTASE INHIBITORS;
   MESENCHYMAL STEM CELLS; MARROW STROMAL CELLS; BONE MINERAL DENSITY;
   FORMATION IN VITRO; OSTEOGENIC DIFFERENTIATION; PROTEIN PRENYLATION;
   ENDOGENOUS LIGANDS; NUCLEAR RECEPTOR
AB Statins, drugs commonly used to lower serum cholesterol, have been shown to stimulate osteoblast differentiation and bone formation. Statins inhibit 3 hydroxy 3 methylglutaryl (HMG) coenzyme A reductase (HMGCR), the first step of the isoprenoid biosynthetic pathway, leading to the depletion of the isoprenoids farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP). The effects of statins on bone have previously been attributed to the depletion of GGPP, because the addition of exogenous GGPP prevented statin stimulated osteoblast differentiation in vitro. However, in a recent report, we demonstrated that the specific depletion of GGPP did not stimulate but, in fact, inhibited osteoblast differentiation. This led us to hypothesize that isoprenoids upstream of GGPP play a role in the regulation of osteoblast differentiation. We demonstrate here that the expression of HMGCR and FPP synthase decreased during primary calvarial osteoblast differentiation, correlating with decreased FPP and GGPP levels during differentiation. Zaragozic acid (ZGA) inhibits the isoprenoid biosynthetic pathway enzyme squalene synthase, leading to an accumulation of the squalene synthase substrate FPP. ZGA treatment of calvarial osteoblasts led to a significant increase in intracellular FPP and resulted in inhibition of osteoblast differentiation as measured by osteoblastic gene expression, alkaline phosphatase activity, and matrix mineralization. Simultaneous HMGCR inhibition prevented the accumulation of FPP and restored osteoblast differentiation. In contrast, specifically inhibiting GGPPS to lower the ZGA induced increase in GGPP did not restore osteoblast differentiation. The specificity of HMGCR inhibition to restore osteoblast differentiation of ZGA treated cultures through the reduction in isoprenoid accumulation was confirmed with the addition of exogenous mevalonate. Similar to ZGA treatment, exogenous FPP inhibited the mineralization of primary calvarial osteoblasts. Interestingly, the effects of FPP accumulation on osteoblasts were found to be independent of protein farnesylation. Our findings are the first to demonstrate that the accumulation of FPP impairs osteoblast differentiation and suggests that the depletion of this isoprenoid may be necessary for normal and statin induced bone formation. (Endocrinology 152: 3113 3122, 2011)
C1 [Weivoda, Megan M.; Hohl, Raymond J.] Univ Iowa, Dept Pharmacol, Iowa City, IA 52242 USA.
   [Hohl, Raymond J.] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA.
C3 University of Iowa; University of Iowa
RP Hohl, RJ (通讯作者)，200 Hawkins Dr,SE 313 Gen Hosp, Iowa City, IA 52242 USA.
EM raymond hohl@uiowa.edu
FU Roy J. Carver Charitable Trust; Roland W. Holden Family Program for
   Experimental Cancer Therapeutics
FX This work was supported by the Roy J. Carver Charitable Trust as a
   Research Program of Excellence and the Roland W. Holden Family Program
   for Experimental Cancer Therapeutics.
CR Bang S, 2010, J BIOL CHEM, V285, P19362, DOI 10.1074/jbc.M109.087742
   Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Canalis E, 2010, J CLIN ENDOCR METAB, V95, P1496, DOI 10.1210/jc.2009 2677
   Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289
   Chen PY, 2010, NUTR RES, V30, P191, DOI 10.1016/j.nutres.2010.03.004
   Chuengsamarn S, 2010, BONE, V46, P1011, DOI 10.1016/j.bone.2009.12.023
   Compston J, 2010, RADIOL CLIN N AM, V48, P477, DOI 10.1016/j.rcl.2010.02.010
   Das S, 2007, MOL ENDOCRINOL, V21, P2672, DOI 10.1210/me.2007 0080
   Duque G, 2007, J BONE MINER RES, V22, P1603, DOI 10.1359/JBMR.070701
   Ebert R, 2009, BONE, V44, P858, DOI 10.1016/j.bone.2009.01.009
   ENDO A, 1992, J LIPID RES, V33, P1569
   ENDO A, 1977, EUR J BIOCHEM, V77, P31, DOI 10.1111/j.1432 1033.1977.tb11637.x
   Forman BM, 1997, P NATL ACAD SCI USA, V94, P10588, DOI 10.1073/pnas.94.20.10588
   FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092 8674(95)90530 8
   Fu LJ, 2008, BONE, V43, P40, DOI 10.1016/j.bone.2008.03.008
   Girotra Monica, 2006, Arq Bras Endocrinol Metab, V50, P745, DOI 10.1590/S0004 27302006000400019
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Gutierrez GE, 2008, J BONE MINER RES, V23, P1722, DOI 10.1359/JBMR.080603
   Holstein SA, 2004, LIPIDS, V39, P293, DOI 10.1007/s11745 004 1233 3
   Idris AI, 2008, CALCIFIED TISSUE INT, V82, P191, DOI 10.1007/s00223 008 9104 y
   Im GI, 2004, BIOMATERIALS, V25, P4105, DOI 10.1016/j.biomaterials.2003.11.024
   KANIS JA, 1994, OSTEOPOROSIS INT, V4, P368, DOI 10.1007/BF01622200
   Kellinsalmi M, 2005, BASIC CLIN PHARMACOL, V97, P382, DOI 10.1111/j.1742 7843.2005.pto_176.x
   Kim HK, 2009, CLIN ORTHOP RELAT R, V467, P3121, DOI 10.1007/s11999 008 0409 y
   Li XD, 2003, BONE, V33, P652, DOI 10.1016/S8756 3282(03)00239 4
   Liliom K, 2006, BBA MOL CELL BIOL L, V1761, P1506, DOI 10.1016/j.bbalip.2006.09.012
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Maeda T, 2003, ENDOCRINOLOGY, V144, P681, DOI 10.1210/en.2002 220682
   Maeda T, 2004, J CELL BIOCHEM, V92, P458, DOI 10.1002/jcb.20074
   Maeda T, 2001, BIOCHEM BIOPH RES CO, V280, P874, DOI 10.1006/bbrc.2000.4232
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Oh DY, 2008, J BIOL CHEM, V283, P21054, DOI 10.1074/jbc.M708908200
   Ohnaka K, 2001, BIOCHEM BIOPH RES CO, V287, P337, DOI 10.1006/bbrc.2001.5597
   Orriss IR, 2009, J CELL BIOCHEM, V106, P109, DOI 10.1002/jcb.21983
   Pagkalos J, 2010, J BONE MINER RES, V25, P2470, DOI 10.1002/jbmr.163
   Panzavolta S, 2009, J INORG BIOCHEM, V103, P101, DOI 10.1016/j.jinorgbio.2008.09.012
   Pozzi S, 2009, CLIN CANCER RES, V15, P5829, DOI 10.1158/1078 0432.CCR 09 0426
   Reinholz GG, 2000, CANCER RES, V60, P6001
   Ruiz Gaspa S, 2007, J CELL BIOCHEM, V101, P1430, DOI 10.1002/jcb.21259
   Shull LW, 2006, BIOORGAN MED CHEM, V14, P4130, DOI 10.1016/j.bmc.2006.02.010
   SIPERSTEIN MD, 1966, J BIOL CHEM, V241, P602
   Skoglund B, 2002, J BONE MINER RES, V17, P2004, DOI 10.1359/jbmr.2002.17.11.2004
   Takase H, 2009, HORM METAB RES, V41, P861, DOI 10.1055/s 0029 1233460
   Tang QO, 2008, EXPERT OPIN INV DRUG, V17, P1435, DOI [10.1517/13543784.17.10.1435, 10.1517/13543784.17.10.1435 ]
   Tong HX, 2005, ANAL BIOCHEM, V336, P51, DOI 10.1016/j.ab.2004.09.024
   Uzzan B, 2007, BONE, V40, P1581, DOI 10.1016/j.bone.2007.02.019
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   Vukelic S, 2010, J BIOL CHEM, V285, P1980, DOI 10.1074/jbc.M109.016741
   Wang PS, 2000, JAMA J AM MED ASSOC, V283, P3211, DOI 10.1001/jama.283.24.3211
   Weivoda MM, 2011, J CELL BIOCHEM, V112, P1506, DOI 10.1002/jcb.23087
   Wiemer AJ, 2007, BIOCHEM BIOPH RES CO, V353, P921, DOI 10.1016/j.bbrc.2006.12.094
   Yoshida T, 2006, FEBS LETT, V580, P5203, DOI 10.1016/j.febslet.2006.08.060
   Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325
NR 54
TC 42
Z9 46
U1 4
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0013 7227
EI 1945 7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD AUG
PY 2011
VL 152
IS 8
BP 3113
EP 3122
DI 10.1210/en.2011 0016
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 795XA
UT WOS:000293010700021
PM 21586555
OA Bronze
DA 2025 08 17
ER

PT J
AU Kim, JK
   Jung, Y
   Wang, JC
   Joseph, J
   Mishra, A
   Hill, EE
   Krebsbach, PH
   Pienta, KJ
   Shiozawa, Y
   Taichman, RS
AF Kim, Jin Koo
   Jung, Younghun
   Wang, Jingcheng
   Joseph, Jeena
   Mishra, Anjali
   Hill, Elliott E.
   Krebsbach, Paul H.
   Pienta, Kenneth J.
   Shiozawa, Yusuke
   Taichman, Russell S.
TI TBK1 Regulates Prostate Cancer Dormancy through mTOR Inhibition
SO NEOPLASIA
LA English
DT Article
ID HEMATOPOIETIC STEM CELLS; LEUKEMIA INITIATING CELLS; TOLL LIKE
   RECEPTORS; TUMOR DORMANCY; SIGNALING PATHWAY; VIRAL INFECTION;
   IKK EPSILON; PHOSPHORYLATION; QUIESCENCE; SURVIVAL
AB The mechanisms that regulate hematopoietic stem cell (HSC) dormancy and self renewal are well established and are largely dependent on signals emanating from the HSC niche. Recently, we found that prostate cancer (PCa) cells target the HSC niche in mouse bone marrow (BM) during metastasis. Little is known, however, as to how the HSC niche may regulate dormancy in cancer cells. In this study, we investigated the effects of TANK binding kinase 1 (TBK1) on PCa dormancy in the BM niche. We found that binding with niche osteoblasts induces the expression of TBK1 in PCa cells PC3 and C4 2B. Interestingly, TBK1 interacts with mammalian target of rapamycin (mTOR) and inhibits its function. Rapamycin, an mTOR inhibitor, induces cell cycle arrest of PCa cells and enhances chemotherapeutic resistance of PCa cells. As a result, the knockdown of TBK1 decreases PCa stem like cells and drug resistance in vitro and in vivo. Taken together, these results strongly indicate that TBK1 plays an important role in the dormancy and drug resistance of PCa.
C1 [Kim, Jin Koo; Jung, Younghun; Wang, Jingcheng; Joseph, Jeena; Mishra, Anjali; Shiozawa, Yusuke; Taichman, Russell S.] Univ Michigan, Sch Dent, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA.
   [Mishra, Anjali; Hill, Elliott E.; Krebsbach, Paul H.] Univ Michigan, Sch Dent, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA.
   [Pienta, Kenneth J.] Brady Urol Inst, Dept Urol Oncol & Pharmacol & Mol Sci, Baltimore, MD USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan
RP Taichman, RS (通讯作者)，Univ Michigan, Sch Dent, 1011 North Univ Ave, Ann Arbor, MI 48109 USA.
EM rtaich@umich.edu
RI Krebsbach, Paul/AAC 4765 2021; Taichman, Russell/NOF 9711 2025; Pienta,
   Kenneth/E 7679 2015
OI Taichman, Russell S./0000 0002 7890 0020; 
FU National Institutes of Health (NIH) through the University of Michigan
   Cancer Center support grant [P30 CA046592]; National Cancer Institute
   [CA163124, CA093900]; Fund for Cancer Research; Department of Defense;
   Prostate Cancer Foundation; NIH [P50 CA69568, P30 CA46592]; National
   Cancer Institute [P30CA046592, P01CA093900] Funding Source: NIH RePORTER
FX This research was supported in part by the National Institutes of Health
   (NIH) through the University of Michigan Cancer Center support grant
   (P30 CA046592). This work was directly supported by the National Cancer
   Institute (CA163124 and CA093900; Y.S., K.J.P., and R. S. T.), the Fund
   for Cancer Research (R. S. T.), the Department of Defense (K.J.P. and R.
   S. T.), and the Prostate Cancer Foundation (Y.S., K.J.P., and R. S. T.).
   K.J.P. receives support as an American Cancer Society Clinical Research
   Professor and from NIH Specialized Program of Research Excellence
   (SPORE) in prostate cancer grant P50 CA69568 and the Cancer Center
   support grant P30 CA46592.
CR Aguirre Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863
   Baldwin AS, 2012, IMMUNOL REV, V246, P327, DOI 10.1111/j.1600 065X.2012.01095.x
   Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460
   Basith S, 2012, ARCH PHARM RES, V35, P1297, DOI 10.1007/s12272 012 0802 7
   Boehm JS, 2007, CELL, V129, P1065, DOI 10.1016/j.cell.2007.03.052
   Castilho RM, 2009, CELL STEM CELL, V5, P279, DOI 10.1016/j.stem.2009.06.017
   Chen C, 2008, J EXP MED, V205, P2397, DOI 10.1084/jem.20081297
   Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804
   Chien YC, 2006, CELL, V127, P157, DOI 10.1016/j.cell.2006.08.034
   Felsher DW, 2008, APMIS, V116, P629, DOI 10.1111/j.1600 0463.2008.01037.x
   Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921
   Frias MA, 2006, CURR BIOL, V16, P1865, DOI 10.1016/j.cub.2006.08.001
   Gan BY, 2010, NATURE, V468, P701, DOI 10.1038/nature09595
   Gan B, 2009, CELL CYCLE, V8, P1003, DOI 10.4161/cc.8.7.8045
   Gan B, 2008, P NATL ACAD SCI USA, V105, P19384, DOI 10.1073/pnas.0810584105
   Ghosh S, 2006, CANCER CELL, V10, P215, DOI 10.1016/j.ccr.2006.08.007
   González Reyes S, 2011, CANCER IMMUNOL IMMUN, V60, P217, DOI 10.1007/s00262 010 0931 0
   Gurumurthy S, 2010, NATURE, V468, P659, DOI 10.1038/nature09572
   Hemmi H, 2004, J EXP MED, V199, P1641, DOI 10.1084/jem.20040520
   Hong F, 2008, MOL CELL, V30, P701, DOI 10.1016/j.molcel.2008.04.027
   Hoshii T, 2012, J CLIN INVEST, V122, P2114, DOI 10.1172/JCI62279
   Hutti JE, 2009, MOL CELL, V34, P461, DOI 10.1016/j.molcel.2009.04.031
   Ito K, 2008, NATURE, V453, P1072, DOI 10.1038/nature07016
   Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183
   Kawai T, 2011, IMMUNITY, V34, P637, DOI 10.1016/j.immuni.2011.05.006
   Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092 8674(02)00808 5
   Korherr C, 2006, P NATL ACAD SCI USA, V103, P4240, DOI 10.1073/pnas.0511319103
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Lu Z, 2008, J CLIN INVEST, V118, P3917, DOI 10.1172/JCI35512
   Matsumoto K, 2009, CANCER RES, V69, P7160, DOI 10.1158/0008 5472.CAN 09 1289
   Matsuoka S, 2008, GENE DEV, V22, P986, DOI 10.1101/gad.1621808
   Nakada D, 2010, NATURE, V468, P653, DOI 10.1038/nature09571
   Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200
   Ou YH, 2011, MOL CELL, V41, P458, DOI 10.1016/j.molcel.2011.01.019
   Paone A, 2008, CARCINOGENESIS, V29, P1334, DOI 10.1093/carcin/bgn149
   Parmar K, 2007, P NATL ACAD SCI USA, V104, P5431, DOI 10.1073/pnas.0701152104
   Perry AK, 2004, J EXP MED, V199, P1651, DOI 10.1084/jem.20040528
   Quesnel B, 2008, CANCER LETT, V267, P10, DOI 10.1016/j.canlet.2008.02.055
   Ranganathan AC, 2006, CANCER BIOL THER, V5, P729, DOI 10.4161/cbt.5.7.2968
   Rankin EB, 2012, CELL, V149, P63, DOI 10.1016/j.cell.2012.01.051
   Rehn M, 2011, BLOOD, V118, P1534, DOI 10.1182/blood 2011 01 332890
   Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Shachaf CM, 2004, NATURE, V431, P1112, DOI 10.1038/nature03043
   Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315
   Shen RR, 2011, ONCOGENE, V30, P631, DOI 10.1038/onc.2010.493
   Shiozawa Y, 2011, J CLIN INVEST, V121, P1298, DOI 10.1172/JCI43414
   Vessella Robert L, 2007, Cancer Biol Ther, V6, P1496
   Wikman H, 2008, APMIS, V116, P754, DOI 10.1111/j.1600 0463.2008.01033.x
   Wilson A, 2009, CURR OPIN GENET DEV, V19, P461, DOI 10.1016/j.gde.2009.08.005
   Yang ZJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028405
   Yilmaz ÖH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703
   Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747
   Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025
NR 54
TC 102
Z9 114
U1 0
U2 26
PU NEOPLASIA PRESS
PI ANN ARBOR
PA 1150 W MEDICAL CENTER DR, MSRB III, RM 9303, ANN ARBOR, MI 48109 0648
   USA
SN 1522 8002
EI 1476 5586
J9 NEOPLASIA
JI Neoplasia
PD SEP
PY 2013
VL 15
IS 9
BP 1064
EP 1074
DI 10.1593/neo.13402
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 267YR
UT WOS:000328134800007
PM 24027431
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wang, H
   Li, T
   Jiang, Y
   Chen, S
   Zou, S
   Bonewald, LF
   Duan, P
AF Wang, H.
   Li, T.
   Jiang, Y.
   Chen, S.
   Zou, S.
   Bonewald, L. F.
   Duan, P.
TI Force Loaded Cementocytes Regulate Osteoclastogenesis via S1P/S1PR1/Rac1
   Axis
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE dental cementum; osteoclasts; cell communication; mechanical stress;
   root resorption, orthodontics
ID KAPPA B LIGAND; NUCLEAR FACTOR; RECEPTOR ACTIVATOR; ROOT RESORPTION;
   TOOTH MOVEMENT; CELL LINE; DIFFERENTIATION; PROLIFERATION; THERAPY
AB Orthodontically induced inflammatory root resorption (OIIRR) is the major iatrogenic complication of orthodontic treatment, seriously endangering tooth longevity and impairing masticatory function. Osteoclasts are thought to be the primary effector cells that initiate the pathological process of OIIRR; however, the cellular and molecular mechanisms responsible for OIIRR remain unclear. Our previous studies revealed that cementocytes, the major mechanically responsive cells in cementum, respond to compressive stress to activate and influence osteoclasts locally. For this study, we hypothesized that the sphingosine 1 phosphate (S1P) signaling pathway, a key mechanotransduction pathway in cementocytes, may regulate osteoclasts under the different magnitudes of either physiologic compressive stress that causes tooth movement or pathologic stress that causes OIIRR. Here, we show a biphasic effect of higher compression force stimulating the synthesis and secretion of S1P, whereas lower compression force reduced signaling in IDG CM6 cementocytes. Using conditioned media from force loaded cementocytes, we verified the cell to cell communication between cementocytes and osteoclasts and show that selective knockdown of S1PR1 and Rac1 plays a role in cementocyte driven osteoclastogenesis via the S1P/S1PR1/Rac1 axis. Most importantly, the use of inhibitors of this axis reduced or prevented the pathological process of OIIRR. The intercellular communication mechanisms between cementocytes and osteoclasts may serve as a promising therapeutic target for OIIRR.
C1 [Wang, H.; Li, T.; Jiang, Y.; Chen, S.; Zou, S.; Duan, P.] State Key Lab Oral Dis, Chengdu, Sichuan, Peoples R China.
   [Wang, H.; Li, T.; Jiang, Y.; Chen, S.; Zou, S.; Duan, P.] Natl Ctr Stomatol, Chengdu, Sichuan, Peoples R China.
   [Wang, H.; Li, T.; Jiang, Y.; Chen, S.; Zou, S.; Duan, P.] Natl Clin Res Ctr Oral Dis, Chengdu, Sichuan, Peoples R China.
   [Wang, H.; Li, T.; Jiang, Y.; Chen, S.; Zou, S.; Duan, P.] Sichuan Univ, West China Hosp Stomatol, Dept Orthodont, 14,3rd Sect Renmin South Rd, Chengdu 610041, Sichuan, Peoples R China.
   [Li, T.] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Sch Med, Dept Orthodont, Shanghai, Peoples R China.
   [Li, T.] Shanghai Jiao Tong Univ, Coll Stomatol, Shanghai, Peoples R China.
   [Li, T.] Natl Ctr Stomatol, Shanghai, Peoples R China.
   [Li, T.] Natl Clin Res Ctr Oral Dis, Shanghai, Peoples R China.
   [Li, T.] Shanghai Key Lab Stomatol, Shanghai, Peoples R China.
   [Li, T.] Shanghai Res Inst Stomatol, Shanghai, Peoples R China.
   [Bonewald, L. F.] Indiana Univ Sch Med, Indiana Ctr Musculoskeletal Hlth, Dept Anat Cell Biol & Physiol & Orthopaed Surg, Indianapolis, IN USA.
C3 Sichuan University; Sichuan University; Shanghai Jiao Tong University;
   Shanghai Jiao Tong University; Indiana University System; Indiana
   University Bloomington
RP Duan, P (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Dept Orthodont, 14,3rd Sect Renmin South Rd, Chengdu 610041, Sichuan, Peoples R China.
EM duanp@scu.edu.cn
RI Bonewald, Lynda/Q 3638 2019
OI Wang, Han/0000 0002 0104 7391
FU Sichuan Science and Technology Program, China [21ZDYF1874]; National
   Natural Science Foundation of China (NSFC) [82271017, 81701005,
   82071150]
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: This work was
   supported by the Sichuan Science and Technology Program, China (No.
   21ZDYF1874) and National Natural Science Foundation of China (NSFC, No.
   82271017, No. 81701005, and No. 82071150).
CR Bao XF, 2013, INT J MOL SCI, V14, P21140, DOI 10.3390/ijms141021140
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   De Rossi A, 2016, J ENDODONT, V42, P1251, DOI 10.1016/j.joen.2016.05.009
   Guo Q, 2021, J BONE MINER RES, V36, P2065, DOI 10.1002/jbmr.4399
   Hannun YA, 2018, NAT REV MOL CELL BIO, V19, P175, DOI 10.1038/nrm.2017.107
   Iglesias Linares A, 2017, J DENT RES, V96, P145, DOI 10.1177/0022034516677539
   Ishii M, 2010, J EXP MED, V207, P2793, DOI 10.1084/jem.20101474
   Ishii M, 2009, NATURE, V458, P524, DOI 10.1038/nature07713
   Jin SH, 2018, BMB REP, V51, P356, DOI 10.5483/BMBRep.2018.51.7.106
   Kim JM, 2016, MOL CELL ENDOCRINOL, V437, P261, DOI 10.1016/j.mce.2016.08.042
   Kundumani Sridharan V, 2013, J BIOL CHEM, V288, P22150, DOI 10.1074/jbc.M113.454082
   Mann C, 2022, AM J ORTHOD DENTOFAC, V162, P238, DOI 10.1016/j.ajodo.2021.03.023
   Mao D, 2021, SCI SIGNAL, V14, DOI 10.1126/scisignal.abc0425
   Nakano T, 2014, ANGLE ORTHOD, V84, P1079, DOI 10.2319/121913 929.1
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Nara Y, 2022, J DENT SCI, V17, P984, DOI 10.1016/j.jds.2021.11.009
   Okamoto N, 2019, BMC ORAL HEALTH, V19, DOI 10.1186/s12903 019 0778 5
   Ryu J, 2006, EMBO J, V25, P5840, DOI 10.1038/sj.emboj.7601430
   Shin BJ, 2020, J BONE MINER RES, V35, P789, DOI 10.1002/jbmr.3945
   Turner H, 1998, J EXP MED, V188, P527, DOI 10.1084/jem.188.3.527
   Ueda Ichinose Y, 2022, ANGLE ORTHOD, V92, P547, DOI [10.2319/072221 578.2547, 10.2319/072221 578.2]
   Wang H, 2022, CLIN ORAL INVEST, V26, P1003, DOI 10.1007/s00784 021 04084 3
   Wang H, 2020, BIOCHEM BIOPH RES CO, V523, P595, DOI 10.1016/j.bbrc.2020.01.003
   Wishney M, 2017, AUST DENT J, V62, P86, DOI 10.1111/adj.12486
   Woo SM, 2011, J BONE MINER RES, V26, P2634, DOI 10.1002/jbmr.465
   Wu S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131498
   Xiao L, 2018, J BONE MINER RES, V33, P1090, DOI 10.1002/jbmr.3396
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Xu S, 2018, CELL DEATH DIFFER, V25, P1549, DOI 10.1038/s41418 017 0049 4
   Yamaguchi M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052388
   Yu H, 2016, J PERIODONTAL RES, V51, P38, DOI 10.1111/jre.12276
   Zhang S, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 03106 4
   Zhao N, 2016, J DENT RES, V95, P734, DOI 10.1177/0022034516641898
   Zhao N, 2016, J BONE MINER RES, V31, P430, DOI 10.1002/jbmr.2690
   Zhao S, 2002, J BONE MINER RES, V17, P2068, DOI 10.1359/jbmr.2002.17.11.2068
   Zheleznyak A, 2021, THERANOSTICS, V11, P7735, DOI 10.7150/thno.60757
NR 36
TC 15
Z9 16
U1 1
U2 15
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022 0345
EI 1544 0591
J9 J DENT RES
JI J. Dent. Res.
PD NOV
PY 2023
VL 102
IS 12
BP 1376
EP 1386
DI 10.1177/00220345231195765
EA SEP 2023
PG 11
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA U8BH4
UT WOS:001079174300001
PM 37735908
DA 2025 08 17
ER

PT J
AU Zhang, XG
   Cheng, G
   Xing, X
   Liu, JC
   Cheng, Y
   Ye, TY
   Wang, Q
   Xiao, XH
   Li, ZB
   Deng, HB
AF Zhang, Xingang
   Cheng, Gu
   Xing, Xin
   Liu, Jiangchao
   Cheng, Yuet
   Ye, Tianyu
   Wang, Qun
   Xiao, Xiangheng
   Li, Zubing
   Deng, Hongbing
TI Near Infrared Light Triggered Porous AuPd Alloy Nanoparticles To Produce
   Mild Localized Heat To Accelerate Bone Regeneration
SO JOURNAL OF PHYSICAL CHEMISTRY LETTERS
LA English
DT Article
ID GOLD NANOPARTICLES; GROWTH FACTORS; REPAIR; DELIVERY; SCAFFOLDS;
   DIFFERENTIATION; BIOMATERIALS; NANOSHEETS; CHEMISTRY; CATALYSIS
AB The treatment of massive bone defects is still a significant challenge for orthopedists. Here we have engineered synthetic porous AuPd alloy nanoparticles (pAuPds) as a hyperthermia agent for in situ bone regeneration through photothermal therapy (PTT). After being swallowed by cells, pAuPds produced a mild localized heat (MLH) (40 43 degrees C) under the irradiation of a near infrared laser, which can greatly accelerate cell proliferation and bone regeneration. Almost 97% of the cranial defect area (8 mm in diameter) was covered by the newly formed bone after 6 weeks of PTT. RNA sequencing analysis was used to obtain insight into the molecular mechanism of the MLH on cell proliferation and bone formation. These results demonstrated that the Wnt signaling pathway was involved in the MLH. This Letter provides a unique strategy with mild heat stimulation and high efficiency for in situ bone regeneration.
C1 [Zhang, Xingang; Liu, Jiangchao; Ye, Tianyu; Xiao, Xiangheng] Wuhan Univ, Dept Phys, Wuhan 430072, Hubei, Peoples R China.
   [Zhang, Xingang; Liu, Jiangchao; Ye, Tianyu; Xiao, Xiangheng] Wuhan Univ, Key Lab Artificial Micro & Nanostruct, Minist Educ, Hubei Nucl Solid Phys Key Lab, Wuhan 430072, Hubei, Peoples R China.
   [Zhang, Xingang; Liu, Jiangchao; Ye, Tianyu; Xiao, Xiangheng] Wuhan Univ, Ctr Ion Beam Applicat, Wuhan 430072, Hubei, Peoples R China.
   [Cheng, Gu; Xing, Xin; Cheng, Yuet; Li, Zubing] Wuhan Univ, State Key Lab Breeding Base Basic Sci Stomatol Hu, Wuhan 430079, Hubei, Peoples R China.
   [Cheng, Gu; Xing, Xin; Cheng, Yuet; Li, Zubing] Wuhan Univ, Key Lab Oral Biomed, Minist Educ, Wuhan 430079, Hubei, Peoples R China.
   [Cheng, Gu; Xing, Xin; Cheng, Yuet; Li, Zubing] Wuhan Univ, Dept Oral & Maxillof Trauma & Plast Surg, Sch & Hosp Stomatol, Wuhan 430079, Hubei, Peoples R China.
   [Deng, Hongbing] Wuhan Univ, Sch Resource & Environm Sci, Wuhan 430079, Hubei, Peoples R China.
   [Deng, Hongbing] Wuhan Univ, Hubei Biomass Resource Chem & Environm Biotechnol, Wuhan 430079, Hubei, Peoples R China.
   [Wang, Qun] Iowa State Univ, Dept Chem & Biol Engn, Ames, IA 50011 USA.
C3 Wuhan University; Wuhan University; Wuhan University; Wuhan University;
   Wuhan University; Wuhan University; Wuhan University; Wuhan University;
   Iowa State University
RP Xiao, XH (通讯作者)，Wuhan Univ, Dept Phys, Wuhan 430072, Hubei, Peoples R China.; Xiao, XH (通讯作者)，Wuhan Univ, Key Lab Artificial Micro & Nanostruct, Minist Educ, Hubei Nucl Solid Phys Key Lab, Wuhan 430072, Hubei, Peoples R China.; Xiao, XH (通讯作者)，Wuhan Univ, Ctr Ion Beam Applicat, Wuhan 430072, Hubei, Peoples R China.; Li, ZB (通讯作者)，Wuhan Univ, State Key Lab Breeding Base Basic Sci Stomatol Hu, Wuhan 430079, Hubei, Peoples R China.; Li, ZB (通讯作者)，Wuhan Univ, Key Lab Oral Biomed, Minist Educ, Wuhan 430079, Hubei, Peoples R China.; Li, ZB (通讯作者)，Wuhan Univ, Dept Oral & Maxillof Trauma & Plast Surg, Sch & Hosp Stomatol, Wuhan 430079, Hubei, Peoples R China.; Deng, HB (通讯作者)，Wuhan Univ, Sch Resource & Environm Sci, Wuhan 430079, Hubei, Peoples R China.; Deng, HB (通讯作者)，Wuhan Univ, Hubei Biomass Resource Chem & Environm Biotechnol, Wuhan 430079, Hubei, Peoples R China.
EM xxh@whu.edu.cn; lizubing@whu.edu.cn; hbdeng@whu.edu.cn
RI Cheng, Yuet/KUD 4809 2024; Wang, Wendy/JWA 0785 2024; Deng,
   Hongbing/J 5318 2014; xiao, xiangheng/AFO 1378 2022; Xing,
   Xin/HJP 0675 2023; ye, ty/KFB 9062 2024
OI Cheng, Gu/0000 0003 3203 3096; Wang, Qun/0000 0002 5660 5602; Cheng,
   Yuet/0000 0003 1529 4032; Xing, Xin/0000 0001 6417 0664; Deng,
   Hongbing/0000 0002 9784 6138; xiao, xiangheng/0000 0001 9111 1619; 
FU NSFC [11722543, U1867215, 81800943]; Fundamental Research Funds for the
   Central Universities [2042019kf0312]; Suzhou Key Industrial Technology
   Innovation Project [SYG201828]
FX We acknowledge the NSFC (11722543, U1867215, 81800943), the Fundamental
   Research Funds for the Central Universities (2042019kf0312), and Suzhou
   Key Industrial Technology Innovation Project (SYG201828).
CR Agarwal R, 2015, ADV DRUG DELIVER REV, V94, P53, DOI 10.1016/j.addr.2015.03.013
   Ali MRK, 2017, P NATL ACAD SCI USA, V114, pE3110, DOI 10.1073/pnas.1619302114
   [Anonymous], 2013, ANGEW CHEM
   Bez M, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3128
   Cancedda R, 2007, BIOMATERIALS, V28, P4240, DOI 10.1016/j.biomaterials.2007.06.023
   Chen JY, 2007, NANO LETT, V7, P1318, DOI 10.1021/nl070345g
   Chen R, 2016, ADV FUNCT MATER, V26, P8810, DOI 10.1002/adfm.201603197
   Chen WS, 2017, ADV MATER, V29, DOI 10.1002/adma.201603864
   Chen XJ, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.108746
   Chen YW, 2016, ADV DRUG DELIVER REV, V105, P190, DOI 10.1016/j.addr.2016.05.022
   Cheng XJ, 2017, ADV MATER, V29, DOI 10.1002/adma.201604894
   Chu CC, 2017, ADV MATER, V29, DOI 10.1002/adma.201605928
   Chung HJ, 2017, J NAT PROD, V80, P434, DOI 10.1021/acs.jnatprod.6b00964
   Daniel MC, 2004, CHEM REV, V104, P293, DOI 10.1021/cr030698+
   Espinosa A, 2018, ACS NANO, V12, P6523, DOI 10.1021/acsnano.8b00482
   Fu Q, 2013, ADV FUNCT MATER, V23, P5461, DOI 10.1002/adfm.201301121
   Hashimoto S, 2012, J PHOTOCH PHOTOBIO C, V13, P28, DOI 10.1016/j.jphotochemrev.2012.01.001
   He WP, 2016, ADV SCI, V3, DOI 10.1002/advs.201600206
   Heo DN, 2014, J MATER CHEM B, V2, P1584, DOI 10.1039/c3tb21246g
   Huang XB, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020561
   Huang XQ, 2011, NAT NANOTECHNOL, V6, P28, DOI [10.1038/nnano.2010.235, 10.1038/NNANO.2010.235]
   Ito S, 2019, J BIOL CHEM, V294, P2133, DOI 10.1074/jbc.TM118.002812
   Khosla S, 2008, J CLIN INVEST, V118, P421, DOI 10.1172/JCI33612
   Kolambkar YM, 2011, BIOMATERIALS, V32, P65, DOI 10.1016/j.biomaterials.2010.08.074
   Lee C, 2017, ADV MATER, V29, DOI 10.1002/adma.201605563
   Lee SH, 2007, ADV DRUG DELIVER REV, V59, P339, DOI 10.1016/j.addr.2007.03.016
   Li QX, 2013, ENDOCRINOLOGY, V154, P446, DOI 10.1210/en.2012 1585
   Lin H, 2017, J AM CHEM SOC, V139, P16235, DOI 10.1021/jacs.7b07818
   Lin YX, 2017, ADV MATER, V29, DOI 10.1002/adma.201701617
   Liu YJ, 2017, ACS NANO, V11, P10539, DOI 10.1021/acsnano.7b05908
   Long R, 2013, J AM CHEM SOC, V135, P3200, DOI 10.1021/ja311739v
   Lutolf MR, 2003, NAT BIOTECHNOL, V21, P513, DOI 10.1038/nbt818
   Mandal BB, 2012, P NATL ACAD SCI USA, V109, P7699, DOI 10.1073/pnas.1119474109
   Mankin HJ, 2005, CLIN ORTHOP RELAT R, P210, DOI 10.1097/01.blo.0000150371.77314.52
   McGrath AJ, 2015, ACS NANO, V9, P12283, DOI 10.1021/acsnano.5b05563
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Petite H, 2000, NAT BIOTECHNOL, V18, P959, DOI 10.1038/79449
   Schwartz CE, 2009, HEALTH QUAL LIFE OUT, V7, DOI 10.1186/1477 7525 7 49
   Shao JD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12967
   Shekaran A, 2014, BIOMATERIALS, V35, P5453, DOI 10.1016/j.biomaterials.2014.03.055
   Song LZ, 2018, NPG ASIA MATER, V10, P509, DOI 10.1038/s41427 018 0053 2
   Stevens MM, 2008, MATER TODAY, V11, P18, DOI 10.1016/S1369 7021(08)70086 5
   Street J, 2002, P NATL ACAD SCI USA, V99, P9656, DOI 10.1073/pnas.152324099
   Taylor D, 2007, NAT MATER, V6, P263, DOI 10.1038/nmat1866
   van Griensven M, 2015, ADV DRUG DELIVER REV, V94, P151, DOI 10.1016/j.addr.2015.07.006
   Vo TN, 2012, ADV DRUG DELIVER REV, V64, P1292, DOI 10.1016/j.addr.2012.01.016
   Yang BW, 2018, CHEM US, V4, P1284, DOI 10.1016/j.chempr.2018.02.012
   Zhang XG, 2017, SMALL, V13, DOI 10.1002/smll.201603347
   Zhou J, 2010, BIOMATERIALS, V31, P1171, DOI 10.1016/j.biomaterials.2009.10.043
NR 49
TC 103
Z9 104
U1 4
U2 143
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948 7185
J9 J PHYS CHEM LETT
JI J. Phys. Chem. Lett.
PD AUG 1
PY 2019
VL 10
IS 15
BP 4185
EP 4191
DI 10.1021/acs.jpclett.9b01735
PG 13
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary; Physics, Atomic, Molecular & Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA IZ6HC
UT WOS:000487181400006
PM 31295998
DA 2025 08 17
ER

PT J
AU Roohani Esfahani, SI
   No, YJ
   Lu, ZF
   Ng, PY
   Chen, YJ
   Shi, J
   Pavlos, NJ
   Zreiqat, H
AF Roohani Esfahani, Seyed Iman
   No, Young Jung
   Lu, Zufu
   Ng, Pei Ying
   Chen, Yongjuan
   Shi, Jeffrey
   Pavlos, Nathan J.
   Zreiqat, Hala
TI A bioceramic with enhanced osteogenic properties to regulate the
   function of osteoblastic and osteocalastic cells for bone tissue
   regeneration
SO BIOMEDICAL MATERIALS
LA English
DT Article
DE bone regeneration; bioceramic; gehlenite; osteoclast; bioactive;
   toxicity; osteoblast
ID BIOACTIVE GLASS; DEFECT REPAIR; IN VITRO; ANGIOGENESIS; BIOMATERIALS;
   OSTEOCLASTS; SCAFFOLDS; MECHANISM; GEHLENITE; SILICON
AB Bioceramics for regenerative medicine applications should have the ability to promote adhesion, proliferation and differentiation of osteoblast and osteoclast cells. Osteogenic properties of the material are essential for rapid bone regeneration and new bone formation. The aim of this study was to develop a silicate based ceramic, gehlenite (GLN, Ca2Al2SiO7), and characterise its physiochemical, biocompatibility and osteogenic properties. A pure GLN powder was synthesised by a facile reactive sintering method and compacted to disc shaped specimens. The sintering behaviour and degradation of the GLN discs in various buffer solutions were fully characterised. The cytotoxicity of GLN was evaluated by direct and indirect methods. In the indirect method, primary human osteoblast cells (HOBs) were exposed to diluted extracts (100, 50, 25, 12.5 and 6.25 mg ml( 1)) of fine GLN particles in culture medium. The results showed that the extracts did not cause any cytotoxic effect on the HOBs with the number of cells increasing significantly from day 1 to day 7. GLN supported HOB attachment and proliferation, and significantly enhanced osteogenic gene expression levels (Runx2, osteocalcin, osteopontin and bone sialoprotein) were compared with biphasic calcium phosphate groups (BCP, a mixture of hydroxyapatite (60wt.%) and beta tricalcium phosphate(40wt.%)). We also demonstrated that in addition to supporting HOB attachment and proliferation, GLN promoted the formation of tartrate acid resistance phosphatase (TRAP) positive multinucleated osteoclastic cells (OCs) derived from mouse bone marrow cells. Results also demonstrated the ability of GLN to support the polarisation of OCs, a prerequisite for their functional resorptive activity which is mainly influenced by the composition and degradability of biomaterials. Overall, the developed GLN is a prospective candidate to be used in bone regeneration applications due its effective osteogenic properties and biocompatibility.
C1 [Roohani Esfahani, Seyed Iman; No, Young Jung; Lu, Zufu; Chen, Yongjuan; Zreiqat, Hala] Univ Sydney, Sch AMME, Biomat & Tissue Engn Res Unit, Sydney, NSW 2006, Australia.
   [Ng, Pei Ying; Pavlos, Nathan J.] Univ Western Australia, Sch Surg, Ctr Orthopaed Res, Perth, WA 6009, Australia.
   [Shi, Jeffrey] Univ Sydney, Sch Chem & Bimol Engn, Sydney, NSW 2006, Australia.
C3 University of Sydney; University of Western Australia; University of
   Sydney
RP Roohani Esfahani, SI (通讯作者)，Univ Sydney, Sch AMME, Biomat & Tissue Engn Res Unit, Sydney, NSW 2006, Australia.
EM iman.roohani@sydney.edu.au; hala.zreiqat@sydney.edu.au
RI ; Roohani, Iman/JMR 3441 2023
OI Lu, ZuFu/0000 0003 4843 4441; Zreiqat, Hala/0000 0003 0521 7711;
   Roohani, Iman/0000 0001 6618 8577; No, Young Jung/0000 0001 8135 4369;
   Pavlos, Nathan/0000 0001 7003 188X; , Iman Roohani/0009 0000 3678 3455
FU Australian National Health and Medical Research Council; Rebecca Cooper
   Foundation
FX The authors gratefully acknowledge the financial support of the
   Australian National Health and Medical Research Council and the Rebecca
   Cooper Foundation. The authors acknowledge the facilities and the
   scientific and technical assistance of the Australian Microscopy &
   Microanalysis Research Facility at the Australian Centre for Microscopy
   & Microanalysis at the University of Sydney. The authors would like to
   thank Ms Leina Suzuki for the preparation of the mechanical testing
   samples.
CR Bohner M, 2009, BIOMATERIALS, V30, P6403, DOI 10.1016/j.biomaterials.2009.08.007
   Calori GM, 2014, INJURY, V45, pS116, DOI 10.1016/j.injury.2014.10.034
   Campana V, 2014, J MATER SCI MATER M, V25, P2445, DOI 10.1007/s10856 014 5240 2
   Castaño O, 2014, ACS APPL MATER INTER, V6, P7512, DOI 10.1021/am500885v
   Chim H, 2006, INT J ORAL MAX SURG, V35, P928, DOI 10.1016/j.ijom.2006.03.024
   Christou C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114122
   Dimitriou R, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 66
   Fan HB, 2014, BIOMATERIALS, V35, P7407, DOI 10.1016/j.biomaterials.2014.05.035
   Habibovic P, 2011, ACTA BIOMATER, V7, P3013, DOI 10.1016/j.actbio.2011.03.027
   Hanifi AR, 2014, J MATER SCI, V49, P4590, DOI 10.1007/s10853 014 8159 6
   Hench LarryL., 1993, INTRO BIOCERAMICS
   Hench LL, 1998, J AM CERAM SOC, V81, P1705
   Henstock JR, 2015, ACTA BIOMATER, V11, P17, DOI 10.1016/j.actbio.2014.09.025
   Hoppe A, 2011, BIOMATERIALS, V32, P2757, DOI 10.1016/j.biomaterials.2011.01.004
   Hou J, 2012, BIOMED MATER, V7, DOI 10.1088/1748 6041/7/3/035002
   Jia D, 2007, J AM CERAM SOC, V90, P2766, DOI 10.1111/j.1551 2916.2007.01835.x
   Johnson AJW, 2011, ACTA BIOMATER, V7, P16, DOI 10.1016/j.actbio.2010.07.012
   Jones JR, 2013, ACTA BIOMATER, V9, P4457, DOI 10.1016/j.actbio.2012.08.023
   Kokubo T, 2003, BIOMATERIALS, V24, P2161, DOI 10.1016/S0142 9612(03)00044 9
   Lakhkar NJ, 2013, ADV DRUG DELIVER REV, V65, P405, DOI 10.1016/j.addr.2012.05.015
   Li H, 2013, ACTA BIOMATER, V9, P6981, DOI 10.1016/j.actbio.2013.02.014
   Li XW, 2012, BIOL TRACE ELEM RES, V150, P502, DOI 10.1007/s12011 012 9523 5
   Lu JX, 2002, J BIOMED MATER RES, V63, P408, DOI 10.1002/jbm.10259
   Munz D., 1999, CERAMICS MECH PROPER
   Murphy S, 2010, J MATER SCI MATER M, V21, P2827, DOI 10.1007/s10856 010 4139 9
   Nath S, 2009, MAT SCI ENG A STRUCT, V513 14, P197, DOI 10.1016/j.msea.2009.02.052
   Nath S, 2009, J BIOMED MATER RES B, V90B, P547, DOI 10.1002/jbm.b.31316
   Ni SY, 2008, J MATER SCI MATER M, V19, P359, DOI 10.1007/s10856 007 3186 3
   Pilia M, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/458253
   Priya A, 2010, J MATER SCI MATER M, V21, P1817, DOI 10.1007/s10856 010 4053 1
   Ptácek P, 2013, SOLID STATE SCI, V26, P53, DOI 10.1016/j.solidstatesciences.2013.09.014
   Ramaswamy Y, 2005, J MATER SCI MATER M, V16, P1199, DOI 10.1007/s10856 005 4729 0
   Ramaswamy Y, 2008, BIOMATERIALS, V29, P4392, DOI 10.1016/j.biomaterials.2008.08.006
   Reichert JC, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003720
   Reichert JC, 2011, INT ORTHOP, V35, P1229, DOI 10.1007/s00264 010 1146 x
   Roohani Esfahani SI, 2014, J MATER CHEM B, V2, P1866, DOI 10.1039/c3tb21504k
   Saldaña L, 2006, J BIOMED MATER RES A, V77A, P220, DOI 10.1002/jbm.a.30599
   Schwartz Z, 2009, BIOMATERIALS, V30, P3390, DOI 10.1016/j.biomaterials.2009.03.047
   Shepherd JH, 2012, J MATER SCI MATER M, V23, P2335, DOI 10.1007/s10856 012 4598 2
   Smith BD, 2015, NAT REV RHEUMATOL, V11, P213, DOI 10.1038/nrrheum.2015.27
   Teti Anna, 2013, Bonekey Rep, V2, P449, DOI 10.1038/bonekey.2013.183
   Vallet Regí M, 2011, ADV MATER, V23, P5177, DOI 10.1002/adma.201101586
   Walker LS, 2011, ACS NANO, V5, P3182, DOI 10.1021/nn200319d
   Wang JL, 2012, J BIOMED MATER RES A, V100A, P2929, DOI 10.1002/jbm.a.34236
   Wang XP, 2011, ACTA BIOMATER, V7, P3638, DOI 10.1016/j.actbio.2011.06.029
   Wenisch S, 2003, J BIOMED MATER RES A, V67A, P713, DOI 10.1002/jbm.a.10091
   Zhai WY, 2013, ACTA BIOMATER, V9, P8004, DOI 10.1016/j.actbio.2013.04.024
   Zhai WY, 2012, ACTA BIOMATER, V8, P341, DOI 10.1016/j.actbio.2011.09.008
   Zreiqat H, 2010, BIOMATERIALS, V31, P3175, DOI 10.1016/j.biomaterials.2010.01.024
NR 49
TC 14
Z9 15
U1 0
U2 51
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 1748 6041
EI 1748 605X
J9 BIOMED MATER
JI Biomed. Mater.
PD JUN
PY 2016
VL 11
IS 3
DI 10.1088/1748 6041/11/3/035018
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA DP0GQ
UT WOS:000378167700019
PM 27305523
DA 2025 08 17
ER

PT J
AU Shi, P
   Qu, KG
   Wang, JS
   Li, M
   Ren, JS
   Qu, XG
AF Shi, Peng
   Qu, Konggang
   Wang, Jiasi
   Li, Meng
   Ren, Jinsong
   Qu, Xiaogang
TI pH responsive NIR enhanced drug release from gold nanocages possesses
   high potency against cancer cells
SO CHEMICAL COMMUNICATIONS
LA English
DT Article
ID MESOPOROUS SILICA; DELIVERY; NANOPARTICLES; BISPHOSPHONATES;
   NANOSTRUCTURES; POLYMERS; BONE
AB We report a smart therapeutic nanoplatform based on Fe3O4@CaP capped gold nanocages, which integrates magnetic targeting, photothermal therapy and chemotherapy for killing cancer cells. Combining photothermal and chemo therapy results in a synergistic effect in cancer treatment.
C1 [Shi, Peng; Qu, Konggang; Wang, Jiasi; Li, Meng; Ren, Jinsong; Qu, Xiaogang] Chinese Acad Sci, Changchun Inst Appl Chem, State Key Lab Rare Earth Resource Utilizat, Div Biol Inorgan Chem,Lab Chem Biol,Grad Sch, Changchun 130022, Jilin, Peoples R China.
C3 Chinese Academy of Sciences; Changchun Institute of Applied Chemistry,
   CAS
RP Qu, XG (通讯作者)，Chinese Acad Sci, Changchun Inst Appl Chem, State Key Lab Rare Earth Resource Utilizat, Div Biol Inorgan Chem,Lab Chem Biol,Grad Sch, Changchun 130022, Jilin, Peoples R China.
EM xqu@ciac.jl.cn
RI Ren, Jinsong/AFF 6945 2022; Wang, Jin/P 5458 2019; Qu,
   Xiaogang/AFA 9894 2022
OI Shi, Peng/0000 0002 8400 2358; Qu, Konggang/0000 0003 2237 3951
FU 973 Project [2011CB936004, 2012CB720602]; NSFC [20831003, 90813001,
   20833006, 90913007]; Chinese Academy of Sciences
FX This work was supported by the 973 Project (2011CB936004, 2012CB720602),
   NSFC (20831003, 90813001, 20833006, and 90913007) and funding from the
   Chinese Academy of Sciences.
CR Au L, 2008, ACS NANO, V2, P1645, DOI 10.1021/nn800370j
   Au L, 2010, ACS NANO, V4, P35, DOI 10.1021/nn901392m
   Brown SD, 2010, J AM CHEM SOC, V132, P4678, DOI 10.1021/ja908117a
   Chen CE, 2011, ANGEW CHEM INT EDIT, V50, P882, DOI 10.1002/anie.201005471
   Chen JY, 2007, NANO LETT, V7, P1318, DOI 10.1021/nl070345g
   Fang WJ, 2012, ADV FUNCT MATER, V22, P842, DOI 10.1002/adfm.201101960
   Gillies ER, 2005, DRUG DISCOV TODAY, V10, P35, DOI 10.1016/S1359 6446(04)03276 3
   Lee HJ, 2010, CHEM COMMUN, V46, P377, DOI 10.1039/b913732g
   Leu CT, 2006, BONE, V38, P628, DOI 10.1016/j.bone.2005.07.023
   MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663
   Moon GD, 2011, J AM CHEM SOC, V133, P4762, DOI 10.1021/ja200894u
   Moore MN, 2006, ENVIRON INT, V32, P967, DOI 10.1016/j.envint.2006.06.014
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Pan HB, 2009, CRYST GROWTH DES, V9, P639, DOI 10.1021/cg801118v
   Rim HP, 2011, ANGEW CHEM INT EDIT, V50, P8853, DOI 10.1002/anie.201101536
   Rozhkova EA, 2011, ADV MATER, V23, pH136, DOI 10.1002/adma.201004714
   Song KH, 2009, NANO LETT, V9, P183, DOI 10.1021/nl802746w
   Tong L, 2010, ANGEW CHEM INT EDIT, V49, P3485, DOI 10.1002/anie.201000440
   Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632
   Vicent MJ, 2006, TRENDS BIOTECHNOL, V24, P39, DOI 10.1016/j.tibtech.2005.11.006
   Wright JEI, 2006, BIOMATERIALS, V27, P769, DOI 10.1016/j.biomaterials.2005.06.012
   Xia YN, 1999, CHEM REV, V99, P1823, DOI 10.1021/cr980002q
   Xia YN, 2011, ACCOUNTS CHEM RES, V44, P914, DOI 10.1021/ar200061q
   Yagüe C, 2010, CHEM COMMUN, V46, P7513, DOI 10.1039/c0cc01897j
   Yang Q, 2005, CHEM MATER, V17, P5999, DOI 10.1021/cm051198v
   Yang XJ, 2012, ADV MATER, V24, P2890, DOI 10.1002/adma.201104797
   Yavuz MS, 2009, NAT MATER, V8, P935, DOI [10.1038/NMAT2564, 10.1038/nmat2564]
NR 27
TC 92
Z9 100
U1 3
U2 122
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1359 7345
EI 1364 548X
J9 CHEM COMMUN
JI Chem. Commun.
PY 2012
VL 48
IS 61
BP 7640
EP 7642
DI 10.1039/c2cc33543c
PG 3
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA 968QF
UT WOS:000305998500031
PM 22735385
DA 2025 08 17
ER

PT J
AU Hwang, YH
   Jang, SA
   Lee, A
   Kim, T
   Ha, H
AF Hwang, Youn Hwan
   Jang, Seon A
   Lee, Ami
   Kim, Taesoo
   Ha, Hyunil
TI Poria CocosAmeliorates Bone Loss in Ovariectomized Mice and
   Inhibits Osteoclastogenesis In Vitro
SO NUTRIENTS
LA English
DT Article
DE Poria cocos; osteoporosis; ovariectomy; osteoclast; menopause
ID COCOS; EXTRACT; MECHANISMS; ADIPOCYTE; MARROW; NFAT
AB Estrogen deprivation in postmenopausal women causes disruption of bone homeostasis, resulting in bone loss and osteoporosis. Conventional therapies can exert adverse effects. The sclerotum ofPoria cocoshas been used in traditional medicine and as a nutritional supplement and to treat various diseases. However, the effects ofP. cocoson the bone remain largely undetermined. In this study, we examined the effects ofP. cocoshydroethanolic extract (PC) on osteoclast differentiation and estrogen deprivation induced bone loss in an ovariectomized mouse model of postmenopausal osteoporosis. PC mediated inhibition of receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclast formation and resorption activity suppressed RANKL induced expression of nuclear factor of activated T cells cytoplasmic 1 (NFATc1), which is a crucial transcription factor for osteoclast differentiation. In ovariectomized mice, PC markedly alleviated trabecular bone loss and reduced the accumulation of lipid droplets in the bone marrow. We additionally identified ten triterpenoid constituents of PC using UPLC MS/MS analysis. Our results indicate that PC negatively regulated osteoclast differentiation and function, and can potentially be used to manage postmenopausal osteoporosis.
C1 [Hwang, Youn Hwan; Jang, Seon A; Lee, Ami; Kim, Taesoo; Ha, Hyunil] Korea Inst Oriental Med, Herbal Med Res Div, Yuseong Daero 1672, Daejeon 34054, South Korea.
   [Hwang, Youn Hwan; Lee, Ami] Univ Sci & Technol UST, Korean Convergence Med Major KIOM, 1672 Yuseongdae Ro, Daejeon 34054, South Korea.
C3 Korea Institute of Oriental Medicine (KIOM); University of Science &
   Technology (UST)
RP Ha, H (通讯作者)，Korea Inst Oriental Med, Herbal Med Res Div, Yuseong Daero 1672, Daejeon 34054, South Korea.
EM hyhhwang@kiom.re.kr; white7068@kiom.re.kr; dmb01367@kiom.re.kr;
   xotn91@kiom.re.kr; hyunil74@kiom.re.kr
RI Hwang, Youn Hwan/AAU 9373 2021
OI Hwang, Youn Hwan/0000 0002 4959 2436
FU Korea Institute of Oriental Medicine, Ministry of Education, Science and
   Technology, Republic of Korea [KSN2012330]
FX This work was funded by the Korea Institute of Oriental Medicine,
   Ministry of Education, Science and Technology, Republic of Korea (grant
   number KSN2012330).
CR Ambrosi TH, 2017, CELL STEM CELL, V20, P771, DOI 10.1016/j.stem.2017.02.009
   An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Comhaire FH, 2015, CLIMACTERIC, V18, P358, DOI 10.3109/13697137.2014.985645
   De Franciscis P, 2019, MEDICINA LITHUANIA, V55, DOI 10.3390/medicina55090544
   Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511
   Fazeli PK, 2013, J CLIN ENDOCR METAB, V98, P935, DOI 10.1210/jc.2012 3634
   Feng GF, 2018, J AGR FOOD CHEM, V66, P8319, DOI 10.1021/acs.jafc.8b02753
   Ha H, 2014, MOLECULES, V19, P3940, DOI 10.3390/molecules19043940
   Huang B, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00900
   Hwang YH, 2019, PLANTA MED, V85, P1128, DOI 10.1055/a 0989 2585
   Hwang YH, 2019, NUTRIENTS, V11, DOI 10.3390/nu11081831
   Jin J, 2019, MOLECULES, V24, DOI 10.3390/molecules24071331
   Kwon J, 2016, J NAT PROD, V79, P1689, DOI 10.1021/acs.jnatprod.6b00207
   Lee S, 2018, BIOORG CHEM, V81, P27, DOI 10.1016/j.bioorg.2018.07.031
   Lee YH, 2013, ORAL DIS, V19, P193, DOI 10.1111/j.1601 0825.2012.01970.x
   Li XL, 2019, J CELL MOL MED, V23, P4, DOI 10.1111/jcmm.13564
   Marinozzi F, 2012, ANN I SUPER SANITA, V48, P19, DOI 10.4415/ANN_12_01_04
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Qian Q, 2018, J CHROMATOGR B, V1102, P34, DOI 10.1016/j.jchromb.2018.10.011
   Riggs BL, 2000, J CLIN INVEST, V106, P1203, DOI 10.1172/JCI11468
   Ríos JL, 2011, PLANTA MED, V77, P681, DOI 10.1055/s 0030 1270823
   Song DZ, 2018, ARCH BIOCHEM BIOPHYS, V647, P76, DOI 10.1016/j.abb.2018.04.011
   Soysa NS, 2016, BIOCHEM BIOPH RES CO, V476, P115, DOI 10.1016/j.bbrc.2016.05.019
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Wang FY, 2015, BIOL PHARM BULL, V38, P1337, DOI 10.1248/bpb.b15 00121
   Wu LF, 2016, MOLECULES, V21, DOI 10.3390/molecules21020227
   Zhu LX, 2019, J FOOD DRUG ANAL, V27, P766, DOI 10.1016/j.jfda.2019.03.002
NR 30
TC 9
Z9 12
U1 1
U2 14
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6643
J9 NUTRIENTS
JI Nutrients
PD MAY
PY 2020
VL 12
IS 5
AR 1383
DI 10.3390/nu12051383
PG 10
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA MB0AV
UT WOS:000542272700102
PM 32408635
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Yu, ZG
   Yuan, J
   Yu, YY
AF Yu, Zuguang
   Yuan, Jun
   Yu, Yuanyuan
TI Heraclenin promotes the osteogenic differentiation of bone marrow
   stromal cells by activating the RhoA/ROCK pathway
SO HISTOLOGY AND HISTOPATHOLOGY
LA English
DT Article
DE Heraclenin; Osteoporosis; Bone marrow stromal cells; Osteogenic
   differentiation; RhoA/ROCK signaling pathway
ID MESENCHYMAL STEM CELLS; INHIBITS OSTEOCLAST DIFFERENTIATION;
   OSTEOPOROSIS; ICARIIN; ISOFLAVONES; PHOSPHATASE; METABOLISM; RESORPTION;
   RUNX2; SHAPE
AB Background. Osteoporosis is a devastating skeletal disease, the pathogenesis of which is related to abnormal bone metabolism, featured by the imbalance between osteoblastic bone formation and osteoclastic bone resorption. Stem cell based therapies have been demonstrated to improve osteoporosis treatment. Previously, the linear furanocoumarin heraclenin was reported to enhance osteoblast differentiation and mineralization in mouse mesenchymal stem cells (MSCs), suggesting its potential for osteogenic differentiation and bone regeneration. Our study was designed to confirm the promotive role of heraclenin on osteogenic differentiation of human bone MSCs (BMSCs) and explore the underlying mechanisms. Methods. Human BMSCs were treated for 24, 48, and 72h with heraclenin (5, 10, 20, 40, and 80 mu M), and cell viability was determined by Cell Counting Kit 8 (CCK 8) assay. To further evaluate the cytotoxicity of heraclenin, cell suspension obtained from BMSCs treated with heraclenin (5, 10, and 20 mu M) for 72h was subjected to a MUSETM cell analyzer for cell viability and count assay. BMSCs were incubated in osteogenic induction medium for 7 days. Then, osteogenic differentiation and mineralization of BMSCs were assessed through alkaline phosphatase (ALP) and Alizarin Red S staining. The expression of osteogenesis markers including ALP, osteocalcin (OCN), osterix (OSX), and runt related transcription factor 2 (RUNX2) was detected via reverse transcription quantitative polymerase chain reaction (RT qPCR) and western blotting. The effects of heraclenin on the RhoA/ROCK pathway were estimated through western blotting. Y27632, the ROCK inhibitor, was used to confirm the role of the RhoA/ROCK pathway in heraclenin mediated osteogenic differentiation of BMSCs. Results. Heraclenin (5 80 mu M) was non toxic on human BMSCs. Heraclenin treatment (5 20 mu M) dose  dependently enhanced ALP activity and calcium deposition. Furthermore, heraclenin promoted ALP, OCN, OSX, and RUNX2 mRNA and protein expression. Mechanically, heraclenin treatment increased RhoA and ROCK1 mRNA expression, stimulated the translocation of ROCK from the cytosolic to the membrane fraction, and elevated the protein levels of phosphorylated cofilin (p cofilin) and active RhoA. Additionally, treatment with Y 27632 overturned the promotion of heraclenin on ALP activity, calcium deposition, the expression of osteogenesis markers, and the RhoA/ROCK signaling pathway. Conclusion. Heraclenin facilitates the osteogenic differentiation of human BMSCs through the activation of the RhoA/ROCK pathway.
C1 [Yu, Zuguang; Yuan, Jun] Wuhan Hosp Tradit Chinese Med, Dept Orthoped, Wuhan, Peoples R China.
   [Yu, Yuanyuan] Wuhan Hosp Tradit Chinese Med, Dept Geriatr, Wuhan, Peoples R China.
RP Yu, YY (通讯作者)，Wuhan Hosp Tradit Chinese Med, 49 Lihuangpi Rd, Wuhan, Peoples R China.
EM yuyuandoctor@hotmail.com
CR Aburima A, 2013, BLOOD, V122, P3533, DOI 10.1182/blood 2013 03 487850
   Ball SG, 2007, INT J BIOCHEM CELL B, V39, P379, DOI 10.1016/j.biocel.2006.09.005
   Behera J, 2022, LIFE SCI, V301, DOI 10.1016/j.lfs.2022.120595
   Bernardi S, 2020, MATERIALS, V13, DOI 10.3390/ma13163546
   Brown C, 2019, J TISSUE ENG REGEN M, V13, P1738, DOI 10.1002/term.2914
   Brown JP, 2021, ENDOCRINOL METAB, V36, P544, DOI 10.3803/EnM.2021.301
   Chen BB, 2017, MOLECULES, V22, DOI 10.3390/molecules22091469
   Chen ZX, 2011, MOL CELL BIOCHEM, V358, P221, DOI 10.1007/s11010 011 0938 7
   Chu DT, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030708
   Cosman F, 2011, J BONE MINER RES, V26, P503, DOI 10.1002/jbmr.238
   Deng ZH, 2019, AM J TRANSL RES, V11, P5324
   Feng C, 2020, EUR REV MED PHARMACO, V24, P434, DOI 10.26355/eurrev_202001_19943
   Galindo M, 2005, J BIOL CHEM, V280, P20274, DOI 10.1074/jbc.M413665200
   Galipeau J, 2018, CELL STEM CELL, V22, P824, DOI 10.1016/j.stem.2018.05.004
   Gao YG, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22158182
   Grayson WL, 2015, NAT REV ENDOCRINOL, V11, P140, DOI 10.1038/nrendo.2014.234
   Hartmann S, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00276
   He JW, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.1028932
   Hoon JL, 2016, CELLS BASEL, V5, DOI 10.3390/cells5020017
   Horcajada Marie Noelle, 2012, Curr Mol Pharmacol, V5, P205
   Hsieh TP, 2011, PHYTOMEDICINE, V18, P176, DOI 10.1016/j.phymed.2010.04.003
   Hsieh TP, 2010, PHYTOMEDICINE, V17, P414, DOI 10.1016/j.phymed.2009.08.007
   Jia M, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/364604
   Jin CY, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 02813 2
   Kawakita S, 2009, CLIN INTERV AGING, V4, P91
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kobayakawa T, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 91248 6
   Komori T, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207513
   Lan YH, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.583234
   Li HX, 2021, CURR MED CHEM, V28, P1489, DOI 10.2174/0929867327666200330142432
   Li M, 2020, ELIFE, V9, DOI 10.7554/eLife.59079
   Li R, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw3896
   Lou S, 2019, OSTEOPOROSIS INT, V30, P59, DOI 10.1007/s00198 018 4790 4
   McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534 5807(04)00075 9
   McClung MR, 2017, CURR OSTEOPOROS REP, V15, P343, DOI 10.1007/s11914 017 0376 x
   Mosaddeghzadeh N, 2021, CELLS BASEL, V10, DOI 10.3390/cells10071831
   Muruganandan S, 2009, CELL MOL LIFE SCI, V66, P236, DOI 10.1007/s00018 008 8429 z
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Numonov S, 2018, NAT PROD RES, V32, P2325, DOI 10.1080/14786419.2017.1413558
   Park CY, 2012, NUTRIENTS, V4, P1610, DOI 10.3390/nu4111610
   Pratap J, 2003, CANCER RES, V63, P5357
   Qu C, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.882581
   Qu XH, 2014, BIOCHEM BIOPH RES CO, V443, P658, DOI 10.1016/j.bbrc.2013.12.029
   Seo CH, 2011, BIOMATERIALS, V32, P9568, DOI 10.1016/j.biomaterials.2011.08.077
   Shanmugam H, 2019, CHEM BIOL INTERACT, V310, DOI 10.1016/j.cbi.2019.108750
   Soundarya SP, 2018, INT J BIOL MACROMOL, V110, P74, DOI 10.1016/j.ijbiomac.2017.09.014
   Tao XF, 2016, PHARMACOL RES, V108, P90, DOI 10.1016/j.phrs.2016.05.003
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   Traven VF, 2004, MOLECULES, V9, P50, DOI 10.3390/90300050
   Wang Z, 2018, OSTEOPOROSIS INT, V29, P535, DOI 10.1007/s00198 017 4255 1
   WHYTE MP, 1994, ENDOCR REV, V15, P439, DOI 10.1210/er.15.4.439
   Woo JT, 2008, J PHARMACOL SCI, V106, P547, DOI 10.1254/jphs.FM0070288
   Xue F, 2021, ELIFE, V10, DOI 10.7554/eLife.64872
   Yan CQ, 2022, MOLECULES, V27, DOI 10.3390/molecules27175538
   Yang XC, 2019, AGING US, V11, P8777, DOI 10.18632/aging.102264
   Ye YP, 2017, BIOMED PHARMACOTHER, V88, P384, DOI 10.1016/j.biopha.2017.01.075
   Yuan F, 2019, INT J SURG, V66, P1, DOI 10.1016/j.ijsu.2019.03.004
   Zeng CY, 2023, PHYTOTHER RES, V37, P252, DOI 10.1002/ptr.7610
   Zhang C, 2010, J ORTHOP SURG RES, V5, DOI 10.1186/1749 799X 5 37
   Zhang L, 2016, CELL PHYSIOL BIOCHEM, V39, P1391, DOI 10.1159/000447843
   Zhang ND, 2016, J ETHNOPHARMACOL, V189, P61, DOI 10.1016/j.jep.2016.05.025
   Zhang Q, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12356
   Zhang QH, 2020, AM J TRANSL RES, V12, P2062
   Zhang WY, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.13058
NR 64
TC 1
Z9 1
U1 1
U2 4
PU F HERNANDEZ
PI MURCIA
PA PLAZA FUENSANTA 2 7 C, 30008 MURCIA, SPAIN
SN 0213 3911
EI 1699 5848
J9 HISTOL HISTOPATHOL
JI Histol. Histopath.
PD AUG
PY 2024
VL 39
IS 8
BP 1065
EP 1077
DI 10.14670/HH 18 702
PG 13
WC Cell Biology; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Pathology
GA C3N5N
UT WOS:001288456400011
PM 38258549
DA 2025 08 17
ER

PT J
AU Kilian, KA
   Bugarija, B
   Lahn, BT
   Mrksich, M
AF Kilian, Kristopher A.
   Bugarija, Branimir
   Lahn, Bruce T.
   Mrksich, Milan
TI Geometric cues for directing the differentiation of mesenchymal stem
   cells
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE cytoskeleton; microcontact printing; Wnt signaling; microenvironment
ID OSTEOGENIC DIFFERENTIATION; SHAPE; ADHESION; RHOA; STIMULATION;
   ACTIVATION; LINEAGE; ADIPOGENESIS; MOTILITY; GROWTH
AB Significant efforts have been directed to understanding the factors that influence the lineage commitment of stem cells. This paper demonstrates that cell shape, independent of soluble factors, has a strong influence on the differentiation of human mesenchymal stem cells (MSCs) from bone marrow. When exposed to competing soluble differentiation signals, cells cultured in rectangles with increasing aspect ratio and in shapes with pentagonal symmetry but with different subcellular curvature and with each occupying the same area display different adipogenesis and osteogenesis profiles. The results reveal that geometric features that increase actomyosin contractility promote osteogenesis and are consistent with in vivo characteristics of the microenvironment of the differentiated cells. Cytoskeletal disrupting pharmacological agents modulate shape based trends in lineage commitment verifying the critical role of focal adhesion and myosin generated contractility during differentiation. Microarray analysis and pathway inhibition studies suggest that contractile cells promote osteogenesis by enhancing c Jun N terminal kinase (JNK) and extracellular related kinase (ERK1/2) activation in conjunction with elevated wingless type (Wnt) signaling. Taken together, this work points to the role that geometric shape cues can play in orchestrating the mechanochemical signals and paracrine/autocrine factors that can direct MSCs to appropriate fates.
C1 [Kilian, Kristopher A.; Mrksich, Milan] Univ Chicago, Dept Chem, Chicago, IL 60637 USA.
   [Bugarija, Branimir; Lahn, Bruce T.] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA.
   [Kilian, Kristopher A.; Bugarija, Branimir; Lahn, Bruce T.; Mrksich, Milan] Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA.
C3 University of Chicago; University of Chicago; University of Chicago;
   Howard Hughes Medical Institute
RP Mrksich, M (通讯作者)，Univ Chicago, Dept Chem, 5735 S Ellis Ave, Chicago, IL 60637 USA.
EM mmrksich@uchicago.edu
RI ; Mrksich, Milan/G 2469 2011; Kilian, Kristopher/E 8634 2011
OI Mrksich, Milan/0000 0002 4964 796X; Kilian,
   Kristopher/0000 0002 8963 9796
FU National Cancer Institute of the National Institutes of Health; National
   Institute of General Medical Sciences [F32GM087048]
FX We thank Dr. Vytas Bindokas for assistance with microscopy data
   analysis. This work was funded by the National Cancer Institute of the
   National Institutes of Health. K. A. K. is supported by a Ruth L.
   Kirstein National Research Service Award Number F32GM087048 from the
   National Institute of General Medical Sciences. Photolithography was
   performed at the Chicago Materials Research Science and Engineering
   Centers microfluidic facility (National Science Foundation).
CR Alfaro MP, 2008, P NATL ACAD SCI USA, V105, P18366, DOI 10.1073/pnas.0803437105
   Arnsdorf EJ, 2009, J CELL SCI, V122, P546, DOI 10.1242/jcs.036293
   Bhadriraju K, 2007, EXP CELL RES, V313, P3616, DOI 10.1016/j.yexcr.2007.07.002
   Bikkavilli RK, 2008, J CELL SCI, V121, P234, DOI 10.1242/jcs.021964
   Brock A, 2003, LANGMUIR, V19, P1611, DOI 10.1021/la026394k
   Caplan AI, 2001, TRENDS MOL MED, V7, P259, DOI 10.1016/S1471 4914(01)02016 0
   Caverzasio J, 2007, ENDOCRINOLOGY, V148, P5323, DOI 10.1210/en.2007 0520
   Chang J, 2007, J BIOL CHEM, V282, P30938, DOI 10.1074/jbc.M702391200
   Chang YC, 2008, MOL BIOL CELL, V19, P2147, DOI 10.1091/mbc.E07 12 1269
   Chen CS, 2003, BIOCHEM BIOPH RES CO, V307, P355, DOI 10.1016/S0006 291X(03)01165 3
   Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425
   Connelly JT, 2008, J CELL PHYSIOL, V217, P145, DOI 10.1002/jcp.21484
   Crisan M, 2008, CELL STEM CELL, V3, P301, DOI 10.1016/j.stem.2008.07.003
   Meirelles LDS, 2006, J CELL SCI, V119, P2204, DOI 10.1242/jcs.02932
   Derda R, 2007, ACS CHEM BIOL, V2, P347, DOI 10.1021/cb700032u
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Feng YZ, 2004, BIOCHEMISTRY US, V43, P15811, DOI 10.1021/bi049174+
   Fu LJ, 2008, BONE, V43, P40, DOI 10.1016/j.bone.2008.03.008
   Graziano A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000496
   Hartmann C, 2006, TRENDS CELL BIOL, V16, P151, DOI 10.1016/j.tcb.2006.01.001
   Hens JR, 2005, J BONE MINER RES, V20, P1103, DOI 10.1359/JBMR.050210
   Ingber DE, 2006, INT J DEV BIOL, V50, P255, DOI 10.1387/ijdb.052044di
   Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645
   James J, 2008, CELL MOTIL CYTOSKEL, V65, P841, DOI 10.1002/cm.20305
   Jiang XY, 2005, P NATL ACAD SCI USA, V102, P975, DOI 10.1073/pnas.0408954102
   Kandere Grzybowska K, 2007, SOFT MATTER, V3, P672, DOI 10.1039/b617308j
   Kassem M, 2006, ANN NY ACAD SCI, V1067, P436, DOI 10.1196/annals.1354.062
   Lee JY, 2006, CURR BIOL, V16, P1986, DOI 10.1016/j.cub.2006.08.090
   McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534 5807(04)00075 9
   McBride SH, 2008, TISSUE ENG PT A, V14, P1573, DOI 10.1089/ten.tea.2008.0113
   Murphy WL, 2005, BIOMATERIALS, V26, P303, DOI 10.1016/j.biomaterials.2004.02.034
   Ni XF, 2008, MICROELECTRON ENG, V85, P1330, DOI 10.1016/j.mee.2008.01.070
   Oh S, 2009, P NATL ACAD SCI USA, V106, P2130, DOI 10.1073/pnas.0813200106
   Ohlstein B, 2004, CURR OPIN CELL BIOL, V16, P693, DOI 10.1016/j.ceb.2004.09.003
   ONEILL C, 1986, CELL, V44, P489, DOI 10.1016/0092 8674(86)90470 8
   Parker KK, 2008, CIRC RES, V103, P340, DOI 10.1161/CIRCRESAHA.108.182469
   Parker KK, 2002, FASEB J, V16, DOI 10.1096/fj.02 0038com
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Robinson JA, 2006, J BIOL CHEM, V281, P31720, DOI 10.1074/jbc.M602308200
   Spatz JP, 2007, METHOD CELL BIOL, V83, P89, DOI 10.1016/S0091 679X(07)83005 6
   Théry M, 2006, CELL MOTIL CYTOSKEL, V63, P341, DOI 10.1002/cm.20126
   Tominaga S, 2005, BIOCHEM BIOPH RES CO, V326, P499, DOI 10.1016/j.bbrc.2004.11.056
   Ward DF, 2007, STEM CELLS DEV, V16, P467, DOI 10.1089/scd.2007.0034
   Wolff J., 1986, LAW BONE REMODELLING, DOI DOI 10.1007/978 3 642 71031 5
   Wozniak MA, 2009, NAT REV MOL CELL BIO, V10, P34, DOI 10.1038/nrm2592
   Yang Y, 1999, DEVELOPMENT, V126, P3027
   Yu WH, 2008, MOL CELL BIOCHEM, V310, P11, DOI 10.1007/s11010 007 9661 9
   Zhang AX, 2007, MOL CELL BIOCHEM, V304, P167, DOI 10.1007/s11010 007 9497 3
NR 48
TC 1515
Z9 1776
U1 9
U2 468
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 16
PY 2010
VL 107
IS 11
BP 4872
EP 4877
DI 10.1073/pnas.0903269107
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 570YI
UT WOS:000275714300016
PM 20194780
OA Green Published
DA 2025 08 17
ER

PT J
AU Liede, A
   Wade, S
   Lethen, J
   Hernandez, RK
   Warner, D
   Abernethy, AP
   Finelli, A
AF Liede, Alexander
   Wade, Sally
   Lethen, Jan
   Hernandez, Rohini K.
   Warner, Douglas
   Abernethy, Amy P.
   Finelli, Antonio
TI An Observational Study of Concomitant Use of Emerging Therapies and
   Denosumab or Zoledronic Acid in Prostate Cancer
SO CLINICAL THERAPEUTICS
LA English
DT Article
DE abiraterone; bone targeted agents; castration resistant prostate cancer;
   denosumab; electronic health records; enzalutamide; zoledronic acid
ID SKELETAL RELATED EVENTS; ABIRATERONE ACETATE; NATURAL HISTORY; INCREASED
   SURVIVAL; OPEN LABEL; BONE; METASTASES; ENZALUTAMIDE; RADIUM 223; IMPACT
AB Purpose: This observational study of oncologic clinical practices was designed to describe real world patterns of use of emerging therapies (abiraterone acetate, cabazitaxel, enzalutamide, radium 223, sipuleucel T) in patients with castration resistant prostate cancer and to characterize their concomitant use with denosumab or zoledronic acid.
   Methods: A retrospective cohort study was conducted using a database of electronic health records from oncology practices across the United States. Eligible patients had a diagnosis of prostate cancer (International Classification of Diseases, Ninth Revision [ICD 9] code 185/International Classification of Diseases, Tenth Revision [ICD 10] code C61) before or concurrent with a visit between January 1, 2013, and December 31, 2015; follow up was performed through June 30, 2016. From this population, we identified those who received an emerging therapy and a subset who also received denosumab or zoledronic acid.
   Findings: A total of 71,606 men met the eligibility criteria, and 5131 (7%) received emerging therapy. In the emerging therapy cohort (at the time of the first use), median age was 75 years, median prostate specific antigen value was 22.7 ng/mL, 56% had bone metastases, and 80% were docetaxel naive. Abiraterone and enzalutamide were the most commonly used first emerging therapies (52% and 31%, respectively), followed by sipuleucel T (9%), cabazitaxel (5%), and radium 223 (1.5%). Of the emerging therapy cohort, 3121 patients (61%) received concomitant denosumab (70%) or zoledronic acid (35%); 5% received both. (C) 2018 Elsevier HS Journals, Inc. All rights reserved.
C1 [Liede, Alexander; Lethen, Jan] Amgen Inc, Ctr Observat Res, 1120 Vet Blvd,ASF3, San Francisco, CA 94080 USA.
   [Wade, Sally] Wade Outcomes Res, Salt Lake City, UT USA.
   [Hernandez, Rohini K.] Amgen Inc, Ctr Observat Res, Thousand Oaks, CA 91320 USA.
   [Warner, Douglas] Amgen Inc, Med Res, Thousand Oaks, CA 91320 USA.
   [Abernethy, Amy P.] Flatiron Hlth Inc, New York, NY USA.
   [Finelli, Antonio] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada.
C3 Amgen; Amgen; Amgen; University of Toronto; University Health Network
   Toronto; Princess Margaret Cancer Centre
RP Liede, A (通讯作者)，Amgen Inc, Ctr Observat Res, 1120 Vet Blvd,ASF3, San Francisco, CA 94080 USA.
EM aliede@amgen.com
FU Amgen Inc, Thousand Oaks, California
FX This study was supported by Amgen Inc, Thousand Oaks, California.
CR Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   Chawla N, 2014, ANN EPIDEMIOL, V24, P666, DOI 10.1016/j.annepidem.2014.06.099
   Cookson M.S., Castration Resistant Prostate Cancer
   De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618
   de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140 6736(10)61389 X
   Felici A, 2012, Front Endocrinol (Lausanne), V3, P85, DOI 10.3389/fendo.2012.00085
   Fizazi K, 2012, LANCET ONCOL, V13, P983, DOI 10.1016/S1470 2045(12)70379 0
   Gillessen S, 2015, ANN ONCOL, V26, P1589, DOI 10.1093/annonc/mdv257
   Jensen Annette Ostergaard, 2009, Clin Epidemiol, V1, P101
   Jun H, 2014, TRANSPL P, V46, P400, DOI 10.1016/j.transproceed.2014.01.004
   Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294
   Liede A, 2015, CLIN EPIDEMIOL, V7, P441, DOI 10.2147/CLEP.S92209
   Lowrance WT, 2016, J UROLOGY, V195, P1444, DOI 10.1016/j.juro.2015.10.086
   Mohler JL, 2011, CANCER RES, V71, P1486, DOI 10.1158/0008 5472.CAN 10 1343
   Montgomery RB, 2008, CANCER RES, V68, P4447, DOI 10.1158/0008 5472.CAN 08 0249
   Mottet N., 2016, EAU   ESTRO   SIOG Guidelines on Prostate Cancer
   Oh WK, 2007, UROLOGY TIMES
   Onukwugha E, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471 2288 14 1
   Oster G, 2013, SUPPORT CARE CANCER, V21, P3279, DOI 10.1007/s00520 013 1887 3
   Parker C, 2015, ANN ONCOL, V26, pV69, DOI 10.1093/annonc/mdv222
   Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755
   Pound CR, 1999, JAMA J AM MED ASSOC, V281, P1591, DOI 10.1001/jama.281.17.1591
   Saad F, 2016, LANCET ONCOL, V17, P1306, DOI 10.1016/S1470 2045(16)30173 5
   Saad F, 2015, EUR UROL, V68, P570, DOI 10.1016/j.eururo.2015.04.032
   Sathiakumar N, 2011, PROSTATE CANCER P D, V14, P177, DOI 10.1038/pcan.2011.7
   Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506
   Shulman MJ, 2004, J UROLOGY, V172, P141, DOI 10.1097/01.ju.0000129051.81608.d8
   Tan PS, 2014, CLIN MED INSIGHTS ON, V8, P29, DOI 10.4137/CMO.S13671
   Vignani F, 2016, CANCER TREAT REV, V44, P61, DOI 10.1016/j.ctrv.2016.02.002
NR 29
TC 12
Z9 12
U1 0
U2 2
PU ELSEVIER
PI BRIDGEWATER
PA 685 ROUTE 202 206, BRIDGEWATER, NJ 08807 USA
SN 0149 2918
EI 1879 114X
J9 CLIN THER
JI Clin. Ther.
PD APR
PY 2018
VL 40
IS 4
BP 536
EP 549
DI 10.1016/j.clinthera.2017.12.015
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA GE7CE
UT WOS:000431386800006
PM 29395290
DA 2025 08 17
ER

PT J
AU Park, S
   Heo, JS
   Mizuno, S
   Kim, M
   An, H
   Hong, E
   Kang, MG
   Kim, J
   Yun, R
   Park, H
   Noh, EH
   Lee, MJ
   Yoon, K
   Kim, P
   Son, M
   Pang, K
   Lee, J
   Park, J
   Ooshima, A
   Kim, TJ
   Park, JY
   Yang, KM
   Myung, SJ
   Bae, H
   Lee, KM
   Letterio, J
   Park, SH
   Takahashi, S
   Kim, SJ
AF Park, Sujin
   Heo, Jin Sun
   Mizuno, Seiya
   Kim, Minwoo
   An, Haein
   Hong, Eunji
   Kang, Min Gi
   Kim, Junil
   Yun, Rebecca
   Park, Hyeyeon
   Noh, Eun Hye
   Lee, Min Jung
   Yoon, Kwiyeom
   Kim, Pyunggang
   Son, Minjung
   Pang, Kyoungwha
   Lee, Jihee
   Park, Jinah
   Ooshima, Akira
   Kim, Tae Jin
   Park, Je Yeon
   Yang, Kyung Min
   Myung, Seung Jae
   Bae, Hyun
   Lee, Kyung Mi
   Letterio, John
   Park, Seok Hee
   Takahashi, Satoru
   Kim, Seong Jin
TI Tm4sf19 deficiency inhibits osteoclast multinucleation and prevents bone
   loss
SO METABOLISM CLINICAL AND EXPERIMENTAL
LA English
DT Article
DE Bone; Tm4sf19; Integrin alpha v beta 3; Osteoclast; Osteoporosis
ID STIMULATORY TRANSMEMBRANE PROTEIN; CELL CELL FUSION; ALPHA(V)BETA(3)
   INTEGRIN; OC STAMP; DC STAMP; RANKL; MICE; ADHESION; OSTEOPETROSIS;
   NFATC1
AB Background: Multinucleation is a hallmark of osteoclast formation and has a unique ability to resorb bone matrix. During osteoclast differentiation, the cytoskeleton reorganization results in the generation of actin belts and eventual bone resorption. Tetraspanins are involved in adhesion, migration and fusion in various cells. However, its function in osteoclast is still unclear. In this study, we identified Tm4sf19, a member of the tetraspanin family, as a regulator of osteoclast function.Materials and methods: We investigate the effect of Tm4sf19 deficiency on osteoclast differentiation using bone marrow derived macrophages obtained from wild type (WT), Tm4sf19 knockout (KO) and Tm4sf19 LEL Delta mice lacking the large extracellular loop (LEL). We analyzed bone mass of young and aged WT, KO and LEL Delta mice by mu CT analysis. The effects of Tm4sf19 LEL Fc fusion protein were accessed in osteoclast differentiation and osteoporosis animal model.Results: We found that deficiency of Tm4sf19 inhibited osteoclast function and LEL of Tm4sf19 was responsible for its function in osteoclasts in vitro. KO and LEL Delta mice exhibited higher trabecular bone mass compared to WT mice. We found that Tm4sf19 interacts with integrin alpha v beta 3 through LEL, and that this binding is important for cytoskeletal rearrangements in osteoclast by regulating signaling downstream of integrin alpha v beta 3. Treatment with LEL Fc fusion protein inhibited osteoclast function in vitro and administration of LEL Fc prevented bone loss in an osteoporosis mouse model in vivo.Conclusion: We suggest that Tm4sf19 regulates osteoclast function and that LEL Fc may be a promising drug to target bone destructive diseases caused by osteoclast hyper differentiation.
C1 [Park, Sujin; Heo, Jin Sun; An, Haein; Hong, Eunji; Kang, Min Gi; Yun, Rebecca; Park, Hyeyeon; Kim, Pyunggang; Son, Minjung; Pang, Kyoungwha; Lee, Jihee; Park, Jinah; Ooshima, Akira; Park, Je Yeon; Kim, Seong Jin] GILO Fdn, GILO Inst, Seoul, South Korea.
   [Mizuno, Seiya] Univ Tsukuba, Inst Med, Lab Anim Resource Ctr, Transborder Med Res Ctr, Tsukuba, Japan.
   [Kim, Minwoo; Noh, Eun Hye; Lee, Min Jung; Yoon, Kwiyeom; Yang, Kyung Min; Kim, Seong Jin] Medpacto Inc, Seoul, South Korea.
   [Kim, Minwoo] Yonsei Univ, Coll Life Sci & Biotechnol, Dept Biochem, Seoul, South Korea.
   [An, Haein; Hong, Eunji; Kang, Min Gi; Park, Hyeyeon; Son, Minjung; Park, Seok Hee] Sungkyunkwan Univ, Dept Biol Sci, Suwon, South Korea.
   [Kim, Junil] Soongsil Univ, Sch Syst Biomed Sci, Seoul, South Korea.
   [Yun, Rebecca] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea.
   [Park, Jinah] Amoris Bio Inc, Seoul, South Korea.
   [Kim, Tae Jin] Korea Inst Radiol & Med Sci, Div Radiat Biomed Res, Seoul, South Korea.
   [Myung, Seung Jae] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Gastroenterol, Seoul, South Korea.
   [Bae, Hyun] Cedars Sinai Med Ctr, Los Angeles, CA USA.
   [Lee, Kyung Mi] Korea Univ, Coll Med, Dept Biochem & Mol Biol, Seoul, South Korea.
   [Letterio, John] Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH USA.
   [Letterio, John] Case Western Reserve Univ, Dept Pediat, Sch Med, Cleveland, OH USA.
   [Letterio, John] Univ Hosp Rainbow Babies & Childrens Hosp, Angie Fowler Adolescent & Young Adult Canc Inst, Cleveland, OH USA.
   [Takahashi, Satoru] Univ Tsukuba, Fac Med, Dept Anat & Embryol, Tsukuba, Japan.
   [Kim, Seong Jin] GILO Fdn, GILO Inst, 92 Myeongdal Ro, Seoul 06668, South Korea.
C3 University of Tsukuba; Yonsei University; Sungkyunkwan University
   (SKKU); Soongsil University; Seoul National University (SNU); Korea
   Institute of Radiological & Medical Sciences; University of Ulsan; Asan
   Medical Center; Cedars Sinai Medical Center; Korea University; Korea
   University Medicine (KU Medicine); University System of Ohio; Case
   Western Reserve University; University System of Ohio; Case Western
   Reserve University; University System of Ohio; Case Western Reserve
   University; Case Western Reserve University Hospital; University
   Hospitals of Cleveland; Rainbow Babies & Children's Hospital; University
   of Tsukuba
RP Kim, SJ (通讯作者)，GILO Fdn, GILO Inst, 92 Myeongdal Ro, Seoul 06668, South Korea.
EM jasonsjkim@gilo.or.kr
RI Yang, Kyungmin/KOC 1513 2024; Kim, Seong/AAV 1869 2020; Sato,
   Takashi/M 2577 2018; Kim, Tae Hee/AAN 9079 2021; Myung,
   Sun Jung/J 5464 2012; Pang, Kyoungwha/JGE 1771 2023
OI Lee, Kyung Mi/0000 0002 5378 9258
FU Korea Drug Development Fund   Ministry of Science and ICT; Korea Drug
   Development Fund   Ministry of Trade, Industry, and Energy; Korea Drug
   Development Fund   Ministry of Health and Welfare (Republic of Korea)
   [RS 2023 00282595]
FX This research was in part supported by Korea Drug Development Fund
   funded by Ministry of Science and ICT, Ministry of Trade, Industry, and
   Energy, and Ministry of Health and Welfare (RS 2023 00282595, Republic
   of Korea).
CR Aghaloo TL, 2014, J BONE MINER RES, V29, P843, DOI 10.1002/jbmr.2097
   Ahmadzadeh K, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.873226
   Aliprantis AO, 2008, J CLIN INVEST, V118, P3775, DOI 10.1172/JCI35711
   Anwar A, 2023, J CELL PHYSIOL, V238, P1431, DOI 10.1002/jcp.31036
   Bi HD, 2017, FRONT MED LAUSANNE, V4, DOI 10.3389/fmed.2017.00234
   Blangy A, 2020, J CELL SCI, V133, DOI 10.1242/jcs.244798
   Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111
   Dharan R, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2208993119
   Ding L, 2020, BIOCHEM BIOPH RES CO, V533, P1204, DOI 10.1016/j.bbrc.2020.08.078
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Faccio R, 2003, J CLIN INVEST, V111, P749, DOI 10.1172/JCI200316924
   Gielen E, 2023, METABOLISM, V145, DOI 10.1016/j.metabol.2023.155638
   Huveneers S, 2009, J CELL SCI, V122, P1059, DOI 10.1242/jcs.039446
   Ishii M, 2006, J BONE MINER RES, V21, P965, DOI 10.1359/JBMR.060308
   Ishii T, 2018, FASEB J, V32, P4016, DOI 10.1096/fj.201701424R
   Ivanusic D, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 89523 7
   Jung YK, 2008, J CELL PHYSIOL, V216, P603, DOI 10.1002/jcp.21438
   Khan UA, 2013, J CELL BIOCHEM, V114, P1772, DOI 10.1002/jcb.24518
   Kim H, 2018, CELL, V175, P1756, DOI 10.1016/j.cell.2018.10.025
   Kim JM, 2018, BMB REP, V51, P230, DOI 10.5483/BMBRep.2018.51.5.198
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kim M, 2022, J CELL PHYSIOL, V237, P846, DOI 10.1002/jcp.30559
   Kloc M, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23126553
   Kodama J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165685
   Kovalenko OV, 2005, BMC STRUCT BIOL, V5, DOI 10.1186/1472 6807 5 11
   Kukita T, 2004, J EXP MED, V200, P941, DOI 10.1084/jem.20040518
   Kumar A, 2021, NATURE, V598, P521, DOI 10.1038/s41586 021 03913 5
   Lampiasi N, 2021, BIOLOGY BASEL, V10, DOI 10.3390/biology10020117
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Levaot N, 2015, BONE, V79, P21, DOI 10.1016/j.bone.2015.05.021
   Lipper CH, 2022, STRUCTURE, V30, P206, DOI 10.1016/j.str.2021.10.007
   LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485
   Makras P, 2015, METABOLISM, V64, P1199, DOI 10.1016/j.metabol.2015.07.011
   McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905
   Miyamoto H, 2012, J BONE MINER RES, V27, P1289, DOI 10.1002/jbmr.1575
   Moon H, 2023, FRONT CHEM, V11, DOI 10.3389/fchem.2023.1151526
   Nakamura I, 2007, J BONE MINER METAB, V25, P337, DOI 10.1007/s00774 007 0773 9
   Nedeva IR, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.641162
   Ng AY, 2018, JBMR PLUS, V2, P328, DOI 10.1002/jbm4.10058
   Rajesh S, 2012, J VIROL, V86, P9606, DOI 10.1128/JVI.00559 12
   Roberts MS, 2003, J BIOL CHEM, V278, P1975, DOI 10.1074/jbc.M208607200
   Rubinstein E, 2011, BIOCHEM SOC T, V39, P501, DOI 10.1042/BST0390501
   Sato Y, 2018, KIDNEY INT, V94, P396, DOI 10.1016/j.kint.2018.02.025
   Soe K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207717
   Stipp CS, 2003, TRENDS BIOCHEM SCI, V28, P106, DOI 10.1016/S0968 0004(02)00014 2
   Takeda Y, 2003, J CELL BIOL, V161, P945, DOI 10.1083/jcb.200212031
   van den Dries K, 2019, J CELL SCI, V132, DOI 10.1242/jcs.236828
   van Deventer S, 2021, TRENDS CELL BIOL, V31, P119, DOI 10.1016/j.tcb.2020.11.004
   van Deventer SJ, 2017, BIOCHEM SOC T, V45, P741, DOI 10.1042/BST20160284
   Wang YQ, 2015, BBA MOL CELL RES, V1853, P1715, DOI 10.1016/j.bbamcr.2015.04.001
   Witwicka H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128275
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   Yáñez Mó M, 2009, TRENDS CELL BIOL, V19, P434, DOI 10.1016/j.tcb.2009.06.004
   Yang M, 2008, J CELL PHYSIOL, V215, P497, DOI 10.1002/jcp.21331
   Yi YW, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020665
   Zou FG, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01606
   Zur Y, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2002979
NR 58
TC 5
Z9 5
U1 5
U2 13
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0026 0495
EI 1532 8600
J9 METABOLISM
JI Metab. Clin. Exp.
PD FEB
PY 2024
VL 151
AR 155746
DI 10.1016/j.metabol.2023.155746
EA NOV 2023
PG 15
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CY2F3
UT WOS:001128720400001
PM 38016540
OA hybrid
DA 2025 08 17
ER

PT J
AU Rundle, CH
   Gomez, GA
   Pourteymoor, S
   Mohan, S
AF Rundle, Charles H. H.
   Gomez, Gustavo A. A.
   Pourteymoor, Sheila
   Mohan, Subburaman
TI Sequential application of small molecule therapy enhances chondrogenesis
   and angiogenesis in murine segmental defect bone repair
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE angiogenesis; chondrogenesis; PHD2 antagonist; segmental defect; sonic
   hedgehog agonist
ID SONIC HEDGEHOG; PROLYL HYDROXYLASE; SKELETAL DEVELOPMENT; FRACTURE
   REPAIR; FEMUR FRACTURE; GROWTH FACTOR; VITAMIN C; EXPRESSION;
   DIFFERENTIATION; OSTEOBLASTS
AB The increasing incidence of physiologic/pathologic conditions that impair the otherwise routine healing of endochondral bone fractures and the occurrence of severe bone injuries necessitate novel approaches to enhance clinically challenging bone fracture repair. To promote the healing of nonunion fractures, we tested an approach that used two small molecules to sequentially enhance cartilage development and conversion to the bone in the callus of a murine femoral segmental defect nonunion model of bone injury. Systemic injections of smoothened agonist 21k (SAG21k) were used to stimulate chondrogenesis through the activation of the sonic hedgehog (SHH) pathway early in bone repair, while injections of the prolyl hydroxylase domain (PHD)2 inhibitor, IOX2, were used to stimulate hypoxia signaling mediated endochondral bone formation. The expression of SHH pathway genes and Phd2 target genes was increased in chondrocyte cell lines in response to SAG21k and IOX2 treatment, respectively. The segmental defect responded to sequential systemic administration of these small molecules with increased chondrocyte expression of PTCH1, GLI1, and SOX9 in response to SAG and increased expression of hypoxia induced factor 1 alpha and vascular endothelial growth factor A in the defect tissues in response to IOX2. At 6 weeks postsurgery, the combined SAG IOX2 therapy produced increased bone formation in the defect with the bony union over the injury. Clinical significance: This therapeutic approach was successful in promoting cartilage and bone formation within a critical size segmental defect and established the utility of a sequential small molecule therapy for the enhancement of fracture callus development in clinically challenging bone injuries.
C1 [Rundle, Charles H. H.; Gomez, Gustavo A. A.; Pourteymoor, Sheila; Mohan, Subburaman] VA Loma Linda Healthcare Syst, Musculoskeletal Dis Ctr, Res Serv 151,11201 Benton St, Loma Linda, CA 92357 USA.
   [Rundle, Charles H. H.; Mohan, Subburaman] Loma Linda Univ, Dept Med, Loma Linda, CA USA.
C3 Loma Linda University
RP Mohan, S (通讯作者)，VA Loma Linda Healthcare Syst, Musculoskeletal Dis Ctr, Res Serv 151,11201 Benton St, Loma Linda, CA 92357 USA.
EM Subburaman.Mohan@va.gov
OI Gomez, Gustavo/0000 0001 9294 4276; Rundle, Charles/0000 0003 4691 8143
FU U.S. Department of Veterans Affairs [1 101 BX 005262, IK6BX005381]
FX U.S. Department of Veterans Affairs, Grant/Award Numbers:
   1 101 BX 005262, IK6BX005381
CR Aghajanian P, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0021 z
   Aghajanian P, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 11050 1
   Aghajanian P, 2015, J BONE MINER RES, V30, P1945, DOI 10.1002/jbmr.2709
   Arrighi I, 2009, BIOMATERIALS, V30, P1763, DOI 10.1016/j.biomaterials.2008.12.023
   Bahney CS, 2019, J ORTHOP RES, V37, P35, DOI 10.1002/jor.24170
   Bahney CS, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00004
   Bassett JHD, 2016, ENDOCR REV, V37, P135, DOI 10.1210/er.2015 1106
   Brunton SA, 2009, BIOORG MED CHEM LETT, V19, P4308, DOI 10.1016/j.bmcl.2009.05.096
   Buza JA, 2016, CLIN CASES MINER BON, V13, P101, DOI 10.11138/ccmbm/2016.13.2.101
   Cai JQ, 2012, CELL BIOL INT, V36, P349, DOI 10.1042/CBI20110284
   Carballo GB, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964 018 0220 7
   Chan MC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132004
   Chen CX, 2022, EUR J PHARMACOL, V921, DOI 10.1016/j.ejphar.2022.174864
   Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899
   Cheng SH, 2016, ENDOCRINOLOGY, V157, P127, DOI 10.1210/en.2015 1473
   Das I, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005983
   Fish EW, 2017, BIRTH DEFECTS RES, V109, P49, DOI 10.1002/bdra.23571
   Garcia P, 2013, EUR CELLS MATER, V26, P1
   Gerstenfeld LC, 2003, J CELL BIOCHEM, V88, P873, DOI 10.1002/jcb.10435
   Gomez GA, 2022, ELIFE, V11, DOI [10.7554/eLife.76730, 10.7554/eLife.76730.sa0, 10.7554/eLife.76730.sa1, 10.7554/eLife.76730.sa2]
   Hashimoto K, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 61825 2
   Hu DP, 2017, DEVELOPMENT, V144, P221, DOI 10.1242/dev.130807
   Hu K, 2016, BONE, V91, P30, DOI 10.1016/j.bone.2016.06.013
   Hu K, 2016, J CLIN INVEST, V126, P509, DOI 10.1172/JCI82585
   Kashiwagi M, 2016, BIOCHEM BIOPH RES CO, V479, P772, DOI 10.1016/j.bbrc.2016.09.134
   Kaur A, 2020, ANIM MODEL EXP MED, V3, P130, DOI 10.1002/ame2.12114
   Kim HY, 2013, BONE RES, V1, DOI 10.4248/BR201302004
   Kimelman N, 2007, TISSUE ENG, V13, P1135, DOI 10.1089/ten.2007.0096
   Kostenuik P, 2017, J ORTHOP RES, V35, P213, DOI 10.1002/jor.23460
   Lee S, 2016, TISSUE ENG PT A, V22, P1357, DOI 10.1089/ten.tea.2016.0167
   Marsell R, 2010, J ORTHOP TRAUMA, V24, pS4, DOI 10.1097/BOT.0b013e3181ca3fab
   Matsumoto K, 2016, IN VIVO, V30, P99
   McKenzie JA, 2019, J ORTHOP RES, V37, P51, DOI 10.1002/jor.24017
   Miyaji T, 2003, HISTOCHEM CELL BIOL, V119, P233, DOI 10.1007/s00418 003 0501 z
   Mohan S, 2005, J BONE MINER RES, V20, P1597, DOI 10.1359/JBMR.050406
   Novicoff WM, 2008, J BONE JOINT SURG AM, V90A, P85, DOI 10.2106/JBJS.G.01521
   Ozolins TRS, 2009, BIOCHEM BIOPH RES CO, V390, P372, DOI 10.1016/j.bbrc.2009.08.057
   Schindeler A, 2008, SEMIN CELL DEV BIOL, V19, P459, DOI 10.1016/j.semcdb.2008.07.004
   Schipani E, 2009, J BONE MINER RES, V24, P1347, DOI [10.1359/JBMR.090602, 10.1359/jbmr.090602]
   Serowoky MA, 2022, NPJ REGEN MED, V7, DOI 10.1038/s41536 022 00225 8
   Shapiro F, 2008, EUR CELLS MATER, V15, P53, DOI 10.22203/eCM.v015a05
   Shen X, 2009, J ORTHOP RES, V27, P1298, DOI 10.1002/jor.20886
   Takebe H, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020677
   Tian RF, 2020, J ORTHOP SURG RES, V15, DOI 10.1186/s13018 020 01904 2
   Wang K, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23115974
   Warzecha J, 2006, J ORTHOP SCI, V11, P491, DOI 10.1007/s00776 006 1058 1
   Wong SA, 2021, J ORTHOP RES, V39, P1622, DOI 10.1002/jor.24904
   Xing WR, 2012, J BONE MINER RES, V27, P1067, DOI 10.1002/jbmr.1551
   Xing WR, 2011, PHYSIOL GENOMICS, V43, P749, DOI 10.1152/physiolgenomics.00229.2010
   Yang L, 2014, P NATL ACAD SCI USA, V111, P12097, DOI 10.1073/pnas.1302703111
   Zhang XP, 2005, J BONE MINER RES, V20, P2124, DOI 10.1359/JBMR.050806
   Zhou H, 2022, CELL PROLIFERAT, V55, DOI 10.1111/cpr.13162
   Zhou X, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004820
NR 53
TC 0
Z9 1
U1 1
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
EI 1554 527X
J9 J ORTHOP RES
JI J. Orthop. Res.
PD JUL
PY 2023
VL 41
IS 7
BP 1471
EP 1481
DI 10.1002/jor.25493
EA DEC 2022
PG 11
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA J7DA5
UT WOS:000903012500001
PM 36448182
OA Green Accepted, hybrid
DA 2025 08 17
ER

PT J
AU Shabir, U
   Bhat, IA
   Pir, BA
   Bharti, MK
   Pandey, S
   Gutulla, SK
   Sarkar, M
   Thirupathi, Y
   Chandra, V
   Sonewane, A
   Gutulla, TS
AF Shabir, Uffaq
   Bhat, Irfan Ahmad
   Pir, Bilal Ahmad
   Bharti, Mukesh Kumar
   Pandey, Sriti
   Gutulla, Sai Kumar
   Sarkar, Mihir
   Thirupathi, Yasotha
   Chandra, Vikash
   Sonewane, Arvind
   Gutulla, Taru Sharma
TI Smad4 and γ secretase knock down effect on osteogenic differentiation
   mediated via Runx2 in canine mesenchymal stem cells
SO RESEARCH IN VETERINARY SCIENCE
LA English
DT Article
DE Mesenchymal; Osteogenic; Differentiation; BMP; Notch; shRNA
ID OSTEOBLASTIC DIFFERENTIATION; INTERNATIONAL SOCIETY; NOTCH; EXPRESSION;
   ACTIVATION; MINERALIZATION; COOPERATION; INDUCTION; CHROMATIN; BINDING
AB Cell lineage determination during mesenchymal stem cell (MSCs) differentiation is a highly orchestrated process involving diverse signaling pathways and distinct classes of regulatory molecules. Bone morphogenetic protein (BMP) signaling positively influence the osteoblast lineage determination, whereas the Notch signaling may have a dimorphic action. Effective regenerative therapy for repairing bone defects requires ample knowledge of the signaling pathways responsible for the differentiation of MSCs. To elucidate the signaling pathways that drives canine bone marrow derived MSCs towards osteogenic lineage, the current work was focused on BMP and Notch signaling. Target genes of Runx2, Smad4 and gamma secretase were silenced by short hairpin RNA (shRNA) in canine MSCs. Evaluation of the effect of gene silencing on in vitro osteogenic differentiation potential was done by quantitative polymerase chain reaction (qPCR) for osteoblastic markers (Osteocalcin and Osteopontin) and Alizarin red S staining for the extracellular deposition of calcium. Silencing of Runx2 significantly reduced the osteocalcin and osteopontin gene expression while a similar trend was observed in the case of smad 4 silencing and their combination groups, but there was no difference found in Hey 1 expression. Runx2 and Smad4 silencing groups showed very less positive staining with Alizarin red S staining, whereas knockdown of 7 secretase and its combination groups showed reverse results as that of Runx2 and Smad4. Runx2 plays an indispensable part in directing the canine mesenchymal stem cells towards osteogenic lineage. Also, Smad mediated BMP signaling induced the osteoblast specific gene expression, whereas the notch pathway negatively regulated the osteogenic differentiation of canine MSCs.
C1 [Shabir, Uffaq; Bhat, Irfan Ahmad; Pir, Bilal Ahmad; Pandey, Sriti; Sarkar, Mihir; Thirupathi, Yasotha; Chandra, Vikash; Gutulla, Taru Sharma] ICAR Indian Vet Res Inst, Div Physiol & Climatol, Izatnagar 243122, Uttar Pradesh, India.
   [Bharti, Mukesh Kumar] BHU, Dept Vet Physiol & Biochem, Fac Vet & Anim Sci, RGSC, Barkachha 231001, Mirzapur, India.
   [Gutulla, Sai Kumar] ICAR Indian Vet Res Inst, Div Vet Pathol, Izatnagar 243122, Uttar Pradesh, India.
   [Sonewane, Arvind] ICAR Indian Vet Res Inst, Div Anim Genet, Izatnagar 243122, Uttar Pradesh, India.
C3 Indian Council of Agricultural Research (ICAR); ICAR   Indian Veterinary
   Research Institute; Banaras Hindu University (BHU); Indian Council of
   Agricultural Research (ICAR); ICAR   Indian Veterinary Research
   Institute; Indian Council of Agricultural Research (ICAR); ICAR   Indian
   Veterinary Research Institute
RP Gutulla, TS (通讯作者)，ICAR Indian Vet Res Inst, Div Physiol & Climatol, Reprod Physiol Lab, Izatnagar 243122, Uttar Pradesh, India.
EM gts553@gmail.com
RI Pandey, Sriti/AAA 2247 2020; CHANDRA, VIKASH/U 6635 2019
FU ICAR Indian Veterinary Research Institute, Izatnagar
FX The authors extend gratitude to the Director, ICAR Indian Veterinary
   Research Institute, Izatnagar for providing necessary fund facilities
   forconducting this study.
CR Bhat IA, 2019, J CELL PHYSIOL, V234, P2705, DOI 10.1002/jcp.27086
   Canalis E, 2013, ENDOCRINOLOGY, V154, P623, DOI 10.1210/en.2012 1732
   Colter DC, 2001, P NATL ACAD SCI USA, V98, P7841, DOI 10.1073/pnas.141221698
   Dailey DD, 2013, BMC VET RES, V9, DOI 10.1186/1746 6148 9 130
   DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092 8674(87)90585 X
   Deregowski V, 2006, J BIOL CHEM, V281, P6203, DOI 10.1074/jbc.M508370200
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Engin FZ, 2008, NAT MED, V14, P299, DOI 10.1038/nm1712
   Engin F, 2010, BONE, V46, P274, DOI 10.1016/j.bone.2009.05.027
   Gugjoo MB, 2018, CURR STEM CELL RES T, V13, P645, DOI 10.2174/1574888X13666180517074444
   Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577
   Hassan MQ, 2004, MOL CELL BIOL, V24, P9248, DOI 10.1128/MCB.24.20.9248 9261.2004
   Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529
   Horwitz EM, 2005, CYTOTHERAPY, V7, P393, DOI 10.1080/14653240500319234
   Javed A, 2001, MOL CELL BIOL, V21, P2891, DOI 10.1128/MCB.21.8.2891 2905.2001
   Javed A, 2008, J BIOL CHEM, V283, P8412, DOI 10.1074/jbc.M705578200
   Ji YT, 2017, AM J TRANSL RES, V9, P2933
   Joseph A, 2020, J CELL PHYSIOL, V235, P5555, DOI 10.1002/jcp.29486
   Kern B, 2001, J BIOL CHEM, V276, P7101, DOI 10.1074/jbc.M006215200
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Lamplot JD, 2013, AM J STEM CELLS, V2, P1
   Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783 8792.2000
   Lee MH, 2005, J BIOL CHEM, V280, P35579, DOI 10.1074/jbc.M502267200
   Li L, 2015, INT J MOL MED, V35, P1641, DOI 10.3892/ijmm.2015.2172
   Li XL, 2006, ANN NY ACAD SCI, V1068, P26, DOI 10.1196/annals.1346.006
   Liu P, 2016, P NATL ACAD SCI USA, V113, pE2152, DOI 10.1073/pnas.1603399113
   Mazzoni E, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.610570
   Nishimura R, 2002, BONE, V31, P303, DOI 10.1016/S8756 3282(02)00826 8
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   Pratheesh MD, 2013, RES VET SCI, V94, P313, DOI 10.1016/j.rvsc.2012.08.002
   Qian GW, 2020, APPL MATER TODAY, V19, DOI 10.1016/j.apmt.2020.100615
   Quarto R, 2001, NEW ENGL J MED, V344, P385, DOI 10.1056/NEJM200102013440516
   Sciaudone M, 2003, ENDOCRINOLOGY, V144, P5631, DOI 10.1210/en.2003 0463
   Shindo K, 2003, EXP CELL RES, V290, P370, DOI 10.1016/S0014 4827(03)00349 5
   Takada I, 2009, NAT REV RHEUMATOL, V5, P442, DOI 10.1038/nrrheum.2009.137
   Tao JN, 2010, ANN NY ACAD SCI, V1192, P257, DOI 10.1111/j.1749 6632.2009.05307.x
   Tu XL, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002577
   Tucek Lubos, 2017, Acta Medica (Hradec Kralove), V60, P12, DOI 10.14712/18059694.2017.43
   Wang Y, 2019, J BIOMED MATER RES B, V107, P149, DOI 10.1002/jbm.b.34105
   Wu H, 2017, BBA GENE REGUL MECH, V1860, P438, DOI 10.1016/j.bbagrm.2017.01.003
   Zamurovic N, 2004, J BIOL CHEM, V279, P37704, DOI 10.1074/jbc.M403813200
   Zhang X, 2006, CALCIFIED TISSUE INT, V79, P169, DOI 10.1007/s00223 006 0083 6
NR 44
TC 4
Z9 4
U1 0
U2 5
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 0034 5288
EI 1532 2661
J9 RES VET SCI
JI Res. Vet. Sci.
PD JUL
PY 2022
VL 145
BP 116
EP 124
DI 10.1016/j.rvsc.2022.02.004
EA FEB 2022
PG 9
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Veterinary Sciences
GA 1J9IE
UT WOS:000798224400015
PM 35183849
DA 2025 08 17
ER

PT J
AU Karakousis, VA
   Liouliou, D
   Loula, A
   Kagianni, N
   Dietrich, EM
   Meditskou, S
   Sioga, A
   Papamitsou, T
AF Karakousis, Vasileios Alexandros
   Liouliou, Danai
   Loula, Aikaterini
   Kagianni, Nikoleta
   Dietrich, Eva Maria
   Meditskou, Soultana
   Sioga, Antonia
   Papamitsou, Theodora
TI Immunohistochemical Femoral Nerve Study Following Bisphosphonates
   Administration
SO MEDICINA LITHUANIA
LA English
DT Article
DE bisphosphonates; femoral nerve; immunohistochemistry; NeuN; Sox10
ID SCHWANN CELLS; SOX10; FRACTURES; INJURY; BONE
AB Background and objectives: Bisphosphonates represent selective inhibitors of excess osteoblastic bone resorption that characterizes all osteopathies, targeting osteoclasts and their precursors. Their long term administration in postmenopausal women suffering from osteoporosis has resulted in neural adverse effects. The current study focuses on the research of possible alterations in the femoral nerve, caused by bisphosphonates. We hypothesized that bisphosphonates, taken orally (per os), may produce degenerative changes to the femoral nerve, affecting lower limb posture and walking neuronal commands. Materials and Methods: In order to support our hypothesis, femoral nerve specimens were extracted from ten female 12 month old Wistar rats given 0.05 milligrams (mg) per kilogram (kg) of body weight (b.w.) per week alendronate per os for 13 weeks and from ten female 12 month old Wistar rats given normal saline that were used as a control group. Specimens were studied using immunohistochemistry for selected antibodies NeuN (Neuronal Nuclear Protein), a protein located within mature, postmitotic neural nucleus, and cytosol and Sox10 (Sex determining Region Y (SRY) High Motility Group (HMG) box 10). The latter marker is fundamental for myelination of peripheral nerves. Obtained slides were examined under a light microscope. Results: Samples extracted from rats given alendronate were more Sox10 positive compared to samples of the control group, where the marker's expression was not so intense. Both groups were equally NeuN positive. Our results are in agreement with previous studies conducted under a transmission electron microscope. Conclusions: The suggested pathophysiological mechanism linked to histological alterations described above is possibly related to toxic drug effects on Schwann and neuronal cells. Our hypothesis enhances the existing scientific evidence of degenerative changes present on femoral nerve following bisphosphonates administration, indicating a possible relationship between alendronate use and neuronal function.
C1 [Karakousis, Vasileios Alexandros; Liouliou, Danai; Loula, Aikaterini; Kagianni, Nikoleta; Meditskou, Soultana; Sioga, Antonia; Papamitsou, Theodora] Aristotle Univ Thessaloniki, Lab Histol & Embryol, Thessaloniki 54124, Greece.
   [Dietrich, Eva Maria] Univ Hosp Erlangen, Dept Oral & Maxillofacial Surg, D 91054 Erlangen, Germany.
C3 Aristotle University of Thessaloniki; University of Erlangen Nuremberg
RP Papamitsou, T (通讯作者)，Aristotle Univ Thessaloniki, Lab Histol & Embryol, Thessaloniki 54124, Greece.
EM vkarakous@auth.gr; danaliou@auth.gr; aikaloul@auth.gr;
   nkagianni@yahoo.com; aeffchen.dietrich@gmail.com; sefthym@auth.gr;
   sioga@med.auth.gr; paptheo@med.auth.gr
RI ; Papamitsou, Theodora/ABA 9855 2020
OI Papamitsou, Theodora/0000 0002 0709 5407; Karakousis, Vasileios
   Alexandros/0009 0004 3719 4715; Meditskou, Soultana/0000 0001 7929 9110;
   Sioga, Antonia/0000 0002 7565 2025
CR Balakrishnan A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153256
   Bird T.D., 2019, GENEREVIEWS, V1
   Cassarino DS, 2017, J CUTAN PATHOL, V44, P544, DOI 10.1111/cup.12939
   Chang KV, 2018, J CLIN MED, V7, DOI 10.3390/jcm7110457
   Chen YZ, 2013, BRAIN RES, V1495, P11, DOI 10.1016/j.brainres.2012.12.006
   Deng J, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000013341
   Dietrich E M., 2015, J Histol Histopathol, V2, P24, DOI [10.7243/2055 091X 2 24, DOI 10.7243/2055 091X 2 24]
   Diniz R.F., 2015, WORLD J DENT, V6, P116
   Dominguez LJ, 2011, BIOGERONTOLOGY, V12, P397, DOI 10.1007/s10522 011 9344 5
   Doyle S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03427 1
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   FERCAKOVA A, 1983, J HIRNFORSCH, V24, P627
   Fukumoto Seiji, 2017, F1000Res, V6, P625, DOI 10.12688/f1000research.10682.1
   Gusel'nikova VV, 2015, ACTA NATURAE, V7, P42, DOI 10.32607/20758251 2015 7 2 42 47
   Gustafson KJ, 2009, J REHABIL RES DEV, V46, P973, DOI 10.1682/JRRD.2008.08.0097
   Hornig J, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003907
   Hu J, 2001, J ORAL MAXIL SURG, V59, P1041, DOI 10.1053/joms.2001.25849
   Hung CY, 2016, AM J PHYS MED REHAB, V95, P698, DOI 10.1097/PHM.0000000000000463
   Hung HA, 2015, J BIOL CHEM, V290, P6937, DOI 10.1074/jbc.M114.622878
   Ilda H, 2004, MUSCLE NERVE, V30, P761, DOI 10.1002/mus.20159
   Inoue Y, 2018, PEDIATR RHEUMATOL, V16, DOI 10.1186/s12969 018 0258 5
   Jachewicz TK, 2017, DENT MED PROBL, V54, P297, DOI 10.17219/dmp/74884
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Kharwadkar N, 2017, BONE JOINT RES, V6, P144, DOI 10.1302/2046 3758.63.BJR 2016 0125.R1
   Lalkhen AG, 2012, BJA EDUC, V12, P38, DOI 10.1093/bjaceaccp/mkr048
   Landesberg R, 2008, J ORAL MAXIL SURG, V66, P839, DOI 10.1016/j.joms.2008.01.026
   Lehman Ronald A Jr, 2004, Spine J, V4, P36, DOI 10.1016/S1529 9430(03)00427 3
   Li W, 2016, NEUROCHEM RES, V41, P844, DOI 10.1007/s11064 015 1761 4
   Mhaskar R, 2018, JAMA J AM MED ASSOC, V320, P1483, DOI 10.1001/jama.2018.13773
   Miettinen M, 2015, AM J SURG PATHOL, V39, P826, DOI 10.1097/PAS.0000000000000398
   Nonaka D, 2008, AM J SURG PATHOL, V32, P1291, DOI 10.1097/PAS.0b013e3181658c14
   Ohishi T, 2018, THER CLIN RISK MANAG, V14, P729, DOI 10.2147/TCRM.S149236
   Papamitsou T., 2020, J BIOL RES, V2, DOI [10.1186/s40709 020 0112 z, DOI 10.1186/S40709 020 0112 Z]
   Pavone V, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00803
   Saita Y, 2015, THER ADV CHRONIC DIS, V6, P185, DOI 10.1177/2040622315584114
   Salzer JL, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020529
   Schiefer MA, 2010, J NEURAL ENG, V7, DOI 10.1088/1741 2560/7/2/026006
   SLADKY JT, 1991, ANN NEUROL, V29, P272, DOI 10.1002/ana.410290308
   Slater BJ, 2013, INVEST OPHTH VIS SCI, V54, P7952, DOI 10.1167/iovs.13 12064
   Srinivasan R, 2012, NUCLEIC ACIDS RES, V40, P6449, DOI 10.1093/nar/gks313
   Sven O., 2015, MEDICATION RELATED O
   Turnescu T, 2018, GLIA, V66, P279, DOI 10.1002/glia.23242
   Van Raamsdonk CD, 2013, PIGM CELL MELANOMA R, V26, P634, DOI 10.1111/pcmr.12134
   Wang YK, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012691
   Zameer S, 2018, PHARMACOL REP, V70, P900, DOI 10.1016/j.pharep.2018.03.011
NR 46
TC 0
Z9 0
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1010 660X
EI 1648 9144
J9 MEDICINA LITHUANIA
JI Med. Lith.
PD MAR
PY 2020
VL 56
IS 3
AR 140
DI 10.3390/medicina56030140
PG 13
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA LA9DU
UT WOS:000524241300008
PM 32204565
OA Green Published
DA 2025 08 17
ER

PT J
AU Wang, WZ
   Huang, MD
   Hui, YG
   Yuan, PW
   Guo, X
   Wang, KZ
AF Wang, Weizhuo
   Huang, Mengdi
   Hui, Yigeng
   Yuan, Puwei
   Guo, Xiong
   Wang, Kunzheng
TI Cryptotanshinone inhibits RANKL induced osteoclastogenesis by regulating
   ERK and NF κB signaling pathways
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE Cryptotanshinone; extracellular signal regulated kinase; NF kappa B;
   osteoclast differentiation; osteoclastogenesis; osteoporosis
ID RECEPTOR ACTIVATOR; C FOS; OSTEOPOROSIS; PREVENTION; DIFFERENTIATION;
   PROTECTS
AB Osteoporosis (OS) is one of the most common healthy problems characterized by low bone mass. Osteoclast, the primary bone resorbing cell, is responsible for destructive bone diseases including osteoporosis (OS). Cryptotanshinone (CTS), an active component extracted from the root of Salvia miltiorrhiza bunge, has been shown to prevent the destruction of cartilage and the thickening of subchondral bone in mice osteoarthritis models. However, its molecular mechanism in osteoclastogenesis needs to be determined. The aim of the current study was to explore the effect of CTS on osteoclastogenesis and further evaluate the underlying mechanism. Our results showed that CTS inhibited receptor activator of NF kappa B ligand (RANKL) induced the increase in tartrate resistant acid phosphatase (TRAP) activity in bone marrow derived macrophages (BMMs). In addition, the expressions of osteoclastogenesis related marker proteins and nuclear factor of activated T cells (NFAT) activation were suppressed by CTS treatment in BMMs. Furthermore, CTS attenuated RANKL induced ERK phosphorylation and NF kappa B activation in BMMs. These findings indicated that CTS inhibited RANKL induced osteoclastogenesis by inhibiting ERK phosphorylation and NF kappa B activation in BMMs. Thus, CTS may function as an inhibitor of osteoclastogenesis and may be considered as an alternative medicine for the prevention and treatment of OS.
C1 [Wang, Weizhuo; Huang, Mengdi; Hui, Yigeng; Wang, Kunzheng] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Orthoped, Xian, Shaanxi, Peoples R China.
   [Yuan, Puwei] Shaanxi Tradit Chinese Med Coll, Xianyang, Peoples R China.
   [Guo, Xiong] Xi An Jiao Tong Univ, Dept Publ Hlth, Hlth Sci Ctr, Key Lab Environm & Genes Related Dis, Xian, Shaanxi, Peoples R China.
C3 Xi'an Jiaotong University; Shaanxi University of Chinese Medicine; Xi'an
   Jiaotong University
RP Wang, WZ (通讯作者)，Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Orthoped Surg, Xian 710004, Shaanxi, Peoples R China.
EM weizhuo_wang1@163.com
RI Yuan, Puwei/G 4891 2015; /AAH 9542 2020
FU Fundamental Research Funds for the Central Universities [xjj2016107];
   Integrative Medicine Research and Innovation Team of Degenerative Bone
   Disease Prevention, Shaanxi Traditional Chinese Medicine College
   [2013KCT26]; Natural Science Foundation of China [81001225];
   international Co operative Plan of Shaanxi [S2016YFKW0013];
   international Cooperative Fund in Xian Jiaotong University [08143004]
FX Fundamental Research Funds for the Central Universities, Grant/Award
   Number: xjj2016107; Integrative Medicine Research and Innovation Team of
   Degenerative Bone Disease Prevention, Shaanxi Traditional Chinese
   Medicine College, Grant/Award Number: 2013KCT26; Natural Science
   Foundation of China, Grant/Award Number: No. 81001225; international
   Co operative Plan of Shaanxi, Grant/Award Number: S2016YFKW0013;
   international Cooperative Fund in Xian Jiaotong University, Grant/Award
   Number: No. 08143004
CR [Anonymous], 2017, Osteoporos Int, V28, P83, DOI 10.1007/s00198 017 3936 0
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Blair HC, 2004, HISTOL HISTOPATHOL, V19, P189, DOI 10.14670/HH 19.189
   Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551
   Feng ZH, 2017, INT IMMUNOPHARMACOL, V50, P161, DOI 10.1016/j.intimp.2017.06.017
   Gambacciani M, 2014, PANMINERVA MED, V56, P115
   Golob AL, 2015, MED CLIN N AM, V99, P587, DOI 10.1016/j.mcna.2015.01.010
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Jin YC, 2009, EUR J PHARMACOL, V614, P91, DOI 10.1016/j.ejphar.2009.04.038
   Kikuta J, 2018, METHODS MOL BIOL, V1763, P1, DOI 10.1007/978 1 4939 7762 8_1
   Kim K, 2015, MOL CELLS, V38, P75, DOI 10.14348/molcells.2015.2241
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Liu C, 2017, ONCOTARGET, V8, P115398, DOI 10.18632/oncotarget.23267
   Ma XJ, 2014, BIOCHEM BIOPH RES CO, V445, P282, DOI 10.1016/j.bbrc.2014.01.145
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   Pai MV, 2017, J OBSTET GYN INDIA, V67, P237, DOI 10.1007/s13224 017 0994 3
   Park JW, 2018, J CELL PHYSIOL, V233, P1481, DOI 10.1002/jcp.26035
   Park JH, 2017, MOL CELLS, V40, P706
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Wang T, 2017, CURR DRUG TARGETS, V18, P1051, DOI 10.2174/1389450118666170321105425
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888
   Zhang FY, 2009, EXP BRAIN RES, V193, P109, DOI 10.1007/s00221 008 1600 9
NR 23
TC 17
Z9 19
U1 1
U2 36
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD MAY
PY 2019
VL 120
IS 5
BP 7333
EP 7340
DI 10.1002/jcb.28008
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA HO6VK
UT WOS:000461070700052
PM 30506914
DA 2025 08 17
ER

PT J
AU Kanakaris, NK
   Petsatodis, G
   Tagil, M
   Giannoudis, PV
AF Kanakaris, Nikolaos K.
   Petsatodis, George
   Tagil, Magnus
   Giannoudis, Peter V.
TI Is there a role for bone morphogenetic proteins in osteoporotic
   fractures?
SO INJURY INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED
LA English
DT Article
DE BMPs; Osteoporosis; Fracture healing; Osteoblasts; Osteoclasts
ID MINERAL DENSITY; GROWTH FACTORS; STEM CELLS; OSTEOBLAST; GENE; HIP;
   MARROW; BMP 7; EPIDEMIOLOGY; ANGIOGENESIS
AB The central role of bone morphogenetic proteins (BMPs) in the remodelling process of the human skeleton has been identified in numerous experimental and clinical studies. BMPs appear to be key agents in the osteoblastic differentiation of mesenchymal stem cells, and more recent evidence implicates them with the cells of the osteoclastic lineage. BMP 2, BMP 4, BMP 6 and BMP 7 have been studied in the context of osteoporosis and have been associated with its pathophysiological pathways.
   The theoretical advantages of local or systemic treatment of osteoporotic fractures with BMPs include the potential of inducing a rapid increase in bone strength locally at the fractured area and systemically in the entire skeleton, as well as accelerating the bone healing period. Animal models of osteoporotic fractures suggested that the induction of new bone by local or systemic use of BMP 7 should be investigated as potential bone augmentation therapy to improve bone quality in symptomatic spinal osteoporosis. As our knowledge expands, new innovations may provide clinicians with advanced biologically based therapies for the successful treatment of osteoporotic fractures. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Kanakaris, Nikolaos K.; Giannoudis, Peter V.] Univ Leeds, Acad Dept Trauma & Orthopaed, Leeds LS2 9JT, W Yorkshire, England.
   [Petsatodis, George] Univ Thessaloniki, Acad Dept Trauma & Orthopaed, Thessaloniki, Greece.
   [Tagil, Magnus] Univ Lund Hosp, S 22185 Lund, Sweden.
C3 University of Leeds; Aristotle University of Thessaloniki; Lund
   University; Skane University Hospital
RP Giannoudis, PV (通讯作者)，Leeds Teaching Hosp NHS Trust, Dept Trauma & Orthopaed, Clarendon Wing, Acad Unit, Great George St, Leeds LS1 3EX, W Yorkshire, England.
EM pgiannoudi@aol.com
RI Giannoudis, Peter/AAA 3617 2020; Tagil, Magnus/N 1778 2019
OI Kanakaris, Nikolaos/0000 0002 1695 1519
CR Abe E, 2000, J BONE MINER RES, V15, P663, DOI 10.1359/jbmr.2000.15.4.663
   Anakwe RE, 2008, INJURY, V39, P1191, DOI 10.1016/j.injury.2008.02.003
   Andreassen TT, 1999, J BONE MINER RES, V14, P960, DOI 10.1359/jbmr.1999.14.6.960
   Augat P, 2005, OSTEOPOROSIS INT, V16, pS36, DOI 10.1007/s00198 004 1728 9
   Barnes GL, 2008, J BONE JOINT SURG AM, V90A, P120, DOI 10.2106/JBJS.G.01443
   BAYLINK DJ, 1993, J BONE MINER RES, V8, pS565
   BESSHO K, 1993, ANN CHIR GYNAECOL FE, V82, P49
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Carano RAD, 2003, DRUG DISCOV TODAY, V8, P980, DOI 10.1016/S1359 6446(03)02866 6
   Claes L, 1997, J ORTHOP RES, V15, P577, DOI 10.1002/jor.1100150414
   CONSTANTZ BR, 1995, SCIENCE, V267, P1796, DOI 10.1126/science.7892603
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   D'Ippolito G, 1999, J BONE MINER RES, V14, P1115, DOI 10.1359/jbmr.1999.14.7.1115
   de Kerkhove MPV, 2008, INJURY, V39, P244, DOI 10.1016/j.injury.2007.07.009
   Deakin DE, 2008, INJURY, V39, P213, DOI 10.1016/j.injury.2007.07.012
   Dean DB, 2009, FRONT BIOSCI LANDMRK, V14, P2878, DOI 10.2741/3419
   Deckers MML, 2002, ENDOCRINOLOGY, V143, P1545, DOI 10.1210/en.143.4.1545
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Fleet JC, 1996, ENDOCRINOLOGY, V137, P4605, DOI 10.1210/en.137.11.4605
   Frihagen F, 2008, INJURY, V39, P1147, DOI 10.1016/j.injury.2008.03.027
   Gerstenfeld LC, 2003, J BONE MINER RES, V18, P1584, DOI 10.1359/jbmr.2003.18.9.1584
   Giannoudis PV, 2007, OSTEOPOROSIS INT, V18, P1565, DOI 10.1007/s00198 007 0441 x
   Giannoudis PV, 2008, INJURY, V39, pS5, DOI 10.1016/S0020 1383(08)70010 X
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Grasser WA, 2007, INT ORTHOP, V31, P759, DOI 10.1007/s00264 007 0407 9
   Gruber R, 2006, EXP GERONTOL, V41, P1080, DOI 10.1016/j.exger.2006.09.008
   Haleem S, 2008, INJURY, V39, P1157, DOI 10.1016/j.injury.2008.03.022
   Holroyd C, 2008, BEST PRACT RES CL EN, V22, P671, DOI 10.1016/j.beem.2008.06.001
   Holt G, 2009, INJURY, V40, P722, DOI 10.1016/j.injury.2008.11.004
   Hosking D, 2009, CURR MED RES OPIN, V25, P263, DOI 10.1185/03007990802645461 
   Islam AAS, 2005, BRIT J ORAL MAX SURG, V43, P383, DOI 10.1016/j.bjoms.2004.10.018
   Jilka RL, 1998, J CLIN INVEST, V101, P1942, DOI 10.1172/JCI1039
   Kanakaris NK, 2008, INJURY, V39, pS83, DOI 10.1016/S0020 1383(08)70019 6
   Kanakaris Nikolaos K, 2008, J Surg Orthop Adv, V17, P133
   Kanis JA, 2001, OSTEOPOROSIS INT, V12, P989, DOI 10.1007/s001980170006
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   Keramaris NC, 2008, INJURY, V39, pS45, DOI 10.1016/S0020 1383(08)70015 9
   Kubo T, 1999, J STEROID BIOCHEM, V68, P197, DOI 10.1016/S0960 0760(99)00032 1
   Lane NE, 2003, ARTHRITIS RES THER, V5, P214, DOI 10.1186/ar797
   LEONG A, 2005, ORTH RES SOC 51 ANN
   Lindner T, 2009, J BONE JOINT SURG BR, V91B, P294, DOI 10.1302/0301 620X.91B3.21273
   Lu J, 2008, SPINE, V33, P242, DOI 10.1097/BRS.0b013e318162451b
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   Matsumoto A, 2001, J PERIODONTAL RES, V36, P175, DOI 10.1034/j.1600 0765.2001.360306.x
   Medici M, 2006, J BONE MINER RES, V21, P845, DOI 10.1359/JBMR.060306
   Miller PD, 2008, BEST PRACT RES CL EN, V22, P849, DOI 10.1016/j.beem.2008.07.004
   Miranda MA, 2007, INJURY, V38, P35, DOI 10.1016/j.injury.2007.08.009
   Moazzaz P, 2005, SPINE, V30, P1706, DOI 10.1097/01.brs.0000172230.01655.55
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Mundy GR, 2006, AM J CLIN NUTR, V83, p427S
   Namkung Matthai H, 2001, BONE, V28, P80, DOI 10.1016/S8756 3282(00)00414 2
   Nikolaou VS, 2009, INJURY, V40, P663, DOI 10.1016/j.injury.2008.10.035
   Phillips Frank M, 2006, Spine J, V6, P500, DOI 10.1016/j.spinee.2006.01.014
   REED MJ, 2004, SCI AGING KNOWLEDGE, P7
   Reginster JY, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.11.024
   Reneland RH, 2005, BMC MED GENET, V6, DOI 10.1186/1471 2350 6 9
   RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203
   Ripamonti U, 2005, J CELL MOL MED, V9, P911, DOI 10.1111/j.1582 4934.2005.tb00388.x
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Schmidmaier G, 2008, INJURY, V39, pS37, DOI 10.1016/S0020 1383(08)70014 7
   SIMIC P, 2005, ASBMR 27 ANN M NASHV
   Simic P, 2006, J BIOL CHEM, V281, P25509, DOI 10.1074/jbc.M513276200
   Styrkarsdottir U, 2003, PLOS BIOL, V1, P351, DOI 10.1371/journal.pbio.0000069
   Suzawa M, 1999, ENDOCRINOLOGY, V140, P2125, DOI 10.1210/en.140.5.2125
   Tang QO, 2008, EXPERT OPIN INV DRUG, V17, P1435, DOI [10.1517/13543784.17.10.1435, 10.1517/13543784.17.10.1435 ]
   Tow BPB, 2009, INJURY, V40, P385, DOI 10.1016/j.injury.2008.09.013
   Turgeman G, 2002, J CELL BIOCHEM, V86, P461, DOI 10.1002/jcb.10231
   Turgeman G, 2001, J GENE MED, V3, P240
   Urist M R, 1985, Prog Clin Biol Res, V187, P77
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   van Alken WG, 2004, WHO TECH REP SER, V926, P1
   Varkey M, 2006, CLIN ORTHOP RELAT R, P113, DOI 10.1097/01.blo.0000200236.84189.87
   Verma R, 2009, INJURY, V40, P368, DOI 10.1016/j.injury.2008.09.008
   von Muhlen D., 2009, OSTEOPOROS INT
   Walsh WR, 1997, CLIN ORTHOP RELAT R, P218
   Wu XW, 2007, ANN NY ACAD SCI, V1116, P29, DOI 10.1196/annals.1402.053
   Xu Shao wen, 2003, Chin J Traumatol, V6, P160
   Zhou S, 2001, J CELL BIOCHEM, P144
NR 78
TC 3
Z9 8
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0020 1383
EI 1879 0267
J9 INJURY
JI Injury Int. J. Care Inj.
PD DEC
PY 2009
VL 40
SU 3
BP 21
EP 26
PG 6
WC Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery
GA 558EV
UT WOS:000274724600006
DA 2025 08 17
ER

PT J
AU Patil, V
   Acharya, S
   Vineetha, R
   Nikhil, K
AF Patil, Vathsala
   Acharya, Shruthi
   Vineetha, Ravindranath
   Nikhil, Krithi
TI Awareness About Medication Related Osteonecrosis of the Jaw Among Dental
   Professionals: A Multicentre Study
SO ORAL HEALTH & PREVENTIVE DENTISTRY
LA English
DT Article
DE antiangiogenic drugs; antiresorptive agents; awareness; bisphosphonates;
   dentists
ID BISPHOSPHONATE RELATED OSTEONECROSIS
AB Purpose: Bisphosphonates and non bisphosphonate antiangiogenic and antiresorptive agents are widely used in the management of bone diseases and cancer. A subset of patients receiving these drugs can manifest with medication related osteonecrosis of the jaw (MRONJ) and it is one of the major complications faced in dental practice. Dentoalveolar and periodontal surgery are the major risk factors associated with it. Therefore, a dentist must have adequate knowledge to promptly identify patients at risk and efficiently manage the condition. This multicentre study was designed with an aim to assess the level of knowledge and awareness regarding MRONJ among dentists from six dental schools.
   Methods and Materials: An online self administered questionnaire was sent to all the dentists from six dental schools through Google forms. The results obtained were statistically analysed. The Kolmogorov Smirnov test was performed to check for normality of data, while the Mann Whitney U test and chi square test were used to compare the responses to each question.
   Results: The questionnaire was sent to 570 dentists, out of which 234 responses were obtained. The majority of participants were aware of the term 'MRONJ' (83.3%), clinical indications of bisphosphonates (61.5%) and its mechanism of action (72.2%). However, 68.4% and 61.5% of dentists had no knowledge about the 'drug holiday' concept and risk factors associated with MRONJ, respectively.
   Conclusion: Although most of the participants had knowledge regarding certain aspects of MRONJ, such as mechanism of action and clinical indications of bisphosphonates, there was a lack of awareness about the drug holiday concept and drug associated risk factors. This emphasises the need to spread awareness among the dental community, not only in tertiary healthcare centres, but also among private dentists and dental interns to prevent cases of MRONJ.
C1 [Patil, Vathsala; Acharya, Shruthi; Vineetha, Ravindranath] Manipal Acad Higher Educ, Manipal Coll Dent Sci, Dept OMR, Manipal 576104, Karnataka, India.
C3 Manipal Academy of Higher Education (MAHE)
RP Acharya, S (通讯作者)，Manipal Acad Higher Educ, Manipal Coll Dent Sci, Dept OMR, Manipal 576104, Karnataka, India.
EM shruthi.acharya@manipal.edu
RI ; Vineetha, Ravindranath/GLV 3608 2022
OI Vineetha, Ravindranath/0000 0003 1907 9858; 
CR Al Mohaya MA, 2011, SAUDI MED J, V32, P830
   Alhussain A, 2017, J ORAL MAXILLOFAC SU, V73, P1095
   Bauer JS, 2012, J CRANIO MAXILL SURG, V40, P277, DOI 10.1016/j.jcms.2011.04.011
   de Lima PB, 2015, SUPPORT CARE CANCER, V23, P3421, DOI 10.1007/s00520 015 2689 6
   El Osta L, 2015, SUPPORT CARE CANCER, V23, P2825, DOI 10.1007/s00520 015 2649 1
   Kim J, 2016, BMC MED EDUC, V16, DOI 10.1186/s12909 016 0672 7
   Kokane G, 2015, J CONT DENT, V5, P1
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Raj DV, 2016, GERODONTOLOGY, V33, P135, DOI 10.1111/ger.12141
   Ruggiero SL, 2009, J ORAL MAXIL SURG, V67, P2, DOI 10.1016/j.joms.2009.01.009
   Ruggiero SL, 2014, AM ASS ORAL MAXILLOF, V72, P1
   Sentürk MF, 2016, J PAK MED ASSOC, V66, P880
   Tanna N, 2017, BRIT DENT J, V222, P121, DOI 10.1038/sj.bdj.2017.79
NR 13
TC 14
Z9 16
U1 0
U2 3
PU QUINTESSENCE PUBLISHING CO INC
PI HANOVER PARK
PA 4350 CHANDLER DRIVE, HANOVER PARK, IL 60133 USA
SN 1602 1622
EI 1757 9996
J9 ORAL HLTH PREV DENT
JI Oral Health Prev. Dent.
PD MAY JUN
PY 2020
VL 18
IS 3
BP 505
EP 509
DI 10.3290/j.ohpd.a43361
PG 5
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA MG5KM
UT WOS:000546070900016
PM 32016175
DA 2025 08 17
ER

PT J
AU Lin, X
   Zhang, KW
   Li, Y
   Nan, F
   Li, J
   Zhang, H
   Deng, W
   Ding, WH
   Li, KX
   Jarhen, N
   Zhou, YT
   Yu, X
   Hao, W
   Shi, D
   Dong, XY
   Wu, SQ
   Yin, XB
AF Lin, Xiao
   Zhang, Kewen
   Li, Yang
   Nan, Fang
   Li, Jun
   Zhang, Hui
   Deng, Wei
   Ding, Weihang
   Li, Kaixuan
   Jarhen, Nur
   Zhou, Yitong
   Yu, Xiao
   Hao, Wan
   Shi, Di
   Dong, Xiangyu
   Wu, Shu Qi
   Yin, Xue Bo
TI High resolution osteoclast targeted imaging guided osteoporosis
   alleviation via persistent luminescence nanocomposite
SO CHEMICAL ENGINEERING JOURNAL
LA English
DT Article
DE Persistent luminescence nanoparticles; Two photon NIR excitation; NIR
   emission; Osteoclast targeted imaging; Osteoporosis alleviation
ID IN VIVO; NANOPARTICLES; DELIVERY
AB Osteoclasts with abnormal activity play an important role in osteoporosis. Deep penetration imaging with high resolution is required for osteoclasts, while targeted drug delivery facilitates osteoporosis elimination. Here we design the persistent luminescence nanoparticles (PLNPs) with near infrared (NIR) persistent emission at 700 nm and NIR two photon excitation at 800 1100 nm. The NIR excitation and NIR emission realize the deep tissue imaging with high resolution. The PLNPs were then modified with D Asp8 peptide for targeting to osteoclasts and integrated alendronate (ALN) for osteoporosis alleviation. Thus, PLNP Asp/ALN composite realized osteoclast imaging in deep bone tissue with high sensitivity as the spot smaller than 0.74 mu m was clearly observed. The results from microcomputed tomography, histochemical staining, and real time quantitative polymerase chain analysis confirm the osteoporosis alleviation due to the integrated ALN. Thus, we design the PLNPs with NIR persistent emission and NIR excitation for interference free deep tissue imaging and introduce ALN to eliminate osteoporosis as a new paradigm for bone related imaging guided therapy.
C1 [Lin, Xiao; Zhang, Kewen; Li, Yang; Nan, Fang; Zhang, Hui; Deng, Wei; Ding, Weihang; Li, Kaixuan; Jarhen, Nur; Zhou, Yitong; Hao, Wan; Shi, Di; Wu, Shu Qi] Northwestern Polytech Univ, Sch Life Sci, Key Lab Space Biosci & Biotechnol, Xian 710072, Peoples R China.
   [Lin, Xiao; Zhang, Kewen; Zhang, Hui; Hao, Wan; Shi, Di] NPU UAB Joint Lab Bone Metab, Xian Key Lab Special Med & Hlth Engn, Res Ctr Special Med & Hlth Syst Engn, Lab Bone Metab, Xian 710072, Peoples R China.
   [Li, Jun] Xian Honghui Hosp, Dept Knee Joint Surg, Xian, Shaanxi, Peoples R China.
   [Yu, Xiao; Dong, Xiangyu] Northwestern Polytech Univ, Queen Mary Univ London Engn Sch, Xian 710072, Peoples R China.
   [Yin, Xue Bo] Shanghai Univ Engn Sci, Inst Frontier Med Technol, Coll Chem & Chem Engn, Shanghai 201620, Peoples R China.
C3 Northwestern Polytechnical University; Northwestern Polytechnical
   University; Shanghai University of Engineering Science
RP Wu, SQ (通讯作者)，Northwestern Polytech Univ, Sch Life Sci, Key Lab Space Biosci & Biotechnol, Xian 710072, Peoples R China.; Yin, XB (通讯作者)，Shanghai Univ Engn Sci, Inst Frontier Med Technol, Coll Chem & Chem Engn, Shanghai 201620, Peoples R China.
EM sqwu@nwpu.edu.cn; xbyin@nankai.edu.cn
RI Zhang, Wei/JKI 3565 2023; Yin, Xue Bo/G 2305 2011; Zhang,
   Hui/G 6203 2017; wu, shuqi/LQK 1700 2024; zhang, kewen/KXR 4680 2024;
   å², è¿ª/KDN 8012 2024
OI Li, Kaixuan/0000 0003 4675 8557; Shi, Di/0009 0005 5681 3427; 
FU National Natural Science Foundation of China [21804109, 22174077,
   22374096]; Guangdong Basic and Applied Basic Research Foundation
   [2023A1515030047]; Seed Foundation of Innovation and Creation for
   Postgraduate Stu  dents in Northwestern Polytechnical University
   [CX2020261]; Fundamental Research Funds for the Central Universities
   [G2021KY0502]; Biomedical Experimental Center of Xi'an Jiaotong Uni 
   versity
FX This work was supported by the National Natural Science Foundation of
   China (No. 21804109, 22174077, and 22374096) , the Guangdong Basic and
   Applied Basic Research Foundation (No. 2023A1515030047) , the Seed
   Foundation of Innovation and Creation for Postgraduate Stu  dents in
   Northwestern Polytechnical University (CX2020261) , and the Fundamental
   Research Funds for the Central Universities (G2021KY0502) . We thank the
   Analytical & Testing Center of North  western Polytechnical University
   for the XRD and TEM characterization. We thank the Biomedical
   Experimental Center of Xi'an Jiaotong Uni  versity for the two  photon
   imaging experiment.
CR Abdukayum A, 2013, J AM CHEM SOC, V135, P14125, DOI 10.1021/ja404243v
   Adami G, 2022, THER ADV MUSCULOSKEL, V14, DOI 10.1177/1759720X221083541
   Blangy A, 2020, J CELL SCI, V133, DOI 10.1242/jcs.244798
   Chen LJ, 2019, ACS APPL MATER INTER, V11, P19894, DOI 10.1021/acsami.9b05870
   Chen QX, 2022, ADV FUNCT MATER, V32, DOI 10.1002/adfm.202201067
   Ding DD, 2021, ACS APPL MATER INTER, V13, P16166, DOI 10.1021/acsami.1c02372
   Fuggle NR, 2019, NAT REV ENDOCRINOL, V15, P535, DOI 10.1038/s41574 019 0220 8
   Furuya M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02541 w
   Han HB, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 36625 7
   Hoque J, 2021, BIOMATERIALS, V273, DOI 10.1016/j.biomaterials.2021.120819
   Ishii M, 2013, J BONE MINER METAB, V31, P507, DOI 10.1007/s00774 013 0437 x
   Jiang Y, 2019, J MATER CHEM B, V7, P3796, DOI 10.1039/c9tb00378a
   Kikuta J, 2018, METHODS MOL BIOL, V1763, P1, DOI 10.1007/978 1 4939 7762 8_1
   Lécuyer T, 2022, NANOSCALE, V14, P15760, DOI 10.1039/d2nr03546d
   Li YJ, 2021, ADV SCI, V8, DOI 10.1002/advs.202004381
   Li ZJ, 2015, J AM CHEM SOC, V137, P5304, DOI 10.1021/jacs.5b00872
   Lin HH, 2017, OPT LETT, V42, P715, DOI 10.1364/OL.42.000715
   Lin WF, 2021, ACS APPL MATER INTER, V13, P32799, DOI 10.1021/acsami.1c07983
   Liu JH, 2019, ADV DRUG DELIVER REV, V138, P193, DOI 10.1016/j.addr.2018.10.015
   Liu J, 2015, BIOMATERIALS, V52, P148, DOI 10.1016/j.biomaterials.2015.02.007
   Maeda H, 2016, NAT CHEM BIOL, V12, P579, DOI [10.1038/NCHEMBIO.2096, 10.1038/nchembio.2096]
   Maldiney T, 2014, NAT MATER, V13, P418, DOI 10.1038/NMAT3908
   Maldiney T, 2012, ACS SYM SER, V1113, P1
   Mi C, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 42001 2
   Minoshima M, 2019, ACS CENTRAL SCI, V5, P1059, DOI 10.1021/acscentsci.9b00220
   Mizuno H, 2018, HISTOCHEM CELL BIOL, V149, P417, DOI 10.1007/s00418 018 1638 0
   Morimoto A, 2020, PHARMACOL THERAPEUT, V206, DOI 10.1016/j.pharmthera.2019.107429
   Noriega Luna B, 2014, J NANOMATER, V2014, DOI 10.1155/2014/507273
   Pan ZF, 2020, J PHYS CHEM C, V124, P8347, DOI 10.1021/acs.jpcc.0c01951
   Ramírez García G, 2017, INT J PHARMACEUT, V532, P686, DOI 10.1016/j.ijpharm.2017.07.015
   Richard C, 2022, LIGHT SCI APPL, V11, DOI 10.1038/s41377 022 00808 6
   Ryu TK, 2016, J CONTROL RELEASE, V232, P152, DOI 10.1016/j.jconrel.2016.04.025
   Sharma SK, 2014, OPT MATER, V36, P1901, DOI 10.1016/j.optmat.2014.06.020
   Shi TH, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.202001166
   Shu G, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202104472
   Sun LM, 2022, CHINESE CHEM LETT, V33, P1946, DOI 10.1016/j.cclet.2021.10.071
   Sun WT, 2019, ACS NANO, V13, P7556, DOI 10.1021/acsnano.9b00097
   Tse JJ, 2021, CURR OSTEOPOROS REP, V19, P532, DOI 10.1007/s11914 021 00699 3
   Viana B, 2016, J LUMIN, V170, P879, DOI 10.1016/j.jlumin.2015.09.014
   Wang J, 2022, ACS NANO, V16, P462, DOI 10.1021/acsnano.1c07243
   Wang YY, 2020, INT J NANOMED, V15, P7967, DOI 10.2147/IJN.S263756
   Wang Y, 2016, ACS NANO, V10, P4164, DOI 10.1021/acsnano.5b07401
   Wu SQ, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201604992
   Wu SQ, 2016, ANAL CHEM, V88, P4114, DOI 10.1021/acs.analchem.6b00449
   Wu SQ, 2020, ACS APPL MATER INTER, V12, P25572, DOI 10.1021/acsami.0c04438
   Wu SQ, 2020, NANO MICRO LETT, V12, DOI 10.1007/s40820 020 0404 8
   Yan CY, 2017, DRUG DELIV TRANSL RE, V7, P408, DOI 10.1007/s13346 017 0373 8
   Yan LX, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.201909042
   Yan R, 2022, ACS NANO, V16, P8399, DOI 10.1021/acsnano.2c02900
   Ye J, 2021, ACS NANO, V15, P13692, DOI 10.1021/acsnano.1c04974
   Zhang HJ, 2020, ANAL CHEM, V92, P1179, DOI 10.1021/acs.analchem.9b04318
   Zhao HX, 2020, NANO LETT, V20, P252, DOI 10.1021/acs.nanolett.9b03755
   Zhu XY, 2022, ANGEW CHEM INT EDIT, V61, DOI 10.1002/anie.202209378
NR 53
TC 3
Z9 3
U1 12
U2 47
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1385 8947
EI 1873 3212
J9 CHEM ENG J
JI Chem. Eng. J.
PD MAR 15
PY 2024
VL 484
AR 149468
DI 10.1016/j.cej.2024.149468
EA FEB 2024
PG 12
WC Engineering, Environmental; Engineering, Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA KN8M3
UT WOS:001180736700001
DA 2025 08 17
ER

PT J
AU Puri, T
   Frost, ML
   Cook, GJ
   Blake, GM
AF Puri, Tanuj
   Frost, Michelle L.
   Cook, Gary J.
   Blake, Glen M.
TI [<SUP>18</SUP>F] Sodium Fluoride PET Kinetic Parameters in Bone Imaging
SO TOMOGRAPHY
LA English
DT Article
DE dynamic positron emission tomography; PET; computed tomography; CT;
   [F 18] sodium fluoride; [F 18]NaF; Hawkins model; kinetic modeling; bone
   metabolism; clinical significance
ID POSITRON EMISSION TOMOGRAPHY; VERTEBRAL FRACTURE RISK; SKELETAL
   BLOOD FLOW; POSTMENOPAUSAL WOMEN; BIOCHEMICAL MARKERS; F 18 FLUORIDE
   PET; PAGETS DISEASE; TC 99M METHYLENE DIPHOSPHONATE;
   PARATHYROID HORMONE; FEMORAL HEAD
AB This report describes the significance of the kinetic parameters (k values) obtained from the analysis of dynamic positron emission tomography (PET) scans using the Hawkins model describing the pharmacokinetics of sodium fluoride ([F 18]NaF) to understand bone physiology. Dynamic [F 18]NaF PET scans may be useful as an imaging biomarker in early phase clinical trials of novel drugs in development by permitting early detection of treatment response signals that may help avoid late stage attrition.
C1 [Puri, Tanuj; Blake, Glen M.] Kings Coll London, Sch Biomed Engn & Imaging Sci, Dept Biomed Engn, London SE1 7EH, England.
   [Frost, Michelle L.] Inst Canc Res, Clin Trials & Stat Unit ICR CTSU, Sutton SM2 5NG, Surrey, England.
   [Cook, Gary J.] Kings Coll London, Sch Biomed Engn & Imaging Sci, Dept Canc Imaging, London SE1 7EH, England.
C3 University of London; King's College London; University of London;
   Institute of Cancer Research   UK; University of London; King's College
   London
RP Blake, GM (通讯作者)，Kings Coll London, Sch Biomed Engn & Imaging Sci, Dept Biomed Engn, London SE1 7EH, England.
EM tanujpuri82@gmail.com; michelle.frost@icr.ac.uk; gary.cook@kcl.ac.uk;
   glen.blake@kcl.ac.uk
RI ; Puri, Tanuj/B 4971 2012
OI Cook, Gary/0000 0002 8732 8134; Puri, Dr. Tanuj/0000 0002 9273 8226
FU National Institute for Health Research (NIHR) Biomedical Research Centre
   at Guy's and St Thomas' NHS Foundation Trust; King's College London
FX The research was supported by the National Institute for Health Research
   (NIHR) Biomedical Research Centre at Guy's and St Thomas' NHS Foundation
   Trust and King's College London. The views expressed are those of the
   author(s) and not necessarily those of the NHS, the NIHR or the
   Department of Health.
CR Aaltonen L, 2021, CALCIFIED TISSUE INT, V109, P605, DOI 10.1007/s00223 021 00874 9
   Aaltonen L, 2020, BONE, V134, DOI 10.1016/j.bone.2020.115267
   Alagiakrishnan K, 2003, J GERONTOL A BIOL, V58, P362
   Arlot M, 2005, J BONE MINER RES, V20, P1244, DOI 10.1359/JBMR.050309
   Azad GK, 2019, J NUCL MED, V60, P322, DOI 10.2967/jnumed.118.208710
   Bjarnason NH, 2001, OSTEOPOROSIS INT, V12, P922, DOI 10.1007/s001980170020
   Blake GM, 2018, QUANT IMAG MED SURG, V8, P47, DOI 10.21037/qims.2018.01.02
   Blake GM, 2011, BONE, V49, P537, DOI 10.1016/j.bone.2011.05.031
   Blake GM, 2009, J NUCL MED, V50, P1747, DOI 10.2967/jnumed.109.063263
   Blake GM, 2001, SEMIN NUCL MED, V31, P28, DOI 10.1053/snuc.2001.18742
   Bloomfield SA, 2002, CLIN ORTHOP RELAT R, P248, DOI 10.1097/00003086 200203000 00036
   Boivin G, 2010, OSTEOPOROSIS INT, V21, P667, DOI 10.1007/s00198 009 1005 z
   Bridgeman G, 1996, J ANAT, V188, P611
   Cherry S R., 2012, Physics in Nuclear Medicine, V4th, P43
   COMPSTON JE, 1991, BONE MINER, V14, P91, DOI 10.1016/0169 6009(91)90086 F
   Cook GJR, 2000, J BONE MINER RES, V15, P763, DOI 10.1359/jbmr.2000.15.4.763
   Cook GJR, 2002, J BONE MINER RES, V17, P854, DOI 10.1359/jbmr.2002.17.5.854
   Crockett JC, 2011, J CELL SCI, V124, P991, DOI 10.1242/jcs.063032
   Delmas PD, 2004, OSTEOPOROSIS INT, V15, P792, DOI 10.1007/s00198 004 1602 9
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Dempster DW, 2001, J BONE MINER RES, V16, P1846, DOI 10.1359/jbmr.2001.16.10.1846
   EASTELL R, 1988, J CLIN ENDOCR METAB, V67, P741, DOI 10.1210/jcem 67 4 741
   Eastell R, 2003, J BONE MINER RES, V18, P1051, DOI 10.1359/jbmr.2003.18.6.1051
   EINHORN TA, 1986, J ORTHOP RES, V4, P180, DOI 10.1002/jor.1100040206
   Eriksen EF, 2007, J BONE MINER RES, V22, P1, DOI 10.1359/JBMR.060910
   Fazzalari NL, 2008, SEMIN CELL DEV BIOL, V19, P467, DOI 10.1016/j.semcdb.2008.08.003
   Fleisch H, 1996, BISPHOSPHONATES MECH
   Frost ML, 2013, J BONE MINER RES, V28, P1337, DOI 10.1002/jbmr.1862
   Frost ML, 2011, J BONE MINER RES, V26, P1002, DOI 10.1002/jbmr.305
   Frost ML, 2009, BONE, V45, P942, DOI 10.1016/j.bone.2009.07.081
   Frost ML, 2003, J BONE MINER RES, V18, P2215, DOI 10.1359/jbmr.2003.18.12.2215
   Frost ML, 2004, J BONE MINER RES, V19, P1797, DOI 10.1359/JBMR.040818
   GARNERO P, 1994, J CLIN ENDOCR METAB, V79, P1693, DOI 10.1210/jc.79.6.1693
   Garnero P, 1996, J CLIN ENDOCR METAB, V81, P140, DOI 10.1210/jc.81.1.140
   Garnero P, 2000, Osteoporos Int, V11 Suppl 6, pS55, DOI 10.1007/s001980070006
   Garnero P, 2000, J BONE MINER RES, V15, P1526, DOI 10.1359/jbmr.2000.15.8.1526
   Garnero P, 1996, J BONE MINER RES, V11, P337, DOI 10.1002/jbmr.5650110307
   Garnero P, 1996, J BONE MINER RES, V11, P1531
   Garnero P., 2020, BONE TURNOVER MARKER, P1801
   Glover SJ, 2009, BONE, V45, P1053, DOI 10.1016/j.bone.2009.07.091
   Gnanasegaran G, 2007, CLIN NUCL MED, V32, P765, DOI 10.1097/RLU.0b013e318148b1dd
   Grados F, 2003, J CLIN ENDOCR METAB, V88, P5175, DOI 10.1210/jc.2002 021968
   Grant FD, 2008, J NUCL MED, V49, P68, DOI 10.2967/jnumed.106.037200
   Griffith JF, 2008, J BONE MINER RES, V23, P1068, DOI [10.1359/jbmr.080233, 10.1359/JBMR.080233]
   Griffith JF, 2006, RADIOLOGY, V241, P831, DOI 10.1148/radiol.2413051858
   GUILLEMART A, 1978, J NUCL MED, V19, P895
   HANSEN MA, 1991, BMJ BRIT MED J, V303, P961, DOI 10.1136/bmj.303.6808.961
   HAWKINS RA, 1992, J NUCL MED, V33, P633
   Heaney RP, 2003, BONE, V33, P457, DOI 10.1016/S8756 3282(03)00236 9
   Hochberg MC, 2002, J CLIN ENDOCR METAB, V87, P1586, DOI 10.1210/jc.87.4.1586
   Hooper G., 1984, FLUID SPACES CANNIE
   HOSKING DJ, 1972, CLIN SCI, V42, P153, DOI 10.1042/cs0420153
   Installé J, 2005, J NUCL MED, V46, P1650
   Jensen JEB, 1997, SCAND J CLIN LAB INV, V57, P351, DOI 10.3109/00365519709099408
   Jiang YB, 2003, J BONE MINER RES, V18, P1932, DOI 10.1359/jbmr.2003.18.11.1932
   LAROCHE M, 1995, OSTEOPOROSIS INT, V5, P213, DOI 10.1007/BF01774009
   Lenora Janaka, 2009, BMC Med Phys, V9, P3, DOI 10.1186/1756 6649 9 3
   Lindsay R, 2007, J BONE MINER RES, V22, P495, DOI 10.1359/JBMR.070104
   Mathavan N, 2019, ACTA BIOMATER, V90, P403, DOI 10.1016/j.actbio.2019.04.008
   McCarthy I, 2006, J BONE JOINT SURG AM, V88A, P4, DOI 10.2106/JBJS.F.00890
   McClung MR, 2005, ARCH INTERN MED, V165, P1762, DOI 10.1001/archinte.165.15.1762
   Melton LJ, 1997, J BONE MINER RES, V12, P1083, DOI 10.1359/jbmr.1997.12.7.1083
   MESSA C, 1993, J CLIN ENDOCR METAB, V77, P949, DOI 10.1210/jc.77.4.949
   Moore AEB, 2008, J NUCL MED, V49, P375, DOI 10.2967/jnumed.107.048595
   MOSEKILDE L, 1987, EUR J CLIN INVEST, V17, P530, DOI 10.1111/j.1365 2362.1987.tb01153.x
   NARITA N, 1990, CALCIFIED TISSUE INT, V46, P200, DOI 10.1007/BF02555045
   O'Connor JPB, 2017, NAT REV CLIN ONCOL, V14, P169, DOI 10.1038/nrclinonc.2016.162
   Papapoulos S, 1996, BISPHOSPHONATES PHAR
   Parfitt AM, 2004, BONE, V35, P1, DOI 10.1016/j.bone.2004.03.022
   Parfitt AM, 2000, BONE, V26, P319, DOI 10.1016/S8756 3282(00)80937 0
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Parfitt AM, 2002, BONE, V30, P807, DOI 10.1016/S8756 3282(02)00735 4
   Park Holohan SJ, 2001, NUCL MED COMMUN, V22, P1037, DOI 10.1097/00006231 200109000 00014
   PATLAK CS, 1985, J CEREBR BLOOD F MET, V5, P584, DOI 10.1038/jcbfm.1985.87
   PHELPS ME, 1979, ANN NEUROL, V6, P371, DOI 10.1002/ana.410060502
   Piert M, 1998, J BONE MINER RES, V13, P1328, DOI 10.1359/jbmr.1998.13.8.1328
   Piert M, 2002, EUR J NUCL MED MOL I, V29, P907, DOI 10.1007/s00259 002 0797 2
   Piert M, 2001, J NUCL MED, V42, P1091
   Prisby RD, 2007, J BONE MINER RES, V22, P1280, DOI 10.1359/JBMR.070415
   Puri T, 2013, OSTEOPOROSIS INT, V24, P633, DOI 10.1007/s00198 012 2006 x
   Puri T, 2021, TOMOGRAPHY, V7, P623, DOI 10.3390/tomography7040053
   Puri T, 2017, EJNMMI RES, V7, DOI 10.1186/s13550 017 0324 x
   Puri T, 2012, J NUCL MED TECHNOL, V4, P168, DOI 10.2967/jnmt.111.100107
   Puri T, 2012, NUCL MED COMMUN, V33, P597, DOI 10.1097/MNM.0b013e3283512adb
   Puri T, 2011, NUCL MED COMMUN, V32, P808, DOI 10.1097/MNM.0b013e328349716f
   Puri T, 2011, NUCL MED COMMUN, V32, P486, DOI 10.1097/MNM.0b013e3283452918
   Ralston SH, 1997, BRIT J RHEUMATOL, V36, P831
   RAWLINSON SCF, 1991, J BONE MINER RES, V6, P1345
   REEVE J, 1988, J CLIN ENDOCR METAB, V66, P1124, DOI 10.1210/jcem 66 6 1124
   Riggs BL, 1996, BONE, V18, pS197, DOI 10.1016/8756 3282(95)00502 1
   Sarkar S, 2004, J BONE MINER RES, V19, P394, DOI 10.1359/JBMR.0301243
   Schiepers C, 1997, J NUCL MED, V38, P1970
   Schiepers C, 1998, ARCH ORTHOP TRAUM SU, V118, P131, DOI 10.1007/s004020050332
   SCHUMICHEN C, 1979, EUR J NUCL MED, V4, P423, DOI 10.1007/BF00300839
   Siddique M, 2012, EUR J NUCL MED MOL I, V39, P337, DOI 10.1007/s00259 011 1966 y
   Szulc P, 2008, ANN RHEUM DIS, V67, P1249, DOI 10.1136/ard.2007.077941
   Uchida K, 2009, J NUCL MED, V50, P1808, DOI 10.2967/jnumed.109.062570
   VANDYKE D, 1965, AM J PHYSIOL, V209, P65, DOI 10.1152/ajplegacy.1965.209.1.65
   Vogt MT, 1997, J BONE MINER RES, V12, P283, DOI 10.1359/jbmr.1997.12.2.283
   Wong JM, 2021, NUCL MED COMMUN, V42, P699, DOI 10.1097/MNM.0000000000001393
   WOOTTON R, 1986, CLIN PHYS PHYSIOL M, V7, P333, DOI 10.1088/0143 0815/7/4/003
NR 101
TC 11
Z9 12
U1 0
U2 7
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
SN 2379 1381
EI 2379 139X
J9 TOMOGRAPHY
JI Tomography
PD DEC
PY 2021
VL 7
IS 4
BP 843
EP 854
DI 10.3390/tomography7040071
PG 12
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA YK5YR
UT WOS:000745288400001
PM 34941643
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU China, SP
   Pal, S
   Chattopadhyay, S
   Porwal, K
   Kushwaha, S
   Bhattacharyya, S
   Mittal, M
   Gurjar, AA
   Barbhuyan, T
   Singh, AK
   Trivedi, AK
   Gayen, JR
   Sanyal, S
   Chattopadhyay, N
AF China, Shyamsundar Pal
   Pal, Subhashis
   Chattopadhyay, Sourav
   Porwal, Konica
   Kushwaha, Sapana
   Bhattacharyya, Sharmishtha
   Mittal, Monika
   Gurjar, Anagha A.
   Barbhuyan, Tarun
   Singh, Abhishek K.
   Trivedi, Arun K.
   Gayen, Jiaur R.
   Sanyal, Sabyasachi
   Chattopadhyay, Naibedya
TI Globular adiponectin reverses osteo sarcopenia and altered body
   composition in ovariectomized rats
SO BONE
LA English
DT Article
DE Adiponectin; Osteopenia; Osteoanabolic; Anti resorptive; Sclerostin;
   Sarcopenia; Adiponectin receptor 1; PGCl alpha
ID BONE MINERAL DENSITY; POSTMENOPAUSAL WOMEN; PARATHYROID HORMONE; MASS;
   DIFFERENTIATION; RECEPTOR; OSTEOPOROSIS; FRACTURES; ADIPOR1; MUSCLE
AB Adiponectin regulates various metabolic processes including glucose flux, lipid breakdown and insulin response. We recently reported that adiponectin receptor1 (adipoR1) activation by a small molecule reverses osteopenia in leptin receptor deficient db/db (diabetic) mice. However, the role of adiponectin in bone metabolism under the setting of post menopausal (estrogen deficiency) osteopenia and associated metabolic derangements has not been studied. Here, we studied the therapeutic effect of the globular form of adiponectin (gAd), which is predominantly an adipoR1 agonist, in aged ovariectomized (OVX) rats and compared it with standard of care anti osteoporosis drugs. In OVX rats with established osteopenia, gAd completely restored BMD and load bearing capacity and improved bone quality. Skeletal effects of gAd were comparable to PTH (osteoanabolic) but better than alendronate (anti catabolic). Both osteoanabolic and anti catabolic mechanisms led to the anti osteoporosis effect of gAd. In cultured osteoblasts and bones, gAd increased a) adipoR1 and peroxisome proliferator activated receptor gamma coactivator 1 alpha (PGC1 alpha) expression to promote mitochondrial respiration, which likely fueled osteoblast differentiation, b) suppressed sclerostin (a wnt antagonist) in a sirtuinl dependent manner and c) decreased receptor activator of nuclear factor kappa B ligand (RANKL) to achieve its anti catabolic effect. The OVX induced sarcopenia and insulin resistance were also improved by gAd. We conclude that gAd has therapeutic efficacy in estrogen deficiency induced osteoporosis, sarcopenia and insulin resistance and hold metabolic disease modifying potential in postmenopausal women. (C) 2017 Elsevier Inc. All tights reserved.
C1 [China, Shyamsundar Pal; Pal, Subhashis; Porwal, Konica; Bhattacharyya, Sharmishtha; Mittal, Monika; Barbhuyan, Tarun; Chattopadhyay, Naibedya] CSIR, Cent Drug Res Inst, Div Endocrinol, Lucknow 226031, Uttar Pradesh, India.
   [China, Shyamsundar Pal; Pal, Subhashis; Porwal, Konica; Bhattacharyya, Sharmishtha; Mittal, Monika; Barbhuyan, Tarun; Chattopadhyay, Naibedya] CSIR, Cent Drug Res Inst, Ctr Res Anabol Skeletal Target Hlth & Illness AST, Lucknow 226031, Uttar Pradesh, India.
   [China, Shyamsundar Pal; Chattopadhyay, Sourav; Mittal, Monika; Gurjar, Anagha A.; Sanyal, Sabyasachi; Chattopadhyay, Naibedya] CSIR, AcSIR, Cent Drug Res Inst Campus, Lucknow 226031, Uttar Pradesh, India.
   [Chattopadhyay, Sourav; Kushwaha, Sapana; Gurjar, Anagha A.; Singh, Abhishek K.; Trivedi, Arun K.; Sanyal, Sabyasachi] CSIR, CDRI, Div Biochem, Lucknow 226031, Uttar Pradesh, India.
   [Gayen, Jiaur R.] CSIR, CDRI, Div Pharmacokinet & Metab, Lucknow 226031, Uttar Pradesh, India.
C3 Council of Scientific & Industrial Research (CSIR)   India; CSIR  
   Central Drug Research Institute (CDRI); Council of Scientific &
   Industrial Research (CSIR)   India; CSIR   Central Drug Research
   Institute (CDRI); Academy of Scientific & Innovative Research (AcSIR);
   Council of Scientific & Industrial Research (CSIR)   India; Council of
   Scientific & Industrial Research (CSIR)   India; CSIR   Central Drug
   Research Institute (CDRI); Council of Scientific & Industrial Research
   (CSIR)   India; CSIR   Central Drug Research Institute (CDRI)
RP Chattopadhyay, N (通讯作者)，CSIR, Cent Drug Res Inst, Div Endocrinol, Lucknow 226031, Uttar Pradesh, India.; Sanyal, S (通讯作者)，CSIR, CDRI, Div Biochem, Lucknow 226031, Uttar Pradesh, India.
EM sanyal@cdri.res.in; n_chattopadhyay@cdri.res.in
RI ; Barbhuyan, Tarun/IWV 3685 2023; Kushwaha, Sapana/AAA 7852 2020; Singh,
   Abhishek/AAP 4908 2020; Sanyal, Sabyasachi/E 8034 2010; Chattopadhyay,
   Naibedya/AAF 2058 2019; Trivedi, Arun/W 1883 2019; Gurjar,
   Anagha/KHW 1695 2024; Pal China, Shyamsundar/AAB 8041 2019; Pal,
   Subhashis/IXD 3635 2023; Chattopadhyay, Sourav/GQY 9508 2022
OI Trivedi, Arun/0000 0002 6316 0947; Pal, Subhashis/0000 0002 3916 5545;
   Gayen, Jiaur/0000 0001 7703 9307; Mittal, Monika/0000 0002 3328 7787;
   Sanyal, Sabyasachi/0000 0002 8603 3828; Chattopadhyay,
   Sourav/0000 0003 0055 5818; Singh, Abhishek Kumar/0000 0002 4474 1367;
   Pal China, Shyamsundar/0000 0003 0062 3593; Kushwaha,
   Sapana/0000 0001 8825 3034; Chattopadhyay, Naibedya/0000 0003 2473 0246;
   Porwal, Konica/0000 0002 6447 4681; 
FU CSIR network project ASTHI [BSC0201]; Council of Scientific and
   Industrial Research (CSIR); University Grants Commission (UGC)
FX Authors thank Dr. Annette G Beck Sickinger (Institute of Biochemistry,
   Leipzig University, Germany) for the kind gift of pET globular
   adiponectin plasmid (gAd pET15b). The plasmid pGL3 hSOSTp ECR8 plasmid
   was a kind gift from Dr. Gabriela G. Loots (Lawrence Berkeley National
   Laboratory, CA, USA) to SB. NC and SS acknowledge funding from CSIR
   network project ASTHI (BSC0201). Authors acknowledge sophisticated
   analytical instrument facility of CSIR CDRI for helps with con focal
   microscopy and flow cytometry. SPC, SP, SK, AAG, TB and AKS are
   recipients of fellowship from the Council of Scientific and Industrial
   Research (CSIR), and SC and MM are recipients of fellowship from
   University Grants Commission (UGC).
CR Abu Amer Y, 2013, OSTEOPOROSIS INT, V24, P2377, DOI 10.1007/s00198 013 2313 x
   Babaei Parvin, 2010, Menopause Int, V16, P100, DOI 10.1258/mi.2010.010028
   Bednarek Tupikowska G, 2004, GYNECOL ENDOCRINOL, V19, P57, DOI 10.1080/09513590412331272328
   Boyce Brendan F, 2007, Curr Osteoporos Rep, V5, P98
   Cantó C, 2009, CURR OPIN LIPIDOL, V20, P98, DOI 10.1097/MOL.0b013e328328d0a4
   Capozza RF, 2008, MENOPAUSE, V15, P905, DOI 10.1097/gme.0b013e318164ee85
   Compston J, 2015, CURR OPIN RHEUMATOL, V27, P414, DOI 10.1097/BOR.0000000000000182
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Costa AG, 2012, CURR OSTEOPOROS REP, V10, P64, DOI 10.1007/s11914 011 0089 5
   Cottet Rousselle C, 2011, CYTOM PART A, V79A, P405, DOI 10.1002/cyto.a.21061
   Esen E, 2015, J BONE MINER RES, V30, P1959, DOI 10.1002/jbmr.2556
   Esen E, 2013, CELL METAB, V17, P745, DOI 10.1016/j.cmet.2013.03.017
   Goldacre MJ, 2002, BRIT MED J, V325, P868, DOI 10.1136/bmj.325.7369.868
   Guntur AR, 2014, ENDOCRINOLOGY, V155, P1589, DOI 10.1210/en.2013 1974
   Heiker JT, 2010, BIOCHEM BIOPH RES CO, V398, P32, DOI 10.1016/j.bbrc.2010.06.020
   Hida T, 2014, AGING DIS, V5, P226, DOI 10.14336/AD.2014.0500226
   Jafarinasabian P., 2017, INT J WOMENS HLTH, V9, P1
   Kajimura D, 2013, CELL METAB, V17, P901, DOI 10.1016/j.cmet.2013.04.009
   Khan K, 2013, OSTEOPOROSIS INT, V24, P1455, DOI 10.1007/s00198 012 2121 8
   Khan K, 2012, MOL NUTR FOOD RES, V56, P1860, DOI 10.1002/mnfr.201200200
   Khan MP, 2015, DIABETES, V64, P2609, DOI 10.2337/db14 1611
   Kiechl S, 2013, NAT MED, V19, P358, DOI 10.1038/nm.3084
   Kim HY, 2012, EXP MOL MED, V44, P394, DOI 10.3858/emm.2012.44.6.045
   Komarova SV, 2000, AM J PHYSIOL CELL PH, V279, pC1220, DOI 10.1152/ajpcell.2000.279.4.C1220
   Lecka Czernik B, 2015, J BONE MINER RES, V30, P1356, DOI 10.1002/jbmr.2574
   Leupin O, 2007, J BONE MINER RES, V22, P1957, DOI 10.1359/JBMR.070804
   Lin YY, 2014, BONE, V64, P147, DOI 10.1016/j.bone.2014.03.051
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Mitsui Y., 2011, BMC MUSCULOSKEL DIS, V12, P1471
   Naot D, 2016, ENDOCRINOLOGY, V157, P3550, DOI 10.1210/en.2016 1059
   NICHOLS FC, 1987, BONE, V8, P105, DOI 10.1016/8756 3282(87)90078 0
   Ormsbee MJ, 2014, J CACHEXIA SARCOPENI, V5, P183, DOI 10.1007/s13539 014 0146 x
   Oshima K, 2005, BIOCHEM BIOPH RES CO, V331, P520, DOI 10.1016/j.bbrc.2005.03.210
   Piemonte S, 2012, J ENDOCRINOL INVEST, V35, P866, DOI 10.3275/8522
   Porwal K, 2017, J NUTR BIOCHEM, V44, P22, DOI 10.1016/j.jnutbio.2017.02.011
   Ravn P, 1999, J BONE MINER RES, V14, P1622, DOI 10.1359/jbmr.1999.14.9.1622
   Richards JB, 2007, J CLIN ENDOCR METAB, V92, P1517, DOI 10.1210/jc.2006 2097
   Ruan H, 2016, J MOL CELL BIOL, V8, P101, DOI 10.1093/jmcb/mjw014
   Rudman KE, 2006, BIOMED ENG ONLINE, V5, DOI 10.1186/1475 925X 5 12
   Sharan K, 2011, J BONE MINER RES, V26, P2096, DOI 10.1002/jbmr.434
   Shinoda Y, 2006, J CELL BIOCHEM, V99, P196, DOI 10.1002/jcb.20890
   Singh AK, 2017, MOL CELL ENDOCRINOL, V439, P273, DOI 10.1016/j.mce.2016.09.013
   Singh AK, 2014, DIABETES, V63, P3530, DOI 10.2337/db13 1619
   Srivastava K, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/519387
   Tohidi M, 2012, BONE, V51, P876, DOI 10.1016/j.bone.2012.08.117
   Tsai JN, 2013, LANCET, V382, P50, DOI 10.1016/S0140 6736(13)60856 9
   Tu QS, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.152405
   Wang F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068497
   Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705
   Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244
NR 50
TC 43
Z9 45
U1 0
U2 30
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD DEC
PY 2017
VL 105
BP 75
EP 86
DI 10.1016/j.bone.2017.08.005
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA FL1SK
UT WOS:000413994500010
PM 28811200
OA Bronze
DA 2025 08 17
ER

PT J
AU Marx, RE
   Tursun, R
AF Marx, R. E.
   Tursun, R.
TI Suppurative osteomyelitis, bisphosphonate induced osteonecrosis,
   osteoradionecrosis: a blinded histopathologic comparison and its
   implications for the mechanism of each disease
SO INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
LA English
DT Article
DE bisphosphonates; osteomyelitis; osteonecrosis; osteoradionecrosis
AB Statistically, significant numbers of central bone specimens of suppurative osteomyelitis of the jaws (SOJ), bisphosphonate induced osteonecrosis of the jaws (BIONJ), and osteoradionecrosis of the jaws (ORNJ) were compared. All three evidenced the common finding of necrotic bone with empty osteocytic lacunae, Haversian and Volkmann canals, but each showed a distinctive histopathologic pattern indicating a different disease mechanism and treatment options. Suppurative osteomyelitis was characterized by intense marrow inflammation and marrow vessel thrombosis with retention of viable osteoclasts and periosteum. Bisphosphonate induced osteonecrosis was characterized by an empty marrow space with empty Howship's lacunae and an absence of osteoclasts but viable periosteum. Osteoradionecrosis was characterized by a collagenous hypocellular, hypovascular marrow space and nonviable periosteum. Histologic evidence in SOJ indicates a microorganism provoked intense inflammation and marrow vascular thrombosis creating an environment conducive to continual bacterial proliferation. BIONJ is seen as a non inflammatory drug toxicity to bone by osteoclastic death leading to over suppression of bone renewal, and ORN as another non inflammatory condition caused by a high linear energy transfer that impairs or kills numerous cell types in the field of radiation including periosteum, bone, and all soft tissue.
C1 [Marx, R. E.; Tursun, R.] Univ Miami, Miller Sch Med, Div Oral & Maxillofacial Surg, Coral Gables, FL 33124 USA.
C3 University of Miami
RP Marx, RE (通讯作者)，Deering Med Plaza,9380 SW 150th St,Suite 170, Miami, FL 33176 USA.
EM mruiz3@med.miami.edu
FU internal University of Miami Division of Oral and Maxillofacial Surgery
FX This study was supported by internal University of Miami Division of
   Oral and Maxillofacial Surgery funds.
CR AAOMS, 2007, J ORAL MAXIL SURG, V65, P369, DOI 10.1016/j.joms.2006.11.003
   Allen MR, 2006, CALCIFIED TISSUE INT, V79, P255, DOI 10.1007/s00223 006 0031 5
   Feher A, 2010, BONE, V46, P203, DOI 10.1016/j.bone.2009.10.023
   Kazuto M, 2009, J IMPLAM RECONSTR DE, V1
   Landesberg R, 2008, J ORAL MAXIL SURG, V66, P839, DOI 10.1016/j.joms.2008.01.026
   Martin TJ., 2000, Aust Prescriber, V23, P130
   MARX RE, 1983, J ORAL MAXIL SURG, V41, P283, DOI 10.1016/0278 2391(83)90294 X
   Rogers MJ, 1999, BONE, V24, p73S, DOI 10.1016/S8756 3282(99)00070 8
   RUBIN P, 1968, CLINICAL RADIATION P, V2, P557
   Russell RGG, 1999, OSTEOPOROSIS INT, V9, P66, DOI 10.1007/PL00004164
   Shah JP, 2003, ORAL CANC, P339
NR 11
TC 98
Z9 104
U1 0
U2 23
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0901 5027
EI 1399 0020
J9 INT J ORAL MAX SURG
JI Int. J. Oral Maxillofac. Surg.
PD MAR
PY 2012
VL 41
IS 3
BP 283
EP 289
DI 10.1016/j.ijom.2011.12.016
PG 7
WC Dentistry, Oral Surgery & Medicine; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine; Surgery
GA 921VL
UT WOS:000302506100001
PM 22244079
DA 2025 08 17
ER

PT J
AU Iram, S
   Kim, CJ
   Hussaini, SS
   Siddiqui, MA
   Khan, MS
   Park, YI
   Hussain, M
AF Iram, Sana
   Kim, Chang Joong
   Hussaini, Syed Sulaiman
   Siddiqui, Mohd Asim
   Khan, Mohd Sajid
   Park, Yong Il
   Hussain, Mushtaq
TI Bromelain facilitated GNPs: A strategic innate anticancer delivery
   system for methotrexate into osteosarcoma cells
SO COLLOIDS AND SURFACES A PHYSICOCHEMICAL AND ENGINEERING ASPECTS
LA English
DT Article
DE Osteosarcoma; Bromelain; Methotrexate; Gold nanoparticles; Targeted
   therapies; Chemotherapy
ID GOLD NANOPARTICLES; BIOMEDICAL APPLICATIONS; MECHANISMS; PATHWAYS; DRUGS
AB Osteosarcoma is the most common malignant bone tumor in children and adolescents during rapid bone growth. Traditional chemotherapy has markedly improved patient outcomes but suffers from nonspecific side effects due to nonspecific drug distribution, highlighting the need for targeted therapies. Methotrexate, although effective, poses toxicity concerns and prompts exploration into advanced drug delivery systems like nanoparticles. Here, we developed a novel method of synthesizing gold nanoparticles using bromelain (G BNPs) as a reducing and capping agent, and we conjugated G BNPs with methotrexate (G B MNPs) via 1 Ethyl 3 (3 dimethylaminopropyl)carbodiimide/N hydroxysuccinimide (EDC/NHS) as crosslinker. Our meticulous characterization, which included UV visible spectroscopy, Transmission electron microscopy (TEM), Dynamic light scattering (DLS), Zeta potential, and Fourier transform infrared spectroscopy (FTIR) analyses confirmed the successful fabrication and drug conjugation of the G BNPs. We then evaluated the cytotoxicity of the G BNPs (sized similar to 21 nm) and G B MNPs (sized similar to 24 nm) on the osteosarcoma cell lines, Saos 2 and MG 63, as well as the noncancerous primary osteoblast cells. Our findings revealed that G B MNPs significantly increased the cytotoxic impact on osteosarcoma cells compared to methotrexate alone while showing minimal toxicity toward primary osteoblast cells. Importantly, using 4`,6 diamidino 2 phenylindole(DAPI), we demonstrated that G B MNPs were delivered directly into the nucleus of the cells without encountering lysosomes. G B MNPs can be considered a potential drug delivery method for osteosarcoma treatment by improving effectiveness and reducing adverse effects, thereby enhancing patient prognosis.
C1 [Iram, Sana] Yeungnam Univ, Dept Med Biotechnol, Gyongsan 38541, South Korea.
   [Kim, Chang Joong; Park, Yong Il] Catholic Univ Korea, Dept Biotechnol, Bucheon 14662, Gyeonggi Do, South Korea.
   [Hussaini, Syed Sulaiman; Siddiqui, Mohd Asim; Hussain, Mushtaq] Univ Technol & Appl Sci, Coll Engn & Technol, Engn Dept, Shinas, Oman.
   [Khan, Mohd Sajid] Integral Univ, Dept Biosci, Nanomed & Nanobiotechnol Lab, Lucknow 226026, India.
C3 Yeungnam University; Catholic University of Korea; Integral University
RP Park, YI (通讯作者)，Catholic Univ Korea, Dept Biotechnol, Bucheon 14662, Gyeonggi Do, South Korea.; Hussain, M (通讯作者)，Univ Technol & Appl Sci, Coll Engn & Technol, Engn Dept, Shinas, Oman.
EM yongil382@catholic.ac.kr; Mushtaq.Hussain@utas.edu.om
RI ; Khan, Mohammad Shahiq/JMP 8399 2023
OI Khan, Mohd Sajid/0000 0002 0883 5200; 
FU Ministry of Higher Education, Research, and Innovation Oman; TRC
   Research Grant [BFP/RGP/EBR/22/227]
FX Dr. Mushtaq Hussain is grateful to the Ministry of Higher Education,
   Research, and Innovation Oman for the financial support. TRC Research
   Grant (TRC Vide No. BFP/RGP/EBR/22/227) .
CR Aminabad NS, 2019, CELL BIOCHEM BIOPHYS, V77, P123, DOI 10.1007/s12013 018 0863 4
   Armaselu A, 2017, FOURIER TRANSFORMS   HIGH TECH APPLICATION AND CURRENT TRENDS, P235, DOI 10.5772/66577
   Bedoui Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205023
   Benmerah A, 2007, TRAFFIC, V8, P970, DOI 10.1111/j.1600 0854.2007.00585.x
   Cao J, 2020, ADV DRUG DELIVER REV, V167, P170, DOI 10.1016/j.addr.2020.06.030
   Carrle D, 2006, INT ORTHOP, V30, P445, DOI 10.1007/s00264 006 0192 x
   Chan ESL, 2010, NAT REV RHEUMATOL, V6, P175, DOI 10.1038/nrrheum.2010.5
   Chen YP, 2017, ACCOUNTS CHEM RES, V50, P310, DOI 10.1021/acs.accounts.6b00506
   Cho Isamu, 2007, Mod Rheumatol, V17, P256, DOI 10.1007/s10165 007 0578 7
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065 2571(84)90007 4
   Drbohlavova J, 2013, CURR DRUG METAB, V14, P547, DOI 10.2174/1389200211314050005
   Dykman LA, 2011, ACTA NATURAE, V3, P34, DOI 10.32607/20758251 2011 3 2 34 56
   Dykman L, 2012, CHEM SOC REV, V41, P2256, DOI 10.1039/c1cs15166e
   Elahi N, 2018, TALANTA, V184, P537, DOI 10.1016/j.talanta.2018.02.088
   Ezhilarasan D, 2021, TOXICOLOGY, V458, DOI 10.1016/j.tox.2021.152840
   Fahelelbom KM, 2022, REV ANAL CHEM, V41, P21, DOI 10.1515/revac 2022 0030
   Gao Y, 2014, BIOTECHNOL ADV, V32, P761, DOI 10.1016/j.biotechadv.2013.10.013
   Gavas S, 2021, NANOSCALE RES LETT, V16, DOI 10.1186/s11671 021 03628 6
   Genestier L, 2000, IMMUNOPHARMACOLOGY, V47, P247, DOI 10.1016/S0162 3109(00)00189 2
   Hamed KM, 2022, CUREUS J MED SCIENCE, V14, DOI 10.7759/cureus.29518
   Hartshorn CM, 2018, ACS NANO, V12, P24, DOI 10.1021/acsnano.7b05108
   Hermanson GT, 2013, BIOCONJUGATE TECHNIQUES, 3RD EDITION, P229, DOI 10.1016/B978 0 12 382239 0.00003 0
   Jiang ZY, 2022, TECHNOL CANCER RES T, V21, DOI 10.1177/15330338221124696
   Joshi P, 2011, J COLLOID INTERF SCI, V355, P402, DOI 10.1016/j.jcis.2010.12.032
   Kasamatsu H, 1998, ANNU REV MICROBIOL, V52, P627, DOI 10.1146/annurev.micro.52.1.627
   Khalil IA, 2006, PHARMACOL REV, V58, P32, DOI 10.1124/pr.58.1.8
   Khan S, 2015, SAUDI J BIOL SCI, V22, P42, DOI 10.1016/j.sjbs.2014.05.009
   Kimura R, 2013, MAR DRUGS, V11, P4267, DOI 10.3390/md11114267
   Klotz LO, 2003, TOXICOL LETT, V140, P125, DOI 10.1016/S0378 4274(02)00511 8
   Klotz LO, 2002, BIOL CHEM, V383, P443, DOI 10.1515/BC.2002.047
   Li SD, 2009, BBA BIOMEMBRANES, V1788, P2259, DOI 10.1016/j.bbamem.2009.06.022
   Liu CG, 2020, INT J NANOMED, V15, P675, DOI 10.2147/IJN.S226186
   Mayor S, 2007, NAT REV MOL CELL BIO, V8, P603, DOI 10.1038/nrm2216
   Mercer J, 2009, NAT CELL BIOL, V11, P510, DOI 10.1038/ncb0509 510
   Oroojalian F, 2020, J CONTROL RELEASE, V321, P442, DOI 10.1016/j.jconrel.2020.02.027
   Pandya N, 2021, GENE REP, V23, DOI 10.1016/j.genrep.2021.101155
   Pecora R, 2000, J NANOPART RES, V2, P123, DOI 10.1023/A:1010067107182
   Picci P, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750 1172 2 6
   Piktel E, 2016, J NANOBIOTECHNOL, V14, DOI 10.1186/s12951 016 0193 x
   Prokop A, 2008, J PHARM SCI US, V97, P3518, DOI 10.1002/jps.21270
   Qi XL, 2016, RSC ADV, V6, P69869, DOI 10.1039/c6ra10716h
   Reed DR, 2017, CANCER AM CANCER SOC, V123, P2206, DOI 10.1002/cncr.30589
   Sabit H, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14081566
   Savitskaya YA, 2012, CLIN SARCOMA RES, V2, DOI 10.1186/2045 3329 2 9
   Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200
   Tian HH, 2007, BULL HOSP JT DIS, V65, P168
   TIMKOVICH R, 1977, ANAL BIOCHEM, V79, P135, DOI 10.1016/0003 2697(77)90387 6
   Tong XQ, 2020, REACT FUNCT POLYM, V148, DOI 10.1016/j.reactfunctpolym.2020.104501
   Zhang S, 2024, PHARMACEUTICS, V16, DOI 10.3390/pharmaceutics16040531
   Zhao X, 2021, BIOMED ENG ONLINE, V20, DOI 10.1186/s12938 021 00860 0
NR 50
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0927 7757
EI 1873 4359
J9 COLLOID SURFACE A
JI Colloid Surf. A Physicochem. Eng. Asp.
PD DEC 5
PY 2024
VL 702
AR 134976
DI 10.1016/j.colsurfa.2024.134976
EA AUG 2024
PN 1
PG 13
WC Chemistry, Physical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA C7P3X
UT WOS:001291251100001
DA 2025 08 17
ER

PT J
AU Hayashi, M
   Morimoto, Y
   Iida, T
   Tanaka, Y
   Sugiyama, S
AF Hayashi, Megumi
   Morimoto, Yoshinari
   Iida, Takatoshi
   Tanaka, Yohei
   Sugiyama, Shuntaro
TI Risk of Delayed Healing of Tooth Extraction Wounds and Osteonecrosis of
   the Jaw among Patients Treated with Potential Immunosuppressive Drugs: A
   Retrospective Cohort Study
SO TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
DE delayed wound healing; eosinophil; immunosuppression; lymphocyte;
   surgical tooth extraction
ID TUMOR NECROSIS FACTOR; CANCER PATIENTS; POSTOPERATIVE COMPLICATIONS;
   CROHNS DISEASE; THERAPY; OSTEOPOROSIS; ASSOCIATION; PREVENTION;
   INFLIXIMAB; DENOSUMAB
AB Bone modifying or antiresorptive agents that target osteoclasts, such as bisphosphonates, are known to cause delayed wound healing and osteonecrosis of the jaw (ONJ) following tooth extraction. However, there are no data on whether such adverse events are also caused by drugs that may suppress the immune system, including corticosteroids, immunosuppressants, biological agents, and disease modifying anti rheumatic drugs (DMARDs). The aim of this retrospective study was to examine the incidence of delayed post extraction wound healing and identify risk factors among patients treated with potential immunosuppressive drugs undergoing tooth extraction. We performed a retrospective cohort study involving 101 patients by reviewing their medical records. The underlying diseases of the enrolled patients included dilated cardiomyopathy, hematological malignancy, sarcoidosis, rheumatoid arthritis, and systemic lupus erythematosus. The sample comprised 131 cases of tooth extraction among the 101 patients; delayed post extraction wound healing occurred in 10 patients (12 cases, 9.2%), including ONJ in three patients (3 cases, 2.3%). The surgical tooth extraction performed for impacted teeth or a residual root (P = 0.009), the number of surgical tooth extraction (P = 0.012), decreased lymphocyte counts (P = 0.008), and decreased eosinophil counts (P = 0.009) were significantly related to delayed wound healing. Thus, among patients taking corticosteroids, immunosuppressants, biological agents, and/or DMARDs, there is a risk of delayed wound healing and ONJ. Moreover, the significant risk factors are low lymphocyte counts, low eosinophil counts, and surgical extraction. It is of particular importance to prevent surgical site infection, when the high risk patients undergo tooth extraction.
C1 [Hayashi, Megumi; Morimoto, Yoshinari; Iida, Takatoshi; Tanaka, Yohei; Sugiyama, Shuntaro] Kanagawa Dent Univ, Grad Sch Dent, Dept Crit Care Med & Dent, 82 Inaoka Cho, Yokosuka, Kanagawa 2388580, Japan.
   [Hayashi, Megumi; Morimoto, Yoshinari] Kyushu Univ Hosp, Special Patient Oral Care Unit, Fukuoka, Fukuoka, Japan.
   [Morimoto, Yoshinari] Natl Cerebral & Cardiovasc Ctr, Dept Dent, Suita, Osaka, Japan.
C3 Kanagawa Dental College; Kyushu University; National Cerebral &
   Cardiovascular Center   Japan
RP Morimoto, Y (通讯作者)，Kanagawa Dent Univ, Grad Sch Dent, Dept Crit Care Med & Dent, 82 Inaoka Cho, Yokosuka, Kanagawa 2388580, Japan.
EM morimoto@kdu.ac.jp
CR [Anonymous], Guidelines for the prevention and treatment of infective endocarditis (JCS2008)
   Bibbo C, 2004, FOOT ANKLE INT, V25, P331, DOI 10.1177/107110070402500510
   Cavalli RC, 2014, ACTA CIR BRAS, V29, P508, DOI 10.1590/S0102 86502014000800005
   Colombel JF, 2004, AM J GASTROENTEROL, V99, P878, DOI 10.1111/j.1572 0241.2004.04148.x
   den Broeder AA, 2007, J RHEUMATOL, V34, P689
   Epstein MS, 2013, OR SURG OR MED OR PA, V116, pE437, DOI 10.1016/j.oooo.2012.01.046
   Guilbeau JM, 2002, ANN PHARMACOTHER, V36, P1391
   Hellstein JW, 2011, J AM DENT ASSOC, V142, P1243, DOI 10.14219/jada.archive.2011.0108
   Huang YF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120756
   Jacobsen EA, 2012, BLOOD, V120, P3882, DOI 10.1182/blood 2012 06 330845
   Kajizono M, 2015, BIOL PHARM BULL, V38, P1850, DOI 10.1248/bpb.b15 00385
   Katsarelis H, 2015, J DENT RES, V94, P534, DOI 10.1177/0022034515572021
   Keen D, 2008, J Wound Care, V17, P218
   Kos M, 2010, INT J ORAL MAX SURG, V39, P1097, DOI 10.1016/j.ijom.2010.04.054
   Kos M, 2015, ARCH MED SCI, V11, P319, DOI 10.5114/aoms.2015.50964
   Lekamwasam S, 2012, OSTEOPOROSIS INT, V23, P2257, DOI 10.1007/s00198 012 1958 1
   Marchal L, 2004, ALIMENT PHARM THER, V19, P749, DOI 10.1111/j.1365 2036.2004.01904.x
   MOONEY DP, 1990, ANN SURG, V211, P124, DOI 10.1097/00000658 199002000 00002
   Petri JB, 1998, EUR J DERMATOL, V8, P104
   Pountos I, 2017, EXPERT OPIN DRUG SAF, V16, P535, DOI 10.1080/14740338.2017.1310839
   Qi WX, 2014, INT J CLIN ONCOL, V19, P403, DOI 10.1007/s10147 013 0561 6
   Radfar L, 2015, OR SURG OR MED OR PA, V120, P594, DOI 10.1016/j.oooo.2015.07.032
   Rapala KT, 1996, EXPERIENTIA, V52, P70, DOI 10.1007/BF01922419
   Rosman Z, 2013, BMC MED, V11, DOI 10.1186/1741 7015 11 88
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Saad F, 2012, ANN ONCOL, V23, P1341, DOI 10.1093/annonc/mdr435
   SALOMON GD, 1991, ANN SURG, V214, P175, DOI 10.1097/00000658 199108000 00012
   Schäffer M, 1998, BJS BRIT J SURG, V85, P444
   Tardast A, 2015, J APPL ORAL SCI, V23, P310, DOI 10.1590/1678 775720140506
   Troeltzsch M, 2012, J CAN DENT ASSOC, V78
   Weinstein RS, 2012, ENDOCRIN METAB CLIN, V41, P595, DOI 10.1016/j.ecl.2012.04.004
   Weinstein RS, 2012, ENDOCRINE, V41, P183, DOI 10.1007/s12020 011 9580 0
NR 32
TC 21
Z9 22
U1 1
U2 6
PU TOHOKU UNIV MEDICAL PRESS
PI SENDAI
PA 2 1, SEIRYO MACHI, AOBA KU, SENDAI, MIYAGI 980 8575, JAPAN
SN 0040 8727
EI 1349 3329
J9 TOHOKU J EXP MED
JI Tohoku J. Exp. Med.
PD DEC
PY 2018
VL 246
IS 4
BP 257
EP 264
DI 10.1620/tjem.246.257
PG 8
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA HG0YT
UT WOS:000454675900008
PM 30568073
OA gold
DA 2025 08 17
ER

PT J
AU Ihn, HJ
   Kim, YS
   Lim, S
   Bae, JS
   Jung, JC
   Kim, YH
   Park, JW
   Wang, Z
   Koh, JT
   Bae, YC
   Baek, MC
   Park, EK
AF Ihn, Hye Jung
   Kim, Yi Seul
   Lim, Soomin
   Bae, Jong Sup
   Jung, Jae Chang
   Kim, Yeo Hyang
   Park, Jin Woo
   Wang, Zhao
   Koh, Jeong Tae
   Bae, Yong Chul
   Baek, Moon Chang
   Park, Eui Kyun
TI PF 3845, a Fatty Acid Amide Hydrolase Inhibitor, Directly Suppresses
   Osteoclastogenesis through ERK and NF κB Pathways In Vitro and Alveolar
   Bone Loss In Vivo
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE PF 3845; osteoclastogenesis; bone resorption; alveolar bone loss; ERK
AB Alveolar bone loss, the major feature of periodontitis, results from the activation of osteoclasts, which can consequently cause teeth to become loose and fall out; the development of drugs capable of suppressing excessive osteoclast differentiation and function is beneficial for periodontal disease patients. Given the difficulties associated with drug discovery, drug repurposing is an efficient approach for identifying alternative uses of commercially available compounds. Here, we examined the effects of PF 3845, a selective fatty acid amide hydrolase (FAAH) inhibitor, on receptor activator of nuclear factor kappa B ligand (RANKL) mediated osteoclastogenesis, its function, and the therapeutic potential for the treatment of alveolar bone destruction in experimental periodontitis. PF 3845 significantly suppressed osteoclast differentiation and decreased the induction of nuclear factor of activated T cells cytoplasmic 1 (NFATc1) and the expression of osteoclast specific markers. Actin ring formation and osteoclastic bone resorption were also reduced by PF 3845, and the anti osteoclastogenic and anti resorptive activities were mediated by the suppression of phosphorylation of rapidly accelerated fibrosarcoma (RAF), mitogen activated protein kinase (MEK), extracellular signal regulated kinase, (ERK) and nuclear factor kappa B (NF kappa B) inhibitor (I kappa B alpha). Furthermore, the administration of PF 3845 decreased the number of osteoclasts and the amount of alveolar bone destruction caused by ligature placement in experimental periodontitis in vivo. The present study provides evidence that PF 3845 is able to suppress osteoclastogenesis and prevent alveolar bone loss, and may give new insights into its role as a treatment for osteoclast related diseases.
C1 [Ihn, Hye Jung] Kyungpook Natl Univ, Cell & Matrix Res Inst, Daegu 41944, South Korea.
   [Kim, Yi Seul; Lim, Soomin; Park, Eui Kyun] Kyungpook Natl Univ, Sch Dent, Dept Oral Pathol & Regenerat Med, IHBR, Daegu 41940, South Korea.
   [Bae, Jong Sup] Kyungpook Natl Univ, Pharmaceut Sci Res Inst, Coll Pharm, CMRI, Daegu 41566, South Korea.
   [Jung, Jae Chang] Kyungpook Natl Univ, Dept Biol, Coll Nat Sci, Daegu 41566, South Korea.
   [Kim, Yeo Hyang] Kyungpook Natl Univ, Sch Med, Dept Pediat, Daegu 41944, South Korea.
   [Park, Jin Woo] Kyungpook Natl Univ, Sch Dent, Dept Periodontol, Daegu 41940, South Korea.
   [Wang, Zhao; Koh, Jeong Tae] Chonnam Natl Univ, Sch Dent, Dept Pharmacol & Dent Therapeut, Gwangju 61186, South Korea.
   [Bae, Yong Chul] Kyungpook Natl Univ, Sch Dent, Dept Oral Anat & Neurobiol, Daegu 41940, South Korea.
   [Baek, Moon Chang] Kyungpook Natl Univ, Sch Med, Dept Mol Med, CMRI, Daegu 41944, South Korea.
C3 Kyungpook National University (KNU); Kyungpook National University
   (KNU); Kyungpook National University (KNU); Kyungpook National
   University (KNU); Kyungpook National University (KNU); Kyungpook
   National University (KNU); Chonnam National University; Kyungpook
   National University (KNU); Kyungpook National University (KNU)
RP Park, EK (通讯作者)，Kyungpook Natl Univ, Sch Dent, Dept Oral Pathol & Regenerat Med, IHBR, Daegu 41940, South Korea.; Baek, MC (通讯作者)，Kyungpook Natl Univ, Sch Med, Dept Mol Med, CMRI, Daegu 41944, South Korea.
EM hjpihn@hanmail.net; ekdms121212@naver.com; friendship1240@hanmail.net;
   baejs@knu.ac.kr; jcjung@knu.ac.kr; kimhmd@knu.ac.kr; jinwoo@knu.ac.kr;
   htwz1996@163.com; jtkoh@chonnam.ac.kr; ycbae@knu.ac.kr;
   mcbaek@knu.ac.kr; epark@knu.ac.kr
RI Bae, Jong Sup/AAU 9724 2020
FU National Research Foundation of Korea (NRF)   Korean government (MSIT)
   [2017R1A5A2015391, 2017M3A9E4047244]; NRF   Ministry of Education
   [2020R1I1A1A01054145]
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korean government (MSIT) (2017R1A5A2015391,
   2017M3A9E4047244) and Basic Science Research Program through the NRF
   funded by the Ministry of Education (2020R1I1A1A01054145).
CR Abe T, 2013, J IMMUNOL METHODS, V394, P49, DOI 10.1016/j.jim.2013.05.002
   Ashburn TT, 2004, NAT REV DRUG DISCOV, V3, P673, DOI 10.1038/nrd1468
   Bedse G, 2018, TRANSL PSYCHIAT, V8, DOI 10.1038/s41398 018 0141 7
   Booker L, 2012, BRIT J PHARMACOL, V165, P2485, DOI 10.1111/j.1476 5381.2011.01445.x
   Chen HJC, 2018, INT J NEUROPSYCHOPH, V21, P786, DOI 10.1093/ijnp/pyy033
   Feng X, 2013, BONE RES, V1, DOI 10.4248/BR201301003
   Graves DT, 2008, J CLIN PERIODONTOL, V35, P89, DOI 10.1111/j.1600 051X.2007.01172.x
   He YZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024780
   Henriksen K, 2006, J BONE MINER RES, V21, P58, DOI 10.1359/JBMR.050905
   Hienz SA, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/615486
   Idris AI, 2005, NAT MED, V11, P774, DOI 10.1038/nm1255
   Idris Aymen I, 2012, Front Endocrinol (Lausanne), V3, P136, DOI 10.3389/fendo.2012.00136
   Ihn HJ, 2019, TISSUE ENG REGEN MED, V16, P265, DOI 10.1007/s13770 019 00186 y
   Ihn HJ, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00367
   Ihn HJ, 2018, TOXICOL APPL PHARM, V355, P9, DOI 10.1016/j.taap.2018.06.017
   Ihn HJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170159
   Irfan U M, 2001, J Int Acad Periodontol, V3, P14
   Miyamoto Takeshi, 2006, Mod Rheumatol, V16, P341
   Ofek O, 2006, P NATL ACAD SCI USA, V103, P696, DOI 10.1073/pnas.0504187103
   Oikawa T, 2013, CELL MOL LIFE SCI, V70, P3341, DOI 10.1007/s00018 012 1238 4
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   Papapanou P N, 1996, Ann Periodontol, V1, P1, DOI 10.1902/annals.1996.1.1.1
   Qin X, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00922
   Rossi F, 2009, BONE, V44, P476, DOI 10.1016/j.bone.2008.10.056
   Salaga M, 2014, J CROHNS COLITIS, V8, P998, DOI 10.1016/j.crohns.2014.01.025
   Seo SW, 2010, BONE, V46, P695, DOI 10.1016/j.bone.2009.10.032
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tchantchou F, 2014, NEUROPHARMACOLOGY, V85, P427, DOI 10.1016/j.neuropharm.2014.06.006
   Wasilewski A, 2017, ACTA BIOCHIM POL, V64, P519, DOI 10.18388/abp.2017_1520
   Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   Yan JC, 2008, HUM MOL GENET, V17, P936, DOI 10.1093/hmg/ddm366
   Yoon JY, 2018, TISSUE ENG REGEN MED, V15, P333, DOI 10.1007/s13770 018 0116 z
NR 34
TC 9
Z9 11
U1 0
U2 9
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD FEB
PY 2021
VL 22
IS 4
AR 1915
DI 10.3390/ijms22041915
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA QP5CZ
UT WOS:000623855300001
PM 33671948
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Deng, CN
   Xu, L
   Zhang, Y
   Zhao, LN
   Yan, LH
   Yu, YN
AF Deng, Chaonan
   Xu, Lin
   Zhang, Ying
   Zhao, Lina
   Yan Linghu
   Yu, Yanni
TI The value of the hedgehog signal in osteoblasts in fluoride induced
   bone tissue injury
SO JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH
LA English
DT Article
DE Osteoblasts; Hh signal; Fluorosis; Bone tissue injury; Skeletal
   fluorosis
AB ObjectiveThis study was designed to observe the expression of important hedgehog (Hh) signal factors in the bone tissue of rats with chronic fluorosis and cultured osteoblasts in order to investigate the role and significance of the Hh signal in fluoride induced bone injury.MethodsHealthy Sprague Dawley (SD) rats were randomly divided into four groups: the control group, the fluorosis group (F Group), the fluoride + blocker group (F + Cycl group: rats were treated with fluoride + cyclopamine), and the fluoride + blocker control group (F + DMSO group). After 6 months of intervention, the urinary fluoride content of rats in each group was detected. The primary osteoblasts of rats were selected for cell experiment, and the experiment was carried out after the cells were passaged from the second to the fourth generation.ResultsThe proliferation rate of primary rat osteoblasts presented time affected and dose affected relationships in a short time under treatment with a low dose of sodium fluoride (NaF), but the proliferation of osteoblasts was inhibited by long term and high dose NaF exposure. In the F group, the alkaline phosphatase (ALP) activity of osteoblasts increased gradually. The ALP activity was lower in the F + Cycl group than in the F group, and there was no significant difference between the F + DMSO group and F group. With the increase in fluoride exposure, the expression of Hh signal factors and osteogenic related factor proteins increased gradually. The expressions of Indian hedgehog (Ihh), smoothened (Smo), Glioma associated oncogene homolog (Gli) 2, and Runt related transcription factor 2 (Runx2)in the F + Cycl group increased with the dose of fluoride but they were significantly inhibited compared with the F group. Compared with the control group, the content of urinary fluoride in the F group was significantly higher (P < 0.05), but there was no significant change in urinary fluoride content in the F + Cycl group and the F + DMSO group. Compared with the control group, the serum bone alkaline phosphatase (BALP) contents of rats in the other groups increased after 6 months' intake of fluoride water (P < 0.05). After drug blocking, the serum BALP content in the F + Cycl group was lower than that in the F + DMSO group (P < 0.05). The BALP content in the F + DMSO group was similar to that in the F group: it did not decrease. The mRNA expressions of Ihh, Smo, Gli2, and Runx2 in bone tissue of the F group were significantly higher than those in the control group (P < 0.05). After cyclopamine blocking, the expressions decreased (P < 0.05), but the differences between the F + DMSO group and F group were not statistically significant.ConclusionHh signal plays an important role in fluoride induced bone injury. The effective inhibition of cyclopamine is expected to be a new target for the treatment of skeletal damage caused by fluorosis.
C1 [Deng, Chaonan; Xu, Lin; Zhang, Ying; Zhao, Lina; Yu, Yanni] GuiZhou Med Univ, Affiliated Hosp, Dept Pathol, 28 Guiyi St, Guiyang 550004, Peoples R China.
   [Deng, Chaonan; Yan Linghu; Yu, Yanni] GuiZhou Med Univ, Dept Pathol, Guiyang 550004, Peoples R China.
   [Xu, Lin; Zhang, Ying] Guiyang Maternal & Child Care Hosp, Guiyang 550004, Peoples R China.
C3 Guizhou Medical University; Guizhou Medical University
RP Yu, YN (通讯作者)，GuiZhou Med Univ, Affiliated Hosp, Dept Pathol, 28 Guiyi St, Guiyang 550004, Peoples R China.; Yu, YN (通讯作者)，GuiZhou Med Univ, Dept Pathol, Guiyang 550004, Peoples R China.
EM yuyanni_87459@163.com
RI Zhao, Lina/GVR 7716 2022; Liu, Ziyang/ABF 3794 2021
FU National Nutural Science Foundation of China [U1812403, 81260419]; The
   Ministry of Education of Doctoral Fund (class tutors) in China
   [20125215110001]; Guizhou Province Science and Technology Cooperation
   Program Project [[2017]7192]; Guizhou Provincial Natural Science
   Foundation [[2018]1135]; Guizhou Medical University 2018 Academic New
   Seedling Cultivation and Innovative Exploration Special Project
   [[2018]5779 37]; Guizhou Provincial Graduate Research Fund
   [KYJJ2017010]; Doctoral Initiates Foundation of Guiyang Medical College
   [[2014]013]
FX The National Nutural Science Foundation of China (U1812403); The
   National Nutural Science Foundation of China (81260419); The Ministry of
   Education of Doctoral Fund (class tutors) in China (20125215110001);
   Guizhou Province Science and Technology Cooperation Program Project
   ([2017]7192); Guizhou Provincial Natural Science Foundation
   ([2018]1135); Guizhou Medical University 2018 Academic New Seedling
   Cultivation and Innovative Exploration Special Project ([2018]5779 37);
   Guizhou Provincial Graduate Research Fund (KYJJ2017010); Doctoral
   Initiates Foundation of Guiyang Medical College ([2014]013).
CR Bechtold TE, 2016, MATRIX BIOL, V52 54, P339, DOI 10.1016/j.matbio.2016.03.001
   Cai HC, 2016, P NATL ACAD SCI USA, V113, P14751, DOI 10.1073/pnas.1612520114
   Cai XY, 2015, ONCOTARGETS THER, V8, DOI 10.2147/OTT.S71034
   CHAMBERS TJ, 1991, VITAM HORM, V46, P41
   Deng A, 2018, EXP THER MED, V15, P789, DOI 10.3892/etm.2017.5458
   Gao L, 2018, AM J TRANSL RES, V10, P315
   Garcia Gonzalo FR, 2015, DEV CELL, V34, P400, DOI 10.1016/j.devcel.2015.08.001
   Hirotsu M, 2010, MOL CANCER, V9, DOI 10.1186/1476 4598 9 5
   Idon Paul Ikhodaro, 2018, Eur J Dent, V12, P184, DOI 10.4103/ejd.ejd_260_17
   Komori T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071694
   Lozito TP, 2015, DEV BIOL, V399, P249, DOI 10.1016/j.ydbio.2014.12.036
   Mak KK, 2008, DEV CELL, V14, P674, DOI 10.1016/j.devcel.2008.02.003
   Qin X, 2019, HUM MOL GENET, V28, P896, DOI 10.1093/hmg/ddy386
   Ruiz Heiland G, 2012, ANN RHEUM DIS, V71, P400, DOI 10.1136/ard.2010.148262
   Sanchez P, 2005, MECH DEVELOP, V122, P223, DOI 10.1016/j.mod.2004.10.002
   Shimoyama A, 2007, MOL BIOL CELL, V18, P2411, DOI 10.1091/mbc.E06 08 0743
   Varjosalo M, 2008, GENE DEV, V22, P2454, DOI 10.1101/gad.1693608
   Yang J, 2015, INT J ORAL SCI, V7, P73, DOI 10.1038/ijos.2015.14
   Zhao LN, 2014, TOXICOL LETT, V225, P318, DOI 10.1016/j.toxlet.2013.12.022
NR 19
TC 4
Z9 6
U1 1
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749 799X
J9 J ORTHOP SURG RES
JI J. Orthop. Surg. Res.
PD FEB 26
PY 2021
VL 16
IS 1
AR 160
DI 10.1186/s13018 021 02287 8
PG 10
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA QQ5HL
UT WOS:000624554000001
PM 33637095
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Qi, BC
   Guo, MZ
   Shi, XW
   Li, MJ
   Wu, YP
   Wang, Y
   Lv, Q
   Fan, XY
   Li, C
   Xu, YQ
AF Qi, Baochuang
   Guo, Minzheng
   Shi, Xiangwen
   Li, Mingjun
   Wu, Yipeng
   Wang, Yi
   Lv, Qian
   Fan, Xinyu
   Li, Chuan
   Xu, Yongqing
TI A Network Pharmacology Approach and Validation Experiments to
   Investigate the Mechanism of Wen Dan Decoction in the Treatment of SINFH
SO COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING
LA English
DT Article
DE Wen dan decoction; steroid induced necrosis of the femoral head; network
   pharmacology; traditional Chinese medicine; target identification; GO
ID WNT/BETA CATENIN PATHWAYS; FEMORAL HEAD; OSTEOBLAST DIFFERENTIATION;
   OSTEONECROSIS; QUERCITRIN; QUERCETIN; RUNX2
AB Introduction Steroid induced necrosis of the femoral head (SINFH) is a femoral head necrotic disease caused by prolonged use of hormones. Wen Dan decoction is used in Chinese clinical practice for the treatment of steroid induced necrosis of the femoral head (SINFH). However, the mechanism and active compounds of Wen Dan decoction used to treat SINFH are not well understood.Objectives We studied the mechanism of action of Wen Dan decoction in treating steroid induced necrosis of the femoral head (SINFH) via network pharmacology and in vivo experiments.Methods The active compounds of Wen Dan decoction and SINFH related target genes were identified through public databases. Then, network pharmacological analysis was conducted to explore the potential key active compounds, core targets and biological processes of Wen Dan decoction in SINFH. The potential mechanisms of Wen Dan decoction in SINFH obtained by network pharmacology were validated through in vivo experiments.Results We identified 608 DEGs (differentially expressed genes) (230 upregulated, 378 downregulated) in SINFH. GO analysis revealed that the SINFH related genes were mainly involved in neutrophil activation and the immune response. KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway analysis showed that the SINFH related genes were mainly associated with cytokine receptor interactions, lipids, atherosclerosis, and tuberculosis. We identified 147 active ingredients of Wen Dan decoction; the core ingredient was quercetin, and licorice was an active ingredient. Moreover, 277 target genes in the treatment of SINFH with Wen Dan decoction were identified, and NCF1, PTGS2, and RUNX2 were selected as core target genes. QRT PCR of peripheral blood from SINFH patients showed higher levels of PGTS2 and NCF1 and showed lower levels of RUNX2 compared to controls. QRT PCR analysis of peripheral blood and femoral bone tissue from a mouse model of SINFH showed higher levels of PGTS2 and NCF1 and lower levels of RUNX2 in the experimental animals than the controls, which was consistent with the bioinformatics results. HE, immunohistochemistry, and TUNEL staining confirmed a significant reduction in hormone induced femoral head necrosis in the quercetin treated mice. HE, immunohistochemistry, and TUNEL staining confirmed significant improvement in hormone induced femoral head necrosis in the quercetin treated mice.Conclusion We provide new insights into the genes and related pathways involved in SINFH and report that PTGS2, RUNX2, and NCF1 are potential drug targets. Quercetin improved SINFH by promoting osteogenesis and inhibiting apoptosis.
C1 [Qi, Baochuang; Guo, Minzheng; Shi, Xiangwen; Li, Mingjun] Kunming Med Univ, Grad Sch, Kunming 650500, Yunnan, Peoples R China.
   [Qi, Baochuang; Guo, Minzheng; Wu, Yipeng; Wang, Yi; Lv, Qian; Fan, Xinyu; Li, Chuan; Xu, Yongqing] 920th Hosp Joint Logist Support Force Chinese Peop, Dept Orthoped, Kunming 650032, Yunnan, Peoples R China.
C3 Kunming Medical University
RP Li, C; Xu, YQ (通讯作者)，920th Hosp Joint Logist Support Force Chinese Peop, Dept Orthoped, Kunming 650032, Yunnan, Peoples R China.
EM xuyongqing1962@126.com; lichuankaka@163.com
RI Fan, Xiulin/AAJ 9893 2020; Shi, Xiangwen/GSD 5770 2022; Wu,
   Yipeng/X 4984 2018
FU Yunnan Orthopedic Trauma Clinical Medical Center [ZX20191001]; Yunnan
   Orthopedics and Sports Rehabilitation Clinical Medicine Research Center
   [202102AA310068]
FX This work was supported by Yunnan Orthopedic Trauma Clinical Medical
   Center (No. ZX20191001) and Yunnan Orthopedics and Sports Rehabilitation
   Clinical Medicine Research Center (No. 202102AA310068 ).
CR Amevor FK, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.860889
   Arbab D, 2016, DTSCH ARZTEBL INT, V113, P31, DOI 10.3238/arztebl.2016.0031
   Chou LY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197210
   Cohen Rosenblum A, 2019, ORTHOP CLIN N AM, V50, P139, DOI 10.1016/j.ocl.2018.10.001
   Cui QJ, 2021, J KOREAN MED SCI, V36, DOI 10.3346/jkms.2021.36.e65
   Fang Yanyan, 2022, Evid Based Complement Alternat Med, V2022, P5382607, DOI 10.1155/2022/5382607
   Feng WW, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000014159
   Gong Z, 2023, SCI IMMUNOL, V8, DOI 10.1126/sciimmunol.add5204
   Gong Z, 2022, IMMUNITY, V55, P1483, DOI 10.1016/j.immuni.2022.07.001
   Guo C, 2017, CELL PHYSIOL BIOCHEM, V43, P1547, DOI 10.1159/000481978
   Guo HL, 2021, J ADV RES, V28, P255, DOI 10.1016/j.jare.2020.06.020
   Ikeuchi K, 2015, MOD RHEUMATOL, V25, P278, DOI 10.3109/14397595.2014.932038
   Ito K, 2013, CPT PHARMACOMET SYST, V2, DOI 10.1038/psp.2013.56
   Jiang X, 2021, CYTOKINE, V143, DOI 10.1016/j.cyto.2021.155512
   Jin SY, 2020, J ORTHOP RES, V38, P2020, DOI 10.1002/jor.24619
   Jin Z, 2020, INT IMMUNOPHARMACOL, V78, DOI 10.1016/j.intimp.2019.105946
   Lan DM, 2022, J MOL ENDOCRINOL, V69, P401, DOI 10.1530/JME 22 0086
   Lan TH, 2018, EVID BASED COMPL ALT, V2018, DOI 10.1155/2018/5170854
   Lesjak M, 2018, J FUNCT FOODS, V40, P68, DOI 10.1016/j.jff.2017.10.047
   Li JH, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.649285
   Li MY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.783944
   Li QJ, 2022, CELL MOL LIFE SCI, V79, DOI 10.1007/s00018 022 04501 0
   Li Z.Y., Clinical Study of Manipulation Combined with Wen dan Decoction in the Treatment of Steroid Induced Femur Head Necrosis (Bone Ero sion Phlegm Dampness Syndrome), DOI [10.26980/d.cnki.gcczc.2021.000265, DOI 10.26980/D.CNKI.GCCZC.2021.000265]
   Li ZC, 2023, PHARMACOL RES, V187, DOI 10.1016/j.phrs.2022.106635
   Liu F, 2017, J RES MED SCI, V22, DOI 10.4103/1735 1995.200273
   Petek D, 2019, EFORT OPEN REV, V4, P85, DOI 10.1302/2058 5241.4.180036
   Qin X, 2021, J BONE MINER RES, V36, P2081, DOI 10.1002/jbmr.4386
   Satue M, 2013, BIOCHEM PHARMACOL, V86, P1476, DOI 10.1016/j.bcp.2013.09.009
   Seamon J, 2012, ARTHRITIS, DOI 10.1155/2012/601763
   Song Q, 2022, INJURY, V53, P1361, DOI 10.1016/j.injury.2021.12.056
   Song Y, 2017, BONE, V101, P104, DOI 10.1016/j.bone.2017.05.002
   Sun F, 2022, BIOCHEM BIOPH RES CO, V602, P149, DOI 10.1016/j.bbrc.2022.02.112
   Takahata Y, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003 021 02717 7
   Tian HL, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010781
   Vardhan H, 2018, INDIAN J ORTHOP, V52, P140, DOI 10.4103/ortho.IJOrtho_292_16
   Wang A, 2018, GENE, V671, P103, DOI 10.1016/j.gene.2018.05.091
   Wong SK, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176448
   Xing L, 2021, Nan Fang Yi Ke Da Xue Xue Bao, V41, P1394, DOI 10.12122/j.issn.1673 4254.2021.09.15
   Yang C, 2023, PHYTOMEDICINE, V110, DOI 10.1016/j.phymed.2022.154629
   Yu T, 2016, COMPLEMENT THER MED, V29, P89, DOI 10.1016/j.ctim.2016.09.010
   Yu Tong, 2016, Zhongguo Zhong Xi Yi Jie He Za Zhi, V36, P659
   Zeng JC, 2018, MOL MED REP, V17, P2121, DOI 10.3892/mmr.2017.8119
   Zhang C, 2022, MOL CANCER THER, V21, P347, DOI 10.1158/1535 7163.MCT 21 0310
   Zhang GH, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906 016 1030 3
   Zhang J, 2022, DIS MARKERS, V2022, DOI 10.1155/2022/2639470
   Zhang QY, 2018, CHINESE MED J PEKING, V131, P2589, DOI 10.4103/0366 6999.244111
   Zhang XY, 2021, SAUDI PHARM J, V29, P1405, DOI 10.1016/j.jsps.2021.10.009
   Zhang YF, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.1039611
   Zhu L, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935 021 01821 2
NR 49
TC 0
Z9 0
U1 2
U2 8
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1386 2073
EI 1875 5402
J9 COMB CHEM HIGH T SCR
JI Comb. Chem. High Throughput Screen
PY 2024
VL 27
IS 11
BP 1576
EP 1591
DI 10.2174/0113862073266310231026070703
PG 16
WC Biochemical Research Methods; Chemistry, Applied; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy
GA RW7R6
UT WOS:001230767200009
PM 38783679
DA 2025 08 17
ER

PT J
AU McClung, MR
   Bolognese, MA
   Brown, JP
   Reginster, JY
   Langdahl, BL
   Maddox, J
   Shi, Y
   Rojeski, M
   Meisner, PD
   Grauer, A
AF McClung, M. R.
   Bolognese, M. A.
   Brown, J. P.
   Reginster, J Y
   Langdahl, B. L.
   Maddox, J.
   Shi, Y.
   Rojeski, M.
   Meisner, P. D.
   Grauer, A.
TI A single dose of zoledronate preserves bone mineral density for up to 2
   years after a second course of romosozumab
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Antiresorptive; Bone mineral density; Follow on regimen; Osteoporosis;
   Romosozumab
ID POSTMENOPAUSAL WOMEN; SCLEROSTIN ANTIBODY; PARATHYROID HORMONE;
   DOUBLE BLIND; DENOSUMAB; OSTEOPOROSIS; TERIPARATIDE; ALENDRONATE;
   PREVENTION; REDUCTION
AB This phase 2 study evaluated the efficacy and safety of transitioning to zoledronate following romosozumab treatment in postmenopausal women with low bone mass. A single dose of 5 mg zoledronate generally maintained the robust BMD gains accrued with romosozumab treatment and was well tolerated. Introduction Follow on therapy with an antiresorptive agent is necessary to maintain the skeletal benefits of romosozumab therapy. We evaluated the use of zoledronate following romosozumab treatment. Methods This phase 2, dose finding study enrolled postmenopausal women with low bone mineral density (BMD). Subjects who received various romosozumab doses or placebo from months 0 24 were rerandomized to denosumab (60 mg SC Q6M) or placebo for 12 months, followed by open label romosozumab (210 mg QM) for 12 months. At month 48, subjects who had received active treatment for 48 months were assigned to no further active treatment and all other subjects were assigned to zoledronate 5 mg IV. Efficacy (BMD, P1NP, and beta CTX) and safety were evaluated for 24 months, up to month 72. Results A total of 141 subjects entered the month 48 72 period, with 51 in the no further active treatment group and 90 in the zoledronate group. In subjects receiving no further active treatment, lumbar spine (LS) BMD decreased by 10.8% from months 48 72 but remained 4.2% above the original baseline. In subjects receiving zoledronate, LS BMD was maintained (percentage changes:   0.8% from months 48 72; 12.8% from months 0 72). Similar patterns were observed for proximal femur BMD in both groups. With no further active treatment, P1NP and beta CTX decreased but remained above baseline at month 72. Following zoledronate, P1NP and beta CTX levels initially decreased but approached baseline by month 72. No new safety signals were observed. Conclusion A zoledronate follow on regimen can maintain robust BMD gains achieved with romosozumab treatment.
C1 [McClung, M. R.] Oregon Osteoporosis Ctr, 2881 NW Cumberland Rd, Portland, OR 97210 USA.
   [McClung, M. R.] Australian Catholic Univ, Mary MacKillop Inst Hlth Res, Melbourne, Vic, Australia.
   [Bolognese, M. A.] Bethesda Hlth Res Ctr, Bethesda, MD USA.
   [Brown, J. P.] Laval Univ, Quebec City, PQ, Canada.
   [Brown, J. P.] CHU Quebec CHUL Res Ctr, Quebec City, PQ, Canada.
   [Reginster, J Y] Univ Liege, Liege, Belgium.
   [Reginster, J Y] King Saud Univ, Riyadh, Saudi Arabia.
   [Langdahl, B. L.] Aarhus Univ Hosp, Aarhus, Denmark.
   [Maddox, J.; Shi, Y.; Rojeski, M.; Grauer, A.] Amgen Inc, Thousand Oaks, CA 91320 USA.
   [Meisner, P. D.] UCB Phanna, Brussels, Belgium.
C3 Oregon Osteoporosis Center; Australian Catholic University; Laval
   University; University of Liege; King Saud University; Aarhus
   University; Amgen
RP McClung, MR (通讯作者)，Oregon Osteoporosis Ctr, 2881 NW Cumberland Rd, Portland, OR 97210 USA.; McClung, MR (通讯作者)，Australian Catholic Univ, Mary MacKillop Inst Hlth Res, Melbourne, Vic, Australia.
EM mmcclung.ooc@gmail.com
RI McClung, Michael/ABA 4100 2021; Reginster, Jean Yves/AGC 6097 2022
OI Brown, Jacques/0000 0003 1910 788X; 
FU Amgen Inc.; UCB Pharma; Astellas
FX This study was funded by Amgen Inc., UCB Pharma, and Astellas.
CR Amgen Inc, 2019, EVENITY ROM AQQG US
   Anastasilakis AD, 2019, J BONE MINER RES, V34, P2220, DOI 10.1002/jbmr.3853
   [Anonymous], 2017, TYML AB PRESCR INF
   [Anonymous], 2019, EVENITY ROM EU SUMM
   [Anonymous], 2012, FORT TER INJ PRESCR
   Ascott Evans BH, 2003, ARCH INTERN MED, V163, P789, DOI 10.1001/archinte.163.7.789
   Austin M, 2012, J BONE MINER RES, V27, P687, DOI 10.1002/jbmr.1472
   Bone HG, 2018, J CLIN ENDOCR METAB, V103, P2949, DOI 10.1210/jc.2018 00163
   Bouxsein ML, 2019, J BONE MINER RES, V34, P632, DOI 10.1002/jbmr.3641
   Camacho PM, 2016, ENDOCR PRACT, V22, P1, DOI 10.4158/EP161435.GL
   Chavassieux P, 2019, J BONE MINER RES, V34, P626, DOI 10.1002/jbmr.3631
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Cosman F, 2018, J BONE MINER RES, V33, P1219, DOI 10.1002/jbmr.3427
   Cosman F, 2017, J BONE MINER RES, V32, P198, DOI 10.1002/jbmr.3051
   Ferrari S, 2015, OSTEOPOROSIS INT, V26, P2763, DOI 10.1007/s00198 015 3179 x
   Freemantle N, 2012, OSTEOPOROSIS INT, V23, P317, DOI 10.1007/s00198 011 1780 1
   Grey A, 2017, CAN MED ASSOC J, V189, pE1130, DOI 10.1503/cmaj.161207
   Jiang YB, 2003, J BONE MINER RES, V18, P1932, DOI 10.1359/jbmr.2003.18.11.1932
   Kendler DL, 2019, OSTEOPOROSIS INT, V30, P2437, DOI 10.1007/s00198 019 05146 9
   Kendler DL, 2018, LANCET, V391, P230, DOI 10.1016/S0140 6736(17)32137 2
   Langdahl BL, 2017, LANCET, V390, P1585, DOI 10.1016/S0140 6736(17)31613 6
   Leder BZ, 2015, LANCET, V386, P1147, DOI 10.1016/S0140 6736(15)61120 5
   McClung M, 2009, OBSTET GYNECOL, V114, P999, DOI 10.1097/AOG.0b013e3181bdce0a
   McClung MR, 2018, J BONE MINER RES, V33, P1397, DOI 10.1002/jbmr.3452
   McClung MR, 2017, CURR OSTEOPOROS REP, V15, P343, DOI 10.1007/s11914 017 0376 x
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Niimi R, 2018, JBMR PLUS, V2, P289, DOI 10.1002/jbm4.10054
   Ominsky MS, 2015, BONE, V81, P380, DOI 10.1016/j.bone.2015.08.007
   Padhi D, 2014, J CLIN PHARMACOL, V54, P168, DOI 10.1002/jcph.239
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Recker RR, 2008, J BONE MINER RES, V23, P6, DOI 10.1359/JBMR.070906
   Reid IR, 2017, CALCIFIED TISSUE INT, V101, P371, DOI 10.1007/s00223 017 0288 x
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Zebaze RM, 2014, BONE, V59, P173, DOI 10.1016/j.bone.2013.11.016
NR 35
TC 37
Z9 40
U1 0
U2 7
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD NOV
PY 2020
VL 31
IS 11
BP 2231
EP 2241
DI 10.1007/s00198 020 05502 0
EA JUL 2020
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA OA0FY
UT WOS:000545298900002
PM 32623487
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Tan, Z
   Cheng, JW
   Liu, Q
   Zhou, L
   Kenny, J
   Wang, T
   Lin, XX
   Yuan, JB
   Quinn, JMW
   Tickner, J
   Hong, GJ
   Qin, A
   Zhao, JM
   Xu, JK
AF Tan, Zhen
   Cheng, Jianwen
   Liu, Qian
   Zhou, Lin
   Kenny, Jacob
   Wang, Tao
   Lin, Xixi
   Yuan, Jinbo
   Quinn, Julian M. W.
   Tickner, Jennifer
   Hong, Guoju
   Qin, An
   Zhao, Jinmin
   Xu, Jiake
TI Neohesperidin suppresses osteoclast differentiation, bone resorption and
   ovariectomised induced osteoporosis in mice
SO MOLECULAR AND CELLULAR ENDOCRINOLOGY
LA English
DT Article
DE Neohesperidin; Osteoclasts; Osteoporosis; Inhibition
ID NF KAPPA B; CELL DERIVED OSTEOCLASTS; CATHEPSIN K; POSTMENOPAUSAL WOMEN;
   SIGNALING PATHWAYS; ACTIVATION; ALPHA; ESTROGEN; SURVIVAL; ACID
AB Excessive bone resorption by osteoclasts plays an important role in osteoporosis. Bone loss occurs in ovariectomised (OVX) mice in a similar manner to that in humans, so this model is suitable for evaluating potential new therapies for osteoporosis. Neohesperidin (NE) is a flavonoid compound isolated from citrus fruits. Its role in bone metabolism is unknown. In this study we found that neohesperidin inhibits osteoclast differentiation, bone resorption and the expression of osteoclast marker genes, tartrate resistant acid phosphatase and cathepsin K. In addition, neohesperidin inhibited receptor activator of NF kappa B ligand (RANKL) induced activation of NF kappa B, and the degradation of inhibitor of kappa B alpha (I kappa B alpha). Furthermore, neohesperidin inhibited RANKL induction of nuclear factor of activated T cells (NFAT) and calcium oscillations. In vivo treatment of ovariectomised mice with neohesperidin protected against bone loss in mice. The results suggest neohesperidin has anti osteoclastic effects in vitro and in vivo and possesses therapeutic potential as a natural anti catabolic treatment in osteoporosis. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Tan, Zhen; Cheng, Jianwen; Liu, Qian; Zhao, Jinmin; Xu, Jiake] Guangxi Med Univ, Affiliated Hosp 1, Dept Orthopaed Surg, Nanning 530021, Guangxi, Peoples R China.
   [Tan, Zhen; Cheng, Jianwen; Liu, Qian; Wang, Tao; Lin, Xixi; Zhao, Jinmin; Xu, Jiake] Guangxi Med Univ, Res Ctr Regenerat Med, Nanning 530021, Guangxi, Peoples R China.
   [Tan, Zhen; Cheng, Jianwen; Liu, Qian; Wang, Tao; Lin, Xixi; Zhao, Jinmin] Guangxi Med Univ, Guangxi Key Lab Regenerat Med, Nanning 530021, Guangxi, Peoples R China.
   [Cheng, Jianwen; Liu, Qian; Zhou, Lin; Kenny, Jacob; Yuan, Jinbo; Tickner, Jennifer; Hong, Guoju; Xu, Jiake] Univ Western Australia, Sch Pathol & Lab Med, Perth, WA 6009, Australia.
   [Quinn, Julian M. W.] Garvan Inst Med Res, Darlinghurst, NSW, Australia.
   [Hong, Guoju] Guangzhou Univ Chinese Med, Natl Key Discipline, Guangzhou 510006, Guangdong, Peoples R China.
   [Hong, Guoju] Guangzhou Univ Chinese Med, Orthoped Lab, Guangzhou 510006, Guangdong, Peoples R China.
   [Qin, An] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Shanghai Key Lab Orthopaed Implant,Dept Orthopaed, Shanghai 200011, Peoples R China.
C3 Guangxi Medical University; Guangxi Medical University; Guangxi Medical
   University; University of Western Australia; Garvan Institute of Medical
   Research; Guangzhou University of Chinese Medicine; Guangzhou University
   of Chinese Medicine; Shanghai Jiao Tong University
RP Zhao, JM (通讯作者)，Guangxi Med Univ, Res Ctr Regenerat Med, Dept Orthopaed Surg, Affiliated Hosp 1, 6 Shuangyong Rd, Nanning, Guangxi, Peoples R China.; Xu, JK (通讯作者)，Univ Western Australia, Sch Pathol & Lab Med, M504, Nedlands, WA 6009, Australia.
EM zhaojinmin@126.com; jiake.xu@uwa.edu.au
RI Qin, An/J 2518 2019; Hong, Guoju/AAV 9433 2020; xi, lin/JOK 1026 2023;
   zhao, jin/LBH 0351 2024; Tickner, Jennifer/H 5965 2014
OI Zhao, Jinmin/0000 0002 1047 8820; Xu, Jiake/0000 0003 2021 8309; Kenny,
   Jacob/0000 0001 8169 9842; Yuan, Jinbo/0000 0002 6240 9333; Tickner,
   Jennifer/0000 0002 5020 0671
FU Co innovation Centre for Bio Medicine, Guangxi Colleges and University
   Key Laboratory of Regenerative Medicine and Innovation Team of Tissue
   Repair and Reconstruction; Department of Orthopaedic Surgery of the
   First Affiliated Hospital of Guangxi Medical University; School of
   Pathology and Laboratory Medicine of the University of Western Australia
   [NHMRC1107828]; Nature Science Foundation of Guangxi
   [2015GXNSFDA139019]; Guangxi Scientific Research and Technology
   Development project [GKG13349003]; China Postdoctoral Science Foundation
   [2015M572421]; Shanghai Pujiang Program [14PJ1406200]
FX This study was supported by Co innovation Centre for Bio Medicine,
   Guangxi Colleges and University Key Laboratory of Regenerative Medicine
   and Innovation Team of Tissue Repair and Reconstruction, the Department
   of Orthopaedic Surgery of the First Affiliated Hospital of Guangxi
   Medical University and the School of Pathology and Laboratory Medicine
   of the University of Western Australia (NHMRC1107828). Tan Zhen is a
   doctoral student at the Graduate School of Guangxi Medical University.
   Jianwen Cheng, Qian Liu, Lin Zhou, Tao Wang and Jiake Xu made mutual
   collaborative visits during the course of study. This study was funded
   by the Nature Science Foundation of Guangxi (2015GXNSFDA139019), the
   Guangxi Scientific Research and Technology Development project
   (GKG13349003), the China Postdoctoral Science Foundation funded project
   (2015M572421) and the Shanghai Pujiang Program (14PJ1406200).
CR Aguda AH, 2014, P NATL ACAD SCI USA, V111, P17474, DOI 10.1073/pnas.1414126111
   Ang ESM, 2011, FEBS LETT, V585, P2755, DOI 10.1016/j.febslet.2011.07.046
   Ang ESM, 2009, J CELL PHYSIOL, V221, P642, DOI 10.1002/jcp.21898
   Archer DF, 2012, CLIMACTERIC, V15, P235, DOI 10.3109/13697137.2012.664401
   Barnabei VM, 2002, OBSTET GYNECOL, V100, P1209, DOI 10.1016/S0029 7844(02)02369 4
   Bossard MJ, 1996, J BIOL CHEM, V271, P12517, DOI 10.1074/jbc.271.21.12517
   Cao DD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021071
   Clapham DE, 2007, CELL, V131, P1047, DOI 10.1016/j.cell.2007.11.028
   Danielsen CC, 1996, BONE, V19, P493, DOI 10.1016/S8756 3282(96)00256 6
   Demicco EG, 2005, MOL CELL BIOL, V25, P10136, DOI 10.1128/MCB.25.22.10136 10147.2005
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511
   Fiume G, 2012, NUCLEIC ACIDS RES, V40, P3548, DOI 10.1093/nar/gkr1224
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Gingery A, 2008, EXP CELL RES, V314, P2725, DOI 10.1016/j.yexcr.2008.06.006
   Golechha M, 2011, BIOL PHARM BULL, V34, P360, DOI 10.1248/bpb.34.360
   Halleen JM, 2003, J BONE MINER RES, V18, P1908, DOI 10.1359/jbmr.2003.18.10.1908
   Halleen JM, 2006, CLIN LAB, V52, P499
   Harada K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078612
   Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704
   He LG, 2014, ACTA PHARMACOL SIN, V35, P203, DOI 10.1038/aps.2013.139
   Iotsova V., 1997, NAT MED, V3, P1285
   Jiang M, 2011, PLANTA MED, V77, P873, DOI 10.1055/s 0030 1270983
   Kafienah W, 1998, BIOCHEM J, V331, P727, DOI 10.1042/bj3310727
   KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169 6009(91)90124 I
   Kim HJ, 2014, MOL CELLS, V37, P598, DOI 10.14348/molcells.2014.0153
   Kim Seung Hee, 2014, Lab Anim Res, V30, P143, DOI 10.5625/lar.2014.30.4.143
   Lee SY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080873
   Li L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043810
   Li ZQ, 2008, J MOL BIOL, V383, P78, DOI 10.1016/j.jmb.2008.07.038
   Lim J, 2013, MOL CELLS, V36, P340, DOI 10.1007/s10059 013 0123 9
   Manthey JA, 2001, CURR MED CHEM, V8, P135, DOI 10.2174/0929867013373723
   Nakamura Midori, 2011, Clin Calcium, V21, P1149, DOI CliCa110811491155
   Novack DV, 2011, CELL RES, V21, P169, DOI 10.1038/cr.2010.159
   O'Dea EL, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100148
   OMI N, 1995, BONE, V17, pS163, DOI 10.1016/8756 3282(95)00329 C
   Palkowitsch L, 2011, J BIOL CHEM, V286, P7522, DOI 10.1074/jbc.M110.155895
   Pavlos NJ, 2005, MOL CELL BIOL, V25, P5253, DOI 10.1128/MCB.25.12.5253 5269.2005
   Pinkerton JV, 2013, CLIN OBSTET GYNECOL, V56, P711, DOI 10.1097/GRF.0b013e3182a9fb02
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Seeman E, 2003, ENDOCRIN METAB CLIN, V32, P25, DOI 10.1016/S0889 8529(02)00078 6
   Spilmont M, 2014, EUR J NUTR, V53, P1155, DOI 10.1007/s00394 013 0615 6
   Suda T, 2001, ARTHRITIS RES THER, V3, DOI 10.1186/ar168
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Toyama S, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3019
   Wang C, 2010, BIOMED CHROMATOGR, V24, P235, DOI 10.1002/bmc.1278
   Weischenfeldt Joachim, 2008, CSH Protoc, V2008, DOI 10.1101/pdb.prot5080
   Xu J, 2003, J CELL BIOCHEM, V88, P1256, DOI 10.1002/jcb.10477
   Xu JK, 2000, J BONE MINER RES, V15, P2178, DOI 10.1359/jbmr.2000.15.11.2178
   Yarilina A, 2011, P NATL ACAD SCI USA, V108, P1573, DOI 10.1073/pnas.1010030108
   Yasuda Y, 2005, ADV DRUG DELIVER REV, V57, P973, DOI 10.1016/j.addr.2004.12.013
   Yong Y, 2011, MOL CELL BIOL, V31, P2802, DOI 10.1128/MCB.00253 10
   YOUSEF AA, 2001, J CLIN INVEST, V107, P1375
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
   Zheng MX, 2014, INT ORTHOP, V38, P627, DOI 10.1007/s00264 013 2184 y
   Zhou J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068392
   Zygler A, 2011, ANAL BIOANAL CHEM, V400, P2159, DOI 10.1007/s00216 011 4937 z
NR 58
TC 39
Z9 43
U1 2
U2 45
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0303 7207
J9 MOL CELL ENDOCRINOL
JI Mol. Cell. Endocrinol.
PD JAN 5
PY 2017
VL 439
IS C
BP 369
EP 378
DI 10.1016/j.mce.2016.09.026
PG 10
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA EH3CX
UT WOS:000391647800039
PM 27664516
DA 2025 08 17
ER

PT J
AU Ashrafi, M
   Ghalichi, F
   Mirzakouchaki, B
   Doblare, M
AF Ashrafi, Mehran
   Ghalichi, Farzan
   Mirzakouchaki, Behnam
   Doblare, Manuel
TI On the effect of antiresorptive drugs on the bone remodeling of the
   mandible after dental implantation: a mathematical model
SO SCIENTIFIC REPORTS
LA English
DT Article
AB Bone remodeling identifies the process of permanent bone change with new bone formation and old bone resorption. Understanding this process is essential in many applications, such as optimizing the treatment of diseases like osteoporosis, maintaining bone density in long term periods of disuse, or assessing the long term evolution of the bone surrounding prostheses after implantation. A particular case of study is the bone remodeling process after dental implantation. Despite the overall success of this type of implants, the increasing life expectancy in developed countries has boosted the demand for dental implants in patients with osteoporosis. Although several studies demonstrate a high success rate of dental implants in osteoporotic patients, it is also known that the healing time and the failure rate increase, necessitating the adoption of pharmacological measures to improve bone quality in those patients. However, the general efficacy of these antiresorptive drugs for osteoporotic patients is still controversial, requiring more experimental and clinical studies. In this work, we investigate the effect of different doses of several drugs, used nowadays in osteoporotic patients, on the evolution of bone density after dental implantation. With this aim, we use a pharmacokinetic pharmacodynamic (PK/PD) mathematical model that includes the effect of antiresorptive drugs on the RANK/RANK L/OPG pathway, as well as the mechano chemical coupling with external mechanical loads. This mechano PK/PD model is then used to analyze the evolution of bone in normal and osteoporotic mandibles after dental implantation with different drug dosages. We show that using antiresorptive agents such as bisphosphonates or denosumab increases bone density and the associated mechanical properties, but at the same time, it also increases bone brittleness. We conclude that, despite the many limitations of these very complex models, the one presented here is capable of predicting qualitatively the evolution of some of the main biological and chemical variables associated with the process of bone remodeling in patients receiving drugs for osteoporosis, so it could be used to optimize dental implant design and coating for osteoporotic patients, as well as the drug dosage protocol for patient specific treatments.
C1 [Ashrafi, Mehran; Ghalichi, Farzan] Sahand Univ Technol, Fac Biomed Engn, Sahand New Town, Tabriz, Iran.
   [Mirzakouchaki, Behnam] Tabriz Univ Med Sci, Tabriz Dent Sch, Orthodont Dept, Tabriz, Iran.
   [Doblare, Manuel] Univ Zaragoza, Aragon Inst Engn Res 13A, R&D Bldg,Block 5,1st Floor,Campus Rio Ebro, Zaragoza 50018, Spain.
   [Doblare, Manuel] Aragon Inst Hlth Res IIS Aragon, R&D Bldg,Block 5,1st Floor,Campus Rio Ebro, Zaragoza 50018, Spain.
   [Doblare, Manuel] Ctr Invest Biomed Red Bioingn Biomat & Nanomed CI, R&D Bldg,Block 5,1st Floor,Campus Rio Ebro, Zaragoza 50018, Spain.
C3 Sahand University of Technology; Tabriz University of Medical Science;
   University of Zaragoza; CIBER   Centro de Investigacion Biomedica en
   Red; CIBERBBN
RP Doblare, M (通讯作者)，Univ Zaragoza, Aragon Inst Engn Res 13A, R&D Bldg,Block 5,1st Floor,Campus Rio Ebro, Zaragoza 50018, Spain.; Doblare, M (通讯作者)，Aragon Inst Hlth Res IIS Aragon, R&D Bldg,Block 5,1st Floor,Campus Rio Ebro, Zaragoza 50018, Spain.; Doblare, M (通讯作者)，Ctr Invest Biomed Red Bioingn Biomat & Nanomed CI, R&D Bldg,Block 5,1st Floor,Campus Rio Ebro, Zaragoza 50018, Spain.
EM mdoblare@unizar.es
RI mirzakouchaki, behnam/G 4727 2017; Ashrafi, Mehran/AAD 3854 2022
CR Agarwal R, 2015, BIOMATERIALS, V63, P137, DOI 10.1016/j.biomaterials.2015.06.025
   Allen MR, 2006, BONE, V39, P872, DOI 10.1016/j.bone.2006.04.028
   Allen MR., 2007, IBMS BoneKEy, V4, P49, DOI [10.1138/20060248, DOI 10.1138/20060248]
   Alsaadi G, 2007, J CLIN PERIODONTOL, V34, P610, DOI 10.1111/j.1600 051X.2007.01077.x
   Amaral CF, 2018, J PROSTHET DENT, V119, P791, DOI 10.1016/j.prosdent.2017.07.016
   Arcos D, 2014, ACTA BIOMATER, V10, P1793, DOI 10.1016/j.actbio.2014.01.004
   Ashrafi M, 2020, BIOMECH MODEL MECHAN, V19, P2499, DOI 10.1007/s10237 020 01353 0
   Ashrafi M, 2020, INT J NUMER METH BIO, V36, DOI 10.1002/cnm.3270
   Augat P, 2005, OSTEOPOROSIS INT, V16, pS36, DOI 10.1007/s00198 004 1728 9
   Bagan J, 2016, ORAL DIS, V22, P324, DOI 10.1111/odi.12447
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   BEAUPRE GS, 1990, J ORTHOP RES, V8, P651, DOI 10.1002/jor.1100080506
   Body JJ, 2006, CLIN CANCER RES, V12, P1221, DOI 10.1158/1078 0432.CCR 05 1933
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Chen JS, 2012, NAT REV ENDOCRINOL, V8, P81, DOI 10.1038/nrendo.2011.146
   Cremers SCLM, 2005, CLIN PHARMACOKINET, V44, P551, DOI 10.2165/00003088 200544060 00001
   de Medeiros FCFL, 2018, INT J ORAL MAX SURG, V47, P480, DOI 10.1016/j.ijom.2017.05.021
   Defranoux NA, 2005, J BONE MINER RES, V20, P1079, DOI 10.1359/JBMR.050401
   Ding X, 2015, MATER DESIGN, V84, P144, DOI 10.1016/j.matdes.2015.06.091
   Donos N, 2014, BRIT DENT J, V217, P425, DOI 10.1038/sj.bdj.2014.911
   Eriksen EF, 2010, REV ENDOCR METAB DIS, V11, P219, DOI 10.1007/s11154 010 9153 1
   Filvaroff E, 1998, CURR BIOL, V8, pR679, DOI 10.1016/S0960 9822(98)70434 8
   García Aznar JM, 2005, BIOMECH MODEL MECHAN, V4, P147, DOI 10.1007/s10237 005 0067 x
   Giro G, 2015, WORLD J ORTHOP, V6, P311, DOI 10.5312/wjo.v6.i2.311
   Glösel B, 2010, INT J ORAL MAX IMPL, V25, P516
   Graham JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063884
   Hambli R, 2016, J MECH BEHAV BIOMED, V60, P492, DOI 10.1016/j.jmbbm.2016.03.010
   Hazelwood SJ, 2001, J BIOMECH, V34, P299, DOI 10.1016/S0021 9290(00)00221 9
   Hernandez CJ, 2000, J REHABIL RES DEV, V37, P235
   Hernandez CJ, 2001, BONE, V29, P74, DOI 10.1016/S8756 3282(01)00467 7
   Hsiao CH, 2020, DENTAL IMPLANT TREATMENT IN MEDICALLY COMPROMISED PATIENTS, P149, DOI 10.1007/978 3 030 28557 9_8
   Jacobs CR, 1994, Numerical simulation of bone adaptation to mechanical loading
   Javed F, 2014, IMPLANT DENT, V23, P679, DOI 10.1097/ID.0000000000000161
   Klika V, 2014, J MATH BIOL, V69, P1383, DOI 10.1007/s00285 013 0736 9
   Komatsubara S, 2003, J BONE MINER RES, V18, P512, DOI 10.1359/jbmr.2003.18.3.512
   KORIOTH TWP, 1992, AM J PHYS ANTHROPOL, V88, P69, DOI 10.1002/ajpa.1330880107
   Lemaire V, 2004, J THEOR BIOL, V229, P293, DOI 10.1016/j.jtbi.2004.03.023
   Li J, 2001, CALCIFIED TISSUE INT, V69, P281, DOI 10.1007/s002230010036
   Lugero G G, 2000, Implant Dent, V9, P303, DOI 10.1097/00008505 200009040 00005
   Marathe A, 2008, J PHARMACOL EXP THER, V326, P555, DOI 10.1124/jpet.108.137703
   Marathe DD, 2011, BIOPHARM DRUG DISPOS, V32, P471, DOI 10.1002/bdd.770
   Martin RB, 2000, BONE, V26, P1, DOI 10.1016/S8756 3282(99)00241 0
   MARTIN RB, 1984, CRIT REV BIOMED ENG, V10, P179
   Martínez Reina J, 2008, J THEOR BIOL, V254, P704, DOI 10.1016/j.jtbi.2008.06.007
   Martínez Reina J, 2009, BIOMECH MODEL MECHAN, V8, P111, DOI 10.1007/s10237 008 0122 5
   Martínez Reina J, 2019, BONE, V125, P87, DOI 10.1016/j.bone.2019.04.022
   Mashiba T, 2001, BONE, V28, P524, DOI 10.1016/S8756 3282(01)00414 8
   McClung MR, 2013, OSTEOPOROSIS INT, V24, P227, DOI 10.1007/s00198 012 2052 4
   Meraw SJ, 1999, J PERIODONTOL, V70, P1228, DOI 10.1902/jop.1999.70.10.1228
   Meraw SJ, 1999, J PERIODONTOL, V70, P151, DOI 10.1902/jop.1999.70.2.151
   Merdji A, 2010, COMP MATER SCI, V49, P126, DOI 10.1016/j.commatsci.2010.04.035
   Merheb J, 2016, CLIN IMPLANT DENT R, V18, P253, DOI 10.1111/cid.12290
   Miller PD, 2008, BONE, V43, P222, DOI 10.1016/j.bone.2008.04.007
   MINER MA, 1945, J APPL MECH T ASME, V12, pA159
   Neuprez A, 2014, OSTEOPOROSIS INT, V25, P393, DOI 10.1007/s00198 013 2437 z
   Ojeda J, 2011, P I MECH ENG H, V225, P897, DOI 10.1177/0954411911410165
   Olgun ZD., 2016, METASTATIC BONE DIS, P121, DOI [10.1007/978 1 4614 5662 9_12, DOI 10.1007/978 1 4614 5662 9_12]
   Peter B., 2004, Computer Methods in Biomechanics and Biomedical Engineering, V7, P73, DOI 10.1080/1025584042000205327
   Peter B, 2006, J BIOMED MATER RES A, V76A, P133, DOI 10.1002/jbm.a.30456
   Peter B., 2001, COMPUT METHOD BIOMEC, V4, P505, DOI [10.1080/10255840108908023, DOI 10.1080/10255840108908023]
   Pillai G, 2004, BRIT J CLIN PHARMACO, V58, P618, DOI 10.1111/j.1365 2125.2004.02224.x
   Pivonka P, 2010, J THEOR BIOL, V262, P306, DOI 10.1016/j.jtbi.2009.09.021
   Reid IR, 2012, NAT REV RHEUMATOL, V8, P90, DOI 10.1038/nrrheum.2011.181
   Reina JM, 2007, J BIOMECH, V40, P828, DOI 10.1016/j.jbiomech.2006.03.007
   Ristow O, 2015, J CRANIO MAXILL SURG, V43, P290, DOI 10.1016/j.jcms.2014.11.014
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   SCHNEIDER VS, 1984, CALCIFIED TISSUE INT, V36, pS151, DOI 10.1007/BF02406149
   TAGUCHI A, 1995, ORAL SURG ORAL MED O, V80, P612, DOI 10.1016/S1079 2104(05)80158 1
   Taylor KH, 2010, BRIT J ORAL MAX SURG, V48, P221, DOI 10.1016/j.bjoms.2009.08.030
   Troeltzsch M, 2016, J CRANIO MAXILL SURG, V44, P1945, DOI 10.1016/j.jcms.2016.09.018
   Viguet Carrin S, 2006, OSTEOPOROSIS INT, V17, P319, DOI 10.1007/s00198 005 2035 9
   Xiao JR, 2011, J ORAL MAXIL SURG, V69, pE273, DOI 10.1016/j.joms.2010.12.006
NR 72
TC 26
Z9 27
U1 1
U2 9
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD FEB 2
PY 2021
VL 11
IS 1
AR 2792
DI 10.1038/s41598 021 82502 y
PG 20
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA QG6PP
UT WOS:000617706100029
PM 33531628
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Liu, W
   Hajibeigi, A
   Lin, M
   Rostollan, CL
   Kovacs, Z
   Öz, OK
   Sun, XK
AF Liu, Wei
   Hajibeigi, Asghar
   Lin, Mai
   Rostollan, Cynthia L.
   Kovacs, Zoltan
   Oz, Orhan K.
   Sun, Xiankai
TI An osteoclast targeting agent for imaging and therapy of bone metastasis
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE bone metastasis; imaging agent; osteoclast; indium 111; bifunctional
   chelator; bisphosphonate
ID LANTHANIDE(III) COMPLEXES; DOTA; BISPHOSPHONATE; BIODISTRIBUTION;
   TOMOGRAPHY; AFFINITY
AB A hybrid compound (DO3A BP) featuring a radiometal bifunctional chelator (1,4,7,10 tetraazacyclotetradecane N,N',N '',N '',N'" tetraacetic acid, DOTA) and an osteoclast targeting moiety ( bisphosphonate) was designed and synthesized. The In 111 labeled complex of DO3A BP showed significantly elevated uptake in osteoclasts compared to the undifferentiated adherent bone marrow derived cells. Biodistribution studies revealed a favorable tissue distribution pro. le in normal mice with high bone uptake and long retention, and low or negligible accumulation in non target organs. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Liu, Wei; Hajibeigi, Asghar; Lin, Mai; Rostollan, Cynthia L.; Oz, Orhan K.; Sun, Xiankai] Univ Texas SW Med Ctr Dallas, Dept Radiol, Dallas, TX 75390 USA.
   [Kovacs, Zoltan] Univ Texas SW Med Ctr Dallas, Adv Imaging Res Ctr, Dallas, TX 75390 USA.
C3 University of Texas System; University of Texas Southwestern Medical
   Center; University of Texas System; University of Texas Southwestern
   Medical Center
RP Sun, XK (通讯作者)，Univ Texas SW Med Ctr Dallas, Dept Radiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
EM Xiankai.Sun@UTSouthwestern.edu
RI Oz, Orhan/GVT 7264 2022
FU NIH [CA119219]
FX This work was partially supported by an NIH R21 grant (CA119219; XS) and
   an unrestricted fund from the endowment of the Effie and Wofford Cain
   Distinguished Chair in Diagnostic Imaging provided by Dr. Robert W.
   Parkey. The authors like to thank Ms. Chandima Siyambalapitiyage for her
   assistance in the cell studies.
CR André JP, 2004, CHEM EUR J, V10, P5804, DOI 10.1002/chem.200400187
   Berenson JR, 2001, CANCER, V91, P1191, DOI 10.1002/1097 0142(20010401)91:7<1191::AID CNCR1119>3.0.CO;2 0
   Body Jean Jacques, 2000, Cancer, V88, P3054, DOI 10.1002/1097 0142(20000615)88:12+<3054::AID CNCR23>3.0.CO;2 Z
   Clézardin P, 2003, CURR MED CHEM, V10, P173, DOI 10.2174/0929867033368529
   De León Rodríguez LM, 2008, BIOCONJUGATE CHEM, V19, P391, DOI 10.1021/bc700328s
   Förster GJ, 2006, J NUCL MED, V47, P140
   Hobolth L, 2008, CLIN NUCL MED, V33, P61, DOI 10.1097/RLU.0b013e31815c5035
   HOLTROP ME, 1977, CLIN ORTHOP RELAT RE, V123
   Hosain F, 1996, J NUCL MED, V37, P105
   Kohno N, 2008, INT J CLIN ONCOL, V13, P18, DOI 10.1007/s10147 007 0726 2
   Kubícek V, 2005, J AM CHEM SOC, V127, P16477, DOI 10.1021/ja054905u
   LI M, 1995, CANCER RES, V55, pS5726
   Liu S, 2002, BIOCONJUGATE CHEM, V13, P902, DOI 10.1021/bc010134h
   Moore AEB, 2008, J NUCL MED, V49, P375, DOI 10.2967/jnumed.107.048595
   Ogawa K, 2006, J NUCL MED, V47, P2042
   Page PCB, 2001, J ORG CHEM, V66, P3704, DOI 10.1021/jo001489h
   Penel N, 2008, SUPPORT CARE CANCER, V16, P387, DOI 10.1007/s00520 007 0322 z
   Peterson JJ, 2003, CLIN ORTHOP RELAT R, pS120, DOI 10.1097/01.blo.0000093051.96273.7c
   Pinkerton JV, 2007, AM J OBSTET GYNECOL, V197, P559, DOI 10.1016/j.ajog.2007.07.022
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Saeed S, 2001, CLIN NUCL MED, V26, P930, DOI 10.1097/00003072 200111000 00008
   Santini D, 2007, ANN ONCOL, V18, P164, DOI 10.1093/annonc/mdm249
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   SCHWARTZ Z, 1993, J NUCL MED, V34, P104
   Silverman SL, 2007, SEMIN ARTHRITIS RHEU, V37, P1, DOI 10.1016/j.semarthrit.2006.12.003
   Stresing V, 2007, CANCER LETT, V257, P16, DOI 10.1016/j.canlet.2007.07.007
   Sun XK, 2005, BIOCONJUGATE CHEM, V16, P294, DOI 10.1021/bc049783u
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Vitha T, 2008, LANGMUIR, V24, P1952, DOI 10.1021/la702753j
   Vitha T, 2008, J MED CHEM, V51, P677, DOI 10.1021/jm7012776
   WHYTE MP, 2008, J BONE MINER RES
   Yeh HS, 2006, EUR J CANCER, V42, P1554, DOI 10.1016/j.ejca.2005.11.035
NR 32
TC 18
Z9 20
U1 0
U2 4
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960 894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD SEP 1
PY 2008
VL 18
IS 17
BP 4789
EP 4793
DI 10.1016/j.bmcl.2008.07.092
PG 5
WC Chemistry, Medicinal; Chemistry, Organic
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Chemistry
GA 347ME
UT WOS:000259144900009
PM 18692394
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Eastell, R
   O'Neill, TW
   Hofbauer, LC
   Langdahl, B
   Reid, IR
   Gold, DT
   Cummings, SR
AF Eastell, Richard
   O'Neill, Terence W.
   Hofbauer, Lorenz C.
   Langdahl, Bente
   Reid, Ian R.
   Gold, Deborah T.
   Cummings, Steven R.
TI Postmenopausal osteoporosis
SO NATURE REVIEWS DISEASE PRIMERS
LA English
DT Article
ID BONE MINERAL DENSITY; QUALITY OF LIFE; SELECTIVE ESTROGEN COMPLEX;
   VERTEBRAL FRACTURE RISK; GOAL DIRECTED TREATMENT; YEARLY ZOLEDRONIC
   ACID; LARGE SCALE ANALYSIS; HIP FRACTURE; VITAMIN D; CALCIUM
   SUPPLEMENTATION
AB Osteoporosis is a metabolic bone disorder that is characterized by low bone mass and micro architectural deterioration of bone tissue. Fractures of the proximal femur, the vertebrae and the distal radius are the most frequent osteoporotic fractures, although most fractures in the elderly are probably at least partly related to bone fragility. The incidence of fractures varies greatly by country, but on average up to 50% of women >50 years of age are at risk of fractures. Fractures severely affect the quality of life of an individual and are becoming a major public health problem owing to the ageing population. Postmenopausal osteoporosis, resulting from oestrogen deficiency, is the most common type of osteoporosis. Oestrogen deficiency results in an increase in bone turnover owing to effects on all types of bone cells. The imbalance in bone formation and resorption has effects on trabecular bone (loss of connectivity) and cortical bone (cortical thinning and porosity). Osteoporosis is diagnosed using bone density measurements of the lumbar spine and proximal femur. Preventive strategies to improve bone health include diet, exercise and abstaining from smoking. Fractures may be prevented by reducing falls in high risk populations. Several drugs are licensed to reduce fracture risk by slowing down bone resorption (such as bisphosphonates and denosumab) or by stimulating bone formation (such as teriparatide). Improved understanding of the cellular basis for osteoporosis has resulted in new drugs targeted to key pathways, which are under development.
C1 [Eastell, Richard] Univ Sheffield, Acad Unit Bone Metab, Sheffield, S Yorkshire, England.
   [Eastell, Richard] Univ Sheffield, Mellanby Ctr Bone Res, Sheffield, S Yorkshire, England.
   [O'Neill, Terence W.] Univ Manchester, MAHSC, Arthrit Res UK Ctr Epidemiol, Ctr Musculoskeletal Res, Manchester, Lancs, England.
   [Hofbauer, Lorenz C.] Tech Univ Dresden, Med Ctr, Div Endocrinol Diabet & Bone Dis, Dresden, Germany.
   [Hofbauer, Lorenz C.] Tech Univ Dresden, Med Ctr, Ctr Hlth Aging, Dresden, Germany.
   [Langdahl, Bente] Aarhus Univ Hosp, Dept Endocrinol & Internal Med, Aarhus, Denmark.
   [Reid, Ian R.] Univ Auckland, Dept Med, Auckland, New Zealand.
   [Gold, Deborah T.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA.
   [Gold, Deborah T.] Duke Univ, Med Ctr, Dept Sociol, Durham, NC USA.
   [Gold, Deborah T.] Duke Univ, Med Ctr, Dept Psychol & Neurosci, Durham, NC USA.
   [Cummings, Steven R.] Calif Pacific Med Ctr Res Inst, San Francisco Coordinating Ctr, San Francisco, CA USA.
   [Cummings, Steven R.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
C3 University of Sheffield; University of Sheffield; University of
   Manchester; Technische Universitat Dresden; Technische Universitat
   Dresden; Aarhus University; University of Auckland; Duke University;
   Duke University; Duke University; California Pacific Medical Center;
   California Pacific Medical Center Research Institute; University of
   California System; University of California San Francisco
RP Eastell, R (通讯作者)，Northern Gen Hosp, Metab Bone Ctr, Herries Rd, Sheffield S5 7AU, S Yorkshire, England.
EM r.eastell@sheffield.ac.uk
RI Eastell, Richard/G 5851 2011; Hofbauer, Lorenz C./G 2490 2010; Hofbauer,
   Lorenz/G 2490 2010
OI O'Neill, Terence/0000 0002 8896 4677; Reid, Ian/0000 0001 6021 5458;
   Hofbauer, Lorenz C./0000 0002 8691 8423; 
FU National Institute of Health Research; Deutsche Forschungsgemeinschaft
   [SFB 655]; Transregio 67; Medical Research Council [MR/K006312/1]
   Funding Source: researchfish; National Institute for Health Research
   [NF SI 0513 10073] Funding Source: researchfish
FX R. E. was supported by a Senior Investigator Award from the National
   Institute of Health Research. L. C. H. was funded by Deutsche
   Forschungsgemeinschaft, SFB 655 and Transregio 67.
CR ALEXEEVA L, 1994, WHO TECH REP SER, V843, P1
   Almeida M, 2010, J BONE MINER RES, V25, P769, DOI 10.1359/jbmr.091017
   Anderson GL, 2004, JAMA J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701
   [Anonymous], 2009, INT POPULATION REPOR
   [Anonymous], 1993, AM J MED, V95, p1S
   [Anonymous], 2016, BUSINESS WIRE
   [Anonymous], 2014, BUSINESS WIRE
   Aubry Rozier B, 2016, OSTEOPOROSIS INT, V27, P1923, DOI 10.1007/s00198 015 3380 y
   Austin M, 2012, J BONE MINER RES, V27, P687, DOI 10.1002/jbmr.1472
   Avenell A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000227.pub4
   Ballane G, 2014, J BONE MINER RES, V29, P1745, DOI 10.1002/jbmr.2218
   Bang UC, 2014, OSTEOPOROSIS INT, V25, P639, DOI 10.1007/s00198 013 2470 y
   Barrett Connor E, 2006, NEW ENGL J MED, V355, P125, DOI 10.1056/NEJMoa062462
   Bhattacharya R, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/1471 244X 14 10
   Billington EO, 2016, MATURITAS, V85, P11, DOI 10.1016/j.maturitas.2015.12.003
   Bischoff Ferrari HA, 2009, BMJ BRIT MED J, V339, DOI 10.1136/bmj.b3692
   Bischoff Ferrari HA, 2007, AM J CLIN NUTR, V86, P1780
   Bischoff Ferrari HA, 2009, J BONE MINER RES, V24, P935, DOI [10.1359/JBMR.081242, 10.1359/jbmr.081242]
   Bischoff Ferrari HA, 2009, ARCH INTERN MED, V169, P551, DOI 10.1001/archinternmed.2008.600
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Bolland MJ, 2010, BMJ BRIT MED J, V341, DOI 10.1136/bmj.c3691
   Bolton KL, 2012, J SCI MED SPORT, V15, P102, DOI 10.1016/j.jsams.2011.08.007
   Bonjour JP, 2014, ENDOCR REV, V35, P820, DOI 10.1210/er.2014 1007
   Brauer CA, 2009, JAMA J AM MED ASSOC, V302, P1573, DOI 10.1001/jama.2009.1462
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Byberg L, 2015, J BONE MINER RES, V30, P976, DOI 10.1002/jbmr.2384
   Cadogan J, 1997, BMJ BRIT MED J, V315, P1255, DOI 10.1136/bmj.315.7118.1255
   Cao JJ, 2010, CURR OPIN CLIN NUTR, V13, P698, DOI 10.1097/MCO.0b013e32833df691
   Cartsos VM, 2008, J AM DENT ASSOC, V139, P23, DOI 10.14219/jada.archive.2008.0016
   Cauley JA, 2000, OSTEOPOROSIS INT, V11, P556, DOI 10.1007/s001980070075
   Cauley JA, 2014, NAT REV ENDOCRINOL, V10, P338, DOI 10.1038/nrendo.2014.51
   Ceglia L, 2009, CURR OPIN CLIN NUTR, V12, P628, DOI 10.1097/MCO.0b013e328331c707
   Chavassieux P, 2014, J BONE MINER RES, V29, P618, DOI 10.1002/jbmr.2074
   Cheng SY, 2011, OSTEOPOROSIS INT, V22, P2575, DOI 10.1007/s00198 011 1596 z
   Chevalley T, 2005, J CLIN ENDOCR METAB, V90, P44, DOI 10.1210/jc.2004 1043
   CHOW J, 1992, J CLIN INVEST, V89, P74, DOI 10.1172/JCI115588
   Clowes JA, 2005, IMMUNOL REV, V208, P207, DOI 10.1111/j.0105 2896.2005.00334.x
   Clynes MA, 2015, CALCIFIED TISSUE INT, V97, P445, DOI 10.1007/s00223 015 0044 z
   Colberg SR, 2010, DIABETES CARE, V33, P2692, DOI [10.2337/dc10 1548, 10.2337/dc10 9990]
   Compston J, 2013, MATURITAS, V75, P392, DOI 10.1016/j.maturitas.2013.05.013
   Cooper C, 2011, OSTEOPOROSIS INT, V22, P1277, DOI 10.1007/s00198 011 1601 6
   COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Cosman F, 2011, J BONE MINER RES, V26, P503, DOI 10.1002/jbmr.238
   Cosman F, 2009, J CLIN ENDOCR METAB, V94, P3772, DOI 10.1210/jc.2008 2719
   Crandall CJ, 2015, BMJ BRIT MED J, V350, DOI 10.1136/bmj.h25
   CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202
   Cummings SR, 2013, J BONE MINER RES, V28, P433, DOI 10.1002/jbmr.1854
   Cummings SR, 2010, NEW ENGL J MED, V362, P686, DOI 10.1056/NEJMoa0808692
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Curtis EM, 2016, BONE, V87, P19, DOI 10.1016/j.bone.2016.03.006
   Dallas SL, 2013, ENDOCR REV, V34, P658, DOI 10.1210/er.2012 1026
   Dawson Hughes B, 2008, OSTEOPOROSIS INT, V19, P449, DOI 10.1007/s00198 008 0559 5
   Dawson Hughes B, 2010, OSTEOPOROSIS INT, V21, P1151, DOI 10.1007/s00198 010 1285 3
   Dawson Hughes B, 2002, AM J CLIN NUTR, V75, P773, DOI 10.1093/ajcn/75.4.773
   Dell RM, 2012, J BONE MINER RES, V27, P2544, DOI 10.1002/jbmr.1719
   Diez Perez A, 2012, OSTEOPOROSIS INT, V23, P2769, DOI 10.1007/s00198 012 2093 8
   Eastell R, 1998, NEW ENGL J MED, V338, P736, DOI 10.1056/NEJM199803123381107
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Eekman DA, 2014, OSTEOPOROSIS INT, V25, P195, DOI 10.1007/s00198 013 2505 4
   Eghbali Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215
   Eisman JA, 2012, J BONE MINER RES, V27, P2039, DOI 10.1002/jbmr.1698
   ELDERS PJM, 1994, J BONE MINER RES, V9, P963
   Ensrud KE, 1997, ARCH INTERN MED, V157, P857, DOI 10.1001/archinte.157.8.857
   Estrada K, 2012, NAT GENET, V44, P491, DOI 10.1038/ng.2249
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   European Medicines Agency, 2014, PROT OSS REM AV FURT
   Falahati Nini A, 2000, J CLIN INVEST, V106, P1553, DOI 10.1172/JCI10942
   Felsenberg D, 2002, J BONE MINER RES, V17, P716
   Fenton TR, 2008, AM J CLIN NUTR, V88, P1159, DOI 10.1093/ajcn/88.4.1159
   Fierce Biotech, 2016, AMG UCB ANN POS TOP
   Fujita K, 2014, J CLIN ENDOCR METAB, V99, pE81, DOI 10.1210/jc.2013 3249
   Garnero P, 1996, J BONE MINER RES, V11, P337, DOI 10.1002/jbmr.5650110307
   Garvan Institute, 2016, FRACT RISK CALC
   Gennari L, 2008, J BONE MINER RES, V23, P1548, DOI 10.1359/jbmr.0810c
   Goettsch C, 2013, J CLIN INVEST, V123, P4731, DOI 10.1172/JCI67603
   Gold D. T., 2003, DOWNWARD SPIRAL VERT
   Gold DT, 1996, BONE, V18, pS185, DOI 10.1016/8756 3282(95)00500 5
   Greenspan SL, 2007, ANN INTERN MED, V146, P326, DOI 10.7326/0003 4819 146 5 200703060 00005
   Harwood RH, 2005, BRIT J OPHTHALMOL, V89, P53, DOI 10.1136/bjo.2004.049478
   HEINONEN A, 1995, BONE, V17, P197, DOI 10.1016/8756 3282(95)00151 3
   Hernandez CJ, 2003, OSTEOPOROSIS INT, V14, P843, DOI 10.1007/s00198 003 1454 8
   Sosa NHD, 2014, CALCIFIED TISSUE INT, V94, P590, DOI 10.1007/s00223 014 9852 9
   Hernlund E, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0136 1
   Hiligsmann M, 2012, ARTHRIT CARE RES, V64, P744, DOI 10.1002/acr.21607
   Hippisley Cox J, 2009, BMJ BRIT MED J, V339, DOI 10.1136/bmj.b4229
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Il Mödder U, 2011, J BONE MINER RES, V26, P27, DOI 10.1002/jbmr.128
   Institute of Medicine, 2011, DIET REF RANG CALC V
   International Osteoporosis Foundation, GUID REF
   Ioannidis JPA, 2004, JAMA J AM MED ASSOC, V292, P2105, DOI 10.1001/jama.292.17.2105
   Iwamoto J, 2001, J Orthop Sci, V6, P128
   Jacques RM, 2012, J BONE MINER RES, V27, P1627, DOI 10.1002/jbmr.1644
   JENSEN J, 1985, NEW ENGL J MED, V313, P973, DOI 10.1056/NEJM198510173131602
   Jha S, 2015, J BONE MINER RES, V30, P2179, DOI 10.1002/jbmr.2565
   JOHNELL O, 1992, OSTEOPOROSIS INT, V2, P298, DOI 10.1007/BF01623186
   Kanis JA, 2008, OSTEOPOROSIS INT, V19, P385, DOI 10.1007/s00198 007 0543 5
   Kanis JA, 2014, OSTEOPOROSIS INT, V25, P2533, DOI 10.1007/s00198 014 2787 1
   Kanis J. A., 2016, FRAX WHO FRACTURE RI
   KANIS JA, 1994, OSTEOPOROSIS INT, V4, P368, DOI 10.1007/BF01622200
   Kanis JA, 2005, OSTEOPOROSIS INT, V16, P737, DOI 10.1007/s00198 004 1734 y
   Kanis JA, 2002, LANCET, V359, P1929, DOI 10.1016/S0140 6736(02)08761 5
   Kemmler W, 2012, OSTEOPOROSIS INT, V23, P1267, DOI 10.1007/s00198 011 1663 5
   Kenny RAM, 2011, J AM GERIATR SOC, V59, P148, DOI 10.1111/j.1532 5415.2010.03234.x
   Keupp K, 2013, AM J HUM GENET, V92, P565, DOI 10.1016/j.ajhg.2013.02.010
   Khastgir G, 2001, J CLIN ENDOCR METAB, V86, P289, DOI 10.1210/jc.86.1.289
   Khosla S, 2015, J BONE MINER RES, V30, P1134, DOI 10.1002/jbmr.2529
   Khosla S, 2012, J CLIN ENDOCR METAB, V97, P2272, DOI 10.1210/jc.2012 1027
   Khosla S, 2010, J CLIN ENDOCR METAB, V95, P3569, DOI 10.1210/jc.2010 0856
   Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092 8674(02)08100 X
   Kovacs CS, 2014, CURR OPIN ENDOCRINOL, V21, P468, DOI 10.1097/MED.0000000000000102
   Krall EA, 1999, J BONE MINER RES, V14, P215, DOI 10.1359/jbmr.1999.14.2.215
   Lang T, 2004, J BONE MINER RES, V19, P1006, DOI 10.1359/JBMR.040307
   Langdahl BL, 2008, BONE, V42, P969, DOI 10.1016/j.bone.2007.11.007
   Leder BZ, 2015, LANCET, V386, P1147, DOI 10.1016/S0140 6736(15)61120 5
   Leder BZ, 2015, J CLIN ENDOCR METAB, V100, P697, DOI 10.1210/jc.2014 3718
   Lee K, 2003, NATURE, V424, P389, DOI 10.1038/424389a
   LEICHTER I, 1989, J ORTHOP RES, V7, P86, DOI 10.1002/jor.1100070112
   Leslie WD, 2009, JAMA J AM MED ASSOC, V302, P883, DOI 10.1001/jama.2009.1231
   Leung KS, 2014, OSTEOPOROSIS INT, V25, P1785, DOI 10.1007/s00198 014 2693 6
   Lewis JR, 2015, J BONE MINER RES, V30, P165, DOI 10.1002/jbmr.2311
   Lin TC, 2014, OSTEOPOROSIS INT, V25, P1503, DOI 10.1007/s00198 014 2624 6
   LINDSAY R, 1980, LANCET, V2, P1151
   Lindsay R, 2009, FERTIL STERIL, V92, P1045, DOI 10.1016/j.fertnstert.2009.02.093
   Lips P, 2005, OSTEOPOROSIS INT, V16, P447, DOI 10.1007/s00198 004 1762 7
   Looker AC, 2012, OSTEOPOROSIS INT, V23, P771, DOI 10.1007/s00198 011 1623 0
   Manolagas SC, 2013, NAT REV ENDOCRINOL, V9, P699, DOI 10.1038/nrendo.2013.179
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254
   McClung M., 2014, ACR
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   McClung MR, 2005, ARCH INTERN MED, V165, P1762, DOI 10.1001/archinte.165.15.1762
   McKay HA, 2005, BRIT J SPORT MED, V39, P521, DOI 10.1136/bjsm.2004.014266
   Medicines and Healthcare Products Regulatory Agency (MHRA), 2013, DRUG SAFETY UPDATE
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   Michael YL, 2010, ANN INTERN MED, V153, P815, DOI 10.7326/0003 4819 153 12 201012210 00008
   Michaëlsson K, 2005, ARCH INTERN MED, V165, P1825, DOI 10.1001/archinte.165.16.1825
   Miller PD, 2008, BONE, V43, P222, DOI 10.1016/j.bone.2008.04.007
   Mirkin S, 2014, MATURITAS, V77, P24, DOI 10.1016/j.maturitas.2013.10.009
   Morin SN, 2013, CURR OSTEOPOROS REP, V11, P263, DOI 10.1007/s11914 013 0168 x
   Murad MH, 2012, J CLIN ENDOCR METAB, V97, P1871, DOI 10.1210/jc.2011 3060
   Nakamura T, 2012, J CLIN ENDOCR METAB, V97, P3097, DOI 10.1210/jc.2011 3479
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Nguyen ND, 2008, OSTEOPOROSIS INT, V19, P1431, DOI 10.1007/s00198 008 0588 0
   Nishiyama KK, 2010, J BONE MINER RES, V25, P882, DOI 10.1359/jbmr.091020
   Office of the Surgeon General (US), 2004, BON HLTH OST REP SUR
   Oliver D, 2007, BRIT MED J, V334, P82, DOI 10.1136/bmj.39049.706493.55
   Oncken C, 2006, J WOMENS HEALTH, V15, P1141, DOI 10.1089/jwh.2006.15.1141
   Oursler MJ, 1998, CRIT REV EUKAR GENE, V8, P125, DOI 10.1615/CritRevEukarGeneExpr.v8.i2.20
   Papaioannou A, 2006, OSTEOPOROSIS INT, V17, P355, DOI 10.1007/s00198 005 2020 3
   Papapoulos S, 2015, OSTEOPOROSIS INT, V26, P2773, DOI 10.1007/s00198 015 3234 7
   Patsch JM, 2013, J BONE MINER RES, V28, P313, DOI 10.1002/jbmr.1763
   Pazianas M, 2008, OSTEOPOROSIS INT, V19, P773, DOI 10.1007/s00198 007 0502 1
   Pike C, 2010, PHARMACOECONOMICS, V28, P395, DOI 10.2165/11531040 000000000 00000
   POCOCK NA, 1987, J CLIN INVEST, V80, P706, DOI 10.1172/JCI113125
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Ralston SH, 2006, PLOS MED, V3, P515, DOI 10.1371/journal.pmed.0030090
   Randell AG, 2000, OSTEOPOROSIS INT, V11, P460, DOI 10.1007/s001980070115
   Recker RR, 2009, J BONE MINER RES, V24, P1358, DOI [10.1359/jbmr.090315, 10.1359/JBMR.090315]
   Reginster JY, 2005, J CLIN ENDOCR METAB, V90, P2816, DOI 10.1210/jc.2004 1774
   Reid IR, 2015, J INTERN MED, V277, P690, DOI 10.1111/joim.12339
   Reid IR, 2015, NAT REV ENDOCRINOL, V11, P418, DOI 10.1038/nrendo.2015.71
   Reid IR, 2004, ARCH INTERN MED, V164, P871, DOI 10.1001/archinte.164.8.871
   Richards JB, 2008, LANCET, V371, P1505, DOI 10.1016/S0140 6736(08)60599 1
   Rizzoli R, 2016, OSTEOPOROSIS INT, V27, P2099, DOI 10.1007/s00198 016 3503 0
   Rossouw JE, 2007, JAMA J AM MED ASSOC, V297, P1465, DOI 10.1001/jama.297.13.1465
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   RUBIN CT, 1992, CALCIFIED TISSUE INT, V50, P306, DOI 10.1007/BF00301627
   Sahni S, 2010, J BONE MINER RES, V25, P2494, DOI 10.1002/jbmr.194
   Santen RJ, 2009, ENDOCR REV, V30, P343, DOI 10.1210/er.2008 0016
   Schilcher J, 2014, NEW ENGL J MED, V371, P974, DOI 10.1056/NEJMc1403799
   Schilcher J, 2011, NEW ENGL J MED, V364, P1728, DOI 10.1056/NEJMoa1010650
   Schwartz AV, 2005, AM J EPIDEMIOL, V161, P180, DOI 10.1093/aje/kwi023
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Serio A, 1999, NEPHRON, V81, P26, DOI 10.1159/000046295
   Shane E, 2014, J BONE MINER RES, V29, P1, DOI 10.1002/jbmr.1998
   Sharifi M, 2014, EXPERT REV CLIN PHAR, V7, P281, DOI 10.1586/17512433.2014.893819
   Shea B, 2002, ENDOCR REV, V23, P552, DOI 10.1210/er.2001 7002
   Silverman SL, 2008, J BONE MINER RES, V23, P1923, DOI 10.1359/JBMR.080710
   Silverman Stuart L, 2005, Curr Rheumatol Rep, V7, P39, DOI 10.1007/s11926 005 0007 x
   Sims NA, 2014, CALCIFIED TISSUE INT, V94, P2, DOI 10.1007/s00223 013 9766 y
   Siris E, 2014, OSTEOPOROSIS INT, V25, P1439, DOI 10.1007/s00198 014 2655 z
   SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604
   Syed FA, 2005, J BONE MINER RES, V20, P1992, DOI 10.1359/JBMR.050713
   Szulc P, 2006, J BONE MINER RES, V21, P1856, DOI 10.1359/JBMR.060904
   Tan KW, 2011, ANN ACAD MED SINGAP, V40, P510
   Tucker M. E., 2015, MEDSCAPE
   Uitterlinden AG, 2006, ANN INTERN MED, V145, P255, DOI 10.7326/0003 4819 145 4 200608150 00005
   van Meurs JBJ, 2008, JAMA J AM MED ASSOC, V299, P1277, DOI 10.1001/jama.299.11.1277
   Van Staa TP, 2001, BONE, V29, P517, DOI 10.1016/S8756 3282(01)00614 7
   Vasikaran S, 2011, OSTEOPOROSIS INT, V22, P391, DOI 10.1007/s00198 010 1501 1
   von Stengel S, 2011, OSTEOPOROSIS INT, V22, P317, DOI 10.1007/s00198 010 1215 4
   Wallace RB, 2011, AM J CLIN NUTR, V94, P270, DOI 10.3945/ajcn.110.003350
   Wang L, 2010, ANN INTERN MED, V152, P315, DOI [10.7326/0003 4819 152 5 201003020 00010, 10.7326/0003 4819 152 8 201004200 00008]
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Winzenberg T, 2006, BMJ BRIT MED J, V333, P775, DOI 10.1136/bmj.38950.561400.55
   Wright NC, 2014, J BONE MINER RES, V29, P2520, DOI 10.1002/jbmr.2269
   Xia WB, 2012, J BONE MINER RES, V27, P125, DOI 10.1002/jbmr.519
   Xie WG, 2015, MED SCI MONITOR, V21, P1333, DOI 10.12659/MSM.894111
   Zheng HF, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002745
NR 201
TC 594
Z9 639
U1 11
U2 282
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2056 676X
J9 NAT REV DIS PRIMERS
JI Nat. Rev. Dis. Primers
PD SEP 29
PY 2016
VL 2
AR 16069
DI 10.1038/nrdp.2016.69
PG 16
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA DY1TO
UT WOS:000384877500001
PM 27681935
DA 2025 08 17
ER

PT J
AU Ren, SW
   Jiao, GJ
   Zhang, L
   You, YH
   Chen, YZ
AF Ren, Shanwu
   Jiao, Guangjun
   Zhang, Lu
   You, Yunhao
   Chen, Yunzhen
TI Bionic Tiger Bone Powder Improves Bone Microstructure and Bone
   Biomechanical Strength of Ovariectomized Rats
SO ORTHOPAEDIC SURGERY
LA English
DT Article
DE Bionic tiger bone powder; Osteoclasts; Osteogenesis; Osteoporosis;
   Ovariectomized rats
ID OSTEOPOROSIS
AB Objective: To study the curative effect of bionic tiger bone powder on osteoporosis in ovariectomized rats and investigate its mechanism.
   Methods: Overall, a 120 female Wistar rats were randomly divided into Sham (sham operated group), ovariectomy (OVX, ovariectomized group), TB (bionic tiger bone powder treatment group after ovariectomy) and TB + VD groups (bionic tiger bone powder + vitamin D treatment group after ovariectomy). The osteoporotic rat model was established 3 months after ovariectomy, and rats were intragastrically administrated with the corresponding drugs. Serum and bone tissue samples were collected from 10 rats in each group at weeks 4, 12 and 24 after intragastric administration. The bone microstructure of L 6 vertebrae was analyzed by MicroCT, the biomechanical strength of left femurs was measured by the three point bending test, and serum bone metabolism markers (P1NP and CTX) were detected by ELISA. Changes in bone collagen were analyzed by Masson's trichrome staining and hydroxyproline detection, and members of the BMP2/SMAD/RUNX2 and OPG/RANKL/RANK signal pathways were detected by immunoblotting.
   Results: Compared with the OVX group, the serum level of P1NP in the TB and TB + VD groups was higher (P < 0.05), while the CTX level was lower (P < 0.05). Bone collagen fiber structures in the TB and TB + VD groups were repaired, and the collagen content was significantly higher than that in the OVX group (P < 0.05). In the TB group, BMP 2, P SMAD1/5, RUNX2 and OPG levels were increased in bone tissue (P < 0.01), RANKL levels were decreased (P < 0.01), and the bone microstructure and biomechanical strength were improved.
   Conclusion: Bionic tiger bone powder promotes osteogenesis by activating the BMP2/SMAD/RUNX2 signaling pathway, suppresses osteoclasts by downregulating the OPG/RANK/RANKL signaling pathway, increases bone collagen content, and improves bone microstructure and bone biomechanical strength.
C1 [Ren, Shanwu; Jiao, Guangjun; Zhang, Lu; You, Yunhao; Chen, Yunzhen] Shandong Univ, Dept Orthoped, Qilu Hosp, Jinan 250012, Shandong, Peoples R China.
   [Ren, Shanwu; Jiao, Guangjun; Zhang, Lu; You, Yunhao; Chen, Yunzhen] Shandong Univ, Spine & Spinal Cord Dis Res Ctr, Jinan 250012, Shandong, Peoples R China.
C3 Shandong University; Shandong University
RP Chen, YZ (通讯作者)，Shandong Univ, Dept Orthoped, Qilu Hosp, Jinan 250012, Shandong, Peoples R China.; Chen, YZ (通讯作者)，Shandong Univ, Spine & Spinal Cord Dis Res Ctr, Jinan 250012, Shandong, Peoples R China.
EM qilucyz@yeah.net
CR Andersen CY, 2015, REPROD BIOMED ONLINE, V31, P128, DOI 10.1016/j.rbmo.2015.05.002
   [Anonymous], 1998, Guidelines for preclinical evaluation and clinical trials in osteoporosis
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Crockett JC, 2011, OSTEOPOROSIS INT, V22, P1, DOI 10.1007/s00198 010 1272 8
   Du, 2001, AMI ACI BIORES, V17, P13
   Han N., 2012, Chin J Tissue Eng Res, V16, P201
   Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2
   Kimura S, 2017, OSTEOPOROSIS INT, V28, P1109, DOI 10.1007/s00198 016 3812 3
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441 009 0832 8
   Laib A, 2001, OSTEOPOROSIS INT, V12, P936, DOI 10.1007/s001980170022
   Leppänen OV, 2008, J BIOMECH, V41, P1623, DOI 10.1016/j.jbiomech.2008.03.017
   Li Y, 2014, CHIN J NAT MEDICINES, V12, P204, DOI 10.1016/S1875 5364(14)60034 0
   Marcus R, 2000, ATLAS OF CLINICAL ENDOCRINOLOGY, VOLUME 3, P1
   PARFITT AM, 1987, CLIN OBSTET GYNECOL, V30, P789, DOI 10.1097/00003081 198712000 00004
   Pratap J, 2011, BONE, V48, P30, DOI 10.1016/j.bone.2010.05.035
   Reffitt DM, 2003, BONE, V32, P127, DOI 10.1016/S8756 3282(02)00950 X
   Sharma C, 2014, PHYTOMEDICINE, V21, P1702, DOI 10.1016/j.phymed.2014.08.008
   Shen, 2012, NEI MONGOL J TRADI C, V03, P77
   Sun SC, 2005, ZHONG GUO GU ZHI SHU, V11, P490
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Verschueren S, 2013, OSTEOPOROSIS INT, V24, P87, DOI 10.1007/s00198 012 2057 z
   Vlacic Zischke J, 2011, BIOMATERIALS, V32, P665, DOI 10.1016/j.biomaterials.2010.09.025
   Xu FF, 2016, J ETHNOPHARMACOL, V177, P148, DOI 10.1016/j.jep.2015.11.007
NR 23
TC 8
Z9 11
U1 0
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1757 7853
EI 1757 7861
J9 ORTHOP SURG
JI Orthop. Surg.
PD MAY
PY 2021
VL 13
IS 3
BP 1111
EP 1118
DI 10.1111/os.12954
EA APR 2021
PG 8
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA SD0QD
UT WOS:000636615100001
PM 33818004
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Huang, Y
   Xu, YQ
   Feng, SY
   He, P
   Sheng, B
   Ni, JD
AF Huang, Yan
   Xu, Yongqiang
   Feng, Siyin
   He, Pan
   Sheng, Bing
   Ni, Jiangdong
TI miR 19b enhances osteogenic differentiation of mesenchymal stem cells
   and promotes fracture healing through the WWP1/Smurf2 mediated
   KLF5/β catenin signaling pathway
SO EXPERIMENTAL AND MOLECULAR MEDICINE
LA English
DT Article
ID STROMAL CELLS; LIGASE WWP1
AB Bone marrow mesenchymal stem cell (BMSC) derived exosomes have been found to enhance fracture healing. In addition, microRNAs contributing to the healing of various bone fractures have attracted widespread attention in recent years, but knowledge of the mechanisms by which they act is still very limited. In this study, we clarified the function of altered microRNA 19b (miR 19b) expression in BMSCs in fracture healing. We modulated miR 19b expression via mimics/inhibitors in BMSCs and via agomirs in mice to explore the effects of these changes on osteogenic factors, bone cell mineralization and the healing status of modeled fractures. Through gain  and loss of function assays, the binding affinity between miR 19b and WWP1/Smurf2 was identified and characterized to explain the underlying mechanism involving the KLF5/beta catenin signaling pathway. miR 19b promoted the differentiation of human BMSCs into osteoblasts by targeting WWP1 and Smurf2. Overexpression of WWP1 or Smurf2 degraded the target protein KLF5 in BMSCs through ubiquitination to inhibit fracture healing. KLF5 knockdown delayed fracture healing by modulating the Wnt/beta catenin signaling pathway. Furthermore, miR 19b enhanced fracture healing via the KLF5/beta catenin signaling pathway by targeting WWP1 or Smurf2. Moreover, miR 19b was found to be enriched in BMSC derived exosomes, and treatment with exosomes promoted fracture healing in vivo. Collectively, these results indicate that mesenchymal stem cell derived exosomal miR 19b represses the expression of WWP1 or Smurf2 and elevates KLF5 expression through the Wnt/beta catenin signaling pathway, thereby facilitating fracture healing.
   Bone healing: Small RNA molecule implicated in fracture repair Understanding how a small regulatory RNA molecule helps to promote fracture healing could lead to new treatments for broken bones. Working with human cells and mouse models, a team led by Yongqiang Xu from the Hunan Provincial People's Hospital in Changsha, China, showed how microRNA 19b in extracellular vesicles secreted by bone marrow stem cells (BMSCs) contributes to the healing process. The researchers found that the microRNA blocks the function of two proteins that normally restrain the activity of a third protein needed for BMSCs to home in on the site of injury and turn into new bone tissue. In mice with leg bone fractures, injections of microRNA 19b filled vesicles derived from BMSCs accelerated healing and recovery, suggesting that similar therapies might be helpful in human patients.
C1 [Huang, Yan; Xu, Yongqiang; Feng, Siyin; He, Pan; Sheng, Bing] Hunan Prov Peoples Hosp, Dept Orthopaed, Changsha, Peoples R China.
   [Huang, Yan; Ni, Jiangdong] Cent South Univ, Dept Orthopaed, Xiangya Hosp 2, Changsha, Peoples R China.
C3 Central South University
RP Xu, YQ (通讯作者)，Hunan Prov Peoples Hosp, Dept Orthopaed, Changsha, Peoples R China.
EM 13469043016@163.com
OI /0000 0002 6536 7845
FU Changsha Science and Technology Project Study on the Treatment of
   Traumatic Bone Defect with New Medical Magnesium Alloy Induced Bone
   Formation [kq1901050]
FX We acknowledge and appreciate our colleagues for their valuable efforts
   and comments on this paper. This study was supported by the Changsha
   Science and Technology Project Study on the Treatment of Traumatic Bone
   Defect with New Medical Magnesium Alloy Induced Bone Formation (No.
   kq1901050).
CR Bao QW, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 02705 0
   Chen CS, 2005, J BIOL CHEM, V280, P41553, DOI 10.1074/jbc.M506183200
   Du JX., 2011, GASTROENTEROLOGY, V140, P40354
   Dulany K, 2020, J BIOMED MATER RES A, V108, P301, DOI 10.1002/jbm.a.36816
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   Furuta T, 2016, STEM CELL TRANSL MED, V5, P1620, DOI 10.5966/sctm.2015 0285
   Gao Jin Yu, 2018, Shanghai Kou Qiang Yi Xue, V27, P28
   Garrison KR, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006950.pub2
   Huang Y, 2012, J ORTHOP RES, V30, P304, DOI 10.1002/jor.21505
   Isaksson H, 2009, J ORTHOP RES, V27, P664, DOI 10.1002/jor.20725
   Jin Q, 2019, CLIN CANCER RES, V25, P222, DOI 10.1158/1078 0432.CCR 18 1740
   Killock David, 2014, Nat Rev Rheumatol, V10, P3, DOI 10.1038/nrrheum.2013.186
   Kodama A, 2012, J BONE JOINT SURG BR, V94B, P998, DOI 10.1302/0301 620X.94B7.28521
   Lacroix D, 2002, J BIOMECH, V35, P1163, DOI 10.1016/S0021 9290(02)00086 6
   Ladang A, 2020, CALCIFIED TISSUE INT, V106, P239, DOI 10.1007/s00223 019 00628 8
   Lagos Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921
   Liu J, 2017, BONE JOINT RES, V6, P154, DOI 10.1302/2046 3758.63.BJR 2016 0237.R1
   Liu W, 2020, ACTA BIOMATER, V103, P196, DOI 10.1016/j.actbio.2019.12.020
   Liu YB, 2019, J CELL MOL MED, V23, P3855, DOI 10.1111/jcmm.14229
   Long HT, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1693 z
   Luo ZW, 2019, NANOSCALE, V11, P20884, DOI 10.1039/c9nr02791b
   Maes C, 2006, J CLIN INVEST, V116, P1230, DOI 10.1172/JCI26772
   Mauney JR, 2005, BIOMATERIALS, V26, P3173, DOI 10.1016/j.biomaterials.2004.08.020
   Qiu PC, 2020, BIOMATERIALS, V227, DOI 10.1016/j.biomaterials.2019.119552
   Rotin D, 2009, NAT REV MOL CELL BIO, V10, P398, DOI 10.1038/nrm2690
   Shu L, 2013, J BONE MINER RES, V28, P1925, DOI 10.1002/jbmr.1938
   Tang JM, 2018, ONCOGENE, V37, P4723, DOI 10.1038/s41388 018 0310 4
   Toosi S, 2020, BIOFACTORS, V46, P326, DOI 10.1002/biof.1598
   Wang XQ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193059
   Zarecki P, 2020, BONE, V130, DOI 10.1016/j.bone.2019.115105
   Zhao D, 2012, CARCINOGENESIS, V33, P59, DOI 10.1093/carcin/bgr242
   Zhu LP, 2018, THERANOSTICS, V8, P6163, DOI 10.7150/thno.28021
   Zhu Y, 2019, CELL BIOL INT, V43, P565, DOI 10.1002/cbin.11133
NR 33
TC 47
Z9 51
U1 2
U2 36
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1226 3613
EI 2092 6413
J9 EXP MOL MED
JI Exp. Mol. Med.
PD MAY
PY 2021
VL 53
IS 5
BP 973
EP 985
DI 10.1038/s12276 021 00631 w
EA MAY 2021
PG 13
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA SN4MU
UT WOS:000654095700003
PM 34035464
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Li, SY
   Han, XB
   Liu, NY
   Chang, J
   Liu, G
   Hu, SW
AF Li, Siying
   Han, Xuebing
   Liu, Naiyuan
   Chang, Jiang
   Liu, Gang
   Hu, Siwang
TI Lactobacillus plantarum attenuates glucocorticoid induced
   osteoporosis by altering the composition of rat gut microbiota and serum
   metabolic profile
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE osteoporosis; glucocorticoids; food active ingredients; dexamethasone;
   probiotics; gut microbes; differential metabolites; L. plantarum
ID BONE MINERAL DENSITY; SOY SKIM MILK; PREVOTELLA HISTICOLA; FEMORAL BONE;
   BISPHOSPHONATES; DIFFERENTIATION; ALENDRONATE; MECHANISM;
   TETRAMETHYLPYRAZINE; PATHOPHYSIOLOGY
AB Introduction: Osteoporosis, one of the most common non communicable human diseases worldwide, is one of the most prevalent disease of the adult skeleton. Glucocorticoid induced osteoporosis(GIOP) is the foremost form of secondary osteoporosis, extensively researched due to its prevalence.Probiotics constitute a primary bioactive component within numerous foods, offering promise as a potential biological intervention for preventing and treating osteoporosis. This study aimed to evaluate the beneficial effects of the probiotic Lactobacillus plantarum on bone health and its underlying mechanisms in a rat model of glucocorticoid dexamethasone induced osteoporosis, using the osteoporosis treatment drug alendronate as a reference.Methods: We examined the bone microstructure (Micro CT and HE staining) and analyzed the gut microbiome and serum metabolome in rats.Results and discussion: The results revealed that L. plantarum treatment significantly restored parameters of bone microstructure, with elevated bone density, increased number and thickness of trabeculae, and decreased Tb.Sp. Gut microbiota sequencing results showed that probiotic treatment increased gut microbial diversity and the ratio of Firmicutes to Bacteroidota decreased. Beneficial bacteria abundance was significantly increased (Lachnospiraceae_NK4A136_group, Ruminococcus, UCG_005, Romboutsia, and Christensenellaceae_R_7_group), and harmful bacteria abundance was significantly decreased (Desulfovibrionaceae). According to the results of serum metabolomics, significant changes in serum metabolites occurred in different groups. These differential metabolites were predominantly enriched within the pathways of Pentose and Glucuronate Interconversions, as well as Propanoate Metabolism. Furthermore, treatment of L. plantarum significantly increased serum levels of Pyrazine and gamma Glutamylcysteine, which were associated with inhibition of osteoclast formation and promoting osteoblast formation. Lactobacillus plantarum can protect rats from DEX induced GIOP by mediating the "gut microbial bone axis" promoting the production of beneficial bacteria and metabolites. Therefore L. plantarum is a potential candidate for the treatment of GIOP.
C1 [Li, Siying; Chang, Jiang; Hu, Siwang] Wenzhou Med Univ, Peoples Hosp Wenling 1, Wenling Hosp, Orthopaed Ctr, Wenzhou, Zhejiang, Peoples R China.
   [Li, Siying; Han, Xuebing; Liu, Naiyuan; Liu, Gang] Hunan Agr Univ, Coll Biosci & Biotechnol, Changsha, Hunan, Peoples R China.
C3 Wenzhou Medical University; Hunan Agricultural University
RP Hu, SW (通讯作者)，Wenzhou Med Univ, Peoples Hosp Wenling 1, Wenling Hosp, Orthopaed Ctr, Wenzhou, Zhejiang, Peoples R China.; Liu, G (通讯作者)，Hunan Agr Univ, Coll Biosci & Biotechnol, Changsha, Hunan, Peoples R China.
EM gangle.liu@gmail.com; siwang_h@wmu.edu.cn
RI Han, Xuebing/JFJ 4053 2023
FU Zhejiang Provincial Program for Medicine and Health [2022KY446,
   2022KY447, 2023KY1345, 2023KY1347]; Social Development Science and
   Technology Foundation of Taizhou [21ywb118, 20ywb143]; Social
   Development Science and Technology Foundation of Wenling [2020S0180083,
   2021S00156, 2020S0180127]
FX The author(s) declare financial support was received for the research,
   authorship, and/or publication of this article. The research was
   supported by the grants from Zhejiang Provincial Program for Medicine
   and Health (2022KY446, 2022KY447, 2023KY1345, 2023KY1347), Social
   Development Science and Technology Foundation of Taizhou (21ywb118,
   20ywb143), Social Development Science and Technology Foundation of
   Wenling (2020S0180083, 2021S00156, 2020S0180127).
CR Anam AK, 2021, MED CLIN N AM, V105, P1117, DOI 10.1016/j.mcna.2021.05.016
   Arafa EA, 2023, BIOMED PHARMACOTHER, V161, DOI 10.1016/j.biopha.2023.114461
   Benford HL, 2001, BONE, V28, P465, DOI 10.1016/S8756 3282(01)00412 4
   Chen TH, 2007, BIOCHEM BIOPH RES CO, V355, P913, DOI 10.1016/j.bbrc.2007.02.057
   Chiang SS, 2012, J SCI FOOD AGR, V92, P328, DOI 10.1002/jsfa.4579
   Chiang SS, 2011, J AGR FOOD CHEM, V59, P7734, DOI 10.1021/jf2013716
   Clowes JA, 2005, IMMUNOL REV, V208, P207, DOI 10.1111/j.0105 2896.2005.00334.x
   Davison S, 2003, CLIN ENDOCRINOL, V58, P249, DOI 10.1046/j.1365 2265.2003.01774.x
   de Villiers TJ, 2013, CLIMACTERIC, V16, P203, DOI 10.3109/13697137.2013.771520
   den Uyl D, 2011, CURR RHEUMATOL REP, V13, P233, DOI 10.1007/s11926 011 0173 y
   Ding SJ, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01152
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Fleisch HA, 1997, ANN MED, V29, P55, DOI 10.3109/07853899708998743
   Föger Samwald U, 2020, EXCLI J, V19, P1017, DOI 10.17179/excli2020 2591
   Hantzschel H, 2004, Z Rheumatol, V63, P501, DOI 10.1007/s00393 004 0660 x
   Hu H, 2018, BIOMED PHARMACOTHER, V105, P66, DOI 10.1016/j.biopha.2018.05.051
   Jin ES, 2023, FOOD SCI ANIM RESOUR, V43, P712, DOI 10.5851/kosfa.2023.e29
   Kanzaki H, 2013, J BIOL CHEM, V288, P23009, DOI 10.1074/jbc.M113.478545
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Kim HJ, 2006, J CLIN INVEST, V116, P2152, DOI 10.1172/JCI28084
   Klotzbuecher CM, 2000, J BONE MINER RES, V15, P721, DOI 10.1359/jbmr.2000.15.4.721
   Komm BS, 2014, J STEROID BIOCHEM, V143, P207, DOI 10.1016/j.jsbmb.2014.03.003
   Lawenius L, 2022, J ENDOCRINOL, V254, P91, DOI 10.1530/JOE 21 0408
   Lee CS, 2021, J APPL MICROBIOL, V130, P2041, DOI 10.1111/jam.14852
   Lee CS, 2020, PROBIOTICS ANTIMICRO, V12, P623, DOI 10.1007/s12602 019 09577 y
   Li B, 2020, BIOMED PHARMACOTHER, V132, DOI 10.1016/j.biopha.2020.110923
   Li J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.348
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Liu JS, 2021, FOOD FUNCT, V12, P4458, DOI [10.1039/D1FO00113B, 10.1039/d1fo00113b]
   Liu TH, 2018, FOOD FUNCT, V9, P4916, DOI 10.1039/c8fo01303a
   Liu XF, 2023, FRONT IMMUNOL, V14, DOI 10.3389/fimmu.2023.1186892
   Lucas S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02490 4
   Luo DS, 2019, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01483
   Ma C, 2023, INT IMMUNOPHARMACOL, V123, DOI 10.1016/j.intimp.2023.110572
   Ma Y, 2022, FRONT NUTR, V9, DOI 10.3389/fnut.2022.947367
   Ma YS, 2018, MOL MED REP, V17, P1633, DOI 10.3892/mmr.2017.8065
   Malkawi AK, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00046
   Mangano KM, 2021, BONE, V144, DOI 10.1016/j.bone.2020.115780
   Mao HM, 2021, NUTR METAB, V18, DOI 10.1186/s12986 021 00602 y
   Mccabe LR, 2013, J CELL PHYSIOL, V228, P1793, DOI 10.1002/jcp.24340
   Miller PD, 2013, J BONE MINER RES, V28, P2049, DOI 10.1002/jbmr.2058
   Morato Martínez M, 2020, NUTRIENTS, V12, DOI 10.3390/nu12082203
   Myeong JY, 2024, PROBIOTICS ANTIMICRO, V16, P541, DOI 10.1007/s12602 023 10065 7
   Nilsson AG, 2018, J INTERN MED, V284, P307, DOI 10.1111/joim.12805
   Oyhanart SR, 2015, PEDIATR RES, V78, P618, DOI 10.1038/pr.2015.163
   Park KB, 2007, BIORESOURCE TECHNOL, V98, P312, DOI 10.1016/j.biortech.2006.01.004
   Partoazar A, 2022, J FOOD BIOCHEM, V46, DOI 10.1111/jfbc.14120
   Rozenberg S, 2020, MATURITAS, V138, P14, DOI 10.1016/j.maturitas.2020.05.004
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Sapra L, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.875788
   Sapra L, 2021, SCI REP UK, V11, DOI 10.1038/s41598 020 80536 2
   Scholz Ahrens KE, 2002, BRIT J NUTR, V87, pS179, DOI 10.1079/BJN/2002535
   Sojan JM, 2023, CELLS BASEL, V12, DOI 10.3390/cells12030364
   Stapleton M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071345
   Stojanov S, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8111715
   Sousa LHT, 2017, ARCH ORAL BIOL, V77, P55, DOI 10.1016/j.archoralbio.2017.01.014
   Tonino RP, 2000, J CLIN ENDOCR METAB, V85, P3109, DOI 10.1210/jc.85.9.3109
   Tsai WH, 2023, FOOD FUNCT, V14, P6929, DOI [10.1039/d3fo00681f, 10.1039/D3FO00681F]
   Villa CR, 2017, CRIT REV FOOD SCI, V57, P1664, DOI 10.1080/10408398.2015.1010034
   Wang G, 2022, J CELL PHYSIOL, V237, P1790, DOI 10.1002/jcp.30642
   Wang H, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.932488
   Wang J, 2019, OSTEOPOROSIS INT, V30, P1491, DOI 10.1007/s00198 019 04892 0
   Wang L, 2017, MOL MED REP, V16, P8307, DOI 10.3892/mmr.2017.7610
   Wang L, 2017, STEM CELLS DEV, V26, P419, DOI 10.1089/scd.2016.0233
   Wang Z, 2020, J ETHNOPHARMACOL, V260, DOI 10.1016/j.jep.2020.112991
   Wang ZX, 2021, AM J CLIN NUTR, V114, P1304, DOI 10.1093/ajcn/nqab194
   Weare Regales N, 2021, J ALLER CL IMM PRACT, V9, P1841, DOI 10.1016/j.jaip.2020.12.050
   Weinstein R S, 2001, Rev Endocr Metab Disord, V2, P65, DOI 10.1023/A:1010007108155
   Weinstein RS, 2011, NEW ENGL J MED, V365, P62, DOI 10.1056/NEJMcp1012926
   Yan J, 2018, GUT MICROBES, V9, P84, DOI 10.1080/19490976.2017.1371893
   Yang LC, 2020, NUTRIENTS, V12, DOI 10.3390/nu12071914
   Yang XH, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 44766 3
   Yang Y, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00731
   Yao ZY, 2022, ZOOL RES, V43, P380, DOI 10.24272/j.issn.2095 8137.2022.023
   Ye XL, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.762691
   Yeom J, 2021, MICROORGANISMS, V9, DOI 10.3390/microorganisms9040673
   Zaiss MM, 2019, J CLIN INVEST, V129, P3018, DOI 10.1172/JCI128521
   Zhai ZY, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01595
   Zhan ZY, 2022, FRONT MICROBIOL, V13, DOI 10.3389/fmicb.2022.976406
   Zhang JY, 2023, EUR J MED CHEM, V259, DOI 10.1016/j.ejmech.2023.115654
   Zhang YW, 2023, MICROORGANISMS, V11, DOI 10.3390/microorganisms11040950
   Zhang YW, 2023, CRIT REV FOOD SCI, V63, P7510, DOI 10.1080/10408398.2022.2047005
   Zhang YW, 2021, FOOD FUNCT, V12, P5703, DOI [10.1039/d0fo03468a, 10.1039/D0FO03468A]
   Zhao HX, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 34574 6
   Zhao H, 2022, NUTRIENTS, V14, DOI 10.3390/nu14224846
   Zhao L, 2017, FOOD FUNCT, V8, P4644, DOI [10.1039/c7fo01383c, 10.1039/C7FO01383C]
   Zhao N, 2023, DRUG DES DEV THER, V17, P579, DOI 10.2147/DDDT.S396649
   Zhen YK, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.848248
   Huanhuan,, 2022, JAMA J AM MED ASSOC, V327, P682, DOI 10.1001/jama.2021.24522
   Zhou BL, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00575
   Zhou J, 2021, TOXICOL SCI, V183, P363, DOI 10.1093/toxsci/kfab096
   Zhou MZ, 2021, FOOD CHEM, V365, DOI 10.1016/j.foodchem.2021.130495
   Zhou PC, 2022, BONE, V164, DOI 10.1016/j.bone.2022.116540
   Zhou QQ, 2022, FRONT NUTR, V9, DOI 10.3389/fnut.2022.972569
   Zhu LH, 2020, IMMUNOL RES, V68, P107, DOI 10.1007/s12026 020 09118 8
   Zhu YT, 2019, INT J BIOL MACROMOL, V121, P342, DOI 10.1016/j.ijbiomac.2018.09.201
   Zielinska KA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00592
   Zijlstra GJ, 2012, EUR RESPIR J, V39, P439, DOI 10.1183/09031936.00017911
   ZUCKNER J, 1964, ANN RHEUM DIS, V23, P456, DOI 10.1136/ard.23.6.456
   Zullo AR, 2018, J AM MED DIR ASSOC, V19, P174, DOI 10.1016/j.jamda.2017.11.008
   Zuo HJ, 2022, ENVIRON RES, V215, DOI 10.1016/j.envres.2022.114206
   Zura R, 2016, JAMA SURG, V151, DOI 10.1001/jamasurg.2016.2775
NR 102
TC 22
Z9 25
U1 7
U2 25
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JAN 9
PY 2024
VL 14
AR 1285442
DI 10.3389/fimmu.2023.1285442
PG 18
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA FV6B4
UT WOS:001148657500001
PM 38264658
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Martini, G
   Gennari, L
   Merlotti, D
   Salvadori, S
   Franci, MB
   Campagna, S
   Avanzati, A
   De Paola, V
   Valleggi, F
   Nuti, R
AF Martini, G.
   Gennari, L.
   Merlotti, D.
   Salvadori, S.
   Franci, M. B.
   Campagna, S.
   Avanzati, A.
   De Paola, V.
   Valleggi, F.
   Nuti, R.
TI Serum OPG and RANKL levels before and after intravenous bisphosphonate
   treatment in Paget's disease of bone
SO BONE
LA English
DT Article
DE Paget's disease of bone; OPG; RANKL; NF kB signaling; pamidronate
ID FAMILIAL EXPANSILE OSTEOLYSIS; OSTEOBLAST LIKE CELLS; POSTMENOPAUSAL
   WOMEN; ZOLEDRONIC ACID; OSTEOPROTEGERIN LIGAND; MINERAL DENSITY;
   GENE EXPRESSION; SQSTM1 GENE; RESORPTION; MUTATIONS
AB Paget 's disease of bone (PDB) is a focal disorder of bone remodeling characterized by increased osteoclast mediated bone resorption. Even though increasing evidence indicates enhanced nuclear factor kB (NF kB) signaling as a common mechanism involved in PDB and other related disorders, few studies investigated circulating osteoprotegerin (OPG) and receptor of activator of NF kB ligand (RANKL) levels in PDB patients. In this study we explored the relationships between OPG or RANKL levels and bone turnover markers in a group of patients with PDB, before and after intravenous bisphosphonate treatment (pamidronate 60 mg). Both OPG and RANKL were markedly elevated in PDB patients with respect to control groups (healthy or osteoporotic postmenopausal women and elderly men) and were positively associated with bone turnover markers. Higher levels of these cytokines were observed in polyostotic than monostotic PDB cases. The ratio between RANKL and OPG was more than 3 fold higher in PDB patients than in controls. Interestingly, in the group of patients treated with pamidronate, we found an increase in OPG levels that become statistically significant after 3 and 6 months from treatment. A trend toward a decrease in RANKL levels after treatment was also observed. The RANKL/OPG ratio was significantly reduced after 3 and 6 months of therapy. In contrast, in patients classified as non responders. OPG and RANKL levels after pamidronate infusion did not significantly differ with respect to pre treatment values. Thus, the positive effect of amino bisphosphonates in the treatment of PDB may be due to either direct or indirect suppression of RANKL induced bone resorption through decreased RANKL and increased OPG production. (c) 2006 Elsevier Inc. All rights reserved.
C1 Univ Siena, Dept Internal Med, Policlin Le Scotte, I 53100 Siena, Italy.
C3 University of Siena
RP Martini, G (通讯作者)，Univ Siena, Dept Internal Med, Policlin Le Scotte, Viale Bracci 1, I 53100 Siena, Italy.
EM martinig@unisi.it
RI Gennari, Luigi/J 7013 2016; Merlotti, Daniela/J 8245 2016; de paola,
   vincenzo/B 4900 2016
OI Merlotti, Daniela/0000 0002 3338 6339; 
CR Alvarez L, 2003, ARTHRITIS RHEUM, V48, P824, DOI 10.1002/art.10834
   Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502
   Cundy T, 2002, HUM MOL GENET, V11, P2119, DOI 10.1093/hmg/11.18.2119
   Deftos LJ, 2005, NEW ENGL J MED, V353, P872, DOI 10.1056/NEJMp058184
   Dobnig H, 2006, OSTEOPOROSIS INT, V17, P693, DOI 10.1007/s00198 005 0035 4
   Eghbali Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215
   Fahrleitner Pammer A, 2003, WIEN KLIN WOCHENSCHR, V115, P291, DOI 10.1007/BF03040334
   Falchetti A, 2004, J BONE MINER RES, V19, P1013, DOI 10.1359/JBMR.040203
   Gennari L, 2003, J BONE MINER RES, V18, pS390
   Giuliani N, 1998, BONE, V22, P455, DOI 10.1016/S8756 3282(98)00033 7
   Giuliani N, 1998, SCAND J RHEUMATOL, V27, P38
   Grigorie D, 2003, Rom J Intern Med, V41, P409
   Halasy Nagy JM, 2001, BONE, V29, P553, DOI 10.1016/S8756 3282(01)00615 9
   Hocking LJ, 2004, J BONE MINER RES, V19, P1122, DOI 10.1359/JBMR.0403015
   Hocking LJ, 2002, HUM MOL GENET, V11, P2735, DOI 10.1093/hmg/11.22.2735
   Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Hughes AE, 2000, NAT GENET, V24, P45, DOI 10.1038/71667
   Indridason OS, 2005, OSTEOPOROSIS INT, V16, P417, DOI 10.1007/s00198 004 1699 x
   Johnson Pais TL, 2003, J BONE MINER RES, V18, P1748, DOI 10.1359/jbmr.2003.18.10.1748
   Kanis JA, 2002, LANCET, V359, P1929, DOI 10.1016/S0140 6736(02)08761 5
   Khan SA, 1996, J BONE MINER RES, V11, P178
   Khosla S, 2002, OSTEOPOROSIS INT, V13, P394, DOI 10.1007/s001980200045
   Khosla S, 2002, J CLIN ENDOCR METAB, V87, P1550, DOI 10.1210/jc.87.4.1550
   Kim YH, 2002, EXP MOL MED, V34, P145, DOI 10.1038/emm.2002.21
   Kudlacek S, 2003, BONE, V32, P681, DOI 10.1016/S8756 3282(03)00090 5
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Laurin N, 2002, AM J HUM GENET, V70, P1582, DOI 10.1086/340731
   Layfield R, 2004, CALCIFIED TISSUE INT, V75, P347, DOI 10.1007/s00223 004 0041 0
   Lyles KW, 2001, J BONE MINER RES, V16, P1379, DOI 10.1359/jbmr.2001.16.8.1379
   Mackle PS, 2001, BRIT J CANCER, V84, P951, DOI 10.1054/bjoc.2000.1679
   MARTINI G, 2003, CALCIFIED TISSUE INT, V72, P780
   Menaa C, 2000, J CLIN INVEST, V105, P1833, DOI 10.1172/JCI9133
   Nakashima T, 2000, BIOCHEM BIOPH RES CO, V275, P768, DOI 10.1006/bbrc.2000.3379
   Nakatsuka K, 2003, J BONE MINER RES, V18, P1381, DOI 10.1359/jbmr.2003.18.8.1381
   Pan BQ, 2004, J BONE MINER RES, V19, P147, DOI 10.1359/jbmr.2004.19.1.147
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Reddy SV, 1999, J BONE MINER RES, V14, P3, DOI 10.1002/jbmr.5650140203
   Reid IR, 2005, NEW ENGL J MED, V353, P898, DOI 10.1056/NEJMoa044241
   Reinholz GG, 2000, CANCER RES, V60, P6001
   Rendina D, 2004, CALCIFIED TISSUE INT, V75, P189, DOI 10.1007/s00223 004 0103 3
   Rogers A, 2002, J CLIN ENDOCR METAB, V87, P4470, DOI 10.1210/jc.2002 020396
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   ROGERS MJ, 1992, BIOCHEM BIOPH RES CO, V189, P414, DOI 10.1016/0006 291X(92)91574 A
   Roodman GD, 2005, J CLIN INVEST, V115, P200, DOI 10.1172/JCI200524281
   Russell RGG, 1999, J BONE MINER RES, V14, P53, DOI 10.1002/jbmr.5650140212
   Selby PL, 2002, BONE, V31, P366, DOI 10.1016/S8756 3282(02)00817 7
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Ueland T, 2003, J CLIN ENDOCR METAB, V88, P1014, DOI 10.1210/jc.2002 020977
   Viereck V, 2002, BIOCHEM BIOPH RES CO, V291, P680, DOI 10.1006/bbrc.2002.6510
   Von Tirpitz C, 2003, ALIMENT PHARM THER, V17, P807, DOI 10.1046/j.1365 2036.2003.01448.x
   Whyte MP, 2002, NEW ENGL J MED, V347, P175, DOI 10.1056/NEJMoa013096
   Whyte MP, 2002, J BONE MINER RES, V17, P26, DOI 10.1359/jbmr.2002.17.1.26
   Yano K, 1999, J BONE MINER RES, V14, P518, DOI 10.1359/jbmr.1999.14.4.518
   Yeung RSM, 2004, J RHEUMATOL, V31, P844
   Zaidi M, 2003, J BONE MINER RES, V18, P599, DOI 10.1359/jbmr.2003.18.4.599
NR 57
TC 58
Z9 66
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD FEB
PY 2007
VL 40
IS 2
BP 457
EP 463
DI 10.1016/j.bone.2006.08.003
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 129ZD
UT WOS:000243767700023
PM 16979395
DA 2025 08 17
ER

PT J
AU Lee, JI
   Kim, HW
   Rhee, WI
   Park, JH
   Lim, SH
   Im, S
   Ko, YJ
AF Lee, Jong In
   Kim, Hye Won
   Rhee, Won Ihl
   Park, Joo Hyun
   Lim, Seong Hoon
   Im, Sun
   Ko, Young Jin
TI The beneficial effect of intravenous zoledronic acid therapy following
   an acute stroke in rats
SO BONE
LA English
DT Article
DE zoledronic acid; stroke; bone mineral density; carboxy terminal
   telopeptide; maximum load
ID CEREBRAL ARTERY OCCLUSION; MECHANICAL STRENGTH; CALCIUM METABOLISM;
   BONE; IMMOBILIZATION; BISPHOSPHONATES; PAMIDRONATE; RISEDRONATE;
   OSTEOPENIA; FRACTURES
AB Purpose: Changes of bone metabolism begin from the initial stages of stroke; therefore, early prevention of these changes has become important. The most appropriate target for preventive therapy is to restrict the profound increase in osteoclastic bone resorption that occur soon after stroke. Oral bisphosphonates, which selectively target osteoclasts and their precursors, are appropriate drugs, but dysphagia or drowsiness after acute stroke can make it difficult to easily administer these compounds to stroke patients. The intravenous (IV) administration of bisphosphonates is an alternative method that can overcome these limitations. In order to determine the effect of IV bisphosphonates at the initial stages of stroke for preventing bone loss, an experiment using ischemic stroke rats was conducted.
   Methods: Female Sprague Dawley rats (n = 100) were randomly divided into four separate groups; sham surgery and vehicle treated group (sham vehicle), stroke and vehicle treated group (stroke vehicle), stroke with low dose zoledronic acid treatment group (stroke low) and stroke with high dose zoledronic acid treatment group (stroke high). Permanent occlusion of the left middle cerebral artery was performed, resulting in right hemiplegia. The bone mineral density (BMD) of the 4th and 5th lumbar vertebrae and the femur on the stroke side were measured in vivo on the day before stroke and on the 10th and 21st day after stroke. The osteocalcin and carboxy terminal telopeptide blood levels were measured on the 10th and 21st day after stroke. The BMD of the excised proximal tibia and the maximum load of femoral neck were measured on the 21st day after stroke.
   Results: After 21 days of stroke, the BMD of the lumbar vertebrae, femur, and excised tibia and the maximum load of the femoral neck in the sham vehicle, stroke low, and stroke high groups were significantly higher than those in the stroke vehicle group (P < 0.05). The carboxyterminal telopeptide levels in the sham vehicle and stroke high groups were significantly lower than those in the stroke vehicle group (P < 0.05).
   Conclusion: The results suggest that IV zoledromic acid treatment might prevent bone loss during the initial stages of stroke. (c) 2006 Elsevier Inc. All rights reserved.
C1 Catholic Univ Korea, Coll Med, Dept Rehabil Med, Seoul 137701, South Korea.
C3 Catholic University of Korea
RP Ko, YJ (通讯作者)，Catholic Univ Korea, Coll Med, Dept Rehabil Med, 505 Banpo Dong, Seoul 137701, South Korea.
EM yjko@catholic.ac.kr
OI Lim, Seong Hoon/0000 0002 5475 4153; Im, Sun/0000 0001 8400 4911
CR Body JJ, 1999, J BONE MINER RES, V14, P1557, DOI 10.1359/jbmr.1999.14.9.1557
   GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627
   Glatt M, 2004, OSTEOPOROSIS INT, V15, P707, DOI 10.1007/s00198 004 1588 3
   Hornby SB, 2003, CALCIFIED TISSUE INT, V72, P519, DOI 10.1007/s00223 002 2015 4
   LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84
   Major P, 2001, J CLIN ONCOL, V19, P558, DOI 10.1200/JCO.2001.19.2.558
   Mosekilde L, 2000, BONE, V27, P639, DOI 10.1016/S8756 3282(00)00375 6
   MULLER K, 1998, DRUG RES, V48, P81
   Pataki A, 1997, ANAT REC, V249, P458, DOI 10.1002/(SICI)1097 0185(199712)249:4<458::AID AR5>3.0.CO;2 N
   Poole KES, 2002, STROKE, V33, P1432, DOI 10.1161/01.STR.0000014510.48897.7D
   Ramnemark A, 1998, OSTEOPOROSIS INT, V8, P92, DOI 10.1007/s001980050053
   Ramnemark A, 2000, STROKE, V31, P1572, DOI 10.1161/01.STR.31.7.1572
   Reid IR, 2002, NEW ENGL J MED, V346, P653, DOI 10.1056/NEJMoa011807
   Russell RGG, 1999, OSTEOPOROSIS INT, V9, P66, DOI 10.1007/PL00004164
   Sato Y, 1998, J NEUROL SCI, V156, P205, DOI 10.1016/S0022 510X(98)00041 0
   Sato Y, 2000, J BONE MINER RES, V15, P2487, DOI 10.1359/jbmr.2000.15.12.2487
   Sato Y, 2005, NEUROLOGY, V64, P811, DOI 10.1212/01.WNL.0000152871.65027.76
   Sato Y, 2000, ARCH PHYS MED REHAB, V81, P117, DOI 10.1053/apmr.2000.0810117
   Sato Y, 2000, J NEUROL SCI, V175, P135, DOI 10.1016/S0022 510X(00)00298 7
   Sato Y, 1996, EUR NEUROL, V36, P278, DOI 10.1159/000117272
   Sato Y, 1998, STROKE, V29, P1373, DOI 10.1161/01.STR.29.7.1373
   Sato Y, 1996, STROKE, V27, P2183, DOI 10.1161/01.STR.27.12.2183
   Warden SJ, 2005, MOL CELL ENDOCRINOL, V242, P1, DOI 10.1016/j.mce.2005.06.005
NR 23
TC 9
Z9 10
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD AUG
PY 2006
VL 39
IS 2
BP 377
EP 382
DI 10.1016/j.bone.2006.02.055
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 059BN
UT WOS:000238708400019
PM 16580897
DA 2025 08 17
ER

PT J
AU Xie, LB
   Song, X
   Lei, L
   Chen, C
   Zhao, H
   Hu, JY
   Yu, Y
   Bai, XL
   Wu, X
   Li, XF
   Yang, X
   Yuan, B
   Li, DX
   Zhu, XD
   Zhang, XD
AF Xie, Linbi
   Song, Xu
   Lei, Ling
   Chen, Chu
   Zhao, Huan
   Hu, Jingyi
   Yu, Yue
   Bai, Xiaolu
   Wu, Xia
   Li, Xiangfeng
   Yang, Xiao
   Yuan, Bo
   Li, Dongxiao
   Zhu, Xiangdong
   Zhang, Xingdong
TI Exploring the potential mechanism of Heng Gu Gu Shang Yu He Ji therapy
   for osteoporosis based on network pharmacology and transcriptomics
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Heng Gu Gu Shang Yu He Ji; Osteoporosis; Network pharmacology; Whole
   gene transcriptome sequencing; PI3K/AKT/mTORC1 signaling pathway
ID BONE; PREVENTION; OSTEOKING
AB Ethnopharmacological relevance: Heng Gu Gu Shang Yu He Ji (Osteoking, OK) is a well known formula for fracture therapy. In clinic, OK is effective in treating fractures while alleviating osteoporosis (OP) symptoms. However, active components of OK and the associated molecular mechanisms remain not fully elucidated. Aim of the study: This study aims to systematically evaluate the anti osteoporosis efficacy of OK and for the first time combine network pharmacology with high throughput whole gene transcriptome sequencing to study its underlying mechanism. Materials and methods: In this study, the osteoporosis model was established by the castration of both ovaries. The level of serum bone turnover factor was detected by enzyme linked immunosorbent assay. Micro CT and HE staining were used to observe the changes of bone histopathology, and nano indentation technique was used to detect the biomechanical properties of rat bone. The main active Chemical components of OK were identified using UPLC DAD. Efficacy verification and mechanism exploration were conducted by network pharmacology, molecular docking, whole gene transcriptomics and in vivo experiments. Results: In our study, OK significantly improved bone microarchitecture and bone biomechanical parameters in OVX rats, reduced osteoclast indexes such as C telopeptide of type I collage (CTX I) and increased Osteoprotegerin (OPG)/Receptor activator of NF kappa B ligand (RANKL) levels. Mechanistically, PI3K/AKT pathway was a common pathway for genome enrichment analysis (KEGG) of both network pharmacology and RNA seq studies. G protein beta like protein (G beta L), Ribosomal protein S6 kinase homolog 2 (S6K2), and Phosphoinositide 3 kinase (PI3K) appeared differentially expression in the PI3K AKT signaling pathway. These results were also confirmed by qRT PCR and immunohistochemistry. Conclusions: OK may be used to treat osteoporosis, at least partly by activating PI3K/AKT/mTORC1 signaling pathway.
C1 [Xie, Linbi; Zhao, Huan] Chengdu Univ Tradit Chinese Med TCM, Sch Pharm, Chengdu 610041, Peoples R China.
   [Xie, Linbi; Lei, Ling; Chen, Chu; Hu, Jingyi; Yu, Yue; Bai, Xiaolu; Wu, Xia; Li, Dongxiao] Sichuan Acad Chinese Med Sci, Sichuan Prov Key Lab Qual & Innovat Res Chinese Ma, Chengdu 610041, Peoples R China.
   [Song, Xu] Sichuan Univ, NMPA Key Lab Qual Res & Control Tissue Regenerat B, Chengdu 610064, Peoples R China.
   [Song, Xu] Sichuan Univ, Inst Regulatory Sci Med Devices, Chengdu 610041, Peoples R China.
   [Song, Xu] Sichuan Univ, NMPA Res Base Regulatory Sci Med Devices, Chengdu 610041, Peoples R China.
   [Li, Xiangfeng; Yang, Xiao; Yuan, Bo; Zhu, Xiangdong; Zhang, Xingdong] Sichuan Univ, Natl Engn Res Ctr Biomat, Sch Biomed Engn, Chengdu 610064, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine; Sichuan University;
   Sichuan University; Sichuan University; Sichuan University
RP Li, DX (通讯作者)，Sichuan Acad Chinese Med Sci, Sichuan Prov Key Lab Qual & Innovat Res Chinese Ma, Chengdu 610041, Peoples R China.; Zhu, XD (通讯作者)，Sichuan Univ, Natl Engn Res Ctr Biomat, Sch Biomed Engn, Chengdu 610064, Peoples R China.
EM right168@163.com; zhu_xd1973@scu.edu.cn
RI Li, Xiangfeng/IXX 0393 2023; Huang, Yan/N 3447 2018; Yuan,
   Bo/GQR 0023 2022
FU Sichuan Provincial Key Laboratory of Quality and Innovation Research of
   Chinese Materia Medica; National En gineering Research Center for
   Biomaterials & School of Biomedical Engineering
FX <B>Acknowledgments</B> We are grateful to the Sichuan Provincial Key
   Laboratory of Quality and Innovation Research of Chinese Materia Medica,
   NMPA Key Labo ratory for Quality Research and Control of Tissue
   Regenerative Bioma terial & Institute of Regulatory Science for Medical
   Devices & NMPA Research Base of Regulatory Science for Medical Devices,
   National En gineering Research Center for Biomaterials & School of
   Biomedical Engineering.
CR Akkawi Ibrahim, 2018, Joints, V6, P122, DOI 10.1055/s 0038 1660790
   An HQ, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000022734
   Ayub N, 2021, J CLIN MED, V10, DOI 10.3390/jcm10133002
   Dai LF, 2015, MOL MED REP, V12, P1066, DOI 10.3892/mmr.2015.3551
   Ding Y, 2019, J CELL BIOCHEM, V120, P16025, DOI 10.1002/jcb.28882
   Fattahi S, 2020, LIFE SCI, V262, DOI 10.1016/j.lfs.2020.118513
   Fukuda M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05187 4
   Gao K, 2021, AGING US, V13, P26003, DOI 10.18632/aging.203786
   Gao YH, 2004, P NATL ACAD SCI USA, V101, P16618, DOI 10.1073/pnas.0404888101
   Gjoksi B, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148 016 0209 2
   Golob AL, 2015, MED CLIN N AM, V99, P587, DOI 10.1016/j.mcna.2015.01.010
   Guo YF, 2021, J CELL PHYSIOL, V236, P4152, DOI 10.1002/jcp.30111
   Hu Y, 2022, LIFE BASEL, V12, DOI 10.3390/life12070980
   Huo MX, 2013, J SURG RES, V180, pE47, DOI 10.1016/j.jss.2012.10.050
   Irelli A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20235841
   Ji Q, 2015, EVID BASED COMPL ALT, V2015, DOI 10.1155/2015/983139
   Kakumoto K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119015
   Kim YJ, 2006, BIOCHEM PHARMACOL, V72, P1268, DOI 10.1016/j.bcp.2006.08.021
   Lagunas Rangel FA, 2023, J BIOMOL STRUCT DYN, V41, P8081, DOI 10.1080/07391102.2022.2126890
   Lewlecki EM, 2008, OBSTET GYN CLIN N AM, V35, P301, DOI 10.1016/j.ogc.2008.03.007
   Li J, 2022, CLIMACTERIC, V25, P562, DOI 10.1080/13697137.2022.2102894
   Li M, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/8223737
   Li P, 2022, BRIEF BIOINFORM, V23, DOI 10.1093/bib/bbab542
   Li YX, 2022, J ETHNOPHARMACOL, V299, DOI 10.1016/j.jep.2022.115674
   Ling HF, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.678810
   Liu H, 2021, MOL CELL ENDOCRINOL, V520, DOI 10.1016/j.mce.2020.111074
   Magnuson B, 2012, BIOCHEM J, V441, P1, DOI 10.1042/BJ20110892
   Peng ZC, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.911326
   Qin D, 2019, J ETHNOPHARMACOL, V244, DOI 10.1016/j.jep.2019.112045
   Qiu J, 2018, MOL MED REP, V17, P6301, DOI 10.3892/mmr.2018.8713
   Rizzoli Rene, 2011, Expert Rev Clin Pharmacol, V4, P593
   Sahbani K, 2022, ENDOCRINOLOGY, V163, DOI 10.1210/endocr/bqab230
   Si YH, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000020773
   Song SS, 2022, PHARMACOL THERAPEUT, V237, DOI 10.1016/j.pharmthera.2022.108168
   Sun Y, 2020, J TRADIT CHIN MED, V40, P422, DOI 10.19852/j.cnki.jtcm.2020.03.010
   Sun Y, 2020, INT J MOL MED, V45, P1543, DOI 10.3892/ijmm.2020.4529
   [孙岩 Sun Yan], 2016, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V22, P1513
   Tanaka H, 2011, BIOCHEM BIOPH RES CO, V411, P690, DOI 10.1016/j.bbrc.2011.07.001
   Tian S, 2015, ADV DRUG DELIVER REV, V86, P2, DOI 10.1016/j.addr.2015.01.009
   Trivedi R, 2008, MOL CELL ENDOCRINOL, V289, P85, DOI 10.1016/j.mce.2008.02.027
   Vasikaran S, 2011, CLIN CHEM LAB MED, V49, P1271, DOI 10.1515/CCLM.2011.602
   Wan DC, 2007, J BIOL CHEM, V282, P26450, DOI 10.1074/jbc.M703282200
   Wan G, 2014, AUTOPHAGY, V10, P70, DOI 10.4161/auto.26534
   Xu WF, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.842101
   Yousefzadeh N, 2020, EXCLI J, V19, P89, DOI 10.17179/excli2019 1990
   Yu CT, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906 019 2435 6
   Yuan B, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc4704
   Zhang AH, 2010, PLANTA MED, V76, P2026, DOI 10.1055/s 0030 1250542
   Zhang ND, 2016, J ETHNOPHARMACOL, V189, P61, DOI 10.1016/j.jep.2016.05.025
   Zhang Y, 2020, J CELL PHYSIOL, V235, P5511, DOI 10.1002/jcp.29261
   Zhou ZC, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/1646905
   Zhu FB, 2021, J IMMUNOL RES, V2021, DOI 10.1155/2021/5707242
   Zhu YJ, 2023, J ORTHOP SURG HONG K, V31, DOI 10.1177/10225536231175237
   Zhuo Y, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.901545
   Zurek A, 2019, TOXICOL APPL PHARM, V374, P53, DOI 10.1016/j.taap.2019.04.024
NR 55
TC 8
Z9 8
U1 4
U2 34
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD MAR 1
PY 2024
VL 321
AR 117480
DI 10.1016/j.jep.2023.117480
EA DEC 2023
PG 13
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA DU3Y4
UT WOS:001134566200001
PM 37995823
DA 2025 08 17
ER

PT J
AU Khotib, J
   Marhaeny, HD
   Miatmoko, A
   Budiatin, AS
   Ardianto, C
   Rahmadi, M
   Pratama, YA
   Tahir, M
AF Khotib, Junaidi
   Marhaeny, Honey Dzikri
   Miatmoko, Andang
   Budiatin, Aniek Setiya
   Ardianto, Chrismawan
   Rahmadi, Mahardian
   Pratama, Yusuf Alif
   Tahir, Muhammad
TI Differentiation of osteoblasts: the links between essential
   transcription factors
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article
DE Bone development; bone remodeling; osteoblast differentiation; essential
   transcription factors; molecular mechanisms; transcriptional regulation;
   bone disorders; ncRNAs
ID MESENCHYMAL STEM CELLS; PROMOTES OSTEOGENIC DIFFERENTIATION; VALVE
   INTERSTITIAL CELLS; MARROW STROMAL CELLS; BONE MARROW; PAGETS DISEASE;
   RUNX2 EXPRESSION; GENE EXPRESSION; CIRCULATING DICKKOPF 1;
   OSTEOPROGENITOR CELLS
AB Osteoblasts, cells derived from mesenchymal stem cells (MSCs) in the bone marrow, are cells responsible for bone formation and remodeling. The differentiation of osteoblasts from MSCs is triggered by the expression of specific genes, which are subsequently controlled by pro osteogenic pathways. Mature osteoblasts then differentiate into osteocytes and are embedded in the bone matrix. Dysregulation of osteoblast function can cause inadequate bone formation, which leads to the development of bone disease. Various key molecules are involved in the regulation of osteoblastogenesis, which are transcription factors. Previous studies have heavily examined the role of factors that control gene expression during osteoblastogenesis, both in vitro and in vivo. However, the systematic relationship of these transcription factors remains unknown. The involvement of ncRNAs in this mechanism, particularly miRNAs, lncRNAs, and circRNAs, has been shown to influence transcriptional factor activity in the regulation of osteoblast differentiation. Here, we discuss nine essential transcription factors involved in osteoblast differentiation, including Runx2, Osx, Dlx5, beta catenin, ATF4, Ihh, Satb2, and Shn3. In addition, we summarize the role of ncRNAs and their relationship to these essential transcription factors in order to improve our understanding of the transcriptional regulation of osteoblast differentiation. Adequate exploration and understanding of the molecular mechanisms of osteoblastogenesis can be a critical strategy in the development of therapies for bone related diseases.Communicated by Ramaswamy H. Sarma
C1 [Khotib, Junaidi; Marhaeny, Honey Dzikri; Budiatin, Aniek Setiya; Ardianto, Chrismawan; Rahmadi, Mahardian; Pratama, Yusuf Alif] Univ Airlangga, Fac Pharm, Dept Pharm Practice, Surabaya, Indonesia.
   [Miatmoko, Andang] Univ Airlangga, Fac Pharm, Dept Pharmaceut Sci, Surabaya, Indonesia.
   [Tahir, Muhammad] Int Islamic Univ Malaysia, Dept Pharmaceut Sci, Kulliyah Pharm, Pahang, Malaysia.
   [Khotib, Junaidi] Univ Airlangga, Fac Pharm, Dept Pharm Practice, Nanizar Zaman Joenoes Bldg, Surabaya 60115, Indonesia.
C3 Airlangga University; Airlangga University; International Islamic
   University Malaysia; Airlangga University
RP Khotib, J (通讯作者)，Univ Airlangga, Fac Pharm, Dept Pharm Practice, Nanizar Zaman Joenoes Bldg, Surabaya 60115, Indonesia.
EM junaidi k@ff.unair.ac.id
RI Rahmadi, Mahardian/ABD 2264 2020; Miatmoko, Andang/AGN 5633 2022;
   Khotib, Junaidi/AAJ 7238 2020; Ardianto, Chrismawan/ABF 1391 2021;
   Pratama, Yusuf Alif/HLR 6702 2023; Taher, Muhammad/A 6019 2016; setiya
   budiatin, aniek/GPF 6443 2022
OI Miatmoko, Andang/0000 0003 1658 0778; Taher,
   Muhammad/0000 0002 1463 3090
FU Ministry of Education, Culture, Research, and Technology of the Republic
   of Indonesia [891/UN3.15/PT/2022]
FX This work was supported by the Ministry of Education, Culture, Research,
   and Technology of the Republic of Indonesia with PMDSU scheme No.
   891/UN3.15/PT/2022.
CR Almeida M, 2013, J CLIN INVEST, V123, P394, DOI 10.1172/JCI65910
   Amarasekara DS, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22062851
   Ambrosi TH, 2017, CELL STEM CELL, V20, P771, DOI 10.1016/j.stem.2017.02.009
   Aurilia C, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22083909
   Baglìo SR, 2013, GENE, V527, P321, DOI 10.1016/j.gene.2013.06.021
   Balagangadharan K, 2018, INT J BIOL MACROMOL, V111, P953, DOI 10.1016/j.ijbiomac.2018.01.122
   Baldini N, 2009, WOODHEAD PUBL MATER, P69, DOI 10.1533/9781845696610.1.69
   Barrett SP, 2016, DEVELOPMENT, V143, P1838, DOI 10.1242/dev.128074
   Bassi A, 2011, WOODHEAD PUBL MATER, P93
   Beermann J, 2016, PHYSIOL REV, V96, P1297, DOI 10.1152/physrev.00041.2015
   Berendsen AD, 2015, BONE, V80, P14, DOI 10.1016/j.bone.2015.04.035
   Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534 5807(04)00058 9
   BIDWELL JP, 1993, P NATL ACAD SCI USA, V90, P3162, DOI 10.1073/pnas.90.8.3162
   Cai N, 2019, YONSEI MED J, V60, P751, DOI 10.3349/ymj.2019.60.8.751
   Camp E, 2018, STEM CELLS DEV, V27, P1621, DOI 10.1089/scd.2018.0083
   Capulli M, 2014, ARCH BIOCHEM BIOPHYS, V561, P3, DOI 10.1016/j.abb.2014.05.003
   Chan WCW, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115445
   Chen FG, 2019, INT J MOL MED, V43, P37, DOI 10.3892/ijmm.2018.3938
   Chen GY, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00208 x
   Chen GY, 2021, INT J BIOL SCI, V17, P1428, DOI 10.7150/ijbs.57887
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen SJ, 2020, AGING DIS, V11, P1058, DOI 10.14336/AD.2019.0724
   Chunhui L., 2020, CHINESE J TISSUE ENG, V24, P1989, DOI [10.3969/j.issn.2095 4344.2053, DOI 10.3969/J.ISSN.2095 4344.2053]
   Cuevas González MV, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/2069410
   Damiati LA, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.682581
   Danciu TE, 2012, J CELL BIOCHEM, V113, P70, DOI 10.1002/jcb.23329
   Davis BN, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478 811X 7 18
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   de Castro GRW, 2019, CUREUS J MED SCIENCE, V11, DOI 10.7759/cureus.4791
   Deng A, 2017, MOL MED REP, V16, P7987, DOI 10.3892/mmr.2017.7669
   Deng Y, 2013, STEM CELLS DEV, V22, P2278, DOI 10.1089/scd.2012.0686
   Dobreva G, 2006, CELL, V125, P971, DOI 10.1016/j.cell.2006.05.012
   DUCY P, 1995, MOL CELL BIOL, V15, P1858
   El Ganzuri M.A., 2016, Ann Cytol Pathol, V1, P5, DOI DOI 10.17352/ACP.000002
   Erceg I, 2003, CROAT MED J, V44, P407
   FitzPatrick DR, 2003, HUM MOL GENET, V12, P2491, DOI 10.1093/hmg/ddg248
   FRIEDENSTEIN AJ, 1970, CELL TISSUE KINET, V3, P393, DOI 10.1111/j.1365 2184.1970.tb00347.x
   Gámez B, 2013, J BIOL CHEM, V288, P14264, DOI 10.1074/jbc.M112.432104
   Xiaoling GL, 2020, BMC MED GENET, V21, DOI 10.1186/s12881 020 0948 y
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Ge XY, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01877 3
   Gennari L, 2019, CALCIFIED TISSUE INT, V104, P483, DOI 10.1007/s00223 019 00522 3
   Gibon E, 2012, TISSUE ENG PT A, V18, P968, DOI [10.1089/ten.tea.2011.0545, 10.1089/ten.TEA.2011.0545]
   Gong YM, 2016, MOL CELL BIOCHEM, V417, P7, DOI 10.1007/s11010 016 2709 y
   Gordon JAR, 2007, BONE, V41, P462, DOI 10.1016/j.bone.2007.04.191
   Guan SY, 2022, ISCIENCE, V25, DOI 10.1016/j.isci.2022.104807
   Guenou H, 2005, HUM MOL GENET, V14, P1429, DOI 10.1093/hmg/ddi152
   Han SJ, 2020, AGING US, V12, P15011, DOI 10.18632/aging.103560
   Hassan MQ, 2010, P NATL ACAD SCI USA, V107, P19879, DOI 10.1073/pnas.1007698107
   He SW, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 2148 2
   He WF, 2022, BIOENGINEERED, V13, P2181, DOI 10.1080/21655979.2021.2023982
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Hilton MJ, 2005, DEVELOPMENT, V132, P4339, DOI 10.1242/dev.02025
   Holleville N, 2007, DEV BIOL, V304, P860, DOI 10.1016/j.ydbio.2007.01.003
   Hu H, 2019, EXP MOL PATHOL, V107, P158, DOI 10.1016/j.yexmp.2019.02.003
   Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564
   Hu LC, 2021, MOL THER NUCL ACIDS, V23, P1345, DOI 10.1016/j.omtn.2021.02.008
   Hu LF, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020360
   Huang W, 2007, FRONT BIOSCI LANDMRK, V12, P3068, DOI 10.2741/2296
   Huang YY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099331
   Huang YP, 2015, STEM CELLS, V33, P3481, DOI 10.1002/stem.2225
   Huang YX, 2020, BIOMED PHARMACOTHER, V129, DOI 10.1016/j.biopha.2020.110365
   Iaquinta MR, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00268
   Ibrahim A, 2016, Open Orthop J, V10, P849, DOI 10.2174/1874325001610010849
   Idolazzi L, 2017, CLIN RHEUMATOL, V36, P925, DOI 10.1007/s10067 016 3497 1
   Inose H, 2009, P NATL ACAD SCI USA, V106, P20794, DOI 10.1073/pnas.0909311106
   Ji F, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00230
   Jonason JH, 2009, J DENT RES, V88, P693, DOI 10.1177/0022034509341629
   Jones DC, 2006, SCIENCE, V312, P1223, DOI 10.1126/science.1126313
   Kang S, 2007, J BIOL CHEM, V282, P14515, DOI 10.1074/jbc.M700030200
   Kapinas K, 2010, J BIOL CHEM, V285, P25221, DOI 10.1074/jbc.M110.116137
   Kawane T, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 31853 0
   Khotib J, 2021, PHARMACEUTICALS BASE, V14, DOI 10.3390/ph14070615
   Kim HK, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.40
   Kim JH, 2013, THER ADV MUSCULOSKEL, V5, P13, DOI 10.1177/1759720X12466608
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   KIM RH, 1994, MATRIX BIOL, V14, P31, DOI 10.1016/0945 053X(94)90027 2
   Knight MN, 2013, ADV WOUND CARE, V2, P306, DOI 10.1089/wound.2012.0420
   Kobayashi Y, 2008, JPN DENT SCI REV, V44, P76, DOI 10.1016/j.jdsr.2007.11.002
   Komaki M, 2007, J CELL BIOCHEM, V100, P303, DOI 10.1002/jcb.21038
   Komori T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071694
   Kureel J, 2017, INT J BIOCHEM CELL B, V85, P35, DOI 10.1016/j.biocel.2017.01.018
   Lavery K, 2009, BONE, V45, P27, DOI 10.1016/j.bone.2009.03.656
   Laxman N, 2017, GENES BASEL, V8, DOI 10.3390/genes8010004
   Lee MH, 2003, BIOCHEM BIOPH RES CO, V309, P689, DOI 10.1016/j.bbrc.2003.08.058
   Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200
   Lee MS, 1999, J CELL BIOCHEM, V75, P566, DOI 10.1002/(SICI)1097 4644(19991215)75:4<566::AID JCB3>3.0.CO;2 0
   Lekka E, 2018, FEBS LETT, V592, P2884, DOI 10.1002/1873 3468.13182
   Li DJ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20246229
   Li H, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.811666
   Li JQ, 2016, J BONE MINER METAB, V34, P367, DOI 10.1007/s00774 015 0734 7
   Li XG, 2019, EUR REV MED PHARMACO, V23, P4521, DOI 10.26355/eurrev_201906_18027
   Li YJ, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00523
   Liang WC, 2016, SCI REP UK, V6, DOI 10.1038/srep20121
   Lin X, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00757
   Liu Q, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.601224
   Liu SC, 2019, EUR REV MED PHARMACO, V23, P4584, DOI 10.26355/eurrev_201906_18035
   Liu TM, 2013, TISSUE ENG PART B RE, V19, P254, DOI [10.1089/ten.TEB.2012.0527, 10.1089/ten.teb.2012.0527]
   Long FX, 2004, DEVELOPMENT, V131, P1309, DOI 10.1242/dev.01006
   Lv H, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232695
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Pino AM, 2012, BIOL RES, V45, P279, DOI 10.4067/S0716 97602012000300009
   Marshall MJ, 2009, CLIN BIOCHEM, V42, P965, DOI 10.1016/j.clinbiochem.2009.04.007
   Martin A, 2011, FASEB J, V25, P2551, DOI 10.1096/fj.10 177816
   Matthews BG, 2020, CALCIFIED TISSUE INT, V106, P208, DOI 10.1007/s00223 019 00624 y
   Matthews BG, 2014, J BONE MINER RES, V29, P1283, DOI 10.1002/jbmr.2140
   Mi BB, 2019, AGING US, V11, P11988, DOI 10.18632/aging.102524
   Michou L, 2019, JOINT BONE SPINE, V86, P538, DOI 10.1016/j.jbspin.2019.01.015
   Miraoui H, 2010, J CELL BIOCHEM, V110, P1147, DOI 10.1002/jcb.22628
   Mouillé M, 2022, ORPHANET J RARE DIS, V17, DOI 10.1186/s13023 022 02229 5
   Nahian A., 2021, StatPearls
   Nakamura T, 1997, BIOCHEM BIOPH RES CO, V237, P465, DOI 10.1006/bbrc.1997.7156
   Nakashima K, 2003, TRENDS GENET, V19, P458, DOI 10.1016/S0168 9525(03)00176 8
   Nardocci G, 2018, J CELL BIOCHEM, V119, P7657, DOI 10.1002/jcb.27113
   Valenzuela EN, 2017, WIEN MED WOCHENSCHR, V167, P2, DOI 10.1007/s10354 016 0496 4
   Nemoto E, 2012, BIOCHEM BIOPH RES CO, V422, P627, DOI 10.1016/j.bbrc.2012.05.039
   NOHNO T, 1995, J BIOL CHEM, V270, P22522, DOI 10.1074/jbc.270.38.22522
   Ogasawara T, 2004, MOL CELL BIOL, V24, P6560, DOI 10.1128/mcb.24.15.6560 6568.2004
   Okamoto M, 2014, SCI REP UK, V4, DOI 10.1038/srep04493
   Omoteyama K, 2010, BIOCHEM BIOPH RES CO, V403, P242, DOI 10.1016/j.bbrc.2010.11.023
   Ouyang ZX, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 2161 5
   Pan T, 2022, BIOACT MATER, V10, P1, DOI 10.1016/j.bioactmat.2021.08.034
   Patil S, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.584118
   Ponzetti M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136651
   Qiu ZY, 2019, WOODH PUBL SER BIOM, P1, DOI 10.1016/B978 0 08 102717 2.00001 1
   Quarto N, 2015, STEM CELLS, V33, P833, DOI 10.1002/stem.1907
   ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632
   Rutkovskiy A, 2016, MED SCI MONIT BASIC, V22, P95, DOI 10.12659/MSMBR.901142
   Samee N, 2008, AM J PATHOL, V173, P773, DOI 10.2353/ajpath.2008.080243
   Santonocito S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115456
   Sayad A, 2020, BIOMED PHARMACOTHER, V129, DOI 10.1016/j.biopha.2020.110362
   Schliephake H, 2001, INT J ORAL MAX SURG, V30, P531, DOI 10.1054/ijom.2001.0164
   Shahi M, 2017, REP BIOCHEM MOL BIOL, V5, P73
   Shen JJ, 2019, EUR REV MED PHARMACO, V23, P7232, DOI 10.26355/eurrev_201909_18826
   Shim JH, 2013, J CLIN INVEST, V123, P4010, DOI 10.1172/JCI69443
   Shimoyama A, 2007, MOL BIOL CELL, V18, P2411, DOI 10.1091/mbc.E06 08 0743
   Silva AM, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0048 9
   St Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072
   STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424
   Syed FA, 2008, OSTEOPOROSIS INT, V19, P1323, DOI 10.1007/s00198 008 0574 6
   Tang WJ, 2011, J BIOL CHEM, V286, P32995, DOI 10.1074/jbc.M111.244236
   Thomson DW, 2016, NAT REV GENET, V17, P272, DOI 10.1038/nrg.2016.20
   Tominaga H, 2008, MOL BIOL CELL, V19, P5373, DOI 10.1091/mbc.E08 03 0329
   Ueyama H, 2021, BMC MUSCULOSKEL DIS, V22, DOI 10.1186/s12891 021 03971 w
   Ullah I, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20150025
   Vimalraj S, 2015, INT J BIOL MACROMOL, V78, P202, DOI 10.1016/j.ijbiomac.2015.04.008
   Wada Y, 1998, BONE, V22, P479, DOI 10.1016/S8756 3282(98)00039 8
   Wang CG, 2020, EXP MOL MED, V52, P1310, DOI 10.1038/s12276 020 0475 0
   Wang WG, 2012, DEVELOPMENT, V139, P601, DOI 10.1242/dev.069575
   Wang WG, 2009, DEVELOPMENT, V136, P4143, DOI 10.1242/dev.043281
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Wei JW, 2012, J CELL BIOL, V197, P509, DOI 10.1083/jcb.201201057
   Wen J, 2020, INT J BIOCHEM CELL B, V122, DOI 10.1016/j.biocel.2020.105719
   Xia T, 2020, INT J MOL MED, V46, P709, DOI 10.3892/ijmm.2020.4615
   Xiao GZ, 2005, J BIOL CHEM, V280, P30689, DOI 10.1074/jbc.M500750200
   Xiao XX, 2017, INT J CARDIOL, V243, P404, DOI 10.1016/j.ijcard.2017.05.037
   Xie Q, 2014, BIOCHEM BIOPH RES CO, V446, P98, DOI 10.1016/j.bbrc.2014.02.058
   Yamaguchi M, 2008, MOL CELL BIOCHEM, V312, P157, DOI 10.1007/s11010 008 9731 7
   Yang J, 2015, INT J ORAL SCI, V7, P73, DOI 10.1038/ijos.2015.14
   Yang JL, 2022, BONE, V162, DOI 10.1016/j.bone.2022.116448
   Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092 8674(04)00344 7
   Yang XL, 2004, J BIOL CHEM, V279, P47109, DOI 10.1074/jbc.M410010200
   Yavropoulou MP, 2012, BONE, V51, P153, DOI 10.1016/j.bone.2012.04.016
   Yi JY, 2019, CELL TISSUE RES, V376, P113, DOI 10.1007/s00441 018 2963 2
   Yin C, 2021, PHARMACOL RES, V163, DOI 10.1016/j.phrs.2020.105230
   Yu C, 2021, J BONE MINER METAB, V39, P360, DOI 10.1007/s00774 020 01164 4
   Yu LY, 2022, INT J ORAL SCI, V14, DOI 10.1038/s41368 022 00184 2
   Yu M, 2017, J PERIODONTOL, V88, pE159, DOI 10.1902/jop.2017.170016
   Yu SB, 2008, J BIOL CHEM, V283, P5542, DOI 10.1074/jbc.M705653200
   Zarka M, 2022, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.788773
   Zhang C, 2008, P NATL ACAD SCI USA, V105, P6936, DOI 10.1073/pnas.0710831105
   Zhang C, 2010, J ORTHOP SURG RES, V5, DOI 10.1186/1749 799X 5 37
   Zhang DD, 2021, CELL DEATH DIFFER, V28, P283, DOI 10.1038/s41418 020 0600 6
   Zhang JJ, 2018, FASEB J, V32, P6537, DOI 10.1096/fj.201800281
   Zhang RF, 2019, EUR REV MED PHARMACO, V23, P6774, DOI 10.26355/eurrev_201908_18715
   Zhang XW, 2014, J THORAC CARDIOV SUR, V148, P1700, DOI 10.1016/j.jtcvs.2014.02.084
   Zhang XY, 2008, J CELL BIOCHEM, V105, P885, DOI 10.1002/jcb.21888
   Zhang Y, 2021, REGEN THER, V16, P23, DOI 10.1016/j.reth.2020.12.003
   Zhou RK, 2021, BIOENGINEERED, V12, P3824, DOI 10.1080/21655979.2021.1949514
   Zhou X, 2010, P NATL ACAD SCI USA, V107, P12919, DOI 10.1073/pnas.0912855107
NR 180
TC 22
Z9 24
U1 1
U2 27
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739 1102
EI 1538 0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
PD NOV 24
PY 2023
VL 41
IS 19
BP 10257
EP 10276
DI 10.1080/07391102.2022.2148749
EA NOV 2022
PG 20
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA X6MY5
UT WOS:000890991100001
PM 36420663
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Hu, GL
   Yu, YL
   Sharma, D
   Pruett Miller, SM
   Ren, YS
   Zhang, GF
   Karner, CM
AF Hu, Guoli
   Yu, Yilin
   Sharma, Deepika
   Pruett Miller, Shondra M.
   Ren, Yinshi
   Zhang, Guo Fang
   Karner, Courtney M.
TI Glutathione limits RUNX2 oxidation and degradation to regulate bone
   formation
SO JCI INSIGHT
LA English
DT Article
ID OSTEOBLAST DIFFERENTIATION; CRUCIAL ROLE; METABOLISM; STRESS; GENE;
   TRANSCRIPTION; ROS; BIOENERGETICS; HOMEOSTASIS; DEPENDENCE
AB Reactive oxygen species (ROS) are natural products of mitochondrial oxidative metabolism and oxidative protein folding. ROS levels must be well controlled, since elevated ROS has been shown to have deleterious effects on osteoblasts. Moreover, excessive ROS is thought to underlie many of the skeletal phenotypes associated with aging and sex steroid deficiency in mice and humans. The mechanisms by which osteoblasts regulate ROS and how ROS inhibits osteoblasts are not well understood. Here, we demonstrate that de novo glutathione (GSH) biosynthesis is essential in neutralizing ROS and establish a proosteogenic reduction and oxidation reaction (REDOX) environment. Using a multifaceted approach, we demonstrate that reducing GSH biosynthesis led to acute degradation of RUNX2, impaired osteoblast differentiation, and reduced bone formation. Conversely, reducing ROS using catalase enhanced RUNX2 stability and promoted osteoblast differentiation and bone formation when GSH biosynthesis was limited. Highlighting the therapeutic implications of these findings, in utero antioxidant therapy stabilized RUNX2 and improved bone development in the Runx2+/  haplo insufficient mouse model of human cleidocranial dysplasia. Thus, our data establish RUNX2 as a molecular sensor of the osteoblast REDOX environment and mechanistically clarify how ROS negatively impacts osteoblast differentiation and bone formation.
C1 [Hu, Guoli; Yu, Yilin; Karner, Courtney M.] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Dallas, TX USA.
   [Sharma, Deepika; Karner, Courtney M.] Duke Univ, Sch Med, Dept Orthopaed Surg, Durham, NC USA.
   [Pruett Miller, Shondra M.] St Jude Childrens Res Hosp, Dept Cell & Mol Biol, Memphis, TN USA.
   [Ren, Yinshi] Texas Scottish Rite Hosp Children, Ctr Excellence Hip Disorders, Dallas, TX USA.
   [Zhang, Guo Fang] Univ Washington, Div Metab Endocrinol & Nutr, Dept Med, Seattle, WA USA.
   [Zhang, Guo Fang] Duke Univ, Sarah W Stedman Nutr & Metab Ctr, Durham, NC USA.
   [Zhang, Guo Fang] Duke Univ, Duke Mol Physiol Inst, Durham, NC USA.
   [Karner, Courtney M.] Univ Texas Southwestern Med Ctr, Charles & Jane Pak Ctr Mineral Metab & Clin Res, Dallas, TX USA.
   [Karner, Courtney M.] 5323 Harry Hines Blvd,F5 102, Dallas, TX 75390 USA.
C3 University of Texas System; University of Texas Southwestern Medical
   Center; Duke University; St Jude Children's Research Hospital; Texas
   Scottish Rite Hospital for Children; University of Washington;
   University of Washington Seattle; Duke University; Duke University;
   University of Texas System; University of Texas Southwestern Medical
   Center
RP Karner, CM (通讯作者)，5323 Harry Hines Blvd,F5 102, Dallas, TX 75390 USA.
EM Courtney.Karner@UTSouthwestern.edu
RI ; Liu, Fang/HTN 2574 2023; Pruett Miller, Shondra/M 9414 2018
OI Ren, Yinshi/0000 0003 3361 6015; Zhang, Guo Fang/0000 0003 3484 5864;
   Hu, Guoli/0000 0002 0909 6569; 
FU Hamon Center for Regenerative Science and Medicine; NIH National
   Institute of Arthritis and Musculoskeletal and Skin Diseases [AR071967];
    [AR076325]
FX Acknowledgments The authors would like to thank Gerard Karsenty for
   providing the Runx2 +/  mice and the UT Southwestern Proteomics Core for
   doing the proteomic analysis. We also appreciate the critical comments
   and helpful suggestions made by Thomas Carroll, Vishal Patel, Ryan Gray,
   and Leyao Shen. We sincerely appreciate the anonymous reviewers for
   their thorough and thoughtful reviews that improved our manuscript. GH
   is partially supported by an award from the Hamon Center for
   Regenerative Science and Medicine. This work was supported by the NIH
   National Institute of Arthritis and Musculoskeletal and Skin Diseases
   (grants AR076325 and AR071967) to CMK.
CR Almeida M, 2007, J BIOL CHEM, V282, P27285, DOI 10.1074/jbc.M702810200
   Almeida M, 2007, J BIOL CHEM, V282, P27298, DOI 10.1074/jbc.M702811200
   Almeida M, 2010, MOL ENDOCRINOL, V24, P2030, DOI 10.1210/me.2010 0189
   Almeida M, 2009, J BIOL CHEM, V284, P27438, DOI 10.1074/jbc.M109.023572
   Ambrogini E, 2010, CELL METAB, V11, P136, DOI 10.1016/j.cmet.2009.12.009
   Arai M, 2007, IUBMB LIFE, V59, P27, DOI 10.1080/15216540601156188
   Arakaki N, 2013, BIOMED RES TOKYO, V34, P161, DOI 10.2220/biomedres.34.161
   Boyadjiev SA, 2011, CLIN GENET, V80, P169, DOI 10.1111/j.1399 0004.2010.01550.x
   Brigelius Flohé R, 2006, BIOL CHEM, V387, P1329, DOI 10.1515/BC.2006.166
   Chen Y, 2005, J BIOL CHEM, V280, P33766, DOI 10.1074/jbc.M504604200
   Collins CL, 1998, J CELL PHYSIOL, V176, P166, DOI 10.1002/(SICI)1097 4652(199807)176:1<166::AID JCP18>3.0.CO;2 5
   Conde de la Rosa L., 2014, Systems Biology of Free Radicals and Antioxidants, P617
   Davies KJA, 2001, BIOCHIMIE, V83, P301, DOI 10.1016/S0300 9084(01)01250 0
   DENEKE SM, 1989, AM J PHYSIOL, V257, pL163, DOI 10.1152/ajplung.1989.257.4.L163
   Esen E, 2013, CELL METAB, V17, P745, DOI 10.1016/j.cmet.2013.03.017
   Finkel T, 2011, J CELL BIOL, V194, P7, DOI 10.1083/jcb.201102095
   Forman HJ, 2009, MOL ASPECTS MED, V30, P1, DOI 10.1016/j.mam.2008.08.006
   Franklin CC, 2009, MOL ASPECTS MED, V30, P86, DOI 10.1016/j.mam.2008.08.009
   Gao J, 2018, CELL DEATH DIFFER, V25, P229, DOI 10.1038/cdd.2017.144
   Guntur AR, 2018, J BONE MINER RES, V33, P1052, DOI 10.1002/jbmr.3390
   Guntur AR, 2014, ENDOCRINOLOGY, V155, P1589, DOI 10.1210/en.2013 1974
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hinoi E, 2006, J BIOL CHEM, V281, P18015, DOI 10.1074/jbc.M600603200
   Iyer S, 2013, J CLIN INVEST, V123, P3409, DOI 10.1172/JCI68049
   Jagger CJ, 2005, ENDOCRINOLOGY, V146, P113, DOI 10.1210/en.2004 1058
   Kaneki H, 2006, J BIOL CHEM, V281, P4326, DOI 10.1074/jbc.M509430200
   Karner CM, 2015, J CLIN INVEST, V125, P551, DOI 10.1172/JCI78470
   Kobayashi K, 2015, SCI REP UK, V5, DOI 10.1038/srep09148
   Komarova SV, 2000, AM J PHYSIOL CELL PH, V279, pC1220, DOI 10.1152/ajpcell.2000.279.4.C1220
   Komori T, 2002, J CELL BIOCHEM, V87, P1, DOI 10.1002/jcb.10276
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Kosower N S, 1978, Int Rev Cytol, V54, P109, DOI 10.1016/S0074 7696(08)60166 7
   Lean JM, 2005, ENDOCRINOLOGY, V146, P728, DOI 10.1210/en.2004 1021
   Lean JM, 2003, J CLIN INVEST, V112, P915, DOI 10.1172/JCI200318859
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Lee WC, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.108108
   Lee WC, 2017, ENDOCR REV, V38, P255, DOI 10.1210/er.2017 00064
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Lou Y, 2009, HUM MOL GENET, V18, P556, DOI 10.1093/hmg/ddn383
   Lu SC, 2009, MOL ASPECTS MED, V30, P42, DOI 10.1016/j.mam.2008.05.005
   Mandal CC, 2011, BIOCHEM J, V433, P393, DOI 10.1042/BJ20100357
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   MEISTER A, 1982, BIOCHEM SOC T, V10, P78, DOI 10.1042/bst0100078
   Misra BB, 2021, METABOLOMICS, V17, DOI 10.1007/s11306 021 01829 9
   Nojiri H, 2011, J BONE MINER RES, V26, P2682, DOI 10.1002/jbmr.489
   Otto F, 2002, HUM MUTAT, V19, P209, DOI 10.1002/humu.10043
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Piemontese M, 2016, SCI REP UK, V6, DOI 10.1038/srep24262
   Rached MT, 2010, CELL METAB, V11, P147, DOI 10.1016/j.cmet.2010.01.001
   Rhee SG, 2006, SCIENCE, V312, P1882, DOI 10.1126/science.1130481
   Rottenberg H, 2017, AGING CELL, V16, P943, DOI 10.1111/acel.12650
   Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047
   Sarmah S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010367
   Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455
   Sayin VI, 2017, ELIFE, V6, DOI 10.7554/eLife.28083
   Schieber M, 2014, CURR BIOL, V24, pR453, DOI 10.1016/j.cub.2014.03.034
   Schoppa AM, 2022, DIS MODEL MECH, V15, DOI 10.1242/dmm.049392
   Sharma D, 2021, ELIFE, V10, DOI [10.7554/eLife.71595, 10.7554/eLife.71595.sa1, 10.7554/eLife.71595.sa2]
   Shen LY, 2022, ELIFE, V11, DOI 10.7554/eLife.76963
   Shringarpure R, 2001, CELL MOL LIFE SCI, V58, P1442, DOI 10.1007/PL00000787
   Stegen S, 2021, J BONE MINER RES, V36, P604, DOI 10.1002/jbmr.4219
   Stegen S, 2020, DEV CELL, V53, P530, DOI 10.1016/j.devcel.2020.05.001
   Stegen S, 2016, CELL METAB, V23, P265, DOI 10.1016/j.cmet.2016.01.002
   Stein GS, 2004, ONCOGENE, V23, P4315, DOI 10.1038/sj.onc.1207676
   Stipanuk MH, 2004, ANNU REV NUTR, V24, P539, DOI 10.1146/annurev.nutr.24.012003.132418
   Sun N, 2016, MOL CELL, V61, P654, DOI 10.1016/j.molcel.2016.01.028
   Takarada T, 2016, DEVELOPMENT, V143, P211, DOI 10.1242/dev.128793
   Townley AK, 2008, J CELL SCI, V121, P3025, DOI 10.1242/jcs.031070
   Wang K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.50
   Wei JW, 2015, CELL, V161, P1576, DOI 10.1016/j.cell.2015.05.029
   Wu H, 2014, GENOME BIOL, V15, DOI 10.1186/gb 2014 15 3 r52
   Xie WJ, 2016, CALCIFIED TISSUE INT, V99, P142, DOI 10.1007/s00223 016 0129 3
   Yu YL, 2019, CELL METAB, V29, P966, DOI 10.1016/j.cmet.2019.01.016
NR 73
TC 28
Z9 28
U1 2
U2 17
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
EI 2379 3708
J9 JCI INSIGHT
JI JCI Insight
PD AUG 22
PY 2023
VL 8
IS 16
AR e166888
DI 10.1172/jci.insight.166888
PG 18
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA Q0DF7
UT WOS:001054292400001
PM 37432749
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Tohmonda, T
   Yoda, M
   Iwawaki, T
   Matsumoto, M
   Nakamura, M
   Mikoshiba, K
   Toyama, Y
   Horiuchi, K
AF Tohmonda, Takahide
   Yoda, Masaki
   Iwawaki, Takao
   Matsumoto, Mono
   Nakamura, Masaya
   Mikoshiba, Katsuhiko
   Toyama, Yoshiaki
   Horiuchi, Keisuke
TI IRE1α/XBP1 mediated branch of the unfolded protein response regulates
   osteoclastogenesis
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID ENDOPLASMIC RETICULUM STRESS; ER STRESS; MULTIPLE MYELOMA;
   IRE1 ALPHA XBP1 PATHWAY; TRANSCRIPTION FACTOR; MESSENGER RNA;
   BONE MARROW; DIFFERENTIATION; EXPRESSION; PATHOGENESIS
AB The unfolded protein response (UPR) is a cellular adaptive mechanism that is activated in response to the accumulation of unfolded proteins in the endoplasmic reticulum. The inositol requiring protein 1 alpha/X box binding protein mediated (IRE1 alpha/XBP1 mediated) branch of the UPR is highly conserved and has also been shown to regulate various cell fate decisions. Herein, we have demonstrated a crucial role for the IRE alpha/XBP1 mediated arm of the UPR in osteoclast differentiation. Using murine models, we found that the conditional abrogation of IRE1 alpha in bone marrow cells increases bone mass as the result of defective osteoclastic bone resorption. In osteoclast precursors, IRE1 alpha was transiently activated during osteoclastogenesis, and suppression of the IRE1 alpha/XBP1 pathway in these cells substantially inhibited the formation of multinucleated osteoclasts in vitro. We determined that XBP1 directly binds the promoter and induces transcription of the gene encoding the master regulator of osteoclastogenesis nuclear factor of activated T cells cytoplasmic 1 (NFATc1). Moreover, activation of IRE1 alpha was partially dependent on Ca2+ oscillation mediated by inositol 1,4,5 trisphosphate receptors 2 and 3 (ITPR2 and ITPR3) in the endoplasmic reticulum, as pharmacological inhibition or deletion of these receptors markedly decreased Xbp1 mRNA processing. The present study thus reveals an intracellular pathway that integrates the UPR and osteoclast differentiation through activation of the IRE1 alpha/XBP1 pathway.
C1 [Tohmonda, Takahide; Yoda, Masaki; Horiuchi, Keisuke] Keio Univ, Sch Med, Dept Antiaging Orthoped Res, Tokyo 1608582, Japan.
   [Tohmonda, Takahide; Mikoshiba, Katsuhiko] RIKEN, Dev Neurobiol Lab, Brain Sci Inst, Wako, Saitama, Japan.
   [Iwawaki, Takao] Gunma Univ, Iwawaki Lab, Adv Sci Res Leaders Dev Unit, Maebashi, Gunma, Japan.
   [Matsumoto, Mono; Nakamura, Masaya; Toyama, Yoshiaki; Horiuchi, Keisuke] Keio Univ, Sch Med, Dept Orthoped Surg, Tokyo 1608582, Japan.
C3 Keio University; RIKEN; Gunma University; Keio University
RP Horiuchi, K (通讯作者)，Keio Univ, Sch Med, Dept Orthoped Surg, Tokyo 1608582, Japan.
EM tohmonda@z7.keio.jp; horiuchi@z3.keio.jp
RI Toyama, Yoshiaki/K 5743 2013; Horiuchi, Keisuke/L 2277 2013; Mikoshiba,
   Katsuhiko/N 7943 2015; Nakamura, Masaya/K 4111 2013
OI Horiuchi, Keisuke/0000 0001 7063 9609; 
FU MEXT KAKENHI [24390358, 24791566]; Grants in Aid for Scientific Research
   [24791566, 24390358] Funding Source: KAKEN
FX The authors thank Shizue Yamanashi, Kaori Sue, and Mayumi Ito for their
   technical assistance, Akemi Ito (Ito Bone Science Institute) for advice
   on bone morphometric analysis, and Taku Saito (The University of Tokyo)
   for technical help with viral gene transfer. This work was supported, in
   part, by MEXT KAKENHI (24390358 to K. Horiuchi; 24791566 to T.
   Tohmonda).
CR Acosta Alvear D, 2007, MOL CELL, V27, P53, DOI 10.1016/j.molcel.2007.06.011
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Auf G, 2010, P NATL ACAD SCI USA, V107, P15553, DOI 10.1073/pnas.0914072107
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Carrasco DR, 2007, CANCER CELL, V11, P349, DOI 10.1016/j.ccr.2007.02.015
   Chen X, 2014, NATURE, V508, P103, DOI 10.1038/nature13119
   Edwards JR, 2011, NAT REV RHEUMATOL, V7, P235, DOI 10.1038/nrrheum.2011.23
   Fujimoto T, 2007, ANTICANCER RES, V27, P127
   Futatsugi A, 2005, SCIENCE, V309, P2232, DOI 10.1126/science.1114110
   Guise TA, 1998, ENDOCR REV, V19, P18, DOI 10.1210/er.19.1.18
   Han D, 2009, CELL, V138, P562, DOI 10.1016/j.cell.2009.07.017
   Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270
   Hetz C, 2011, PHYSIOL REV, V91, P1219, DOI 10.1152/physrev.00001.2011
   Hetz C, 2009, MOL CELL, V35, P551, DOI 10.1016/j.molcel.2009.08.021
   Iwawaki T, 2009, P NATL ACAD SCI USA, V106, P16657, DOI 10.1073/pnas.0903775106
   Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005
   Kiviluoto S, 2013, BBA MOL CELL RES, V1833, P1612, DOI 10.1016/j.bbamcr.2013.01.026
   KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125
   Kuroda Y, 2008, P NATL ACAD SCI USA, V105, P8643, DOI 10.1073/pnas.0800642105
   Lazarowski ER, 2003, MOL PHARMACOL, V64, P785, DOI 10.1124/mol.64.4.785
   Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448 7459.2003
   Mahoney DJ, 2011, CANCER CELL, V20, P443, DOI 10.1016/j.ccr.2011.09.005
   Martinon F, 2011, CURR OPIN IMMUNOL, V23, P35, DOI 10.1016/j.coi.2010.10.016
   McInnes IB, 2007, NAT REV IMMUNOL, V7, P429, DOI 10.1038/nri2094
   Mimura N, 2012, BLOOD, V119, P5772, DOI 10.1182/blood 2011 07 366633
   Murakami T, 2009, NAT CELL BIOL, V11, P1205, DOI 10.1038/ncb1963
   Nakashima T, 2012, TRENDS ENDOCRIN MET, V23, P582, DOI 10.1016/j.tem.2012.05.005
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Niederreiter L, 2013, J EXP MED, V210, P2041, DOI 10.1084/jem.20122341
   Papandreou I, 2011, BLOOD, V117, P1311, DOI 10.1182/blood 2010 08 303099
   Patterson RL, 2004, ANNU REV BIOCHEM, V73, P437, DOI 10.1146/annurev.biochem.73.071403.161303
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199
   Ruiz A, 2009, CELL CALCIUM, V46, P273, DOI 10.1016/j.ceca.2009.08.005
   Saito A, 2011, J BIOL CHEM, V286, P4809, DOI 10.1074/jbc.M110.152900
   Saito A, 2009, NAT CELL BIOL, V11, P1197, DOI 10.1038/ncb1962
   Semerad CL, 2005, BLOOD, V106, P3020, DOI 10.1182/blood 2004 01 0272
   Sha HB, 2011, TRENDS ENDOCRIN MET, V22, P374, DOI 10.1016/j.tem.2011.05.002
   Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469
   Tabas I, 2011, NAT CELL BIOL, V13, P184, DOI 10.1038/ncb0311 184
   TAKAHASHI N, 1988, ENDOCRINOLOGY, V122, P1373, DOI 10.1210/endo 122 4 1373
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tohmonda T, 2013, J BIOL CHEM, V288, P1691, DOI 10.1074/jbc.C112.424606
   Tohmonda T, 2011, EMBO REP, V12, P451, DOI 10.1038/embor.2011.34
   Vincenz L, 2013, MOL CANCER THER, V12, P831, DOI 10.1158/1535 7163.MCT 12 0782
   Wagner LE, 2012, J PHYSIOL LONDON, V590, P3245, DOI 10.1113/jphysiol.2012.228320
   Wang SY, 2012, J CELL BIOL, V197, P857, DOI 10.1083/jcb.201110131
   Weinstein RS, 2002, J CLIN INVEST, V109, P1041, DOI 10.1172/JCI200214538
   Willey JS, 2010, BONE, V46, P101, DOI 10.1016/j.bone.2009.09.002
   Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092 8674(01)00611 0
NR 50
TC 53
Z9 63
U1 0
U2 5
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021 9738
EI 1558 8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD AUG
PY 2015
VL 125
IS 8
BP 3269
EP 3279
DI 10.1172/JCI76765
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA CO3CS
UT WOS:000359034800033
PM 26193638
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Ferroni, L
   Gardin, C
   Dolkart, O
   Salai, M
   Barak, S
   Piattelli, A
   Amir Barak, H
   Zavan, B
AF Ferroni, Letizia
   Gardin, Chiara
   Dolkart, Oleg
   Salai, Moshe
   Barak, Shlomo
   Piattelli, Adriano
   Amir Barak, Hadar
   Zavan, Barbara
TI Pulsed electromagnetic fields increase osteogenetic commitment of MSCs
   via the mTOR pathway in TNF α mediated inflammatory conditions: an
   in vitro study
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MESENCHYMAL STEM CELLS; HUMAN BONE MARROW; ADIPOGENIC DIFFERENTIATION;
   DIFFERENT INTENSITIES; WEIGHT GAIN; ACTIVATION; THERAPY; SURVIVAL;
   GROWTH; BETA
AB Pulsed electromagnetic fields (PEMFs) have been considered a potential treatment modality for fracture healing, however, the mechanism of their action remains unclear. Mammalian target of rapamycin (mTOR) signaling may affect osteoblast proliferation and differentiation. This study aimed to assess the osteogenic differentiation of mesenchymal stem cells (MSCs) under PEMF stimulation and the potential involvement of mTOR signaling pathway in this process. PEMFs were generated by a novel miniaturized electromagnetic device. Potential changes in the expression of mTOR pathway components, including receptors, ligands and nuclear target genes, and their correlation with osteogenic markers and transcription factors were analyzed. Involvement of the mTOR pathway in osteogenesis was also studied in the presence of proinflammatory mediators. PEMF exposure increased cell proliferation and adhesion and the osteogenic commitment of MSCs even in inflammatory conditions. Osteogenic related genes were over expressed following PEMF treatment. Our results confirm that PEMFs contribute to activation of the mTOR pathway via upregulation of the proteins AKT, MAPP kinase, and RRAGA, suggesting that activation of the mTOR pathway is required for PEMF stimulated osteogenic differentiation. Our findings provide insights into how PEMFs influence osteogenic differentiation in normal and inflammatory environments.
C1 [Ferroni, Letizia; Gardin, Chiara; Zavan, Barbara] Univ Padua, Dept Biomed Sci, Via G Colombo 3, Padua, Italy.
   [Dolkart, Oleg; Salai, Moshe] Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Div Orthopaed Surg, Tel Aviv, Israel.
   [Piattelli, Adriano] Univ G dAnnunzio, Dept Med Oral & Biotechnol Sci, Chieti, Italy.
   [Amir Barak, Hadar] Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Dept Internal Med E, Tel Aviv, Israel.
C3 University of Padua; Tel Aviv University; Sackler Faculty of Medicine;
   Tel Aviv Sourasky Medical Center; G d'Annunzio University of
   Chieti Pescara; Tel Aviv University; Sackler Faculty of Medicine; Tel
   Aviv Sourasky Medical Center
RP Dolkart, O (通讯作者)，Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Div Orthopaed Surg, Tel Aviv, Israel.
EM dolkarto@gmail.com
RI ; Ferroni, Letizia/IUQ 7673 2023
OI Ferroni, Letizia/0000 0002 5457 0338; ferroni,
   letizia/0000 0002 2640 4105
FU Mgdent Ltd.
FX Research support (including PEMF generting devices and partial support
   in lab supplies) was provided by Mgdent Ltd.
CR Aguiari P, 2008, P NATL ACAD SCI USA, V105, P1226, DOI 10.1073/pnas.0711402105
   Anderson JM, 2008, SEMIN IMMUNOL, V20, P86, DOI 10.1016/j.smim.2007.11.004
   Ardeshirylajimi A, 2015, CELL MOL BIOL, V61, P36
   Ardeshirylajimi A, 2018, ASAIO J, V64, P253, DOI 10.1097/MAT.0000000000000631
   Arjmand M, 2018, J CELL PHYSIOL, V233, P1061, DOI 10.1002/jcp.25962
   Barak S, 2016, CLIN ORAL IMPLAN RES, V27, P935, DOI 10.1111/clr.12661
   Bonora M, 2014, CELL DEATH DIFFER, V21, P1198, DOI 10.1038/cdd.2014.35
   Brånemark R, 2001, J REHABIL RES DEV, V38, P175
   Brun P, 2012, J BIOMED MATER RES B, V100B, P2073, DOI 10.1002/jbm.b.32771
   Chang K, 2003, BIOELECTROMAGNETICS, V24, P431, DOI 10.1002/bem.10118
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022 1759(86)90368 6
   Deshpande S, 2013, J SURG RES, V185, P278, DOI 10.1016/j.jss.2013.06.063
   Ferroni L, 2017, EUR J HISTOCHEM, V61, P186, DOI 10.4081/ejh.2017.2800
   Ferroni L, 2017, J TISSUE ENG REGEN M, V11, P1332, DOI 10.1002/term.2031
   Ferroni L, 2016, LIFE SCI, V152, P44, DOI 10.1016/j.lfs.2016.03.020
   Fu YC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091581
   Gharibi B, 2014, STEM CELLS, V32, P2256, DOI 10.1002/stem.1709
   Glantschnig H, 2003, CELL DEATH DIFFER, V10, P1165, DOI 10.1038/sj.cdd.4401285
   Indo Y, 2013, J BONE MINER RES, V28, P2392, DOI 10.1002/jbmr.1976
   Kim MO, 2015, INT J MOL MED, V35, P153, DOI 10.3892/ijmm.2014.1978
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Laplante M, 2013, J CELL SCI, V126, P1713, DOI 10.1242/jcs.125773
   Li JKJ, 2007, ELECTROMAGN BIOL MED, V26, P153, DOI 10.1080/15368370701572837
   Lin CC, 2015, BIOELECTROMAGNETICS, V36, P494, DOI 10.1002/bem.21933
   Martin SK, 2015, STEM CELLS, V33, P1359, DOI 10.1002/stem.1931
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Ongaro A, 2014, BIOELECTROMAGNETICS, V35, P426, DOI 10.1002/bem.21862
   Pavan C, 2010, PHARMACOGENOMICS J, V10, P408, DOI 10.1038/tpj.2009.67
   Petecchia L, 2015, SCI REP UK, V5, DOI 10.1038/srep13856
   Pinton P, 2011, PHARMACOGENOMICS, V12, P453, DOI [10.2217/pgs.11.25, 10.2217/PGS.11.25]
   Purdue P Edward, 2006, HSS J, V2, P102, DOI 10.1007/s11420 006 9003 6
   Rimessi A, 2017, NEUROPSYCHOPHARMACOL, V42, P1491, DOI 10.1038/npp.2017.20
   Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029
   Song MY, 2014, BIOELECTROMAGNETICS, V35, P479, DOI 10.1002/bem.21867
   Sundfeldt M, 2006, ACTA ORTHOP, V77, P177, DOI 10.1080/17453670610045902
   Trindade R, 2016, CLIN IMPLANT DENT R, V18, P192, DOI 10.1111/cid.12274
   Xian LL, 2012, NAT MED, V18, P1095, DOI 10.1038/nm.2793
   Xiang XX, 2011, ACTA BIOCH BIOPH SIN, V43, P501, DOI 10.1093/abbs/gmr041
   Yong Y, 2016, J TISSUE ENG REGEN M, V10, pE537, DOI 10.1002/term.1864
NR 40
TC 47
Z9 50
U1 2
U2 12
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD MAR 23
PY 2018
VL 8
AR 5108
DI 10.1038/s41598 018 23499 9
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA GA2OD
UT WOS:000428162000029
PM 29572540
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Farrell, KB
   Zinnen, S
   Thamm, DH
   Karpeisky, A
AF Farrell, Kristen B.
   Zinnen, Shawn
   Thamm, Douglas H.
   Karpeisky, Alexander
TI Gemcitabine Ibandronate Conjugate Enables the Bone Targeted Combination
   Therapy in Bone Cancer: Synthesis and Efficacy in Combination with
   Docetaxel
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID TRIFLUOROACETIC ANHYDRIDE; TUMOR; BISPHOSPHONATES; EPIDEMIOLOGY
AB Patients with cancer induced bone disease, including primary bone cancers such as osteosarcoma (OS) and metastases from other tissues of origin, present a high unmet medical need. We present a potential therapeutic approach built upon a proven bone targeting bisphosphonate conjugate platform with the known synergies of gemcitabine (GEM) and docetaxel (DTX). The synthesis of rationally designed GEM  IB, the conjugate of GEM 5 ' phosphate with ibandronate (IB), is presented. GEM IB as a single agent or in combination with DTX demonstrated reduced tumor burden, preservation of the bone architecture, and improved the survival in a murine model of OS. This is the first demonstration of a bone targeting conjugate in combination with a second drug to create effective drug ratios in the bone compartment.
C1 [Farrell, Kristen B.; Zinnen, Shawn; Karpeisky, Alexander] MBC Pharma Inc, Aurora, CO 80045 USA.
   [Thamm, Douglas H.] Colorado State Univ, Flint Anim Canc Ctr, Ft Collins, CO 80523 USA.
C3 Colorado State University System; Colorado State University Fort Collins
RP Karpeisky, A (通讯作者)，MBC Pharma Inc, Aurora, CO 80045 USA.
EM alkarp@mbcpharma.com
RI Thamm, Douglas/I 5976 2013
OI Karpeisky, Alexander/0000 0002 9226 8789
FU NIH [R43CA 203166, R44CA203166]
FX This work was performed with the funding of NIH grants R43CA 203166 and
   R44CA203166 awarded to MBC Pharma, Inc. Authors would like to thank Dr.
   Vijay Kumar for performing NMR spectroscopy and Dr. Michael Wempe for
   performing mass spectral analysis (Medicinal Chemistry Core, University
   of Colorado Anschutz Medical Campus, Skaggs School of Pharmacy and
   Pharmaceutical Sciences) . Thanks to the Colorado State University Flint
   Animal Cancer Center for the use of facilities and Colorado State
   University Laboratory Animal Resources for the animal care. Special
   thanks to Laura Chubb for performing microCT scans, Dr. Travis Meuten
   and Amanda Jenkins for the assistance with tumor implantation
   procedures, Aubree Peterson for the assistance with weight collections,
   and Barbara Rose for the cell line preparation.
CR Beigelman L, 2010, Substituted nucleoside and nucleotide analogs, Patent No. [WO 2010108140 A1, 2010108140]
   Bogachev VS, 1996, BIOORG KHIM+, V22, P699
   BOGACHEV VS, 1995, BIOORG KHIM+, V21, P212
   Boye Pierre, 2020, Oncotarget, V11, P4281, DOI 10.18632/oncotarget.27801
   Clézardin P, 2011, BONE, V48, P71, DOI 10.1016/j.bone.2010.07.016
   David E, 2019, BIOCONJUGATE CHEM, V30, P1665, DOI 10.1021/acs.bioconjchem.9b00210
   Farrell Kristen B, 2018, Bone Rep, V9, P47, DOI 10.1016/j.bonr.2018.06.007
   Jorfi S, 2015, SCI REP UK, V5, DOI 10.1038/srep13006
   Junankar S, 2015, CANCER DISCOV, V5, P35, DOI 10.1158/2159 8290.CD 14 0621
   Kaczmarek R, 2014, SYNLETT, V25, P1851, DOI 10.1055/s 0034 1378353
   Kadokura M, 2000, J ORG CHEM, V65, P5104, DOI 10.1021/jo991432z
   Le HK, 2009, INT IMMUNOPHARMACOL, V9, P900, DOI 10.1016/j.intimp.2009.03.015
   Macedo F, 2017, ONCOL REV, V11, P43, DOI 10.4081/oncol.2017.321
   Mason KA, 1997, CLIN CANCER RES, V3, P2431
   Mirabello L, 2009, CANCER AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121
   Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976 0105.177703
   Ora M, 2008, J ORG CHEM, V73, P4123, DOI 10.1021/jo800317e
   Ossipov D. A, POLYMERS BASEL, V13, P2106
   Palmerini E, 2016, BMC CANCER, V16, DOI 10.1186/s12885 016 2312 3
   Plesselova S, 2021, J MED CHEM, V64, P12245, DOI 10.1021/acs.jmedchem.1c00887
   Ratan R, 2016, CANCER AM CANCER SOC, V122, P2952, DOI 10.1002/cncr.30191
   Reinholz MM, 2010, BONE, V47, P12, DOI 10.1016/j.bone.2010.03.006
   Ricci S, 2017, GYNECOL ONCOL, V145, P208, DOI 10.1016/j.ygyno.2017.02.019
   Risbood PA, 2008, BIOORG MED CHEM LETT, V18, P2957, DOI 10.1016/j.bmcl.2008.03.063
   Sandblom V, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0225260
   Siegel RL, 2019, CA CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Van Acker HH, 2016, PHARMACOL THERAPEUT, V158, P24, DOI 10.1016/j.pharmthera.2015.11.008
   Wong PP, 2015, CANCER CELL, V27, P123, DOI 10.1016/j.ccell.2014.10.015
   Xing LP, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115492
   Young RN, 2018, CURR OPIN PHARMACOL, V40, P87, DOI 10.1016/j.coph.2018.03.010
   Zhang Y, 2018, ONCOL LETT, V16, P6228, DOI 10.3892/ol.2018.9434
   Zinnen SP, 2019, ONCOLOGIST, V24, P303, DOI 10.1634/theoncologist.2018 0707
NR 32
TC 4
Z9 4
U1 1
U2 9
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1043 1802
EI 1520 4812
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD DEC 15
PY 2021
VL 32
IS 12
BP 2530
EP 2539
DI 10.1021/acs.bioconjchem.1c00507
EA NOV 2021
PG 10
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Multidisciplinary; Chemistry, Organic
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Biochemistry & Molecular Biology; Chemistry
GA XR0EB
UT WOS:000731911200007
PM 34779607
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Costelloe, CM
   Lin, PP
   Chuang, HH
   Amini, B
   Chainitikun, S
   Yu, TK
   Ueno, NT
   Murphy, WA
   Madewell, JE
AF Costelloe, Colleen M.
   Lin, Patrick P.
   Chuang, Hubert H.
   Amini, Behrang
   Chainitikun, Sudpreeda
   Yu, Tse Kuan
   Ueno, Naoto T.
   Murphy, William A.
   Madewell, John E.
TI Bone Metastases: Mechanisms of the Metastatic Process, Imaging and
   Therapy
SO SEMINARS IN ULTRASOUND CT AND MRI
LA English
DT Article
ID WHOLE BODY MRI; PROPHYLACTIC INTERNAL FIXATION; PAINFUL OSSEOUS
   METASTASES; DIXON BASED MULTISEQUENCE; SKELETAL RELATED EVENTS;
   MAGNETIC RESONANCE; BREAST CANCER; MULTIPLE MYELOMA; PROSTATE CANCER;
   ZOLEDRONIC ACID
AB The mechanisms by which tumors metastasize to bone are complex. Upon the successful establishment of metastatic deposits in the skeleton, detection of the disease becomes essential for therapeutic planning. The roles of CT, skeletal scintigraphy, SPECT/CT, MRI, PET/CT and PET/MRI will be reviewed. Therapeutic response criteria specifically designed to evaluate bone metastases (MD Anderson/MDA criteria) can guide image interpretation. Knowledge of therapeutic strategies such as systemic therapy with bisphosphonates or radiopharmaceuticals, radiation therapy, surgery, and percutaneous interventions such as vertebroplasty and radiofrequency ablation can help the radiologist produce reports that will provide maximum benefit to clinicians and patients. Semin Ultrasound CT MRI 42:164 183 Published by Elsevier Inc.
C1 [Costelloe, Colleen M.; Amini, Behrang; Murphy, William A.; Madewell, John E.] Univ Texas MD Anderson Canc Ctr, Dept Musculoskeletal Imaging, Houston, TX 77030 USA.
   [Lin, Patrick P.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA.
   [Chuang, Hubert H.] Univ Texas MD Anderson Canc Ctr, Dept Nucl Med, Houston, TX 77030 USA.
   [Chainitikun, Sudpreeda; Ueno, Naoto T.] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA.
   [Yu, Tse Kuan] Houston Precis Canc Ctr, Radiat Oncol, Houston, TX USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; University of Texas System;
   UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson
   Cancer Center
RP Costelloe, CM (通讯作者)，Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd,Unit 1475, Houston, TX 77030 USA.
EM ccostelloe@mdanderson.org
OI Ueno, Naoto/0000 0002 0166 7275
CR Abe K, 2005, ANN NUCL MED, V19, P573, DOI 10.1007/BF02985050
   Aboulafia AJ, 2007, SEMIN ONCOL, V34, P206, DOI 10.1053/j.seminoncol.2007.03.002
   Bujanda DA, 2007, ANN ONCOL, V18, P556, DOI 10.1093/annonc/mdl408
   AISEN AM, 1986, AM J ROENTGENOL, V146, P749, DOI 10.2214/ajr.146.4.749
   Alberts AS, 1997, RADIOTHER ONCOL, V43, P175, DOI 10.1016/S0167 8140(97)01912 9
   [Anonymous], 2017, INT J MOL SCI, V388
   Antoch G, 2003, JAMA J AM MED ASSOC, V290, P3199, DOI 10.1001/jama.290.24.3199
   Arano Y, 2002, ANN NUCL MED, V16, P79, DOI 10.1007/BF02993710
   ARDRAN GM, 1951, BRIT J RADIOL, V24, P107, DOI 10.1259/0007 1285 24 278 107
   AVRAHAMI E, 1989, J COMPUT ASSIST TOMO, V13, P598, DOI 10.1097/00004728 198907000 00008
   Balliu E, 2010, CLIN RADIOL, V65, P989, DOI 10.1016/j.crad.2010.07.002
   Bamias A, 2005, J CLIN ONCOL, V23, P8580, DOI 10.1200/JCO.2005.02.8670
   Baziotis N, 1998, ONCOLOGY BASEL, V55, P377, DOI 10.1159/000011881
   BEALS RK, 1971, CANCER, V28, P1350, DOI 10.1002/1097 0142(1971)28:5<1350::AID CNCR2820280539>3.0.CO;2 6
   Beiderwellen K, 2014, EUR RADIOL, V24, P2023, DOI 10.1007/s00330 014 3229 3
   Breighner RE, 2019, AM J SPORT MED, V47, P3460, DOI 10.1177/0363546519878170
   Bruland OS, 2006, CLIN CANCER RES, V12, p6250S, DOI 10.1158/1078 0432.CCR 06 0841
   CLAIN A, 1965, BRIT J CANCER, V19, P15, DOI 10.1038/bjc.1965.3
   COLEMAN RE, 1988, J NUCL MED, V29, P1354
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   CORCORAN RJ, 1976, RADIOLOGY, V121, P663, DOI 10.1148/121.3.663
   Costelloe CM, 2007, AM J ROENTGENOL, V188, P855, DOI 10.2214/AJR.05.1132
   Costelloe CM, 2013, J CANCER, V4, P524, DOI 10.7150/jca.6259
   Costelloe CM, 2013, MAGN RESON IMAGING, V31, P669, DOI 10.1016/j.mri.2012.10.017
   Costelloe CM, 2012, J MAGN RESON IMAGING, V35, P399, DOI 10.1002/jmri.22815
   Costelloe CM, 2010, PET CLIN, V5, P281, DOI 10.1016/j.cpet.2010.04.001
   Costelloe CM, 2009, LANCET ONCOL, V10, P606, DOI 10.1016/S1470 2045(09)70088 9
   DAFFNER RH, 1986, AM J ROENTGENOL, V146, P353, DOI 10.2214/ajr.146.2.353
   Dimopoulos MA, 2009, ANN ONCOL, V20, P117, DOI 10.1093/annonc/mdn554
   Dimopoulos MA, 2006, HAEMATOL HEMATOL J, V91, P968
   Dupuy DE, 2010, CANCER AM CANCER SOC, V116, P989, DOI 10.1002/cncr.24837
   Durie BGM, 2005, NEW ENGL J MED, V353, P99
   Edelstyn G A, 1967, Clin Radiol, V18, P158, DOI 10.1016/S0009 9260(67)80010 2
   Edwards BJ, 2016, J BONE MINER RES, V31, P1569, DOI 10.1002/jbmr.2818
   Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026
   Engelhard K, 2004, EUR RADIOL, V14, P99, DOI 10.1007/s00330 003 1968 7
   Eustace S, 1997, AM J ROENTGENOL, V169, P1655, DOI 10.2214/ajr.169.6.9393186
   Even Sapir E, 2006, J NUCL MED, V47, P287
   FARHANGHI M, 1992, J NUCL MED, V33, P1451
   Farrugia MC, 2006, LARYNGOSCOPE, V116, P115, DOI 10.1097/01.mlg.0000187398.51857.3c
   FIDLER M, 1981, ACTA ORTHOP SCAND, V52, P623, DOI 10.3109/17453678108992157
   FIDLER M, 1973, BRIT MED J, V1, P341, DOI 10.1136/bmj.1.5849.341
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Geiger TR, 2009, BBA REV CANCER, V1796, P293, DOI 10.1016/j.bbcan.2009.07.006
   GODERSKY JC, 1987, NEUROSURGERY, V21, P676, DOI 10.1227/00006123 198711000 00013
   GOECKELER WF, 1993, NUCL MED BIOL, V20, P657, DOI 10.1016/0969 8051(93)90036 T
   Goetz MP, 2004, J CLIN ONCOL, V22, P300, DOI 10.1200/JCO.2004.03.097
   GREEN JR, 1994, J BONE MINER RES, V9, P745
   Hahn S, 2018, BRIT J RADIOL, V91, DOI 10.1259/bjr.20170782
   Hamaoka T, 2004, J CLIN ONCOL, V22, P2942, DOI 10.1200/jco.2004.08.181
   Hamaoka T, 2010, BRIT J CANCER, V102, P651, DOI 10.1038/sj.bjc.6605546
   Han LJ, 1998, EUR J NUCL MED, V25, P635, DOI 10.1007/s002590050266
   Hartsell WF, 2005, JNCI J NATL CANCER I, V97, P798, DOI 10.1093/jnci/dji139
   Hayashi N, 2013, CLIN BREAST CANCER, V13, P24, DOI 10.1016/j.clbc.2012.09.004
   Hiraga T, 2019, J ORAL BIOSCI, V61, P95, DOI 10.1016/j.job.2019.02.002
   Horger M, 2006, SEMIN NUCL MED, V36, P286, DOI 10.1053/j.semnuclmed.2006.05.001
   HORTOBAGYI GN, 1984, CANCER AM CANCER SOC, V53, P577, DOI 10.1002/1097 0142(19840201)53:3<577::AID CNCR2820530335>3.0.CO;2 U
   Hortobagyi GN, 1998, J CLIN ONCOL, V16, P2038, DOI 10.1200/JCO.1998.16.6.2038
   Hortobagyi GN, 1996, NEW ENGL J MED, V335, P1785, DOI 10.1056/NEJM199612123352401
   Horvath LJ, 1999, RADIOLOGY, V211, P119, DOI 10.1148/radiology.211.1.r99ap33119
   Ibrahim T, 2008, ONCOLOGIST, V13, P330, DOI 10.1634/theoncologist.2007 0159
   Jhaveri P, 2008, ONCOLOGY NY, V22, P782
   Kalus S, 2019, EUR RADIOL, V29, P5700, DOI 10.1007/s00330 019 06132 9
   Kasalicky J, 1998, EUR J NUCL MED, V25, P1362, DOI 10.1007/s002590050309
   Kato H, 2005, ANTICANCER RES, V25, P4439
   Khodarahmi I, 2019, SEMIN MUSCULOSKEL R, V23, pE68, DOI 10.1055/s 0039 1687898
   Kim JR, 2019, SCI REP UK, V9, DOI 10.1038/s41598 018 36501 1
   Lam MGEH, 2007, ANTI CANCER AGENT ME, V7, P381
   Langer C, 2010, LUNG CANCER, V67, P4, DOI 10.1016/j.lungcan.2009.08.020
   Larkman DJ, 2007, PHYS MED BIOL, V52, pR15, DOI 10.1088/0031 9155/52/7/R01
   Lauenstein TC, 2004, RADIOLOGY, V233, P139, DOI 10.1148/radiol.2331030777
   Lauenstein TC, 2002, EUR RADIOL, V12, P2091, DOI 10.1007/s00330 002 1344 z
   Lee B, 2009, EUR J CANCER, V45, P1597, DOI 10.1016/j.ejca.2009.01.021
   LEWINGTON VJ, 1991, EUR J CANCER, V27, P954, DOI 10.1016/0277 5379(91)90257 E
   Lin PP, 2007, J BONE JOINT SURG AM, V89A, P1794, DOI 10.2106/JBJS.F.00603
   Lipton A, 2012, EUR J CANCER, V48, P3082, DOI 10.1016/j.ejca.2012.08.002
   Lutz S, 2017, PRACT RADIAT ONCOL, V7, P4, DOI 10.1016/j.prro.2016.08.001
   Ma JF, 2009, J MAGN RESON IMAGING, V29, P1154, DOI 10.1002/jmri.21746
   Maerevoet M, 2005, NEW ENGL J MED, V353, P100
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Maxwell Cathy, 2003, Clin J Oncol Nurs, V7, P403, DOI 10.1188/03.CJON.403 408
   McArthur TA, 2017, CURR PROBL DIAGN RAD, V46, P282, DOI 10.1067/j.cpradiol.2016.11.007
   McGee HM, 2019, PRACT RADIAT ONCOL, V9, P89, DOI 10.1016/j.prro.2018.11.009
   Mcquay H.J., 2013, Cochrane Database Syst Rev., DOI [DOI 10.1002/14651858.CD001793, 10.1002/14651858.CD001793.PUB2]
   Mendel E, 2009, SPINE, V34, pS93, DOI 10.1097/BRS.0b013e3181b77895
   Messiou C, 2019, RADIOLOGY, V291, P4, DOI 10.1148/radiol.2019181949
   MIRELS H, 1989, CLIN ORTHOP RELAT R, P256
   MORGANPARKES JH, 1995, AM J ROENTGENOL, V164, P1075, DOI 10.2214/ajr.164.5.7717206
   Nazarian A, 2015, CLIN CANCER RES, V21, P2514, DOI 10.1158/1078 0432.CCR 14 2668
   Nilsson S, 2016, ANN ONCOL, V27, P868, DOI 10.1093/annonc/mdw065
   Ohno Y, 2007, J MAGN RESON IMAGING, V26, P498, DOI 10.1002/jmri.21031
   Ohta M, 2001, NUCL MED COMMUN, V22, P875, DOI 10.1097/00006231 200108000 00005
   Padhani AR, 2017, EUR UROL, V71, P81, DOI 10.1016/j.eururo.2016.05.033
   Palma DA, 2019, BMC CANCER, V19, DOI 10.1186/s12885 019 5977 6
   Parent EE, 2018, J NUCL MED, V59, P733, DOI 10.2967/jnumed.117.204032
   Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755
   Paszkowski AL, 1999, CLIN NUCL MED, V24, P852, DOI 10.1097/00003072 199911000 00006
   Patchell RA, 2005, LANCET, V366, P643, DOI 10.1016/S0140 6736(05)66954 1
   Pons F, 1997, EUR J NUCL MED, V24, P1210, DOI 10.1007/s002590050143
   Prologo JD, 2014, SKELETAL RADIOL, V43, P1551, DOI 10.1007/s00256 014 1939 x
   Ripamonti CI, 2009, ANN ONCOL, V20, P137, DOI 10.1093/annonc/mdn526
   Robinson R G, 1989, Radiographics, V9, P271
   Robson MD, 2003, J COMPUT ASSIST TOMO, V27, P825, DOI 10.1097/00004728 200311000 00001
   Römer W, 2006, J NUCL MED, V47, P1102
   Roodman G David, 2008, Hematology Am Soc Hematol Educ Program, P313, DOI 10.1182/asheducation 2008.1.313
   Roodman GD, 2004, BLOOD CELL MOL DIS, V32, P290, DOI 10.1016/j.bcmd.2004.01.001
   Rosen LS, 2001, CANCER J, V7, P377
   Rosen LS, 2003, CANCER AM CANCER SOC, V98, P1735, DOI 10.1002/cncr.11701
   Samarin A, 2015, NUCL MED COMMUN, V36, P1165, DOI 10.1097/MNM.0000000000000387
   SARPEL S, 1987, CANCER AM CANCER SOC, V59, P1112, DOI 10.1002/1097 0142(19870315)59:6<1112::AID CNCR2820590612>3.0.CO;2 6
   Sartor O, 2017, ANN ONCOL, V28, P2464, DOI 10.1093/annonc/mdx331
   Sartor O, 2004, UROLOGY, V63, P940, DOI 10.1016/j.urology.2004.01.034
   Saussez S, 2009, LARYNGOSCOPE, V119, P323, DOI 10.1002/lary.20076
   Schirrmeister H, 1999, J NUCL MED, V40, P1623
   Schlemmer HP, 2005, INVEST RADIOL, V40, P64, DOI 10.1097/01.rli.0000149250.37033.7c
   Schmidt GP, 2007, EUR RADIOL, V17, P939, DOI 10.1007/s00330 006 0361 8
   SCHNEIDER JA, 1994, J NUCL MED, V35, P1748
   Sedonja I, 1999, CLIN NUCL MED, V24, P407, DOI 10.1097/00003072 199906000 00006
   Serafini AN, 2001, J NUCL MED, V42, P895
   Sheikhbahaei S, 2019, ANN NUCL MED, V33, P351, DOI 10.1007/s12149 019 01343 y
   Shie P, 2008, CLIN NUCL MED, V33, P97, DOI 10.1097/RLU.0b013e31815f23b7
   Shreve PD, 1996, RADIOLOGY, V199, P751, DOI 10.1148/radiology.199.3.8638000
   Smith M, 2019, LANCET ONCOL, V20, P408, DOI 10.1016/S1470 2045(18)30860 X
   Spencer KL, 2019, JNCI J NATL CANCER I, V111, P1023, DOI 10.1093/jnci/djz101
   Sprave T, 2018, RADIOTHER ONCOL, V128, P274, DOI 10.1016/j.radonc.2018.04.030
   Stecco A, 2018, DIAGNOSTICS, V8, DOI 10.3390/diagnostics8030045
   Steinborn MM, 1999, J COMPUT ASSIST TOMO, V23, P123, DOI 10.1097/00004728 199901000 00026
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Tang HS, 2018, MAGN RESON IMAGING C, V26, P559, DOI 10.1016/j.mric.2018.06.010
   TEHRANZADEH J, 1989, J COMPUT ASSIST TOMO, V13, P466, DOI 10.1097/00004728 198905000 00019
   Theriault RL, 1999, J CLIN ONCOL, V17, P846, DOI 10.1200/JCO.1999.17.3.846
   Tsai YC, 2019, INT J HYPERTHER, V36, P932, DOI 10.1080/02656736.2019.1655593
   TURNER JH, 1991, EUR J CANCER, V27, P1084, DOI 10.1016/0277 5379(91)90297 Q
   Uematsu T, 2005, AM J ROENTGENOL, V184, P1266, DOI 10.2214/ajr.184.4.01841266
   Ueno NT, 2020, CANCER MED US, V9, P1025, DOI 10.1002/cam4.2780
   Umer M, 2018, ANN MED SURG, V27, P9, DOI 10.1016/j.amsu.2018.01.002
   Van Poznak C, 2017, J CLIN ONCOL, V35, P3978, DOI 10.1200/JCO.2017.75.4614
   van Vucht N, 2019, SKELETAL RADIOL, V48, P1861, DOI 10.1007/s00256 019 03271 4
   Voggenreiter G, 2005, SPINE, V30, P2806, DOI 10.1097/01.brs.0000190885.85675.a0
   Wade AA, 2006, AM J ROENTGENOL, V186, P1783, DOI 10.2214/AJR.05.0225
   Walker R, 2000, JMRI J MAGN RESON IM, V11, P343, DOI 10.1002/(SICI)1522 2586(200004)11:4<343::AID JMRI1>3.3.CO;2 G
   Wang EP, 2007, J ORAL MAXIL SURG, V65, P1328, DOI 10.1016/j.joms.2007.03.006
   Xu JY, 2016, J CLIN ENDOCR METAB, V101, P4871, DOI 10.1210/jc.2016 2815
   Yang SN, 2002, J CANCER RES CLIN, V128, P325, DOI 10.1007/s00432 002 0342 5
   Yu T, 2019, BRIT J RADIOL, V92, DOI 10.1259/bjr.20181048
   Zervas K, 2006, BRIT J HAEMATOL, V134, P620, DOI 10.1111/j.1365 2141.2006.06230.x
   Zheng GZ, 2017, EUR J CANCER CARE, V26, DOI 10.1111/ecc.12541
   ZIMMER WD, 1985, RADIOLOGY, V155, P709, DOI 10.1148/radiology.155.3.4001374
   Zunk K, 1996, THEOR APPL GENET, V92, P375, DOI 10.1007/BF00223682
NR 149
TC 1
Z9 1
U1 1
U2 6
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0887 2171
EI 1558 5034
J9 SEMIN ULTRASOUND CT
JI Semin. Ultrasound CT MRI
PD APR
PY 2021
VL 42
IS 2
BP 164
EP 183
DI 10.1053/j.sult.2020.08.016
EA APR 2021
PG 20
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA RX6WT
UT WOS:000647362300006
PM 33814103
DA 2025 08 17
ER

PT J
AU Tai, YT
   Acharya, C
   An, G
   Moschetta, M
   Zhong, MY
   Feng, XY
   Cea, M
   Cagnetta, A
   Wen, K
   van Eenennaam, H
   van Elsas, A
   Qiu, LG
   Richardson, P
   Munshi, N
   Anderson, KC
AF Tai, Yu Tzu
   Acharya, Chirag
   An, Gang
   Moschetta, Michele
   Zhong, Mike Y.
   Feng, Xiaoyan
   Cea, Michele
   Cagnetta, Antonia
   Wen, Kenneth
   van Eenennaam, Hans
   van Elsas, Andrea
   Qiu, Lugui
   Richardson, Paul
   Munshi, Nikhil
   Anderson, Kenneth C.
TI APRIL and BCMA promote human multiple myeloma growth and
   immunosuppression in the bone marrow microenvironment
SO BLOOD
LA English
DT Article
ID CELL MATURATION ANTIGEN; CHRONIC LYMPHOCYTIC LEUKEMIA; KAPPA B PATHWAY;
   DRUG RESISTANCE; PLASMA CELLS; MONOCLONAL ANTIBODY; IMMUNE CHECKPOINT;
   POOR PROGNOSIS; STROMAL CELLS; T CELLS
AB Here we show that overexpression or activation of B cell maturation antigen(BCMA) by its ligand, a proliferation inducing ligand (APRIL), promotes human multiple myeloma (MM) progression in vivo. BCMA downregulation strongly decreases viability and MM colony formation; conversely, BCMA overexpression augments MM cell growth and survival via induction of protein kinase B (AKT), MAPK, and nuclear factor (NF) kappa B signaling cascades. Importantly, BCMA promotes in vivo growth of xenografted MM cells harboring p53 mutation in mice. BCMA overexpressing tumors exhibit significantly increased CD31/microvessel density and vascular endothelial growth factor compared with paired control tumors. These tumors also express increased transcripts crucial for osteoclast activation, adhesion, and angiogenesis/metastasis, as well as genes mediating immune inhibition including programmed death ligand 1, transforming growth factor beta, and interleukin 10. These target genes are consistently induced by paracrine APRIL binding to BCMA on MM cells, which is blocked by an antagonistic anti APRIL monoclonal antibody hAPRIL01A (01A). 01A is cytotoxic against MM cells even in the presence of protective bone marrow (BM) myeloid cells including osteoclasts, macrophages, and plasmacytoid dendritic cells. 01Afurther decreases APRIL induced adhesion and migration of MM cells via blockade of canonical and noncanonical NF kappa B pathways. Moreover, 01A prevents in vivo MM cell growth within implanted human bone chips in SCID mice. Finally, the effect of 01A on MM cell viability is enhanced by lenalidomide and bortezomib. Taken together, these data delineate new molecular mechanisms of in vivo MM growth and immunosuppression critically dependent on BCMA and APRIL in the BM microenvironment, further supporting targeting this prominent pathway in MM.
C1 [Tai, Yu Tzu; Acharya, Chirag; An, Gang; Moschetta, Michele; Zhong, Mike Y.; Feng, Xiaoyan; Cea, Michele; Cagnetta, Antonia; Wen, Kenneth; Richardson, Paul; Munshi, Nikhil; Anderson, Kenneth C.] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Dept Med Oncol, Boston, MA 02115 USA.
   [Tai, Yu Tzu; Richardson, Paul; Munshi, Nikhil; Anderson, Kenneth C.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA.
   [van Eenennaam, Hans; van Elsas, Andrea] Aduro Biotech Europe, Oss, Netherlands.
   [Qiu, Lugui] Chinese Acad Med Sci, Inst Hematol, Dept Lymphoma & Myeloma, Tianjin Cord Blood Bank, Tianjin, Peoples R China.
   [Qiu, Lugui] Peking Union Med Coll, Tianjin, Peoples R China.
C3 Harvard University; Harvard University Medical Affiliates; Dana Farber
   Cancer Institute; Boston University; Chinese Academy of Medical Sciences
     Peking Union Medical College; Institute of Hematology & Blood Diseases
   Hospital   CAMS; Chinese Academy of Medical Sciences   Peking Union
   Medical College; Peking Union Medical College
RP Tai, YT (通讯作者)，Dana Farber Canc Inst, Dept Med Oncol, M551,450 Brookline Ave, Boston, MA 02215 USA.
EM yu tzu_tai@dfci.harvard.edu
RI CEA, MICHELE/K 3863 2018; cagnetta, antonia/ADY 7966 2022; Munshi,
   Nikhil/ABE 2338 2021; Yang, Yong/GLQ 5561 2022; Anderson,
   Kenneth/ACP 5073 2022; cea, Michele/K 3863 2018
OI CEA, MICHELE/0000 0002 1530 6729; van Eenennaam,
   Hans/0000 0003 0099 3738; CAGNETTA, ANTONIA/0000 0003 1973 3768; 
FU National Institutes of Health, National Cancer Institute [RO1050947,
   R01 CA178264, PO1 CA078378]; Dana Farber/Harvard Cancer Center
   Specialized Program in Research Excellence SPORE in Multiple Myeloma
   [P50CA100707]; BioNovion
FX This work was supported by National Institutes of Health, National
   Cancer Institute grants RO1050947, R01 CA178264, PO1 CA078378, and the
   Dana Farber/Harvard Cancer Center Specialized Program in Research
   Excellence SPORE in Multiple Myeloma P50CA100707. K.C.A. is an American
   Cancer Society Clinical Research Professor. Fellowship support provided
   by BioNovion.
CR Abe M, 2006, LEUKEMIA, V20, P1313, DOI 10.1038/sj.leu.2404228
   Abe M, 2004, BLOOD, V104, P2484, DOI 10.1182/blood 2003 11 3839
   Annunziata CM, 2007, CANCER CELL, V12, P115, DOI 10.1016/j.ccr.2007.07.004
   Avery DT, 2003, J CLIN INVEST, V112, P286, DOI 10.1172/JCI200318025
   Bai LC, 2014, PHARMACOL THERAPEUT, V144, P82, DOI 10.1016/j.pharmthera.2014.05.007
   Belnoue E, 2008, BLOOD, V111, P2755, DOI 10.1182/blood 2007 09 110858
   Bolkun L, 2014, ANN HEMATOL, V93, P635, DOI 10.1007/s00277 013 1924 9
   Brown R, 2004, BRIT J HAEMATOL, V125, P743, DOI 10.1111/j.1365 2141.2004.04984.x
   Carpenter RO, 2013, CLIN CANCER RES, V19, P2048, DOI 10.1158/1078 0432.CCR 12 2422
   Chauhan D, 2004, BLOOD, V103, P3158, DOI 10.1182/blood 2003 08 2873
   Chauhan D, 2003, BLOOD, V102, P3379, DOI 10.1182/blood 2003 05 1417
   Chauhan D, 2009, CANCER CELL, V16, P309, DOI 10.1016/j.ccr.2009.08.019
   Chiu A, 2007, BLOOD, V109, P729, DOI 10.1182/blood 2006 04 015958
   Claudio JO, 2002, BLOOD, V100, P2175, DOI 10.1182/blood 2002 01 0008
   Demchenko YN, 2010, BLOOD, V115, P3541, DOI 10.1182/blood 2009 09 243535
   Dennis KL, 2013, CURR OPIN ONCOL, V25, P637, DOI 10.1097/CCO.0000000000000006
   GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413
   Görgün G, 2015, CLIN CANCER RES, V21, P4607, DOI 10.1158/1078 0432.CCR 15 0200
   Gu ZJ, 1996, BLOOD, V88, P3972, DOI 10.1182/blood.V88.10.3972.bloodjournal88103972
   Guadagnoli M, 2011, BLOOD, V117, P6856, DOI 10.1182/blood 2011 01 330852
   Hendriks J, 2005, CELL DEATH DIFFER, V12, P637, DOI 10.1038/sj.cdd.4401647
   Huang HW, 2013, P NATL ACAD SCI USA, V110, P10928, DOI 10.1073/pnas.1309417110
   Ingold K, 2005, J EXP MED, V201, P1375, DOI 10.1084/jem.20042309
   Jiang H, 2016, LEUKEMIA, V30, P399, DOI 10.1038/leu.2015.240
   Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003
   Kimberley FC, 2009, J CELL PHYSIOL, V218, P1, DOI 10.1002/jcp.21561
   Krepler C, 2013, CLIN CANCER RES, V19, P1784, DOI 10.1158/1078 0432.CCR 12 2518
   Lascano V, 2015, ONCOGENESIS, V4, DOI 10.1038/oncsis.2014.50
   Lei X, 2015, ONCOTARGET, V6, P40622, DOI 10.18632/oncotarget.5872
   Liu JZ, 2007, BLOOD, V110, P296, DOI 10.1182/blood 2006 10 051482
   Lokhorst HM, 2015, NEW ENGL J MED, V373, P1207, DOI 10.1056/NEJMoa1506348
   Lonial S, 2015, NEW ENGL J MED, V373, P621, DOI 10.1056/NEJMoa1505654
   Mahajan K, 2015, ONCOGENE, V34, P4162, DOI 10.1038/onc.2014.350
   Mahajan K, 2013, CANCER LETT, V338, P185, DOI 10.1016/j.canlet.2013.04.004
   Mahtouk K, 2007, CLIN CANCER RES, V13, P7289, DOI 10.1158/1078 0432.CCR 07 1758
   Mahtouk K, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 198
   Matthes T, 2015, LEUKEMIA, V29, P1882, DOI 10.1038/leu.2015.145
   Matthes T, 2015, LEUKEMIA, V29, P1901, DOI 10.1038/leu.2015.68
   Matthes T, 2011, BLOOD, V118, P1838, DOI 10.1182/blood 2011 01 332940
   Moreaux J, 2005, BLOOD, V106, P1021, DOI 10.1182/blood 2004 11 4512
   Moreaux J, 2004, BLOOD, V103, P3148, DOI 10.1182/blood 2003 06 1984
   Moreaux J, 2011, BLOOD, V117, P1280, DOI 10.1182/blood 2010 04 279760
   Moreaux J, 2009, BMC CANCER, V9, DOI 10.1186/1471 2407 9 83
   Moreaux J, 2009, EUR J HAEMATOL, V83, P119, DOI 10.1111/j.1600 0609.2009.01262.x
   Munari F, 2011, BLOOD, V117, P6612, DOI 10.1182/blood 2010 06 293266
   Nijhof IS, 2015, CLIN CANCER RES, V21, P2802, DOI 10.1158/1078 0432.CCR 14 1813
   Novak AJ, 2004, BLOOD, V103, P689, DOI 10.1182/blood 2003 06 2043
   O'Connor BP, 2004, J EXP MED, V199, P91, DOI 10.1084/jem.20031330
   Palumbo A, 2015, EXPERT REV HEMATOL, V8, P481, DOI 10.1586/17474086.2015.1053866
   Peperzak V, 2013, NAT IMMUNOL, V14, P290, DOI 10.1038/ni.2527
   Pinzon Charry A, 2005, IMMUNOL CELL BIOL, V83, P451, DOI 10.1111/j.1440 1711.2005.01371.x
   Planelles L, 2007, HAEMATOLOGICA, V92, P1284, DOI 10.3324/haematol.10317
   Quinn J, 2011, BLOOD, V117, P890, DOI 10.1182/blood 2010 01 264424
   Ray A, 2015, LEUKEMIA, V29, P1441, DOI 10.1038/leu.2015.11
   Reijmers RM, 2013, FEBS J, V280, P2180, DOI 10.1111/febs.12180
   Rossi JF, 2009, BRIT J CANCER, V101, P1051, DOI 10.1038/sj.bjc.6605241
   Sakurai D, 2007, BLOOD, V109, P2961, DOI 10.1182/blood 2006 08 041772
   Tai YT, 2014, LEUKEMIA, V28, P155, DOI 10.1038/leu.2013.115
   Tai YT, 2003, BLOOD, V101, P2762, DOI 10.1182/blood 2002 09 2813
   Tai YT, 2008, BLOOD, V112, P1329, DOI 10.1182/blood 2007 08 107292
   Tai YT, 2006, CANCER RES, V66, P6675, DOI 10.1158/0008 5472.CAN 06 0190
   Tai YT, 2015, IMMUNOTHERAPY UK, V7, P1187, DOI 10.2217/imt.15.77
   Tai YT, 2014, BLOOD, V123, P3128, DOI 10.1182/blood 2013 10 535088
   Tai YT, 2012, BLOOD, V120, P1877, DOI 10.1182/blood 2011 12 396853
   Tamura H, 2013, LEUKEMIA, V27, P464, DOI 10.1038/leu.2012.213
   Taylor A, 2006, IMMUNOLOGY, V117, P433, DOI 10.1111/j.1365 2567.2006.02321.x
   Nguyen Pham TN, 2015, J IMMUNOTHER, V38, P330, DOI 10.1097/CJI.0000000000000097
   Thuringer D, 2013, FASEB J, V27, P4169, DOI 10.1096/fj.12 226977
   Tiedemann RE, 2012, CANCER RES, V72, P757, DOI 10.1158/0008 5472.CAN 11 2781
   Vanneman M, 2012, NAT REV CANCER, V12, P237, DOI 10.1038/nrc3237
   Varfolomeev E, 2004, MOL CELL BIOL, V24, P997, DOI 10.1128/MCB.24.3.997 1006.2004
   Yang Y, 2014, ONCOTARGET, V5, P11986, DOI 10.18632/oncotarget.2388
   Zhang H, 2016, METHODS MOL BIOL, V1360, P107, DOI 10.1007/978 1 4939 3073 9_9
   Zheng Y, 2013, LEUKEMIA, V27, P702, DOI 10.1038/leu.2012.272
   Zhou W, 2013, CANCER CELL, V23, P48, DOI 10.1016/j.ccr.2012.12.001
NR 75
TC 263
Z9 301
U1 2
U2 48
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006 4971
EI 1528 0020
J9 BLOOD
JI Blood
PD JUN 23
PY 2016
VL 127
IS 25
BP 3225
EP 3236
DI 10.1182/blood 2016 01 691162
PG 12
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA DP2RK
UT WOS:000378337700016
PM 27127303
OA Green Published
DA 2025 08 17
ER

PT J
AU Ruiz Gaspa, S
   Nogues, X
   Enjuanes, A
   Monllau, JC
   Blanch, J
   Carreras, R
   Mellibovsky, L
   Grinberg, D
   Balcells, S
   Díez Perez, A
   Pedro Botet, J
AF Ruiz Gaspa, Silvia
   Nogues, Xavier
   Enjuanes, Anna
   Monllau, Joan C.
   Blanch, Josep
   Carreras, Ramon
   Mellibovsky, Leonardo
   Grinberg, Daniel
   Balcells, Susana
   Diez Perez, Adolfo
   Pedro Botet, Juan
TI Simvastatin and atorvastatin enhance gene expression of collagen type 1
   and osteocalcin in primary human osteoblasts and MG 63 cultures
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE cholesterol lowering drugs; human osteoblast; collagen; calcium
ID BONE MINERAL DENSITY; RANDOMIZED CONTROLLED TRIAL; POSTMENOPAUSAL WOMEN;
   MC3T3 E1 CELLS; FRACTURE RISK; IN VITRO; STATINS; OSTEOPOROSIS;
   DIFFERENTIATION; TURNOVER
AB To clarify the mechanism of the stimulatory effect of statins on bone formation, we have assessed the effect of simvastatin and atorvastatin on osteoblast activity by analysing cell proliferation, as we I I as collagen, osteocalcin, and bone morphogenetic protein 2 (BMP2) gene expression in primary human osteoblast(hOB) and MG 63 cell line cultures. Explants of bone from patients without any metabolic disease under orthopedic hip procedures were used to obtain hOB. Cell cultures were established, synchronized, and different concentrations of simvastatin or atorvastatin were added (10( 9) M, 10( 8) M, 10( 7) M, 10( 6) M) during the experiment. Cell proliferation was analyzed after 24 h. Collagen polypeptide alpha 1 type 1 (COL1A1) gene expression, osteocalcin, and BMP2 expression levels were quantified by real time PCR after 24 h incubation with statins. There was a statistically significant decrease in cell proliferation related to simvastatin or atorvastatin addition at all concentrations in primary hOB compared with those not treated. A significant increase in COL1A1, osteocalcin, and BMP2 gene expression was detected when hOB cultures were treated with simvastatin or atorvastatin at different concentrations. Similar but less significant effects were found on MG 63 cells. After statin treatment we observed both an arrest of proliferation in hOB cells and an increase in collagen, osteocalcin, and BMP2 gene expression, consistent with a stimulatory effect towards mature osteoblast differentiation. These findings support the bone forming effect of statins, probably through the BMP2 pathway.
C1 Hosp del Mar, Med Interna Serv, UAB, IMIM,URFOA, E 08003 Barcelona, Spain.
   Univ Autonoma Barcelona, E 08193 Barcelona, Spain.
   Univ Barcelona, Dept Genet, Barcelona, Spain.
   Hosp del Mar, Dept Med, Barcelona, Spain.
C3 Hospital del Mar Research Institute; Hospital del Mar; Autonomous
   University of Barcelona; Autonomous University of Barcelona; University
   of Barcelona; Hospital del Mar Research Institute; Hospital del Mar
RP Nogues, X (通讯作者)，Hosp del Mar, Med Interna Serv, UAB, IMIM,URFOA, Passeig Maritim 5 29, E 08003 Barcelona, Spain.
EM xnogues@imas.imim.es
RI ; Monllau, Joan/AAP 7118 2020; Balcells, Susana/C 5222 2017; ENJUANES,
   Anna/H 3245 2015; Grinberg, Daniel/F 3641 2010; Mellibovsky,
   Leonardo/IRG 7294 2023; Enjuanes, Anna/H 3245 2015; Blanch,
   Josep Salvador/A 2533 2009
OI Nogues, Xavier/0000 0001 8201 9933; Balcells,
   Susana/0000 0003 1211 1907; Grinberg, Daniel/0000 0001 9859 2590;
   Diez Perez, Adolfo/0000 0001 8162 0209; Nogues,
   Xavier/0000 0002 5537 1859; Enjuanes, Anna/0000 0002 4679 6687;
   Mellibovsky, Leonardo/0009 0001 7921 8840; 
CR Bauer DC, 2004, ARCH INTERN MED, V164, P146, DOI 10.1001/archinte.164.2.146
   Berthold HK, 2004, OSTEOPOROSIS INT, V15, P459, DOI 10.1007/s00198 004 1598 1
   Chan MHM, 2001, J CLIN ENDOCR METAB, V86, P4556
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   García Moreno C, 1998, BONE, V22, P233, DOI 10.1016/S8756 3282(97)00270 6
   Hamerman D, 2005, QJM INT J MED, V98, P467, DOI 10.1093/qjmed/hci077
   Hatzigeorgiou C, 2005, OSTEOPOROSIS INT, V16, P990, DOI 10.1007/s00198 004 1793 0
   Hodgson Stephen F, 2003, Endocr Pract, V9, P544
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Li XD, 2003, BONE, V33, P652, DOI 10.1016/S8756 3282(03)00239 4
   Maeda T, 2004, J CELL BIOCHEM, V92, P458, DOI 10.1002/jcb.20074
   MARIE PJ, 1989, IN VITRO CELL DEV B, V25, P373
   Maritz FJ, 2001, ARTERIOSCL THROM VAS, V21, P1636, DOI 10.1161/hq1001.097781
   Montagnani A, 2003, BONE, V32, P427, DOI 10.1016/S8756 3282(03)00034 6
   Mukhtar RYA, 2005, INT J CLIN PRACT, V59, P239, DOI 10.1111/j.1742 1241.2005.00461.x
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Ohnaka K, 2001, BIOCHEM BIOPH RES CO, V287, P337, DOI 10.1006/bbrc.2001.5597
   Oxlund H, 2004, BONE, V34, P609, DOI 10.1016/j.bone.2003.12.014
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   Rejnmark L, 2004, OSTEOPOROSIS INT, V15, P452, DOI 10.1007/s00198 003 1568 z
   Rejnmark L, 2004, J BONE MINER RES, V19, P737, DOI 10.1359/JBMR.040209
   Scranton RE, 2005, ARCH INTERN MED, V165, P2007, DOI 10.1001/archinte.165.17.2007
   Skoglund B, 2002, J BONE MINER RES, V17, P2004, DOI 10.1359/jbmr.2002.17.11.2004
   Song CL, 2003, BIOCHEM BIOPH RES CO, V308, P458, DOI 10.1016/S0006 291X(03)01408 6
   Staal A, 2003, J BONE MINER RES, V18, P88, DOI 10.1359/jbmr.2003.18.1.88
   Sugiyama M, 2000, BIOCHEM BIOPH RES CO, V271, P688, DOI 10.1006/bbrc.2000.2697
   Viereck V, 2005, J CELL BIOCHEM, V96, P1244, DOI 10.1002/jcb.20598
   Wang XD, 2003, ARCH BIOCHEM BIOPHYS, V415, P6, DOI 10.1016/S0003 9861(03)00213 3
NR 30
TC 78
Z9 83
U1 0
U2 10
PU WILEY LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0730 2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD AUG 15
PY 2007
VL 101
IS 6
BP 1430
EP 1438
DI 10.1002/jcb.21259
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 200PI
UT WOS:000248774900009
PM 17252541
DA 2025 08 17
ER

PT J
AU Adami, G
   Rossini, M
   Gatti, D
   Orsolini, G
   Idolazzi, L
   Viapiana, O
   Scarpa, A
   Canalis, E
AF Adami, Giovanni
   Rossini, Maurizio
   Gatti, Davide
   Orsolini, Giovanni
   Idolazzi, Luca
   Viapiana, Ombretta
   Scarpa, Aldo
   Canalis, Ernesto
TI Hajdu Cheney Syndrome; report of a novel NOTCH2 mutation and
   treatment with denosumab
SO BONE
LA English
DT Article
DE NOTCH; Bone remodeling; Fractures; Acroosteolysis; Denosumab;
   Splenomegaly
ID POLYCYSTIC KIDNEY SYNDROME; TRUNCATING MUTATIONS; CELLS;
   OSTEOCLASTOGENESIS; ACTIVATION; DISORDER; GENOME
AB Notch receptors play a central role in skeletal development and homeostasis. Hajdu Cheney Syndrome (HCS) is a rare disease associated with mutations of NOTCH2 that lead to the translation of a truncated, presumably stable, NOTCH2 protein. As a consequence, a gain of NOTCH2 function is manifested. We report a subject presenting with HCS and her child, both harboring a new heterozygous mutation in Exon 34 of NOTCH2 upstream of the PEST domain. The subject presented with osteoporosis, fractures, acroosteolysis and splenomegaly but did not have neurological complications, cardiovascular defects or polycystic kidneys. Sequencing of genomic DNA revealed a previously unreported mutation at nucleotide 6667C > T leading to a Gln2223Ter protein product in the subject and her son. Preclinical studies have demonstrated that the bone loss in HCS is secondary to enhanced osteoclastogenesis and bone resorption, and the same mechanism may operate in humans. Accordingly, the case we report was treated and responded to therapy with denosumab with an increase in bone mineral density (BMD). However, acroosteolysis progressed and was not modified by denosumab. In conclusion, we report a case of HCS associated with a novel mutation in NOTCH2 and its response to denosumab on BMD. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Adami, Giovanni; Rossini, Maurizio; Gatti, Davide; Orsolini, Giovanni; Idolazzi, Luca; Viapiana, Ombretta] Univ Verona, Rheumatol Unit, Dept Med, Piazzale L Scuro 2, I 37134 Verona, Italy.
   [Scarpa, Aldo] Univ & Hosp Trust Verona, ARC Net Res Ctr, Piazzale L Scuro 2, I 37134 Verona, Italy.
   [Canalis, Ernesto] UConn Hlth, UConn Musculoskeletal Inst, Dept Orthopaed Surg, Farmington, CT 06030 USA.
C3 University of Verona; University of Verona; Azienda Ospedaliera
   Universitaria Integrata Verona
RP Adami, G (通讯作者)，Univ Verona, Rheumatol Unit, Dept Med, Piazzale L Scuro 2, I 37134 Verona, Italy.
EM gio90it90@gmail.com
RI Idolazzi, Luca/X 4024 2019; Adami, Giovanni/AAQ 2160 2021; scarpa,
   aldo/K 6832 2016; rossini, maurizio/D 6610 2011; orsolini,
   giovanni/AAC 4774 2022; Davide, Gatti/ABP 6506 2022; Scarpa,
   Aldo/K 6832 2016
OI Rossini, Maurizio/0000 0001 9692 2293; Adami,
   Giovanni/0000 0002 8915 0755; VIAPIANA, Ombretta/0000 0003 1917 5655;
   Idolazzi, Luca/0000 0002 7254 4686; gatti, davide/0000 0002 7471 3076;
   Scarpa, Aldo/0000 0003 1678 739X
FU National Institutes of Health (NIH) [DK045227]
FX This work was supported in part by a grant from the National Institutes
   of Health (NIH) DK045227 (EC). The work is solely the responsibility of
   the authors and does not necessarily represent the official views of the
   NIH.
CR Bai S, 2008, J BIOL CHEM, V283, P6509, DOI 10.1074/jbc.M707000200
   Canalis E, 2016, CURR OSTEOPOROS REP, V14, P126, DOI 10.1007/s11914 016 0311 6
   Canalis E, 2016, J BIOL CHEM, V191, P1538, DOI 10.1074/jbc.M115.685453
   Canalis E, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/s13023 014 0200 y
   Canalis E, 2013, J BIOL CHEM, V288, P25614, DOI 10.1074/jbc.M113.470492
   Canalis E, 2013, ENDOCRINOLOGY, V154, P623, DOI 10.1210/en.2012 1732
   CHENEY WD, 1965, AMER J ROENTGENOL RA, V94, P595
   Cingolani Pablo, 2012, Frontiers in Genetics, V3, P35, DOI 10.3389/fgene.2012.00035
   Descartes M, 2014, CLIN DYSMORPHOL, V23, P88, DOI 10.1097/MCD.0000000000000034
   ELIAS AN, 1978, AM J MED, V65, P627, DOI 10.1016/0002 9343(78)90851 3
   Fortini ME, 2009, DEV CELL, V16, P633, DOI 10.1016/j.devcel.2009.03.010
   Fukushima H, 2008, MOL CELL BIOL, V28, P6402, DOI 10.1128/MCB.00299 08
   Galli Tsinopoulou A, 2012, MINERVA ENDOCRINOL, V32, P283
   Gray MJ, 2012, EUR J HUM GENET, V20, P122, DOI 10.1038/ejhg.2011.125
   HAJDU N, 1948, BRIT J RADIOL, V21, P42, DOI 10.1259/0007 1285 21 241 42
   Hampel F, 2011, BLOOD, V118, P6321, DOI 10.1182/blood 2010 12 325944
   Isidor B, 2011, HUM MUTAT, V32, P1239, DOI 10.1002/humu.21563
   Isidor B, 2011, NAT GENET, V43, P306, DOI 10.1038/ng.778
   Kaler S.G., 1990, Dysmorphology and clinical genetics, V4, P43
   Kiel MJ, 2012, J EXP MED, V209, P1553, DOI 10.1084/jem.20120910
   Lee SY, 2009, CANCER SCI, V100, P920, DOI 10.1111/j.1349 7006.2009.01130.x
   McKiernan FE, 2008, OSTEOPOROSIS INT, V19, P379, DOI 10.1007/s00198 007 0461 6
   McLaren W, 2010, BIOINFORMATICS, V26, P2069, DOI 10.1093/bioinformatics/btq330
   Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960
   NUNZIATA V, 1990, J ENDOCRINOL INVEST, V13, P251, DOI 10.1007/BF03349553
   Rossi D, 2012, J EXP MED, V209, P1537, DOI 10.1084/jem.20120904
   Saito T, 2003, IMMUNITY, V18, P675, DOI 10.1016/S1074 7613(03)00111 0
   Sargin G, 2013, KAOHSIUNG J MED SCI, V29, P343, DOI 10.1016/j.kjms.2012.10.009
   Simbolo M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062692
   Simpson MA, 2011, NAT GENET, V43, P303, DOI 10.1038/ng.779
   Witt CM, 2003, J IMMUNOL, V171, P2783, DOI 10.4049/jimmunol.171.6.2783
   Zanotti S, 2016, ENDOCR REV, V37, P223, DOI 10.1210/er.2016 1002
   Zanotti S, 2013, EUR J ENDOCRINOL, V168, pR95, DOI 10.1530/EJE 13 0115
   Zanotti S, 2013, ENDOCRINOLOGY, V154, P762, DOI 10.1210/en.2012 1925
   Zhao W, 2013, OSTEOPOROSIS INT, V24, P2275, DOI 10.1007/s00198 013 2298 5
NR 35
TC 37
Z9 41
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD NOV
PY 2016
VL 92
BP 150
EP 156
DI 10.1016/j.bone.2016.08.025
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA DZ2TC
UT WOS:000385693400018
PM 27592446
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Kim, A
   Hong, JH
   Shin, W
   Yoo, H
   Jung, JG
   Reginster, JY
   Kim, S
   Bae, Y
   Suh, J
   Kim, S
   Lee, E
   Silverman, S
AF Kim, Anhye
   Hong, Jang Hee
   Shin, Wonsuk
   Yoo, Hyounggyoon
   Jung, Jin Gyu
   Reginster, Jean Yves
   Kim, Sunghyun
   Bae, Yunju
   Suh, Jeehye
   Kim, Sera
   Lee, Eunkyung
   Silverman, Stuart
TI A randomized, double blind, single dose, phase 1 study comparing the
   pharmacokinetics, pharmacodynamics, safety, and immunogenicity of
   denosumab biosimilar CT P41 and reference denosumab in healthy males
SO EXPERT OPINION ON BIOLOGICAL THERAPY
LA English
DT Article
DE Biosimilar; CT P41; denosumab; immunogenicity; pharmacodynamics;
   pharmacokinetics
ID BONE MINERAL DENSITY; POSTMENOPAUSAL WOMEN; TURNOVER; RISK
AB BackgroundThis study's objective was to demonstrate pharmacokinetic (PK) similarity and safety of denosumab biosimilar, CT P41, and United States licensed reference denosumab (US denosumab) in healthy male Asian adults, considering also pharmacodynamic (PD) outcomes.Research design and methodsThis double blind, two arm, parallel group, Phase 1 study randomized (1:1) healthy males to a single (60 mg) subcutaneous dose of CT P41 or US denosumab. Primary endpoints were area under the concentration   time curve (AUC) from time zero to infinity (AUC0 inf), AUC from time zero to the last quantifiable concentration (AUC0 last), and maximum serum concentration (Cmax). PK equivalence was determined if 90% confidence intervals (CIs) for ratios of geometric least squares means (gLSMs) were within the predefined 80 125% equivalence margin. Secondary PK, PD, safety, and immunogenicity outcomes were also evaluated.ResultsOf 154 participants randomized (76 CT P41; 78 US denosumab), 151 received study drug (74 CT P41; 77 US denosumab). Primary and secondary PK results, PD results, safety, and immunogenicity were comparable between groups. Ninety percent CIs for ratios of gLSMs were within the predefined equivalence margin for AUC0 inf (100.4 114.7), AUC0 last (99.9 114.3), and Cmax (95.2 107.3).ConclusionsFollowing a single dose in healthy males, CT P41 demonstrated PK equivalence with US denosumab.Trial registrationClinicalTrials.gov: NCT06037395
C1 [Kim, Anhye; Shin, Wonsuk; Yoo, Hyounggyoon] CHA Univ, Sch Med, Seongnam, South Korea.
   [Hong, Jang Hee; Jung, Jin Gyu] Chungnam Natl Univ, Taejon 305764, Chungnam, South Korea.
   [Reginster, Jean Yves] WHO Collaborating Ctr Publ Hlth, Aspects Musculoskeletal Hlth & Aging, Liege, Belgium.
   [Reginster, Jean Yves] Kind Saud Univ, Riyadh, Saudi Arabia.
   [Kim, Sunghyun; Bae, Yunju; Suh, Jeehye; Kim, Sera; Lee, Eunkyung] Celltrion Inc, Incheon, South Korea.
   [Silverman, Stuart] Cedars Sinai Med Ctr, Los Angeles, CA USA.
   [Silverman, Stuart] OMC Clin Res Ctr, Beverly Hills, CA USA.
   [Silverman, Stuart] OMC Clin Res Ctr, 8641 Wilshire Blvd,Suite 301, Beverly Hills, CA 90211 USA.
C3 Pochon Cha University; Chungnam National University; Celltrion; Cedars
   Sinai Medical Center
RP Silverman, S (通讯作者)，OMC Clin Res Ctr, 8641 Wilshire Blvd,Suite 301, Beverly Hills, CA 90211 USA.
EM stuarts@bhillsra.com
RI ; Kim, Anhye/LXA 0046 2024; Reginster, Jean Yves/AGC 6097 2022
OI Hong, Jang Hee/0000 0002 0623 5455; Yoo,
   Hyounggyoon/0000 0003 2785 4383; 
FU Celltrion [2023]; Celltrion, Inc. (Incheon, Republic of Korea)
FX We thank all participants and investigators involved in the study.
   Medical writing support, including development of a draft outline and
   subsequent drafts in consultation with the authors, collating author
   comments, copyediting, fact checking, and referencing, was provided by
   Samantha Booth, PhD, at Aspire Scientific Limited (Bollington, UK).
   Funding for medical writing support for this article was provided by
   Celltrion, Inc. (Incheon, Republic of Korea). Selected results from the
   study were presented as a poster presentation at the American Society
   for Bone and Mineral Research 2023 Annual Meeting (Vancouver, BC,
   Canada; October 13 16, 2023).
CR An GH, 2020, J CLIN PHARMACOL, V60, P149, DOI 10.1002/jcph.1545
   Baumgart DC, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00279
   Bone HG, 2008, J CLIN ENDOCR METAB, V93, P2149, DOI 10.1210/jc.2007 2814
   Camacho PM, 2020, ENDOCR PRACT, V26, P1, DOI 10.4158/GL 2020 0524SUPPL
   Chen Q, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197984
   ClinicalTrials.gov, 2023, PHASE 3 STUDY COMPAR
   Curtis EM, 2022, AGING CLIN EXP RES, V34, P695, DOI 10.1007/s40520 022 02100 4
   European Medicines Agency, 2023, PROLIA SUMMARY PRODU
   European Medicines Agency, 2022, XGEVA SUMMARY PRODUC
   Gillett Melissa J, 2021, Clin Biochem Rev, V42, P3, DOI 10.33176/AACB 20 0001
   Hanley DA, 2012, INT J CLIN PRACT, V66, P1139, DOI 10.1111/ijcp.12022
   Kanis JA, 2020, OSTEOPOROSIS INT, V31, P1, DOI 10.1007/s00198 019 05176 3
   Kendler DL, 2010, J BONE MINER RES, V25, P72, DOI 10.1359/jbmr.090716
   Lewiecki EM, 2007, J BONE MINER RES, V22, P1832, DOI 10.1359/JBMR.070809
   Nakamura T, 2014, J CLIN ENDOCR METAB, V99, P2599, DOI 10.1210/jc.2013 4175
   Pitale Shailesh, 2015, Indian J Endocrinol Metab, V19, P148, DOI 10.4103/2230 8210.146871
   U.S. Food and Drug Administration, 2019, Immunogenicity testing of therapeutic protein products developing and validating assays for anti drug antibody detection. Guidance for industry
   US Food and Drug Administration, 2023, PROLIA PRESCRIBING I
   US Food and Drug Administration, 2020, XGEVA PRESCRIBING IN
NR 19
TC 2
Z9 2
U1 0
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1471 2598
EI 1744 7682
J9 EXPERT OPIN BIOL TH
JI Expert Opin. Biol. Ther.
PD JUL 2
PY 2024
VL 24
IS 7
SI SI
BP 655
EP 663
DI 10.1080/14712598.2024.2316846
EA FEB 2024
PG 9
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA A0T4J
UT WOS:001171584600001
PM 38349618
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Kwak, JH
   Lee, SR
   Park, HJ
   Byun, HE
   Sohn, EH
   Kim, BO
   Rhee, DK
   Pyo, S
AF Kwak, Jong Hwan
   Lee, Sung Ryul
   Park, Hye Jin
   Byun, Hye Eun
   Sohn, Eun Hwa
   Kim, Byung Oh
   Rhee, Dong Kwon
   Pyo, Suhkneung
TI Kobophenol A enhances proliferation of human osteoblast like cells with
   activation of the p38 pathway
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Kobophenol A; Osteoblast; Proliferation; p38 MAPK; ROS
ID BCL 2 FAMILY MEMBERS; NITRIC OXIDE; PROTEIN KINASE; MAP KINASE; BONE
   LOSS; ALKALINE PHOSPHATASE; HEME OXYGENASE 1; KAPPA B; APOPTOSIS;
   MITOCHONDRIA
AB Bone cell proliferation, bone formation, and bone resorption are the main factors involved in the homeostasis of the bone mass. Osteoblast death is a problem experienced by postmenopause women. Herbal medicines have attracted considerable attention for use as a drug or a drug substitute in the treatment of bone related diseases, such as osteoporosis. This study investigated the effects of kobophenol A on the proliferation in human osteoblast cells. Kobophenol A stimulated the proliferation of osteoblast cells by the increases in DNA synthesis and the enhancement of cell cycle progression. Kobophenol A stimulation induced the expression of the cyclin B1 and cyclin dependent kinase 1 (CDK1). Treatment of osteoblast cells with p38 MAPK inhibitor SB203580 significantly inhibited kobophenol A enhanced proliferation. In addition, kobophenol A induced phosphorylation of p38 MAPK Treatment of osteoblast cells with kobophenol A resulted in improvement of ROS scavenging activity. Moreover, kobophenol A treatment up regulated the Bcl 2 level, but down regulated the level of Bax expression. We also demonstrate that kobophenol A increased alkaline phosphatase (ALP) activity after 2 days. Taken together, the results of this study reveal that kobophenol A has proliferative effects and enhances ALP activity in osteoblast cells and these findings provide insights into the development of a therapeutic approach of kobophenol A in the prevention of osteoporosis and other bone disorders. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Kwak, Jong Hwan; Lee, Sung Ryul; Park, Hye Jin; Byun, Hye Eun; Rhee, Dong Kwon; Pyo, Suhkneung] Sungkyunkwan Univ, Div Immunopharmacol, Sch Pharm, Suwon 440746, Kyunggi Do, South Korea.
   [Sohn, Eun Hwa] Kangwon Natl Univ, Dept Herbal Med Resource, Kangwon Do 245711, South Korea.
   [Kim, Byung Oh] Kyungpook Natl Univ, Dept Appl Biol, Sangju 742711, Gyeongsangbuk D, South Korea.
C3 Sungkyunkwan University (SKKU); Kangwon National University; Kyungpook
   National University (KNU)
RP Pyo, S (通讯作者)，Sungkyunkwan Univ, Div Immunopharmacol, Sch Pharm, Suwon 440746, Kyunggi Do, South Korea.
EM snpyo@skku.edu
CR Acuña UM, 2002, PHYTOTHER RES, V16, P63, DOI 10.1002/ptr.1031
   Aherne SA, 2000, FREE RADICAL BIO MED, V29, P507, DOI 10.1016/S0891 5849(00)00360 9
   Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264 6021:3570593
   Alekel DL, 2000, AM J CLIN NUTR, V72, P844
   Alexandersen P, 2001, JAMA J AM MED ASSOC, V285, P1482, DOI 10.1001/jama.285.11.1482
   BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891 5849(94)00198 S
   Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066
   Chen RM, 2005, J ORTHOP RES, V23, P462, DOI 10.1016/j.orthres.2004.08.011
   Choudhary S, 2004, BIOCHEM BIOPH RES CO, V322, P395, DOI 10.1016/j.bbrc.2004.07.129
   Cuschieri J, 2005, CRIT CARE MED, V33, pS417, DOI 10.1097/01.CCM.0000191714.39495.A6
   Davies KJA, 1999, IUBMB LIFE, V48, P41, DOI 10.1080/152165499307404
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Dulak J, 2004, ANTIOXID REDOX SIGN, V6, P858, DOI 10.1089/ars.2004.6.858
   Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470 2045(05)70168 6
   Fosslien E, 2000, ANN CLIN LAB SCI, V30, P3
   Garcia Moreno C, 2004, BONE, V35, P170, DOI 10.1016/j.bone.2004.02.021
   Granchi D, 2004, INT J CANCER, V111, P829, DOI 10.1002/ijc.20308
   Greenblatt MB, 2010, J CLIN INVEST, V120, P2457, DOI 10.1172/JCI42285
   Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899
   Hock JM, 2001, J BONE MINER RES, V16, P975, DOI 10.1359/jbmr.2001.16.6.975
   Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793
   Kakita A, 2004, PROSTAG LEUKOTR ESS, V70, P469, DOI 10.1016/j.plefa.2003.09.003
   Katavic V, 2003, J IMMUNOL, V170, P1540, DOI 10.4049/jimmunol.170.3.1540
   Kousteni S, 2002, SCIENCE, V298, P843, DOI 10.1126/science.1074935
   KULANTHAIVEL P, 1995, PLANTA MED, V61, P41, DOI 10.1055/s 2006 957996
   KURIHARA H, 1991, PHYTOCHEMISTRY, V30, P649, DOI 10.1016/0031 9422(91)83745 7
   Lee SR, 2007, BIOORG MED CHEM LETT, V17, P1879, DOI 10.1016/j.bmcl.2007.01.078
   Lee SR, 2011, INT IMMUNOPHARMACOL, V11, P1251, DOI 10.1016/j.intimp.2011.04.004
   Martinou JC, 2011, DEV CELL, V21, P92, DOI 10.1016/j.devcel.2011.06.017
   Neve RM, 2002, ONCOGENE, V21, P4567, DOI 10.1038/sj.onc.1205555
   Ohyama K, 2005, INT J BIOCHEM CELL B, V37, P1496, DOI 10.1016/j.biocel.2005.02.016
   Rey A, 2007, BONE, V41, P59, DOI 10.1016/j.bone.2007.02.031
   Rodan GA., 2002, PRINCIPLES BONE BIOL, P1275
   Sasaki T, 2005, VIRCHOWS ARCH, V446, P525, DOI 10.1007/s00428 005 1247 x
   Suzuki A, 2002, BONE, V30, P91, DOI 10.1016/S8756 3282(01)00660 3
   Tian CY, 2003, ACTA BIOCH BIOPH SIN, V35, P77
   Tian CY, 2002, ACTA PHARMACOL SIN, V23, P572
   Tomkinson A, 1997, J CLIN ENDOCR METAB, V82, P3128, DOI 10.1210/jc.82.9.3128
   Ueno T, 2011, J BIOMED MATER RES A, V99A, P523, DOI 10.1002/jbm.a.33211
   van't Hof RJ, 2001, IMMUNOLOGY, V103, P255, DOI 10.1046/j.1365 2567.2001.01261.x
   Yalin S, 2005, CLIN EXP RHEUMATOL, V23, P689
NR 41
TC 12
Z9 14
U1 1
U2 10
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD NOV
PY 2013
VL 17
IS 3
SI SI
BP 704
EP 713
DI 10.1016/j.intimp.2013.08.015
PG 10
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA 255ZU
UT WOS:000327280100030
PM 24021754
DA 2025 08 17
ER

PT J
AU Antoci, V
   Adams, CS
   Hickok, NJ
   Shapiro, IM
   Parvizi, J
AF Antoci, Valentin, Jr.
   Adams, Christopher S.
   Hickok, Noreen J.
   Shapiro, Irving M.
   Parvizi, Javad
TI Antibiotics for local delivery systems cause skeletal cell toxicity in
   vitro
SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
LA English
DT Article
ID TOTAL KNEE ARTHROPLASTY; CONTAINING BONE CEMENT; GENTAMICIN; INFECTION;
   ELUTION; DEBRIDEMENT; IRRIGATION; TOBRAMYCIN; OSTEOBLASTS; CEFAZOLIN
AB Antibiotic concentrations associated with antibiotic bone cements may cause skeletal cell toxicity and prevent fracture healing. We investigated toxicity effects of dose and treatment time after exposure to three antibiotics commonly used in orthopaedic local drug delivery systems. We hypothesized a threshold exists for toxicity of osteoblasts and chondrocytes after treatment with ciprofloxacin, vancomycin, or tobramycin. To test this hypothesis, we first determined whether treatment with antibiotics caused differences in cellular morphology. Cells exposed to ciprofloxacin showed considerable changes in spread, cell membrane, and extensions. We next asked what dosage of antibiotic would cause reductions in osteoblast and chondrocyte cell numbers. Ciprofloxacin at a dose greater than 100 mu g/mL and vancomycin and tobramycin at doses greater than 2000 mu g/mL severely decreased cellular proliferation. Finally, we questioned whether observed decreases in cell numbers were the result of increased cellular toxicity or senescence. Released lactate dehydrogenase ratios were severely increased in osteoblasts. These data suggest the balance between the targeted microbicidal effects and host cellular toxicity is critical for skeletal cell survival and function.
C1 Thomas Jefferson Univ, Dept Orthopaed Surg, Philadelphia, PA 19107 USA.
   Rothman Inst, Philadelphia, PA USA.
C3 Thomas Jefferson University; Rothman Institute
RP Parvizi, J (通讯作者)，Thomas Jefferson Univ, Rothman Inst Orthopaed, 925 Chestnut St, Philadelphia, PA 19107 USA.
EM parvj@aol.com
RI Antoci, Valentin/AAC 4511 2021; Adams, Christopher/Z 2537 2019
OI Adams, Christopher/0000 0003 2100 4417
FU NIAMS NIH HHS [AR 051303] Funding Source: Medline; NIDCR NIH HHS
   [DE 13319] Funding Source: Medline
CR BELT H, 2001, ACTA ORTHOP SCAND, V72, P557
   Buttaro M, 2004, ACTA ORTHOP SCAND, V75, P427
   Chang YH, 2006, CLIN ORTHOP RELAT R, P242, DOI 10.1097/01.blo.0000229324.75911.c7
   Deirmengian C, 2003, CLIN ORTHOP RELAT R, P129, DOI 10.1097/01.blo.0000092996.90435.35
   Dyce J, 2002, VET SURG, V31, P552, DOI 10.1053/jvet.2002.34670
   Edin ML, 1996, CLIN ORTHOP RELAT R, P245
   Greene N, 1998, Am J Orthop (Belle Mead NJ), V27, P201
   HARTMAN MB, 1991, CLIN ORTHOP RELAT R, P113
   HOFMANN AA, 1995, CLIN ORTHOP RELAT R, P45
   Huddleston PM, 2000, J BONE JOINT SURG AM, V82A, P161, DOI 10.2106/00004623 200002000 00002
   Kalteis T, 2004, Z ORTHOP GRENZGEB, V142, P666, DOI 10.1055/s 2004 832317
   Kandziora F, 2002, J NEUROSURG, V97, P40, DOI 10.3171/spi.2002.97.1.0040
   KAYSINGER KK, 1995, J ORTHOP TRAUMA, V9, P303, DOI 10.1097/00005131 199509040 00006
   LAPPALAINEN K, 1994, PHARMACEUT RES, V11, P1127, DOI 10.1023/A:1018932714745
   LYNCH M, 1987, J BONE JOINT SURG BR, V69, P355, DOI 10.1302/0301 620X.69B3.3584184
   Masri BA, 1998, J ARTHROPLASTY, V13, P331, DOI 10.1016/S0883 5403(98)90179 6
   McLaren AC, 2004, CLIN ORTHOP RELAT R, P25, DOI 10.1097/01.blo.0000143556.41472.2a
   McLaren AC, 2002, CLIN ORTHOP RELAT R, P54, DOI 10.1097/01.blo.0000030069.92399.9b
   McLaren AC, 2004, CLIN ORTHOP RELAT R, P101, DOI 10.1097/01.blo.0000143554.56897.26
   MICLAU T, 1995, J ORTHOP TRAUMA, V9, P401, DOI 10.1097/00005131 199505000 00007
   Nelson CL, 2004, CLIN ORTHOP RELAT R, P72, DOI 10.1097/01.bio.0000143741.92384.18
   Neut D, 2001, J ANTIMICROB CHEMOTH, V47, P885, DOI 10.1093/jac/47.6.885
   Nijhof MW, 2000, J BIOMED MATER RES, V52, P709, DOI 10.1002/1097 4636(20001215)52:4<709::AID JBM16>3.3.CO;2 N
   Nijhof MW, 2000, J BIOMED MATER RES, V52, P754, DOI 10.1002/1097 4636(20001215)52:4<754::AID JBM21>3.3.CO;2 R
   Snedecor G. W., 1989, Ames Iowa State Univ Press Iowa, V8th
   Stevens CM, 2005, J ORTHOP RES, V23, P27, DOI 10.1016/j.orthres.2004.03.003
   Waertel G, 1996, J BONE JOINT SURG AM, V78A, P472, DOI 10.2106/00004623 199603000 00021
   Waldman BJ, 2000, J ARTHROPLASTY, V15, P430, DOI 10.1054/arth.2000.4637
NR 28
TC 168
Z9 185
U1 0
U2 22
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009 921X
EI 1528 1132
J9 CLIN ORTHOP RELAT R
JI Clin. Orthop. Rel. Res.
PD SEP
PY 2007
IS 462
BP 200
EP 206
DI 10.1097/BLO.0b013e31811ff866
PG 7
WC Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Surgery
GA 210IL
UT WOS:000249449800031
PM 17572634
DA 2025 08 17
ER

PT J
AU Hata, S
AF Hata, Saya
TI Effect of Oral Administration of Simvastatin on Bone Regeneration
   Process in Ovariectomized Rat
SO JOURNAL OF HARD TISSUE BIOLOGY
LA English
DT Article
DE Simvastatin; Ovariectomized rat; Oral administration; Bone regeneration
   process
ID MINERAL DENSITY; OSTEOBLAST DIFFERENTIATION; POSTMENOPAUSAL WOMEN;
   MC3T3 E1 CELLS; DRUG THERAPY; STATINS; OSTEOPOROSIS; OSTEOGENESIS;
   MECHANISMS; PREVENTION
AB It has been reported that simvastatin (SV), which is a cholesterol synthesis inhibitor and a therapeutic drug for hypercholesterolemia, stimulates bone morphogenetic protein 2 (BMP 2) expression in osteoblasts. The purpose of this study is to evaluate the efficacy of oral administration of SV on the bone healing process in the cortical bone defects of the tibiae of ovariectomized (OVX) rats. Cortical bone defects (1 mm diameter) of the tibia were created through the medial cortex and medulla. After 1 day of operation, SV/physiological saline solution (10mg/kg) was orally administrated as experimental group. Only physiological saline solution was orally administrated as sham group. OVX rat was used as a model of osteoporosis.
   There were no significant differences in body weight, calcium and phosphorus concentration and alkaline phosphatase activity in serum between S V and sham groups during 3 weeks of administration. On the contrary, the serum level of total cholesterol of SV group was significantly lower than sham group.
   After 3 weeks of administration, the tibia bone was excised. Micro high resolution microfocus X ray computed tomography showed the formation of new bone in SV group. Quantitative analysis for bone mineral density (BMD) was performed through three dimensional images. BMD in SV group was significantly higher than sham group. Histological sections stained with hematoxylin and eosin were observed under light microscope. In the sham group, thin granulation tissue with small amount of new bone and blood clot were observed inside the defects. A few osteoblasts were identified around new bone. On the contrary, the bone defect areas were filled with new bone in SV group Cand a greater number of osteoblasts was observed. New bone was also identified inside bone marrow. Interestingly, in SV group there were fewer amount of osteoclast like giant cells around newly bone compared with the sham group.
   Immunostaining for osteocalcin, osteonectin, osteopontin, BMP 2 and BMP 4 was performed to investigate the mechanism of the efficacy of bone healing process by SV administration. SV group showed stronger osteoblastic protein expression than sham group after immunostaining. The positive cell rates of SV group for anti osteocalcin, anti osteonectin, anti BMP 2 and anti BMP 4 antibodies were significantly greater than sham group.
   In conclusion, the present results revealed that oral administration of S V might provide a beneficial effect on bone healing process in OVX rats, which could be a promising drug for bone regeneration in osteoporosis therapy.
C1 Nihon Univ, Grad Sch Dent Matsudo, Dept Dentomaxillofacial Surg, Chiba 2718587, Japan.
C3 Nihon University
RP Hata, S (通讯作者)，Nihon Univ, Grad Sch Dent Matsudo, Dept Dentomaxillofacial Surg, 20870 1 Sakaecho Nishi, Chiba 2718587, Japan.
EM hata.saya@nihon u.ac.jp
FU Department of Dental Biomaterials
FX The author would like to thank Professor Yoshiaki Akimoto (Department of
   Oral Surgery), Professor Hirotsugu Yamamoto (Department of Oral
   Pathology), Professor Hiroshi Sugiya (Department of Physiology), and
   Professor Yorimasa Ogata (Department of Periodontology) for helpful
   advice. Finally, the author would like to thank Associate Professor
   Tohru Hayakawa (Department of Dental Biomaterials) for his helpful
   instruction, support and advice.
CR Adah F, 2005, BIOMED SCI INSTRUM, V41, P54
   Akiyama Y, 1999, JPN J PHARMACOL, V80, P67, DOI 10.1254/jjp.80.67
   Ayukawa Y, 2004, CLIN ORAL IMPLAN RES, V15, P346, DOI 10.1046/j.1600 0501.2003.01015.x
   Christiansen C, 1990, Osteoporos Int, V1, P7
   FLEISH H, 1961, AM J PHYSIOL, V200, P1296, DOI 10.1152/ajplegacy.1961.200.6.1296
   Garrett IR, 2002, ARTHRITIS RES, V4, P237, DOI 10.1186/ar413
   Horiuchi N, 2006, ORAL DIS, V12, P85, DOI 10.1111/j.1601 0825.2005.01172.x
   ITO I, 2006, J JPN STOMATOL SOC, V55, P10
   Junqueira Juliana C, 2002, J Oral Sci, V44, P117
   Kawane T, 2004, ENDOCRINE, V24, P121, DOI 10.1385/ENDO:24:2:121
   Lips P, 1997, Am J Med, V103, p3S
   Maeda T, 2004, J CELL BIOCHEM, V92, P458, DOI 10.1002/jcb.20074
   Maeda T, 2001, BIOCHEM BIOPH RES CO, V280, P874, DOI 10.1006/bbrc.2000.4232
   Maritz FJ, 2001, ARTERIOSCL THROM VAS, V21, P1636, DOI 10.1161/hq1001.097781
   Marx RE, 2007, J ORAL MAXIL SURG, V65, P2397, DOI 10.1016/j.joms.2007.08.003
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Mundy GR, 2001, BONE, V29, P495, DOI 10.1016/S8756 3282(01)00606 8
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Nishibe A, 1998, J BONE MINER METAB, V16, P21, DOI 10.1007/s007740050024
   Nyan M, 2007, J PHARMACOL SCI, V104, P384, DOI 10.1254/jphs.SC0070184
   Ohnaka K, 2001, BIOCHEM BIOPH RES CO, V287, P337, DOI 10.1006/bbrc.2001.5597
   Oxlund H, 2004, BONE, V34, P609, DOI 10.1016/j.bone.2003.12.014
   Parhami F, 2002, J BONE MINER RES, V17, P1997, DOI 10.1359/jbmr.2002.17.11.1997
   Phillips BW, 2001, BIOCHEM BIOPH RES CO, V284, P478, DOI 10.1006/bbrc.2001.4987
   Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219
   RIGGS BL, 1992, NEW ENGL J MED, V327, P620
   Sakou T, 1998, BONE, V22, P591, DOI 10.1016/S8756 3282(98)00053 2
   Sato D., 2005, J Oral Tissue Engin, V2, P81, DOI [10.11223/jarde.2.81, DOI 10.11223/JARDE.2.81]
   Sugiyama M, 2000, BIOCHEM BIOPH RES CO, V271, P688, DOI 10.1006/bbrc.2000.2697
   TANAKA S, 2007, BONE BIOL, P129
   TAYA K, 2007, JPN J CONSER DENT, V50, P52
   TERASHIMA S, 2005, OHU U DENT J, V32, P93
   WRONSKI TJ, 1988, CALCIFIED TISSUE INT, V43, P179, DOI 10.1007/BF02571317
   Yoshinari M, 2007, DENT MATER J, V26, P451, DOI 10.4012/dmj.26.451
   Yoshinari M, 2006, BIOMED RES TOKYO, V27, P29, DOI 10.2220/biomedres.27.29
NR 35
TC 8
Z9 8
U1 0
U2 4
PU JOURNAL HARD TISSUE BIOLOGY
PI MINATO KU
PA NIHON GAKUKUTSU KYORYOKU ZAIDAN, 3  24  20, NISHIAZABU, MINATO KU, TOKYO
   106 0031, JAPAN
SN 1341 7649
J9 J HARD TISSUE BIOL
JI J. Hard Tissue Biol.
PD APR
PY 2009
VL 18
IS 1
BP 47
EP 56
PG 10
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA 589PA
UT WOS:000277163100008
DA 2025 08 17
ER

PT J
AU Zhao, HB
   Väänänen, HK
AF Zhao, HB
   Väänänen, HK
TI Pharmacological sequestration of intracellular cholesterol in late
   endosomes disrupts ruffled border formation in osteoclasts
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE osteoclast; ruffled border; cholesterol; late endosome; lysosome
ID BONE RESORBING OSTEOCLASTS; CATHEPSIN K; LIPID TRAFFICKING;
   PLASMA MEMBRANE; CELL BIOLOGY; RAB PROTEINS; PROTON PUMP; C1 DISEASE;
   H+ ATPASE; RESORPTION
AB We showed that the ruffled border lacks a late endosomal lipid, LBPA, but is enriched in cholesterol. A hydrophobic amine, U18666A, causes cholesterol accumulation in LBPA(+) late endosomes in osteoclasts. Specific targeting of cathepsin K and the vactiolar H+ ATPase at the ruffled border is blocked by U18666A. A membrane trafficking pathway from baso lateral membrane toward the resorptive organelle is also arrested by the inhibitor. These results indicate cholesterol homeostasis regulates late endosomal/ lysosomal trafficking and polarized secretion in resorbing osteoclasts.
   Introduction: Protons and acidic proteases are secreted into the resorption lacuna through the ruffled border to solubilize bone mineral and digest the organic bone matrix, respectively. Whereas evidence suggests this event occurs through a vesicular trafficking mechanism, this issue remains unresolved.
   Materials and Methods: The distribution of lysobisphosphatidic acid (LBPA) and cholesterol in resorbing osteoclasts was examined by laser scanning confocal microscopy. The effects of U18666A on ruffled border formation were observed by electron microscopy.
   Results and Conclusions: The ruffled border does not contain LBPA but is enriched in cholesterol. We found a hydrophobic amine, U18666A, which blocks the efflux of cholesterol from late endosomes in other cells, causes cholesterol accumulation in LBPA containing late endosomes in osteoclasts, leading to diminished cholesterol at the ruffled border. Reflecting the U18666A mediated inhibition of late endosome/lysosome transport, the resorptive membrane is disrupted and contains a paucity of cathepsin K and the vacuolar H+ ATPase. These results indicate that the ruffled border is formed by the fusion of lysosomes with the plasma membrane in osteoclasts through a process that is cholesterol regulated.
C1 Univ Turku, Inst Biomed, Dept Anat, FIN 20520 Turku, Finland.
C3 University of Turku
RP Zhao, HB (通讯作者)，Washington Univ, Sch Med, Dept Pathol & Immunol, Campus Box 8118,660 S Euclid St, St Louis, MO 63110 USA.
EM hzhao@wustl.edu
RI Zhao, Haibo/ABG 9729 2021
OI ZHAO, HAIBO/0000 0003 0836 7555
CR BARON R, 1988, J CELL BIOL, V106, P1863, DOI 10.1083/jcb.106.6.1863
   BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207
   Blott EJ, 2002, NAT REV MOL CELL BIO, V3, P122, DOI 10.1038/nrm732
   Bossard MJ, 1996, J BIOL CHEM, V271, P12517, DOI 10.1074/jbc.271.21.12517
   Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228
   Choudhury A, 2002, J CLIN INVEST, V109, P1541, DOI 10.1172/JCI200215420
   Coxon FP, 2001, J BIOL CHEM, V276, P48213, DOI 10.1074/jbc.M106473200
   Coxon FP, 2003, CALCIFIED TISSUE INT, V72, P80, DOI 10.1007/s00223 002 2017 2
   Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511
   Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236
   Gowen M, 1999, J BONE MINER RES, V14, P1654, DOI 10.1359/jbmr.1999.14.10.1654
   Hoekstra D, 2000, CURR OPIN CELL BIOL, V12, P496, DOI 10.1016/S0955 0674(00)00122 8
   Johnson MR, 1996, GENOME RES, V6, P1050, DOI 10.1101/gr.6.11.1050
   Ko DC, 2001, MOL BIOL CELL, V12, P601, DOI 10.1091/mbc.12.3.601
   Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084
   Kobayashi T, 1998, SEMIN CELL DEV BIOL, V9, P517, DOI 10.1006/scdb.1998.0257
   Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440
   Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092 8674(01)00206 9
   LAKKAKORPI P, 1989, J BONE MINER RES, V4, P817
   Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563
   LISCUM L, 1989, J BIOL CHEM, V264, P11796
   Martinez I, 2000, J CELL BIOL, V148, P1141, DOI 10.1083/jcb.148.6.1141
   Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575
   Millard EE, 2000, J BIOL CHEM, V275, P38445, DOI 10.1074/jbc.M003180200
   Mukhejee S, 2004, BBA MOL CELL BIOL L, V1685, P28, DOI 10.1016/j.bbalip.2004.08.009
   Mulari MTK, 2003, TRAFFIC, V4, P113, DOI 10.1034/j.1600 0854.2003.40206.x
   Mullock BM, 1998, J CELL BIOL, V140, P591, DOI 10.1083/jcb.140.3.591
   Naureckiene S, 2000, SCIENCE, V290, P2298, DOI 10.1126/science.290.5500.2298
   Nesbitt SA, 1997, SCIENCE, V276, P266, DOI 10.1126/science.276.5310.266
   Ory DS, 2000, BBA MOL CELL BIOL L, V1529, P331, DOI 10.1016/S1388 1981(00)00158 X
   Palokangas H, 1997, J CELL SCI, V110, P1767
   Pichler H, 2004, BBA BIOMEMBRANES, V1666, P51, DOI 10.1016/j.bbamem.2004.05.011
   Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453
   Salo J, 1997, SCIENCE, V276, P270, DOI 10.1126/science.276.5310.270
   Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721
   Soccio RE, 2004, ARTERIOSCL THROM VAS, V24, P1150, DOI 10.1161/01.ATV.0000131264.66417.d5
   Sprong H, 2001, NAT REV MOL CELL BIO, V2, P504, DOI 10.1038/35080071
   Stenbeck G, 2002, SEMIN CELL DEV BIOL, V13, P285, DOI 10.1016/S1084952102000587
   Stinchcombe JC, 1999, J CELL BIOL, V147, P1, DOI 10.1083/jcb.147.1.1
   Stroup GB, 2001, J BONE MINER RES, V16, P1739, DOI 10.1359/jbmr.2001.16.10.1739
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Toyomura T, 2003, J BIOL CHEM, V278, P22023, DOI 10.1074/jbc.M302436200
   Väänänen HK, 2000, J CELL SCI, V113, P377
   VAANANEN HK, 1990, J CELL BIOL, V111, P1305, DOI 10.1083/jcb.111.3.1305
   VAANANEN HK, 1995, J CELL SCI, V108, P2729
   Väänänen K, 2005, ADV DRUG DELIVER REV, V57, P959, DOI 10.1016/j.addr.2004.12.018
   Yamaza T, 1998, BONE, V23, P499, DOI 10.1016/S8756 3282(98)00138 0
   Zhang M, 2001, P NATL ACAD SCI USA, V98, P4466, DOI 10.1073/pnas.081070898
   Zhao HB, 2002, BIOCHEM BIOPH RES CO, V293, P1060, DOI 10.1016/S0006 291X(02)00326 1
   Zhao HB, 2001, J BIOL CHEM, V276, P39295, DOI 10.1074/jbc.M010999200
NR 50
TC 22
Z9 26
U1 0
U2 3
PU AMER SOC BONE & MINERAL RES
PI WASHINGTON
PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036 3309 USA
SN 0884 0431
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD MAR
PY 2006
VL 21
IS 3
BP 456
EP 465
DI 10.1359/JBMR.051204
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 016UE
UT WOS:000235645100014
PM 16491294
DA 2025 08 17
ER

PT J
AU Zhang, WH
   Yu, LL
   Wang, F
   Chen, MJ
   Li, H
AF Zhang, Wenhao
   Yu, Leilei
   Wang, Fang
   Chen, Minjie
   Li, Hui
TI Rosavin regulates bone homeostasis through HDAC1 induced epigenetic
   regulation of EEF2
SO CHEMICO BIOLOGICAL INTERACTIONS
LA English
DT Article
DE Rosavin; HDAC1; EEF2; Osteoporosis; Bone homeostasis
ID OSTEOPOROSIS
AB Bioactive constituents from Rhodiola rosea L. show a myriad of pharmacological effects on diverse diseases. Rosavin has been linked to reduced osteoclastogenesis, while its role in regulating osteogenesis remains unclear. The present study investigated whether and how Rosavin alleviates ovariectomy (OVX) induced osteoporosis (OP) in mice. Rosavin had a therapeutic effect on OP in ovariectomized mice and inhibited osteoclast viability and promoted osteoblast viability. Integrated transcriptome sequencing, GO enrichment analysis, and PPI network construction revealed that the HDAC1/EEF2 axis was an important axis of gene action for Rosavin treatment. Mechanistically, HDAC1 suppressed EEF2 expression through histone deacetylation. Rescue experiments exhibited that HDAC1 promoted osteoclast viability, while EEF2 reversed the action of HDAC1 to restore bone homeostasis. In mice with OP, HDAC1 mitigated the effects of Rosavin, resulting in enhanced bone resorption and diminished bone formation, while EEF2 contributed to reduced bone resorption and elevated bone formation in mice. NF kappa B and MAPK pathways were inhibited by Rosavin, enhanced by HDAC1, and blocked again by EEF2. To summarize, our results proved that Rosavin maintained bone homeostasis in OP via regulation of histone acetylation of EEF2, thus playing a key role as a therapeutic candidate for OP treatment.
C1 [Zhang, Wenhao; Yu, Leilei; Wang, Fang; Chen, Minjie; Li, Hui] Shanghai Jiao Tong Univ, People Hosp s 9, Sch Med, Dept Oral & Craniofacial Surg, Shanghai 200011, Peoples R China.
   [Chen, Minjie; Li, Hui] Shanghai Jiao Tong Univ, Dept Oral & Craniomaxillofacial Sci, Peoples Hosp 9, Sch Med, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University
RP Chen, MJ; Li, H (通讯作者)，Shanghai Jiao Tong Univ, Dept Oral & Craniomaxillofacial Sci, Peoples Hosp 9, Sch Med, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
EM Chenminjietougao@126.com; Zwh262381@126.com
RI zhang, wenhao/HZI 7592 2023; Wang, Fang/B 1923 2016
FU Interdisciplinary Program of Shanghai Jiao Tong University [YG2019QNB08,
   YG2022QN050]; Medical and engineering cross project of Shanghai Ninth
   People's Hospital, Shanghai Jiao Tong University [JYLJ201902]; Shanghai
   Municipal Science and Technology Commission Biomedicine Key Project
   [21Y11903500]; Shanghai Jiao Tong University School of Medicine: Nursing
   Development Program
FX This work was supported by the Interdisciplinary Program of Shanghai
   Jiao Tong University (YG2022QN050) ; the Interdisciplinary Program of
   Shanghai Jiao Tong University (YG2019QNB08) ; Medical and engineering
   cross project of Shanghai Ninth People's Hospital, Shanghai Jiao Tong
   University (JYLJ201902) ; Shanghai Municipal Science and Technology
   Commission Biomedicine Key Project (21Y11903500) and Shanghai Jiao Tong
   University School of Medicine: Nursing Development Program.
CR Ali D, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/2379546
   An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Borgonetti V, 2020, PHYTOMEDICINE, V68, DOI 10.1016/j.phymed.2019.153143
   Cao HH, 2019, EXP THER MED, V17, P1262, DOI 10.3892/etm.2018.7095
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Choudhary N, 2020, CHEM BIOL INTERACT, V324, DOI 10.1016/j.cbi.2020.109095
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Faulkner B, 2019, MOLECULES, V24, DOI 10.3390/molecules24071355
   Gao YG, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22158182
   Ghayor C, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091446
   Guo CJ, 2019, BIOMED PHARMACOTHER, V115, DOI 10.1016/j.biopha.2019.01.031
   He JB, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01344
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Kushwaha P, 2016, J BIOL CHEM, V291, P3959, DOI 10.1074/jbc.M115.687152
   Kwon JY, 2018, J MED FOOD, V21, P364, DOI 10.1089/jmf.2017.4034
   Lee HW, 2006, MOL ENDOCRINOL, V20, P2432, DOI 10.1210/me.2006 0061
   Li X, 2021, CELL BIOL TOXICOL, V37, P849, DOI 10.1007/s10565 020 09578 6
   Novack DV, 2011, CELL RES, V21, P169, DOI 10.1038/cr.2010.159
   Panossian A, 2010, PHYTOMEDICINE, V17, P481, DOI 10.1016/j.phymed.2010.02.002
   Park JS, 2018, J TRANSL MED, V16, DOI 10.1186/s12967 018 1410 1
   Rantlha M, 2017, ARCH PHARM RES, V40, P79, DOI 10.1007/s12272 016 0790 0
   Wang T, 2017, CURR DRUG TARGETS, V18, P1051, DOI 10.2174/1389450118666170321105425
   Xin XB, 2019, BIOMED PHARMACOTHER, V115, DOI 10.1016/j.biopha.2019.108870
   Xu F, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.619301
   Xu YX, 2021, J BONE MINER METAB, V39, P914, DOI 10.1007/s00774 021 01249 8
   Zhang WH, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm 20 4255
   Zhong LY, 2020, MOLECULES, V25, DOI 10.3390/molecules25163664
   Zou HY, 2023, CLIN EXP PHARMACOL P, V50, P664, DOI 10.1111/1440 1681.13781
NR 28
TC 5
Z9 5
U1 0
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0009 2797
EI 1872 7786
J9 CHEM BIOL INTERACT
JI Chem. Biol. Interact.
PD OCT 1
PY 2023
VL 384
AR 110696
DI 10.1016/j.cbi.2023.110696
PG 15
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
GA CO0F3
UT WOS:001126064600001
PM 37689331
DA 2025 08 17
ER

PT J
AU Park, M
   Cho, YJ
   Kim, B
   Ko, YJ
   Jang, Y
   Moon, YH
   Hyun, H
   Lim, W
AF Park, Mineon
   Cho, Yong Jin
   Kim, Bora
   Ko, Young Jong
   Jang, Yuria
   Moon, Yeon Hee
   Hyun, Hoon
   Lim, Wonbong
TI RANKL immunisation inhibits prostate cancer metastasis by modulating EMT
   through a RANKL dependent pathway
SO SCIENTIFIC REPORTS
LA English
DT Article
ID NF KAPPA B; EPITHELIAL MESENCHYMAL TRANSITION; CATENIN SIGNALING
   PATHWAY; RECEPTOR ACTIVATOR; BREAST CANCER; OSTEOCLAST DIFFERENTIATION;
   OSTEOPROTEGERIN LIGAND; ZOLEDRONIC ACID; BONE METASTASIS; MURINE MODEL
AB Prostate cancer (PCa) morbidity in the majority of patients is due to metastatic events, which are a clinical obstacle. Therefore, a better understanding of the mechanism underlying metastasis is imperative if we are to develop novel therapeutic strategies. Receptor activator of nuclear factor kappa B (NF kappa B) ligand (RANKL) regulates bone remodelling. Thus, agents that suppress RANKL signalling may be useful pharmacological treatments. Here, we used preclinical experimental models to investigate whether an inactive form of RANKL affects bone metastasis in RANKL induced PCa. RANKL was associated with epithelial mesenchymal transition (EMT) and expression of metastasis related genes in PC3 cells. Therefore, we proposed a strategy to induce anti cytokine antibodies using mutant RANKL as an immunogen. RANKL promoted migration and invasion of PC3 cells through EMT, and induced a significant increase in binding of beta  catenin to TCF 4, an EMT induced transcription factor in PCa cells, via mitogen activated protein kinase and beta  catenin/TCF 4 signalling. Thus, RANKL increased EMT and the metastatic properties of PC3 cells, suggesting a role as a therapeutic target to prevent PCa metastasis. Treatment with mutant RANKL reduced EMT and metastasis of PC3 PCa cells in an experimental metastasis model. Thus, mutant RANKL could serve as a potential vaccine to prevent and treat metastatic PCa.
C1 [Park, Mineon; Cho, Yong Jin; Kim, Bora; Ko, Young Jong; Jang, Yuria; Lim, Wonbong] Chosun Univ Hosp, Lab Orthopaed Res, Gwangju 61452, South Korea.
   [Park, Mineon; Cho, Yong Jin; Kim, Bora; Ko, Young Jong; Jang, Yuria; Lim, Wonbong] Chosun Univ Hosp, Dept Orthopaed Surg, Gwangju 61452, South Korea.
   [Moon, Yeon Hee] Chodang Univ, Dept Dent Hyg, Muan Cty 58530, Jeollanam Do, South Korea.
   [Hyun, Hoon] Chonnam Natl Univ, Dept Biomed Sci, Med Sch, Gwangju 61469, South Korea.
   [Lim, Wonbong] Chosun Univ, Coll Med, Dept Premed Sci, Gwangju 61452, South Korea.
C3 Chosun University; Chosun University; Chonnam National University;
   Chosun University
RP Lim, W (通讯作者)，Chosun Univ Hosp, Lab Orthopaed Res, Gwangju 61452, South Korea.; Lim, W (通讯作者)，Chosun Univ Hosp, Dept Orthopaed Surg, Gwangju 61452, South Korea.; Lim, W (通讯作者)，Chosun Univ, Coll Med, Dept Premed Sci, Gwangju 61452, South Korea.
EM wonbong@chosun.ac.kr
RI Kim, Bora/GQZ 2209 2022; Cho, YongJin/A 1143 2013
FU Chosun University
FX This study was supported by research funding from Chosun University
   (awarded in 2020).
CR Anand M, 2011, HAEMATOL HEMATOL J, V96, P253, DOI 10.3324/haematol.2010.027086
   Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850
   [Anonymous], 2011, BONE, V48, pS162
   Armstrong AP, 2008, PROSTATE, V68, P92, DOI 10.1002/pros.20678
   Bachmann MF, 2004, NAT REV DRUG DISCOV, V3, P81, DOI 10.1038/nrd1284
   Chen G, 2006, CANCER AM CANCER SOC, V107, P289, DOI 10.1002/cncr.21978
   Cho KB, 2010, CANCER LETT, V293, P230, DOI 10.1016/j.canlet.2010.01.013
   Collin Osdoby P, 2001, J BIOL CHEM, V276, P20659, DOI 10.1074/jbc.M010153200
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Francis JC, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003180
   Goldstein DA, 2018, HAEMATOLOGICA, V103, P753, DOI 10.3324/haematol.2017.185264
   Harjunpää H, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01078
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   JACOBS SC, 1983, UROLOGY, V21, P337, DOI 10.1016/0090 4295(83)90147 4
   Jiang YG, 2007, INT J UROL, V14, P1034, DOI 10.1111/j.1442 2042.2007.01866.x
   Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524
   Kartsogiannis V, 1999, BONE, V25, P525, DOI 10.1016/S8756 3282(99)00214 8
   Ko Y, 2020, OSTEOPOROSIS INT, V31, P983, DOI 10.1007/s00198 019 05200 6
   Kodaira K, 1999, GENE, V230, P121, DOI 10.1016/S0378 1119(99)00025 6
   Kong YY, 1999, IMMUNOL CELL BIOL, V77, P188, DOI 10.1046/j.1440 1711.1999.00815.x
   Krishna M, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00021
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Lipton A, 2012, EUR J CANCER, V48, P3082, DOI 10.1016/j.ejca.2012.08.002
   Liu CZ, 2015, SCI REP UK, V5, DOI 10.1038/srep14150
   Liu Z, 2014, MOL CANCER RES, V12, P491, DOI 10.1158/1541 7786.MCR 13 0418
   Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528
   Montanari M, 2017, ONCOTARGET, V8, P35376, DOI 10.18632/oncotarget.15686
   Neudert M, 2003, INT J CANCER, V107, P468, DOI 10.1002/ijc.11397
   Odero Marah VA, 2008, CELL RES, V18, P858, DOI 10.1038/cr.2008.84
   Ohtaka M, 2017, INT J SURG CASE REP, V30, P106, DOI 10.1016/j.ijscr.2016.11.042
   Ooi LL, 2010, BONE, V47, P795, DOI 10.1016/j.bone.2010.07.012
   Pedone E, 2019, GENES BASEL, V10, DOI 10.3390/genes10020176
   Price JT, 2005, CANCER RES, V65, P4929, DOI 10.1158/0008 5472.CAN 04 4458
   Rawla P, 2019, WORLD J ONCOL, V10, P63, DOI 10.14740/wjon1191
   Renema N, 2016, BIOSCIENCE REP, V36, DOI 10.1042/BSR20160150
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Rosol Thomas J, 2004, Cancer Treat Res, V118, P47
   Santini D, 2011, J CELL PHYSIOL, V226, P780, DOI 10.1002/jcp.22402
   Savagner P, 2010, ANN ONCOL, V21, P89, DOI 10.1093/annonc/mdq292
   Schramek D, 2010, NATURE, V468, P98, DOI 10.1038/nature09387
   Semerano L, 2012, AUTOIMMUN REV, V11, P785, DOI 10.1016/j.autrev.2012.02.003
   Sharma P, 2011, NAT REV CANCER, V11, P805, DOI 10.1038/nrc3153
   Simmons JK, 2015, VET PATHOL, V52, P827, DOI 10.1177/0300985815586223
   Spencer GJ, 2006, J CELL SCI, V119, P1283, DOI 10.1242/jcs.02883
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Tan EJ, 2015, NUCLEIC ACIDS RES, V43, P162, DOI 10.1093/nar/gku1293
   Tan W, 2011, NATURE, V470, P548, DOI 10.1038/nature09707
   Vatansever HS, 2014, MINERVA UROL NEFROL, V66, P249
   Wang XF, 2013, MOL MED REP, V7, P1169, DOI 10.3892/mmr.2013.1335
   Wang Yifan, 2013, Cancer Hallm, V1, P38
   Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075
   Wu TL, 2018, INT IMMUNOPHARMACOL, V64, P326, DOI 10.1016/j.intimp.2018.09.022
   Zheng Y, 2007, BONE, V40, P471, DOI 10.1016/j.bone.2006.09.016
   Zheng Y, 2011, PROSTATE, V71, P1012, DOI 10.1002/pros.21316
   Ziaee S, 2015, TRANSL ANDROL UROL, V4, P438, DOI 10.3978/j.issn.2223 4683.2015.04.10
NR 56
TC 16
Z9 16
U1 0
U2 5
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD JUN 9
PY 2021
VL 11
IS 1
AR 12186
DI 10.1038/s41598 021 91721 2
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA SV4DO
UT WOS:000663771100002
PM 34108600
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Taylor, S
   Gruen, M
   Kukanich, K
   Lascelles, BD
   Monteiro, BP
   Sampietro, LR
   Robertson, S
   Steagall, P
AF Taylor, Samantha
   Gruen, Margaret
   Kukanich, Kate
   Lascelles, B. Duncan
   Monteiro, Beatriz P.
   Sampietro, Llibertat Real
   Robertson, Sheilah
   Steagall, Paulo, V
TI 2024 ISFM and AAFP consensus guidelines on the long term use of NSAIDs
   in cats
SO JOURNAL OF FELINE MEDICINE AND SURGERY
LA English
DT Article
DE Carprofen; meloxicam; robenacoxib; analgesia; chronic kidney disease;
   osteoarthritis; degenerative joint disease; pain management; chronic
   pain
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TRANSITIONAL CELL CARCINOMA;
   GLOMERULAR FILTRATION RATE; CHRONIC KIDNEY DISEASE; COX 2 EXPRESSION;
   URINARY BLADDER; ADVERSE EVENTS; CHRONIC PAIN; AGED CATS; MELOXICAM
AB Practical relevance: Non steroidal anti inflammatory drugs (NSAIDs) are widely used and are effective for the management of pain in cats. These Guidelines will support veterinarians in decision making around prescribing NSAIDs in situations of chronic pain, to minimise adverse effects and optimise pain management. Information is provided on mechanism of action, indications for use, screening prior to prescription, use in the presence of comorbidities, monitoring of efficacy, and avoidance and management of adverse effects.Clinical challenges: The cat's unique metabolism should be considered when prescribing any medications, including NSAIDs. Chronic pain may be challenging to detect in this species and comorbidities, particularly chronic kidney disease, are common in senior cats. Management of chronic pain may be complicated by prescription of other drugs with the potential for interactions with NSAIDs.Evidence base: These Guidelines have been created by a panel of experts brought together by the International Society of Feline Medicine (ISFM) and American Association of Feline Practitioners (AAFP). Information is based on the available literature, expert opinion and the panel members' experience.
C1 [Taylor, Samantha] Int Soc Feline Med, Int Cat Care, Tisbury, Wiltshire, England.
   [Gruen, Margaret] North Carolina State Univ, Coll Vet Med, Dept Clin Sci, Comparat Pain Res Lab, Raleigh, NC USA.
   [Gruen, Margaret] North Carolina State Univ, Coll Vet Med, Dept Clin Sci, Behav Med Serv, Raleigh, NC USA.
   [Kukanich, Kate] Kansas State Univ, Coll Vet Med, Dept Clin Sci, Manhattan, KS USA.
   [Lascelles, B. Duncan] North Carolina State Univ, Coll Vet Med, Translat Res Pain TRiP Program, Dept Clin Sci, Raleigh, NC USA.
   [Lascelles, B. Duncan] North Carolina State Univ, Comparat Pain Res & Educ Ctr CPREC, Raleigh, NC USA.
   [Monteiro, Beatriz P.; Steagall, Paulo, V] Univ Montreal, Fac Vet Med, Dept Clin Sci, St Hyacinthe, PQ, Canada.
   [Sampietro, Llibertat Real] CV Ayavet, Madrid, Spain.
   [Robertson, Sheilah] Lap Love Vet Hosp, Lutz, FL USA.
   [Robertson, Sheilah] Univ Florida, Shelter Med Program, Gainesville, FL USA.
   [Steagall, Paulo, V] City Univ Hong Kong, Jockey Club Coll Vet Med & Life Sci, Dept Vet Clin Sci, Hong Kong, Peoples R China.
   [Steagall, Paulo, V] City Univ Hong Kong, Jockey Club Coll Vet Med & Life Sci, Ctr Anim Hlth & Welf, Hong Kong, Peoples R China.
C3 North Carolina State University; North Carolina State University; Kansas
   State University; North Carolina State University; North Carolina State
   University; Universite de Montreal; State University System of Florida;
   University of Florida; City University of Hong Kong; City University of
   Hong Kong
RP Taylor, S (通讯作者)，Int Soc Feline Med, Int Cat Care, Tisbury, Wiltshire, England.
EM sam.taylor@icatcare.org
RI ; Steagall, Paulo/HLQ 3252 2023; Taylor, Samantha/LFT 3060 2024;
   Monteiro, Beatriz/W 7596 2019
OI Lascelles, B. Duncan X./0000 0002 2950 9009; Taylor,
   Samantha/0000 0002 8668 0777; Steagall, Paulo/0000 0003 4150 6043;
   Gruen, Margaret/0000 0002 6036 8849; 
CR Adhiyaman V, 2001, J ROY SOC MED, V94, P512, DOI 10.1177/014107680109401005
   Adrian D, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 87023 2
   Aldrich LA, 2021, AM J VET RES, V82, P840, DOI 10.2460/ajvr.82.10.840
   Anstee QM, 2012, J HEPATOL, V57, P1097, DOI 10.1016/j.jhep.2012.04.041
   Barbeau Grégoire M, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms231810384
   Beam SL, 2003, VET PATHOL, V40, P496, DOI 10.1354/vp.40 5 496
   Behera NS, 2022, CLIN GERIATR MED, V38, P323, DOI 10.1016/j.cger.2021.11.004
   Benito J, 2013, VET J, V196, P368, DOI 10.1016/j.tvjl.2012.12.015
   Benito J, 2013, J VET INTERN MED, V27, P474, DOI 10.1111/jvim.12077
   Benito de la Víbora J, 2008, VET ANAESTH ANALG, V35, P501, DOI 10.1111/j.1467 2995.2008.00407.x
   Bennett D, 2009, J FELINE MED SURG, V11, P997, DOI 10.1016/j.jfms.2009.09.016
   Bommer NX, 2012, J FELINE MED SURG, V14, P527, DOI 10.1177/1098612X12442041
   Boyd LM, 2008, J VET INTERN MED, V22, P1111, DOI 10.1111/j.1939 1676.2008.0163.x
   Buffington CAT, 2006, J FELINE MED SURG, V8, P261, DOI 10.1016/j.jfms.2006.02.002
   Bulman Fleming JC, 2010, J FELINE MED SURG, V12, P262, DOI 10.1016/j.jfms.2009.09.007
   Butler RK, 2009, PROG NEUROBIOL, V88, P184, DOI 10.1016/j.pneurobio.2009.04.003
   Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699
   Choi KH, 2010, J KOREAN MED SCI, V25, P337, DOI 10.3346/jkms.2010.25.3.337
   Clinard F, 2004, EUR J CLIN PHARMACOL, V60, P279, DOI 10.1007/s00228 004 0761 0
   Corbee RJ, 2013, J ANIM PHYSIOL AN N, V97, P846, DOI 10.1111/j.1439 0396.2012.01329.x
   Court MH, 2013, VET CLIN N AM SMALL, V43, P1039, DOI 10.1016/j.cvsm.2013.05.002
   DANAN G, 1993, J CLIN EPIDEMIOL, V46, P1323, DOI 10.1016/0895 4356(93)90101 6
   de Azevedo AF, 2023, J FELINE MED SURG, V25, DOI 10.1177/1098612X221149384
   Delsart A, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms231911780
   Dernie F, 2021, EXP GERONTOL, V143, DOI 10.1016/j.exger.2020.111163
   Desforges EJ, 2016, APPL ANIM BEHAV SCI, V178, P60, DOI 10.1016/j.applanim.2016.03.006
   DiBernardi L, 2007, PROSTAG LEUKOTR ESS, V76, P245, DOI 10.1016/j.plefa.2007.01.006
   Dorsch R, 2016, J FELINE MED SURG, V18, P925, DOI 10.1177/1098612X15621603
   Eigner DR, 2023, J FELINE MED SURG, V25, DOI 10.1177/1098612X231201683
   Enomoto M, 2022, J FELINE MED SURG, V24, P142, DOI 10.1177/1098612X211011984
   Enomoto M, 2020, J FELINE MED SURG, V22, P1137, DOI 10.1177/1098612X20907424
   Food and Drug Administration (FDA), 2021, Generic Drug Facts.
   Foy MC, 2019, ENDOCRIN METAB CLIN, V48, P859, DOI 10.1016/j.ecl.2019.08.013
   Gassel AD, 2006, J AM ANIM HOSP ASSOC, V42, P212, DOI 10.5326/0420212
   Giraudel JM, 2010, AM J VET RES, V71, P710, DOI 10.2460/ajvr.71.7.710
   Goodman LA, 2009, AM J VET RES, V70, P826, DOI 10.2460/ajvr.70.7.826
   Gowan RA, 2012, J FELINE MED SURG, V14, P876, DOI 10.1177/1098612X12454418
   Gowan RA, 2011, J FELINE MED SURG, V13, P752, DOI 10.1016/j.jfms.2011.06.008
   Grudé P, 2010, J VET PHARMACOL THER, V33, P396, DOI 10.1111/j.1365 2885.2010.01157.x
   Gruen ME, 2017, VET REC, V180, DOI 10.1136/vr.104168
   Gruen ME, 2016, J VET INTERN MED, V30, P1138, DOI 10.1111/jvim.13972
   Gruen ME, 2022, J AM ANIM HOSP ASSOC, V58, P55, DOI 10.5326/JAAHA MS 7292
   Gruen ME, 2021, J VET INTERN MED, V35, P2752, DOI 10.1111/jvim.16291
   Gruen ME, 2021, FRONT VET SCI, V8, DOI 10.3389/fvets.2021.610028
   Gruen ME, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169576
   Gruen ME, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131839
   Guedes AGP, 2018, JAVMA J AM VET MED A, V253, P579, DOI 10.2460/javma.253.5.579
   Guedes AGP, 2018, JAVMA J AM VET MED A, V252, P565, DOI 10.2460/javma.252.5.565
   Guillot M, 2013, VET J, V196, P360, DOI 10.1016/j.tvjl.2013.01.009
   Gunew MN, 2008, J FELINE MED SURG, V10, P235, DOI 10.1016/j.jfms.2007.10.007
   Gunn Moore DA, 2003, J FELINE MED SURG, V5, P133, DOI 10.1016/S1098 612X(02)00129 8
   Hampshire VA, 2004, JAVMA J AM VET MED A, V225, P533, DOI 10.2460/javma.2004.225.533
   Hayes A, 2007, VET COMP ONCOL, V5, P1, DOI 10.1111/j.1476 5829.2006.00111.x
   Hayes A, 2006, J COMP PATHOL, V135, P93, DOI 10.1016/j.jcpa.2006.06.001
   Heit MC, 2020, BMC VET RES, V16, DOI 10.1186/s12917 020 02553 7
   Hetrick PE, 2013, JAVMA J AM VET MED A, V243, P512, DOI 10.2460/javma.243.4.512
   Hung YP, 2014, VET J, V202, P76, DOI 10.1016/j.tvjl.2014.06.006
   Hunt JR, 2015, VET J, V206, P183, DOI 10.1016/j.tvjl.2015.07.025
   Jennings MW, 2015, JAVMA J AM VET MED A, V246, P654, DOI 10.2460/javma.246.6.654
   JONES RD, 1992, J AM VET MED ASSOC, V201, P475
   Keepman SJ, 2022, J FELINE MED SURG, V24, P1187, DOI 10.1177/1098612X211067023
   Khwanjai V, 2012, J VET PHARMACOL THER, V35, P13, DOI 10.1111/j.1365 2885.2011.01282.x
   King JN, 2006, J VET INTERN MED, V20, P1054, DOI 10.1892/0891 6640(2006)20[1054:TAEOBI]2.0.CO;2
   King JN, 2021, J VET INTERN MED, V35, P2384, DOI 10.1111/jvim.16148
   King JN, 2021, J VET PHARMACOL THER, V44, P411, DOI 10.1111/jvp.12973
   King JN, 2016, J FELINE MED SURG, V18, P632, DOI 10.1177/1098612X15590870
   King JN, 2016, BMC VET RES, V12, DOI 10.1186/s12917 016 0734 4
   King JN, 2013, AM J VET RES, V74, P465, DOI 10.2460/ajvr.74.3.465
   Klinck MP, 2018, J FELINE MED SURG, V20, P728, DOI [10.1177/1098612X17730172, 10.1177/1098612x17730172]
   Klinck MP, 2015, ANIMALS BASEL, V5, P1252, DOI 10.3390/ani5040410
   Klinck MP, 2012, CAN VET J, V53, P1181
   Kruger JM, 2015, JAVMA J AM VET MED A, V247, P508, DOI 10.2460/javma.247.5.508
   KuKanich K, 2021, J FELINE MED SURG, V23, P138, DOI 10.1177/1098612X20935750
   KuKanich K, 2017, JAVMA J AM VET MED A, V251, P835, DOI 10.2460/javma.251.7.835
   LaForge JM, 2023, ADV THER, V40, P2082, DOI 10.1007/s12325 023 02481 6
   Lamminen T, 2023, ANIMALS BASEL, V13, DOI 10.3390/ani13030371
   Lascelles B D, 2001, J Small Anim Pract, V42, P587, DOI 10.1111/j.1748 5827.2001.tb06034.x
   Lascelles BDX, 2010, J VET INTERN MED, V24, P487, DOI 10.1111/j.1939 1676.2010.0495.x
   Lascelles BDX, 2007, J VET INTERN MED, V21, P410, DOI 10.1892/0891 6640(2007)21[410:EOCOMA]2.0.CO;2
   Lascelles BDX, 2005, JAVMA J AM VET MED A, V227, P1112, DOI 10.2460/javma.2005.227.1112
   Lehr T, 2010, J VET PHARMACOL THER, V33, P277, DOI 10.1111/j.1365 2885.2009.01134.x
   Lidbury JA., 2013, Canine Feline Gastroenterology, V1st, P863
   Marino CL, 2014, J FELINE MED SURG, V16, P465, DOI 10.1177/1098612X13511446
   Marks SL, 2018, J VET INTERN MED, V32, P1823, DOI 10.1111/jvim.15337
   McCleane G, 2003, CNS DRUGS, V17, P1031, DOI 10.2165/00023210 200317140 00003
   Monteiro B., 2019, J Small Anim Pract, V60
   Monteiro BP, 2023, J SMALL ANIM PRACT, V64, P177, DOI 10.1111/jsap.13566
   Monteiro B, 2019, VET CLIN N AM SMALL, V49, P993, DOI 10.1016/j.cvsm.2019.07.009
   Monteiro BP, 2019, J FELINE MED SURG, V21, P601, DOI [10.1177/1098612X19856179, 10.1177/1098612x19856179]
   Monteiro BP, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175565
   Monteiro BP, 2016, VET ANAESTH ANALG, V43, P643, DOI 10.1111/vaa.12360
   Monteiro Steagall BP, 2013, J VET INTERN MED, V27, P1011, DOI 10.1111/jvim.12127
   Nivy R, 2019, J VET INTERN MED, V33, P2117, DOI 10.1111/jvim.15594
   Pavlova E, 2021, J VET INTERN MED, V35, P2697, DOI 10.1111/jvim.16275
   Pelligand L, 2015, BMC VET RES, V11, DOI 10.1186/s12917 015 0598 z
   Pypendop BH, 2008, J VET PHARMACOL THER, V31, P52, DOI 10.1111/j.1365 2885.2007.00921.x
   Quimby JM, 2024, J FELINE MED SURG, V26, DOI 10.1177/1098612X241240326
   Rainville P, 2005, PAIN, V118, P306, DOI 10.1016/j.pain.2005.08.022
   Raja SN, 2020, PAIN, V161, P1976, DOI 10.1097/j.pain.0000000000001939
   Rausch Derra LC, 2016, AM J VET RES, V77, P688, DOI 10.2460/ajvr.77.7.688
   Rees WD, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.583919
   Robertson SA, 2018, J FELINE MED SURG, V20, P602, DOI [10.1177/1098612X18781391, 10.1177/1098612x18781391]
   Rodan I, 2022, J FELINE MED SURG, V24, P1093, DOI 10.1177/1098612X221128760
   Roy M, 2011, EUR J PAIN, V15, DOI 10.1016/j.ejpain.2010.11.013
   Runk A, 1999, J AM ANIM HOSP ASSOC, V35, P52, DOI 10.5326/15473317 35 1 52
   Sayasith K, 2009, VET PATHOL, V46, P423, DOI 10.1354/vp.08 VP 0161 D FL
   Schmierer PA, 2020, VET SURG, V49, P905, DOI 10.1111/vsu.13411
   Schneider M, 2021, VET J, V270, DOI 10.1016/j.tvjl.2021.105625
   Shipley H, 2021, J FELINE MED SURG, V23, P568, DOI 10.1177/1098612X20967639
   Sivén M, 2017, VET REC, V180, P250, DOI 10.1136/vr.103991
   Smolensky MH, 2007, ADV DRUG DELIVER REV, V59, P828, DOI 10.1016/j.addr.2007.07.001
   Soltero Rivera M, 2023, J FELINE MED SURG, V25, DOI 10.1177/1098612X231186834
   Sparkes AH, 2010, J FELINE MED SURG, V12, P521, DOI 10.1016/j.jfms.2010.05.004
   Spitznagel MB, 2023, J FELINE MED SURG, V25, DOI 10.1177/1098612X221145835
   Stadig S, 2019, VET REC, V185, DOI [10.1136/vetrec 2018 105115, 10.1136/vr.105115]
   Steagall PVM, 2009, VET REC, V164, P359, DOI 10.1136/vr.164.12.359
   Steagall PV, 2022, J FELINE MED SURG, V24, P4, DOI 10.1177/1098612X211066268
   Storrer A, 2023, J FELINE MED SURG, V25, DOI 10.1177/1098612X231198416
   Surdyk KK, 2013, AM J VET RES, V74, P648, DOI 10.2460/ajvr.74.4.648
   Syme HM, 2002, J AM VET MED ASSOC, V220, P1799, DOI 10.2460/javma.2002.220.1799
   Tajiri K, 2008, WORLD J GASTROENTERO, V14, P6774, DOI 10.3748/wjg.14.6774
   Taylor S, 2022, J FELINE MED SURG, V24, P1133, DOI 10.1177/1098612X221128763
   Taylor S, 2022, J FELINE MED SURG, V24, P1283, DOI 10.1177/1098612X221083752
   Taylor SS, 2017, J FELINE MED SURG, V19, P288, DOI 10.1177/1098612X17693500
   Chatzimanouil MKT, 2023, MOL CELL PEDIATR, V10, DOI 10.1186/s40348 023 00160 8
   van Haaften KA, 2017, JAVMA J AM VET MED A, V251, P1175, DOI 10.2460/javma.251.10.1175
   Watanabe R, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213195
   Westropp JL, 2006, AM J VET RES, V67, P731, DOI 10.2460/ajvr.67.4.731
   Wiech K, 2009, NEUROIMAGE, V47, P987, DOI 10.1016/j.neuroimage.2009.05.059
   Wilson HM, 2007, JAVMA J AM VET MED A, V231, P101, DOI 10.2460/javma.231.1.101
   Winer JN, 2016, FRONT VET SCI, V3, DOI 10.3389/fvets.2016.00054
   Yabuki A, 2012, RES VET SCI, V93, P892, DOI 10.1016/j.rvsc.2011.12.017
   Yeowell G, 2021, FRONT VET SCI, V8, DOI 10.3389/fvets.2021.582148
NR 133
TC 10
Z9 10
U1 1
U2 7
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1098 612X
EI 1532 2750
J9 J FELINE MED SURG
JI J. Feline Med. Surg.
PD APR
PY 2024
VL 26
IS 4
AR 1098612X241241951
DI 10.1177/1098612X241241951
PG 26
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Veterinary Sciences
GA UA5C5
UT WOS:001245345200002
PM 38587872
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Giner, M
   Rios, MJ
   Montoya, MJ
   Vázquez, MA
   Miranda, C
   Pérez Cano, R
AF Giner, Merce
   Jose Rios, Ma
   Jose Montoya, Ma
   Angeles Vazquez, Ma
   Miranda, Cristina
   Perez Cano, Ramon
TI Alendronate and raloxifene affect the osteoprotegerin/RANKL system in
   human osteoblast primary cultures from patients with osteoporosis and
   osteoarthritis
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Human osteoblast culture; Osteoporosis; Osteoprotegerin/RANKL;
   Alendronate and raloxifene
ID ESTROGEN RECEPTOR MODULATORS; MARROW STROMAL CELLS; IN VITRO; ZOLEDRONIC
   ACID; BONE RESORPTION; POSTMENOPAUSAL OSTEOPOROSIS; BISPHOSPHONATE
   THERAPY; REGULATES OSTEOCLAST; GENE EXPRESSION; MECHANISMS
AB The osteoprotegerin/RANKL system modulates bone remodelling. Alendronate and raloxifene are anti resorptive drugs effective in osteoporotic disease. They reduce fracture risk, the activity of bone remodelling and increase bone mineral density. It is not known if they can exert a direct effect in osteoblasts via the osteoprotegerin/RANKL system. Our objective was to assess the effects of alendronate and raloxifene among osteoprotegerin production (ELISA), as well as osteoprotegerin and RANKL expression (RT PCR), in primary cultures of human osteoblasts (hOB). We compared 17 osteoporotic patients with 16 patients affected by osteoarthritis in basal conditions and after incubation with alendronate (10( 6) M), raloxifene (10( 7) M) or 17 beta estradiol (10( 7) M) for 24 h. The statistical analysis was determined by ANOVA. Osteoprotegerin protein secretion in hOB cultures was higher in patients with osteoporosis than osteoarthritis. Osteoprotegerin secretion levels remained unchanged after each treatment. The osteoporotic group was more sensitive to treatment. Both raloxifene (34%) and estradiol (37%) increased osteoprotegerin mRNA expression, and alendronate (118%) and raloxifene (61%) increased the mRNA expression of RANKL. The RANKL/osteoprotegerin mRNA ratio was higher in osteoporotic than osteoarthritic patients. In the osteoporotic group, the RANKL/osteoprotegerin mRNA ratio was significantly increased after treatment with alendronate (112%) and after treatment with raloxifene (60%). These results indicate a direct action of alendronate and raloxifene on hOB cultures from osteoporotic patients, and the cited drugs are able to modulate the osteoprotegerin/RANKL system. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Giner, Merce; Miranda, Cristina; Perez Cano, Ramon] Univ Hosp Virgen Macarena, Bone Metab Unit, Dept Internal Med, Seville 41009, Spain.
   [Giner, Merce; Jose Rios, Ma; Jose Montoya, Ma; Angeles Vazquez, Ma; Perez Cano, Ramon] Univ Seville, Med Dept Med, Seville, Spain.
C3 Hospital Universitario Virgen Macarena; Virgen del Rocio University
   Hospital; University of Sevilla; University of Sevilla
RP Giner, M (通讯作者)，Univ Hosp Virgen Macarena, Bone Metab Unit, Dept Internal Med, Ave Dr Fedriani S N, Seville 41009, Spain.
EM merce_giner@yahoo.es
RI Vazquez Gamez, MA/K 8889 2014; Vázquez Gámez, MA/K 8889 2014; Giner,
   Mercè/L 4547 2014; Moreno Fernández, Ana María/F 2816 2010;
   Montoya García, María José/L 3177 2014; Giner, Merce/L 4547 2014;
   Montoya Garcia, Maria Jose/L 3177 2014
OI Vazquez Gamez, MA/0000 0001 7689 6999; RIOS MORENO, MARIA
   JOSE/0000 0002 6654 0507; Giner, Merce/0000 0002 8285 0767;
   Montoya Garcia, Maria Jose/0000 0002 4946 6667
FU Fondo de Investigacion Sanitaria (FIS) of Spain [PI031164 2003]
FX This work was supported in part by the "Fondo de Investigacion Sanitaria
   (FIS PI031164 2003)" of Spain. The authors thank the staff in the
   Biochemistry and Trauma & Orthopaedic Department of the Hospital "Virgen
   Macarena", and also to Merck, Sharp & Dohne and Lilly for supplying us
   with alendronate and raloxifene molecules used in this study.
CR Bashir A, 2005, STEROIDS, V70, P847, DOI 10.1016/j.steroids.2005.04.011
   Bitto A, 2008, BRIT J PHARMACOL, V155, P896, DOI 10.1038/bjp.2008.305
   Cheung J, 2003, J ENDOCRINOL, V177, P423, DOI 10.1677/joe.0.1770423
   Compston JE, 2001, PHYSIOL REV, V81, P419, DOI 10.1152/physrev.2001.81.1.419
   Ettinger B, 2004, J BONE MINER RES, V19, P745, DOI 10.1359/JBMR.040117
   Fernández García D, 2008, J ENDOCRINOL INVEST, V31, P416, DOI 10.1007/BF03346385
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   García Moreno C, 1998, BONE, V22, P233, DOI 10.1016/S8756 3282(97)00270 6
   Giner M, 2008, HORM METAB RES, V40, P869, DOI 10.1055/s 0028 1082083
   Giner M, 2009, J STEROID BIOCHEM, V113, P46, DOI 10.1016/j.jsbmb.2008.11.005
   Giuliani N, 1998, BONE, V22, P455, DOI 10.1016/S8756 3282(98)00033 7
   Greiner S, 2007, J BIOMED MATER RES A, V80A, P769, DOI 10.1002/jbm.a.30950
   Idris AI, 2008, CALCIFIED TISSUE INT, V82, P191, DOI 10.1007/s00223 008 9104 y
   Im GI, 2004, BIOMATERIALS, V25, P4105, DOI 10.1016/j.biomaterials.2003.11.024
   Jonsson KB, 1999, ACTA ORTHOP SCAND, V70, P365, DOI 10.3109/17453679908997826
   Kim YH, 2002, EXP MOL MED, V34, P145, DOI 10.1038/emm.2002.21
   Kostenuik PJ, 2005, CURR OPIN PHARMACOL, V5, P618, DOI 10.1016/j.coph.2005.06.005
   Kudlacek S, 2003, BONE, V32, P681, DOI 10.1016/S8756 3282(03)00090 5
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Lonard DM, 2002, STEROIDS, V67, P15, DOI 10.1016/S0039 128X(01)00133 7
   Michael H, 2007, BRIT J PHARMACOL, V151, P384, DOI 10.1038/sj.bjp.0707232
   Olivier S, 2005, BIOCHEM PHARMACOL, V69, P891, DOI 10.1016/j.bcp.2004.11.030
   Pan BQ, 2004, J BONE MINER RES, V19, P147, DOI 10.1359/jbmr.2004.19.1.147
   Panzavolta S, 2009, J INORG BIOCHEM, V103, P101, DOI 10.1016/j.jinorgbio.2008.09.012
   Parfitt AM, 1996, J BONE MINER RES, V11, P150
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Reszka AA, 1999, J BIOL CHEM, V274, P34967, DOI 10.1074/jbc.274.49.34967
   Riggs BL, 2002, J BONE MINER RES, V17, P11, DOI 10.1359/jbmr.2002.17.1.11
   Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Stefanik D, 2008, ORAL DIS, V14, P465, DOI 10.1111/j.1601 0825.2007.01402.x
   Stolina M, 2007, J BONE MINER RES, V22, pS475
   Taranta A, 2002, BONE, V30, P368, DOI 10.1016/S8756 3282(01)00685 8
   Thirunavukkarasu K, 2001, J BIOL CHEM, V276, P36241, DOI 10.1074/jbc.M104319200
   TOBIAS JH, 1993, BONE, V14, P619, DOI 10.1016/8756 3282(93)90083 M
   Tou LQ, 2001, MOL CELL ENDOCRINOL, V183, P71, DOI 10.1016/S0303 7207(01)00594 9
   Varghese S, 2000, J BONE MINER RES, V15, P2345, DOI 10.1359/jbmr.2000.15.12.2345
   Velasco J, 2010, OSTEOPOROSIS INT, V21, P109, DOI 10.1007/s00198 009 0931 0
   Viereck V, 2003, J CLIN ENDOCR METAB, V88, P4206, DOI 10.1210/jc.2002 021877
   Viereck V, 2002, BIOCHEM BIOPH RES CO, V291, P680, DOI 10.1006/bbrc.2002.6510
   von Knoch F, 2005, BIOMATERIALS, V26, P6941, DOI 10.1016/j.biomaterials.2005.04.059
   Weinstein RS, 2009, NEW ENGL J MED, V360, P53, DOI 10.1056/NEJMoa0802633
NR 44
TC 23
Z9 28
U1 0
U2 17
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014 2999
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD JAN 15
PY 2011
VL 650
IS 2 3
BP 682
EP 687
DI 10.1016/j.ejphar.2010.10.058
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 763JW
UT WOS:000290553600025
PM 21050847
DA 2025 08 17
ER

PT J
AU Pastorelli, R
   Carpi, D
   Airoldi, L
   Chiabrando, C
   Bagnati, R
   Fanelli, R
   Moverare, S
   Ohlsson, C
AF Pastorelli, R
   Carpi, D
   Airoldi, L
   Chiabrando, C
   Bagnati, R
   Fanelli, R
   Moverare, S
   Ohlsson, C
TI Proteome analysis for the identification of in vitro
   estrogen regulated proteins in bone
SO PROTEOMICS
LA English
DT Article
DE bone; estrogen; mass spectrometry; ovariectomy
ID INTERLEUKIN 1 RECEPTOR ANTAGONIST; TROPOMYOSIN ISOFORMS; OSTEOCLAST
   FORMATION; OVARIECTOMIZED MICE; BINDING PROTEIN; GENE EXPRESSION;
   MESSENGER RNA; SEX STEROIDS; ER ALPHA; OSTEOBLASTS
AB Estrogen deficiency results in a reduced bone mass, which can be prevented by treatment with estrogens. This study used a proteomic approach for the first time to obtain a global perspective of estrogens' effects on whole bone proteins. Bone proteome profiles were examined in three groups of mice: (1) sham operated with normal ovarian functions, (2) ovariectomised and (3) ovariectomised with estrogen replacement therapy. Bone proteins extracted from the humerus were separated by 2 DE and visualised by CBB colloidal staining. Spot detection and quantification was done by image analysis. Differentially expressed proteins were identified by MS and database search, using peptide mass fingerprint and peptide sequence analysis. Differential expression analysis in the three experimental groups showed significant changes for 14 proteins. These included proteins related to bone metabolism, cytoskeleton components and energy metabolic pathways. Our data suggest that some proteins related to cytoskeleton and to energy pathways, such as tropomyosins, aconitase 2 and enolase beta, might be new molecular targets responsive to the effects of estrogen. Differentially expressed proteins identified in this model may offer a useful starting point for elucidating novel aspects of the pleiotropic effects of estrogens on bone.
C1 Ist Ric Farmacol Mario Negri, Mol Toxicol Lab, Dept Environm Hlth Sci, I 20157 Milan, Italy.
   Univ Gothenburg, Sahlgrenska Acad, Dept Internal Med, Ctr Bone Res, Gothenburg, Sweden.
C3 Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of
   Gothenburg
RP Ist Ric Farmacol Mario Negri, Mol Toxicol Lab, Dept Environm Hlth Sci, Via Eritrea 62, I 20157 Milan, Italy.
EM rpastorelli@marionegri.it
RI ; Ohlsson, Claes/HIR 6959 2022; Bagnati, Renzo/J 6492 2018; Ohlsson,
   Claes/AGP 3544 2022; Pastorelli, Roberta/AAA 6736 2020
OI Pastorelli, Roberta/0000 0001 5097 600X; Ohlsson,
   Claes/0000 0002 9633 2805; Bagnati, Renzo/0000 0002 6535 2686; 
CR Ammann P, 1997, J CLIN INVEST, V99, P1699, DOI 10.1172/JCI119333
   Anderson L, 1997, ELECTROPHORESIS, V18, P533, DOI 10.1002/elps.1150180333
   Brage M, 2004, BONE, V34, P412, DOI 10.1016/j.bone.2003.11.018
   Chang EJ, 2004, FEBS LETT, V564, P166, DOI 10.1016/S0014 5793(04)00338 2
   Destaing O, 2003, MOL BIOL CELL, V14, P407, DOI 10.1091/mbc.E02 07 0389
   Fry TJ, 2002, BLOOD, V99, P3892, DOI 10.1182/blood.V99.11.3892
   Gohel A, 1999, ENDOCRINOLOGY, V140, P5339, DOI 10.1210/en.140.11.5339
   Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720
   HEGMANN TE, 1989, J CELL BIOL, V109, P1141, DOI 10.1083/jcb.109.3.1141
   Hoebertz A, 2003, TRENDS PHARMACOL SCI, V24, P290, DOI 10.1016/S0165 6147(03)00123 8
   Hoebertz A, 2002, J CELL BIOCHEM, V86, P413, DOI 10.1002/jcb.10236
   Hofbauer LC, 1999, BONE, V25, P255, DOI 10.1016/S8756 3282(99)00162 3
   Hurst IR, 2004, J BONE MINER RES, V19, P499, DOI 10.1359/JBMR.0301238
   Hwang R, 2004, J BIOL CHEM, V279, P21239, DOI 10.1074/jbc.M312771200
   Kamioka H, 2004, J BONE MINER RES, V19, P471, DOI 10.1359/JBMR.040128
   KIMBLE RB, 1994, CALCIFIED TISSUE INT, V55, P260, DOI 10.1007/BF00310403
   Kimble RB, 1996, J BIOL CHEM, V271, P28890, DOI 10.1074/jbc.271.46.28890
   KITAZAWA R, 1994, J CLIN INVEST, V94, P2397, DOI 10.1172/JCI117606
   Kousteni S, 2002, SCIENCE, V298, P843, DOI 10.1126/science.1074935
   Kubota K, 2003, PROTEOMICS, V3, P616, DOI 10.1002/pmic.200300410
   Lin J J, 1997, Int Rev Cytol, V170, P1, DOI 10.1016/S0074 7696(08)61619 8
   Lindberg MK, 2003, MOL ENDOCRINOL, V17, P203, DOI 10.1210/me.2002 0206
   Lindberg MK, 2002, J BONE MINER RES, V17, P2183, DOI 10.1359/jbmr.2002.17.12.2183
   Lindberg MK, 2002, J ENDOCRINOL, V174, DOI 10.1677/joe.0.1740167
   Lorenzo JA, 1998, ENDOCRINOLOGY, V139, P3022, DOI 10.1210/en.139.6.3022
   McCarthy TL, 2003, J BIOL CHEM, V278, P43121, DOI 10.1074/jbc.M306531200
   Molloy MP, 2003, PROTEOMICS, V3, P1912, DOI 10.1002/pmic.200300534
   Morrison MS, 1998, J PHYSIOL LONDON, V511, P495, DOI 10.1111/j.1469 7793.1998.495bh.x
   Nishihara JC, 2002, ELECTROPHORESIS, V23, P2203, DOI 10.1002/1522 2683(200207)23:14<2203::AID ELPS2203>3.0.CO;2 H
   Nyåkern Meazza M, 2002, J BIOL CHEM, V277, P28774, DOI 10.1074/jbc.M203360200
   Percival JM, 2000, CELL MOTIL CYTOSKEL, V47, P189, DOI 10.1002/1097 0169(200011)47:3<189::AID CM3>3.0.CO;2 C
   Qu Q, 1999, BONE, V25, P211, DOI 10.1016/S8756 3282(99)00153 2
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Riggs BL, 2000, J CLIN INVEST, V106, P1203, DOI 10.1172/JCI11468
   Roggia C, 2001, P NATL ACAD SCI USA, V98, P13960, DOI 10.1073/pnas.251534698
   Roman Roman S, 2003, BONE, V32, P474, DOI 10.1016/S8756 3282(03)00052 8
   ROSIERS CD, 1995, J BIOL CHEM, V270, P10027, DOI 10.1074/jbc.270.17.10027
   Stossi F, 2004, ENDOCRINOLOGY, V145, P3473, DOI 10.1210/en.2003 1682
   Tumber A, 2003, J ENDOCRINOL, V178, P437, DOI 10.1677/joe.0.1780437
   Vanderschueren D, 2004, ENDOCR REV, V25, P389, DOI 10.1210/er.2003 0003
   Wang Q, 2003, J CELL BIOL, V160, P565, DOI 10.1083/jcb.200207036
   Weitzmann MN, 2000, BLOOD, V96, P1873, DOI 10.1182/blood.V96.5.1873.h8001873_1873_1878
NR 42
TC 35
Z9 44
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1615 9853
EI 1615 9861
J9 PROTEOMICS
JI Proteomics
PD DEC
PY 2005
VL 5
IS 18
BP 4936
EP 4945
DI 10.1002/pmic.200401325
PG 10
WC Biochemical Research Methods; Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 999TM
UT WOS:000234413400028
PM 16237733
DA 2025 08 17
ER

PT J
AU Huegel, J
   Chan, PYW
   Weiss, SN
   Nuss, CA
   Raja, H
   Waldorff, E
   Zhang, NAL
   Ryaby, JT
   Soslowsky, LJ
   Kuntz, AF
AF Huegel, Julianne
   Chan, Peter Y. W.
   Weiss, Stephanie N.
   Nuss, Courtney A.
   Raja, Harina
   Waldorff, Erik, I
   Zhang, Nianli
   Ryaby, James T.
   Soslowsky, Louis J.
   Kuntz, Andrew F.
TI Pulsed electromagnetic field therapy alters early healing in a rat model
   of rotator cuff injury and repair: Potential mechanisms
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE animal model; inflammation; pulsed electromagnetic field; rotator cuff
   repair; therapeutics
ID GREATER TUBEROSITY; TENDON; EXPRESSION; STIMULATION; INTEGRITY; CELLS;
   BMP 2; PEMF
AB Rotator cuff repair failure remains common due to poor tendon healing, particularly at the enthesis. We previously showed that pulsed electromagnetic field (PEMF) therapy improved the mechanical properties of the rat supraspinatus tendon postoperatively. However, little is known about the mechanisms behind PEMF dependent contributions to improved healing in this injury model. The objective of this study was to determine the influence of PEMF treatment on tendon gene expression and cell composition, as well as bone microarchitecture and dynamic bone metabolism during early stages of healing. We hypothesized that PEMF treatment would amplify tendon healing related signaling pathways while mitigating inflammation and improve bone metabolism at the repair site. Rats underwent rotator cuff injury and repair followed by assignment to either control (non PEMF) or PEMF treatment groups. Gene and protein expression as well as tendon and bone histological assessments were performed 3, 7, 14, 21, and 28 days after injury. Gene expression data demonstrated an upregulation in the bone morphogenetic protein 2 signaling pathway and increases in pro osteogenic genes at the insertion, supporting important processes to re establish the tendon bone interface. PEMF also downregulated genes related to a fibrotic healing response. Anti inflammatory effects were demonstrated by both gene expression and macrophage phenotype. PEMF significantly increased the rate of kinetic bone formation directly adjacent to the tendon enthesis as well as the number of cuboidal surface osteoblasts (active osteoblasts) in the humeral head. This study has provided insight into how PEMF affects cellular and molecular processes in the supraspinatus tendon and adjacent bone after injury and repair.
C1 [Huegel, Julianne; Chan, Peter Y. W.; Weiss, Stephanie N.; Nuss, Courtney A.; Raja, Harina; Soslowsky, Louis J.; Kuntz, Andrew F.] Univ Penn, McKay Orthopaed Res Lab, Philadelphia, PA 19104 USA.
   [Waldorff, Erik, I; Zhang, Nianli; Ryaby, James T.] Orthofix Med Inc, Lewisville, TX USA.
   [Soslowsky, Louis J.; Kuntz, Andrew F.] Univ Penn, Perelman Sch Med, Dept Orthopaed Surg, 3737 Market St,Suite 600, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; University of Pennsylvania
RP Kuntz, AF (通讯作者)，Univ Penn, Perelman Sch Med, Dept Orthopaed Surg, 3737 Market St,Suite 600, Philadelphia, PA 19104 USA.
EM Andrew.Kuntz@pennmedicine.upenn.edu
OI Chan, Peter/0000 0002 3498 6301; Huegel, Julianne/0000 0002 7051 861X;
   Kuntz, Andrew/0000 0003 3053 5500
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases
   [5P30AR069619]; Orthofix Medical, Inc
FX National Institute of Arthritis and Musculoskeletal and Skin Diseases,
   Grant/Award Number: 5P30AR069619; Orthofix Medical, Inc
CR Ackerman JE, 2021, CURR RHEUMATOL REP, V23, DOI 10.1007/s11926 021 00981 4
   Ackerman JE, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181127
   Boland Katy, 2021, J Clin Orthop Trauma, V18, P13, DOI 10.1016/j.jcot.2021.04.007
   Carpenter JE, 1998, J SHOULDER ELB SURG, V7, P599, DOI 10.1016/S1058 2746(98)90007 6
   Chan AK, 2019, JOR SPINE, V2, DOI 10.1002/jsp2.1069
   Cong XX, 2018, STEM CELLS, V36, P527, DOI 10.1002/stem.2765
   Dakin SG, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac4269
   De Micheli AJ, 2020, AM J PHYSIOL CELL PH, V319, pC885, DOI 10.1152/ajpcell.00372.2020
   Fjeldbo CS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156259
   Galatz LM, 2004, J BONE JOINT SURG AM, V86A, P219, DOI 10.2106/00004623 200402000 00002
   Garland D E, 1991, Contemp Orthop, V22, P295
   Gimbel JA, 2004, J BIOMECH, V37, P739, DOI 10.1016/j.jbiomech.2003.09.019
   Harper WL, 2015, INT MED CASE REP J, V8, P13, DOI 10.2147/IMCRJ.S73068
   Huegel J, 2020, J ORTHOP RES, V38, P70, DOI 10.1002/jor.24487
   Huegel J, 2018, J SHOULDER ELB SURG, V27, P553, DOI 10.1016/j.jse.2017.09.024
   Jiang YB, 2002, SKELETAL RADIOL, V31, P522, DOI 10.1007/s00256 002 0536 6
   Juneja SC, 2013, CONNECT TISSUE RES, V54, P218, DOI 10.3109/03008207.2013.787418
   Kaji DA, 2020, ELIFE, V9, DOI 10.7554/eLife.51779
   Kholinne E, 2018, ACTA ORTHOP TRAUMATO, V52, P22, DOI 10.1016/j.aott.2017.10.002
   Kubat NJ, 2015, J INFLAMM RES, V8, P59, DOI 10.2147/JIR.S78631
   Ladermann Alexandre, 2016, J ISAKOS, V1, P32
   Lim J, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 17384 0
   Mauro A, 2016, RES VET SCI, V105, P92, DOI 10.1016/j.rvsc.2016.01.014
   Mendias CL, 2015, J PHYSIOL LONDON, V593, P2037, DOI 10.1113/jphysiol.2014.287144
   Midura RJ, 2005, J ORTHOP RES, V23, P1035, DOI 10.1016/j.orthres.2005.03.015
   Miller SL, 2016, SPINE J, V16, P770, DOI 10.1016/j.spinee.2016.01.003
   Minami K, 2018, EXP THER MED, V15, P4465, DOI 10.3892/etm.2018.5959
   MOONEY V, 1990, SPINE, V15, P708, DOI 10.1097/00007632 199007000 00016
   Mowbray FI, 2019, CAN J NURS RES, V51, P31, DOI 10.1177/0844562118786647
   Patterson TE, 2006, BIOELECTROMAGNETICS, V27, P535, DOI 10.1002/bem.20244
   Peltz CD, 2009, J BONE JOINT SURG AM, V91A, P2421, DOI 10.2106/JBJS.H.01121
   Schwarting T, 2016, CONNECT TISSUE RES, V57, P99, DOI 10.3109/03008207.2015.1087516
   Selvarnurugan N, 2007, J ORTHOP RES, V25, P1213, DOI 10.1002/jor.20409
   Snedeker JG, 2017, ACTA BIOMATER, V63, P18, DOI 10.1016/j.actbio.2017.08.032
   Taylor EM, 2015, J SURG RES, V193, P504, DOI 10.1016/j.jss.2014.08.007
   Thomopoulos S, 2003, J ORTHOP RES, V21, P413, DOI 10.1016/S0736 0266(03)00057 3
   Tian XG, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/3849760
   Tucker JJ, 2017, J ORTHOP RES, V35, P902, DOI 10.1002/jor.23333
   US Food and Drug Administration, 1986, P850007 PMA US FDA D
   Vinhas A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155441
   Yao ZX, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951 021 00906 4
   Yeh LCC, 2008, J CELL BIOCHEM, V104, P2107, DOI 10.1002/jcb.21768
NR 42
TC 12
Z9 12
U1 0
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
EI 1554 527X
J9 J ORTHOP RES
JI J. Orthop. Res.
PD JUL
PY 2022
VL 40
IS 7
BP 1593
EP 1603
DI 10.1002/jor.25185
EA OCT 2021
PG 11
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 2H2MZ
UT WOS:000707729400001
PM 34657312
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Rong, LY
   Liu, HH
   Yang, SH
   Xu, HX
   Zhang, GH
   Sun, PB
AF Rong, Lingyan
   Liu, Huihui
   Yang, Shaohui
   Xu, Hongxia
   Zhang, Guihua
   Sun, Pengbo
TI Network Based Pharmacology to Explore the Role of Drynaria
   fortunei in Combination with Platelet Rich Plasma Intervention for
   Fracture Healing Disorders
SO INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Osteoclast; platelet  rich plasma; fracture healing; network  based
   pharmacology
AB Based on network pharmacology and molecular docking techniques and methods, to explore the active components and potential effects of Drynaria fortunei combined with platelet rich plasma intervention therapy on fracture healing diseases. The gene cards database, the human Mendelian genetic database, Online Mendelian Inheritance in Man database, and the DisGeNET database were searched to identify fracture related targets. Then, the active chemical components and targets in Rhizoma Drynariae were screened through the traditional Chinese medicine systematic pharmacology and analysis platform database. Then, the characteristic genes of platelet rich plasma were searched through the GSE203196, and the common targets of drugs and diseases were screened through R language. Construct a drug candidate compound target network diagram. Use the protein interaction network function enrichment analysis database and the Cytoscape software to build a protein interaction network, use AutoDock Vina for analysis and docking, use R language to conduct Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analysis on the critical targets of the fracture of the combination of Drynaria fortunei and platelet rich plasma intervention therapy, and determine the core target and mechanism of the variety of Drynaria fortunei and platelet rich plasma treatment of the fracture. A total of 18 active compounds were obtained from Rhizoma Drynariae. There are 18 overlapping targets of Drynaria and platelet rich plasma fracture. There are 13 active ingredients related to disease targets. Rhizoma Drynariae and plateletrich plasma are mainly involved in regulating prostaglandin endoper oxide synthase 2, androgen receptor, caspase 2, and B cell lymphoma 2 to play a role in treating fractures. The treatment of fracture with Drynaria fortunei combined with platelet rich plasma is a complex process of multicomponents, multi targets, and multi pathways related to the coordinated regulation of multiple targets and signal pathways.
C1 [Rong, Lingyan; Liu, Huihui; Yang, Shaohui; Xu, Hongxia; Sun, Pengbo] Wendeng Hosp Tradit Chinese Orthoped & Traumatol S, Dept Pharm, Wendeng 264400, Shandong, Peoples R China.
   [Zhang, Guihua] Wendeng Hosp Tradit Chinese Orthoped & Traumatol S, Dept Osteoarthritis, Wendeng 264400, Shandong, Peoples R China.
RP Sun, PB (通讯作者)，Wendeng Hosp Tradit Chinese Orthoped & Traumatol S, Dept Pharm, Wendeng 264400, Shandong, Peoples R China.
EM Baoweifang001@163.com
RI Rong, Lingyan/NFT 8136 2025; zhang, guihua/AAU 4587 2020; Liu,
   huihui/HME 1734 2023
FU Foundation of Shandong Pharmaceutical Association; Tianji Health Care
   under the project "Study on the clinical effect of TCM Jiegu Formula
   combined with PRP intervention therapy on fracture healing"
   [hlyy2021 010]
FX The project was supported by Young Research Foundation of Shandong
   Pharmaceutical Association and Tianji Health Care under the project
   "Study on the clinical effect of TCM Jiegu Formula combined with PRP
   intervention therapy on fracture healing" (No: hlyy2021 010) .
CR Chen JF, 2019, CELLS BASEL, V8, DOI 10.3390/cells8111318
   Chen YJ, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.803880
   Dai WR, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.920485
   Duan HXY, 2021, PHARMACOL RES, V168, DOI 10.1016/j.phrs.2021.105599
   Jeong JC, 2005, J ETHNOPHARMACOL, V96, P489, DOI 10.1016/j.jep.2004.09.038
   Johnson L, 2019, J CLIN MED, V8, DOI 10.3390/jcm8111998
   Johnston CB, 2020, MED CLIN N AM, V104, P873, DOI 10.1016/j.mcna.2020.06.004
   Karim K, 2021, J ETHNOPHARMACOL, V280, DOI 10.1016/j.jep.2021.114236
   Lei SS, 2021, INT J BIOL MACROMOL, V193, P1996, DOI 10.1016/j.ijbiomac.2021.11.030
   Liang B, 2022, CELL MOL BIOL LETT, V27, DOI 10.1186/s11658 022 00371 3
   Liu JT, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI148073
   Marongiu G, 2020, BONE REP, V12, DOI 10.1016/j.bonr.2020.100249
   Shen W, 2018, CHIN MED UK, V13, DOI 10.1186/s13020 018 0200 2
   Soliman AT, 1998, Study of growth and bone mineral density and factors affecting them in children and adolescents with thalassaemia major and sickle cell disease
   Tent PA, 2018, NIGER J CLIN PRACT, V21, P1570, DOI 10.4103/njcp.njcp_256_18
   Wildemann B, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572 021 00289 8
   Xu B, 2022, NAT PROD COMMUN, V17, DOI 10.1177/1934578X221086904
   Xu PC, 2022, J ETHNOPHARMACOL, V293, DOI 10.1016/j.jep.2022.115269
   Zang LH, 2021, ANAL BIOCHEM, V628, DOI 10.1016/j.ab.2021.114258
   Zhang T, 2019, FASEB J, V33, P5399, DOI 10.1096/fj.201801797R
   Zhao Y, 2022, MOLECULES, V27, DOI 10.3390/molecules27123697
   Zhu Z, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/6016874
NR 22
TC 0
Z9 0
U1 1
U2 2
PU INDIAN PHARMACEUTICAL ASSOC
PI MUMBAI
PA KALINA, SANTA CRUZ EAST, MUMBAI, 00000, INDIA
SN 0250 474X
EI 1998 3743
J9 INDIAN J PHARM SCI
JI Indian J. Pharm. Sci.
PY 2024
VL 86
SI SI
BP 114
EP 121
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA WC9R6
UT WOS:001252793500015
DA 2025 08 17
ER

PT J
AU Ho, HJ
   Shirakawa, H
   Giriwono, PE
   Ito, A
   Komai, M
AF Ho, Hsin Jung
   Shirakawa, Hitoshi
   Giriwono, Puspo E.
   Ito, Asagi
   Komai, Michio
TI A novel function of geranylgeraniol in regulating testosterone
   production
SO BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Geranylgeraniol; cAMP; PKA; steroidogenesis; testosterone; progesterone
ID NITROGEN CONTAINING BISPHOSPHONATES; FACTOR KAPPA B;
   CARDIOVASCULAR DISEASE; OSTEOCLAST FORMATION; BONE RESORPTION; CELLS;
   INHIBITION; ACTIVATION; SUPPRESSES; APOPTOSIS
AB Isoprenoids play widely differing roles in various physiological processes in animals and plants. Geranylgeraniol (GGOH) is an isoprenoid found in plants, and is an important metabolic derivative in the isoprenoid/cholesterol synthesis pathway. Earlier studies focused on GGOH's ability to improve the side effects of bisphosphonate therapy by regulating the mevalonate pathway. More recently, the mevalonate pathway independent effects of GGOH have been described, including anti inflammatory, anti tumorigenic, and neuroprotective activities. It is noteworthy that GGOH regulates the steroidogenesis pathway in testis derived I 10 tumor cells. Testosterone is a hormone produced via steroidogenesis in testicles and plays a role in fetal development and the male reproductive system. GGOH enhanced testosterone and progesterone (its precursor) levels in I 10 cells by activating adenylate cyclase via cAMP/PKA signaling, without altering phosphodiesterase activity. These findings highlight the potential benefits of GGOH as a therapeutic agent for low testosterone levels, such as late onset hypogonadism in men.
C1 [Ho, Hsin Jung; Shirakawa, Hitoshi; Giriwono, Puspo E.; Ito, Asagi; Komai, Michio] Tohoku Univ, Grad Sch Agr Sci, Lab Nutr, Sendai, Miyagi, Japan.
   [Shirakawa, Hitoshi] Tohoku Univ, Grad Sch Agr Sci, Int Educ & Res Ctr Food Agr Immunol, Sendai, Miyagi, Japan.
   [Giriwono, Puspo E.] Bogor Agr Univ, Southeast Asian Food & Agr Sci & Technol SEAFAST, Bogor, Indonesia.
C3 Tohoku University; Tohoku University; Bogor Agricultural University
RP Shirakawa, H (通讯作者)，Tohoku Univ, Grad Sch Agr Sci, Lab Nutr, Sendai, Miyagi, Japan.
EM shirakah@tohoku.ac.jp
RI ; Ho, Hsinjung/AAI 6809 2020; Shirakawa, Hitoshi/D 1406 2009; Giriwono,
   Puspo Edi/GPP 1107 2022
OI SHIRAKAWA, HITOSHI/0000 0002 4828 5274; 
FU Japan Society for the Promotion of Science (JSPS) [17H03814]; JSPS
   Core to Core Program A (Advanced Research Networks) entitled:
   "Establishment of international agricultural immunology research core
   for a quantum improvement in food safety"; Grants in Aid for Scientific
   Research [17H03814] Funding Source: KAKEN
FX This work was partially supported by a Grant in Aid for Scientific
   Research from the Japan Society for the Promotion of Science (JSPS) to
   HS [grant number #17H03814], and by the JSPS Core to Core Program A
   (Advanced Research Networks) entitled: "Establishment of international
   agricultural immunology research core for a quantum improvement in food
   safety."
CR Ahlquist L, 1978, Prog Chem Fats Other Lipids, V16, P231
   Akishita M, 2010, ATHEROSCLEROSIS, V210, P232, DOI 10.1016/j.atherosclerosis.2009.10.037
   Araujo AB, 2011, J CLIN ENDOCR METAB, V96, P3007, DOI 10.1210/jc.2011 1137
   Bach TJ, 2012, ISOPRENOID SYNTHESIS, P505
   Beatrice AM, 2014, DIABETES METAB SYNDR, V7, P481, DOI 10.2147/DMSO.S50777
   Benford HL, 1999, MOL PHARMACOL, V56, P131, DOI 10.1124/mol.56.1.131
   Caminiti G, 2009, J AM COLL CARDIOL, V54, P919, DOI 10.1016/j.jacc.2009.04.078
   Campia I, 2009, BRIT J PHARMACOL, V158, P1777, DOI 10.1111/j.1476 5381.2009.00465.x
   CHAPPELL J, 1995, ANNU REV PLANT PHYS, V46, P521, DOI 10.1146/annurev.pp.46.060195.002513
   Chowdhury RR, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00049
   Christianson DW, 2008, CURR OPIN CHEM BIOL, V12, P141, DOI 10.1016/j.cbpa.2007.12.008
   Cragg GM, 1998, MED RES REV, V18, P315, DOI 10.1002/(SICI)1098 1128(199809)18:5<315::AID MED3>3.0.CO;2 W
   Dhingra V, 1999, LIFE SCI, V66, P279, DOI 10.1016/S0024 3205(99)00356 2
   Dudek P, 2017, MENOPAUSE REV, V16, P66, DOI 10.5114/pm.2017.68595
   Fernandes NV, 2013, EXP BIOL MED, V238, P1265, DOI 10.1177/1535370213492693
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Fisher JE, 2013, CALCIFIED TISSUE INT, V92, P531, DOI 10.1007/s00223 013 9711 0
   Frenkel J, 2002, ARTHRITIS RHEUM, V46, P2794, DOI 10.1002/art.10550
   Gancedo JM, 2013, BIOL REV, V88, P645, DOI 10.1111/brv.12020
   Gershenzon J, 2007, NAT CHEM BIOL, V3, P408, DOI 10.1038/nchembio.2007.5
   Giriwono PE, 2013, EUR J NUTR, V52, P1191, DOI 10.1007/s00394 012 0429 y
   Hacker BM, 1998, GENOMICS, V50, P97, DOI 10.1006/geno.1998.5293
   Hiruma Y, 2004, BIOCHEM BIOPH RES CO, V314, P24, DOI 10.1016/j.bbrc.2003.12.051
   Ho HJ, 2016, BIOSCI BIOTECH BIOCH, V80, DOI 10.1080/09168451.2015.1123612
   Holstein SA, 2004, LIPIDS, V39, P293, DOI 10.1007/s11745 004 1233 3
   Huhtaniemi I, 2014, ASIAN J ANDROL, V16, P192, DOI 10.4103/1008 682X.122336
   Inoue Y, 2005, ANTIMICROB AGENTS CH, V49, P1770, DOI 10.1128/AAC.49.5.1770 1774.2005
   Ito A, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476 511X 10 158
   Joo JH, 2010, CANCER LETT, V287, P123, DOI 10.1016/j.canlet.2009.05.015
   Kim J, 2013, J LIPID RES, V54, P3430, DOI 10.1194/jlr.M042549
   Lange BM, 2000, P NATL ACAD SCI USA, V97, P13172, DOI 10.1073/pnas.240454797
   Mailman T, 2011, J NEUROCHEM, V119, P1002, DOI 10.1111/j.1471 4159.2011.07474.x
   Marcuzzi A, 2008, PEDIATR RES, V64, P177, DOI 10.1203/PDR.0b013e3181761870
   Marcuzzi A, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030365
   Masuda Y, 2006, BIOCHEM BIOPH RES CO, V346, P454, DOI 10.1016/j.bbrc.2006.05.161
   Montero MT, 2004, J IMMUNOL, V173, P4936, DOI 10.4049/jimmunol.173.8.4936
   Morris PD, 2012, ASIAN J ANDROL, V14, P428, DOI 10.1038/aja.2012.21
   Muraguchi T, 2011, J CLIN BIOCHEM NUTR, V49, P8, DOI 10.3164/jcbn.10 110
   OHIZUMI H, 1995, J BIOCHEM TOKYO, V117, P11, DOI 10.1093/oxfordjournals.jbchem.a124695
   Ohsaki Y, 2010, J NUTR BIOCHEM, V21, P1120, DOI 10.1016/j.jnutbio.2009.09.011
   Ownby SE, 2002, LIPIDS, V37, P185, DOI 10.1007/s11745 002 0879 1
   Pabst AM, 2015, CLIN ORAL INVEST, V19, P1625, DOI 10.1007/s00784 014 1394 z
   Payne A.H., 2007, Contemporary endocrinology: The leydig cell in health and disease, P157, DOI DOI 10.1007/978 1 59745 453 7
   Riebeling C, 2002, BRIT J CANCER, V87, P366, DOI 10.1038/sj.bjc.6600476
   Saad F, 2011, EUR J ENDOCRINOL, V165, P675, DOI 10.1530/EJE 11 0221
   Shores MM, 2006, ARCH INTERN MED, V166, P1660, DOI 10.1001/archinte.166.15.1660
   Sriraman V, 2005, REPROD BIOMED ONLINE, V11, P507, DOI 10.1016/S1472 6483(10)61147 9
   Steegborn C, 2014, BBA MOL BASIS DIS, V1842, P2535, DOI 10.1016/j.bbadis.2014.08.012
   Stocco DM, 2005, MOL ENDOCRINOL, V19, P2647, DOI 10.1210/me.2004 0532
   Van Beek ER, 2002, BONE, V30, P64, DOI 10.1016/S8756 3282(01)00655 X
   Yeap BB, 2015, CURR OPIN ENDOCRINOL, V22, P193, DOI 10.1097/MED.0000000000000161
   Yeganehjoo H, 2017, NUTR CANCER, V69, P682, DOI 10.1080/01635581.2017.1299876
   Ziebart T, 2011, ORAL ONCOL, V47, P195, DOI 10.1016/j.oraloncology.2010.12.003
NR 53
TC 35
Z9 38
U1 1
U2 17
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0916 8451
EI 1347 6947
J9 BIOSCI BIOTECH BIOCH
JI Biosci. Biotechnol. Biochem.
PY 2018
VL 82
IS 6
SI SI
BP 956
EP 962
DI 10.1080/09168451.2017.1415129
PG 7
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Chemistry, Applied; Food Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Chemistry; Food Science & Technology
GA GH0WG
UT WOS:000433122300005
PM 29303051
OA Bronze
DA 2025 08 17
ER

PT J
AU Miyazawa, Y
   Sekine, Y
   Syuto, T
   Nomura, M
   Koike, H
   Matsui, H
   Shibata, Y
   Ito, K
   Suzuki, K
AF Miyazawa, Yoshiyuki
   Sekine, Yoshitaka
   Syuto, Takahiro
   Nomura, Masashi
   Koike, Hidekazu
   Matsui, Hiroshi
   Shibata, Yasuhiro
   Ito, Kazuto
   Suzuki, Kazuhiro
TI Evaluation of Bone Turnover / Quality Markers and Bone Mineral Density
   in Prostate Cancer Patients Receiving Androgen Deprivation Therapy with
   or without Denosumab
SO ANTICANCER RESEARCH
LA English
DT Article
DE Prostate cancer; denosumab; bone quality; pentosidine
ID FRACTURE RISK; PENTOSIDINE; COLLAGEN; MEN; SERUM; MECHANISMS; INCREASES;
   DISEASE
AB Background/Aim: Androgen deprivation therapy (ADT) is a mainstay therapy for prostate cancer (PCa). ADT induces bone loss and increases the risk of osteoporosis and fractures. Recently, loss of bone quality has received attention as a factor that causes loss of bone strength independent of bone mineral density (BMD). Pentosidine has been identified as a surrogate marker of bone quality. Therefore, bone quality markers were evaluated retrospectively in PCa patients receiving ADT with or without denosumab. Patients and Methods: This study included 46 PCa patients. Twenty patients received denosumab. We measured pentosidine as bone quality marker and TRACP 5b as bone turnover marker. Pre  and 12month BMD was measured in the lumbar spine and femoral neck. Results: In the denosumab group (D+), BMD at the lumbar spine was increased by 6.7% compared with the group that did not receive denosumab (D ) at 12 months (p=0.0015). BMD at the femoral neck was increased by 3.1% at 12 months (p=0.0076). The mean value of TRAP 5b was lower in the D+ group than the D group at 12 months (p<0.001). The mean serum levels of pentosidine in the D+ group were decreased by  39.6% compared with the D group at 12 months (p=0.0036). Conclusion: Denosumab increased BMD during ADT for PCa and inhibited the increasing levels of serum pentosidine in PCa patients undergoing ADT.
C1 [Miyazawa, Yoshiyuki; Sekine, Yoshitaka; Syuto, Takahiro; Nomura, Masashi; Koike, Hidekazu; Matsui, Hiroshi; Shibata, Yasuhiro; Ito, Kazuto; Suzuki, Kazuhiro] Gunma Univ, Grad Sch Med, Dept Urol, 3 9 22 Showa Machi, Maebashi, Gunma 3718511, Japan.
C3 Gunma University
RP Miyazawa, Y (通讯作者)，Gunma Univ, Grad Sch Med, Dept Urol, 3 9 22 Showa Machi, Maebashi, Gunma 3718511, Japan.
EM miya.yoshi@hotmail.co.jp
OI Sekine, Yoshitaka/0000 0002 8094 4524; Miyazawa,
   Yoshiyuki/0000 0002 8416 2394
CR [Anonymous], 2016, 2 NCCN GUIDELINES VE
   Bailey AJ, 1998, MECH AGEING DEV, V106, P1, DOI 10.1016/S0047 6374(98)00119 5
   Bolla M, 2002, LANCET, V360, P103, DOI 10.1016/S0140 6736(02)09408 4
   Chiba D, 2017, J BONE MINER METAB, V35, P65, DOI 10.1007/s00774 015 0727 6
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Falahati Nini A, 2000, J CLIN INVEST, V106, P1553, DOI 10.1172/JCI10942
   Hernandez CJ, 2005, BONE, V37, P825, DOI 10.1016/j.bone.2005.07.019
   Ito K, 2014, NAT REV UROL, V11, P197, DOI 10.1038/nrurol.2014.42
   Leali PT, 2011, CLIN CASES MINER BON, V8, P11
   Odetti P, 2005, ANN NY ACAD SCI, V1043, P710, DOI 10.1196/annals.1333.082
   Saito M, 2006, OSTEOPOROSIS INT, V17, P986, DOI 10.1007/s00198 006 0087 0
   Saito M, 2010, OSTEOPOROSIS INT, V21, P195, DOI 10.1007/s00198 009 1066 z
   Saito M, 2006, CALCIFIED TISSUE INT, V79, P160, DOI 10.1007/s00223 006 0035 1
   Saito M, 2014, CURR OSTEOPOROS REP, V12, P181, DOI 10.1007/s11914 014 0202 7
   Schwartz AV, 2009, J CLIN ENDOCR METAB, V94, P2380, DOI 10.1210/jc.2008 2498
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Shahinian VB, 2005, NEW ENGL J MED, V352, P154, DOI 10.1056/NEJMoa041943
   Sharifi N, 2005, JAMA J AM MED ASSOC, V294, P238, DOI 10.1001/jama.294.2.238
   Smith MR, 2008, J UROLOGY, V179, P152, DOI 10.1016/j.juro.2007.08.137
   Smith MR, 2015, ANN ONCOL, V26, P368, DOI 10.1093/annonc/mdu519
   Smith MR, 2011, J BONE MINER RES, V26, P2827, DOI 10.1002/jbmr.492
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   Smith MR, 2005, J CLIN ONCOL, V23, P7897, DOI 10.1200/JCO.2004.00.6908
   Smith MR, 2003, J UROLOGY, V169, P2008, DOI 10.1097/01.ju.0000063820.94994.95
   Vaculík J, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891 016 1168 7
   Vashishth Deepak, 2009, IBMS Bonekey, V6, P268
   Wang X, 2002, BONE, V31, P1, DOI 10.1016/S8756 3282(01)00697 4
   Yamamoto M, 2008, J CLIN ENDOCR METAB, V93, P1013, DOI 10.1210/jc.2007 1270
NR 29
TC 9
Z9 9
U1 0
U2 0
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250 7005
EI 1791 7530
J9 ANTICANCER RES
JI Anticancer Res.
PD JUL
PY 2017
VL 37
IS 7
BP 3667
EP 3671
DI 10.21873/anticanres.11737
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA FJ2OV
UT WOS:000412569900036
PM 28668858
OA Bronze
DA 2025 08 17
ER

PT J
AU Magone, K
   Luckenbill, D
   Goswami, T
AF Magone, Kevin
   Luckenbill, Daniel
   Goswami, Tarun
TI Metal ions as inflammatory initiators of osteolysis
SO ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY
LA English
DT Article
DE Osteolysis; Joint replacement; Cytokines; Metallic ions
ID TOTAL HIP ARTHROPLASTY; TOTAL JOINT REPLACEMENT; PERIPROSTHETIC BONE
   LOSS; TOTAL KNEE ARTHROPLASTY; CELLS IN VITRO; WEAR DEBRIS; POLYETHYLENE
   WEAR; BEARING SURFACES; CHROMIUM IONS; IMMUNE SYSTEM
AB Osteolysis and aseptic loosening currently contribute 75 % of implant failures. Furthermore, with over four million joint replacements projected to be performed in the United States annually, osteolysis and aseptic loosening may continue to pose a significant morbidity. This paper reviews the osteolysis cascade leading to osteoclast activation and bone resorption at the biochemical level. Additionally, the metal ion release mechanism from metallic implants is elucidated. Even though metal ions are not the predominating initiator of osteolysis, they do increase the concentration of key inflammatory cytokines that stimulate osteoclasts and prove to be a contributor to osteolysis and aseptic loosening. Osteolysis is a competitive mechanism among a number of biological reactions, which includes debris release, macrophage and osteoclast activation, an inflammatory response as well as metal ion release. Pharmacological therapy for component loosening has also been reviewed. A non surgical treatment of osteolysis has not been found in the literature and thus may become an area of future research. Even though this research is warranted, comprehensively understanding the immune response to orthopedic implants and their metallic ions, and thus, creating improved prostheses appears to be the most cost effective approach to decrease the morbidity related to osteolysis and to design implants with greater longevity. The ionic forms, cytokines, toxicity, gene expression, biological effects, and hypersensitivity responses of metallic elements from metal implants are summarized as well.
C1 [Magone, Kevin] McLaren Flint Michigan State Univ, Dept Orthopaed Surg, Flint, MI USA.
   [Luckenbill, Daniel] Wright State Univ, Dept Orthopaed Surg, Dayton, OH 45435 USA.
   [Goswami, Tarun] Wright State Univ, Dept Biomed Ind & Human Factors Engn, Dayton, OH 45435 USA.
C3 University System of Ohio; Wright State University Dayton; University
   System of Ohio; Wright State University Dayton
RP Goswami, T (通讯作者)，Wright State Univ, Dept Biomed Ind & Human Factors Engn, Dayton, OH 45435 USA.
EM tarun.goswami@wright.edu
CR Arabmotlagh M, 2009, J ORTHOP RES, V27, P183, DOI 10.1002/jor.20748
   Beck RT, 2011, REV PERIPROSTHETIC O
   Burton L, 2012, ORTHOPEDIC WEAR DEBR
   Cadosch D, 2008, TITANIUM 4 IONS INDU
   Cadosch D, 2009, TITANIUM UPTAKE INDU
   Cadosch D, 2009, METAL IS NOT INERT R
   Caicedo MS, 2009, SOLUBLE IONS MORE PA
   Caicedo MS, 2008, SOLUBLE PARTICULATE
   Callaghan JJ, 2007, ADULT HIP, V2, P1505
   Carr AM, 2008, ANZ J SURG, V78, P144, DOI 10.1111/j.1445 2197.2007.04390.x
   Catelas I, 2003, BIOMATERIALS, V24, P383, DOI 10.1016/S0142 9612(02)00351 4
   Catelas Isabelle, 2010, Instr Course Lect, V59, P3
   Chan E, 2011, J APPL BIOMATER BIOM, V9, P137, DOI 10.5301/JABB.2011.8567
   Chan EPH, 2009, METALLOMICS, V1, P166, DOI 10.1039/b820871a
   CHARNLEY J, 1971, ANN RHEUM DIS, V30, P560, DOI 10.1136/ard.30.6.560
   CLARKE IC, 1992, CLIN ORTHOP RELAT R, P19
   Cooper HJ, 2010, CLIN ORTHOP RELAT R, V468, P3278, DOI 10.1007/s11999 010 1361 1
   Delaunay C, 2010, ORTHOP TRAUMATOL SUR, V96, P894, DOI 10.1016/j.otsr.2010.05.008
   Desai MA, 2008, ORTHOPEDICS, V31, P1
   Dumbleton JH, 2002, J ARTHROPLASTY, V17, P649, DOI 10.1054/arth.2002.33664
   Emmanuel AR, 2014, J ARTHROPLASTY, V29, P186, DOI 10.1016/j.arth.2013.04.022
   Fang Q, 2011, J SURG RES, V168, pE163, DOI 10.1016/j.jss.2010.12.006
   Gallo J, 2008, PHYSIOL RES, V57, P339, DOI 10.33549/physiolres.931140
   Gallo J, 2010, RELATIONSHIP POLYETH
   Gallo J, 2012, IEEE AER C MARCH, V19, P1
   Gallo J, 2012, BIOMED PAP, V156, P204, DOI 10.5507/bp.2012.063
   Gallo Jiri, 2002, Biomedical Papers (Olomouc), V146, P21
   Goodman SB, 2010, BIOMATERIALS, V31, P5045, DOI 10.1016/j.biomaterials.2010.03.046
   Griem P, 1995, CURR OPIN IMMUNOL, V7, P831, DOI 10.1016/0952 7915(95)80056 5
   Gustafson K, 2014, ACTA ORTHOP, V85, P348, DOI 10.3109/17453674.2014.922730
   Hagmann S, 2013, ORTHOPADE, V42, P643, DOI 10.1007/s00132 012 2039 z
   Haleem Smith H, 2012, J ORTHOP RES, V30, P853, DOI 10.1002/jor.22002
   Hallab NJ, 2009, BULL HOSP JT DIS, V67, P182
   Hallab NJ, 2013, J ORTHOP RES, V31, P173, DOI 10.1002/jor.22214
   Hallab NJ, 2002, J BIOMED MATER RES, V60, P420, DOI 10.1002/jbm.10106
   Hallab NJ., 2008, J Orthop Surg Res, V3, P6, DOI [10.1186/1749 799X 3 6, DOI 10.1186/1749 799X 3 6]
   Hallab NJ, 2009, IN VITRO REACTIVITY
   Hallab NJ, 2003, INTERFACIAL KINETICS
   Hanawa T, 2004, MAT SCI ENG C BIO S, V24, P745, DOI 10.1016/j.msec.2004.08.018
   Hjorth MH, 2014, ACTA ORTHOP, V85, P355, DOI 10.3109/17453674.2014.922731
   Hosman AH, 2010, ACTA ORTHOP, V81, P526, DOI 10.3109/17453674.2010.519169
   Ingham E, 2003, Hip Int, V13, P17, DOI 10.5301/HIP.2013.11458
   Ingham E, 2005, BIOMATERIALS, V26, P1271, DOI 10.1016/j.biomaterials.2004.04.035
   Ingham E, 2000, P I MECH ENG H, V214, P21, DOI 10.1243/0954411001535219
   Khurjekar K. S., 2006, SMJ Singapore Medical Journal, V47, P897
   Kinov Plamen, 2006, Acta Orthop Belg, V72, P44
   Kurtz S, 2007, J BONE JOINT SURG AM, V89A, P780, DOI 10.2106/JBJS.F.00222
   Langlois J, 2011, INT ORTHOP, V35, P245, DOI 10.1007/s00264 010 1143 0
   Lewis JB, 2003, METAL IONS ALTER LIP
   Lin HY, 2004, J ORTHOP RES, V22, P1231, DOI 10.1016/j.orthres.2004.04.005
   Lohmann CH, 2002, BIOMATERIALS, V23, P1855, DOI 10.1016/S0142 9612(01)00312 X
   Meneghini R Michael, 2005, Instr Course Lect, V54, P481
   Merkel KD, 1999, AM J PATHOL, V154, P203, DOI 10.1016/S0002 9440(10)65266 2
   Minoda Y, 2009, J BONE JOINT SURG AM, V91A, P67, DOI 10.2106/JBJS.I.00447
   Mishra PK, 2011, J IMMUNOL, V187, P6491, DOI 10.4049/jimmunol.1101392
   Espigares JLN, 2008, GAC SANIT, V22, P337, DOI 10.1157/13125355
   Nehme A, 2003, REV CHIR ORTHOP, V89, P593
   Nho JH, 2013, YONSEI MED J, V54, P1550, DOI 10.3349/ymj.2013.54.6.1550
   Nichols KG, 1997, J BIOMED MATER RES, V35, P265
   Niki Y, 2003, BIOMATERIALS, V24, P1447, DOI 10.1016/S0142 9612(02)00531 8
   Nikolaou VS, 2012, J BONE JOINT SURG BR, V94B, P459, DOI 10.1302/0301 620X.94B4.27735
   Ollivere B, 2012, J BONE JOINT SURG BR, V94B, P10, DOI 10.1302/0301 620X.94B1.28047
   Patton MS, 2008, ACTA ORTHOP, V79, P820, DOI 10.1080/17453670810016911
   Rao AJ, 2012, ACTA BIOMATER, V8, P2815, DOI 10.1016/j.actbio.2012.03.042
   Ritchlin C. T., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P276
   Sadoghi P, 2012, INT ORTHOP, V36, P2197, DOI 10.1007/s00264 012 1614 6
   Sargeant A, 2007, MATER DESIGN, V28, P155, DOI 10.1016/j.matdes.2005.05.018
   Sargeant Alene, 2006, J Surg Orthop Adv, V15, P111
   Sato T, 2012, J ORTHOP RES, V30, P2031, DOI 10.1002/jor.22148
   Savarino L, 2007, METAL ION RELEASE FR
   Schwab LP, 2011, MACROPHAGE RESPONSE
   Schwarz EM, 2000, ARTHRITIS RES, V2, P165, DOI 10.1186/ar81
   Shon WY, 2009, J ARTHROPLASTY, V24, P743, DOI 10.1016/j.arth.2008.02.012
   Shrivastava R, 2002, FEMS IMMUNOL MED MIC, V34, P1, DOI 10.1111/j.1574 695X.2002.tb00596.x
   Sidaginamale RP, 2013, BONE JOINT RES, V2, P84, DOI 10.1302/2046 3758.25.2000148
   Singh JA, 2010, MAYO CLIN PROC, V85, P898, DOI 10.4065/mcp.2010.0115
   Sinha R, 2001, EFFECTS OSTEOLYSIS A
   Talmo CT, 2012, CLIN GERIATR MED, V28, P471, DOI 10.1016/j.cger.2012.05.006
   Talmo CT, 2010, CLIN GERIATR MED, V26, P517, DOI 10.1016/j.cger.2010.04.002
   Tapaninen TS, 2010, SCAND J SURG, V99, P32, DOI 10.1177/145749691009900108
   Tomazic Jezic VJ, 2001, J BIOMED MATER RES, V55, P523, DOI 10.1002/1097 4636(20010615)55:4<523::AID JBM1045>3.0.CO;2 G
   Vasudevan A, 2012, ARTHRITIS RHEUM US, V64, P1005, DOI 10.1002/art.33459
   Vermes C, 2001, J ARTHROPLASTY, V16, P95, DOI 10.1054/arth.2001.28719
   Wang JY, 1996, BIOMATERIALS, V17, P2233, DOI 10.1016/0142 9612(96)00072 5
   Wang JY, 1997, CLIN ORTHOP RELAT R, P216
   Wei S, 2008, PATHOL RES PRACT, V204, P695, DOI 10.1016/j.prp.2008.07.002
   Yadav Jessica, 2013, Open Orthop J, V7, P605, DOI 10.2174/1874325001307010605
NR 87
TC 55
Z9 57
U1 0
U2 31
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0936 8051
EI 1434 3916
J9 ARCH ORTHOP TRAUM SU
JI Arch. Orthop. Trauma Surg.
PD MAY
PY 2015
VL 135
IS 5
BP 683
EP 695
DI 10.1007/s00402 015 2196 8
PG 13
WC Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Surgery
GA CG4XG
UT WOS:000353291800014
PM 25795427
DA 2025 08 17
ER

PT J
AU Krishnan, V
   Ma, YFL
   Chen, CZ
   Thorne, N
   Bullock, H
   Tawa, G
   Javella Cauley, C
   Chu, SY
   Li, WM
   Kohn, W
   Adrian, MD
   Benson, C
   Liu, LF
   Sato, M
   Zheng, W
   Pilon, AM
   Yang, NN
   Bryant, HU
AF Krishnan, Venkatesh
   Ma, Yanfei L.
   Chen, Catherine Z.
   Thorne, Natasha
   Bullock, Heather
   Tawa, Gregory
   Javella Cauley, Christy
   Chu, Shaoyou
   Li, Weiming
   Kohn, Wayne
   Adrian, Mary D.
   Benson, Charles
   Liu, Lifei
   Sato, Masahiko
   Zheng, Wei
   Pilon, Andre M.
   Yang, N. Nora
   Bryant, Henry U.
TI Repurposing a novel parathyroid hormone analogue to treat
   hypoparathyroidism
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article
ID 1 34 REPLACEMENT THERAPY; LONG TERM TREATMENT; TERIPARATIDE THERAPY;
   CONCISE GUIDE; OPEN LABEL; RECEPTOR; BONE; EFFICACY; PHARMACOLOGY; TRIAL
AB Background and PurposeHuman parathyroid hormone (PTH) is critical for maintaining physiological calcium homeostasis and plays an important role in the formation and maintenance of the bone. Full length PTH and a truncated peptide form are approved for treatment of hypoparathyroidism and osteoporosis respectively. Our initial goal was to develop an improved PTH therapy for osteoporosis, but clinical development was halted. The novel compound was then repurposed as an improved therapy for hypoparathyroidism.
   Experimental ApproachA longer acting form of PTH was synthesised by altering the peptide to increase cell surface residence time of the bound ligand to its receptor. In vitro screening identified a compound, which was tested in an animal model of osteoporosis before entering human trials. This compound was subsequently tested in two independent animal models of hypoparathyroidism.
   Key ResultsThe peptide identified, LY627 2K, exhibited delayed internalization kinetics. In an ovariectomy induced bone loss rat model, LY627 2K demonstrated improved vertebral bone mineral density and biomechanical properties at skeletal sites and a modest increase in serum calcium. In a Phase I clinical study, dose dependent increases in serum calcium were reproduced. These observations prompted us to explore a second indication, hypoparathyroidism. In animal models of this disease, LY627 2K restored serum calcium, comparing favourably to treatment with wild type PTH.
   Conclusions and ImplicationsWe summarize the repositioning of a therapeutic candidate with substantial preclinical and clinical data. Our results support its repurposing and continued development, from a common indication (osteoporosis) to a rare disease (hypoparathyroidism) by exploiting a shared molecular target.
C1 [Chen, Catherine Z.; Thorne, Natasha; Tawa, Gregory; Zheng, Wei; Pilon, Andre M.; Yang, N. Nora] NIH, NCATS, TRND, Bethesda, MD 20892 USA.
   [Krishnan, Venkatesh; Ma, Yanfei L.; Bullock, Heather; Javella Cauley, Christy; Adrian, Mary D.; Benson, Charles; Sato, Masahiko; Bryant, Henry U.] Eli Lilly & Co, Lilly Res Labs, Musculoskeletal Res, Indianapolis, IN 46285 USA.
   [Chu, Shaoyou; Li, Weiming] Eli Lilly & Co, Lilly Corp Ctr, Lead Optimizat Biol, Indianapolis, IN 46285 USA.
   [Kohn, Wayne] Eli Lilly & Co, Lilly Res Labs, Biotechnol Discovery Res, Indianapolis, IN 46285 USA.
C3 National Institutes of Health (NIH)   USA; NIH National Center for
   Advancing Translational Sciences (NCATS); Eli Lilly; Lilly Research
   Laboratories; Eli Lilly; Lilly Research Laboratories; Eli Lilly; Lilly
   Research Laboratories
RP Yang, NN (通讯作者)，NIH, NCATS, TRND, Bethesda, MD 20892 USA.; Bryant, HU (通讯作者)，Eli Lilly & Co, Lilly Res Labs, Musculoskeletal Res, Indianapolis, IN 46285 USA.
EM nora.yang@nih.gov; bryant_henry_u@lilly.com
RI Zheng, Wei/J 8889 2014; Liu, Lifei/H 4034 2015; CHU,
   SHAOYOU/MZS 0672 2025; Zheng, Wei/GOE 5990 2022; li/F 2833 2014
OI Zheng, Wei/0000 0003 1034 0757; 
FU Eli Lilly and Company; National Institutes of Health, NCATS
FX This research was supported by Eli Lilly and Company and by the
   Intramural Research Program of the National Institutes of Health, NCATS.
CR Abate Ejigayehu G, 2016, Front Endocrinol (Lausanne), V7, P172, DOI 10.3389/fendo.2016.00172
   ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732
   Alexander SPH, 2015, BRIT J PHARMACOL, V172, P5744, DOI 10.1111/bph.13348
   Alexander SPH, 2015, BRIT J PHARMACOL, V172, P6024, DOI 10.1111/bph.13354
   BENJAMINI Y, 1995, J ROY STAT SOC B, V57, P289, DOI 10.1111/j.2517 6161.1995.tb02031.x
   Bilezikian JP, 2011, J BONE MINER RES, V26, P2317, DOI 10.1002/jbmr.483
   Bouxsein ML, 2005, J BONE MINER RES, V20, P635, DOI 10.1359/JBMR.041204
   Castro M, 2005, P NATL ACAD SCI USA, V102, P16084, DOI 10.1073/pnas.0503942102
   Clarke BL, 2014, CLIN THER, V36, P722, DOI 10.1016/j.clinthera.2014.04.001
   Conway BR, 1999, J BIOMOL SCREEN, V4, P75, DOI 10.1177/108705719900400207
   Curtis MJ, 2015, BRIT J PHARMACOL, V172, P3461, DOI 10.1111/bph.12856
   Cusano NE, 2013, J CLIN ENDOCR METAB, V98, P137, DOI 10.1210/jc.2012 2984
   Eriksen EF, 2014, BONE, V67, P246, DOI 10.1016/j.bone.2014.07.014
   Gafni RI, 2012, J BONE MINER RES, V27, P1811, DOI 10.1002/jbmr.1627
   Guo J, 2017, J BONE MINER RES, V32, P86, DOI 10.1002/jbmr.2917
   Harris JM, 2003, NAT REV DRUG DISCOV, V2, P214, DOI 10.1038/nrd1033
   HOLLANDER M, 1973, NONPARAMETRIC STAT M
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Kilkenny C, 2010, BRIT J PHARMACOL, V160, P1577, DOI [10.1038/jcbfm.2010.220, 10.1111/j.1476 5381.2010.00872.x]
   Langdahl BL, 1996, BONE, V18, P103, DOI 10.1016/8756 3282(95)00443 2
   Lelovas PP, 2008, COMPARATIVE MED, V58, P424
   Ma YFL, 2011, ENDOCRINOLOGY, V152, P1767, DOI 10.1210/en.2010 1112
   Mannstadt M, 2013, LANCET DIABETES ENDO, V1, P275, DOI 10.1016/S2213 8587(13)70106 2
   McGrath JC, 2015, BRIT J PHARMACOL, V172, P3189, DOI 10.1111/bph.12955
   Mendonça ML, 2013, BMC ENDOCR DISORD, V13, DOI 10.1186/1472 6823 13 1
   MOSES AM, 1976, AM J MED, V61, P184, DOI 10.1016/0002 9343(76)90168 6
   Nussey S, 2001, Endocrinology: an integrated approach
   Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577
   Rubin MR, 2010, ARQ BRAS ENDOCRINOL, V54, P220, DOI 10.1590/S0004 27302010000200019
   Santonati A, 2015, J CLIN ENDOCR METAB, V100, P3590, DOI 10.1210/jc.2015 1855
   Sato M, 2010, J BONE MINER RES, V25, P1326, DOI 10.1002/jbmr.15
   Shah M, 2015, JAMA OTOLARYNGOL, V141, P822, DOI 10.1001/jamaoto.2015.1497
   Shimizu M, 2016, J BONE MINER RES, V31, P1405, DOI 10.1002/jbmr.2811
   Southan C, 2016, NUCLEIC ACIDS RES, V44, pD1054, DOI 10.1093/nar/gkv1037
   Theman TA, 2009, J BONE MINER RES, V24, P964, DOI 10.1359/JBMR.081233
   Thomsen ARB, 2016, CELL, V166, P907, DOI 10.1016/j.cell.2016.07.004
   Underbjerg L, 2015, J BONE MINER RES, V30, P1738, DOI 10.1002/jbmr.2501
   Upreti Vimal, 2017, Indian J Endocrinol Metab, V21, P415, DOI 10.4103/ijem.IJEM_340_16
   Winer KK, 2014, J PEDIATR US, V165, P556, DOI 10.1016/j.jpeds.2014.04.060
   Winer KK, 2012, J CLIN ENDOCR METAB, V97, P391, DOI 10.1210/jc.2011 1908
   Winer KK, 2010, J CLIN ENDOCR METAB, V95, P2680, DOI 10.1210/jc.2009 2464
   Winer KK, 2003, J CLIN ENDOCR METAB, V88, P4214, DOI 10.1210/jc.2002 021736
   Winer KK, 1998, J CLIN ENDOCR METAB, V83, P3480, DOI 10.1210/jc.83.10.3480
   Yu EW, 2011, BONE, V48, P713, DOI 10.1016/j.bone.2010.11.012
NR 44
TC 13
Z9 14
U1 0
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0007 1188
EI 1476 5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD JAN
PY 2018
VL 175
IS 2
SI SI
BP 262
EP 271
DI 10.1111/bph.14028
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA FS2HR
UT WOS:000419599900008
PM 28898923
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Dlamini, N
   Mukaya, HE
   Van Zyl, RL
   Chen, CT
   Zeevaart, RJ
   Mbianda, XY
AF Dlamini, N.
   Mukaya, H. E.
   Van Zyl, R. L.
   Chen, C. T.
   Zeevaart, R. J.
   Mbianda, X. Y.
TI Synthesis, characterization, kinetic drug release and anticancer
   activity of bisphosphonates multi walled carbon nanotube conjugates
SO MATERIALS SCIENCE AND ENGINEERING C MATERIALS FOR BIOLOGICAL
   APPLICATIONS
LA English
DT Article
DE Multi walled carbon nanotubes; Bisphosphonates; Multi walled carbon
   nanotubes conjugates; Anticancer activity; Drug release; Water soluble
   multi walled carbon nanotubes
ID ENHANCED PERMEABILITY; DELIVERY; BONE; TUMOR; NANOPARTICLES;
   PURIFICATION; ALENDRONATE; CHEMISTRY; SODIUM; CELLS
AB The statistical proof that most forms of cancer metastasize to bone tissue has redirected research focus to the development of efficient secondary bone cancer treatment regimens. Bisphosphonates (BPs) have been earmarked as a drug of choice for bone metastasis. However, they have a shortcoming of being released before reaching targeted sites due to their low molecular weight. In haste to attain increased efficacy, there a tendency for drug overdose to occur, resulting in systemic toxicity. One way to curb this is by employing drug delivery systems for targeted and controlled release of the drugs. Having been explored as versatile and innovative drug carriers, multi walled carbon nanotubes (MWCNTs) have emerged as potential drug delivery systems. Hence, in the present study, alendronate, neridronate and pamidronate are three classes of bisphosphonates that were conjugated onto multi walled carbon nanotubes. Conjugation was confirmed by characterization techniques including SEM, TEM, EDX, FTIR, Raman and TGA. Drug release studies were also conducted at pH 1.2, 5.5 and 7.4 to study the mechanism of release for neridronate. Results obtained were fitted into Zero order (42.6%), Higuchi (26%) and Korsmeyer Peppas (22%). The best models describing the release of neridronate from MWCNTs were Zero order, Higuchi and Korsmeyer Peppas at pH 1.2, 5.5 and 7.4, respectively. A tetrazolium cell viability assay was performed to assess the anticancer activity of the MWCNTs conjugated BPs.
C1 [Dlamini, N.; Mukaya, H. E.; Mbianda, X. Y.] Univ Johannesburg, Dept Appl Chem, Doornfontein Campus,POB 17011, Johannesburg, South Africa.
   [Dlamini, N.; Mukaya, H. E.; Mbianda, X. Y.] Univ Johannesburg, Fac Sci, Doornfontein Campus,POB 17011, Johannesburg, South Africa.
   [Van Zyl, R. L.; Chen, C. T.] Univ Witwatersrand, Fac Hlth Sci, Pharmacol Div, Dept Pharm & Pharmacol, Johannesburg, South Africa.
   [Van Zyl, R. L.; Chen, C. T.] Univ Witwatersrand, Fac Hlth Sci, WITS Inst Malaria WRIM, Johannesburg, South Africa.
   [Zeevaart, R. J.] NECSA South African Nucl Energy Corp Ltd, Radiochem, Pretoria, South Africa.
C3 University of Johannesburg; University of Johannesburg; University of
   Witwatersrand; University of Witwatersrand; The South African Nuclear
   Energy Corporation SOC Limited (Necsa)
RP Mbianda, XY (通讯作者)，Univ Johannesburg, Dept Appl Chem, Doornfontein Campus,POB 17011, Johannesburg, South Africa.; Mbianda, XY (通讯作者)，Univ Johannesburg, Fac Sci, Doornfontein Campus,POB 17011, Johannesburg, South Africa.
EM mbianday@uj.ac.za
RI Van Zyl, Robyn/ABC 1678 2020; Mukaya, Elie/AAE 5749 2020
OI Yangkou Mbianda, Xavier/0000 0002 6512 937X; Mukaya, Hembe
   E/0000 0002 8033 8161
FU University of Johannesburg; University of the Witwatersrand,
   Johannesburg
FX The financial support from the University of Johannesburg and University
   of the Witwatersrand, Johannesburg are hereby acknowledged.
CR Abdou WM, 2009, ARKIVOC, P143, DOI 10.3998/ark.5550190.0010.910
   Alanne AL, 2012, MOLECULES, V17, P10928, DOI 10.3390/molecules170910928
   Balas F, 2006, J AM CHEM SOC, V128, P8116, DOI 10.1021/ja062286z
   Bianco A, 2005, CURR OPIN CHEM BIOL, V9, P674, DOI 10.1016/j.cbpa.2005.10.005
   BOEHM HP, 1994, CARBON, V32, P759, DOI 10.1016/0008 6223(94)90031 0
   Boehm HP, 2002, CARBON, V40, P145, DOI 10.1016/S0008 6223(01)00165 8
   Costa L, 2007, BREAST, V16, pS16, DOI 10.1016/j.breast.2007.10.005
   Datsyuk V, 2008, CARBON, V46, P833, DOI 10.1016/j.carbon.2008.02.012
   Dyke CA, 2003, J AM CHEM SOC, V125, P1156, DOI 10.1021/ja0289806
   Ezra A, 2000, ADV DRUG DELIVER REV, V42, P175, DOI 10.1016/S0169 409X(00)00061 2
   Fang J, 2011, ADV DRUG DELIVER REV, V63, P136, DOI 10.1016/j.addr.2010.04.009
   Haley B, 2008, UROL ONCOL SEMIN ORI, V26, P57, DOI 10.1016/j.urolonc.2007.03.015
   Hou PX, 2008, CARBON, V46, P2003, DOI 10.1016/j.carbon.2008.09.009
   Iyer AK, 2006, DRUG DISCOV TODAY, V11, P812, DOI 10.1016/j.drudis.2006.07.005
   Jeyamohan P, 2013, INT J NANOMED, V8, P2653, DOI 10.2147/IJN.S46054
   Karimi Maleh H, 2015, IND ENG CHEM RES, V54, P3634, DOI 10.1021/ie504438z
   Kieczykowski GR, 1995, J ORG CHEM, V60, P8310, DOI 10.1021/jo00130a036
   Koba M, 2008, ACTA POL PHARM, V65, P289
   Kuljanin J, 2002, J PHARMACEUT BIOMED, V28, P1215, DOI 10.1016/S0731 7085(02)00021 3
   Liu Z, 2007, ACS NANO, V1, P50, DOI 10.1021/nn700040t
   MacKenzie K, 2009, SEP PURIF TECHNOL, V66, P209, DOI 10.1016/j.seppur.2009.01.017
   Maeda H, 2006, ADV POLYM SCI, V193, P103, DOI 10.1007/12_026
   Maeda H, 2001, ADV ENZYME REGUL, V41, P189, DOI 10.1016/S0065 2571(00)00013 3
   Maeda H, 2009, EUR J PHARM BIOPHARM, V71, P409, DOI 10.1016/j.ejpb.2008.11.010
   Major PP, 2000, CANCER, V88, P6, DOI 10.1002/(SICI)1097 0142(20000101)88:1<6::AID CNCR3>3.3.CO;2 4
   Mamba G, 2013, CARBOHYD POLYM, V98, P470, DOI 10.1016/j.carbpol.2013.06.034
   Matsumoto K, 2007, DIAM RELAT MATER, V16, P1188, DOI 10.1016/j.diamond.2006.12.004
   Monteiro Riviere NA, 2005, NANOMED NANOTECHNOL, V1, P293, DOI 10.1016/j.nano.2005.10.007
   Mukaya HE, 2015, J INORG ORGANOMET P, V25, P411, DOI 10.1007/s10904 015 0205 6
   Neves M, 2002, NUCL MED BIOL, V29, P329, DOI 10.1016/S0969 8051(01)00305 5
   Osswald S, 2005, CHEM PHYS LETT, V402, P422, DOI 10.1016/j.cplett.2004.12.066
   Page PCB, 2001, J ORG CHEM, V66, P3704, DOI 10.1021/jo001489h
   Pasa G, 2012, INT J PHARMACEUT, V2, P97
   Prakash S, 2011, ADV DRUG DELIVER REV, V63, P1340, DOI 10.1016/j.addr.2011.06.013
   Rao DVNS, 2007, SYNTHETIC COMMUN, V37, P4359, DOI 10.1080/00397910701578545
   Serp P, 2001, CARBON, V39, P621, DOI 10.1016/S0008 6223(00)00324 9
   Shih H., 1930, SEARCH THIS J
   Silva GG, 2009, J MATER SCI, V44, P3498, DOI 10.1007/s10853 009 3468 x
   Simate G.S., 2013, TREATMENT BREWERY WA
   Singh P, 2009, CHEM SOC REV, V38, P2214, DOI 10.1039/b518111a
   Sun YP, 2002, ACCOUNTS CHEM RES, V35, P1096, DOI 10.1021/ar010160v
   Tessonnier JP, 2009, CARBON, V47, P1779, DOI 10.1016/j.carbon.2009.02.032
   Tse LF, 2008, BONE, V42, P68, DOI 10.1016/j.bone.2007.08.038
   Vachal P, 2006, J MED CHEM, V49, P3060, DOI 10.1021/jm060398v
   Vittorio O, 2009, NANOMED NANOTECHNOL, V5, P424, DOI 10.1016/j.nano.2009.02.006
   Wu W, 2005, ANGEW CHEM INT EDIT, V44, P6358, DOI 10.1002/anie.200501613
   Yola ML, 2014, BIOSENS BIOELECTRON, V60, P277, DOI 10.1016/j.bios.2014.04.045
   Yola ML, 2014, ELECTROCHIM ACTA, V119, P24, DOI 10.1016/j.electacta.2013.12.028
   Yu BD, 2016, MAT SCI ENG C MATER, V68, P579, DOI 10.1016/j.msec.2016.06.025
   Zhang T, 2008, CARBON, V46, P1782, DOI 10.1016/j.carbon.2008.07.033
NR 50
TC 17
Z9 18
U1 0
U2 38
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0928 4931
EI 1873 0191
J9 MAT SCI ENG C MATER
JI Mater. Sci. Eng. C Mater. Biol. Appl.
PD NOV
PY 2019
VL 104
AR 109967
DI 10.1016/j.msec.2019.109967
PG 9
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA JA1HY
UT WOS:000487569300124
PM 31499981
DA 2025 08 17
ER

PT J
AU Huang, M
   Wang, Y
   Wang, ZN
   Qin, QZ
   Zhang, HY
   Liu, SR
   Cui, JT
   Zhang, Y
   Jiang, XX
   Xu, LL
AF Huang, Meng
   Wang, Yan
   Wang, Zhenning
   Qin, Qiaozhen
   Zhang, Heyang
   Liu, Shuirong
   Cui, Jiantong
   Zhang, Yu
   Jiang, Xiaoxia
   Xu, Lulu
TI miR 134 5p inhibits osteoclastogenesis through a novel
   miR 134 5p/Itgb1/MAPK pathway
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID REGULATES OSTEOCLASTOGENESIS; PROMOTES OSTEOCLASTOGENESIS; BONE LOSS;
   INTEGRIN; DIFFERENTIATION; MICRORNAS; RNAS
AB Osteoporosis affects approximately 200 million people and severely affects quality of life, but the exact pathological mechanisms behind this disease remain unclear. Various miRNAs have been shown to play a predominant role in the regulation of osteoclast formation. In this study, we explored the role of miR 134 5p in osteoclastogenesis both in vivo and in vitro. We constructed an ovariectomized (OVX) mouse model and performed microarray analysis using bone tissue from OVX mice and their control counterparts. Quantitative RT PCR data from bone tissue and bone marrow macrophages (BMMs) confirmed the decreased expression of miR 134 5p in OVX mice observed in microarray analysis. In addition, a decrease in miR 134 5p was also observed during induced osteoclastogenesis of BMMs collected from C57BL/6N mice. Through transfection with miR 134 5p agomirs and antago mirs, we found that miR 134 5p knockdown significantly accelerated osteoclast formation and cell proliferation and inhibited apoptosis. Furthermore, a luciferase reporter assay showed that miR 134 5p directly targets the integrin surface receptor gene Itgb1. Cotransfection with Itgb1 siRNA reversed the effect of the miR 134 5p antagomir in promoting osteo clastogenesis. Moreover, the abundance levels of MAPK pathway proteins phosphorylated p38 (p p38) and phosphorylated ERK (p ERK) were significantly increased after transfection with the miR 134 5p antagomir but decreased after transfection with the miR 134 5p agomir or Itgb1 siRNA, which indicated a potential relationship between the miR 134 5p/Itgb1 axis and the MAPK pathway. Collectively, these re sults revealed that miR 134 5p inhibits osteoclast differentia tion of BMMs both in vivo and in vitro and that the miR 134 5p/Itgb1/MAPK pathway might be a potential target for oste oporosis therapy.
C1 [Huang, Meng; Wang, Zhenning; Cui, Jiantong; Zhang, Yu] Med Sch Chinese PLA, Beijing, Peoples R China.
   [Huang, Meng; Wang, Zhenning; Zhang, Yu; Xu, Lulu] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Orthodont, Beijing, Peoples R China.
   [Wang, Yan; Qin, Qiaozhen; Zhang, Heyang; Liu, Shuirong; Jiang, Xiaoxia] Beijing Inst Basic Med Sci, Beijing, Peoples R China.
C3 Chinese People's Liberation Army General Hospital; Chinese People's
   Liberation Army General Hospital; Academy of Military Medical Sciences  
   China; Institute of Basic Medical Sciences (IBMS)
RP Xu, LL (通讯作者)，Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Orthodont, Beijing, Peoples R China.; Jiang, XX (通讯作者)，Beijing Inst Basic Med Sci, Beijing, Peoples R China.
EM smilovjiang@163.com; xululu1977@163.com
RI JIANG, xx/KHV 3752 2024; Zhang, heyang/LBH 8236 2024
OI Wang, Yan/0000 0002 3711 5202; 
FU National Natural Science Foundation of China [82170986]; Beijing Natural
   Science Foundation [7202149]; PLA General Hospital Project of Youth
   Development [QNC19044]
FX Funding and additional information This study was supported by grants
   from the National Natural Science Foundation of China (No. 81771998 to
   X. J. and No. 31971285 to X. J.) , the Beijing Natural Science
   Foundation (No. 7202149 to X. J.) , the National Natural Science
   Foundation of China (No. 82170986 to L. X.) , and the PLA General
   Hospital Project of Youth Development (No. QNC19044 to L. X.) .
CR Baby N, 2020, AGING CELL, V19, DOI 10.1111/acel.13046
   Baek JM, 2019, BIOCHEM BIOPH RES CO, V510, P296, DOI 10.1016/j.bbrc.2019.01.094
   Batoon L, 2021, BIOMATERIALS, V275, DOI 10.1016/j.biomaterials.2021.120936
   Chen C, 2014, J BONE MINER RES, V29, P338, DOI 10.1002/jbmr.2032
   Chen CL, 2019, FEBS LETT, V593, P1089, DOI 10.1002/1873 3468.13387
   Cheng P, 2013, J BONE MINER RES, V28, P1180, DOI 10.1002/jbmr.1845
   Choe N, 2020, J CELL MOL MED, V24, P10542, DOI 10.1111/jcmm.15670
   Chong MMW, 2010, GENE DEV, V24, P1951, DOI 10.1101/gad.1953310
   Chu CY, 2007, J CELL PHYSIOL, V213, P412, DOI 10.1002/jcp.21230
   Cong Q, 2017, SCI REP UK, V7, DOI 10.1038/srep45964
   Datta HK, 2008, J CLIN PATHOL, V61, P577, DOI 10.1136/jcp.2007.048868
   Denais C, 2011, HUM MUTAT, V32, P231, DOI 10.1002/humu.21413
   Dinesh P, 2020, J CELL PHYSIOL, V235, P9497, DOI 10.1002/jcp.29757
   Gebert LFR, 2019, NAT REV MOL CELL BIO, V20, P21, DOI 10.1038/s41580 018 0045 7
   Gong M, 2014, MOL CANCER RES, V12, P101, DOI 10.1158/1541 7786.MCR 13 0136
   Gu BH, 2018, MATRIX BIOL, V73, P52, DOI 10.1016/j.matbio.2018.03.012
   Gu HJ, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000019120
   Guo LJ, 2014, EXP CELL RES, V321, P142, DOI 10.1016/j.yexcr.2013.12.001
   He YD, 2022, BIOACT MATER, V8, P109, DOI 10.1016/j.bioactmat.2021.06.033
   Hong PY, 2021, MOL THER NUCL ACIDS, V26, P665, DOI 10.1016/j.omtn.2021.08.028
   Huang J, 2018, THERANOSTICS, V8, P2435, DOI 10.7150/thno.22144
   Huang YZ, 2021, J BIOL CHEM, V296, DOI 10.1016/j.jbc.2021.100617
   Inoue K, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.651161
   Jia J, 2017, MOL MED REP, V15, P1539, DOI 10.3892/mmr.2017.6168
   Kitaura H, 2014, SCI WORLD J, DOI 10.1155/2014/617032
   Kodama J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165685
   Lai CF, 2005, J BONE MINER RES, V20, P330, DOI 10.1359/JBMR.041013
   Lee KS, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12152
   Lee K, 2016, INT J BIOL SCI, V12, P235, DOI 10.7150/ijbs.13814
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li HW, 2018, CURR DRUG TARGETS, V19, P422, DOI 10.2174/1389450117666160502144329
   Li XL, 2019, EUR REV MED PHARMACO, V23, P3487, DOI 10.26355/eurrev_201904_17714
   Li X, 2021, CELL BIOL TOXICOL, V37, P849, DOI 10.1007/s10565 020 09578 6
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   Lin LS, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.814949
   Liu J, 2017, SCI REP UK, V7, DOI 10.1038/srep40487
   Luo SM, 2020, J MOL HISTOL, V51, P729, DOI 10.1007/s10735 020 09918 0
   Mun SH, 2021, BONE RES, V9, DOI 10.1038/s41413 021 00162 0
   Nakamachi Y, 2016, ANN RHEUM DIS, V75, P601, DOI 10.1136/annrheumdis 2014 206417
   NESBITT S, 1993, J BIOL CHEM, V268, P16737
   Pisani P, 2016, WORLD J ORTHOP, V7, P171, DOI 10.5312/wjo.v7.i3.171
   Plosa EJ, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.129259
   Puissant E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165004
   Rao HW, 2006, J BONE MINER RES, V21, P1657, DOI 10.1359/JBMR.060718
   Shen GY, 2020, THERANOSTICS, V10, P4334, DOI 10.7150/thno.42982
   Shen GS, 2018, CELL PHYSIOL BIOCHEM, V50, P1916, DOI 10.1159/000494872
   Souza PPC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01663
   Sun CC, 2016, ONCOTARGET, V7, P35960, DOI 10.18632/oncotarget.8482
   Sun MY, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0798 0
   Sun WJ, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.15
   Tang L, 2017, CELL PHYSIOL BIOCHEM, V43, P1663, DOI 10.1159/000484027
   Tsukasaki M, 2019, NAT REV IMMUNOL, V19, P626, DOI 10.1038/s41577 019 0178 8
   Wang XD, 2015, CELL METAB, V22, P811, DOI 10.1016/j.cmet.2015.09.010
   Wu KR, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 25473 y
   Wu YZ, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22105232
   Xu B, 2020, BRAZ J MED BIOL RES, V53, DOI [10.1590/1414 431x20209732, 10.1590/1414 431X20209732]
   Xu SG, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.726361
   Yang C, 2021, J OBSTET GYNAECOL RE, V47, P4037, DOI 10.1111/jog.14983
   Yedavally Yellayi S, 2019, PRIMARY CARE, V46, P175, DOI 10.1016/j.pop.2018.10.014
   Zhang L, 2019, MOL THER NUCL ACIDS, V18, P627, DOI 10.1016/j.omtn.2019.09.025
   Zhang Q, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01028
   Zhang XH, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15037674
   Zhu SP, 2018, BIOL REV, V93, P469, DOI 10.1111/brv.12353
NR 63
TC 9
Z9 12
U1 0
U2 13
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUL
PY 2022
VL 298
IS 7
AR 102116
DI 10.1016/j.jbc.2022.102116
PG 16
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 2Z2QL
UT WOS:000826428300001
PM 35691339
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Ma, X
   Yang, J
   Liu, T
   Li, J
   Lan, YY
   Wang, YL
   Wang, AM
   Tian, Y
   Li, YJ
AF Ma, Xue
   Yang, Jian
   Liu, Ting
   Li, Jing
   Lan, Yanyu
   Wang, Yonglin
   Wang, Aimin
   Tian, Ye
   Li, Yongjun
TI Gukang Capsule Promotes Fracture Healing by Activating BMP/SMAD and
   Wnt/β Catenin Signaling Pathways
SO EVIDENCE BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID BONE MORPHOGENETIC PROTEIN 2; STEM CELLS; DIFFERENTIATION; MEDICINE;
   LIGAND
AB Background. Gukang capsule (GKC) is a traditional Chinese medicine formulation which has been used extensively in the clinical treatment of bone fractures. However, the mechanisms underlying its effects on fracture healing remain unclear.Methods. In this study we used a rabbit radius fracture model, and we measured the serum content of bone alkaline phosphatase (ALP), calcium, and phosphorus and examined pathology of the fracture site as indicators of the fracture healing effects of GKC. SaOS 2 human osteosarcoma cells were used to measure (i) ALP activity, (ii) ornithine transcarbamylase (OTC), calcium, and mineralization levels, (iii) the expression of osteogenic related genes, that is, runt related transcription factor 2 (RUNX2), bone morphogenetic protein 2 (BMP2), collagen I (COL I), osteopontin (OPN), OTC, and osterix (Osx), and (iv) the expression of key proteins in the Wnt/beta catenin and BMP/SMAD signaling pathways to study the mechanisms by which GKC promotes fracture healing.Results.We found that GKC effectively promotes radius fracture healing in rabbits and enhances ALP activity, increases OTC and calcium levels, and stimulates the formation of mineralized nodules in SaOS 2 cells. Moreover, COL I, OTC, Osx, BMP2, and OPN expression levels were higher in SaOS 2 cells treated with GKC than control cells. GKC upregulates glycogen synthase kinase 3 beta(GSK3 beta) phosphorylation and Smad1/5 and beta catenin protein levels, thereby activating Wnt/beta catenin and BMP/Smad signaling pathways. Inhibitors of the Wnt/beta catenin and BMP/Smad signaling pathways (DKK1 and Noggin, respectively) suppress the osteogenic effects of GKC.Conclusions. GKC promotes fracture healing by activating the Wnt/beta catenin and BMP/Smad signaling pathways and increasing osteoprotegerin (OPG) secretion by osteoblasts (OBs), which prevents receptor activator of nuclear factor kappa B ligand (RANKL) binding to RANK.
C1 [Ma, Xue; Yang, Jian; Lan, Yanyu; Wang, Aimin; Li, Yongjun] Guizhou Med Univ, State Key Lab Funct & Applicat Med Plants, Engn Res Ctr Dev & Applicat Ethn Med & TCM, Minist Educ, 4 Beijing Rd, Guiyang 550004, Peoples R China.
   [Liu, Ting; Li, Jing; Wang, Yonglin] Guizhou Med Univ, Key Lab Pharmaceut Guizhou Prov, Guiyang 550004, Peoples R China.
   [Li, Jing] Guizhou Med Univ, Sch Pharm, Guiyang 550004, Peoples R China.
   [Tian, Ye] Northwestern Polytech Univ, Lab Bone Metab, Key Lab Space Biosci & Biotechnol, Sch Life Sci, 127 West Youyi Rd, Xian 710072, Peoples R China.
C3 Guizhou Medical University; Guizhou Medical University; Guizhou Medical
   University; Northwestern Polytechnical University
RP Li, YJ (通讯作者)，Guizhou Med Univ, State Key Lab Funct & Applicat Med Plants, Engn Res Ctr Dev & Applicat Ethn Med & TCM, Minist Educ, 4 Beijing Rd, Guiyang 550004, Peoples R China.; Tian, Y (通讯作者)，Northwestern Polytech Univ, Lab Bone Metab, Key Lab Space Biosci & Biotechnol, Sch Life Sci, 127 West Youyi Rd, Xian 710072, Peoples R China.
EM xuema0111@163.com; yjian1023@163.com; liuting@gmc.edu.cn;
   bjyx234@163.com; yanyu626@126.com; gywyl@gmc.edu.cn; gywam100@163.com;
   tianye@nwpu.edu.cn; liyongjun026@gmc.edu.cn
RI Wang, Yonglin/JFK 5415 2023
FU Major Special Project of Guizhou Science and Technology Department
   [[2015]2002]; Special Projects of the Central Government [20184006];
   Talent Team Project of Guizhou Science and Technology Department
   [20165613/20165677]
FX This research was funded by the Major Special Project of Guizhou Science
   and Technology Department ([2015]2002), Special Projects of the Central
   Government to Guide Local Science and Technology Development (20184006),
   and Talent Team Project of Guizhou Science and Technology Department
   (20165613/20165677).
CR Chen Y, 2007, J BIOL CHEM, V282, P526, DOI 10.1074/jbc.M602700200
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   Guo WJ, 2019, MED SCI MONITOR, V25, P3133, DOI 10.12659/MSM.914568
   Hsueh TP, 2012, COMPLEMENT THER MED, V20, P431, DOI 10.1016/j.ctim.2012.08.002
   Huang R, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.129144
   Katagiri T, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021899
   Kusu N, 2003, J BIOL CHEM, V278, P24113, DOI 10.1074/jbc.M301716200
   Li H, 2018, RSC ADV, V8, P15547, DOI 10.1039/c8ra00750k
   Li YT, 2018, CHEM BIOL INTERACT, V283, P51, DOI 10.1016/j.cbi.2018.02.005
   Liao HH, 2015, J ETHNOPHARMACOL, V173, P11, DOI 10.1016/j.jep.2015.07.014
   Liu Y, 2014, INT J ONCOL, V45, P795, DOI 10.3892/ijo.2014.2456
   MacDonald BT, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007880
   Miyazono K, 2010, J BIOCHEM, V147, P35, DOI 10.1093/jb/mvp148
   Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549
   Mukwaya E, 2014, PHARM BIOL, V52, P1223, DOI 10.3109/13880209.2014.884606
   [宁涛 Ning Tao], 2016, [西安交通大学学报. 医学版, Journal of Xi'an Jiaotong University. Medical Sciences], V37, P886
   Peng LH, 2010, J ETHNOPHARMACOL, V131, P282, DOI 10.1016/j.jep.2010.06.039
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Salazar VS, 2016, NAT REV ENDOCRINOL, V12, P203, DOI 10.1038/nrendo.2016.12
   Schoppet M, 2002, ARTERIOSCL THROM VAS, V22, P549, DOI 10.1161/01.ATV.0000012303.37971.DA
   Vahle JL, 2002, TOXICOL PATHOL, V30, P312, DOI 10.1080/01926230252929882
   Verkaar F, 2011, DRUG DISCOV TODAY, V16, P35, DOI 10.1016/j.drudis.2010.11.007
   Wagner DR, 2019, WORLD J STEM CELLS, V11, P281, DOI 10.4252/wjsc.v11.i6.281
   Wang J., 1997, CHINESE J TRADITIONA, V5, P3
   Wang Wei, 2015, Zhong Yao Cai, V38, P193
   Wang WL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131999
   Wu H., 2003, ACTA U MEDICTNAE TAN, V32, P92
   Wu ZX, 2011, J ORTHOP SCI, V16, P99, DOI 10.1007/s00776 010 0019 x
   Xu C, 2005, GENE, V357, P1, DOI 10.1016/j.gene.2005.06.017
   Xu J. S., 2017, LIAONING J TRADITION, V44, P751
   Yamazaki M, 2009, J BIOL CHEM, V284, P35987, DOI 10.1074/jbc.M109.070540
   Yang BY, 2016, J ETHNOPHARMACOL, V191, P107, DOI 10.1016/j.jep.2016.05.017
   Yun HM, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.185
   Zhang RR, 2013, BONE, V52, P145, DOI 10.1016/j.bone.2012.09.029
   Zhang T, 2019, FASEB J, V33, P5399, DOI 10.1096/fj.201801797R
   Zhao Z. M., 2017, WORLD CLIN DRUGS, V38, P121
NR 36
TC 6
Z9 9
U1 2
U2 11
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741 427X
EI 1741 4288
J9 EVID BASED COMPL ALT
JI Evid. based Complement Altern. Med.
PD SEP 30
PY 2020
VL 2020
AR 7184502
DI 10.1155/2020/7184502
PG 12
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA OF9IX
UT WOS:000581512700007
PM 33062020
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Kaliya Perumal, AK
   Carney, TJ
   Ingham, PW
AF Kaliya Perumal, Arun Kumar
   Carney, Tom J.
   Ingham, Philip W.
TI Fibrodysplasia ossificans progressiva: current concepts from bench to
   bedside
SO DISEASE MODELS & MECHANISMS
LA English
DT Article
DE Bone morphogenetic protein; ACVR1; Fibrodysplasia ossificans
   progressiva; Heterotopic ossification; Inflammation
ID TISSUE PROGENITOR CELLS; HETEROTOPIC OSSIFICATION; I RECEPTOR; SIGNALING
   PATHWAYS; INDIAN HEDGEHOG; DIFFERENTIATION; MOUSE; BISPHOSPHONATES;
   GENERATION; INHIBITION
AB Heterotopic ossification (HO) is a disorder characterised by the formation of ectopic bone in soft tissue. Acquired HO typically occurs in response to trauma and is relatively common, yet its aetiology remains poorly understood. Genetic forms, by contrast, are very rare, but provide insights into the mechanisms of HO pathobiology. Fibrodysplasia ossificans progressive (FOP) is the most debilitating form of HO. All patients reported to date carry heterozygous gain offunction mutations in the gene encoding activin A receptor type I (ACVR1). These mutations cause dysregulated bone morphogenetic protein (BMP) signalling, leading to HO at extraskeletal sites including, but not limited to, muscles, ligaments, tendons and fascia. Ever since the identification of the causative gene, developing a cure for FOP has been a focus of investigation, and studies have decoded the pathophysiology at the molecular and cellular levels, and explored novel management strategies. Based on the established role of BMP signalling throughout HO in FOP, therapeutic modalities that target multiple levels of the signalling cascade have been designed, and some drugs have entered clinical trials, holding out hope of a cure. A potential role of other signalling pathways that could influence the dysregulated BMP signalling and present alternative therapeutic targets remains a matter of debate. Here, we review the recent FOP literature, including pathophysiology, clinical aspects, animal models and current management strategies. We also consider how this research can inform our understanding of other types of HO and highlight some of the remaining knowledge gaps.
C1 [Kaliya Perumal, Arun Kumar; Carney, Tom J.; Ingham, Philip W.] Nanyang Technol Univ Singapore, Lee Kong Chian Sch Med, 59 Nanyang Dr, Singapore 636921, Singapore.
   [Carney, Tom J.; Ingham, Philip W.] ASTAR, Inst Mol & Cell Biol IMCB, 61 Biopolis Dr, Singapore 138673, Singapore.
C3 Nanyang Technological University; Agency for Science Technology &
   Research (A*STAR); A*STAR   Institute of Molecular & Cell Biology (IMCB)
RP Ingham, PW (通讯作者)，Nanyang Technol Univ Singapore, Lee Kong Chian Sch Med, 59 Nanyang Dr, Singapore 636921, Singapore.; Ingham, PW (通讯作者)，ASTAR, Inst Mol & Cell Biol IMCB, 61 Biopolis Dr, Singapore 138673, Singapore.
EM pingham@ntu.edu.sg
RI Kaliya Perumal, Arun Kumar/U 1188 2018; Ingham, Philip
   William/G 9903 2011; Carney, Tom/ACF 9214 2022; Ingham,
   Philip/AAH 5884 2020; Kaliya Perumal, Arun Kumar/U 1188 2018
OI Ingham, Philip William/0000 0001 8224 9958; Carney,
   Tom/0000 0003 2371 1924; Kaliya Perumal, Arun Kumar/0000 0002 2747 4500
FU Nanyang Technological University (Lee Kong Chian School of Medicine)
   Research Scholarship; Toh Kian Chui Foundation
FX A. K.K. P. is supported by a Nanyang Technological University (Lee Kong
   Chian School of Medicine) Research Scholarship. P.W.I. is supported by
   the Toh Kian Chui Foundation.
CR Agarwal S, 2016, P NATL ACAD SCI USA, V113, pE338, DOI 10.1073/pnas.1515397113
   Barruet E, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.122958
   Baujat G, 2017, ORPHANET J RARE DIS, V12, DOI 10.1186/s13023 017 0674 5
   Billings PC, 2008, J BONE MINER RES, V23, P305, DOI 10.1359/JBMR.071030
   Brantus JF, 1998, CLIN ORTHOP RELAT R, P117
   Brennan TA, 2018, BONE, V109, P259, DOI 10.1016/j.bone.2017.08.023
   Cappato S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19040989
   Chakkalakal SA, 2016, J BONE MINER RES, V31, P1666, DOI 10.1002/jbmr.2820
   Chakkalakal SA, 2012, J BONE MINER RES, V27, P1746, DOI 10.1002/jbmr.1637
   CONNOR JM, 1993, J MED GENET, V30, P687, DOI 10.1136/jmg.30.8.687
   Convente MR, 2018, J BONE MINER RES, V33, P269, DOI 10.1002/jbmr.3304
   Dey D, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1090
   Fukuda T, 2012, ACTA PHARM SIN B, V2, P23, DOI 10.1016/j.apsb.2011.12.011
   Fukuda T, 2006, GENESIS, V44, P159, DOI 10.1002/dvg.20201
   Furuya H, 2008, AM J MED GENET A, V146A, P459, DOI 10.1002/ajmg.a.32151
   Gilbert S., 2000, Osteogenesis: The Development of Bone
   Gomes WA, 2003, DEV BIOL, V255, P164, DOI 10.1016/S0012 1606(02)00037 4
   Gregson CL, 2020, J BONE MINER RES, V35, P92, DOI 10.1002/jbmr.3875
   Hatsell SJ, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac4358
   Haupt J, 2014, HUM MOL GENET, V23, P5364, DOI 10.1093/hmg/ddu255
   Hino K, 2017, J CLIN INVEST, V127, P3345, DOI 10.1172/JCI93521
   Hüning I, 2014, MOL SYNDROMOL, V5, P201, DOI 10.1159/000365770
   IFOPA, 2020, ONG CLIN TRIALS FOP
   Jiao S, 2013, AM J MED GENET A, V161A, P892, DOI 10.1002/ajmg.a.35771
   Kan C, 2018, BONE, V109, P43, DOI 10.1016/j.bone.2017.04.014
   Kan LX, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/309287
   Kan LX, 2004, AM J PATHOL, V165, P1107, DOI 10.1016/S0002 9440(10)63372 X
   Kaplan F.S., 2019, Clin Proc Int Clin Council FOP, V1, P1
   Kaplan FS, 2008, BEST PRACT RES CL RH, V22, P191, DOI 10.1016/j.berh.2007.11.007
   Kaplan FS, 2005, CLIN REV BONE MINER, V3, P213, DOI 10.1385/BMM:3:3 4:213
   Kaplan FS, 2012, DIS MODEL MECH, V5, P756, DOI 10.1242/dmm.010280
   Kaplan FS, 2011, ANN NY ACAD SCI, V1237, P5, DOI 10.1111/j.1749 6632.2011.06195.x
   Kaplan FS, 2010, J BONE JOINT SURG AM, V92A, P686, DOI 10.2106/JBJS.I.00705
   Kaplan Frederick S, 2009, Hum Mutat, V30, P379, DOI 10.1002/humu.20868
   Kaplan FS, 2000, J BONE MINER RES, V15, P2084, DOI 10.1359/jbmr.2000.15.11.2084
   KAPLAN FS, 1993, J BONE JOINT SURG AM, V75A, P1214, DOI 10.2106/00004623 199308000 00011
   Katagiri T, 2018, ENDOCRINOL METAB, V33, P331, DOI 10.3803/EnM.2018.33.3.331
   Katagiri T, 2018, BONE, V109, P241, DOI 10.1016/j.bone.2017.07.024
   LaBonty M, 2018, ZEBRAFISH, V15, P536, DOI 10.1089/zeb.2018.1611
   LaBonty M, 2018, DEV DYNAM, V247, P279, DOI [10.1002/dvdy.24606, 10.1002/DVDY.24606]
   LaBonty M, 2017, ZEBRAFISH, V14, P293, DOI 10.1089/zeb.2016.1398
   Lai LP, 2005, J CELL BIOCHEM, V96, P1163, DOI 10.1002/jcb.20635
   Lees Shepard JB, 2018, ELIFE, V7, DOI 10.7554/eLife.40814
   Lees Shepard JB, 2018, BONE, V109, P178, DOI 10.1016/j.bone.2018.01.029
   Levy C E, 1999, Am J Audiol, V8, P29, DOI 10.1044/1059 0889(1999/011)
   Long FX, 2004, DEVELOPMENT, V131, P1309, DOI 10.1242/dev.01006
   Macías Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628
   Martelli A, 2014, ORGANOGENESIS, V10, P303, DOI 10.4161/org.29206
   Meyers C, 2019, JBMR PLUS, V3, DOI 10.1002/jbm4.10172
   Miao JL, 2012, GENES GENET SYST, V87, P213, DOI 10.1266/ggs.87.213
   Neal M, 2018, BONE, V109, P285, DOI 10.1016/j.bone.2017.08.032
   Pabst AM, 2014, CLIN ORAL INVEST, V18, P1015, DOI 10.1007/s00784 013 1060 x
   PENNANEN N, 1995, PHARMACEUT RES, V12, P916, DOI 10.1023/A:1016281608773
   Petrie KA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005005
   Pignolo RJ, 2005, CLIN REV BONE MINER, V3, P195, DOI 10.1385/BMM:3:3 4:195
   Pignolo RJ, 2013, PEDIATR ENDOCR REV P, V10, P437
   Pignolo RJ, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750 1172 6 80
   Pignolo RJ, 2011, J BONE MINER RES, V26, P1685, DOI 10.1002/jbmr.370
   Pulik L, 2020, CELLS BASEL, V9, DOI 10.3390/cells9061324
   Qi ZJ, 2017, INTRACTABLE RARE DIS, V6, P242, DOI 10.5582/irdr.2017.01055
   Ranganathan K, 2015, J BONE JOINT SURG AM, V97A, P1101, DOI 10.2106/JBJS.N.01056
   Regard JB, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007997
   Sanchez Duffhues G, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.10.62
   Sanvitale CE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062721
   Schäper C, 2011, J INVEST ALLERG CLIN, V21, P51
   Setiawati R., 2019, OSTEOGENESIS BONE RE, DOI [10.5772/intechopen.82452, DOI 10.5772/INTECHOPEN.82452]
   Shen Q, 2009, J CLIN INVEST, V119, P3462, DOI 10.1172/JCI37412
   Sheng NY, 2010, P NATL ACAD SCI USA, V107, P18886, DOI 10.1073/pnas.1009244107
   Shimono K, 2011, NAT MED, V17, P454, DOI 10.1038/nm.2334
   Shore EM, 2010, NAT REV RHEUMATOL, V6, P518, DOI 10.1038/nrrheum.2010.122
   Shore EM, 2006, NAT GENET, V38, P525, DOI 10.1038/ng1783
   St Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072
   Trigui M, 2011, ACTA ORTHOP BELG, V77, P139
   Tsukamoto S, 2014, SCI REP UK, V4, DOI 10.1038/srep07596
   Twombly V, 2009, GENETICS, V183, P563, DOI 10.1534/genetics.109.105585
   Wang HT, 2018, BONE, V109, P218, DOI 10.1016/j.bone.2017.11.014
   Wang HT, 2016, J BONE MINER RES, V31, P1652, DOI 10.1002/jbmr.2848
   Wang RN, 2014, GENES DIS, V1, P87, DOI 10.1016/j.gendis.2014.07.005
   Werner Clement M L, 2013, HSS J, V9, P166, DOI 10.1007/s11420 013 9335 y
   Wolken DMA, 2018, BONE, V109, P210, DOI 10.1016/j.bone.2017.06.011
   Wosczyna MN, 2012, J BONE MINER RES, V27, P1004, DOI 10.1002/jbmr.1562
   Yamamoto R, 2013, J BONE MINER METAB, V31, P26, DOI 10.1007/s00774 012 0380 2
   Yang YZ, 2020, FASEB J, V34, DOI 10.1096/fasebj.2020.34.s1.00208
   Yelick PC, 1998, DEV DYNAM, V211, P352, DOI 10.1002/(SICI)1097 0177(199804)211:4<352::AID AJA6>3.0.CO;2 G
   Yu PB, 2008, NAT MED, V14, P1363, DOI 10.1038/nm.1888
NR 85
TC 21
Z9 21
U1 1
U2 9
PU COMPANY BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND
SN 1754 8403
EI 1754 8411
J9 DIS MODEL MECH
JI Dis. Model. Mech.
PD SEP
PY 2020
VL 13
IS 9
AR dmm046441
DI 10.1242/dmm.046441
PG 9
WC Cell Biology; Medicine, Research & Experimental; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine; Pathology
GA NZ0KI
UT WOS:000576780200003
PM 32988985
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Matsumoto, K
   Shimo, T
   Kurio, N
   Okui, T
   Ibaragi, S
   Kunisada, Y
   Obata, K
   Masui, M
   Pai, P
   Horikiri, Y
   Yamanaka, N
   Takigawa, M
   Sasaki, A
AF Matsumoto, Kenichi
   Shimo, Tsuyoshi
   Kurio, Naito
   Okui, Tatsuo
   Ibaragi, Soichiro
   Kunisada, Yuki
   Obata, Kyoichi
   Masui, Masanori
   Pai, Pang
   Horikiri, Yuu
   Yamanaka, Nobuyuki
   Takigawa, Masaharu
   Sasaki, Akira
TI Low intensity pulsed ultrasound stimulation promotes osteoblast
   differentiation through hedgehog signaling
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE fracture; LIPUS; osteoblast; primary cilia; sonic hedgehog
ID PRIMARY CILIA; SONIC HEDGEHOG; GROWTH PLATE; BONE CELLS; EXPRESSION;
   MECHANISM; CARTILAGE
AB Low intensity pulsed ultrasound (LIPUS) has been used as an adjunct to fracture healing therapies, but the mechanisms underlying its action are not known. We reported that sonic hedgehog (SHH) signaling was activated in osteoblasts at the dynamic remodeling site of a bone fracture. Mechanical stimulation is a crucial factor in bone remodeling, and it is related to the primary cilia as a sensor of hedgehog signaling. Here we observed that LIPUS promoted callus formation in accord with Gli2 positive cells after 14 days at the mouse femur fractured site compared with a control group. An immunofluorescence analysis showed that the numbers of primary cilia and cilia/osterix double positive osteoblasts were increased at the fracture site by LIPUS. LIPUS stimulated not only the number and the length of primary cilia, but also the levels of ciliated protein, Ift88 mRNA, and SHH, Gli1, and Gli2 in MC3T3 E1 cells. Further experiments revealed that LIPUS stimulated osteogenic differentiation in the presence of smoothened agonist (SAG) treatment. These results indicate that LIPUS stimulates osteogenic differentiation and the maturation of osteoblasts by a primary cilium mediated activation of hedgehog signaling.
C1 [Matsumoto, Kenichi; Shimo, Tsuyoshi; Okui, Tatsuo; Ibaragi, Soichiro; Kunisada, Yuki; Obata, Kyoichi; Masui, Masanori; Horikiri, Yuu; Sasaki, Akira] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Oral & Maxillofacial Surg, Okayama, Japan.
   [Shimo, Tsuyoshi; Takigawa, Masaharu] Okayama Univ, Dent Sch, Grad Sch Med & Pharmaceut Sci, Adv Res Ctr Oral & Craniofacial Sci, Okayama, Japan.
   [Kurio, Naito] Tokushima Univ, Dept Oral Surg, Subdiv Mol Oral Med,Grad Sch, Div Integrated Sci Translat Res,Inst Hlt Biosci, Tokushima, Japan.
   [Pai, Pang] China Med Univ, Dept Oromaxillofacial Head & Neck Surg, Dept Oral & Maxillofacial Surg, Sch Stomatol, Shenyang, Liaoning, Peoples R China.
   [Yamanaka, Nobuyuki] Ito Co, Ltb, Tokyo, Japan.
C3 Okayama University; Okayama University; Tokushima University; China
   Medical University
RP Shimo, T (通讯作者)，Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Oral & Maxillofacial Surg, Kita Ku, 2 5 1 Shikata Cho, Okayama 7008525, Japan.; Takigawa, M (通讯作者)，Okayama Univ, Dent Sch, Grad Sch Med Dent & Pharmaceut Sci, Adv Res,Ctr Oral & Craniofacial Sci,Kita Ku, 2 5 1 Shikata Cho, Okayama 7008525, Japan.
EM shimotsu@md.okayama u.ac.jp; takigawa@md.okayama u.ac.jp
RI Shimo, Tsuyoshi/AAT 8358 2020; okui, tatsuo/HZM 1246 2023
OI Shimo, Tsuyoshi/0000 0002 7811 2366; 
FU Japan Society for the promotion of Sciences [JP26293428]; Grants in Aid
   for Scientific Research [15H05014, 16H06992] Funding Source: KAKEN
FX Japan Society for the promotion of Sciences, Grant number: JP26293428
CR Atherton P, 2017, J CELL SCI, V130, P2277, DOI 10.1242/jcs.192781
   Chang CF, 2013, J ORTHOP RES, V31, P350, DOI 10.1002/jor.22237
   Chen JC, 2016, FASEB J, V30, P1504, DOI 10.1096/fj.15 276402
   Coughlin TR, 2015, CALCIFIED TISSUE INT, V96, P65, DOI 10.1007/s00223 014 9928 6
   Eggenschwiler JT, 2007, ANNU REV CELL DEV BI, V23, P345, DOI 10.1146/annurev.cellbio.23.090506.123249
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   Fávaro Pípi E, 2011, PHOTOMED LASER SURG, V29, P311, DOI 10.1089/pho.2010.2841
   Goetz SC, 2010, NAT REV GENET, V11, P331, DOI 10.1038/nrg2774
   Horikiri Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076785
   Ishikawa H, 2011, NAT REV MOL CELL BIO, V12, P222, DOI 10.1038/nrm3085
   Kashiwagi M, 2016, BIOCHEM BIOPH RES CO, V479, P772, DOI 10.1016/j.bbrc.2016.09.134
   Koyama E, 2007, DEVELOPMENT, V134, P2159, DOI 10.1242/dev.001586
   Kwon RY, 2010, FASEB J, V24, P2859, DOI 10.1096/fj.09 148007
   Li L, 2012, BIOCHEM BIOPH RES CO, V418, P296, DOI 10.1016/j.bbrc.2012.01.014
   Li WL, 2015, INT J CLIN EXP PATHO, V8, P117
   Malone AMD, 2007, P NATL ACAD SCI USA, V104, P13325, DOI 10.1073/pnas.0700636104
   Matsumoto K, 2016, IN VIVO, V30, P99
   Nishida T, 2017, OSTEOARTHR CARTILAGE, V25, P759, DOI 10.1016/j.joca.2016.10.003
   Pang P, 2015, BIOCHEM BIOPH RES CO, V467, P21, DOI 10.1016/j.bbrc.2015.09.139
   Phua SC, 2017, CELL, V168, P264, DOI 10.1016/j.cell.2016.12.032
   Qiu N, 2012, J CELL SCI, V125, P1945, DOI 10.1242/jcs.095893
   Robert A, 2007, J CELL SCI, V120, P628, DOI 10.1242/jcs.03366
   Shimo T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151731
   Tajali SB, 2012, AM J PHYS MED REHAB, V91, P349, DOI 10.1097/PHM.0b013e31822419ba
   Temiyasathit S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033368
   Xie YF, 2016, BONE, V93, P22, DOI 10.1016/j.bone.2016.09.008
   Yuan X, 2016, J DENT RES, V95, P1341, DOI 10.1177/0022034516652383
NR 27
TC 35
Z9 40
U1 2
U2 27
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JUN
PY 2018
VL 119
IS 6
BP 4352
EP 4360
DI 10.1002/jcb.26418
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA GD7CP
UT WOS:000430667200014
PM 28981158
DA 2025 08 17
ER

PT J
AU Li, QS
   Chen, YX
   Dong, SJ
   Liu, SJ
   Zhang, XD
   Si, X
   Zhou, YM
AF Li, Qiushi
   Chen, Yingxin
   Dong, Shujun
   Liu, Shujie
   Zhang, Xiaodan
   Si, Xi
   Zhou, Yanmin
TI Laser irradiation promotes the proliferation of mouse pre osteoblast
   cell line MC3T3 E1 through hedgehog signaling pathway
SO LASERS IN MEDICAL SCIENCE
LA English
DT Article
DE Low level laser; Osteoblast proliferation; Hedgehog signaling pathway;
   MC3T3 E1Cs
ID LOW ENERGY LASER; BONE REPAIR; DIFFERENTIATION; RATS; THERAPY;
   EXPRESSION; PROTEINS
AB Low level laser could promote osteoblast proliferation, and it has been applied in clinical practice to promote wound healing and tissue regeneration. However, the mechanism related to laser irradiation remains unclear. This study aimed to investigate the effects of low level laser irradiation on the cell proliferation and the expressions of hedgehog signaling molecules Indian hedgehog (Ihh), Ptch, and Gli in vitro. In our present study, the MTT method was used to evaluate the effect on cell proliferation of laser irradiation on MC3T3 E1 cells. And cell cycle was examined by flow cytometry. Gene and protein expressions of hedgehog signaling molecules, including Ihh, Ptch, Smoothened (Smo), and Gli, were examined by qRT PCR and western blot analysis. The results showed that laser irradiation at dosage of 3.75 J/cm(2) enhances the proliferation of MC3T3 E1 cells compared with control groups (p = 0.00). Moreover, laser irradiation (3.75 J/cm(2)) increased the cell amount at S phase (p = 0.00). In addition, the expressions of Ihh, Ptch, Smo, and Gli were significantly increased compared to the control during laser irradiation (3.75 J/cm(2)) induced MC3T3 E1 osteoblast proliferation. After adding the hedgehog signaling inhibitor CY (cyclopamine), cell proliferation and Ihh, Ptch, Smo, and Gli expressions were inhibited (p = 0.00), and the cell amount at S phase was reduced compared with combination groups (p = 0.00). These results indicated that laser irradiation promotes proliferation of MC3T3 E1 cells through hedgehog signaling pathway. Our findings provide insights into the mechanistic link between laser irradiation induced osteogenesis and hedgehog signaling pathway.
C1 [Li, Qiushi; Chen, Yingxin; Dong, Shujun; Liu, Shujie] Jilin Univ, Sch & Hosp Stomatol, VIP Integrated Dept, Changchun, Jilin, Peoples R China.
   [Zhang, Xiaodan] Harbin Med Univ, Affiliated Stomatol Hosp, Dept Oral Hlth Sci, Harbin, Heilongjiang, Peoples R China.
   [Si, Xi] Hainan Med Univ, Dept Oral Med, Haikou, Hainan, Peoples R China.
   [Zhou, Yanmin] Jilin Univ, Sch & Hosp Stomatol, Dept Oral Implantol, Changchun 130021, Peoples R China.
C3 Jilin University; Harbin Medical University; Hainan Medical University;
   Jilin University
RP Zhou, YM (通讯作者)，Jilin Univ, Sch & Hosp Stomatol, Dept Oral Implantol, Changchun 130021, Peoples R China.
EM zhouym62@126.com
RI Zhang, Xiaodan/GQR 0608 2022
CR Aleksic V, 2010, LASER MED SCI, V25, P559, DOI 10.1007/s10103 010 0761 5
   Alfredo PP, 2012, CLIN REHABIL, V26, P523, DOI 10.1177/0269215511425962
   Alman BA, 2015, NAT REV RHEUMATOL, V11, P552, DOI 10.1038/nrrheum.2015.84
   da Silva JP, 2010, PHOTOMED LASER SURG, V28, P17, DOI 10.1089/pho.2008.2372
   Enomoto Iwamoto M, 2000, J BONE MINER RES, V15, P1659, DOI 10.1359/jbmr.2000.15.9.1659
   Feng J, 2012, CELL SIGNAL, V24, P1116, DOI 10.1016/j.cellsig.2012.01.013
   Goetz SC, 2009, METHOD CELL BIOL, V94, P199, DOI 10.1016/S0091 679X(08)94010 3
   Huangfu D, 2006, DEVELOPMENT, V133, P3, DOI 10.1242/dev.02169
   Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601
   Kawasaki K, 2000, LASER SURG MED, V26, P282, DOI 10.1002/(SICI)1096 9101(2000)26:3<282::AID LSM6>3.0.CO;2 X
   Kesper DA, 2010, DEV DYNAM, V239, P1818, DOI 10.1002/dvdy.22301
   Ko CY, 2013, LASER MED SCI, V28, P1495, DOI 10.1007/s10103 013 1265 x
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Long FX, 2004, DEVELOPMENT, V131, P1309, DOI 10.1242/dev.01006
   MESTER E, 1985, LASER SURG MED, V5, P31, DOI 10.1002/lsm.1900050105
   Mester E, 1968, Radiobiol Radiother (Berl), V9, P621
   Nakamura T, 1997, BIOCHEM BIOPH RES CO, V237, P465, DOI 10.1006/bbrc.1997.7156
   Oliveira FA, 2016, J PHOTOCH PHOTOBIO B, V163, P14, DOI 10.1016/j.jphotobiol.2016.08.006
   Pejcic A, 2010, PHOTOMED LASER SURG, V28, P69, DOI 10.1089/pho.2008.2301
   Petri Alice Dias, 2010, Braz. Dent. J., V21, P491, DOI 10.1590/S0103 64402010000600003
   TAKEDA Y, 1988, INT J ORAL MAX SURG, V17, P388, DOI 10.1016/S0901 5027(88)80070 5
   Tim CR, 2014, LASER MED SCI, V29, P147, DOI 10.1007/s10103 013 1302 9
   Warzecha J, 2006, J ORTHOP SCI, V11, P491, DOI 10.1007/s00776 006 1058 1
   Yaakobi T, 1996, CALCIFIED TISSUE INT, V59, P297, DOI 10.1007/s002239900126
   Yang J, 2015, INT J ORAL SCI, V7, P73, DOI 10.1038/ijos.2015.14
NR 25
TC 18
Z9 18
U1 0
U2 16
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0268 8921
EI 1435 604X
J9 LASER MED SCI
JI Lasers Med. Sci.
PD SEP
PY 2017
VL 32
IS 7
BP 1489
EP 1496
DI 10.1007/s10103 017 2269 8
PG 8
WC Engineering, Biomedical; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Surgery
GA FE8UL
UT WOS:000408480800006
PM 28667508
DA 2025 08 17
ER

PT J
AU Pourvasei, R
   Lee, E
   Eschenberg, M
   Patel, V
   Macaraeg, C
   Pandya, K
   Shih, J
   Ma, M
   Lee, JW
   DeSilva, B
AF Pourvasei, Ramak
   Lee, Ed
   Eschenberg, Michael
   Patel, Vimal
   Macaraeg, Chris
   Pandya, Kinnari
   Shih, Judy
   Ma, Mark
   Lee, Jean W.
   DeSilva, Binodh
TI Specific Method Validation and Sample Analysis Approaches for
   Biocomparability Studies of Denosumab Addressing Method and Manufacture
   Site Changes
SO AAPS JOURNAL
LA English
DT Article
DE biocomparability; denosumab; ligand binding assay; method validation;
   pharmacokinetics
ID BIOANALYTICAL METHOD VALIDATION; LIGAND BINDING ASSAYS; OSTEOCLAST
   DIFFERENTIATION; OSTEOPROTEGERIN LIGAND; MACROMOLECULES; ACTIVATION
AB Manufacturing changes during a biological drug product life cycle occur often; one common change is that of the manufacturing site. Comparability studies may be required to ensure that the changes will not affect the pharmacokinetic properties of the drug. In addition, the bioanalytical method for sample analysis may evolve during the course of drug development. This paper illustrates the scenario of both manufacturing and bioanalytical method changes encountered during the development of denosumab, a fully human monoclonal antibody which inhibits bone resorption by targeting RANK Ligand. Here, we present a rational approach to address the bioanalytical method changes and provide considerations for method validation and sample analysis in support of biocomparability studies. An updated and improved ELISA method was validated, and its performance was compared to the existing method. The analytical performances, i.e., the accuracy and precision of standards and validation samples prepared from both manufacturing formulation lots, were evaluated and found to be equivalent. One of the lots was used as the reference standard for sample analysis of the biocomparability study. This study was sufficiently powered using a parallel design. The bioequivalence acceptance criteria for small molecule drugs were adopted. The pharmacokinetic parameters of the subjects dosed with both formulation lots were found to be comparable.
C1 [Pourvasei, Ramak; Lee, Ed; Patel, Vimal; Macaraeg, Chris; Shih, Judy; Ma, Mark; Lee, Jean W.] Amgen Inc, Dept Pharmacokinet & Drug Metab, Thousand Oaks, CA 91320 USA.
   [Eschenberg, Michael] Amgen Inc, Dept Biostat, Thousand Oaks, CA 91320 USA.
   [Pandya, Kinnari] Amgen Inc, BioStorage Technol, Thousand Oaks, CA 91320 USA.
   [DeSilva, Binodh] Bristol Myers Squibb Co, Dept Immunochem & Biomarker Dev, Princeton, NJ 08543 USA.
C3 Amgen; Amgen; Amgen; Bristol Myers Squibb
RP Pourvasei, R (通讯作者)，Amgen Inc, Dept Pharmacokinet & Drug Metab, 1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.
EM ramakp@amgen.com
OI DeSilva, Binodh/0000 0001 5404 2570
CR Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Block GA, 2012, J BONE MINER RES, V27, P1471, DOI 10.1002/jbmr.1613
   Bovle WJ, 2003, NATURE, V423, P337
   Chirino AJ, 2004, NAT BIOTECHNOL, V22, P1383, DOI 10.1038/nbt1030
   DeSilva B, 2003, PHARM RES DORDR, V20, P1885, DOI 10.1023/B:PHAM.0000003390.51761.3d
   EMEA, 2007, EMEACHMPBMWP10169520
   FDA Guidance for Industry; CDER, 2001, FDA GUID IND CDER ST
   FDA Guidance for Industry (Draft Guidance), 2003, FDA GUID IND DRAFT G
   FDA Guideline for Industry, 2003, BIOAVAILABILITY BIOE
   Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997
   *ICH, 2004, ICH HARM TRIP GUID Q
   ICH. International Conference on Harmonization (ICH) of technical requirements for registration of pharmaceuticals for human use, 1999, ICH HARM TRIP GUDI Q
   Kelley M, 2007, AAPS J, V9, pE156, DOI 10.1208/aapsj0902017
   Lacey DL, 2000, AM J PATHOL, V157, P435, DOI 10.1016/S0002 9440(10)64556 7
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee JW, 2011, BIOANALYSIS, V3, P613, DOI [10.4155/BIO.11.25, 10.4155/bio.11.25]
   Lipton A, 2002, CLIN CANCER RES, V8, P2306
   Pandya K, 2010, J PHARMACEUT BIOMED, V53, P623, DOI 10.1016/j.jpba.2010.04.025
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
NR 19
TC 2
Z9 3
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1550 7416
J9 AAPS J
JI AAPS J.
PD JAN
PY 2013
VL 15
IS 1
BP 70
EP 77
DI 10.1208/s12248 012 9414 x
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 063RJ
UT WOS:000313017300007
PM 23054973
OA Green Published
DA 2025 08 17
ER

PT J
AU Song, JY
   Zhang, YF
   Jin, XH
   Zhu, YF
   Li, YT
   Hu, M
AF Song, Jiyu
   Zhang, Yongfeng
   Jin, Xinghui
   Zhu, Yanfeng
   Li, Yutong
   Hu, Min
TI Eucommia ulmoides Oliver polysaccharide alleviates
   glucocorticoid induced osteoporosis by stimulating bone formation via
   ERK/BMP 2/SMAD signaling
SO SCIENTIFIC REPORTS
LA English
DT Article
DE Eucommia ulmoides Oliver; Polysaccharide; Osteoporosis;
   Osteoblast differentiation; ERK/BMP 2/SMAD signaling
ID OSTEOBLAST DIFFERENTIATION; IN VIVO; OSTERIX; RUNX2
AB Osteoporosis (OP) is a metabolic disease characterized by low bone mineral mass owing to osteoblast dysfunction. Eucommia ulmoides Oliver (EuO) is a Chinese herbal medicine traditionally used to treat OP. Here, a polysaccharide purified from the EuO cortex (EuOCP3) was administered to OP mice constructed with dexamethasone (Dex) to investigate its anti OP activity. EuOCP3 significantly improved Dex induced bone microarchitecture destruction, increased osteoblast numbers and surface, and stimulated an increase in the expression of osteoblast differentiation markers in the femurs of OP mice. Furthermore, EuOCP3 was applied to MC3T3 E1 cells to further explore its effects on osteoblast differentiation. EuOCP3 significantly promoted osteoblast differentiation and increased the level of phosphorylated extracellular signal regulated kinase1/2 (ERK1/2) and SMAD1/5/8. The EuOCP3 mediated enhancement of osteoblast differentiation related proteins and phosphorylated SMAD1/5/8 expression levels was strongly suppressed by an ERK inhibitor (PD98059), which confirmed the critical role of ERK signaling in EuOCP3 induced osteoblast differentiation. In summary, EuOCP3 can stimulate bone formation by improving osteoblast differentiation via ERK/BMP 2/SMAD signaling, indicating the potential use of EuOCP3 as a functional ingredient in food products for anti OP treatment.
C1 [Song, Jiyu; Li, Yutong; Hu, Min] Jilin Univ, Hosp Stomatol, Dept Orthodont, Changchun 130021, Peoples R China.
   [Song, Jiyu; Li, Yutong; Hu, Min] Jilin Univ, Key Lab Pathobiol, Minist Educ, Changchun 130021, Peoples R China.
   [Zhang, Yongfeng; Jin, Xinghui; Zhu, Yanfeng] Jilin Univ, Sch Life Sci, Changchun 130012, Peoples R China.
C3 Jilin University; Jilin University; Jilin University
RP Li, YT; Hu, M (通讯作者)，Jilin Univ, Hosp Stomatol, Dept Orthodont, Changchun 130021, Peoples R China.; Li, YT; Hu, M (通讯作者)，Jilin Univ, Key Lab Pathobiol, Minist Educ, Changchun 130021, Peoples R China.
EM liyutong@jlu.edu.cn; humin@jlu.edu.cn
FU Jilin Provincial Department of Finance Science and Technology Project
   [jcsz2023481 31]; National Natural Science Foundation of China
   [82201105, 82170994]
FX This research was funded by the Jilin Provincial Department of Finance
   Science and Technology Project (jcsz2023481 31), National Natural
   Science Foundation of China (82201105 and 82170994).
CR Sanchez MA, 2020, MAT SCI ENG C MATER, V115, DOI 10.1016/j.msec.2020.110931
   Amarasekara DS, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22062851
   Camacho PM, 2020, ENDOCR PRACT, V26, P1, DOI 10.4158/GL 2020 0524SUPPL
   Carvalho MS, 2020, J CELL PHYSIOL, V235, P7496, DOI 10.1002/jcp.29653
   Chan WCW, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115445
   Chang YY, 2019, J ORTHOP TRANSL, V19, P47, DOI 10.1016/j.jot.2019.02.001
   Deng YQ, 2019, INT J BIOL MACROMOL, V140, P727, DOI 10.1016/j.ijbiomac.2019.08.145
   Ebeling PR, 2022, ENDOCR REV, V43, P240, DOI 10.1210/endrev/bnab028
   Ge CX, 2012, J BONE MINER RES, V27, P538, DOI 10.1002/jbmr.561
   Guan MQ, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/3641317
   Halloran D, 2020, J DEV BIOL, V8, DOI 10.3390/jdb8030019
   Huang D, 2020, CARBOHYD POLYM, V231, DOI 10.1016/j.carbpol.2019.115732
   Huang LC, 2021, CHIN MED UK, V16, DOI 10.1186/s13020 021 00482 7
   Jiang X, 2021, FOOD FUNCT, V12, P6725, DOI [10.1039/d1fo00666e, 10.1039/D1FO00666E]
   Jun JH, 2010, J BIOL CHEM, V285, P36410, DOI 10.1074/jbc.M110.142307
   Kawane T, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 31853 0
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kim BS, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2014.95
   Kim JM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081803
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Komori T, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207513
   Komori T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071694
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441 009 0832 8
   Kong YY, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1493 5
   Lane NE, 2006, J BONE MINER RES, V21, P466, DOI 10.1359/JBMR.051103
   Lei SS, 2021, INT J BIOL MACROMOL, V193, P1996, DOI 10.1016/j.ijbiomac.2021.11.030
   Li HX, 2021, CURR MED CHEM, V28, P1489, DOI 10.2174/0929867327666200330142432
   Li Q, 2017, CARBOHYD POLYM, V169, P304, DOI 10.1016/j.carbpol.2017.04.034
   Li YT, 2020, AGING US, V12, P2226, DOI 10.18632/aging.102742
   Lin X, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00757
   Lin ZZ, 2021, CARBOHYD POLYM, V259, DOI 10.1016/j.carbpol.2020.117553
   Liu Q, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.601224
   Lu N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20153792
   Marie PJ, 2015, CELL MOL LIFE SCI, V72, P1347, DOI 10.1007/s00018 014 1801 2
   Matsushita T, 2009, MOL CELL BIOL, V29, P5843, DOI 10.1128/MCB.01549 08
   Mueller A, 2000, GLYCOBIOLOGY, V10, P339, DOI 10.1093/glycob/10.4.339
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Qadir A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010349
   Salazar VS, 2016, NAT REV ENDOCRINOL, V12, P203, DOI 10.1038/nrendo.2016.12
   Sinha KM, 2013, J CELL BIOCHEM, V114, P975, DOI 10.1002/jcb.24439
   Song JY, 2023, CARBOHYD POLYM, V306, DOI 10.1016/j.carbpol.2023.120601
   Song SS, 2022, PHARMACOL THERAPEUT, V237, DOI 10.1016/j.pharmthera.2022.108168
   Su JL, 2010, J BIOL CHEM, V285, P31325, DOI 10.1074/jbc.M109.087122
   Wang FJ, 2021, J ETHNOPHARMACOL, V271, DOI 10.1016/j.jep.2021.113899
   Wang J, 2023, INT J BIOL MACROMOL, V248, DOI 10.1016/j.ijbiomac.2023.125879
   Wang T, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 10769 w
   Weinstein RS, 2012, ENDOCRIN METAB CLIN, V41, P595, DOI 10.1016/j.ecl.2012.04.004
   Xu JK, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 24957 0
   Xu SY, 2021, J CELL MOL MED, V25, P4572, DOI 10.1111/jcmm.16216
   Yang HX, 2022, NUTRIENTS, V14, DOI 10.3390/nu14163299
   Yu PL, 2024, INT J BIOL MACROMOL, V275, DOI 10.1016/j.ijbiomac.2024.133686
   Zhang R, 2009, BONE, V45, P553, DOI 10.1016/j.bone.2008.08.127
   Zhang R, 2014, J ETHNOPHARMACOL, V155, P104, DOI 10.1016/j.jep.2014.04.031
   Zhang Y, 2024, CURR PHARM DESIGN, V30, P2410, DOI 10.2174/0113816128298755240613100018
   Zou ML, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.593310
NR 55
TC 3
Z9 3
U1 11
U2 18
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD NOV 28
PY 2024
VL 14
IS 1
AR 29647
DI 10.1038/s41598 024 80859 4
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA N9E4O
UT WOS:001367280000008
PM 39609585
OA gold
DA 2025 08 17
ER

PT J
AU Abdelaziz, DM
   Stone, LS
   Komarova, SV
AF Abdelaziz, Dareen M.
   Stone, Laura S.
   Komarova, Svetlana V.
TI Localized experimental bone metastasis drives osteolysis and sensory
   hypersensitivity at distant non tumor bearing sites
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Breast cancer metastases; Distant pain; Neuroplasticity; Pamidronate;
   Rapamycin; Systemic bone loss
ID IMAGE NEUROPATHIC PAIN; CANCER PAIN; PROINFLAMMATORY CYTOKINES;
   SPINAL CORD; RAT MODEL; MECHANICAL HYPERSENSITIVITY; ASTROCYTES
   CONTRIBUTES; GLIAL ACTIVATION; MAMMALIAN TARGET; PERSISTENT PAIN
AB Patients with breast cancer metastasis to bone suffer from inadequate pain relief. Animal models provide increased understanding of cancer induced bone and sensory alterations. The objective of this study was to investigate the measures of pain at distant non tumor bearing sites in animals with localized bone metastasis. Immunocompetent BALB/c mice are injected intra tibially with murine mammary carcinoma cells (4T1) or saline, and the sensitivity to mechanical and thermal stimuli in the contralateral paw was examined. In addition to previously demonstrated development of osteolysis and hypersensitivity to mechanical and thermal stimuli in the cancer injected tibia, these animals exhibited an increase in sensory hypersensitivity in the contralateral limb. No bone lesions were evident on radiographs of the contralateral limbs. Histomorphometry detected decreased bone volume per tissue volume and increased osteoclast number in the contralateral tibia and vertebral bones of cancer bearing animals. Neuroplasticity was examined by immunofluorescence for calcitonin gene related peptide (CGRP) in sensory neurons and glial fibrillary acidic protein (GFAP) in lumbar spinal cords. CGRP immunoreactivity and GFAP immunoreactivity were significantly elevated both ipsilateral and contralateral in tumor bearing animals. The anti inflammatory and osteolysis targeting drug rapamycin reduced hypersensitivity to mechanical and cold stimuli, attenuated GFAP over expression, and lowered osteoclast number. The osteoclast targeting drug pamidronate reduced sensitivity to cold and protected against bone loss. Localized bone cancer drives hypersensitivity, bone remodeling, and sensory neuron plasticity at sites distant from the primary tumor area. Drugs targeting these mechanisms may be useful in the treatment of pain distant from the primary tumor site.
C1 [Abdelaziz, Dareen M.; Stone, Laura S.; Komarova, Svetlana V.] McGill Univ, Fac Dent, Montreal, PQ, Canada.
   [Abdelaziz, Dareen M.; Stone, Laura S.] Alan Edwards Ctr Res Pain, Montreal, PQ, Canada.
   [Stone, Laura S.] McGill Univ, Fac Med, Dept Anaesthesiol, Montreal, PQ, Canada.
   [Stone, Laura S.] McGill Univ, Fac Med, Dept Pharmacol & Therapeut, Montreal, PQ, Canada.
   [Stone, Laura S.] McGill Univ, Integrated Program Neurosci, Montreal, PQ, Canada.
   [Komarova, Svetlana V.] Shriners Hosp Children Canada, Montreal, PQ H3G IA6, Canada.
C3 McGill University; McGill University; McGill University; McGill
   University
RP Komarova, SV (通讯作者)，McGill Univ, Fac Dent, Montreal, PQ, Canada.
EM svetlana.komarova@mcgill.ca
RI Komarova, Svetlana/MTR 5042 2025
OI Komarova, Svetlana/0000 0003 3570 3147
FU Cancer Research Society/Quebec Breast Cancer Foundation grant; Ministry
   of Higher Education, Egypt
FX We thank Dr. Peter Siegel for providing the 4T1 cells, Drs. Magali
   Millecamps, Osama Hussein, and Catherine Ferland Legault for
   methodological and intellectual support, Drs. Monzur Murshed and Frank
   Rauch for advice on histomorphometry and McGill University undergraduate
   students Anita Ramachandran, Jingwen Chen, Katia Fox, and Robert Samberg
   for their help in performing the animal studies. This study was
   supported by the Cancer Research Society/Quebec Breast Cancer Foundation
   grant to LSS and SVK. DMA was supported by Ministry of Higher Education,
   Egypt. SVK holds Canada Research Chair in Osteoclast Biology.
CR Abdelaziz DM, 2014, BREAST CANCER RES TR, V143, P227, DOI 10.1007/s10549 013 2799 0
   Andrews N.A., 2012, IBMS BONEKEY, V9
   Arguis MJ, 2008, REGION ANESTH PAIN M, V33, P211, DOI 10.1016/j.rapm.2007.12.003
   BOWSHER D, 1988, PAIN, V33, P63, DOI 10.1016/0304 3959(88)90204 7
   Cai Beilei, 2013, J Pain Palliat Care Pharmacother, V27, P28, DOI 10.3109/15360288.2012.757267
   CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165 0270(94)90144 9
   CHOI Y, 1994, PAIN, V59, P369, DOI 10.1016/0304 3959(94)90023 X
   Codeluppi S, 2009, J NEUROSCI, V29, P1093, DOI 10.1523/JNEUROSCI.4103 08.2009
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Constantin CE, 2008, J NEUROSCI, V28, P5072, DOI 10.1523/JNEUROSCI.4476 07.2008
   Doré Savard L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013774
   Faccio R, 2011, ANN NY ACAD SCI, V1237, P71, DOI 10.1111/j.1749 6632.2011.06244.x
   Feng QX, 2010, NEUROSCIENCE, V167, P501, DOI 10.1016/j.neuroscience.2010.02.005
   Ferland CE, 2011, PHARMACOL BIOCHEM BE, V97, P603, DOI 10.1016/j.pbb.2010.11.003
   Géranton SM, 2009, J NEUROSCI, V29, P15017, DOI 10.1523/JNEUROSCI.3451 09.2009
   Goldberg JE, 2010, CURR DRUG TARGETS, V11, P1133
   Gregory EN, 2010, NEUROSCIENCE, V169, P1392, DOI 10.1016/j.neuroscience.2010.05.067
   Halper J, 2010, VET PATHOL, V47, P77, DOI 10.1177/0300985809352981
   HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304 3959(88)90026 7
   Honore P, 2000, NEUROSCIENCE, V98, P585, DOI 10.1016/S0306 4522(00)00110 X
   Jensen EC, 2013, ANAT REC, V296, P378, DOI 10.1002/ar.22641
   Ji RR, 2013, PAIN, V154, pS10, DOI 10.1016/j.pain.2013.06.022
   Jiang F, 2013, MOL PAIN, V9, DOI 10.1186/1744 8069 9 50
   Jimenez Andrade JM, 2010, ANN NY ACAD SCI, V1198, P173, DOI 10.1111/j.1749 6632.2009.05429.x
   Kimble RB, 1997, J BONE MINER RES, V12, P935, DOI 10.1359/jbmr.1997.12.6.935
   Koltzenburg M, 1999, TRENDS NEUROSCI, V22, P122, DOI 10.1016/S0166 2236(98)01302 2
   Kozai T, 2007, GLIA, V55, P595, DOI 10.1002/glia.20483
   Lee BH, 2005, YONSEI MED J, V46, P252, DOI 10.3349/ymj.2005.46.2.252
   Mao Ying QL, 2006, BIOCHEM BIOPH RES CO, V345, P1292, DOI 10.1016/j.bbrc.2006.04.186
   Mao Ying QL, 2012, MOL BRAIN, V5, DOI 10.1186/1756 6606 5 16
   Milligan ED, 2003, J NEUROSCI, V23, P1026
   Mundy GR, 1997, CANCER AM CANCER SOC, V80, P1546, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1546::AID CNCR4>3.3.CO;2 R
   Obata H, 2006, J PAIN, V7, P816, DOI 10.1016/j.jpain.2006.04.004
   Paplomata E, 2014, THER ADV MED ONCOL, V6, P154, DOI 10.1177/1758834014530023
   Psaila Bethan, 2006, Breast Dis, V26, P65
   Racz I, 2008, J NEUROSCI, V28, P12125, DOI 10.1523/JNEUROSCI.3400 08.2008
   Rao Arati, 2004, J Natl Cancer Inst Monogr, P150
   Romas E, 2002, BONE, V30, P340, DOI 10.1016/S8756 3282(01)00682 2
   Schmidt BL, 2010, MOL INTERV, V10, P164, DOI 10.1124/mi.10.3.7
   Schreiber KL, 2008, NEUROSCI LETT, V440, P63, DOI 10.1016/j.neulet.2008.05.044
   Seong J, 2004, ANN NY ACAD SCI, V1030, P179, DOI 10.1196/annals.1329.023
   Sevcik MA, 2005, PAIN, V115, P128, DOI 10.1016/j.pain.2005.02.022
   Shen W, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742 2094 11 75
   Shih MH, 2012, J PAIN, V13, P338, DOI 10.1016/j.jpain.2011.12.006
   Smith HS, 2014, AM J THER, V21, P106, DOI 10.1097/MJT.0b013e3182456dff
   Svensson CI, 2010, MOL INTERV, V10, P25, DOI 10.1124/mi.10.1.6
   Twining CM, 2004, PAIN, V110, P299, DOI 10.1016/j.pain.2004.04.008
   Wacnik PW, 2005, PAIN, V115, P95, DOI 10.1016/j.pain.2005.02.024
   Wang XW, 2012, NEUROSCIENCE, V217, P172, DOI 10.1016/j.neuroscience.2012.04.065
   Woolf CJ, 2011, PAIN, V152, pS2, DOI 10.1016/j.pain.2010.09.030
   Yardley DA, 2013, ADV THER, V30, P870, DOI 10.1007/s12325 013 0060 1
   Yoon SY, 2013, J PAIN, V14, P205, DOI 10.1016/j.jpain.2012.11.002
   ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304 3959(83)90201 4
NR 53
TC 8
Z9 8
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167 6806
EI 1573 7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD AUG
PY 2015
VL 153
IS 1
BP 9
EP 20
DI 10.1007/s10549 015 3517 x
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA CP3JL
UT WOS:000359775100003
PM 26208488
DA 2025 08 17
ER

PT J
AU Huynh, H
   Wan, YH
AF HoangDinh Huynh
   Wan, Yihong
TI mTORC1 impedes osteoclast differentiation via calcineurin and NFATc1
SO COMMUNICATIONS BIOLOGY
LA English
DT Article
ID ACTIVATED T CELLS; BONE LOSS; NUCLEAR FACTOR; RECEPTOR ACTIVATOR; MOUSE
   MODEL; IN VITRO; OSTEOPROTEGERIN; LIGAND; GROWTH; MICE
AB Rapamycins are immunosuppressant and anti cancer drugs that inhibit the kinase mTOR. Clinically, they often cause bone pain, bone necrosis, and high bone turnover, yet the mechanisms are unclear. Here we show that mTORC1 activity is high in osteoclast precursors but downregulated upon RANKL treatment. Loss of function genetic models reveal that while early Raptor deletion in hematopoietic stem cells blunts osteoclastogenesis due to compromised proliferation/survival, late Raptor deletion in osteoclast precursors instead augments osteoclastogenesis. Gain of function genetic models by TSC1 deletion in HSCs or osteoclast precursors cause constitutive mTORC1 activation, impairing osteoclastogenesis. Pharmacologically, rapamycin treatment at low but clinically relevant doses exacerbates osteoclast differentiation and bone resorption, leading to bone loss. Mechanistically, RANKL inactivates mTORC1 via calcineurin mediated mTORC1 dephosphorylation, consequently activating NFATc1 by reducing mTORC1 mediated NFATc1 phosphorylation. These findings uncover biphasic roles of mTORC1 in osteoclastogenesis, dosage dependent effects of rapamycin on bone, and a previously unrecognized calcineurin mTORC1 NFATc1 phosphorylation regulatory signaling cascade.
C1 [HoangDinh Huynh; Wan, Yihong] Univ Texas Southwestern Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA.
C3 University of Texas System; University of Texas Southwestern Medical
   Center
RP Wan, YH (通讯作者)，Univ Texas Southwestern Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA.
EM yihong.wan@utsouthwestern.edu
RI Wan, Yihong/J 8681 2012
FU NIH [R01DK089113]; CPRIT [RP130145]; DOD [W81XWH 13 1 0318]; Welch
   Foundation [I 1751]; March of Dimes [6 FY13 137]; UTSW Endowed Scholar
   Startup Fund
FX We thank Drs. Paul Dechow and Jerry Feng (Baylor College of Dentistry)
   for assistance with histomorphometry; Dr. Sean Morrison (UT Southwestern
   Medical Center) for assistance with mu CT. Y.W. is Lawrence Raisz
   Professor in Bone Cell Metabolism and a Virginia Murchison Linthicum
   Scholar in Medical Research. This work was in part supported by NIH
   (R01DK089113, Y.W.), CPRIT (RP130145, Y.W.), DOD (W81XWH 13 1 0318,
   Y.W.), The Welch Foundation (I 1751, Y.W.), March of Dimes (#6 FY13 137,
   Y.W.) and UTSW Endowed Scholar Startup Fund (Y.W.).
CR Broom RJ, 2015, CLIN GENITOURIN CANC, V13, P50, DOI 10.1016/j.clgc.2014.07.002
   Browne AJ, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058 017 0885 7
   Campistol JM, 2005, TRANSPL INT, V18, P1028, DOI 10.1111/j.1432 2277.2005.00163.x
   Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960
   Crabtree GR, 2009, CELL, V138, DOI 10.1016/j.cell.2009.06.026
   Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092 8674(02)00699 2
   Dai QG, 2017, J BIOL CHEM, V292, P196, DOI 10.1074/jbc.M116.764761
   de Boer J, 2003, EUR J IMMUNOL, V33, P314, DOI 10.1002/immu.200310005
   DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475
   FALCONER DS, 1951, J GENET, V50, P192, DOI 10.1007/BF02996215
   FRYKMAN PK, 1995, P NATL ACAD SCI USA, V92, P8453, DOI 10.1073/pnas.92.18.8453
   Glantschnig H, 2003, CELL DEATH DIFFER, V10, P1165, DOI 10.1038/sj.cdd.4401285
   Gnant M, 2013, JNCI J NATL CANCER I, V105, P654, DOI 10.1093/jnci/djt026
   Graef IA, 2001, CURR OPIN GENET DEV, V11, P505, DOI 10.1016/S0959 437X(00)00225 2
   Haynes DR, 2001, RHEUMATOLOGY, V40, P623, DOI 10.1093/rheumatology/40.6.623
   Huynh H, 2017, CELL REP, V19, P2014, DOI 10.1016/j.celrep.2017.05.037
   Hofbauer LC, 2001, BIOCHEM BIOPH RES CO, V280, P334, DOI 10.1006/bbrc.2000.4130
   Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703
   Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073
   Hsu PP, 2011, SCIENCE, V332, P1317, DOI 10.1126/science.1199498
   Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096 1132
   Indo Y, 2013, J BONE MINER RES, V28, P2392, DOI 10.1002/jbmr.1976
   Johnson SC, 2013, SCIENCE, V342, P1524, DOI 10.1126/science.1244360
   Joseph C, 2013, CELL STEM CELL, V13, P520, DOI 10.1016/j.stem.2013.10.010
   Kameda T, 1997, J EXP MED, V186, P489, DOI 10.1084/jem.186.4.489
   Kaneda MM, 2016, NATURE, V539, P437, DOI 10.1038/nature19834
   Kiani A, 2004, J LEUKOCYTE BIOL, V76, P1057, DOI 10.1189/jlb.0404259
   Kim JH, 2014, CELL DEATH DIFFER, V21, P1613, DOI 10.1038/cdd.2014.71
   Kim JH, 2011, BIOCHEM J, V436, P253, DOI 10.1042/BJ20110062
   Kim JH, 2010, J BIOL CHEM, V285, P5224, DOI 10.1074/jbc.M109.042812
   Kim K, 2007, BLOOD, V109, P3253, DOI 10.1182/blood 2006 09 048249
   Kneissel M, 2004, BONE, V35, P1144, DOI 10.1016/j.bone.2004.07.013
   Knight ZA, 2014, ELIFE, V3, DOI 10.7554/eLife.01913
   Knoechel B, 2014, NAT GENET, V46, P364, DOI 10.1038/ng.2913
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Kousteni S, 2002, SCIENCE, V298, P843, DOI 10.1126/science.1074935
   Krzeszinski JY, 2014, NATURE, V512, P431, DOI 10.1038/nature13375
   Kuroda Y, 2012, WORLD J ORTHOP, V3, P167, DOI 10.5312/wjo.v3.i11.167
   Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Lee J, 2006, BLOOD, V107, P2686, DOI 10.1182/blood 2005 07 2798
   Lee Y, 2013, BONE, V56, P383, DOI 10.1016/j.bone.2013.07.007
   Li L, 2016, ONCOL REP, V36, P918, DOI 10.3892/or.2016.4904
   Li XX, 2015, ELIFE, V4, DOI 10.7554/eLife.07217
   Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884
   López Rodríguez C, 2001, IMMUNITY, V15, P47, DOI 10.1016/S1074 7613(01)00165 0
   Masuda ES, 1997, MOL CELL BIOL, V17, P2066, DOI 10.1128/MCB.17.4.2066
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Mócsai A, 2004, P NATL ACAD SCI USA, V101, P6158, DOI 10.1073/pnas.0401602101
   Mognol GP, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.97
   Mulholland DJ, 2011, CANCER CELL, V19, P792, DOI 10.1016/j.ccr.2011.05.006
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Roy J, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2100re9
   Rubert Mercedes, 2015, Bone Rep, V2, P74, DOI 10.1016/j.bonr.2015.05.003
   Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974
   Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]
   SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167 5699(92)90111 J
   Sengupta S, 2010, NATURE, V468, P1100, DOI 10.1038/nature09584
   SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404
   Shui C, 2002, CALCIFIED TISSUE INT, V71, P437, DOI 10.1007/s00223 001 1138 3
   Song I, 2009, FEBS LETT, V583, P2435, DOI 10.1016/j.febslet.2009.06.047
   Soysa Niroshani Surangika, 2012, J Med Dent Sci, V59, P65
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Takeshita S, 2002, NAT MED, V8, P943, DOI 10.1038/nm752
   Tchetina EV, 2015, J OSTEOPOROS, V2015, DOI 10.1155/2015/802694
   Tiedemann K, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00054
   Wan YH, 2007, NAT MED, V13, P1496, DOI 10.1038/nm1672
   Wei W, 2014, CELL METAB, V19, P927, DOI 10.1016/j.cmet.2014.03.016
   Wei W, 2012, P NATL ACAD SCI USA, V109, P3143, DOI 10.1073/pnas.1200797109
   Wei W, 2011, MOL CELL BIOL, V31, P4706, DOI 10.1128/MCB.05980 11
   Wesselborg S, 1996, J BIOL CHEM, V271, P1274, DOI 10.1074/jbc.271.3.1274
   Westenfeld R, 2011, NEPHROL DIAL TRANSPL, V26, P4115, DOI 10.1093/ndt/gfr214
   Whyte MP, 2006, ANN NY ACAD SCI, V1068, P143, DOI 10.1196/annals.1346.016
   Winkeler CL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042005
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yasui T, 2011, J BONE MINER RES, V26, P2665, DOI 10.1002/jbmr.464
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zhang Y, 2017, J BONE MINER RES, V32, P1829, DOI 10.1002/jbmr.3172
   Zhao BH, 2009, NAT MED, V15, P1066, DOI 10.1038/nm.2007
NR 83
TC 55
Z9 63
U1 1
U2 8
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013 1917 USA
EI 2399 3642
J9 COMMUN BIOL
JI Commun. Biol.
PY 2018
VL 1
AR 29
DI 10.1038/s42003 018 0028 4
PG 15
WC Biology; Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics; Science & Technology   Other
   Topics
GA HO7LC
UT WOS:000461126500029
PM 30271915
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wu, XJ
   Tao, ZS
   Cheng, WJ
AF Wu, Xingjing
   Tao, Zhoushan
   Cheng, Wenjing
TI Microrna 206 induces hypoxic necrosis of femoral head by inhibiting
   VEGF/PI3K/AKT signaling pathway
SO FRONTIERS IN GENETICS
LA English
DT Article
DE hypoxic necrosis of femoral head; VEGF; PI3K; Akt signal pathway;
   microRNA 206 molecule; chemotherapy drug delivery system; anoxic
   necrosis
AB The most common form of non traumatic necrosis of the femoral head is anoxic necrosis of the femoral head, which is a metabolic disease, mainly involving young and middle aged people. Apoptosis and its related signal regulation pathway play an important role in the occurrence and development of hypoxic necrosis of the femoral head. In order to investigate the possible pathological manifestations of miR 206 and VEGF/PI3K/AKT signal pathway genes and their interactions in hypoxic necrosis of the femoral head, this paper intended to systematically study the expression and regulation mechanism of miR 206 and VEGF/PI3K/AKT signal pathway genes. The interaction between miR 206 and VEGF/PI3K/AKT signaling pathway and its regulation on apoptosis, differentiation and proliferation of human osteoblast cell line hFOB1.19 (SV40 transfer of human osteoblasts) were studied by double luciferase reporter gene analysis, overexpression and inhibition of miR 206, and gene silencing of VEGF/PI3K/AKT signaling pathway. After 24 h and 48 h of intervention with MicroRNA 206 on osteoblasts, it was found that the fluorescence intensity of caspase 3 was higher than that of 0 h group (p < 0.05). This paper has provided an important research basis for the research of femoral head necrosis and the development of new diagnosis and therapeutic drugs for this kind of disease. It also has provided a reference for the further promotion of the chemotherapy drug delivery system.
C1 [Wu, Xingjing; Tao, Zhoushan; Cheng, Wenjing] Yijishan Hosp, Wannan Med Coll, Dept Orthoped, Wuhu, Anhui, Peoples R China.
C3 Wannan Medical College
RP Wu, XJ (通讯作者)，Yijishan Hosp, Wannan Med Coll, Dept Orthoped, Wuhu, Anhui, Peoples R China.
EM 164903303@stu.cuz.edu.cn
FU Science and Technology Project Fund of Wuhu City, Anhui Province, China
   [2021yf62, KY20260018]; Doctor Research Foundation for Wannan Medical
   College Yijishan Hospital of China
FX Funding This study was supported by Science and Technology Project Fund
   of Wuhu City, Anhui Province, China (2021yf62) and grant KY20260018 from
   Doctor Research Foundation for Wannan Medical College Yijishan Hospital
   of China.
CR Calori GM, 2017, EFORT OPEN REV, V2, P41, DOI 10.1302/2058 5241.2.150006
   Hua KC, 2019, J ORTHOP SURG RES, V14, DOI 10.1186/s13018 019 1359 7
   Landgraeber S, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891 017 1811 y
   Leibold CS, 2020, OPER ORTHOP TRAUMATO, V32, P116, DOI 10.1007/s00064 019 00642 x
   Li W, 2017, ORTHOPADE, V46, P440, DOI 10.1007/s00132 016 3360 8
   Luo P, 2018, INT ORTHOP, V42, P1747, DOI 10.1007/s00264 018 3994 8
   Ma JX, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 13643 2
   Narayanan A, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 10817 w
   Peng PJ, 2021, FEBS OPEN BIO, V11, P312, DOI 10.1002/2211 5463.13037
   Petek D, 2019, EFORT OPEN REV, V4, P85, DOI 10.1302/2058 5241.4.180036
   Sheng Z, 2021, GENOMICS, V113, P490, DOI 10.1016/j.ygeno.2020.12.034
   Shu P, 2020, HUM GENE THER, V31, P286, DOI 10.1089/hum.2019.306
   Wang TS, 2017, EXP THER MED, V13, P669, DOI 10.3892/etm.2016.3991
   Wang YJ, 2019, BIOCHEM BIOPH RES CO, V508, P25, DOI 10.1016/j.bbrc.2018.11.097
   Wen PF, 2020, BMC MUSCULOSKEL DIS, V21, DOI 10.1186/s12891 020 03242 0
   Wu W, 2018, INT ORTHOP, V42, P133, DOI 10.1007/s00264 017 3679 8
   Yan YQ, 2018, BMC MUSCULOSKEL DIS, V19, DOI 10.1186/s12891 018 2208 2
   Zhang M, 2017, POULTRY SCI, V96, P1609, DOI 10.3382/ps/pew466
   Zhang Y, 2017, ORTHOPADE, V46, P737, DOI 10.1007/s00132 017 3408 4
   Zhu WW, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2496 y
NR 20
TC 1
Z9 1
U1 1
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1664 8021
J9 FRONT GENET
JI Front. Genet.
PD FEB 22
PY 2023
VL 14
AR 1118831
DI 10.3389/fgene.2023.1118831
PG 12
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA 9R7HV
UT WOS:000945820300001
PM 36911416
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Huang, TB
   Wang, YC
   Yu, Z
   Miao, XY
   Jiang, ZW
   Yu, K
   Fu, MD
   Lai, KC
   Wang, Y
   Yang, GL
AF Huang, Tingben
   Wang, Yuchen
   Yu, Zhou
   Miao, Xiaoyan
   Jiang, Zhiwei
   Yu, Ke
   Fu, Mengdie
   Lai, Kaichen
   Wang, Ying
   Yang, Guoli
TI Effect of mitophagy in the formation of osteomorphs derived from
   osteoclasts
SO ISCIENCE
LA English
DT Article
ID UP REGULATION; BONE; AUTOPHAGY; OSTEOPOROSIS; DISEASE; CELLS;
   DIFFERENTIATION; PATHOGENESIS; PROTEINS; NFATC1
AB Osteoclasts are specialized multinucleated giant cells with unique bone destroying capacities. A recent study revealed that osteoclasts undergo an alternative cell fate by dividing into daughter cells called osteomorphs. To date, no studies have focused on the mechanisms of osteoclast fission. In this study, we analyzed the alternative cell fate process in vitro and, herein, reported the high expression of mitophagy related proteins during osteoclast fission. Mitophagy was further confirmed by the colocalization of mitochondria with lysosomes, as observed in fluorescence images and transmission electron microscopy. We investigated the role played by mitophagy in osteoclast fission via drug stimulation experiments. The results showed that mitophagy promoted osteoclast division, and inhibition of mitophagy induced osteoclast apoptosis. In summary, this study reveals the role played by mitophagy as the decisive link in osteoclasts' fate, providing a new therapeutic target and perspective for the clinical treatment of osteoclast related diseases.
C1 [Huang, Tingben; Wang, Yuchen; Yu, Zhou; Miao, Xiaoyan; Jiang, Zhiwei; Yu, Ke; Fu, Mengdie; Lai, Kaichen; Wang, Ying; Yang, Guoli] Zhejiang Univ, Canc Ctr, Stomatol Hosp, Zhejiang Prov Clin Res Ctr Oral Dis,Sch Med,Sch St, Hangzhou 310006, Zhejiang, Peoples R China.
   [Huang, Tingben; Wang, Yuchen; Yu, Zhou; Jiang, Zhiwei; Yu, Ke; Fu, Mengdie; Lai, Kaichen; Yang, Guoli] Zhejiang Univ, Affiliated Stomatol Hosp, Dept Implantol, Sch Med, Hangzhou 310006, Zhejiang, Peoples R China.
   [Wang, Ying] Zhejiang Univ, Affiliated Stomatol Hosp, Dept Endodont, Sch Med, Hangzhou 310006, Zhejiang, Peoples R China.
C3 Zhejiang University; Zhejiang University; Zhejiang University
RP Wang, Y; Yang, GL (通讯作者)，Zhejiang Univ, Canc Ctr, Stomatol Hosp, Zhejiang Prov Clin Res Ctr Oral Dis,Sch Med,Sch St, Hangzhou 310006, Zhejiang, Peoples R China.; Yang, GL (通讯作者)，Zhejiang Univ, Affiliated Stomatol Hosp, Dept Implantol, Sch Med, Hangzhou 310006, Zhejiang, Peoples R China.; Wang, Y (通讯作者)，Zhejiang Univ, Affiliated Stomatol Hosp, Dept Endodont, Sch Med, Hangzhou 310006, Zhejiang, Peoples R China.
EM 7314032@zju.edu.cn; guo_li1214@zju.edu.cn
RI ; Wang, Ying/KQU 2949 2024; Yu, Zhou/N 8542 2018
OI Yang, Guoli/0000 0002 1780 8757; Jiang, Zhiwei/0000 0001 8203 6151; 
FU National Natural Science Foundation of China [82201008]; Zhejiang
   Provincial Key Research and Development Program of China [2021C03113]
FX ACKNOWLEDGMENTS This work was supported by the National Natural Science
   Foundation of China (Grant No.: 82201008) and Zhejiang Provincial Key
   Research and Development Program of China (Grant No.: 2021C03113) . We
   thank Yuchen Zhang in the Center of Cryo Electron Microscopy (CCEM) ,
   Zhejiang University, for her technical assistance on transmission
   electron microscopy.
CR Al Bari MAA, 2020, J CELL MOL MED, V24, P11667, DOI 10.1111/jcmm.15879
   An HK, 2020, AUTOPHAGY, V16, P1598, DOI 10.1080/15548627.2019.1695398
   Ang E, 2009, J CELL PHYSIOL, V220, P450, DOI 10.1002/jcp.21787
   Baechler BL, 2019, AUTOPHAGY, V15, P1606, DOI 10.1080/15548627.2019.1591672
   Boyce BF, 2013, J BONE MINER RES, V28, P711, DOI 10.1002/jbmr.1885
   Brunelle JK, 2009, J CELL SCI, V122, P437, DOI 10.1242/jcs.031682
   Burchell VS, 2013, NAT NEUROSCI, V16, P1257, DOI 10.1038/nn.3489
   Chan DC, 2020, ANNU REV PATHOL MECH, V15, P235, DOI 10.1146/annurev pathmechdis 012419 032711
   Choi GE, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 020 20679 y
   Chotiyarnwong P, 2020, NAT REV ENDOCRINOL, V16, P437, DOI 10.1038/s41574 020 0341 0
   Cloonan SM, 2016, NAT MED, V22, P163, DOI 10.1038/nm.4021
   Delgado Camprubi M, 2017, CELL DEATH DIFFER, V24, P120, DOI 10.1038/cdd.2016.104
   Deng CF, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 22454 z
   Deng H, 2013, JAMA NEUROL, V70, P20, DOI 10.1001/jamaneurol.2013.572
   Fan SQ, 2021, AUTOPHAGY, V17, P2305, DOI 10.1080/15548627.2020.1823123
   Fang EF, 2019, NAT NEUROSCI, V22, P401, DOI 10.1038/s41593 018 0332 9
   Hasegawa T, 2019, NAT IMMUNOL, V20, P1631, DOI 10.1038/s41590 019 0526 7
   Jacome Galarza CE, 2019, NATURE, V568, P541, DOI 10.1038/s41586 019 1105 7
   Jansen IDC, 2012, CALCIFIED TISSUE INT, V90, P515, DOI 10.1007/s00223 012 9600 y
   Kim CJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010125
   Komatsu N, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI143060
   Krum SA, 2008, EMBO J, V27, P535, DOI 10.1038/sj.emboj.7601984
   Laha D, 2019, AUTOPHAGY, V15, P2063, DOI 10.1080/15548627.2019.1596491
   Lin QS, 2021, AUTOPHAGY, V17, P2975, DOI 10.1080/15548627.2020.1848971
   Lin QS, 2019, REDOX BIOL, V26, DOI 10.1016/j.redox.2019.101254
   Lindsay R., 2018, J BONE MINER RES
   Ling W, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.146728
   Liu W, 2018, AUTOPHAGY, V14, P1293, DOI 10.1080/15548627.2018.1474991
   Liu Y, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.131834
   Liu YH, 2019, THERANOSTICS, V9, P4648, DOI 10.7150/thno.35414
   Livingston MJ, 2019, AUTOPHAGY, V15, P2142, DOI 10.1080/15548627.2019.1615822
   Ma QY, 2021, BONE RES, V9, DOI 10.1038/s41413 020 00121 1
   Ma QY, 2020, THERANOSTICS, V10, P6825, DOI 10.7150/thno.45170
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   McDonald M.M., 1940, CELL, V184, DOI [10.1016/j., DOI 10.1016/J]
   Moon YJ, 2019, CELL DEATH DIFFER, V26, P2358, DOI 10.1038/s41418 019 0306 9
   Ng MYW, 2021, DEV CELL, V56, P881, DOI 10.1016/j.devcel.2021.02.009
   Nguyen TN, 2016, TRENDS CELL BIOL, V26, P733, DOI 10.1016/j.tcb.2016.05.008
   Okamoto K, 2017, PHYSIOL REV, V97, P1295, DOI 10.1152/physrev.00036.2016
   Palikaras K, 2015, NATURE, V521, P525, DOI 10.1038/nature14300
   Park Min KH, 2019, SEMIN IMMUNOPATHOL, V41, P565, DOI 10.1007/s00281 019 00757 0
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rea SL, 2013, ENDOCR REV, V34, P501, DOI 10.1210/er.2012 1034
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Romeo SG, 2019, NAT CELL BIOL, V21, P430, DOI 10.1038/s41556 019 0304 7
   Rosa N, 2022, CELL DEATH DIFFER, V29, P788, DOI 10.1038/s41418 021 00894 w
   Song HW, 2019, AUTOPHAGY, V15, P1419, DOI 10.1080/15548627.2019.1586246
   Stathakos P, 2021, AUTOPHAGY, V17, P855, DOI 10.1080/15548627.2020.1739441
   Su BH, 2018, IRAN J BASIC MED SCI, V21, P806, DOI 10.22038/IJBMS.2018.29347.7093
   Sun XW, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101309
   Tang CY, 2020, NAT REV NEPHROL, V16, P489, DOI 10.1038/s41581 020 0309 2
   Teresak P, 2022, AUTOPHAGY, V18, P24, DOI 10.1080/15548627.2021.1888244
   Wan MC, 2021, ACTA BIOMATER, V136, P137, DOI 10.1016/j.actbio.2021.09.039
   Wang LJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14146 6
   Wang S, 2020, INT J BIOL SCI, V16, P2675, DOI 10.7150/ijbs.46627
   Wang WZ, 2021, BIOMATERIALS, V276, DOI 10.1016/j.biomaterials.2021.121015
   Wang ZL, 2021, MOL THER, V29, P263, DOI 10.1016/j.ymthe.2020.09.024
   Wei LH, 2022, PHARMACOL RES, V184, DOI 10.1016/j.phrs.2022.106400
   Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108
   Weivoda MM, 2023, J BONE MINER RES, V38, P359, DOI 10.1002/jbmr.4773
   Wong SW, 2020, CELL DEATH DIFFER, V27, P71, DOI 10.1038/s41418 019 0341 6
   Wu HK, 2020, AUTOPHAGY, V16, P683, DOI [10.1080/15548627.2019.1635380, 10.1080/15548627.2019.1596482]
   Xian HX, 2019, AUTOPHAGY, V15, P2107, DOI 10.1080/15548627.2019.1596494
   Xie LL, 2018, CANCER SCI, V109, P3686, DOI 10.1111/cas.13830
   Xu JK, 2009, CYTOKINE GROWTH F R, V20, P7, DOI 10.1016/j.cytogfr.2008.11.007
   Yahara Y, 2020, NAT CELL BIOL, V22, P49, DOI 10.1038/s41556 019 0437 8
   Yamaguchi Y, 2018, CELL MOL LIFE SCI, V75, P33, DOI 10.1007/s00018 017 2607 9
   Yin X, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0058 7
   Zhang T, 2022, AUTOPHAGY, V18, P1216, DOI 10.1080/15548627.2021.1975914
   Zhang Y, 2012, BLOOD, V119, P2895, DOI 10.1182/blood 2011 08 372383
   Zhao SJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 1256 8
   Zhao Y, 2012, J CELL PHYSIOL, V227, P639, DOI 10.1002/jcp.22768
   Zhao YW, 2020, BRAIN, V143, P2220, DOI 10.1093/brain/awaa167
NR 73
TC 11
Z9 11
U1 5
U2 35
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
EI 2589 0042
J9 ISCIENCE
JI iScience
PD MAY 19
PY 2023
VL 26
IS 5
AR 106682
DI 10.1016/j.isci.2023.106682
EA MAY 2023
PG 24
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA I0RN0
UT WOS:000999935300001
PM 37250312
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Hsieh, E
   Fraenkel, L
   Han, Y
   Xia, WB
   Insogna, KL
   Yin, MT
   Zhu, T
   Cheng, XQ
   Li, TS
AF Hsieh, Evelyn
   Fraenkel, Liana
   Han, Yang
   Xia, Weibo
   Insogna, Karl L.
   Yin, Michael T.
   Zhu, Ting
   Cheng, Xinqi
   Li, Taisheng
TI Longitudinal increase in vitamin D binding protein levels after
   initiation of tenofovir/lamivudine/efavirenz among individuals with HIV
SO AIDS
LA English
DT Article
DE bone loss; skeletal metabolism; tenofovir; vitamin D binding protein
ID TENOFOVIR DISOPROXIL FUMARATE; SERUM 25 HYDROXYVITAMIN D; BONE MINERAL
   DENSITY; ANTIRETROVIRAL THERAPY; D DEFICIENCY; ABACAVIR LAMIVUDINE;
   PARATHYROID HORMONE; POSITIVE PATIENTS; CONTROLLED TRIAL; FRACTURE RISK
AB Objective: To examine longitudinal change in vitamin D binding protein (DBP) levels during the first year after initiation of tenofovir disoproxil fumarate (TDF)/lamivudine/efavirenz and compare these findings with concurrent changes in markers of skeletal metabolism.
   Design: Secondary analysis of plasma samples collected from an ongoing multicenter clinical trial.
   Methods: Plasma samples collected at 0, 24, and 48 weeks after initiation of TDF + lamivudine + efavirenz from 134 adult participants enrolled in a multicenter randomized trial were analyzed. Data regarding sociodemographic and clinical characteristics were obtained as part of the parent study. Laboratory analyses included plasma DBP, intact parathyroid hormone, total 25 hydroxy vitamin D, phosphorus, the bone resorption marker collagen type 1 cross linked C telopeptide, and the bone formation marker total procollagen type 1 N terminal propeptide. Repeated measures analysis of variance was used to measure changes in biomarkers over time.
   Results: Our sample included 108 men and 26 women (mean age 33.6 +/  9.6 years). Median levels of DBP increased significantly from baseline to 48 weeks [154 (91.8 257.4) versus 198.3 (119.6 351.9) mu g/ml, P < 0.001]. A concurrent rise in intact parathyroid hormone levels was observed over the same period [32.3 (24.4 40.9) versus 45.2 (35.1 60.4) pg/ml, P < 0.001]; however, 25 hydroxy vitamin D and phosphorus levels remained stable. Bone resorption and formation markers rapidly increased from 0 to 24 weeks, followed by a slight decline or plateau, but remained significantly elevated at 48 weeks (P < 0.001).
   Conclusion: Our study provides longitudinal data supporting a potential role for DBP in bone loss associated with TDF based therapy. Further research to elucidate the mechanistic pathways and clinical impact of these findings is warranted. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.
C1 [Hsieh, Evelyn; Han, Yang; Zhu, Ting; Li, Taisheng] Beijing Union Med Coll Hosp, Dept Infect Dis, Beijing, Peoples R China.
   [Hsieh, Evelyn; Fraenkel, Liana] Yale Sch Med, Rheumatol Sect, New Haven, CT USA.
   [Xia, Weibo] Beijing Union Med Coll Hosp, Dept Endocrinol, Key Lab Endocrinol, Beijing, Peoples R China.
   [Insogna, Karl L.] Yale Sch Med, Endocrinol Sect, New Haven, CT USA.
   [Yin, Michael T.] Columbia Univ, Med Ctr, Div Infect Dis, New York, NY USA.
   [Cheng, Xinqi] Beijing Union Med Coll Hosp, Clin Lab, Beijing, Peoples R China.
C3 Chinese Academy of Medical Sciences   Peking Union Medical College;
   Peking Union Medical College Hospital; Yale University; Chinese Academy
   of Medical Sciences   Peking Union Medical College; Peking Union Medical
   College Hospital; Yale University; Columbia University; Chinese Academy
   of Medical Sciences   Peking Union Medical College; Peking Union Medical
   College Hospital
RP Li, TS (通讯作者)，Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Infect Dis, 1 Shuaifuyuan,Wangfujing St, Beijing 100730, Peoples R China.; Li, TS (通讯作者)，Chinese Acad Med Sci, 1 Shuaifuyuan,Wangfujing St, Beijing 100730, Peoples R China.
EM litsh@263.net
RI ; han, yang/GRS 2388 2022; wang, yi/KBB 3614 2024
OI Insogna, Karl/0000 0001 6973 5679; Hsieh, Evelyn/0000 0001 5018 8409;
   Yin, Michael T/0000 0002 9346 9056; 
FU NCATS NIH HHS [UL1 TR001863] Funding Source: Medline; NIAMS NIH HHS [T32
   AR007107, K24 AR060231] Funding Source: Medline
CR Bahn I, 2014, INT J ENDOCRINOL
   Bedimo R, 2012, AIDS, V26, P825, DOI 10.1097/QAD.0b013e32835192ae
   Bischoff Ferrari HA, 2006, ARCH INTERN MED, V166, P424
   Blanton D, 2011, DIABETES, V60, P2566, DOI 10.2337/db11 0576
   Brown TT, 2011, ANTIVIR THER, V16, P1063, DOI 10.3851/IMP1874
   Brown TT, 2010, ANTIVIR THER, V15, P425, DOI [10.3851/IMP15021, 10.3851/IMP1502]
   Cauley JA, 2011, J BONE MINER RES, V26, P2378, DOI 10.1002/jbmr.449
   Cauley JA, 2010, J BONE MINER RES, V25, P545, DOI 10.1359/jbmr.090826
   Chun RF, 2012, CELL BIOCHEM FUNCT, V30, P445, DOI 10.1002/cbf.2835
   Dao CN, 2011, CLIN INFECT DIS, V52, P396, DOI 10.1093/cid/ciq158
   Denburg MR, 2013, PEDIATR NEPHROL, V28, P1843, DOI 10.1007/s00467 013 2493 9
   Focà E, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471 2334 12 38
   Hamzah L, 2015, AIDS, V29, P1785, DOI 10.1097/QAD.0000000000000760
   Havens PL, 2013, ANTIMICROB AGENTS CH, V57, P5619, DOI 10.1128/AAC.01096 13
   Havens PL, 2012, CLIN INFECT DIS, V54, P1013, DOI 10.1093/cid/cir968
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Hsieh E, 2015, OSTEOPOROSIS INT, V26, P1035, DOI 10.1007/s00198 014 2874 3
   Jeng L, 2009, J TRANSL MED, V7, DOI 10.1186/1479 5876 7 28
   Klassen K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044845
   Lu HK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047264
   Madden K, 2015, ANN AM THORAC SOC, V12, P1654, DOI 10.1513/AnnalsATS.201503 160OC
   Masiá M, 2012, AIDS RES HUM RETROV, V28, P242, DOI [10.1089/aid.2011.0052, 10.1089/AID.2011.0052]
   McComsey GA, 2011, J INFECT DIS, V203, P1791, DOI 10.1093/infdis/jir188
   Moller UK, 2013, NUTRIENTS, V5, P3470, DOI 10.3390/nu5093470
   Nelson MR, 2007, AIDS, V21, P1273, DOI 10.1097/QAD.0b013e3280b07b33
   Ofotokun I, 2016, AIDS, V30, P405, DOI 10.1097/QAD.0000000000000918
   Overton ET, 2015, ANN INTERN MED, V162, P815, DOI 10.7326/M14 1409
   Powe CE, 2011, J BONE MINER RES, V26, P1609, DOI 10.1002/jbmr.387
   Rosenvinge MM, 2010, JAIDS J ACQ IMM DEF, V54, P496, DOI 10.1097/QAI.0b013e3181caebaa
   Stellbrink HJ, 2010, CLIN INFECT DIS, V51, P963, DOI 10.1086/656417
   Stokes CS, 2013, LIVER INT, V33, P338, DOI 10.1111/liv.12106
   Waldron JL, 2013, J CLIN PATHOL, V66, P620, DOI 10.1136/jclinpath 2012 201301
   Woodward CLN, 2009, HIV MED, V10, P482, DOI 10.1111/j.1468 1293.2009.00716.x
   Yombi JC, 2014, AIDS, V28, P621, DOI 10.1097/QAD.0000000000000103
   Yousefzadeh P, 2014, INT J ENDOCRINOL, V2014, DOI 10.1155/2014/981581
   Zhao J, 2011, MENOPAUSE, V18, P1237, DOI 10.1097/gme.0b013e31821d7ff7
NR 36
TC 17
Z9 20
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269 9370
EI 1473 5571
J9 AIDS
JI Aids
PD JUL 31
PY 2016
VL 30
IS 12
BP 1935
EP 1942
DI 10.1097/QAD.0000000000001131
PG 8
WC Immunology; Infectious Diseases; Virology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Infectious Diseases; Virology
GA DR6MK
UT WOS:000380015800010
PM 27124896
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Zhang, Y
   Wei, L
   Miron, RJ
   Zhang, Q
   Bian, Z
AF Zhang, Y.
   Wei, L.
   Miron, R. J.
   Zhang, Q.
   Bian, Z.
TI Prevention of Alveolar Bone Loss in an Osteoporotic Animal Model via
   Interference of Semaphorin 4d
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE anabolic bone formation; osteoporosis; osteopenic; bone remodeling or
   bone metabolism; age related disorder; bisphosphonates
ID PERIODONTAL DISEASE; POSTMENOPAUSAL WOMEN; IN VIVO; GUIDANCE;
   OSTEOCLASTOGENESIS; ASSOCIATION; HOMEOSTASIS; EXPRESSION; RECEPTORS;
   SCAFFOLDS
AB Semaphorin 4d (Sema4d) has been proposed as a novel target gene for the treatment of osteoporosis. Recently, we fabricated a site specific bone targeting system from polymeric nanoparticles that demonstrates an ability to prevent bone loss in an osteoporotic model by interfering with Sema4d gene expression using small interference RNA (siRNA) molecules. The aim of the present investigation was to determine the effects of this targeting system on the periodontium, an area of high bone turnover. We demonstrated, by single photon emission computed tomography, that intravenous injection of this molecule in ovariectomized Balb/C mice is able to target alveolar bone peaking 4 hr post injection. We then compared, by histological analysis, the bone volume/total volume (BV/TV), alveolar bone height loss, immunohistochemical expression of Sema4d, and total number of osteoclasts in mandibular alveolar bone. Four treatment modalities were compared as follows: (1) sham operated, (2) OVX operated, (3) OVX+estrogen replacement therapy, and (4) OVX+siRNA Sema4d animals. The results from the present study demonstrate that an osteoporotic condition significantly increases alveolar bone height loss, and that the therapeutic effects via bone targeting systems featuring interference of Sema4d are able to partly counteract alveolar bone loss caused by osteoporosis. While the future therapeutic demand for the large number of patients suffering from osteoporosis faces many challenges, we demonstrate within the present study an effective drug delivery moiety with anabolic effects on the bone remodeling cycle able to locate and target alveolar bone regeneration.
C1 [Zhang, Y.; Wei, L.; Miron, R. J.; Zhang, Q.; Bian, Z.] Wuhan Univ, State Key Lab Breeding Base Basic Sci Stomatol Hu, Sch & Hosp Stomatol, Minist Educ, Wuhan 430072, Peoples R China.
   [Zhang, Y.; Wei, L.; Miron, R. J.; Zhang, Q.; Bian, Z.] Wuhan Univ, Key Lab Oral Biomed, Sch & Hosp Stomatol, Minist Educ, Wuhan 430072, Peoples R China.
   [Zhang, Y.] Wuhan Univ, Dept Dent Implantol, Sch & Hosp Stomatol, Wuhan 430072, Peoples R China.
C3 Wuhan University; Wuhan University; Wuhan University
RP Bian, Z (通讯作者)，Wuhan Univ, State Key Lab Breeding Base Basic Sci Stomatol Hu, Sch & Hosp Stomatol, Minist Educ, Wuhan 430072, Peoples R China.
EM bianzhuan@whu.edu.cn
RI ; Zhang, Qingjun/GSI 4342 2022; Zhang, Yufeng/GZL 1973 2022; Wei,
   Lingfei/AAM 4323 2020; Miron, Richard/J 4995 2012
OI Zhang, Yufeng/0000 0001 8702 5291; 
FU Program for New Century Excellent Talents in University [NCET 11 0414];
   National Natural Science Foundation of China [81271108, 81120108010];
   Pre National Basic Research Program of China (973 Plan) [2012CB722404]
FX This work was supported by the Program for New Century Excellent Talents
   in University (NCET 11 0414), by funds from the National Natural Science
   Foundation of China [81271108 to Y.F. Zhang, and 81120108010
   (international cooperation and exchange projects) to Z. Bian], and by
   the Pre National Basic Research Program of China (973 Plan)
   (2012CB722404 to Z. Bian). The authors declare no potential conflicts of
   interest with respect to the authorship and/or publication of this
   article.
CR Cheng N, 2013, J MATER SCI MATER M, V24, P1963, DOI 10.1007/s10856 013 4945 y
   Delorme G, 2005, BIOL CELL, V97, P589
   Dickson BJ, 2002, SCIENCE, V298, P1959, DOI 10.1126/science.1072165
   Fukuda T, 2013, NATURE, V497, P490, DOI 10.1038/nature12115
   Genant HK, 1999, OSTEOPOROSIS INT, V10, P259, DOI 10.1007/s001980050224
   GRUBER HE, 1986, MINER ELECTROL METAB, V12, P246
   Hao YJ, 2007, BONE, V41, P631, DOI 10.1016/j.bone.2007.06.006
   Hayashi M, 2012, NATURE, V485, P69, DOI 10.1038/nature11000
   Huber AB, 2003, ANNU REV NEUROSCI, V26, P509, DOI 10.1146/annurev.neuro.26.010302.081139
   Irie N, 2009, J BIOL CHEM, V284, P14637, DOI 10.1074/jbc.M807598200
   Janssen BJC, 2010, NATURE, V467, P1118, DOI 10.1038/nature09468
   KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802
   Larrivée B, 2009, CIRC RES, V104, P428, DOI 10.1161/CIRCRESAHA.108.188144
   Leah Emma, 2011, Nat Rev Rheumatol, V7, P681, DOI 10.1038/nrrheum.2011.175
   Luo T, 2012, J BIOMED MATER RES A, V100A, P2269, DOI 10.1002/jbm.a.34161
   Moazzaz P, 2005, SPINE, V30, P1706, DOI 10.1097/01.brs.0000172230.01655.55
   Namkung Matthai H, 2001, BONE, V28, P80, DOI 10.1016/S8756 3282(00)00414 2
   Negishi Koga T, 2011, NAT MED, V17, P1473, DOI 10.1038/nm.2489
   Ohlsson C, 2013, NAT REV ENDOCRINOL, V9, P72, DOI 10.1038/nrendo.2012.252
   Passos JD, 2010, J PERIODONTOL, V81, P1773, DOI 10.1902/jop.2010.100143
   Rawlinson SCF, 2009, J DENT RES, V88, P615, DOI 10.1177/0022034509340132
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Roush K, 2011, AM J NURS, V111, P26, DOI 10.1097/01.NAJ.0000403358.44058.f7
   Silva BC, 2011, ANNU REV MED, V62, P307, DOI 10.1146/annurev med 061709 145401
   Sultan N, 2011, MED ORAL PATOL ORAL, V16, pE440, DOI 10.4317/medoral.16.e440
   Sutton ALM, 2008, MOL ENDOCRINOL, V22, P1370, DOI 10.1210/me.2007 0363
   Suzuki K, 2008, NAT IMMUNOL, V9, P17, DOI 10.1038/ni1553
   Takegahara N, 2006, NAT CELL BIOL, V8, P615, DOI 10.1038/ncb1416
   Tamagnone L, 2000, TRENDS CELL BIOL, V10, P377, DOI 10.1016/S0962 8924(00)01816 X
   Tönges L, 2006, RNA, V12, P1431, DOI 10.1261/rna.2252206
   Tran TS, 2007, ANNU REV CELL DEV BI, V23, P263, DOI 10.1146/annurev.cellbio.22.010605.093554
   Tuominen VJ, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2615
   VONWOWERN N, 1994, J PERIODONTOL, V65, P1134, DOI 10.1902/jop.1994.65.12.1134
   Wang D, 2006, MOL PHARMACEUT, V3, P717, DOI 10.1021/mp0600539
   Wang Y, 2010, CURR DRUG METAB, V11, P182, DOI 10.2174/138920010791110863
   Yang S, 2014, CLIN IMPLAN IN PRESS
   Yuan HP, 2013, P NATL ACAD SCI USA, V110, pE5059, DOI 10.1073/pnas.1320862110
   Zhang Y, 2014, J BONE MINE IN PRESS
   Zhang YF, 2012, BIOMATERIALS, V33, P6698, DOI 10.1016/j.biomaterials.2012.06.021
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
NR 40
TC 31
Z9 36
U1 1
U2 19
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022 0345
EI 1544 0591
J9 J DENT RES
JI J. Dent. Res.
PD NOV
PY 2014
VL 93
IS 11
BP 1095
EP 1100
DI 10.1177/0022034514552676
PG 6
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA AS0NU
UT WOS:000343975100008
PM 25252878
OA Green Published
DA 2025 08 17
ER

PT J
AU Duong, LT
   Clark, S
   Pickarski, M
   Giezek, H
   Cohn, D
   Massaad, R
   Stoch, SA
AF Duong, L. T.
   Clark, S.
   Pickarski, M.
   Giezek, H.
   Cohn, D.
   Massaad, R.
   Stoch, S. A.
TI Effects of odanacatib on bone turnover markers in osteoporotic
   postmenopausal women: a post hoc analysis of the LOFT study
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Biochemical markers of bone turnover; Cathepsin K; Collagen;
   Osteoclasts; Osteoporosis
ID C TERMINAL TELOPEPTIDE; I COLLAGEN; CATHEPSIN K; DIAGNOSIS; FRAGMENTS;
   THERAPY; DISEASE; SERUM
AB This post hoc analysis and modeling study examined the mechanism of action of odanacatib using a statistical model to explain sCTx response in ODN treated patients as a function of other bone turnover biomarkers that, with other observed biomarker changes, showed that odanacatib persistently inhibited osteoclastic bone removal activity without preventing osteoclastogenesis. Introduction Odanacatib (ODN) is an oral selective cathepsin K (CatK) inhibitor, previously in development for osteoporosis treatment. A post hoc analysis examined ODN's mechanism of action on bone turnover biomarkers. Methods A subset of patients who completed 60 months' treatment in the Long Term Odanacatib Fracture Trial (LOFT; NCT00529373) (N = 112 [57 ODN, 55 placebo]) were evaluated. Serum (s) and urine (u) samples were assayed at baseline and months 6 60 for 10 known bone remodeling biomarkers: sCTx, u alpha alpha  and u beta beta CTx/Cr, uNTx/Cr, sNTx, uDPD/Cr, sICTP, sTRAP5b, sPINP, and sBSAP. Because the CrossLaps (R) CTx assay identifies the CTx peptide as well as larger molecular weight CTx containing peptides, including ICTP, a best fit model was developed to explain the transient sCTx reduction in ODN treated patients. Results ODN persistently reduced the bone resorption markers sNTx, uNTx/Cr, u alpha alpha  and u beta beta CTx/Cr, and uDPD/Cr, and gradually increased the target engagement marker sICTP and osteoclast number (sTRAP5b), versus placebo from baseline to month 60. sCTx was transiently reduced with ODN within 12 months, returning to baseline by month 48. Modeling suggested that sCTx changes in the ODN group were primarily due to increased accumulation of larger CTx species, including sICTP. The bone formation markers sPINP and sBSAP showed partial reductions, versus placebo, in the first 6 months but approached baseline by months 48 60. Conclusion Observed changes in bone turnover biomarkers support the persistent efficacy of ODN in direct inhibition of osteoclastic bone resorption activity, without inhibition of osteoclastogenesis. Long term evaluation also underscores the unique mechanism of ODN on osteoclastic collagen processing and subsequently osteoblastic bone formation.
C1 [Duong, L. T.; Clark, S.; Pickarski, M.; Cohn, D.; Stoch, S. A.] Merck & Co Inc, Rahway, NJ 07065 USA.
   [Giezek, H.; Massaad, R.] MSD Europe Inc, Brussels, Belgium.
C3 Merck & Company; Merck & Company USA; Merck & Company; Merck & Comany
   Belgium
RP Clark, S (通讯作者)，Merck & Co Inc, Rahway, NJ 07065 USA.
EM seth_clark@merck.com
OI Clark, Seth/0000 0003 3907 2215
FU Merck Sharp Dohme LLC
FX Funding for this research was provided by Merck Sharp & Dohme LLC, a
   subsidiary of Merck & Co., Inc., Rahway, NJ, USA. The study sponsor was
   involved in the study design, collection, analysis and interpretation of
   data, and writing of the report. Although a clearance review of this
   manuscript was performed by the sponsor to protect intellectual property
   or competitive information and prevent inadvertent disclosure, all
   authors had access to the study data, contributed to the development of
   this manuscript, approved content, and agreed with the decision to
   submit for publication.
CR BEARDSWORTH LJ, 1990, J BONE MINER RES, V5, P671
   Bone HG, 2015, OSTEOPOROSIS INT, V26, P699, DOI 10.1007/s00198 014 2944 6
   Cloos PAC, 2003, CALCIFIED TISSUE INT, V72, P8, DOI 10.1007/s00223 002 2034 1
   Colwell A, 1996, J BONE MINER RES, V11, P1976
   Crofton PM, 2002, CLIN CHEM, V48, P671
   Duong Le T, 2012, Bonekey Rep, V1, P67, DOI 10.1038/bonekey.2012.67
   Eastell R, 2000, J BONE MINER RES, V15, P594, DOI 10.1359/jbmr.2000.15.3.594
   Eisman JA, 2011, J BONE MINER RES, V26, P242, DOI 10.1002/jbmr.212
   Fledelius C, 1997, J BIOL CHEM, V272, P9755
   Garnero P, 1997, J BONE MINER RES, V12, P1407, DOI 10.1359/jbmr.1997.12.9.1407
   Garnero P, 2003, J BONE MINER RES, V18, P859, DOI 10.1359/jbmr.2003.18.5.859
   Garnero P, 1998, J BIOL CHEM, V273, P32347, DOI 10.1074/jbc.273.48.32347
   Garnero P, 1999, J BONE MINER RES, V14, P1614, DOI 10.1359/jbmr.1999.14.9.1614
   Garnero P, 2008, MOL DIAGN THER, V12, P157, DOI 10.1007/BF03256280
   Immunodiagnostic Systems, 2017, SER CROSSL CTX I ELI
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Kuo TR, 2017, BIOMARK RES, V5, DOI 10.1186/s40364 017 0097 4
   Langdahl B, 2012, J BONE MINER RES, V27, P2251, DOI 10.1002/jbmr.1695
   Leung P, 2011, BONE, V49, P623, DOI 10.1016/j.bone.2011.06.014
   McClung MR, 2019, LANCET DIABETES ENDO, V7, P899, DOI 10.1016/S2213 8587(19)30346 8
   Pennypacker BL, 2016, J ORTHOP RES, V34, P72, DOI 10.1002/jor.22982
   Recker R, 2020, J BONE MINER RES, V35, P1289, DOI 10.1002/jbmr.3994
   Sassi ML, 2000, BONE, V26, P367, DOI 10.1016/S8756 3282(00)00235 0
   Vonesh EF, 2014, GEN LINEAR NONLINEAR, P205
   Yamauchi M, 2012, ESSAYS BIOCHEM, V52, P113, DOI [10.1042/BSE0520113, 10.1042/bse0520113]
   Zaitseva O V, 2015, Ukr Biochem J, V87, P21
NR 26
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD OCT
PY 2022
VL 33
IS 10
BP 2165
EP 2175
DI 10.1007/s00198 022 06406 x
EA JUN 2022
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 5D6LS
UT WOS:000811964800001
PM 35711006
DA 2025 08 17
ER

PT J
AU Yukata, K
   Xie, C
   Li, TF
   Takahata, M
   Hoak, D
   Kondabolu, S
   Zhang, XP
   Awad, HA
   Schwarz, EM
   Beck, CA
   Jonason, JH
   O'Keefe, RJ
AF Yukata, Kiminori
   Xie, Chao
   Li, Tian Fang
   Takahata, Masahiko
   Hoak, Donna
   Kondabolu, Sirish
   Zhang, Xinping
   Awad, Hani A.
   Schwarz, Edward M.
   Beck, Christopher A.
   Jonason, Jennifer H.
   O'Keefe, Regis J.
TI Aging periosteal progenitor cells have reduced regenerative
   responsiveness to bone injury and to the anabolic actions of PTH 1 34
   treatment
SO BONE
LA English
DT Article
DE Fracture healing; Parathyroid hormone; Periosteum; Wnt beta catenin
   signaling; Mesenchymal stem cell
ID PARATHYROID HORMONE 1 34; FRACTURE REPAIR; AGED MICE; MECHANICAL
   STRENGTH; FEMORAL FRACTURES; CALLUS FORMATION; CANCELLOUS BONE;
   UP REGULATION; HIP FRACTURE; OLDER RATS
AB A stabilized tibia fracture model was used in young (8 week old) and aged (1 year old) mice to define the relative bone regenerative potential and the relative responsiveness of the periosteal progenitor population with aging and PTH 1 34 (PTH) systemic therapy. Bone regeneration was assessed through gene expressions, radiographic imaging, histology/histomorphometry, and biomechanical testing. Radiographs and microCT showed increased calcified callus tissue and enhanced bone healing in young compared to aged mice. A key mechanism involved reduced proliferation, expansion, and differentiation of periosteal progenitor cell populations in aged mice. The experiments showed that PTH increased calcified callus tissue and torsional strength with a greater response in young mice. Histology and quantitative histomorphometry confirmed that PTH increased callus tissue area due primarily to an increase in bone formation, since minimal changes in cartilage and mesenchyme tissue area occurred. Periosteum examined at 3, 5, and 7 days showed that PTH increased cyclin D1 expression, the total number of cells in the periosteum, and width of the periosteal regenerative tissue. Gene expression showed that aging delayed differentiation of both bone and cartilage tissues during fracture healing. PTH resulted in sustained Col10a1 expression consistent with delayed chondrocyte maturation, but otherwise minimally altered cartilage gene expression. In contrast, PTH 1 34 stimulated expression of Runx2 and Osterix, but resulted in reduced Osteocalcin. beta Catenin staining was present in mesenchymal chondroprogenitors and chondrocytes in early fracture healing, but was most intense in osteoblastic cells at later times. PTH increased active beta catenin staining in the osteoblast populations of both young and aged mice, but had a lesser effect in cartilage. Altogether the findings show that reduced fracture healing in aging involves decreased proliferation and differentiation of stem cells fining the bone surface. While PTH 1 34 enhances the proliferation and expansion of the periosteai stem cell population and accelerates bone formation and fracture healing, the effects are proportionately reduced in aged mice compared to young mice. beta Catenin is induced by PTH in early and late fracture healing and is a potential target of PTH 1 34 effects. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Xie, Chao; Li, Tian Fang; Takahata, Masahiko; Hoak, Donna; Kondabolu, Sirish; Zhang, Xinping; Awad, Hani A.; Schwarz, Edward M.; Jonason, Jennifer H.; O'Keefe, Regis J.] Univ Rochester, Ctr Musculoskeletal Res, Rochester, NY 14642 USA.
   [Beck, Christopher A.] Univ Rochester, Dept Biostat & Computat Biol, Rochester, NY 14642 USA.
   [Yukata, Kiminori] Tokushima Univ Hosp, Dept Orthoped, Tokushima, Japan.
C3 University of Rochester; University of Rochester; Tokushima University
RP O'Keefe, RJ (通讯作者)，Univ Rochester, Ctr Musculoskeletal Res, Box 665,601 Elmwood Ave, Rochester, NY 14642 USA.
EM Kiminori_Yukata@URMC.Rochester.edu; Chao_Xie@URMC.Rochester.edu;
   TianFang_Li@URMC.Rochester.edu; Masahiko_Takahata@URMC.Rochester.edu;
   Sirish_Kondabolu@URMC.Rochester.edu; Xinping_Zhang@URMC.Rochester.edu;
   Hani_Awad@URMCRochester.edu; Edward_Schwarz@URMC.Rochester.edu;
   Beck@BST.Rochester.edu; Jennifer_Jonason@URMCRochester.edu;
   Regis_OKeefe@URMC.Rochester.edu
RI Awad, Hani/G 6976 2014; Takahata, Masahiko/E 1929 2012; Mostafa,
   Taymour/H 6834 2019; Kiminori, Yukata/S 1331 2019
OI Awad, Hani/0000 0003 2197 2610; Xie, Chao/0000 0001 6197 2506; 
FU National Health Services awards NIH [RO1 AR48681]; NIH [P50, AR054041]
FX We would like to thank Ryan Tierry, Sarah Mack and Nehal Porecha for
   their assistance with histological work and Michael Thullen for microCT
   analyses. This study is supported by National Health Services awards NIH
   RO1 AR48681 and NIH P50, AR054041.
CR Alkhiary YM, 2005, J BONE JOINT SURG AM, V87A, P731, DOI 10.2106/JBJS.D.02115
   Andreassen TT, 1999, J BONE MINER RES, V14, P960, DOI 10.1359/jbmr.1999.14.6.960
   Andreassen TT, 2001, ACTA ORTHOP SCAND, V72, P304, DOI 10.1080/00016470152846673
   Baron R, 2012, J CLIN ENDOCR METAB, V97, P311, DOI 10.1210/jc.2011 2332
   Becker David J, 2010, Curr Rheumatol Rep, V12, P186, DOI 10.1007/s11926 010 0097 y
   Chen Y, 2007, PLOS MED, V4, P1216, DOI 10.1371/journal.pmed.0040249
   Colnot C, 2009, J BONE MINER RES, V24, P274, DOI 10.1359/JBMR.081003
   Cutler DM, 2012, NEW ENGL J MED, V366, P1075, DOI 10.1056/NEJMp1113361
   Doyon A, 2010, CALCIFIED TISSUE INT, V87, P68, DOI 10.1007/s00223 010 9370 3
   Fan W, 2008, BONE, V42, P81, DOI 10.1016/j.bone.2007.08.048
   Friedl G, 2007, J ORTHOP RES, V25, P1454, DOI 10.1002/jor.20433
   Gerstenfeld LC, 2003, J CELL BIOCHEM, V88, P873, DOI 10.1002/jcb.10435
   Gruber R, 2006, EXP GERONTOL, V41, P1080, DOI 10.1016/j.exger.2006.09.008
   Hanyu R, 2012, P NATL ACAD SCI USA, V109, P7433, DOI 10.1073/pnas.1109036109
   Hardy Rowan, 2011, Front Endocrinol (Lausanne), V2, P24, DOI 10.3389/fendo.2011.00024
   Hee HT, 2001, ACTA ORTHOP SCAND, V72, P385, DOI 10.1080/000164701753542050
   Histing T, 2011, BONE, V49, P591, DOI 10.1016/j.bone.2011.07.007
   Kaback LA, 2008, J CELL BIOCHEM, V105, P219, DOI 10.1002/jcb.21816
   Kakar S, 2007, J BONE MINER RES, V22, P1903, DOI 10.1359/JBMR.070724
   Kim JB, 2007, J BONE MINER RES, V22, P1913, DOI 10.1359/JBMR.070802
   Kraenzlin ME, 2011, NAT REV ENDOCRINOL, V7, P647, DOI 10.1038/nrendo.2011.108
   Kwong FNK, 2008, J AM ACAD ORTHOP SUR, V16, P619, DOI 10.5435/00124635 200811000 00001
   Li CY, 2011, BONE, V49, P1178, DOI 10.1016/j.bone.2011.08.012
   Li M, 2007, INT ORTHOP, V31, P767, DOI 10.1007/s00264 007 0406 x
   Li TF, 2006, J BIOL CHEM, V281, P21296, DOI 10.1074/jbc.M600514200
   Li XD, 2011, J BONE MINER RES, V26, P2610, DOI 10.1002/jbmr.472
   Lindsay R, 2007, J BONE MINER RES, V22, P495, DOI 10.1359/JBMR.070104
   Ling L, 2009, GENE, V433, P1, DOI 10.1016/j.gene.2008.12.008
   Lloyd BD, 2009, J GERONTOL A BIOL, V64, P599, DOI 10.1093/gerona/glp003
   Lu CY, 2008, J ORTHOP RES, V26, P1384, DOI 10.1002/jor.20667
   Lu CY, 2005, J ORTHOP RES, V23, P1300, DOI 10.1016/j.orthres.2005.04.003
   Lui JC, 2011, ENDOCR DEV, V20, P187, DOI 10.1159/000321244
   Mangione KK, 2010, J AM GERIATR SOC, V58, P1911, DOI 10.1111/j.1532 5415.2010.03076.x
   Mehta M, 2010, BONE, V47, P219, DOI 10.1016/j.bone.2010.05.029
   Meyer MH, 2007, J ORTHOP RES, V25, P488, DOI 10.1002/jor.20334
   Meyer RA, 2003, J BONE JOINT SURG AM, V85A, P1243, DOI 10.2106/00004623 200307000 00010
   Misof BM, 2010, J BONE MINER RES, V25, P2297, DOI 10.1002/jbmr.198
   Naik AA, 2009, J BONE MINER RES, V24, P251, DOI [10.1359/jbmr.081002, 10.1359/JBMR.081002]
   Nakazawa T, 2005, BONE, V37, P711, DOI 10.1016/j.bone.2005.06.013
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   NIEMINEN S, 1981, ANN CHIR GYNAECOL, V70, P26
   NILSSON BE, 1969, GERIATRICS, V24, P112
   Nozaka K, 2008, BONE, V42, P90, DOI 10.1016/j.bone.2007.08.041
   O'Driscoll SWM, 2001, J ORTHOPAED RES, V19, P95, DOI 10.1016/S0736 0266(00)00014 0
   Ominsky MS, 2011, J BONE MINER RES, V26, P1012, DOI 10.1002/jbmr.307
   Ono N, 2012, J CELL PHYSIOL, V227, P408, DOI 10.1002/jcp.22986
   Paralkar VM, 2003, P NATL ACAD SCI USA, V100, P6736, DOI 10.1073/pnas.1037343100
   Park JY, 2006, CLIN IMMUNOL, V119, P229, DOI 10.1016/j.clim.2006.01.016
   Reynolds DG, 2011, BONE, V48, P562, DOI 10.1016/j.bone.2010.10.003
   Rhee Y, 2011, J BONE MINER RES, V26, P1035, DOI 10.1002/jbmr.304
   Romero G, 2010, J BIOL CHEM, V285, P14756, DOI 10.1074/jbc.M110.102970
   Seeman E, 2007, OSTEOPOROSIS INT, V18, P123, DOI 10.1007/s00198 006 0296 6
   Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963
   Sims NA, 2010, J BONE MINER RES, V25, P175, DOI 10.1002/jbmr.53
   Sugimoto Y, 2007, J BIOL CHEM, V282, P11613, DOI 10.1074/jbc.R600038200
   Sun P, 2010, CALCIFIED TISSUE INT, V86, P495, DOI 10.1007/s00223 010 9363 2
   Tägil M, 2010, BONE, V46, P852, DOI 10.1016/j.bone.2009.11.009
   Tanaka M, 2004, BONE, V34, P940, DOI 10.1016/j.bone.2004.01.002
   Turner C. H., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P342
   Wahl EC, 2010, J BONE MINER RES, V25, P114, DOI 10.1359/jbmr.090708
   Wan M, 2008, GENE DEV, V22, P2968, DOI 10.1101/gad.1702708
   Xie C, 2009, AM J PATHOL, V175, P772, DOI 10.2353/ajpath.2009.081099
   Xie C, 2008, BONE, V43, P1075, DOI 10.1016/j.bone.2008.08.109
   Xing ZQ, 2010, J ORTHOP RES, V28, P1000, DOI 10.1002/jor.21087
   Yu YY, 2010, BONE, V47, P65, DOI 10.1016/j.bone.2010.03.012
   Zhang XP, 2005, J BONE MINER RES, V20, P2124, DOI 10.1359/JBMR.050806
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
   Zidén L, 2010, DISABIL REHABIL, V32, P18, DOI 10.3109/09638280902980910
NR 68
TC 64
Z9 76
U1 1
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAY
PY 2014
VL 62
BP 79
EP 89
DI 10.1016/j.bone.2014.02.002
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AD6NU
UT WOS:000333378300013
PM 24530870
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Li, MY
   Wang, YM
   Xue, J
   Xu, QQ
   Zhang, YR
   Liu, J
   Xu, H
   Guan, Z
   Bian, CY
   Zhang, GD
   Yu, Y
AF Li, Mengyuan
   Wang, Yumeng
   Xue, Jing
   Xu, Qingqing
   Zhang, Yuerong
   Liu, Jie
   Xu, Hai
   Guan, Zhuo
   Bian, Chengyue
   Zhang, Guangdong
   Yu, Yan
TI Baicalin can enhance odonto/osteogenic differentiation of inflammatory
   dental pulp stem cells by inhibiting the NF κB and β catenin/Wnt
   signaling pathways
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article
DE Baicalin; Dental pulp stem cells; Nuclear factor kappa B;
   beta catenin/Wnt signaling pathway; Odonto/osteogenic differentiation
ID GROWTH FACTOR 1; SCUTELLARIA BAICALENSIS; IN VITRO; OSTEOGENESIS;
   RESORPTION; ACTIVATOR; PROMOTE; KINASE; MODEL
AB Background Scutellaria baicalensis Georgi is a famous traditional Chinese medicine, which is widely used in treating fever, upper respiratory tract infection and other diseases. Pharmacology study showed it can exhibit anti bacterial, anti inflammation and analgesic effects. In this study, we investigated the effect of baicalin on the odonto/osteogenic differentiation of inflammatory dental pulp stem cells (iDPSCs).
   Methods and results iDPSCs were isolated from the inflamed pulps collected from pulpitis. The proliferation of iDPSCs was detected by 3 (4,5 dimethylthiazol 2 yl) 2,5 diphenyl 2,5 tetrazolium bromide (MTT) assay and flow cytometry. Alkaline phosphatase (ALP) activity assay, alizarin red staining, Real time reverse transcription polymerase chain reaction (RT PCR) and Western blot assay were conducted to examine the differentiation potency along with the involvement of nuclear factor kappa B(NF kappa B) and beta catenin/Wnt signaling pathway. MTT assay and cell cycle analysis demonstrated that baicalin had no influence on the proliferation of iDPSCs. ALP activity assay and alizarin red staining demonstrated that baicalin could obviously enhance ALP activity and calcified nodules formed in iDPSCs. RT PCR and Western blot showed that the odonto/ osteogenic markers were upregulated in baicalin treated iDPSCs. Moreover, expression of cytoplastic phosphor P65, nuclear P65, and beta catenin in iDPSCs was significantly increased compared with DPSCs, but the expression in baicalin treated iDPSCs was inhibited. In addition, 20 mu M Baicalin could accelerate odonto/osteogenic differentiation of iDPSCs via inhibition of NF kappa B and beta catenin/Wnt signaling pathways.
   Conclusion Baicalin can promote odonto/osteogenic differentiation of iDPSCs through inhibition of NF kappa B and beta catenin/Wnt pathways, thus providing direct evidence that baicalin may be effective in repairing pulp with early irreversible pulpitis.
C1 [Li, Mengyuan; Wang, Yumeng; Xu, Qingqing; Zhang, Yuerong; Liu, Jie; Xu, Hai; Guan, Zhuo; Bian, Chengyue; Zhang, Guangdong; Yu, Yan] Nanjing Med Univ, Jiangsu Key Lab Oral Dis, Shang Hai Rd 1Th, Nanjing 210029, Jiangsu, Peoples R China.
   [Xue, Jing] Changsha Tradit Chinese Med Hosp, Dept Crit Care, Changsha, Hunan, Peoples R China.
   [Xu, Hai; Yu, Yan] Nanjing Med Univ, Affiliated Hosp Stomatol, Dept Conservat Dent & Endodont, Shang Hai Rd 1Th, Nanjing, Jiangsu, Peoples R China.
   [Li, Mengyuan; Wang, Yumeng; Xu, Qingqing; Zhang, Yuerong; Liu, Jie; Guan, Zhuo; Bian, Chengyue; Zhang, Guangdong] Nanjing Med Univ, Affiliated Hosp Stomatol, Dept Gen Dent, Shang Hai Rd 1Th, Nanjing, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University; Nanjing Medical
   University
RP Zhang, GD; Yu, Y (通讯作者)，Nanjing Med Univ, Jiangsu Key Lab Oral Dis, Shang Hai Rd 1Th, Nanjing 210029, Jiangsu, Peoples R China.; Yu, Y (通讯作者)，Nanjing Med Univ, Affiliated Hosp Stomatol, Dept Conservat Dent & Endodont, Shang Hai Rd 1Th, Nanjing, Jiangsu, Peoples R China.; Zhang, GD (通讯作者)，Nanjing Med Univ, Affiliated Hosp Stomatol, Dept Gen Dent, Shang Hai Rd 1Th, Nanjing, Jiangsu, Peoples R China.
EM 644927169@qq.com; 1875154596@qq.com; xuej0521@163.com;
   laporteduciel@163.com; 812124327@qq.com; 2834999474@qq.com;
   598904131@qq.com; 3272313221@qq.com; 1032180986@qq.com;
   egd_zhang@njmu.edu.cn; yuyan0102@163.com
RI Xu, Hai/KLD 4095 2024; XU, Qingqing/LUZ 9328 2024; wang,
   yumeng/KVY 4584 2024
FU Priority Academic Program Development of Jiangsu Higher Education
   Institutions [PAPD_2018 87]; Natural Science Foundation of Jiangsu
   Province [BK_20191347]
FX AcknowledgementsThis research was supported by the Priority Academic
   Program Development of Jiangsu Higher Education Institutions (grant
   number PAPD_2018 87) and Natural Science Foundation of Jiangsu Province
   (grant number BK_20191347).
CR An HJ, 2022, CELLS BASEL, V11, DOI 10.3390/cells11193076
   Arora S, 2021, INT ENDOD J, V54, P1263, DOI 10.1111/iej.13524
   Astudillo P, 2014, CURR MOL MED, V14, P209, DOI 10.2174/1566524014666140128105352
   Burns VE, 2021, J IMMUNOL, V207, P1437, DOI 10.4049/jimmunol.2100355
   Cao DX, 2012, WORLD J GASTROENTERO, V18, P3923, DOI 10.3748/wjg.v18.i30.3923
   Capece D, 2022, TRENDS IMMUNOL, V43, P757, DOI 10.1016/j.it.2022.07.004
   Chang J, 2005, J DENT RES, V84, P994, DOI 10.1177/154405910508401105
   Chen J, 2015, CAN J PHYSIOL PHARM, V93, P233, DOI 10.1139/cjpp 2014 0262
   Cheng XY, 2022, POULTRY SCI, V101, DOI 10.1016/j.psj.2021.101572
   CHUNG CP, 1995, PLANTA MED, V61, P150, DOI 10.1055/s 2006 958036
   Ciesielska A, 2021, CELL MOL LIFE SCI, V78, P1233, DOI 10.1007/s00018 020 03656 y
   De Luca F, 2020, MOL CELL ENDOCRINOL, V514, DOI 10.1016/j.mce.2020.110916
   Fu YJ, 2021, ACTA PHARMACOL SIN, V42, P88, DOI 10.1038/s41401 020 0411 9
   Giraud T, 2019, DENT MATER, V35, P24, DOI 10.1016/j.dental.2018.09.008
   Gopinathan G, 2023, GENES BASEL, V14, DOI 10.3390/genes14010201
   Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797
   Gu YZ, 2024, ORAL DIS, V30, P1429, DOI 10.1111/odi.14523
   Guan XY, 2022, J PERIODONTOL, V93, P1589, DOI 10.1002/JPER.21 0474
   Guo AJY, 2011, J BIOL CHEM, V286, P27882, DOI 10.1074/jbc.M111.236281
   Guo B, 2021, J MATER CHEM B, V9, P9720, DOI 10.1039/d1tb00618e
   Guo L, 2022, INT IMMUNOPHARMACOL, V108, DOI 10.1016/j.intimp.2022.108757
   Inostroza C, 2020, J ENDODONT, V46, P1091, DOI 10.1016/j.joen.2020.05.003
   Jin SE, 2022, BIOACT MATER, V8, P559, DOI 10.1016/j.bioactmat.2021.06.028
   Kim E, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24010329
   Komori T, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23105776
   Liao J, 2011, J ENDODONT, V37, P1217, DOI 10.1016/j.joen.2011.05.022
   Lin P, 2020, J INT MED RES, V48, DOI 10.1177/0300060520955070
   Liu C, 2022, CELL DEATH DISCOV, V8, DOI 10.1038/s41420 022 00900 1
   Liu JQ, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392 021 00762 6
   Liu Y, 2023, INT ENDOD J, V56, P92, DOI 10.1111/iej.13843
   Maeda K, 2013, J MOL MED, V91, P15, DOI 10.1007/s00109 012 0974 0
   Marrelli M, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01685
   Park JC, 2011, J CLIN PERIODONTOL, V38, P721, DOI 10.1111/j.1600 051X.2011.01716.x
   Pereira LO, 2012, INT ENDOD J, V45, P1080, DOI 10.1111/j.1365 2591.2012.02068.x
   Qian GW, 2023, APPL SURF SCI, V614, DOI 10.1016/j.apsusc.2022.156108
   Rothermund K, 2022, J ENDODONT, V48, P1378, DOI 10.1016/j.joen.2022.08.010
   Sato D, 2013, MOL CLIN ONCOL, V1, P105, DOI 10.3892/mco.2012.14
   Scheller EL, 2008, J DENT RES, V87, P126, DOI 10.1177/154405910808700206
   Shen BY, 2023, MOLECULES, V28, DOI 10.3390/molecules28041873
   Shi C, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.593626
   Shuai CJ, 2018, CHEM ENG J, V347, P322, DOI 10.1016/j.cej.2018.04.092
   Songkiatisak P, 2022, IMMUN AGEING, V19, DOI 10.1186/s12979 022 00277 w
   Sun X, 2019, INT ENDOD J, V52, P1691, DOI 10.1111/iej.13179
   Vandomme J, 2014, STEM CELLS DEV, V23, P839, DOI 10.1089/scd.2013.0400
   Wade Gueye NM, 2012, BONE, V50, P1064, DOI 10.1016/j.bone.2012.02.014
   Wang JLS, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.584147
   Wang MC, 2023, CLIN ORAL INVEST, V27, P1207, DOI 10.1007/s00784 022 04734 0
   Wang SN, 2012, STEM CELL RES, V8, P346, DOI 10.1016/j.scr.2011.12.005
   Wang ZZ, 2022, RSC ADV, V12, P8737, DOI 10.1039/d1ra07553e
   Wang ZY, 2010, J ENDODONT, V36, P820, DOI 10.1016/j.joen.2010.02.003
   Wu QP, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419 022 04806 9
   Xia K, 2020, INT J NANOMED, V15, P6631, DOI 10.2147/IJN.S253576
   Xiang JY, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419 022 04512 6
   Xie XD, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.826023
   Xing F, 2018, INT J MOL MED, V41, P2079, DOI 10.3892/ijmm.2018.3391
   Yu JH, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471 2121 11 32
   Zhao TT, 2019, J PHARM PHARMACOL, V71, P1353, DOI 10.1111/jphp.13129
   Zhao YX, 2021, J PROTEOME RES, V20, P3475, DOI 10.1021/acs.jproteome.1c00093
NR 58
TC 10
Z9 11
U1 1
U2 16
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301 4851
EI 1573 4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD MAY
PY 2023
VL 50
IS 5
BP 4435
EP 4446
DI 10.1007/s11033 023 08398 1
EA APR 2023
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA E3OQ2
UT WOS:000961868800001
PM 37009956
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Xiao, JRMT
   Han, QG
   Yu, ZC
   Liu, MM
   Sun, J
   Wu, M
   Yin, H
   Fu, JY
   Guo, Y
   Wang, LN
   Ma, Y
AF Xiao, Jirimutu
   Han, Qiuge
   Yu, Ziceng
   Liu, Mengmin
   Sun, Jie
   Wu, Mao
   Yin, Heng
   Fu, Jingyue
   Guo, Yang
   Wang, Lining
   Ma, Yong
TI Morroniside Inhibits Inflammatory Bone Loss through the TRAF6 Mediated
   NF κB/MAPK Signalling Pathway
SO PHARMACEUTICALS
LA English
DT Article
DE morroniside; osteoporosis; inflammation; osteogenic differentiation;
   TRAF6 mediated MAPK/NF kappa B signaling pathway
ID FRACTURE; MARROW; CELLS; RISK; TURNOVER
AB Osteoporosis is a chronic inflammatory disease that severely affects quality of life. Cornus officinalis is a Chinese herbal medicine with various bioactive ingredients, among which morroniside is its signature ingredient. Although anti bone resorption drugs are the main treatment for bone loss, promoting bone anabolism is more suitable for increasing bone mass. Therefore, identifying changes in bone formation induced by morroniside may be conducive to developing effective intervention methods. In this study, morroniside was found to promote the osteogenic differentiation of bone marrow stem cells (BMSCs) and inhibit inflammation induced bone loss in an in vivo mouse model of inflammatory bone loss. Morroniside enhanced bone density and bone microstructure, and inhibited the expression of IL6, IL1 beta, and ALP in serum (p < 0.05). Furthermore, in in vitro experiments, BMSCs exposed to 0 256 mu M morroniside did not show cytotoxicity. Morroniside inhibited the expression of IL6 and IL1 beta and promoted the expression of the osteogenic transcription factors Runx2 and OCN. Furthermore, morroniside promoted osteocalcin and Runx2 expression and inhibited TRAF6 mediated NF kappa B and MAPK signaling, as well as osteoblast growth and NF kappa B nuclear transposition. Thus, morroniside promoted osteogenic differentiation of BMSCs, slowed the occurrence of the inflammatory response, and inhibited bone loss in mice with inflammatory bone loss.
C1 [Xiao, Jirimutu; Han, Qiuge; Yu, Ziceng; Liu, Mengmin; Sun, Jie; Fu, Jingyue; Guo, Yang; Wang, Lining; Ma, Yong] Nanjing Univ Chinese Med, Inst Traumatol & Orthoped, Lab New Tech Restorat & Reconstruct, Nanjing 210023, Peoples R China.
   [Xiao, Jirimutu] Inner Mongolia Med Univ, Mongolian Med Sch, Hohhot 010110, Peoples R China.
   [Han, Qiuge; Yu, Ziceng; Liu, Mengmin; Fu, Jingyue; Wang, Lining; Ma, Yong] Nanjing Univ Chinese Med, Sch Chinese Med, Sch Integrated Chinese & Western Med, Nanjing 210023, Peoples R China.
   [Wu, Mao; Yin, Heng; Guo, Yang; Ma, Yong] Nanjing Univ Chinese Med, Wuxi TCM Hosp, Jiangsu CM Clin Innovat Ctr Degenerat Bone & Joint, Wuxi 214071, Peoples R China.
C3 Nanjing University of Chinese Medicine; Inner Mongolia Medical
   University; Nanjing University of Chinese Medicine; Nanjing University
   of Chinese Medicine
RP Wang, LN; Ma, Y (通讯作者)，Nanjing Univ Chinese Med, Inst Traumatol & Orthoped, Lab New Tech Restorat & Reconstruct, Nanjing 210023, Peoples R China.; Wang, LN; Ma, Y (通讯作者)，Nanjing Univ Chinese Med, Sch Chinese Med, Sch Integrated Chinese & Western Med, Nanjing 210023, Peoples R China.; Ma, Y (通讯作者)，Nanjing Univ Chinese Med, Wuxi TCM Hosp, Jiangsu CM Clin Innovat Ctr Degenerat Bone & Joint, Wuxi 214071, Peoples R China.
EM 034995889@163.com; hqg@njucm.edu.cn; 20200502@njucm.edu.cn;
   829004@njucm.edu.cn; 20193017@njucm.edu.cn; wxkfhmm@sina.cn;
   wxzy011@njucm.edu.cn; 20220013@njucm.edu.cn; drguoyang@njucm.edu.cn;
   wln@njucm.edu.cn; mayong@njucm.edu.cn
FU Natinal Natural Science Foundation of China [82074458, 82174411];
   Jiangsu Provincial Natural Science Foundation of China [BK20221351,
   BK20220470]; Foundation of Jiangsu CM Clinical Innovation Center of
   Degenerative Bone & Joint Disease (Jiangsu Science and Education of
   Traditional Chinese Medicine) [4]; Jiangsu Provincial Research and
   Practice Innovation Program [KYCX22_1882]
FX This study was supported by the Natinal Natural Science Foundation of
   China (82074458 and 82174411), Jiangsu Provincial Natural Science
   Foundation of China (BK20221351 and BK20220470), the Foundation of
   Jiangsu CM Clinical Innovation Center of Degenerative Bone & Joint
   Disease (Jiangsu Science and Education of Traditional Chinese Medicine)
   (2021) (no. 4), and the Jiangsu Provincial Research and Practice
   Innovation Program (KYCX22_1882), which are gratefully acknowledged.
CR Ben Neriah Y, 2002, NAT IMMUNOL, V3, P20, DOI 10.1038/ni0102 20
   Boonen S, 2007, J CLIN ENDOCR METAB, V92, P1415, DOI 10.1210/jc.2006 1404
   Carrero R, 2012, STEM CELL REV REP, V8, P905, DOI 10.1007/s12015 012 9364 9
   Chen YJ, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.803880
   Cheng L, 2015, J CELL MOL MED, V19, P1877, DOI 10.1111/jcmm.12559
   Dhillon B, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00104
   Gao XY, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10505
   GIRASOLE G, 1992, J CLIN INVEST, V89, P883, DOI 10.1172/JCI115668
   Hirotani T, 2005, BIOCHEM BIOPH RES CO, V328, P383, DOI 10.1016/j.bbrc.2004.12.184
   Hu NW, 2013, MOL MED REP, V7, P1565, DOI 10.3892/mmr.2013.1399
   Huang KX, 2023, NUCLEIC ACIDS RES, V51, pD805, DOI 10.1093/nar/gkac847
   Ishikawa K, 2016, THER CLIN RISK MANAG, V12, P1831, DOI 10.2147/TCRM.S123172
   Justesen J, 2001, BIOGERONTOLOGY, V2, P165, DOI 10.1023/A:1011513223894
   Krueger CD, 2007, ANN PHARMACOTHER, V41, P276, DOI 10.1345/aph.1H521
   Lee CG, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221910642
   Li FZ, 2021, CELL CYCLE, V20, P661, DOI 10.1080/15384101.2021.1889186
   Liu HR, 2018, HISTOCHEM CELL BIOL, V149, P393, DOI 10.1007/s00418 018 1643 3
   Loi F, 2016, BONE, V86, P119, DOI 10.1016/j.bone.2016.02.020
   Ma YC, 2022, EVID BASED COMPL ALT, V2022, DOI 10.1155/2022/8099724
   Mountziaris PM, 2008, TISSUE ENG PART B RE, V14, P179, DOI 10.1089/ten.teb.2008.0038
   Mountziaris PM, 2011, TISSUE ENG PART B RE, V17, P393, DOI [10.1089/ten.teb.2011.0182, 10.1089/ten.TEB.2011.0182]
   Noh JY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207623
   Park CH, 2009, BIOL PHARM BULL, V32, P1734, DOI 10.1248/bpb.32.1734
   Park C, 2021, ARCH BIOCHEM BIOPHYS, V706, DOI 10.1016/j.abb.2021.108926
   Park E, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22062987
   Park HJ, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9070588
   Perazella MA, 2008, KIDNEY INT, V74, P1385, DOI 10.1038/ki.2008.356
   Pi WX, 2017, MOLECULES, V22, DOI 10.3390/molecules22010163
   Raicevic G, 2010, HUM IMMUNOL, V71, P235, DOI 10.1016/j.humimm.2009.12.005
   Ratajczak AE, 2020, NUTRIENTS, V12, DOI 10.3390/nu12082263
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   Shi YF, 2012, TRENDS IMMUNOL, V33, P136, DOI 10.1016/j.it.2011.11.004
   Skaug B, 2009, ANNU REV BIOCHEM, V78, P769, DOI 10.1146/annurev.biochem.78.070907.102750
   Solling AS, 2023, CURR OSTEOPOROS REP, V21, P95, DOI 10.1007/s11914 022 00771 6
   Song HF, 2022, BIOCHEM BIOPH RES CO, V627, P45, DOI 10.1016/j.bbrc.2022.08.039
   Sun DS, 2022, J MUSCULOSKEL NEURON, V22, P536
   Sun Y, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12866
   Szulc P, 2008, ANN RHEUM DIS, V67, P1249, DOI 10.1136/ard.2007.077941
   Tang LY, 2021, J BONE MINER RES, V36, P779, DOI 10.1002/jbmr.4230
   Wang YS, 2017, PHARM BIOL, V55, P2196, DOI 10.1080/13880209.2017.1397177
   Yi T, 2012, GENE, V497, P131, DOI 10.1016/j.gene.2012.01.073
   Yi XJ, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.1056460
   Yong EL, 2021, SINGAP MED J, V62, P159, DOI 10.11622/smedj.2021036
   Yuan JH, 2020, INT IMMUNOPHARMACOL, V81, DOI 10.1016/j.intimp.2020.106240
   Zhu J, 2017, INT IMMUNOPHARMACOL, V43, P236, DOI 10.1016/j.intimp.2016.12.020
NR 45
TC 13
Z9 13
U1 8
U2 20
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1424 8247
J9 PHARMACEUTICALS BASE
JI Pharmaceuticals
PD OCT
PY 2023
VL 16
IS 10
AR 1438
DI 10.3390/ph16101438
PG 15
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA X6EB9
UT WOS:001099351600001
PM 37895909
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Haynes, KR
   Pettit, AR
   Duan, R
   Tseng, HW
   Glant, TT
   Brown, MA
   Thomas, GP
AF Haynes, Katelin R.
   Pettit, Allison R.
   Duan, Ran
   Tseng, Hsu Wen
   Glant, Tibor T.
   Brown, Matthew A.
   Thomas, Gethin P.
TI Excessive bone formation in a mouse model of ankylosing spondylitis is
   associated with decreases in Wnt pathway inhibitors
SO ARTHRITIS RESEARCH & THERAPY
LA English
DT Article
ID PROTEOGLYCAN INDUCED ARTHRITIS; RADIOGRAPHIC PROGRESSION; OSTEOBLAST
   FUNCTION; ANIMAL MODEL; DISEASE; HLA B27; JOINT; MICE; INFLAMMATION;
   REGULATOR
AB Introduction: Ankylosing spondylitis (AS) is unique in its pathology where inflammation commences at the entheses before progressing to an osteoproliferative phenotype generating excessive bone formation that can result in joint fusion. The underlying mechanisms of this progression are poorly understood. Recent work has suggested that changes in Wnt signalling, a key bone regulatory pathway, may contribute to joint ankylosis in AS. Using the proteoglycan induced spondylitis (PGISp) mouse model which displays spondylitis and eventual joint fusion following an initial inflammatory stimulus, we have characterised the structural and molecular changes that underlie disease progression.
   Methods: PGISp mice were characterised 12 weeks after initiation of inflammation using histology, immunohistochemistry (IHC) and expression profiling.
   Results: Inflammation initiated at the periphery of the intervertebral discs progressing to disc destruction followed by massively excessive cartilage and bone matrix formation, as demonstrated by toluidine blue staining and IHC for collagen type I and osteocalcin, leading to syndesmophyte formation. Expression levels of DKK1 and SOST, Wnt signalling inhibitors highly expressed in joints, were reduced by 49% and 63% respectively in the spine PGISp compared with control mice (P < 0.05) with SOST inhibition confirmed by IHC. Microarray profiling showed genes involved in inflammation and immune regulation were altered. Further, a number of genes specifically involved in bone regulation including other members of the Wnt pathway were also dysregulated.
   Conclusions: This study implicates the Wnt pathway as a likely mediator of the mechanism by which inflammation induces bony ankylosis in spondyloarthritis, raising the potential that therapies targeting this pathway may be effective in preventing this process.
C1 [Haynes, Katelin R.; Duan, Ran; Tseng, Hsu Wen; Brown, Matthew A.; Thomas, Gethin P.] Univ Queensland, Princess Alexandra Hosp, Diamantina Inst, Brisbane, Qld 4101, Australia.
   [Pettit, Allison R.] Univ Queensland, Clin Res Ctr, Herston, Qld 4029, Australia.
   [Glant, Tibor T.] Rush Univ, Med Ctr, Dept Orthoped Surg, Chicago, IL 60612 USA.
C3 Princess Alexandra Hospital; University of Queensland; University of
   Queensland; Rush University
RP Thomas, GP (通讯作者)，Univ Queensland, Princess Alexandra Hosp, Diamantina Inst, Ipswich Rd, Brisbane, Qld 4101, Australia.
EM gethin.thomas@uq.edu.au
RI ; Pettit, Allison/O 4462 2019; Thomas, Gethin/A 3624 2011; Brown,
   Matthew/E 5749 2010; Brown, Matthew A/E 5749 2010
OI Thomas, Gethin/0000 0001 9081 3686; Pettit, Allison/0000 0003 4707 7892;
   Brown, Matthew A/0000 0003 0538 8211
FU Australian National Health and Medical Research Council (NHMRC)
   [APP1006450]; NHMRC [519744, 455836]; Lions Medical Research Foundation;
   NIH/NIAMS [R01 AR040310]
FX This study was supported by Australian National Health and Medical
   Research Council (NHMRC) grant #APP1006450. ARP is supported by NHMRC
   Career Development Fellowship #519744. GPT is supported by the Lions
   Medical Research Foundation Senior Fellowship. MAB is supported by NHMRC
   Principal Research Fellowship #455836. TTG is supported by NIH/NIAMS
   grant R01 AR040310. We thank the staff at the Biological Research
   Facility at Princess Alexandra Hospital for technical support and animal
   care.
CR Appel H, 2009, CLIN EXP RHEUMATOL, V27, pS15
   Appel H, 2009, ARTHRITIS RHEUM US, V60, P3257, DOI 10.1002/art.24888
   Bárdos T, 2005, ANN RHEUM DIS, V64, P981, DOI 10.1136/ard.2004.029710
   Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Benjamin M, 2009, ADV EXP MED BIOL, V649, P57
   Boldizsar F, 2009, INT IMMUNOL, V21, P511, DOI 10.1093/intimm/dxp018
   CALIN A, 1988, BRIT J RHEUMATOL, V27, P393
   CAPKOVA J, 1992, FOLIA BIOL PRAGUE, V38, P258
   CAWLEY MID, 1972, ANN RHEUM DIS, V31, P345, DOI 10.1136/ard.31.5.345
   Chang MK, 2008, J IMMUNOL, V181, P1232, DOI 10.4049/jimmunol.181.2.1232
   Chen CH, 2006, RHEUMATOLOGY, V45, P414, DOI 10.1093/rheumatology/kei208
   Daoussis D, 2010, ARTHRITIS RHEUM US, V62, P150, DOI 10.1002/art.27231
   Davidson SI, 2011, ANN RHEUM DIS, V70, P289, DOI 10.1136/ard.2010.133322
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Doodes PD, 2010, J IMMUNOL, V184, P1552, DOI 10.4049/jimmunol.0902907
   Du P, 2008, BIOINFORMATICS, V24, P1547, DOI 10.1093/bioinformatics/btn224
   Duan R, 2010, ANN RHEUM DIS, V69, P1724, DOI 10.1136/ard.2009.111690
   Evans DM, 2011, NAT GENET, V43, P761, DOI 10.1038/ng.873
   Finnegan A, 2002, J IMMUNOL, V169, P3345, DOI 10.4049/jimmunol.169.6.3345
   Glant TT, 2003, CRIT REV IMMUNOL, V23, P199, DOI 10.1615/CritRevImmunol.v23.i3.20
   GLANT TT, 1987, ARTHRITIS RHEUM US, V30, P201, DOI 10.1002/art.1780300211
   Gruber HE, 2002, BIOTECH HISTOCHEM, V77, P81, DOI 10.1080/714028181
   HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092 8674(90)90512 D
   Hayer S, 2010, ANN RHEUM DIS, V69, P1403, DOI 10.1136/ard.2010.129148
   Kabasakal Y, 1996, BRIT J RHEUMATOL, V35, P660
   Kenna TJ, 2012, ARTHRITIS RHEUM US, V64, P1420, DOI 10.1002/art.33507
   Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074 7613(00)80038 2
   Lories RJU, 2007, ARTHRITIS RHEUM, V56, P489, DOI 10.1002/art.22372
   Lories RJU, 2004, ANN RHEUM DIS, V63, P595, DOI 10.1136/ard.2003.013599
   Maksymowych WP, 2007, ARTHRITIS RHEUM US, V56, P1846, DOI 10.1002/art.22589
   Maksymowych WP, 2010, NAT REV RHEUMATOL, V6, P75, DOI 10.1038/nrrheum.2009.258
   Maksymowych WP, 2009, ARTHRITIS RHEUM US, V60, P93, DOI 10.1002/art.24132
   Pedersen SJ, 2011, ARTHRITIS RHEUM US, V63, P3789, DOI 10.1002/art.30627
   Pimentel Santos FM, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3309
   Raj P Prithvi, 2008, Pain Pract, V8, P18, DOI 10.1111/j.1533 2500.2007.00171.x
   Redlich K, 2004, ARTHRITIS RHEUM, V50, P1001, DOI 10.1002/art.20194
   Ronneberger M, 2011, CURRENT RHEUMATOLOGY, P1
   Shen H, 2009, ARTHRITIS RHEUM US, V60, P1647, DOI 10.1002/art.24568
   Simon R, 2007, CANCER INFORM, V3, P11
   Sims AM, 2008, ANN RHEUM DIS, V67, P1305, DOI 10.1136/ard.2007.081364
   Strange A, 2010, NAT GENET, V42, P985, DOI 10.1038/ng.694
   Thomas G, 2003, J BIOL CHEM, V278, P50563, DOI 10.1074/jbc.M307310200
   Tran TM, 2006, ARTHRITIS RHEUM US, V54, P1317, DOI 10.1002/art.21740
   Uderhardt S, 2010, ANN RHEUM DIS, V69, P592, DOI 10.1136/ard.2008.102046
   van der Heijde D, 2008, ARTHRITIS RHEUM US, V58, P3063, DOI 10.1002/art.23901
   Walsh NC, 2009, J BONE MINER RES, V24, P1572, DOI [10.1359/JBMR.090320, 10.1359/jbmr.090320]
NR 46
TC 72
Z9 85
U1 0
U2 13
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1478 6354
EI 1478 6362
J9 ARTHRITIS RES THER
JI Arthritis Res. Ther.
PY 2012
VL 14
IS 6
AR R253
DI 10.1186/ar4096
PG 12
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 093LB
UT WOS:000315192300029
PM 23171658
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Zhuang, XQ
   Zhang, H
   Li, XY
   Li, XX
   Cong, M
   Peng, FL
   Yu, JY
   Zhang, X
   Yang, QF
   Hu, GH
AF Zhuang, Xueqian
   Zhang, Hao
   Li, Xiaoyan
   Li, Xiaoxun
   Cong, Min
   Peng, Fangli
   Yu, Jingyi
   Zhang, Xue
   Yang, Qifeng
   Hu, Guohong
TI Differential effects on lung and bone metastasis of breast cancer by Wnt
   signalling inhibitor DKK1
SO NATURE CELL BIOLOGY
LA English
DT Article
ID WNT/BETA CATENIN; BETA CATENIN; PATHWAY; DICKKOPF 1; CELLS; FAMILY;
   GENES; INDUCTION; CARCINOMA; INVASION
AB Metastatic cancer is a systemic disease, and metastasis determinants might elicit completely different effects in various target organs. Here we show that tumour secreted DKK1 is a serological marker of breast cancer metastasis organotropism and inhibits lung metastasis. DKK1 suppresses PTGS2 induced macrophage and neutrophil recruitment in lung metastases by antagonizing cancer cell non canonical WNT/PCP RAC1 JNK signalling. In the lungs, DKK1 also inhibits WNT/Ca2+ CaMKII NF kappa B signalling and suppresses LTBP1 mediated TGF beta secretion of cancer cells. In contrast, DKK1 promotes breast to bone metastasis by regulating canonical WNT signalling of osteoblasts. Importantly, targeting canonical WNT may not be beneficial to treatment of metastatic cancer, while combinatory therapy against JNK and TGF beta signalling effectively prevents metastasis to both the lungs and bone. Thus, DKK1 represents a class of Janus faced molecules with dichotomous roles in organotropic metastasis, and our data provide a rationale for new anti metastasis approaches.
EM qifengy_sdu@163.com; ghhu@sibs.ac.cn
RI Liu, Suling/N 2796 2013; 胡, 国宏/HOH 6469 2023
OI Hu, Guohong/0000 0002 2980 5166; Yang, Qifeng/0000 0003 0576 8513; 
FU National Natural Science Foundation of China [81430070, 81661148048,
   31371409]; Chinese Academy of Sciences [QYZDB SSW SMC013, XDA12050101];
   Ministry of Science and Technology of China [2013CB910904]; Science and
   Technology Commission of Shanghai Municipality [14431900800]
FX We thank L. Li at SIBS for providing the TOP/FOPFLASH, Delta N CTNNB1
   and Delta C LEF1 constructs; D. Xie at SIBS for providing the Delta
   N TCF4 construct; Y. Xiao at SIBS for providing the RELA construct; M.
   Liu at SIBS for providing the PTGS2 construct; and X. Miao, H. Zhang, S
   Yan and P. Zhou at the Institute of Health Sciences core facilities for
   technical support. G.H. was funded by the National Natural Science
   Foundation of China (81430070, 81661148048, 31371409), the Chinese
   Academy of Sciences (QYZDB SSW SMC013, XDA12050101), the Ministry of
   Science and Technology of China (2013CB910904) and the Science and
   Technology Commission of Shanghai Municipality (14431900800).
CR Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042
   Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419
   Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Bronte V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12150
   Buijs Jeroen T, 2012, Bonekey Rep, V1, P96, DOI 10.1038/bonekey.2012.96
   Caneparo L, 2007, GENE DEV, V21, P465, DOI 10.1101/gad.406007
   Cha SW, 2008, DEVELOPMENT, V135, P3719, DOI 10.1242/dev.029025
   Coffelt SB, 2016, NAT REV CANCER, V16, P431, DOI 10.1038/nrc.2016.52
   De A, 2011, ACTA BIOCH BIOPH SIN, V43, P745, DOI 10.1093/abbs/gmr079
   Fatima S, 2012, ONCOGENE, V31, P4233, DOI 10.1038/onc.2011.580
   Gao C, 2010, CELL SIGNAL, V22, P717, DOI 10.1016/j.cellsig.2009.11.021
   Ghajar CM, 2013, NAT CELL BIOL, V15, P807, DOI 10.1038/ncb2767
   Gleizes PE, 1997, STEM CELLS, V15, P190, DOI 10.1002/stem.150190
   Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848
   Hoang BH, 2004, CANCER RES, V64, P2734, DOI 10.1158/0008 5472.CAN 03 1952
   Kalinski P, 2012, J IMMUNOL, V188, P21, DOI 10.4049/jimmunol.1101029
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378 1119(99)00365 0
   Labelle M, 2014, P NATL ACAD SCI USA, V111, pE3053, DOI 10.1073/pnas.1411082111
   Lelekakis M, 1999, CLIN EXP METASTAS, V17, P163, DOI 10.1023/A:1006689719505
   Li L, 2002, J BIOL CHEM, V277, P5977, DOI 10.1074/jbc.M111131200
   Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727
   Lu D, 2016, LAB INVEST, V96, P239, DOI 10.1038/labinvest.2015.145
   Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694
   Malladi S, 2016, CELL, V165, P45, DOI 10.1016/j.cell.2016.02.025
   Mao BY, 2003, GENE, V302, P179, DOI 10.1016/S0378 1119(02)01106 X
   Mariz K, 2015, CLIN EXP METASTAS, V32, P857, DOI 10.1007/s10585 015 9750 1
   Michigami T, 2002, BREAST CANCER RES TR, V75, P249, DOI 10.1023/A:1019905111666
   Mikheev AM, 2008, BREAST CANCER RES TR, V112, P263, DOI 10.1007/s10549 007 9867 2
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Minn AJ, 2007, P NATL ACAD SCI USA, V104, P6740, DOI 10.1073/pnas.0701138104
   MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460 2075.1991.tb08049.x
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Niehrs C, 2006, ONCOGENE, V25, P7469, DOI 10.1038/sj.onc.1210054
   Niida A, 2004, ONCOGENE, V23, P8520, DOI 10.1038/sj.onc.1207892
   Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046
   Pukrop T, 2006, P NATL ACAD SCI USA, V103, P5454, DOI 10.1073/pnas.0509703103
   Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138
   Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070
   Smid M, 2008, CANCER RES, V68, P3108, DOI 10.1158/0008 5472.CAN 07 5644
   Talmadge JE, 2013, NAT REV CANCER, V13, P739, DOI 10.1038/nrc3581
   Wang FS, 2007, BONE, V40, P485, DOI 10.1016/j.bone.2006.09.004
NR 45
TC 225
Z9 245
U1 6
U2 108
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465 7392
EI 1476 4679
J9 NAT CELL BIOL
JI Nat. Cell Biol.
PD OCT
PY 2017
VL 19
IS 10
BP 1274
EP +
DI 10.1038/ncb3613
PG 26
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA FI5HP
UT WOS:000412013400019
PM 28892080
DA 2025 08 17
ER

PT J
AU Widler, L
   Jahnke, W
   Green, JR
AF Widler, Leo
   Jahnke, Wolfgang
   Green, Jonathan R.
TI The Chemistry of Bisphosphonates: From Antiscaling Agents to Clinical
   Therapeutics
SO ANTI CANCER AGENTS IN MEDICINAL CHEMISTRY
LA English
DT Article
DE Alendronate; Bisphosphonate; Farnesyl pyrophosphate synthase;
   Ibandronate; Pamidronate; Zoledronic acid
ID NITROGEN CONTAINING BISPHOSPHONATES; BONE RESORPTION INHIBITORS; CALCIUM
   PHOSPHATE CRYSTALS; ZOLEDRONIC ACID; IN VIVO;
   PHARMACOLOGICAL ACTIVITIES; INORGANIC PYROPHOSPHATE; TISSUE CULTURE;
   HYDROXYAPATITE; CALCIFICATION
AB In the early 1960s, inorganic pyrophosphate (PPi) was found to be present in body fluids and to act as a natural inhibitor of calcification by its interaction with hydroxyapatite. In addition to inhibiting the formation of calcium phosphate, PPi also inhibited dissolution of hydroxyapatite crystals, which made it interesting for pharmacologic applications in the treatment of diseases associated with excessive bone resorption. However, PPi is metabolically unstable because of rapid hydrolysis of the P O P backbone by hydrolytic enzymes in the gastrointestinal tract. In the search for more stable analogues of PPi, attention turned to the chemical class of bisphosphonates (BPs). The first BPs were synthesized in the 19th century and widely used for industrial applications. Bisphosphonates are formally derived from PPi by replacement of the bridging oxygen atom by a carbon atom, resulting in a P C P moiety that is resistant to hydrolysis. In addition to its decisive role in stability, the central carbon atom also provides an attachment point for 2 additional substituents (R 1 and R 2). While R 1 is preferentially a hydroxy group, allowing such derivatives to act as powerful tridentate ligands for calcium (bone hook), R 2 is mainly responsible for antiresorptive potency. The clinically available BPs can be divided into 2 subclasses based on their structure and molecular mechanism of action. The simple, non nitrogen containing derivatives can be incorporated into non hydrolyzable cytotoxic ATP analogues. The more potent nitrogen containing BPs inhibit FPPS, a key enzyme in the mevalonate pathway. Details of this crucial molecular interaction have recently been elucidated. Members of this class have a wide therapeutic window between therapeutic inhibition of bone resorption and undesired inhibition of bone formation, and several have found widespread use for the treatment of benign and malignant bone disease.
C1 [Widler, Leo; Jahnke, Wolfgang; Green, Jonathan R.] Novartis Inst BioMed Res, CH 4057 Basel, Switzerland.
C3 Novartis
RP Widler, L (通讯作者)，Novartis Inst BioMed Res, CH 4057 Basel, Switzerland.
EM leo.widler@novartis.com
FU Novartis Pharmaceuticals Corporation
FX Financial support for formatting assistance to ProEd Communications,
   Inc.(R) was provided by Novartis Pharmaceuticals Corporation.
CR BASSETT CAL, 1969, LANCET, V2, P845
   Blomen Leo J. M. J., 1995, P111
   BOYCE BF, 1984, LANCET, V1, P821
   Breuil V, 1999, REV RHUM, V66, P339
   Chen CKM, 2008, J MED CHEM, V51, P5594, DOI 10.1021/jm800325y
   Coleman R, 2011, CANCER AM CANCER SOC, V117, P11, DOI 10.1002/cncr.25529
   Devold HM, 2010, EUR J CLIN PHARMACOL, V66, P299, DOI 10.1007/s00228 009 0746 0
   Dunford JE, 2008, J MED CHEM, V51, P2187, DOI 10.1021/jm7015733
   Ebetino FH, 1996, PHOSPHORUS SULFUR, V109, P217
   Ebetino Frank H., 1995, P139
   Eidtmann H, 2010, ANN ONCOL, V21, P2188, DOI 10.1093/annonc/mdq217
   FLEISCH H, 1962, NATURE, V195, P911, DOI 10.1038/195911a0
   FLEISCH H, 1966, P SOC EXP BIOL MED, V122, P317
   FLEISCH H, 1969, SCIENCE, V165, P1262, DOI 10.1126/science.165.3899.1262
   FLEISCH H, 1968, CALC TISS RES, VS  2, P10, DOI 10.1007/BF02065192
   FLEISCH H, 1966, NATURE, V212, P901, DOI 10.1038/212901a0
   FLEISCH H, 1962, AM J PHYSIOL, V203, P671, DOI 10.1152/ajplegacy.1962.203.4.671
   FLEISCH HA, 1970, EUR J CLIN INVEST, V1, P12, DOI 10.1111/j.1365 2362.1970.tb00591.x
   Francis M. D., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P2
   FRANCIS MD, 1969, SCIENCE, V165, P1264, DOI 10.1126/science.165.3899.1264
   Geddes A D., 1994, Bone and Mineral Research, P265
   Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087
   Gnant M, 2011, LANCET ONCOL, V12, P631, DOI 10.1016/S1470 2045(11)70122 X
   Green JR, 1997, PHARMACOL TOXICOL, V80, P225, DOI 10.1111/j.1600 0773.1997.tb01964.x
   Hollingworth SA, 2010, DRUG AGING, V27, P255, DOI 10.2165/11318400 000000000 00000
   Huang CH, 2010, PROTEINS, V78, P888, DOI 10.1002/prot.22614
   Jahnke W, 2010, NAT CHEM BIOL, V6, P660, DOI [10.1038/NCHEMBIO.421, 10.1038/nchembio.421]
   Jastrzab R, 2010, J SOLUTION CHEM, V39, P909, DOI 10.1007/s10953 010 9558 1
   JUNG A, 1973, CALC TISS RES, V11, P269, DOI 10.1007/BF02547227
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Lawson MA, 2010, J BIOMED MATER RES B, V92B, P149, DOI 10.1002/jbm.b.31500
   Lehenkari PP, 2002, MOL PHARMACOL, V61, P1255, DOI 10.1124/mol.61.5.1255
   Melani C, 2007, CANCER RES, V67, P11438, DOI 10.1158/0008 5472.CAN 07 1882
   Menschutkin N., 1865, ANN CHEM PHARM, V133, P317, DOI [10.1002/jlac.18651330307, DOI 10.1002/JLAC.18651330307]
   Mönkkönen H, 2006, BRIT J PHARMACOL, V147, P437, DOI 10.1038/sj.bjp.0706628
   MUHLBAUER RC, 1991, J BONE MINER RES, V6, P1003
   Pataki A, 1997, ANAT REC, V249, P458, DOI 10.1002/(SICI)1097 0185(199712)249:4<458::AID AR5>3.0.CO;2 N
   Roelofs AJ, 2008, PRINCIPLES OF BONE BIOLOGY, VOL 2, 3RD EDITION, P1737, DOI 10.1016/B978 0 12 373884 4.00095 1
   Roelofs AJ, 2010, J BONE MINER RES, V25, P606, DOI 10.1359/jbmr.091009
   Roelofs AJ, 2009, BRIT J HAEMATOL, V144, P245, DOI 10.1111/j.1365 2141.2008.07435.x
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Rondeau JM, 2006, CHEMMEDCHEM, V1, P267, DOI 10.1002/cmdc.200500059
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 2006, ANN NY ACAD SCI, V1068, P367, DOI 10.1196/annals.1346.041
   Russell RGG, 1999, OSTEOPOROSIS INT, V9, P66, DOI 10.1007/PL00004164
   RUSSELL RGG, 1970, CALC TISS RES, V6, P183, DOI 10.1007/BF02196199
   RUSSELL RGG, 1971, J CLIN INVEST, V50, P961, DOI 10.1172/JCI106589
   RUSSELL RGG, 1970, LANCET, V2, P899, DOI 10.1016/S0140 6736(70)92070 2
   SCHIBLER D, 1968, CLIN SCI, V35, P363
   SHINODA H, 1983, CALCIFIED TISSUE INT, V35, P87, DOI 10.1007/BF02405012
   SIETSEMA WK, 1989, DRUG EXP CLIN RES, V15, P389
   Singh AP, 2010, ANTIMICROB AGENTS CH, V54, P2987, DOI 10.1128/AAC.00198 10
   SUNBERG RJ, 1991, CHEMTECH, V21, P304
   Swislocki Arthur L M, 2007, Endocr Pract, V13, P194
   Takeuchi M, 1998, CHEM PHARM BULL, V46, P1703
   TAKEUCHI M, 1993, CHEM PHARM BULL, V41, P688
   vanBeek E, 1996, J BONE MINER RES, V11, P1492
   Varela I, 2008, NAT MED, V14, P767, DOI 10.1038/nm1786
   Wasko BM, 2011, J PHARMACOL EXP THER, V337, P540, DOI 10.1124/jpet.110.175521
   Widler L, 2002, J MED CHEM, V45, P3721, DOI 10.1021/jm020819i
NR 60
TC 19
Z9 19
U1 0
U2 26
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1871 5206
EI 1875 5992
J9 ANTI CANCER AGENT ME
JI Anti Cancer Agents Med. Chem.
PD FEB
PY 2012
VL 12
IS 2
BP 95
EP 101
DI 10.2174/187152012799014959
PG 7
WC Oncology; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA 936TK
UT WOS:000303612700002
PM 21864230
DA 2025 08 17
ER

PT J
AU Liu, CZ
   Walter, TS
   Huang, P
   Zhang, SQ
   Zhu, XK
   Wu, Y
   Wedderburn, LR
   Tang, PF
   Owens, RJ
   Stuart, DI
   Ren, JS
   Gao, B
AF Liu, Changzhen
   Walter, Thomas S.
   Huang, Peng
   Zhang, Shiqian
   Zhu, Xuekai
   Wu, Ying
   Wedderburn, Lucy R.
   Tang, Peifu
   Owens, Raymond J.
   Stuart, David I.
   Ren, Jingshan
   Gao, Bin
TI Structural and Functional Insights of RANKL RANK Interaction and
   Signaling
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID TUMOR NECROSIS FACTOR; OSTEOCLAST DIFFERENTIATION FACTOR; FACTOR
   RECEPTOR FAMILY; CRYSTAL STRUCTURE; OSTEOPROTEGERIN LIGAND;
   TNF RECEPTOR; EXTRACELLULAR DOMAIN; INHIBITORY FACTOR; MOUSE RANK;
   T CELLS
AB Bone remodeling involves bone resorption by osteoclasts and synthesis by osteoblasts and is tightly regulated by the receptor activator of the NF kappa B ligand (RANKL)/receptor activator of the NF kappa B (RANK)/osteoprotegerin molecular triad. RANKL, a member of the TNF superfamily, induces osteoclast differentiation, activation and survival upon interaction with its receptor RANK. The decoy receptor osteoprotegerin inhibits osteoclast formation by binding to RANKL. Imbalance in this molecular triad can result in diseases, including osteoporosis and rheumatoid arthritis. In this study, we report the crystal structures of unliganded RANK and its complex with RANKL and elucidation of critical residues for the function of the receptor pair. RANK represents the longest TNFR with four full cysteine rich domains (CRDs) in which the CRD4 is stabilized by a sodium ion and a rigid linkage with CRD3. On association, RANK moves via a hinge region between the CRD2 and CRD3 to make close contact with RANKL; a significant structural change previously unseen in the engagement of TNFR superfamily 1A with its ligand. The high affinity interaction between RANK and RANKL, maintained by continuous contact between the pair rather than the patched interaction commonly observed, is necessary for the function because a slightly reduced affinity induced by mutation produces significant disruption of osteoclast formation. The structures of RANK and RANKL RANK complex and the biological data presented in the paper are essential for not only our understanding of the specific nature of the signaling mechanism and of disease related mutations found in patients but also structure based drug design. The Journal of Immunology, 2010, 184: 6910 6919.
C1 [Liu, Changzhen; Zhu, Xuekai; Wu, Ying; Gao, Bin] Chinese Acad Sci, Inst Microbiol, China Japan Joint Lab Mol Immunol & Virol, Key Lab Pathogen Microbiol & Immunol, Beijing 100101, Peoples R China.
   [Liu, Changzhen; Zhu, Xuekai; Wu, Ying; Gao, Bin] Chinese Acad Sci, Ctr Mol Immunol, Beijing 100101, Peoples R China.
   [Huang, Peng; Tang, Peifu] Chinese Peoples Liberat Army Gen Hosp, Dept Orthopaed, Beijing, Peoples R China.
   [Zhang, Shiqian] Harbin Med Coll, Dept Orthopaed, Clin Coll 1, Harbin, Peoples R China.
   [Walter, Thomas S.; Owens, Raymond J.; Stuart, David I.; Ren, Jingshan] Univ Oxford, Div Struct Biol, Oxford Prot Prod Facil, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   [Wedderburn, Lucy R.; Gao, Bin] UCL, Rheumatol Unit, Inst Child Hlth, London, England.
C3 Chinese Academy of Sciences; Institute of Microbiology, CAS; Chinese
   Academy of Sciences; Chinese People's Liberation Army General Hospital;
   Harbin Medical University; University of Oxford; Wellcome Centre for
   Human Genetics; University of London; University College London
RP Gao, B (通讯作者)，Chinese Acad Sci, Inst Microbiol, China Japan Joint Lab Mol Immunol & Virol, Key Lab Pathogen Microbiol & Immunol, 1 Beichn Xilu Rd, Beijing 100101, Peoples R China.
EM ren@strubi.ox.ac.uk; bgao2004@gmail.com
RI ; gao, bin/JYW 5418 2024; Walter, Thomas/S 8636 2017; huang,
   peng/KBC 5715 2024; Walter, Thomas/S 5104 2019; Ren,
   Jingshan/AAT 7729 2021
OI Wedderburn, Lucy/0000 0002 7495 1429; Walter,
   Thomas/0000 0002 0030 7235; Stuart, David/0000 0002 3426 4210; Ren,
   Jingshan/0000 0003 4015 1404; Owens, Ray/0000 0002 3705 2993; Gao,
   Bin/0009 0001 8207 0568
FU Ministry of Science and Technology [2006CB504306]; National Natural
   Science Foundation of China [30700749, 30600623]; National S and T Major
   Project [2009ZX09503 007]; Ministry of Science and Technology Science
   Exchange Program [2007DFC30240]; Beijing Municipal Natural Science
   Foundation [7072072]; United Kingdom Medical Research Council;
   Biotechnology Biological Sciences Research Council; Medical Research
   Council [G0701506, G1100525, G0500365] Funding Source: researchfish; MRC
   [G0500365, G0701506] Funding Source: UKRI
FX This work was supported by the 973 Scheme of Ministry of Science and
   Technology ( Grant 2006CB504306), the National Natural Science
   Foundation of China ( Grant 30700749 and 30600623), the National S and T
   Major Project ( Grant 2009ZX09503 007), the Ministry of Science and
   Technology Science Exchange Program ( Grant 2007DFC30240), the Beijing
   Municipal Natural Science Foundation ( Grant 7072072), and the United
   Kingdom Medical Research Council and Biotechnology Biological Sciences
   Research Council.
CR Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092 8674(93)90132 A
   Binder NB, 2009, NAT MED, V15, P417, DOI 10.1038/nm.1945
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brunger AT, 2007, NAT PROTOC, V2, P2728, DOI 10.1038/nprot.2007.406
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527
   *CCP4, 1994, ACTA CRYSTALLOGR C
   Chung JY, 2002, J CELL SCI, V115, P679
   Cohen SB, 2008, ARTHRITIS RHEUM, V58, P1299, DOI 10.1002/art.23417
   Compaan DM, 2006, STRUCTURE, V14, P1321, DOI 10.1016/j.str.2006.06.015
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Dougall WC, 2006, CANCER METAST REV, V25, P541, DOI 10.1007/s10555 006 9021 3
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092 8674(00)00103 3
   Feng X, 2005, GENE, V350, P1, DOI 10.1016/j.gene.2005.01.014
   GOH CR, 1991, PROTEIN ENG, V4, P785
   Graham SC, 2007, J MOL BIOL, V372, P660, DOI 10.1016/j.jmb.2007.06.082
   Guerrini MM, 2008, AM J HUM GENET, V83, P64, DOI 10.1016/j.ajhg.2008.06.015
   Hanada R, 2009, NATURE, V462, P505, DOI 10.1038/nature08596
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Hymowitz SG, 1999, MOL CELL, V4, P563, DOI 10.1016/S1097 2765(00)80207 5
   Ito S, 2002, J BIOL CHEM, V277, P6631, DOI 10.1074/jbc.M106525200
   JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0
   Karpusas M, 1995, STRUCTURE, V3, P1426
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lam J, 2001, J CLIN INVEST, V108, P971, DOI 10.1172/JCI13890
   Lamothe B, 2007, J BIOL CHEM, V282, P4102, DOI 10.1074/jbc.M609503200
   Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566
   Liu W, 2004, J BIOL CHEM, V279, P54759, DOI 10.1074/jbc.M404687200
   Loser K, 2006, NAT MED, V12, P1372, DOI 10.1038/nm1518
   MARSTERS SA, 1992, J BIOL CHEM, V267, P5747
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   Mongkolsapaya J, 1999, NAT STRUCT BIOL, V6, P1048
   Müller P, 2003, ACTA CRYSTALLOGR D, V59, P32, DOI 10.1107/S0907444902018000
   Naismith JH, 1996, STRUCTURE, V4, P1251, DOI 10.1016/S0969 2126(96)00134 7
   Naismith JH, 1998, TRENDS BIOCHEM SCI, V23, P74, DOI 10.1016/S0968 0004(97)01164 X
   NAISMITH JH, 1995, J BIOL CHEM, V270, P13303, DOI 10.1074/jbc.270.22.13303
   Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788
   Nieba L, 1997, ANAL BIOCHEM, V252, P217, DOI 10.1006/abio.1997.2326
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076 6879(97)76066 X
   Park YC, 1999, NATURE, V398, P533, DOI 10.1038/19110
   Polek TC, 2003, J BIOL CHEM, V278, P32317, DOI 10.1074/jbc.M302518200
   Schneeweis LA, 2005, J BIOL CHEM, V280, P41155, DOI 10.1074/jbc.M506366200
   Schneider P, 1997, J BIOL CHEM, V272, P18827, DOI 10.1074/jbc.272.30.18827
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Sobacchi C, 2007, NAT GENET, V39, P960, DOI 10.1038/ng2076
   Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a
   Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753
   Tomoyasu A, 1998, BIOCHEM BIOPH RES CO, V245, P382, DOI 10.1006/bbrc.1998.8443
   Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766
   Villa A, 2009, CALCIFIED TISSUE INT, V84, P1, DOI 10.1007/s00223 008 9196 4
   Walsh MC, 2006, ANNU REV IMMUNOL, V24, P33, DOI 10.1146/annurev.immunol.24.021605.090646
   Walter TS, 2009, ACTA CRYSTALLOGR F, V65, P597, DOI 10.1107/S1744309109015735
   Walter TS, 2005, ACTA CRYSTALLOGR D, V61, P651, DOI 10.1107/S0907444905007808
   Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190
   Xing LP, 2005, IMMUNOL REV, V208, P19, DOI 10.1111/j.0105 2896.2005.00336.x
   YAMAGISHI J, 1990, PROTEIN ENG, V3, P713, DOI 10.1093/protein/3.8.713
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888
NR 62
TC 106
Z9 129
U1 2
U2 16
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022 1767
EI 1550 6606
J9 J IMMUNOL
JI J. Immunol.
PD JUN 15
PY 2010
VL 184
IS 12
BP 6910
EP 6919
DI 10.4049/jimmunol.0904033
PG 10
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA 607PB
UT WOS:000278516700039
PM 20483727
OA Bronze
DA 2025 08 17
ER

PT J
AU Cai, MX
   Yang, L
   Zhang, SF
   Liu, JF
   Sun, Y
   Wang, XG
AF Cai, Mingxiang
   Yang, Li
   Zhang, Shufan
   Liu, Jiafan
   Sun, Yao
   Wang, Xiaogang
TI A bone resorption surface targeting nanoparticle to deliver anti miR214
   for osteoporosis therapy
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE osteoporosis; microRNA; bone resorption; targeting delivery;
   nanoparticle
ID IN VITRO; PEPTIDE; MIR 214; SIRNA; OSTEOCLASTOGENESIS; DIFFERENTIATION;
   EXPRESSION; MICRORNAS; SYSTEM; BREAST
AB With increasing fracture risks due to fragility, osteoporosis is a global health problem threatening postmenopausal women. In these patients, osteoclasts play leading roles in bone loss and fracture. How to inhibit osteoclast activity is the key issue for osteoporosis treatment. In recent years, miRNA based gene therapy through gene regulation has been considered a potential therapeutic method. However, in light of the side effects, the use of therapeutic miRNAs in osteoporosis treatment is still limited by the lack of tissue/cell specific delivery systems. Here, we developed polyurethane (PU) nanomicelles modified by the acidic peptide Asp(8). Our data showed that without overt toxicity or eliciting an immune response, this delivery system encapsulated and selectively deliver miRNAs to OSCAR(+) osteoclasts at bone resorption surface in vivo. With the Asp(8) PU delivery system, anti miR214 was delivered to osteoclasts, and bone microarchitecture and bone mass were improved in ovariectomized osteoporosis mice. Therefore, Asp(8) PU could be a useful bone resorption surface targeting delivery system for treatment of osteoclast induced bone diseases and aging related osteoporosis.
C1 [Cai, Mingxiang; Zhang, Shufan; Sun, Yao] Tongji Univ, Engn Res Ctr Tooth Restorat & Regenerat, Dept Oral Implantol, Sch Stomatol, Shanghai, Peoples R China.
   [Yang, Li; Liu, Jiafan; Wang, Xiaogang] Jinan Univ, Dept Cell Biol, Inst Biomed, Coll Life Sci & Technol, Guangzhou, Guangdong, Peoples R China.
C3 Tongji University; Jinan University
RP Wang, XG (通讯作者)，Jinan Univ, Inst Biomed, Dept Cell Biol, 601 Huangpu Ave West, Guangzhou 510632, Guangdong, Peoples R China.; Sun, Y (通讯作者)，Tongji Univ, Shanghai Engn Res Ctr Tooth Restorat & Regenerat, Dept Implantol, Sch Stomatol, 399 Middle Yanchang Rd, Shanghai 200072, Peoples R China.
EM yaosun@tongji.edu.cn; txg_wang@jnu.edu.cn
RI sun, yao/MEP 9275 2025; wang, Xiaogang/J 5003 2017; cai,
   mingxiang/IYT 1913 2023
OI Wang, Xiaogang/0000 0001 9798 834X
FU Key Project of Chinese National Programs for Research and Development
   [2016YFC1102705]; National Science Technology Support Plan Projects
   [2014BAI04B07]; National Natural Science Foundation [81370971, 81722031,
   81770873, 81470715, 81771043]; Shanghai Health System Academic Leader
   Program [2017BR009]; Guangdong Natural Science Funds [2014A030313358,
   2015A030313333]; Major Science Project in Guangdong Province
   [2014KZDXM011]; Science and Technology Planning Project of Guangdong
   Province [2013B090500105, 2014A020210015]; Guangdong Natural Science
   Funds for Distinguished Young Scholars [S2013050013880]; Recruitment
   Program of Global Experts 1000 Plan
FX This study was supported by the Key Project of Chinese National Programs
   for Research and Development (2016YFC1102705), National Science
   Technology Support Plan Projects (2014BAI04B07), National Natural
   Science Foundation Projects (81370971, 81722031, 81770873 to WXG,
   81470715, 81771043 to SY), Shanghai Health System Academic Leader
   Program (2017BR009); Guangdong Natural Science Funds (2014A030313358,
   2015A030313333), Major Science Project in Guangdong Province
   (2014KZDXM011), Science and Technology Planning Project of Guangdong
   Province (2013B090500105, 2014A020210015), Guangdong Natural Science
   Funds for Distinguished Young Scholars (S2013050013880), and the 2012
   Recruitment Program of Global Experts 1000 Plan (YS).
CR Adair JE, 2014, MOL THER, V22, P1397, DOI 10.1038/mt.2014.119
   Aho J, 2016, J PHARM SCI US, V105, P160, DOI 10.1016/j.xphs.2015.11.029
   Akduman C, 2016, MAT SCI ENG C MATER, V64, P383, DOI 10.1016/j.msec.2016.04.005
   [Anonymous], DENT RES J ISFAHAN
   Barbehenn EK, 2001, TRENDS ENDOCRIN MET, V12, P383, DOI 10.1016/S1043 2760(01)00489 1
   Binder NB, 2009, NAT MED, V15, P417, DOI 10.1038/nm.1945
   Camacho KM, 2016, NANOMEDICINE UK, V11, P1139, DOI 10.2217/nnm.16.33
   Cao JY, 2015, BIOMATER SCI UK, V3, P1545, DOI 10.1039/c5bm00161g
   Chen H, 2011, GASTRIC CANCER, V14, P339, DOI 10.1007/s10120 011 0049 x
   Cheng KW, 2017, INT J NANOMED, V12, P1775, DOI 10.2147/IJN.S120290
   Choi KY, 2014, NAT PROTOC, V9, P1900, DOI 10.1038/nprot.2014.128
   Ding MM, 2013, ACS NANO, V7, P1918, DOI 10.1021/nn4002769
   Ell Brian, 2014, Bonekey Rep, V3, P549, DOI 10.1038/bonekey.2014.44
   Gencturk A, 2017, ARTIF CELL NANOMED B, V45, P655, DOI 10.3109/21691401.2016.1173047
   Giza DE, 2016, CELL DEATH DIFFER, V23, P1906, DOI 10.1038/cdd.2016.94
   Gjoksi B, 2015, BONE, V78, P114, DOI 10.1016/j.bone.2015.05.004
   Guo HH, 2013, BRAZ J MED BIOL RES, V46, P831, DOI 10.1590/1414 431X20133092
   Heckt T, 2016, BONE, V92, P85, DOI 10.1016/j.bone.2016.08.016
   Hoiberg MP, 2016, BONE, V92, P58, DOI 10.1016/j.bone.2016.08.011
   Hydbring Per, 2013, F1000Res, V2, P136, DOI 10.12688/f1000research.2 136.v1
   Iwaniec UT, 2007, J BONE MINER RES, V22, P394, DOI 10.1359/JBMR.061118
   Katsuyama T, 2015, PEPTIDES, V73, P88, DOI 10.1016/j.peptides.2015.09.007
   Khajuria DK, 2017, MAT SCI ENG C MATER, V71, P698, DOI 10.1016/j.msec.2016.10.066
   Khajuria DK, 2016, MAT SCI ENG C MATER, V63, P78, DOI 10.1016/j.msec.2016.02.062
   Khatri N, 2014, J CONTROL RELEASE, V182, P45, DOI 10.1016/j.jconrel.2014.03.003
   Kim JH, 2010, CELL SIGNAL, V22, P1341, DOI 10.1016/j.cellsig.2010.05.001
   Kitaura H, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/181849
   Li K, 2015, J BIOL CHEM, V290, P8185, DOI 10.1074/jbc.M114.633990
   Lippuner Kurt, 2012, Ther Umsch, V69, P137, DOI 10.1024/0040 5930/a000266
   Liu J, 2015, BIOMATERIALS, V52, P148, DOI 10.1016/j.biomaterials.2015.02.007
   Mazziotti G, 2016, ENDOCRINE, V54, P603, DOI 10.1007/s12020 016 1146 8
   Melton LJ, 2004, J BONE MINER RES, V19, P1055, DOI 10.1359/JBMR.040316
   Mizoguchi F, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4282
   Mozzati M, 2013, OSTEOPOROSIS INT, V24, P1707, DOI 10.1007/s00198 012 2239 8
   Newa M, 2014, MOL PHARMACEUT, V11, P81, DOI 10.1021/mp400188r
   Nik J, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913 016 1686 x
   Ohno S, 2013, MOL THER, V21, P185, DOI 10.1038/mt.2012.180
   Rai K, 2011, MOL CANCER THER, V10, P1720, DOI 10.1158/1535 7163.MCT 11 0220
   REID IR, 1988, LANCET, V2, P1144
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Sato Y, 2017, BIOCHEM BIOPH RES CO, V482, P1430, DOI 10.1016/j.bbrc.2016.12.053
   Schwarz EM, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2171
   Sipos W, 2008, CURR MED CHEM, V15, P127, DOI 10.2174/092986708783330638
   SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152
   Sun WJ, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.15
   Sun Y, 2016, ACS NANO, V10, P5759, DOI 10.1021/acsnano.5b07828
   Suzuki M, 2011, CLIN EXP IMMUNOL, V163, P88, DOI 10.1111/j.1365 2249.2010.04276.x
   Tanaka S, 2001, Clin Calcium, V11, P598
   Tivnan A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038129
   Wang D, 2007, BIOCONJUGATE CHEM, V18, P1375, DOI 10.1021/bc7002132
   Wang L, 2015, CELL DEATH DIFFER, V22, P1654, DOI 10.1038/cdd.2015.14
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Wang XJ, 2012, BIOCHEM BIOPH RES CO, V428, P525, DOI 10.1016/j.bbrc.2012.10.039
   Wang XX, 2016, SCI REP UK, V6, DOI 10.1038/srep31506
   Wang YW, 2012, ADV DRUG DELIVER REV, V64, P1341, DOI 10.1016/j.addr.2011.09.002
   Wu C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066416
   Wu YT, 2017, ONCOTARGET, V8, P19866, DOI 10.18632/oncotarget.15189
   Xiao Y, 2016, P NATL ACAD SCI USA, V113, pE5792, DOI 10.1073/pnas.1612277113
   Yang YM, 2015, AGE, V37, DOI 10.1007/s11357 014 9743 z
   Yanokura M, 2015, EXCLI J, V14, P190, DOI 10.17179/excli2014 590
   Yigit MV, 2017, ONCOGENE, V36, P2628, DOI 10.1038/onc.2016.413
   Yu B, 2016, TRENDS MOL MED, V22, P641, DOI 10.1016/j.molmed.2016.06.002
   Yu SJ, 2014, ADV HEALTHC MATER, V3, P752, DOI 10.1002/adhm.201300308
   Zhao CY, 2015, RNA BIOL, V12, P343, DOI 10.1080/15476286.2015.1017205
   Zhou HF, 2014, J CLIN INVEST, V124, P4363, DOI 10.1172/JCI75673
NR 65
TC 50
Z9 53
U1 1
U2 48
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178 2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2017
VL 12
BP 7469
EP 7482
DI 10.2147/IJN.S139775
PG 14
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Pharmacology & Pharmacy
GA FJ8RE
UT WOS:000413035500001
PM 29075114
OA gold, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Fairfield, H
   Falank, C
   Harris, E
   Demambro, V
   McDonald, M
   Pettitt, JA
   Mohanty, ST
   Croucher, P
   Kramer, I
   Kneissel, M
   Rosen, CJ
   Reagan, MR
AF Fairfield, Heather
   Falank, Carolyne
   Harris, Elizabeth
   Demambro, Victoria
   McDonald, Michelle
   Pettitt, Jessica A.
   Mohanty, Sindhu T.
   Croucher, Peter
   Kramer, Ina
   Kneissel, Michaela
   Rosen, Clifford J.
   Reagan, Michaela R.
TI The skeletal cell derived molecule sclerostin drives bone marrow
   adipogenesis
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE bone marrow adipose; bone marrow microenvironment; osteocyte derived
   factors; sclerostin
ID HIGH FAT DIET; ADIPOSE TISSUE; MINERAL DENSITY; POSTMENOPAUSAL WOMEN;
   ANTIBODY TREATMENT; MULTIPLE MYELOMA; RAT MODEL; BODY COMPOSITION; MOUSE
   MODEL; IN VIVO
AB The bone marrow niche is a dynamic and complex microenvironment that can both regulate, and be regulated by the bone matrix. Within the bone marrow (BM), mesenchymal stromal cell (MSC) precursors reside in a multi potent state and retain the capacity to differentiate down osteoblastic, adipogenic, or chondrogenic lineages in response to numerous biochemical cues. These signals can be altered in various pathological states including, but not limited to, osteoporotic induced fracture, systemic adiposity, and the presence of bone homing cancers. Herein we provide evidence that signals from the bone matrix (osteocytes) determine marrow adiposity by regulating adipogenesis in the bone marrow. Specifically, we found that physiologically relevant levels of Sclerostin (SOST), which is a Wnt inhibitory molecule secreted from bone matrix embedded osteocytes, can induce adipogenesis in 3T3 L1 cells, mouse ear  and BM derived MSCs, and human BM derived MSCs. We demonstrate that the mechanism of SOST induction of adipogenesis is through inhibition of Wnt signaling in pre adipocytes. We also demonstrate that a decrease of sclerostin in vivo, via both genetic and pharmaceutical methods, significantly decreases bone marrow adipose tissue (BMAT) formation. Overall, this work demonstrates a direct role for SOST in regulating fate determination of BM adipocyte progenitors. This provides a novel mechanism for which BMAT is governed by the local bone microenvironment, which may prove relevant in the pathogenesis of certain diseases involving marrow adipose. Importantly, with anti sclerostin therapy at the forefront of osteoporosis treatment and a greater recognition of the role of BMAT in disease, these data are likely to have important clinical implications.
C1 [Fairfield, Heather; Falank, Carolyne; Harris, Elizabeth; Demambro, Victoria; Rosen, Clifford J.; Reagan, Michaela R.] Maine Med Ctr Res Inst, Ctr Clin & Translat Res, Scarborough, ME USA.
   [Fairfield, Heather; Falank, Carolyne; Harris, Elizabeth; Demambro, Victoria; Rosen, Clifford J.; Reagan, Michaela R.] Univ Maine, Grad Sch Biomed Sci & Engn, Orono, ME USA.
   [Fairfield, Heather; Falank, Carolyne; Harris, Elizabeth; Demambro, Victoria; Rosen, Clifford J.; Reagan, Michaela R.] Tufts Univ, Sch Med, Boston, MA 02111 USA.
   [McDonald, Michelle; Pettitt, Jessica A.; Mohanty, Sindhu T.; Croucher, Peter] Garvan Inst Med Res, Sydney, NSW, Australia.
   [Kramer, Ina; Kneissel, Michaela] Novartis Inst BioMed Res, Basel, Switzerland.
C3 Maine Medical Center; University of Maine System; University of Maine
   Orono; Tufts University; Garvan Institute of Medical Research; Novartis
RP Reagan, MR (通讯作者)，Ctr Mol Med, 81 Res Dr, Scarborough, ME 04074 USA.; Reagan, MR (通讯作者)，Ctr Translat Res, 81 Res Dr, Scarborough, ME 04074 USA.
EM michaela.r.reagan@gmail.com
RI ; McDonald, Michelle/AAD 4760 2019; Reagan, Michaela/E 3549 2017; rosen,
   clifford/JOZ 3228 2023
OI McDonald, Michelle/0000 0002 3928 2506; Croucher,
   Peter/0000 0002 7102 2413; Reagan, Michaela/0000 0003 2884 6481; 
FU Maine Medical Center Research Institute; National Institute of Diabetes
   and Digestive and Kidney Diseases [R24DK092759]; National Institute of
   General Medical Sciences [P30GM106391]; American Cancer Society
   [IRG 16 191 33]
FX Maine Medical Center Research Institute, Grant number: Start up funding;
   National Institute of Diabetes and Digestive and Kidney Diseases, Grant
   number: R24DK092759; National Institute of General Medical Sciences,
   Grant number: P30GM106391; American Cancer Society Research Grant, Grant
   number: IRG 16 191 33
CR Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200
   Amrein K, 2012, J CLIN ENDOCR METAB, V97, P148, DOI 10.1210/jc.2011 2152
   Costa AG, 2014, EXPERT OPIN BIOL TH, V14, P697, DOI 10.1517/14712598.2014.895808
   de Paula FJA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129764
   Devlin MJ, 2011, AM J HUM BIOL, V23, P577, DOI 10.1002/ajhb.21202
   Devlin MJ, 2010, J BONE MINER RES, V25, P2078, DOI 10.1002/jbmr.82
   Doucette CR, 2015, J CELL PHYSIOL, V230, P2032, DOI 10.1002/jcp.24954
   Falank C, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00067
   Fan Y, 2017, CELL METAB, V25, P661, DOI 10.1016/j.cmet.2017.01.001
   Florio M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11505
   Fulzele K, 2010, CELL, V142, P309, DOI 10.1016/j.cell.2010.06.002
   Genant HK, 2017, J BONE MINER RES, V32, P181, DOI 10.1002/jbmr.2932
   Griffith JF, 2005, RADIOLOGY, V236, P945, DOI 10.1148/radiol.2363041425
   Gustafson B, 2012, DIABETES, V61, P1217, DOI 10.2337/db11 1419
   Hardouin P, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00085
   Heath DJ, 2009, J BONE MINER RES, V24, P425, DOI 10.1359/JBMR.081104
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Kennell JA, 2005, J BIOL CHEM, V280, P24004, DOI 10.1074/jbc.M501080200
   Kim SW, 2017, J BONE MINER RES, V32, P892, DOI 10.1002/jbmr.3038
   Kugel H, 2001, J MAGN RESON IMAGING, V13, P263, DOI 10.1002/1522 2586(200102)13:2<263::AID JMRI1038>3.0.CO;2 M
   Li CY, 2011, BONE, V49, P1178, DOI 10.1016/j.bone.2011.08.012
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Li XD, 2014, ENDOCRINOLOGY, V155, P4785, DOI 10.1210/en.2013 1905
   Liaw L, 2016, J CELL BIOCHEM, V117, P2182, DOI 10.1002/jcb.25522
   Ma YHV, 2014, J CLIN ENDOCR METAB, V99, pE2584, DOI 10.1210/jc.2013 4493
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Moe SM, 2015, J BONE MINER RES, V30, P539, DOI 10.1002/jbmr.2372
   Morris EV, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00090
   Morrison RF, 1999, J BIOL CHEM, V274, P17088, DOI 10.1074/jbc.274.24.17088
   Morse A, 2015, BONE, V71, P155, DOI 10.1016/j.bone.2014.10.018
   Mosialou I, 2017, NATURE, V543, P385, DOI 10.1038/nature21697
   Ominsky MS, 2017, BONE, V96, P63, DOI 10.1016/j.bone.2016.10.019
   Qiu WM, 2007, J BONE MINER RES, V22, P1720, DOI 10.1359/JBMR.070721
   Reagan MR, 2014, BLOOD, V124, P3250, DOI 10.1182/blood 2014 02 558007
   Roschger A, 2014, BONE, V66, P182, DOI 10.1016/j.bone.2014.06.015
   Saini V, 2013, J BIOL CHEM, V288, P20122, DOI 10.1074/jbc.M112.441360
   Schaffler MB, 2014, CALCIFIED TISSUE INT, V94, P5, DOI 10.1007/s00223 013 9790 y
   Scheller EL, 2014, ANN NY ACAD SCI, V1311, P14, DOI 10.1111/nyas.12327
   Scheller EL, 2014, METHOD ENZYMOL, V537, P123, DOI 10.1016/B978 0 12 411619 1.00007 0
   Schutze Norbert, 2005, Cell Commun Signal, V3, P5, DOI 10.1186/1478 811X 3 5
   Shen W, 2007, OSTEOPOROSIS INT, V18, P641, DOI 10.1007/s00198 006 0285 9
   Shen W, 2014, J CLIN DENSITOM, V17, P163, DOI 10.1016/j.jocd.2013.02.009
   Shen W, 2012, J CLIN ENDOCR METAB, V97, P1337, DOI 10.1210/jc.2011 2605
   Singh L, 2016, BONE, V85, P29, DOI 10.1016/j.bone.2016.01.014
   Stern AR, 2012, BIOTECHNIQUES, V52, P361, DOI 10.2144/0000113876
   Styner M, 2014, BONE, V64, P39, DOI 10.1016/j.bone.2014.03.044
   Takeshita S, 2014, J BIOL CHEM, V289, P16699, DOI 10.1074/jbc.M114.547919
   Tian XY, 2011, BONE, V48, P197, DOI 10.1016/j.bone.2010.09.009
   Tu XL, 2012, BONE, V50, P209, DOI 10.1016/j.bone.2011.10.025
   Ukita M, 2016, J CELL BIOCHEM, V117, P1419, DOI 10.1002/jcb.25432
   Urano T, 2012, J CLIN ENDOCR METAB, V97, pE1473, DOI 10.1210/jc.2012 1218
   Urs S, 2010, FASEB J, V24, P3264, DOI 10.1096/fj.10 155127
   van Dinther M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062295
   Yee CS, 2016, BONE, V82, P122, DOI 10.1016/j.bone.2015.04.048
   Yoshikawa Y, 2011, J BONE MINER RES, V26, P2012, DOI 10.1002/jbmr.417
NR 55
TC 110
Z9 117
U1 3
U2 49
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD FEB
PY 2018
VL 233
IS 2
BP 1156
EP 1167
DI 10.1002/jcp.25976
PG 12
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA FL9RB
UT WOS:000414593500039
PM 28460416
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Wu, XN
   Wang, YQ
   Wang, H
   Ma, MR
   Hao, ZC
   Ma, YY
AF Wu, Xiangnan
   Wang, Yiqiao
   Wang, Hang
   Ma, Meirui
   Hao, Zhichao
   Ma, Yuanyuan
TI Neuropeptide Y regulates osteocyte phenotype and function through
   AHNAK Smad signalling
SO JOURNAL OF MOLECULAR ENDOCRINOLOGY
LA English
DT Article
DE osteocytes; neuropeptide Y; Smad signalling; AHNAK
ID BONE; DIFFERENTIATION; OSTEOBLAST; NPY; HOMEOSTASIS; RECEPTORS; CELLS
AB Neuropeptide Y (NPY) is a widespread hormone in the central and peripheral nervous systems that maintains body homeostasis. Central actions of hypothalamic NPY have been identified in bone metabolism. Osteocytes are the main source of NPY in bone tissue, indicating that osteocytic NPY could be a local alternative pathway for hypothalamic mediated regulation of bone and bone cells. Here, we show that osteocytic NPY induces cell viability and proliferation. Osteocyte derived factors are also closely associated with changes in cellular NPY mRNA levels. Furthermore, osteoblast mineralization was significantly induced by conditioned medium collected from NPY overexpressing osteocytes (P < 0.05). Importantly, the NPY AHNAK interaction was identified for the first time by co immunoprecipitation, and significant inactivation of p Smad1/5/9 was found in osteocytes with NPY or AHNAK insufficiency (P < 0.05). The activation of p Smad1/5/9 reversed NPY insufficiency caused decreases in the expression of osteocytic proliferating cell nuclear antigen and osteoblast markers including osteocalcin and Runx2 (P < 0.05); these findings showed an additional molecular mechanism by which NPY acts on cells through AHNAK mediated Smad1/5/9 signalling. Collectively, our findings provide novel insights into the function of NPY in regulating osteocyte phenotype and function and provide new insights for further investigation into osteocytic NPY mediated therapy.
C1 [Wu, Xiangnan; Wang, Yiqiao; Ma, Meirui; Hao, Zhichao; Ma, Yuanyuan] Sun Yat Sen Univ, Hosp Stomatol, Guanghua Sch Stomatol, Guangdong Prov Key Lab Stomatol, Guangzhou, Peoples R China.
   [Wang, Hang] Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu, Peoples R China.
   [Wang, Hang] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Chengdu, Peoples R China.
C3 Sun Yat Sen University; Sichuan University; Sichuan University
RP Hao, ZC; Ma, YY (通讯作者)，Sun Yat Sen Univ, Hosp Stomatol, Guanghua Sch Stomatol, Guangdong Prov Key Lab Stomatol, Guangzhou, Peoples R China.
EM haozhch3@mail.sysu.edu.cn; mayy5@mail.sysu.edu.cn
RI ; Hao, Zhichao/KLY 8312 2024; Ma, Meirui/NYS 3818 2025
OI Hao, Zhaichao/0000 0001 6077 3089; 
FU National Natural Science Foundation of China [81300856, 82201098];
   Natural Science Foundation of Guangdong Province [2018A030313153];
   Guangdong Basic and Appied Basic Research Foundation [2022A1515012494,
   2021A1515010782, 2019A1515110810]
FX Acknowledgements This work was supported by the National Natural Science
   Foundation of China (81300856, 82201098), the Natural Science Foundation
   of Guangdong Province (2018A030313153) and Guangdong Basic and Appied
   Basic Research Foundation (2022A1515012494, 2021A1515010782,
   2019A1515110810).
CR Agoro R, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00592
   Amano S, 2007, BBA GEN SUBJECTS, V1770, P966, DOI 10.1016/j.bbagen.2007.02.009
   Baldock PA, 2014, J BONE MINER RES, V29, P2238, DOI 10.1002/jbmr.2205
   Baldock PA, 2007, J BIOL CHEM, V282, P19092, DOI 10.1074/jbc.M700644200
   Baldock PA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008415
   Bonewald LF, 2017, ENDOCRIN METAB CLIN, V46, P1, DOI [10.1016/j.ec1.2016.09.003, 10.1016/j.ecl.2016.09.003]
   Chen QC, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.833485
   Chen WC, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.580378
   Compton JT, 2014, J BONE JOINT SURG AM, V96A, P1659, DOI 10.2106/JBJS.M.01096
   Dallas SL, 2010, ANN NY ACAD SCI, V1192, P437, DOI 10.1111/j.1749 6632.2009.05246.x
   Delgado Calle J, 2022, PHYSIOL REV, V102, DOI 10.1152/physrev.00043.2020
   Dong PH, 2018, PHARMACOLOGY, V102, P272, DOI 10.1159/000492576
   Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092 8674(00)81558 5
   Farrow EG, 2009, BONE, V44, P287, DOI 10.1016/j.bone.2008.10.040
   Feng JQ, 2013, BONE, V54, P213, DOI 10.1016/j.bone.2013.01.046
   Gu XC, 2016, NEUROPEPTIDES, V60, P61, DOI 10.1016/j.npep.2016.09.005
   Guo YF, 2021, J CELL PHYSIOL, V236, P4152, DOI 10.1002/jcp.30111
   Han YJ, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0019 6
   Idelevich A, 2020, J BONE MINER RES, V35, P1107, DOI 10.1002/jbmr.3967
   Igwe JC, 2009, J CELL BIOCHEM, V108, P621, DOI 10.1002/jcb.22294
   Kim I, 2020, ANAT SCI INT, V95, P323, DOI 10.1007/s12565 020 00525 3
   Kim YN, 2021, EXP MOL MED, V53, P468, DOI 10.1038/s12276 021 00573 3
   Lee IH, 2008, J BIOL CHEM, V283, P6312, DOI 10.1074/jbc.M706878200
   Lee NJ, 2010, J BONE MINER RES, V25, P1736, DOI 10.1002/jbmr.61
   Liu S, 2016, NEUROPEPTIDES, V56, P105, DOI 10.1016/j.npep.2015.12.008
   Ma YY, 2014, MOL CELL ENDOCRINOL, V384, P155, DOI 10.1016/j.mce.2014.01.021
   Ma YY, 2012, MOL CELLS, V33, P611, DOI 10.1007/s10059 012 0053 y
   Matic I, 2012, J MUSCULOSKEL NEURON, V12, P209
   Michel MC, 1998, PHARMACOL REV, V50, P143
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Park MH, 2016, STEM CELLS, V34, P2145, DOI 10.1002/stem.2383
   Pierrefite Carle V, 2015, AGEING RES REV, V24, P206, DOI 10.1016/j.arr.2015.08.004
   Qin L, 2020, BONE RES, V8, DOI 10.1038/s41413 020 0099 y
   Robling AG, 2020, ANNU REV PHYSIOL, V82, P485, DOI 10.1146/annurev physiol 021119 034332
   Shin S, 2016, OBESITY, V24, P398, DOI 10.1002/oby.21367
   Sousa DM, 2013, J ORTHOP RES, V31, P1570, DOI 10.1002/jor.22400
   Sundararaj S, 2021, CELL CALCIUM, V96, DOI 10.1016/j.ceca.2021.102403
   Teixeira L, 2009, J CELL BIOCHEM, V107, P908, DOI 10.1002/jcb.22194
   Woo JK, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0873 6
   Wu WQ, 2021, J CELL PHYSIOL, V236, P1903, DOI 10.1002/jcp.29973
   Yang Insook, 2022, BMB Rep, V55, P401
   Zaidi M, 2018, ENDOCR REV, V39, P701, DOI 10.1210/er.2018 00050
   Zhang B, 2020, MOL MED REP, V22, P4376, DOI 10.3892/mmr.2020.11506
   Zhang Y, 2021, ADV SCI, V8, DOI 10.1002/advs.202100808
NR 44
TC 0
Z9 0
U1 2
U2 9
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA STARLING HOUSE, 1600 BRISTOL PARKWAY N, BRISTOL, ENGLAND
SN 0952 5041
EI 1479 6813
J9 J MOL ENDOCRINOL
JI J. Mol. Endocrinol.
PD AUG 1
PY 2023
VL 71
IS 2
AR e230011
DI 10.1530/JME 23 0011
PG 15
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA O2ES0
UT WOS:001042008200003
PM 37163251
DA 2025 08 17
ER

PT J
AU Asakawa, A
   Fujimiya, M
   Niijima, A
   Fujino, K
   Kodama, N
   Sato, Y
   Kato, I
   Nanba, H
   Laviano, A
   Meguid, MM
   Inui, A
AF Asakawa, Akihiro
   Fujimiya, Mineko
   Niijima, Akira
   Fujino, Kazunori
   Kodama, Noriko
   Sato, Yuki
   Kato, Ikuo
   Nanba, Hiroaki
   Laviano, Alessandro
   Meguid, Michael M.
   Inui, Akio
TI Parathyroid hormone related protein has an anorexigenic activity via
   activation of hypothalamic urocortins 2 and 3
SO PSYCHONEUROENDOCRINOLOGY
LA English
DT Article
DE Parathyroid hormone related protein; Vagal nerve; Hypothalamus; Feeding
   behavior; Gut motility; Cachexia
ID HUMORAL HYPERCALCEMIA; FOOD INTAKE; MOTOR ACTIVITY; RATS; GHRELIN;
   CANCER; CACHEXIA; PEPTIDE; MALIGNANCY; ANTIBODY
AB Cancer cachexia is reported to be a major cause of cancer related death. Since the pathogenesis is not entirely understood, only few effective therapies have been established. Since myriad tumors produce parathyroid hormone related protein (PTHrP), plasma concentrations of PTHrP are increased in cancer cachexia. We measured the food intake, gastric emptying, conditioned taste aversion (CTA), and gene expression of hypothalamic neuropeptides in mice after administering PTHrP intraperitoneally. We administered PTHrP intravenously in rats and examined the gastroduodenal motility and vagal nerve activities. We also examined whether chronic administration of PTHrP influenced the food intake and body weight. Peripherally administered PTHrP induced negative energy balance by decreasing the food intake and gastric emptying; however, it did not induce CTA. The mechanism involved the activation of hypothalamic urocortins 2 and 3 through vagal afferent pathways and the suppression of gastroduodenal motor activity. The continuous infusion of PTHrP reduced the food intake and body weight gain with a concomitant decrease in the fat and skeletal muscle. Our findings suggest that PTHrP influences the food intake and body weight; therefore, PTHrP can be considered as a therapeutic target for cancer cachexia. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Asakawa, Akihiro; Inui, Akio] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Social & Behav Med, Kagoshima 8908544, Japan.
   [Fujimiya, Mineko] Sapporo Med Univ, Dept Anat, Sapporo, Hokkaido 5202192, Japan.
   [Niijima, Akira] Niigata Univ, Sch Med, Dept Physiol, Niigata 9518510, Japan.
   [Fujino, Kazunori] Shiga Univ Med Sci, Dept Surg, Otsu, Shiga 5202192, Japan.
   [Kodama, Noriko; Nanba, Hiroaki] Kobe Pharmaceut Univ, Dept Microbial Chem, Kobe, Hyogo 6588558, Japan.
   [Sato, Yuki; Kato, Ikuo] Hokuriku Univ, Dept Bioorgan Chem, Kanazawa, Ishikawa 9201181, Japan.
   [Laviano, Alessandro] Univ Roma La Sapienza, Dept Clin Med, I 00185 Rome, Italy.
   [Meguid, Michael M.] Suny Upstate Med Univ, Dept Surg, Syracuse, NY 13210 USA.
C3 Kagoshima University; Sapporo Medical University; Niigata University;
   Shiga University of Medical Science; Kobe Pharmaceutical University;
   Hokuriku University; Sapienza University Rome; State University of New
   York (SUNY) System; SUNY Upstate Medical University
RP Inui, A (通讯作者)，Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Social & Behav Med, 8 35 1 Sakuragaoka, Kagoshima 8908544, Japan.
EM inui@m.kufm.kagoshima u.ac.jp
RI Laviano, Alessandro/AFP 0597 2022
FU Hokuriku University
FX The work was partially supported by a special grant from Hokuriku
   University.
CR Asakawa A, 2001, GASTROENTEROLOGY, V120, P337, DOI 10.1053/gast.2001.22158
   BERNSTEIN IL, 1983, BEHAV NEURAL BIOL, V37, P134, DOI 10.1016/S0163 1047(83)91145 7
   BURTIS WJ, 1990, NEW ENGL J MED, V322, P1106, DOI 10.1056/NEJM199004193221603
   BURTIS WJ, 1987, J BIOL CHEM, V262, P7151
   Chen CY, 2005, GASTROENTEROLOGY, V129, P8, DOI 10.1053/j.gastro.2005.04.015
   Czimmer J, 2006, AM J PHYSIOL GASTR L, V290, pG511, DOI 10.1152/ajpgi.00289.2005
   Dautzenberg FM, 2002, TRENDS PHARMACOL SCI, V23, P71, DOI 10.1016/S0165 6147(02)01946 6
   DUGGAN JP, 1986, SCIENCE, V231, P609, DOI 10.1126/science.3511527
   Flier JS, 1998, CELL, V92, P437, DOI 10.1016/S0092 8674(00)80937 X
   Forero A, 2003, SEMIN ONCOL, V30, P1, DOI 10.1053/j.seminoncol.2003.10.002
   Fujino K, 2003, J PHYSIOL LONDON, V550, P227, DOI 10.1113/jphysiol.2003.040600
   GAICH G, 1990, ENDOCRINOLOGY, V127, P1444, DOI 10.1210/endo 127 3 1444
   GEARY N, 1993, AM J PHYSIOL, V264, pR116, DOI 10.1152/ajpregu.1993.264.1.R116
   HARVEY KB, 1979, CANCER, V43, P2065, DOI 10.1002/1097 0142(197905)43:5+<2065::AID CNCR2820430714>3.0.CO;2 1
   Hsu SY, 2001, NAT MED, V7, P605, DOI 10.1038/87936
   Iguchi H, 2006, J BONE MINER METAB, V24, P16, DOI 10.1007/s00774 005 0640 5
   Inui A, 2002, CA CANCER J CLIN, V52, P72, DOI 10.3322/canjclin.52.2.72
   Inui A, 2004, FASEB J, V18, P439, DOI 10.1096/fj.03 0641rev
   KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277
   Koda S, 2005, ENDOCRINOLOGY, V146, P2369, DOI 10.1210/en.2004 1266
   MOSELEY JM, 1987, P NATL ACAD SCI USA, V84, P5048, DOI 10.1073/pnas.84.14.5048
   Niijima A, 1995, OBES RES, V3, pS741, DOI 10.1002/j.1550 8528.1995.tb00494.x
   Ohata H, 2004, PEPTIDES, V25, P1703, DOI 10.1016/j.peptides.2004.05.023
   Onuma E, 2005, INT J CANCER, V116, P471, DOI 10.1002/ijc.21038
   Pardo FS, 2004, CANCER, V101, P2622, DOI 10.1002/cncr.20689
   Sato K, 2003, SEMIN ONCOL, V30, P167, DOI 10.1053/j.seminoncol.2003.08.019
   Schnell FM, 2003, ONCOLOGIST, V8, P187, DOI 10.1634/theoncologist.8 2 187
   Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534
   Strewler GJ, 2000, NEW ENGL J MED, V342, P177, DOI 10.1056/NEJM200001203420306
   STREWLER GJ, 1987, J CLIN INVEST, V80, P1803, DOI 10.1172/JCI113275
   TOOMEY D, 1995, CANCER AM CANCER SOC, V76, P2418, DOI 10.1002/1097 0142(19951215)76:12<2418::AID CNCR2820761204>3.0.CO;2 C
   VAUGHAN J, 1995, NATURE, V378, P287, DOI 10.1038/378287a0
   Zhang JV, 2005, SCIENCE, V310, P996, DOI 10.1126/science.1117255
NR 33
TC 19
Z9 20
U1 0
U2 1
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306 4530
J9 PSYCHONEUROENDOCRINO
JI Psychoneuroendocrinology
PD SEP
PY 2010
VL 35
IS 8
BP 1178
EP 1186
DI 10.1016/j.psyneuen.2010.02.003
PG 9
WC Endocrinology & Metabolism; Neurosciences; Psychiatry
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry
GA 644IU
UT WOS:000281369300007
PM 20188481
DA 2025 08 17
ER

PT J
AU Peng, JX
   Zhao, KX
   Zhu, JL
   Wang, YB
   Sun, P
   Yang, QC
   Zhang, T
   Han, WQ
   Hu, WJ
   Yang, WL
   Ruan, JW
   Qian, Y
AF Peng, Jiaxuan
   Zhao, Kangxian
   Zhu, Jiling
   Wang, Yanben
   Sun, Peng
   Yang, Qichang
   Zhang, Tan
   Han, Weiqi
   Hu, Wenjun
   Yang, Wanlei
   Ruan, Jianwei
   Qian, Yu
TI Sarsasapogenin Suppresses RANKL Induced Osteoclastogenesis in vitro and
   Prevents Lipopolysaccharide Induced Bone Loss in vivo
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Article
DE sarsasapogenin; osteoclast; osteoclastogenesis; NF kappa B; MAPK;
   NFATc1; therapeutics
AB Introduction: Osteoclasts are giant polynuclear cells; their main function is bone resorption. An increased number of osteoclasts and enhanced bone resorption exert significant effects on osteoclast related bone lytic diseases, including osteoporosis. Given the limitations of current therapies for osteolytic diseases, it is urgently required to develop safer and more effective alternatives. Sarsasapogenin, a major sapogenin from Anemarrhena asphodeloides Bunge, possesses potent antitumor effects and inhibits NF kappa B and MAPK signaling. However, the manner in which it affects osteoclasts is unclear.
   Methods: We investigated the effects of anti osteoclastogenic and anti resorptive of sarsasapogenin on bone marrow derived osteoclasts.
   Results: Sarsasapogenin inhibited multiple RANKL induced signaling cascades, thereby inhibiting the induction of key osteoclast transcription factor NFATc1. The in vivo and in vitro results were consistent: sarsasapogenin treatment protected against bone loss in a mouse osteolysis model induced by lipopolysaccharide.
   Conclusion: Our research confirms that sarsasapogenin can be used as a new treatment for osteoclast related osteolytic diseases.
C1 [Peng, Jiaxuan; Qian, Yu] Guangxi Med Univ, Guangxi Key Lab Regenerat Med, Nanning 530021, Guangxi, Peoples R China.
   [Zhao, Kangxian; Sun, Peng; Yang, Qichang; Qian, Yu] Wenzhou Med Univ, Affiliated Hosp 2, Wenzhou 325000, Zhejiang, Peoples R China.
   [Zhao, Kangxian; Sun, Peng; Yang, Qichang; Qian, Yu] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou 325000, Zhejiang, Peoples R China.
   [Zhu, Jiling] Shaoxing Univ, Dept Clin Med, Med Coll, Shaoxing 312000, Zhejiang, Peoples R China.
   [Wang, Yanben; Zhang, Tan; Han, Weiqi; Hu, Wenjun; Yang, Wanlei; Qian, Yu] Zhejiang Univ, Shaoxing Peoples Hosp, Dept Orthopaed, Sch Med, Shaoxing 312000, Zhejiang, Peoples R China.
   [Wang, Yanben] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Orthopaed, Hangzhou, Zhejiang, Peoples R China.
   [Ruan, Jianwei] Taizhou Municipal Hosp, Dept Orthopaed, Taizhou 318000, Zhejiang, Peoples R China.
C3 Guangxi Medical University; Wenzhou Medical University; Wenzhou Medical
   University; Shaoxing University; Zhejiang University; Zhejiang
   University; Taizhou University
RP Qian, Y (通讯作者)，Zhejiang Univ, Shaoxing Peoples Hosp, Dept Orthopaed, Sch Med, Shaoxing 312000, Zhejiang, Peoples R China.
EM doctor120@hotmail.com
RI Sun, Peng/KDO 4243 2024
FU National Science Foundation of China [81871801]; Zhejiang Basic Public
   Welfare Research Project [LGF18H060010]; Natural Science Foundation of
   Zhejiang Province [LQ19H060001]; Projects of Medical and Health
   Technology Development Program in Zhejiang Province [2018KY824];
   Zhejiang Medical and Health Science and Technology Project [2019KY712]
FX This study was supported by the National Science Foundation of China
   (Grant No. 81871801), Zhejiang Basic Public Welfare Research Project
   (LGF18H060010), Natural Science Foundation of Zhejiang Province (Grant
   No. LQ19H060001), Projects of Medical and Health Technology Development
   Program in Zhejiang Province (2018KY824), and Zhejiang Medical and
   Health Science and Technology Project (2019KY712).
CR Angel NZ, 2000, J BONE MINER RES, V15, P103, DOI 10.1359/jbmr.2000.15.1.103
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Bao WN, 2007, CELL BIOL INT, V31, P887, DOI 10.1016/j.cellbi.2007.02.001
   Black DM, 2019, ENDOCR REV, V40, P333, DOI 10.1210/er.2018 00001
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cackowski FC, 2010, BLOOD, V115, P140, DOI 10.1182/blood 2009 08 237628
   Darnay BG, 2007, ADV EXP MED BIOL, V597, P152
   Dong D, 2017, ACTA PHARMACOL SIN, V38, P699, DOI 10.1038/aps.2016.180
   Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Hu B, 2019, FASEB J, V33, P2574, DOI 10.1096/fj.201800920R
   Huang C, 2017, CNS NEUROSCI THER, V23, P498, DOI 10.1111/cns.12697
   Jiang YF, 2018, J CELL MOL MED, V22, P3941, DOI 10.1111/jcmm.13674
   Kashiwada M, 1998, J EXP MED, V187, P237, DOI 10.1084/jem.187.2.237
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Kim JM, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906 016 1550 x
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kim MS, 2010, J BIOL CHEM, V285, P6913, DOI 10.1074/jbc.M109.051557
   Lim SM, 2015, INT IMMUNOPHARMACOL, V25, P493, DOI 10.1016/j.intimp.2015.02.016
   Lorenzo J, 2008, ENDOCR REV, V29, P403, DOI 10.1210/er.2007 0038
   Ma DS, 2001, CLIN CHIM ACTA, V314, P107, DOI 10.1016/S0009 8981(01)00638 6
   Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992 1000.2002
   Nich Christophe, 2011, Arthritis Res Ther, V13, pR100, DOI 10.1186/ar3381
   Park BK, 2018, BIOMOL THER, V26, P553, DOI 10.4062/biomolther.2017.249
   Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301 472X(99)00061 2
   Sapkota M, 2018, FOOD CHEM TOXICOL, V120, P418, DOI 10.1016/j.fct.2018.07.032
   Shen SY, 2013, BIOCHEM BIOPH RES CO, V441, P519, DOI 10.1016/j.bbrc.2013.10.101
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109 004 0612 6
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Wagner EF, 2010, ANN RHEUM DIS, V69, P86, DOI 10.1136/ard.2009.119396
   Wang B, 2018, J CELL MOL MED, V22, P4236, DOI 10.1111/jcmm.13703
   Wang QQ, 2019, J CELL MOL MED, V23, P380, DOI 10.1111/jcmm.13942
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097 2765(00)80232 4
   Wotton CJ, 2019, BONE, V124, P69, DOI 10.1016/j.bone.2019.04.003
   Wu ZX, 2019, J CELL PHYSIOL, V234, P17812, DOI 10.1002/jcp.28408
   Yang HL, 2016, BIOMATERIALS, V80, P1, DOI 10.1016/j.biomaterials.2015.11.046
   Yuan GX, 2019, CANCER LETT, V443, P135, DOI 10.1016/j.canlet.2018.11.038
   Zhai ZJ, 2014, BRIT J PHARMACOL, V171, P663, DOI 10.1111/bph.12463
   Zhang T, 2019, J CELL PHYSIOL, V234, P2719, DOI 10.1002/jcp.27087
NR 42
TC 11
Z9 11
U1 0
U2 4
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177 8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2020
VL 14
BP 3435
EP 3447
DI 10.2147/DDDT.S256867
PG 13
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA NE8OI
UT WOS:000562864600001
PM 32943842
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wu, ZX
   Hu, LF
   Ru, K
   Zhang, WJ
   Xu, X
   Liu, SY
   Liu, H
   Jia, YX
   Liang, SJ
   Chen, ZH
   Qian, AR
AF Wu, Zixiang
   Hu, Lifang
   Ru, Kang
   Zhang, Wenjuan
   Xu, Xia
   Liu, Shuyu
   Liu, Hua
   Jia, Yunxia
   Liang, Shujing
   Chen, Zhihao
   Qian, Airong
TI Ellagic acid inhibits CDK12 to increase osteoblast differentiation and
   alleviate osteoporosis in hindlimb unloaded and ovariectomized mice
SO PHYTOMEDICINE
LA English
DT Article
DE CDK12; Ellagic acid; Hindlimb unloaded; Ovariectomized; Osteoblast
   differentiation; Simulated microgravity
ID BONE LOSS
AB Background: Osteoporosis is a highly prevalent bone disease occurred commonly in astronauts and post menopausal women due to mechanical unloading and estrogen deficiency, respectively. At present, there are some traditional Chinese medicine compounds for preventing and treating osteoporosis induced by simulated microgravity, but the detailed components of the traditional Chinese medicines still need to be confirmed and osteoporosis is still untreatable due to a lack of effective small molecule natural medicine.
   Purpose: To explore the role of cyclin dependent kinase 12 (CDK12) in osteoporosis induced by simulated microgravity and the therapeutic effect of CDK12 targeted Ellagic Acid (EA) on osteoporosis.
   Methods: Our previous study has suggested that CDK12 as a potential target for treating and preventing osteo porosis. In this study, the role of CDK12 in osteoblasts and mice bone tissues was further studied under simulated microgravity. And by targeting CDK12, natural small molecule product EA was screened out based on a large scale through the weighted set similarity (WES) method and the therapeutic effects of EA on osteoporosis was investigated in hindlimb unloaded (HU) mouse model and ovariectomized (OVX) model.
   Results: The results demonstrated that simulated microgravity inhibited bone formation and up regulated the expression of CDK12. Furthermore, CDK12 siRNA or THZ531 (an inhibitor of CDK 12) promoted osteoblast differentiation, while the overexpression of CDK12 inhibited osteoblasts differentiation. And we further proved that CDK12 targeted EA showed a rescue effect on osteoblast differentiation inhibition caused by simulated microgravity. EA (50 mg.kg( 1).day( 1)) daily intragastric administration alleviated the symptoms of osteoporosis and accompanied with the improvement of trabecular bone and cortical bone parameters with significantly overexpression of CDK12.
   Conclusion: EA efficiently improves osteoporosis by targeting CDK12, which is a suppresser of osteoblast dif ferentiation and a novel therapeutic target for treating osteoporosis.
C1 [Wu, Zixiang; Hu, Lifang; Ru, Kang; Zhang, Wenjuan; Xu, Xia; Liu, Shuyu; Liu, Hua; Jia, Yunxia; Liang, Shujing; Chen, Zhihao; Qian, Airong] Northwestern Polytech Univ, Sch Life Sci, Xian Key Lab Special Med & Hlth Engn, Lab Bone Metab, Xian 710072, Peoples R China.
   [Wu, Zixiang; Hu, Lifang; Ru, Kang; Zhang, Wenjuan; Xu, Xia; Liu, Shuyu; Liu, Hua; Jia, Yunxia; Liang, Shujing; Chen, Zhihao; Qian, Airong] Northwestern Polytech Univ, Sch Life Sci, Key Lab Space Biosci & Biotechnol, Xian 710072, Peoples R China.
   [Wu, Zixiang; Hu, Lifang; Ru, Kang; Zhang, Wenjuan; Xu, Xia; Liu, Shuyu; Liu, Hua; Jia, Yunxia; Liang, Shujing; Chen, Zhihao; Qian, Airong] Northwestern Polytech Univ, Res Ctr Special Med & Hlth Syst Engn, Sch Life Sci, Xian 710072, Peoples R China.
   [Wu, Zixiang; Hu, Lifang; Ru, Kang; Zhang, Wenjuan; Liu, Shuyu; Liu, Hua; Jia, Yunxia; Liang, Shujing; Chen, Zhihao; Qian, Airong] Northwestern Polytech Univ, Sch Life Sci, NPU UAB Joint Lab Bone Metab, Xian 710072, Peoples R China.
   [Hu, Lifang; Qian, Airong] Northwestern Polytech Univ, Sch Life Sci, 127 West Youyi Rd, Xian 710072, Shaanxi, Peoples R China.
C3 Northwestern Polytechnical University; Northwestern Polytechnical
   University; Northwestern Polytechnical University; Northwestern
   Polytechnical University; Northwestern Polytechnical University
RP Hu, LF; Qian, AR (通讯作者)，Northwestern Polytech Univ, Sch Life Sci, 127 West Youyi Rd, Xian 710072, Shaanxi, Peoples R China.
EM hulifang@nwpu.edu.cn; qianair@nwpu.edu.cn
RI ; Hu, Lifang/W 8020 2019; Chen, Zhihao/ACK 3514 2022
OI Liu, Shuyu/0000 0001 9095 0496; Hu, Lifang/0000 0003 1648 4428; Chen,
   Zhihao/0000 0003 0128 1409
FU National Natural Science Foundation of China [81772017, 82072106];
   Natural Science Basic Research Plan in Shaanxi Province of China
   [2023 JC YB  163]; Young Talent Fund of University Association for
   Science and Technology in Shaanxi, China [20170401]
FX This work was supported by the National Natural Science Foundation of
   China (81772017, 82072106) , the Project Supported by Natural Science
   Basic Research Plan in Shaanxi Province of China (2023 JC YB  163) and
   Young Talent Fund of University Association for Science and Technology
   in Shaanxi, China (20170401) .
CR Ahmad M, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00195 z
   Alexander JM, 2001, J BONE MINER RES, V16, P1665, DOI 10.1359/jbmr.2001.16.9.1665
   Amirhosseini M., 2019, J CELL PHYSIOL
   Amirhosseini M, 2019, J CELL PHYSIOL, V234, P16503, DOI 10.1002/jcp.28321
   Can A, 2012, JOVE J VIS EXP, DOI 10.3791/3769
   Chen L, 2014, STEM CELLS, V32, P902, DOI 10.1002/stem.1615
   El Desoky AHH, 2022, J NAT MED TOKYO, V76, P575, DOI 10.1007/s11418 022 01622 5
   Fujita M, 2002, BIOCHEM BIOPH RES CO, V299, P222, DOI 10.1016/S0006 291X(02)02640 2
   Gabel L, 2022, BRIT J SPORT MED, V56, P196, DOI 10.1136/bjsports 2020 103602
   Hu LF, 2021, CELL DEATH DIFFER, V28, P2160, DOI 10.1038/s41418 021 00744 9
   Jin X, 2022, NPJ MICROGRAVITY, V8, DOI 10.1038/s41526 022 00210 x
   Kciuk M, 2022, BBA REV CANCER, V1877, DOI 10.1016/j.bbcan.2022.188716
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kim HN, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222111711
   Krüger BT, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10020404
   Li C, 2021, BIOL TRACE ELEM RES, V199, P1215, DOI 10.1007/s12011 020 02239 z
   Liu HY, 2022, COMPUT METHOD BIOMEC, V25, P1757, DOI 10.1080/10255842.2022.2037130
   Liu Y, 2022, EUR J MED CHEM, V229, DOI 10.1016/j.ejmech.2021.114056
   Ma XL, 2021, EUR J PHARMACOL, V911, DOI 10.1016/j.ejphar.2021.174555
   Malumbres M, 2014, GENOME BIOL, V15, DOI 10.1186/gb4184
   Medina Contreras JML, 2020, MOL CELL BIOCHEM, V475, P261, DOI 10.1007/s11010 020 03879 4
   Peng ZC, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.911326
   Qian DY, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.754088
   Rantlha M, 2017, ARCH PHARM RES, V40, P79, DOI 10.1007/s12272 016 0790 0
   Sanders S, 2013, SOUTH MED J, V106, P698, DOI 10.1097/SMJ.0b013e3182a0df8b
   Shakeri A, 2018, CURR PHARM DESIGN, V24, P106, DOI 10.2174/1381612823666171115094557
   Sibonga JD, 2015, AEROSP MED HUM PERF, V86, pA38, DOI 10.3357/AMHP.EC06.2015
   SMITH EL, 1986, ACTA MED SCAND, P149
   Smith JK, 2020, LIFE BASEL, V10, DOI 10.3390/life10090207
   Sun ZY, 2019, J CELL BIOCHEM, V120, P4009, DOI 10.1002/jcb.27685
   Takahashi A, 2018, J BIOL CHEM, V293, P19387, DOI 10.1074/jbc.RA118.004834
   Wang X, 2022, FOOD FUNCT, V13, P2913, DOI [10.1039/d1fo02755g, 10.1039/D1FO02755G]
   Wei W, 2022, EUR J PHARMACOL, V921, DOI 10.1016/j.ejphar.2022.174865
   Xu WF, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.842101
   Yousefzadeh N, 2020, EXCLI J, V19, P89, DOI 10.17179/excli2019 1990
   Zhang MN, 2021, AM J CANCER RES, V11, P1913
   Zhang ND, 2016, J ETHNOPHARMACOL, V189, P61, DOI 10.1016/j.jep.2016.05.025
   Zheng CL, 2015, SCI REP UK, V5, DOI 10.1038/srep11970
   Zhou TX, 2021, J HEALTHC ENG, V2021, DOI 10.1155/2021/2852661
NR 39
TC 5
Z9 5
U1 1
U2 41
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0944 7113
EI 1618 095X
J9 PHYTOMEDICINE
JI Phytomedicine
PD JUN
PY 2023
VL 114
AR 154745
DI 10.1016/j.phymed.2023.154745
EA MAR 2023
PG 14
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA A0BW7
UT WOS:000951875800001
PM 36931096
DA 2025 08 17
ER

PT J
AU Chen, QY
   Wang, YH
   Shi, C
   Tong, MC
   Sun, HB
   Dong, M
   Liu, S
   Wang, LA
AF Chen, Qianyang
   Wang, Yuhan
   Shi, Chun
   Tong, Meichen
   Sun, Haibo
   Dong, Ming
   Liu, Shuo
   Wang, Lina
TI Molecular Mechanism of the Asarum Angelica Drug Pair in the Treatment of
   Periodontitis Based on Network Pharmacology and Experimental
   Verification
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE Asarum Angelica; drug pair; network pharmacology; docking simulation;
   periodontitis
ID FACTOR KAPPA B; EXPRESSION; SINENSIS; RECEPTOR; DISEASE; FAMILY
AB (1) To examine the potential mechanism of the Asarum Angelica drug pair against periodontitis and provide an experimental basis for the treatment of periodontitis with herbal medicine. (2) The core components and core targets of the Asarum Angelica drug pair in the treatment of periodontitis were detected according to network pharmacology methods. Finally, the effect of the Asarum Angelica drug pair on osteogenic differentiation was observed in mouse embryonic osteoblast precursor cells. (3) According to the results of network pharmacology, there are 10 potential active ingredients in the Asarum Angelica drug pair, and 44 potential targets were obtained by mapping the targets with periodontitis treatment. Ten potential active ingredients, such as kaempferol and beta sitosterol, may play a role in treating periodontitis. Cell experiments showed that the Asarum Angelica drug pair can effectively promote the expression of osteoblast markers alkaline phosphatase (ALP), Runt related Transcription Factor 2 (RUNX2), and BCL2 mRNA and protein in an inflammatory environment (p < 0.05). (4) Network pharmacology effectively analyzed the molecular mechanism of Asarum Angelica in the treatment of periodontitis, and the Asarum Angelica drug pair can promote the differentiation of osteoblasts.
C1 [Chen, Qianyang; Wang, Yuhan; Shi, Chun; Tong, Meichen; Sun, Haibo; Dong, Ming; Liu, Shuo; Wang, Lina] Dalian Med Univ, Coll Stomatol, Dept Endodont & Periodont, 9 West Sect,Lvshun South Rd, Dalian 116044, Peoples R China.
   [Chen, Qianyang; Shi, Chun; Tong, Meichen; Sun, Haibo; Dong, Ming; Liu, Shuo; Wang, Lina] Dalian Med Univ, Academician Lab Immune & Oral Dev & Regenerat, Dalian 116044, Peoples R China.
C3 Dalian Medical University; Dalian Medical University
RP Liu, S; Wang, LA (通讯作者)，Dalian Med Univ, Coll Stomatol, Dept Endodont & Periodont, 9 West Sect,Lvshun South Rd, Dalian 116044, Peoples R China.; Liu, S; Wang, LA (通讯作者)，Dalian Med Univ, Academician Lab Immune & Oral Dev & Regenerat, Dalian 116044, Peoples R China.
EM cqy01090@163.com; 13604258520@163.com; shichun33@163.com;
   tmc1765421025@163.com; sun05190207@163.com; 13998495831@139.com;
   lius04@dmu.edu.cn; wanglina@dmu.edu.cn
FU National Natural Science Foundation of China
FX No Statement Available
CR Abbass MM, 2012, ARCH ORAL BIOL, V57, P1342, DOI 10.1016/j.archoralbio.2012.06.007
   An XD, 2021, BIOMED PHARMACOTHER, V137, DOI 10.1016/j.biopha.2021.111267
   Ang L, 2020, COMPLEMENT THER CLIN, V39, DOI 10.1016/j.ctcp.2020.101174
   Athanasios A, 2017, CURR DRUG METAB, V18, P5, DOI [10.2174/1389200217666161102150602, 10.2174/138920021801170119204832]
   Bakrim S, 2022, ANTIOXIDANTS BASEL, V11, DOI 10.3390/antiox11101912
   Balli U, 2016, J PERIODONTAL IMPLAN, V46, P84, DOI 10.5051/jpis.2016.46.2.84
   Belibasakis GN, 2018, ARCH ORAL BIOL, V96, P230, DOI 10.1016/j.archoralbio.2018.10.001
   Choi IS, 2013, J PERIODONTOL, V84, P545, DOI 10.1902/jop.2012.120180
   Gaillard T, 2018, J CHEM INF MODEL, V58, P1697, DOI 10.1021/acs.jcim.8b00312
   Graziani F, 2017, PERIODONTOL 2000, V75, P152, DOI 10.1111/prd.12201
   Grosdidier A, 2011, NUCLEIC ACIDS RES, V39, pW270, DOI 10.1093/nar/gkr366
   Hathaway Schrader JD, 2021, PERIODONTOL 2000, V86, P157, DOI 10.1111/prd.12368
   Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118
   Wu JS, 2022, J TRADIT CHIN MED, V42, P479, DOI 10.19852/j.cnki.jtcm.20220408.003
   Jie F, 2022, BIOMED PHARMACOTHER, V153, DOI 10.1016/j.biopha.2022.113317
   Jin WQ, 2022, EVID BASED COMPL ALT, V2022, DOI 10.1155/2022/3853303
   Jin Y, 2016, J ETHNOPHARMACOL, V181, P158, DOI 10.1016/j.jep.2016.01.033
   Kassebaum NJ, 2014, J DENT RES, V93, P1045, DOI 10.1177/0022034514552491
   Komori T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071694
   Kwon T, 2021, INT DENT J, V71, P462, DOI 10.1111/idj.12630
   Larvin H, 2021, J CLIN PERIODONTOL, V48, P1587, DOI 10.1111/jcpe.13536
   Le TT, 2022, CHEM BIODIVERS, V19, DOI 10.1002/cbdv.202100986
   Li WH, 2023, AGEING RES REV, V89, DOI 10.1016/j.arr.2023.101981
   Li YL, 2021, J PERIODONTAL RES, V56, P837, DOI 10.1111/jre.12914
   Liu HZ, 2022, J ETHNOPHARMACOL, V297, DOI 10.1016/j.jep.2022.115569
   Liu M, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104896
   Liu R, 2019, PHARM BIOL, V57, P161, DOI 10.1080/13880209.2019.1577461
   Liu SY, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.761593
   Luo D, 2023, PHYTOTHER RES, V37, P3820, DOI 10.1002/ptr.7920
   Ma JH, 2019, J ETHNOPHARMACOL, V231, P152, DOI 10.1016/j.jep.2018.10.040
   Meyle J, 2015, PERIODONTOL 2000, V69, P7, DOI 10.1111/prd.12104
   Nie FJ, 2020, LIFE SCI, V258, DOI 10.1016/j.lfs.2020.118143
   Nogales C, 2022, TRENDS PHARMACOL SCI, V43, P136, DOI 10.1016/j.tips.2021.11.004
   Nonaka K, 2018, J PERIODONTAL RES, V53, P334, DOI 10.1111/jre.12518
   Özcan E, 2017, CLIN ORAL INVEST, V21, P1113, DOI 10.1007/s00784 016 1871 7
   Peng ZC, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.911326
   Piñero J, 2017, NUCLEIC ACIDS RES, V45, pD833, DOI 10.1093/nar/gkw943
   Piñero J, 2015, DATABASE OXFORD, DOI 10.1093/database/bav028
   Pinzi L, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184331
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Sherman BT, 2022, NUCLEIC ACIDS RES, V50, pW216, DOI 10.1093/nar/gkac194
   Shi SH, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.782096
   Siddiqui WA, 2015, ARCH TOXICOL, V89, P289, DOI 10.1007/s00204 014 1448 7
   Slots J, 2020, PERIODONTOL 2000, V83, P272, DOI 10.1111/prd.12325
   Slots J, 2017, PERIODONTOL 2000, V75, P7, DOI 10.1111/prd.12221
   Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157
   Sun L, 2022, MOLECULES, V27, DOI 10.3390/molecules27103269
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI [10.1093/nar/gky1131, 10.1093/nar/gkac1000]
   Valm AM, 2019, J MOL BIOL, V431, P2957, DOI 10.1016/j.jmb.2019.05.016
   Vimalraj S, 2020, GENE, V754, DOI 10.1016/j.gene.2020.144855
   Wang Q., 2017, Ph.D. Dissertation
   Wang Z.S., 2008, Shennongs Herb, VVolume 2, P62
   Wei WL, 2016, J ETHNOPHARMACOL, V190, P116, DOI 10.1016/j.jep.2016.05.023
   West K, 2009, CURR OPIN INVEST DR, V10, P491
   Wu Y, 2022, SCI REP UK, V12, DOI 10.1038/s41598 021 03980 8
   Yalniz FF, 2019, DRUGS, V79, P1287, DOI 10.1007/s40265 019 01163 4
   Yang H, 2014, J PERIODONTAL RES, V49, P382, DOI 10.1111/jre.12117
   Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308
   Yu SJ, 2012, J PERIODONTOL, V83, P119, DOI 10.1902/jop.2011.100754
   Zhao H, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.896637
   Zheng YX, 2022, TRANSL PEDIATR, V11, P1534, DOI 10.21037/tp 22 386
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09234 6
NR 62
TC 3
Z9 4
U1 8
U2 31
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD DEC
PY 2023
VL 24
IS 24
AR 17389
DI 10.3390/ijms242417389
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA DK9F0
UT WOS:001132047300001
PM 38139216
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Uribe Etxebarria, V
   García Gallastegui, P
   Pérez Garrastachu, M
   Casado Andrés, M
   Irastorza, I
   Unda, F
   Ibarretxe, G
   Subirán, N
AF Uribe Etxebarria, Veronica
   Garcia Gallastegui, Patricia
   Perez Garrastachu, Miguel
   Casado Andres, Maria
   Irastorza, Igor
   Unda, Fernando
   Ibarretxe, Gaskon
   Subiran, Nerea
TI Wnt 3a Induces Epigenetic Remodeling in Human Dental Pulp Stem Cells
SO CELLS
LA English
DT Article
DE dental pulp stem cells; chromatin remodeling; cell cycle; pluripotency;
   DNA methylation; histone acetylation; histone methylation; Notch
   pathway; Wnt pathway
ID BIVALENT HISTONE MODIFICATIONS; DNA METHYLATION; SOMATIC CELLS;
   SELF RENEWAL; 3RD MOLAR; G1 PHASE; IN VITRO; DIFFERENTIATION;
   PLURIPOTENCY; NOTCH
AB Dental pulp stem cells (DPSCs) from adult teeth show the expression of a very complete repertoire of stem pluripotency core factors and a high plasticity for cell reprogramming. Canonical Wnt and Notch signaling pathways regulate stemness and the expression of pluripotency core factors in DPSCs, and even very short term (48 h) activations of the Wnt pathway induce a profound remodeling of DPSCs at the physiologic and metabolic levels. In this work, DPSC cultures were exposed to treatments modulating Notch and Wnt signaling, and also induced to differentiate to osteo/adipocytes. DNA methylation, histone acetylation, histone methylation, and core factor expression levels where assessed by mass spectroscopy, Western blot, and qPCR. A short term activation of Wnt signaling by WNT 3A induced a genomic DNA demethylation, and increased histone acetylation and histone methylation in DPSCs. The efficiency of cell reprogramming methods relies on the ability to surpass the epigenetic barrier, which determines cell lineage specificity. This study brings important information about the regulation of the epigenetic barrier by Wnt signaling in DPSCs, which could contribute to the development of safer and less aggressive reprogramming methodologies with a view to cell therapy.
C1 [Uribe Etxebarria, Veronica; Garcia Gallastegui, Patricia; Perez Garrastachu, Miguel; Casado Andres, Maria; Irastorza, Igor; Unda, Fernando; Ibarretxe, Gaskon] Univ Basque Country, Cell Biol & Histol Dept, UPV EHU, Barrio Sarriena S N, Leioa 48940, Spain.
   [Uribe Etxebarria, Veronica] NYU, Pathol Dept, 550 1St Ave, New York, NY 10016 USA.
   [Casado Andres, Maria] Univ Bordeaux, INSERM, UMR1029, Unite Mixte Rech, F 33000 Bordeaux, France.
   [Subiran, Nerea] Univ Basque Country, Physiol Dept, UPV EHU, Barrio Sarriena S N, Leioa 48940, Spain.
C3 University of Basque Country; New York University; Institut National de
   la Sante et de la Recherche Medicale (Inserm); Universite de Bordeaux;
   University of Basque Country
RP Ibarretxe, G (通讯作者)，Univ Basque Country, Cell Biol & Histol Dept, UPV EHU, Barrio Sarriena S N, Leioa 48940, Spain.
EM vero18791@gmail.com; patricia.garcia@ehu.eus; mperez282@gmail.com;
   mdcasado002@gmail.com; iirastorza004@gmail.com; fernando.unda@ehu.eus;
   gaskon.ibarretxe@ehu.eus; nerea.subiran@ehu.eus
RI ; Garcia Gallastegi, Patricia/AAF 9405 2019; Perez Garrastachu,
   Miguel/I 5001 2015; Subirán, Nerea/AAA 4395 2019; Ibarretxe,
   Gaskon/AAE 7244 2022
OI CASADO ANDRES, MARIA DEL ROSARIO/0000 0002 0174 0153; Irastorza Epelde,
   Igor/0000 0002 4438 4988; Uribe Etxebarria,
   Veronica/0000 0001 6621 8377; Perez Garrastachu,
   Miguel/0000 0001 6919 3347; Ibarretxe, Gaskon/0000 0002 4961 7402;
   Subiran, Nerea/0000 0001 9202 1287; GARCIA GALLASTEGI,
   PATRICIA/0000 0002 5140 3390
FU UPV/EHU [GIU16/66, UFI 11/44]; Basque Government (GV/EJ) [Ikerketa
   Taldeak IT831 13, ELKARTEK KK 2019 00093]; ISCIII [DTS18/00142]
FX This work was funded by the UPV/EHU (GIU16/66, UFI 11/44; to F.U.), the
   Basque Government (GV/EJ; Ikerketa Taldeak IT831 13; to G.I. and
   ELKARTEK KK 2019 00093; to F.U.) and ISCIII (DTS18/00142; to N.S.).
CR Androutsellis Theotokis A, 2006, NATURE, V442, P823, DOI 10.1038/nature04940
   [Anonymous], 2012, STEM CELLS INT, DOI DOI 10.1155/2012/103503
   Atari M, 2011, HISTOL HISTOPATHOL, V26, P1057, DOI 10.14670/HH 26.1057
   Atari M, 2012, J CELL SCI, V125, P3343, DOI 10.1242/jcs.096537
   Aurrekoetxea M, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00289
   Azuara V, 2006, NAT CELL BIOL, V8, P532, DOI 10.1038/ncb1403
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Borghese L, 2010, STEM CELLS, V28, P955, DOI 10.1002/stem.408
   Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020
   Cartwright P, 2005, DEVELOPMENT, V132, P885, DOI 10.1242/dev.01670
   Chambers I, 2009, DEVELOPMENT, V136, P2311, DOI 10.1242/dev.024398
   Chandrabose ST, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0796 2
   Chédin F, 2011, PROG MOL BIOL TRANSL, V101, P255, DOI 10.1016/B978 0 12 387685 0.00007 X
   Clevers H, 2014, SCIENCE, V346, P54, DOI 10.1126/science.1248012
   Coronado D, 2013, STEM CELL RES, V10, P118, DOI 10.1016/j.scr.2012.10.004
   D'Alessio AC, 2007, MOL CELL BIOL, V27, P7462, DOI 10.1128/MCB.01120 07
   David L, 2011, GENES BASEL, V2, P81, DOI 10.3390/genes2010081
   Diomede F, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00419
   Dravid G, 2005, STEM CELLS, V23, P1489, DOI 10.1634/stemcells.2005 0034
   Ferro F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041774
   Fox V, 2008, STEM CELLS, V26, P715, DOI 10.1634/stemcells.2007 0368
   Ghule PN, 2011, J CELL PHYSIOL, V226, P1149, DOI 10.1002/jcp.22440
   Griscelli F, 2012, AM J PATHOL, V180, P2084, DOI 10.1016/j.ajpath.2012.01.011
   Gronthos S, 2002, J DENT RES, V81, P531, DOI 10.1177/154405910208100806
   Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797
   Hackett JA, 2014, CELL STEM CELL, V15, P416, DOI 10.1016/j.stem.2014.09.015
   Hanna J, 2010, P NATL ACAD SCI USA, V107, P9222, DOI 10.1073/pnas.1004584107
   Harikumar A, 2015, EMBO REP, V16, P1609, DOI 10.15252/embr.201541011
   Hoang M, 2016, STEM CELL RES, V17, P111, DOI 10.1016/j.scr.2016.05.021
   Huang GTJ, 2009, J DENT RES, V88, P792, DOI 10.1177/0022034509340867
   Huang K, 2014, STEM CELL REP, V2, P36, DOI 10.1016/j.stemcr.2013.11.003
   Ichida JK, 2014, NAT CHEM BIOL, V10, P632, DOI 10.1038/nchembio.1552
   Janebodin K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027526
   Jin H, 2013, TISSUE ENG PT A, V19, P613, DOI [10.1089/ten.tea.2012.0163, 10.1089/ten.TEA.2012.0163]
   Kaukua N, 2014, NATURE, V513, P551, DOI 10.1038/nature13536
   Kellner M, 2014, ARCH ORAL BIOL, V59, P559, DOI 10.1016/j.archoralbio.2014.02.014
   Kerkis I, 2006, CELLS TISSUES ORGANS, V184, P105, DOI 10.1159/000099617
   Kitajima K, 2016, EXP HEMATOL, V44, P68, DOI 10.1016/j.exphem.2015.09.007
   Klinz FJ, 2012, HISTOCHEM CELL BIOL, V137, P697, DOI 10.1007/s00418 012 0920 9
   Langenbach F, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt328
   Li J, 2012, MOL CELL BIOCHEM, V362, P233, DOI 10.1007/s11010 011 1148 z
   Li VC, 2014, P NATL ACAD SCI USA, V111, P9503, DOI 10.1073/pnas.1408638111
   Lin HN, 2011, BIOORG CHEM, V39, P161, DOI 10.1016/j.bioorg.2011.06.001
   Liu JJ, 2015, STEM CELLS, V33, P627, DOI 10.1002/stem.1909
   Liu Z, 2016, SCI REP UK, V6, DOI 10.1038/srep27447
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lluis F, 2008, CELL STEM CELL, V3, P493, DOI 10.1016/j.stem.2008.08.017
   Lowell S, 2006, PLOS BIOL, V4, P805, DOI 10.1371/journal.pbio.0040121
   Luzuriaga Jon, 2019, Cell Physiol Biochem, V52, P1361, DOI 10.33594/000000096
   Marmorstein R, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a018762
   Mattout A, 2015, GENOME BIOL, V16, DOI 10.1186/s13059 015 0760 8
   Mizutani K, 2007, NATURE, V449, P351, DOI 10.1038/nature06090
   Moore LD, 2013, NEUROPSYCHOPHARMACOL, V38, P23, DOI 10.1038/npp.2012.112
   Moussaieff A, 2015, CELL METAB, V21, P392, DOI 10.1016/j.cmet.2015.02.002
   Nashun B, 2015, EMBO J, V34, P1296, DOI 10.15252/embj.201490649
   Nichols J, 2009, CELL STEM CELL, V4, P487, DOI 10.1016/j.stem.2009.05.015
   Owen OE, 2002, J BIOL CHEM, V277, P30409, DOI 10.1074/jbc.R200006200
   Paino F, 2010, EUR CELLS MATER, V20, P295
   Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]
   Perdigoto CN, 2013, BBA GEN SUBJECTS, V1830, P2307, DOI 10.1016/j.bbagen.2012.08.009
   Pierdomenico L, 2005, TRANSPLANTATION, V80, P836, DOI 10.1097/01.tp.0000173794.72151.88
   Pisciotta A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050542
   Pissios P, 2017, TRENDS ENDOCRIN MET, V28, P340, DOI 10.1016/j.tem.2017.02.004
   Polo JM, 2012, CELL, V151, P1617, DOI 10.1016/j.cell.2012.11.039
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Rosa V, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/5957806
   Scheller EL, 2008, J DENT RES, V87, P126, DOI 10.1177/154405910808700206
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Simandi Z, 2016, MOL CELL, V63, P647, DOI 10.1016/j.molcel.2016.06.039
   Sommer CA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051711
   Sommer CA, 2010, STEM CELL RES THER, V1, DOI 10.1186/scrt26
   Sperber H, 2015, NAT CELL BIOL, V17, P1523, DOI 10.1038/ncb3264
   Takahashi K, 2007, NAT PROTOC, V2, P3081, DOI 10.1038/nprot.2007.418
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tessarz P, 2014, NAT REV MOL CELL BIO, V15, P703, DOI 10.1038/nrm3890
   Ulanovskaya OA, 2013, NAT CHEM BIOL, V9, P300, DOI [10.1038/NCHEMBIO.1204, 10.1038/nchembio.1204]
   Unterberger A, 2006, MOL CELL BIOL, V26, P7575, DOI 10.1128/MCB.01887 05
   Uribe Etxebarria V, 2017, EUR CELLS MATER, V34, P249, DOI 10.22203/eCM.v034a16
   Uribe Etxebarria V, 2019, J CELL PHYSIOL, V234, P13068, DOI 10.1002/jcp.27977
   Vaissière T, 2008, MUTAT RES REV MUTAT, V659, P40, DOI 10.1016/j.mrrev.2008.02.004
   Vasanthan P, 2015, J CELL MOL MED, V19, P566, DOI 10.1111/jcmm.12381
   Vastenhouw NL, 2012, CURR OPIN CELL BIOL, V24, P374, DOI 10.1016/j.ceb.2012.03.009
   Voigt P, 2013, GENE DEV, V27, P1318, DOI 10.1101/gad.219626.113
   Wang AY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056095
   Wang T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102117
   Wilson R, 2015, STEM CELL TRANSL MED, V4, P905, DOI 10.5966/sctm.2014 0196
   Wu W, 2015, MOL MED REP, V12, P5127, DOI 10.3892/mmr.2015.4106
   Yamagata Y, 2012, EPIGENETICS US, V7, P141, DOI 10.4161/epi.7.2.18906
   Yan X, 2010, STEM CELLS DEV, V19, P469, DOI 10.1089/scd.2009.0314
   Yiew NKH, 2017, J BIOL CHEM, V292, P6312, DOI 10.1074/jbc.M116.758078
   Young RA, 2011, CELL, V144, P940, DOI 10.1016/j.cell.2011.01.032
   Yu JH, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471 2121 11 32
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Zhang DQ, 2015, J ENDODONT, V41, P640, DOI 10.1016/j.joen.2014.12.006
   Zhou VW, 2011, NAT REV GENET, V12, P7, DOI 10.1038/nrg2905
NR 95
TC 33
Z9 33
U1 0
U2 10
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4409
J9 CELLS BASEL
JI Cells
PD MAR
PY 2020
VL 9
IS 3
AR 652
DI 10.3390/cells9030652
PG 21
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA LI2TV
UT WOS:000529337400129
PM 32156036
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Iwaya, C
   Suzuki, A
   Iwata, J
AF Iwaya, Chihiro
   Suzuki, Akiko
   Iwata, Junichi
TI Loss of Sc5d results in micrognathia due to a failure in osteoblast
   differentiation
SO JOURNAL OF ADVANCED RESEARCH
LA English
DT Article
DE Craniofacial bone formation; Cholesterol metabolism; Sc5d; Mandible
   hypoplasia; Primary cilia
ID CHOLESTEROL MODIFICATION; DIGIT NUMBER; GLI3; LATHOSTEROLOSIS;
   MALFORMATION; TRAFFICKING; MECHANISMS; DISORDERS; MUTATION; PROTEIN
AB Introduction: Mutations in genes related to cholesterol metabolism, or maternal diet and health status, affect craniofacial bone formation. However, the precise role of intracellular cholesterol metabolism in craniofacial bone development remains unclear. Objective: The aim of this study is to determine how cholesterol metabolism aberrations affect craniofacial bone development. Methods: Mice with a deficiency in Sc5d, which encodes an enzyme involved in cholesterol synthesis, were analyzed with histology, micro computed tomography (microCT), and cellular and molecular biological methods. Results: Sc5d null mice exhibited mandible hypoplasia resulting from defects in osteoblast differentiation. The activation of the hedgehog and WNT/b catenin signaling pathways, which induce expression of osteogenic genes Col1a1 and Spp1, was compromised in the mandible of Sc5d null mice due to a failure in the formation of the primary cilium, a cell surface structure that senses extracellular cues. Treatments with an inducer of hedgehog or WNT/(3 catenin signaling or with simvastatin, a drug that restores abnormal cholesterol production, partially rescued the defects in osteoblast differentiation seen in Sc5d mutant cells. Conclusion: Our results indicate that loss of Sc5d results in mandibular hypoplasia through defective primary cilia mediated hedgehog and WNT/(3 catenin signaling pathways. (c) 2024 The Authors. Published by Elsevier B.V. on behalf of Cairo University. This is an open access article under the CC BY NC ND license (http://creativecommons.org/licenses/by nc nd/4.0/).
C1 [Iwaya, Chihiro; Suzuki, Akiko; Iwata, Junichi] Univ Texas Hlth Sci Ctr Houston, Sch Dent, Dept Diagnost & Biomed Sci, Houston, TX 77054 USA.
   [Iwaya, Chihiro; Suzuki, Akiko; Iwata, Junichi] Univ Texas Hlth Sci Ctr Houston, Ctr Craniofacial Res, Sch Dent, Houston, TX 77054 USA.
   [Iwata, Junichi] Univ Texas MD Anderson Canc Ctr, UTHealth Grad Sch Biomed Sci, Therapeut & Pharmacol Program, Houston, TX 77030 USA.
   [Iwaya, Chihiro] Univ Missouri Kansas City, Sch Dent, Kansas City, MO 64108 USA.
C3 University of Texas System; University of Texas Health Science Center
   Houston; University of Texas System; University of Texas Health Science
   Center Houston; University of Texas System; UTMD Anderson Cancer Center;
   University of Missouri System; University of Missouri Kansas City
RP Iwata, J (通讯作者)，1941 East Rd, BBS 4208, Houston, TX 77054 USA.
EM Junichi.Iwata@uth.tmc.edu
RI Iwaya, Chihiro/ACP 9772 2022
OI Iwaya, Chihiro/0000 0002 4987 592X
FU NIH [R01DE026767, R01DE029818]; UTHealth School of Dentistry
FX We thank the MicroCT Lab of Baylor College of Medicine for technical
   assistance. We thank Dr. Forbes D. Porter at The Eunice Kennedy Shriver
   National Institute of Child Health and Human Development (NICHD) ,
   National Institutes of Health (NIH) , for providing the Sc5d KO mice,
   and technical assistance from Yurie Mikami, Junbo Shim, and Hiroki
   Yoshioka. This study was supported by grants from the National Institute
   of Dental and Craniofacial Research (NIDCR) , NIH (R01DE026767 and
   R01DE029818 to JI) , and UTHealth School of Dentistry faculty funding to
   JI.r facial Research (NIDCR) , NIH (R01DE026767 and R01DE029818 to JI) ,
   and UTHealth School of Dentistry faculty funding to JI.
CR Anderson R, 2019, JIMD Rep, V44, P79, DOI 10.1007/8904_2018_127
   Anderson RH, 2021, CELL REP, V37, DOI 10.1016/j.celrep.2021.110008
   Anvarian Z, 2019, NAT REV NEPHROL, V15, P199, DOI 10.1038/s41581 019 0116 9
   Brunetti Pierri N, 2002, AM J HUM GENET, V71, P952, DOI 10.1086/342668
   Castro VL, 2020, GENESIS, V58, DOI 10.1002/dvg.23397
   Chang CF, 2015, CURR TOP DEV BIOL, V111, P97, DOI 10.1016/bs.ctdb.2014.11.004
   Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0
   Cobourne MT, 2009, DEV BIOL, V331, P38, DOI 10.1016/j.ydbio.2009.04.021
   Dubey V, 2020, PLOS COMPUT BIOL, V16, DOI 10.1371/journal.pcbi.1007554
   Emechebe U, 2016, ELIFE, V5, DOI 10.7554/eLife.07897
   Emmer BT, 2010, J CELL SCI, V123, P529, DOI 10.1242/jcs.062968
   Fantini J, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00031
   Feng WG, 2013, GENESIS, V51, P677, DOI 10.1002/dvg.22416
   Findakly S, 2021, J CELL BIOL, V220, DOI 10.1083/jcb.202002026
   Gao B, 2009, NATURE, V458, P1196, DOI 10.1038/nature07862
   Haycraft CJ, 2007, DEVELOPMENT, V134, P307, DOI 10.1242/dev.02732
   Janda CY, 2015, BIOCHEM SOC T, V43, P211, DOI 10.1042/BST20140249
   Jeong J, 2002, J CLIN INVEST, V110, P591, DOI 10.1172/JCI200216506
   Kinnebrew M, 2022, SCI ADV, V8, DOI 10.1126/sciadv.abm5563
   Kinnebrew M, 2019, ELIFE, V8, DOI 10.7554/eLife.50051
   KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634
   Kopinke D, 2021, SEMIN CELL DEV BIOL, V110, P89, DOI 10.1016/j.semcdb.2020.05.029
   Krakowiak PA, 2003, HUM MOL GENET, V12, P1631, DOI 10.1093/hmg/ddg172
   Lee HJ, 2018, MOL CANCER RES, V16, P974, DOI 10.1158/1541 7786.MCR 17 0665
   Li YN, 2006, P NATL ACAD SCI USA, V103, P6548, DOI 10.1073/pnas.0600124103
   Lin X, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00757
   Litingtung Y, 2002, NATURE, V418, P979, DOI 10.1038/nature01033
   Lopez Rios J, 2012, DEV CELL, V22, P837, DOI 10.1016/j.devcel.2012.01.006
   Maerz LD, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003 018 0272 7
   Maharjan Y, 2020, EMBO REP, V21, DOI 10.15252/embr.201948901
   May EA, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.664279
   Miyamoto T, 2020, EMBO J, V39, DOI 10.15252/embj.2019103499
   Mukhopadhyay M, 2001, DEV CELL, V1, P423, DOI 10.1016/S1534 5807(01)00041 7
   Nachury MV, 2010, ANNU REV CELL DEV BI, V26, P59, DOI 10.1146/annurev.cellbio.042308.113337
   Nozawa YI, 2013, CURR OPIN GENET DEV, V23, P429, DOI 10.1016/j.gde.2013.04.008
   Platt FM, 2014, ANNU REV GENOM HUM G, V15, P173, DOI 10.1146/annurev genom 091212 153412
   Porter FD, 2011, J LIPID RES, V52, P6, DOI 10.1194/jlr.R009548
   Prasun P, 2019, J PEDIATR GASTR NUTR, V69, pE142, DOI 10.1097/MPG.0000000000002434
   Purohit R, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003 020 0977 2
   Quinn ME, 2012, HUM MOL GENET, V21, P1888, DOI 10.1093/hmg/dds002
   Quintana AM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180856
   Radhakrishnan A, 2020, NAT CHEM BIOL, V16, P1303, DOI 10.1038/s41589 020 00678 2
   Raleigh DR, 2018, MOL CELL, V72, P316, DOI 10.1016/j.molcel.2018.08.034
   Rix S, 2011, HUM MOL GENET, V20, P1306, DOI 10.1093/hmg/ddr013
   Sheng R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5393
   Sheng R, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2221
   St Clair JW, 2019, BBA BIOMEMBRANES, V1861, P1112, DOI 10.1016/j.bbamem.2019.03.012
   Suzuki A, 2020, BONE RES, V8, DOI 10.1038/s41413 019 0078 3
   Suzuki A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21238992
   Suzuki A, 2015, MOL CELL BIOL, V35, P1763, DOI 10.1128/MCB.01180 14
   Sweet HO, 1996, J HERED, V87, P87, DOI 10.1093/oxfordjournals.jhered.a022981
   Tickle C, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00014
   Tüysüz N, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14578
   Weatherbee SD, 2006, DEVELOPMENT, V133, P4993, DOI 10.1242/dev.02696
   Weiss LE, 2019, P NATL ACAD SCI USA, V116, P5550, DOI 10.1073/pnas.1816747116
   Wheway G, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00008
   Winklmayr M, 2010, BMC MOL BIOL, V11, DOI 10.1186/1471 2199 11 2
   Zheng SQ, 2022, ADV SCI, V9, DOI 10.1002/advs.202200750
   Zhu JJ, 2022, DEV CELL, V57, P2048, DOI 10.1016/j.devcel.2022.07.016
NR 59
TC 5
Z9 5
U1 2
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2090 1232
EI 2090 1224
J9 J ADV RES
JI J. Adv. Res.
PD NOV
PY 2024
VL 65
BP 153
EP 165
DI 10.1016/j.jare.2023.12.008
EA OCT 2024
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA J6Y9D
UT WOS:001338512300001
PM 38086515
OA hybrid
DA 2025 08 17
ER

PT J
AU Wan, X
   Zhao, Y
   Burge, R
   Jiang, Y
AF Wan, X.
   Zhao, Y.
   Burge, R.
   Jiang, Y.
TI Actions of osteoporosis treatments on bone histomorphometric remodeling:
   a two fold principal component analysis
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Bone formation; Bone histomorphometric remodeling; Bone resorption;
   Osteoporosis drug therapy; Principal component analysis
ID PARATHYROID HORMONE; POSTMENOPAUSAL WOMEN; RANDOMIZED TRIAL; MINERAL
   DENSITY; ALENDRONATE; TERIPARATIDE; FRACTURES; PREVENTION; ESTROGEN;
   BISPHOSPHONATES
AB This was the first study to apply principal component analysis method to bone histomorphometric parameters. The results corroborated teriparatide's distinct, yet different, mechanisms of action, which stimulate both bone formation and resorption.
   Introduction This study consolidated bone histomorphometric parameters and compared the effects of two osteoporosis treatments on bone remodeling by using a principal component analysis (PCA).
   Methods Included in this analysis were postmenopausal women with osteoporosis who were treated with either teriparatide or alendronate and who completed transiliac bone biopsy at either 6 or 18 months in the randomized, double blind Forteo Alendronate Comparator Trial. Eighteen histomorphometric parameters were grouped into formation and resorption categories. The first principal component of each category was estimated through the PCA. The summation of principal formation component (PFC) and principal resorption component (PRC) was calculated to represent the overall level of bone turnover. The difference between PFC and PRC was computed to determine the balance between formation and resorption.
   Results The PFC was significantly higher in the teriparatide group than in the alendronate group (P<0.0001), while the PRC was numerically lower in the alendronate group (P=0.18). The mean difference between the PFC and PRC was positive in the teriparatide group and negative in the alendronate group.
   Conclusions Our approach of consolidating bone histomorphometric remodeling parameters corroborated the idea that the distinct, yet different, mechanisms of action of teriparatide treatment stimulate both bone formation and resorption, and alendronate treatment suppresses both bone formation and resorption.
C1 [Wan, X.; Zhao, Y.] Novartis Pharmaceut, E Hanover, NJ USA.
   [Burge, R.] Eli Lilly & Co, Global Hlth Outcomes, Indianapolis, IN 46285 USA.
   [Jiang, Y.] Univ Michigan, Dept Radiol, Osteoporosis & Arthrit Lab, Ann Arbor, MI 48109 USA.
   [Jiang, Y.] Univ Michigan, Dept Radiol, Musculoskeletal Div, Ann Arbor, MI 48109 USA.
C3 Novartis; Novartis USA; Eli Lilly; University of Michigan System;
   University of Michigan; University of Michigan System; University of
   Michigan
RP Wan, X (通讯作者)，Novartis Pharmaceut, E Hanover, NJ USA.
EM robert.wan@novartis.com
RI Burge, Russel/AAI 2390 2021
FU Eli Lilly and Company
FX This study was supported by Eli Lilly and Company, and the authors thank
   all the participants and investigators from the original clinical study.
   The authors also would like to thank Dr. Jarrett Coffindaffer, Ph.D., of
   PharmaNet/i3, part of the inVentiv Health Company, for assistance in
   writing and preparing the manuscript and Yuqin Li of PharmaNet/i3 for
   statistical programming assistance.
CR Abdi H, 2010, WIRES COMPUT STAT, V2, P433, DOI 10.1002/wics.101
   [Anonymous], 2004, Bone Health and Osteoporosis: A report of the Surgeon General
   Arlot M, 2005, J BONE MINER RES, V20, P1244, DOI 10.1359/JBMR.050309
   Bilezikian John P, 2008, Curr Osteoporos Rep, V6, P24, DOI 10.1007/s11914 008 0005 9
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Cummings SR, 1998, JAMA J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Dempster DW, 2001, J BONE MINER RES, V16, P1846, DOI 10.1359/jbmr.2001.16.10.1846
   Ensrud KE, 2004, J BONE MINER RES, V19, P1259, DOI 10.1359/JBMR.040326
   FINKELSTEIN JS, 1994, NEW ENGL J MED, V331, P1618, DOI 10.1056/NEJM199412153312404
   Finkelstein JS, 1998, JAMA J AM MED ASSOC, V280, P1067, DOI 10.1001/jama.280.12.1067
   Frost H. M., 1963, BONE REMODELING DYNA
   Khan SA, 1997, J BONE MINER RES, V12, P1700, DOI 10.1359/jbmr.1997.12.10.1700
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140 6736(97)02342 8
   McClung MR, 2005, ARCH INTERN MED, V165, P1762, DOI 10.1001/archinte.165.15.1762
   Misof BM, 2003, J CLIN ENDOCR METAB, V88, P1150, DOI 10.1210/jc.2002 021988
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Orwoll E, 2003, J BONE MINER RES, V18, P9, DOI 10.1359/jbmr.2003.18.1.9
   RIGGS BL, 1995, BONE, V17, pS505, DOI 10.1016/8756 3282(95)00258 4
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   STEINICHE T, 1991, BONE, V12, P155, DOI 10.1016/8756 3282(91)90038 K
   Stepan JJ, 2010, OSTEOPOROSIS INT, V21, P2027, DOI 10.1007/s00198 009 1168 7
NR 27
TC 1
Z9 3
U1 0
U2 5
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD DEC
PY 2013
VL 24
IS 12
BP 3011
EP 3019
DI 10.1007/s00198 013 2414 6
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 281MK
UT WOS:000329105500011
PM 23881284
DA 2025 08 17
ER

PT J
AU Ma, XY
   Ma, TC
   Feng, YF
   Xiang, G
   Lei, W
   Zhou, DP
   Yu, HL
   Xiang, LB
   Wang, L
AF Ma, Xiang Yu
   Ma, Tian Cheng
   Feng, Ya Fei
   Xiang, Geng
   Lei, Wei
   Zhou, Da Peng
   Yu, Hai Long
   Xiang, Liang Bi
   Wang, Lin
TI Promotion of osteointegration under diabetic conditions by a silk
   fibroin coating on 3D printed porous titanium implants via a
   ROS mediated NF κB pathway
SO BIOMEDICAL MATERIALS
LA English
DT Article
DE titanium; silk fibroin; diabetes; ROS; NF &#954; B
AB Clinical evidence indicates the compromised application of titanium implants (TIs) in diabetics, associated with reactive oxygen species (ROS) overproduction at the bone implant interface. Silk fibroin (SF) has displayed impressive biocompatibility in the application of biomedical material and optimal anti diabetic effects in oriental medicine. We proposed that SF coated titanium implants (STIs) could alleviate diabetes induced compromised osteointegration, which has rarely been reported before. To confirm this hypothesis and explore the underlying mechanisms, rat osteoblasts cultured on 3 dimensional (3D)  printed titanium implants (TIs) and STIs were subjected to normal serum (NS), diabetic serum (DS), DS with N acetyl L cysteine (a ROS inhibitor) or SN50 (an NF kappa B inhibitor). An in vivo study was performed on diabetic sheep with TIs or STIs implanted into bone defects on the crista iliaca. The results demonstrated that ROS overproduction induced by diabetes lead to osteoblast dysfunctions and cellular apoptosis on the TI substrate, associated with the activation of an NF kappa B signaling pathway in osteoblasts. Importantly, the STI substrate significantly attenuated ROS production and NF kappa Bp65 phosphorylation, thereby ameliorating the osteoblast biological dysfunctions. These results were further confirmed in vivo by the improved osteointegration of the STIs, as evidenced by Micro CT and histological examinations compared with those of TIs. These results demonstrated that the ROS mediated NF kappa B signaling pathway played a crucial role in diabetes induced implant destabilization. Importantly, the SF coating, as a promising material for biomaterial engineering, markedly improved the clinical treatment effect of TIs under diabetic conditions, possibly associated with the suppression of the NF kappa B pathway.
C1 [Ma, Xiang Yu; Zhou, Da Peng; Yu, Hai Long; Xiang, Liang Bi] Gen Hosp Northern Theater Command PLA, Dept Orthoped, Shenyang 110016, Liaoning, Peoples R China.
   [Ma, Xiang Yu; Ma, Tian Cheng; Feng, Ya Fei; Xiang, Geng; Lei, Wei; Wang, Lin] Air Force Med Univ, Affiliated Hosp 1, Dept Orthoped, Xian 710032, Shaanxi, Peoples R China.
C3 Air Force Medical University
RP Xiang, LB (通讯作者)，Gen Hosp Northern Theater Command PLA, Dept Orthoped, Shenyang 110016, Liaoning, Peoples R China.; Wang, L (通讯作者)，Air Force Med Univ, Affiliated Hosp 1, Dept Orthoped, Xian 710032, Shaanxi, Peoples R China.
EM xiangliangbi1963@sina.com; wanglinxj@fmmu.edu.cn
RI Xiang, Geng/JKI 5434 2023; yu, hailong/F 7716 2011; Wang,
   Lin/J 8805 2018; MA, XIANGYU/AAS 6485 2021
OI Wang, Lin/0000 0002 5995 8446; 
FU Research Fund for the National Natural Science Foundation of China
   [81702131]; Liao Ning Province Natural Science Foundation of China
   [201601411, 2019 ZD 1029]
FX This work was supported by the Research Fund for the National Natural
   Science Foundation of China (No. 81702131) to Xiang Yu Ma, Liao Ning
   Province Natural Science Foundation of China (No. 201601411) to Xiang Yu
   Ma, and Liao Ning Province Natural Science Foundation of China (No.
   2019 ZD 1029) to Xiang Yu Ma.
CR Andela VB, 2002, BIOCHEM BIOPH RES CO, V297, P237, DOI 10.1016/S0006 291X(02)02141 1
   Anselme K, 2000, BIOMATERIALS, V21, P667, DOI 10.1016/S0142 9612(99)00242 2
   Bai XC, 2005, J BIOL CHEM, V280, P17497, DOI 10.1074/jbc.M409332200
   Bai XC, 2004, BIOCHEM BIOPH RES CO, V314, P197, DOI 10.1016/j.bbrc.2003.12.073
   Bays JL, 2017, CELL MOL LIFE SCI, V74, P2999, DOI 10.1007/s00018 017 2511 3
   Bhattacharjee M, 2013, BIOMATERIALS, V34, P8161, DOI 10.1016/j.biomaterials.2013.07.018
   Callaway DA, 2015, J BONE MINER METAB, V33, P359, DOI 10.1007/s00774 015 0656 4
   Chon JW, 2012, INT J MOL MED, V30, P1203, DOI 10.3892/ijmm.2012.1120
   Declercq H, 2004, BIOMATERIALS, V25, P757, DOI 10.1016/S0142 9612(03)00580 5
   Deng M, 2014, COLLOID SURFACE B, V116, P465, DOI 10.1016/j.colsurfb.2014.01.021
   Deyama Y, 2001, BIOCHEM BIOPH RES CO, V282, P1080, DOI 10.1006/bbrc.2001.4693
   Do SG, 2012, J VET SCI, V13, P339, DOI 10.4142/jvs.2012.13.4.339
   Domazetovic V, 2017, CLIN CASES MINER BON, V14, P209, DOI 10.11138/ccmbm/2017.14.1.209
   Drube S, 2015, ONCOTARGET, V6, P5354, DOI 10.18632/oncotarget.3022
   Feng YF, 2013, BIOMATERIALS, V34, P2234, DOI 10.1016/j.biomaterials.2012.12.023
   Fujibayashi S, 2011, EUR SPINE J, V20, P1486, DOI 10.1007/s00586 011 1728 3
   Hu XF, 2018, ACTA BIOMATER, V73, P470, DOI 10.1016/j.actbio.2018.04.008
   Hyeon S, 2013, FREE RADICAL BIO MED, V65, P789, DOI 10.1016/j.freeradbiomed.2013.08.005
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Javed F, 2009, J PERIODONTOL, V80, P1719, DOI 10.1902/jop.2009.090283
   Jia D, 2014, NEUROSCIENCE, V258, P228, DOI 10.1016/j.neuroscience.2013.11.016
   Jia TT, 2018, ENDOCR CONNECT, V7, P1186, DOI 10.1530/EC 18 0241
   Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621
   King S, 2016, ARCH OSTEOPOROS, V11, DOI 10.1007/s11657 016 0284 1
   Klopfleisch R, 2017, J BIOMED MATER RES A, V105, P927, DOI 10.1002/jbm.a.35958
   Komori T, 2016, HORM METAB RES, V48, P755, DOI 10.1055/s 0042 110571
   Kotsovilis S, 2006, CLIN ORAL IMPLAN RES, V17, P587, DOI 10.1111/j.1600 0501.2005.01245.X
   Kuo WW, 2013, INT J CARDIOL, V168, P270, DOI 10.1016/j.ijcard.2012.09.080
   Le Nga N, 2011, J Diabetes Sci Technol, V5, P605
   Li X, 2015, BIOMATERIALS, V36, P44, DOI 10.1016/j.biomaterials.2014.09.012
   Li Y, 2015, ACS APPL MATER INTER, V7, P5715, DOI 10.1021/acsami.5b00331
   Luttikhuizen DT, 2006, TISSUE ENG, V12, P1955, DOI 10.1089/ten.2006.12.1955
   Lyu Z, 2019, INT IMMUNOPHARMACOL, V72, P348, DOI 10.1016/j.intimp.2019.04.005
   Ma XY, 2018, BIOCHIMIE, V152, P31, DOI 10.1016/j.biochi.2018.04.022
   Ma XY, 2014, BIOMATERIALS, V35, P7259, DOI 10.1016/j.biomaterials.2014.05.028
   Ma ZY, 2016, BIOCHEM BIOPH RES CO, V471, P576, DOI 10.1016/j.bbrc.2016.02.029
   Maló P, 2016, CLIN IMPLANT DENT R, V18, P649, DOI 10.1111/cid.12346
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   McGilvray KC, 2018, SPINE J, V18, P1250, DOI 10.1016/j.spinee.2018.02.018
   Mody N, 2001, FREE RADICAL BIO MED, V31, P509, DOI 10.1016/S0891 5849(01)00610 4
   Mogi M, 2004, BONE, V35, P507, DOI 10.1016/j.bone.2004.03.003
   Motyl KJ, 2011, AM J PHYSIOL REG I, V300, pR1250, DOI 10.1152/ajpregu.00764.2010
   MOY RL, 1991, AM FAM PHYSICIAN, V44, P2123
   Park JH, 2011, J BIOCHEM MOL TOXIC, V25, P238, DOI 10.1002/jbt.20381
   Park YR, 2018, ACTA BIOMATER, V67, P183, DOI 10.1016/j.actbio.2017.12.006
   Parthasarathy J, 2010, J MECH BEHAV BIOMED, V3, P249, DOI 10.1016/j.jmbbm.2009.10.006
   Pereira AM, 2017, ACTA BIOMATER, V47, P50, DOI 10.1016/j.actbio.2016.10.002
   Qian YN, 2018, BIOMATERIALS, V164, P22, DOI 10.1016/j.biomaterials.2018.02.038
   Ramanathan T, 2002, CARDIOVASC RES, V55, P749, DOI 10.1016/S0008 6363(02)00497 2
   Rao PJ, 2014, ORTHOP SURG, V6, P81, DOI 10.1111/os.12098
   Retzepi M, 2010, CLIN ORAL IMPLAN RES, V21, P673, DOI 10.1111/j.1600 0501.2010.01923.x
   Tsaryk R, 2013, BIOMATERIALS, V34, P8075, DOI 10.1016/j.biomaterials.2013.07.030
   Waddington RJ, 2011, CELLS TISSUES ORGANS, V194, P307, DOI 10.1159/000324251
   Wang CR, 2019, INT J MED SCI, V16, P486, DOI 10.7150/ijms.30832
   Wang X, 2012, BIOCHIMIE, V94, P1705, DOI 10.1016/j.biochi.2012.03.024
   Xu ZP, 2019, MAT SCI ENG C MATER, V95, P302, DOI 10.1016/j.msec.2018.11.010
   Yu Y, 2012, J ALZHEIMERS DIS, V30, P263, DOI 10.3233/JAD 2012 110779
   Zhong ZM, 2009, CELL PHYSIOL BIOCHEM, V24, P105, DOI 10.1159/000227818
NR 58
TC 18
Z9 18
U1 4
U2 101
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 1748 6041
EI 1748 605X
J9 BIOMED MATER
JI Biomed. Mater.
PD MAY 1
PY 2021
VL 16
IS 3
AR 035015
DI 10.1088/1748 605X/abaaa1
PG 17
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA QP7JM
UT WOS:000624009100001
PM 32726758
DA 2025 08 17
ER

PT J
AU Zhang, SY
   Mi, YX
   Ye, TT
   Lu, XY
   Liu, L
   Qian, J
   Fan, XH
AF Zhang, Shiyu
   Mi, Yinxiao
   Ye, Tingting
   Lu, Xiaoyan
   Liu, Li
   Qian, Jing
   Fan, Xiaohui
TI Carbohydrates and ginsenosides in shenmai injection jointly improve
   hematopoietic function during chemotherapy induced myelosuppression in
   mice
SO CHINESE MEDICINE
LA English
DT Article
DE Bone marrow stromal cells; Carbohydrates; Myelosuppression; RNA
   sequencing; Shenmai injection; Traditional Chinese medicine
ID BONE MORPHOGENETIC PROTEINS; MARROW; MYELOFIBROSIS; MECHANISMS;
   ADHESION; GSTM1; GSTT1
AB Background: Shenmai injection (SMI), a traditional Chinese medicine (TCM) injection prepared from Red ginseng and Ophiopogon japonicus, is widely used in clinics to treat chemotherapy induced myelosuppression. Similar to other TCM injections, SMI contains a high amount of carbohydrates (fructose, sucrose, and maltose) in addition to the bioactive substances, specifically ginsenosides (Rg1, Re, and Rb1). To date, the role of these carbohydrates in the hematopoietic function of SMI remains unclear.
   Purpose: We aimed to investigate the hematopoietic effects and potential mechanisms of SMI and its components, focusing on the carbohydrates present in SMI.
   Experimental design/methods: First, we evaluated the hematopoietic effect of SMI on 5 fluorouracil (5 FU) induced myelotoxicity in a tumor bearing mouse model. Then we prepared mixtures of ginsenosides and carbohydrates according to their proportions in SMI and evaluated their hematopoietic function in mice with 5 FU induced myelosuppression. Finally, hematopoiesis related molecular networks were built based on RNA sequencing (RNA seq) of the bone marrow stromal cells (BMSCs), and the potential mechanisms of carbohydrates and ginsenosides were evaluated.
   Results: SMI attenuated 5 FU induced myelotoxicity in tumor bearing mice. Both ginsenosides and carbohydrates increased the bone marrow nucleated cell (BMNC) count and improved the bone marrow morphology in myelosuppressive mice; they promoted the proliferation of BMSCs derived from those myelosuppressive mice. Bioinformatics analyses revealed ECM receptor interaction, Hippo signaling, and Wnt signaling are common pathways regulated by both ginsenosides and carbohydrates; Gstt1, Gstp2, Gsta4 and Oplah in Glutathione metabolism pathway and Cd19, Cd79a, and Cd79b in B cell receptor pathway are uniquely regulated genes related to carbohydrates but not ginsenosides.
   Conclusions: Carbohydrates may collaborate with ginsenosides and contribute to the hematopoietic function of SMI. Carbohydrates could be considered as a bioactive component in this TCM injection.
C1 [Zhang, Shiyu; Mi, Yinxiao; Ye, Tingting; Lu, Xiaoyan; Qian, Jing; Fan, Xiaohui] Zhejiang Univ, Coll Pharmaceut Sci, Pharmaceut Informat Inst, Hangzhou 310058, Peoples R China.
   [Mi, Yinxiao; Liu, Li] Chiatai Qingchunbao Pharmaceut Co Ltd, Hangzhou 310030, Peoples R China.
   [Qian, Jing; Fan, Xiaohui] Zhejiang Univ, Jinhua Inst, Jinhua 321016, Zhejiang, Peoples R China.
   [Fan, Xiaohui] Innovat Inst Artificial Intelligence Med Zhejiang, Hangzhou 310058, Peoples R China.
   [Fan, Xiaohui] Tianjin Univ Tradit Chinese Med, State Key Lab Component Based Chinese Med, Tianjin 301617, Peoples R China.
C3 Zhejiang University; Zhejiang University; Tianjin University of
   Traditional Chinese Medicine
RP Qian, J; Fan, XH (通讯作者)，Zhejiang Univ, Coll Pharmaceut Sci, Pharmaceut Informat Inst, Hangzhou 310058, Peoples R China.; Qian, J; Fan, XH (通讯作者)，Zhejiang Univ, Jinhua Inst, Jinhua 321016, Zhejiang, Peoples R China.; Fan, XH (通讯作者)，Innovat Inst Artificial Intelligence Med Zhejiang, Hangzhou 310058, Peoples R China.; Fan, XH (通讯作者)，Tianjin Univ Tradit Chinese Med, State Key Lab Component Based Chinese Med, Tianjin 301617, Peoples R China.
EM jingqian@zju.edu.cn; fanxh@zju.edu.cn
RI QIAN, JING/Q 1447 2017; Fan, Xiaohui/F 6458 2010
FU National Natural Science Foundation of China [81973701, 81973541];
   Natural Science Foundation of Zhejiang Province [LZ20H290002];
   Innovation Team and Talents Cultivation Program of National
   Administration of Traditional Chinese Medicine [ZYYCXTD D 202002]
FX This study was supported by grants from the National Natural Science
   Foundation of China (Grant No. 81973701, 81973541), the Natural Science
   Foundation of Zhejiang Province (LZ20H290002), and the Innovation Team
   and Talents Cultivation Program of National Administration of
   Traditional Chinese Medicine (ZYYCXTD D 202002).
CR Abou Zahr A, 2016, HAEMATOLOGICA, V101, P660, DOI 10.3324/haematol.2015.141283
   [Anonymous], about us
   Aydin Sayitoglu M, 2006, AM J HEMATOL, V81, P162, DOI 10.1002/ajh.20434
   Bock O, 2008, AM J PATHOL, V172, P951, DOI 10.2353/ajpath.2008.071030
   Chen DM, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01442
   Fan XH, 2006, J PHARMACEUT BIOMED, V40, P591, DOI 10.1016/j.jpba.2005.10.036
   Glodek AM, 2003, J EXP MED, V197, P461, DOI 10.1084/jem.20021477
   Goode DK, 2016, DEV CELL, V36, P572, DOI 10.1016/j.devcel.2016.01.024
   Grcevic D, 2010, LEUKEMIA RES, V34, P742, DOI 10.1016/j.leukres.2009.10.016
   Han JH, 2020, J GINSENG RES, V44, P291, DOI 10.1016/j.jgr.2019.01.001
   Han JH, 2019, J GINSENG RES, V43, P618, DOI 10.1016/j.jgr.2018.07.009
   Han JH, 2019, J AGR FOOD CHEM, V67, P1402, DOI 10.1021/acs.jafc.8b06073
   Khadilkar RJ, 2020, CURR BIOL, V30, P3316, DOI 10.1016/j.cub.2020.06.027
   Kopp HG, 2005, PHYSIOLOGY, V20, P349, DOI 10.1152/physiol.00025.2005
   Liu MX, 2014, J ETHNOPHARMACOL, V152, P575, DOI 10.1016/j.jep.2014.02.012
   Lorthongpanich C, 2017, THROMB HAEMOSTASIS, V117, P116, DOI 10.1160/TH16 07 0564
   Mun Y, 2021, CURR TOP MICROBIOL, V434, P55, DOI 10.1007/978 3 030 86016 5_3
   Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976 0105.177703
   NCBI, MUS MUSC ID 828339 B
   Ni MW, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.631170
   Prosper F, 2001, J LEUKOCYTE BIOL, V69, P307
   Qin GW, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/7929165
   Rehman S, 2015, ANN HEMATOL, V94, P1965, DOI 10.1007/s00277 015 2482 0
   Repetto L, 2009, CRIT REV ONCOL HEMAT, V72, P170, DOI 10.1016/j.critrevonc.2009.03.004
   Sathiyanathan P, 2020, STEM CELLS, V38, P1124, DOI 10.1002/stem.3203
   Shi Shu Zhen, 2021, Zhongguo Zhong Yao Za Zhi, V46, P3998, DOI 10.19540/j.cnki.cjcmm.20210113.501
   STRING, About us
   Su YY, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/9837035
   Undi RB, 2016, INDIAN J HEMATOL BLO, V32, P123, DOI 10.1007/s12288 015 0585 3
   Wang LP, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.770705
   Xu SF, 2012, EUR J PHARMACOL, V695, P7, DOI 10.1016/j.ejphar.2012.07.050
   Xu Y., 2011, QILU PHARM AFFAIRS, V30, P636
   Zmorzynski S, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01056
NR 33
TC 6
Z9 6
U1 4
U2 33
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749 8546
J9 CHIN MED UK
JI Chin. Med.
PD NOV 4
PY 2022
VL 17
IS 1
AR 124
DI 10.1186/s13020 022 00678 5
PG 15
WC Integrative & Complementary Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine; Pharmacology & Pharmacy
GA 5Y1GY
UT WOS:000879039500002
PM 36333798
OA gold, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Yang, X
   Webster, JB
   Kovalenko, D
   Nadeau, RJ
   Zubanova, O
   Chen, PY
   Friesel, R
AF Yang, X
   Webster, JB
   Kovalenko, D
   Nadeau, RJ
   Zubanova, O
   Chen, PY
   Friesel, R
TI Sprouty genes are expressed in osteoblasts and inhibit fibroblast growth
   factor mediated osteoblast responses
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE sprouty; fibroblast growth factor; osteoblast; differentiation; receptor
   tyrosine kinase
ID FACTOR RECEPTOR 2; TYROSINE PHOSPHORYLATION; CROUZON SYNDROME; IDENTICAL
   MUTATIONS; SKELETAL DYSPLASIA; ACTIVATION; FGF; PFEIFFER;
   CRANIOSYNOSTOSIS; TRANSMEMBRANE
AB Fibroblast growth factors (FGFs) and fibroblast growth factor receptors (FGFRs) are major regulators of skeletal growth and development. Signal transduction via FGFRs is complex and mediates proliferation, differentiation, or migration depending upon the cellular context. Members of the Spry gene family antagonize the FGFR signal transduction pathway and inhibit lung morphogenesis, angiogenesis, and chondrogenesis. We examined the expression of Spry2 in the osteoblastic MC3T3 E1 cell line. MC3T3 E1 cells express Spry2 in response to FGF1 stimulation. Treatment of MC3T3 E1 cells with FGF1 results in the expression of Spry2 in a manner consistent with an early response gene. Pharmacological inhibitors of mitogen activated protein kinase activation inhibit FGF1 induced expression of Spry2 mRNA. Transient overexpression of Spry2 in MC3T3 E1 resulted in decreased FGF1 mediated extracellular signal regulated kinase phosphorylation and FGF1 stimulated osteopontin promoter activity. Furthermore, we show that Spry2 interacts with Raf 1 in a glutathione S transferase pulldown assay and that this interaction may involve multiple sites. Finally, Spry2 expression precedes the onset of the expression of osteoblast differentiation markers in an in vitro assay of primary osteoblast differentiation. Taken together, these results indicate that Spry2 expression is an early response to stimulation by FGF1 in MC3T3 E1 cells and acts as a feedback inhibitor of FGF1 induced osteoblast responses, possibly through interaction with Raf1.
C1 Maine Med Ctr, Res Inst, Ctr Mol Med, Scarborough, ME 04074 USA.
   Univ Maine, Cooperat Grad Program Mol Genet & Cell Biol, Orono, ME 04469 USA.
C3 Maine Medical Center; University of Maine System; University of Maine
   Orono
RP Maine Med Ctr, Res Inst, Ctr Mol Med, 81 Res Dr, Scarborough, ME 04074 USA.
EM friesr@mail.mmc.org
RI Chen, Pei Yu/H 1669 2013
FU NHLBI NIH HHS [HL65301] Funding Source: Medline; NIDCR NIH HHS [DE13248]
   Funding Source: Medline; PHS HHS [P20 15555] Funding Source: Medline
CR Bellus GA, 2000, AM J HUM GENET, V67, P1411, DOI 10.1086/316892
   Bellus GA, 1996, NAT GENET, V14, P174, DOI 10.1038/ng1096 174
   Burke D, 1998, TRENDS BIOCHEM SCI, V23, P59, DOI 10.1016/S0968 0004(97)01170 5
   Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092 8674(00)80576 0
   Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496 390
   Debiais F, 1998, J BONE MINER RES, V13, P645, DOI 10.1359/jbmr.1998.13.4.645
   Delany AM, 1998, J BIOL CHEM, V273, P16595, DOI 10.1074/jbc.273.26.16595
   Fong CW, 2003, J BIOL CHEM, V278, P33456, DOI 10.1074/jbc.M301317200
   FRIESEL R, 1992, DEVELOPMENT, V116, P1051
   GUO XJ, 1995, MOL CELL BIOL, V15, P476, DOI 10.1128/MCB.15.1.476
   Guy GR, 2003, J CELL SCI, V116, P3061, DOI 10.1242/jcs.00652
   Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092 8674(00)80919 8
   Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867
   Iwanami M, 2005, GENES CELLS, V10, P743, DOI 10.1111/j.1365 2443.2005.00871.x
   JABS EW, 1994, NAT GENET, V8, P275, DOI 10.1038/ng1194 275
   Kim HJ, 2004, NAT REV MOL CELL BIO, V5, P441, DOI 10.1038/nrm1400
   Kovalenko D, 2003, J BIOL CHEM, V278, P14087, DOI 10.1074/jbc.C200606200
   Kramer S, 1999, DEVELOPMENT, V126, P2515
   Lemonnier J, 2001, AM J PATHOL, V158, P1833, DOI 10.1016/S0002 9440(10)64139 9
   Li X, 2004, J CELL SCI, V117, P6007, DOI 10.1242/jcs.01519
   LI X, 2005, BIOCHEM SOC T, V31, P1445
   Malcolm S, 1996, ANN NY ACAD SCI, V785, P164, DOI 10.1111/j.1749 6632.1996.tb56255.x
   Mansukhani A, 2000, J CELL BIOL, V149, P1297, DOI 10.1083/jcb.149.6.1297
   Mason JM, 2004, MOL BIOL CELL, V15, P2176, DOI 10.1091/mbc.E03 07 0503
   MEYERS GA, 1995, NAT GENET, V11, P462, DOI 10.1038/ng1295 462
   Minowada G, 1999, DEVELOPMENT, V126, P4465
   Morriss Kay G M, 2001, Novartis Found Symp, V232, P102
   MUENKE M, 1994, NAT GENET, V8, P269, DOI 10.1038/ng1194 269
   Naski M C, 1998, Front Biosci, V3, pd781
   Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696 233
   NEILSON KM, 1995, J BIOL CHEM, V270, P26037, DOI 10.1074/jbc.270.44.26037
   Neilson KM, 1996, J BIOL CHEM, V271, P25049, DOI 10.1074/jbc.271.40.25049
   Newberry EP, 1997, MOL ENDOCRINOL, V11, P1129, DOI 10.1210/me.11.8.1129
   Ornitz D M, 2001, Novartis Found Symp, V232, P63
   Ornitz D. M., 2001, NOVART FDN SYMP, V232, P272
   Ozaki K, 2001, BIOCHEM BIOPH RES CO, V285, P1084, DOI 10.1006/bbrc.2001.5295
   Perl AKT, 2003, DEV BIOL, V258, P154, DOI 10.1016/S0012 1606(03)00106 4
   Placzek M, 1999, CURR BIOL, V9, pR506, DOI 10.1016/S0960 9822(99)80322 4
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   REARDON W, 1994, NAT GENET, V8, P98, DOI 10.1038/ng0994 98
   Reich A, 1999, DEVELOPMENT, V126, P4139
   Rousseau F, 1996, HUM MOL GENET, V5, P509, DOI 10.1093/hmg/5.4.509
   Rubin C, 2005, J BIOL CHEM, V280, P9735, DOI 10.1074/jbc.M408308200
   RUTLAND P, 1995, NAT GENET, V9, P173, DOI 10.1038/ng0295 173
   Sasaki A, 2003, NAT CELL BIOL, V5, P427, DOI 10.1038/ncb978
   SCHELL U, 1995, HUM MOL GENET, V4, P323, DOI 10.1093/hmg/4.3.323
   Strayhorn CL, 1999, J PERIODONTOL, V70, P1345, DOI 10.1902/jop.1999.70.11.1345
   Suzuma T, 2002, EUR J CANCER, V38, pS62, DOI 10.1016/S0959 8049(02)80177 0
   Tavormina PL, 1999, AM J HUM GENET, V64, P722, DOI 10.1086/302275
   TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395 321
   Tefft JD, 1999, CURR BIOL, V9, P219, DOI 10.1016/S0960 9822(99)80094 3
   Warburton D, 2000, MECH DEVELOP, V92, P55, DOI 10.1016/S0925 4773(99)00325 1
   WILKIE AOM, 1995, NAT GENET, V9, P165, DOI 10.1038/ng0295 165
   Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493
   Yang XH, 2004, J BIOL CHEM, V279, P38099, DOI 10.1074/jbc.C400318200
   Yusoff P, 2002, J BIOL CHEM, V277, P3195, DOI 10.1074/jbc.M108368200
NR 56
TC 23
Z9 25
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD APR
PY 2006
VL 78
IS 4
BP 233
EP 240
DI 10.1007/s00223 005 0231 4
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 032CH
UT WOS:000236751000006
PM 16604287
DA 2025 08 17
ER

PT J
AU Prados, B
   del Toro, R
   MacGrogan, D
   Gómez Apiñániz, P
   Papoutsi, T
   Muñoz Cánoves, P
   Méndez Ferrer, S
   de la Pompa, JL
AF Prados, Belen
   del Toro, Raquel
   MacGrogan, Donal
   Gomez Apinaniz, Paula
   Papoutsi, Tania
   Munoz Canoves, Pura
   Mendez Ferrer, Simon
   Luis de la Pompa, Jose
TI Heterotopic ossification in mice overexpressing Bmp2 in Tie2+lineages
SO CELL DEATH & DISEASE
LA English
DT Article
ID TRANSGENIC MICE; BONE FORMATION; CELLS; PROGENITORS; PATHWAY;
   DIFFERENTIATION; CONTRIBUTE; RESIDENT; MUTATION; DISTINCT
AB Bone morphogenetic protein (Bmp) signaling is critical for organismal development and homeostasis. To elucidate Bmp2 function in the vascular/hematopoietic lineages we generated a new transgenic mouse line in which ectopic Bmp2 expression is controlled by the Tie2 promoter. Tie2(CRE/+);Bmp2(tg/tg) mice develop aortic valve dysfunction postnatally, accompanied by pre calcific lesion formation in valve leaflets. Remarkably, Tie2(CRE/+);Bmp2(tg/tg) mice develop extensive soft tissue bone formation typical of acquired forms of heterotopic ossification (HO) and genetic bone disorders, such as Fibrodysplasia Ossificans Progressiva (FOP). Ectopic ossification in Tie2(CRE/+);Bmp2(tg/tg) transgenic animals is accompanied by increased bone marrow hematopoietic, fibroblast and osteoblast precursors and circulating pro inflammatory cells. Transplanting wild type bone marrow hematopoietic stem cells into lethally irradiated Tie2(CRE/+);Bmp2(tg/tg) mice significantly delays HO onset but does not prevent it. Moreover, transplanting Bmp2 transgenic bone marrow into wild type recipients does not result in HO, but hematopoietic progenitors contribute to inflammation and ectopic bone marrow colonization rather than to endochondral ossification. Conversely, aberrant Bmp2 signaling activity is associated with fibroblast accumulation, skeletal muscle fiber damage, and expansion of a Tie2+ fibro adipogenic precursor cell population, suggesting that ectopic bone derives from a skeletal muscle resident osteoprogenitor cell origin. Thus, Tie2(CRE/+);Bmp2(tg/tg) mice recapitulate HO pathophysiology, and might represent a useful model to investigate therapies seeking to mitigate disorders associated with aberrant extra skeletal bone formation.
C1 [Prados, Belen; MacGrogan, Donal; Gomez Apinaniz, Paula; Papoutsi, Tania; Luis de la Pompa, Jose] Ctr Nacl Invest Cardiovasc CNIC, Intercellular Signaling Cardiovasc Dev & Dis Lab, Melchor Fernandez Almagro 3, Madrid 28029, Spain.
   [Prados, Belen; del Toro, Raquel; MacGrogan, Donal; Gomez Apinaniz, Paula; Papoutsi, Tania; Luis de la Pompa, Jose] CIBER Enfermedades Cardiovasc, Madrid, Spain.
   [del Toro, Raquel] Ctr Nacl Invest Cardiovasc CNIC, Madrid, Spain.
   [del Toro, Raquel] Univ Seville, Inst Biomed Sevilla IBIS, Cardiovasc Physiophatol Grp, Hosp Univ Virgen del Rocio,CSIC, Manuel Siurot S N, Seville 41013, Spain.
   [Munoz Canoves, Pura] Ctr Nacl Invest Cardiovasc CNIC, Tissue Regenerat Lab, Madrid, Spain.
   [Munoz Canoves, Pura] Univ Pompeu Fabra UPF, Dept Expt & Hlth Sci, ICREA, Dr Aiguader 88, Barcelona, Spain.
   [Munoz Canoves, Pura] CIBERNED, Dr Aiguader 88, Barcelona, Spain.
   [Mendez Ferrer, Simon] Univ Cambridge, Wellcome Trust Med Res Council Cambridge Stem Cel, Cambridge CB2 0AW, England.
   [Mendez Ferrer, Simon] Univ Cambridge, Dept Haematol, Cambridge CB2 0AW, England.
   [Mendez Ferrer, Simon] Cambridge Biomed Campus, Natl Hlth Serv Blood & Transplant, Cambridge CB2 0AW, England.
   [Mendez Ferrer, Simon] Cambridge Biomed Campus, Natl Hlth Serv Blood & Transplant, Cambridge CB2 0PT, England.
C3 Centro Nacional de Investigaciones Cardiovasculares (CNIC); CIBER  
   Centro de Investigacion Biomedica en Red; CIBERCV; Centro Nacional de
   Investigaciones Cardiovasculares (CNIC); Consejo Superior de
   Investigaciones Cientificas (CSIC); University of Sevilla; CSIC JA USE  
   Instituto de Biomedicina de Sevilla (IBIS); Virgen del Rocio University
   Hospital; Centro Nacional de Investigaciones Cardiovasculares (CNIC);
   ICREA; Pompeu Fabra University; CIBERNED; University of Cambridge;
   University of Cambridge; NHS Blood & Transplant (NHSBT); NHS Blood &
   Transplant (NHSBT)
RP de la Pompa, JL (通讯作者)，Ctr Nacl Invest Cardiovasc CNIC, Intercellular Signaling Cardiovasc Dev & Dis Lab, Melchor Fernandez Almagro 3, Madrid 28029, Spain.; de la Pompa, JL (通讯作者)，CIBER Enfermedades Cardiovasc, Madrid, Spain.
EM jlpompa@cnic.es
RI del Toro Estevez, Raquel/H 4788 2014; MacGrogan, Donal/AAR 7392 2021; De
   La Pompa, Jose Luis/F 9719 2014; Mendez Ferrer, Simon/L 8088 2014;
   Munoz Canoves, Pura/B 3889 2015; Méndez Ferrer, Simón/L 8088 2014; del
   Toro, Raquel/H 4788 2014; De La Pompa Mínguez, José Luis/F 9719 2014;
   Prados, Belen/JQJ 3292 2023; Papoutsi, Tania/F 2324 2016
OI del Toro Estevez, Raquel/0000 0002 1379 7990; Prados,
   Belen/0000 0001 6240 5626; De La Pompa, Jose Luis/0000 0001 6761 7265;
   Mendez Ferrer, Simon/0000 0002 9805 9988; 
FU Spanish Ministry of Science, Innovation, and Universities (MCIU)
   [PID2019 104776RB I00, SAF2016 78370 R, CB16/11/00399, RD16/0011/0021];
   FEDER funds; MCIU; Pro CNIC Foundation; Severo Ochoa Center of
   Excellence [SEV 2015 0505]; MRC [MR/V005421/1, MC_PC_17230] Funding
   Source: UKRI
FX Grants PID2019 104776RB I00, SAF2016 78370 R, CB16/11/00399 (CIBER CV),
   and RD16/0011/0021 (TERCEL) from the Spanish Ministry of Science,
   Innovation, and Universities (MCIU) to JLDLP. The cost of this
   publication was supported in part with FEDER funds. The CNIC is
   supported by the MCIU and the Pro CNIC Foundation, and is a Severo Ochoa
   Center of Excellence (SEV 2015 0505). The authors declare no competing
   interests.
CR Akiyama S, 1997, EXP CELL RES, V235, P362, DOI 10.1006/excr.1997.3680
   Al Ghamdi AM, 2005, ECHOCARDIOGR J CARD, V22, P195, DOI 10.1111/j.0742 2822.2005.03109.x
   Allen RS, 2020, ELIFE, V9, DOI 10.7554/eLife.53761
   Biferali B, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01074
   Brazil DP, 2015, TRENDS CELL BIOL, V25, P249, DOI 10.1016/j.tcb.2014.12.004
   Cejalvo T, 2007, IMMUNOLOGY, V121, P94, DOI 10.1111/j.1365 2567.2007.02541.x
   Crisan M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9040
   Cruz Adalia A, 2010, CIRCULATION, V122, P1396, DOI 10.1161/CIRCULATIONAHA.110.952820
   Dey D, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1090
   Edwards DS, 2016, J ORTHOP TRAUMA, V30, pS27, DOI 10.1097/BOT.0000000000000666
   Gomez Stallons MV, 2016, ARTERIOSCL THROM VAS, V36, P1398, DOI 10.1161/ATVBAHA.116.307526
   Hager Theodorides AL, 2014, CELL CYCLE, V13, P324, DOI 10.4161/cc.27118
   Halloran D, 2020, J DEV BIOL, V8, DOI 10.3390/jdb8030019
   Hatsell SJ, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac4358
   Haupt J, 2019, MOL BIOL CELL, V30, P17, DOI 10.1091/mbc.E18 05 0311
   Hildebrand L, 2017, CELL SIGNAL, V29, P23, DOI 10.1016/j.cellsig.2016.10.001
   Hino K, 2015, P NATL ACAD SCI USA, V112, P15438, DOI 10.1073/pnas.1510540112
   Huang YF, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964 020 0509 1
   Joe AWB, 2010, NAT CELL BIOL, V12, P153, DOI 10.1038/ncb2015
   Kaliya Perumal AK, 2020, DIS MODEL MECH, V13, DOI 10.1242/dmm.046441
   Kan C, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0074 7
   Kan LX, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/309287
   Kan LX, 2004, AM J PATHOL, V165, P1107, DOI 10.1016/S0002 9440(10)63372 X
   Kaplan FS, 2008, BEST PRACT RES CL RH, V22, P191, DOI 10.1016/j.berh.2007.11.007
   Kaplan FS, 2007, J BONE JOINT SURG AM, V89A, P347, DOI 10.2106/JBJS.F.00472
   Kaplan FS, 2016, SEMIN CELL DEV BIOL, V49, P30, DOI 10.1016/j.semcdb.2015.12.013
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Kim AJ, 2019, ANAT REC, V302, P125, DOI 10.1002/ar.23916
   Kisanuki YY, 2001, DEV BIOL, V230, P230, DOI 10.1006/dbio.2000.0106
   Kraft CT, 2016, J TRAUMA ACUTE CARE, V80, P156, DOI 10.1097/TA.0000000000000883
   Lees Shepard JB, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 02872 2
   Lounev VY, 2009, J BONE JOINT SURG AM, V91A, P652, DOI 10.2106/JBJS.H.01177
   Luna Zurita L, 2010, J CLIN INVEST, V120, P3493, DOI 10.1172/JCI42666
   Lyons SA, 2000, J CEREBR BLOOD F MET, V20, P1537, DOI 10.1097/00004647 200011000 00003
   Maguer Satta W, 2003, EXP CELL RES, V282, P110, DOI 10.1016/S0014 4827(02)00013 7
   Medici D, 2010, NAT MED, V16, P1400, DOI 10.1038/nm.2252
   Meyers C, 2019, JBMR PLUS, V3, DOI 10.1002/jbm4.10172
   Mohler ER, 2001, CIRCULATION, V103, P1522, DOI 10.1161/01.cir.103.11.1522
   Naka K, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a027987
   Nigam V, 2009, J MOL CELL CARDIOL, V47, P828, DOI 10.1016/j.yjmcc.2009.08.008
   Nus M, 2011, ARTERIOSCL THROM VAS, V31, P1580, DOI 10.1161/ATVBAHA.111.227561
   Papoutsi T, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.163378
   Pascau J., 2006, SCI PAPERS MOL IMAGI, V8, P97, DOI DOI 10.1007/S11307 006 0031 X
   Pignolo RJ, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750 1172 6 80
   Prados B, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0442 z
   Pulik L, 2020, CELLS BASEL, V9, DOI 10.3390/cells9061324
   Rivera Feliciano J, 2006, DEV BIOL, V295, P580, DOI 10.1016/j.ydbio.2006.03.043
   Shore EM, 2006, NAT GENET, V38, P525, DOI 10.1038/ng1783
   Shu B, 2011, J CELL SCI, V124, P3428, DOI 10.1242/jcs.083659
   Suda RK, 2009, STEM CELLS, V27, P2209, DOI 10.1002/stem.150
   Thibault HB, 2010, CIRC CARDIOVASC IMAG, V3, P157, DOI 10.1161/CIRCIMAGING.109.887109
   Uezumi A, 2010, NAT CELL BIOL, V12, P143, DOI 10.1038/ncb2014
   Wada MR, 2002, DEVELOPMENT, V129, P2987
   Wang RN, 2014, GENES DIS, V1, P87, DOI 10.1016/j.gendis.2014.07.005
   Warsi S, 2021, HAEMATOLOGICA, V106, P2203, DOI 10.3324/haematol.2019.236125
   Wolken DMA, 2018, BONE, V109, P210, DOI 10.1016/j.bone.2017.06.011
   Wosczyna MN, 2012, J BONE MINER RES, V27, P1004, DOI 10.1002/jbmr.1562
NR 57
TC 18
Z9 22
U1 2
U2 9
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2041 4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD JUL 22
PY 2021
VL 12
IS 8
AR 729
DI 10.1038/s41419 021 04003 0
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA TX8RY
UT WOS:000683355100004
PM 34294700
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Li, ZK
   Chen, C
   Zhu, XD
   Li, YF
   Yu, RH
   Xu, W
AF Li, Zhikun
   Chen, Chao
   Zhu, Xiaodong
   Li, Yifan
   Yu, Ronghua
   Xu, Wei
TI Glycyrrhizin Suppresses RANKL Induced Osteoclastogenesis and Oxidative
   Stress Through Inhibiting NF κB and MAPK and Activating AMPK/Nrf2
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Osteoclast; Glycyrrhizin; AMPK; Reactive oxygen species; Nrf2
ID ESTROGEN RECEPTOR MODULATORS; DRUG TARGETS; INFLAMMATION; OSTEOPOROSIS;
   CELLS; ACID; DIFFERENTIATION; PATHWAY; NFATC1; CANCER
AB The treatment for osteoporosis involves inhibiting bone resorption and osteoclastogenesis. Glycyrrhizin (GLY) is a triterpenoid saponin glycoside known to be as the most medically efficacious component of the licorice plant. It has strong anti inflammatory, antioxidant, and antitumor properties. We investigated the effect of GLY on osteoclastogenesis, bone resorption, and intracellular oxidative stress and its molecular mechanisms. In vitro osteoclastogenesis assays were performed using bone marrow monocytes with and without glycyrrhizin. We also evaluated the effects of glycyrrhizin on the secretion of TNF alpha, IL 1 beta, and IL 6 in LPS stimulated RAW 264.7 cells using ELISA. The effects of glycyrrhizin on the expression of osteoclast related genes, such as Nfatc1, c fos, Trap, and cathepsin K (CK), were investigated by RT PCR. Intracellular reactive oxygen species (ROS) were detected in receptor activator of nuclear factor kappa I' ligand (RANKL) stimulated osteoclasts in the presence and absence of glycyrrhizin. During the inhibition of osteoclastogenesis by glycyrrhizin, phosphorylation of AMPK, Nrf2, NF kappa B, and MAPK was analyzed using western blotting. Our results showed that glycyrrhizin significantly inhibited RANKL induced osteoclastogenesis, downregulated the expression of NFATc1, c fos, TRAP, CK, DC STAMP, and OSCAR, and inhibited p65, p38, and JNK. Glycyrrhizin was found to significantly decrease the secretion of inflammatory cytokines (TNF alpha, IL 1 beta, and IL 6). Additionally, glycyrrhizin reduced the formation of ROS in osteoclasts by inducing AMPK phosphorylation and nuclear transfer of NRF2, resulting in an upregulation of antioxidant enzymes, such as HO 1, NQO 1, and GCLC. In summary, we found that glycyrrhizin inhibited RANKL induced osteoclastogenesis. It was also indicated that glycyrrhizin could reduce oxidative stress by inhibiting the MAPK and NF kappa B pathways and activating the AMPK/NRF2 signaling. Therefore, glycyrrhizin may be used as an effective therapeutic agent against osteoporosis and bone resorption.
C1 [Li, Zhikun; Chen, Chao; Zhu, Xiaodong; Li, Yifan; Yu, Ronghua; Xu, Wei] Shanghai Jiao Tong Univ, TongRen Hosp, Sch Med, Dept Spine Surg, 1111 Xianxia Rd, Shanghai 200336, Peoples R China.
C3 Shanghai Jiao Tong University
RP Xu, W (通讯作者)，Shanghai Jiao Tong Univ, TongRen Hosp, Sch Med, Dept Spine Surg, 1111 Xianxia Rd, Shanghai 200336, Peoples R China.
EM XW2107@shtrhospital.com
RI XU, WEI/AAA 4666 2019
OI Li, zhikun/0000 0002 1732 5931
CR Akanda MR, 2017, BIOMED PHARMACOTHER, V95, P1139, DOI 10.1016/j.biopha.2017.09.031
   Baek KH, 2010, CALCIFIED TISSUE INT, V87, P226, DOI 10.1007/s00223 010 9393 9
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chakraborty C, 2013, CURR DRUG TARGETS, V14, P1707, DOI 10.2174/13894501113146660233
   Chan LP, 2017, ONCOTARGET, V8, P56375, DOI 10.18632/oncotarget.16914
   Choi JH, 2017, J CELL BIOCHEM, V118, P860, DOI 10.1002/jcb.25763
   Deal C, 2009, NAT CLIN PRACT RHEUM, V5, P20, DOI 10.1038/ncprheum0977
   Dharmapatni AASSK, 2017, INFLAMMATION, V40, P1566, DOI 10.1007/s10753 017 0597 2
   Ekanayaka SA, 2018, J OCUL PHARMACOL TH, V34, P239, DOI 10.1089/jop.2017.0094
   El Magd NFA, 2018, LIFE SCI, V193, P159, DOI 10.1016/j.lfs.2017.11.005
   Hasan MK, 2018, ENDOCRINOLOGY, V159, P931, DOI 10.1210/en.2017 00594
   Hsiao FY, 2017, JPN J CLIN ONCOL, V47, P935, DOI 10.1093/jjco/hyx111
   Ito K, 2001, J BIOL CHEM, V276, P30208, DOI 10.1074/jbc.M103604200
   Jin J, 2014, FOOD CHEM TOXICOL, V73, P95, DOI 10.1016/j.fct.2014.08.009
   Kanzaki H, 2016, REDOX BIOL, V8, P186, DOI 10.1016/j.redox.2016.01.006
   Kim JH, 2015, MOL CELLS, V38, P904, DOI 10.14348/molcells.2015.0177
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Kumar R, 2018, MOL CARCINOGEN, V57, P57, DOI 10.1002/mc.22731
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Oloyede HOB, 2017, MICROB PATHOGENESIS, V111, P338, DOI 10.1016/j.micpath.2017.08.012
   Omar HR, 2012, THER ADV ENDOCRINOL, V3, P125, DOI 10.1177/2042018812454322
   Pellegrini GG, 2016, NUTRIENTS, V8, DOI 10.3390/nu8070423
   Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006
   Sadeghi A, 2017, J CELL BIOCHEM, V118, P2654, DOI 10.1002/jcb.25868
   Song MK, 2018, J CELL MOL MED, V22, P849, DOI 10.1111/jcmm.13370
   Thakur V, 2017, NEPHRON, V137, P137, DOI 10.1159/000477820
   Thummuri D, 2017, J MOL MED, V95, P1065, DOI 10.1007/s00109 017 1553 1
   Tian YL, 2016, MOL CELL BIOCHEM, V422, P75, DOI 10.1007/s11010 016 2807 x
   Wakabayashi N, 2010, ANTIOXID REDOX SIGN, V13, P1649, DOI 10.1089/ars.2010.3216
   Wang CD, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00407
   Wilson Carol, 2014, Nat Rev Endocrinol, V10, P3, DOI 10.1038/nrendo.2013.225
   Wu MR, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13700
   Wu X, 2012, J BONE MINER RES, V27, P1298, DOI 10.1002/jbmr.1576
   Xu BB, 2017, J DIABETES COMPLICAT, V31, P773, DOI 10.1016/j.jdiacomp.2016.12.010
   Yang YH, 2014, FREE RADICAL BIO MED, V77, P10, DOI 10.1016/j.freeradbiomed.2014.08.028
   Zeng XZ, 2016, ACTA PHARMACOL SIN, V37, P255, DOI 10.1038/aps.2015.85
   Zhang X, 2017, CANCER MED US, V6, P1941, DOI 10.1002/cam4.1127
   Zhao CH, 2017, BIOCHEM BIOPH RES CO, V490, P552, DOI 10.1016/j.bbrc.2017.06.076
   Zhao WJ, 2016, CELL SIGNAL, V28, P1401, DOI 10.1016/j.cellsig.2016.06.018
   Zhou W, 2017, CELL PHYSIOL BIOCHEM, V43, P331, DOI 10.1159/000480413
   Zhou XH, 2018, BBA MOL BASIS DIS, V1864, P488, DOI 10.1016/j.bbadis.2017.11.009
NR 41
TC 58
Z9 69
U1 0
U2 43
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD SEP
PY 2018
VL 103
IS 3
BP 324
EP 337
DI 10.1007/s00223 018 0425 1
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA GR0JK
UT WOS:000442200800009
PM 29721581
DA 2025 08 17
ER

PT J
AU Hausdorf, J
   Sievers, B
   Schmitt Sody, M
   Jansson, V
   Maier, M
   Mayer Wagner, S
AF Hausdorf, Joerg
   Sievers, Birte
   Schmitt Sody, Marcus
   Jansson, Volkmar
   Maier, Markus
   Mayer Wagner, Susanne
TI Stimulation of bone growth factor synthesis in human osteoblasts and
   fibroblasts after extracorporeal shock wave application
SO ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY
LA English
DT Article
DE Extracorporeal shock wave therapy (ESWT); Bone growth factor;
   Osteoblast; Fibroblast; FGF 2; TGF beta(1)
ID CHRONIC PLANTAR FASCIITIS; MESENCHYMAL STEM CELLS; IN VITRO;
   MESSENGER RNA; THERAPY; EXPRESSION; INVITRO; DIFFERENTIATION;
   OSTEOGENESIS; CHONDROCYTES
AB Nonunion is a common problem in Orthopedic Surgery. In the recent years alternatives to the standard surgical procedures were tested clinically and in vitro. Extracorporeal shock wave therapy (ESWT) showed promising results in both settings. We hypothesized that in target tissue cells from nonunions like fibroblasts and osteoblasts ESWT increases the release of bone growth factors.
   Fibroblasts and osteoblasts were suspended in 3 ml cryotubes and subjected to 250/500 shock waves at 25 kV using an experimental electrohydraulic lithotripter. After ESWT, cell viability was determined and cells were seeded at 1 x 10(5) cells in 12 well plates. After 24, 48, and 72 h cell number was determined and supernatant was frozen. The levels of growth factors FGF 2 and TGF beta(1) were examined using ELISA. A control group was treated equally without receiving ESWT.
   After 24 h there was a significant increase in FGF 2 levels (p < 0.05) with significant correlation to the number of impulses (p < 0.05) observed. TGF beta(1) showed a time dependent increase with a peak at 48 h which was not significantly different from the control group.
   FGF 2, an important growth factor in new bone formation, was shown to be produced by human fibroblasts and osteoblasts after treatment with ESWT. These findings demonstrate that ESWT is able to cause bone healing through a molecular way by inducing growth factor synthesis.
C1 [Hausdorf, Joerg; Sievers, Birte; Schmitt Sody, Marcus; Jansson, Volkmar; Maier, Markus; Mayer Wagner, Susanne] Univ Munich, Dept Orthopaed, D 81377 Munich, Germany.
C3 University of Munich
RP Hausdorf, J (通讯作者)，Univ Munich, Dept Orthopaed, Campus Grosshadern,Marchioninistr 15, D 81377 Munich, Germany.
EM joerg.hausdorf@med.uni muenchen.de
RI Mayer, Susanne/LVS 7069 2024; Mayer Wagner, Susanne/LVS 7069 2024
OI Mayer, Susanne/0000 0001 6391 4086; 
CR Basso N, 2002, BONE, V30, P347, DOI 10.1016/S8756 3282(01)00678 0
   Buchbinder R, 2005, COCHRANE DB SYST REV, V19
   CANALIS E, 1988, J CLIN INVEST, V81, P1572, DOI 10.1172/JCI113490
   Chen YJ, 2004, J ORTHOP RES, V22, P526, DOI 10.1016/j.orthres.2003.10.005
   Delius M, 1999, CANCER RES, V59, P5227
   Dorotka R, 2003, ARCH ORTHOP TRAUM SU, V123, P345, DOI 10.1007/s00402 003 0551 7
   GOLDRING MB, 1990, CLIN ORTHOP RELAT R, P245
   Hofmann A, 2008, J TRAUMA, V65, P1402, DOI 10.1097/TA.0b013e318173e7c2
   Ikeda K, 1999, J TRAUMA, V47, P946, DOI 10.1097/00005373 199911000 00024
   JOHANNES EJ, 1994, J SURG RES, V57, P677, DOI 10.1006/jsre.1994.1200
   Kusnierczak D, 2000, Z ORTHOP GRENZGEB, V138, P29, DOI 10.1055/s 2000 10109
   LEAN JM, 1995, AM J PHYSIOL ENDOC M, V268, pE318, DOI 10.1152/ajpendo.1995.268.2.E318
   Lean JM, 1996, AM J PHYSIOL ENDOC M, V270, pE937, DOI 10.1152/ajpendo.1996.270.6.E937
   Lieberman JR, 2002, J BONE JOINT SURG AM, V84A, P1032, DOI 10.2106/00004623 200206000 00022
   Maier M, 2004, ORTHOPADE, V33, P1401, DOI 10.1007/s00132 004 0734 0
   Maier M, 2003, CLIN ORTHOP RELAT R, P237, DOI 10.1097/01.blo.0000030173.56585.8f
   Maier M, 2001, ARCH ORTHOP TRAUM SU, V121, P379, DOI 10.1007/s004020100261
   Maier M, 2000, J RHEUMATOL, V27, P2455
   Martini L, 2003, CLIN ORTHOP RELAT R, P269, DOI 10.1097/01.blo.0000073344.50837.cd
   Mayer Wagner S, 2010, J ORTHOP RES, V28, P1050, DOI 10.1002/jor.21074
   Ogden JA, 2001, CLIN ORTHOP RELAT R, P47, DOI 10.1097/00003086 200106000 00007
   PFEILSCHIFTER J, 1993, J BONE MINER RES, V8, P707
   Renz H, 2009, ARCH ORTHOP TRAUM SU, V129, P641, DOI 10.1007/s00402 008 0668 9
   ROBEY PG, 1985, CALCIFIED TISSUE INT, V37, P453, DOI 10.1007/BF02557826
   Rompe JD, 1998, J BONE JOINT SURG BR, V80B, P546, DOI 10.1302/0301 620X.80B3.8434
   Rompe JD, 2002, J BONE JOINT SURG AM, V84A, P335, DOI 10.2106/00004623 200203000 00001
   Rompe JD, 2001, CLIN ORTHOP RELAT R, P102, DOI 10.1097/00003086 200106000 00014
   Rompe JD, 2001, CLIN ORTHOP RELAT R, P72
   Rubin J, 2006, GENE, V367, P1, DOI 10.1016/j.gene.2005.10.028
   SCHADEN W, 2001, CLIN ORTHOP RELAT R, V387, P90
   Skutek M, 2001, EUR J APPL PHYSIOL, V86, P48, DOI 10.1007/s004210100502
   Solchaga LA, 2005, J CELL PHYSIOL, V203, P398, DOI 10.1002/jcp.20238
   WANG CJ, 2001, CLIN ORTHOP RELAT R, V387, P837
   WANG CJ, 2001, CLIN ORTHOP RELAT R, V387, P95
   Wang FS, 2002, J BIOL CHEM, V277, P10931, DOI 10.1074/jbc.M104587200
   Wang FS, 2001, BIOCHEM BIOPH RES CO, V287, P648, DOI 10.1006/bbrc.2001.5654
   Weiss S, 2002, J BONE MINER RES, V17, P1280, DOI 10.1359/jbmr.2002.17.7.1280
   YEAMAN LD, 1989, J UROLOGY, V141, P670, DOI 10.1016/S0022 5347(17)40929 3
NR 38
TC 29
Z9 33
U1 0
U2 11
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0936 8051
EI 1434 3916
J9 ARCH ORTHOP TRAUM SU
JI Arch. Orthop. Trauma Surg.
PD MAR
PY 2011
VL 131
IS 3
BP 303
EP 309
DI 10.1007/s00402 010 1166 4
PG 7
WC Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Surgery
GA 722QZ
UT WOS:000287450700004
PM 20730589
DA 2025 08 17
ER

PT J
AU Escribano Núñez, A
   Cornelis, FMF
   De Roover, A
   Sermon, A
   Cailotto, F
   Lories, RJ
   Monteagudo, S
AF Escribano Nunez, Ana
   Cornelis, Frederique M. F.
   De Roover, Astrid
   Sermon, An
   Cailotto, Frederic
   Lories, Rik J.
   Monteagudo, Silvia
TI IGF1 drives Wnt induced joint damage and is a potential therapeutic
   target for osteoarthritis
SO NATURE COMMUNICATIONS
LA English
DT Article
ID GROWTH FACTOR I; ARTICULAR CHONDROCYTES; GENE; CARTILAGE; ASSOCIATION;
   POLYMORPHISM; HYPERTROPHY; INSTABILITY; ACTIVATION; SEVERITY
AB Osteoarthritis is the most common joint disease and a global leading cause of pain and disability. Current treatment is limited to symptom relief, yet there is no disease modifying therapy. Its multifactorial etiology includes excessive activation of Wnt signaling, but how Wnt causes joint destruction remains poorly understood. Here, we identify that Wnt signaling promotes the transcription of insulin like growth factor 1 (IGF1) in articular chondrocytes and that IGF1 is a major driver of Wnt induced joint damage. Male mice with cartilage specific Igf1 deficiency are protected from Wnt triggered joint disease. Mechanistically, Wnt induced IGF1 transcription depends on beta catenin and binding of Wnt transcription factor TCF4 to the IGF1 gene promoter. In a clinically relevant mouse model of post traumatic osteoarthritis, cartilage specific deletion of Igf1 protects against the disease in male mice. IGF1 silencing in chondrocytes from patients with osteoarthritis restores a healthy molecular profile. Our findings reveal that reducing Wnt induced IGF1 is a potential therapeutic strategy for osteoarthritis.
   Osteoarthritis is a common, yet untreatable, joint disease associated with high Wnt signaling, but how Wnt causes joint destruction is unknown. Here, the authors show that Wnt induces IGF1 which leads to joint damage, and targeting this mechanism offers a potential therapeutic opportunity in osteoarthritis.
C1 [Escribano Nunez, Ana; Cornelis, Frederique M. F.; De Roover, Astrid; Lories, Rik J.; Monteagudo, Silvia] Katholieke Univ Leuven, Skeletal Biol & Engn Res Ctr, Dept Dev & Regenerat, Lab Tissue Homeostasis & Dis, Leuven, Belgium.
   [Sermon, An] Univ Hosp Leuven, Div Trauma Surg, Leuven, Belgium.
   [Sermon, An] Katholieke Univ Leuven, Dept Dev & Regenerat, Locomotor & Neurol Disorders Unit, Leuven, Belgium.
   [Cailotto, Frederic] Univ Lorraine, CNRS, Mol Engn & Articular Physiopathol, Biopole,Campus Biol Sante, Vandoeuvre Les Nancy, France.
   [Lories, Rik J.] Univ Hosp Leuven, Div Rheumatol, Leuven, Belgium.
C3 KU Leuven; KU Leuven; University Hospital Leuven; KU Leuven; Centre
   National de la Recherche Scientifique (CNRS); Universite de Lorraine; KU
   Leuven; University Hospital Leuven
RP Monteagudo, S (通讯作者)，Katholieke Univ Leuven, Skeletal Biol & Engn Res Ctr, Dept Dev & Regenerat, Lab Tissue Homeostasis & Dis, Leuven, Belgium.
EM silvia.monteagudo@kuleuven.be
RI De Roover, Astrid/HTN 0913 2023; Lories, Rik/T 2196 2017; Escribano
   Núñez, Ana/MEP 6456 2025
OI Cailotto, Frederic/0000 0002 4941 9238; Lories, Rik/0000 0002 5986 3092;
   Cornelis, Frederique/0000 0002 4144 5861; De Roover,
   Astrid/0000 0003 0321 2896; Escribano Nunez, Ana/0000 0002 4057 8400; 
FU Fonds Wetenschappelijk Onderzoek (Research Foundation Flanders); UZ
   Leuven traumatology [G097118N, G056822N, G059223N]; Flanders Research
   Foundation (FWO Vlaanderen) [12AMS24N]; FWO Vlaanderen
FX We are grateful to L. Storms and A. Hens for their technical support of
   this study and for taking care of the animal facility management. We are
   indebted to the UZ Leuven traumatology and orthopedics nursing staff for
   their efforts to provide cartilage samples for ex vivo and in vitro
   work. This work was supported by grants from the Flanders Research
   Foundation (FWO Vlaanderen): G097118N (R.L.), G056822N (S.M.), and
   G059223N (S.M.). A.E.N. is the recipient of a fundamental research PhD
   fellowship from FWO Vlaanderen (11L1822N). A.D.R. is the recipient of a
   junior postdoctoral fellowship from FWO Vlaanderen (12AMS24N).
CR Aguirre GA, 2018, REV PHYSIOL BIOCH P, V175, P1, DOI 10.1007/112_2017_8
   [Anonymous], 2016, Osteoarthritis: a serious disease
   BERESFORD JN, 1984, METAB BONE DIS RELAT, V5, P229, DOI 10.1016/0221 8747(84)90064 X
   Bergmann MW, 2010, CIRC RES, V107, P1198, DOI 10.1161/CIRCRESAHA.110.223768
   Betancourt MCC, 2012, P NATL ACAD SCI USA, V109, P8218, DOI 10.1073/pnas.1119899109
   Biadgo Belete, 2020, Rev Diabet Stud, V16, P24, DOI 10.1900/RDS.2020.16.24
   Boer CG, 2021, CELL, V184, P4784, DOI 10.1016/j.cell.2021.07.038
   Boer CG, 2021, ANN RHEUM DIS, V80, P367, DOI 10.1136/annrheumdis 2020 217834
   Cadigan KM, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007906
   Chen BA, 2010, EXP MOL MED, V42, P684, DOI 10.3858/emm.2010.42.10.067
   Chen J, 2021, MOL CELL BIOCHEM, V476, P2219, DOI 10.1007/s11010 021 04086 5
   Conaghan PG, 2014, ANN RHEUM DIS, V73, P1442, DOI 10.1136/annrheumdis 2013 204660
   Cooper KL, 2013, NATURE, V495, P375, DOI 10.1038/nature11940
   Cornelis FMF, 2019, OSTEOARTHR CARTILAGE, V27, P513, DOI 10.1016/j.joca.2018.11.008
   Cunningham F, 2022, NUCLEIC ACIDS RES, V50, pD988, DOI 10.1093/nar/gkab1049
   Dehkhoda F, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00035
   Dell'Accio F, 2008, ARTHRITIS RHEUM US, V58, P1410, DOI 10.1002/art.23444
   DORE S, 1995, ARTHRITIS RHEUM, V38, P413, DOI 10.1002/art.1780380319
   Dreos R, 2015, NUCLEIC ACIDS RES, V43, pD92, DOI 10.1093/nar/gku1111
   DUERR RL, 1995, J CLIN INVEST, V95, P619, DOI 10.1172/JCI117706
   Ekenstedt KJ, 2006, ARTHRITIS RHEUM US, V54, P3850, DOI 10.1002/art.22254
   Ewart D, 2020, CONNECT TISSUE RES, V61, P95, DOI 10.1080/03008207.2019.1635590
   Glasson SS, 2007, OSTEOARTHR CARTILAGE, V15, P1061, DOI 10.1016/j.joca.2007.03.006
   Glasson SS, 2010, OSTEOARTHR CARTILAGE, V18, pS17, DOI 10.1016/j.joca.2010.05.025
   Goldring SR, 2016, NAT REV RHEUMATOL, V12, P632, DOI 10.1038/nrrheum.2016.148
   Greene CS, 2015, NAT GENET, V47, P569, DOI 10.1038/ng.3259
   Hunter DJ, 2020, LANCET, V396, P1711, DOI 10.1016/S0140 6736(20)32230 3
   Jiang LJ, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.703110
   Kineman RD, 2018, J MOL ENDOCRINOL, V61, pT187, DOI 10.1530/JME 18 0076
   Lietman C, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.96308
   Litherland GJ, 2014, ARTHRITIS RHEUMATOL, V66, P2175, DOI 10.1002/art.38681
   Liu HH, 2024, GEROSCIENCE, DOI 10.1007/s11357 024 01230 z
   Liu JL, 1998, MOL ENDOCRINOL, V12, P1452, DOI 10.1210/me.12.9.1452
   Lo Cascio L, 2014, GENESIS, V52, P110, DOI 10.1002/dvg.22734
   Lodewyckx L, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3695
   Lories RJ, 2020, RHEUMATOL THER, V7, P259, DOI 10.1007/s40744 020 00205 8
   Lories RJU, 2007, ARTHRITIS RHEUM US, V56, P4095, DOI 10.1002/art.23137
   Loughlin J, 2004, P NATL ACAD SCI USA, V101, P9757, DOI 10.1073/pnas.0403456101
   Lu M, 2019, SIGNAL TRANSDUCT TAR, V4, DOI 10.1038/s41392 019 0036 y
   Ma B, 2013, J BIOL CHEM, V288, P17552, DOI 10.1074/jbc.M113.453985
   Ma HL, 2007, OSTEOARTHR CARTILAGE, V15, P695, DOI 10.1016/j.joca.2006.11.005
   Meulenbelt I, 1998, ANN RHEUM DIS, V57, P371, DOI 10.1136/ard.57.6.371
   Monteagudo S, 2017, NAT REV RHEUMATOL, V13, P670, DOI 10.1038/nrrheum.2017.171
   Monteagudo S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15889
   Müller S, 2020, J ORTHOP RES, V38, P653, DOI 10.1002/jor.24491
   Mukherjee A, 2016, AM J PHYSIOL ENDOC M, V311, pE519, DOI 10.1152/ajpendo.00212.2016
   Nalesso G, 2017, ANN RHEUM DIS, V76, P218, DOI 10.1136/annrheumdis 2015 208577
   Oki S, 2018, EMBO REP, V19, DOI 10.15252/embr.201846255
   Philippou A, 2014, MOL MED, V20, P202, DOI 10.2119/molmed.2014.00011
   Poudel SB, 2021, AGING CELL, V20, DOI 10.1111/acel.13427
   Ramakrishnan Aravinda Bharathi, 2017, F1000Res, V6, P746, DOI 10.12688/f1000research.11034.1
   Repudi SR, 2013, J CELL SCI, V126, P1650, DOI 10.1242/jcs.119859
   SILBERBERG R, 1972, PATHOL MICROBIOL, V38, P417, DOI 10.1159/000162458
   Singh P, 2019, ANN NY ACAD SCI, V1442, P17, DOI 10.1111/nyas.13930
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI [10.1093/nar/gky1131, 10.1093/nar/gkac1000]
   Tapia Rojas C, 2018, NEURAL REGEN RES, V13, P1705, DOI 10.4103/1673 5374.238606
   Thysen S, 2015, OSTEOARTHR CARTILAGE, V23, P275, DOI 10.1016/j.joca.2014.10.010
   Törnqvist AE, 2019, AM J PHYSIOL ENDOC M, V317, pE1150, DOI 10.1152/ajpendo.00330.2019
   Urano T, 2008, SPINE, V33, P1256, DOI 10.1097/BRS.0b013e3181715304
   Vigneri PG, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00230
   Vijayakumar Archana, 2011, Front Endocrinol (Lausanne), V2, P32, DOI 10.3389/fendo.2011.00032
   Wallis M, 2009, GROWTH HORM IGF RES, V19, P12, DOI 10.1016/j.ghir.2008.05.001
   Wang J, 1999, FASEB J, V13, P1985, DOI 10.1096/fasebj.13.14.1985
   Wen CN, 2021, ARTHRITIS RES THER, V23, DOI 10.1186/s13075 021 02662 0
   Westwood AJ, 2014, NEUROLOGY, V82, P1613, DOI 10.1212/WNL.0000000000000382
   Zhai G, 2004, ANN RHEUM DIS, V63, P544, DOI 10.1136/ard.2003.010751
   Zhao H, 2022, MOL CANCER, V21, DOI 10.1186/s12943 022 01616 7
   Zhou YC, 2017, CURR RHEUMATOL REP, V19, DOI 10.1007/s11926 017 0679 z
   Zhu M, 2009, J BONE MINER RES, V24, P12, DOI [10.1359/jbmr.080901, 10.1359/JBMR.080901]
   Zhu SA, 2023, ARTHRITIS RHEUMATOL, V75, P1139, DOI 10.1002/art.42470
NR 70
TC 3
Z9 3
U1 5
U2 19
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2041 1723
J9 NAT COMMUN
JI Nat. Commun.
PD OCT 24
PY 2024
VL 15
IS 1
AR 9170
DI 10.1038/s41467 024 53604 8
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA K2F9L
UT WOS:001342098500047
PM 39448593
OA gold
DA 2025 08 17
ER

PT J
AU Zhang, ST
   Li, H
   Tang, HZ
   Huo, SC
   Nie, BE
   Qu, XH
   Yue, B
AF Zhang, Shutao
   Li, Hui
   Tang, Haozheng
   Huo, Shicheng
   Nie, Bin'en
   Qu, Xinhua
   Yue, Bing
TI Felodipine blocks osteoclast differentiation and ameliorates
   estrogen dependent bone loss in mice by modulating p38 signaling pathway
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE Felodipine; Osteoclast differentiation; Osteoporosis; MAPK; RNA Seq
ID CALCIUM CHANNEL BLOCKERS; POSTMENOPAUSAL WOMEN; FRACTURE RISK;
   HYPERTENSION; OSTEOPOROSIS; OSTEONECROSIS; RESORPTION
AB Postmenopausal osteoporosis is one of the most common types of osteoporosis resulting from estrogen deficiency in elderly women. In addition, hypertension is another common disease in the elderly, and it has become an independent risk factor for osteoporosis and osteoporotic fractures. Here, we report for the first time that felodipine, a first line antihypertensive agent, significantly prevents postmenopausal osteoporosis in addition to its vasodilation properties. Quantitative RT PCR analysis revealed that treatment with felodipine significantly downregulated the genes associated with osteoclast differentiation. RNA sequencing and western blotting suggested that felodipine could inhibit bone resorption by suppressing MAPK pathway phosphorylation. Moreover, micro CT scanning and histological analysis in an ovariectomy (OVX) induced bone loss mouse model indicated that felodipine might be a potent drug for preventing osteoporotic fractures. Therefore, this study proposes an attractive and promising agent with vasodilation properties to treat postmenopausal osteoporosis.
C1 [Zhang, Shutao; Li, Hui; Tang, Haozheng; Huo, Shicheng; Nie, Bin'en; Qu, Xinhua; Yue, Bing] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Bone & Joint Surg, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University
RP Qu, XH; Yue, B (通讯作者)，Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Bone & Joint Surg, Shanghai, Peoples R China.
EM xinhua_qu@126.com; advbmp2@163.com
RI Qu, Xinhua/Q 3950 2016; Huo, Shicheng/HGU 2326 2022
OI Qu, Xinhua/0000 0002 8889 0890; 
FU National Natural Science Foundation of China [81972086, 81672196,
   51971222]; Shanghai "Rising Stars of Medical Talent Youth Development
   Program (Youth Medical Talents  Specialist Program) [2019 72];
   "Technology Innovation Action Plan" Key Project of Shanghai Science and
   Technology Commission [19411962800]; Shanghai municipal education
   commission Gaofeng clinical medicine grant [20161423]; Clinical
   Scientific innovation and Cultivation Fund of Renji Hospital Affiliated
   School of Medicine, Shanghai Jiaotong University [PY20184 02]
FX This research was supported by the National Natural Science Foundation
   of China (grant no. 81972086, 81672196 and 51971222); Shanghai "Rising
   Stars of Medical Talent Youth Development Program (Youth Medical Talents
    Specialist Program)(grant no. 2019 72); "Technology Innovation Action
   Plan" Key Project of Shanghai Science and Technology Commission (grant
   no. 19411962800); Shanghai municipal education commission Gaofeng
   clinical medicine grant support (grant no. 20161423); Clinical
   Scientific innovation and Cultivation Fund of Renji Hospital Affiliated
   School of Medicine, Shanghai Jiaotong University(grant no. PY20184 02).
CR Abernethy DR, 1999, NEW ENGL J MED, V341, P1447, DOI 10.1056/NEJM199911043411907
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Butt DA, 2013, OSTEOPOROSIS INT, V24, P2649, DOI 10.1007/s00198 013 2369 7
   Butt DA, 2012, ARCH INTERN MED, V172, P1739, DOI 10.1001/2013.jamainternmed.469
   Cappola AR, 2016, JAMA J AM MED ASSOC, V316, P715, DOI 10.1001/jama.2016.11032
   Chambers TJ, 2000, J PATHOL, V192, P4
   Compston J, 2017, ARCH OSTEOPOROS, V12, DOI 10.1007/s11657 017 0324 5
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Drake MT, 2015, CLIN THER, V37, P1837, DOI 10.1016/j.clinthera.2015.06.006
   Eastell R, 1998, NEW ENGL J MED, V338, P736, DOI 10.1056/NEJM199803123381107
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   Ilic K, 2013, CALCIFIED TISSUE INT, V92, P217, DOI 10.1007/s00223 012 9671 9
   Ishida M, 2019, BIOMED PHARMACOTHER, V109, P242, DOI 10.1016/j.biopha.2018.10.052
   Kanis JA, 2020, OSTEOPOROSIS INT, V31, P801, DOI [10.1007/s00198 018 4704 5, 10.1007/s00198 020 05303 5, 10.1007/s00223 018 00512 x]
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Lee K, 2016, INT J BIOL SCI, V12, P235, DOI 10.7150/ijbs.13814
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   Rejnmark L, 2006, J HYPERTENS, V24, P581, DOI 10.1097/01.hjh.0000203845.26690.cb
   Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301 472X(99)00061 2
   Rosen CJ, 2005, NEW ENGL J MED, V353, P595, DOI 10.1056/NEJMcp043801
   Ruths S, 2015, BMC GERIATR, V15, DOI 10.1186/s12877 015 0154 5
   Singer A, 2015, MAYO CLIN PROC, V90, P53, DOI 10.1016/j.mayocp.2014.09.011
   Takaoka S, 2013, J BONE MINER METAB, V31, P102, DOI 10.1007/s00774 012 0389 6
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   TODD PA, 1992, DRUGS, V44, P251, DOI 10.2165/00003495 199244020 00008
   Vestergaard P, 2009, CALCIFIED TISSUE INT, V84, P103, DOI 10.1007/s00223 008 9198 2
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
   Xiao F, 2015, EXP CELL RES, V330, P91, DOI 10.1016/j.yexcr.2014.07.005
   Xie Z, 2018, J BONE MINER RES, V33, P667, DOI 10.1002/jbmr.3334
   Yang S, 2014, OSTEOPOROSIS INT, V25, P97, DOI 10.1007/s00198 013 2457 8
NR 40
TC 11
Z9 12
U1 1
U2 21
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0014 4827
EI 1090 2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD FEB 15
PY 2020
VL 387
IS 2
AR 111800
DI 10.1016/j.yexcr.2019.111800
PG 10
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA KK1AK
UT WOS:000512482300012
PM 31877305
DA 2025 08 17
ER

PT J
AU Huang, AY
   Xiong, ZC
   Liu, KK
   Chang, YN
   Shu, L
   Gao, GL
   Zhang, C
AF Huang, Ann Yehong
   Xiong, Zhencheng
   Liu, Kuankuan
   Chang, Yanan
   Shu, Li
   Gao, Guolan
   Zhang, Chi
TI Identification of kaempferol as an OSX upregulator by network
   pharmacology based analysis of qianggu Capsule for osteoporosis
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE kaempferol; osteoporosis; qianggu capsule; gusuibu; OSX; network
   pharmacology
ID TRANSCRIPTION FACTOR OSTERIX; DRYNARIA FORTUNEI; POSTMENOPAUSAL
   OSTEOPOROSIS; J. SM.; DIFFERENTIATION; FLAVONOIDS; GUSUIBU
AB Osteoporosis is the most common metabolic disease of skeleton with reduced bone density and weaker bone. Qianggu Capsule as a traditional chinese medicine has been widely used to treat osteoporosis. The potential pharmacological mechanism of its active ingredient Gusuibu is not well understood. The purpose of this work is to analyze the anti osteoporosis function of Gusuibu based on network pharmacology, and further explore the potential mechanism of Qianggu Capsule. The active compounds and their corresponding targets of Gusuibu were obtained from TCMSP, TCMID, and BATMAN TCM databases. Potential therapeutic targets for osteoporosis were obtained through DisGeNET, TTD, GeneCards, MalaCards, CTD, and OMIM databases. The overlapping targets of Gusuibu and osteoporosis were obtained. GO and KEGG pathway enrichment analysis were performed. The "Gusuibu active compounds target genes osteoporosis " network and protein protein interaction (PPI) network were constructed, and the top hub genes were screened by using the plug in CytoHubba. Molecular docking was used to verify the binding activity of hub genes and key compounds. We identified 21 active compounds and 140 potential therapeutic targets that may be related to Gusuibu and 10 hub genes (AKT1, IL6, JUN, TNF, MAPK3, VEGFA, EGFR, MAPK1, CASP3, PTGS2). Molecular docking analysis demonstrated that four key active small molecules in Gusuibu (including Luteolin, Naringenin, Kaempferol, and Beta sitosterol) have excellent binding affinity to the target proteins encoded by the top 10 hub genes. Our new findings indicated that one key active compound kaempferol activated the expression of osteoblast specific transcription factor OSX through JNK kinase pathway.
C1 [Huang, Ann Yehong] Univ Texas Southwestern Med Ctr, Dept Biochem, Dallas, TX USA.
   [Xiong, Zhencheng; Liu, Kuankuan; Chang, Yanan; Shu, Li; Zhang, Chi] Peking Univ Int Hosp, Cent Lab, Beijing, Peoples R China.
   [Gao, Guolan] Peking Univ Int Hosp, Dept Obstet & Gynecol, Beijing, Peoples R China.
   [Zhang, Chi] Peking Univ Int Hosp, Dept Orthoped, Beijing, Peoples R China.
   [Zhang, Chi] Peking Univ, Biomed Engn Dept, Beijing, Peoples R China.
C3 University of Texas System; University of Texas Southwestern Medical
   Center; Peking University; Peking University; Peking University; Peking
   University
RP Zhang, C (通讯作者)，Peking Univ Int Hosp, Cent Lab, Beijing, Peoples R China.; Zhang, C (通讯作者)，Peking Univ Int Hosp, Dept Orthoped, Beijing, Peoples R China.; Zhang, C (通讯作者)，Peking Univ, Biomed Engn Dept, Beijing, Peoples R China.
EM chi.zhang@case.edu
RI Zhencheng, Xiong/AAA 1619 2020
OI gao, guolan/0009 0009 5789 5902
FU Beijing Municipal Science and Technology Commission;  [Z181100001818006]
FX Funding This work was supported by the Beijing Municipal Science and
   Technology Commission (Grant Number: Z181100001818006).
CR Amberger Joanna S, 2017, Curr Protoc Bioinformatics, V58, DOI 10.1002/cpbi.27
   Chang JY, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/7617261
   Chen Long, 2009, Zhonghua Yi Xue Za Zhi, V89, P1930
   Chin CH, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752 0509 8 S4 S11
   Davis AP, 2021, NUCLEIC ACIDS RES, V49, pD1138, DOI 10.1093/nar/gkaa891
   Dong GC, 2020, TURK J MED SCI, V50, P1444, DOI 10.3906/sag 2001 148
   Ge JR, 2018, CHIN J INTEGR MED, V24, P415, DOI 10.1007/s11655 016 2744 2
   Gene Ontology Consortium, 2015, NUCLEIC ACIDS RES, V43, pD1049, DOI DOI 10.1093/NAR/GKU1179
   Guo DY, 2011, J ETHNOPHARMACOL, V138, P451, DOI 10.1016/j.jep.2011.09.034
   Huang L, 2018, NUCLEIC ACIDS RES, V46, pD1117, DOI 10.1093/nar/gkx1028
   Huang Zhi ming, 2011, Zhong Xi Yi Jie He Xue Bao, V9, P173, DOI 10.3736/jcim20110210
   Hung TY, 2010, J ETHNOPHARMACOL, V131, P70, DOI 10.1016/j.jep.2010.05.063
   Jackson RD, 2014, SEMIN REPROD MED, V32, P454, DOI 10.1055/s 0034 1384629
   Jing Z, 2019, J CELL PHYSIOL, V234, P4472, DOI 10.1002/jcp.27252
   Kanehisa M, 2008, NUCLEIC ACIDS RES, V36, pD480, DOI 10.1093/nar/gkm882
   Kanis JA, 2002, LANCET, V359, P1929, DOI 10.1016/S0140 6736(02)08761 5
   Li GD, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20201349
   Li JY, 2017, CLIN INTERV AGING, V12, P45, DOI 10.2147/CIA.S117597
   Li JY, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/6957825
   Li Ming He, 2017, Shanghai Kou Qiang Yi Xue, V26, P17
   Liu H, 2021, MOL CELL ENDOCRINOL, V520, DOI 10.1016/j.mce.2020.111074
   Liu HC, 2001, J FORMOS MED ASSOC, V100, P383
   Liu WJ, 2020, J ETHNOPHARMACOL, V257, DOI 10.1016/j.jep.2020.112871
   Liu ZY, 2016, SCI REP UK, V6, DOI 10.1038/srep21146
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Ouyang Gui lin, 2012, Zhong Xi Yi Jie He Xue Bao, V10, P1394, DOI 10.3736/jcim20121210
   Piñero J, 2020, NUCLEIC ACIDS RES, V48, pD845, DOI 10.1093/nar/gkz1021
   Rappaport N, 2017, NUCLEIC ACIDS RES, V45, pD877, DOI 10.1093/nar/gkw1012
   Renaux A, 2018, NUCLEIC ACIDS RES, V46, P2699, DOI 10.1093/nar/gky092
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Ruangsuriya J, 2020, BMC COMPLEMENT MED, V20, DOI 10.1186/s12906 020 02892 w
   Saul D, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010401
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shen Z, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.503524
   Sheng S, 2021, CHIN J INTEGR MED, V27, P106, DOI 10.1007/s11655 020 3199 z
   Shuai YM, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/7049812
   Stelzer Gil, 2016, Curr Protoc Bioinformatics, V54, DOI 10.1002/cpbi.5
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937
   Tang WJ, 2012, J BIOL CHEM, V287, P1671, DOI 10.1074/jbc.M111.288472
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Tsaioun K, 2016, ALTEX ALTERN ANIM EX, V33, P343, DOI 10.14573/altex.1610101
   Wang XL, 2008, CHEM PHARM BULL, V56, P46, DOI 10.1248/cpb.56.46
   Wang YX, 2020, NUCLEIC ACIDS RES, V48, pD1031, DOI 10.1093/nar/gkz981
   Wei X, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906 017 1617 3
   Wong R., 2007, CHIN MED UK, V2, P13, DOI [10.1186/1749 8546 2 13, DOI 10.1186/1749 8546 2 13]
   Wu ZH, 2017, J BIOL REG HOMEOS AG, V31, P359
   中华医学会骨质疏松和骨矿盐疾病分会, 2019, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V25, P281
   Xiao WY, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/7275057
   Xiong ZC, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/5510290
   Xu CQ, 2021, BIOMED PHARMACOTHER, V133, DOI 10.1016/j.biopha.2020.110962
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zhang C, 2008, P NATL ACAD SCI USA, V105, P6936, DOI 10.1073/pnas.0710831105
   Zhang YL, 2017, DRUG DES DEV THER, V11, P1881, DOI 10.2147/DDDT.S139804
   Zheng HY, 2020, TOXICOL APPL PHARM, V409, DOI 10.1016/j.taap.2020.115271
NR 54
TC 13
Z9 14
U1 0
U2 29
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD SEP 23
PY 2022
VL 13
AR 1011561
DI 10.3389/fphar.2022.1011561
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 5D5ZQ
UT WOS:000865019800001
PM 36210811
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU de Wildt, BWM
   van der Meijden, R
   Bartels, PAA
   Sommerdijk, NAJM
   Akiva, A
   Ito, K
   Hofmann, S
AF de Wildt, Bregje W. M.
   van der Meijden, Robin
   Bartels, Paul A. A.
   Sommerdijk, Nico A. J. M.
   Akiva, Anat
   Ito, Keita
   Hofmann, Sandra
TI Bioinspired Silk Fibroin Mineralization for Advanced In Vitro Bone
   Remodeling Models
SO ADVANCED FUNCTIONAL MATERIALS
LA English
DT Article
DE biomineralizations; bone remodeling; in vitro models; poly aspartic
   acid; silk fibroins
ID TISSUE; MATRIX; COLLAGEN; GLYCOSAMINOGLYCANS; HYDROXYAPATITE;
   BIOMINERALIZATION; OSTEOPONTIN; MECHANISMS; RESORPTION; OSTEOBLAST
AB Human in vitro bone models can create the possibility for investigation of physiological bone remodeling while addressing the principle of replacement, reduction and refinement of animal experiments (3R). Current in vitro models lack cell matrix interactions and their spatiotemporal complexity. To facilitate these analyses, a bone mimetic template is developed in this study, inspired by bone's extracellular matrix composition and organization. Silk fibroin (SF) is used as an organic matrix, poly aspartic acid (pAsp) is used to mimic the functionality of noncollagenous proteins, and 10x simulated body fluid serves as mineralization solution. By using pAsp in the mineralization solution, minerals are guided toward the SF material resulting in mineralization inside and as a coating on top of the SF. After cytocompatibility testing, remodeling experiments are performed in which mineralized scaffold remodeling by osteoclasts and osteoblasts is tracked with nondestructive microcomputed tomography and medium analyses over a period of 42 d. The mineralized scaffolds support osteoclastic resorption and osteoblastic mineralization, in the physiological bone remodeling specific sequence. This model could therefore facilitate the investigation of cell matrix interactions and may thus reduce animal experiments and advance in vitro drug testing for bone remodeling pathologies like osteoporosis, where cell matrix interactions need to be targeted.
C1 [de Wildt, Bregje W. M.; Ito, Keita; Hofmann, Sandra] Eindhoven Univ Technol, Dept Biomed Engn, Orthopaed Biomech, POB 513, NL 5600 MB Eindhoven, Netherlands.
   [de Wildt, Bregje W. M.; Bartels, Paul A. A.; Ito, Keita; Hofmann, Sandra] Eindhoven Univ Technol, Dept Biomed Engn, Inst Complex Mol Syst ICMS, POB 513, NL 5600 MB Eindhoven, Netherlands.
   [van der Meijden, Robin; Sommerdijk, Nico A. J. M.; Akiva, Anat] Radboud Univ Nijmegen Med Ctr, Radboud Inst Mol Life Sci, Dept Biochem, POB 9101, NL 6525 GA Nijmegen, Netherlands.
   [Bartels, Paul A. A.] Eindhoven Univ Technol, Dept Biomed Engn, POB 513, NL 5600 MB Eindhoven, Netherlands.
C3 Eindhoven University of Technology; Eindhoven University of Technology;
   Radboud University Nijmegen; Eindhoven University of Technology
RP Hofmann, S (通讯作者)，Eindhoven Univ Technol, Dept Biomed Engn, Orthopaed Biomech, POB 513, NL 5600 MB Eindhoven, Netherlands.; Hofmann, S (通讯作者)，Eindhoven Univ Technol, Dept Biomed Engn, Inst Complex Mol Syst ICMS, POB 513, NL 5600 MB Eindhoven, Netherlands.
EM s.hofmann@tue.nl
RI Akiva, Anat/A 2086 2017; Sommerdijk, Nico/B 7239 2013; De Wildt,
   Bregje/AAQ 7056 2021
OI de Wildt, Bregje/0000 0001 7502 8794; Hofmann,
   Sandra/0000 0002 2568 8388
FU research program TTW   Netherlands Organization for Scientific Research
   (NWO) [TTW 016.Vidi.188.021]; European Research Council (ERC)
   [H2020 ERC 2017 ADV 788982 COLMIN]; NWO [VI.Veni.192.094]
FX The authors thank Dewy van der Valk and Jasper Aarts for their help with
   the chemical characterization of the samples. The authors gratefully
   acknowledge the financial support for B.W.M.d.W. and S.H. by the
   research program TTW with project number TTW 016.Vidi.188.021 to S.H.,
   which was financed by the Netherlands Organization for Scientific
   Research (NWO). R.v.d.M, N.S., and A.A. were supported by the European
   Research Council (ERC) Advanced Investigator grant
   (H2020 ERC 2017 ADV 788982 COLMIN). A.A. was supported by the NWO
   (VI.Veni.192.094).
CR Akiva A, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202010524
   Allison H, 2019, AM J PHYSIOL CELL PH, V317, pC969, DOI 10.1152/ajpcell.00168.2019
   Altman GH, 2002, BIOMATERIALS, V23, P4131, DOI 10.1016/S0142 9612(02)00156 4
   Ansari S, 2022, ACS OMEGA, V7, P12724, DOI 10.1021/acsomega.1c07225
   Ansari S, 2021, PHARMACEUTICALS BASE, V14, DOI 10.3390/ph14040289
   Aper SJA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114983
   Barre Sinoussi F, 2015, FUTUR SCI OA, V1, DOI [10.4155/fso.15.63, 10.4155/FSO.15.63]
   Bergara Muguruza L, 2021, ACS APPL MATER INTER, V13, P58270, DOI 10.1021/acsami.1c14358
   Bernhardt A, 2017, EUR CELLS MATER, V33, P28, DOI 10.22203/eCM.v033a03
   Bernhardt A, 2010, J BIOMED MATER RES A, V95A, P848, DOI 10.1002/jbm.a.32856
   Bi YM, 2005, J BIOL CHEM, V280, P30481, DOI 10.1074/jbc.M500573200
   Bishop N, 2016, J BONE MINER RES, V31, P699, DOI 10.1002/jbmr.2835
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Boyan BD, 2017, TISSUE ENG PT A, V23, P1479, DOI [10.1089/ten.tea.2017.0048, 10.1089/ten.TEA.2017.0048]
   Chellaiah MA, 2003, MOL BIOL CELL, V14, P173, DOI 10.1091/mbc.E02 06 0354
   Chen JW, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.760532
   Christen P, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5855
   de Wildt BWM, 2019, CURR OPIN BIOMED ENG, V10, P107, DOI 10.1016/j.cobme.2019.05.005
   Deng X, 2018, INT IMMUNOPHARMACOL, V60, P41, DOI 10.1016/j.intimp.2018.04.037
   Domaschke H, 2006, TISSUE ENG, V12, P949, DOI 10.1089/ten.2006.12.949
   Ehtesabi H, 2021, MATER TODAY SUSTAIN, V13, DOI 10.1016/j.mtsust.2021.100075
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   ERIKSEN EF, 1984, METAB BONE DIS RELAT, V5, P243, DOI 10.1016/0221 8747(84)90066 3
   Facchetti D, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23010139
   FARNDALE RW, 1982, CONNECT TISSUE RES, V9, P247, DOI 10.3109/03008208209160269
   Gebauer D., 2017, NEW PERSPECTIVES MIN
   Gorski JP, 2011, FRONT BIOSCI LANDMRK, V16, P2598, DOI 10.2741/3875
   Hikita A, 2015, BONE, V76, P5, DOI 10.1016/j.bone.2015.02.030
   Hofmann S, 2007, BIOMATERIALS, V28, P1152, DOI 10.1016/j.biomaterials.2006.10.019
   Jin YS, 2015, COLLOID SURFACE B, V134, P339, DOI 10.1016/j.colsurfb.2015.07.015
   Karunaratne A, 2016, BONE, V84, P15, DOI 10.1016/j.bone.2015.11.019
   Kim D, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03041 1
   Kim HJ, 2008, BONE, V42, P1226, DOI 10.1016/j.bone.2008.02.007
   Kohli N, 2018, BONE, V110, P38, DOI 10.1016/j.bone.2018.01.015
   Kokubo T, 2006, BIOMATERIALS, V27, P2907, DOI 10.1016/j.biomaterials.2006.01.017
   Li CM, 2005, J MATER RES, V20, P3374, DOI 10.1557/JMR.2005.0425
   Lian WS, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1942 1
   Linder CH, 2017, CALCIFIED TISSUE INT, V101, P92, DOI 10.1007/s00223 017 0259 2
   Liu YQ, 2015, BIOTECHNOL LETT, V37, P219, DOI 10.1007/s10529 014 1661 8
   Luukkonen J, 2019, HISTOCHEM CELL BIOL, V151, P475, DOI 10.1007/s00418 019 01770 y
   Ma XL, 2010, EXPRESS POLYM LETT, V4, P321, DOI 10.3144/expresspolymlett.2010.40
   Maher M, 2021, ACTA BIOMATER, V131, P41, DOI 10.1016/j.actbio.2021.06.035
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Marelli B, 2012, BIOMATERIALS, V33, P102, DOI 10.1016/j.biomaterials.2011.09.039
   MCKEE MD, 1995, ANN NY ACAD SCI, V760, P177, DOI 10.1111/j.1749 6632.1995.tb44629.x
   Melke J, 2018, EUR CELLS MATER, V36, P57, DOI 10.22203/eCM.v036a05
   Melke J, 2016, ACTA BIOMATER, V31, P1, DOI 10.1016/j.actbio.2015.09.005
   ODGAARD A, 1993, BONE, V14, P173, DOI 10.1016/8756 3282(93)90245 6
   Olszta MJ, 2007, MAT SCI ENG R, V58, P77, DOI 10.1016/j.mser.2007.05.001
   Oosterlaken BM, 2021, ADV MATER, V33, DOI 10.1002/adma.202004418
   Owen R, 2018, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00134
   Pereira DD, 2022, BIOACT MATER, V8, P241, DOI 10.1016/j.bioactmat.2021.06.036
   Popescu DC, 2006, ANGEW CHEM INT EDIT, V45, P1762, DOI 10.1002/anie.200502602
   R Core Team, 2022, R: A language and environment for statistical computing
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Remmers S, 2020, EUR CELLS MATER, V40, P189, DOI 10.22203/eCM.v040a12
   Remmers SJA, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0257724
   Ren XY, 2019, J TISSUE ENG REGEN M, V13, P823, DOI 10.1002/term.2834
   Reznikov N, 2018, SCIENCE, V360, P507, DOI 10.1126/science.aao2189
   Reznikov N, 2014, ACTA BIOMATER, V10, P3815, DOI 10.1016/j.actbio.2014.05.024
   Rico Llanos GA, 2021, POLYMERS BASEL, V13, DOI 10.3390/polym13040599
   Rossi E, 2018, TISSUE ENG PART C ME, V24, P391, DOI [10.1089/ten.tec.2018.0061, 10.1089/ten.TEC.2018.0061]
   Ru JY, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 03059 8
   Scheinpflug J, 2018, GENES BASEL, V9, DOI 10.3390/genes9050247
   Scheuren AC, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.566346
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schulze S, 2018, J CELL PHYSIOL, V233, P4391, DOI 10.1002/jcp.26076
   Shemesh M, 2017, J R SOC INTERFACE, V14, DOI 10.1098/rsif.2016.0958
   Shih YV, 2019, BIOMATERIALS, V198, P107, DOI 10.1016/j.biomaterials.2018.06.005
   Shin K, 2017, TISSUE ENG PT A, V23, P1169, DOI [10.1089/ten.tea.2016.0556, 10.1089/ten.TEA.2016.0556]
   Sims NA, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00041
   Singh A, 2018, PROG ORTHOD, V19, DOI 10.1186/s40510 018 0216 2
   Song Q, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav9075
   Tas AC, 2004, J MATER RES, V19, P2742, DOI 10.1557/JMR.2004.0349
   Tatara Y, 2017, GLYCOBIOLOGY, V27, P1089, DOI 10.1093/glycob/cwx083
   Thomas D. W., 2015, Clinical Development Success Rates 2006 2015
   Vetsch JR, 2016, J R SOC INTERFACE, V13, DOI 10.1098/rsif.2016.0425
   Wang WG, 2016, MATERIALS, V9, DOI 10.3390/ma9120992
   Weinstein RS, 2000, AM J MED, V108, P153, DOI 10.1016/S0002 9343(99)00420 9
   Wojtas M, 2020, P NATL ACAD SCI USA, V117, P12636, DOI 10.1073/pnas.1914899117
   Wu LL, 2015, ACTA BIOMATER, V27, P294, DOI 10.1016/j.actbio.2015.08.042
   Wu RJ, 2021, ACS APPL BIO MATER, V4, P6630, DOI 10.1021/acsabm.1c00654
   Xu YF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 18846 2
   Zhang K, 2010, ACTA BIOMATER, V6, P2165, DOI 10.1016/j.actbio.2009.12.030
   Zvicer J, 2019, POLYM TEST, V76, P464, DOI 10.1016/j.polymertesting.2019.04.004
NR 85
TC 30
Z9 30
U1 15
U2 117
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1616 301X
EI 1616 3028
J9 ADV FUNCT MATER
JI Adv. Funct. Mater.
PD OCT
PY 2022
VL 32
IS 41
AR 2206992
DI 10.1002/adfm.202206992
EA AUG 2022
PG 17
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA 5E4ZP
UT WOS:000837018400001
OA Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Huang, LT
   Su, W
   Wu, ZQ
   Zheng, LD
   Lv, C
AF Huang, Lintuo
   Su, Wei
   Wu, Ziqian
   Zheng, Lidan
   Lv, Chen
TI Glucosamine suppresses oxidative stress and induces protective autophagy
   in osteoblasts by blocking the ROS/Akt/mTOR signaling pathway
SO CELL BIOLOGY INTERNATIONAL
LA English
DT Article
DE autophagy; Glucosamine; Osteoblast; ROS; Akt; mTOR signaling pathway
ID INDUCED APOPTOSIS; INHIBITION; ACTIVATION; DAMAGE
AB Oxidative stress is the crucial pathogenic factor in osteoporosis. Cell autophagy, a major form of self digestion, plays critical functions in different forms of stress by devouring harmful cytosolic proteins or organelles for the renewal of organelles and to maintain cellular homeostasis. Glucosamine (GlcN) has been widely utilized in treatments for patients with osteoarthritis related joint pain. It has potential antioxidant effects and its pharmacological effect in osteoblasts remains unclear. The present study aimed to investigate whether autophagy participates in the protective effects of GlcN in osteoblasts under oxidative stress and the possible mechanism. First of all, MC3T3 E1 cells were treated with hydrogen peroxide (H2O2) to induce oxidative stress, as assessed by viability assays, apoptosis, the intracellular reactive oxygen species production. GlcN was capable of inducing autophagy and protected osteoblasts from those cytotoxic effects. Moreover, it significantly attenuated H2O2 induced oxidative stress as measured by malondialdehyde, glutathione, nitrite, and superoxide dismutase levels. Importantly, the autophagy level increased in osteoblasts treated with GlcN as represented by an increase in both Beclin1 expression and the LC3 II/I ratio. Immunofluorescence analysis of autophagosomes also confirmed the above results. In addition, GlcN decreased the mammalian target of rapamycin (mTOR) and protein kinase B (Akt). However, the Akt activator (SC79) suppressed the autophagy level induced by GlcN in osteoblasts. Consequently, the antioxidant effects of GlcN were mediated, at least in part, by enhancing autophagy through the Akt/mTOR pathway. These results suggested that GlcN might be a promising candidate for osteoporosis treatment.
C1 [Huang, Lintuo; Su, Wei; Zheng, Lidan; Lv, Chen] Wenzhou Med Univ, Affiliated Hosp 1, Dept Orthoped, Nanbaixiang St, Wenzhou 325000, Zhejiang, Peoples R China.
   [Wu, Ziqian] Wenzhou Chinese Med Hosp, Dept Neurol Rehabil, Wenzhou, Peoples R China.
C3 Wenzhou Medical University
RP Lv, C (通讯作者)，Wenzhou Med Univ, Affiliated Hosp 1, Dept Orthoped, Nanbaixiang St, Wenzhou 325000, Zhejiang, Peoples R China.
EM lvchen136@sina.com
FU Natural Science Foundation of Zhejiang Province [LQ20H060003]; Zhejiang
   Medical and Health Science and Technology Project [2020KY633];
   Technology Bureau Projects of Wenzhou City [Y20190393, Y2020397]
FX This study was supported by the Natural Science Foundation of Zhejiang
   Province (LQ20H060003), Zhejiang Medical and Health Science and
   Technology Project (2020KY633), and the Technology Bureau Projects of
   Wenzhou City (Y20190393) and (Y2020397).
CR Alers S, 2012, MOL CELL BIOL, V32, P2, DOI 10.1128/MCB.06159 11
   Aviello G, 2018, MUCOSAL IMMUNOL, V11, P1011, DOI 10.1038/s41385 018 0021 8
   Bolduc JA, 2019, FREE RADICAL BIO MED, V132, P73, DOI 10.1016/j.freeradbiomed.2018.08.038
   Chagin AS, 2016, CURR OPIN PHARMACOL, V28, P1, DOI 10.1016/j.coph.2016.02.004
   Chen J, 2020, AGING US, V12, P24242, DOI 10.18632/aging.104160
   D'Arcy MS, 2019, CELL BIOL INT, V43, P582, DOI 10.1002/cbin.11137
   Demontiero O, 2012, THER ADV MUSCULOSKEL, V4, P61, DOI 10.1177/1759720X11430858
   Fan H, 2021, INT J ONCOL, V58, P9, DOI 10.3892/ijo.2020.5152
   Fan XG, 2021, ACTA PHARMACOL SIN, V42, P1256, DOI 10.1038/s41401 020 00516 0
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Funderburk SF, 2010, TRENDS CELL BIOL, V20, P355, DOI 10.1016/j.tcb.2010.03.002
   Gu XL, 2016, ONCOTARGET, V7, P65218, DOI 10.18632/oncotarget.11573
   Igarashi M, 2011, INT J MOL MED, V28, P373, DOI 10.3892/ijmm.2011.686
   Iwamoto I, 2004, GYNECOL ENDOCRINOL, V19, P97, DOI 10.1080/09513590412331284389
   Jane EP, 2017, MOL CARCINOGEN, V56, P1251, DOI 10.1002/mc.22587
   Kim YR, 2017, EXP GERONTOL, V92, P87, DOI 10.1016/j.exger.2017.03.015
   Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529
   Liu Y, 2004, J BONE MINER RES, V19, P479, DOI 10.1359/JBMR.0301242
   Lv C, 2018, BIOMED PHARMACOTHER, V99, P271, DOI 10.1016/j.biopha.2018.01.066
   Ma Y, 2018, AGING CELL, V17, DOI 10.1111/acel.12709
   Mody N, 2001, FREE RADICAL BIO MED, V31, P509, DOI 10.1016/S0891 5849(01)00610 4
   Nuti R, 2019, INTERN EMERG MED, V14, P85, DOI 10.1007/s11739 018 1874 2
   Park JH, 2016, ENVIRON TOXICOL PHAR, V42, P1, DOI 10.1016/j.etap.2015.12.014
   Shen C, 2015, OSTEOARTHR CARTILAGE, V23, P2279, DOI 10.1016/j.joca.2015.06.020
   Shi Y, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109566
   Suzuki M, 2015, FREE RADICAL BIO MED, V89, P369, DOI 10.1016/j.freeradbiomed.2015.08.015
   Tang N, 2019, J CELL PHYSIOL, V234, P5023, DOI 10.1002/jcp.27304
   Tarantino G, 2013, ANN MED, V45, P348, DOI 10.3109/07853890.2013.770333
   Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001
   Xu ZF, 2017, AGING DIS, V8, P760, DOI 10.14336/AD.2016.0620
   Zhou YX, 2014, PHYTOTHER RES, V28, P961, DOI 10.1002/ptr.5083
NR 31
TC 12
Z9 13
U1 1
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1065 6995
EI 1095 8355
J9 CELL BIOL INT
JI Cell Biol. Int.
PD MAY
PY 2022
VL 46
IS 5
BP 829
EP 839
DI 10.1002/cbin.11783
EA MAR 2022
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 0Q1YH
UT WOS:000774183500001
PM 35191133
DA 2025 08 17
ER

PT J
AU Orriss, IR
   Arnett, TR
   George, J
   Witham, MD
AF Orriss, Isabel R.
   Arnett, Timothy R.
   George, Jacob
   Witham, Miles D.
TI Allopurinol and oxypurinol promote osteoblast differentiation and
   increase bone formation
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE Bone formation; Allopurinol; Oxypurinol; Osteoblast differentiation
ID SERUM URIC ACID; XANTHINE OXIDASE; IN VITRO; HEREDITARY XANTHINURIA;
   POSTMENOPAUSAL WOMEN; MINERAL DENSITY; OXIDOREDUCTASE; RESORPTION;
   FRACTURE; CALCIFICATION
AB Allopurinol and its active metabolite, oxypurinol are widely used in the treatment of gout and hyperuricemia. They inhibit xanthine oxidase (XO) an enzyme in the purine degradation pathway that converts xanthine to uric acid. This investigation examined the effect of allopurinol and oxypurinol on bone formation, cell number and viability, gene expression and enzyme activity in differentiating and mature, bone forming osteoblasts. Although mRNA expression remained relatively constant, XO activity decreased over time with mature osteoblasts displaying reduced levels of uric acid (20% decrease). Treatment with allopurinol and oxypurinol (0.1 1 mu M) reduced XO activity by up to 30%. At these concentrations, allopurinol and oxypurinol increased bone formation by osteoblasts similar to 4 fold and similar to 3 fold, respectively. Cell number and viability were unaffected. Both drugs increased tissue non specific alkaline phosphatase (TNAP) activity up to 65%. Osteocalcin and TNAP mRNA expression was increased, 5 fold and 2 fold, respectively. Expression of NPP1, the enzyme responsible for generating the mineralisation inhibitor, pyrophosphate, was decreased 5 fold. Col1 alpha 1 mRNA expression and soluble collagen levels were unchanged. Osteoclast formation and resorptive activity were not affected by treatment with allopurinol or oxypurinol. Our data suggest that inhibition of XO activity promotes osteoblast differentiation, leading to increased bone formation in vitro. (C) 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
C1 [Orriss, Isabel R.] Univ London Royal Vet Coll, Dept Comparat Biomed Sci, 32 Belgrave Sq, London NW1 0TU, England.
   [Arnett, Timothy R.] UCL, Dept Cell & Dev Biol, London, England.
   [George, Jacob; Witham, Miles D.] Univ Dundee, Med Res Inst, Dundee, Scotland.
C3 University of London; University of London Royal Veterinary College;
   University of London; University College London; University of Dundee
RP Orriss, IR (通讯作者)，Univ London Royal Vet Coll, Dept Comparat Biomed Sci, 32 Belgrave Sq, London NW1 0TU, England.
EM iorriss@rvc.ac.uk
RI ; Orriss, Isabel/GRS 3934 2022; Arnett, Tim/AAW 4445 2021
OI George, Jacob/0000 0001 8154 8278; Witham, Miles/0000 0002 1967 0990;
   Orriss, Isabel/0000 0002 7847 050X; George, Jacob/0000 0002 8421 5476; 
FU Arthritis Research UK [19205]; Versus Arthritis [19205] Funding Source:
   researchfish
FX The authors are grateful for the support of Arthritis Research UK (Grant
   number: 19205)
CR Ahn SH, 2013, OSTEOPOROSIS INT, V24, P2961, DOI 10.1007/s00198 013 2377 7
   Allaeys I, 2011, LAB INVEST, V91, P905, DOI 10.1038/labinvest.2011.46
   Bai XC, 2005, J BIOL CHEM, V280, P17497, DOI 10.1074/jbc.M409332200
   Basu U, 2016, BONE, V84, P189, DOI 10.1016/j.bone.2016.01.003
   Bernabei R, 2014, CLIN CASES MINER BON, V11, P201, DOI 10.11138/ccmbm/2014.11.3.201
   Berry C. E., 2009, J PHYSIOL LONDON, V555, P589
   Brandao Burch A, 2005, CALCIFIED TISSUE INT, V77, P167, DOI 10.1007/s00223 004 0285 8
   Burns CM, 2012, THER ADV CHRONIC DIS, V3, P271, DOI 10.1177/2040622312462056
   Cheung KJ, 2007, CELL METAB, V5, P115, DOI 10.1016/j.cmet.2007.01.005
   Chhana A, 2011, ANN RHEUM DIS, V70, P1684, DOI 10.1136/ard.2010.144774
   Danielyan Kristine E., 2013, Central Nervous System Agents in Medicinal Chemistry, V13, P108
   Dennison EM, 2015, ARCH OSTEOPOROS, V10, DOI 10.1007/s11657 015 0241 4
   EMMERSON BT, 1987, BRIT J RHEUMATOL, V26, P445
   Fatokun AA, 2008, EUR J PHARMACOL, V587, P35, DOI 10.1016/j.ejphar.2008.03.024
   FLEISCH H, 1962, NATURE, V195, P911, DOI 10.1038/195911a0
   FLEISCH H, 1962, AM J PHYSIOL, V203, P671, DOI 10.1152/ajplegacy.1962.203.4.671
   Fraser JHE, 1996, BONE, V19, P223, DOI 10.1016/8756 3282(96)00177 9
   GARRETT IR, 1990, J CLIN INVEST, V85, P632, DOI 10.1172/JCI114485
   Hessle L, 2002, P NATL ACAD SCI USA, V99, P9445, DOI 10.1073/pnas.142063399
   Ichida K, 2012, INT J MOL SCI, V13, P15475, DOI 10.3390/ijms131115475
   Iwata H, 1999, THERIOGENOLOGY, V51, P613, DOI 10.1016/S0093 691X(99)00014 X
   Kanczler JM, 2003, FREE RADICAL RES, V37, P179, DOI 10.1080/1071576021000040673
   Kim BJ, 2014, OSTEOPOROSIS INT, V25, P1837, DOI 10.1007/s00198 014 2697 2
   Kim WK, 2010, J CELL BIOCHEM, V111, P1199, DOI 10.1002/jcb.22846
   Lane NE, 2014, J BONE MINER RES, V29, P1701, DOI 10.1002/jbmr.2164
   Makovey J, 2013, BONE, V52, P400, DOI 10.1016/j.bone.2012.10.025
   Mauck KF, 2006, MAYO CLIN PROC, V81, P662, DOI 10.4065/81.5.662
   Mehat MZ, 2010, J BONE MINER METAB, V28, P503, DOI 10.1007/s00774 010 0159 2
   Mody N, 2001, FREE RADICAL BIO MED, V31, P509, DOI 10.1016/S0891 5849(01)00610 4
   Nabipour I, 2011, J BONE MINER RES, V26, P955, DOI 10.1002/jbmr.286
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Ohtsubo T, 2004, CIRC RES, V95, P1118, DOI 10.1161/01.RES.0000149571.96304.36
   Ohtsubo T, 2009, HYPERTENSION, V54, P868, DOI 10.1161/HYPERTENSIONAHA.109.135152
   Orriss IR, 2007, ENDOCRINOLOGY, V148, P4208, DOI 10.1210/en.2007 0066
   Orriss IR, 2015, AUTON NEUROSCI BASIC, V191, P124, DOI 10.1016/j.autneu.2015.04.013
   Orriss IR, 2012, METHODS MOL BIOL, V816, P103, DOI 10.1007/978 1 61779 415 5_8
   Orriss IR, 2012, METHODS MOL BIOL, V816, P31, DOI 10.1007/978 1 61779 415 5_3
   Orriss IR, 2009, J CELL PHYSIOL, V220, P155, DOI 10.1002/jcp.21745
   Pacher P, 2006, PHARMACOL REV, V58, P87, DOI 10.1124/pr.58.1.6
   Patel JJ, 2014, CELL BIOCHEM FUNCT, V32, P368, DOI 10.1002/cbf.3025
   Pea E, 2005, CONTRIB NEPHROL, V147, P35, DOI 10.1159/000082540
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Reinders MK, 2010, CLIN INTERV AGING, V5, P7
   Spiekermann S, 2003, CIRCULATION, V107, P1383, DOI 10.1161/01.CIR.0000056762.69302.46
   Syberg S, 2012, J BONE MINER RES, V27, P2373, DOI 10.1002/jbmr.1690
   Taylor Sarah E B, 2014, Bonekey Rep, V3, P585, DOI 10.1038/bonekey.2014.80
   Terkeltaub RA, 2003, NEW ENGL J MED, V349, P1647, DOI 10.1056/NEJMcp030733
   Vanden Bossche LC, 2007, J ORTHOP RES, V25, P267, DOI 10.1002/jor.20296
   Zannolli R, 2003, J MED GENET, V40
   Zhang DH, 2015, J BONE MINER RES, V30, P992, DOI 10.1002/jbmr.2430
NR 50
TC 25
Z9 26
U1 2
U2 17
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0014 4827
EI 1090 2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD MAR 15
PY 2016
VL 342
IS 2
BP 166
EP 174
DI 10.1016/j.yexcr.2016.03.004
PG 9
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA DJ4VL
UT WOS:000374206100008
PM 26968635
OA Green Published, Green Accepted, hybrid
DA 2025 08 17
ER

PT J
AU Dolan, EB
   Haugh, MG
   Voisin, MC
   Tallon, D
   McNamara, LM
AF Dolan, Eimear B.
   Haugh, Matthew G.
   Voisin, Muriel C.
   Tallon, David
   McNamara, Laoise M.
TI Thermally Induced Osteocyte Damage Initiates a Remodelling Signaling
   Cascade
SO PLOS ONE
LA English
DT Article
ID MESENCHYMAL STEM CELLS; MECHANICALLY STIMULATED OSTEOCYTES;
   GAP JUNCTIONS; OSTEOGENIC DIFFERENTIATION; OSTEOCLAST DIFFERENTIATION;
   BONE RESORPTION; IN VIVO; APOPTOSIS; PROLIFERATION; ACTIVATION
AB Thermal elevations experienced by bone during orthopaedic procedures, such as cutting and drilling, exothermal reactions from bone cement, and thermal therapies such as tumor ablation, can result in thermal damage leading to death of native bone cells (osteocytes, osteoblasts, osteoclasts and mesenchymal stem cells). Osteocytes are believed to be the orchestrators of bone remodeling, which recruit nearby osteoclast and osteoblasts to control resorption and bone growth in response to mechanical stimuli and physical damage. However, whether heat induced osteocyte damage can directly elicit bone remodelling has yet to be determined. This study establishes the link between osteocyte thermal damage and the remodeling cascade. We show that osteocytes directly exposed to thermal elevations (47 degrees C for 1 minute) become significantly apoptotic and alter the expression of osteogenic genes (Opg and Cox2). The Rankl/Opg ratio is consistently down regulated, at days 1, 3 and 7 in MLO Y4s heat treated to 47 degrees C for 1 minute. Additionally, the pro osteoblastogenic signaling marker Cox2 is significantly up regulated in heat treated MLO Y4s by day 7. Furthermore, secreted factors from heat treated MLO Y4s administered to MSCs using a novel co culture system are shown to activate pre osteoblastic MSCs to increase production of the pro osteoblastic differentiation marker, alkaline phosphatase (day 7, 14), and calcium deposition (day 21). Most interestingly, an initial pro osteoclastogenic signaling response (increase Rankl and Rankl/Opg ratio at day 1) followed by later stage pro osteoblastogenic signaling (down regulation in Rankl and the Rankl/Opg ratio and an up regulation in Opg and Cox2 by day 7) was observed in non heat treated MLO Y4s in co culture when these were exposed to the biochemicals produced by heat treated MLO Y4s. Taken together, these results elucidate the vital role of osteocytes in detecting and responding to thermal damage by means of thermally induced apoptosis followed by a cascade of remodelling responses.
C1 [Dolan, Eimear B.; Haugh, Matthew G.; Voisin, Muriel C.; McNamara, Laoise M.] Natl Univ Ireland, Coll Engn & Informat, Biomed Engn, Biomech Res Ctr BMEC, Galway, Ireland.
   [Dolan, Eimear B.; Haugh, Matthew G.; Voisin, Muriel C.; McNamara, Laoise M.] Natl Univ Ireland, Natl Ctr Biomed Engn Sci, Galway, Ireland.
   [Tallon, David] Stryker Ireland, Cork, Ireland.
C3 Ollscoil na Gaillimhe University of Galway; Ollscoil na
   Gaillimhe University of Galway
RP McNamara, LM (通讯作者)，Natl Univ Ireland, Coll Engn & Informat, Biomed Engn, Biomech Res Ctr BMEC, Galway, Ireland.
EM Laoise.McNamara@nuigalway.ie
OI Dolan, Eimear/0000 0002 6742 8461; McNamara, Laoise/0000 0002 5050 9230
FU National University of Ireland, Galway Fellowship Scheme; National
   University of Ireland Travelling Scholarships in Engineering; European
   Research Council (ERC) [258992]
FX The work was supported by National University of Ireland, Galway
   Fellowship Scheme (ED LMcN), The National University of Ireland
   Travelling Scholarships in Engineering (ED LMcN), and the European
   Research Council (ERC) (under grant no. 258992; BONEMECHBIO) (LMcN). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR BERMAN AT, 1984, CLIN ORTHOP RELAT R, P284
   Birmingham E, 2012, EUR CELLS MATER, V23, P13, DOI 10.22203/eCM.v023a02
   Birmingham E., 2012, Osteogenic differentiation of mesenchymal stem cells is regulated by osteocyte and osteoblast cells in a simplified bone niche
   Bonewald LF, 1999, J BONE MINER METAB, V17, P61, DOI 10.1007/s007740050066
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cardoso L, 2009, J BONE MINER RES, V24, P597, DOI 10.1359/JBMR.081210
   Dolan EB, 2012, J R SOC INTERFACE, V9, P3503, DOI 10.1098/rsif.2012.0520
   Dolan EB, 2014, J BIOMECH ENG T ASME, V136, DOI 10.1115/1.4026177
   DOTY SB, 1981, CALCIFIED TISSUE INT, V33, P509, DOI 10.1007/BF02409482
   ERIKSSON A, 1982, INT J ORAL MAXILLOF, V11, P115, DOI 10.1016/S0300 9785(82)80020 3
   ERIKSSON AR, 1984, ACTA ORTHOP SCAND, V55, P629, DOI 10.3109/17453678408992410
   Feng X, 2002, ENDOCRINOLOGY, V143, P4868, DOI 10.1210/en.2002 220467
   Freeman F, 2013, J TISSUE ENG REGENER
   Grimaud E, 2003, AM J PATHOL, V163, P2021, DOI 10.1016/S0002 9440(10)63560 2
   Heino TJ, 2004, EXP CELL RES, V294, P458, DOI 10.1016/j.yexcr.2003.11.016
   Hoey DA, 2011, BIOCHEM BIOPH RES CO, V412, P182, DOI 10.1016/j.bbrc.2011.07.072
   Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014
   Kennedy OD, 2014, BONE
   Kennedy OD, 2012, BONE, V50, P1115, DOI 10.1016/j.bone.2012.01.025
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Kirkham G., 2007, Topics in Tissue Engineering, V3
   Kobayashi D, 2013, PROSTATE, V73, P913, DOI 10.1002/pros.22637
   Kogianni G, 2008, J BONE MINER RES, V23, P915, DOI 10.1359/JBMR.080207
   Kogianni Giolanta, 2007, Curr Osteoporos Rep, V5, P81
   LEON SA, 1993, INT J HYPERTHER, V9, P77, DOI 10.3109/02656739309061480
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lundskog J, 1972, Scand J Plast Reconstr Surg, V9, P1
   Mann V., 2006, Journal of Musculoskeletal & Neuronal Interactions, V6, P408
   MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545
   Mulcahy LE, 2011, BONE, V48, P182, DOI 10.1016/j.bone.2010.09.014
   Mullen CA, 2013, J MECH BEHAV BIOMED, V28, P183, DOI 10.1016/j.jmbbm.2013.06.013
   Noble Brendon, 2003, European Cells & Materials, V6, P46
   Norgaard R, 2006, ANN NY ACAD SCI, V1067, P443, DOI 10.1196/annals.1354.063
   Peister A, 2004, BLOOD, V103, P1662, DOI 10.1182/blood 2003 09 3070
   Qiu S J, 1997, T ORTHOPEDIC RES SOC, V22
   Rucci N, 2007, J CELL BIOCHEM, V100, P464, DOI 10.1002/jcb.21059
   Santiago FR, 2009, CURR REV MUSCULOSKE, V2, P43, DOI 10.1007/s12178 008 9042 3
   Schaffler MB, 2014, CALCIFIED TISSUE INT, V94, P5, DOI 10.1007/s00223 013 9790 y
   Schaffler MB, 2012, CURR OSTEOPOROS REP, V10, P118, DOI 10.1007/s11914 012 0105 4
   Shui CX, 2001, J BONE MINER RES, V16, P731, DOI 10.1359/jbmr.2001.16.4.731
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Sims NA, 2012, CURR OSTEOPOROS REP, V10, P109, DOI 10.1007/s11914 012 0096 1
   Stanczyk M, 2004, J BIOMECH, V37, P1803, DOI [10.1016/j.biomech.2004.03.002, 10.1016/j.jbiomech.2004.03.002]
   Taylor AF, 2007, AM J PHYSIOL CELL PH, V292, pC545, DOI 10.1152/ajpcell.00611.2005
   TOKSVIGLARSEN S, 1991, J BONE JOINT SURG BR, V73, P13, DOI 10.1302/0301 620X.73B1.1991747
   Verborgt O, 2000, J BONE MINER RES, V15, P60, DOI 10.1359/jbmr.2000.15.1.60
   Wang JH, 2013, BONE, V57, P311, DOI 10.1016/j.bone.2013.08.015
   Yellowley CE, 2000, J BONE MINER RES, V15, P209, DOI 10.1359/jbmr.2000.15.2.209
   You LD, 2008, BONE, V42, P172, DOI 10.1016/j.bone.2007.09.047
   Zhang KQ, 2006, MOL CELL BIOL, V26, P4539, DOI 10.1128/MCB.02120 05
NR 52
TC 33
Z9 34
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD MAR 18
PY 2015
VL 10
IS 3
AR e0119652
DI 10.1371/journal.pone.0119652
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CE9BN
UT WOS:000352138500125
PM 25785846
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Briot, K
   Paccou, J
   Beuzeboc, P
   Bonneterre, J
   Bouvard, B
   Confavreux, CB
   Cormier, C
   Cortet, B
   Hannoun Lévi, JM
   Hennequin, C
   Javier, RM
   Lespessailles, E
   Mayeur, D
   Artus, PM
   Vieillard, MH
   Debiais, F
AF Briot, Karine
   Paccou, Julien
   Beuzeboc, Philippe
   Bonneterre, Jacques
   Bouvard, Beatrice
   Confavreux, Cyrille B.
   Cormier, Catherine
   Cortet, Bernard
   Hannoun Levi, Jean Michel
   Hennequin, Christophe
   Javier, Rose Marie
   Lespessailles, Eric
   Mayeur, Didier
   Artus, Pierre Mongiat
   Vieillard, Marie Helene
   Debiais, Francoise
TI French recommendations for osteoporosis prevention and treatment in
   patients with prostate cancer treated by androgen deprivation
SO JOINT BONE SPINE
LA English
DT Article
DE Prostate cancer; Bone loss; Fracture; Osteoporosis; LHRH agonists;
   Surgical orchiectomy; Androgen deprivation therapy; Prevention;
   Bisphosphonates; Denosumab; Recommendations
ID BONE MINERAL DENSITY; RANDOMIZED CONTROLLED TRIAL; FRACTURE RISK;
   VERTEBRAL FRACTURES; RADIATION THERAPY; ZOLEDRONIC ACID; HORMONE
   AGONISTS; MEN; SUPPRESSION; TERM
AB Androgen deprivation therapy (ADT) in patients with prostate cancer can be achieved surgically or chemically, notably by prescribing LHRH analogs. Major bone loss occurs rapidly in both cases, due to the decrease in testosterone levels, and can increase the fracture risk. The objective of developing these recommendations was to achieve a practical consensus among various scientific societies, based on a literature review, about osteoporosis prevention and treatment in patients on ADT. The following scientific societies contributed to the work: Societe francaise de rhumatologie (SFR), Groupe de recherche et d'information sur les osteoporoses (GRIO), Groupe europeen d'etudes des metastases osseuses (GEMO), Association francophone pour les soins de support (AFSOS), Association francaise d'urologie (AFU), Societe francaise de radiotherapie oncologique (SFRO). Medication prescription and reimbursement modalities in France were taken into account. The recommendations state that a fracture risk evaluation and interventions targeting risk factors for fractures should be provided to all patients on ADT. Those patients with a history of severe osteoporotic fracture and/or a T score <  2.5 should receive osteoporosis therapy. Patients whose T score is between  1.5 and  2.5 should be treated if they exhibit at least two other risk factors among the following: age >= 75 years, history of non severe fracture after 50 years of age, body mass index < 19 kg/m(2), at least three comorbidities (e.g., cardiovascular disease, depression, Parkinson's disease, and dementia), current glucocorticoid therapy, and repeated falls. When the decision is difficult, FRAX (R) score determination and an assessment by a bone disease specialist may be helpful. When osteoporosis therapy is not indicated, general measures should be applied, and bone mineral density measured again after 12 24 months. The anti tumor effects of bisphosphonates and denosumab fall outside the scope of these recommendations. (C) 2018 Published by Elsevier Masson SAS on behalf of Societe francaise de rhumatologie.
C1 [Briot, Karine; Cormier, Catherine] Hop Cochin, Serv Rhumatol, F 74014 Paris, France.
   [Paccou, Julien; Cortet, Bernard; Vieillard, Marie Helene] CHU Lille, Serv Rhumatol, F 59037 Lille, France.
   [Beuzeboc, Philippe] Inst Curie, Dept Oncol Med, F 75005 Paris, France.
   [Bonneterre, Jacques] Ctr Oscar Lambret, Dept Cancerol Senol, F 59000 Lille, France.
   [Bouvard, Beatrice] CHU Angers, Serv Rhumatol, F 49100 Angers, France.
   [Confavreux, Cyrille B.] Hosp Civils Lyon, Serv Rhumatol, F 69003 Lyon, France.
   [Confavreux, Cyrille B.] Univ Lyon, INSERM, UMR 1003 Lyos, F 69000 Lyon, France.
   [Hannoun Levi, Jean Michel] Ctr Antoine Lacassagne, Serv Radiotherapie, F 06100 Nice, France.
   [Hennequin, Christophe] Hop St Louis, Serv Cancerol & Radiotherapie, F 75010 Paris, France.
   [Javier, Rose Marie] CHU Strasbourg, Serv Rhumatol, F 67000 Strasbourg, France.
   [Lespessailles, Eric] CHR Orleans, Serv Rhumatol, F 45067 Orleans, France.
   [Mayeur, Didier] Ctr Hosp Versailles, Serv Oncol, F 78150 Le Chesnay, France.
   [Artus, Pierre Mongiat] Hop St Louis, Serv Urol, F 75010 Paris, France.
   [Vieillard, Marie Helene] Ctr Oscar Lambret, Serv Oncol, F 59000 Lille, France.
   [Debiais, Francoise] CHU Poitiers, Serv Rhumatol, 2 Rue Miletrie, F 86021 Poitiers, France.
C3 Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite;
   Hopital Universitaire Cochin   APHP; Universite de Lille; CHU Lille;
   UNICANCER; Universite PSL; Institut Curie; UNICANCER; Centre Oscar
   Lambret; Universite d'Angers; Centre Hospitalier Universitaire d'Angers;
   CHU Lyon; Institut National de la Sante et de la Recherche Medicale
   (Inserm); UNICANCER; Centre Antoine Lacassagne; Universite Paris Cite;
   Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Saint Louis   APHP; CHU Strasbourg; Universites de Strasbourg
   Etablissements Associes; Universite de Strasbourg; Centre Hospitalier
   Universitaire d'Orleans; Universite Paris Saclay; Centre Hospitalier de
   Versailles; Assistance Publique Hopitaux Paris (APHP); Universite Paris
   Cite; Hopital Universitaire Saint Louis   APHP; UNICANCER; Centre Oscar
   Lambret; Universite de Poitiers; CHU Poitiers
RP Debiais, F (通讯作者)，CHU Poitiers, Serv Rhumatol, 2 Rue Miletrie, F 86021 Poitiers, France.
EM f.debiais@chu poitiers.fr
RI ; Confavreux, Cyrille/HTT 0045 2023; BOUVARD, Béatrice/ABA 8078 2021;
   LESPESSAILLES, Eric/JVM 7803 2024; paccou, julien/JFA 4185 2023; Briot,
   Karine/P 2116 2016; Bouvard, Beatrice/ABA 8078 2021
OI LESPESSAILLES, Eric/0000 0003 1009 8518; paccou,
   julien/0000 0001 6599 8623; Briot, Karine/0000 0002 6238 2601; Bouvard,
   Beatrice/0000 0003 1609 8113
CR Abrahamsen B, 2007, BJU INT, V100, P749, DOI 10.1111/j.1464 410X.2007.07163.x
   Ahlborg HG, 2008, BONE, V43, P556, DOI 10.1016/j.bone.2008.05.003
   Alibhai SMH, 2013, OSTEOPOROSIS INT, V24, P2571, DOI 10.1007/s00198 013 2343 4
   Alibhai SMH, 2010, J UROLOGY, V184, P918, DOI 10.1016/j.juro.2010.04.068
   Angeli A, 2006, BONE, V39, P253, DOI 10.1016/j.bone.2006.02.005
   [Anonymous], 2016, CANC FRANC
   [Anonymous], 2012, GUID AFF LONG DUR CA
   Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095
   Benhamou CL, 2011, PRESSE MED, V40, P673, DOI 10.1016/j.lpm.2011.04.001
   Berruti A, 2002, J UROLOGY, V167, P2361, DOI 10.1016/S0022 5347(05)64985 3
   Bhoopalam N, 2009, J UROLOGY, V182, P2257, DOI 10.1016/j.juro.2009.07.046
   BINKLEY NC, 2002, J CLIN DENSITOM, V5, P219
   Bliuc D, 2009, JAMA J AM MED ASSOC, V301, P513, DOI 10.1001/jama.2009.50
   Bolla M, 2010, LANCET ONCOL, V11, P1066, DOI 10.1016/S1470 2045(10)70223 0
   Bolla M, 2009, NEW ENGL J MED, V360, P2516, DOI 10.1056/NEJMoa0810095
   Briot K, 2009, JOINT BONE SPINE, V76, P129, DOI 10.1016/j.jbspin.2008.07.014
   Bylow K, 2011, UROLOGY, V77, P934, DOI 10.1016/j.urology.2010.11.024
   Choo R, 2013, INT J RADIAT ONCOL, V85, P1239, DOI 10.1016/j.ijrobp.2012.11.007
   Crook JM, 2012, NEW ENGL J MED, V367, P895, DOI 10.1056/NEJMoa1201546
   D'Amico AV, 1998, JAMA J AM MED ASSOC, V280, P969, DOI 10.1001/jama.280.11.969
   D'Amico AV, 2004, JAMA J AM MED ASSOC, V292, P821, DOI 10.1001/jama.292.7.821
   Daniell HW, 2000, J UROLOGY, V163, P181, DOI 10.1016/S0022 5347(05)68000 7
   DargentMolina P, 1996, LANCET, V348, P145, DOI 10.1016/S0140 6736(96)01440 7
   De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618
   de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140 6736(10)61389 X
   Faulkner KG, 2002, J CLIN DENSITOM, V5, P87, DOI 10.1385/JCD:5:1:087
   Gandini S, 2011, INT J CANCER, V128, P1414, DOI 10.1002/ijc.25439
   Gilbert R, 2011, CANCER CAUSE CONTROL, V22, P319, DOI 10.1007/s10552 010 9706 3
   Gralow JR, 2013, J NATL COMPR CANC NE, V11, pS1
   Greenspan SL, 2007, ANN INTERN MED, V146, P416, DOI 10.7326/0003 4819 146 6 200703200 00006
   Greenspan SL, 2013, J BONE MINER RES, V28, P325, DOI 10.1002/jbmr.1771
   Higano C, 2004, UROLOGY, V64, P1182, DOI 10.1016/j.urology.2004.07.019
   Hussain M, 2013, NEW ENGL J MED, V368, P1314, DOI 10.1056/NEJMoa1212299
   Kanis JA, 2008, OSTEOPOROSIS INT, V19, P385, DOI 10.1007/s00198 007 0543 5
   Klotz LH, 2013, EUR UROL, V63, P927, DOI 10.1016/j.eururo.2012.09.007
   Lau YK, 2009, CAN J UROL, V16, P4908
   Leslie WD, 2006, J CLIN DENSITOM, V9, P22, DOI 10.1016/j.jocd.2006.05.004
   Magno C, 2005, EUR UROL, V47, P575, DOI 10.1016/j.eururo.2005.01.012
   Maillefert JF, 1999, J UROLOGY, V161, P1219, DOI 10.1016/S0022 5347(01)61639 2
   Michaelson MD, 2007, J CLIN ONCOL, V25, P1038, DOI 10.1200/JCO.2006.07.3361
   Mittan D, 2002, J CLIN ENDOCR METAB, V87, P3656, DOI 10.1210/jc.87.8.3656
   Morabito N, 2004, J BONE MINER RES, V19, P1766, DOI 10.1359/JBMR.040813
   Morote J, 2006, J UROLOGY, V175, P1679, DOI 10.1016/S0022 5347(05)00999 7
   Morote J, 2007, UROLOGY, V69, P500, DOI 10.1016/j.urology.2006.11.002
   Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755
   Planas J, 2009, BJU INT, V104, P1637, DOI 10.1111/j.1464 410X.2009.08622.x
   Preston DM, 2002, PROSTATE CANCER P D, V5, P304, DOI 10.1038/sj.pcan.4500599
   Rizzoli R, 2013, OSTEOPOROSIS INT, V24, P2929, DOI 10.1007/s00198 013 2530 3
   Rozet F, 2016, Prog Urol, V27 Suppl 1, pS95, DOI 10.1016/S1166 7087(16)30705 9
   Ryan CW, 2006, J UROLOGY, V176, P972, DOI 10.1016/j.juro.2006.04.078
   Saylor PJ, 2011, J UROLOGY, V186, P482, DOI 10.1016/j.juro.2011.03.111
   Shahinian VB, 2005, NEW ENGL J MED, V352, P154, DOI 10.1056/NEJMoa041943
   Shao YH, 2013, BJU INT, V111, P745, DOI 10.1111/j.1464 410X.2012.11758.x
   Shepherd JA, 2015, J CLIN DENSITOM, V18, P274, DOI 10.1016/j.jocd.2015.06.013
   Smith MR, 2010, J UROLOGY, V184, P1316, DOI 10.1016/j.juro.2010.06.022
   Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056/NEJMoa0809003
   Smith MR, 2005, J CLIN ONCOL, V23, P7897, DOI 10.1200/JCO.2004.00.6908
   Smith MR, 2003, J UROLOGY, V169, P2008, DOI 10.1097/01.ju.0000063820.94994.95
   Smith MR, 2001, NEW ENGL J MED, V345, P948, DOI 10.1056/NEJMoa010845
   Soubeyran P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115060
   Spry NA, 2009, BJU INT, V104, P806, DOI 10.1111/j.1464 410X.2009.08458.x
   Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720
   Taxel P, 2010, BJU INT, V106, P1473, DOI 10.1111/j.1464 410X.2010.09329.x
   White DB, 2004, B MAR SCI, V75, P335
   Xu YH, 2014, J CANCER RES CLIN, V140, P1465, DOI 10.1007/s00432 014 1706 3
   Yin L, 2009, CANCER EPIDEMIOL, V33, P435, DOI 10.1016/j.canep.2009.10.014
   Yu EY, 2012, J CLIN ONCOL, V30, P1864, DOI 10.1200/JCO.2011.38.3745
   Zapatero A, 2015, LANCET ONCOL, V16, P320, DOI 10.1016/S1470 2045(15)70045 8
NR 68
TC 28
Z9 29
U1 0
U2 10
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 1297 319X
EI 1778 7254
J9 JOINT BONE SPINE
JI Joint Bone Spine
PD JAN
PY 2019
VL 86
IS 1
BP 21
EP 28
DI 10.1016/j.jbspin.2018.09.017
PG 8
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA HH4AP
UT WOS:000455662700005
PM 30287350
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Moura, SR
   Bras, JP
   Freitas, J
   Osório, H
   Barbosa, MA
   Santos, SG
   Almeida, MI
AF Moura, Sara Reis
   Bras, Joao Paulo
   Freitas, Jaime
   Osorio, Hugo
   Barbosa, Mario Adolfo
   Santos, Susana Gomes
   Almeida, Maria Ines
TI miR 99a in bone homeostasis: Regulating osteogenic lineage commitment
   and osteoclast differentiation
SO BONE
LA English
DT Article
DE Cell differentiation; Osteoporosis; Bone remodeling; Osteoprotegerin;
   Gene therapy
ID OSTEOPROTEGERIN; CELLS; MICRORNAS; CALCIFICATION; OSTEOPOROSIS;
   CHITOSAN; SCAFFOLD; RANKL
AB Background: The tight coupling between osteoblasts and osteoclasts is essential to maintain bone homeostasis. Deregulation of this process leads to loss and deterioration of the bone tissue causing diseases, such as osteoporosis. MicroRNAs are able to control bone related mechanisms and have been explored as therapeutic tools. In this study, we investigated the potential of miR 99a 5p to modulate osteogenic differentiation, osteoclastogenesis, and the osteoblasts osteoclasts crosstalk.
   Methods: To achieve this goal, human primary Mesenchymal Stem/Stromal Cells (MSC) were differentiated into osteoblasts and adipocytes, and miR 99a 5p expression was evaluated by RT qPCR. Knockdown and overexpression experiments were conducted to modulate miR 99a 5p expression in MC3T3 cells. Cell proliferation and cell death/apoptosis were evaluated by resazurin assay and flow cytometry, respectively. Proteomic analysis was used to identify the miR 99a 5p regulatory network, and ELISA to evaluate OPG levels in the cell culture supernatant. Conditioned media from MC3T3 transfected cells was used to culture RAW 264.7 cells and the effect on osteoclast differentiation was assessed. Human primary monocytes were isolated to induce osteoclastogenesis and evaluate miR 99a 5p expression. Finally, levels of miR 99a 5p were modulated in RAW 264.7 cells to understand the impact on osteoclastogenesis.
   Results: The results show that miR 99a 5p is significantly downregulated during the early stages of human primary MSCs osteogenic differentiation and during MC3T3 osteogenic differentiation. On the other hand, miR99a 5p levels are increased during the initial stages of adipogenic differentiation. Inhibition of miR 99a 5p in MC3T3 pre osteoblastic cells promoted osteogenic differentiation, whereas its overexpression suppressed the levels of osteogenic specific genes (Runx2 and Alpl), as well as mineralization, with no effect on proliferation or apoptosis. Proteomic analysis of miR 99a 5p transfected cells showed that numerous proteins known to be involved in cell differentiation were altered, including osteogenic differentiation markers and extracellular matrix proteins. While inhibition of miR 99a 5p increased the Tnfrsf11b (OPG encoding gene)/Tnfsf11 (RANKL encoding gene) mRNA expression ratio, in addition to increasing OPG secretion, miR 99a 5p overexpression resulted in the opposite effect. The cell culture supernatant of miR 99a 5p inhibited MC3T3 cells impaired the osteoclastogenic potential of RAW 264.7 cells by decreasing the number of multinucleated cells and reducing the expression of osteoclastogenic markers. Interestingly, miR 99a 5p expression is increased during osteoclasts differentiation, both in human primary monocytes and RAW 264.7. These results show that miR 99a 5p per se is a positive regulator of osteoclastogenic differentiation.
   Conclusions: Globally, our findings show that miR 99a 5p inhibition promotes the commitment into osteogenic differentiation, impairs osteoclastogenic differentiation, and control bone cells communication. Ultimately, it supports miR 99a 5p as a target candidate for future miRNA based therapies for bone diseases associated with bone remodeling deregulation.
C1 [Moura, Sara Reis; Bras, Joao Paulo; Freitas, Jaime; Osorio, Hugo; Barbosa, Mario Adolfo; Santos, Susana Gomes; Almeida, Maria Ines] Univ Porto, I3S, P 4200135 Porto, Portugal.
   [Moura, Sara Reis; Bras, Joao Paulo; Freitas, Jaime; Barbosa, Mario Adolfo; Santos, Susana Gomes; Almeida, Maria Ines] Univ Porto, INEB Inst Engn Biomed, P 4200135 Porto, Portugal.
   [Bras, Joao Paulo; Barbosa, Mario Adolfo; Santos, Susana Gomes; Almeida, Maria Ines] Univ Porto, ICBAS, P 4050313 Porto, Portugal.
   [Osorio, Hugo] Univ Porto, Ipatimup Inst Patol & Imunol Mol, P 4200135 Porto, Portugal.
   [Osorio, Hugo] Univ Porto, FMUP Fac Med, P 4200319 Porto, Portugal.
C3 Universidade do Porto; i3S   Instituto de Investigacao e Inovacao em
   Saude, Universidade do Porto; Universidade do Porto; Universidade do
   Porto; Universidade do Porto; Universidade do Porto
RP Almeida, MI (通讯作者)，Rua Alfredo Allen 208, P 4200135 Porto, Portugal.
EM ines.almeida@ineb.up.pt
RI ; Brás, João/AAI 5050 2020; Freitas, Jaime/K 1328 2013; Freitas,
   Jaime/P 4419 2019; Osorio, Hugo/A 7847 2012; Moura, Sara/JLL 6608 2023;
   Barbosa, Mario/F 5964 2011; Moura, Sara Reis/JLL 6608 2023; Almeida,
   Maria/AAP 2376 2021; Santos, Susana/L 9351 2013; Barbosa,
   Mário/F 5964 2011
OI Bras, Joao/0000 0003 1867 0486; Osorio, Hugo/0000 0002 6362 8255;
   Freitas, Jaime/0000 0003 3229 3293; Almeida, Maria
   Ines/0000 0003 2072 8587; Moura, Sara/0000 0001 9880 6683; Barbosa,
   Mario/0000 0003 3568 7482; Santos, Susana/0000 0002 8604 2978; 
FU Fundacao para a Ciencia e a Tecnologia (FCT) under the PORTUGAL 2020
   Partnership Agreement, through ERDF [POCI 01 0145 FEDER 031402R2Bone];
   FEDER/FNR; FCT Fundacao para a Ciencia e a Tecnologia, I.P.; FCT
   [SFRH/BD/147229/2019, PD/BD/135490/2018]; Portuguese Mass Spectrometry
   Network, integrated in the National Roadmap of Research Infrastructures
   of Strategic Relevance [ROTEIRO/0028/2013, LISBOA01 0145 FEDER 022125];
   Fundação para a Ciência e a Tecnologia [PD/BD/135490/2018,
   SFRH/BD/147229/2019] Funding Source: FCT
FX This project is supported by Fundacao para a Ciencia e a Tecnologia
   (FCT)  in the framework of the project POCI 01 0145 FEDER 031402R2Bone,
   under the PORTUGAL 2020 Partnership Agreement, through ERDF, co funded
   by FEDER/FNR, and national funding (through FCT Fundacao para a Ciencia
   e a Tecnologia, I.P., provided by the contractprogram and according to
   numbers 4, 5 and 6 of art. 23 of Law No. 57/2016 of 29 August 2016, as
   amended by Law No. 57/2017 of 19 July 2017). SRM and JB are supported by
   FCT (SFRH/BD/147229/2019, PD/BD/135490/2018, respectively; BiotechHealth
   PhD program). The mass spectrometry technique was performed at the i3S
   Proteomics Scientific Platform. This work had support from the
   Portuguese Mass Spectrometry Network, integrated in the National Roadmap
   of Research Infrastructures of Strategic Relevance (ROTEIRO/0028/2013;
   LISBOA01 0145 FEDER 022125).
CR Almeida MI, 2011, MUTAT RES FUND MOL M, V717, P1, DOI 10.1016/j.mrfmmm.2011.03.009
   Almeida MI, 2016, ONCOTARGET, V7, P7, DOI 10.18632/oncotarget.6589
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Brändström H, 2001, BIOCHEM BIOPH RES CO, V280, P831, DOI 10.1006/bbrc.2000.4223
   Bras JP, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188530
   Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Collin Osdoby P, 2012, METHODS MOL BIOL, V816, P187, DOI 10.1007/978 1 61779 415 5_13
   Cui L, 2012, BMC CANCER, V12, DOI 10.1186/1471 2407 12 546
   de la Rica L, 2015, GENOME BIOL, V16, DOI 10.1186/s13059 014 0561 5
   De Ugarte L, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920 015 0149 2
   Ding W, 2019, CLIN LAB, V65, P1727, DOI 10.7754/Clin.Lab.2019.190327
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Dweep H, 2011, J BIOMED INFORM, V44, P839, DOI 10.1016/j.jbi.2011.05.002
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Franceschetti T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107262
   Freitas J, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143430
   Gardner CR, 2007, CELL BIOL INT, V31, P672, DOI 10.1016/j.cellbi.2006.12.008
   Garmilla Ezquerra P, 2015, CALCIFIED TISSUE INT, V96, P30, DOI 10.1007/s00223 014 9935 7
   Goldberg M, 2006, J HISTOCHEM CYTOCHEM, V54, P525, DOI 10.1369/jhc.5A6650.2005
   Gulyaeva LF, 2016, J TRANSL MED, V14, DOI 10.1186/s12967 016 0893 x
   Hadjiargyrou M, 2016, BONE, V87, P78, DOI 10.1016/j.bone.2016.03.011
   Hamann A, 2019, J BIOL ENG, V13, DOI 10.1186/s13036 019 0140 0
   Kanis JA, 2009, NAT REV RHEUMATOL, V5, P425, DOI 10.1038/nrrheum.2009.139
   Kearns AE, 2008, ENDOCR REV, V29, P155, DOI 10.1210/er.2007 0014
   Kelch S, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 16113 x
   Krzeszinski JY, 2014, NATURE, V512, P431, DOI 10.1038/nature13375
   Li CJ, 2018, J CLIN INVEST, V128, P5251, DOI 10.1172/JCI99044
   Li DF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10872
   Liang XL, 2016, J CELL SCI, V129, P2182, DOI 10.1242/jcs.170373
   Liu X, 2016, ACTA BIOMATER, V42, P378, DOI 10.1016/j.actbio.2016.06.019
   Lourenço AH, 2019, MAT SCI ENG C MATER, V99, P1289, DOI 10.1016/j.msec.2019.02.053
   Mei LL, 2017, CANCER BIOMARK, V20, P527, DOI 10.3233/CBM 170345
   Min H, 2000, J EXP MED, V192, P463, DOI 10.1084/jem.192.4.463
   Ng AY, 2018, JBMR PLUS, V2, P328, DOI 10.1002/jbm4.10058
   Nguyen John, 2017, J Biochem Anal Stud, V2, DOI 10.16966/2576 5833.109
   Oliveira MI, 2012, EUR CELLS MATER, V24, P136, DOI 10.22203/eCM.v024a10
   Papaioannou G, 2014, CELL MOL LIFE SCI, V71, P4747, DOI 10.1007/s00018 014 1700 6
   Pinheiro A, 2018, J CONTROL RELEASE, V289, P56, DOI 10.1016/j.jconrel.2018.09.019
   Qin HZ, 2019, J CELL PHYSIOL, V234, P3526, DOI 10.1002/jcp.26906
   Ren XY, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw4991
   Seeliger C, 2014, J BONE MINER RES, V29, P1718, DOI 10.1002/jbmr.2175
   Silva AM, 2018, THERANOSTICS, V8, P3902, DOI 10.7150/thno.24444
   Silva AM, 2017, EUR J PHARM SCI, V98, P86, DOI 10.1016/j.ejps.2016.09.017
   Silva AM, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0048 9
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191
   Tang Y, 2018, J CELL MOL MED, V22, P2162, DOI 10.1111/jcmm.13490
   Torres AL, 2013, ACTA BIOMATER, V9, P6553, DOI 10.1016/j.actbio.2013.01.015
   Tsai TF, 2018, ONCOTARGETS THER, V11, P239, DOI 10.2147/OTT.S114276
   Turchinovich A, 2011, NUCLEIC ACIDS RES, V39, P7223, DOI 10.1093/nar/gkr254
   Waki T, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891 016 0931 0
   Wolter JM, 2017, GENOME RES, V27, P53, DOI 10.1101/gr.209361.116
   Yan S, 2019, MOL CELL BIOCHEM, V455, P135, DOI 10.1007/s11010 018 3477 7
   Zhou L, 2019, INT J MOL MED, V43, P727, DOI 10.3892/ijmm.2018.4017
NR 56
TC 24
Z9 25
U1 0
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAY
PY 2020
VL 134
AR 115303
DI 10.1016/j.bone.2020.115303
PG 15
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA LG1DP
UT WOS:000527850700030
PM 32126314
DA 2025 08 17
ER

PT J
AU Anastasilakis, AD
   Goulis, DG
   Polyzos, SA
   Gerou, S
   Pavlidou, V
   Koukoulis, G
   Avramidis, A
AF Anastasilakis, Athanasios D.
   Goulis, Dimirtios G.
   Polyzos, Stergios A.
   Gerou, Spiridon
   Pavlidou, Vasiliki
   Koukoulis, George
   Avramidis, Avraam
TI Acute changes in serum osteoprotegerin and receptor activator for
   nuclear factor κB ligand levels in women with established osteoporosis
   treated with teriparatide
SO EUROPEAN JOURNAL OF ENDOCRINOLOGY
LA English
DT Article
ID RANKL MESSENGER RNA; PARATHYROID HORMONE; CIRCULATING OSTEOPROTEGERIN;
   PRIMARY HYPERPARATHYROIDISM; POSTMENOPAUSAL WOMEN; BONE FORMATION;
   IN VIVO; EXPRESSION; ASSOCIATION; SECRETION
AB Objective: The mechanisms regulating the anabolic response of the skeleton to intermittent exogenous parathyroid hormone (PTH) administration are not fully elucidated. The aim of this prospective study was to evaluate the acute effect (up to 1 month) of teriparatide (TPTD: human recombinant PTH 1 34) on serum levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in women with established osteoporosis.
   Design: Twenty three postmenopausal Caucasian women with established osteoporosis (mean age 66.7 +/  1.6 years) received daily injections of 20 mu g TPTD for 12 months.
   Methods: Serum samples for total calcium (Ca), phosphate, alkaline phosphatase, N terminal propeptide of type I collagen, intact PTH (iPTH), OPG, and RANKL were obtained at baseline, 1 h, 1 day, and 1 month after initiation of therapy. Lumbar spine bone mineral density (BMD) was measured before and 12 months after TPTD treatment. Results: Serum total Ca increased and iPTH gradually decreased with TPTD treatment. Serum OPG levels remained unchanged, while RANKL increased gradually during the study (P < 0.001). There was no correlation between OPG or RANKL and BMD changes or iPTH levels.
   Conclusions: TPTD therapy in women with postmenopausal osteoporosis results in acute increase in serum RANKL levels but does not affect serum OPG. These changes may reflect an increase in the number of active osteoblasts with therapy and might be responsible for the acceleration of bone turnover rate that characterizes TPTD.
C1 [Anastasilakis, Athanasios D.; Polyzos, Stergios A.; Avramidis, Avraam] Hippocrat Gen Hosp, Dept Endocrinol, Thessaloniki 54642, Greece.
   [Goulis, Dimirtios G.] Aristotle Univ Thessaloniki, Unit Reprod Endocrinol, Dept Obstet & Gynecol 1, Thessaloniki 54603, Greece.
   [Gerou, Spiridon; Pavlidou, Vasiliki] Anal Labs, Thessaloniki 54623, Greece.
   [Koukoulis, George] Univ Thessalia, Dept Internal Med, Larisa 41222, Greece.
C3 Aristotle University of Thessaloniki; University of Thessaly
RP Anastasilakis, AD (通讯作者)，Soulini 4, Sykies, Greece.
EM anastath@endo.gr
RI Polyzos, Stergios/H 2844 2019; Goulis, Dimitrios/AAG 4589 2020;
   Pavlidou, Vasiliki/C 2944 2011; Anastasilakis, Athanasios/AAF 7669 2020
OI Goulis, Dimitrios/0000 0002 5005 1995; Koukoulis,
   George/0000 0002 6560 3537; Anastasilakis,
   Athanasios/0000 0002 9624 6296; Polyzos, Stergios/0000 0001 9232 4042
CR Buxton EC, 2004, J CLIN ENDOCR METAB, V89, P3332, DOI 10.1210/jc.2003 032066
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Chen D, 2001, CLIN CHEM, V47, P747
   Coetzee M, 2007, J NUTR BIOCHEM, V18, P54, DOI 10.1016/j.jnutbio.2006.03.002
   COSMAN F, 1991, J CLIN ENDOCR METAB, V73, P1345, DOI 10.1210/jcem 73 6 1345
   Dobnig H, 2005, J CLIN ENDOCR METAB, V90, P3970, DOI 10.1210/jc.2003 1703
   Eghbali Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215
   Gori F, 2000, ENDOCRINOLOGY, V141, P4768, DOI 10.1210/en.141.12.4768
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Hofbauer LC, 2000, J CLIN ENDOCR METAB, V85, P2355, DOI 10.1210/jc.85.7.2355
   Huang JC, 2004, J BONE MINER RES, V19, P235, DOI 10.1359/JBMR.0301226
   Iida Klein A, 2002, J BONE MINER RES, V17, P808, DOI 10.1359/jbmr.2002.17.5.808
   Khosla S, 2002, J CLIN ENDOCR METAB, V87, P1550, DOI 10.1210/jc.87.4.1550
   Kinyamu HK, 1996, J BONE MINER RES, V11, P1400
   Kondo H, 2002, J BONE MINER RES, V17, P1667, DOI 10.1359/jbmr.2002.17.9.1667
   Lee SK, 1999, ENDOCRINOLOGY, V140, P3552, DOI 10.1210/en.140.8.3552
   Ma YFL, 2006, J BONE MINER RES, V21, P855, DOI 10.1359/JBMR.060314
   Ma YFL, 2001, ENDOCRINOLOGY, V142, P4047, DOI 10.1210/en.142.9.4047
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Rogers A, 2005, J CLIN ENDOCR METAB, V90, P6323, DOI 10.1210/jc.2005 0794
   Rubin J, 2002, J CLIN ENDOCR METAB, V87, P4273, DOI 10.1210/jc.2002 020656
   Seck T, 2001, EUR J ENDOCRINOL, V145, P199, DOI 10.1530/eje.0.1450199
   Stilgren LS, 2004, BONE, V35, P256, DOI 10.1016/j.bone.2004.03.012
   Stilgren LS, 2003, CALCIFIED TISSUE INT, V73, P210, DOI 10.1007/s00223 002 2100 8
   Takami M, 2000, ENDOCRINOLOGY, V141, P4711, DOI 10.1210/en.141.12.4711
   Ueno Y, 2003, J CELL BIOCHEM, V90, P267, DOI 10.1002/jcb.10623
   Wang LM, 2004, J BONE MINER RES, V19, P1661, DOI 10.1359/JBMR.040708
NR 28
TC 27
Z9 31
U1 0
U2 2
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA STARLING HOUSE, 1600 BRISTOL PARKWAY N, BRISTOL, ENGLAND
SN 0804 4643
EI 1479 683X
J9 EUR J ENDOCRINOL
JI Eur. J. Endocrinol.
PD MAR
PY 2008
VL 158
IS 3
BP 411
EP 415
DI 10.1530/EJE 07 0528
PG 5
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 272JB
UT WOS:000253854600018
PM 18299476
OA Bronze
DA 2025 08 17
ER

PT J
AU Pal, S
   Porwal, K
   Singh, H
   Malik, MY
   Rashid, M
   Kulkarni, C
   Khan, Y
   Jagavelu, K
   Wahajuddin, M
   Chattopadhyay, N
AF Pal, Subhashis
   Porwal, Konica
   Singh, Himalaya
   Malik, Mohd Yaseen
   Rashid, Mamunur
   Kulkarni, Chirag
   Khan, Yasir
   Jagavelu, Kumaravelu
   Wahajuddin, Muhammad
   Chattopadhyay, Naibedya
TI Reversal of Osteopenia in Ovariectomized Rats by Pentoxifylline:
   Evidence of Osteogenic and Osteo Angiogenic Roles of the Drug
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Pharmacokinetics; Bone turnover; Bone formation; Osteopenia;
   Vascularity; Angiogenesis
ID ISCHEMIA REPERFUSION; POSTMENOPAUSAL WOMEN; BONE FORMATION;
   OSTEOPOROSIS; EXPRESSION; RECEPTOR; CELLS; VEGF; DISCONTINUATION;
   INHIBITOR
AB Pentoxifylline (PTX) is a non selective phosphodiesterase inhibitor and is used for the management of intermittent claudication. We tested whether PTX has oral efficacy in stimulating new bone formation. Rat calvarial osteoblasts (RCO) were used to study the effect of PTX on osteoblast differentiation and angiogenesis. Pharmacokinetic and pharmacodynamic studies were carried out in rats to determine an oral dose of PTX. In ovariectomized (OVX) rats with osteopenia, the effect of PTX on various skeletal parameters was studied, and compared with teriparatide. Effect of PTX on angiogenic signaling was studied by immunoblotting and relevant pharmacologic inhibitors. Bone vascularity was measured by intravenous injection of polystyrene fluorospheres followed by in vivo imaging, and angiogenesis was studied in vitro by tubulogenesis of endothelial cells and in vivo by Matrigel plug assay. Effective concentration (EC50) of PTX in RCO was 8.2 nM and plasma PTX level was 7 nM/mL after single oral dosing of 25 mg/kg, which was 1/6th the clinically used dose. At this dose, PTX enhanced bone regeneration at femur osteotomy site and completely restored bone mass, microarchitecture, and strength in OVX rats. Furthermore, PTX increased surface referent bone formation parameters and serum bone formation marker (PINP) without affecting the resorption marker (CTX 1). PTX increased the expression of vascular endothelial growth factor and its receptor in bones and osteoblasts. PTX also increased skeletal vascularity, tubulogenesis of endothelial cells and in vivo angiogenesis. Taken together, our study suggested that PTX at 16% of adult human oral dose completely reversed osteopenia in OVX rats by osteogenic and osteo angiogenic mechanisms.
C1 [Pal, Subhashis; Porwal, Konica; Kulkarni, Chirag; Khan, Yasir; Chattopadhyay, Naibedya] CSIR, Cent Drug Res Inst, Div Endocrinol, Lucknow 226031, Uttar Pradesh, India.
   [Singh, Himalaya; Jagavelu, Kumaravelu] CSIR, Div Pharmacol, CDRI, Lucknow 226031, Uttar Pradesh, India.
   [Malik, Mohd Yaseen; Rashid, Mamunur; Wahajuddin, Muhammad] CSIR, Div Pharmaceut, CDRI, Lucknow 226031, Uttar Pradesh, India.
C3 Council of Scientific & Industrial Research (CSIR)   India; CSIR  
   Central Drug Research Institute (CDRI); Council of Scientific &
   Industrial Research (CSIR)   India; CSIR   Central Drug Research
   Institute (CDRI); Council of Scientific & Industrial Research (CSIR)  
   India; CSIR   Central Drug Research Institute (CDRI)
RP Chattopadhyay, N (通讯作者)，CSIR, Cent Drug Res Inst, Div Endocrinol, Lucknow 226031, Uttar Pradesh, India.
EM n_chattopadhyay@cdri.res.in
RI Malik, Muhammad/X 5316 2018; Pal, Subhashis/IXD 3635 2023; Rashid,
   Mamunur/AAQ 1623 2021; Chattopadhyay, Naibedya/AAF 2058 2019;   ,
   Wahajuddin/B 4413 2010; Jagavelu, Kumaravelu/L 8053 2019
OI Pal, Subhashis/0000 0002 3916 5545; Porwal, Konica/0000 0002 6447 4681;
   , Wahajuddin/0000 0003 3362 7558; Malik, Mohd
   Yaseen/0000 0002 5514 0364; Jagavelu, Kumaravelu/0000 0002 9235 0600;
   Kulkarni, Chirag/0000 0002 8237 4182; Chattopadhyay,
   Naibedya/0000 0003 2473 0246; Rashid, Mamunur/0000 0003 3122 2784
FU Council of Scientific and Industrial Research, Government of India
FX Council of Scientific and Industrial Research, Government of India to
   Naibedya Chattopadhyay.
CR AHARONI D, 1995, EXP CELL RES, V218, P271, DOI 10.1006/excr.1995.1156
   ArmamentoVillareal R, 1997, J BONE MINER RES, V12, P384, DOI 10.1359/jbmr.1997.12.3.384
   Athanasopoulos AN, 2007, J BIOL CHEM, V282, P26746, DOI 10.1074/jbc.M705200200
   BURKHARDT R, 1987, BONE, V8, P157, DOI 10.1016/8756 3282(87)90015 9
   Cakmak G, 2015, ACTA ORTHOP TRAUMATO, V49, P676, DOI 10.3944/AOTT.2015.15.0158
   Chen GF, 2014, CELL RES, V24, P1121, DOI 10.1038/cr.2014.112
   China SP, 2017, BONE, V105, P75, DOI 10.1016/j.bone.2017.08.005
   Cosman F, 2016, OSTEOPOROSIS INT, V27, P377, DOI 10.1007/s00198 015 3392 7
   Costa N, 2009, CYTOKINE, V46, P376, DOI 10.1016/j.cyto.2009.03.012
   DAUBER IM, 1992, J PHARMACOL EXP THER, V260, P1250
   Deckers MML, 2002, ENDOCRINOLOGY, V143, P1545, DOI 10.1210/en.143.4.1545
   Deckers MML, 2000, ENDOCRINOLOGY, V141, P1667, DOI 10.1210/en.141.5.1667
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   FRAMPTON JE, 1995, DRUG AGING, V7, P480, DOI 10.2165/00002512 199507060 00007
   Giallauria F, 2011, AM J HYPERTENS, V24, P970, DOI 10.1038/ajh.2011.80
   Griffith JF, 2008, J BONE MINER RES, V23, P1068, DOI [10.1359/jbmr.080233, 10.1359/JBMR.080233]
   HARTMANN A, 1983, EUR NEUROL, V22, P108, DOI 10.1159/000115659
   Hock J. M., 2001, Journal of Musculoskeletal & Neuronal Interactions, V2, P33
   HORTON JW, 1993, J SURG RES, V55, P282, DOI 10.1006/jsre.1993.1141
   Hu K, 2016, J CLIN INVEST, V126, P509, DOI 10.1172/JCI82585
   Huang JC, 2004, J BONE MINER RES, V19, P235, DOI 10.1359/JBMR.0301226
   Insel PA, 2012, ACTA PHYSIOL, V204, P277, DOI 10.1111/j.1748 1716.2011.02273.x
   Iwamoto J, 2006, YONSEI MED J, V47, P157, DOI 10.3349/ymj.2006.47.2.157
   Jain M, 2017, J CARDIOVASC PHARM, V70, P176, DOI 10.1097/FJC.0000000000000503
   Jiang BB, 1998, J CARDIOVASC PHARM, V31, pS142, DOI 10.1097/00005344 199800001 00042
   Krishnan V, 2003, MOL ENDOCRINOL, V17, P423, DOI 10.1210/me.2002 0225
   Leder BZ, 2009, J CLIN ENDOCR METAB, V94, P2915, DOI 10.1210/jc.2008 2630
   Ma L, 2010, J BONE MINER RES, V25, P1305, DOI 10.1002/jbmr.19
   Mestek ML, 2010, BONE, V47, P542, DOI 10.1016/j.bone.2010.05.041
   Modi A, 2017, OSTEOPOROSIS INT, V28, P1355, DOI 10.1007/s00198 016 3886 y
   Morley Paul, 2005, Expert Opin Drug Deliv, V2, P993, DOI 10.1517/17425247.2.6.993
   OKANO K, 1994, ENDOCRINOLOGY, V135, P1093, DOI 10.1210/en.135.3.1093
   Pal S, 2019, BIOCHEM PHARMACOL, V164, P34, DOI 10.1016/j.bcp.2019.03.024
   Pal S, 2019, BONE, V123, P28, DOI 10.1016/j.bone.2019.03.010
   Pal S, 2016, TOXICOL APPL PHARM, V295, P12, DOI 10.1016/j.taap.2016.02.002
   Patyna S, 2008, TOXICOL PATHOL, V36, P905, DOI 10.1177/0192623308326151
   Prisby R, 2011, J BONE MINER RES, V26, P2583, DOI 10.1002/jbmr.459
   Pufe T, 2007, CALCIFIED TISSUE INT, V80, P184, DOI 10.1007/s00223 006 0275 0
   Qin L, 2005, J BIOL CHEM, V280, P3104, DOI 10.1074/jbc.M409846200
   Salhiyyah K, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005262.pub3
   Serrat MA, 2009, NAT PROTOC, V4, P1749, DOI 10.1038/nprot.2009.190
   Sharan K, 2011, J BONE MINER RES, V26, P2096, DOI 10.1002/jbmr.434
   Singh N, 2017, EUR J PHARMACOL, V815, P462, DOI 10.1016/j.ejphar.2017.09.042
   Sleeman A, 2019, AM J HEALTH SYST PH, V76, P130, DOI 10.1093/ajhp/zxy022
   Tripathi JK, 2015, BIOMATERIALS, V56, P92, DOI 10.1016/j.biomaterials.2015.03.046
   Trivedi R, 2010, CURR MOL MED, V10, P14, DOI 10.2174/156652410791065372
   Trivedi R, 2010, EXPERT OPIN INV DRUG, V19, P995, DOI 10.1517/13543784.2010.501077
   Vashghani Farahani Mohammad Mahdi, 2017, Lab Anim Res, V33, P15, DOI 10.5625/lar.2017.33.1.15
   Vogt MT, 1997, J AM GERIATR SOC, V45, P140, DOI 10.1111/j.1532 5415.1997.tb04498.x
   Wallner C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118823
   Whitfield JF, 1997, CALCIFIED TISSUE INT, V60, P302, DOI 10.1007/s002239900233
   Yang XH, 2009, CANCER RES, V69, P1668, DOI 10.1158/0008 5472.CAN 07 6385
   Yao W., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P119
   Yaqoob U, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098130
   Zheng LW, 2008, BONE, V43, P355, DOI 10.1016/j.bone.2008.04.002
NR 55
TC 20
Z9 21
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD SEP
PY 2019
VL 105
IS 3
BP 294
EP 307
DI 10.1007/s00223 019 00567 4
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA IR4SY
UT WOS:000481425800007
PM 31175387
DA 2025 08 17
ER

PT J
AU Wang, YL
   Hu, XX
   Dai, J
   Wang, J
   Tan, YN
   Yang, XD
   Yang, S
   Yuan, Q
   Zhang, YF
AF Wang, Yulan
   Hu, Xiaoxia
   Dai, Jing
   Wang, Jie
   Tan, Yaning
   Yang, Xiangdong
   Yang, Shuang
   Yuan, Quan
   Zhang, Yufeng
TI A 3D graphene coated bioglass scaffold for bone defect therapy based on
   the molecular targeting approach
SO JOURNAL OF MATERIALS CHEMISTRY B
LA English
DT Article
ID MESOPOROUS BIOACTIVE GLASSES; IN VITRO; OSTEOGENIC DIFFERENTIATION;
   MECHANICAL PROPERTIES; TRABECULAR BONE; STROMAL CELLS; STEM CELLS;
   OSTEOBLASTS; REGENERATION; MARROW
AB Development of a cell free scaffold with excellent mechanical properties and osteoconductivity is of significant need for bone regeneration. Herein, a reduced graphene oxide (rGO) functionalized hierarchical macro mesoporous bioactive glass scaffold integrated with an osteoblast specific aptamer is rationally designed to recruit and induce the rapid differentiation of osteoblasts for bone regeneration. This scaffold exhibits a macroporous structure with fully interconnected open pores and shows excellent mechanical properties with a Young's modulus of similar to 80 kPa, which provides a strong scaffold to support the growth of osteoblasts and bone tissue regeneration. Furthermore, the scaffold displays good performance in accelerating osteoblast differentiation and promoting new bone formation. The osteoblast recruitment is achieved since the osteoblast specific aptamer can specifically target osteoblasts with strong binding affinity. Micro computed tomography and histological tests confirmed that the large bone defects fully heal with new plate like pattern bone appearing both peripherally and centrally, suggesting the outstanding bone regeneration performance of this cell free and graphene functionalized scaffold. Considering the promising bioapplications of the graphene functionalized bioactive glass scaffold with osteoblast recruitment capacity, our strategy paves a way for the design of new bioactive functional materials for tissue regeneration and shows attractive prospects in targeted therapy.
C1 [Wang, Yulan; Dai, Jing; Yang, Shuang; Zhang, Yufeng] Wuhan Univ, State Key Lab Breeding Base Basic Sci Stomatol Hu, Sch & Hosp Stomatol, Wuhan, Hubei, Peoples R China.
   [Wang, Yulan; Dai, Jing; Yang, Shuang; Zhang, Yufeng] Wuhan Univ, Key Lab Oral Biomed, Minist Educ, Sch & Hosp Stomatol, Wuhan, Hubei, Peoples R China.
   [Wang, Yulan; Zhang, Yufeng] Wuhan Univ, Sch Med, Med Res Inst, Wuhan, Hubei, Peoples R China.
   [Hu, Xiaoxia; Wang, Jie; Tan, Yaning; Yang, Xiangdong; Yuan, Quan] Wuhan Univ, Key Lab Analyt Chem Biol & Med, Minist Educ, Coll Chem & Mol Sci, Wuhan, Hubei, Peoples R China.
C3 Wuhan University; Wuhan University; Wuhan University; Wuhan University
RP Zhang, YF (通讯作者)，Wuhan Univ, State Key Lab Breeding Base Basic Sci Stomatol Hu, Sch & Hosp Stomatol, Wuhan, Hubei, Peoples R China.; Zhang, YF (通讯作者)，Wuhan Univ, Key Lab Oral Biomed, Minist Educ, Sch & Hosp Stomatol, Wuhan, Hubei, Peoples R China.; Zhang, YF (通讯作者)，Wuhan Univ, Sch Med, Med Res Inst, Wuhan, Hubei, Peoples R China.; Yuan, Q (通讯作者)，Wuhan Univ, Key Lab Analyt Chem Biol & Med, Minist Educ, Coll Chem & Mol Sci, Wuhan, Hubei, Peoples R China.
EM yuanquan@whu.edu.cn; zyf@whu.edu.cn
RI Wang, Jie/GNM 9907 2022; Yang, Xiangdong/GRJ 4189 2022; Zhang,
   Yufeng/GZL 1973 2022
OI , jie/0000 0003 4170 8470; Yang, Xiangdong/0000 0002 0797 8293; Yuan,
   Quan/0000 0002 3085 431X; Zhang, Yufeng/0000 0001 8702 5291
FU National Natural Science Foundation of China [81271108, 81570954,
   21675120, 21422105]; Fundamental Research Funds for the Central
   Universities [410500041]; Ten Thousand Talents Program for Young Talents
FX This work was supported by the National Natural Science Foundation of
   China (81271108, 81570954, 21675120 and 21422105), the Fundamental
   Research Funds for the Central Universities (410500041), and Ten
   Thousand Talents Program for Young Talents (to Quan Yuan). Q. Yuan
   thanks the Large scale Instrument and Equipment Sharing Foundation of
   Wuhan University. The authors declare no competing financial interest.
CR Calori GM, 2011, INJURY, V42, pS56, DOI 10.1016/j.injury.2011.06.011
   Chen Y, 2015, CHEM SOC REV, V44, P2681, DOI 10.1039/c4cs00300d
   Fang XH, 2010, ACCOUNTS CHEM RES, V43, P48, DOI 10.1021/ar900101s
   Frank IW, 2007, J VAC SCI TECHNOL B, V25, P2558, DOI 10.1116/1.2789446
   Fu QA, 2011, ADV FUNCT MATER, V21, P1058, DOI 10.1002/adfm.201002030
   Geim AK, 2007, NAT MATER, V6, P183, DOI 10.1038/nmat1849
   Grayson WL, 2015, NAT REV ENDOCRINOL, V11, P140, DOI 10.1038/nrendo.2014.234
   Greenblatt MB, 2013, ANNU REV CELL DEV BI, V29, P63, DOI 10.1146/annurev cellbio 101512 122347
   Gruskin E, 2012, ADV DRUG DELIVER REV, V64, P1063, DOI 10.1016/j.addr.2012.06.008
   Hong GS, 2015, CHEM REV, V115, P10816, DOI 10.1021/acs.chemrev.5b00008
   Karsenty G, 2008, ANNU REV GENOM HUM G, V9, P183, DOI 10.1146/annurev.genom.9.081307.164437
   Kostarelos K, 2014, SCIENCE, V344, P261, DOI 10.1126/science.1246736
   Lee J, 2009, SMALL, V5, P1213, DOI 10.1002/smll.200801788
   Lee WC, 2011, ACS NANO, V5, P7334, DOI 10.1021/nn202190c
   Legrand E, 2000, J BONE MINER RES, V15, P13, DOI 10.1359/jbmr.2000.15.1.13
   Li C, 2014, ADV MATER, V26, P3992, DOI 10.1002/adma.201306104
   Liang C, 2015, NAT MED, V21, P288, DOI 10.1038/nm.3791
   Liang H, 2014, ACCOUNTS CHEM RES, V47, P1891, DOI 10.1021/ar500078f
   Maes C, 2010, DEV CELL, V19, P329, DOI 10.1016/j.devcel.2010.07.010
   Mehrali M, 2014, ACS APPL MATER INTER, V6, P3947, DOI 10.1021/am500845x
   Meinel L, 2005, BONE, V37, P688, DOI 10.1016/j.bone.2005.06.010
   Nayak TR, 2011, ACS NANO, V5, P4670, DOI 10.1021/nn200500h
   Oh Y, 2015, ACS NANO, V9, P4103, DOI 10.1021/acsnano.5b00170
   Park D, 2012, CELL STEM CELL, V10, P259, DOI 10.1016/j.stem.2012.02.003
   Prockop DJ, 2009, MOL THER, V17, P939, DOI 10.1038/mt.2009.62
   Qazi TH, 2015, BIOMATERIALS, V53, P502, DOI 10.1016/j.biomaterials.2015.02.110
   Robinson JT, 2011, J AM CHEM SOC, V133, P6825, DOI 10.1021/ja2010175
   Scherf H, 2016, AM J PHYS ANTHROPOL, V159, P106, DOI 10.1002/ajpa.22835
   Shi QH, 2006, ADV MATER, V18, P1038, DOI 10.1002/adma.200502292
   Shin YC, 2015, CARBON, V95, P1051, DOI 10.1016/j.carbon.2015.09.028
   Siclari VA, 2013, BONE, V53, P575, DOI 10.1016/j.bone.2012.12.013
   Tellado SF, 2015, ADV DRUG DELIVER REV, V94, P126, DOI 10.1016/j.addr.2015.03.004
   Wang YJ, 2014, J BONE MINER RES, V29, P685, DOI 10.1002/jbmr.2081
   Wang YF, 2015, ADV FUNCT MATER, V25, P126, DOI 10.1002/adfm.201402952
   Wu CT, 2016, ACS APPL MATER INTER, V8, P11342, DOI 10.1021/acsami.6b03100
   Wu CT, 2014, J CONTROL RELEASE, V193, P282, DOI 10.1016/j.jconrel.2014.04.026
   Xiao Y, 2004, CELL TRANSPLANT, V13, P15, DOI 10.3727/000000004772664851
   Yan X., 2004, ANGEW CHEM, V116, P6106
   Yan XX, 2004, ANGEW CHEM INT EDIT, V43, P5980, DOI 10.1002/anie.200460598
   Zhang YL, 2015, NANOSCALE, V7, P19207, DOI 10.1039/c5nr05421d
   Zhang YF, 2013, J MATER CHEM B, V1, P5711, DOI 10.1039/c3tb21047b
NR 41
TC 30
Z9 31
U1 2
U2 83
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2050 750X
EI 2050 7518
J9 J MATER CHEM B
JI J. Mat. Chem. B
PD SEP 7
PY 2017
VL 5
IS 33
BP 6794
EP 6800
DI 10.1039/c7tb01515a
PG 7
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA FE5SB
UT WOS:000408270200009
PM 32264329
DA 2025 08 17
ER

PT J
AU Ranzoni, AM
   Corcelli, M
   Hau, KL
   Kerns, JG
   Vanleene, M
   Shefelbine, S
   Jones, GN
   Moschidou, D
   Dala Ali, B
   Goodship, AE
   De Coppi, P
   Arnett, TR
   Guillot, PV
AF Ranzoni, Anna M.
   Corcelli, Michelangelo
   Hau, Kwan Leong
   Kerns, Jemma G.
   Vanleene, Maximilien
   Shefelbine, Sandra
   Jones, Gemma N.
   Moschidou, Dafni
   Dala Ali, Benan
   Goodship, Allen E.
   De Coppi, Paolo
   Arnett, Timothy R.
   Guillot, Pascale V.
TI Counteracting bone fragility with human amniotic mesenchymal stem cells
SO SCIENTIFIC REPORTS
LA English
DT Article
ID STROMAL CELLS; GROWTH FACTOR; FLUID; FETAL; DIFFERENTIATION; MODEL;
   TRANSPLANTATION; RESORPTION
AB The impaired maturation of bone forming osteoblasts results in reduced bone formation and subsequent bone weakening, which leads to a number of conditions such as osteogenesis imperfecta (OI). Transplantation of human fetal mesenchymal stem cells has been proposed as skeletal anabolic therapy to enhance bone formation, but the mechanisms underlying the contribution of the donor cells to bone health are poorly understood and require further elucidation. Here, we show that intraperitoneal injection of human amniotic mesenchymal stem cells (AFSCs) into a mouse model of OI (oim mice) reduced fracture susceptibility, increased bone strength, improved bone quality and micro architecture, normalised bone remodelling and reduced TNF alpha and TGF beta sigalling. Donor cells engrafted into bones and differentiated into osteoblasts but importantly, also promoted endogenous osteogenesis and the maturation of resident osteoblasts. Together, these findings identify AFSC transplantation as a countermeasure to bone fragility. These data have wider implications for bone health and fracture reduction.
C1 [Ranzoni, Anna M.; Corcelli, Michelangelo; Hau, Kwan Leong; Moschidou, Dafni; Guillot, Pascale V.] UCL, Inst Womens Hlth, London, England.
   [Kerns, Jemma G.] Univ Lancaster, Lancaster Med Sch, Lancaster, England.
   [Vanleene, Maximilien] Reg Univ Hosp Lille, ONCOLille, Lille, France.
   [Shefelbine, Sandra] Northeastern Univ, Dept Mech & Ind Engn, Boston, MA 02115 USA.
   [Jones, Gemma N.] Imperial Coll London, Inst Reprod & Dev Biol, London, England.
   [Dala Ali, Benan; Goodship, Allen E.] Univ Coll London, Royal Natl Orthopaed Hosp, Inst Orthopaed & Musculoskeletal Sci, Stanmore, Middx, England.
   [De Coppi, Paolo] UCL, UCL Great Ormond St Inst Child Hlth, London, England.
   [Arnett, Timothy R.] UCL, Dept Cell & Dev Biol, London, England.
C3 University of London; University College London; Lancaster University;
   Universite de Lille; CHU Lille; Northeastern University; Imperial
   College London; University of London; University College London; Royal
   National Orthopaedic Hospital NHS Trust; University of London;
   University College London; University of London; University College
   London
RP Guillot, PV (通讯作者)，UCL, Inst Womens Hlth, London, England.
EM p.guillot@ucl.ac.uk
RI ; Arnett, Tim/AAW 4445 2021; Ranzoni, Anna/AAG 2097 2020
OI David, Anna/0000 0002 0199 6140; Ranzoni, Anna
   Maria/0000 0002 2573 1382; De Coppi, Paolo/0000 0002 1659 0207; Guillot,
   Pascale V/0000 0002 3796 1572
FU Action Medical Research; Rosetrees Trust; Newlife Foundation; National
   Institute for Health Research Biomedical Research Centre at Great Ormond
   Street Hospital for Children NHS Foundation Trust; University College
   London; EPSRC [EP/H002693/1] Funding Source: UKRI; Action Medical
   Research [1749] Funding Source: researchfish; Engineering and Physical
   Sciences Research Council [EP/H002693/1] Funding Source: researchfish;
   National Institute for Health Research [RP_2014 04 046] Funding Source:
   researchfish; Rosetrees [M396] Funding Source: researchfish
FX This work was supported by grants from Action Medical Research,
   Rosetrees Trust and Newlife Foundation, and by the National Institute
   for Health Research Biomedical Research Centre at Great Ormond Street
   Hospital for Children NHS Foundation Trust and University College
   London.
CR Abdulrazzak H, 2013, CURR STEM CELL RES T, V8, P117, DOI 10.2174/1574888X11308020002
   Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858
   Bi YM, 2006, BONE, V38, P778, DOI 10.1016/j.bone.2005.11.005
   Camacho NP, 2001, CALCIFIED TISSUE INT, V69, P94, DOI 10.1007/s002230010045
   Chang SW, 2012, BIOPHYS J, V102, P640, DOI 10.1016/j.bpj.2011.11.3999
   CHIPMAN SD, 1993, P NATL ACAD SCI USA, V90, P1701, DOI 10.1073/pnas.90.5.1701
   De Coppi P, 2007, NAT BIOTECHNOL, V25, P100, DOI 10.1038/nbt1274
   Di Trapani M, 2015, STEM CELLS DEV, V24, P132, DOI 10.1089/scd.2014.0234
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Dziadosz M, 2016, AM J OBSTET GYNECOL, V214, P321, DOI 10.1016/j.ajog.2015.12.061
   Forlino A, 2016, LANCET, V387, P1657, DOI 10.1016/S0140 6736(15)00728 X
   Forlino A, 2011, NAT REV ENDOCRINOL, V7, P540, DOI 10.1038/nrendo.2011.81
   Grafel I, 2014, NAT MED, V20, P670, DOI 10.1038/nm.3544
   Guillot PV, 2008, DIFFERENTIATION, V76, P946, DOI 10.1111/j.1432 0436.2008.00279.x
   Guillot PV, 2008, BLOOD, V111, P1717, DOI 10.1182/blood 2007 08 105809
   Guillot PV, 2007, STEM CELLS, V25, P646, DOI 10.1634/stemcells.20060208
   HAHN M, 1992, BONE, V13, P327, DOI 10.1016/8756 3282(92)90078 B
   Jakowlew S. B., 2010, TRANSFORMING GROWTH, VI, DOI [10.1007/978 1 59745 292 2, DOI 10.1007/978 1 59745 292 2.]
   Jones GN, 2014, STEM CELLS DEV, V23, P262, DOI 10.1089/scd.2013.0132
   Kalajzic I, 2002, ENDOCRINOLOGY, V143, P1594, DOI 10.1210/en.143.5.1594
   Keating A, 2012, CELL STEM CELL, V10, P709, DOI 10.1016/j.stem.2012.05.015
   Kim BS, 2012, BMC MED, V10, DOI 10.1186/1741 7015 10 94
   Le Blanc K, 2003, CYTOTHERAPY, V5, P485, DOI 10.1080/14653240310003611
   Lee WE., 1994, CERAMIC MICROSTRUCTU
   Li HT, 2010, AM J PATHOL, V176, P2405, DOI 10.2353/ajpath.2010.090704
   MARIE PJ, 1990, AM J PHYSIOL, V258, pE275, DOI 10.1152/ajpendo.1990.258.2.E275
   McElderry JDP, 2013, J SOLID STATE CHEM, V206, P192, DOI 10.1016/j.jssc.2013.08.011
   Moschidou D, 2013, CURR STEM CELL RES T, V8, P73, DOI 10.2174/1574888X11308010009
   Moschidou D, 2013, STEM CELLS DEV, V22, P444, DOI 10.1089/scd.2012.0267
   Panaroni C, 2009, BLOOD, V114, P459, DOI 10.1182/blood 2008 12 195859
   Peister A, 2009, TISSUE ENG PT A, V15, P3129, DOI [10.1089/ten.tea.2008.0536, 10.1089/ten.TEA.2008.0536]
   Peister A, 2008, BIO MED MATER ENG, V18, P241, DOI 10.3233/BME 2008 0532
   Ramachandra DL, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00270
   Rauch F, 2000, BONE, V26, P581, DOI 10.1016/S8756 3282(00)00269 6
   Rodrigues MT, 2012, TISSUE ENG PT A, V18, P2518, DOI 10.1089/ten.tea.2011.0672
   Savickiene J, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/319238
   Souza PPC, 2013, IMMUNOL INVEST, V42, P555, DOI 10.3109/08820139.2013.822766
   Tran C, 2015, THER ADV UROL, V7, P22, DOI 10.1177/1756287214553968
   Trohatou O, 2013, CURR STEM CELL RES T, V8, P125, DOI 10.2174/1574888X11308020003
   Vanleene M, 2011, BLOOD, V117, P1053, DOI 10.1182/blood 2010 05 287565
NR 40
TC 21
Z9 24
U1 0
U2 10
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD DEC 20
PY 2016
VL 6
AR 39656
DI 10.1038/srep39656
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA EE9YX
UT WOS:000389983400001
PM 27995994
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Canalis, E
   Parker, K
   Feng, JQ
   Zanotti, S
AF Canalis, Ernesto
   Parker, Kristen
   Feng, Jian Q.
   Zanotti, Stefano
TI Osteoblast Lineage Specific Effects of Notch Activation in the Skeleton
SO ENDOCRINOLOGY
LA English
DT Article
ID CRE RECOMBINASE; TRANSCRIPTION COMPLEXES; ANABOLIC THERAPIES; SIGNALING
   PATHWAY; BONE HOMEOSTASIS; GENE EXPRESSION; TRANSGENIC MICE;
   BLOOD VESSELS; I COLLAGEN; DIFFERENTIATION
AB Transgenic overexpression of the Notch1 intracellular domain inhibits osteoblast differentiation and causes osteopenia, and inactivation of Notch1 and Notch2 increases bone volume transiently and induces osteoblastic differentiation. However, the biology of Notch is cell context dependent, and consequences of Notch activation in cells of the osteoblastic lineage at various stages of differentiation and in osteocytes have not been defined. For this purpose, Rosa(Notch) mice, where a loxP flanked STOP cassette placed between the Rosa26 promoter and the NICD coding sequence, were crossed with transgenics expressing the Cre recombinase under the control of the Osterix (Osx), Osteocalcin (Oc), Collagen 1a1 (Col2.3), or Dentin matrix protein1 (Dmp1) promoters. At 1 month, Osx Cre;Rosa(Notch) and Oc Cre;Rosa(Notch) mice exhibited osteopenia due to impaired bone formation. In contrast, Col2.3 Cre;Rosa(Notch) and Dmp1 Cre;Rosa(Notch) exhibited increased femoral trabecular bone volume due to a decrease in osteoclast number and eroded surface. In the four lines studied, cortical bone was either not present, was porous, or had the appearance of trabecular bone. Oc Cre;Rosa(Notch) and Col2.3 Cre;Rosa(Notch) mice exhibited early lethality so that their adult phenotype was not established. At 3 months, Osx Cre;Rosa(Notch) and Dmp1 Cre;Rosa(Notch) mice displayed increased bone volume, and increased osteoblasts although calcein demeclocycline labels were diffuse and fragmented, indicating abnormal bone formation. In conclusion, Notch effects in the skeleton are cell context dependent. When expressed in immatureosteoblasts, Notch arrests their differentiation, causing osteopenia, and when expressed in osteocytes, it causes an initial suppression of bone resorption and increased bone volume, a phenotype that evolves as the mice mature. (Endocrinology 154: 623 634, 2013)
C1 [Canalis, Ernesto; Parker, Kristen; Zanotti, Stefano] St Francis Hosp & Med Ctr, Dept Res, Hartford, CT 06105 USA.
   [Canalis, Ernesto; Zanotti, Stefano] Univ Connecticut, Sch Med, Farmington, CT 06030 USA.
   [Feng, Jian Q.] Baylor Coll Dent, Texas A&M Hlth Sci Ctr, Dallas, TX 75246 USA.
C3 Saint Francis Hospital & Medical Center; University of Connecticut;
   Texas A&M University System; Texas A&M University College Station; Texas
   A&M Health Science Center
RP Canalis, E (通讯作者)，St Francis Hosp & Med Ctr, Dept Res, 114 Woodland St, Hartford, CT 06105 USA.
EM ecanalis@stfranciscare.org
RI ; Zanotti, Stefano/C 6006 2009
OI Zanotti, Stefano/0000 0001 9711 5522; 
FU National Institute of Diabetes and Digestive and Kidney Diseases
   [DK045227]
FX This work was supported by grant DK045227 (to E. C.) from the National
   Institute of Diabetes and Digestive and Kidney Diseases.
CR AARDEN EM, 1994, J CELL BIOCHEM, V55, P287, DOI 10.1002/jcb.240550304
   Bai S, 2008, J BIOL CHEM, V283, P6509, DOI 10.1074/jbc.M707000200
   Bianco P, 2000, J CLIN INVEST, V105, P1663, DOI 10.1172/JCI10413
   Bidder M, 1998, J BONE MINER RES, V13, P609, DOI 10.1359/jbmr.1998.13.4.609
   BOGDANOVIC Z, 1994, J BONE MINER RES, V9, P285
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Borggrefe T, 2012, CELL CYCLE, V11, P264, DOI 10.4161/cc.11.2.18995
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Buchholz F, 1996, NUCLEIC ACIDS RES, V24, P4256, DOI 10.1093/nar/24.21.4256
   Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002 0023
   Canalis E, 2005, NEW ENGL J MED, V352, P2014, DOI 10.1056/NEJMe058080
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Canalis E, 2010, J CLIN ENDOCR METAB, V95, P1496, DOI 10.1210/jc.2009 2677
   Clarkin C, 2010, CELL METAB, V12, P314, DOI 10.1016/j.cmet.2010.09.009
   Dacquin R, 2002, DEV DYNAM, V224, P245, DOI 10.1002/dvdy.10100
   Dallas DJ, 1999, BONE, V25, P9, DOI 10.1016/S8756 3282(99)00099 X
   Dong YF, 2010, DEVELOPMENT, V137, P1461, DOI 10.1242/dev.042911
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Elefteriou F, 2011, BONE, V49, P1242, DOI 10.1016/j.bone.2011.08.021
   Engin FZ, 2008, NAT MED, V14, P299, DOI 10.1038/nm1712
   Feng JQ, 2006, NAT GENET, V38, P1310, DOI 10.1038/ng1905
   Fortini ME, 2009, DEV CELL, V16, P633, DOI 10.1016/j.devcel.2009.03.010
   Frenkel B, 1997, ENDOCRINOLOGY, V138, P2109, DOI 10.1210/en.138.5.2109
   Glatt V, 2007, J BONE MINER RES, V22, P1197, DOI 10.1359/JBMR.070507
   Hilton MJ, 2008, NAT MED, V14, P306, DOI 10.1038/nm1716
   Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208
   Iso T, 2001, MOL CELL BIOL, V21, P6071, DOI 10.1128/MCB.21.17.6071 6079.2001
   Kalajzic I, 2002, J BONE MINER RES, V17, P15, DOI 10.1359/jbmr.2002.17.1.15
   Kalajzic Z, 2002, BONE, V31, P654, DOI 10.1016/S8756 3282(02)00912 2
   Kovall RA, 2008, ONCOGENE, V27, P5099, DOI 10.1038/onc.2008.223
   Kream B E, 1995, Connect Tissue Res, V31, P261, DOI 10.3109/03008209509010819
   KREBSBACH PH, 1993, MOL CELL BIOL, V13, P5168, DOI 10.1128/MCB.13.9.5168
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566
   Liu F, 2004, INT J DEV BIOL, V48, P645, DOI 10.1387/ijdb.041816fl
   Lu Y, 2007, J DENT RES, V86, P320, DOI 10.1177/154405910708600404
   Maes C, 2010, DEV CELL, V19, P329, DOI 10.1016/j.devcel.2010.07.010
   Murtaugh LC, 2003, P NATL ACAD SCI USA, V100, P14920, DOI 10.1073/pnas.2436557100
   Nakagawa O, 1999, DEV BIOL, V216, P72, DOI 10.1006/dbio.1999.9454
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Nam Y, 2006, CELL, V124, P973, DOI 10.1016/j.cell.2005.12.037
   Nazarenko I, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e37
   Nazarenko I, 2002, NUCLEIC ACIDS RES, V30, P2089, DOI 10.1093/nar/30.9.2089
   Ominsky MS, 2009, J BONE MINER RES, V24, P1234, DOI [10.1359/JBMR.090215, 10.1359/jbmr.090215]
   Paic F, 2009, BONE, V45, P682, DOI 10.1016/j.bone.2009.06.010
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Park D, 2012, CELL STEM CELL, V10, P259, DOI 10.1016/j.stem.2012.02.003
   Pereira RMR, 2002, J CELL BIOCHEM, V85, P252, DOI 10.1002/jcb.10125
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Sahlgren C, 2006, REGEN MED, V1, P195, DOI 10.2217/17460751.1.2.195
   SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166
   Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Stanger BZ, 2005, P NATL ACAD SCI USA, V102, P12443, DOI 10.1073/pnas.0505690102
   STEIN GS, 1990, FASEB J, V4, P3111, DOI 10.1096/fasebj.4.13.2210157
   Tatsumi S, 2007, CELL METAB, V5, P464, DOI 10.1016/j.cmet.2007.05.001
   TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485
   Wilson JJ, 2006, CELL, V124, P985, DOI 10.1016/j.cell.2006.01.035
   Xiong JH, 2012, J BONE MINER RES, V27, P499, DOI 10.1002/jbmr.1547
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Yeo HJ, 2007, J BIOL CHEM, V282, P35318, DOI 10.1074/jbc.M702435200
   Zanotti S, 2008, ENDOCRINOLOGY, V149, P3890, DOI 10.1210/en.2008 0140
   Zanotti S, 2010, MOL CELL BIOL, V30, P886, DOI 10.1128/MCB.01285 09
   Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200
NR 65
TC 112
Z9 121
U1 0
U2 13
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815 5817 USA
SN 0013 7227
J9 ENDOCRINOLOGY
JI Endocrinology
PD FEB
PY 2013
VL 154
IS 2
BP 623
EP 634
DI 10.1210/en.2012 1732
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 076ME
UT WOS:000313959800008
PM 23275471
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Zhang, LM
   Pattanayak, A
   Li, WQ
   Ko, HK
   Fowler, G
   Gordon, R
   Bergan, R
AF Zhang, Limin
   Pattanayak, Abhinandan
   Li, Wenqi
   Ko, Hyun Kyung
   Fowler, Graham
   Gordon, Ryan
   Bergan, Raymond
TI A Multifunctional Therapy Approach for Cancer: Targeting Raf1 Mediated
   Inhibition of Cell Motility, Growth, and Interaction with the
   Microenvironment
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID PROSTATE CANCER; SKELETAL COMPLICATIONS; METASTASIS; DOCETAXEL;
   ENZALUTAMIDE; MITOXANTRONE; PROGRESSION; PREDNISONE; RESISTANCE;
   PATHWAYS
AB Prostate cancer cells move from their primary site of origin, interact with a distant microenvironment, grow, and thereby cause death. It had heretofore not been possible to selectively inhibit cancer cell motility. Our group has recently shown that inhibition of intracellular activation of Raf1 with the small molecule therapeutic KBU2046 permits, for the first time, selective inhibition of cell motility. We hypothesized that simultaneous disruption of multiple distinct functions that drive progression of prostate cancer to induce death would result in advanced disease control. Using a murine orthotopic implantation model of human prostate cancer metastasis, we demonstrate that combined treatment with KBU2046 and docetaxel retains docetaxel's antitumor action, but provides improved inhibition of metastasis, compared with monotherapy. KBU2046 does not interfere with hormone therapy, inclusive of enzalutamide mediated inhibition of androgen receptor (AR) function and cell growth inhibition, and inclusive of the ability of castration to inhibit LNCaP AR cell outgrowth in mice. Cell movement is necessary for osteoclast mediated bone degradation. KBU2046 inhibits Raf1 and its downstream activation of MEK1/2 and ERK1/2 in osteoclasts, inhibiting cytoskeleton rearrangement, resorptive cavity formation, and bone destruction in vitro, with improved effects observed when the bone microenvironment is chemically modified by pretreatment with zoledronic acid. Using a murine cardiac injection model of human prostate cancer bone destruction quantified by CT, KBU2046 plus zoledronic exhibit improved inhibitory efficacy, compared with monotherapy. The combined disruption of pathways that drive cell movement, interaction with bone, and growth constitutes a multifunctional targeting strategy that provides advanced disease control.
C1 [Zhang, Limin; Pattanayak, Abhinandan; Li, Wenqi; Ko, Hyun Kyung; Fowler, Graham; Gordon, Ryan; Bergan, Raymond] Oregon Hlth & Sci Univ, Knight Canc Inst, Div Hematol Oncol, Portland, OR 97201 USA.
   [Zhang, Limin] Fudan Univ, Huashan Hosp, Dept Urol, Shanghai, Peoples R China.
C3 Oregon Health & Science University; Fudan University
RP Bergan, R (通讯作者)，Oregon Hlth & Sci Univ, L586,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM bergan@ohsu.edu
RI ; Pattanayak, Abhinandan/K 8905 2013; Ko, Hyun Kyung/H 7596 2017
OI Zhang, Limin/0000 0002 8470 1247; Bergan, Raymond/0000 0001 8690 4876;
   Pattanayak, Abhinandan/0000 0001 5822 6430; 
FU United States Veterans Administration [IBX002842A]; United States
   Department of Defense [W81XWH 15 1 0527]
FX This study was supported with funding to R. Bergan by the United States
   Veterans Administration (IBX002842A) and the United States Department of
   Defense (W81XWH 15 1 0527). The authors would like to thank William
   Packwood for his assistance in performing the high resolution CT
   imaging.
CR Abe K, 2012, INT J MOL MED, V29, P1007, DOI 10.3892/ijmm.2012.952
   Alejandro EU, 2008, J BIOL CHEM, V283, P2407, DOI 10.1074/jbc.M703612200
   Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095
   Bradley EW, 2008, J CELL BIOCHEM, V104, P1439, DOI 10.1002/jcb.21719
   Chu K, 2008, MOL CANCER RES, V6, P1259, DOI 10.1158/1541 7786.MCR 08 0077
   Costa L, 2008, SUPPORT CARE CANCER, V16, P879, DOI 10.1007/s00520 008 0418 0
   Cremers S, 2011, BONE, V49, P42, DOI 10.1016/j.bone.2011.01.014
   de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140 6736(10)61389 X
   Ding Yongzeng, 2007, J Biomol Tech, V18, P321
   Ebos JML, 2009, CLIN CANCER RES, V15, P5020, DOI 10.1158/1078 0432.CCR 09 0095
   Ellis LM, 2009, NATURE, V458, P290, DOI 10.1038/458290a
   Fang YF, 1996, J BIOL CHEM, V271, P28697, DOI 10.1074/jbc.271.45.28697
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Funakoshi K, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 13402 3
   Furr BJA, 1996, EUR UROL, V29, P83
   Gomella LG, 2010, THER ADV UROL, V2, P171, DOI 10.1177/1756287210375270
   Gordon RR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104271
   Guise T. A., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P570
   Guise TA, 1998, ENDOCR REV, V19, P18, DOI 10.1210/er.19.1.18
   Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   He YZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024780
   Hollingshead MG, 2008, JNCI J NATL CANCER I, V100, DOI 10.1093/jnci/djn351
   Hussain M, 2018, NEW ENGL J MED, V378, P2465, DOI 10.1056/NEJMoa1800536
   Korenchuk S, 2001, IN VIVO, V15, P163
   Krishna SN, 2014, FUTURE MED CHEM, V6, P223, DOI 10.4155/fmc.13.201
   Lakshman M, 2011, CLIN EXP METASTAS, V28, P39, DOI 10.1007/s10585 010 9356 6
   Liu YQ, 2001, PROSTATE CANCER P D, V4, P81, DOI 10.1038/sj.pcan.4500506
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Logothetis C, 2018, CANCER METAST REV, V37, P189, DOI 10.1007/s10555 017 9719 4
   Lyseng Williamson KA, 2005, DRUGS, V65, P2513, DOI 10.2165/00003495 200565170 00007
   Masood I, 2016, TUMORI J, V102, P6, DOI 10.5301/tj.5000387
   Minn AJ, 2008, CANC PRINCIPALS PRAC, P135
   Nakamura H, 2003, J BONE MINER RES, V18, P1198, DOI 10.1359/jbmr.2003.18.7.1198
   Norgaard M, 2010, J UROLOGY, V184, P162, DOI 10.1016/j.juro.2010.03.034
   Pavese J, 2013, JOVE J VIS EXP, DOI 10.3791/50873
   Pavese JM, 2014, CANCER LETT, V352, P179, DOI 10.1016/j.canlet.2014.06.012
   Polascik Thomas J, 2008, Ther Clin Risk Manag, V4, P261
   Pound CR, 1999, JAMA J AM MED ASSOC, V281, P1591, DOI 10.1001/jama.281.17.1591
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   Seyfried Thomas N., 2013, Critical Reviews in Oncogenesis, V18, P43
   Talmadge JE, 2010, CANCER RES, V70, P5649, DOI 10.1158/0008 5472.CAN 10 1040
   Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720
   Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175
   Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179
   Xu L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 04465 5
   Yotova I, 2012, J CELL MOL MED, V16, P2127, DOI 10.1111/j.1582 4934.2011.01520.x
NR 47
TC 6
Z9 6
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1535 7163
EI 1538 8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD JAN
PY 2020
VL 19
IS 1
BP 39
EP 51
DI 10.1158/1535 7163.MCT 19 0222
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA KA3AE
UT WOS:000505667900004
PM 31582531
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Liu, YH
   Zeng, WZ
   Ma, C
   Wang, ZY
   Wang, C
   Li, SB
   He, W
   Zhang, QW
   Xu, JK
   Zhou, C
AF Liu, Yuhao
   Zeng, Weizai
   Ma, Chao
   Wang, Ziyi
   Wang, Chao
   Li, Shaobin
   He, Wei
   Zhang, Qingwen
   Xu, Jiake
   Zhou, Chi
TI Maackiain dampens osteoclastogenesis via attenuating RANKL stimulated
   NF κB signalling pathway and NFATc1 activity
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE maackiain; nuclear factor of activated T cells 1; nuclear factor kappa
   B; osteoclast; receptor activator of nuclear factor kappa B ligand
ID BONE RESORPTION; DIFFERENTIATION; ( ) MAACKIAIN; TRANSCRIPTION;
   OSTEOPOROSIS; INDUCTION
AB Osteolytic diseases are typified by over enhanced formation and resorbing function of osteoclasts and have a major impact on human health. Inhibition of osteoclastic differentiation and function is a key strategy for clinical therapy of osteolytic conditions. Maackiain is a natural compound extracted fromSophora flavescens, which has been applied to anti allergic and anti tumour treatments. The present results showed that Maackiain could restrain receptor activator of nuclear factor kappa B ligand (RANKL) stimulated osteoclast formation and hydroxyapatite resorption dose dependently, and interrupt the structures of F actin belts in the mature osteoclasts. It also repressed the expressions of osteoclast specific genes and proteins. Furthermore, Maackiain could inhibit RANKL stimulated NF kappa B and calcium signalling pathways, and dampen Nuclear factor of activated T cell cytoplasmic 1 activity, protein expression and translocation into the nucleus. These results revealed that Maackiain may have a potential therapeutic effect on osteoclast related disorders.
C1 [Liu, Yuhao; He, Wei; Zhang, Qingwen; Xu, Jiake; Zhou, Chi] Guangzhou Univ Chinese Med, Inst Orthoped, Affiliated Hosp 1, Guangzhou, Peoples R China.
   [Liu, Yuhao; Wang, Ziyi; Wang, Chao; Xu, Jiake] Univ Western Australia, Sch Biomed Sci, Perth, WA 6009, Australia.
   [Liu, Yuhao; Ma, Chao; Li, Shaobin; He, Wei; Zhang, Qingwen; Zhou, Chi] Guangzhou Univ Chinese Med, Clin Med Coll 1, Guangzhou, Peoples R China.
   [Zeng, Weizai] Chinese Med Hosp Zengcheng Dist, Guangzhou, Peoples R China.
C3 Guangzhou University of Chinese Medicine; University of Western
   Australia; Guangzhou University of Chinese Medicine
RP Xu, JK (通讯作者)，Univ Western Australia, Sch Biomed Sci, Perth, WA 6009, Australia.; Zhou, C (通讯作者)，Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou 510405, Guangdong, Peoples R China.
EM jiake.xu@uwa.edu.au; zcmzy1@163.com
RI Li, shaobin/AGT 5155 2022; Liu, Yuhao/LDE 7575 2024
OI Xu, Jiake/0000 0003 2021 8309; Ma, Chao/0000 0002 1049 6172; Ma,
   Chao/0000 0002 7735 235X; Liu, Yuhao/0000 0002 0447 6677; Wang,
   Ziyi/0000 0002 1334 7287
FU Australian National Health and Medical Research Council [APP1107828];
   Inheritance Studio Construction Project of Prestigious TCM Doctors of
   Guangdong Province [YZYBH[2017]17]; Excellent Doctoral Dissertation
   Incubation Grant from Guangzhou University of Chinese Medicine (GZUCM)
   [GZYY[2018]62]; Research Project of Innovating to Strengthen the First
   Hospital of GZUCM [2019IIT06]; China Scholarship Council
   [LJF[2018]3101/201808440486]; Postgraduate Exchange Program from GZUCM
   [GZYY[2016]83]
FX This study was supported in part by the Australian National Health and
   Medical Research Council (No. APP1107828), Inheritance Studio
   Construction Project of Prestigious TCM Doctors (Wei He) of Guangdong
   Province (No. YZYBH[2017]17), Excellent Doctoral Dissertation Incubation
   Grant from Guangzhou University of Chinese Medicine (GZUCM, No.
   GZYY[2018]62) and Research Project of Innovating to Strengthen the First
   Hospital of GZUCM (No. 2019IIT06). Yuhao Liu was sponsored by PhD
   scholarships under the State Scholarship Fund from China Scholarship
   Council (No. LJF[2018]3101/201808440486) and Postgraduate Exchange
   Program from GZUCM (No. GZYY[2016]83). We acknowledge the facilities and
   technical assistance from the Centre for Microscopy, Characterization &
   Analysis (CMCA), University of Western Australia.
CR Aratanechemuge Y, 2004, ONCOL REP, V12, P1183
   Bezerra Silva PC, 2015, EXP PARASITOL, V153, P160, DOI 10.1016/j.exppara.2015.03.018
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen K, 2020, INT J BIOL SCI, V16, P1888, DOI 10.7150/ijbs.40917
   Chen K, 2019, THERANOSTICS, V9, P1634, DOI 10.7150/thno.30206
   Chen K, 2019, J CELL PHYSIOL, V234, P6477, DOI 10.1002/jcp.27385
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Dinger J, 2016, CLIMACTERIC, V19, P349, DOI 10.1080/13697137.2016.1183624
   He JB, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01344
   Hwang YH, 2019, INT J BIOL MACROMOL, V123, P314, DOI 10.1016/j.ijbiomac.2018.11.075
   Jurdic P, 2006, EUR J CELL BIOL, V85, P195, DOI 10.1016/j.ejcb.2005.09.008
   Kim Jung Ha, 2016, Chonnam Med J, V52, P12, DOI 10.4068/cmj.2016.52.1.12
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Lee BS, 2018, BIOMOLECULES, V8, DOI 10.3390/biom8040157
   Lee HW, 2016, BIOORG MED CHEM LETT, V26, P4714, DOI 10.1016/j.bmcl.2016.08.044
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Liu YH, 2020, J CELL MOL MED, V24, P3303, DOI 10.1111/jcmm.15003
   Liu YH, 2019, THERANOSTICS, V9, P4648, DOI 10.7150/thno.35414
   Nariai Y, 2015, J BIOL CHEM, V290, P27393, DOI 10.1074/jbc.M115.657023
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Scotto di Carlo F, 2020, J BONE MINER RES, V35, P1387, DOI 10.1002/jbmr.3964
   SKINNIDER L, 1986, EXPERIENTIA, V42, P568, DOI 10.1007/BF01946707
   Sobacchi C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00629
   Spivakovsky Silvia, 2017, Evid Based Dent, V18, P56, DOI 10.1038/sj.ebd.6401243
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Wang QQ, 2020, J BONE MINER RES, V35, P1582, DOI 10.1002/jbmr.4025
   Wang XP, 2018, PHYTOTHER RES, V32, P1354, DOI 10.1002/ptr.6069
   Xu JK, 2009, CYTOKINE GROWTH F R, V20, P7, DOI 10.1016/j.cytogfr.2008.11.007
   Xu JK, 2000, J BONE MINER RES, V15, P2178, DOI 10.1359/jbmr.2000.15.11.2178
   Zhou CH, 2018, BRIT J PHARMACOL, V175, P859, DOI 10.1111/bph.14092
NR 34
TC 17
Z9 19
U1 0
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1582 1838
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD NOV
PY 2020
VL 24
IS 21
BP 12308
EP 12317
DI 10.1111/jcmm.15647
EA SEP 2020
PG 10
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA OV1EP
UT WOS:000569858000001
PM 32939977
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Chang, Q
   Li, C
   Lu, YJ
   Geng, R
   Wei, JN
   Hu, JZ
AF Chang, Qing
   Li, Chao
   Lu, Yunjie
   Geng, Rui
   Wei, Ji nan
   Hu, Jun zheng
TI Adipose derived mesenchymal stromal cells suppress osteoclastogenesis
   and bone erosion in collagen induced arthritis
SO SCANDINAVIAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
DE cells; cytokines; inflammation; molecules; processes; stromal cells
ID RHEUMATOID ARTHRITIS; STEM CELLS; RECEPTOR ACTIVATOR; LIGAND;
   DIFFERENTIATION; OSTEOPROTEGERIN; MODULATION; DISEASE; MICE
AB Osteoclasts are responsible for bone destruction in rheumatoid arthritis (RA), and adipose derived mesenchymal stromal cells (ADSCs) can inhibit experimental collagen induced arthritis model. This study aims to determine whether ADSCs also suppresses osteoclastogenesis and bone erosion in collagen induced arthritis (CIA). Osteoclasts were induced from bone marrow derived CD11b(+)cells with receptor activator of nuclear factor kappa B ligand (RANKL) and macrophage colony stimulating factor (M CSF) stimulation and assessed with tartrate resistant acid phosphatase (TRAP) staining. For human cells, osteoclasts were produced from human CD14(+)cells. ADSCs were generated and added to cultures with different ratios with CD11b(+)cells. Transwell and antibody blockade experiments were performed to define the mechanism of action. NF kappa B and RANKL expression were determined by Western blotting and RT qPCR. About 2 x 10(6)ADSCs or fibroblast cells were adoptively transferred to DBA1/J mice on day 14 after immunization with type II collagen/complete Freund's adjuvant (CII/CFA) while the onset and severity of the CIA were monitored. Adipose derived mesenchymal stromal cells but not fibroblast cells completely suppressed osteoclastogenesis in vitro for human and mice. ADSCs injected after immunization and before of onset of CIA significantly suppressed disease development. Treatment with ADSCs dramatically decreased the levels of NF kappa B p65/p50 in osteoclasts in vitro and P65/50 and RANKL expression by synovial tissues in vivo. We have demonstrated that ADSCs can inhibit RANKL induced osteoclasts genesis via CD39 signals. Our findings also suggest that ADSCs can inhibit osteoclasts genesis without the involvement of regulatory T cells. ADSCs might represent a promising strategy for stem cell based therapies for RA. Thus, manipulation of ADSCs may have therapeutic effects on RA and other bone erosion related diseases.
C1 [Chang, Qing; Li, Chao; Geng, Rui; Wei, Ji nan; Hu, Jun zheng] Southeast Univ, Zhongda Hosp, Med Sch, Dept Orthopaed, 87 Ding Jia Qiao Rd, Nanjing 210009, Jiangsu, Peoples R China.
   [Lu, Yunjie] Soochow Univ, Peoples Hosp Changzhou 1, Hosp 3, Changzhou, Peoples R China.
C3 Southeast University   China; Soochow University   China
RP Chang, Q; Hu, JZ (通讯作者)，Southeast Univ, Zhongda Hosp, Med Sch, Dept Orthopaed, 87 Ding Jia Qiao Rd, Nanjing 210009, Jiangsu, Peoples R China.
EM kbrcq@126.com; hujunzheng880309@sina.com
RI Lu, Yunjie/AAF 2600 2019
FU National Natural Science Foundation of China [81971504] Funding Source:
   Medline
CR Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood 2004 04 1559
   Anderson P, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/2389753
   Bessout R, 2015, J PATHOL, V237, P435, DOI 10.1002/path.4590
   Brand D.D., 2007, NAT PROTOC, V2007, P7
   Bubonja Sonje M, 2013, W INDIAN MED J, V62, P270
   Chabannes D, 2007, BLOOD, V110, P3691, DOI 10.1182/blood 2007 02 075481
   Chatzidionysiou K, 2015, ANN RHEUM DIS, V74, P890, DOI 10.1136/annrheumdis 2013 204714
   Chen MG, 2013, ARTHRITIS RHEUM US, V65, P1181, DOI 10.1002/art.37894
   Di Nicola M, 2002, BLOOD, V99, P3838, DOI 10.1182/blood.V99.10.3838
   Gao Z, 2005, TRANSPL P, V37, P2300, DOI 10.1016/j.transproceed.2005.03.117
   Gashi Afrim A, 2014, Med Arch, V68, P51
   Haase D, 2012, IMMUNOL RES, V53, P200, DOI 10.1007/s12026 012 8267 9
   Halenius A, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/472978
   Haynes DR, 2001, RHEUMATOLOGY, V40, P623, DOI 10.1093/rheumatology/40.6.623
   Ikonomidis I, 2014, CIRC CARDIOVASC IMAG, V7, P619, DOI 10.1161/CIRCIMAGING.113.001193
   Kong N., 2012, ANN RHEUM DIS, V2012, P6
   Kong N, 2012, ARTHRITIS RHEUM US, V64, P2548, DOI 10.1002/art.34513
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Liu YY, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3187
   Lopez Santalla M, 2016, IMMUN INFLAMM DIS, V4, P213, DOI 10.1002/iid3.106
   Pira GL, 2006, HUM IMMUNOL, V67, P976, DOI 10.1016/j.humimm.2006.08.298
   Ruoff G, 2014, J FAM PRACTICE, V63, pS27
   Smolen JS, 2014, ANN RHEUM DIS, V73, P1616, DOI 10.1136/annrheumdis 2013 205137
   Sucur A, 2014, INT ORTHOP, V38, P1893, DOI 10.1007/s00264 014 2386 y
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Tamas MM, 2014, RHEUMATOLOGY, V53, P1100, DOI 10.1093/rheumatology/ket484
   Thiolat A, 2014, ARTHRITIS RHEUMATOL, V66, P273, DOI 10.1002/art.38246
   Yin F, 2014, STEM CELLS, V32, P1278, DOI 10.1002/stem.1638
   Zheng T, 2014, EUR J PHARMACOL, V737, P185, DOI 10.1016/j.ejphar.2014.04.047
NR 29
TC 18
Z9 18
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0300 9475
EI 1365 3083
J9 SCAND J IMMUNOL
JI Scand. J. Immunol.
PD AUG
PY 2020
VL 92
IS 2
AR e12877
DI 10.1111/sji.12877
PG 10
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA MV8TG
UT WOS:000556622600002
PM 32145090
OA Bronze
DA 2025 08 17
ER

PT J
AU Yamada, T
   Yoshii, T
   Yasuda, H
   Okawa, A
   Sotome, S
AF Yamada, Tsuyoshi
   Yoshii, Toshitaka
   Yasuda, Hiroaki
   Okawa, Atsushi
   Sotome, Shinichi
TI Dexamethasone Regulates EphA5, a Potential Inhibitory Factor with
   Osteogenic Capability of Human Bone Marrow Stromal Cells
SO STEM CELLS INTERNATIONAL
LA English
DT Article
ID MESENCHYMAL STEM CELLS; INTEGRIN FUNCTION; TYROSINE KINASE;
   DOWN REGULATION; RECEPTOR; EPHRIN; DIFFERENTIATION; ADHESION; LIGANDS;
   ACTIVATION
AB We previously demonstrated the importance of quality management procedures for the handling of human bone marrow stromal cells (hBMSCs) and provided evidence for the existence of osteogenic inhibitor molecules in BMSCs. One candidate inhibitor is the ephrin type A receptor 5 (EphA5), which is expressed in hBMSCs and upregulated during long term culture. In this study, forced expression of EphA5 diminished the expression of osteoblast phenotypic markers. Downregulation of endogenous EphA5 by dexamethasone treatment promoted osteoblast marker expression. EphA5 could be involved in the normal growth regulation of BMSCs and could be a potential marker for replicative senescence. Although Eph forward signaling stimulated by ephrin B Fc promoted the expression of ALP mRNA in BMSCs, exogenous addition of EphA5 Fc did not affect the ALP level. The mechanism underlying the silencing of EphA5 in early cultures remains unclear. EphA5 promoter was barely methylated in hBMSCs while histone deacetylation could partially suppress EphA5 expression in early passage cultures. In repeatedly passaged cultures, the upregulation of EphA5 independent of methylation could competitively inhibit osteogenic signal transduction pathways such as EphB forward signaling. Elucidation of the potential inhibitory function of EphA5 in hBMSCs may provide an alternative approach for lineage differentiation in cell therapy strategies and regenerative medicine.
C1 [Yamada, Tsuyoshi; Yoshii, Toshitaka; Yasuda, Hiroaki; Okawa, Atsushi] Tokyo Med & Dent Univ, Grad Sch, Dept Orthopaed & Spinal Surg, Tokyo 1138510, Japan.
   [Yamada, Tsuyoshi; Okawa, Atsushi] Tokyo Med & Dent Univ, Int Res Ctr Mol Sci Tooth & Bone Dis, GCOE Program, Tokyo 1138510, Japan.
   [Sotome, Shinichi] Tokyo Med & Dent Univ, Sect Regenerat Therapeut Spine & Spinal Cord, Tokyo 1138510, Japan.
C3 Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU)
RP Sotome, S (通讯作者)，Tokyo Med & Dent Univ, Sect Regenerat Therapeut Spine & Spinal Cord, Tokyo 1138510, Japan.
EM sotome.orth@tmd.ac.jp
RI Yoshii, Toshitaka/HTL 9865 2023
FU Japan Society for the Promotion of Science; Grants in Aid for Scientific
   Research [26462259] Funding Source: KAKEN
FX The authors gratefully thank Tetsuya Jinno, MD, and Daisuke Koga, MD,
   for the collection of bone marrow aspirates during the operation
   procedure; Ryuta Sakuma, Ph.D., for help with lentivirus production; and
   Yusuke Hirabayashi, Ph.D., for valuable suggestions. This work was
   supported by a Grant in Aid for Scientific Research from the Japan
   Society for the Promotion of Science.
CR Abdul Aziz NM, 2009, INT J DEV BIOL, V53, P559, DOI 10.1387/ijdb.082777na
   Akaneya Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012486
   Alam SM, 2008, BRIT J CANCER, V98, P845, DOI 10.1038/sj.bjc.6604216
   Almog N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044001
   Almog N, 2009, CANCER RES, V69, P836, DOI 10.1158/0008 5472.CAN 08 2590
   Aoki M, 2004, J BIOL CHEM, V279, P32643, DOI 10.1074/jbc.M313247200
   Arthur A, 2011, BONE, V48, P533, DOI 10.1016/j.bone.2010.10.180
   Astin JW, 2010, NAT CELL BIOL, V12, P1194, DOI 10.1038/ncb2122
   Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959 437X(02)00279 4
   Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001
   Carvalho RF, 2006, NAT NEUROSCI, V9, P322, DOI 10.1038/nn1655
   Derfoul A, 2006, STEM CELLS, V24, P1487, DOI 10.1634/stemcells.2005 0415
   Dong YC, 2009, MODERN PATHOL, V22, P151, DOI 10.1038/modpathol.2008.188
   Flenniken AM, 1996, DEV BIOL, V179, P382, DOI 10.1006/dbio.1996.0269
   Freywald A, 2002, J BIOL CHEM, V277, P3823, DOI 10.1074/jbc.M108011200
   Fu DY, 2010, HUM PATHOL, V41, P48, DOI 10.1016/j.humpath.2009.06.007
   Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896 6273(00)80276 7
   Gu C, 2001, MOL CELL BIOL, V21, P4579, DOI 10.1128/MCB.21.14.4579 4597.2001
   Hamidouche Z, 2009, P NATL ACAD SCI USA, V106, P18587, DOI 10.1073/pnas.0812334106
   Hara Y, 2010, STEM CELLS, V28, P974, DOI 10.1002/stem.427
   Herath NI, 2010, INT J CANCER, V126, P2003, DOI 10.1002/ijc.25147
   Holen HL, 2008, J LEUKOCYTE BIOL, V84, P1183, DOI 10.1189/jlb.1207829
   Holmberg J, 2005, GENE DEV, V19, P462, DOI 10.1101/gad.326905
   Hornberger MR, 1999, NEURON, V22, P731, DOI 10.1016/S0896 6273(00)80732 1
   Huai JS, 2001, J BIOL CHEM, V276, P6689, DOI 10.1074/jbc.M008127200
   Indrawattana N, 2004, BIOCHEM BIOPH RES CO, V320, P914, DOI 10.1016/j.bbrc.2004.06.029
   Irie N, 2009, J BIOL CHEM, V284, P14637, DOI 10.1074/jbc.M807598200
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   Jülich D, 2009, DEVELOPMENT, V136, P2913, DOI 10.1242/dev.038935
   Kim D, 2011, BIOCHEM BIOPH RES CO, V415, P551, DOI 10.1016/j.bbrc.2011.10.087
   Li SB, 2015, BMC CANCER, V15, DOI 10.1186/s12885 015 1025 3
   Marquardt T, 2005, CELL, V121, P127, DOI 10.1016/j.cell.2005.01.020
   Miao H, 2005, J BIOL CHEM, V280, P923, DOI 10.1074/jbc.M411383200
   Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008
   Miao H, 2012, SEMIN CELL DEV BIOL, V23, P16, DOI 10.1016/j.semcdb.2011.10.013
   Mundy GR, 2006, CELL, V126, P441, DOI 10.1016/j.cell.2006.07.015
   Murai KK, 2003, J CELL SCI, V116, P2823, DOI 10.1242/jcs.00625
   Nievergall E, 2012, CELL MOL LIFE SCI, V69, P1813, DOI 10.1007/s00018 011 0900 6
   NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635
   Noren NK, 2009, BIOCHEM J, V422, P433, DOI 10.1042/BJ20090014
   Oshina H, 2007, BONE, V41, P575, DOI 10.1016/j.bone.2007.06.022
   Pasquale EB, 2005, NAT REV MOL CELL BIO, V6, P462, DOI 10.1038/nrm1662
   Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Schmucker D, 2001, CELL, V105, P701, DOI 10.1016/S0092 8674(01)00391 9
   Sekiya I, 2001, BIOCHEM BIOPH RES CO, V284, P411, DOI 10.1006/bbrc.2001.4898
   Sharfe N, 2008, MOL IMMUNOL, V45, P1208, DOI 10.1016/j.molimm.2007.09.019
   Stiffel V, 2014, J BONE MINER RES, V29, P804, DOI 10.1002/jbmr.2084
   Tanabe S, 2008, J BIOCHEM, V144, P399, DOI 10.1093/jb/mvn082
   Tanaka M, 2005, J BIOL CHEM, V280, P42375, DOI 10.1074/jbc.M503786200
   Ting MJ, 2010, EXP HEMATOL, V38, P1087, DOI 10.1016/j.exphem.2010.07.007
   Vacanti V, 2005, J CELL PHYSIOL, V205, P194, DOI 10.1002/jcp.20376
   Wagner W, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002213
   Wang BC, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002153
   Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092 8674(00)81436 1
   Yamada T, 2013, BONE, V57, P343, DOI 10.1016/j.bone.2013.08.028
   Yamazaki T, 2009, J CELL SCI, V122, P243, DOI 10.1242/jcs.036467
   Yuasa M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116462
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
   Zimmer G, 2007, J NEUROSCI, V27, P5643, DOI 10.1523/JNEUROSCI.0954 07.2007
NR 61
TC 11
Z9 12
U1 0
U2 5
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687 966X
EI 1687 9678
J9 STEM CELLS INT
JI Stem Cells Int.
PY 2016
VL 2016
AR 1301608
DI 10.1155/2016/1301608
PG 20
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA DB9LV
UT WOS:000368838400001
PM 27057165
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Löfdahl, E
   Rådegran, G
   Fagher, K
AF Lofdahl, Eveline
   Radegran, Goran
   Fagher, Katarina
TI Bone health and cardiac transplantation
SO BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
LA English
DT Article
DE Bone metabolism; Heart transplantation; bone mineral density;
   immunosuppressive therapy
ID GLUCOCORTICOID INDUCED OSTEOPOROSIS; LOOP DIURETIC USE; VITAMIN D;
   HEART TRANSPLANTATION; CYCLOSPORINE A; RECIPIENTS; EXPRESSION;
   MANAGEMENT; FRACTURE; DENSITY
AB Patients who undergo heart transplantation (HT) have increased loss of bone mineral density (BMD) [g/cm2]. The greatest drop in BMD occurs within the first year after HT with a decrease 3.5 8.5% in the lumbar spine and 5.6 10.5% in the femoral neck. Thereafter, BMD tend to stabilize or even recover to some degree. Accordingly, risk of fracture correlates to BMD evolution, with the highest rate of fractures during the first year, with a cumulative incidence of 12 36%. Fragility fractures contributes to increased morbidity and increased mortality.The pathophysiology behind BMD impairment in HT patients is complex and involves side effects of the immunosuppressive therapy and of heart failure medications, as well as organ failure. Of the immunosuppressive agents, corticosteroids (CS) exerts the greatest impact on BMD through multiple cellular pathways. Also, calcineurin inhibitors seem have a negative impact on BMD, mainly mediated through enhancement of bone resorption. Additionally, kidney dysfunction has a significant effect on bone homeostasis and is frequently present in HT patients.The optimal timing and type of pharmacological treatment of osteoporosis in HT patients are not yet known. However, bisphosphonates and monoclonal antibody against RANK ligand (Denosumab) may have beneficial effects on bone metabolism in HT patients. However, their efficacy and safety in have not been thoroughly studied in this particular patient population. Therefore, careful individual evaluation of prescription, frequency, and possible treatment options is advisable in this patient population.(c) 2022 Published by Elsevier Ltd.
C1 [Lofdahl, Eveline; Radegran, Goran; Fagher, Katarina] Lund Univ, Dept Clin Sci Lund, Lund, Sweden.
   [Lofdahl, Eveline; Radegran, Goran] Skane Univ Hosp, Sect Heart Failure & Valvular Dis, VO Heart & Lung Med, Lund, Sweden.
   [Fagher, Katarina] Skane Univ Hosp, Dept Endocrinol, Lund, Sweden.
C3 Lund University; Lund University; Skane University Hospital; Lund
   University; Skane University Hospital
RP Löfdahl, E (通讯作者)，Lund Univ, Dept Clin Sci Lund, Lund, Sweden.
EM eveline.lofdahl@med.lu.se
RI Fagher, Katarina/GSN 7633 2022
OI Fagher, Katarina/0000 0002 7967 2576
FU ALF's Foundations, Lund, Sweden
FX This work was funded by unrestricted research grants from Anna  Lisa &
   Sven  Erik Lundgrens , as well as from ALF's Foundations, Lund, Sweden.
   The contributors had no role in the collection, analysis or
   interpretation of the data, and had no right to restrict the
   dissemination or publication of the results.
CR Abrahamsen B, 2009, OSTEOPOROSIS INT, V20, P1633, DOI 10.1007/s00198 009 0920 3
   [Anonymous], 2009, Kidney Int, V76113, pS3, DOI 10.1038/ki.2009.189
   Bakhireva LN, 2004, AM J PREV MED, V26, P436, DOI 10.1016/j.ampere.2004.02.013
   Bodenner D, 2007, CLIN INTERV AGING, V2, P499
   Bonani M, 2016, AM J TRANSPLANT, V16, P1882, DOI 10.1111/ajt.13692
   Bone HG, 2017, LANCET DIABETES ENDO, V5, P513, DOI 10.1016/S2213 8587(17)30138 9
   Braith RW, 2003, J HEART LUNG TRANSPL, V22, P1082, DOI 10.1016/S1053 2498(02)01184 1
   Brown JP, 2014, CAN FAM PHYSICIAN, V60, P324
   Byun Ji Hye, 2017, J Bone Metab, V24, P37
   Carbone LD, 2009, ARCH INTERN MED, V169, P132, DOI 10.1001/archinternmed.2008.526
   Carmeliet G, 2015, BEST PRACT RES CL EN, V29, P621, DOI 10.1016/j.beem.2015.06.001
   Costanzo MR, 2010, J HEART LUNG TRANSPL, V29, P914, DOI 10.1016/j.healun.2010.05.034
   Cranney Ann, 2007, Evid Rep Technol Assess (Full Rep), P1
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   CVETKOVIC M, 1994, TRANSPLANTATION, V57, P1231, DOI 10.1097/00007890 199404270 00016
   Dolgos S, 2010, CLIN TRANSPLANT, V24, pE145, DOI 10.1111/j.1399 0012.2010.01231.x
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Finkelstein JS, 2008, J CLIN ENDOCR METAB, V93, P861, DOI 10.1210/jc.2007 1876
   Gal Moscovici A, 2007, SEMIN DIALYSIS, V20, P423, DOI 10.1111/j.1525 139X.2007.00319.x
   Gourlay M, 2007, CLIN RHEUMATOL, V26, P144, DOI 10.1007/s10067 006 0315 1
   Gregorini M, 2017, TRANSPL P, V49, P650, DOI 10.1016/j.transproceed.2017.02.023
   Gröber U, 2012, DERM ENDOCRINOL, V4, P158, DOI 10.4161/derm.20731
   HENDERSON NK, 1995, LANCET, V346, P905, DOI 10.1016/S0140 6736(95)92748 4
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   Huybers S, 2007, AM J PHYSIOL GASTR L, V292, pG92, DOI 10.1152/ajpgi.00317.2006
   Igarashi K, 2004, BONE, V35, P47, DOI 10.1016/j.bone.2004.02.009
   Jia D, 2006, ENDOCRINOLOGY, V147, P5592, DOI 10.1210/en.2006 0459
   Jilka RL, 2003, MED PEDIATR ONCOL, V41, P182, DOI 10.1002/mpo.10334
   Johansson H, 2014, J BONE MINER RES, V29, P223, DOI 10.1002/jbmr.2017
   Kanis JA, 2009, BONE, V44, P734, DOI 10.1016/j.bone.2009.01.373
   Kerschan Schindl K, 2008, TRANSPL INT, V21, P255, DOI 10.1111/j.1432 2277.2007.00598.x
   Kneissel M, 2004, BONE, V35, P1144, DOI 10.1016/j.bone.2004.07.013
   Kwok T, 2012, OSTEOPOROSIS INT, V23, P2159, DOI 10.1007/s00198 011 1831 7
   Leidig Bruckner G, 2001, LANCET, V357, P342, DOI 10.1016/S0140 6736(00)03641 2
   Lim LS, 2008, ARCH INTERN MED, V168, P735, DOI 10.1001/archinte.168.7.735
   Löfdahl E, 2019, CLIN TRANSPLANT, V33, DOI 10.1111/ctr.13477
   Löfdahl E, 2017, TRANSPLANT REV ORLAN, V31, P232, DOI 10.1016/j.trre.2017.08.002
   Mehra MR, 2005, AM J TRANSPLANT, V5, P1137, DOI 10.1111/j.1600 6143.2005.00809.x
   Reichrath J, 2010, J PHOTOCH PHOTOBIO B, V101, P150, DOI 10.1016/j.jphotobiol.2010.04.001
   Rubin J, 1998, ENDOCRINOLOGY, V139, P1006, DOI 10.1210/en.139.3.1006
   SAMBROOK PN, 1994, J HEART LUNG TRANSPL, V13, P116
   Seibel MJ, 2013, LANCET DIABETES ENDO, V1, P59, DOI 10.1016/S2213 8587(13)70045 7
   Shane E, 1996, J CLIN ENDOCR METAB, V81, P1740, DOI 10.1210/jc.81.5.1740
   Shane E, 1997, J CLIN ENDOCR METAB, V82, P1497, DOI 10.1210/jc.82.5.1497
   Shane E, 1997, AM J MED, V103, P197, DOI 10.1016/S0002 9343(97)00142 3
   Stein EM, 2009, CLIN TRANSPLANT, V23, P861, DOI 10.1111/j.1399 0012.2009.00989.x
   Terrovitis J, 2012, EUR J HEART FAIL, V14, P326, DOI 10.1093/eurjhf/hfs002
   VANCLEEMPUT J, 1995, TRANSPLANT INT, V8, P196
   Wang TKM, 2013, TRANSPL P, V45, P2357, DOI 10.1016/j.transproceed.2012.09.117
   Westenfeld R, 2011, NEPHROL DIAL TRANSPL, V26, P4115, DOI 10.1093/ndt/gfr214
NR 50
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1521 6942
EI 1521 1770
J9 BEST PRACT RES CL RH
JI Best Pract. Res. Clin. Rheumatol.
PD SEP
PY 2022
VL 36
IS 3
SI SI
AR 101770
DI 10.1016/j.berh.2022.101770
PG 6
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 6Z8EC
UT WOS:000898002100010
PM 36127249
DA 2025 08 17
ER

PT J
AU Cuyàs, E
   Corominas Faja, B
   Martín, MMS
   Martin Castillo, B
   Lupu, R
   Brunet, J
   Bosch Barrera, J
   Menendez, JA
AF Cuyas, Elisabet
   Corominas Faja, Bruna
   Munoz San Martin, Maria
   Martin Castillo, Begona
   Lupu, Ruth
   Brunet, Joan
   Bosch Barrera, Joaquim
   Menendez, Javier A.
TI BRCA1 haploinsufficiency cell autonomously activates RANKL
   expression and generates denosumab responsive breast cancer initiating
   cells
SO ONCOTARGET
LA English
DT Article
DE denosumab; RANK; RANKL; cancer stem cells; BRCA1
ID EPITHELIAL MESENCHYMAL TRANSITION; NF KAPPA B; CARCINOMA IN SITU;
   ZOLEDRONIC ACID; STEM CELLS; RECEPTOR ACTIVATOR; BONE METASTASES;
   OSTEOCLAST DIFFERENTIATION; LIGAND RANKL; SELF RENEWAL
AB Denosumab, a monoclonal antibody to the receptor activator of nuclear factor kappa B ligand (RANKL), might be a novel preventative therapy for BRCA1 mutation carriers at high risk of developing breast cancer. Beyond its well recognized bone targeted activity impeding osteoclastogenesis, denosumab has been proposed to interfere with the cross talk between RANKL producing sensor cells and cancer initiating RANK(+) responder cells that reside within premalignant tissues of BRCA1 mutation carriers. We herein tested the alternative but not mutually exclusive hypothesis that BRCA1 deficiency might cell autonomously activate RANKL expression to generate cellular states with cancer stem cell (CSC) like properties. Using isogenic pairs of normal like human breast epithelial cells in which the inactivation of a single BRCA1 allele results in genomic instability, we assessed the impact of BRCA1 haploinsufficiency on the expression status of RANK and RANKL. RANK expression remained unaltered but RANKL was dramatically up regulated in BRCA1(mut/+) haploinsufficient cells relative to isogenic BRCA1(+/+) parental cells. Neutralizing RANKL with denosumab significantly abrogated the ability of BRCA1 haploinsufficient cells to survive and proliferate as floating microtumors or "mammospheres" under non adherent/non differentiating conditions, an accepted surrogate of the relative proportion and survival of CSCs. Intriguingly, CSC like states driven by epithelial to mesenchymal transition or HER2 overexpression traits responded to some extent to denosumab. We propose that breast epithelium specific mono allelic inactivation of BRCA1 might suffice to cell autonomously generate RANKL addicted, denosumab responsive CSC like states. The convergent addiction to a hyperactive RANKL/RANK axis of CSC like states from
C1 [Cuyas, Elisabet; Corominas Faja, Bruna; Menendez, Javier A.] Catalan Inst Oncol, Metab & Canc Grp, Program Canc Therapeut Resistance ProCURE, Girona, Catalonia, Spain.
   [Cuyas, Elisabet; Corominas Faja, Bruna; Martin Castillo, Begona; Menendez, Javier A.] Girona Biomed Res Inst IDIBGI, Mol Oncol Grp, Girona, Catalonia, Spain.
   [Munoz San Martin, Maria] Dr Josep Trueta Univ Hosp, Girona Biomed Res Inst IDIBGI, Neuroimmunol & Multiple Sclerosis Unit, Girona, Catalonia, Spain.
   [Martin Castillo, Begona] Catalan Inst Oncol, Unit Clin Res, Girona, Catalonia, Spain.
   [Lupu, Ruth] Mayo Clin, Div Expt Pathol, Dept Lab Med & Pathol, Rochester, MN USA.
   [Lupu, Ruth] Mayo Clin, Canc Ctr, Rochester, MN USA.
   [Brunet, Joan; Bosch Barrera, Joaquim] Catalan Inst Oncol, Deparment Med Oncol, Girona, Catalonia, Spain.
   [Brunet, Joan; Bosch Barrera, Joaquim] Univ Girona, Med Sch, Dept Med Sci, Girona, Catalonia, Spain.
C3 Institut Catala d'Oncologia; Universitat de Girona; Girona University
   Hospital Dr. Josep Trueta; Institut d'Investigacio Biomedica de Girona
   (IDIBGI); Universitat de Girona; Girona University Hospital Dr. Josep
   Trueta; Institut d'Investigacio Biomedica de Girona (IDIBGI); Institut
   Catala d'Oncologia; Mayo Clinic; Mayo Clinic; Institut Catala
   d'Oncologia; Universitat de Girona
RP Menendez, JA (通讯作者)，Catalan Inst Oncol, Metab & Canc Grp, Program Canc Therapeut Resistance ProCURE, Girona, Catalonia, Spain.; Menendez, JA (通讯作者)，Girona Biomed Res Inst IDIBGI, Mol Oncol Grp, Girona, Catalonia, Spain.
EM jmenendez@iconcologia.net
RI ; Brunet, Joan/C 5292 2018; Muñoz San Martín, María/ABF 7126 2020;
   MENENDEZ, JAVIER/C 6148 2016; MENENDEZ MENENDEZ, JAVIER
   ABEL/C 6148 2016; Cuyas, Elisabet/G 8582 2018
OI Munoz San Martin, Maria/0000 0002 7249 5343; Cuyas,
   Elisabet/0000 0001 5353 440X; Brunet, Joan/0000 0003 1945 3512;
   Martin Castillo, Begona/0000 0001 8344 8174; MENENDEZ MENENDEZ, JAVIER
   ABEL/0000 0001 8733 4561; Bosch Barrera, Joaquim/0000 0002 0893 7821; 
FU Ministerio de Ciencia e Innovacion [SAF2016 80639 P]; Plan Nacional de
   I+D+I, Spain; Agencia de Gestio d'Ajuts Universitaris i de Recerca
   (AGAUR) [2014 SGR229]; Departament d'Economia i Coneixement, Catalonia,
   Spain; Ministerio de Sanidad y Consumo, Fondo de Investigacion Sanitaria
   (FIS), Spain [CD15/00033]; AGAUR [2016 FI B01171]; Spanish Society of
   Medical Oncology (SEOM, Madrid, Spain); Pfizer [WI190764]
FX We are greatly indebted to Prof. Robert A. Weinberg (Whitehead Institute
   for Biomedical Research, Cambridge, MA) for providing the
   HMLER<SUP>shCntrol</SUP> and HMLER<SUP>shEcad</SUP> cells used in this
   work. This work was supported by grants from the Ministerio de Ciencia e
   Innovacion (Grant SAF2016 80639 P to J. A. Menendez), Plan Nacional de
   I+D+I, Spain and the Agencia de Gestio d'Ajuts Universitaris i de
   Recerca (AGAUR) (Grant 2014 SGR229 to J. A. Menendez), Departament
   d'Economia i Coneixement, Catalonia, Spain. Elisabet Cuyas is supported
   by the Sara Borrell post doctoral contract (CD15/00033) from the
   Ministerio de Sanidad y Consumo, Fondo de Investigacion Sanitaria (FIS),
   Spain. Maria Munoz San Martin is supported by the 2016 FI B01171 AGAUR
   fellowship. Joaquim Bosch Barrera was supported by an Emerging Research
   Grant (2013) from the Spanish Society of Medical Oncology (SEOM, Madrid,
   Spain), and a Research Grant from Pfizer (WI190764). The authors would
   like to thank Dr. Kenneth McCreath for editorial support.
CR Barnabas N, 2013, INT J BREAST CANCER, V2013, DOI 10.1155/2013/872743
   Behbod F, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2358
   Bhowmik SK, 2015, ONCOTARGET, V6, P42651, DOI 10.18632/oncotarget.4765
   Bizzarro V, 2015, ONCOTARGET, V6, P25074, DOI 10.18632/oncotarget.4725
   Blake ML, 2014, CLIN EXP METASTAS, V31, P233, DOI 10.1007/s10585 013 9624 3
   Bosch Barrera J, 2011, CLIN TRANSL ONCOL, V13, P148, DOI 10.1007/s12094 011 0634 9
   Casas A, 2013, BREAST, V22, P585, DOI 10.1016/j.breast.2013.05.007
   Chakrabarti R, 2012, NAT CELL BIOL, V14, P1212, DOI 10.1038/ncb2607
   Chakrabarti R, 2012, STEM CELLS, V30, P1496, DOI 10.1002/stem.1112
   Coleman R, 2012, JNCI J NATL CANCER I, V104, P1059, DOI 10.1093/jnci/djs263
   Cordero A, 2016, STEM CELLS, V34, P1027, DOI 10.1002/stem.2271
   Corominas Faja B, 2014, ONCOTARGET, V5, P8306, DOI 10.18632/oncotarget.2059
   Cuyàs E, 2016, ONCOTARGET, V7, P52974, DOI 10.18632/oncotarget.9732
   Cuyàs E, 2015, CELL CYCLE, V14, P3527, DOI 10.1080/15384101.2015.1044173
   Cuyàs E, 2014, ONCOTARGET, V5, P3970, DOI 10.18632/oncotarget.2147
   De Castro J, 2015, CLIN LUNG CANCER, V16, P431, DOI 10.1016/j.cllc.2015.06.004
   Desai B, 2007, MOL CANCER, V6, DOI 10.1186/1476 4598 6 18
   Duru N, 2016, ONCOTARGET, V7, P47511, DOI 10.18632/oncotarget.10203
   Espinoza I, 2011, MOL CANCER THER, V10, P732, DOI 10.1158/1535 7163.MCT 10 0836
   Galluzzi L, 2016, CELL RES, V26, P751, DOI 10.1038/cr.2016.79
   Gnant M, CANC RES, V76, pS2
   Gnant M, 2015, LANCET, V386, P433, DOI 10.1016/S0140 6736(15)60995 3
   Gnant M, 2012, CANCER TREAT REV, V38, P407, DOI 10.1016/j.ctrv.2011.09.003
   Gonzalez Guerrico AM, 2016, ONCOTARGET, V7, P71151, DOI 10.18632/oncotarget.9463
   González Suárez E, 2016, FEBS J, V283, P2018, DOI 10.1111/febs.13645
   Gonzalez Suarez E, 2010, NATURE, V468, P103, DOI 10.1038/nature09495
   Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034
   Harmsen MG, 2015, CRIT REV ONCOL HEMAT, V96, P555, DOI 10.1016/j.critrevonc.2015.07.010
   Hu H, 2014, BREAST CANCER RES TR, V146, P515, DOI 10.1007/s10549 014 3049 9
   Ishii T, 2004, BIOCHEM BIOPH RES CO, V316, P809, DOI 10.1016/j.bbrc.2004.02.124
   Ithimakin S, 2013, CANCER RES, V73, P1635, DOI 10.1158/0008 5472.CAN 12 3349
   Jia XH, 2015, ONCOTARGET, V6, P26018, DOI 10.18632/oncotarget.4658
   Kato J, 2016, INT J CANCER, V138, P1516, DOI 10.1002/ijc.29881
   Kimachi K, 2011, N S ARCH PHARMACOL, V383, P297, DOI 10.1007/s00210 010 0596 4
   Konishi H, 2011, P NATL ACAD SCI USA, V108, P17773, DOI 10.1073/pnas.1110969108
   Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207
   Korkaya H, 2013, CANCER RES, V73, P3489, DOI 10.1158/0008 5472.CAN 13 0260
   Kotsopoulos J, 2017, BREAST CANCER RES TR, V161, P11, DOI 10.1007/s10549 016 4029 z
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Lee CH, 2016, ONCOTARGET, V7, P1215, DOI 10.18632/oncotarget.6261
   Lewiecki EM, 2012, CLIN PHARMACOL THER, V91, P123, DOI 10.1038/clpt.2011.268
   Li Q, 2014, ONCOGENE, V33, P2589, DOI 10.1038/onc.2013.226
   Li QL, 2014, J BIOL CHEM, V289, P1303, DOI 10.1074/jbc.M113.502278
   Li XX, 2008, JNCI J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123
   Liu Y, 2016, ONCOTARGET, V7, P25328, DOI 10.18632/oncotarget.8291
   Magnifico A, 2009, CLIN CANCER RES, V15, P2010, DOI 10.1158/1078 0432.CCR 08 1327
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Iglesias JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077281
   Marra M, 2009, INT J CANCER, V125, P2004, DOI 10.1002/ijc.24648
   Martin Castillo B, 2015, ONCOTARGET, V6, P32317, DOI 10.18632/oncotarget.6094
   May CD, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2789
   Menendez JA, 2016, ONCOTARGET, V7, P11959, DOI 10.18632/oncotarget.7867
   Morel AP, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002723
   Nakagawa T, 2015, ARCH ORAL BIOL, V60, P557, DOI 10.1016/j.archoralbio.2014.09.012
   Nakamura H, 2008, J BONE MINER METAB, V26, P642, DOI 10.1007/s00774 008 0857 1
   Nakanishi T, 2010, BRIT J CANCER, V102, P815, DOI 10.1038/sj.bjc.6605553
   Nolan E, 2016, NAT MED, V22, P933, DOI 10.1038/nm.4118
   Odero Marah VA, 2008, CELL RES, V18, P858, DOI 10.1038/cr.2008.84
   Palafox M, 2012, CANCER RES, V72, P2879, DOI 10.1158/0008 5472.CAN 12 0044
   Pan BQ, 2004, J BONE MINER RES, V19, P147, DOI 10.1359/jbmr.2004.19.1.147
   Pandey PR, 2013, ONCOGENE, V32, P5111, DOI 10.1038/onc.2012.519
   Pasquale P, 2013, STEM CELLS, V31, P1954, DOI 10.1002/stem.1454
   Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635
   Roesler R, 2010, LANCET ONCOL, V11, P225, DOI 10.1016/S1470 2045(09)70404 8
   Rolfo C, 2014, EXPERT OPIN BIOL TH, V14, P15, DOI 10.1517/14712598.2013.843667
   Roukos DH, 2007, NAT CLIN PRACT ONCOL, V4, P578, DOI 10.1038/ncponc0930
   Sarkar TR, 2015, ONCOGENE, V34, P2958, DOI 10.1038/onc.2014.245
   Scagliotti GV, 2012, J THORAC ONCOL, V7, P1823, DOI 10.1097/JTO.0b013e31826aec2b
   Schech AJ, 2013, MOL CANCER THER, V12, P1356, DOI 10.1158/1535 7163.MCT 12 0304
   Schramek D, 2010, NATURE, V468, P98, DOI 10.1038/nature09387
   Sharma Bhawna, 2011, J Carcinog, V10, P36, DOI 10.4103/1477 3163.91119
   Shevde LA, 2010, J CELL MOL MED, V14, P1693, DOI 10.1111/j.1582 4934.2009.00821.x
   Sigl V, 2016, CELL RES, V26, P761, DOI 10.1038/cr.2016.69
   Sohn W, 2014, BRIT J CLIN PHARMACO, V78, P477, DOI 10.1111/bcp.12355
   Song FN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108507
   Stachnik A, 2014, P NATL ACAD SCI USA, V111, P17995, DOI 10.1073/pnas.1421422111
   Tai TW, 2014, BONE, V67, P166, DOI 10.1016/j.bone.2014.07.003
   Tanos T, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005654
   Tsubaki M, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756 9966 32 62
   Widschwendter M, 2015, EBIOMEDICINE, V2, P1331, DOI 10.1016/j.ebiom.2015.08.037
   Yamada T, 2011, AM J PATHOL, V178, P2845, DOI 10.1016/j.ajpath.2011.02.003
   Yoldi G, 2016, CANCER RES, V76, P5857, DOI 10.1158/0008 5472.CAN 15 2745
   Yuen T, 2014, P NATL ACAD SCI USA, V111, P17989, DOI 10.1073/pnas.1421410111
NR 83
TC 12
Z9 14
U1 1
U2 7
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD MAY 23
PY 2017
VL 8
IS 21
BP 35019
EP 35032
DI 10.18632/oncotarget.16558
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA EV8RY
UT WOS:000402051700089
PM 28388533
OA gold, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Nicolin, V
   Baldini, G
   Bareggi, R
   Zweyer, M
   Zauli, G
   Vaccarezza, M
   Narducci, P
AF Nicolin, Vanessa
   Baldini, Giovanna
   Bareggi, Renato
   Zweyer, Marina
   Zauli, Giorgio
   Vaccarezza, Mauro
   Narducci, Paola
TI Morphological features of osteoclasts derived from a co culture system
SO JOURNAL OF MOLECULAR HISTOLOGY
LA English
DT Article
DE opsteoclast; pre osteoclast; receptor activator of NfKB ligand;
   transmission electron microscopy; scanning electron microscopy
ID DIFFERENTIATION; PODOSOMES
AB The interaction between the receptor activator of NfKB (RANK) and its ligand receptor activator of NfKB ligand (RANKL) has recently been proven to be pivotal for osteoclast differentiation and activation. The influence of RANK RANKL signaling on osteoclast formation was established by co culturing murine osteoblasts (type CRL 12257) and murine mononuclear monocytes (RAW 264.7). The aim of the present study was to examine, by means of morphological techniques, the interaction between these two cell lines grown in the absolute absence of exogenous cytokines and other stimulating factors. Moreover, we wanted to show that our model could provide a system to analyze the bone resorption process. Mineralized matrix induced morphological changes of osteoclasts (OC) by the formation of organized ruffled border and a large number of secondary lysosomal vesicles. On the contrary, OC grown on glass coverslips without dentin showed no organized ruffled border or secondary lysosomes. The study of the relationship between these two cell types could establish new approaches for a potential pharmacological control of these cell types and tissues in health and disease.
C1 Univ Trieste, Sect Human Morphol & Mol Biol, Dept Biomed, I 34138 Trieste, Italy.
   Univ Cassino, Dept Hlth & Human Movement Sci, I 03043 Cassino, Italy.
C3 University of Trieste; University of Cassino
RP Nicolin, V (通讯作者)，Univ Trieste, Sect Human Morphol & Mol Biol, Dept Biomed, Via Manzoni 16, I 34138 Trieste, Italy.
EM nicolin@units.it
RI VACCAREZZA, Mauro/S 9637 2019; Zauli, Giorgio/ABE 8001 2020
OI Zauli, Giorgio/0000 0002 3750 8698; VACCAREZZA,
   Mauro/0000 0003 3060 318X; Nicolin, Vanessa/0000 0002 5665 6493
CR Atkins GJ, 2003, J BONE MINER RES, V18, P1088, DOI 10.1359/jbmr.2003.18.6.1088
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Destaing O, 2003, MOL BIOL CELL, V14, P407, DOI 10.1091/mbc.E02 07 0389
   Husheem M, 2005, CALCIFIED TISSUE INT, V76, P222, DOI 10.1007/s00223 004 0123 z
   Kirstein B, 2006, J CELL BIOCHEM, V98, P1085, DOI 10.1002/jcb.20835
   Lader CS, 2001, BRIT J HAEMATOL, V112, P430, DOI 10.1046/j.1365 2141.2001.02437.x
   Linder S, 2003, TRENDS CELL BIOL, V13, P376, DOI 10.1016/S0962 8924(03)00128 4
   Miyazaki Tsuyoshi, 2006, Mod Rheumatol, V16, P68
   Nicolin V, 2005, ANAT REC PART A, V286A, P945, DOI 10.1002/ar.a.20239
   Sabokbar A, 2001, J MATER SCI MATER M, V12, P659, DOI 10.1023/A:1011267005465
   Saltel F, 2004, MOL BIOL CELL, V15, P5231, DOI 10.1091/mbc.E04 06 0522
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   VESELY P, 1992, J ANAT, V181, P277
   Zauli G, 2004, BLOOD, V104, P2044, DOI 10.1182/blood 2004 03 1196
NR 14
TC 17
Z9 20
U1 0
U2 8
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1567 2379
EI 1567 2387
J9 J MOL HISTOL
JI J. Mol. Histol.
PD MAY
PY 2006
VL 37
IS 3 4
BP 171
EP 177
DI 10.1007/s10735 006 9058 1
PG 7
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 098WR
UT WOS:000241554200009
PM 16977429
DA 2025 08 17
ER

PT J
AU Keller, E
   Clocchiatti, S
   Rupel, K
   Ottaviani, G
   Ratti, C
   Canton, G
   Di Lenarda, R
   Murena, L
   Biasotto, M
AF Keller, Edgar
   Clocchiatti, Susanna
   Rupel, Katia
   Ottaviani, Giulia
   Ratti, Chiara
   Canton, Gianluca
   Di Lenarda, Roberto
   Murena, Luigi
   Biasotto, Matteo
TI Chronic Diffuse Sclerosing Osteomyelitis of the Mandible: The Use of
   Bisphosphonates as a Treatment for a Rare and Challenging Condition
SO MEDICINA LITHUANIA
LA English
DT Article
DE antiresorptive therapy; bisphosphonates; CDSO; sclerosing osteomyelitis
ID RECURRENT MULTIFOCAL OSTEOMYELITIS; OSTEITIS SAPHO SYNDROME;
   HYPEROSTOSIS; PUSTULOSIS; SYNOVITIS; ACNE; CRMO; DSO
AB Chronic diffuse sclerosing osteomyelitis is a very rare condition, described as a non suppurative, inflammatory disease of the bone and characterized by a proliferative endosteal reaction, which clinically reveals itself with cyclic pain of the jaw and swelling. We reported two clinical cases, where patients suffered recurrent swelling and pain at the mandible irradiating to the preauricular area, denying any previous trauma or significant medical history. Odontogenic causes were excluded. An initial treatment with antibiotics and NSAIDs temporarily relieved the symptoms without complete resolution, prompting further investigations. After a comprehensive array of diagnostic tools (X rays, CT scans, scintigraphy, bone biopsy, serum markers), both patients were diagnosed with chronic diffuse sclerosing osteomyelitis of the mandible. Bisphosphonates (clodronate and zolendronate) with different treatment schemes were used to treat the condition, until a full recovery from symptoms was reported. Bisphosphonates could therefore represent an effective option in managing this rare but impactful condition. Further research is warranted to better understand the underlying mechanisms of the disease and to optimize treatment strategies.
C1 [Keller, Edgar; Rupel, Katia; Ottaviani, Giulia; Di Lenarda, Roberto; Biasotto, Matteo] Univ Trieste, Dept Med Surg & Hlth Sci, I 34100 Trieste, Italy.
   [Clocchiatti, Susanna; Ratti, Chiara; Canton, Gianluca; Murena, Luigi] Azienda Sanit Univ GiulianoIsontina ASUGI, Osped Cattinara, Clin Ortoped & Traumatol, I 34100 Trieste, Italy.
C3 University of Trieste
RP Ottaviani, G (通讯作者)，Univ Trieste, Dept Med Surg & Hlth Sci, I 34100 Trieste, Italy.
EM kelleredgar93@gmail.com; susanna.clocchiatti@libero.it; krupel@units.it;
   gottaviani@units.it; chiara.ratti@asugi.sanita.fvg.it; gcanton@units.it;
   rdilenarda@units.it; lmurena@units.it; m.biasotto@fmc.units.it
RI ; Ottaviani, Giulia/W 4164 2019; Rupel, Katia/HDO 8147 2022; Canton,
   Gianluca/ABD 5270 2021; Ratti, Chiara/LTD 2425 2024
OI OTTAVIANI, GIULIA/0000 0002 3427 0514; ratti,
   chiara/0009 0007 5798 9269; RUPEL, KATIA/0000 0002 6150 9439
CR Al Rashid M, 2015, ORTHOP CLIN N AM, V46, P577, DOI 10.1016/j.ocl.2015.06.008
   Antao Candice Jacinta, 2019, Ann Maxillofac Surg, V9, P188, DOI 10.4103/ams.ams_257_18
   Campisi G, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17165998
   Chundoo S, 2022, BMJ CASE REP, V15, DOI 10.1136/bcr 2021 246789
   GROOT RH, 1992, ORAL SURG ORAL MED O, V74, P727, DOI 10.1016/0030 4220(92)90398 A
   Hofmann SR, 2017, CURR OSTEOPOROS REP, V15, P542, DOI 10.1007/s11914 017 0405 9
   HUDSON JW, 1993, J ORAL MAXIL SURG, V51, P1294, DOI 10.1016/S0278 2391(10)80131 4
   JACOBSSON S, 1984, INT J ORAL MAXILLOF, V13, P363, DOI 10.1016/S0300 9785(84)80062 9
   Jelusic M, 2018, ACTA DERMATOVENER CR, V26, P212
   Jerkovic D, 2023, ACTA STOMATOL CROAT, V57, P62, DOI 10.15644/asc57/1/7
   Kahn MF, 1996, ORAL SURG ORAL MED O, V81, P633, DOI 10.1016/S1079 2104(96)80065 5
   KAHN MF, 1994, ORAL SURG ORAL MED O, V78, P594, DOI 10.1016/0030 4220(94)90170 8
   MALMSTROM M, 1983, INT J ORAL MAXILLOF, V12, P6, DOI 10.1016/S0300 9785(83)80074 X
   Marí A, 2014, J CRANIO MAXILL SURG, V42, P1990, DOI 10.1016/j.jcms.2014.09.004
   Matharu J, 2020, OR SURG OR MED OR PA, V129, P437, DOI 10.1016/j.oooo.2019.11.010
   Montonen M, 2001, INT J ORAL MAX SURG, V30, P313, DOI 10.1054/ijom.2001.0061
   Otto S, 2015, J CRANIO MAXILL SURG, V43, P1837, DOI 10.1016/j.jcms.2015.08.028
   Ruggiero SL, 2022, J ORAL MAXIL SURG, V80, P920, DOI 10.1016/j.joms.2022.02.008
   SUEI Y, 1995, ORAL SURG ORAL MED O, V80, P401, DOI 10.1016/S1079 2104(05)80332 4
   Thong ISK, 2018, SCAND J PAIN, V18, P99, DOI 10.1515/sjpain 2018 0012
   van de Meent MM, 2020, BRIT J ORAL MAX SURG, V58, P385, DOI 10.1016/j.bjoms.2020.01.012
   VANMERKESTEYN JPR, 1990, ORAL SURG ORAL MED O, V70, P414, DOI 10.1016/0030 4220(90)90200 C
NR 22
TC 1
Z9 1
U1 1
U2 7
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1010 660X
EI 1648 9144
J9 MEDICINA LITHUANIA
JI Med. Lith.
PD JUN
PY 2024
VL 60
IS 6
AR 917
DI 10.3390/medicina60060917
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA WR5W0
UT WOS:001256622900001
PM 38929534
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Hamidouche, Z
   Fromigué, O
   Nuber, U
   Vaudin, P
   Pages, JC
   Ebert, R
   Jakob, F
   Miraoui, H
   Marie, PJ
AF Hamidouche, Zahia
   Fromigue, Olivia
   Nuber, Ulrike
   Vaudin, Pascal
   Pages, Jean Christophe
   Ebert, Regina
   Jakob, Franz
   Miraoui, Hichem
   Marie, Pierre J.
TI Autocrine Fibroblast Growth Factor 18 Mediates Dexamethasone Induced
   Osteogenic Differentiation of Murine Mesenchymal Stem Cells
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID OSTEOBLAST DIFFERENTIATION; BONE FORMATION; STROMAL CELLS; MARROW;
   RUNX2; EXPRESSION; PROLIFERATION; OSF2/CBFA1; MECHANISMS; INDUCTION
AB The potential of mesenchymal stem cells (MSC) to differentiate into functional bone forming cells provides an important tool for bone regeneration. The identification of factors capable of promoting osteoblast differentiation in MSCs is therefore critical to enhance the osteogenic potential of MSCs. Using microarray analysis combined with biochemical and molecular approach, we found that FGF18, a member of the FGF family, is upregulated during osteoblast differentiation induced by dexamethasone in murine MSCs. We showed that overexpression of FGF18 by lentiviral (LV) infection, or treatment of MSCs with recombinant human (rh)FGF18 increased the expression of the osteoblast specific transcription factor Runx2, and enhanced osteoblast phenotypic marker gene expression and in vitro osteogenesis. Molecular silencing using lentiviral shRNA demonstrated that downregulation of FGFR1 or FGFR2 abrogated osteoblast gene expression induced by either LV FGF18 or rhFGF18, indicating that FGF18 enhances osteoblast differentiation in MSCs via activation of FGFR1 or FGFR2 signaling. Biochemical and pharmacological analyses showed that the induction of phenotypic osteoblast markers by LV FGF18 is mediated by activation of ERK1/2 MAPKs and PI3K signaling in MSCs. These results reveal that FGF18 is an essential autocrine positive regulator of the osteogenic differentiation program in murine MSCs and indicate that osteogenic differentiation induced by FGF18 in MSCs is triggered by FGFR1/FGFR2 mediated ERK1/2 MAPKs and PI3K signaling. J. Cell. Physiol. 224: 509 515, 2010. (C) 2010 Wiley Liss, Inc.
C1 [Marie, Pierre J.] Hop Lariboisiere, INSERM, U606, Lab Osteoblast Biol & Pathol, F 75475 Paris 10, France.
   [Hamidouche, Zahia; Fromigue, Olivia; Miraoui, Hichem; Marie, Pierre J.] Univ Paris Diderot, Paris, France.
   [Nuber, Ulrike] Lund Univ, Lund Strateg Res Ctr Stem Cell Biol, Lund, Sweden.
   [Vaudin, Pascal; Pages, Jean Christophe] INSERM, U966, Tours, France.
   [Vaudin, Pascal; Pages, Jean Christophe] Univ Tours, Tours, France.
   [Ebert, Regina; Jakob, Franz] Univ Wurzburg, Orthoped Ctr Musculoskeletal Res Expt & Clin Oste, D 97070 Wurzburg, Germany.
C3 Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP);
   Hopital Universitaire Lariboisiere Fernand Widal   APHP; Institut
   National de la Sante et de la Recherche Medicale (Inserm); Universite
   Paris Cite; Lund University; Institut National de la Sante et de la
   Recherche Medicale (Inserm); Universite de Tours; University of Wurzburg
RP Marie, PJ (通讯作者)，Hop Lariboisiere, INSERM, U606, Lab Osteoblast Biol & Pathol, 2 Rue Ambroise Pare, F 75475 Paris 10, France.
EM pierre.marie@inserm.fr
RI ; Pagès, Jean Christophe/IAM 2849 2023; Jakob, Franz/D 8526 2015;
   Fromigue, Olivia/B 8225 2013; Ebert, Regina/D 5760 2016; Vaudin,
   Pascal/J 1870 2014
OI Pages, Jean Christophe/0000 0002 6852 5546; Fromigue,
   Olivia/0000 0002 3050 6155; Ebert, Regina/0000 0002 8192 869X; 
FU Establissemt Francais du Sang (EFS, France) [2004 08, 2005.11]; European
   Commission [FP6 LSHB CT 2003 503161]; Association Rhumatisme et Travil
   (Hopital Lariboisiere, Paris, France)
FX Contract grant sponsor: Establissemt Francais du Sang (EFS,
   France).Contract grant numbers: 2004 08, 2005.11.Contract grant sponsor:
   Integrated Project of the European Commission.Contract grant number: FP6
   LSHB CT 2003 503161.Contract grant sponsor: Association Rhumatisme et
   Travil (Hopital Lariboisiere, Paris, France).
CR Baksh D, 2007, J CELL PHYSIOL, V212, P817, DOI 10.1002/jcp.21080
   Beak JY, 2007, J BONE MINER RES, V22, P1234, DOI 10.1359/JBMR.070503
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19 3 180
   CHENG SL, 1994, ENDOCRINOLOGY, V134, P277, DOI 10.1210/en.134.1.277
   Dailey L, 2005, CYTOKINE GROWTH F R, V16, P233, DOI 10.1016/j.cytogfr.2005.01.007
   Davidson D, 2005, J BIOL CHEM, V280, P20509, DOI 10.1074/jbc.M410148200
   Dennis JE, 1999, J BONE MINER RES, V14, P700, DOI 10.1359/jbmr.1999.14.5.700
   Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001
   Etheridge SL, 2004, STEM CELLS, V22, P849, DOI 10.1634/stemcells.22 5 849
   Fromigue O, 1997, CYTOKINE, V9, P613, DOI 10.1006/cyto.1997.0209
   Fromigué O, 2008, J CELL BIOCHEM, V104, P620, DOI 10.1002/jcb.21648
   Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Gori F, 1999, J BONE MINER RES, V14, P1522, DOI 10.1359/jbmr.1999.14.9.1522
   Gowen LC, 2003, J BIOL CHEM, V278, P1998, DOI 10.1074/jbc.M203250200
   Gregory CA, 2005, ANN NY ACAD SCI, V1049, P97, DOI 10.1196/annals.1334.010
   Gurok U, 2004, J NEUROSCI, V24, P5982, DOI 10.1523/JNEUROSCI.0809 04.2004
   Hamidouche Z, 2008, FASEB J, V22, P3813, DOI 10.1096/fj.08 106302
   Hinoi E, 2006, GENE DEV, V20, P2937, DOI 10.1101/gad.1482906
   Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645
   Kassem M, 2006, ANN NY ACAD SCI, V1067, P436, DOI 10.1196/annals.1354.062
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Kimelman N, 2006, REGEN MED, V1, P549, DOI 10.2217/17460751.1.4.549
   Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797 307
   Lian JB, 2004, CRIT REV EUKAR GENE, V14, P1, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i12.10
   Liu ZH, 2002, GENE DEV, V16, P859, DOI 10.1101/gad.965602
   Marie PJ, 2008, ARCH BIOCHEM BIOPHYS, V473, P98, DOI 10.1016/j.abb.2008.02.030
   Marie PJ, 2006, REGEN MED, V1, P539, DOI 10.2217/17460751.1.4.539
   Marie PJ, 2003, GENE, V316, P23, DOI 10.1016/S0378 1119(03)00748 0
   Martin I, 1997, ENDOCRINOLOGY, V138, P4456, DOI 10.1210/en.138.10.4456
   Miraoui H, 2009, J BIOL CHEM, V284, P4897, DOI 10.1074/jbc.M805432200
   Ohbayashi N, 2002, GENE DEV, V16, P870, DOI 10.1101/gad.965702
   Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702
   Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007 0637
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Pri Chen S, 1998, BONE, V23, P111, DOI 10.1016/S8756 3282(98)00087 8
   Reinhold MI, 2007, J BIOL CHEM, V282, P3653, DOI 10.1074/jbc.M608995200
   RICKARD DJ, 1994, DEV BIOL, V161, P218, DOI 10.1006/dbio.1994.1022
   Xiao LP, 2004, J BIOL CHEM, V279, P27743, DOI 10.1074/jbc.M314323200
NR 41
TC 63
Z9 83
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD AUG
PY 2010
VL 224
IS 2
BP 509
EP 515
DI 10.1002/jcp.22152
PG 7
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA 619GZ
UT WOS:000279418600027
PM 20432451
DA 2025 08 17
ER

PT J
AU Zhu, MP
   Liu, H
   Sun, K
   Liu, J
   Mou, Y
   Qi, DH
   Zhou, CK
   Abudunaibi, M
   Tasiken, B
   Li, JW
   Cheng, H
   Huang, H
AF Zhu, Meipeng
   Liu, Hui
   Sun, Kai
   Liu, Jian
   Mou, Yan
   Qi, Dahu
   Zhou, Chuankun
   Abudunaibi, Maihaiti
   Tasiken, Bahebieergan
   Li, Jianwen
   Cheng, Hao
   Huang, Hui
TI Vinpocetine inhibits RANKL induced osteoclastogenesis and attenuates
   ovariectomy induced bone loss
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE vinpocetine(Vinp); Osteoporosis; Osteoclastogenesis; MAPK; NF kappa B;
   Reactive oxygen species
ID NF KAPPA B; MODULATES OSTEOCLASTOGENESIS; DIFFERENTIATION; OSTEOPOROSIS;
   INFLAMMATION; METABOLISM; ACTIVATION; EXPRESSION; PATHWAYS
AB Osteoporosis is a result of impaired bone formation and/or excessive bone resorption. Osteoclasts are the only cells in the body that have a bone resorption function. Inhibiting osteoclast activity and differentiation is a way to treat osteoporosis. The current pharmacological treatment for osteoporosis has many shortcomings, and more effective treatments are needed. Vinpocetine (Vinp), a derivative of the alkaloid vincamine, has been used to treat cerebrovascular disorders and cognitive impairment for a long time. Vinp inhibits mitogen activated protein kinase (MAPK) and nuclear factor kappa B (NF kappa B) dependent inflammatory responses and oxidative damage in which osteoclasts are often involved. However, the effects of Vinp on the regulation of osteoclast activity remain unknown. In this study, we found that Vinp significantly inhibited receptor activator of NF kappa B ligand (RANKL) induced osteoclast and F actin formation and decreased osteoclastic bone resorption in vitro. Vinp also suppressed the expression of osteoclast specific genes, including NFATc1, c Fos, tartrate resistant acid phosphatase (TRAP), matrix metalloproteinase 9 (MMP 9), and cathepsin K (CTSK) at both the mRNA and protein levels. Vinp reduced activation of NF kappa B, MAPK, and AKT signaling during osteoclastogenesis and prevented the production of reactive oxygen species with increased nuclear factor erythroid 2 related factor 2, heme oxygenase 1, and NAD(P)H:quinone acceptor oxidoreductase 1 expression. Animal experiments consistently demonstrated that Vinp treatment significantly attenuated ovariectomy induced bone loss with a decrease in the osteoclast number and decreases in serum levels of RANKL, TRAP, interleukin 1 beta, and tumor necrosis factor alpha, as well as increased serum levels of osteoprotegerin. Taken together, our findings reveal that Vinp may be a potential pharmacological choice for preventing and treating osteoporosis.
C1 [Zhu, Meipeng; Liu, Hui; Sun, Kai; Liu, Jian; Qi, Dahu; Zhou, Chuankun; Abudunaibi, Maihaiti; Tasiken, Bahebieergan; Li, Jianwen; Cheng, Hao; Huang, Hui] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Orthoped, Wuhan 430030, Hubei, Peoples R China.
   [Mou, Yan] Three Gorges Univ, Coll Med, Hosp Yichang 1, Inst Neural Regenerat & Repair, Yichang 443000, Hubei, Peoples R China.
   [Mou, Yan] Three Gorges Univ, Coll Med, Hosp Yichang 1, Dept Neurol, Yichang 443000, Hubei, Peoples R China.
C3 Huazhong University of Science & Technology; China Three Gorges
   University; China Three Gorges University
RP Cheng, H; Huang, H (通讯作者)，1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China.
EM chenghao@tjh.tjmu.edu.cn; hhawk2019@sina.com
RI Kai, Sun/AGH 0704 2022
FU National Natural Science Foundation of China [31800059]; National Health
   and Family Planning Commission of the People's Republic of China
   [ZX 01 C2016157]
FX This research was funded by the National Natural Science Foundation of
   China (Grant no. 31800059) and National Health and Family Planning
   Commission of the People's Republic of China (Grant no. ZX 01 C2016157)
CR Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bae S, 2017, J CLIN INVEST, V127, P2555, DOI 10.1172/JCI89935
   Bagoly E., 2007, ORV HETIL, V148
   BALESTRERI R, 1987, J AM GERIATR SOC, V35, P425, DOI 10.1111/j.1532 5415.1987.tb04664.x
   Bönöczk P, 2000, BRAIN RES BULL, V53, P245, DOI 10.1016/S0361 9230(00)00354 3
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brunetti Giacomina, 2011, Front Biosci (Elite Ed), V3, P1154
   Cai YJ, 2012, J PHARMACOL EXP THER, V343, P479, DOI 10.1124/jpet.112.195446
   Chen K, 2019, THERANOSTICS, V9, P1634, DOI 10.7150/thno.30206
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Dong YH, 2017, CELL SIGNAL, V34, P55, DOI 10.1016/j.cellsig.2017.03.004
   Fandy TE, 2016, CANCER CHEMOTH PHARM, V77, P259, DOI 10.1007/s00280 015 2924 3
   Forrester SJ, 2018, CIRC RES, V122, P877, DOI 10.1161/CIRCRESAHA.117.311401
   Goettsch C, 2013, J CLIN INVEST, V123, P4731, DOI 10.1172/JCI67603
   Jeon KI, 2010, P NATL ACAD SCI USA, V107, P9795, DOI 10.1073/pnas.0914414107
   Kim H, 2017, J BONE MINER RES, V32, P397, DOI 10.1002/jbmr.2974
   Kim NJ, 2019, EXP MOL MED, V51, DOI 10.1038/s12276 018 0198 7
   Kovalev I. V., 2003, Eksperimental'naya i Klinicheskaya Farmakologiya, V66, P25
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Li ZK, 2018, CALCIFIED TISSUE INT, V103, P324, DOI 10.1007/s00223 018 0425 1
   Lin TH, 2014, ACTA BIOMATER, V10, P1, DOI 10.1016/j.actbio.2013.09.034
   Liu RZT, 2014, EXP EYE RES, V127, P49, DOI 10.1016/j.exer.2014.07.003
   Medina AE, 2011, FRONT NEUROSCI SWITZ, V5, DOI 10.3389/fnins.2011.00021
   Michalski MN, 2017, PHARMACOL THERAPEUT, V174, P43, DOI 10.1016/j.pharmthera.2017.02.017
   Miyauchi Y, 2013, P NATL ACAD SCI USA, V110, P16568, DOI 10.1073/pnas.1308755110
   Patyar S, 2011, PHARMACOL REP, V63, P618, DOI 10.1016/S1734 1140(11)70574 6
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rothwarf D M, 1999, Sci STKE, V1999, pRE1, DOI 10.1126/stke.1999.5.re1
   Ruiz Miyazawa KW, 2015, CHEM BIOL INTERACT, V237, P9, DOI 10.1016/j.cbi.2015.05.007
   Shi J, 2015, BONE, V79, P222, DOI 10.1016/j.bone.2015.06.014
   Snezhkina AV, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/6175804
   Solanki P, 2011, FOOD CHEM TOXICOL, V49, P917, DOI 10.1016/j.fct.2010.12.015
   Song DZ, 2018, J CELL PHYSIOL, V233, P9674, DOI 10.1002/jcp.26882
   Sun YX, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929 015 0212 5
   Walsh MC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00511
   Wang HX, 2014, NEUROSCI LETT, V566, P247, DOI 10.1016/j.neulet.2014.02.045
   Wang LJ, 2018, FASEB J, V32, P875, DOI 10.1096/fj.201700672RR
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yip KHM, 2005, J BONE MINER RES, V20, P1462, DOI 10.1359/JBMR.050324
   Zhao LM, 2018, BONE, V110, P177, DOI 10.1016/j.bone.2018.01.035
   Zhuang JH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082509
NR 45
TC 24
Z9 28
U1 0
U2 7
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD MAR
PY 2020
VL 123
AR 109769
DI 10.1016/j.biopha.2019.109769
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA KF8HB
UT WOS:000509476800082
PM 31846839
OA gold
DA 2025 08 17
ER

PT J
AU Verdrengh, M
   Bokarewa, M
   Ohlsson, C
   Stolina, M
   Tarkowski, A
AF Verdrengh, Margareta
   Bokarewa, Maria
   Ohlsson, Claes
   Stolina, Marina
   Tarkowski, Andrej
TI RANKL targeted therapy inhibits bone resorption in experimental
   Staphylococcus aureus induced arthritis
SO BONE
LA English
DT Article
DE Arthritis RANKL; osteoprotegrin therapy
ID COLLAGEN INDUCED ARTHRITIS; NF KAPPA B; SEPTIC ARTHRITIS; RECEPTOR
   ACTIVATOR; CLINICAL FEATURES; JOINT INFECTIONS; MINERAL DENSITY;
   OSTEOPROTEGERIN; INFLAMMATION; LIGAND
AB Introduction: Bacterial arthritis causes rapidly progressing joint destruction ill humans. We have shown that addition of bisphosphonates or corticosteroids to conventional antimicrobial agents decreases the activity of osteoclasts, thereby reducing bone destruction. Here we assess the effect of RANKL targeted treatments using soluble receptor decoy and osteprotegerin (OPG) oil the course and Outcome of staphylococcal arthritis.
   Methods: Treatment was initiated 3 days after Staphylococcus aureus inoculation and included RANK Fc, OPG Fc, and OPG Fc in combination with antibiotics. Control groups were treated with antibiotics, huFc, and PBS. joints were evaluated for clinical signs of arthritis and histologically for bone and cartilage destruction. Bone mineral density (BMD) was evaluated using a peripheral quantitative computed tomography. Circulating markets of bone metabolism, inflammatory cytokines, and chemokines were analyzed in each group.
   Results: Mice treated with RANK Fc or OPG Fc in combination with antibiotics preserved total BMD and trabecular bone as compared to huFc or antibiotics. Treatment with RANK Fc OF OPG Fc diminished the levels of bone resorption markers (osteocalcin, CTX 1, and TRACP5b). Neither RANK Fc nor OPG Fc influenced significantly the frequency and severity of arthritis.
   Conclusions: Inhibition of RANKL signalling efficiently prevents bone loss in the mouse model of bacterial arthritis even when started in the overt phase of infection. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Verdrengh, Margareta; Bokarewa, Maria; Tarkowski, Andrej] Sahlgrens Acad, Dept Rheumatol & Inflammat Res, S 41346 Gothenburg, Sweden.
   [Ohlsson, Claes] Sahlgrens Acad, Ctr Bone Res, Gothenburg, Sweden.
   [Stolina, Marina] Amgen Inc, Dept Metab Res, Thousand Oaks, CA 91320 USA.
C3 University of Gothenburg; University of Gothenburg; Amgen
RP Bokarewa, M (通讯作者)，Sahlgrens Acad, Dept Rheumatol & Inflammat Res, Guldhedsgatan 10A, S 41346 Gothenburg, Sweden.
EM maria.bokarewa@rheuma.gu.se
RI Bokarewa, Maria/A 8114 2019; Ohlsson, Claes/HIR 6959 2022; Ohlsson,
   Claes/AGP 3544 2022
OI Ohlsson, Claes/0000 0002 9633 2805; 
FU Goteborg Medical Society; King Gustav V's 80 years' foundation;
   Sahlgrenska Foundation; Borje Dahlin Foundation; Association against
   Rheumatism; Swedish Medical Research Council; Reumaforskningsfond
   Margareta; Nanna Svartz'Foundation; Inflammation Network; Infection and
   Vaccination Network; A.M.E. Wolff Foundation; Magnus Bergwall
   Foundation; Goteborg Association against Rheumatism
FX We thank Anette Hansevi, Maud Peterson, Berit Ericsson, and Denise Dwyer
   for excellent technical assistance. This project was Support from grants
   of the Goteborg Medical Society, King Gustav V's 80 years' foundation,
   Sahlgrenska Foundation, Borje Dahlin Foundation, Association against
   Rheumatism, Swedish Medical Research Council, Reumaforskningsfond
   Margareta, Nanna Svartz'Foundation, Inflammation Network, Infection and
   Vaccination Network, A.M.E. Wolff Foundation, Magnus Bergwall
   Foundation, and Goteborg Association against Rheumatism.
CR ABDELNOUR A, 1993, INFECT IMMUN, V61, P3879, DOI 10.1128/IAI.61.9.3879 3885.1993
   Bekker PJ, 2001, J BONE MINER RES, V16, P348, DOI 10.1359/jbmr.2001.16.2.348
   BREMELL T, 1990, ARTHRITIS RHEUM US, V33, P1739, DOI 10.1002/art.1780331120
   BREMELL T, 1992, INFECT IMMUN, V60, P2976, DOI 10.1128/IAI.60.7.2976 2985.1992
   Campagnuolo G, 2002, ARTHRITIS RHEUM US, V46, P1926, DOI 10.1002/art.10369
   Davis JS, 2005, INTERN MED J, V35, pS79, DOI 10.1111/j.1444 0903.2005.00982.x
   Geirsson AJ, 2008, ANN RHEUM DIS, V67, P638, DOI 10.1136/ard.2007.077131
   Gresham HD, 2000, J IMMUNOL, V164, P3713, DOI 10.4049/jimmunol.164.7.3713
   HELLE M, 1988, EUR J IMMUNOL, V18, P1535, DOI 10.1002/eji.1830181010
   Holen I, 2006, CLIN SCI, V110, P279, DOI 10.1042/CS20050175
   Ichinose Y, 2004, CALCIFIED TISSUE INT, V75, P338, DOI 10.1007/s00223 004 0028 x
   Jin QM, 2007, J PERIODONTOL, V78, P1300, DOI 10.1902/jop.2007.070073
   Kaandorp CJE, 1997, ARTHRITIS RHEUM US, V40, P884, DOI 10.1002/art.1780400516
   Kostenuik PJ, 2005, CURR OPIN PHARMACOL, V5, P618, DOI 10.1016/j.coph.2005.06.005
   Lipsky BA, 2007, INFECT CONT HOSP EP, V28, P1290, DOI 10.1086/520743
   Mochizuki S, 2002, J BONE MINER METAB, V20, P14, DOI 10.1007/s774 002 8441 x
   Neumann T, 2006, INFLAMM RES, V55, P32, DOI 10.1007/s00011 005 0005 5
   Romas E, 2002, AM J PATHOL, V161, P1419, DOI 10.1016/S0002 9440(10)64417 3
   Saidenberg Kermanac'h N, 2004, BONE, V35, P1200, DOI 10.1016/j.bone.2004.07.004
   Sakurai A, 2003, INFECT IMMUN, V71, P6019, DOI 10.1128/IAI.71.10.6019 6026.2003
   Schett G, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2110
   Smith JW, 2006, CLIN MICROBIOL INFEC, V12, P309, DOI 10.1111/j.1469 0691.2006.01366.x
   Song KM, 2000, J EXP MED, V191, P1095, DOI 10.1084/jem.191.7.1095
   Stolina M, 2003, CLIN IMMUNOL, V109, P347, DOI 10.1016/j.clim.2003.09.001
   Verdrengh M, 2000, ARTHRITIS RHEUM, V43, P2276, DOI 10.1002/1529 0131(200010)43:10<2276::AID ANR15>3.0.CO;2 C
   Verdrengh M, 1997, INFECT IMMUN, V65, P2517, DOI 10.1128/IAI.65.7.2517 2521.1997
   Verdrengh M, 2007, J ORTHOP RES, V25, P304, DOI 10.1002/jor.20317
   Verdrengh M, 2006, J INFECT DIS, V194, P1597, DOI 10.1086/508751
   Vitovski S, 2007, J BIOL CHEM, V282, P31601, DOI 10.1074/jbc.M706078200
   Walsh NC, 2005, IMMUNOL REV, V208, P228, DOI 10.1111/j.0105 2896.2005.00338.x
   Weston VC, 1999, ANN RHEUM DIS, V58, P214, DOI 10.1136/ard.58.4.214
   Windahl SH, 1999, J CLIN INVEST, V104, P895, DOI 10.1172/JCI6730
   Zauli G, 2007, BLOOD, V110, P536, DOI 10.1182/blood 2007 01 068395
   Zhao YX, 1996, ARTHRITIS RHEUM US, V39, P959, DOI 10.1002/art.1780390613
NR 34
TC 24
Z9 25
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAR
PY 2010
VL 46
IS 3
BP 752
EP 758
DI 10.1016/j.bone.2009.10.028
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 564WJ
UT WOS:000275248600024
PM 19879986
DA 2025 08 17
ER

PT J
AU Lindsay, R
   Zhou, H
   Cosman, F
   Nieves, J
   Dempster, DW
   Hodsman, AB
AF Lindsay, Robert
   Zhou, Hua
   Cosman, Felicia
   Nieves, Jeri
   Dempster, David W.
   Hodsman, Anthony B.
TI Effects of a one month treatment with PTH(1 34) on bone formation on
   cancellous, endocortical, and periosteal surfaces of the human ilium
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE teriparatide; bone formation; bone histomorphometry; anabolic; apoptosis
ID PARATHYROID HORMONE 1 34; POSTMENOPAUSAL WOMEN; CORTICAL BONE;
   MECHANICAL PROPERTIES; OSTEOBLAST APOPTOSIS; THERAPY; MASS; CALCITONIN;
   TURNOVER; POROSITY
AB Introduction: The precise mechanisms by which hPTH(1 34) increases bone mass and improves bone structure are unclear. Using bone histomorphometry, we studied the early effects of treating postmenopausal women with osteoporosis with hPTH(1 34).
   Materials and Methods: Tetracycline labeled iliac crest bone biopsies were obtained from 27 postmenopausal women with osteoporosis who were treated for I month with hPTH(1 34), 50 mu g daily subcutaneously. The results were compared with tetracycline labeled biopsies from a representative control group of 13 postmenopausal women with osteoporosis.
   Results: The bone formation rate on the cancellous and endocortical surfaces was higher in hPTH(1 34)treated women than in control women by factors of 4.5 and 5.0, respectively. We also showed a 4 fold increase in bone formation rate on the periosteal surface, suggesting that hPTH(1 34) has the potential to increase bone diameter in humans. On the cancellous and endocortical surfaces, the increased bone formation rate was primarily caused by stimulation of formation in ongoing remodeling units, with a modest amount of increased formation on previously quiescent surfaces. hPTH(1 34) stimulated bone formation was associated with an increase in osteoblast apoptosis, which may reflect enhanced turnover of the osteoblast population and may contribute to the anabolic action of hPTH(1 34).
   Conclusions: These findings provide new insight into the cellular basis by which hPTH(1 34) improves cancellous and cortical bone architecture and geometry in patients with osteoporosis.
C1 Helen Hayes Hosp, Clin Res Ctr, W Haverstraw, NY 10993 USA.
   Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY USA.
   Helen Hayes Hosp, Reg Bone Ctr, W Haverstraw, NY 10993 USA.
   Columbia Univ, Coll Phys & Surg, Dept Epidemiol, New York, NY USA.
   Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY USA.
   Univ Western Ontario, St Josephs Hlth Care, London, ON, Canada.
C3 Columbia University; Columbia University; Columbia University; Western
   University (University of Western Ontario); University Western Ontario
   Hospital
RP Lindsay, R (通讯作者)，Helen Hayes Hosp, Clin Res Ctr, Route 9W, W Haverstraw, NY 10993 USA.
EM lindsayr@helenhayeshosp.org
RI Hodsman, Anthony/G 3303 2011
OI Nieves, Jeri/0000 0001 8593 343X
FU NIAMS NIH HHS [AR051454] Funding Source: Medline
CR Beck TJ, 2000, J BONE MINER RES, V15, P2297, DOI 10.1359/jbmr.2000.15.12.2297
   Burr DB, 2001, J BONE MINER RES, V16, P157, DOI 10.1359/jbmr.2001.16.1.157
   Chen HL, 2002, J BIOL CHEM, V277, P19374, DOI 10.1074/jbc.M108913200
   Cosman F, 2001, J BONE MINER RES, V16, P925, DOI 10.1359/jbmr.2001.16.5.925
   Dempster DW, 2001, J BONE MINER RES, V16, P1846, DOI 10.1359/jbmr.2001.16.10.1846
   DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632
   FROST HM, 1992, J LONG TERM EFF MED, V2, P9
   Frost HM., 1995, INTRO NEW SKELETAL P, VI
   Hirano T, 2000, CALCIFIED TISSUE INT, V66, P456, DOI 10.1007/s002230010091
   Hirano T, 1999, J BONE MINER RES, V14, P536, DOI 10.1359/jbmr.1999.14.4.536
   Hock JM, 2001, J BONE MINER RES, V16, P975, DOI 10.1359/jbmr.2001.16.6.975
   Hodsman AB, 1997, J CLIN ENDOCR METAB, V82, P620, DOI 10.1210/jc.82.2.620
   HODSMAN AB, 1991, BONE MINER, V14, P67, DOI 10.1016/0169 6009(91)90103 7
   HODSMAN AB, 1993, J CLIN INVEST, V91, P1138, DOI 10.1172/JCI116273
   Hodsman AB, 2000, BONE, V27, P311, DOI 10.1016/S8756 3282(00)00316 1
   Jerome CP, 1999, BONE, V25, P301, DOI 10.1016/S8756 3282(99)00166 0
   Jiang YB, 2003, J BONE MINER RES, V18, P1932, DOI 10.1359/jbmr.2003.18.11.1932
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Kobayashi S, 2003, BONE, V32, P163, DOI 10.1016/S8756 3282(02)00947 X
   Lindsay R, 2006, J BONE MINER RES, V21, P366, DOI 10.1359/JBMR.051109
   Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140 6736(97)02342 8
   Ma YFL, 2006, J BONE MINER RES, V21, P855, DOI 10.1359/JBMR.060314
   Mashiba T, 2001, BONE, V28, P538, DOI 10.1016/S8756 3282(01)00433 1
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Stanislaus D, 2000, BONE, V27, P209, DOI 10.1016/S8756 3282(00)00309 4
   Takahashi H., 1964, Henry Ford Hosp Med Bull, V12, P359
   Uusi Rasi K, 2005, BONE, V36, P948, DOI 10.1016/j.bone.2005.03.003
   Zanchetta JR, 2003, J BONE MINER RES, V18, P539, DOI 10.1359/jbmr.2003.18.3.539
NR 28
TC 195
Z9 206
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD APR
PY 2007
VL 22
IS 4
BP 495
EP 502
DI 10.1359/JBMR.070104
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 150RK
UT WOS:000245234000002
PM 17227219
OA Bronze
DA 2025 08 17
ER

PT J
AU Wu, TL
   Guan, B
   Luo, JZ
   Li, L
   Zhang, BB
   Yang, ZL
   Tan, L
   Tao, HR
AF Wu, Tailin
   Guan, Bin
   Luo, Jianzhou
   Li, Lin
   Zhang, Bobo
   Yang, Zili
   Tan, Lei
   Tao, Huiren
TI In silicon desinging of RANKL targeting vaccine for protection of
   osteoporosis based on the epitope of Denosumab
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
ID B CELL; POSTMENOPAUSAL WOMEN; PREDICTION; WEB; RECOGNITION; FRACTURES;
   THERAPY; SERVER; ACID; TOLL
AB Background: Life quality of osteoporosis patients is affected significantly due to the severely complications of fracture and pain. RANKL, indicated as the key mediator of osteoporosis, plays a pathogenic role of osteoclasts induction. To target this program, two medications, bisphosphonate and Denosumab, were developed and achieved remarkable advantages in clinics. Unfortunately, fracture related side effects always emerge unavoidably, after either long term administration of bisphosphonates or Denosumab withdrawing. To address these challenges, vaccine based approach has been adopted to achieve sustainable protection through induction and maintenance of effective antibodies in mild level over decades. Methods: A Denosumab binding peptide was firstly identified as the basic component of vaccine. This peptide was then fused with diphtheria toxin T domain, a widely used adjuvant protein. Its capabilities to penetrate the autologous tolerance and induce the immune responses was then demonstrated with in silicon evaluation. Finally, the efficacy of the DR3 vaccine was assessed through immunization on the human RANKL transgenic mice model of osteoporosis. Results: The DTT RANKL (220 245)3 vaccine, termed as DR3, were predicted as highly antigenic and non allergenicity. This molecule was comprised of 46.5 % of helix, 8.5 % strand and 45.1 % coil, the optimized Z value of the tertiary structure was 6.39, and the favored area in the Ramachandran plot was 96.1 % after refinement. Molecular docking showed a tight binding of DR3 vaccine to TLR2 ( 9.2 kcal/mol) and TLR4 ( 9.5 kcal/mol). In addition, the immune stimulation indicated robust responses post administration of DR3 vaccine, including high level production of of antibodies and cytokines, activated T and B lymphocytes, and the long last immune memory. In agree with the simulation, vaccinated mice generated high titers anti hRANKL antibodies and elevated levels of IL 4 and IL 10 at 7th week post immunization. Conclusion: DR3 vaccine was aroused to benefit the prevention and treatment of osteoporosis, and other bone resorptive diseases potentially.
C1 [Wu, Tailin] Xi An Jiao Tong Univ, Sch Life Sci & Technol, Key Lab Biomed Informat Engn, Minist Educ, Xian 710049, Shaanxi, Peoples R China.
   [Wu, Tailin; Li, Lin; Tao, Huiren] Univ Hong Kong, Shenzhen Hosp, Orthopaed Ctr, Shenzhen 518000, Guangdong, Peoples R China.
   [Guan, Bin] Hlth Serv Ctr Weifang Community, Prevent Hlth Care Sect, Shanghai 200122, Peoples R China.
   [Luo, Jianzhou; Yang, Zili] Shenzhen Univ, Hlth Sci Ctr, Shenzhen 518000, Guangdong, Peoples R China.
   [Zhang, Bobo] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Orthopaed, Xian 710061, Shaanxi, Peoples R China.
   [Tan, Lei] Nanjing Med Univ, State Key Lab Reprod Med & Offspring Hlth, Nanjing 211166, Peoples R China.
   [Tan, Lei] Nanjing Med Univ, Innovat Ctr Suzhou, Suzhou 215000, Jiangsu, Peoples R China.
   [Tan, Lei] Natl Ctr Technol Innovat Biopharmaceut, Suzhou 215000, Jiangsu, Peoples R China.
   [Tan, Lei] Chinese Acad Sci, Inst Biomed & Biotechnol, Shenzhen Inst Adv Technol, Ctr Energy Metab & Reprod, Shenzhen 518000, Guangdong, Peoples R China.
C3 Xi'an Jiaotong University; University of Hong Kong; Shenzhen University;
   Xi'an Jiaotong University; Nanjing Medical University; Nanjing Medical
   University; Chinese Academy of Sciences; Shenzhen Institute of Advanced
   Technology, CAS
RP Tao, HR (通讯作者)，Univ Hong Kong, Shenzhen Hosp, Orthopaed Ctr, Shenzhen 518000, Guangdong, Peoples R China.; Tan, L (通讯作者)，Nanjing Med Univ, State Key Lab Reprod Med & Offspring Hlth, Nanjing 211166, Peoples R China.
EM lei.tan@siat.ac.cn; taohr@hku.hk
RI Luo, Jianzhou/KUD 6392 2024; Wu, Tailin/AAH 6178 2019
FU National Natural Science Foundation of China [81970761]; Shenzhen
   Nanshan Technology Research Develop ment and Creative Design Project
   [NS2023129]; Shenzhen Key Medical Discipline Construction Fund
   [SZXK2020084]; Sanming Project of Medicine in Shenzhen, China
   [SZSM202211004]
FX This study was funded by National Natural Science Foundation of China
   (81970761) , Shenzhen Nanshan Technology Research Develop ment and
   Creative Design Project (NS2023129) , Shenzhen Key Medical Discipline
   Construction Fund (No. SZXK2020084) , Sanming Project of Medicine in
   Shenzhen, China (No. SZSM202211004) .
CR Andongma BT, 2023, COMPUT STRUCT BIOTEC, V21, P991, DOI 10.1016/j.csbj.2023.01.019
   Bahadori Z, 2024, INT J BIOL MACROMOL, V258, DOI 10.1016/j.ijbiomac.2023.128924
   Bar Shavit Z, 2008, AUTOIMMUNITY, V41, P195, DOI 10.1080/08916930701694469
   Bone HG, 2017, LANCET DIABETES ENDO, V5, P513, DOI 10.1016/S2213 8587(17)30138 9
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Chang CY, 2016, OSTEOPOROSIS INT, V27, P665, DOI 10.1007/s00198 015 3238 3
   Chang LL, 2022, NEW ENGL J MED, V386, P1467, DOI 10.1056/NEJMclde2115900
   Chen X, 2013, HYPERTENSION, V61, P408, DOI 10.1161/HYPERTENSIONAHA.112.201020
   Cheng C, 2018, CELL PHYSIOL BIOCHEM, V46, P46, DOI 10.1159/000488408
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Dimitrov I, 2014, J MOL MODEL, V20, DOI 10.1007/s00894 014 2278 5
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471 2105 8 4
   Ensrud Kristine E, 2021, JAMA, V325, P96, DOI 10.1001/jama.2020.2923
   Feng T, 2017, J CHEMINFORMATICS, V9, DOI 10.1186/s13321 017 0254 7
   Ferrari S, 2023, NAT REV RHEUMATOL, V19, P307, DOI 10.1038/s41584 023 00935 3
   Fok JA, 2020, CHEMBIOCHEM, V21, P3291, DOI 10.1002/cbic.202000343
   Gasteiger E., 2005, The proteomics protocols handbook, P571, DOI [DOI 10.1385/1 59259 890 0:571, 10.1385/1 59259 584 7:531]
   Gonzalez Rodriguez E, 2020, J CLIN ONCOL, V38, P1641, DOI 10.1200/JCO.19.02678
   Gruenewald J, 2008, P NATL ACAD SCI USA, V105, P11276, DOI 10.1073/pnas.0804157105
   Grünewald J, 2009, P NATL ACAD SCI USA, V106, P4337, DOI 10.1073/pnas.0900507106
   Händel MN, 2023, BMJ BRIT MED J, V381, DOI 10.1136/bmj 2021 068033
   Hebditch M, 2017, BIOINFORMATICS, V33, P3098, DOI [10.1093/bioinformatics/btx345, 10.1093/BIOINFORMATICS/BTX345]
   Jespersen MC, 2017, NUCLEIC ACIDS RES, V45, pW24, DOI 10.1093/nar/gkx346
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863
   Kessel C, 2014, ARTHRITIS RHEUMATOL, V66, P610, DOI 10.1002/art.38237
   Ko J, 2012, NUCLEIC ACIDS RES, V40, pW294, DOI 10.1093/nar/gks493
   Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022
   Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148
   Laskowski RA, 2018, PROTEIN SCI, V27, P129, DOI 10.1002/pro.3289
   Li F, 2018, BIOCHEM BIOPH RES CO, V499, P648, DOI 10.1016/j.bbrc.2018.03.205
   Li MC, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392 022 00996 y
   Lin MJ, 2022, NAT CANCER, V3, P911, DOI 10.1038/s43018 022 00418 6
   Luan XD, 2012, J IMMUNOL, V189, P245, DOI 10.4049/jimmunol.1103387
   Lyu HC, 2023, BMJ BRIT MED J, V381, DOI 10.1136/bmj 2022 073435
   Magnan CN, 2010, BIOINFORMATICS, V26, P2936, DOI 10.1093/bioinformatics/btq551
   Magnan CN, 2009, BIOINFORMATICS, V25, P2200, DOI 10.1093/bioinformatics/btp386
   McDonald MM, 2021, CELL, V184, P1330, DOI 10.1016/j.cell.2021.02.002
   Mirdita M, 2022, NAT METHODS, V19, P679, DOI 10.1038/s41592 022 01488 1
   Mitka M, 2007, JAMA J AM MED ASSOC, V298, P2854, DOI 10.1001/jama.298.24.2854
   Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471 2105 9 514
   López Blanco JR, 2014, NUCLEIC ACIDS RES, V42, pW271, DOI 10.1093/nar/gku339
   Rapin N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009862
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Reynisson B, 2020, NUCLEIC ACIDS RES, V48, pW449, DOI 10.1093/nar/gkaa379
   Reynisson B, 2020, J PROTEOME RES, V19, P2304, DOI 10.1021/acs.jproteome.9b00874
   Saha S, 2006, PROTEINS, V65, P40, DOI 10.1002/prot.21078
   Samad A, 2022, J BIOMOL STRUCT DYN, V40, P14, DOI 10.1080/07391102.2020.1792347
   Solling AS, 2023, CURR OSTEOPOROS REP, V21, P95, DOI 10.1007/s11914 022 00771 6
   Walker MD, 2023, NEW ENGL J MED, V389, P1979, DOI 10.1056/NEJMcp2307353
   Wan YH, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01326
   Wherrett DK, 2011, LANCET, V378, P319, DOI 10.1016/S0140 6736(11)60895 7
   Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290
   Williams CJ, 2018, PROTEIN SCI, V27, P293, DOI 10.1002/pro.3330
   Wu TL, 2018, INT IMMUNOPHARMACOL, V64, P326, DOI 10.1016/j.intimp.2018.09.022
   Xu AZ, 2017, CANCER IMMUNOL IMMUN, V66, P181, DOI 10.1007/s00262 016 1928 0
   Xue LC, 2016, BIOINFORMATICS, V32, P3676, DOI 10.1093/bioinformatics/btw514
   Zhang L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163080
   Zhang Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02472
   Zhong C, 2017, J THROMB HAEMOST, V15, P122, DOI 10.1111/jth.13561
NR 60
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD JAN 10
PY 2025
VL 144
AR 113610
DI 10.1016/j.intimp.2024.113610
EA NOV 2024
PG 15
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA N5N9B
UT WOS:001364815300001
PM 39580862
OA hybrid
DA 2025 08 17
ER

PT J
AU Qin, YH
   Tang, SB
   Zhen, GH
   Ding, Q
   Ding, S
   Cao, X
AF Qin, Yunhao
   Tang, Shibing
   Zhen, Gehua
   Ding, Qiang
   Ding, Sheng
   Cao, Xu
TI Bone targeted delivery of TGF β type 1 receptor inhibitor rescues
   uncoupled bone remodeling in Camurati Engelmann disease
SO ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
LA English
DT Article
DE Camurati Engelmann disease; TGF beta 1 signaling; bone remodeling
ID GROWTH FACTOR BETA; MESENCHYMAL STROMAL CELLS; OSTEOGENESIS; MUTATIONS
AB Camurati Engelmann disease (CED) is a genetic bone modeling disorder mainly caused by mutations in the gene that encodes transforming growth factor beta 1 (TGF beta 1). Symptoms of CED include bone pain, fractures, and dysplasia. Currently, effective therapies for bone fracture and dysplasia in CED are urgently needed. We have demonstrated that TGF beta 1 is a coupling factor for bone remodeling and is aberrantly activated in CED. Daily injection of TGF beta type 1 receptor inhibitor (T beta R1I) attenuated CED symptoms, but this systemic administration caused serious side effects. In this study, we created a conjugate linking T beta R1I and alendronate, which delivered T beta R1I specifically to bone. After weekly injection of the conjugate for 8 weeks, normal bone morphology and remodeling in CED mice was maintained with a minimum effective dose 700 times lower than T beta R1I injection. Additionally, we found that the conjugate restored normal bone turnover by reducing the number of osteoblasts and osteoclasts, maintained a regular osteogenic microenvironment by regulating the formation of CD31 and Endomucin double positive vessels, and preserved ordinary bone formation via inhibition of the migration of leptin receptor positive cells. Thus, targeting delivery of T beta R1I to bone is a promising therapy for CED and other uncoupled bone remodeling disorders.
C1 [Qin, Yunhao; Zhen, Gehua; Cao, Xu] Johns Hopkins Univ, Sch Med, Dept Orthopaed Surg, 720 Rutland Ave,Ross Bldg, Baltimore, MD 21205 USA.
   [Qin, Yunhao] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Shanghai, Peoples R China.
   [Tang, Shibing; Ding, Sheng] Univ Calif San Francisco, Dept Pharmaceut Chem, Gladstone Inst Cardiovasc Dis, 1650 Owens St, San Francisco, CA 94158 USA.
   [Tang, Shibing] Guangzhou Inst Biomed & Hlth, Drug Discovery Pipeline, Guangzhou, Guangdong, Peoples R China.
   [Ding, Qiang] Othro Therapeut Co Ltd, Guangzhou, Guangdong, Peoples R China.
C3 Johns Hopkins University; Shanghai Jiao Tong University; University of
   California System; University of California San Francisco; The J David
   Gladstone Institutes; Chinese Academy of Sciences; Guangzhou Institute
   of Biomedicine & Health, CAS
RP Cao, X (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Orthopaed Surg, 720 Rutland Ave,Ross Bldg, Baltimore, MD 21205 USA.; Ding, S (通讯作者)，Univ Calif San Francisco, Dept Pharmaceut Chem, Gladstone Inst Cardiovasc Dis, 1650 Owens St, San Francisco, CA 94158 USA.
EM sheng.ding@gladstone.ucsf.edu; xcao11@jhmi.edu
RI Tang, Shibing/G 1602 2016
FU US National Institutes of Health [AR 063943]; CIRM; National Heart,
   Lung, and Blood Institute; National Institutes of Health; Roddenberry
   Foundation; Gladstone Institutes; China Scholarship Council
   [201506230085]
FX We thank Min Xie for suggestions and discussions. We thank Crystal
   Herron for critical reading and editing of this manuscript. This
   research was supported by US National Institutes of Health grant AR
   063943 (to X.C.). S.D. was supported by the CIRM; the National Heart,
   Lung, and Blood Institute; the National Institutes of Health; the
   Roddenberry Foundation; and the Gladstone Institutes. Y.Q. was supported
   by the China Scholarship Council (201506230085).
CR Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254
   Borbas KE, 2006, BIOCONJUGATE CHEM, V17, P638, DOI 10.1021/bc050337w
   Crane JL, 2016, METHODS MOL BIOL, V1344, P287, DOI 10.1007/978 1 4939 2966 5_18
   Ghosh AK, 2015, J MED CHEM, V58, P2895, DOI 10.1021/jm501371s
   Herbertz S, 2015, DRUG DES DEV THER, V9, P4479, DOI 10.2147/DDDT.S86621
   Hirayama T, 2002, J ENDOCRINOL, V175, P155, DOI 10.1677/joe.0.1750155
   Iba K, 2008, J BONE MINER METAB, V26, P107, DOI 10.1007/s00774 007 0783 7
   Janssens K, 2000, NAT GENET, V26, P273, DOI 10.1038/81563
   Janssens K, 2006, J MED GENET, V43, P1, DOI 10.1136/jmg.2005.033522
   Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004 0001
   Kinoshita A, 2000, NAT GENET, V26, P19, DOI 10.1038/79128
   Kusumbe AP, 2015, NAT PROTOC, V10, P1904, DOI 10.1038/nprot.2015.125
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Li HY, 2008, J MED CHEM, V51, P2302, DOI 10.1021/jm701199p
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Porras AG, 1999, CLIN PHARMACOKINET, V36, P315, DOI 10.2165/00003088 199936050 00002
   Ramasamy SK, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13601
   Szweras M, 2002, J BIOL CHEM, V277, P19991, DOI 10.1074/jbc.M112234200
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0
   Yue R, 2016, CELL STEM CELL, V18, P782, DOI 10.1016/j.stem.2016.02.015
   Zhou BO, 2014, CELL STEM CELL, V15, P154, DOI 10.1016/j.stem.2014.06.008
   Zhou L, 2011, CANCER RES, V71, P955, DOI 10.1158/0008 5472.CAN 10 2933
NR 23
TC 18
Z9 19
U1 1
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0077 8923
EI 1749 6632
J9 ANN NY ACAD SCI
JI Ann. N.Y. Acad. Sci.
PD DEC
PY 2018
VL 1433
IS 1
SI SI
BP 29
EP 40
DI 10.1111/nyas.13941
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA HC5EK
UT WOS:000451826100005
PM 30091466
DA 2025 08 17
ER

PT J
AU Xu, XW
   Sun, ML
   Wang, DD
   Bu, WH
   Wang, ZL
   Shen, YQ
   Zhang, K
   Zhou, D
   Yang, B
   Sun, HC
AF Xu, Xiaowei
   Sun, Maolei
   Wang, Dandan
   Bu, Wenhuan
   Wang, Zilin
   Shen, Yuqin
   Zhang, Kai
   Zhou, Ding
   Yang, Bai
   Sun, Hongchen
TI Bone formation promoted by bone morphogenetic protein 2 plasmid loaded
   porous silica nanoparticles with the involvement of autophagy
SO NANOSCALE
LA English
DT Article
ID GENE THERAPY; OSTEOBLAST DIFFERENTIATION; INDUCE AUTOPHAGY; DELIVERY;
   EXPRESSION; STIMULATION; OSTEOCLASTS; INHIBITION; VECTORS; CELLS
AB Gene therapy is one of the most common and effective ways for the regeneration of defective bone tissue, but even highly efficient gene delivery vectors are insufficient. In this study, bone morphogenetic protein 2 plasmid (pBMP 2) was encapsulated by polyethylenimine modified porous silica nanoparticles (PPSNs), which were synthesized via an ethyl ether emulsion method. Owing to the high specific surface area and high absorption characteristics, low cytotoxicy PPSNs can efficiently load and protect pBMP 2. The resulting PPSN/pBMP 2 can transfect MC3T3 E1 cells effectively to promote osteogenic differentiation and increase calcium deposition in vitro. Interestingly, the mass of calcium deposition nodules decreased dur to the presence of an autophagy inhibitor, demonstrating that PPSNs stimulated the autophagy pathway. Because of their excellent biocompatibility, high transfection efficiency, and ability to stimulate autophagy, the as prepared PPSN/pBMP 2 could efficiently transfect local cells in a defect area in vivo. Micro computed tomography and histological images demonstrated that PPSN/pBMP 2 could efficiently promote new bone formation in a 5 mm sized rat calvarial defect model. Taken together, our newly synthesized PPSNs could efficiently carry pBMP 2 and deliver it to the target cells as well as stimulating the autophagy pathway, resulting in significant osteogenic differentiation and bone regeneration.
C1 [Xu, Xiaowei; Sun, Maolei; Wang, Dandan; Bu, Wenhuan; Wang, Zilin; Shen, Yuqin] Jilin Univ, Sch & Hosp Stomatol, Changchun 130021, Jilin, Peoples R China.
   [Zhang, Kai; Yang, Bai] Jilin Univ, AState Key Lab Supramol Struct & Mat, Coll Chem, Changchun 130012, Jilin, Peoples R China.
   [Zhou, Ding] Chinese Acad Sci, State Key Lab Luminescence & Applicat, Changchun Inst Opt Fine Mech & Phys, Changchun 130033, Jilin, Peoples R China.
   [Sun, Hongchen] China Med Univ, Sch & Hosp Stomatol, Shenyang 110122, Liaoning, Peoples R China.
C3 Jilin University; Jilin University; Chinese Academy of Sciences;
   Changchun Institute of Optics, Fine Mechanics & Physics, CAS; China
   Medical University
RP Xu, XW (通讯作者)，Jilin Univ, Sch & Hosp Stomatol, Changchun 130021, Jilin, Peoples R China.; Zhou, D (通讯作者)，Chinese Acad Sci, State Key Lab Luminescence & Applicat, Changchun Inst Opt Fine Mech & Phys, Changchun 130033, Jilin, Peoples R China.; Sun, HC (通讯作者)，China Med Univ, Sch & Hosp Stomatol, Shenyang 110122, Liaoning, Peoples R China.
EM xiaoweixu@jlu.edu.cn; zhouding@ciomp.ac.cn; sunhongchen@cmu.edu.cn
RI Bu, Wenhuan/MTG 2079 2025; Wang, Zilin/HTT 2378 2023; Sun,
   Hongchen/X 7152 2019; Zhang, Kai/AAX 4721 2020; Xu, Xiaowei/I 6687 2018;
   Wang, Dandan/AEC 1897 2022; Bu, Wenhuan/MTG 3392 2025
OI Bu, Wenhuan/0000 0003 1760 1606; Wang, Zilin/0000 0002 9598 3331; 
FU National Key Research and Development Program of China [2016YFC1102800];
   Natural Science Foundation of China [81970946, 81600879, 81600890];
   Young Elite Scientist Sponsorship Program by CAST [2018QNRC001]; China
   Postdoctoral Science Foundation [2018T110259, 2016M601386]; Jilin
   Province Education Department Science and Technology Research
   [JJKH20190106KJ]; Jilin Province Science and Technology Research
   [20190103088JH]; JLU Science and Technology Innovative Research Team
   [2017TD 11]
FX This work was supported by grants from the National Key Research and
   Development Program of China 2016YFC1102800, the Natural Science
   Foundation of China (81970946, 81600879 and 81600890), Young Elite
   Scientist Sponsorship Program by CAST (2018QNRC001), China Postdoctoral
   Science Foundation (2018T110259 and 2016M601386), Jilin Province
   Education Department Science and Technology Research (JJKH20190106KJ),
   Jilin Province Science and Technology Research (20190103088JH), and JLU
   Science and Technology Innovative Research Team (2017TD 11).
CR Alderuccio F, 2009, TRENDS MOL MED, V15, P344, DOI 10.1016/j.molmed.2009.06.002
   Beck GR, 2012, NANOMED NANOTECHNOL, V8, P793, DOI 10.1016/j.nano.2011.11.003
   Betz VM, 2008, FRONT BIOSCI LANDMRK, V13, DOI 10.2741/2724
   Booth C, 2016, TRENDS MOL MED, V22, P317, DOI 10.1016/j.molmed.2016.02.002
   Buckland KF, 2014, ADV DRUG DELIVER REV, V73, P162, DOI 10.1016/j.addr.2014.02.010
   Chen FM, 2016, PROG POLYM SCI, V53, P86, DOI 10.1016/j.progpolymsci.2015.02.004
   Cottrell JA, 2014, J APPL BIOMED, V12, P127, DOI 10.1016/j.jab.2014.02.003
   Dou C, 2018, ADV SCI, V5, DOI 10.1002/advs.201700578
   Du X, 2013, ADV MATER, V25, P5981, DOI 10.1002/adma.201302189
   El Aneed A, 2004, J CONTROL RELEASE, V94, P1, DOI 10.1016/j.jconrel.2003.09.013
   Fu XK, 2018, ADV SCI, V5, DOI 10.1002/advs.201700755
   Gao JQ, 2010, INT J PHARMACEUT, V387, P286, DOI 10.1016/j.ijpharm.2009.12.033
   Garimella R, 2008, J HISTOCHEM CYTOCHEM, V56, P569, DOI 10.1369/jhc.2008.950394
   Ha SW, 2014, ACS NANO, V8, P5898, DOI 10.1021/nn5009879
   Hassan MH, 2009, ADV DRUG DELIVER REV, V61, P822, DOI 10.1016/j.addr.2009.04.023
   Hocking LJ, 2012, J BONE MINER RES, V27, P1439, DOI 10.1002/jbmr.1668
   Jin H, 2014, INT J NANOMED, V9, P2179, DOI 10.2147/IJN.S60937
   Kaluderovic MR, 2014, CELLS TISSUES ORGANS, V200, P265, DOI 10.1159/000434625
   Klionsky DJ, 2010, AUTOPHAGY, V6, P438, DOI 10.4161/auto.6.4.12244
   Li JJ, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201701061
   Liu F, 2013, J BONE MINER RES, V28, P2414, DOI 10.1002/jbmr.1971
   MacLaren RE, 2014, LANCET, V383, P1129, DOI 10.1016/S0140 6736(13)62117 0
   Manshian BB, 2014, BIOMATERIALS, V35, P9941, DOI 10.1016/j.biomaterials.2014.08.031
   Metavarayuth K, 2015, ADV SCI, V2, DOI 10.1002/advs.201500026
   Mirzaei HR, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01850
   Neuberg P, 2014, ADV GENET, V88, P263, DOI 10.1016/B978 0 12 800148 6.00009 2
   Nollet M, 2014, AUTOPHAGY, V10, P1965, DOI 10.4161/auto.36182
   O'Connor DM, 2015, TRENDS MOL MED, V21, P504, DOI 10.1016/j.molmed.2015.06.001
   O'Keefe RJ, 2011, TISSUE ENG PART B RE, V17, P389, DOI [10.1089/ten.teb.2011.0475, 10.1089/ten.TEB.2011.0475]
   Oryan A, 2014, BIOFACTORS, V40, P459, DOI 10.1002/biof.1177
   Park K, 2017, J CONTROL RELEASE, V254, P137, DOI 10.1016/j.jconrel.2017.05.002
   Pelaz B, 2015, ACS NANO, V9, P6996, DOI 10.1021/acsnano.5b01326
   Radu DR, 2004, J AM CHEM SOC, V126, P13216, DOI 10.1021/ja046275m
   Ramamoorth M, 2015, J CLIN DIAGN RES, V9, pGE1, DOI 10.7860/JCDR/2015/10443.5394
   Roohani Esfahani SI, 2017, NANOMEDICINE UK, V12, P419, DOI 10.2217/nnm 2016 0423
   Roy I, 2005, P NATL ACAD SCI USA, V102, P279, DOI 10.1073/pnas.0408039101
   Scarfì S, 2016, WORLD J STEM CELLS, V8, P1, DOI 10.4252/wjsc.v8.i1.1
   Sharma A, 2012, BONE JOINT RES, V1, P145, DOI 10.1302/2046 3758.17.2000082
   Sheyn D, 2008, GENE THER, V15, P257, DOI 10.1038/sj.gt.3303070
   Slowing II, 2008, ADV DRUG DELIVER REV, V60, P1278, DOI 10.1016/j.addr.2008.03.012
   Soenen SJ, 2015, CHEM REV, V115, P2109, DOI 10.1021/cr400714j
   Stern ST, 2008, TOXICOL SCI, V106, P140, DOI 10.1093/toxsci/kfn137
   Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916
   Voicu SNP, 2015, INT J MOL SCI, V16, P29398, DOI 10.3390/ijms161226171
   Wang HY, 2015, ADV DRUG DELIVER REV, V81, P142, DOI 10.1016/j.addr.2014.10.031
   Wang J, 2017, INT J NANOMED, V12, P809, DOI 10.2147/IJN.S123596
   Wang Y, 2015, ADV MATER, V27, P2627, DOI 10.1002/adma.201405926
   Yin H, 2014, NAT REV GENET, V15, P541, DOI 10.1038/nrg3763
   Yu YB, 2014, J HAZARD MATER, V270, P176, DOI 10.1016/j.jhazmat.2014.01.028
   Zhao SC, 2015, ACTA BIOMATER, V12, P270, DOI 10.1016/j.actbio.2014.10.015
NR 50
TC 18
Z9 18
U1 3
U2 96
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2040 3364
EI 2040 3372
J9 NANOSCALE
JI Nanoscale
PD DEC 7
PY 2019
VL 11
IS 45
BP 21953
EP 21963
DI 10.1039/c9nr07017f
PG 11
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA JT1SU
UT WOS:000500778500027
PM 31709429
DA 2025 08 17
ER

PT J
AU Kim, HJ
   Park, C
   Kim, GY
   Park, EK
   Jeon, YJ
   Kim, S
   Hwang, HJ
   Choi, YH
AF Kim, Hong Jae
   Park, Cheol
   Kim, Gi Young
   Park, Eui Kyun
   Jeon, You Jin
   Kim, Suhkmann
   Hwang, Hye Jin
   Choi, Yung Hyun
TI Sargassum serratifolium attenuates RANKL induced osteoclast
   differentiation and oxidative stress through inhibition of NF κB and
   activation of the Nrf2/HO 1 signaling pathway
SO BIOSCIENCE TRENDS
LA English
DT Article
DE Sargassum serratifolium; osteoclasts; RANKL; NF kappa B; Nrf2/HO 1
ID SULFATED POLYSACCHARIDE; ESTROGEN DEFICIENCY; RAW264.7 CELLS;
   EXPRESSION; OSTEOPOROSIS; MECHANISMS; MAPKS
AB Sargassum serratifolium C. Agardh is a marine brown alga that has long been used as an ingredient for food and medicine by many people living along Asian coastlines. Recently, various beneficial effects of extracts or compounds isolated from S. serratifolium have been reported, but their efficacies against bone destruction are unclear. Therefore, in this study, we investigated the inhibitory property of an ethanol extract of S. serratifolium (EESS) on osteoclast differentiation by focusing on the receptor activator of nuclear factor kappa B ligand (RANKL) stimulated osteoclastogenesis model using RAW 264.7 macrophages. Our results demonstrated that EESS reduced RANKL induced osteoclast differentiation in RAW 264.7 cells, by inhibiting tartrate resistant acid phosphatase (TRAP) activity and destroying the F actin ring formation. EESS also attenuated RANKL induced expressions of key osteoclast specific genes, such as nuclear factor of activated T cells cytoplasmic 1 (NFATC1), TRAP, cathepsin K and matrix metalloproteinase 9. These effects were mediated by impaired nuclear translocation of nuclear factor (NF) kappa B and suppression of I kappa B alpha degradation. In addition, EESS effectively inhibited the production of reactive oxygen species (ROS) by RANKL. which was associated with enhanced expression of nuclear translocation of nuclear factor erythroid 2 related factor 2 (Nrf2) and home oxygenase 1 (HO 1). Overall, our findings provide evidence that EESS suppresses RANKL induced osteoclastogenesis and oxidative stress through suppression of NF kappa B and activation of Nrf2/HO 1 signaling pathway, indicating that S. serratifolium has a potential application the prevention and treatment of osteoclastogenic bone disease.
C1 [Kim, Hong Jae; Choi, Yung Hyun] Dong Eui Univ, Antiaging Res Ctr, Busan, South Korea.
   [Park, Cheol] Dong Eui Univ, Dept Mol Biol, Coll Nat Sci, Busan, South Korea.
   [Kim, Gi Young; Jeon, You Jin] Jeju Natl Univ, Dept Marine Life Sci, Jeju, South Korea.
   [Park, Eui Kyun] Kyungpook Natl Univ, Inst Hard Tissue & Biotooth Regenerat, Sch Dent, Dept Oral Pathol & Regenerat Med, Daegu, South Korea.
   [Kim, Suhkmann] Pusan Natl Univ, Dept Chem, Coll Nat Sci, Ctr Proteome Biophys, Busan, South Korea.
   [Kim, Suhkmann] Pusan Natl Univ, Chem Inst Funct Mat, Busan, South Korea.
   [Hwang, Hye Jin] Dong Eui Univ, Dept Food & Nutr, Coll Nat Sci & Human Ecol, Busan, South Korea.
   [Choi, Yung Hyun] Dong Eui Univ, Dept Biochem, Coll Korean Med, Busan 47227, South Korea.
C3 Dong Eui University; Dong Eui University; Jeju National University;
   Kyungpook National University (KNU); Pusan National University; Pusan
   National University; Dong Eui University; Dong Eui University
RP Choi, YH (通讯作者)，Dong Eui Univ, Dept Biochem, Coll Korean Med, Busan 47227, South Korea.
EM choiyh@deu.ac.kr
RI Kim, Kyoung Sook/A 7768 2017; Kim, Sun Jae/A 1790 2009; Jeon,
   You Jin/AAR 5061 2020
OI Kim, Gi Young/0000 0002 6878 0790
FU Ministry of Oceans and Fisheries, Republic of Korea [20150242,
   2017 0377]
FX This research was supported the project titled 'Omics based on fishery
   disease control technology development and industrialization (20150242)'
   and 'Development of functional food products with natural materials
   derived from marine resources (2017 0377)', funded by the Ministry of
   Oceans and Fisheries, Republic of Korea.
CR Almeida M, 2013, J GERONTOL A BIOL, V68, P1197, DOI 10.1093/gerona/glt079
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bak SU, 2017, BMB REP, V50, P103, DOI 10.5483/BMBRep.2017.50.2.220
   Banfi G, 2008, CLIN CHEM LAB MED, V46, P1550, DOI 10.1515/CCLM.2008.302
   Bi HD, 2017, FRONT MED LAUSANNE, V4, DOI 10.3389/fmed.2017.00234
   Colins JA, 2018, CURR OPIN RHEUMATOL, V30, P101, DOI 10.1097/BOR.0000000000000456
   Das SK, 2010, J AGR FOOD CHEM, V58, P6090, DOI 10.1021/jf100303k
   Domazetovic V, 2017, CLIN CASES MINER BON, V14, P209, DOI 10.11138/ccmbm/2017.14.1.209
   El Osta Lana, 2016, J Med Liban, V64, P228
   Galson Deborah L, 2014, J Bone Metab, V21, P85, DOI 10.11005/jbm.2014.21.2.85
   Hayman AR, 2008, AUTOIMMUNITY, V41, P218, DOI 10.1080/08916930701694667
   Hong S, 2014, MOL CELL BIOL, V34, P3515, DOI 10.1128/MCB.00293 14
   Honma M, 2014, CURR OSTEOPOROS REP, V12, P115, DOI 10.1007/s11914 014 0189 0
   Ihn HJ, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122635
   Kagiya T, 2013, J PERIODONTAL RES, V48, P373, DOI 10.1111/jre.12017
   Kang KA, 2017, TOX RESEARCH, V33, P1, DOI 10.5487/TR.2017.33.1.001
   Kikuta J, 2013, RHEUMATOLOGY, V52, P226, DOI 10.1093/rheumatology/kes259
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kim KJ, 2017, J CLIN MED, V6, DOI 10.3390/jcm6030032
   Kim YW, 2014, INT J MOL SCI, V15, P18840, DOI 10.3390/ijms151018840
   Komai E, 2006, BIOL PHARM BULL, V29, P1980, DOI 10.1248/bpb.29.1980
   Kong XY, 2015, INT J BIOL SCI, V11, P1204, DOI 10.7150/ijbs.12296
   Koyama T, 2011, ADV FOOD NUTR RES, V64, P443, DOI 10.1016/B978 0 12 387669 0.00034 X
   Kuroda Y, 2012, WORLD J ORTHOP, V3, P167, DOI 10.5312/wjo.v3.i11.167
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Loboda A, 2016, CELL MOL LIFE SCI, V73, P3221, DOI 10.1007/s00018 016 2223 0
   Lu BR, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.64
   Marchev AS, 2017, ANN NY ACAD SCI, V1401, P114, DOI 10.1111/nyas.13407
   Mundy GR, 2007, NUTR REV, V65, pS147, DOI [10.1111/j.1753 4887.2007.tb00353.x, 10.1301/nr.2007.dec.S147 S151]
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   Park JH, 2017, MOL CELLS, V40, P706
   Ralston SH, 2012, CALCIFIED TISSUE INT, V91, P97, DOI 10.1007/s00223 012 9599 0
   Reid Ian R, 2002, Expert Opin Drug Saf, V1, P93, DOI 10.1517/14740338.1.1.93
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Salimi A, 2017, TOX RESEARCH, V33, P233, DOI 10.5487/TR.2017.33.3.233
   Soysa NS, 2016, BIOCHEM BIOPH RES CO, V476, P115, DOI 10.1016/j.bbrc.2016.05.019
   Srinivasan S, 2010, ANN NY ACAD SCI, V1192, P245, DOI 10.1111/j.1749 6632.2009.05377.x
   Sun YX, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929 015 0212 5
   Sundaram K, 2007, EXP CELL RES, V313, P168, DOI 10.1016/j.yexcr.2006.10.001
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Ueno M, 2018, PHYTOTHER RES, V32, P452, DOI 10.1002/ptr.5988
   Vadala M, 2015, Clin Ter, V166, pe281, DOI 10.7417/T.2015.1875
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Yoo HS, 2017, NUTR RES PRACT, V11, P190, DOI 10.4162/nrp.2017.11.3.190
   Yoon WJ, 2013, BIOCHEM BIOPH RES CO, V434, P892, DOI 10.1016/j.bbrc.2013.04.046
   Yoon WJ, 2012, FOOD CHEM TOXICOL, V50, P3273, DOI 10.1016/j.fct.2012.06.022
   Yuan FL, 2015, BONE, V75, P128, DOI 10.1016/j.bone.2015.02.017
   Ziskoven C, 2010, ORTHOP REV, V2, P95, DOI 10.4081/or.2010.e23
NR 48
TC 21
Z9 23
U1 0
U2 8
PU IRCA BSSA
PI TOKYO
PA PEARL CITY KOISHIKAWA 603, 2 4 5 KASUGA, BUNKYO KU, TOKYO, 112 0003,
   JAPAN
SN 1881 7815
EI 1881 7823
J9 BIOSCI TRENDS
JI BioSci. Trends
PD JUN
PY 2018
VL 12
IS 3
BP 257
EP 265
DI 10.5582/bst.2018.01107
PG 9
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA GM4VC
UT WOS:000438122100005
PM 30012915
OA Bronze
DA 2025 08 17
ER

PT J
AU Darle, A
   Mahiet, T
   Aubin, D
   Doyen, M
   El Kassar, L
   Parfait, B
   Lemaitre, G
   Baldeschi, C
   Allouche, J
   Holic, N
AF Darle, Annabelle
   Mahiet, Thibault
   Aubin, Deborah
   Doyen, Manon
   El Kassar, Lina
   Parfait, Beatrice
   Lemaitre, Gilles
   Baldeschi, Christine
   Allouche, Jennifer
   Holic, Nathalie
TI Generation of heterozygous and homozygous NF1 lines from human induced
   pluripotent stem cells using CRISPR/Cas9 to investigate bone defects
   associated with neurofibromatosis type 1
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE neurofibromatosis type I; gene editing; CRISPR/Cas9; human induced
   pluripotent stem cells; osteogenic differentiation; disease modeling
ID OSTEOBLAST DIFFERENTIATION; CONGENITAL PSEUDOARTHROSIS; DOUBLE
   INACTIVATION; OSTEOCLASTS; THERAPY; DISEASE
AB Neurofibromatosis type 1 (NF1) is one of the most common genetic disorders caused by heterozygous germline NF1 mutations. NF1 affects many systems, including the skeletal system. To date, no curative therapies are available for skeletal manifestations such as scoliosis and tibial dysplasia, mainly due to the lack of knowledge about the mechanisms that underlie this process. By using CRISPR/Cas9 mediated gene editing in human induced pluripotent stem cells (hiPSCs) to minimize the variability due to genetic background and epigenetic factors, we generated isogenic heterozygous and homozygous NF1 deficient hiPSC lines to investigate the consequences of neurofibromin inactivation on osteoblastic differentiation. Here, we demonstrate that loss of one or both copies of NF1 does not alter the potential of isogenic hiPSCs to differentiate into mesenchymal stem cells (hiPSC MSCs). However, NF1 (+/ ) and NF1 ( / ) hiPSC MSCs show a defect in osteogenic differentiation and mineralization. In addition, we show that a mono allelic deletion in NF1 in an isogenic context is sufficient to impair cell differentiation into osteoblasts. Overall, this study highlights the relevance of generating isogenic lines, which may help in genotype phenotype correlation and provide a human cellular model to understand the molecular mechanisms underlying NF1 and, thus, discover new therapeutic strategies.
C1 [Darle, Annabelle; Mahiet, Thibault; El Kassar, Lina] Ctr Etud Cellules Souches, Corbeil Essonnes, France.
   [Aubin, Deborah; Doyen, Manon; Lemaitre, Gilles; Baldeschi, Christine; Allouche, Jennifer; Holic, Nathalie] Univ Evry, Univ Paris Saclay, Corbeil Essonnes, France.
   [Aubin, Deborah; Doyen, Manon; Lemaitre, Gilles; Baldeschi, Christine; Allouche, Jennifer; Holic, Nathalie] Assoc Francaise Myopathies AFM, Inst Stem Cell Therapy & Explorat Monogenic Dis, INSERM U861, I Stem, Corbeil Essonnes, France.
   [Aubin, Deborah] Phenocell SAS, Grasse, France.
   [Parfait, Beatrice] UMR INSERM 1016, Equipe Genomique & Epigenet Tumeurs Rares, Paris, France.
   [Parfait, Beatrice] Univ Paris Cite, Inst Cochin, Paris, France.
   [Parfait, Beatrice] Univ Paris Cite, Hop Cochin, GHU AP HP Ctr, Serv Med Genom Malad Syst & Organe, Paris, France.
C3 Universite Paris Saclay; Universite Paris Saclay; Institut National de
   la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite;
   Universite Paris Cite; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Universite
   Paris Cite; Hopital Universitaire Cochin   APHP
RP Allouche, J; Holic, N (通讯作者)，Univ Evry, Univ Paris Saclay, Corbeil Essonnes, France.; Allouche, J; Holic, N (通讯作者)，Assoc Francaise Myopathies AFM, Inst Stem Cell Therapy & Explorat Monogenic Dis, INSERM U861, I Stem, Corbeil Essonnes, France.
EM nholic@istem.fr; jallouche@istem.fr
RI ; PARFAIT, Beatrice/HLV 7346 2023; Lemaître, Gilles/AAL 5889 2021
OI Lemaitre, Gilles/0000 0002 0898 1582; 
FU Biotherapies Institute for Rare Diseases; Association Franaise contre
   les Myopathies (AFM); INSERM
FX The author(s) declare that financial support was received for the
   research, authorship, and/or publication of this article. I STEM is part
   of the Biotherapies Institute for Rare Diseases supported by the
   Association Francaise contre les Myopathies (AFM) Telethon, INSERM and
   Universite d'Evry Val d'Essonne/Paris Saclay.r The author(s) declare
   that financial support was received for the research, authorship, and/or
   publication of this article. I STEM is part of the Biotherapies
   Institute for Rare Diseases supported by the Association Francaise
   contre les Myopathies (AFM) Telethon, INSERM and Universite d'Evry Val
   d'Essonne/Paris Saclay.
CR Ahmed R, 2022, J BONE MINER RES, V37, P1603, DOI 10.1002/jbmr.4633
   Alanne MH, 2012, J CELL BIOCHEM, V113, P2136, DOI 10.1002/jcb.24088
   Allouche J, 2015, P NATL ACAD SCI USA, V112, P9034, DOI 10.1073/pnas.1501032112
   Anastasaki C, 2020, STEM CELL REP, V14, P541, DOI 10.1016/j.stemcr.2020.03.007
   Bergqvist C, 2020, ORPHANET J RARE DIS, V15, DOI 10.1186/s13023 020 1310 3
   BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019
   Carrió M, 2019, STEM CELL REP, V12, P411, DOI 10.1016/j.stemcr.2019.01.001
   Chen IP, 2020, BIO PROTOCOL, V10, DOI 10.21769/BioProtoc.3854
   Csobonyeiova M, 2017, J ADV RES, V8, P321, DOI 10.1016/j.jare.2017.02.004
   Denis JA, 2011, STEM CELLS DEV, V20, P1395, DOI 10.1089/scd.2010.0331
   Diaz Hernandez ME, 2023, BIO PROTOCOL, V13, DOI 10.21769/BioProtoc.4885
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Elefteriou F, 2006, CELL METAB, V4, P441, DOI 10.1016/j.cmet.2006.10.010
   Elefteriou F, 2009, AM J MED GENET A, V149A, P2327, DOI 10.1002/ajmg.a.33045
   Ferrara UP, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 07855 4
   Heervä E, 2010, BONE, V47, P583, DOI 10.1016/j.bone.2010.06.001
   JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794 353
   Karagiannis P, 2019, PHYSIOL REV, V99, P79, DOI 10.1152/physrev.00039.2017
   Kolanczyk M, 2007, HUM MOL GENET, V16, P874, DOI 10.1093/hmg/ddm032
   Kühnisch J, 2014, BONE, V66, P155, DOI 10.1016/j.bone.2014.06.012
   Lee SM, 2012, J ORTHOP RES, V30, P1535, DOI 10.1002/jor.22121
   Legius E, 2021, GENET MED, V23, P1506, DOI 10.1038/s41436 021 01170 5
   Leskelä HV, 2009, BONE, V44, P243, DOI 10.1016/j.bone.2008.10.050
   Li YQ, 2019, J CELL BIOCHEM, V120, P2886, DOI 10.1002/jcb.26626
   Liang GY, 2013, CELL STEM CELL, V13, P149, DOI 10.1016/j.stem.2013.07.001
   Liu C, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.156166
   Ma Y, 2020, GENET MED, V22, P1786, DOI 10.1038/s41436 020 0885 3
   Margraf RL, 2019, J MOL NEUROSCI, V68, P11, DOI 10.1007/s12031 019 01277 0
   Mazuelas H, 2022, CELL REP, V38, DOI 10.1016/j.celrep.2022.110385
   Mo J, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI139807
   Pacot L, 2024, BRIT J DERMATOL, V190, P226, DOI 10.1093/bjd/ljad390
   Paria N, 2023, J BONE MINER RES, V38, P288, DOI 10.1002/jbmr.4755
   Paria N, 2014, J BONE MINER RES, V29, P2636, DOI 10.1002/jbmr.2298
   Rössler U, 2021, J BONE MINER RES, V36, P1621, DOI 10.1002/jbmr.4322
   Sharma R, 2013, HUM MOL GENET, V22, P4818, DOI 10.1093/hmg/ddt333
   Silva Pedrosa R, 2023, CELLS BASEL, V12, DOI 10.3390/cells12060930
   Stevenson DA, 2006, AM J HUM GENET, V79, P143, DOI 10.1086/504441
   Stevenson DA, 2011, AM J MED GENET A, V155A, P1050, DOI 10.1002/ajmg.a.33965
   Volpato V, 2020, DIS MODEL MECH, V13, DOI 10.1242/dmm.042317
   Wang W, 2021, FRONT NEUROL, V12, DOI 10.3389/fneur.2021.704639
   Wang WX, 2011, HUM MOL GENET, V20, P3910, DOI 10.1093/hmg/ddr310
   Wegscheid ML, 2018, EXP NEUROL, V299, P270, DOI 10.1016/j.expneurol.2017.04.001
   Wong PK, 2023, CRISPR J, V6, P196, DOI 10.1089/crispr.2023.0013
   Wu XH, 2006, HUM MOL GENET, V15, P2837, DOI 10.1093/hmg/ddl208
   Yang FC, 2006, J CLIN INVEST, V116, P2880, DOI 10.1172/JCI29092
   Yzaguirre AD, 2015, ELIFE, V4, DOI 10.7554/eLife.07780
   Zhang W, 2011, BONE, V48, P1378, DOI 10.1016/j.bone.2011.03.760
NR 47
TC 0
Z9 0
U1 1
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD FEB 28
PY 2024
VL 12
AR 1359561
DI 10.3389/fcell.2024.1359561
PG 12
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA KU6K1
UT WOS:001182514800001
PM 38481529
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU El Mabhouh, AA
   Angelov, CA
   Cavell, R
   Mercer, JR
AF El Mabhouh, Amal A.
   Angelov, Christo A.
   Cavell, Ron
   Mercer, John R.
TI A <SUP>99m</SUP>Tc labeled gemcitabine bisphosphonate drug conjugate as
   a probe to assess the potential for targeted chemotherapy of metastatic
   bone cancer
SO NUCLEAR MEDICINE AND BIOLOGY
LA English
DT Article
DE Tc 99m labeling; bisphosphonates; metastatic bone disease; targeted
   chemotherapy; gemcitabine
ID IN VIVO; ACCUMULATION; NEPHROTOXICITY; PAMIDRONATE; MECHANISMS;
   SCHEDULE; AGENTS; MODEL; RATS
AB Introduction: A novel compound with the potential for "targeted" therapy for cancer patients was prepared using a conjugate between the potent anticancer drug Gemzar (gemcitabine) and a bisphosphonate. This conjugate would be expected to accumulate at sites of bone metastatic cancer by virtue of an affinity of the bisphosphonate for bone undergoing osteoclastic and osteoblastic remodeling. Release of the anticancer drug at the site of the tumor would provide high local concentrations of the drug but avoid systemic toxicity.
   Methods: The conjugate was tested for bone binding by labeling with technetium 99m and using an in vitro test procedure with either purified hydroxyapatite (HA) or powdered bovine bone. Biodistribution and pharmacokinetic studies in mice were used to determine the excretion and bone binding characteristics of the test compound.
   Results and Conclusions: The conjugate binds readily to powdered bone and HA using the in vitro test systems. In animal studies, the conjugate is found predominantly in bone with low soft tissue uptake after intravenous dosing, Unbound compound undergoes renal excretion. The gemcitabine bisphosphonate complex is a promising lead compound for investigation in metastatic bone cancer that may provide a therapeutic effect without undue toxicity. (c) 2006 Elsevier Inc. All rights reserved.
C1 Cross Canc Inst, Fac Med, Edmonton, AB T6G 1Z2, Canada.
   Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2N8, Canada.
   Univ Alberta, Dept Chem, Edmonton, AB T6G 2G2, Canada.
C3 University of Alberta; University of Alberta; University of Alberta
RP Mercer, JR (通讯作者)，Cross Canc Inst, Fac Med, Edmonton, AB T6G 1Z2, Canada.
EM johnmerc@cancerboard.ab.ca
CR [Anonymous], CAN CANC STAT 2005
   Arteaga De Murphy Consuelo, 1997, Nuclear Medicine and Biology, V24, P27
   Barri YM, 2004, KIDNEY INT, V65, P634, DOI 10.1111/j.1523 1755.2004.00426.x
   Barton Burke M, 1999, CANCER NURS, V22, P176, DOI 10.1097/00002820 199904000 00011
   BOVEN E, 1993, BRIT J CANCER, V68, P52, DOI 10.1038/bjc.1993.285
   BRAAKHUIS BJM, 1995, SEMIN ONCOL, V22, P42
   Buesa JM, 2004, CANCER AM CANCER SOC, V101, P2261, DOI 10.1002/cncr.20612
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   El Mabhouh A, 2005, APPL RADIAT ISOTOPES, V62, P541, DOI 10.1016/j.apradiso.2004.10.004
   El Mabhouh A, 2004, CANCER BIOTHER RADIO, V19, P627, DOI 10.1089/cbr.2004.19.627
   FELRYA J, 2001, GLOBOCAN 2000 CANC I
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   HAYS MT, 1977, J NUCL MED, V18, P898
   Hirschberg R, 2004, TOXICOLOGY, V196, P165, DOI 10.1016/j.tox.2003.11.012
   Hosain F, 1996, J NUCL MED, V37, P105
   KANISHI D, 1993, ORAL SURG ORAL MED O, V75, P239, DOI 10.1016/0030 4220(93)90100 I
   Kantoci D, 1996, SYNTHETIC COMMUN, V26, P2037, DOI 10.1080/00397919608003560
   Lake DE, 2004, DRUGS, V64, P1851, DOI 10.2165/00003495 200464170 00001
   Laznicek M, 1996, NUCL MED COMMUN, V17, P1016, DOI 10.1097/00006231 199612000 00003
   Markowitz GS, 2001, J AM SOC NEPHROL, V12, P1164, DOI 10.1681/ASN.V1261164
   OKAMOTO Y, 1995, ORAL SURG ORAL MED O, V80, P115, DOI 10.1016/S1079 2104(95)80027 1
   SCHULTZ RM, 1993, ONCOL RES, V5, P223
   SHIPLEY LA, 1992, DRUG METAB DISPOS, V20, P849
   Szeto CC, 2005, RENAL FAILURE, V27, P329, DOI 10.1081/JDI 200056595
   Uludag H, 2002, BIOTECHNOL PROGR, V18, P604, DOI 10.1021/bp0200447
   Veerman G, 1996, CANCER CHEMOTH PHARM, V38, P335, DOI 10.1007/s002800050492
NR 26
TC 38
Z9 45
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0969 8051
EI 1872 9614
J9 NUCL MED BIOL
JI Nucl. Med. Biol.
PD AUG
PY 2006
VL 33
IS 6
BP 715
EP 722
DI 10.1016/j.nucmedbio.2006.06.004
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA 083FM
UT WOS:000240441800005
PM 16934690
DA 2025 08 17
ER

PT J
AU Noggle, SA
   James, D
   Brivanlou, AH
AF Noggle, Scott A.
   James, Daylon
   Brivanlou, Ali H.
TI A molecular basis for human embryonic stem cell pluripotency
SO STEM CELL REVIEWS
LA English
DT Article
DE transcriptional profile; FGF; TGF beta; bone morphogenic protein; Wnt;
   chemical genetics; Xenopus; glycogen synthase kinase 3 (GSK 3);
   indirubins; 6 bromoindirubin 3 ' oxine (BIO); leukemia inhibitory factor
   (LIF); SMAD2/3; SB 431542
ID GENE EXPRESSION; SELF RENEWAL; DIFFERENTIATION; MICROARRAY; ACTIVATION;
   INHIBITORS; OLIGONUCLEOTIDE; MAINTENANCE; CULTURE; NANOG
AB Embryonic stem cells (ESCs) are able to generate a wide array of differentiated cell fates while maintaining self renewal. Understanding the biology of these choices may be central to the use of human embryonic stem cells (HESCs), both as a model for early human development as well as a resource for cell based therapies. Efforts to dissect the molecular mechanisms that mediate stem cell identity are underway, and in this review we summarize recent progress in defining the markers and pathways involved in these decisions. We discuss recent efforts efforts to assess the molecular signature of pluripotent HESCs and highlight work demonstrating a set of genes, including representitives from the FGF, TGF beta, Nd Wnt signaling pathways, that consistantly mark the undifferentiated state. In addition, we describe experiments in which signaling of HESCs is augmented by chemical probing with small molecule compounds. Using these compounds, we have demonstrated an important role for Wnt signaling in HESC pluripotency and shown a requirement for TGF beta signaling in the maintenance of the undifferentiated state. These experiments have revealed some molecular aspects of the pluripotent state and demonstrated clear differences between mouse and human ESCs in the maintenance of this identity.
C1 Rockefeller Univ, Lab Mol Vertebrate Embryol, New York, NY 10021 USA.
C3 Rockefeller University
RP Brivanlou, AH (通讯作者)，Rockefeller Univ, Lab Mol Vertebrate Embryol, 1230 York Ave, New York, NY 10021 USA.
EM brvnlou@rockefeller.edu
OI Noggle, Scott/0000 0002 0374 2240
CR Abeyta MJ, 2004, HUM MOL GENET, V13, P601, DOI 10.1093/hmg/ddh068
   Barczak A, 2003, GENOME RES, V13, P1775, DOI 10.1101/gr.1048803
   Besser D, 2004, J BIOL CHEM, V279, P45076, DOI 10.1074/jbc.M404979200
   Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092 8674(01)00409 3
   Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355
   Brivanlou AH, 2003, SCIENCE, V300, P913, DOI 10.1126/science.1082940
   Burdon T, 1999, DEV BIOL, V210, P30, DOI 10.1006/dbio.1999.9265
   Buzzard JJ, 2004, NAT BIOTECHNOL, V22, P381, DOI 10.1038/nbt0404 381
   Carpenter MK, 2004, DEV DYNAM, V229, P243, DOI 10.1002/dvdy.10431
   Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092 8674(03)00392 1
   Chang CB, 2003, DEV BIOL, V255, P1, DOI 10.1016/S0012 1606(02)00075 1
   Dani C, 1998, DEV BIOL, V203, P149, DOI 10.1006/dbio.1998.9026
   Ding S, 2004, NAT BIOTECHNOL, V22, P833, DOI 10.1038/nbt987
   Draper JS, 2004, NAT BIOTECHNOL, V22, P53, DOI 10.1038/nbt922
   GEARING DP, 1992, NEW BIOL, V4, P61
   GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460 2075.1991.tb07833.x
   Granata A, 2003, DEV BIOL, V258, P397, DOI 10.1016/S0012 1606(03)00131 3
   Hamatani T, 2004, DEV CELL, V6, P117, DOI 10.1016/S1534 5807(03)00373 3
   HemmatiBrivanlou A, 1997, CELL, V88, P13, DOI 10.1016/S0092 8674(00)81853 X
   Huelsken J, 2000, J CELL BIOL, V148, P567, DOI 10.1083/jcb.148.3.567
   Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823
   JAMES DW, IN PRESS
   Knockaert M, 2002, TRENDS PHARMACOL SCI, V23, P417, DOI 10.1016/S0165 6147(02)02071 0
   Kothapalli R, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471 2105 3 22
   Kuo WP, 2002, BIOINFORMATICS, V18, P405, DOI 10.1093/bioinformatics/18.3.405
   Li J, 2002, TOXICOL SCI, V69, P383, DOI 10.1093/toxsci/69.2.383
   Marshall E, 2004, SCIENCE, V306, P630, DOI 10.1126/science.306.5696.630
   Martin MJ, 2005, NAT MED, V11, P228, DOI 10.1038/nm1181
   Martinez A, 2002, MED RES REV, V22, P373, DOI 10.1002/med.10011
   Meijer L, 2003, CHEM BIOL, V10, P1255, DOI 10.1016/j.chembiol.2003.11.010
   Mitalipova MM, 2005, NAT BIOTECHNOL, V23, P19, DOI 10.1038/nbt0105 19
   Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092 8674(03)00393 3
   Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549
   Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199
   Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048
   Pera MF, 2004, J CELL SCI, V117, P1269, DOI 10.1242/jcs.00970
   Pirvola U, 2004, DEV BIOL, V273, P350, DOI 10.1016/j.ydbio.2004.06.010
   Ramalho Santos M, 2004, BIOESSAYS, V26, P1013, DOI 10.1002/bies.20053
   Ramalho Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530
   Rosler ES, 2004, DEV DYNAM, V229, P259, DOI 10.1002/dvdy.10430
   Sato N, 2003, DEV BIOL, V260, P404, DOI 10.1016/S0012 1606(03)00256 2
   Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979
   SMITH AG, 1987, DEV BIOL, V121, P1, DOI 10.1016/0012 1606(87)90132 1
   Smith AG, 2001, ANNU REV CELL DEV BI, V17, P435, DOI 10.1146/annurev.cellbio.17.1.435
   SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0
   Suárez Fariñas M, 2005, BMC GENOMICS, V6, DOI 10.1186/1471 2164 6 99
   Vallier L, 2004, DEV BIOL, V275, P403, DOI 10.1016/j.ydbio.2004.08.031
   van Es JH, 2003, CURR OPIN GENET DEV, V13, P28, DOI 10.1016/S0959 437X(02)00012 6
   Wei CL, 2005, STEM CELLS, V23, P166, DOI 10.1634/stemcells.2004 0162
   Willerton L, 2004, INT J DEV BIOL, V48, P637, DOI 10.1387/ijdb.031778lw
   WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0
   Xu CH, 2001, NAT BIOTECHNOL, V19, P971, DOI 10.1038/nbt1001 971
   Xu RH, 2002, NAT BIOTECHNOL, V20, P1261, DOI 10.1038/nbt761
   Yamamoto M, 2004, NATURE, V428, P387, DOI 10.1038/nature02418
   Yauk CL, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh123
   Yuen T, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e48
   Zwaka TP, 2005, DEVELOPMENT, V132, P227, DOI 10.1242/dev.01586
NR 57
TC 21
Z9 41
U1 0
U2 8
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1550 8943
EI 1558 6804
J9 STEM CELL REV
JI Stem Cell Rev.
PY 2005
VL 1
IS 2
BP 111
EP 118
DI 10.1385/SCR:1:2:111
PG 8
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA 083OT
UT WOS:000240468800005
PM 17142845
DA 2025 08 17
ER

PT J
AU Cabrera Pérez, R
   Monguió Tortajada, M
   Gámez Valero, A
   Rojas Márquez, R
   Borràs, FE
   Roura, S
   Vives, J
AF Cabrera Perez, Raquel
   Monguio Tortajada, Marta
   Gamez Valero, Ana
   Rojas Marquez, Raquel
   Borras, Francesc Enric
   Roura, Santiago
   Vives, Joaquim
TI Osteogenic commitment of Wharton's jelly mesenchymal stromal cells:
   mechanisms and implications for bioprocess development and clinical
   application
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Mesenchymal stromal cells; Bone marrow; Wharton's jelly; Osteogenic
   differentiation; Bone regeneration
ID STEM CELLS; BONE MARROW; OSTEOBLAST DIFFERENTIATION; EXTRACELLULAR
   VESICLES; GROWTH FACTOR; UP REGULATION; EXPRESSION; THERAPY; PROTEINS;
   DLX5
AB Background Orthopaedic diseases are one of the major targets for regenerative medicine. In this context, Wharton's jelly (WJ) is an alternative source to bone marrow (BM) for allogeneic transplantation since its isolation does not require an invasive procedure for cell collection and does not raise major ethical concerns. However, the osteogenic capacity of human WJ derived multipotent mesenchymal stromal cells (MSC) remains unclear. Methods Here, we compared the baseline osteogenic potential of MSC from WJ and BM cell sources by cytological staining, quantitative real time PCR and proteomic analysis, and assessed chemical and biological strategies for priming undifferentiated WJ MSC. Concretely, different inhibitors/activators of the TGF beta 1 BMP2 signalling pathway as well as the secretome of differentiating BM MSC were tested. Results Cytochemical staining as well as gene expression and proteomic analysis revealed that osteogenic commitment was poor in WJ MSC. However, stimulation of the BMP2 pathway with BMP2 plus tanshinone IIA and the addition of extracellular vesicles or protein enriched preparations from differentiating BM MSC enhanced WJ MSC osteogenesis. Furthermore, greater outcome was obtained with the use of conditioned media from differentiating BM MSC. Conclusions Altogether, our results point to the use of master banks of WJ MSC as a valuable alternative to BM MSC for orthopaedic conditions.
C1 [Cabrera Perez, Raquel; Rojas Marquez, Raquel; Vives, Joaquim] Blood & Tissue Bank BST, Cell Therapy Serv, Barcelona, Catalonia, Spain.
   [Cabrera Perez, Raquel; Vives, Joaquim] Vall dHebron Res Inst VHIR, Musculoskeletal Tissue Engn Grp, Barcelona, Catalonia, Spain.
   [Cabrera Perez, Raquel; Vives, Joaquim] UAB, Barcelona, Catalonia, Spain.
   [Monguio Tortajada, Marta; Gamez Valero, Ana; Borras, Francesc Enric] Hlth Sci Res Inst Germans Trias & Pujol IGTP, REMAR IVECAT Grp, Badalona, Catalonia, Spain.
   [Rojas Marquez, Raquel] Ctr Genom Regulat CRG, Gene Regulat Stem Cells & Canc Program, Barcelona, Catalonia, Spain.
   [Borras, Francesc Enric] Germans Trias & Pujol Univ Hosp, Nephrol Serv, Badalona, Catalonia, Spain.
   [Roura, Santiago] Hlth Sci Res Inst Germans Trias & Pujol IGTP, ICREC Res Program, Badalona, Catalonia, Spain.
   [Vives, Joaquim] UAB, Med Dept, Badalona, Catalonia, Spain.
C3 Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron;
   Vall d'Hebron Institut de Recerca (VHIR); Autonomous University of
   Barcelona; Fundacio Institut d'Investigacio en Ciencies de la Salut
   Germans Trias i Pujol (IGTP); Barcelona Institute of Science &
   Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG);
   Fundacio Institut d'Investigacio en Ciencies de la Salut Germans Trias i
   Pujol (IGTP); Autonomous University of Barcelona
RP Cabrera Pérez, R; Vives, J (通讯作者)，Blood & Tissue Bank BST, Cell Therapy Serv, Barcelona, Catalonia, Spain.; Cabrera Pérez, R; Vives, J (通讯作者)，Vall dHebron Res Inst VHIR, Musculoskeletal Tissue Engn Grp, Barcelona, Catalonia, Spain.; Cabrera Pérez, R; Vives, J (通讯作者)，UAB, Barcelona, Catalonia, Spain.; Vives, J (通讯作者)，UAB, Med Dept, Badalona, Catalonia, Spain.
EM rcabrera@bst.cat; jvives@bst.cat
RI Vives, Joaquim/J 6303 2019; Borràs, Francesc/P 2287 2017; BORRAS,
   FRANCESC E./P 2287 2017; Monguió Tortajada, Marta/Y 7446 2019;
   GÁMEZ VALERO, ANA/AAH 8932 2019; Roura, Santiago/B 2623 2013; Pérez,
   Raquel/AAE 4039 2021
OI Rojas Marquez, Raquel/0000 0001 6119 6930; BORRAS, FRANCESC
   E./0000 0003 4038 1912; Roura, Santiago/0000 0003 4063 9661; Vives,
   Joaquim/0000 0001 9719 5235; Monguio Tortajada,
   Marta/0000 0003 2125 0810; GAMEZ VALERO, ANA/0000 0002 9530 2751; 
FU Spanish Cell Therapy Network (TerCel) [RD16/0011/0028, RD16/00111/0006];
   Ministerio de Ciencia Innovacion y Universidades de Espana (Instituto de
   Salud Carlos III) [PI19/01788]; Fundacio la Marato de TV3 [122831];
   ISCIII REDinREN [RD16/0009]; ACCIO (Catalonia Trade Investment;
   Generalitat de Catalunya) under the Catalonian ERDF operational
   programme (European Regional Development Fund) 2014 2020; Health
   Department of the Catalan Government (Generalitat de Catalunya);
   Generalitat de Catalunya [2017 SGR 719, 2017 SGR 301, 2017 SGR 483]
FX Work in our laboratory is supported by the Spanish Cell Therapy Network
   (TerCel, expedient No. RD16/0011/0028 and RD16/00111/0006), Ministerio
   de Ciencia Innovacion y Universidades de Espana (Instituto de Salud
   Carlos III, expedient No. PI19/01788), Fundacio la Marato de TV3
   (expedient number: 122831), and ISCIII REDinREN (RD16/0009 Feder Funds),
   and developed in the context of AdvanceCat with the support of ACCIO
   (Catalonia Trade & Investment; Generalitat de Catalunya) under the
   Catalonian ERDF operational programme (European Regional Development
   Fund) 2014 2020. FEB is a researcher from Fundacio Institut de Recerca
   en Ciencies de la Salut Germans Trias i Pujol, supported by the Health
   Department of the Catalan Government (Generalitat de Catalunya). Our
   laboratory is awarded by the Generalitat de Catalunya as Consolidated
   Research Groups (ref. 2017 SGR 719, 2017 SGR 301 and 2017 SGR 483).
CR Annamalai RT, 2019, BIOMATERIALS, V208, P32, DOI 10.1016/j.biomaterials.2019.04.001
   Baker N, 2015, BONE, V70, P37, DOI 10.1016/j.bone.2014.10.014
   Batsali AK, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0555 9
   Beederman M., 2013, J BIOMEDICAL SCI ENG, V6, P32, DOI DOI 10.4236/JBISE.2013.68A1004
   Blanco JF, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1166 4
   Caminal M, 2017, J TISSUE ENG REGEN M, V11, P3408, DOI 10.1002/term.2254
   Cho TJ, 2002, J BONE MINER RES, V17, P513, DOI 10.1359/jbmr.2002.17.3.513
   Choudhery MS, 2012, CELL BIOL INT, V36, P747, DOI 10.1042/CBI20110183
   Codinach M, 2016, CYTOTHERAPY, V18, P1197, DOI 10.1016/j.jcyt.2016.05.012
   Davies JE, 2017, STEM CELL TRANSL MED, V6, P1620, DOI 10.1002/sctm.16 0492
   Deuse T, 2011, CELL TRANSPLANT, V20, P655, DOI 10.3727/096368910X536473
   Dimmeler S, 2008, CIRC RES, V102, P1319, DOI 10.1161/CIRCRESAHA.108.175943
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Giannotti S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073893
   Gómez Barrena E, 2019, BIOMATERIALS, V196, P100, DOI 10.1016/j.biomaterials.2018.03.033
   Grafe I, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a022202
   Guadix JA, 2017, MED CLIN BARCELONA, V148, P408, DOI 10.1016/j.medcli.2016.11.033
   Guerrero F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089179
   Heo JS, 2017, INT J MOL MED, V40, P1486, DOI 10.3892/ijmm.2017.3142
   Hsieh JY, 2010, STEM CELLS DEV, V19, P1895, DOI 10.1089/scd.2009.0485
   Hu GZ, 2001, DEVELOPMENT, V128, P2373
   Im GI, 2017, EUR CELLS MATER, V33, P183, DOI 10.22203/eCM.v033a14
   Izu Y, 2016, CELL TISSUE RES, V364, P623, DOI 10.1007/s00441 015 2345 y
   Kaigler D, 2013, CELL TRANSPLANT, V22, P767, DOI 10.3727/096368912X652968
   Kalra H, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001450
   Karantalis V, 2015, CIRC RES, V116, P12, DOI 10.1161/CIRCRESAHA.114.305495
   Kim DK, 2015, BIOINFORMATICS, V31, P933, DOI 10.1093/bioinformatics/btu741
   Kim HJ, 2010, AMINO ACIDS, V39, P1217, DOI 10.1007/s00726 010 0557 8
   Kim YJ, 2004, J BIOL CHEM, V279, P50773, DOI 10.1074/jbc.M404145200
   Kretlow JD, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471 2121 9 60
   La Rocca G, 2013, CURR STEM CELL RES T, V8, P100, DOI 10.2174/1574888X11308010012
   Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200
   Liebergall M, 2013, MOL THER, V21, P1631, DOI 10.1038/mt.2013.109
   Mathivanan S, 2009, PROTEOMICS, V9, P4997, DOI 10.1002/pmic.200900351
   Mehrara BJ, 1999, PLAST RECONSTR SURG, V104, P435, DOI 10.1097/00006534 199908000 00017
   Mendes SC, 2002, TISSUE ENG, V8, P911, DOI 10.1089/107632702320934010
   Mirabel C, 2018, J TRANSL MED, V16, DOI 10.1186/s12967 018 1659 4
   Miyama K, 1999, DEV BIOL, V208, P123, DOI 10.1006/dbio.1998.9197
   Mohal JS, 2012, CURR STEM CELL RES T, V7, P103
   Monguio Tortajada Marta, 2019, Curr Protoc Stem Cell Biol, V49, pe82, DOI 10.1002/cpsc.82
   Monguió Tortajada M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01577
   Monguió Tortajada M, 2017, THERANOSTICS, V7, P270, DOI 10.7150/thno.16154
   Murphy MB, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.94
   Naji A, 2019, CELL MOL LIFE SCI, V76, P3323, DOI 10.1007/s00018 019 03125 1
   Newberry EP, 1998, BIOCHEMISTRY US, V37, P16360, DOI 10.1021/bi981878u
   Oliver Vila I, 2018, CYTOTECHNOLOGY, V70, P31, DOI 10.1007/s10616 017 0186 0
   Oliver Vila I, 2016, CYTOTHERAPY, V18, P25, DOI 10.1016/j.jcyt.2015.10.001
   Perez JR, 2018, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00105
   Prat S, 2018, J TISSUE ENG REGEN M, V12, pE532, DOI 10.1002/term.2323
   Rahman S, 2015, TGF BMP SIGNALING OT, V3, P15005, DOI [10.1038/boneres.2015.5, DOI 10.1038/BONERES.2015.5]
   Roura S, 2019, METABOLISM, V95, P102, DOI 10.1016/j.metabol.2019.02.006
   Roura S, 2019, PROTEOMICS, V19, DOI 10.1002/pmic.201800397
   Sampson S, 2015, PM&R, V7, pS26, DOI 10.1016/j.pmrj.2015.01.023
   Shirakabe K, 2001, GENES CELLS, V6, P851, DOI 10.1046/j.1365 2443.2001.00466.x
   Spinella Jaegle S, 2001, BONE, V29, P323, DOI 10.1016/S8756 3282(01)00580 4
   Ulsamer A, 2008, J BIOL CHEM, V283, P3816, DOI 10.1074/jbc.M704724200
   Vives J, 2018, Reference module in biomedical sciences
   Wang XQ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193059
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Yingling Jonathan M, 2018, Oncotarget, V9, P6659, DOI 10.18632/oncotarget.23795
   Zhou Y., 2018, J. Stem Cell Res. Ther, V8, P2, DOI [10.4172/2157 7633.1000415, DOI 10.4172/2157 7633.1000415]
NR 61
TC 26
Z9 26
U1 1
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1757 6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD NOV 28
PY 2019
VL 10
IS 1
AR 356
DI 10.1186/s13287 019 1450 3
PG 11
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA JS0RQ
UT WOS:000500022500005
PM 31779673
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Diepenhorst, NA
   Nowell, CJ
   Rueda, P
   Henriksen, K
   Pierce, T
   Cook, AE
   Pastoureau, P
   Sabatini, M
   Charman, WN
   Christopoulos, A
   Summers, RJ
   Sexton, PM
   Langmead, CJ
AF Diepenhorst, Natalie A.
   Nowell, Cameron J.
   Rueda, Patricia
   Henriksen, Kim
   Pierce, Tracie
   Cook, Anna E.
   Pastoureau, Philippe
   Sabatini, Massimo
   Charman, William N.
   Christopoulos, Arthur
   Summers, Roger J.
   Sexton, Patrick M.
   Langmead, Christopher J.
TI High throughput, quantitative analysis of human osteoclast
   differentiation and activity
SO ANALYTICAL BIOCHEMISTRY
LA English
DT Article
DE Osteoclast; Tartrate resistant acid phosphatase (TRAP); Bone resorption;
   High throughput; Quantitative image analysis; ImageJ
ID RESISTANT ACID PHOSPHATASE; BONE RESORPTION; RECEPTOR; NUCLEI; CELLS;
   MODULATION; PRECURSORS; BEHAVIOR
AB Osteoclasts are multinuclear cells that degrade bone under both physiological and pathophysiological conditions. Osteoclasts are therefore a major target of osteoporosis therapeutics aimed at preserving bone. Consequently, analytical methods for osteoclast activity are useful for the development of novel biomarkers and/or pharmacological agents for the treatment of osteoporosis.
   The nucleation state of an osteoclast is indicative of its maturation and activity. To date, activity is routinely measured at the population level with only approximate consideration of the nucleation state (an 'osteoclast population' is typically defined as cells with >= 3 nuclei). Using a fluorescent substrate for tartrate resistant acid phosphatase (TRAP), a routinely used marker of osteoclast activity, we developed a multi labelled imaging method for quantitative measurement of osteoclast TRAP activity at the single cell level. Automated image analysis enables interrogation of large osteoclast populations in a high throughput manner using open source software.
   Using this methodology, we investigated the effects of receptor activator of nuclear factor kappa B ligand (RANK L) on osteoclast maturation and activity and demonstrated that TRAP activity directly correlates with osteoclast maturity (i.e. nuclei number). This method can be applied to high throughput screening of osteoclast targeting compounds to determine changes in maturation and activity. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Diepenhorst, Natalie A.; Nowell, Cameron J.; Rueda, Patricia; Pierce, Tracie; Cook, Anna E.; Charman, William N.; Christopoulos, Arthur; Summers, Roger J.; Sexton, Patrick M.; Langmead, Christopher J.] Monash Univ, Monash Inst Pharmaceut Sci, Drug Discovery Biol, 381 Royal Parade, Parkville, Vic 3052, Australia.
   [Henriksen, Kim] Nord Biosci, Biomarkers & Res, Herlev, Denmark.
   [Pastoureau, Philippe; Sabatini, Massimo] Inst Rech Servier, Therapeut Innovat Pole Rheumatol, Suresnes, France.
C3 Monash University; Nordic Bioscience; Servier; Institut de Recherches
   Internationales Servier
RP Langmead, CJ (通讯作者)，Monash Univ, Monash Inst Pharmaceut Sci, Drug Discovery Biol, 381 Royal Parade, Parkville, Vic 3052, Australia.
EM chris.langmead@monash.edu
RI Summers, Roger/F 6351 2011; Sexton, Patrick/B 1319 2008; Diepenhorst,
   Natalie/HHS 2496 2022; Christopoulos, Arthur/B 6207 2013
OI Sexton, Patrick/0000 0001 8902 2473; Summers, Roger/0000 0002 8367 4056;
   Christopoulos, Arthur/0000 0003 4442 3294; Pierce,
   Tracie/0000 0002 6999 6008; Nowell, Cameron/0000 0002 8662 9840; Rueda,
   Patricia/0000 0003 1553 0840; Charman, William/0000 0002 7051 2023;
   Diepenhorst, Natalie/0000 0001 5875 7207; Langmead,
   Christopher/0000 0003 3483 1120
FU Servier
FX AC is a NHMRC Senior Principal Research Fellow and PMS is a NHMRC
   Principal Research Fellow. This study was performed as part of a
   Servier funded collaboration between Monash University and Servier.
CR Bayly J. R., 2007, CLIN TRIALS OSTEOPOR, P189
   Boissy P, 2002, ENDOCRINOLOGY, V143, P1913, DOI 10.1210/en.143.5.1913
   Chitu V, 2012, BLOOD, V120, P3126, DOI 10.1182/blood 2012 04 425595
   Creed SJ, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058 015 0655 3
   Durand M, 2013, ARTHRITIS RHEUM US, V65, P148, DOI 10.1002/art.37722
   Halleen JM, 2006, CLIN LAB, V52, P499
   Hayman AR, 2008, AUTOIMMUNITY, V41, P218, DOI 10.1080/08916930701694667
   Hayman AR, 2000, J HISTOCHEM CYTOCHEM, V48, P219, DOI 10.1177/002215540004800207
   Helfrich M.H., 2003, Bone research protocols, V80
   Henriksen K, 2004, AM J PATHOL, V164, P1537, DOI 10.1016/S0002 9440(10)63712 1
   Karsdal MA, 2003, J BIOL CHEM, V278, P44975, DOI 10.1074/jbc.M303905200
   Kirstein B, 2006, J CELL BIOCHEM, V98, P1085, DOI 10.1002/jcb.20835
   Matsuo K, 2008, ARCH BIOCHEM BIOPHYS, V473, P201, DOI 10.1016/j.abb.2008.03.027
   Nicholson GC, 2000, CLIN SCI, V99, P133, DOI 10.1042/CS19990355
   PIPER K, 1992, ANAT EMBRYOL, V186, P291
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Sims NA, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00041
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   ten Harkel B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139564
   Tintut Y, 2002, J BIOL CHEM, V277, P14221, DOI 10.1074/jbc.M111551200
   Walker J. M., 2012, METHOD MOL BIOL, P630
   Zhang T, 2016, CHROMOSOME RES, V24, P243, DOI 10.1007/s10577 016 9519 7
NR 23
TC 9
Z9 13
U1 1
U2 14
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0003 2697
EI 1096 0309
J9 ANAL BIOCHEM
JI Anal. Biochem.
PD FEB 15
PY 2017
VL 519
BP 51
EP 56
DI 10.1016/j.ab.2016.12.010
PG 6
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Analytical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA EI5UM
UT WOS:000392560300009
PM 27988276
DA 2025 08 17
ER

PT J
AU Kwak, SC
   Jeong, D
   Cheon, YH
   Lee, CH
   Yoon, KH
   Kim, JY
   Lee, MS
AF Kwak, Sung Chul
   Jeong, Da Hye
   Cheon, Yoon Hee
   Lee, Chang Hoon
   Yoon, Kwon Ha
   Kim, Ju Young
   Lee, Myeung Su
TI Securinine suppresses osteoclastogenesis and ameliorates inflammatory
   bone loss
SO PHYTOTHERAPY RESEARCH
LA English
DT Article
DE bone disease; bone resorption; osteoclast differentiation; RANKL;
   securinine
ID CELL CELL FUSION; NUCLEAR FACTOR; IN VITRO; RESORPTION; MICE;
   OSTEOPROTEGERIN; ANTAGONIST; EXPRESSION; RECEPTORS
AB Securinine (Sec) is a naturally derived compound separated from the roots of Securinega suffruticosa, which has long been used as a herbal medicine. Sec is widely known as a GABA receptor antagonist, it is also known as an innate immune cell agonist and has been reported to increase macrophage activity and promote monocyte maturation. On the basis of these studies, we investigated the effect of Sec on osteoclast differentiation and bone resorbing function. We have found that Sec inhibits RANKL induced osteoclast differentiation, fusion, actin ring formation, and bone resorbing function by the inhibition of gene expression associated with each stage. Moreover, Sec significantly suppressed osteoclastogenesis by decreasing the phosphorylation of p38, Akt, JNK, I kappa B, and PLC gamma 2, in pathways involved in early osteoclastogenesis as well as through the subsequent suppression of c Fos and NFATc1. Finally, Sec effectively protected bone loss induced by the excessive inflammatory responses and activity of osteoclasts in vivo by a micro CT and histological analysis. In conclusion, our findings suggest that Sec may be a promising drug for bone metabolic diseases such as osteoporosis, which is associated with the excessive activity of osteoclasts.
C1 [Kwak, Sung Chul] Wonkwang Univ, Sch Med, Dept Anat, Iksan, South Korea.
   [Jeong, Da Hye; Lee, Chang Hoon; Lee, Myeung Su] Wonkwang Univ Hosp, Dept Internal Med, Div Rheumatol, Iksan, South Korea.
   [Cheon, Yoon Hee] Wonkwang Univ, Core Res Facil Ctr, Sch Med, Iksan, South Korea.
   [Cheon, Yoon Hee; Lee, Chang Hoon; Kim, Ju Young; Lee, Myeung Su] Wonkwang Univ, Sch Med, Musculoskeletal & Immune Dis Res Inst, Iksan, South Korea.
   [Yoon, Kwon Ha] Wonkwang Univ Hosp, Dept Radiol, Iksan, South Korea.
   [Yoon, Kwon Ha; Kim, Ju Young] Wonkwang Univ Hosp, Med Convergence Res Ctr, 460 Iksandae Ro, Iksan 54538, Jeonbuk, South Korea.
C3 Wonkwang University; Wonkwang University; Wonkwang University; Wonkwang
   University; Wonkwang University; Wonkwang University
RP Kim, JY (通讯作者)，Wonkwang Univ Hosp, Med Convergence Res Ctr, 460 Iksandae Ro, Iksan 54538, Jeonbuk, South Korea.; Lee, MS (通讯作者)，Wonkwang Univ, Sch Med, Dept Internal Med, Div Rheumatol, 460 Iksandae Ro, Iksan 54538, Jeonbuk, South Korea.
EM kimjy1014@gmail.com; ckhlms@wku.ac.kr
RI Lee, Sang Hoon/ABH 6210 2020
OI Kim, Ju Young/0000 0002 4493 0264
FU National Research Foundation of Korea [NRF 2018R1D1A1B07049679,
   NRF 2019R1I1A1A02059434]
FX National Research Foundation of Korea, Grant/Award Numbers:
   NRF 2018R1D1A1B07049679, NRF 2019R1I1A1A02059434
CR Aliprantis AO, 2008, J CLIN INVEST, V118, P3775, DOI 10.1172/JCI35711
   Baek JM, 2018, EXP MOL MED, V50, DOI 10.1038/s12276 018 0076 3
   BEUTLER JA, 1985, BRAIN RES, V330, P135, DOI 10.1016/0006 8993(85)90014 9
   Bi HD, 2017, FRONT MED LAUSANNE, V4, DOI 10.3389/fmed.2017.00234
   Blair HC, 1998, BIOESSAYS, V20, P837, DOI 10.1002/(SICI)1521 1878(199810)20:10<837::AID BIES9>3.0.CO;2 D
   BURAVTSEVA G R, 1958, Farmakol Toksikol, V21, P7
   Engelman VW, 1997, J CLIN INVEST, V99, P2284, DOI 10.1172/JCI119404
   Faccio R, 2003, J CELL BIOL, V162, P499, DOI 10.1083/jcb.200212082
   Han SW, 2017, ONCOL LETT, V14, P4243, DOI 10.3892/ol.2017.6693
   Harvey AL, 2008, DRUG DISCOV TODAY, V13, P894, DOI 10.1016/j.drudis.2008.07.004
   Ho N, 1999, J BONE MINER RES, V14, P1649, DOI 10.1359/jbmr.1999.14.10.1649
   Ishizuya Toshinori, 2012, Clin Calcium, V22, P357, DOI CliCa1203357363
   Kameda T, 1997, J EXP MED, V186, P489, DOI 10.1084/jem.186.4.489
   Kim JY, 2015, BONE, V79, P242, DOI 10.1016/j.bone.2015.06.011
   Kim Jung Ha, 2016, Chonnam Med J, V52, P12, DOI 10.4068/cmj.2016.52.1.12
   Kim K, 2005, J BIOL CHEM, V280, P35209, DOI 10.1074/jbc.M505815200
   Kiviranta R, 2005, BONE, V36, P159, DOI 10.1016/j.bone.2004.09.020
   Leonoudakis D, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/8302636
   Lubick K, 2007, J LEUKOCYTE BIOL, V82, P1062, DOI 10.1189/jlb.0407255
   McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905
   Miyamoto H, 2012, J BONE MINER RES, V27, P1289, DOI 10.1002/jbmr.1575
   Möhler H, 2006, J RECEPT SIG TRANSD, V26, P731, DOI 10.1080/10799890600920035
   Shipman M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041278
   Song RL, 2014, INT J MOL MED, V34, P856, DOI 10.3892/ijmm.2014.1846
   Takahata Y, 2011, J BIOL CHEM, V286, P32906, DOI 10.1074/jbc.M111.253526
   Takito J, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19040984
   Xiao YL, 2015, STEM CELL REP, V4, P984, DOI 10.1016/j.stemcr.2015.04.012
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
NR 28
TC 6
Z9 8
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0951 418X
EI 1099 1573
J9 PHYTOTHER RES
JI Phytother. Res.
PD NOV
PY 2020
VL 34
IS 11
BP 3029
EP 3040
DI 10.1002/ptr.6735
EA JUN 2020
PG 12
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA OS7SL
UT WOS:000538605600001
PM 32510717
DA 2025 08 17
ER

PT J
AU Luo, Y
   Wu, WB
   Gu, J
   Zhang, XM
   Dang, JL
   Wang, JL
   Zheng, YJ
   Huang, F
   Yuan, J
   Xue, YQ
   Fu, QL
   Kandalam, U
   Colello, J
   Zheng, SG
AF Luo, Yang
   Wu, Wenbin
   Gu, Jian
   Zhang, Ximei
   Dang, Junlong
   Wang, Julie
   Zheng, Yongjiang
   Huang, Feng
   Yuan, Jia
   Xue, Youqiu
   Fu, Qingling
   Kandalam, Umadevi
   Colello, Jacob
   Zheng, Song Guo
TI Human gingival tissue derived MSC suppress osteoclastogenesis and bone
   erosion via CD39 adenosine signal pathway in autoimmune arthritis
SO EBIOMEDICINE
LA English
DT Article
DE Rheumatoid arthritis; Mesenchymal stem cells; CD39; Adenosine
ID MESENCHYMAL STEM CELLS; COLLAGEN INDUCED ARTHRITIS;
   RHEUMATOID ARTHRITIS; DIFFERENTIATION; ADENOSINE; DISEASE; MODEL; MICE
AB Background: Bone destruction is one of many severe complications that occurs in patients with rheumatoid arthritis (RA) and current therapies are unable to cure this manifestation. This study here aims to determine whether GMSC can directly inhibit osteoclast formation and eventually attenuate osteodastogenesis and bone erosion in an inflammatory milieu.
   Method: GMSC were co cultured with osteoclast precursors with or without CD39 inhibitor, CD73 inhibitor or adenosine receptors inhibitors pretreatment and osteoclast formation were evaluated in vitro. 2x 10<^>6 GMSC per mouse were transferred to CIA mice and pathology scores, the frequency of osteoclasts, bone erosion in joints were assessed in vivo.
   Finding: GMSC but not control cells, markedly suppressed human or mice osteodastogenesis in vitro. GMSC treatment also resulted in a dramatically decreased level of NF kappa B p65/p50 in osteoclasts in vitro. Infusion of GMSC to CIA significantly attenuated the severity of arthritis, pathology scores, frequency of osteoclasts, particularly bone erosion, as well as a decreased expression of RANKL in synovial tissues in vivo. Blockade of CD39/CD73 or adenosine receptors has significantly abrogated the suppressive ability of GMSC in vitro and therapeutic effect of GMSC on bone erosion during CIA in vivo.
   Interpretation: GMSC inhibit osteoclast formation in vitro and in vivo partially via CD39 CD73 adenosine signals. Manipulation of GMSC may have a therapeutic implication on rheumatoid arthritis and other bone erosion related diseases. (C) 2019 The Authors. Published by Elsevier B.V.
C1 [Luo, Yang; Wu, Wenbin; Zhang, Ximei; Dang, Junlong; Huang, Feng; Yuan, Jia; Xue, Youqiu] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Clin Immunol, Guangzhou 510000, Guangdong, Peoples R China.
   [Luo, Yang; Gu, Jian; Zhang, Ximei; Dang, Junlong; Wang, Julie; Zheng, Yongjiang; Xue, Youqiu; Colello, Jacob] Penn State Coll Med, Dept Med, Div Rheumatol, Hershey, PA 17033 USA.
   [Luo, Yang; Gu, Jian; Zhang, Ximei; Dang, Junlong; Wang, Julie; Zheng, Yongjiang; Xue, Youqiu; Colello, Jacob] Milton S Hershey Med Ctr, Hershey, PA 17033 USA.
   [Luo, Yang] Lanzhou Univ, Hosp 1, Dept Neurol, Lanzhou 730000, Peoples R China.
   [Gu, Jian] Univ Southern Calif, Keck Sch Med, Div Rheumatol & Immunol, Los Angeles, CA 90033 USA.
   [Zhang, Ximei; Wang, Julie; Xue, Youqiu; Zheng, Song Guo] Ohio State Univ, Coll Med, Dept Internal Med, Div Rheumatol & Immunol, Columbus, PA 43201 USA.
   [Fu, Qingling] Sun Yat Sen Univ, Affiliated Hosp 1, Otorhinolaryngol Hosp, 58 Zhongshan Rd 2, Guangzhou 510080, Guangdong, Peoples R China.
   [Kandalam, Umadevi] Nova Southeastern Univ, Coll Dent Med, Dept Pediat Dent, Davie, FL 33328 USA.
C3 Sun Yat Sen University; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); Pennsylvania State University; Penn State Health;
   Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Penn State Health; Lanzhou University;
   University of Southern California; Sun Yat Sen University; Nova
   Southeastern University
RP Zheng, SG (通讯作者)，Ohio State Univ, Coll Med, 480 Med Ctr Dr, Columbus, OH 43201 USA.; Zheng, SG (通讯作者)，Ohio State Univ, Wexner Med Ctr, 480 Med Ctr Dr, Columbus, OH 43201 USA.
EM SongGuo.Zheng@osumc.edu
RI Gu, Jian/AAG 2779 2021; huang, feng/HSF 2323 2023; Yuan,
   Jia/KWU 8157 2024
FU National Key R&D Program of China [2017YFA0105801]; Zhujiang Innovative
   and Entrepreneurial Talent Team Award of Guangdong Province [2016 ZT 06S
   252]; National Institutes of Health [R01 AR059103, R61 AR073409];
   National Institutes of Health (NIH Star Award)
FX This study was supported by grants from the National Key R&D Program of
   China (2017YFA0105801 to F.H); the Zhujiang Innovative and
   Entrepreneurial Talent Team Award of Guangdong Province (2016 ZT 06S 252
   to F.H) and National Institutes of Health (R01 AR059103, R61 AR073409
   and NIH Star Award to S.G.Z).
CR Ansboro S, 2017, CURR OPIN RHEUMATOL, V29, P201, DOI 10.1097/BOR.0000000000000370
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Brand DD, 2007, NAT PROTOC, V2, P1269, DOI 10.1038/nprot.2007.173
   Bubonja Sonje M, 2013, W INDIAN MED J, V62, P270
   Chatzidionysiou K, 2015, ANN RHEUM DIS, V74, P890, DOI 10.1136/annrheumdis 2013 204714
   Chen MG, 2013, ARTHRITIS RHEUM US, V65, P1181, DOI 10.1002/art.37894
   Chen WQ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01662
   Colucci S, 2004, BLOOD, V104, P3722, DOI 10.1182/blood 2004 02 0474
   Galani IE, 2010, INT J CANCER, V127, P1131, DOI 10.1002/ijc.25132
   Gashi Afrim A, 2014, Med Arch, V68, P51
   Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529 0131(200002)43:2<250::AID ANR3>3.0.CO;2 P
   Halenius A, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/472978
   Huang F, 2018, CURR STEM CELL RES T, V13, P345, DOI 10.2174/1574888X13666180220141114
   Huang F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00068
   Ikonomidis I, 2014, CIRC CARDIOVASC IMAG, V7, P619, DOI 10.1161/CIRCIMAGING.113.001193
   Kamijo S, 2006, BIOCHEM BIOPH RES CO, V347, P124, DOI 10.1016/j.bbrc.2006.06.098
   Kang IS, 2016, SCI REP UK, V6, DOI 10.1038/srep38014
   Katebi M, 2009, J LEUKOCYTE BIOL, V85, P438, DOI 10.1189/jlb.0908520
   Kong N, 2012, ANN RHEUM DIS, V71, P1567, DOI 10.1136/annrheumdis 2011 201052
   Kong N, 2012, ARTHRITIS RHEUM US, V64, P2548, DOI 10.1002/art.34513
   Liu YY, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3187
   Maria S, 2018, J PINEAL RES, V64, DOI 10.1111/jpi.12465
   Papadopoulou A, 2012, ANN RHEUM DIS, V71, P1733, DOI 10.1136/annrheumdis 2011 200985
   Patel SA, 2010, J IMMUNOL, V184, P5885, DOI 10.4049/jimmunol.0903143
   Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002 9440(10)63016 7
   Ruoff G, 2014, J FAM PRACTICE, V63, pS27
   Sattler C, 2011, CELL TRANSPLANT, V20, P1221, DOI 10.3727/096368910X546553
   Schuler PJ, 2014, CLIN EXP IMMUNOL, V177, P531, DOI 10.1111/cei.12354
   Smolen JS, 2014, ANN RHEUM DIS, V73, P1616, DOI 10.1136/annrheumdis 2013 205137
   Su WR, 2017, J MOL CELL BIOL, V9, P289, DOI 10.1093/jmcb/mjx022
   Su WR, 2015, J ALLERGY CLIN IMMUN, V136, P423, DOI 10.1016/j.jaci.2014.12.1926
   Sucur A, 2014, INT ORTHOP, V38, P1893, DOI 10.1007/s00264 014 2386 y
   Tamas MM, 2014, RHEUMATOLOGY, V53, P1100, DOI 10.1093/rheumatology/ket484
   Thiolat A, 2014, ARTHRITIS RHEUMATOL, V66, P273, DOI 10.1002/art.38246
   Uccelli A, 2015, ANN NY ACAD SCI, V1351, P114, DOI 10.1111/nyas.12815
   Walsh MC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00511
   Yin F, 2014, STEM CELLS, V32, P1278, DOI 10.1002/stem.1638
   Zhang QZ, 2010, STEM CELLS, V28, P1856, DOI 10.1002/stem.503
   Zhang QZ, 2009, J IMMUNOL, V183, P7787, DOI 10.4049/jimmunol.0902318
   Zhang W, 2004, STEM CELLS DEV, V13, P263, DOI 10.1089/154732804323099190
   Zhang W, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 14979 5
   Zhang XM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00878
   Zheng T, 2014, EUR J PHARMACOL, V737, P185, DOI 10.1016/j.ejphar.2014.04.047
   Zou YY, 2018, J CLIN INVEST, V128, P4510, DOI 10.1172/JCI97965
NR 44
TC 76
Z9 79
U1 1
U2 15
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2352 3964
J9 EBIOMEDICINE
JI EBioMedicine
PD MAY
PY 2019
VL 43
BP 620
EP 631
DI 10.1016/j.ebiom.2019.04.058
PG 12
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA IB2HZ
UT WOS:000470091600070
PM 31076346
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Sakai, E
   Aoki, Y
   Yoshimatsu, M
   Nishishita, K
   Iwatake, M
   Fukuma, Y
   Okamoto, K
   Tanaka, T
   Tsukuba, T
AF Sakai, Eiko
   Aoki, Yuri
   Yoshimatsu, Masako
   Nishishita, Kazuhisa
   Iwatake, Mayumi
   Fukuma, Yutaka
   Okamoto, Kuniaki
   Tanaka, Takashi
   Tsukuba, Takayuki
TI Sanguiin H 6, a constituent of Rubus parvifolius L., inhibits
   receptor activator of nuclear factor κB ligand induced
   osteoclastogenesis and bone resorption in vitro and prevents
   tumor necrosis factor α induced osteoclast formation in vivo
SO PHYTOMEDICINE
LA English
DT Article
DE Sanguiin H 6; Osteoclast; Receptor activator of nuclear factor kappa b;
   Nuclear factor of activated T cells; cytoplasmic 1; c Fos
ID HEME OXYGENASE 1; P38 MAPK; T CELLS; EXPRESSION; NFATC1;
   DIFFERENTIATION; OSTEOPETROSIS; LEADS
AB Background: Osteoclasts are multinucleated bone resorbing cells that differentiate in response to receptor activator of nuclear factor kappa B (NF kappa B) ligand (RANKL). Enhanced osteoclastogenesis contributes to bone diseases, such as osteoporosis and rheumatoid arthritis. Rubus parvifolius L. is traditionally used as an herbal medicine for rheumatism; however, its detailed chemical composition and the molecular mechanisms responsible for its biological action have not been elucidated.
   Purpose: To investigate the mechanisms by which R. parvifolius L. extract and its major constituent sanguiin H 6, inhibit osteoclastogenesis and bone resorption.
   Methods: Cell proliferation, cell differentiation, and bone resorption were detected in vitro. Inhibition of signaling pathways, marker protein expression, and protein nuclear translocation were evaluated by western blot analysis. Tumor necrosis factor alpha (TNF alpha) mediated osteoclastogenesis was examined in vivo.
   Results: R. parvifolius L. extract inhibited the bone resorption activity of osteoclasts. In addition, sanguiin H 6 markedly inhibited RANKL induced osteoclast differentiation and bone resorption, reduced reactive oxygen species production, and inhibited the phosphorylation of inhibitor of NF kappa B alpha (I kappa B alpha) and p38 mitogen activated protein kinase. Sanguiin H 6 also decreased the protein levels of nuclear factor of activated T cells cytoplasmic 1 (NFATc1), cathepsin K, and c Src. Moreover, sanguiin H 6 inhibited the nuclear translocation of NFATc1, c Fos, and NF kappa B in vitro, as well as TNF alpha mediated osteoclastogenesis in vivo.
   Conclusions: Our data revealed that R. parvifolius L. has anti bone resorption activity and suggest that its constituent, sanguiin H 6, can potentially be used for the prevention and treatment of bone diseases associated with excessive osteoclast formation and subsequent bone destruction. (C) 2016 Elsevier GmbH. All rights reserved.
C1 [Sakai, Eiko; Aoki, Yuri; Nishishita, Kazuhisa; Iwatake, Mayumi; Fukuma, Yutaka; Okamoto, Kuniaki; Tsukuba, Takayuki] Nagasaki Univ, Grad Sch Biomed Sci, Dept Dev & Reconstruct Med, Div Dent Pharmacol, Nagasaki 8528588, Japan.
   [Yoshimatsu, Masako] Nagasaki Univ, Grad Sch Biomed Sci, Dept Dev & Reconstruct Med, Div Orthodont & Dentofacial Orthoped, Nagasaki 8528588, Japan.
   [Tanaka, Takashi] Nagasaki Univ, Grad Sch Biomed Sci, Dept Mol Med Sci, Div Nat Prod Chem, Nagasaki 8528131, Japan.
C3 Nagasaki University; Nagasaki University; Nagasaki University
RP Sakai, E (通讯作者)，Nagasaki Univ, Grad Sch Biomed Sci, Dept Dev & Reconstruct Med, Div Dent Pharmacol, Nagasaki 8528588, Japan.
EM eiko s@nagasaki u.ac.jp
RI ; Tsukuba, Takayuki/I 9542 2018
OI Tanaka, Takashi/0000 0001 7762 7432; sakai, eiko/0000 0002 6776 6540
FU Ministry of Education, Science, and Culture of Japan [25462892];
   Grants in Aid for Scientific Research [25462892, 16K15790, 15H05298,
   15K11079] Funding Source: KAKEN
FX We thank Mr. Shun Narahara, Mrs. Haruna Matsushima Narahara, and Dr.
   Jin Ping Hu from the Division of Dental Pharmacology, Nagasaki
   University, and Mr. Tomomichi Kobayashi from the Biopathology Institute
   for their help with the in vivo study. This study was partly supported
   by Grants in Aid for Scientific Research from Ministry of Education,
   Science, and Culture of Japan to E. S. (grant number: 25462892)
CR Abu Amer Y, 1998, J BIOL CHEM, V273, P29417, DOI 10.1074/jbc.273.45.29417
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chuvpilo S, 2002, IMMUNITY, V16, P881, DOI 10.1016/S1074 7613(02)00329 1
   COPE AP, 1995, J RHEUMATOL, V22, P382
   Gao J, 2011, J ZHEJIANG UNIV SC B, V12, P135, DOI 10.1631/jzus.B1000117
   Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236
   He X, 2010, BIOCHEM BIOPH RES CO, V401, P356, DOI 10.1016/j.bbrc.2010.09.053
   Kamiya T, 1998, J BIOCHEM TOKYO, V123, P752
   Kitaura H, 2004, J IMMUNOL, V173, P4838, DOI 10.4049/jimmunol.173.8.4838
   Lakkakorpi PT, 2001, J CELL SCI, V114, P149
   Lee NH, 2010, INT J MOL MED, V26, P201, DOI 10.3892/ijmm_00000453
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Lee SY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080873
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Naidu S, 2009, J IMMUNOL, V182, P7048, DOI 10.4049/jimmunol.0900006
   Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925
   Ryter SW, 2006, PHYSIOL REV, V86, P583, DOI 10.1152/physrev.00011.2005
   Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453
   Sakai E, 2013, J PHARMACOL SCI, V121, P288, DOI 10.1254/jphs.12243FP
   Sakai E, 2012, J CELL BIOCHEM, V113, P486, DOI 10.1002/jcb.23372
   SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181
   Sharma SM, 2007, J BIOL CHEM, V282, P15921, DOI 10.1074/jbc.M609723200
   Song I, 2009, FEBS LETT, V583, P2435, DOI 10.1016/j.febslet.2009.06.047
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   TANAKA T, 1985, J CHEM RES, P176
   Watanabe T, 2004, J ENDOCRINOL, V180, P193, DOI 10.1677/joe.0.1800193
   Yokozawa T, 2002, BIOCHEM PHARMACOL, V63, P853, DOI 10.1016/S0006 2952(01)00930 3
NR 32
TC 14
Z9 17
U1 0
U2 21
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0944 7113
EI 1618 095X
J9 PHYTOMEDICINE
JI Phytomedicine
PD JUL 15
PY 2016
VL 23
IS 8
BP 828
EP 837
DI 10.1016/j.phymed.2016.04.002
PG 10
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA DO1NA
UT WOS:000377544000005
PM 27288918
DA 2025 08 17
ER

PT J
AU Zheng, ZG
   Cheng, HM
   Zhou, YP
   Zhu, ST
   Thu, PM
   Li, HJ
   Li, P
   Xu, XJ
AF Zheng, Zu Guo
   Cheng, Hui Min
   Zhou, Ya Ping
   Zhu, Si Tong
   Thu, Pyone Myat
   Li, Hui Jun
   Li, Ping
   Xu, Xiaojun
TI Dual targeting of SREBP2 and ERRα by carnosic acid suppresses
   RANKL mediated osteoclastogenesis and prevents ovariectomy induced bone
   loss
SO CELL DEATH AND DIFFERENTIATION
LA English
DT Article
ID ESTROGEN RELATED RECEPTOR; TRANSCRIPTIONAL CONTROL; INSULIN RESISTANCE;
   CHOLESTEROL; MECHANISMS; DIFFERENTIATION; DISEASE; CANCER; RISK;
   ANHYDROICARITIN
AB Osteoporosis develops because of impaired bone formation and/or excessive bone resorption. Several pharmacological treatment of osteoporosis has been developed; however, new treatments are still necessary. Cholesterol and estrogen receptor related receptor alpha (ERR alpha) promote osteoclasts formation, survival, and cellular fusion and thus become high risk factors of osteoporosis. In this study, we identified that carnosic acid (CA) suppressed bone loss by dual targeting of sterol regulatory element binding protein 2 (SREBP2, a major regulator that regulates cholesterol synthesis) and ERR alpha. Mechanistically, CA reduced nuclear localization of mature SREBP2 and suppressed de novo biogenesis of cholesterol. CA subsequently decreased the interaction between ERR alpha and peroxisome proliferator activated receptor gamma coactivator 1 beta (PGC1 beta), resulting in decreased the transcription activity of ERR alpha and its target genes expression. Meanwhile, CA directly bound to the ligand binding domain of ERR alpha and significantly promoted its ubiquitination and proteasomal degradation. Subsequently, STUB1 was identified as the E3 ligase of ERR alpha. The lysine residues (K51 and K68) are essential for ubiquitination and proteasomal degradation of ERR alpha by CA. In conclusion, CA dually targets SREBP2 and ERR alpha, thus inhibits the RANKL induced osteoclast formation and improves OVX induced bone loss. CA may serve as a lead compound for pharmacological control of osteoporosis.
C1 [Zheng, Zu Guo; Cheng, Hui Min; Zhou, Ya Ping; Zhu, Si Tong; Thu, Pyone Myat; Li, Hui Jun; Li, Ping; Xu, Xiaojun] China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Jiangsu, Peoples R China.
   [Xu, Xiaojun] China Pharmaceut Univ, Jiangsu Key Lab Drug Discovery Metab Dis, Nanjing 210009, Jiangsu, Peoples R China.
C3 China Pharmaceutical University; China Pharmaceutical University
RP Li, P; Xu, XJ (通讯作者)，China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Jiangsu, Peoples R China.; Xu, XJ (通讯作者)，China Pharmaceut Univ, Jiangsu Key Lab Drug Discovery Metab Dis, Nanjing 210009, Jiangsu, Peoples R China.
EM liping2004@126.com; xiaojunxu2000@163.com
RI Li, Hui Jun/F 9837 2013; Zhou, Yaping/E 1448 2012; Zhong,
   Qing/GLT 4858 2022; Li, Ping/GYV 4914 2022
OI Xu, Xiaojun/0000 0003 4379 8748; 
FU Ministry of Science and Technology of China [2019YFC1711000]; National
   Natural Science Foundation of China [81773957, 81421005, 81903871];
   National Key Subject of Drug Innovation [2017ZX09301012003]; China
   Postdoctoral Science Foundation [2018M642380]; 111 Project [B16046];
   Project Program of State Key Laboratory of Natural Medicines, China
   Pharmaceutical University [SKLNMZZCX201820]; "Double First Class"
   University Project [CPU2018GF04]
FX This work was supported by the Ministry of Science and Technology of
   China (2019YFC1711000), the National Natural Science Foundation of China
   (81773957, 81421005, 81903871), the National Key Subject of Drug
   Innovation (No. 2017ZX09301012003), China Postdoctoral Science
   Foundation (2018M642380), the 111 Project (B16046). This project was
   also supported by the Project Program of State Key Laboratory of Natural
   Medicines, China Pharmaceutical University (SKLNMZZCX201820), the
   "Double First Class" University Project (CPU2018GF04).
CR ADAMI HO, 1989, INT J CANCER, V44, P833, DOI 10.1002/ijc.2910440515
   An SA, 2018, EBIOMEDICINE, V36, P553, DOI 10.1016/j.ebiom.2018.09.005
   Birtic S, 2015, PHYTOCHEMISTRY, V115, P9, DOI 10.1016/j.phytochem.2014.12.026
   Bondeson DP, 2015, NAT CHEM BIOL, V11, P611, DOI [10.1038/NCHEMBIO.1858, 10.1038/nchembio.1858]
   Bonnelye E, 2016, ENDOCRINOL METAB SYN, V5
   Bonnelye E, 2013, J BONE MINER RES, V28, P225, DOI 10.1002/jbmr.1836
   Buckley DL, 2012, J AM CHEM SOC, V134, P4465, DOI 10.1021/ja209924v
   Chung SH, 2010, TRENDS ENDOCRIN MET, V21, P504, DOI 10.1016/j.tem.2010.03.005
   Clemons M, 2001, NEW ENGL J MED, V344, P276, DOI 10.1056/NEJM200101253440407
   Curry SJ, 2018, JAMA J AM MED ASSOC, V319, P2521, DOI 10.1001/jama.2018.7498
   Derby CA, 2009, AM J EPIDEMIOL, V169, P1352, DOI 10.1093/aje/kwp043
   Eichner LJ, 2011, MITOCHONDRION, V11, P544, DOI 10.1016/j.mito.2011.03.121
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Gallet M, 2010, TRENDS ENDOCRIN MET, V21, P637, DOI 10.1016/j.tem.2010.06.008
   Ghadiri Anari A, 2016, INT J REPROD BIOMED, V14, P597
   Grasser W. A., 2003, Journal of Musculoskeletal & Neuronal Interactions, V3, P53
   Hotokezaka H, 2002, J BIOL CHEM, V277, P47366, DOI 10.1074/jbc.M208284200
   Ikebuchi Y, 2018, NATURE, V561, P195, DOI 10.1038/s41586 018 0482 7
   Inoue K, 2015, BBA MOL BASIS DIS, V1852, P2432, DOI 10.1016/j.bbadis.2015.08.018
   Inoue K, 2014, J BONE MINER RES, V29, P1823, DOI 10.1002/jbmr.2229
   Jarzabek K, 2009, J STEROID BIOCHEM, V113, P127, DOI 10.1016/j.jsbmb.2008.12.005
   Jeong T. D., 2014, BioMed Research International, V2014, P1
   Jie ZW, 2019, BBA MOL BASIS DIS, V1865, P115, DOI 10.1016/j.bbadis.2018.10.026
   Karsenty G, 2008, ANNU REV GENOM HUM G, V9, P183, DOI 10.1146/annurev.genom.9.081307.164437
   Li S, 2014, ARTHRITIS RHEUMATOL, V66, P1854, DOI 10.1002/art.38521
   Lindsay R, 2002, JAMA J AM MED ASSOC, V287, P2668, DOI 10.1001/jama.287.20.2668
   Llaverias G, 2011, AM J PATHOL, V178, P402, DOI 10.1016/j.ajpath.2010.11.005
   Luegmayr E, 2004, CELL DEATH DIFFER, V11, pS108, DOI 10.1038/sj.cdd.4401399
   Makovey J, 2009, BONE, V44, P208, DOI 10.1016/j.bone.2008.09.020
   Mandal CC, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00165
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   Marino Silvia, 2014, Bonekey Rep, V3, P570, DOI 10.1038/bonekey.2014.65
   Meier CR, 2000, JAMA J AM MED ASSOC, V283, P3205, DOI 10.1001/jama.283.24.3205
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Nelson ER, 2014, TRENDS ENDOCRIN MET, V25, P649, DOI 10.1016/j.tem.2014.10.001
   Pei HX, 2019, RSC ADV, V9, P16967, DOI 10.1039/c9ra03423d
   Peng LJ, 2019, ACS MED CHEM LETT, V10, P767, DOI 10.1021/acsmedchemlett.9b00025
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Prideaux M, 2016, CURR OPIN PHARMACOL, V28, P24, DOI 10.1016/j.coph.2016.02.003
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Ruan F, 2012, BIOSCIENCE REP, V32, P511, DOI 10.1042/BSR20110118
   Sato T, 1998, BONE, V23, P135, DOI 10.1016/S8756 3282(98)00082 9
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Stein RA, 2009, J STEROID BIOCHEM, V114, P106, DOI 10.1016/j.jsbmb.2009.02.010
   Suzuki T, 2004, CANCER RES, V64, P4670, DOI 10.1158/0008 5472.CAN 04 0250
   Tanaka Yoshiya, 2005, Current Drug Targets   Inflammation and Allergy, V4, P325, DOI 10.2174/1568010054022015
   Vargas G, 2019, ONCOGENE, V38, P950, DOI 10.1038/s41388 018 0579 3
   Wan YH, 2010, TRENDS ENDOCRIN MET, V21, P722, DOI 10.1016/j.tem.2010.08.006
   Wei W, 2016, CELL METAB, V23, P479, DOI 10.1016/j.cmet.2015.12.010
   Wei W, 2010, CELL METAB, V11, P503, DOI 10.1016/j.cmet.2010.04.015
   Willy PJ, 2004, P NATL ACAD SCI USA, V101, P8912, DOI 10.1073/pnas.0401420101
   Xie ZS, 2017, J FUNCT FOODS, V31, P217, DOI 10.1016/j.jff.2017.01.040
   Yamaguchi T, 2002, ENDOCR J, V49, P211, DOI 10.1507/endocrj.49.211
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zheng ZG, 2017, EUR J PHARMACOL, V809, P156, DOI 10.1016/j.ejphar.2017.05.017
   Zheng ZG, 2016, BIOCHEM PHARMACOL, V122, P42, DOI 10.1016/j.bcp.2016.10.016
NR 56
TC 51
Z9 55
U1 1
U2 65
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1350 9047
EI 1476 5403
J9 CELL DEATH DIFFER
JI Cell Death Differ.
PD JUL
PY 2020
VL 27
IS 7
BP 2048
EP 2065
DI 10.1038/s41418 019 0484 5
EA JAN 2020
PG 18
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA MA5RO
UT WOS:000508173000001
PM 31907393
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Enríquez, J
   Lemus, AE
   Chimal Monroy, J
   Arzate, H
   García, GA
   Herrero, B
   Larrea, F
   Pérez Palacios, G
AF Enriquez, Juana
   Lemus, Ana Elena
   Chimal Monroy, Jesus
   Arzate, Higinio
   Garcia, Gustavo A.
   Herrero, Bertha
   Larrea, Fernando
   Perez Palacios, Gregorio
TI The effects of synthetic 19 norprogestins on osteoblastic cell function
   are mediated by their non phenolic reduced metabolites
SO JOURNAL OF ENDOCRINOLOGY
LA English
DT Article
ID ESTROGEN RECEPTOR ALPHA; BONE COLLAGEN SYNTHESIS; POSTMENOPAUSAL WOMEN;
   MEDROXYPROGESTERONE ACETATE; ESTABLISHED OSTEOPOROSIS; NANDROLONE
   DECANOATE; SEX STEROIDS; IN VITRO; PROGESTERONE; NORETHISTERONE
AB The key role of estrogens on osteoblastic cell function is well documented; however, the role of progesterone (P) and synthetic progestins remains controversial. While several reports indicate that P has no significant effects on bone cells, a number of clinical studies have shown that 19 norprogestins restore postmenopausal bone loss. The mechanisms by which 19 norprogestins induce estrogen like effects on bone cells are not fully understood. To assess whether the actions of 19 norprogestins on osteoblasts are mediated by their non phenolic metabolites, we studied the effects of norethisterone (NET), levonorgestrel (LNG), and two of their A ring reduced derivatives upon cell proliferation and differentiation in neonatal rat osteoblasts. Osteoblast function was assessed by determining cell DNA, cell associated osteocalcin and calcium content, alkaline phosphatase activity, and mineral deposition. P failed to induce changes on osteoblasts, while NET and LNG exerted a number of actions. The most striking finding was that the 3 beta,5 alpha  and 3 alpha,5 alpha tetrahydro derivatives of NET and LNG induced osteoblast proliferation and differentiation with higher potency than those exerted by their parent compounds, mimicking the effects of estradiol. Interestingly, osteoblast differentiation and mineral deposition induced by NET and LNG were abolished by finasteride, a 5 alpha reductases inhibitor, while the potent effect on osteoblast proliferation induced by progestin derivatives was abolished by a steroidal antiestrogen. Results demonstrate that A ring reduced derivatives of NET and LNG exhibit intrinsic estrogen like potency on rat osteoblasts, offering a plausible explanation for the mechanism of action of 19 norprogestins in bone restoration in postmenopausal women and providing new insights for hormone replacement therapy research.
C1 Univ Nacl Autonoma Mexico, Hosp Gen Mexico, Natl Inst Perinatol, Mexico City 11000, DF, Mexico.
   Univ Nacl Autonoma Mexico, Hosp Gen Mexico, Sch Med, Mexico City 11000, DF, Mexico.
   Inst Nacl Ciencias Med & Nutr S Zubiran, Dept Reprod Biol, Mexico City 14000, DF, Mexico.
   Univ Autonoma Metropolitana Iztapalapa, Dept Reprod Biol, Mexico City 09340, DF, Mexico.
   Univ Nacl Autonoma Mexico, Inst Biomed Res, Mexico City 04510, DF, Mexico.
   Univ Nacl Autonoma Mexico, Sch Dent, Mexico City 04510, DF, Mexico.
   Univ Nacl Autonoma Mexico, Sch Chem, Mexico City 04510, DF, Mexico.
   INCMNSZ, Dept Nephrol & Mineral Metab, Mexico City 14000, DF, Mexico.
C3 Universidad Nacional Autonoma de Mexico; Hospital General de Mexico;
   Hospital General de Mexico; Universidad Nacional Autonoma de Mexico;
   Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran  
   Mexico; Universidad Autonoma Metropolitana   Mexico; Universidad
   Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico;
   Universidad Nacional Autonoma de Mexico
RP Pérez Palacios, G (通讯作者)，Univ Nacl Autonoma Mexico, Hosp Gen Mexico, Natl Inst Perinatol, Montes Urales 800,Col Lomas Virreyes, Mexico City 11000, DF, Mexico.
EM gperezpal@prodigy.net.mx
RI Larrea, Fernando/AAC 1900 2021; Arzate, Higinio/K 1934 2019
OI Chimal Monroy, Jesus/0000 0002 6511 7408; 
CR ABDALLA HI, 1985, OBSTET GYNECOL, V66, P789
   Arzate H, 1998, J PERIODONTAL RES, V33, P249, DOI 10.1111/j.1600 0765.1998.tb02197.x
   BAIN SD, 1997, J BONE MINER RES, V12, pS461
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   CANALIS E, 1978, CALC TISS RES, V25, P105, DOI 10.1007/BF02010758
   CHAVEZ BA, 1985, J STEROID BIOCHEM, V22, P121, DOI 10.1016/0022 4731(85)90151 7
   CHRISTIANSEN C, 1990, J CLIN ENDOCR METAB, V71, P836, DOI 10.1210/jcem 71 4 836
   Ciriza I, 2006, J NEUROBIOL, V66, P916, DOI 10.1002/neu.20293
   Di XO, 1999, CONTRACEPTION, V60, P161, DOI 10.1016/S0010 7824(99)00080 3
   GALLAGHER JC, 1991, AM J MED, V90, P171
   García Becerra R, 2002, J STEROID BIOCHEM, V82, P333, DOI 10.1016/S0960 0760(02)00192 9
   Garcia Becerra R, 2006, J STEROID BIOCHEM, V99, P108, DOI 10.1016/j.jsbmb.2006.01.005
   Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471 4159.2003.01881.x
   GUAL C, 1962, ENDOCRINOLOGY, V71, P920, DOI 10.1210/endo 71 6 920
   HOROWITZ M, 1993, CLIN ENDOCRINOL, V39, P649, DOI 10.1111/j.1365 2265.1993.tb02422.x
   Issa S, 2002, J CLIN ENDOCR METAB, V87, P5401, DOI 10.1210/jc.2001 011902
   KALU DN, 1991, BONE MINER, V15, P109, DOI 10.1016/0169 6009(91)90002 H
   KAPLOW LS, 1955, BLOOD, V10, P1023, DOI 10.1182/blood.V10.10.1023.1023
   Khastgir G, 2001, J CLIN ENDOCR METAB, V86, P289, DOI 10.1210/jc.86.1.289
   LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003 2697(80)90165 7
   LARREA F, 1987, J STEROID BIOCHEM, V27, P657, DOI 10.1016/0022 4731(87)90134 8
   Larrea F, 2001, ENDOCRINOLOGY, V142, P3791, DOI 10.1210/en.142.9.3791
   LAU KHW, 1994, J BONE MINER RES, V9, P695
   LEMUS AE, 1992, J STEROID BIOCHEM, V41, P881, DOI 10.1016/0960 0760(92)90442 L
   Li XD, 2000, J BONE MINER METAB, V18, P258, DOI 10.1007/PL00010639
   Liu JH, 2005, AM J OBSTET GYNECOL, V192, P1316, DOI 10.1016/j.ajog.2004.12.067
   LOWRY OH, 1954, J BIOL CHEM, V207, P19
   MONTGOMERY DC, 1991, DESIGN ANAL EXPT, P537
   MORALI G, 1990, PHARMACOL BIOCHEM BE, V37, P477, DOI 10.1016/0091 3057(90)90016 B
   NIBBERING PH, 1990, J IMMUNOL METHODS, V131, P25, DOI 10.1016/0022 1759(90)90228 N
   Paiva LC, 1998, CONTRACEPTION, V58, P351
   PASSERI M, 1993, MATURITAS, V17, P211, DOI 10.1016/0378 5122(93)90049 N
   Pérez Palacios G, 2006, J ENDOCRINOL, V190, P805, DOI 10.1677/joe.1.06407
   PEREZPALACIOS G, 1981, ACTA ENDOCRINOL COP, V97, P320, DOI 10.1530/acta.0.0970320
   Qu Q, 1998, BONE, V22, P201, DOI 10.1016/S8756 3282(97)00276 7
   Rhodes ME, 2004, PHARMACOL BIOCHEM BE, V78, P505, DOI 10.1016/j.pbb.2004.04.021
   Rickard DJ, 2002, J BONE MINER RES, V17, P580, DOI 10.1359/jbmr.2002.17.4.580
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   RIIS BJ, 1990, J CLIN ENDOCR METAB, V70, P920, DOI 10.1210/jcem 70 4 920
   RIIS BJ, 1987, AM J OBSTET GYNECOL, V156, P61, DOI 10.1016/0002 9378(87)90203 1
   Santillán R, 2001, EUR J PHARMACOL, V427, P167, DOI 10.1016/S0014 2999(01)01263 8
   SCHEVEN BAA, 1992, BIOCHEM BIOPH RES CO, V186, P54, DOI 10.1016/S0006 291X(05)80774 0
   Scholes D, 2002, EPIDEMIOLOGY, V13, P581, DOI 10.1097/00001648 200209000 00015
   Shimodaira K, 1996, BIOCHEM MOL BIOL INT, V39, P109
   STEIN GS, 1990, FASEB J, V4, P3111, DOI 10.1096/fasebj.4.13.2210157
   Suzuki T, 2001, J CLIN ENDOCR METAB, V86, P2250, DOI 10.1210/jc.86.5.2250
   TREMOLLIERES FA, 1992, ACTA ENDOCRINOL COP, V126, P329, DOI 10.1530/acta.0.1260329
   VILCHIS F, 1986, J STEROID BIOCHEM, V24, P525, DOI 10.1016/0022 4731(86)90115 9
   VITTEK J, 1974, ENDOCRINOLOGY, V94, P325, DOI 10.1210/endo 94 2 325
   Wiebe JP, 2003, BMC CANCER, V3, DOI 10.1186/1471 2407 3 9
   Yamamoto Y, 1998, BONE, V22, P533, DOI 10.1016/S8756 3282(98)00034 9
NR 51
TC 14
Z9 15
U1 0
U2 2
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
   ENGLAND
SN 0022 0795
EI 1479 6805
J9 J ENDOCRINOL
JI J. Endocrinol.
PD JUN
PY 2007
VL 193
IS 3
BP 493
EP 504
DI 10.1677/JOE 06 0038
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 181IO
UT WOS:000247430600016
PM 17535886
OA Bronze
DA 2025 08 17
ER

PT J
AU Popov, K
   Oshchepkov, M
   Tkachenko, S
   Sergienko, V
   Oshchepkov, A
AF Popov, Konstantin
   Oshchepkov, Maxim
   Tkachenko, Sergey
   Sergienko, Vladimir
   Oshchepkov, Aleksandr
TI Bisphosphonates: Synthesis, structures, properties, medical and
   industrial applications
SO JOURNAL OF MOLECULAR LIQUIDS
LA English
DT Article
DE Bisphosphonates; Scale inhibition; Corrosion inhibition; Bone diseases;
   Nano drugs; Contrasting agents
ID X RAY DIFFRACTION; METHANE DIPHOSPHONIC ACIDS; CALCIUM BINDING
   MOLECULES; EARTH METAL COMPLEXES; ONE POT SYNTHESIS; CRYSTAL STRUCTURE;
   MAGNETIC PROPERTIES; STABILITY CONSTANTS; ZOLEDRONIC ACID;
   ETHANE 1 HYDROXY 1,1 DIPHOSPHONIC ACID
AB This review is a first attempt to overview both medical and industrial applications of bisphosphonates (BPs) at once, with an emphasis on structure   property relationships. The manuscript embraces synthesis, crystallographic data, thermodynamics of complex formation in aqueous phase, and solubility data. All these aspects are treated as a background for BPs major industrial applications (scale and corrosion inhibition; cation separations) and for numerous applications in medicine: drugs for bone diseases (hypercalcemia, osteoporosis and Paget's disease); drugs for cancer treatment; drug carriers; contrasting agents. A special focus is set on the nanodrugs.
   Industrial applications of BPs as scale and corrosion inhibitors are presented with the focus on novel information on the mechanisms of their activity, provided by fluorescent tagged bisphosphonates. It is demonstrated, that visualization of inhibitor does become a powerful tool for better understanding of scale and corrosion inhibition mechanisms. A summary of traditional medical applications of BPs is supplemented by their novel applications as nanomaterials. At the same time the nanocomposites on the grounds of BPs represent very promising materials for industry. Thus, the present review is illustrated by some recent examples of nanoscale BPs materials. (C) 2022 Elsevier B.V. All rights reserved.
C1 [Popov, Konstantin; Oshchepkov, Maxim; Tkachenko, Sergey] JSC Fine Chem R&D Ctr, Krasnobogatyrskaya Str 42,B 1, Moscow 107258, Russia.
   [Oshchepkov, Maxim; Tkachenko, Sergey] Mendeleev Univ Chem Technol Russia, Miusskaya Sq 9, Moscow 125047, Russia.
   [Sergienko, Vladimir] Kurnakov Inst Inorgan Chem, Leninskii Prosp 31, Moscow 119991, Russia.
   [Oshchepkov, Aleksandr] Tech Univ Chemnitz, Fac Nat Sci, D 09107 Chemnitz, Germany.
   [Oshchepkov, Aleksandr] Max Planck Inst Sci Light, Dept Phys, D 91058 Erlangen, Germany.
C3 Mendeleev University of Chemical Technology of Russia; Russian Academy
   of Sciences; Kurnakov Institute of General & Inorganic Chemistry of the
   Russian Academy of Sciences; Technische Universitat Chemnitz; Max Planck
   Society
RP Popov, K (通讯作者)，JSC Fine Chem R&D Ctr, Krasnobogatyrskaya Str 42,B 1, Moscow 107258, Russia.; Oshchepkov, A (通讯作者)，Tech Univ Chemnitz, Fac Nat Sci, D 09107 Chemnitz, Germany.
EM ki popov49@yandex.ru; aleksandr.oshchepkov@chemie.tu chemnitz.de
RI Popov, Konstantin/K 1921 2013; Oshchepkov, Alexander/AAK 3145 2020;
   Oshchepkov, Maxim/E 9393 2014; Tkachenko, Sergey/AAE 5895 2019; Popov,
   Konstantin/AAH 8666 2020
OI Popov, Konstantin/0000 0001 6034 7143; Oshchepkov,
   Alexander/0000 0002 1321 8485; 
FU Ministry of Science and Higher Education of Russian Federation
   [075 15 2020 792, RF 190220X0031]
FX The study was supported by a grant of Ministry of Science and Higher
   Education of Russian Federation. 075 15 2020 792 (Unique identifier RF
   190220X0031). We are also grateful to Dr. Anatoly Redchuk for molecular
   modeling of BPs and NBPs, and to Dr. Anastasya Ryabova for fluorescent
   images of steel surface.
CR Abu Shandi K, 2005, Z NATURFORSCH B, V60, P1250, DOI 10.1515/znb 2005 1206
   Adair BA, 2003, CHEM MATER, V15, P1518, DOI 10.1021/cm020650x
   Afonin, 2000, ZH NEORG KHIM, V45, P961
   Afonin EG, 1997, RUSS J COORD CHEM+, V23, P794
   Alanne AL, 2012, MOLECULES, V17, P10928, DOI 10.3390/molecules170910928
   Alderighi L, 1999, INORG CHIM ACTA, V285, P39, DOI 10.1016/S0020 1693(98)00302 8
   Aleksandrov GG, 2001, CRYSTALLOGR REP+, V46, P46, DOI 10.1134/1.1343125
   Aleksandrov GG, 1997, CRYSTALLOGR REP+, V42, P392
   Alvarez E, 2013, CRYSTENGCOMM, V15, P9899, DOI 10.1039/c3ce41346b
   Alvarez Valdes A, 2019, J INORG BIOCHEM, V191, P112, DOI 10.1016/j.jinorgbio.2018.11.010
   Anderegg, 1972, CRITICAL SURVEY STAB, P42
   [Anonymous], 2011, STABILITY CONSTANTS
   [Anonymous], MONSANTO TECHICAL B
   [Anonymous], 1975, COORDIN CHEM REV, V17, P358, DOI [10.1016/S0010 8545(00)80382 3, DOI 10.1016/S0010 8545(00)80382 3]
   Babaryk AA, 2012, ACTA CRYSTALLOGR C, V68, pM242, DOI 10.1107/S0108270112031368
   Barbey C, 2002, Z KRIST NEW CRYST ST, V217, P137
   Barbosa JS, 2021, J MED CHEM, V64, P1260, DOI 10.1021/acs.jmedchem.0c01292
   Barbosa JS, 2020, MOLECULES, V25, DOI 10.3390/molecules25122821
   Barik D, 2021, J PHARM SCI US, V110, P3757, DOI 10.1016/j.xphs.2021.08.028
   Barthelet K, 2002, CHEM MATER, V14, P4910, DOI 10.1021/cm021146v
   Berkova Z, 2013, CHEMMEDCHEM, V8, P614, DOI 10.1002/cmdc.201200439
   Bodrin GV, 2018, RUSS J GEN CHEM+, V88, P1792, DOI 10.1134/S1070363218090050
   Boichenko AP, 2009, CENT EUR J CHEM, V7, P8, DOI [10.2478/s11532 008 0099 z, 10.1109/PTC.2009.5282263]
   Bouhsina S, 2004, INORG CHIM ACTA, V357, P305, DOI 10.1016/S0020 1693(03)00445 6
   Boulmier A, 2017, INORG CHEM, V56, P7558, DOI 10.1021/acs.inorgchem.7b01114
   Bretti C, 2017, J SOLUTION CHEM, V46, P1903, DOI 10.1007/s10953 017 0660 5
   BroucaCabarrecq C, 1996, ACTA CRYSTALLOGR C, V52, P1903, DOI 10.1107/S0108270195014715
   Browning FH, 1996, LANGMUIR, V12, P5231, DOI 10.1021/la9603277
   Cao DK, 2007, INORG CHEM, V46, P7571, DOI 10.1021/ic701098t
   CARROLL RL, 1967, INORG CHEM, V6, P1994, DOI 10.1021/ic50057a013
   Chakraborty S, 2018, CHEM BIOL DRUG DES, V92, P1618, DOI 10.1111/cbdd.13327
   Chen LH, 2016, CHEM EUR J, V22, P11954, DOI 10.1002/chem.201602863
   Chmielewska E, 2016, MOLECULES, V21, DOI 10.3390/molecules21111474
   CLAESSENS RAMJ, 1984, J INORG BIOCHEM, V21, P73, DOI 10.1016/0162 0134(84)85040 0
   Clezardin Philippe, 2013, Bonekey Rep, V2, P267, DOI 10.1038/bonekey.2013.1
   Cohen H, 1999, PHARMACEUT RES, V16, P1399, DOI 10.1023/A:1018951025493
   COIRO VM, 1989, ACTA CRYSTALLOGR C, V45, P446, DOI 10.1107/S0108270188011576
   Coleman R, 2020, BONE, V140, DOI 10.1016/j.bone.2020.115570
   Coleman RE, 2011, BONE, V49, P71, DOI 10.1016/j.bone.2011.02.003
   COLLINS AJ, 1977, J APPL CHEM BIOTECHN, V27, P651, DOI 10.1002/jbt.2570270605
   Compain JD, 2010, CHEM EUR J, V16, P13741, DOI 10.1002/chem.201001626
   Cortes Pacheco A, 2020, BEILSTEIN J ORG CHEM, V16, P1277, DOI 10.3762/bjoc.16.108
   Deacon GB, 2011, J COORD CHEM, V64, P179, DOI 10.1080/00958972.2010.538389
   DELAMATTER D, 1973, J PHYS CHEM US, V77, P1146, DOI 10.1021/j100628a013
   Deluchat V, 1996, PHOSPHORUS SULFUR, V109, P209
   Deluchat V, 1997, TALANTA, V44, P897, DOI 10.1016/S0039 9140(96)02136 4
   Demkowicz S, 2016, RSC ADV, V6, P7101, DOI 10.1039/c5ra25446a
   Demoro B, 2010, J INORG BIOCHEM, V104, P1252, DOI 10.1016/j.jinorgbio.2010.08.004
   Dolbecq A, 2012, CHEM COMMUN, V48, P8299, DOI 10.1039/c2cc31667f
   Dolbecq A, 2009, CHEM EUR J, V15, P733, DOI 10.1002/chem.200800719
   Dou TT, 2018, INORG CHEM COMMUN, V95, P117, DOI 10.1016/j.inoche.2018.07.012
   Dufau C, 1995, PHOSPHORUS SULFUR, V107, P145, DOI 10.1080/10426509508027930
   Duro MVV, 2019, ORGANOPHOSPHORUS CHEMISTRY: FROM MOLECULES TO APPLICATIONS, P499
   Dyatlova N.V., 1988, COMPLEXONES METAL CO, P544
   Dyba M, 1998, POL J CHEM, V72, P1148
   Dyba M, 1996, J CHEM SOC DALTON, P1119, DOI 10.1039/dt9960001119
   Ebrahimpour A, 1995, MINERAL SCALE FORMATION AND INHIBITION, P295
   El Moll H, 2012, CHEM EUR J, V18, P3845, DOI 10.1002/chem.201200140
   El Moll H, 2012, INORG CHEM, V51, P2291, DOI 10.1021/ic202299d
   Elhabiri M, 2015, CHEM EUR J, V21, P6535, DOI 10.1002/chem.201500155
   Evans OR, 2001, J AM CHEM SOC, V123, P10395, DOI 10.1021/ja0163772
   Fernandes C, 2014, J ORGANOMET CHEM, V760, P197, DOI 10.1016/j.jorganchem.2013.10.038
   Fernández D, 2003, ACTA CRYSTALLOGR C, V59, pM543, DOI 10.1107/S0108270103025599
   Fernández D, 2004, ACTA CRYSTALLOGR C, V60, pM73, DOI 10.1107/S0108270104000216
   Fernández D, 2002, ACTA CRYSTALLOGR C, V58, pM494, DOI 10.1107/S010827010201497X
   Fleisch H, 1997, HORM METAB RES, V29, P145, DOI 10.1055/s 2007 979008
   Franco J.P., 2020, Adv. Chem. Eng. Sci., V10, P225, DOI [10.4236/aces.2020.103017, DOI 10.4236/ACES.2020.103017]
   Freire E, 2013, INORG CHIM ACTA, V394, P229, DOI 10.1016/j.ica.2012.06.045
   Galezowska J, 2012, COORDIN CHEM REV, V256, P105, DOI 10.1016/j.ccr.2011.07.002
   Genady AR, 2020, ACS APPL NANO MATER, V3, P11819, DOI 10.1021/acsanm.0c02339
   GRABENSTETTER RJ, 1971, J PHYS CHEM US, V75, P676
   Greenfield TJ, 2019, POLYHEDRON, V169, P162, DOI 10.1016/j.poly.2019.05.022
   Griffiths DV, 1997, TETRAHEDRON, V53, P17815, DOI 10.1016/S0040 4020(97)10245 9
   GRIGOREV AI, 1987, ZH NEORG KHIM+, V32, P1326
   Guenin E, 2004, EUR J ORG CHEM, V2004, P2983
   Guo ZF, 2014, TRANSIT METAL CHEM, V39, P353, DOI 10.1007/s11243 014 9808 y
   Herlinger AW, 1997, POLYHEDRON, V16, P1843, DOI 10.1016/S0277 5387(96)00495 0
   Holub J, 2015, CONTRAST MEDIA MOL I, V10, P122, DOI 10.1002/cmmi.1606
   Hounslow AM, 2008, J MED CHEM, V51, P4170, DOI 10.1021/jm7015792
   Hui LF, 2017, CELL CHEM TECHNOL, V51, P301
   Jena LN, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951 021 00856 x
   Jerez HE, 2021, EUR J PHARM BIOPHARM, V160, P42, DOI 10.1016/j.ejpb.2021.01.001
   Jokiniemi J, 2007, CRYSTENGCOMM, V9, P158, DOI 10.1039/b616077h
   Juan DW, 2012, INORG CHEM, V51, P6906, DOI 10.1021/ic300742p
   Junankar S, 2015, CANCER DISCOV, V5, P35, DOI 10.1158/2159 8290.CD 14 0621
   KABACHNI.MI, 1967, DOKL AKAD NAUK SSSR+, V177, P582
   KABACHNIK MI, 1979, IAN SSSR KH, P1726
   Kashemirov BA, 2008, BIOCONJUGATE CHEM, V19, P2308, DOI 10.1021/bc800369c
   Kenny GD, 2016, J FLUORINE CHEM, V184, P58, DOI 10.1016/j.jfluchem.2016.02.008
   Kieczykowski GR, 1995, J ORG CHEM, V60, P8310, DOI 10.1021/jo00130a036
   Kontturi M, 2005, INORG CHEM, V44, P2400, DOI 10.1021/ic048329z
   Kontturi M, 2004, EUR J INORG CHEM, P2627, DOI 10.1002/ejic.200400236
   Kontturi M, 2004, ACTA CRYSTALLOGR E, V60, pM1060, DOI 10.1107/S1600536804015764
   Kontturi M, 2002, J CHEM SOC DALTON, P1969, DOI 10.1039/b201124g
   Kontturi M, 2006, SOLID STATE SCI, V8, P1098, DOI 10.1016/j.solidstatesciences.2006.02.055
   Kozachkova OM, 2018, INORG CHIM ACTA, V474, P96, DOI 10.1016/j.ica.2018.01.034
   Krinitskaya, 1976, THESIS IREA MOSCOW, P25
   Krol, 1990, RUSS J INORG CHEM, V35, P1600
   Kubícek V, 2005, J AM CHEM SOC, V127, P16477, DOI 10.1021/ja054905u
   Kubícek V, 2007, EUR J INORG CHEM, P333, DOI 10.1002/ejic.200600615
   Kunnas Hiltunen S, 2010, Z ANORG ALLG CHEM, V636, P710, DOI 10.1002/zaac.200900555
   Kunnas Hiltunen S, 2010, DALTON T, V39, P5310, DOI 10.1039/c002403a
   Kunnas Hiltunen S, 2009, EUR J INORG CHEM, P5335, DOI 10.1002/ejic.200900500
   Kunnas Hiltunen S, 2009, POLYHEDRON, V28, P200, DOI 10.1016/j.poly.2008.10.030
   Kushikbayeva, 1988, SYNTHESIS PROPERTIES
   Kuznetsov YI, 2017, INT J CORROS SCALE I, V6, P384, DOI 10.17675/2305 6894 2017 6 4 3
   Kuznik A, 2020, EUR J PHARMACOL, V866, DOI 10.1016/j.ejphar.2019.172773
   Le Cong H, 2010, J MOL LIQ, V154, P76, DOI 10.1016/j.molliq.2010.03.014
   Lecouvey M, 2001, TETRAHEDRON LETT, V42, P8475, DOI 10.1016/S0040 4039(01)01844 5
   Liao ZL, 2013, DALTON T, V42, P6793, DOI 10.1039/c3dt33025g
   LIBSON K, 1980, J AM CHEM SOC, V102, P2476, DOI 10.1021/ja00527a066
   Lin YL, 2021, ACS APPL BIO MATER, V4, P2490, DOI 10.1021/acsabm.0c01455
   Mady MF, 2021, ACS OMEGA, V6, P6488, DOI 10.1021/acsomega.1c00379
   Malhotra K, 2020, CHEM MATER, V32, P4002, DOI 10.1021/acs.chemmater.0c00547
   Martell A.e., 1977, Critical Stability Constants Vol. 1 (Amino Acids), V1
   Martell A.E., 1989, Critical Stability Constant, V1 6
   Martell A.E., 1976, CRITICAL STABILITY C, V1
   Martell A.E., 1975, Critical Stability Constants, V1
   Martell A.E., 1982, Critical Stability Constants: Amino Acids, V1
   MARTELL AE, 1974, CRITICAL STABILITY C, V1
   Martello P, 1998, INORG CHEM, V37, P3111, DOI 10.1021/ic971624h
   Maruk AY, 2021, MOLECULES, V26, DOI 10.3390/molecules26082357
   Matczak Jon E, 2005, COORDIN CHEM REV, V249, P2458, DOI 10.1016/j.ccr.2005.06.001
   Matkovskaya T A., 2001, Bisphosphonates. Properties, Structure
   McKenna C.E., 2020, Encyclopedia of Bone Biology, P551, DOI DOI 10.1016/B978 0 12 801238 3.11260 7
   Menschutkin N., 1865, ANN CHEM PHARM, V133, P317, DOI [10.1002/jlac.18651330307, DOI 10.1002/JLAC.18651330307]
   Merino P, 2017, RSC ADV, V7, P10947, DOI 10.1039/c6ra28316k
   Miao MY, 2018, COLLOID SURFACE A, V543, P144, DOI 10.1016/j.colsurfa.2018.01.056
   Migianu E, 2005, SYNLETT, P425, DOI 10.1055/s 2004 837226
   Monteil M, 2005, Z KRIST NEW CRYST ST, V220, P411
   Moore SN, 2015, CELL CYCLE, V14, P1354, DOI 10.1080/15384101.2015.1024585
   Moschona A, 2021, CHEM ENG J, V405, DOI 10.1016/j.cej.2020.126864
   Muller KA, 2015, Z KRIST NEW CRYST ST, V230, P349, DOI 10.1515/ncrs 2014 0249
   Nadar RA, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 62039 2
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   NANCOLLAS GH, 1982, PURE APPL CHEM, V54, P2675, DOI 10.1351/pac198254122675
   NANCOLLAS GH, 1981, CORROSION, V37, P76, DOI 10.5006/1.3593849
   NARDELLI M, 1983, INORG CHIM A BIOINOR, V80, P259, DOI 10.1016/S0020 1693(00)91293 3
   NASH KL, 1991, RADIOCHIM ACTA, V54, P171
   NASH KL, 1990, INORG CHIM ACTA, V169, P245, DOI 10.1016/S0020 1693(00)80524 1
   NASH KL, 1994, J ALLOY COMPD, V213, P300, DOI 10.1016/0925 8388(94)90919 9
   NGUYEN LM, 1987, J MED CHEM, V30, P1426, DOI 10.1021/jm00391a027
   Niu QJ, 2016, J COORD CHEM, V69, P1447, DOI 10.1080/00958972.2016.1181756
   Niu QJ, 2016, TRANSIT METAL CHEM, V41, P365, DOI 10.1007/s11243 016 0030 y
   Ofitserov, 2007, BUTLEROV COMMUNICATI, V12, P1
   Oms O, 2016, INORG CHEM, V55, P1551, DOI 10.1021/acs.inorgchem.5b02456
   Oshchepkov A, 2020, SENSOR ACTUAT B CHEM, V314, DOI 10.1016/j.snb.2020.128047
   Oshchepkov MS, 2021, THERM ENG+, V68, P370, DOI [10.1134/S0040601521040054, 10.1134/S0040363621040056]
   Oshchepkov M, 2021, SEP PURIF TECHNOL, V255, DOI 10.1016/j.seppur.2020.117382
   Oshchepkov M, 2019, CHEMNANOMAT, V5, P586, DOI 10.1002/cnma.201800660
   Palazzo B, 2007, ADV FUNCT MATER, V17, P2180, DOI 10.1002/adfm.200600361
   Palma E, 2011, MOL BIOSYST, V7, P2950, DOI 10.1039/c1mb05242j
   Pang J, 2019, CRYST GROWTH DES, V19, P2919, DOI 10.1021/acs.cgd.9b00139
   Pang YC, 2020, NANO LETT, V20, P829, DOI 10.1021/acs.nanolett.9b02916
   Paul AK, 2017, CRYST GROWTH DES, V17, P5620, DOI 10.1021/acs.cgd.7b01110
   Popov K, 1999, NEW J CHEM, V23, P1209, DOI 10.1039/a907045a
   Popov K, 2001, PURE APPL CHEM, V73, P1641, DOI 10.1351/pac200173101641
   Popov K., IN PRESS, P2021
   Popov K. I., 2016, Thermal Engineering, V63, P122, DOI 10.1134/S0040601516010092
   Popov KI, 2005, ACS SYM SER, V910, P50
   Popov K, 2017, DESALIN WATER TREAT, V69, P163, DOI 10.5004/dwt.2017.0336
   Popov K, 2016, ADV MATER SCI ENG, V2016, DOI 10.1155/2016/7635329
   PORAIKOSHITS MA, 1984, KOORDINATS KHIM+, V10, P725
   PRENTICE JB, 1972, J AM CHEM SOC, V94, P6119, DOI 10.1021/ja00772a032
   Qiu L, 2015, EUR J MED CHEM, V89, P42, DOI 10.1016/j.ejmech.2014.10.028
   Rocha J, 2010, CHEM EUR J, V16, P7741, DOI 10.1002/chem.201000431
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Rojek T, 2020, POLYHEDRON, V185, DOI 10.1016/j.poly.2020.114594
   Rojek T, 2018, NEW J CHEM, V42, P7830, DOI 10.1039/c8nj00118a
   Rojek T, 2018, POLYHEDRON, V141, P44, DOI 10.1016/j.poly.2017.11.018
   Rojek T, 2017, DALTON T, V46, P6900, DOI 10.1039/c7dt00410a
   Rom T, 2020, DALTON T, V49, P13618, DOI 10.1039/d0dt02796k
   Rom T, 2020, INORG CHEM, V59, P9465, DOI 10.1021/acs.inorgchem.0c01239
   Romanenko V., 2018, ADV SYNTHESIS FUNCTI, P200
   RUEL R, 1995, J ORG CHEM, V60, P5209, DOI 10.1021/jo00121a044
   Ruiz Agudo E, 2010, CRYST GROWTH DES, V10, P3022, DOI 10.1021/cg1000864
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Sangnier AP, 2018, BEILSTEIN J NANOTECH, V9, P2947, DOI 10.3762/bjnano.9.273
   Sanna D, 1996, J CHEM SOC DALTON, P87, DOI 10.1039/dt9960000087
   SCHLEMPER EO, 1977, J CRYST MOL STRUCT, V7, P81, DOI 10.1007/BF01369834
   Schmelter D, 2021, DALTON T, V50, P7314, DOI 10.1039/d1dt00736j
   Sedghizadeh PP, 2017, J MED CHEM, V60, P2326, DOI 10.1021/acs.jmedchem.6b01615
   Serezhkin VN, 2000, RUSS J INORG CHEM+, V45, P521
   Sergienko, 1993, RUSS J COORD CHEM, V19, P297
   Sergienko, 1994, RUSS J COORD CHEM, V20, P195
   Sergienko, 1993, ZH NEORG KHIM, V38, P1311
   Sergienko VS, 1997, CRYSTALLOGR REP+, V42, P974
   Sergienko VS, 1998, RUSS J COORD CHEM+, V24, P276
   Sergienko VS, 1999, RUSS J COORD CHEM+, V25, P301
   Sergienko VS, 2001, RUSS J COORD CHEM+, V27, P681, DOI 10.1023/A:1012334908835
   Shcherbakov BK, 1998, RUSS CHEM B+, V47, P1732, DOI 10.1007/BF02495695
   Shi FN, 2008, J AM CHEM SOC, V130, P150, DOI 10.1021/ja074119k
   SHKOLNIKOVA LM, 1987, B ACAD SCI USSR CH+, V36, P1394, DOI 10.1007/BF01557509
   Sikorska M, 2012, ACTA CRYSTALLOGR E, V68, pM820, DOI 10.1107/S1600536812022532
   Soltau J, 2004, DRUG FUTURE, V29, P911, DOI 10.1358/dof.2004.029.09.854177
   Song HH, 2002, J CHEM SOC DALTON, P2752, DOI 10.1039/b200814a
   Sridhar B, 2014, ACTA CRYSTALLOGR C, V70, P67, DOI 10.1107/S2053229613033172
   Stahl K, 2005, ACTA CRYSTALLOGR E, V61, pM132, DOI 10.1107/S1600536804032568
   STEPHENS FS, 1969, J CHEM SOC A, P1723, DOI 10.1039/j19690001723
   Studnik H, 2015, NEW BIOTECHNOL, V32, P1, DOI 10.1016/j.nbt.2014.06.007
   Sun B, 2021, ACS APPL MATER INTER, V13, P14015, DOI 10.1021/acsami.1c01401
   Sun ST, 2016, BIOCONJUGATE CHEM, V27, P329, DOI 10.1021/acs.bioconjchem.5b00369
   Sun XP, 2017, SYNTHETIC MET, V223, P19, DOI 10.1016/j.synthmet.2016.11.035
   Suva LJ, 2021, BONE, V142, DOI 10.1016/j.bone.2020.115711
   Tan HQ, 2010, CRYSTENGCOMM, V12, P4017, DOI 10.1039/c0ce00104j
   Tan HQ, 2011, DALTON T, V40, P8414, DOI 10.1039/c0dt01729a
   Tavakoli S, 2019, MRS ADV, V4, P1231, DOI 10.1557/adv.2019.117
   Tereshin, 1977, RUSS J COORD CHEM, V3, P1189
   TERESHIN GS, 1974, ZH NEORG KHIM+, V19, P1131
   Thapa R, 2021, SEP PURIF TECHNOL, V272, DOI 10.1016/j.seppur.2021.118913
   Thapa R, 2020, MICROPOR MESOPOR MAT, V296, DOI 10.1016/j.micromeso.2019.109980
   Tian LL, 2018, ACS NANO, V12, P11541, DOI 10.1021/acsnano.8b06699
   Tolkacheva, 1991, SYNTHESIS PROPERTIES, P25
   Tomane S, 2019, NANOSCALE ADV, V1, P3400, DOI 10.1039/c9na00401g
   Turhanen PA, 2005, SYNTHESIS STUTTGART, P3063, DOI 10.1055/s 2005 916032
   Turhanen PA, 2015, SCI REP UK, V5, DOI 10.1038/srep08992
   UCHTMAN VA, 1972, J PHYS CHEM US, V76, P1304, DOI 10.1021/j100653a014
   UCHTMAN VA, 1972, J PHYS CHEM US, V76, P1298, DOI 10.1021/j100653a013
   Van Acker HH, 2016, PHARMACOL THERAPEUT, V158, P24, DOI 10.1016/j.pharmthera.2015.11.008
   Van Velthoven N, 2020, ACS APPL MATER INTER, V12, P47457, DOI 10.1021/acsami.0c12325
   Vega D, 1998, ACTA CRYSTALLOGR C, V54, P324, DOI 10.1107/S0108270197013553
   Vitha T, 2009, DALTON T, P3204, DOI 10.1039/b820705d
   Vitha T, 2008, J MED CHEM, V51, P677, DOI 10.1021/jm7012776
   Von Baeyer H., 1897, BEITR DTSCH CHEM GES, V30, P1973, DOI [10.1002/CBER.189703002157, DOI 10.1002/CBER.189703002157]
   Wang CC, 2002, INORG CHEM, V41, P429, DOI 10.1021/ic010873+
   Wang D, 2014, INORG CHEM COMMUN, V46, P241, DOI 10.1016/j.inoche.2014.06.014
   Wang D, 2021, COLLOID SURFACE A, V612, DOI 10.1016/j.colsurfa.2020.126009
   Wang H, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10030154
   Wang L, 2006, J AM CHEM SOC, V128, P13358, DOI 10.1021/ja0651355
   Wang YH, 2020, CHEM MATER, V32, P2910, DOI 10.1021/acs.chemmater.9b05095
   WIERS BH, 1971, INORG CHEM, V10, P2581, DOI 10.1021/ic50105a041
   Wu ZB, 2003, ACTA CRYSTALLOGR E, V59, pM521, DOI 10.1107/S1600536803013278
   Yi XY, 2003, INORG CHEM, V42, P2827, DOI 10.1021/ic034069u
   Yin P, 2003, EUR J INORG CHEM, P726
   Zapf PJ, 1996, J SOLID STATE CHEM, V125, P182, DOI 10.1006/jssc.1996.0283
   Zeevaart JR, 1997, S AFR J CHEM S AFR T, V50, P189
   Zeng B, 2013, WATER SCI TECHNOL, V67, P1544, DOI 10.2166/wst.2013.021
   Zhang R, 2018, J HEALTHC ENG, V2018, DOI 10.1155/2018/2376317
   Zhang YJ, 2019, POLYHEDRON, V174, DOI 10.1016/j.poly.2019.114161
   Zhang ZQ, 2018, INORG CHEM, V57, P3315, DOI 10.1021/acs.inorgchem.7b03261
   Zheng LM, 2002, INORG CHEM, V41, P4084, DOI 10.1021/ic015631o
   Zheng LM, 2000, COMMENT INORG CHEM, V22, P129, DOI 10.1080/02603590008050866
   Zhong YA, 2014, BIOMACROMOLECULES, V15, P1955, DOI 10.1021/bm5003009
NR 243
TC 9
Z9 9
U1 3
U2 50
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0167 7322
EI 1873 3166
J9 J MOL LIQ
JI J. Mol. Liq.
PD APR 1
PY 2022
VL 351
AR 118619
DI 10.1016/j.molliq.2022.118619
EA FEB 2022
PG 21
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Physics
GA YY1ET
UT WOS:000754535800011
DA 2025 08 17
ER

PT J
AU Kamel, AA
   Khidre, MD
AF Kamel, Azza A.
   Khidre, Maha D.
TI A practical synthesis and the pharmacological potency of
   gem diphosphono substituted pyrimidines for treatment of bone
   resorption
SO ARKIVOC
LA English
DT Article
DE Wittig Horner carbanions; heteroarylmethylene 1,1 bisphosphonates;
   nitrogen containing bisphosphonates; bone resorption
ID KNOEVENAGEL CONDENSATIONS; BISPHOSPHONATES; ETHENYLIDENEBISPHOSPHONATES;
   METHYLENEBISPHOSPHONATE; MECHANISMS; ESTERS
AB A series of substituted arylidenes was allowed to react with the Wittig Horner reagent, tetraethyl methylene 1,1 bisphosphonate to give the corresponding N containing bisphosphonates (BPs). Acid hydrolysis of one of the BPs gave the corresponding bisphosphonic acid. The in vivo anti resorptive activities of the products in the rat adjuvant model are discussed in terms of structure activity relationships (SAR).
C1 [Kamel, Azza A.; Khidre, Maha D.] Natl Res Ctr, Dept Pesticide Chem, Cairo, Egypt.
C3 Egyptian Knowledge Bank (EKB); National Research Centre (NRC)
RP Kamel, AA (通讯作者)，Natl Res Ctr, Dept Pesticide Chem, D 12622, Cairo, Egypt.
EM azza_kamel@yahoo.com
OI Khidre, Maha/0000 0002 6171 6016; Kamel, Azza/0000 0002 8485 7604
FU Egyptian Government (National Research Centre)
FX This research has been supported by the Egyptian Government (National
   Research Centre).
CR Abdou WM, 2006, LETT ORG CHEM, V3, P634, DOI 10.2174/157017806778559536
   Abdou WM, 2006, MONATSH CHEM, V137, P105, DOI 10.1007/s00706 005 0403 y
   Abdou WM, 2003, SYNLETT, P785, DOI 10.1055/s 2003 38729
   ABDOU WM, 2007, EUR J MED CHEM, P675
   Akabori S., 1933, CHEM BER, V66, P139, DOI 10.1002/cber.19330660212
   [Anonymous], 1981, SPECTROSCOPIC IDENTI
   DEGENHARDT CR, 1986, J ORG CHEM, V51, P3488, DOI 10.1021/jo00368a017
   DUFAU C, 1992, PHOSPHORUS SULFUR, V69, P93, DOI 10.1080/10426509208036858
   Ebetino FH, 1998, REV CONTEMP PHARMACO, V9, P233
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Fleisch H, 2002, BREAST CANCER RES, V4, P30, DOI 10.1186/bcr414
   Fleisch H., 1988, HDB EXPT PHARM, V83, P441
   GREEN JR, 1994, J BONE MINER RES, V9, P745
   HUTCHINSON DW, 1988, J ORGANOMET CHEM, V346, P341, DOI 10.1016/0022 328X(88)80134 7
   Kaupp G, 2003, TETRAHEDRON, V59, P3753, DOI 10.1016/S0040 4020(03)00554 4
   LEHNERT W, 1974, TETRAHEDRON, V30, P301, DOI 10.1016/S0040 4020(01)91461 9
   RUSSELL RGG, 1999, PHOSPHORUS SULFUR, V793, P144
   SCHENK R, 1973, CALC TISS RES, V11, P196, DOI 10.1007/BF02547219
   SHINODA H, 1983, CALCIFIED TISSUE INT, V35, P87, DOI 10.1007/BF02405012
   STURTZ G, 1991, SYNTHESIS STUTTGART, P661
   XU Y, 1988, TETRAHEDRON, V54, P6319
   YUAN CY, 1992, PHOSPHORUS SULFUR, V69, P75, DOI 10.1080/10426509208036856
NR 22
TC 1
Z9 1
U1 0
U2 5
PU ARKAT USA INC
PI GAINESVILLE
PA C/O ALAN R KATRITZKY, UNIV FLORIDA, DEPT CHEMISTRY, PO BOX 117200,
   GAINESVILLE, FL 32611 USA
SN 1424 6376
J9 ARKIVOC
JI Arkivoc
PY 2008
BP 273
EP 286
PG 14
WC Chemistry, Organic
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA 433GC
UT WOS:000265191300026
DA 2025 08 17
ER

PT J
AU Brum, AM
   van de Peppel, J
   Nguyen, L
   Aliev, A
   Schreuders Koedam, M
   Gajadien, T
   van der Leije, CS
   van Kerkwijk, A
   Eijken, M
   van Leeuwen, JPTM
   van der Eerden, BCJ
AF Brum, Andrea M.
   van de Peppel, Jeroen
   Nguyen, Linh
   Aliev, Abidin
   Schreuders Koedam, Marijke
   Gajadien, Tarini
   van der Leije, Cindy S.
   van Kerkwijk, Anke
   Eijken, Marco
   van Leeuwen, Johannes P. T. M.
   van der Eerden, B. C. J.
TI Using the Connectivity Map to discover compounds influencing human
   osteoblast differentiation
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE bone; Connectivity Map; differentiation; hMSC; osteoblast; osteoporosis
ID SMALL MOLECULE INHIBITOR; SKELETAL MUSCLE ATROPHY; FOLINIC ACID;
   LOCAL ANESTHETICS; MATRIX MINERALIZATION; EXPRESSION SIGNATURES;
   WITHANIA SOMNIFERA; OXIDATIVE STRESS; HEME OXYGENASE 1; CANCER CELLS
AB Osteoporosis is a common skeletal disorder characterized by low bone mass leading to increased bone fragility and fracture susceptibility. Identification of factors influencing osteoblast differentiation and bone formation is very important. Previously, we identified parbendazole to be a novel compound that stimulates osteogenic differentiation of human mesenchymal stromal cells (hMSCs), using gene expression profiling and bioinformatic analyzes, including the Connectivity Map (CMap), as an in silico approach. The aim for this paper is to identify additional compounds affecting osteoblast differentiation using the CMap. Gene expression profiling was performed on hMSCs differentiated to osteoblasts using Illumina microarrays. Our osteoblast gene signature, the top regulated genes 6hr after induction by dexamethasone, was uploaded into CMap (/). Through this approach we identified compounds with gene signatures positively correlating (withaferin A, calcium folinate, amylocaine) or negatively correlating (salbutamol, metaraminol, diprophylline) to our osteoblast gene signature. All positively correlating compounds stimulated osteogenic differentiation, as indicated by increased mineralization compared to control treated cells. One of three negatively correlating compounds, salbutamol, inhibited dexamethasone induced osteoblastic differentiation, while the other two had no effect. Based on gene expression data of withaferin A and salbutamol, we identified HMOX1 and STC1 as being strongly differentially expressed . shRNA knockdown of HMOX1 or STC1 in hMSCs inhibited osteoblast differentiation. These results confirm that the CMap is a powerful approach to identify positively compounds that stimulate osteogenesis of hMSCs, and through this approach we can identify genes that play an important role in osteoblast differentiation and could be targets for novel bone anabolic therapies.
C1 [Brum, Andrea M.; van de Peppel, Jeroen; Nguyen, Linh; Aliev, Abidin; Schreuders Koedam, Marijke; Gajadien, Tarini; van der Leije, Cindy S.; van Leeuwen, Johannes P. T. M.; van der Eerden, B. C. J.] Erasmus MC, Dept Internal Med, Wytemaweg 80, NL 3015 CN Rotterdam, Netherlands.
   [van Kerkwijk, Anke; Eijken, Marco] Arcarios BV, Rotterdam, Netherlands.
C3 Erasmus University Rotterdam; Erasmus MC
RP van der Eerden, BCJ (通讯作者)，Erasmus MC, Dept Internal Med, Wytemaweg 80, NL 3015 CN Rotterdam, Netherlands.
EM b.vandereerden@erasmusmc.nl
RI van Leeuwen, Johannes/D 5015 2014; van de Peppel, Jeroen/K 6683 2019;
   van der Eerden, Bram/I 7496 2012
OI van Leeuwen, Johannes/0000 0002 2282 4006; van de peppel,
   jeroen/0000 0002 6524 727X; Brum, Andrea/0000 0001 6881 1123; Eijken,
   Marco/0000 0002 9043 3971; van der Eerden, Bram/0000 0003 4403 6497
FU Netherlands Institute for Regenerative Medicine [FES0908]
FX Netherlands Institute for Regenerative Medicine, Grant number: FES0908
CR Barbagallo I, 2010, J BONE MINER METAB, V28, P276, DOI 10.1007/s00774 009 0134 y
   Bonnet N, 2007, J APPL PHYSIOL, V102, P1502, DOI 10.1152/japplphysiol.00815.2006
   Bonnet N, 2005, BONE, V37, P622, DOI 10.1016/j.bone.2005.07.012
   Bonnet N, 2005, MED SCI SPORT EXER, V37, P1493, DOI 10.1249/01.mss.0000177592.82507.95
   Brum AM, 2015, P NATL ACAD SCI USA, V112, P12711, DOI 10.1073/pnas.1501597112
   Campbell JD, 2012, GENOME MED, V4, DOI 10.1186/gm367
   Chang M, 2010, MOL PAIN, V6, DOI 10.1186/1744 8069 6 56
   Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227
   Chou MY, 2015, INT J BIOL SCI, V11, P122, DOI 10.7150/ijbs.10773
   COURTNEY KR, 1980, J PHARMACOL EXP THER, V213, P114
   Dyle MC, 2014, J BIOL CHEM, V289, P14913, DOI 10.1074/jbc.M114.556241
   Eijken M, 2006, MOL CELL ENDOCRINOL, V248, P87, DOI 10.1016/j.mce.2005.11.034
   Eijken M, 2007, FASEB J, V21, P2949, DOI 10.1096/fj.07 8080com
   Fan CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046915
   Fan CM, 2009, BONE, V44, P61, DOI 10.1016/j.bone.2008.09.014
   Faria CC, 2015, ONCOTARGET, V6, P21718, DOI 10.18632/oncotarget.4304
   Gao L, 2014, FEBS J, V281, P1110, DOI 10.1111/febs.12672
   Georgiou KR, 2015, J CELL PHYSIOL, V230, P648, DOI 10.1002/jcp.24788
   Ghattas MH, 2002, INT J BIOCHEM CELL B, V34, P1619, DOI 10.1016/S1357 2725(02)00097 3
   Grogan PT, 2014, INVEST NEW DRUG, V32, P604, DOI 10.1007/s10637 014 0084 7
   Harper KN, 2013, CANCER EPIDEM BIOMAR, V22, P1052, DOI 10.1158/1055 9965.EPI 13 0114
   Hirota K, 1997, BRIT J ANAESTH, V78, P185, DOI 10.1093/bja/78.2.185
   Iqbal MP, 2003, ACTA PAEDIATR, V92, P1438, DOI 10.1080/08035250310006890
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Kanis JA, 2005, OSTEOPOROSIS INT, V16, P229, DOI 10.1007/s00198 004 1811 2
   Karube K, 2013, CANCER LETT, V333, P47, DOI 10.1016/j.canlet.2012.12.022
   Khedgikar V, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.294
   Khedgikar V, 2015, NUTRITION, V31, P205, DOI 10.1016/j.nut.2014.05.010
   Koh LWH, 2013, ANTIOXID REDOX SIGN, V19, P2261, DOI 10.1089/ars.2012.4999
   Kunkel SD, 2011, CELL METAB, V13, P627, DOI 10.1016/j.cmet.2011.03.020
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Larsen MJ, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/651751
   Le W, 1999, J NEUROSCI RES, V56, P652
   LEESON S, 1992, ANESTHESIOLOGY, V77, P324, DOI 10.1097/00000542 199208000 00016
   Park JW, 2015, INT J MOL MED, V35, P247, DOI 10.3892/ijmm.2014.1983
   Patel M, 2011, EXPERT OPIN PHARMACO, V12, P1133, DOI 10.1517/14656566.2011.571210
   Qu XYA, 2012, DRUG DISCOV TODAY, V17, P1289, DOI 10.1016/j.drudis.2012.07.017
   RAGSDALE DS, 1991, MOL PHARMACOL, V40, P756
   Roy RV, 2013, J NAT PROD, V76, P1909, DOI 10.1021/np400441f
   van Leeuwen, 2011, CURR PROTOC STEM CEL, V17, DOI DOI 10.1002/9780470151808.SC01H03S17
   Vanella L, 2010, BONE, V46, P236, DOI 10.1016/j.bone.2009.10.012
   Wang GP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014573
   Xian CJ, 2008, J CELL PHYSIOL, V214, P777, DOI 10.1002/jcp.21274
   Yoshiko Y, 2003, ENDOCRINOLOGY, V144, P4134, DOI 10.1210/en.2003 0130
   Zhong YF, 2013, J AM SOC NEPHROL, V24, P801, DOI 10.1681/ASN.2012060590
NR 45
TC 26
Z9 27
U1 0
U2 36
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD JUN
PY 2018
VL 233
IS 6
BP 4895
EP 4906
DI 10.1002/jcp.26298
PG 12
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA FX6JP
UT WOS:000426190900043
PM 29194609
DA 2025 08 17
ER

PT J
AU Zhao, YW
   Richardson, K
   Yang, R
   Bousraou, Z
   Lee, YK
   Fasciano, S
   Wang, S
AF Zhao, Yuwen
   Richardson, Kiarra
   Yang, Rui
   Bousraou, Zoe
   Lee, Yoo Kyoung
   Fasciano, Samantha
   Wang, Shue
TI Notch signaling and fluid shear stress in regulating osteogenic
   differentiation
SO FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
LA English
DT Article
DE osteogenic differentiation; mesenchymal stem cells; notch signaling;
   shear stress; LNA/DNA nanobiosensor; single cell gene expression; Dll4
   mRNA expression
ID MESENCHYMAL STEM CELLS; GENE EXPRESSION; CONTRACTILITY; PROMOTES;
   PATHWAY; FATE
AB Osteoporosis is a common bone and metabolic disease that is characterized by bone density loss and microstructural degeneration. Human bone marrow derived mesenchymal stem cells (hMSCs) are multipotent progenitor cells with the potential to differentiate into various cell types, including osteoblasts, chondrocytes, and adipocytes, which have been utilized extensively in the field of bone tissue engineering and cell based therapy. Although fluid shear stress plays an important role in bone osteogenic differentiation, the cellular and molecular mechanisms underlying this effect remain poorly understood. Here, a locked nucleic acid (LNA)/DNA nanobiosensor was exploited to monitor mRNA gene expression of hMSCs that were exposed to physiologically relevant fluid shear stress to examine the regulatory role of Notch signaling during osteogenic differentiation. First, the effects of fluid shear stress on cell viability, proliferation, morphology, and osteogenic differentiation were investigated and compared. Our results showed shear stress modulates hMSCs morphology and osteogenic differentiation depending on the applied shear and duration. By incorporating this LNA/DNA nanobiosensor and alkaline phosphatase (ALP) staining, we further investigated the role of Notch signaling in regulating osteogenic differentiation. Pharmacological treatment is applied to disrupt Notch signaling to investigate the mechanisms that govern shear stress induced osteogenic differentiation. Our experimental results provide convincing evidence supporting that physiologically relevant shear stress regulates osteogenic differentiation through Notch signaling. Inhibition of Notch signaling mediates the effects of shear stress on osteogenic differentiation, with reduced ALP enzyme activity and decreased Dll4 mRNA expression. In conclusion, our results will add new information concerning osteogenic differentiation of hMSCs under shear stress and the regulatory role of Notch signaling. Further studies may elucidate the mechanisms underlying the mechanosensitive role of Notch signaling in stem cell differentiation.
C1 [Zhao, Yuwen; Richardson, Kiarra; Yang, Rui; Bousraou, Zoe; Lee, Yoo Kyoung; Wang, Shue] Univ New Haven, Dept Chem Chem & Biomed Engn, West Haven, CT 06516 USA.
   [Zhao, Yuwen] Lehigh Univ, Dept Bioengn, Bethlehem, PA USA.
   [Richardson, Kiarra] Duke Univ, Dept Biomed Engn, Durham, NC USA.
   [Yang, Rui] Univ Connecticut, Dept Biomed Engn, Storrs, CT USA.
   [Fasciano, Samantha] Univ New Haven, Dept Cellular & Mol Biol, West Haven, CT USA.
C3 University New Haven; Lehigh University; Duke University; University of
   Connecticut; University New Haven
RP Wang, S (通讯作者)，Univ New Haven, Dept Chem Chem & Biomed Engn, West Haven, CT 06516 USA.
EM swang@newhaven.edu
RI ZHAO, Yuwen/GSN 2399 2022
OI Zhao, Yuwen/0000 0001 5020 9134
FU NSF CAREER [P 1558]; NASA CT Space Grant Consortium Faculty Research
   Grant [CMMI: 2143151]; Provost Graduate Fellowship; NASA CT Student
   Research Grant
FX This work is supported by NSF CAREER (CMMI: 2143151) and NASA CT Space
   Grant Consortium Faculty Research Grant (Award Number: P 1558). YZ is
   supported by the Provost Graduate Fellowship. KR is supported by NASA CT
   Student Research Grant.
CR Artavanis Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770
   Asada H, 2005, J VASC SURG, V42, P772, DOI 10.1016/j.jvs.2005.05.046
   Assunçao M, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.602009
   Bagheri L, 2018, J TISSUE ENG REGEN M, V12, P304, DOI 10.1002/term.2455
   Bjornson CRR, 2012, STEM CELLS, V30, P232, DOI 10.1002/stem.773
   Cao JJ, 2017, INT J MOL MED, V40, P378, DOI 10.3892/ijmm.2017.3037
   Cappellesso R, 2015, Endocr Regul, V49, P231
   Dardik A, 2005, J VASC SURG, V41, P869, DOI 10.1016/j.jvs.2005.01.020
   Dean ZS, 2016, ANAL CHEM, V88, P8902, DOI 10.1021/acs.analchem.6b02608
   Gambacurta A, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 44593 6
   Gonzalez BA, 2020, FRONT CARDIOVASC MED, V7, DOI 10.3389/fcvm.2020.00069
   Guilak F, 2009, CELL STEM CELL, V5, P17, DOI 10.1016/j.stem.2009.06.016
   Han Y, 2019, CELLS BASEL, V8, DOI 10.3390/cells8080886
   Hellström M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571
   Heo SJ, 2016, ELIFE, V5, DOI 10.7554/eLife.18207
   Hu KZ, 2017, BIOMED PHARMACOTHER, V91, P841, DOI 10.1016/j.biopha.2017.04.094
   Iovene A, 2021, J FUNCT BIOMATER, V12, DOI 10.3390/jfb12010014
   Jiang YH, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.12956
   Jiao F, 2022, J BIOMED MATER RES A, V110, P1636, DOI 10.1002/jbm.a.37413
   Karystinou A, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0639 9
   Kashani SY, 2021, MAT SCI ENG C MATER, V121, DOI 10.1016/j.msec.2020.111794
   Kim KM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092427
   Lim KT, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/316803
   Liu LY, 2010, BIOMECH MODEL MECHAN, V9, P659, DOI 10.1007/s10237 010 0206 x
   Liu YS, 2015, SCI REP UK, V5, DOI 10.1038/srep16522
   Lorthongpanich C, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1494 4
   Mizutani K, 2007, NATURE, V449, P351, DOI 10.1038/nature06090
   Moreira BG, 2005, BIOCHEM BIOPH RES CO, V327, P473, DOI 10.1016/j.bbrc.2004.12.035
   Navran S, 2008, BIOTECHNOL ANN REV, V14, P275, DOI 10.1016/S1387 2656(08)00011 2
   Nelson BR, 2007, DEV BIOL, V304, P479, DOI 10.1016/j.ydbio.2007.01.001
   Pape HC, 2010, J ORTHOP TRAUMA, V24, pS36, DOI 10.1097/BOT.0b013e3181cec4a1
   Poon C, 2022, J MECH BEHAV BIOMED, V126, DOI 10.1016/j.jmbbm.2021.105024
   Qin X, 2019, BIOCHEM BIOPH RES CO, V510, P219, DOI 10.1016/j.bbrc.2019.01.065
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Rath S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141802
   Reible B, 2017, GROWTH FACTORS, V35, P179, DOI 10.1080/08977194.2017.1401618
   Riahi R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7556
   Riahi R, 2014, ACS NANO, V8, P3597, DOI 10.1021/nn500107g
   Sacks MS, 2007, PHILOS T R SOC B, V362, P1369, DOI 10.1098/rstb.2007.2122
   Saghati S, 2021, STEM CELL REV REP, V17, P1294, DOI 10.1007/s12015 021 10130 0
   Song BQ, 2015, CELL PHYSIOL BIOCHEM, V36, P1991, DOI 10.1159/000430167
   Tao S, 2014, CANCER RES, V74, P7430, DOI 10.1158/0008 5472.CAN 14 1439
   Wagley Y, 2020, STEM CELLS, V38, P1332, DOI 10.1002/stem.3245
   Wang F, 2012, J MOL DIAGN, V14, P22, DOI 10.1016/j.jmoldx.2011.08.002
   Wang SE, 2019, ACS SYNTH BIOL, V8, P1079, DOI 10.1021/acssynbio.8b00530
   Wang S, 2018, SYN BIOL, V3, DOI 10.1093/synbio/ysy005
   Wang S, 2018, BIOMATERIALS, V156, P56, DOI 10.1016/j.biomaterials.2017.11.026
   Wang S, 2017, ADV BIOSYST, V1, DOI 10.1002/adbi.201600019
   Wang S, 2015, ADV MATER, V27, P6034, DOI 10.1002/adma.201502814
   Wang YK, 2012, STEM CELLS DEV, V21, P1176, DOI 10.1089/scd.2011.0293
   Weber M., 2012, FASEB J, V26, P1151, DOI [10.1096/fasebj.26.1_supplement.1151.7, DOI 10.1096/FASEBJ.26.1_SUPPLEMENT.1151.7]
   Weycker Derek, 2016, Bone Rep, V5, P186, DOI 10.1016/j.bonr.2016.07.005
   Williams A, 2017, J BIOMECH, V65, P40, DOI 10.1016/j.jbiomech.2017.09.035
   Xu C, 2022, ELIFE, V11, DOI [10.7554/eLife.60183, 10.7554/eLife.60183.sa0, 10.7554/eLife.60183.sa1, 10.7554/eLife.60183.sa2]
   Xue XF, 2017, BIOMATERIALS, V134, P22, DOI 10.1016/j.biomaterials.2017.04.039
   Xue XF, 2016, BIOPHYS J, V110, p134A, DOI 10.1016/j.bpj.2015.11.768
   Yang LL, 2020, ACS APPL MATER INTER, V12, P25591, DOI 10.1021/acsami.0c05012
   Yourek G, 2010, REGEN MED, V5, P713, DOI 10.2217/RME.10.60
   Yu J, 2006, SCIENCE, V311, P1600, DOI 10.1126/science.1119623
   Yu J, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115474
   Zhao YW, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 14437 x
   Zheng Y, 2017, LAB CHIP, V17, P1948, DOI 10.1039/c7lc00186j
NR 62
TC 17
Z9 19
U1 5
U2 30
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 4185
J9 FRONT BIOENG BIOTECH
JI Front. Bioeng. Biotechnol.
PD OCT 5
PY 2022
VL 10
AR 1007430
DI 10.3389/fbioe.2022.1007430
PG 14
WC Biotechnology & Applied Microbiology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Engineering
GA 5T0TY
UT WOS:000875591700001
PM 36277376
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Zou, X
   Yu, KT
   Chu, XY
   Shu, Y
   Yang, LL
   Wang, CL
AF Zou, Xuan
   Yu, Kaitao
   Chu, Xiaoyang
   Shu, Yao
   Yang, Lili
   Wang, Chenglong
TI Asiaticoside Enhances the Osteoblast Potential of LPS induced
   Periodontal Ligament Stem Cells through TLR4/NF κB Pathway
SO LETTERS IN DRUG DESIGN & DISCOVERY
LA English
DT Article
DE Asiaticoside; periodontal ligament stem cells; osteoblast
   differentiation; anti inflammatory; TLR4/NF kappa B signaling pathway;
   cell apoptosis
ID CENTELLA ASIATICA; DIFFERENTIATION; INFLAMMATION; GINGIVALIS; THERAPY
AB Objective: Asiaticoside (AS), an active compound extracted from Centella asiatica, can promote the osteogenic differentiation of human periodontal ligament cells. In this study, we investigated the impact of AS on lipopolysaccharide (LPS) induced osteoblast differentiation and inflammatory response in human periodontal ligament stem cells (hPDLSCs) and its possible mechanisms.
   Methods: hPDLSCs were treated with LPS to establish a model mimicking periodontitis and then administered with different concentrations of AS (30, 60, and 120 mu M). Flow cytometry and CCK 8 were conducted to assess cell apoptosis and proliferation rates, ELISA to detect the levels of inflammatory factors (IL 1 ss, IL 8, and TNF alpha) in the cell supernatant, and Western blot to determine the expression of osteoblast differentiation proteins ( Runx2, and OPN) and TLR4/ NF kappa B signaling pathway proteins (TLR4, MyD88, P65, p P65) with ALP and Alizarin red staining conducted.
   Results: LPS induced apoptosis of hPDLSCs, and inhibited proliferation and osteoblast differentiation when increasing the levels of inflammatory factors. However, these alterations were restored upon AS treatment dose dependently when cell apoptosis decreased, proliferation rate increased, IL  1 ss, IL 8, TNF alpha levels decreased, and osteoblast differentiation enhanced. Additionally, LPS activated the TLR4/NF kappa B signaling pathway in hPDLSCs, up regulating TLR4, MyD88, and p P65 expression, which was abrogated by AS.
   Conclusion: AS ameliorates LPS induced inflammation and apoptosis in hPDLSCs through TLR4/NF kappa B pathway and that AS can be expected to become a therapeutic drug for periodontal tissue regeneration treatment.
C1 [Zou, Xuan; Yu, Kaitao; Chu, Xiaoyang; Shu, Yao; Yang, Lili; Wang, Chenglong] Chinese Peoples Liberat Army Gen Hosp, Dept Stomatol, Med Ctr 5, Beijing 100071, Peoples R China.
C3 Chinese People's Liberation Army General Hospital; Fifth Medical Center
   of Chinese PLA General Hospital
RP Zou, X (通讯作者)，Chinese Peoples Liberat Army Gen Hosp, Dept Stomatol, Med Ctr 5, Beijing 100071, Peoples R China.
EM zouxuan307@163.com
CR Bylka W, 2014, PHYTOTHER RES, V28, P1117, DOI 10.1002/ptr.5110
   Cao C, 2018, SHOCK, V50, P595, DOI 10.1097/SHK.0000000000001104
   Chen FM, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0288 1
   Cheng MS, 2021, CELLS TISSUES ORGANS, V209, P227, DOI 10.1159/000511702
   Choi MJ, 2016, MOL MED REP, V14, P4521, DOI 10.3892/mmr.2016.5809
   Cochet F, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112318
   Deas DE, 2016, PERIODONTOL 2000, V71, P128, DOI 10.1111/prd.12114
   Ding G, 2010, STEM CELLS, V28, P1829, DOI 10.1002/stem.512
   Duan Y, 2020, INT J MOL MED, V45, P1918, DOI 10.3892/ijmm.2020.4554
   Duan Y, 2019, MED SCI MONITOR, V25, P9499, DOI 10.12659/MSM.918940
   Ebersole JL, 2016, PERIODONTOL 2000, V72, P54, DOI 10.1111/prd.12135
   Feng G, 2018, CELL IMMUNOL, V328, P86, DOI 10.1016/j.cellimm.2018.04.002
   Fitri AR, 2018, J PERIODONTOL, V89, P596, DOI 10.1002/JPER.17 0471
   Gu K, 2020, J CELL BIOCHEM, V121, P1101, DOI 10.1002/jcb.29346
   Hernández Monjaraz B, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19040944
   Kato H, 2014, ARCH ORAL BIOL, V59, P167, DOI 10.1016/j.archoralbio.2013.11.008
   Lee JH, 2017, J PERIODONTAL IMPLAN, V47, P264, DOI 10.5051/jpis.2017.47.5.264
   Li CH, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt456
   Li CJ, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009197.pub3
   Maldonado RF, 2016, FEMS MICROBIOL REV, V40, P480, DOI 10.1093/femsre/fuw007
   Menicanin D, 2014, STEM CELLS DEV, V23, P1001, DOI 10.1089/scd.2013.0490
   Moghadam ET, 2020, EUR J PHARMACOL, V889, DOI 10.1016/j.ejphar.2020.173665
   Nowwarote N, 2013, PHYTOTHER RES, V27, P457, DOI 10.1002/ptr.4742
   Nuñez J, 2019, PERIODONTOL 2000, V79, P107, DOI 10.1111/prd.12250
   Oeckinghaus A, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000034
   Pandula PKCP, 2014, J INVESTIG CLIN DENT, V5, P81, DOI 10.1111/jicd.12089
   Plóciennikowska A, 2015, CELL MOL LIFE SCI, V72, P557, DOI 10.1007/s00018 014 1762 5
   Raedel M, 2019, J DENT, V80, P30, DOI 10.1016/j.jdent.2018.11.001
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Slots J, 2017, PERIODONTOL 2000, V75, P7, DOI 10.1111/prd.12221
   Smith MM, 2017, PERIODONTOL 2000, V74, P63, DOI 10.1111/prd.12190
   Sun BJ, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.568032
   Tomokiyo A, 2019, STEM CELLS DEV, V28, P974, DOI 10.1089/scd.2019.0031
   Xu WZ, 2020, ADV PROTEIN CHEM STR, V120, P45, DOI 10.1016/bs.apcsb.2019.12.001
   Yan BB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207760
   Zhang L, 2021, J PERIODONTOL, V92, P103, DOI 10.1002/JPER.20 0869
   Zheng W, 2015, INT J MOL MED, V36, P915, DOI 10.3892/ijmm.2015.2314
NR 37
TC 1
Z9 1
U1 1
U2 2
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1570 1808
EI 1875 628X
J9 LETT DRUG DES DISCOV
JI Lett. Drug Des. Discov.
PY 2023
VL 20
IS 7
BP 838
EP 844
DI 10.2174/1570180819666220429100342
PG 7
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA K7QS6
UT WOS:001018355100005
DA 2025 08 17
ER

PT J
AU Barnes, GL
   Kakar, S
   Vora, S
   Morgan, EE
   Gerstenfeld, LC
   Einhorn, TA
AF Barnes, George L.
   Kakar, Sanjeev
   Vora, Siddarth
   Morgan, Elise E.
   Gerstenfeld, Louis C.
   Einhorn, Thomas A.
TI Stimulation of fracture healing with systemic intermittent parathyroid
   hormone treatment
SO JOURNAL OF BONE AND JOINT SURGERY AMERICAN VOLUME
LA English
DT Article; Proceedings Paper
CT Symposium of the
   American Academy of Orthopaedic Surgeons/National Institutes of Health
CY APR 25 28, 2007
CL Miami Beach, FL
SP Amer Acad Orthopaed Surg, NIH
ID BONE MINERAL DENSITY; MECHANICAL STRENGTH; HUMAN
   PARATHYROID HORMONE (1 34); CHONDROCYTE DIFFERENTIATION;
   CLINICAL APPLICATIONS; POSTMENOPAUSAL WOMEN; CALLUS FORMATION; RISK
   REDUCTION; OSTEOPOROSIS; TERIPARATIDE
AB Over the past several years, there has been an increasing interest in the biology of bone repair and potential technologies for enhancing fracture healing. Part of this interest is derived from the growing age of the population and the recognition that increased age carries an increased risk of complications after fracture. Although use of locally implanted or injected growth factors has received the most attention, systemic treatments for the enhancement of bone repair, especially for situations in which bone repair may be diminished or delayed, are now under investigation. Since the approval of parathyroid hormone (PTH) as an anabolic treatment for osteoporosis, there has been an increasing interest in other potential clinical uses for this compound in musculoskeletal conditions. It is now widely recognized that PTH administration is an effective therapy to increase bone mineral density and prevent fractures in patients with osteoporosis. More recently, a growing body of evidence has supported the conclusion that PTH will also be an effective anabolic therapy for the enhancement of bone repair after fracture. This review focuses on the recent research demonstrating the potential of PTH in the management of bone repair in a number of fracture models and also highlights the ongoing studies into the mechanisms of PTH actions on endochondral bone repair.
C1 [Barnes, George L.; Kakar, Sanjeev; Vora, Siddarth; Morgan, Elise E.; Gerstenfeld, Louis C.; Einhorn, Thomas A.] Boston Univ, Med Ctr, Dept Orthopaed Surg, Boston, MA 02118 USA.
C3 Boston University
RP Barnes, GL (通讯作者)，Boston Univ, Med Ctr, Dept Orthopaed Surg, 715 Albany St,R 205, Boston, MA 02118 USA.
EM GBarries@bu.edu
RI Morgan, Elise/L 1706 2013; Gerstenfeld, Louis/AAA 5396 2022
OI Einhorn, Thomas/0000 0002 5075 4885; /0000 0002 0477 1211; 
CR Alkhiary YM, 2005, J BONE JOINT SURG AM, V87A, P731, DOI 10.2106/JBJS.D.02115
   Andreassen TT, 2004, J CRANIOFAC SURG, V15, P424, DOI 10.1097/00001665 200405000 00014
   Andreassen TT, 2004, CALCIFIED TISSUE INT, V74, P351, DOI 10.1007/s00223 003 0093 6
   Andreassen TT, 1999, J BONE MINER RES, V14, P960, DOI 10.1359/jbmr.1999.14.6.960
   Andreassen TT, 2001, ACTA ORTHOP SCAND, V72, P304, DOI 10.1080/00016470152846673
   Beaver R, 1997, J La State Med Soc, V149, P200
   Chung UI, 1998, P NATL ACAD SCI USA, V95, P13030, DOI 10.1073/pnas.95.22.13030
   Einhorn TA, 2003, J BONE JOINT SURG AM, V85A, P82, DOI 10.2106/00004623 200300003 00014
   Hock J. M., 2001, Journal of Musculoskeletal & Neuronal Interactions, V2, P33
   Hock JM, 2001, J BONE MINER RES, V16, P975, DOI 10.1359/jbmr.2001.16.6.975
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Holzer G, 1999, CLIN ORTHOP RELAT R, P258, DOI 10.1097/00003086 199909000 00033
   Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564
   Jahng JS, 2000, ORTHOPEDICS, V23, P1089
   KAKAR S, 2007, J BONE MINER RE 0806
   Kaufman JM, 2005, OSTEOPOROSIS INT, V16, P510, DOI 10.1007/s00198 004 1713 3
   Khan SN, 2005, J AM ACAD ORTHOP SUR, V13, P77, DOI 10.5435/00124635 200501000 00010
   Kobayashi T, 2005, J CLIN INVEST, V115, P1734, DOI 10.1172/JCI24397
   Komatsubara S, 2005, BONE, V36, P678, DOI 10.1016/j.bone.2005.02.002
   Kulkarni NH, 2005, J CELL BIOCHEM, V95, P1178, DOI 10.1002/jcb.20506
   Lieberman JR, 2002, J BONE JOINT SURG AM, V84A, P1032, DOI 10.2106/00004623 200206000 00022
   Lindsay R, 2004, ARCH INTERN MED, V164, P2024, DOI 10.1001/archinte.164.18.2024
   Long FX, 2004, DEVELOPMENT, V131, P1309, DOI 10.1242/dev.01006
   Miao DS, 2002, J CLIN INVEST, V109, P1173, DOI 10.1172/JCI200214817
   Murray TM, 2005, ENDOCR REV, V26, P78, DOI 10.1210/er.2003 0024
   Nakajima A, 2002, J BONE MINER RES, V17, P2038, DOI 10.1359/jbmr.2002.17.11.2038
   Nakazawa T, 2005, BONE, V37, P711, DOI 10.1016/j.bone.2005.06.013
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Prince R, 2005, J BONE MINER RES, V20, P1507, DOI 10.1359/JBMR.050501
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Seebach C, 2004, J ORTHOP RES, V22, P472, DOI 10.1016/j.orthers.2003.08.018
NR 31
TC 94
Z9 113
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0021 9355
EI 1535 1386
J9 J BONE JOINT SURG AM
JI J. Bone Joint Surg. Am. Vol.
PD FEB
PY 2008
VL 90A
SU 1
BP 120
EP 127
DI 10.2106/JBJS.G.01443
PG 8
WC Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Orthopedics; Surgery
GA 260AE
UT WOS:000252981300019
PM 18292366
DA 2025 08 17
ER

PT J
AU D'Angelo, R
   Mangini, M
   Fonderico, J
   Fulle, S
   Mayo, E
   Aramini, A
   Mariggiò, S
AF D'Angelo, Rosa
   Mangini, Maria
   Fonderico, Jole
   Fulle, Stefania
   Mayo, Emilia
   Aramini, Andrea
   Mariggio, Stefania
TI Inhibition of osteoclast activity by complement regulation with DF3016A,
   a novel small molecular weight C5aR inhibitor
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Complement system; C5aR; Osteoclastogenesis process; Allosteric
   antagonism
ID RECEPTOR CD88; BONE; ANAPHYLATOXIN; PHOSPHORYLATION; DIFFERENTIATION;
   CANCER; CELLS; C5L2; C3A; INTERNALIZATION
AB Recent insights have indicated an active role of the complex complement system not only in immunity, but also in bone remodeling. Evidence from knockout mice and observations from skeletal diseases have drawn attention to the C5a/C5aR axis of the complement cascade in the modulation of osteoclast functions and as potential therapeutic targets for treatment of bone pathologies. With the aim to identify novel C5aR regulators, a medicinal chemistry program was initiated, driven by structural information on a minor pocket of C5aR that has been proposed to be a key motif for C5aR intracellular activation. The impact of the peptidomimetic orthosteric C5aR antagonist (PMX 53), of two newly synthesized allosteric C5aR antagonists (DF2593A, DF3016A), and of C5aR down regulation by specific siRNAs, were examined for regulation of osteoclastogenesis, using a well validated in vitro model starting from RAW264.7 precursor cells. Both pharmacological and molecular approaches reduced osteoclast maturation of RAW264.7 cells induced by receptor activator of nuclear factor kappa B ligand (RANKL), which limited the transcription of several differentiation markers evaluated by real time PCR, including nuclear factor of activated T cell 1, matrix metalloproteinase 9, cathepsin K, and tartrate resistant acid phosphatase. These treatments were ineffective on the subsequent step of osteoclast syncytium formation, apparently as a consequence of reduction of C5aR mRNA levels in the course of osteoclastogenesis, as monitored by real time PCR. Among the C5aR antagonists analyzed, DF3016A inhibited osteoclast degradation activity through inhibition of C5aR signal transduction and transcription. These data confirm the preclinical relevance of this novel therapeutic candidate.
C1 [D'Angelo, Rosa; Mangini, Maria; Mayo, Emilia; Mariggio, Stefania] CNR, Inst Prot Biochem, Naples, Italy.
   [Fonderico, Jole; Fulle, Stefania] G dAnnunzio Univ Chieti Pescara, Dept Neurosci Imaging & Clin Sci, Chieti, Italy.
   [Aramini, Andrea] Res & Early Dev Dompe Farmaceut SpA, Naples, Italy.
C3 Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle
   Proteine (IBP CNR); G d'Annunzio University of Chieti Pescara
RP Mariggiò, S (通讯作者)，CNR, Inst Prot Biochem, Naples, Italy.
EM s.mariggio@ibp.cnr.it
RI Mariggio', Stefania/H 5467 2015; Fulle, Stefania/F 3328 2013; Fonderico,
   Jole/AAT 1886 2021; Mangini, Maria/AAL 9201 2021
OI Aramini, Andrea/0000 0001 8390 6614; Mangini, Maria/0000 0002 4524 6317;
   MARIGGIO, STEFANIA/0000 0002 6397 3016; 
FU Ministry of Education, University and Research (MIUR), Italy, P.O.R.
   FESR Campania SATIN; Ministry of Education, University and Research
   (MIUR), Italy, PRIN project [2012CK5RPF_05]; Ministry of Education,
   University and Research (MIUR), Italy, FSE FESR [DOT1353500]
FX We thank Chris Berrie for editorial assistance. This work was supported
   by the Ministry of Education, University and Research (MIUR), Italy,
   P.O.R. FESR Campania SATIN; and Ministry of Education, University and
   Research (MIUR), Italy, PRIN project 2012CK5RPF_05 (toSM); JF has a PhD
   fellowship (code n. DOT1353500) in the framework of PON RI 2014/2020,
   Action I.1 "Innovative PhDs with industrial characterization", funded by
   Ministry of Education, University and Research (MIUR), Italy,
   FSE FESR.We thank all colleagues who kindly provided reagents.
CR Abe T, 2012, J IMMUNOL, V189, P5442, DOI 10.4049/jimmunol.1202339
   Ajona D, 2018, AM J RESP CRIT CARE, V197, P1164, DOI 10.1164/rccm.201703 0660OC
   Allegretti M, 2005, CURR MED CHEM, V12, P217, DOI 10.2174/0929867053363379
   Andrades JA, 1996, EXP CELL RES, V227, P208, DOI 10.1006/excr.1996.0269
   Banda NK, 2012, J IMMUNOL, V188, P1469, DOI 10.4049/jimmunol.1102310
   Beato C, 2013, J CHEM INF MODEL, V53, P1503, DOI 10.1021/ci400079k
   Beccari AR, 2013, J CHEM INF MODEL, V53, P1518, DOI 10.1021/ci400078g
   Billiard J, 2003, J CELL BIOCHEM, V89, P389, DOI 10.1002/jcb.10514
   Bjorge L, 2005, BRIT J CANCER, V92, P895, DOI 10.1038/sj.bjc.6602334
   Boulay F, 1997, ANN NY ACAD SCI, V832, P69, DOI 10.1111/j.1749 6632.1997.tb46238.x
   Brandolini L, 2019, NEUROTOX RES, V36, P439, DOI 10.1007/s12640 019 00049 3
   Braun L, 2003, J BIOL CHEM, V278, P4277, DOI 10.1074/jbc.M210120200
   Breivik T, 2011, J PERIODONTAL RES, V46, P643, DOI 10.1111/j.1600 0765.2011.01383.x
   Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   Chiou WF, 2004, INT IMMUNOPHARMACOL, V4, P1329, DOI 10.1016/j.intimp.2004.05.017
   Chiou WF, 2003, EUR J PHARMACOL, V458, P217, DOI 10.1016/S0014 2999(02)02733 4
   Collin Osdoby P, 2012, METHODS MOL BIOL, V816, P187, DOI 10.1007/978 1 61779 415 5_13
   Cuetara BLV, 2006, IN VITRO CELL DEV AN, V42, P182, DOI 10.1290/0510075.1
   DeSantis C, 2014, CA CANCER J CLIN, V64, P52, DOI 10.3322/caac.21203
   Ehrnthaller C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081341
   Ehrnthaller C, 2011, MOL MED, V17, P317, DOI 10.2119/molmed.2010.00149
   Giuliani N, 2006, BLOOD, V108, P3992, DOI 10.1182/blood 2006 05 026112
   Grant EP, 2002, J EXP MED, V196, P1461, DOI 10.1084/jem.20020205
   Hernandez MX, 2017, ASN NEURO, V9, DOI 10.1177/1759091416687871
   Hsu WC, 2014, CELL SIGNAL, V26, P1409, DOI 10.1016/j.cellsig.2014.02.021
   Huber Lang M, 2006, NAT MED, V12, P682, DOI 10.1038/nm1419
   Ignatius A, 2011, J TRAUMA, V71, P952, DOI 10.1097/TA.0b013e3181f8aa2d
   Ignatius A, 2011, J CELL BIOCHEM, V112, P2594, DOI 10.1002/jcb.23186
   Koehl J, 2006, CURR OPIN MOL THER, V8, P529
   Kovtun A, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 14444 3
   Langkabel P, 1999, EUR J IMMUNOL, V29, P3035, DOI 10.1002/(SICI)1521 4141(199909)29:09<3035::AID IMMU3035>3.0.CO;2 Z
   Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008 5472.CAN 05 4005
   Li R, 2013, FASEB J, V27, P855, DOI 10.1096/fj.12 220509
   Liang S, 2011, J IMMUNOL, V186, P869, DOI 10.4049/jimmunol.1003252
   Lim EJ, 2010, EXP MOL MED, V42, P712, DOI 10.3858/emm.2010.42.10.070
   Markiewski MM, 2008, NAT IMMUNOL, V9, P1225, DOI 10.1038/ni.1655
   Maurya MR, 2007, BIOPHYS J, V93, P729, DOI 10.1529/biophysj.106.097501
   Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00262
   Modinger Y, 2018, SEMIN IMMUNOL, V37, P53, DOI 10.1016/j.smim.2018.01.001
   Moriconi A, 2014, P NATL ACAD SCI USA, V111, P16937, DOI 10.1073/pnas.1417365111
   Natarajan M, 2006, NAT CELL BIOL, V8, P571, DOI 10.1038/ncb1418
   NICULESCU F, 1992, AM J PATHOL, V140, P1039
   Nitta H, 2013, CLIN CANCER RES, V19, P2004, DOI 10.1158/1078 0432.CCR 12 1204
   Otto M, 2004, J BIOL CHEM, V279, P142, DOI 10.1074/jbc.M310078200
   Owen R, 2018, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00134
   Park JH, 2017, MOL CELLS, V40, P706
   Pobanz JM, 2000, J PERIODONTAL RES, V35, P137, DOI 10.1034/j.1600 0765.2000.035003137.x
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   Roman Roman S, 2003, BONE, V32, P474, DOI 10.1016/S8756 3282(03)00052 8
   Rosenkilde MM, 2010, TRENDS PHARMACOL SCI, V31, P567, DOI 10.1016/j.tips.2010.08.006
   SATO T, 1993, ENDOCRINOLOGY, V133, P397, DOI 10.1210/en.133.1.397
   Schett G, 2010, NAT REV ENDOCRINOL, V6, P698, DOI 10.1038/nrendo.2010.190
   Schraufstatter IU, 2009, J IMMUNOL, V182, P3827, DOI 10.4049/jimmunol.0803055
   Suvorova ES, 2005, TRAFFIC, V6, P100, DOI 10.1111/j.1600 0854.2004.00256.x
   Tu Z, 2010, BLOOD, V116, P4456, DOI 10.1182/blood 2010 01 263590
   Xing LP, 2005, IMMUNOL REV, V208, P19, DOI 10.1111/j.0105 2896.2005.00336.x
NR 56
TC 8
Z9 8
U1 0
U2 4
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD MAR
PY 2020
VL 123
AR 109764
DI 10.1016/j.biopha.2019.109764
PG 9
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA KF8HB
UT WOS:000509476800046
PM 31901551
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Park, SY
   Kim, J
   Chung, HY
AF Park, S. Y.
   Kim, J.
   Chung, H. Y.
TI Denosumab induced hypocalcemia in a patient with hyperthyroidism: a case
   report
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Denosumab; Hyperthyroidism; Hypocalcemia; Osteoporosis
ID POSTMENOPAUSAL OSTEOPOROSIS; BONE; RISK; STIMULATION; WOMEN
AB Denosumab is a humanized monoclonal antibody targeting the receptor activator of nuclear factor kappa B ligand (RANKL). Denosumab is an effective treatment for osteoporosis but can cause hypocalcemia. We present a case of denosumab induced hypocalcemia in a patient with hyperthyroidism with a high bone turnover state. A 48 year old postmenopausal woman was diagnosed with hyperthyroidism and osteoporosis and received antithyroid drugs (propylthiouracil 200 mg/day) and denosumab. After 2 months of taking medication, the patient complained of numbness and tingling in the hands and feet and was diagnosed with hypocalcemia (calcium, 5.8 mg/dL; ionized calcium, 0.83 mmol/L). Alfacalcidol (0.5 mu g/day) and calcium carbonate (3000 mg/day) were prescribed. Subsequently, the patient's symptoms improved, and her serum calcium level normalized. The risk of denosumab induced hypocalcemia may be increased in patients with diseases related to high bone turnover, such as hyperthyroidism; therefore, caution is needed.
C1 [Park, S. Y.] Kyung Hee Univ Hosp, Dept Endocrinol & Metab, Seoul, South Korea.
   [Kim, J.] Chaum, Dept Endocrinol & Metab, Seoul, South Korea.
   [Chung, H. Y.] Kyung Hee Univ, Kyung Hee Univ Hosp Gangdong, Dept Endocrinol & Metab, Sch Med, 892 Dongnam Ro, Seoul 05278, South Korea.
C3 Kyung Hee University; Kyung Hee University Hospital; Kyung Hee
   University; Kyung Hee University Hospital
RP Chung, HY (通讯作者)，Kyung Hee Univ, Kyung Hee Univ Hosp Gangdong, Dept Endocrinol & Metab, Sch Med, 892 Dongnam Ro, Seoul 05278, South Korea.
EM hychung@khnmc.or.kr
OI Chung, Ho yeon/0000 0002 4529 8280
CR Asano T, 2019, J BONE MINER METAB, V37, P351, DOI 10.1007/s00774 018 0928 x
   Body JJ, 2015, EUR J CANCER, V51, P1812, DOI 10.1016/j.ejca.2015.05.016
   Bone HG, 2017, LANCET DIABETES ENDO, V5, P513, DOI 10.1016/S2213 8587(17)30138 9
   Bridgeman MB, 2011, CLIN THER, V33, P1547, DOI 10.1016/j.clinthera.2011.10.008
   BRITTO JM, 1994, ENDOCRINOLOGY, V134, P169, DOI 10.1210/en.134.1.169
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Dave V, 2015, AM J NEPHROL, V41, P129, DOI 10.1159/000380960
   Delmas PD, 2008, J CLIN DENSITOM, V11, P325, DOI 10.1016/j.jocd.2008.02.002
   Farinola N, 2013, INTERN MED J, V43, P1243, DOI 10.1111/imj.12283
   Huynh ALH, 2016, PHARMACOEPIDEM DR S, V25, P1274, DOI 10.1002/pds.4045
   Ishikawa K, 2018, CLIN INTERV AGING, V13, P1929, DOI 10.2147/CIA.S180614
   Ishikawa K, 2016, THER CLIN RISK MANAG, V12, P1831, DOI 10.2147/TCRM.S123172
   Jamal SA, 2011, J BONE MINER RES, V26, P1829, DOI 10.1002/jbmr.403
   Khosla S, 2018, J CLIN INVEST, V128, P4832, DOI 10.1172/JCI122151
   Lechner B, 2014, SUPPORT CARE CANCER, V22, P1765, DOI 10.1007/s00520 014 2142 2
   MUNDY GR, 1976, J CLIN INVEST, V58, P529, DOI 10.1172/JCI108497
   Okada N, 2013, BIOL PHARM BULL, V36, P1622, DOI 10.1248/bpb.b13 00496
   Park So Young, 2019, J Bone Metab, V26, P213, DOI 10.11005/jbm.2019.26.4.213
   Shin Terry, 2015, BMJ Case Rep, V2015, DOI 10.1136/bcr 2014 206967
   Tsvetov G, 2020, OSTEOPOROSIS INT, V31, P655, DOI 10.1007/s00198 019 05261 7
NR 20
TC 3
Z9 3
U1 0
U2 3
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD JAN
PY 2022
VL 33
IS 1
BP 305
EP 308
DI 10.1007/s00198 021 06059 2
EA JUL 2021
PG 4
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA YG3BY
UT WOS:000671910600002
PM 34232341
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Pignatello, R
   Cenni, E
   Micieli, D
   Fotia, C
   Salerno, M
   Granchi, D
   Avnet, S
   Sarpietro, M
   Castelli, F
   Baldini, N
AF Pignatello, Rosario
   Cenni, Elisabetta
   Micieli, Dorotea
   Fotia, Caterina
   Salerno, Manuela
   Granchi, Donatella
   Avnet, Sofia
   Sarpietro, Maria
   Castelli, Francesco
   Baldini, Nicola
TI A novel biomaterial for osteotropic drug nanocarriers: synthesis and
   biocompatibility evaluation of a PLGA ALE conjugate
SO NANOMEDICINE
LA English
DT Article
DE alendronate; biocompatibility; bisphosphonates; nanoparticles; ODDS;
   poly(lactide co glycolide); polymer conjugates; osteotropic
   drug delivery systems
ID DELIVERY SYSTEMS; IN VITRO; BONE; NANOPARTICLES; BISPHOSPHONATE;
   MICROSPHERES; RELEASE; POLY(D,L LACTIDE CO GLYCOLIDE); PROTEINS;
   ADHESION
AB Background & aims: Osteotropic drug delivery systems have been proposed as a means to provide drugs with affinity to bone tissues. Drugs or proteins have been linked chemically to bone seeking agents, such as bisphosphonates (BPs); alternatively, drug loaded nanoparticles have been used to target specific tissues, such as tumor areas. In our current research, these approaches were merged by synthesizing a novel bone seeking polymer conjugate, from which targetable nanoparticles can be produced. Materials & methods: An amino BP, alendronate (ALE) was bound covalently to a biodegradable polymer, poly (lactic co glycolide) (PLGA), containing a free end carboxylic group. Blood compatibility and cytotoxicity were assessed in vitro. Results & discussion: By a classical solvent evaporation method, nanoparticles with a mean size of 200300 nm were prepared from the conjugate; sterilization was achieved by gamma irradiation, confirming their potential as injectable drug nanocarriers. Owing to the presence of the BP residue, PLGA ALE nanoparticles were adsorbed onto hydroxyapatite to a higher extent than pure PLGA nanoparticles. The PLGA ALE conjugate did not induce either hemolysis or alterations of the plasmatic phase of coagulation, or cytotoxic effects on endothelial cells and trabecular osteoblasts. Conclusion: The prepared conjugate represents a novel biomaterial that is able to provide nanoparticles, which can be further loaded with drugs, such as anticancer agents, and addressed to osteolytic or other bone diseases.
C1 [Pignatello, Rosario] Univ Catania, Citta Univ, Dept Pharmaceut Sci, Catania, Italy.
   [Cenni, Elisabetta; Salerno, Manuela; Granchi, Donatella; Avnet, Sofia; Baldini, Nicola] Ist Ortoped Rizzoli, Lab Pathophysiol Orthoped Implants, I 40136 Bologna, Italy.
   [Micieli, Dorotea; Sarpietro, Maria; Castelli, Francesco] Univ Catania, Dept Chem Sci, Catania, Italy.
   [Baldini, Nicola] Univ Catania, Dept Human Anat & Musculoskeletal Pathophysiol, Catania, Italy.
C3 University of Catania; IRCCS Istituto Ortopedico Rizzoli; University of
   Catania; University of Catania
RP Pignatello, R (通讯作者)，Univ Catania, Citta Univ, Dept Pharmaceut Sci, Catania, Italy.
EM r.pignatello@unict.it
RI pignatello, rosario/G 3176 2010; Granchi, Donatella/J 3647 2016;
   Castelli, Fabio/M 1177 2013; Avnet, Sofia/B 3220 2018; Baldini,
   Nicola/J 4806 2016; Pignatello, Rosario/G 3176 2010
OI Granchi, Donatella/0000 0001 7225 0023; Avnet,
   Sofia/0000 0002 7843 0591; Baldini, Nicola/0000 0003 2228 3833;
   CASTELLI, Francesco/0000 0002 1982 8065; Pignatello,
   Rosario/0000 0002 5937 4192
CR [Anonymous], CANC NANOTECHNOLOGY
   Astete CE, 2006, J BIOMAT SCI POLYM E, V17, P247, DOI 10.1163/156856206775997322
   Bala I, 2004, CRIT REV THER DRUG, V21, P387, DOI 10.1615/CritRevTherDrugCarrierSyst.v21.i5.20
   Barrett J, 2004, J CLIN PHARMACOL, V44, P951, DOI 10.1177/0091270004267594
   Blanco Prieto MJ, 2004, J CONTROL RELEASE, V96, P437, DOI 10.1016/j.jconrel.2004.02.015
   Bondi ML, 2007, DRUG DELIV, V14, P61, DOI 10.1080/10717540600739914
   Choi SW, 2007, J CONTROL RELEASE, V122, P24, DOI 10.1016/j.jconrel.2007.06.003
   Costantino L, 2005, J CONTROL RELEASE, V108, P84, DOI 10.1016/j.jconrel.2005.07.013
   Crivellari D, 2001, ANN ONCOL, V12, P353, DOI 10.1023/A:1011132609055
   CUTRIGHT DE, 1974, ORAL SURG ORAL MED O, V37, P142, DOI 10.1016/0030 4220(74)90171 6
   DISILVIO L, 2001, OSTEOBLASTS HUMAN CE, V5, pCH11
   Ezra A, 2000, J MED CHEM, V43, P3641, DOI 10.1021/jm980645y
   Gittens SA, 2005, ADV DRUG DELIVER REV, V57, P1011, DOI 10.1016/j.addr.2004.12.015
   GREF R, 1994, SCIENCE, V263, P1600, DOI 10.1126/science.8128245
   Greish K, 2007, J DRUG TARGET, V15, P457, DOI 10.1080/10611860701539584
   HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022 1759(89)90397 9
   Hengst V, 2007, INT J PHARMACEUT, V331, P224, DOI 10.1016/j.ijpharm.2006.11.024
   Hirabayashi H, 2003, CLIN PHARMACOKINET, V42, P1319, DOI 10.2165/00003088 200342150 00002
   Hirabayashi H, 2001, J CONTROL RELEASE, V70, P183, DOI 10.1016/S0168 3659(00)00355 2
   JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470
   Langer R, 1998, NATURE, V392, P5
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   Liu XM, 2008, BIOMATERIALS, V29, P1686, DOI 10.1016/j.biomaterials.2007.12.023
   Liu XM, 2007, J CONTROL RELEASE, V122, P54, DOI 10.1016/j.jconrel.2007.06.021
   Low SP, 2006, BIOMATERIALS, V27, P4538, DOI 10.1016/j.biomaterials.2006.04.015
   Lu W, 2006, CANCER RES, V66, P11878, DOI 10.1158/0008 5472.CAN 06 2354
   MCKENNA GB, 1988, COMPREHENSIVE POLYM, V1
   Mitra A, 2006, CURR PHARM DESIGN, V12, P4729, DOI 10.2174/138161206779026317
   Niemi R, 1999, J MED CHEM, V42, P5053, DOI 10.1021/jm991109o
   NOEL TR, 1995, INT J BIOL MACROMOL, V17, P81, DOI 10.1016/0141 8130(95)93521 X
   Ogawa K, 2006, J NUCL MED, V47, P2042
   Okada H, 1997, ADV DRUG DELIVER REV, V28, P43, DOI 10.1016/S0169 409X(97)00050 1
   PETRIE SEB, 1972, J POLYM SCI A2, V10, P1255, DOI 10.1002/pol.1972.160100706
   Pridgen EM, 2007, NANOMEDICINE UK, V2, P669, DOI 10.2217/17435889.2.5.669
   RODRIGUEZLORENZ.V, 2006, 20 EUR C BIOM NANT F
   Sousa SR, 2008, J BIOMED MATER RES A, V84A, P281, DOI 10.1002/jbm.a.31201
   Tosi G, 2005, BIOMATERIALS, V26, P4189, DOI 10.1016/j.biomaterials.2004.10.025
   von Knoch F, 2005, BIOMATERIALS, V26, P6941, DOI 10.1016/j.biomaterials.2005.04.059
   Wang D, 2005, ADV DRUG DELIVER REV, V57, P1049, DOI 10.1016/j.addr.2004.12.011
   Wang D, 2003, BIOCONJUGATE CHEM, V14, P853, DOI 10.1021/bc034090j
   Wright JEI, 2006, BIOMATERIALS, V27, P769, DOI 10.1016/j.biomaterials.2005.06.012
   ZIMMER A, 1995, ADV DRUG DELIVER REV, V16, P61, DOI 10.1016/0169 409X(95)00017 2
NR 42
TC 58
Z9 64
U1 0
U2 31
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743 5889
J9 NANOMEDICINE UK
JI Nanomedicine
PD FEB
PY 2009
VL 4
IS 2
BP 161
EP 175
DI 10.2217/17435889.4.2.161
PG 15
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Science & Technology   Other
   Topics
GA 411BA
UT WOS:000263621200012
PM 19193183
DA 2025 08 17
ER

PT J
AU Keller, KK
   Thomsen, JS
   Stengaard Pedersen, K
   Dagnæs Hansen, F
   Nyengaard, JR
   Hauge, EM
AF Keller, Kresten Krarup
   Thomsen, Jesper Skovhus
   Stengaard Pedersen, Kristian
   Dagnaes Hansen, Frederik
   Nyengaard, Jens Randel
   Hauge, Ellen Margrethe
TI Bone Formation and Resorption Are Both Increased in Experimental
   Autoimmune Arthritis
SO PLOS ONE
LA English
DT Article
ID OSTEOCLAST DIFFERENTIATION FACTOR; COLLAGEN INDUCED ARTHRITIS;
   RHEUMATOID ARTHRITIS; ARBITRARY PARTICLES; NUMBER; CELLS; SIZE;
   OSTEOPROTEGERIN; REGULATOR; CYTOKINE
AB Introduction: Arthritic bone loss in the joints of patients with rheumatoid arthritis is the result of a combination of osteoclastic bone resorption and osteoblastic bone formation. This process is not completely understood, and especially the importance of local inflammation needs further investigation. We evaluated how bone formation and bone resorption are altered in experimental autoimmune arthritis.
   Methods: Twenty one female SKG mice were randomized to either an arthritis group or a control group. Tetracycline was used to identify mineralizing surfaces. After six weeks the right hind paws were embedded undecalcified in methylmethacrylate. The paws were cut exhaustively according to the principles of vertical sectioning and systematic sampling. 3D design based methods were used to estimate the total number of osteoclasts, mineralizing surfaces, eroded surfaces, and osteoclast covered bone surfaces. In addition the presence of adjacent inflammation was ascertained.
   Results: The total number of osteoclasts, mineralizing surfaces, eroded surfaces, and osteoclast covered surfaces were elevated in arthritic paws compared to normal paws. Mineralizing surfaces were elevated adjacent to as well as not adjacent to inflammation in arthritic mice compared to normal mice. In arthritic mice, eroded surfaces and osteoclast covered surfaces were larger on bone surfaces adjacent to inflammation than on bone surfaces without adjacent inflammation. However, we found no difference between mineralizing surfaces at bone surfaces with or without inflammation in arthritic mice.
   Conclusions: Inflammation induced an increase in resorptive bone surfaces as well as formative bone surfaces. The bone formative response may be more general, since formative bone surfaces were also increased when not associated with inflammation. Thus, the bone loss may be the result of a substantial local bone resorption, which cannot be compensated by the increased local bone formation. These findings may be valuable for the development of new osteoblast targeting drugs in RA.
C1 [Keller, Kresten Krarup; Stengaard Pedersen, Kristian; Hauge, Ellen Margrethe] Aarhus Univ Hosp, Dept Rheumatol, DK 8000 Aarhus, Denmark.
   [Thomsen, Jesper Skovhus; Dagnaes Hansen, Frederik] Aarhus Univ, Dept Biomed, Aarhus, Denmark.
   [Nyengaard, Jens Randel] Aarhus Univ Hosp, Stereol & Electron Microscopy Lab, Ctr Stochast Geometry & Adv Bioimaging, DK 8000 Aarhus, Denmark.
C3 Aarhus University; Aarhus University; Aarhus University
RP Keller, KK (通讯作者)，Aarhus Univ Hosp, Dept Rheumatol, DK 8000 Aarhus, Denmark.
EM kresten@ana.au.dk
RI ; Keller, Kresten/S 2067 2019; Thomsen, Jesper/HKN 2794 2023
OI Stengaard Pedersen, Kristian/0000 0001 7991 2456; Keller, Kresten
   Krarup/0000 0003 2474 3389; Thomsen, Jesper Skovhus/0000 0001 9386 6679;
   Dagnaes Hansen, Frederik/0000 0002 6622 0853; 
FU Danish Rheumatism Association; A. P. Moller Foundation for the
   Advancement of Medical Science; Horslev Foundation, Clinical Institute
   Aarhus University, Peter Ryholts Grant; Hede Nielsens Family Foundation;
   Aase and Ejnar Danielsens Foundation; Villum Foundation
FX This work was supported by grants from the Danish Rheumatism
   Association, The A. P. Moller Foundation for the Advancement of Medical
   Science, the Horslev Foundation, Clinical Institute Aarhus University,
   Peter Ryholts Grant, the Hede Nielsens Family Foundation, and Aase and
   Ejnar Danielsens Foundation. Centre for Stochastic Geometry and Advanced
   Bioimaging is supported by Villum Foundation. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR BADDELEY AJ, 1986, J MICROSC OXFORD, V142, P259, DOI 10.1111/j.1365 2818.1986.tb04282.x
   Caetano Lopes J, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2908
   Choi Y, 2009, NAT REV RHEUMATOL, V5, P543, DOI 10.1038/nrrheum.2009.175
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Dorph Petersen KA, 2001, J MICROSC OXFORD, V204, P232, DOI 10.1046/j.1365 2818.2001.00958.x
   Erben RG, 1996, ANAT REC, V246, P39, DOI 10.1002/(SICI)1097 0185(199609)246:1<39::AID AR5>3.0.CO;2 A
   Ferguson SJ, 1999, MED ENG PHYS, V21, P111, DOI 10.1016/S1350 4533(99)00032 6
   Görtz B, 2004, J BONE MINER RES, V19, P990, DOI 10.1359/JBMR.040205
   Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529 0131(200002)43:2<250::AID ANR3>3.0.CO;2 P
   GUNDERSEN HJG, 1986, J MICROSC OXFORD, V143, P3, DOI 10.1111/j.1365 2818.1986.tb02764.x
   GUNDERSEN HJG, 1987, J MICROSC OXFORD, V147, P229, DOI 10.1111/j.1365 2818.1987.tb02837.x
   Hashimoto M, 2010, J EXP MED, V207, P1135, DOI 10.1084/jem.20092301
   Hata H, 2004, J CLIN INVEST, V114, P582, DOI 10.1172/JCI200421795
   Hirota K, 2007, J EXP MED, V204, P41, DOI 10.1084/jem.20062259
   Hyde DM, 2007, TOXICOL PATHOL, V35, P41, DOI 10.1080/01926230601059977
   Ito Y, 2009, ARTHRITIS RHEUM US, V60, P2294, DOI 10.1002/art.24687
   Jimi E, 1999, J IMMUNOL, V163, P434
   Karmakar S, 2010, RHEUM DIS CLIN N AM, V36, P385, DOI 10.1016/j.rdc.2010.03.003
   Keller KK, 2011, CLIN EXP RHEUMATOL, V29, P536
   Kitaura H, 2005, J CLIN INVEST, V115, P3418, DOI 10.1172/JCI26132
   Kobayashi K, 2006, INFLAMM RES, V55, P335, DOI 10.1007/s00011 006 5208 x
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   McQueen FM, 2003, ARTHRITIS RHEUM, V48, P1814, DOI 10.1002/art.11162
   NYENGAARD JR, 1993, DIABETOLOGIA, V36, P1126, DOI 10.1007/BF00401056
   Rau R, 2006, CLIN EXP RHEUMATOL, V24, pS41
   Redlich K, 2004, AM J PATHOL, V164, P543, DOI 10.1016/S0002 9440(10)63144 6
   Rioja I, 2008, ARTHRITIS RHEUM US, V58, P2257, DOI 10.1002/art.23667
   Romas E, 2000, ARTHRITIS RHEUM, V43, P821, DOI 10.1002/1529 0131(200004)43:4<821::AID ANR12>3.0.CO;2 T
   Roux C, 2011, OSTEOPOROSIS INT, V22, P421, DOI 10.1007/s00198 010 1319 x
   Sakaguchi N, 2003, NATURE, V426, P454, DOI 10.1038/nature02119
   Schett G, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2110
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   STERIO DC, 1984, J MICROSC OXFORD, V134, P127, DOI 10.1111/j.1365 2818.1984.tb02501.x
   Tang Y, 2009, ANAT REC, V292, P1630, DOI 10.1002/ar.20952
   Walsh NC, 2010, IMMUNOL REV, V233, P301, DOI 10.1111/j.0105 2896.2009.00857.x
   Walsh NC, 2009, J BONE MINER RES, V24, P1572, DOI [10.1359/JBMR.090320, 10.1359/jbmr.090320]
NR 38
TC 16
Z9 17
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD DEC 27
PY 2012
VL 7
IS 12
AR e53034
DI 10.1371/journal.pone.0053034
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 061EA
UT WOS:000312829100111
PM 23300855
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Low, SA
   Galliford, CV
   Yang, JY
   Low, PS
   Kopecek, J
AF Low, Stewart A.
   Galliford, Chris V.
   Yang, Jiyuan
   Low, Philip S.
   Kopecek, Jindrich
TI Biodistribution of Fracture Targeted GSK3β Inhibitor Loaded Micelles for
   Improved Fracture Healing
SO BIOMACROMOLECULES
LA English
DT Article
ID BONE MORPHOGENETIC PROTEINS; DRUG DELIVERY; OSTEOCLAST DIFFERENTIATION;
   PROSTAGLANDIN E 1; RISK FACTORS; RATS; THERAPEUTICS; ARTHRITIS;
   BISPHOSPHONATES; ANGIOGENESIS
AB Bone fractures constitute a major cause of morbidity and mortality especially in the elderly. Complications associated with osteoporosis drugs and the age of the patient slow bone turnover and render such fractures difficult to heal. Increasing the speed of fracture repair by administration of a fracture targeted bone anabolic agent could find considerable application. Aspartic acid oligopeptides are negatively charged molecules at physiological pH that adsorb to hydroxyapatite, the mineral portion of bone. This general adsorption is the strongest where bone turnover is highest or where hydroxyapatite is freshly exposed. Importantly, both of these conditions are prominent at fracture sites. GSK3 beta inhibitors are potent anabolic agents that can promote tissue repair when concentrated in a damaged tissue. Unfortunately, they can also cause significant toxicity when administered systemically and are furthermore difficult to deliver due to their strong hydrophobicity. In this paper, we solve both problems by conjugating the hydrophobic GSK3 beta inhibitor to a hydrophilic aspartic acid octapeptide using a hydrolyzable bond, thereby generating a bone fracture targeted water soluble form of the drug. The resulting amphiphile is shown to assemble into micelles, extending its circulation time while maintaining its fracture targeting abilities. For measurement of pharmacokinetics, an I 125 was introduced at the location of the bromine in the GSK3 beta inhibitor to minimize any structural differences. Biodistribution studies demonstrate a greater than 4 fold increase in fracture accumulation over healthy bone.
C1 [Low, Stewart A.; Kopecek, Jindrich] Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA.
   [Yang, Jiyuan; Kopecek, Jindrich] Univ Utah, Dept Pharmaceut & Pharmaceut Chem, Salt Lake City, UT 84112 USA.
   [Galliford, Chris V.; Low, Philip S.] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.
C3 Utah System of Higher Education; University of Utah; Utah System of
   Higher Education; University of Utah; Purdue University System; Purdue
   University
RP Kopecek, J (通讯作者)，Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA.
EM jindrich.kopecek@utah.edu
RI ; Low, Stewart/JTU 2123 2023
OI Low, Philip/0000 0001 9042 5528; Low, Stewart/0000 0002 7387 3545; 
FU NIH [RO1 GM69847]; Purdue University
FX We thank Drs. Ananda K Kanduluru, Skarapalayam Mahalingam, and Pengcheng
   Lu for assisting with the animal work. We also thank Dr. Aaron B. Taylor
   and Jennifer Lu for their advising on instrumentation. This research was
   supported in part by NIH Grant RO1 GM69847 (to J.K.) and Purdue
   University.
CR Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Bartl R., 2009, Osteoporosis: Diagnosis, prevention, therapy
   Bishop GB, 2007, INT ORTHOP, V31, P721, DOI 10.1007/s00264 007 0424 8
   Burgess T., 1998, CELL, V93, P165
   Chen Y, 2007, PLOS MED, V4, P1216, DOI 10.1371/journal.pmed.0040249
   Corcoran EB, 2012, ORG LETT, V14, P4630, DOI 10.1021/ol302076d
   Dempster David W, 2011, Am J Manag Care, V17 Suppl 6, pS164
   Fournier P, 2002, CANCER RES, V62, P6538
   Fukuda T, 2010, DIFFERENTIATION, V80, P46, DOI 10.1016/j.diff.2010.05.002
   Ganapathy ME, 1998, BIOCHEM BIOPH RES CO, V246, P470, DOI 10.1006/bbrc.1998.8628
   Georgiou KR, 2012, BONE, V50, P1223, DOI 10.1016/j.bone.2012.03.027
   Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hoff AO, 2008, J BONE MINER RES, V23, P826, DOI [10.1359/JBMR.080205, 10.1359/jbmr.080205]
   Ishizaki J, 2009, J BONE MINER METAB, V27, P1, DOI 10.1007/s00774 008 0004 z
   Jia Z, 2015, J CONTROL RELEASE, V200, P23, DOI 10.1016/j.jconrel.2014.12.028
   KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0
   Krause U, 2010, P NATL ACAD SCI USA, V107, P4147, DOI 10.1073/pnas.0914360107
   Looker AC, 2010, J BONE MINER RES, V25, P64, DOI 10.1359/jbmr.090706
   Low SA, 2014, BIOCONJUGATE CHEM, V25, P2012, DOI 10.1021/bc500392x
   Low SA, 2012, ADV DRUG DELIVER REV, V64, P1189, DOI 10.1016/j.addr.2012.01.012
   MADISON JF, 1963, ARCH DERMATOL, V88, P58, DOI 10.1001/archderm.1963.01590190064008
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   McCarroll AJ, 2000, J CHEM SOC PERK T 2, P1868, DOI 10.1039/b003273p
   Metselaar JM, 2004, ANN RHEUM DIS, V63, P348, DOI 10.1136/ard.2003.009944
   Miller SC, 2008, PHARM RES DORDR, V25, P2889, DOI 10.1007/s11095 008 9706 0
   MYERS HM, 1968, AM J PHYS ANTHROPOL, V29, P179, DOI 10.1002/ajpa.1330290211
   Newman J., 2008, PHYS LIFE SCI
   Oden A, 1998, OSTEOPOROSIS INT, V8, P599, DOI 10.1007/s001980050105
   Ong KL, 2010, SPINE, V35, P1794, DOI 10.1097/BRS.0b013e3181ecf6e4
   Pan HZ, 2013, BIOMATERIALS, V34, P6528, DOI 10.1016/j.biomaterials.2013.05.003
   Piters E, 2008, ARCH BIOCHEM BIOPHYS, V473, P112, DOI 10.1016/j.abb.2008.03.006
   Polychronopoulos P, 2004, J MED CHEM, V47, P935, DOI 10.1021/jm031016d
   Quan LD, 2014, ACS NANO, V8, P458, DOI 10.1021/nn4048205
   Ren K, 2011, MOL PHARMACEUT, V8, P1043, DOI 10.1021/mp2000555
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Schindeler A, 2008, SEMIN CELL DEV BIOL, V19, P459, DOI 10.1016/j.semcdb.2008.07.004
   Sekido T, 2001, J DRUG TARGET, V9, P111, DOI 10.3109/10611860108997922
   Sisask G, 2013, BONE, V54, P126, DOI 10.1016/j.bone.2013.01.019
   Solomon DH, 2009, OSTEOPOROSIS INT, V20, P895, DOI 10.1007/s00198 008 0759 z
   SWENSON O, 1946, J BONE JOINT SURG, V28, P288
   Väänänen HK, 2000, J CELL SCI, V113, P377
   Vernillo A T, 1998, Adv Dent Res, V12, P56
   Wang D, 2005, ADV DRUG DELIVER REV, V57, P1049, DOI 10.1016/j.addr.2004.12.011
   Wang D, 2003, BIOCONJUGATE CHEM, V14, P853, DOI 10.1021/bc034090j
   Wang D, 2007, BIOCONJUGATE CHEM, V18, P1375, DOI 10.1021/bc7002132
   Wang D, 2006, MOL PHARMACEUT, V3, P717, DOI 10.1021/mp0600539
   Wang FS, 2009, LIFE SCI, V85, P685, DOI 10.1016/j.lfs.2009.09.009
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yuan F, 2012, ADV DRUG DELIVER REV, V64, P1205, DOI 10.1016/j.addr.2012.03.006
   Ziebart T, 2011, CLIN ORAL INVEST, V15, P105, DOI 10.1007/s00784 009 0365 2
NR 51
TC 25
Z9 32
U1 0
U2 11
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1525 7797
EI 1526 4602
J9 BIOMACROMOLECULES
JI Biomacromolecules
PD OCT
PY 2015
VL 16
IS 10
BP 3145
EP 3153
DI 10.1021/acs.biomac.5b00777
PG 9
WC Biochemistry & Molecular Biology; Chemistry, Organic; Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA CT5PW
UT WOS:000362863500007
PM 26331790
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Elsafadi, M
   Manikandan, M
   Dawud, RA
   Alajez, NM
   Hamam, R
   Alfayez, M
   Kassem, M
   Aldahmash, A
   Mahmood, A
AF Elsafadi, M.
   Manikandan, M.
   Dawud, R. A.
   Alajez, N. M.
   Hamam, R.
   Alfayez, M.
   Kassem, M.
   Aldahmash, A.
   Mahmood, A.
TI Transgelin is a TGFβ inducible gene that regulates osteoblastic and
   adipogenic differentiation of human skeletal stem cells through actin
   cytoskeleston organization
SO CELL DEATH & DISEASE
LA English
DT Article
ID GROWTH FACTOR BETA; SMOOTH MUSCLE; OSTEOGENIC DIFFERENTIATION; EXPRESSED
   PROTEINS; MATRIX STIFFNESS; BONE FORMATION; SM22 ALPHA; MIGRATION;
   COMPLEX; SHAPE
AB Regenerative medicine is a novel approach for treating conditions in which enhanced bone regeneration is required. We identified transgelin (TAGLN), a transforming growth factor beta (TGF beta) inducible gene, as an upregulated gene during in vitro osteoblastic and adipocytic differentiation of human bone marrow derived stromal (skeletal) stem cells (hMSC). siRNA mediated gene silencing of TAGLN impaired lineage differentiation into osteoblasts and adipocytes but enhanced cell proliferation. Additional functional studies revealed that TAGLN deficiency impaired hMSC cell motility and in vitro transwell cell migration. On the other hand, TAGLN overexpression reduced hMSC cell proliferation, but enhanced cell migration, osteoblastic and adipocytic differentiation, and in vivo bone formation. In addition, deficiency or overexpression of TAGLN in hMSC was associated with significant changes in cellular and nuclear morphology and cytoplasmic organelle composition as demonstrated by high content imaging and transmission electron microscopy that revealed pronounced alterations in the distribution of the actin filament and changes in cytoskeletal organization. Molecular signature of TAGLN deficient hMSC showed that several genes and genetic pathways associated with cell differentiation, including regulation of actin cytoskeleton and focal adhesion pathways, were downregulated. Our data demonstrate that TAGLN has a role in generating committed progenitor cells from undifferentiated hMSC by regulating cytoskeleton organization. Targeting TAGLN is a plausible approach to enrich for committed hMSC cells needed for regenerative medicine application.
C1 [Elsafadi, M.; Manikandan, M.; Alajez, N. M.; Hamam, R.; Alfayez, M.; Kassem, M.; Aldahmash, A.; Mahmood, A.] King Saud Univ, Dept Anat, Coll Med, Stem Cells Unit, Riyadh 11461, Saudi Arabia.
   [Elsafadi, M.; Kassem, M.; Aldahmash, A.] Odense Univ Hosp, Dept Endocrinol, KMEB, Odense, Denmark.
   [Elsafadi, M.; Kassem, M.; Aldahmash, A.] Univ Southern Denmark, Odense, Denmark.
   [Dawud, R. A.] Charite, Berlin Brandenburg Ctr Regenerat Therapies, Berlin, Germany.
   [Dawud, R. A.] King Faisal Specialist Hosp & Res Ctr, Dept Comparat Med, Riyadh, Saudi Arabia.
   [Aldahmash, A.] King Saud Univ, Prince Naif Hlth Res Ctr, Riyadh 11461, Saudi Arabia.
C3 King Saud University; University of Southern Denmark; Odense University
   Hospital; University of Southern Denmark; Free University of Berlin;
   Humboldt University of Berlin; Charite Universitatsmedizin Berlin; King
   Faisal Specialist Hospital & Research Center; King Saud University
RP Elsafadi, M (通讯作者)，King Saud Univ, Dept Anat, Coll Med, Stem Cells Unit, POB 295577, Riyadh 11351, Saudi Arabia.; Mahmood, A (通讯作者)，POB 2925,28, Riyadh 11461, Saudi Arabia.
EM monasafadi@gmail.com; ammahmood@ksu.edu.sa
RI Kassem, Moustapha/J 7688 2013; Mahmood, Amer/A 9514 2011; muthurangan,
   manikandan/GVU 5356 2022; Aldahmash, Abdullah/D 4693 2015
OI Kassem, Moustapha/0000 0003 1557 0869; muthurangan,
   manikandan/0000 0003 3057 1851; Alajez, Nehad/0000 0002 1546 1091;
   Elsafadi, Mona/0000 0002 7096 998X; Mahmood, Amer/0000 0002 9199 0120; 
FU College of Medicine Research Centre (CMRC), Deanship of Scientific
   Research, King Saud University, Riyadh, Saudi Arabia; Novo Nordisk
   Fonden [NNF15OC0016284] Funding Source: researchfish
FX These studies are supported by a grant from the College of Medicine
   Research Centre (CMRC), Deanship of Scientific Research, King Saud
   University, Riyadh, Saudi Arabia.
CR Abdallah BM, 2015, STEM CELL RES, V15, P449, DOI 10.1016/j.scr.2015.09.005
   Abdallah BM, 2015, BONE, V70, P28, DOI 10.1016/j.bone.2014.07.028
   Abdallah Basem M., 2008, V455, P89, DOI 10.1007/978 1 59745 104 8_6
   Abdallah BM, 2005, BIOCHEM BIOPH RES CO, V326, P527, DOI 10.1016/j.bbrc.2004.11.059
   Ahmad R, 2007, NAT CELL BIOL, V9, P1419, DOI 10.1038/ncb1661
   Al Nbaheen M, 2013, STEM CELL REV REP, V9, P32, DOI 10.1007/s12015 012 9365 8
   ANTRAS J, 1989, BIOL CELL, V66, P247, DOI 10.1016/0248 4900(89)90177 9
   BONEWALD LF, 1990, CLIN ORTHOP RELAT R, P261
   Cevallos M, 2006, DIFFERENTIATION, V74, P552, DOI 10.1111/j.1432 0436.2006.00089.x
   Chen CS, 2003, BIOCHEM BIOPH RES CO, V307, P355, DOI 10.1016/S0006 291X(03)01165 3
   Chen L, 2015, STEM CELL RES, V15, P281, DOI 10.1016/j.scr.2015.06.009
   Chen SY, 2003, NUCLEIC ACIDS RES, V31, P1302, DOI 10.1093/nar/gkg224
   Erlebacher A, 1998, MOL BIOL CELL, V9, P1903, DOI 10.1091/mbc.9.7.1903
   FAN JY, 1983, J CELL SCI, V61, P219
   Filvaroff E, 1999, DEVELOPMENT, V126, P4267
   Friedman JR, 2011, TRENDS CELL BIOL, V21, P709, DOI 10.1016/j.tcb.2011.07.004
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Hamam D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.462
   Hamidouche Z, 2009, P NATL ACAD SCI USA, V106, P18587, DOI 10.1073/pnas.0812334106
   Harmey D, 2004, J BONE MINER RES, V19, P661, DOI 10.1359/JBMR.040105
   HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527
   Jian HY, 2006, GENE DEV, V20, P666, DOI 10.1101/gad.1388806
   Karaöz E, 2011, J CELL PHYSIOL, V226, P1367, DOI 10.1002/jcp.22468
   Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058
   Lawson D, 1997, CELL MOTIL CYTOSKEL, V38, P250, DOI 10.1002/(SICI)1097 0169(1997)38:3<250::AID CM3>3.0.CO;2 9
   Li L, 1996, CIRC RES, V78, P188, DOI 10.1161/01.RES.78.2.188
   Li SY, 2010, HEPATOB PANCREAT DIS, V9, P149
   Lian J B, 1995, Iowa Orthop J, V15, P118
   Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30
   Lin Y, 2009, NEOPLASIA, V11, P864, DOI 10.1593/neo.09542
   LOMRI A, 1987, FEBS LETT, V222, P311, DOI 10.1016/0014 5793(87)80392 7
   Lu L, 2009, MOL BIOL CELL, V20, P3471, DOI 10.1091/mbc.E09 04 0327
   Maeda S, 2004, EMBO J, V23, P552, DOI 10.1038/sj.emboj.7600067
   Massagué J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745
   Mathews S, 2012, DIFFERENTIATION, V84, P185, DOI 10.1016/j.diff.2012.05.001
   Mathieu PS, 2012, TISSUE ENG PART B RE, V18, P436, DOI [10.1089/ten.teb.2012.0014, 10.1089/ten.TEB.2012.0014]
   Palomäki S, 2013, STEM CELLS, V31, P1902, DOI 10.1002/stem.1435
   Park JS, 2011, BIOMATERIALS, V32, P3921, DOI 10.1016/j.biomaterials.2011.02.019
   Peng JY, 2009, ELECTROPHORESIS, V30, P2976, DOI 10.1002/elps.200900203
   Pietilä M, 2012, STEM CELLS DEV, V21, P575, DOI 10.1089/scd.2011.0023
   Qiu P, 2003, J MOL CELL CARDIOL, V35, P1407, DOI 10.1016/j.yjmcc.2003.09.002
   Sakai D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024847
   Salasznyk RM, 2007, EXP CELL RES, V313, P22, DOI 10.1016/j.yexcr.2006.09.013
   Serra Rosa, 2003, Birth Defects Research, V69, P333, DOI 10.1002/bdrc.10023
   SHAPLAND C, 1993, J CELL BIOL, V121, P1065, DOI 10.1083/jcb.121.5.1065
   SHAPLAND C, 1988, J CELL BIOL, V107, P153, DOI 10.1083/jcb.107.1.153
   Sheppard Dean, 2006, Proc Am Thorac Soc, V3, P413, DOI 10.1513/pats.200601 008AW
   Shih YRV, 2011, J BONE MINER RES, V26, P730, DOI 10.1002/jbmr.278
   Sinha S, 2004, AM J PHYSIOL CELL PH, V287, pC1560, DOI 10.1152/ajpcell.00221.2004
   Small JV, 1998, ACTA PHYSIOL SCAND, V164, P341
   Talele NP, 2015, STEM CELL REP, V4, P1016, DOI 10.1016/j.stemcr.2015.05.004
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Treiser MD, 2010, P NATL ACAD SCI USA, V107, P610, DOI 10.1073/pnas.0909597107
   Untergasser G, 2005, MECH AGEING DEV, V126, P59, DOI 10.1016/j.mad.2004.09.023
   Wang DJ, 2004, J BIOL CHEM, V279, P43725, DOI 10.1074/jbc.M407368200
   Xue XY, 2014, TUMOR BIOL, V35, P7853, DOI 10.1007/s13277 014 1982 1
   Yourek G, 2007, ASAIO J, V53, P219, DOI 10.1097/MAT.0b013e31802deb2d
   Yu HY, 2008, FASEB J, V22, P1778, DOI 10.1096/fj.07 083857
   Zeidan A, 2004, FEBS LETT, V562, P141, DOI 10.1016/S0014 5793(04)00220 0
   Zhang J, 2011, INT J IMMUNOPATH PH, V24, P849, DOI 10.1177/039463201102400404
   Zhang JCL, 2001, MOL CELL BIOL, V21, P1336, DOI 10.1128/MCB.2001.21.4.1336 1344.2001
NR 61
TC 99
Z9 110
U1 0
U2 16
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041 4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD AUG
PY 2016
VL 7
AR e2321
DI 10.1038/cddis.2016.196
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA DU2YP
UT WOS:000382077800024
PM 27490926
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Tahaei, SE
   Couasnay, G
   Ma, Y
   Paria, N
   Gu, J
   Lemoine, BF
   Wang, X
   Rios, JJ
   Elefteriou, F
AF Tahaei, S. E.
   Couasnay, G.
   Ma, Y.
   Paria, N.
   Gu, J.
   Lemoine, B. F.
   Wang, X.
   Rios, J. J.
   Elefteriou, F.
TI The reduced osteogenic potential of Nf1 deficient
   osteoprogenitors is EGFR independent
SO BONE
LA English
DT Article
DE Neurofibromatosis type 1; Epiregulin; EGFR; Bone marrow stromal cells;
   Osteoblasts; Differentiation; RAS MAPK signaling
ID EPIDERMAL GROWTH FACTOR; BONE MORPHOGENETIC PROTEIN 7; SUPPRESSES
   OSTEOBLAST DIFFERENTIATION; CONGENITAL PSEUDOARTHROSIS; FACTOR BETA;
   TGF BETA; TIBIAL PSEUDOARTHROSIS; CELL PROLIFERATION; FIBROUS HAMARTOMA;
   FACTOR RECEPTOR
AB Neurofibromatosis type I (NF1) is a common genetic disorder caused by mutations in the NF1 gene. Recalcitrant bone healing following fracture (i.e. pseudarthrosis) is one of the most problematic skeletal complications associated with NF1. The etiology of this condition is still unclear; thus, pharmacological options for clinical management are limited. Multiple studies have shown the reduced osteogenic potential of Nf1 deficient osteoprogenitors. A recent transcriptome profiling investigation revealed that EREG and EGFR, encoding epiregulin and its receptor Epidermal Growth Factor Receptor 1, respectively, were among the top over expressed genes in cells of the NF1 pseudarthrosis site. Because EGFR stimulation is known to inhibit osteogenic differentiation, we hypothesized that increased EREG and EGFR expression in NF1 deficient skeletal progenitors may contribute to their reduced osteogenic differentiation potential. In this study, we first confirmed via single cell mRNA sequencing that EREG over expression was associated with NF1 second hit somatic mutations in human bone cells, whereas Transforming Growth Factor beta 1 (TGF beta 1) expression was unchanged. Second, using ex vivo recombined Nf1 deficient mouse bone marrow stromal cells (mBMSC5), we show that this molecular signature is conserved between mice and humans, and that epiregulin generated by these cells is overexpressed and active, whereas soluble TGF beta 1 expression and activity are not affected. However, blocking either epiregulin function or EGFR signaling by EGFR1 or pan EGFR inhibition (using AG 1478 and Poziotinib respectively) did not correct the differentiation defect of Nf1 deficient mBMSCs, as measured by the expression of Alpl, Ibsp and alkaline phosphatase activity. These results suggest that clinically available drugs aimed at inhibiting EGFR signaling are unlikely to have a significant benefit for the management of bone non union in children with NF1 PA. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Tahaei, S. E.] Vanderbilt Univ, Dept Pharmacol, Nashville, TN USA.
   [Tahaei, S. E.; Couasnay, G.; Ma, Y.; Elefteriou, F.] Baylor Coll Med, Dept Orthoped Surg, Houston, TX 77030 USA.
   [Paria, N.; Rios, J. J.] Texas Scottish Rite Hosp Children, Seay Ctr Musculoskeletal Res, Dallas, TX 75219 USA.
   [Gu, J.; Lemoine, B. F.; Wang, X.] Baylor Inst Immunol Res, Dallas, TX USA.
   [Rios, J. J.] UT Southwestern Med Ctr, Dept Pediat, Dallas, TX USA.
   [Rios, J. J.] UT Southwestern Med Ctr, McDermott Ctr Human Growth & Dev, Dallas, TX USA.
   [Rios, J. J.] UT Southwestern Med Ctr, Dept Orthopaed Surg, Dallas, TX USA.
   [Elefteriou, F.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
C3 Vanderbilt University; Baylor College of Medicine; Texas Scottish Rite
   Hospital for Children; Baylor Scott & White Health; University of Texas
   System; University of Texas Southwestern Medical Center; University of
   Texas System; University of Texas Southwestern Medical Center;
   University of Texas System; University of Texas Southwestern Medical
   Center; Baylor College of Medicine
RP Elefteriou, F (通讯作者)，Baylor Coll Med, Dept Orthoped Surg & Mol & Human Genet, Houston, TX 77030 USA.
EM florente@bcm.edu
RI Couasnay, Greig/CAI 8439 2022; Elefteriou, Florent/P 2586 2017; Ma,
   Yun/HRD 3253 2023
OI couasnay, greig/0000 0002 8190 7178; Elefteriou,
   Florent/0000 0002 2972 5633; Tahaei, Seyedmohammad
   Ebrahim/0000 0003 1647 0851; , Yun/0000 0003 2122 3695; Lemoine,
   Benjamin/0000 0001 8444 3826; 
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases of
   the National Institutes of Health [R56AR055966]; Texas Scottish Rite
   Hospital for Children and the Pediatric Orthopaedic Society of North
   America; Children Tumor Foundation [2015 01 015]
FX Research reported in this publication was supported by the National
   Institute of Arthritis and Musculoskeletal and Skin Diseases of the
   National Institutes of Health under Award Number R56AR055966 (FE), by
   the Texas Scottish Rite Hospital for Children and the Pediatric
   Orthopaedic Society of North America (JR), Children Tumor Foundation
   Young Investigator Award Number 2015 01 015 (SET). The content is solely
   the responsibility of the authors and does not necessarily represent the
   official views of the National Institutes of Health.
CR Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254
   Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638
   [Anonymous], 1988, ARCH NEUROL CHICAGO, V45, P575, DOI 10.1097/00005537 199606000 00007
   Anticevic D, 2006, J PEDIATR ORTHOP B, V15, P220, DOI 10.1097/01.bpb.0000194439.75378.ac
   ANTOSZ ME, 1987, J BONE MINER RES, V2, P385
   Baht GS, 2017, BONE, V98, P31, DOI 10.1016/j.bone.2017.02.012
   Chen JC, 2016, PHYSIOL REV, V96, P1025, DOI 10.1152/physrev.00030.2015
   Chen YH, 2015, GENE DEV, V29, P1677, DOI 10.1101/gad.261677.115
   Chien HH, 2000, CALCIFIED TISSUE INT, V67, P141, DOI 10.1007/s00223001128
   Cho TJ, 2008, J BONE JOINT SURG AM, V90A, P2735, DOI 10.2106/JBJS.H.00014
   Cichowski K, 2001, CELL, V104, P593, DOI 10.1016/S0092 8674(01)00245 8
   de la Croix Ndong J., 2014, NAT MED, V20, P904
   de la Croix Ndong J., 2014, J BONE MINER RES
   Dodt Matthias, 2012, Biology (Basel), V1, P895, DOI 10.3390/biology1030895
   El Hoss J, 2014, J BONE JOINT SURG AM, V96A, DOI 10.2106/JBJS.M.00862
   Elefteriou F, 2009, AM J MED GENET A, V149A, P2327, DOI 10.1002/ajmg.a.33045
   Fabeck L, 2006, J BONE JOINT SURG BR, V88B, P116, DOI 10.1302/0301 620X.88B1.16619
   FINE A, 1987, J BIOL CHEM, V262, P3897
   Fouletier Dilling CM, 2005, HUM GENE THER, V16, P1287, DOI 10.1089/hum.2005.16.1287
   FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447
   Genetos DC, 2010, CELL TISSUE RES, V340, P81, DOI 10.1007/s00441 010 0929 0
   Ghadakzadeh S., 2016, FASEB J
   HUNTER T, 1981, CELL, V24, P741, DOI 10.1016/0092 8674(81)90100 8
   HUSON SM, 1989, J MED GENET, V26, P704, DOI 10.1136/jmg.26.11.704
   Ippolito E, 2000, J PEDIATR ORTHOP B, V9, P3, DOI 10.1097/01202412 200001000 00002
   JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794 353
   Janssens K, 2006, J MED GENET, V43, P1, DOI 10.1136/jmg.2005.033522
   Kamiya N, 2017, J BONE MINER RES, V32, P1716, DOI 10.1002/jbmr.3155
   Kang JS, 2005, EMBO J, V24, P2543, DOI 10.1038/sj.emboj.7600729
   Karolak MR, 2015, HUM MOL GENET, V24, P2552, DOI 10.1093/hmg/ddv019
   Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]
   Kirmani S, 2010, AM J MED GENET A, V152A, P1016, DOI 10.1002/ajmg.a.33356
   Korpal M, 2009, NAT MED, V15, P960, DOI 10.1038/nm.1943
   Krampera M, 2005, BLOOD, V106, P59, DOI 10.1182/blood 2004 09 3645
   Lee DY, 2011, CLIN ORTHOP SURG, V3, P230, DOI 10.4055/cios.2011.3.3.230
   Lee FYI, 2006, J BONE JOINT SURG AM, V88A, P627, DOI 10.2106/JBJS.D.02201
   Lian N, 2012, J BIOL CHEM, V287, P35975, DOI 10.1074/jbc.M112.372458
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0550 8
   Mulcrone PL, 2017, J BONE MINER RES, V32, P1442, DOI 10.1002/jbmr.3133
   Nakamura T, 2010, CELL STRUCT FUNCT, V35, P53, DOI 10.1247/csf.10001
   Nam HJ, 2011, CANCER LETT, V302, P155, DOI 10.1016/j.canlet.2011.01.010
   NICOLAS V, 1990, BONE MINER, V8, P145, DOI 10.1016/0169 6009(90)90117 X
   Ono K, 2013, HUM MOL GENET, V22, P3048, DOI 10.1093/hmg/ddt162
   Ottmann O.G., 1988, J IMMUNOL, V140
   Paria N, 2014, J BONE MINER RES, V29, P2636, DOI 10.1002/jbmr.2298
   Qin L, 2005, J BIOL CHEM, V280, P3974, DOI 10.1074/jbc.M409807200
   Rhodes SD, 2013, J BONE MINER RES, V28, P2476, DOI 10.1002/jbmr.1992
   Richards BS, 2016, J PEDIAT ORTHOP
   Riese DJ, 2014, SEMIN CELL DEV BIOL, V28, P49, DOI 10.1016/j.semcdb.2014.03.005
   Samarakoon R, 2013, CELL SIGNAL, V25, P2198, DOI 10.1016/j.cellsig.2013.07.007
   Sharma R, 2013, HUM MOL GENET, V22, P4818, DOI 10.1093/hmg/ddt333
   Shirakata Y, 2000, J BIOL CHEM, V275, P5748, DOI 10.1074/jbc.275.8.5748
   Stevenson DA, 2006, AM J HUM GENET, V79, P143, DOI 10.1086/504441
   Stevenson DA, 1999, AM J MED GENET, V84, P413, DOI 10.1002/(SICI)1096 8628(19990611)84:5<413::AID AJMG5>3.0.CO;2 1
   Stevenson DA, 2013, J PEDIATR ORTHOPED, V33, P269, DOI 10.1097/BPO.0b013e31828121b8
   TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495
   Upadhyaya M, 1996, AM J MED GENET, V67, P421, DOI 10.1002/(SICI)1096 8628(19960726)67:4<421::AID AJMG20>3.0.CO;2 K
   Vitale MG, 2002, CLIN ORTHOP RELAT R, P107, DOI 10.1097/01.blo.0000022199.37246.c9
   Wang WX, 2011, HUM MOL GENET, V20, P3910, DOI 10.1093/hmg/ddr310
   Wang WX, 2010, J BONE MINER RES, V25, P1658, DOI 10.1002/jbmr.42
   WILNER HI, 1964, JAMA J AM MED ASSOC, V187, P490
   Wu XH, 2006, HUM MOL GENET, V15, P2837, DOI 10.1093/hmg/ddl208
   Yang FC, 2006, J CLIN INVEST, V116, P2880, DOI 10.1172/JCI29092
   Yu S, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.363
   Zhou Y, 2015, INT J MOL SCI, V16, P12345, DOI 10.3390/ijms160612345
   Zhu J, 2011, J CELL BIOCHEM, V112, P1749, DOI 10.1002/jcb.23094
   Zhu Y, 2001, GENE DEV, V15, P859, DOI 10.1101/gad.862101
NR 67
TC 16
Z9 19
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JAN
PY 2018
VL 106
BP 103
EP 111
DI 10.1016/j.bone.2017.10.012
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA FP3XV
UT WOS:000417552200014
PM 29032173
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Liu, W
   Li, YJ
   An, YY
   Zhao, RY
   Wei, CX
   Ren, XB
   He, HB
AF Liu, Wang
   Li, Yanjie
   An, Yuanyuan
   Zhao, Ruoyu
   Wei, Chenxi
   Ren, Xiaobin
   He, Hongbing
TI Yunnan Baiyao Might Mitigate Periodontitis Bone Destruction by
   Inhibiting Autophagy and Promoting Osteoblast Differentiation in vivo,
   ex vivo and in vitro
SO JOURNAL OF INFLAMMATION RESEARCH
LA English
DT Article
DE Yunnan Baiyao; periodontitis; osteoblasts; autophagy
AB Background and Objective: Periodontitis is an inflammatory disease that eventually destroys tooth  supporting tissue. Yunnan Baiyao (YNBY), a traditional Chinese medicine compound with haemostatic and anti inflammatory properties has shown therapeutic potential in several diseases. Our previous study revealed that YNBY suppressed osteoclast differentiation in periodontitis. The purpose of this study is to investigate the influences of YNBY on osteoblasts and explore its potential mechanisms. Materials and Methods: A rat periodontitis model was established by ligation of maxillary second molars. After the end of modelling, histopathological observation by hematoxylin eosin (HE) staining and Masson trichrome staining, detection of bone resorption by Micro  CT scanning, detection of osteoclasts by tartrate  resistant acid phosphatase (TRAP) staining, expression of osteocalcin (OCN) and microtubule associated protein 1 light chain 3 (LC3) by immunohistochemistry. Lipopolysaccharides was used to irritate MC3T3 E1 osteoblastic cells and ex vivo calvarial organ as an in vitro model of inflammation. CCK 8 assay was performed to examine the toxicity of YNBY to MC3T3 E1 osteoblastic cells. Osteogenesis was assessed with alizarin red staining, immunofluorescence staining, Western blot and immunohistochemical staining. Transmission electron microscopy, fluorescent double staining, Western blot and immunohistochemical staining were employed to detect autophagy. Results: Histological and micro  CT analyses revealed that YNBY gavage reduced bone loss caused by experimental periodontitis and upregulated osteogenic proteins in vivo. YNBY attenuated the production of autophagy related proteins in periodontitis rats. Additionally, YNBY promoted osteogenesis by inhibiting inflammation  induced autophagy in vitro. Furthermore, YNBY suppressed LPS mediated bone resorption and promoted the production of osteoblast related proteins in inflamed calvarial tissues ex vivo. Conclusion: This study demonstrated, through in vivo, in vitro and ex vivo experiments, that YNBY promoted osteoblast differentiation by suppressing autophagy, which markedly alleviated bone destruction caused by periodontitis.
C1 [Liu, Wang; Li, Yanjie; An, Yuanyuan; Zhao, Ruoyu; Wei, Chenxi; Ren, Xiaobin; He, Hongbing] Kunming Med Univ, Sch & Hosp Stomatol, Dept Periodontol, Kunming 650106, Peoples R China.
   [Liu, Wang; Li, Yanjie; An, Yuanyuan; Zhao, Ruoyu; Wei, Chenxi] Yunnan Key Lab Stomatol, Kunming 650106, Peoples R China.
C3 Kunming Medical University
RP Ren, XB; He, HB (通讯作者)，Kunming Med Univ, Sch & Hosp Stomatol, Dept Periodontol, Kunming 650106, Peoples R China.
EM Renxiaobin6688@163.com; hehongbing@kmmu.edu.cn
RI AN, ano/IZE 1209 2023; wei, chenxi/LRT 3277 2024; Ren,
   Xiaobin/GPX 1169 2022
FU National Natural Science Foundation of China [8166040056]; Natural
   Science Foundation of Yunnan, China [202001AY070001 085, 2019FE001 168];
   Yunnan Provincial Oral Disease Clinical Medical Research Center
   Scientific Research Fund [2022ZD001, 2022YB001]; Technical Innovation
   Personnel Training Object Item [202305AD350016]
FX The present study was supported by the National Natural Science
   Foundation of China (grant No. 8166040056) , the Natural Science
   Foundation of Yunnan, China (grant nos. 2019FE001 168 and
   202001AY070001 085) , the Yunnan Provincial Oral Disease Clinical
   Medical Research Center Scientific Research Fund (2022ZD001 and
   2022YB001) and Technical Innovation Personnel Training Object Item
   (202305AD350016) .
CR Armitage GC, 2004, PERIODONTOL 2000, V34, P9, DOI 10.1046/j.0906 6713.2002.003421.x
   Baek I, 2022, J TISSUE ENG, V13, DOI 10.1177/20417314221116754
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Bu TT, 2022, NUTRIENTS, V14, DOI 10.3390/nu14153135
   Chang Y, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082904
   Cheat B, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.839929
   Dang HX, 2023, SCI REP UK, V13, DOI 10.1038/s41598 023 28710 0
   Fujiwara T, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.86330
   Greabu M, 2020, MOLECULES, V25, DOI 10.3390/molecules25184338
   Gruber R, 2019, J CLIN PERIODONTOL, V46, P52, DOI 10.1111/jcpe.13056
   Hao YJ, 2022, AGING CELL, V21, DOI 10.1111/acel.13677
   Hienz SA, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/615486
   Hirata N, 2019, NUTRIENTS, V11, DOI 10.3390/nu11020368
   Huang D, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 33006 4
   Kadriu B, 2018, MOL PSYCHIATR, V23, P1626, DOI 10.1038/mp.2017.109
   Kang Y, 2023, BIOACT MATER, V20, P663, DOI 10.1016/j.bioactmat.2022.07.007
   Kuo CH, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.821492
   Laha D, 2019, AUTOPHAGY, V15, P2063, DOI 10.1080/15548627.2019.1596491
   Lee HA, 2020, J PERIODONTOL, V91, P1682, DOI 10.1002/JPER.19 0639
   Li N, 2022, MATER TODAY BIO, V16, DOI 10.1016/j.mtbio.2022.100360
   Li Y, 2023, Int Dent J, V1, P3
   Li Y, 2018, INT J MOL MED, V41, P2535, DOI 10.3892/ijmm.2018.3498
   Liu CC, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00439
   Liu J, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/1000213
   Liu J, 2019, INT J MED SCI, V16, P1078, DOI 10.7150/ijms.33723
   Ma Y.J., 2023, Jsuanji Yu Xiandaihua, V3, P1
   Momen Heravi F, 2021, J DENT RES, V100, P549, DOI 10.1177/0022034520979614
   Mueller Buehl AM, 2021, BIOLOGY BASEL, V10, DOI 10.3390/biology10050383
   Ni KR, 2021, INT IMMUNOPHARMACOL, V93, DOI 10.1016/j.intimp.2021.107399
   Nollet M, 2014, AUTOPHAGY, V10, P1965, DOI 10.4161/auto.36182
   Novello S, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14040729
   Onal M, 2013, J BIOL CHEM, V288, P17432, DOI 10.1074/jbc.M112.444190
   Park SW, 2022, NUCLEIC ACIDS RES, V50, P7856, DOI 10.1093/nar/gkac584
   Piemontese M, 2016, SCI REP UK, V6, DOI 10.1038/srep24262
   Ren XB, 2020, J FOOD BIOCHEM, V44, DOI 10.1111/jfbc.13182
   Tamura H, 2023, PHARMACEUTICALS BASE, V16, DOI 10.3390/ph16020303
   Uenaka M, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 28673 2
   Um S, 2018, INT J ORAL SCI, V10, DOI 10.1038/s41368 018 0028 8
   Vicencio E, 2020, CELLS BASEL, V9, DOI 10.3390/cells9051221
   Wang B, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.926622
   Wang YH, 2022, STEM CELLS INT, V2022, DOI 10.1155/2022/8124085
   Yao Q, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.773185
   Yao W, 2013, BONE, V54, P279, DOI 10.1016/j.bone.2013.01.034
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Zhao J, 2022, ELIFE, V11, DOI 10.7554/eLife.72128
NR 45
TC 3
Z9 3
U1 4
U2 11
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
EI 1178 7031
J9 J INFLAMM RES
JI J. Inflamm. Res.
PY 2024
VL 17
BP 2271
EP 2284
DI 10.2147/JIR.S454694
PG 14
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA OI3M3
UT WOS:001206603200001
PM 38645877
OA gold
DA 2025 08 17
ER

PT J
AU Pande, S
   Browne, G
   Padmanabhan, S
   Zaidi, SK
   Lian, JB
   Van Wijnen, AJ
   Stein, JL
   Stein, GS
AF Pande, Sandhya
   Browne, Gillian
   Padmanabhan, Srivatsan
   Zaidi, Sayyed K.
   Lian, Jane B.
   Van Wijnen, Andre J.
   Stein, Janet L.
   Stein, Gary S.
TI Oncogenic cooperation between PI3K/Akt signaling and transcription
   factor Runx2 promotes the invasive properties of metastatic breast
   cancer cells
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID GENE EXPRESSION; BONE; PROGRESSION; PATHWAY; GROWTH; OSTEOBLAST;
   MOTILITY; DISEASE; ROLES; TUMOR
AB The serine/threonine kinase Akt/PKB promotes cancer cell growth and invasion through several downstream targets. Identification of novel substrates may provide new avenues for therapeutic intervention. Our study shows that Akt phosphorylates the cancer related transcription factor Runx2 resulting in stimulated DNA binding of the purified recombinant protein in vitro. Pharmacological inhibition of the PI3K/Akt pathway in breast cancer cells reduces DNA binding activity of Runx2 with concomitant reduction in the expression of metastasis related Runx2 target genes. Akt phosphorylates Runx2 at three critical residues within the runt DNA binding domain to enhance its in vivo genomic interactions with a target gene promoter, MMP13. Mutation of these three phosphorylation sites reduces Runx2 DNA binding activity. However, Akt signaling does not appear to interefere with CBF Runx2 interactions. Consequently, expression of multiple metastasis related genes is decreased and Runx2 mediated cell invasion is supressed. Thus, our work identifies Runx2 as a novel and important downstream mediator of the PI3K/Akt pathway that is linked to metastatic properties of breast cancer cells. J. Cell. Physiol. 228: 17841792, 2013. (c) 2013 Wiley Periodicals, Inc.
C1 [Pande, Sandhya; Browne, Gillian; Padmanabhan, Srivatsan; Zaidi, Sayyed K.; Lian, Jane B.; Van Wijnen, Andre J.; Stein, Janet L.; Stein, Gary S.] Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA.
   [Pande, Sandhya; Browne, Gillian; Padmanabhan, Srivatsan; Zaidi, Sayyed K.; Lian, Jane B.; Van Wijnen, Andre J.; Stein, Janet L.; Stein, Gary S.] Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA USA.
   [Browne, Gillian; Zaidi, Sayyed K.; Lian, Jane B.; Stein, Janet L.; Stein, Gary S.] Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA.
   [Browne, Gillian; Zaidi, Sayyed K.; Lian, Jane B.; Stein, Janet L.; Stein, Gary S.] Univ Vermont, Coll Med, Ctr Canc, Burlington, VT 05405 USA.
   [Van Wijnen, Andre J.] Mayo Clin, Dept Orthoped Surg & Biochem & Mol Biol, Rochester, MN USA.
C3 University of Massachusetts System; University of Massachusetts
   Worcester; University of Massachusetts System; University of
   Massachusetts Worcester; University of Vermont; University of Vermont;
   Mayo Clinic
RP Stein, GS (通讯作者)，Univ Vermont, Coll Med, Dept Biochem, 149 Beaumont Ave, Burlington, VT 05405 USA.
EM gary.stein@med.uvm.edu
RI ; van Wijnen, Andre/AAG 3578 2019
OI Browne, Gillian/0000 0003 2116 6555; Padmanabhan,
   Srivatsan/0000 0003 2958 1390; Zaidi, Kaleem/0000 0001 6664 5168; van
   Wijnen, Andre J./0000 0002 4458 0946
FU National Institutes of Health [P01 CA082834, P01 AR048818, R01 AR039588,
   5P01 CA140043]
FX This work was supported in part by National Institutes of Health grants
   P01 CA082834, P01 AR048818, and R01 AR039588, 5P01 CA140043. The
   contents of this manuscript are solely the responsibility of the authors
   and do not necessarily represent the official views of the National
   Institutes of Health.
CR Afzal F, 2005, J CELL PHYSIOL, V204, P63, DOI 10.1002/jcp.20258
   Arboleda MJ, 2003, CANCER RES, V63, P196
   Barnes GL, 2004, CANCER RES, V64, P4506, DOI 10.1158/0008 5472.CAN 03 3851
   Barnes GL, 2003, CANCER RES, V63, P2631
   BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412
   Da Silva L, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2603
   Das K, 2009, EUR J CANCER, V45, P2239, DOI 10.1016/j.ejca.2009.06.021
   Dave B, 2011, J CLIN ONCOL, V29, P166, DOI 10.1200/JCO.2009.27.7814
   Dunlap J, 2010, BREAST CANCER RES TR, V120, P409, DOI 10.1007/s10549 009 0406 1
   Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Ge CX, 2012, J BONE MINER RES, V27, P538, DOI 10.1002/jbmr.561
   Gershtein ES, 2007, ANTICANCER RES, V27, P1777
   GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954
   Ito Y, 2008, ADV CANCER RES, V99, P33, DOI 10.1016/S0065 230X(07)99002 8
   Javed A, 2005, P NATL ACAD SCI USA, V102, P1454, DOI 10.1073/pnas.0409121102
   Jiang P, 2008, CANCER RES, V68, P1310, DOI 10.1158/0008 5472.CAN 07 5111
   Jonason JH, 2009, J DENT RES, V88, P693, DOI 10.1177/0022034509341629
   Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058
   Leong DT, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2762
   Lian J. B., 2003, Current Pharmaceutical Design, V9, P2677, DOI 10.2174/1381612033453659
   Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002 9440(10)63568 7
   Ling L, 2010, J BIOL CHEM, V285, P26233, DOI 10.1074/jbc.M110.122069
   Liu W, 2007, FRONT BIOSCI LANDMRK, V12, P4011, DOI 10.2741/2367
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   Ng SW, 2009, J BIOL CHEM, V284, P24767, DOI 10.1074/jbc.M109.011692
   Onodera Y, 2010, CANCER SCI, V101, P2670, DOI 10.1111/j.1349 7006.2010.01742.x
   Pratap J, 2006, CANCER METAST REV, V25, P589, DOI 10.1007/s10555 006 9032 0
   Pratap J, 2005, MOL CELL BIOL, V25, P8581, DOI 10.1128/MCB.25.19.8581 8591.2005
   Pratap J, 2011, BONE, V48, P30, DOI 10.1016/j.bone.2010.05.035
   Pratap J, 2009, CANCER RES, V69, P6807, DOI 10.1158/0008 5472.CAN 09 1471
   Qiao M, 2007, CANCER RES, V67, P5293, DOI 10.1158/0008 5472.CAN 07 0877
   Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110
   Selvamurugan N, 2004, J BIOL CHEM, V279, P27764, DOI 10.1074/jbc.M312870200
   Sutherland BW, 2005, ONCOGENE, V24, P4281, DOI 10.1038/sj.onc.1208590
   Yang SY, 2011, J BIOL CHEM, V286, P19149, DOI 10.1074/jbc.M110.197905
   Yoeli Lerner M, 2005, MOL CELL, V20, P539, DOI 10.1016/j.molcel.2005.10.033
   Zaidi SK, 2006, J CELL PHYSIOL, V209, P935, DOI 10.1002/jcp.20791
   Zaidi SK, 2001, J CELL SCI, V114, P3093
   Zhang HJ, 2011, CANCER RES, V71, P3257, DOI 10.1158/0008 5472.CAN 10 2603
   ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960 9822(00)00221 9
NR 41
TC 56
Z9 61
U1 0
U2 46
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD AUG
PY 2013
VL 228
IS 8
BP 1784
EP 1792
DI 10.1002/jcp.24339
PG 9
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA 133UE
UT WOS:000318165300018
PM 23389849
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Boukhechba, F
   Balaguer, T
   Michiels, JF
   Ackermann, K
   Quincey, D
   Bouler, JM
   Pyerin, W
   Carle, GF
   Rochet, N
AF Boukhechba, Florian
   Balaguer, Thierry
   Michiels, Jean Francois
   Ackermann, Karin
   Quincey, Danielle
   Bouler, Jean Michel
   Pyerin, Walter
   Carle, Georges F.
   Rochet, Nathalie
TI Human Primary Osteocyte Differentiation in a 3D Culture System
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE osteoblast; osteocyte; osteoid matrix; 3D culture; biphasic calcium
   phosphate
ID MARROW STROMAL CELLS; BONE FORMATION; IN VIVO; PARATHYROID HORMONE;
   STEM CELLS; EXPRESSION; HYDROGEL; MICE; VITRO; GENE
AB Studies on primary osteocytes, which compose > 90 95% of bone cells, embedded throughout the mineralized matrix, are a major challenge because of their difficult accessibility and the very rare models available in vitro. We engineered a 3D culture method of primary human osteoblast differentiation into osteocytes. These 3D differentiated osteocytes were compared with 2D cultured cells and with human microdissected cortical osteocytes obtained from bone cryosections. Human primary osteoblasts were seeded either within the interspace of calibrated biphasic calcium phosphate particles or on plastic culture dishes and cultured for 4 wk in the absence of differentiation factors. Osteocyte differentiation was assessed by histological and immunohistological analysis after paraffin embedding of culture after various times, as well as by quantitative RT PCR analysis of a panel of osteoblast and osteocyte markers after nucleic acid extraction. Histological analysis showed, after only 1 wk, the presence of an osteoid matrix including many lacunae in which the cells were individually embedded, exhibiting characteristics of osteocyte like cells. Real time PCR expression of a set of bone related genes confirmed their osteocyte phenotype. Comparison with plastic cultured cells and mature osteocytes microdissected from human cortical bone allowed to assess their maturation stage as osteoid osteocytes. This model of primary osteocyte differentiation is a new tool to gain insights into the biology of osteocytes. It should be a suitable method to study the osteoblast osteocyte differentiation pathway, the osteocyte interaction with the other bone cells, and orchestration of bone remodeling transmitted by mechanical loading and shear stress. It should be used in important cancer research areas such as the cross talk of osteocytes with tumor cells in bone metastasis, because it has been recently shown that gene expression in osteocytes is strongly affected by cancer cells of different origin. It could also be a very efficient tool for drug testing and bone tissue engineering applications. J Bone Miner Res 2009;24:1927 1935. Published online on May 4, 2009; doi: 10.1359/JBMR.090517
C1 [Boukhechba, Florian; Balaguer, Thierry; Quincey, Danielle; Carle, Georges F.; Rochet, Nathalie] Univ Nice Sophia Antipolis, CNRS, GEPITOS, UFR Med, F 06100 Nice, France.
   [Balaguer, Thierry] Hosp St Roch, CHU Nice, Serv Chirurg Plast Reparatrice & Esthet, Nice, France.
   [Michiels, Jean Francois] Hop Louis Pasteur, CHU Nice, Serv Anatomopathol, F 06002 Nice, France.
   [Ackermann, Karin; Pyerin, Walter] Deutsch Krebsforschungszentrum, D 6900 Heidelberg, Germany.
   [Bouler, Jean Michel] Univ Nantes, LIOAD, INSERM, UFR Odontol Nantes,UMR 791, Nantes, France.
C3 Universite Cote d'Azur; Centre National de la Recherche Scientifique
   (CNRS); CHU Nice; CHU Nice; Helmholtz Association; German Cancer
   Research Center (DKFZ); Nantes Universite; Ecole Nationale Veterinaire,
   Agroalimentaire et de l'Alimentation Nantes Atlantique; Institut
   National de la Sante et de la Recherche Medicale (Inserm)
RP Rochet, N (通讯作者)，Univ Nice Sophia Antipolis, CNRS, GEPITOS, UFR Med, 28 Ave Valombrose, F 06100 Nice, France.
EM rochet@unice.fr
RI ; ROCHET, Nathalie/N 1819 2018; ROCHET, Nathalie/S 3027 2019; BOULER,
   Jean Michel/C 2099 2011; Carle, Georges/GWC 5240 2022
OI Carle, Georges/0000 0002 3901 1052; ROCHET,
   Nathalie/0000 0002 9995 6699; BOULER, Jean Michel/0000 0001 9784 5584
FU MRT fellowship; Centre National de la Recherche Scientifique (CNRS)
FX The authors thank Berangere Czczepaniak and all the staff of the
   Anatomy Pathology Department for excellent technical assistance. This
   work was supported by a MRT fellowship for F.B. and by a grant from the
   Centre National de la Recherche Scientifique (CNRS).
CR Addison WN, 2008, J BONE MINER RES, V23, P1638, DOI 10.1359/JBMR.080601
   Akamine R, 2007, J BIOCHEM BIOPH METH, V70, P481, DOI 10.1016/j.jbbm.2006.11.008
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   BONEWALD L, 2006, BONEKEY OSTEOVISION, V10, P7
   CASSERBETTE M, 1990, CALCIFIED TISSUE INT, V46, P46, DOI 10.1007/BF02555824
   Eisenberger S, 2004, ANAL BIOCHEM, V335, P260, DOI 10.1016/j.ab.2004.09.037
   Elabd C, 2007, BIOCHEM BIOPH RES CO, V361, P342, DOI 10.1016/j.bbrc.2007.06.180
   Elsenberger S, 2008, J PATHOL, V214, P617, DOI 10.1002/path.2322
   Feng JQ, 2006, NAT GENET, V38, P1310, DOI 10.1038/ng1905
   Ferrera D, 2002, BONE, V30, P718, DOI 10.1016/S8756 3282(02)00691 9
   Gerber I., 2002, European Cells & Materials, V3, P19
   Gluhak Heinrich J, 2003, J BONE MINER RES, V18, P807, DOI 10.1359/jbmr.2003.18.5.807
   Gu GL, 2006, CELL TISSUE RES, V323, P263, DOI 10.1007/s00441 005 0066 3
   Harris S. E., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P313
   Kale S, 2000, NAT BIOTECHNOL, V18, P954, DOI 10.1038/79439
   Kato Hisayoshi, 2001, Bulletin of Gunma Museum of Natural History, V5, P9
   Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Locklin RM, 2003, J CELL BIOCHEM, V89, P180, DOI 10.1002/jcb.10490
   Mankani MH, 2001, BIOTECHNOL BIOENG, V72, P96, DOI 10.1002/1097 0290(20010105)72:1<96::AID BIT13>3.0.CO;2 A
   Marotti G, 1998, ANN ANAT, V180, P449, DOI 10.1016/S0940 9602(98)80106 4
   MIKUNITAKAGAKI Y, 1995, J BONE MINER RES, V10, P231, DOI 10.1002/jbmr.5650100209
   Noble BS, 2008, ARCH BIOCHEM BIOPHYS, V473, P106, DOI 10.1016/j.abb.2008.04.009
   O'Brien CA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002942
   PALUMBO C, 2004, ANAT REC PART A, V1, P474
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Schiavi SC, 2006, NAT GENET, V38, P1230, DOI 10.1038/ng1106 1230
   Trojani C, 2006, BIOMATERIALS, V27, P3256, DOI 10.1016/j.biomaterials.2006.01.057
   Trojani C, 2005, BIOMATERIALS, V26, P5509, DOI 10.1016/j.biomaterials.2005.02.001
   VANDERPLAS A, 1992, J BONE MINER RES, V7, P389
   Weinand C, 2006, BONE, V38, P555, DOI 10.1016/j.bone.2005.10.016
   WONG G, 1974, NATURE, V252, P713, DOI 10.1038/252713a0
   You LD, 2008, BONE, V42, P172, DOI 10.1016/j.bone.2007.09.047
   ZAHIN AM, 2008, BONE, V1, P25
NR 34
TC 98
Z9 112
U1 0
U2 34
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD NOV
PY 2009
VL 24
IS 11
BP 1927
EP 1935
DI 10.1359/JBMR.090517
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 518XU
UT WOS:000271730200017
PM 19419324
OA Bronze
DA 2025 08 17
ER

PT J
AU Jackson, MA
   Iwaniec, UT
   Turner, RT
   Wronski, TJ
   Kalra, SP
AF Jackson, M. A.
   Iwaniec, U. T.
   Turner, R. T.
   Wronski, T. J.
   Kalra, S. P.
TI Effects of increased hypothalamic leptin gene expression on
   ovariectomy induced bone loss in rats
SO PEPTIDES
LA English
DT Article
DE Bone marrow adiposity; White adipose tissue; mu CT; Histomorphometry;
   Osteoclasts; Osteoblasts
ID BODY WEIGHT; MINERAL DENSITY; SERUM INSULIN; FAT; THERAPY; ADIPOGENESIS;
   SUPPRESSION; BALANCE; GAIN; MASS
AB Estrogen deficiency results in accelerated bone turnover with a net increase in bone resorption. Subcutaneous administration of leptin attenuates bone loss in ovariectomized (ovx) rats by reducing bone resorption. However, in addition to its direct beneficial effects, leptin has been reported to have indirect (central nervous system mediated) antiosteogenic effects on bone, which may limit the efficacy of elevated serum leptin to prevent estrogen deficiency associated bone loss. The present study evaluated the long term effects of increased hypothalamic leptin transgene expression, using recombinant adeno associated virus leptin (rAAV Lep) gene therapy, on bone mass, architecture, and cellular endpoints in sexually mature ovx Sprague Dawley rats. Ovx rats were implanted with cannulae in the 3rd ventricle of the hypothalamus and injected with either rAAV Lep or rAAV GFP (control vector encoding green fluorescent protein) and maintained for 10 weeks. Additional controls consisted of ovary intact rats and ovx rats pair fed to rAAV Lep rats. Lumbar vertebrae were analyzed by micro computed tomography and tibiae by histomorphometry. Cancellous bone volume was lower and osteoclast perimeter, osteoblast perimeter, and bone marrow adipocyte density were greater in ovx rats compared to ovary intact controls. In contrast, differences among ovx groups were not detected for any endpoint evaluated. In conclusion, whereas estrogen deficiency resulted in marked cancellous osteopenia, increased bone turnover and marrow adiposity, increasing hypothalamic leptin transgene expression in ovx rats had neither detrimental nor beneficial effects on bone mass, architecture, or cellular endpoints. These findings demonstrate that the antiresorptive effects of subcutaneous leptin administration in ovx rats are mediated through leptin targets in the periphery. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Iwaniec, U. T.] Oregon State Univ, Dept Nutr & Exercise Sci, Skeletal Biol Lab, Corvallis, OR 97331 USA.
   [Wronski, T. J.] Univ Florida, Dept Physiol Sci, Gainesville, FL 32610 USA.
   [Kalra, S. P.] Univ Florida, McKnight Brain Inst, Dept Neurosci, Gainesville, FL 32610 USA.
C3 Oregon State University; State University System of Florida; University
   of Florida; State University System of Florida; University of Florida
RP Iwaniec, UT (通讯作者)，Oregon State Univ, Dept Nutr & Exercise Sci, Skeletal Biol Lab, 108 Milam Hall, Corvallis, OR 97331 USA.
EM urszula.iwaniec@oregonstate.edu
FU National Institute of Health [AR 054609, DK 37273, 27372]; Center for
   Healthy Aging Research Life Scholar Award, Oregon State University
FX This work was supported by grants from the National Institute of Health
   to U.T. Iwaniec (AR 054609) and S.P. Kalra (DK 37273 and 27372) and the
   Center for Healthy Aging Research Life Scholar Award, Oregon State
   University to MA Jackson.
CR Astudillo P, 2008, J CELL BIOCHEM, V103, P1054, DOI 10.1002/jcb.21516
   Beretta E, 2002, PEDIATR RES, V52, DOI 10.1203/00006450 200208000 00010
   Boghossian S, 2005, PEPTIDES, V26, P1512, DOI 10.1016/j.peptides.2005.03.039
   Bredella MA, 2011, OBESITY, V19, P49, DOI 10.1038/oby.2010.106
   Burguera B, 2001, ENDOCRINOLOGY, V142, P3546, DOI 10.1210/en.142.8.3546
   Cornish J, 2002, J ENDOCRINOL, V175, P405, DOI 10.1677/joe.0.1750405
   De Laet C, 2005, OSTEOPOROSIS INT, V16, P1330, DOI 10.1007/s00198 005 1863 y
   DESIMONE DP, 1993, J BONE MINER RES, V8, P625
   Dhillon H, 2001, MOL THER, V4, P139, DOI 10.1006/mthe.2001.0427
   Dhillon H, 2001, REGUL PEPTIDES, V99, P69, DOI 10.1016/S0167 0115(01)00237 3
   DHILLON H, 2000, EFFECTS RECOMBINANT
   Dube MG, 2008, PEPTIDES, V29, P593, DOI 10.1016/j.peptides.2008.01.001
   Ecklund K, 2010, J BONE MINER RES, V25, P298, DOI 10.1359/jbmr.090805
   El Hage R, 2009, J BONE MINER METAB, V27, P629, DOI 10.1007/s00774 009 0074 6
   Farooqi IS, 2009, AM J CLIN NUTR, V89, p980S, DOI 10.3945/ajcn.2008.26788C
   Fogelholm GM, 2001, OSTEOPOROSIS INT, V12, P199, DOI 10.1007/s001980170130
   Friedl G, 2007, J ORTHOP RES, V25, P1454, DOI 10.1002/jor.20433
   Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376
   Hamrick MW, 2008, OSTEOPOROSIS INT, V19, P905, DOI 10.1007/s00198 007 0487 9
   Hamrick MW, 2007, CELL TISSUE RES, V327, P133, DOI 10.1007/s00441 006 0312 3
   Holloway WR, 2002, J BONE MINER RES, V17, P200, DOI 10.1359/jbmr.2002.17.2.200
   Iwaniec UT, 2008, OSTEOPOROSIS, VOLS I AND II, 3RD EDITION, P985
   Iwaniec Urszula T., 2008, V447, P325, DOI 10.1007/978 1 59745 242 7_21
   IWANIEC UT, J BONE MINE IN PRESS
   Kalra SP, 2007, CURR TOP MED CHEM, V7, P1675, DOI 10.2174/156802607782340993
   Kalra SP, 2010, PROG BRAIN RES, V181, P17, DOI 10.1016/S0079 6123(08)81002 3
   Lamghari M, 2006, J CELL BIOCHEM, V98, P1123, DOI 10.1002/jcb.20853
   Lecklin A, 2005, PEPTIDES, V26, P1176, DOI 10.1016/j.peptides.2005.01.021
   Lee YJ, 2002, FEBS LETT, V528, P43, DOI 10.1016/S0014 5793(02)02889 2
   LORENTZON R, 1986, Diabetes Research and Clinical Practice, V2, P157, DOI 10.1016/S0168 8227(86)80017 1
   Magni P, 2010, CURR MOL MED, V10, P522
   Maness LM, 1998, ENDOCRINOLOGY, V139, P4556, DOI 10.1210/en.139.11.4556
   Menagh PJ, 2010, J BONE MINER RES, V25, P757, DOI 10.1359/jbmr.091015
   Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185
   Nuttall ME, 2004, CURR OPIN PHARMACOL, V4, P290, DOI 10.1016/j.coph.2004.03.002
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Rachon D, 2010, MOL CELL ENDOCRINOL, V316, P172, DOI 10.1016/j.mce.2009.09.026
   Reid IR, 2010, ARCH BIOCHEM BIOPHYS, V503, P20, DOI 10.1016/j.abb.2010.06.027
   Rosen CJ, 2009, AM J MED, V122, P409, DOI 10.1016/j.amjmed.2008.11.027
   Sharp JC, 2000, J BONE MINER RES, V15, P138, DOI 10.1359/jbmr.2000.15.1.138
   Sibonga JD, 2000, J GERONTOL A BIOL, V55, pB71
   SIBONGA JD, 2000, J GERONTOL A BIOL, V55, pB9
   SMITH CK, 1984, METABOLISM, V33, P853, DOI 10.1016/0026 0495(84)90114 8
   Steppan CM, 2000, REGUL PEPTIDES, V92, P73, DOI 10.1016/S0167 0115(00)00152 X
   Takada I, 2009, EXPERT OPIN THER TAR, V13, P593, DOI [10.1517/14728220902915310 , 10.1517/14728220902915310]
   Tamasi JA, 2003, J BONE MINER RES, V18, P1605, DOI 10.1359/jbmr.2003.18.9.1605
   Thomas T, 2001, BONE, V29, P114, DOI 10.1016/S8756 3282(01)00487 2
   Torto R, 2006, OBESITY, V14, P1312, DOI 10.1038/oby.2006.149
   TURNER RT, 1994, ENDOCR REV, V15, P275, DOI 10.1210/er.15.3.275
   Turner RT, 2008, PRINCIPLES OF BONE BIOLOGY, VOL 1, 3RD EDITION, P855, DOI 10.1016/B978 0 12 373884 4.00057 4
   Ueno N, 2004, ENDOCRINOLOGY, V145, P4176, DOI 10.1210/en.2004 0262
   Westerlind KC, 1997, P NATL ACAD SCI USA, V94, P4199, DOI 10.1073/pnas.94.8.4199
   WILLIAMS GA, J BONE MINE IN PRESS
   Yamauchi M, 2001, CLIN ENDOCRINOL, V55, P341, DOI 10.1046/j.1365 2265.2001.01361.x
NR 54
TC 14
Z9 15
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0196 9781
EI 1873 5169
J9 PEPTIDES
JI Peptides
PD AUG
PY 2011
VL 32
IS 8
BP 1575
EP 1580
DI 10.1016/j.peptides.2011.04.029
PG 6
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism;
   Pharmacology & Pharmacy
GA 816BD
UT WOS:000294572800002
PM 21640774
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Qiu, C
   Li, ZW
   Peng, PJ
AF Qiu, Chen
   Li, Zhaowen
   Peng, Puji
TI Human umbilical cord mesenchymal stem cells protect MC3T3 E1 osteoblasts
   from dexamethasone induced apoptosis via induction of the Nrf2 ARE
   signaling pathway
SO REGENERATIVE THERAPY
LA English
DT Article
DE Human umbilical cord mesenchymal stem; cell; Dexamethasone; Nrf2 ARE
   signaling pathway; Apoptosis; Oxidative stress
ID OXIDATIVE STRESS; INJURY; OSTEONECROSIS; ACTIVATION; EXPRESSION; RISK;
   GENE
AB Objective: To investigate the protective effect human umbilical cord mesenchymal stem cells (hUC MSCs) have on Dexamethasone (Dex) induced apoptosis in osteogenesis via the Nrf2 ARE signaling pathway. Methods: Glucocorticoid induced osteonecrosis of the femoral head (GC ONFH) was developed in rats through the administration of lipopolysaccharide and methylprednisolone. The incidence of femoral head necrosis, cavity notch, apoptosis of osteoblasts, and bone density were observed by HE staining, TUNEL staining, and Micro  CT. HUC MSCs were co  cultured with mouse pre osteoblast MC3T3 E1. The survival rate of osteoblasts was determined by CCK8, and apoptosis and ROS levels of osteoblasts were determined by flow cytometer. The viability of antioxidant enzymes SOD, GSH Px, and CAT was analyzed by biochemistry. Nrf2 expression levels and those of its downstream proteins and apoptosis related proteins were analyzed by Western blotting. Results: In rats, hUC MSCs can reduce the rates of empty bone lacuna and osteoblast apoptosis that are induced by glucocorticoids (GCs), while reducing the incidence of GC ONFH. hUC MSCs can signi ficantly improve the survival rate and antioxidant SOD, GSH Px, and CAT activity of MC3T3 E1 cells caused by Dex, and inhibit apoptosis and oxidative stress levels. In addition, hUC MSCs can up  regulate the expression of osteoblast antioxidant protein Nrf2 and its downstream protein HO  1, NQO 1, GCLC, GCLM, and apoptosis related protein bcl 2, while also down  regulating the expression of apoptosis related protein bax, cleaved caspase 3, cleaved caspase 9, and cytochrome C in MC3T3 E1 cells. hUC MSCs improve the ability of MC3T3 E1 cells to mineralize to osteogenesis. However, the promoting effects of hUC MSCs were abolished following the blocking of the Nrf2 ARE signaling pathway for osteoblasts. Conclusion: The results reveal that hUC MSCs can reduce Dex induced apoptosis in osteoblasts via the Nrf2 ARE signaling pathway. (c) 2024, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is an open access article under the CC BY  NC  ND license (http://creativecommons.org/licenses/by nc nd/ 4.0/).
C1 [Qiu, Chen; Li, Zhaowen] Wuhan Sports Univ, Dept Sports Med, Affiliated Hosp, Wuhan 430000, Peoples R China.
   [Peng, Puji] Henan Prov Peoples Hosp, Dept Orthoped, Zhengzhou 450003, Peoples R China.
C3 Wuhan Sports University; Zhengzhou University
RP Peng, PJ (通讯作者)，Henan Prov Peoples Hosp, Dept Orthoped, Zhengzhou 450003, Peoples R China.
EM pengpuji@126.com
RI Li, Zhaowen/LJL 3124 2024
FU Henan Provincial Science and Technology Research Project (Scienti fic
   and Techno logical Research) [232102310327]
FX This study was funded by grants from the Henan Provincial Science and
   Technology Research Project (Scienti fic and Techno logical Research,
   232102310327) .
CR Brand MD, 2004, FREE RADICAL BIO MED, V37, P755, DOI 10.1016/j.freeradbiomed.2004.05.034
   Chang CL, 2019, AM J TRANSL RES, V11, P3955
   Chen MF, 2006, INT J RADIAT ONCOL, V66, P244, DOI 10.1016/j.ijrobp.2006.03.062
   DeSantiago J, 2013, STEM CELLS DEV, V22, P2497, DOI 10.1089/scd.2013.0136
   Dodson M, 2019, ANNU REV PHARMACOL, V59, P555, DOI 10.1146/annurev pharmtox 010818 021856
   Guruvayoorappan C, 2008, J ENVIRON PATHOL TOX, V27, P197, DOI 10.1615/JEnvironPatholToxicolOncol.v27.i3.40
   Ichiseki T, 2005, RHEUMATOLOGY, V44, P456, DOI 10.1093/rheumatology/keh518
   Ichiseki T, 2004, J ORTHOP SCI, V9, P509, DOI 10.1007/s00776 004 0816 1
   Iyer SS, 2010, STEM CELLS INT, V2010, DOI 10.4061/2010/868076
   Keum YS, 2014, MOLECULES, V19, P10074, DOI 10.3390/molecules190710074
   Kim TH, 2008, OSTEOARTHR CARTILAGE, V16, P1060, DOI 10.1016/j.joca.2008.02.004
   Liu B, 2018, NEPHROLOGY, V23, P728, DOI 10.1111/nep.13099
   Ma Q, 2013, ANNU REV PHARMACOL, V53, P401, DOI 10.1146/annurev pharmtox 011112 140320
   Mahrouf Yorgov M, 2017, CELL DEATH DIFFER, V24, P1224, DOI 10.1038/cdd.2017.51
   Martire A, 2016, BASIC RES CARDIOL, V111, DOI 10.1007/s00395 016 0573 2
   MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926
   Moya Angeler J, 2015, WORLD J ORTHOP, V6, P590, DOI 10.5312/wjo.v6.i8.590
   Nakano M, 2016, SCI REP UK, V6, DOI 10.1038/srep24805
   Pulavendran S, 2010, INT IMMUNOPHARMACOL, V10, P513, DOI 10.1016/j.intimp.2010.01.014
   Shah KN, 2015, CURR REV MUSCULOSKE, V8, P201, DOI 10.1007/s12178 015 9277 8
   Shalaby SM, 2014, CYTOTHERAPY, V16, P764, DOI 10.1016/j.jcyt.2013.12.006
   Si XY, 2015, INT J CLIN EXP PATHO, V8, P12368
   Tkachev VO, 2011, BIOCHEMISTRY MOSCOW+, V76, P407, DOI 10.1134/S0006297911040031
   Tsuji M, 2006, PATHOBIOLOGY, V73, P304, DOI 10.1159/000099125
   Vomund S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122772
   Wang T, 2015, J TRANSL MED, V13, DOI 10.1186/s12967 015 0499 8
   Wen Q, 2012, J CELL MOL MED, V16, P1260, DOI 10.1111/j.1582 4934.2011.01407.x
   Zalavras C, 2003, CRIT REV EUKAR GENE, V13, P221, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i24.140
   Zhao H, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/7174319
NR 29
TC 1
Z9 2
U1 3
U2 15
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352 3204
J9 REGEN THER
JI Regen. Ther.
PD DEC
PY 2024
VL 27
BP 1
EP 11
DI 10.1016/j.reth.2024.02.009
EA MAR 2024
PG 11
WC Cell & Tissue Engineering; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering
GA PT3K9
UT WOS:001216293700001
PM 38476629
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wadas, TJ
   Deng, HJ
   Sprague, JE
   Zheleznyak, A
   Weilbaecher, KN
   Anderson, CJ
AF Wadas, Thaddeus J.
   Deng, Hongju
   Sprague, Jennifer E.
   Zheleznyak, Alexander
   Weilbaecher, Katherine N.
   Anderson, Carolyn J.
TI Targeting the αvβ3 Integrin for Small Animal PET/CT of
   Osteolytic Bone Metastases
SO JOURNAL OF NUCLEAR MEDICINE
LA English
DT Article
DE bone; metastasis; integrin; PET; bisphosphonate
ID CROSS BRIDGED CYCLAM; IN VIVO; ALPHA V; BISPHOSPHONATES; VITRONECTIN;
   OSTEOCLASTS; INHIBITOR; PEPTIDE; CU 64; MODEL
AB This article describes the evaluation of the radiopharmaceutical Cu 64 CB TE2A c(RGDyK) (Cu 64 RGD) as an imaging agent for osteolytic bone metastases and their associated inflammation by targeting of the alpha v beta 3 integrin on osteoclasts and the proinflammatory cells involved at the bone metastatic site. Methods: The Cu 64 RGD radiotracer was evaluated in the transgenic mouse expressing Tax (Tax(+)), which spontaneously develops osteolytic tumors throughout the vertebrae and hind limbs, using biodistribution studies and small animal PET/CT. Histologic analysis was also performed on Tax(+) mouse tails, using hematoxylin and eosin and tartrate resistant acid phosphatase to confirm the presence of osteolytic bone lesions and the presence of osteoclasts, respectively. Additionally, a proof of principle study was conducted with a small group of Tax(+) animals presenting with osteolytic lesions. These animals were treated with the bisphosphonate zoledronic acid and imaged with Cu 64 RGD to determine whether this radiopharmaceutical was sensitive enough to detect a response to the bisphosphonate therapy. Results: Biodistribution studies using Cu 64 RGD demonstrated that Tax(+) mice between the ages of 6 and 12 mo had a greater accumulation of activity in their tail vertebrae than did the wildtype (WT) cohort (P = 0.013). Additionally, Tax(+) mice between the ages of 6 and 12 mo had significantly more tracer activity associated with their tail vertebrae than did Tax(+) mice older than 12 mo (P = 0.003), suggesting that earlier bone metastases cause an increased recruitment of alpha v beta 3 expressing cells. Small animal PET/CT with Cu 64 RGD was conducted on Tax(+) and WT mice. On the basis of standardized uptake value analysis, Tax(+) mice had approximately 2 fold more tail associated activity than did WT animals (P = 0.0157). Additionally, decreases in uptake were observed in the tails of Tax(+) mice after treatment with the osteoclast inhibitor zoledronic acid, and histologic analysis of Tax(+) mouse tail vertebrae revealed the presence of Tax(+) tumor cells, osteoclasts, and proinflammatory cells within the bone microenvironment. Conclusion: Together, these data suggest that Cu 64 RGD has the potential to effectively image osteolytic bone metastases and monitor the physiologic changes in the bone metastatic microenvironment after osteoclast inhibiting bisphosphonate therapy.
C1 [Wadas, Thaddeus J.; Sprague, Jennifer E.; Zheleznyak, Alexander; Anderson, Carolyn J.] Washington Univ, Mallinckrodt Inst Radiol, Sch Med, St Louis, MO 63110 USA.
   [Deng, Hongju; Weilbaecher, Katherine N.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.
   [Sprague, Jennifer E.] Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, St Louis, MO 63110 USA.
   [Anderson, Carolyn J.] Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA.
   [Anderson, Carolyn J.] Washington Univ, Dept Chem, St Louis, MO 63110 USA.
C3 Washington University (WUSTL); Washington University (WUSTL); Washington
   University (WUSTL); Washington University (WUSTL); Washington University
   (WUSTL)
RP Anderson, CJ (通讯作者)，Washington Univ, Mallinckrodt Inst Radiol, Sch Med, 510 S Kingshighway Blvd,Campus Box 8225, St Louis, MO 63110 USA.
EM andersoncj@wustl.edu
OI Wadas, Thad/0000 0002 9913 0336; Anderson, Carolyn/0000 0002 5663 282X
FU NIH [F32 CA115148, R21 CA098698, R24 CA86307, P30 CA91842, P01 100730];
   Department of Defense [W81XWH 04 1 0396]
FX We acknowledge Dr. Riccardo Ferdani for synthesis of CB TE2A, Drs.
   Samuel Achilefu and Yunpeng Ye for synthesis of the CB TE2A c(RGDyK)
   conjugate, Christopher Sherman for technical assistance, Drs. Zhying Xu
   and Ozge Uluckan for assistance with the animal model, and Crystal Darby
   for expert histologic sample preparation. We gratefully acknowledge NIH
   grants F32 CA115148, R21 CA098698, R24 CA86307 (production of
   <SUP>64</SUP>Cu at Washington University School of Medicine), P30
   CA91842 (Alvin J. Siteman Cancer Center at Washington University in St.
   Louis), P01 100730, and the Department of Defense Breast Cancer Research
   Program grant W81XWH 04 1 0396.
CR Bakewell SJ, 2003, P NATL ACAD SCI USA, V100, P14205, DOI 10.1073/pnas.2234372100
   Bhushan KR, 2007, ANGEW CHEM INT EDIT, V46, P7969, DOI 10.1002/anie.200701216
   Bombardieri E, 2001, Q J NUCL MED, V45, P245
   Boswell CA, 2004, J MED CHEM, V47, P1465, DOI 10.1021/jm030383m
   Chen XY, 2005, NEOPLASIA, V7, P271, DOI 10.1593/neo.04538
   Chen XY, 2004, NUCL MED BIOL, V31, P179, DOI 10.1016/j.nucmedbio.2003.10.002
   Chen XY, 2004, MOL IMAGING BIOL, V6, P350, DOI 10.1016/j.mibio.2004.06.004
   Clezardin P, 1998, CELL MOL LIFE SCI, V54, P541, DOI 10.1007/s000180050182
   Cook Gary J. R., 2000, Cancer, V88, P2927, DOI 10.1002/1097 0142(20000615)88:12+<2927::AID CNCR8>3.0.CO;2 V
   Gao L, 2005, BLOOD, V106, P4294, DOI 10.1182/blood 2005 04 1730
   GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057
   Hamaoka T, 2004, J CLIN ONCOL, V22, P2942, DOI 10.1200/jco.2004.08.181
   Hendey B, 1996, BLOOD, V87, P2038
   Horton MA, 1997, INT J BIOCHEM CELL B, V29, P721, DOI 10.1016/S1357 2725(96)00155 0
   Hsu WK, 2008, J NUCL MED, V49, P414, DOI 10.2967/jnumed.107.045666
   Hua J, 2005, CIRCULATION, V111, P3255, DOI 10.1161/CIRCULATIONAHA.104.485029
   Jin H, 2004, BRIT J CANCER, V90, P561, DOI 10.1038/sj.bjc.6601576
   Kim MK, 2006, J PHARMACOL EXP THER, V318, P555, DOI 10.1124/jpet.106.102798
   Kumar S, 2007, BONE, V40, P122, DOI 10.1016/j.bone.2006.07.015
   Liu W, 2008, BIOORG MED CHEM LETT, V18, P4789, DOI 10.1016/j.bmcl.2008.07.092
   McCarthy DW, 1997, NUCL MED BIOL, V24, P35, DOI 10.1016/S0969 8051(96)00157 6
   Moon DH, 1998, J NUCL MED, V39, P431
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nicholson GC, 2000, CLIN SCI, V99, P133, DOI 10.1042/CS19990355
   Padalecki SS, 2002, BREAST CANCER RES, V4, P35, DOI 10.1186/bcr415
   Qaim SM, 2007, RADIOCHIM ACTA, V95, P67, DOI 10.1524/ract.2007.95.2.67
   Russell RGG, 2007, ANN NY ACAD SCI, V1117, P209, DOI 10.1196/annals.1402.089
   Sprague JE, 2007, J NUCL MED, V48, P311
   Sun XK, 2002, J MED CHEM, V45, P469, DOI 10.1021/jm0103817
   Tanaka S, 2001, Mod Rheumatol, V11, P177, DOI 10.3109/s101650170001
   Wadas TJ, 2006, NAT PROTOC, V1, P3062, DOI 10.1038/nprot.2006.431
   WEISMAN GR, 1990, J AM CHEM SOC, V112, P8604, DOI 10.1021/ja00179a067
NR 32
TC 41
Z9 43
U1 0
U2 8
PU SOC NUCLEAR MEDICINE INC
PI RESTON
PA 1850 SAMUEL MORSE DR, RESTON, VA 20190 5316 USA
SN 0161 5505
EI 1535 5667
J9 J NUCL MED
JI J. Nucl. Med.
PD NOV
PY 2009
VL 50
IS 11
BP 1873
EP 1880
DI 10.2967/jnumed.109.067140
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA 529YA
UT WOS:000272554100022
PM 19875645
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Tanaka, T
   Takahashi, A
   Kobayashi, Y
   Saito, M
   Sun, XL
   Chen, JQ
   Ito, Y
   Kato, T
   Ochi, H
   Sato, S
   Yoshii, T
   Okawa, A
   Carlsson, P
   Inose, H
AF Tanaka, Tomoyuki
   Takahashi, Akira
   Kobayashi, Yutaka
   Saito, Masanori
   Sun Xiaolong
   Chen Jingquan
   Ito, Yoshiaki
   Kato, Tsuyoshi
   Ochi, Hiroki
   Sato, Shingo
   Yoshii, Toshitaka
   Okawa, Atsushi
   Carlsson, Peter
   Inose, Hiroyuki
TI Foxf2 represses bone formation via Wnt2b/β catenin signaling
SO EXPERIMENTAL AND MOLECULAR MEDICINE
LA English
DT Article
ID TRANSCRIPTION FACTOR FOXF2; OSTEOBLASTIC DIFFERENTIATION; TURNOVER
   MARKERS; RISK; PROGENITORS; EXPRESSION; FRACTURES; NONUNION; PROTEINS;
   CELLS
AB Bone formation: crucial regulatory protein implicated A regulatory protein called FOXF2 plays a critical role in mediating the formation of bone tissue. Hiroyuki Inose from Tokyo Medical and Dental University, Japan, and colleagues profiled the genes expressed by mouse stem cells as they differentiated into osteoblasts, bone producing cells. They identified the gene encoding FOXF2 as one of the most highly activated during this developmental transition. To understand how this regulatory protein inhibits bone formation, the researchers blocked the expression of FOXF2, which led to enhanced bone formation, both in mice and human bone marrow mesenchymal stem cells. The researchers also documented a correlation between FOXF2 levels and hip bone mineral density of older women. The findings point to FOXF2 as a promising drug target for the treatment of osteoporosis, non healing fractures and other bone related disorders.
   Differentiation of mesenchymal stem cells (MSCs) into osteoblasts is a critical process for proper skeletal development and acquisition/maintenance of bone mass. However, since this regulatory mechanism has not yet been fully elucidated, the treatment of severe osteoporosis and fractures is a challenge. Here, through a comprehensive analysis of gene expression during the differentiation of MSCs into osteoblasts, we show that the forkhead transcription factor Foxf2 is a crucial regulator of this process. Foxf2 expression transiently increased during MSC osteoblastic differentiation. Overexpression of Foxf2 in MSCs inhibited osteoblastic differentiation, and conversely, knockdown of Foxf2 expression promoted this process. Osteoprogenitor specific Foxf2 knockout mice developed a high bone mass phenotype due to increased bone formation. RNA seq analysis and molecular experiments revealed that Foxf2 regulation of bone formation is mediated by Wnt2b. Knockdown of Foxf2 in mouse femurs enhanced bone regeneration in vivo. FOXF2 expression was correlated with hip bone mineral density in postmenopausal women with low bone mass. Finally, inhibition of FOXF2 promoted osteoblastic differentiation of human MSCs. This study uncovers a critical role of Foxf2 in the differentiation of MSCs into osteoblasts and provides insight into the pathogenesis associated with bone related diseases such as osteoporosis and nonunion after fracture.
C1 [Tanaka, Tomoyuki; Takahashi, Akira; Kobayashi, Yutaka; Saito, Masanori; Sun Xiaolong; Chen Jingquan; Kato, Tsuyoshi; Yoshii, Toshitaka; Okawa, Atsushi; Inose, Hiroyuki] Tokyo Med & Dent Univ, Grad Sch, Dept Orthopaed, Bunkyo Ku, 1 5 45 Yushima, Tokyo 1138519, Japan.
   [Ito, Yoshiaki] Tokyo Med & Dent Univ, Bunkyo Ku, Res Core, 1 5 45 Yushima, Tokyo 1138519, Japan.
   [Ochi, Hiroki] Natl Rehabil Ctr Persons Disabil, Res Inst, Dept Rehabil Movement Funct, 4 1 Namiki, Tokorozawa, Saitama 3598555, Japan.
   [Sato, Shingo] Tokyo Med & Dent Univ Hosp, Ctr Innovat Canc Treatment, Bunkyo Ku, 1 5 45 Yushima, Tokyo 1138519, Japan.
   [Carlsson, Peter] Univ Gothenburg, Dept Chem & Mol Biol, Box 462, SE 40530 Gothenburg, Sweden.
   [Inose, Hiroyuki] Tokyo Med & Dent Univ, Grad Sch, Dept Orthoped & Trauma Res, Bunkyo Ku, 1 5 45 Yushima, Tokyo 1138519, Japan.
C3 Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   University of Gothenburg; Institute of Science Tokyo; Tokyo Medical &
   Dental University (TMDU)
RP Inose, H (通讯作者)，Tokyo Med & Dent Univ, Grad Sch, Dept Orthopaed, Bunkyo Ku, 1 5 45 Yushima, Tokyo 1138519, Japan.; Inose, H (通讯作者)，Tokyo Med & Dent Univ, Grad Sch, Dept Orthoped & Trauma Res, Bunkyo Ku, 1 5 45 Yushima, Tokyo 1138519, Japan.
EM inose.orth@tmd.ac.jp
RI Yoshii, Toshitaka/HTL 9865 2023; Carlsson, Peter/B 5551 2008; Sun,
   Xiaolong/JWO 9967 2024; Saito, Masanori/GRR 1714 2022
FU Japan Society for the Promotion of Science; Japanese Society for Bone
   and Mineral Research; Grants in Aid for Scientific Research [23K24455,
   22H03196, 22K09302, 22K09394, 21K19556, 20KK0205, 20H03800] Funding
   Source: KAKEN
FX The authors would like to thank Dr. Philipp Kaldis and Dr. Daisuke
   Kajimura for the discussion and Nobuko Nakajima for patient recruitment.
   The authors would also like to thank Drs. Takashi Hirai, Motonori
   Hashimoto, Yu Matsukura, and Hisato Higashikawa for collecting human
   samples. This work was supported by the Japan Society for the Promotion
   of Science grants (to T.K., A.O., and H.I.) and a grant from the
   Japanese Society for Bone and Mineral Research (to H.I.).
CR Aitola M, 2000, DEV DYNAM, V218, P136, DOI 10.1002/(SICI)1097 0177(200005)218:1<136::AID DVDY12>3.0.CO;2 U
   Asadipooya K, 2019, ARTERIOSCL THROM VAS, V39, P1343, DOI 10.1161/ATVBAHA.119.312371
   Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   CSERJESI P, 1992, DEVELOPMENT, V115, P1087
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Ensrud KE, 2013, J GERONTOL A BIOL, V68, P1236, DOI 10.1093/gerona/glt092
   Finnes TE, 2014, BONE, V64, P1, DOI 10.1016/j.bone.2014.03.010
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Fukuda T, 2015, FEBS LETT, V589, P3302, DOI 10.1016/j.febslet.2015.09.024
   Gerin I, 2009, J BIOL CHEM, V284, P10755, DOI 10.1074/jbc.M809115200
   Greenbaum A, 2013, NATURE, V495, P227, DOI 10.1038/nature11926
   Hellqvist M, 1996, J BIOL CHEM, V271, P4482
   Inose H, 2020, SPINE, V45, P895, DOI 10.1097/BRS.0000000000003413
   Inose H, 2018, SPINE, V43, pE29, DOI 10.1097/BRS.0000000000001995
   Jia B, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1161 9
   Kang LJ, 2019, FASEB J, V33, P6564, DOI 10.1096/fj.201801916R
   Kósa JP, 2009, MENOPAUSE, V16, P367, DOI 10.1097/gme.0b013e318188b260
   Kuo TR, 2017, BIOMARK RES, V5, DOI 10.1186/s40364 017 0097 4
   Lam EWF, 2013, NAT REV CANCER, V13, P482, DOI 10.1038/nrc3539
   Logan M, 2002, GENESIS, V33, P77, DOI 10.1002/gene.10092
   Long FX, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008334
   MacDonald BT, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007880
   Manolagas SC, 2014, MATURITAS, V78, P233, DOI 10.1016/j.maturitas.2014.04.013
   Maridas DE, 2018, JOVE J VIS EXP, DOI 10.3791/56750
   Medio M, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00375
   Meyer Schaller N, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058 018 1043 6
   Moore ER, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0930 1
   Mulati M, 2020, BONE, V130, DOI 10.1016/j.bone.2019.115076
   Ormestad M, 2006, DEVELOPMENT, V133, P833, DOI 10.1242/dev.02252
   Oryan A, 2017, CELLS TISSUES ORGANS, V204, P59, DOI 10.1159/000469704
   Reyahi A, 2015, DEV CELL, V34, P19, DOI 10.1016/j.devcel.2015.05.008
   Reynolds K, 2019, DIS MODEL MECH, V12, DOI 10.1242/dmm.037051
   Saad MA, 2021, EGYPT RHEUMATOL REH, V48, DOI 10.1186/s43166 021 00069 y
   Semënov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200
   Shibata YU, 2004, BIOCHEM BIOPH RES CO, V325, P1194, DOI 10.1016/j.bbrc.2004.10.157
   Takahashi A, 2018, J BIOL CHEM, V293, P19387, DOI 10.1074/jbc.RA118.004834
   Tehrani SS, 2020, ASIAN BIOMED, V14, P97, DOI 10.1515/abm 2020 0015
   Uppal S, 2008, NAT GENET, V40, P789, DOI 10.1038/ng.153
   van Dinther M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062295
   Wang CC, 2016, J CLIN INVEST, V126, P1471, DOI 10.1172/JCI80672
   Wang S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10379 7
   Wang T, 2003, DEV BIOL, V259, P83, DOI 10.1016/S0012 1606(03)00176 3
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Xu J, 2020, J DENT RES, V99, P463, DOI 10.1177/0022034520904018
   Yamada T, 2013, BONE, V57, P343, DOI 10.1016/j.bone.2013.08.028
   Yamaguchi A, 1996, BIOCHEM BIOPH RES CO, V220, P366, DOI 10.1006/bbrc.1996.0411
   Yan J, 2012, AM J PATHOL, V181, P234, DOI 10.1016/j.ajpath.2012.03.038
NR 48
TC 10
Z9 11
U1 2
U2 12
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1226 3613
EI 2092 6413
J9 EXP MOL MED
JI Exp. Mol. Med.
PD JUN
PY 2022
VL 54
IS 6
BP 753
EP 764
DI 10.1038/s12276 022 00779 z
EA JUN 2022
PG 12
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA 2R4BH
UT WOS:000806699100001
PM 35668101
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Abuna, RPF
   Almeida, LO
   Souza, ATP
   Fernandes, RR
   Sverzut, TFV
   Rosa, AL
   Beloti, MM
AF Abuna, Rodrigo P. F.
   Almeida, Luciana O.
   Souza, Alann T. P.
   Fernandes, Roger R.
   Sverzut, Thales F. V.
   Rosa, Adalberto L.
   Beloti, Marcio M.
TI Osteoporosis and osteoblasts cocultured with adipocytes inhibit
   osteoblast differentiation by downregulating histone acetylation
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE adipocyte; histone; mesenchymal stromal cell; osteoblast; osteoporosis
ID MESENCHYMAL STEM CELLS; BONE MARROW; OSTEOGENIC DIFFERENTIATION;
   TNF ALPHA; IN VITRO; GENE; H3; POSTMENOPAUSAL; DIAGNOSIS; CULTURE
AB Osteoporosis is characterized by decreased bone mass and adipocyte accumulation within the bone marrow that inhibits osteoblast maturation, leading to a high risk of fractures. Thus, we hypothesized that osteoblasts, besides being negatively affected by interacting with adipocytes, reduce the differentiation of neighboring osteoblasts through the same mechanisms that affect osteoblasts under osteoporotic conditions. We investigated the effect of osteoporosis on osteoblast differentiation and the effect of the conditioned medium of osteoblasts cocultured with adipocytes on the differentiation of other osteoblasts. Osteoporosis was induced by orchiectomy in rats and bone marrow mesenchymal stromal cells (MSCs) were differentiated into osteoblasts. Also, the bone marrow and adipose tissue MSCs were obtained from healthy rats and differentiated into osteoblasts and adipocytes, respectively. Messenger RNA expression, in situ alkaline phosphatase activity, and mineralization confirmed the inhibitory effect of osteoporosis on osteoblast differentiation. This harmful effect was mimicked by the in vitro model using the conditioned medium and it was demonstrated that osteoblasts keep the memory of the negative impact of interacting with adipocytes, revealing an unknown mechanism relevant to the osteoporotic bone loss. Finally, we showed the involvement of acetyl histone 3 (AcH3) in bone homeostasis as its reduction induced by osteoporosis and conditioned medium impaired osteoblast differentiation. The AcH3 involvement was proved by treating osteoblasts with Trichostatin A that recovered the AcH3 expression and osteoblast differentiation capacity in both situations. Together, our findings indicated that AcH3 might be a target for future studies focused on epigenetic based therapies to treat bone diseases.
C1 [Abuna, Rodrigo P. F.; Almeida, Luciana O.; Souza, Alann T. P.; Fernandes, Roger R.; Sverzut, Thales F. V.; Rosa, Adalberto L.; Beloti, Marcio M.] Univ Sao Paulo, Bone Res Lab, Sch Dent Ribeirao Preto, Ave Cafe S N, BR 14040904 Ribeirao Preto, SP, Brazil.
C3 Universidade de Sao Paulo
RP Beloti, MM (通讯作者)，Univ Sao Paulo, Bone Res Lab, Sch Dent Ribeirao Preto, Ave Cafe S N, BR 14040904 Ribeirao Preto, SP, Brazil.
EM mmbeloti@usp.br
RI Rosa, Adalberto Luiz/A 6314 2008; Beloti, Marcio/E 7473 2012; Almeida,
   Luciana/G 8452 2012; Beloti, Marcio/AAX 4014 2020; Flores Abuna, Rodrigo
   Paolo/F 5853 2012; Oliveira de Almeida, Luciana/O 1013 2014; Rosa,
   Adalberto/A 6314 2008; Souza, Alann/E 4194 2018
OI Rosa, Adalberto Luiz/0000 0002 6495 2778; Beloti,
   Marcio/0000 0003 0149 7189; Flores Abuna, Rodrigo
   Paolo/0000 0002 3973 2044; Oliveira de Almeida,
   Luciana/0000 0002 5342 0434; 
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   [303464/2016 0]; Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   [2016/14171 0, 2016/14711 4, 2017/12622 7, 2018/13290 0, 2018/17356 6];
   Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [16/14711 4, 18/17356 6, 18/13290 0, 17/12622 7] Funding Source: FAPESP
FX Conselho Nacional de Desenvolvimento Cientifico e Tecnologico,
   Grant/Award Number: 303464/2016 0; Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior; Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo, Grant/Award Numbers: 2016/14171 0, 2016/14711 4,
   2017/12622 7, 2018/13290 0, 2018/17356 6
CR Abuna RPF, 2016, J CELL PHYSIOL, V231, P204, DOI 10.1002/jcp.25073
   Al Saedi A, 2020, CALCIFIED TISSUE INT, V107, P126, DOI 10.1007/s00223 020 00700 8
   BENNETT JH, 1991, J CELL SCI, V99, P131
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Fani N, 2016, EXP CELL RES, V344, P176, DOI 10.1016/j.yexcr.2015.10.009
   Feigenson M, 2017, J BONE MINER RES, V32, P2453, DOI 10.1002/jbmr.3236
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Freitas GP, 2020, BIO PROTOCOL, V10, DOI 10.21769/BioProtoc.3534
   Gibney ER, 2010, HEREDITY, V105, P4, DOI 10.1038/hdy.2010.54
   Gómez MPA, 2020, QUANT IMAG MED SURG, V10, P1614, DOI 10.21037/qims.2020.01.11
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   HAHN BH, 1988, B RHEUM DIS, V38, P1
   Hamam D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.462
   Han YJ, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0019 6
   Horstman AM, 2012, J GERONTOL A BIOL, V67, P1140, DOI 10.1093/gerona/gls068
   Hsu YH, 2012, J CLIN ENDOCR METAB, V97, pE1958, DOI 10.1210/jc.2012 1890
   Hu LF, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020360
   Hu XQ, 2013, STEM CELLS DEV, V22, P248, DOI 10.1089/scd.2012.0105
   Huang J, 2010, STEM CELLS, V28, P357, DOI 10.1002/stem.288
   Huynh Nam Cong Nhat, 2017, Bone Rep, V7, P33, DOI 10.1016/j.bonr.2017.08.001
   Justesen J, 2001, BIOGERONTOLOGY, V2, P165, DOI 10.1023/A:1011513223894
   Kimura A, 1998, FEBS LETT, V431, P131, DOI 10.1016/S0014 5793(98)00752 2
   Kotrych D, 2016, EUR J OBSTET GYN R B, V199, P92, DOI 10.1016/j.ejogrb.2016.01.037
   Lee HW, 2006, MOL ENDOCRINOL, V20, P2432, DOI 10.1210/me.2006 0061
   MANOLAGAS SC, 1995, INT J IMMUNOPHARMACO, V17, P109, DOI 10.1016/0192 0561(94)00089 7
   MEUNIER P, 1971, CLIN ORTHOP RELAT R, P147, DOI 10.1097/00003086 197110000 00021
   Montecino M, 2015, BONE, V81, P733, DOI 10.1016/j.bone.2015.03.013
   Muruganandan S, 2009, CELL MOL LIFE SCI, V66, P236, DOI 10.1007/s00018 008 8429 z
   Huynh NCN, 2017, BONE, V95, P76, DOI 10.1016/j.bone.2016.11.017
   NODA M, 1987, J CELL BIOL, V105, P1671, DOI 10.1083/jcb.105.4.1671
   Pillai R, 2004, DEV DYNAM, V231, P647, DOI 10.1002/dvdy.20168
   Riggs BL, 2008, J BONE MINER RES, V23, P205, DOI 10.1359/JBMR.071020
   Rosen CJ, 2006, NAT CLIN PRACT RHEUM, V2, P35, DOI 10.1038/ncprheum0070
   Rosen CJ, 2009, CRIT REV EUKAR GENE, V19, P109, DOI 10.1615/CritRevEukarGeneExpr.v19.i2.20
   Schroeder TM, 2005, J BONE MINER RES, V20, P2254, DOI 10.1359/JBMR.050813
   Shen J, 2003, MOL ENDOCRINOL, V17, P743, DOI 10.1210/me.2002 0122
   SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237
   Takada I, 2007, ANN NY ACAD SCI, V1116, P182, DOI 10.1196/annals.1402.034
   Tyagi AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044552
   Vega RB, 2004, CELL, V119, P555, DOI 10.1016/j.cell.2004.10.024
   Vondracek SF, 2009, CLIN INTERV AGING, V4, P121
   Xu S, 2013, ACTA PHARMACOL SIN, V34, P699, DOI 10.1038/aps.2012.182
   Zardo G, 2008, LEUKEMIA, V22, P1503, DOI 10.1038/leu.2008.141
   Zarrow M. X., 1964, EXPT ENDOCRINOLOGY S, P136
   Zhao XD, 2007, CELL STEM CELL, V1, P286, DOI 10.1016/j.stem.2007.08.004
   Zippo A, 2009, CELL, V138, P1122, DOI 10.1016/j.cell.2009.07.031
NR 47
TC 24
Z9 27
U1 1
U2 35
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD MAY
PY 2021
VL 236
IS 5
BP 3906
EP 3917
DI 10.1002/jcp.30131
EA OCT 2020
PG 12
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA QO7JN
UT WOS:000582843200001
PM 33124698
DA 2025 08 17
ER

PT J
AU Wei, M
   Jiang, Y
   Huang, YQ
AF Wei, Min
   Jiang, Yi
   Huang, Yuanqing
TI TSG Targeting KDM5A Affects Osteogenic Differentiation of Bone
   Mesenchymal Stem Cells Induced by Bone Morphogenetic Protein 2
SO JOURNAL OF HEALTHCARE ENGINEERING
LA English
DT Article
ID COORDINATED REGULATION; DEMETHYLASE KDM5A; H3K4 DEMETHYLASE;
   2,3,5,4' TETRAHYDROXYSTILBENE 2 O BETA D GLUCOSIDE; PERFORMANCE; ICARIIN
AB Objectives. To investigate the effect of 2,3,5,4 '  tetrahydroxystilbene 2 O beta  D glucoside (TSG) on the osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) and its molecular mechanism. Methods. After TSG treatment of rBMSCs, alkaline phosphatase (ALP) activity was compared between the drug treatment group and the control group. The effects of TSG on alkaline phosphatase positive cloning and mineralized nodule formation were also detected. Total mRNA and protein were extracted, and the effects of TSG on the expression levels of osteopontin (OPN), osteocalcin (OCN), Runt related transcription factor 2 (Runx2), Osterix, and Col1a1 were detected by real time fluorescence quantitative PCR. Western blotting was used to detect the inhibitory effect of TSG on KDM5A. BMSCs were transfected with small interfering RNA (siRNA) targeting KDM5A (si KMD5A) and pcDNA3.1 KMD5A. Results. TSG significantly increased the activity of ALP, the number of alkaline phosphatase clones, and calcified nodule formation. The OPN, OCN, Runx2, and Osterix expression levels were significantly increased among the osteoblasts after TSG treatment. A mechanistic study showed that the effect of TSG is realized by inhibiting KDM5A. Conclusions. KDM5A signaling may be involved in the regulation of osteogenic differentiation of rBMSCs. TSG can promote osteogenic differentiation and maturation of rBMSCs at 0.1 50 mu mol/L. The mechanism of action was realized by inhibiting the expression of KDM5A.
C1 [Wei, Min; Jiang, Yi; Huang, Yuanqing] Hunan Univ Med, Sch Stomatol, Huaihua 418000, Hunan, Peoples R China.
C3 Hunan University of Medicine
RP Huang, YQ (通讯作者)，Hunan Univ Med, Sch Stomatol, Huaihua 418000, Hunan, Peoples R China.
EM hyqhunan1523@163.com
CR Baker N, 2015, BONE, V70, P37, DOI 10.1016/j.bone.2014.10.014
   Bianco P, 2013, NAT MED, V19, P35, DOI 10.1038/nm.3028
   Boschiero C, 2013, J APPL GENET, V54, P103, DOI 10.1007/s13353 012 0129 6
   Carbonare LD, 2009, ARTHRITIS RHEUM US, V60, P3356, DOI 10.1002/art.24884
   Dabiri Y, 2019, ISCIENCE, V12, P168, DOI 10.1016/j.isci.2019.01.012
   Dahl JA, 2016, NATURE, V537, P548, DOI 10.1038/nature19360
   Durbin SM, 2012, APPL PHYSIOL NUTR ME, V37, P1179, DOI 10.1139/h2012 099
   Guan M, 2012, NAT MED, V18, P456, DOI 10.1038/nm.2665
   Hou JL, 2012, AM J TRANSL RES, V4, P247
   Huang C, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742 2094 10 129
   Li GuoPing Li GuoPing, 2011, Chinese Archives of Traditional Chinese Medicine, V29, P2131
   Lin CL, 2017, BIOMED RES INT UK, V2017, DOI 10.1155/2017/3634915
   Long Shi yin, 2011, Chinese Pharmacological Bulletin, V27, P1353, DOI 10.3969/j.issn.1001 1978.2011.10.006
   Muruganandan S, 2009, CELL MOL LIFE SCI, V66, P236, DOI 10.1007/s00018 008 8429 z
   Nishibuchi G, 2014, J BIOL CHEM, V289, P28956, DOI 10.1074/jbc.M114.573725
   Olivares Navarrete R, 2015, BONE, V73, P208, DOI 10.1016/j.bone.2014.12.057
   Pasini D, 2008, GENE DEV, V22, P1345, DOI 10.1101/gad.470008
   Shi Yin L., 2011, CHINESE J ARTERIOSCL, V66
   Song F, 2015, LIFE SCI, V132, P68, DOI 10.1016/j.lfs.2015.04.001
   Su Jin K., 2018, INT J MOL SCI, V19, P2554
   Torres IO, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7204
   Wang ZQ, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/356260
   Xiang K, 2014, THROMB RES, V133, P211, DOI 10.1016/j.thromres.2013.11.006
   Yang LJ, 2014, CELL BIOCHEM BIOPHYS, V70, P485, DOI 10.1007/s12013 014 9945 0
   Yang XP, 2014, NEUROSCI LETT, V576, P79, DOI 10.1016/j.neulet.2014.05.045
   Zhai YK, 2014, INT J ENDOCRINOL, V2014, DOI 10.1155/2014/921954
   Zhai YK, 2014, BONE, V66, P189, DOI 10.1016/j.bone.2014.06.016
   [张晨 Zhang Chen], 2014, [医用生物力学, Journal of Medical Biomechanics], V29, P285
   Zhao DZ, 2016, CELL REP, V15, P288, DOI 10.1016/j.celrep.2016.03.035
   Zhao YY, 2013, J SEP SCI, V36, P863, DOI 10.1002/jssc.201200668
   Zhou S, 2008, AGING CELL, V7, P335, DOI 10.1111/j.1474 9726.2008.00377.x
NR 31
TC 3
Z9 4
U1 1
U2 9
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2040 2295
EI 2040 2309
J9 J HEALTHC ENG
JI J. Healthc. Eng.
PD JAN 25
PY 2022
VL 2022
AR 6472864
DI 10.1155/2022/6472864
PG 10
WC Health Care Sciences & Services
WE Science Citation Index Expanded (SCI EXPANDED)
SC Health Care Sciences & Services
GA 0J4LE
UT WOS:000780075100030
PM 35126937
OA hybrid, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Xu, L
   Li, Y
   Mei, L
   Qi, HX
   Fang, J
   Li, Y
AF Xu, Lin
   Li, Yuan
   Mei, Li
   Qi, Hexu
   Fang, Jie
   Li, Yu
TI Local injection of abaloparatide promotes mandibular condyle lengthening
   in adolescent rats via enhancing chondrogenesis and ossification
SO JOURNAL OF ORAL REHABILITATION
LA English
DT Article
DE abaloparatide; mandibular condylar chondrocyte; mandibular condyle;
   mandibular hypoplasia; PTHrP
ID PARATHYROID HORMONE 1 34; GROWTH PLATE; PTH/PTHRP RECEPTOR; IN VIVO;
   PTHRP; CHONDROCYTES; SOX9; ULTRASOUND; THERAPY; TISSUE
AB BackgroundMandibular condylar hypoplasia negatively affects patient's facial appearance and dentofacial function.ObjectiveTo investigate the effect of local injection of the drug abaloparatide (ABL), an analogue of parathyroid hormone related protein (PTHrP), on promoting lengthening of the mandibular condyle.MethodsThirty adolescent male Sprague Dawley rats were randomly divided into two groups, which received the injection of ABL or normal saline (the control) every 3 days in the temporomandibular joint (TMJ) cavity. Cone beam computed tomography and immunohistochemistry assays were performed at 2, 4 and 6 weeks since the injection. Mandibular condylar chondrocytes (MCC) and pre osteoblasts were treated with ABL or PBS, followed by the CCK 8 detection, IC50, real time PCR assay, Western Blot and immunofluorescence staining.ResultsIn vivo, compared with the control, the ABL group significantly increased the mandibular condylar process length (by 1.34 & PLUSMN; 0.59 mm at 6 weeks), the thickness of the cartilage layer, and enhanced the matrix synthesis. The ABL group had significant up regulation of SOX 9, COL II, PTHrP and PTH1R, down regulation of COL X in the cartilage, up regulation of RUNX 2, and unchanged osteoclastogenesis in the subchondral bone. In vitro, the intra TMJ injection of ABL promoted the MCC proliferation, with up regulated expression of chondrogenic genes, and enhanced osteogenic differentiation of the pre osteoblasts.ConclusionsIntra TMJ injection of abaloparatide promotes mandibular condyle lengthening in the adolescent rats via enhancing chondrogenesis in the mandibular condylar cartilage and ossification in the subchondral bone.
   ABL promoted lengthening of the mandibular condylar process (Co Mf) and enhanced thickening of the mandibular condylar cartilage layers. The possible mechanism is that ABL promoted chondrogenesis by up regulating SOX 9.image
C1 [Xu, Lin; Li, Yuan; Qi, Hexu; Fang, Jie; Li, Yu] Sichuan Univ, West China Hosp Stomatol, Natl Ctr Stomatol, Natl Clin Res Ctr Oral Dis,Dept Orthodont,State Ke, Chengdu, Sichuan, Peoples R China.
   [Mei, Li] Univ Otago, Fac Dent, Dept Oral Sci, Discipline Orthodont, Dunedin, New Zealand.
   [Fang, Jie; Li, Yu] Sichuan Univ, West China Hosp Stomatol, Natl Ctr Stomatol, Natl Clin Res Ctr Oral Dis,Dept Orthodont,State Ke, 14 3rd Sect,South Renmin Rd, Chengdu 610041, Peoples R China.
C3 Sichuan University; University of Otago; Sichuan University
RP Fang, J; Li, Y (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Natl Ctr Stomatol, Natl Clin Res Ctr Oral Dis,Dept Orthodont,State Ke, 14 3rd Sect,South Renmin Rd, Chengdu 610041, Peoples R China.
EM jiefangscu@qq.com; yuli@scu.edu.cn
RI Fang, Jie/MFZ 5201 2025; Mei, Lei/L 4274 2013; Li, Yu/G 6649 2011
OI Fang, Jie/0000 0003 2545 604X; Li, Yu/0000 0001 8578 7268; 
FU National Natural Science Foundation of China [31971247, 82371003]
FX National Natural Science Foundation of China, Grant/Award Number:
   31971247 and 82371003
CR Akiyama H, 2004, GENE DEV, V18, P1072, DOI 10.1101/gad.1171104
   Al Rezami KF, 2022, CLIN ORAL INVEST, V26, P7253, DOI 10.1007/s00784 022 04686 5
   Barna M, 2007, DEV CELL, V12, P931, DOI 10.1016/j.devcel.2007.04.016
   Chen CH, 2021, BONE JOINT RES, V10, P514, DOI 10.1302/2046 3758.108.BJR 2020 0165.R2
   Crossman J, 2019, ARCH ORAL BIOL, V104, P112, DOI 10.1016/j.archoralbio.2019.05.032
   Dai J, 2008, ANGLE ORTHOD, V78, P89, DOI 10.2319/102606 441.1
   Deng ZN, 2014, ARCH ORAL BIOL, V59, P1032, DOI 10.1016/j.archoralbio.2014.04.012
   El Bialy T, 2015, ANGLE ORTHOD, V85, P233, DOI 10.2319/030914 170.1
   El Bialy T, 2010, TISSUE ENG PART C ME, V16, P1315, DOI 10.1089/ten.TEC.2009.0564
   Enomoto A, 2010, EUR J ORTHODONT, V32, P66, DOI 10.1093/ejo/cjp060
   Eswaramoorthy R, 2012, ACTA BIOMATER, V8, P2254, DOI 10.1016/j.actbio.2012.03.015
   Foncatti CF, 2017, AM J ORTHOD DENTOFAC, V152, P663, DOI 10.1016/j.ajodo.2017.03.029
   Fukaya S, 2017, AM J ORTHOD DENTOFAC, V152, P820, DOI 10.1016/j.ajodo.2017.05.023
   Guasto A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094321
   Guo J, 2002, DEV CELL, V3, P183, DOI 10.1016/S1534 5807(02)00218 6
   Hichijo N, 2014, J ORAL REHABIL, V41, P581, DOI 10.1111/joor.12171
   Huang WD, 2001, P NATL ACAD SCI USA, V98, P160, DOI 10.1073/pnas.011393998
   Itoh Kouichi, 2003, Journal of Medical and Dental Sciences, V50, P79
   Karamani II, 2022, INT J ENV RES PUB HE, V19, DOI 10.3390/ijerph19052706
   Kristensen KD, 2017, AM J ORTHOD DENTOFAC, V152, P214, DOI 10.1016/j.ajodo.2016.12.020
   Kumar D, 2009, MOL CELL BIOL, V29, P4262, DOI 10.1128/MCB.01779 08
   Le Henaff C, 2020, J BONE MINER RES, V35, P714, DOI 10.1002/jbmr.3930
   Luder HU, 1998, ANAT REC, V251, P439
   Makino A, 2018, CALCIFIED TISSUE INT, V103, P289, DOI 10.1007/s00223 018 0422 4
   Martin TJ, 2021, ENDOCR REV, V42, P383, DOI 10.1210/endrev/bnab005
   Mizuhashi K, 2018, NATURE, V563, P254, DOI 10.1038/s41586 018 0662 5
   Nakajima M, 2000, J BONE MINER METAB, V18, P9, DOI 10.1007/s007740050003
   Oksayan R, 2015, PHOTOMED LASER SURG, V33, P252, DOI 10.1089/pho.2014.3870
   Oksayan Ridvan, 2014, Eur J Dent, V8, P291, DOI 10.4103/1305 7456.137624
   Platas J, 2017, J GERONTOL A BIOL, V72, P624, DOI 10.1093/gerona/glw100
   Rabie ABM, 2003, J DENT RES, V82, P627, DOI 10.1177/154405910308200811
   Saito Y, 2021, J DENT SCI, V16, P287, DOI 10.1016/j.jds.2020.04.002
   Shao L, 2020, BONE JOINT RES, V9, P675, DOI 10.1302/2046 3758.910.BJR 2020 0018.R1
   Shirley M, 2017, DRUGS, V77, P1363, DOI 10.1007/s40265 017 0780 7
   Spalj S, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/4861924
   Suzuki S, 2004, J Orthod, V31, P138, DOI 10.1179/146531204225020436
   Topol LL, 2009, J BIOL CHEM, V284, P3323, DOI 10.1074/jbc.M808048200
   Waheedul Hamid AS., 2003, PAK ORAL DENT J, V23, P137
   Wang S, 2018, ANGLE ORTHOD, V88, P624, DOI 10.2319/120417 829.1
   Weisser A, 2002, EXP CELL RES, V279, P1, DOI 10.1006/excr.2002.5580
   Yamazaki K, 1999, ARCH ORAL BIOL, V44, P853, DOI 10.1016/S0003 9969(99)00068 0
   Yang YM, 2019, BIOCHEM BIOPH RES CO, V509, P960, DOI 10.1016/j.bbrc.2019.01.049
   Zhang M, 2022, MATER TODAY BIO, V14, DOI 10.1016/j.mtbio.2022.100223
   Zhang Q, 2008, TISSUE ENG PT A, V14, P237, DOI 10.1089/tea.2007.0261
   Zhang W, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4025
NR 45
TC 3
Z9 3
U1 1
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0305 182X
EI 1365 2842
J9 J ORAL REHABIL
JI J. Oral Rehabil.
PD FEB
PY 2024
VL 51
IS 2
BP 380
EP 393
DI 10.1111/joor.13597
EA SEP 2023
PG 14
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA GQ1M8
UT WOS:001066332100001
PM 37727017
DA 2025 08 17
ER

PT J
AU Um, SY
   Chung, MW
   Kim, KB
   Kim, SH
   Oh, JS
   Oh, HY
   Lee, HJ
   Choi, KH
AF Um, So Young
   Chung, Myeon Woo
   Kim, Kyu Bong
   Kim, Seon Hwa
   Oh, Ji Seon
   Oh, Hye Young
   Lee, Hwa Jeong
   Choi, Ki Hwan
TI Pattern Recognition Analysis for the Prediction of Adverse Effects by
   Nonsteroidal Anti inflammatory Drugs Using <SUP>1</SUP>H NMR Based
   Metabolomics in Rats
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID RHEUMATOID ARTHRITIS; IN VIVO; METABONOMICS; CELECOXIB; DAMAGE;
   INHIBITION; INDOMETHACIN; DISCOVERY; ROFECOXIB; BIOMARKER
AB Nonsteroidal anti inflammatory drugs (NSAIDs) are commonly used to treat rheumatoid arthritis, osteoarthritis, acute pain, and fever. However, NSAIDs have side effects that include gastric erosions, ulceration, bleeding, and perforation, etc. Selective cyclooxygenase (COX) 2 inhibitors have been developed to avoid the adverse drug reaction of traditional NSAIDs. The COX 2 inhibitors have a different mechanism of action from nonselective COX inhibitors. In this study, pattern recognition analysis of the H 1 nuclear magnetic resonance (NMR) spectra of urine was performed to develop surrogate biomarkers related to the gastrointestinal (GI) damage induced by NSAIDs in rats. Urine was collected for 5 h after administering the following NSAIDs at high doses: celecoxib (133 mg kg( 1), po), a COX 2 selective inhibitor; and indomethacin (25 mg kg( 1), po) or ibuprofen (800 mg kg( 1), po), nonselective COX inhibitors. The urine was analyzed using 600 M H 1 NMR for spectral binning and targeted profiling. The level of gastric damage in each animal was also determined. Indomethacin and ibuprofen caused severe gastric damage, but no lesions were observed in the celecoxid treated rats. The H 1 NMR urine spectra were divided into spectral bins (0.04 ppm) for global profiling, and 36 endogenous metabolites were assigned for targeted profiling. Multivariate data analyses were carried out to recognize the spectral pattern of endogenous metabolites related to NSAIDs using partial least squares discrimination analysis (PLS DA). There were different clusterings of H 1 NMR spectra according to the gastric damage scores in global profiling. In targeted profiling, a few endogenous metabolites of allantoine, taurine, and dimethylamine were selected as putative biomarkers for the gastric damage induced by NSAIDs. The results of global and targeted profilings suggest that the gastric damage induced by NSAIDs can be screened in the preclinical stage of drug development using a current metabolomics study. In addition, the putative biomarkers might also be useful for predicting the risk of adverse effects caused by NSAIDs.
C1 [Um, So Young; Lee, Hwa Jeong] Ewha Womans Univ, Div Life & Pharmaceut Sci, Seoul, South Korea.
   [Um, So Young; Chung, Myeon Woo; Kim, Kyu Bong; Kim, Seon Hwa; Oh, Ji Seon; Oh, Hye Young; Choi, Ki Hwan] Korea Food & Drug Adm, Dept Pharmacol, Natl Inst Toxicol Res, Seoul, South Korea.
C3 Ewha Womans University
RP Lee, HJ (通讯作者)，Ewha Womans Univ, Div Life & Pharmaceut Sci, 11 1 Daehyun Dong, Seoul, South Korea.
EM hwalee@ewha.ac.kr; hyokwa@kfda.go.kr
RI Kim, Dong/AAH 2257 2021; Choi, Kihwan/AAG 3275 2021
FU Korea Food and Drug Administration [07151KFDA631]
FX This study was supported by a 2007 Grant (07151KFDA631) from the Korea
   Food and Drug Administration.
CR Bennett A, 2000, Expert Opin Pharmacother, V1, P277, DOI 10.1517/14656566.1.2.277
   Bijlsma S, 2006, ANAL CHEM, V78, P567, DOI 10.1021/ac051495j
   Bonabello A, 2003, ANESTH ANALG, V97, P402, DOI 10.1213/01.ANE.0000073349.04610.42
   Chang D, 2007, PACIFIC SYMPOSIUM ON BIOCOMPUTING 2007, P115
   Connor SC, 2007, METABOLOMICS, V3, P29, DOI 10.1007/s11306 006 0039 x
   Davis RA, 2007, CHEMOMETR INTELL LAB, V85, P144, DOI 10.1016/j.chemolab.2006.08.014
   Daykin A.C., 2006, FRONT DRUG DES DISCO, V2, P151
   De Meyer T, 2008, ANAL CHEM, V80, P3783, DOI 10.1021/ac7025964
   Dhawan V, 2005, FREE RADICAL BIO MED, V39, P1191, DOI 10.1016/j.freeradbiomed.2005.06.011
   Diehl KH, 2001, J APPL TOXICOL, V21, P15, DOI 10.1002/jat.727
   Dieterle F, 2007, CHEM RES TOXICOL, V20, P1291, DOI 10.1021/tx700151t
   EBLE JN, 1971, NATURE, V231, P181, DOI 10.1038/231181a0
   Ehrich EW, 1999, CLIN PHARMACOL THER, V65, P336, DOI 10.1016/S0009 9236(99)70113 X
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Fiehn O, 2001, COMP FUNCT GENOM, V2, P155, DOI 10.1002/cfg.82
   Flower RJ, 2003, NAT REV DRUG DISCOV, V2, P179, DOI 10.1038/nrd1034
   GABRIEL SE, 1992, J CLIN EPIDEMIOL, V45, P1041, DOI 10.1016/0895 4356(92)90127 9
   German JB, 2004, J NUTR, V134, P2729, DOI 10.1093/jn/134.10.2729
   Goodacre R, 2004, TRENDS BIOTECHNOL, V22, P245, DOI 10.1016/j.tibtech.2004.03.007
   Holmes E, 2002, ANALYST, V127, P1549, DOI 10.1039/b208254n
   Kato S, 2002, JPN J PHARMACOL, V89, P1, DOI 10.1254/jjp.89.1
   Kim KB, 1998, J PHARM PHARMACOL, V50, P521, DOI 10.1111/j.2042 7158.1998.tb06194.x
   Kim KB, 2008, METABOLOMICS, V4, P377, DOI 10.1007/s11306 008 0131 5
   Laudanno OM, 2001, DIGEST DIS SCI, V46, P779, DOI 10.1023/A:1010748316889
   Lee Y, 2003, BIOINFORMATICS, V19, P1132, DOI 10.1093/bioinformatics/btg102
   Liu YC, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471 2105 5 70
   MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228
   Nguyen DV, 2002, BIOINFORMATICS, V18, P1625, DOI 10.1093/bioinformatics/18.12.1625
   Nicholson JK, 2002, NAT REV DRUG DISCOV, V1, P153, DOI 10.1038/nrd728
   Nicholson JK, 2005, NAT REV MICROBIOL, V3, P431, DOI 10.1038/nrmicro1152
   Paulson SK, 2001, J PHARMACOL EXP THER, V297, P638
   PAULUS HE, 1985, ARTHRITIS RHEUM, V28, P1168, DOI 10.1002/art.1780281014
   Penning TD, 1997, J MED CHEM, V40, P1347, DOI 10.1021/jm960803q
   RAZ A, 1988, J BIOL CHEM, V263, P3022
   Robertson DG, 2005, TOXICOL SCI, V85, P809, DOI 10.1093/toxsci/kfi102
   Schnackenberg Laura K, 2007, Drug Discov Today Technol, V4, P13, DOI 10.1016/j.ddtec.2007.10.012
   Silverstein FE, 2000, JAMA J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247
   Simon LS, 1999, JAMA J AM MED ASSOC, V282, P1921, DOI 10.1001/jama.282.20.1921
   Slupsky CM, 2007, ANAL CHEM, V79, P6995, DOI 10.1021/ac0708588
   Weljie AM, 2006, ANAL CHEM, V78, P4430, DOI 10.1021/ac060209g
   WHITTLE BJR, 1981, GASTROENTEROLOGY, V80, P94
   Zamora Z, 2008, INFLAMM RES, V57, P39, DOI 10.1007/s00011 007 7034 1
NR 42
TC 29
Z9 33
U1 1
U2 33
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003 2700
EI 1520 6882
J9 ANAL CHEM
JI Anal. Chem.
PD JUN 15
PY 2009
VL 81
IS 12
BP 4734
EP 4741
DI 10.1021/ac9000282
PG 8
WC Chemistry, Analytical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA 457XN
UT WOS:000266969700010
PM 19462990
DA 2025 08 17
ER

PT J
AU Sun, P
   Jia, KH
   Zheng, CB
   Zhu, XL
   Li, J
   He, L
   Siwko, S
   Xue, F
   Liu, MY
   Luo, J
AF Sun, Peng
   Jia, Kunhang
   Zheng, Chunbing
   Zhu, Xinlei
   Li, Jing
   He, Liang
   Siwko, Stefan
   Xue, Feng
   Liu, Mingyao
   Luo, Jian
TI Loss of Lgr4 inhibits differentiation, migration and apoptosis,
   and promotes proliferation in bone mesenchymal stem cells
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE adipogenesis; BMSC; Lgr4; myoblast; osteogenesis
ID GLAND DEVELOPMENT; EXPRESSION; RECEPTOR; GENE; ASSOCIATION; ABLATION;
   LEADS; LOCI; ACTS
AB The key signaling networks regulating bone marrow mesenchymal stem cells (BMSCs) are poorly defined. Lgr4, which belongs to the leucine rich repeat containing G protein coupled receptor (LGR) family, is widely expressed in multiple tissues from early embryogenesis to adulthood. We investigated whether Lgr4 functions in BMSCs and in osteogenesis, adipogenesis, and skeletal myoblasts, using mice with a  geo gene trap inserted into the Lgr4 gene. Abundant Lgr4 expression was detected in skeletal, adipose and muscular tissue of Lgr4(+/ ) mice at E16.5 by  gal staining, and Lgr4 deficiency promoted BMSC proliferation (16 +/  4 in wild type [WT] and 28 +/  2 in Lgr4( / )) using colony forming units fibroblast assay, while suppressing BMSC migration (from 103 +/  18 in WT to 57 +/  10 in Lgr4( / )) by transwell migration assay and apoptosis ratio (from 0.0720 +/  0.0123 to 0.0189 +/  0.0051) by annexin V staining assay. Deletion of Lgr4 decreased bone mass (BV/TV from 19.16 +/  2.14 in WT mice to 10.36 +/  1.96 in KO) and fat mass through inhibiting BMSC differentiation to osteoblasts or adipocytes. Furthermore, LGR4 regulated osteogenic, adipogenic, and myogenic gene expression. Importantly, our data showed that loss of Lgr4 inhibited fracture healing by suppressing osteoblast differentiation. Moreover, deletion of Lgr4 in BMSCs delayed fracture healing following stem cell therapy by BMSC transplantation. Together, our results demonstrated that LGR4 is essential for mesoderm derived tissue development and BMSC differentiation, demonstrating that LGR4 could be a promising drug target for related diseases and a critical protein for stem cell therapy.
C1 [Sun, Peng; Jia, Kunhang; Zheng, Chunbing; Zhu, Xinlei; He, Liang; Liu, Mingyao; Luo, Jian] East China Normal Univ, Shanghai Fengxian Dist Cent Hosp, Shanghai, Peoples R China.
   [Sun, Peng; Jia, Kunhang; Zheng, Chunbing; Zhu, Xinlei; He, Liang; Liu, Mingyao; Luo, Jian] East China Normal Univ, East China Normal Univ Joint Ctr Translat Med, Shanghai Key Lab Regulatory Biol, Inst Biomed Sci, Shanghai, Peoples R China.
   [Sun, Peng; Jia, Kunhang; Zheng, Chunbing; Zhu, Xinlei; He, Liang; Liu, Mingyao; Luo, Jian] East China Normal Univ, Sch Life Sci, Shanghai, Peoples R China.
   [Sun, Peng] East China Normal Univ, Minist Educ, Key Lab Adolescent Hlth Assessment & Exercise Int, Shanghai, Peoples R China.
   [Li, Jing; Xue, Feng] Shanghai Fengxian Dist Cent Hosp, 6600 Nanfeng Rd, Shanghai 201400, Peoples R China.
   [Li, Jing; Xue, Feng] East China Normal Univ Joint Ctr Translat Med, Dept Orthopaed, Shanghai Fengxian Dist Cent Hosp, Shanghai, Peoples R China.
   [Siwko, Stefan; Liu, Mingyao] Texas A&M Univ, Hlth Sci Ctr, Inst Biosci & Technol, Dept Mol & Cellular Med, Houston, TX USA.
C3 East China Normal University; East China Normal University; East China
   Normal University; East China Normal University; Texas A&M University
   System; Texas A&M University College Station; Texas A&M Health Science
   Center; University of Texas System; University of Texas Health Science
   Center Houston
RP Xue, F (通讯作者)，Shanghai Fengxian Dist Cent Hosp, 6600 Nanfeng Rd, Shanghai 201400, Peoples R China.; Liu, MY; Luo, J (通讯作者)，East China Normal Univ, Shanghai Key Lab Regulatory Biol, Inst Biomed Sci, Sch Life Sci, 500 Dongchuan Rd, Shanghai 200241, Peoples R China.
EM xuefengmd@sina.com; myliu@bio.ecnu.edu.cn; jluo@bio.ecnu.edu.cn
RI Luo, Jian/H 3362 2016
OI Luo, Jian/0000 0003 3583 0154; Sun, Peng/0000 0002 0615 2510; Siwko,
   Stefan/0000 0003 4260 2985
FU National Key Research and Development Program of China [2016YFC0902102,
   2018YFC1105102]; National Natural Science Foundation of China
   [8171101485, 81722020, 81330049, 81472048]
FX National Key Research and Development Program of China, Grant/Award
   Numbers: 2016YFC0902102, 2018YFC1105102; National Natural Science
   Foundation of China, Grant/Award Numbers: 8171101485, 81722020,
   81330049, 81472048
CR Armand AS, 2008, J BIOL CHEM, V283, P29004, DOI 10.1074/jbc.M801297200
   Carmon KS, 2011, P NATL ACAD SCI USA, V108, P11452, DOI 10.1073/pnas.1106083108
   de Lageneste OD, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03124 z
   desLau W, 2011, NATURE, V476, P293
   Du B, 2013, J BIOL CHEM, V288, P15131, DOI 10.1074/jbc.M113.455535
   Grefte S, 2012, BIOMED MATER, V7, DOI 10.1088/1748 6041/7/5/055004
   Hirose K, 2011, GENE EXPR PATTERNS, V11, P378, DOI 10.1016/j.gep.2011.04.002
   Hu Y., 2018, STEM CELLS INT, V2018
   Kato S, 2007, FEBS LETT, V581, P4685, DOI 10.1016/j.febslet.2007.08.064
   Kettunen J, 2009, INT J OBESITY, V33, P1235, DOI 10.1038/ijo.2009.168
   Luo J, 2016, NAT MED, V22, P539, DOI 10.1038/nm.4076
   Luo J, 2009, DEVELOPMENT, V136, P2747, DOI 10.1242/dev.033571
   Luo WJ, 2013, STEM CELLS, V31, P2492, DOI 10.1002/stem.1484
   Mahasarakham CPN, 2016, J CELL PHYSIOL, V231, P887, DOI 10.1002/jcp.25180
   Marion NW, 2006, METHOD ENZYMOL, V420, P339, DOI 10.1016/S0079 6879(06)20016 8
   MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306
   Mohri Y, 2008, DEV DYNAM, V237, P2235, DOI 10.1002/dvdy.21639
   Omoto M, 2009, INVEST OPHTH VIS SCI, V50, P2109, DOI 10.1167/iovs.08 2262
   Polymeri A, 2016, HORM METAB RES, V48, P700, DOI 10.1055/s 0042 118458
   Qian Y, 2013, DEVELOPMENT, V140, P1751, DOI 10.1242/dev.093641
   Richardson SM, 2008, CURR PAIN HEADACHE R, V12, P83, DOI 10.1007/s11916 008 0016 3
   Shi Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 02171 2
   Sone M, 2013, FASEB J, V27, P4917, DOI 10.1096/fj.13 232215
   Styrkarsdottir U, 2013, NATURE, V497, P517, DOI 10.1038/nature12124
   Sun YK, 2015, BIOCHEM BIOPH RES CO, V464, P396, DOI 10.1016/j.bbrc.2015.06.066
   Thorleifsson G, 2009, NAT GENET, V41, P18, DOI 10.1038/ng.274
   Tian H, 2010, BIOMATERIALS, V31, P870, DOI 10.1016/j.biomaterials.2009.10.001
   Wang F, 2014, J MOL ENDOCRINOL, V52, P133, DOI 10.1530/JME 13 0042
   Wang JQ, 2013, NAT CELL BIOL, V15, P1455, DOI 10.1038/ncb2867
   Wang J, 2012, J AM SOC NEPHROL, V23, P281, DOI 10.1681/ASN.2011040351
   Wang Y, 2013, STEM CELLS, V31, P1921, DOI 10.1002/stem.1438
   Wei X, 2013, ACTA PHARMACOL SIN, V34, P747, DOI 10.1038/aps.2013.50
   Weng JS, 2008, P NATL ACAD SCI USA, V105, P6081, DOI 10.1073/pnas.0708257105
   Yamashita R, 2009, DEV DYNAM, V238, P993, DOI 10.1002/dvdy.21900
   Yi TF, 2014, J BIOL CHEM, V289, P8767, DOI 10.1074/jbc.M113.530816
   Yue Z., 2018, FASEB J, V32
   Zhao B, 2018, INT J MOL MED, V42, P219, DOI 10.3892/ijmm.2018.3578
   Zhu C, 2016, CELL SIGNAL, V28, P989, DOI 10.1016/j.cellsig.2016.04.010
   Zou YY, 2017, OBESITY, V25, P252, DOI 10.1002/oby.21704
NR 39
TC 30
Z9 33
U1 1
U2 47
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD JUL
PY 2019
VL 234
IS 7
BP 10855
EP 10867
DI 10.1002/jcp.27927
PG 13
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA HQ8AL
UT WOS:000462645700087
PM 30536377
DA 2025 08 17
ER

PT J
AU del Real, A
   Ciordia, S
   Sañudo, C
   Garcia Ibarbia, C
   Roa Bautista, A
   Ocejo Viñals, JG
   Corrales, F
   Riancho, JA
AF del Real, Alvaro
   Ciordia, Sergio
   Sanudo, Carolina
   Garcia Ibarbia, Carmen
   Roa Bautista, Adriel
   Ocejo Vinals, Javier G.
   Corrales, Fernando
   Riancho, Jose A.
TI Analysis of Serum Proteome after Treatment of Osteoporosis with Anabolic
   or Antiresorptive Drugs
SO METABOLITES
LA English
DT Article
DE proteome; osteoporosis; bone; antiresorptive drugs; teriparatide
ID POSTMENOPAUSAL WOMEN; FRACTURE RISK; BONE; IDENTIFICATION; PREVENTION;
   DENOSUMAB; HIP
AB The aim of the study was to explore new markers in serum proteome associated with the response to antiosteoporosis drugs, namely teriparatide and denosumab. We obtained serum samples from 14 patients with osteoporosis, both at baseline and after 6 months of treatment with teriparatide (n = 10) or denosumab (n = 4). Samples were analyzed by nanoliquid chromatography coupled to high resolution mass spectrometry on a QTOF 5600 (SCIEX) apparatus. The spectrometry data were analyzed with Mascot against the UniProtKB base and then several quality control filters were applied for the identification of peptides (false discovery rate, FDR q < 0.02) and their quantification (FDR q < 0.05). In the group treated with teriparatide, 28 proteins were identified with significant differences before and after treatment. A pathway analysis by using the Reactome database revealed significant enrichment in the Insulin Like Growth Factor 1 (IGF I) (FDR q 4 x 10( 2)) and innate immune system (FDR q 2 x 10( 3)) pathways. Among patients treated with denosumab, we observed significant differences in the levels of 10 proteins, which were also enriched in the pathways related to the innate immune system (FDR q 3 x 10( 2)). These results suggest that the innate immune system may be involved in the response to antiosteoporosis drugs.
C1 [del Real, Alvaro; Sanudo, Carolina; Garcia Ibarbia, Carmen; Riancho, Jose A.] Univ Cantabria, Dept Med & Psiquiatria, IDIVAL, Santander 39008, Spain.
   [Ciordia, Sergio; Corrales, Fernando] CSIC, Lab Proteom Func, Proteored ISCIII, Ctr Nacl Biotecnol, Madrid 28049, Spain.
   [Garcia Ibarbia, Carmen; Riancho, Jose A.] Hosp Univ Marques de Valdecilla, Serv Med Interna, Santander 39008, Spain.
   [Roa Bautista, Adriel; Ocejo Vinals, Javier G.] Hosp Univ Marques de Valdecilla, Serv Inmunol, IDIVAL, Santander 39008, Spain.
C3 Universidad de Cantabria; Consejo Superior de Investigaciones
   Cientificas (CSIC); CSIC   Centro Nacional de Biotecnologia (CNB);
   Hospital Universitario Marques de Valdecilla (HUMV); Hospital
   Universitario Marques de Valdecilla (HUMV)
RP Riancho, JA (通讯作者)，Univ Cantabria, Dept Med & Psiquiatria, IDIVAL, Santander 39008, Spain.; Riancho, JA (通讯作者)，Hosp Univ Marques de Valdecilla, Serv Med Interna, Santander 39008, Spain.
EM delreala@unican.es; proteomics.masas@cnb.csic.es;
   carolinasanudo@gmail.com; carmen.garciai@scsalud.es;
   adrielantonio.roa@scsalud.es; javiergonzalo.ocejo@scsalud.es;
   fcorrales@cnb.csic.es; rianchoj@unican.es
RI ; Ocejo Viñals, Javier Gonzalo/ISA 5220 2023; del real,
   alvaro/AAI 7841 2020
OI del Real, Alvaro/0000 0002 1057 461X; Ocejo Vinyals, J.
   Gonzalo/0000 0003 2245 4639; Corrales, Fernando/0000 0002 0231 5159;
   Sanudo, Carolina/0000 0002 4287 1336; Ciordia,
   Sergio/0000 0002 5726 853X; 
FU FEIOMM [17/0025]; ProteoRed ISCIII
FX Supported by grants from FEIOMM (Grant No.17/0025) and ProteoRed ISCIII.
CR Barrionuevo P, 2019, J CLIN ENDOCR METAB, V104, P1623, DOI 10.1210/jc.2019 00192
   Bouxsein ML, 2019, J BONE MINER RES, V34, P632, DOI 10.1002/jbmr.3641
   Cronin O, 2022, CALCIFIED TISSUE INT, V110, P273, DOI 10.1007/s00223 021 00924 2
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Dahl J, 2021, BONE, V153, DOI 10.1016/j.bone.2021.116110
   Diker Cohen T, 2020, J CLIN ENDOCR METAB, V105, DOI 10.1210/clinem/dgz322
   Donham C, 2020, CURR OSTEOPOROS REP, V18, P32, DOI 10.1007/s11914 020 00563 w
   Garnero P, 2017, MOL DIAGN THER, V21, P401, DOI 10.1007/s40291 017 0272 1
   Gillespie M, 2022, NUCLEIC ACIDS RES, V50, pD687, DOI 10.1093/nar/gkab1028
   Hsu E, 2018, CALCIFIED TISSUE INT, V102, P512, DOI 10.1007/s00223 017 0321 0
   Li JY, 2020, J CLIN INVEST, V130, P1767, DOI 10.1172/JCI133473
   Liao YX, 2019, NUCLEIC ACIDS RES, V47, pW199, DOI 10.1093/nar/gkz401
   Lopez Serra P, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4608
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Nielson CM, 2017, J BONE MINER RES, V32, P1559, DOI 10.1002/jbmr.3125
   Omata Y, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031104
   Pacifici R, 2021, J CLIN ENDOCR METAB, V106, P636, DOI 10.1210/clinem/dgaa895
   Ramos Fernández A, 2008, MOL CELL PROTEOMICS, V7, P1748, DOI 10.1074/mcp.M800122 MCP200
   Saxena Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.687037
   Shabestari M, 2020, INT J RHEUM DIS, V23, P788, DOI 10.1111/1756 185X.13843
   Szklarczyk D, 2021, NUCLEIC ACIDS RES, V49, pD605, DOI 10.1093/nar/gkaa1074
   Tabacco G, 2019, BRIT J CLIN PHARMACO, V85, P1084, DOI 10.1111/bcp.13766
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Takegahara N, 2022, BONE, V159, DOI 10.1016/j.bone.2022.116353
   Toscani D, 2015, ANN NY ACAD SCI, V1335, P45, DOI 10.1111/nyas.12578
   Yu MC, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14148 4
   Yu MC, 2018, EMBO REP, V19, P156, DOI 10.15252/embr.201744421
NR 27
TC 5
Z9 5
U1 0
U2 7
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2218 1989
J9 METABOLITES
JI Metabolites
PD MAY
PY 2022
VL 12
IS 5
AR 399
DI 10.3390/metabo12050399
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 1O6YM
UT WOS:000801475000001
PM 35629903
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Srikulmontree, T
   Massey, HD
   Roberts, WN
AF Srikulmontree, Thitinan
   Massey, H. Davis
   Roberts, W. Neal
TI Treatment of skeletal Erdheim Chester disease with zoledronic acid: case
   report and proposed mechanisms of action
SO RHEUMATOLOGY INTERNATIONAL
LA English
DT Article
DE Erdheim Chester disease/diagnosis; Erdheim Chester disease/pathology;
   Erdheim Chester disease/treatment; bone biology; bisphosphonate
ID LANGERHANS CELL HISTIOCYTOSIS; BISPHOSPHONATE TREATMENT; THERAPY
AB Erdheim Chester disease (ECD) is a rare non Langerhans cell histiocytosis characterized by tissue infiltration of lipid laden macrophages, multinucleated giant cells, and inflammatory infiltrate of lymphocytes and histiocytes. The disease typically involves long bone, but may also affect the central nervous system, the orbit, retroperitoneal organs, and the lungs. Patients with visceral involvement tend to have poorer outcome. There is no proven effective treatment for ECD to date. However, recent data suggested the potential use of bisphosphonates for the treatment of this rare disease. Here we report a case of biopsy proven skeletal ECD, who received treatment with zoledronic acid, an aminobisphosphonate, with remarkable clinical improvement. We also discuss possible mechanisms of action of bisphosphonates in this disorder, especially their roles in inhibition of inflammatory cytokines and macrophage infiltration.
C1 Hunter Holmes McGuire Med Ctr, Rheumatol Sect, Richmond, VA 23249 USA.
   Virginia Commonwealth Univ, Hlth Syst, Dept Med, Sect Rheumatol Allergy & Immunol, Richmond, VA 23298 USA.
   Virginia Commonwealth Univ, Hlth Syst, Dept Pathol, Richmond, VA 23298 USA.
C3 Hunter Holmes McGuire Veterinary Affairs Medical Center; Virginia
   Commonwealth University; Virginia Commonwealth University
RP Srikulmontree, T (通讯作者)，Hunter Holmes McGuire Med Ctr, Rheumatol Sect, 1201 Broad Rock Blvd, Richmond, VA 23249 USA.
EM thitinan.srikulmontree@va.gov
CR Al Quran S, 2002, MODERN PATHOL, V15, P666, DOI 10.1038/modpathol.3880583
   BRAITEH F, 2005, BLOOD           0714
   Brown RE, 2001, MED PEDIATR ONCOL, V36, P641, DOI 10.1002/mpo.1142
   Bukowski JF, 2005, BIOCHEM BIOPH RES CO, V328, P746, DOI 10.1016/j.bbrc.2004.11.075
   Esmaeli B, 2001, AM J OPHTHALMOL, V132, P945, DOI 10.1016/S0002 9394(01)01141 2
   Eyigör S, 2005, ARCH PHYS MED REHAB, V86, P1053, DOI 10.1016/j.apmr.2004.05.005
   Farran RP, 2001, J PEDIAT HEMATOL ONC, V23, P54, DOI 10.1097/00043426 200101000 00013
   Goto H, 2003, ARTHRITIS RHEUM, V48, P3538, DOI 10.1002/art.11362
   Jendro MC, 2004, CLIN RHEUMATOL, V23, P52, DOI 10.1007/s10067 003 0801 7
   Kamizono J, 2002, J BONE MINER RES, V17, P1926, DOI 10.1359/jbmr.2002.17.11.1926
   Li EC, 2003, CLIN THER, V25, P2669, DOI 10.1016/S0149 2918(03)80327 2
   Mossetti G, 2003, CLIN EXP RHEUMATOL, V21, P232
   Myra C, 2004, BRIT J OPHTHALMOL, V88, P844, DOI 10.1136/bjo.2003.035584
   Santini D, 2003, CLIN CANCER RES, V9, P2893
   VeyssierBelot C, 1996, MEDICINE, V75, P157, DOI 10.1097/00005792 199605000 00005
NR 15
TC 15
Z9 16
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0172 8172
J9 RHEUMATOL INT
JI Rheumatol. Int.
PD JAN
PY 2007
VL 27
IS 3
BP 303
EP 307
DI 10.1007/s00296 006 0190 8
PG 5
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 124VS
UT WOS:000243399200016
PM 16932956
DA 2025 08 17
ER

PT J
AU Park, J
   Rodionov, D
   De Schutter, JW
   Lin, YS
   Tsantrizos, YS
   Berghuis, AM
AF Park, Jaeok
   Rodionov, Dmitry
   De Schutter, Joris W.
   Lin, Yih Shyan
   Tsantrizos, Youla S.
   Berghuis, Albert M.
TI Crystallographic and thermodynamic characterization of
   phenylaminopyridine bisphosphonates binding to human farnesyl
   pyrophosphate synthase
SO PLOS ONE
LA English
DT Article
ID NITROGEN CONTAINING BISPHOSPHONATES; STRUCTURAL BASIS; INHIBITION;
   DESIGN; DRUGS
AB Human farnesyl pyrophosphate synthase (hFPPS) catalyzes the production of the 15 carbon isoprenoid farnesyl pyrophosphate. The enzyme is a key regulator of the mevalonate pathway and a well established drug target. Notably, it was elucidated as the molecular target of nitrogen containing bisphosphonates, a class of drugs that have been widely successful against bone resorption disorders. More recently, research has focused on the anticancer effects of these inhibitors. In order to achieve increased non skeletal tissue exposure, we created phenylaminopyridine bisphosphonates (PNP BPs) that have bulky hydrophobic side chains through a structure based approach. Some of these compounds have proven to be more potent than the current clinical drugs in a number of antiproliferation assays using multiple myeloma cell lines. In the present work, we characterized the binding of our most potent PNP BPs to the target enzyme, hFPPS. Co crystal structures demonstrate that the molecular interactions designed to elicit tighter binding are indeed established. We carried out thermodynamic studies as well; the newly introduced protein ligand interactions are clearly reflected in the enthalpy of binding measured, which is more favorable for the new PNP BPs than for the lead compound. These studies also indicate that the affinity of the PNP BPs to hFPPS is comparable to that of the current drug risedronate. Risedronate forms additional polar interactions via its hydroxyl functional group and thus exhibits more favorable binding enthalpy; however, the entropy of binding is more favorable for the PNP BPs, owing to the greater desolvation effects resulting from their large hydrophobic side chains. These results therefore confirm the overall validity of our drug design strategy. With a distinctly different molecular scaffold, the PNP BPs described in this report represent an interesting new group of future drug candidates. Further investigation should follow to characterize the tissue distribution profile and assess the potential clinical benefits of these compounds.
C1 [Park, Jaeok; Rodionov, Dmitry; Tsantrizos, Youla S.; Berghuis, Albert M.] McGill Univ, Dept Biochem, Montreal, PQ, Canada.
   [De Schutter, Joris W.; Lin, Yih Shyan; Tsantrizos, Youla S.] McGill Univ, Dept Chem, Montreal, PQ, Canada.
   [Rodionov, Dmitry] Formulatrix, Bedford, MA USA.
   [De Schutter, Joris W.] Putnam Associates, Boston, MA USA.
   [Lin, Yih Shyan] APRINOIR Therapeut, Taipei, Taiwan.
C3 McGill University; McGill University
RP Berghuis, AM (通讯作者)，McGill Univ, Dept Biochem, Montreal, PQ, Canada.
EM albert.berghuis@mcgill.ca
RI Park, Jaeok/U 6904 2019; Berghuis, Albert/A 6495 2008
OI Berghuis, Albert/0000 0002 2663 025X; Park, Jaeok/0000 0002 8180 3950;
   Rodionov, Dmitry/0009 0001 3897 7584
FU Canadian Institutes of Health Research [MOP 126062, MOP 114889]; Fonds
   de Recherche du Quebec   Nature et Technologies [PR 181227]
FX This work was supported by grants from the Canadian Institutes of Health
   Research (www.cihr irsc.gc.ca) to YST (MOP 126062) and AMB (MOP 114889)
   and the Fonds de Recherche du Quebec   Nature et Technologies
   (www.frgnt.gouv.qc.ca.) to both YST and AMB (PR 181227). The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Alyar H, 2011, COMPUT THEOR CHEM, V977, P22, DOI 10.1016/j.comptc.2011.09.001
   Berndt N, 2011, NAT REV CANCER, V11, P775, DOI 10.1038/nrc3151
   Cremers S, 2011, BONE, V49, P42, DOI 10.1016/j.bone.2011.01.014
   De Schutter JW, 2012, BIOORGAN MED CHEM, V20, P5583, DOI 10.1016/j.bmc.2012.07.019
   DEMEIJERE A, 1979, ANGEW CHEM INT EDIT, V18, P809, DOI 10.1002/anie.197908093
   Dunford JE, 2008, J MED CHEM, V51, P2187, DOI 10.1021/jm7015733
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   GE Healthcare Life Sciences, 2012, MICR ITC200 SYST US
   Hosfield DJ, 2004, J BIOL CHEM, V279, P8526, DOI 10.1074/jbc.C300511200
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Koul HK, 2012, PROSTATE CANCER P D, V15, P111, DOI 10.1038/pcan.2011.41
   Lawson MA, 2010, J BIOMED MATER RES B, V92B, P149, DOI 10.1002/jbm.b.31500
   Lin YS, 2012, J MED CHEM, V55, P3201, DOI 10.1021/jm201657x
   McTaggart SJ, 2006, CELL MOL LIFE SCI, V63, P255, DOI 10.1007/s00018 005 5298 6
   Murshudov GN, 2011, ACTA CRYSTALLOGR D, V67, P355, DOI 10.1107/S0907444911001314
   Park J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14132
   Park J, 2012, BMC STRUCT BIOL, V12, DOI 10.1186/1472 6807 12 32
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Rondeau JM, 2006, CHEMMEDCHEM, V1, P267, DOI 10.1002/cmdc.200500059
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Schüttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679
   Winter G, 2013, ACTA CRYSTALLOGR D, V69, P1260, DOI 10.1107/S0907444913015308
NR 22
TC 8
Z9 8
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD OCT 16
PY 2017
VL 12
IS 10
AR e0186447
DI 10.1371/journal.pone.0186447
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA FJ8YP
UT WOS:000413054800036
PM 29036218
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Kuijjer, ML
   Peterse, EFP
   van den Akker, BEWM
   Briaire de Bruijn, IH
   Serra, M
   Meza Zepeda, LA
   Myklebost, O
   Hassan, AB
   Hogendoorn, PCW
   Cleton Jansen, AM
AF Kuijjer, Marieke L.
   Peterse, Elisabeth F. P.
   van den Akker, Brendy E. W. M.
   Briaire de Bruijn, Inge H.
   Serra, Massimo
   Meza Zepeda, Leonardo A.
   Myklebost, Ola
   Hassan, A. Bassim
   Hogendoorn, Pancras C. W.
   Cleton Jansen, Anne Marie
TI IR/IGF1R signaling as potential target for treatment of high grade
   osteosarcoma
SO BMC CANCER
LA English
DT Article
DE Osteosarcoma; IGF1R signaling; Signal transduction; IGF1R; OSI 906; Bone
   neoplasm; Sarcoma
ID FACTOR TYPE 1 RECEPTOR; PROTEIN 3 IGF2BP3; MONOCLONAL ANTIBODY;
   BINDING PROTEINS; MESSENGER RNA; I RECEPTOR; PHASE II; INSULIN; GROWTH;
   GENES
AB Background: High grade osteosarcoma is an aggressive tumor most often developing in the long bones of adolescents, with a second peak in the 5th decade of life. Better knowledge on cellular signaling in this tumor may identify new possibilities for targeted treatment.
   Methods: We performed gene set analysis on previously published genome wide gene expression data of osteosarcoma cell lines (n=19) and pretreatment biopsies (n=84). We characterized overexpression of the insulin like growth factor receptor (IGF1R) signaling pathways in human osteosarcoma as compared with osteoblasts and with the hypothesized progenitor cells of osteosarcoma   mesenchymal stem cells. This pathway plays a key role in the growth and development of bone. Since most profound differences in mRNA expression were found at and upstream of the receptor of this pathway, we set out to inhibit IR/IGF1R using OSI 906, a dual inhibitor for IR/IGF1R, on four osteosarcoma cell lines. Inhibitory effects of this drug were measured by Western blotting and cell proliferation assays.
   Results: OSI 906 had a strong inhibitory effect on proliferation of 3 of 4 osteosarcoma cell lines, with IC(50)s below 100 nM at 72 hrs of treatment. Phosphorylation of IRS 1, a direct downstream target of IGF1R signaling, was inhibited in the responsive osteosarcoma cell lines. Conclusions: This study provides an in vitro rationale for using IR/IGF1R inhibitors in preclinical studies of osteosarcoma.
C1 [Kuijjer, Marieke L.; Peterse, Elisabeth F. P.; van den Akker, Brendy E. W. M.; Briaire de Bruijn, Inge H.; Hogendoorn, Pancras C. W.; Cleton Jansen, Anne Marie] Leiden Univ, Dept Pathol, Med Ctr, NL 2300 RC Leiden, Netherlands.
   [Serra, Massimo] Ist Ortoped Rizzoli, Lab Expt Oncol Res, I 40136 Bologna, Italy.
   [Meza Zepeda, Leonardo A.; Myklebost, Ola] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Tumor Biol, N 0310 Oslo, Norway.
   [Hassan, A. Bassim] Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England.
C3 Leiden University   Excl LUMC; Leiden University; Leiden University
   Medical Center (LUMC); IRCCS Istituto Ortopedico Rizzoli; University of
   Oslo; University of Oxford
RP Cleton Jansen, AM (通讯作者)，Leiden Univ, Dept Pathol, Med Ctr, Albinusdreef 2, NL 2300 RC Leiden, Netherlands.
EM a.m.cleton jansen@lumc.nl
RI Hogendoorn, Pancras/H 5859 2015; Hogendoorn, Pancras C W/H 5859 2015;
   Kuijjer, Marieke/AAG 5844 2019; Meza Zepeda, Leonardo/CAG 5229 2022;
   Myklebost, Ola/GZL 6171 2022; Serra, Massimo/J 4878 2016
OI Hogendoorn, Pancras C W/0000 0002 1513 8104; Hassan,
   Andrew/0000 0002 2517 6681; Kuijjer, Mariike/0000 0001 6280 3130; Serra,
   Massimo/0000 0003 0742 1177
FU EuroBoNet [LSHC CT 2006 018814]; Dutch Cancer Society (KWF) [2008 4060];
   Norwegian Cancer Society [71572   PR 2006 0396, 107359   PR 2007 0163];
   Andraa's Legacy; defense against cancer; association for children with
   cancer research legacy; Cancer Research UK [9891] Funding Source:
   researchfish
FX This study was funded by EuroBoNet (LSHC CT 2006 018814), the Dutch
   Cancer Society (KWF, 2008 4060 to MLK), the Norwegian Cancer Society
   (71572   PR 2006 0396, 107359   PR 2007 0163 to OM and LAMZ,
   respectively), Andraa's Legacy (to OM), and defense against cancer and
   the association for children with cancer research legacy (to LAMZ).
CR [Anonymous], ASCO ANN M
   [Anonymous], ASCO ANN M
   [Anonymous], STAT APPL GENET MOL
   Arora RS, 2011, CANCER CAUSE CONTROL, V22, P681, DOI 10.1007/s10552 011 9740 9
   Bagatell R, 2011, CLIN CANCER RES, V17, P611, DOI 10.1158/1078 0432.CCR 10 1731
   Benini S, 2006, INT J CANCER, V119, P1039, DOI 10.1002/ijc.21929
   Bernardo ME, 2007, CONNECT TISSUE RES, V48, P132, DOI 10.1080/03008200701228464
   Buck E, 2010, MOL CANCER THER, V9, P2652, DOI 10.1158/1535 7163.MCT 10 0318
   Cai YP, 2010, J PATHOL, V220, P24, DOI 10.1002/path.2628
   Chen D, 2011, CLIN CANCER RES, V17, P6693, DOI 10.1158/1078 0432.CCR 10 2774
   Cleton Jansen AM, 2009, BRIT J CANCER, V101, P2064, DOI 10.1038/sj.bjc.6605482
   Conover CA, 2008, AM J PHYSIOL ENDOC M, V294, pE10, DOI 10.1152/ajpendo.00648.2007
   Eselgrim M, 2006, PEDIATR BLOOD CANCER, V47, P42, DOI 10.1002/pbc.20608
   Foulstone E, 2005, J PATHOL, V205, P145, DOI 10.1002/path.1712
   Fulzele K, 2007, J BIOL CHEM, V282, P25649, DOI 10.1074/jbc.M700651200
   Garofalo C, 2011, ONCOGENE, V30, P2730, DOI 10.1038/onc.2010.640
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb 2004 5 10 r80
   Goeman JJ, 2004, BIOINFORMATICS, V20, P93, DOI 10.1093/bioinformatics/btg382
   Grimberg A, 2000, J CELL PHYSIOL, V183, P1, DOI 10.1002/(SICI)1097 4652(200004)183:1<1::AID JCP1>3.0.CO;2 J
   Houghton PJ, 2010, PEDIATR BLOOD CANCER, V54, P921, DOI 10.1002/pbc.22367
   Hutchison MR, 2010, MOL ENDOCRINOL, V24, P193, DOI 10.1210/me.2009 0228
   Juergens H, 2011, J CLIN ONCOL, V29, P4534, DOI 10.1200/JCO.2010.33.0670
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kirpensteijn J, 2008, VET SURG, V37, P454, DOI 10.1111/j.1532 950X.2008.00407.x
   Kolb EA, 2008, PEDIATR BLOOD CANCER, V50, P1190, DOI 10.1002/pbc.21450
   Kolb EA, 2010, PEDIATR BLOOD CANCER, V55, P67, DOI 10.1002/pbc.22479
   Kolb EA, 2009, CURR ONCOL REP, V11, P307, DOI 10.1007/s11912 009 0043 1
   Kuijjer ML, 2012, GENE CHROMOSOME CANC, V51, P696, DOI 10.1002/gcc.21956
   Lewis IJ, 2007, JNCI J NATL CANCER I, V99, P112, DOI 10.1093/jnci/djk015
   Liao BS, 2005, J BIOL CHEM, V280, P18517, DOI 10.1074/jbc.M500270200
   LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092 8674(05)80084 4
   Maki RG, 2010, J CLIN ONCOL, V28, P4985, DOI 10.1200/JCO.2009.27.5040
   Mirabello L, 2011, CANCER CAUSE CONTROL, V22, P899, DOI 10.1007/s10552 011 9763 2
   Mohseny AB, 2012, EUR J CANCER, V48, P3429, DOI 10.1016/j.ejca.2012.06.018
   Mulvihill MJ, 2009, FUTURE MED CHEM, V1, P1153, DOI 10.4155/FMC.09.89
   Namlos HM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048086
   Namlos Heidi M., 2012, Sarcoma, V2012, P639038, DOI 10.1155/2012/639038
   Olmos D, 2010, CANCER J, V16, P183, DOI 10.1097/PPO.0b013e3181dbebf9
   Ottaviano L, 2010, GENE CHROMOSOME CANC, V49, P40, DOI 10.1002/gcc.20717
   Pappo AS, 2011, J CLIN ONCOL, V29, P4541, DOI 10.1200/JCO.2010.34.0000
   Pollak M, 2012, NAT REV CANCER, V12, P159, DOI 10.1038/nrc3215
   R Development Core Team, 2011, R: A language and environment for statistical computing.
   Raymond A., 2002, WHO CLASSIFICATION T, P264
   Rikhof B, 2009, J PATHOL, V217, P469, DOI 10.1002/path.2499
   Schaeffer DF, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 59
   SCHARLA SH, 1993, J CLIN ENDOCR METAB, V77, P1190, DOI 10.1210/jc.77.5.1190
   Schrage YM, 2009, CANCER RES, V69, P6216, DOI 10.1158/0008 5472.CAN 08 4801
   Selvarajah GT, 2010, VET J, V185, P28, DOI 10.1016/j.tvjl.2010.04.010
   Shiozawa Y, 2010, NEOPLASIA, V12, P116, DOI 10.1593/neo.91384
   Siddle Kenneth, 2012, Front Endocrinol (Lausanne), V3, P34, DOI 10.3389/fendo.2012.00034
   Siddle K, 2011, J MOL ENDOCRINOL, V47, pR1, DOI 10.1530/JME 11 0022
   Subbiah Vivek, 2011, Sarcoma, V2011, P686985, DOI 10.1155/2011/686985
   Sutter NB, 2007, SCIENCE, V316, P112, DOI 10.1126/science.1137045
   Suvasini R, 2011, J BIOL CHEM, V286, P25882, DOI 10.1074/jbc.M110.178012
   Tap WD, 2012, J CLIN ONCOL, V30, P1849, DOI 10.1200/JCO.2011.37.2359
NR 55
TC 77
Z9 88
U1 0
U2 12
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471 2407
J9 BMC CANCER
JI BMC Cancer
PD MAY 20
PY 2013
VL 13
AR 245
DI 10.1186/1471 2407 13 245
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 157GW
UT WOS:000319885100001
PM 23688189
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Tannir, N
   Jonasch, E
   Pagliaro, LC
   Mathew, P
   Siefker Radtke, A
   Rhines, L
   Lin, P
   Tibbs, R
   Do, KA
   Lin, SH
   Tu, SM
AF Tannir, Nizar
   Jonasch, Eric
   Pagliaro, Lance C.
   Mathew, Paul
   Siefker Radtke, Arlene
   Rhines, Laurence
   Lin, Patrick
   Tibbs, Rita
   Do, Kim Anh
   Lin, Sue Hwa
   Tu, Shi Ming
TI Pilot trial of bone targeted therapy with zoledronate, thalidomide, and
   interferon γ for metastatic renal cell carcinoma
SO CANCER
LA English
DT Article
DE renal cell carcinoma; bone metastasis; bisphosphonates; zoledronate
ID PHASE II; IN VITRO; RESORPTION; DISEASE; MARKERS
AB BACKGROUND. The purpose of the study was to evaluate the efficacy and safety of a bone targeted regimen consisting of zoledronate, thalidomide, and interferon gamma in patients with renal cell carcinoma and bone metastases.
   METHODS. Eligible patients had radiographic evidence of bone metastasis. Impending pathologic fractures or spinal cord compressions must have been controlled by surgery or radiation therapy before enrollment. Zoledronate (4 mg) was given intravenously every 4 weeks, thalidomide (300 mg) was given orally once a day, and interferon gamma (100 mu g) was given subcutaneously once a week. Patients were evaluated for time to skeletal related events, the appearance of calcification in osteolytic metastases, and levels of the bone formation/resorption markers.
   RESULTS. Fifteen patients were treated between November 2002 and November 2003; 12 had previously undergone surgery, radiation, or embolization for their bone metastases; 11 had more than 3 sites of bone involvement; and 9 also had nonosseous metastases in the lung, liver, lymph node, pancreas, or adrenal gland. The median time to progression was 8.3 weeks (range, 2.1 48 weeks). The median time to a skeletal related event was 12.0 weeks (range, 3.9 46.4 weeks). Two patients discontinued treatment because of adverse drug reactions (1 deep venous thrombosis and I myocardial infarction). Two patients experienced pain improvement and developed calcification in osseous metastases; these patients also showed favorable changes in bone marker levels.
   CONCLUSIONS. In this pilot study a bone targeted regimen combining zoledronate, thalidomide, and interferon gamma was well tolerated and might provide clinical benefit for a small subset of patients with renal cell carcinoma and bone metastases.
C1 Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77230 USA.
   Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA.
   Univ Texas, MD Anderson Canc Ctr, Dept Orthoped Surg, Houston, TX 77030 USA.
   Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.
   Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA.
   Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; University of Texas System;
   UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson
   Cancer Center; University of Texas System; UTMD Anderson Cancer Center;
   University of Texas System; UTMD Anderson Cancer Center
RP Tu, SM (通讯作者)，Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Unit 1374,1155 Herman Pressler,POB 304139, Houston, TX 77230 USA.
EM stu@mdanderson.org
OI Siefker Radtke, Arlene/0000 0002 6328 9599
CR [Anonymous], BREAST
   Aparicio A, 1998, LEUKEMIA, V12, P220, DOI 10.1038/sj.leu.2400892
   Atkins MB, 2004, CLIN CANCER RES, V10, p6342S, DOI 10.1158/1078 0432.CCR 040029
   Atkins MB, 2004, J CLIN ONCOL, V22, P909, DOI 10.1200/JCO.2004.08.185
   AULITZKY W, 1989, J CLIN ONCOL, V7, P1875, DOI 10.1200/JCO.1989.7.12.1875
   Coleman RE, 2005, J CLIN ONCOL, V23, P4925, DOI 10.1200/JCO.2005.06.091
   Corral LG, 1999, J IMMUNOL, V163, P380
   Daliani DD, 2002, CANCER, V95, P758, DOI 10.1002/cncr.10740
   Demers Laurence M., 2000, Cancer, V88, P2919, DOI 10.1002/1097 0142(20000615)88:12+<2919::AID CNCR7>3.0.CO;2 Z
   Eisen TG, 2000, ONCOLOGY NY, V14, P17
   ELLERHORST JA, 1994, J UROLOGY, V152, P841, DOI 10.1016/S0022 5347(17)32587 9
   ESCUDIER B, 2005, P AM SOC CLIN ONC AS
   Geitz H, 1996, IMMUNOPHARMACOLOGY, V31, P213, DOI 10.1016/0162 3109(95)00050 X
   Gleave ME, 1998, NEW ENGL J MED, V338, P1265, DOI 10.1056/NEJM199804303381804
   Haslett PAJ, 1998, J EXP MED, V187, P1885, DOI 10.1084/jem.187.11.1885
   Izumi M, 2001, CANCER, V91, P1487, DOI 10.1002/1097 0142(20010415)91:8<1487::AID CNCR1156>3.0.CO;2 2
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   Lipton A, 1998, EUR J CANCER, V34, P2021, DOI 10.1016/S0959 8049(98)00277 9
   Lipton A, 2003, CANCER, V98, P962, DOI 10.1002/cncr.11571
   MOTZER RJ, 2005, P AM SOC CLIN ONCOL
   NIELSEN OS, 1991, J CLIN ONCOL, V9, P509, DOI 10.1200/JCO.1991.9.3.509
   RINI B, 2005, P AM SOC CLIN ONCOL
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Savage AD, 1996, BLOOD, V88, P409
   Shipman CM, 1998, CANCER RES, V58, P5294
   SWANSON DA, 1981, UROLOGY, V18, P556, DOI 10.1016/0090 4295(81)90455 6
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Vinholes J, 1999, BRIT J CANCER, V80, P221, DOI 10.1038/sj.bjc.6690506
   Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491
NR 29
TC 11
Z9 11
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0008 543X
EI 1097 0142
J9 CANCER AM CANCER SOC
JI Cancer
PD AUG 1
PY 2006
VL 107
IS 3
BP 497
EP 505
DI 10.1002/cncr.22038
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 065KC
UT WOS:000239157800008
PM 16795067
OA Bronze
DA 2025 08 17
ER

PT J
AU Liu, ZY
   Au, MT
   He, TW
   Yang, B
   Liu, B
   Zhang, LM
   Luo, CX
   Rong, LM
   Wen, CY
AF Liu, Zhong Yu
   Au, Man Ting
   He, Tian Wei
   Yang, Bu
   Liu, Bin
   Zhang, Liang Ming
   Luo, Chun Xiao
   Rong, Li Min
   Wen, Chun Yi
TI Less Vertebral Bone Mass after Treatment with Macitentan in Mice: A
   Pilot Study
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID ENDOTHELIN 1; HYPERTENSION; OSTEOPOROSIS; EXPRESSION; CALCIUM
AB Purpose. Blood vessels and skeleton interact together. Endothelin 1 is a potent vasoconstrictor and also has an effect on bone metabolism. The dual antagonist to both endothelin 1 type A and B receptors, Macitentan, has been approved for clinical management of pulmonary arterial hypertension while little is known about the secondary effect of the drug on spine. We aimed to answer how vertebral bone mass responded to Macitentan treatment in mice. Methods. Sixteen male balb/c mice at 6 months were randomly assigned into 2 groups. Vehicle and Macitentan were administrated via intraperitoneal injection to Control group and Treatment group, respectively, for 4 months. At sacrifice, plasma endothelin 1 was evaluated with ELISA and vertebral bone mass was evaluated with Microcomputed Tomography and histological analysis. Results. We found higher plasma endothelin 1 level (p<0.01) and less vertebral bone mass (p<0.05) in Treatment group compared to controls. Moreover, less osteoblasts and more osteoclasts were observed in the vertebral trabecular bone in the Treatment group compared to controls, by immunohistochemistry of the cell specific markers. Conclusions. Treatment with Macitentan is associated with significant lower vertebral bone mass and therefore the secondary effect of dual antagonists to endothelin 1 receptors on the skeleton should be monitored and investigated in clinical practice. Both osteoblasts and osteoclasts may be involved while the molecular mechanism needs to be further explored.
C1 [Liu, Zhong Yu; He, Tian Wei; Yang, Bu; Liu, Bin; Zhang, Liang Ming; Luo, Chun Xiao; Rong, Li Min] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Spine Surg, Inst Drug Clin Trial Orthoped Dis, Guangzhou, Guangdong, Peoples R China.
   [Au, Man Ting; Wen, Chun Yi] Hong Kong Polytech Univ, Fac Engn, Interdisciplinary Div Biomed Engn, Hong Kong, Peoples R China.
C3 Sun Yat Sen University; Hong Kong Polytechnic University
RP Rong, LM (通讯作者)，Sun Yat Sen Univ, Affiliated Hosp 3, Dept Spine Surg, Inst Drug Clin Trial Orthoped Dis, Guangzhou, Guangdong, Peoples R China.; Wen, CY (通讯作者)，Hong Kong Polytech Univ, Fac Engn, Interdisciplinary Div Biomed Engn, Hong Kong, Peoples R China.
EM ronglm21@163.com; chunyi.wen@polyu.edu.hk
RI WEN, Chunyi/P 4168 2017; Li, Ming/H 5746 2019; Zhong,
   Wenzhao/C 3388 2008
OI WEN, Chunyi/0000 0003 1949 7822; Au, Man Ting/0000 0003 1786 6006; Rong,
   Limin/0000 0003 0373 7393; 
FU National Natural Science Foundation of China [8177090663]; Hong Kong
   Research Grant Council General Research Fund [HKU M17105314]
FX The authors thank Dorcas Li, Kekao Long, and Professor Helen Law for
   their assistance in histological processing. They also thank Michael
   Tai, Kelvin Tse, and Echo Wan for their technical support in mu CT
   analysis. This study was funded by the National Natural Science
   Foundation of China (No. 8177090663) and Hong Kong Research Grant
   Council General Research Fund (HKU M17105314).
CR Busnadiego O, 2015, J AM SOC NEPHROL, V26, P173, DOI 10.1681/ASN.2013070799
   Caplan AI, 2017, J ORTHOP RES, V35, P1151, DOI 10.1002/jor.23560
   Chan CKF, 2018, CELL, V175, P43, DOI 10.1016/j.cell.2018.07.029
   Clines GA, 2011, J BONE MINER RES, V26, P2523, DOI 10.1002/jbmr.450
   Coelho SC, 2018, HYPERTENSION, V71, P208, DOI 10.1161/HYPERTENSIONAHA.117.09925
   D'Amelio P, 2009, J Endocrinol Invest, V32, P6
   Grünhagen J, 2015, J BONE MINER RES, V30, P796, DOI 10.1002/jbmr.2412
   Grune J, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.01287 2018
   Gulhan I, 2009, GYNECOL ENDOCRINOL, V25, P674, DOI 10.1080/09513590903015429
   Hu LW, 2017, EXP CELL RES, V357, P25, DOI 10.1016/j.yexcr.2017.04.018
   Kitano Y, 1998, J BONE MINER RES, V13, P237, DOI 10.1359/jbmr.1998.13.2.237
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Lee MS, 2019, FASEB J, V33, P996, DOI 10.1096/fj.201800614R
   Manrique N, 2015, CLIN ORAL INVEST, V19, P1319, DOI 10.1007/s00784 014 1369 0
   Maruyama H, 2015, J HEART LUNG TRANSPL, V34, P468, DOI 10.1016/j.healun.2014.09.011
   Park JS, 2015, CALCIFIED TISSUE INT, V96, P417, DOI 10.1007/s00223 015 9972 x
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   Sin A, 2015, OSTEOARTHR CARTILAGE, V23, P516, DOI 10.1016/j.joca.2014.11.002
   Soon E, 2015, AM J RESP CRIT CARE, V192, P859, DOI 10.1164/rccm.201408 1509OC
   Szulc P, 2009, J BONE MINER RES, V24, P2023, DOI [10.1359/JBMR.090531, 10.1359/jbmr.090531]
   Towler DA, 2006, ANN NY ACAD SCI, V1068, P327, DOI 10.1196/annals.1346.036
   Tsuchihashi K, 2000, NEPHRON, V84, P13, DOI 10.1159/000045533
   Wilson J. L., 2018, PLOS ONE, V13
   Wu S, 2018, ATHEROSCLEROSIS, V272, P1, DOI 10.1016/j.atherosclerosis.2018.02.034
   YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0
   Zhen GH, 2013, NAT MED, V19, P704, DOI 10.1038/nm.3143
NR 26
TC 2
Z9 2
U1 0
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314 6133
EI 2314 6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2019
VL 2019
AR 2075968
DI 10.1155/2019/2075968
PG 6
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA HN5IS
UT WOS:000460218200001
PM 30911541
OA Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Cho, E
   Chen, Z
   Lee, J
   Lee, S
   Lee, TH
AF Cho, Eunjin
   Chen, Zhihao
   Lee, Jinkyung
   Lee, Sunwoo
   Lee, Tae Hoon
TI PSTP 3,5 Me Inhibits Osteoclast Differentiation and Bone Resorption
SO MOLECULES
LA English
DT Article
DE osteoclastogenesis; osteoporosis; PSTP; NFATc1
ID CELL CELL FUSION; TRANSMEMBRANE PROTEIN; DC STAMP; NFAT; OSTEOPOROSIS;
   ACTIVATION; INDUCTION
AB Osteogenesis is an orchestrated process regulated by osteoclastogenesis and osteoblastogenesis. Excessive osteoclastogenesis causes bone diseases, such as osteoporosis. Although a few drugs are effective in osteoporosis treatment, these drugs lead to side effects, including cellulitis, flatulence, and hypocalcemia. In this study, we reported a 2 (N Phenylmethylsulfonamido) N (2 (phenylthio)phenyl)propanamide (PSTP) compound, PSTP 3,5 Me, as a potential therapeutic agent for osteoporosis. Mouse bone marrow derived macrophages (BMMs) were differentiated into osteoclasts by receptor activator of nuclear factor kappa B ligand (RANKL) and macrophage colony stimulating factor (M CSF) in the presence of PSTP 3,5 Me. PSTP 3,5 Me inhibited osteoclast differentiation by reduced tartrate resistant acid phosphatase (TRAP) positive osteoclasts, and suppressed the expression of osteoclast marker genes, such as cathepsin K (Ctsk) and TRAP (Acp5). We investigated signaling pathways mediated by RANKL and its receptor, RANK, and found that PSTP 3,5 Me inhibits nucleus translocation of nuclear factor of activated T cell cytoplasmic 1 (NFATc1). Moreover, PSTP 3,5 Me inhibited F actin ring formation and mineral resorption. Overall, our data suggests that PSTP 3,5 Me attenuates osteoclast differentiation by blocking the activation of NFATc1.
C1 [Cho, Eunjin; Lee, Jinkyung; Lee, Tae Hoon] Chonnam Natl Univ, Dept Oral Biochem, Dent Sci Res Inst, Sch Dent, Gwangju 61186, South Korea.
   [Chen, Zhihao; Lee, Tae Hoon] Chonnam Natl Univ, Grad Sch, Dept Mol Med BK21plus, Gwangju 61186, South Korea.
   [Lee, Sunwoo] Chonnam Natl Univ, Dept Chem, Gwangju 61186, South Korea.
C3 Chonnam National University; Chonnam National University; Chonnam
   National University
RP Lee, TH (通讯作者)，Chonnam Natl Univ, Dept Oral Biochem, Dent Sci Res Inst, Sch Dent, Gwangju 61186, South Korea.; Lee, TH (通讯作者)，Chonnam Natl Univ, Grad Sch, Dept Mol Med BK21plus, Gwangju 61186, South Korea.
EM ag8414@gmail.com; chinaczhihao@gmail.com; wlsrud1945@naver.com;
   sunwoo@chonnam.ac.kr; thlee83@jnu.ac.kr
RI Lee, Sunwoo/E 2373 2012; Lee, Tae Hoon/AAR 3708 2021
OI Lee, Sunwoo/0000 0001 5079 3860; Lee, Jinkyung/0000 0003 1613 6490;
   ZHIHAO, CHEN/0000 0002 8433 5400; Lee, Tae Hoon/0000 0003 0105 1750
FU Basic Science Research Program of the National Research Foundation (NRF)
     Ministry of Science, ICT & Future Planning. South Korea
   [2017R1A2B2005938]
FX This work was supported by the Basic Science Research Program
   (2017R1A2B2005938) of the National Research Foundation (NRF) funded by
   the Ministry of Science, ICT & Future Planning. South Korea
CR Abbas Y. A., 1995, Egyptian Journal of Pharmaceutical Sciences, V36, P187
   Ahn SH, 2018, MOLECULES, V23, DOI 10.3390/molecules23123139
   Aliprantis AO, 2008, J CLIN INVEST, V118, P3775, DOI 10.1172/JCI35711
   Chiu YH, 2017, J CELL PHYSIOL, V232, P2538, DOI 10.1002/jcp.25638
   Cho E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113436
   Cicek M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017522
   Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092 8674(02)00699 2
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Goldfarb D.A., 2009, US Patent, Patent No. [20090163545 A1 20090625, 20090163545]
   Graef IA, 2001, CURR OPIN GENET DEV, V11, P505, DOI 10.1016/S0959 437X(00)00225 2
   Greig IR, 2013, BIOORG MED CHEM LETT, V23, P816, DOI 10.1016/j.bmcl.2012.11.067
   Huynh H, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003 018 0028 4
   Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703
   Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073
   Kiani A, 2004, J LEUKOCYTE BIOL, V76, P1057, DOI 10.1189/jlb.0404259
   Kim JH, 2019, BONE, V120, P432, DOI 10.1016/j.bone.2018.12.010
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kim JH, 2010, J BIOL CHEM, V285, P5224, DOI 10.1074/jbc.M109.042812
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kim N.D., 2017, Patent No. [KR 2017026798 A, 2017026798]
   Kolluri S.K., 2018, Pct. Int. Appl, Patent No. [WO 2018102766 A2, 2018102766]
   Li J, 2015, SCI REP UK, V5, DOI 10.1038/srep17605
   Milat F, 2016, MED J AUSTRALIA, V205, P185, DOI 10.5694/mja16.00568
   Miyamoto H, 2012, J BONE MINER RES, V27, P1289, DOI 10.1002/jbmr.1575
   Miyamoto Takeshi, 2011, Keio Journal of Medicine, V60, P101
   Nagy V, 2015, GERONTOLOGY, V61, P534, DOI 10.1159/000371845
   Narahara S, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 40240 2
   Palagano E, 2018, CURR OSTEOPOROS REP, V16, P13, DOI 10.1007/s11914 018 0415 2
   Park JH, 2017, MOL CELLS, V40, P706
   Peichl P, 2005, J BONE MINER METAB, V23, P243, DOI 10.1007/s00774 004 0591 2
   Rahman MM, 2015, BONE, V81, P392, DOI 10.1016/j.bone.2015.08.008
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Song I, 2009, FEBS LETT, V583, P2435, DOI 10.1016/j.febslet.2009.06.047
   Tabatabaei Malazy O, 2017, DARU, V25, DOI 10.1186/s40199 017 0167 z
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Trajanoska K, 2019, BONE, V126, P2, DOI 10.1016/j.bone.2019.04.005
   Ukon Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102557
   Vahle JL, 2004, TOXICOL PATHOL, V32, P426, DOI 10.1080/01926230490462138
   Winslow MM, 2006, DEV CELL, V10, P771, DOI 10.1016/j.devcel.2006.04.006
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   Yagi M, 2007, J BONE MINER RES, V22, P992, DOI 10.1359/JBMR.070401
   Yang P, 2013, J MED CHEM, V56, P2045, DOI 10.1021/jm3017464
   Zanker J, 2019, J AM GERIATR SOC, V67, P831, DOI 10.1111/jgs.15716
NR 46
TC 15
Z9 17
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1420 3049
J9 MOLECULES
JI Molecules
PD SEP
PY 2019
VL 24
IS 18
AR 3346
DI 10.3390/molecules24183346
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA JB8ON
UT WOS:000488830500138
PM 31540026
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Lin, ZM
   Liu, YT
   Xu, YS
   Yang, XQ
   Zhu, FH
   Tang, W
   He, SJ
   Zuo, JP
AF Lin, Ze Min
   Liu, Yu Ting
   Xu, Yan Sheng
   Yang, Xiao Qian
   Zhu, Feng Hua
   Tang, Wei
   He, Shi Jun
   Zuo, Jian Ping
TI Cervus and cucumis peptides ameliorates bone erosion in experimental
   arthritis by inhibiting osteoclastogenesis
SO LUPUS SCIENCE & MEDICINE
LA English
DT Article
ID NF KAPPA B; RHEUMATOID ARTHRITIS; METHOTREXATE; MECHANISM;
   DIFFERENTIATION; FUSION; RATS
AB Objective Rheumatoid arthritis is an autoimmune disease characterised by inflammation and bone loss, leading to joint destruction and deformity. The cervus and cucumis polypeptide (CCP) injection, one of the traditional Chinese medicine injections combined extracts from deer horn and sweet melon seeds, is widely used to treat arthritis and bone fracture in China. The present study investigated the therapeutic efficacy and mechanism of CCP on pathological immune cells and bone homoeostasis in rodent experimental arthritis.
   Methods The effects of CCP (4 mg/kg and 2 mg/kg) on clinical arthritis symptoms, bone erosion, proinflammatory cytokines and pathological immune cells induced by complete Freund's adjuvant was evaluated in male Sprague Dawley rats. The impacts of CCP (2 mg/kg) on joint erythema and swelling, production of pathogenic antibodies and the proportion of inflammatory cells were assessed in collagen induced arthritis (CIA) in DBA/1J mice. Regulation of osteoclastogenesis by CCP was observed in the murine macrophage like RAW264.7 cells treated with receptor activator of nuclear factor kappa B ligand (RANKL) and macrophage colony stimulating factor (M CSF).
   Results CCP administration significantly prevented disease progression in both adjuvant induced arthritis (AIA) rats and CIA mice. The therapeutic benefits were accompanied by reduction of paw oedema, reversed bone destruction, decreased pathological changes and osteoclast numbers in joints in AIA rats, as well as attenuated clinical manifestation and autoantibodies production in CIA mice. Meanwhile, in vitro supplemented of CCP concentration dependently inhibited RANKL/M CSF induced osteoclast differentiation, without showing cytotoxicity in RAW264.7 cells. Further, the presence of CCP dampened the augmented downstream signalling transduction as well as activation of osteoclast specific genes and transcription factors induced by RANKL/M CSF in RAW264.7 cells.
   Conclusion Our study suggested that the therapeutic effects of CCP in experimental arthritis could be attributed to its intervention on RANKL induced osteoclastogenesis signalling pathway in osteoclast precursor cells.
C1 [Lin, Ze Min; Liu, Yu Ting; Yang, Xiao Qian; Zhu, Feng Hua; Tang, Wei; He, Shi Jun; Zuo, Jian Ping] Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Lab Immunopharmacol, Shanghai, Peoples R China.
   [Liu, Yu Ting; Tang, Wei; Zuo, Jian Ping] Univ Chinese Acad Sci, Beijing, Peoples R China.
   [Xu, Yan Sheng; Zuo, Jian Ping] Shanghai Univ Tradit Chinese Med, Lab Immunol & Virol, Shanghai, Peoples R China.
C3 Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS;
   Chinese Academy of Sciences; University of Chinese Academy of Sciences,
   CAS; Shanghai University of Traditional Chinese Medicine
RP He, SJ; Zuo, JP (通讯作者)，Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Lab Immunopharmacol, Shanghai, Peoples R China.; Zuo, JP (通讯作者)，Univ Chinese Acad Sci, Beijing, Peoples R China.; Zuo, JP (通讯作者)，Shanghai Univ Tradit Chinese Med, Lab Immunol & Virol, Shanghai, Peoples R China.
EM heshijun@simm.ac.cn; jpzuo@simm.ac.cn
RI ; Lin, Zemin/ADR 2173 2022; Tang, Wei/IZQ 1283 2023
OI lin, zemin/0000 0002 3665 874X; 
FU 'Personalized Medicines Molecular Signature based Drug Discovery and
   Development", Strategic Priority Research Program of the Chinese Academy
   of Sciences [XDA12020107]; National Basic Research Program of China (973
   Program) [2014CB541906]; National Nature Science foundation of China
   [81402939]
FX This work was supported by the 'Personalized Medicines Molecular
   Signature based Drug Discovery and Development", Strategic Priority
   Research Program of the Chinese Academy of Sciences (grant number:
   XDA12020107); The National Basic Research Program of China (973 Program)
   (grant number: 2014CB541906) and the National Nature Science foundation
   of China (grant number: 81402939)
CR Amarasekara DS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e8
   [Anonymous], 2014, J NANOMATER
   Bendele A. M., 2001, Journal of Musculoskeletal & Neuronal Interactions, V1, P377
   BENSLAY DN, 1991, AGENTS ACTIONS, V34, P254, DOI 10.1007/BF01993296
   Boyle DL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084818
   Chang Y, 2011, RHEUMATOLOGY, V50, P862, DOI 10.1093/rheumatology/keq404
   Cronstein BN, 1996, ARTHRITIS RHEUM US, V39, P1951, DOI 10.1002/art.1780391203
   Han X, 2016, J ETHNOPHARMACOL, V194, P228, DOI 10.1016/j.jep.2016.09.008
   Huang H, 2006, CELL DEATH DIFFER, V13, P1879, DOI 10.1038/sj.cdd.4401882
   Iwasaki R, 2008, BIOCHEM BIOPH RES CO, V377, P899, DOI 10.1016/j.bbrc.2008.10.076
   Jung SM, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/263625
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kimpel D, 2003, ARTHRITIS RHEUM US, V48, P3557, DOI 10.1002/art.11424
   Mahmoud K, 2017, CURR OPIN RHEUMATOL, V29, P486, DOI 10.1097/BOR.0000000000000421
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   Min HK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138201
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   PEARSON CM, 1956, P SOC EXP BIOL MED, V91, P95, DOI 10.3181/00379727 91 22179
   Sato K, 2006, CURR OPIN RHEUMATOL, V18, P419, DOI 10.1097/01.bor.0000231912.24740.a5
   Schett G, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2110
   Scott DL, 2000, RHEUMATOLOGY, V39, P122, DOI 10.1093/rheumatology/39.2.122
   SEGAL R, 1990, SEMIN ARTHRITIS RHEU, V20, P190, DOI 10.1016/0049 0172(90)90060 S
   [陶海鹰 Tao Haiying], 2003, [中华实验外科杂志, Chinese Journal of Experimental Surgery], V20, P831
   Thouverey C., 2015, BONEKEY REP, V4
   van Eden W., 2001, CURR PROTOC IMMUNOL, DOI [10.1002/0471142735. im1504s19, DOI 10.1002/0471142735.IM1504S19]
   Wang WY, 2018, EUR J MED CHEM, V158, P502, DOI 10.1016/j.ejmech.2018.09.027
   Welsing PMJ, 2001, ARTHRITIS RHEUM, V44, P2009, DOI 10.1002/1529 0131(200109)44:9<2009::AID ART349>3.0.CO;2 L
   Y f ZHU., 2011, Journal of Clinical Orthopaedics, V14, P334
   Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329
   Yu J, 2016, J BIOL CHEM, V291, P20643, DOI 10.1074/jbc.M116.728303
   Zeng XZ, 2016, ACTA PHARMACOL SIN, V37, P255, DOI 10.1038/aps.2015.85
   Zhao DF, 2018, J PHARMACOL SCI, V137, P76, DOI 10.1016/j.jphs.2018.03.007
   Zhao G., 2005, Chinese Journal Of Bone And Joint Injury, V20, P537
   Zhao N, 2015, LIFE SCI, V143, P1, DOI 10.1016/j.lfs.2015.10.027
   Zhou R, 2006, J PHARMACOL EXP THER, V318, P35, DOI 10.1124/jpet.106.101113
   Zoma A, 2004, LUPUS, V13, P851, DOI 10.1191/0961203303lu2021oa
NR 37
TC 7
Z9 7
U1 3
U2 9
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2053 8790
J9 LUPUS SCI MED
JI Lupus Sci. Med.
PD JAN
PY 2019
VL 6
IS 1
AR UNSP e000331
DI 10.1136/lupus 2019 000331
PG 10
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA ID8JC
UT WOS:000471929000014
PM 31168402
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Hassani, A
   Avci, ÇB
   Kerdar, SN
   Amini, H
   Amini, M
   Ahmadi, M
   Sakai, S
   Bagca, BG
   Ozates, NP
   Rahbarghazi, R
   Khoshfetrat, AB
AF Hassani, Ayla
   Avci, Cigir Biray
   Kerdar, Sajed Nazif
   Amini, Hassan
   Amini, Meisam
   Ahmadi, Mahdi
   Sakai, Shinji
   Bagca, Bakiye Goker
   Ozates, Neslihan Pinar
   Rahbarghazi, Reza
   Khoshfetrat, Ali Baradar
TI Interaction of alginate with nano hydroxyapatite collagen using
   strontium provides suitable osteogenic platform
SO JOURNAL OF NANOBIOTECHNOLOGY
LA English
DT Article
DE Alginate Nanohydroxyapatite Collagen hydrogel; Ionic cross linkers;
   Osteogenic capacity; Cell dynamic growth; Critical sized bone
   regeneration
ID MESENCHYMAL STEM CELLS; TISSUE REGENERATION FABRICATION;
   MECHANICAL PROPERTIES; LADEN HYDROGELS; DRUG DELIVERY; BONE; SCAFFOLDS;
   MICROSPHERES; CALCIUM; BA2+
AB Background: Hydrogels based on organic/inorganic composites have been at the center of attention for the fabrication of engineered bone constructs. The establishment of a straightforward 3D microenvironment is critical to maintaining cell to cell interaction and cellular function, leading to appropriate regeneration. Ionic cross linkers, Ca2+, Ba2+, and Sr2+, were used for the fabrication of Alginate Nanohydroxyapatite Collagen (Alg nHA Col) microspheres, and osteogenic properties of human osteoblasts were examined in in vitro and in vivo conditions after 21 days.
   Results: Physicochemical properties of hydrogels illustrated that microspheres cross linked with Sr2+ had reduced swelling, enhanced stability, and mechanical strength, as compared to the other groups. Human MG 63 osteoblasts inside Sr2+ cross linked microspheres exhibited enhanced viability and osteogenic capacity indicated by mineralization and the increase of relevant proteins related to bone formation. PCR (Polymerase Chain Reaction) array analysis of the Wnt (Wingless related integration site) signaling pathway revealed that Sr2+ cross linked microspheres appropriately induced various signaling transduction pathways in human osteoblasts leading to osteogenic activity and dynamic growth. Transplantation of Sr2+ cross linked microspheres with rat osteoblasts into cranium with critical size defect in the rat model accelerated bone formation analyzed with micro CT and histological examination.
   Conclusion: Sr2+ cross linked Alg nHA Col hydrogel can promote functionality and dynamic growth of osteoblasts.
C1 [Hassani, Ayla; Kerdar, Sajed Nazif; Khoshfetrat, Ali Baradar] Sahand Univ Technol, Chem Engn Fac, Tabriz 513351996, Iran.
   [Hassani, Ayla; Kerdar, Sajed Nazif; Khoshfetrat, Ali Baradar] Sahand Univ Technol, Stem Cell & Tissue Engn Res Lab, Tabriz 513351996, Iran.
   [Avci, Cigir Biray; Bagca, Bakiye Goker; Ozates, Neslihan Pinar] Ege Univ, Fac Med, Dept Med Biol, Izmir, Turkey.
   [Amini, Hassan; Rahbarghazi, Reza] Tabriz Univ Med Sci, Stem Cell Res Ctr, Tabriz, Iran.
   [Amini, Hassan] Tabriz Univ Med Sci, Dept Gen & Vasc Surg, Tabriz, Iran.
   [Amini, Meisam] Tabriz Univ Med Sci, Student Res Comm, Tabriz, Iran.
   [Ahmadi, Mahdi] Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz, Iran.
   [Sakai, Shinji] Osaka Univ, Grad Sch Engn Sci, Dept Mat Sci & Engn, Div Chem Engn, Osaka 5608531, Japan.
   [Rahbarghazi, Reza] Tabriz Univ Med Sci, Fac Adv Med Sci, Dept Appl Cell Sci, Tabriz, Iran.
C3 Sahand University of Technology; Sahand University of Technology; Ege
   University; Tabriz University of Medical Science; Tabriz University of
   Medical Science; Tabriz University of Medical Science; Tabriz University
   of Medical Science; University of Osaka; Tabriz University of Medical
   Science
RP Khoshfetrat, AB (通讯作者)，Sahand Univ Technol, Chem Engn Fac, Tabriz 513351996, Iran.; Rahbarghazi, R (通讯作者)，Tabriz Univ Med Sci, Stem Cell Res Ctr, Tabriz, Iran.
EM rezarahbardvm@gmail.com; khoshfetrat@sut.ac.ir
RI ; Rahbarghazi, Reza/L 7238 2017; Goker Bagca, Bakiye/KBQ 4243 2024;
   Nazifkerdar, Sajed/HSF 1624 2023; ahmadi/M 4295 2017; Biray Avcı,
   Çığır/GWV 1665 2022; Özateş, Neslihan Pınar/HKN 9361 2023; Amini,
   Hassan/ABB 6351 2020
OI ahmadi, mahdi/0000 0002 0774 9378; Nazifkerdar,
   Sajed/0000 0003 1171 6971; 
FU Sahand University of Technology
FX This study was supported by a grant from Sahand University of
   Technology.
CR Aghdam SK, 2020, INT J BIOL MACROMOL, V156, P1270, DOI 10.1016/j.ijbiomac.2019.11.164
   Ahmad T, 2020, BIOMATERIALS, V230, DOI 10.1016/j.biomaterials.2019.119652
   Ahn S, 2012, J MATER CHEM, V22, P15901, DOI 10.1039/c2jm33310d
   Amini H, 2020, INT J BIOL MACROMOL, V161, P969, DOI 10.1016/j.ijbiomac.2020.06.018
   Bajpai SK, 2004, REACT FUNCT POLYM, V59, P129, DOI 10.1016/j.reactfunctpolym.2004.01.002
   Bi YG, 2019, MAT SCI ENG C MATER, V100, P576, DOI 10.1016/j.msec.2019.03.040
   Bianco S, 2017, REDOX BIOL, V12, P499, DOI 10.1016/j.redox.2017.03.015
   Bierhalz ACK, 2014, LWT FOOD SCI TECHNOL, V57, P494, DOI 10.1016/j.lwt.2014.02.021
   Bobbert FSL, 2017, J MATER CHEM B, V5, P6175, DOI 10.1039/c7tb00741h
   Chatterjee K, 2010, BIOMATERIALS, V31, P5051, DOI 10.1016/j.biomaterials.2010.03.024
   Chen MQ, 2011, BIOMATERIALS, V32, P7532, DOI 10.1016/j.biomaterials.2011.06.054
   Cheng Y, 2011, SOFT MATTER, V7, P5677, DOI 10.1039/c1sm05210a
   Cheshmedzhieva D, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11111576
   Ching SH, 2017, CRIT REV FOOD SCI, V57, P1133, DOI 10.1080/10408398.2014.965773
   Cui YX, 2006, J MICROENCAPSUL, V23, P663, DOI 10.1080/02652040600789245
   Dalheim MO, 2016, BIOMATERIALS, V80, P146, DOI 10.1016/j.biomaterials.2015.11.043
   De Witte TM, 2018, REGEN BIOMATER, V5, P197, DOI 10.1093/rb/rby013
   Detsch R., 2014, BioNanoMaterials, V15, P79, DOI [DOI 10.1515/BNM 2014 0007, 10.1515/bnm 2014 0007]
   Donati I, 2009, J PHYS CHEM B, V113, P12877, DOI 10.1021/jp902912m
   Ehara A, 2003, BIOMATERIALS, V24, P831, DOI 10.1016/S0142 9612(02)00411 8
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Firouzi N, 2020, J BIOMED MATER RES A, V108, P340, DOI 10.1002/jbm.a.36820
   Gasperini L, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2014.0817
   Geng Z, 2021, J MATER SCI TECHNOL, V79, P35, DOI 10.1016/j.jmst.2020.11.041
   Geng Z, 2021, BIOACT MATER, V6, P905, DOI 10.1016/j.bioactmat.2020.09.024
   Geng Z, 2018, BIOMATER SCI UK, V6, P2694, DOI 10.1039/c8bm00716k
   Goh CH, 2012, CARBOHYD POLYM, V88, P1, DOI 10.1016/j.carbpol.2011.11.012
   Goycoolea FM, 2011, MACROMOL CHEM PHYS, V212, P887, DOI 10.1002/macp.201000301
   Griffith LG, 2002, SCIENCE, V295, P1009, DOI 10.1126/science.1069210
   Guarino V, 2015, AIMS MATER SCI, V2, P497, DOI 10.3934/matersci.2015.4.497
   Harley BA, 2007, ACTA BIOMATER, V3, P463, DOI 10.1016/j.actbio.2006.12.009
   Hassani A, 2022, CARBOHYD POLYM, V277, DOI 10.1016/j.carbpol.2021.118807
   Helsen JA, 2010, BIOMATERIALS, P269
   Hutmacher DW, 2000, BIOMATERIALS, V21, P2529, DOI 10.1016/S0142 9612(00)00121 6
   JORIS SJ, 1971, J PHYS CHEM US, V75, P3172, DOI 10.1021/j100689a025
   Kachouie NN, 2010, ORGANOGENESIS, V6, P234, DOI 10.4161/org.6.4.12650
   Kaklamani G, 2014, J MECH BEHAV BIOMED, V36, P135, DOI 10.1016/j.jmbbm.2014.04.013
   Kesireddy V, 2016, J MATER CHEM B, V4, P6773, DOI [10.1039/c6tb00783j, 10.1039/C6TB00783J]
   Khatami N, 2019, J CELL BIOCHEM, V120, P15069, DOI 10.1002/jcb.28768
   Kim HY, 2017, J TISSUE ENG REGEN M, V11, P44, DOI 10.1002/term.1856
   Kim Y, 2013, J MATER CHEM B, V1, P3185, DOI 10.1039/c3tb20485e
   Li XM, 2017, POLYMERS BASEL, V9, DOI 10.3390/polym9080309
   Li XM, 2017, J MATER CHEM B, V5, P5753, DOI 10.1039/c7tb01350g
   Limmahakhun S, 2017, ADDIT MANUF, V15, P93, DOI 10.1016/j.addma.2017.03.010
   Lin KL, 2013, CHEM ENG J, V222, P49, DOI 10.1016/j.cej.2013.02.037
   Lin TH, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020326
   Lueckgen A, 2019, BIOMATERIALS, V217, DOI 10.1016/j.biomaterials.2019.119294
   MATHLOUTHI M, 1986, ADV CARBOHYD CHEM BI, V44, P7
   Mohan L, 2012, CERAM INT, V38, P3435, DOI 10.1016/j.ceramint.2011.12.056
   Montalbano G, 2018, MAT SCI ENG C MATER, V91, P236, DOI 10.1016/j.msec.2018.04.101
   Morch YA, 2006, BIOMACROMOLECULES, V7, P1471, DOI 10.1021/bm060010d
   Moshaverinia A, 2013, BIOMATERIALS, V34, P6572, DOI 10.1016/j.biomaterials.2013.05.048
   Nabavinia M, 2019, MAT SCI ENG C MATER, V97, P67, DOI 10.1016/j.msec.2018.12.033
   Nguyen TT, 2014, ANALYST, V139, P2482, DOI 10.1039/c3an00353a
   Nichol JW, 2010, BIOMATERIALS, V31, P5536, DOI 10.1016/j.biomaterials.2010.03.064
   Orive G, 2004, TRENDS BIOTECHNOL, V22, P87, DOI 10.1016/j.tibtech.2003.11.004
   Qin L, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 04019 7
   Rajzer I, 2014, MAT SCI ENG C MATER, V44, P183, DOI 10.1016/j.msec.2014.08.017
   Ramalingam M., 2013, Micro and Nanotechnologies in Engineering Stem Cells and Tissues, V1st
   Rana D, 2014, J BIOMATER TISS ENG, V4, P507, DOI 10.1166/jbt.2014.1206
   Rockwood DN, 2011, ACTA BIOMATER, V7, P144, DOI 10.1016/j.actbio.2010.07.020
   Sandvig I, 2015, J BIOMED MATER RES A, V103, P896, DOI 10.1002/jbm.a.35230
   Sergeeva A, 2019, MICROMACHINES BASEL, V10, DOI 10.3390/mi10060357
   Shi JB, 2012, J MATER CHEM, V22, P23952, DOI 10.1039/c2jm34862d
   Siffert R. S., 1951, Journal of Experimental Medicine, V93, P415, DOI 10.1084/jem.93.5.415
   Silverstein R.M., 1962, Journal of Chemical Education, V39, P546
   Slaughter BV, 2009, ADV MATER, V21, P3307, DOI 10.1002/adma.200802106
   STOKKE BT, 1991, MACROMOLECULES, V24, P4637, DOI 10.1021/ma00016a026
   Sugawara Y, 2005, BONE, V36, P877, DOI 10.1016/j.bone.2004.10.008
   Sun J., 2013
   Tanaka H, 2005, LIFE SCI, V77, P2273, DOI 10.1016/j.lfs.2005.02.022
   Taubenberger AV, 2019, ADV BIOSYST, V3, DOI 10.1002/adbi.201900128
   Terzi A, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 19786 0
   Truong NF, 2019, ACTA BIOMATER, V94, P160, DOI 10.1016/j.actbio.2019.02.054
   Tsou YH, 2016, BIOACT MATER, V1, P39, DOI 10.1016/j.bioactmat.2016.05.001
   Venkatesan J, 2014, ADV FOOD NUTR RES, V73, P45, DOI 10.1016/B978 0 12 800268 1.00004 4
   Vitale Brovarone C, 2009, J MATER SCI MATER M, V20, P809, DOI 10.1007/s10856 008 3635 7
   Wu XC, 2019, BIOMATER SCI UK, V7, P2675, DOI 10.1039/c9bm00230h
   Yamada KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006
   Yang F, 2011, STEM CELLS, V29, P981, DOI 10.1002/stem.646
   Zhang DW, 2018, BIOACT MATER, V3, P129, DOI 10.1016/j.bioactmat.2017.08.004
   Zhang YY, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/4025083
   Zigon Branc S, 2019, TISSUE ENG PT A, V25, P1369, DOI [10.1089/ten.TEA.2018.0237, 10.1089/ten.tea.2018.0237]
NR 83
TC 34
Z9 34
U1 3
U2 33
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1477 3155
J9 J NANOBIOTECHNOL
JI J. Nanobiotechnol.
PD JUN 28
PY 2022
VL 20
IS 1
AR 310
DI 10.1186/s12951 022 01511 9
PG 22
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Science & Technology   Other
   Topics
GA 2O4LY
UT WOS:000819032900002
PM 35765003
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kalajzic, Z
   Li, H
   Wang, LP
   Jiang, X
   Lamothe, K
   Adams, DJ
   Aguila, HL
   Rowe, DW
   Kalajzic, I
AF Kalajzic, Zana
   Li, Haitao
   Wang, Li Ping
   Jiang, Xi
   Lamothe, Katie
   Adams, Douglas J.
   Aguila, Hector L.
   Rowe, David W.
   Kalajzic, Ivo
TI Use of an alpha smooth muscle actin GFP reporter to identify an
   osteoprogenitor population
SO BONE
LA English
DT Article
DE myofibroblast; pericyte; osteoblast; adult progenitor cell; GFP
ID MESENCHYMAL STEM CELLS; HUMAN BONE MARROW; OSTEOBLAST LINEAGE;
   TRANSGENIC MICE; MONOCLONAL ANTIBODY; MURINE BONE; IN VITRO; TARGETED
   OVEREXPRESSION; HEPATIC FIBROSIS; GENE EXPRESSION
AB Identification of a reliable marker of skeletal precursor cells within calcified and Soft tissues remains a major challenge for the field. To address this, we used a transgenic model in which osteoblasts can be eliminated by pharmacological treatment. Following osteoblast ablation a dramatic increase in a population of alpha smooth muscle actin (alpha SMA) positive cells was observed. During early recovery phase from ablation we have detected cells with the Simultaneous expression of a SMA and a preosteoblastic 3.6GFP market, indicating the potential for transition of alpha SMA(+) cells towards osteoprogenitor lineage. Utilizing alpha SMAGFP transgene, alpha SMAGFP(+) positive cells were detected in the microvasculature and in the osteoprogenitor Population within bone marrow stromal cells. Osteogenic and adipogenic induction stimulated expression of bone and fat markers in the alpha SMAGFP(+) population derived from bone marrow or adipose tissue. In adipose tissue, alpha SMA(+) cells were localized within the smooth muscle cell layer and in pericytes. After in vitro expansion, alpha SMA(+)/CD45( )/Sca1(+) progenitors were highly enriched. Following cell sorting and transplantation of expanded pericyte/myofibroblast populations, donor derived differentiated osteoblasts and new bone formation was detected. Our results Show that cells with a pericyte/myofibroblast phenotype have the potential to differentiate into functional osteoblasts. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Li, Haitao; Rowe, David W.; Kalajzic, Ivo] Univ Connecticut, Ctr Hlth, Dept Reconstruct Sci, Farmington, CT 06032 USA.
   [Kalajzic, Zana; Wang, Li Ping; Jiang, Xi; Rowe, David W.; Kalajzic, Ivo] Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06032 USA.
   [Lamothe, Katie; Aguila, Hector L.] Univ Connecticut, Ctr Hlth, Dept Immunol, Farmington, CT 06032 USA.
   [Adams, Douglas J.] Univ Connecticut, Ctr Hlth, Dept Orthopaed Surg, Farmington, CT 06032 USA.
C3 University of Connecticut; University of Connecticut; University of
   Connecticut; University of Connecticut
RP Kalajzic, I (通讯作者)，Univ Connecticut, Ctr Hlth, Dept Reconstruct Sci, MC 3705,263 Farmington Ave, Farmington, CT 06032 USA.
EM ikalaj@neuron.uchc.edu
RI Adams, David/GMW 8541 2022
FU National Institutes of Health [R01 AR043457, R03 AR053275]; NIH
   [UDE016495A]
FX The authors would like to thank Dr. Sanai Sato and Dr. Jen Yue Tsai for
   providing us with the alpha SMAGFP transgenic mice. This work has been
   supported by grants from the National Institutes of Health
   (R01 AR043457) to DWR, (R03 AR053275) and Institutional support by NIH
   grant (UDE016495A) to IK.
CR Abedin M, 2004, CIRC RES, V95, P671, DOI 10.1161/01.RES.0000143421.27684.12
   Bi YM, 2007, NAT MED, V13, P1219, DOI 10.1038/nm1630
   Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19 3 180
   Bilic Curcic I, 2005, GENESIS, V43, P87, DOI 10.1002/gene.20156
   Bonyadi M, 2003, P NATL ACAD SCI USA, V100, P5840, DOI 10.1073/pnas.1036475100
   Bosch P, 2000, J ORTHOP RES, V18, P933, DOI 10.1002/jor.1100180613
   Bowen MA, 1997, EUR J IMMUNOL, V27, P1469, DOI 10.1002/eji.1830270625
   Bruder SP, 1998, J BONE MINER RES, V13, P655, DOI 10.1359/jbmr.1998.13.4.655
   Bruder SP, 1997, BONE, V21, P225, DOI 10.1016/S8756 3282(97)00127 0
   Carpino G, 2005, DIGEST LIVER DIS, V37, P349, DOI 10.1016/j.dld.2004.11.009
   CELESTE AJ, 1986, EMBO J, V5, P1885, DOI 10.1002/j.1460 2075.1986.tb04440.x
   CONNOR JM, 1982, BRIT J ORAL SURG, V20, P117, DOI 10.1016/0007 117X(82)90018 X
   Cowan CM, 2004, NAT BIOTECHNOL, V22, P560, DOI 10.1038/nbt958
   Meirelles LDS, 2006, J CELL SCI, V119, P2204, DOI 10.1242/jcs.02932
   Dacic S, 2001, J BONE MINER RES, V16, P1228, DOI 10.1359/jbmr.2001.16.7.1228
   Dennis JE, 2002, CELLS TISSUES ORGANS, V170, P73, DOI 10.1159/000046182
   Deschaseaux F, 2000, J CELL PHYSIOL, V184, P319, DOI 10.1002/1097 4652(200009)184:3<319::AID JCP5>3.0.CO;2 N
   Doherty MJ, 1998, J BONE MINER RES, V13, P828, DOI 10.1359/jbmr.1998.13.5.828
   Farrington Rock C, 2004, CIRCULATION, V110, P2226, DOI 10.1161/01.CIR.0000144457.55518.E5
   FEI J, 2006, J BONE MINER RES, V21
   GENOVESE C, 1984, BIOCHEMISTRY US, V23, P6210, DOI 10.1021/bi00320a049
   GRIGORIADIS AE, 1988, J CELL BIOL, V106, P2139, DOI 10.1083/jcb.106.6.2139
   Gronthos S, 1999, J BONE MINER RES, V14, P47, DOI 10.1359/jbmr.1999.14.1.47
   Gronthos S, 2003, J CELL SCI, V116, P1827, DOI 10.1242/jcs.00369
   Guyot C, 2006, INT J BIOCHEM CELL B, V38, P135, DOI 10.1016/j.biocel.2005.08.021
   Hinz B., 2007, AM J PATHOL
   Jahoda CAB, 2003, EXP DERMATOL, V12, P849, DOI 10.1111/j.0906 6705.2003.00161.x
   Jiang X, 2005, J HISTOCHEM CYTOCHEM, V53, P593, DOI 10.1369/jhc.4A6401.2005
   Joyner CJ, 1997, BONE, V21, P1, DOI 10.1016/S8756 3282(97)00074 4
   Kalajzic I, 2005, J BIOL CHEM, V280, P24618, DOI 10.1074/jbc.M413834200
   Kalajzic I, 2002, J BONE MINER RES, V17, P15, DOI 10.1359/jbmr.2002.17.1.15
   KALAJZIC I, 2007, J MUSCULOSK IN PRESS
   Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092 8674(01)00328 2
   Maeda S, 1999, ENDOCRINOLOGY, V140, P1815, DOI 10.1210/en.140.4.1815
   Marusic A, 2000, LAB INVEST, V80, P1761, DOI 10.1038/labinvest.3780186
   Mody N, 2003, J NUCL CARDIOL, V10, P177, DOI 10.1067/mnc.2003.0012
   Ogawa R, 2004, BIOCHEM BIOPH RES CO, V313, P871, DOI 10.1016/j.bbrc.2003.12.017
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Sacchetti B, 2007, CELL, V131, P324, DOI 10.1016/j.cell.2007.08.025
   Salingcarnboriboon R, 2003, EXP CELL RES, V287, P289, DOI 10.1016/S0014 4827(03)00107 1
   SAMBROOK J, 1989, MOL CLONING LAB MANU, V1
   Shi IM, 1999, J PATHOL, V189, P4, DOI 10.1002/(SICI)1096 9896(199909)189:1<4::AID PATH332>3.0.CO;2 P
   Shi S, 2003, J BONE MINER RES, V18, P696, DOI 10.1359/jbmr.2003.18.4.696
   Short B, 2003, ARCH MED RES, V34, P565, DOI 10.1016/j.arcmed.2003.09.007
   SIMMONS PJ, 1991, BLOOD, V78, P55
   SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810
   Stewart K, 2003, CELL TISSUE RES, V313, P281, DOI 10.1007/s00441 003 0762 9
   Stoeger T, 2002, GROWTH FACTORS, V20, P197, DOI 10.1080/0897719021000069579
   Towler DA, 1998, J BIOL CHEM, V273, P30427, DOI 10.1074/jbc.273.46.30427
   VANVLASSELAER P, 1994, BLOOD, V84, P753, DOI 10.1182/blood.V84.3.753.bloodjournal843753
   Visnjic D, 2001, J BONE MINER RES, V16, P2222, DOI 10.1359/jbmr.2001.16.12.2222
   Wang JW, 1997, J CLIN INVEST, V100, P1425, DOI 10.1172/JCI119663
   Wang LP, 2005, BLOOD, V106, P3650, DOI 10.1182/blood 2005 02 0582
   Welm BE, 2002, DEV BIOL, V245, P42, DOI 10.1006/dbio.2002.0625
   Yokota T, 2006, STEM CELLS, V24, P13, DOI 10.1634/stemcells.2004 0346
   YOUNG MF, 1994, MAMM GENOME, V5, P108, DOI 10.1007/BF00292337
   Zannettino ACW, 2008, J CELL PHYSIOL, V214, P413, DOI 10.1002/jcp.21210
   Zannettino ACW, 2003, J CELL BIOCHEM, V89, P56, DOI 10.1002/jcb.10481
   ZHANG K, 1994, AM J PATHOL, V145, P114
NR 59
TC 137
Z9 159
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD SEP
PY 2008
VL 43
IS 3
BP 501
EP 510
DI 10.1016/j.bone.2008.04.023
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 344UW
UT WOS:000258953800012
PM 18571490
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Park, JH
   Jeong, E
   Lin, J
   Ko, R
   Kim, JH
   Yi, S
   Choi, Y
   Kang, IC
   Lee, D
   Lee, SY
AF Park, Jin Hee
   Jeong, Eutteum
   Lin, Jingjing
   Ko, Ryeojin
   Kim, Ji Hee
   Yi, Sol
   Choi, Youngjin
   Kang, In Cheol
   Lee, Daekee
   Lee, Soo Young
TI RACK1 interaction with c Src is essential for osteoclast function
SO EXPERIMENTAL AND MOLECULAR MEDICINE
LA English
DT Article
ID PROTEIN KINASE C; SIGNAL TRANSDUCTION PATHWAY; BONE RESORPTION;
   RECEPTOR; ACTIVATION; INTEGRIN; COMPLEX; ORGANIZATION; REQUIREMENT;
   EXPRESSION
AB The scaffolding protein receptor for activated C kinase 1 (RACK1) mediates receptor activator of nuclear factor.. ligand (RANKL) dependent activation of p38 MAPK in osteoclast precursors; however, the role of RACK1 in mature osteoclasts is unclear. The aim of our study was to identify the interaction between RACK1 and c Src that is critical for osteoclast function. A RACK1 mutant protein (mutations of tyrosine 228 and 246 residues to phenylalanine; RACK1 Y228F/Y246F) did not interact with c Src. The mutant retained its ability to differentiate into osteoclasts; however, the integrity of the RANKL mediated cytoskeleton, bone resorption activity, and phosphorylation of c Src was significantly decreased. Importantly, lysine 152 (K152) within the Src homology 2 (SH2) domain of c Src is involved in RACK1 binding. The c Src K152R mutant (mutation of lysine 152 into arginine) impaired the resorption of bone by osteoclasts. These findings not only clarify the role of the RACK1 c Src axis as a key regulator of osteoclast function but will also help to develop new antiresorption therapies to prevent bone loss related diseases.
C1 [Park, Jin Hee; Jeong, Eutteum; Lin, Jingjing; Ko, Ryeojin; Kim, Ji Hee; Yi, Sol; Lee, Daekee; Lee, Soo Young] Ewha Womans Univ, Dept Life Sci, Seoul 03760, South Korea.
   [Park, Jin Hee; Jeong, Eutteum; Lin, Jingjing; Ko, Ryeojin; Lee, Soo Young] Ewha Womans Univ, Res Ctr Cellular Homeostasis, Seoul 03760, South Korea.
   [Choi, Youngjin] Hoseo Univ, Dept Food Sci & Technol, Asan 31499, South Korea.
   [Kang, In Cheol] BioChip Res Ctr, Coll Nat Sci, Dept Biol Sci, Asan 31499, South Korea.
   [Kang, In Cheol] Hoseo Univ, Asan 31499, South Korea.
C3 Ewha Womans University; Ewha Womans University; Hoseo University; Hoseo
   University
RP Lee, SY (通讯作者)，Ewha Womans Univ, Dept Life Sci, Seoul 03760, South Korea.; Lee, SY (通讯作者)，Ewha Womans Univ, Res Ctr Cellular Homeostasis, Seoul 03760, South Korea.
EM leesy@ewha.ac.kr
RI ; KIM, JEONGSEON/AAA 4643 2022; Lee, Daekee/HLG 9254 2023
OI Lin, Jingjing/0000 0002 9194 6154; Lee, Daekee/0000 0001 8130 2059; Kim,
   Jihee/0000 0002 4755 3169; 
FU National Research Foundation of Korea [2016R1A2B3010699,
   2012R1A5A1048236, 2018R1A6A3A11047668]
FX This work was supported by grants from the National Research Foundation
   of Korea (2016R1A2B3010699 and 2012R1A5A1048236 to S.Y.L. and
   2018R1A6A3A11047668 to J.H.P.).
CR Adams DR, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478 811X 9 22
   Alper Ö, 2005, CURR PHARM DESIGN, V11, P1119, DOI 10.2174/1381612053507576
   Armstrong AP, 2002, J BIOL CHEM, V277, P44347, DOI 10.1074/jbc.M202009200
   Besson A, 2002, J BIOL CHEM, V277, P22073, DOI 10.1074/jbc.M111644200
   Bird RJ, 2010, BIOCHEM J, V432, P207, DOI 10.1042/BJ20101010
   BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527
   Chang BY, 2002, ONCOGENE, V21, P7619, DOI 10.1038/sj.onc.1206002
   Choi HK, 2013, CELL RES, V23, P524, DOI 10.1038/cr.2013.33
   Destaing O, 2008, MOL BIOL CELL, V19, P394, DOI 10.1091/mbc.E07 03 0227
   Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111
   Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997
   Goldring SR, 2000, ARTHRITIS RES, V2, P33, DOI 10.1186/ar67
   HORNE WC, 1992, J CELL BIOL, V119, P1003, DOI 10.1083/jcb.119.4.1003
   Ikeda Kyoji, 2014, J Bone Metab, V21, P163, DOI 10.11005/jbm.2014.21.3.163
   Izawa T, 2012, MOL CELL BIOL, V32, P2943, DOI 10.1128/MCB.00077 12
   Jang HD, 2011, J BIOL CHEM, V286, P39043, DOI 10.1074/jbc.M111.256768
   Kiely PA, 2002, J BIOL CHEM, V277, P22581, DOI 10.1074/jbc.M201758200
   Kim H, 2009, J CLIN INVEST, V119, P813, DOI 10.1172/JCI36809
   Kim JM, 2005, CLIN EXP IMMUNOL, V140, P450, DOI 10.1111/j.1365 2249.2005.02804.x
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kim N, 2002, J EXP MED, V195, P201, DOI 10.1084/jem.20011681
   Ko R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7765
   Kobayashi T, 2004, MICROBES INFECT, V6, P1333, DOI 10.1016/j.micinf.2004.09.001
   Lakkakorpi PT, 1996, MICROSC RES TECHNIQ, V33, P171, DOI 10.1002/(SICI)1097 0029(19960201)33:2<171::AID JEMT7>3.0.CO;2 W
   LAKKAKORPI PT, 1991, J BONE MINER RES, V6, P817
   Lin J, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005867
   Lowell CA, 1996, GENE DEV, V10, P1845, DOI 10.1101/gad.10.15.1845
   Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655
   Mamidipudi V, 2007, ONCOGENE, V26, P2914, DOI 10.1038/sj.onc.1210091
   Mamidipudi V, 2009, ONCOGENE, V28, P4421, DOI 10.1038/onc.2009.293
   Martin T John, 2014, J Bone Metab, V21, P8, DOI 10.11005/jbm.2014.21.1.8
   McCahill A, 2002, MOL PHARMACOL, V62, P1261, DOI 10.1124/mol.62.6.1261
   Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200
   Park SJ, 2016, SCI REP UK, V6, DOI 10.1038/srep26186
   Pierce BG, 2014, BIOINFORMATICS, V30, P1771, DOI 10.1093/bioinformatics/btu097
   Playford MP, 2004, ONCOGENE, V23, P7928, DOI 10.1038/sj.onc.1208080
   Robles MS, 2010, SCIENCE, V327, P463, DOI 10.1126/science.1180067
   RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839
   Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181
   Sato S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255
   Schwartzberg PL, 1997, GENE DEV, V11, P2835, DOI 10.1101/gad.11.21.2835
   Shim JH, 2005, GENE DEV, V19, P2668, DOI 10.1101/gad.1360605
   Song I, 2009, FEBS LETT, V583, P2435, DOI 10.1016/j.febslet.2009.06.047
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Teitelbaum SL, 2011, ANN NY ACAD SCI, V1240, P14, DOI 10.1111/j.1749 6632.2011.06283.x
   Wang J, 2010, J NEUROSCI, V30, P10187, DOI 10.1523/JNEUROSCI.2268 10.2010
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097 2765(00)80232 4
   Zou W, 2007, J CELL BIOL, V176, P877, DOI 10.1083/jcb.200611083
NR 52
TC 20
Z9 21
U1 0
U2 6
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1226 3613
EI 2092 6413
J9 EXP MOL MED
JI Exp. Mol. Med.
PD JUL 29
PY 2019
VL 51
AR 86
DI 10.1038/s12276 019 0285 4
PG 9
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA IO3YE
UT WOS:000479315900002
PM 31358728
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Shi, B
   Lin, CC
   Lee, CJ
   Ning, DS
   Lin, CC
   Zhao, HW
   Yang, CS
   Deng, SX
   Chiu, YJ
   Wang, CC
AF Shi, Bin
   Lin, Che Chun
   Lee, Chia Jung
   Ning, De Shan
   Lin, Chao Chi
   Zhao, Hong Wei
   Yang, Chang Syun
   Deng, Shun Xin
   Chiu, Yung Jia
   Wang, Ching Chiung
TI Anti osteoporotic effects of Yi Mai Jian on bone metabolism of
   ovariectomized rats
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE anti osteoporotic effects; Eucommiae Folium; Astragali Radix; Ligustri
   Lucidi Fructus; Elaeagnus Fructus; Yi Mai Jian herbal formula
ID ELAEAGNUS ANGUSTIFOLIA; MODEL; DIFFERENTIATION; PREVENTION; MECHANISMS;
   EXTRACT; CELLS
AB Yi Mai Jian herbal formula (YMJ) is formulated with Eucommiae Folium, Astragali Radix, Ligustri Lucidi Fructus, and Elaeagnus Fructus to improve bone function in traditional Chinese medicine. The anti osteoporotic effects of YMJ in bone metabolism were evaluated in ovariectomized (OVX) rats. The skeletal structure of the femur and vertebrae was analyzed after treating OVX rats with YMJ for 114 days. The results showed that YMJ significantly increased the bone mineral density (BMD) and trabecular number (Tb. N) of the femur and 5th lumbar vertebrae and reduced trabecular separation (Tb. Sp). Moreover, trabecular bone volume/total tissue volume (BV/TV), bone stiffness, and maximum femur load were significantly increased. The serum concentrations of NTX1 and PYD were significantly decreased. According to these results, YMJ could ameliorate osteoporosis in ovariectomized rats. Eucommiae Folium and Elaeagnus Fructus inhibited osteoclast differentiation, Ligustri Lucidi Fructus inhibited calcium reabsorption, Astragali Radix stimulated osteoblast proliferation, and Astragali Radix and Eucommiae Folium stimulated mineralization. Therefore, the combination of the four herbs into one formula, YMJ, could alleviate bone remodeling caused by low estrogen levels. We suggest that YMJ could be a healthy food candidate for preventing post menopausal osteoporosis.
C1 [Shi, Bin; Ning, De Shan; Zhao, Hong Wei] Infinitus China Co Ltd, Guangxhou, Guangdong, Peoples R China.
   [Lin, Che Chun; Lee, Chia Jung; Deng, Shun Xin; Wang, Ching Chiung] Taipei Med Univ, Coll Pharm, PhD Program Clin Drug Dev Herbal Med, Guangzhou, Taiwan.
   [Lee, Chia Jung; Wang, Ching Chiung] Taipei Med Univ, Grad Inst Pharmacognosy, Coll Pharm, Taipei, Taiwan.
   [Lee, Chia Jung; Wang, Ching Chiung] Taipei Med Univ Hosp, Tradit Herbal Med Res Ctr, Taipei, Taiwan.
   [Lin, Chao Chi; Yang, Chang Syun; Chiu, Yung Jia; Wang, Ching Chiung] Taipei Med Univ, Coll Pharm, Sch Pharm, Taipei, Taiwan.
C3 Taipei Medical University; Taipei Medical University; Taipei Medical
   University Hospital; Taipei Medical University
RP Wang, CC (通讯作者)，Taipei Med Univ, Coll Pharm, PhD Program Clin Drug Dev Herbal Med, Guangzhou, Taiwan.; Wang, CC (通讯作者)，Taipei Med Univ, Grad Inst Pharmacognosy, Coll Pharm, Taipei, Taiwan.; Wang, CC (通讯作者)，Taipei Med Univ Hosp, Tradit Herbal Med Res Ctr, Taipei, Taiwan.; Wang, CC (通讯作者)，Taipei Med Univ, Coll Pharm, Sch Pharm, Taipei, Taiwan.
EM crystal@tmu.edu.tw
RI lee, chia jung/JBI 9734 2023; Chiu, Ynug Jia/JXN 4182 2024
FU Herbiotek Co., Ltd. [A 107 021]
FX The author(s) declare that financial support was received for the
   research, authorship, and/or publication of this article. This work was
   supported by grants from Herbiotek Co., Ltd. (Project code: A 107 021).
   The funder was not involved in the study design, collection, analysis,
   interpretation of data, the writing of this article, or the decision to
   submit it for publication.
CR Bian Q, 2011, PHARMAZIE, V66, P63, DOI 10.1691/ph.2011.0219
   Chen BB, 2017, MOLECULES, V22, DOI 10.3390/molecules22091469
   Chen HL, 2015, OSTEOPOROSIS INT, V26, P589, DOI 10.1007/s00198 014 2908 x
   Chen XH, 2019, EUR REV MED PHARMACO, V23, P6352, DOI 10.26355/eurrev_201907_18459
   COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Dabbaghmanesh MH, 2017, AVICENNA J PHYTOMEDI, V7, P261
   Delaisse JM, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.644503
   Fernandes Marina, 2013, J Conserv Dent, V16, P4, DOI 10.4103/0972 0707.105290
   Gong XF, 2021, OSTEOPOROSIS INT, V32, P1785, DOI 10.1007/s00198 021 05849 y
   Guan MQ, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/3641317
   Hertrampf T, 2009, TOXICOL LETT, V184, P198, DOI 10.1016/j.toxlet.2008.11.006
   Huo J., 2016, Genetics and Molecular Research, V15, P15049169
   Jurado S, 2023, REV OSTEOPOR METAB M, V15, P6, DOI [10.20960/RevOsteoporosMetabMiner.00005, 10.20960/revosteoporosmetabminer.00005]
   Kim JH, 2019, INT J MOL MED, V44, P913, DOI 10.3892/ijmm.2019.4269
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Kuo TR, 2017, BIOMARK RES, V5, DOI 10.1186/s40364 017 0097 4
   Kuroda Y, 2012, WORLD J ORTHOP, V3, P167, DOI 10.5312/wjo.v3.i11.167
   Lee GH, 2018, BIOMED PHARMACOTHER, V97, P1164, DOI 10.1016/j.biopha.2017.11.035
   Li DJ, 2020, EUR REV MED PHARMACO, V24, P5905, DOI 10.26355/eurrev_202006_21483
   Li LY, 2018, ADV EXP MED BIOL, V1086, P199, DOI 10.1007/978 981 13 1117 8_13
   Liu L, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00228
   Liu M, 2018, INT J BIOL MACROMOL, V107, P137, DOI 10.1016/j.ijbiomac.2017.08.151
   Liu ZS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116194
   Ma B, 2012, ACTA PHARMACOL SIN, V33, P479, DOI 10.1038/aps.2011.177
   Mousavi S, 2023, MOL BIOL REP, V50, P3693, DOI 10.1007/s11033 023 08311 w
   Nakashima T, 2011, ANN NY ACAD SCI, V1240, pE13, DOI 10.1111/j.1749 6632.2011.06373.x
   Nozaki R, 2020, BIOMED RES TOKYO, V41, P139, DOI 10.2220/biomedres.41.139
   Ou L, 2019, ACTA CIR BRAS, V34, DOI 10.1590/s0102 865020190050000002
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Soysa NS, 2019, BONE REP, V11, DOI 10.1016/j.bonr.2019.100225
   Szulc P, 2018, BEST PRACT RES CL EN, V32, P725, DOI 10.1016/j.beem.2018.05.003
   Tehranizadeh ZA, 2016, BIOIMPACTS, V6, P155, DOI 10.15171/bi.2016.22
   Vakili S, 2021, J CELL PHYSIOL, V236, P3495, DOI 10.1002/jcp.30087
   Xiao Ya Ping, 2018, Zhongguo Zhong Yao Za Zhi, V43, P21, DOI 10.19540/j.cnki.cjcmm.20171106.002
   Yousefzadeh N, 2020, EXCLI J, V19, P89, DOI 10.17179/excli2019 1990
   Zhang J, 2017, BIOCHEM BIOPH RES CO, V482, P289, DOI 10.1016/j.bbrc.2016.11.056
   [张立超 Zhang Lichao], 2013, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V19, P217
   Zhao X, 2020, FOOD SCI NUTR, V8, P4897, DOI 10.1002/fsn3.1779
NR 39
TC 2
Z9 2
U1 1
U2 8
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD MAR 28
PY 2024
VL 15
AR 1326415
DI 10.3389/fphar.2024.1326415
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA NI3E2
UT WOS:001199776100001
PM 38606179
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Xia, TS
   Dong, X
   Jiang, YP
   Lin, LY
   Dong, ZM
   Shen, Y
   Xin, HL
   Zhang, QY
   Qin, LP
AF Xia, Tianshuang
   Dong, Xin
   Jiang, Yiping
   Lin, Liuyue
   Dong, Zhimin
   Shen, Yi
   Xin, Hailiang
   Zhang, Qiaoyan
   Qin, Luping
TI Metabolomics Profiling Reveals Rehmanniae Radix Preparata Extract
   Protects against Glucocorticoid Induced Osteoporosis Mainly via
   Intervening Steroid Hormone Biosynthesis
SO MOLECULES
LA English
DT Article
DE Rehmanniae Radix Preparata; glucocorticoid induced osteoporosis;
   metabolomics; osteoblast; steroid hormone biosynthesis
ID OSTEOBLAST; PREGNENOLONE; AROMATASE; PATHWAY
AB Rehmanniae Radix Preparata (RR), the dry rhizome of Rehmannia glutinosa Libosch., is a traditional herbal medicine for improving the liver and kidney function. Ample clinical and pharmacological experiments show that RR can prevent post menopausal osteoporosis and senile osteoporosis. In the present study, in vivo and in vitro experiments, as well as a UHPLC Q/TOF MS based metabolomics study, were used to explore the preventing effect of RR on glucocorticoid induced osteoporosis (GIOP) and its underlying mechanisms. As a result, RR significantly enhanced bone mineral density (BMD), improved the micro architecture of trabecular bone, and intervened in biochemical markers of bone metabolism in dexamethasone (DEX) treated rats. For the in vitro experiment, RR increased the cell proliferation and alkaline phosphatase (ALP) activity, enhanced the extracellular matrix mineralization level, and improved the expression of runt related transcription factor 2 (RUNX2) and osteopontin (OPN) in DEX injured osteoblasts. For the metabolomics study, a total of 27 differential metabolites were detected in the DEX group vs. the control group, of which 10 were significantly reversed after RR treatment. These metabolites were majorly involved in steroid hormone biosynthesis, sex steroids regulation, and amino acid metabolism. By metabolic pathway and Western blotting analysis, it was further ascertained that RR protected against DEX induced bone loss, mainly via interfering steroid hormone biosynthesis, as evidenced by the up regulation of cytochrome P450 17A1 (CYP17A1) and aromatase (CYP19A1), and the down regulation of 11 hydroxysteroid dehydrogenase (HSD11B1). Collectively, these results indicated that RR had a notable preventing effect on GIOP, and the action mechanism might be related to steroid hormone biosynthesis.
C1 [Xia, Tianshuang; Dong, Xin; Jiang, Yiping; Lin, Liuyue; Dong, Zhimin; Shen, Yi; Xin, Hailiang; Zhang, Qiaoyan; Qin, Luping] Second Mil Med Univ, Sch Pharm, Dept Pharmacognosy, Shanghai 200433, Peoples R China.
   [Zhang, Qiaoyan; Qin, Luping] Zhejiang Chinese Med Univ, Sch Pharm, Hangzhou 310053, Zhejiang, Peoples R China.
C3 Naval Medical University; Zhejiang Chinese Medical University
RP Xin, HL; Zhang, QY; Qin, LP (通讯作者)，Second Mil Med Univ, Sch Pharm, Dept Pharmacognosy, Shanghai 200433, Peoples R China.; Zhang, QY; Qin, LP (通讯作者)，Zhejiang Chinese Med Univ, Sch Pharm, Hangzhou 310053, Zhejiang, Peoples R China.
EM xiatianshuang@smmu.edu.cn; dongxinsmmu@126.com; msjyp@163.com;
   linliuyue2016@163.com; dongzhiminedu@163.com; 18065148122@163.com;
   hailiangxin@163.com; zqy1965@163.com; qinsmmu@126.com
RI Shen, Yinan/NEU 1436 2025
FU National High tech R&D Program of China (863 Program) [2013AA093003];
   National Natural Science Foundation of China [U1505226, U1603283]
FX This research was funded by National High tech R&D Program of China (863
   Program, Grant no. 2013AA093003), and National Natural Science
   Foundation of China (Grant no. U1505226, U1603283).
CR Abrahamsen B, 2010, CALCIFIED TISSUE INT, V86, P421, DOI 10.1007/s00223 010 9364 1
   Asri SFM, 2016, MOLECULES, V21, DOI 10.3390/molecules21111523
   Atanasov Atanas G., 2007, Endocrine Metabolic & Immune Disorders Drug Targets, V7, P125, DOI 10.2174/187153007780832082
   Bulun SE, 2014, FERTIL STERIL, V101, P323, DOI 10.1016/j.fertnstert.2013.12.022
   Carson JA, 2015, BONE, V80, P67, DOI 10.1016/j.bone.2015.04.015
   Chao J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096969
   Eijken M, 2005, MOL ENDOCRINOL, V19, P621, DOI 10.1210/me.2004 0212
   Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138
   Gao ZP, 2000, J SHANXI COLL TRADIT, P1
   Ge J., 2016, CHIN J INTEGR MED, V24, P1
   Gu G, 2005, APOPTOSIS, V10, P583, DOI 10.1007/s10495 005 1893 0
   Khosla S, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031211
   Liu CY, 2017, J ETHNOPHARMACOL, V198, P351, DOI 10.1016/j.jep.2017.01.021
   Mak W, 2009, CALCIFIED TISSUE INT, V85, P538, DOI 10.1007/s00223 009 9303 1
   Marx CE, 2011, NEUROSCIENCE, V191, P78, DOI 10.1016/j.neuroscience.2011.06.076
   Matsuzaki Y, 2006, CURR PHARM DESIGN, V12, P3411, DOI 10.2174/138161206778194015
   Maurya SW, 2017, BIOORG MED CHEM LETT, V27, P1390, DOI 10.1016/j.bmcl.2017.02.004
   Miller WL, 2002, MOL CELL ENDOCRINOL, V198, P7, DOI 10.1016/S0303 7207(02)00363 5
   Oh KO, 2003, CLIN CHIM ACTA, V334, P185, DOI 10.1016/S0009 8981(03)00238 9
   Pozzi S, 2007, LEUKEMIA LYMPHOMA, V48, P56, DOI 10.1080/10428190600977690
   Seibel MJ, 2013, LANCET DIABETES ENDO, V1, P59, DOI 10.1016/S2213 8587(13)70045 7
   Somner J, 2004, J CLIN ENDOCR METAB, V89, P344, DOI 10.1210/jc.2003 030164
   Vimalraj S, 2015, INT J BIOL MACROMOL, V78, P202, DOI 10.1016/j.ijbiomac.2015.04.008
   Weinstein RS, 2012, ENDOCRIN METAB CLIN, V41, P595, DOI 10.1016/j.ecl.2012.04.004
   Xia BJ, 2014, J ETHNOPHARMACOL, V153, P133, DOI 10.1016/j.jep.2014.01.040
   Yang Y, 2017, J ETHNOPHARMACOL, V201, P91, DOI 10.1016/j.jep.2017.02.033
   Yantsevich AV, 2014, FEBS J, V281, P1700, DOI 10.1111/febs.12733
   Yodthong T, 2018, MOLECULES, V23, DOI 10.3390/molecules23123086
NR 28
TC 33
Z9 40
U1 6
U2 57
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1420 3049
J9 MOLECULES
JI Molecules
PD JAN 2
PY 2019
VL 24
IS 2
AR 253
DI 10.3390/molecules24020253
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA HJ4IH
UT WOS:000457137200039
PM 30641909
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Liu, GX
   Li, BQ
   Li, J
   Dong, JX
   Baulin, V
   Feng, YJ
   Jia, DC
   Petrov, YV
   Tsivadze, AY
   Zhou, Y
AF Liu, Guanxiong
   Li, Baoqiang
   Li, Jie
   Dong, Jiaxin
   Baulin, Vladimir
   Feng, Yujie
   Jia, Dechang
   Petrov, Yuri V.
   Tsivadze, Aslan Yu
   Zhou, Yu
TI EGTA Derived Carbon Dots with Bone Targeting Ability: Target Oriented
   Synthesis and Calcium Affinity
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article; Early Access
DE carbon dots; chelating ability; bone targeting; free
   radicalpolymerization; hydrothermal carbonization
ID ONE STEP SYNTHESIS; HYDROTHERMAL TREATMENT; YIELD SYNTHESIS; CHAIN
   TRANSFER; NANODOTS; GREEN; NANOPARTICLES; BISPHOSPHONATES; STABILITY;
   MECHANISM
AB Thebone targeting mechanism of clinic bisphosphonate typedrugs,such as alendronate, risedronate, and ibandronate, relies on chelatedcalcium ions on the surface of the bone mineralized matrix for thetreatment of osteoporosis. EGTA with aminocarboxyl chelating ligandscan specifically chelate calcium ions. Inspired by the bone targetingmechanism of bisphosphonates, we hypothesize that EGTA derived carbondots (EGTA CDs) hold bone targeting ability. For the target orientedsynthesis of EGTA CDs and to endow CDs with bone targeting, we designedcalcium ion chelating agents as precursors, including aminocarboxylchelating agents (EGTA and EDTA) and bisphosphonate agents (ALN andHEDP) for the target oriented synthesis of aminocarboxyl derived CDs(EGTA CDs and EDTA CDs) and bisphosphonate derived CDs (ALN CDs andHEDP CDs) with high synthetic yield. The synthetic yield of EGTA CDsreached 87.6%. Aminocarboxyl derived CDs and bisphosphonate derivedCDs retain the chelation ability of calcium ions and can specificallybind calcium ions. The chemical environment bone targeting value coordinationconstant K and chelation sites of EGTA CDs were 6.48 x 10(4) M 1 and 4.12, respectively. A novel methodwas established to demonstrate the bone targeting capability of chelate functionalizedcarbon dots using fluorescence quenching in a simulated bone traumamicroenvironment. EGTA CDs exhibit superior bone targeting abilitycompared with other aminocarboxyl derived CDs and bisphosphonate derivedCDs. EGTA CDs display exceptional specificity toward calcium ionsand better bone affinity than ALN CDs, suggesting their potentialas novel bone targeting drugs. EGTA CDs with strong calcium ion chelatingability have calcium ion affinity in simulated body fluid and bone targetingability in a simulated bone trauma microenvironment. These findingsoffer new avenues for the development of advanced bone targeting strategies.
C1 [Liu, Guanxiong; Li, Baoqiang; Li, Jie; Dong, Jiaxin; Feng, Yujie; Jia, Dechang; Zhou, Yu] Harbin Inst Technol, Inst Adv Ceram, State Key Lab Urban Water Resource & Environm, Harbin 150001, Peoples R China.
   [Baulin, Vladimir] Russian Acad Sci, Inst Physiol Act Cpds, Chernogolovka 142432, Russia.
   [Li, Baoqiang; Jia, Dechang; Zhou, Yu] Harbin Inst Technol, MIIT Key Lab Adv Struct Funct Integrat Mat & Green, Harbin 150001, Peoples R China.
   [Li, Baoqiang; Petrov, Yuri V.] St Petersburg State Univ, Lab Dynam & Extreme Characterist Promising Nanostr, St Petersburg 199034, Russia.
   [Tsivadze, Aslan Yu] Russian Acad Sci, Inst Phys Chem & Electrochem, Moscow 119071, Russia.
C3 Harbin Institute of Technology; Russian Academy of Sciences; Institute
   of Physiologically Active Compounds of the Russian Academy of Sciences;
   Harbin Institute of Technology; Saint Petersburg State University;
   Russian Academy of Sciences; Frumkin Institute of Physical Chemistry &
   Electrochemistry
RP Li, BQ (通讯作者)，Harbin Inst Technol, Inst Adv Ceram, State Key Lab Urban Water Resource & Environm, Harbin 150001, Peoples R China.; Li, BQ (通讯作者)，Harbin Inst Technol, MIIT Key Lab Adv Struct Funct Integrat Mat & Green, Harbin 150001, Peoples R China.; Li, BQ (通讯作者)，St Petersburg State Univ, Lab Dynam & Extreme Characterist Promising Nanostr, St Petersburg 199034, Russia.
EM libq@hit.edu.cn
RI Li, Baoqiang/J 4526 2012; Petrov, Yuri/K 4577 2013; Baulin,
   Vladimir/AAB 8593 2019
OI Li, Baoqiang/0000 0003 0278 4542; 
FU National Natural Science Foundation of China [52061135204, 51972086];
   Heilongjiang Provincial Key Ramp;D projects [2022ZX02C24]; Ministry of
   Science and Higher Education of the Russian Federation
   [075 15 2022 1114]; Key Laboratory of Bio based Material Science amp;
   Technology (Northeast Forestry University) Ministry of Education
   [SWZ ZD202103]; State Key Laboratory of Urban Water Resource and
   Environment of Harbin Institute of Technology [2022TS21];
   Interdisciplinary Research Foundation of HIT [IR2021105]; Russian
   Science Foundation [21 43 00020]; China Scholarship Council
   [202006120197]
FX This work was financially supported by the National Natural Science
   Foundation of China (52061135204 and 51972086), Heilongjiang Provincial
   Key R & D projects (2022ZX02C24), Ministry of Science and Higher
   Education of the Russian Federation (075 15 2022 1114), Key Laboratory
   of Bio based Material Science & Technology (Northeast Forestry
   University) Ministry of Education (SWZ ZD202103), State Key Laboratory
   of Urban Water Resource and Environment of Harbin Institute of
   Technology (2022TS21), Interdisciplinary Research Foundation of HIT
   (IR2021105), Russian Science Foundation (21 43 00020), and China
   Scholarship Council (202006120197).
CR Ankireddy SR, 2018, SENSOR ACTUAT B CHEM, V255, P3425, DOI 10.1016/j.snb.2017.09.172
   BARRA M, 1990, J AM CHEM SOC, V112, P8075, DOI 10.1021/ja00178a034
   BENESI HA, 1949, J AM CHEM SOC, V71, P2703, DOI 10.1021/ja01176a030
   Bhunia SK, 2013, SCI REP UK, V3, DOI 10.1038/srep01473
   Boskey AL, 2007, ELEMENTS, V3, P385, DOI 10.2113/GSELEMENTS.3.6.385
   Chen BS, 2013, NANOSCALE, V5, P1967, DOI 10.1039/c2nr32675b
   Cheng J, 2016, RSC ADV, V6, P37189, DOI 10.1039/c5ra27808b
   Chiem LT, 2006, J COLLOID INTERF SCI, V297, P54, DOI 10.1016/j.jcis.2005.10.037
   Chuang EY, 2013, J CONTROL RELEASE, V169, P296, DOI 10.1016/j.jconrel.2012.11.011
   Consoli GML, 2023, ACS APPL MATER INTER, DOI 10.1021/acsami.2c22500
   Ding H, 2020, CARBON, V167, P322, DOI 10.1016/j.carbon.2020.06.024
   Ding H, 2016, ACS NANO, V10, P484, DOI 10.1021/acsnano.5b05406
   Ding H, 2015, RSC ADV, V5, P66528, DOI 10.1039/c5ra11796h
   Dong JX, 2022, CARBON, V199, P151, DOI 10.1016/j.carbon.2022.07.035
   Dordevic L, 2022, NAT NANOTECHNOL, V17, P112, DOI 10.1038/s41565 021 01051 7
   Ebrahimpour A, 1995, MINERAL SCALE FORMATION AND INHIBITION, P295
   Ezati P, 2022, SUSTAIN MATER TECHNO, V32, DOI 10.1016/j.susmat.2022.e00397
   Fiori F, 2022, MATERIALS, V15, DOI 10.3390/ma15072395
   Garbuz DS, 2008, J BONE JOINT SURG AM, V90A, P1090, DOI 10.2106/JBJS.G.00415
   Ge SG, 2015, NEW J CHEM, V39, P2380, DOI 10.1039/c4nj01783h
   Godwin SL, 2002, BONE, V30, P559, DOI 10.1016/S8756 3282(01)00700 1
   Gottschalk F, 2013, ENVIRON POLLUT, V181, P287, DOI 10.1016/j.envpol.2013.06.003
   Hegde S, 2006, COLLOID SURFACE A, V280, P116, DOI 10.1016/j.colsurfa.2006.01.041
   HOLLOWAY JH, 1960, ANAL CHEM, V32, P249, DOI 10.1021/ac60158a033
   Hu GZ, 2023, CARBON, V203, P1, DOI 10.1016/j.carbon.2022.11.048
   Hu YF, 2019, ANAL BIOANAL CHEM, V411, P3603, DOI 10.1007/s00216 019 01842 x
   Huang P, 2023, ACS APPL MATER INTER, P6735, DOI 10.1021/acsami.2c18859
   Kang ZH, 2019, NANOSCALE, V11, P19214, DOI 10.1039/c9nr05647e
   Karimi S, 2021, NEW J CHEM, V45, P6397, DOI 10.1039/d0nj06261h
   KOSTYUK PG, 1977, J PHYSIOL LONDON, V270, P569, DOI 10.1113/jphysiol.1977.sp011969
   Ladomenou K, 2021, SUSTAIN ENERG FUELS, V5, P449, DOI 10.1039/d0se01630f
   Lee KK, 2019, RSC ADV, V9, P2708, DOI 10.1039/c8ra09729a
   Leu CT, 2006, BONE, V38, P628, DOI 10.1016/j.bone.2005.07.023
   Li CF, 2023, ACS APPL MATER INTER, DOI 10.1021/acsami.2c21319
   Li HT, 2012, J MATER CHEM, V22, P24230, DOI 10.1039/c2jm34690g
   Li HT, 2011, CARBON, V49, P605, DOI 10.1016/j.carbon.2010.10.004
   Li NY, 2016, COLLOID SURFACE B, V142, P344, DOI 10.1016/j.colsurfb.2016.03.015
   Li W, 2013, ANGEW CHEM INT EDIT, V52, P8151, DOI 10.1002/anie.201303927
   Li ZY, 2021, ACS APPL MATER INTER, V13, P29340, DOI 10.1021/acsami.1c05079
   Lin F, 2020, ANGEW CHEM INT EDIT, V59, P4324, DOI 10.1002/anie.201914603
   Lin FM, 2022, SMALL STRUCT, V3, DOI 10.1002/sstr.202200033
   Liong M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2745
   Liu GX, 2019, APPL SURF SCI, V487, P1167, DOI 10.1016/j.apsusc.2019.05.069
   Liu J, 2022, ADV MATER, V34, DOI 10.1002/adma.202200152
   Liu S, 2012, ADV MATER, V24, P2037, DOI 10.1002/adma.201200164
   Liu SW, 2023, ACS APPL MATER INTER, DOI 10.1021/acsami.2c18371
   Liu YQ, 2019, NANOSCALE, V11, P13678, DOI 10.1039/c9nr02955a
   Magee C, 2014, POLYM CHEM UK, V5, P2259, DOI 10.1039/c3py01441j
   Nocito G, 2021, CANCERS, V13, DOI 10.3390/cancers13091991
   Okazaki T, 2011, ANIM SCI J, V82, P412, DOI 10.1111/j.1740 0929.2010.00856.x
   PARFITT AM, 1988, CALCIFIED TISSUE INT, V42, P284, DOI 10.1007/BF02556360
   Perikala M, 2023, ACS APPL MATER INTER, V15, P281, DOI 10.1021/acsami.2c16046
   Popov K, 2022, J MOL LIQ, V351, DOI 10.1016/j.molliq.2022.118619
   Ràfols C, 2016, TALANTA, V154, P354, DOI 10.1016/j.talanta.2016.03.075
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Sahu S, 2012, CHEM COMMUN, V48, P8835, DOI 10.1039/c2cc33796g
   Sharma R, 2006, MACROMOLECULES, V39, P4680, DOI 10.1021/ma060374y
   SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014 4827(88)90191 7
   Song HQ, 2019, SCI BULL, V64, P1788, DOI 10.1016/j.scib.2019.10.006
   Sun LL, 2021, SPECTROCHIM ACTA A, V251, DOI 10.1016/j.saa.2021.119468
   Sun ZS, 2021, NANOSCALE, V13, P2472, DOI 10.1039/d0nr07245a
   Wang BY, 2022, MATTER US, V5, P110, DOI 10.1016/j.matt.2021.10.016
   Wang BY, 2021, COORDIN CHEM REV, V442, DOI 10.1016/j.ccr.2021.214010
   Wang JH, 2020, ENVIRON TECHNOL INNO, V20, DOI 10.1016/j.eti.2020.101088
   Wang L, 2017, J MATER CHEM B, V5, P7848, DOI 10.1039/c7tb01114h
   Wang L, 2016, BIOSENS BIOELECTRON, V79, P1, DOI 10.1016/j.bios.2015.11.085
   Wang ZH, 2023, CHEM ENG J, V457, DOI 10.1016/j.cej.2022.140997
   Wareing TC, 2021, ACS NANO, V15, P15471, DOI 10.1021/acsnano.1c03886
   Wu Q, 2022, ACS SUSTAIN CHEM ENG, V10, P3027, DOI 10.1021/acssuschemeng.1c08299
   Wu WT, 2015, ANGEW CHEM INT EDIT, V54, P6540, DOI 10.1002/anie.201501912
   Xia CL, 2018, CHEM EUR J, V24, P11303, DOI 10.1002/chem.201802712
   Xiao CQ, 2011, PHOTOCH PHOTOBIO SCI, V10, P1110, DOI 10.1039/c1pp05008g
   Yang YH, 2012, CHEM COMMUN, V48, P380, DOI 10.1039/c1cc15678k
   Yang ZC, 2011, CHEM COMMUN, V47, P11615, DOI 10.1039/c1cc14860e
   Ye CP, 2000, BONE, V27, P21, DOI 10.1016/S8756 3282(00)00288 X
   Yue J, 2019, ACS APPL MATER INTER, V11, P44566, DOI 10.1021/acsami.9b13737
   Zhang BY, 2021, RSC ADV, V11, P2656, DOI 10.1039/d0ra09164b
   Zhang L., 2023, ACS APPL MATER INTER
   Zhang T., 2023, ACS Appl. Mater. Interfaces
   Zhang YZ, 2009, J HAZARD MATER, V163, P1345, DOI 10.1016/j.jhazmat.2008.07.132
   Zhao QL, 2022, APPL SURF SCI, V598, DOI 10.1016/j.apsusc.2022.153892
   Zhao R, 2017, ACTA BIOMATER, V59, P338, DOI 10.1016/j.actbio.2017.07.009
   Zheng M, 2014, ADV MATER, V26, P3554, DOI 10.1002/adma.201306192
NR 83
TC 11
Z9 11
U1 17
U2 76
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944 8244
EI 1944 8252
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD 2023 AUG 21
PY 2023
DI 10.1021/acsami.3c05184
EA AUG 2023
PG 15
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA P6XH0
UT WOS:001052079000001
PM 37603390
DA 2025 08 17
ER

PT J
AU Chen, J
   He, DW
   Li, QP
   Wu, ZW
   Huang, WJ
   Zhu, Y
AF Chen, Jian
   He, Dengwei
   Li, Qiaoping
   Wu, Zhongwei
   Huang, Wenjun
   Zhu, Ye
TI Ursolic acid protects MC3T3 E1 cells against dexamethasone mediated
   apoptosis, ROS generation and inflammation through activation of IGF 1
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE Osteoporosis; osteoblasts; ursolic acid; IGF 1
ID GLUCOCORTICOID INDUCED OSTEOPOROSIS; IN VITRO; OLEANOLIC ACID;
   GASTRIC CANCER; BONE FORMATION; PROLIFERATION; DIFFERENTIATION;
   OSTEOBLASTS; EXPRESSION; RELEVANCE
AB Ursolic acid (UA), a pentacyclic triterpenoid found in a variety of plants, has attracted considerable attention because of its important biological and pharmacological activities. However, its effect on osteoclasts and mechanism of action require further investigation. In the current study, MC3T3 E1 cells were treated with dexamethasone (DEX), a well known synthetic glucocorticoid, to establish a glucocorticoid induced osteoporosis model. Our findings demonstrated that treatment of MC3T3 E1 cells with DEX significantly decreased cell proliferation and expression level of insulin like growth factor 1 (IGF 1) in a dose dependent manner. However, pretreatment of MC3T3 E1 cells with UA before exposure to DEX significantly attenuated DEX induced apoptosis and ROS generation and secretions of TNF alpha and IL 6. In addition, pretreatment with UA markedly reduced DEX induced IGF 1 downregulation. Similar to the protective effect of UA, overexpression of IGF 1 depressed not only DEX induced cytotoxicity, but also BMP2 downregulation and decreases in ratio of OPG/RANKL and Bax/Bcl 2. Taken together, the findings of the present study have demonstrated for the first time that UA protects MC3T3 E1 cells against DEX induced apoptosis, oxidative stress and inflammation through activating IGF 1.
C1 [Chen, Jian; He, Dengwei; Li, Qiaoping; Wu, Zhongwei; Huang, Wenjun; Zhu, Ye] Wenzhou Med Univ, Lishui Cent Hosp, Affiliated Hosp 5, Dept Orthoped, 289 Kuocang Rd, Lishui 323000, Peoples R China.
C3 Wenzhou Medical University
RP Zhu, Y (通讯作者)，Wenzhou Med Univ, Lishui Cent Hosp, Affiliated Hosp 5, Dept Orthoped, 289 Kuocang Rd, Lishui 323000, Peoples R China.
EM zhuye1978@163.com
RI HUANG, WENJUN/GXM 9167 2022
FU Lishui Science and Technology program foundation of China [2014GYX006]
FX This study was supported by the Lishui Science and Technology program
   foundation of China (2014GYX006).
CR Alm JJ, 2012, TISSUE ENG PART C ME, V18, P658, DOI [10.1089/ten.tec.2011.0675, 10.1089/ten.TEC.2011.0675]
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Checker R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031318
   Cusano NE, 2012, ENDOCRIN METAB CLIN, V41, P643, DOI 10.1016/j.ecl.2012.04.005
   Feng ZH, 2010, TRENDS CELL BIOL, V20, P427, DOI 10.1016/j.tcb.2010.03.004
   Hurson CJ, 2007, BMC MUSCULOSKEL DIS, V8, DOI 10.1186/1471 2474 8 12
   Ikeda Y, 2008, MOL NUTR FOOD RES, V52, P26, DOI 10.1002/mnfr.200700389
   Kanbur NÖ, 2005, J BONE MINER METAB, V23, P76, DOI 10.1007/s00774 004 0544 9
   Kudo O, 2003, BONE, V32, P1, DOI 10.1016/S8756 3282(02)00915 8
   Lee SU, 2008, PHARMACOL RES, V58, P290, DOI 10.1016/j.phrs.2008.08.008
   Li HZ, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1632
   Liu YF, 2016, MOL MED REP, V13, P41, DOI 10.3892/mmr.2015.4510
   Lu JH, 2006, FEBS LETT, V580, P3539, DOI 10.1016/j.febslet.2006.05.031
   Lu J, 2007, BIOCHEM PHARMACOL, V74, P1078, DOI 10.1016/j.bcp.2007.07.007
   McLaughlin F, 2002, BONE, V30, P924, DOI 10.1016/S8756 3282(02)00737 8
   Muñoz Torres M, 2001, CLIN ENDOCRINOL, V55, P759, DOI 10.1046/j.1365 2265.2001.01390.x
   Ovesná Z, 2004, NEOPLASMA, V51, P327
   Ovesná Z, 2006, MUTAT RES FUND MOL M, V600, P131, DOI 10.1016/j.mrfmmm.2006.03.008
   OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304
   Perrini S, 2008, J Endocrinol Invest, V31, P79
   Perrini S, 2008, ENDOCRINOLOGY, V149, P1302, DOI 10.1210/en.2007 1349
   Ramachandran S, 2008, CHEM BIOL INTERACT, V176, P99, DOI 10.1016/j.cbi.2008.08.010
   Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541
   Rosen CJ, 2004, BEST PRACT RES CL EN, V18, P423, DOI 10.1016/j.beem.2004.02.007
   Lacativa PGS, 2010, ARQ BRAS ENDOCRINOL, V54, P123, DOI 10.1590/S0004 27302010000200007
   Saravanan R, 2006, PHARMACOL REP, V58, P41
   Shishodia S, 2003, CANCER RES, V63, P4375
   Spreafico A, 2006, J CELL BIOCHEM, V98, P1007, DOI 10.1002/jcb.20836
   Sun M, 2014, TUMOR BIOL, V35, P1065, DOI 10.1007/s13277 013 1142 z
   TANAKA H, 1994, BONE, V15, P647, DOI 10.1016/8756 3282(94)90313 1
   Tsai SJ, 2008, J FOOD SCI, V73, pH174, DOI 10.1111/j.1750 3841.2008.00864.x
   Walsh S, 2001, RHEUMATOLOGY, V40, P74, DOI 10.1093/rheumatology/40.1.74
   Wen B, 2001, BRIT J CANCER, V85, P2017, DOI 10.1054/bjoc.2001.2171
   Yun SI, 2009, J BONE MINER METAB, V27, P140, DOI 10.1007/s00774 008 0019 5
   Zhu FB, 2015, INT J CLIN EXP MED, V8, P12337
NR 35
TC 0
Z9 0
U1 0
U2 3
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940 5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2016
VL 9
IS 12
BP 23019
EP 23030
PG 12
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA EG7UF
UT WOS:000391261000011
DA 2025 08 17
ER

PT J
AU Josephs, TM
   Keller, AN
   Khajehali, E
   DeBono, A
   Langmead, CJ
   Conigrave, AD
   Ben Capuano
   Kufareva, I
   Gregory, KJ
   Leach, K
AF Josephs, Tracy M.
   Keller, Andrew N.
   Khajehali, Elham
   DeBono, Aaron
   Langmead, Christopher J.
   Conigrave, Arthur D.
   Ben Capuano
   Kufareva, Irina
   Gregory, Karen J.
   Leach, Katie
TI Negative allosteric modulators of the human calcium sensing receptor
   bind to overlapping and distinct sites within the 7 transmembrane domain
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article
ID PARATHYROID HORMONE SECRETION; POSTMENOPAUSAL WOMEN; HEALTHY VOLUNTEERS;
   ANTAGONIST; RONACALERET; BONE; DRUG; OSTEOPOROSIS; MECHANISM; PEPTIDES
AB Background and Purpose Negative allosteric modulators (NAMs) that target the calcium sensing receptor (CaS receptor) were originally developed for the treatment of osteoporosis by stimulating the release of endogenous parathyroid hormone, but failed in human clinical trials. Several chemically and structurally distinct NAM scaffolds have been described, but it is not known how these different scaffolds interact with the CaS receptor to inhibit receptor signalling in response to agonists.
   Experimental Approach In the present study, we used a mutagenesis approach combined with analytical pharmacology and computational modelling to probe the binding sites of four distinct NAM scaffolds.
   Key Results Although all four scaffolds bind to the 7 transmembrane and/or extracellular or intracellular loops, they occupy distinct regions, as previously shown for positive allosteric modulators of the CaS receptor. Furthermore, different NAM scaffolds mediate negative allosteric modulation via distinct amino acid networks.
   Conclusion and Implications These findings aid our understanding of how different NAMs bind to and inhibit the CaS receptor. Elucidation of allosteric binding sites in the CaS receptor has implications for the discovery of novel allosteric modulators.
C1 [Josephs, Tracy M.; Keller, Andrew N.; Khajehali, Elham; DeBono, Aaron; Langmead, Christopher J.; Ben Capuano; Gregory, Karen J.; Leach, Katie] Monash Univ, Monash Inst Pharmaceut Sci, Drug Discovery Biol, 381 Royal Parade, Parkville, Vic 3052, Australia.
   [Josephs, Tracy M.; Keller, Andrew N.; Khajehali, Elham; DeBono, Aaron; Langmead, Christopher J.; Ben Capuano; Gregory, Karen J.; Leach, Katie] Monash Univ, Monash Inst Pharmaceut Sci, Dept Pharmacol, 381 Royal Parade, Parkville, Vic 3052, Australia.
   [Conigrave, Arthur D.] Univ Sydney, Sch Life & Environm Sci, Sydney, NSW, Australia.
   [Kufareva, Irina] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, San Diego, CA 92103 USA.
C3 Monash University; Monash University; University of Sydney; University
   of California System; University of California San Diego
RP Leach, K (通讯作者)，Monash Univ, Monash Inst Pharmaceut Sci, Drug Discovery Biol, 381 Royal Parade, Parkville, Vic 3052, Australia.; Leach, K (通讯作者)，Monash Univ, Monash Inst Pharmaceut Sci, Dept Pharmacol, 381 Royal Parade, Parkville, Vic 3052, Australia.
EM katie.leach@monash.edu
RI ; Kufareva, Irina/LKK 4967 2024; Khajehali, Elham/AAE 8638 2020
OI Langmead, Christopher/0000 0003 3483 1120; Josephs,
   Tracy/0000 0002 7799 3683; Conigrave, Arthur/0000 0002 7232 3891;
   Kufareva, Irina/0000 0001 9083 7039; 
FU National Institute of General Medical Sciences [GM117424]; National
   Institute of Allergy and Infectious Diseases [AI118985]; National
   Institute of Health General Medical Sciences [GM117424]; Australian
   Research Council [DP170104228]; National Health and Medical Research
   Council of Australia (NHMRC) [APP1085143, APP1138891]
FX National Institute of General Medical Sciences, Grant/Award Number:
   GM117424; National Institute of Allergy and Infectious Diseases,
   Grant/Award Number: AI118985; National Institute of Health General
   Medical Sciences, Grant/Award Number: GM117424; Australian Research
   Council, Grant/Award Number: DP170104228; National Health and Medical
   Research Council of Australia (NHMRC), Grant/Award Numbers: APP1085143,
   APP1138891
CR ABAGYAN R, 1994, J MOL BIOL, V235, P983, DOI 10.1006/jmbi.1994.1052
   Alexander ST, 2015, MOL PHARMACOL, V88, P853, DOI 10.1124/mol.115.098392
   Alexander SPH, 2019, BRIT J PHARMACOL, V176, pS21, DOI 10.1111/bph.14748
   Arey BJ, 2005, ENDOCRINOLOGY, V146, P2015, DOI 10.1210/en.2004 1318
   Bikle D, 2019, IUPHAR BPS GUIDE PHA, V2019
   Bottegoni G, 2008, J COMPUT AID MOL DES, V22, P311, DOI 10.1007/s10822 008 9188 5
   Bu L, 2008, PROTEINS, V71, P215, DOI 10.1002/prot.21685
   Chen Y, 2008, MOL PHARMACOL, V73, P909, DOI 10.1124/mol.107.040097
   Christopher JA, 2015, J MED CHEM, V58, P6653, DOI 10.1021/acs.jmedchem.5b00892
   Christopoulos A, 1998, TRENDS PHARMACOL SCI, V19, P351, DOI 10.1016/S0165 6147(98)01240 1
   Conigrave AD, 2012, DISEASES OF THE PARATHYROID GLANDS, P13, DOI 10.1007/979 1 4419 5550 0_2
   Conigrave AD, 2010, PHARMACOL THERAPEUT, V127, P252, DOI 10.1016/j.pharmthera.2010.04.007
   Cook AE, 2015, BRIT J PHARMACOL, V172, P185, DOI 10.1111/bph.12937
   Cosman F, 2016, OSTEOPOROSIS INT, V27, P377, DOI 10.1007/s00198 015 3392 7
   Curtis MJ, 2018, BRIT J PHARMACOL, V175, P987, DOI 10.1111/bph.14153
   Davey AE, 2012, ENDOCRINOLOGY, V153, P1232, DOI 10.1210/en.2011 1426
   Doré AS, 2014, NATURE, V511, P557, DOI 10.1038/nature13396
   Fitzpatrick LA, 2012, J BONE MINER RES, V27, P255, DOI 10.1002/jbmr.554
   Fitzpatrick LA, 2011, BONE, V49, P845, DOI 10.1016/j.bone.2011.06.017
   Fitzpatrick LA, 2011, J CLIN ENDOCR METAB, V96, P2441, DOI 10.1210/jc.2010 2855
   Geng Y, 2016, ELIFE, V5, DOI 10.7554/eLife.13662
   Gowen M, 2000, J CLIN INVEST, V105, P1595, DOI 10.1172/JCI9038
   Gregory KJ, 2018, ACS PHARMACOL TRANSL, V1, P96, DOI 10.1021/acsptsci.8b00021
   Gregory KJ, 2020, MOL PHARMACOL, V97, P35, DOI 10.1124/mol.119.118091
   Halse J, 2014, J CLIN ENDOCR METAB, V99, pE2207, DOI 10.1210/jc.2013 4009
   Harding SD, 2018, NUCLEIC ACIDS RES, V46, pD1091, DOI 10.1093/nar/gkx1121
   Hu JX, 2006, J BIOL CHEM, V281, P21558, DOI 10.1074/jbc.M603682200
   Jacobsen SE, 2017, SCI REP UK, V7, DOI 10.1038/srep46355
   John MR, 2014, BONE, V64, P204, DOI 10.1016/j.bone.2014.04.015
   Keller AN, 2018, MOL PHARMACOL, V93, P619, DOI 10.1124/mol.118.112086
   Leach K, 2017, PHARMACOL RES, V116, P105, DOI 10.1016/j.phrs.2016.12.006
   Leach K, 2016, CELL RES, V26, P574, DOI 10.1038/cr.2016.36
   Leach K, 2012, ENDOCRINOLOGY, V153, P4304, DOI 10.1210/en.2012 1449
   Li B, 2013, J ORG CHEM, V78, P1273, DOI 10.1021/jo302515c
   Miedlich SU, 2004, J BIOL CHEM, V279, P7254, DOI 10.1074/jbc.M307191200
   Neves MAC, 2012, J COMPUT AID MOL DES, V26, P675, DOI 10.1007/s10822 012 9547 0
   Noetzel MJ, 2013, MOL PHARMACOL, V83, P835, DOI 10.1124/mol.112.082891
   Petrel C, 2004, J BIOL CHEM, V279, P18990, DOI 10.1074/jbc.M400724200
   Petrel C, 2003, J BIOL CHEM, V278, P49487, DOI 10.1074/jbc.M308010200
   Roberts MS, 2019, J BONE MINER RES, V34, P1609, DOI 10.1002/jbmr.3747
   Schapira M, 1999, J MOL RECOGNIT, V12, P177, DOI 10.1002/(SICI)1099 1352(199905/06)12:3<177::AID JMR451>3.0.CO;2 Z
   Smithkline Beecham Corporation, 2002, CALC COMP, Patent No. WO/2002/038106
   Totrov M., 1999, Annual Conference on Research in Computational Molecular Biology, V3, P312, DOI DOI 10.1145/299432.299509
   Widler L, 2008, J BONE MINER RES, V23, pS49
   Widler L, 2010, J MED CHEM, V53, P2250, DOI 10.1021/jm901811v
   Wu HX, 2014, SCIENCE, V344, P58, DOI 10.1126/science.1249489
   Yang W, 2009, J MED CHEM, V52, P1204, DOI 10.1021/jm801178c
   Yarova PL, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa0282
   Zhang C, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600241
NR 49
TC 15
Z9 15
U1 1
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0007 1188
EI 1476 5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD APR
PY 2020
VL 177
IS 8
BP 1917
EP 1930
DI 10.1111/bph.14961
EA FEB 2020
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA KU0MR
UT WOS:000512904500001
PM 31881094
OA Green Published
DA 2025 08 17
ER

PT J
AU Hidaka, Y
   Chiba Ohkuma, R
   Karakida, T
   Onuma, K
   Yamamoto, R
   Fujii Abe, K
   Saito, MM
   Yamakoshi, Y
   Kawahara, H
AF Hidaka, Yukihiko
   Chiba Ohkuma, Risako
   Karakida, Takeo
   Onuma, Kazuo
   Yamamoto, Ryuji
   Fujii Abe, Keiko
   Saito, Mari M.
   Yamakoshi, Yasuo
   Kawahara, Hiroshi
TI Combined Effect of Midazolam and Bone Morphogenetic Protein 2 for
   Differentiation Induction from C2C12 Myoblast Cells to Osteoblasts
SO PHARMACEUTICS
LA English
DT Article
DE drug repositioning; cell; hydroxyapatite; bone; midazolam
ID MESENCHYMAL STEM CELLS; OSTEOGENIC DIFFERENTIATION; APOPTOSIS; PATHWAY;
   BENZODIAZEPINE; BIOACTIVITY; RECEPTORS; OSTERIX; BINDING; GROWTH
AB In drug repositioning research, a new concept in drug discovery and new therapeutic opportunities have been identified for existing drugs. Midazolam (MDZ) is an anesthetic inducer used for general anesthesia. Here, we demonstrate the combined effects of bone morphogenetic protein 2 (BMP 2) and MDZ on osteogenic differentiation. An immortalized mouse myoblast cell line (C2C12 cell) was cultured in the combination of BMP 2 and MDZ (BMP 2+MDZ). The differentiation and signal transduction of C2C12 cells into osteoblasts were investigated at biological, immunohistochemical, and genetic cell levels. Mineralized nodules formed in C2C12 cells were characterized at the crystal engineering level. BMP 2+MDZ treatment decreased the myotube cell formation of C2C12 cells, and enhanced alkaline phosphatase activity and expression levels of osteoblastic differentiation marker genes. The precipitated nodules consisted of randomly oriented hydroxyapatite nanorods and nanoparticles. BMP 2+MDZ treatment reduced the immunostaining for both alpha 1 and gamma 2 subunits antigens on the gamma aminobutyric acid type A (GABAA) receptor in C2C12 cells, but enhanced that for BMP signal transducers. Our investigation showed that BMP 2+MDZ has a strong ability to induce the differentiation of C2C12 cells into osteoblasts and has the potential for drug repositioning in bone regeneration.
C1 [Hidaka, Yukihiko; Fujii Abe, Keiko; Kawahara, Hiroshi] Tsurumi Univ, Sch Dent Med, Dept Dent Anesthesiol, Tsurumi Ku, 2 1 3 Tsurumi, Yokohama, Kanagawa 2308501, Japan.
   [Chiba Ohkuma, Risako; Karakida, Takeo; Yamamoto, Ryuji; Saito, Mari M.; Yamakoshi, Yasuo] Tsurumi Univ, Sch Dent Med, Dept Biochem & Mol Biol, Tsurumi Ku, 2 1 3 Tsurumi, Yokohama, Kanagawa 2308501, Japan.
   [Onuma, Kazuo] Natl Inst Adv Ind Sci & Technol, Cent 6,1 1 1 Higashi, Tsukuba, Ibaraki 3058566, Japan.
C3 Tsurumi University; Tsurumi University; National Institute of Advanced
   Industrial Science & Technology (AIST)
RP Yamakoshi, Y (通讯作者)，Tsurumi Univ, Sch Dent Med, Dept Biochem & Mol Biol, Tsurumi Ku, 2 1 3 Tsurumi, Yokohama, Kanagawa 2308501, Japan.
EM 2911002@stu.tsurumi u.ac.jp; chiba r@tsurumi u.ac.jp;
   karakida t@tsurumi u.ac.jp; espkaz009@gmail.com;
   yamamoto rj@tsurumi u.ac.jp; fujii keiko@tsurumi u.ac.jp;
   saito mari@tsurumi u.ac.jp; yamakoshi y@tsurumi u.ac.jp;
   kawahara h@tsurumi u.ac.jp
RI Saito, Mari/IQU 0165 2023
OI Saito, Mari/0000 0003 4058 7371
FU JSPS KAKENHI [17K11975, 18K09627]; MEXT Supported Program for the
   Strategic Research Foundation at Private Universities [S1511018];
   Grants in Aid for Scientific Research [18K09627, 17K11975, 20K10000]
   Funding Source: KAKEN
FX This study was supported by a JSPS KAKENHI Grant in Aid for Scientific
   Research (17K11975 and 18K09627) and the MEXT Supported Program for the
   Strategic Research Foundation at Private Universities (S1511018).
CR Aubin J E, 2001, Rev Endocr Metab Disord, V2, P81, DOI 10.1023/A:1010011209064
   Benson JA, 1998, FEBS LETT, V431, P400, DOI 10.1016/S0014 5793(98)00803 5
   BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092 8674(83)90300 8
   Boileau AJ, 1998, MOL PHARMACOL, V53, P295, DOI 10.1124/mol.53.2.295
   Charbord P, 2010, HUM GENE THER, V21, P1045, DOI 10.1089/hum.2010.115
   Ding S, 2016, COLLOID SURFACE B, V145, P140, DOI 10.1016/j.colsurfb.2016.04.045
   Huang ZN, 2007, TISSUE ENG, V13, P2311, DOI 10.1089/ten.2006.0423
   Hwang SY, 2015, INT J MOL MED, V36, P1073, DOI 10.3892/ijmm.2015.2311
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   Karakida T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030670
   Karakida T, 2011, CONNECT TISSUE RES, V52, P365, DOI 10.3109/03008207.2010.541309
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Mackay AM, 1998, TISSUE ENG, V4, P415, DOI 10.1089/ten.1998.4.415
   Mafi R, 2011, Open Orthop J, V5 Suppl 2, P242, DOI 10.2174/1874325001105010242
   Matsubara T, 2008, J BIOL CHEM, V283, P29119, DOI 10.1074/jbc.M801774200
   Mehta AK, 1999, BRAIN RES REV, V29, P196, DOI 10.1016/S0165 0173(98)00052 6
   Mishra SK, 2013, MOL CELLS, V36, P219, DOI 10.1007/s10059 013 0050 9
   Nagano T, 2006, J PERIODONTOL, V77, P1688, DOI 10.1902/jop.2006.050352
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nitiputri K, 2016, ACS NANO, V10, P6826, DOI 10.1021/acsnano.6b02443
   Ohno S, 2012, ANTICANCER RES, V32, P4737
   Olkkola K. T., 2008, V182, P335, DOI 10.1007/978 3 540 74806 9_16
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   PUCHTLER H, 1969, J HISTOCHEM CYTOCHEM, V17, P110, DOI 10.1177/17.2.110
   Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092 8674(03)00432 X
   Sieghart W, 2015, ADV PHARMACOL, V72, P53, DOI 10.1016/bs.apha.2014.10.002
   Smith R, 2017, AUST PRESCR, V40, P23, DOI 10.18773/austprescr.2017.005
   So EC, 2016, ONCOTARGETS THER, V9, P2519, DOI 10.2147/OTT.S101671
   Stevens MF, 2011, REGION ANESTH PAIN M, V36, P343, DOI 10.1097/AAP.0b013e318217a6c7
   Sugiura Y, 2015, AM MINERAL, V100, P1624, DOI 10.2138/am 2015 5179
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0
   Ye J, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471 2105 13 134
   Zammit PS, 2017, SEMIN CELL DEV BIOL, V72, P19, DOI 10.1016/j.semcdb.2017.11.011
   Zhang T, 2014, EUR REV MED PHARMACO, V18, P1411
   Zhou HJ, 2009, BIOMATERIALS, V30, P1715, DOI 10.1016/j.biomaterials.2008.12.016
NR 38
TC 13
Z9 14
U1 0
U2 6
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1999 4923
J9 PHARMACEUTICS
JI Pharmaceutics
PD MAR
PY 2020
VL 12
IS 3
AR 218
DI 10.3390/pharmaceutics12030218
PG 18
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA LE2GH
UT WOS:000526541000090
PM 32131534
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Nassar, PO
   Nassar, CA
   Guimaraes, MR
   Aquino, SG
   Andia, DC
   Muscara, MN
   Spolidorio, DMP
   Rossa, C
   Spolidorio, LC
AF Nassar, P. O.
   Nassar, C. A.
   Guimaraes, M. R.
   Aquino, S. G.
   Andia, D. C.
   Muscara, M. N.
   Spolidorio, D. M. P.
   Rossa, C., Jr.
   Spolidorio, L. C.
TI Simvastatin therapy in cyclosporine A induced alveolar bone loss in rats
SO JOURNAL OF PERIODONTAL RESEARCH
LA English
DT Article
DE simvastatin; cyclosporine A; alveolar bone loss; periodontitis
ID NITRIC OXIDE SYNTHASE; HMG COA REDUCTASE; MARROW TRANSPLANTATION;
   MOLECULAR MECHANISMS; PERIODONTAL DISEASE; PROTEIN PRENYLATION;
   IN VITRO; INHIBITION; STATINS; CELLS
AB Background and Objective:
   Cyclosporine A treatment is important in the therapy of a number of medical conditions; however, alveolar bone loss is an important negative side effect of this drug. As such, we evaluated whether concomitant administration of simvastatin would minimize cyclosporine A associated alveolar bone loss in rats subjected, or not, to experimental periodontal disease.
   Material and Methods:
   Groups of 10 rats each were treated with cyclosporine A (10 mg/kg/day), simvastatin (20 mg/kg/day), cyclosporine A and simvastatin concurrently (cyclosporine A/simvastatin) or vehicle for 30 days. Four other groups of 10 rats each received a cotton ligature around the lower first molar and were treated similarly with cyclosporine A, simvastatin, cyclosporine A/simvastatin or vehicle. Calcium (Ca2+), phosphorus and alkaline phosphatase levels were evaluated in serum. Expression levels of interleukin 1 beta, prostaglandin E 2 and inducible nitric oxide synthase were evaluated in the gingivomucosal tissues. Bone volume and numbers of osteoblasts and osteoclasts were also analyzed.
   Results:
   Treatment with cyclosporine A in rats, with or without ligature, was associated with bone loss, represented by a lower bone volume and an increase in the number of osteoclasts. Treatment with cyclosporine A was associated with bone resorption, whereas simvastatin treatment improved cyclosporine A associated alveolar bone loss in all parameters studied. In addition, simvastatin, in the presence of inflammation, can act as an anti inflammatory agent.
   Conclusion:
   This study shows that simvastatin therapy leads to a reversal of the cyclosporine A induced bone loss, which may be mediated by downregulation of interleukin 1 beta and prostaglandin E 2 production.
C1 [Nassar, P. O.; Guimaraes, M. R.; Aquino, S. G.; Andia, D. C.; Spolidorio, D. M. P.; Rossa, C., Jr.] State Univ Sao Paulo, Dent Sch Araraquara, Dept Periodontol, Araraquara, SP, Brazil.
   [Nassar, C. A.] Univ State W Parana Unioeste, Cascavel Dent Sch, Dept Periodontol, Cascavel, Parana, Brazil.
   [Spolidorio, L. C.] State Univ Sao Paulo UNESP, Dent Sch Araraquara, Dept Physiol & Pathol, Araraquara, SP, Brazil.
   [Muscara, M. N.] Univ Sao Paulo, Inst Biomed Sci, Dept Pharmacol, Sao Paulo, Brazil.
C3 Universidade Estadual Paulista; Universidade Estadual Paulista;
   Universidade de Sao Paulo; Institute Biomed Science, University Sao
   Paulo
RP Spolidorio, LC (通讯作者)，State Univ Sao Paulo, Dent Sch Araraquara UNESP, Dept Physiol & Pathol, Rua Humaita 1380, Araraquara, SP, Brazil.
EM lcs@foar.unesp.br
RI ; Palomari Spolidorio, Denise Madalena/P 3530 2016; guimaraes,
   morgana/C 8966 2014; Rossa Jr, Carlos/D 8328 2012; Andia,
   Denise/F 1080 2012; Nassar, Carlos/U 7076 2019; de Aquino,
   Sabrina/E 8483 2014; Spolidorio, Luís/G 1857 2012; Muscara,
   Marcelo/F 3250 2012; Spolidorio, Denise/P 3530 2016; Muscará,
   Marcelo/F 3250 2012; STABILI, MORGANA/ABC 9852 2021; Spolidorio, Luis
   Carlos/G 1857 2012
OI Nassar, Carlos Augusto/0000 0002 8647 413X; Palomari Spolidorio, Denise
   Madalena/0000 0003 2376 1024; guimaraes, morgana/0000 0002 1297 9717;
   Rossa Jr, Carlos/0000 0003 1705 5481; Andia, Denise/0000 0002 0049 0201;
   Nassar, Patricia/0000 0003 3791 0334; de Aquino,
   Sabrina/0000 0002 3988 1939; Muscara, Marcelo/0000 0002 8342 5586;
   Spolidorio, Luis Carlos/0000 0002 0592 542X
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) Foundation
   [04/09851 4.]
FX This work was supported by the Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP) Foundation; grant number 04/09851 4. The authors
   are extremely grateful for the technical assistance of Jose Antonio
   Zuanon.
CR BARON R, 1989, ANAT RECORD, V224, P317, DOI 10.1002/ar.1092240220
   Batista AC, 2002, ORAL DIS, V8, P254, DOI 10.1034/j.1601 0825.2002.02852.x
   BUCHINSKY FJ, 1995, J BONE MINER RES, V10, P1556
   Cerri PS, 2005, ANAT REC PART A, V286A, P833, DOI 10.1002/ar.a.20220
   Chae HJ, 1997, J PHARM PHARMACOL, V49, P897, DOI 10.1111/j.2042 7158.1997.tb06132.x
   Chang CT, 2005, TRANSPL INT, V18, P871, DOI 10.1111/j.1432 2277.2005.00152.x
   Cohen A, 2003, OSTEOPOROSIS INT, V14, P617, DOI 10.1007/s00198 003 1426 z
   Desager JP, 1996, CLIN PHARMACOKINET, V31, P348, DOI 10.2165/00003088 199631050 00003
   ENDO A, 1997, EUR J BIOCHEM, V77, P31
   Esteves FOG, 2000, J CHEM NEUROANAT, V20, P185, DOI 10.1016/S0891 0618(00)00091 0
   Hikiji H, 2008, PROG LIPID RES, V47, P107, DOI 10.1016/j.plipres.2007.12.003
   Hofbauer LC, 2001, BIOCHEM BIOPH RES CO, V280, P334, DOI 10.1006/bbrc.2000.4130
   Holzhausen M, 2002, J PERIODONTOL, V73, P1030, DOI 10.1902/jop.2002.73.9.1030
   Horiuchi N, 2006, ORAL DIS, V12, P85, DOI 10.1111/j.1601 0825.2005.01172.x
   Hughes A, 2007, CALCIFIED TISSUE INT, V81, P403, DOI 10.1007/s00223 007 9078 1
   Huja SS, 2006, ANAT REC PART A, V288A, P1243, DOI 10.1002/ar.a.20396
   Igarashi K, 2004, BONE, V35, P47, DOI 10.1016/j.bone.2004.02.009
   Istvan ES, 2001, SCIENCE, V292, P1160, DOI 10.1126/science.1059344
   JUNQUEIRA JC, 2002, J ORAL SCI, V4, P117
   KASTEN TP, 1994, P NATL ACAD SCI USA, V91, P3569, DOI 10.1073/pnas.91.9.3569
   Lee WY, 2004, BONE MARROW TRANSPL, V34, P89, DOI 10.1038/sj.bmt.1704535
   Maeda T, 2003, ENDOCRINOLOGY, V144, P681, DOI 10.1210/en.2002 220682
   Maeda T, 2001, BIOCHEM BIOPH RES CO, V280, P874, DOI 10.1006/bbrc.2000.4232
   MARSHALL I, 1995, BONE S1, V16, pS1
   Mason JC, 2004, J BIOL CHEM, V279, P41611, DOI 10.1074/jbc.M407981200
   Matejka M, 1998, J PERIODONTAL RES, V33, P517
   MOVSOWITZ C, 1988, ENDOCRINOLOGY, V123, P2571, DOI 10.1210/endo 123 5 2571
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Nassar CA, 2004, J PERIODONTAL RES, V39, P143, DOI 10.1111/j.1600 0765.2004.00739.x
   Ohno T, 2003, TRANSPLANTATION, V76, P869, DOI 10.1097/01.TP.0000074992.49236.58
   PARFITT AM, 1988, BONE MINER, V4, P1
   Pietschmann P, 2001, EXP GERONTOL, V36, P1749, DOI 10.1016/S0531 5565(01)00125 5
   RUCINSKI B, 1994, METABOLISM, V43, P1114, DOI 10.1016/0026 0495(94)90053 1
   RYFFEL B, 1993, BIOCHEM BIOPH RES CO, V194, P1074, DOI 10.1006/bbrc.1993.1931
   Segal E, 2003, ISR MED ASSOC J, V5, P859
   Sorsa T, 2004, ORAL DIS, V10, P311, DOI 10.1111/j.1601 0825.2004.01038.x
   Spolidorio LC, 2007, J PERIODONTAL RES, V42, P466, DOI 10.1111/j.1600 0765.2007.00970.x
   Spolidorio LC, 2004, J PERIODONTAL RES, V39, P257, DOI 10.1111/j.1600 0765.2004.00734.x
   Spolidorio LC, 2007, CALCIFIED TISSUE INT, V81, P114, DOI 10.1007/s00223 007 9040 2
   Staal A, 2003, J BONE MINER RES, V18, P88, DOI 10.1359/jbmr.2003.18.1.88
   Stoyanova I, 2005, J MOL HISTOL, V36, P187, DOI 10.1007/s10735 005 1694 3
   Sunyer T, 1997, ENDOCRINOLOGY, V138, P2148, DOI 10.1210/en.138.5.2148
   Wada K, 2006, CIRC J, V70, P1307, DOI 10.1253/circj.70.1307
   WASSEF R, 1985, TRANSPLANTATION, V40, P489, DOI 10.1097/00007890 198511000 00004
   Yeo H, 2006, ANN NY ACAD SCI, V1068, P564, DOI 10.1196/annals.1346.053
   Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325
NR 46
TC 38
Z9 40
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3484
EI 1600 0765
J9 J PERIODONTAL RES
JI J. Periodont. Res.
PD AUG
PY 2009
VL 44
IS 4
BP 479
EP 488
DI 10.1111/j.1600 0765.2008.01143.x
PG 10
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 463IZ
UT WOS:000267426900008
PM 19076990
DA 2025 08 17
ER

PT J
AU Wang, JQ
   Wu, SN
   Li, ZB
   Liu, L
   Pang, Y
   Wei, JM
AF Wang, Jianqi
   Wu, Shuainan
   Li, Zhaobao
   Liu, Lu
   Pang, Ying
   Wei, Jianming
TI Inhibition of nuclear factor kappa B inducing kinase suppresses
   inflammatory responses and the symptoms of chronic periodontitis in a
   mouse model
SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
LA English
DT Article
DE periodontitis; NIK inhibitor; non canonical NF KB pathway; inflammation
ID DIFFERENTIATION; NF KAPPA B2; ACTIVATION; EXPRESSION; THERAPY
AB Chronic periodontitis is an inflammatory disease that represents a major public health issue nowadays. Here, we investigated the protective role of nuclear factor kappa B (NF KB) inducing kinase (NIK) inhibitor on chronic periodontitis and revealed the underlying molecular mechanism. NIK inhibitor was synthesized, and its functions were examined in primary osteoclasts and wild type (WT) and NIK /  chronic periodontitis mouse model. Lipopolysaccharides (LPS) or activator of NF KB was applied to stimulate inflammatory response of osteoclasts. The qRT PCR, ELISA and Western blot were used to measure the expression of pro inflammatory and osteoclastrelated genes, and the activation of NF KB signaling. Osteoclastogenesis and bone damage were detected by TRAP staining and micro CT. NIK knockdown mice had lower expression of osteoclast related genes and improved CEJ ABC damage. Similarly, NIK inhibitor administration inhibited inflammatory responses and CEJABC damage in chronic periodontitis models. NIK inhibitor suppressed osteoclastogenesis and osteoclast related genes expression through inhibiting the non canonical NF KB signaling. NIK plays important role in bone destruction of chronic periodontitis and NIK inhibitor represents a promising therapeutic strategy for this disease.
C1 [Wang, Jianqi; Wu, Shuainan; Li, Zhaobao; Liu, Lu; Pang, Ying; Wei, Jianming] Cangzhou Cent Hosp, Dept Stomatol Clin, 16 Xinhua West Rd, Cangzhou 061000, Hebei, Peoples R China.
RP Wang, JQ (通讯作者)，Cangzhou Cent Hosp, Dept Stomatol Clin, 16 Xinhua West Rd, Cangzhou 061000, Hebei, Peoples R China.
EM wangjianqi0612@163.com
CR Al Sadi R, 2016, AM J PATHOL, V186, P1151, DOI 10.1016/j.ajpath.2015.12.016
   AlQranei MS, 2020, J ORAL BIOSCI, V62, P123, DOI 10.1016/j.job.2020.02.002
   [Anonymous], 2015, J ORAL BIOL CRANIOFA, DOI DOI 10.1016/J.JOBCR.2015.06.008
   Aya K, 2005, J CLIN INVEST, V115, P1848, DOI 10.1172/JCI23763
   Beinke S, 2004, BIOCHEM J, V382, P393, DOI 10.1042/BJ20040544
   Brightbill HD, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02672 0
   Chen L, 2008, EUR J IMMUNOL, V38, P2845, DOI 10.1002/eji.200838192
   Chen ZM, 2017, MOL METAB, V6, P863, DOI 10.1016/j.molmet.2017.03.016
   Eberhard J, 2008, J CLIN PERIODONTOL, V35, P591, DOI 10.1111/j.1600 051X.2008.01239.x
   Eshima K, 2014, IMMUNOLOGY, V141, P222, DOI 10.1111/imm.12186
   Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997
   Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020
   Hienz SA, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/615486
   Kinane DF, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.38
   Kornman KS, 2017, PERIODONTOL 2000, V75, P353, DOI 10.1111/prd.12217
   Kramer CD, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00255
   Lin WJ, 2011, P NATL ACAD SCI USA, V108, P18354, DOI 10.1073/pnas.1109427108
   Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23
   Ma XJ, 2016, CELL MOL IMMUNOL, V13, P240, DOI 10.1038/cmi.2015.70
   Marchesan J, 2018, NAT PROTOC, V13, P2247, DOI 10.1038/s41596 018 0035 4
   Meimandi M, 2017, J LASERS MED SCI, V8, pS7, DOI 10.15171/jlms.2017.s2
   Morishita M, 2013, J DENT RES, V92, P241, DOI 10.1177/0022034512473309
   Nabet C, 2010, J CLIN PERIODONTOL, V37, P37, DOI 10.1111/j.1600 051X.2009.01503.x
   Papadaki M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00097
   Park JH, 2017, MOL CELLS, V40, P706
   Peng CH, 2017, INTERNAL MED, V56, P1015, DOI 10.2169/internalmedicine.56.7322
   Petersen PE, 2012, PERIODONTOL 2000, V60, P7, DOI 10.1111/j.1600 0757.2012.00452.x
   Ridker PM, 2017, NEW ENGL J MED, V377, P1119, DOI 10.1056/NEJMoa1707914
   Shaddox L, 2010, J DENT RES, V89, P143, DOI 10.1177/0022034509353397
   Shaddox LM, 2013, J DENT RES, V92, P702, DOI 10.1177/0022034513495242
   Shih VFS, 2011, CELL RES, V21, P86, DOI 10.1038/cr.2010.161
   STRAUSS RP, 1993, J AM DENT ASSOC, V124, P105, DOI 10.14219/jada.archive.1993.0019
   Sun SC, 2017, NAT REV IMMUNOL, V17, P545, DOI 10.1038/nri.2017.52
   Sun SC, 2012, IMMUNOL REV, V246, P125, DOI 10.1111/j.1600 065X.2011.01088.x
   Valiño Rivas L, 2019, TRENDS MOL MED, V25, P341, DOI 10.1016/j.molmed.2019.02.005
   Van der Weijden GA, 2002, J CLIN PERIODONTOL, V29, P55, DOI 10.1034/j.1600 051X.29.s3.3.x
   Wittwer T, 2008, BIOCHEM BIOPH RES CO, V371, P294, DOI 10.1016/j.bbrc.2008.04.069
   Yücel G, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 03147 4
   Zhang HY, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6798
   Zhu YQ, 2020, J MED CHEM, V63, P6748, DOI 10.1021/acs.jmedchem.0c00055
NR 40
TC 6
Z9 6
U1 2
U2 14
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1357 2725
EI 1878 5875
J9 INT J BIOCHEM CELL B
JI Int. J. Biochem. Cell Biol.
PD OCT
PY 2021
VL 139
AR 106052
DI 10.1016/j.biocel.2021.106052
EA AUG 2021
PG 7
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA WA3HD
UT WOS:000702779300005
PM 34364989
DA 2025 08 17
ER

PT J
AU Zheng, G
   Peng, XS
   Zhang, YH
   Wang, P
   Xie, ZY
   Li, JT
   Liu, WJ
   Ye, GW
   Lin, YC
   Li, GJ
   Liu, HT
   Zeng, CY
   Li, LH
   Wu, YF
   Shen, HY
AF Zheng, Guan
   Peng, Xiaoshuai
   Zhang, Yunhui
   Wang, Peng
   Xie, Zhongyu
   Li, Jinteng
   Liu, Wenjie
   Ye, Guiwen
   Lin, Yucong
   Li, Guojian
   Liu, Huatao
   Zeng, Chenying
   Li, Lihua
   Wu, Yanfeng
   Shen, Huiyong
TI A novel Anti ROS osteoblast specific delivery system for ankylosing
   spondylitis treatment via suppression of both inflammation and
   pathological new bone formation
SO JOURNAL OF NANOBIOTECHNOLOGY
LA English
DT Article
DE Ankylosing spondylitis; ROS scavenging; Targeted therapy; Nanomedicine
ID MESENCHYMAL STEM CELLS; NF KAPPA B; OSTEOGENIC DIFFERENTIATION;
   AUTOIMMUNE ARTHRITIS; TNF ALPHA; DOUBLE BLIND; SAFETY; MULTICENTER;
   HIF 1 ALPHA; INHIBITION
AB Ankylosing spondylitis (AS) is a common rheumatic disorder distinguished by chronic inflammation and heterotopic ossification at local entheses sites. Currently available medications, including nonsteroidal anti inflammatory drugs (NSAIDs), disease modifying anti rheumatic drugs (DMARDs) and TNF inhibitors, are limited by side effects, high costs and unclear inhibitory effects on heterotopic ossification. Herein, we developed manganese ferrite nanoparticles modified by the aptamer CH6 (CH6 MF NPs) that can efficiently scavenge ROS and actively deliver siRNA into hMSCs and osteoblasts in vivo for effective AS treatment. CH6 MF NPs loaded with BMP2 siRNA (CH6 MF Si NPs) effectively suppressed abnormal osteogenic differentiation under inflammatory conditions in vitro. During their circulation and passive accumulation in inflamed joints in the Zap70(mut) mouse model, CH6 MF Si NPs attenuated local inflammation and rescued heterotopic ossification in the entheses. Thus, CH6 MF NPs may be an effective inflammation reliever and osteoblast specific delivery system, and CH6 MF Si NPs have potential for the dual treatment of chronic inflammation and heterotopic ossification in AS.
C1 [Zheng, Guan; Peng, Xiaoshuai; Zhang, Yunhui; Wang, Peng; Xie, Zhongyu; Li, Jinteng; Liu, Wenjie; Ye, Guiwen; Lin, Yucong; Li, Guojian; Liu, Huatao; Shen, Huiyong] Sun Yat Sen Univ, Affiliated Hosp 8, Dept Orthoped, 3025 Shennan Rd, Shenzhen, Peoples R China.
   [Zeng, Chenying; Wu, Yanfeng] Sun Yat Sen Univ, Affiliated Hosp 8, Ctr Biotherapy, 3025 Shennan Rd, Shenzhen, Peoples R China.
   [Li, Lihua] Hong Kong Polytech Univ, Dept Appl Phys, Hung Hom, Hong Kong, Peoples R China.
   [Li, Lihua] South China Normal Univ, Future Technol Res Inst, 55 Zhongshan Dadao, Guangzhou, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University; Hong Kong Polytechnic
   University; South China Normal University
RP Shen, HY (通讯作者)，Sun Yat Sen Univ, Affiliated Hosp 8, Dept Orthoped, 3025 Shennan Rd, Shenzhen, Peoples R China.; Wu, YF (通讯作者)，Sun Yat Sen Univ, Affiliated Hosp 8, Ctr Biotherapy, 3025 Shennan Rd, Shenzhen, Peoples R China.; Li, LH (通讯作者)，Hong Kong Polytech Univ, Dept Appl Phys, Hung Hom, Hong Kong, Peoples R China.; Li, LH (通讯作者)，South China Normal Univ, Future Technol Res Inst, 55 Zhongshan Dadao, Guangzhou, Peoples R China.
EM lihua361@126.com; wuyf@mail.sysu.edu.cn; shenhuiy@mail.sysu.edu.cn
RI Xie, Zhongyu/V 6518 2019; Lin, Yucong/O 2455 2016; Zhang,
   Yunhui/AAO 4648 2021
CR Apparailly F, 2013, NAT REV RHEUMATOL, V9, P56, DOI 10.1038/nrrheum.2012.176
   Appel H, 2006, ARTHRITIS RHEUM US, V54, P1805, DOI 10.1002/art.21907
   Baraliakos X, 2014, ANN RHEUM DIS, V73, P1819, DOI 10.1136/annrheumdis 2013 203425
   Bernardo ME, 2013, CELL STEM CELL, V13, P392, DOI 10.1016/j.stem.2013.09.006
   Bianco P, 2008, CELL STEM CELL, V2, P313, DOI 10.1016/j.stem.2008.03.002
   Blaser H, 2016, TRENDS CELL BIOL, V26, P249, DOI 10.1016/j.tcb.2015.12.002
   Braun J, 2002, LANCET, V359, P1187, DOI 10.1016/S0140 6736(02)08215 6
   Cao FF, 2019, ANGEW CHEM INT EDIT, V58, P16236, DOI 10.1002/anie.201908289
   Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092 8674(03)00154 5
   Czech MP, 2011, NAT REV ENDOCRINOL, V7, P473, DOI 10.1038/nrendo.2011.57
   Das S, 2018, NANOSCALE, V10, P21069, DOI 10.1039/c8nr04640a
   Davis JC, 2003, ARTHRITIS RHEUM, V48, P3230, DOI 10.1002/art.11325
   Denu RA, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/2989076
   Hata H, 2004, J CLIN INVEST, V114, P582, DOI 10.1172/JCI200421795
   Hayden MS, 2014, SEMIN IMMUNOL, V26, P253, DOI 10.1016/j.smim.2014.05.004
   Hess K, 2009, BONE, V45, P367, DOI 10.1016/j.bone.2009.04.252
   Inman RD, 2008, ARTHRITIS RHEUM US, V58, P3402, DOI 10.1002/art.23969
   Keller KK, 2013, RHEUMATOL INT, V33, P1127, DOI 10.1007/s00296 012 2500 7
   Kim J, 2019, ACS NANO, V13, P3206, DOI 10.1021/acsnano.8b08785
   Klingberg E, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4368
   Klingberg E, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3833
   Knop K, 2010, ANGEW CHEM INT EDIT, V49, P6288, DOI 10.1002/anie.200902672
   Kumar S, 2019, BIOMATERIALS, V224, DOI 10.1016/j.biomaterials.2019.119467
   Li LH, 2021, ADV HEALTHC MATER, V10, DOI 10.1002/adhm.202100316
   Li QQ, 2017, PROTEIN CELL, V8, P439, DOI 10.1007/s13238 017 0385 7
   Li X, 2018, ARTHRITIS RHEUMATOL, V70, P1056, DOI 10.1002/art.40468
   Liang C, 2015, NAT MED, V21, P288, DOI 10.1038/nm.3791
   Maillefert JF, 2001, OSTEOPOROSIS INT, V12, P605, DOI 10.1007/s001980170084
   Maksymowych WP, 2010, NAT REV RHEUMATOL, V6, P75, DOI 10.1038/nrrheum.2009.258
   Manabe H, 2008, INFLAMM RES, V57, P4, DOI 10.1007/s00011 007 7036 z
   Petrocca F, 2011, J CLIN ONCOL, V29, P747, DOI 10.1200/JCO.2009.27.6287
   Pineault KM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 11100 4
   Rudwaleit M, 2009, ANN RHEUM DIS, V68, P777, DOI 10.1136/ard.2009.108233
   Ruutu M, 2012, ARTHRITIS RHEUM US, V64, P2211, DOI 10.1002/art.34423
   Sakaguchi N, 2003, NATURE, V426, P454, DOI 10.1038/nature02119
   Schett G, 2017, NAT REV RHEUMATOL, V13, P731, DOI 10.1038/nrrheum.2017.188
   Shankar J, 2009, BIOCHEM BIOPH RES CO, V387, P223, DOI 10.1016/j.bbrc.2009.01.086
   Shimizu T, 2017, OSTEOPOROSIS INT, V28, P709, DOI 10.1007/s00198 016 3781 6
   Sieper J, 2017, LANCET, V390, P73, DOI 10.1016/S0140 6736(16)31591 4
   van der Heijde D, 2008, ARTHRITIS RHEUM US, V58, P1324, DOI 10.1002/art.23471
   van der Heijde D, 2008, ARTHRITIS RHEUM US, V58, P3063, DOI 10.1002/art.23901
   van der Heijde D, 2006, ARTHRITIS RHEUM US, V54, P2136, DOI 10.1002/art.21913
   van der Heijde D, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2794
   van der Weijden MAC, 2012, CLIN RHEUMATOL, V31, P1529, DOI 10.1007/s10067 012 2018 0
   Vernekar AA, 2016, CHEM ASIAN J, V11, P72, DOI 10.1002/asia.201500942
   Wang CM, 2019, MEDIAT INFLAMM, V2019, DOI 10.1155/2019/8029863
   Wang D, 2011, MOL PHARMACEUT, V8, P991, DOI 10.1021/mp200328t
   Wang P, 2014, CELL TRANSPLANT, V23, P1293, DOI 10.3727/096368913X667727
   Ward MM, 2019, ARTHRITIS RHEUMATOL, V71, P1599, DOI [10.1002/art.41042, 10.1002/acr.24025]
   Xie ZY, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 25710 4
   Xie ZY, 2016, ARTHRITIS RHEUMATOL, V68, P430, DOI 10.1002/art.39433
   Yang YH, 2021, BIOMATERIALS, V264, DOI 10.1016/j.biomaterials.2020.120390
   Yang Y, 2015, INT J MOL MED, V36, P565, DOI 10.3892/ijmm.2015.2248
   Yu H, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392 020 00312 6
   Zhao ZM, 2020, CELL, V181, P151, DOI 10.1016/j.cell.2020.02.001
   Zheng G, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1586 1
   Zhou BO, 2014, CELL STEM CELL, V15, P154, DOI 10.1016/j.stem.2014.06.008
   Zhu GZ, 2018, ADV DRUG DELIVER REV, V134, P65, DOI 10.1016/j.addr.2018.08.005
   Zubkova ES, 2016, J CELL BIOCHEM, V117, P180, DOI 10.1002/jcb.25263
NR 59
TC 15
Z9 16
U1 5
U2 41
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1477 3155
J9 J NANOBIOTECHNOL
JI J. Nanobiotechnol.
PD MAY 26
PY 2023
VL 21
IS 1
AR 168
DI 10.1186/s12951 023 01906 2
PG 18
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Science & Technology   Other
   Topics
GA H1GO9
UT WOS:000993517000001
PM 37231465
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Gu, RL
   Liu, H
   Hu, ML
   Zhu, Y
   Liu, XA
   Wang, FL
   Wu, LK
   Song, DY
   Liu, YS
AF Gu, Ranli
   Liu, Hao
   Hu, Menglong
   Zhu, Yuan
   Liu, Xuenan
   Wang, Feilong
   Wu, Likun
   Song, Danyang
   Liu, Yunsong
TI D Mannose prevents bone loss under weightlessness
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE D mannose; Bone; UTI; Osteoclast; Cell fusion; Weightlessness
ID OSTEOCLAST DIFFERENTIATION; CRANBERRY PRODUCTS; TRABECULAR BONE;
   SPACE FLIGHT; MASS; SUPPLEMENTATION; PHYTOCHEMICALS; MICROGRAVITY;
   SPACEFLIGHT; INHIBITION
AB Background Astronauts undergo significant microgravity induced bone loss during space missions, which has become one of the three major medical problems hindering human's long term space flight. A risk free and antiresorptive drug is urgently needed to prevent bone loss during space missions. D mannose is a natural C 2 epimer of D glucose and is abundant in cranberries. This study aimed to investigate the protective effects and potential mechanisms of D mannose against bone loss under weightlessness. Methods The hind legs of tail suspended (TS) rats were used to mimic weightlessness on Earth. Rats were administered D mannose intragastrically. The osteoclastogenic and osteogenic capacity of D mannose in vitro and in vivo was analyzed by micro computed tomography, biomechanical assessment, bone histology, serum markers of bone metabolism, cell proliferation assay, quantitative polymerase chain reaction, and western blotting. RNA seq transcriptomic analysis was performed to detect the underlying mechanisms of D mannose in bone protection. Results The TS rats showed lower bone mineral density (BMD) and poorer bone morphological indices. D mannose could improve BMD in TS rats. D mannose inhibited osteoclast proliferation and fusion in vitro, without apparent effects on osteoblasts. RNA seq transcriptomic analysis showed that D mannose administration significantly inhibited the cell fusion molecule dendritic cell specific transmembrane protein (DC STAMP) and two indispensable transcription factors for osteoclast fusion (c Fos and nuclear factor of activated T cells 1 [NFATc1]). Finally, TS rats tended to experience dysuria related urinary tract infections (UTIs), which were suppressed by treatment with D mannose. Conclusion D mannose protected against bone loss and UTIs in rats under weightlessness. The bone protective effects of D mannose were mediated by inhibiting osteoclast cell fusion. Our findings provide a potential strategy to protect against bone loss and UTIs during space missions.
C1 [Gu, Ranli; Hu, Menglong; Zhu, Yuan; Liu, Xuenan; Wang, Feilong; Wu, Likun; Song, Danyang; Liu, Yunsong] Peking Univ, Sch & Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Dept Prosthodont,Natl Engn Lab Digital & Mat Techn, Beijing 100081, Peoples R China.
   [Liu, Hao] Peking Univ, Sch & Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Cent Lab,Natl Engn Lab Digital & Mat Technol Stoma, Beijing 100081, Peoples R China.
C3 Peking University; Peking University
RP Liu, YS (通讯作者)，Peking Univ, Sch & Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Dept Prosthodont,Natl Engn Lab Digital & Mat Techn, Beijing 100081, Peoples R China.
EM kqliuyunsong@hsc.pku.edu.cn
RI ; GU, Ranlii/U 5392 2017; Liu, Yunsong/AAS 6801 2020
OI Liu, Yunsong/0000 0001 8364 1898; 
FU National Natural Science Foundation of China; Natural Science
   Founda tion of Beijing Municipality [81970908, 82170929]; Peking
   University Medicine Fund of Fostering Young Scholars' Scientific &
   Technological Innovation [L222145];  [BMU2022PY010]
FX This study was supported by grants from the National Natural Science
   Foundation of China (No.81970908 and 82170929 to YSL), Natural Science
   Founda tion of Beijing Municipality (No. L222145 to HL), Peking
   University Medicine Fund of Fostering Young Scholars' Scientific &
   Technological Innovation (No. BMU2022PY010 to HL).
CR Ala Jaakkola R, 2022, NUTR J, V21, DOI 10.1186/s12937 022 00769 x
   BIKLE DD, 1994, J BONE MINER RES, V9, P1777
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Chatani M, 2015, SCI REP UK, V5, DOI 10.1038/srep14172
   Chen KM, 2007, PHARMAZIE, V62, P785, DOI 10.1691/ph.2007.10.7504
   Chiou JT, 2021, CELLS BASEL, V10, DOI 10.3390/cells10082073
   Chiu YH, 2017, J CELL PHYSIOL, V232, P2538, DOI 10.1002/jcp.25638
   CHRISTMAN JW, 1992, AM J RESP CELL MOL, V7, P455, DOI 10.1165/ajrcmb/7.4.455
   Collins MT, 2016, HORM METAB RES, V48, P687, DOI 10.1055/s 0042 119907
   De Nunzio C, 2021, ANTIBIOTICS BASEL, V10, DOI 10.3390/antibiotics10040373
   Deyhim F, 2006, NUTRITION, V22, P559, DOI 10.1016/j.nut.2005.12.002
   Deymier AC, 2019, ACTA BIOMATER, V83, P302, DOI 10.1016/j.actbio.2018.10.024
   Domazetovic V, 2019, FEBS OPEN BIO, V9, P1082, DOI 10.1002/2211 5463.12634
   Dou C, 2021, ADV SCI, V8, DOI 10.1002/advs.202102286
   Eyal S, 2019, PHARM RES DORDR, V36, DOI 10.1007/s11095 019 2679 3
   Feghali K, 2012, J AGR FOOD CHEM, V60, P5728, DOI 10.1021/jf203304v
   Franssen M, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen 2020 037128
   GLOBUS RK, 1986, ENDOCRINOLOGY, V118, P733, DOI 10.1210/endo 118 2 733
   Grünert SC, 2019, ORPHANET J RARE DIS, V14, DOI 10.1186/s13023 019 1213 3
   Guay DRP, 2009, DRUGS, V69, P775, DOI 10.2165/00003495 200969070 00002
   Guo LJ, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/7168231
   Guo Rui, 2005, Space Med Med Eng (Beijing), V18, P165
   Häkkinen SH, 1999, J AGR FOOD CHEM, V47, P2274, DOI 10.1021/jf9811065
   HALLORAN BP, 1986, ENDOCRINOLOGY, V118, P948, DOI 10.1210/endo 118 3 948
   Ichikawa M, 2014, J BIOL CHEM, V289, P6751, DOI 10.1074/jbc.M113.544064
   JEE WSS, 1983, AM J PHYSIOL, V244, pR310, DOI 10.1152/ajpregu.1983.244.3.R310
   Jepson R, 2013, JAMA J AM MED ASSOC, V310, P1395, DOI 10.1001/jama.2013.277509
   Jones TW, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00584
   Kitano VJF, 2020, J CELL SCI, V133, DOI 10.1242/jcs.243840
   Kodama Y, 1997, J BONE MINER RES, V12, P1058, DOI 10.1359/jbmr.1997.12.7.1058
   Kong LB, 2019, J CELL MOL MED, V23, P3077, DOI 10.1111/jcmm.14277
   Kuzmenko A. V., 2020, Urologiya (Moscow), P128, DOI 10.18565/urology.2020.3.128 132
   Kuzmenko A. V, 2019, Urologiya (Moscow), P38, DOI 10.18565/urology.2019.6.38 43
   Kyriakides R, 2021, EUR UROL FOCUS, V7, P1166, DOI 10.1016/j.euf.2020.09.004
   Lang T, 2004, J BONE MINER RES, V19, P1006, DOI 10.1359/JBMR.040307
   Laurens C, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00321
   Lenger SM, 2020, AM J OBSTET GYNECOL, V223, DOI 10.1016/j.ajog.2020.05.048
   Li SH, 2021, SMALL, V17, DOI 10.1002/smll.202104359
   Liu H, 2020, THER ADV CHRONIC DIS, V11, DOI 10.1177/2040622320912661
   Liu H, 2020, J ORAL REHABIL, V47, P83, DOI 10.1111/joor.12840
   Lloyd SA, 2015, BONE, V81, P562, DOI 10.1016/j.bone.2015.08.021
   McDonald MM, 2021, CELL, V184, P1330, DOI 10.1016/j.cell.2021.02.002
   Millward DJ, 2017, NUTR RES REV, V30, P50, DOI 10.1017/S0954422416000238
   Miyamoto Takeshi, 2011, Keio Journal of Medicine, V60, P101
   Morii Y, 2015, PHYTOTHER RES, V29, P1950, DOI 10.1002/ptr.5489
   Neto CC, 2007, J NUTR, V137, p186S, DOI 10.1093/jn/137.1.186S
   Pappas E, 2009, CRIT REV FOOD SCI, V49, P741, DOI 10.1080/10408390802145377
   Place DE, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 020 20807 8
   Qin YX, 2019, J ORTHOP TRANSL, V18, P48, DOI 10.1016/j.jot.2018.11.004
   Radulescu D, 2020, EXP THER MED, V20, P3399, DOI 10.3892/etm.2020.8970
   Ruel G, 2007, MOL NUTR FOOD RES, V51, P692, DOI 10.1002/mnfr.200600286
   Sato C, 2021, J BONE MINER METAB, V39, P385, DOI 10.1007/s00774 020 01184 0
   Shi Z, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/6947612
   Singh NK, 2018, MICROBIOME, V6, DOI 10.1186/s40168 018 0585 2
   Smith BJ, 2002, J NUTR, V132, P190, DOI 10.1093/jn/132.2.190
   Song CC, 2019, J CELL PHYSIOL, V234, P11969, DOI 10.1002/jcp.27852
   Sonnenfeld G, 2002, NUTRITION, V18, P899, DOI 10.1016/S0899 9007(02)00903 6
   Taday R, 2021, ORPHANET J RARE DIS, V16, DOI 10.1186/s13023 021 01988 x
   Tanabe S, 2011, MOLECULES, V16, P2365, DOI 10.3390/molecules16032365
   Taylor PW, 2015, INFECT DRUG RESIST, V8, P249, DOI 10.2147/IDR.S67275
   Tian TR, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00212 1
   Torretta S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 20164 6
   Tsukasaki M, 2019, NAT REV IMMUNOL, V19, P626, DOI 10.1038/s41577 019 0178 8
   Urbaniak C, 2018, SCI REP UK, V8, DOI 10.1038/s41598 017 18506 4
   Vico L, 2000, LANCET, V355, P1607, DOI 10.1016/S0140 6736(00)02217 0
   von Kroge S, 2021, EUR CELLS MATER, V42, P220, DOI 10.22203/eCM.v042a16
   Wallace TC, 2010, J FOOD SCI, V75, pC690, DOI 10.1111/j.1750 3841.2010.01799.x
   Wilson JW, 2007, P NATL ACAD SCI USA, V104, P16299, DOI 10.1073/pnas.0707155104
   Wu YL, 2022, MILITARY MED RES, V9, DOI 10.1186/s40779 022 00404 0
   Yang H, 2023, J PERIODONTOL, V94, P542, DOI 10.1002/JPER.22 0294
   Yang JC, 2020, BONE, V130, DOI 10.1016/j.bone.2019.115108
   Yarmanova EN, 2015, AEROSP MED HUM PERF, V86, pA32, DOI 10.3357/AMHP.EC05.2015
   Zhang DF, 2017, NAT MED, V23, P1036, DOI 10.1038/nm.4375
   Zhou M, 2021, BIOACT MATER, V6, P1676, DOI 10.1016/j.bioactmat.2020.11.018
NR 74
TC 10
Z9 10
U1 2
U2 29
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1479 5876
J9 J TRANSL MED
JI J. Transl. Med.
PD JAN 9
PY 2023
VL 21
IS 1
AR 8
DI 10.1186/s12967 022 03870 1
PG 19
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 7S8CO
UT WOS:000910978600001
PM 36617569
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wang, YX
   Li, X
   Zhou, SJ
   Li, JR
   Zhu, Y
   Wang, Q
   Zhao, FC
AF Wang, Yuxin
   Li, Xiang
   Zhou, Shengji
   Li, Jiarui
   Zhu, Yi
   Wang, Quan
   Zhao, Fengchao
TI MCU Inhibitor Ruthenium Red Alleviates the Osteoclastogenesis and
   Ovariectomized Osteoporosis via Suppressing RANKL Induced ROS Production
   and NFATc1 Activation through P38 MAPK Signaling Pathway
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
ID MITOCHONDRIAL CALCIUM UNIPORTER; KAPPA B LIGAND; RECEPTOR ACTIVATOR;
   CA2+ UPTAKE; DIFFERENTIATION; RISK; OSTEOPROTEGERIN; PROTEIN; CANCER
AB Osteoporosis is a disorder of bone metabolism that is extremely common in elderly patients as well as in postmenopausal women. The main manifestation is that the bone resorption capacity is greater than the bone formation capacity, which eventually leads to a decrease in bone mass, increasing the risk of fracture. There is growing evidence that inhibiting osteoclast formation and resorption ability can be effective in treating and preventing the occurrence of osteoporosis. Our study is the first time to explore the role of the mitochondrial calcium uniporter (MCU) and its inhibitor ruthenium red (RR) in bone metabolism, clarifying the specific mechanism by which it inhibits osteoclast formation in vitro and plays a therapeutic role in osteoporosis in vivo. We verified the suppressive effects of RR on the receptor activator of nuclear factor kappa B ligand (RANKL ) induced differentiation and bone resorption function of osteoclasts in vitro. The reactive oxygen species (ROS) production stimulated by RANKL and the expression level of P38 MAPK/NFATc1 were also found to be inhibited by RR. Moreover, the promotion of RR on osteogenesis differentiation was investigated by alkaline phosphatase (ALP) and alizarin red S (ARS) staining and the detection of osteogenesis specific gene expression levels by quantitative polymerase chain reaction (qPCR) and western blotting. Moreover, in ovariectomy (OVX ) induced osteoporosis models, RR can downregulate the expression and function of the MCU, relieving bone loss and promoting osteogenesis to present a therapeutic effect on osteoporosis. This new finding will provide an important direction for the study of RR and MCU in the study of bone metabolism therapy targets.
C1 [Wang, Yuxin; Li, Xiang; Zhou, Shengji; Li, Jiarui; Wang, Quan; Zhao, Fengchao] Zhejiang Univ, Affiliated Hosp 1, Dept Orthopaed Surg, Sch Med, Hangzhou 310003, Peoples R China.
   [Zhu, Yi] Lihuili Hosp, Dept Neurol, Ningbo Med Ctr, Ningbo 315000, Peoples R China.
C3 Zhejiang University
RP Zhao, FC (通讯作者)，Zhejiang Univ, Affiliated Hosp 1, Dept Orthopaed Surg, Sch Med, Hangzhou 310003, Peoples R China.
EM wangyuxin@zju.edu.cn; idea_lixiang@163.com; 22118120@zju.edu.cn;
   2812642479@qq.com; zhuyi986@sina.com; docwangquan@163.com;
   zhaofengchao@zju.edu.cn
RI 李, 佳睿/JDW 5769 2023; Lee, Leonard/GOJ 8927 2022
OI Zhao, Fengchao/0000 0002 6000 7197
FU Natural Science Foundation of Zhejiang Province in China; 
   [LGF22H060003]
FX AcknowledgmentsThis research was supported by the Natural Science
   Foundation of Zhejiang Province in China under Grant No. LGF22H060003.
CR Aliprantis AO, 2008, J CLIN INVEST, V118, P3775, DOI 10.1172/JCI35711
   Arai M, 2007, IUBMB LIFE, V59, P27, DOI 10.1080/15216540601156188
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Bamias A, 2005, J CLIN ONCOL, V23, P8580, DOI 10.1200/JCO.2005.02.8670
   Baughman JM, 2011, NATURE, V476, P341, DOI 10.1038/nature10234
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen K, 2019, THERANOSTICS, V9, P1634, DOI 10.7150/thno.30206
   Chen X, 2019, RNA BIOL, V16, P1249, DOI 10.1080/15476286.2019.1624470
   Chotiyarnwong P, 2020, NAT REV ENDOCRINOL, V16, P437, DOI 10.1038/s41574 020 0341 0
   COLOMBO PM, 1977, J ULTRA MOL STRUCT R, V60, P135, DOI 10.1016/S0022 5320(77)80060 9
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   García Rivas GD, 2006, BRIT J PHARMACOL, V149, P829, DOI 10.1038/sj.bjp.0706932
   De Stefani D, 2011, NATURE, V476, P336, DOI 10.1038/nature10230
   Evans J, 2015, MICROVASC RES, V98, P145, DOI 10.1016/j.mvr.2014.04.011
   Glancy B, 2013, BIOCHEMISTRY US, V52, P2793, DOI 10.1021/bi3015983
   Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140 6736(96)07308 4
   Guan LC, 2019, INT J IMPLANT DENT, V5, DOI 10.1111/jcmm.14662
   György H, 2006, CELL CALCIUM, V40, P553, DOI 10.1016/j.ceca.2006.08.016
   Hauser M, 2018, BONE, V112, P107, DOI 10.1016/j.bone.2018.04.017
   Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023
   Kim MS, 2010, J BIOL CHEM, V285, P6913, DOI 10.1074/jbc.M109.051557
   Kirichok Y, 2004, NATURE, V427, P360, DOI 10.1038/nature02246
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Li X, 2021, CELL BIOL TOXICOL, V37, P849, DOI 10.1007/s10565 020 09578 6
   Liu Y, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392 020 0155 5
   Liu YH, 2019, THERANOSTICS, V9, P4648, DOI 10.7150/thno.35414
   Marchi S, 2019, CELL CYCLE, V18, P914, DOI 10.1080/15384101.2019.1598729
   Motohashi H, 2004, TRENDS MOL MED, V10, P549, DOI 10.1016/j.molmed.2004.09.003
   Narod SA, 2011, NAT REV CLIN ONCOL, V8, P669, DOI 10.1038/nrclinonc.2011.110
   Ohyama Y, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191192
   Okada H, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010180
   Park S, 2011, CELL CALCIUM, V50, P73, DOI 10.1016/j.ceca.2011.05.009
   Porras AG, 1999, CLIN PHARMACOKINET, V36, P315, DOI 10.2165/00003088 199936050 00002
   Raffaello A, 2013, EMBO J, V32, P2362, DOI 10.1038/emboj.2013.157
   Ren T, 2017, ONCOGENE, V36, P5897, DOI 10.1038/onc.2017.167
   Rimessi A, 2013, AUTOPHAGY, V9, P1677, DOI 10.4161/auto.24795
   Rizzuto R, 2012, NAT REV MOL CELL BIO, V13, P566, DOI 10.1038/nrm3412
   Saag KG, 2007, NEW ENGL J MED, V357, P2028, DOI 10.1056/NEJMoa071408
   Seidlmayer LK, 2015, CARDIOVASC RES, V106, P237, DOI 10.1093/cvr/cvv097
   Sharma Y, 2020, BRAIN RES BULL, V164, P121, DOI 10.1016/j.brainresbull.2020.08.020
   Si L, 2015, OSTEOPOROSIS INT, V26, P1929, DOI 10.1007/s00198 015 3093 2
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi Hiroshi, 2007, Clin Calcium, V17, P484
   Tomar D, 2019, CELL REP, V26, P3709, DOI 10.1016/j.celrep.2019.02.107
   Tosatto A, 2016, EMBO MOL MED, V8, P569, DOI 10.15252/emmm.201606255
   Trouvin AP, 2010, CLIN INTERV AGING, V5, P345, DOI 10.2147/CIA.S10153
   Wang YX, 2021, FRONT MED LAUSANNE, V8, DOI 10.3389/fmed.2021.674986
   Wen JX, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01135
   Xu L, 1999, J BIOL CHEM, V274, P32680, DOI 10.1074/jbc.274.46.32680
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yoo J, 2018, SCIENCE, V361, P506, DOI 10.1126/science.aar4056
   Zhu J, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.488
NR 52
TC 9
Z9 13
U1 2
U2 14
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942 0900
EI 1942 0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PD SEP 13
PY 2022
VL 2022
AR 7727006
DI 10.1155/2022/7727006
PG 27
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 5C9VE
UT WOS:000864599100003
PM 36148414
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Paiva, AE
   Lousado, L
   Almeida, VM
   Andreotti, JP
   Santos, GSP
   Azevedo, PO
   Sena, IFG
   Prazeres, PHDM
   Borges, IT
   Azevedo, V
   Mintz, A
   Birbrair, A
AF Paiva, Ana E.
   Lousado, Luiza
   Almeida, Viviani M.
   Andreotti, Julia P.
   Santos, Gabryella S. P.
   Azevedo, Patrick O.
   Sena, Isadora F. G.
   Prazeres, Pedro H. D. M.
   Borges, Isabella T.
   Azevedo, Vasco
   Mintz, Akiva
   Birbrair, Alexander
TI Endothelial Cells as Precursors for Osteoblasts in the Metastatic
   Prostate Cancer Bone
SO NEOPLASIA
LA English
DT Article
ID PHENOTYPIC HETEROGENEITY; PERICYTES PARTICIPATE; RECEPTOR; TIE2;
   DIFFERENTIATION; REGENERATION; EXPRESSION; DISEASE; LINEAGE; BIOLOGY
AB Prostate cancer cells metastasize to the bones, causing ectopic bone formation, which results in fractures and pain. The cellular mechanisms underlying new bone production are unknown. In a recent study, Lin and colleagues, by using state of the art techniques, including prostate cancer mouse models in combination with sophisticated in vivo lineage tracing technologies, revealed that endothelial cells form osteoblasts induced by prostate cancer metastasis in the bone. Strikingly, genetic deletion of osteorix protein from endothelial cells affected prostate cancer induced osteogenesis in vivo. Deciphering the osteoblasts origin in the bone microenvironment may result in the development of promising new molecular targets for prostate cancer therapy.
C1 [Paiva, Ana E.; Lousado, Luiza; Almeida, Viviani M.; Andreotti, Julia P.; Santos, Gabryella S. P.; Azevedo, Patrick O.; Sena, Isadora F. G.; Prazeres, Pedro H. D. M.; Borges, Isabella T.; Birbrair, Alexander] Univ Fed Minas Gerais, Dept Pathol, Belo Horizonte, MG, Brazil.
   [Azevedo, Vasco] Univ Fed Minas Gerais, Inst Biol Sci, Dept Gen Biol, Belo Horizonte, MG, Brazil.
   [Mintz, Akiva] Columbia Univ, Med Ctr, Dept Radiol, New York, NY USA.
C3 Universidade Federal de Minas Gerais; Universidade Federal de Minas
   Gerais; Columbia University
RP Birbrair, A (通讯作者)，Univ Fed Minas Gerais, Inst Biol Sci, Dept Pathol, Belo Horizonte, MG, Brazil.
EM birbrair@icb.ufmg.br
RI ; Sena, Isadora/E 5373 2018; Birbrair, Alexander/H 2497 2012; Azevedo,
   Vasco/B 1556 2019; Almeida, Viviani/KSL 9359 2024; vasco,
   azevedo/F 4315 2011
OI Fernandes Gilson Sena, Isadora/0000 0002 4304 9707; Birbrair,
   Alexander/0000 0003 1015 2561; Mendes de Almeida,
   Viviani/0000 0001 6061 8038; Andreotti, Julia/0000 0003 4235 1186;
   vasco, azevedo/0000 0002 4775 2280
FU Pro reitoria de Pesquisa da Universidade Federal de Minas Gerais
   (PRPq/UFMG) [Edital 05/2016]; National Institutes of Health
   [1R01CA179072 01A1]; American Cancer Society Mentored Research Scholar
   grant [124443 MRSG 13 121 01 CDD]
FX Alexander Birbrair is supported by a grant from Pro reitoria de Pesquisa
   da Universidade Federal de Minas Gerais (PRPq/UFMG) (Edital 05/2016);
   Akiva Mintz is supported by the National Institutes of Health
   (1R01CA179072 01A1) and by the American Cancer Society Mentored Research
   Scholar grant (124443 MRSG 13 121 01 CDD).
CR Aird WC, 2007, CIRC RES, V100, P158, DOI 10.1161/01.RES.0000255691.76142.4a
   Aird WC, 2007, CIRC RES, V100, P174, DOI 10.1161/01.RES.0000255690.03436.ae
   Almeida V. M., 2017, NEUROSCIENT IN PRESS
   Andreotti JP, 2017, CELL STEM CELL, V21, P293, DOI 10.1016/j.stem.2017.08.005
   Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004
   Asada N, 2017, NAT CELL BIOL, V19, P214, DOI 10.1038/ncb3475
   Azevedo PO, 2017, NEUROSCIENCE
   Birbrair A, 2017, STEM CELLS DEV, V26, P1013, DOI 10.1089/scd.2017.0044
   Birbrair A, 2017, STEM CELL TRANSL MED, V6, P471, DOI 10.5966/sctm.2016 0007
   Birbrair A, 2016, ANN NY ACAD SCI, V1370, P82, DOI 10.1111/nyas.13016
   Birbrair A, 2015, STEM CELL REV REP, V11, P547, DOI 10.1007/s12015 015 9588 6
   Birbrair A, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt512
   Birbrair A, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00245
   Birbrair A, 2015, CLIN SCI, V128, P81, DOI 10.1042/CS20140278
   Birbrair A, 2014, AM J PHYSIOL CELL PH, V307, pC25, DOI 10.1152/ajpcell.00084.2014
   Birbrair A, 2013, AM J PHYSIOL CELL PH, V305, pC1098, DOI 10.1152/ajpcell.00171.2013
   Birbrair A, 2013, STEM CELLS DEV, V22, P2298, DOI 10.1089/scd.2012.0647
   Birbrair A, 2013, STEM CELL RES, V10, P67, DOI 10.1016/j.scr.2012.09.003
   Birbrair A, 2013, EXP CELL RES, V319, P45, DOI 10.1016/j.yexcr.2012.09.008
   Birbrair A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016816
   Borges IDT, 2017, STEM CELL R IN PRESS
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen MJ, 2009, NATURE, V457, P887, DOI 10.1038/nature07619
   Coatti GC, 2017, STEM CELL R IN PRESS
   Constien R, 2001, GENESIS, V30, P36, DOI 10.1002/gene.1030
   de Caestecker M, 2004, CYTOKINE GROWTH F R, V15, P1, DOI 10.1016/j.cytogfr.2003.10.004
   de Lange WJ, 2008, PHYSIOL GENOMICS, V35, P1, DOI 10.1152/physiolgenomics.90284.2008
   Prazeres PHDM, 2017, DEV BIOL, V427, P6, DOI 10.1016/j.ydbio.2017.05.001
   Dy GW, 2017, EUR UROL, V71, P437, DOI 10.1016/j.eururo.2016.10.008
   Gartrell BA, 2014, NAT REV CLIN ONCOL, V11, P335, DOI 10.1038/nrclinonc.2014.70
   GREENBERG NM, 1994, MOL ENDOCRINOL, V8, P230, DOI 10.1210/me.8.2.230
   Hensel J, 2016, UROLOGY, V92, P6, DOI 10.1016/j.urology.2015.12.039
   Hirschi KK, 2012, BLOOD, V119, P4823, DOI 10.1182/blood 2011 12 353466
   Kan C, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101674
   Khan JA, 2016, SCIENCE, V351, P176, DOI 10.1126/science.aad0084
   Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535 7163.MCT 07 0234
   Kisanuki YY, 2001, DEV BIOL, V230, P230, DOI 10.1006/dbio.2000.0106
   Lebrin F, 2005, CARDIOVASC RES, V65, P599, DOI 10.1016/j.cardiores.2004.10.036
   Lin SC, 2017, DEV CELL, V41, P467, DOI 10.1016/j.devcel.2017.05.005
   Lousado L, 2017, CELLS CELL IN PRESS
   Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55
   Medvinsky A, 1996, CELL, V86, P897, DOI 10.1016/S0092 8674(00)80165 8
   Park DY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15296
   Nguyen PD, 2014, NATURE, V512, P314, DOI 10.1038/nature13678
   Prazeres P, 2017, CELL MOL NEUROBIOL
   Rafii S, 2016, NATURE, V529, P316, DOI 10.1038/nature17040
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Santos GSP, 2017, EYE IN PRESS
   SCHNURCH H, 1993, DEVELOPMENT, V119, P957
   Sena I. F. G., 2017, CELL CYCLE IN PRESS
   Sena IFG, 2017, EXP HEMATOL IN PRESS
   STEWART AF, 1982, J CLIN ENDOCR METAB, V55, P219, DOI 10.1210/jcem 55 2 219
   Takakura N, 1998, IMMUNITY, V9, P677, DOI 10.1016/S1074 7613(00)80665 2
   Tang YF, 2010, GENESIS, V48, P563, DOI 10.1002/dvg.20654
   Thorin E, 1998, PHARMACOL THERAPEUT, V78, P155, DOI 10.1016/S0163 7258(98)00005 9
   Wylie Sears J, 2011, ARTERIOSCL THROM VAS, V31, P598, DOI 10.1161/ATVBAHA.110.216184
   Zeisberg EM, 2008, J AM SOC NEPHROL, V19, P2282, DOI 10.1681/ASN.2008050513
   Zheng B, 2013, J ORTHOP RES, V31, P1089, DOI 10.1002/jor.22335
   Zhou BO, 2014, CELL STEM CELL, V15, P154, DOI 10.1016/j.stem.2014.06.008
NR 59
TC 26
Z9 26
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1476 5586
J9 NEOPLASIA
JI Neoplasia
PD NOV
PY 2017
VL 19
IS 11
BP 928
EP 931
DI 10.1016/j.neo.2017.08.007
PG 4
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA FL3TR
UT WOS:000414147400007
PM 28957694
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Zhou, CH
   Meng, JH
   Yang, YT
   Hu, B
   Hong, JQ
   Lv, ZT
   Chen, K
   Heng, BC
   Jiang, GY
   Zhu, J
   Cheng, ZH
   Zhang, W
   Cao, L
   Wang, W
   Shen, WL
   Yan, SG
   Wu, HB
AF Zhou, Chen he
   Meng, Jia hong
   Yang, Yu te
   Hu, Bin
   Hong, Jian qiao
   Lv, Zheng tao
   Chen, Kun
   Heng, Boon Chin
   Jiang, Guang yao
   Zhu, Jian
   Cheng, Zhao hui
   Zhang, Wei
   Cao, Le
   Wang, Wei
   Shen, Wei liang
   Yan, Shi gui
   Wu, Hao bo
TI Cepharanthine Prevents Estrogen Deficiency Induced Bone Loss by
   Inhibiting Bone Resorption
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE cepharanthine; osteoclasts; osteoporosis; Akt; JNK
ID NF KAPPA B; BISCOCLAURINE ALKALOID CEPHARANTHINE; IN VITRO; OSTEOCLAST
   DIFFERENTIATION; ELDERLY WOMEN; OSTEOPOROSIS; FRACTURES; THERAPIES;
   NLRC3; HYDROCHLORIDE
AB Osteoporosis is a common health problem worldwide caused by an imbalance of bone formation vs. bone resorption. However, current therapeutic approaches aimed at enhancing bone formation or suppressing bone resorption still have some limitations. In this study, we demonstrated for the first time that cepharanthine (CEP, derived from Stephania cepharantha Hayata) exerted a protective effect on estrogen deficiency induced bone loss. This protective effect was confirmed to be achieved through inhibition of bone resorption in vivo, rather than through enhancement of bone formation in vivo. Furthermore, the in vitro study revealed that CEP attenuated receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclast formation, and suppressed bone resorption by impairing the c Jun N terminal kinase (JNK) and phosphatidylinositol 3 kinase (PI3K) AKT signaling pathways. The inhibitory effect of CEP could be partly reversed by treatment with anisomycin (a JNK and p38 agonist) and/or SC79 (an AKT agonist) in vitro. Our results thus indicated that CEP could prevent estrogen deficiency induced bone loss by inhibiting osteoclastogenesis. Hence, CEP might be a novel therapeutic agent for anti osteoporosis therapy.
C1 [Zhou, Chen he; Meng, Jia hong; Yang, Yu te; Hu, Bin; Hong, Jian qiao; Jiang, Guang yao; Zhu, Jian; Zhang, Wei; Cao, Le; Wang, Wei; Shen, Wei liang; Yan, Shi gui; Wu, Hao bo] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Orthoped Surg, Hangzhou, Zhejiang, Peoples R China.
   [Zhou, Chen he; Meng, Jia hong; Yang, Yu te; Hu, Bin; Hong, Jian qiao; Jiang, Guang yao; Zhu, Jian; Zhang, Wei; Cao, Le; Wang, Wei; Shen, Wei liang; Yan, Shi gui; Wu, Hao bo] Zhejiang Univ, Orthoped Res Inst, Hangzhou, Zhejiang, Peoples R China.
   [Lv, Zheng tao; Chen, Kun] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Orthoped, Wuhan, Peoples R China.
   [Heng, Boon Chin] Univ Hong Kong, Fac Dent, Hong Kong, Hong Kong, Peoples R China.
   [Cheng, Zhao hui] Taizhou First Peoples Hosp, Dept Orthopaed Surg, Taizhou, Peoples R China.
C3 Zhejiang University; Zhejiang University; Huazhong University of Science
   & Technology; University of Hong Kong
RP Shen, WL; Yan, SG; Wu, HB (通讯作者)，Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Orthoped Surg, Hangzhou, Zhejiang, Peoples R China.; Shen, WL; Yan, SG; Wu, HB (通讯作者)，Zhejiang Univ, Orthoped Res Inst, Hangzhou, Zhejiang, Peoples R China.
EM wlshen@zju.edu.cn; zrjwsj@zju.edu.cn; 2505014@zju.edu.cn
RI Chen, Kun/AAG 9227 2021; Zhang, Wei/HOF 7252 2023; Zhou,
   Chenhe/AAI 9226 2020; Heng, Boon/E 5462 2016
OI SHEN, WEI LIANG/0000 0001 8131 325X; Chen, Kun/0000 0003 0507 7640; Yan,
   Shigui/0000 0001 9096 2868; Heng, Boon Chin/0000 0003 2541 3699
FU National Natural Science Foundation of China [81371954, 81472113,
   81401785, 81572157, 81601878, 81772360]; Zhejiang Medical and Health
   Science and Technology Program [2017KY715, 2016RCA016]; Zhejiang Natural
   Science Foundation [LY17H060004, LY18H060005]
FX This study was supported by research grants from the National Natural
   Science Foundation of China (81371954, 81472113, 81401785, 81572157,
   81601878, 81772360), the Zhejiang Medical and Health Science and
   Technology Program (2017KY715, 2016RCA016), and Zhejiang Natural Science
   Foundation (LY17H060004, LY18H060005).
CR BARON R, 1986, CELL, V46, P311, DOI 10.1016/0092 8674(86)90748 8
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Budhia S, 2012, PHARMACOECONOMICS, V30, P147, DOI 10.2165/11596880 000000000 00000
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Charles JF, 2014, TRENDS MOL MED, V20, P449, DOI 10.1016/j.molmed.2014.06.001
   Chen S, 2015, SCI REP UK, V5, DOI 10.1038/srep12853
   Cranney A, 2002, ENDOCR REV, V23, P570, DOI 10.1210/er.2001 9002
   Furusawa S, 2007, LIFE SCI, V80, P1073, DOI 10.1016/j.lfs.2006.12.001
   Gatti D, 2009, EXPERT OPIN DRUG MET, V5, P1305, DOI 10.1517/17425250903029190
   Harslof T, 2016, CURR OPIN PHARMACOL, V28, P38, DOI 10.1016/j.coph.2016.02.012
   Ita M, 2008, CANCER BIOL THER, V7, P1104, DOI 10.4161/cbt.7.7.6172
   Ivaska KK, 2010, J BONE MINER RES, V25, P393, DOI 10.1359/jbmr.091006
   Jimi E, 1999, J IMMUNOL, V163, P434
   Karki R, 2016, NATURE, V540, P583, DOI 10.1038/nature20597
   Kawai M, 2011, NAT REV DRUG DISCOV, V10, P141, DOI 10.1038/nrd3299
   Khan AA, 2009, J RHEUMATOL, V36, P478, DOI 10.3899/jrheum.080759
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Koh JSB, 2010, J ORTHOP TRAUMA, V24, P75, DOI 10.1097/BOT.0b013e3181b6499b
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Leibbrandt A, 2008, ANN NY ACAD SCI, V1143, P123, DOI 10.1196/annals.1443.016
   Liu WQ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12794
   Lotinun S, 2018, CALCIFIED TISSUE INT, V102, P93, DOI 10.1007/s00223 017 0334 8
   Lotinun S, 2013, J CLIN INVEST, V123, P666, DOI 10.1172/JCI64840
   Makihira S, 2011, EUR J PHARMACOL, V670, P409, DOI 10.1016/j.ejphar.2011.08.044
   Morita K, 2002, J DERMATOL, V29, P661, DOI 10.1111/j.1346 8138.2002.tb00199.x
   Ng PY, 2013, J BONE MINER RES, V28, P119, DOI 10.1002/jbmr.1725
   Ohta T, 1990, Rinsho Hoshasen, V35, P471
   Okamoto M, 2001, BIOCHEM PHARMACOL, V62, P747, DOI 10.1016/S0006 2952(01)00692 X
   Omiya T, 2018, BONE, V107, P18, DOI 10.1016/j.bone.2017.10.021
   Paudel KR, 2016, TOXICOL IN VITRO, V34, P16, DOI 10.1016/j.tiv.2016.03.010
   Pfister AK, 2006, SOUTH MED J, V99, P123, DOI 10.1097/01.smj.0000202090.30647.61
   Rogosnitzky M, 2011, PHARMACOL REP, V63, P337, DOI 10.1016/S1734 1140(11)70500 X
   Saito T, 2017, OSTEOPOROSIS INT, V28, P3289, DOI 10.1007/s00198 017 4175 0
   Satoh K, 2003, BIOCHEM PHARMACOL, V66, P379, DOI 10.1016/S0006 2952(03)00210 7
   Schneider M, 2012, NAT IMMUNOL, V13, P823, DOI 10.1038/ni.2378
   Stevenson DA, 2011, CLIN GENET, V80, P566, DOI 10.1111/j.1399 0004.2010.01619.x
   Tabata R, 2012, INT IMMUNOPHARMACOL, V13, P242, DOI 10.1016/j.intimp.2012.04.015
   Takahashi Makise N, 2009, INT J CANCER, V125, P1464, DOI 10.1002/ijc.24521
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tocker AM, 2017, J IMMUNOL, V199, P2896, DOI 10.4049/jimmunol.1601370
   Vasikaran S, 2011, CLIN CHEM LAB MED, V49, P1271, DOI 10.1515/CCLM.2011.602
   Watts NB, 2008, J CLIN DENSITOM, V11, P473, DOI 10.1016/j.jocd.2008.04.003
   Watts Nelson B, 2010, Endocr Pract, V16 Suppl 3, P1
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097 2765(00)80232 4
   Wu MR, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13700
   Xie Z, 2018, J BONE MINER RES, V33, P667, DOI 10.1002/jbmr.3334
   Yuan FL, 2015, BONE, V75, P128, DOI 10.1016/j.bone.2015.02.017
   Zhou CF, 2017, WILDLIFE BIOL, P1, DOI 10.2981/wlb.00258
   Zhou YB, 2012, EUR J PHARMACOL, V683, P10, DOI 10.1016/j.ejphar.2012.02.030
NR 49
TC 19
Z9 23
U1 1
U2 24
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD MAR 27
PY 2018
VL 9
AR 210
DI 10.3389/fphar.2018.00210
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA GA5VV
UT WOS:000428402900001
PM 29636680
OA Green Published, gold
DA 2025 08 17
ER

PT J
CA Kidney Dis Improving Global
TI KDIGO 2017 CLINICAL PRACTICE GUIDELINE UPDATE FOR THE DIAGNOSIS,
   EVALUATION, PREVENTION, AND TREATMENT OF CHRONIC KIDNEY DISEASE MINERAL
   AND BONE DISORDER (CKD MBD)
SO KIDNEY INTERNATIONAL SUPPLEMENTS
LA English
DT Article
DE bone abnormalities; bone mineral density; calcium; chronic kidney
   disease; CKD MBD; dialysis; guideline; hyperparathyroidism;
   hyperphosphatemia; KDIGO; kidney transplantation; mineral and bone
   disorder; parathyroid hormone; phosphate; phosphorus; systematic review
ID PATIENTS RECEIVING HEMODIALYSIS; CORONARY ARTERY CALCIFICATION; STAGE
   RENAL DISEASE; EARLY CORTICOSTEROID WITHDRAWAL; SERUM
   PARATHYROID HORMONE; CINACALCET HCL THERAPY; YOUNG ADULT MEN; DOSE
   VITAMIN D; SECONDARY HYPERPARATHYROIDISM; CALCIUM CARBONATE
AB The Kidney Disease: Improving Global Outcomes (KDIGO) 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of chronic kidney disease mineral and bone disorder (CKD MBD) represents a selective update of the prior guideline published in 2009. This update, along with the 2009 publication, is intended to assist the practitioner caring for adults and children with CKD, those on chronic dialysis therapy, or individuals with a kidney transplant. Specifically, the topic areas for which updated recommendations are issued include diagnosis of bone abnormalities in CKD MBD; treatment of CKD MBD by targeting phosphate lowering and calcium maintenance, treatment of abnormalities in parathyroid hormone in CKD MBD; treatment of bone abnormalities by antiresorptives and other osteoporosis therapies; and evaluation and treatment of kidney transplant bone disease. Development of this guideline update followed an explicit process of evidence review and appraisal. Treatment approaches and guideline recommendations are based on systematic reviews of relevant trials, and appraisal of the quality of the evidence and the strength of recommendations followed the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. Limitations of the evidence are discussed, with areas of future research also presented.
CR Akaberi S, 2008, AM J TRANSPLANT, V8, P2647, DOI 10.1111/j.1600 6143.2008.02423.x
   Alem AM, 2000, KIDNEY INT, V58, P396, DOI 10.1046/j.1523 1755.2000.00178.x
   Alharthi AA, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000401
   Amerling R, 2010, BLOOD PURIFICAT, V29, P293, DOI 10.1159/000276666
   Anderson JJB, 2001, PRESENT KNOWLEDGE NU
   Atkins D, 2004, BMJ BRIT MED J, V328, P1490
   Bailey DA, 2000, J BONE MINER RES, V15, P2245, DOI 10.1359/jbmr.2000.15.11.2245
   Ball AM, 2002, JAMA J AM MED ASSOC, V288, P3014, DOI 10.1001/jama.288.23.3014
   Baxter Jones ADG, 2011, J BONE MINER RES, V26, P1729, DOI 10.1002/jbmr.412
   Beaubrun AC, 2013, J AM SOC NEPHROL, V24, P1461, DOI 10.1681/ASN.2012090916
   Behets GJ, 2015, KIDNEY INT, V87, P846, DOI 10.1038/ki.2014.349
   Benini O, 2011, J RENAL NUTR, V21, P303, DOI 10.1053/j.jrn.2010.06.021
   Berger C, 2010, J BONE MINER RES, V25, P1948, DOI 10.1002/jbmr.95
   Bianchi ML, 2014, J CLIN DENSITOM, V17, P281, DOI 10.1016/j.jocd.2014.01.005
   Bishop N, 2014, J CLIN DENSITOM, V17, P275, DOI 10.1016/j.jocd.2014.01.004
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Block GA, 2017, J AM SOC NEPHROL, V28, P1933, DOI 10.1681/ASN.2016080855
   Block GA, 2017, JAMA J AM MED ASSOC, V317, P146, DOI 10.1001/jama.2016.19456
   Block GA, 2017, JAMA J AM MED ASSOC, V317, P156, DOI 10.1001/jama.2016.19468
   Block GA, 2013, CLIN J AM SOC NEPHRO, V8, P2132, DOI 10.2215/CJN.04260413
   Block GA, 2012, J AM SOC NEPHROL, V23, P1407, DOI 10.1681/ASN.2012030223
   Bonani M, 2016, AM J TRANSPLANT, V16, P1882, DOI 10.1111/ajt.13692
   Brunelli SM, 2015, AM J KIDNEY DIS, V66, P655, DOI 10.1053/j.ajkd.2015.03.038
   Caldeira D, 2011, J RENAL NUTR, V21, P285, DOI 10.1053/j.jrn.2010.11.006
   Calvo MS, 1996, J NUTR, V126, pS1168, DOI 10.1093/jn/126.suppl_4.1168S
   Calvo MS, 2000, NUTRITION, V16, P564, DOI 10.1016/S0899 9007(00)00313 0
   Cannata Andía B, 2013, KIDNEY INT, V84, P998, DOI 10.1038/ki.2013.185
   Chartsrisak K, 2013, BMC NEPHROL, V14, DOI 10.1186/1471 2369 14 14
   Chertow GM, 2012, NEW ENGL J MED, V367, P2482, DOI 10.1056/NEJMoa1205624
   Chonchol M, 2009, AM J KIDNEY DIS, V53, P197, DOI 10.1053/j.ajkd.2008.09.021
   Chue CD, 2013, J AM SOC NEPHROL, V24, P842, DOI 10.1681/ASN.2012070719
   Civilibal M, 2006, PEDIATR NEPHROL, V21, P1426, DOI 10.1007/s00467 006 0159 6
   Coburn JW, 2004, AM J KIDNEY DIS, V43, P877, DOI 10.1053/j.ajkd.2004.01.012
   Coen G, 2010, BMC NEPHROL, V11, DOI 10.1186/1471 2369 11 10
   Connolly GM, 2009, TRANSPLANTATION, V87, P1040, DOI 10.1097/TP.0b013e31819cd122
   Coyne D, 2006, AM J KIDNEY DIS, V47, P263, DOI 10.1053/j.ajkd.2005.10.007
   Coyne DW, 2014, CLIN J AM SOC NEPHRO, V9, P1620, DOI 10.2215/CJN.10661013
   Crabtree NJ, 2014, J CLIN DENSITOM, V17, P225, DOI 10.1016/j.jocd.2014.01.003
   Darelid A, 2012, J BONE MINER RES, V27, P2198, DOI 10.1002/jbmr.1675
   de Boer IH, 2009, AM J KIDNEY DIS, V53, P399, DOI 10.1053/j.ajkd.2008.07.036
   Denburg MR, 2016, J AM SOC NEPHROL, V27, P543, DOI 10.1681/ASN.2015020152
   Denburg MR, 2013, J CLIN ENDOCR METAB, V98, P1930, DOI 10.1210/jc.2012 4188
   Di Iorio B, 2013, AM J KIDNEY DIS, V62, P771, DOI 10.1053/j.ajkd.2013.03.023
   Di Iorio B, 2012, CLIN J AM SOC NEPHRO, V7, P487, DOI 10.2215/CJN.03820411
   Dotis J, 2013, J PEDIATR ENDOCR MET, V26, P39, DOI 10.1515/jpem 2012 0214
   Durose CL, 2004, J AM DIET ASSOC, V104, P35, DOI 10.1016/j.jada.2003.10.016
   Eddington H, 2010, CLIN J AM SOC NEPHRO, V5, P2251, DOI 10.2215/CJN.00810110
   El Borolossy R, 2016, PEDIATR NEPHROL, V31, P289, DOI 10.1007/s00467 015 3208 1
   Evenepoel P, 2014, AM J TRANSPLANT, V14, P2545, DOI 10.1111/ajt.12911
   Evenepoel P., Nephrol Dial Transplant
   Evenepoel P, 2016, KIDNEY INT, V90, P1184, DOI 10.1016/j.kint.2016.06.041
   Evenepoel P, 2013, SEMIN NEPHROL, V33, P191, DOI 10.1016/j.semnephrol.2012.12.019
   Fein Paul A, 2013, Adv Perit Dial, V29, P61
   Fishbane S, 2009, AM J KIDNEY DIS, V54, P647, DOI 10.1053/j.ajkd.2009.04.036
   Fliser D, 2007, J AM SOC NEPHROL, V18, P2600, DOI 10.1681/ASN.2006080936
   Floege J, 2014, KIDNEY INT, V86, P638, DOI 10.1038/ki.2014.58
   Floege J, 2011, NEPHROL DIAL TRANSPL, V26, P1948, DOI 10.1093/ndt/gfq219
   Fouque D, 2013, NEPHROL DIAL TRANSPL, V28, P360, DOI 10.1093/ndt/gfs404
   Fukagawa M, 2014, AM J KIDNEY DIS, V63, P979, DOI 10.1053/j.ajkd.2013.08.011
   Gallieni M, 2012, BONE, V51, P332, DOI 10.1016/j.bone.2012.06.002
   Goodman WG, 2000, NEW ENGL J MED, V342, P1478, DOI 10.1056/NEJM200005183422003
   Gotch FA, 2010, KIDNEY INT, V78, P343, DOI 10.1038/ki.2010.157
   Griffin LM, 2012, PEDIATR NEPHROL, V27, P1139, DOI 10.1007/s00467 012 2116 x
   Gross P, 2014, CIRC J, V78, P2339, DOI 10.1253/circj.CJ 14 0735
   Guyatt G, 2013, J CLIN EPIDEMIOL, V66, P151, DOI 10.1016/j.jclinepi.2012.01.006
   Guyatt GH, 2008, BMJ BRIT MED J, V336, P1049, DOI 10.1136/bmj.39493.646875.AE
   Guyatt GH, 2013, J CLIN EPIDEMIOL, V66, P158, DOI 10.1016/j.jclinepi.2012.01.012
   Guyatt GH, 2013, J CLIN EPIDEMIOL, V66, P173, DOI 10.1016/j.jclinepi.2012.08.001
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1294, DOI 10.1016/j.jclinepi.2011.03.017
   Haghverdi F, 2014, IRAN J KIDNEY DIS, V8, P461
   Hahn D, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008327.pub2
   HAMDY NAT, 1995, BRIT MED J, V310, P358, DOI 10.1136/bmj.310.6976.358
   Hayden JA, 2013, ANN INTERN MED, V158, P280, DOI 10.7326/0003 4819 158 4 201302190 00009
   Heaf JG, 2003, TRANSPLANTATION, V75, P315, DOI 10.1097/01.TP.0000043926.74349.6D
   Higgins JP, 2011, AM J PUBLIC HEALTH, DOI DOI 10.2105/AJPH.2020.305609
   Hill KM, 2013, KIDNEY INT, V83, P959, DOI 10.1038/ki.2012.403
   Iimori S, 2012, NEPHROL DIAL TRANSPL, V27, P345, DOI 10.1093/ndt/gfr317
   Isakova T, 2009, J AM SOC NEPHROL, V20, P388, DOI 10.1681/ASN.2008060609
   Ishani A, 2008, J AM SOC NEPHROL, V19, P1430, DOI 10.1681/ASN.2007050555
   Iyer SP, 2014, J AM SOC NEPHROL, V25, P1331, DOI 10.1681/ASN.2013080851
   Jadoul M, 2006, KIDNEY INT, V70, P1358, DOI 10.1038/sj.ki.5001754
   Jamal SA, 2007, J BONE MINER RES, V22, P503, DOI 10.1359/JBMR.070112
   Jamal SA, 2013, LANCET, V382, P1268, DOI 10.1016/S0140 6736(13)60897 1
   Jamal SA, 2011, J BONE MINER RES, V26, P1829, DOI 10.1002/jbmr.403
   Kalantar Zadeh K, 2006, KIDNEY INT, V70, P771, DOI 10.1038/sj.ki.5001514
   Karavetian M, 2015, PATIENT EDUC COUNS, V98, P1116, DOI 10.1016/j.pec.2015.05.005
   Ketteler M, 2015, KIDNEY INT, V87, P502, DOI 10.1038/ki.2014.425
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188
   Kim HW, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001694
   Kovesdy CP, 2012, AM J KIDNEY DIS, V59, P58, DOI 10.1053/j.ajkd.2011.06.027
   Kubo Y, 2015, PHARM STAT, V14, P242, DOI 10.1002/pst.1680
   Lacson E, 2009, AM J KIDNEY DIS, V53, P79, DOI 10.1053/j.ajkd.2008.07.031
   Lemos MM, 2013, CLIN NEPHROL, V80, P1, DOI 10.5414/CN107630
   Lewis JB, 2015, J AM SOC NEPHROL, V26, P493, DOI 10.1681/ASN.2014020212
   Li XH, 2015, NEPHROLOGY, V20, P706, DOI 10.1111/nep.12505
   Lin ZZ, 2014, BONE, V64, P235, DOI 10.1016/j.bone.2014.04.017
   Litwin M, 2008, NEPHROL DIAL TRANSPL, V23, P2552, DOI 10.1093/ndt/gfn083
   Liu ZZ, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010350.pub2
   Lopes AA, 2012, AM J KIDNEY DIS, V60, P90, DOI 10.1053/j.ajkd.2011.12.025
   Lou LM, 2012, CLIN NEPHROL, V77, P476, DOI 10.5414/CN107218
   Fernandez Martín JL, 2015, NEPHROL DIAL TRANSPL, V30, P1542, DOI 10.1093/ndt/gfv099
   Maravic M, 2014, OSTEOPOROSIS INT, V25, P159, DOI 10.1007/s00198 013 2435 1
   Markaki A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052350
   McGovern AP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074996
   Miller PD, 2007, OSTEOPOROSIS INT, V18, P59, DOI 10.1007/s00198 006 0189 8
   Miller PD, 2005, J BONE MINER RES, V20, P2105, DOI 10.1359/JBMR.050817
   Mitsnefes MM, 2005, J AM SOC NEPHROL, V16, P2796, DOI 10.1681/ASN.2005030291
   Mittalhenkle A, 2004, AM J KIDNEY DIS, V44, P672, DOI 10.1053/j.ajkd.2004.07.001
   Moe S, 2006, KIDNEY INT, V69, P1945, DOI 10.1038/sj.ki.5000414
   Moe SM, 2015, CIRCULATION, V132, P27, DOI 10.1161/CIRCULATIONAHA.114.013876
   Moe SM, 2015, J AM SOC NEPHROL, V26, P1466, DOI 10.1681/ASN.2014040414
   Moe SM, 2011, CLIN J AM SOC NEPHRO, V6, P257, DOI 10.2215/CJN.05040610
   Moe SM, 2010, CLIN J AM SOC NEPHRO, V5, P299, DOI 10.2215/CJN.07131009
   Moore J, 2011, CLIN TRANSPLANT, V25, P406, DOI 10.1111/j.1399 0012.2010.01292.x
   Nair SS, 2014, AM J TRANSPLANT, V14, P943, DOI 10.1111/ajt.12652
   Nakai S, 2008, THER APHER DIAL, V12, P49, DOI 10.1111/j.1744 9987.2007.00540.x
   Nakano C, 2012, CLIN J AM SOC NEPHRO, V7, P810, DOI 10.2215/CJN.08680811
   Naylor KL, 2016, TRANSPLANTATION, V100, P167, DOI 10.1097/TP.0000000000000808
   Naylor KL, 2015, CLIN J AM SOC NEPHRO, V10, P646, DOI 10.2215/CJN.06040614
   Newsome B, 2013, AM J KIDNEY DIS, V61, P1045, DOI 10.1053/j.ajkd.2013.01.007
   Nichols Kristen R, 2014, J Pediatr Pharmacol Ther, V19, P202, DOI 10.5863/1551 6776 19.3.202
   Nickolas TL, 2006, J AM SOC NEPHROL, V17, P3223, DOI 10.1681/ASN.2005111194
   Nikkel LE, 2012, AM J TRANSPLANT, V12, P649, DOI 10.1111/j.1600 6143.2011.03872.x
   NORDAL KP, 1988, J CLIN ENDOCR METAB, V67, P929, DOI 10.1210/jcem 67 5 929
   Oh J, 2002, CIRCULATION, V106, P100, DOI 10.1161/01.CIR.0000020222.63035.C0
   Ohlsson C, 2011, J CLIN ENDOCR METAB, V96, P2262, DOI 10.1210/jc.2010 2751
   Ok E, 2016, J AM SOC NEPHROL, V27, P2475, DOI 10.1681/ASN.2015030268
   Oksa A, 2008, KIDNEY BLOOD PRESS R, V31, P322, DOI 10.1159/000157177
   Padhi D, 2012, PEDIATR NEPHROL, V27, P1953, DOI 10.1007/s00467 012 2186 9
   Palmer SC, 2016, AM J KIDNEY DIS, V68, P691, DOI 10.1053/j.ajkd.2016.05.015
   Parfrey PS, 2015, CLIN J AM SOC NEPHRO, V10, P791, DOI 10.2215/CJN.07730814
   Parfrey PS, 2013, J CLIN ENDOCR METAB, V98, P4834, DOI 10.1210/jc.2013 2975
   Patel L, 2016, CLIN J AM SOC NEPHRO, V11, P232, DOI 10.2215/CJN.06800615
   Peter WLS, 2009, CLIN J AM SOC NEPHRO, V4, P354, DOI 10.2215/CJN.05241008
   Pieper AK, 2006, AM J KIDNEY DIS, V47, P625, DOI 10.1053/j.ajkd.2005.12.039
   Platt C, 2010, PEDIATR NEPHROL, V25, P143, DOI 10.1007/s00467 009 1294 7
   Raggi P, 2004, J HEART VALVE DIS, V13, P134
   Raggi P, 2011, NEPHROL DIAL TRANSPL, V26, P1327, DOI 10.1093/ndt/gfq725
   Riccio E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118174
   Russo D, 2007, KIDNEY INT, V72, P1255, DOI 10.1038/sj.ki.5002518
   RUTHERFORD WE, 1975, KIDNEY INT, V8, P320, DOI 10.1038/ki.1975.119
   Salusky IB, 2005, J AM SOC NEPHROL, V16, P2501, DOI 10.1681/ASN.2004100885
   Scialla JJ, 2013, J AM SOC NEPHROL, V24, P125, DOI 10.1681/ASN.2012070713
   Sekercioglu N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156891
   Selamet U, 2016, KIDNEY INT, V89, P176, DOI 10.1038/ki.2015.284
   Sherman RA, 2015, THER INNOV REGUL SCI, V49, P886, DOI 10.1177/2168479015592194
   Sherman RA, 2009, CLIN J AM SOC NEPHRO, V4, P1370, DOI 10.2215/CJN.02830409
   Shroff RC, 2007, J AM SOC NEPHROL, V18, P2996, DOI 10.1681/ASN.2006121397
   Silva AP, 2013, J DIABETES COMPLICAT, V27, P328, DOI 10.1016/j.jdiacomp.2013.02.007
   Spasovski G, 2007, BONE, V41, P698, DOI 10.1016/j.bone.2007.06.014
   Spiegel DM, 2012, KIDNEY INT, V81, P1116, DOI 10.1038/ki.2011.490
   Sprague SM, 2016, AM J NEPHROL, V44, P316, DOI 10.1159/000450766
   Sprague SM, 2016, AM J KIDNEY DIS, V67, P559, DOI 10.1053/j.ajkd.2015.06.023
   Sullivan C, 2009, JAMA J AM MED ASSOC, V301, P629, DOI 10.1001/jama.2009.96
   Tentori F, 2008, AM J KIDNEY DIS, V52, P519, DOI 10.1053/j.ajkd.2008.03.020
   Tentori F, 2014, KIDNEY INT, V85, P166, DOI 10.1038/ki.2013.279
   Thadhani R, 2012, JAMA J AM MED ASSOC, V307, P674, DOI 10.1001/jama.2012.120
   Toussaint ND, 2010, AM J KIDNEY DIS, V56, P57, DOI 10.1053/j.ajkd.2009.12.039
   Tsertsvadze A, 2011, J CLIN EPIDEMIOL, V64, P1208, DOI 10.1016/j.jclinepi.2011.03.011
   Uhlig K, 2006, KIDNEY INT, V70, P2058, DOI 10.1038/sj.ki.5001875
   Ureña Torres P, 2013, NEPHROL DIAL TRANSPL, V28, P1241, DOI 10.1093/ndt/gfs568
   Van Buren PN, 2015, AM J KIDNEY DIS, V66, P479, DOI 10.1053/j.ajkd.2015.03.013
   Vautour LM, 2004, OSTEOPOROSIS INT, V15, P160, DOI 10.1007/s00198 003 1532 y
   Viaene L, 2012, AM J NEPHROL, V35, P242, DOI 10.1159/000336308
   Wang AYM, 2014, J AM SOC NEPHROL, V25, P175, DOI 10.1681/ASN.2013010103
   West SL, 2015, J BONE MINER RES, V30, P913, DOI 10.1002/jbmr.2406
   Wetmore JB, 2015, CLIN J AM SOC NEPHRO, V10, P1031, DOI 10.2215/CJN.07050714
   Wren TAL, 2014, J PEDIATR US, V164, P1280, DOI 10.1016/j.jpeds.2013.12.040
   Xu LR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076657
   Yenchek RH, 2012, CLIN J AM SOC NEPHRO, V7, P1130, DOI 10.2215/CJN.12871211
   ZELLER K, 1991, NEW ENGL J MED, V324, P78, DOI 10.1056/NEJM199101103240202
   Zemel BS, 2011, J CLIN ENDOCR METAB, V96, P3160, DOI 10.1210/jc.2011 1111
   Zemel BS, 2010, J CLIN ENDOCR METAB, V95, P1265, DOI 10.1210/jc.2009 2057
NR 173
TC 1507
Z9 1587
U1 14
U2 105
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 2157 1724
EI 2157 1716
J9 KIDNEY INT SUPPL
JI Kidney Int. Suppl.
PD JUL
PY 2017
VL 7
IS 1
BP 1
EP +
PG 47
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA EY2VG
UT WOS:000403829800001
PM 30675420
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Chen, TP
   Swarnkar, G
   Mbalaviele, G
   Abu Amer, Y
AF Chen, TH P
   Swarnkar, G.
   Mbalaviele, G.
   Abu Amer, Y.
TI Myeloid lineage skewing due to exacerbated NF κB signaling facilitates
   osteopenia in Scurfy mice
SO CELL DEATH & DISEASE
LA English
DT Article
ID REGULATORY T CELLS; BONE LOSS; OSTEOCLAST PRECURSORS; JOINT DESTRUCTION;
   IMMUNE SYSTEM; M CSF; FOXP3; ARTHRITIS; OSTEOIMMUNOLOGY; DIFFERENTIATION
AB Immune surveillance through Foxp3+ regulatory T cells plays a crucial role in bone homeostasis. Scurfy, the mouse model of autoimmune IPEX syndrome, bears a loss of function mutation in Foxp3 that leads to multi organ inflammation. Herein, we report that scurfy mice exhibit severe bone loss mediated by accelerated osteoclastogenesis. Mechanistically, Foxp3 deficiency results in the upregulation of NF kappa B in T helper cells through the loss of repressive Foxp3/NEMO interaction, thereby unleashing NF kappa B mediated over production of pro osteoclastogenic cytokines. Flow cytometry analysis shows marked increase in lin Sca 1(+)c kit(+) hematopoietic stem cells (LSK HSCs) and granulocyte/macrophage progenitors (GMPs) in bone marrow of scurfy mice with corresponding exacerbated osteoclastogenic potential, implying that osteoclast progenitors are affected at a very primitive stage in this disorder. Scurfy LSK HSCs exhibit greater sensitivity to M CSF and contain abundant PU.1+Sf LSK HSCs compared with WT. Accordingly, genetic or pharmacological inhibition of M CSF or mTOR signaling, but not IL 17 signaling, attenuates osteoclastogenesis and osteopenia in scurfy. Thus, our study suggests that Foxp3 deficiency leads to osteopenia owing to dysregulated NF kappa B activity and subsequent cytokine mediated hyper proliferation of myeloid precursors, and positions the NF kappa B pathway as a potential target for therapeutic intervention for this disorder.
C1 [Chen, TH P; Swarnkar, G.; Abu Amer, Y.] Washington Univ, Dept Orthoped Surg & Cell Biol Physiol, Sch Med, St Louis, MO 63110 USA.
   [Mbalaviele, G.] Washington Univ, Dept Internal Med, Sch Med, Div Bone & Mineral Dis, St Louis, MO 63110 USA.
C3 Washington University (WUSTL); Washington University (WUSTL)
RP Abu Amer, Y (通讯作者)，Washington Univ, Dept Orthoped Surg & Cell Biol Physiol, Sch Med, 425 S Euclid Ave Box 8233, St Louis, MO 63110 USA.
EM abuamery@wustl.edu
RI SWARNKAR, GAURAV/AAE 3223 2021
FU Shriners Hospital for Children [85600]; National Institute of Health
   [AR054326, AR049192]
FX This work was supported by grants from the Shriners Hospital for
   Children (grant 85600) and the National Institute of Health (grant #
   AR054326, AR049192) to YA.
CR Abu Amer Y, 2013, OSTEOPOROSIS INT, V24, P2377, DOI 10.1007/s00198 013 2313 x
   Abu Amer Y, 2001, J CLIN INVEST, V107, P1375, DOI 10.1172/JCI10530
   Bettelli E, 2005, P NATL ACAD SCI USA, V102, P5138, DOI 10.1073/pnas.0501675102
   Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784
   Caetano Lopes J, 2009, AUTOIMMUN REV, V8, P250, DOI 10.1016/j.autrev.2008.07.038
   Cejka D, 2010, ARTHRITIS RHEUM US, V62, P2294, DOI 10.1002/art.27504
   Charles JF, 2012, J CLIN INVEST, V122, P4592, DOI 10.1172/JCI60920
   Glantschnig H, 2003, CELL DEATH DIFFER, V10, P1165, DOI 10.1038/sj.cdd.4401285
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490
   Kim YG, 2007, BIOCHEM BIOPH RES CO, V357, P1046, DOI 10.1016/j.bbrc.2007.04.042
   King KY, 2011, NAT REV IMMUNOL, V11, P685, DOI 10.1038/nri3062
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Mossadegh Keller N, 2013, NATURE, V497, P239, DOI 10.1038/nature12026
   Ramsdell F, 2014, NAT REV IMMUNOL, V14, P343, DOI 10.1038/nri3650
   Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009
   Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775
   Sawant A, 2013, CANCER RES, V73, P672, DOI 10.1158/0008 5472.CAN 12 2202
   Schett G, 2010, NAT REV ENDOCRINOL, V6, P698, DOI 10.1038/nrendo.2010.190
   Sharma R, 2011, J IMMUNOL, V186, P1268, DOI 10.4049/jimmunol.1002677
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   Walsh MC, 2006, ANNU REV IMMUNOL, V24, P33, DOI 10.1146/annurev.immunol.24.021605.090646
   Xing LP, 2005, IMMUNOL REV, V208, P19, DOI 10.1111/j.0105 2896.2005.00336.x
   YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0
   Zaiss MM, 2007, ARTHRITIS RHEUM, V56, P4104, DOI 10.1002/art.23138
   Zaiss MM, 2010, ARTHRITIS RHEUM US, V62, P2328, DOI 10.1002/art.27535
   Zheng Y, 2007, NAT IMMUNOL, V8, P457, DOI 10.1038/ni1455
NR 28
TC 15
Z9 16
U1 1
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041 4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD APR
PY 2015
VL 6
AR e1723
DI 10.1038/cddis.2015.87
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA CM2LL
UT WOS:000357511500016
PM 25880090
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Moore, ER
   Maridas, DE
   Gamer, L
   Chen, GV
   Burton, K
   Rosen, V
AF Moore, Emily R.
   Maridas, David E.
   Gamer, Laura
   Chen, Gavin
   Burton, Kathryn
   Rosen, Vicki
TI A periosteum derived cell line to study the role of BMP/TGFβ signaling
   in periosteal cell behavior and function
SO FRONTIERS IN PHYSIOLOGY
LA English
DT Article
DE periosteum; cell line; BMP signaling; TGF beta signaling;
   mechanotransduction
ID OSTEOGENIC DIFFERENTIATION; BONE FORMATION; EXPRESSION; RELEASE; MARROW
AB The periosteum is a thin tissue surrounding each skeletal element that contains stem and progenitor cells involved in bone development, postnatal appositional bone growth, load induced bone formation, and fracture repair. BMP and TGF beta signaling are important for periosteal activity and periosteal cell behavior, but thorough examination of the influence of these pathways on specific cell populations resident in the periosteum is lacking due to limitations associated with primary periosteal cell isolations and in vitro experiments. Here we describe the generation of a novel periosteum derived clonal cell (PDC) line from postnatal day 14 mice and use it to examine periosteal cell behavior in vitro. PDCs exhibit key characteristics of periosteal cells observed during skeletal development, maintenance, and bone repair. Specifically, PDCs express established periosteal markers, can be expanded in culture, demonstrate the ability to differentiate into chondrocytes, osteoblasts, and adipocytes, and exhibit an osteogenic response to physical stimulation. PDCs also engage in BMP and/or TGF beta signaling when treated with the activating ligands BMP2 and TGF beta 1, and in response to mechanical stimulation via fluid shear. We believe that this PDC line will be useful for large scale, long term experiments that were not feasible when using primary periosteal cells. Anticipated future uses include advancing our understanding of the signaling interactions that occur during appositional bone growth and fracture repair and developing drug screening platforms to discover novel growth and fracture healing factors.
C1 [Moore, Emily R.; Maridas, David E.; Gamer, Laura; Chen, Gavin; Burton, Kathryn; Rosen, Vicki] Harvard Sch Dent Med, Dept Dev Biol, Boston, MA 02115 USA.
C3 Harvard University; Harvard School of Dental Medicine
RP Moore, ER (通讯作者)，Harvard Sch Dent Med, Dept Dev Biol, Boston, MA 02115 USA.
EM emily_moore@hsdm.harvard.edu
RI Maridas, David/ABA 8941 2021
FU This work is supported by the National Institute of Arthritis and
   Musculoskeletal and Skin Diseases (NIAMS) grant R01AR077432.
   [R01AR077432]; National Institute of Arthritis and Musculoskeletal and
   Skin Diseases (NIAMS)
FX We would like to thank Dr. Diana Carlone (Boston Children's Hospital,
   Boston, MA) and Dr. Francesca Gori (Harvard School of Dental Medicine,
   Boston, MA) for scientific conversations that facilitated generation of
   this cell line. We also thank Elizabeth Gonzalez, CEO and Senior
   Cytogeneticist at KaryoLogic, Inc., for her expertise in interpreting
   our karyotyping results.r This work is supported by the National
   Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
   grant R01AR077432.
CR Arnsdorf EJ, 2009, TISSUE ENG PT A, V15, P2637, DOI 10.1089/ten.TEA.2008.0244
   Arnsdorf EJ, 2009, J CELL SCI, V122, P546, DOI 10.1242/jcs.036293
   Bradaschia Correa V, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 41639 7
   Brown S, 2023, JBMR PLUS, V7, DOI 10.1002/jbm4.10707
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen JC, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt318
   Colnot C, 2012, J ORTHOP RES, V30, P1869, DOI 10.1002/jor.22181
   Colnot C, 2009, J BONE MINER RES, V24, P274, DOI 10.1359/JBMR.081003
   De Bari C, 2006, ARTHRITIS RHEUM, V54, P1209, DOI 10.1002/art.21753
   de Lageneste OD, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03124 z
   Debnath S, 2018, NATURE, V562, P133, DOI 10.1038/s41586 018 0554 8
   Deveza L, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190909
   Esposito A, 2020, BONE, V139, DOI 10.1016/j.bone.2020.115521
   Gamer LW, 2018, J BONE MINER RES, V33, P1708, DOI 10.1002/jbmr.3441
   Grcevic D, 2012, STEM CELLS, V30, P187, DOI 10.1002/stem.780
   Greenfeld H, 2021, PLOS BIOL, V19, DOI 10.1371/journal.pbio.3001059
   Hoey DA, 2012, STEM CELLS, V30, P2561, DOI 10.1002/stem.1235
   Jeffery EC, 2022, CELL STEM CELL, V29, P1547, DOI 10.1016/j.stem.2022.10.002
   Jo CH, 2019, TISSUE ENG REGEN MED, V16, P151, DOI 10.1007/s13770 019 00182 2
   Julien A, 2022, J BONE MINER RES, V37, P1545, DOI 10.1002/jbmr.4616
   Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014
   Kawanami A, 2009, BIOCHEM BIOPH RES CO, V386, P477, DOI 10.1016/j.bbrc.2009.06.059
   KLEINNULEND J, 1995, J CELL PHYSIOL, V163, P115, DOI 10.1002/jcp.1041630113
   Kokabu S, 2018, FEBS OPEN BIO, V8, P168, DOI 10.1002/2211 5463.12347
   Komorowski M, 2022, CELL SYST, V13, P349, DOI 10.1016/j.cels.2022.04.002
   Kopf J, 2012, BMC BIOL, V10, DOI 10.1186/1741 7007 10 37
   Lademann F, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.586031
   Mattei G, 2015, SCI REP UK, V5, DOI 10.1038/srep14590
   Matthews BG, 2021, ELIFE, V10, DOI 10.7554/eLife.58534
   Matthews BG, 2014, J BONE MINER RES, V29, P1283, DOI 10.1002/jbmr.2140
   McBride Gagyi SH, 2015, BONE, V81, P533, DOI 10.1016/j.bone.2015.09.003
   Monteiro DA, 2021, FASEB J, V35, DOI 10.1096/fj.202001998R
   Moore ER, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115738
   Moore ER, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/3094154
   Moore ER, 2018, J CELL SCI, V131, DOI 10.1242/jcs.217828
   Moore ER, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0930 1
   Nguyen J, 2020, BONE, V131, DOI 10.1016/j.bone.2019.115148
   Olivares Navarrete R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170312
   Ono N, 2022, CELL REP MED, V3, DOI 10.1016/j.xcrm.2022.100807
   Ortinau LC, 2019, CELL STEM CELL, V25, P784, DOI 10.1016/j.stem.2019.11.003
   Perrin S, 2022, CURR OSTEOPOROS REP, V20, P334, DOI 10.1007/s11914 022 00737 8
   Perrin S, 2021, BIO PROTOCOL, V11, DOI 10.21769/BioProtoc.4107
   Piasecka A, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 82706 2
   Ponik SM, 2004, J APPL PHYSIOL, V97, P135, DOI 10.1152/japplphysiol.01260.2003
   RAABCULLEN DM, 1994, CALCIFIED TISSUE INT, V55, P473, DOI 10.1007/BF00298562
   Sakai K, 1998, CALCIFIED TISSUE INT, V63, P515, DOI 10.1007/s002239900567
   Salazar VS, 2019, ELIFE, V8, DOI 10.7554/eLife.42386
   Salazar VS, 2016, NAT REV ENDOCRINOL, V12, P203, DOI 10.1038/nrendo.2016.12
   Shi Y, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109542
   Shi Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 02171 2
   Stepanenko AA, 2015, GENE, V569, P182, DOI 10.1016/j.gene.2015.05.065
   Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916
   Vermeulen S, 2020, BIOMATERIALS, V259, DOI 10.1016/j.biomaterials.2020.120331
   Wadhwa S, 2002, BIOCHEM BIOPH RES CO, V297, P46, DOI 10.1016/S0006 291X(02)02124 1
   Wang LQ, 2019, J BONE MINER RES, V34, P520, DOI 10.1002/jbmr.3626
   Wang QX, 2022, CELL PROLIFERAT, V55, DOI 10.1111/cpr.13172
   Wang T, 2017, J CELL PHYSIOL, V232, P913, DOI 10.1002/jcp.25641
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Xia CJ, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12904
   Xiao H, 2020, J CELL MOL MED, V24, P12199, DOI 10.1111/jcmm.15891
   Xu JJ, 2022, BONE RES, V10, DOI 10.1038/s41413 021 00176 8
   Zhang T, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12338
NR 62
TC 2
Z9 3
U1 2
U2 12
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1664 042X
J9 FRONT PHYSIOL
JI Front. Physiol.
PD SEP 20
PY 2023
VL 14
AR 1221152
DI 10.3389/fphys.2023.1221152
PG 11
WC Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Physiology
GA T3DA6
UT WOS:001076810300001
PM 37799511
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Brent, MB
   Brüel, A
   Thomsen, JS
AF Brent, Mikkel Bo
   Bruel, Annemarie
   Thomsen, Jesper Skovhus
TI Anti sclerostin antibodies and abaloparatide have additive effects when
   used as a countermeasure against disuse osteopenia in female rats
SO BONE
LA English
DT Article
DE DXA; Osteoporosis; Bone loss; Abaloparatide; Romosozumab; Scl Ab
ID BONE FORMATION; PARATHYROID HORMONE; SOST; PTH; RESORPTION
AB Prolonged disuse and substantial mechanical unloading are particularly damaging to skeletal integrity. Preclinical studies in rodents and clinical studies have highlighted the need for potent bone anabolic drugs to counteract disuse induced osteopenia. The aim of present study was to compare the efficacy of romosozumab (Scl Ab) and abaloparatide (ABL), alone or in combination, to prevent botulinum toxin (BTX) induced bone loss in a rat model. Eighty female Wistar rats were divided into the following six groups: 1. Baseline (n = 12); 2. Control (Ctrl) (n = 12); 3. BTX (n = 12); 4. BTX + Scl Ab (n = 16); 5. BTX + ABL (n = 12); and 6. BTX + Scl Ab + ABL (n = 16). Disuse was achieved by injecting 4 IU BTX into the hind limb musculature at study start. Scl Ab (25 mg/kg) was injected s.c. twice weekly, while ABL (80 mu g/kg) was injected s.c. five days a week for four weeks. Hind limb disuse dramatically decreased muscle mass and skeletal integrity and deteriorated the cortical morphology and trabecular microstructure. Treatment with Scl Ab alone prevented most of the adverse cortical and trabecular effects of disuse, while ABL monotherapy mainly attenuated the disuse induced loss of femoral areal bone mineral density (aBMD). Moreover, the combination of Scl Ab and ABL not only counteracted most of the negative skeletal effects of unloading, but also increased aBMD (+10% and +20%), epiphyseal trabecular bone volume fraction (BV/TV) (+25% and +73%), and metaphyseal bone strength (+18% and +30%) significantly above that of Scl Ab or ABL monotherapy, respectively. The potent and additive osteoanabolic effect of Scl Ab and ABL, when given in combination, is highly intriguing and underlines that an osteoanabolic bone gain can be maximized by utilizing two pharmaceuticals targeting different cellular signaling pathways. From a clinical perspective, a combination treatment may be warranted in patients where the osteoanabolic effect of either monotherapy is not sufficient, or if a dose reduction is required due to adverse effects.
C1 [Brent, Mikkel Bo; Bruel, Annemarie; Thomsen, Jesper Skovhus] Aarhus Univ, Dept Biomed, Aarhus, Denmark.
   [Brent, Mikkel Bo] Aalborg Univ Hosp, Dept Orthoped Surg, Aalborg, Denmark.
C3 Aarhus University; Aalborg University; Aalborg University Hospital
RP Brent, MB (通讯作者)，Aarhus Univ, Dept Biomed, Hlth, Wilhelm Meyers Alle 3, DK 8000 Aarhus C, Denmark.
EM mbb@biomed.au.dk
RI ; Brent, Mikkel Bo/Q 2703 2019; Thomsen, Jesper/HKN 2794 2023; Bruel,
   Annemarie/AAT 2310 2020; Brent, Mikkel/Q 2703 2019
OI Thomsen, Jesper Skovhus/0000 0001 9386 6679; Brent, Mikkel
   Bo/0000 0002 3475 4295; Bruel, Annemarie/0000 0003 4833 0888; 
CR Allison N., 1921, SURG GYNECOL OBSTET, V33, P250
   Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brent MB, 2021, EUR J PHARMACOL, V909, DOI 10.1016/j.ejphar.2021.174409
   Brent MB, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.628994
   Brent MB, 2021, CALCIFIED TISSUE INT, V108, P561, DOI 10.1007/s00223 020 00799 9
   Brent MB, 2021, BONE, V142, DOI 10.1016/j.bone.2020.115692
   Brent MB, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.588773
   Brent MB, 2020, METHODSX, V7, DOI 10.1016/j.mex.2020.101079
   Brent MB, 2018, BONE, V110, P244, DOI 10.1016/j.bone.2018.02.017
   Bromer FD, 2021, HIGH ALT MED BIOL, V22, P225, DOI 10.1089/ham.2020.0164
   Brüel A, 2013, BONE, V53, P51, DOI 10.1016/j.bone.2012.11.037
   Chappard D, 2001, BONE, V28, P72, DOI 10.1016/S8756 3282(00)00438 5
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Gaudio A, 2010, J CLIN ENDOCR METAB, V95, P2248, DOI 10.1210/jc.2010 0067
   Hattersley G, 2016, ENDOCRINOLOGY, V157, P141, DOI 10.1210/en.2015 1726
   Kanis JA, 1998, MATURITAS, V30, P229, DOI 10.1016/S0378 5122(98)00090 5
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   Kramer I, 2010, TRENDS ENDOCRIN MET, V21, P237, DOI 10.1016/j.tem.2009.12.002
   Kramer I, 2010, J BONE MINER RES, V25, P178, DOI 10.1359/jbmr.090730
   Le Henaff C, 2020, J BONE MINER RES, V35, P714, DOI 10.1002/jbmr.3930
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Lin JT, 2020, Z GERONTOL GERIATR, V53, P163, DOI 10.1007/s00391 019 01685 2
   Makino A, 2021, BONE, V142, DOI 10.1016/j.bone.2020.115651
   McClung M.R., N ENGL
   Miller P.D., J AM MED
   Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976 0105.177703
   Ominsky MS, 2015, BONE, V81, P380, DOI 10.1016/j.bone.2015.08.007
   Quattrocchi E, 2004, CLIN THER, V26, P841, DOI 10.1016/S0149 2918(04)90128 2
   Ricarte FR, 2018, J BIOL CHEM, V293, P20200, DOI 10.1074/jbc.RA118.004751
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Rodríguez García C, 2021, RESP MED, V187, DOI 10.1016/j.rmed.2021.106595
   Ross PD, 1996, ARCH INTERN MED, V156, P1399, DOI 10.1001/archinte.156.13.1399
   Ruiz Villaverde R, 2022, INT J DERMATOL, V61, P1029, DOI 10.1111/ijd.15784
   Sorensen TG, 2020, BONE, V131, DOI 10.1016/j.bone.2019.115183
   Spatz J.M., J BIOL CHEM 290
   Tang MJ, 2021, TOXINS, V13, DOI 10.3390/toxins13030213
   Teguh DA, 2021, BONE, V144, DOI 10.1016/j.bone.2020.115801
   Tella SH, 2017, CUREUS J MED SCIENCE, V9, DOI 10.7759/cureus.1300
   Tian XY, 2011, BONE, V48, P197, DOI 10.1016/j.bone.2010.09.009
   Turner RT, 2006, J APPL PHYSIOL, V101, P881, DOI 10.1152/japplphysiol.01622.2005
   Warner SE, 2006, BONE, V38, P257, DOI 10.1016/j.bone.2005.08.009
   Zhang DY, 2016, BONE, V87, P161, DOI 10.1016/j.bone.2016.02.005
   Zhao W, 2018, CALCIFIED TISSUE INT, V103, P443, DOI 10.1007/s00223 018 0439 8
NR 47
TC 13
Z9 14
U1 2
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JUL
PY 2022
VL 160
AR 116417
DI 10.1016/j.bone.2022.116417
EA APR 2022
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 1A3LB
UT WOS:000791661600004
PM 35398589
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Landspersky, T
   Stein, M
   Saçma, M
   Geuder, J
   Braitsch, K
   Rivière, J
   Hettler, F
   Marquez, SR
   Vilne, B
   Hameister, E
   Richter, D
   Schönhals, E
   Tuckermann, J
   Verbeek, M
   Herhaus, P
   Hecker, JS
   Bassermann, F
   Götze, KS
   Enard, W
   Geiger, H
   Oostendorp, RAJ
   Schreck, C
AF Landspersky, Theresa
   Stein, Merle
   Sacma, Mehmet
   Geuder, Johanna
   Braitsch, Krischan
   Riviere, Jennifer
   Hettler, Franziska
   Marquez, Sandra Romero
   Vilne, Baiba
   Hameister, Erik
   Richter, Daniel
   Schoenhals, Emely
   Tuckermann, Jan
   Verbeek, Mareike
   Herhaus, Peter
   Hecker, Judith S.
   Bassermann, Florian
   Goetze, Katharina S.
   Enard, Wolfgang
   Geiger, Hartmut
   Oostendorp, Robert A. J.
   Schreck, Christina
TI Targeting CDC42 reduces skeletal degeneration after hematopoietic stem
   cell transplantation
SO BLOOD ADVANCES
LA English
DT Article
ID BONE MINERAL DENSITY; MYOSIN VI; AUTOPHAGY; PROGENITORS; BLOOD;
   BISPHOSPHONATES; DIFFERENTIATION; REGENERATION; MITOCHONDRIA;
   OSTEOPOROSIS
AB Osteopenia and osteoporosis are common long term complications of the cytotoxic conditioning regimen for hematopoietic stem cell transplantation (HSCT). We examined mesenchymal stem and progenitor cells (MSPCs), which include skeletal progenitors, from mice undergoing HSCT. Such MSPCs showed reduced fibroblastic colony forming units frequency, increased DNA damage, and enhanced occurrence of cellular senescence, whereas there was a reduced bone volume in animals that underwent HSCT. This reduced MSPC function correlated with elevated activation of the small Rho guanosine triphosphate hydrolase CDC42, disorganized F actin distribution, mitochondrial abnormalities, and impaired mitophagy in MSPCs. Changes and defects similar to those in mice were also observed in MSPCs from humans undergoing HSCT. A pharmacological treatment that attenuated the elevated activation of CDC42 restored F actin fiber alignment, mitochondrial function, and mitophagy in MSPCs in vitro. Finally, targeting CDC42 activity in vivo in animals undergoing transplants improved MSPC quality to increase both bone volume and trabecular bone thickness. Our study shows that attenuation of CDC42 activity is sufficient to attenuate reduced function of MSPCs in a BM transplant setting.
C1 [Landspersky, Theresa; Braitsch, Krischan; Riviere, Jennifer; Hettler, Franziska; Marquez, Sandra Romero; Hameister, Erik; Schoenhals, Emely; Verbeek, Mareike; Herhaus, Peter; Hecker, Judith S.; Bassermann, Florian; Goetze, Katharina S.; Oostendorp, Robert A. J.; Schreck, Christina] Tech Univ Munich, Sch Med, Dept Internal Med 3, Munich, Germany.
   [Stein, Merle; Richter, Daniel; Tuckermann, Jan] Ulm Univ, Inst Comparat Mol Endocrinol, Ulm, Germany.
   [Sacma, Mehmet; Geiger, Hartmut] Ulm Univ, Inst Mol Med Stem Cells & Aging, Ulm, Germany.
   [Geuder, Johanna; Enard, Wolfgang] Ludwig Maximilians Univ Munchen, Fac Biol, Anthropol & Human Genom, Munich, Germany.
   [Vilne, Baiba] Riga Stradins Univ, Bioinformat Lab, Riga, Latvia.
C3 University of Munich; Technical University of Munich; Ulm University;
   Ulm University; University of Munich; Riga Stradins University
RP Oostendorp, RAJ; Schreck, C (通讯作者)，Tech Univ Munich, Dept Vasc Surg, Klinikum Rechts Isar, Ismaninger Str 22, DE 81675 Munich, Germany.
EM robert.oostendorp@tum.de; christina.schreck@tum.de
RI ; Richter, Daniel/M 6970 2013; Oostendorp, Robert/K 9841 2018; VILNE,
   BAIBA/GQZ 2721 2022; Oostendorp, Robert A.J./K 9841 2018; Enard,
   Wolfgang/K 3483 2014
OI Braitsch, Krischan/0000 0003 4028 5357; Riviere,
   Jennifer/0000 0002 4680 2071; Oostendorp, Robert
   A.J./0000 0002 4947 0412; Stein, Merle/0000 0003 2926 6219; Vilne,
   Baiba/0000 0002 1084 7067
FU German Research Foundation (DFG) [FOR 2033, OO 8/18, OO 8/21]; European
   Research Council under the European Union [953407]
FX This study was funded by the German Research Foundation (DFG; grants FOR
   2033 [project B3] , OO 8/18 and OO 8/21 [R.A.J.O.] ) . K.S.G received
   funding from the European Research Council under the European Union's '
   s Horizon 2020 Marie Sklodowska Curie Innovative Training Network (grant
   agreement no. 953407) .
CR Bártová E, 2019, AGING US, V11, P2488, DOI 10.18632/aging.101917
   Cai YS, 2022, SCI CHINA LIFE SCI, V65, P2354, DOI 10.1007/s11427 022 2161 3
   Chandra A, 2022, AGING CELL, V21, DOI 10.1111/acel.13602
   Chandra A, 2018, FASEB J, V32, P52, DOI 10.1096/fj.201700375R
   Chandra A, 2017, J BONE MINER RES, V32, P360, DOI 10.1002/jbmr.2996
   D'Souza AB, 2006, INTERN MED J, V36, P600, DOI 10.1111/j.1445 5994.2006.01154.x
   de Jonge JJ, 2019, FEBS LETT, V593, P1494, DOI 10.1002/1873 3468.13486
   Díaz PAC, 2023, BLOOD, V142, P533, DOI 10.1182/blood.2022017933
   Dunford JE, 2006, J BONE MINER RES, V21, P684, DOI 10.1359/JBMR.060118
   Ebeling PR, 1999, J BONE MINER RES, V14, P342, DOI 10.1359/jbmr.1999.14.3.342
   Florian MC, 2012, CELL STEM CELL, V10, P520, DOI 10.1016/j.stem.2012.04.007
   Fröbel J, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.705410
   Fung TS, 2022, CURR BIOL, V32, P1577, DOI 10.1016/j.cub.2022.02.058
   Gatica D, 2018, NAT CELL BIOL, V20, P233, DOI 10.1038/s41556 018 0037 z
   Gomes LC, 2011, NAT CELL BIOL, V13, P589, DOI 10.1038/ncb2220
   Harada K, 2023, STEM CELLS, V41, P39, DOI 10.1093/stmcls/sxac072
   Ho TT, 2017, NATURE, V543, P205, DOI 10.1038/nature21388
   Inamoto Y, 2017, HAEMATOLOGICA, V102, P614, DOI 10.3324/haematol.2016.150250
   König T, 2021, NAT CELL BIOL, V23, P1271, DOI 10.1038/s41556 021 00798 4
   Kruppa AJ, 2018, AUTOPHAGY, V14, P1644, DOI 10.1080/15548627.2018.1486152
   Kruppa AJ, 2018, DEV CELL, V44, P484, DOI 10.1016/j.devcel.2018.01.007
   Landspersky T, 2022, BLOOD, V139, P690, DOI 10.1182/blood.2021011775
   Li QQ, 2017, PROTEIN CELL, V8, P439, DOI 10.1007/s13238 017 0385 7
   Liu ZZ, 2021, AUTOPHAGY, V17, P2766, DOI 10.1080/15548627.2020.1839286
   López Otin C, 2023, CELL, V186, P243, DOI 10.1016/j.cell.2022.11.001
   Lymperi S, 2011, BLOOD, V117, P1540, DOI 10.1182/blood 2010 05 282855
   Ma Y, 2018, AGING CELL, V17, DOI 10.1111/acel.12709
   Mansour A, 2011, CELL RES, V21, P1102, DOI 10.1038/cr.2011.21
   Mo CY, 2022, EMBO J, V41, DOI 10.15252/embj.2021108415
   Mukherjee S, 2008, J CLIN INVEST, V118, P491, DOI [10.1172/JCI33102, 10.1172/JC133102]
   Nakamura Y, 2010, BLOOD, V116, P1422, DOI 10.1182/blood 2009 08 239194
   Nalapareddy K, 2022, STEM CELL REP, V17, P734, DOI 10.1016/j.stemcr.2022.02.003
   Olivieri F, 2015, ONCOTARGET, V6, P35509, DOI 10.18632/oncotarget.5899
   Peterson JR, 2006, CHEM BIOL, V13, P443, DOI 10.1016/j.chembiol.2006.02.009
   Pundole X, 2017, BONE MARROW TRANSPL, V52, P663, DOI 10.1038/bmt.2016.312
   Qadir A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010349
   Qiu YP, 2022, AUTOPHAGY, V18, P73, DOI 10.1080/15548627.2021.1908722
   Quach JM, 2015, J BONE MINER RES, V30, P886, DOI 10.1002/jbmr.2415
   Rachner TD, 2022, BONE, V158, DOI 10.1016/j.bone.2020.115684
   Russell RGG, 2007, PEDIATRICS, V119, pS150, DOI 10.1542/peds.2006 2023H
   Safiulina D, 2019, AUTOPHAGY, V15, P930, DOI 10.1080/15548627.2019.1586260
   Savani BN, 2007, BIOL BLOOD MARROW TR, V13, P517, DOI 10.1016/j.bbmt.2007.01.085
   Schimmer AD, 2000, BIOL BLOOD MARROW TR, V6, P175, DOI 10.1016/S1083 8791(00)70040 1
   Schimmer AD, 2001, BONE MARROW TRANSPL, V28, P387, DOI 10.1038/sj.bmt.1703149
   Schreck C, 2017, J EXP MED, V214, P165, DOI 10.1084/jem.20151414
   Serio B, 2013, TRANSL MED UNISA, V5, P7
   Sweeney Ambros AR, 2022, J ORTHOP RES, V40, P2843, DOI 10.1002/jor.25317
   Tauchmanovà L, 2005, J CLIN ENDOCR METAB, V90, P627, DOI 10.1210/jc.2004 0509
   Tiwari RL, 2021, AGING US, V13, P4778, DOI 10.18632/aging.202694
   Touaitahuata Heiani, 2014, Small GTPases, V5, pe28119, DOI 10.4161/sgtp.28119
   Tumbarello DA, 2012, NAT CELL BIOL, V14, P1024, DOI 10.1038/ncb2589
   Ukon Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102557
   Wan MC, 2021, ACTA BIOMATER, V136, P137, DOI 10.1016/j.actbio.2021.09.039
   Weickert MT, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 85122 8
   Weilbaecher KN, 2000, BIOL BLOOD MARROW TR, V6, P165, DOI 10.1016/S1083 8791(00)70039 5
   Yao S, 2010, BIOL BLOOD MARROW TR, V16, P1130, DOI 10.1016/j.bbmt.2010.02.017
   Zhang C, 2023, BIOMED PHARMACOTHER, V163, DOI 10.1016/j.biopha.2023.114834
   Zhang HW, 2023, BONE RES, V11, DOI 10.1038/s41413 023 00249 w
   Zhong LL, 2020, ELIFE, V9, DOI 10.7554/eLife.54695
   Zhu H, 2010, NAT PROTOC, V5, P550, DOI 10.1038/nprot.2009.238
NR 60
TC 0
Z9 0
U1 2
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2473 9529
EI 2473 9537
J9 BLOOD ADV
JI Blood Adv.
PD OCT 22
PY 2024
VL 8
IS 20
BP 5400
EP 5414
DI 10.1182/bloodadvances.2024012879
EA OCT 2024
PG 15
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA J4B8T
UT WOS:001336543600001
PM 39159429
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Sungkamanee, S
   Wattanathorn, J
   Muchimapura, S
   Thukham mee, W
AF Sungkamanee, Sudarat
   Wattanathorn, Jintanaporn
   Muchimapura, Supaporn
   Thukham mee, Wipawee
TI Antiosteoporotic Effect of Combined Extract of Morus alba and
   Polygonum odoratum
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
ID OXIDATIVE STRESS; ANTIOXIDANT ACTIVITY; BONE LOSS; OSTEOPOROSIS; RAT;
   DIFFERENTIATION; AGONIST; LEAVES; PTH
AB Due to the limitation of osteoporosis therapy, the alternative therapies from natural sources have been considered. In this study, we aimed to determine the antiosteoporotic effect of the combined extract of Morus alba and Polygonum odoratum leaves. Ovariectomized rats, weighing 200 220 g, were orally given the combined extract at doses of 5, 150, and 300 mg.kg( 1) BW for 3 months. At the end of study, blood was collected to determine serum osteocalcin, calcium, and alkaline phosphatase level. In addition, tibia bone was isolated to determine bone oxidative stress markers, cortical bone thickness, and density of osteoblast. The combined extract decreased oxidative stress and osteoclast density but increased osteoblast density and cortical thickness. The elevation of serum calcium, alkaline phosphatase, and osteocalcin was also observed. These results suggested the antiosteoporotic effect of the combined extract via the increased growth formation together with the suppression of bone resorption. However, further studies concerning chronic toxicity and the underlying mechanism are required.
C1 [Sungkamanee, Sudarat; Wattanathorn, Jintanaporn; Muchimapura, Supaporn; Thukham mee, Wipawee] Khon Kaen Univ, Fac Med, Dept Physiol, Khon Kaen 40000, Thailand.
   [Sungkamanee, Sudarat] Khon Kaen Univ, Fac Med, Grad Sch, Neurosci Program, Khon Kaen 40000, Thailand.
   [Sungkamanee, Sudarat; Wattanathorn, Jintanaporn; Muchimapura, Supaporn; Thukham mee, Wipawee] Khon Kaen Univ, Integrated Complementary Alternat Med Res & Dev C, Khon Kaen 40000, Thailand.
C3 Khon Kaen University; Khon Kaen University; Khon Kaen University
RP Wattanathorn, J (通讯作者)，Khon Kaen Univ, Fac Med, Dept Physiol, Khon Kaen 40000, Thailand.
EM jintanapornw@yahoo.com
OI Muchimapura, Supaporn/0000 0001 7756 1955
FU Faculty of Medicine, Khon Kaen University; Integrative Complementary
   Alternative Medicine Research and Development Center, Khon Kaen
   University, Khon Kaen, Thailand
FX This study was supported by Invitation Research Grant of Faculty of
   Medicine, Khon Kaen University, and Integrative Complementary
   Alternative Medicine Research and Development Center, Khon Kaen
   University, Khon Kaen, Thailand.
CR Abujazia MA, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/525079
   Al Anazi Abdullah Foraih, 2011, J Nat Sci Biol Med, V2, P154, DOI 10.4103/0976 9668.92322
   [Anonymous], KOREAN J SERICULTURA
   Banfi G, 2008, CLIN CHEM LAB MED, V46, P1550, DOI 10.1515/CCLM.2008.302
   Basma AA, 2011, ASIAN PAC J TROP MED, V4, P386, DOI 10.1016/S1995 7645(11)60109 0
   Becker David J, 2010, Curr Rheumatol Rep, V12, P186, DOI 10.1007/s11926 010 0097 y
   Chiechi L. M., 2005, Current Topics in Nutraceutical Research, V3, P15
   COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184
   Dabhade P., 2012, BIONANO FRONTIER 2, V5, P72
   Derakhshanian H, 2013, CAN J PHYSIOL PHARM, V91, P380, DOI 10.1139/cjpp 2012 0190
   Doi K, 2000, BIOL PHARM BULL, V23, P1066, DOI 10.1248/bpb.23.1066
   Dundar K, 2005, CLIN EXP PHARMACOL P, V32, P926, DOI 10.1111/j.1440 1681.2005.04286.x
   Enkhmaa B, 2005, J NUTR, V135, P729, DOI 10.1093/jn/135.4.729
   Gambacciani M, 2004, Minerva Med, V95, P507
   Gundberg CM, 2012, ADV NUTR, V3, P149, DOI 10.3945/an.112.001834
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Jagger CJ, 2005, ENDOCRINOLOGY, V146, P113, DOI 10.1210/en.2004 1058
   Juajun O., 2012, Food and Nutrition Sciences, V3, P1631, DOI 10.4236/fns.2012.312213
   Lelovas PP, 2008, COMPARATIVE MED, V58, P424
   Li N, 2009, MOLECULES, V14, P2049, DOI 10.3390/molecules14062049
   Liu AL, 2004, CELL BIOL INT, V28, P905, DOI 10.1016/j.cellbi.2004.09.004
   Mackie EJ, 2003, INT J BIOCHEM CELL B, V35, P1301, DOI 10.1016/S1357 2725(03)00107 9
   MCCORD JM, 1969, J BIOL CHEM, V244, P6049
   McGowan HW, 2014, J MUSCULOSKEL NEURON, V14, P162
   Mody N, 2001, FREE RADICAL BIO MED, V31, P509, DOI 10.1016/S0891 5849(01)00610 4
   Nanasombat S, 2009, J MED PLANTS RES, V3, P443
   OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003 2697(79)90738 3
   Ohlsson C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092368
   Ozgocmen S, 2007, MOL CELL BIOCHEM, V295, P45, DOI 10.1007/s11010 006 9270 z
   Potu Bhagath Kumar, 2010, Chang Gung Med J, V33, P252
   Pourmorad F, 2006, AFR J BIOTECHNOL, V5, P1142
   Rickard DJ, 2006, BONE, V39, P1361, DOI 10.1016/j.bone.2006.06.010
   Rosen CJ, 2004, TRENDS ENDOCRIN MET, V15, P229, DOI 10.1016/j.tem.2004.05.005
   Srivastava S, 2006, INT J FOOD SCI NUTR, V57, P305, DOI 10.1080/09637480600801837
   Zhang M, 2011, ADV EXP MED BIOL, V701, P283, DOI 10.1007/978 1 4419 7756 4_38
NR 35
TC 17
Z9 19
U1 0
U2 14
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942 0900
EI 1942 0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PY 2014
VL 2014
AR 579305
DI 10.1155/2014/579305
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA AU1GS
UT WOS:000345369600001
PM 25478061
OA hybrid, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Licata, AA
AF Licata, Angelo A.
TI Clinical perspectives on bone quality in osteoporosis
SO DRUGS & AGING
LA English
DT Article
ID FRACTURE INTERVENTION TRIAL; OVARIECTOMIZED CYNOMOLGUS MONKEYS;
   PARATHYROID HORMONE 1 34; HUMAN CORTICAL BONE; POSTMENOPAUSAL WOMEN;
   VERTEBRAL FRACTURES; COLLAGEN QUALITY; ESTROGEN THERAPY; MINERAL
   DENSITY; CANCELLOUS BONE
AB Treatment of primary osteoporosis has advanced dramatically during the past decade, with more therapeutic options being available now than at any other time. Anti resorptive (anti catabolic) drugs have been prominent in the treatment of osteoporosis for decades. However, over time, several clinical observations made during use of these agents have challenged the prevailing dogma about mechanisms of drug action, changes in bone density and fracture reduction during treatment. It has become clear that changes in bone density are only a small part of the explanation for the dramatic reduction of fractures with treatment. From this paradox developed the notion of 'bone quality'   an operational term describing a number of characteristics that enable bone to resist fracturing. This article reviews this concept from a clinical perspective. It discusses the historical paradoxes found in clinical practice that have led to this notion, identifies the major areas of bone physiology circumscribed by the concept and focuses on present therapies and their effects on bone quality.
C1 Cleveland Clin, Ctr Space Med, Metab Bone Ctr, Orthoped Res Council,Dept Endocrinol, Cleveland, OH 44195 USA.
   Cleveland Clin, Ctr Space Med, Metab Bone Ctr, Orthoped Res Council,Dept Diabet, Cleveland, OH 44195 USA.
   Cleveland Clin, Ctr Space Med, Metab Bone Ctr, Orthoped Res Council,Dept Metab, Cleveland, OH 44195 USA.
C3 Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland
   Clinic Foundation
RP Licata, AA (通讯作者)，Cleveland Clin, Ctr Space Med, Metab Bone Ctr, Orthoped Res Council,Dept Endocrinol, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM licataa@ccf.org
CR AARON JE, 1989, CLIN ORTHOP RELAT R, P294
   Adachi JD, 2005, AGING CLIN EXP RES, V17, P150
   Allen MR, 2006, BONE, V39, P872, DOI 10.1016/j.bone.2006.04.028
   Bauer DC, 2006, J BONE MINER RES, V21, P292, DOI 10.1359/JBMR.051018
   Beck TJ, 2001, J BONE MINER RES, V16, P2103, DOI 10.1359/jbmr.2001.16.11.2103
   Black DM, 2000, J CLIN ENDOCR METAB, V85, P4118, DOI 10.1210/jc.85.11.4118
   Boivin G, 2005, BONE, V36, P562, DOI 10.1016/j.bone.2004.12.009
   Borah B, 2005, BONE, V37, P1, DOI 10.1016/j.bone.2005.03.017
   Bouxsein Mary L, 2006, Curr Osteoporos Rep, V4, P49, DOI 10.1007/s11914 006 0002 9
   Brownbill Rhonda A, 2003, Curr Osteoporos Rep, V1, P25, DOI 10.1007/s11914 003 0005 8
   Carbonare LD, 2005, MICRON, V36, P645, DOI 10.1016/j.micron.2005.07.009
   CHAI BF, 1994, CHINESE MED J PEKING, V107, P505
   CHAPURLAT RD, 2002, OSTEOPOROSIS INT, V16, P842
   Chesnut CH, 2005, J BONE MINER RES, V20, P1548, DOI 10.1359/JBMR.050411
   Cranney A, 2002, ENDOCR REV, V23, P570, DOI 10.1210/er.2001 9002
   Cummings SR, 2002, JAMA J AM MED ASSOC, V288, P1889, DOI 10.1001/jama.288.15.1889
   Cummings SR, 2002, AM J MED, V112, P281, DOI 10.1016/S0002 9343(01)01124 X
   Currey JD, 2003, J BIOMECH, V36, P1487, DOI 10.1016/S0021 9290(03)00124 6
   Currey John D, 2005, Curr Osteoporos Rep, V3, P52, DOI 10.1007/s11914 005 0004 z
   Dominguez LJ, 2005, BIOCHEM BIOPH RES CO, V330, P1, DOI 10.1016/j.bbrc.2005.02.050
   Eriksen EF, 2002, BONE, V31, P620, DOI 10.1016/S8756 3282(02)00869 4
   Felsenberg D, 2005, CLIN THER, V27, P1, DOI 10.1016/j.clinthera.2004.12.020
   Fischer KJ, 2006, J BIOMED MATER RES B, V76B, P143, DOI 10.1002/jbm.b.30341
   Genant HK, 2007, OSTEOPOROSIS INT, V18, P69, DOI 10.1007/s00198 006 0199 6
   Gonnelli S, 1997, J BONE MINER RES, V12, P624, DOI 10.1359/jbmr.1997.12.4.624
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   HEANEY RP, 1994, J BONE MINER RES, V9, P1515
   Jerome CP, 2001, BONE, V28, P150, DOI 10.1016/S8756 3282(00)00430 0
   Kleerekoper M, 1991, Osteoporos Int, V1, P155, DOI 10.1007/BF01625446
   Knott L, 1998, BONE, V22, P181, DOI 10.1016/S8756 3282(97)00279 2
   Lee TC, 2003, J ANAT, V203, P161, DOI 10.1046/j.1469 7580.2003.00211.x
   Löfman O, 2005, CLIN CHIM ACTA, V356, P67, DOI 10.1016/j.cccn.2004.12.014
   Maricic M, 2002, ARCH INTERN MED, V162, P1140, DOI 10.1001/archinte.162.10.1140
   Meunier PJ, 1999, INT J CLIN PRACT, P14
   Miller PD, 2005, CURR MED RES OPIN, V21, P545, DOI 10.1185/030079905X41390
   Müller R, 2004, J BONE MINER RES, V19, P1787, DOI 10.1359/JBMR.040809
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   NIMNI BS, 1993, CONNECT TISSUE RES, V29, P133, DOI 10.3109/03008209309014240
   O'Brien Fergal J, 2005, Curr Osteoporos Rep, V3, P39, DOI 10.1007/s11914 005 0002 1
   Pal GP, 1998, ANAT REC, V252, P185, DOI 10.1002/(SICI)1097 0185(199810)252:2<185::AID AR4>3.0.CO;2 2
   Paschalis EP, 2003, J BONE MINER RES, V18, P769, DOI 10.1359/jbmr.2003.18.4.769
   Paschalis EP, 2005, J CLIN ENDOCR METAB, V90, P4644, DOI 10.1210/jc.2004 2489
   Recker R, 2005, CURR MED RES OPIN, V21, P185, DOI 10.1185/030079904X20259
   RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203
   Riggs BL, 2002, J BONE MINER RES, V17, P11, DOI 10.1359/jbmr.2002.17.1.11
   RIGGS BL, 1994, J BONE MINER RES, V9, P265
   Sarkar S, 2002, J BONE MINER RES, V17, P1, DOI 10.1359/jbmr.2002.17.1.1
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Seibel MJ, 2004, J BONE MINER RES, V19, P323, DOI 10.1359/JBMR.0301231
   TEITELBAUM SL, 1980, CLIN ENDOCRINOL META, V9, P43, DOI 10.1016/S0300 595X(80)80020 X
   Tolar J, 2004, NEW ENGL J MED, V351, P2839, DOI 10.1056/NEJMra040952
   Vashishth D., 2005, Journal of Musculoskeletal & Neuronal Interactions, V5, P316
   Waarsing J. H., 2005, Journal of Musculoskeletal & Neuronal Interactions, V5, P310
   Wang XD, 2003, ANN BIOMED ENG, V31, P1365, DOI 10.1114/1.1623488
   Watts NB, 2003, J CLIN ENDOCR METAB, V88, P542, DOI 10.1210/jc.2002 020400
   Zioupos P, 1999, J BIOMED MATER RES, V45, P108, DOI 10.1002/(SICI)1097 4636(199905)45:2<108::AID JBM5>3.3.CO;2 1
NR 56
TC 5
Z9 5
U1 0
U2 1
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1170 229X
EI 1179 1969
J9 DRUG AGING
JI Drugs Aging
PY 2007
VL 24
IS 7
BP 529
EP 535
DI 10.2165/00002512 200724070 00001
PG 7
WC Geriatrics & Gerontology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Geriatrics & Gerontology; Pharmacology & Pharmacy
GA 202DF
UT WOS:000248881500001
PM 17658904
DA 2025 08 17
ER

PT J
AU Chhabrani, A
   Avinash, BS
   Bharadwaj, RS
   Kale, R
   Kathuria, A
AF Chhabrani, Ankita
   Avinash, B. S.
   Bharadwaj, R. Sumukh
   Kale, Revati
   Kathuria, Abhinav
TI 'Microgravity's dental dilemma: Navigating oral health challenges in
   space, from effect on bone to therapeutic frontiers   A review'
SO ACTA ASTRONAUTICA
LA English
DT Article
DE Microgravity; Bone; Osteoblast; Muscle; Teeth
ID TRANSCRANIAL MAGNETIC STIMULATION; SIMULATED MICROGRAVITY;
   SKELETAL MUSCLE; STREPTOCOCCUS MUTANS; OSTEOCLAST DIFFERENTIATION;
   CELL DIFFERENTIATION; MUTACIN PRODUCTION; UBIQUITIN LIGASES; STEM CELLS;
   BED REST
AB For many years, space human factors research has focused on the impact of microgravity on human physiology and the health risks astronauts face during space flights of various durations. Our review paper reveals that microgravity leads to both reversible and non reversible effects on astronauts' oral health. In addition to oral health concerns, astronauts often experience muscle degeneration during space missions, which is closely tied to bone loss. Despite our knowledge of high bone resorption and rapid mineral and calcium loss in microgravity, the exact underlying mechanisms remain unclear. However, to fully understand these processes and develop effective strategies to counteract the consequences of microgravity, more research is needed. This includes a deeper exploration of how these molecules and other biomarkers work, identification of early mechanotransduction sensors, and a comprehensive understanding of the physiological effects of weightlessness. Current solutions primarily involve administering antioxidants, regular exercise, and appropriate nutrition. Additionally, innovative approaches such as experimental drug therapies using anti myostatin antibodies and r irisin have gained attention. Further large scale, long term studies are required to understand the effects of microgravity on the oral cavity and prevent its adverse consequences.
C1 [Chhabrani, Ankita; Avinash, B. S.; Bharadwaj, R. Sumukh; Kale, Revati; Kathuria, Abhinav] JSS Acad Higher Educ & Res, JSS Dent Coll & Hosp, Mysuru 570015, Karnataka, India.
   [Avinash, B. S.] JSS Acad Higher Educ & Res, JSS Dent Coll & Hosp, Dept Periodontol, Room 09, Mysuru 570015, Karnataka, India.
C3 JSS Academy of Higher Education & Research; JSS Dental College &
   Hospital, Mysuru; JSS Academy of Higher Education & Research; JSS Dental
   College & Hospital, Mysuru
RP Avinash, BS (通讯作者)，JSS Acad Higher Educ & Res, JSS Dent Coll & Hosp, Dept Periodontol, Room 09, Mysuru 570015, Karnataka, India.
EM dr.avinashbs@jssuni.edu.in
RI Bettahalli Shivamallu, Avinash/AAS 3513 2021
OI Chhabrani, Ankita/0009 0002 4208 8170; Kale, Revati/0009 0007 3912 9839;
   Bettahalli Shivamallu, Avinash/0000 0003 1899 9169; Bharadwaj, Dr. R
   Sumukh/0000 0003 4123 0665
CR Agha NH, 2020, J APPL PHYSIOL, V128, P264, DOI 10.1152/japplphysiol.00560.2019
   Aguirre JI, 2006, J BONE MINER RES, V21, P605, DOI 10.1359/JBMR.060107
   André Obadia N, 2011, PAIN, V152, P1233, DOI 10.1016/j.pain.2010.12.027
   Andreev D, 2020, J CLIN INVEST, V130, P4811, DOI 10.1172/JCI134214
   Apone S, 1997, BONE, V21, P129, DOI 10.1016/S8756 3282(97)00105 1
   Basso N, 2006, BONE, V39, P807, DOI 10.1016/j.bone.2006.04.014
   Bodine SC, 2014, AM J PHYSIOL ENDOC M, V307, pE469, DOI 10.1152/ajpendo.00204.2014
   Bradamante S, 2018, MICROGRAVITY SCI TEC, V30, P713, DOI 10.1007/s12217 018 9653 2
   Brocca L, 2012, J PHYSIOL LONDON, V590, P5211, DOI 10.1113/jphysiol.2012.240267
   Bucaro MA, 2007, J CELL BIOCHEM, V102, P483, DOI 10.1002/jcb.21310
   Bucaro MA, 2004, ANN NY ACAD SCI, V1027, P64, DOI 10.1196/annals.1324.007
   Caillot Augusseau A, 1998, CLIN CHEM, V44, P578
   Caillot Augusseau A, 2000, CLIN CHEM, V46, P1136
   CAIOZZO VJ, 1994, J APPL PHYSIOL, V76, P1764, DOI 10.1152/jappl.1994.76.4.1764
   CALDER IM, 1986, FORENSIC SCI INT, V30, P237, DOI 10.1016/0379 0738(86)90133 7
   Canepari M, 2010, SCAND J MED SCI SPOR, V20, P10, DOI 10.1111/j.1600 0838.2009.00965.x
   Cannavino J, 2014, J PHYSIOL LONDON, V592, P4575, DOI 10.1113/jphysiol.2014.275545
   Cazzaniga A, 2016, BIOCHEM BIOPH RES CO, V473, P181, DOI 10.1016/j.bbrc.2016.03.075
   CHAN AC, 1993, CAN J PHYSIOL PHARM, V71, P725, DOI 10.1139/y93 109
   Cheng XQ, 2014, FEMS MICROBIOL LETT, V359, P94, DOI 10.1111/1574 6968.12573
   Chitkara N., 2017, Int. Healthcare Res. J., V1, P5
   Colaianni G, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 02557 8
   Colaianni G, 2015, P NATL ACAD SCI USA, V112, P12157, DOI 10.1073/pnas.1516622112
   Collet P, 1997, BONE, V20, P547, DOI 10.1016/S8756 3282(97)00052 5
   Colucci S, 2020, FASEB J, V34, P10096, DOI 10.1096/fj.202000216R
   Convertino V A, 1990, Exerc Sport Sci Rev, V18, P119
   Crawford Young SJ, 2006, INT J DEV BIOL, V50, P183, DOI 10.1387/ijdb.052077sc
   Dai ZQ, 2007, CELL PROLIFERAT, V40, P671, DOI 10.1111/j.1365 2184.2007.00461.x
   Di Lazzaro V, 2005, J PHYSIOL LONDON, V565, P945, DOI 10.1113/jphysiol.2005.087288
   Dong JJ, 2021, NPJ MICROGRAVITY, V7, DOI 10.1038/s41526 021 00131 1
   Dugan C., 2021, INT C E HLTH BIOENG, P1, DOI [10.1109/EHB52898.2021.9657555, DOI 10.1109/EHB52898.2021.9657555]
   EDGERTON VR, 1995, J APPL PHYSIOL, V78, P1733, DOI 10.1152/jappl.1995.78.5.1733
   Ekhtiari H, 2019, NEUROSCI BIOBEHAV R, V104, P118, DOI 10.1016/j.neubiorev.2019.06.007
   Ethiraj P, 2018, J CELL BIOCHEM, V119, P5696, DOI 10.1002/jcb.26750
   Ferrando AA, 1996, AM J PHYSIOL ENDOC M, V270, pE627, DOI 10.1152/ajpendo.1996.270.4.E627
   Fitts RH, 2000, J APPL PHYSIOL, V89, P823, DOI 10.1152/jappl.2000.89.2.823
   Frontera WR, 2015, CALCIFIED TISSUE INT, V96, P183, DOI 10.1007/s00223 014 9915 y
   Gambacurta A, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 44593 6
   GARDETTO PR, 1989, J APPL PHYSIOL, V66, P2739, DOI 10.1152/jappl.1989.66.6.2739
   Gioia M, 2018, CELL DEATH DISCOV, V4, DOI 10.1038/s41420 018 0055 4
   Guignandon A, 1997, EXP CELL RES, V236, P66, DOI 10.1006/excr.1997.3703
   Guignandon A, 2014, FASEB J, V28, P4077, DOI 10.1096/fj.14 249714
   Gutierrez JA, 1999, MICROBIOL UK, V145, P357, DOI 10.1099/13500872 145 2 357
   Harika PD, 2023, CUREUS J MED SCIENCE, V15, DOI 10.7759/cureus.49035
   Hayacibara MF, 2004, CARBOHYD RES, V339, P2127, DOI 10.1016/j.carres.2004.05.031
   He BR, 2020, CAN J PHYSIOL PHARM, V98, P678, DOI 10.1139/cjpp 2019 0632
   Hirayama A, 2006, PAIN, V122, P22, DOI 10.1016/j.pain.2005.12.001
   Hosoyama T, 2017, BIOCHEM BIOPH RES CO, V493, P998, DOI 10.1016/j.bbrc.2017.09.103
   Hossain MS, 2011, APPL ENVIRON MICROB, V77, P2428, DOI 10.1128/AEM.02320 10
   Hu LF, 2013, ADV SPACE RES, V51, P107, DOI 10.1016/j.asr.2012.07.036
   Hughes Fulford M, 2003, ADV SPACE RES SERIES, V32, P1585, DOI 10.1016/S0273 1177(03)90399 1
   Hughes Fulford M, 1998, Gravit Space Biol Bull, V11, P51
   HughesFulford M, 1996, EXP CELL RES, V224, P103, DOI 10.1006/excr.1996.0116
   Ikegame M, 2019, J PINEAL RES, V67, DOI 10.1111/jpi.12594
   Kalb R, 2007, ARCH NEUROL CHICAGO, V64, P485, DOI 10.1001/archneur.64.4.485
   Kaushik SK., 2009, IND J AEROSPACE MED, V53, P6
   Koo H, 2009, INT J ORAL SCI, V1, P229, DOI 10.4248/IJOS.09086
   Kreth J, 2007, MICROBIOL SGM, V153, P1799, DOI 10.1099/mic.0.2007/005975 0
   Kreth J, 2006, FEMS MICROBIOL LETT, V265, P11, DOI 10.1111/j.1574 6968.2006.00459.x
   Kroes M.J., 2010, Aircraft Maintenance and Repair, Vsixth, P531
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Landis WJ, 2000, J BONE MINER RES, V15, P1099, DOI 10.1359/jbmr.2000.15.6.1099
   LEBLANC A, 1995, AVIAT SPACE ENVIR MD, V66, P1151
   Lee PHU, 2022, AM J PHYSIOL CELL PH, V322, pC567, DOI 10.1152/ajpcell.00203.2021
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Li YH, 2001, J BACTERIOL, V183, P6875, DOI 10.1128/JB.183.23.6875 6884.2001
   Li YH, 2020, ACTA ASTRONAUT, V166, P607, DOI 10.1016/j.actaastro.2019.01.032
   Lin CW, 2009, J BONE MINER RES, V24, P1651, DOI [10.1359/JBMR.090411, 10.1359/jbmr.090411]
   Maffei M, 2014, ACTA PHYSIOL, V212, P316, DOI 10.1111/apha.12320
   Maillet A, 2001, CURR OPIN CLIN NUTR, V4, P301, DOI 10.1097/00075197 200107000 00010
   Makihira S, 2008, CELL BIOL INT, V32, P1176, DOI 10.1016/j.cellbi.2008.04.027
   Mann V, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061357
   Matsui R, 2010, FUTURE MICROBIOL, V5, P403, DOI 10.2217/FMB.09.129
   Matsumoto A, 2014, ACTA HISTOCHEM, V116, P936, DOI 10.1016/j.acthis.2014.03.006
   Merritt J, 2005, MOL MICROBIOL, V57, P960, DOI 10.1111/j.1365 2958.2005.04733.x
   Metzger CE, 2020, NPJ MICROGRAVITY, V6, DOI 10.1038/s41526 020 00118 4
   Metzger CE, 2017, BONE, V105, P26, DOI 10.1016/j.bone.2017.08.002
   Nabavi N, 2011, BONE, V49, P965, DOI 10.1016/j.bone.2011.07.036
   Narici MV, 2011, EUR J APPL PHYSIOL, V111, P403, DOI 10.1007/s00421 010 1556 x
   Nomura J, 2000, J Gravit Physiol, V7, pP65
   OHIRA Y, 1992, J APPL PHYSIOL, V73, pS51, DOI 10.1152/jappl.1992.73.2.S51
   Ontiveros C, 2003, J CELL BIOCHEM, V88, P427, DOI 10.1002/jcb.10410
   Pagano RL, 2011, EUR J PAIN, V15, DOI 10.1016/j.ejpain.2010.08.003
   Pan Z, 2008, STEM CELLS DEV, V17, P795, DOI 10.1089/scd.2008.0254
   Pardo SJ, 2005, AM J PHYSIOL CELL PH, V288, pC1211, DOI 10.1152/ajpcell.00222.2004
   Patel MJ, 2007, J CELL BIOCHEM, V101, P587, DOI 10.1002/jcb.21218
   Plow EB, 2012, J PAIN, V13, P411, DOI 10.1016/j.jpain.2012.02.001
   Powers SK, 2007, J APPL PHYSIOL, V102, P2389, DOI 10.1152/japplphysiol.01202.2006
   Powers SK, 2014, SPORTS MED, V44, pS155, DOI 10.1007/s40279 014 0255 x
   Qi FX, 2004, INFECT IMMUN, V72, P4895, DOI 10.1128/IAI.72.8.4895 4899.2004
   Qian AR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051036
   Qiao XY, 2016, SCI REP UK, V6, DOI 10.1038/srep18732
   Rai B, 2011, INT J DENT, V2011, DOI 10.1155/2011/548068
   Rai B, 2013, J ORAL SCI, V55, P139, DOI 10.2334/josnusd.55.139
   Rai B, 2011, J PERIODONTOL, V82, P1478, DOI 10.1902/jop.2011.100711
   Rai Balwant, 2011, J Oral Sci, V53, P143
   Rai Balwant, 2010, J Oral Sci, V52, P385
   RAMBAUT PC, 1979, ACTA ASTRONAUT, V6, P1113, DOI 10.1016/0094 5765(79)90059 6
   Reinhart RMG, 2017, ATTEN PERCEPT PSYCHO, V79, P3, DOI 10.3758/s13414 016 1224 2
   Rodionova NV, 2002, ADV SPACE RES, V30, P765, DOI 10.1016/S0273 1177(02)00393 9
   ROY RR, 1987, J APPL PHYSIOL, V62, P2348, DOI 10.1152/jappl.1987.62.6.2348
   Ru JY, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 03059 8
   Rucci N, 2007, J CELL BIOCHEM, V100, P464, DOI 10.1002/jcb.21059
   Sambandam Y, 2014, BONE, V61, P125, DOI 10.1016/j.bone.2014.01.004
   Sambandam Y, 2010, J CELL BIOCHEM, V111, P1179, DOI 10.1002/jcb.22840
   Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092 8674(04)00400 3
   Saxena R, 2011, J BONE MINER METAB, V29, P111, DOI 10.1007/s00774 010 0201 4
   Schulte Leah M., 1993, American Journal of Physiology, V264, pC1308
   Shi WG, 2020, BONE, V136, DOI 10.1016/j.bone.2020.115346
   Sibonga JD, 2007, BONE, V41, P973, DOI 10.1016/j.bone.2007.08.022
   Sibonga JD, 2015, AEROSP MED HUM PERF, V86, pA38, DOI 10.3357/AMHP.EC06.2015
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Slentz DH, 2001, IN VITRO CELL DEV AN, V37, P148
   Smith SM, 2005, J NUTR, V135, P437, DOI 10.1093/jn/135.3.437
   Smith SM, 2005, J BONE MINER RES, V20, P208, DOI 10.1359/JBMR.041105
   Smith SM, 1998, J CLIN ENDOCR METAB, V83, P3584, DOI 10.1210/jc.83.10.3584
   Spatz JM, 2015, J BIOL CHEM, V290, P16744, DOI 10.1074/jbc.M114.628313
   Stein TP, 2002, NUTRITION, V18, P867, DOI 10.1016/S0899 9007(02)00938 3
   Stein TP, 1999, AM J PHYSIOL ENDOC M, V276, pE1014
   Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097 2765(04)00211 4
   Stoetzer M, 2012, CASE REP DENT, V2012, DOI 10.1155/2012/453415
   Strollo F, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01551
   Sun H, 2022, FRONT MICROBIOL, V13, DOI 10.3389/fmicb.2022.1056637
   Sun ZY, 2019, J CELL BIOCHEM, V120, P4009, DOI 10.1002/jcb.27685
   Tamma R, 2009, FASEB J, V23, P2549, DOI 10.1096/fj.08 127951
   Tarantino Umberto, 2020, Cell Physiol Biochem, V54, P736, DOI 10.33594/000000252
   Tatsumi S, 2007, CELL METAB, V5, P464, DOI 10.1016/j.cmet.2007.05.001
   THOMASON DB, 1989, AM J PHYSIOL, V257, pR300, DOI 10.1152/ajpregu.1989.257.2.R300
   TILTON FE, 1980, AVIAT SPACE ENVIR MD, V51, P1209
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   Vico L, 2000, LANCET, V355, P1607, DOI 10.1016/S0140 6736(00)02217 0
   VICO L, 1988, AM J PHYSIOL, V255, pR243, DOI 10.1152/ajpregu.1988.255.2.R243
   Vico L, 2017, J BONE MINER RES, V32, P2010, DOI 10.1002/jbmr.3188
   Vorselen D, 2014, FASEB J, V28, P536, DOI 10.1096/fj.13 236356
   Walston JD, 2012, CURR OPIN RHEUMATOL, V24, P623, DOI 10.1097/BOR.0b013e328358d59b
   WHEDON GD, 1976, CALC TISS RES, V21, P423
   Widrick JJ, 1999, J PHYSIOL LONDON, V516, P915, DOI 10.1111/j.1469 7793.1999.0915u.x
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Yamamoto T, 2020, BIOMED RES TOKYO, V41, P279, DOI 10.2220/biomedres.41.279
   Yang Tang bin, 2003, Space Med Med Eng (Beijing), V16, P455
   Yang X, 2015, MICROGRAVITY SCI TEC, V27, P473, DOI 10.1007/s12217 015 9439 8
   Yu SG, 2014, PROG BIOPHYS MOL BIO, V114, P14, DOI 10.1016/j.pbiomolbio.2013.11.002
   Yuge L, 2003, IN VITRO CELL DEV AN, V39, P89
   Yuge L, 2006, STEM CELLS DEV, V15, P921, DOI 10.1089/scd.2006.15.921
   Zadik Y, 2006, AVIAT SPACE ENVIR MD, V77, P654
   Zadik Y, 2009, BRIT DENT J, V206, P11, DOI 10.1038/sj.bdj.2008.1121
   Zhang J, 2017, BONE RES, V5, DOI 10.1038/boneres.2016.56
   Zittermann A, 2000, EUR J CLIN INVEST, V30, P1036, DOI 10.1046/j.1365 2362.2000.00682.x
   Zuo L, 2015, FRONT PHYSIOL, V6, DOI [10.3389/fphys.7015.00338, 10.3389/fphys.2015.00338]
NR 150
TC 1
Z9 1
U1 5
U2 8
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0094 5765
EI 1879 2030
J9 ACTA ASTRONAUT
JI Acta Astronaut.
PD JUN
PY 2024
VL 219
BP 363
EP 375
DI 10.1016/j.actaastro.2024.03.014
EA MAR 2024
PG 13
WC Engineering, Aerospace
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA RA3X4
UT WOS:001224924100001
DA 2025 08 17
ER

PT J
AU Saviola, G
   Abdi Ali, L
   Povino, MR
AF Saviola, G.
   Abdi Ali, L.
   Povino, M. R.
TI CLODRONATE: OLD DRUG, NEW USES
SO JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
LA English
DT Article
DE clodronate; osteoarthritis; extra articular calcifications; aseptic
   mobilization of prosthesis
ID DOUBLE BLIND; KNEE; OSTEOARTHRITIS; OSTEOPOROSIS; AMINOBISPHOSPHONATES;
   BISPHOSPHONATES; INHIBITION; CELLS; WOMEN; RISK
AB Clodronate (CLO) is a bisphosphonate (BP) with proved efficacy in the treatment of osteoporosis. The reason of its activity is the anti resorptive action, which is a common characteristic of BPs. Contrary to other BPs, CLO has a relatively low affinity for bone and a peculiar mechanism of action. CLO is effective in several diseases associated to excessive bone resorption as bone Paget's disease and CRPS type I. Moreover, there are data showing activity of CLO in the erosive osteoarthritis of the hands, in the osteoarthritis of the knees, in the treatment of extra articular calcifications and in preventing the mobilization of knee and hip prosthesis.
C1 [Saviola, G.; Abdi Ali, L.; Povino, M. R.] Salvatore Maugeri Fdn Irccs, Rheumatol & Rehabil Unit, I 46042 Castel Goffredo, Mantua, Italy.
C3 Istituti Clinici Scientifici Maugeri IRCCS
RP Saviola, G (通讯作者)，Salvatore Maugeri Fdn Irccs, Rheumatol & Rehabil Unit, Via Osped 36, I 46042 Castel Goffredo, Mantua, Italy.
EM gianantonio.saviola@fsm.it
RI SAVIOLA, GIANANTONIO/AAC 1647 2020; Abdi Ali, Lul/AAB 8929 2020;
   Saviola, Gianantonio/AAC 1647 2020
OI SAVIOLA, GIANANTONIO/0000 0002 0186 9520; 
CR BERGMAN AG, 1994, SKELETAL RADIOL, V23, P445
   Carbone LD, 2004, ARTHRITIS RHEUM US, V50, P3516, DOI 10.1002/art.20627
   Diel IJ, 2007, CRIT REV ONCOL HEMAT, V64, P198, DOI 10.1016/j.critrevonc.2007.07.005
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Frediani B, 2003, BONE, V33, P575, DOI 10.1016/S8756 3282(03)00208 4
   Frediani B, 2009, CLIN DRUG INVEST, V29, P359, DOI 10.2165/00044011 200929060 00001
   Ghonoi V, 2002, EXPERT OPIN PHARMACO, V3, P1643
   Hewitt RE, 2005, CLIN EXP IMMUNOL, V139, P101, DOI 10.1111/j.1365 2249.2005.02665.x
   Hilding M, 2006, ACTA ORTHOP, V77, P912, DOI 10.1080/17453670610013213
   Lehenkari PP, 2002, MOL PHARMACOL, V61, P1255, DOI 10.1124/mol.61.5.1255
   Liu L, 2006, J DENT RES, V85, P757, DOI 10.1177/154405910608500813
   Massari L, 2002, GIOT, V28
   McCloskey E, 2004, J BONE MINER RES, V19, P728, DOI 10.1359/JBMR.040116
   McCloskey EV, 2007, J BONE MINER RES, V22, P135, DOI 10.1359/JBMR.061008
   Prieto Alhambra D, 2013, BMJ BRIT MED J, V347, pf6956
   Prieto Alhambra D, 2014, ARTHRITIS RHEUMATOL, V66, P3233, DOI 10.1002/art.38789
   Rosa RG, 2014, OSTEOARTHR CARTILAGE, V22, P1327, DOI 10.1016/j.joca.2014.07.009
   Rossini M, 2015, RHEUMATOL INT, V35, P255, DOI 10.1007/s00296 014 3100 5
   Rossini M, 2009, RHEUMATOLOGY, V48, P773, DOI 10.1093/rheumatology/kep084
   Saviola G, 2000, G Ital Med Lav Ergon, V22, P328
   Saviola G, 2012, MOD RHEUMATOL, V22, P256, DOI 10.1007/s10165 011 0506 8
   Saviola G, 2011, RHEUMATOL INT, V31, P415, DOI 10.1007/s00296 010 1575 2
   Shanbhag AS, 2006, J AM ACAD ORTHOP SUR, V14, P215, DOI 10.5435/00124635 200604000 00003
   Trevisan C, 2010, CALCIFIED TISSUE INT, V86, P436, DOI 10.1007/s00223 010 9356 1
   Zhen GH, 2013, NAT MED, V19, P704, DOI 10.1038/nm.3143
NR 25
TC 6
Z9 6
U1 0
U2 4
PU BIOLIFE SAS
PI SILVA MARINA (TE)
PA VIA S STEFANO 39 BIS, 64029 SILVA MARINA (TE), ITALY
SN 0393 974X
EI 1724 6083
J9 J BIOL REG HOMEOS AG
JI J. Biol. Regul. Homeost. Agents
PD JUL SEP
PY 2015
VL 29
IS 3
BP 719
EP 722
PG 4
WC Endocrinology & Metabolism; Immunology; Medicine, Research &
   Experimental; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Immunology; Research & Experimental
   Medicine; Physiology
GA CT2GQ
UT WOS:000362620400024
PM 26403413
DA 2025 08 17
ER

PT J
AU Li, XF
   Zhu, GY
   Wang, JP
   Wang, Y
AF Li, Xu Fang
   Zhu, Guo Ying
   Wang, Jian Ping
   Wang, Yu
TI Inhibitory effects of autologous γ irradiated cell conditioned medium on
   osteoblasts in vitro
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE abscopal effect; radiotherapy; osteoblast; irradiation
ID INDUCED INSUFFICIENCY FRACTURES; RADIATION THERAPY; CYTOKINE RELEASE;
   ALPHA PARTICLES; X IRRADIATION; LOW FLUENCES; BONE GROWTH; ABSCOPAL;
   PROLIFERATION; SIGNAL
AB Skeletal complications from radiation therapy have been reported in patients with breast, brain and pelvic cancer, and types of blood cancer. However, it remains to be elucidated whether localized radiotherapy may result in systemic adverse effects on the unirradiated skeleton through an abscopal mechanism. The present study investigated the abscopal effect of radiation on osteoblasts mediated by autologous  irradiated cell conditioned medium. Osteoblasts obtained from calvarial bones were incubated with irradiated cell conditioned medium (ICCM) and changes in cell viability, alkaline phosphatase (ALP) activity, mineralization ability, cell apoptosis and the gene expression levels of ALP, osteocalcin (BGP), osteoprotegerin (OPG), receptor activator of nuclear factor B ligand (RANKL) and caspase 3 were observed. Notably, ICCM regulated osteoblast function, inhibiting viability and differentiation, resulting in apoptosis or cell death. ICCM at 10 or 20%, from osteoblasts irradiated with 10 Gy  rays, significantly inhibited the proliferation of osteoblastic cells (P<0.001). In addition, an increase in apoptosis was noted in the osteoblasts incubated with ICCM at 40% with increasing doses of radiation, accompanied by an upregulation in the mRNA expression of caspase 3. In addition, ICCM at 20% inhibited the ALP activity in the 5 and 10 Gy groups and osteoblast mineralization, particularly at 10 Gy ICCM. Additionally, the mRNA expression levels of ALP, BGP, OPG and RANKL of the cells treated with ICCM at 20% were downregulated significantly compared with those treated with medium from unirradiated cells. The present study provided novel evidence to elucidate radiation therapy associated side effects on the skeleton.
C1 [Li, Xu Fang; Zhu, Guo Ying; Wang, Jian Ping; Wang, Yu] Fudan Univ, Inst Radiat Med, Dept Environm Epidemiol & Bone Toxicol, Shanghai 200032, Peoples R China.
C3 Fudan University
RP Zhu, GY (通讯作者)，Fudan Univ, Inst Radiat Med, Dept Environm Epidemiol & Bone Toxicol, 2094 Xietu Rd, Shanghai 200032, Peoples R China.
EM zhugy@shmu.edu.cn
FU Shanghai Municipal Health Bureau [2009003, 12GWZX0401]
FX The present study was supported by the Shanghai Municipal Health Bureau
   (grant nos. 2009003 and 12GWZX0401).
CR ABE H, 1992, AM J ROENTGENOL, V158, P599, DOI 10.2214/ajr.158.3.1739002
   Aksnes LH, 2007, ACTA ONCOL, V46, P490, DOI 10.1080/02841860701218642
   Azzam EI, 1998, RADIAT RES, V150, P497, DOI 10.2307/3579865
   Azzam EI, 2000, CANCER RES, V60, P2623
   Baxter NN, 2005, JAMA J AM MED ASSOC, V294, P2587, DOI 10.1001/jama.294.20.2587
   Belyakov OV, 2003, BRIT J CANCER, V88, P767, DOI 10.1038/sj.bjc.6600804
   Bentzen SM, 2006, NAT REV CANCER, V6, P702, DOI 10.1038/nrc1950
   Blomlie V, 1996, AM J ROENTGENOL, V167, P1205, DOI 10.2214/ajr.167.5.8911181
   Chen Z, 2009, OSTEOPOROSIS INT, V20, P527, DOI 10.1007/s00198 008 0721 0
   COLLETT WK, 1966, J DENT RES, V45, P1529, DOI 10.1177/00220345660450054301
   CONARD RA, 1964, ANN NY ACAD SCI, V114, P335
   Dare A, 1997, J DENT RES, V76, P658, DOI 10.1177/00220345970760020601
   Facoetti A, 2006, RADIAT PROT DOSIM, V122, P271, DOI 10.1093/rpd/ncl431
   Facoetti A, 2009, INT J RADIAT BIOL, V85, P690, DOI 10.1080/09553000903020016
   Ghandhi SA, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755 8794 1 63
   HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022 1759(89)90397 9
   Hinoi E, 2002, BIOCHEM BIOPH RES CO, V294, P1177, DOI 10.1016/S0006 291X(02)00578 8
   Hopewell JW, 2003, MED PEDIATR ONCOL, V41, P208, DOI 10.1002/mpo.10338
   Jia D, 2011, RADIAT RES, V176, P624, DOI 10.1667/RR2505.1
   Jia D, 2010, RADIAT RES, V173, P579, DOI 10.1667/RR2030.1
   Kirsch T, 1997, J CELL BIOL, V137, P1149, DOI 10.1083/jcb.137.5.1149
   KURNICK NB, 1964, ANN NY ACAD SCI, V114, P528
   Lehnert BE, 1997, CANCER RES, V57, P2164
   Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092 8674(00)80434 1
   Lyng FM, 2011, INT J RADIAT BIOL, V87, P683, DOI 10.3109/09553002.2010.549533
   Lyng FM, 2000, BRIT J CANCER, V83, P1223, DOI 10.1054/bjoc.2000.1433
   Lyng FM, 2006, RADIAT RES, V165, P400, DOI 10.1667/RR3527.1
   Lyng FM, 2002, RADIAT PROT DOSIM, V99, P169, DOI 10.1093/oxfordjournals.rpd.a006753
   MONTOUR JL, 1971, ACTA RADIOL THER PHY, V10, P150, DOI 10.3109/02841867109129751
   Mothersill C, 1998, RADIAT RES, V149, P256, DOI 10.2307/3579958
   Mothersill C, 2001, CARCINOGENESIS, V22, P1465, DOI 10.1093/carcin/22.9.1465
   Mothersill C, 2010, RADIAT RES, V174, P119, DOI 10.1667/RR2036.1
   Nelson HD, 2002, ANN INTERN MED, V137, P529, DOI 10.7326/0003 4819 137 6 200209170 00015
   NOBLER MP, 1969, RADIOLOGY, V93, P410, DOI 10.1148/93.2.410
   PAPPAS AM, 1963, J BONE JOINT SURG AM, V45, P765, DOI 10.2106/00004623 196345040 00008
   Robbins MEC, 2004, INT J RADIAT BIOL, V80, P251, DOI 10.1080/09553000410001692726
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Shao C, 2008, ONCOGENE, V27, P434, DOI 10.1038/sj.onc.1210653
   TRAVIS EL, 1980, INT J RADIAT ONCOL, V6, P345, DOI 10.1016/0360 3016(80)90145 5
   Van der Meeren A, 2005, RADIAT RES, V163, P144, DOI 10.1667/RR3293
   Van Staa TP, 2005, J BONE MINER RES, V20, P1486, DOI 10.1359/jbmr.2005.20.8.1486
   Zhou GQ, 2013, BIOL TRACE ELEM RES, V153, P411, DOI 10.1007/s12011 013 9655 2
   Zuppinger A, 1959, UN INT C PEAC US AT, V22, P247
NR 43
TC 4
Z9 4
U1 1
U2 6
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD JUL
PY 2015
VL 12
IS 1
BP 273
EP 280
DI 10.3892/mmr.2015.3354
PG 8
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA CN0WJ
UT WOS:000358134400039
PM 25684548
OA Bronze
DA 2025 08 17
ER

PT J
AU Tian, XN
   Cong, F
   Guo, H
   Fan, JZ
   Chao, G
   Song, T
AF Tian, Xiaoning
   Cong, Fei
   Guo, Hua
   Fan, Jinzhu
   Chao, Gao
   Song, Tao
TI Downregulation of Bach1 protects osteoblasts against hydrogen
   peroxide induced oxidative damage in vitro by enhancing the
   activation of Nrf2/ARE signaling
SO CHEMICO BIOLOGICAL INTERACTIONS
LA English
DT Article
DE Bach1; Osteoblast; Osteoporosis; Oxidative stress; Nrf2
ID ADENOASSOCIATED VIRUS; TRANSCRIPTIONAL REPRESSOR; GENE THERAPY;
   OSTEOCLASTOGENESIS; STRESS; CELLS; BONE; EXPRESSION; DELETION; SIRNA
AB Oxidative stress induced osteoblast dysfunction plays an important role in the development and progression of osteoporosis. BTB and CNC homology 1 (Bach1) has been suggested as a critical regulator of oxidative stress; however, whether Bach1 plays a role in regulating oxidative stress induced osteoblast dysfunction remains unknown. Thus, we investigated the potential role and mechanism of Bach1 in regulating oxidative stress induced osteoblast dysfunction. Osteoblasts were treated with hydrogen peroxide (H2O2) to mimic a pathological environment for osteoporosis in vitro. H(2)O(2 )exposure induced Bach1 expression in osteoblasts. Functional experiments demonstrated that Bach1 silencing improved cell viability and reduced cell apoptosis and reactive oxygen species (ROS) production in H2O2 treated cells, while Bach1 overexpression produced the opposite effects. Notably, Bach1 inhibition upregulated alkaline phosphatase activity and osteoblast mineralization. Mechanism research revealed that Bach1 inhibition increased the activation of nuclear factor erythroid 2 related factor 2 (Nrf2)/antioxidant response element (ARE) signaling and upregulated heme oxygenase 1 and NAD(P) H:quinone oxidoreductase 1 mRNA expression. The Bach1 inhibition mediated protective effect was partially reversed by silencing Nrf2 in H2O2 exposed osteoblasts. Taken together, these results demonstrate that Bach1 inhibition alleviates oxidative stress induced osteoblast apoptosis and dysfunction by enhancing Nrf2/ARE signaling activation, findings that suggest a critical role for the Bach1/Nrf2/ARE regulation axis in osteoporosis progression. Our study suggests that Bach1 may serve as a potential therapeutic target for treating osteoporosis.
C1 [Tian, Xiaoning; Cong, Fei; Fan, Jinzhu; Chao, Gao; Song, Tao] Xi An Jiao Tong Univ, Honghui Hosp, Dept Bone Reconstruct Microsurg, Xian 710054, Shaanxi, Peoples R China.
   [Guo, Hua] Xi An Jiao Tong Univ, Honghui Hosp, Dept Emergency Med, Xian 710054, Shaanxi, Peoples R China.
C3 Xi'an Jiaotong University; Xi'an Jiaotong University
RP Guo, H (通讯作者)，Xi An Jiao Tong Univ, Honghui Hosp, Dept Emergency Med, Xian 710054, Shaanxi, Peoples R China.
EM guo_huahh@163.com
RI Song, Tao/E 7419 2013
CR Aletaha M, 2017, BIOMED PHARMACOTHER, V88, P34, DOI 10.1016/j.biopha.2017.01.030
   Callaway DA, 2015, J BONE MINER METAB, V33, P359, DOI 10.1007/s00774 015 0656 4
   Cervellati C., 2014, BIOMED RES INT, V12
   Chapple SJ, 2016, FREE RADICAL BIO MED, V92, P152, DOI 10.1016/j.freeradbiomed.2015.12.013
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Davudian S, 2016, GENE, V588, P30, DOI 10.1016/j.gene.2016.04.040
   Franceschi RT, 1999, CRIT REV ORAL BIOL M, V10, P40, DOI 10.1177/10454411990100010201
   Hama M, 2012, ARTHRITIS RHEUM US, V64, P1518, DOI 10.1002/art.33497
   Hyeon S, 2013, FREE RADICAL BIO MED, V65, P789, DOI 10.1016/j.freeradbiomed.2013.08.005
   Ito H, 2004, GENE THER, V11, P34, DOI 10.1038/sj.gt.3302102
   Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76
   Ka SO, 2017, FASEB J, V31, P3999, DOI 10.1096/fj.201700098RR
   Kanzaki H, 2017, FASEB J, V31, P781, DOI 10.1096/fj.201600826R
   Kitamuro T, 2003, J BIOL CHEM, V278, P9125, DOI 10.1074/jbc.M209939200
   Kondo K., 2013, AM J PHYSIOL ENDOC M, V305, P23
   Kostenuik PJ, 2004, BONE, V34, P656, DOI 10.1016/j.bone.2003.12.006
   Lin H, 2015, BIOCHEM BIOPH RES CO, V460, P422, DOI 10.1016/j.bbrc.2015.03.049
   Liu Y, 2017, INT J MOL MED, V39, P91, DOI 10.3892/ijmm.2016.2823
   Nie E, 2016, SCI REP UK, V6, DOI 10.1038/srep39743
   Oyake T, 1996, MOL CELL BIOL, V16, P6083
   Pomatto LCD, 2018, FREE RADICAL BIO MED, V121, P86, DOI 10.1016/j.freeradbiomed.2018.04.574
   Reichard JF, 2007, NUCLEIC ACIDS RES, V35, P7074, DOI 10.1093/nar/gkm638
   Shajari N, 2018, ARTIF CELL NANOMED B, V46, P1495, DOI 10.1080/21691401.2017.1374284
   Sun XY, 2018, BIOCHEM BIOPH RES CO, V507, P114, DOI 10.1016/j.bbrc.2018.10.182
   Sun YX, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929 015 0212 5
   Sun YX, 2015, BONE, V74, P1, DOI 10.1016/j.bone.2014.12.066
   Suzuki H, 2003, J BIOL CHEM, V278, P49246, DOI 10.1074/jbc.M306764200
   Ulrich Vinther M, 2007, ACTA ORTHOP, V78, P5
   Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960
   Wang X., 2016, OXID MED CELL LONGEV, V29
   Wilson C., 2014, NAT REV ENDOCRINOL, V10, P5
   Xia G, 2017, BIOCHEM BIOPH RES CO, V491, P807, DOI 10.1016/j.bbrc.2017.06.184
   Xing Y, 2018, J CELL BIOCHEM, V119, P10376, DOI 10.1002/jcb.27383
   Xu DW, 2017, ONCOTARGET, V8, P59225, DOI 10.18632/oncotarget.19486
   Yano Y, 2006, GENES CELLS, V11, P791, DOI 10.1111/j.1365 2443.2006.00979.x
   Zaiss AK, 2008, GENE THER, V15, P808, DOI 10.1038/gt.2008.54
   Zhang SJ, 2018, INT J BIOL MACROMOL, V107, P2094, DOI 10.1016/j.ijbiomac.2017.10.080
   Zhu GD, 2018, BIOCHEM BIOPH RES CO, V499, P120, DOI 10.1016/j.bbrc.2018.02.178
NR 38
TC 28
Z9 33
U1 0
U2 25
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0009 2797
EI 1872 7786
J9 CHEM BIOL INTERACT
JI Chem. Biol. Interact.
PD AUG 25
PY 2019
VL 309
AR 108706
DI 10.1016/j.cbi.2019.06.019
PG 8
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
GA IS5FS
UT WOS:000482178500015
PM 31194955
DA 2025 08 17
ER

PT J
AU Miao, JS
   Yao, HB
   Liu, J
   Huang, ZX
   Shi, CG
   Lu, XY
   Jiang, JC
   Ren, RF
   Wang, CY
   Pan, YJ
   Wang, T
   Jin, HM
AF Miao, Jiansen
   Yao, Hanbing
   Liu, Jian
   Huang, Zhixian
   Shi, Chengge
   Lu, Xinyu
   Jiang, Junchen
   Ren, Rufeng
   Wang, Chenyu
   Pan, Youjin
   Wang, Te
   Jin, Haiming
TI Inhibition of KIF11 ameliorates osteoclastogenesis via regulating
   mTORC1 mediated NF κB signaling
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE Caudatin; KIF11; mTORC; RANKL; Osteoclastogenesis; Osteoporosis
ID RECEPTOR ACTIVATOR; OSTEOPOROSIS; CELLS; GROWTH
AB Osteoporosis, characterized by over production and activation of osteoclasts, has become a major health problem especially in elderly women. In our study, we first tested the effect of Caudatin (Cau) in osteoclastogenesis, which is separated from Cynanchum auriculatum as a species of C 21 steroidal glyosides. The results indicated that Cau suppressed osteoclastogenesis in a time and dose dependent manner in vitro. Mechanistically, Cau was identified to inhibit NF kappa B signaling pathway via modulation of KIF11 mediated mTORC1 activity. In vivo, by establishing an ovariectomized (OVX) mouse model to mimic osteoporosis, we confirmed that Cau treatment prevented OVX induced bone loss in mice. In conclusion, we demonstrated that Cau inhibited NF kappa B signaling pathway via modulation of KIF11 mediated mTORC1 activity to suppress osteoclast differentiation in vitro as well as OVX induced bone loss in vivo. This provides the possibility of a novel prospective drug for osteoporosis remedies.
C1 [Miao, Jiansen; Wang, Te; Jin, Haiming] Wenzhou Med Univ, Affiliated Hosp & Yuying Childrens Hosp 2, Dept Orthopaed, Wenzhou, Peoples R China.
   [Yao, Hanbing; Liu, Jian; Huang, Zhixian; Shi, Chengge; Lu, Xinyu] Wenzhou Med Univ, Sch Med 1, Wenzhou, Peoples R China.
   [Jiang, Junchen; Ren, Rufeng; Wang, Chenyu] Wenzhou Med Univ, Sch Med 2, Wenzhou, Peoples R China.
   [Pan, Youjin] Wenzhou Med Univ, Affiliated Hosp & Yuying Childrens Hosp 2, Dept Endocrinol, Wenzhou, Peoples R China.
C3 Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical
   University; Wenzhou Medical University
RP Wang, T; Jin, HM (通讯作者)，Wenzhou Med Univ, Affiliated Hosp & Yuying Childrens Hosp 2, Dept Orthopaed, Wenzhou, Peoples R China.; Pan, YJ (通讯作者)，Wenzhou Med Univ, Affiliated Hosp & Yuying Childrens Hosp 2, Dept Endocrinol, Wenzhou, Peoples R China.
EM panyj6190@163.com; 289726269@qq.com; jinhaiming@wmu.edu.cn
RI Jin, Haiming/LZE 3453 2025; Lu, Xinyu/KIB 5798 2024
OI wang, haoyu/0009 0001 2467 5331
FU National Natural Science Foundation of China [82202757]; Natural Science
   Foundation of Zhejiang Province [LTGD23H070001, LQ21H060010]; Wenzhou
   Municipal Science and Technology Bureau [Y2020004]; Basic research
   projects of Wenzhou Medical University [KYYW202028]
FX This work was supported by the National Natural Science Foundation of
   China (82202757) , Natural Science Foundation of Zhejiang Province
   (LQ21H060010) , Natural Science Foundation of Zhejiang Province
   (LTGD23H070001) , Wenzhou Municipal Science and Technology Bureau
   (Y2020004) , and Basic research projects of Wenzhou Medical University
   (KYYW202028) .
CR Alliston T, 2002, NATURE, V416, P686, DOI 10.1038/416686a
   Bai XC, 2010, CELL MOL LIFE SCI, V67, P239, DOI 10.1007/s00018 009 0163 7
   Bailly C, 2021, STEROIDS, V172, DOI 10.1016/j.steroids.2021.108855
   Battaglioni S, 2022, CELL, V185, P1814, DOI 10.1016/j.cell.2022.04.013
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Fei HR, 2012, J CELL BIOCHEM, V113, P3403, DOI 10.1002/jcb.24216
   Ferenz NP, 2010, SEMIN CELL DEV BIOL, V21, P255, DOI 10.1016/j.semcdb.2010.01.019
   Garcia Saez I, 2021, BIOCHEM PHARMACOL, V184, DOI 10.1016/j.bcp.2020.114364
   Gopinath V, 2023, MED CLIN N AM, V107, P213, DOI 10.1016/j.mcna.2022.10.013
   Grabowski P, 2009, ENDOCR DEV, V16, P32, DOI 10.1159/000223687
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hiraiwa M, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00684
   Hirokawa N, 2015, EXP CELL RES, V334, P16, DOI 10.1016/j.yexcr.2015.02.016
   Hou J, 2022, PHARM BIOL, V60, P764, DOI 10.1080/13880209.2022.2050768
   Hu ZD, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/2676745
   Jang YG, 2020, MOL CELLS, V43, P705, DOI 10.14348/molcells.2020.0089
   Kang HG, 2023, REPROD SCI, V30, P1625, DOI 10.1007/s43032 022 01117 4
   Kim HY, 2023, FOOD SCI BIOTECHNOL, V32, P1101, DOI 10.1007/s10068 023 01251 y
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Lawrence CJ, 2004, J CELL BIOL, V167, P19, DOI 10.1083/jcb.200408113
   Lippuner K, 2012, SWISS MED WKLY, V142, DOI 10.4414/smw.2012.13624
   Newman DJ, 2007, J NAT PROD, V70, P461, DOI 10.1021/np068054v
   Qi XY, 2023, EUR J MED CHEM, V246, DOI 10.1016/j.ejmech.2022.114948
   Quinn JMW, 2000, J BONE MINER RES, V15, P1459, DOI 10.1359/jbmr.2000.15.8.1459
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Sawyer A, 2003, BIOTECH HISTOCHEM, V78, P271, DOI 10.1080/10520290310001646668
   Song J, 2020, MOL MED REP, V22, P697, DOI 10.3892/mmr.2020.11135
   Suzuki A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21238992
   Takahashi N, 2003, METH MOLEC MED, V80, P129
   Tan ZW, 2016, INT J ONCOL, V49, P1638, DOI 10.3892/ijo.2016.3662
   Uzbekov R, 1999, MICROSC RES TECHNIQ, V45, P31, DOI 10.1002/(SICI)1097 0029(19990401)45:1<31::AID JEMT3>3.0.CO;2 K
   Wang QQ, 2019, J CELL MOL MED, V23, P380, DOI 10.1111/jcmm.13942
   Xu JK, 2000, J BONE MINER RES, V15, P2178, DOI 10.1359/jbmr.2000.15.11.2178
   Zhang Y, 2017, J BONE MINER RES, V32, P1829, DOI 10.1002/jbmr.3172
   Zhen X, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10060925
   Zhou L, 2016, J BONE MINER RES, V31, P964, DOI 10.1002/jbmr.2771
   Zhu LZ, 2016, CELL BIOL TOXICOL, V32, P333, DOI 10.1007/s10565 016 9338 9
NR 37
TC 2
Z9 2
U1 0
U2 3
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006 2952
EI 1873 2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD NOV
PY 2023
VL 217
AR 115817
DI 10.1016/j.bcp.2023.115817
EA OCT 2023
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA W0VH8
UT WOS:001088888700001
PM 37757917
DA 2025 08 17
ER

PT J
AU Wang, J
   Guan, HF
   Liu, H
   Lei, ZW
   Kang, HL
   Guo, Q
   Dong, YM
   Liu, HY
   Sun, YL
   Fang, Z
   Li, F
AF Wang, Jia
   Guan, Hanfeng
   Liu, Hui
   Lei, Zuowei
   Kang, Honglei
   Guo, Qian
   Dong, Yimin
   Liu, Huiyong
   Sun, Yunlong
   Fang, Zhong
   Li, Feng
TI Inhibition of PFKFB3 suppresses osteoclastogenesis and prevents
   ovariectomy induced bone loss
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE glycolysis; MAPKs; NF kappa B; osteoclast; PFKFB3
ID 6 PHOSPHOFRUCTO 2 KINASE PFKFB3; GLUCOSE METABOLISM; ACTIVATION; GROWTH;
   DIFFERENTIATION; INFLAMMATION; GLYCOLYSIS
AB Osteoclasts are multinucleated cells derived from the monocyte/macrophage cell lineage under the regulation of receptor activator of nuclear factor kappa B ligand (RANKL). In previous studies, stimulation by RANKL during osteoclastogenesis was shown to induce a metabolic switch to enhanced glycolytic metabolism. Thus, we hypothesized that blockage of glycolysis might serve as a novel strategy to treat osteoclast related diseases. In the present study, 6 phosphofructo 2 kinase/fructose 2,6 bisphosphatase 3 (PFKFB3), an essential regulator of glycolysis, was up regulated during osteoclast differentiation. Genetic and pharmacological inhibition of PFKFB3 in bone marrow derived macrophages suppressed the differentiation and function of osteoclasts. Moreover, intraperitoneal administration of the PFKFB3 inhibitor PFK15 prevented ovariectomy induced bone loss. In addition, glycolytic activity characterized by lactate accumulation and glucose consumption in growth medium was reduced by PFKFB3 inhibition. Further investigation indicated that the administration of L lactate partially reversed the repression of osteoclastogenesis caused by PFKFB3 inhibition and abrogated the inhibitory effect of PFK15 on the activation of NF kappa B and MAPK pathways. In conclusion, the results of this study suggest that blockage of glycolysis by targeting PFKFB3 represents a potential therapeutic strategy for osteoclast related disorders.
C1 [Wang, Jia; Guan, Hanfeng; Liu, Hui; Lei, Zuowei; Kang, Honglei; Guo, Qian; Dong, Yimin; Liu, Huiyong; Sun, Yunlong; Fang, Zhong; Li, Feng] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Orthoped, Tongji Med Coll, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China.
C3 Huazhong University of Science & Technology
RP Fang, Z; Li, F (通讯作者)，Huazhong Univ Sci & Technol, Tongji Hosp, Dept Orthoped, Tongji Med Coll, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China.
EM zhongfangtjh@yahoo.com; lifengmd@hust.edu.cn
RI ; Guo, Qian/NPI 7671 2025
OI Li, Feng/0000 0002 7961 3728; 
FU National Natural Science Foundation of China [81874024]; National Key
   Research and Development Program of China [2016YFB1101305]
FX National Natural Science Foundation of China, Grant/Award Number:
   81874024; National Key Research and Development Program of China,
   Grant/Award Number: 2016YFB1101305
CR Ahn H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153886
   Alfarouk KO, 2016, J ENZYM INHIB MED CH, V31, P859, DOI 10.3109/14756366.2016.1140753
   Alfarouk Khalid O, 2014, Oncoscience, V1, P777
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Awasthi H, 2018, MED RES REV, V38, P2024, DOI 10.1002/med.21504
   Biniecka M, 2016, ANN RHEUM DIS, V75, P2192, DOI 10.1136/annrheumdis 2015 208476
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brown D, 1996, J EXP BIOL, V199, P2345
   Chen LL, 2016, SCI REP UK, V6, DOI 10.1038/srep24324
   Clem BF, 2013, MOL CANCER THER, V12, P1461, DOI 10.1158/1535 7163.MCT 13 0097
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Czupalla C, 2005, PROTEOMICS, V5, P3868, DOI 10.1002/pmic.200402059
   Finucane OM, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 40619 1
   Gustafsson NMS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 06287 x
   Indo Y, 2013, J BONE MINER RES, V28, P2392, DOI 10.1002/jbmr.1976
   Jiang H, 2016, J IMMUNOL, V197, P2880, DOI 10.4049/jimmunol.1600474
   Kim JM, 2007, CELL PHYSIOL BIOCHEM, V20, P935, DOI 10.1159/000110454
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kwak HB, 2010, BONE, V46, P724, DOI 10.1016/j.bone.2009.10.042
   Lemma S, 2017, BBA MOL BASIS DIS, V1863, P3254, DOI 10.1016/j.bbadis.2017.08.030
   Li HM, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046 016 0481 1
   Mahlknecht U, 2003, INT J ONCOL, V23, P883
   Menon MB, 2017, NAT CELL BIOL, V19, P1248, DOI 10.1038/ncb3614
   Monaco C, 2004, P NATL ACAD SCI USA, V101, P5634, DOI 10.1073/pnas.0401060101
   O'Neal J, 2016, BREAST CANCER RES TR, V160, P29, DOI 10.1007/s10549 016 3968 8
   Pisani P, 2016, WORLD J ORTHOP, V7, P171, DOI 10.5312/wjo.v7.i3.171
   Shi LL, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.44
   Tang Y, 2019, J CELL PHYSIOL, V234, P11165, DOI 10.1002/jcp.27765
   Tawakol A, 2015, ARTERIOSCL THROM VAS, V35, P1463, DOI 10.1161/ATVBAHA.115.305551
   VANSCHAFTINGEN E, 1987, ADV ENZYMOL RAMB, V59, P315
   VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191
   Végran F, 2011, CANCER RES, V71, P2550, DOI 10.1158/0008 5472.CAN 10 2828
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   WEBER G, 1977, NEW ENGL J MED, V296, P541, DOI 10.1056/NEJM197703102961005
   Wolfe H, 2018, J NEUROIMMUNOL, V317, P24, DOI 10.1016/j.jneuroim.2018.02.007
   Xu YM, 2014, ARTERIOSCL THROM VAS, V34, P1231, DOI 10.1161/ATVBAHA.113.303041
   Zou YY, 2017, BRIT J PHARMACOL, V174, P893, DOI 10.1111/bph.13762
NR 37
TC 11
Z9 13
U1 0
U2 40
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1582 1838
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD FEB
PY 2020
VL 24
IS 3
BP 2294
EP 2307
DI 10.1111/jcmm.14912
EA DEC 2019
PG 14
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA KJ9OQ
UT WOS:000504506700001
PM 31880389
OA Green Published
DA 2025 08 17
ER

PT J
AU Park, YH
   Kim, HJ
   Lee, K
   Choi, Y
   Heo, TH
AF Park, Yeon Hwa
   Kim, Hee Jung
   Lee, Kyeong
   Choi, Yongseok
   Heo, Tae Hwe
TI Combination of gp130 targeting and TNF targeting small molecules
   in alleviating arthritis through the down regulation of
   Th17 differentiation and osteoclastogenesis
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE LMT 28; Tetrahydropapaverine; Collagen induced arthritis;
   Fibroblast like synoviocytes; Th17; Osteoclastogenesis
ID TUMOR NECROSIS FACTOR; ALPHA; TETRAHYDROPAPAVERINE; CYTOKINES; BLOCKADE;
   RANKL; CELLS
AB Rheumatoid arthritis (RA) is a systemic, chronic inflammatory disease that is characterized by T helper 17 (Th17) cell  and osteoclast induced joint destruction and inflammation. In RA, several cytokines (interleukin (IL) 1, 6,17, and tumor necrosis factor (TNF)) are involved in almost all aspects of articular inflammation and destruction. This study aimed to evaluate the combinatorial effect of TNF and IL 6 inhibitors on the differentiation and activation of Th17 cells and osteoclasts in the context of RA, and to identify the RA related mechanisms through IL 6 signaling. Tetrahydropapaverine (THP) showed direct binding to TNF in screening ELISA, and SPR and TNF neutralization assays. In a previous study, the therapeutic effect of gp130 targeting LMT 28 was confirmed in RA. Combinatorial treatment with LMT 28 and THP reduced the arthritis index and showed protective effects against bone and cartilage destruction in CIA mice. The secretion levels of TNF, IL 6, and IL 1 beta significantly decreased upon combinatorial treatment with LMT 28 and THP. Further, the LMT 28 and THP combination suppressed the differentiation and activation of Th17 cells in mouse splenocytes and human PBMCs. In human RA FLS, the LMT 28 and THP combination inhibited cell proliferation and downregulated IL 6 and/or TNF mediated signaling relative to that observed upon independent treatment with LMT 28 or THP. Furthermore, the combination of LMT 28 and THP significantly inhibited the differentiation of mouse bone marrow monocytes (BMMs) into osteoclasts. In conclusion, the LMT 28 and THP combination can attenuate RA through the inhibition of Th17 differentiation and osteoclastogenesis, and suppression of IL 6 or TNF induced signaling pathways. This combinatorial therapy could be used as a new strategy for the treatment of RA. (C) 2019 Elsevier Inc. All rights reserved.
C1 [Park, Yeon Hwa; Kim, Hee Jung; Heo, Tae Hwe] Catholic Univ Korea, Lab Pharmacoimmunol, Bucheon 420743, South Korea.
   [Lee, Kyeong] Dongguk Univ Seoul, Coll Pharm, Goyang 10326, South Korea.
   [Choi, Yongseok] Korea Univ, Sch Life Sci & Biotechnol, Seoul 136713, South Korea.
C3 Catholic University of Korea; Dongguk University; Korea University
RP Heo, TH (通讯作者)，Catholic Univ Korea, Lab Pharmacoimmunol, Coll Pharm, 43 Jibong Ro, Bucheon Si 14662, Gyeonggi Do, South Korea.
EM thhur92@catholic.ac.kr
RI Kim, Hee Jung/O 4581 2019; CHOI, YONGSEOK/HTQ 1556 2023
OI Kim, Hee Jung/0000 0002 6122 6906; 
FU Korea Health Technology R&D Project through the Korea Health Industry
   Development Institute   Ministry of Health andWelfare, Republic of Korea
   [HI16C1761]; Basic Science Research Program through the National
   Research Foundation of Korea (NRF)   Ministry of Education
   [2018R1A6A1A03025108, 2018R1A5A2023127]; Catholic University of Korea;
   BK21 Plus project of the NRF   Ministry of Education of Korea
   [22A20130012250]
FX This research was supported by the Korea Health Technology R&D Project
   through the Korea Health Industry Development Institute funded by the
   Ministry of Health andWelfare, Republic of Korea (HI16C1761), the Basic
   Science Research Program through the National Research Foundation of
   Korea (NRF) funded by the Ministry of Education (grant no.
   2018R1A6A1A03025108 and 2018R1A5A2023127) and by the Research Fund 2019
   of the Catholic University of Korea, and BK21 Plus project of the NRF
   funded by Ministry of Education of Korea(22A20130012250). We thank Dr.
   Stefan Rose John for providing Hyper IL 6.
CR Bartok B, 2010, IMMUNOL REV, V233, P233, DOI 10.1111/j.0105 2896.2009.00859.x
   Fischer M, 1997, NAT BIOTECHNOL, V15, P142, DOI 10.1038/nbt0297 142
   Goto K, 1997, BRAIN RES, V754, P260, DOI 10.1016/S0006 8993(97)00093 0
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Hashizume M, 2008, RHEUMATOLOGY, V47, P1635, DOI 10.1093/rheumatology/ken363
   Hong SS, 2015, J IMMUNOL, V195, P237, DOI 10.4049/jimmunol.1402908
   Jia TT, 2013, VACCINE, V31, P4063, DOI 10.1016/j.vaccine.2013.06.101
   Kim EI, 2004, LIFE SCI, V75, P1949, DOI 10.1016/j.lfs.2004.04.017
   Kim GW, 2015, ARCH PHARM RES, V38, P575, DOI 10.1007/s12272 015 0569 8
   Kim KW, 2015, AM J PATHOL, V185, P3011, DOI 10.1016/j.ajpath.2015.07.017
   Kingsley G, 2011, BEST PRACT RES CL RH, V25, P585, DOI 10.1016/j.berh.2011.10.003
   Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710
   Lee CJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0433 0
   Li P, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00460
   Luchetti MM, 2016, CURR DRUG SAF, V11, P22, DOI 10.2174/1574886310666151014115401
   MAINI RN, 1995, CLIN EXP IMMUNOL, V101, P207
   McInnes IB, 2007, NAT REV IMMUNOL, V7, P429, DOI 10.1038/nri2094
   Miao Ping, 2018, Oncotarget, V9, P20366, DOI 10.18632/oncotarget.23917
   Nalbant Ayten, 2016, Front Biosci (Elite Ed), V8, P427
   Neumann E, 2010, TRENDS MOL MED, V16, P458, DOI 10.1016/j.molmed.2010.07.004
   Notley CA, 2008, J EXP MED, V205, P2491, DOI 10.1084/jem.20072707
   Scott DL, 2010, LANCET, V376, P1094, DOI 10.1016/S0140 6736(10)60826 4
   Yao ZQ, 2017, J BIOL CHEM, V292, P10169, DOI 10.1074/jbc.M116.771816
NR 23
TC 6
Z9 6
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD FEB 19
PY 2020
VL 522
IS 4
BP 1030
EP 1036
DI 10.1016/j.bbrc.2019.11.183
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA LB5XZ
UT WOS:000524710200033
PM 31818460
DA 2025 08 17
ER

PT J
AU Urbaniak, MM
   Rudnicka, K
   Plocinski, P
   Chmiela, M
AF Urbaniak, Mateusz M.
   Rudnicka, Karolina
   Plocinski, Przemyslaw
   Chmiela, Magdalena
TI Exploring the Osteoinductive Potential of Bacterial Pyomelanin Derived
   from Pseudomonas aeruginosa in a Human Osteoblast Model
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE pyomelanin; osteoinduction; osteoblast; bone regeneration
ID OSTEOCLAST DIFFERENTIATION; BONE FORMATION; INTERLEUKIN 10; MELANIN;
   EXPRESSION; MECHANISM; APOPTOSIS; TURNOVER; BIOLOGY; GROWTH
AB Alkaptonuria (AKU) is a genetically determined disease associated with disorders of tyrosine metabolism. In AKU, the deposition of homogentisic acid polymers contributes to the pathological ossification of cartilage tissue. The controlled use of biomimetics similar to deposits observed in cartilage during AKU potentially may serve the development of new bone regeneration therapy based on the activation of osteoblasts. The proposed biomimetic is pyomelanin (PyoM), a polymeric biomacromolecule synthesized by Pseudomonas aeruginosa. This work presents comprehensive data on the osteoinductive, pro regenerative, and antibacterial properties, as well as the cytocompatibility, of water soluble (PyoMsol) or water insoluble (PyoMinsol) PyoM. Both variants of PyoM support osteoinductive processes as well as the maturation of osteoblasts in cell cultures in vitro due to the upregulation of bone formation markers, osteocalcin (OC), and alkaline phosphatase (ALP). Furthermore, the cytokines involved in these processes were elevated in cell cultures of osteoblasts exposed to PyoM: tumor necrosis factor (TNF) alpha, interleukin (IL) 6, and IL 10. The PyoM variants are cytocompatible in a wide concentration range and limit the doxorubicin induced apoptosis of osteoblasts. This cytoprotective PyoM activity is correlated with an increased migration of osteoblasts. Moreover, PyoMsol and PyoMinsol exhibit antibacterial activity against staphylococci isolated from infected bones. The osteoinductive, pro regenerative, and antiapoptotic effects achieved through PyoM stimulation prompt the development of new biocomposites modified with this bacterial biopolymer for medical use.
C1 [Urbaniak, Mateusz M.; Rudnicka, Karolina; Plocinski, Przemyslaw; Chmiela, Magdalena] Univ Lodz, Fac Biol & Environm Protect, Dept Immunol & Infect Biol, 12 16 Banacha St, PL 90237 Lodz, Poland.
   [Urbaniak, Mateusz M.] Univ Lodz, Fac Chem, Dept Inorgan & Analyt Chem, 12 Tamka St, PL 91403 Lodz, Poland.
C3 University of Lodz; University of Lodz
RP Chmiela, M (通讯作者)，Univ Lodz, Fac Biol & Environm Protect, Dept Immunol & Infect Biol, 12 16 Banacha St, PL 90237 Lodz, Poland.
EM mateusz.urbaniak@edu.uni.lodz.pl; karolina.rudnicka@biol.uni.lodz.pl;
   przemyslaw.plocinski@biol.uni.lodz.pl;
   magdalena.chmiela@biol.uni.lodz.pl
RI Plocinski, Przemyslaw/S 5587 2017; Rudnicka, Karolina/HZJ 3797 2023;
   Urbaniak, Mateusz M./JLK 9099 2023; Płociński, Przemysław/S 5587 2017
OI Plocinski, Przemyslaw/0000 0002 6623 3494; Rudnicka,
   Karolina/0000 0002 3412 9000; Urbaniak, Mateusz M./0000 0002 2800 2054; 
FU European Regional Development Fund [POIR.04.04.00 00 16D7/18 00];
   Foundation for Polish Science through the European Union under the
   European Regional Development Fund [13/2024]; University of Lodz
FX Foundation for Polish Science through the European Union under the
   European Regional Development Fund, within the "TEAM NET" program,
   entitled "Multifunctional biologically active composite for application
   in bone regenerative medicine" [grant number
   POIR.04.04.00 00 16D7/18 00]. University of Lodz ("IDUB
   Interdisciplinary Research Grants" program, entitled "DarkBacLight.
   Microbial solar energy conversion system based on pyomelanin
   photovoltaic cells" [grant number 13/2024]).
CR Amarasekara DS, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22062851
   Ansari M, 2019, PROG BIOMATER, V8, P223, DOI 10.1007/s40204 019 00125 z
   Asmae Z., 2014, J. Biotechnol. Lett, V5, P87
   Behzadi P, 2021, ANTIBIOTICS BASEL, V10, DOI 10.3390/antibiotics10010042
   Berendsen AD, 2015, BONE, V80, P14, DOI 10.1016/j.bone.2015.04.035
   Blair HC, 2017, TISSUE ENG PART B RE, V23, P268, DOI [10.1089/ten.teb.2016.0454, 10.1089/ten.TEB.2016.0454]
   Blanchard F, 2009, CYTOKINE GROWTH F R, V20, P19, DOI 10.1016/j.cytogfr.2008.11.004
   Blumer MJF, 2021, ANN ANAT, V235, DOI 10.1016/j.aanat.2021.151704
   Chen EM, 2018, FASEB J, V32, P4917, DOI 10.1096/fj.201701256RRR
   Chow WY, 2020, ANGEW CHEM INT EDIT, V59, P11937, DOI 10.1002/anie.202000618
   Claudino M, 2010, EUR J ORAL SCI, V118, P19, DOI 10.1111/j.1600 0722.2009.00706.x
   Crockett JC, 2011, J CELL SCI, V124, P991, DOI 10.1242/jcs.063032
   Croes M, 2019, J ORTHOP RES, V37, P2067, DOI 10.1002/jor.24422
   Davison AS, 2020, ANN CLIN BIOCHEM, V57, P106, DOI 10.1177/0004563219879957
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Dresner Pollak R, 2004, GASTROENTEROLOGY, V127, P792, DOI 10.1053/j.gastro.2004.06.013
   El Naggar NEA, 2022, POLYMERS BASEL, V14, DOI 10.3390/polym14071339
   ElObeid AS, 2017, BASIC CLIN PHARMACOL, V120, P515, DOI 10.1111/bcpt.12748
   European Committee on Antimicrobial Susceptibility Testing, 2023, Breakpoint tables for interpretation of mics and zone diameters
   Farshidfar N, 2023, MAR DRUGS, V21, DOI 10.3390/md21030189
   Ferraz AR, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph182010562
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Gao SQ, 2023, STEM CELL RES, V66, DOI 10.1016/j.scr.2022.103010
   Ge SX, 2020, BIOINFORMATICS, V36, P2628, DOI 10.1093/bioinformatics/btz931
   Itoh S, 2006, BONE, V39, P505, DOI 10.1016/j.bone.2006.02.074
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793
   Katagiri T, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021899
   Kawka M, 2023, FRONT IMMUNOL, V14, DOI 10.3389/fimmu.2023.1238132
   Kitaura H, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031481
   Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275
   Kurian NK, 2018, DATA BRIEF, V18, P1889, DOI 10.1016/j.dib.2018.04.123
   Kurzyk A, 2023, SCI REP UK, V13, DOI 10.1038/s41598 023 42271 2
   Langdahl B, 2016, THER ADV MUSCULOSKEL, V8, P225, DOI 10.1177/1759720X16670154
   Le Vinh B, 2022, ADV THER GERMANY, V5, DOI 10.1002/adtp.202100219
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Li J, 2022, BONE JOINT RES, V11, P49, DOI 10.1302/2046 3758.112.BJR 2021 0299.R1
   Lin X, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00757
   Liu DH, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10061250
   Liu DW, 2006, EUR J ORAL SCI, V114, P42, DOI 10.1111/j.1600 0722.2006.00283.x
   Lorquin F, 2022, J IND MICROBIOL BIOT, V49, DOI 10.1093/jimb/kuac013
   Lorquin F, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 87328 2
   Marcello E, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.647007
   Mnich E, 2016, WORLD J GASTROENTERO, V22, P7536, DOI 10.3748/wjg.v22.i33.7536
   Nadzir MM, 2021, POLYMERS BASEL, V13, DOI 10.3390/polym13040530
   Moser SC, 2019, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00794
   Murphy CN, 2009, GLOB INST, P1
   Noh JY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207623
   Ono T, 2020, INFLAMM REGEN, V40, DOI 10.1186/s41232 019 0111 3
   Osta B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00048
   Piszko P, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22168587
   Powell D. R., 2015, Degust: Interactive RNASeq Analysis
   Prasadh S, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 12490 0
   Rashki Kemmak Asma, 2020, Med J Islam Repub Iran, V34, P154, DOI 10.34171/mjiri.34.154
   Ren RY, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.13122
   Roberts NB, 2015, JIMD REP, V24, P51, DOI 10.1007/8904_2015_453
   Roy S, 2022, CRIT REV FOOD SCI, V62, P4629, DOI 10.1080/10408398.2021.1878097
   Sandberg ME, 2009, J MICROBIOL METH, V78, P104, DOI 10.1016/j.mimet.2009.04.014
   Schiavone ML, 2020, J CELL PHYSIOL, V235, P6808, DOI 10.1002/jcp.29575
   Shuaishuai W, 2023, FRONT BIOENG BIOTECH, V11, DOI 10.3389/fbioe.2023.1081446
   Slota D, 2023, NANOMATERIALS BASEL, V13, DOI 10.3390/nano13091469
   Szulc P, 2018, BEST PRACT RES CL EN, V32, P725, DOI 10.1016/j.beem.2018.05.003
   Szwed Georgiou A, 2023, ACS BIOMATER SCI ENG, V9, P5222, DOI 10.1021/acsbiomaterials.3c00609
   Taylor AM, 2017, RHEUMATOLOGY, V56, P156, DOI 10.1093/rheumatology/kew355
   Urbaniak MM, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms241813911
   Urbaniak MM, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24097846
   Vimalraj S, 2020, GENE, V754, DOI 10.1016/j.gene.2020.144855
   Weycker Derek, 2016, Bone Rep, V5, P186, DOI 10.1016/j.bonr.2016.07.005
   Wu AM, 2021, LANCET HEALTH LONGEV, V2, pE580, DOI 10.1016/S2666 7568(21)00172 0
   Xu C, 2017, FOOD CONTROL, V73, P1445, DOI 10.1016/j.foodcont.2016.10.048
   Xu J, 2023, FRONT IMMUNOL, V14, DOI 10.3389/fimmu.2023.1222129
   XU LX, 1995, J CELL PHYSIOL, V165, P624, DOI 10.1002/jcp.1041650321
   Yoshitake F, 2008, J BIOL CHEM, V283, P11535, DOI 10.1074/jbc.M607999200
   Zayzafoon M, 2006, J CELL BIOCHEM, V97, P56, DOI 10.1002/jcb.20675
   Zoch ML, 2016, BONE, V82, P42, DOI 10.1016/j.bone.2015.05.046
NR 75
TC 0
Z9 0
U1 1
U2 4
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD DEC
PY 2024
VL 25
IS 24
AR 13406
DI 10.3390/ijms252413406
PG 20
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA Q4V1T
UT WOS:001384667900001
PM 39769171
OA gold
DA 2025 08 17
ER

PT J
AU Chen, YY
   Fang, CX
   Yang, ZY
   Qiu, GS
   Tang, SY
AF Chen, Yiyu
   Fang, Chuxuan
   Yang, Zhiyong
   Qiu, Guosheng
   Tang, Shuangyi
TI Hypercalcemia in children induced by denosumab: a case report and an
   analysis of the FDA adverse event reporting system database
SO EXPERT OPINION ON DRUG SAFETY
LA English
DT Article
DE Children; denosumab; FAERS; hypercalcemia; adverse events
ID GIANT CELL TUMOR; OSTEOGENESIS IMPERFECTA; RANK LIGAND; BONE;
   DISCONTINUATION; EFFICACY; THERAPY; SAFETY
AB BackgroundThe potential risks of denosumab on pediatric patients have raised concerns about its safety. This article aims to analyze the adverse effects of denosumab in minors, with a specific focus on hypercalcemia.Research design and methodsA case study involving a child was analyzed. The OpenVigil 2.1 was utilized to extract adverse event data from the FAERS database, focusing on denosumab as the primary suspect drug in pediatric patients. The study also reviewed published cases of children developing hypercalcemia after discontinuing denosumab.ResultsThe incidence of denosumab induced hypercalcemia in individuals under 18 years old is significantly higher than the overall incidence. The signal value for hypercalcemia was higher in the male group and was highest in the adolescent group. Hypercalcemia usually appeared approximately 4 months after denosumab discontinuation. Males had a higher peak blood calcium level. Patients aged 0 11 years had a higher average peak serum calcium compared to aged 12 17 years.ConclusionsThis study highlights the risk of hypercalcemia after discontinuation of denosumab in minors, with young age and male gender identified as potential high risk factors. These findings offer valuable safety warnings and preventative measures for the secure administration of this drug in pediatric populations.
C1 [Chen, Yiyu; Fang, Chuxuan; Tang, Shuangyi] Guangxi Med Univ, Dept Pharm, Affiliated Hosp 1, 6 Shuangyong Rd, Nanning 530021, Guangxi, Peoples R China.
   [Yang, Zhiyong; Qiu, Guosheng] Guangxi Med Univ, Dept PICU, Affiliated Hosp 1, Nanning, Peoples R China.
C3 Guangxi Medical University; Guangxi Medical University
RP Tang, SY (通讯作者)，Guangxi Med Univ, Dept Pharm, Affiliated Hosp 1, 6 Shuangyong Rd, Nanning 530021, Guangxi, Peoples R China.
EM tshy369@sina.com
FU Guangxi University teachers research basic ability improvement project
   [2023KY0119]; Medical empowerment project [CRCF YXFN 202301004]
FX This paper was funded by Guangxi University teachers research basic
   ability improvement project [2023KY0119] and Medical empowerment project
   [CRCF YXFN 202301004].
CR Anastasilakis AD, 2021, OSTEOPOROSIS INT, V32, P2377, DOI 10.1007/s00198 021 06002 5
   [Anonymous], 2017, Horm Res Paediatr, V88 Suppl 1, P1, DOI 10.1159/000481424
   Boyce AM, 2017, CURR OSTEOPOROS REP, V15, P283, DOI 10.1007/s11914 017 0380 1
   Boyce AM, 2012, J BONE MINER RES, V27, P1462, DOI 10.1002/jbmr.1603
   Choe M, 2021, PEDIATR BLOOD CANCER, V68, DOI 10.1002/pbc.28778
   Del Sindaco G, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.698963
   Dempster DW, 2012, CLIN THER, V34, P521, DOI 10.1016/j.clinthera.2012.02.002
   Deodati A, 2022, J ENDOCRINOL INVEST, V45, P159, DOI 10.1007/s40618 021 01630 4
   Dürr HR, 2019, BMC MUSCULOSKEL DIS, V20, DOI 10.1186/s12891 019 2855 y
   Ferriero K, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.00515
   Foertsch A, 2016, PEDIATR BLOOD CANCER, V63, pS88
   Gibiansky Leonid, 2012, Clin Pharmacokinet, V51, P247, DOI 10.2165/11598090 000000000 00000
   Gossai N, 2015, PEDIATR BLOOD CANCER, V62, P1078, DOI 10.1002/pbc.25393
   Grasemann C, 2013, J CLIN ENDOCR METAB, V98, P3121, DOI 10.1210/jc.2013 1143
   Harcus M, 2020, CASE REP PEDIAT, V2020, DOI 10.1155/2020/8854441
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Horiuchi K, 2021, BONE REP, V15, DOI 10.1016/j.bonr.2021.101148
   Hoyer Kuhn H, 2016, J MUSCULOSKEL NEURON, V16, P24
   Irmola T, 2018, EUR SPINE J, V27, pS555, DOI 10.1007/s00586 018 5651 8
   Jazbinsek S, 2023, HORM RES PAEDIAT, V96, P590, DOI 10.1159/000523868
   Kawamura H, 2020, J PEDIATR ENDOCR MET, V33, P963, DOI 10.1515/jpem 2019 0581
   Kurucu N, 2018, PEDIATR BLOOD CANCER, V65, DOI 10.1002/pbc.26926
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lietman SA, 2010, CURR OPIN PEDIATR, V22, P508, DOI 10.1097/MOP.0b013e32833b7c23
   Mariz BALA, 2021, SPEC CARE DENT, V41, P519, DOI 10.1111/scd.12588
   Litao MKS., 2021, J ENDOCR SOC, V5, pA218, DOI [10.1210/jendso/bvab048.442, DOI 10.1210/JENDSO/BVAB048.442]
   Marpuri I., 2021, J ENDOCR SOC, V5, pA706, DOI [10.1210/jendso/bvab048.1439, DOI 10.1210/JENDSO/BVAB048.1439]
   Naidu A, 2014, J ORAL MAXIL SURG, V72, P2469, DOI 10.1016/j.joms.2014.06.456
   Nandiraju D, 2019, FERTIL STERIL, V112, P775, DOI 10.1016/j.fertnstert.2019.10.005
   Pan KS, 2021, CURR OSTEOPOROS REP, V19, P141, DOI 10.1007/s11914 021 00657 z
   Papapoulos SE, 2007, NEW ENGL J MED, V356, P1075, DOI 10.1056/NEJMc062792
   Raborn LN, 2021, OSTEOPOROSIS INT, V32, P1889, DOI 10.1007/s00198 021 05895 6
   Raux S, 2019, ORTHOP TRAUMATOL SUR, V105, P1181, DOI 10.1016/j.otsr.2019.04.028
   Rhou YJJ, 2022, CALCIFIED TISSUE INT, V110, P464, DOI 10.1007/s00223 021 00935 z
   Roukain A, 2022, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.794988
   Rutten C, 2024, PEDIATR RADIOL, V54, P1224, DOI 10.1007/s00247 024 05895 8
   Setsu N, 2016, J BONE MINER METAB, V34, P118, DOI 10.1007/s00774 015 0677 z
   Sutjandra L, 2011, CLIN PHARMACOKINET, V50, P793, DOI 10.2165/11594240 000000000 00000
   Sydlik C, 2020, WORLD J PEDIATR, V16, P520, DOI 10.1007/s12519 020 00378 w
   Szymczuk V, 2023, LANCET, V402, pE4, DOI 10.1016/S0140 6736(23)00915 7
   Taylor Miller T, 2021, BONE REP, V14, DOI 10.1016/j.bonr.2020.100738
   Trejo P, 2018, J MUSCULOSKEL NEURON, V18, P76
   Uday S, 2018, J CLIN ENDOCR METAB, V103, P596, DOI 10.1210/jc.2017 02025
   Upfill Brown A, 2019, JBMR PLUS, V3, DOI 10.1002/jbm4.10210
   Vanderniet JA, 2024, J CLIN ENDOCR METAB, V109, P1371, DOI 10.1210/clinem/dgad657
   Vanderniet JA, 2022, BONE, V159, DOI 10.1016/j.bone.2022.116395
   Xia XH, 2023, ENDOCRINE, V81, P175, DOI 10.1007/s12020 023 03347 1
NR 47
TC 1
Z9 1
U1 0
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1474 0338
EI 1744 764X
J9 EXPERT OPIN DRUG SAF
JI Expert Opin. Drug Saf.
PD JUN 3
PY 2025
VL 24
IS 6
BP 719
EP 730
DI 10.1080/14740338.2024.2379446
EA JUL 2024
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 2XH8X
UT WOS:001268427400001
PM 39007894
DA 2025 08 17
ER

PT J
AU Peng, W
   Zhang, WJ
   Wu, QC
   Cai, SY
   Jia, TT
   Sun, JR
   Lin, ZC
   Alitongbieke, G
   Chen, YX
   Su, Y
   Lin, JM
   Cai, LS
   Sun, YQ
   Pan, YT
   Xue, Y
AF Peng, Wei
   Zhang, Wenjuan
   Wu, Qici
   Cai, Shunyou
   Jia, Tingting
   Sun, Jiarui
   Lin, Zhichao
   Alitongbieke, Gulimiran
   Chen, Yixuan
   Su, Yi
   Lin, Jinmei
   Cai, Lisheng
   Sun, Yuqin
   Pan, Yutian
   Xue, Yu
TI Agaricus bisporus Derived Glucosamine Hydrochloride Facilitates
   Skeletal Injury Repair through Bmp Signaling in Zebrafish Osteoporosis
   Model
SO JOURNAL OF NATURAL PRODUCTS
LA English
DT Article
ID OSTEOBLAST DIFFERENTIATION; COLLAGEN EXPRESSION; BONE RESORPTION;
   CARTILAGE; GROWTH; CHITOSAN; MUTANTS; OSTERIX; FISH
AB Glucosamine hydrochloride (GAH), one of the most basic and important derivatives of chitin, is obtained by hydrolysis of chitin in concentrated hydrochloric acid. At present, little is known about how GAH functions in skeletal development. In this report, we demonstrate that GAH, extracted from the cell wall of Agaricus bisporus, acts in a dose dependent manner to promote not only cartilage and bone development in larvae but also caudal fin regeneration in adult fish. Furthermore, GAH treatment causes a significant increase in expression of bone related marker genes, indicating its important role in promoting skeletal development. We show that in both larval and adult osteoporosis models induced by high iron osteogenic defects are significantly ameliorated after treatment with GAH, which regulates expression of a series of bone related genes. Finally, we demonstrate that GAH promotes skeletal development and injury repair through bone morphogenetic protein (Bmp) signaling, and it works at the downstream of the receptor level. Taken together, our findings not only provide a strong research foundation and strategy for the screening of natural osteoporosis drugs and product development using a zebrafish model but also establish the potential for the development of Agaricus bisporus derived GAH as a new drug for osteoporosis treatment.
C1 [Peng, Wei; Zhang, Wenjuan; Wu, Qici; Jia, Tingting; Sun, Jiarui; Lin, Zhichao; Alitongbieke, Gulimiran; Chen, Yixuan; Su, Yi; Lin, Jinmei; Pan, Yutian; Xue, Yu] Minnan Normal Univ, Engn Technol Ctr Mushroom Ind, Zhangzhou 363000, Fujian, Peoples R China.
   [Peng, Wei; Wu, Qici; Jia, Tingting; Sun, Jiarui; Lin, Zhichao; Alitongbieke, Gulimiran; Chen, Yixuan; Su, Yi; Lin, Jinmei; Pan, Yutian; Xue, Yu] Fujian Fungal Act Subst Engn Technol Ctr, Zhangzhou 363000, Fujian, Peoples R China.
   [Zhang, Wenjuan] Anhui Zhifei Longcom Biopharmaceut Co Ltd, Hefei 230088, Anhui, Peoples R China.
   [Cai, Shunyou] Minnan Normal Univ, Sch Chem, Key Lab Modern Analyt Sci & Separat Technol Fujia, Zhangzhou 363000, Fujian, Peoples R China.
   [Cai, Lisheng; Sun, Yuqin] Zhangzhou Municipal Hosp, Zhangzhou 363000, Fujian, Peoples R China.
C3 MinNan Normal University; MinNan Normal University
RP Pan, YT; Xue, Y (通讯作者)，Minnan Normal Univ, Engn Technol Ctr Mushroom Ind, Zhangzhou 363000, Fujian, Peoples R China.; Pan, YT; Xue, Y (通讯作者)，Fujian Fungal Act Subst Engn Technol Ctr, Zhangzhou 363000, Fujian, Peoples R China.
EM pytmnnu@126.com; xueyu0614@163.com
OI Pan, Yu Tian/0000 0001 9842 9320; Wu, Qi Ci/0000 0001 5921 6138
FU National Natural Science Foundation of China [31501174, 81903665];
   General Project of Natural Science Foundation of Fujian Province
   [2019J01602, 2019J01744, 2020J1822, 2020J01823, 2020J011301]; Key
   Science and Technology Project of Fujian Province [2013Y0081]; Science
   and Technology Project of Fujian Education Department [JB06150]; project
   of the education Department in Fujian Province [JAT190357]; National
   Science and Technology Support Plan of the Ministry of Science and
   Technology during the 12th Five Year Plan Period [2012BAD36B0504]
FX We are grateful to the members of Pan Laboratory from MNNU and Meng
   Laboratory from THU for discussion and technical assistance. This work
   was financially supported by grants from the National Natural Science
   Foundation of China (grant numbers 31501174 and 81903665), from General
   Project of Natural Science Foundation of Fujian Province (grant numbers
   2019J01602, 2019J01744, 2020J1822, 2020J01823, and 2020J011301), from
   Key Science and Technology Project of Fujian Province (grant number
   2013Y0081), from Science and Technology Project of Fujian Education
   Department (grant number JB06150), from project of the education
   Department in Fujian Province (grant number JAT190357), and from
   National Science and Technology Support Plan of the Ministry of Science
   and Technology during the 12th Five Year Plan Period (grant number
   2012BAD36B0504).
CR Ali AA, 2011, ARCH BIOCHEM BIOPHYS, V510, P11, DOI 10.1016/j.abb.2011.03.014
   Birkholz DA, 2009, DEV DYNAM, V238, P2575, DOI 10.1002/dvdy.22090
   Bliddal Henning, 2006, Ugeskr Laeger, V168, P4405
   Chan PS, 2005, OSTEOARTHR CARTILAGE, V13, P387, DOI 10.1016/j.joca.2005.01.003
   Chen S. Q., 2006, HYDROLYSIS CHITIN PR
   Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0
   Du SJ, 2001, DEV BIOL, V238, P239, DOI 10.1006/dbio.2001.0390
   Duan L., 2004, DRUG STANOAROS CHINA, V4, P610
   Foot M, 2005, J PHARMACEUT BIOMED, V38, P397, DOI 10.1016/j.jpba.2005.01.026
   Ghormade V, 2017, INT J BIOL MACROMOL, V104, P1415, DOI 10.1016/j.ijbiomac.2017.01.112
   Green H, 2000, J BONE MINER RES, V15, P1066, DOI 10.1359/jbmr.2000.15.6.1066
   Henderson R. W., 2007, Patent, Patent No. [WO1998048816A1, 1998048816]
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580
   Javidan Y, 2004, METHOD CELL BIOL, V76, P415
   Ji T, 2017, AM J PHYSIOL GASTR L, V312, pG24, DOI 10.1152/ajpgi.00169.2016
   Jia P, 2012, J ORTHOP RES, V30, P1843, DOI 10.1002/jor.22133
   Kato M, 2007, P NATL ACAD SCI USA, V104, P3432, DOI 10.1073/pnas.0611192104
   Li GF, 2012, OSTEOPOROSIS INT, V23, P2403, DOI 10.1007/s00198 012 1982 1
   Link TM, 1999, EUR RADIOL, V9, P1781, DOI 10.1007/s003300050922
   Malluche H. H., 1986, OXYGEN TRANSPORT TIS, V208, P289
   Mei W, 2005, BIOCHEM BIOPH RES CO, V328, P651, DOI 10.1016/j.bbrc.2004.11.067
   MIYAKE T, 1994, J EXP ZOOL, V268, P22, DOI 10.1002/jez.1402680105
   Miyazono K, 2010, J BIOCHEM, V147, P35, DOI 10.1093/jb/mvp148
   Murtaugh LC, 1999, GENE DEV, V13, P225, DOI 10.1101/gad.13.2.225
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   NESZMELYI A, 1982, J AM CHEM SOC, V104, P5342, DOI 10.1021/ja00384a016
   Nieto N, 2000, J BIOL CHEM, V275, P20136, DOI 10.1074/jbc.M001422200
   Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191
   Orwoll E, 2003, J BONE MINER RES, V18, P9, DOI 10.1359/jbmr.2003.18.1.9
   Piotrowski T, 1996, DEVELOPMENT, V123, P345
   Renn J, 2009, DEV DYNAM, V238, P241, DOI 10.1002/dvdy.21836
   Schartl M, 2014, DIS MODEL MECH, V7, P181, DOI 10.1242/dmm.012245
   Sorbera LA, 2003, DRUG FUTURE, V28, P328, DOI 10.1358/dof.2003.028.04.726503
   Sousa S, 2012, BIOL OPEN, V1, P915, DOI 10.1242/bio.2012877
   Walker MB, 2007, BIOTECH HISTOCHEM, V82, P23, DOI 10.1080/10520290701333558
   Walker MB, 2006, DEV BIOL, V295, P194, DOI 10.1016/j.ydbio.2006.03.028
   Wehner D, 2015, TRENDS GENET, V31, P336, DOI 10.1016/j.tig.2015.03.012
   Willey JS, 2013, INT J RADIAT BIOL, V89, P268, DOI 10.3109/09553002.2013.747015
   Wu T, 2004, J AGR FOOD CHEM, V52, P7905, DOI 10.1021/jf0492565
   Xue Y, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4766
   Yeo H, 2007, BONE, V40, P1502, DOI 10.1016/j.bone.2007.02.017
   Zhang WJ, 2018, BIOCHEM BIOPH RES CO, V496, P654, DOI 10.1016/j.bbrc.2017.12.172
NR 43
TC 8
Z9 9
U1 5
U2 61
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0163 3864
EI 1520 6025
J9 J NAT PROD
JI J. Nat. Prod.
PD APR 23
PY 2021
VL 84
IS 4
BP 1294
EP 1305
DI 10.1021/acs.jnatprod.1c00002
EA FEB 2021
PG 12
WC Plant Sciences; Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy
GA RT5CX
UT WOS:000644478400037
PM 33635072
DA 2025 08 17
ER

PT J
AU Nemeth, EF
   Shoback, D
AF Nemeth, Edward F.
   Shoback, Dolores
TI Calcimimetic and calcilytic drugs for treating bone and mineral related
   disorders
SO BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
DE calcium sensing receptor; calcimimetic; calcilytic; hyperparathyroidism;
   osteoporosis; cinacalcet; hypophosphatemia; hypercalcemia
ID DOSE VITAMIN D; SECONDARY HYPERPARATHYROIDISM; SERUM CALCIUM;
   CINACALCET; HEMODIALYSIS; EVALUATE; THERAPY
AB The calcium sensing receptor (CaSR) plays a pivotal role in regulating systemic Ca2+ homeostasis and is a target for drugs designed to treat certain disorders of bone and mineral metabolism. Calcimimetics are agonists or positive allosteric modulators of the CaSR; they inhibit parathyroid hormone (PTH) secretion and stimulate renal Ca2+ excretion. The first calcimimetic drug is cinacalcet, a positive allosteric modulator of the CaSR that is approved for treating secondary hyperparathyroidism (HPT) in patients on renal replacement therapy and for some forms of primary HPT characterized by clinically significant hypercalcemia. Cinacalcet is also being investigated as a therapy for other hypercalcemic conditions and certain hypophosphatemic disorders. Calcilytics are CaSR inhibitors that stimulate the secretion of PTH and decrease renal excretion of Ca2+. Although calcilytics have failed thus far as anabolic therapies for osteoporosis, they are currently being evaluated as novel therapies for new indications involving hypocalcemia and/or hypercalciuria. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Nemeth, Edward F.] MetisMedica, Toronto, ON M4V 2M7, Canada.
   [Shoback, Dolores] Univ Calif San Francisco, Endocrine Res Unit 111N, Dept Vet Affairs, Med Ctr, San Francisco, CA 94121 USA.
C3 University of California System; University of California San Francisco
RP Nemeth, EF (通讯作者)，MetisMedica, 13 Poplar Plains Rd, Toronto, ON M4V 2M7, Canada.
EM enemeth@metismedica.com; Dolores.shoback@ucsf.edu
FU Amgen
FX D.S. is a Principal Investigator on clinical trials on the use of
   cinacalcet in primary hyperparathyroidism and parathyroid cancer. E.F.N.
   is an inventor on certain patents covering calcimimetic and calcilytic
   compounds and has received payments for expert testimony (Amgen) and
   consulting (NPS Pharmaceuticals).
CR Alon US, 2008, CLIN J AM SOC NEPHRO, V3, P658, DOI 10.2215/CJN.04981107
   Alon US, 2010, PEDIATR NEPHROL, V25, P1747, DOI 10.1007/s00467 010 1547 5
   Behets G, 2012, ISN NEX S BON KIDN, P43
   Block GA, 2010, KIDNEY INT, V78, P578, DOI 10.1038/ki.2010.167
   Chertow GM, 2012, NEW ENGL J MED, V367, P2482, DOI 10.1056/NEJMoa1205624
   Chertow GM, 2012, HEMODIAL INT, V16, P188, DOI 10.1111/j.1542 4758.2011.00642.x
   Chonchol M, 2009, AM J KIDNEY DIS, V53, P197, DOI 10.1053/j.ajkd.2008.09.021
   Cohen JB, 2012, TRANSPLANTATION, V94, P1041, DOI 10.1097/TP.0b013e31826c3968
   Dvorak Ewell MM, 2011, J BONE MINER RES, V26, P2935, DOI 10.1002/jbmr.520
   Evans M, 2010, KIDNEY INT, V78, P535, DOI 10.1038/ki.2010.220
   Falchetti A, 2008, NAT CLIN PRACT ENDOC, V4, P351, DOI 10.1038/ncpendmet0816
   Filopanti M, 2012, EUR J ENDOCRINOL, V167, P157, DOI 10.1530/EJE 12 0117
   Fishbane S, 2008, CLIN J AM SOC NEPHRO, V3, P1718, DOI 10.2215/CJN.01040308
   Fitzpatrick LA, 2012, J BONE MINER RES, V27, P255, DOI 10.1002/jbmr.554
   Geller JL, 2007, J BONE MINER RES, V22, P931, DOI 10.1359/JBMR.070304
   Halse J, 2012, AM SOC BON MIN RES A
   Hirai T, 2010, NEPHRON CLIN PRACT, V114, pC187, DOI 10.1159/000262301
   Ichii M, 2010, NEPHRON CLIN PRACT, V115, pC195, DOI 10.1159/000313035
   Ketteler M, 2012, NEPHROL DIAL TRANSPL, V27, P3270, DOI 10.1093/ndt/gfs018
   Komaba H, 2010, CLIN J AM SOC NEPHRO, V5, P2305, DOI 10.2215/CJN.02110310
   Marcocci C, 2009, J CLIN ENDOCR METAB, V94, P2766, DOI 10.1210/jc.2008 2640
   Moe SM, 2005, NEPHROL DIAL TRANSPL, V20, P2186, DOI 10.1093/ndt/gfh966
   Moyes VJ, 2010, INT J ENDOCRINOL, V2010, DOI 10.1155/2010/906163
   Nemeth EF., 2008, IBMS BoneKey, V5, P196, DOI [10.1138/20080318, DOI 10.1138/20080318]
   Nemeth EF, 2010, SPECTRUM MINERAL BON, P443
   Nemeth EF, 2013, DRUG DISCOVERY TODAY
   Padhi D, 2012, PEDIATR NEPHROL, V27, P1953, DOI 10.1007/s00467 012 2186 9
   Peacock M, 2005, J CLIN ENDOCR METAB, V90, P135, DOI 10.1210/jc.2004 0842
   Peacock M, 2009, J CLIN ENDOCR METAB, V94, P4860, DOI 10.1210/jc.2009 1472
   Raggi P, 2011, NEPHROL DIAL TRANSPL, V26, P1327, DOI 10.1093/ndt/gfq725
   Reh CMS, 2011, J CLIN ENDOCR METAB, V96, pE707, DOI 10.1210/jc.2010 1306
   Shoback DM, 2003, J CLIN ENDOCR METAB, V88, P5644, DOI 10.1210/jc.2002 021597
   Silverberg SJ, 2007, J CLIN ENDOCR METAB, V92, P3803, DOI 10.1210/jc.2007 0585
   Stubbs JR, 2011, SEMIN DIALYSIS, V24, P298, DOI 10.1111/j.1525 139X.2011.00935.x
   Wilhelm Bals A, 2012, PEDIATRICS, V129, pE812, DOI 10.1542/peds.2011 0128
NR 35
TC 66
Z9 69
U1 0
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1521 690X
EI 1532 1908
J9 BEST PRACT RES CL EN
JI Best Pract. Res. Clin. Endoc. Metab.
PD JUN
PY 2013
VL 27
IS 3
BP 373
EP 384
DI 10.1016/j.beem.2013.02.008
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 195DY
UT WOS:000322683700009
PM 23856266
DA 2025 08 17
ER

PT J
AU Chmielnicka, M
   Wozniacka, A
   Torzecka, JD
AF Chmielnicka, Marlena
   Wozniacka, Anna
   Torzecka, Jolanta D.
TI The influence of corticosteroid treatment on the OPG/RANK/RANKL pathway
   and osteocalcin in patients with pemphigus
SO POSTEPY DERMATOLOGII I ALERGOLOGII
LA English
DT Article
DE pemphigus; corticosteroids; OPG/RANK/RANKL pathway; osteocalcin
ID GLUCOCORTICOID INDUCED OSTEOPOROSIS; BONE LOSS; MANAGEMENT; THERAPY
AB Introduction: Pemphigus is a rare autoimmune blistering disease, which requires prolonged administration of corticosteroids at high doses. Although this therapy improves the health and lives of patients, it may have various side effects, for example osteoporosis.
   Aim: To assess the concentration of osteoprotegerin (OPG), the soluble receptor activator of nuclear factor kappa beta ligand (sRANKL) and osteocalcin in patients with pemphigus.
   Material and methods: The study comprised a group of 29 patients with pemphigus (17 women and 12 men) aged between 23 years and 75 years treated from 1994 to 2009 in the Department of Dermatology and Venereology, Medical University of Lodz, as well as 24 healthy volunteers matched appropriately in terms of gender and age.
   Results: In patients with pemphigus, the mean osteoprotegerin concentration was up to 16.46% higher than in the control group. The average RANKL concentration in serum of patients with pemphigus was 26.88% higher. However, the patient group demonstrated a significantly lower concentration of osteocalcin by up to 18.03%.
   Conclusions: Under corticosteroid treatment, RANKL, which is released by osteoblasts, links with the RANK specific osteoclast receptor and stimulates osteoclastogenesis. This reaction can be blocked by osteoprotegerin, which is a competitive inhibitor to the same receptor site. A decreased osteoblast activity stimulates bone loss. The reduced level of osteocalcin, which is regarded as a marker for bone formation, and a simultaneously elevated RANK level reveal the promotion of osteoclast proliferation in patients treated with corticosteroids.
C1 [Chmielnicka, Marlena; Wozniacka, Anna; Torzecka, Jolanta D.] Med Univ Lodz, Dept Dermatol & Venereol, PL 90647 Lodz, Poland.
C3 Medical University Lodz
RP Chmielnicka, M (通讯作者)，Med Univ Lodz, Dept Dermatol & Venereol, 1 Pl Hallera,Bldg 6, PL 90647 Lodz, Poland.
EM marlena_chmielnicka@tlen.pl
RI Torzecka, Jolanta/S 9793 2016; Wozniacka, Anna/S 9674 2016
OI Wozniacka, Anna/0000 0003 3698 960X; 
FU Medical University of Lodz, Poland [503/1 152 01/503 01]; European Union
   from the European Social Fund; state budget under the Integrated
   Regional Operational Programme
FX This work was supported by the grant from Medical University of Lodz,
   Poland No 503/1 152 01/503 01. Funded by the European Union from the
   European Social Fund and the state budget under the Integrated Regional
   Operational Programme.
CR [Anonymous], 2009, STANDARDY MEDYCZNE, V6, P875
   Bell R, 1997, J ROY COLL PHYS LOND, V31, P158
   Buckley L, 2001, ARTHRITIS RHEUM, V44, P1496
   Bystryn JC, 1996, ARCH DERMATOL, V132, P203, DOI 10.1001/archderm.132.2.203
   Calvo MS, 1996, ENDOCR REV, V17, P333, DOI 10.1210/er.17.4.333
   Carson PJ, 1996, J AM ACAD DERMATOL, V34, P645, DOI 10.1016/S0190 9622(96)80066 1
   Chmurova N, 2009, BRATISL MED J, V110, P500
   Cisto M, 2004, PRZEGL DERMATOL, V91, P7
   Czerwinski E, 2006, MED DYPL, V4, P1
   Eastell R, 1998, J INTERN MED, V244, P271, DOI 10.1046/j.1365 2796.1998.00408.x
   Harman KE, 2003, BRIT J DERMATOL, V149, P926, DOI 10.1111/j.1365 2133.2003.05665.x
   KANIS JA, 1994, OSTEOPOROSIS INT, V4, P368, DOI 10.1007/BF01622200
   Kanwar Amrinder J., 1994, Journal of Dermatology (Tokyo), V21, P655, DOI 10.1111/j.1346 8138.1994.tb01811.x
   Karlinska M, 2010, POSTEP DERM ALERGOL, V27, P484
   Looker AC, 1997, J BONE MINER RES, V12, P1761, DOI 10.1359/jbmr.1997.12.11.1761
   Mazziotti G, 2006, TRENDS ENDOCRIN MET, V17, P144, DOI 10.1016/j.tem.2006.03.009
   Murrell DE, 2008, J AM ACAD DERMATOL, V58, P1043, DOI 10.1016/j.jaad.2008.01.012
   Olejniczak T., 2000, PRZEW LEK, V9, P39
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763
   Saag KG, 2003, ENDOCRIN METAB CLIN, V32, P135, DOI 10.1016/S0889 8529(02)00064 6
   Sambrook PN, 2000, J BONE MINER RES, V15, P1645, DOI 10.1359/jbmr.2000.15.9.1645
   Skowronska Jozwiak E, 2006, ENDOKRYNOL POL, V3, P260
   STAZI C, 1991, Clinica Terapeutica, V137, P9
   Summey BT, 2006, ARCH DERMATOL, V142, P82, DOI 10.1001/archderm.142.1.82
   Torzecka JD, 2004, PEMPHIGUS IMMUNOLOGI
   van Staa TP, 2000, RHEUMATOLOGY, V39, P1383, DOI 10.1093/rheumatology/39.12.1383
   van Staa TP, 2002, OSTEOPOROSIS INT, V13, P777, DOI 10.1007/s001980200108
   Vega D, 2007, J CLIN ENDOCR METAB, V92, P4514, DOI 10.1210/jc.2007 0646
NR 29
TC 14
Z9 16
U1 0
U2 0
PU TERMEDIA PUBLISHING HOUSE LTD
PI POZNAN
PA KLEEBERGA ST 2, POZNAN, 61 615, POLAND
SN 1642 395X
J9 POSTEP DERM ALERGOL
JI Postep. Dermatol. Alergol.
PY 2014
VL 31
IS 5
BP 281
EP 288
DI 10.5114/pdia.2014.44016
PG 8
WC Allergy; Dermatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Allergy; Dermatology
GA AS9SR
UT WOS:000344582300001
PM 25395923
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Yoshimura, R
   Hayashi, M
   Mizukami, T
   Abiko, Y
AF Yoshimura, Rie
   Hayashi, Miho
   Mizukami, Tetsuya
   Abiko, Yoshimitsu
TI Enhancement of GDP Dissociation Inhibitor Gene Expression in Osteoblasts
   by Low Level Laser Irradiation
SO JOURNAL OF HARD TISSUE BIOLOGY
LA English
DT Article
DE Low level laser; Osteoblasts; GDP dissociation inhibitor; Gene
   expression
ID HE NE IRRADIATION; BONE REPAIR; RHO; PROTEINS; ALPHA; CELLS; GTPASES;
   TIBIA
AB Low level laser irradiation (LLLI) stimulates bone regeneration and may be useful for bone fracture and oral implant therapy. However, the molecular mechanism of LLLI in accelerating bone formation is not well known. In order to understand the mechanism of LLLI in accelerating bone formation, we attempted to identify gene expressions enhanced by LLLI by a subtractive gene cloning and DNA microarray analysis. Osteoblastic cell MC3T3 E1 was treated with 830 nm Ga Al As diode laser irradiation and total mRNA was recovered and used to construct a subtractive gene library of genes with transcription enhanced by LLLI. The DNA sequences of subtracted gene was subjected to a homology search using BLASTN program in the National Center for Biotechnology Information (NCBI). Genes with mRNA levels altered by LLLI were also analysed using Affymetrix GeneChip. The mRNA levels were confirmed by RT PCR and real time PCR. Subtracted gene clones MCL101 indicated high homology with GDP dissociation inhibitor beta (GDPIB) genes. Affymetrix GeneChip (TM) analysis was further analyzed and found that GDI alpha gene expression was also enhanced by LLLI. The increased mRNA level of GDIA and GDIB by LLLI was successfully confirmed by RT PCR and real time PCR. Since the up regulation of GDIA is one of the mechanisms underlying the synergistic bone forming effect of parathyroid hormone and oestrogen. Moreover, GDIA and GDIB involve in the regulation of vesicle mediated cellular transport and anti apoptosis, the enhancement of GDIA and GDIB gene expressions by LLLI may be a part of mechanisms in the acceleration of bone formation by LLLI.
C1 [Yoshimura, Rie; Hayashi, Miho; Mizukami, Tetsuya; Abiko, Yoshimitsu] Nihon Univ, Sch Dent Matsudo, Dept Biochem & Mol Biol, Matsudo, Chiba 271, Japan.
C3 Nihon University
RP Abiko, Y (通讯作者)，Nihon Univ, Sch Dent Matsudo, Dept Biochem & Mol Biol, 2 870 1 Sakaecho Nishi, Matsudo, Chiba 2718587, Japan.
EM abiko.yoshimitsu@nihon u.ac.jp
CR BACHNER D, 1995, HUM MOL GENET, V4, P701, DOI 10.1093/hmg/4.4.701
   BARUSHKA O, 1995, BONE, V16, P47, DOI 10.1016/S8756 3282(94)00006 9
   Erickson JW, 2004, BIOCHEMISTRY US, V43, P837, DOI 10.1021/bi036026v
   Gandhi PN, 2004, BIOCHEM J, V378, P409, DOI 10.1042/BJ20030979
   Hosoya Shiki, 1997, Laser Therapy, V9, P107
   Ishizaki H, 2006, J IMMUNOL, V177, P8512, DOI 10.4049/jimmunol.177.12.8512
   Kodama H.A., 1981, J ORAL BIOL, V23, P899, DOI DOI 10.2330/JORALBIOSCI1965.23.899
   McDougall KE, 2003, ENDOCRINOLOGY, V144, P1994, DOI 10.1210/en.2002 0074
   NAGASAWA A, 1991, Laser Therapy, V3, P59
   NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505
   Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898 6568(98)00063 1
   Ozawa Y, 1998, BONE, V22, P347, DOI 10.1016/S8756 3282(97)00294 9
   Scheffzek K, 2000, NAT STRUCT BIOL, V7, P122, DOI 10.1038/72392
   Su LF, 2001, J BIOL CHEM, V276, P3231, DOI 10.1074/jbc.M005547200
   Sun ZF, 2009, ACTA PHARMACOL SIN, V30, P1001, DOI 10.1038/aps.2009.60
   Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153
   TRELLES MA, 1987, LASER SURG MED, V7, P36, DOI 10.1002/lsm.1900070107
   Yaakobi T, 1996, CALCIFIED TISSUE INT, V59, P297, DOI 10.1007/s002239900126
   Zhang BL, 2005, CANCER RES, V65, P6054, DOI 10.1158/0008 5472.CAN 05 0175
NR 19
TC 0
Z9 0
U1 1
U2 3
PU JOURNAL HARD TISSUE BIOLOGY
PI MINATO KU
PA NIHON GAKUKUTSU KYORYOKU ZAIDAN, 3  24  20, NISHIAZABU, MINATO KU, TOKYO
   106 0031, JAPAN
SN 1341 7649
J9 J HARD TISSUE BIOL
JI J. Hard Tissue Biol.
PD DEC
PY 2011
VL 20
IS 3
BP 211
EP 215
DI 10.2485/jhtb.20.211
PG 5
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA 878QH
UT WOS:000299271100006
OA Bronze
DA 2025 08 17
ER

PT J
AU Daddona, PE
   Matriano, JA
   Mandema, J
   Maa, YF
AF Daddona, Peter E.
   Matriano, James. A.
   Mandema, Jaap
   Maa, Yuh Fun
TI Parathyroid Hormone (1 34) Coated Microneedle Patch System: Clinical
   Pharmacokinetics and Pharmacodynamics for Treatment of Osteoporosis
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE Parathyroid hormone; PTH (1 34); teriparatide; osteoporosis; transdermal
   microneedle patch; pharmacokinetics; pharmacodynamics; Macroflux
ID BONE MINERAL DENSITY; POSTMENOPAUSAL WOMEN; MATHEMATICAL MODEL;
   TERIPARATIDE; DELIVERY
AB Objectives To evaluate the clinical PK/PD of PTH(1 34) delivered by a novel transdermal drug coated microneedle patch system (ZP PTH) for the treatment of osteoporosis.
   Methods Phase 1 PK studies evaluated the effect of site of administration, patch wear time and dose in normal volunteers, ages 40 85 yrs. Phase 2 was conducted in post menopausal women with osteoporosis to determine the patch dose response compared to placebo patch and FORTEO (R) injection.
   Results Phase 1 ZP PTH patch delivery demonstrated a rapid PTH plasma pulse profile with T max 3 times shorter and apparent T 1/2 2 times shorter than FORTEO (R). In Phase 2, ZP PTH 20, 30 and 40 mu g doses showed a proportional increase in plasma PTH AUC. Inter subject and intra subject AUC variability was similar for all patch doses and comparable to injection. All patch doses produced a significant increase in spine bone mineral density. Unexpectedly, ZP PTH also produced an early increase in hip bone mineral density, an effect not observed with the injection.
   Conclusions These studies suggest that this novel ZP PTH patch system can deliver a consistent and therapeutically relevant PTH PK profile. Based on encouraging Phase 2 safety and efficacy data, the program is advancing into a pivotal Phase 3 clinical study.
C1 [Daddona, Peter E.; Matriano, James. A.; Maa, Yuh Fun] Zosano Pharma Inc, Fremont, CA 94555 USA.
   [Mandema, Jaap] Quantitat Solut Inc, Menlo Pk, CA 94025 USA.
RP Daddona, PE (通讯作者)，Zosano Pharma Inc, 34790 Ardentech Court, Fremont, CA 94555 USA.
EM pdaddona@zosanopharma.com
CR Ameri M, 2009, AAPS J S2, V11, pT2245
   Ameri M, 2010, PHARM RES DORDR, V27, P303, DOI 10.1007/s11095 009 0019 8
   Ameri M, 2009, PHARM RES DORDR, V26, P2454, DOI 10.1007/s11095 009 9960 9
   Chen K, 2006, AAPS J S2, V8, P1995
   Cormier M, 2004, J CONTROL RELEASE, V97, P503, DOI 10.1016/j.jconrel.2004.04.003
   CORMIER M, 2003, Patent No. 0914178
   Cosman F, 2010, J CLIN ENDOCR METAB, V95, P151, DOI 10.1210/jc.2009 0358
   Cosman F, 2008, CURR OPIN ENDOCRINOL, V15, P495, DOI 10.1097/MED.0b013e32831a46d6
   Fraenkel L, 2007, PATIENT EDUC COUNS, V65, P237, DOI 10.1016/j.pec.2006.08.004
   Fraenkel L, 2006, ARTHRIT RHEUM ARTHR, V55, P729, DOI 10.1002/art.22229
   Fraher LJ, 1999, J CLIN ENDOCR METAB, V84, P2739, DOI 10.1210/jc.84.8.2739
   Frolik CA, 2003, BONE, V33, P372, DOI 10.1016/S8756 3282(03)00202 3
   Govalakrishnan V, 2004, J BONE MINER RES, V19, pS460
   HOCK JM, 1992, J BONE MINER RES, V7, P65, DOI 10.1002/jbmr.5650070110
   KITAZAWA R, 1991, BONE MINER, V12, P157, DOI 10.1016/0169 6009(91)90029 Y
   Komarova SV, 2005, ENDOCRINOLOGY, V146, P3589, DOI 10.1210/en.2004 1642
   Matriano JA, 2002, PHARMACEUT RES, V19, P63, DOI 10.1023/A:1013607400040
   McClung MR, 2005, ARCH INTERN MED, V165, P1762, DOI 10.1001/archinte.165.15.1762
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Obermayer Pietsch BM, 2008, J BONE MINER RES, V23, P1591, DOI 10.1359/JBMR.080506
   PE Daddona, 2002, DRUG DEV DELIV, V2, P54
   Potter LK, 2005, BONE, V37, P159, DOI 10.1016/j.bone.2005.04.011
   Sathyan G., 2004, AAPS J, V6, P665
   Trautman JC, 2008, US Patent, Patent No. [7,131,960, 7131960]
   TRAUTMAN JC, 2002, Patent No. 6855372
   Widera G, 2006, VACCINE, V24, P1653, DOI 10.1016/j.vaccine.2005.09.049
NR 26
TC 188
Z9 215
U1 1
U2 78
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724 8741
EI 1573 904X
J9 PHARM RES DORDR
JI Pharm. Res.
PD JAN
PY 2011
VL 28
IS 1
BP 159
EP 165
DI 10.1007/s11095 010 0192 9
PG 7
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA 700PS
UT WOS:000285757000015
PM 20567999
DA 2025 08 17
ER

PT J
AU Kim, HJ
   Zhang, KH
   Zhang, LH
   Ross, FP
   Teitelbaum, SL
   Faccio, R
AF Kim, Hyun Ju
   Zhang, Kaihua
   Zhang, Lihong
   Ross, F. Patrick
   Teitelbaum, Steven L.
   Faccio, Roberta
TI The Src family kinase, Lyn, suppresses osteoclastogenesis in vitro and
   in vivo
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE c Src; osteoclast; SFK
ID NEGATIVELY REGULATES NEUTROPHIL; C SRC; SIGNALING COMPLEX;
   BONE RESORPTION; DEFICIENT MICE; INTEGRIN; PHOSPHORYLATION; PROTEIN;
   RANKL; SHP 1
AB c Src kinase is a rate limiting activator of osteoclast (OC) function and Src inhibitors are therefore candidate antiosteoporosis drugs. By affecting alpha nu beta 3 and macrophage colony stimulating factor (M CSF) induced signaling, c Src is central to osteoclast activity, but not differentiation. We find Lyn, another member of Src family kinases (SFK) is, in contrast, a negative regulator of osteoclastic bone resorption. The absence of Lyn enhances receptor activator of NF kappa B ligand (RANKL) mediated differentiation of osteoclast precursors without affecting proliferation and survival, while its overexpression decreases osteoclast formation. In further contrast to c Src, Lyn deficiency does not impact the activity of the mature cell. Reflecting increased osteoclast development in vitro, Lyn /  mice undergo accelerated osteoclastogenesis and bone loss, in vivo, in response to RANKL. Mechanistically, Lyn forms a complex with receptor activator of NF kappa B (RANK), the tyrosine phosphatase, SHP 1, and the adapter protein, Grb2 associated binder 2 (Gab2). Upon RANKL exposure, Gab2 phosphorylation, JNK, and NF kappa B activation are enhanced in Lyn /  osteoclasts, all critical events in osteoclast development. We therefore establish that Lyn regulates osteoclast formation and does it in a manner antithetical to that of c Src. The most pragmatic aspect of our findings is that successful therapeutic inhibition of c Src, in the context of the osteoclast, will require its stringent targeting.
C1 [Zhang, Kaihua; Zhang, Lihong; Faccio, Roberta] Washington Univ, Dept Orthoped, St Louis, MO 63110 USA.
   [Kim, Hyun Ju; Ross, F. Patrick; Teitelbaum, Steven L.] Washington Univ, Dept Pathol & Immunol, St Louis, MO 63110 USA.
   [Kim, Hyun Ju] Kyungpook Natl Univ, Sch Med, Skeletal Dis Genome Res Ctr, Taegu 700422, South Korea.
C3 Washington University (WUSTL); Washington University (WUSTL); Kyungpook
   National University (KNU)
RP Faccio, R (通讯作者)，Washington Univ, Dept Orthoped, St Louis, MO 63110 USA.
EM faccior@wustl.edu
RI ; Kim, Jeehoon/K 3763 2012; Zhang, Kaihua/AAD 7882 2022
OI Kim, HongJoo/0000 0001 9787 4684; Teitelbaum,
   Steven/0000 0002 4054 6679; 
FU Arthritis Foundation; National Institutes of Health [R01 AR52921,
   R01 AR032788, R01 AR046523, R01 AR046852, R01 AR054190]
FX We thank Paulette Shubert for assistance with manuscript preparation.
   This work was supported by the Arthritis Foundation ( R. F.) and by
   National Institutes of Health Grants R01 AR52921 to R. F., R01 AR032788
   and R01 AR046523 to S. L. T., and R01 AR046852 and R01 AR054190 to F. P.
   R.
CR Adams S, 1998, J IMMUNOL, V161, P1853
   Aoki K, 1999, BONE, V25, P261, DOI 10.1016/S8756 3282(99)00174 X
   Bai ST, 2005, J CLIN INVEST, V115, P2742, DOI 10.1172/JCI24921
   Baran CP, 2003, J BIOL CHEM, V278, P38628, DOI 10.1074/jbc.M305021200
   BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032
   Boyce BF, 2006, CLIN CANCER RES, V12, p6291S, DOI 10.1158/1078 0432.CCR 06 0991
   Chan VWF, 1997, IMMUNITY, V7, P69, DOI 10.1016/S1074 7613(00)80511 7
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Faccio R, 2003, J CELL BIOL, V162, P499, DOI 10.1083/jcb.200212082
   Faccio R, 2007, J BIOL CHEM, V282, P18991, DOI 10.1074/jbc.M610937200
   Harder KW, 2001, IMMUNITY, V15, P603, DOI 10.1016/S1074 7613(01)00208 4
   Hernandez Hansen V, 2004, J LEUKOCYTE BIOL, V75, P143, DOI 10.1189/jlb.0503224
   Hibbs ML, 1997, INT J BIOCHEM CELL B, V29, P397, DOI 10.1016/S1357 2725(96)00104 5
   HORNE WC, 1992, J CELL BIOL, V119, P1003, DOI 10.1083/jcb.119.4.1003
   Insogna KL, 1997, J CLIN INVEST, V100, P2476, DOI 10.1172/JCI119790
   Kim HJ, 2006, J CLIN INVEST, V116, P2152, DOI 10.1172/JCI28084
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Kurosaki T, 1999, ANNU REV IMMUNOL, V17, P555, DOI 10.1146/annurev.immunol.17.1.555
   Lowell CA, 2004, MOL IMMUNOL, V41, P631, DOI 10.1016/j.molimm.2004.04.010
   Lowell CA, 1996, GENE DEV, V10, P1845, DOI 10.1101/gad.10.15.1845
   Maeda A, 1999, ONCOGENE, V18, P2291, DOI 10.1038/sj.onc.1202552
   Malbec O, 1998, J IMMUNOL, V160, P1647
   Malbec O, 2002, MOL IMMUNOL, V38, P1295, DOI 10.1016/S0161 5890(02)00078 0
   Mao DL, 2006, J CLIN INVEST, V116, P2869, DOI 10.1172/JCI28775
   Mundy GR, 2007, NUTR REV, V65, pS147, DOI [10.1111/j.1753 4887.2007.tb00353.x, 10.1301/nr.2007.dec.S147 S151]
   Nishizumi H, 1998, J EXP MED, V187, P1343, DOI 10.1084/jem.187.8.1343
   Novack DV, 2003, J EXP MED, V198, P771, DOI 10.1084/jem.20030116
   Odom S, 2004, J EXP MED, V199, P1491, DOI 10.1084/jem.20040382
   Parravicini V, 2002, NAT IMMUNOL, V3, P741, DOI 10.1038/ni817
   Pereira S, 2003, J IMMUNOL, V171, P1319, DOI 10.4049/jimmunol.171.3.1319
   Pereira S, 2004, J IMMUNOL, V173, P5757, DOI 10.4049/jimmunol.173.9.5757
   Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181
   SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092 8674(93)90369 2
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   Takeshita S, 2002, NAT MED, V8, P943, DOI 10.1038/nm752
   Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105 2896.2005.00327.x
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Umeda S, 1999, AM J PATHOL, V155, P223, DOI 10.1016/S0002 9440(10)65116 4
   Vaira S, 2008, J CLIN INVEST, V118, P2088, DOI 10.1172/JCI33392
   Vaira S, 2008, P NATL ACAD SCI USA, V105, P3897, DOI 10.1073/pnas.0708576105
   Vidalain PO, 2000, EMBO J, V19, P3304, DOI 10.1093/emboj/19.13.3304
   Wada T, 2005, NAT MED, V11, P394, DOI 10.1038/nm1203
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097 2765(00)80232 4
   Zhang ZY, 2003, J IMMUNOL, V171, P3620, DOI 10.4049/jimmunol.171.7.3620
   Zou W, 2007, J CELL BIOL, V176, P877, DOI 10.1083/jcb.200611083
NR 46
TC 42
Z9 46
U1 0
U2 1
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 17
PY 2009
VL 106
IS 7
BP 2325
EP 2330
DI 10.1073/pnas.0806963106
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 409OQ
UT WOS:000263516100045
PM 19171907
OA Green Published
DA 2025 08 17
ER

PT J
AU Colombo, MV
   Bersini, S
   Arrigoni, C
   Gilardi, M
   Sansoni, V
   Ragni, E
   Candiani, G
   Lombardi, G
   Moretti, M
AF Colombo, Maria Vittoria
   Bersini, Simone
   Arrigoni, Chiara
   Gilardi, Mara
   Sansoni, Veronica
   Ragni, Enrico
   Candiani, Gabriele
   Lombardi, Giovanni
   Moretti, Matteo
TI Engineering the early bone metastatic niche through human vascularized
   immuno bone minitissues
SO BIOFABRICATION
LA English
DT Article
DE 3D in vitro models; breast cancer; bone metastases; bone&#8211; tumor
   interactions; drug efficacy
ID TUMOR ASSOCIATED MACROPHAGES; A(3) ADENOSINE RECEPTOR; BREAST CANCER
   CELLS; IN VITRO MODEL; ENDOTHELIAL CELLS; CULTURE MODEL; TISSUE;
   OSTEOBLASTS; RAPAMYCIN; GROWTH
AB Bone metastases occur in 65% 80% advanced breast cancer patients. Although significant progresses have been made in understanding the biological mechanisms driving the bone metastatic cascade, traditional 2D in vitro models and animal studies are not effectively reproducing breast cancer cells (CCs) interactions with the bone microenvironment and suffer from species specific differences, respectively. Moreover, simplified in vitro models cannot realistically estimate drug anti tumoral properties and side effects, hence leading to pre clinical testing frequent failures. To solve this issue, a 3D metastatic bone minitissue (MBm) is designed with embedded human osteoblasts, osteoclasts, bone resident macrophages, endothelial cells and breast CCs. This minitissue recapitulates key features of the bone metastatic niche, including the alteration of macrophage polarization and microvascular architecture, along with the induction of CC micrometastases and osteomimicry. The minitissue reflects breast CC organ specific metastatization to bone compared to a muscle minitissue. Finally, two FDA approved drugs, doxorubicin and rapamycin, have been tested showing that the dose required to impair CC growth is significantly higher in the MBm compared to a simpler CC monoculture minitissue. The MBm allows the investigation of metastasis key biological features and represents a reliable tool to better predict drug effects on the metastatic bone microenvironment.
C1 [Colombo, Maria Vittoria; Bersini, Simone; Arrigoni, Chiara; Moretti, Matteo] Ente Osped Cantonale, Regenerat Med Technol Lab, CH 6900 Lugano, Switzerland.
   [Colombo, Maria Vittoria; Candiani, Gabriele] Politecn Milan, Dept Chem Mat & Chem Engn Giulio Natta, Biocompatibil & Cell Culture Lab BioCell, I 20133 Milan, Italy.
   [Gilardi, Mara] Univ Hosp Basel, Inst Pathol, CH 4056 Basel, Switzerland.
   [Sansoni, Veronica; Lombardi, Giovanni] IRCCS Ist Ortoped Galeazzi, Lab Expt Biochem & Mol Biol, I 20161 Milan, Italy.
   [Ragni, Enrico] IRCCS Ist Ortoped Galeazzi, Orthoped Biotechnol Lab, I 20161 Milan, Italy.
   [Moretti, Matteo] IRCCS Ist Ortoped Galeazzi, Cell & Tissue Engn Lab, I 20161 Milan, Italy.
   [Moretti, Matteo] Univ Svizzera Italiana, Fac Biomed Sci, CH 6900 Lugano, Switzerland.
   [Lombardi, Giovanni] Poznan Univ Phys Educ, Dept Athlet Strength & Conditioning, PL 61871 Poznan, Poland.
C3 Polytechnic University of Milan; University of Basel; IRCCS Istituto
   Ortopedico Galeazzi; IRCCS Istituto Ortopedico Galeazzi; IRCCS Istituto
   Ortopedico Galeazzi; Universita della Svizzera Italiana; Poznan
   University of Physical Education
RP Moretti, M (通讯作者)，Ente Osped Cantonale, Regenerat Med Technol Lab, CH 6900 Lugano, Switzerland.; Moretti, M (通讯作者)，IRCCS Ist Ortoped Galeazzi, Cell & Tissue Engn Lab, I 20161 Milan, Italy.; Moretti, M (通讯作者)，Univ Svizzera Italiana, Fac Biomed Sci, CH 6900 Lugano, Switzerland.
EM matteo.moretti@eoc.ch
RI Lombardi, Giovanni/I 2414 2012; Arrigoni, Chiara/A 3389 2013; Bersini,
   Simone/K 6783 2016; Sansoni, Veronica/B 1375 2017; Ragni,
   Enrico/J 4292 2015; Candiani, Gabriele/A 9744 2009; Moretti,
   Matteo/AIC 6221 2022
OI Moretti, Matteo/0000 0002 7301 1208; Arrigoni,
   Chiara/0000 0001 6808 1642; Colombo, Maria Vittoria/0000 0002 6018 9920;
   Bersini, Simone/0000 0003 4620 3500; Sansoni,
   Veronica/0000 0003 0337 975X; Lombardi, Giovanni/0000 0002 8365 985X;
   Candiani, Gabriele/0000 0003 0575 068X; 
FU Swiss National Science Foundation [SNF 310030_179167]; Swiss National
   Science Foundation (SNF) [310030_179167] Funding Source: Swiss National
   Science Foundation (SNF)
FX This study was partially funded by the Swiss National Science Foundation
   (SNF 310030_179167).
CR Arrigoni C, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091405
   Awolaran O, 2016, BREAST, V30, P156, DOI 10.1016/j.breast.2016.09.017
   Barilli A, 2008, CARDIOVASC RES, V78, P563, DOI 10.1093/cvr/cvn024
   Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093
   Bernhardt A, 2010, J BIOMED MATER RES A, V95A, P848, DOI 10.1002/jbm.a.32856
   Bersini S, 2018, CELL REP, V25, P3858, DOI 10.1016/j.celrep.2018.11.092
   Bersini S, 2016, DRUG DISCOV TODAY, V21, P1429, DOI 10.1016/j.drudis.2016.04.015
   Bersini S, 2016, BIOMATERIALS, V76, P157, DOI 10.1016/j.biomaterials.2015.10.057
   Bersini S, 2014, BIOMATERIALS, V35, P2454, DOI 10.1016/j.biomaterials.2013.11.050
   Bingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027
   Binnemars Postma K, 2018, FASEB J, V32, P969, DOI 10.1096/fj.201700629R
   Bongio M, 2016, NANOMEDICINE UK, V11, P1073, DOI 10.2217/nnm 2015 0021
   Brancato V, 2020, FRONT MATER, V7, DOI 10.3389/fmats.2020.00116
   Cappetta D, 2018, PHARMACOL RES, V127, P4, DOI 10.1016/j.phrs.2017.03.016
   Chiechi A, 2013, CLIN CANCER RES, V19, P2473, DOI 10.1158/1078 0432.CCR 12 3416
   Clarke MSF, 2013, ACTA BIOMATER, V9, P7908, DOI 10.1016/j.actbio.2013.04.051
   Correia C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028352
   Cortini M, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00814
   Cserni G, 2008, EUR J CANCER, V44, P2185, DOI 10.1016/j.ejca.2008.06.033
   de Peppo GM, 2014, METHODS MOL BIOL, V1202, P173, DOI 10.1007/7651_2013_52
   Deligiorgi MV, 2020, CLIN EXP METASTAS, V37, P13, DOI 10.1007/s10585 019 09997 8
   Fishman P, 2004, ONCOGENE, V23, P2465, DOI 10.1038/sj.onc.1207355
   Fornetti J, 2018, J BONE MINER RES, V33, P2099, DOI 10.1002/jbmr.3618
   Forte L, 2016, ACTA BIOMATER, V32, P298, DOI 10.1016/j.actbio.2015.12.013
   Francesca S, 2016, ONCOTARGET, V7, P76966, DOI 10.18632/oncotarget.12763
   García Castro A, 2015, CARCINOGENESIS, V36, P574, DOI 10.1093/carcin/bgv020
   Gershovich JG, 2013, TISSUE ENG PT A, V19, P2565, DOI [10.1089/ten.tea.2013.0256, 10.1089/ten.TEA.2013.0256]
   Ghajar CM, 2013, NAT CELL BIOL, V15, P807, DOI 10.1038/ncb2767
   Graney PL, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay6391
   Hao SJ, 2018, SMALL, V14, DOI 10.1002/smll.201702787
   Hellsten Y, 1998, CIRCULATION, V98, P6, DOI 10.1161/01.CIR.98.1.6
   Helm O, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.946818
   Heuzé Vourc'h N, 2005, BIOCHEM BIOPH RES CO, V333, P470, DOI 10.1016/j.bbrc.2005.05.122
   Hirt C, 2014, ADV DRUG DELIVER REV, V79 80, P145, DOI 10.1016/j.addr.2014.05.003
   Hoarau Véchot J, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010181
   Indraccolo S, 2006, P NATL ACAD SCI USA, V103, P4216, DOI 10.1073/pnas.0506200103
   Inoue K, 2006, J BIOL CHEM, V281, P33814, DOI 10.1074/jbc.M607290200
   James Bhasin M, 2018, J FUNCT BIOMATER, V9, DOI 10.3390/jfb9040072
   Jeon JS, 2015, P NATL ACAD SCI USA, V112, P214, DOI 10.1073/pnas.1417115112
   Kim J, 2018, CELL REP, V24, P224, DOI 10.1016/j.celrep.2018.06.020
   Krishnan V, 2014, J CELL PHYSIOL, V229, P453, DOI 10.1002/jcp.24464
   Kusumbe AP, 2016, J BONE ONCOL, V5, P112, DOI 10.1016/j.jbo.2016.04.003
   Labelle M, 2012, CANCER DISCOV, V2, P1091, DOI 10.1158/2159 8290.CD 12 0329
   Langley RR, 2011, INT J CANCER, V128, P2527, DOI 10.1002/ijc.26031
   Le Pape F, 2016, J BONE ONCOL, V5, P93, DOI 10.1016/j.jbo.2016.02.008
   Li J, 2014, CELL METAB, V19, P373, DOI 10.1016/j.cmet.2014.01.001
   Lin YX, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045 019 0760 3
   Lovitt CJ, 2018, BMC CANCER, V18, DOI 10.1186/s12885 017 3953 6
   Madi L, 2004, CLIN CANCER RES, V10, P4472, DOI 10.1158/1078 0432.CCR 03 0651
   Martinez FO, 2008, FRONT BIOSCI LANDMRK, V13, P453, DOI 10.2741/2692
   McMillin DW, 2013, NAT REV DRUG DISCOV, V12, P217, DOI 10.1038/nrd3870
   Mills CD, 2000, J IMMUNOL, V164, P6166, DOI 10.4049/jimmunol.164.12.6166
   Morinobu M, 2003, J BONE MINER RES, V18, P1706, DOI 10.1359/jbmr.2003.18.9.1706
   MOSER GH, 1989, AM J PHYSIOL, V256, pC799, DOI 10.1152/ajpcell.1989.256.4.C799
   Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008
   Naumov GN, 1999, J CELL SCI, V112, P1835
   Ney JT., 2013, TUMOR DIAGNOSTICS TH, V72, P385, DOI [10.1055 / s 0033 1335193, DOI 10.1055/S 0033 1335193]
   Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622
   Pagani S, 2018, J CELL PHYSIOL, V233, P291, DOI 10.1002/jcp.25875
   Pang XC, 2019, PHARMACOL RES, V144, P235, DOI 10.1016/j.phrs.2019.04.030
   Parlakian A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009299
   Pelekanou V, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00301
   Popielarski M, 2019, AM J CANCER RES, V9, P1554
   Quent VMC, 2018, J TISSUE ENG REGEN M, V12, P494, DOI 10.1002/term.2517
   Rao VA, 2009, CANCER RES, V69, P948, DOI 10.1158/0008 5472.CAN 08 1437
   Renema N, 2016, BIOSCIENCE REP, V36, DOI 10.1042/BSR20160150
   Rivankar S, 2014, J CANCER RES THER, V10, P853, DOI 10.4103/0973 1482.139267
   Roca H, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.75
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Seibel Markus J, 2005, Clin Biochem Rev, V26, P97
   Shay T, 2013, P NATL ACAD SCI USA, V110, P2946, DOI 10.1073/pnas.1222738110
   Shimamura T, 2005, BIOMED RES TOKYO, V26, P159, DOI 10.2220/biomedres.26.159
   Son B, 2017, ONCOTARGET, V8, P3933, DOI 10.18632/oncotarget.13907
   Sonowal H, 2018, BIOCHEM PHARMACOL, V150, P179, DOI 10.1016/j.bcp.2018.02.018
   Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793
   Sousa S, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058 015 0621 0
   Steeland S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051442
   Sun YZ, 2017, INT J CLIN EXP PATHO, V10, P10167
   Villasante A, 2017, TISSUE ENG PART C ME, V23, P98, DOI [10.1089/ten.tec.2016.0371, 10.1089/ten.TEC.2016.0371]
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Wessels DJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218854
   Wyckoff JB, 2007, CANCER RES, V67, P2649, DOI 10.1158/0008 5472.CAN 06 1823
   Yamada KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006
   Yellen P, 2011, CELL CYCLE, V10, P3948, DOI 10.4161/cc.10.22.18124
   Zenger S, 2011, CLIN EXP METASTAS, V28, P65, DOI 10.1007/s10585 010 9358 4
   Zhang H, 2019, CIRC RES, V125, P552, DOI 10.1161/CIRCRESAHA.119.315491
   Zhou X, 2016, ACS APPL MATER INTER, V8, P30017, DOI 10.1021/acsami.6b10673
NR 87
TC 15
Z9 15
U1 0
U2 27
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 1758 5082
EI 1758 5090
J9 BIOFABRICATION
JI Biofabrication
PD JUL
PY 2021
VL 13
IS 3
AR 035036
DI 10.1088/1758 5090/abefea
PG 16
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA RU2ZN
UT WOS:000645018600001
PM 33735854
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Rossi, F
   Tortora, C
   Di Martino, M
   Di Paola, A
   Di Pinto, D
   Marrapodi, MM
   Argenziano, M
   Pota, E
AF Rossi, Francesca
   Tortora, Chiara
   Di Martino, Martina
   Di Paola, Alessandra
   Di Pinto, Daniela
   Marrapodi, Maria Maddalena
   Argenziano, Maura
   Pota, Elvira
TI Alteration of osteoclast activity in childhood cancer survivors: Role of
   iron and of CB2/TRPV1 receptors
SO PLOS ONE
LA English
DT Article
ID BONE MINERAL DENSITY; YOUNG ADULT SURVIVORS; CANNABINOID RECEPTOR;
   CHELATION THERAPY; PHYSICAL ACTIVITY; METABOLISM; INFLAMMATION;
   EFFICACY; FRAILTY; HEALTH
AB Childhood cancer survivors (CCS) are predisposed to the onset of osteoporosis (OP). It is known that iron overload induces osteoclasts (OCs) overactivity and that the iron chelator Deferasirox (DFX) can counteract it. The Cannabinoid Receptor type 2 (CB2) and the transient receptor potential vanilloid type 1 (TRPV1) are potential therapeutic targets for OP. In this study we isolated OCs from peripheral blood of 20 CCS and investigated osteoclast biomarkers expression and iron metabolism evaluating iron release by OCs and the expression of several molecules involved in its regulation. Moreover, we analyzed the effects of CB2 and TRPV1 stimulation in combination with DFX on osteoclast activity and iron metabolism. We observed, for the first time, an osteoclast hyperactivation in CCS suggesting a role for iron in its development. Moreover, we confirmed the well known role of CB2 and TRPV1 receptors in bone metabolism, suggesting the receptors as possible key biomarkers of bone damage. Moreover, we demonstrated a promising synergism between pharmacological compounds, stimulating CB2 or inhibiting/desensitizing TRPV1 and DFX, in counteracting osteoclast overactivity in CCS to improve their quality of life.
C1 [Rossi, Francesca; Tortora, Chiara; Di Martino, Martina; Di Paola, Alessandra; Di Pinto, Daniela; Marrapodi, Maria Maddalena; Argenziano, Maura; Pota, Elvira] Univ Campania Luigi Vanvitelli, Dept Woman Child & Gen & Specialist Surg, Naples, Italy.
C3 Universita della Campania Vanvitelli
RP Rossi, F (通讯作者)，Univ Campania Luigi Vanvitelli, Dept Woman Child & Gen & Specialist Surg, Naples, Italy.
EM francesca.rossi@unicampania.it
RI ; Di Paola, Alessandra/LUA 0359 2024; Rossi, Francesca/HTP 5870 2023
OI Di Paola, Alessandra/0000 0001 5634 3967; Rossi,
   Francesca/0000 0003 2879 6277
FU  [VALERE19]
FX This research was funded by VALERE19 "In CHICAS Name of author receiving
   grant: Francesca Rossi (FR).
CR Aisenberg J, 1998, J PEDIAT HEMATOL ONC, V20, P241, DOI 10.1097/00043426 199805000 00010
   Ali MK, 2020, J PATHOL, V251, P49, DOI 10.1002/path.5401
   Alves P, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104822
   Ariffin H, 2017, CANCER AM CANCER SOC, V123, P4207, DOI 10.1002/cncr.30857
   Bab I, 2008, J NEUROENDOCRINOL, V20, P69, DOI 10.1111/j.1365 2826.2008.01675.x
   Balogh E, 2018, PHARMACEUTICALS BASE, V11, DOI 10.3390/ph11040107
   Baumgartner A, 2019, BONE MARROW TRANSPL, V54, P1651, DOI 10.1038/s41409 019 0484 6
   Bellini G, 2017, PHARMACOL RES, V115, P267, DOI 10.1016/j.phrs.2016.11.039
   Bloomhardt HM, 2020, CANCER AM CANCER SOC, V126, P202, DOI 10.1002/cncr.32512
   Camaschella C, 2020, HAEMATOLOGICA, V105, P260, DOI 10.3324/haematol.2019.232124
   Che JM, 2020, BIOL TRACE ELEM RES, V195, P353, DOI 10.1007/s12011 019 01867 4
   Chemaitilly W, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2017.76.3268
   den Hoed MAH, 2015, OSTEOPOROSIS INT, V26, P521, DOI 10.1007/s00198 014 2878 z
   Dev S, 2017, HEMODIAL INT, V21, pS6, DOI 10.1111/hdi.12542
   Du Q, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01064
   Felicetti F, 2020, PEDIATR BLOOD CANCER, V67, DOI 10.1002/pbc.28106
   Fernandes JL, 2016, BLOOD, V128, P1555, DOI 10.1182/blood 2016 06 721183
   French SA, 2000, PREV MED, V31, P722, DOI 10.1006/pmed.2000.0758
   Ginzburg YZ, 2019, VITAM HORM, V110, P17, DOI 10.1016/bs.vh.2019.01.002
   Hayek S, 2020, J CLIN ONCOL, V38, P232, DOI 10.1200/JCO.19.01226
   Ishii K, 2009, NAT MED, V15, P259, DOI 10.1038/nm.1910
   Jia Y, 2020, NEUROSCI LETT, V720, DOI 10.1016/j.neulet.2020.134779
   Jin HY, 2020, ANN PEDIATR ENDOCRIN, V25, P137, DOI 10.6065/apem.2040060.030
   Kernan KF, 2017, INT IMMUNOL, V29, P401, DOI 10.1093/intimm/dxx031
   Kontoghiorghe CN, 2016, DRUG DES DEV THER, V10, P465, DOI 10.2147/DDDT.S79458
   Kumfu S, 2021, J CELL PHYSIOL, V236, P5108, DOI 10.1002/jcp.30219
   Kumfu S, 2018, EUR J PHARMACOL, V822, P43, DOI 10.1016/j.ejphar.2018.01.015
   Landier W, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2017.77.0180
   LaVoy ECP, 2016, EXERC IMMUNOL REV, V22, P82
   Ledesma Colunga MG, 2020, BONE, V137, DOI 10.1016/j.bone.2020.115400
   Leonardi GC, 2018, IMMUN AGEING, V15, DOI 10.1186/s12979 017 0112 5
   Liu QJ, 2021, FREE RADICAL BIO MED, V165, P1, DOI 10.1016/j.freeradbiomed.2021.01.025
   Mandel K, 2004, J CLIN ONCOL, V22, P1215, DOI 10.1200/JCO.2004.04.199
   Ness KK, 2015, CANCER AM CANCER SOC, V121, P1540, DOI 10.1002/cncr.29211
   Ofek O, 2006, P NATL ACAD SCI USA, V103, P696, DOI 10.1073/pnas.0504187103
   Oudit GY, 2006, J MOL MED, V84, P349, DOI 10.1007/s00109 005 0029 x
   Proia P, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.704647
   Punzo F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208102
   Rossi F, 2009, BONE, V44, P476, DOI 10.1016/j.bone.2008.10.056
   Rossi F, 2014, HAEMATOLOGICA, V99, P1876, DOI 10.3324/haematol.2014.104463
   Rossi F, 2013, PHARMACOL RES, V68, P7, DOI 10.1016/j.phrs.2012.10.017
   Rossi F, 2011, BONE, V48, P997, DOI 10.1016/j.bone.2011.01.001
   Seo YA, 2016, BIOCHEM J, V473, P4243, DOI 10.1042/BCJ20160674
   Skou AS, 2014, PEDIATR BLOOD CANCER, V61, P1638, DOI 10.1002/pbc.25069
   Sulicka Grodzicka J, 2021, CANCER MED US, V10, P1772, DOI 10.1002/cam4.3788
   Tillmann V, 2002, J BONE MINER RES, V17, P1073, DOI 10.1359/jbmr.2002.17.6.1073
   Tortora C, 2020, J PEDIATR GASTR NUTR, V71, P633, DOI 10.1097/MPG.0000000000002863
   Ueda N, 2018, NUTRIENTS, V10, DOI 10.3390/nu10091173
   van Atteveld JE, 2019, J CLIN ONCOL, V37, P2217, DOI 10.1200/JCO.18.01917
   van der Willik KD, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058 018 1062 3
   Wang TT, 2020, CURR DRUG TARGETS, V21, P213, DOI 10.2174/1389450120666190821161259
   Xu Z, 2017, BONE, V94, P152, DOI 10.1016/j.bone.2016.09.023
   Zhang J, 2019, TOXICOL LETT, V313, P50, DOI 10.1016/j.toxlet.2019.06.007
   Zhang J, 2018, CONNECT TISSUE RES, V59, P509, DOI 10.1080/03008207.2018.1439482
   Zhang J, 2019, BONE, V120, P50, DOI 10.1016/j.bone.2018.10.005
   Zhang YY, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/6864723
   Zuo L, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184472
NR 57
TC 6
Z9 6
U1 1
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JUL 21
PY 2022
VL 17
IS 7
AR e0271730
DI 10.1371/journal.pone.0271730
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 7T4CW
UT WOS:000911392100239
PM 35862357
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wang, X
   Liang, XT
   Wang, TH
   Zhan, YX
   Liu, HY
   Li, C
   Li, XB
   Ma, H
   Hu, ZQ
   Wang, XL
   Xiao, SS
   Ban, L
   He, J
   Li, YM
   Fang, Y
AF Wang, Xuan
   Liang, Xintong
   Wang, Tenghua
   Zhan, Yaoxuan
   Liu, Haiyan
   Li, Chen
   Li, Xianbo
   Ma, Hui
   Hu, Zhiqin
   Wang, Xiaole
   Xiao, Shuangshuang
   Ban, Li
   He, Jin
   Li, Yongmei
   Fang, Yi
TI Biosimilarity Assessment of the Biosimilar Teriparatide Candidate and
   the Reference Drug in Healthy Subjects
SO CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT
LA English
DT Article
DE biosimilarity; parathyroid hormone; pharmacokinetics; safety; SAL001;
   teriparatide
ID HUMAN PARATHYROID HORMONE; CALCIUM; PTH; PHARMACODYNAMICS;
   PHARMACOKINETICS; TOLERABILITY; MECHANISMS; SAFETY
AB SAL001, a recombinant form of parathyroid hormone, is a biosimilar drug to teriparatide and is planned to be used in osteoporosis treatment. A single dose, randomized, open label, 2 way crossover trial was conducted in healthy subjects to compare the pharmacokinetics (PK) and safety between SAL001 and the reference drug. Sixty four subjects were enrolled in the study, and 61 subjects completed the study. In each period, 20 mu g of the test or reference formulation was administered subcutaneously. SAL001 was administered by autoinjector pen, whereas the reference drug was administered by a self matched injection pen. Serial blood samples were obtained for the analyses of PK and serum calcium concentration. Geometric mean ratios with 90%CIs for the maximum plasma concentration (C max) and area under the plasma concentration time curve (AUC) were estimated. The safety of these 2 formulations was also evaluated. Overall, the 90%CIs for the geometric mean ratios of C max, AUC from time 0 to the last quantifiable time point, and AUC from time 0 extrapolated to infinity of the test or reference product were within 80.0% 125.0% of biosimilarity criteria. Other PK parameters, serum calcium concentration, and safety profiles had no significant differences between the 2 formulations. SAL001 demonstrated PK similarity to the reference drug, and the serum calcium concentration and safety profiles of SAL001 were also considered comparable to the reference drug.
C1 [Wang, Xuan; Zhan, Yaoxuan; Liu, Haiyan; Li, Xianbo; Xiao, Shuangshuang] Guangzhou Med Univ, Affiliated Hosp 5, Dept Phase 1, Clin Trial Unit, Guangzhou, Guangdong, Peoples R China.
   [Liang, Xintong; Wang, Tenghua; Li, Chen; Hu, Zhiqin; Wang, Xiaole; Ban, Li; He, Jin; Li, Yongmei; Fang, Yi] Guangzhou Med Univ, Affiliated Hosp 5, Dept Pharm, Guangzhou, Guangdong, Peoples R China.
   [Ma, Hui] Shenzhen Salubris Pharmaceut Co Ltd, Shenzhen, Peoples R China.
   [Fang, Yi] Peking Univ, Peoples Hosp, Dept Pharm, Beijing, Peoples R China.
   [Fang, Yi] Guangzhou Med Univ, Affiliated Hosp 5, Key Lab Mol Target & Clin Pharmacol, Guangzhou, Guangdong, Peoples R China.
   [Fang, Yi] Guangzhou Med Univ, Sch Pharmaceut Sci, Guangzhou, Guangdong, Peoples R China.
   [Fang, Yi] Guangzhou Med Univ, Affiliated Hosp 5, Dept Phase 1, Clin Trial Unit, Guangzhou 510700, Guangdong, Peoples R China.
C3 Guangzhou Medical University; Guangzhou Medical University; Peking
   University; Guangzhou Medical University; Guangzhou Medical University;
   Guangzhou Medical University
RP Fang, Y (通讯作者)，Guangzhou Med Univ, Affiliated Hosp 5, Dept Phase 1, Clin Trial Unit, Guangzhou 510700, Guangdong, Peoples R China.
EM phaseistudy@163.com
RI Li, Chen/HTO 9578 2023; Ban, Li/KJL 2446 2024; shuang, xiao/E 8194 2015
CR Bacchetta J, 2020, PEDIATR NEPHROL, V35, P493, DOI 10.1007/s00467 019 04400 w
   Blaine J, 2015, CLIN J AM SOC NEPHRO, V10, P1257, DOI 10.2215/CJN.09750913
   Chiavistelli S, 2015, BONE RES, V3, DOI 10.1038/boneres.2014.49
   Feng X, 2013, BONE RES, V1, DOI 10.4248/BR201301003
   Feurer E, 2014, EXPERT OPIN EMERG DR, V19, P385, DOI 10.1517/14728214.2014.936377
   FRIEDMAN PA, 1995, PHYSIOL REV, V75, P429, DOI 10.1152/physrev.1995.75.3.429
   Hanyu R, 2012, P NATL ACAD SCI USA, V109, P7433, DOI 10.1073/pnas.1109036109
   Horwitz MJ, 2011, J BONE MINER RES, V26, P2287, DOI 10.1002/jbmr.415
   Jacquillet G, 2019, PFLUG ARCH EUR J PHY, V471, P83, DOI 10.1007/s00424 018 2231 z
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Khundmiri SJ, 2016, COMPR PHYSIOL, V6, P561, DOI 10.1002/cphy.c140071
   Li SS, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.717065
   Liu YN, 2014, CLIN THER, V36, P940, DOI 10.1016/j.clinthera.2014.03.015
   Liu Y, 2012, BASIC CLIN PHARMACOL, V110, P154, DOI 10.1111/j.1742 7843.2011.00768.x
   Moriya S, 2015, J CELL BIOCHEM, V116, P142, DOI 10.1002/jcb.24953
   Robinson LJ, 2010, ANN NY ACAD SCI, V1192, P351, DOI 10.1111/j.1749 6632.2009.05219.x
   Sim IW, 2020, J CLIN ONCOL, V38, P2971, DOI 10.1200/JCO.19.02192
   Tsai JN, 2013, LANCET, V382, P50, DOI 10.1016/S0140 6736(13)60856 9
   Wein MN, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031237
   Wojda SJ, 2018, J ORTHOP RES, V36, P2586, DOI 10.1002/jor.24075
   Zaidi M, 2004, BIOL REV, V79, P79, DOI 10.1017/S1464793103006262
   Zhang CG, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.607017
   Zhao Y, 2019, ACTA BIOMATER, V93, P200, DOI 10.1016/j.actbio.2019.04.007
NR 23
TC 3
Z9 3
U1 4
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2160 7648
J9 CLIN PHARM DRUG DEV
JI Clin. Pharmacol. Drug Dev.
PD MAY
PY 2023
VL 12
IS 5
BP 518
EP 524
DI 10.1002/cpdd.1221
EA JAN 2023
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA E3OI8
UT WOS:000919177600001
PM 36710466
DA 2025 08 17
ER

PT J
AU El Kady, AM
   Farag, MM
   El Rashedi, AMI
AF El Kady, Abeer M.
   Farag, Mohammad M.
   El Rashedi, Ahlam M. I.
TI Bioactive glass nanoparticles designed for multiple deliveries of
   lithium ions and drugs: Curative and restorative bone treatment
SO EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Bioactive glass; Nanoparticles; Lithium; Vancomycin; 5 FU; Drug delivery
ID MESENCHYMAL STEM CELLS; IN VITRO; 5 FLUOROURACIL DELIVERY;
   MOLECULAR MECHANISM; WNT; VIVO; BIOCOMPATIBILITY; NANOTECHNOLOGY;
   NANOMATERIALS; REGENERATION
AB Lithium modified bioactive glass nanoparticles were prepared for multiple deliveries of lithium ions and drugs. The particle size, structure and thermal behavior of nanoparticles were analyzed using TEM, FTIR and DSC respectively. The porosity% and specific surface area of glass nanoparticles were about 68.6% and 224.92 (m(2)/g), respectively. The in vitro bioactivity evaluation in SBF revealed that glass nanoparticles were capable of inducing apatite layer over their surfaces. This could be considered as a good indicator for their future abilities to regenerate bone tissue in vivo. Also, lithium ions were released from glass nanoparticles via diffusion controlled process which could activate Wnt signaling pathway and enhance osteogenesis. As a final point, the possibility of utilizing the glass nanoparticles as a controlled delivery device for vancomycin or 5 FU was verified. Fitting vancomycin or 5 FU release profiles to various mathematical models pointed out that both drugs were released by a diffusion controlled mode. (C) 2016 Elsevier B.V. All rights reserved.
C1 [El Kady, Abeer M.; Farag, Mohammad M.] Natl Res Ctr, Biomat Dept, 33 El Bohooth St, Cairo 12622, Egypt.
   [El Kady, Abeer M.; Farag, Mohammad M.] Natl Res Ctr, Ctr Excellence, Adv Mat & Nanotechnol Lab, Cairo 12622, Egypt.
   [El Rashedi, Ahlam M. I.] AL Azhar Univ Girls, Fac Sci, Dept Phys, Biophys Branch, Cairo, Egypt.
C3 Egyptian Knowledge Bank (EKB); National Research Centre (NRC); Egyptian
   Knowledge Bank (EKB); National Research Centre (NRC); Egyptian Knowledge
   Bank (EKB); Al Azhar University
RP El Kady, AM (通讯作者)，Natl Res Ctr, Biomat Dept, 33 El Bohooth St, Cairo 12622, Egypt.
EM abeerelkady_2000@yahoo.co.uk
RI ; Farag, Mohammad/Y 4052 2018
OI El Kady, Abeer/0000 0002 6733 5396; Farag, Mohammad/0000 0001 5069 9030
CR Abed N, 2014, INT J ANTIMICROB AG, V43, P485, DOI 10.1016/j.ijantimicag.2014.02.009
   Arioka M, 2014, BIOCHEM PHARMACOL, V90, P397, DOI 10.1016/j.bcp.2014.06.011
   Ashwanikumar N, 2014, COLLOID SURFACE B, V122, P520, DOI 10.1016/j.colsurfb.2014.07.024
   Cabañas MV, 2009, EUR J PHARM SCI, V37, P249, DOI 10.1016/j.ejps.2009.02.011
   Cerruti MG, 2005, BIOMATERIALS, V26, P4903, DOI 10.1016/j.biomaterials.2005.01.013
   Chiang CY, 2009, DENT MATER, V25, P1022, DOI 10.1016/j.dental.2009.03.001
   Clément Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102
   El Kady AM, 2015, J NANOMATER, V2015, DOI 10.1155/2015/839207
   El Kady AM, 2012, CERAM INT, V38, P1195, DOI 10.1016/j.ceramint.2011.07.069
   El Kady AM, 2012, CERAM INT, V38, P177, DOI 10.1016/j.ceramint.2011.05.158
   El Kady AM, 2010, MAT SCI ENG C MATER, V30, P120, DOI 10.1016/j.msec.2009.09.008
   ElBatal FH, 2008, MATER CHEM PHYS, V110, P352, DOI 10.1016/j.matchemphys.2008.02.011
   ElBatal HA, 2003, MATER CHEM PHYS, V80, P599, DOI 10.1016/S0254 0584(03)00082 8
   Goh YF, 2013, MATER CHEM PHYS, V137, P1031, DOI 10.1016/j.matchemphys.2012.11.022
   Gregory CA, 2006, DRUG NEWS PERSPECT, V19, P445, DOI 10.1358/dnp.2006.19.8.1043960
   Hedgepeth CM, 1997, DEV BIOL, V185, P82, DOI 10.1006/dbio.1997.8552
   HENCH LL, 1991, J AM CERAM SOC, V74, P1487, DOI 10.1111/j.1151 2916.1991.tb07132.x
   HIGUCHI T, 1963, J PHARM SCI, V52, P1145, DOI 10.1002/jps.2600521210
   Hoppe A, 2011, BIOMATERIALS, V32, P2757, DOI 10.1016/j.biomaterials.2011.01.004
   Huh AJ, 2011, J CONTROL RELEASE, V156, P128, DOI 10.1016/j.jconrel.2011.07.002
   Hum J, 2012, J MATER SCI MATER M, V23, P2317, DOI 10.1007/s10856 012 4580 z
   Jones JR, 2013, ACTA BIOMATER, V9, P4457, DOI 10.1016/j.actbio.2012.08.023
   Kaur G, 2014, J BIOMED MATER RES A, V102, P254, DOI 10.1002/jbm.a.34690
   Kavitha R.J., 2014, INT J INNOVATIVE RES, V1, P2347
   Khorami M, 2011, MAT SCI ENG C MATER, V31, P1584, DOI 10.1016/j.msec.2011.07.011
   Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455
   Kokubo T, 2006, BIOMATERIALS, V27, P2907, DOI 10.1016/j.biomaterials.2006.01.017
   Li JJ, 2009, MAT SCI ENG C BIO S, V29, P1207, DOI 10.1016/j.msec.2008.09.038
   Li W, 2014, J EUR CERAM SOC, V34, P505, DOI 10.1016/j.jeurceramsoc.2013.08.032
   Liu GZ, 2009, J CELL BIOL, V185, P67, DOI 10.1083/jcb.200810137
   Luz GM, 2014, TISSUE ENG USING CER, V2, P153
   Miguez Pacheco V., 2015, J NONCRYST SOLIDS
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291
   Noble W, 2005, P NATL ACAD SCI USA, V102, P6990, DOI 10.1073/pnas.0500466102
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Radin S, 2009, BIOMATERIALS, V30, P850, DOI 10.1016/j.biomaterials.2008.09.066
   Rahaman M.N., 2014, Tissue Engineering Using Ceramics and Polymers, VSecond, P67
   Rao TP, 2010, CIRC RES, V106, P1798, DOI 10.1161/CIRCRESAHA.110.219840
   Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593
   RITGER P L, 1987, Journal of Controlled Release, V5, P23, DOI 10.1016/0168 3659(87)90034 4
   Safari J, 2014, J SAUDI CHEM SOC, V18, P85, DOI 10.1016/j.jscs.2012.12.009
   Santos C, 2009, CERAM INT, V35, P1587, DOI 10.1016/j.ceramint.2008.08.015
   Webster TJ, 2004, BIOMATERIALS, V25, P4731, DOI 10.1016/j.biomaterials.2003.12.002
   Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611
   Wong J., 1977, Glass: Structure by Spectroscopy
   Wu CT, 2014, J CONTROL RELEASE, V193, P282, DOI 10.1016/j.jconrel.2014.04.026
   Xia W, 2007, MATER LETT, V61, P3251, DOI 10.1016/j.matlet.2006.11.048
   Zadpoor AA, 2014, MAT SCI ENG C MATER, V35, P134, DOI 10.1016/j.msec.2013.10.026
   Zhang F, 2003, J BIOL CHEM, V278, P33067, DOI 10.1074/jbc.M212635200
   Zhang LF, 2008, MAT SCI ENG C BIO S, V28, P141, DOI 10.1016/j.msec.2007.01.005
   Zhang LJ, 2009, NANO TODAY, V4, P66, DOI 10.1016/j.nantod.2008.10.014
   Zhang Y, 2011, J COLLOID INTERF SCI, V354, P202, DOI 10.1016/j.jcis.2010.10.054
NR 53
TC 46
Z9 47
U1 0
U2 34
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0928 0987
EI 1879 0720
J9 EUR J PHARM SCI
JI Eur. J. Pharm. Sci.
PD AUG 25
PY 2016
VL 91
BP 243
EP 250
DI 10.1016/j.ejps.2016.05.004
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA DU9JE
UT WOS:000382532100029
PM 27155253
DA 2025 08 17
ER

PT J
AU Park, YE
   Bava, U
   Lin, JM
   Cornish, J
   Naot, D
   Reid, IR
AF Park, Young Eun
   Bava, Usha
   Lin, Jian Ming
   Cornish, Jillian
   Naot, Dorit
   Reid, Ian R.
TI Bone Bound Bisphosphonates Inhibit Proliferation of Breast Cancer Cells
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Bisphosphonates; Breast cancer cells; Zoledronates; Bone bound
   zoledronate; MCF7; MDA MB 231
ID NITROGEN CONTAINING BISPHOSPHONATES; S PHASE ARREST; ZOLEDRONIC ACID;
   INDUCE APOPTOSIS; PROSTATE CANCER; LUNG CANCER; 3RD GENERATION
   BISPHOSPHONATE; ADJUVANT BISPHOSPHONATE; POSTMENOPAUSAL WOMEN;
   MEVALONATE PATHWAY
AB Bisphosphonates are used in treating patients with breast cancer. In vitro studies have shown that bisphosphonates act directly on tumour cells, inhibiting cell proliferation and inducing apoptosis. In most such studies, drugs were added to culture media exposing cells to high bisphosphonate concentrations in solution. However, since bisphosphonates bind to bone hydroxyapatite with high affinity and remain bound for very long periods of time, these experimental systems are not an optimal model for the action of the drugs in vivo. The aim of this study was to determine whether bone bound zoledronate has direct effects on adjacent breast cancer cells. Bone slices were pre incubated with bisphosphonate solutions, washed, and seeded with cells of the breast cancer cell lines, MCF7 or MDA MB 231. Proliferation was assessed by cell counts and thymidine incorporation for up to 72 h. Inhibition of the mevalonate pathway was tested by measuring the levels of unprenylated Rap1A, and apoptosis was examined by the presence of cleaved caspase 8 on western blots. The proliferation rate of breast cancer cells on zoledronate treated bone was significantly lower compared to cells on control bone. Other bisphosphonates showed a similar inhibitory effect, with an order of potency similar to their clinical potencies. Unprenylated Rap1A accumulated in MCF7 cells on zoledronate treated bone, suggesting zoledronate acted through the inhibition of the mevalonate pathway. Accumulation of cleaved caspase 8 in MDA MB 231 cells on bisphosphonate treated bone indicated increased apoptosis in the cells. In conclusion, bone bound zoledronate inhibits breast cancer cell proliferation, an activity that may contribute to its clinical anti tumour effects.
C1 [Park, Young Eun; Bava, Usha; Lin, Jian Ming; Cornish, Jillian; Naot, Dorit; Reid, Ian R.] Univ Auckland, Fac Med & Hlth Sci, Dept Med, Private Bag 92019, Auckland, New Zealand.
C3 University of Auckland
RP Reid, IR (通讯作者)，Univ Auckland, Fac Med & Hlth Sci, Dept Med, Private Bag 92019, Auckland, New Zealand.
EM y.park@auckland.ac.nz; u.bava@auckland.ac.nz; j.lin@auckland.ac.nz;
   j.cornish@auckland.ac.nz; d.naot@auckland.ac.nz; i.reid@auckland.ac.nz
OI Reid, Ian/0000 0001 6021 5458; Park, Young Eun/0000 0001 9912 5513;
   Naot, Dorit/0000 0001 9498 2639; Cornish, Jillian/0000 0001 5565 1714
FU Health Research Council of New Zealand [15/576]
FX This study was funded by the Health Research Council of New Zealand
   (Grant 15/576  Reid Mechanisms and Management of Musculoskeletal
   Disease).
CR Aft R, 2010, LANCET ONCOL, V11, P421, DOI 10.1016/S1470 2045(10)70054 1
   [Anonymous], 33 ANN SAN ANT BREAS
   Boissier S, 2000, CANCER RES, V60, P2949
   Boissier S, 1997, CANCER RES, V57, P3890
   Brown JE, 2005, JNCI J NATL CANCER I, V97, P59, DOI 10.1093/jnci/dji002
   Chang J, 2012, ONCOL LETT, V4, P299, DOI 10.3892/ol.2012.723
   Chlebowski Rowan T, 2011, Breast Dis, V33, P93, DOI 10.3233/BD 2010 0324
   Coleman R, 2015, LANCET, V386, P1353, DOI 10.1016/S0140 6736(15)60908 4
   Cornish J, 2011, BONE, V49, P710, DOI 10.1016/j.bone.2011.07.020
   Coxon JP, 2004, BJU INT, V94, P164, DOI 10.1111/j.1464 4096.2004.04831.x
   Dhar Swati, 2010, Cancer Immun, V10, P10
   Di Salvatore M, 2011, CELL PROLIFERAT, V44, P139, DOI 10.1111/j.1365 2184.2011.00745.x
   Eidtmann H, 2010, ANN ONCOL, V21, P2188, DOI 10.1093/annonc/mdq217
   EILON G, 1978, NATURE, V276, P726, DOI 10.1038/276726a0
   Forsea AM, 2004, BRIT J CANCER, V91, P803, DOI 10.1038/sj.bjc.6602052
   Fromigue O, 2000, J BONE MINER RES, V15, P2211, DOI 10.1359/jbmr.2000.15.11.2211
   GALASKO CSB, 1969, BRIT J SURG, V56, P757, DOI 10.1002/bjs.1800561017
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Grey Andrew, 2006, Ther Clin Risk Manag, V2, P77
   Gschwantler Kaulich D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185566
   Guo RT, 2007, P NATL ACAD SCI USA, V104, P10022, DOI 10.1073/pnas.0702254104
   Hiraga T, 2001, CANCER RES, V61, P4418
   Holen I, 2010, CURR PHARM DESIGN, V16, P1262, DOI 10.2174/138161210791034003
   Ibrahim T, 2012, CANCER CELL INT, V12, DOI 10.1186/1475 2867 12 48
   Iguchi T, 2003, CELL SIGNAL, V15, P719, DOI 10.1016/S0898 6568(03)00007 X
   Iorns E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047995
   Jagdev SP, 2001, BRIT J CANCER, V84, P1126, DOI 10.1054/bjoc.2001.1727
   Jiang PF, 2016, ONCOTARGET, V7, P57932, DOI 10.18632/oncotarget.10773
   Koto K, 2010, ONCOL REP, V24, P233, DOI 10.3892/or_00000851
   Koto K, 2009, CANCER LETT, V274, P271, DOI 10.1016/j.canlet.2008.09.026
   Kuiper JWP, 2012, BRIT J PHARMACOL, V165, P532, DOI 10.1111/j.1476 5381.2011.01592.x
   Lambrinoudaki I, 2008, CLIN INTERV AGING, V3, P445, DOI 10.2147/CIA.S2046
   Lan YC, 2013, ANTICANCER RES, V33, P3807
   Lehenkari PP, 2002, MOL PHARMACOL, V61, P1255, DOI 10.1124/mol.61.5.1255
   Li YY, 2008, LUNG CANCER, V59, P180, DOI 10.1016/j.lungcan.2007.08.026
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   Liu J, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002014
   Mansouri M, 2014, BIOCHIMIE, V99, P71, DOI 10.1016/j.biochi.2013.11.010
   Manzano Moreno FJ, 2015, J CRANIO MAXILL SURG, V43, P396, DOI 10.1016/j.jcms.2014.12.008
   Matsumoto S, 2005, LUNG CANCER, V47, P31, DOI 10.1016/j.lungcan.2004.06.003
   Mauri D, 2010, J NATL COMPR CANC NE, V8, P279, DOI 10.6004/jnccn.2010.0020
   Merrell MA, 2007, EUR J PHARMACOL, V570, P27, DOI 10.1016/j.ejphar.2007.05.075
   Miwa S, 2005, CANCER RES, V65, P8818, DOI 10.1158/0008 5472.CAN 05 0540
   Mullen PJ, 2016, NAT REV CANCER, V16, P718, DOI 10.1038/nrc.2016.76
   Muller S, 2005, ANTICANCER RES, V25, P2655
   Mystakidou K, 2005, MED ONCOL, V22, P195, DOI 10.1385/MO:22:2:195
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Neville Webbe HL, 2010, BRIT J CANCER, V102, P1010, DOI 10.1038/sj.bjc.6605579
   Ohnuki H, 2012, ARCH ORAL BIOL, V57, P906, DOI 10.1016/j.archoralbio.2011.11.015
   Okamoto S, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.475
   Ory B, 2007, MOL PHARMACOL, V71, P333, DOI 10.1124/mol.106.028837
   Rack B, 2010, ANTICANCER RES, V30, P1807
   Reid IR, 2018, NEW ENGL J MED, V379, P2407, DOI 10.1056/NEJMoa1808082
   Reid IR, 2002, NEW ENGL J MED, V346, P653, DOI 10.1056/NEJMoa011807
   Rizzoli R, 2011, QJM INT J MED, V104, P281, DOI 10.1093/qjmed/hcq259
   Romani AA, 2009, BIOCHEM PHARMACOL, V78, P133, DOI 10.1016/j.bcp.2009.04.004
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Senaratne SG, 2002, BRIT J CANCER, V86, P1479, DOI 10.1038/sj.bjc.6600297
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   Stresing V, 2007, CANCER LETT, V257, P16, DOI 10.1016/j.canlet.2007.07.007
   Suva LJ, 2009, ENDOCR RELAT CANCER, V16, P703, DOI 10.1677/ERC 09 0012
   Tamura T, 2011, ONCOL REP, V25, P1139, DOI 10.3892/or.2011.1152
   Tevaarwerk A, 2007, J CLIN ONCOL, V25
   Valachis A, 2013, ONCOLOGIST, V18, P353, DOI 10.1634/theoncologist.2012 0261
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   vanderPluijm G, 1996, J CLIN INVEST, V98, P698, DOI 10.1172/JCI118841
   Zekri J, 2014, J BONE ONCOL, V3, P25, DOI 10.1016/j.jbo.2013.12.001
   Zhang Y, 2006, J MED CHEM, V49, P5804, DOI 10.1021/jm060280e
NR 68
TC 6
Z9 6
U1 0
U2 16
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD NOV
PY 2019
VL 105
IS 5
BP 497
EP 505
DI 10.1007/s00223 019 00590 5
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA JD9ES
UT WOS:000490290100005
PM 31324954
DA 2025 08 17
ER

PT J
AU Kaminogo, K
   Yamaguchi, S
   Chen, H
   Yagita, H
   Toyama, N
   Urata, Y
   Hibi, H
AF Kaminogo, Kento
   Yamaguchi, Satoshi
   Chen, Hui
   Yagita, Hideo
   Toyama, Naoto
   Urata, Yusuke
   Hibi, Hideharu
TI Preventive Effects of Dental Pulp Stem Cell conditioned Media on
   Anti RANKL Antibody Related Osteonecrosis of the Jaw
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Medication related osteonecrosis of the jaw; Denosumab related
   osteonecrosis of the jaw; Dental pulp stem cell conditioned media;
   Anti RANKL antibody
ID BISPHOSPHONATE RELATED OSTEONECROSIS; MEDICATION RELATED OSTEONECROSIS;
   BENEFITS; DISEASE
AB Medication related osteonecrosis of the jaw is a serious disease occurring in patients with cancer and osteoporosis, who are undergoing treatment with antiresorptive agents (ARAs) such as bisphosphonate (BP) or denosumab, an antibody targeting receptor activator of NF kappa B ligand. Recently, stem cell based therapy has been shown to be effective in preventing the development of bisphosphonate related osteonecrosis of the jaw. However, studies on denosumab related osteonecrosis of the jaw (DRONJ) remain limited. Here, the efficacy of treatment with dental pulp stem cell conditioned media (DPSC CM) in preventing DRONJ in a murine model was evaluated. Local administration of DPSC CM into the extraction socket of a mouse with DRONJ decreased the number of empty osteocyte lacunae and the prevalence of ONJ. In tissues surrounding the extraction sockets in the DPSC CM treated group, the expression of inflammatory cytokines was attenuated and that of osteogenesis related molecules was enhanced compared to that in the control group. Further, the expression of Wnt signaling molecules, which had been suppressed, was improved. These findings collectively suggest that DPSC CM prevents ONJ development in a murine DRONJ model.
C1 [Kaminogo, Kento; Yamaguchi, Satoshi; Chen, Hui; Toyama, Naoto; Hibi, Hideharu] Nagoya Univ, Dept Oral & Maxillofacial Surg, Grad Sch Med, 65 Tsurumai Cho,Showa Ku, Nagoya, Aichi 4668550, Japan.
   [Yagita, Hideo] Juntendo Univ, Sch Med, Dept Immunol, Tokyo, Japan.
   [Toyama, Naoto] Iwata City Hosp, Dept Oral & Maxillofacial Surg, Iwata, Japan.
   [Urata, Yusuke; Hibi, Hideharu] Nagoya Univ Hosp, Dept Oral & Maxillofacial Surg, Nagoya, Japan.
C3 Nagoya University; Juntendo University; Nagoya University
RP Yamaguchi, S (通讯作者)，Nagoya Univ, Dept Oral & Maxillofacial Surg, Grad Sch Med, 65 Tsurumai Cho,Showa Ku, Nagoya, Aichi 4668550, Japan.
EM syamaguchi@med.nagoya u.ac.jp
RI ; Yagita, Hideo/AEX 0830 2022; Hibi, Hideharu/E 4443 2015
OI Yamaguchi, Satoshi/0000 0003 2691 7100; Kaminogo,
   Kento/0000 0003 3009 9833
FU Nagoya University; Department of Immunology, Faculty of Medicine and
   Graduate School of Medicine
FX The authors thank Yuka Tanno from the Department of Immunology, Faculty
   of Medicine and Graduate School of Medicine, Juntendo University, for
   her technical guidance. The authors would also like to thank the
   Division for Medical Research Engineering, Nagoya University Graduate
   School of Medicine, for the use of their micro CT, fluorescence
   microscopy, and real time PCR facilities.
CR Aguirre JI, 2021, BONE, V153, DOI 10.1016/j.bone.2021.116184
   Ferreira VCD, 2021, CLIN ORAL INVEST, V25, P673, DOI 10.1007/s00784 020 03551 7
   de Sousa VC, 2022, BONE, V164, DOI 10.1016/j.bone.2022.116523
   Fujio M, 2017, J TISSUE ENG REGEN M, V11, P2116, DOI 10.1002/term.2109
   Hanyu S, 2019, J HARD TISSUE BIOL, V28, P281, DOI 10.2485/jhtb.28.281
   Hayano H, 2020, BONE, V135, DOI 10.1016/j.bone.2020.115308
   He LN, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368 020 00093 2
   Hirata M, 2016, STEM CELL TRANSL MED, V5, P1416, DOI 10.5966/sctm.2015 0353
   Hokugo A, 2019, BONE, V123, P115, DOI 10.1016/j.bone.2019.03.027
   Houschyar KS, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00170
   Ishikawa J, 2016, BONE, V83, P210, DOI 10.1016/j.bone.2015.11.012
   Ito S, 2022, BONE REP, V16, DOI 10.1016/j.bonr.2022.101522
   Kamijo S, 2006, BIOCHEM BIOPH RES CO, V347, P124, DOI 10.1016/j.bbrc.2006.06.098
   Kikuiri T, 2010, J BONE MINER RES, V25, P1668, DOI 10.1002/jbmr.37
   Kuroshima S, 2019, J ORAL BIOSCI, V61, P99, DOI 10.1016/j.job.2019.03.005
   Kuroshima S, 2016, CLIN ORAL INVEST, V20, P727, DOI 10.1007/s00784 015 1550 0
   Liu JQ, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392 021 00762 6
   Marx P., 2003, SOC THOUGHT, V5, P1, DOI [10.1080/15426432.1979.10383302, DOI 10.1080/15426432.1979.10383302]
   Miller Paul D, 2009, Curr Osteoporos Rep, V7, P18
   Ogata K, 2015, BONE, V74, P95, DOI 10.1016/j.bone.2015.01.011
   Oh JS, 2017, BRAZ ORAL RES, V31, DOI 10.1590/1807 3107bor 2017.vol31.0099
   Ohara G, 2023, J ORAL PATHOL MED, V52, P718, DOI 10.1111/jop.13457
   Park S, 2015, J BIOL CHEM, V290, P17349, DOI 10.1074/jbc.M115.652305
   Pinzone JJ, 2009, BLOOD, V113, P517, DOI 10.1182/blood 2008 03 145169
   Ruggiero SL, 2022, J ORAL MAXIL SURG, V80, P920, DOI 10.1016/j.joms.2022.02.008
   Sakai K, 2012, J CLIN INVEST, V122, P80, DOI 10.1172/JCI59251
   Shimojima C, 2016, J IMMUNOL, V196, P4164, DOI 10.4049/jimmunol.1501457
   Srivichit B, 2022, ARCH TOXICOL, V96, P1227, DOI 10.1007/s00204 021 03220 y
   Sun YJ, 2016, J BIOL CHEM, V291, P20602, DOI 10.1074/jbc.M116.735795
   Takegahara N, 2022, BONE, V159, DOI 10.1016/j.bone.2022.116353
   Tanahashi Y, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020926
   Taylor KH, 2010, BRIT J ORAL MAX SURG, V48, P221, DOI 10.1016/j.bjoms.2009.08.030
   Wang MH, 2020, DIFFERENTIATION, V111, P1, DOI 10.1016/j.diff.2019.10.003
   Watanabe J, 2020, J DENT RES, V99, P552, DOI 10.1177/0022034520906793
   Williams DW, 2014, AM J PATHOL, V184, P3084, DOI 10.1016/j.ajpath.2014.07.010
   Yamaguchi S, 2015, SCI REP UK, V5, DOI 10.1038/srep16295
   Zhang RR, 2013, BONE, V52, P145, DOI 10.1016/j.bone.2012.09.029
NR 37
TC 0
Z9 0
U1 1
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD AUG
PY 2024
VL 115
IS 2
BP 185
EP 195
DI 10.1007/s00223 024 01232 1
EA MAY 2024
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA YZ7M4
UT WOS:001234549200001
PM 38809297
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Yang, ML
   Wang, F
   Lu, GH
   Cheng, MZ
   Zhao, W
   Zou, CY
AF Yang, Meiling
   Wang, Fen
   Lu, Guohao
   Cheng, Mingzhe
   Zhao, Wei
   Zou, Changye
TI Single cell transcriptome analysis reveals T cell exhaustion in
   denosumab treated giant cell tumor of bone
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE Denosumab; giant cell tumor of bone; T cell exhaustion; periostin;
   single cell RNA seq; RANKL
ID FACTOR FAMILY MEMBER; RECEPTOR ACTIVATOR; POOR PROGNOSIS; UP REGULATION;
   OPEN LABEL; KAPPA B; PERIOSTIN; LIGAND; EXPRESSION; OSTEOCLAST
AB Denosumab (DMAB), a human monoclonal antibody against the receptor activator of the nuclear factor kappa B ligand, is used for the treatment for unresectable giant cell tumor of bone (GCTB). However, little is known about the molecular and functional characteristics of GCTB infiltrating lymphocytes after DMAB treatment. Here, we performed single cell RNA sequencing and immunostaining assays to delineate the immune landscape of GCTB in the presence and absence of DMAB. We found that exhausted CD8(+) T cells were preferentially enriched in DMAB treated GCTB. A distinct M2 skewed type of tumor associated macrophages (TAMs) comprises the majority of GCTB TAMs. We identified cytokines, including interleukin 10, and inhibitory receptors of M2 TAMs as important mediators of CD8(+) T cell exhaustion. We further revealed that DMAB treatment notably increased the expression levels of periostin (POSTN) in GCTB cells. Furthermore, POSTN expression was transcriptionally regulated by c FOS signaling and correlated with GCTB recurrence in patients after DMAB treatment. Collectively, our findings reveal that CD8(+) T cells undergo unappreciated exhaustion during DMAB therapy and that GCTB cell derived POSTN educates TAMs and establishes a microenvironmental niche that facilitates GCTB recurrence.
C1 [Yang, Meiling; Zhao, Wei] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangdong Cardiovasc Inst, Guangzhou, Peoples R China.
   [Wang, Fen] Sun Yat Sen Univ, Affiliated Hosp 1, Pathol Dept, Guangzhou, Peoples R China.
   [Lu, Guohao; Zhao, Wei] Sun Yat Sen Univ, Key Lab Stem Cells & Tissue Engn, Minist Educ, Guangzhou, Peoples R China.
   [Cheng, Mingzhe; Zou, Changye] Sun Yat Sen Univ, Affiliated Hosp 1, Musculoskeletal Oncol Dept, Guangzhou, Peoples R China.
C3 Southern Medical University   China; Guangdong Academy of Medical
   Sciences & Guangdong General Hospital; Sun Yat Sen University; Sun Yat
   Sen University; Sun Yat Sen University
RP Zhao, W (通讯作者)，Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangdong Cardiovasc Inst, Guangzhou, Peoples R China.; Zhao, W (通讯作者)，Sun Yat Sen Univ, Key Lab Stem Cells & Tissue Engn, Minist Educ, Guangzhou, Peoples R China.; Zou, CY (通讯作者)，Sun Yat Sen Univ, Affiliated Hosp 1, Musculoskeletal Oncol Dept, Guangzhou, Peoples R China.
EM zhaowei23@mail.sysu.edu.cn; zouchy@mail.sysu.edu.cn
RI ; Yang, Meiling/ITR 9206 2023
OI Yang, Meiling/0000 0002 5763 2741; 
FU National Natural Science Foundation of China [81972507, 81972651,
   82172698]; CSCO GCT research Project [Y 2020GCT 003]
FX This work was supported by the National Natural Science Foundation of
   China (81972507, 81972651, and 82172698), and CSCO GCT research Project
   (Y 2020GCT 003).
CR Agarwal MG, 2018, CLIN ORTHOP RELAT R, V476, P1773, DOI 10.1007/s11999.0000000000000243
   Ahern E, 2018, NAT REV CLIN ONCOL, V15, P676, DOI 10.1038/s41571 018 0095 y
   Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Aponte Tinao LA, 2015, CLIN ORTHOP RELAT R, V473, P3050, DOI 10.1007/s11999 015 4249 2
   Atkins GJ, 2006, J BONE MINER RES, V21, P1339, DOI 10.1359/JBMR.060604
   Azizi E, 2018, CELL, V174, P1293, DOI 10.1016/j.cell.2018.05.060
   Bachmann MF, 1999, J EXP MED, V189, P1025, DOI 10.1084/jem.189.7.1025
   Bi K, 2021, CANCER CELL, V39, P649, DOI 10.1016/j.ccell.2021.02.015
   Chawla S, 2019, LANCET ONCOL, V20, P1719, DOI 10.1016/S1470 2045(19)30663 1
   Chawla S, 2013, LANCET ONCOL, V14, P901, DOI 10.1016/S1470 2045(13)70277 8
   Cheng ML, 2014, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00329
   Cheng SJ, 2021, CELL, V184, P792, DOI 10.1016/j.cell.2021.01.010
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Errani C, 2018, J BONE JOINT SURG AM, V100, P496, DOI 10.2106/JBJS.17.00057
   Feng WY, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.715552
   Gómez Aleza C, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 20138 8
   González González L, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00225
   Hao YH, 2021, CELL, V184, P3573, DOI 10.1016/j.cell.2021.04.048
   Hu F, 2016, INT J EXP PATHOL, V97, P86, DOI 10.1111/iep.12171
   Hu WX, 2016, CELL PHYSIOL BIOCHEM, V38, P1199, DOI 10.1159/000443068
   Huang L, 2000, AM J PATHOL, V156, P761, DOI 10.1016/S0002 9440(10)64942 5
   Huang R, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.19
   Jin SZ, 2020, CELL RES, V30, P950, DOI 10.1038/s41422 020 00402 8
   Jin SQ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 21246 9
   Josien R, 2000, J EXP MED, V191, P495, DOI 10.1084/jem.191.3.495
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Leibbrandt A, 2008, ANN NY ACAD SCI, V1143, P123, DOI 10.1196/annals.1443.016
   Lincoln V, 2021, EXP DERMATOL, V30, P698, DOI 10.1111/exd.14281
   Liu Y, 2016, TUMOR BIOL, V37, P15283, DOI 10.1007/s13277 016 5321 6
   Lu B, 2021, ADV SCI, V8, DOI 10.1002/advs.202101895
   Maynard A, 2020, CELL, V182, P1232, DOI 10.1016/j.cell.2020.07.017
   Müller S, 2017, GENOME BIOL, V18, DOI 10.1186/s13059 017 1362 4
   Noh BJ, 2018, HUM PATHOL, V81, P1, DOI 10.1016/j.humpath.2018.06.017
   Qiu XJ, 2017, NAT METHODS, V14, P979, DOI [10.1038/NMETH.4402, 10.1038/nmeth.4402]
   Qiu XJ, 2017, NAT METHODS, V14, P309, DOI [10.1038/NMETH.4150, 10.1038/nmeth.4150]
   Ratajczak Wielgomas K, 2017, INT J ONCOL, V51, P1300, DOI 10.3892/ijo.2017.4109
   Roux S, 2002, AM J CLIN PATHOL, V117, P210
   Ryner L, 2015, CLIN CANCER RES, V21, P2941, DOI 10.1158/1078 0432.CCR 14 3111
   Sun YF, 2021, CELL, V184, P404, DOI 10.1016/j.cell.2020.11.041
   Sung PL, 2016, ONCOTARGET, V7, P4036, DOI 10.18632/oncotarget.6700
   Thomas D, 2010, LANCET ONCOL, V11, P275, DOI 10.1016/S1470 2045(10)70010 3
   Trapnell C, 2014, NAT BIOTECHNOL, V32, P381, DOI 10.1038/nbt.2859
   van der Heijden L, 2017, EUR J CANCER, V77, P75, DOI 10.1016/j.ejca.2017.02.021
   Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862
   Wiethe C, 2003, J IMMUNOL, V171, P4121, DOI 10.4049/jimmunol.171.8.4121
   Zhang QM, 2019, CELL, V179, P829, DOI 10.1016/j.cell.2019.10.003
   Zhang W, 2022, NEOPLASMA, V69, P491, DOI 10.4149/neo_2021_211025N1521
   Zheng LT, 2021, SCIENCE, V374, P1462, DOI 10.1126/science.abe6474
   Zhou Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 20059 6
NR 49
TC 6
Z9 6
U1 0
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD SEP 12
PY 2022
VL 13
AR 934078
DI 10.3389/fimmu.2022.934078
PG 14
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA 4Y5YD
UT WOS:000861602300001
PM 36172351
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Falconi, G
   Fabiani, E
   Fianchi, L
   Criscuolo, M
   Raffaelli, CS
   Bellesi, S
   Hohaus, S
   Voso, MT
   D'Alò, F
   Leone, G
AF Falconi, Giulia
   Fabiani, Emiliano
   Fianchi, Luana
   Criscuolo, Marianna
   Raffaelli, Chiara Spertilli
   Bellesi, Silvia
   Hohaus, Stefan
   Voso, Maria Teresa
   D'Alo, Francesco
   Leone, Giuseppe
TI Impairment of PI3K/AKT and WNT/β catenin pathways in bone marrow
   mesenchymal stem cells isolated from patients with myelodysplastic
   syndromes
SO EXPERIMENTAL HEMATOLOGY
LA English
DT Article
ID STROMAL CELLS; ROLES; DIFFERENTIATION; SENESCENCE; EXPRESSION; GSK 3;
   NICHE
AB Bone marrow mesenchymal stem cells (BM MSCs) exhibit multiple abnormalities in myelodysplastic syndromes (MDS), including impaired proliferative and clonogenic capacity, altered morphology, increased senescence, impaired immunoregulatory properties, and reduced hematopoietic support capacity. Common signaling pathways, such as PI3K/AKT and WNT/beta catenin, regulate multiple MSC properties, including proliferation, differentiation, and cell cell interaction. Here, with polymerase chain reaction arrays, we investigated the expression of 84 genes belonging to the PI3K/AKT signaling pathways in BM MSCs isolated from patients with MDS, acute myeloid leukemia, and therapy related myeloid neoplasms, using as a control BM MSCs isolated from patients with untreated early stage lymphomas without BM involvement. Statistically significant downregulation of GSK3 beta, SOS1, RASA1, and MTCP1 gene expression was observed in BM MSCs isolated from patients with de novo MDS, as compared with controls. Moreover, expression of the GSK3 beta protein was reduced in MDS derived MSCs, and was associated with concomitant reduction of phosphorylation at Ser 9. The role of GSK3 beta in the downstream WNT/beta catenin signaling pathway was assessed. We investigated beta catenin protein levels and expression of 84 genes belonging to the WNT target gene pathway using PCR arrays in MDS BM MSCs, as compared with control BM MSCs. GSK3 beta impairment translated into decreased beta catenin protein levels and downregulation of several WNT/beta catenin target genes (SOX9, EGR1, WISP1). These findings suggest that deregulation of genes involved in the PI3K/AKT and WNT signaling pathways may contribute to the phenotypical abnormalities of MDS BM MSCs. Copyright (C) 2016 ISEH   International Society for Experimental Hematology. Published by Elsevier Inc.
C1 [Falconi, Giulia; Fabiani, Emiliano; Fianchi, Luana; Criscuolo, Marianna; Raffaelli, Chiara Spertilli; Bellesi, Silvia; Hohaus, Stefan; D'Alo, Francesco; Leone, Giuseppe] Univ Cattolica Sacro Cuore, Inst Hematol, I 00168 Rome, Italy.
   [Voso, Maria Teresa] Univ Roma Tor Vergata, Dept Biomed & Prevent, Rome, Italy.
C3 Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   University of Rome Tor Vergata
RP D'Alò, F (通讯作者)，Univ Cattolica Sacro Cuore, Inst Hematol, I 00168 Rome, Italy.
EM fdalo@rm.unicatt.it
RI Hohaus, Stefan/K 9718 2016; Leone, Giuseppe/I 9166 2019; FALCONI,
   giulia/AAB 7670 2019; CRISCUOLO, Marianna/LNR 0511 2024; Fabiani,
   Emiliano/AAP 7934 2020; Bellesi, Silvia/LQL 2558 2024; D'Alò,
   Francesco/LDI 6746 2024; Voso, Maria Teresa/F 1172 2014; VOSO, Maria
   Teresa/F 1172 2014
OI D'ALO', Francesco/0000 0003 3576 8522; Bellesi,
   Silvia/0000 0001 7400 1215; Fianchi, Luana/0000 0002 7113 7202; FABIANI,
   Emiliano/0000 0002 6209 8934; VOSO, Maria Teresa/0000 0002 6164 4761
FU Associazione Italiana per la Ricerca sul Cancro (AIRC)
FX This study was supported by Investigator Grant 2011, Code 11486, from
   the Associazione Italiana per la Ricerca sul Cancro (AIRC).
CR Aanei CM, 2012, STEM CELLS DEV, V21, P1604, DOI 10.1089/scd.2011.0390
   Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802
   Baksh D, 2007, J CELL PHYSIOL, V212, P817, DOI 10.1002/jcp.21080
   Blau O, 2011, BLOOD, V118, P5583, DOI 10.1182/blood 2011 03 343467
   Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284
   Bulycheva E, 2015, LEUKEMIA, V29, P259, DOI 10.1038/leu.2014.325
   Chen J, 2013, TISSUE ENG PART B RE, V19, P516, DOI [10.1089/ten.teb.2012.0672, 10.1089/ten.TEB.2012.0672]
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Fabiani E, 2014, EXP HEMATOL, V42, P731, DOI 10.1016/j.exphem.2014.04.011
   Fei CM, 2014, EUR J HAEMATOL, V93, P476, DOI 10.1111/ejh.12385
   Geyh S, 2013, LEUKEMIA, V27, P1841, DOI 10.1038/leu.2013.193
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   James AW, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/684736
   Kim M, 2015, PLOS ONE, V10
   Kode A, 2014, NATURE, V506, P240, DOI 10.1038/nature12883
   McCubrey JA, 2014, LEUKEMIA, V28, P15, DOI 10.1038/leu.2013.184
   McCubrey James A., 2014, Advances in Biological Regulation, V54, P176, DOI 10.1016/j.jbior.2013.09.013
   Medyouf H, 2014, CELL STEM CELL, V14, P824, DOI 10.1016/j.stem.2014.02.014
   Pavlaki K, 2014, STEM CELLS DEV, V23, P1568, DOI 10.1089/scd.2013.0283
   Poloni A, 2014, LEUKEMIA, V28, P2241, DOI 10.1038/leu.2014.197
   Raaijmakers MHGP, 2010, NATURE, V464, P852, DOI 10.1038/nature08851
   Santamaría C, 2012, HAEMATOL HEMATOL J, V97, P1218, DOI 10.3324/haematol.2011.054437
   Schlegelmilch K, 2014, GENE, V551, P243, DOI 10.1016/j.gene.2014.09.002
   Spaapen F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058083
   Sun Y, 2012, NAT MED, V18, P1359, DOI 10.1038/nm.2890
   Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178
   Trimboli AJ, 2009, NATURE, V461, P1084, DOI 10.1038/nature08486
   Vardiman JW, 2002, BLOOD, V100, P2292, DOI 10.1182/blood 2002 04 1199
   Zhao YS, 2015, HAEMATOLOGICA, V100, P194, DOI 10.3324/haematol.2014.109769
   Zhao ZG, 2012, CANCER LETT, V317, P136, DOI 10.1016/j.canlet.2011.08.030
NR 30
TC 45
Z9 51
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0301 472X
EI 1873 2399
J9 EXP HEMATOL
JI Exp. Hematol.
PD JAN
PY 2016
VL 44
IS 1
BP 75
EP 83
DI 10.1016/j.exphem.2015.10.005
PG 9
WC Hematology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology; Research & Experimental Medicine
GA CZ0HJ
UT WOS:000366785400009
PM 26521017
OA Bronze
DA 2025 08 17
ER

PT J
AU Fitri, AR
   Pavasant, P
   Chamni, S
   Sumrejkanchanakij, P
AF Fitri, Atika Resti
   Pavasant, Prasit
   Chamni, Supakarn
   Sumrejkanchanakij, Piyamas
TI Asiaticoside induces osteogenic differentiation of human periodontal
   ligament cells through the Wnt pathway
SO JOURNAL OF PERIODONTOLOGY
LA English
DT Article
DE DMP1 protein, human; osteogenesis; periodontal ligament; regeneration;
   triterpenes; Wnt signal transduction
ID MESENCHYMAL STEM CELLS; DENTAL FOLLICLE CELLS; CENTELLA ASIATICA;
   BETA CATENIN; MOUSE TEETH; BONE; DKK1; SIALOPHOSPHOPROTEIN; EXPRESSION;
   REGULATOR
AB Background: Asiaticoside is a compound isolated from Herb Centella asiatica, which has been shown to promote osteogenic differentiation of human periodontal ligament (hPDL) cells. This study investigated the molecular mechanism underlying the asiaticoside induced osteogenic differentiation of hPDL cells.
   Methods: hPDL cells were incubated with various concentrations of asiaticoside to test cell viability by MTT assay. The mRNA expression levels were analyzed by using quantitative real time polymerase chain reaction (PCR). Osteogenic differentiation was determined by alkaline phosphatase activity assay and alizarin red staining. The subcellular localization of beta catenin was analyzed by both immunofluorescence and western blot.
   Results: The results showed that asiaticoside had no effect on the cell viability at any of the tested concentrations. Real time PCR revealed that osterix (OSX) and dentin matrix protein1 (DMP1) mRNA were significantly enhanced by asiaticoside treatment. Alkaline phosphatase activity and in vitro mineralization were also significantly induced. Interestingly, asiaticoside dose dependently increased WNT3A mRNA expression, but not WNT5A and WNT10B. The activation of Wnt signaling was shown to result in nuclear accumulation of beta catenin as evaluated by immunofluorescence staining and western blot analysis. Pre treatment with recombinant human Dickkopf1 (rhDKK1) inhibited asiaticoside induced beta caten in nuclear translocation and osteoblast marker gene expression. Moreover, rhDKK1 attenuated asiaticoside induced DMP1 protein expression.
   Conclusion: The data demonstrate that asiaticoside induces osteogenic differentiation of hPDL cells by activating the Wnt/beta catenin signaling pathway. The findings suggest that asiaticoside could be used as a novel therapeutic drug for periodontal tissue regeneration.
C1 [Fitri, Atika Resti; Pavasant, Prasit; Sumrejkanchanakij, Piyamas] Chulalongkorn Univ, Fac Dent, Mineralized Tissue Res Unit, Bangkok, Thailand.
   [Pavasant, Prasit; Sumrejkanchanakij, Piyamas] Chulalongkorn Univ, Fac Dent, Dept Anat, Henri Dunant Rd, Bangkok 10330, Thailand.
   [Chamni, Supakarn] Chulalongkorn Univ, Fac Pharmaceut Sci, Dept Pharmacognosy & Pharmaceut Bot, Bangkok, Thailand.
C3 Chulalongkorn University; Chulalongkorn University; Chulalongkorn
   University
RP Sumrejkanchanakij, P (通讯作者)，Chulalongkorn Univ, Fac Dent, Dept Anat, Henri Dunant Rd, Bangkok 10330, Thailand.
EM piyamas.s@chula.ac.th
RI ; Fitri, Atika/AAU 5441 2020
OI Fitri, Atika Resti/0000 0002 4858 4493; 
FU Faculty Research Grant, Faculty of Dentistry, Chulalongkorn University
   [DRF59018]; Ratchadaphisek Sompoch Endowment Fund of Chulalongkorn
   University [CU 56 334 HR]; National Science and Technology Development
   Agency (NSTDA); Graduate School, Chulalongkorn University
FX This study was supported by the Faculty Research Grant, Faculty of
   Dentistry, Chulalongkorn University (DRF59018) to P.S., the
   Ratchadaphisek Sompoch Endowment Fund 2013 of Chulalongkorn University
   (CU 56 334 HR) to S.C and P.P. and the Research Chair Grant 2012 from
   the National Science and Technology Development Agency (NSTDA). The
   Scholarship from the Graduate School, Chulalongkorn University to
   commemorate 72nd Anniversary of his Majesty King Bhumibol Adulyadej is
   gratefully acknowledged. The authors thank Assoc. Prof. Dr. Thanaphum
   Osathanon (Department of Anatomy, Chulalongkorn University) for the
   helpful comments and editing of the manuscript. The authors declare no
   potential conflicts of interest with respect to the authorship and/or
   publication of this article.
CR Augustin JM, 2011, PHYTOCHEMISTRY, V72, P435, DOI 10.1016/j.phytochem.2011.01.015
   Bylka W, 2014, PHYTOTHER RES, V28, P1117, DOI 10.1002/ptr.5110
   Cawthorn WP, 2012, BONE, V50, P477, DOI 10.1016/j.bone.2011.08.010
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Feng JQ, 2003, J DENT RES, V82, P776, DOI 10.1177/154405910308201003
   Gohil KJ, 2010, INDIAN J PHARM SCI, V72, P546, DOI 10.4103/0250 474X.78519
   Han NN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088890
   Hayrapetyan A, 2015, TISSUE ENG PART B RE, V21, P75, DOI [10.1089/ten.teb.2014.0119, 10.1089/ten.TEB.2014.0119]
   James JT, 2009, MOLECULES, V14, P3922, DOI 10.3390/molecules14103922
   Kao RT, 2009, PERIODONTOL 2000, V50, P127, DOI 10.1111/j.1600 0757.2008.00287.x
   Kim JH, 2013, THER ADV MUSCULOSKEL, V5, P13, DOI 10.1177/1759720X12466608
   Kramer I, 2010, MOL CELL BIOL, V30, P3071, DOI 10.1128/MCB.01428 09
   Lee JH, 2012, PHYTOMEDICINE, V19, P1223, DOI 10.1016/j.phymed.2012.08.002
   Lerner UH, 2015, J INTERN MED, V277, P630, DOI 10.1111/joim.12368
   Lim WH, 2014, J PERIODONTAL RES, V49, P751, DOI 10.1111/jre.12158
   Lim WH, 2014, AM J ORTHOD DENTOFAC, V146, P337, DOI 10.1016/j.ajodo.2014.05.027
   Ling YF, 2005, J BONE MINER RES, V20, P2169, DOI 10.1359/JBMR.050815
   Liu GZ, 2009, J CELL BIOL, V185, P67, DOI 10.1083/jcb.200810137
   Liu N, 2011, J BONE MINER RES, V26, P2082, DOI 10.1002/jbmr.440
   Liu Q, 2015, SCI REP UK, V5, DOI 10.1038/srep13142
   Lu J, 2016, ACTA ODONTOL SCAND, V74, P217, DOI 10.3109/00016357.2015.1090011
   Mak W, 2009, CALCIFIED TISSUE INT, V85, P538, DOI 10.1007/s00223 009 9303 1
   Mikels AJ, 2006, ONCOGENE, V25, P7461, DOI 10.1038/sj.onc.1210053
   Monroe DG, 2012, GENE, V492, P1, DOI 10.1016/j.gene.2011.10.044
   Moses T, 2014, CRIT REV BIOCHEM MOL, V49, P439, DOI 10.3109/10409238.2014.953628
   Nemoto E, 2016, J PERIODONTAL RES, V51, P164, DOI 10.1111/jre.12294
   Niida A, 2004, ONCOGENE, V23, P8520, DOI 10.1038/sj.onc.1207892
   Nowwarote N, 2013, PHYTOTHER RES, V27, P457, DOI 10.1002/ptr.4742
   Osathanon T, 2013, J BIOMED MATER RES A, V101, P358, DOI 10.1002/jbm.a.34332
   Pedersen L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025550
   Sreenath T, 2003, J BIOL CHEM, V278, P24874, DOI 10.1074/jbc.M303908200
   Sumrejkanchanakij P, 2003, ONCOGENE, V22, P8723, DOI 10.1038/sj.onc.1206870
   Suzuki S, 2012, ARCH ORAL BIOL, V57, P1165, DOI 10.1016/j.archoralbio.2012.03.005
   Tang B, 2011, ARCH DERMATOL RES, V303, P563, DOI 10.1007/s00403 010 1114 8
   Tang Y, 2014, J DENT RES, V93, P175, DOI 10.1177/0022034513512507
   Yang YL, 2014, BONE, V63, P158, DOI 10.1016/j.bone.2014.03.006
   Ye L, 2004, J BIOL CHEM, V279, P19141, DOI 10.1074/jbc.M400490200
   Yin ZJ, 2015, BEHAV BRAIN RES, V292, P288, DOI 10.1016/j.bbr.2015.06.024
   Zhang R, 2013, INT J BIOL SCI, V9, P228, DOI 10.7150/ijbs.5476
   Zhou H, 2009, DEVELOPMENT, V136, P427, DOI 10.1242/dev.027706
NR 40
TC 31
Z9 31
U1 1
U2 18
PU AMER ACAD PERIODONTOLOGY
PI CHICAGO
PA 737 NORTH MICHIGAN AVENUE, SUITE 800, CHICAGO, IL 60611 2690 USA
SN 0022 3492
EI 1943 3670
J9 J PERIODONTOL
JI J. Periodont.
PD MAY
PY 2018
VL 89
IS 5
BP 596
EP 605
DI 10.1002/JPER.17 0471
PG 10
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA GI1MT
UT WOS:000434135300012
PM 29520784
DA 2025 08 17
ER

PT J
AU Arnsdorf, EJ
   Tummala, P
   Jacobs, CR
AF Arnsdorf, Emily J.
   Tummala, Padmaja
   Jacobs, Christopher R.
TI Non Canonical Wnt Signaling and N Cadherin Related β Catenin Signaling
   Play a Role in Mechanically Induced Osteogenic Cell Fate
SO PLOS ONE
LA English
DT Article
AB Background: Understanding how the mechanical microenvironment influences cell fate, and more importantly, by what molecular mechanisms, will enhance not only the knowledge of mesenchymal stem cell biology but also the field of regenerative medicine. Mechanical stimuli, specifically loading induced oscillatory fluid flow, plays a vital role in promoting healthy bone development, homeostasis and morphology. Recent studies suggest that such loading induced fluid flow has the potential to regulate osteogenic differentiation via the upregulation of multiple osteogenic genes; however, the molecular mechanisms involved in the transduction of a physical signal into altered cell fate have yet to be determined.
   Methods and Principal Findings: Using immuno staining, western blot analysis and luciferase assays, we demonstrate the oscillatory fluid flow regulates beta catenin nuclear translocation and gene transcription. Additionally, real time RT PCR analysis suggests that flow induces Wnt5a and Ror2 upregulation, both of which are essential for activating the small GTPase, RhoA, upon flow exposure. Furthermore, although beta catenin phosphorylation is not altered by flow, its association with N cadherin is, indicating that flow induced beta catenin signaling is initiated by adherens junction signaling.
   Conclusion: We propose that the mechanical microenvironment of bone has the potential to regulate osteogenic differentiation by initiating multiple key molecular pathways that are essential for such lineage commitment. Specifically, non canonical Wnt5a signaling involving Ror2 and RhoA as well as N cadherin mediated beta catenin signaling are necessary for mechanically induced osteogenic differentiation.
RP Arnsdorf, EJ (通讯作者)，VA Palo Alto Hlth Care Syst, Bone & Joint R&D Ctr, Palo Alto, CA USA.
EM emily.arnsdorf@gmail.com
FU NIAMS NIH HHS [R01 AR045989, AR45989] Funding Source: Medline
CR Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097 4644(19960616)61:4<514::AID JCB4>3.0.CO;2 R
   Arnsdorf EJ, 2009, J CELL SCI, V122, P546, DOI 10.1242/jcs.036293
   Bain G, 2003, BIOCHEM BIOPH RES CO, V301, P84, DOI 10.1016/S0006 291X(02)02951 0
   Baksh D, 2007, J CELL BIOCHEM, V101, P1109, DOI 10.1002/jcb.21097
   Baksh D, 2007, J CELL PHYSIOL, V212, P817, DOI 10.1002/jcp.21080
   Baron R, 2006, CURR TOP DEV BIOL, V76, P103, DOI 10.1016/S0070 2153(06)76004 5
   Batra NN, 2005, J BIOMECH, V38, P1909, DOI 10.1016/j.jbiomech.2004.08.009
   Bodine PVN, 2006, REV ENDOCR METAB DIS, V7, P33, DOI 10.1007/s11154 006 9002 4
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   BROWN TD, 1990, J BIOMECH, V23, P893, DOI 10.1016/0021 9290(90)90354 6
   Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286
   CARTER DR, 1989, J BIOMECH, V22, P231, DOI 10.1016/0021 9290(89)90091 2
   Carter DR, 1998, CLIN ORTHOP RELAT R, pS41
   Chamorro MN, 2005, EMBO J, V24, P73, DOI 10.1038/sj.emboj.7600460
   Chen Y, 2007, J BIOL CHEM, V282, P526, DOI 10.1074/jbc.M602700200
   Dehority W, 1999, AM J PHYSIOL ENDOC M, V276, pE62
   Dong YF, 2006, J CELL PHYSIOL, V208, P77, DOI 10.1002/jcp.20656
   DU SJ, 1995, MOL CELL BIOL, V15, P2625
   El Tanani M, 2001, CANCER RES, V61, P5619
   FROST HM, 1988, CALCIFIED TISSUE INT, V42, P145, DOI 10.1007/BF02556327
   FROST HM, 1987, BONE MINER, V2, P73
   Ganz A, 2006, BIOL CELL, V98, P721, DOI 10.1042/BC20060039
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Goldring MB, 2006, J CELL BIOCHEM, V97, P33, DOI 10.1002/jcb.20652
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Hanai J, 2002, J CELL BIOL, V158, P529, DOI 10.1083/jcb.200203064
   Haÿ E, 2009, MOL CELL BIOL, V29, P953, DOI 10.1128/MCB.00349 08
   He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117
   Huang W, 2007, FRONT BIOSCI LANDMRK, V12, P3068, DOI 10.2741/2296
   Jacobs CR, 1998, J BIOMECH, V31, P969, DOI 10.1016/S0021 9290(98)00114 6
   Katoh M, 2005, ONCOL REP, V14, P1583
   Katoh M, 2006, CANCER BIOL THER, V5, P1059, DOI 10.4161/cbt.5.9.3151
   Katoh Y, 2005, INT J ONCOL, V27, P275
   Kim CH, 2006, BONE, V39, P1043, DOI 10.1016/j.bone.2006.05.017
   Kim JB, 2007, J BONE MINER RES, V22, P1913, DOI 10.1359/JBMR.070802
   Kitaori T, 2009, ARTHRITIS RHEUM US, V60, P813, DOI 10.1002/art.24330
   KRAHL H, 1994, AM J SPORT MED, V22, P751, DOI 10.1177/036354659402200605
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Kühl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/S0168 9525(00)02028 X
   Lamb KJ, 2003, INT J EXP PATHOL, V84, P191, DOI 10.1046/j.1365 2613.2003.00353.x
   Li YJ, 2004, J ORTHOP RES, V22, P1283, DOI 10.1016/j.orthres.2004.04.002
   Liu Y., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P323
   Liu Y, 2007, MOL ENDOCRINOL, V21, P376, DOI 10.1210/me.2006 0342
   McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534 5807(04)00075 9
   Mikels AJ, 2006, PLOS BIOL, V4, P570, DOI 10.1371/journal.pbio.0040115
   Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311
   Müller T, 2002, EXP CELL RES, V280, P119, DOI 10.1006/excr.2002.5630
   Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291
   Norvell SM, 2004, CALCIFIED TISSUE INT, V75, P396, DOI 10.1007/s00223 004 0213 y
   OBERLENDER SA, 1994, CELL ADHES COMMUN, V2, P521, DOI 10.3109/15419069409014216
   OBERLENDER SA, 1994, DEVELOPMENT, V120, P177
   Orsulic S, 1999, J CELL SCI, V112, P1237
   Papkoff J, 1996, MOL CELL BIOL, V16, P2128
   Pavalko FM, 2003, J CELL BIOCHEM, V88, P104, DOI 10.1002/jcb.10284
   Reinhold MI, 2007, J BIOL CHEM, V282, P3653, DOI 10.1074/jbc.M608995200
   Ren XD, 2000, METHOD ENZYMOL, V325, P264
   Riddle RC, 2006, AM J PHYSIOL CELL PH, V290, pC776, DOI 10.1152/ajpcell.00082.2005
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Ruff C, 2006, AM J PHYS ANTHROPOL, V129, P484, DOI 10.1002/ajpa.20371
   Saunders MM, 2003, BONE, V32, P350, DOI 10.1016/S8756 3282(03)00025 5
   Semenov MV, 2006, J BIOL CHEM, V281, P38276, DOI 10.1074/jbc.M609509200
   Shimokawa T, 2003, CANCER RES, V63, P6116
   Smith JC, 2000, PHILOS T ROY SOC B, V355, P923, DOI 10.1098/rstb.2000.0627
   Später D, 2006, EUR CELLS MATER, V12, P71
   Srinivasan S, 2000, MED ENG PHYS, V22, P127, DOI 10.1016/S1350 4533(00)00021 7
   Steck R, 2000, MED ENG PHYS, V22, P117, DOI 10.1016/S1350 4533(00)00017 5
   Tate MLK, 2000, J EXP BIOL, V203, P2737
   Taurin S, 2006, J BIOL CHEM, V281, P9971, DOI 10.1074/jbc.M508778200
   Toyofuku T, 2000, J CELL BIOL, V150, P225, DOI 10.1083/jcb.150.1.225
   Triplett Jason W., 2007, Molecular & Cellular Biomechanics, V4, P13
   Tuli R, 2003, J BIOL CHEM, V278, P41227, DOI 10.1074/jbc.M305312200
   Turner CH, 2006, ANN NY ACAD SCI, V1068, P429, DOI 10.1196/annals.1346.039
   Wang FS, 2007, BONE, V40, P485, DOI 10.1016/j.bone.2006.09.004
   Wang Y, 2007, J TISSUE ENG REGEN M, V1, P39, DOI 10.1002/term.6
   Wolff J, 1986, LAW BONE REMODEL
   Woods A, 2005, J BIOL CHEM, V280, P11626, DOI 10.1074/jbc.M409158200
   Woods A, 2006, J BIOL CHEM, V281, P13134, DOI 10.1074/jbc.M509433200
   Woods A, 2007, J BIOL CHEM, V282, P23500, DOI 10.1074/jbc.M700680200
   Wu XM, 2008, CELL, V133, P340, DOI 10.1016/j.cell.2008.01.052
   You J, 2001, J BIOL CHEM, V276, P13365, DOI 10.1074/jbc.M009846200
   Zhang C, 2008, P NATL ACAD SCI USA, V105, P6936, DOI 10.1073/pnas.0710831105
   Zhong N, 2006, BONE, V39, P5, DOI 10.1016/j.bone.2005.12.008
   Zhu SZ, 2006, CELL SIGNAL, V18, P359, DOI 10.1016/j.cellsig.2005.05.019
   Zou LJ, 2006, ADV EXP MED BIOL, V585, P431
NR 84
TC 143
Z9 178
U1 0
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD APR 29
PY 2009
VL 4
IS 4
AR e5388
DI 10.1371/journal.pone.0005388
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 439BG
UT WOS:000265601100022
PM 19401766
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Guo, Y
   Bao, SM
   Guo, W
   Diao, ZL
   Wang, LY
   Han, X
   Guo, WK
   Liu, WH
AF Guo, Yan
   Bao, Shumin
   Guo, Wang
   Diao, Zongli
   Wang, Liyan
   Han, Xue
   Guo, Weikang
   Liu, Wenhu
TI Bone marrow mesenchymal stem cell derived exosomes alleviate high
   phosphorus induced vascular smooth muscle cells calcification by
   modifying microRNA profiles
SO FUNCTIONAL & INTEGRATIVE GENOMICS
LA English
DT Article
DE Chronic kidney disease; Vascular calcification; Exosomes; Bone
   mesenchymal stem cells; MicroRNA
ID OSTEOGENIC DIFFERENTIATION; GENE EXPRESSION; STROMAL CELLS; DISEASE;
   TARGET
AB Vascular calcification is a common complication in patients with chronic kidney disease (CKD). It is an important predictor of cardiovascular disease and all cause mortality. Previous studies have confirmed that bone marrow mesenchymal stem cell (BMSC) therapy can reduce vascular calcification, but the specific mechanism is still controversial. In this study, we aimed to investigate the mechanisms of BMSC derived exosomes (EXO) in improving vascular calcification. BMSCs were cultured and EXO were isolated using the Total Exosome Isolation Reagent. Human aortic vascular smooth muscle cells (HA VSMCs) were cultured into three groups: control group, high phosphorus group, and high phosphorus plus EXO group. Then, indicators related to smooth muscle cell calcification and microRNA profiles were analyzed. BMSC derived exosomes inhibited high phosphorus induced calcification in HA VSMCs. Besides, EXO treatment reduced calcium content and decreased the alkaline phosphatase (AKP) activity in high phosphorus co incubated HA VSMCs. MicroRNA (miRNA) and mRNA expression profiles analyses revealed that 63 miRNAs were significantly upregulated and 1424 genes were significantly downregulated in HA VSMCs after EXO treatment. Functional miRNA gene regulatory network revealed that mTOR, MAPK, and Wnt signaling pathway were involved in vascular calcification. BMSC derived exosomes alleviated high phosphorus induced calcification in HA VSMC through modifying miRNA profiles.
C1 [Guo, Yan; Bao, Shumin; Guo, Wang; Diao, Zongli; Wang, Liyan; Han, Xue; Guo, Weikang; Liu, Wenhu] Capital Med Univ, Beijing Friendship Hosp, Fac Kidney Dis, Dept Nephrol, Beijing 100050, Peoples R China.
C3 Capital Medical University
RP Guo, WK; Liu, WH (通讯作者)，Capital Med Univ, Beijing Friendship Hosp, Fac Kidney Dis, Dept Nephrol, Beijing 100050, Peoples R China.
EM gwk0777@qq.com; liuwh0211@126.com
RI liu, wenhu/GXN 2105 2022; Wang, Liyan/AFI 8414 2022
FU Beijing Talents Fund [2016000021469G223]; National Natural Science
   Foundation of China [81570660]; Beijing Municipal Administration of
   Hospitals Clinical Medicine Development of Special Funding Support
   [ZYLX201824]
FX The authors wish to thank the Beijing Talents Fund (No.
   2016000021469G223), the National Natural Science Foundation of China
   (No. 81570660), and the Beijing Municipal Administration of Hospitals
   Clinical Medicine Development of Special Funding Support (No.
   ZYLX201824) for financial support.
CR Albanese I, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.007356
   Badi I, 2018, ARTERIOSCL THROM VAS, V38, P2079, DOI 10.1161/ATVBAHA.118.311298
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Batista BS, 2011, J PROTEOME RES, V10, P4624, DOI 10.1021/pr200434y
   Chaikriangkrai K, 2017, INT J CARDIOL, V236, P473, DOI 10.1016/j.ijcard.2017.01.132
   Chao CT, 2017, ARTERIOSCL THROM VAS, V37, P1402, DOI 10.1161/ATVBAHA.117.309566
   Crompot E, 2017, HAEMATOLOGICA, V102, P1594, DOI 10.3324/haematol.2016.163337
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Fang T, 2016, EXP CELL RES, V347, P74, DOI 10.1016/j.yexcr.2016.07.010
   Feng YL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088685
   Frith JE, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02486 0
   Fujii H, 2018, CALCIFIED TISSUE INT, V102, P310, DOI 10.1007/s00223 017 0347 3
   Godfrey TC, 2018, J BIOL CHEM, V293, P17646, DOI 10.1074/jbc.RA118.003052
   Haarhaus M, 2017, NAT REV NEPHROL, V13, P429, DOI 10.1038/nrneph.2017.60
   Izadpanahi M, 2018, MAT SCI ENG C MATER, V93, P686, DOI 10.1016/j.msec.2018.08.023
   Kang H, 2015, BMB REP, V48, P319, DOI 10.5483/BMBRep.2015.48.6.206
   Kim D, 2016, NAT GENET, V48, P1517, DOI 10.1038/ng.3694
   Lai RC, 2010, STEM CELL RES, V4, P214, DOI 10.1016/j.scr.2009.12.003
   Lazar E, 2018, WORLD J STEM CELLS, V10, P106, DOI 10.4252/wjsc.v10.i8.106
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li WY, 2018, ACS APPL MATER INTER, V10, P5240, DOI 10.1021/acsami.7b17620
   Liu J, 2019, J NEPHROL, V32, P101, DOI 10.1007/s40620 018 0486 2
   Liu L, 2017, CELL PHYSIOL BIOCHEM, V43, P52, DOI 10.1159/000480317
   Luther KM, 2018, J MOL CELL CARDIOL, V119, P125, DOI 10.1016/j.yjmcc.2018.04.012
   Ma T, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/3290372
   Mackenzie NCW, 2014, CELL BIOCHEM FUNCT, V32, P209, DOI 10.1002/cbf.3005
   Müller P, 2018, CELL PHYSIOL BIOCHEM, V48, P2607, DOI 10.1159/000492704
   Ohno S, 2013, MOL THER, V21, P185, DOI 10.1038/mt.2012.180
   Paraskevopoulou MD, 2013, NUCLEIC ACIDS RES, V41, pW169, DOI 10.1093/nar/gkt393
   Reid IR, 2016, J INTERN MED, V279, P524, DOI 10.1111/joim.12464
   Reiss AB, 2018, ATHEROSCLEROSIS, V278, P49, DOI 10.1016/j.atherosclerosis.2018.08.046
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Silva WA, 2003, STEM CELLS, V21, P661, DOI 10.1634/stemcells.21 6 661
   Speer MY, 2009, CIRC RES, V104, P733, DOI 10.1161/CIRCRESAHA.108.183053
   Sudo R, 2015, GENES CELLS, V20, P1077, DOI 10.1111/gtc.12311
   Timmers L, 2008, STEM CELL RES, V1, P129, DOI 10.1016/j.scr.2008.02.002
   Wang X., 2018, J AM HEART ASSOC, V7, DOI DOI 10.1161/JAHA.118.008737
   Xiao CC, 2018, CIRC RES, V123, P564, DOI 10.1161/CIRCRESAHA.118.312758
   Yang YF, 2018, REDOX BIOL, V16, P97, DOI 10.1016/j.redox.2018.02.009
   Yeo RWY, 2013, ADV DRUG DELIVER REV, V65, P336, DOI 10.1016/j.addr.2012.07.001
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zhang H, 2018, TOXICOL LETT, V284, P29, DOI 10.1016/j.toxlet.2017.11.033
   Zhang H, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/4328362
NR 43
TC 38
Z9 40
U1 0
U2 30
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 1438 793X
EI 1438 7948
J9 FUNCT INTEGR GENOMIC
JI Funct. Integr. Genomics
PD JUL
PY 2019
VL 19
IS 4
BP 633
EP 643
DI 10.1007/s10142 019 00669 0
PG 11
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA ID5PA
UT WOS:000471727200008
PM 30850904
DA 2025 08 17
ER

PT J
AU Xie, CL
   Yue, YT
   Xu, JP
   Li, N
   Lin, T
   Ji, GR
   Yang, XW
   Xu, R
AF Xie, Chun Lan
   Yue, Yu Ting
   Xu, Jing Ping
   Li, Na
   Lin, Ting
   Ji, Guang Rong
   Yang, Xian Wen
   Xu, Ren
TI Penicopeptide A (PPA) from the deep sea derived fungus promotes
   osteoblast mediated bone formation and alleviates ovariectomy induced
   bone loss by activating the AKT/GSK 3β/β catenin signaling pathway
SO PHARMACOLOGICAL RESEARCH
LA English
DT Article
DE Osteoporosis; Osteoblasts; Penicopeptide A; Marine natural product;
   AKT/GSK 3 beta/beta catenin
ID OSTEOGENIC DIFFERENTIATION; OSTEOPOROSIS; PURMORPHAMINE; FAT
AB The potential of marine natural products as effective drugs for osteoporosis treatment is an understudied area. In this study, we investigated the ability of lead compounds from deep sea derived Penicillium solitum MCCC 3A00215 to promote bone formation in vitro and in vivo. We found that penicopeptide A (PPA) promoted osteoblast mineralization among bone marrow mesenchymal stem cells (BMSCs) in a concentration dependent manner, and thus, we selected this natural peptide for further testing. Our further experiments showed that PPA significantly promoted the osteogenic differentiation of BMSCs while inhibiting their adipogenic differen tiation and not affecting their chondrogenic differentiation. Mechanistic studies showed that PPA binds directly to the AKT and GSK 3 beta and activates phosphorylation of AKT and GSK 3 beta, resulting in the accumulation of beta catenin. We also evaluated the therapeutic potential of PPA in a female mouse model of ovariectomy induced systemic bone loss. In this model, PPA treatment prevented decreases in bone volume and trabecular thickness. In conclusion, our in vitro and in vivo results demonstrated that PPA could promote osteoblast related bone formation via the AKT, GSK 3 beta, and beta catenin signaling pathways, indicating the clinical potential of PPA as a candidate compound for osteoporosis prevention.
C1 [Xu, Jing Ping; Li, Na; Xu, Ren] Xiamen Univ, Sch Med, Fujian Prov Key Lab Organ & Tissue Regenerat, Xiamen 361102, Peoples R China.
   [Yang, Xian Wen] Minist Nat Resources, Inst Oceanog 3, Key Lab Marine Genet Resources, Xiamen 361005, Peoples R China.
   [Xu, Ren] Xiamen Univ, Affiliated Hosp 1, Fac Med & Life Sci, ICMRS Collaborating Ctr Skeletal Stem Cells,State, Xiamen 361102, Peoples R China.
   [Ji, Guang Rong] Xiamen Univ, Xiangan Hosp, Sch Med, Dept Orthoped Surg, Xiamen 361102, Peoples R China.
   [Lin, Ting] Xiamen Univ, Sch Pharmaceut Sci, Fujian Prov Key Lab Innovat Drug Target Res, Xiamen 361102, Peoples R China.
C3 Xiamen University; Third Institute of Oceanography, Ministry of Natural
   Resources; Ministry of Natural Resources of the People's Republic of
   China; Xiamen University; Xiamen University; Xiamen University
RP Xu, R (通讯作者)，Xiamen Univ, Sch Med, Fujian Prov Key Lab Organ & Tissue Regenerat, Xiamen 361102, Peoples R China.; Yang, XW (通讯作者)，Minist Nat Resources, Inst Oceanog 3, Key Lab Marine Genet Resources, Xiamen 361005, Peoples R China.; Ji, GR (通讯作者)，Xiamen Univ, Xiangan Hosp, Sch Med, Dept Orthoped Surg, Xiamen 361102, Peoples R China.
EM jiguangrong@sina.cn; yangxianwen@tio.org.cn; xuren526@xmu.edu.cn
RI Yang, Xian Wen/AAL 4272 2021; YANG, Xian Wen/AAL 4272 2021
OI Xie, Chun Lan/0000 0001 7314 4193; YANG, Xian Wen/0000 0002 4967 0844
CR Atanasov AG, 2021, NAT REV DRUG DISCOV, V20, P200, DOI 10.1038/s41573 020 00114 z
   Beloti MM, 2005, CELL BIOL INT, V29, P537, DOI 10.1016/j.cellbi.2005.02.007
   Bonyadi M, 2003, P NATL ACAD SCI USA, V100, P5840, DOI 10.1073/pnas.1036475100
   Carroll AR, 2022, NAT PROD REP, V39, P1122, DOI 10.1039/d1np00076d
   Chaugule SR, 2017, FRONT MAR SCI, V4, DOI 10.3389/fmars.2017.00384
   El Desoky AHH, 2022, J NAT MED TOKYO, V76, P575, DOI 10.1007/s11418 022 01622 5
   Faghihi F, 2013, BIOMED PHARMACOTHER, V67, P31, DOI 10.1016/j.biopha.2012.10.004
   Gkastaris K, 2020, J MUSCULOSKEL NEURON, V20, P372
   Gu DS, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.377382
   Guan M, 2012, NAT MED, V18, P456, DOI 10.1038/nm.2665
   He ZH, 2023, J NAT PROD, V86, P157, DOI 10.1021/acs.jnatprod.2c00866
   He ZH, 2021, MAR DRUGS, V19, DOI 10.3390/md19100580
   Katsara O, 2011, STEM CELLS DEV, V20, P1550, DOI 10.1089/scd.2010.0280
   MARTIN RB, 1991, BONE, V12, P123, DOI 10.1016/8756 3282(91)90011 7
   MINAIRE P, 1984, CALCIFIED TISSUE INT, V36, P338, DOI 10.1007/BF02405340
   Patsch JM, 2011, METABOLISM, V60, P243, DOI 10.1016/j.metabol.2009.11.023
   Sun WN, 2016, SCI REP UK, V6, DOI 10.1038/srep26418
   Sun Y, 2015, CELL PHYSIOL BIOCHEM, V36, P1331, DOI 10.1159/000430300
   WANG GJ, 1977, J BONE JOINT SURG AM, V59, P729, DOI 10.2106/00004623 197759060 00003
   Wang XY, 2020, FITOTERAPIA, V142, DOI 10.1016/j.fitote.2020.104482
   Wang ZX, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 29191 x
   Wu DQ, 2010, TRENDS BIOCHEM SCI, V35, P161, DOI 10.1016/j.tibs.2009.10.002
   Xu R, 2018, NAT MED, V24, P823, DOI 10.1038/s41591 018 0020 z
   Yang F, 2011, STEM CELLS, V29, P981, DOI 10.1002/stem.646
   Yoo TK, 2013, YONSEI MED J, V54, P1321, DOI 10.3349/ymj.2013.54.6.1321
   Zhao ZF, 2022, AM J CHINESE MED, V50, P441, DOI 10.1142/S0192415X22500173
   Zhu DY, 2019, INT J NANOMED, V14, P1085, DOI 10.2147/IJN.S193576
NR 27
TC 18
Z9 20
U1 4
U2 35
PU ACADEMIC PRESS LTD  ELSEVIER SCIENCE LTD
PI LONDON
PA 24 28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043 6618
EI 1096 1186
J9 PHARMACOL RES
JI Pharmacol. Res.
PD NOV
PY 2023
VL 197
AR 106968
DI 10.1016/j.phrs.2023.106968
EA OCT 2023
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA Y5BV0
UT WOS:001105418200001
PM 37866705
OA hybrid
DA 2025 08 17
ER

PT J
AU Zhao, XY
   Mei, LJ
   Pei, JJ
   Liu, ZG
   Shao, Y
   Tao, YD
   Zhang, XL
   Jiang, L
AF Zhao, Xiaoying
   Mei, Lijuan
   Pei, Jinjin
   Liu, Zenggen
   Shao, Yun
   Tao, Yanduo
   Zhang, Xiaoling
   Jiang, Lei
TI Sophoridine from Sophora Flower Attenuates Ovariectomy Induced
   Osteoporosis through the RANKL ERK NFAT Pathway
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Article
DE osteoporosis; sophora flower; sophoridine; osteoclast differentiation;
   MAPK; NFATc1
ID BONE LOSS; AGENTS
AB An imbalance in osteogenesis and osteoclastogenesis is a crucial pathological factor in the development of osteoporosis. Osteoclasts (OCs) play a pivotal role in osteoporosis, whose new therapy exploration has been focused on the suppression of OC formation. Sophoridine is found from the Chinese traditional food sophora flower to exhibit anti osteoporosis capacity by screening. This study is focused on its anti  osteoporosis mechanism evaluation. The anti  osteoporosis effect of sophoridine, (15 mg kg( 1) body), was evaluated in ovariectomized (OVX) mice by monitoring changes in bone histomorphometry index, formation of osteoclasts from blood derived mononuclear cells, and changes in the synthesis of pro osteodastogenic cytokines. Signal pathways were investigated by QPCR, Western blot, and immunofluorescence. Sophoridine has a significant anti osteoporosis effect in vivo, which can inhibit RANKL induced OC formation, the appearance of OC specific marker genes, and OC marker protein in vitro. Mechanistically, sophoridine dose  and time dependently blocks the RANKL induced OC formation and the activation of ERK and c Fos as well as the induction and nucleus translocation of NFATc1. Sophora flower might be a useful alternative functional food in preventing or treating osteoporosis.
C1 [Mei, Lijuan; Pei, Jinjin; Liu, Zenggen; Shao, Yun; Tao, Yanduo; Jiang, Lei] Chinese Acad Sci, Northwest Plateau Inst Biol, Key Lab Tibetan Med Res, Xining 810001, Qinghai, Peoples R China.
   [Zhao, Xiaoying; Zhang, Xiaoling] Shanghai Jiao Tong Univ, Sch Med, Inst Hlth Sci, Key Lab Stem Cell Biol, Shanghai 200025, Peoples R China.
   [Zhao, Xiaoying; Zhang, Xiaoling] Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai 200025, Peoples R China.
   [Zhao, Xiaoying; Zhang, Xiaoling] Shanghai Jiao Tong Univ, Sch Med, Xin Hua Hosp, Dept Orthoped Surg, Shanghai 200092, Peoples R China.
   [Pei, Jinjin] Shaanxi Univ Technol, Shaanxi Key Lab Bioresources & Biol, Hanzhong 723001, Peoples R China.
C3 Chinese Academy of Sciences; Northwest Institute of Plateau Biology,
   CAS; Shanghai Jiao Tong University; Chinese Academy of Sciences;
   Shanghai Jiao Tong University; Shaanxi University of Technology
RP Jiang, L (通讯作者)，23 Xinning Rd, Xining, Qinghai, Peoples R China.; Zhang, XL (通讯作者)，320 Yueyang Rd, Shanghai, Peoples R China.
EM jianglei@nwipb.cas.cn
RI Zhang, Xiaoling/J 1666 2016; shao, yun/KLC 3238 2024; 刘,
   增根/AAY 7356 2021
OI Zhang, Xiaoling/0000 0002 0134 1347; 
FU Natural Science Foundation of Qinghai [2016 ZJ 942Q]; West Light
   Foundation of the Chinese Academy of Sciences [Y629071211]; National
   Natural Science Foundation of China [81572123, 31701243]; Science and
   Technology Commission of Shanghai Municipality [14431900900,
   115411951100, 116430723500]; Shanghai Municipal Education
   Commission Gaofeng Clinical Medicine Grant Support [20161314]
FX This work was supported by grants from Natural Science Foundation of
   Qinghai (No. 2016 ZJ 942Q), West Light Foundation of the Chinese Academy
   of Sciences (No. Y629071211), National Natural Science Foundation of
   China (No. 81572123, No. 31701243), Science and Technology Commission of
   Shanghai Municipality (No. 14431900900, No. 115411951100, No.
   116430723500), and Shanghai Municipal Education Commission Gaofeng
   Clinical Medicine Grant Support (No. 20161314).
CR Akiyama T, 2008, MOL CANCER THER, V7, P3461, DOI 10.1158/1535 7163.MCT 08 0530
   Bi CW, 2014, ACS MED CHEM LETT, V5, P1225, DOI 10.1021/ml500289h
   Chen JX, 2016, VIRUS RES, V215, P104, DOI 10.1016/j.virusres.2015.12.005
   Goessl C, 2012, ANN NY ACAD SCI, V1263, P29, DOI 10.1111/j.1749 6632.2012.06674.x
   Hiraga T, 2016, EXPERT OPIN INV DRUG, V25, P319, DOI 10.1517/13543784.2016.1142972
   Jiang YP, 2013, ACTA ORTHOP BELG, V79, P1
   Jonasson G, 2016, CLIN COSMET INV DENT, V8, P95, DOI 10.2147/CCIDE.S92774
   Kim Jung Ha, 2016, Chonnam Med J, V52, P12, DOI 10.4068/cmj.2016.52.1.12
   Li G., 2008, Patent No. [CN101095719, 2008 01 02, 101095719]
   Lu YC, 2016, SCI REP UK, V6, DOI 10.1038/srep25206
   McDonald MM, 2017, CALCIFIED TISSUE INT, V100, P433, DOI 10.1007/s00223 016 0162 2
   Nakamura I, 2012, MOD RHEUMATOL, V22, P167, DOI 10.1007/s10165 011 0530 8
   Nakashima T, 2012, TRENDS ENDOCRIN MET, V23, P582, DOI 10.1016/j.tem.2012.05.005
   Nevius E, 2016, CLIN REV ALLERG IMMU, V51, P59, DOI 10.1007/s12016 015 8520 9
   Sharifi M, 2015, REV ENDOCR METAB DIS, V16, P149, DOI 10.1007/s11154 015 9311 6
   Zhang S., 2005, J JILIN U, P561
   Zheng Y, 2014, CHIN J EXP TRADIT ME, P133
NR 17
TC 18
Z9 20
U1 1
U2 27
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021 8561
EI 1520 5118
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD NOV 8
PY 2017
VL 65
IS 44
BP 9647
EP 9654
DI 10.1021/acs.jafc.7b03666
PG 8
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science &
   Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Agriculture; Chemistry; Food Science & Technology
GA FM4WE
UT WOS:000415028700010
PM 29058425
DA 2025 08 17
ER

PT J
AU Sévère, N
   Miraoui, H
   Marie, PJ
AF Severe, Nicolas
   Miraoui, Hichem
   Marie, Pierre J.
TI The Casitas B Lineage Lymphoma (Cbl) Mutant G306E Enhances Osteogenic
   Differentiation in Human Mesenchymal Stromal Cells in Part by Decreased
   Cbl mediated Platelet derived Growth Factor Receptor α and Fibroblast
   Growth Factor Receptor 2 Ubiquitination
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID PHOSPHOTYROSINE BINDING DOMAIN; STEM CELLS; C CBL; IN VITRO; NEGATIVE
   REGULATION; DOWN REGULATION; BONE FORMATION; TYROSINE; APOPTOSIS;
   PHOSPHORYLATION
AB Human bone marrow derived mesenchymal stromal cells (hMSCs) have the capacity to differentiate into several cell types including osteoblasts and are therefore an important cell source for bone tissue regeneration. A crucial issue is to identify mechanisms that trigger hMSC osteoblast differentiation to promote osteogenic potential. Casitas B lineage lymphoma (Cbl) is an E3 ubiquitin ligase that ubiquitinates and targets several molecules for degradation. We hypothesized that attenuation of Cbl mediated degradation of receptor tyrosine kinases (RTKs) may promote osteogenic differentiation in hMSCs. We show here that specific inhibition of Cbl interaction with RTKs using a Cbl mutant (G306E) promotes expression of osteoblast markers (Runx2, alkaline phosphatase, type 1 collagen, osteocalcin) and increases osteogenic differentiation in clonal bone marrow derived hMSCs and primary hMSCs. Analysis of molecular mechanisms revealed that the Cbl mutant increased PDGF receptor alpha and FGF receptor 2 but not EGF receptor expression in hMSCs, resulting in increased ERK1/2 and PI3K signaling. Pharmacological inhibition of FGFR or PDGFR abrogated in vitro osteogenesis induced by the Cbl mutant. The data reveal that specific inhibition of Cbl interaction with RTKs promotes the osteogenic differentiation program in hMSCs in part by decreased Cbl mediated PDGFR alpha and FGFR2 ubiquitination, providing a novel mechanistic approach targeting Cbl to promote the osteogenic capacity of hMSCs.
C1 [Severe, Nicolas; Miraoui, Hichem; Marie, Pierre J.] Hop Lariboisiere, INSERM, U606, Lab Osteoblast Biol & Pathol, F 75475 Paris 10, France.
   [Severe, Nicolas; Miraoui, Hichem; Marie, Pierre J.] Univ Paris Diderot, UMR606, F 75475 Paris, France.
C3 Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite;
   Hopital Universitaire Lariboisiere Fernand Widal   APHP; Institut
   National de la Sante et de la Recherche Medicale (Inserm); Universite
   Paris Cite
RP Marie, PJ (通讯作者)，Hop Lariboisiere, INSERM, U606, Lab Osteoblast Biol & Pathol, 2 Rue Ambroise Pare, F 75475 Paris 10, France.
EM pierre.marie@inserm.fr
FU Institut National de la Sante et de la Recherche Medicale; Ministere de
   la Recherche (Paris, France)
FX This work was supported in part by Institut National de la Sante et de
   la Recherche Medicale. Recipients of a Ph.D. award from the Ministere de
   la Recherche (Paris, France).
CR Ahdjoudj S, 2001, J CELL BIOCHEM, V81, P23, DOI 10.1002/1097 4644(20010401)81:1<23::AID JCB1021>3.0.CO;2 H
   [Anonymous], SCI STKE
   Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19 3 180
   Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597
   Cárcamo Orive I, 2010, J BONE MINER RES, V25, P2115, DOI 10.1002/jbmr.120
   Charbord P, 2011, STEM CELL REV REP, V7, P32, DOI 10.1007/s12015 010 9125 6
   CHENG SL, 1994, ENDOCRINOLOGY, V134, P277, DOI 10.1210/en.134.1.277
   Dardalhon V, 2001, GENE THER, V8, P190, DOI 10.1038/sj.gt.3301378
   Dufour C, 2008, BONE, V42, P1032, DOI 10.1016/j.bone.2008.02.009
   Duval M, 2003, J BIOL CHEM, V278, P20091, DOI 10.1074/jbc.M301410200
   Fong CW, 2003, J BIOL CHEM, V278, P33456, DOI 10.1074/jbc.M301317200
   Franceschi RT, 1999, CRIT REV ORAL BIOL M, V10, P40, DOI 10.1177/10454411990100010201
   Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369
   Fromigué O, 2006, CELL DEATH DIFFER, V13, P1845, DOI 10.1038/sj.cdd.4401873
   Fromigué O, 2001, J BONE MINER RES, V16, P1600, DOI 10.1359/jbmr.2001.16.9.1600
   Garrett IR, 2003, J CLIN INVEST, V111, P1771, DOI 10.1172/JCI200316198
   Giuliani N, 2007, BLOOD, V110, P334, DOI 10.1182/blood 2006 11 059188
   Gronthos S, 2007, STEM CELLS DEV, V16, P953, DOI 10.1089/scd.2007.0069
   Gruber R, 2004, PLATELETS, V15, P29, DOI 10.1080/09537100310001643999
   Guenou H, 2006, AM J PATHOL, V169, P1303, DOI 10.2353/ajpath.2006.060102
   Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645
   Kaabeche K, 2005, J CELL SCI, V118, P1223, DOI 10.1242/jcs.01679
   Kaabeche K, 2004, J BIOL CHEM, V279, P36259, DOI 10.1074/jbc.M402469200
   Kassem M, 2004, CLONING STEM CELLS, V6, P369, DOI 10.1089/clo.2004.6.369
   Kassenbrock CK, 2004, J BIOL CHEM, V279, P28017, DOI 10.1074/jbc.M404114200
   Kratchmarova I, 2005, SCIENCE, V308, P1472, DOI 10.1126/science.1107627
   LANGDON WY, 1990, CURR TOP MICROBIOL, V166, P159
   Lian JB, 2004, CRIT REV EUKAR GENE, V14, P1, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i12.10
   Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063
   Lupher ML Jr, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140
   Marie PJ, 2006, REGEN MED, V1, P539, DOI 10.2217/17460751.1.4.539
   Marie PJ, 2003, GENE, V316, P23, DOI 10.1016/S0378 1119(03)00748 0
   Mason JM, 2006, TRENDS CELL BIOL, V16, P45, DOI 10.1016/j.tcb.2005.11.004
   Miraoui H, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3146re9
   Miraoui H, 2010, HUM MOL GENET, V19, P1678, DOI 10.1093/hmg/ddq045
   Miraoui H, 2009, J BIOL CHEM, V284, P4897, DOI 10.1074/jbc.M805432200
   Mitlak BH, 1996, J BONE MINER RES, V11, P238
   Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619
   Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2 3.30
   Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927
   Moenning A, 2009, MOL CELL BIOL, V29, P881, DOI 10.1128/MCB.00885 08
   Molero JC, 2004, J CLIN INVEST, V114, P1326, DOI 10.1172/JCI21480
   Mukherjee S, 2008, J CLIN INVEST, V118, P491, DOI [10.1172/JCI33102, 10.1172/JC133102]
   Orosco A, 2007, CANCER RES, V67, P3708, DOI 10.1158/0008 5472.CAN 06 4164
   Oyajobi BO, 1999, J BONE MINER RES, V14, P351, DOI 10.1359/jbmr.1999.14.3.351
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   Pittenger MF, 2004, CIRC RES, V95, P9, DOI 10.1161/01.RES.0000135902.99383.6f
   Prockop DJ, 2003, P NATL ACAD SCI USA, V100, P11917, DOI 10.1073/pnas.1834138100
   Rahimi N, 2009, BIOCHEM SOC T, V37, P1189, DOI 10.1042/BST0371189
   Ryan PE, 2006, TRENDS BIOCHEM SCI, V31, P79, DOI 10.1016/j.tibs.2005.12.004
   Schlessinger J, 2004, SCIENCE, V306, P1506, DOI 10.1126/science.1105396
   Schmidt MHH, 2005, NAT REV MOL CELL BIO, V6, P907, DOI 10.1038/nrm1762
   Smit GDV, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000217
   Suzue N, 2006, J BONE MINER RES, V21, P722, DOI 10.1359/JBMR.060207
   Swaminathan G, 2006, J CELL PHYSIOL, V209, P21, DOI 10.1002/jcp.20694
   Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193
   Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100
   Ueno H, 1997, J BIOL CHEM, V272, P8739, DOI 10.1074/jbc.272.13.8739
   Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151
   Wong A, 2002, P NATL ACAD SCI USA, V99, P6684, DOI 10.1073/pnas.052138899
   Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493
NR 61
TC 31
Z9 38
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUL 8
PY 2011
VL 286
IS 27
BP 24443
EP 24450
DI 10.1074/jbc.M110.197525
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 786HO
UT WOS:000292294900084
PM 21596750
OA Green Published
DA 2025 08 17
ER

PT J
AU Chandran, SV
   Vairamani, M
   Selvamurugan, N
AF Chandran, S. Viji
   Vairamani, M.
   Selvamurugan, N.
TI Osteostimulatory effect of biocomposite scaffold containing
   phytomolecule diosmin by Integrin/FAK/ERK signaling pathway in mouse
   mesenchymal stem cells
SO SCIENTIFIC REPORTS
LA English
DT Article
ID OSTEOGENIC DIFFERENTIATION; IN VITRO; OSTEOBLAST DIFFERENTIATION;
   KINASE ACTIVITY; DRUG DELIVERY; BONE; GELATIN; PROLIFERATION; MATRIX;
   RUNX2
AB Non availability of an ideal alternative for autografts in treating critical size bone defects is a major challenge in orthopedics. Phytocompounds have been proven to enhance osteogenesis via various osteogenic signaling pathways, but its decreased bioavailability and increased renal clearance limit its application. In this study, we designed a biocomposite scaffold comprising gelatin (Gel) and nanohydroxyapatite (nHAp) incorporated with diosmin (DM) and we investigated its bone forming potential in vitro and in vivo. Physiochemical characterization of the scaffold showed that DM had no effect on altering the material characteristics of the scaffold. The addition of DM enhanced the osteoblast differentiation potential of the scaffold in mouse mesenchymal stem cells at both cellular and molecular levels, possibly via the integrin mediated activation of FAK and ERK signaling components. Using the rat tibial bone defective model, we identified the effect of DM in Gel/nHAp scaffold on enhancing bone formation in vivo. Based on our results, we suggest that Gel/nHAp/DM can be a potential therapeutic agent in scaffold mediated bone regeneration.
C1 [Chandran, S. Viji; Vairamani, M.; Selvamurugan, N.] SRM Inst Sci & Technol, Sch Bioengn, Dept Biotechnol, Kattankulathur, Tamil Nadu, India.
C3 SRM Institute of Science & Technology Chennai
RP Selvamurugan, N (通讯作者)，SRM Inst Sci & Technol, Sch Bioengn, Dept Biotechnol, Kattankulathur, Tamil Nadu, India.
EM selvamun@srmist.edu.in
RI Selvamurugan, Nagarajan/P 7894 2016
OI Selvamurugan, Nagarajan/0000 0003 3713 1920
FU SRM Institute of Science and Technology
FX We thank the SRM Institute of Science and Technology, in part, for
   providing the financial support and the Nanotechnology Research Centre,
   SRMIST for providing the instrument facility.
CR Ai FW, 2014, IRAN J PHARM RES, V13, P1115
   Ajita J, 2015, MAT SCI ENG C MATER, V53, P142, DOI 10.1016/j.msec.2015.04.041
   Amini Ami R., 2012, Critical Reviews in Biomedical Engineering, V40, P363
   Anwer MK, 2014, J MOL LIQ, V199, P35, DOI 10.1016/j.molliq.2014.08.012
   Artigas N, 2014, J BIOL CHEM, V289, P27105, DOI 10.1074/jbc.M114.576793
   Arumugam B, 2019, BIOCHIMIE, V158, P43, DOI 10.1016/j.biochi.2018.12.006
   Arumugam B, 2018, J CELL COMMUN SIGNAL, V12, P561, DOI 10.1007/s12079 018 0449 3
   Arumugam B, 2018, J CELL PHYSIOL, V233, P1082, DOI 10.1002/jcp.25964
   Bacáková L, 2004, PHYSIOL RES, V53, pS35, DOI 10.33549/physiolres.930000.53.S35
   Bellis SL, 2011, BIOMATERIALS, V32, P4205, DOI 10.1016/j.biomaterials.2011.02.029
   Bergan JJ, 2001, ANGIOLOGY, V52, pS43, DOI 10.1177/0003319701052001S06
   Besheli NH, 2017, ACS APPL MATER INTER, V9, P5128, DOI 10.1021/acsami.6b14912
   Bohner M, 2010, MATER TODAY, V13, P24, DOI 10.1016/S1369 7021(10)70014 6
   Bose S, 2012, ACTA BIOMATER, V8, P1401, DOI 10.1016/j.actbio.2011.11.017
   Bruzauskaite I, 2016, CYTOTECHNOLOGY, V68, P355, DOI 10.1007/s10616 015 9895 4
   Chang MC, 2007, J MATER SCI MATER M, V18, P2045, DOI 10.1007/s10856 007 3152 0
   Chen SH, 2012, ACTA BIOMATER, V8, P3128, DOI 10.1016/j.actbio.2012.04.030
   Davidenko N, 2016, J MATER SCI MATER M, V27, DOI 10.1007/s10856 016 5763 9
   Dhivya S, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12408
   Dhivya S, 2015, J NANOBIOTECHNOL, V13, DOI 10.1186/s12951 015 0099 z
   Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097 4652(200009)184:3<341::AID JCP8>3.3.CO;2 Q
   Dzobo K, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/2495848
   Ebisuya M, 2005, J CELL SCI, V118, P2997, DOI 10.1242/jcs.02505
   Fan JJ, 2011, MOLECULES, V16, P10123, DOI 10.3390/molecules161210123
   Foox M, 2015, EXPERT OPIN DRUG DEL, V12, P1547, DOI 10.1517/17425247.2015.1037272
   Frick RW, 2000, ANGIOLOGY, V51, P197, DOI 10.1177/000331970005100303
   Geiger M., 2016, Journal of Oral Health and Craniofacial Science, V1, P012, DOI [10.29328/journal.johcs.1001002, DOI 10.29328/JOURNAL.JOHCS.1001002]
   Hardcastle AC, 2011, J BONE MINER RES, V26, P941, DOI 10.1002/jbmr.285
   Hsu YL, 2007, BIOCHEM PHARMACOL, V73, P504, DOI 10.1016/j.bcp.2006.10.020
   Hu J, 2016, SCI REP UK, V6, DOI 10.1038/srep20875
   Hunter DJ, 2008, RHEUM DIS CLIN N AM, V34, P623, DOI 10.1016/j.rdc.2008.05.004
   Karsenty G, 2009, ANNU REV CELL DEV BI, V25, P629, DOI 10.1146/annurev.cellbio.042308.113308
   Kim HJ, 2005, BIOMATERIALS, V26, P4442, DOI 10.1016/j.biomaterials.2004.11.013
   Kim HW, 2005, BIOMATERIALS, V26, P5221, DOI 10.1016/j.biomaterials.2005.01.047
   Kokubo T, 2006, BIOMATERIALS, V27, P2907, DOI 10.1016/j.biomaterials.2006.01.017
   Lai YX, 2018, BIOMATERIALS, V153, P1, DOI 10.1016/j.biomaterials.2017.10.025
   Langenbach F, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt328
   Leena RS, 2017, COLLOID SURFACE B, V158, P308, DOI 10.1016/j.colsurfb.2017.06.048
   Li Y, 2013, J APPL POLYM SCI, V130, P1539, DOI [10.1002/APP.39339, 10.1002/app.39339]
   Lim SS, 2017, OR SURG OR MED OR PA, V123, P8, DOI 10.1016/j.oooo.2016.08.009
   Matsubara T, 2008, J BIOL CHEM, V283, P29119, DOI 10.1074/jbc.M801774200
   Menon AH, 2018, CARBOHYD POLYM, V195, P356, DOI 10.1016/j.carbpol.2018.04.115
   Miraoui H, 2009, J BIOL CHEM, V284, P4897, DOI 10.1074/jbc.M805432200
   Morris C, 2006, J NUTR, V136, P1166, DOI 10.1093/jn/136.5.1166
   O'Brien FJ, 2011, MATER TODAY, V14, P88, DOI 10.1016/S1369 7021(11)70058 X
   Olivares Navarrete R, 2015, BIOMATERIALS, V51, P69, DOI 10.1016/j.biomaterials.2015.01.035
   Pari L, 2010, BIOMED PHARMACOTHER, V64, P477, DOI 10.1016/j.biopha.2010.02.001
   Saito K, 2016, RSC ADV, V6, P64165, DOI 10.1039/c6ra07602e
   Salasznyk RM, 2007, EXP CELL RES, V313, P22, DOI 10.1016/j.yexcr.2006.09.013
   Saravanan S, 2017, INT J BIOL MACROMOL, V104, P1975, DOI 10.1016/j.ijbiomac.2017.01.034
   Saravanan S, 2015, J BIOMED NANOTECHNOL, V11, P1124, DOI 10.1166/jbn.2015.2057
   Selvamurugan N, 2006, J CELL BIOCHEM, V99, P545, DOI 10.1002/jcb.20878
   Shalkami AS, 2018, HUM EXP TOXICOL, V37, P78, DOI 10.1177/0960327117694075
   Soundarya SP, 2018, INT J BIOL MACROMOL, V110, P74, DOI 10.1016/j.ijbiomac.2017.09.014
   Srilatha D, 2013, International Scholarly Research Notices, DOI [10.1155/2013/534830, DOI 10.1155/2013/534830]
   Srinivasan S, 2012, CHEM BIOL INTERACT, V195, P43, DOI 10.1016/j.cbi.2011.10.003
   Tamura Y, 2001, J BONE MINER RES, V16, P1772, DOI 10.1359/jbmr.2001.16.10.1772
   Thouverey C, 2009, OSTEOARTHR CARTILAGE, V17, P64, DOI 10.1016/j.joca.2008.05.020
   Vater C, 2011, ACTA BIOMATER, V7, P463, DOI 10.1016/j.actbio.2010.07.037
   Villa MM, 2015, J BIOMED MATER RES B, V103, P243, DOI 10.1002/jbm.b.33225
   Weiner S, 1998, ANNU REV MATER SCI, V28, P271, DOI 10.1146/annurev.matsci.28.1.271
   Wojtowicz AM, 2010, BIOMATERIALS, V31, P2574, DOI 10.1016/j.biomaterials.2009.12.008
   Xing Q, 2014, SCI REP UK, V4, DOI 10.1038/srep04706
   Younger E M, 1989, J Orthop Trauma, V3, P192, DOI 10.1097/00005131 198909000 00002
   Zhang X, 2015, MOL CELL BIOCHEM, V407, P41, DOI 10.1007/s11010 015 2452 9
NR 65
TC 34
Z9 34
U1 0
U2 5
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD AUG 15
PY 2019
VL 9
AR 11900
DI 10.1038/s41598 019 48429 1
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA IQ3VX
UT WOS:000480680800014
PM 31417150
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Chen, CH
   Lai, CH
   Hong, YK
   Lu, JM
   Lin, SY
   Lee, TC
   Chang, LY
   Ho, ML
   Conway, EM
   Wu, HL
   Cheng, TL
AF Chen, Chung Hwan
   Lai, Chao Han
   Hong, Yi Kai
   Lu, Jui Ming
   Lin, Sung Yen
   Lee, Tien Ching
   Chang, Lan Yun
   Ho, Mei Ling
   Conway, Edward M.
   Wu, Hua Lin
   Cheng, Tsung Lin
TI Thrombomodulin Functional Domains Support Osteoblast Differentiation and
   Bone Healing in Diabetes in Mice
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE BONE DEFECT HEALING; DIABETES; MG63 CELLS; OSTEOBLAST; THROMBOMODULIN
ID LECTIN LIKE DOMAIN; PROTEIN C; EXPRESSION; ANGIOGENESIS; MECHANISMS;
   ADHESION; MODEL
AB Thrombomodulin (TM) is a transmembrane glycoprotein that contains five functional domains. Soluble TM (sTM), comprising extracellular domains TMD1 (lectin like), TMD2 (epidermal growth factor [EGF] like repeat containing), and TMD3 (serine threonine rich), can be shed from cells by the intramembrane protease rhomboid like 2 (RHBDL2). TM is expressed by osteoblasts, yet its role there has not been determined. Herein we aimed to investigate the properties of TM and its domains in osteoblast function and bone repair following injury in diabetes. In response to a scratch injury of cultured osteoblast like MG63 cells, expression of TM and RHBDL2 was enhanced, with increased release of sTM. Conditioned media from the injured cells promoted osteoblast migration, an effect that was lacking with conditioned media from MG63 cells in which TM was silenced by shRNA. Exogenous recombinant TMD1 had no effect on osteoblast activities or on bone repair in vivo. However, TM domains 2 and 3 (TMD2/3), induced MG63 cell migration, proliferation and mineralization in vitro, and when locally administered in mice, improved in vivo healing of injured calvarium. This beneficial effect of TMD2/3, mediated via fibroblast growth factor receptor (FGFR)/ERK signaling pathways, was also observed in vitro under high glucose conditions where endogenous TM expression was reduced, and in vivo in diabetic mice following tibia fracture or calvarium injury, where the osteoblastic response and healing were otherwise dampened. Taken together, osteoblast TM participates in bone healing, and recombinant TMD2/3 holds promise as a novel therapy for diabetic bone defect healing. (c) 2020 American Society for Bone and Mineral Research.
C1 [Chen, Chung Hwan; Lin, Sung Yen; Lee, Tien Ching; Ho, Mei Ling; Cheng, Tsung Lin] Kaohsiung Med Univ, Orthopaed Res Ctr, Kaohsiung, Taiwan.
   [Chen, Chung Hwan; Lin, Sung Yen] Kaohsiung Med Univ, Coll Med, Dept Orthoped, Kaohsiung, Taiwan.
   [Chen, Chung Hwan; Lin, Sung Yen] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Orthoped, Div Adult Reconstruct Surg, Kaohsiung, Taiwan.
   [Chen, Chung Hwan; Lin, Sung Yen] Kaohsiung Med Univ, Kaohsiung Municipal Ta Tung Hosp, Dept Orthoped, Kaohsiung, Taiwan.
   [Chen, Chung Hwan; Lin, Sung Yen; Ho, Mei Ling; Cheng, Tsung Lin] Kaohsiung Med Univ, Regenerat Med & Cell Therapy Res Ctr, Kaohsiung, Taiwan.
   [Chen, Chung Hwan] Natl Sun Yat Sen Univ, Inst Med Sci & Technol, Kaohsiung, Taiwan.
   [Lai, Chao Han] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Surg, Tainan, Taiwan.
   [Hong, Yi Kai] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan, Taiwan.
   [Lu, Jui Ming; Chang, Lan Yun; Wu, Hua Lin] Natl Cheng Kung Univ, Coll Med, Dept Biochem & Mol Biol, Tainan, Taiwan.
   [Ho, Mei Ling; Cheng, Tsung Lin] Kaohsiung Med Univ, Coll Med, Sch Med, Dept Physiol, Kaohsiung 807378, Taiwan.
   [Conway, Edward M.] Univ British Columbia, Fac Med, Ctr Blood Res, Life Sci Inst, Vancouver, BC, Canada.
C3 Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung
   Medical University; Kaohsiung Medical University Hospital; Kaohsiung
   Medical University; Kaohsiung Municipal Ta Tung Hospital; Kaohsiung
   Medical University; National Sun Yat Sen University; National Cheng Kung
   University; National Cheng Kung University Hospital; National Cheng Kung
   University; National Cheng Kung University; Kaohsiung Medical
   University; University of British Columbia
RP Cheng, TL (通讯作者)，Kaohsiung Med Univ, Coll Med, Sch Med, Dept Physiol, Kaohsiung 807378, Taiwan.
EM junglecc@gmail.com
RI Lee, Tien Ching/ABF 4544 2021; Chen, Chung Hwan/D 4036 2009; Lai,
   Chao Han/JAX 5678 2023; Ho, Mei Ling/D 5515 2009
OI Lai, Chao Han/0000 0002 1382 1495; Chen, Chung Hwan/0000 0001 8941 4792;
   Ho, Mei Ling/0000 0001 8064 8488; Lee, Tien Ching/0000 0002 1510 8079; 
FU Ministry of Science and Technology [MOST 106 2314 B 037 009 MY3, MOST
   105 2320 B 006 039 MY3, MOST 108 2320 B 006 014 ]; Executive Yuan,
   Taiwan; Kaohsiung Medical University Research Center [KMU TC108A02];
   Kaohsiung Municipal Ta Tung Hospital, Kaohsiung, Taiwan [kmtth 107 042]
FX This work was supported by grants from the Ministry of Science and
   Technology (MOST 106 2314 B 037 009 MY3 to Tsung Lin Cheng; MOST
   105 2320 B 006 039 MY3, MOST 108 2320 B 006 014  to Hua Lin Wu),
   Executive Yuan, Taiwan; Kaohsiung Medical University Research Center
   (KMU TC108A02), and Kaohsiung Municipal Ta Tung Hospital
   (kmtth 107 042), Kaohsiung, Taiwan.
CR BARTHA K, 1993, J BIOL CHEM, V268, P421
   Bellows CG, 2001, J BONE MINER RES, V16, P1983, DOI 10.1359/jbmr.2001.16.11.1983
   Carter LE, 2012, BMC BIOTECHNOL, V12, DOI 10.1186/1472 6750 12 5
   Chen G, 2011, BIOL PROCED ONLINE, V13, DOI 10.1186/1480 9222 13 1
   Cheng R, 2015, REV ENDOCR METAB DIS, V16, P67, DOI 10.1007/s11154 015 9310 7
   Cheng TL, 2018, J MOL MED, V96, P1333, DOI 10.1007/s00109 018 1702 1
   Cheng TL, 2016, SCI REP UK, V6, DOI 10.1038/srep28340
   Cheng TL, 2015, J INVEST DERMATOL, V135, P1668, DOI 10.1038/jid.2015.32
   Cheng TL, 2011, J INVEST DERMATOL, V131, P2486, DOI 10.1038/jid.2011.230
   Cheng TL, 2009, J CELL BIOCHEM, V107, P1002, DOI 10.1002/jcb.22200
   Conway EM, 2002, J EXP MED, V196, P565, DOI 10.1084/jem.20020077
   ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164
   Fu YC, 2015, INT J NANOMED, V10, P7231, DOI 10.2147/IJN.S88134
   Gilbert L, 2000, ENDOCRINOLOGY, V141, P3956, DOI 10.1210/en.141.11.3956
   HAMADA H, 1995, BLOOD, V86, P225, DOI 10.1182/blood.V86.1.225.bloodjournal861225
   Hsu YY, 2012, FASEB J, V26, P3440, DOI 10.1096/fj.12 204917
   Huang HC, 2003, J BIOL CHEM, V278, P46750, DOI 10.1074/jbc.M305216200
   ISHII H, 1985, J CLIN INVEST, V76, P2178, DOI 10.1172/JCI112225
   Jiao HL, 2015, CURR OSTEOPOROS REP, V13, P327, DOI 10.1007/s11914 015 0286 8
   Kao YC, 2010, MOL CELL BIOL, V30, P4767, DOI 10.1128/MCB.01021 09
   Kuo CH, 2012, BLOOD, V119, P1302, DOI 10.1182/blood 2011 08 376038
   Leslie WD, 2012, J BONE MINER RES, V27, P2231, DOI 10.1002/jbmr.1759
   Lin SY, 2019, PHYTOMEDICINE, V55, P165, DOI 10.1016/j.phymed.2018.07.012
   Loghmani H, 2018, BLOOD, V132, P148, DOI 10.1182/blood 2017 12 768994
   Lohi O, 2004, CURR BIOL, V14, P236, DOI 10.1016/j.cub.2004.01.025
   Ma CY, 2012, J IMMUNOL, V188, P6328, DOI 10.4049/jimmunol.1102266
   MAILLARD C, 1993, ENDOCRINOLOGY, V133, P668, DOI 10.1210/en.133.2.668
   MCCACHREN SS, 1991, BLOOD, V78, P3128
   Mehta SK, 2010, FOOT ANKLE CLIN, V15, P411, DOI 10.1016/j.fcl.2010.03.005
   Peng J, 2016, CONNECT TISSUE RES, V57, P277, DOI 10.3109/03008207.2016.1171858
   RAIFE TJ, 1994, J CLIN INVEST, V93, P1846, DOI 10.1172/JCI117171
   Schwartz AV, 2003, CALCIFIED TISSUE INT, V73, P515, DOI 10.1007/s00223 003 0023 7
   Shi CS, 2008, BLOOD, V112, P3661, DOI 10.1182/blood 2008 03 142760
   Shi CS, 2005, CIRCULATION, V111, P1627, DOI 10.1161/01.CIR.0000160364.05405.B5
   STANFORD CM, 1995, J BIOL CHEM, V270, P9420, DOI 10.1074/jbc.270.16.9420
   StearnsKurosawa DJ, 1996, P NATL ACAD SCI USA, V93, P10212, DOI 10.1073/pnas.93.19.10212
   Tarroni P, 2012, J CELL BIOCHEM, V113, P640, DOI 10.1002/jcb.23392
   Thrailkill KM, 2005, DIABETES, V54, P2875, DOI 10.2337/diabetes.54.10.2875
   TSIANG M, 1992, J BIOL CHEM, V267, P6164
   Wang CC, 2018, J BONE MINER RES, V33, P283, DOI 10.1002/jbmr.3305
   Weiler H, 2003, J THROMB HAEMOST, V1, P1515, DOI 10.1046/j.1538 7836.2003.00306.x
   Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200
NR 42
TC 12
Z9 13
U1 1
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD SEP
PY 2020
VL 35
IS 9
BP 1812
EP 1823
DI 10.1002/jbmr.4036
EA MAY 2020
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA NL6ZL
UT WOS:000531630100001
PM 32329910
OA Bronze
DA 2025 08 17
ER

PT J
AU Liu, XN
   Li, Z
   Liu, H
   Zhu, Y
   Xia, DD
   Wang, SY
   Gu, RL
   Wu, WL
   Zhang, P
   Liu, YS
   Zhou, YS
AF Liu, Xuenan
   Li, Zheng
   Liu, Hao
   Zhu, Yuan
   Xia, Dandan
   Wang, Siyi
   Gu, Ranli
   Wu, Weiliang
   Zhang, Ping
   Liu, Yunsong
   Zhou, Yongsheng
TI Low concentration flufenamic acid enhances osteogenic differentiation of
   mesenchymal stem cells and suppresses bone loss by inhibition of the
   NF κB signaling pathway
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Flufenamic acid; Mesenchymal stem cells; Osteogenesis; Osteoporosis;
   Nuclear factor kappa B
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ASPIRIN; PROLIFERATION; ACTIVATION
AB Background: As the representative of fenamic acids, an important group of NSAIDs, flufenamic acid (FFA) has been used for anti inflammation and analgesia in the clinic. Recently, researches have focused on the role of some members of NSAIDs in promoting osteogenesis. However, little attention has been paid to the subgroup of fenamic acids, and it remains unclear whether FFA and other fenamic acids could regulate mesenchymal stem cells' (MSCs) lineage commitment and bone regeneration.
   Methods: Here we treated two kinds of human MSCs with FFA at different concentrations in vitro and examined the effect of FFA on osteogenic differentiation of human MSCs. This was followed by heterotopic bone formation assay in nude mice. In addition, ovariectomized and aged mice were used as osteoporotic models to test the effect of FFA on osteoporosis. Besides, activators and inhibitor of nuclear factor kappa B (NF kappa B) signaling pathway and western blot were used to clarify the mechanism of the promoting effect of low concentration FFA on osteogenesis.
   Results: Our results indicated that low concentrations of FFA could significantly enhance osteogenic differentiation of human MSCs in vitro, as well as in vivo. In addition, FFA treatment suppressed bone loss in ovariectomized and aged mice. Mechanistically, FFA at low concentrations promoted osteogenesis differentiation of human MSCs by inhibition of the NF kappa B signaling pathway.
   Conclusions: Collectively, our study suggested that low concentration FFA could be used in bone tissue engineering or osteoporosis by promoting osteogenic differentiation of human MSCs.
C1 [Liu, Xuenan; Li, Zheng; Liu, Hao; Zhu, Yuan; Wang, Siyi; Gu, Ranli; Zhang, Ping; Liu, Yunsong; Zhou, Yongsheng] Peking Univ, Natl Lab Digital & Mat Technol Stomatol, Beijing Key Lab Digital Stomatol,Dept Prosthodont, Sch & Hosp Stomatol,Natl Clin Res Ctr Oral Dis, 22 Zhongguancun South Ave, Beijing 100081, Peoples R China.
   [Xia, Dandan] Peking Univ, Dept Mat Sci & Engn, Coll Engn, Beijing 100871, Peoples R China.
   [Wu, Weiliang] Fujian Med Univ, Affiliated Stomatol Hosp, Dept Implantol 2, Fuzhou 350001, Fujian, Peoples R China.
C3 Peking University; Peking University; Fujian Medical University
RP Zhang, P; Liu, YS (通讯作者)，Peking Univ, Natl Lab Digital & Mat Technol Stomatol, Beijing Key Lab Digital Stomatol,Dept Prosthodont, Sch & Hosp Stomatol,Natl Clin Res Ctr Oral Dis, 22 Zhongguancun South Ave, Beijing 100081, Peoples R China.
EM zhangping332@bjmu.edu.cn; liuyunsong@hsc.pku.edu.cn
RI Xia, Dandan/AGY 3391 2022; Li, Zheng/LXB 3517 2024; Liu,
   Xuenan/NCV 8049 2025; Liu, Yunsong/AAS 6801 2020; Zhou,
   Yanheng/AFX 1820 2022
OI Liu, Yunsong/0000 0001 8364 1898; 
FU National Key Research and Development Program of China [2016YFC1102900];
   National Natural Science Foundation of China [81771039]; Peking
   University Medicine Seed Fund for Interdisciplinary Research
   [BMU2018ME005]; Beijing Nova Program [Z181100006218037]
FX This study was supported by grants from the National Key Research and
   Development Program of China (No. 2016YFC1102900 to YL), the National
   Natural Science Foundation of China (No. 81771039 to YL), Peking
   University Medicine Seed Fund for Interdisciplinary Research (No.
   BMU2018ME005 to YL), and the Beijing Nova Program (No. Z181100006218037
   to PZ).
CR BARNARDO DE, 1966, BMJ BRIT MED J, V2, P342, DOI 10.1136/bmj.2.5509.342
   Cao Y, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0200 4
   Carbonare LD, 2009, ARTHRITIS RHEUM US, V60, P3356, DOI 10.1002/art.24884
   Chang JK, 2007, BIOCHEM PHARMACOL, V74, P1371, DOI 10.1016/j.bcp.2007.06.047
   Chang JK, 2009, TOXICOLOGY, V258, P148, DOI 10.1016/j.tox.2009.01.016
   Chang J, 2013, P NATL ACAD SCI USA, V110, P9469, DOI 10.1073/pnas.1300532110
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Chen Q, 2013, J BONE MINER RES, V28, P1214, DOI 10.1002/jbmr.1851
   De Luna Bertos E, 2015, BIOL RES NURS, V17, P62, DOI 10.1177/1099800414527155
   Díaz Rodríguez L, 2012, BIOL RES NURS, V14, P98, DOI 10.1177/1099800411398933
   Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0
   Evans CE, 2004, J BONE JOINT SURG BR, V86B, P444, DOI 10.1302/0301 620X.86B3.14592
   García Martínez O, 2011, ARCH ORAL BIOL, V56, P317, DOI 10.1016/j.archoralbio.2010.10.018
   Hadjicharalambous C, 2016, J PHARM PHARMACOL, V68, P1403, DOI 10.1111/jphp.12595
   Hennemann Alexandra, 2002, Med Monatsschr Pharm, V25, P164
   Hess R, 2005, J CELL BIOCHEM, V94, P50, DOI 10.1002/jcb.20330
   Huang J, 2014, J BONE MINER RES, V29, P1531, DOI 10.1002/jbmr.2200
   Jin CY, 2017, J BONE MINER RES, V32, P508, DOI 10.1002/jbmr.3009
   Kua HY, 2012, NAT CELL BIOL, V14, P727, DOI 10.1038/ncb2528
   Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491
   Li Y, 2007, J BONE MINER RES, V22, P646, DOI 10.1359/JBMR.070121
   Lin S, 2016, EUR J PHARMACOL, V791, P331, DOI 10.1016/j.ejphar.2016.09.018
   Liu H, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0195 x
   Liu Y, 2011, NAT MED, V17, P1594, DOI 10.1038/nm.2542
   Lv LW, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.37
   MEUNIER PJ, 1980, CLIN ORTHOP RELAT R, P304
   MONCADA S, 1973, NATURE, V246, P217, DOI 10.1038/246217a0
   Novack DV, 2011, CELL RES, V21, P169, DOI 10.1038/cr.2010.159
   Pongkorpsakol P, 2017, EUR J PHARMACOL, V798, P94, DOI 10.1016/j.ejphar.2017.01.026
   Post S, 2008, BONE, V43, P32, DOI 10.1016/j.bone.2008.03.011
   RAJAN KT, 1967, ANN RHEUM DIS, V26, P43, DOI 10.1136/ard.26.1.43
   Rius J, 2008, NATURE, V453, P807, DOI 10.1038/nature06905
   Sriram D, 2010, MED CHEM, P235
   Tarapore RS, 2016, J BONE MINER RES, V31, P52, DOI 10.1002/jbmr.2592
   TURNER RT, 1994, ENDOCR REV, V15, P275, DOI 10.1210/er.15.3.275
   VANE JR, 1976, J ALLERGY CLIN IMMUN, V58, P691, DOI 10.1016/0091 6749(76)90181 0
   VANE JR, 1971, NATURE NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0
   Zhang P, 2016, J BONE MINER RES, V31, P391, DOI 10.1002/jbmr.2704
NR 38
TC 20
Z9 23
U1 1
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1757 6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD JUL 19
PY 2019
VL 10
AR 213
DI 10.1186/s13287 019 1321 y
PG 14
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA IK4KG
UT WOS:000476555200001
PM 31324207
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Bhandari, KH
   Newa, M
   Uludag, H
   Doschak, MR
AF Bhandari, Krishna Hari
   Newa, Madhuri
   Uludag, Hasan
   Doschak, Michael R.
TI Synthesis, characterization and in vitro evaluation of a bone
   targeting delivery system for salmon Calcitonin
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Calcitonin; Bisphosphonate; Bone targeting; Drug delivery system;
   Osteoporosis; Paget's disease; Bone cancer; Rheumatoid arthritis;
   Osteoarthritis
ID BISPHOSPHONATE CONJUGATION; RECEPTORS; PEPTIDE; IDENTIFICATION;
   DISPOSITION; AFFINITY; BEHAVIOR; SITES
AB Synthetic salmon Calcitonin (sCT) is currently used to treat and manage conditions associated with low bone mass, and elicits its antiresorptive effect by acting upon Calcitonin receptors (CTRs) located on bone resorbing osteoclast cells. However, CTRs are also widely distributed in many non skeletal tissues (such as kidney, brain, and lung), and the competitive uptake of available sCT amongst such CTRs likely reduces sCT availability for bone resident osteoclast cells, particularly if the drug is administered systemically and not specifically targeted to bone. Hence, the objective of this study was to synthesize and characterize a bisphosphonate (BP) mediated bone targeting delivery system for sCT and to determine whether the bioactivity of sCT was retained after BP conjugation. BP sCT conjugates were synthesized by initially reacting sCT with sulfosuccinimidyl 4 [N maleimidomethylicyclohexane 1 carboxylate (sulfo SMCC) in dimethyl formamide in the presence of triethylamine (TEA) at room temperature. Thiolated (Thiol) BP was then reacted with the sCT sulfo SMCC conjugates to generate sCT BP conjugates, which were purified by dialysis and assayed using the micro BCA protein assay. Non BP containing control sCT Cysteine conjugates were also synthesized using the same procedure. Reactions were monitored and characterized using matrix assisted laser desorption ionization time of flight mass spectrometer (MALDI TOF) analysis and Tris Tricine SDS PAGE. Conjugates were evaluated for in vitro bone mineral affinity using a hydroxyapatite binding test, for bone mineral specificity using different calcium salt binding affinity assays, and for continued sCT bioactivity after conjugation using an intracellular cAMP stimulation in human T47D breast cancer cells. Our results confirmed that BP conjugated sCT exhibited significantly greater affinity and specificity for bone mineral over unmodified sCT, and that sCT BP conjugates retained strong CT bioactivity after conjugation. Our conjugation strategy holds the promise of facilitating the delivery of sCT preferentially to skeletal bony tissues, thereby increasing its local concentration to bone surfaces. This peptide hormone bisphosphonate drug system represents a new class of antiresorptive drug that has not previously been attempted, nor has a bone targeting formulation of sCT been reported. Crown Copyright (C) 2010 Published by Elsevier B.V. All rights reserved.
C1 [Bhandari, Krishna Hari; Newa, Madhuri; Uludag, Hasan; Doschak, Michael R.] Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2N8, Canada.
   [Uludag, Hasan] Univ Alberta, Dept Chem & Mat Engn, Edmonton, AB T6G 2N8, Canada.
C3 University of Alberta; University of Alberta
RP Doschak, MR (通讯作者)，Univ Alberta, Fac Pharm & Pharmaceut Sci, 2121 Dent Pharm Ctr, Edmonton, AB T6G 2N8, Canada.
EM mdoschak@ualberta.ca
OI Bhandari, Krishna/0000 0003 4526 2023; Doschak,
   Michael/0000 0002 0293 6596
FU The (Canadian) Arthritis Society (TAS); Alberta Heritage Foundation for
   Medical Research (AHFMR)
FX This research was funded by The (Canadian) Arthritis Society (TAS), and
   by the OA Alberta Team Grant from the Alberta Heritage Foundation for
   Medical Research (AHFMR).
CR AIDA S, 1994, ANN RHEUM DIS, V53, P247, DOI 10.1136/ard.53.4.247
   BAUER HH, 1995, J STRUCT BIOL, V115, P1, DOI 10.1006/jsbi.1995.1024
   Cenni E, 2008, BIOMATERIALS, V29, P1400, DOI 10.1016/j.biomaterials.2007.12.022
   CHAMBERS TJ, 1982, J PATHOL, V136, P27, DOI 10.1002/path.1711360104
   CHAUSMER A, 1980, J LAB CLIN MED, V96, P933
   Cheng WQ, 2007, PHARM RES, V24, P99, DOI 10.1007/s11095 006 9128 9
   Cholewinski M, 1996, Pharm Acta Helv, V71, P405, DOI 10.1016/S0031 6865(96)00049 0
   Doschak MR, 2009, MOL PHARMACEUT, V6, P634, DOI 10.1021/mp8002368
   DSANTOS CS, 1988, ENDOCRINOLOGY, V123, P1483, DOI 10.1210/endo 123 3 1483
   Farley J, 2000, CALCIFIED TISSUE INT, V67, P247, DOI 10.1007/s002230001112
   FOUCHEREAUPERON M, 1981, P NATL ACAD SCI BIOL, V78, P3973, DOI 10.1073/pnas.78.6.3973
   Fujisaki J, 1997, BIOL PHARM BULL, V20, P1183
   Gittens SA, 2003, PHARMACEUT RES, V20, P978, DOI 10.1023/A:1024445903306
   GOLTZMAN D, 1985, SCIENCE, V227, P1343, DOI 10.1126/science.2983422
   GORN AH, 1992, J CLIN INVEST, V90, P1726, DOI 10.1172/JCI116046
   Heymsfield S, 2005, HUMAN BODY COMPOSITI
   Hirabayashi H, 2003, CLIN PHARMACOKINET, V42, P1319, DOI 10.2165/00003088 200342150 00002
   Karsdal MA, 2007, ANN NY ACAD SCI, V1117, P181, DOI 10.1196/annals.1402.041
   Kasugai S, 2000, J BONE MINER RES, V15, P936, DOI 10.1359/jbmr.2000.15.5.936
   Lee KC, 2003, CALCIFIED TISSUE INT, V73, P545, DOI 10.1007/s00223 002 0034 9
   Lee YH, 2000, ADV DRUG DELIVER REV, V42, P225, DOI 10.1016/S0169 409X(00)00063 6
   Naot D, 2008, BONE, V43, P813, DOI 10.1016/j.bone.2008.07.003
   NICHOLSON GC, 1988, BIOCHEM J, V250, P877, DOI 10.1042/bj2500877
   Okubo Y, 2000, BIOCHEM BIOPH RES CO, V269, P317, DOI 10.1006/bbrc.2000.2294
   ORME MW, 1994, BIOORG MED CHEM LETT, V4, P1375, DOI 10.1016/S0960 894X(01)80365 6
   PIERCE WM, 1987, P SOC EXP BIOL MED, V186, P96
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   RITTEL W, 1976, EXPERIENTIA, V32, P246, DOI 10.1007/BF01937791
   Rogers MJ, 1999, BONE, V24, p73S, DOI 10.1016/S8756 3282(99)00070 8
   Shin BS, 2004, CHEM PHARM BULL, V52, P957, DOI 10.1248/cpb.52.957
   SILVESTRONI L, 1987, J CLIN ENDOCR METAB, V65, P742, DOI 10.1210/jcem 65 4 742
   Torres Lugo M, 2000, BIOMATERIALS, V21, P1191, DOI 10.1016/S0142 9612(00)00011 9
   Uludag H, 2000, BIOTECHNOL PROGR, V16, P1115, DOI 10.1021/bp000066y
   Uludag H, 2000, BIOTECHNOL PROGR, V16, P258, DOI 10.1021/bp990154m
   WARSHAWSKY H, 1980, J CELL BIOL, V85, P682, DOI 10.1083/jcb.85.3.682
   Yokogawa K, 2001, ENDOCRINOLOGY, V142, P1228, DOI 10.1210/en.142.3.1228
   Youn YS, 2006, J CONTROL RELEASE, V114, P334, DOI 10.1016/j.jconrel.2006.06.007
NR 37
TC 21
Z9 30
U1 0
U2 25
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378 5173
EI 1873 3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD JUL 15
PY 2010
VL 394
IS 1 2
BP 26
EP 34
DI 10.1016/j.ijpharm.2010.04.015
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 623EH
UT WOS:000279720400003
PM 20412845
DA 2025 08 17
ER

PT J
AU Rossi, E
   Mracsko, E
   Papadimitropoulos, A
   Allafi, N
   Reinhardt, D
   Mehrkens, A
   Martin, I
   Knuesel, I
   Scherberich, A
AF Rossi, Eleonora
   Mracsko, Eva
   Papadimitropoulos, Adam
   Allafi, Nima
   Reinhardt, Dieter
   Mehrkens, Arne
   Martin, Ivan
   Knuesel, Irene
   Scherberich, Arnaud
TI An In Vitro Bone Model to Investigate the Role of Triggering
   Receptor Expressed on Myeloid Cells 2 in Bone Homeostasis
SO TISSUE ENGINEERING PART C METHODS
LA English
DT Article
DE in vitro 3D model; human progenitors; TREM 2; bone homeostasis
ID OSTEOCLAST DIFFERENTIATION; TREM2 VARIANTS
AB Triggering receptor expressed on myeloid cells 2 (TREM 2), a transmembrane receptor expressed by macrophages, microglia, and osteoclasts (OCs), plays a protective role in late onset Alzheimer Disease (AD). To validate TREM 2 as a therapeutic target in AD, its potential secondary parallel effect on bone homeostasis should be clarified. However, animal models and monolayer cultures of human cells were shown poorly predictive of TREM 2 function in human. Therefore, this study aimed to engineer a tridimensional in vitro model using human progenitors differentiated into osteoblasts and OCs, recapitulating physiological bone homeostasis. Human bone marrow derived mesenchymal cells were seeded and cultured under perfusion inside a collagen type I scaffold for 3 weeks, generating osteoblasts and mineralized matrix. Human peripheral blood derived CD14(+) monocytes were subsequently seeded through the generated tissue, thanks to perfusion flow, and further cultured for up to 3 weeks with an inductive medium, generating mature OCs. This culture system supported collagenous matrix deposition and resorption, allowing for the investigation of kinetic of soluble TREM 2 over the coculture time. Agonistic activation of TREM 2 in this model had no effect on OC activity or on mineralized matrix turnover. In conclusion, the engineered culture system represents a tridimensional, in vitro human bone model for drug testing and suggested no effect of TREM 2 agonist on bone resorption.
C1 [Rossi, Eleonora; Papadimitropoulos, Adam; Allafi, Nima; Mehrkens, Arne; Martin, Ivan; Scherberich, Arnaud] Univ Basel, Univ Hosp Basel, Dept Biomed, Hebelstr 20, CH 4104 Basel, Switzerland.
   [Mracsko, Eva; Reinhardt, Dieter; Knuesel, Irene] Roche Innovat Ctr, Roche Pharmaceut Res & Early Dev, Basel, Switzerland.
   [Scherberich, Arnaud] Univ Hosp Basel, Clin Plast Reconstruct & Aesthet Surg, Basel, Switzerland.
C3 University of Basel; Roche Holding; University of Basel
RP Martin, I (通讯作者)，Univ Basel, Univ Hosp Basel, Dept Biomed, Hebelstr 20, CH 4104 Basel, Switzerland.
EM ivan.martin@usb.ch
RI ; Scherberich, Arnaud/H 9554 2019; Martin, Ivan/K 9286 2016
OI Mehrkens, Arne/0000 0002 9189 4278; Scherberich,
   Arnaud/0000 0003 3468 6955; Rossi, Eleonora/0000 0002 4471 6524;
   Knuesel, Irene/0000 0003 0396 9952; Martin, Ivan/0000 0001 6493 0432
FU Roche Pharmaceuticals, Basel, Switzerland
FX This work was funded by Roche Pharmaceuticals, Basel, Switzerland.
   Authors are grateful to Dr. Fabiana Gullotta and Dr. Atanas Torodov for
   the scientific advice and technical support.
CR Bianchin MM, 2004, CELL MOL NEUROBIOL, V24, P1, DOI 10.1023/B:CEMN.0000012721.08168.ee
   Bouchon A, 2001, J EXP MED, V194, P1111, DOI 10.1084/jem.194.8.1111
   Colonna M, 2007, ADV EXP MED BIOL, V602, P97
   Colonna M, 2016, NAT REV NEUROSCI, V17, P201, DOI 10.1038/nrn.2016.7
   Guerreiro R, 2013, NEW ENGL J MED, V368, P117, DOI 10.1056/NEJMoa1211851
   Hickman SE, 2014, BIOCHEM PHARMACOL, V88, P495, DOI 10.1016/j.bcp.2013.11.021
   Jiang T, 2013, MOL NEUROBIOL, V48, P180, DOI 10.1007/s12035 013 8424 8
   Jonsson T, 2013, NEW ENGL J MED, V368, P107, DOI 10.1056/NEJMoa1211103
   Kim Y., 2005, J BIOL CHEM, V280, P32
   Kleinberger G, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009093
   Otero K, 2012, J IMMUNOL, V188, P2612, DOI 10.4049/jimmunol.1102836
   Paloneva J, 2003, J EXP MED, V198, P669, DOI 10.1084/jem.20030027
   Papadimitropoulos A, 2011, EUR CELLS MATER, V21, P445, DOI 10.22203/eCM.v021a33
   Pearce AI, 2007, EUR CELLS MATER, V13, P1
   Piccio L, 2008, BRAIN, V131, P3081, DOI 10.1093/brain/awn217
   Poliani PL, 2015, J CLIN INVEST, V125, P2161, DOI 10.1172/JCI77983
   Schmid CD, 2002, J NEUROCHEM, V83, P1309, DOI 10.1046/j.1471 4159.2002.01243.x
   Tortelli F, 2009, TISSUE ENG PT A, V15, P2373, DOI 10.1089/ten.tea.2008.0501
   Villasante A, 2017, TISSUE ENG PART C ME, V23, P98, DOI [10.1089/ten.tec.2016.0371, 10.1089/ten.TEC.2016.0371]
   Wang YM, 2016, J EXP MED, V213, P667, DOI 10.1084/jem.20151948
   Wendt D, 2003, BIOTECHNOL BIOENG, V84, P205, DOI 10.1002/bit.10759
   Yaghmoor Noorsaeed A.F., 2014, J ALZHEIMERS DIS PAR, V4
   Yuan P, 2016, NEURON, V92, P252, DOI 10.1016/j.neuron.2016.09.016
NR 23
TC 6
Z9 6
U1 0
U2 8
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3384
EI 1937 3392
J9 TISSUE ENG PART C ME
JI Tissue Eng. Part C Methods
PD JUL
PY 2018
VL 24
IS 7
BP 391
EP 398
DI 10.1089/ten.tec.2018.0061
PG 8
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA GM9ER
UT WOS:000438547000002
PM 29897015
DA 2025 08 17
ER

PT J
AU Arshad, F
   Bishop, N
AF Arshad, Fawaz
   Bishop, Nick
TI Osteogenesis imperfecta in children
SO BONE
LA English
DT Article
DE Fragility; Multidisciplinary; Hypermineralisation; Hyperosteocytosis
ID BRITTLE BONE; MOUSE MODEL; SCLEROSTIN ANTIBODY; BISPHOSPHONATE
   TREATMENT; INTRAVENOUS PAMIDRONATE; MECHANICAL PROPERTIES; RECESSIVE
   MUTATION; GENOTYPE PHENOTYPE; FEMORAL FRACTURES; MUSCLE FUNCTION
AB Osteogenesis imperfecta (OI) is a disease characterised by altered bone tissue material properties together with abnormal micro and macro architecture and thus bone fragility, increased bone turnover and hyperosteocytosis. Increasingly appreciated are the soft tissue changes, sarcopenia in particular. Approaches to treatment are now multidisciplinary, with bisphosphonates having been the primary pharmacological intervention over the last 20 years. Whilst meta analyses suggest that anti fracture efficacy across the life course is equivocal, there is good evidence that for children bisphosphonates reduce fracture risk, increase vertebral size and improve vertebral shape, as well as improving motor function and mobility. The genetics of OI continues to provide insights into the molecular pathogenesis of the disease, although the pathophysiology is less clear.
   The complexity of the multi scale interactions of bone tissue with cellular function are gradually being disentangled, but the fundamental question of why increased tissue brittleness should be associated with so many other changes is unclear; ER stress, pro inflammatory cytokines, accelerated senesence and altered matrix component release might all contribute, but a unifying hypothesis remains elusive.
   New approaches to therapy are focussed on increasing bone mass, following the paradigm established by the treatment of postmenopausal osteoporosis. For adults, this brings the prospect of restoring previously lost bone ? for children, particularly at the severe end of the spectrum, the possibility of further reducing fracture frequency and possibly altering growth and long term function are attractive. The alternatives that might affect tissue brittleness are autophagy enhancement (through the removal of abnormal type I collagen aggregates) and stem cell transplantation ? both still at the preclinical stage of assessment. Preclinical assessment is not supportive of targeting inflammatory pathways, although understanding why TGFb signalling is increased, and whether that presents a treatment target in OI, remains to be established.
C1 [Arshad, Fawaz; Bishop, Nick] Univ Sheffield, Dept Oncol & Metab, Sheffield Childrens Hosp, Acad Unit Child Hlth, Sheffield S10 2TH, S Yorkshire, England.
C3 University of Sheffield; Sheffield Children's NHS Foundation Trust;
   Sheffield Children's Hospital
RP Bishop, N (通讯作者)，Univ Sheffield, Dept Oncol & Metab, Sheffield Childrens Hosp, Acad Unit Child Hlth, Sheffield S10 2TH, S Yorkshire, England.
EM n.j.bishop@shef.ac.uk
CR Arundel P, 2011, J BONE MINER RES, V26, P894, DOI 10.1002/jbmr.258
   Åström E, 1998, ACTA PAEDIATR, V87, P64
   Balasubramanian M, 2015, AM J MED GENET A, V167, P587, DOI 10.1002/ajmg.a.36916
   Balasubramanian M, 2013, CLIN DYSMORPHOL, V22, P93, DOI 10.1097/MCD.0b013e32836032f0
   Balooch G, 2005, P NATL ACAD SCI USA, V102, P18813, DOI 10.1073/pnas.0507417102
   Barbehenn EK, 2001, TRENDS ENDOCRIN MET, V12, P383, DOI 10.1016/S1043 2760(01)00489 1
   Bargman R, 2012, OSTEOPOROSIS INT, V23, P1141, DOI 10.1007/s00198 011 1742 7
   Barnes AM, 2013, HUM MUTAT, V34, P1279, DOI 10.1002/humu.22362
   Barnes AM, 2006, NEW ENGL J MED, V355, P2757, DOI 10.1056/NEJMoa063804
   Bart ZR, 2014, CONNECT TISSUE RES, V55, P4, DOI 10.3109/03008207.2014.923860
   BATEMAN JF, 1984, BIOCHEM J, V217, P103, DOI 10.1042/bj2170103
   Bateman JF, 2019, J CELL MOL MED, V23, P1735, DOI 10.1111/jcmm.14072
   Becker J, 2011, AM J HUM GENET, V88, P362, DOI 10.1016/j.ajhg.2011.01.015
   Besio R., 2019, DIS MODEL MECH, V12
   Bishop N, 2007, ARCH DIS CHILD, V92, P251, DOI 10.1136/adc.2006.106120
   Bishop N, 2016, J BONE MINER RES, V31, P699, DOI 10.1002/jbmr.2835
   Bishop N, 2013, LANCET, V382, P1424, DOI 10.1016/S0140 6736(13)61091 0
   Bishop N, 2010, J BONE MINER RES, V25, P32, DOI 10.1359/jbmr.090712
   Boyde A, 1999, CALCIFIED TISSUE INT, V64, P185, DOI 10.1007/s002239900600
   Bronheim R, 2019, SPINE, V44, P1057, DOI 10.1097/BRS.0000000000003012
   Brumsen C, 1997, MEDICINE, V76, P266, DOI 10.1097/00005792 199707000 00005
   Cabral WA, 2007, NAT GENET, V39, P359, DOI 10.1038/ng1968
   Camacho NP, 1999, J BONE MINER RES, V14, P264, DOI 10.1359/jbmr.1999.14.2.264
   Capo Chichi JM, 2015, EUR J MED GENET, V58, P637, DOI 10.1016/j.ejmg.2015.11.005
   Carriero A, 2014, J BONE MINER RES, V29, P1392, DOI 10.1002/jbmr.2172
   Chang SW, 2012, BIOPHYS J, V102, P640, DOI 10.1016/j.bpj.2011.11.3999
   Cheung MS, 2007, J BONE MINER RES, V22, P1181, DOI 10.1359/jbmr.070418
   CHIPMAN SD, 1993, P NATL ACAD SCI USA, V90, P1701, DOI 10.1073/pnas.90.5.1701
   Cho TJ, 2012, AM J HUM GENET, V91, P343, DOI 10.1016/j.ajhg.2012.06.005
   Chougui K, 2020, AM J MED GENET A, V182, P842, DOI 10.1002/ajmg.a.61497
   Christiansen HE, 2010, AM J HUM GENET, V86, P389, DOI 10.1016/j.ajhg.2010.01.034
   Cremers S, 2019, BRIT J CLIN PHARMACO, V85, P1052, DOI 10.1111/bcp.13867
   Cundy T, 2018, J BONE MINER RES, V33, P1260, DOI 10.1002/jbmr.3424
   Cunningham VJ, 2010, BONE, V47, P591, DOI 10.1016/j.bone.2010.06.004
   DEVOGELAER JP, 1987, SKELETAL RADIOL, V16, P360, DOI 10.1007/BF00350961
   DiGirolamo DJ, 2015, BONE RES, V3, DOI 10.1038/boneres.2014.42
   DiMeglio LA, 2006, J BONE MINER RES, V21, P132, DOI 10.1359/JBMR.051006
   Doyard M, 2018, J MED GENET, V55, P278, DOI 10.1136/jmedgenet 2017 104999
   Engelbert RHH, 2000, EUR J PEDIATR, V159, P615, DOI 10.1007/s004310000505
   Engelbert RHH, 2000, J PEDIATR US, V137, P397, DOI 10.1067/mpd.2000.107892
   Fahiminiya S, 2013, J MED GENET, V50, P345, DOI 10.1136/jmedgenet 2013 101567
   Forlino A, 2016, LANCET, V387, P1657, DOI 10.1016/S0140 6736(15)00728 X
   Fratzl P, 1996, J CLIN INVEST, V97, P396, DOI 10.1172/JCI118428
   Fratzl Zelman N, 2014, BONE, V60, P122, DOI 10.1016/j.bone.2013.11.023
   Garbes L, 2015, AM J HUM GENET, V96, P432, DOI 10.1016/j.ajhg.2015.01.002
   Gatti D, 2005, J BONE MINER RES, V20, P758, DOI 10.1359/JBMR.041232
   Gensure RC, 2005, J CLIN INVEST, V115, P1250, DOI 10.1172/JCI200522760
   Glorieux FH, 2000, J BONE MINER RES, V15, P1650, DOI 10.1359/jbmr.2000.15.9.1650
   Glorieux FH, 1998, NEW ENGL J MED, V339, P947, DOI 10.1056/NEJM199810013391402
   Glorieux FH, 2017, J BONE MINER RES, V32, P1496, DOI 10.1002/jbmr.3143
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Grafe I, 2016, J BONE MINER RES, V31, P1030, DOI 10.1002/jbmr.2776
   Grafel I, 2014, NAT MED, V20, P670, DOI 10.1038/nm.3544
   Guarnieri V, 2019, AM J MED GENET A, V179, P846, DOI 10.1002/ajmg.a.61100
   Ha Vinh R, 2004, AM J MED GENET A, V131A, P115, DOI 10.1002/ajmg.a.30231
   Hald JD, 2015, J BONE MINER RES, V30, P929, DOI 10.1002/jbmr.2410
   Hartikka H, 2005, J BONE MINER RES, V20, P783, DOI 10.1359/JBMR.050101
   Hennies HC, 2008, NAT GENET, V40, P1410, DOI 10.1038/ng.252
   Hoyer Kuhn H, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/s13023 014 0145 1
   Hoyer Kuhn H, 2013, CALCIFIED TISSUE INT, V93, P565, DOI 10.1007/s00223 013 9799 2
   Itonaga I, 2004, BONE, V34, P57, DOI 10.1016/j.bone.2003.08.008
   Jeong Y, 2018, J BONE MINER RES, V33, P1760, DOI 10.1002/jbmr.3473
   Jeong Y, 2018, MUSCLE NERVE, V57, P294, DOI 10.1002/mus.25706
   Joeng KS, 2017, J CLIN INVEST, V127, P2678, DOI 10.1172/JCI92617
   Joeng KS, 2014, HUM MOL GENET, V23, P4035, DOI 10.1093/hmg/ddu117
   Kamoun Goldrat A, 2008, EUR J ORAL SCI, V116, P195, DOI 10.1111/j.1600 0722.2008.00529.x
   Kämpe AJ, 2017, J BONE MINER RES, V32, P2394, DOI 10.1002/jbmr.3233
   Kang H, 2017, TRANSL RES, V181, P27, DOI 10.1016/j.trsl.2016.11.005
   Keupp K, 2013, AM J HUM GENET, V92, P565, DOI 10.1016/j.ajhg.2013.02.010
   Kobayashi E, 2015, LANCET, V385, P539, DOI 10.1016/S0140 6736(14)61338 6
   Kuurila K, 2000, EUR J PEDIATR, V159, P515, DOI 10.1007/s004310051322
   Kuurila K, 2002, ANN OTO RHINOL LARYN, V111, P939, DOI 10.1177/000348940211101014
   Lapunzina P, 2010, AM J HUM GENET, V87, P110, DOI 10.1016/j.ajhg.2010.05.016
   Letocha AD, 2005, J BONE MINER RES, V20, P977, DOI 10.1359/JBMR.050109
   Lindahl K, 2015, EUR J HUM GENET, V23, P1042, DOI 10.1038/ejhg.2015.81
   Lindahl K, 2011, HUM MUTAT, V32, P598, DOI 10.1002/humu.21475
   Lindert U, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11920
   Lisse TS, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040007
   Lund AM, 1999, ARCH DIS CHILD, V80, P524, DOI 10.1136/adc.80.6.524
   Malfait F, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750 1172 8 78
   Mallet E, 2008, HORM RES, V69, P180, DOI 10.1159/000112592
   Malmgren B, 2020, CALCIFIED TISSUE INT, V107, P143, DOI 10.1007/s00223 020 00707 1
   Marini JC, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.52
   Marr C, 2017, J MULTIDISCIP HEALTH, V10, P1, DOI 10.2147/JMDH.S113483
   Matthews BG, 2017, BONE, V103, P1, DOI 10.1016/j.bone.2017.06.004
   Mendoza Londono R, 2015, AM J HUM GENET, V96, P979, DOI 10.1016/j.ajhg.2015.04.021
   Mohammad KS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005275
   Montpetit K, 2003, PEDIATRICS, V111, pE601, DOI 10.1542/peds.111.5.e601
   Moosa S, 2019, AM J HUM GENET, V105, P836, DOI 10.1016/j.ajhg.2019.08.008
   Morello R, 2006, CELL, V127, P291, DOI 10.1016/j.cell.2006.08.039
   Morlino S, 2020, CLIN GENET, V97, P396, DOI 10.1111/cge.13683
   Mortier GR, 2019, AM J MED GENET A, V179, P2393, DOI 10.1002/ajmg.a.61366
   Munns CFJ, 2004, J BONE MINER RES, V19, P1779, DOI 10.1359/JBMR.040814
   Munns CF, 2015, AM J HUM GENET, V96, P971, DOI 10.1016/j.ajhg.2015.04.017
   Nicolaou N, 2012, J CHILD ORTHOP, V6, P21, DOI 10.1007/s11832 011 0380 0
   Palomo T, 2014, BONE, V67, P63, DOI 10.1016/j.bone.2014.06.041
   Paolacci S, 2018, J MED GENET, V55, P837, DOI 10.1136/jmedgenet 2018 105528
   Pekkinen M, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.126180
   Rauch F, 2000, BONE, V26, P581, DOI 10.1016/S8756 3282(00)00269 6
   Rauch F, 2004, LANCET, V363, P1377, DOI 10.1016/S0140 6736(04)16051 0
   Rauch F, 2002, J CLIN INVEST, V110, P1293, DOI 10.1172/JCI200215952
   Rauch F, 2015, AM J HUM GENET, V96, P425, DOI 10.1016/j.ajhg.2014.12.027
   Rauch F, 2009, J BONE MINER RES, V24, P1282, DOI [10.1359/jbmr.090213, 10.1359/JBMR.090213]
   Ritelli M., 2019, GENES BASEL, V10
   Rolvien T, 2017, J BONE MINER RES, V32, P277, DOI 10.1002/jbmr.2980
   Rossi V, 2019, CURR OPIN PEDIATR, V31, P708, DOI 10.1097/MOP.0000000000000813
   Sakkers R, 2004, LANCET, V363, P1427, DOI 10.1016/S0140 6736(04)16101 1
   Salter L, 2018, ARCH DIS CHILD, V103, P767, DOI 10.1136/archdischild 2017 313859
   Scheiber AL, 2019, BIOCHEM BIOPH RES CO, V509, P235, DOI 10.1016/j.bbrc.2018.12.111
   Schwarze U, 2013, HUM MOL GENET, V22, P1, DOI 10.1093/hmg/dds371
   Seikaly MG, 2005, J PEDIATR ORTHOPED, V25, P786, DOI 10.1097/01.bpo.0000176162.78980.ed
   Semler O, 2012, AM J HUM GENET, V91, P349, DOI 10.1016/j.ajhg.2012.06.011
   Senthilnathan S, 2008, ARCH DIS CHILD, V93, P398, DOI 10.1136/adc.2007.125468
   Shaheen R, 2012, J MED GENET, V49, P630, DOI 10.1136/jmedgenet 2012 101142
   SILLENCE DO, 1979, J MED GENET, V16, P101, DOI 10.1136/jmg.16.2.101
   Simm PJ, 2018, J PAEDIATR CHILD H, V54, P223, DOI 10.1111/jpc.13768
   Sinder BP, 2015, BONE, V71, P115, DOI 10.1016/j.bone.2014.10.012
   Symoens Sofie, 2013, Orphanet J Rare Dis, V8, P154, DOI 10.1186/1750 1172 8 154
   Thompson JB, 2001, NATURE, V414, P773, DOI 10.1038/414773a
   Trejo P, 2017, J BONE MINER RES, V32, P1034, DOI 10.1002/jbmr.3071
   Van Dijk FS, 2014, AM J MED GENET A, V164, P1470, DOI 10.1002/ajmg.a.36545
   van Dijk FS, 2020, AM J HUM GENET, V107, P989, DOI 10.1016/j.ajhg.2020.09.009
   van Dijk FS, 2009, AM J HUM GENET, V85, P521, DOI 10.1016/j.ajhg.2009.09.001
   Vanleene M, 2012, BONE, V50, P1317, DOI 10.1016/j.bone.2012.03.007
   Veilleux LN, 2017, J MUSCULOSKEL NEURON, V17, P1
   Veilleux LN, 2017, CALCIFIED TISSUE INT, V101, P362, DOI 10.1007/s00223 017 0287 y
   Veilleux LN, 2015, BONE, V79, P52, DOI 10.1016/j.bone.2015.05.019
   Veilleux LN, 2014, J CLIN ENDOCR METAB, V99, pE356, DOI 10.1210/jc.2013 3209
   Vuorimies I, 2017, J CLIN ENDOCR METAB, V102, P1333, DOI 10.1210/jc.2016 3745
   Vuorimies I, 2017, BONE, V94, P29, DOI 10.1016/j.bone.2016.10.004
   Ward LM, 2011, J CLIN ENDOCR METAB, V96, P355, DOI 10.1210/jc.2010 0636
   Ward LM, 2002, BONE, V31, P12, DOI 10.1016/S8756 3282(02)00790 1
   Whyte MP, 2012, NEW ENGL J MED, V366, P904, DOI 10.1056/NEJMoa1106173
   Whyte MP, 2003, NEW ENGL J MED, V349, P457, DOI 10.1056/NEJMoa023110
   Wuyts W, 2005, AM J MED GENET A, V135A, P66, DOI 10.1002/ajmg.a.30663
   Yang SH, 2006, J CLIN INVEST, V116, P2115, DOI 10.1172/JCI28968
NR 136
TC 16
Z9 16
U1 1
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JUL
PY 2021
VL 148
AR 115914
DI 10.1016/j.bone.2021.115914
EA APR 2021
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA RW1BI
UT WOS:000646258000003
PM 33722772
DA 2025 08 17
ER

PT J
AU Arellano, J
   González, JM
   Qian, Y
   Habib, M
   Mohamed, AF
   Gatta, F
   Hauber, AB
   Posner, J
   Califaretti, N
   Chow, E
AF Arellano, J.
   Gonzalez, J. M.
   Qian, Y.
   Habib, M.
   Mohamed, A. F.
   Gatta, F.
   Hauber, A. B.
   Posner, J.
   Califaretti, N.
   Chow, E.
TI Physician preferences for bone metastasis drug therapy in Canada
SO CURRENT ONCOLOGY
LA English
DT Article
DE Bone metastases; skeletal related events; physician preferences;
   conjoint analysis; discrete choice experiments; bone targeted agents
ID SKELETAL RELATED EVENTS; CONJOINT ANALYSIS APPLICATIONS; ZOLEDRONIC
   ACID; EXPERIMENTAL DESIGN; PROSTATE CANCER; TASK FORCE; HEALTH;
   DENOSUMAB; TRIALS; OSTEONECROSIS
AB Background Currently in Canada, several bone targeted agents (BTAS) with varying characteristics are available for the prevention of skeletal related events (SRES) in patients with bone metastasis secondary to solid tumours. In the present study, we evaluated the preferences of physicians in Canada for the various attributes of the available BTAS.
   Methods Physicians treating patients with bone metastasis from solid tumours were invited to complete an online discrete choice experiment. Respondents were asked to choose between pairs of hypothetical medications for virtual patients. Each hypothetical medication was described based on predefined key attributes: time until first SRE, time until worsening of pain, medication related annual risk of osteonecrosis of the jaw (ONJ), medication related annual risk of renal impairment, and mode of administration. A random parameters logit model was used to analyze the choices between hypothetical medications and thus infer physician preferences for medication attributes.
   Results Responses from the 200 physicians who completed the discrete choice experiment suggested that months until first SRE, risk of renal impairment, and months until worsening of pain were considered the most important attributes affecting choice of BTA. The annual risk of ONJ was considered the least important attribute.
   Conclusions When making treatment decisions about the choice of BTA for patients with bone metastasis from solid tumours, delaying SRES and worsening of pain, and reducing the risk of renal impairment are primary considerations for physicians in Canada.
C1 [Arellano, J.; Qian, Y.] Amgen Inc, Thousand Oaks, CA USA.
   [Gonzalez, J. M.; Mohamed, A. F.; Hauber, A. B.; Posner, J.] RTI Hlth Solut, Res Triangle Pk, NC USA.
   [Habib, M.] Amgen Canada, Toronto, ON, Canada.
   [Gatta, F.] Amgen Europe, Zug, Switzerland.
   [Califaretti, N.] Grand River Reg Canc Ctr, Waterloo, ON, Canada.
   [Chow, E.] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada.
C3 Amgen; Research Triangle Institute; Amgen; AMGEN Europe; University of
   Toronto; Sunnybrook Health Science Center; Sunnybrook Research Institute
RP Gatta, F (通讯作者)，Amgen Europe GmbH, Dammstr 23, CH 6301 Zug, Switzerland.
EM fgatta@amgen.com
RI GONZALEZ, Juan/KSL 6454 2024; qian, yi/HZH 4175 2023
OI Gonzalez, Juan Marcos/0000 0002 5386 0907; 
FU Amgen, Inc., Thousand Oaks, CA, U.S.A
FX Funding for this study was obtained from Amgen, Inc., Thousand Oaks, CA,
   U.S.A.
CR Agrillo A, 2012, EUR REV MED PHARMACO, V16, P1741
   Amgen Inc, 2013, XGEV DEN FULL PRESCR
   [Anonymous], ISPOR 16 ANN EUR C D
   Arellano J, 2015, VALUE HEALTH, V18, P78, DOI 10.1016/j.jval.2014.10.004
   Bayer Australia Limited, 2013, PROD INF BON SOD CLO
   Bridges JFP, 2011, VALUE HEALTH, V14, P403, DOI 10.1016/j.jval.2010.11.013
   Bridges JFP, 2008, PATIENT, V1, P273, DOI [10.2165/01312067 200801040 00009, 10.2165/1312067 200801040 00009]
   Chow E, 2006, CLIN ONCOL UK, V18, P67, DOI 10.1016/j.clon.2005.06.016
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Coleman RE, 2004, ONCOLOGIST, V9, P14, DOI 10.1634/theoncologist.9 90004 14
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   de Bekker Grob EW, 2012, HEALTH ECON, V21, P145, DOI 10.1002/hec.1697
   Delea T, 2004, ONCOLOGY BASEL, V67, P390, DOI 10.1159/000082923
   Fairchild A, 2009, INT J RADIAT ONCOL, V75, P1501, DOI 10.1016/j.ijrobp.2008.12.084
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Gonzalez JM, 2014, VALUE HLTH, V17
   Hauber AB, 2013, OSTEOARTHR CARTILAGE, V21, P289, DOI 10.1016/j.joca.2012.11.007
   Henry D, 2014, SUPPORT CARE CANCER, V22, P679, DOI 10.1007/s00520 013 2022 1
   Hird A, 2009, INT J RADIAT ONCOL, V75, P193, DOI 10.1016/j.ijrobp.2008.10.044
   Huber J, 1996, J MARKETING RES, V33, P307, DOI 10.2307/3152127
   Johnson FR, 2013, VALUE HEALTH, V16, P3, DOI 10.1016/j.jval.2012.08.2223
   Kelly M, 2012, CAN J SURG, V55, P95, DOI 10.1503/cjs.049009
   KUHFELD WF, 1994, J MARKETING RES, V31, P545, DOI 10.2307/3151882
   Lage MJ, 2008, AM J MANAG CARE, V14, P317
   Langer C, 2010, LUNG CANCER, V67, P4, DOI 10.1016/j.lungcan.2009.08.020
   Lipton A, 2012, EUR J CANCER, V48, P3082, DOI 10.1016/j.ejca.2012.08.002
   Marshall D, 2010, PATIENT, V3, P249, DOI 10.2165/11539650 000000000 00000
   Novartis Pharmaceuticals Corporation, 2012, AR PAM DIS INJ
   Novartis Pharmaceuticals Corporation, 2012, ZOM ZOL AC FULL PRES
   Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755
   Polascik Thomas J, 2008, Ther Clin Risk Manag, V4, P261
   Saad F, 2012, ANN ONCOL, V23, P1341, DOI 10.1093/annonc/mdr435
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Train K., 2002, DISCRETE CHOICE METH, DOI [10.1017/CBO9780511753930, DOI 10.1017/CBO9780511753930]
   Train K., 2005, Applications of Simulation Methods in Environmental Resource Economics, P117
NR 35
TC 10
Z9 10
U1 0
U2 7
PU MULTIMED INC
PI TORONTO
PA 66 MARTIN ST, TORONTO, ON L9T 2R2, CANADA
SN 1198 0052
J9 CURR ONCOL
JI Curr. Oncol.
PD OCT
PY 2015
VL 22
IS 5
BP E342
EP E348
DI 10.3747/co.22.2380
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA CU1YI
UT WOS:000363317900005
PM 26628874
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Gorvin, CM
   Hannan, FM
   Howles, SA
   Babinsky, VN
   Piret, SE
   Rogers, A
   Freidin, AJ
   Stewart, M
   Paudyal, A
   Hough, TA
   Nesbit, MA
   Wells, S
   Vincent, TL
   Brown, SDM
   Cox, RD
   Thakker, RV
AF Gorvin, Caroline M.
   Hannan, Fadil M.
   Howles, Sarah A.
   Babinsky, Valerie N.
   Piret, Sian E.
   Rogers, Angela
   Freidin, Andrew J.
   Stewart, Michelle
   Paudyal, Anju
   Hough, Tertius A.
   Nesbit, M. Andrew
   Wells, Sara
   Vincent, Tonia L.
   Brown, Stephen D. M.
   Cox, Roger D.
   Thakker, Rajesh V.
TI Gα11 mutation in mice causes hypocalcemia rectifiable by
   calcilytic therapy
SO JCI INSIGHT
LA English
DT Article
ID CALCIUM SENSING RECEPTOR; AUTOSOMAL DOMINANT HYPOCALCEMIA; OF FUNCTION
   MUTATION; PARATHYROID HORMONE; INDEPENDENT REGULATION; CA2+ SENSING
   RECEPTOR; EXTRACELLULAR DOMAIN; BONE FORMATION; MOUSE MODEL; SKIN COLOR
AB Heterozygous germline gain of function mutations of G protein subunit alpha(11) (G alpha(11)), a signaling partner for the calcium sensing receptor (CaSR), result in autosomal dominant hypocalcemia type 2 (ADH2). ADH2 may cause symptomatic hypocalcemia with low circulating parathyroid hormone (PTH) concentrations. Effective therapies for ADH2 are currently not available, and a mouse model for ADH2 would help in assessment of potential therapies. We hypothesized that a previously reported dark skin mouse mutant (Dsk7)   which has a germline hypermorphic G alpha(11) mutation, Ile62Val   may be a model for ADH2 and allow evaluation of calcilytics, which are CaSR negative allosteric modulators, as a targeted therapy for this disorder. Mutant Dsk7/+ and Dsk7/Dsk7 mice were shown to have hypocalcemia and reduced plasma PTH concentrations, similar to ADH2 patients. In vitro studies showed the mutant Val62 G alpha(11) to upregulate CaSR mediated intracellular calcium and MAPK signaling, consistent with a gain of function. Treatment with NPS 2143, a calcilytic compound, normalized these signaling responses. In vivo, NPS 2143 induced a rapid and marked rise in plasma PTH and calcium concentrations in Dsk7/Dsk7 and Dsk7/+ mice, which became normocalcemic. Thus, these studies have established Dsk7 mice, which harbor a germline gain of function G alpha(11) mutation, as a model for ADH2 and have demonstrated calcilytics as a potential targeted therapy.
C1 [Gorvin, Caroline M.; Hannan, Fadil M.; Howles, Sarah A.; Babinsky, Valerie N.; Piret, Sian E.; Nesbit, M. Andrew; Thakker, Rajesh V.] Univ Oxford, Radcliffe Dept Med, Acad Endocrine Unit, Oxford OX1 2JD, England.
   [Hannan, Fadil M.] Univ Liverpool, Inst Ageing & Chron Dis, Dept Musculoskeletal Biol, Liverpool L69 3BX, Merseyside, England.
   [Freidin, Andrew J.; Vincent, Tonia L.] Univ Oxford, ARUK Ctr Osteoarthrit Pathogenesis, Kennedy Inst Rheumatol, Oxford OX1 2JD, England.
   [Stewart, Michelle; Hough, Tertius A.; Wells, Sara; Brown, Stephen D. M.; Cox, Roger D.] MRC, Mammalian Genet Unit, London, England.
   [Stewart, Michelle; Paudyal, Anju; Hough, Tertius A.; Brown, Stephen D. M.; Cox, Roger D.] Mary Lyon Ctr, MRC Harwell Inst, Harwell Sci & Innovation Campus, London, England.
   [Nesbit, M. Andrew] Univ Ulster, Biomed Sci Res Inst, Coleraine BT52 1SA, Londonderry, North Ireland.
C3 University of Oxford; University of Liverpool; University of Oxford;
   Kennedy Institute for Rheumatology; MRC Harwell; Ulster University
RP Thakker, RV (通讯作者)，Churchill Hosp, Acad Endocrine Unit, OCDEM, Radcliffe Dept Med, Oxford OX3 7LJ, England.
EM rajesh.thakker@ndm.ox.ac.uk
RI ; Vincent, Tyrone/A 8923 2013; Gorvin, Caroline/T 2406 2019
OI Howles, Sarah/0000 0001 6342 0895; Hannan, Fadil/0000 0002 2975 5170;
   Gorvin, Caroline/0000 0002 1361 9174; Cox, Roger/0000 0001 7170 5014;
   Piret, Sian/0000 0002 3586 7654
FU United Kingdom MRC program [G9825289, G1000467]; NIH Research (NIHR)
   Oxford Biomedical Research Centre Programme; European Commission Seventh
   Framework Programme [FP7 264663]; MRC [MR/K006312/1, MC_UP_1502/1,
   G1000467, MC_U142684172, MC_U142661184] Funding Source: UKRI; Medical
   Research Council [G1000467, MC_U142661184, MR/K006312/1, G9825289,
   MC_U142684172, MC_UP_1502/1] Funding Source: researchfish; National
   Institute for Health Research [CL 2015 13 005] Funding Source:
   researchfish; Wellcome Trust [106995/Z/15/Z] Funding Source:
   researchfish
FX This work was supported by the United Kingdom MRC program grants
   G9825289 and G1000467 (to MAN, FMH, CMG, and RVT), the NIH Research
   (NIHR) Oxford Biomedical Research Centre Programme (to MAN and RVT), and
   the European Commission Seventh Framework Programme (FP7 264663) (to
   VNB). SAH was a Wellcome Trust Clinical Training Fellow; and RVT is a
   Wellcome Trust Investigator and NIHR Senior Investigator.
CR Babinsky VN, 2016, J BIOL CHEM, V291, P10876, DOI 10.1074/jbc.M115.696401
   Bentley L, 2014, ENDOCRINOLOGY, V155, P908, DOI 10.1210/en.2013 1247
   Chang WH, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1159945
   Chattopadhyay N, 1997, BIOCHEM BIOPH RES CO, V233, P801, DOI 10.1006/bbrc.1997.6553
   Cheng ZQ, 2013, J BONE MINER RES, V28, P1087, DOI 10.1002/jbmr.1846
   Dong BZ, 2015, J BONE MINER RES, V30, P1980, DOI 10.1002/jbmr.2551
   Esapa CT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122650
   Gil AG, 2010, J AM ASSOC LAB ANIM, V49, P52
   Gorvin CM, 2016, J BONE MINER RES, V31, P1200, DOI 10.1002/jbmr.2778
   Gowen M, 2000, J CLIN INVEST, V105, P1595, DOI 10.1172/JCI9038
   Hannan FM, 2015, HUM MOL GENET, V24, P5079, DOI 10.1093/hmg/ddv226
   Hannan FM, 2015, ENDOCRINOLOGY, V156, P3114, DOI 10.1210/en.2015 1269
   Hannan FM, 2012, HUM MOL GENET, V21, P2768, DOI 10.1093/hmg/dds105
   Hofer AM, 2003, NAT REV MOL CELL BIO, V4, P530, DOI 10.1038/nrm1154
   Hough TA, 2004, P NATL ACAD SCI USA, V101, P13566, DOI 10.1073/pnas.0405516101
   Howles SA, 2016, NEW ENGL J MED, V374, P1396, DOI 10.1056/NEJMc1511646
   Huang Y, 2009, BIOCHEMISTRY US, V48, P388, DOI 10.1021/bi8014604
   HUNTER AGW, 1981, J MED GENET, V18, P431, DOI 10.1136/jmg.18.6.431
   Kumar S, 2010, BONE, V46, P534, DOI 10.1016/j.bone.2009.09.028
   Leach K, 2012, ENDOCRINOLOGY, V153, P4304, DOI 10.1210/en.2012 1449
   Li D, 2014, J CLIN ENDOCR METAB, V99, pE1774, DOI 10.1210/jc.2014 1029
   Loupy A, 2012, J CLIN INVEST, V122, P3355, DOI 10.1172/JCI57407
   Mannstadt M, 2013, NEW ENGL J MED, V368, P2532, DOI 10.1056/NEJMc1300278
   Nemeth EF, 2013, BEST PRACT RES CL EN, V27, P373, DOI 10.1016/j.beem.2013.02.008
   Nemeth EF, 2001, J PHARMACOL EXP THER, V299, P323
   Nesbit MA, 2013, NEW ENGL J MED, V368, P2476, DOI 10.1056/NEJMoa1300253
   Nesbit MA, 2013, NAT GENET, V45, P93, DOI 10.1038/ng.2492
   Newey PJ, 2013, NEW ENGL J MED, V369, P2012, DOI 10.1056/NEJMoa1307557
   Nishimura A, 2010, P NATL ACAD SCI USA, V107, P13666, DOI 10.1073/pnas.1003553107
   Pearce SHS, 1996, NEW ENGL J MED, V335, P1115, DOI 10.1056/NEJM199610103351505
   Piret SE, 2016, J BONE MINER RES, V31, P1207, DOI 10.1002/jbmr.2797
   Quarles LD, 2012, EXP CELL RES, V318, P1040, DOI 10.1016/j.yexcr.2012.02.027
   Raue F, 2011, CLIN ENDOCRINOL, V75, P760, DOI 10.1111/j.1365 2265.2011.04142.x
   Rodriguez Ortiz ME, 2012, J AM SOC NEPHROL, V23, P1190, DOI 10.1681/ASN.2011101006
   SCHULTZ VL, 1995, J BONE MINER RES, V10, P1298
   Shoback DM, 2016, J CLIN ENDOCR METAB, V101, P2300, DOI 10.1210/jc.2015 3909
   Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75
   Stechman MJ, 2010, LAB ANIM UK, V44, P218, DOI 10.1258/la.2010.009128
   Sun DW, 2015, NAT STRUCT MOL BIOL, V22, P686, DOI 10.1038/nsmb.3070
   Tenhola S, 2016, EUR J ENDOCRINOL, V175, P211, DOI 10.1530/EJE 16 0109
   Toka HR, 2012, J AM SOC NEPHROL, V23, P1879, DOI 10.1681/ASN.2012030323
   Van Raamsdonk CD, 2010, NEW ENGL J MED, V363, P2191, DOI 10.1056/NEJMoa1000584
   Van Raamsdonk CD, 2009, PIGM CELL MELANOMA R, V22, P819, DOI 10.1111/j.1755 148X.2009.00609.x
   Van Raamsdonk CD, 2004, NAT GENET, V36, P961, DOI 10.1038/ng1412
   Vargas Poussou R, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000025781.16723.68
   Watanabe S, 2002, LANCET, V360, P692, DOI 10.1016/S0140 6736(02)09842 2
   Wettschureck N, 2007, MOL ENDOCRINOL, V21, P274, DOI 10.1210/me.2006 0110
NR 47
TC 24
Z9 26
U1 0
U2 5
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 2379 3708
J9 JCI INSIGHT
JI JCI Insight
PD FEB 9
PY 2017
VL 2
IS 3
AR e91103
DI 10.1172/jci.insight.91103
PG 15
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA EK1TN
UT WOS:000393708800017
PM 28194447
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Liu, X
   Yang, XL
   Hu, Q
   Liu, MS
   Peng, T
   Xu, WF
   Huang, QH
   Li, B
   Liao, XL
AF Liu, Xue
   Yang, Xiao Ling
   Hu, Qiao
   Liu, Mao Shi
   Peng, Tao
   Xu, Wen Feng
   Huang, Qiu Hong
   Li, Bo
   Liao, Xiao Ling
TI Arg Gly Asp Peptide Functionalized Superparamagnetic
   γ Fe2O3 Nanoparticles Enhance Osteoblast Migration
   In Vitro
SO JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY
LA English
DT Article
DE Superparamagnetic Iron Oxide Nanoparticles; Arg Gly Asp Peptide;
   Osteoblasts; Cell Migration; Bone Regeneration
ID IRON OXIDE NANOPARTICLES; CELLS; MECHANOTRANSDUCTION; PROLIFERATION;
   ADHESION; DELIVERY; MODEL
AB Making osteoblast migration manageably target to injury sites has been the key challenging in cell therapy for bone and cartilage regeneration. Superparamagnetic materials, the magnetic guide for cell migration, have been applied to increase cell retention. However, additional targeting modifications are still needed to accelerate the low uptake efficiency and moving speed. Arg Gly Asp peptide (RGD) functionalized magnetic nanoparticles showed cutting edge competence in cell differentiation control and targeted drug delivery. However, more evidence was required to corroborate its role in osteoblast migration in bone repair. In the present study, RGD modified gamma Fe2O3 nanoparticles (RGD Fe2O3 NPs) were prefabricated with the grafting ratio of 33.3 37.4%. The RGD Fe2O3 NPs unveiled excellent water dispersibility with uniform size distribution at 5 6 nm and negligibly low cytotoxicity. As a result, MC3T3 E1 osteoblasts treated with RGD Fe2O3 NPs boosted its migration speed in a magnetic field compared with those incubated with unmodified Fe2O3 NPs. Furthermore, osteoblasts treated with RGD Fe2O3 NPs exhibited more Fe uptake. The results exposed the fact that RGD mediated specific cellular uptake presented higher efficiency than the non RGD mediated one, resulting from a stronger superparamagnetic force between the labeled cells and the magnetic field. These findings indicate that the RGD functionalized Fe2O3 NPs can promote osteoblast migration in the magnetic field, providing a promising strategy in magnet guided cell therapy for bone and cartilage regeneration.
C1 [Liu, Xue; Yang, Xiao Ling; Hu, Qiao; Liu, Mao Shi; Peng, Tao; Xu, Wen Feng; Huang, Qiu Hong; Li, Bo; Liao, Xiao Ling] Chongqing Univ Sci & Technol, Inst Biomed Engn, Chongqing Engn Lab Nano Micro Biol Med Detect Tec, Chongqing Key Lab Nano Micro Composite Mat & Devi, Chongqing 401331, Peoples R China.
C3 Chongqing University of Science & Technology
RP Liao, XL (通讯作者)，Chongqing Univ Sci & Technol, Inst Biomed Engn, Chongqing Engn Lab Nano Micro Biol Med Detect Tec, Chongqing Key Lab Nano Micro Composite Mat & Devi, Chongqing 401331, Peoples R China.
OI Liu, Xue/0000 0002 5563 5850
FU Ning Gu's Lab at Southeast University, Nanjing, China; National Natural
   Science Foundation of China [11532004, 31600848]; Natural Science
   Foundation Project of CQ CSTC [CSTC2018JCYJAX0286, CSTC2015JCYJA10031];
   Program for Innovation Teams in University of Chongqing
   [CXTDX201601032]; Research Foundation of Chongqing University of Science
   and Technology [CK2017ZKYB017, YKJCX1720201, CK2016Z02]
FX This work was supported by Ning Gu's Lab at Southeast University,
   Nanjing, China and financially supported by grants from the National
   Natural Science Foundation of China (11532004, 31600848), the Natural
   Science Foundation Project of CQ CSTC (CSTC2018JCYJAX0286,
   CSTC2015JCYJA10031), the Program for Innovation Teams in University of
   Chongqing (CXTDX201601032) and the Research Foundation of Chongqing
   University of Science and Technology (CK2017ZKYB017, YKJCX1720201,
   CK2016Z02).
CR Barrow M, 2015, CHEM SOC REV, V44, P6733, DOI 10.1039/c5cs00331h
   Chen B, 2016, MATER LETT, V170, P93, DOI 10.1016/j.matlet.2016.02.006
   Dai ZC, 2018, NANOSCALE, V10, P11597, DOI 10.1039/c8nr03085e
   El Haj AJ, 2015, J TISSUE ENG REGEN M, V9, P724, DOI 10.1002/term.1636
   Fraioli R, 2015, COLLOID SURFACE B, V128, P191, DOI 10.1016/j.colsurfb.2014.12.057
   Henstock J, 2015, REGEN MED, V10, P377, DOI [10.2217/RME.15.23, 10.2217/rme.15.23]
   Henstock JR, 2014, STEM CELL TRANSL MED, V3, P1363, DOI 10.5966/sctm.2014 0017
   Huang LL, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00083
   Huang ZY, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt360
   Ikuta Y, 2015, CTS CLIN TRANSL SCI, V8, P467, DOI 10.1111/cts.12284
   Kamei G, 2013, AM J SPORT MED, V41, P1255, DOI 10.1177/0363546513483270
   Kamei N, 2018, REGEN THER, V9, P116, DOI 10.1016/j.reth.2018.10.001
   Kang H, 2017, ACS NANO, V11, P9636, DOI 10.1021/acsnano.7b02857
   Kim M, 2018, J CONTROL RELEASE, V269, P337, DOI 10.1016/j.jconrel.2017.11.033
   Kotaka S, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/9514719
   Lee JH, 2013, MOL CELLS, V35, P274
   Luo Y, 2015, NANOSCALE, V7, P14538, DOI 10.1039/c5nr04003e
   Oshima S, 2010, J BONE JOINT SURG BR, V92B, P1606, DOI 10.1302/0301 620X.92B11.23491
   Rotherham M, 2018, NANOMED NANOTECHNOL, V14, P173, DOI 10.1016/j.nano.2017.09.008
   Sasaki H, 2011, SPINE, V36, P933, DOI 10.1097/BRS.0b013e3181eb9fb0
   Schottelius M, 2009, ACCOUNTS CHEM RES, V42, P969, DOI 10.1021/ar800243b
   Silva LHA, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0523 4
   Sun XL, 2017, METHODS MOL BIOL, V1570, P73, DOI 10.1007/978 1 4939 6840 4_5
   Tabatabaei FS, 2017, REGEN MED, V12, P983, DOI 10.2217/rme 2017 0029
   Takayama T, 2017, J BIOMATER APPL, V31, P1049, DOI 10.1177/0885328216686727
   Yanada S, 2006, J BIOMED MATER RES A, V77A, P773, DOI 10.1002/jbm.a.30635
   Yang S.W., 2017, J BIOMATER APPL, V32, P800
NR 27
TC 3
Z9 4
U1 1
U2 38
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381 0751 USA
SN 1533 4880
EI 1533 4899
J9 J NANOSCI NANOTECHNO
JI J. Nanosci. Nanotechnol.
PD OCT
PY 2020
VL 20
IS 10
BP 6173
EP 6179
DI 10.1166/jnn.2020.17484
PG 7
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA LM2IY
UT WOS:000532076600026
PM 32384968
DA 2025 08 17
ER

PT J
AU Hayashi, M
   Baker, A
   Goldstein, SD
   Albert, CM
   Jackson, KW
   McCarty, G
   Kahlert, UD
   Loeb, DM
AF Hayashi, Masanori
   Baker, Alissa
   Goldstein, Seth D.
   Albert, Catherine M.
   Jackson, Kyle W.
   McCarty, Gregory
   Kahlert, Ulf D.
   Loeb, David M.
TI Inhibition of porcupine prolongs metastasis free survival in a mouse
   xenograft model of Ewing sarcoma
SO ONCOTARGET
LA English
DT Article
DE metastasis; patient derived xenograft; preclinical model; Wnt signaling;
   Ewing sarcoma
ID EPITHELIAL MESENCHYMAL TRANSITION; CHILDRENS ONCOLOGY GROUP; CANCER
   STEM CELLS; WNT/BETA CATENIN; WNT; ACTIVATION; TRANSCRIPTION;
   OSTEOSARCOMA; GROWTH; TRIAL
AB The most pressing unmet clinical need for patients with Ewing sarcoma (ES) is the prevention and treatment of metastasis. The Wnt signaling pathway regulates a number of cellular functions associated with metastasis, including proliferation, motility, and stem cell self renewal. Functional interaction between Wnt ligands and their receptors requires palmitoylation by Porcupine (Porcn), making this an ideal therapeutic target. We studied the effect of WNT974, a potent, selective Porcn inhibitor, on ES metastasis. In vitro, WNT974 does not affect ES proliferation or sarcosphere formation, but suppresses multiple transcriptional regulators of metastasis and inhibits cell migration. In vivo, in an orthotopic implantation/amputation model of spontaneous distant metastasis, single agent WNT974 treatment leads to a significant delay in formation of lung metastasis and a substantial improvement in post amputation survival without a major effect on primary tumor growth. The drug produces no survival benefit in a tail vein injection model, supporting the hypothesis that WNT974 inhibits early steps in the metastatic cascade, such as migration and invasion. Our findings strongly implicate Wnt signaling in the early steps of ES metastasis and demonstrate that WNT974 has the potential to significantly improve the survival of ES patients through the specific inhibition of metastasis.
C1 [Hayashi, Masanori; Baker, Alissa; Goldstein, Seth D.; Albert, Catherine M.; Jackson, Kyle W.; McCarty, Gregory; Kahlert, Ulf D.; Loeb, David M.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21218 USA.
   [Kahlert, Ulf D.] Univ Med Ctr Dusseldorf, Neurosurg Clin, Dusseldorf, Germany.
   [Albert, Catherine M.] Univ Washington, Seattle Childrens Hosp, Seattle, WA 98195 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Heinrich Heine
   University Dusseldorf; Heinrich Heine University Dusseldorf Hospital;
   Seattle Children's Hospital; University of Washington; University of
   Washington Seattle
RP Loeb, DM (通讯作者)，Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21218 USA.
EM loebda@jhmi.edu
RI ; Kahlert, Ulf/V 7875 2019
OI Kahlert, Ulf Dietrich/0000 0002 6021 1841; Goldstein,
   Seth/0000 0001 7806 4109; Baker, Alissa/0000 0001 9388 5650; Hayashi,
   Masanori/0000 0002 9508 0159
FU National Institutes of Health grant [1R01CA138212 01]; Liddy Shriver
   Sarcoma Initiative; Core Grant supporting the Sidney Kimmel
   Comprehensive Cancer Center [2P30 CA006973]; Giant Food Children's
   Cancer Research Fund; National Pediatric Cancer Foundation; Pablove
   Foundation Pediatric Cancer Research grant; SARC Sarcoma SPORE Career
   Development Award [5U54CA168512 02]; Strategic Research Fund of the
   Heinrich Heine University
FX This work was supported by National Institutes of Health grant
   (1R01CA138212 01) (DML) and the Liddy Shriver Sarcoma Initiative (DML)
   as well as the Core Grant supporting the Sidney Kimmel Comprehensive
   Cancer Center, 2P30 CA006973. Work was also supported by Giant Food
   Children's Cancer Research Fund and the National Pediatric Cancer
   Foundation. M.H. vas supported by a Pablove Foundation Pediatric Cancer
   Research grant and by the SARC Sarcoma SPORE Career Development Award
   (5U54CA168512 02). UDK is supported by the Strategic Research Fund of
   the Heinrich Heine University.
CR Bernstein ML, 2006, J CLIN ONCOL, V24, P152, DOI 10.1200/JCO.2005.02.1717
   Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092 8674(00)00122 7
   Chang YW, 2015, CANCER RES, V75, P3398, DOI 10.1158/0008 5472.CAN 14 3265
   Dieudonné FX, 2010, CANCER RES, V70, P5399, DOI 10.1158/0008 5472.CAN 10 0090
   Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463 8471.1998
   El Naggar AM, 2015, CANCER CELL, V27, P682, DOI 10.1016/j.ccell.2015.04.003
   Endo Y, 2008, MOL CELL BIOL, V28, P2368, DOI 10.1128/MCB.01780 07
   Fadul John, 2015, Genes Cancer, V6, P129
   FALK S, 1967, SURG GYNECOL OBSTETR, V124, P319
   Gaspar N, 2015, J CLIN ONCOL, V33, P3036, DOI 10.1200/JCO.2014.59.5256
   Ghahhari NM, 2015, EUR J CANCER, V51, P1638, DOI 10.1016/j.ejca.2015.04.021
   Goldstein SD, 2015, CLIN EXP METASTAS, V32, P703, DOI 10.1007/s10585 015 9738 x
   Hatano M, 2015, CLIN EXP METASTAS, V32, P579, DOI 10.1007/s10585 015 9729 y
   Janku F, 2015, AACR NCI EORTC INT C
   Jin YR, 2012, INT J BIOCHEM CELL B, V44, P2278, DOI 10.1016/j.biocel.2012.09.006
   Jung HY, 2015, CELL STEM CELL, V16, P1, DOI 10.1016/j.stem.2014.12.005
   Kahlert UD, 2012, CANCER LETT, V325, P42, DOI 10.1016/j.canlet.2012.05.024
   Ladenstein R, 2010, J CLIN ONCOL, V28, P3284, DOI 10.1200/JCO.2009.22.9864
   Lawlor Elizabeth R., 2015, Critical Reviews in Oncogenesis, V20, P155, DOI 10.1615/CritRevOncog.2015013553
   Liu H, 2015, CELL SIGNAL, V27, P510, DOI 10.1016/j.cellsig.2015.01.001
   Liu J, 2013, P NATL ACAD SCI USA, V110, P20224, DOI 10.1073/pnas.1314239110
   Navarro D, 2010, CARCINOGENESIS, V31, P394, DOI 10.1093/carcin/bgp317
   Pedersen EA, 2016, CANCER RES, V76, P5040, DOI 10.1158/0008 5472.CAN 15 3422
   PHILLIPS RF, 1967, J PEDIATR US, V70, P391, DOI 10.1016/S0022 3476(67)80136 7
   Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394
   Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593
   Scannell CA, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00081
   Üren A, 2004, PEDIATR BLOOD CANCER, V43, P243, DOI 10.1002/pbc.20124
   Veeman MT, 2003, CURR BIOL, V13, P680, DOI 10.1016/S0960 9822(03)00240 9
   Vijayakumar S, 2011, CANCER CELL, V19, P601, DOI 10.1016/j.ccr.2011.03.010
   Wend P, 2010, SEMIN CELL DEV BIOL, V21, P855, DOI 10.1016/j.semcdb.2010.09.004
   Wiles Elizabeth T, 2013, Genes Cancer, V4, P486, DOI 10.1177/1947601913506115
   Womer RB, 2012, J CLIN ONCOL, V30, P4148, DOI 10.1200/JCO.2011.41.5703
   Zhang YJ, 2015, ONCOTARGET, V6, P7244, DOI 10.18632/oncotarget.3133
   Zhao S, 2015, ONCOGENE, V34, P5069, DOI 10.1038/onc.2014.429
NR 35
TC 25
Z9 27
U1 0
U2 5
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD OCT 3
PY 2017
VL 8
IS 45
BP 78265
EP 78276
DI 10.18632/oncotarget.19432
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA FI6MT
UT WOS:000412111300011
PM 29108227
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Moon, HH
   Clines, KL
   O'Day, PJ
   Al Barghouthi, BM
   Farber, EA
   Farber, CR
   Auchus, RJ
   Clines, GA
AF Moon, Henry H.
   Clines, Katrina L.
   O'Day, Patrick J.
   Al Barghouthi, Basel M.
   Farber, Emily A.
   Farber, Charles R.
   Auchus, Richard J.
   Clines, Gregory A.
TI Osteoblasts Generate Testosterone From DHEA and Activate Androgen
   Signaling in Prostate Cancer Cells
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE SEX STEROIDS; TESTOSTERONE; DHEA; OSTEOBLASTS; PROSTATE CANCER
ID PREMATURE ADRENARCHE; 3 BETA HYDROXY DELTA(5) C 27 STEROID
   OXIDOREDUCTASE; ABIRATERONE ACETATE; DEPRIVATION THERAPY; BONE;
   RECEPTOR; GROWTH; LNCAP; SUPPRESSES; EXPRESSION
AB Bone metastasis is a complication of prostate cancer in up to 90% of men afflicted with advanced disease. Therapies that reduce androgen exposure remain at the forefront of treatment. However, most prostate cancers transition to a state whereby reducing testicular androgen action becomes ineffective. A common mechanism of this transition is intratumoral production of testosterone (T) using the adrenal androgen precursor dehydroepiandrosterone (DHEA) through enzymatic conversion by 3 beta  and 17 beta hydroxysteroid dehydrogenases (3 beta HSD and 17 beta HSD). Given the ability of prostate cancer to form blastic metastases in bone, we hypothesized that osteoblasts might be a source of androgen synthesis. RNA expression analyses of murine osteoblasts and human bone confirmed that at least one 3 beta HSD and 17 beta HSD enzyme isoform was expressed, suggesting that osteoblasts are capable of generating androgens from adrenal DHEA. Murine osteoblasts were treated with 100 nM and 1 mu M DHEA or vehicle control. Conditioned media from these osteoblasts were assayed for intermediate and active androgens by liquid chromatography tandem mass spectrometry. As DHEA was consumed, the androgen intermediates androstenediol and androstenedione were generated and subsequently converted to T. Conditioned media of DHEA treated osteoblasts increased androgen receptor (AR) signaling, prostate specific antigen (PSA) production, and cell numbers of the androgen sensitive prostate cancer cell lines C4 2B and LNCaP. DHEA did not induce AR signaling in osteoblasts despite AR expression in this cell type. We describe an unreported function of osteoblasts as a source of T that is especially relevant during androgen responsive metastatic prostate cancer invasion into bone. (c) 2021 American Society for Bone and Mineral Research (ASBMR). This article has been contributed to by US Government employees and their work is in the public domain in the USA.
C1 [Moon, Henry H.; Clines, Katrina L.; O'Day, Patrick J.; Auchus, Richard J.; Clines, Gregory A.] Univ Michigan, Dept Internal Med, Div Metab Endocrinol & Diabet, Ann Arbor, MI 48109 USA.
   [Al Barghouthi, Basel M.; Farber, Emily A.; Farber, Charles R.] Univ Virginia, Ctr Publ Hlth Genom, Charlottesville, VA USA.
   [Farber, Charles R.] Univ Virginia, Dept Publ Hlth Sci, Charlottesville, VA USA.
   [Farber, Charles R.] Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA USA.
   [Auchus, Richard J.; Clines, Gregory A.] Vet Affairs Med Ctr, Med Serv, Endocrinol & Metab Sect, Ann Arbor, MI USA.
C3 University of Michigan System; University of Michigan; University of
   Virginia; University of Virginia; University of Virginia; US Department
   of Veterans Affairs; Veterans Health Administration (VHA)
RP Clines, GA (通讯作者)，Univ Michigan, Div Metab Endocrinol & Diabet, Dept Internal Med, Endocrinol & Metab Sect,Ann Arbor VA Med Ctr, 2215 Fuller Rd,Res 151, Ann Arbor, MI 48105 USA.
EM clines@umich.edu
OI Clines, Gregory/0000 0002 3755 7529; Farber,
   Charles/0000 0002 6748 4711; Al Barghouthi, Basel/0000 0001 9816 8044
FU Department of Veterans Affairs Merit Award [I01 BX001370]; University of
   Michigan Integrative Musculoskeletal Health Core Center Pilot &
   Feasibility award [NIH P30 AR069620]; National Institutes of Health,
   Biomedical Data Sciences Training Grant [5T32LM012416]; National
   Institute of Arthritis and Musculoskeletal and Skin Diseases
   [P30AR069620] Funding Source: NIH RePORTER
FX This work was funded by a Department of Veterans Affairs Merit Award
   (I01 BX001370) to GC and a University of Michigan Integrative
   Musculoskeletal Health Core Center Pilot & Feasibility award (NIH P30
   AR069620) to GC. BA was supported in part by a National Institutes of
   Health, Biomedical Data Sciences Training Grant (5T32LM012416).
CR Almeida M, 2017, PHYSIOL REV, V97, P135, DOI 10.1152/physrev.00033.2015
   Amanatullah DF, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058 017 0910 x
   Armstrong AJ, 2019, J CLIN ONCOL, V37, P2974, DOI 10.1200/JCO.19.00799
   Auchus RJ, 2020, ANNU REV MED, V71, P33, DOI 10.1146/annurev med 051418 060357
   Auchus RJ, 2004, TRENDS ENDOCRIN MET, V15, P432, DOI 10.1016/j.tem.2004.09.004
   Bakker AD, 2012, METHODS MOL BIOL, V816, P19, DOI 10.1007/978 1 61779 415 5_2
   Banker M, 2021, J CLIN ENDOCR METAB, V106, P665, DOI 10.1210/clinem/dgaa909
   Blaszczyk N, 2004, CLIN CANCER RES, V10, P1860, DOI 10.1158/1078 0432.CCR 0974 3
   Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   Campana C, 2016, J STEROID BIOCHEM, V156, P17, DOI 10.1016/j.jsbmb.2015.11.005
   Chang KH, 2014, BRIT J CANCER, V111, P1249, DOI 10.1038/bjc.2014.268
   Chen SY, 1997, J BIOL CHEM, V272, P14087, DOI 10.1074/jbc.272.22.14087
   Cheng JB, 2003, J CLIN ENDOCR METAB, V88, P1833, DOI 10.1210/jc.2002 021580
   Chiang C, 2009, J BONE MINER RES, V24, P621, DOI [10.1359/jbmr.081217, 10.1359/JBMR.081217]
   Clines GA, 2007, MOL ENDOCRINOL, V21, P486, DOI 10.1210/me.2006 0346
   Dai JL, 2008, CANCER RES, V68, P5785, DOI 10.1158/0008 5472.CAN 07 6541
   Davey Rachel A, 2016, Clin Biochem Rev, V37, P3
   Davio A, 2020, J CLIN ENDOCR METAB, V105, pE2921, DOI 10.1210/clinem/dgaa343
   Davis ID, 2019, NEW ENGL J MED, V381, P121, DOI 10.1056/NEJMoa1903835
   Dillard PR, 2008, MOL CELL ENDOCRINOL, V295, P115, DOI 10.1016/j.mce.2008.08.013
   Dobbs RW, 2019, PROSTATE CANCER P D, V22, P185, DOI 10.1038/s41391 018 0081 6
   Efstathiou E, 2012, J CLIN ONCOL, V30, P637, DOI 10.1200/JCO.2010.33.7675
   Eisenberger MA, 1998, NEW ENGL J MED, V339, P1036, DOI 10.1056/NEJM199810083391504
   Farr JN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138347
   Feix M, 2001, MOL CELL ENDOCRINOL, V171, P163, DOI 10.1016/S0303 7207(00)00393 2
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Fournier PGJ, 2015, CANCER CELL, V27, P809, DOI 10.1016/j.ccell.2015.04.009
   GRINO PB, 1990, ENDOCRINOLOGY, V126, P1165, DOI 10.1210/endo 126 2 1165
   Hall CL, 2005, CANCER RES, V65, P7554, DOI 10.1158/0008 5472.CAN 05 1317
   Hearn JWD, 2016, LANCET ONCOL, V17, P1435, DOI 10.1016/S1470 2045(16)30227 3
   Hofland J, 2010, CANCER RES, V70, P1256, DOI 10.1158/0008 5472.CAN 09 2092
   Ihle CL, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00357
   Im SC., 2020, ENDOCRINOLOGY, V161, P1
   Kampa M, 2002, FASEB J, V16, P1429, DOI 10.1096/fj.02 0131fje
   Karantanos T, 2013, ONCOGENE, V32, P5501, DOI 10.1038/onc.2013.206
   Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]
   Kimura T, 2010, CLIN CANCER RES, V16, P121, DOI 10.1158/1078 0432.CCR 09 0982
   Kuwano Y, 1997, ENDOCR J, V44, P847, DOI 10.1507/endocrj.44.847
   Liu XH, 2007, CANCER RES, V67, P5747, DOI 10.1158/0008 5472.CAN 07 0478
   Maatta Jorma A, 2013, Bonekey Rep, V2, P440, DOI 10.1038/bonekey.2013.174
   Montgomery RB, 2008, CANCER RES, V68, P4447, DOI 10.1158/0008 5472.CAN 08 0249
   NORMINGTON K, 1992, J BIOL CHEM, V267, P19548
   Notini AJ, 2007, J BONE MINER RES, V22, P347, DOI 10.1359/JBMR.061117
   O'Reilly MW, 2017, J CLIN ENDOCR METAB, V102, P840, DOI 10.1210/jc.2016 3285
   Pertea M, 2015, NAT BIOTECHNOL, V33, P290, DOI 10.1038/nbt.3122
   Rege J, 2018, J CLIN ENDOCR METAB, V103, P4589, DOI 10.1210/jc.2018 00736
   Saito H, 1998, J INT MED RES, V26, P1
   Schwarz M, 2000, J CLIN INVEST, V106, P1175, DOI 10.1172/JCI10902
   Seidenfeld J, 2000, ANN INTERN MED, V132, P566, DOI 10.7326/0003 4819 132 7 200004040 00009
   Shea HC, 2007, P NATL ACAD SCI USA, V104, P11526, DOI 10.1073/pnas.0705089104
   Sigma Aldrich, PREP CHARC STRIPP FE
   Sinnesael M, 2012, J BONE MINER RES, V27, P2535, DOI 10.1002/jbmr.1713
   Song WT, 2014, ASIAN J ANDROL, V16, P864, DOI 10.4103/1008 682X.129132
   Sopher AB, 2001, J CLIN ENDOCR METAB, V86, P5269, DOI 10.1210/jc.86.11.5269
   Sopher AB, 2011, OBESITY, V19, P1259, DOI 10.1038/oby.2010.305
   Sowder ME, 2019, JBMR PLUS, V3, DOI 10.1002/jbm4.10126
   Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008 5472.CAN 05 4000
   Thulin MH, 2016, MOL CELL ENDOCRINOL, V422, P182, DOI 10.1016/j.mce.2015.11.013
   Titus MA, 2005, CLIN CANCER RES, V11, P4653, DOI 10.1158/1078 0432.CCR 05 0525
   Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175
   Turcu AF, 2016, EUR J ENDOCRINOL, V174, P601, DOI 10.1530/EJE 15 1181
   Ucer S, 2015, J BONE MINER RES, V30, P1138, DOI 10.1002/jbmr.2485
   Uemura M, 2008, CANCER SCI, V99, P81, DOI 10.1111/j.1349 7006.2007.00656.x
   Utriainen P, 2015, HORM RES PAEDIAT, V83, P221, DOI 10.1159/000369458
   Wan XH, 2012, BONE, V50, P695, DOI 10.1016/j.bone.2011.11.022
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Wright C, 2020, EUR J ENDOCRINOL, V182, P413, DOI 10.1530/EJE 19 0905
   Wu TT, 1998, INT J CANCER, V77, P887, DOI 10.1002/(SICI)1097 0215(19980911)77:6<887::AID IJC15>3.0.CO;2 Z
   Yu P, 2017, INT J MOL MED, V40, P1426, DOI 10.3892/ijmm.2017.3125
   Zhu YS, 2003, J ANDROL, V24, P681
NR 70
TC 6
Z9 6
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD AUG
PY 2021
VL 36
IS 8
BP 1566
EP 1579
DI 10.1002/jbmr.4313
EA MAY 2021
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA TU3UB
UT WOS:000651551900001
PM 33900658
OA Green Accepted, Green Published
DA 2025 08 17
ER

PT J
AU Chen, YQ
   Sun, JJ
   Dou, C
   Li, N
   Kang, F
   Wang, Y
   Cao, Z
   Yang, XC
   Dong, SW
AF Chen, Yueqi
   Sun, Jingjing
   Dou, Ce
   Li, Nan
   Kang, Fei
   Wang, Yuan
   Cao, Zhen
   Yang, Xiaochao
   Dong, Shiwu
TI Alliin Attenuated RANKL Induced Osteoclastogenesis by Scavenging
   Reactive Oxygen Species through Inhibiting Nox1
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE alliin; osteoclast; reactive oxygen species; Nox1
ID NADPH OXIDASES; ROS PRODUCTION; CRUCIAL ROLE; BONE LOSS;
   DIFFERENTIATION; ACTIVATION; CELLS; RECEPTOR; PATHWAY; STRESS
AB The healthy skeleton requires a perfect coordination of the formation and degradation of bone. Metabolic bone disease like osteoporosis is resulted from the imbalance of bone formation and/or bone resorption. Osteoporosis also reflects lower level of bone matrix, which is contributed by up regulated osteoclast mediated bone resorption. It is reported that monocytes/macrophage progenitor cells or either hematopoietic stem cells (HSCs) gave rise to multinucleated osteoclasts. Thus, inhibition of osteoclastic bone resorption generally seems to be a predominant therapy for treating osteoporosis. Recently, more and more natural compounds have been discovered, which have the ability of inhibiting osteoclast differentiation and fusion. Alliin (S allyl l cysteine sulfoxides, SACSO) is the major component of aged garlic extract (AGE), bearing broad spectrum natural antioxidant properties. However, its effects on bone health have not yet been explored. Hence, we designed the current study to explore its effects and role in receptor activator of nuclear factor B ligand (RANKL) induced osteoclast fusion and differentiation. It was revealed that alliin had an inhibitory effect in osteoclasteogenesis with a dose dependent manner via blocking the c Fos NFATc1 signaling pathway. In addition, alliin decreased the generation of reactive oxygen species (ROS) and down regulated the expression of NADPH oxidase 1 (Nox1). The overall results revealed that alliin could be a potential therapeutic agent in the treatment of osteoporosis.
C1 [Chen, Yueqi; Sun, Jingjing; Dou, Ce; Li, Nan; Kang, Fei; Wang, Yuan; Cao, Zhen; Yang, Xiaochao; Dong, Shiwu] Third Mil Med Univ, Sch Biomed Engn, Dept Biomed Mat Sci, Gaotanyan St 30, Chongqing 400038, Peoples R China.
   [Chen, Yueqi] Third Mil Med Univ, Student Camp Four, Chongqing 400038, Peoples R China.
C3 Army Medical University; Army Medical University
RP Dong, SW (通讯作者)，Third Mil Med Univ, Sch Biomed Engn, Dept Biomed Mat Sci, Gaotanyan St 30, Chongqing 400038, Peoples R China.
EM chenyueqi1012@sina.com; Sjjhx2012@163.com; lance.douce@gmail.com;
   li_nan1900@126.com; kangfeilove2007@126.com; wangyuancxh@163.com;
   zhenyacy@163.com; xcyang@tmmu.edu.cn; dongshiwu@tmmu.edu.cn
RI ; Dou, Ce/B 8841 2012; Yang, Xiaochao/AAM 8083 2021; Chen,
   Yueqi/AAU 1724 2020
OI Dou, Ce/0000 0002 6983 6354; Chen, Yueqi/0000 0001 6975 2874; 
FU Nature Science Foundation of China [81572164]; National Key Technology
   Research and Development Program of China [2012BAI42G01]; National
   High tech Research and Development Program of China (863 Program)
   [2015AA020315]; China Postdoctoral Science Foundation [2016M592937]; Key
   project of Logistics Research Plan of PLA [BWS13C014]
FX This work was supported by the Nature Science Foundation of China
   (81572164), the National Key Technology Research and Development Program
   of China (2012BAI42G01), the National High tech Research and Development
   Program of China (863 Program, 2015AA020315), the China Postdoctoral
   Science Foundation (2016M592937), and Key project of Logistics Research
   Plan of PLA (BWS13C014).
CR Arai M, 2007, IUBMB LIFE, V59, P27, DOI 10.1080/15216540601156188
   Banfi G, 2008, CLIN CHEM LAB MED, V46, P1550, DOI 10.1515/CCLM.2008.302
   Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chiu YG, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2915
   Choi J, 2013, CELL SIGNAL, V25, P1222, DOI 10.1016/j.cellsig.2013.02.015
   Cully Megan, 2013, Nat Rev Rheumatol, V9, P446, DOI 10.1038/nrrheum.2013.111
   Deepak V, 2015, BIOFACTORS, V41, P403, DOI 10.1002/biof.1241
   Dou C, 2016, OSTEOPOROSIS INT, V27, P2335, DOI 10.1007/s00198 016 3496 8
   Dou C, 2014, BBA GENE REGUL MECH, V1839, P1084, DOI 10.1016/j.bbagrm.2014.08.002
   Ell B, 2013, CANCER CELL, V24, P542, DOI 10.1016/j.ccr.2013.09.008
   Iciek M, 2009, ENVIRON MOL MUTAGEN, V50, P247, DOI 10.1002/em.20474
   Jones MG, 2004, J EXP BOT, V55, P1903, DOI 10.1093/jxb/erh138
   Kanzaki H, 2013, J BIOL CHEM, V288, P23009, DOI 10.1074/jbc.M113.478545
   Kim MH, 2008, FOOD CHEM TOXICOL, V46, P3375, DOI 10.1016/j.fct.2008.08.016
   Lambeth JD, 2007, FREE RADICAL BIO MED, V43, P319, DOI 10.1016/j.freeradbiomed.2007.03.028
   Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810
   Lean JM, 2003, J CLIN INVEST, V112, P915, DOI 10.1172/JCI200318859
   Lee JH, 2010, MOL PHARMACOL, V77, P17, DOI 10.1124/mol.109.057877
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Lee SH, 2015, EXP CELL RES, V331, P267, DOI 10.1016/j.yexcr.2014.12.018
   Lee SH, 2014, INT J MOL SCI, V15, P10605, DOI 10.3390/ijms150610605
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Nirala BK, 2015, EUR REV MED PHARMACO, V19, P2125
   Ray B, 2011, J NEUROCHEM, V117, P388, DOI 10.1111/j.1471 4159.2010.07145.x
   Sakai E, 2013, J PHARMACOL SCI, V121, P288, DOI 10.1254/jphs.12243FP
   Schröder K, 2015, CELL MOL LIFE SCI, V72, P25, DOI 10.1007/s00018 014 1712 2
   Srinivasan S, 2010, ANN NY ACAD SCI, V1192, P245, DOI 10.1111/j.1749 6632.2009.05377.x
   STOLL A, 1947, EXPERIENTIA, V3, P115, DOI 10.1007/BF02137699
   Tanaka Yoshiya, 2005, Current Drug Targets   Inflammation and Allergy, V4, P325, DOI 10.2174/1568010054022015
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
NR 32
TC 29
Z9 33
U1 0
U2 14
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD SEP
PY 2016
VL 17
IS 9
AR 1516
DI 10.3390/ijms17091516
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA DZ0JU
UT WOS:000385525500141
PM 27657047
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Vikulina, T
   Fan, XA
   Yamaguchi, M
   Roser Page, S
   Zayzafoon, M
   Guidot, DM
   Ofotokun, I
   Weitzmann, MN
AF Vikulina, Tatyana
   Fan, Xian
   Yamaguchi, Masayoshi
   Roser Page, Susanne
   Zayzafoon, Majd
   Guidot, David M.
   Ofotokun, Ighovwerha
   Weitzmann, M. Neale
TI Alterations in the immuno skeletal interface drive bone destruction in
   HIV 1 transgenic rats
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE AIDS; osteoprotegerin; osteoporosis; receptor activator of NF kappa B
   ligand; osteoclast
ID B CELLS; ESTROGEN DEFICIENCY; OSTEOCLASTOGENESIS; INFECTION; PREVALENCE;
   RESORPTION; RECEPTOR; RANKL; RISK; MASS
AB Osteoporosis and bone fractures are increasingly recognized complications of HIV 1 infection. Although antiretroviral therapy itself has complex effects on bone turnover, it is now evident that the majority of HIV infected individuals already exhibit reduced bone mineral density before therapy. The mechanisms responsible are likely multifactorial and have been difficult to delineate in humans. The HIV 1 transgenic rat recapitulates many key features of human AIDS. We now demonstrate that, like their human counterparts, HIV 1 transgenic rats undergo severe osteoclastic bone resorption, a consequence of an imbalance in the ratio of receptor activator of NF kappa B ligand, the key osteoclastogenic cytokine, to that of its physiological decoy receptor osteoprotegerin. This imbalance stemmed from a switch in production of osteoprotegerin to that of receptor activator of NF kappa B ligand by B cells, and was further compounded by a significantly elevated number of osteoclast precursors. With the advancing age of individuals living with HIV/AIDS, low bone mineral density associated with HIV infection is likely to collide with the pathophysiology of skeletal aging, leading to increased fracture risk. Understanding the mechanisms driving bone loss in HIV infected individuals will be critical to developing effective therapeutic strategies.
C1 [Vikulina, Tatyana; Yamaguchi, Masayoshi; Weitzmann, M. Neale] Emory Univ, Sch Med, Div Endocrinol & Metab & Lipids, Atlanta, GA 30322 USA.
   [Fan, Xian; Guidot, David M.] Emory Univ, Sch Med, Div Pulm Allergy & Crit Care Med, Atlanta, GA 30322 USA.
   [Fan, Xian; Roser Page, Susanne; Guidot, David M.; Weitzmann, M. Neale] Atlanta Vet Affairs Med Ctr, Decatur, GA 30033 USA.
   [Zayzafoon, Majd] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
   [Ofotokun, Ighovwerha] Emory Univ, Sch Med, Dept Med, Div Infect Dis, Atlanta, GA 30322 USA.
   [Weitzmann, M. Neale] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA.
C3 Emory University; Emory University; US Department of Veterans Affairs;
   Veterans Health Administration (VHA); Atlanta VA Health Care System;
   University of Alabama System; University of Alabama Birmingham; Emory
   University; Emory University
RP Weitzmann, MN (通讯作者)，Emory Univ, Sch Med, Div Endocrinol & Metab & Lipids, Atlanta, GA 30322 USA.
EM mweitzm@emory.edu
RI Ofotokun, Ighovwerha/L 6545 2015
FU National Institutes of Health [P30 AR46031]; National Institute of
   Arthritis and Musculoskeletal and Skin Diseases [AR059364, AR053607,
   AR056090, MZ AR053898]; Biomedical Laboratory Research and Development
   Service of the Veterans Affairs Office of Research and Development
   [5I01BX000105]; National Institute of Allergy and Infectious Diseases
   [K23 A1073119]
FX We thank Xiaoying Yang for technical assistance with mu CT. We
   gratefully acknowledge the histological services of the University of
   Alabama at Birmingham, Center for Metabolic Bone
   Disease Histomorphometry and Molecular Analysis Core Laboratory,
   supported by National Institutes of Health Grant P30 AR46031. This study
   was supported in part by National Institute of Arthritis and
   Musculoskeletal and Skin Diseases Grants AR059364 (to M.N.W. and I.O.)
   and AR053607 (to M.N.W.). M.N.W. was also supported in part by National
   Institute of Arthritis and Musculoskeletal and Skin Diseases Grant
   AR056090 and Biomedical Laboratory Research and Development Service of
   the Veterans Affairs Office of Research and Development Grant
   5I01BX000105. I.O. was also supported in part by National Institute of
   Allergy and Infectious Diseases Grant K23 A1073119 and National
   Institute of Arthritis and Musculoskeletal and Skin Diseases Grant MZ
   AR053898.
CR Borderi Marco, 2006, Infez Med, V14, P117
   Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066
   Choi Y, 2001, EUR J IMMUNOL, V31, P2179, DOI 10.1002/1521 4141(200107)31:7<2179::AID IMMU2179>3.0.CO;2 X
   Deeks Steven G, 2009, Top HIV Med, V17, P118
   Eghbali Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215
   Guaraldi G, 2001, AIDS, V15, P137, DOI 10.1097/00002030 200101050 00025
   Haine V, 2006, J NEUROIMMUNE PHARM, V1, P32, DOI 10.1007/s11481 005 9003 1
   Hasegawa A, 2009, BLOOD, V114, P2917, DOI 10.1182/blood 2009 02 204263
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Kawai T, 2006, AM J PATHOL, V169, P987, DOI 10.2353/ajpath.2006.060180
   Kim SY, 2010, NAT REV RHEUMATOL, V6, P165, DOI 10.1038/nrrheum.2009.279
   Kim WK, 2010, J LEUKOCYTE BIOL, V87, P557, DOI 10.1189/jlb.0209082
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Lassiter Coy, 2009, AIDS Res Ther, V6, P1, DOI 10.1186/1742 6405 6 1
   Lewis JR, 2006, INJURY, V37, P698, DOI 10.1016/j.injury.2006.04.121
   Li Y, 2007, BLOOD, V109, P3839, DOI 10.1182/blood 2006 07 037994
   Moir S, 2008, J EXP MED, V205, P1797, DOI 10.1084/jem.20072683
   Moir S, 2009, NAT REV IMMUNOL, V9, P235, DOI 10.1038/nri2524
   Mondy K, 2003, CLIN INFECT DIS, V36, P482, DOI 10.1086/367569
   Morrow M, 2008, AIDS RES HUM RETROV, V24, P621, DOI 10.1089/aid.2007.0186
   Nguyen N, 2008, CLIN INTERV AGING, V3, P453
   Reid W, 2004, VIROLOGY, V321, P111, DOI 10.1016/j.virol.2003.12.010
   Reid W, 2001, P NATL ACAD SCI USA, V98, P9271, DOI 10.1073/pnas.161290298
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
   Tebas P, 2000, AIDS, V14, pF63, DOI 10.1097/00002030 200003100 00005
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Thomas J, 2003, JAIDS J ACQ IMM DEF, V33, P281, DOI 10.1097/00126334 200307010 00001
   Triant VA, 2008, J CLIN ENDOCR METAB, V93, P3499, DOI 10.1210/jc.2008 0828
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Yin MT, 2010, J CLIN ENDOCR METAB, V95, P620, DOI 10.1210/jc.2009 0708
   Yun TJ, 1998, J IMMUNOL, V161, P6113
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
NR 32
TC 104
Z9 113
U1 1
U2 2
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
EI 1091 6490
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 3
PY 2010
VL 107
IS 31
BP 13848
EP 13853
DI 10.1073/pnas.1003020107
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 634SP
UT WOS:000280605900054
PM 20643942
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Alfino, LN
   Wilczewski Shirai, KC
   Cronise, KE
   Coy, J
   Glapa, K
   Ehrhart, EJ
   Charles, JB
   Duval, DL
   Regan, DP
AF Alfino, Lauren N.
   Wilczewski Shirai, Kai C.
   Cronise, Kathryn E.
   Coy, Jonathan
   Glapa, Kristina
   Ehrhart, E. J.
   Charles, Joseph B.
   Duval, Dawn L.
   Regan, Daniel P.
TI Role of Periostin Expression in Canine Osteosarcoma Biology and Clinical
   Outcome
SO VETERINARY PATHOLOGY
LA English
DT Article
DE osteosarcoma; dogs; periostin; immunohistochemistry; gene expression
ID HIGH LEVEL EXPRESSION; TUMOR ANGIOGENESIS; POOR PROGNOSIS; MESENCHYMAL
   TRANSITION; EPITHELIAL TRANSITION; MATRICELLULAR PROTEIN; THERAPEUTIC
   TARGET; MURAMYL TRIPEPTIDE; GENE EXPRESSION; FASCICLIN I
AB Periostin is a matricellular protein important in regulating bone, tooth, and cardiac development. In pathologic conditions, periostin drives allergic and fibrotic inflammatory diseases and is also overexpressed in certain cancers. Periostin signaling in tumors has been shown to promote angiogenesis, metastasis, and cancer stem cell survival in rodent models, and its overexpression is associated with poor prognosis in human glioblastoma. However, the role of periostin in regulating tumorigenesis of canine cancers has not been evaluated. Given its role in bone development, we sought to evaluate mRNA and protein expression of periostin in canine osteosarcoma (OS) and assess its association with patient outcome. We validated an anti human periostin antibody cross reactive to canine periostin via western blot and immunohistochemistry and evaluated periostin expression in microarray data from 49 primary canine OS tumors and 8 normal bone samples. Periostin mRNA was upregulated greater than 40 fold in canine OS tumors compared to normal bone and was significantly correlated with periostin protein expression based on quantitative image analysis. However, neither periostin mRNA nor protein expression were associated with time to metastasis in this cohort. Gene Set Enrichment Analysis demonstrated significant enhancement of pro tumorigenic pathways including canonical WNT signaling, epithelial mesenchymal transition, and angiogenesis in periostin high tumors, while periostin low tumors demonstrated evidence of heightened antitumor immune responses. Overall, these data identify a novel antibody that can be used as a tool for evaluation of periostin expression in dogs and suggest that investigation of Wnt pathway targeted drugs in periostin overexpressing canine OS may be a potential therapeutic target.
C1 [Alfino, Lauren N.; Wilczewski Shirai, Kai C.; Cronise, Kathryn E.; Coy, Jonathan; Glapa, Kristina; Charles, Joseph B.; Duval, Dawn L.; Regan, Daniel P.] Colorado State Univ, Ft Collins, CO 80523 USA.
   [Ehrhart, E. J.] Ethos Diagnost Sci, Wheat Ridge, CO USA.
C3 Colorado State University System; Colorado State University Fort Collins
RP Regan, DP (通讯作者)，Colorado State Univ, Dept Microbiol Immunol & Pathol, 1678 Campus Delivery, Ft Collins, CO 80523 USA.
EM daniel.regan@colostate.edu
OI Cronise, Kathryn/0000 0003 3224 1469; Regan, Daniel/0000 0002 3148 1332
FU National Institutes of Health, Office of the Director [K01ODO22982,
   R03OD028265]; Short Term National Research Award [T35OD015130]; National
   Center for Advancing Translational Sciences [L30 TR002126]; Boehringer
   Ingelheim Veterinary Scholar Fellowship; NIH Office of the Director
   [R03OD028265, T35OD015130] Funding Source: NIH RePORTER
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: Research
   reported in this publication was supported by The National Institutes of
   Health, Office of the Director, Award Number K01ODO22982 (DPR) and
   R03OD028265 (DPR); Short Term National Research Award, Award Number
   T35OD015130 (LNA); and National Center for Advancing Translational
   Sciences, Award Number L30 TR002126 (DPR). This work was also supported
   by Boehringer Ingelheim Veterinary Scholar Fellowship (LNA).
CR [Anonymous], 1980, OCCURRENCE TUMORS DO
   Bao SD, 2004, CANCER CELL, V5, P329, DOI 10.1016/S1535 6108(04)00081 9
   Ben QW, 2009, INT J ONCOL, V34, P821, DOI 10.3892/ijo_00000208
   Bindea G, 2013, IMMUNITY, V39, P782, DOI 10.1016/j.immuni.2013.10.003
   Bonnet N, 2012, P NATL ACAD SCI USA, V109, P15048, DOI 10.1073/pnas.1203085109
   Bozyk PD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031336
   Brown JM, 2018, CLIN SARCOMA RES, V8, DOI 10.1186/s13569 018 0105 y
   Bruland OS, 2005, CLIN CANCER RES, V11, P4666, DOI 10.1158/1078 0432.CCR 05 0165
   Butcher JT, 2007, DEV BIOL, V302, P256, DOI 10.1016/j.ydbio.2006.09.048
   Charoentong P, 2017, CELL REP, V18, P248, DOI 10.1016/j.celrep.2016.12.019
   Chen K, 2008, PEDIATR BLOOD CANCER, V51, P349, DOI 10.1002/pbc.21595
   Chen Y, 2015, ONCOTARGET, V6, P23708, DOI 10.18632/oncotarget.4291
   Conway SJ, 2014, CELL MOL LIFE SCI, V71, P1279, DOI 10.1007/s00018 013 1494 y
   Conway SJ, 2008, CURR GENOMICS, V9, P548, DOI 10.2174/138920208786847917
   Das S, 2019, MOL CANCER THER, V18, P1460, DOI 10.1158/1535 7163.MCT 18 1346
   Dernell WS., 2007, WITHROW MACEWENS SMA, V4th, P540
   DORN CR, 1967, CALIF MED, V107, P481
   Dwivedi SKD, 2015, ONCOTARGET, V6, P14646, DOI 10.18632/oncotarget.3711
   ELKINS T, 1990, J CELL BIOL, V110, P1825, DOI 10.1083/jcb.110.5.1825
   Fan Timothy M, 2015, Vet Sci, V2, P210, DOI 10.3390/vetsci2030210
   Feng ZM, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15037844
   Fenger JM, 2014, ILAR J, V55, P69, DOI 10.1093/ilar/ilu009
   Fowles JS, 2017, VET COMP ONCOL, V15, P481, DOI 10.1111/vco.12192
   Garris CS, 2018, IMMUNITY, V49, P1148, DOI 10.1016/j.immuni.2018.09.024
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb 2004 5 10 r80
   Gillan L, 2002, CANCER RES, V62, P5358
   González González L, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00225
   Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313
   Guo Y, 2007, J ORTHOP RES, V25, P964, DOI 10.1002/jor.20356
   Haydon RC, 2002, INT J CANCER, V102, P338, DOI 10.1002/ijc.10719
   Hoang BH, 2004, INT J CANCER, V109, P106, DOI 10.1002/ijc.11677
   Horiuchi K, 1999, J BONE MINER RES, V14, P1239, DOI 10.1359/jbmr.1999.14.7.1239
   Hu F, 2016, INT J EXP PATHOL, V97, P86, DOI 10.1111/iep.12171
   Hu F, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477 7819 12 287
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   JAFFE N, 1985, J CLIN ONCOL, V3, P1101, DOI 10.1200/JCO.1985.3.8.1101
   Jia GQ, 2012, J ALLERGY CLIN IMMUN, V130, P647, DOI 10.1016/j.jaci.2012.06.025
   Kager L, 2003, J CLIN ONCOL, V21, P2011, DOI 10.1200/JCO.2003.08.132
   Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556
   Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982
   Khanna C, 2014, CLIN CANCER RES, V20, P4200, DOI 10.1158/1078 0432.CCR 13 2574
   Kikuchi Y, 2008, J HISTOCHEM CYTOCHEM, V56, P753, DOI 10.1369/jhc.2008.951061
   Kudo Y, 2007, HISTOL HISTOPATHOL, V22, P1167, DOI 10.14670/HH 22.1167
   Kurzman ID, 1995, CLIN CANCER RES, V1, P1595
   Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004
   Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694
   Marth C, 2004, AM J OBSTET GYNECOL, V191, P1598, DOI 10.1016/j.ajog.2004.05.007
   Masuoka M, 2012, J CLIN INVEST, V122, P2590, DOI 10.1172/JCI58978
   Meyers PA, 2005, J CLIN ONCOL, V23, P2004, DOI 10.1200/JCO.2005.06.031
   Mikheev AM, 2015, NEURO ONCOLOGY, V17, P372, DOI 10.1093/neuonc/nou161
   Mirabello L, 2009, CANCER AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Morello E, 2011, VET J, V189, P268, DOI 10.1016/j.tvjl.2010.08.014
   Morra L, 2011, VIRCHOWS ARCH, V459, P465, DOI 10.1007/s00428 011 1151 5
   Müller CR, 2005, ACTA ONCOL, V44, P475, DOI 10.1080/02841860510029978
   Naik PK, 2012, AM J PHYSIOL LUNG C, V303, pL1046, DOI 10.1152/ajplung.00139.2012
   Nie ZG, 2018, ONCOL LETT, V16, P6502, DOI 10.3892/ol.2018.9453
   O'Donoghue LE, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 506
   Paoloni M, 2009, BMC GENOMICS, V10, DOI 10.1186/1471 2164 10 625
   Park SY, 2016, MOL CANCER THER, V15, P2187, DOI 10.1158/1535 7163.MCT 15 0427
   Qi Y, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182680
   RANGES GE, 1987, J EXP MED, V166, P991, DOI 10.1084/jem.166.4.991
   Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033
   Rowell JL, 2011, TRENDS MOL MED, V17, P380, DOI 10.1016/j.molmed.2011.02.004
   Rubin EM, 2010, MOL CANCER THER, V9, P731, DOI 10.1158/1535 7163.MCT 09 0147
   Sannino G, 2017, CANCER RES, V77, P4556, DOI 10.1158/0008 5472.CAN 17 0032
   Selmic LE, 2014, J VET INTERN MED, V28, P554, DOI 10.1111/jvim.12313
   Selvarajah GT, 2009, MOL CANCER, V8, DOI 10.1186/1476 4598 8 72
   Shao R, 2004, MOL CELL BIOL, V24, P3992, DOI 10.1128/MCB.24.9.3992 4003.2004
   Snider P, 2008, CIRC RES, V102, P752, DOI 10.1161/CIRCRESAHA.107.159517
   Soltermann A, 2008, CLIN CANCER RES, V14, P7430, DOI 10.1158/1078 0432.CCR 08 0935
   STRAW RC, 1992, J ORTHOPAED RES, V10, P434, DOI 10.1002/jor.1100100316
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sun FY, 2018, INT J CLIN EXP PATHO, V11, P1569
   Sung PL, 2016, ONCOTARGET, V7, P4036, DOI 10.18632/oncotarget.6700
   TAKESHITA S, 1993, BIOCHEM J, V294, P271, DOI 10.1042/bj2940271
   Tilman G, 2007, MOL CANCER, V6, DOI 10.1186/1476 4598 6 80
   Uchida M, 2012, AM J RESP CELL MOL, V46, P677, DOI 10.1165/rcmb.2011 0115OC
   WITHROW SJ, 1993, CANCER AM CANCER SOC, V71, P2484, DOI 10.1002/1097 0142(19930415)71:8<2484::AID CNCR2820710810>3.0.CO;2 D
   Withrow SJ, 2010, ILAR J, V51, P208, DOI 10.1093/ilar.51.3.208
   Wojtowicz Praga S, 2003, INVEST NEW DRUG, V21, P21, DOI 10.1023/A:1022951824806
   Yamashita O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079753
   Yun H, 2018, BIOMOL NMR ASSIGN, V12, P95, DOI 10.1007/s12104 017 9786 z
   Zhou WC, 2015, NAT CELL BIOL, V17, P170, DOI 10.1038/ncb3090
   Zhu M, 2010, GYNECOL ONCOL, V119, P337, DOI 10.1016/j.ygyno.2010.07.008
   Zhu SM, 2009, J CELL PHYSIOL, V218, P584, DOI 10.1002/jcp.21633
   ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092 8674(88)90574 0
   Zitvogel L, 2015, NAT REV IMMUNOL, V15, P405, DOI 10.1038/nri3845
NR 88
TC 3
Z9 4
U1 0
U2 4
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0300 9858
EI 1544 2217
J9 VET PATHOL
JI Vet. Pathol.
PD SEP
PY 2021
VL 58
IS 5
BP 981
EP 993
AR 0300985821996671
DI 10.1177/0300985821996671
EA MAR 2021
PG 13
WC Pathology; Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pathology; Veterinary Sciences
GA UM3EB
UT WOS:000649058400001
PM 33685296
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Lee, C
   Whang, YM
   Campbell, P
   Mulcrone, PL
   Elefteriou, F
   Cho, SW
   Park, SI
AF Lee, Changki
   Whang, Young Mi
   Campbell, Preston
   Mulcrone, Patrick L.
   Elefteriou, Florent
   Cho, Sun Wook
   Park, Serk In
TI Dual targeting c met and VEGFR2 in osteoblasts suppresses growth and
   osteolysis of prostate cancer bone metastasis
SO CANCER LETTERS
LA English
DT Article
DE Prostate cancer; Bone metastasis; Osteoblasts; c Met; VEGFR2
ID KINASE INHIBITOR; TUMOR GROWTH; CABOZANTINIB; RECEPTOR; CELLS; SOIL
AB Prostate cancer characteristically induces osteoblastic bone metastasis, for which no therapies are available. A dual kinase inhibitor of c Met and VEGFR 2 (cabozantinib) was shown to reduce prostate cancer growth in bone, with evidence for suppressing osteoblastic activity. However, c Met and VEGFR2 signaling in osteoblasts in the context of bone metastasis remain unclear. Here we show using cultured osteoblasts that hepatocyte growth factor (HGF) and VEGF A increased receptor activator of NF kappa B ligand (RANKL) and M CSF, two essential factors for osteoclastogenesis. Insulin like growth factor 1 (IGF1) also increased RANKL and M CSF via c Met transactivation. The conditioned media from IGF1 , HGF , or VEGFA treated osteoblasts promoted osteoclastogenesis that was reversed by inhibiting c Met and/or VEGFR2 in osteoblasts. In vivo experiments used cabozantinib resistant prostate cancer cells (PC 3 and C4 2B) to test the effects of c Met/VEGFR2 inhibition specifically in osteoblasts. Cabozantinib (60 mg/kg, 3 weeks) suppressed tumor growth in bone and reduced expression of RANKL and M CSF and subsequent tumor induced osteolysis. Collectively, inhibition of c Met and VEGFR2 in osteoblasts reduced RANKL and M CSF expression, and associated with reduction of tumor induced osteolysis, suggesting that c Met and VEGFR2 are promising therapeutic targets in bone metastasis. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Lee, Changki; Campbell, Preston; Mulcrone, Patrick L.; Elefteriou, Florent; Park, Serk In] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA.
   [Lee, Changki; Campbell, Preston; Mulcrone, Patrick L.; Elefteriou, Florent; Park, Serk In] Vanderbilt Univ, Sch Med, Vanderbilt Ctr Bone Biol, Nashville, TN 37212 USA.
   [Whang, Young Mi] Chung Ang Univ, Coll Med, Dept Urol, Seoul, South Korea.
   [Elefteriou, Florent] Baylor Coll Med, Dept Human & Mol Genet, Houston, TX 77030 USA.
   [Elefteriou, Florent] Baylor Coll Med, Dept Orthoped Surg, Houston, TX 77030 USA.
   [Cho, Sun Wook] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea.
   [Park, Serk In] Korea Univ, Coll Med, Dept Biochem & Mol Biol, Seoul, South Korea.
   [Park, Serk In] Korea Univ, Coll Med, Plus Program BK21, Seoul, South Korea.
C3 Vanderbilt University; Vanderbilt University; Chung Ang University;
   Chung Ang University Hospital; Baylor College of Medicine; Baylor
   College of Medicine; Seoul National University (SNU); Seoul National
   University Hospital; Korea University; Korea University Medicine (KU
   Medicine); Korea University; Korea University Medicine (KU Medicine)
RP Park, SI (通讯作者)，Munsuk Med Hall Room 319,73 Inchon Ro, Seoul 02841, South Korea.
EM serkin@korea.edu
RI Cho, Sun/HPB 9019 2023; Elefteriou, Florent/P 2586 2017; Park,
   Serk/D 2840 2011; Park, Serk In/D 2840 2011
OI Elefteriou, Florent/0000 0002 2972 5633; Park, Serk
   In/0000 0001 8643 5096
FU National Research Foundation of Korea [2015R1C1A1A01051508,
   2016RD1A1B03933826]; Ministry of Health and Welfare of the Republic of
   Korea (National R&D Program for Cancer) [1720140]
FX This work was in part supported by the National Research Foundation of
   Korea (Grants No. 2015R1C1A1A01051508 to S.I.P. and 2016RD1A1B03933826
   to Y.M.W.) and the Ministry of Health and Welfare of the Republic of
   Korea (National R&D Program for Cancer, No. 1720140 to S.W.C. and
   S.I.P).
CR Basch E, 2015, EUR UROL, V67, P310, DOI 10.1016/j.eururo.2014.02.013
   Breindel JL, 2013, CANCER RES, V73, P5053, DOI 10.1158/0008 5472.CAN 12 3775
   Buenrostro D, 2016, CURR OSTEOPOROS REP, V14, P151, DOI 10.1007/s11914 016 0315 2
   Buenrostro D, 2014, BIOMED RES INT UK, V2014, DOI 10.1155/2014/875305
   Campbell JP, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001363
   Chen HT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038378
   Dai JL, 2014, CLIN CANCER RES, V20, P617, DOI 10.1158/1078 0432.CCR 13 0839
   Fioramonti M, 2017, ONCOTARGET, V8, P20113, DOI 10.18632/oncotarget.15390
   Fujita H, 2013, MOL CANCER THER, V12, P2685, DOI 10.1158/1535 7163.MCT 13 0459
   HARRIS SA, 1995, J BONE MINER RES, V10, P178
   Hess KR, 2006, CANCER, V106, P1624, DOI 10.1002/cncr.21778
   Jeong HM, 2016, ENDOCRINOL METAB, V31, P485, DOI 10.3803/EnM.2016.31.4.485
   Lee RJ, 2014, CLIN CANCER RES, V20, P525, DOI 10.1158/1078 0432.CCR 13 2636
   Martin T John, 2014, J Bone Metab, V21, P8, DOI 10.11005/jbm.2014.21.1.8
   Park SI, 2016, BIOCHEM BIOPH RES CO, V469, P363, DOI 10.1016/j.bbrc.2015.11.122
   Park SI, 2013, CANCER RES, V73, P6574, DOI 10.1158/0008 5472.CAN 12 4692
   Park SI, 2011, CANCER MICROENVIRON, V4, P237, DOI 10.1007/s12307 011 0081 8
   Park SI., 2010, CURR PROTOC PHARM
   Patnaik A, 2017, CANCER DISCOV, V7, P750, DOI 10.1158/2159 8290.CD 16 0778
   Shiozawa Y, 2011, J CLIN INVEST, V121, P1298, DOI 10.1172/JCI43414
   Smith DC, 2013, J CLIN ONCOL, V31, P412, DOI 10.1200/JCO.2012.45.0494
   Smith M, 2016, J CLIN ONCOL, V34, P3005, DOI 10.1200/JCO.2015.65.5597
   Soki FN, 2012, FUTURE ONCOL, V8, P803, DOI [10.2217/fon.12.76, 10.2217/FON.12.76]
   Tsai SY, 2012, INT IMMUNOPHARMACOL, V13, P156, DOI 10.1016/j.intimp.2012.03.026
   Varkaris A, 2013, INT J CANCER, V133, P1536, DOI 10.1002/ijc.28169
   Varkaris A, 2011, EXPERT OPIN INV DRUG, V20, P1677, DOI 10.1517/13543784.2011.631523
   Watanabe K, 2016, J BIOL CHEM, V291, P20891, DOI 10.1074/jbc.M116.727875
   Whang YM, 2017, ONCOTARGET, V8, P53168, DOI 10.18632/oncotarget.18230
   Yakes FM, 2011, MOL CANCER THER, V10, P2298, DOI 10.1158/1535 7163.MCT 11 0264
NR 29
TC 51
Z9 52
U1 0
U2 19
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304 3835
EI 1872 7980
J9 CANCER LETT
JI Cancer Lett.
PD FEB 1
PY 2018
VL 414
BP 205
EP 213
DI 10.1016/j.canlet.2017.11.016
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA FS5CK
UT WOS:000419810900021
PM 29174801
DA 2025 08 17
ER

PT J
AU Antal, I
   Pápai, Z
   Szendroi, M
   Perlaky, T
   Dezso, K
   Lippai, Z
   Sápi, Z
AF Antal, Imre
   Papai, Zsuzsanna
   Szendroi, Miklos
   Perlaky, Tamas
   Dezso, Katalin
   Lippai, Zoltan
   Sapi, Zoltan
TI The Activation of PDGFRβ on Mononuclear Stromal/Tumor Cells in Giant
   Cell Tumor of Bone After Denosumab Treatment. An Immunohistochemical
   Study of Five Cases
SO PATHOLOGY & ONCOLOGY RESEARCH
LA English
DT Article
DE giant cell tumor of bone; denosumab; PDGFR beta; combination therapy;
   sunitinib
ID RECURRENCE
AB Due to the relatively high recurrence rate and the destructive nature of the tumor, the treatment of giant cell tumor is still a challenge. Denosumab appeared to be a promising candidate as a therapeutic drug. However, several studies have reported that tumors can recur during/after treatment with denosumab. Based on activated receptor tyrosine kinase signaling pattern of the stromal/tumor cells, a combination treatment with denosumab and sunitinib has recently been proposed to inhibit recurrences. This prompted us to investigate the PDGFR beta expression of five denosumab treated cases using both primary and recurrent tumors during and after denosumab treatment. In addition, to recognise morphological changes, immunohistochemical analysis of H3F3A and PDGFR beta was also performed. As an effect of denosumab treatment, the permanent absence of giant cells associated with severe to mild fibrosis was the most consistent morphological change, but H3F3A positive stromal/tumor cells were observed in all cases. Furthermore, an increased immunopositivity of PDGFR beta in stromal/tumor cells was evident in all recurrent cases during denosumab treatment. Upon tumor recurrence (after the discontinuation of denosumab treatment) the intensity of PDGFR beta immunostaining in stromal/tumor cells was restored/decreased. Our results confirm (for the first time) the activation of PDGFR beta on mononuclear stromal/tumor cells at protein level as an effect of denosumab treatment, which has so far only been demonstrated by phosphoprotein array analysis (protein lysates). The decreased PDGFR beta activity after the discontinuation of denosumab treatmeant and the increased PDGFR beta activity during denosumab treatment underlines the need for denosumab and sunitinib combination therapy.
C1 [Antal, Imre; Szendroi, Miklos; Perlaky, Tamas] Semmelweis Univ, Dept Orthopaed, Budapest, Hungary.
   [Papai, Zsuzsanna] Hungarian Def Forces Med Ctr, Dept Oncol, Budapest, Hungary.
   [Dezso, Katalin; Lippai, Zoltan; Sapi, Zoltan] Semmelweis Univ, Dept Pathol & Expt Canc Res, Budapest, Hungary.
C3 Semmelweis University; Semmelweis University
RP Sápi, Z (通讯作者)，Semmelweis Univ, Dept Pathol & Expt Canc Res, Budapest, Hungary.
EM sapi.zoltan.dr@gmail.com
RI ; Lippai, Zoltán/AAL 7849 2020; Antal MD PhD, Imre/JKI 2179 2023
OI Lippai, Zoltan/0000 0001 9064 2493; 
FU European Social Fund;  [EFOP 3.6.3];  [VEKOP 16 2017 00009]
FX Funding This research was financially supported by the following grant
   agencies: European Social Fund (EFOP 3.6.3. VEKOP 16 2017 00009).
CR Amary F, 2017, AM J SURG PATHOL, V41, P1059, DOI 10.1097/PAS.0000000000000859
   Athanasou NABM., 2013, CLASSIFICATION TUMOR, V4th ed., P321
   Atkins GJ, 2006, J BONE MINER RES, V21, P1339, DOI 10.1359/JBMR.060604
   Balke M, 2008, J CANCER RES CLIN, V134, P969, DOI 10.1007/s00432 008 0370 x
   Behjati S, 2013, NAT GENET, V45, P1479, DOI 10.1038/ng.2814
   Chen X, 2020, BMC MUSCULOSKEL DIS, V21, DOI 10.1186/s12891 020 03294 2
   Cottone L, 2021, J PATHOL, V255, pS16
   Forsyth RG, 2021, CANCERS, V13, DOI 10.3390/cancers13205119
   Hasenfratz M, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 85319 x
   Jamshidi K, 2018, ARCH BONE JT SURG AB, V6, P260
   Knochentumoren A, 2008, J BONE JOINT SURG AM, V90A, P1060, DOI 10.2106/JBJS.D.02771
   Lipplaa A, 2019, CURR OPIN ONCOL, V31, P329, DOI 10.1097/CCO.0000000000000529
   Mahdal M, 2021, CANCERS, V13, DOI 10.3390/cancers13143543
   Matcuk GR, 2015, SKELETAL RADIOL, V44, P1027, DOI 10.1007/s00256 015 2117 5
   Moskovszky L, 2009, GENE CHROMOSOME CANC, V48, P468, DOI 10.1002/gcc.20656
   Palmerini E, 2021, BMC CANCER, V21, DOI 10.1186/s12885 020 07739 8
   Roitman PD, 2017, HUM PATHOL, V63, P89, DOI 10.1016/j.humpath.2017.02.008
   Roux S, 2002, AM J CLIN PATHOL, V117, P210
   Szendröi M, 2004, J BONE JOINT SURG BR, V86B, P5, DOI 10.1302/0301 620X.86B1.14053
   Thomas D, 2010, LANCET ONCOL, V11, P275, DOI 10.1016/S1470 2045(10)70010 3
   Traub F, 2016, EUR J CANCER, V59, P1, DOI 10.1016/j.ejca.2016.01.006
   van der Heijden L, 2017, EUR J CANCER, V77, P75, DOI 10.1016/j.ejca.2017.02.021
   WHO, 2020, SOFT TISS BON TUM
NR 23
TC 5
Z9 5
U1 0
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1219 4956
EI 1532 2807
J9 PATHOL ONCOL RES
JI Pathol. Oncol. Res.
PD AUG 24
PY 2022
VL 28
AR 1610633
DI 10.3389/pore.2022.1610633
PG 8
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pathology
GA 6D9HD
UT WOS:000882994000001
PM 36091939
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Barger, AM
   Fan, TM
   de Lorimier, LP
   Sprandel, IT
   O'Dell Anderson, K
AF Barger, Anne M.
   Fan, Timothy M.
   de Lorimier, Louis Philippe
   Sprandel, Ian T.
   O'Dell Anderson, Kristen
TI Expression of receptor activator of nuclear factor κ B ligand (RANKL) in
   neoplasms of dogs and cats
SO JOURNAL OF VETERINARY INTERNAL MEDICINE
LA English
DT Article; Proceedings Paper
CT 25th Annual Meeting of the Veterinary Cancer Society
CY OCT, 2005
CL Huntington Beach, CA
SP Vet Canc Soc
DE bone pain; cancer; companion animals; dual energy x ray absorptiometry;
   immunocytochemistry; malignant osteolysis
ID SQUAMOUS CELL CARCINOMA; OSTEOCLAST DIFFERENTIATION; BONE;
   INTERLEUKIN 11; HYPERCALCEMIA; TUMOR
AB Background: Receptor activator of nuclear factor K B (RANK), RANK ligand (RANKL), and the Soluble decoy receptor osteoprotegerin (OPG) form a key axis modulating osteoclastogenesis. In health, RANKL expressing bone stromal cells and osteoblasts activate osteoclasts through RANK ligation, resulting in homeostatic bone resorption. Skeletal tumors of dogs and cats, whether primary or metastatic, may express RANKL and directly induce malignant osteolysis.
   Hypothesis: Bone malignancies of dogs and cats may express RANKL, thereby contributing to pathologic bone resorption and pain. Furthermore, relative RANKL expression in bone tumors may correlate with radiographic characteristics of bone pathology.
   Animals: Forty two dogs and 6 cats with spontaneously occurring tumors involving bones or soft tissues were evaluated.
   Methods: A polyclonal anti human RANKL antibody was validated for use in canine and feline cells by flow cytometry and immunocytochemistry. Fifty cytologic specimens were collected from bone and soft tissue tumors of 48 tumor bearing animals and assessed for RANKL expression. In 15 canine osteosarcoma (OSA) samples, relative RANKL expression was correlated with radiographic characteristics of bone pathology.
   Results: Expression of RANKL by neoplastic cells was identified in 32/44 canine and 5/6 feline tumor samples. In 15 dogs with OSA, relative RANKL expression did not correlate with either radiographic osteolysis or bone mineral density as assessed by dual energy x ray absorptiometry.
   Conclusions and Clinical Importance: In dogs and cats, tumors classically involving bone and causing pain, often may express RANKL. Confirming RANKL expression in tumors is a necessary step toward the rational institution of novel therapies targeting malignant osteolysis via RANKL antagonism.
C1 Univ Illinois, Dept Pathobiol, Urbana, IL 61802 USA.
   Univ Illinois, Dept Vet Clin Med, Urbana, IL 61802 USA.
C3 University of Illinois System; University of Illinois Urbana Champaign;
   University of Illinois System; University of Illinois Urbana Champaign
RP Barger, AM (通讯作者)，Univ Illinois, Dept Pathobiol, 1008 W Hazelwood Dr, Urbana, IL 61802 USA.
EM abarger@uiuc.edu
RI Barger, Anne/ABE 3091 2021
OI Fan, Timothy/0000 0003 2510 7050
CR Body JJ, 2006, CLIN CANCER RES, V12, P1221, DOI 10.1158/1078 0432.CCR 05 1933
   BUNDRED NJ, 1995, WORLD J SURG, V19, P297
   Clines GA, 2005, ENDOCR RELAT CANCER, V12, P549, DOI 10.1677/erc.1.00543
   Clohisy D. R., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P293
   Cui NH, 2005, CLIN CANCER RES, V11, P2713, DOI 10.1158/1078 0432.CCR 04 1767
   Fan TM, 2005, J VET INTERN MED, V19, P74, DOI 10.1892/0891 6640(2005)19<74:EOIPAI>2.0.CO;2
   Good CR, 2002, J SURG ONCOL, V79, P174, DOI 10.1002/jso.10067
   Huang L, 2002, J CLIN PATHOL, V55, P877, DOI 10.1136/jcp.55.11.877
   Kinpara K, 2000, J IMMUNOASSAY, V21, P327, DOI 10.1080/01971520009349540
   Kobayashi A, 2005, SCAND J RHEUMATOL, V34, P480, DOI 10.1080/03009740510026788
   Lacoste H, 2006, J VET INTERN MED, V20, P335, DOI 10.1892/0891 6640(2006)20[335:UNEIDW]2.0.CO;2
   Lee Y, 2003, J ORTHOP RES, V21, P62, DOI 10.1016/S0736 0266(02)00095 5
   Morinaga Y, 1997, INT J CANCER, V71, P422, DOI 10.1002/(SICI)1097 0215(19970502)71:3<422::AID IJC20>3.3.CO;2 Y
   Nishimura M, 2005, J ORTHOP RES, V23, P979, DOI 10.1016/j.orthres.2005.01.004
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Roux S, 2002, BRIT J HAEMATOL, V117, P86, DOI 10.1046/j.1365 2141.2002.03417.x
   Tada T, 2005, INT J CANCER, V116, P253, DOI 10.1002/ijc.21008
   Takayanagi H, 2005, J PERIODONTAL RES, V40, P287, DOI 10.1111/j.1600 0765.2005.00814.x
   Wittrant Y, 2004, BBA REV CANCER, V1704, P49, DOI 10.1016/j.bbcan.2004.05.002
   Yeung SCJ, 1998, HORM RES, V49, P288, DOI 10.1159/000023188
   Zhang Y, 1998, ONCOGENE, V16, P693, DOI 10.1038/sj.onc.1201581
NR 21
TC 19
Z9 21
U1 1
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0891 6640
EI 1939 1676
J9 J VET INTERN MED
JI J. Vet. Intern. Med.
PD JAN FEB
PY 2007
VL 21
IS 1
BP 133
EP 140
DI 10.1892/0891 6640(2007)21[133:EORAON]2.0.CO;2
PG 8
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Veterinary Sciences
GA 135OH
UT WOS:000244162400020
PM 17338161
DA 2025 08 17
ER

PT J
AU Zhang, GY
   Kang, YH
   Dong, JZ
   Shi, DY
   Xiang, Y
   Gao, HH
   Lin, ZQ
   Wei, XJ
   Ding, R
   Fan, BB
   Zhang, HM
   Zhu, TH
   Wang, LR
   Yan, XY
AF Zhang, Guoyang
   Kang, Yuhao
   Dong, Jizhao
   Shi, Dingyi
   Xiang, Yu
   Gao, Haihan
   Lin, Zhiqi
   Wei, Xiaojuan
   Ding, Ren
   Fan, Beibei
   Zhang, Hongmei
   Zhu, Tonghe
   Wang, Liren
   Yan, Xiaoyu
TI Fluffy hybrid nanoadjuvants for reversing the imbalance of osteoclastic
   and osteogenic niches in osteoporosis
SO BIOACTIVE MATERIALS
LA English
DT Article
DE Osteoporosis; nanoadjuvants; topological morphology; bone niches;
   Adhesion
ID MESOPOROUS SILICA NANOPARTICLES; OVARIECTOMIZED RAT MODEL; BIOACTIVE
   GLASS MICROSPHERES; DELIVERY SYSTEM; MECHANICAL PROPERTIES;
   BONE FORMATION; DRUG; ALENDRONATE; CELLS; REGENERATION
AB Osteoporosis is majorly caused by an imbalance between osteoclastic and osteogenic niches. Despite the development of nationally recognized first  line anti  osteoporosis drugs, including alendronate (AL), their low bioavailability, poor uptake rate, and dose  related side effects present significant challenges in treatment. This calls for an urgent need for more effective bone  affinity drug delivery systems. In this study, we produced hybrid structures with bioactive components and stable fluffy topological morphology by cross  linking calcium and phosphorus precursors based on mesoporous silica to fabricate nanoadjuvants for AL delivery. The subsequent grafting of  PEG DAsp 8 ensured superior biocompatibility and bone targeting capacity. RNA sequencing revealed that these fluffy nanoadjuvants effectively activated adhesion pathways through CARD11 and CD34 molecular mechanisms, hence promoting cellular uptake and intracellular delivery of AL. Experiments showed that smalldose AL nanoadjuvants effectively suppress osteoclast formation and potentially promote osteogenesis. In vivo results restored the balance between osteogenic and osteoclastic niches against osteoporosis as well as the consequent significant recovery of bone mass. Therefore, this study constructed a drug nanoadjuvant with peculiar topological structures and high bone targeting capacities, efficient intracellular drug delivery as well as bone bioactivity. This provides a novel perspective on drug delivery for osteoporosis and treatment strategies for other bone diseases.
C1 [Zhang, Guoyang; Dong, Jizhao; Xiang, Yu; Lin, Zhiqi; Wei, Xiaojuan; Wang, Liren; Yan, Xiaoyu] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Sch Med, 600 Yishan Rd, Shanghai 200233, Peoples R China.
   [Zhang, Guoyang; Kang, Yuhao; Dong, Jizhao; Shi, Dingyi; Xiang, Yu; Lin, Zhiqi; Wang, Liren; Yan, Xiaoyu] Shanghai Jiao Tong Univ, Sch Med, 227 Chongqing South Rd, Shanghai 200025, Peoples R China.
   [Zhang, Hongmei; Zhu, Tonghe] Shanghai Univ Engn Sci, Inst Frontier Med Technol, Multidisciplinary Ctr Adv Mat, Sch Chem & Chem Engn, 333 Longteng Rd, Shanghai 201620, Peoples R China.
   [Gao, Haihan; Ding, Ren] Shanghai Baoshan Dist Hosp Integrated Tradit Chine, Dept Orthoped, 181 Youyi Rd, Shanghai 201900, Peoples R China.
   [Fan, Beibei] Shanghai Baoshan Dist Hosp Integrated Tradit Chine, Dept Pharm, 181 Youyi Rd, Shanghai 201900, Peoples R China.
   [Zhang, Guoyang; Kang, Yuhao; Shi, Dingyi; Wang, Liren] Shanghai Jiao Tong Univ, Regenerat Sports Med & Translat Youth Sci & Techno, Sch Med, 227 South Chongqing Rd, Shanghai 200025, Peoples R China.
   [Zhang, Guoyang; Dong, Jizhao; Xiang, Yu; Lin, Zhiqi; Wei, Xiaojuan; Wang, Liren; Yan, Xiaoyu] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Inst Microsurg Extrem, Regenerat Sports Med Lab,Sch Med, 600 Yishan Rd, Shanghai 200233, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai
   University of Engineering Science; Shanghai Jiao Tong University;
   Shanghai Jiao Tong University
RP Wang, LR; Yan, XY (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Sch Med, 600 Yishan Rd, Shanghai 200233, Peoples R China.; Zhu, TH (通讯作者)，Shanghai Univ Engn Sci, Inst Frontier Med Technol, Multidisciplinary Ctr Adv Mat, Sch Chem & Chem Engn, 333 Longteng Rd, Shanghai 201620, Peoples R China.; Fan, BB (通讯作者)，Shanghai Baoshan Dist Hosp Integrated Tradit Chine, Dept Pharm, 181 Youyi Rd, Shanghai 201900, Peoples R China.
EM jessiefan2012@163.com; zhutonghe89@sues.edu.cn; wangliren13@163.com;
   xyyan@sjtu.edu.cn
RI 朱, 朱/JNS 1507 2023; Gao, Haihan/HGS 3763 2022; Yan,
   Xiaoyu/ABA 7470 2020; ZHIQI, LIN/AED 2244 2022; xiang, yu/KOC 9302 2024;
   Wang, Liren/JQJ 6673 2023
OI Zhang, Guoyang/0009 0001 4906 0712; Wei, Xiaojuan/0000 0002 4422 6234
FU National Natural Science Foundation of China [82172233]; Shanghai
   Baoshan District Science and Technology Commission medical health
   project [21 E52]
FX National Natural Science Foundation of China 82172233 (X. Y.). Shanghai
   Baoshan District Science and Technology Commission medical health
   project 21 E52 (B. F.).
CR Ayers C, 2023, ANN INTERN MED, V176, DOI 10.7326/M22 0684
   Blanco E, 2015, NAT BIOTECHNOL, V33, P941, DOI 10.1038/nbt.3330
   Buccitelli C, 2020, NAT REV GENET, V21, P630, DOI 10.1038/s41576 020 0258 4
   Chang CC, 2020, J ENDODONT, V46, P1256, DOI 10.1016/j.joen.2020.05.016
   Chen W, 2019, ACCOUNTS CHEM RES, V52, P1531, DOI 10.1021/acs.accounts.9b00116
   Chu HY, 2006, MOL CELL BIOL, V26, P1817, DOI 10.1128/MCB.26.5.1817 1825.2006
   Cirillo N, 2009, CELL MOL LIFE SCI, V66, P3517, DOI 10.1007/s00018 009 0139 7
   Colman EG, 2003, J BONE MINER RES, V18, P1125, DOI 10.1359/jbmr.2003.18.6.1125
   Cummings SR, 2020, BONE, V137, DOI 10.1016/j.bone.2020.115411
   Deardorff WJ, 2022, JAMA INTERN MED, V182, P33, DOI 10.1001/jamainternmed.2021.6745
   Duan HB, 2016, MATER LETT, V167, P201, DOI 10.1016/j.matlet.2015.12.162
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   El Fiqi A, 2015, ACS APPL MATER INTER, V7, P1140, DOI 10.1021/am5077759
   El Fiqi A, 2013, ACTA BIOMATER, V9, P9508, DOI 10.1016/j.actbio.2013.07.036
   Fink HA, 2019, ANN INTERN MED, V171, P37, DOI 10.7326/M19 0533
   Flanagan J.G, Transmembrane form of the kit ligand growth factor is determined by alternative splicing and is Missing in The Nd Mutant
   Fleischmann A, 2003, CANCER CELL, V4, P477, DOI 10.1016/S1535 6108(03)00280 0
   Foessl I, 2023, NAT REV ENDOCRINOL, V19, P520, DOI 10.1038/s41574 023 00866 9
   Gao JC, 2024, NAT NANOTECHNOL, V19, DOI 10.1038/s41565 023 01551 8
   Gao YG, 2023, BIOMOLECULES, V13, DOI 10.3390/biom13030483
   Gosavi P, 2011, CELL MOL LIFE SCI, V68, P1439, DOI 10.1007/s00018 010 0531 3
   Gupta S, 2021, J CONTROL RELEASE, V335, P481, DOI 10.1016/j.jconrel.2021.05.043
   Han YH, 2022, CHEM ENG J, V435, DOI 10.1016/j.cej.2022.134820
   Harris JM, 2003, NAT REV DRUG DISCOV, V2, P214, DOI 10.1038/nrd1033
   He QJ, 2011, BIOMATERIALS, V32, P7711, DOI 10.1016/j.biomaterials.2011.06.066
   Hu S, 2016, OSTEOPOROSIS INT, V27, P797, DOI 10.1007/s00198 015 3284 x
   Huang CL, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202010637
   Huang LL, 2023, ACS NANO, V17, P9155, DOI 10.1021/acsnano.2c12660
   Huang Y, 2023, ACS NANO, DOI 10.1021/acsnano.3c03195
   Idris AI, 2008, CALCIFIED TISSUE INT, V82, P191, DOI 10.1007/s00223 008 9104 y
   Itonaga I, EVect of Osteoprotegerin and Osteoprotegerin Ligand on Osteoclast Formation by Arthroplasty Membrane Derived Macrophages
   Jia F, 2023, BIOMATERIALS, V296, DOI 10.1016/j.biomaterials.2023.122059
   Kankala RK, 2020, ADV MATER, V32, DOI 10.1002/adma.201907035
   Kokubo T, 2006, BIOMATERIALS, V27, P2907, DOI 10.1016/j.biomaterials.2006.01.017
   Kukita T, 2004, J EXP MED, V200, P941, DOI 10.1084/jem.20040518
   Lanza FL, 2000, GASTROENTEROLOGY, V119, P631, DOI 10.1053/gast.2000.16517
   Lee JH, 2013, MATER LETT, V105, P136, DOI 10.1016/j.matlet.2013.04.082
   Lérida Viso A, 2023, ADV DRUG DELIVER REV, V201, DOI 10.1016/j.addr.2023.115049
   Li X, 2007, MICROPOR MESOPOR MAT, V102, P151, DOI 10.1016/j.micromeso.2006.12.048
   Lin D, 2013, AM J GASTROENTEROL, V108, P1576, DOI 10.1038/ajg.2013.222
   Liu CC, 2015, J BONE MINER RES, V30, P670, DOI 10.1002/jbmr.2382
   Liu J, 2021, NATURE AGING, V1, P368, DOI 10.1038/s43587 021 00050 6
   Liu S, 2024, ADV FUNCT MATER, V34, DOI 10.1002/adfm.202306534
   Liu YH, 2023, ACS NANO, V18, P951, DOI 10.1021/acsnano.3c09692
   Lobo RA, 2022, LANCET DIABETES ENDO, V10, P457, DOI 10.1016/S2213 8587(21)00269 2
   Londoño Restrepo SM, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 42269 9
   Lotz EM, 2020, J BIOMED MATER RES A, V108, P1774, DOI 10.1002/jbm.a.36944
   Lowe C.E., 2000, Upper Gastrointestinal Toxicity of Alendronate, P95
   Meejoo S, 2006, THERMOCHIM ACTA, V447, P115, DOI 10.1016/j.tca.2006.04.013
   Miao GH, 2013, MAT SCI ENG C MATER, V33, P4236, DOI 10.1016/j.msec.2013.06.022
   Miller SC, 2008, PHARM RES DORDR, V25, P2889, DOI 10.1007/s11095 008 9706 0
   Neidhart M, 2009, ANN RHEUM DIS, V68, P1334, DOI 10.1136/ard.2008.092494
   Porras AG, 1999, CLIN PHARMACOKINET, V36, P315, DOI 10.2165/00003088 199936050 00002
   Roberson ED, 2007, SCIENCE, V316, P750, DOI 10.1126/science.1141736
   Salari N, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02772 0
   Sassetti C, 2000, J BIOL CHEM, V275, P9001, DOI 10.1074/jbc.275.12.9001
   Schumacher M, 2021, BIOACT MATER, V6, P1921, DOI 10.1016/j.bioactmat.2020.12.007
   Sharpe M, 2001, DRUGS, V61, P999, DOI 10.2165/00003495 200161070 00010
   Shi C, 2020, PHARMACOL THERAPEUT, V207, DOI 10.1016/j.pharmthera.2020.107473
   Silva RAB, 2020, INT ENDOD J, V53, P84, DOI 10.1111/iej.13206
   Srivastava R, 2010, J BIOL CHEM, V285, P11100, DOI 10.1074/jbc.M109.068999
   Stellos K, 2008, CIRCULATION, V117, P206, DOI 10.1161/CIRCULATIONAHA.107.714691
   Sun T, 2023, J CONTROL RELEASE, V353, P337, DOI 10.1016/j.jconrel.2022.11.047
   Taha EA, 2003, CHEM PHARM BULL, V51, P1444, DOI 10.1248/cpb.51.1444
   Nguyen TL, 2019, ADV MATER, V31, DOI 10.1002/adma.201803953
   Turner A. Simon, 2001, European Cells & Materials, V1, P66
   TURNER RT, 1987, J BONE MINER RES, V2, P115
   Wang WX, 2020, CHEM US, V6, P1097, DOI 10.1016/j.chempr.2020.01.010
   Wang WX, 2017, ACS CENTRAL SCI, V3, P839, DOI 10.1021/acscentsci.7b00257
   Wei PF, 2019, CHEM ENG J, V368, P577, DOI 10.1016/j.cej.2019.02.202
   Wen J, 2017, CHEM SOC REV, V46, P6024, DOI 10.1039/c7cs00219j
   Wu JR, 2021, BIOMATERIALS, V276, DOI 10.1016/j.biomaterials.2021.121001
   Wu JR, 2018, ACS APPL MATER INTER, V10, P42115, DOI 10.1021/acsami.8b16448
   Xu C, 2015, SMALL, V11, P5949, DOI 10.1002/smll.201501449
   Yousefzadeh N, 2020, EXCLI J, V19, P89, DOI 10.17179/excli2019 1990
   Yu HY, 2023, ANGEW CHEM INT EDIT, V62, DOI 10.1002/anie.202216188
   Zheng LM, 2022, BIOACT MATER, V14, P250, DOI 10.1016/j.bioactmat.2021.11.012
   Zhou YX, 2018, ACTA PHARM SIN B, V8, P165, DOI 10.1016/j.apsb.2018.01.007
NR 78
TC 4
Z9 4
U1 10
U2 47
PU KEAI PUBLISHING LTD
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, Building 5, Room 411, BEIJING, DONGCHENG
   DISTRICT 100009, PEOPLES R CHINA
EI 2452 199X
J9 BIOACT MATER
JI Bioact. Mater.
PD SEP
PY 2024
VL 39
BP 354
EP 374
DI 10.1016/j.bioactmat.2024.05.037
PG 21
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA UQ0I8
UT WOS:001249402900001
PM 38846529
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Torres, HM
   VanCleave, AM
   Vollmer, M
   Callahan, DL
   Smithback, A
   Conn, JM
   Rodezno Antunes, T
   Gao, ZL
   Cao, YX
   Afeworki, Y
   Tao, JN
AF Torres, Haydee M.
   VanCleave, Ashley M.
   Vollmer, Mykayla
   Callahan, Dakota L.
   Smithback, Austyn
   Conn, Josephine M.
   Rodezno Antunes, Tania
   Gao, Zili
   Cao, Yuxia
   Afeworki, Yohannes
   Tao, Jianning
TI Selective Targeting of Class I Histone Deacetylases in a Model of Human
   Osteosarcoma
SO CANCERS
LA English
DT Article
DE osteosarcoma; epigenetics; 4SC 202; domatinostat; histone deacetylase
   inhibitor; xenografts; osteoblast like differentiation; transcriptome;
   signaling pathways
ID TESTING STAGE 1; INHIBITOR TRICHOSTATIN; ANTITUMOR ACTIVITY; SODIUM
   VALPROATE; GENE EXPRESSION; HDAC INHIBITORS; DOWN REGULATION;
   CELL LINES; CANCER; APOPTOSIS
AB Simple Summary Osteosarcoma is the predominant form of primary bone cancer and outcomes for patients with metastatic disease have not improved for several decades. Recent genomic and pharmacological studies have implicated dysregulated histone deacetylases as druggable targets to treat several types of cancers, including osteosarcoma. This study aimed to assess the inhibitory effects of 4SC 202, a next generation inhibitor for class I histone deacetylases, on human osteosarcoma cell growth in vitro and in vivo. We demonstrated that the anti tumor effect of 4SC 202 involves combined cell cycle arrest and apoptosis, as well as a reduction in cell invasion and migration. Moreover, 4SC 202 revised the global transcriptome and induced distinct signatures of gene expression in vitro. Additionally, 4SC 202 decreased tumor growth of established human tumor xenografts in immunodeficient mice in vivo. Our study suggests that 4SC 202 may be exploited as a valuable drug to promote more effective treatment of patients. Dysregulation of histone deacetylases (HDACs) is associated with the pathogenesis of human osteosarcoma, which may present an epigenetic vulnerability as well as a therapeutic target. Domatinostat (4SC 202) is a next generation class I HDAC inhibitor that is currently being used in clinical research for certain cancers, but its impact on human osteosarcoma has yet to be explored. In this study, we report that 4SC 202 inhibits osteosarcoma cell growth in vitro and in vivo. By analyzing cell function in vitro, we show that the anti tumor effect of 4SC 202 involves the combined induction of cell cycle arrest at the G2/M phase and apoptotic program, as well as a reduction in cell invasion and migration capabilities. We also found that 4SC 202 has little capacity to promote osteogenic differentiation. Remarkably, 4SC 202 revised the global transcriptome and induced distinct signatures of gene expression in vitro. Moreover, 4SC 202 decreased tumor growth of established human tumor xenografts in immunodeficient mice in vivo. We further reveal key targets regulated by 4SC 202 that contribute to tumor cell growth and survival, and canonical signaling pathways associated with progression and metastasis of osteosarcoma. Our study suggests that 4SC 202 may be exploited as a valuable drug to promote more effective treatment of patients with osteosarcoma and provide molecular insights into the mechanism of action of class I HDAC inhibitors.
C1 [Torres, Haydee M.; VanCleave, Ashley M.; Rodezno Antunes, Tania; Cao, Yuxia; Tao, Jianning] Sanford Res, Canc Biol & Immunotherapies Grp, Sioux Falls, SD 57104 USA.
   [Torres, Haydee M.; Tao, Jianning] South Dakota State Univ, Dept Chem & Biochem, Brookings, SD 57007 USA.
   [Vollmer, Mykayla] Univ South Dakota, Res Program, Vermillion, SD 57069 USA.
   [Callahan, Dakota L.] Univ Sioux Falls, Sanford Program Undergrad Res, Sioux Falls, SD 57104 USA.
   [Smithback, Austyn] Harrisburg High Sch, Sanford PROMISE Scholar Program, Sioux Falls, SD 57104 USA.
   [Conn, Josephine M.] Carleton Coll, Sanford Program Undergrad Res, Northfield, MN 55057 USA.
   [Gao, Zili] Flow Cytometry Core Sanford Res, Sioux Falls, SD 57104 USA.
   [Afeworki, Yohannes] Sanford Res, Funct Genom & Bioinformat Core Facil, Sioux Falls, SD 57104 USA.
   [Tao, Jianning] Univ South Dakota, Sanford Sch Med, Dept Pediat, Vermillion, SD 57069 USA.
C3 Sanford Health; South Dakota State University; University of South
   Dakota; Carleton College; Sanford Health; University of South Dakota
RP Tao, JN (通讯作者)，Sanford Res, Canc Biol & Immunotherapies Grp, Sioux Falls, SD 57104 USA.; Tao, JN (通讯作者)，South Dakota State Univ, Dept Chem & Biochem, Brookings, SD 57007 USA.; Tao, JN (通讯作者)，Univ South Dakota, Sanford Sch Med, Dept Pediat, Vermillion, SD 57069 USA.
EM Haydee.Torres@SanfordHealth.org; amv5802@psu.edu;
   Mykayla.L.Vollmer@coyotes.usd.edu; Dakota.Callahan2@SanfordHealth.org;
   aesmithback@gmail.com; josiemausconn@gmail.com; rodeznoa@ualberta.ca;
   gaozili1989@hotmail.com; Yuxia.Cao@SanfordHealth.org;
   Yohannes.Tecleab@SanfordHealth.org; jianning.tao@sanfordhealth.org
RI Li, Yuanzheng/AAH 5306 2020; Tao, Jianning/U 5213 2017
OI VanCleave, Ashley/0000 0002 2033 1822; Torres,
   Haydee/0000 0002 9912 6230; Afeworki, Yohannes/0000 0002 1126 1527; Tao,
   Jianning/0000 0001 5678 9272
FU National Institutes of Health [P20 GM103620, P20 GM103548, R25
   HD097633]; National Cancer Institute of the National Institutes of
   Health [P30CA042014 31S2]; GMaP6 Research Stimulus Award; Sanford
   Research Fund
FX This research was supported by the National Institutes of Health under
   award numbers P20 GM103620 (D.A. Pearce), P20 GM103548 (K. W.
   Miskimins), and R25 HD097633 (L. Lee/J. M. Weimer). This research was in
   part supported by the National Cancer Institute of the National
   Institutes of Health under award number P30CA042014 31S2 (C.M. Ulrich)
   and the GMaP6 Research Stimulus Award (H.M. Torres). This research was
   in part supported the Sanford Research Fund (J. Tao).
CR Allis CD, 2016, NAT REV GENET, V17, P487, DOI 10.1038/nrg.2016.59
   Bai YJ, 2019, ARCH MED SCI, V15, P204, DOI 10.5114/aoms.2018.73860
   BENJAMINI Y, 1995, J ROY STAT SOC B, V57, P289, DOI 10.1111/j.2517 6161.1995.tb02031.x
   Blattmann C, 2012, STRAHLENTHER ONKOL, V188, P168, DOI 10.1007/s00066 011 0028 5
   Blattmann C, 2010, INT J RADIAT ONCOL, V78, P237, DOI 10.1016/j.ijrobp.2010.03.010
   Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133
   Bradley EW, 2011, CRIT REV EUKAR GENE, V21, P101, DOI 10.1615/CritRevEukarGeneExpr.v21.i2.10
   Cain Jason E., 2013, Sarcoma, V2013, P608964, DOI 10.1155/2013/608964
   Capobianco E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095596
   Carol H, 2014, PEDIATR BLOOD CANCER, V61, P245, DOI 10.1002/pbc.24724
   Castillo Juárez P, 2021, ANTI CANCER AGENT ME, V21, P1451, DOI 10.2174/1871520620666200728125356
   Castillo Tandazo W, 2019, CURR OSTEOPOROS REP, V17, P343, DOI 10.1007/s11914 019 00534 w
   Chaiyawat P, 2018, MODERN PATHOL, V31, P264, DOI 10.1038/modpathol.2017.125
   Cheng DD, 2012, ASIAN PAC J CANCER P, V13, P1395, DOI 10.7314/APJCP.2012.13.4.1395
   Chiappetta C, 2017, ONCOTARGET, V8, P80416, DOI 10.18632/oncotarget.19010
   Collier CD, 2020, ADV EXP MED BIOL, V1258, P55, DOI 10.1007/978 3 030 43085 6_4
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   Deng ZT, 2016, INT J BIOL SCI, V12, P1298, DOI 10.7150/ijbs.16569
   Di Pompo G, 2015, J MED CHEM, V58, P4073, DOI 10.1021/acs.jmedchem.5b00126
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   El Naggar AM, 2019, EMBO REP, V20, DOI 10.15252/embr.201948375
   Engin F, 2009, HUM MOL GENET, V18, P1464, DOI 10.1093/hmg/ddp057
   Enomoto M, 2009, ONCOGENE, V28, P3197, DOI 10.1038/onc.2009.175
   Falkenberg KJ, 2014, NAT REV DRUG DISCOV, V13, P673, DOI 10.1038/nrd4360
   Fang Fang, 2018, Oncotarget, V9, P36780, DOI 10.18632/oncotarget.26377
   Flavahan WA, 2017, SCIENCE, V357, DOI 10.1126/science.aal2380
   Foley JM, 2015, J TRANSL MED, V13, DOI 10.1186/s12967 015 0466 4
   Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339
   Fu ML, 2016, BIOCHEM BIOPH RES CO, V471, P267, DOI 10.1016/j.bbrc.2016.01.030
   Gardner HL, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003 019 0487 2
   Graham C, 2006, CLIN CANCER RES, V12, P223, DOI 10.1158/1078 0432.CCR 05 1225
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Gruber W, 2018, INT J CANCER, V142, P968, DOI 10.1002/ijc.31117
   Han R, 2020, MOL THER ONCOLYTICS, V19, P8, DOI 10.1016/j.omto.2020.08.017
   HARRIS SA, 1995, J BONE MINER RES, V10, P178
   He Y, 2019, CANCER MED US, V8, P3479, DOI 10.1002/cam4.2206
   Hirose T, 2003, ONCOGENE, V22, P7762, DOI 10.1038/sj.onc.1207091
   Hoang BH, 2004, INT J CANCER, V109, P106, DOI 10.1002/ijc.11677
   Hoffman MM, 2020, CANCERS, V12, DOI 10.3390/cancers12030756
   Hou MY, 2018, ONCOL LETT, V16, P4663, DOI 10.3892/ol.2018.9224
   Huang ZJ, 2016, TUMOR BIOL, V37, P10257, DOI 10.1007/s13277 016 4868 6
   Hughes DPM, 2009, CANCER TREAT RES, V152, P479, DOI 10.1007/978 1 4419 0284 9_28
   Inoue K, 2019, J CLIN INVEST, V129, P1295, DOI 10.1172/JCI124030
   Ito T, 2005, CANCER LETT, V224, P311, DOI 10.1016/j.canlet.2004.10.030
   Jaboin J, 2002, CANCER RES, V62, P6108
   Kalin JH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02242 4
   Kansara M, 2009, J CLIN INVEST, V119, P837, DOI 10.1172/JCI37175
   Kelly RDW, 2013, BIOCHEM SOC T, V41, P741, DOI 10.1042/BST20130010
   Keshelava N, 2009, PEDIATR BLOOD CANCER, V53, P505, DOI 10.1002/pbc.21988
   Khalid U., 2021, SYNERGISTIC INTERACT, DOI [10.1101/2021.04.22.440879, DOI 10.1101/2021.04.22.440879]
   Khalil MA, 2012, NEOPLASMA, V59, P737, DOI 10.4149/neo_2012_093
   Khanna C, 2014, CLIN CANCER RES, V20, P4200, DOI 10.1158/1078 0432.CCR 13 2574
   Kiany S, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1333214
   Kolde Raivo, 2019, CRAN
   Kopljar I, 2016, STEM CELL TRANSL MED, V5, P602, DOI 10.5966/sctm.2015 0279
   Koshkina NV, 2011, CANCER AM CANCER SOC, V117, P3457, DOI 10.1002/cncr.25884
   La Noce M, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046 018 0978 x
   Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037
   Lee HW, 2006, MOL ENDOCRINOL, V20, P2432, DOI 10.1210/me.2006 0061
   Li J, 2019, CELL BIOL TOXICOL, V35, P423, DOI 10.1007/s10565 019 09459 7
   Liao D, 2020, NAT CELL BIOL, V22, P868, DOI 10.1038/s41556 020 0522 z
   Liu GC, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18051027
   Loh AHP, 2019, CANCER LETT, V442, P262, DOI 10.1016/j.canlet.2018.10.033
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0550 8
   Ma XT, 2018, NATURE, V555, P371, DOI 10.1038/nature25795
   Matsubara H, 2009, J PHARMACOL EXP THER, V328, P839, DOI 10.1124/jpet.108.147462
   McGee Lawrence ME, 2016, J BONE MINER RES, V31, P116, DOI 10.1002/jbmr.2602
   McGee Lawrence ME, 2013, BONE, V52, P296, DOI 10.1016/j.bone.2012.10.015
   McGee Lawrence ME, 2011, GENE, V474, P1, DOI 10.1016/j.gene.2010.12.003
   McGuire JJ, 2020, INT J CANCER, V147, P2811, DOI 10.1002/ijc.33046
   Messerli SM, 2017, BRAIN SCI, V7, DOI 10.3390/brainsci7110147
   Mishra VK, 2017, NUCLEIC ACIDS RES, V45, P6334, DOI 10.1093/nar/gkx212
   Molyneux SD, 2010, J CLIN INVEST, V120, P3310, DOI 10.1172/JCI42391
   Morrow JJ, 2018, NAT MED, V24, P176, DOI 10.1038/nm.4475
   Mu XD, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/290368
   Murahari S, 2017, BMC CANCER, V17, DOI 10.1186/s12885 017 3046 6
   Muscal JA, 2013, PEDIATR BLOOD CANCER, V60, P390, DOI 10.1002/pbc.24271
   Nomura M, 2019, JNCI J NATL CANCER I, V111, P1216, DOI 10.1093/jnci/djz026
   Okada T, 2006, INT J CANCER, V118, P90, DOI 10.1002/ijc.21297
   Ozaki T, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.127
   Palermo R, 2012, ONCOGENE, V31, P3807, DOI 10.1038/onc.2011.533
   Park KK, 2003, BIOCHEM BIOPH RES CO, V306, P239, DOI 10.1016/S0006 291X(03)00941 0
   Patatsos K, 2018, VET COMP ONCOL, V16, P544, DOI 10.1111/vco.12413
   Perego S, 2018, INT J IMMUNOPATH PH, V31, DOI 10.1177/0394632017752240
   Pinkerneil M, 2016, TARGET ONCOL, V11, P783, DOI 10.1007/s11523 016 0444 7
   R Core Team, 2020, R: A language and environment for statistical computing
   Rickel K, 2017, BONE, V102, P69, DOI 10.1016/j.bone.2016.10.017
   Roberts RD, 2019, CANCER AM CANCER SOC, V125, P3514, DOI 10.1002/cncr.32351
   ROBERTS WM, 1989, CANCER RES, V49, P5407
   Roh MS, 2004, APOPTOSIS, V9, P583, DOI 10.1023/B:APPT.0000038037.68908.6e
   Rokita JL, 2019, CELL REP, V29, P1675, DOI 10.1016/j.celrep.2019.09.071
   Sayles LC, 2019, CANCER DISCOV, V9, P46, DOI 10.1158/2159 8290.CD 17 1152
   Schofield AV, 2013, BIOCHEM BIOPH RES CO, V436, P571, DOI 10.1016/j.bbrc.2013.05.076
   Schott C, 2020, ADV EXP MED BIOL, V1258, P1, DOI 10.1007/978 3 030 43085 6_1
   Scott MC, 2015, J BIOL CHEM, V290, P28070, DOI 10.1074/jbc.M115.679696
   Seto E, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a018713
   Shats I, 2013, CANCER RES, V73, P6056, DOI 10.1158/0008 5472.CAN 13 0453
   Shen T, 2012, INT J BIOCHEM CELL B, V44, P423, DOI 10.1016/j.biocel.2011.11.018
   Shi Y, 2017, ONCOL RES, V25, P1421, DOI 10.3727/096504016X14826089198805
   Singla A, 2020, ADV EXP MED BIOL, V1258, P125, DOI 10.1007/978 3 030 43085 6_8
   Smeester BA, 2020, BONE, V136, DOI 10.1016/j.bone.2020.115353
   Song LN, 2021, J INVEST DERMATOL, V141, P903, DOI 10.1016/j.jid.2020.08.023
   Tanaka M, 2009, BRIT J CANCER, V100, P1957, DOI 10.1038/sj.bjc.6605060
   Tao J., 2013, Primer on the Metabolic Bone Diseases and Disorders ofMineral Metabolism, V8th, P702, DOI 10.1002/9781118453926.ch9781118453985
   Tao JN, 2014, CANCER CELL, V26, P390, DOI 10.1016/j.ccr.2014.07.023
   Tao JN, 2011, CANCER CELL, V19, P159, DOI 10.1016/j.ccr.2011.01.043
   Taylor EL, 2021, ADV EXP MED BIOL, V1283, P53, DOI 10.1007/978 981 15 8104 5_4
   Torres HM, 2020, CANCER RES, V80, DOI 10.1158/1538 7445.AM2020 2917
   VanCleave Ashley, 2020, Oncotarget, V11, P2597, DOI 10.18632/oncotarget.27611
   von Tresckow B, 2019, EUR J HAEMATOL, V102, P163, DOI 10.1111/ejh.13188
   Wang SD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00377
   Wang WL, 2020, AM J TRANSL RES, V12, P2968
   Watanabe K, 2005, CELL DEATH DIFFER, V12, P10, DOI 10.1038/sj.cdd.4401507
   West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738
   Westendorf JJ, 2007, J CELL BIOCHEM, V102, P332, DOI 10.1002/jcb.21486
   WINKLER K, 1988, J CLIN ONCOL, V6, P329, DOI 10.1200/JCO.1988.6.2.329
   Wirries Andre, 2018, Oncotarget, V9, P32997, DOI 10.18632/oncotarget.26038
   Wittenburg LA, 2012, J CELL BIOCHEM, V113, P773, DOI 10.1002/jcb.23403
   Wobser M, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045 019 0719 4
   Wu ZK, 2013, J BUON, V18, P1032
   Xie CH, 2016, ONCOTARGETS THER, V9, P4005, DOI 10.2147/OTT.S105418
   Yamagata K, 2012, J BIOL CHEM, V287, P1588, DOI 10.1074/jbc.M111.315127
   Yamanegi K, 2015, INT J ONCOL, V46, P1994, DOI 10.3892/ijo.2015.2924
   Yamanegi K, 2010, ONCOL REP, V24, P1621, DOI 10.3892/or_00001026
   Yamanegi K, 2009, J CANCER RES CLIN, V135, P879, DOI 10.1007/s00432 008 0522 z
   Yang C, 2011, CANCER CHEMOTH PHARM, V67, P439, DOI 10.1007/s00280 010 1344 7
   Yang XJ, 2008, NAT REV MOL CELL BIO, V9, P206, DOI 10.1038/nrm2346
   Yelin E, 2016, SEMIN ARTHRITIS RHEU, V46, P259, DOI 10.1016/j.semarthrit.2016.07.013
   Yen ML, 2007, STEM CELLS, V25, P125, DOI 10.1634/stemcells.2006 0295
   Young MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb 2010 11 2 r14
   Yu D, 2015, SCI REP UK, V5, DOI 10.1038/srep16991
   Yustein JT, 2010, P NATL ACAD SCI USA, V107, P3534, DOI 10.1073/pnas.0901230107
   Zeng H, 2016, ONCOTARGET, V7, P7329, DOI 10.18632/oncotarget.6940
   Zhang AL, 2014, CANCER CELL INT, V14, DOI 10.1186/1475 2867 14 15
   Zhang C, 2017, ONCOTARGET, V8, P56110, DOI 10.18632/oncotarget.18125
   Zhang MM, 2017, ONCOTARGET, V8, P99402, DOI 10.18632/oncotarget.19660
NR 136
TC 9
Z9 9
U1 2
U2 6
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6694
J9 CANCERS
JI Cancers
PD AUG
PY 2021
VL 13
IS 16
AR 4199
DI 10.3390/cancers13164199
PG 24
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA UF9LN
UT WOS:000688887700001
PM 34439353
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Nakamura, M
   Han, B
   Nishishita, T
   Bai, Y
   Kakudo, K
AF Nakamura, Misa
   Han, Bo
   Nishishita, Toshihide
   Bai, Yanhua
   Kakudo, Kennichi
TI Calcitonin targets extracellular signal regulated kinase signaling
   pathway in human cancers
SO JOURNAL OF MOLECULAR ENDOCRINOLOGY
LA English
DT Article
ID ACTIVATED PROTEIN KINASE; RENAL CELL CARCINOMA; HUMAN BREAST CANCER; MAP
   KINASE; CONSTITUTIVE ACTIVATION; PLASMINOGEN ACTIVATOR; IN VIVO;
   PARATHYROID HORMONE; UROKINASE RECEPTOR; ADENYLYL CYCLASE
AB The mitogen activated protein kinases (MAPKs) signaling pathway is a potential target in cancer therapy. Constitutive phosphorylated extracellular signal regulated kinase (ERK1/2), which is one of the MAPKs has been detected in a variety of tumors. Calcitonin (CT) is a polypepticle hormone secreted by the thyroid gland and has been used to treat the osteoporosis and humoral hypercalcemia of malignancy. We report that CT decreases ERK1/2 phosphorylation in cancer cells showing constitutive phosphorylated ERK1/2. In MDA MB 231 cells, a breast cancer cell line showing constitutive phosphorylated ERK1/2, CT phosphorylated c Raf at Ser(259) via the protein kinase A pathway, resulting in suppression of ERK1/2 phosphorylation. CT significantly reduced the tumor volume of MDA MB 231 cells showing constitutive phosphorylated ERK1/2 compared with saline buffer. However, CT did not exert any significant effects on the proliferation of MCF 7 cells, a breast cancercell line, showing non constitutive phosphorylated EIRK 1/2. These novel findings indicate that CT may be used to target ERK in the treatment of cancer.
C1 [Nakamura, Misa; Han, Bo; Bai, Yanhua; Kakudo, Kennichi] Wakayama Med Univ, Dept Pathol, Wakayama 6410012, Japan.
   [Nakamura, Misa] Osaka Kawasaki Rehabil Univ, Dept Rehabil, Kaizuka City, Osaka 5970104, Japan.
   [Nishishita, Toshihide] Univ Tokyo, Inst Med Sci, Dept Adv Med Sci, Minato Ku, Tokyo 1088639, Japan.
C3 Wakayama Medical University; University of Tokyo
RP Nakamura, M (通讯作者)，Wakayama Med Univ, Dept Pathol, Kimiidera 811 1, Wakayama 6410012, Japan.
EM nakamuram@kawasakigakuen.ac.jp
CR Ahmed N, 2002, J CELL BIOCHEM, V84, P675, DOI 10.1002/jcb.10080
   Avruch J, 2001, RECENT PROG HORM RES, V56, P127, DOI 10.1210/rp.56.1.127
   Berlot CH, 2002, J BIOL CHEM, V277, P21080, DOI 10.1074/jbc.M201330200
   CHABRE O, 1992, MOL ENDOCRINOL, V6, P551, DOI 10.1210/me.6.4.551
   CHAMBERS TJ, 1982, J PATHOL, V136, P27, DOI 10.1002/path.1711360104
   Chaudhary LR, 1998, MOL CELL BIOCHEM, V178, P59, DOI 10.1023/A:1006807221545
   Chen TS, 1999, CANCER RES, V59, P213
   Chen Y, 1998, J BIOL CHEM, V273, P19809, DOI 10.1074/jbc.273.31.19809
   Chigurupati S, 2005, CANCER RES, V65, P8519, DOI 10.1158/0008 5472.CAN 05 0848
   Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716
   COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092 8674(94)90133 3
   Culig Z, 2005, ENDOCR RELAT CANCER, V12, P229, DOI 10.1677/erc.1.00775a
   DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065 230X(08)60028 7
   Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237 3246.2002
   DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686
   Duesbery NS, 1999, NAT MED, V5, P736, DOI 10.1038/10457
   Dumaz N, 2003, J BIOL CHEM, V278, P29819, DOI 10.1074/jbc.C300182200
   FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170
   Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470 2045(05)70168 6
   FORCE T, 1992, AM J PHYSIOL, V262, pF1110, DOI 10.1152/ajprenal.1992.262.6.F1110
   Ghiso JAA, 1999, EUR J BIOCHEM, V263, P295, DOI 10.1046/j.1432 1327.1999.00507.x
   Guo YJ, 2000, FASEB J, V14, P1400, DOI 10.1096/fj.14.10.1400
   Han B, 2006, INT J ONCOL, V28, P807
   Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367
   Jagger C, 1999, ENDOCRINOLOGY, V140, P492, DOI 10.1210/en.140.1.492
   Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682
   Kaiser E, 2003, BIOCHEM BIOPH RES CO, V305, P573, DOI 10.1016/S0006 291X(03)00820 9
   Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955 0674(99)00075 7
   Kim SC, 1999, BLOOD, V93, P3893, DOI 10.1182/blood.V93.11.3893.407k14_3893_3899
   King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184
   Lacroix M, 1998, EUR J PHARMACOL, V344, P279, DOI 10.1016/S0014 2999(97)01578 1
   Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065 230X(08)60765 4
   LIANG B, 2005, GASTROENTEROLOGY, V7, P623
   Light Y, 2002, MOL CELL BIOL, V22, P4984, DOI 10.1128/MCB.22.14.4984 4996.2002
   Ma Z, 2001, J CELL SCI, V114, P3387
   MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857
   Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137
   MCDERMOTT MT, 1987, ENDOCR REV, V8, P377, DOI 10.1210/edrv 8 4 377
   Nakamura M, 2002, BIOCHEM BIOPH RES CO, V290, P1483, DOI 10.1006/bbrc.2001.6260
   NG KW, 1983, CANCER RES, V43, P794
   OFFERMANNS S, 1996, MOL ENDOCRINOL, V10, P5665
   OKA H, 1995, CANCER RES, V55, P4182
   OSSOWSKI L, 1991, CANCER RES, V51, P274
   Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Putz T, 1999, CANCER RES, V59, P227
   Rabbani SA, 2002, CANCER RES, V62, P2390
   Rae JM, 2007, BREAST CANCER RES TR, V104, P13, DOI 10.1007/s10549 006 9392 8
   Sabbisetti V, 2006, INT J CANCER, V118, P2694, DOI 10.1002/ijc.21625
   Sabbisetti VS, 2005, INT J CANCER, V117, P551, DOI 10.1002/ijc.21158
   Satyamoorthy K, 2003, CANCER RES, V63, P756
   Sebolt Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533
   Segawa N, 2001, CANCER RES, V61, P6060
   SHAH GV, 1994, ENDOCRINOLOGY, V134, P596, DOI 10.1210/en.134.2.596
   Shyu JF, 1996, J BIOL CHEM, V271, P31127, DOI 10.1074/jbc.271.49.31127
   Shyu JF, 1999, EUR J BIOCHEM, V262, P95, DOI 10.1046/j.1432 1327.1999.00346.x
   Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309
   Staehler M, 2005, CURR DRUG TARGETS, V6, P835, DOI 10.2174/138945005774574498
   Swarthout JT, 2001, J BIOL CHEM, V276, P7586, DOI 10.1074/jbc.M007400200
   Takata M, 2005, J INVEST DERMATOL, V125, P318, DOI 10.1111/j.0022 202X.2005.23812.x
   Thomas S, 2005, CANCER BIOL THER, V4, P1226, DOI 10.4161/cbt.4.11.2093
   Thomas S, 2006, MOL ENDOCRINOL, V20, P1894, DOI 10.1210/me.2005 0284
   Wang J, 1998, DEVELOPMENT, V125, P4293
   Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773
   Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551
   Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014 5793(01)03288 4
   ZAIDI M, 1990, CRIT REV CL LAB SCI, V28, P109, DOI 10.3109/10408369009105900
   Zhu LJ, 1998, ENDOCRINOLOGY, V139, P330, DOI 10.1210/en.139.1.330
NR 68
TC 18
Z9 21
U1 0
U2 1
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
   ENGLAND
SN 0952 5041
J9 J MOL ENDOCRINOL
JI J. Mol. Endocrinol.
PD NOV DEC
PY 2007
VL 39
IS 5 6
BP 375
EP 384
DI 10.1677/JME 07 0036
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 247QE
UT WOS:000252093600006
PM 18055485
OA Bronze
DA 2025 08 17
ER

PT J
AU Liò, P
   Paoletti, N
   Moni, MA
   Atwell, K
   Merelli, E
   Viceconti, M
AF Lio, Pietro
   Paoletti, Nicola
   Moni, Mohammad Ali
   Atwell, Kathryn
   Merelli, Emanuela
   Viceconti, Marco
TI Modelling osteomyelitis
SO BMC BIOINFORMATICS
LA English
DT Article
ID IN SILICO BIOLOGY; MATHEMATICAL MODEL; BONE; EXPRESSION;
   OSTEOPROTEGERIN; OSTEOPOROSIS; INFECTIONS; FRAMEWORK; CELLS; GENE
AB Background: This work focuses on the computational modelling of osteomyelitis, a bone pathology caused by bacteria infection (mostly Staphylococcus aureus). The infection alters the RANK/RANKL/OPG signalling dynamics that regulates osteoblasts and osteoclasts behaviour in bone remodelling, i.e. the resorption and mineralization activity. The infection rapidly leads to severe bone loss, necrosis of the affected portion, and it may even spread to other parts of the body. On the other hand, osteoporosis is not a bacterial infection but similarly is a defective bone pathology arising due to imbalances in the RANK/RANKL/OPG molecular pathway, and due to the progressive weakening of bone structure.
   Results: Since both osteoporosis and osteomyelitis cause loss of bone mass, we focused on comparing the dynamics of these diseases by means of computational models. Firstly, we performed meta analysis on a gene expression data of normal, osteoporotic and osteomyelitis bone conditions. We mainly focused on RANKL/OPG signalling, the TNF and TNF receptor superfamilies and the NF kB pathway. Using information from the gene expression data we estimated parameters for a novel model of osteoporosis and of osteomyelitis. Our models could be seen as a hybrid ODE and probabilistic verification modelling framework which aims at investigating the dynamics of the effects of the infection in bone remodelling. Finally we discuss different diagnostic estimators defined by formal verification techniques, in order to assess different bone pathologies (osteopenia, osteoporosis and osteomyelitis) in an effective way.
   Conclusions: We present a modeling framework able to reproduce aspects of the different bone remodeling defective dynamics of osteomyelitis and osteoporosis. We report that the verification based estimators are meaningful in the light of a feed forward between computational medicine and clinical bioinformatics.
C1 [Paoletti, Nicola; Merelli, Emanuela] Univ Camerino, Div Comp Sci, Sch Sci & Technol, I 62019 Camerino, MC, Italy.
   [Lio, Pietro; Moni, Mohammad Ali; Atwell, Kathryn] Univ Cambridge, Comp Lab, Cambridge CB3 0FD, England.
   [Viceconti, Marco] Univ Sheffield, Dept Mech Engn, Sheffield S1 3JD, S Yorkshire, England.
C3 University of Camerino; University of Cambridge; University of Sheffield
RP Paoletti, N (通讯作者)，Univ Camerino, Div Comp Sci, Sch Sci & Technol, Via Madonna Carceri 9, I 62019 Camerino, MC, Italy.
EM nicola.paoletti@unicam.it
RI ; Merelli, Emanuela/H 6375 2016; Paoletti, Nicola/AAM 2322 2020;
   Viceconti, Marco/N 9164 2013; Moni, Mohammad/ABG 3606 2020; P. Lió,
   Pietro/AAV 3358 2021; Viceconti, Marco/HOF 5985 2023
OI Moni, Mohammad Ali/0000 0003 0756 1006; Merelli,
   Emanuela/0000 0002 1321 4134; Paoletti, Nicola/0000 0002 4723 5363; Lio,
   Pietro/0000 0002 0540 5053; Viceconti, Marco/0000 0002 2293 1530; 
CR [Anonymous], 2000, ACM Trans. Comput. Logic, DOI DOI 10.1145/343369.343402
   Ardura MI, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005446
   Ayati BP, 2010, BIOL DIRECT, V5, DOI 10.1186/1745 6150 5 28
   Chaussabel D, 2008, IMMUNITY, V29, P150, DOI 10.1016/j.immuni.2008.05.012
   Claro T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018748
   Dayar Tugrul, 2010, Proceedings 2010 International Multiconference on Computer Science and Information Technology (IMCSIT 2010), P289
   Gerhard FA, 2009, PHILOS T R SOC A, V367, P2011, DOI 10.1098/rsta.2008.0297
   Geris L, 2009, PHILOS T R SOC A, V367, P2031, DOI 10.1098/rsta.2008.0293
   He ZY, 2000, PROTEIN PEPTIDE LETT, V7, P233
   Jabbar S, 2011, J CLIN PATHOL, V64, P354, DOI 10.1136/jcp.2010.086595
   Karsenty G, 2010, J CLIN ENDOCR METAB, V95, P4795, DOI 10.1210/jc.2010 1030
   Komarova SV, 2003, BONE, V33, P206, DOI 10.1016/S8756 3282(03)00157 1
   Kwiatkowska Marta, 2011, Computer Aided Verification. Proceedings 23rd International Conference, CAV 2011, P585, DOI 10.1007/978 3 642 22110 1_47
   Liò P, 2011, ELECTRON PROC THEOR, P82, DOI 10.4204/EPTCS.67.8
   Manolagas SC, 2010, TRENDS ENDOCRIN MET, V21, P369, DOI 10.1016/j.tem.2010.01.010
   Morabito N, 2004, J BONE MINER RES, V19, P722, DOI 10.1359/JBMR.040113
   Paoletti N, 2012, IEEE ACM T COMPUTATI, P99
   PARFITT AM, 1994, J CELL BIOCHEM, V55, P273, DOI 10.1002/jcb.240550303
   Pivonka P, 2010, BONE, V47, P181, DOI 10.1016/j.bone.2010.04.601
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Ramilo O, 2007, BLOOD, V109, P2066, DOI 10.1182/blood 2006 02 002477
   Soetaert K, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i09
   Whitfield JF., 2007, Growing Bone, VSecond
   Xiao P, 2008, J BONE MINER RES, V23, P644, DOI 10.1359/JBMR.080105
NR 24
TC 27
Z9 30
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471 2105
J9 BMC BIOINFORMATICS
JI BMC Bioinformatics
PD SEP 7
PY 2012
VL 13
SU 14
AR S12
DI 10.1186/1471 2105 13 S14 S12
PG 14
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
GA 014ES
UT WOS:000309358500012
PM 23095605
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zhao, W
   Zhang, WL
   Ma, HD
   Yang, MW
AF Zhao, Wei
   Zhang, Weilin
   Ma, Hongdong
   Yang, Maowei
TI NIPA2 regulates osteoblast function by modulating mitophagy in type 2
   diabetes osteoporosis
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PINK1/PARKIN MEDIATED MITOPHAGY; BONE FORMATION; MAGNESIUM; AUTOPHAGY;
   PATHWAY; DIFFERENTIATION; APOPTOSIS; RECEPTOR; CELLS; RISK
AB The highly selective magnesium transporter non imprinted in Prader Willi/Angelman syndrome region protein 2 (NIPA2) has recently been associated with the development and progression of type 2 diabetes osteoporosis, but the mechanisms involved are still poorly understood. Because mitophagy is involved in the pathology of type 2 diabetes osteoporosis, the present study aimed to explore the relationship among NIPA2, mitophagy and osteoblast osteogenic capacity. NIPA2 expression was reduced in C57BKS background db/db mice and in vitro models of type 2 diabetes osteoporosis, and the activation of mitophagy in primary culture osteoblast derived from db/db mice and in high glucose treated human fetal osteoblastic cells (hFOB1.19) was observed. Knockdown, overexpression of NIPA2 and pharmacological inhibition of peroxisome proliferator activated receptor gamma coactivator 1 alpha (PGC 1 alpha) showed that NIPA2 increased osteoblast function, which was likely regulated by PTEN induced kinase 1 (PINK1)/E3 ubiquitin ligase PARK2 (Parkin) mediated mitophagy via the PGC 1 alpha forkhead box O3a(FoxO3a)/mitochondrial membrane potential (MMP) pathway. Furthermore, the negative effect of mitophagy on osteoblast function was confirmed by pharmacological regulation of mitophagy and knockdown of Parkin. Taken together, these results suggest that NIPA2 positively regulates the osteogenic capacity of osteoblasts via the mitophagy pathway in type 2 diabetes.
C1 [Zhao, Wei; Zhang, Weilin] China Med Univ, Hosp 4, Dept Orthoped, Shenyang, Liaoning, Peoples R China.
   [Ma, Hongdong; Yang, Maowei] China Med Univ, Hosp 1, Dept Orthoped, Shenyang, Liaoning, Peoples R China.
C3 China Medical University; China Medical University
RP Yang, MW (通讯作者)，China Med Univ, Hosp 1, Dept Orthoped, Shenyang, Liaoning, Peoples R China.
EM mwyang@cmu.edu.cn
OI Zhao, Wei/0000 0002 7196 1357
FU National Natural Science Foundation of China; Shenyang Municipal Science
   and Technology Fund [81471094, 20180551005, F16 205 1 30]; Natural
   Science Foundation of Liaoning Province
FX This study was supported by the National Natural Science Foundation of
   China, Natural Science Foundation of Liaoning Province, Shenyang
   Municipal Science and Technology Fund (81471094, 20180551005,
   F16 205 1 30).
CR Abdulameer SA, 2012, PATIENT PREFER ADHER, V6, P435, DOI 10.2147/PPA.S32745
   Al Alawi AM, 2018, INT J ENDOCRINOL, V2018, DOI 10.1155/2018/9041694
   Barbagallo Mario, 2003, Molecular Aspects of Medicine, V24, P39, DOI 10.1016/S0098 2997(02)00090 0
   Cai ZY, 2018, BIOCHEM BIOPH RES CO, V503, P428, DOI 10.1016/j.bbrc.2018.04.052
   Chan KHK, 2015, J NUTR, V145, P418, DOI 10.3945/jn.114.203489
   Charoenphandhu N, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 50414 7
   Chen YM, 2019, J BIOMED MATER RES A, V107, P1253, DOI 10.1002/jbm.a.36634
   Cheng YZ, 2018, LIFE SCI, V205, P184, DOI 10.1016/j.lfs.2018.04.042
   Deng XQ, 2018, J DIABETES RES, V2018, DOI 10.1155/2018/5765478
   Gladkova C, 2018, NATURE, V559, P411, DOI 10.1038/s41586 018 0224 x
   Gomes PS, 2016, BIOMED MATER, V11, DOI 10.1088/1748 6041/11/4/045007
   Goytain A, 2008, AM J PHYSIOL CELL PH, V295, pC944, DOI 10.1152/ajpcell.00091.2008
   Ha BG, 2016, BIOMED PHARMACOTHER, V83, P477, DOI 10.1016/j.biopha.2016.07.009
   He YF, 2013, BIOL TRACE ELEM RES, V152, P292, DOI 10.1007/s12011 013 9605 z
   Jia P, 2012, J ORTHOP RES, V30, P1843, DOI 10.1002/jor.22133
   Jing D, 2016, J BONE MINER RES, V31, P1713, DOI 10.1002/jbmr.2837
   Kang CH, 2016, FREE RADICAL BIO MED, V93, P32, DOI 10.1016/j.freeradbiomed.2015.12.032
   Karsenty G, 2001, RECENT PROG HORM RES, V56, P401, DOI 10.1210/rp.56.1.401
   Khan ZA, 2005, FREE RADICAL RES, V39, P1203, DOI 10.1080/10715760500143254
   Li HX, 2018, AUTOPHAGY, V14, P1726, DOI 10.1080/15548627.2018.1483807
   Li YQ, 2018, CELL BIOL INT, V42, P205, DOI 10.1002/cbin.10888
   Liang D, 2012, BIOL TRACE ELEM RES, V148, P420, DOI 10.1007/s12011 012 9387 8
   Lin NY, 2016, ANN RHEUM DIS, V75, P1203, DOI 10.1136/annrheumdis 2015 207240
   Liu F, 2017, INT J MED SCI, V14, P275, DOI 10.7150/ijms.17860
   Liu M, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123182
   Meng HZ, 2015, J BIOL CHEM, V290, P28189, DOI 10.1074/jbc.M115.669499
   Narendra DP, 2011, ANTIOXID REDOX SIGN, V14, P1929, DOI 10.1089/ars.2010.3799
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Park YS, 2018, TOXICOL LETT, V284, P120, DOI 10.1016/j.toxlet.2017.12.004
   RESNICK LM, 1993, DIABETOLOGIA, V36, P767, DOI 10.1007/BF00401149
   Sheng JQ, 2018, CELL PHYSIOL BIOCHEM, V48, P1675, DOI 10.1159/000492292
   Shiraki M, 2019, FASEB J, V33, P8836, DOI 10.1096/fj.201802322RR
   Shukla S, 2014, FREE RADICAL BIO MED, V76, P185, DOI 10.1016/j.freeradbiomed.2014.07.039
   Sinha KM, 2010, EMBO J, V29, P68, DOI 10.1038/emboj.2009.332
   Vangipurapu J, 2012, J INTERN MED, V272, P402, DOI 10.1111/j.1365 2796.2012.02540.x
   Wang DT, 2018, MOL NUTR FOOD RES, V62, DOI 10.1002/mnfr.201700941
   Xiao ZF, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075 018 1701 1
   Yang YH, 2014, FREE RADICAL BIO MED, V77, P10, DOI 10.1016/j.freeradbiomed.2014.08.028
   Yoshizawa S, 2014, CONNECT TISSUE RES, V55, P155, DOI 10.3109/03008207.2014.923877
   Yoshizawa S, 2014, ACTA BIOMATER, V10, P2834, DOI 10.1016/j.actbio.2014.02.002
   Zha ZM, 2017, INT J CARDIOL, V227, P201, DOI 10.1016/j.ijcard.2016.11.161
   Zhang WL, 2016, ONCOTARGET, V7, P52179, DOI 10.18632/oncotarget.10538
   Zhang WL, 2015, INT J MED SCI, V12, P441, DOI 10.7150/ijms.11986
   Zhang XL, 2013, BIOL TRACE ELEM RES, V151, P138, DOI 10.1007/s12011 012 9533 3
   Zhao W, 2019, BIOCHEM BIOPH RES CO, V513, P883, DOI 10.1016/j.bbrc.2019.04.030
NR 45
TC 41
Z9 46
U1 2
U2 28
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD FEB 20
PY 2020
VL 10
IS 1
AR 3078
DI 10.1038/s41598 020 59743 4
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA NF1RV
UT WOS:000563080400005
PM 32080264
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yang, S
   Hao, L
   McConnell, M
   Zhou, XD
   Wang, M
   Zhang, Y
   Mountz, JD
   Reddy, M
   Eleazer, PD
   Li, YP
   Chen, W
AF Yang, Sen
   Hao, Liang
   McConnell, Matthew
   Zhou, Xuedong
   Wang, Min
   Zhang, Yan
   Mountz, John D.
   Reddy, Michael
   Eleazer, Paul D.
   Li, Yi Ping
   Chen, Wei
TI Inhibition of Rgs10 Expression Prevents Immune Cell Infiltration in
   Bacteria induced Inflammatory Lesions and Osteoclast mediated Bone
   Destruction
SO BONE RESEARCH
LA English
DT Article
DE Rgs10; immune cell; AAV mediated RNAi knockdown; gene therapy;
   periodontal disease; gingival inflammation; bone resorption
ID GINGIVALIS INDUCED PERIODONTITIS; ADENOASSOCIATED VIRUS VECTORS;
   GTPASE ACTIVATING PROTEIN; PORPHYROMONAS GINGIVALIS;
   CARDIOVASCULAR DISEASE; SIGNALING PATHWAYS; RNA INTERFERENCE; LIGAMENT
   CELLS; MOUSE MODEL; GENE
AB Regulator of G protein Signaling 10 (Rgs10) plays an important function in osteoclast differentiation. However, the role of Rgs10 in immune cells and inflammatory responses, which activate osteoclasts in inflammatory lesions, such as bacteria induced periodontal disease lesions, remains largely unknown. In this study, we used an adeno associated virus (AAV ) mediated RNAi (AAV shRNA Rgs10) knockdown approach to study Rgs10's function in immune cells and osteoclasts in bacteria induced inflammatory lesions in a mouse model of periodontal disease. We found that AAV shRNA Rgs10 mediated Rgs10 knockdown impaired osteoclastogenesis and osteoclast mediated bone resorption, in vitro and in vivo. Interestingly, local injection of AAV shRNA Rgs10 into the periodontal tissues in the bacteria induced inflammatory lesion greatly decreased the number of dendritic cells, T cells and osteoclasts, and protected the periodontal tissues from local inflammatory damage and bone destruction. Importantly, AAV mediated Rgs10 knockdown also reduced local expression of osteoclast markers and pro inflammatory cytokines. Our results demonstrate that AAV shRNA Rgs10 knockdown in periodontal disease tissues can prevent bone resorption and inflammation simultaneously. Our data indicate that Rgs10 may regulate dendritic cell proliferation and maturation, as well as the subsequent stimulation of T cell proliferation and maturation, and osteoclast differentiation and activation. Our study suggests that AAV shRNA Rgs10 can be useful as a therapeutic treatment of periodontal disease.
C1 [Yang, Sen; Hao, Liang; McConnell, Matthew; Zhang, Yan; Li, Yi Ping; Chen, Wei] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
   [Zhou, Xuedong; Wang, Min] Sichuan Univ, West China Coll Stomatol, State Key Lab Oral Dis, Chengdu, Sichuan, Peoples R China.
   [Mountz, John D.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
   [Reddy, Michael] Univ Alabama Birmingham, Dept Periodontol, Birmingham, AL 35294 USA.
   [Eleazer, Paul D.] Univ Alabama Birmingham, Dept Endodont, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham; Sichuan
   University; University of Alabama System; University of Alabama
   Birmingham; University of Alabama System; University of Alabama
   Birmingham; University of Alabama System; University of Alabama
   Birmingham
RP Li, YP (通讯作者)，Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
EM ypli@uab.edu; wechen@uab.edu
RI ; Li, Yi Ping/ABF 9245 2020; Zhou, Xuedong/LSL 0410 2024
OI Zhou, Xuedong/0000 0002 9319 7302; McConnell,
   Matthew/0000 0003 0194 5287; 
FU NIH [RC1 DE 020533, AR 055307]; Center for Metabolic Bone Disease at the
   University of Alabama at Birmingham [P30 AR046031]; Neuroscience
   Molecular Detection Core Laboratory at the University of Alabama at
   Birmingham [P30 NS0474666, P30 AR048311]; Small Animal Phenotyping Core,
   Metabolism Core
FX We thank Ms. Christie Paulson for her excellent assistance with this
   manuscript. We appreciate the assistance of the Center for Metabolic
   Bone Disease at the University of Alabama at Birmingham (P30 AR046031).
   We are also grateful for the assistance of the Small Animal Phenotyping
   Core, Metabolism Core, and Neuroscience Molecular Detection Core
   Laboratory at the University of Alabama at Birmingham (P30 NS0474666)
   and (P30 AR048311). This work was supported by NIH grants RC1 DE 020533
   (Y.P.L.) and AR 055307 (Y.P.L.). The authors declare no competing
   financial interests.
CR Alexander B, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001079
   Asagiri M, 2008, SCIENCE, V319, P624, DOI 10.1126/science.1150110
   BAKER PJ, 1994, ARCH ORAL BIOL, V39, P1035, DOI 10.1016/0003 9969(94)90055 8
   Beadling C, 1999, J IMMUNOL, V162, P2677
   Beck J, 1996, J PERIODONTOL, V67, P1123, DOI 10.1902/jop.1996.67.10s.1123
   Blair HC, 2005, BIOCHEM BIOPH RES CO, V328, P728, DOI 10.1016/j.bbrc.2004.11.077
   Carter BJ, 2005, HUM GENE THER, V16, P541, DOI 10.1089/hum.2005.16.541
   Chambrone L, 2011, J CLIN PERIODONTOL, V38, P795, DOI 10.1111/j.1600 051X.2011.01755.x
   Chen W, 2007, HUM MOL GENET, V16, P410, DOI 10.1093/hmg/ddl474
   Cho H, 2000, MOL PHARMACOL, V58, P569, DOI 10.1124/mol.58.3.569
   Cirelli JA, 2009, GENE THER, V16, P426, DOI 10.1038/gt.2008.174
   Conus S, 2010, SWISS MED WKLY, V140, P4, DOI 10.4414/smw.2010.13042
   D'Aiuto F, 2004, J DENT RES, V83, P156, DOI 10.1177/154405910408300214
   de Pablo P, 2009, NAT REV RHEUMATOL, V5, P218, DOI 10.1038/nrrheum.2009.28
   Demmer RT, 2006, J AM DENT ASSOC, V137, p14S, DOI 10.14219/jada.archive.2006.0402
   Evans C, 2010, J RHEUMATOL, V37, P683, DOI 10.3899/jrheum.100055
   Feng SM, 2009, BIOCHEM J, V417, P195, DOI 10.1042/BJ20081073
   García Bernal D, 2011, J IMMUNOL, V187, P1264, DOI 10.4049/jimmunol.1002960
   Heximer SP, 1997, DNA CELL BIOL, V16, P589, DOI 10.1089/dna.1997.16.589
   Hommel JD, 2003, NAT MED, V9, P1539, DOI 10.1038/nm964
   Hurst JH, 2009, BIOCHEM PHARMACOL, V78, P1289, DOI 10.1016/j.bcp.2009.06.028
   Jiang HB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058599
   Kelly KA, 1998, ENDOCRINOLOGY, V139, P2092, DOI 10.1210/en.139.4.2092
   Krajewski AC, 2009, APMIS, V117, P746, DOI 10.1111/j.1600 0463.2009.02532.x
   Kunze M, 2009, J DENT, V37, P502, DOI 10.1016/j.jdent.2009.03.001
   Kuula H, 2009, INFECT IMMUN, V77, P850, DOI 10.1128/IAI.00873 08
   Linden GJ, 2013, J CLIN PERIODONTOL, V40, pS8, DOI [10.1111/jcpe.12064, 10.1902/jop.2013.1340010]
   LOE H, 1993, DIABETES CARE, V16, P329, DOI 10.2337/diacare.16.1.329
   Lundberg K, 2010, NAT REV RHEUMATOL, V6, P727, DOI 10.1038/nrrheum.2010.139
   Ma JQ, 2013, INFECT IMMUN, V81, P1021, DOI 10.1128/IAI.00756 12
   Musatov S, 2006, P NATL ACAD SCI USA, V103, P10456, DOI 10.1073/pnas.0603045103
   Sasaki H, 2004, J PERIODONTAL RES, V39, P432, DOI 10.1111/j.1600 0765.2004.00760.x
   Sasaki H, 2008, J IMMUNOL, V180, P6193, DOI 10.4049/jimmunol.180.9.6193
   Scheschonka A, 2000, MOL PHARMACOL, V58, P719, DOI 10.1124/mol.58.4.719
   Schwäble J, 2005, BLOOD, V105, P2107, DOI 10.1182/blood 2004 03 0940
   Schwartz Z, 1997, PERIODONTOL 2000, V14, P158, DOI 10.1111/j.1600 0757.1997.tb00196.x
   Shankar SP, 2012, J IMMUNOL, V188, P6347, DOI 10.4049/jimmunol.1103781
   Shay K, 2002, CLIN INFECT DIS, V34, P1215, DOI 10.1086/339865
   Silva MJB, 2012, J ENDODONT, V38, P346, DOI 10.1016/j.joen.2011.12.029
   Taubman MA, 2005, J PERIODONTOL, V76, P2033, DOI 10.1902/jop.2005.76.11 S.2033
   Tomar RS, 2003, ONCOGENE, V22, P5712, DOI 10.1038/sj.onc.1206733
   Trepagnier C M, 1977, J Endod, V3, P194, DOI 10.1016/S0099 2399(77)80096 4
   Trindade SC, 2013, J PERIODONTOL, V84, P650, DOI 10.1902/jop.2012.120230
   Trombone AP, 2010, GENES IMMUN, V11, P479, DOI 10.1038/gene.2010.13
   Van Dyke TE, 2003, J DENT RES, V82, P82, DOI 10.1177/154405910308200202
   Wilensky A, 2009, J CLIN PERIODONTOL, V36, P915, DOI 10.1111/j.1600 051X.2009.01464.x
   Yang SY, 2007, J CELL SCI, V120, P3362, DOI 10.1242/jcs.008300
   Yang SY, 2007, GENE DEV, V21, P1803, DOI 10.1101/gad.1544107
   Yu H, 2011, GENE THER, V18, P344, DOI 10.1038/gt.2010.139
NR 49
TC 36
Z9 42
U1 0
U2 14
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2095 4700
EI 2095 6231
J9 BONE RES
JI Bone Res.
PD SEP 25
PY 2013
VL 1
BP 260
EP 274
DI 10.4248/BR201303005
PG 15
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA AT5OQ
UT WOS:000344992500002
PM 24761229
OA Green Accepted, Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Shen, YP
   Lv, YG
AF Shen, Yaping
   Lv, Yonggang
TI Dual targeted zeolitic imidazolate framework nanoparticles for treating
   metastatic breast cancer and inhibiting bone destruction
SO COLLOIDS AND SURFACES B BIOINTERFACES
LA English
DT Article
DE Bone metastase; Bone targeting; Osteoclast; Zeolitic imidazolate
   framework; Alendronate; Hyaluronic acid
ID OSTEOCLAST
AB Tumor bone metastasis is still difficult to cure despite the development of various treatment strategies. Drug delivery systems can improve the poor biological distribution of anticancer drugs in tumors. But only a very small number of nanoparticles can cross the physiological barrier to reach the tumor. In addition, the progression of bone metastasis is influenced by tumor cells, osteoclasts and bone matrix. To address these problems, a bone and tumor dual targeted nanocarrier was developed by utilizing NF  KB inhibitor loaded into zeolitic imidazolate framework 8 (ZIF 8) (CZ), which was then coated with hyaluronic acid/alendronate (HA/ALN). The CZ prepared by two step method had high loading capacity, and the loading efficiency of Cur was to be 47.55 +/  4.03%. HA/ALN functionalization avoided explosive release of reagents and improved the stability of nanoparticles. The dual targeted ZIF 8 nanoparticle (CZ@HA/ALN) had a pH triggered drug release performance, which effectively inhibited breast cancer cells growth and osteoclastogenesis in vitro. Uptake experiments showed that the conjugation of ALN with HA did not affect targeting ability of HA. Moreover, HA/ALN functionalized nano particles were more aggregated at bone metastasis sites than HA functionalized nanoparticles. CZ@HA/ALN could block the PD 1 immune check point, leading to Raw 264.7 cells differentiation into anti tumor macrophage rather than osteoclast. The antitumor experiments in vivo exhibited that the dual targeted ZIF 8 nanoparticle effectively inhibited bone resorption and tumor progress, thereby improving the bone microenvironment. Therefore, this single but versatile nanoparticle provided a promising therapeutic scheme for bone metastasis treatment.
C1 [Shen, Yaping] Chongqing Univ, Bioengn Coll, Mechanobiol & Regenerat Med Lab, Chongqing 400044, Peoples R China.
   [Lv, Yonggang] Wuhan Text Univ, State Key Lab New Text Mat & Adv Proc Technol, Wuhan 430200, Peoples R China.
   [Lv, Yonggang] Wuhan Text Univ, State Key Lab New Text Mat & Adv Proc Technol, Dean Inst Sci Res & Dev, 1 Sunshine Ave, Wuhan 430200, Hubei, Peoples R China.
C3 Chongqing University; Wuhan Textile University; Wuhan Textile University
RP Lv, YG (通讯作者)，Wuhan Text Univ, State Key Lab New Text Mat & Adv Proc Technol, Dean Inst Sci Res & Dev, 1 Sunshine Ave, Wuhan 430200, Hubei, Peoples R China.
EM yglv@wtu.edu.cn
FU National Natural Science Foundation of China [11872134]; Natural Science
   Foundation of Chongqing, China [cstc2020jcyj msxmX0035]
FX This work was supported in part by grants from the National Natural
   Science Foundation of China (11872134) and the Natural Science
   Foundation of Chongqing, China (cstc2020jcyj msxmX0035) .
CR Bianco P, 2011, BLOOD, V117, P5281, DOI 10.1182/blood 2011 01 315069
   Chen WJ, 2020, PROG LIPID RES, V79, DOI 10.1016/j.plipres.2020.101052
   Clézardin P, 2021, PHYSIOL REV, V101, P797, DOI 10.1152/physrev.00012.2019
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Coleman RE, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572 020 00216 3
   de Groot AF, 2018, CANCER TREAT REV, V62, P18, DOI 10.1016/j.ctrv.2017.10.010
   Gao S, 2017, ACS APPL MATER INTER, V9, P32509, DOI 10.1021/acsami.7b09331
   Heo DN, 2014, ACS NANO, V8, P12049, DOI 10.1021/nn504329u
   Huang LP, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 12771 9
   Jacome Galarza CE, 2019, NATURE, V568, P541, DOI 10.1038/s41586 019 1105 7
   Khalifehzadeh R, 2020, ADV COLLOID INTERFAC, V279, DOI 10.1016/j.cis.2020.102157
   Kim WK, 2011, J CELL BIOCHEM, V112, P3159, DOI 10.1002/jcb.23242
   Kunihiro AG, 2020, MOL NUTR FOOD RES, V64, DOI 10.1002/mnfr.202000072
   Li YC, 2020, J CONTROL RELEASE, V323, P483, DOI 10.1016/j.jconrel.2020.05.007
   Mortezaee K, 2019, J CELL PHYSIOL, V234, P12537, DOI 10.1002/jcp.28122
   Mu CF, 2018, BIOMATERIALS, V155, P191, DOI 10.1016/j.biomaterials.2017.11.029
   Nakai Y, 2019, BONE RES, V7, DOI 10.1038/s41413 018 0036 5
   Park Min KH, 2019, SEMIN IMMUNOPATHOL, V41, P565, DOI 10.1007/s00281 019 00757 0
   Shalini S, 2015, CELL DEATH DIFFER, V22, P526, DOI 10.1038/cdd.2014.216
   Signorell RD, 2018, EUR J PHARM BIOPHARM, V128, P188, DOI 10.1016/j.ejpb.2018.04.003
   Song CC, 2019, J CELL PHYSIOL, V234, P11969, DOI 10.1002/jcp.27852
   Wilhelm S, 2016, NAT REV MATER, V1, DOI 10.1038/natrevmats.2016.14
   Wu LL, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1500 x
   Xu R, 2021, CARBOHYD POLYM, V261, DOI 10.1016/j.carbpol.2021.117846
   Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308
   Yu SX, 2021, COLLOID SURFACE B, V203, DOI 10.1016/j.colsurfb.2021.111759
   Zhang D, 2018, ACS APPL MATER INTER, V10, P30092, DOI 10.1021/acsami.8b09098
   Zhao YP, 2017, NANOSCALE, V9, P6264, DOI 10.1039/c7nr00962c
   Zheng M, 2015, ACS APPL MATER INTER, V7, P22181, DOI 10.1021/acsami.5b04315
NR 29
TC 19
Z9 19
U1 5
U2 49
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0927 7765
EI 1873 4367
J9 COLLOID SURFACE B
JI Colloid Surf. B Biointerfaces
PD NOV
PY 2022
VL 219
AR 112826
DI 10.1016/j.colsurfb.2022.112826
PG 11
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biophysics; Chemistry; Materials Science
GA 4V0WM
UT WOS:000859206200001
PM 36115265
DA 2025 08 17
ER

PT J
AU Bishop, RT
   Miller, AK
   Froid, M
   Nerlakanti, N
   Li, T
   Frieling, JS
   Nasr, MM
   Nyman, KJ
   Sudalagunta, PR
   Canevarolo, RR
   Silva, AS
   Shain, KH
   Lynch, CC
   Basanta, D
AF Bishop, Ryan T.
   Miller, Anna K.
   Froid, Matthew
   Nerlakanti, Niveditha
   Li, Tao
   Frieling, Jeremy S.
   Nasr, Mostafa M.
   Nyman, Karl J.
   Sudalagunta, Praneeth R.
   Canevarolo, Rafael R.
   Silva, Ariosto Siqueira
   Shain, Kenneth H.
   Lynch, Conor C.
   Basanta, David
TI The bone ecosystem facilitates multiple myeloma relapse and the
   evolution of heterogeneous drug resistant disease
SO NATURE COMMUNICATIONS
LA English
DT Article
ID MARROW MICROENVIRONMENT; ZOLEDRONIC ACID; STROMAL CELLS; PROTEASOME
   INHIBITOR; PROSTATE CANCER; PLASMA CELLS; BORTEZOMIB; PATHOGENESIS;
   OSTEOBLAST; APOPTOSIS
AB Multiple myeloma (MM) is an osteolytic malignancy that is incurable due to the emergence of treatment resistant disease. Defining how, when and where myeloma cell intrinsic and extrinsic bone microenvironmental mechanisms cause relapse is challenging with current biological approaches. Here, we report a biology driven spatiotemporal hybrid agent based model of the MM bone microenvironment. Results indicate MM intrinsic mechanisms drive the evolution of treatment resistant disease but that the protective effects of bone microenvironment mediated drug resistance (EMDR) significantly enhances the probability and heterogeneity of resistant clones arising under treatment. Further, the model predicts that targeting of EMDR deepens therapy response by eliminating sensitive clones proximal to stroma and bone, a finding supported by in vivo studies. Altogether, our model allows for the study of MM clonal evolution over time in the bone microenvironment and will be beneficial for optimizing treatment efficacy so as to significantly delay disease relapse.
   Here, the authors develop a hybrid agent based model to quantify the contributions of intrinsic cellular mechanisms and bone ecosystem factors to therapy resistance in multiple myeloma. They show that intrinsic mechanisms are essential for resistance, and that the bone microenvironment provides a protective niche that increases the likelihood.
C1 [Bishop, Ryan T.; Nerlakanti, Niveditha; Li, Tao; Frieling, Jeremy S.; Nasr, Mostafa M.; Nyman, Karl J.; Shain, Kenneth H.; Lynch, Conor C.] H Lee Moffitt Canc Ctr & Res Inst, Dept Tumor Microenvironm & Metastasis, Tampa, FL 33612 USA.
   [Miller, Anna K.; Froid, Matthew; Basanta, David] H Lee Moffitt Canc Ctr & Res Inst, Dept Integrated Math Oncol, Tampa, FL 33612 USA.
   [Froid, Matthew; Nerlakanti, Niveditha; Nasr, Mostafa M.; Nyman, Karl J.] Univ S Florida, Canc Biol PhD Program, Tampa, FL USA.
   [Sudalagunta, Praneeth R.; Canevarolo, Rafael R.; Silva, Ariosto Siqueira] H Lee Moffitt Canc Ctr & Res Inst, Dept Metab & Physiol, Tampa, FL USA.
   [Shain, Kenneth H.] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA.
C3 H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer
   Center & Research Institute; State University System of Florida;
   University of South Florida; H Lee Moffitt Cancer Center & Research
   Institute; H Lee Moffitt Cancer Center & Research Institute
RP Lynch, CC (通讯作者)，H Lee Moffitt Canc Ctr & Res Inst, Dept Tumor Microenvironm & Metastasis, Tampa, FL 33612 USA.; Basanta, D (通讯作者)，H Lee Moffitt Canc Ctr & Res Inst, Dept Integrated Math Oncol, Tampa, FL 33612 USA.
EM conor.lynch@moffitt.org; david@cancerevo.org
RI ; Nerlakanti, Niveditha/X 5741 2019; Nasr, Mostafa/IYT 1368 2023;
   Sudalagunta, Praneeth Reddy/P 2010 2015; Miller, Anna/AAY 5673 2021;
   Canevarolo, Rafael/L 5909 2016; Renatino Canevarolo, Rafael/L 5909 2016;
   Sudalagunta, Praneeth/P 2010 2015
OI Miller, Anna/0000 0002 3099 1648; Basanta, David/0000 0002 8527 0776;
   Nerlakanti, Niveditha/0000 0001 8808 2220; Sudalagunta, Praneeth
   Reddy/0000 0003 1283 9332; Bishop, Ryan/0000 0002 1332 4798; Renatino
   Canevarolo, Rafael/0000 0002 8722 8512; 
FU NCI U01CA244101; Pentecost Myeloma Research Center (PMRC); Flow
   Cytometry core [P30 CA076292, NCI U01CA244101, NCI U54CA193489,
   NCI R01CA239214]; Collaborative Data Services Core (CDSC) the
   non therapeutic research office (NTRO); H. Lee Moffitt Cancer Center's
   Team Science Grant; Miles for Moffitt Foundation; Pentecost Myeloma
   Research Center
FX The authors would like to thank the patients at H. Lee Moffitt Cancer
   Center and Pentecost Myeloma Research Center (PMRC). This work has been
   supported in part by the Small Animal Imaging Laboratory (SAIL), the
   Flow Cytometry core, the Cancer pharmacokinetics and pharmacodynamics
   core (CPPC), the Collaborative Data Services Core (CDSC) the
   non therapeutic research office (NTRO), and the Analytical Microscopy
   Core (AMC) at the Moffitt Cancer Center, an NCI designated Comprehensive
   Cancer Center (P30 CA076292). This work was supported in part by funds
   from NCI U01CA244101 (to C.C.L and D.B) and NCI U54CA193489 (to K.H.S
   and A.S), NCI R01CA239214 (to C.C.L), H. Lee Moffitt Cancer Center's
   Team Science Grant (A.S., K.H.S.), Miles for Moffitt Foundation (A.S.).
   Additionally, this work was supported by philanthropic support from the
   Pentecost Myeloma Research Center (to K.H.S., A.S. and others).
CR Abdi J, 2013, ONCOTARGET, V4, P2186, DOI 10.18632/oncotarget.1497
   Accardi F, 2015, BIOMED RES INT UK, V2015, DOI 10.1155/2015/172458
   Alfonso JCL, 2021, NEOPLASIA, V23, P1110, DOI 10.1016/j.neo.2021.09.003
   Anderson ARA, 2006, CELL, V127, P905, DOI 10.1016/j.cell.2006.09.042
   Anderson ARA, 2005, MATH MED BIOL, V22, P163, DOI 10.1093/imammb/dqi005
   Araujo A, 2021, CANCERS, V13, DOI 10.3390/cancers13040677
   Araujo A, 2018, B MATH BIOL, V80, P1046, DOI 10.1007/s11538 018 0416 4
   Araujo A, 2014, CANCER RES, V74, P2391, DOI 10.1158/0008 5472.CAN 13 2652
   Ayati BP, 2010, BIOL DIRECT, V5, DOI 10.1186/1745 6150 5 28
   Azab AK, 2012, BLOOD, V119, P5782, DOI 10.1182/blood 2011 09 380410
   Azab AK, 2009, BLOOD, V113, P4341, DOI 10.1182/blood 2008 10 186668
   Bianchi G, 2015, BLOOD, V125, P3049, DOI 10.1182/blood 2014 11 568881
   Bishop R. T., 2023, Open Science Framework, DOI [10.17605/OSF.IO/TNAX17609, DOI 10.17605/OSF.IO/TNAX17609]
   Bishop RT, 2019, CANCER LETT, V450, P76, DOI 10.1016/j.canlet.2019.02.032
   Brady Nicholls R, 2021, NEOPLASIA, V23, P851, DOI 10.1016/j.neo.2021.06.013
   Bravo RR, 2020, PLOS COMPUT BIOL, V16, DOI 10.1371/journal.pcbi.1007635
   Chen S., 2014, BIM TARGETING STRATE
   Chen S, 2014, BLOOD, V124, P2687, DOI 10.1182/blood 2014 03 564534
   Chen S, 2012, CANCER RES, V72, P4225, DOI 10.1158/0008 5472.CAN 12 1118
   Civitelli R, 2008, ARCH BIOCHEM BIOPHYS, V473, P188, DOI 10.1016/j.abb.2008.04.005
   Cook LM, 2016, SCI REP UK, V6, DOI 10.1038/srep29384
   Cowan AJ, 2022, JAMA J AM MED ASSOC, V327, P464, DOI 10.1001/jama.2022.0003
   Croucher PI, 2003, J BONE MINER RES, V18, P482, DOI 10.1359/jbmr.2003.18.3.482
   Derenne S, 1999, J BONE MINER RES, V14, P2048, DOI 10.1359/jbmr.1999.14.12.2048
   Di Marzo L, 2016, ONCOTARGET, V7, P60698, DOI 10.18632/oncotarget.10849
   Dingli D, 2009, BRIT J CANCER, V101, P1130, DOI 10.1038/sj.bjc.6605288
   Duesberg P, 2000, P NATL ACAD SCI USA, V97, P14295, DOI 10.1073/pnas.97.26.14295
   Durdan MM, 2022, SEMIN CELL DEV BIOL, V123, P4, DOI 10.1016/j.semcdb.2021.10.008
   Edwards CM, 2008, BONE, V42, P1007, DOI 10.1016/j.bone.2008.01.027
   Edwards JR, 2010, J BONE MINER RES, V25, P2419, DOI 10.1002/jbmr.139
   Frankenstein Z, 2020, NAT ECOL EVOL, V4, P870, DOI 10.1038/s41559 020 1157 y
   Gallaher J, 2018, J THEOR BIOL, V458, P31, DOI 10.1016/j.jtbi.2018.08.037
   Gallaher J, 2014, CLIN EXP METASTAS, V31, P991, DOI 10.1007/s10585 014 9674 1
   Gallaher JA, 2020, PLOS COMPUT BIOL, V16, DOI 10.1371/journal.pcbi.1007672
   Gallaher JA, 2018, CANCER RES, V78, P2127, DOI 10.1158/0008 5472.CAN 17 2649
   Galson Deborah L, 2012, Bonekey Rep, V1, P135, DOI 10.1038/bonekey.2012.135
   Gatenby RA, 2009, CANCER RES, V69, P4894, DOI 10.1158/0008 5472.CAN 08 3658
   Ghobrial IM, 2020, CLIN CANCER RES, V26, P344, DOI 10.1158/1078 0432.CCR 19 0647
   Ghobrial IM, 2019, AM J HEMATOL, V94, P1244, DOI 10.1002/ajh.25627
   Guder C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00058
   Hao M, 2011, LEUKEMIA LYMPHOMA, V52, P1787, DOI 10.3109/10428194.2011.576791
   Hewett DR, 2017, NEOPLASIA, V19, P972, DOI 10.1016/j.neo.2017.09.004
   Howlader N., 2019, SEER Cancer Statistics Review, 1975 2016
   Hurchla MA, 2013, LEUKEMIA, V27, P430, DOI 10.1038/leu.2012.183
   Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004 0001
   Jenner AL, 2022, ISCIENCE, V25, DOI 10.1016/j.isci.2022.104395
   Ji B, 2016, INT J NUMER METH BIO, V32, DOI 10.1002/cnm.2735
   Ji B, 2014, INT J NUMER METH BIO, V30, P1085, DOI 10.1002/cnm.2645
   Jilka RL, 2003, MED PEDIATR ONCOL, V41, P182, DOI 10.1002/mpo.10334
   Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793
   Jones EA, 2006, CYTOM PART B CLIN CY, V70B, P391, DOI 10.1002/cyto.b.20118
   Kassen D, 2016, BRIT J HAEMATOL, V172, P64, DOI 10.1111/bjh.13790
   Kawano Y, 2015, IMMUNOL REV, V263, P160, DOI 10.1111/imr.12233
   Keats JJ, 2012, BLOOD, V120, P1067, DOI 10.1182/blood 2012 01 405985
   Kumar S, 2017, BLOOD, V130, P2401, DOI 10.1182/blood 2017 06 788786
   Lawson MA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9983
   LeBlanc R, 2002, CANCER RES, V62, P4996
   Lemaire V, 2004, J THEOR BIOL, V229, P293, DOI 10.1016/j.jtbi.2004.03.023
   Macklin P, 2012, J THEOR BIOL, V301, P122, DOI 10.1016/j.jtbi.2012.02.002
   Manasanch EE, 2017, NAT REV CLIN ONCOL, V14, P417, DOI [10.1007/s12079 011 0121 7, 10.1038/nrclinonc.2016.206]
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Marino S, 2021, BRIT J PHARMACOL, V178, P1907, DOI 10.1111/bph.14889
   Marino S, 2019, METHODS MOL BIOL, V1914, P71, DOI 10.1007/978 1 4939 8997 3_5
   Markovina S, 2010, MOL CANCER, V9, DOI 10.1186/1476 4598 9 176
   Martin TJ, 2005, TRENDS MOL MED, V11, P76, DOI 10.1016/j.molmed.2004.12.004
   McGuire JJ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 20962 6
   Meads MB, 2008, CLIN CANCER RES, V14, P2519, DOI 10.1158/1078 0432.CCR 07 2223
   Meads MB, 2009, NAT REV CANCER, V9, P665, DOI 10.1038/nrc2714
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   Mori G, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/720504
   Moser Katz T, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.625199
   Noll JE, 2014, HAEMATOLOGICA, V99, P163, DOI 10.3324/haematol.2013.090977
   Novack DV, 2011, AGEING RES REV, V10, P54, DOI 10.1016/j.arr.2009.09.005
   Paíno T, 2015, LEUKEMIA, V29, P1186, DOI 10.1038/leu.2014.321
   Paiva B, 2016, BLOOD, V127, P1896, DOI 10.1182/blood 2015 08 665679
   Pan BQ, 2004, BONE, V34, P112, DOI 10.1016/j.bone.2003.08.013
   Pasetto S, 2022, B MATH BIOL, V84, DOI 10.1007/s11538 021 00953 w
   Paton Hough J, 2019, J BONE MINER RES, V34, P783, DOI 10.1002/jbmr.3606
   Pennisi A, 2009, AM J HEMATOL, V84, P6, DOI 10.1002/ajh.21310
   Pérez Velazquez J, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00319
   Pérez Velázquez J, 2016, ADV EXP MED BIOL, V936, P149, DOI 10.1007/978 3 319 42023 3_8
   Picco N, 2017, CANCER RES, V77, P5409, DOI 10.1158/0008 5472.CAN 17 0835
   Plotkin LI, 2013, BONE, V52, P157, DOI 10.1016/j.bone.2012.09.030
   Qiao MN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143206
   Roccaro AM, 2013, J CLIN INVEST, V123, P1542, DOI 10.1172/JCI66517
   Roodman GD, 2010, J CELL BIOCHEM, V109, P283, DOI 10.1002/jcb.22403
   Sartakhti JS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168856
   Schenck RO, 2022, MOL BIOL EVOL, V39, DOI 10.1093/molbev/msac058
   Scheper MA, 2009, SUPPORT CARE CANCER, V17, P1553, DOI 10.1007/s00520 009 0710 7
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   SESHADRI R, 1987, CANCER RES, V47, P407
   Shain KH, 2009, CANCER RES, V69, P1009, DOI 10.1158/0008 5472.CAN 08 2419
   Shay G, 2016, J MOL MED, V94, P21, DOI 10.1007/s00109 015 1345 4
   Shipman CM, 1997, BRIT J HAEMATOL, V98, P665, DOI 10.1046/j.1365 2141.1997.2713086.x
   Sims NA, 2020, ANNU REV PHYSIOL, V82, P507, DOI 10.1146/annurev physiol 021119 034425
   Stains Joseph P, 2005, Birth Defects Res C Embryo Today, V75, P72, DOI 10.1002/bdrc.20034
   Stains JP, 2014, CALCIFIED TISSUE INT, V94, P55, DOI 10.1007/s00223 013 9742 6
   Su J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085059
   Suzuki K, 2021, CANCERS, V13, DOI 10.3390/cancers13020215
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Touzeau C, 2018, LEUKEMIA, V32, P1899, DOI 10.1038/s41375 018 0223 9
   UCHIYAMA H, 1993, BLOOD, V82, P3712
   Vander Velde R, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 16212 w
   Walker BA, 2014, LEUKEMIA, V28, P384, DOI 10.1038/leu.2013.199
   Wang LJ, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00190 4
   Wang Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027494
   Watkins M, 2011, MOL BIOL CELL, V22, P1240, DOI 10.1091/mbc.E10 07 0571
   West J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 22123 1
   West JB, 2019, CLIN CANCER RES, V25, P4413, DOI 10.1158/1078 0432.CCR 19 0006
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Wuillème Toumi S, 2005, LEUKEMIA, V19, P1248, DOI 10.1038/sj.leu.2403784
   Zangari M, 2006, CLIN LYMPHOMA MYELOM, V7, P109, DOI 10.3816/CLM.2006.n.047
   Zavidij O, 2020, NAT CANCER, V1, DOI 10.1038/s43018 020 0053 3
   Zhang JS, 2022, ELIFE, V11, DOI 10.7554/eLife.76284
NR 114
TC 3
Z9 3
U1 3
U2 14
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2041 1723
J9 NAT COMMUN
JI Nat. Commun.
PD MAR 19
PY 2024
VL 15
IS 1
AR 2458
DI 10.1038/s41467 024 46594 0
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA LO9X5
UT WOS:001187872900009
PM 38503736
OA gold
DA 2025 08 17
ER

PT S
AU Huang, HJ
   Schulman, IG
AF Huang, Huey Jing
   Schulman, Ira G.
BA Bowen, R
BF Bowen, R
TI Regulation of Metabolism by Nuclear Hormone Receptors
SO EQUILIBRIUM STATES AND THE ERGODIC THEORY OF ANOSOV DIFFEOMORPHISMS,
   SECOND EDITION
SE Lecture Notes in Mathematics
LA English
DT Article; Book Chapter
ID GTPASE ACTIVATING PROTEIN; WNT SIGNALING PATHWAY; SKELETAL MUSCLE CELLS;
   C ELEGANS; CAENORHABDITIS ELEGANS; GENE EXPRESSION; RGS PROTEINS;
   ROR ALPHA; MEMBRANE ANCHOR; TRANSCRIPTIONAL REGULATION
AB The worldwide epidemic of metabolic disease indicates that a better understanding of the pathways contributing to the pathogenesis of this constellation of diseases need to be determined. Nuclear hormone receptors comprise a superfamily of ligand activated transcription factors that control development, differentiation, and metabolism. Over the last 15 years a growing number of nuclear receptors have been identified that coordinate genetic networks regulating lipid metabolism and energy utilization. Several of these receptors directly sample the levels of metabolic intermediates and use this information to regulate the synthesis, transport, and breakdown of the metabolite of interest. In contrast, other family members sense metabolic activity via the presence or absence of interacting proteins. The ability of these nuclear receptors to impact metabolism and inflammation will be discussed and the potential of each receptor subfamily to serve as drug targets for metabolic disease will be highlighted.
C1 [Huang, Huey Jing] Exelixis Inc, Dept Biol, San Diego, CA 92121 USA.
   [Schulman, Ira G.] Univ Virginia Hlth Syst, Dept Pharmacol, Charlottesville, VA 22908 USA.
   [Schulman, Ira G.] Univ Virginia Hlth Syst, Ctr Mol Design, Charlottesville, VA 22908 USA.
C3 Exelixis, Inc.; University of Virginia; University of Virginia (UVA)
   Health System; University of Virginia; University of Virginia (UVA)
   Health System
RP Huang, HJ (通讯作者)，Exelixis Inc, Dept Biol, 4757 Nexus Ctr Dr, San Diego, CA 92121 USA.
CR André E, 1998, EMBO J, V17, P3867, DOI 10.1093/emboj/17.14.3867
   AVERY L, 1993, GENETICS, V133, P897
   Ballon DR, 2006, CELL, V126, P1079, DOI 10.1016/j.cell.2006.07.030
   Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028
   Bastiani Carol, 2006, WormBook, P1
   Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209
   Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999
   BRENNER S, 1974, GENETICS, V77, P71
   Brundage L, 1996, NEURON, V16, P999, DOI 10.1016/S0896 6273(00)80123 3
   Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483
   Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221
   CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295
   Charlie NK, 2006, GENETICS, V172, P943, DOI 10.1534/genetics.105.049577
   Chase DL, 2004, NAT NEUROSCI, V7, P1096, DOI 10.1038/nn1316
   Chase DL, 2001, CURR BIOL, V11, P222, DOI 10.1016/S0960 9822(01)00071 9
   Cheever ML, 2008, NAT STRUCT MOL BIOL, V15, P155, DOI 10.1038/nsmb.1377
   DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0
   DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916
   Dohlman HG, 1996, MOL CELL BIOL, V16, P5194
   Dong MQ, 2000, GENE DEV, V14, P2003
   Drenan RM, 2005, J CELL BIOL, V169, P623, DOI 10.1083/jcb.200502007
   Drenan RM, 2006, J BIOL CHEM, V281, P28222, DOI 10.1074/jbc.M604428200
   Eisenmann David M, 2005, WormBook, P1, DOI 10.1895/wormbook.1.7.1
   Ferkey DM, 2007, NEURON, V53, P39, DOI 10.1016/j.neuron.2006.11.015
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Fitzgerald K, 2006, PLOS GENET, V2, P425, DOI 10.1371/journal.pgen.0020057
   Fletcher JE, 1998, J BIOL CHEM, V273, P636, DOI 10.1074/jbc.273.1.636
   FORMAN BM, 1994, MOL ENDOCRINOL, V8, P1253, DOI 10.1210/me.8.9.1253
   Fukuto HS, 2004, NEURON, V42, P581, DOI 10.1016/S0896 6273(04)00252 1
   Gleason JE, 2002, GENE DEV, V16, P1281, DOI 10.1101/gad.981602
   Gonczy Pierre, 2005, WormBook, P1
   Gotta M, 2001, NAT CELL BIOL, V3, P297, DOI 10.1038/35060092
   Green JL, 2008, CELL, V134, P646, DOI 10.1016/j.cell.2008.06.026
   Hajdu Cronin YM, 1999, GENE DEV, V13, P1780, DOI 10.1101/gad.13.14.1780
   Hamilton BA, 1996, NATURE, V379, P736, DOI 10.1038/379736a0
   Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112
   He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896 6273(00)80437 7
   Hess HA, 2004, CELL, V119, P209, DOI 10.1016/j.cell.2004.09.025
   Hess HA., 2006, WORMBOOK, DOI [10.1895/worm book.1.47.1, DOI 10.1895/WORMBOOK.1.47.1, 10.1895/wormbook.1.47.1]
   Hiley E, 2006, EMBO J, V25, P5884, DOI 10.1038/sj.emboj.7601458
   Hilliard MA, 2005, EMBO J, V24, P63, DOI 10.1038/sj.emboj.7600493
   Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527
   Hooks SB, 2003, J BIOL CHEM, V278, P10087, DOI 10.1074/jbc.M211382200
   HORVITZ HR, 1982, SCIENCE, V216, P1012, DOI 10.1126/science.6805073
   Hu G, 2002, P NATL ACAD SCI USA, V99, P9755, DOI 10.1073/pnas.152094799
   Hu YQ, 2008, BIOL REPROD, V79, P1021, DOI 10.1095/biolreprod.107.067504
   Jansen G, 1999, NAT GENET, V21, P414, DOI 10.1038/7753
   Kallen JA, 2002, STRUCTURE, V10, P1697, DOI 10.1016/S0969 2126(02)00912 7
   Kang HS, 2007, PHYSIOL GENOMICS, V31, P281, DOI 10.1152/physiolgenomics.00098.2007
   Kehrl JH, 2002, GENOMICS, V79, P860, DOI 10.1006/geno.2002.6773
   Kinchen JM, 2008, NAT CELL BIOL, V10, P556, DOI 10.1038/ncb1718
   Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092 8674(00)80998 8
   Korswagen HC, 2002, GENE DEV, V16, P1291, DOI 10.1101/gad.981802
   Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109
   Lackner MR, 1999, NEURON, V24, P335, DOI 10.1016/S0896 6273(00)80848 X
   Lau P, 2004, J BIOL CHEM, V279, P36828, DOI 10.1074/jbc.M404927200
   Lau P, 2008, J BIOL CHEM, V283, P18411, DOI 10.1074/jbc.M710526200
   Liu XX, 2005, CURR BIOL, V15, P1989, DOI 10.1016/j.cub.2005.10.050
   LOCHRIE MA, 1991, CELL REGUL, V2, P135, DOI 10.1091/mbc.2.2.135
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Maloof JN, 1999, DEVELOPMENT, V126, P37
   Mamontova A, 1998, CIRCULATION, V98, P2738, DOI 10.1161/01.CIR.98.24.2738
   Martemyanov KA, 2005, J BIOL CHEM, V280, P5133, DOI 10.1074/jbc.C400596200
   MatysiakScholze U, 1997, GENOMICS, V43, P78, DOI 10.1006/geno.1997.4757
   MENDEL JE, 1995, SCIENCE, V267, P1652, DOI 10.1126/science.7886455
   Miller KG, 1999, NEURON, V24, P323, DOI 10.1016/S0896 6273(00)80847 8
   Nakamura K, 2005, GENE DEV, V19, P1749, DOI 10.1101/gad.1323705
   Narayanan V, 2007, BIOCHEMISTRY US, V46, P6859, DOI 10.1021/bi700524w
   NGUYEN M, 1995, GENETICS, V140, P527
   Nunn C, 2006, SEMIN CELL DEV BIOL, V17, P390, DOI 10.1016/j.semcdb.2006.04.001
   Nurrish S, 1999, NEURON, V24, P231, DOI 10.1016/S0896 6273(00)80835 1
   Oosterveen T, 2007, DEV BIOL, V308, P438, DOI 10.1016/j.ydbio.2007.05.043
   Patikoglou GA, 2002, J BIOL CHEM, V277, P47004, DOI 10.1074/jbc.M208186200
   Pollin TI, 2008, SCIENCE, V322, P1702, DOI 10.1126/science.1161524
   Raichur S, 2007, J MOL ENDOCRINOL, V39, P29, DOI 10.1677/jme.1.00010
   Raspé E, 2001, J BIOL CHEM, V276, P2865, DOI 10.1074/jbc.M004982200
   Robatzek M, 2000, GENETICS, V156, P1069
   Robatzek M, 2001, CURR BIOL, V11, P288, DOI 10.1016/S0960 9822(01)00074 4
   Rose LS, 1998, DEVELOPMENT, V125, P1337
   Sato M, 2003, LIFE SCI, V73, P917, DOI 10.1016/S0024 3205(03)00355 2
   Schmitz C, 2007, P NATL ACAD SCI USA, V104, P834, DOI 10.1073/pnas.0510527104
   SEGALAT L, 1995, SCIENCE, V267, P1648, DOI 10.1126/science.7886454
   Siderovski DP, 2005, INT J BIOL SCI, V1, P51, DOI 10.7150/ijbs.1.51
   Siderovski DP, 1999, CRIT REV BIOCHEM MOL, V34, P215, DOI 10.1080/10409239991209273
   Song JH, 2006, J BIOL CHEM, V281, P15361, DOI 10.1074/jbc.M600749200
   Stehlin Gaon C, 2003, NAT STRUCT BIOL, V10, P820, DOI 10.1038/nsb979
   Steinmayr M, 1998, P NATL ACAD SCI USA, V95, P3960, DOI 10.1073/pnas.95.7.3960
   Stemmle LN, 2006, MOL PHARMACOL, V70, P1461, DOI 10.1124/mol.106.023705
   Subramaniam S, 1998, PROTEINS, V32, P1
   SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012 1606(77)90158 0
   Tanis JE, 2008, GENETICS, V178, P157, DOI 10.1534/genetics.107.079780
   Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378 1119(00)00579 5
   TRENT C, 1983, GENETICS, V104, P619
   Tsou MFB, 2003, DEVELOPMENT, V130, P5717, DOI 10.1242/dev.00790
   Tsou MFB, 2002, DEVELOPMENT, V129, P4469
   van der Linden AM, 2001, GENETICS, V158, P221
   van Swinderen B, 2001, GENETICS, V158, P643
   Vu Dac N, 1998, J BIOL CHEM, V273, P25713, DOI 10.1074/jbc.273.40.25713
   VuDac N, 1997, J BIOL CHEM, V272, P22401, DOI 10.1074/jbc.272.36.22401
   WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092 8674(95)90220 1
   WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056
   Yang XY, 2006, CELL, V126, P801, DOI 10.1016/j.cell.2006.06.050
   Yau DM, 2003, P NATL ACAD SCI USA, V100, P14748, DOI 10.1073/pnas.2533143100
   Zhang H, 2008, J CELL SCI, V121, P155, DOI 10.1242/jcs.015966
NR 104
TC 1
Z9 2
U1 0
U2 3
PU SPRINGER VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D 14197 BERLIN, GERMANY
SN 0075 8434
EI 1617 9692
BN 978 3 540 77695 6; 978 3 540 77605 5
J9 LECT NOTES MATH
JI Lect. Notes Math.
PY 2008
VL 470
BP 1
EP 51
DI 10.1016/S1877 1173(09)87001 4
D2 10.1007/978 3 540 77695 6
PG 51
WC Mathematics
WE Book Citation Index– Science (BKCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Mathematics
GA BBH69
UT WOS:000306858700003
DA 2025 08 17
ER

PT J
AU Ren, C
   Gong, W
   Li, F
   Xie, M
AF Ren, Cong
   Gong, Wei
   Li, Feng
   Xie, Ming
TI Protective and therapeutic effects of Pilose antler against
   kidney deficiency induced osteoporosis
SO CELLULAR AND MOLECULAR BIOLOGY
LA English
DT Article
DE Pilose antler polypeptide; Pilose antler polysaccharide; Osteoporosis;
   Kidney deficiency; Traditional Chinese Medicine (TCM)
ID BONE; DIFFERENTIATION; OSTEOBLASTS; EXPRESSION
AB This study was carried out to evaluate the preventive and curative effects of Pilose antler against osteoporosis due to kidney deficiency, and investigate its potential mechanism of action. A model of osteoporosis due to kidney deficiency was established in rats using bilateral ovariectomy. Pilose antler polypeptide (PAP), Pilose antler polysaccharide (PAP'), and their mixture (PAP+PAP') were separately administered to the rats for 12 weeks, with progynova and xianlingubao tablets (XLGB) as the positive control groups. We determined the bone mineral density (BMD) and uterus Index of the rats. Osteoblastic bone metabolism related indices in serum and bone tissue were measured with ELISA. Western blotting and RT PCR were used to investigate the protein and mRNA expressions of Bmp 2, Smad1, Smad5, Runx2 in bone tissue. The morphology of bone tissue was determined using immunohistochemical methods. Compared with control group, PAP, PAP', PAP+PAP' increased BMD and regulated bone metabolism indices in serum and bone tissue. Treatment with Pilose antler up regulated the mNRA and protein expressions of Bmp 2, Smad1, Smad5 and Runx2. Immunohistochemical staining showed that Bmp 2, Smad1, Smad5 and Runx2 were stained brown, indicating that all of them were positive. There were abnormal changes in the protein expressions of Bmp 2, Smad1, Smad5 and Runx2 in bone tissue, which may be an important mechanism underlying the development of kidney deficiency osteoporosis. Moreover, PAP, PAP' and PAP+PAP' had some preventive effects on osteoporosis, probably via the activation of the Bmp 2/Smad1 and Smad5/Runx2 signaling pathways through induction of high expressions of their mRNAs and proteins.
C1 [Ren, Cong; Li, Feng; Xie, Ming] Liaoning Univ Tradit Chinese Med, Dept Pharm, Dalian, Liaoning, Peoples R China.
   [Gong, Wei] Liaoning Univ Tradit Chinese Med, Affiliated Hosp, Shenyang, Liaoning, Peoples R China.
C3 Liaoning University of Traditional Chinese Medicine; Liaoning University
   of Traditional Chinese Medicine
RP Li, F; Xie, M (通讯作者)，Liaoning Univ Tradit Chinese Med, Dept Pharm, Dalian, Liaoning, Peoples R China.
EM zhanglijiayi@163.com; x6m6@163.com
RI Xie, Ming/B 9908 2014
FU National Natural Science Foundation of China [81473314]
FX This study was supported by the National Natural Science Foundation of
   China (grant No. 81473314).
CR [邓昶 Deng Chang], 2017, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V23, P1105
   Feng LK, 2019, J TONGHUA NORMAL U, V40, P51
   Franceschi RT, 2009, CELLS TISSUES ORGANS, V189, P144, DOI 10.1159/000151747
   Gaur T, 2010, DEV BIOL, V340, P10, DOI 10.1016/j.ydbio.2010.01.008
   Gong W., 2011, STUDY RELATIONSHIP R
   Gong W, 2014, BIOMED RES INDIA, V25, P249
   [胡军 Hu Jun], 2005, [中华实验外科杂志, Chinese Journal of Experimental Surgery], V22, P147
   Hu ZM, 2009, BIOMED ENVIRON SCI, V22, P164, DOI 10.1016/S0895 3988(09)60041 6
   Karageorgiou V, 2004, J BIOMED MATER RES A, V71A, P528, DOI 10.1002/jbm.a.30186
   Kato S, 2009, LIFE SCI, V84, P302, DOI 10.1016/j.lfs.2008.12.011
   Kim K, 2001, BIOMATER, V32, P3750
   Kobune M, 2005, EXP HEMATOL, V33, P1544, DOI 10.1016/j.exphem.2005.09.004
   Komori T, 2008, FRONT BIOSCI LANDMRK, V13, P898, DOI 10.2741/2730
   Lee JC, 2007, PHYTOMEDICINE, V14, P390, DOI 10.1016/j.phymed.2006.09.012
   Li CQ, 2007, J ETHNOPHARMACOL, V114, P212, DOI 10.1016/j.jep.2007.08.002
   Li HF, 2003, MOD CLIN MED BIOENG, V9, P450
   Li YH, 2008, TISSUE ENG RES CHINA, V22, P1956
   LINDSAY R, 1990, OBSTET GYNECOL, V76, P290
   Liu ZH, 1998, OSTEOPOROSIS, P142
   Lo KWH, 2012, ADV DRUG DELIVER REV, V64, P1277, DOI 10.1016/j.addr.2012.03.014
   Luo T, 2014, HUNAN J TRADIT CHIN, V30, P148
   National Pharmacopoeia Committee, 2015, CHINESE PHARMACOPOEI, VOne, P323
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Ren YL, 2012, CHIN J EXP TRADIT ME, V10, P190
   Shi CD, 2015, J SICHUAN TRADIT CHI, V33, P61
   Smoljanovic T, 2012, J NEUROSURG SPINE, V17, P98, DOI 10.3171/2011.1.SPINE1140
   Sun WenPing Sun WenPing, 2011, Zhongguo Weishengtaxixue Zazhi / Chinese Journal of Microecology, V23, P881
   Tachi K, 2010, CELL TISSUE RES, V342, P213, DOI 10.1007/s00441 010 1052 y
   ten Dijke P, 2006, CURR MED RES OPIN, V22, pS7, DOI 10.1185/030079906X80576
   Wang B., 2016, INFORM TRADIT CHIN M, V33, P128
   Wang HF, 1995, CHIN J OSTEOPOROS, V2, P8
   Xu C, 2005, GENE, V357, P1, DOI 10.1016/j.gene.2005.06.017
   Ye J, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471 2105 13 134
   Yeung DKW, 2010, J MAGN RESON IMAGING, V2, P279
NR 34
TC 10
Z9 15
U1 1
U2 48
PU C M B  ASSOC
PI POITIERS
PA 34 BOULEVARD SOLFERINO, 86000 POITIERS, FRANCE
SN 0145 5680
EI 1165 158X
J9 CELL MOL BIOL
JI Cell. Mol. Biol.
PY 2019
VL 65
IS 5
BP 24
EP 31
DI 10.14715/cmb/2019.65.5.4
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA II6PQ
UT WOS:000475316200004
PM 31304902
DA 2025 08 17
ER

PT J
AU Chen, Y
   Whetstone, HC
   Lin, AC
   Nadesan, P
   Wei, QX
   Poon, R
   Alman, BA
AF Chen, Yan
   Whetstone, Heather C.
   Lin, Alvin C.
   Nadesan, Puviindran
   Wei, Qingxia
   Poon, Raymond
   Alman, Benjamin A.
TI Beta catenin signaling plays a disparate role in different phases of
   fracture repair: Implications for therapy to improve bone healing
SO PLOS MEDICINE
LA English
DT Article
ID CHONDROCYTE SPECIFIC ENHANCER; CONVERGENT EXTENSION; MOLECULAR ASPECTS;
   LITHIUM CHLORIDE; STEM CELLS; WNT; PROLIFERATION; OSTEOBLAST;
   REGENERATION; ACTIVATION
AB Background Delayed fracture healing causes substantial disability and usually requires additional surgical treatments. Pharmacologic management to improve fracture repair would substantially improve patient outcome. The signaling pathways regulating bone healing are beginning to be unraveled, and they provide clues into pharmacologic management. The beta catenin signaling pathway, which activates T cell factor (TCF) dependent transcription, has emerged as a key regulator in embryonic skeletogenesis, positively regulating osteoblasts. However, its role in bone repair is unknown. The goal of this study was to explore the role of beta catenin signaling in bone repair.
   Methods and Findings Western blot analysis showed significant up regulation of beta catenin during the bone healing process. Using a beta Gal activity assay to observe activation during healing of tibia fractures in a transgenic mouse model expressing a TCF reporter, we found that beta catenin mediated, TCF dependent transcription was activated in both bone and cartilage formation during fracture repair. Using reverse transcription PCR, we observed that several WNT ligands were expressed during fracture repair. Treatment with DKK1 (an antagonist of WNT/beta catenin pathway) inhibited beta catenin signaling and the healing process, suggesting that WNT ligands regulate bcatenin. Healing was significantly repressed in mice conditionally expressing either null or stabilized beta catenin alleles induced by an adenovirus expressing Cre recombinase. Fracture repair was also inhibited in mice expressing osteoblast specific beta catenin null alleles. In stark contrast, there was dramatically enhanced bone healing in mice expressing an activated form of beta catenin, whose expression was restricted to osteoblasts. Treating mice with lithium activated beta catenin in the healing fracture, but healing was enhanced only when treatment was started subsequent to the fracture.
   Conclusions These results demonstrate that beta catenin functions differently at different stages of fracture repair. In early stages, precise regulation of beta catenin is required for pluripotent mesenchymal cells to differentiate to either osteoblasts or chondrocytes. Once these undifferentiated cells have become committed to the osteoblast lineage, beta catenin positively regulates osteoblasts. This is a different function for beta catenin than has previously been reported during development. Activation of beta catenin by lithium treatment has potential to improve fracture healing, but only when utilized in later phases of repair, after mesenchymal cells have become committed to the osteoblast lineage.
C1 Univ Toronto, Hosp Sick Children, Program Dev & Stem Cell Biol, Toronto, ON M5G 1X8, Canada.
   Univ Toronto, Dept Surg, Div Orthopaed Surg, Toronto, ON M5G 1X8, Canada.
C3 University of Toronto; Hospital for Sick Children (SickKids); University
   of Toronto
RP Alman, BA (通讯作者)，Univ Toronto, Hosp Sick Children, Program Dev & Stem Cell Biol, Toronto, ON M5G 1X8, Canada.
EM benjamin.alman@sickkids.ca
CR Akiyama T, 2000, CYTOKINE GROWTH F R, V11, P273, DOI 10.1016/S1359 6101(00)00011 3
   Behrens J, 2000, J CELL SCI, V113, P911
   Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Brault V, 2001, DEVELOPMENT, V128, P1253
   Bridgewater LC, 1998, J BIOL CHEM, V273, P14998, DOI 10.1074/jbc.273.24.14998
   BRUDER SP, 1994, J CELL BIOCHEM, V56, P283, DOI 10.1002/jcb.240560303
   CAPLAN AI, 1987, BIOESSAYS, V6, P171, DOI 10.1002/bies.950060406
   Carron C, 2005, MECH DEVELOP, V122, P1234, DOI 10.1016/j.mod.2005.06.007
   Cheon SS, 2006, FASEB J, V20, P692, DOI 10.1096/fj.05 4759com
   Cheon SS, 2004, EXP CELL RES, V293, P267, DOI 10.1016/j.yexcr.2003.09.029
   Cheon SS, 2002, P NATL ACAD SCI USA, V99, P6973, DOI 10.1073/pnas.102657399
   Clément Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102
   Dacquin R, 2002, DEV DYNAM, V224, P245, DOI 10.1002/dvdy.10100
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Dehpour AR, 2002, PHARMACOL TOXICOL, V90, P89, DOI 10.1034/j.1600 0773.2002.900206.x
   Dimitriou R, 2005, INJURY, V36, P1392, DOI 10.1016/j.injury.2005.07.019
   Ducy P, 2000, DEV DYNAM, V219, P461, DOI 10.1002/1097 0177(2000)9999:9999<::AID DVDY1074>3.0.CO;2 C
   Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955 0674(99)80031 3
   Einhorn TA, 1998, CLIN ORTHOP RELAT R, pS7
   French DM, 2004, AM J PATHOL, V165, P855, DOI 10.1016/S0002 9440(10)63348 2
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Gregory CA, 2005, J BIOL CHEM, V280, P2309, DOI 10.1074/jbc.M406275200
   Hadjiargyrou M, 2002, J BIOL CHEM, V277, P30177, DOI 10.1074/jbc.M203171200
   Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931
   Hartmann C, 2000, DEVELOPMENT, V127, P3141
   Heisenberg CP, 2000, NATURE, V405, P76, DOI 10.1038/35011068
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   HILTUNEN A, 1993, J ORTHOP RES, V11, P305, DOI 10.1002/jor.1100110219
   Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564
   Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371
   Koay MA, 2005, TRENDS MOL MED, V11, P129, DOI 10.1016/j.molmed.2005.01.004
   Kuhnert F, 2004, P NATL ACAD SCI USA, V101, P266, DOI 10.1073/pnas.2536800100
   Le AX, 2001, J ORTHOPAED RES, V19, P78, DOI 10.1016/S0736 0266(00)00006 1
   Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336
   Noble W, 2005, P NATL ACAD SCI USA, V102, P6990, DOI 10.1073/pnas.0500466102
   Phiel CJ, 2001, ANNU REV PHARMACOL, V41, P789, DOI 10.1146/annurev.pharmtox.41.1.789
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Ryu JH, 2002, DEVELOPMENT, V129, P5541, DOI 10.1242/dev.00110
   Schneider RA., 1998, Current Opinion in Orthopaedics, V9, P20
   Schou M, 2001, J AFFECT DISORDERS, V67, P21, DOI 10.1016/S0165 0327(01)00380 9
   Seto ES, 2004, TRENDS CELL BIOL, V14, P45, DOI 10.1016/j.tcb.2003.11.004
   Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960 9822(99)80310 8
   van der Horst G, 2005, J BONE MINER RES, V20, P1867, DOI 10.1359/JBMR.050614
   Veeman MT, 2003, CURR BIOL, V13, P680, DOI 10.1016/S0960 9822(03)00240 9
   Vortkamp A, 1998, MECH DEVELOP, V71, P65, DOI 10.1016/S0925 4773(97)00203 7
   Yang Yingzi, 2003, Birth Defects Research, V69, P305, DOI 10.1002/bdrc.10026
   Yang YZ, 2003, DEVELOPMENT, V130, P1003, DOI 10.1242/dev.00324
   Zhang F, 2003, J BIOL CHEM, V278, P33067, DOI 10.1074/jbc.M212635200
   Zhong N, 2006, BONE, V39, P5, DOI 10.1016/j.bone.2005.12.008
NR 52
TC 325
Z9 390
U1 0
U2 35
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1549 1277
EI 1549 1676
J9 PLOS MED
JI PLos Med.
PD JUL
PY 2007
VL 4
IS 7
BP 1216
EP 1229
AR e249
DI 10.1371/journal.pmed.0040249
PG 14
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA 195IQ
UT WOS:000248406300015
PM 17676991
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Hengst, V
   Oussoren, C
   Kissel, T
   Storm, G
AF Hengst, V.
   Oussoren, C.
   Kissel, T.
   Storm, G.
TI Bone targeting potential of bisphosphonate targeted liposomes  
   Preparation, characterization and hydroxyapatite binding in vitro
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article; Proceedings Paper
CT 6th European Workshop on Particulate Systems
CY MAR 13 24, 2006
CL Geneva, SWITZERLAND
DE bisphosphonates; hydroxyapatite; liposomes; bone targeting
AB The main constituent of bone is hydroxyapatite (HAP). Since HAP is only present in 'hard' tissues like bone and teeth, it represents a promising target for the selective drug delivery to bone. Due to the exceptional affinity of bisphosphonates (BP) for HAP, cholesteryl trisoxyethylenebisphosphonic acid (CHOL TOE BP), a new tailor made BP derivative, was used as bone targeting moiety for liposomes. CHOL TOE BP targeted liposomes were designed for the treatment of bone related diseases to achieve prolonged local exposure to high concentrations of the bioactive compounds, thereby enhancing therapeutic efficacy and minimizing systemic side effects. The CHOL TOE BP targeted liposomes were characterized regarding particle size and zeta potential. To study the bone targeting potential of these conjugates, an in vitro HAP binding assay was established. The obtained binding data indicate that CHOL TOE BP is useful as targeting device for liposomal drug delivery to bone. (c) 2006 Elsevier B.V. All rights reserved.
C1 Univ Utrecht, Utrecht Inst Pharmaceut Sci, Dept Pharmaceut, Utrecht, Netherlands.
   MCS Micro Carrier Syst GmbH, D 41460 Neuss, Germany.
   Univ Marburg, Dept Pharmaceut & Biopharm, D 35032 Marburg, Germany.
C3 Utrecht University; Philipps University Marburg
RP Storm, G (通讯作者)，Univ Utrecht, Utrecht Inst Pharmaceut Sci, Dept Pharmaceut, POB 80082, Utrecht, Netherlands.
EM g.storm@pharm.uu.nl
RI Storm, Gerrit/O 8696 2016
CR Allen TM, 1997, DRUGS, V54, P8, DOI 10.2165/00003495 199700544 00004
   Bauss F, 1996, CALCIFIED TISSUE INT, V59, P168, DOI 10.1007/s002239900104
   CROMMELIN DJ, 2002, BUSINESS BRIEFING PH
   FLEISCH H, 1987, BONE, V8, pS23
   Fleisch H, 2002, BREAST CANCER RES, V4, P30, DOI 10.1186/bcr414
   Fujisawa R, 1996, BBA PROTEIN STRUCT M, V1292, P53, DOI 10.1016/0167 4838(95)00190 5
   Gil L, 1999, BIOORGAN MED CHEM, V7, P901, DOI 10.1016/S0968 0896(99)00045 0
   GOLOMB G, 1992, J PHARM SCI, V81, P1004, DOI 10.1002/jps.2600811009
   Gonzalez KA, 2002, BIOORGAN MED CHEM, V10, P1991, DOI 10.1016/S0968 0896(02)00049 4
   GREB W, 2005, Patent No. 2005070952
   Grossmann G, 2000, MAGN RESON CHEM, V38, P11, DOI 10.1002/(SICI)1097 458X(200001)38:1<11::AID MRC597>3.0.CO;2 V
   KLENNER T, 1990, CANCER TREAT REV, V17, P253, DOI 10.1016/0305 7372(90)90056 L
   KLIBANOV AL, 1998, LONG CIRCULATING LIP
   Lisic EC, 2001, NUCL MED BIOL, V28, P419, DOI 10.1016/S0969 8051(00)00205 5
   Neves M, 2002, NUCL MED BIOL, V29, P329, DOI 10.1016/S0969 8051(01)00305 5
   SHINODA H, 1983, CALCIFIED TISSUE INT, V35, P87, DOI 10.1007/BF02405012
NR 16
TC 107
Z9 119
U1 1
U2 31
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378 5173
EI 1873 3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD MAR 1
PY 2007
VL 331
IS 2
BP 224
EP 227
DI 10.1016/j.ijpharm.2006.11.024
PG 4
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Pharmacology & Pharmacy
GA 144PZ
UT WOS:000244809700015
PM 17150316
DA 2025 08 17
ER

PT J
AU Ye, XL
   Cheng, SM
   Dong, YB
   Ren, J
   Su, LN
   Liu, JL
   Zhou, J
   Liu, QM
   Zhu, NW
AF Ye, Xiaolu
   Cheng, Shimeng
   Dong, Yabing
   Ren, Jie
   Su, Lina
   Liu, Jianlan
   Zhou, Jing
   Liu, Qingmei
   Zhu, Ningwen
TI Exendin 4 promotes proliferation of adipose derived stem cells through
   PI3K/Akt Wnt signaling pathways
SO NEUROSCIENCE LETTERS
LA English
DT Article
DE Exendin 4; Adipose derived stem cell; Proliferation; PI3K Akt; GSK3
   beta; Wnt beta catenin pathway
ID GLUCAGON LIKE PEPTIDE 1; SYNTHASE KINASE 3 BETA; DISEASE; ACTIVATION;
   THERAPIES; WNT; OSTEOGENESIS; EXPRESSION; ISCHEMIA; RECEPTOR
AB Adipose derived stem cell (ADSC) transplantation has emerged as a potential tool for the treatment of cardiovascular disease and skin wounds. However, with a limited renewal capacity and the need for mass cells during the engraftment, strategies are needed to enhance ADSC proliferative capacity. In this study, we explored the effects of Exendin 4, a glucagon like peptide 1 analog, on the growth of ADSCs, focusing in particular on phosphatidylinositol 3 kinase (PI3K) protein kinase B (Akt) and Wnt signaling pathways. Firstly, ADSCs were isolated and cultured in vitro. Then, flow cytometry demonstrated that ADSCs were positive for CD44, CD90 and CD29 but negative for CD31, CD34, and CD45. Exendin 4 (0 200 nM) treatment increased ADSC proliferation. In order to examine specific signaling pathways, a western blotting assay was performed. Our results demonstrate that after treated with 50 nM Exendin 4 for 48 h, the phosphorylation of PI3K, Akt, and GSK3 beta were increased and phosphorylation of beta catenin was decreased. From these results, we concluded that PI3K Akt and Wnt beta catenin signaling pathways mediate Exendin 4 induced ADSC proliferation, the function of which might contribute to the regulation of ADSC proliferation. Our findings provided new insights into the function of the mechanisms underlying Exendin 4 of ADSCs.
C1 [Ye, Xiaolu; Cheng, Shimeng; Dong, Yabing; Ren, Jie; Su, Lina; Liu, Jianlan; Zhou, Jing; Liu, Qingmei; Zhu, Ningwen] Fudan Univ, Huashan Hosp, Dept Dermatol, 12 Middle Wu Lu Mu Qi Rd, Shanghai 200040, Peoples R China.
C3 Fudan University
RP Zhu, NW (通讯作者)，Fudan Univ, Huashan Hosp, Dept Dermatol, 12 Middle Wu Lu Mu Qi Rd, Shanghai 200040, Peoples R China.
EM zhuningwen@fudan.edu.cn
RI Liu, Liqun/HRE 2145 2023; liu, jianlan/HLW 1889 2023
OI Zhu, Ningwen/0000 0003 4224 4188; 
FU National High tech R&D program (863 program) [2014AA020705]
FX The present study was supported by the National High tech R&D program
   (863 program, 2014AA020705).
CR Alexeev V, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt411
   Anagnostis P, 2011, DIABETES OBES METAB, V13, P302, DOI 10.1111/j.1463 1326.2010.01345.x
   Ban K, 2008, CIRCULATION, V117, P2340, DOI 10.1161/CIRCULATIONAHA.107.739938
   Carthy JM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019809
   Du XJ, 2014, MOL BIOL REP, V41, P3853, DOI 10.1007/s11033 014 3252 0
   Duan WJ, 2016, EXP THER MED, V12, P3107, DOI 10.3892/etm.2016.3730
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Gittenberger de Groot AC, 2010, J CELL MOL MED, V14, P1056, DOI 10.1111/j.1582 4934.2010.01077.x
   He WJ, 2016, MOL CELL ENDOCRINOL, V436, P240, DOI 10.1016/j.mce.2016.07.032
   Hyun JS, 2013, BIOTECHNOL ADV, V31, P736, DOI 10.1016/j.biotechadv.2012.11.003
   Jang YJ, 2016, FOOD FUNCT, V7, P4984, DOI [10.1039/C6FO01127F, 10.1039/c6fo01127f]
   Jia LW, 2008, BIOCHEM BIOPH RES CO, V368, P483, DOI 10.1016/j.bbrc.2008.01.097
   Kim SE, 2007, CELL SIGNAL, V19, P511, DOI 10.1016/j.cellsig.2006.08.008
   Lai Yan Ru, 2016, Zhongguo Dang Dai Er Ke Za Zhi, V18, P656
   Lee JH, 2016, J MOL CELL CARDIOL, V97, P169, DOI 10.1016/j.yjmcc.2016.05.011
   Li CB, 2015, TOXICOL IN VITRO, V30, P394, DOI 10.1016/j.tiv.2015.09.023
   Li J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.348
   Li PC, 2016, BMC NEUROSCI, V17, DOI 10.1186/s12868 016 0272 9
   Li XC, 2014, PHARMACOEPIDEM DR S, V23, P234, DOI 10.1002/pds.3542
   Li YH, 2005, DIABETES, V54, P482, DOI 10.2337/diabetes.54.2.482
   Lin CS, 2012, STEM CELLS DEV, V21, P2770, DOI 10.1089/scd.2012.0176
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Luo Xiao, 2015, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V40, P843, DOI 10.11817/j.issn.1672 7347.2015.08.004
   Mukai E, 2011, DIABETES, V60, P218, DOI 10.2337/db10 0021
   Naftilan AJ, 2011, HEART FAIL CLIN, V7, P345, DOI 10.1016/j.hfc.2011.03.006
   Nakayama M, 2009, J BIOL CHEM, V284, P1612, DOI 10.1074/jbc.M806981200
   Nishimoto T, 2016, CELL MOL BIOL, V62, P74, DOI 10.14715/cmb/2016.62.12.13
   Van Pham P, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt277
   Wang YP, 2014, FRONT BIOSCI LANDMRK, V19, P379, DOI 10.2741/4214
   Wang Z, 2015, SCI REP UK, V5, DOI 10.1038/srep15280
   Wu DQ, 2010, TRENDS BIOCHEM SCI, V35, P161, DOI 10.1016/j.tibs.2009.10.002
   Xie B. Y., 2017, BIOCH BIOPHYS RES CO, V482
   Xu JF, 2012, MOL CELL BIOCHEM, V371, P55, DOI 10.1007/s11010 012 1422 8
   Zhang D, 2011, J BIOL CHEM, V286, P44913, DOI 10.1074/jbc.M111.310052
   Zhang Y, 2016, IN VITRO CELL DEV AN, V52, P598, DOI 10.1007/s11626 016 0003 7
   Zhou Hao, 2014, Nan Fang Yi Ke Da Xue Xue Bao, V34, P1395
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
NR 37
TC 7
Z9 7
U1 2
U2 11
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304 3940
EI 1872 7972
J9 NEUROSCI LETT
JI Neurosci. Lett.
PD OCT 15
PY 2018
VL 685
BP 196
EP 202
DI 10.1016/j.neulet.2018.06.028
PG 7
WC Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology
GA GZ1LF
UT WOS:000449128900032
PM 29920298
DA 2025 08 17
ER

PT J
AU Liu, Q
   Wang, ZT
   Zhou, XH
   Tang, MY
   Tan, W
   Sun, TS
   Deng, YW
AF Liu, Qing
   Wang, Zhenting
   Zhou, Xiaohua
   Tang, Mingying
   Tan, Wei
   Sun, Tianshi
   Deng, Youwen
TI miR 342 5p inhibits osteosarcoma cell growth, migration, invasion, and
   sensitivity to Doxorubicin through targeting Wnt7b
SO CELL CYCLE
LA English
DT Article
DE Osteosarcoma (OS); Wnt/beta catenin signaling; miR 342 5p; Wnt7b
ID CANCER STEM CELLS; SIGNALING PATHWAYS; PROLIFERATION; APOPTOSIS
AB Osteosarcoma (OS) accounts for 9 percent of cancer related deaths in young people. The PI3K/Akt signaling, a well known carcinogenic signaling pathway in human cancer, cooperates with other signaling pathways such as Wnt signaling to promote cancer progression. Wnt7b, as a transforming member of the Wnt family, could activate mTORC1 through PI3K AKT signaling and is upregulated in OS. In the present study, we found that miR 342 5p inhibits Wnt7b expression via direct binding to Wnt7b 3' UTR. miR 342 5p overexpression remarkably suppressed the viability and invasion while enhanced the apoptosis of OS cells; meanwhile, Wnt7b, beta catenin, c myc, and cyclin D1 proteins were reduced while E cadherin protein showed to be increased. Consistent with its expression pattern, Wnt7b exerted oncogenic effects on OS cells. Wnt7b could significantly attenuate the impacts of miR 342 5p. In conclusion, we demonstrated a miR 342 5p/Wnt7b axis that regulates the capacity of OS cells to proliferate and to invade through Wnt/beta catenin signaling. The miR 342 5p/Wnt7b axis might be novel targets for OS targeted therapy, which needs further in vivo and clinical investigations.
C1 [Liu, Qing; Wang, Zhenting; Tan, Wei; Deng, Youwen] Cent S Univ, Xiangya Hosp 2, Dept Spine Surg, Changsha, Hunan, Peoples R China.
   [Zhou, Xiaohua; Tang, Mingying; Sun, Tianshi; Deng, Youwen] Cent S Univ, Xiangya Hosp 2, Dept Emergency Med, Changsha, Hunan, Peoples R China.
C3 Central South University; Central South University
RP Deng, YW (通讯作者)，Cent S Univ, Xiangya Hosp 2, Dept Spine Surg, Changsha, Hunan, Peoples R China.; Deng, YW (通讯作者)，Cent S Univ, Xiangya Hosp 2, Dept Emergency Med, Changsha, Hunan, Peoples R China.
EM drywdeng@csu.edu.cn
RI qing, liu/KPB 1841 2024
OI Tan, Wei/0000 0002 5739 2258
FU Hunan Science and Technology Innovation Plan [2018SK2105, kq1606001];
   Fundamental Research Funds for the Central Universities [2019zzts019,
   2019zzts809]; Key Scientific Research and Innovation Projects of Hunan
   Postgraduates [CX20190074]
FX This work was supported by the Hunan Science and Technology Innovation
   Plan [2018SK2105 and kq1606001]; the Fundamental Research Funds for the
   Central Universities [2019zzts019 and 2019zzts809] and the Key
   Scientific Research and Innovation Projects of Hunan Postgraduates
   (CX20190074).
CR Arensman MD, 2014, ONCOGENE, V33, P899, DOI 10.1038/onc.2013.23
   Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776
   Broadhead Matthew L., 2011, Sarcoma, V2011, P959248, DOI 10.1155/2011/959248
   Buil TD, 1998, BRIT J CANCER, V77, P319, DOI 10.1038/bjc.1998.49
   Chen J, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004688
   Cittelly DM, 2010, MOL CANCER, V9, DOI 10.1186/1476 4598 9 317
   Diao CY, 2014, ASIAN PAC J CANCER P, V15, P1817, DOI 10.7314/APJCP.2014.15.4.1817
   Fujii H, 2009, INT J ONCOL, V34, P1381, DOI 10.3892/ijo_00000265
   Gillette JM, 2009, CANCER BIOL THER, V8, P553, DOI 10.4161/cbt.8.6.8142
   Grady WM, 2008, ONCOGENE, V27, P3880, DOI 10.1038/onc.2008.10
   He HT, 2014, ONCOL LETT, V7, P1352, DOI 10.3892/ol.2014.1935
   He JP, 2014, ASIAN PAC J CANCER P, V15, P5967, DOI 10.7314/APJCP.2014.15.15.5967
   Hu K, 2016, ONCOL REP, V36, P1219, DOI 10.3892/or.2016.4922
   Ji F, 2013, BONE, V56, P220, DOI 10.1016/j.bone.2013.05.020
   Jin J, 2013, ASIAN PAC J CANCER P, V14, P3681, DOI 10.7314/APJCP.2013.14.6.3681
   Kirikoshi H, 2001, INT J ONCOL, V19, P779
   Li H, 2015, ONCOL LETT, V10, P1662, DOI 10.3892/ol.2015.3378
   Lin CH, 2014, ADV EXP MED BIOL, V804, P33, DOI 10.1007/978 3 319 04843 7_2
   Lindholm Evita Maria, 2019, Microrna, V8, P155, DOI 10.2174/2211536608666181206124922
   Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284
   Liu ZB, 2019, EUR REV MED PHARMACO, V23, P1418, DOI 10.26355/eurrev_201902_17098
   Longhi A, 2006, CANCER TREAT REV, V32, P423, DOI 10.1016/j.ctrv.2006.05.005
   Ma YM, 2013, BIOCHEM BIOPH RES CO, V431, P274, DOI 10.1016/j.bbrc.2012.12.118
   Ottaviani G, 2009, CANCER TREAT RES, V152, P3, DOI 10.1007/978 1 4419 0284 9_1
   Papagiannakopoulos T, 2008, BMC MED, V6, DOI 10.1186/1741 7015 6 15
   Perry JA, 2014, P NATL ACAD SCI USA, V111, pE5564, DOI 10.1073/pnas.1419260111
   Porta C, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00064
   Radisky DC, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2885
   Shiah SG, 2014, CANCER RES, V74, P7560, DOI 10.1158/0008 5472.CAN 14 0978
   Wang J, 2014, TUMOR BIOL, V35, P4859, DOI 10.1007/s13277 014 1637 2
   Wang ZL, 2016, EXP THER MED, V11, P1293, DOI 10.3892/etm.2016.3085
   Xu HD, 2014, CELL BIOCHEM BIOPHYS, V69, P163, DOI 10.1007/s12013 013 9783 5
   Yang HJ, 2016, ONCOTARGET, V7, P2709, DOI 10.18632/oncotarget.6458
   Yang JL, 2013, CURR OPIN ONCOL, V25, P398, DOI 10.1097/CCO.0b013e3283622c1b
   Yu F, 2010, ONCOGENE, V29, P4194, DOI 10.1038/onc.2010.167
   Zhang AL, 2014, CANCER CELL INT, V14, DOI 10.1186/1475 2867 14 15
   Zhang C, 2018, GENE, V672, P172, DOI 10.1016/j.gene.2018.06.030
   Zhang J, 2015, CLIN CHIM ACTA, V444, P182, DOI 10.1016/j.cca.2014.12.041
   Zheng DL, 2013, MOL CANCER RES, V11, P482, DOI 10.1158/1541 7786.MCR 12 0520
   Zheng ZH, 2015, ONCOL REP, V33, P1291, DOI 10.3892/or.2014.3687
   Zhou WY, 2014, DISCOV MED, V17, P301
NR 41
TC 41
Z9 41
U1 0
U2 8
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538 4101
EI 1551 4005
J9 CELL CYCLE
JI Cell Cycle
PY 2019
VL 18
IS 23
BP 3325
EP 3336
DI 10.1080/15384101.2019.1676087
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA KF2SV
UT WOS:000509098700008
PM 31601147
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Kong, LB
   Yang, CF
   Yu, LF
   Smith, W
   Zhu, S
   Zhu, JY
   Zhu, QS
AF Kong, Lingbo
   Yang, Chongfei
   Yu, Lifeng
   Smith, Wanli
   Zhu, Shu
   Zhu, Jinyu
   Zhu, Qingsheng
TI Pyrroloquinoline Quinine Inhibits RANKL Mediated Expression of NFATc1 in
   Part via Suppression of c Fos in Mouse Bone Marrow Cells and Inhibits
   Wear Particle Induced Osteolysis in Mice
SO PLOS ONE
LA English
DT Article
ID NUCLEAR FACTOR; OSTEOCLAST DIFFERENTIATION; SIGNALING PATHWAYS;
   IN VITRO; QUINONE; RECEPTOR; ACTIVATION; DERIVATIVES; TITANIUM
AB The effects of pyrroloquinoline quinine (PQQ) on RANKL induced osteoclast differentiation and on wear particle induced osteolysis were examined in this study. PQQ inhibited RANKL mediated osteoclast differentiation in bone marrow macrophages (BMMs) in a dose dependent manner without any evidence of cytotoxicity. The mRNA expression of c Fos, NFATc1, and TRAP in RANKL treated BMMs was inhibited by PQQ treatment. Moreover, RANKL induced c Fos and NFATc1 protein expression was suppressed by PQQ. PQQ additionally inhibited the bone resorptive activity of differentiated osteoclasts. Further a UHMWPE induced murine calvaria erosion model study was performed to assess the effects of PQQ on wear particle induced osteolysis in vivo. Mice treated with PQQ demonstrated marked attenuation of bone erosion based on Micro CT and histologic analysis of calvaria. These results collectively suggested that PQQ demonstrated inhibitory effects on osteoclast differentiation in vitro and may suppress wear particle induced osteolysis in vivo, indicating that PQQ may therefore serve as a useful drug in the prevention of bone loss.
C1 [Kong, Lingbo; Yang, Chongfei; Yu, Lifeng; Zhu, Shu; Zhu, Jinyu; Zhu, Qingsheng] Fourth Mil Med Univ, Xijing Hosp, Inst Orthoped Surg, Xian 710032, Peoples R China.
   [Smith, Wanli] Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA.
C3 Air Force Medical University; University System of Maryland; University
   of Maryland Baltimore
RP Zhu, QS (通讯作者)，Fourth Mil Med Univ, Xijing Hosp, Inst Orthoped Surg, Xian 710032, Peoples R China.
EM qingshengzhu@hotmail.co.uk
RI kong, lingbo/O 7491 2017
OI ZHU, JINYU/0000 0002 7811 752X
FU Fourth Military Medical University
FX This work was supported in part by a grant in aid for scientific
   research from the Fourth Military Medical University. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Baxter RM, 2011, CLIN ORTHOP RELAT R, V469, P2308, DOI 10.1007/s11999 010 1713 x
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Childs LM, 2001, J BONE JOINT SURG AM, V83A, P1789, DOI 10.2106/00004623 200112000 00004
   Chowanadisai W, 2010, J BIOL CHEM, V285, P142, DOI 10.1074/jbc.M109.030130
   GALLOP PM, 1993, CONNECT TISSUE RES, V29, P153, DOI 10.3109/03008209309014242
   GOLDRING SR, 1986, ARTHRITIS RHEUM US, V29, P836, DOI 10.1002/art.1780290704
   Greenfield EM, 2005, J BIOMED MATER RES B, V72B, P179, DOI 10.1002/jbm.b.30150
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   HAMAGISHI Y, 1990, J PHARMACOL EXP THER, V255, P980
   HARRIS WH, 1995, CLIN ORTHOP RELAT R, P46
   Hefferan TE, 2003, J APPL PHYSIOL, V95, P1775, DOI 10.1152/japplphysiol.00455.2002
   HOBARA N, 1988, PHARMACOLOGY, V37, P264, DOI 10.1159/000138475
   Hotokezaka H, 2002, J BIOL CHEM, V277, P47366, DOI 10.1074/jbc.M208284200
   Ingham E, 2005, BIOMATERIALS, V26, P1271, DOI 10.1016/j.biomaterials.2004.04.035
   JENSEN FE, 1994, NEUROSCIENCE, V62, P399, DOI 10.1016/0306 4522(94)90375 1
   Kim K, 2005, J BIOL CHEM, V280, P35209, DOI 10.1074/jbc.M505815200
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Kumazawa T, 2007, INT J MOL MED, V19, P765
   Kwak HB, 2010, BONE, V46, P724, DOI 10.1016/j.bone.2009.10.042
   Masui T, 2005, BIOMATERIALS, V26, P1695, DOI 10.1016/j.biomaterials.2004.05.017
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Merkel KD, 1999, AM J PATHOL, V154, P203, DOI 10.1016/S0002 9440(10)65266 2
   Mitchell AE, 1999, ANAL BIOCHEM, V269, P317, DOI 10.1006/abio.1999.4039
   Murase K, 2009, J BIOL CHEM, V290, P35209
   Nakashima T, 2009, J CLIN IMMUNOL, V29, P555, DOI 10.1007/s10875 009 9316 6
   Odkhuu E, 2012, IMMUNOL LETT, V142, P34, DOI 10.1016/j.imlet.2011.12.001
   Rucker R, 2009, ALTERN MED REV, V14, P268
   Sanchez RM, 2000, J NEUROSCI, V20, P2409
   Schwarz EM, 2000, J ORTHOPAED RES, V18, P849, DOI 10.1002/jor.1100180602
   Soysa NS, 2009, BIOCHEM BIOPH RES CO, V378, P1, DOI 10.1016/j.bbrc.2008.10.146
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tsutsumi R, 2008, J ORTHOP RES, V26, P1340, DOI 10.1002/jor.20620
   Urakami T, 1997, J NUTR SCI VITAMINOL, V43, P19, DOI 10.3177/jnsv.43.19
   Warashina H, 2003, BIOMATERIALS, V24, P3655, DOI 10.1016/S0142 9612(03)00120 0
   Wei S, 2008, PATHOL RES PRACT, V204, P695, DOI 10.1016/j.prp.2008.07.002
   XU F, 1993, BIOCHEM BIOPH RES CO, V193, P434, DOI 10.1006/bbrc.1993.1642
   Zhao QX, 2010, INT J BIOCHEM CELL B, V42, P576, DOI 10.1016/j.biocel.2009.12.018
NR 38
TC 24
Z9 25
U1 0
U2 25
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD APR 17
PY 2013
VL 8
IS 4
AR e61013
DI 10.1371/journal.pone.0061013
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 130IK
UT WOS:000317907200024
PM 23613773
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Iacovelli, R
   Santini, D
   Rizzo, M
   Felici, A
   Santoni, M
   Verzoni, E
   Masini, C
   Massari, F
   Calvani, N
   Mosca, A
   Procopio, G
AF Iacovelli, Roberto
   Santini, Daniele
   Rizzo, Mimma
   Felici, Alessandra
   Santoni, Matteo
   Verzoni, Elena
   Masini, Cristina
   Massari, Francesco
   Calvani, Nicola
   Mosca, Alessandra
   Procopio, Giuseppe
TI Bone metastases affect prognosis but not effectiveness of third line
   targeted therapies in patients with metastatic renal cell carcinoma
SO CUAJ CANADIAN UROLOGICAL ASSOCIATION JOURNAL
LA English
DT Article
ID SKELETAL RELATED EVENTS; BISPHOSPHONATES; COMPLICATIONS; PROGRESSION;
   SUNITINIB; SURVIVAL; CANCER
AB Introduction: Treatment of metastatic renal cell carcinoma (mRCC) has improved with the use of targeted therapies, but bone metastases continue to be negative prognostic factor.
   Methods: Patients with mRCC treated with everolimus (EV) or sorafenib (SO) after two previous lines of targeted therapies were included in the analysis. Overall survival (OS) and progression free survival (PFS) were assessed based on the presence of bone metastases and type of therapy; they were also adjusted based on prognostic criteria.
   Results: Of the 233 patients with mRCC, 76 had bone metastases. Of the 233 patients, EV and SO were administered in 143 and 90 patients, respectively. Median OS was 10.4 months in patients with BMs and 17.4 months in patients without bone metastases (p = 0.002). EV decreased the risk of death by 18% compared to SO (adjusted hazard ratio [HR] 0.82, 95% confidence interval [CI] 0.74 0.91; p < 0.001), with comparable effects in patients with or without bone metastases. In the same manner, EV decreased the risk of progression by 12% compared to SO (adjusted HR 0.88, 95% CI 0.82 0.96; p = 0.002), but this difference was not significant in patients without bone metastases. The major limitations of the study are its retrospective nature, the heterogeneity of the methods to detect bone metastases, and the lack of data about patients treated with bisphosphonates.
   Conclusions: The relative benefit of targeted therapies in mRCC is not affected by the presence of bone metastases, but patients without bone metastases have longer response to therapy and overall survival.
C1 [Iacovelli, Roberto; Santini, Daniele; Rizzo, Mimma; Felici, Alessandra; Santoni, Matteo; Verzoni, Elena; Masini, Cristina; Massari, Francesco; Calvani, Nicola; Mosca, Alessandra] Univ Roma La Sapienza, Dept Radiol Oncol & Human Pathol, I 00161 Rome, Italy.
   [Procopio, Giuseppe] Fdn IRCCS Ist Nazl Tumori, Div Med Oncol, Rome, Italy.
C3 Sapienza University Rome; Fondazione IRCCS Istituto Nazionale Tumori
   Milan
RP Iacovelli, R (通讯作者)，Univ Roma La Sapienza, Viale Regina Elena 324, I 00161 Rome, Italy.
EM roberto.iacovelli@alice.it
RI Iacovelli, Roberto/AAB 9850 2019; Mosca, Alessandra/O 7975 2016; Masini,
   Cristina/J 9674 2018; Massari, Francesco/K 7239 2016; Procopio,
   Giuseppe/K 2072 2016; Verzoni, Elena/K 6025 2016; Rizzo,
   Mimma/AAB 9892 2020
OI Santoni, Matteo/0000 0001 7340 6173; Mosca,
   Alessandra/0000 0003 2538 8411; Iacovelli, Roberto/0000 0002 1750 2117;
   Masini, Cristina/0000 0002 9926 8458; Massari,
   Francesco/0000 0001 6476 6871; Procopio, Giuseppe/0000 0002 2498 402X;
   Verzoni, Elena/0000 0001 9756 6112; Rizzo, Mimma/0000 0001 7743 741X; 
CR Althausen P, 1997, CANCER, V80, P1103
   Beuselinck B, 2011, ANN ONCOL, V22, P794, DOI 10.1093/annonc/mdq554
   Bianchi M, 2012, ANN ONCOL, V23, P973, DOI 10.1093/annonc/mdr362
   Christodoulou C, 2009, ONCOLOGY BASEL, V76, P209, DOI 10.1159/000201931
   Galasko C., 1981, Bone metastases, P49
   Heng DYC, 2009, J CLIN ONCOL, V27, P5794, DOI 10.1200/JCO.2008.21.4809
   Iacovelli R, 2014, AM J CLIN ONCOL CANC, V37, P611, DOI 10.1097/COC.0b013e31827de888
   Iacovelli R, 2013, EUR J CANCER, V49, P2134, DOI 10.1016/j.ejca.2013.02.032
   Ibrahim T, 2009, TUMORI J, V95, P291
   Keizman D, 2012, EUR J CANCER, V48, P1031, DOI 10.1016/j.ejca.2012.02.050
   Koga S, 2001, J UROLOGY, V166, P2126, DOI 10.1016/S0022 5347(05)65519 X
   Lipton A, 2003, CANCER, V98, P962, DOI 10.1002/cncr.11571
   Palazzo A, 2010, CURR CANCER DRUG TAR, V10, P433, DOI 10.2174/156800910791517145
   Procopio G, 2010, TUMORI J, V96, P794, DOI 10.1177/030089161009600528
   Santini D, 2012, J CLIN ONCOL, V30
   Smith MR, 2005, CANCER TREAT REV, V31, pS19, DOI 10.1016/j.ctrv.2005.09.004
   Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205
   Tunn UW, 2012, CAN J UROL, V19, P6261
   Woodward E, 2011, BONE, V48, P160, DOI 10.1016/j.bone.2010.09.008
   Zekri J, 2001, INT J ONCOL, V19, P379
NR 20
TC 6
Z9 6
U1 0
U2 1
PU CANADIAN UROLOGICAL ASSOCIATION
PI DORVAL
PA 185 DORVAL AVENUE, STE 401, DORVAL, QC H9S 5J9, CANADA
SN 1911 6470
EI 1920 1214
J9 CUAJ CAN UROL ASSOC
JI CUAJ Can. Urol. Assoc. J.
PD AUG
PY 2015
VL 9
IS 7 8
BP 263
EP 267
DI 10.5489/cuaj.2377
PG 5
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA CO9GR
UT WOS:000359483100017
PM 26316911
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Paschalis, EP
   Gamsjaeger, S
   Burr, DB
AF Paschalis, E. P.
   Gamsjaeger, S.
   Burr, D. B.
TI Bone quality in an ovariectomized monkey animal model treated with two
   doses of teriparatide for either 18 months, or 12 months followed by
   withdrawal for 6 months
SO BONE
LA English
DT Article
DE Raman microspectroscopic analysis; Bone quality; Recombinant human
   parathyroid hormone (1 34); Osteoporosis; Ovariectomized monkey
ID POSTMENOPAUSAL WOMEN; PARATHYROID HORMONE; HYDROXYAPATITE FORMATION;
   COLLAGEN QUALITY; CORTICAL BONE; PROTEOGLYCANS; MINERALIZATION; GROWTH;
   ESTROGEN; MASS
AB Previous studies of ovariectomized (OVX) monkeys, treated with recombinant human parathyroid hormone (PTH) (1 34) at 1 or 5 mu g/kg/day for 18 months or for 12 months followed by 6 months withdrawal from treatment, displayed significant changes in geometry, histomorphometry, and bone quality, but without strict tissue age criteria, of the midshaft humerus. Since bone quality significantly depends on tissue age among other factors, the aim of the present study was to establish the bone turnover independent effects of two doses of PTH, as well as the effects of treatment withdrawal on bone quality by measuring bone material composition at precisely known tissue ages ranging from osteoid, to mineralized tissue older than 373 days. Raman microspectroscopic analysis of bone tissue from the mid shaft humerus of OVX monkeys demonstrated that the clinically relevant dose of PTH administered for 18 months reverses the effects of ovariectomy on bone quality when compared against SHAM. Both doses investigated in this study restore the mineralization regulation mechanisms to SHAM levels. The study also showed that the beneficial effects induced by 12 months of clinically relevant PTH therapy were sustained after six months of therapy withdrawal.
C1 [Paschalis, E. P.; Gamsjaeger, S.] Hanusch Hosp OEGK, Ludwig Boltzmann Inst Osteol, Vienna, Austria.
   [Paschalis, E. P.; Gamsjaeger, S.] Hanusch Hosp, Med Dept 1, AUVA Trauma Ctr Meidling, Vienna, Austria.
   [Burr, D. B.] Indiana Univ Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA.
   [Burr, D. B.] Indiana Univ Purdue Univ, Dept Biomed Engn, Indianapolis IUPUI, Indianapolis, IN 46202 USA.
C3 Ludwig Boltzmann Institute; Ludwig Boltzmann Institute for Osteology;
   WGKK   Hanusch Hospital; Indiana University System; Indiana University
   Bloomington; Purdue University System; Purdue University; Purdue
   University in Indianapolis
RP Paschalis, EP (通讯作者)，Hanusch Hosp OEGK, Ludwig Boltzmann Inst Osteol, Vienna, Austria.; Paschalis, EP (通讯作者)，Hanusch Hosp, Med Dept 1, AUVA Trauma Ctr Meidling, Vienna, Austria.
EM lpaschalis@gmx.net
RI Gamsjaeger, Sonja/AAD 3956 2019
OI Paschalis, Eleftherios/0000 0002 2079 435X
FU Allgemeine Unfallversicherungsanstalt (AUVA); Austrian workers
   compensation board; Osterreichische Gesundheitskasse (OGK); Eli Lilly
   Co.
FX The present study was supported by the Allgemeine
   Unfallversicherungsanstalt (AUVA), research funds of the Austrian
   workers compensation board, and the Osterreichische Gesundheitskasse
   (OGK). It was also supported in part by Eli Lilly & Co.
CR Allen MR, 2004, BONE, V35, P1003, DOI 10.1016/j.bone.2004.07.014
   Bidan CM, 2013, ADV HEALTHC MATER, V2, P186, DOI 10.1002/adhm.201200159
   Bidan CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036336
   Birkhold AI, 2016, SCI REP UK, V6, DOI 10.1038/srep23480
   Blank RD, 2003, CONNECT TISSUE RES, V44, P134, DOI 10.1080/03008200390223918
   Bonucci E, 2014, TOXICOL PATHOL, V42, P957, DOI 10.1177/0192623313512428
   Bord S, 2001, J CLIN ENDOCR METAB, V86, P2309, DOI 10.1210/jc.86.5.2309
   BOSKEY AL, 1992, CELL MATER, V2, P209
   Boskey AL, 1997, CALCIFIED TISSUE INT, V61, P298, DOI 10.1007/s002239900339
   BOSKEY AL, 1991, CALCIFIED TISSUE INT, V49, P389, DOI 10.1007/BF02555848
   BOSKEY AL, 1992, J ORTHOPAED RES, V10, P313, DOI 10.1002/jor.1100100302
   Boskey AL, 1997, J CELL BIOCHEM, V64, P632, DOI 10.1002/(SICI)1097 4644(19970315)64:4<632::AID JCB11>3.0.CO;2 E
   Burr DB, 2010, LANCET, V375, P1672, DOI 10.1016/S0140 6736(10)60444 8
   Burr DB, 2001, J BONE MINER RES, V16, P157, DOI 10.1359/jbmr.2001.16.1.157
   CHEN CC, 1985, CALCIFIED TISSUE INT, V37, P395, DOI 10.1007/BF02553709
   Donnelly E, 2010, CALCIFIED TISSUE INT, V87, P450, DOI 10.1007/s00223 010 9404 x
   Donnelly E, 2010, J BIOMED MATER RES A, V92A, P1048, DOI 10.1002/jbm.a.32442
   Finkelstein JS, 1998, JAMA J AM MED ASSOC, V280, P1067, DOI 10.1001/jama.280.12.1067
   Fratzl P, 2004, J MATER CHEM, V14, P2115, DOI 10.1039/b402005g
   Gamsjaeger S, 2014, BONE, V69, P89, DOI 10.1016/j.bone.2014.09.012
   Gamsjaeger S, 2014, J RAMAN SPECTROSC, V45, P794, DOI 10.1002/jrs.4552
   Gamsjaeger S, 2014, J BONE MINER RES, V29, P608, DOI 10.1002/jbmr.2073
   Gamsjaeger S, 2010, BONE, V47, P392, DOI 10.1016/j.bone.2010.04.608
   Gourion Arsiquaud S, 2009, J BONE MINER RES, V24, P1565, DOI [10.1359/jbmr.090414, 10.1359/JBMR.090414]
   Hodsman AB, 1997, J CLIN ENDOCR METAB, V82, P620, DOI 10.1210/jc.82.2.620
   Horiuchi K, 1999, J BONE MINER RES, V14, P1239, DOI 10.1359/jbmr.1999.14.7.1239
   Iwaniec U T., 2013, Osteoporosis, P939
   Kazanci M, 2007, BONE, V41, P456, DOI 10.1016/j.bone.2007.04.200
   Kazanci M, 2006, J STRUCT BIOL, V156, P489, DOI 10.1016/j.jsb.2006.06.011
   Kazanci M, 2006, CALCIFIED TISSUE INT, V79, P354, DOI 10.1007/s00223 006 0011 9
   Kommareddy KP, 2010, BIOINTERPHASES, V5, P45, DOI 10.1116/1.3431524
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Lindsay R, 2004, ARCH INTERN MED, V164, P2024, DOI 10.1001/archinte.164.18.2024
   Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140 6736(97)02342 8
   McCreery R.L., 2000, Raman Spectrosc. Chem. Anal, P49, DOI DOI 10.1002/0471721646.CH4
   McNerny EMB, 2015, J BONE MINER RES, V30, P446, DOI 10.1002/jbmr.2356
   MELSEN F, 1980, ACTA PATH MICRO IM A, V88, P83
   Midura RJ, 2003, J BIOL CHEM, V278, P51462, DOI 10.1074/jbc.M307567200
   Misof BM, 2012, J BONE MINER RES, V27, P2551, DOI 10.1002/jbmr.1699
   Mochida Y, 2003, BIOCHEM BIOPH RES CO, V305, P6, DOI 10.1016/S0006 291X(03)00693 4
   Mochida Y, 2009, MATRIX BIOL, V28, P44, DOI 10.1016/j.matbio.2008.11.003
   Morris MD, 2011, CLIN ORTHOP RELAT R, V469, P2160, DOI 10.1007/s11999 010 1692 y
   Napoli N, 2018, CALCIFIED TISSUE INT, V103, P359, DOI 10.1007/s00223 018 0437 x
   Nielsen KL, 2003, J BONE MINER RES, V18, P2152, DOI 10.1359/jbmr.2003.18.12.2152
   Oshima A, 2002, J CELL BIOCHEM, V86, P792, DOI 10.1002/jcb.10272
   Paschalis EP, 2019, BONE, V120, P279, DOI 10.1016/j.bone.2018.11.004
   Paschalis EP, 2017, BONE, V95, P55, DOI 10.1016/j.bone.2016.10.029
   Paschalis EP, 2011, BONE, V49, P1232, DOI 10.1016/j.bone.2011.08.027
   Paschalis EP, 2021, BONE, V145, DOI 10.1016/j.bone.2021.115848
   Paschalis EP, 2016, J BONE MINER RES, V31, P1050, DOI 10.1002/jbmr.2780
   Paschalis EP, 2016, J BONE MINER RES, V31, P347, DOI 10.1002/jbmr.2696
   Paschalis EP, 2003, J BONE MINER RES, V18, P769, DOI 10.1359/jbmr.2003.18.4.769
   Paschalis EP, 2004, J BONE MINER RES, V19, P2000, DOI 10.1359/JBMR.040820
   Paschalis EP, 2005, J CLIN ENDOCR METAB, V90, P4644, DOI 10.1210/jc.2004 2489
   Reinwald S, 2008, J BONE MINER RES, V23, P1353, DOI 10.1359/JBMR.080516
   Reinwald S, 2011, OSTEOPOROSIS RESEARCH: ANIMAL MODELS, P159, DOI 10.1007/978 0 85729 293 3_13
   Robins SP, 2007, BIOCHEM SOC T, V35, P849, DOI 10.1042/BST0350849
   Rumpler M, 2007, J BIOMED MATER RES A, V81A, P40, DOI 10.1002/jbm.a.30940
   Rumpler M, 2008, J R SOC INTERFACE, V5, P1173, DOI 10.1098/rsif.2008.0064
   SAUREN YMHF, 1992, ANAT REC, V232, P36, DOI 10.1002/ar.1092320105
   Smith AJ, 1997, HISTOCHEM J, V29, P1, DOI 10.1023/A:1026406932452
   Thompson WR, 2011, J BONE MINER RES, V26, P618, DOI 10.1002/jbmr.236
   Tian Y, 2011, MOL CELL BIOCHEM, V355, P211, DOI 10.1007/s11010 011 0856 8
   Vahle JL, 2008, J BONE MINER RES, V23, P2033, DOI 10.1359/JBMR.080807
   Wassen MHM, 2000, J BONE MINER RES, V15, P1776, DOI 10.1359/jbmr.2000.15.9.1776
NR 65
TC 3
Z9 3
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAY
PY 2022
VL 158
AR 116366
DI 10.1016/j.bone.2022.116366
EA FEB 2022
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA ZZ8ZQ
UT WOS:000773553300009
PM 35167989
DA 2025 08 17
ER

PT J
AU Wang, KP
   Li, Y
   Lin, JX
AF Wang, KunPeng
   Li, Ye
   Lin, JinXiu
TI Identification of diagnostic biomarkers for osteoarthritis through
   bioinformatics and machine learning
SO HELIYON
LA English
DT Article
DE Osteoarthritis; Differentially expressed genes; Enrichment analysis;
   Co expression modules; Characteristic genes; Immune cell infiltration
ID RADIOGRAPHIC PROGRESSION; GENE EXPRESSION; RISK FACTORS; PROTEIN
AB Osteoarthritis (OA) is a prevalent degenerative joint disease characterized by cartilage degradation, inflammatory arthritis, and joint dysfunction. Currently, there is a lack of effective early diagnostic methods and treatment strategies for OA. Bioinformatics and biomarker research provide new possibilities for early detection and personalized therapy of OA. In this study, we investigated the molecular mechanisms of OA and important signaling pathways involved in disease progression through bioinformatics analysis. Firstly, using the limma package, we analyzed the differentially expressed genes (DEGs) between normal healthy samples and OA cartilage tissue samples. These DEGs were found to be primarily involved in biological processes such as extracellular matrix (ECM) binding, immune receptor activity, and cytokine activity, as well as signaling pathways including cytokine receptors, ECM receptor interaction, and PI3K Akt. Gene set enrichment analysis revealed that in the OA group, signaling pathways such as AMPK, B cell receptor, IL 17, and PPAR were downregulated, while calcium signaling pathway, cell adhesion molecules, ECM receptor interaction, TGF beta signaling pathway, and Wnt signaling pathway were upregulated. Additionally, we constructed a co expression module network using WGCNA and identified key modules associated with OA, from which we selected 7 most predictive OA characteristic genes. Among them, ANTXR1, KCNS3, SGCD, and LIN7A were correlated with the level of immune cell infiltration. This study elucidates the mechanisms underlying the development of OA and identifies potential diagnostic markers and therapeutic targets, providing important insights for early diagnosis and treatment of OA.
C1 [Wang, KunPeng; Li, Ye; Lin, JinXiu] Zibo First Hosp, Dept Cardiol, 4 Emeishan East Rd, Zibo 255200, Shandong, Peoples R China.
RP Lin, JX (通讯作者)，Zibo First Hosp, Dept Cardiol, 4 Emeishan East Rd, Zibo 255200, Shandong, Peoples R China.
EM 526457856@qq.com; haiker527@163.com; drlinjx@qq.com
RI Wang, Kunpeng/HCH 0099 2022
CR Al Mahrouqi MM, 2018, J ORTHOP SPORT PHYS, V48, P449, DOI 10.2519/jospt.2018.7569
   Bai B, 2016, J ORTHOP SURG RES, V11, DOI 10.1186/s13018 016 0483 x
   Bannuru RR, 2019, OSTEOARTHR CARTILAGE, V27, P1578, DOI 10.1016/j.joca.2019.06.011
   Buzzatto Leite I, 2022, Osteoarthr Cartil Open, V4
   Carlesso LC, 2017, ARTHRIT CARE RES, V69, P826, DOI 10.1002/acr.23086
   Chaganti RK, 2011, CURR REV MUSCULOSKE, V4, P99, DOI 10.1007/s12178 011 9088 5
   Cheng BF, 2020, STEM CELL TRANSL MED, V9, P273, DOI 10.1002/sctm.19 0190
   Chu CR, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3845
   Cruz JA, 2006, CANCER INFORM, V2, P59
   Feng F, 2023, ACTA BIOMATER, V158, P80, DOI 10.1016/j.actbio.2023.01.006
   Friedland DR, 2007, HEARING RES, V228, P31, DOI 10.1016/j.heares.2007.01.024
   Gao X, 2019, EXP THER MED, V18, P2479, DOI 10.3892/etm.2019.7848
   Guermazi A, 2013, RHEUM DIS CLIN N AM, V39, P567, DOI 10.1016/j.rdc.2013.02.001
   Hadzic E, 2023, EXPERT OPIN THER TAR, V27, P111, DOI 10.1080/14728222.2023.2185133
   Huet A, 2023, CYTOL GENET+, V57, P128, DOI 10.3103/S009545272302010X
   Justen H P, 2000, Mol Cell Biol Res Commun, V3, P165, DOI 10.1006/mcbr.2000.0211
   Khil PP, 2004, NAT GENET, V36, P642, DOI 10.1038/ng1368
   Ma TW, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018 018 0938 3
   Maly K, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052242
   Pickarski M, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 197
   PUJOL JP, 1991, J RHEUMATOL, V18, P76
   Sharif M, 2000, ANN RHEUM DIS, V59, P71, DOI 10.1136/ard.59.1.71
   Sniekers YH, 2008, OSTEOARTHR CARTILAGE, V16, P533, DOI 10.1016/j.joca.2008.01.002
   Steinbusch MMF, 2017, SCI REP UK, V7, DOI 10.1038/srep43558
   Sun H, 2023, HELIYON, V9, DOI 10.1016/j.heliyon.2023.e19975
   Vilím V, 2002, OSTEOARTHR CARTILAGE, V10, P707, DOI 10.1053/joca.2002.0819
   Wang B, 2021, COMB CHEM HIGH T SCR, V24, P1151, DOI 10.2174/1386207323666200902140656
   Wang Q, 2015, ACTA HISTOCHEM, V117, P40, DOI 10.1016/j.acthis.2014.10.010
   Wang YC, 2022, FRONT GENET, V13, DOI 10.3389/fgene.2022.1036156
   Weber AE, 2021, INT ORTHOP, V45, P335, DOI 10.1007/s00264 020 04838 w
   Wojdasiewicz P, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/561459
   Yoo HJ, 2023, J ORTHOP RES, V41, P583, DOI 10.1002/jor.25398
   Zhan RQ, 2019, J CELL PHYSIOL, V234, P17433, DOI 10.1002/jcp.28365
   Zhang JF, 2018, BMC MUSCULOSKEL DIS, V19, DOI 10.1186/s12891 018 1932 y
   Zhang RQ, 2019, MOL MED REP, V19, P30, DOI 10.3892/mmr.2018.9677
   Zhang W, 2016, OSTEOARTHR CARTILAGE, V24, P827, DOI 10.1016/j.joca.2015.12.004
   Zhou Q, 2022, COMPUT MATH METHOD M, V2022, DOI 10.1155/2022/8953807
   Zhu NQ, 2020, COMPUT BIOL CHEM, V85, DOI 10.1016/j.compbiolchem.2020.107225
NR 38
TC 7
Z9 7
U1 1
U2 6
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
EI 2405 8440
J9 HELIYON
JI Heliyon
PD MAR 30
PY 2024
VL 10
IS 6
AR e27506
DI 10.1016/j.heliyon.2024.e27506
EA MAR 2024
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA UV8S6
UT WOS:001250935800001
PM 38496843
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Stefanucci, A
   Marrone, A
   Agamennone, M
AF Stefanucci, Azzurra
   Marrone, Alessandro
   Agamennone, Mariangela
TI Investigation of the N BP Binding at FPPS by Combined Computational
   Approaches
SO MEDICINAL CHEMISTRY
LA English
DT Article
DE Bisphosphonate; docking; FPPS; MM GBSA; post docking refinement
ID FARNESYL PYROPHOSPHATE SYNTHASE; NITROGEN CONTAINING BISPHOSPHONATES;
   CORONAVIRUS MAIN PROTEINASE; INFLUENZA A VIRUS; DRUG DESIGN;
   MOLECULAR DYNAMICS; DIPHOSPHATE SYNTHASE; BIOLOGICAL EVALUATION;
   TERTIARY STRUCTURE; COLLECTIVE MOTION
AB Nitrogen containing bisphosphonates (N BPs) are important drugs widely used in a variety of bone resorption diseases. These compounds target the farnesyl pyrophosphate synthase (FPPS), a key enzyme of the mevalonate pathway involved in several pathologies. The inhibition of FPPS is a promising pharmacological approach and the development of structure based methods for the prediction of the enzyme inhibitor binding energy, can provide a guide for the rational design of new N BPs. In this study multiple docking and post docking strategies were applied to develop an effective computational workflow able to correctly predict the binding geometry and energy of a diverse set of known N BPs. Preliminarily, we identified a model structure of the target allowing to predict the binding pose for all studied ligands and improving the estimation of the target ligand interaction energies. A significant correlation between calculated and experimental binding affinities was found by dividing the whole group of N BPs inhibitors into two subsets according to the structure's size, suggesting that the contributions to the binding energy are differently weighted in the two groups and that the FPPS inhibition mechanism may be based on ligand dimensions. The ob tained quantitative models can be further exploited for either screening or optimization studies of newly designed N BPs.
C1 [Stefanucci, Azzurra; Marrone, Alessandro; Agamennone, Mariangela] Univ G dAnnunzio Chieti, Dipartimento Farm, I 66013 Chieti, Italy.
C3 G d'Annunzio University of Chieti Pescara
RP Agamennone, M (通讯作者)，Univ G dAnnunzio Chieti, Dipartimento Farm, Via Vestini 31, I 66013 Chieti, Italy.
EM m.agamennone@unich.it
RI Agamennone, Mariangela/J 2916 2012
OI Agamennone, Mariangela/0000 0001 5198 0051; Stefanucci,
   Azzurra/0000 0001 7525 2913; Marrone, Alessandro/0000 0002 8311 8172
FU Italian Ministero dell'Istruzione, dell'Universita e della Ricerca
FX This work was accomplished thanks to the financial support of the
   Italian Ministero dell'Istruzione, dell'Universita e della Ricerca.
CR [Anonymous], 2009, PYMOL TM VERS 1 2
   [Anonymous], 2012, MAESTR V 9 3 GLID V
   Caetano M.S., 2012, J BIOMOL STRUCT DYN, V30, P125
   Cai L, 2011, MED CHEM, V7, P121, DOI 10.2174/157340611794859343
   Cho AE, 2005, J COMPUT CHEM, V26, P915, DOI 10.1002/jcc.20222
   CHOU KC, 1984, BIOPHYS CHEM, V20, P61, DOI 10.1016/0301 4622(84)80005 8
   Chou KC, 2003, BIOCHEM BIOPH RES CO, V308, P148, DOI 10.1016/S0006 291X(03)01342 1
   Chou KC, 2005, J PROTEOME RES, V4, P1681, DOI 10.1021/pr050145a
   Chou KC, 2004, J PROTEOME RES, V3, P1284, DOI 10.1021/pr049849v
   CHOU KC, 1989, TRENDS BIOCHEM SCI, V14, P212, DOI 10.1016/0968 0004(89)90026 1
   Chou KC, 2004, CURR MED CHEM, V11, P2105, DOI 10.2174/0929867043364667
   Chou KC, 1997, FEBS LETT, V419, P49, DOI 10.1016/S0014 5793(97)01246 5
   Chou KC, 1999, BIOCHEM BIOPH RES CO, V259, P420, DOI 10.1006/bbrc.1999.0792
   Chou KC, 2000, FEBS LETT, V470, P249, DOI 10.1016/S0014 5793(00)01333 8
   CHOU KC, 1988, BIOPOLYMERS, V27, P1795, DOI 10.1002/bip.360271109
   CHOU KC, 1988, BIOPHYS CHEM, V30, P3, DOI 10.1016/0301 4622(88)85002 6
   CHOU KC, 1994, BIOPOLYMERS, V34, P143, DOI 10.1002/bip.360340114
   Chou KC, 2011, J THEOR BIOL, V273, P236, DOI 10.1016/j.jtbi.2010.12.024
   da Cunha EFF, 2012, MED CHEM RES, V21, P590, DOI 10.1007/s00044 011 9554 z
   de Graaf C, 2005, J MED CHEM, V48, P2308, DOI 10.1021/jm049650u
   De Schutter JW, 2012, BIOORGAN MED CHEM, V20, P5583, DOI 10.1016/j.bmc.2012.07.019
   De Schutter JW, 2010, BIOORG MED CHEM LETT, V20, P5781, DOI 10.1016/j.bmcl.2010.07.133
   Deprele S, 2008, BIOORG MED CHEM LETT, V18, P2878, DOI 10.1016/j.bmcl.2008.03.088
   Du QH, 2005, ANAL BIOCHEM, V337, P262, DOI 10.1016/j.ab.2004.10.003
   Du QS, 2008, CURR PROTEIN PEPT SC, V9, P248, DOI 10.2174/138920308784534005
   Du QS, 2009, J COMPUT CHEM, V30, P295, DOI 10.1002/jcc.21056
   Dunford JE, 2008, J MED CHEM, V51, P2187, DOI 10.1021/jm7015733
   Fernández D, 2013, J COMPUT AID MOL DES, V27, P739, DOI 10.1007/s10822 013 9674 2
   Hansson T, 1995, PROTEIN ENG, V8, P1137, DOI 10.1093/protein/8.11.1137
   Huang RB, 2008, BIOCHEM BIOPH RES CO, V377, P1243, DOI 10.1016/j.bbrc.2008.10.148
   Huang SY, 2010, PHYS CHEM CHEM PHYS, V12, P12899, DOI 10.1039/c0cp00151a
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Lannutti F, 2011, J MOL GRAPH MODEL, V29, P865, DOI 10.1016/j.jmgm.2011.02.002
   Li XB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028111
   Li Y, 2007, MED CHEM, V3, P576, DOI 10.2174/157340607782360362
   Liao QH, 2011, MED CHEM, V7, P24, DOI 10.2174/157340611794072698
   Lin YS, 2012, J MED CHEM, V55, P3201, DOI 10.1021/jm201657x
   Liu B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106691
   Lu YP, 2007, J CHEM INF MODEL, V47, P668, DOI 10.1021/ci6003527
   Mancini DT, 2012, J BIOMOL STRUCT DYN, V30, P125, DOI 10.1080/07391102.2012.674293
   Mao JH, 2006, J AM CHEM SOC, V128, P14485, DOI 10.1021/ja061737c
   Marma MS, 2007, J MED CHEM, V50, P5967, DOI 10.1021/jm0702884
   Martin MB, 1999, BIOCHEM BIOPH RES CO, V263, P754, DOI 10.1006/bbrc.1999.1404
   Min JL, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/701317
   Mitrofan LM, 2009, BONE, V45, P1153, DOI 10.1016/j.bone.2009.08.010
   Mönkkönen H, 2006, BRIT J PHARMACOL, V147, P437, DOI 10.1038/sj.bjp.0706628
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   Mucha A, 2011, J MED CHEM, V54, P5955, DOI 10.1021/jm200587f
   Mukherjee S, 2009, J AM CHEM SOC, V131, P8374, DOI 10.1021/ja902895p
   Sanchez VM, 2006, J PHYS CHEM B, V110, P18052, DOI 10.1021/jp063099q
   Ohno K, 2011, CURR MED CHEM, V18, P220, DOI 10.2174/092986711794088335
   Park J, 2012, BMC STRUCT BIOL, V12, DOI 10.1186/1472 6807 12 32
   POULTER CD, 1976, BIOCHEMISTRY US, V15, P1079, DOI 10.1021/bi00650a019
   Prado Prado FJ, 2008, BIOORGAN MED CHEM, V16, P5871, DOI 10.1016/j.bmc.2008.04.068
   Prado Prado FJ, 2009, BIOORGAN MED CHEM, V17, P569, DOI 10.1016/j.bmc.2008.11.075
   Qiu WR, 2015, J BIOMOL STRUCT DYN, V33, P1731, DOI 10.1080/07391102.2014.968875
   Qiu WR, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/947416
   Rocha MVJ, 2013, J BIOMOL STRUCT DYN, V31, P1175, DOI 10.1080/07391102.2012.726533
   Rondeau JM, 2006, CHEMMEDCHEM, V1, P267, DOI 10.1002/cmdc.200500059
   Russell RGG, 2007, BONE, V40, pS21, DOI 10.1016/j.bone.2007.03.002
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Simoni D, 2008, J MED CHEM, V51, P6800, DOI 10.1021/jm801003y
   Song YC, 2008, BIOORGAN MED CHEM, V16, P8959, DOI 10.1016/j.bmc.2008.08.047
   Wang JF, 2008, PROTEIN PEPTIDE LETT, V15, P27
   Wang JF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018414
   Wang JF, 2010, PROTEIN ENG DES SEL, V23, P663, DOI 10.1093/protein/gzq040
   Wang JF, 2009, BIOCHEM BIOPH RES CO, V390, P608, DOI 10.1016/j.bbrc.2009.10.014
   Wang JF, 2009, PROTEIN ENG DES SEL, V22, P349, DOI 10.1093/protein/gzp012
   Wang SQ, 2007, BIOCHEM BIOPH RES CO, V354, P634, DOI 10.1016/j.bbrc.2006.12.235
   Wei H, 2009, MED CHEM, V5, P305, DOI 10.2174/157340609788681430
   Xu RF, 2015, J BIOMOL STRUCT DYN, V33, P1720, DOI 10.1080/07391102.2014.968624
   Xu Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105018
   Yin FL, 2006, J AM CHEM SOC, V128, P3524, DOI 10.1021/ja0601639
   Zhang JW, 2002, PROTEINS, V48, P447, DOI 10.1002/prot.10173
   Zhang Rui, 2006, Med Chem, V2, P309, DOI 10.2174/157340606776930736
   Zhang YH, 2009, J AM CHEM SOC, V131, P5153, DOI 10.1021/ja808285e
NR 76
TC 8
Z9 11
U1 0
U2 12
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1573 4064
EI 1875 6638
J9 MED CHEM
JI Med. Chem.
PY 2015
VL 11
IS 5
BP 417
EP 431
DI 10.2174/1573406410666141226132630
PG 15
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA CM3LK
UT WOS:000357583400001
PM 25541745
DA 2025 08 17
ER

PT J
AU Chen, HM
   Li, MJ
   Sanchez, E
   Wang, CS
   Lee, T
   Soof, CM
   Casas, CE
   Cao, J
   Xie, CL
   Udd, KA
   DeCorso, K
   Tang, GY
   Spektor, TM
   Berenson, JR
AF Chen, Haiming
   Li, Mingjie
   Sanchez, Eric
   Wang, Cathy S.
   Lee, Tiffany
   Soof, Camilia M.
   Casas, Christian E.
   Cao, Jasmin
   Xie, Colin
   Udd, Kyle A.
   DeCorso, Kevin
   Tang, George Y.
   Spektor, Tanya M.
   Berenson, James R.
TI Combined TRAF6 Targeting and Proteasome Blockade Has Anti myeloma and
   Anti Bone Resorptive Effects
SO MOLECULAR CANCER RESEARCH
LA English
DT Article
ID REFRACTORY MULTIPLE MYELOMA; TUMOR NECROSIS FACTOR; FACTOR KAPPA B;
   COMBINATION THERAPY; KINASE ACTIVATION; PHASE I/II; BORTEZOMIB;
   INHIBITION; MELPHALAN; GROWTH
AB TNF receptor associated factor 6 (TRAF6) has been implicated in polyubiquitin mediated IL1R/TLR signaling through activation of I kappa B kinase (IKK) to regulate the NF kappa B and JNK signaling pathways. Here, TRAF6 protein was determined to be overexpressed in bone marrow mononuclear cells (BMMC) from patients with multiple myeloma. TRAF6 expression in BMMCs from patients with progressive disease is significantly elevated as compared with individuals in complete remission, with monoclonal gammopathy of undetermined significance, or healthy subjects. Furthermore, TRAF6 dominant negative (TRAF6dn) peptides were constructed which specifically reduced TRAF6 signaling and activation of IKK. TRAF6 not only reduced cellular growth but also increased the apoptosis of multiple myeloma tumor cells in a concentration dependent fashion. Because TRAF6 activates IKK through polyubiquitination, independent of its proteasome activity, a TRAF6dn peptide was combined with the proteasome inhibitors bortezomib or carfilzomib to treat multiple myeloma. Importantly, targeting of TRAF6 in the presence of proteasome inhibition enhanced anti multiple myeloma effects and also decreased TLR/TRAF6/NF kappa B related signaling. Finally, TRAF6dn dose dependently inhibited osteoclast cell formation from CD14(+) monocytes, induced with RANKL and mCSF, and markedly reduced bone resorption in dentin pits. In all, these data demonstrate that blocking TRAF6 signaling has anti multiple myeloma effects and reduces bone loss.
   Implications: The ability to target TRAF6 signaling and associated pathways in multiple myeloma suggests a promising new therapeutic approach.
C1 [Chen, Haiming; Li, Mingjie; Sanchez, Eric; Wang, Cathy S.; Lee, Tiffany; Soof, Camilia M.; Casas, Christian E.; Cao, Jasmin; Xie, Colin; Udd, Kyle A.; DeCorso, Kevin; Tang, George Y.; Spektor, Tanya M.; Berenson, James R.] Inst Myeloma & Bone Canc Res, 9201 W Sunset Blvd Ste 300, West Hollywood, CA 90069 USA.
RP Berenson, JR (通讯作者)，Inst Myeloma & Bone Canc Res, 9201 W Sunset Blvd Ste 300, West Hollywood, CA 90069 USA.
EM jberenson@imbcr.org
RI ; Tang, George/W 3219 2018; li, mingjie/HKD 9699 2023
OI Lee, Tiffany/0000 0002 6875 8200; 
FU Skirball Foundation; Annenberg Foundation (Los Angeles, CA); Kramer
   Foundation (San Francisco, CA); Myeloma Research Fund (San Jose, CA)
FX This research was supported by the Skirball Foundation, Annenberg
   Foundation (Los Angeles, CA), Kramer Foundation (San Francisco, CA), and
   Myeloma Research Fund (San Jose, CA).
CR Arron JR, 2002, CURR PROTOC IMMUNOL, V11
   Berenson JR, 2008, ANN HEMATOL, V87, P623, DOI 10.1007/s00277 008 0501 0
   Berenson JR, 2007, CLIN LYMPHOMA MYELOM, V7, pS182, DOI 10.3816/CLM.2007.s.020
   Berenson JR, 2007, CLIN CANCER RES, V13, P1762, DOI 10.1158/1078 0432.CCR 06 1812
   Berenson JR, 2014, ANN HEMATOL, V93, P89, DOI 10.1007/s00277 013 1910 2
   Berenson JR, 2013, BRIT J HAEMATOL, V160, P321, DOI 10.1111/bjh.12129
   Berenson JR, 2011, BRIT J HAEMATOL, V155, P580, DOI 10.1111/j.1365 2141.2011.08884.x
   Berenson JR, 2006, CANCER BIOL THER, V5, P1082, DOI 10.4161/cbt.5.9.3307
   Berenson JR, 2006, CANCER BIOL THER, V5, P1078, DOI 10.4161/cbt.5.9.3306
   Berenson JR, 2002, BLOOD, V99, P3163, DOI 10.1182/blood.V99.9.3163
   Berenson JR, 2001, SEMIN ONCOL, V28, P626, DOI 10.1053/sonc.2001.29542
   Boone DL, 2004, NAT IMMUNOL, V5, P1052, DOI 10.1038/ni1110
   Campbell RA, 2010, EUR J HAEMATOL, V84, P201, DOI 10.1111/j.1600 0609.2009.01384.x
   Cao Z, 1999, COLD SPRING HARB SYM, V64, P473, DOI 10.1101/sqb.1999.64.473
   Chen H, 2006, ONCOGENE, V25, P6520, DOI 10.1038/sj.onc.1209653
   Chen ZJJ, 2012, IMMUNOL REV, V246, P95, DOI 10.1111/j.1600 065X.2012.01108.x
   Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805 758
   Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092 8674(00)00126 4
   Dimopoulos M, 2013, LANCET ONCOL, V14, P1129, DOI 10.1016/S1470 2045(13)70398 X
   Emmerich CH, 2013, P NATL ACAD SCI USA, V110, P15247, DOI 10.1073/pnas.1314715110
   Hideshima T, 2011, MOL CANCER THER, V10, P2034, DOI 10.1158/1535 7163.MCT 11 0433
   Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745
   Jin W, 2008, J CLIN INVEST, V118, P1858, DOI 10.1172/JCI34257
   Kortuem KM, 2013, BLOOD, V121, P893, DOI 10.1182/blood 2012 10 459883
   Kyle RA, 2008, BLOOD, V111, P2962, DOI 10.1182/blood 2007 10 078022
   Lacy MQ, 2013, BLOOD, V122, P2305, DOI 10.1182/blood 2013 05 484782
   Lamothe B, 2007, J BIOL CHEM, V282, P4102, DOI 10.1074/jbc.M609503200
   LeBlanc R, 2002, CANCER RES, V62, P4996
   Liu AG, 2012, J BIOL CHEM, V287, P16132, DOI 10.1074/jbc.M111.310102
   Liu H, 2012, CL LYMPH MYELOM LEUK, V12, P155, DOI 10.1016/j.clml.2012.01.006
   Ma MH, 2003, CLIN CANCER RES, V9, P1136
   Munshi NC, 2013, CLIN CANCER RES, V19, P3337, DOI 10.1158/1078 0432.CCR 12 1881
   Murray MY, 2015, CELL CYCLE, V14, P2367, DOI 10.1080/15384101.2014.998067
   Parlati F, 2009, BLOOD, V114, P3439, DOI 10.1182/blood 2009 05 223677
   Poblenz AT, 2007, BIOCHEM BIOPH RES CO, V359, P510, DOI 10.1016/j.bbrc.2007.05.151
   Restuccia DF, 2009, SCIENCE, V325, P1083, DOI 10.1126/science.1179972
   Sabokbar A, 2016, CLIN REV ALLERG IMMU, V51, P16, DOI 10.1007/s12016 015 8523 6
   Sacco A, 2011, CLIN CANCER RES, V17, P1753, DOI 10.1158/1078 0432.CCR 10 2130
   Sanchez E, 2012, LEUKEMIA RES, V36, P1422, DOI 10.1016/j.leukres.2012.07.018
   Sanda T, 2005, CLIN CANCER RES, V11, P1974, DOI 10.1158/1078 0432.CCR 04 1936
   Satoh M, 2011, J PHARM PHARM SCI, V14, P78
   Schwartz RN, 2008, J MANAGE CARE PHARM, V14, pS12, DOI 10.18553/jmcp.2008.14.S7 A.12
   Shah SP, 2015, MOL CANCER RES, V13, P1163, DOI 10.1158/1541 7786.MCR 15 0135
   Toyosaki Maeda T, 2001, ARTHRITIS RES, V3, P306, DOI 10.1186/ar320
   Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597
   Yang WL, 2009, SCIENCE, V325, P1134, DOI 10.1126/science.1175065
   Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888
   Zhang HW, 2013, J BIOL CHEM, V288, P22359, DOI 10.1074/jbc.M112.442459
NR 48
TC 19
Z9 20
U1 1
U2 10
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1541 7786
EI 1557 3125
J9 MOL CANCER RES
JI Mol. Cancer Res.
PD MAY
PY 2017
VL 15
IS 5
BP 598
EP 609
DI 10.1158/1541 7786.MCR 16 0293
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA ET9KN
UT WOS:000400626200010
PM 28122920
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Cepeda, SB
   Cutini, PH
   Valle, MI
   Campelo, AE
   Massheimer, VL
   Sandoval, MJ
AF Cepeda, Sabrina B.
   Cutini, Pablo H.
   Valle, Maria I.
   Campelo, Adrian E.
   Massheimer, Virginia L.
   Sandoval, Marisa J.
TI Bone action of the phytoestrogen genistein under hypoestrogenism and
   obesity
SO MOLECULAR AND CELLULAR ENDOCRINOLOGY
LA English
DT Article
DE Genistein; Osteoblasts; Obesity; Oxidative stress
ID ADIPOSE TISSUE; DIFFERENTIATION; OSTEOPOROSIS; PROLIFERATION; AUTOPHAGY;
   ESTROGENS; ANDROGEN; LEPTIN; ALPHA; CELLS
AB Osteoporosis and obesity are prevalent diseases in menopause. The phytoestrogen genistein (Gen) is an antioxidant/anti inflammatory agent proposed as natural therapy to counteract syndromes associated to menopause. In this work we evaluated the bone effect of Gen in a stress environment induced by hypoestrogenism and obesity. Bilaterally ovariectomized female Wistar rats were fed with high fat diet (obese), or standard diet (non obese). Osteoblasts (OB) primary cultures from femoral shafts, and retroperitoneal explants of white adipose tissue (WAT) in vitro exposed to Gen were employed as experimental systems. In obese rats, bone oxidative stress revealed by enhancement on H2O2 release, and significant reduction in OB nitric oxide (NO) production, cell growth, alkaline phosphatase activity (ALP), matrix mineralization and collagen deposition was detected. In OB WAT co cultures, Gen treatment inhibited H2O2 secretion, and prompted OB differentiation. A direct action of Gen on WAT was demonstrated. The phytoestrogen inhibited H2O2 and TBARS production, and diminished the secretion of the inflammatory adipokine leptin, through a mechanism of action mediated by estrogen receptor (ER) involvement, and MAPK and PI3K signal transduction pathways participation. A directional interaction from WAT to bone was evidenced by the incubation OB with conditioned medium obtained from WAT exposed to Gen (Gen CM). The presence of Gen CM improved OB growth, and reduced H2O2 production. The antioxidative effect of Gen on obese bone cells was partially dependent on its ability to reduce leptin secretion by WAT. Altogether, the results suggest that, under obesity, Gen may improve bone metabolism through a direct action on WAT.
C1 [Cepeda, Sabrina B.; Cutini, Pablo H.; Valle, Maria I.; Campelo, Adrian E.; Massheimer, Virginia L.; Sandoval, Marisa J.] Univ Nacl Sur UNS, Consejo Nacl Invest Cient & Tecn CONICET, Dept Biol Bioquim & Farm, Inst Ciencias Biol & Biomed INBIOSUR,UNS, Bahia Blanca, Buenos Aires, Argentina.
C3 National University of the South; Consejo Nacional de Investigaciones
   Cientificas y Tecnicas (CONICET)
RP Massheimer, VL; Sandoval, MJ (通讯作者)，Univ Nacl Sur UNS, Consejo Nacl Invest Cient & Tecn CONICET, Dept Biol Bioquim & Farm, Inst Ciencias Biol & Biomed INBIOSUR,UNS, Bahia Blanca, Buenos Aires, Argentina.
EM massheim@uns.edu.ar; msandova@criba.edu.ar
OI Cutini, Pablo Hernan/0000 0003 2200 4128; MASSHEIMER,
   VIRGINIA/0000 0002 2613 8142; Cepeda, Sabrina/0000 0001 9565 9235
FU Secretaria General de Ciencia y Tecnologia (SGCyT); Universidad Nacional
   del Sur, Bahia Blanca, Argentina [PGI 24/B331]; Consejo Nacional de
   Investigaciones Cientificas y Tecnicas (CONICET, Argentina)
   [PIP 2022 0233]; Agencia Nacional de Promocion Cientifica, Argentina
   [PICT 2017 1096]
FX This research was supported by grants from the Secretaria General de
   Ciencia y Tecnologia (SGCyT), Universidad Nacional del Sur, Bahia
   Blanca, Argentina (PGI 24/B331) and Consejo Nacional de Investigaciones
   Cientificas y Tecnicas (CONICET, Argentina, PIP 2022 0233) and Agencia
   Nacional de Promocion Cientifica, Argentina (PICT 2017  1096). The
   funders were not involved in the study or manuscript preparation.
CR Abdia F, 2016, CLIMACTERIC, V19, P535, DOI 10.1080/13697137.2016.1238451
   Abuna RPF, 2016, J CELL PHYSIOL, V231, P204, DOI 10.1002/jcp.25073
   Bernasochi GB, 2019, COMPR PHYSIOL, V9, P457, DOI 10.1002/cphy.c180009
   Bitto A, 2009, J ENDOCRINOL, V200, P367, DOI 10.1677/JOE 08 0206
   Bjune JI, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.828780
   Cassano S, 2014, METABOLISM, V63, P1272, DOI 10.1016/j.metabol.2014.06.010
   Cepeda S, 2019, Rol del fitoestrogeno genisteina en los sistemas vascular y oseo, P160
   Cepeda SB, 2020, J PHYSIOL BIOCHEM, V76, P99, DOI 10.1007/s13105 019 00722 3
   Coelho M, 2013, ARCH MED SCI, V9, P191, DOI 10.5114/aoms.2013.33181
   Compston JE, 2011, AM J MED, V124, P1043, DOI 10.1016/j.amjmed.2011.06.013
   Cooke PS, 2004, EXP BIOL MED, V229, P1127, DOI 10.1177/153537020422901107
   Crescitelli M.C., 2022, Efectos del estrogeno estrona en la biologia osea y calcificaciones vasculares, P150
   Cutini PH, 2022, VASC MED, V27, P425, DOI 10.1177/1358863X221112168
   Cutini PH, 2019, MOL CELL ENDOCRINOL, V498, DOI 10.1016/j.mce.2019.110543
   Declercq H, 2004, BIOMATERIALS, V25, P757, DOI 10.1016/S0142 9612(03)00580 5
   dos Santos LE, 2023, J MED FOOD, V26, P104, DOI 10.1089/jmf.2022.0055
   Ehrlich PJ, 2002, OSTEOPOROSIS INT, V13, P688, DOI 10.1007/s001980200095
   Heino TJ, 2004, EXP CELL RES, V294, P458, DOI 10.1016/j.yexcr.2003.11.016
   Hellings A, 2019, CURR DEV NUTR, V3, DOI 10.1093/cdn/nzz121
   Huang Z, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.608680
   Johnston BD, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/635023
   Kling JM, 2014, J WOMENS HEALTH, V23, P563, DOI 10.1089/jwh.2013.4611
   Koenig S, 2014, BRAIN BEHAV IMMUN, V36, P128, DOI 10.1016/j.bbi.2013.10.019
   Kozakowski J, 2017, MENOPAUSE REV, V16, P61, DOI 10.5114/pm.2017.68594
   Kurylowicz A, 2020, NUTRIENTS, V12, DOI 10.3390/nu12020582
   Li J, 2020, CYTOKINE GROWTH F R, V52, P88, DOI 10.1016/j.cytogfr.2020.02.003
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Manolagas SC, 2013, NAT REV ENDOCRINOL, V9, P699, DOI 10.1038/nrendo.2013.179
   Maury E, 2010, MOL CELL ENDOCRINOL, V314, P1, DOI 10.1016/j.mce.2009.07.031
   Megaloikonomos PD, 2018, CURR PHARM BIOTECHNO, V19, P19, DOI 10.2174/1389201019666180418101323
   Michelin RM, 2016, DIABET METAB SYND OB, V9, P63, DOI 10.2147/DMSO.S97600
   Rochester E, 2019, FOOD FUNCT, V10, P6851, DOI [10.1039/c9fo01292c, 10.1039/C9FO01292C]
   Shin S, 2013, BRIT J NUTR, V110, P1926, DOI 10.1017/S0007114513001219
   Valle MI, 2024, MOL CELL ENDOCRINOL, V583, DOI 10.1016/j.mce.2023.112142
   Wiren KM, 2002, J ENDOCRINOL, V175, P683, DOI 10.1677/joe.0.1750683
   Yang YH, 2021, FREE RADICAL BIO MED, V166, P226, DOI 10.1016/j.freeradbiomed.2021.02.025
   Zhang Y, 2021, J CELL PHYSIOL, V236, P7874, DOI 10.1002/jcp.30414
NR 37
TC 1
Z9 1
U1 2
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0303 7207
EI 1872 8057
J9 MOL CELL ENDOCRINOL
JI Mol. Cell. Endocrinol.
PD DEC 1
PY 2024
VL 594
AR 112388
DI 10.1016/j.mce.2024.112388
EA OCT 2024
PG 11
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA J8Q8R
UT WOS:001339662100001
PM 39419340
DA 2025 08 17
ER

PT J
AU Zakaria, M
   Matta, J
   Honjol, Y
   Schupbach, D
   Mwale, F
   Harvey, E
   Merle, G
AF Zakaria, Matthew
   Matta, Justin
   Honjol, Yazan
   Schupbach, Drew
   Mwale, Fackson
   Harvey, Edward
   Merle, Geraldine
TI Decoding Cold Therapy Mechanisms of Enhanced Bone Repair through Sensory
   Receptors and Molecular Pathways
SO BIOMEDICINES
LA English
DT Article
DE cold; bone healing; tissue engineering; hypoxia; vasculature;
   osteogenesis; shock proteins; osteoblasts
ID WATER IMMERSION; BLOOD FLOW; METABOLISM; CHANNELS; PIMONIDAZOLE;
   ANGIOGENESIS; OSTEOBLASTS; EXPRESSION; GROWTH; TISSUE
AB Applying cold to a bone injury can aid healing, though its mechanisms are complex. This study investigates how cold therapy impacts bone repair to optimize healing. Cold was applied to a rodent bone model, with the physiological responses analyzed. Vasoconstriction was mediated by an increase in the transient receptor protein channels (TRPs), transient receptor potential ankyrin 1 (TRPA1; p = 0.012), and transient receptor potential melastatin 8 (TRPM8; p < 0.001), within cortical defects, enhancing the sensory response and blood flow regulation. Cold exposure also elevated hypoxia (p < 0.01) and vascular endothelial growth factor expression (VEGF; p < 0.001), promoting angiogenesis, vital for bone regeneration. The increased expression of osteogenic proteins peroxisome proliferator activated receptor gamma coactivator (PGC 1 alpha; p = 0.039) and RNA binding motif protein 3 (RBM3; p < 0.008) suggests that the reparative processes have been stimulated. Enhanced osteoblast differentiation and the presence of alkaline phosphatase (ALP) at day 5 (three fold, p = 0.021) and 10 (two fold, p < 0.001) were observed, along with increased osteocalcin (OCN) at day 10 (two fold, p = 0.019), indicating the presence of mature osteoblasts capable of mineralization. These findings highlight cold therapy's multifaceted effects on bone repair, offering insights for therapeutic strategies.
C1 [Zakaria, Matthew; Matta, Justin; Honjol, Yazan; Schupbach, Drew; Harvey, Edward; Merle, Geraldine] McGill Univ, Fac Med, Surg & Intervent Sci Div, Montreal, PQ H3A 2B2, Canada.
   [Schupbach, Drew; Harvey, Edward] McGill Univ, Fac Med, Dept Surg, Montreal, PQ H3A 0C5, Canada.
   [Mwale, Fackson] Jewish Gen Hosp, Lady Davis Inst Med Res, Lady Davies Inst, 3755 Cote St Catherine Rd,Room 602, Montreal, PQ H3T 1E2, Canada.
   [Merle, Geraldine] Ecole Polytech Montreal, Dept Chem Engn, Montreal, PQ H3T 1J4, Canada.
C3 McGill University; McGill University; Lady Davis Institute; Jewish
   General Hospital   Montreal; Universite de Montreal; Polytechnique
   Montreal
RP Merle, G (通讯作者)，McGill Univ, Fac Med, Surg & Intervent Sci Div, Montreal, PQ H3A 2B2, Canada.; Merle, G (通讯作者)，Ecole Polytech Montreal, Dept Chem Engn, Montreal, PQ H3T 1J4, Canada.
EM matthew.zakaria@mail.mcgill.ca; justin.matta@mail.mcgill.ca;
   yazan.honjol@mail.mcgill.ca; drew.schupbach@mail.mcgill.ca;
   fackson.mwale@mcgill.ca; edward.harvey@mcgill.ca;
   geraldine.merle@polymtl.ca
RI Matta, Justin/KBD 0766 2024
OI harvey, edward/0000 0003 3934 8920; Zakaria, Matthew/0009 0008 4440 7423
FU Merle; NSERC; FRQS chercheur boursier J1
FX This research was funded by Merle, NSERC discovery, and FRQS chercheur
   boursier J1.
CR Abe Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03868 8
   Abhinand CS, 2016, J CELL COMMUN SIGNAL, V10, P347, DOI 10.1007/s12079 016 0352 8
   Aisha MD, 2014, EXP CELL RES, V326, P46, DOI 10.1016/j.yexcr.2014.06.003
   Ali E, 2021, BONE JOINT RES, V10, P611, DOI 10.1302/2046 3758.109.BJR 2020 0497.R1
   Arteel GE, 1998, EUR J BIOCHEM, V253, P743, DOI 10.1046/j.1432 1327.1998.2530743.x
   Aubdool AA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6732
   Boonrungsiman S, 2012, P NATL ACAD SCI USA, V109, P14170, DOI 10.1073/pnas.1208916109
   Buccoliero C, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094670
   Casali C, 2024, EUR J CELL BIOL, V103, DOI 10.1016/j.ejcb.2023.151373
   Castano D, 2019, TISSUE ENG PT A, V25, P554, DOI [10.1089/ten.tea.2018.0191, 10.1089/ten.TEA.2018.0191]
   Chen HL, 2022, J BONE MINER METAB, V40, P1, DOI 10.1007/s00774 021 01263 w
   Cheng Y, 2019, SMALL, V15, DOI 10.1002/smll.201904290
   Cheng ZQ, 2020, J BONE MINER RES, V35, P143, DOI 10.1002/jbmr.3864
   Coassin M, 2010, BRIT J OPHTHALMOL, V94, P1678, DOI 10.1136/bjo.2009.168864
   Dey P, 2024, COMMUN BIOL, V7, DOI 10.1038/s42003 024 06196 4
   Du JK, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.733582
   Duvall CL, 2007, J BONE MINER RES, V22, P286, DOI 10.1359/JBMR.061103
   Earley S, 2015, PHYSIOL REV, V95, P645, DOI 10.1152/physrev.00026.2014
   EINHORN TA, 1988, CLIN ORTHOP RELAT R, P219
   El Husseiny HM, 2022, MATER TODAY BIO, V13, DOI 10.1016/j.mtbio.2021.100186
   Fowler EP, 1942, ARCHIV OTOLARYNGOL, V36, P455
   Gregson W, 2011, AM J SPORT MED, V39, P1316, DOI 10.1177/0363546510395497
   Hang K, 2018, CELL STRESS CHAPERON, V23, P1153, DOI 10.1007/s12192 018 0932 z
   Hu YJ, 2022, J CELL PHYSIOL, V237, P3788, DOI 10.1002/jcp.30852
   Ihsan M, 2021, FRONT SPORTS ACT LIV, V3, DOI 10.3389/fspor.2021.714148
   Iommarini L, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00286
   Jansky L, 1996, EUR J APPL PHYSIOL O, V72, P445, DOI 10.1007/BF00242274
   Kim DY, 2018, BIOCHEM BIOPH RES CO, V498, P459, DOI 10.1016/j.bbrc.2018.02.209
   Kim JC, 2005, ACTA PHYSIOL SCAND, V183, P389, DOI 10.1111/j.1365 201X.2005.01415.x
   Kleiter MM, 2006, INT J RADIAT ONCOL, V64, P592, DOI 10.1016/j.ijrobp.2005.09.010
   Krock Bryan L, 2011, Genes Cancer, V2, P1117, DOI 10.1177/1947601911423654
   Larson C, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17165740
   Leegwater NC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171492
   Li JY, 2024, WORLD J STEM CELLS, V16, DOI 10.4252/wjsc.v16.i2.151
   Lieben Liesbet, 2012, Front Endocrinol (Lausanne), V3, P99, DOI 10.3389/fendo.2012.00099
   Lindquist JA, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964 018 0274 6
   McGee Lawrence ME, 2014, BONE, V66, P277, DOI 10.1016/j.bone.2014.06.022
   McKee MD, 2011, CELLS TISSUES ORGANS, V194, P313, DOI 10.1159/000324244
   McKemy DD, 2013, ACS CHEM NEUROSCI, V4, P238, DOI 10.1021/cn300193h
   Molkenova A, 2024, ADV SCI, V11, DOI 10.1002/advs.202306684
   Morgan R, 2024, CELL REP MED, V5, DOI 10.1016/j.xcrm.2024.101607
   Negri S, 2020, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01618
   Nie YZ, 2015, INT J CLIN EXP PATHO, V8, P10875
   Nielsen MM, 2005, J INSECT PHYSIOL, V51, P1320, DOI 10.1016/j.jinsphys.2005.08.002
   Oryan A, 2015, BIOMED ENVIRON SCI, V28, P57, DOI 10.3967/bes2015.006
   Pan Y, 2018, PFLUG ARCH EUR J PHY, V470, P779, DOI 10.1007/s00424 017 2085 9
   Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092 8674(00)81410 5
   SCHOUTENS A, 1979, AM J PHYSIOL, V236, pH1, DOI 10.1152/ajpheart.1979.236.1.H1
   Shakurov AV, 2023, J THERM BIOL, V113, DOI 10.1016/j.jtherbio.2023.103501
   Shi HZ, 2019, STRESS, V22, P366, DOI 10.1080/10253890.2019.1568987
   Szczsny G., 2018, Trauma Surgery, DOI [10.5772/intechopen.76252, DOI 10.5772/INTECHOPEN.76252]
   Tanaka T, 2010, AM J PHYSIOL REG I, V298, pR661, DOI 10.1152/ajpregu.00732.2009
   Thapa D, 2021, ELIFE, V10, DOI [10.7554/eLife.70153, 10.7554/eLife.70153.sa0, 10.7554/eLife.70153.sa1, 10.7554/eLife.70153.sa2]
   Vrenken KS, 2016, BBA MOL CELL RES, V1863, P1436, DOI 10.1016/j.bbamcr.2015.11.008
   Wang HB, 2013, CELL BIOL INT, V37, P1259, DOI 10.1002/cbin.10148
   Wang Qian, 2020, Biomater Transl, V1, P1, DOI 10.3877/cma.j.issn.2096 112X.2020.01.001
   Wang XR, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.599281
   White GE, 2013, EXTREME PHYSIOL MED, V2, DOI 10.1186/2046 7648 2 26
   Xu L, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.22
   Xue Y, 2009, CELL METAB, V9, P99, DOI 10.1016/j.cmet.2008.11.009
   Zakaria M, 2025, TISSUE ENG PT A, V31, P303, DOI [10.1089/ten.tea.2024.0069, 10.1089/ten.TEA.2024.0069]
   Zeng Zhao Lin, 2022, Biomater Transl, V3, P175, DOI 10.12336/biomatertransl.2022.03.002
   Zhang C, 2021, ACTA BIOMATER, V122, P101, DOI 10.1016/j.actbio.2020.12.042
   Zhang ZY, 2021, INT J BIOL SCI, V17, P2853, DOI 10.7150/ijbs.60354
NR 64
TC 2
Z9 3
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2227 9059
J9 BIOMEDICINES
JI Biomedicines
PD SEP
PY 2024
VL 12
IS 9
AR 2045
DI 10.3390/biomedicines12092045
PG 17
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA H8V2Q
UT WOS:001326153200001
PM 39335558
OA gold
DA 2025 08 17
ER

PT J
AU Zhang, DJ
   Jiang, YF
   Song, DW
   Zhu, ZK
   Zhou, C
   Dai, L
   Xu, X
AF Zhang, Dongjiao
   Jiang, Yanfei
   Song, Dawei
   Zhu, Zhenkun
   Zhou, Cong
   Dai, Li
   Xu, Xin
TI Tyrosine protein phosphatase non receptor type 2 inhibits alveolar bone
   resorption in diabetic periodontitis via dephosphorylating CSF1 receptor
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE 25(OH)2D(3); alveolar bone resorption; CSF1R; diabetic periodontitis;
   tyrosine protein phosphatase non receptor type 2
ID OSTEOCLAST DIFFERENTIATION; NEGATIVE REGULATOR; SIGNALING PATHWAY;
   TC PTP; CELL; MELLITUS; AUTOPHAGY; LIGAND; TCPTP
AB Tyrosine protein phosphatase non receptor type 2 (PTPN2) is an important protection factor for diabetes and periodontitis, but the underlying mechanism remains elusive. This study aimed to identify the substrate of PTPN2 in mediating beneficial effects of 25 Hydroxyvitamin D 3 (25(OH)2D(3)) on diabetic periodontitis. 25(OH)2D(3) photo affinity probe was synthesized with the minimalist linker and its efficacy to inhibit alveolar bone loss, and inflammation was evaluated in diabetic periodontitis mice. The probe was used to pull down the lysates of primary gingival fibroblasts. We identified PTPN2 as a direct target of 25(OH)2D(3), which effectively inhibited inflammation and bone resorption in diabetic periodontitis mice. In addition, we found that colony stimulating factor 1 receptor (CSF1R) rather than JAK/STAT was the substrate of PTPN2 to regulate bone resorption. PTPN2 direct interacted with CSF1R and dephosphorylated Tyr807 residue. In conclusion, PTPN2 dephosphorylates CSF1R at Y807 site and inhibits alveolar bone resorption in diabetic periodontitis mice. PTPN2 and CSF1R are potential targets for the therapy of diabetic periodontitis or other bone loss related diseases.
C1 [Zhang, Dongjiao; Zhu, Zhenkun; Zhou, Cong; Dai, Li; Xu, Xin] Shandong Univ, Sch Stomatol, Shandong Prov Key Lab Oral Tissue Regenerat, Jinan, Shandong, Peoples R China.
   [Zhang, Dongjiao; Zhu, Zhenkun; Zhou, Cong; Dai, Li; Xu, Xin] Shandong Univ, Sch Stomatol, Dept Implantol, 44 1 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.
   [Jiang, Yanfei] Tsinghua Univ, Beijing Tsinghua Changgung Hosp, Beijing, Peoples R China.
   [Song, Dawei] Seventh Peoples Hosp Shenzhen, Shenzhen, Peoples R China.
C3 Shandong University; Shandong University; Tsinghua University
RP Xu, X (通讯作者)，Shandong Univ, Sch Stomatol, Dept Implantol, 44 1 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.
EM xinxu@sdu.edu.cn
FU Department of Science & Technology of Shandong Province [2014fwyyd05];
   Fundamental Research Funds of Shandong University [2018GN024]
FX This study was funded by the Department of Science & Technology of
   Shandong Province (No. 2014fwyyd05 to Xu Xin) and the Fundamental
   Research Funds of Shandong University (No. 2018GN024 to Dongjiao Zhang).
   We thank Liu Xiao Hui of Tianjin University (Tianjin, China) for help
   with probe synthesis.
CR Abdo JA, 2013, J PERIODONTOL, V84, P1401, DOI 10.1902/jop.2012.120366
   Carminati SA, 2018, BIOCELL, V42, P13, DOI 10.32604/biocell.2018.07008
   Aoki N, 2002, MOL ENDOCRINOL, V16, P58, DOI 10.1210/me.16.1.58
   Aranow C, 2011, J INVEST MED, V59, P881, DOI 10.2310/JIM.0b013e31821b8755
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bascones Martínez A, 2015, MED CLIN BARCELONA, V145, P31, DOI 10.1016/j.medcli.2014.07.019
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Christakos S, 2003, J CELL BIOCHEM, V88, P695, DOI 10.1002/jcb.10423
   Doody KM, 2012, ARTHRITIS RHEUM US, V64, P752, DOI 10.1002/art.33399
   Engebretson S, 2013, J CLIN PERIODONTOL, V40, pS153, DOI [10.1902/jop.2013.1340017, 10.1111/jcpe.12084]
   Giraud Billoud M, 2018, BIOCELL, V42, P35, DOI 10.32604/biocell.2018.07010
   Giulietti A, 2007, DIABETES RES CLIN PR, V77, P47, DOI 10.1016/j.diabres.2006.10.007
   Gully N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100838
   Hajishengallis G, 2015, NAT REV IMMUNOL, V15, P30, DOI 10.1038/nri3785
   Thi HTH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162724
   Kim JH, 2014, ACTA ODONTOL SCAND, V72, P265, DOI 10.3109/00016357.2013.822551
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Li H, 2013, STEROIDS, V78, P115, DOI 10.1016/j.steroids.2012.10.015
   Li XJ, 2000, CLIN MICROBIOL REV, V13, P547, DOI 10.1128/CMR.13.4.547 558.2000
   Li ZQ, 2013, ANGEW CHEM INT EDIT, V52, P8551, DOI 10.1002/anie.201300683
   Chávarry NGM, 2009, ORAL HLTH PREV DENT, V7, P107
   Salvi GE, 2008, J CLIN PERIODONTOL, V35, P398, DOI 10.1111/j.1600 051X.2008.01282.x
   Shields BJ, 2008, CANCER CELL, V14, P166, DOI 10.1016/j.ccr.2008.06.003
   Shields BJ, 2013, MOL CELL BIOL, V33, P557, DOI 10.1128/MCB.01016 12
   Simoncic PD, 2006, MOL CELL BIOL, V26, P4149, DOI 10.1128/MCB.01932 05
   Simoncic PD, 2002, CURR BIOL, V12, P446, DOI 10.1016/S0960 9822(02)00697 8
   van Schoor N, 2017, ENDOCRIN METAB CLIN, V46, P845, DOI 10.1016/j.ecl.2017.07.002
   Yamamoto T, 2002, BIOCHEM BIOPH RES CO, V297, P811, DOI 10.1016/S0006 291X(02)02291 X
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yu WF, 2012, J BIOL CHEM, V287, P13694, DOI 10.1074/jbc.M112.355610
NR 30
TC 10
Z9 11
U1 0
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1582 1838
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD OCT
PY 2019
VL 23
IS 10
BP 6690
EP 6699
DI 10.1111/jcmm.14545
EA AUG 2019
PG 10
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA JN9WX
UT WOS:000484246100001
PM 31373168
OA Green Published
DA 2025 08 17
ER

PT J
AU Shen, YP
   Zou, Y
   Bie, BL
   Lv, YG
AF Shen, Yaping
   Zou, Yang
   Bie, Binglin
   Lv, Yonggang
TI Hierarchically Released Liquid Metal Nanoparticles for Mild Photothermal
   Therapy/Chemotherapy of Breast Cancer Bone Metastases via Remodeling
   Tumor Stromal Microenvironment
SO ADVANCED HEALTHCARE MATERIALS
LA English
DT Article
DE bone metastases; hierarchical drug releases; mild photothermal therapy;
   tumor penetrations; tumor stromal microenvironments
ID EXTRACELLULAR MATRIX; TGF BETA; DRUG DELIVERY; FIBROBLASTS; CELLS
AB Currently, the treatment strategy for bone metastasis is mainly to inhibit the growth of tumor cells and the activity of osteoclasts, while ignoring the influence of the tumor stromal microenvironment (TSM) on the progression of bone metastasis. Herein, a dual target liquid metal (LM) based drug delivery system (DDS) with favorable photothermal performance is designed to spatially program the delivery of multiple therapeutic agents to enhance the treatment of bone metastasis through TSM remodeling. Briefly, mesoporous silicon coated LM is integrated into zeolitic imidazolate framework 8 (ZIF 8) with both bone seeking and tumor targeting capacities. Curcumin (Cur), a tumor microenvironment modulator, is encapsulated into ZIF 8, and doxorubicin (DOX) is enclosed inside mesoporous silicon. Specific accumulation of the LM based DDS in bone metastases first relieves the tumor stroma by releasing Cur in response to the acidic tumor microenvironment and then releases DOX deep into the tumor under near infrared light irradiation. The combined strategy of the LM based DDS and mild photothermal therapy has been shown to effectively restrain cross talk between osteoclasts and tumor cells by inhibiting the secretion of transforming growth factor & beta;, degrading extracellular matrix components, and increasing infiltration of CD4(+) and CD8(+) T cells, which provides a promising strategy for the treatment of bone metastases.
C1 [Shen, Yaping] Chongqing Univ, Bioengn Coll, Mechanobiol & Regenerat Med Lab, 174 Shazheng St, Chongqing 400044, Peoples R China.
   [Zou, Yang] Wuhan Text Univ, Sch Environm Engn, State Key Lab New Text Mat & Adv Proc Technol, 1 Sunshine Ave, Wuhan 430200, Hubei, Peoples R China.
   [Bie, Binglin; Lv, Yonggang] Wuhan Text Univ, State Key Lab New Text Mat & Adv Proc Technol, 1 Sunshine Ave, Wuhan 430200, Hubei, Peoples R China.
C3 Chongqing University; Wuhan Textile University; Wuhan Textile University
RP Lv, YG (通讯作者)，Wuhan Text Univ, State Key Lab New Text Mat & Adv Proc Technol, 1 Sunshine Ave, Wuhan 430200, Hubei, Peoples R China.
EM yglv@wtu.edu.cn
FU National Natural Science Foundation of China [11872134]; Natural Science
   Foundation of Hubei, China [2022CFA023]
FX Acknowledgements This work was supported in part by grants from the
   National Natural Science Foundation of China (grant No. 11872134), and
   the Natural Science Foundation of Hubei, China (grant No. 2022CFA023).
CR Boche M, 2018, DRUG DELIV TRANSL RE, V8, P1078, DOI 10.1007/s13346 018 0558 9
   Chakravarthy A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 06654 8
   Chauhan VP, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3516
   Chen TW, 2022, CANCER LETT, V543, DOI 10.1016/j.canlet.2022.215795
   Chen Y, 2021, NAT REV CLIN ONCOL, V18, P792, DOI 10.1038/s41571 021 00546 5
   Clézardin P, 2021, PHYSIOL REV, V101, P797, DOI 10.1152/physrev.00012.2019
   Dai Q, 2018, ACS NANO, V12, P8423, DOI 10.1021/acsnano.8b03900
   Ding XL, 2022, BIOMATERIALS, V281, DOI 10.1016/j.biomaterials.2022.121369
   Esposito M, 2021, NAT CELL BIOL, V23, P257, DOI 10.1038/s41556 021 00641 w
   Harbeck N, 2019, NAT REV DIS PRIMERS, V5, DOI [10.1038/s41572 019 0111 2, 10.1038/s41572 019 0122 z]
   Hofbauer LC, 2021, NAT REV CLIN ONCOL, V18, P488, DOI 10.1038/s41571 021 00499 9
   Horn LA, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI155148
   Hu JJ, 2019, BIOMATERIALS, V207, P76, DOI 10.1016/j.biomaterials.2019.03.043
   Jensen P, 2022, BLOOD ADV, V6, P2549, DOI 10.1182/bloodadvances.2021006330
   Jiang W, 2018, ACS APPL MATER INTER, V10, P34513, DOI 10.1021/acsami.8b13487
   Katta S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194891
   Kunihiro AG, 2022, J NUTR BIOCHEM, V99, DOI 10.1016/j.jnutbio.2021.108842
   Lei ZD, 2019, ADV MATER, V31, DOI 10.1002/adma.201807456
   Liu J, 2022, J COLLOID INTERF SCI, V617, P315, DOI 10.1016/j.jcis.2022.02.132
   Liyanage PY, 2019, BBA REV CANCER, V1871, P419, DOI 10.1016/j.bbcan.2019.04.006
   Mao XQ, 2021, MOL CANCER, V20, DOI 10.1186/s12943 021 01428 1
   Pan QS, 2018, ACS APPL MATER INTER, V10, P33070, DOI 10.1021/acsami.8b13393
   Rejinold NS, 2018, ACS APPL MATER INTER, V10, P28458, DOI 10.1021/acsami.8b10426
   Roper DK, 2007, J PHYS CHEM C, V111, P3636, DOI 10.1021/jp064341w
   Shen YP, 2023, ACTA BIOMATER, V157, P578, DOI 10.1016/j.actbio.2022.11.044
   Shen YP, 2022, COLLOID SURFACE B, V219, DOI 10.1016/j.colsurfb.2022.112826
   Shi Y, 2020, THERANOSTICS, V10, P7921, DOI 10.7150/thno.49577
   Subhan MA, 2019, TRANSL RES, V214, P62, DOI 10.1016/j.trsl.2019.07.006
   Tian QW, 2011, ACS NANO, V5, P9761, DOI 10.1021/nn203293t
   Trivedi T, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11111643
   Vanderburgh JP, 2019, J CONTROL RELEASE, V311, P257, DOI 10.1016/j.jconrel.2019.08.038
   Wang BH, 2017, J CONTROL RELEASE, V268, P225, DOI 10.1016/j.jconrel.2017.10.029
   Wang XL, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201800318
   Wang ZF, 2022, ACTA BIOMATER, V137, P276, DOI 10.1016/j.actbio.2021.10.028
   Xiao Y, 2021, ACTA BIOMATER, V122, P291, DOI 10.1016/j.actbio.2020.12.045
   Yamauchi M, 2020, MATRIX BIOL, V91 92, P8, DOI 10.1016/j.matbio.2020.05.001
   Yin XL, 2022, COLLOID SURFACE B, V216, DOI 10.1016/j.colsurfb.2022.112507
   Zhang L, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 30105 0
   Zheng M, 2015, ACS APPL MATER INTER, V7, P22181, DOI 10.1021/acsami.5b04315
NR 39
TC 19
Z9 19
U1 14
U2 84
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2192 2640
EI 2192 2659
J9 ADV HEALTHC MATER
JI Adv. Healthc. Mater.
PD OCT
PY 2023
VL 12
IS 27
DI 10.1002/adhm.202301080
EA JUL 2023
PG 14
WC Engineering, Biomedical; Nanoscience & Nanotechnology; Materials
   Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Science & Technology   Other Topics; Materials Science
GA W1BR4
UT WOS:001030154800001
PM 37436138
OA Bronze
DA 2025 08 17
ER

PT J
AU Lima, CAD
   Javorski, NR
   Souza, APO
   Barbosa, AD
   Valença, APMC
   Crovella, S
   Souza, PRE
   Silva, JD
   Sandrin Garcia, P
AF Lima, C. A. D.
   Javorski, N. R.
   Souza, A. P. O.
   Barbosa, A. D.
   Valenca, A. P. M. C.
   Crovella, S.
   Souza, P. R. E.
   De Azevedo Silva, J.
   Sandrin Garcia, P.
TI Polymorphisms in key bone modulator cytokines genes influence
   bisphosphonates therapy in postmenopausal women
SO INFLAMMOPHARMACOLOGY
LA English
DT Article
DE Osteoimmunology; Osteoporosis therapy; Bone mineral density; Bone
   biochemical markers; Genetics of osteoporosis
ID ALENDRONATE TREATMENT; MINERAL DENSITY; LEPTIN RECEPTOR; OSTEOPOROSIS;
   ASSOCIATION; PREVENTION; CELLS; INTERFERON; IL23R; TH17
AB Osteoporosis is a multifactorial and debilitating disease resulting from decreased bone mineral density (BMD) and loss of tissue microarchitecture. Ineffective therapies may lead to bone fractures and subsequent death. Single nucleotide polymorphisms (SNPs) in key immune regulator genes have been associated with therapeutic response to bisphosphonates, which are the first therapeutic line of choice for osteoporosis. However, cytokine pathways and their relation with therapeutic adhesion remain to be fully elucidated. Aimed at better understanding these processes, we investigated the response to bisphosphonate therapy in postmenopausal women and four SNPs in key proinflammatory cytokines genes: IL23R +2284 (C > A) (rs10889677), IL17A +672 (G > A) (rs7747909), IL12B +1188 (T > G) (rs3212227) and INF gamma  1616 (G > A) (rs2069705). A total of 69 patients treated with bisphosphonate were followed for a period of 1 up to 4 years, genotyped and compared according to their changes in bone mineral density (BMD) and level of biochemical markers during their treatment. The INF gamma  1616 G/G associated with increased BMD values in femoral neck (GG/AA, p = 0.016) and decreased BMD values in total hip (GG/GA, p = 0.019; GG/AA, p = 0.011). In relation to biochemical markers, INF gamma  1616 SNP associated with increased alkaline phosphatase (GG/AA; p < 0.0001) and parathyroid hormone levels (AA/GA; p = 0.017). Vitamin D values changes were related to IL17A +672 (GG/GA, p = 0.034) and to IL12B +1188 (TT/TG, p = 0.046) SNPs. Besides, significant differences in changes of calcium levels correlated with IL23R +2284 (CC/CA, p = 0.016) genotypes. Altogether, we suggest that these polymorphisms may play an important role for therapeutic decisions in osteoporosis treatment.
C1 [Lima, C. A. D.; Javorski, N. R.; Crovella, S.; De Azevedo Silva, J.; Sandrin Garcia, P.] Fed Univ Pernambuco UFPE, Dept Genet, Recife, PE, Brazil.
   [Lima, C. A. D.; Javorski, N. R.; Souza, A. P. O.; Barbosa, A. D.; Crovella, S.; Souza, P. R. E.; De Azevedo Silva, J.; Sandrin Garcia, P.] Fed Univ Pernambuco UFPE, Lab Immunopathol Keizo Asami, Recife, PE, Brazil.
   [Barbosa, A. D.] Fed Univ Pernambuco UFPE, Div Rheumatol, Clin Hosp, Recife, PE, Brazil.
   [Valenca, A. P. M. C.] Fed Univ Pernambuco UFPE, Dept Oceanog, Recife, PE, Brazil.
   [Souza, P. R. E.] Rural Fed Univ Pernambuco UFRPE, Dept Genet, Recife, PE, Brazil.
C3 Universidade Federal de Pernambuco; Universidade Federal de Pernambuco;
   Universidade Federal de Pernambuco; Universidade Federal de Pernambuco;
   Universidade Federal Rural de Pernambuco (UFRPE)
RP Lima, CAD (通讯作者)，Fed Univ Pernambuco UFPE, Dept Genet, Recife, PE, Brazil.; Lima, CAD (通讯作者)，Fed Univ Pernambuco UFPE, Lab Immunopathol Keizo Asami, Recife, PE, Brazil.
EM camilladelima@gmail.com
RI ; Sandrin Garcia, Paula/GLR 7506 2022; de Barros, Ana/C 3631 2019;
   Crovella, Sergio/LUZ 5866 2024; Filho, Antonio/S 5475 2019; Valenca de
   Barros, Ana Paula Maria Cavalcanti/C 3631 2019
OI Lima, Camilla/0000 0003 0320 3674; DE SOUZA, PAULO ROBERTO
   ELEUTERIO/0000 0002 9186 9849; Sandrin Garcia,
   Paula/0000 0003 4641 7429; Valenca de Barros, Ana Paula Maria
   Cavalcanti/0000 0002 8985 4699
FU CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior);
   CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico);
   FACEPE (Fundacao de Amparo a Ciencia e Tecnologia de Pernambuco)
FX We thank the following Brazilian funding agencies: CAPES (Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior), CNPq (Conselho Nacional
   de Desenvolvimento Cientifico e Tecnologico), and FACEPE (Fundacao de
   Amparo a Ciencia e Tecnologia de Pernambuco) for financial support.
CR Abrahamsen B, 2016, J BONE MINER RES, V31, P488, DOI 10.1002/jbmr.2801
   Annunziato F, 2015, J ALLERGY CLIN IMMUN, V135, P626, DOI 10.1016/j.jaci.2014.11.001
   Arron JR, 2000, NATURE, V408, P535, DOI 10.1038/35046196
   Baccaro LF, 2015, CLIN INTERV AGING, V10, DOI 10.2147/CIA.S54614
   Bignon J.D., 1995, TECHN HDB 12 INT HIS
   Boron D, 2014, EUR J MED RES, V19, DOI 10.1186/s40001 014 0069 1
   Carmeliet G, 2015, BEST PRACT RES CL EN, V29, P621, DOI 10.1016/j.beem.2015.06.001
   Christakos S, 2016, PHYSIOL REV, V96, P365, DOI 10.1152/physrev.00014.2015
   Cunha EP, 2011, OSTEOPOROSE TRATAM S
   Czerny B, 2010, EUR J OBSTET GYN R B, V149, P82, DOI 10.1016/j.ejogrb.2009.12.010
   Damsker JM, 2010, ANN NY ACAD SCI, V1183, P211, DOI 10.1111/j.1749 6632.2009.05133.x
   Drake MT, 2015, CLIN THER, V37, P1837, DOI 10.1016/j.clinthera.2015.06.006
   Duque G, 2011, J BONE MINER RES, V26, P1472, DOI 10.1002/jbmr.350
   Gao YH, 2007, J CLIN INVEST, V117, P122, DOI 10.1172/JCI30074
   GENANT HK, 1993, J BONE MINER RES, V8, P1137, DOI 10.1002/jbmr.5650080915
   Guerrini MM, 2014, ARCH BIOCHEM BIOPHYS, V561, P118, DOI 10.1016/j.abb.2014.06.003
   Hartmaier RJ, 2012, MOL ENDOCRINOL, V26, P220, DOI 10.1210/me.2011 1032
   Haynes D. R., 2006, Inflammopharmacology, V14, P193, DOI 10.1007/s10787 006 0006 1
   Hiligsmann M, 2015, CURR RHEUMATOL REP, V17, DOI 10.1007/s11926 015 0533 0
   Iolascon G, 2013, CLIN CASES MINER BON, V10, P47, DOI 10.11138/ccmbm/2013.10.1.047
   Iwakura Y, 2006, J CLIN INVEST, V116, P1218, DOI 10.1172/JCI28508
   Jadon D, 2013, RHEUMATOLOGY, V52, P261, DOI 10.1093/rheumatology/kes254
   Kanis JA, 2008, TECHNICAL REPORT
   Kerschan Schindl K, 2016, WIEN MED WOCHENSCHR, V166, P22, DOI 10.1007/s10354 015 0417 y
   Khader SA, 2010, VIRULENCE, V1, P423, DOI 10.4161/viru.1.5.12862
   Kruk M, 2009, CALCIFIED TISSUE INT, V84, P171, DOI 10.1007/s00223 008 9207 5
   Lee HJ, 2014, MENOPAUSE, V21, P67, DOI [10.1097/GME.0b013e31829366ed, 10.1097/gme.0b013e31829366ed]
   Legiran S, 2012, CLIN CASES MINER BON, V9, P145
   Liu SG, 2015, SCI REP UK, V5, DOI 10.1038/srep13887
   López Delgado L, 2016, EXPERT OPIN DRUG MET, V12, P389, DOI 10.1517/17425255.2016.1154533
   Louahchi S, 2016, ACTA REUMATOL PORT, V41, P151
   Makras P, 2015, METABOLISM, V64, P1199, DOI 10.1016/j.metabol.2015.07.011
   Marini F, 2014, BEST PRACT RES CL EN, V28, P783, DOI 10.1016/j.beem.2014.07.004
   Miller PD, 2016, J CLIN ENDOCR METAB, V101, P852, DOI 10.1210/jc.2015 3156
   Nasr A, 2014, MALARIA J, V13, DOI 10.1186/1475 2875 13 314
   Pham Trang T, 2013, Genes Cancer, V4, P419, DOI 10.1177/1947601913513950
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Ramana CV, 2002, TRENDS IMMUNOL, V23, P96, DOI 10.1016/S1471 4906(01)02118 4
   Raphael I, 2015, CYTOKINE, V74, P5, DOI 10.1016/j.cyto.2014.09.011
   Riancho JA, 2012, PHARMACOGENOMICS, V13, P815, DOI [10.2217/PGS.12.50, 10.2217/pgs.12.50]
   Roush K, 2011, AM J NURS, V111, P26, DOI 10.1097/01.NAJ.0000403358.44058.f7
   Roy SK, 2002, P NATL ACAD SCI USA, V99, P7945, DOI 10.1073/pnas.122075799
   Sharma U, 2014, INDIAN J CLIN BIOCHE, V29, P269, DOI 10.1007/s12291 013 0408 y
   Sun T, 2014, INT IMMUNOPHARMACOL, V22, P200, DOI 10.1016/j.intimp.2014.06.023
   Sutton CE, 2009, IMMUNITY, V31, P331, DOI 10.1016/j.immuni.2009.08.001
   Swanberg M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047964
   Takayanagi H, 2005, IMMUNOL REV, V208, P181, DOI 10.1111/j.0105 2896.2005.00337.x
   Talaat RM, 2015, INFLAMMOPHARMACOLOGY, V23, P119, DOI 10.1007/s10787 015 0233 4
   Tastan Y, 2016, CLIN RHEUMATOL, V35, P2789, DOI 10.1007/s10067 016 3237 6
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   Tu B, 2015, EXP CELL RES, V339, P81, DOI 10.1016/j.yexcr.2015.10.015
   Wang C, 2015, PHARMACOGENOMICS J, V15, P158, DOI 10.1038/tpj.2014.52
   Wong LH, 2002, J BIOL CHEM, V277, P19408, DOI 10.1074/jbc.M111302200
   Ye XL, 2013, ENDOCRINE, V44, P481, DOI 10.1007/s12020 013 9899 9
   Yuan FL, 2012, MOL BIOL REP, V39, P771, DOI 10.1007/s11033 011 0797 z
   Zhang J, 2015, GYNECOL ENDOCRINOL, V31, P183, DOI 10.3109/09513590.2014.975683
   Zheng H, 2016, PHARMACOGENET GENOM, V26, P12, DOI 10.1097/FPC.0000000000000181
   Zhou PR, 2014, PHARMACOGENOMICS, V15, P821, DOI [10.2217/PGS.14.12, 10.2217/pgs.14.12]
   Zhou PR, 2015, PHARMACOGENOMICS, V16, P1077, DOI [10.2217/PGS.15.76, 10.2217/pgs.15.76]
NR 59
TC 2
Z9 2
U1 0
U2 7
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 0925 4692
EI 1568 5608
J9 INFLAMMOPHARMACOLOGY
JI Inflammopharmacology
PD APR
PY 2017
VL 25
IS 2
BP 191
EP 201
DI 10.1007/s10787 017 0322 7
PG 11
WC Immunology; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy; Toxicology
GA ER3SS
UT WOS:000398719300003
PM 28220389
DA 2025 08 17
ER

PT J
AU Coleman, RE
AF Coleman, R. E.
TI Adjuvant bisphosphonates in breast cancer: Are we witnessing the
   emergence of a new therapeutic strategy?
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE Breast; Therapeutics
ID ZOLEDRONIC ACID; SKELETAL METASTASES; ORAL PAMIDRONATE; CLODRONATE;
   APOPTOSIS; CELLS; DOXORUBICIN; MECHANISMS; REDUCTION; DISEASE
AB Great strides have been made over the last 20 years in the treatment of breast cancer and, despite an increasing incidence, the number of deaths has fallen sharply since the late 1980s. The widespread use of new adjuvant therapies including trastuzumab, taxanes and aromatase inhibitors should decrease this even further. However, for women, metastatic breast cancer still remains the number one cause of cancer death in Europe, and the detection and treatment of micrometastatic disease represent the most important challenge in breast cancer management.
   Bone is the most frequent site of distant relapse, accounting for 30 40% of all first recurrence. In addition to the well recognised release of bone cell activating factors from the tumour, a wealth of pre clinical data indicates that the release of bone derived growth factors and cytokines into the microenvironment can both attract cancer cells to the bone surface and facilitate their growth and proliferation. Bisphosphonates are potent inhibitors of bone osteolysis and may interrupt this so called 'viscous cycle', thereby impeding both the development of bone metastases and the survival of dormant cells in the marrow microenvironment for the subsequent dissemination to extra osseus sites. Additionally, the potent amino bisphosphonates may also have direct effects on tumour cells, especially when administered in combination with chemotherapy.
   Clinical trial results with the early oral bisphosphonate and clodronate were judged to be inconclusive but the recent data with zoledronic acid suggest that bone targeted treatments may indeed modify the course of the disease. The results of ongoing large metastasis prevention trials are however, required before routine use of adjuvant bisphosphonates can be recommended. (c) 2009 Elsevier Ltd. All rights reserved.
C1 Weston Pk Hosp NHS Trust, Acad Unit Clin Oncol, Canc Res Ctr, Sheffield S10 2SJ, S Yorkshire, England.
C3 Weston Park Hospital
RP Coleman, RE (通讯作者)，Weston Pk Hosp NHS Trust, Acad Unit Clin Oncol, Canc Res Ctr, Sheffield S10 2SJ, S Yorkshire, England.
EM R.E.Coleman@sheffield.ac.uk
CR Albain Kathy S, 2005, Clin Breast Cancer, V6, P412, DOI 10.3816/CBC.2005.n.045
   [Anonymous], CANC RES
   BRUFSKY A, 2007, BREAST S1, V16, pS57
   Burkinshaw R, 2008, CANCER TREAT REV, V34, pS75, DOI 10.1016/j.ctrv.2008.03.113
   COLEMAN R, 2006, BREAST CANC RES T S1, V100
   Coleman RE, 2004, ONCOLOGIST, V9, P14, DOI 10.1634/theoncologist.9 90004 14
   Diel IJ, 2008, ANN ONCOL, V19, P2007, DOI 10.1093/annonc/mdn429
   Diel IJ, 1998, NEW ENGL J MED, V339, P357, DOI 10.1056/NEJM199808063390601
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   EIDTMANN H, 2008, CANC RES S2, V69
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Jagdev SP, 2001, BRIT J CANCER, V84, P1126, DOI 10.1054/bjoc.2001.1727
   JUNG J, 2005, ASCO ANN M P
   Kanis JA, 1996, BONE, V19, P663, DOI 10.1016/S8756 3282(96)00285 2
   KOKUFU I, 2004, ASCO ANN M P, V22
   Kristensen B, 2008, ACTA ONCOL, V47, P740, DOI 10.1080/02841860801964988
   Mönkkönen H, 2006, BRIT J PHARMACOL, V147, P437, DOI 10.1038/sj.bjp.0706628
   Mundy GR, 2001, SEMIN ONCOL, V28, P35, DOI 10.1053/sonc.2001.24158
   Neville Webbe HL, 2005, INT J CANCER, V113, P364, DOI 10.1002/ijc.20602
   Ottewell PD, 2008, JNCI J NATL CANCER I, V100, P1167, DOI 10.1093/jnci/djn240
   Powles T, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1384
   Rack B, 2008, DEUT MED WOCHENSCHR, V133, P285, DOI 10.1055/s 2008 1046707
   Ralston SH, 2006, GENE DEV, V20, P2492, DOI 10.1101/gad.1449506
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Saarto T, 2004, ACTA ONCOL, V43, P650, DOI 10.1080/02841860410032885
   Santini D, 2002, CLIN CANCER RES, V8, P1080
   Shibuya K, 2002, BMC CANCER, V2, DOI 10.1186/1471 2407 2 37
   VanHoltenVerzantvoort ATM, 1997, MEDICINA BUENOS AIRE, V57, P109
   Winter MC, 2008, CANCER TREAT REV, V34, P453, DOI 10.1016/j.ctrv.2008.02.004
   WINTER MC, 2008, CANC RES S2, V69
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
   Woodward JKL, 2005, ANTI CANCER DRUG, V16, P11, DOI 10.1097/00001813 200501000 00002
   Yin JJ, 2005, CELL RES, V15, P57, DOI 10.1038/sj.cr.7290266
   Yoneda T, 2005, BIOCHEM BIOPH RES CO, V328, P679, DOI 10.1016/j.bbrc.2004.11.070
NR 35
TC 51
Z9 60
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959 8049
EI 1879 0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD JUL
PY 2009
VL 45
IS 11
BP 1909
EP 1915
DI 10.1016/j.ejca.2009.04.022
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 476UX
UT WOS:000268472700004
PM 19447606
DA 2025 08 17
ER

PT J
AU Song, DZ
   Cao, Z
   Liu, ZB
   Tickner, J
   Qiu, H
   Wang, C
   Chen, K
   Wang, ZY
   Dong, SW
   Xu, JK
AF Song, Dezhi
   Cao, Zhen
   Liu, Zaibing
   Tickner, Jennifer
   Qiu, Heng
   Wang, Chao
   Chen, Kai
   Wang, Ziyi
   Dong, Shiwu
   Xu, Jiake
TI Cistanche deserticola polysaccharide attenuates
   osteoclastogenesis and bone resorption via inhibiting RANKL signaling
   and reactive oxygen species production
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE bone resorption; Cistanche deserticola polysaccharide; MAPK; osteoclast;
   reactive oxygen species
ID RESISTANT ACID PHOSPHATASE; KAPPA B LIGAND; INDUCED OSTEOPOROSIS;
   RECEPTOR ACTIVATOR; RICH EXTRACT; DIFFERENTIATION; NFATC1; ANTIOXIDANT;
   PATHWAYS; PROMOTER
AB Osteoporosis is a metabolic disease characterized by osteopenia and bone microstructural deterioration. Osteoclasts are the primary effector cells that degrade bone matrix and their abnormal function leads to the development of osteoporosis. Reactive oxygen species (ROS) accumulation during cellular metabolism promotes osteoclast proliferation and differentiation, therefore, playing an important role in osteoporosis. Cistanche deserticola polysaccharide (CDP) possesses antitumor, anti inflammatory, and antioxidant activity. However, the impact of CDP on osteoclasts is unclear. In this study, tartrate resistant acid phosphatase staining, immunofluorescence, reverse transcription polymerase chain reaction, and western blot analysis were utilized to demonstrate that CDP inhibited osteoclastogenesis and hydroxyapatite resorption. In addition, CDP also inhibited the expression of osteoclast maker genes including Ctsk, Mmp9, and Acp5 and had no effect on receptor activator of nuclear factor B (RANK) expression. Mechanistic analyses revealed that CDP increases the expression of antioxidant enzymes to attenuate RANKL mediated ROS production in osteoclasts and inhibits nuclear factor of activated T cells and mitogen activated protein kinase activation. These results suggest that CDP may represent a candidate drug for the treatment of osteoporosis caused by excessive osteoclast activity.
C1 [Song, Dezhi] Guangxi Med Univ, Res Ctr Regenerat Med, Nanning, Peoples R China.
   [Song, Dezhi] Guangxi Med Univ, Guangxi Key Lab Regenerat Med, Nanning, Peoples R China.
   [Song, Dezhi] Guangxi Med Univ, Dept Microbiol, Nanning, Peoples R China.
   [Song, Dezhi; Cao, Zhen; Tickner, Jennifer; Qiu, Heng; Wang, Chao; Chen, Kai; Wang, Ziyi; Xu, Jiake] Univ Western Australia, Sch Biomed Sci, Div Regenerat Med, Perth, WA, Australia.
   [Cao, Zhen; Dong, Shiwu] Third Mil Med Univ, Sch Biomed Engn, Dept Biomed Mat Sci, Gaotanyan St 30, Chongqing 400038, Peoples R China.
   [Liu, Zaibing] Peoples Hosp Zhangqiu Dist, Dept Radiol, Jinan, Peoples R China.
C3 Guangxi Medical University; Guangxi Medical University; Guangxi Medical
   University; University of Western Australia; Army Medical University
RP Dong, SW (通讯作者)，Third Mil Med Univ, Sch Biomed Engn, Dept Biomed Mat Sci, Gaotanyan St 30, Chongqing 400038, Peoples R China.; Xu, JK (通讯作者)，Univ Western Australia, Sch Biomed Sci, Perth, WA 6009, Australia.
EM dongshiwu@tmmu.edu.cn; jiake.xu@uwa.edu.au
RI ; Tickner, Jennifer/H 5965 2014; Chen, KaiJie/A 1743 2016; Song,
   Dezhi/AAL 9799 2020
OI Wang, Ziyi/0000 0002 5410 3385; Xu, Jiake/0000 0003 2021 8309; Qiu,
   Heng/0000 0002 0864 317X; Wang, Ziyi/0000 0002 1334 7287; Tickner,
   Jennifer/0000 0002 5020 0671; Chen, Kai/0000 0001 6850 1723; Dong,
   Shiwu/0000 0002 5032 4893
FU University of Western Australia (UWA); University Science and Technology
   Research Project of Guangxi Province [KY2015YB054]; Australian Health
   and Medical Research Council [1027932]; NHMRC [1107828]; Arthritis
   Australia foundation; National Key Technology Research and Development
   Program of China [2017YFC1103300]; Guangxi Scientific Research and
   Technology Development Plan Project [1598013 15, GKG13349003]; Natural
   Science Foundation of Guangxi Province [2016GXNSFAA380295]; Western
   Australia Medical & Health Research Infrastructure Fund; Nature Science
   Foundation of China [81572164]; National Health and Medical Research
   Council of Australia [1107828] Funding Source: NHMRC
FX The University of Western Australia (UWA) Research Collaboration Awards;
   University Science and Technology Research Project of Guangxi Province,
   Grant/Award Number: KY2015YB054; Australian Health and Medical Research
   Council, Grant/Award Numbers: 1027932, NHMRC, No 1107828; Arthritis
   Australia foundation; National Key Technology Research and Development
   Program of China, Grant/Award Number: 2017YFC1103300; Guangxi Scientific
   Research and Technology Development Plan Project, Grant/Award Numbers:
   1598013 15, GKG13349003; the Natural Science Foundation of Guangxi
   Province, Grant/Award Number: 2016GXNSFAA380295; Western Australia
   Medical & Health Research Infrastructure Fund; Nature Science Foundation
   of China, Grant/Award Number: 81572164
CR Ahn J, 2017, MOLECULES, V22, DOI 10.3390/molecules22071138
   Balkan W, 2009, GENE, V446, P90, DOI 10.1016/j.gene.2009.06.013
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cai RL, 2010, PHYTOTHER RES, V24, P313, DOI 10.1002/ptr.2927
   Cheng JW, 2018, J CELL PHYSIOL, V233, P2502, DOI 10.1002/jcp.26126
   COOPER C, 1992, TRENDS ENDOCRIN MET, V3, P224, DOI 10.1016/1043 2760(92)90032 V
   Crotti TN, 2008, J CELL PHYSIOL, V215, P636, DOI 10.1002/jcp.21344
   Feng HT, 2009, J BIOL CHEM, V284, P14667, DOI 10.1074/jbc.M901670200
   Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669
   Gruber R, 2015, WIEN MED WOCHENSCHR, V165, P48, DOI 10.1007/s10354 014 0310 0
   Guo YH, 2016, INT J BIOL MACROMOL, V93, P678, DOI 10.1016/j.ijbiomac.2016.09.039
   Ha H, 2004, EXP CELL RES, V301, P119, DOI 10.1016/j.yexcr.2004.07.035
   Hyeon S, 2013, FREE RADICAL BIO MED, V65, P789, DOI 10.1016/j.freeradbiomed.2013.08.005
   Ikeda K, 2008, GERIATR GERONTOL INT, V8, P213, DOI 10.1111/j.1447 0594.2008.00481.x
   Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200
   Jia YM, 2012, PHYTOTHER RES, V26, P812, DOI 10.1002/ptr.3637
   Kanzaki H, 2017, FASEB J, V31, P781, DOI 10.1096/fj.201600826R
   Kim Jung Ha, 2016, Chonnam Med J, V52, P12, DOI 10.4068/cmj.2016.52.1.12
   Koh JM, 2006, J BONE MINER RES, V21, P1003, DOI 10.1359/JBMR.060406
   Liu Q, 2013, BIOCHEM PHARMACOL, V86, P1775, DOI 10.1016/j.bcp.2013.09.017
   Lorenzo J, 2017, J CLIN INVEST, V127, P2530, DOI 10.1172/JCI94606
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Manolagas SC, 2013, NAT REV ENDOCRINOL, V9, P699, DOI 10.1038/nrendo.2013.179
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252
   Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992 1000.2002
   Nan ZD, 2013, FITOTERAPIA, V89, P167, DOI 10.1016/j.fitote.2013.05.008
   SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337
   SNIPES RG, 1986, BLOOD, V67, P729
   Snytnikova OA, 2012, DOKL BIOCHEM BIOPHYS, V447, P300, DOI 10.1134/S1607672912060087
   Song FM, 2016, J CELL PHYSIOL, V231, P1983, DOI 10.1002/jcp.25304
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   van der Kraan AGJ, 2013, BIOCHEM J, V451, P235, DOI 10.1042/BJ20121626
   Xu JK, 2000, J BONE MINER RES, V15, P2178, DOI 10.1359/jbmr.2000.15.11.2178
   Yip KHM, 2005, J BONE MINER RES, V20, P1462, DOI 10.1359/JBMR.050324
   Yu Q, 2016, ANN VASC SURG, V34, P234, DOI 10.1016/j.avsg.2016.04.002
   Zhou L, 2016, J BONE MINER RES, V31, P964, DOI 10.1002/jbmr.2771
   Zhu SP, 2018, BIOL REV, V93, P469, DOI 10.1111/brv.12353
NR 40
TC 40
Z9 51
U1 0
U2 69
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD DEC
PY 2018
VL 233
IS 12
BP 9674
EP 9684
DI 10.1002/jcp.26882
PG 11
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA GW7LE
UT WOS:000447148600056
PM 29968926
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Niu, YM
   Yang, HB
   Yu, ZY
   Gao, CC
   Ji, SS
   Yan, J
   Han, L
   Huo, Q
   Xu, M
   Liu, Y
AF Niu, Yimin
   Yang, Hongbin
   Yu, Zhenyan
   Gao, Cuicui
   Ji, Shuaishuai
   Yan, Jie
   Han, Lei
   Huo, Qiang
   Xu, Ming
   Liu, Yang
TI Intervention with the Bone Associated Tumor Vicious Cycle through
   Dual Protein Therapeutics for Treatment of Skeletal Related Events and
   Bone Metastases
SO ACS NANO
LA English
DT Article
DE bone associated tumor vicious cycle; RANKL antibody; bone metastases;
   skeletal related events; protein toxin
ID DELIVERY; CANCER; RANKL
AB Bone metastasis is a common metastasis site such as lung cancer, prostate cancer, and other malignant tumors. The occurrence of bone metastases of lung cancer is often accompanied by bone loss, fracture, and other skeletal related events (SREs) caused by tumor proliferation and osteoclast activation. Furthermore, along with the differentiation and maturation of osteoclasts in the bone microenvironment, it will further promote the occurrence and development of bone metastasis. Protein drugs are one of the most promising therapeutic pharmaceuticals, but in vivo delivery of protein therapeutics still confronts great challenges. In order to more effectively conquer bone metastases and alleviate SREs, herein, we constructed biomineralized metal organic framework (MOF) nanoparticles carrying protein toxins with both bone seeking and CD44 receptor targeting abilities. More importantly, through combination with Receptor Activator of Nuclear Factor kappa B Ligand (RANKL) antibody, in vivo results demonstrated that these two protein agents not only enhanced the detraction effects of protein toxin agents as ribosome inactivating protein (RIP) on bone metastatic tumor cells but also exhibited synergistic intervention of the crosstalk between bone cells and tumor cells and reduced SREs such as bone loss. Collectively, we expect that this strategy can provide an effective and safe option in regulating bone tumor microenvironments to overcome bone metastasis and SREs.
C1 [Niu, Yimin] Southeast Univ, Zhongda Hosp, Sch Med, Dept Pharm, Nanjing 210009, Jiangsu, Peoples R China.
   [Niu, Yimin] Southeast Univ, Zhongda Hosp, Sch Med, Dept Neurol, Nanjing 210009, Jiangsu, Peoples R China.
   [Yang, Hongbin; Yu, Zhenyan; Ji, Shuaishuai; Yan, Jie; Huo, Qiang] Bengbu Med Coll, Sch Pharm, Bengbu 233030, Anhui, Peoples R China.
   [Gao, Cuicui; Liu, Yang] Nanjing Med Univ, Sch Pharm, Dept Pharmaceut, Nanjing 211166, Jiangsu, Peoples R China.
   [Gao, Cuicui] Shenyang Pharmaceut Univ, Sch Pharm, Shenyang 110016, Liaoning, Peoples R China.
   [Han, Lei; Xu, Ming] Jiangsu Prov Ctr Dis Control & Prevent, Dept Occupat Dis Prevent, Nanjing 210009, Jiangsu, Peoples R China.
C3 Southeast University   China; Southeast University   China; Bengbu
   Medical University; Nanjing Medical University; Shenyang Pharmaceutical
   University; Jiangsu Provincial Center for Disease Control & Prevention
RP Liu, Y (通讯作者)，Nanjing Med Univ, Sch Pharm, Dept Pharmaceut, Nanjing 211166, Jiangsu, Peoples R China.; Xu, M (通讯作者)，Jiangsu Prov Ctr Dis Control & Prevent, Dept Occupat Dis Prevent, Nanjing 210009, Jiangsu, Peoples R China.
EM sosolou@jscdc.cn; yangliunano@njmu.edu.cn
RI ; 徐, 酩/MXL 8994 2025; Niu, Yimin/AEJ 6817 2022; Yang, Hong
   Bin/ACB 4662 2022
OI Xu, Ming/0000 0001 8846 2880; Niu, Yimin/0009 0000 3335 5762; 
FU National Natural Science Foundation of China [81901863, 81703201,
   81502796]; Major Project of Natural Science Research for Colleges and
   Universities of Anhui Province, China [KJ2020ZD52]; Natural Science
   Foundation of Jiangsu Province [BK20201485]; Jiangsu Provincial 333
   Project [BRA2018398]
FX This study was financially supported by the National Natural Science
   Foundation of China (81901863, 81703201, 81502796), the Major Project of
   Natural Science Research for Colleges and Universities of Anhui
   Province, China (KJ2020ZD52), the Natural Science Foundation of Jiangsu
   Province (BK20201485), and Jiangsu Provincial 333 Project (BRA2018398).
CR Asano T, 2019, NAT METAB, V1, P868, DOI 10.1038/s42255 019 0104 1
   Chen J, 2016, CHEM MATER, V28, P8792, DOI 10.1021/acs.chemmater.6b04404
   Chen TT, 2018, J AM CHEM SOC, V140, P9912, DOI 10.1021/jacs.8b04457
   Cheng G, 2018, J AM CHEM SOC, V140, P7282, DOI 10.1021/jacs.8b03584
   Chiou AE, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abf2283
   Cole LE, 2016, ADV DRUG DELIVER REV, V99, P12, DOI 10.1016/j.addr.2015.10.005
   De Castro J, 2015, CLIN LUNG CANCER, V16, P431, DOI 10.1016/j.cllc.2015.06.004
   de Groot AF, 2018, CANCER TREAT REV, V62, P18, DOI 10.1016/j.ctrv.2017.10.010
   Esposito M, 2019, NAT CELL BIOL, V21, P627, DOI 10.1038/s41556 019 0309 2
   Fornetti J, 2018, J BONE MINER RES, V33, P2099, DOI 10.1002/jbmr.3618
   Gao X, 2021, BIOMATERIALS, V265, DOI 10.1016/j.biomaterials.2020.120404
   He W, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.201910566
   Hofbauer LC, 2021, NAT REV CLIN ONCOL, V18, P488, DOI 10.1038/s41571 021 00499 9
   Huang YJ, 2020, J CONTROL RELEASE, V319, P119, DOI 10.1016/j.jconrel.2019.12.043
   Ikebuchi Y, 2018, NATURE, V561, P195, DOI 10.1038/s41586 018 0482 7
   Jiang Y, 2018, ACS NANO, V12, P11070, DOI 10.1021/acsnano.8b05265
   Kurotaki D, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115471
   Le Saux S, 2021, ADV THER GERMANY, V4, DOI 10.1002/adtp.202100009
   Li CY, 2017, ADV MATER, V29, DOI 10.1002/adma.201605754
   Liao HJ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1353 3
   Long MM, 2021, J CONTROL RELEASE, V334, P303, DOI 10.1016/j.jconrel.2021.04.035
   Lozano C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00375
   Macedo F, 2017, ONCOL REV, V11, P43, DOI 10.4081/oncol.2017.321
   Martínez Reina J, 2019, BONE, V125, P87, DOI 10.1016/j.bone.2019.04.022
   Ming J, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01283
   Pang YC, 2020, NANO LETT, V20, P829, DOI 10.1021/acs.nanolett.9b02916
   Qin XF, 2019, ADV MATER, V31, DOI 10.1002/adma.201902791
   Riquelme MA, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.567844
   Sánchez Navarro M, 2021, ADV DRUG DELIVER REV, V171, P187, DOI 10.1016/j.addr.2021.02.003
   Shi JJ, 2020, BIOMATERIALS, V256, DOI 10.1016/j.biomaterials.2020.120221
   Sun WT, 2019, ACS NANO, V13, P7556, DOI 10.1021/acsnano.9b00097
   Vijayaraghavalu S, 2020, BIOMATERIALS, V227, DOI 10.1016/j.biomaterials.2019.119558
   Wang MN, 2020, BONE RES, V8, DOI 10.1038/s41413 020 00105 1
   Wang MF, 2019, BIOCHEM PHARMACOL, V166, P23, DOI 10.1016/j.bcp.2019.05.005
   Wang QY, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03390 x
   Wang YT, 2018, BIOMATERIALS, V183, P10, DOI 10.1016/j.biomaterials.2018.08.033
   Wu S., 2021, ADV SCI, V9
   Xu J, 2020, NAT NANOTECHNOL, V15, P1043, DOI 10.1038/s41565 020 00781 4
   Yan Y, 2022, BIOACT MATER, V7, P333, DOI 10.1016/j.bioactmat.2021.05.041
   Zhang D, 2021, ADV SCI, V8, DOI 10.1002/advs.202003504
   Zhang WJ, 2021, CELL, V184, P2471, DOI 10.1016/j.cell.2021.03.011
   Zhou X, 2021, BIOMATERIALS, V269, DOI 10.1016/j.biomaterials.2020.120345
   Zhu JH, 2018, NANOSCALE, V10, P18387, DOI 10.1039/c8nr03899f
NR 43
TC 26
Z9 28
U1 4
U2 71
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936 0851
EI 1936 086X
J9 ACS NANO
JI ACS Nano
PD FEB 22
PY 2022
VL 16
IS 2
BP 2209
EP 2223
DI 10.1021/acsnano.1c08269
PG 15
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA 0E4ZW
UT WOS:000776691400044
PM 35077154
DA 2025 08 17
ER

PT J
AU Yamashita, J
   Koi, K
   Yang, DY
   McCauley, LK
AF Yamashita, Junro
   Koi, Kiyono
   Yang, Dong Ye
   McCauley, Laurie K.
TI Effect of Zoledronate on Oral Wound Healing in Rats
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID OSTEOCLAST FORMATION; ANGIOGENIC FACTORS; GROWTH FACTOR; TUMOR GROWTH;
   BONE MARROW; BISPHOSPHONATE; ACID; CELLS; ACTIVATION; NECROSIS
AB Purpose: Osteonecrosis of the jaw (ONJ) is a growing concern in patients who receive bisphosphonates that target osteoclasts. As osteoclasts play multifunctional roles in the bone marrow, their suppression likely affects bone homeostasis and alters wound healing of the jaw. The objective was to delineate the impact of osteoclast suppression in the bone marrow and wound healing of the jaw.
   Experimental Design: Zoledronate was administered to senile rats for 14 weeks. A portion of the gingiva was removed to denude the palatal bone. Gene expression in the bone marrow was assessed and histologic sections were analyzed to determine the wound healing status.
   Results: Angiogenesis related genes, CD31 and VEGF A, were not altered by zoledronate. VEGF C, which plays a role in lymphangiogenesis, was suppressed. There was a decrease in gene expression of Tcirg1 and MMP 13. Bone denudation caused extensive osteocyte death indicative of bone necrosis. In zoledronate treated rats, the necrotic bone was retained in the wound while, in controls, osteoclastic resorption of the necrotic bone was prominent. Even though large necrotic bone areas existed in zoledronate treated rats, overlaying soft tissue healed clinically. Immunohistochemical staining showed rich vascularity in the overlaying soft tissue.
   Conclusions: Zoledronate therapy impacts bone marrow by suppressing genes associated with lymphangiogenesis and tissue remodeling, such as VEGF C and MMP 13. Zoledronate was associated with impaired osseous wound healing but had no effect on angiogenic markers in the bone marrow or soft tissue wound healing. Zoledronate selectively blunts healing in bone but does not affect soft tissue healing in the oral cavity. Clin Cancer Res; 17(6); 1405 14. (C)2010 AACR.
C1 [Yamashita, Junro; Koi, Kiyono; Yang, Dong Ye] Univ Michigan, Sch Dent, Dept Biol Mat & Sci, Ann Arbor, MI 48109 USA.
   [McCauley, Laurie K.] Univ Michigan, Sch Dent, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA.
   [McCauley, Laurie K.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan
RP Yamashita, J (通讯作者)，Univ Michigan, Sch Dent, Dept Biol Mat & Sci, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.
EM yamashit@umich.edu
RI Yamashita, Junro/D 4787 2019; Koi, Kiyono/IUO 1847 2023; McCauley,
   Laurie/G 4041 2012
OI Yamashita, Junro/0000 0002 5486 1362; 
FU International Team for Implantology (ITI) [SGA510]; NCI [P01 CA093900];
   NIDCR [R03DE018923]; National Cancer Institute [P01CA093900] Funding
   Source: NIH RePORTER
FX This study was supported by the International Team for Implantology
   (ITI) grant SGA510, NCI P01 CA093900, and NIDCR grant R03DE018923.
CR Allen MR, 2008, J ORAL MAXIL SURG, V66, P987, DOI 10.1016/j.joms.2008.01.038
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Cackowski FC, 2010, BLOOD, V115, P140, DOI 10.1182/blood 2009 08 237628
   Cardoso L, 2009, J BONE MINER RES, V24, P597, DOI 10.1359/JBMR.081210
   Costa L, 2009, NAT CLIN PRACT ONCOL, V6, P163, DOI 10.1038/ncponc1323
   Coxon FP, 2008, BONE, V42, P848, DOI 10.1016/j.bone.2007.12.225
   Croucher PI, 2003, J BONE MINER RES, V18, P482, DOI 10.1359/jbmr.2003.18.3.482
   Dobson KR, 1999, CALCIFIED TISSUE INT, V65, P411, DOI 10.1007/s002239900723
   ENLOW DH, 1966, J DENT RES, V45, P213, DOI 10.1177/00220345660450011901
   Fournier P, 2002, CANCER RES, V62, P6538
   Green JR, 2001, SEMIN ONCOL, V28, P4, DOI 10.1053/sonc.2001.24154
   Haeusler G, 2005, CALCIFIED TISSUE INT, V76, P326, DOI 10.1007/s00223 004 0161 6
   Hale LV, 2007, BONE, V40, P1103, DOI 10.1016/j.bone.2006.11.027
   Hirbe AC, 2009, BONE, V44, P908, DOI 10.1016/j.bone.2009.01.010
   Horner A, 2001, BONE, V28, P65, DOI 10.1016/S8756 3282(00)00422 1
   Huja SS, 2008, ANAT REC, V291, P1, DOI 10.1002/ar.20619
   Kobayashi Y, 2010, J BONE MINER METAB, V28, P165, DOI 10.1007/s00774 009 0128 9
   Kollet O, 2006, NAT MED, V12, P657, DOI 10.1038/nm1417
   Landesberg R, 2008, J ORAL MAXIL SURG, V66, P839, DOI 10.1016/j.joms.2008.01.026
   LESTER KS, 1969, J ULTRA MOL STRUCT R, V28, P481, DOI 10.1016/S0022 5320(69)80035 3
   Li D, 2010, ANN NY ACAD SCI, V1192, P84, DOI 10.1111/j.1749 6632.2009.05210.x
   Li HY, 2010, BLOOD, V116, P210, DOI 10.1182/blood 2009 11 255026
   Maruyama K, 2007, AM J PATHOL, V170, P1178, DOI 10.2353/ajpath.2007.060018
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Miyamoto T, 2001, BLOOD, V98, P2544, DOI 10.1182/blood.V98.8.2544
   Nannuru KC, 2010, CANCER RES, V70, P3494, DOI 10.1158/0008 5472.CAN 09 3251
   OREFFO ROC, 1989, BIOCHEM BIOPH RES CO, V158, P817, DOI 10.1016/0006 291X(89)92795 2
   Peyruchaud O, 2001, J BONE MINER RES, V16, P2027, DOI 10.1359/jbmr.2001.16.11.2027
   PIERCE AM, 1986, CALCIFIED TISSUE INT, V39, P109, DOI 10.1007/BF02553299
   PIETROKOVSKI J, 1967, J DENT RES, V46, P222, DOI 10.1177/00220345670460011501
   Quarello P, 2004, J BONE MINER RES, V19, P1194, DOI 10.1359/JBMR.040407
   Rothe L, 1998, ENDOCRINOLOGY, V139, P4353, DOI 10.1210/en.139.10.4353
   Rothmann C, 1998, HISTOCHEM J, V30, P539, DOI 10.1023/A:1003235201563
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Santini D, 2003, CLIN CANCER RES, V9, P2893
   Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006
   Singh S, 2004, LAB INVEST, V84, P1666, DOI 10.1038/labinvest.3700181
   SMINIA T, 1986, CALCIFIED TISSUE INT, V39, P263, DOI 10.1007/BF02555216
   Tas F, 2008, MED ONCOL, V25, P346, DOI 10.1007/s12032 008 9043 5
   Taylor PR, 2005, ANNU REV IMMUNOL, V23, P901, DOI 10.1146/annurev.immunol.23.021704.115816
   Utku N, 1998, IMMUNITY, V9, P509, DOI 10.1016/S1074 7613(00)80634 2
   Weinstein RS, 2009, NEW ENGL J MED, V360, P53, DOI 10.1056/NEJMoa0802633
   Yaccoby S, 2002, BRIT J HAEMATOL, V116, P278, DOI 10.1046/j.1365 2141.2002.03257.x
   Yamashita J, 2008, J BONE MINER RES, V23, P621, DOI 10.1359/JBMR.071211
   Yao ZQ, 2008, J BIOL CHEM, V283, P9917, DOI 10.1074/jbc.M706415200
   Zhou ZJ, 2004, CANCER RES, V64, P4699, DOI 10.1158/0008 5472.CAN 04 0810
   Zwolak P, 2010, J BONE JOINT SURG AM, V92A, P162, DOI 10.2106/JBJS.H.01679
NR 47
TC 88
Z9 94
U1 2
U2 16
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1078 0432
EI 1557 3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD MAR 15
PY 2011
VL 17
IS 6
BP 1405
EP 1414
DI 10.1158/1078 0432.CCR 10 1614
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 735RR
UT WOS:000288435300021
PM 21149614
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Eudy Byrne, RJ
   Gillespie, W
   Riggs, MM
   Gastonguay, MR
AF Eudy Byrne, Rena J.
   Gillespie, William
   Riggs, Matthew M.
   Gastonguay, Marc R.
TI A model of fracture risk used to examine the link between bone mineral
   density and the impact of different therapeutic mechanisms on fracture
   outcomes in patients with osteoporosis
SO JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
LA English
DT Article
DE Bone mineral density; Fracture; Osteoporosis; Hazard model; MBMA
ID POSTMENOPAUSAL WOMEN; VERTEBRAL FRACTURES; RANDOMIZED TRIAL; ZOLEDRONIC
   ACID; PTH 1 34; ALENDRONATE; DENOSUMAB; RISEDRONATE; REDUCTION; EFFICACY
AB A hazard model of fracture was developed using individual patient data (IPD) from the NHANES (2005 2008) database and summary level data from an aggregate dataset (AD). The AD was built by performing a comprehensive and systematic literature search of clinical studies published from 1995 to 2015, recording fracture rate and bone mineral density (BMD) for both treatment and placebo arms. The search resulted in a metadata set comprised of 21 studies investigating the effects of various bisphosphonates, teriparatide, denosumab, and raloxifene in 65,254 patients over a cumulative 56.75 years of study. The IPD was used to augment an AD in a model based meta analysis (MBMA) hierarchical modeling approach. The resulting model predicts the probability of fracture events in patients with osteoporosis. The object of model building using this approach was to promote understanding of the impact of therapeutic drug effects on the probability of fracture together with, or independent of their effects on BMD. Candidate models were evaluated by deviance information criteria and posterior predictive check. The model with covariates for lumbar spine BMD with interaction with a drug effect on BMD, and patient body mass index, years post menopause, fracture measure method (clinical or radiological) and an additional drug effect outperformed those models without interaction and without additional drug effects. The model quantitatively supports the widely held notion that changes in bone microarchitecture, which cannot be measured by areal BMD elicited by therapy contribute in a significant way to a reduction in fracture. Furthermore, this model can be used to simulate fracture risk in a clinical cohort similar to those contained in the MBMA.
C1 [Eudy Byrne, Rena J.; Gillespie, William; Riggs, Matthew M.; Gastonguay, Marc R.] Metrum Res Grp LLC, 2 Tunxis Rd,Suite 112, Tariffville, CT 06081 USA.
C3 Metrum Research Group
RP Eudy Byrne, RJ (通讯作者)，Metrum Res Grp LLC, 2 Tunxis Rd,Suite 112, Tariffville, CT 06081 USA.
EM renae@metrumrg.com
RI Riggs, Matthew/AAF 3325 2020
CR Bai H, 2013, J INT MED RES, V41, P697, DOI 10.1177/0300060513480917
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Black DM, 2006, JAMA J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Bone HG, 2013, J CLIN ENDOCR METAB, V98, P4483, DOI 10.1210/jc.2013 1597
   Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325
   Cummings SR, 1998, JAMA J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Ensrud KE, 2004, J BONE MINER RES, V19, P1259, DOI 10.1359/JBMR.040326
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   Faulkner KG, 1996, OSTEOPOROSIS INT, V6, P432, DOI 10.1007/BF01629574
   Gross JL, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen 2012 001844
   Hagino H, 2012, J BONE MINER METAB, V30, P439, DOI 10.1007/s00774 011 0332 2
   Haneuse SJPA, 2007, BIOMETRICS, V63, P128, DOI 10.1111/j.1541 0420.2006.00673.x
   Hansen S, 2013, J BONE MINER RES, V28, P736, DOI 10.1002/jbmr.1784
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   Jackson C, 2006, STAT MED, V25, P2136, DOI 10.1002/sim.2370
   Jackson C, 2008, J R STAT SOC A STAT, V171, P159
   Jansen JP, 2012, RES SYNTH METHODS, V3, P177, DOI 10.1002/jrsm.1048
   Leslie WD, 2016, ANN INTERN MED, V165, P465, DOI 10.7326/M15 2937
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   McCloskey EV, 2016, J BONE MINER RES, V31, P940, DOI 10.1002/jbmr.2734
   Mellström DD, 2004, CALCIFIED TISSUE INT, V75, P462, DOI 10.1007/s00223 004 0286 7
   Nakamura T, 2014, J CLIN ENDOCR METAB, V99, P2599, DOI 10.1210/jc.2013 4175
   Nakamura T, 2012, J CLIN ENDOCR METAB, V97, P3097, DOI 10.1210/jc.2011 3479
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Oswald AJ, 2014, CALCIFIED TISSUE INT, V94, P176, DOI 10.1007/s00223 013 9788 5
   Ott S, 2015, BONE PHYSIOL
   Recker R, 2004, BONE, V34, P890, DOI 10.1016/j.bone.2004.01.008
   Recker RR, 2007, BONE, V40, P843, DOI 10.1016/j.bone.2006.11.001
   Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010
   Seeman E, 2010, J BONE MINER RES, V25, P1886, DOI 10.1002/jbmr.81
   Sorensen OH, 2003, BONE, V32, P120, DOI 10.1016/S8756 3282(02)00946 8
   Sornay Rendu E, 2007, J BONE MINER RES, V22, P425, DOI 10.1359/JBMR.061206
   Sugimoto T, 2015, OSTEOPOROSIS INT, V26, P765, DOI 10.1007/s00198 014 2964 2
   Watts NB, 2008, OSTEOPOROSIS INT, V19, P365, DOI 10.1007/s00198 007 0460 7
   World Health Organization Collaborating Centre for Metabolic Bone Diseases University of Sheffield U, 2014, FRAX WHO FRACT RISK
NR 38
TC 7
Z9 7
U1 0
U2 12
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1567 567X
EI 1573 8744
J9 J PHARMACOKINET PHAR
JI J. Pharmacokinet. Pharmacodyn.
PD DEC
PY 2017
VL 44
IS 6
BP 599
EP 609
DI 10.1007/s10928 017 9551 z
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA FM8XO
UT WOS:000415375800007
PM 29081020
DA 2025 08 17
ER

PT J
AU Xu, KH
   He, RZ
   Zhang, Y
   Qin, S
   Wang, GC
   Wei, Q
   Zhang, H
   Ji, F
AF Xu, Kaihang
   He, Rongzhi
   Zhang, Yuan
   Qin, Sheng
   Wang, Guangchao
   Wei, Qiang
   Zhang, Hao
   Ji, Fang
TI Forsythiaside inhibited titanium particle induced inflammation
   via the NF κB signaling pathway and RANKL induced
   osteoclastogenesis and titanium particle induced periprosthetic
   osteolysis via JNK, p38, and ERK signaling pathways
SO RSC ADVANCES
LA English
DT Article
ID IN VIVO; ANTIOXIDANT; SUPPRESSION; MELATONIN
AB Wear particle induced periprosthetic osteolysis is the primary complication of the total joint replacement; however, no conservative treatment except for reversal surgery is available for this disease. During the past decade, Chinese herbal medicines have been widely investigated to inhibit osteoclast differentiation, which may exhibit the potential to treat wear particle induced periprosthetic osteolysis. The present study was aimed at the investigation of the effects of forsythiaside on osteocytes. The current data revealed that the forsythiaside treatment notably inhibited the titanium (Ti) particle induced inflammation through impaired NF B signaling, thereby inhibiting TNF  and IL 1. In addition, the in vitro study demonstrated that forsythiaside effectively prevented the RANKL induced differentiation of osteoclasts and inhibited the expression of osteoclast specific genes in osteoclasts via inhibition of the JNK signaling pathway. The in vivo study of Ti particle induced implant associated osteolysis indicated that forsythiaside could also inhibit osteoclastogenesis. In summary, forsythiaside could inhibit osteoclastogenesis and particle induced inflammation, resulting in decreased secretion of inflammatory cytokines such as TNF  and IL 1. On the other hand, forsythiaside could inhibit RANKL induced osteoclastogenesis and Ti particle induced periprosthetic osteolysis via JNK, ERK and p38 signaling pathways. Both the abovementioned biofunctions of forsythiaside contributed to the implant associated particle induced osteolysis. Thus, forsythiaside can act as a candidate drug for the precaution of implant associated particle induced osteolysis.
C1 [Xu, Kaihang; He, Rongzhi; Qin, Sheng; Wang, Guangchao; Wei, Qiang; Zhang, Hao; Ji, Fang] Navy Mil Med Univ, Changhai Hosp, Dept Orthoped, 168 Changhai Rd, Shanghai 200433, Peoples R China.
   [Zhang, Yuan] Navy Mil Med Univ, Changhai Hosp, Dept Ophthalmol, Shanghai, Peoples R China.
C3 Naval Medical University; Naval Medical University
RP Zhang, H; Ji, F (通讯作者)，Navy Mil Med Univ, Changhai Hosp, Dept Orthoped, 168 Changhai Rd, Shanghai 200433, Peoples R China.
EM zhanghsmmu@126.com; doctorjif@126.com
RI ji, fang/JXN 5517 2024; Zhang, Hao/GXF 4628 2022
FU Shanghai Committee of Science and Technology Foundation [13411951500];
   Second Military Medical University School Program [2016QN09]
FX This work was supported by the grants received from the Shanghai
   Committee of Science and Technology Foundation (No. 13411951500) and The
   Second Military Medical University School Program (2016QN09).
CR Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cheng GD, 2014, EXP THER MED, V7, P179, DOI 10.3892/etm.2013.1378
   Gallo J, 2014, ACTA BIOMATER, V10, P2354, DOI 10.1016/j.actbio.2014.02.003
   Hallab NJ, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00005
   Harshan S, 2018, PEERJ, V6, DOI 10.7717/peerj.5743
   Jämsen E, 2017, J BIOMED MATER RES A, V105, P454, DOI 10.1002/jbm.a.35913
   Jiang YP, 2013, ACTA ORTHOP BELG, V79, P1
   Landgraeber S, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/185150
   Li HF, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018 018 0834 x
   Liu FX, 2009, BIOMATERIALS, V30, P1756, DOI 10.1016/j.biomaterials.2008.12.018
   Liu XQ, 2014, BIOMATERIALS, V35, P5721, DOI 10.1016/j.biomaterials.2014.04.006
   Ma JJ, 2015, BIOCHEM J, V469, P399, DOI 10.1042/BJ20150151
   Ouyang ZX, 2014, BIOCHEM PHARMACOL, V90, P276, DOI 10.1016/j.bcp.2014.06.009
   Ping ZC, 2017, ACTA BIOMATER, V62, P362, DOI 10.1016/j.actbio.2017.08.046
   Ping ZC, 2017, ACTA BIOMATER, V51, P513, DOI 10.1016/j.actbio.2017.01.034
   Qian J, 2017, EUR J PHARMACOL, V812, P250, DOI 10.1016/j.ejphar.2017.07.033
   Qu HH, 2008, J PHARM PHARMACOL, V60, P261, DOI 10.1211/jpp.60.2.0016
   Qu HH, 2012, BIOORG CHEM, V40, P87, DOI 10.1016/j.bioorg.2011.09.005
   Qu XH, 2018, BIOCHEM BIOPH RES CO, V501, P547, DOI 10.1016/j.bbrc.2018.05.035
   Tai YT, 2016, BLOOD, V127, P3225, DOI 10.1182/blood 2016 01 691162
   WANG J, 2018, FRONT PHARMACOL, V9
   Wang JH, 2016, SCI REP UK, V6, DOI 10.1038/srep23827
   Wu CL, 2015, BIOCHEM PHARMACOL, V93, P59, DOI 10.1016/j.bcp.2014.10.019
   Zeng XY, 2017, INT J MOL MED, V40, P243, DOI 10.3892/ijmm.2017.2990
   Zhai ZJ, 2014, BRIT J PHARMACOL, V171, P663, DOI 10.1111/bph.12463
NR 25
TC 5
Z9 5
U1 0
U2 8
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2046 2069
J9 RSC ADV
JI RSC Adv.
PY 2019
VL 9
IS 22
BP 12384
EP 12393
DI 10.1039/c8ra10007a
PG 10
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA HW5VU
UT WOS:000466758200025
PM 35515832
OA Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Setia, S
   Sanyal, SN
AF Setia, Shruti
   Sanyal, Sankar Nath
TI Downregulation of NF κB and PCNA in the regulatory pathways of apoptosis
   by cyclooxygenase 2 inhibitors in experimental lung cancer
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article
DE DMBA; NSAIDs; PCNA; Redox signaling
ID GROWTH INHIBITION; CELL DEATH; OSTEOPROTEGERIN; EXPRESSION; INDUCTION;
   MORTALITY; DISEASE; AGENTS; LINES; RAT
AB Non steroidal anti inflammatory drugs (NSAIDs) are emerging as novel chemopreventive agents against a variety of cancers owing to their capability in blocking the tumor development by cellular proliferation, angiogenesis and by promoting apoptosis. The present study further explored the comparative role of a traditional NSAID, indomethacin and a newly developed coxib, etoricoxib against 9,10 dimethylbenz(a)anthracene (DMBA) induced lung carcinogenesis in rats. Morphological and histological analysis revealed the occurrence of tumors and lesions along with constricted alveolar spaces in the DMBA treated animals which were largely corrected both by indomethacin and etoricoxib. COX 1 was found to be uniformly expressed in all the groups while COX 2 levels were raised prominently in the DMBA treated animals. Proliferation, as studied by PCNA expression was found to be markedly increased in the DMBA group as compared to the others. Increased NF kappa B expression in the DMBA group was found to correct with the co administration of NSAIDs. Also, fluorescent co staining of the isolated lung cells revealed a significantly decreased apoptosis and altered mitochondrial membrane potential. In conclusion, these parameters indicate to the chemopreventive action of the two NSAIDs studied in lung cancer and as their mechanism of action suggests, can be achievable both by COX dependent and COX independent pathways.
C1 [Setia, Shruti; Sanyal, Sankar Nath] Panjab Univ, Dept Biophys, Chandigarh 160014, India.
C3 Panjab University
RP Sanyal, SN (通讯作者)，Panjab Univ, Dept Biophys, Chandigarh 160014, India.
EM sanyalpu@gmail.com
CR Alberts Keith., 2008, Molecular Biology of the Cell, V5th, P1115
   [Anonymous], 1996, APOPTOSIS
   [Anonymous], BMC CANC
   [Anonymous], MOL CLONING LAB MANU
   BAKER AJ, 1994, J CLIN INVEST, V94, P2105, DOI 10.1172/JCI117565
   Bingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Chandel NS, 2000, J IMMUNOL, V165, P1013, DOI 10.4049/jimmunol.165.2.1013
   Cossarizza A., 2001, Curr Protoc Cytom, V9, P14, DOI [10.1002/0471142956.cy0914s13, DOI 10.1002/0471142956.CY0914S13]
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Croce CM, 2008, NEW ENGL J MED, V358, P502, DOI 10.1056/NEJMra072367
   Fleury C, 2002, BIOCHIMIE, V84, P131, DOI 10.1016/S0300 9084(02)01369 X
   Harris RE, 2007, INT J BIOL SCI, V3, P328
   Harris RE, 2002, ONCOL REP, V9, P693
   Haynes A, 2003, PHARM RES DORDR, V20, P1485, DOI 10.1023/A:1025774630993
   Hida T, 2002, CLIN CANCER RES, V8, P2443
   Jabs T, 1999, BIOCHEM PHARMACOL, V57, P231, DOI 10.1016/S0006 2952(98)00227 5
   Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092 8674(00)81698 0
   Johnson DG, 1999, ANNU REV PHARMACOL, V39, P295, DOI 10.1146/annurev.pharmtox.39.1.295
   Karthikeyan R, 2011, J APPL PHYCOL, V23, P257, DOI 10.1007/s10811 010 9564 0
   Kim HS, 2001, OPHTHALMIC RES, V33, P329, DOI 10.1159/000055689
   LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012
   LEHRACH H, 1977, BIOCHEMISTRY US, V16, P4743, DOI 10.1021/bi00640a033
   LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365 2184.1991.tb01150.x
   Lieb W, 2010, ARTERIOSCL THROM VAS, V30, P1849, DOI 10.1161/ATVBAHA.109.199661
   Mittal N, 2010, AM J BIOMED SCI, V2, P239
   Mungrue Imran N, 2002, Heart Fail Rev, V7, P407, DOI 10.1023/A:1020762401408
   Nelson DE, 2004, SCIENCE, V306, P704, DOI 10.1126/science.1099962
   Pearse AGE, 1968, HISTOCHEMISTRY THEOR, V1, P660
   Ramasamy K, 2011, CLIN CANCER RES, V17, P753, DOI 10.1158/1078 0432.CCR 10 2290
   Riendeau D, 2001, J PHARMACOL EXP THER, V296, P558
   Saini RK, 2008, DRUG CHEM TOXICOL, V31, P459, DOI [10.1080/01480540802390544, 10.1080/01480540802390544 ]
   Saini RK, 2009, ONCOL RES, V17, P505, DOI 10.3727/096504009789745520
   Sanders LM, 2004, J NUTR, V134, P3233, DOI 10.1093/jn/134.12.3233
   Seo SK, 2007, APOPTOSIS, V12, P195, DOI 10.1007/s10495 006 0527 5
   Setia S, 2012, MOL CELL BIOCHEM, V366, P89, DOI 10.1007/s11010 012 1286 y
   SMILEY ST, 1991, P NATL ACAD SCI USA, V88, P3671, DOI 10.1073/pnas.88.9.3671
   Sodini D, 2008, BRIT J PHARMACOL, V153, P1631, DOI 10.1038/bjp.2008.36
   Spiegel A, 2005, BIOCHEM PHARMACOL, V70, P993, DOI 10.1016/j.bcp.2005.06.027
   Stolimenov I, 2009, BIOCHEM SOC T, V37, P605, DOI 10.1042/BST0370605
   STUEHR DJ, 1987, CANCER RES, V47, P5590
   Thakur P, 2010, J ENVIRON PATHOL TOX, V29, P255, DOI 10.1615/JEnvironPatholToxicolOncol.v29.i3.80
   Thakur P, 2010, EXP MOL PATHOL, V88, P394, DOI 10.1016/j.yexmp.2010.03.005
   Thomas LL, 2002, FASEB J, V16, pA1238, DOI 10.1096/fj.01 0590fje
   Venuraju SM, 2010, J AM COLL CARDIOL, V55, P2049, DOI 10.1016/j.jacc.2010.03.013
   Williams JL, 2003, CANCER RES, V63, P7613
   Zhang J. M, NEUROSCIENCE, V105, P663, DOI [10.1016/s0306 4522(01)00206 8, DOI 10.1016/S0306 4522(01)00206 8]
   Zimmermann KC, 1999, CANCER RES, V59, P486
NR 48
TC 18
Z9 20
U1 0
U2 5
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300 8177
EI 1573 4919
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD OCT
PY 2012
VL 369
IS 1 2
BP 75
EP 86
DI 10.1007/s11010 012 1370 3
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 996EK
UT WOS:000308067100009
PM 22752388
DA 2025 08 17
ER

PT J
AU Luo, XJ
   Chen, J
   Song, WX
   Tang, N
   Luo, JY
   Deng, ZL
   Sharff, KA
   He, G
   Bi, Y
   He, BC
   Bennett, E
   Huang, JY
   Kang, Q
   Jiang, W
   Su, YX
   Zhu, GH
   Yin, H
   He, Y
   Wang, Y
   Souris, JS
   Chen, L
   Zuo, GW
   Montag, AG
   Reid, RR
   Haydon, RC
   Luu, HH
   He, TC
AF Luo, Xiaoji
   Chen, Jin
   Song, Wen Xin
   Tang, Ni
   Luo, Jinyong
   Deng, Zhong Liang
   Sharff, Katie A.
   He, Gary
   Bi, Yang
   He, Bai Cheng
   Bennett, Erwin
   Huang, Jiayi
   Kang, Quan
   Jiang, Wei
   Su, Yuxi
   Zhu, Gao Hui
   Yin, Hong
   He, Yun
   Wang, Yi
   Souris, Jeffrey S.
   Chen, Liang
   Zuo, Guo Wei
   Montag, Anthony G.
   Reid, Russell R.
   Haydon, Rex C.
   Luu, Hue H.
   He, Tong Chuan
TI Osteogenic BMPs promote tumor growth of human osteosarcomas that harbor
   differentiation defects
SO LABORATORY INVESTIGATION
LA English
DT Article
DE BMPs; bone tumors; mesenchymal stem cells; osteosarcoma; osteogenic
   differentiation
ID BONE MORPHOGENETIC PROTEINS; MESENCHYMAL STEM CELLS; OSTEOBLAST
   DIFFERENTIATION; RECOMBINANT ADENOVIRUSES; SKELETAL DEVELOPMENT;
   SARCOMA; RETINOBLASTOMA; EXPRESSION; TISSUE; BETA
AB Osteosarcoma (OS) is the most common primary malignancy of bone. Here, we investigated a possible role of defective osteoblast differentiation in OS tumorigenesis. We found that basal levels of the early osteogenic marker alkaline phosphatase (ALP) activity were low in OS lines. Osteogenic regulators Runx2 and OSX, and the late marker osteopontin (OPN) expressed at low levels in most OS lines, indicating that most OS cells fail to undergo terminal differentiation. Furthermore, OS cells were refractory to osteogenic BMP induced increases in ALP activity. Osteogenic BMPs were shown to upregulate early target genes, but not late osteogenic markers OPN and osteocalcin (OC). Furthermore, osteogenic BMPs failed to induce bone formation from human OS cells, rather effectively promoted OS tumor growth in an orthotopic OS model. Exogenous expression of early target genes enhanced BMP stimulated OS tumor growth, whereas osteogenic BMP promoted OS tumor growth was inhibited by exogenous Runx2 expression. These results suggest that alterations in osteoprogenitors may disrupt osteogenic differentiation pathway. Thus, identifying potential differentiation defects in OS tumors would allow us to reconstruct the tumorigenic events in osteoprogenitors and to develop rational differentiation therapies for clinical OS management.
C1 [He, Tong Chuan] Univ Chicago, Med Ctr, Dept Surg, Mol Oncol Lab, Chicago, IL 60637 USA.
   [Luo, Xiaoji; Chen, Jin; Tang, Ni; Luo, Jinyong; Deng, Zhong Liang; Bi, Yang; He, Bai Cheng; Huang, Jiayi; Kang, Quan; Su, Yuxi; Zhu, Gao Hui; He, Yun; Wang, Yi; Chen, Liang; Zuo, Guo Wei; Reid, Russell R.; He, Tong Chuan] Chongqing Med Univ, Childrens Hosp, Chinese Minist Educ, Key Lab Diagnost Med, Chongqing, Peoples R China.
   [Luo, Xiaoji; Chen, Jin; Tang, Ni; Luo, Jinyong; Deng, Zhong Liang; Bi, Yang; He, Bai Cheng; Huang, Jiayi; Kang, Quan; Jiang, Wei; Su, Yuxi; Zhu, Gao Hui; He, Yun; Wang, Yi; Chen, Liang; Zuo, Guo Wei; He, Tong Chuan] Chongqing Med Univ, Childrens Hosp, Dept Pediat Surg, Chongqing, Peoples R China.
   [He, Gary; Montag, Anthony G.] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA.
   [Souris, Jeffrey S.] Univ Chicago, Opt Imaging Core Facil, Chicago, IL 60637 USA.
   [Souris, Jeffrey S.] Univ Chicago, Dept Radiol, Chicago, IL 60637 USA.
C3 University of Chicago; University of Chicago Medical Center; Chongqing
   Medical University; Chongqing Medical University; University of Chicago;
   University of Chicago; University of Chicago
RP He, TC (通讯作者)，Univ Chicago, Med Ctr, Dept Surg, Mol Oncol Lab, 5841 S Maryland Ave,MC 3079, Chicago, IL 60637 USA.
EM hluu@surgery.bsd.uchicago.edu; tche@surgery.bsd.uchicago.edu
RI Reid, Russell/LIF 6227 2024; huang, jiayi/AAR 3913 2021; Tang,
   Ni/Z 5133 2019
FU China Natural Science Foundation; China Ministry of Science and
   Technology; American Cancer Society; Brinson Foundation; National
   Institutes of Health; Orthopaedic Research and Education Foundation; The
   University of Chicago Cancer Research Center
FX We are grateful for Dr Michael Simon and Dr Terrance Peabody of The
   University of Chicago Medical Center for their encouragement of this
   work and assistance on collecting human OS samples. We thank Dr Thomas C
   Spelsberg of Mayo Clinic College of Medicine, Rochester, MN, for
   generous provision of the hFOB1.19 osteoblast cell line. This work was
   supported in part by research grants from China Natural Science
   Foundation (JL, ZLD, and QK), the China Ministry of Science and
   Technology (JL, ZLD, BCH, QK, LC, and TCH), the American Cancer Society
   (TCH and HHL). The Brinson Foundation (TCH), the National Institutes of
   Health (RCH, TCH and HHL), and the Orthopaedic Research and Education
   Foundation (HHL). The Xenogen bioluminescence imaging performed at the
   Optical Imaging Core Facility was supported by a pilot grant from The
   University of Chicago Cancer Research Center.
CR ABRAMSON DH, 1984, OPHTHALMOLOGY, V91, P1351
   Arndt CAS, 1999, NEW ENGL J MED, V341, P342, DOI 10.1056/NEJM199907293410507
   Aubin J E, 2001, Rev Endocr Metab Disord, V2, P81, DOI 10.1023/A:1010011209064
   Bruland OS, 1997, EUR J CANCER, V33, P1725, DOI 10.1016/S0959 8049(97)00252 9
   Caplan AI, 2001, TRENDS MOL MED, V7, P259, DOI 10.1016/S1471 4914(01)02016 0
   Carpio L, 2001, AM J PHYSIOL ENDOC M, V281, pE489, DOI 10.1152/ajpendo.2001.281.3.E489
   Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623 200308000 00017
   Deng ZL, 2008, FRONT BIOSCI LANDMRK, V13, P2001, DOI 10.2741/2819
   Dorfman H D, 1984, Semin Diagn Pathol, V1, P215
   DRAPER GJ, 1986, BRIT J CANCER, V53, P661, DOI 10.1038/bjc.1986.110
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Gobbi G, 2002, INT J ONCOL, V20, P143
   Gorlick R, 2003, CLIN CANCER RES, V9, P5442
   Guo W, 1999, CLIN ORTHOP RELAT R, P175
   HARRIS SA, 1995, J BONE MINER RES, V10, P178
   Haydon RC, 2002, INT J CANCER, V102, P338, DOI 10.1002/ijc.10719
   Haydon RC, 2002, CLIN CANCER RES, V8, P1288
   Haydon RC, 2007, CLIN ORTHOP RELAT R, P237, DOI 10.1097/BLO.0b013e31802b683c
   He T. C., 2005, Journal of Musculoskeletal & Neuronal Interactions, V5, P363
   He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092 8674(00)81664 5
   Helman LJ, 2003, NAT REV CANCER, V3, P685, DOI 10.1038/nrc1168
   Hoang BH, 2004, CANCER RES, V64, P2734, DOI 10.1158/0008 5472.CAN 03 1952
   Hong SH, 2000, AM J VET RES, V61, P69, DOI 10.2460/ajvr.2000.61.69
   HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775
   Kang Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298
   Keel SB, 2001, MODERN PATHOL, V14, P969, DOI 10.1038/modpathol.3880420
   Lengner CJ, 2006, J CELL BIOL, V172, P909, DOI 10.1083/jcb.200508130
   Luo J, 2005, CURR GENE THER, V5, P167, DOI 10.2174/1566523053544218
   Luo J, 2007, NAT PROTOC, V2, P1236, DOI 10.1038/nprot.2007.135
   Luo JY, 2007, LAB INVEST, V87, P97, DOI 10.1038/labinvest.3700509
   Luo Q, 2004, J BIOL CHEM, V279, P55958, DOI 10.1074/jbc.M407810200
   Luo Q, 2007, GENE, V395, P160, DOI 10.1016/j.gene.2007.02.030
   Luu HH, 2005, CANCER LETT, V229, P135, DOI 10.1016/j.canlet.2005.02.015
   Luu HH, 2005, CLIN EXP METASTAS, V22, P319, DOI 10.1007/s10585 005 0365 9
   Luu HH, 2004, CURR CANCER DRUG TAR, V4, P653, DOI 10.2174/1568009043332709
   Luu HH, 2007, J ORTHOP RES, V25, P665, DOI 10.1002/jor.20359
   MARK RJ, 1994, CANCER, V73, P2653, DOI 10.1002/1097 0142(19940515)73:10<2653::AID CNCR2820731030>3.0.CO;2 G
   Meyers PA, 1997, PEDIATR CLIN N AM, V44, P973, DOI 10.1016/S0031 3955(05)70540 X
   Nozaki K, 1999, J VET MED SCI, V61, P649, DOI 10.1292/jvms.61.649
   Peng Y, 2004, J BIOL CHEM, V279, P32941, DOI 10.1074/jbc.M403344200
   Peng Y, 2003, J CELL BIOCHEM, V90, P1149, DOI 10.1002/jcb.10744
   Postiglione L, 2003, CALCIFIED TISSUE INT, V72, P85, DOI 10.1007/s00223 001 2088 5
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Sandberg AA, 2003, CANCER GENET CYTOGEN, V145, P1, DOI 10.1016/S0165 4608(03)00105 5
   Si WK, 2006, MOL CELL BIOL, V26, P2955, DOI 10.1128/MCB.26.8.2955 2964.2006
   Siggelkow H, 2002, J CELL BIOCHEM, V85, P279, DOI 10.1002/jcb.10122
   Sulzbacher I, 2002, J CLIN PATHOL, V55, P381, DOI 10.1136/jcp.55.5.381
   Thomas DM, 2004, J CELL BIOL, V167, P925, DOI 10.1083/jcb.200409187
   Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097 2765(01)00327 6
   Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027
   Torchia EC, 2003, CANCER RES, V63, P3464
   TSENG YH, 2007, CELL SCI REV, V3, P324
   UNNI KK, 1989, SEMIN ROENTGENOL, V24, P143, DOI 10.1016/0037 198X(89)90010 2
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   Yeny CT, 2005, CANCER RES, V65, P8698, DOI 10.1158/0008 5472.CAN 05 1704
   YOSHIKAWA H, 1988, CANCER AM CANCER SOC, V61, P569, DOI 10.1002/1097 0142(19880201)61:3<569::AID CNCR2820610324>3.0.CO;2 Z
   Yoshikawa H, 2004, J ORTHOP SCI, V9, P334, DOI 10.1007/s00776 004 0764 9
   YOSHIKAWA H, 1994, CANCER, V74, P842, DOI 10.1002/1097 0142(19940801)74:3<842::AID CNCR2820740309>3.0.CO;2 B
   Zenmyo M, 2001, HUM PATHOL, V32, P410, DOI 10.1053/hupa.2001.23524
   Zhou L, 2003, CANCER LETT, V193, P161, DOI 10.1016/S0304 3835(03)00013 2
NR 63
TC 186
Z9 204
U1 0
U2 19
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013 1917 USA
SN 0023 6837
EI 1530 0307
J9 LAB INVEST
JI Lab. Invest.
PD DEC
PY 2008
VL 88
IS 12
BP 1264
EP 1277
DI 10.1038/labinvest.2008.98
PG 14
WC Medicine, Research & Experimental; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pathology
GA 375JD
UT WOS:000261109100002
PM 18838962
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Subedi, L
   Pandey, P
   Kang, SH
   Kim, KT
   Cho, SS
   Chang, KY
   Byun, Y
   Shim, JH
   Park, JW
AF Subedi, Laxman
   Pandey, Prashant
   Kang, Seo Hee
   Kim, Ki Taek
   Cho, Seung Sik
   Chang, Kwan Young
   Byun, Youngro
   Shim, Jung Hyun
   Park, Jin Woo
TI Enhanced oral absorption of teriparatide with therapeutic potential for
   management of osteoporosis
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Teriparatide; Bile acid derivative; Permeability; Oral bioavailability;
   Antiosteoporosis
ID PARATHYROID HORMONE; BONE FORMATION; BILE ACID; MICRODAMAGE
   ACCUMULATION; SKELETAL SITES; DRUG DELIVERY; IN VITRO; PEPTIDE;
   FORMULATIONS; EFFICACY
AB In this study, a system for oral delivery of recombinant human parathyroid hormone [rhPTH(1 34); teriparatide (TRP)] was developed to enhance oral absorption and to demonstrate an equivalent therapeutic effect to that of subcutaneous (SC) TRP injection. The solid oral formulation of TRP was prepared by electrostatic complexation with L lysine linked deoxycholic acid (LDA) and deoxycholic acid (DA) at a molar ratio of 1:5:7 in the aqueous dispersion of non ionic n dodecyl beta D maltoside (DM) at a 1:15 weight ratio, followed by freeze drying the dispersal, yielding TRP(1:5:7) 15. As expected, TRP(1:5:7) 15 showed a 414% increase in permeability across the Caco 2/HT29 MTX E12 cell monolayer, resulting in a 13.0 fold greater oral bioavailability compared with free TRP. In addition, the intestinal transport mechanisms in the presence of specific inhibitors of clathrin mediated endocytosis, macropinocytosis, and bile acid transporters revealed 44.4%, 28.7%, and 51.2% decreases in transport, respectively, confirming that these routes play crucial roles in the permeation of TRP in TRP(1:5:7) 15. Notably, this formulation showed similar activation of the release of cyclic adenosine monophosphate (cAMP) compared with TRP, suggesting equivalent efficacy in the parathyroid hormone receptor adenylate cyclase system of osteosarcoma cells. Furthermore, oral TRP(1:5:7) 15 (equivalent to 0.4 mg/kg TRP) demonstrated increases in bone mineral density (36.9%) and trabecular thickness (31.3%) compared with untreated glucocorticoid induced osteoporotic mice. Moreover, the elevated levels of biomarkers of bone formation, including osteocalcin, were also comparable with those after SC injection of TRP (0.02 mg/kg). These findings suggest that TRP(1:5:7) 15 can be used as an effective oral therapy for the management of osteoporosis.
C1 [Subedi, Laxman; Pandey, Prashant; Kim, Ki Taek; Cho, Seung Sik; Shim, Jung Hyun; Park, Jin Woo] Mokpo Natl Univ, Biomed & Healthcare Res Inst, Dept Biomed Hlth & Life Convergence Sci, BK21 Four, Jeonnam 58554, South Korea.
   [Kang, Seo Hee; Chang, Kwan Young] Global R&D Ctr, IcureBNP, Seoul 07985, South Korea.
   [Kim, Ki Taek; Cho, Seung Sik; Shim, Jung Hyun; Park, Jin Woo] Mokpo Natl Univ, Coll Pharm, Jeonnam 58554, South Korea.
   [Cho, Seung Sik; Shim, Jung Hyun] Mokpo Natl Univ, Nat Med Res Inst, Jeonnam 58554, South Korea.
   [Byun, Youngro] Seoul Natl Univ, Res Inst Pharmaceut Sci, Coll Pharm, Seoul 08826, South Korea.
   [Byun, Youngro] Seoul Natl Univ, Coll Pharm, Grad Sch Convergence Sci & Technol, Dept Mol Med & Biopharmaceut Sci, Seoul 08826, South Korea.
   [Shim, Jung Hyun; Park, Jin Woo] 1666 Youngsan Ro, Jeonnam 58554, South Korea.
C3 Mokpo National University; Mokpo National University; Mokpo National
   University; Seoul National University (SNU); Seoul National University
   (SNU)
RP Shim, JH; Park, JW (通讯作者)，1666 Youngsan Ro, Jeonnam 58554, South Korea.
EM s1004jh@gmail.com; jwpark@mokpo.ac.kr
RI Subedi, Laxman/LOR 9277 2024; Park, Jin Woo/AGY 9085 2022; Cho, Seung
   Sik/JFJ 2665 2023
OI Subedi, Laxman/0000 0003 0857 4458; Pandey,
   Prashant/0000 0003 0575 8120; 
FU Technology Development Program   Ministry of SMEs and Startups (MSS),
   Korea [S2883658]; National Research Foundation of Korea (NRF)   Korea
   government (MSIT) [2022R1A5A8033794]
FX This work was supported by the Technology Development Program funded by
   the Ministry of SMEs and Startups (MSS) , Korea (no. S2883658) ; the
   National Research Foundation of Korea (NRF) grant funded by the Korea
   government (MSIT) (no. 2022R1A5A8033794) . We thank the Convergence
   Research Laboratory (established by the MNU Innovation Support Project
   in 2020) for granting us permission to conduct this research.
CR Abdolvahab MH, 2014, J INTERF CYTOK RES, V34, P894, DOI 10.1089/jir.2013.0131
   ArmamentoVillareal R, 1997, J BONE MINER RES, V12, P384, DOI 10.1359/jbmr.1997.12.3.384
   Bak A, 2015, AAPS J, V17, P144, DOI 10.1208/s12248 014 9688 2
   Burd CG, 2011, TRAFFIC, V12, P948, DOI 10.1111/j.1600 0854.2011.01188.x
   BURTON PS, 1991, ADV DRUG DELIVER REV, V7, P365, DOI 10.1016/0169 409X(91)90014 4
   Chambers EE, 2013, J CHROMATOGR B, V938, P96, DOI 10.1016/j.jchromb.2013.08.027
   Chou LYT, 2011, CHEM SOC REV, V40, P233, DOI 10.1039/c0cs00003e
   Deng FY, 2020, J CONTROL RELEASE, V327, P100, DOI 10.1016/j.jconrel.2020.07.034
   Deshmukh DD, 2010, DRUG DELIV, V17, P145, DOI 10.3109/10717541003604882
   Diab DL, 2013, THER ADV MUSCULOSKEL, V5, P107, DOI 10.1177/1759720X13477714
   Donahue ND, 2019, ADV DRUG DELIVER REV, V143, P68, DOI 10.1016/j.addr.2019.04.008
   Eswaramoorthy R, 2012, ACTA BIOMATER, V8, P2254, DOI 10.1016/j.actbio.2012.03.015
   Fan WW, 2016, DRUG DISCOV TODAY, V21, P856, DOI 10.1016/j.drudis.2016.04.007
   Fein KC, 2022, EUR J PHARM BIOPHARM, V170, P70, DOI 10.1016/j.ejpb.2021.11.010
   Fetih G, 2005, INT J PHARMACEUT, V293, P127, DOI 10.1016/j.ijpharm.2004.12.017
   Fraher LJ, 1999, J CLIN ENDOCR METAB, V84, P2739, DOI 10.1210/jc.84.8.2739
   Gradauer K, 2017, MOL PHARMACEUT, V14, P4734, DOI 10.1021/acs.molpharmaceut.7b00297
   Guo LT, 2011, INT J PHARMACEUT, V420, P172, DOI 10.1016/j.ijpharm.2011.08.029
   He B, 2013, BIOMATERIALS, V34, P6082, DOI 10.1016/j.biomaterials.2013.04.053
   Hwang SR, 2016, INT J NANOMED, V11, P4231, DOI 10.2147/IJN.S110573
   Jannin V, 2008, ADV DRUG DELIVER REV, V60, P734, DOI 10.1016/j.addr.2007.09.006
   Jeon OC, 2016, EUR J PHARM SCI, V82, P1, DOI 10.1016/j.ejps.2015.11.004
   JONKMAN JHG, 1983, PHARM WEEKBLAD, V5, P41, DOI 10.1007/BF01960074
   Kim SK, 2010, MOL PHARMACEUT, V7, P708, DOI 10.1021/mp9002688
   Kusuma MB, 2021, J CHROMATOGR B, V1187, DOI 10.1016/j.jchromb.2021.123046
   Langguth P, 1997, J CONTROL RELEASE, V46, P39, DOI 10.1016/S0168 3659(96)01586 6
   Lee S, 2006, ANTIMICROB AGENTS CH, V50, P1869, DOI 10.1128/AAC.50.5.1869 1871.2006
   Leone Bay A, 2001, PHARMACEUT RES, V18, P964, DOI 10.1023/A:1010936227570
   Li M, 1999, BONE, V24, P95, DOI 10.1016/S8756 3282(98)00167 7
   Li M, 2020, PHARMACOL THERAPEUT, V212, DOI 10.1016/j.pharmthera.2020.107539
   Luessen HL, 1996, PHARM RES DORDR, V13, P1668, DOI 10.1023/A:1016488623022
   Maharjan R, 2021, DRUG DELIV, V28, P2313, DOI 10.1080/10717544.2021.1995077
   Maher S, 2016, ADV DRUG DELIVER REV, V106, P277, DOI 10.1016/j.addr.2016.06.005
   Mandal T, 2018, SOFT MATTER, V14, P2694, DOI [10.1039/C8SM00274F, 10.1039/c8sm00274f]
   Marx UC, 2000, BIOCHEM BIOPH RES CO, V267, P213, DOI 10.1006/bbrc.1999.1958
   Mashiba T, 2001, BONE, V28, P524, DOI 10.1016/S8756 3282(01)00414 8
   Matsson P, 2017, J MED CHEM, V60, P1662, DOI 10.1021/acs.jmedchem.7b00237
   Meng QQ, 2018, INT J NANOMED, V13, P705, DOI 10.2147/IJN.S151474
   MITCHELL J, 1990, ENDOCRINOLOGY, V126, P2327, DOI 10.1210/endo 126 5 2327
   Mohan S, 2000, BONE, V27, P471, DOI 10.1016/S8756 3282(00)00355 0
   MOSEKILDE L, 1995, BONE, V16, P223, DOI 10.1016/8756 3282(94)00033 V
   Otzen D, 2011, BBA PROTEINS PROTEOM, V1814, P562, DOI 10.1016/j.bbapap.2011.03.003
   Pangeni R, 2020, INT J NANOMED, V15, P7719, DOI 10.2147/IJN.S267424
   Pangeni R, 2018, INT J NANOMED, V13, P3329, DOI 10.2147/IJN.S167958
   Pangeni R, 2016, INT J NANOMED, V11, P6379, DOI 10.2147/IJN.S121114
   Park JW, 2010, MOL PHARMACEUT, V7, P836, DOI 10.1021/mp900319k
   Park J, 2017, BIOMATERIALS, V147, P145, DOI 10.1016/j.biomaterials.2017.09.022
   Postnov A, 2009, CALCIFIED TISSUE INT, V85, P530, DOI 10.1007/s00223 009 9301 3
   Pouton CW, 2000, EUR J PHARM SCI, V11, pS93, DOI 10.1016/S0928 0987(00)00167 6
   Raimondi F, 2008, AM J PHYSIOL GASTR L, V294, pG906, DOI 10.1152/ajpgi.00043.2007
   Rifkin RA, 2011, J NEUROIMMUNE PHARM, V6, P158, DOI 10.1007/s11481 010 9226 7
   Rizzoli R, 2015, NAT REV RHEUMATOL, V11, P98, DOI 10.1038/nrrheum.2014.188
   Stepan JJ, 2007, BONE, V41, P378, DOI 10.1016/j.bone.2007.04.198
   Suzuki Y, 2014, J BONE MINER METAB, V32, P337, DOI 10.1007/s00774 014 0586 6
   Wang T, 2010, EUR J PHARM SCI, V39, P373, DOI 10.1016/j.ejps.2010.01.006
   Watanabe A, 2018, J TOXICOL SCI, V43, P435, DOI 10.2131/jts.43.435
   Watanabe A, 2012, J TOXICOL SCI, V37, P617
   Whyte MP, 2003, NEW ENGL J MED, V349, P457, DOI 10.1056/NEJMoa023110
   Wibel R, 2020, EUR J PHARM BIOPHARM, V151, P73, DOI 10.1016/j.ejpb.2020.04.004
   Wu L, 2010, DRUG DEV IND PHARM, V36, P362, DOI [10.1080/03639040903173580, 10.3109/03639040903173580]
   Yao W, 2008, ARTHRITIS RHEUM, V58, P3485, DOI 10.1002/art.23954
   Zapadka KL, 2017, INTERFACE FOCUS, V7, DOI 10.1098/rsfs.2017.0030
NR 62
TC 12
Z9 15
U1 1
U2 55
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168 3659
EI 1873 4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD SEP
PY 2022
VL 349
BP 502
EP 519
DI 10.1016/j.jconrel.2022.07.012
EA JUL 2022
PG 18
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA 4F2MH
UT WOS:000848349600009
PM 35835400
DA 2025 08 17
ER

PT J
AU Wang, YX
   Wang, K
   Hu, ZB
   Zhou, H
   Zhang, LJ
   Wang, H
   Li, GZ
   Zhang, S
   Cao, XS
   Shi, F
AF Wang, Yixuan
   Wang, Ke
   Hu, Zebing
   Zhou, Hua
   Zhang, Lijun
   Wang, Han
   Li, Gaozhi
   Zhang, Shu
   Cao, Xinsheng
   Shi, Fei
TI MicroRNA 139 3p regulates osteoblast differentiation and apoptosis by
   targeting ELK1 and interacting with long noncoding RNA ODSM
SO CELL DEATH & DISEASE
LA English
DT Article
ID SIMULATED MICROGRAVITY; BONE FORMATION; GENE EXPRESSIONS; SPACE FLIGHT;
   CANCER; TRANSCRIPTION; WEIGHTLESSNESS; PROLIFERATION; METABOLISM;
   FEATURES
AB Recent studies have confirmed that microRNAs and lncRNAs can affect bone cell differentiation and bone formation. In this study, miR 139 3p was upregulated in the femurs of hindlimb unloading mice and MC3T3 E1 cells under simulated microgravity; this effect was related to osteoblast differentiation and apoptosis. Silencing miR 139 3p attenuated the suppression of differentiation and the promotion of MC3T3 E1 cell apoptosis induced by simulated microgravity. ELK1 is a target of miR 139 3p and is essential for miR 139 3p to regulate osteoblast differentiation and apoptosis. An osteoblast differentiation related lncRNA that could interact with miR 139 3p (lncRNA ODSM) was identified in MC3T3 E1 cells under simulated microgravity. Further investigations demonstrated that lncRNA ODSM could promote MC3T3 E1 cell differentiation. Therefore, this research was the first to reveal the critical role of the lncRNA ODSM/miR 139 3p/ELK1 pathway in osteoblasts, and these findings suggest the potential value of miR 139 3p in osteoporosis diagnosis and therapy.
C1 [Wang, Yixuan; Wang, Ke; Hu, Zebing; Zhou, Hua; Zhang, Lijun; Wang, Han; Li, Gaozhi; Zhang, Shu; Cao, Xinsheng; Shi, Fei] Air Force Med Univ, Key Lab Aerosp Med, Minist Educ, Xian 710032, Shaanxi, Peoples R China.
C3 Air Force Medical University
RP Zhang, S; Cao, XS; Shi, F (通讯作者)，Air Force Med Univ, Key Lab Aerosp Med, Minist Educ, Xian 710032, Shaanxi, Peoples R China.
EM shuzhang89@hotmail.com; caoxinsh@fmmu.edu.cn; sdfapple719@126.com
OI Zhang, Shu/0000 0002 4380 1268
FU National Natural Science Foundation of China [31570939, 81701856,
   81471815, 31170889]; Key Pre research Project of Manned Spaceflight
   [020106]
FX The present study was supported by grants from the National Natural
   Science Foundation of China (grant nos. 31570939, 81701856, 81471815,
   and 31170889) and the Key Pre research Project of Manned Spaceflight
   (grant no. 020106).
CR Arfat Y, 2014, CALCIFIED TISSUE INT, V94, P569, DOI 10.1007/s00223 014 9851 x
   Basso N, 2005, BONE, V36, P173, DOI 10.1016/j.bone.2004.09.016
   Bhaskaran M, 2014, VET PATHOL, V51, P759, DOI 10.1177/0300985813502820
   Caillot Augusseau A, 1998, CLIN CHEM, V44, P578
   Canalis E, 2009, J CELL BIOCHEM, V108, P769, DOI 10.1002/jcb.22322
   Chen JY, 2015, DRUG DEVELOP RES, V76, P235, DOI 10.1002/ddr.21260
   Clarke BL, 2010, RADIOL CLIN N AM, V48, P483, DOI 10.1016/j.rcl.2010.02.014
   Fischer S. E., 2015, CURR PROTOC MOL BIOL, V112
   GLOBUS RK, 1984, ENDOCRINOLOGY, V114, P2264, DOI 10.1210/endo 114 6 2264
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hargens AR, 2016, J APPL PHYSIOL, V120, P891, DOI 10.1152/japplphysiol.00935.2015
   Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564
   Hu ZB, 2017, MOL MED REP, V16, P8180, DOI 10.3892/mmr.2017.7671
   Hu ZB, 2015, SCI REP UK, V5, DOI 10.1038/srep18655
   Huang P, 2016, BIOMED PHARMACOTHER, V83, P850, DOI 10.1016/j.biopha.2016.07.050
   Kawahara T, 2016, PROSTATE, V76, P744, DOI 10.1002/pros.23164
   Kim HK, 2014, FOOD FUNCT, V5, P573, DOI 10.1039/c3fo60509d
   Kousteni S, 2003, J CLIN INVEST, V111, P1651, DOI 10.1172/JCI200317261
   Laliotis A, 2013, BREAST, V22, P89, DOI 10.1016/j.breast.2012.09.013
   LeBlanc A., 2000, Journal of Musculoskeletal & Neuronal Interactions, V1, P157
   Long HT, 2017, DNA CELL BIOL, V36, P715, DOI 10.1089/dna.2017.3657
   Mohr AM, 2015, SEMIN LIVER DIS, V35, P3, DOI 10.1055/s 0034 1397344
   Morris JF, 2013, HUM PATHOL, V44, P766, DOI 10.1016/j.humpath.2012.08.001
   Nagaraja MP, 2013, J CELL BIOCHEM, V114, P1001, DOI 10.1002/jcb.24454
   Nakashima K, 2003, TRENDS GENET, V19, P458, DOI 10.1016/S0168 9525(03)00176 8
   Ng L, 2017, ONCOTARGET, V8, P27393, DOI 10.18632/oncotarget.16171
   Papaioannou G, 2014, CELL MOL LIFE SCI, V71, P4747, DOI 10.1007/s00018 014 1700 6
   Pietschmann P, 2016, GERONTOLOGY, V62, P128, DOI 10.1159/000431091
   Quinn JJ, 2016, NAT REV GENET, V17, P47, DOI 10.1038/nrg.2015.10
   Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev biochem 051410 092902
   Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014
   Schwarz R P, 1992, J Tissue Cult Methods, V14, P51, DOI 10.1007/BF01404744
   Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076
   Shi J, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.44
   Shi WG, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 02049 9
   Smith SM, 2002, NUTRITION, V18, P849, DOI 10.1016/S0899 9007(02)00895 X
   Sun ZY, 2015, BONE, V76, P121, DOI 10.1016/j.bone.2015.04.006
   Tezuka K, 2002, J BONE MINER RES, V17, P231, DOI 10.1359/jbmr.2002.17.2.231
   Tsao Y D, 1992, Physiologist, V35, pS49
   Wang H, 2016, SCI REP UK, V6, DOI 10.1038/srep23170
   Weissgerber TL, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002128
   Wiren KM, 2004, J MOL ENDOCRINOL, V32, P209, DOI 10.1677/jme.0.0320209
   Wu CC, 2006, J CELL BIOCHEM, V98, P632, DOI 10.1002/jcb.20697
   Ying W, 2016, SCI REP UK, V6, DOI 10.1038/srep20176
   Yonemori M, 2016, CANCER SCI, V107, P1233, DOI 10.1111/cas.13002
   Zhang Y, 2009, J BIOL CHEM, V284, P3125, DOI 10.1074/jbc.M807466200
   Zhuang WZ, 2015, STEM CELLS, V33, P1985, DOI 10.1002/stem.1989
NR 47
TC 64
Z9 69
U1 0
U2 20
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041 4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD OCT 31
PY 2018
VL 9
AR 1107
DI 10.1038/s41419 018 1153 1
PG 16
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA GZ5QC
UT WOS:000449479500002
PM 30382082
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Querques, F
   Cantilena, B
   Cozzolino, C
   Esposito, MT
   Passaro, F
   Parisi, S
   Lombardo, B
   Russo, T
   Pastore, L
AF Querques, Francesca
   Cantilena, Bruno
   Cozzolino, Carmine
   Esposito, Maria Teresa
   Passaro, Fabiana
   Parisi, Silvia
   Lombardo, Barbara
   Russo, Tommaso
   Pastore, Lucio
TI Angiotensin Receptor I Stimulates Osteoprogenitor Proliferation Through
   TGFβ Mediated Signaling
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID CONVERTING ENZYME INHIBITOR; MESENCHYMAL STEM CELLS; AORTIC ANEURYSM;
   MARFAN SYNDROME; BONE MASS; AT(1) RECEPTOR; SELF RENEWAL; OSTEOPOROSIS;
   OSTEOBLASTS; LOSARTAN
AB Clinical studies of large human populations and pharmacological interventions in rodent models have recently suggested that anti hypertensive drugs that target angiotensin II (Ang II) activity may also reduce loss of bone mineral density. Here, we identified in a genetic screening the Ang II type I receptor (AT1R) as a potential determinant of osteogenic differentiation and, implicitly, bone formation. Silencing of AT1R expression by RNA interference severely impaired the maturation of a multipotent mesenchymal cell line (W20 17) along the osteoblastic lineage. The same effect was also observed after the addition of the AT1R antagonist losartan but not the AT2R inhibitor PD123,319. Additional cell culture assays traced the time of greatest losartan action to the early stages of W20 17 differentiation, namely during cell proliferation. Indeed, addition of Ang II increased proliferation of differentiating W20 17 and primary mesenchymal stem cells and this stimulation was reversed by losartan treatment. Cells treated with losartan also displayed an appreciable decrease of activated (phosphorylated) Smad2/3 proteins. Moreover, Ang II treatment elevated endogenous transforming growth factor (TGF) expression considerably and in an AT1R dependent manner. Finally, exogenous TGF was able to restore high proliferative activity to W20 17 cells that were treated with both Ang II and losartan. Collectively, these results suggest a novel mechanism of Ang II action in bone metabolism that is mediated by TGF and targets proliferation of osteoblast progenitors. J. Cell. Physiol. 230: 1466 1474, 2015. (c) 2015 Wiley Periodicals, Inc., A Wiley Company
C1 [Querques, Francesca; Cantilena, Bruno; Cozzolino, Carmine; Esposito, Maria Teresa; Passaro, Fabiana; Parisi, Silvia; Lombardo, Barbara; Russo, Tommaso; Pastore, Lucio] CEINGE Biotecnol Avanzate, I 80145 Naples, Italy.
   [Querques, Francesca; Cozzolino, Carmine; Passaro, Fabiana; Parisi, Silvia; Lombardo, Barbara; Russo, Tommaso; Pastore, Lucio] Univ Naples Federico II, Dipartimento Med Mol & Biotecnol Med, Naples, Italy.
   [Cantilena, Bruno; Esposito, Maria Teresa; Parisi, Silvia] SEMM European Sch Mol Med, Naples Site, Italy.
C3 CEINGE Biotecnologie Avanzate; University of Naples Federico II
RP Pastore, L (通讯作者)，CEINGE Biotecnol Avanzate, Via Gaetano Salvatore 486, I 80145 Naples, Italy.
EM pastore@ceinge.unina.it
RI Passaro, Fabiana/I 5941 2012; RUSSO, Tommaso/K 1331 2016; Russo,
   Tommaso/JAX 3321 2023; Pastore, Lucio/AAF 3487 2019; Esposito, Maria
   Teresa/X 3817 2019; PASSARO, Fabiana/I 5941 2012
OI RUSSO, Tommaso/0000 0003 4426 0106; Lombardo,
   Barbara/0000 0003 3884 1043; Pastore, Lucio/0000 0001 6894 9317;
   PASSARO, Fabiana/0000 0003 0150 5302
FU Regione Campania [DDRC 161/07]; MIUR [PS 35 126/Ind]
FX Contract grant sponsor: Regione Campania; Contract grant number: DDRC
   161/07. Contract grant sponsor: MIUR; Contract grant number: PS
   35 126/Ind.
CR Asaba Y, 2009, J BONE MINER RES, V24, P241, DOI [10.1359/jbmr.081006, 10.1359/JBMR.081006]
   Brooke BS, 2008, NEW ENGL J MED, V358, P2787, DOI 10.1056/NEJMoa0706585
   Broulík PD, 2001, PHYSIOL RES, V50, P353, DOI 10.33549/physiolres.9300102
   Bruder SP, 1997, J CELL BIOCHEM, V64, P278, DOI 10.1002/(SICI)1097 4644(199702)64:2<278::AID JCB11>3.0.CO;2 F
   Cohn RD, 2007, NAT MED, V13, P204, DOI 10.1038/nm1536
   Daniels D, 2007, EXP PHYSIOL, V92, P523, DOI 10.1113/expphysiol.2006.036897
   Dennis MS, 2002, STROKE, V33, P728, DOI 10.1161/hs0302.103621
   DiGirolamo CM, 1999, BRIT J HAEMATOL, V107, P275, DOI 10.1046/j.1365 2141.1999.01715.x
   Erlebacher A, 1996, J CELL BIOL, V132, P195, DOI 10.1083/jcb.132.1.195
   Esposito MT, 2009, TISSUE ENG PT A, V15, P2525, DOI 10.1089/ten.tea.2008.0509
   Gu SS, 2012, BIOSCI BIOTECH BIOCH, V76, P1367, DOI 10.1271/bbb.120123
   Habashi JP, 2006, SCIENCE, V312, P117, DOI 10.1126/science.1124287
   Hagiwara H, 1998, J ENDOCRINOL, V156, P543, DOI 10.1677/joe.0.1560543
   Hiruma Y, 1997, BIOCHEM BIOPH RES CO, V230, P176, DOI 10.1006/bbrc.1996.5914
   Izu Y, 2009, J BIOL CHEM, V284, P4857, DOI 10.1074/jbc.M807610200
   Kanis J, 2001, STROKE, V32, P702, DOI 10.1161/01.STR.32.3.702
   Karsenty G, 2006, CELL METAB, V4, P341, DOI 10.1016/j.cmet.2006.10.008
   Kawaguchi Y, 2004, ARTHRITIS RHEUM US, V50, P216, DOI 10.1002/art.11364
   Kitahara K, 2003, ENDOCRINOLOGY, V144, P2132, DOI 10.1210/en.2002 220996
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Li GY, 2014, ARCH ORAL BIOL, V59, P513, DOI 10.1016/j.archoralbio.2014.02.015
   Li XC, 2008, AM J PHYSIOL CELL PH, V294, pC1034, DOI 10.1152/ajpcell.00432.2007
   Lucarini L, 2009, ATHEROSCLEROSIS, V202, P205, DOI 10.1016/j.atherosclerosis.2008.04.038
   Lynn H, 2006, BONE, V38, P584, DOI 10.1016/j.bone.2005.09.011
   Mariotti E, 2008, STEM CELLS DEV, V17, P1039, DOI 10.1089/scd.2008.0212
   Nakai K, 2013, BIOCHIMIE, V95, P922, DOI 10.1016/j.biochi.2012.12.016
   Nistala H, 2010, HUM MOL GENET, V19, P4790, DOI 10.1093/hmg/ddq409
   Nistala H, 2010, ANN NY ACAD SCI, V1192, P253, DOI 10.1111/j.1749 6632.2009.05350.x
   Ono N, 2007, J BIOL CHEM, V282, P25509, DOI 10.1074/jbc.M610782200
   Parisi S, 2008, J CELL SCI, V121, P2629, DOI 10.1242/jcs.027599
   Ramirez F, 2007, J CELL PHYSIOL, V213, P326, DOI 10.1002/jcp.21189
   Ramirez F, 2007, CURR OPIN GENET DEV, V17, P252, DOI 10.1016/j.gde.2007.04.006
   Roelen Bernard A J, 2003, J Orthop Sci, V8, P740, DOI 10.1007/s00776 003 0702 2
   Shimizu H, 2008, FASEB J, V22, P2465, DOI 10.1096/fj.07 098954
   Shimizu H, 2009, HYPERTENS RES, V32, P786, DOI 10.1038/hr.2009.99
   Urano T, 1999, J BIOL CHEM, V274, P12197, DOI 10.1074/jbc.274.18.12197
   von der Recke P, 1999, AM J MED, V106, P273, DOI 10.1016/S0002 9343(99)00028 5
   Zhang Y, 2014, HYPERTENS RES, V37, P43, DOI 10.1038/hr.2013.119
   Zhao X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092085
NR 39
TC 19
Z9 19
U1 0
U2 22
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD JUL
PY 2015
VL 230
IS 7
BP 1466
EP 1474
DI 10.1002/jcp.24887
PG 9
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA CE5AQ
UT WOS:000351842500009
PM 25556973
OA Green Published, Green Accepted
DA 2025 08 17
ER

PT J
AU Nanes, MS
   Kallen, CB
AF Nanes, Mark S.
   Kallen, Caleb B.
TI Clinical assessment of fracture risk and novel therapeutic strategies to
   combat osteoporosis
SO FERTILITY AND STERILITY
LA English
DT Article
DE Osteoporosis; bone mineral density; fracture; risk assessment; FRAX
ID BONE MINERAL DENSITY; GROWTH FACTOR I; CONTINUING OUTCOMES RELEVANT;
   VITAMIN D SUPPLEMENTATION; POSTMENOPAUSAL WOMEN; VERTEBRAL FRACTURE;
   PARATHYROID HORMONE; RANDOMIZED TRIAL; STRONTIUM RANELATE; CALCIUM
   SUPPLEMENTATION
AB Objective: To review the latest tools in the clinical assessment of fracture risk and to review new and emerging options for osteoporosis therapy.
   Design: Retrospective analysis of published studies regarding the diagnosis and treatment of osteoporosis.
   Result(s): Large scale epidemiologic data were recently assembled by the World Health Organization to produce a Web based clinical assessment tool, FRAX, which uses clinical and historical data to provide prompt assessment and quantitation of fracture risk. The FRAX models were developed from studying population based cohorts in Europe, North America, Asia, and Australia. The FRAX algorithms indicate the 10 year probability of hip fracture and the 10 year probability of a major osteoporotic fracture (at the clinical spine, forearm, hip, or shoulder) on which to base treatment decisions. Recent progress in the study of bone metabolism including anabolic pathways that enhance bone maintenance, is anticipated to improve the ways in which skeletal health can be maintained and osteoporosis can be treated.
   Conclusion(s): Using FRAX, fracture risk in now easily assessed in the clinical setting. New and emerging treatment strategies for bone maintenance are reviewed. Improved assessment of fracture risk, combined with tailored therapies for at risk patients, will increase the number of patients who receive appropriate bone sparing therapies. (Fertil Steril (R) 2009;92:403 12. (C)2009 by American Society for Reproductive Medicine.)
C1 [Kallen, Caleb B.] Emory Univ, Sch Med, Dept Gynecol & Obstet, Div Reprod Endocrinol & Infertil, Atlanta, GA 30322 USA.
   [Nanes, Mark S.] Emory Univ, Sch Med, Dept Med, Div Endocrinol Metab & Lipids, Atlanta, GA 30322 USA.
   [Nanes, Mark S.] Vet Affairs Med Ctr, Med Serv 111, Decatur, GA 30033 USA.
C3 Emory University; Emory University; US Department of Veterans Affairs;
   Veterans Health Administration (VHA)
RP Kallen, CB (通讯作者)，Emory Univ, Sch Med, Dept Gynecol & Obstet, Div Reprod Endocrinol & Infertil, 1639 Pierce Dr,WMB 4211, Atlanta, GA 30322 USA.
EM caleb.kallen@emory.edu
OI Kallen, Caleb/0000 0002 4156 6719
CR Anderson GL, 2004, JAMA J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701
   Barrett Connor E, 2006, NEW ENGL J MED, V355, P125, DOI 10.1056/NEJMoa062462
   Bilezikian JP, 2006, NEW ENGL J MED, V355, P2278, DOI 10.1056/NEJMp068157
   Bischoff Ferrari HA, 2006, ARCH INTERN MED, V166, P424
   Bischoff Ferrari HA, 2005, JAMA J AM MED ASSOC, V293, P2257, DOI 10.1001/jama.293.18.2257
   Bischoff Ferrari HA, 2008, AM J CLIN NUTR, V87, P1945, DOI 10.1093/ajcn/87.6.1945
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Black DM, 2006, JAMA J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Black DM, 2005, NEW ENGL J MED, V353, P555, DOI 10.1056/NEJMoa050336
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Bodine PVN, 2006, REV ENDOCR METAB DIS, V7, P33, DOI 10.1007/s11154 006 9002 4
   Bone HG, 2008, J CLIN ENDOCR METAB, V93, P2149, DOI 10.1210/jc.2007 2814
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/JBMR.0809010, 10.1359/jbmr.080901]
   Bush TL, 1996, JAMA J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389
   Canalis E, 2005, J Endocrinol Invest, V28, P3
   CANALIS E, 1989, J CLIN INVEST, V83, P60, DOI 10.1172/JCI113885
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Chesnut CH, 2005, CURR MED RES OPIN, V21, P391, DOI 10.1185/030079905X30752
   Chesnut CH III, 2000, AM J MED, V109, P267, DOI 10.1016/S0002 9343(00)00490 3
   Cranney A, 2002, ENDOCR REV, V23, P570, DOI 10.1210/er.2001 9002
   Cummings SR, 1998, JAMA J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077
   Dawson Hughes B, 2008, OSTEOPOROSIS INT, V19, P449, DOI 10.1007/s00198 008 0559 5
   Dawson Hughes B, 2007, J BONE MINER RES, V22, pV59, DOI 10.1359/JBMR.07S209
   DELANY AM, 1994, J CELL BIOCHEM, V55, P328, DOI 10.1002/jcb.240550309
   Delmas PD, 2002, J CLIN ENDOCR METAB, V87, P3609, DOI 10.1210/jc.87.8.3609
   Deregowski V, 2006, J BIOL CHEM, V281, P6203, DOI 10.1074/jbc.M508370200
   Ensrud KE, 2004, J BONE MINER RES, V19, P1259, DOI 10.1359/JBMR.040326
   Ettinger B, 2004, J BONE MINER RES, V19, P745, DOI 10.1359/JBMR.040117
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   Ettinger B, 2008, MENOPAUSE, V15, P1023, DOI 10.1097/gme.0b013e31817f3e4d
   Gazzerro E, 2006, REV ENDOCR METAB DIS, V7, P51, DOI 10.1007/s11154 006 9000 6
   Giustina A, 2008, ENDOCR REV, V29, P535, DOI 10.1210/er.2007 0036
   Greenspan SL, 2003, JAMA J AM MED ASSOC, V289, P2525, DOI 10.1001/jama.289.19.2525
   Greenspan SL, 2007, ANN INTERN MED, V146, P326, DOI 10.7326/0003 4819 146 5 200703060 00005
   Grinspoon S, 2002, J CLIN ENDOCR METAB, V87, P2883, DOI 10.1210/jc.87.6.2883
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   HUI SL, 1988, J CLIN INVEST, V81, P1804, DOI 10.1172/JCI113523
   Jackson RD, 2006, NEW ENGL J MED, V354, P669, DOI 10.1056/NEJMoa055218
   Kanis JA, 2005, OSTEOPOROSIS INT, V16, P737, DOI 10.1007/s00198 004 1734 y
   Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623
   KELSEY JL, 1992, AM J EPIDEMIOL, V135, P477, DOI 10.1093/oxfordjournals.aje.a116314
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   LEVY FL, 1995, AM J MED, V98, P50, DOI 10.1016/S0002 9343(99)80080 1
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Lilliu H, 2003, MATURITAS, V44, P299, DOI 10.1016/S0378 5122(03)00038 0
   Looker AC, 1997, J BONE MINER RES, V12, P1761, DOI 10.1359/jbmr.1997.12.11.1761
   Luciano AA, 2001, HOSP PHYS OBSTET GYN, V7, P16
   Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941
   Martino S, 2004, J NATL CANCER I, V96, P1751, DOI 10.1093/jnci/djh319
   MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P301, DOI 10.1210/endo 124 1 301
   McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   Miller PD, 2008, BONE, V43, P222, DOI 10.1016/j.bone.2008.04.007
   Miyakoshi N, 2001, ENDOCRINOLOGY, V142, P4349, DOI 10.1210/en.142.10.4349
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   O'Donnell S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005326.pub2
   Rabenda V, 2008, J BONE JOINT SURG AM, V90A, P2142, DOI 10.2106/JBJS.G.00864
   REID IR, 1995, AM J MED, V98, P331, DOI 10.1016/S0002 9343(99)80310 6
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Roux C, 2008, RHEUMATOLOGY, V47, P20, DOI 10.1093/rheumatology/ken166
   Roux C, 2006, J BONE MINER RES, V21, P536, DOI 10.1359/JBMR.060101
   Rubin J, 2002, J CLIN ENDOCR METAB, V87, P4273, DOI 10.1210/jc.2002 020656
   RYDZIEL S, 1995, ENDOCRINOLOGY, V136, P4254, DOI 10.1210/en.136.10.4254
   Schuit SCE, 2004, BONE, V34, P195, DOI 10.1016/j.bone.2003.10.001
   Siris ES, 2005, J BONE MINER RES, V20, P1514, DOI 10.1359/JBMR.050509
   Stoch SA, 2008, CLIN PHARMACOL THER, V83, P172, DOI 10.1038/sj.clpt.6100450
   Takada I, 2007, NAT CELL BIOL, V9, P1273, DOI 10.1038/ncb1647
   Tannenbaum C, 2002, J CLIN ENDOCR METAB, V87, P4431, DOI 10.1210/jc.2002 020275
   Tosteson ANA, 2008, OSTEOPOROSIS INT, V19, P437, DOI 10.1007/s00198 007 0550 6
   Vestergaard P, 2008, OSTEOPOROSIS INT, V19, P257, DOI 10.1007/s00198 007 0437 6
   Weitzmann MN, 2007, ANN NY ACAD SCI, V1116, P360, DOI 10.1196/annals.1402.068
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Yadav VK, 2008, CELL, V135, P825, DOI 10.1016/j.cell.2008.09.059
   Zhao G, 2000, ENDOCRINOLOGY, V141, P2674, DOI 10.1210/en.141.7.2674
NR 76
TC 12
Z9 17
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0015 0282
EI 1556 5653
J9 FERTIL STERIL
JI Fertil. Steril.
PD AUG
PY 2009
VL 92
IS 2
BP 403
EP 412
DI 10.1016/j.fertnstert.2009.05.049
PG 10
WC Obstetrics & Gynecology; Reproductive Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Obstetrics & Gynecology; Reproductive Biology
GA 482UU
UT WOS:000268915200001
PM 19559412
OA Bronze
DA 2025 08 17
ER

PT J
AU Tang, ZL
   Zhang, WJ
   Wang, DX
   Chen, JM
   Ma, H
   Wu, DR
AF Tang, Zheng Long
   Zhang, Wen Juan
   Wang, Dong Xiang
   Chen, Jia Min
   Ma, Hong
   Wu, Dan Rong
TI An Experimental Study Addressing the Promotion of Mandibular Defect
   Repair Through the Intermittent Subcutaneous Injection of Parathyroid
   Hormone
SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
LA English
DT Article
ID BONE FORMATION; POSTMENOPAUSAL WOMEN; BIOCHEMICAL MARKERS;
   GROWTH HORMONE; TERIPARATIDE; OSTEOPOROSIS; REGENERATION; RATS;
   FRACTURES; THERAPY
AB Purpose: Parathyroid hormone (PTH) is a major regulator of bone metabolism. Various animal studies and clinical trials have addressed the treatment of osteoporosis and fracture healing with the intermittent administration of PTH, whereas few studies have investigated the effects of PTH on mandibular defect repair. This study sought to examine the feasibility of using recombinant human PTH (rhPTH) to promote the repair of mandibular defects and to provide a preliminary investigation of the underlying mechanisms of this phenomenon.
   Materials and Methods: A mandibular defect model was established using Japanese white rabbits. The experimental animals were randomly divided into a control group that received postoperative subcutaneous injections of normal saline on alternate days and an experimental group that received postoperative subcutaneous injections of rhPTH 25 mu g on alternate days. The experimental animals were sacrificed at 1, 2, 3, and 4 weeks after the operation to perform x ray imaging and bone histomorphometric examinations of the defect areas. Changes in serum levels of bone specific alkaline phosphatase (bALP) and osteoprotegerin (OPG) over time were examined.
   Results: Compared with the control group, the experimental group exhibited newly generated bone matrix in the mandibular defect area at earlier stages. In the experimental group, the bone trabeculae were arranged in an orderly manner, and uniform calcification was observed. Marked hyperplasia of osteoblasts was observed in the new bone tissue of the experimental group, but significantly less hyperplasia of osteoblasts was observed in the control group. In the 2 groups, the average serum bALP and OPG levels increased after the operation and then gradually decreased. In the experimental group, levels of bALP and OPG at 1 week and 2 weeks after the operation were significantly different from preoperative levels. In the control group, the OPG level at 2 weeks after the operation was significantly different from the preoperative OPG level. A comparison of serum bALP and OPG levels at each examined time point showed no significant difference between the 2 groups.
   Conclusion: The intermittent subcutaneous injection of rhPTH 25 mg/day promotes the healing of mandibular defects in rabbits. The application of rhPTH may facilitate mandible regeneration by increasing quantities of osteoblasts, accelerating bone turnover metabolism, and upregulating OPG levels. (C) 2014 American Association of Oral and Maxillofacial Surgeons
C1 [Tang, Zheng Long; Zhang, Wen Juan; Wang, Dong Xiang; Chen, Jia Min; Ma, Hong] Guiyang Med Coll, Affiliated Hosp, Dept Oral & Maxillofacial Surg, Guiyang 550004, Guizhou, Peoples R China.
   [Wu, Dan Rong] Guiyang Med Coll, Affiliated Hosp, Dept Endocrine & Metab Dis, Guiyang 550004, Guizhou, Peoples R China.
C3 Guizhou Medical University; Guizhou Medical University
RP Tang, ZL (通讯作者)，Guiyang Med Coll, Affiliated Hosp, Dept Oral & Maxillofacial Surg, Guiyang 550004, Guizhou, Peoples R China.
EM zhenglongtang@hotmail.com
RI Wang, Dongxiang/G 9216 2012; chen, jiamin/KWU 2539 2024
CR Aleksyniene Ramune, 2004, Medicina (Kaunas), V40, P842
   Alsousou J, 2009, J BONE JOINT SURG BR, V91B, P987, DOI 10.1302/0301 620X.91B8.22546
   Andreassen TT, 2004, J CRANIOFAC SURG, V15, P424, DOI 10.1097/00001665 200405000 00014
   Andreassen TT, 2001, ACTA ORTHOP SCAND, V72, P304, DOI 10.1080/00016470152846673
   Bashutski JD, 2010, NEW ENGL J MED, V363, P2396, DOI 10.1056/NEJMoa1005361
   Body JJ, 2002, J CLIN ENDOCR METAB, V87, P4528, DOI 10.1210/jc.2002 020334
   Brixen KT, 2004, BASIC CLIN PHARMACOL, V94, P260
   Chalidis B, 2007, EXPERT OPIN INV DRUG, V16, P441, DOI 10.1517/13543784.16.4.441
   Chen H, 2003, CLIN ORTHOP RELAT R, P291, DOI 10.1097/01.blo.0000079443.64912.18
   Chen PQ, 2005, J BONE MINER RES, V20, P962, DOI 10.1359/JBMR.050105
   Dimitriou R, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 66
   Dobnig H, 2005, J CLIN ENDOCR METAB, V90, P3970, DOI 10.1210/jc.2003 1703
   Finkemeier CG, 2002, J BONE JOINT SURG AM, V84A, P454, DOI 10.2106/00004623 200203000 00020
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Kempen DHR, 2010, TISSUE ENG PT A, V16, P3769, DOI [10.1089/ten.tea.2010.0173, 10.1089/ten.TEA.2010.0173]
   Kousteni Stavroula, 2008, Curr Osteoporos Rep, V6, P72, DOI 10.1007/s11914 008 0013 9
   Masi L, 2005, J Endocrinol Invest, V28, P37
   Miller SC, 1997, J DENT RES, V76, P1471, DOI 10.1177/00220345970760080901
   Miloro M, 2010, J ORAL MAXIL SURG, V68, P1225, DOI 10.1016/j.joms.2009.09.090
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Obermayer Pietsch BM, 2008, J BONE MINER RES, V23, P1591, DOI 10.1359/JBMR.080506
   Ohlsson C, 1998, ENDOCR REV, V19, P55, DOI 10.1210/er.19.1.55
   Roberts MD, 2009, J BIOMECH, V42, P2431, DOI 10.1016/j.jbiomech.2009.08.030
   Rowshan HH, 2010, J ORAL MAXIL SURG, V68, P260, DOI 10.1016/j.joms.2009.09.045
   Rubin MR, 2005, DRUGS, V65, P2481, DOI 10.2165/00003495 200565170 00005
   Tran GT, 2009, EXPERT OPIN INV DRUG, V18, P887, DOI 10.1517/13543780902893069
   UZAWA T, 1995, BONE, V16, P477
NR 27
TC 11
Z9 18
U1 0
U2 16
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0278 2391
EI 1531 5053
J9 J ORAL MAXIL SURG
JI J. Oral Maxillofac. Surg.
PD FEB
PY 2014
VL 72
IS 2
BP 419
EP 430
DI 10.1016/j.joms.2013.07.037
PG 12
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 290KV
UT WOS:000329756500035
PM 24071373
DA 2025 08 17
ER

PT J
AU Tan, X
   Du, YP
   Luo, Q
   Zhan, XB
   Kuang, YS
   Liang, X
   Zhang, Y
   Wang, L
   Chen, B
   Wen, M
AF Tan, Xin
   Du, Yan Ping
   Luo, Qian
   Zhan, Xue Bing
   Kuang, Yun Shu
   Liang, Xiao
   Zhang, Yun
   Wang, Lin
   Chen, Bing
   Wen, Ming
TI Network Pharmacology and Molecular Docking Analysis of the Mechanism
   Underlying Yikunyin's Therapeutic Effect on Menopausal Syndrome
SO EVIDENCE BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID OSTEOCLAST DIFFERENTIATION; CARDIOVASCULAR DISEASE; BETA;
   ATHEROSCLEROSIS; PREVALENCE; ACTIVATION; APOPTOSIS; CELLS; WOMEN; MICE
AB Objective. Yikunyin is an empirical prescription that exhibits good efficacy in the clinical treatment of menopausal syndrome; however, its underlying mechanism remains unclear. This study investigates the mechanism implicated in the therapeutic effect of Yikunyin by identifying its hub genes, central pathways, and key active ingredients. Method. The active ingredients and targets of Yikunyin were obtained from the Traditional Chinese Medicine Systems Pharmacology database, whereas the targets related to menopausal syndrome were obtained from GeneCards, PharmGKB, Therapeutic Target Database (TTD), and Comparative Toxicogenomics Database (CTD). To reveal the pharmacological mechanism, the component target and the intersecting protein protein interaction (PPI) networks were constructed, and Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed. Finally, molecular docking was carried out to assess the strength of binding between the key active ingredients and key targets. Results. A total of 418 targets and 121 active ingredients were identified in Yikunyin. The intersection of Yikunyin's 418 targets with the 2822 targets related to menopausal syndrome shows that there are 247 common targets that can be considered potential targets of Yikunyin in the treatment of menopausal syndrome. The topology analysis of the constructed PPI network conducted using the Cytoscape software shows that there are 15 hub genes implicated in the therapeutic effect of Yikunyin: AKT1, PRKCA, TLR9, CXCL10, PRKCD, PARP1, ABCB1, TP53, CAV1, MAPK8, PPARA, GRB2, EGFR, IL 6, and JAK2. Moreover, the key active components acting on these genes are paeoniflorin, luteolin, quercetin, beta sitosterol, and kaempferol. GO and KEGG analyses indicate that Yikunyin can treat menopausal syndrome by regulating cellular response to chemical stress (GO:0062197), cellular response to oxidative stress (GO:0034599), phosphatase binding (GO:0019902), cytokine receptor binding (GO:0005126), PI3K Akt signaling (hsa04151), lipid and atherosclerosis (hsa05417), and hepatitis B (hsa05161). Finally, the results of molecular docking suggest that the key active ingredients and key targets can bind well, with binding energies of less than  5 kJ/mol. Conclusion. The research conducted herein reveals that Yikunyin treats menopausal syndrome by targeting AKT1 and IL 6 and by regulating the PI3K Akt signaling pathway. Moreover, it provides a new idea for understanding the therapeutic effects of traditional Chinese medicines.
C1 [Tan, Xin; Du, Yan Ping; Luo, Qian; Zhan, Xue Bing; Kuang, Yun Shu; Liang, Xiao; Chen, Bing] Wannan Med Coll, Dept Pathol, Wuhu 241002, Anhui, Peoples R China.
   [Zhang, Yun; Wang, Lin; Wen, Ming] First Peoples Hosp Wuhu City, Dept Gynaecol & Obstet, Wuhu 241001, Anhui, Peoples R China.
C3 Wannan Medical College
RP Chen, B (通讯作者)，Wannan Med Coll, Dept Pathol, Wuhu 241002, Anhui, Peoples R China.; Wen, M (通讯作者)，First Peoples Hosp Wuhu City, Dept Gynaecol & Obstet, Wuhu 241001, Anhui, Peoples R China.
EM tanxin42@outlook.com; 1684541404@qq.com; 1730906896@qq.com;
   2665405413@qq.com; 455679367@qq.com; 2524233201@qq.com;
   474938219@qq.com; wl_doctor@126.com; chenbing@wnmc.edu.cn;
   2579243169@qq.com
RI ; wang, lin/HZK 4145 2023; Liang, Xiao/AAY 2579 2021
OI Chen, Bing/0000 0003 4385 0315; Du, Yanping/0000 0002 9383 1676; Tan,
   Xin/0000 0002 4528 1390
FU Scientific and Technological Achievements Transformation plan of WUHU
   [2019cg18]; Scientific Research Project of Teaching Hospital of Wannan
   Medical College [XJ2021001101]; Scientific Research Project of Anhui
   Provincial Health Commission [AHWJ2021b059]
FX AcknowledgmentsThe authors thank LetPub (https//www.letpub.com) for its
   linguistic assistance during the preparation of this manuscript. This
   research was funded by the Scientific and Technological Achievements
   Transformation plan of WUHU (grant no. 2019cg18), the Scientific
   Research Project of Teaching Hospital of Wannan Medical College (grant
   no. XJ2021001101), and the Scientific Research Project of Anhui
   Provincial Health Commission (grant no. AHWJ2021b059).
CR Ahmed D, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472 6882 14 155
   Ahmed S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165622
   Akter A, 2022, BIOLOGIA, V77, P1337, DOI 10.1007/s11756 022 01057 z
   Bari MS, 2021, J ETHNOPHARMACOL, V271, DOI 10.1016/j.jep.2021.113834
   Brooks HL, 2016, PHYSIOLOGY, V31, P250, DOI 10.1152/physiol.00057.2014
   Cao Y, 2021, BIOENGINEERED, V12, P10345, DOI 10.1080/21655979.2021.1996317
   Chakraborty AJ, 2021, LIFE BASEL, V11, DOI 10.3390/life11040317
   Chin CH, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752 0509 8 S4 S11
   Dessalvi CC, 2019, HEART FAIL REV, V24, P915, DOI 10.1007/s10741 019 09820 2
   Dong YH, 2017, CELL SIGNAL, V34, P55, DOI 10.1016/j.cellsig.2017.03.004
   El Khoudary SR, 2020, MATURITAS, V141, P33, DOI 10.1016/j.maturitas.2020.06.007
   Feng SM, 2018, BBA MOL CELL BIOL L, V1863, P1274, DOI 10.1016/j.bbalip.2018.08.004
   Fischer Posovszky P, 2012, MOL CELL ENDOCRINOL, V358, P135, DOI 10.1016/j.mce.2012.03.018
   Freitas MA, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11040592
   GERHARD M, 1995, CARDIOLOGY, V86, P349, DOI 10.1159/000176899
   Haddadi N, 2018, MOL CANCER, V17, DOI 10.1186/s12943 018 0803 3
   He S, 2022, J ETHNOPHARMACOL, V282, DOI 10.1016/j.jep.2021.114615
   Huang LW, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22137054
   Huang WY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169216
   Huang XF, 2020, INT IMMUNOPHARMACOL, V83, DOI 10.1016/j.intimp.2020.106423
   Huang Y, 2021, AM J PHYSIOL ENDOC M, V320, pE1085, DOI 10.1152/ajpendo.00034.2021
   Ihn HJ, 2019, NUTRIENTS, V11, DOI 10.3390/nu11061392
   Islam F, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222312638
   Iwasa T, 2014, CYTOKINE, V65, P65, DOI 10.1016/j.cyto.2013.10.004
   Jiang YH, 2020, FOOD FUNCT, V11, P1881, DOI [10.1039/C9FO01976F, 10.1039/c9fo01976f]
   Kangas R, 2018, ONCOTARGET, V9, P2279, DOI 10.18632/oncotarget.23406
   Khan MF, 2020, BIOMED PHARMACOTHER, V131, DOI 10.1016/j.biopha.2020.110774
   Kim JH, 2016, INT J MOL MED, V37, P649, DOI 10.3892/ijmm.2016.2477
   Kipari T, 2013, FASEB J, V27, P1519, DOI 10.1096/fj.12 219105
   Koo HJ, 2014, J ETHNOPHARMACOL, V151, P951, DOI 10.1016/j.jep.2013.12.008
   Lee E, 2020, INT J BIOL MACROMOL, V165, P1029, DOI 10.1016/j.ijbiomac.2020.09.165
   Lee JH, 2018, PHYTOMEDICINE, V48, P1, DOI 10.1016/j.phymed.2018.05.005
   Li H, 2017, INFLAMMATION, V40, P2042, DOI 10.1007/s10753 017 0644 z
   Liu TT, 2021, J ETHNOPHARMACOL, V274, DOI 10.1016/j.jep.2021.114037
   Lu XL, 2017, BIOMED PHARMACOTHER, V85, P658, DOI 10.1016/j.biopha.2016.11.077
   Ludka FK, 2016, J PSYCHIATR RES, V82, P50, DOI 10.1016/j.jpsychires.2016.07.004
   Meng QH, 2020, BIOCHEM PHARMACOL, V180, DOI 10.1016/j.bcp.2020.114134
   Nie GN, 2017, MENOPAUSE, V24, P546, DOI 10.1097/GME.0000000000000784
   Pacello P, 2018, MENOPAUSE, V25, P683, DOI 10.1097/GME.0000000000001066
   Parvez MK, 2021, ACS OMEGA, V6, P29100, DOI 10.1021/acsomega.1c04320
   PRINCE RL, 1995, J BONE MINER RES, V10, P835
   Qiao YL, 2021, PHYTOMEDICINE, V81, DOI 10.1016/j.phymed.2020.153436
   Rahman MM, 2022, J INTEGR NEUROSCI, V21, DOI 10.31083/j.jin2101042
   Rajendran P, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010217
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Santo Signorelli S, 2006, MATURITAS, V53, P77, DOI 10.1016/j.maturitas.2005.03.001
   Santoro N, 2015, ENDOCRIN METAB CLIN, V44, P497, DOI 10.1016/j.ecl.2015.05.001
   Tagde P, 2021, MOLECULES, V26, DOI 10.3390/molecules26237109
   Tian S, 2015, ADV DRUG DELIVER REV, V86, P2, DOI 10.1016/j.addr.2015.01.009
   Tian S, 2011, MOL PHARMACEUT, V8, P841, DOI 10.1021/mp100444g
   Wang Jun C.X, 2011, PRACTICAL GERIATRICS, V25
   Wang Y, 2019, J CELL BIOCHEM, V120, P9291, DOI 10.1002/jcb.28204
   Wang Y, 2019, J ETHNOPHARMACOL, V234, P8, DOI 10.1016/j.jep.2019.01.010
   Watt FE, 2016, MATURITAS, V83, P13, DOI 10.1016/j.maturitas.2015.09.007
   Xiong M, 2019, CLIN TRANSL GASTROEN, V10, DOI 10.14309/ctg.0000000000000085
   Yan HX, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/6812374
   Yoshihisa Y, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/804298
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Yuan NJ, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00284
NR 59
TC 2
Z9 2
U1 2
U2 15
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741 427X
EI 1741 4288
J9 EVID BASED COMPL ALT
JI Evid. based Complement Altern. Med.
PD JUN 6
PY 2022
VL 2022
AR 7302419
DI 10.1155/2022/7302419
PG 14
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA 2G9YZ
UT WOS:000813958100011
PM 35707470
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wang, T
   Fan, LM
   Feng, S
   Ding, XL
   An, XX
   Chen, JH
   Wang, MJ
   Zhai, XF
   Li, Y
AF Wang, Ting
   Fan, Liming
   Feng, Shuai
   Ding, Xinli
   An, Xinxin
   Chen, Jiahuan
   Wang, Minjuan
   Zhai, Xifeng
   Li, Yang
TI Network pharmacology of iridoid glycosides from Eucommia ulmoides
   Oliver against osteoporosis
SO SCIENTIFIC REPORTS
LA English
DT Article
ID OSTEOGENIC DIFFERENTIATION; SYSTEMS PHARMACOLOGY; MOLECULAR DOCKING;
   GREEN LEAVES; WEB SERVICE; BONE LOSS; OSTEOBLAST; EXTRACT;
   OSTEOCLASTOGENESIS; MINERALIZATION
AB Eucommia ulmoides Oliver is one of the commonly used traditional Chinese medicines for the treatment of osteoporosis, and iridoid glycosides are considered to be its active ingredients against osteoporosis. This study aims to clarify the chemical components and molecular mechanism of iridoid glycosides of Eucommia ulmoides Oliver in the treatment of osteoporosis by integrating network pharmacology and molecular simulations. The active iridoid glycosides and their potential targets were retrieved from text mining as well as Swiss Target Prediction, TargetNet database, and STITCH databases. At the same time, DisGeNET, GeneCards, and Therapeutic Target Database were used to search for the targets associated with osteoporosis. A protein protein interaction network was built to analyze the interactions between targets. Then, DAVID bioinformatics resources and R 3.6.3 project were used to carry out Gene Ontology enrichment analysis and Kyoto Encyclopedia of Genes and Genomes pathway analysis. Moreover, interactions between active compounds and potential targets were investigated through molecular docking, molecular dynamic simulation, and binding free energy analysis. The results showed that a total of 12 iridoid glycosides were identified as the active iridoid glycosides of Eucommia ulmoides Oliver in the treatment of osteoporosis. Among them, aucubin, reptoside, geniposide and ajugoside were the core compounds. The enrichment analysis suggested iridoid glycosides of Eucommia ulmoides Oliver prevented osteoporosis mainly through PI3K Akt signaling pathway, MAPK signaling pathway and Estrogen signaling pathway. Molecular docking results indicated that the 12 iridoid glycosides had good binding ability with 25 hub target proteins, which played a critical role in the treatment of osteoporosis. Molecular dynamic and molecular mechanics Poisson Boltzmann surface area results revealed these compounds showed stable binding to the active sites of the target proteins during the simulations. In conclusion, our research demonstrated that iridoid glycosides of Eucommia ulmoides Oliver in the treatment of osteoporosis involved a multi component, multi target and multi pathway mechanism, which provided new suggestions and theoretical support for treating osteoporosis.
C1 [Wang, Ting; Fan, Liming; Feng, Shuai; Ding, Xinli; An, Xinxin; Chen, Jiahuan; Li, Yang] Northwest Univ, Coll Life Sci, Biomed Key Lab Shaanxi Prov, Xian 710069, Peoples R China.
   [Wang, Minjuan] Shaanxi Prov Ctr Dis Control & Prevent, Phys & Chem Lab, Xian 710054, Peoples R China.
   [Zhai, Xifeng] Xian Med Univ, Sch Pharmaceut Sci, Xian 710021, Peoples R China.
C3 Northwest University Xi'an; Xi'an Medical University
RP Li, Y (通讯作者)，Northwest Univ, Coll Life Sci, Biomed Key Lab Shaanxi Prov, Xian 710069, Peoples R China.
EM ly2011@nwu.edu.cn
RI Liming, Fan/G 4331 2017
OI Li, Yang/0000 0003 0934 2771
FU National Natural Science Foundation of China [31200253]; Natural Science
   Basic Research Plan in Shaanxi Province of China [2020JZ 45]; Natural
   Science Foundation of Shaanxi Province [2021JQ 935]; Student's Platform
   for Innovation and Entrepreneurship Training Program of Northwest
   University [2021463]; "Challenge Cup" College Student Entrepreneurship
   Plan Competition of Northwest University [2022128]
FX These works were supported by the National Natural Science Foundation of
   China (No. 31200253), Natural Science Basic Research Plan in Shaanxi
   Province of China (No. 2020JZ 45), Natural Science Foundation of Shaanxi
   Province (No. 2021JQ 935), Student's Platform for Innovation and
   Entrepreneurship Training Program of Northwest University (No.2021463)
   and "Challenge Cup" College Student Entrepreneurship Plan Competition of
   Northwest University (No.2022128).
CR Abraham Mark James, 2015, SoftwareX, V1 2, P19, DOI 10.1016/j.softx.2015.06.001
   Arron JR, 2000, NATURE, V408, P535, DOI 10.1038/35046196
   Assenov Y, 2008, BIOINFORMATICS, V24, P282, DOI 10.1093/bioinformatics/btm554
   Bateman A, 2021, NUCLEIC ACIDS RES, V49, pD480, DOI 10.1093/nar/gkaa1100
   Bellavia D, 2021, TRENDS ENDOCRIN MET, V32, P846, DOI 10.1016/j.tem.2021.07.011
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Bian F, 2021, PHARMAZIE, V76, P244, DOI 10.1691/ph.2021.1378
   BIANCO A, 1974, TETRAHEDRON, V30, P4117, DOI 10.1016/S0040 4020(01)97394 6
   Chen LR, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092213
   Chen L, 2020, INT IMMUNOPHARMACOL, V80, DOI 10.1016/j.intimp.2019.106121
   Chen X, 2021, BONE JOINT RES, V10, P237, DOI 10.1302/2046 3758.104.BJR 2020 0255.R2
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Cornish TC, 2021, METHODSX, V8, DOI 10.1016/j.mex.2021.101264
   Daina A, 2019, NUCLEIC ACIDS RES, V47, pW357, DOI 10.1093/nar/gkz382
   Diemar SS, 2019, EPILEPSY BEHAV, V100, DOI 10.1016/j.yebeh.2019.106511
   Ensrud Kristine E, 2021, JAMA, V325, P96, DOI 10.1001/jama.2020.2923
   Erukainure Ochuko L., 2014, Journal of Dietary Supplements, V11, P19, DOI 10.3109/19390211.2013.859213
   Feng S, 2022, RSC ADV, V12, P2181, DOI 10.1039/d1ra05799e
   Fischer V, 2022, SEMIN CELL DEV BIOL, V123, P14, DOI 10.1016/j.semcdb.2021.05.014
   Gautam R, 2011, J ETHNOPHARMACOL, V133, P928, DOI 10.1016/j.jep.2010.11.003
   Geoghegan IP, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 88633 6
   Guan MQ, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/3641317
   Ha H, 2003, ARCH PHARM RES, V26, P929, DOI 10.1007/BF02980202
   Hairul Islam MI, 2017, INT IMMUNOPHARMACOL, V53, P114, DOI 10.1016/j.intimp.2017.10.022
   Han LH, 2018, J FUNCT FOODS, V47, P447, DOI 10.1016/j.jff.2018.06.004
   He MZ, 2018, J CHROMATOGR A, V1554, P81, DOI 10.1016/j.chroma.2018.04.036
   He YQ, 2018, CHEM BIOL INTERACT, V291, P128, DOI 10.1016/j.cbi.2018.06.015
   Hirata T, 2011, BIOORG MED CHEM LETT, V21, P1786, DOI 10.1016/j.bmcl.2011.01.060
   Hsin KY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083922
   Huang LC, 2021, CHIN MED UK, V16, DOI 10.1186/s13020 021 00482 7
   Jiao XL, 2012, BIOINFORMATICS, V28, P1805, DOI 10.1093/bioinformatics/bts251
   Kanehisa M, 2020, PROTEIN SCI, V29, P28, DOI 10.1002/pro.3711
   Kim S, 2016, NUCLEIC ACIDS RES, V44, pD1202, DOI 10.1093/nar/gkv951
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Kwofie SK, 2020, COMPUT BIOL MED, V122, DOI 10.1016/j.compbiomed.2020.103811
   Kwofie SK, 2019, COMPUT BIOL MED, V113, DOI 10.1016/j.compbiomed.2019.103414
   Li A, 2021, FOOD FUNCT, V12, P5607, DOI [10.1039/d0fo02802a, 10.1039/D0FO02802A]
   Li R, 2021, CHEM BIODIVERS, V18, DOI 10.1002/cbdv.202100331
   Li Y, 2014, J ETHNOPHARMACOL, V151, P452, DOI 10.1016/j.jep.2013.10.067
   Li Y, 2011, PHYTOTHER RES, V25, P1895, DOI 10.1002/ptr.3543
   Li YT, 2018, CHEM BIOL INTERACT, V283, P51, DOI 10.1016/j.cbi.2018.02.005
   Liu ZW, 2020, COMPUT BIOL MED, V127, DOI 10.1016/j.compbiomed.2020.104074
   Ma YG, 2021, SCI TOTAL ENVIRON, V750, DOI 10.1016/j.scitotenv.2020.141638
   Meng JH, 2020, BIOCHEM PHARMACOL, V171, DOI 10.1016/j.bcp.2019.113715
   Mukherjee A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093040
   Niu B, 2019, COMPUT STRUCT BIOTEC, V17, P39, DOI 10.1016/j.csbj.2018.11.007
   Niu XL, 2016, IND CROP PROD, V79, P160, DOI 10.1016/j.indcrop.2015.11.027
   O'Donoghue SI, 2010, NAT METHODS, V7, pS42, DOI [10.1038/NMETH.1427, 10.1038/nmeth.1427]
   Oliveros JC, 2007, VENNY INTERACTIVE TO
   Ou L, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02751 5
   Pan YL, 2014, AM J CHINESE MED, V42, P143, DOI 10.1142/S0192415X14500104
   Piñero J, 2020, NUCLEIC ACIDS RES, V48, pD845, DOI 10.1093/nar/gkz1021
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Ryu YK, 2018, J NEURAL TRANSM, V125, P1319, DOI 10.1007/s00702 018 1902 4
   Safran M, 2010, DATABASE OXFORD, DOI 10.1093/database/baq020
   Saul D, 2021, ENDOCRIN METAB CLIN, V50, P179, DOI 10.1016/j.ecl.2021.03.010
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Singh A, 2019, GENE, V693, P114, DOI 10.1016/j.gene.2019.01.029
   Song LG, 2013, EUR J PHARMACOL, V714, P15, DOI 10.1016/j.ejphar.2013.05.039
   Streicher C, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 06614 0
   Stroet M, 2018, J CHEM THEORY COMPUT, V14, P5834, DOI 10.1021/acs.jctc.8b00768
   Sun P, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/2532081
   Szklarczyk D, 2021, NUCLEIC ACIDS RES, V49, pD605, DOI 10.1093/nar/gkaa1074
   Szklarczyk D, 2016, NUCLEIC ACIDS RES, V44, pD380, DOI 10.1093/nar/gkv1277
   Takamura C, 2007, J NAT PROD, V70, P1312, DOI 10.1021/np0780046
   Takamura C, 2007, J NAT MED TOKYO, V61, P220, DOI 10.1007/s11418 006 0027 5
   Tong HJ, 2021, PHYTOMEDICINE, V86, DOI 10.1016/j.phymed.2021.153558
   Wang CY, 2019, AM J CHINESE MED, V47, P259, DOI 10.1142/S0192415X19500137
   Wang FF, 2021, ARAB J CHEM, V14, DOI 10.1016/j.arabjc.2021.103144
   Wang J, 2019, PHARM BIOL, V57, P193, DOI 10.1080/13880209.2019.1577466
   Wang SJ, 2016, CURR PHARM DESIGN, V22, P312
   Wu HB, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0540 y
   Xiang HL, 2021, TOXICOL APPL PHARM, V424, DOI 10.1016/j.taap.2021.115594
   Xiao PT, 2021, J ETHNOPHARMACOL, V264, DOI 10.1016/j.jep.2020.113380
   Xie BC, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.739326
   Xie BC, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00411
   Yao ZJ, 2016, J COMPUT AID MOL DES, V30, P413, DOI 10.1007/s10822 016 9915 2
   Yue C, 2021, J CELL MOL MED, V25, P10175, DOI 10.1111/jcmm.16954
   Zeng XC, 2020, FITOTERAPIA, V140, DOI 10.1016/j.fitote.2019.104443
   Zhang D, 2020, J CLEAN PROD, V264, DOI 10.1016/j.jclepro.2020.121537
   Zhang R, 2009, BONE, V45, P553, DOI 10.1016/j.bone.2008.08.127
   Zhang WJ, 2019, LIFE SCI, V235, DOI 10.1016/j.lfs.2019.116820
   Zhao Y, 2021, J ETHNOPHARMACOL, V268, DOI 10.1016/j.jep.2020.113644
   Zheng HM, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00463
   Zhou Y, 2022, NUCLEIC ACIDS RES, V50, pD1398, DOI 10.1093/nar/gkab953
   Zhou YH, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02797 5
   Zuo Y. M, 2014, J CHIN MED, V37
NR 88
TC 21
Z9 25
U1 1
U2 46
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD MAY 6
PY 2022
VL 12
IS 1
AR 7430
DI 10.1038/s41598 022 10769 w
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 1A5WC
UT WOS:000791825700053
PM 35523810
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Tang, WY
   Wang, HP
   Zhao, XH
   Liu, SY
   Kong, SK
   Ho, A
   Chen, TN
   Feng, H
   He, H
AF Tang, Wanyi
   Wang, Haipeng
   Zhao, Xiaohui
   Liu, Shiyue
   Kong, Siu Kai
   Ho, Aaron
   Chen, Tunan
   Feng, Hua
   He, Hao
TI Stem cell differentiation with consistent lineage commitment induced by
   a flash of ultrafast laser activation in vitro and in vivo
SO CELL REPORTS
LA English
DT Article
ID OSTEOBLAST; CATENIN
AB Recent technological advancements on stem cell differentiation induction have been making great progress in stem cell research, regenerative medicine, and therapeutic applications. However, the risk of off target differentiation limits the wide application of stem cell therapy strategies. Here, we report a non invasive all optical strategy to induce stem cell differentiation in vitro and in vivo that activates individual target stem cells in situ by delivering a transient 100 ms irradiation of a tightly focused femtosecond laser to a submicron cytoplasmic region of primary adipose derived stem cells (ADSCs). The ADSCs differentiate to osteoblasts with stable lineage commitment that cannot further transdifferentiate because of simultaneous initiation of multiple signaling pathways through specific Ca2+ kinetic patterns. This method can work in vivo to direct mouse cerebellar granule neuron progenitors to granule neurons in intact mouse cerebellums through the skull. Hence, this optical method without any genetic manipulations or exogenous biomaterials holds promising potential in biomedical research and cell based therapies.
C1 [Tang, Wanyi; Wang, Haipeng; Zhao, Xiaohui; He, Hao] Shanghai Jiao Tong Univ, Sch Biomed Engn, Shanghai 200030, Peoples R China.
   [Liu, Shiyue; Kong, Siu Kai] Chinese Univ Hong Kong, Sch Life Sci, Hong Kong 999077, Peoples R China.
   [Ho, Aaron] Chinese Univ Hong Kong, Dept Biomed Engn, Hong Kong 999077, Peoples R China.
   [Chen, Tunan; Feng, Hua] Third Mil Med Univ, Army Med Univ, Southwest Hosp, Inst Neurosurg, Chongqing 400038, Peoples R China.
C3 Shanghai Jiao Tong University; Chinese University of Hong Kong; Chinese
   University of Hong Kong; Army Medical University
RP He, H (通讯作者)，Shanghai Jiao Tong Univ, Sch Biomed Engn, Shanghai 200030, Peoples R China.
EM haohe@sjtu.edu.cn
RI ; Feng, Hua/ITV 6671 2023; Tang, Wanyi/GNH 4408 2022; ZHAO,
   Xiaohui/KHC 3491 2024
OI Tang, Wanyi/0000 0001 8347 6116; Feng, Hua/0000 0003 4489 9217; 
FU National Natural Science Foundation of China [NSFC 62022056, 61975118,
   81661168014]; NSFC/RGC [N_ CUHK407/16]; Science and Technology
   Commission of Shanghai Municipality [18QA1402300]; Talents Training
   Program of Army Medical University [2019MPRC021/SWH2018QNWQ 05]
FX We thank Weiqiang Gao for the gift of the animal model
   Math1 GFP;DcxdsRed double reporter mouse model and Dan Zhu for help with
   in vivo microscopy. The work was supported by the National Natural
   Science Foundation of China (NSFC 62022056, 61975118, and 81661168014),
   NSFC/RGC funding (N_ CUHK407/16), the Science and Technology Commission
   of Shanghai Municipality 18QA1402300, and the Talents Training Program
   of Army Medical University (2019MPRC021/SWH2018QNWQ 05).
CR Abella A, 2005, CELL METAB, V2, P239, DOI 10.1016/j.cmet.2005.09.003
   Anne SL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081769
   Arany PR, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008234
   AUBIN JE, 1995, BONE, V17, pS77, DOI 10.1016/8756 3282(95)00183 E
   Bateman ME, 2018, STEM CELLS, V36, P1311, DOI 10.1002/stem.2847
   Behesti H, 2009, INT J BIOCHEM CELL B, V41, P435, DOI 10.1016/j.biocel.2008.06.017
   BENJAMINI Y, 1995, J ROY STAT SOC B, V57, P289, DOI 10.1111/j.2517 6161.1995.tb02031.x
   Binétruy B, 2007, STEM CELLS, V25, P1090, DOI 10.1634/stemcells.2006 0612
   Camp JG, 2018, NAT METHODS, V15, P661, DOI 10.1038/s41592 018 0113 0
   Ceccarelli S, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00236
   Donati G, 2014, P NATL ACAD SCI USA, V111, pE1501, DOI 10.1073/pnas.1312880111
   Ferreira Gonzalez S, 2018, NAT COMMUN, V9, DOI [10.1038/s41467 018 03299 5, 10.1038/s41467 018 06183 4]
   Gao SN, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1772 1
   Harasymiak Krzyzanowska I, 2013, CELL MOL BIOL LETT, V18, P479, DOI 10.2478/s11658 013 0101 4
   Herberts CA, 2011, J TRANSL MED, V9, DOI 10.1186/1479 5876 9 29
   Hsieh TJ, 2012, J CELL PHYSIOL, V227, P108, DOI 10.1002/jcp.22707
   Ichida JK, 2009, CELL STEM CELL, V5, P491, DOI 10.1016/j.stem.2009.09.012
   Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233
   Ke X, 2019, J ALLERGY CLIN IMMUN, V143, P1560, DOI 10.1016/j.jaci.2018.08.023
   Lavoie H, 2020, NAT REV MOL CELL BIO, V21, P607, DOI 10.1038/s41580 020 0255 7
   Lee AS, 2013, NAT MED, V19, P998, DOI 10.1038/nm.3267
   Lee Hae Young, 2009, J Vis Exp, DOI 10.3791/990
   Liu YY, 2011, J MOL CELL BIOL, V3, P239, DOI 10.1093/jmcb/mjr011
   Lumpkin EA, 2003, GENE EXPR PATTERNS, V3, P389, DOI 10.1016/S1567 133X(03)00089 9
   Madl CM, 2018, NATURE, V557, P335, DOI 10.1038/s41586 018 0089 z
   Mancuso R, 2019, NAT NEUROSCI, V22, P2111, DOI 10.1038/s41593 019 0525 x
   McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534 5807(04)00075 9
   Pang ZPP, 2011, NATURE, V476, P220, DOI 10.1038/nature10202
   Park PJ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145000
   Picke AK, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao6806
   Qu AH, 2021, NAT BIOMED ENG, V5, P103, DOI 10.1038/s41551 020 00634 4
   Sato K, 2006, NAT MED, V12, P1410, DOI 10.1038/nm1515
   Silkstone D, 2008, NAT CLIN PRACT RHEUM, V4, P413, DOI 10.1038/ncprheum0838
   Spence JR, 2011, NATURE, V470, P105, DOI 10.1038/nature09691
   Takasato M, 2014, NAT CELL BIOL, V16, P118, DOI 10.1038/ncb2894
   Trounson A, 2015, CELL STEM CELL, V17, P11, DOI 10.1016/j.stem.2015.06.007
   Velten L, 2017, NAT CELL BIOL, V19, P271, DOI 10.1038/ncb3493
   Vining KH, 2017, NAT REV MOL CELL BIO, V18, P728, DOI 10.1038/nrm.2017.108
   Vogel A, 2005, APPL PHYS B LASERS O, V81, P1015, DOI 10.1007/s00340 005 2036 6
   von Erlach TC, 2018, NAT MATER, V17, P237, DOI 10.1038/s41563 017 0014 0
   Wang T., 2021, CELL DEATH DISCOV, V7, P1
   Watabe T, 2009, CELL RES, V19, P103, DOI 10.1038/cr.2008.323
   Yang R, 2015, STEM CELL REP, V5, P816, DOI 10.1016/j.stemcr.2015.09.019
   Zaman WSWK, 2014, J TISSUE ENG REGEN M, V8, P67, DOI 10.1002/term.1501
   Zayzafoon M, 2005, J BIOL CHEM, V280, P7049, DOI 10.1074/jbc.M412680200
   Zhao X, 2016, SCI REP UK, V6, DOI 10.1038/srep19237
NR 46
TC 5
Z9 6
U1 2
U2 26
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2211 1247
J9 CELL REP
JI Cell Reports
PD MAR 8
PY 2022
VL 38
IS 10
AR 110486
DI 10.1016/j.celrep.2022.110486
EA MAR 2022
PG 16
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA ZS3RN
UT WOS:000768385700002
PM 35263591
OA gold
DA 2025 08 17
ER

PT J
AU Strait, K
   Li, Y
   Dillehay, DL
   Weitzmann, MN
AF Strait, Karen
   Li, Yan
   Dillehay, Dirck L.
   Weitzmann, M. Neale
TI Suppression of NF κB activation blocks osteoclastic bone resorption
   during estrogen deficiency
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE nuclear factor kappa B; ovariectomy; osteoporosis; osteoclast
ID TUMOR NECROSIS FACTOR; FACTOR ALPHA; PYRROLIDINE DITHIOCARBAMATE;
   CHRONIC INFLAMMATION; TNF ALPHA; LIGAND; CELLS; INHIBITION; PATHWAYS;
   RECEPTOR
AB Postmenopausal osteoporosis stems from an imbalance in osteoclastic bone resorption with respect to osteoblastic bone formation, a consequence of estrogen deficiency. The nuclear factor kappa B (NF kappa B) signal transduction pathway is critical for osteoclast formation and resorption, and suppression of NF kappa B activation has been shown to block bone resorption in vitro, and to ameliorate inflammatory bone loss in vivo. The use of NF kappa B antagonists to blunt the bone loss associated with estrogen deficiency however, has not been previously reported. In this study, we investigated whether pharmacological suppression of NF kappa B signaling protects mice against ovariectomy (ovx) induced bone loss. Ovx mice were treated with the potent NF kappa B inhibitor pyrrolidine dithiocarbamate (PDTC) for 4 weeks and bone mineral density (BMD) and indices of bone structure quantitated by dual energy X ray absorptiometry (DXA), and mu computed tomography (mu CT). In vivo indices of bone resorption were quantitated in mouse serum using the biochemical marker C terminal telopeptide of collagen (CTx). Our data revealed that NF kappa B suppression significantly prevented ovx induced bone destruction by preventing the increase in ovx induced osteoclastic bone resorption. Our data suggest that NF kappa B inhibitors may represent novel anticatabolic therapeutic agents for the amelioration of postmenopausal bone loss.
C1 [Strait, Karen; Dillehay, Dirck L.] Emory Univ, Sch Med, Div Anim Resources, Atlanta, GA 30322 USA.
   [Dillehay, Dirck L.] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA.
   [Li, Yan; Weitzmann, M. Neale] Emory Univ, Sch Med, Div Endocrinol Metab & Lipids, Dept Med, Atlanta, GA 30322 USA.
C3 Emory University; Emory University; Emory University
RP Weitzmann, MN (通讯作者)，Emory Univ, Sch Med, Div Endocrinol Metab & Lipids, Dept Med, 101 Woodruff Circle,WMRB 1305, Atlanta, GA 30322 USA.
EM mweitzm@emory.edu
FU NIDDK NIH HHS [DK007298] Funding Source: Medline
CR Boyce BF, 1999, BONE, V25, P137, DOI 10.1016/S8756 3282(99)00105 2
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Carlson CG, 2005, NEUROBIOL DIS, V20, P719, DOI 10.1016/j.nbd.2005.05.003
   Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066
   Cuzzocrea S, 2002, BRIT J PHARMACOL, V135, P496, DOI 10.1038/sj.bjp.0704463
   Dai S, 2004, J BIOL CHEM, V279, P37219, DOI 10.1074/jbc.C400258200
   Feng RT, 2007, BLOOD, V109, P2130, DOI 10.1182/blood 2006 07 027458
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Fuller K, 2002, ENDOCRINOLOGY, V143, P1108, DOI 10.1210/en.143.3.1108
   GILBERT LC, 2005, AM J PHYSIOL ENDOC M, V288, pE101
   HALL TJ, 1995, BIOCHEM BIOPH RES CO, V207, P280, DOI 10.1006/bbrc.1995.1184
   Hofbauer LC, 1999, BONE, V25, P255, DOI 10.1016/S8756 3282(99)00162 3
   Jawien J, 2005, J PHYSIOL PHARMACOL, V56, P483
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Lewis JR, 2006, INJURY, V37, P698, DOI 10.1016/j.injury.2006.04.121
   LI Y, IN PRESS J BONE MINE
   LOTSOVA V, 1997, NAT MED, V3, P1285
   Lu XH, 2006, J BIOL CHEM, V281, P6297, DOI 10.1074/jbc.M507804200
   Makarov SS, 2000, MOL MED TODAY, V6, P441, DOI 10.1016/S1357 4310(00)01814 1
   Nanes MS, 2003, GENE, V321, P1, DOI 10.1016/S0378 1119(03)00841 2
   Toraldo G, 2003, P NATL ACAD SCI USA, V100, P125, DOI 10.1073/pnas.0136772100
   Valentine HL, 2006, TOXICOL SCI, V89, P485, DOI 10.1093/toxsci/kfj047
   Wei S, 2005, J CLIN INVEST, V115, P282, DOI 10.1172/JCI200523394
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
NR 24
TC 31
Z9 37
U1 0
U2 3
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107 3756
EI 1791 244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD APR
PY 2008
VL 21
IS 4
BP 521
EP 525
PG 5
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 279LX
UT WOS:000254357800016
PM 18360699
DA 2025 08 17
ER

PT J
AU Chatterjee, S
   Yin, HS
   Li, WN
   Lee, J
   Yechoor, VK
   Ma, K
AF Chatterjee, Somik
   Yin, Hongshan
   Li, Weini
   Lee, Jeongkyung
   Yechoor, Vijay K.
   Ma, Ke
TI The Nuclear Receptor and Clock Repressor Rev erbaα Suppresses Myogenesis
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MUSCLE SATELLITE CELLS; SKELETAL MUSCLE; CIRCADIAN CLOCK;
   TRANSCRIPTIONAL ARCHITECTURE; SELF RENEWAL; DIFFERENTIATION; CYCLE;
   ACTIVATION; EXPRESSION; BEHAVIOR
AB Rev erb alpha is a ligand dependent nuclear receptor and a key repressor of the molecular clock transcription network. Accumulating evidence indicate that the circadian clock machinery governs diverse biological processes in skeletal muscle, including muscle growth, repair and mass maintenance. The physiological function of Rev erb alpha in myogenic regulation remains largely unknown. Here we show that Rev erb alpha exerts cell autonomous inhibitory effects on proliferation and differentiation of myogenic precursor cells, and these actions concertedly inhibit muscle regeneration in vivo. Mechanistic studies reveal Rev erb alpha direct transcriptional control of two major myogenic mechanisms, proliferative pathway and the Wnt signaling cascade. Consistent with this finding, primary myoblasts lacking Rev erb alpha display significantly enhanced proliferative growth and myogenic progression. Furthermore, pharmacological activation of Rev erb alpha activity attenuates, whereas its inhibition by an antagonist promotes these processes. Notably, upon muscle injury, the loss of function of Rev erb alpha in vivo augmented satellite cell proliferative expansion and regenerative progression during regeneration. Collectively, our study identifies Rev erb alpha as a novel inhibitory regulator of myogenic progenitor cell properties that suppresses postnatal myogenesis. Pharmacological interventions to dampen Rev erb alpha activity may have potential utilities to enhance regenerative capacity in muscle diseases.
C1 [Chatterjee, Somik; Yin, Hongshan] Houston Methodist Res Inst, Ctr Diabet Res, Dept Med, Houston, TX 77030 USA.
   [Yin, Hongshan] Hebei Med Univ, Affiliated Hosp 3, Dept Cardiovasc Med, Shijiazhuang 050051, Hebei, Peoples R China.
   [Li, Weini; Ma, Ke] Beckman Res Inst City Hope, Dept Diabet Complicat & Metab, Duarte, CA 91010 USA.
   [Lee, Jeongkyung; Yechoor, Vijay K.] Univ Pittsburgh, Dept Med, Diabet & Beta Cell Biol Ctr, Div Endocrinol Diabet & Metab, 930 Scaife Hall, Pittsburgh, PA 15213 USA.
C3 Houston Methodist; Hebei Medical University; City of Hope; Beckman
   Research Institute of City of Hope; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh
RP Ma, K (通讯作者)，Beckman Res Inst City Hope, Dept Diabet Complicat & Metab, Duarte, CA 91010 USA.
EM kema@coh.org
RI Chatterjee, Somik/P 1581 2016; Yechoor, Vijay/AAX 3244 2021
OI Chatterjee, Somik/0000 0001 6869 4019; 
FU Muscular Dystrophy Association [381294]; American Heart Association
   [17GRNT33370012]; National Institute of Health [1R01DK112794,
   DK097160 01, P30CA33572]; American Heart Association (AHA)
   [17GRNT33370012] Funding Source: American Heart Association (AHA)
FX We thank the Histology Core Laboratory at Baylor College of Medicine for
   their expert technical assistance. We also thank Dr. Aijun Zhang,
   Methodist Hospital Research Institute, for help with microarray
   analysis. This project was supported by grants from Muscular Dystrophy
   Association 381294, American Heart Association 17GRNT33370012, and
   National Institute of Health 1R01DK112794 to K. M.; and National
   Institute of Health grant DK097160 01 to V. Y. K. M. as a faculty member
   of the City of Hope National Cancer Institute designated Comprehensive
   Cancer Center is also supported by National Institute of Health award
   P30CA33572.
CR Abbas A, 2010, J ROY COLL PHYS EDIN, V40, P311, DOI 10.4997/JRCPE.2010.406
   Andrews JL, 2010, P NATL ACAD SCI USA, V107, P19090, DOI 10.1073/pnas.1014523107
   Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166 4328(01)00297 2
   Bernet JD, 2014, NAT MED, V20, P265, DOI 10.1038/nm.3465
   BISCHOFF R, 1986, DEV BIOL, V115, P140, DOI 10.1016/0012 1606(86)90235 6
   Bouchard Cannon P, 2013, CELL REP, V5, P961, DOI 10.1016/j.celrep.2013.10.037
   Brack AS, 2008, CELL STEM CELL, V2, P50, DOI 10.1016/j.stem.2007.10.006
   Brack AS, 2009, DEV BIOL, V335, P93, DOI 10.1016/j.ydbio.2009.08.014
   Buckingham M, 2006, CURR OPIN GENET DEV, V16, P525, DOI 10.1016/j.gde.2006.08.008
   Burris TP, 2008, MOL ENDOCRINOL, V22, P1509, DOI 10.1210/me.2007 0519
   Chargé SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003
   Chatterjee S, 2014, EXPT CELL RES
   Chatterjee Somik, 2016, F1000Res, V5, P1549, DOI 10.12688/f1000research.9076.1
   Chatterjee S, 2013, J CELL SCI, V126, P2213, DOI 10.1242/jcs.120519
   Cho H, 2012, NATURE, V485, P123, DOI 10.1038/nature11048
   Christov C, 2007, MOL BIOL CELL, V18, P1397, DOI 10.1091/mbc.E06 08 0693
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Cossu G, 1999, EMBO J, V18, P6867, DOI 10.1093/emboj/18.24.6867
   Cvoro A, 2015, STEM CELLS, V33, P416, DOI 10.1002/stem.1875
   Dibner C, 2010, ANNU REV PHYSIOL, V72, P517, DOI 10.1146/annurev physiol 021909 135821
   DOWNES M, 1995, MOL ENDOCRINOL, V9, P1666, DOI 10.1210/me.9.12.1666
   Duan CM, 2010, GEN COMP ENDOCR, V167, P344, DOI 10.1016/j.ygcen.2010.04.009
   Duez H, 2009, J APPL PHYSIOL, V107, P1972, DOI 10.1152/japplphysiol.00570.2009
   Engert JC, 1996, J CELL BIOL, V135, P431, DOI 10.1083/jcb.135.2.431
   Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/er.17.5.481
   Gibbs JE, 2012, P NATL ACAD SCI USA, V109, P582, DOI 10.1073/pnas.1106750109
   Janich P, 2011, NATURE, V480, P209, DOI 10.1038/nature10649
   Karpowicz P, 2013, CELL REP, V3, P996, DOI 10.1016/j.celrep.2013.03.016
   Koike N, 2012, SCIENCE, V338, P349, DOI 10.1126/science.1226339
   Kojetin D, 2011, ACS CHEM BIOL, V6, P131, DOI 10.1021/cb1002575
   Kondratov RV, 2006, GENE DEV, V20, P1868, DOI 10.1101/gad.1432206
   Lam MTY, 2013, NATURE, V498, P511, DOI 10.1038/nature12209
   Le Grand F, 2007, CURR OPIN CELL BIOL, V19, P628, DOI 10.1016/j.ceb.2007.09.012
   Lucassen EA, 2016, CURR BIOL, V26, P1843, DOI 10.1016/j.cub.2016.05.038
   Masri S, 2013, CURR OPIN CELL BIOL, V25, P730, DOI 10.1016/j.ceb.2013.07.013
   McDearmon EL, 2006, SCIENCE, V314, P1304, DOI 10.1126/science.1132430
   Miller BH, 2007, P NATL ACAD SCI USA, V104, P3342, DOI 10.1073/pnas.0611724104
   Mitchell KJ, 2010, NAT CELL BIOL, V12, P257, DOI 10.1038/ncb2025
   Murphy MM, 2011, DEVELOPMENT, V138, P3625, DOI 10.1242/dev.064162
   Nam D, 2016, ADIPOCYTE, V5, P243, DOI 10.1080/21623945.2015.1082015
   Nam D, 2015, SCI REP UK, V5, DOI 10.1038/srep11239
   Nam D, 2015, J CELL SCI, V128, P1835, DOI 10.1242/jcs.167643
   Plikus MV, 2013, P NATL ACAD SCI USA, V110, pE2106, DOI 10.1073/pnas.1215935110
   Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092 8674(02)00825 5
   RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259
   ROBERTSON TA, 1993, EXP CELL RES, V207, P321, DOI 10.1006/excr.1993.1199
   Sabourin LA, 1999, J CELL BIOL, V144, P631, DOI 10.1083/jcb.144.4.631
   Schnell A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099883
   SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328
   Smyth G. K., 2004, Statistical Applications in Genetics and Molecular Biology, V3, P1, DOI [DOI 10.2202/1544 6115.1027, 10.2202/1544 6115.1027]
   Solt LA, 2012, TRENDS ENDOCRIN MET, V23, P619, DOI 10.1016/j.tem.2012.05.012
   Solt LA, 2012, NATURE, V485, P62, DOI 10.1038/nature11030
   Solt LA, 2011, NATURE, V472, P491, DOI 10.1038/nature10075
   Soták M, 2014, ANN MED, V46, P221, DOI 10.3109/07853890.2014.892296
   Stewart R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024714
   Stratmann M, 2012, CELL METAB, V15, P791, DOI 10.1016/j.cmet.2012.05.006
   Takahashi JS, 2017, NAT REV GENET, V18, P164, DOI 10.1038/nrg.2016.150
   Thompson J, 2004, MOL CELL NEUROSCI, V27, P441, DOI 10.1016/j.mcn.2004.07.007
   Wang YJ, 2015, BIOCHEM PHARMACOL, V96, P315, DOI 10.1016/j.bcp.2015.06.010
   Wang YJ, 2010, ACS CHEM BIOL, V5, P1029, DOI 10.1021/cb100223d
   Welch RD, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 17496 7
   Wen YF, 2012, MOL CELL BIOL, V32, P2300, DOI 10.1128/MCB.06753 11
   Woldt E, 2013, NAT MED, V19, P1039, DOI 10.1038/nm.3213
   Yin Lei, 2010, Nucl Recept Signal, V8, pe001, DOI 10.1621/nrs.08001
NR 64
TC 36
Z9 39
U1 0
U2 8
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD MAR 14
PY 2019
VL 9
AR 4585
DI 10.1038/s41598 019 41059 7
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA HO7WB
UT WOS:000461159600062
PM 30872796
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Zhu, JX
   Zhen, GH
   An, SB
   Wang, X
   Wan, M
   Li, YS
   Chen, ZY
   Guan, Y
   Dong, XZ
   Hu, YH
   Cao, X
AF Zhu, Jianxi
   Zhen, Gehua
   An, Senbo
   Wang, Xiao
   Wan, Mei
   Li, Yusheng
   Chen, Zhiyong
   Guan, Yun
   Dong, Xinzhong
   Hu, Yihe
   Cao, Xu
TI Aberrant subchondral osteoblastic metabolism modifies Nav 1.8
   for osteoarthritis
SO ELIFE
LA English
DT Article
ID SODIUM CHANNEL NA(V)1.8; PROSTAGLANDIN E 2; INFLAMMATORY PAIN;
   PROTEIN KINASE; OSTEOCHONDRAL JUNCTION; MOLECULAR MECHANISMS; SYNOVIAL
   TISSUE; GROWTH FACTOR; NERVE GROWTH; MOUSE MODEL
AB Pain is the most prominent symptom of osteoarthritis (OA) progression. However, the relationship between pain and OA progression remains largely unknown. Here we report osteoblast secret prostaglandin E2 (PGE2) during aberrant subchondral bone remodeling induces pain and OA progression in mice. Specific deletion of the major PGE2 producing enzyme cyclooxygenase 2 (COX2) in osteoblasts or PGE2 receptor EP4 in peripheral nerve markedly ameliorates OA symptoms. Mechanistically, PGE2 sensitizes dorsal root ganglia (DRG) neurons by modifying the voltage gated sodium channel Na(v)1.8, evidenced by that genetically or pharmacologically inhibiting Na(v)1.8 in DRG neurons can substantially attenuate OA. Moreover, drugs targeting aberrant subchondral bone remodeling also attenuates OA through rebalancing PGE2 production and Na(v)1.8 modification. Thus, aberrant subchondral remodeling induced Na(v)1.8 neuronal modification is an important player in OA and is a potential therapeutic target in multiple skeletal degenerative diseases.
C1 [Zhu, Jianxi; Zhen, Gehua; An, Senbo; Wang, Xiao; Wan, Mei; Li, Yusheng; Cao, Xu] Johns Hopkins Univ, Sch Med, Dept Orthopaed Surg, Baltimore, MD 21205 USA.
   [Zhu, Jianxi; Zhen, Gehua; An, Senbo; Wang, Xiao; Wan, Mei; Li, Yusheng; Cao, Xu] Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA.
   [Zhu, Jianxi; Zhen, Gehua; An, Senbo; Wang, Xiao; Wan, Mei; Li, Yusheng; Cao, Xu] Johns Hopkins Univ, Sch Med, Inst Cell Engn, Baltimore, MD 21205 USA.
   [Zhu, Jianxi; An, Senbo; Li, Yusheng; Hu, Yihe] Cent South Univ, Xiangya Hosp, Dept Orthopaed Surg, Changsha, Peoples R China.
   [Chen, Zhiyong; Guan, Yun] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA.
   [Dong, Xinzhong] Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Neurosci Neurosurg & Dermatol,Ctr Sensory Bi, Baltimore, MD 21205 USA.
C3 Johns Hopkins University; Johns Hopkins University; Johns Hopkins
   University; Central South University; Johns Hopkins University; Johns
   Hopkins University; Howard Hughes Medical Institute
RP Cao, X (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Orthopaed Surg, Baltimore, MD 21205 USA.; Cao, X (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA.; Cao, X (通讯作者)，Johns Hopkins Univ, Sch Med, Inst Cell Engn, Baltimore, MD 21205 USA.; Hu, YH (通讯作者)，Cent South Univ, Xiangya Hosp, Dept Orthopaed Surg, Changsha, Peoples R China.
EM huyh1964@163.com; xcao11@jhmi.edu
RI zhiyong, chen/AAL 8840 2021; zhu, jianxi/HLH 8668 2023
OI Zhu, Jianxi/0000 0003 4637 0704; guan, yun/0000 0003 1321 6655; CHEN,
   ZHIYONG/0000 0003 0475 3491; Wan, Mei/0000 0001 9404 540X
FU National Institutes of Health [AR071432, AR063943]
FX National Institutes of Health AR071432 Xu Cao National Institutes of
   Health AR063943 Xu Cao The funders had no role in study design, data
   collection and interpretation, or the decision to submit the work for
   publication.
CR Abdel Magid AF, 2014, ACS MED CHEM LETT, V5, P10, DOI [10.1021/ml5000367, 10.1021/ml400508g]
   Akopian AN, 1999, NAT NEUROSCI, V2, P541, DOI 10.1038/9195
   Akopian AN, 1996, NATURE, V379, P257, DOI 10.1038/379257a0
   Ashraf S, 2011, ANN RHEUM DIS, V70, P523, DOI 10.1136/ard.2010.137844
   Basbaum AI, 2009, CELL, V139, P267, DOI 10.1016/j.cell.2009.09.028
   Benito MJ, 2005, ANN RHEUM DIS, V64, P1263, DOI 10.1136/ard.2004.025270
   Berenbaum F, 2018, NAT REV RHEUMATOL, V14, P674, DOI 10.1038/s41584 018 0073 x
   Bierhaus A, 2012, NAT MED, V18, P926, DOI 10.1038/nm.2750
   Bohnsack M, 2005, ARCH ORTHOP TRAUM SU, V125, P592, DOI 10.1007/s00402 005 0796 4
   Boyd MJ, 2011, BIOORG MED CHEM LETT, V21, P484, DOI 10.1016/j.bmcl.2010.10.106
   BRAIN SD, 1985, NATURE, V313, P54, DOI 10.1038/313054a0
   Buch T, 2005, NAT METHODS, V2, P419, DOI 10.1038/NMETH762
   Chen D, 2017, BONE RES, V5, DOI 10.1038/boneres.2016.44
   Chen H, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 018 08097 7
   Chen Y, 2008, RESPIROLOGY, V13, P1014, DOI 10.1111/j.1440 1843.2008.01365.x
   Davies Tuck ML, 2009, ANN RHEUM DIS, V68, P904, DOI 10.1136/ard.2008.092973
   Dore D, 2009, J BONE MINER RES, V24, P2007, DOI [10.1359/JBMR.090532, 10.1359/jbmr.090532]
   Duan GY, 2018, MOL PAIN, V14, DOI 10.1177/1744806918763275
   Eijkelkamp N, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2673
   England S, 1996, J PHYSIOL LONDON, V495, P429, DOI 10.1113/jphysiol.1996.sp021604
   Ferreira Gomes J, 2010, ARTHRITIS RHEUM US, V62, P3677, DOI 10.1002/art.27713
   Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871
   Glasson SS, 2010, OSTEOARTHR CARTILAGE, V18, pS17, DOI 10.1016/j.joca.2010.05.025
   Glasson SS, 2005, NATURE, V434, P644, DOI 10.1038/nature03369
   Gold MS, 1998, J NEUROSCI, V18, P10345
   Grässel S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18050931
   Hayami T, 2004, ARTHRITIS RHEUM US, V50, P1193, DOI 10.1002/art.20124
   Hudmon A, 2008, J NEUROSCI, V28, P3190, DOI 10.1523/JNEUROSCI.4403 07.2008
   Jarvis MF, 2007, P NATL ACAD SCI USA, V104, P8520, DOI 10.1073/pnas.0611364104
   Julius D, 2001, NATURE, V413, P203, DOI 10.1038/35093019
   Kameda Takuya, 2017, J Exp Orthop, V4, P31, DOI 10.1186/s40634 017 0105 5
   Kapoor M, 2011, NAT REV RHEUMATOL, V7, P33, DOI 10.1038/nrrheum.2010.196
   Kc R, 2016, ANN RHEUM DIS, V75, P2133, DOI 10.1136/annrheumdis 2015 208444
   Kim AY, 2008, CELL, V133, P475, DOI 10.1016/j.cell.2008.02.053
   Kim JH, 2014, CELL, V156, P730, DOI 10.1016/j.cell.2014.01.007
   Kim YS, 2014, NEURON, V81, P873, DOI 10.1016/j.neuron.2013.12.011
   Kuner R, 2010, NAT MED, V16, P1258, DOI 10.1038/nm.2231
   Kwoh CK, 2013, NAT REV RHEUMATOL, V9, P7, DOI 10.1038/nrrheum.2012.217
   Lakes EH, 2016, OSTEOARTHR CARTILAGE, V24, P1837, DOI 10.1016/j.joca.2016.03.008
   Lane NE, 2017, NAT REV RHEUMATOL, V13, P76, DOI 10.1038/nrrheum.2016.224
   Lane NE, 2010, NEW ENGL J MED, V363, P1521, DOI 10.1056/NEJMoa0901510
   Libicher M, 2005, EUR RADIOL, V15, P390, DOI 10.1007/s00330 004 2486 y
   Lin CR, 2006, J PHARMACOL EXP THER, V319, P1096, DOI 10.1124/jpet.106.105569
   Liu C, 2010, TRAFFIC, V11, P405, DOI 10.1111/j.1600 0854.2009.01027.x
   Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896 6273(02)00828 0
   Majumdar S, 2004, EUR RADIOL, V14, P1440, DOI 10.1007/s00330 004 2355 8
   Malfait AM, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0747 6
   Malfait AM, 2013, NAT REV RHEUMATOL, V9, P654, DOI 10.1038/nrrheum.2013.138
   Mapp PI, 2012, NAT REV RHEUMATOL, V8, P390, DOI 10.1038/nrrheum.2012.80
   Martel Pelletier J, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.72
   Massicotte F, 2002, OSTEOARTHR CARTILAGE, V10, P491, DOI 10.1053/joca.2002.0528
   McCoy JM, 2002, J CLIN INVEST, V110, P651, DOI 10.1172/JCI200215528
   Midwood K, 2009, NAT MED, V15, P774, DOI 10.1038/nm.1987
   Miller RE, 2018, ARTHRITIS RHEUMATOL, V70, P88, DOI 10.1002/art.40342
   Miller RE, 2017, ARTHRITIS RHEUMATOL, V69, P1429, DOI 10.1002/art.40118
   Mittag F, 2016, ACTA ORTOP BRAS, V24, P43, DOI 10.1590/1413 785220162401150767
   Nakao K, 2007, J PHARMACOL EXP THER, V322, P686, DOI 10.1124/jpet.107.122010
   Qin YH, 2018, ANN NY ACAD SCI, V1433, P29, DOI 10.1111/nyas.13941
   Samad TA, 2001, NATURE, V410, P471, DOI 10.1038/35068566
   Sellam J, 2010, NAT REV RHEUMATOL, V6, P625, DOI 10.1038/nrrheum.2010.159
   Skou ST, 2015, NEW ENGL J MED, V373, P1597, DOI 10.1056/NEJMoa1505467
   Southall MD, 2001, J BIOL CHEM, V276, P16083, DOI 10.1074/jbc.M011408200
   Strickland IT, 2008, EUR J PAIN, V12, P564, DOI 10.1016/j.ejpain.2007.09.001
   Suri S, 2007, ANN RHEUM DIS, V66, P1423, DOI 10.1136/ard.2006.063354
   Taylor Clark TE, 2008, MOL PHARMACOL, V73, P274, DOI 10.1124/mol.107.040832
   Tomlinson RE, 2016, CELL REP, V16, P2723, DOI 10.1016/j.celrep.2016.08.002
   Tu ML, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0071 x
   Usoskin D, 2015, NAT NEUROSCI, V18, P145, DOI 10.1038/nn.3881
   Walsh DA, 2010, RHEUMATOLOGY, V49, P1852, DOI 10.1093/rheumatology/keq188
   Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765
   Wu DF, 2012, J CLIN INVEST, V122, P1306, DOI 10.1172/JCI61934
   Yoshida K, 2002, P NATL ACAD SCI USA, V99, P4580, DOI 10.1073/pnas.062053399
   Zhen GH, 2013, NAT MED, V19, P704, DOI 10.1038/nm.3143
   Zhu SA, 2019, J CLIN INVEST, V129, P1076, DOI 10.1172/JCI121561
   Zurborg S, 2011, MOL PAIN, V7, DOI 10.1186/1744 8069 7 66
NR 75
TC 45
Z9 53
U1 1
U2 28
PU ELIFE SCIENCES PUBLICATIONS LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050 084X
J9 ELIFE
JI eLife
PD MAY 22
PY 2020
VL 9
AR e57656
DI 10.7554/eLife.57656
PG 27
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA MD0ZH
UT WOS:000543704400001
PM 32441256
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Lin, WZ
   Hu, SH
   Li, K
   Shi, Y
   Pan, C
   Xu, ZB
   Li, DD
   Wang, HH
   Li, B
   Chen, H
AF Lin, Wenzheng
   Hu, Sihan
   Li, Ke
   Shi, Yu
   Pan, Chun
   Xu, Zhuobin
   Li, Dandan
   Wang, Huihui
   Li, Bin
   Chen, Hao
TI Breaking Osteoclast Acid Vicious Cycle to Rescue Osteoporosis via an
   Acid Responsive Organic Framework Based Neutralizing and Gene Editing
   Platform
SO SMALL
LA English
DT Article
DE acid neutralization; gene editing; metal organic framework;
   osteoporosis; receptor activator of nuclear factor kappa B ligand
ID RANKL INDUCED OSTEOCLASTOGENESIS; REACTIVE OXYGEN; IN VITRO; BONE;
   HYDROXYAPATITE; NANOPARTICLES; MECHANISMS; DELIVERY; RELEASE; SYSTEM
AB In the osteoporotic microenvironment, the acidic microenvironment generated by excessive osteoclasts not only causes irreversible bone mineral dissolution, but also promotes reactive oxygen species (ROS) production to induce osteoblast senescence and excessive receptor activator of nuclear factor kappa B ligand (RANKL) production, which help to generate more osteoclasts. Hence, targeting the acidic microenvironment and RANKL production may break this vicious cycle to rescue osteoporosis. To achieve this, an acid responsive and neutralizing system with high in vivo gene editing capacity is developed by loading sodium bicarbonate (NaHCO3) and RANKL CRISPR/Cas9 (RC) plasmid in a metal organic framework. This results showed ZIF8 NaHCO3@Cas9 (ZNC) effective neutralized acidic microenvironment and inhibited ROS production . Surprisingly, nanoparticles loaded with NaHCO3 and plasmids show higher transfection efficiency in the acidic environments as compared to the ones loaded with plasmid only. Finally, micro CT proves complete reversal of bone volume in ovariectomized mice after ZNC injection into the bone remodeling site. Overall, the newly developed nanoparticles show strong effect in neutralizing the acidic microenvironment to achieve bone protection through promoting osteogenesis and inhibiting osteolysis in a bidirectional manner. This study provides new insights into the treatment of osteoporosis for biomedical and clinical therapies.
   ZIF8 NaHCO3@Cas9 (ZNC) effectively neutralizes the microenvironment and blocks nuclear factor kappa B ligand (RANKL) production to reshape a healthy bone microenvironment, which effectively rescues osteoporosis. image
C1 [Lin, Wenzheng; Li, Ke; Shi, Yu; Pan, Chun; Xu, Zhuobin; Li, Dandan; Wang, Huihui; Chen, Hao] Yangzhou Univ, Inst Translat Med, Med Coll, Yangzhou 225001, Peoples R China.
   [Lin, Wenzheng; Li, Ke; Shi, Yu; Chen, Hao] Yangzhou Univ, Affiliated Hosp, Dept Orthoped, Yangzhou 225000, Peoples R China.
   [Lin, Wenzheng; Wang, Huihui; Chen, Hao] Yangzhou Univ, Jiangsu Key Lab Integrated Tradit Chinese & Wester, Yangzhou 225001, Peoples R China.
   [Hu, Sihan; Li, Bin] Soochow Univ, Affiliated Hosp 1, Orthoped Inst, Suzhou Med Coll,Dept Orthoped Surg, Suzhou 215006, Peoples R China.
C3 Yangzhou University; Yangzhou University; Yangzhou University; Soochow
   University   China
RP Wang, HH; Chen, H (通讯作者)，Yangzhou Univ, Inst Translat Med, Med Coll, Yangzhou 225001, Peoples R China.; Chen, H (通讯作者)，Yangzhou Univ, Affiliated Hosp, Dept Orthoped, Yangzhou 225000, Peoples R China.; Wang, HH; Chen, H (通讯作者)，Yangzhou Univ, Jiangsu Key Lab Integrated Tradit Chinese & Wester, Yangzhou 225001, Peoples R China.; Li, B (通讯作者)，Soochow Univ, Affiliated Hosp 1, Orthoped Inst, Suzhou Med Coll,Dept Orthoped Surg, Suzhou 215006, Peoples R China.
EM wanghh56@yzu.edu.cn; binli@suda.edu.cn; hchen2020@yzu.edu.cn
RI Li, Bin/AAW 6911 2020
FU National Natural Science Foundation of China; Natural Science Foundation
   of Jiangsu Province [SBK2021022619]; Natural Science Fund for Colleges
   and Universities in Jiangsu Province [21KJB320009]; Science and
   Technology Projects Fund of Yangzhou City [SSF2021000051]; New Medical
   Interdisciplinary Innovation Team of Yangzhou University
   [AHYZUCXTD202101];  [81802132];  [8217090346]
FX W.L. and S.H. contributed equally to this study. This study was
   supported by the National Natural Science Foundation of China (81802132
   and 8217090346), the Natural Science Foundation of Jiangsu Province
   (SBK2021022619), the Natural Science Fund for Colleges and Universities
   in Jiangsu Province (21KJB320009), the Science and Technology Projects
   Fund of Yangzhou City (SSF2021000051), and the New Medical
   Interdisciplinary Innovation Team of Yangzhou University
   (AHYZUCXTD202101).
CR Alsaiari SK, 2018, J AM CHEM SOC, V140, P143, DOI 10.1021/jacs.7b11754
   Alyami MZ, 2020, J AM CHEM SOC, V142, P1715, DOI 10.1021/jacs.9b11638
   Andreopoulou P, 2015, ANNU REV MED, V66, P329, DOI 10.1146/annurev med 070313 022841
   Ansari N, 2020, HANDB EXP PHARMACOL, V262, P1, DOI 10.1007/164_2019_343
   Bernhardt A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052451
   Bone HG, 2017, LANCET DIABETES ENDO, V5, P513, DOI 10.1016/S2213 8587(17)30138 9
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bushinsky DA, 2001, EUR J NUTR, V40, P238, DOI 10.1007/s394 001 8351 5
   Bushinsky DA, 1996, AM J PHYSIOL RENAL, V271, pF216, DOI 10.1152/ajprenal.1996.271.1.F216
   Chandra A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073553
   Chen MH, 2022, BIOACT MATER, V18, P56, DOI 10.1016/j.bioactmat.2022.02.006
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Davalli P, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3565127
   Dungan CM, 2022, AGING CELL, V21, DOI 10.1111/acel.13528
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   Figueira TR, 2013, ANTIOXID REDOX SIGN, V18, P2029, DOI 10.1089/ars.2012.4729
   Gao WW, 2010, MOL PHARMACEUT, V7, P1913, DOI 10.1021/mp100253e
   Granchi D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181230
   Guo XB, 2019, ADV BIOSYST, V3, DOI 10.1002/adbi.201800253
   Hewawaduge C, 2021, PATHOG DIS, V79, DOI 10.1093/femspd/ftab002
   Hughes MG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180719
   Jaber S, 2018, LANCET, V392, P31, DOI 10.1016/S0140 6736(18)31080 8
   Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829
   Kaunitz JD, 2008, J CELL BIOCHEM, V105, P655, DOI 10.1002/jcb.21885
   Khajuria DK, 2017, MAT SCI ENG C MATER, V71, P698, DOI 10.1016/j.msec.2016.10.066
   Khajuria DK, 2016, MAT SCI ENG C MATER, V63, P78, DOI 10.1016/j.msec.2016.02.062
   Khajuria DK, 2015, EUR J PHARM SCI, V66, P173, DOI 10.1016/j.ejps.2014.10.015
   Komori T, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207513
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Lee YH, 2010, CELL BIOCHEM FUNCT, V28, P678, DOI 10.1002/cbf.1708
   Li JM, 2021, BIOACT MATER, V6, P3839, DOI 10.1016/j.bioactmat.2021.03.039
   Li K, 2023, NANO TODAY, V50, DOI 10.1016/j.nantod.2023.101839
   Li YT, 2019, ADV MATER, V31, DOI 10.1002/adma.201901570
   Lin XF, 2020, J AM CHEM SOC, V142, P17543, DOI 10.1021/jacs.0c07309
   Liu D, 2016, THERANOSTICS, V6, P1306, DOI 10.7150/thno.14858
   Ma YN, 2022, ACS APPL MATER INTER, V14, P6358, DOI 10.1021/acsami.1c21700
   Madeswaran Sathyasree, 2018, Indian J Dent Res, V29, P672, DOI 10.4103/ijdr.IJDR_30_17
   Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033
   Marie PJ, 2014, J BONE MINER RES, V29, P1311, DOI 10.1002/jbmr.2190
   Minoshima M, 2019, ACS CENTRAL SCI, V5, P1059, DOI 10.1021/acscentsci.9b00220
   Nagy V, 2015, GERONTOLOGY, V61, P534, DOI 10.1159/000371845
   Park KS, 2006, P NATL ACAD SCI USA, V103, P10186, DOI 10.1073/pnas.0602439103
   Park KR, 2022, PHARMACOL RES, V184, DOI 10.1016/j.phrs.2022.106423
   Poddar A, 2019, SMALL, V15, DOI 10.1002/smll.201902268
   Porteus MH, 2003, SCIENCE, V300, P763, DOI 10.1126/science.1078395
   Qu XH, 2022, ADV MATER, V34, DOI 10.1002/adma.202200096
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Reid IR, 2020, NAT REV ENDOCRINOL, V16, P333, DOI 10.1038/s41574 020 0339 7
   Robling AG, 2020, ANNU REV PHYSIOL, V82, P485, DOI 10.1146/annurev physiol 021119 034332
   Sandomierski M, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 13187 0
   Seeman E, 2019, NAT REV RHEUMATOL, V15, P225, DOI 10.1038/s41584 019 0172 3
   Shen YH, 2011, LANGMUIR, V27, P2701, DOI 10.1021/la104876w
   Sun CY, 2012, DALTON T, V41, P6906, DOI 10.1039/c2dt30357d
   Tao HQ, 2020, ACTA BIOCH BIOPH SIN, V52, P1055, DOI 10.1093/abbs/gmaa098
   Teixeira J, 2018, REDOX BIOL, V15, P394, DOI 10.1016/j.redox.2017.12.018
   Thummuri D, 2015, PHARMACOL RES, V99, P63, DOI 10.1016/j.phrs.2015.05.006
   Tian K, 2020, LIFE SCI, V244, DOI 10.1016/j.lfs.2020.117336
   Tran VA, 2021, RSC ADV, V11, P9222, DOI 10.1039/d0ra10423j
   Tsukasaki M, 2019, NAT REV IMMUNOL, V19, P626, DOI 10.1038/s41577 019 0178 8
   Wang HM, 2019, ANGEW CHEM INT EDIT, V58, P7380, DOI 10.1002/anie.201902714
   Wesson DE, 2019, LANCET, V393, P1417, DOI 10.1016/S0140 6736(18)32562 5
   Wu W, 2018, THERANOSTICS, V8, P3038, DOI 10.7150/thno.23459
   Xu Z, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14570
   Zhang LL, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22126522
   Zhang XJ, 2021, BIOMATERIALS, V275, DOI 10.1016/j.biomaterials.2021.120987
   Zorov DB, 2014, PHYSIOL REV, V94, P909, DOI 10.1152/physrev.00026.2013
NR 67
TC 15
Z9 15
U1 14
U2 53
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1613 6810
EI 1613 6829
J9 SMALL
JI Small
PD MAY
PY 2024
VL 20
IS 22
DI 10.1002/smll.202307595
EA DEC 2023
PG 16
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA SO8P7
UT WOS:001128462500001
PM 38126648
DA 2025 08 17
ER

PT J
AU Legakis, I
   Syrigos, K
AF Legakis, Ioannis
   Syrigos, Konstantinos
TI Osteoporosis in Patients with Breast and Prostate Cancer: Effect of
   Disease and Treatment Modalities
SO ENDOCRINE METABOLIC & IMMUNE DISORDERS DRUG TARGETS
LA English
DT Article
DE Aromatase inhibitors; alendronate; bisphosphonate; breast cancer;
   denosumab; mevalonate pathway; osteoporosis; prostate cancer; RANK;
   zoledronic acid
ID BONE MINERAL DENSITY; ANDROGEN DEPRIVATION THERAPY; RANDOMIZED
   CONTROLLED TRIAL; HORMONE AGONISTS; ZOLEDRONIC ACID; AROMATASE
   INHIBITORS; GENE EXPRESSION; FRACTURE RISK; ELDERLY WOMEN; ESTROGEN
AB The skeleton is constantly being remodelled through the simultaneous resorption of bone and formation of new bone. Significant effects on bone metabolism are produced due to cancer treatment especially of breast and prostate origin, even in the absence of bone metastases. These pathological changes are known as cancer treatment induced bone loss. Bone mass loss and osteoporosis may cause an increased risk of fractures due to a reduction in bone volume and microarchitectural deterioration. On the other hand, the skeleton is both the most common organ affected by metastatic cancer and the site that produces the greatest morbidity for patients.
   Recent advances in our understanding of bone biology and the pathways by which cancer metastasizes and spreads to bone have contributed to the development of several important new drugs targeting these processes. This article summarizes our current knowledge and recommendations to advanced biology of metastasis, focusing on breast and prostate cancer.
C1 [Legakis, Ioannis] Henry Dunant Hosp, Dept Endocrinol & Metab, Athens 11851, Greece.
   [Syrigos, Konstantinos] Univ Athens, Sch Med, Sotiria Gen Hosp, Dept Internal Med 3,Oncol Unit, GR 11527 Athens, Greece.
C3 Henry Dunant Hospital; National & Kapodistrian University of Athens
RP Legakis, I (通讯作者)，Henry Dunant Hosp, Endocrinol & Metab Unit, Alimousion 33, Athens 11851, Greece.
EM ilegak@med.uoa.gr
RI Syrigos, Kostas/AAE 8045 2019
CR Almeida M, 2007, J BIOL CHEM, V282, P27285, DOI 10.1074/jbc.M702810200
   Alver K, 2005, OSTEOPOROSIS INT, V16, P623, DOI 10.1007/s00198 004 1722 2
   Amgen Incorporated, 2010, PROL 60 MG SOL INJ P
   Bosco D, 2012, CLIN CASES MINER BON, V9, P89
   Bryden AAG, 2002, BRIT J CANCER, V86, P322, DOI 10.1038/sj/bjc/6600115
   Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   Carlin Bruce I., 2000, Cancer, V88, P2989, DOI 10.1002/1097 0142(20000615)88:12+<2989::AID CNCR14>3.0.CO;2 Q
   Coetzee M, 2004, SOUTH MED J, V97, P506, DOI 10.1097/00007611 200405000 00018
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   COOPER C, 1992, OSTEOPOROSIS INT, V2, P285, DOI 10.1007/BF01623184
   Cummings SR, 2002, JAMA J AM MED ASSOC, V288, P1889, DOI 10.1001/jama.288.15.1889
   Cummings SR, 1998, NEW ENGL J MED, V339, P733, DOI 10.1056/NEJM199809103391104
   Di Gregorio GB, 2001, J CLIN INVEST, V107, P803, DOI 10.1172/JCI11653
   Eastell R, 2008, J CLIN ONCOL, V26, P1051, DOI 10.1200/JCO.2007.11.0726
   Eaton CL, 2003, CANCER TREAT REV, V29, P189, DOI 10.1016/S0305 7372(03)00071 9
   Ellis GK, 2008, J CLIN ONCOL, V26, P4875, DOI 10.1200/JCO.2008.16.3832
   Ettinger B, 2004, OBSTET GYNECOL, V104, P443, DOI 10.1097/01.AOG.0000137833.43248.79
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Frenkel B, 2010, J CELL PHYSIOL, V224, P305, DOI 10.1002/jcp.22159
   Fricia T, 2010, G GERONTOL, V58, P31
   Frydenberg M, 1997, LANCET, V349, P1681, DOI 10.1016/S0140 6736(96)07393 X
   Goessl C, 2012, ANN NY ACAD SCI, V1263, P29, DOI 10.1111/j.1749 6632.2012.06674.x
   Greenspan SL, 2005, J CLIN ENDOCR METAB, V90, P6410, DOI 10.1210/jc.2005 0183
   Greenspan SL, 2008, J CLIN ENDOCR METAB, V93, P2, DOI 10.1210/jc.2007 1402
   Greenspan SL, 2007, ANN INTERN MED, V146, P416, DOI 10.7326/0003 4819 146 6 200703200 00006
   Hadji P, 2012, BREAST CANCER RES TR, V133, P1089, DOI 10.1007/s10549 012 2023 7
   Hadji P, 2009, CRIT REV ONCOL HEMAT, V69, P73, DOI 10.1016/j.critrevonc.2008.07.013
   Hawse JR, 2008, J CELL BIOCHEM, V103, P383, DOI 10.1002/jcb.21425
   Hawse JR, 2008, MOL ENDOCRINOL, V22, P1579, DOI 10.1210/me.2007 0253
   Higano CS, 2004, UROL CLIN N AM, V31, P331, DOI 10.1016/j.ucl.2004.01.001
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4367, DOI 10.1210/en.140.9.4367
   Huggins C, 2002, J UROLOGY, V168, P9, DOI 10.1016/S0022 5347(05)64820 3
   Iguchi K, 2012, YAKUGAKU ZASSHI, V132, P1025, DOI 10.1248/yakushi.132.1025
   Ito K, 2012, J CLIN ONCOL, V30, P1468, DOI 10.1200/JCO.2011.38.7001
   Kanis JA, 2002, LANCET, V359, P1929, DOI 10.1016/S0140 6736(02)08761 5
   KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802
   Khosla S, 2008, BONE, V43, P414, DOI 10.1016/j.bone.2008.05.005
   Khosla S, 2010, J CLIN ENDOCR METAB, V95, P3569, DOI 10.1210/jc.2010 0856
   Legakis I, 2009, INT J ENDOCRINOL MET, V7, P56
   Legakis I., 2012, ENDOCRINOLOGY STUDIE, pe1
   Lipton A, 2012, CLIN MED INSIGHTS ON, V6, DOI 10.4137/CMO.S8511
   Lunt M, 1997, J BONE MINER RES, V12, P1883, DOI 10.1359/jbmr.1997.12.11.1883
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Markopoulos C, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2565
   Melton LJ, 2004, J BONE MINER RES, V19, P25, DOI 10.1359/JBMR.0301212
   Messing EM, 1999, NEW ENGL J MED, V341, P1781, DOI 10.1056/NEJM199912093412401
   Michael A, 2009, PROSTATE CANCER P D, V12, P13, DOI 10.1038/pcan.2008.32
   Michaelson MD, 2007, J CLIN ONCOL, V25, P1038, DOI 10.1200/JCO.2006.07.3361
   Mincey Betty A, 2003, Curr Oncol Rep, V5, P53, DOI 10.1007/s11912 003 0086 7
   Mountzios G, 2010, TRANSL RES, V155, P247, DOI 10.1016/j.trsl.2010.01.002
   *MRC PROST CANC WO, 1997, BRIT J UROL, V72, P235
   Naessen T, 1997, AM J OBSTET GYNECOL, V177, P115, DOI 10.1016/S0002 9378(97)70448 4
   Paller CJ, 2012, CLIN INTERV AGING, V7, P363, DOI 10.2147/CIA.S27930
   Pandya N, 2006, SEMIN ONCOL, V33, P688, DOI 10.1053/j.seminoncol.2006.08.011
   PECK WA, 1993, AM J MED, V94, P646
   Pfeilschifter J, 2000, J CLIN ONCOL, V18, P1570, DOI 10.1200/JCO.2000.18.7.1570
   Polyzos A, 2010, BREAST CANCER RES TR, V119, P95, DOI 10.1007/s10549 009 0468 0
   Ramaswamy B, 2003, SEMIN ONCOL, V30, P763, DOI 10.1053/j.seminoncol.2003.08.028
   Reichman ME, 2010, CANCER EPIDEM BIOMAR, V19, P144, DOI 10.1158/1055 9965.EPI 09 0807
   RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605
   Roodman GD, 1997, CANCER, V80, P1557, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1557::AID CNCR5>3.3.CO;2 K
   Rudnik V, 2008, J CELL BIOCHEM, V103, P896, DOI 10.1002/jcb.21459
   Saad F, 2004, EUR UROL, V45, P26, DOI 10.1016/j.eururo.2003.10.003
   Schech AJ, 2012, J STEROID BIOCHEM, V132, P195, DOI 10.1016/j.jsbmb.2012.05.008
   Schneider A., 2001, OSTEOPOROSIS, P303
   Shahinian VB, 2005, CANCER AM CANCER SOC, V103, P1615, DOI 10.1002/cncr.20955
   Shahinian VB, 2005, NEW ENGL J MED, V352, P154, DOI 10.1056/NEJMoa041943
   Smith MR, 2005, J CLIN ONCOL, V23, P7897, DOI 10.1200/JCO.2004.00.6908
   Smith MR, 2003, J UROLOGY, V169, P2008, DOI 10.1097/01.ju.0000063820.94994.95
   Smith MR, 2004, J CLIN ENDOCR METAB, V89, P3841, DOI 10.1210/jc.2003 032058
   Stavridi F, 2010, CANCER TREAT REV, V36, P122, DOI 10.1016/j.ctrv.2009.06.001
   Syrigos KN, 2005, ANTICANCER RES, V25, P4527
   Tomkinson A, 1997, J CLIN ENDOCR METAB, V82, P3128, DOI 10.1210/jc.82.9.3128
   Townsend MF, 1997, CANCER, V79, P545, DOI 10.1002/(SICI)1097 0142(19970201)79:3<545::AID CNCR17>3.0.CO;2 3
   Van Poznak C, 2010, J CLIN ONCOL, V28, P967, DOI 10.1200/JCO.2009.24.5902
   Vehmanen L, 2001, EUR J CANCER, V37, P2373, DOI 10.1016/S0959 8049(01)00317 3
   Venken K, 2008, OSTEOPOROSIS INT, V19, P1517, DOI 10.1007/s00198 008 0609 z
   Winters Stone KM, 2013, OSTEOPOROSIS INT, V24, P1637, DOI 10.1007/s00198 012 2143 2
   World Health Organisation, 1994, WHO TECHN SUPP SER
NR 79
TC 3
Z9 3
U1 0
U2 4
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1871 5303
EI 2212 3873
J9 ENDOCR METAB IMMUNE
JI Endocr. Metab. Immune Disord. Drug Targets
PD JUN
PY 2013
VL 13
IS 2
BP 168
EP 174
DI 10.2174/18715303112129990027
PG 7
WC Endocrinology & Metabolism; Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Immunology; Pharmacology & Pharmacy
GA 242GZ
UT WOS:000326228100005
PM 23244490
DA 2025 08 17
ER

PT J
AU Valsecchi, WM
   Delfino, JM
   Santos, J
   Villamil, SHF
AF Valsecchi, W. M.
   Delfino, J. M.
   Santos, J.
   Villamil, S. H. Fernandez
TI Zoledronate repositioning as a potential trypanocidal drug.
   Trypanosoma cruzi HPRT an alternative target to be considered
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE Trypanosoma cruzi; Growth inhibition; Bisphosphonates; Zoledronate;
   Hypoxanthine phosphoribosyltransferase(HPRT)
ID HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE; IN VITRO; INHIBITORS;
   BISPHOSPHONATES; STATE
AB Chagas disease is caused by the protozoan parasite Trypanosoma cruzi and affects 7 million people worldwide. Considering the side effects and drug resistance shown by current treatments, the development of new anti Chagas therapies is an urgent need. T. cruzi hypoxanthine phosphoribosyltransferase (TcHPRT), the key enzyme of the purine salvage pathway, is essential for the survival of trypanosomatids. Previously, we assessed the inhibitory effect of different bisphosphonates (BPs), HPRT substrate analogues, on the activity of the isolated enzyme. BPs are used as a treatment for bone diseases and growth inhibition studies on T. cruzi have associated BPs action with the farnesyl diphosphate synthase inhibition. Here, we demonstrated significant growth inhibition of epimastigotes in the presence of BPs and a strong correlation with our previous results on the isolated TcHPRT, suggesting this enzyme as a possible and important target for these drugs. We also found that the parasites exhibited a delay at S phase in the presence of zoledronate pointing out enzymes involved in the cell cycle, such as TcHPRT, as intracellular targets. Moreover, we validated that micromolar concentrations of zoledronate are capable to interfere with the progression of cell infection by this parasite. Altogether, our findings allow us to propose the repositioning of zoledronate as a promising candidate against Chagas disease and TcHPRT as a new target for future rational design of antiparasitic drugs.
C1 [Valsecchi, W. M.; Delfino, J. M.; Santos, J.; Villamil, S. H. Fernandez] Univ Buenos Aires UBA, Fac Farm & Bioquim, Dept Quim Biol, Junin 956, RA 1113 Buenos Aires, DF, Argentina.
   [Valsecchi, W. M.; Delfino, J. M.; Santos, J.] Inst Quim & Fisicoquim Biol IQUIFIB CONICET, Buenos Aires, DF, Argentina.
   [Villamil, S. H. Fernandez] Inst Invest Ingn Genet & Biol Mol INGEBI CONICET, Buenos Aires, DF, Argentina.
   [Santos, J.] UBA, Inst Biociencias Biotecnol & Biol Traslac iB3, Dept Fisiol & Biol Mol & Celular, Fac Ciencias Exactas & Nat, Buenos Aires, DF, Argentina.
C3 University of Buenos Aires; Consejo Nacional de Investigaciones
   Cientificas y Tecnicas (CONICET); Consejo Nacional de Investigaciones
   Cientificas y Tecnicas (CONICET); University of Buenos Aires
RP Valsecchi, WM (通讯作者)，Univ Buenos Aires UBA, Fac Farm & Bioquim, Dept Quim Biol, Junin 956, RA 1113 Buenos Aires, DF, Argentina.; Villamil, SHF (通讯作者)，Vuelta Obligado 2490, RA 1428 Buenos Aires, DF, Argentina.
EM wvalsecchi@qb.ffyb.uba.ar; s.villamil@ingebi.conicet.gov.ar
RI dos Santos, José Cleiton/F 4710 2014; Valsecchi, wanda/JTS 4625 2023
OI Delfino, Jose/0009 0002 0140 2899; Santos, Javier/0000 0002 1140 8234;
   Valsecchi, Wanda Mariela/0000 0002 8066 5445
FU Agencia Nacional de Promocion Cientifica y Tecnologica [PICT 2015 0898];
   Universidad de Buenos Aires
FX We thank Dra. Miriam Dziubecki and Dr. Emilio Roldan from GADOR SA,
   Buenos Aires for providing the set of BPs used in this work. We also
   thank Rodrigo G. Ducati, PhD (Albert Einstein College of Medicine, USA),
   for gently providing us with HsHPRT, William A. Agudelo (Fundacion
   Instituto de Inmunologia de Colombia (FIDIC), Bogota D.C., Colombia),
   for his comments and suggestions, and Salome C. Vilchez Larrea, PhD
   (INGEBI, Argentina), for her collaboration in cell culture and
   ss galactosidase trypomastigotes production. This work was supported by
   Agencia Nacional de Promocion Cientifica y Tecnologica PICT 2015 0898
   and Universidad de Buenos Aires.
CR Albert S.G, 2017, ENDROCRINE PRACTICE, V27, P38
   BERENS RL, 1981, MOL BIOCHEM PARASIT, V3, P187, DOI 10.1016/0166 6851(81)90049 9
   Boitz JM, 2006, J BIOL CHEM, V281, P16084, DOI 10.1074/jbc.M600188200
   Buckner F., 1996, MICROBIOLOGY, V40, P6
   Cai G., 2020, JAMA J AM MED ASSOC, V323, P11
   Christensen AT, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/9025627
   Custodio Leite TO, 2019, REV MED PHARM SCI, V23, P11
   DAWSON PA, 1993, MOL BIOCHEM PARASIT, V60, P153, DOI 10.1016/0166 6851(93)90039 Z
   Demoro B, 2018, J BIOL INORG CHEM, V23, P303, DOI 10.1007/s00775 018 1535 y
   Fernández D, 2004, BIOORG MED CHEM LETT, V14, P4501, DOI 10.1016/j.bmcl.2004.06.042
   Freymann DM, 2000, CHEM BIOL, V7, P957, DOI 10.1016/S1074 5521(00)00045 4
   Garzoni LR, 2004, INT J ANTIMICROB AG, V23, P273, DOI 10.1016/j.ijantimicag.2003.07.020
   Ghosh S, 2004, J MED CHEM, V47, P175, DOI 10.1021/jm030084x
   Gralow J.R., 2020, J NATL CANC I, V112, P36
   Grey A, 2016, THERAP ADV MUSCULOSK, V8, P5
   Keough DT, 2018, ACS CHEM BIOL, V13, P82, DOI 10.1021/acschembio.7b00916
   La Beck NM, 2021, SEMIN CANCER BIOL, V68, P175, DOI 10.1016/j.semcancer.2019.12.001
   Le Nours J, 2011, J BIOL CHEM, V286, P40706, DOI 10.1074/jbc.M111.291138
   Li CM, 1999, NAT STRUCT BIOL, V6, P582, DOI 10.1038/9367
   Li ZH, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.02628 16
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Martin D, 2020, PROTOZOOL RES
   McClung M, 2013, AM J MED, V126, P13, DOI 10.1016/j.amjmed.2012.06.023
   Miranda MR, 2019, CURR MED CHEM, V26, P6517, DOI 10.2174/092986732636191202125919
   Molina I, 2014, NEW ENGL J MED, V370, P1899, DOI 10.1056/NEJMoa1313122
   Muller F, 2020, KNEE SURG SPORT TR A, V28, P408, DOI 10.1007/s00167 019 05598 w
   No J.H., 2012, PNAS, V109, P6
   Nwaka S, 2006, NAT REV DRUG DISCOV, V5, P941, DOI 10.1038/nrd2144
   Papadopoulou MV, 2015, BIOORGAN MED CHEM, V23, P6467, DOI 10.1016/j.bmc.2015.08.014
   Paucar R, 2016, CURR MED CHEM, V23, P3154, DOI 10.2174/0929867323999160625124424
   Pedroza Jorge M., 2020, COSM INVESTIG DENT, V12, P7
   Potenza M, 2012, EXP PARASITOL, V132, P537, DOI 10.1016/j.exppara.2012.09.002
   Puente V., 2018, PLOS NEGL TROP DIS, V12, P13
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   SANCHEZDELGADO RA, 1993, J MED CHEM, V36, P2041, DOI 10.1021/jm00066a014
   Santos SS, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105906
   Saye M., 2020, PLOS NEGL TROP DIS, V14, P23
   Simoes F, 2019, PARASITOLGY, P7
   Skerjanec A, 2003, J CLIN PHARMACOL, V43, P154, DOI 10.1177/0091270002239824
   Sözel H, 2021, J ONCOL PHARM PRACT, V27, P494, DOI 10.1177/1078155220940411
   Szajnman SH, 2003, BIOORG MED CHEM LETT, V13, P3231, DOI 10.1016/S0960 894X(03)00663 2
   Urbina JA, 2010, ACTA TROP, V115, P55, DOI 10.1016/j.actatropica.2009.10.023
   Valsecchi WM, 2016, BBA PROTEINS PROTEOM, V1864, P655, DOI 10.1016/j.bbapap.2016.03.005
   Yang G, 2015, ANTIMICROB AGENTS CH, V59, P7530, DOI 10.1128/AAC.01873 15
   Zafar S, 2014, J ORAL PATHOL MED, V43, P711, DOI 10.1111/jop.12181
NR 45
TC 5
Z9 5
U1 0
U2 3
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006 2952
EI 1873 2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD JUN
PY 2021
VL 188
AR 114524
DI 10.1016/j.bcp.2021.114524
EA MAR 2021
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA SK4PF
UT WOS:000656198800004
PM 33741333
OA Green Published
DA 2025 08 17
ER

PT J
AU Jia, YY
   Duan, MM
   Yang, Y
   Wang, DX
   Dong, Q
   Liao, J
   Mao, L
   Liu, PY
   Feng, L
   Chen, J
   Tang, ZL
AF Jia, Yuanyuan
   Duan, Mianmian
   Yang, Yan
   Wang, Dongxiang
   Dong, Qiang
   Liao, Jian
   Mao, Ling
   Liu, Poyu
   Feng, Ling
   Chen, Jin
   Tang, Zhenglong
TI The Promoting Effect of a Local Pulsatile Parathyroid Hormone Delivery
   on Healing of the Mandibular Fracture in Rats
SO TISSUE ENGINEERING PART A
LA English
DT Article
DE PTH; pulsatile release; carboxymethyl chitosan; mandibular fracture;
   bone regeneration
ID TERIPARATIDE; COMPLICATIONS; INTERMITTENT
AB Parathyroid hormone (PTH) can promote bone formation and mineralization in mandibular fractures, and is systemically administered through daily injections. In this study, the local delivery of PTH using carboxymethyl chitosan/polyvinyl alcohol and alginate was investigated. Bovine serum albumin was used as a drug substitute, and the delivery system was verified to release drugs in a pulsed rhythm. After the delivery system was subcutaneously implanted in Sprague Dawley (SD) rats, no rejection reaction was detected, indicating that it has good biocompatibility and biodegradability in vivo. Then, an SD rat model of mandibular fracture was established, and 24 rats were randomly divided into two groups. The control group was reduced and fixed with screws and a microplate, and the experimental group received pulsatile PTH release system (14 mu g PTH) + screws and microplate fixation. The animals were euthanized on postoperative weeks 1 4. Observation of gross specimens, digital radiography, and hematoxylin and eosin showed that the local PTH pulsatile release system promoted osteogenesis and accelerated fracture healing. In summary, PTH can be loaded by biomaterials to locally target the fracture and stimulate bone formation. Moreover, the pulsatile PTH release system provides a potential therapeutic protocol for mandibular fracture.
   Impact statementOur study prepares a drug release system that could impulsively release parathyroid hormone. The system could enhance bone regeneration in rats with mandibular fracture. These data provide a foundation for future studies aimed to understand and optimize the use of bioactive molecule pulsatile delivery for bone regeneration and tissue engineering applications.
C1 [Jia, Yuanyuan; Duan, Mianmian; Wang, Dongxiang; Tang, Zhenglong] Guizhou Med Univ, Sch & Hosp Stomatol, Dept Oral & Maxillofacial Surg, Guiyang, Peoples R China.
   [Dong, Qiang; Liao, Jian] Guizhou Med Univ, Sch & Hosp Stomatol, Dept Prosthodont & Implantol, Guiyang, Peoples R China.
   [Liu, Poyu] Guizhou Med Univ, Sch & Hosp Stomatol, Dept Oral Radiol, Guiyang, Peoples R China.
   [Feng, Ling] Guizhou Med Univ, Sch & Hosp Stomatol, Dept Oral Histopathol, Guiyang, Peoples R China.
   [Jia, Yuanyuan; Tang, Zhenglong] Guizhou Med Univ, Sch Basic Med Sci, Dept Physiol & Pathol, Guiyang, Peoples R China.
   [Yang, Yan] Guizhou Med Univ, Ctr Tissue Engn & Stem Cell Res, Guiyang, Peoples R China.
   [Mao, Ling] Guizhou Med Univ, Sch & Hosp stomatol, Lab Head & Neck Canc Res, Guiyang, Peoples R China.
   [Chen, Jin] Sch Biol & Engn, Immune Cells & Antibody Engn Res Ctr Guizhou Prov, Key Lab Biol & Med Engn, Guiyang, Peoples R China.
   [Tang, Zhenglong] Guizhou Med Univ, Sch & Hosp Stomatol, Dept Oral & Maxillofacial Surg, Guiyang 550000, Peoples R China.
C3 Guizhou Medical University; Guizhou Medical University; Guizhou Medical
   University; Guizhou Medical University; Guizhou Medical University;
   Guizhou Medical University; Guizhou Medical University; Guizhou Medical
   University
RP Tang, ZL (通讯作者)，Guizhou Med Univ, Sch & Hosp Stomatol, Dept Oral & Maxillofacial Surg, Guiyang 550000, Peoples R China.
EM zhenglongtang@gmc.edu.cn
RI LIU, PO YU/AHB 4861 2022; Chen, Jin/Q 3714 2017; JIA,
   YUANYUAN/NIU 2427 2025; Wang, Dongxiang/G 9216 2012
OI Jia, Yuanyuan/0000 0002 8706 1281; 
CR Abosadegh MM, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/9024763
   Ahmed A, 2022, BRIT J ORAL MAX SURG, V60, P266, DOI 10.1016/j.bjoms.2021.07.005
   Arifin DY, 2006, ADV DRUG DELIVER REV, V58, P1274, DOI 10.1016/j.addr.2006.09.007
   Ashrafizadeh M, 2022, EXPERT OPIN DRUG DEL, V19, P355, DOI 10.1080/17425247.2022.2041598
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Cosman F, 2010, J CLIN ENDOCR METAB, V95, P151, DOI 10.1210/jc.2009 0358
   Dang M, 2017, BIOMATERIALS, V114, P1, DOI 10.1016/j.biomaterials.2016.10.049
   Dempster DW, 2001, J BONE MINER RES, V16, P1846, DOI 10.1359/jbmr.2001.16.10.1846
   Díaz Soto G, 2012, HORM METAB RES, V44, P708, DOI 10.1055/s 0032 1308971
   Ferreira LD, 2021, OSTEOPOROSIS INT, V32, P2449, DOI 10.1007/s00198 021 06078 z
   Eastman K, 2021, OSTEOPOROSIS INT, V32, P1531, DOI 10.1007/s00198 021 05847 0
   Hämmerle SP, 2012, BONE, V50, P965, DOI 10.1016/j.bone.2012.01.009
   Han MM, 2020, INT J NANOMED, V15, P3433, DOI 10.2147/IJN.S241448
   Hatano M, 2020, ARCH OSTEOPOROS, V15, DOI 10.1007/s11657 020 00849 7
   Jia YY, 2021, EXP BIOL MED, V246, P2249, DOI 10.1177/15353702211027114
   Jiang YB, 2003, J BONE MINER RES, V18, P1932, DOI 10.1359/jbmr.2003.18.11.1932
   Kanala S, 2021, ANN ROY COLL SURG, V103, P18, DOI 10.1308/rcsann.2020.0171
   McGoldrick DM, 2018, BRIT J ORAL MAX SURG, V56, P496, DOI 10.1016/j.bjoms.2018.04.001
   Murphy PZ, 2018, CONSULT PHARM, V33, P365, DOI 10.4140/TCP.n.2018.365
   Osagie Clouard L, 2021, BONE JOINT RES, V10, P659, DOI [10.1302/2046 3758.1010, 10.1302/2046 3758.1010.BJR 2019 0371.R2]
   Pearson RG, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11060265
   Pelled G, 2020, J TISSUE ENG REGEN M, V14, P1037, DOI 10.1002/term.3075
   Perez D, 2020, SEMIN PLAST SURG, V34, P225, DOI 10.1055/s 0040 1721758
   Perry AC, 2003, CLIN ORTHOP RELAT R, P95, DOI 10.1097/01.blo.0000087322.60612.14
   Petrova NL, 2021, DIABETES CARE, V44, P1613, DOI 10.2337/dc21 0008
   Rosen CJ, 2001, J CLIN ENDOCR METAB, V86, P957, DOI 10.1210/jc.86.3.957
   Tang ZL, 2016, PLAST RECONSTR SURG, V137, p347E, DOI 10.1097/01.prs.0000475780.68585.cc
   Thiruchelvam N, 2014, CASE REP ENDOCRINOL, V2014, DOI 10.1155/2014/802473
   UZAWA T, 1995, BONE, V16, P477
   Wang JP, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006637
   Wang LC, 2007, J MATER SCI MATER M, V18, P1125, DOI 10.1007/s10856 007 0159 5
   Wojda SJ, 2021, TISSUE ENG PT A, V27, P246, DOI [10.1089/ten.tea.2020.0119, 10.1089/ten.TEA.2020.0119]
   Wojda SJ, 2020, J ORTHOP RES, V38, P536, DOI 10.1002/jor.24502
   Yoshida W, 2019, J CLIN PERIODONTOL, V46, P1030, DOI 10.1111/jcpe.13170
   Zhang CG, 2021, J ORTHOP RES, V39, P2103, DOI 10.1002/jor.24953
   Zou ZY, 2021, BIOACT MATER, V6, P1839, DOI 10.1016/j.bioactmat.2020.11.021
NR 36
TC 4
Z9 5
U1 2
U2 23
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3341
EI 1937 335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD FEB 1
PY 2023
VL 29
IS 3 4
BP 69
EP 79
DI 10.1089/ten.tea.2022.0136
EA FEB 2023
PG 11
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA 9E2XX
UT WOS:000929447100001
PM 36200640
DA 2025 08 17
ER

PT J
AU Kuang, W
   Xu, X
   Lin, J
   Cao, Y
   Xu, Y
   Chen, L
   Jin, L
   Tan, JL
AF Kuang, Wei
   Xu, Xin
   Lin, Jiong
   Cao, Yang
   Xu, Yue
   Chen, Lin
   Jin, Liang
   Tan, Jiali
TI Functional and Molecular Changes of MSCs in Aging
SO CURRENT STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Cell aging; cell differentiation; epigenetic regulation; MiRNA; MSC;
   oxidative stress; signaling pathways; transcription factor
ID MESENCHYMAL STEM CELLS; MARROW STROMAL CELLS; OXIDATION PROTEIN
   PRODUCTS; AGE RELATED CHANGES; OSTEOGENIC DIFFERENTIATION; OSTEOBLAST
   DIFFERENTIATION; BONE FORMATION; ADIPOGENIC DIFFERENTIATION; OSTEOCALCIN
   GENE; PRECURSOR CELLS
AB Mesenchymal stem cells (MSCs) are ideal candidates for different cellular therapies due to their simple isolation, extensive expansion potential, and low immunogenicity. For various therapeutic approaches, such as bone and cartilage repair, MSCs are expected to replace the damaged tissues by direct differentiation. However, age related changes in MSCs lead to the loss of differentiation potential, loss of proliferation potential and increase in senescent cell numbers, which involve a steady loss of bone mass and frequently result in osteoporosis. In this review, we will introduce the characteristic and age related changes of MSCs. In addition, we will also summarize the potential rescue mechanisms of age related bone loss involved in differentiation regulation and proliferation regulation, including transcription factors, signal pathways, epigenetic regulation, and oxidative stress regulation.
C1 [Kuang, Wei] Guangzhou Mil Command, Guangzhou Gen Hosp, Dept Stomatol, Guangzhou 510010, Guangdong, Peoples R China.
   [Xu, Xin] Sichuan Univ, State Key Lab Oral Dis, Chengdu 610041, Peoples R China.
   [Lin, Jiong; Cao, Yang; Xu, Yue; Chen, Lin; Tan, Jiali] Sun Yat Sen Univ, Hosp Stomatol, Guanghua Sch Stomatol, Dept Orthodont, Guangzhou 510055, Guangdong, Peoples R China.
   [Lin, Jiong; Cao, Yang; Xu, Yue; Chen, Lin; Tan, Jiali] Guangdong Prov Key Lab Stomatol, Guangzhou 510055, Guangdong, Peoples R China.
C3 Southern Theater Command General Hospital; Sichuan University; Sun Yat
   Sen University
RP Tan, JL (通讯作者)，Sun Yat Sen Univ, Hosp Stomatol, Guanghua Sch Stomatol, Dept Orthodont, Guangzhou 510055, Guangdong, Peoples R China.
EM jasminenov@163.com
RI xu, xin/HNQ 6671 2023; Chen, Lili/HJY 7871 2023; Xu, yue/HGE 1737 2022
OI Xu, Yue/0000 0002 8065 8253; Xu, Xin/0000 0003 4608 4556
FU National Natural Science Foundation of China [81100240]; "985" project
   of Sun Yat Sen University grant; Sun yat sen university young teachers
   training project [13YKPY42]; Natural Science Foundation of Guangdong
   Province, China [S2012010009495]; Science and Technology Planning
   Project of Guangdong Province, China [2012B031800185]
FX This study was funded by the National Natural Science Foundation of
   China (81100240), "985" project of Sun Yat Sen University grant, Sun
   yat sen university young teachers training project (13YKPY42), Natural
   Science Foundation of Guangdong Province, China (S2012010009495) and
   Science and Technology Planning Project of Guangdong Province, China
   (2012B031800185).
CR Arnsdorf EJ, 2010, J BIOMECH, V43, P2881, DOI 10.1016/j.jbiomech.2010.07.033
   Arthur A, 2009, J CELL PHYSIOL, V218, P237, DOI 10.1002/jcp.21592
   Auwerx J, 1996, J MOL MED, V74, P347, DOI 10.1007/BF00210629
   Awad HA, 1999, TISSUE ENG, V5, P267, DOI 10.1089/ten.1999.5.267
   Banfi A, 2000, EXP HEMATOL, V28, P707, DOI 10.1016/S0301 472X(00)00160 0
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Baxter MA, 2004, STEM CELLS, V22, P675, DOI 10.1634/stemcells.22 5 675
   Bellantuono I, 2009, BBA MOL BASIS DIS, V1792, P364, DOI 10.1016/j.bbadis.2009.01.008
   Bessa PC, 2008, J TISSUE ENG REGEN M, V2, P81, DOI 10.1002/term.74
   Bochkis IM, 2013, MOL METAB, V2, P447, DOI 10.1016/j.molmet.2013.08.005
   Boehm M, 2005, SCIENCE, V310, P1954, DOI 10.1126/science.1115596
   Bonab MM, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471 2121 7 14
   Cai P, 2013, COLLOID SURFACE A, V434, P110, DOI 10.1016/j.colsurfa.2013.05.041
   Chen D, 1998, J CELL BIOL, V142, P295, DOI 10.1083/jcb.142.1.295
   Conget PA, 1999, J CELL PHYSIOL, V181, P67, DOI 10.1002/(SICI)1097 4652(199910)181:1<67::AID JCP7>3.0.CO;2 C
   Crane JL, 2013, BONE RES, V1, DOI 10.4248/BR201302007
   D'Alimonte I, 2013, STEM CELL REV REP, V9, P642, DOI 10.1007/s12015 013 9436 5
   de Lencastre A, 2010, CURR BIOL, V20, P2159, DOI 10.1016/j.cub.2010.11.015
   Deng ZL, 2008, FRONT BIOSCI LANDMRK, V13, P2001, DOI 10.2741/2819
   DiGirolamo CM, 1999, BRIT J HAEMATOL, V107, P275, DOI 10.1046/j.1365 2141.1999.01715.x
   DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Fontaine C, 2008, STEM CELLS, V26, P1037, DOI 10.1634/stemcells.2007 0974
   FRIEDENSTEIN AJ, 1974, EXP HEMATOL, V2, P83
   Galli C, 2013, CLIN ORAL IMPLAN RES, V24, P921, DOI 10.1111/j.1600 0501.2012.02488.x
   GALMICHE MC, 1993, BLOOD, V82, P66, DOI 10.1182/blood.V82.1.66.bloodjournal82166
   Gao B, 2013, BONE RES, V1, DOI 10.4248/BR201302006
   Gerson SL, 1999, NAT MED, V5, P262, DOI 10.1038/6470
   Granero Moltó F, 2011, STEM CELLS, V29, P1537, DOI 10.1002/stem.697
   Grillari J, 2010, BIOGERONTOLOGY, V11, P501, DOI 10.1007/s10522 010 9272 9
   Gronthos S, 2001, BONE, V28, P174, DOI 10.1016/S8756 3282(00)00424 5
   Guerrero F, 2014, PLOS ONE, V9
   Guillot PV, 2007, STEM CELLS, V25, P646, DOI 10.1634/stemcells.20060208
   Hassan MQ, 2007, MOL CELL BIOL, V27, P3337, DOI 10.1128/MCB.01544 06
   HAYNESWORTH SE, 1992, BONE, V13, P69, DOI 10.1016/8756 3282(92)90363 2
   Hong IS, 2013, BONE, V56, P416, DOI 10.1016/j.bone.2013.07.016
   Hsiao SH, 2010, BIOCHEM BIOPH RES CO, V400, P305, DOI 10.1016/j.bbrc.2010.08.048
   Hu R, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.176099
   Hupkes M, 2014, BMC MOL BIOL, V15, DOI 10.1186/1471 2199 15 1
   Hwang S, 2014, FEBS LETT, V10, P00438
   Inoue K, 1997, J BONE MINER RES, V12, P989, DOI 10.1359/jbmr.1997.12.6.989
   James AW, 2010, TISSUE ENG PT A, V16, P2605, DOI [10.1089/ten.tea.2010.0048, 10.1089/ten.TEA.2010.0048]
   James AW, 2012, STEM CELLS DEV, V21, P2170, DOI 10.1089/scd.2011.0461
   James AW, 2011, BIOCHEM BIOPH RES CO, V411, P126, DOI 10.1016/j.bbrc.2011.06.111
   Javazon EH, 2004, EXP HEMATOL, V32, P414, DOI 10.1016/j.exphem.2004.02.004
   Jensen ED, 2010, BIOFACTORS, V36, P25, DOI 10.1002/biof.72
   Jung RE, 2009, CLIN ORAL IMPLAN RES, V20, P660, DOI 10.1111/j.1600 0501.2008.01648.x
   Justesen J, 2002, CALCIFIED TISSUE INT, V71, P36, DOI 10.1007/s00223 001 2059 x
   Kang Q, 2009, STEM CELLS DEV, V18, P545, DOI 10.1089/scd.2008.0130
   Karsenty G, 2008, ANNU REV GENOM HUM G, V9, P183, DOI 10.1146/annurev.genom.9.081307.164437
   Kim J, 2014, CELL DEATH DIFFER, V20, P80
   Kirkland JL, 2002, EXP GERONTOL, V37, P757, DOI 10.1016/S0531 5565(02)00014 1
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Kumar S, 2008, GENE THER, V15, P711, DOI 10.1038/gt.2008.35
   Kume S, 2005, J BONE MINER RES, V20, P1647, DOI 10.1359/JBMR.050514
   Lacasa D, 2002, ANN NY ACAD SCI, V973, P423, DOI 10.1111/j.1749 6632.2002.tb04676.x
   Le Blanc K, 2003, EXP HEMATOL, V31, P890, DOI 10.1016/S0301 472X(03)00110 3
   Lee HW, 2006, MOL ENDOCRINOL, V20, P2432, DOI 10.1210/me.2006 0061
   Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887
   Li H, 2009, J CLIN INVEST, V119, P3666, DOI 10.1172/JCI39832
   Li HX, 2008, MOL CELL ENDOCRINOL, V291, P116, DOI 10.1016/j.mce.2008.05.005
   Li MY, 2010, ANTIOXID REDOX SIGN, V12, P641, DOI 10.1089/ars.2009.2854
   Liu C, 2013, INT J MED SCI, V10, P1181, DOI 10.7150/ijms.6657
   Liu T, 2014, IUBMB LIFE, V23
   Liu TM, 2013, TISSUE ENG PART B RE, V19, P254, DOI [10.1089/ten.TEB.2012.0527, 10.1089/ten.teb.2012.0527]
   Liu XZ, 2013, J PINEAL RES, V55, P14, DOI 10.1111/jpi.12045
   Liu YL, 2011, STEM CELLS, V29, P1804, DOI 10.1002/stem.728
   Mackay AM, 1998, TISSUE ENG, V4, P415, DOI 10.1089/ten.1998.4.415
   Mak KK, 2008, DEV CELL, V14, P674, DOI 10.1016/j.devcel.2008.02.003
   Mei Y, 2013, J CELL BIOCHEM, V114, P1374, DOI 10.1002/jcb.24479
   Mutyaba PL, 2014, J ORTHOP TRAUMA, V28, pS20, DOI 10.1097/BOT.0000000000000064
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Neumann K, 2007, J CELL BIOCHEM, V102, P626, DOI 10.1002/jcb.21319
   Oh SA, 2012, TISSUE ENG PT A, V18, P1087, DOI [10.1089/ten.TEA.2011.0360, 10.1089/ten.tea.2011.0360]
   Oliveira FS, 2012, J CELL BIOCHEM, V113, P204, DOI 10.1002/jcb.23345
   Peister A, 2004, BLOOD, V103, P1662, DOI 10.1182/blood 2003 09 3070
   Phipps MC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040831
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Plaisant M, 2009, STEM CELLS, V27, P703, DOI 10.1634/stemcells.2008 0888
   Qu B, 2014, BIOCHEM BIOPH RES CO, V448, P241, DOI 10.1016/j.bbrc.2014.04.091
   Reyes M, 2001, BLOOD, V98, P2615, DOI 10.1182/blood.V98.9.2615
   ROSENBERGER RF, 1995, BIOESSAYS, V17, P257, DOI 10.1002/bies.950170312
   Sethe S, 2006, AGEING RES REV, V5, P91, DOI 10.1016/j.arr.2005.10.001
   Sharpless NE, 2004, J CLIN INVEST, V113, P160, DOI 10.1172/JCI200420761
   Shen BJ, 2009, INT J BIOL SCI, V5, P192
   Shen J, 2003, MOL ENDOCRINOL, V17, P743, DOI 10.1210/me.2002 0122
   Smith Vikos T, 2012, J CELL SCI, V125, P7, DOI 10.1242/jcs.099200
   Sordi V, 2005, BLOOD, V106, P419, DOI 10.1182/blood 2004 09 3507
   Stenderup K, 2003, BONE, V33, P919, DOI 10.1016/j.bone.2003.07.005
   Stolzing A, 2008, MECH AGEING DEV, V129, P163, DOI 10.1016/j.mad.2007.12.002
   Sun N, 2013, INT J MOL MED, V32, P485, DOI 10.3892/ijmm.2013.1402
   Sun Y, 2011, FASEB J, V25, P1474, DOI 10.1096/fj.10 161497
   Taipaleenmäki H, 2011, EXP CELL RES, V317, P745, DOI 10.1016/j.yexcr.2010.12.015
   Takada I, 2009, NAT REV RHEUMATOL, V5, P442, DOI 10.1038/nrrheum.2009.137
   Tan J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006792
   TheinHan WW, 2013, BONE RES, V1, P371, DOI 10.4248/BR201304008
   Tomlinson RE, 2013, BONE RES, V1, P311, DOI 10.4248/BR201304002
   Trohatou O, 2014, STEM CELL TRANSL MED, V3, P54, DOI 10.5966/sctm.2013 0081
   Vigneron A, 2010, AGING US, V2, P471, DOI 10.18632/aging.100189
   Villagra A, 2002, J CELL BIOCHEM, V85, P112, DOI 10.1002/jcb.10113
   WAKITANI S, 1995, MUSCLE NERVE, V18, P1417, DOI 10.1002/mus.880181212
   WANG EA, 1993, GROWTH FACTORS, V9, P57, DOI 10.3109/08977199308991582
   Wang JS, 2010, STEM CELLS DEV, V19, P1375, DOI 10.1089/scd.2009.0258
   Wei YK, 2011, NAT CELL BIOL, V13, P87, DOI 10.1038/ncb2139
   Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097 4547(20000815)61:4<364::AID JNR2>3.0.CO;2 C
   Wu KM, 2013, ACS APPL MATER INTER, V5, P2733, DOI 10.1021/am400374c
   Yilgor P, 2010, J MATER SCI MATER M, V21, P2999, DOI 10.1007/s10856 010 4150 1
   Yu KR, 2013, J CELL SCI, V126, P5422, DOI 10.1242/jcs.133314
   Zheng CY, 2003, BIOPOLYMERS, V68, P539, DOI 10.1002/bip.10303
   Zheng F, 2014, PLOS ONE, V9
   Zhong ZM, 2009, CELL PHYSIOL BIOCHEM, V24, P105, DOI 10.1159/000227818
NR 113
TC 4
Z9 6
U1 0
U2 30
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1574 888X
EI 2212 3946
J9 CURR STEM CELL RES T
JI Curr. Stem Cell Res. Ther.
PY 2015
VL 10
IS 5
BP 384
EP 391
DI 10.2174/1574888X10666150211162933
PG 8
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA CQ1SK
UT WOS:000360378900003
PM 25670060
DA 2025 08 17
ER

PT J
AU Lolli, ML
   Rolando, B
   Tosco, P
   Chaurasia, S
   Di Stilo, A
   Lazzarato, L
   Gorassini, E
   Ferracini, R
   Oliaro Bosso, S
   Fruttero, R
   Gasco, A
AF Lolli, Marco L.
   Rolando, Barbara
   Tosco, Paolo
   Chaurasia, Shilpi
   Di Stilo, Antonella
   Lazzarato, Loretta
   Gorassini, Eva
   Ferracini, Riccardo
   Oliaro Bosso, Simonetta
   Fruttero, Roberta
   Gasco, Alberto
TI Synthesis and preliminary pharmacological characterisation of a new
   class of nitrogen containing bisphosphonates (N BPs)
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE Bisphosphonates; Nitric oxide; Osteoclastogenesis; Cardiovascular
   diseases
ID PH METRIC LOG; NITRIC OXIDE; AUTOMATED DOCKING; CRYSTAL STRUCTURE;
   SYNTHASE; BONE; OSTEOPOROSIS; INHIBITION; MECHANISMS; PROTEINS
AB A new series of bisphosphonates bearing either the nitrogen containing NO donor furoxan (1,2,5 oxadiazole 2 oxide) system or the related furazan (1,2,5 oxadiazole) in lateral chain has been developed. pK(a) values and affinity for hydroxyapatite were determined for all the compounds. The products were able to inhibit osteoclastogenesis on RAW 246.7 cells at 10 mu M concentration. The most active compounds were further assayed on human PBMC cells and on rat microsomes. Unlike most nitrogen containing bisphosphonates which target farnesyl pyrophosphate synthase, experimental and theoretical investigations suggest that the activity of our derivatives may be related to different mechanisms. The furoxan derivatives were also tested for their ability to relax rat aorta strips in view of their potential NO dependent vasodilator properties. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Lolli, Marco L.; Rolando, Barbara; Tosco, Paolo; Chaurasia, Shilpi; Di Stilo, Antonella; Lazzarato, Loretta; Oliaro Bosso, Simonetta; Fruttero, Roberta; Gasco, Alberto] Univ Turin, Dipartimento Sci & Tecnol Farm, I 10125 Turin, Italy.
   [Gorassini, Eva; Ferracini, Riccardo] Univ Turin, CeRMS, I 10126 Turin, Italy.
   [Gorassini, Eva; Ferracini, Riccardo] ASO San Giovanni Battista, I 10126 Turin, Italy.
C3 University of Turin; University of Turin; A.O.U. Citta della Salute e
   della Scienza di Torino; AOU San Giovanni Battista Molinette
RP Lazzarato, L (通讯作者)，Univ Turin, Dipartimento Sci & Tecnol Farm, Via Pietro Giuria 9, I 10125 Turin, Italy.
EM loretta.lazzarato@unito.it
RI ; Ferracini, Riccardo/AAL 4622 2020
OI Rolando, Barbara/0000 0001 6138 1503; Tosco, Paolo/0000 0002 0034 9494;
   Fruttero, Roberta/0000 0001 6726 1254; Lazzarato,
   Loretta/0000 0001 7100 8593; LOLLI, Marco Lucio/0000 0002 3030 3163
FU Regione Piemonte (Ricerca sanitaria finalizzata) [2008]
FX This work was supported by a grant from Regione Piemonte (Ricerca
   sanitaria finalizzata 2008).
CR [Anonymous], [No title captured]
   [Anonymous], 2008, MOE VERS 2008 10
   AVDEEF A, 1993, ANAL CHEM, V65, P42, DOI 10.1021/ac00049a010
   AVDEEF A, 1993, J PHARM SCI, V82, P183, DOI 10.1002/jps.2600820214
   Bertinaria M, 2003, DRUG DEVELOP RES, V60, P225, DOI 10.1002/ddr.10284
   Boschi D, 1997, PHARM RES DORDR, V14, P1750, DOI 10.1023/A:1012136030849
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   CALVINO R, 1980, EUR J MED CHEM, V15, P485
   Case DA., 2008, AMBER 10 University of California
   Cohen H, 1998, PHARMACEUT RES, V15, P606, DOI 10.1023/A:1011990129437
   Cummings SR, 2007, NEW ENGL J MED, V356, P1895, DOI 10.1056/NEJMc076132
   DEFILIPPI A, 1988, ARCH PHARM, V321, P77, DOI 10.1002/ardp.19883210207
   Di Stilo A, 1998, J MED CHEM, V41, P5393, DOI 10.1021/jm9803267
   Di Stilo A, 2009, ARZNEIMITTELFORSCH, V59, P111, DOI 10.1055/s 0031 1296372
   Dunford JE, 2008, J MED CHEM, V51, P2187, DOI 10.1021/jm7015733
   FIELD RB, 1979, LIPIDS, V14, P741, DOI 10.1007/BF02533900
   Gasco A, 2005, NITRIC OXIDE DONORS: FOR PHARMACEUTICAL AND BIOLOGICAL APPLICATIONS, P131, DOI 10.1002/3527603751.ch6
   GOODSELL DS, 1990, PROTEINS, V8, P195, DOI 10.1002/prot.340080302
   Green JR, 2002, AM J CLIN ONCOL CANC, V25, pS3, DOI 10.1097/00000421 200212001 00002
   Hamerman D, 2005, QJM INT J MED, V98, P467, DOI 10.1093/qjmed/hci077
   JORK H, 1990, THIN LAYER CHROMAT A, V1
   Kavanagh KL, 2006, J BIOL CHEM, V281, P22004, DOI 10.1074/jbc.M602603200
   KERWIN JF, 1995, J MED CHEM, V38, P4343, DOI 10.1021/jm00022a001
   Kieczykowski GR, 1995, J ORG CHEM, V60, P8310, DOI 10.1021/jo00130a036
   KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333
   Lazzarato L, 2005, J MED CHEM, V48, P1322, DOI 10.1021/jm040830d
   Loscalzo Joseph., 2000, NITRIC OXIDE CARDIOV
   McFarlane SI, 2004, ENDOCRINE, V23, P1, DOI 10.1385/ENDO:23:1:01
   Morris GM, 1996, J COMPUT AID MOL DES, V10, P293, DOI 10.1007/BF00124499
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096 987X(19981115)19:14<1639::AID JCC10>3.0.CO;2 B
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Pandit J, 2000, J BIOL CHEM, V275, P30610, DOI 10.1074/jbc.M004132200
   POPJAK G, 1969, METHOD ENZYMOL, V15, P393
   Reszka Alfred A, 2003, Curr Rheumatol Rep, V5, P65, DOI 10.1007/s11926 003 0085 6
   Rogers MJ, 1999, BONE, V24, p73S, DOI 10.1016/S8756 3282(99)00070 8
   Rondeau JM, 2006, CHEMMEDCHEM, V1, P267, DOI 10.1002/cmdc.200500059
   Russell RGG, 1999, OSTEOPOROSIS INT, V9, P66, DOI 10.1007/PL00004164
   SCHMIDT MW, 1993, J COMPUT CHEM, V14, P1347, DOI 10.1002/jcc.540141112
   Sorba G, 1996, J HETEROCYCLIC CHEM, V33, P327, DOI 10.1002/jhet.5570330220
   Szabo CM, 2002, J MED CHEM, V45, P2185, DOI 10.1021/jm010412y
   van't Hof RJ, 2001, IMMUNOLOGY, V103, P255, DOI 10.1046/j.1365 2567.2001.01261.x
   Wallace JL, 2007, BRIT J PHARMACOL, V152, P421, DOI 10.1038/sj.bjp.0707396
   Wang JM, 2000, J COMPUT CHEM, V21, P1049, DOI 10.1002/1096 987X(200009)21:12<1049::AID JCC3>3.0.CO;2 F
   Widler L, 2002, J MED CHEM, V45, P3721, DOI 10.1021/jm020819i
   Ylitalo R, 2002, GEN PHARMACOL, V35, P287
NR 45
TC 23
Z9 24
U1 0
U2 24
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968 0896
EI 1464 3391
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD APR
PY 2010
VL 18
IS 7
BP 2428
EP 2438
DI 10.1016/j.bmc.2010.02.058
PG 11
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA 577YA
UT WOS:000276258700007
PM 20299227
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Wei, YE
   Wu, B
   Liu, MQ
   Cui, CP
AF Wei, Yange
   Wu, Bo
   Liu, Mingqiu
   Cui, Chun Ping
TI The Discovery of a Specific CKIP 1 Ligand for the Potential Treatment of
   Disuse Osteoporosis
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE casein kinase 2 interacting protein 1; proteolysis targeting chimeras;
   DNA encoded libraries; von Hippel Lindau; disuse osteoporosis
ID UBIQUITIN LIGASE; PROTEIN DEGRADATION; BONE FORMATION; OSTEOBLASTS;
   SMURF1
AB Bone homeostasis relies on the delicate balance between osteoblast mediated bone formation and osteoclast mediated bone resorption. The casein kinase 2 interacting protein 1 (CKIP 1), a specific CK2 alpha subunit interacting protein, has been documented as one of the crucial negative regulators of bone formation. CKIP 1 siRNA therapy has constraints that limit its use in clinical applications. Therefore, it is necessary to explore effective targeting strategies for CKIP 1. In this study, we observed an upregulation of CKIP 1 protein expression in the microgravity environment, while its ubiquitination levels decreased. We further investigated the interaction between CKIP 1 and VHL and found that VHL enhanced CKIP 1 degradation through the ubiquitylation proteasome system (UPS). Additionally, we discovered a small molecule ligand, named C77, through DNA encoded library (DEL) screening, which binds to CKIP 1 both in vivo and in vitro, as confirmed by Surface Plasmon Resonance (SPR) and the Cellular Thermal shift assay (CETSA), respectively. Our findings demonstrated the potential of VHL and C77 as guiding factors in the development of CKIP 1 based Proteolysis Targeting Chimeras (PROTACs), which could be future therapeutic interventions in disuse osteoporosis.
C1 [Wei, Yange; Wu, Bo; Liu, Mingqiu; Cui, Chun Ping] Beijing Inst Life, Natl Ctr Prot Sci Beijing, State Key Lab Med Prote, Beijing 100850, Peoples R China.
RP Cui, CP (通讯作者)，Beijing Inst Life, Natl Ctr Prot Sci Beijing, State Key Lab Med Prote, Beijing 100850, Peoples R China.
EM weiyange2013@126.com; soldier2158wubo@163.com; mingqiurui@163.com;
   cui_chunping2000@aliyun.com
RI Wu, Bo/AAD 9842 2020
FU National Natural Science Foundation of China [82273931, 82172503];
   National Natural Science Foundation of China, China
FX This work was supported by the National Natural Science Foundation of
   China, China (82273931, 82172503).
CR Békés M, 2022, NAT REV DRUG DISCOV, V21, P181, DOI 10.1038/s41573 021 00371 6
   Caine Elizabeth A, 2020, Curr Protoc Pharmacol, V91, pe81, DOI 10.1002/cpph.81
   Cao CG, 2022, CHEM SOC REV, V51, P7066, DOI 10.1039/d2cs00220e
   Cardote TAF, 2017, STRUCTURE, V25, P901, DOI 10.1016/j.str.2017.04.009
   Chamberlain PP, 2019, NAT CHEM BIOL, V15, P937, DOI 10.1038/s41589 019 0362 y
   Chen GY, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00208 x
   Cheng C, 2020, ANNU REV MED, V71, P277, DOI 10.1146/annurev med 052218 020620
   Fu JY, 2021, NPJ MICROGRAVITY, V7, DOI 10.1038/s41526 021 00147 7
   Fu L, 2019, AGEING RES REV, V53, DOI 10.1016/j.arr.2019.05.002
   Guenette RG, 2022, CHEM SOC REV, V51, P5740, DOI 10.1039/d2cs00200k
   Guo BS, 2014, BONE, V59, P76, DOI 10.1016/j.bone.2013.11.007
   Khan S, 2019, NAT MED, V25, P1938, DOI 10.1038/s41591 019 0668 z
   Lai AC, 2017, NAT REV DRUG DISCOV, V16, P101, DOI 10.1038/nrd.2016.211
   LeBlanc A. D., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P33
   Lee SJ, 2020, P NATL ACAD SCI USA, V117, P23942, DOI 10.1073/pnas.2014716117
   Li K, 2022, CHEM SOC REV, V51, P5214, DOI 10.1039/d2cs00193d
   Li P, 2013, ACTA CRYSTALLOGR F, V69, P324, DOI 10.1107/S1744309113003382
   Liang C, 2015, NAT MED, V21, P288, DOI 10.1038/nm.3791
   Ling SK, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00040
   Ling SK, 2012, CIRCULATION, V126, P3028, DOI 10.1161/CIRCULATIONAHA.112.102780
   Liu J, 2017, AGING CELL, V16, P360, DOI 10.1111/acel.12566
   Liu J, 2017, SCI REP UK, V7, DOI 10.1038/srep41295
   Liu XX, 2020, ADV SCI, V7, DOI 10.1002/advs.201902040
   Lu KF, 2008, NAT CELL BIOL, V10, P994, DOI 10.1038/ncb1760
   Mochi F, 2022, NPJ MICROGRAVITY, V8, DOI 10.1038/s41526 022 00236 1
   Morabito C, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/754283
   Mullard A, 2021, NAT REV DRUG DISCOV, V20, P247, DOI 10.1038/d41573 021 00052 4
   Neri D, 2018, ANNU REV BIOCHEM, V87, P479, DOI 10.1146/annurev biochem 062917 012550
   Nie J, 2013, AGEING RES REV, V12, P276, DOI 10.1016/j.arr.2012.07.002
   Niu QN, 2021, REGEN MED, V16, P847, DOI 10.2217/rme 2020 0119
   Peng X, 2018, BONE JOINT RES, V7, P173, DOI 10.1302/2046 3758.72.BJR 2017 0172.R1
   Rosen CJ, 2012, NAT MED, V18, P202, DOI 10.1038/nm.2630
   Salhotra A, 2020, NAT REV MOL CELL BIO, V21, P696, DOI 10.1038/s41580 020 00279 w
   Schapira M, 2019, NAT REV DRUG DISCOV, V18, P949, DOI 10.1038/s41573 019 0047 y
   Schneider M, 2021, NAT REV DRUG DISCOV, V20, P789, DOI 10.1038/s41573 021 00245 x
   Setten RL, 2019, NAT REV DRUG DISCOV, V18, P421, DOI 10.1038/s41573 019 0017 4
   Sibonga J, 2019, BONE, V128, DOI 10.1016/j.bone.2019.07.013
   Sosic I, 2022, CHEM SOC REV, V51, P3487, DOI 10.1039/d2cs00148a
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Tian XG, 2020, CHINESE MED J PEKING, V133, P1935, DOI 10.1097/CM9.0000000000000951
   Vico L, 2018, NAT REV RHEUMATOL, V14, P229, DOI 10.1038/nrrheum.2018.37
   Wang LJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14146 6
   Wang YF, 2012, EMBO REP, V13, P1004, DOI 10.1038/embor.2012.144
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Yang Y, 2022, BIOCHEM PHARMACOL, V206, DOI 10.1016/j.bcp.2022.115339
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
   Zhang LQ, 2006, CELL SIGNAL, V18, P1386, DOI 10.1016/j.cellsig.2005.10.017
   Zhang LQ, 2005, EMBO J, V24, P766, DOI 10.1038/sj.emboj.7600532
   Zhang XC, 2016, PROG BIOPHYS MOL BIO, V122, P140, DOI 10.1016/j.pbiomolbio.2016.09.007
   Zhu Q, 2023, SIGNAL TRANSDUCT TAR, V8, DOI 10.1038/s41392 023 01354 2
   Zorba A, 2018, P NATL ACAD SCI USA, V115, pE7285, DOI 10.1073/pnas.1803662115
NR 51
TC 2
Z9 2
U1 3
U2 9
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD AUG
PY 2024
VL 25
IS 16
AR 8870
DI 10.3390/ijms25168870
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA E7K2K
UT WOS:001304750400001
PM 39201556
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wong, ECL
   Kapoor, A
AF Wong, Emily C. L.
   Kapoor, Anil
TI Does Bone targeted Therapy Benefit Patients with Metastatic Renal Cell
   Carcinoma?
SO TRANSLATIONAL ONCOLOGY
LA English
DT Article
ID SKELETAL RELATED EVENTS; ZOLEDRONIC ACID; CANCER; OSTEOPROTEGERIN;
   EXPRESSION
AB INTRODUCTION: In metastatic renal cell carcinoma (mRCC), the bone is the second most common site of metastasis and is associated with increased morbidity and poorer quality of life. Bone targeted therapies (BTTs) such as denosumab and zoledronic acid may prevent skeletal related events (SREs). However, the benefit of BTTs in combination with tyrosine kinase inhibitors (TKIs) remains unclear. METHODS: We performed a retrospective chart review at the Urologic Cancer Centre for Research and Innovation. Patients with mRCC were included if they had bone metastases treated with TKIs between 2010 and 2017. Our primary outcome was overall survival (OS), defined as the time elapsed from clinical diagnosis of mRCC to death, and modelled using the Kaplan Meier method. Secondary outcomes included the median time to SRE and the analysis of prognostic factors of OS using Cox proportional hazards regression. RESULTS: In total, 230 patients with mRCC were identified; of which, 46 had bone metastases treated with TKIs and were included in the study (TKI only, n = 37; TKI + BTT, n = 9). In the TKI + BTT cohort, patients received either denosumab (n = 5) or zoledronic acid (n = 4). At the time of analysis, 63% of patients were deceased. We observed an OS trend favouring the TKI + BTT cohort (13.8 months [95% confidence interval {CI}: 12.3 15.2] vs. 29.6 months [95% CI: 7.2 51.9], hazard ratio [HR]: 1.66 (95% CI: 0.62 4.45), P = 0.31). When patients in the TKI + BTT cohort were stratified by type of therapy (denosumab or zoledronic acid), the median time to SRE was similar between the groups (4.2 months [95% CI: 2.28 6.14] vs. 2.2 months [95% CI: not available], P = 0.71). On univariate or multivariate analysis, it was found that age, gender, comorbidities, International metastatic RCC database consortium (IMDC) prognostic group and pathologic tumour grade were not significant predictors of worse OS. Pathologic stage 3 or 4 was an independent predictor of worse OS (HR: 5.8, 95% CI: 1.41 24.03, P = 0.015). CONCLUSION: BTTs may have a continued role in the era of targeted therapy and immunotherapy. Further prospective data are required to validate our findings.
C1 [Wong, Emily C. L.; Kapoor, Anil] McMaster Univ, Dept Surg, Div Urol, Hamilton, ON, Canada.
C3 McMaster University
RP Kapoor, A (通讯作者)，G344 50 Charlton Ave East, Hamilton, ON L8N 4A6, Canada.
EM akapoor@mcmaster.ca
RI Kapoor, Anil/AAQ 7184 2021; Wong, Emily/JGM 0118 2023
OI Kapoor, Anil/0000 0001 9180 8029; 
CR Broom RJ, 2015, CLIN GENITOURIN CANC, V13, P50, DOI 10.1016/j.clgc.2014.07.002
   Escudier B, 2018, J CLIN ONCOL, V36, P765, DOI 10.1200/JCO.2017.74.7352
   Fizazi K, 2003, CLIN CANCER RES, V9, P2587
   FORBES GS, 1977, AM J ROENTGENOL, V129, P61, DOI 10.2214/ajr.129.1.61
   Grunwald V, 2018, NAT REV UROL, V1
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Ibrahim A, 2003, CLIN CANCER RES, V9, P2394
   Ivanyi P, 2016, WORLD J UROL, V34, P909, DOI 10.1007/s00345 015 1707 0
   Kume H, 2011, J UROLOGY, V185, P1611, DOI 10.1016/j.juro.2010.12.037
   Lipton A, 2004, CLIN CANCER RES, V10, p6397S, DOI 10.1158/1078 0432.CCR 040030
   Lipton A, 2012, EUR J CANCER, V48, P3082, DOI 10.1016/j.ejca.2012.08.002
   McKay RR, 2014, EUR UROL, V66, P502, DOI 10.1016/j.eururo.2014.02.040
   Omae K, 2017, ONCOTARGET, V8, P68890, DOI 10.18632/oncotarget.20323
   Portenoy RK, 2011, LANCET, V377, P2236, DOI 10.1016/S0140 6736(11)60236 5
   Rosen LS, 2003, J CLIN ONCOL, V21, P3150, DOI 10.1200/JCO.2003.04.105
   Ruatta F, 2019, J CLIN ONCOL, V35, P463
   Toyoda Y, 2007, EUR UROL, V52, P163, DOI 10.1016/j.eururo.2006.10.060
   Tunn UW, 2012, CAN J UROL, V19, P6261
   Van Poznak C, 2006, J CLIN PATHOL, V59, P56, DOI 10.1136/jcp.2005.026534
   Wood SL, 2012, CANCER TREAT REV, V38, P284, DOI 10.1016/j.ctrv.2011.06.011
   Yuasa T, 2011, CLIN EXP METASTAS, V28, P405, DOI 10.1007/s10585 011 9379 7
NR 21
TC 7
Z9 8
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1936 5233
J9 TRANSL ONCOL
JI Transl. Oncol.
PD FEB
PY 2020
VL 13
IS 2
BP 241
EP 244
DI 10.1016/j.tranon.2019.10.009
PG 4
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA KM2DM
UT WOS:000513932000013
PM 31869748
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Chen, HY
   Li, GL
   Chi, HR
   Wang, DL
   Tu, CL
   Pan, LJ
   Zhu, LJ
   Qiu, F
   Guo, FL
   Zhu, XY
AF Chen, Hongying
   Li, Guolin
   Chi, Huirong
   Wang, Dali
   Tu, Chunlai
   Pan, Lijie
   Zhu, Lijuan
   Qiu, Feng
   Guo, Fulin
   Zhu, Xinyuan
TI Alendronate Conjugated Amphiphilic Hyperbranched Polymer Based on
   Boltorn H40 and Poly(ethylene glycol) for Bone Targeted Drug Delivery
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID IN VITRO; UNIMOLECULAR MICELLES; ANTITUMOR ACTIVITY; DESIGN;
   NANOPARTICLES; COPOLYMER; BISPHOSPHONATES; NANOCARRIERS; PACLITAXEL;
   THERAPY
AB A novel type of alendronate(ALE) conjugated amphiphilic hyperbranched copolymer based on a hydrophobic hyperbranched Boltorn H40 (H40) core with ALE targeting moiety and many hydrophilic poly(ethylene glycol) (PEG) arms was synthesized as a carrier for bone targeted drug delivery. The star copolymer H40 star PEG/ALE was characterized using nuclear magnetic resonance (NMR), Fourier transformed infrared spectroscopy (FTIR), and gel permeation chromatography (GPC) analysis. Benefiting from its highly branched structure, H40 star PEG/ALE could form micelles in aqueous solution, which was confirmed by transmission electron microscopy (TEM) and dynamic light scattering (DLS) techniques. The cytotoxicity and hemolysis of the H40 star PEG/ALE micelles were evaluated via methylthiazoletetrazolium (MTT) assay against NIH/3T3 normal cells and red blood cell (RBC) lysis assay, respectively. As a model anticancer drug, doxorubicin (DOX) was encapsulated into the H40 star PEG/ALE micelles. The anticancer activity of DOX loaded micelles was evaluated by MTT assay against an HN 6 human head and neck carcinoma cell line. The strong affinity of H40 star PEG/ALE micelles to bone was confirmed by the hydroxyapatite (HA) binding assay. These results indicate that the H40 star PEG/ALE micelles are highly promising bone targeted drug carriers for skeletal metastases.
C1 [Chen, Hongying; Li, Guolin; Chi, Huirong; Guo, Fulin] Harbin Med Univ, Dept Oral & Maxillofacial Surg, Affiliated Hosp 1, Harbin 150001, Peoples R China.
   [Pan, Lijie] Harbin Med Univ, Dept Prevent Oral Hlth, Affiliated Hosp 1, Harbin 150001, Peoples R China.
   [Wang, Dali; Tu, Chunlai; Zhu, Lijuan; Qiu, Feng; Zhu, Xinyuan] Shanghai Jiao Tong Univ, State Key Lab Met Matrix Composites, Sch Chem & Chem Engn, Shanghai 200240, Peoples R China.
C3 Harbin Medical University; Harbin Medical University; Shanghai Jiao Tong
   University
RP Guo, FL (通讯作者)，Harbin Med Univ, Dept Oral & Maxillofacial Surg, Affiliated Hosp 1, 23 Youzheng St, Harbin 150001, Peoples R China.
EM flguo1967@yahoo.com.cn; xyzhu@sjtu.edu.cn
OI Zhu, Lijuan/0000 0002 1409 7443
FU Provincial Natural Science Foundation of Heilongjiang [D200848]; First
   Affiliated Hospital of Harbin Medical University Science Research Funds
   [2012B011, 2011BS003]; Provincial Youth Science Funds of Heilongjiang
   [QC2011C037]; National Natural Science Foundation of China [81272466];
   China National Funds for Distinguished Young Scientists [21025417]
FX This study was financially supported by Provincial Natural Science
   Foundation of Heilongjiang (D200848), the First Affiliated Hospital of
   Harbin Medical University Science Research Funds (2012B011), Provincial
   Youth Science Funds of Heilongjiang (QC2011C037), the First Affiliated
   Hospital of Harbin Medical University Science Research Funds
   (2011BS003), the National Natural Science Foundation of China
   (81272466), and China National Funds for Distinguished Young Scientists
   (21025417).
CR Bae Y, 2003, ANGEW CHEM INT EDIT, V42, P4640, DOI 10.1002/anie.200250653
   Brigger I, 2002, ADV DRUG DELIVER REV, V54, P631, DOI 10.1016/S0169 409X(02)00044 3
   Chen S, 2008, BIOMACROMOLECULES, V9, P2578, DOI 10.1021/bm800371n
   Choi SW, 2007, J CONTROL RELEASE, V122, P24, DOI 10.1016/j.jconrel.2007.06.003
   Claesson H, 2002, POLYMER, V43, P3511, DOI 10.1016/S0032 3861(02)00073 3
   Clementi C, 2011, MOL PHARMACEUT, V8, P1063, DOI 10.1021/mp2001445
   Colleoni M, 2000, J CLIN ONCOL, V18, P3925, DOI 10.1200/JCO.2000.18.23.3925
   de Rosales RTM, 2009, CHEM COMMUN, P4847, DOI 10.1039/b908652h
   DuBois S, 2007, CANCER AM CANCER SOC, V109, P813, DOI 10.1002/cncr.22455
   Guise TA, 2008, CANCER TREAT REV, V34, pS19, DOI 10.1016/j.ctrv.2008.03.006
   Hengst V, 2007, INT J PHARMACEUT, V331, P224, DOI 10.1016/j.ijpharm.2006.11.024
   Jin Y, 2011, BIOMACROMOLECULES, V12, P3460, DOI 10.1021/bm200956u
   Li GL, 2011, BIOMACROMOLECULES, V12, P2016, DOI 10.1021/bm200372s
   Liu JY, 2011, BIOMACROMOLECULES, V12, P1567, DOI 10.1021/bm200275j
   Liu JY, 2010, BIOMACROMOLECULES, V11, P1564, DOI 10.1021/bm100188h
   Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168 3659(99)00248 5
   Miller K, 2011, MOL PHARMACEUT, V8, P1052, DOI 10.1021/mp200083n
   Miller K, 2009, ANGEW CHEM INT EDIT, V48, P2949, DOI 10.1002/anie.200805133
   Özcan I, 2011, J PHARM SCI US, V100, P4877, DOI 10.1002/jps.22678
   Pang Y, 2011, POLYM CHEM UK, V2, P1661, DOI 10.1039/c1py00053e
   Pang Y, 2010, BIOCONJUGATE CHEM, V21, P2093, DOI 10.1021/bc100325a
   Pang Y, 2010, BIOMACROMOLECULES, V11, P575, DOI 10.1021/bm100007s
   Pignatello R, 2009, NANOMEDICINE UK, V4, P161, DOI 10.2217/17435889.4.2.161
   Prabaharan M, 2009, BIOMATERIALS, V30, P3009, DOI 10.1016/j.biomaterials.2009.02.011
   Richardson DS, 1997, BLOOD REV, V11, P201, DOI 10.1016/S0268 960X(97)90020 5
   Salerno M, 2010, CURR CANCER DRUG TAR, V10, P649, DOI 10.2174/156800910793605767
   Schmalenberg KE, 2001, BIOMACROMOLECULES, V2, P851, DOI 10.1021/bm010042v
   Segal E, 2011, BIOMATERIALS, V32, P4450, DOI 10.1016/j.biomaterials.2011.02.059
   Shea JE, 2005, ADV DRUG DELIVER REV, V57, P945, DOI 10.1016/j.addr.2004.12.017
   Shi ZQ, 2008, MACROMOL RAPID COMM, V29, P412, DOI 10.1002/marc.200700673
   Tian HY, 2005, BIOMATERIALS, V26, P4209, DOI 10.1016/j.biomaterials.2004.11.002
   Uludag H, 2000, BIOTECHNOL PROGR, V16, P258, DOI 10.1021/bp990154m
   Uludag H, 2002, CURR PHARM DESIGN, V8, P1929, DOI 10.2174/1381612023393585
   Wang D, 2003, BIOCONJUGATE CHEM, V14, P853, DOI 10.1021/bc034090j
   Wang DL, 2011, BIOMACROMOLECULES, V12, P1370, DOI 10.1021/bm200155t
   Wartenberg M, 1998, CYTOMETRY, V31, P137, DOI 10.1002/(SICI)1097 0320(19980201)31:2<137::AID CYTO9>3.0.CO;2 J
   Xiao YL, 2012, BIOMATERIALS, V33, P3071, DOI 10.1016/j.biomaterials.2011.12.030
   Yang XQ, 2010, BIOCONJUGATE CHEM, V21, P496, DOI 10.1021/bc900422j
   Yewle JN, 2011, BIOCONJUGATE CHEM, V22, P2496, DOI 10.1021/bc2003132
   Zhang WL, 2010, BIOMACROMOLECULES, V11, P1331, DOI 10.1021/bm100116g
NR 40
TC 80
Z9 86
U1 3
U2 132
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1043 1802
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD SEP
PY 2012
VL 23
IS 9
BP 1915
EP 1924
DI 10.1021/bc3003088
PG 10
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Multidisciplinary; Chemistry, Organic
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 006QJ
UT WOS:000308833600023
PM 22946621
DA 2025 08 17
ER

PT J
AU Massicotte, F
   Fernandes, JC
   Martel Pelletier, J
   Pelletier, JP
   Lajeunesse, D
AF Massicotte, F
   Fernandes, JC
   Martel Pelletier, J
   Pelletier, JP
   Lajeunesse, D
TI Modulation of insulin like growth factor 1 levels in human
   osteoarthritic subchondral bone osteoblasts
SO BONE
LA English
DT Article
DE osteoarthritis; subchondral bone; insulin like growth factor 1;
   prostaglandins
ID GROWTH FACTOR I; E RECEPTOR SUBTYPES; PROSTAGLANDIN E 2;
   PARATHYROID HORMONE; ENRICHED CULTURES; EP1 SUBTYPE; EXPRESSION;
   CHONDROCYTES; COLLAGEN; CLONING
AB Human osteoarthritis (OA) is characterized by cartilage loss, bone sclerosis, osteophyte formation and inflammation of the synovial membrane. We previously reported that OA osteoblasts (Ob) show abnormal phenotypic characteristics possibly responsible for bone sclerosis and that two subgroups of OA patients can be identified by low or high endogenous production of prostaglandin E 2 (PGE(2)) by OA Ob. Here, we determined that the elevated PGE2 levels in the high OA subgroup were linked with enhanced cyclooxygenase 2 (COX 2) protein levels compared to normal and low OA Ob. A linear relationship was observed between endogenous PGE2 levels and insulin like growth factor I (IGF 1) levels in OA Ob. As parathyroid hormone (PTH) and PGE(2) are known stimulators of IGF 1 production in Ob, we next evaluated their effect in OA Ob. Both subgroups increased their IGF 1 production similarly in response to PGE2, while the high OA subgroup showed a blunted response to PTH compared to the low OA group. Conversely, only the high OA group showed a significant inhibition of IGF 1 production when PGE2 synthesis was reduced with Naproxen, a non steroidal anti inflammatory drug (NSAID) that inhibits cyclooxygenases (COX). The PGE(2) dependent stimulation of IGF 1 synthesis was due in part to the cAMP/protein kinase A pathway since both the direct inhibition of this pathway with H 89 and the inhibition of EP2 or EP4 receptors, linked to cAMP production, reduced IGF 1 synthesis. The production of the most abundant IGF 1 binding proteins (IGFBPs) in bone tissue, IGFBP 3,  4, and  5, was lower in OA compared to normal Ob independently of the OA group. Under basal condition, OA Ob expressed similar IGF 1 mRNA to normal Ob; however, PGE2 stimulated IGF 1 mRNA expression more in OA than normal Ob. These data suggest that increased IGF 1 levels correlate with elevated endogenous PGE2 levels in OA Ob and that higher IGF 1 levels in OA Ob could be important for bone sclerosis in OA. (c) 2005 Elsevier Inc. All rights reserved.
C1 CRCHUM, Notre Dame Hosp, Unite Rech Arthrose, Montreal, PQ H2L 4M1, Canada.
   Univ Montreal, Grp Rech Transport Membranaire, Montreal, PQ H3C 3J7, Canada.
C3 Universite de Montreal; Universite de Montreal
RP CRCHUM, Notre Dame Hosp, Unite Rech Arthrose, Montreal, PQ H2L 4M1, Canada.
EM daniel.lajeunesse@umontreal.ca
RI ; Martel Pelletier, Johanne/AAG 2928 2019; Lajeunesse,
   Daniel/U 2223 2019; Pelletier, Jean Pierre/AAG 2896 2019
OI Lajeunesse, Daniel/0000 0001 6958 5906; 
CR ALTMAN R, 1986, ARTHRITIS RHEUM US, V29, P1039, DOI 10.1002/art.1780290816
   Benito MJ, 2005, ANN RHEUM DIS, V64, P1263, DOI 10.1136/ard.2004.025270
   BICHELL DP, 1993, ENDOCRINOLOGY, V133, P1020, DOI 10.1210/en.133.3.1020
   CANALIS E, 1989, J CLIN INVEST, V83, P60, DOI 10.1172/JCI113885
   COLEMAN RA, 1994, PROSTAGLANDINS, V47, P151, DOI 10.1016/0090 6980(94)90084 1
   Di Battista JA, 1996, J CELL BIOCHEM, V62, P1
   DiBattista JA, 1997, J CELL BIOCHEM, V65, P408, DOI 10.1002/(SICI)1097 4644(19970601)65:3<408::AID JCB10>3.3.CO;2 H
   DORE S, 1995, ARTHRITIS RHEUM, V38, P413, DOI 10.1002/art.1780380319
   EDWALL D, 1992, J BONE MINER RES, V7, P207
   Fujieda M, 1999, J CELL BIOCHEM, V75, P215, DOI 10.1002/(SICI)1097 4644(19991101)75:2<215::AID JCB4>3.0.CO;2 S
   GEVERS G, 1987, COLLAGEN REL RES, V7, P435
   Gordeladze JO, 2002, J CELL BIOCHEM, V85, P825, DOI 10.1002/jcb.10156
   Guévremont M, 2003, J BONE MINER RES, V18, P1073, DOI 10.1359/jbmr.2003.18.6.1073
   Hilal G, 1998, ARTHRITIS RHEUM, V41, P891, DOI 10.1002/1529 0131(199805)41:5<891::AID ART17>3.0.CO;2 X
   Hilal G, 2001, J BONE MINER RES, V16, P713, DOI 10.1359/jbmr.2001.16.4.713
   Hilal G, 1999, ARTHRITIS RHEUM, V42, P2112, DOI 10.1002/1529 0131(199910)42:10<2112::AID ANR11>3.0.CO;2 N
   Kanety H, 1996, J RHEUMATOL, V23, P815
   KASUGAI S, 1995, BONE, V17, P1, DOI 10.1016/8756 3282(95)00134 Y
   KATSUYAMA M, 1995, FEBS LETT, V372, P151, DOI 10.1016/0014 5793(95)00966 D
   Kozawa O, 1998, BONE, V22, P355, DOI 10.1016/S8756 3282(97)00293 7
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lajeunesse D, 1996, J CLIN INVEST, V98, P1835, DOI 10.1172/JCI118984
   LAJEUNESSE D, 1991, BONE MINER, V14, P237, DOI 10.1016/0169 6009(91)90025 U
   Lajeunesse D, 1999, OSTEOARTHR CARTILAGE, V7, P321, DOI 10.1053/joca.1998.0180
   Lavigne P, 2004, BONE, V34, P478, DOI 10.1016/j.bone.2003.10.006
   Lavigne P, 2002, OSTEOARTHR CARTILAGE, V10, P898, DOI 10.1053/joca.2002.0846
   LINKHART TA, 1989, ENDOCRINOLOGY, V125, P1484, DOI 10.1210/endo 125 3 1484
   Mansell JP, 1998, J CLIN INVEST, V101, P1596, DOI 10.1172/JCI867
   Martel Pelletier J, 1998, INFLAMM RES, V47, P90, DOI 10.1007/s000110050288
   Massicotte F, 2002, OSTEOARTHR CARTILAGE, V10, P491, DOI 10.1053/joca.2002.0528
   MCCARTHY TL, 1990, J BIOL CHEM, V265, P15353
   McCarthy TL, 2000, ENDOCRINOLOGY, V141, P127, DOI 10.1210/en.141.1.127
   MCCARTHY TL, 1994, J CELL PHYSIOL, V160, P163, DOI 10.1002/jcp.1041600119
   MCCARTHY TL, 1991, ENDOCRINOLOGY, V128, P2895, DOI 10.1210/endo 128 6 2895
   MCCARTHY TL, 1993, ADV EXP MED BIOL, V343, P407
   Paredes Y, 2002, ARTHRITIS RHEUM, V46, P1804, DOI 10.1002/art.10357
   PASH JM, 1995, ENDOCRINOLOGY, V136, P33, DOI 10.1210/en.136.1.33
   RADIN EL, 1986, CLIN ORTHOP RELAT R, P34
   RO J, 1976, ACTA ORTHOP SCAND, V47, P588, DOI 10.3109/17453677608988744
   SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003 2697(85)90442 7
   Suda M, 1998, CALCIFIED TISSUE INT, V62, P327, DOI 10.1007/s002239900440
   Suda M, 1996, ENDOCRINOLOGY, V137, P1698, DOI 10.1210/en.137.5.1698
   SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463
   SUGIMOTO Y, 1994, AM J PHYSIOL, V266, pF823, DOI 10.1152/ajprenal.1994.266.5.F823
   Tardif G, 1999, ARTHRITIS RHEUM, V42, P1147, DOI 10.1002/1529 0131(199906)42:6<1147::AID ANR11>3.0.CO;2 Y
   Tavera C, 1996, OSTEOARTHR CARTILAGE, V4, P263, DOI 10.1016/S1063 4584(05)80104 9
   USHIKUBI F, 1995, J LIPID MEDIAT CELL, V12, P343, DOI 10.1016/0929 7855(95)00022 I
   WATABE A, 1993, J BIOL CHEM, V268, P20175
   Weinreb M, 1999, AM J PHYSIOL ENDOC M, V276, pE376, DOI 10.1152/ajpendo.1999.276.2.E376
   Westacott CI, 1997, ARTHRITIS RHEUM, V40, P1282, DOI 10.1002/1529 0131(199707)40:7<1282::AID ART13>3.0.CO;2 E
NR 50
TC 49
Z9 57
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAR
PY 2006
VL 38
IS 3
BP 333
EP 341
DI 10.1016/j.bone.2005.09.007
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 022JL
UT WOS:000236051600006
PM 16257278
DA 2025 08 17
ER

PT J
AU Ertorer, ME
   Bakiner, O
   Anaforoglu, I
   Sezgin, N
   Dernirag, NG
   Tutuncu, NB
AF Ertorer, Melek Eda
   Bakiner, Okan
   Anaforoglu, Inan
   Sezgin, Nurzen
   Dernirag, Nilgun Guvener
   Tutuncu, Neslihan Bascil
TI Serum osteoprotegerin concentration with strontium ranelate treatment
   for postmenopausal osteoporosis: An open prospective study
SO CURRENT THERAPEUTIC RESEARCH CLINICAL AND EXPERIMENTAL
LA English
DT Article; Proceedings Paper
CT 29th National Meeting of the
   Turkish Society of Endocrinology and Metabolism
CY SEP 06 10, 2006
CL Antalya, TURKEY
SP Turkish Soc Endocrinol & Metabolism
DE strontium ranelate; osteoporosis; osteoprotegerin
ID SUPPRESSED BONE TURNOVER; EXTRACELLULAR CALCIUM; OSTEOCLAST; RECEPTOR;
   MICRODAMAGE; RESORPTION; FRACTURE; DENSITY; LIGAND; RISK
AB Background: Strontium ranelate (SR) is a new antiosteoporotic agent with antiresorptive and bone forming properties. The exact mechanism by which SR exerts its effects is not clearly understood. Bone resorption requires interaction between osteoblasts and osteoclasts. Osteoblasts produce a ligand for receptor activator of nuclear factor kappa B (RANK). They also secrete osteoprotegerin, a decoy protein that blocks the interaction of RANK with its ligand, thereby inhibiting the differentiation and activity of osteoclasts. SR also has been associated with osteoblast proliferation and decreased osteoblast induced osteoclast differentiation via increased osteoprotegerin messenger RNA expression in human osteoblasts.
   Objective: The aim of this study was to investigate the relationship between SR treatment and serum osteoprotegerin concentration in women with postmenopausal osteoporosis (PMO).
   Methods: This open, prospective study was conducted in women admitted to the outpatient endocrinology clinic of Baskent University Faculty of Medicine, Adana Medical Center, Ankara, Turkey, for the evaluation of PMO. Women with PMO who enrolled were administered elemental calcium 1000 mg/d and vitamin D 800 IU/d for 1 month before the study period. After obtaining baseline serum samples for determining osteoprotegerin concentrations, patients were assigned to the treatment or control groups at a 5:2 ratio and SR 2 g/d was administered to the treatment group. The control group continued to receive only calcium and vitamin D. Serum osteoprotegerin concentration was measured again after 3 months of treatment.
   Results: Thirty five women (treatment group: n = 25; mean [SD] age, 59.80 [7.38] years; control group: n = 10; mean [SD] age, 56.60 [5.06] years) enrolled in the study. A total of 32 women 24 in the treatment group and 8 in the control group completed the study. Compared with baseline, mean [SD] serum osteoprotegerin concentration did not change significantly after 3 months in either the treatment group (4.91 [1.24] pmol/L vs 4.71 [1.19] pmol/L) or the control group (5.36 [2.82] pmol/L vs 5.10 [2.19] pmol/L).
   Conclusion: The results of this small study found that serum osteoprotegerin concentrations were not significantly changed by SR treatment for 3 months among women with PMO.
C1 Baskent Univ, Fac Med, Div Endocrinol & Metab, TR 06490 Ankara, Turkey.
   Baskent Univ, Fac Med, Dept Biochem, TR 06490 Ankara, Turkey.
C3 Baskent University; Baskent University
RP Ertorer, ME (通讯作者)，Baskent Univ, Fac Med, Div Endocrinol & Metab, Adana Med Ctr, Dadaloglu Mah Serin Evler 39 Sokak 6, TR 01250 Adana, Turkey.
EM e_ertorer@yahoo.com
RI Tütüncü, Neslihan/ABG 5027 2020; Ertorer, Melek Eda/ABI 3705 2020;
   ANAFOROĞLU, İNAN/AAG 8413 2021; ERTORER, MELEK EDA/ABI 3705 2020; Bascil
   Tutuncu, Neslihan/ABG 5027 2020; Bakıner, Okan/AAK 5525 2021
OI Ertorer, Melek Eda/0000 0001 7357 8709; Bascil Tutuncu,
   Neslihan/0000 0002 1816 3903; 
CR Baron R, 2002, EUR J PHARMACOL, V450, P11, DOI 10.1016/S0014 2999(02)02040 X
   Baylink DJ, 2000, Z RHEUMATOL, V59, P42
   Brennan T., 2006, Calcified Tissue International, V78, pS129
   Brown EM, 2003, OSTEOPOROSIS INT, V14, pS25, DOI 10.1007/s00198 002 1343 6
   Canalis E, 1996, BONE, V18, P517, DOI 10.1016/8756 3282(96)00080 4
   Choudhary S, 2003, J BONE MINER RES, V18, P1813, DOI 10.1359/jbmr.2003.18.10.1813
   Coulombe J, 2004, BIOCHEM BIOPH RES CO, V323, P1184, DOI 10.1016/j.bbrc.2004.08.209
   CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202
   Delmas PD, 2005, OSTEOPOROSIS INT, V16, P1, DOI 10.1007/s00198 004 1813 0
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Dupont WD, 1997, CONTROL CLIN TRIALS, V18, P274, DOI 10.1016/S0197 2456(97)00074 3
   Eghbali Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215
   GINDLER EM, 1972, AM J CLIN PATHOL, V58, P376
   GRYNPAS MD, 1990, BONE, V11, P313, DOI 10.1016/8756 3282(90)90086 E
   Komatsubara S, 2004, J BONE MINER RES, V19, P999, DOI 10.1359/JBMR.040126
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Marie P J, 2006, Bone, V38, pS10
   Marie PJ, 2005, OSTEOPOROSIS INT, V16, pS7, DOI 10.1007/s00198 004 1753 8
   MARIE PJ, 1985, MINER ELECTROL METAB, V11, P5
   Mashiba T, 2001, BONE, V28, P524, DOI 10.1016/S8756 3282(01)00414 8
   Mentaverri R, 2005, BONE, V36, pS403
   Meunier PJ, 2002, J CLIN ENDOCR METAB, V87, P2060, DOI 10.1210/jc.87.5.2060
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   Miller PD, 1998, J CLIN DENSITOM, V1, P211, DOI 10.1385/JCD:1:3:211
   MILSOM S, 1987, BMJ BRIT MED J, V295, P231, DOI 10.1136/bmj.295.6592.231
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Raisz LG, 2005, NEW ENGL J MED, V353, P164, DOI 10.1056/NEJMcp042092
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Rapuri PB, 2002, J CLIN ENDOCR METAB, V87, P2024, DOI 10.1210/jc.87.5.2024
   Riggs BL, 2005, J BONE MINER RES, V20, P177, DOI 10.1359/JBMR.041114
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Szalay F, 2003, J HEPATOL, V38, P395, DOI 10.1016/S0168 8278(02)00435 X
   Takahashi N, 2003, J BONE MINER RES, V18, P1082, DOI 10.1359/jbmr.2003.18.6.1082
   Wattel A, 2005, BONE, V36, pS400
   1974, CLIN CHEM PRINCIPLES, P723
NR 35
TC 0
Z9 0
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0011 393X
EI 1879 0313
J9 CURR THER RES CLIN E
JI Curr. Ther. Res. Clin. Exp.
PD JUL AUG
PY 2007
VL 68
IS 4
BP 217
EP 225
DI 10.1016/j.curtheres.2007.08.001
PG 9
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 214ZS
UT WOS:000249777500002
PM 24683212
OA gold, Green Accepted, Green Published
DA 2025 08 17
ER

PT J
AU Li, ZY
   Liu, C
   Liu, XL
   Wang, N
   Gao, L
   Bao, XX
   Liu, SJ
   Xue, P
AF Li, Ziyi
   Liu, Chang
   Liu, Xiaoli
   Wang, Na
   Gao, Liu
   Bao, Xiaoxue
   Liu, Sijing
   Xue, Peng
TI Aucubin Impeded Preosteoclast Fusion and Enhanced CD31<SUP>hi</SUP>
   EMCN<SUP>hi</SUP> Vessel Angiogenesis in Ovariectomized Mice
SO STEM CELLS INTERNATIONAL
LA English
DT Article
ID RANKL INDUCED OSTEOCLASTOGENESIS; ENDOTHELIAL CELLS; BONE; PATHWAY;
   OSTEOPOROSIS; INHIBITION; CARTILAGE; P38; JNK
AB Osteogenesis is tightly correlated with angiogenesis during the process of bone development, regeneration, and remodeling. In addition to providing nutrients and oxygen for bone tissue, blood vessels around bone tissue also secrete some factors to regulate bone formation. Type H vessels which were regulated by platelet derived growth factor BB (PDGF BB) were confirmed to couple angiogenesis and osteogenesis. Recently, preosteoclasts have been identified as the most important source of PDGF BB. Therefore, inhibiting osteoclast maturation, improving PDGF BB secretion, stimulating type H angiogenesis, and subsequently accelerating bone regeneration may be potent treatments for bone loss disease. In the present study, aucubin, an iridoid glycoside extracted from Aucuba japonica and Eucommia ulmoides, was found to inhibit bone loss in ovariectomized mice. We further confirmed that aucubin could inhibit the fusion of tartrate resistant acid phosphatase (TRAP)(+) preosteoclasts into mature osteoclasts and indirectly increasing angiogenesis of type H vessel. The underlying mechanism is the aucubin induced inhibition of MAPK/NF kappa B signaling, which increases the preosteoclast number and subsequently promotes angiogenesis via PDGF BB. These results prompted that aucubin could be an antiosteoporosis drug candidate, which needs further research.
C1 [Li, Ziyi; Liu, Chang; Wang, Na; Gao, Liu; Bao, Xiaoxue; Xue, Peng] Hebei Med Univ, Dept Endocrinol, Hosp 3, Shijiazhuang 050051, Peoples R China.
   [Li, Ziyi; Liu, Chang; Wang, Na; Gao, Liu; Bao, Xiaoxue; Xue, Peng] Key Orthopaed Biomech Lab Hebei Prov, Shijiazhuang 050051, Peoples R China.
   [Liu, Xiaoli] Hebei Med Univ, Sch & Hosp Stomatol, Dept Pediat Dent, Shijiazhuang 050017, Peoples R China.
   [Liu, Xiaoli] Hebei Med Univ, Hebei Key Lab Stomatol, Shijiazhuang 050017, Peoples R China.
   [Liu, Sijing] Hebei Med Univ, Editorial Dept, Shijiazhuang 050017, Peoples R China.
C3 Hebei Medical University; Hebei Medical University; Hebei Medical
   University; Hebei Medical University
RP Xue, P (通讯作者)，Hebei Med Univ, Dept Endocrinol, Hosp 3, Shijiazhuang 050051, Peoples R China.; Xue, P (通讯作者)，Key Orthopaed Biomech Lab Hebei Prov, Shijiazhuang 050051, Peoples R China.; Liu, SJ (通讯作者)，Hebei Med Univ, Editorial Dept, Shijiazhuang 050017, Peoples R China.
EM 1418808727@qq.com; 15613171905@163.com; liuxiaoli198807@126.com;
   sjzzizi@126.com; 15232126366@163.com; 931533893@qq.com; hbydxbl@126.com;
   hebmuxuepeng@163.com
RI Liu, Xiaoli/AAB 5964 2022
FU Government Foundation for Outstanding Medical Personnel of Hebei
   Province; Key R&D Program of Hebei Province; Returned Overseas Personnel
   Program of Hebei Province; Medical Science Research Project of Hebei
   Province;  [361005];  [22377761D];  [C20220509];  [20221156]
FX AcknowledgmentsThis work was supported by the Government Foundation for
   Outstanding Medical Personnel of Hebei Province (No. 361005), the Key
   R&D Program of Hebei Province (No. 22377761D), the Returned Overseas
   Personnel Program of Hebei Province (No. C20220509), and the Medical
   Science Research Project of Hebei Province (No. 20221156).
CR Al Mamun MA, 2020, J CELL MOL MED, V24, P2542, DOI 10.1111/jcmm.14948
   Chang EJ, 2008, J CELL SCI, V121, P2555, DOI 10.1242/jcs.028217
   Chen HX, 2018, BIOMED PHARMACOTHER, V97, P1155, DOI 10.1016/j.biopha.2017.11.044
   Chen J, 2020, STEM CELL REP, V15, P110, DOI 10.1016/j.stemcr.2020.06.007
   Chen L, 2017, J STEROID BIOCHEM, V172, P149, DOI 10.1016/j.jsbmb.2017.07.007
   Filipowska J, 2017, ANGIOGENESIS, V20, P291, DOI 10.1007/s10456 017 9541 1
   Gao B, 2019, J CLIN INVEST, V129, P2578, DOI 10.1172/JCI98857
   Gao SY, 2021, BONE, V144, DOI 10.1016/j.bone.2019.115117
   Guo P, 2003, AM J PATHOL, V162, P1083, DOI 10.1016/S0002 9440(10)63905 3
   He YZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024780
   Hu YJ, 2020, J ORTHOP TRANSL, V24, P12, DOI 10.1016/j.jot.2020.04.008
   Jiang YH, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.12956
   Jung E, 2019, MOLECULES, V24, DOI 10.3390/molecules24244437
   Kim HJ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218396
   Langen UH, 2017, NAT CELL BIOL, V19, P189, DOI 10.1038/ncb3476
   Li XQ, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb7135
   Li YT, 2020, AGING US, V12, P2226, DOI 10.18632/aging.102742
   Liang SH, 2017, CELL PHYSIOL BIOCHEM, V41, P2333, DOI 10.1159/000475652
   Liu JH, 2020, DIS MODEL MECH, V13, DOI 10.1242/dmm.043620
   Liu YH, 2019, THERANOSTICS, V9, P4648, DOI 10.7150/thno.35414
   Ma B, 2019, PHYTOMEDICINE, V64, DOI 10.1016/j.phymed.2019.153057
   Mansky KC, 2002, J BIOL CHEM, V277, P11077, DOI 10.1074/jbc.M111696200
   Matei D, 2007, CANCER BIOL THER, V6, P1951, DOI 10.4161/cbt.6.12.4976
   Moller AMJ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176368
   Peng Y, 2020, J BONE MINER RES, V35, P1188, DOI 10.1002/jbmr.3987
   Peng Y, 2020, THERANOSTICS, V10, P426, DOI 10.7150/thno.34126
   Shen BY, 2019, J CELL MOL MED, V23, P4063, DOI 10.1111/jcmm.14293
   Sivan U, 2019, OPEN BIOL, V9, DOI 10.1098/rsob.190144
   Song Y, 2020, ACS APPL MATER INTER, V12, P16058, DOI 10.1021/acsami.0c00470
   Su WP, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.135446
   Wang L, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.36
   Wang SN, 2015, INT IMMUNOPHARMACOL, V24, P408, DOI 10.1016/j.intimp.2014.12.029
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   Yang P, 2018, BONE, V114, P1, DOI 10.1016/j.bone.2018.05.025
   Yang SF, 2019, J CELL PHYSIOL, V234, P13639, DOI 10.1002/jcp.28044
   Yang Z, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/4327901
   Zhang ML, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/3272098
   Zhang ND, 2016, J ETHNOPHARMACOL, V189, P61, DOI 10.1016/j.jep.2016.05.025
   Zhang SL, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.544124
   Zheng X, 2019, J CELL MOL MED, V23, P8314, DOI 10.1111/jcmm.14709
   Zhu SP, 2020, THERANOSTICS, V10, P5957, DOI 10.7150/thno.45422
   Zhu ZG, 2018, MOL MED REP, V18, P2561, DOI 10.3892/mmr.2018.9286
NR 43
TC 4
Z9 6
U1 3
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1687 966X
EI 1687 9678
J9 STEM CELLS INT
JI Stem Cells Int.
PD NOV 9
PY 2022
VL 2022
AR 5226771
DI 10.1155/2022/5226771
PG 19
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 6M9RO
UT WOS:000889199100001
PM 36406003
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Guo, BS
   Zhang, BT
   Zheng, LZ
   Tang, T
   Liu, J
   Wu, H
   Yang, ZJ
   Peng, SL
   He, XJ
   Zhang, HQ
   Yue, KKM
   He, FC
   Zhang, LQ
   Qin, L
   Bian, ZX
   Tan, WH
   Liang, ZC
   Lu, AP
   Zhang, G
AF Guo, Baosheng
   Zhang, Baoting
   Zheng, Lizhen
   Tang, Tao
   Liu, Jin
   Wu, Heng
   Yang, Zhijun
   Peng, Songlin
   He, Xiaojuan
   Zhang, Hongqi
   Yue, Kevin K. M.
   He, Fuchu
   Zhang, Lingqiang
   Qin, Ling
   Bian, Zhaoxiang
   Tan, Weihong
   Liang, Zicai
   Lu, Aiping
   Zhang, Ge
TI Therapeutic RNA interference targeting CKIP 1 with a cross species
   sequence to stimulate bone formation
SO BONE
LA English
DT Article
DE CKIP 1; Cross species; siRNA sequences; Bone formation
ID PARATHYROID HORMONE; OSTEOGENIC DIFFERENTIATION; POSTMENOPAUSAL WOMEN;
   NONHUMAN PRIMATES; I COLLAGEN; OSTEOPOROSIS; SIRNAS; GENE; FRACTURES;
   CELLS
AB Objectives: Casein kinase 2 interacting protein 1 (CKIP 1) is a newly discovered intracellular negative regulator of bone formation without affecting bone resorption. In this study, we aimed to identify a cross species siRNA sequence targeting CKIP 1 to facilitate developing a novel RNAi based bone anabolic drug for reversing established osteoporosis.
   Methods: Eight specifically designed cross species CKIP 1 siRNA sequences were screened in human, rhesus, rat and mouse osteoblast like cells in vitro to identify the optimal sequence with the highest knockdown efficiency. The effect of this optimal siRNA sequence on osteogenic differentiation and matrix mineralization was further examined in osteoblast like cells across different species, followed by an immunogenicity assessment in human peripheral blood mononuclear cells in vitro. The intra osseous localization and silencing efficiency of the optimal siRNA were examined in vivo using a biophotonic system and real time polymerase chain reaction, respectively. The RNAi mediated cleavage of the CKIP 1 transcript was confirmed by rapid amplification of the 5' cDNA ends in vivo. Furthermore, the effect of the optimal siRNA sequence on osteogenic differentiation, bone turnover biomarkers, bone mass and micro architecture parameters was investigated in healthy and osteoporotic rodents.
   Results: The CKIP 1 siRNA sequence (si 3) was identified as the optimal sequence, which consistently maintained CKIP 1 mRNA/protein expression at the lowest level across species in vitro. The si 3 significantly increased mRNA expression levels of osteoblast phenotypic genes and matrix mineralization across species without inducing an immunostimulatory activity in vitro. The intra osseous localization and RNAi mediated CKIP 1 silencing with high efficiency were confirmed in vivo. Periodic intravenous injections of si 3 promoted mRNA expression of osteoblast phenotypic genes, enhanced bone formation, increased bone mass and elevated serum level of bone formation marker without raising urine level of bone resorption marker in the healthy rodents. Moreover, the si 3 treatment promoted bone formation, improved trabecular micro architecture and reversed bone loss in the osteoporotic mice.
   Conclusions: The identified optimal CKIP 1 siRNA sequence (si 3) could promote osteogenic differentiation across species in vitro, stimulate bone formation in the healthy rodents and reverse bone loss in the osteoporotic mice. (C) 2013 Published by Elsevier Inc.
C1 [Guo, Baosheng; Liu, Jin; Wu, Heng; Yang, Zhijun; Peng, Songlin; Zhang, Hongqi; Yue, Kevin K. M.; Bian, Zhaoxiang; Tan, Weihong; Lu, Aiping; Zhang, Ge] Hong Kong Baptist Univ, Inst Adv Translat Med Bone & Joint Dis, Sch Chinese Med, Hong Kong, Hong Kong, Peoples R China.
   [Guo, Baosheng; Liu, Jin; Wu, Heng; Yang, Zhijun; Peng, Songlin; Zhang, Hongqi; Yue, Kevin K. M.; Bian, Zhaoxiang; Tan, Weihong; Lu, Aiping; Zhang, Ge] Hong Kong Baptist Univ, Branch State Key Lab Chemobiosensing, Hong Kong, Hong Kong, Peoples R China.
   [Guo, Baosheng; Liu, Jin; Wu, Heng; Yang, Zhijun; Peng, Songlin; Zhang, Hongqi; Yue, Kevin K. M.; Bian, Zhaoxiang; Tan, Weihong; Lu, Aiping; Zhang, Ge] Chemometr Hunan Univ, Hong Kong, Hong Kong, Peoples R China.
   [Guo, Baosheng; Liu, Jin; Wu, Heng; Yang, Zhijun; Peng, Songlin; Zhang, Hongqi; Yue, Kevin K. M.; Bian, Zhaoxiang; Tan, Weihong; Lu, Aiping; Zhang, Ge] HKBU Shenzhen Res Inst & Continuing Educ, Inst Integrated Bioinfomed & Translat Sci, Shenzhen, Peoples R China.
   [Guo, Baosheng; Liu, Jin; Wu, Heng; Yang, Zhijun; Bian, Zhaoxiang; Liang, Zicai; Lu, Aiping; Zhang, Ge] Acad CHAN Sun Chi Albert Workroom Adv Translat Me, Kunshan RNAi Inst, Kunshan Ind Technol Res Inst, Kunshan, Jiangsu, Peoples R China.
   [Zhang, Baoting; Zheng, Lizhen; Tang, Tao; Qin, Ling] Chinese Univ Hong Kong, Sch Chinese Med, Dept Orthopaed & Traumatol, Hong Kong, Hong Kong, Peoples R China.
   [He, Xiaojuan; Lu, Aiping] China Acad Chinese Med Sci, Inst Basic Res Clin Med, Beijing 100700, Peoples R China.
   [He, Fuchu; Zhang, Lingqiang] Beijing Proteome Res Ctr, State Key Lab Prote, Beijing Inst Radiat Med, Beijing, Peoples R China.
   [Tan, Weihong] Hunan Univ, Mol Sci & Biomed Lab, State Key Lab ChemobioSensing & Chemometr, Coll Chem & Chem Engn,Coll Biol,Collaborat Innova, Changsha 410082, Hunan, Peoples R China.
   [Liang, Zicai] Peking Univ, Lab Nucle Acid Technol, Inst Mol Med, Beijing 100871, Peoples R China.
C3 Hong Kong Baptist University; Hong Kong Baptist University; Chinese
   University of Hong Kong; Institute of Basic Research In Clinical
   Medicine, CACMS; China Academy of Chinese Medical Sciences; Academy of
   Military Medical Sciences   China; Hunan University; Peking University
RP Zhang, BT (通讯作者)，Hong Kong Baptist Univ, Inst Adv Translat Med Bone & Joint Dis, Sch Chinese Med, Hong Kong, Hong Kong, Peoples R China.
EM zhangbaoting@cuhk.edu.hk; aipinglu@hkbu.edu.hk; zhangge@hkbu.edu.hk
RI Tan, Weihong/A 5412 2008; ZHANG, HONGJIE/N 4186 2013; peng,
   sl/ISA 1370 2023; ZHANG, Ge/N 4150 2013; He, FC/KGL 6713 2024; Zheng,
   Lizhen/C 6550 2014; Guo, Baosheng/ABD 4800 2021; Zhang, Ge/N 4150 2013;
   qin, ling/KIB 1029 2024; Qin, Ling/J 9047 2018; LU,
   Aiping/JDX 0577 2023; Zhang, Baoting/B 6273 2015
OI Yue, Kevin/0000 0002 9250 2416; ZHANG, Ge/0000 0002 7807 7695; Yang,
   Zhijun/0000 0002 6094 0438; Zhang, Hong Qi/0000 0003 4316 9378; Qin,
   Ling/0000 0001 6173 6167; Peng, Songlin/0000 0002 4042 7071; Zhang,
   Bao Ting/0000 0003 1421 0212; Guo, Baosheng/0000 0002 4510 5418
FU Suzhou Ribo Life Science Co. Ltd. [Ribo HK001]; Hong Kong General
   Research Fund [HKBU479111, HKBU478312, HKBU261113]; Hong Kong Research
   Grants Council (RGC) Early Career Scheme (ECS) [489213]; Grants Council
   & Natural Science Foundation Council [N_HKBU435/12]; Natural Science
   Foundation Council [81272045]
FX This study was supported by Contract Grant (Ribo HK001) from Suzhou Ribo
   Life Science Co. Ltd., Hong Kong General Research Fund (HKBU479111,
   HKBU478312 and HKBU261113), Hong Kong Research Grants Council (RGC)
   Early Career Scheme (ECS) (489213), Grants Council & Natural Science
   Foundation Council (N_HKBU435/12) and Natural Science Foundation Council
   (81272045).
CR Ahn J, 2012, CELL MOL LIFE SCI, V69, P3147, DOI 10.1007/s00018 012 0998 1
   [Anonymous], WHO 1998
   Bancroft GN, 2002, P NATL ACAD SCI USA, V99, P12600, DOI 10.1073/pnas.202296599
   Choung S, 2006, BIOCHEM BIOPH RES CO, V342, P919, DOI 10.1016/j.bbrc.2006.02.049
   Cosman F, 2005, NEW ENGL J MED, V353, P566, DOI 10.1056/NEJMoa050157
   David S, 2010, PHARMACOL RES, V62, P100, DOI 10.1016/j.phrs.2009.11.013
   Davidson BL, 2006, NAT BIOTECHNOL, V24, P951, DOI 10.1038/nbt0806 951
   Díaz Martín MA, 1999, SCAND J CLIN LAB INV, V59, P125, DOI 10.1080/00365519950185850
   Far RKK, 2003, NUCLEIC ACIDS RES, V31, P4417, DOI 10.1093/nar/gkg649
   FDA, 1997, GUID PRECL CLIN EV A
   Frank Kamenetsky M, 2008, P NATL ACAD SCI USA, V105, P11915, DOI 10.1073/pnas.0805434105
   Furset G, 2007, BIOCHEM BIOPH RES CO, V352, P642, DOI 10.1016/j.bbrc.2006.11.059
   Garnero P, 2008, CLIN CHEM, V54, P188, DOI 10.1373/clinchem.2007.094953
   Guo BS, 2012, IOF ECCE012 EUR C OS
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Irie K, 1998, ANAT RECORD, V252, P554
   John M, 2007, NATURE, V449, P745, DOI 10.1038/nature06179
   Judge AD, 2005, NAT BIOTECHNOL, V23, P457, DOI 10.1038/nbt1081
   Khosla S, 2008, J CLIN INVEST, V118, P421, DOI 10.1172/JCI33612
   Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140 6736(97)02342 8
   Lu KF, 2008, NAT CELL BIOL, V10, P994, DOI 10.1038/ncb1760
   Marie PJ, 2008, ARCH BIOCHEM BIOPHYS, V473, P98, DOI 10.1016/j.abb.2008.02.030
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Novina CD, 2004, NATURE, V430, P161, DOI 10.1038/430161a
   Peng SL, 2013, BONE, V55, P230, DOI 10.1016/j.bone.2013.02.012
   POSNER AS, 1975, ACCOUNTS CHEM RES, V8, P273, DOI 10.1021/ar50092a003
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Shin D, 2007, BIOCHEM BIOPH RES CO, V364, P436, DOI 10.1016/j.bbrc.2007.10.012
   Shin H, 2005, BIOMATERIALS, V26, P3645, DOI 10.1016/j.biomaterials.2004.09.050
   Sioud M, 2006, J BIOMED BIOTECHNOL, DOI 10.1155/JBB/2006/23429
   Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121
   Takayama T, 2007, LIFE SCI, V80, P965, DOI 10.1016/j.lfs.2006.11.037
   Thompson RN, 2012, J BONE JOINT SURG BR, V94B, P385, DOI 10.1302/0301 620X.94B3.27999
   Vegni FE, 2004, NEW ENGL J MED, V350, P189
   Vickers TA, 2003, J BIOL CHEM, V278, P7108, DOI 10.1074/jbc.M210326200
   Yarbrough DK, 2010, CALCIFIED TISSUE INT, V86, P58, DOI 10.1007/s00223 009 9312 0
   Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
   Zhang LQ, 2007, CELL SIGNAL, V19, P932, DOI 10.1016/j.cellsig.2006.11.002
   Zimmermann TS, 2006, NATURE, V441, P111, DOI 10.1038/nature04688
NR 40
TC 36
Z9 44
U1 0
U2 53
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD FEB
PY 2014
VL 59
BP 76
EP 88
DI 10.1016/j.bone.2013.11.007
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 287QZ
UT WOS:000329558600011
PM 24246247
DA 2025 08 17
ER

PT J
AU Sanfilippo, KM
   Gage, B
   Luo, S
   Weilbaecher, K
   Tomasson, M
   Vij, R
   Colditz, G
   Carson, K
AF Sanfilippo, K. M.
   Gage, B.
   Luo, S.
   Weilbaecher, K.
   Tomasson, M.
   Vij, R.
   Colditz, G.
   Carson, K.
TI Comparative effectiveness on survival of zoledronic acid versus
   pamidronate in multiple myeloma
SO LEUKEMIA & LYMPHOMA
LA English
DT Article
DE Multiple myeloma; bisphosphonates; mortality; comparative effectiveness
   research
ID BONE; CANCER; BISPHOSPHONATES; MECHANISMS; DISODIUM; THERAPY; DISEASE;
   SAFETY; POTENT
AB Zoledronic acid and pamidronate are the two bisphosphonates approved in the United States to reduce multiple myeloma skeletal complications. Little prior evidence exists comparing survival outcomes between the two. We evaluated the incidence of skeletal related events and overall survival in patients with myeloma treated with zoledronic acid versus pamidronate using a cohort of 1018 United States veterans. At a median follow up of 26.9 months, patients receiving zoledronic acid had a 22% reduction in risk of death compared to pamidronate (hazard ratio 0.78; 95% confidence interval, 0.67 0.92). The benefit persisted after controlling for potential confounders. Adjusted Cox modeling with inverse probability weighting and propensity score matching supported these findings. Zoledronic acid was also associated with a 25% decrease in skeletal related events. Zoledronic acid is associated with increased overall survival and decreased skeletal related events compared to pamidronate in patients with multiple myeloma and should become the preferred bisphosphonate.
C1 [Sanfilippo, K. M.; Luo, S.; Carson, K.] St Louis Vet Hlth Adm Med Ctr, St Louis, MO USA.
   [Sanfilippo, K. M.; Gage, B.; Weilbaecher, K.; Tomasson, M.; Vij, R.; Colditz, G.; Carson, K.] Washington Univ, Sch Med, St Louis, MO 63130 USA.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Washington University (WUSTL)
RP Sanfilippo, KM (通讯作者)，Washington Univ, Sch Med, Div Hematol, 660 S Euclid Ave,Campus Box 8125, St Louis, MO 63110 USA.
EM ksanfili@dom.wustl.edu
RI Colditz, Graham/A 3963 2009; Sanfilippo, Kristen/X 8251 2019
OI Colditz, Graham/0000 0002 7307 0291; Gage, Brian/0000 0002 4727 8742;
   Tomasson, Michael/0000 0003 4518 7123
FU Barnes Jewish Hospital Foundation;  [NHLBI/5K12HL087107]; 
   [NCI/KM1CA156708];  [NHLBI/U54 HL112303]
FX Funding that supported completion of this study includes:
   NHLBI/5K12HL087107, Barnes Jewish Hospital Foundation, NCI/KM1CA156708
   and NHLBI/U54 HL112303.
CR Berenson J, 2004, ONCOLOGIST, V9, P319, DOI 10.1634/theoncologist.9 3 319
   Cole SR, 2004, COMPUT METH PROG BIO, V75, P45, DOI 10.1016/j.cmpb.2003.10.004
   Coleman R, 2013, ANN ONCOL, V24, P398, DOI 10.1093/annonc/mds277
   Coleman R, 2012, JNCI J NATL CANCER I, V104, P1059, DOI 10.1093/jnci/djs263
   Corso A, 2005, HEMATOLOGY, V10, P215, DOI 10.1080/10245330500094714
   Croucher PI, 2003, J BONE MINER RES, V18, P482, DOI 10.1359/jbmr.2003.18.3.482
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   GREEN JR, 1994, J BONE MINER RES, V9, P745
   Guenther A, 2010, INT J CANCER, V126, P239, DOI 10.1002/ijc.24758
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   Krupski TL, 2007, J UROLOGY, V178, P1423, DOI 10.1016/j.juro.2007.05.135
   Kyle RA, 2003, MAYO CLIN PROC, V78, P21, DOI 10.4065/78.1.21
   Lipton A, 2011, EXPERT REV ANTICANC, V11, P999, DOI [10.1586/ERA.11.71, 10.1586/era.11.71]
   McCarthy PL, 2013, BIOL BLOOD MARROW TR, V19, P1116, DOI 10.1016/j.bbmt.2013.04.027
   Mhaskar R, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD003188.pub3, 10.1002/14651858.CD003188.pub4]
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   Oranger A, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/289458
   ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1075, DOI 10.1016/0895 4356(93)90103 8
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Rosen LS, 2003, CANCER AM CANCER SOC, V98, P1735, DOI 10.1002/cncr.11701
   Russell RGG, 2007, ANN NY ACAD SCI, V1117, P209, DOI 10.1196/annals.1402.089
   Saad F, 2007, CANCER AM CANCER SOC, V110, P1860, DOI 10.1002/cncr.22991
   Shipman CM, 1997, BRIT J HAEMATOL, V98, P665, DOI 10.1046/j.1365 2141.1997.2713086.x
   Sohn Min Woong, 2006, Popul Health Metr, V4, P2, DOI 10.1186/1478 7954 4 2
   Terpos E, 2013, J CLIN ONCOL, V31, P2347, DOI 10.1200/JCO.2012.47.7901
   Velde NV, 2011, PROSTATE CANCER P D, V14, P79, DOI 10.1038/pcan.2010.49
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Widler L, 2002, J MED CHEM, V45, P3721, DOI 10.1021/jm020819i
NR 28
TC 32
Z9 36
U1 0
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1042 8194
EI 1029 2403
J9 LEUKEMIA LYMPHOMA
JI Leuk. Lymphoma
PD MAR
PY 2015
VL 56
IS 3
BP 615
EP 621
DI 10.3109/10428194.2014.924117
PG 7
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Hematology
GA CD5RC
UT WOS:000351144500012
PM 24844358
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Matsumae, G
   Shimizu, T
   Tian, Y
   Takahashi, D
   Ebata, T
   Alhasan, H
   Yokota, S
   Kadoya, K
   Terkawi, MA
   Iwasaki, N
AF Matsumae, Gen
   Shimizu, Tomohiro
   Tian, Yuan
   Takahashi, Daisuke
   Ebata, Taku
   Alhasan, Hend
   Yokota, Shunichi
   Kadoya, Ken
   Terkawi, Mohamad Alaa
   Iwasaki, Norimasa
TI Targeting thymidine phosphorylase as a potential therapy for bone loss
   associated with periprosthetic osteolysis
SO BIOENGINEERING & TRANSLATIONAL MEDICINE
LA English
DT Article
DE aseptic loosening; kinase inhibitor; macrophage factors; TYMP
ID NF KAPPA B; INFLAMMATORY OSTEOLYSIS; RHEUMATOID ARTHRITIS; EXPRESSION;
   DIFFERENTIATION; MACROPHAGES; FYN; INHIBITION; SURVIVAL;
   OSTEOCLASTOGENESIS
AB Macrophages are generally thought to play a key role in the pathogenesis of aseptic loosening through initiating periprosthetic inflammation and pathological bone resorption. The aim of this study was to identify macrophage derived factors that promote osteoclast differentiation and periprosthetic bone destruction. To achieve this, we examined the effects of 12 macrophage derived factors that were identified by RNA seq analysis of stimulated macrophages on osteoclast differentiation. Surprisingly, thymidine phosphorylase (TYMP) was found to trigger significant number of osteoclasts that exhibited resorbing activities on dentine slices. Functionally, TYMP knockdown reduced the number of osteoclasts in macrophages that had been stimulated with polyethylene debris. TYMP were detected in serum and synovial tissues of patients that had been diagnosed with aseptic loosening. Moreover, the administration of TYMP onto calvariae of mice induced pathological bone resorption that was accompanied by an excessive infiltration of inflammatory cells and osteoclasts. The RNA seq for TYMP induced osteoclasts was then performed in an effort to understand action mode of TYMP. TYMP stimulation appeared to activate the tyrosine kinase FYN signaling associated with osteoclast formation. Oral administration of saracatinib, a FYN kinase inhibitor, significantly suppressed formation of bone osteolytic lesions in a polyethylene debris induced osteolysis model. Our findings highlight a novel molecular target for therapeutic intervention in periprosthetic osteolysis.
C1 [Matsumae, Gen; Shimizu, Tomohiro; Tian, Yuan; Takahashi, Daisuke; Ebata, Taku; Alhasan, Hend; Yokota, Shunichi; Kadoya, Ken; Terkawi, Mohamad Alaa; Iwasaki, Norimasa] Hokkaido Univ, Dept Orthoped Surg, Fac Med, Sapporo, Hokkaido, Japan.
   [Matsumae, Gen; Shimizu, Tomohiro; Tian, Yuan; Takahashi, Daisuke; Ebata, Taku; Alhasan, Hend; Yokota, Shunichi; Kadoya, Ken; Terkawi, Mohamad Alaa; Iwasaki, Norimasa] Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan.
   [Terkawi, Mohamad Alaa; Iwasaki, Norimasa] Hokkaido Univ, Frontier Res Ctr Adv Mat & Life Sci Bldg 2, Global Inst Collaborat Res & Educ GI CoRE, Sapporo, Hokkaido, Japan.
C3 Hokkaido University; Hokkaido University; Hokkaido University
RP Terkawi, MA (通讯作者)，Hokkaido Univ, Fac Med, Dept Orthopaed Surg, Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido, Japan.; Terkawi, MA (通讯作者)，Hokkaido Univ, Grad Sch Med, Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido, Japan.
EM materkawi@med.hokudai.ac.jp
RI Kadoya, Ken/LPP 9136 2024; Terkawi, M/NDT 1351 2025; Takahashi,
   Daisuke/F 7647 2014
OI Kadoya, Ken/0000 0001 5432 3866; Terkawi, Alaa/0000 0002 5481 8516
FU Akiyama Life Science Foundation; Japan Agency for Medical Research and
   Development [JP20gm6210004]; Japan Society for the Promotion of Science
   [17K10993]; Kobayashi Foundation; Grants in Aid for Scientific Research
   [17K10993] Funding Source: KAKEN
FX Akiyama Life Science Foundation; Japan Agency for Medical Research and
   Development, Grant/Award Number: JP20gm6210004; Japan Society for the
   Promotion of Science, Grant/Award Number: 17K10993; Kobayashi Foundation
CR [Anonymous], 2018, NAT REV RHEUMATOL, V14, DOI 10.1038/nrrheum.2017.194
   Bronckaers A, 2009, MED RES REV, V29, P903, DOI 10.1002/med.20159
   Brunetti G, 2014, ONCOTARGET, V5, P12950, DOI 10.18632/oncotarget.2633
   Chen DS, 2012, INT J MOL MED, V30, P1417, DOI 10.3892/ijmm.2012.1145
   Chen SF, 2018, BIOINFORMATICS, V34, P884, DOI 10.1093/bioinformatics/bty560
   Cobelli N, 2011, NAT REV RHEUMATOL, V7, P600, DOI 10.1038/nrrheum.2011.128
   Danson S, 2019, J BONE ONCOL, V19, DOI 10.1016/j.jbo.2019.100261
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Feldmann M, 2003, NAT MED, V9, P1245, DOI 10.1038/nm939
   Garrigues GE, 2005, BIOMATERIALS, V26, P2933, DOI 10.1016/j.biomaterials.2004.06.034
   Goto T, 2012, ANTICANCER RES, V32, P1757
   Gu QL, 2017, J ORTHOP TRANSL, V10, P86, DOI 10.1016/j.jot.2017.05.002
   Hannon RA, 2010, J BONE MINER RES, V25, P463, DOI 10.1359/jbmr.090830
   Heusschen R, 2016, ONCOTARGET, V7, P30712, DOI 10.18632/oncotarget.8750
   Hirano M, 2005, GENE, V354, P152, DOI 10.1016/j.gene.2005.04.041
   Huang JB, 2013, ARTIF ORGANS, V37, P298, DOI 10.1111/j.1525 1594.2012.01568.x
   Ingham E, 2005, BIOMATERIALS, V26, P1271, DOI 10.1016/j.biomaterials.2004.04.035
   Kandahari AM, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.14
   Kawahara A, 2010, ONCOL REP, V24, P405, DOI 10.3892/or_00000873
   Kim HJ, 2010, J CELL BIOCHEM, V111, P1107, DOI 10.1002/jcb.22841
   Kitaura H, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/181849
   Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471 2105 12 323
   Li W, 2018, TRENDS CARDIOVAS MED, V28, P157, DOI 10.1016/j.tcm.2017.10.003
   Liang XQ, 2004, J NEUROSCI, V24, P7140, DOI 10.1523/JNEUROSCI.5319 03.2004
   Liu H, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad8949
   Lovatt M, 2006, MOL CELL BIOL, V26, P8655, DOI 10.1128/MCB.00168 06
   Mbalaviele G, 2017, J CLIN INVEST, V127, P2030, DOI 10.1172/JCI93356
   Miron RJ, 2016, BIOMATERIALS, V82, P1, DOI 10.1016/j.biomaterials.2015.12.017
   Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200
   Nakagawa M, 2000, FEBS LETT, V473, P161, DOI 10.1016/S0014 5793(00)01520 9
   Nakashima T, 2011, ANN NY ACAD SCI, V1240, pE13, DOI 10.1111/j.1749 6632.2011.06373.x
   Nich C, 2013, J BIOMED MATER RES A, V101, P3033, DOI 10.1002/jbm.a.34599
   Quintela López T, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1636 8
   Ritchlin CT, 2003, J CLIN INVEST, V111, P821, DOI 10.1172/JCI200316069
   Sabokbar A, 2016, CLIN REV ALLERG IMMU, V51, P16, DOI 10.1007/s12016 015 8523 6
   Sabokbar Afsie, 2017, World J Exp Med, V7, P49, DOI 10.5493/wjem.v7.i2.49
   Shimaoka S, 2000, CANCER, V88, P2220, DOI 10.1002/(SICI)1097 0142(20000515)88:10<2220::AID CNCR4>3.3.CO;2 3
   Tabata S, 2014, ONCOTARGET, V5, P10473, DOI 10.18632/oncotarget.2242
   Terkawi MA, 2019, ACTA BIOMATER, V89, P242, DOI 10.1016/j.actbio.2019.03.028
   Terkawi MA, 2018, ACTA BIOMATER, V65, P417, DOI 10.1016/j.actbio.2017.11.001
   Tian Y, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01720
   Toyoda Y, 2014, ARTHRITIS RHEUMATOL, V66, P560, DOI 10.1002/art.38263
   Udalova IA, 2016, NAT REV RHEUMATOL, V12, P472, DOI 10.1038/nrrheum.2016.91
   Werner JH, 2018, EXPERT REV CLIN IMMU, V14, P695, DOI 10.1080/1744666X.2018.1511428
   Wooley PH, 2004, GENE THER, V11, P402, DOI 10.1038/sj.gt.3302202
   Yu H, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392 020 00312 6
   Zhou F, 2010, J INT MED RES, V38, P2023, DOI 10.1177/147323001003800616
NR 47
TC 15
Z9 15
U1 1
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
EI 2380 6761
J9 BIOENG TRANSL MED
JI Bioeng. Transl. Med.
PD SEP
PY 2021
VL 6
IS 3
AR e10232
DI 10.1002/btm2.10232
EA JUN 2021
PG 13
WC Biotechnology & Applied Microbiology; Engineering, Biomedical;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Engineering; Pharmacology &
   Pharmacy
GA UT8RP
UT WOS:000658790600001
PM 34589604
OA Green Published
DA 2025 08 17
ER

PT J
AU Dong, J
   Xu, XQ
   Zhang, QY
   Yuan, ZN
   Tan, BY
AF Dong, Jun
   Xu, Xiqiang
   Zhang, Qingyu
   Yuan, Zenong
   Tan, Bingyi
TI The PI3K/AKT pathway promotes fracture healing through its crosstalk
   with Wnt/β catenin
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE PI3K; AKT; Wnt; Crosstalk; Fracture healing; Osteoblast
ID GLYCOGEN SYNTHASE KINASE 3; BETA CATENIN; WNT PATHWAY; INSULIN; PTEN;
   PHOSPHORYLATION; INHIBITOR; MUTATIONS; THERAPY
AB PI3K/AKT is one of the key pathways that regulate cell behaviors including apoptosis, proliferation, and differentiation. Although previous studies have demonstrated that this pathway is a crucial regulator of osteoblasts, the role of PI3K/AKT in fracture healing remains unclear. It is well known that the Wnt/beta catenin pathway plays an essential role in bone regeneration. However, whether there exists crosstalk between Wnt/beta catenin and PI3K/AKT in regulating osteoblasts and bone repair has not been reported. To address these issues, we establish a stabilized fracture model in mice and show that PI3K inhibitor LY294002 substantially inhibits the bone healing process, suggesting that PI3K/AKT promotes fracture repair. More importantly, we report that PI3K/AKT increases phosphorylation of GSK 3 beta at Ser9 and phosphorylation of beta catenin at Ser552 in fracture callus and murine osteoblastic MC3T3 E1 cells, both of which lead to beta catenin stabilization, nuclear translocation, as well as beta catenin mediated TCF dependent transcription, suggesting that beta catenin is activated downstream of PI3K/ AKT. Furthermore, we show that ICG001, the inhibitor of beta catenin transcriptional activity, attenuates PI3K/AKT induced osteoblast proliferation, differentiation, and mineralization, indicating that the PI3K/AKT/beta catenin axis is functional in regulating osteoblasts. Notably, the PI3K/AKT pathway is also activated by Wnt3a and is involved in Wnt3a induced osteoblast proliferation and differentiation. Hence, our results reveal the existence of a Wnt/PI3K/AKT/beta catenin signaling nexus in osteoblasts, highlighting complex crosstalk between PI3K/AKT and Wnt/beta catenin pathways that are critically implicated in fracture healing.
C1 [Dong, Jun; Xu, Xiqiang; Zhang, Qingyu; Yuan, Zenong; Tan, Bingyi] Shandong First Med Univ, Shangdong Prov Hosp, Dept Orthopaed, Jinan, Shandong, Peoples R China.
C3 Shandong First Medical University & Shandong Academy of Medical Sciences
RP Tan, BY (通讯作者)，Shangdong Prov Hosp, Dept Orthopaed, 324 Five Weft Seven Rd, Jinan 250021, Shandong, Peoples R China.
EM bingyitan07@gmail.com
OI Tian, Bingyi/0000 0003 4986 3272
FU Incentive Research Program of Shangdong Provincial Hospital Affiliated
   to Shandong First Medical University, China
FX This work was supported by an Incentive Research Program of Shangdong
   Provincial Hospital Affiliated to Shandong First Medical University,
   China. We also thank Mr. Anthony Johnson at the Shandong University for
   the critical reading of this manuscript.
CR Akiyama T, 2000, CYTOKINE GROWTH F R, V11, P273, DOI 10.1016/S1359 6101(00)00011 3
   Anderson EC, 2010, GASTROENTEROLOGY, V139, P718, DOI 10.1053/j.gastro.2010.07.012
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Burgers TA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063857
   Cai Y, 2014, J CELL BIOCHEM, V115, P625, DOI 10.1002/jcb.24708
   Chalhoub N, 2009, ANNU REV PATHOL MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311
   Chen Y, 2007, PLOS MED, V4, P1216, DOI 10.1371/journal.pmed.0040249
   Chen Y, 2009, J CELL BIOCHEM, V106, P353, DOI 10.1002/jcb.22020
   CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0
   Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819
   Dimitriou R, 2005, INJURY, V36, P1392, DOI 10.1016/j.injury.2005.07.019
   Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200
   Egan KP, 2012, HISTOPATHOLOGY, V61, P1168, DOI 10.1111/j.1365 2559.2012.04333.x
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200
   Fukumoto S, 2001, J BIOL CHEM, V276, P17479, DOI 10.1074/jbc.C000880200
   Georgescu Maria Magdalena, 2010, Genes Cancer, V1, P1170, DOI 10.1177/1947601911407325
   Gui SY, 2013, J CELL BIOCHEM, V114, P1488, DOI 10.1002/jcb.24490
   HILTUNEN A, 1993, J ORTHOP RES, V11, P305, DOI 10.1002/jor.1100110219
   Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058
   Kim SE, 2007, CELL SIGNAL, V19, P511, DOI 10.1016/j.cellsig.2006.08.008
   Komatsu DE, 2010, J ORTHOP RES, V28, P928, DOI 10.1002/jor.21078
   Leucht P, 2019, BIOMATERIALS, V196, P46, DOI 10.1016/j.biomaterials.2018.03.029
   McGonnell Imelda M, 2012, Front Endocrinol (Lausanne), V3, P88, DOI 10.3389/fendo.2012.00088
   Mukherjee A, 2009, J CELL SCI, V122, P716, DOI 10.1242/jcs.042770
   Ng SS, 2009, J BIOL CHEM, V284, P35308, DOI 10.1074/jbc.M109.078261
   Palsgaard J, 2012, J BIOL CHEM, V287, P12016, DOI 10.1074/jbc.M111.337048
   Papa A, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9040153
   Polivka J, 2014, PHARMACOL THERAPEUT, V142, P164, DOI 10.1016/j.pharmthera.2013.12.004
   Seto ES, 2004, TRENDS CELL BIOL, V14, P45, DOI 10.1016/j.tcb.2003.11.004
   Shan JF, 2005, BIOCHEMISTRY US, V44, P15495, DOI 10.1021/bi0512602
   Sisask G, 2013, BONE, V54, P126, DOI 10.1016/j.bone.2013.01.019
   SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014 5793(94)80112 6
   SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015
   Taniguchi CM, 2006, NAT REV MOL CELL BIO, V7, P85, DOI 10.1038/nrm1837
   Ulici V, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471 213X 8 40
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Xiong Y, 2019, MOL THER NUCL ACIDS, V17, P223, DOI 10.1016/j.omtn.2019.06.001
   Yang Yingzi, 2003, Birth Defects Research, V69, P305, DOI 10.1002/bdrc.10026
NR 39
TC 87
Z9 98
U1 10
U2 59
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0014 4827
EI 1090 2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD SEP 1
PY 2020
VL 394
IS 1
AR 112137
DI 10.1016/j.yexcr.2020.112137
PG 10
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA NB5EL
UT WOS:000560535300014
PM 32534061
DA 2025 08 17
ER

PT J
AU Ma, YS
   Hou, ZJ
   Li, Y
   Zheng, BB
   Wang, JM
   Wang, WB
AF Ma, Yong Sheng
   Hou, Zhan Jiang
   Li, You
   Zheng, Beng Beng
   Wang, Jia Ming
   Wang, Wen Bo
TI Unveiling the Pharmacological Mechanisms of Eleutheroside E Against
   Postmenopausal Osteoporosis Through UPLC Q/TOF MS Based Metabolomics
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE metabolomics; ultra high performance liquid tandem quadrupole
   time of flight mass spectrometry; osteoporosis; effects; pharmacological
   mechanism; biomarkers
ID GROWTH FACTOR 1; OSTEOBLAST PROLIFERATION; BILE FORMATION; BONE;
   DIFFERENTIATION; INSULIN; ASSOCIATION; TURNOVER; ACID; RATS
AB Postmenopausal osteoporosis (PMOP) is a common metabolic bone disease in postmenopausal women in the Worldwide, and seriously affects the quality of life of middle aged and elderly women. Therefore, there is an urgent need to discover a highly effective drug for PMOP treatment. In this study, ultra high performance liquid tandem quadrupole time of flight mass spectrometry (UPLC Q/TOF MS) was used to analyze the urine metabolic profiling and potential biomarkers, the relevant metabolic network of PMOP rats, and further to evaluate the intervention effect of Eleutheroside E (EE) against PMOP. Using multivariate statistical analysis combined with UPLC Q/TOF MS, a total of 27 biomarkers were identified, which related with 16 metabolic pathways, mainly involving steroidogenesis, beta oxidation of very long chain fatty acids, glutathione metabolism, carnitine synthesis, estrone metabolism, oxidation of branched chain fatty acids, etc. After treatment of EE, these biomarkers were markedly regulated, mainly involving steroid hormone biosynthesis, arachidonic acid metabolism, primary bile acid biosynthesis, indicating that EE had the therapeutic effect on PMOP. This study identified the potential urine metabolic markers and related metabolic pathways of the PMOP, explained the metabolic effect and pharmacological mechanisms of EE against PMOP, and provided a basis for the pharmacological study of EE.
C1 [Ma, Yong Sheng; Li, You; Zheng, Beng Beng; Wang, Jia Ming] Harbin Med Univ, Dept Orthoped 2, Affiliated Hosp 1, Harbin, Peoples R China.
   [Hou, Zhan Jiang] Harbin Med Univ, Emergency Surg Dept, Affiliated Hosp 1, Harbin, Peoples R China.
   [Wang, Wen Bo] Harbin Med Univ, Dept Orthoped 3, Affiliated Hosp 1, Harbin, Peoples R China.
C3 Harbin Medical University; Harbin Medical University; Harbin Medical
   University
RP Wang, WB (通讯作者)，Harbin Med Univ, Dept Orthoped 3, Affiliated Hosp 1, Harbin, Peoples R China.
EM pathway961@126.com
RI Wang, Jiaming/V 8621 2019; ma, yongsheng/MEQ 3011 2025
CR Al Anazi Abdullah Foraih, 2011, J Nat Sci Biol Med, V2, P154, DOI 10.4103/0976 9668.92322
   BOUCHARD G, 1993, LIVER, V13, P193
   Boyer JL, 2013, COMPR PHYSIOL, V3, P1035, DOI 10.1002/cphy.c120027
   Brennan MA, 2014, HORM METAB RES, V46, P537, DOI 10.1055/s 0033 1363265
   Brown C, 2017, NATURE, V550, pS15, DOI 10.1038/550S15a
   CERVELLATI C, 2014, BIOMED RES INT, V2014, DOI DOI 10.1155/2014/569563
   Chen H, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 018 08097 7
   Dera AA, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 46068 0
   Eastell R, 1998, NEW ENGL J MED, V338, P736, DOI 10.1056/NEJM199803123381107
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Eisenhauer A, 2019, BONE REP, V10, DOI 10.1016/j.bonr.2019.100200
   Elie H., 2020, HORMONAL SIGNALING B, P565, DOI [10.1016/B978 0 12 813814 4.00025 0, DOI 10.1016/B978 0 12 813814 4.00025 0]
   Hamidi MS, 2012, J BONE MINER RES, V27, P1368, DOI 10.1002/jbmr.1566
   Hanly R, 2013, NUCL MED COMMUN, V34, P597, DOI 10.1097/MNM.0b013e3283608993
   Isomura H, 2004, TOXICOLOGY, V197, P93, DOI 10.1016/j.tox.2003.12.006
   Kamani L., 2017, RES CL EN, V31, P459
   KINDMARK A, 1995, CALCIFIED TISSUE INT, V57, P242, DOI 10.1007/BF00310266
   Kraus V. B., 2015, RARE OSTEOARTHRITIS, V2, P1536, DOI DOI 10.1016/B978 0 323 09138 1.00185 6
   Kruger MC, 2012, EUR J CLIN NUTR, V66, P856, DOI 10.1038/ejcn.2012.54
   Liu Zhenping, 2008, Rev Diabet Stud, V5, P232, DOI 10.1900/RDS.2008.5.232
   Lorentzon M, 2001, J BONE MINER METAB, V19, P302, DOI 10.1007/s007740170014
   Mirsaidi A, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 02650 y
   Miyauchi Y, 2013, P NATL ACAD SCI USA, V110, P16568, DOI 10.1073/pnas.1308755110
   Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311
   Mundy GR, 2001, BEST PRACT RES CL RH, V15, P727, DOI 10.1053/berh.2001.0190
   NAWATA H, 1995, J STEROID BIOCHEM, V53, P165, DOI 10.1016/0960 0760(95)00031 T
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Reckenbeil J, 2017, ARCH ORAL BIOL, V73, P142, DOI 10.1016/j.archoralbio.2016.10.010
   Reynolds RM, 2005, CALCIFIED TISSUE INT, V77, P134, DOI 10.1007/s00223 004 0270 2
   Saeed A, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 55988 w
   Schmidt A, 1996, P NATL ACAD SCI USA, V93, P3068, DOI 10.1073/pnas.93.7.3068
   Shalev M, 2019, BBA MOL CELL RES, V1866, P114, DOI 10.1016/j.bbamcr.2018.07.005
   Simmons DL, 2004, PHARMACOL REV, V56, P387, DOI 10.1124/pr.56.3.3
   Yaacobi E, 2017, INJURY, V48, pS34, DOI 10.1016/j.injury.2017.08.036
   Yang JH, 2010, CELL BIOCHEM FUNCT, V28, P334, DOI 10.1002/cbf.1668
   Yang XH, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 44766 3
   Yasuda Y, 2005, ADV DRUG DELIVER REV, V57, P973, DOI 10.1016/j.addr.2004.12.013
   Zhang AH, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00553
   Zhang W, 2012, CELL BIOCHEM FUNCT, V30, P297, DOI 10.1002/cbf.2801
   Zhao HX, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 34574 6
   Zheng ZG, 2020, CELL DEATH DIFFER, V27, P2048, DOI 10.1038/s41418 019 0484 5
NR 41
TC 10
Z9 15
U1 4
U2 29
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD AUG 26
PY 2020
VL 11
AR 1316
DI 10.3389/fphar.2020.01316
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA NP9XH
UT WOS:000570522900001
PM 32982736
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yu, GY
   Corn, PG
   Mak, CSL
   Liang, X
   Zhang, M
   Troncoso, P
   Song, JH
   Lin, SC
   Song, XZ
   Liu, JJ
   Zhang, JH
   Logothetis, CJ
   Melancon, MP
   Panaretakis, T
   Wang, GC
   Lin, SH
AF Yu, Guoyu
   Corn, Paul G.
   Mak, Celia Sze Ling
   Liang, Xin
   Zhang, Miao
   Troncoso, Patricia
   Song, Jian H.
   Lin, Song   Chang
   Song, Xingzhi
   Liu, Jingjing
   Zhang, Jianhua
   Logothetis, Christopher J.
   Melancon, Marites P.
   Panaretakis, Theocharis
   Wang, Guocan
   Lin, Sue   Hwa
TI Prostate cancer induced endothelial cell to osteoblast transition drives
   immunosuppression in the bone tumor microenvironment through Wnt
   pathway induced M2 macrophage polarization
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE macrophage; bone metastasis; prostate cancer; tumor  induced bone; EC 
   to OSB transition
ID METASTASIS; RADIUM 223; EXPRESSION; SURVIVAL; CXCL14
AB Immune checkpoint therapy has limited efficacy for patients with bone  metastatic castration  resistant prostate cancer (bmCRPC). To improve immunotherapy for bmCRPC, we aimed to identify the mechanism of bmCRPC  induced changes in the immune microenvironment. Among bmCRPC patients, higher levels of a 32  gene M2  like macrophage signature in bone metastasis samples correlated with shorter overall survival. Immunohistochemistry showed that CD206  positive (CD206+) macrophages were enriched in bmCRPC bone biopsy specimens compared with primary tumors or lymph node metastases. In preclinical osteogenic prostate cancer (Pca) xenograft models, CD206+ macrophages were recruited to areas with tumor  induced bone. RNA sequencing (RNAseq) analysis showed higher expression of an M2  like gene signature, with activated canonical and noncanonical Wnt pathways, in tumor  associated macrophages isolated from osteogenic tumors (bone TAMs) than in TAMs isolated from nonosteogenic tumors (ctrl  TAMs). Mechanistic studies showed that endothelial cells (ECs) that had undergone EC  to  osteoblast (EC  to OSB) transition, the precursors of tumor  induced OSBs, produced paracrine factors, including Wnts, CXCL14, and lysyl oxidase, which induced M2 polarization and recruited M2  like TAMs to the bone tumor microenvironment (bone TME). Bone TAMs suppressed CD8+ T cells' proliferation and cytolytic activity, and these effects were partially reversed by treating bone TAMs with Wnt inhibitors. Genetic or pharmacological inhibition of Pca induced EC  to OSB transition reduced the levels of M2  like macrophages in osteogenic tumors. Our study demonstrates that Pca induced EC  to OSB transition drives immunosuppression in the bone TME, suggesting that therapies that reduce Pca induced bone formation may improve immunotherapeutic outcomes for bmCRPC.
C1 [Yu, Guoyu; Lin, Song   Chang; Lin, Sue   Hwa] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA.
   [Corn, Paul G.; Mak, Celia Sze Ling; Liang, Xin; Song, Jian H.; Logothetis, Christopher J.; Panaretakis, Theocharis; Wang, Guocan; Lin, Sue   Hwa] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA.
   [Zhang, Miao; Troncoso, Patricia] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.
   [Song, Xingzhi; Liu, Jingjing; Zhang, Jianhua] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA.
   [Melancon, Marites P.] Univ Texas MD Anderson Canc Ctr, Dept Intervent Radiol, Houston, TX 77030 USA.
   [Melancon, Marites P.; Wang, Guocan; Lin, Sue   Hwa] MD Anderson Canc Ctr UTHealth, Grad Sch Biomed Sci, Therapeut & Pharmacol Program, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; University of Texas System;
   UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson
   Cancer Center; University of Texas System; UTMD Anderson Cancer Center
RP Lin, SH (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA.; Wang, GC; Lin, SH (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA.; Wang, GC; Lin, SH (通讯作者)，MD Anderson Canc Ctr UTHealth, Grad Sch Biomed Sci, Therapeut & Pharmacol Program, Houston, TX 77030 USA.
EM gwang6@mdanderson.org; slin@mdanderson.org
RI Wang, Guocan/F 1530 2011; Melancon, Marites/B 4114 2009
OI Troncoso, Patricia/0000 0002 8241 1430; Corn, Paul/0000 0002 4106 6335; 
FU NIH [R01CA174798, 5P50CA140388, P30CA16672, CA276235 01]; DoD
   [DOD PCRP Idea W81XWH 21 1  0522]; Cancer Prevention Research Institute
   of Texas [CPRIT RP230247]; CPRIT [RP180734]
FX We thank Drs. Suyu Liu and Jianliang Dai in the Department of
   Biostatistics for their help with statistical analysis and Stephanie
   Deming, ELS, in Research Medical Library, for editing the manuscript.
   This work was supported by grants from the NIH [R01CA174798 (S.  H.L) ,
   5P50CA140388 (C.J.L. and S.  H.L.) , CA276235 01 (G.W.) , P30CA16672
   (Cancer Center Support Grant) ] , DoD [DOD PCRP Idea W81XWH 21 1  0522
   (G.W.) ] , and Cancer Prevention Research Institute of Texas [CPRIT
   RP230247 (S.  H.L.) ] . We acknowledge technical support (with RNAseq)
   from CPRIT RP180734.
CR Abida W, 2019, P NATL ACAD SCI USA, V116, P11428, DOI 10.1073/pnas.1902651116
   Beer TM, 2017, J CLIN ONCOL, V35, P40, DOI 10.1200/JCO.2016.69.1584
   Bianchi ME, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02109
   Boutilier AJ, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136995
   Cassetta L, 2019, CANCER CELL, V35, P588, DOI 10.1016/j.ccell.2019.02.009
   Cereijo R, 2018, CELL METAB, V28, P750, DOI 10.1016/j.cmet.2018.07.015
   Chen PW, 2019, CANCER CELL, V35, P868, DOI 10.1016/j.ccell.2019.05.003
   Cheong JE, 2018, TRENDS PHARMACOL SCI, V39, P307, DOI 10.1016/j.tips.2017.11.007
   Dai JL, 2005, CANCER RES, V65, P8274, DOI 10.1158/0008 5472.CAN 05 1891
   De Sanctis F, 2023, SEMIN IMMUNOPATHOL, V45, P163, DOI 10.1007/s00281 022 00965 1
   Dondossola E, 2019, JNCI J NATL CANCER I, V111, P1042, DOI 10.1093/jnci/djz007
   Ellwood Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535 6108(03)00197 1
   Ferri M, 2017, EUR J MED CHEM, V142, P506, DOI 10.1016/j.ejmech.2017.09.030
   Fizazi K, 2003, CLIN CANCER RES, V9, P2587
   Goswami S, 2023, NAT REV IMMUNOL, V23, P106, DOI 10.1038/s41577 022 00737 w
   Halabi S, 2016, J CLIN ONCOL, V34, P1652, DOI 10.1200/JCO.2015.65.7270
   Hara T, 2012, J BIOCHEM, V151, P469, DOI 10.1093/jb/mvs030
   Huang Y, 2019, MOL IMMUNOL, V107, P1, DOI 10.1016/j.molimm.2018.12.027
   Huynh J, 2021, CANCER IMMUNOL RES, V9, P735, DOI 10.1158/2326 6066.CIR 19 1023
   Jiao SP, 2019, CELL, V179, P1177, DOI 10.1016/j.cell.2019.10.029
   Kfoury Y, 2021, CANCER CELL, V39, P1464, DOI 10.1016/j.ccell.2021.09.005
   Kouzeli A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.561404
   Kuchimaru T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05366 3
   Lee YC, 2022, ONCOGENE, V41, P757, DOI 10.1038/s41388 021 02131 7
   Lee YC, 2011, CANCER RES, V71, P5194, DOI 10.1158/0008 5472.CAN 10 4374
   Li ZG, 2008, J CLIN INVEST, V118, P2697, DOI 10.1172/JCI33093
   Lin SC, 2023, ISCIENCE, V26, DOI 10.1016/j.isci.2023.105994
   Lin SC, 2017, DEV CELL, V41, P467, DOI 10.1016/j.devcel.2017.05.005
   Liu JF, 2018, CELL, V173, P400, DOI 10.1016/j.cell.2018.02.052
   Liu J, 2013, P NATL ACAD SCI USA, V110, P20224, DOI 10.1073/pnas.1314239110
   Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528
   Lopez Yrigoyen M, 2021, ANN NY ACAD SCI, V1499, P18, DOI 10.1111/nyas.14377
   Ma F, 2022, CANCER RES, V82, P1518, DOI 10.1158/0008 5472.CAN 21 1807
   Ma RY, 2022, TRENDS IMMUNOL, V43, P546, DOI 10.1016/j.it.2022.04.008
   Mariotti L, 2017, BRIT J PHARMACOL, V174, P4611, DOI 10.1111/bph.14038
   Mia S, 2014, SCAND J IMMUNOL, V79, P305, DOI 10.1111/sji.12162
   Morris MJ, 2019, NAT REV UROL, V16, P745, DOI 10.1038/s41585 019 0251 x
   Morrissey C, 2010, NEOPLASIA, V12, P192, DOI 10.1593/neo.91836
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]
   Nishimura K, 2023, J BONE MINER METAB, V41, P317, DOI 10.1007/s00774 023 01435 w
   Nordstrand A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041223
   Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010
   Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755
   Pettit AR, 2008, BONE, V43, P976, DOI 10.1016/j.bone.2008.08.128
   Rojo RD, 2021, INT J HYPERTHER, V38, P650, DOI 10.1080/02656736.2021.1914873
   Sarode P, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz6105
   Schneider MA, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abc8188
   Sjöberg E, 2019, CLIN CANCER RES, V25, P3702, DOI 10.1158/1078 0432.CCR 18 1294
   Vitale I, 2019, CELL METAB, V30, P36, DOI 10.1016/j.cmet.2019.06.001
   Voloshanenko O, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 20641 5
   Wang YY, 2018, J CLIN INVEST, V128, P5235, DOI 10.1172/JCI99974
   Watson PA, 2005, CANCER RES, V65, P11565, DOI 10.1158/0008 5472.CAN 05 3441
   Westrich JA, 2020, MOL CARCINOGEN, V59, P794, DOI 10.1002/mc.23188
   Witte A, 2021, CARDIOVASC RES, V117, P903, DOI 10.1093/cvr/cvaa080
   Xie YW, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935 021 02381 1
   Xu YY, 2024, CANCER RES, V84, P994, DOI 10.1158/0008 5472.CAN 23 1307
   Ye L, 2019, NAT REV IMMUNOL, V19, P614, DOI 10.1038/s41577 019 0182 z
   Yu Guoyu, 2021, GEO
   Yu GY, 2022, CANCER RES, V82, P3158, DOI 10.1158/0008 5472.CAN 22 0170
   Yu GY, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102388
   Zhang Q, 2019, CLIN CANCER RES, V25, P3476, DOI 10.1158/1078 0432.CCR 19 0853
   Zhao YM, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.680834
NR 63
TC 7
Z9 7
U1 1
U2 13
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
EI 1091 6490
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 13
PY 2024
VL 121
IS 33
AR e2402903121
DI 10.1073/pnas.2402903121
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA L0R9T
UT WOS:001347892400003
PM 39102549
OA hybrid
DA 2025 08 17
ER

PT J
AU Man, XJ
   Yang, LY
   Liu, SY
   Yang, L
   Li, MY
   Fu, Q
AF Man, Xiangji
   Yang, Liyu
   Liu, Shengye
   Yang, Lei
   Li, Mingyang
   Fu, Qin
TI Arbutin promotes MC3T3 E1 mouse osteoblast precursor cell proliferation
   and differentiation via the Wnt/β catenin signaling pathway
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE arbutin; MC3T3 E1 cells; osteoporosis; proliferation; osteogenic
   differentiation
ID ALKALINE PHOSPHATASE; ANABOLIC THERAPIES; BONE FORMATION; BETA CATENIN;
   OSTEOPOROSIS; WNT; MECHANISMS; EXPRESSION; MANAGEMENT; DISEASE
AB Arbutin is a natural compound extracted from various plants, including bearberry leaves, that exerts multiple effects including skin whitening, anti inflammatory and oxidative stress protective properties. However, the effects of arbutin on osteoblasts remain unknown. The aim of the present study was to investigate the function and the mechanisms of arbutin on the proliferation and differentiation of MC3T3 E1 mouse osteoblast precursor cells in vitro. The proliferation of MC3T3 E1 cells treated with arbutin was assessed using a Cell Counting Kit 8 assay and a 5 ethynyl 2 ' deoxyuridine labeling assay. Additionally, cell cycle and apoptosis were examined using flow cytometry analysis. The effects of arbutin on osteoblast differentiation were investigated using alkaline phosphatase (ALP) staining and by examining the mRNA expression levels of collagen type I alpha 1 chain (COL1A1), bone gamma carboxyglutamate protein (BGLAP) and Sp7 transcription factor (SP7). To further investigate the molecular mechanism underlying arbutin function in promoting osteogenesis, the mRNA and protein expression levels of runt related transcription factor 2 (RUNX2) and beta catenin were analyzed by reverse transcription quantitative polymerase chain reaction and western blotting. Arbutin significantly promoted MC3T3 E1 cell proliferation and increased the ratio of cells in S phase. Treatment with arbutin increased ALP activity and the mRNA expression levels of COL1A1, BGLAP and SP7 in MC3T3 E1 cells. Furthermore, the protein and the mRNA expression levels of RUNX2 and beta catenin increased significantly following treatment with arbutin. Collectively, the present findings suggested that arbutin was able to promote proliferation and differentiation of MC3T3 E1 cells via the Wnt/beta catenin signaling pathway.
C1 [Man, Xiangji; Yang, Liyu; Liu, Shengye; Yang, Lei; Li, Mingyang; Fu, Qin] China Med Univ, Shengjing Hosp, Dept Orthoped Surg, 36 Sanhao St, Shenyang 110000, Liaoning, Peoples R China.
C3 China Medical University
RP Fu, Q (通讯作者)，China Med Univ, Shengjing Hosp, Dept Orthoped Surg, 36 Sanhao St, Shenyang 110000, Liaoning, Peoples R China.
EM fuqincmu@hotmail.com
RI Li, Mingyang/JQI 8930 2023; Liu, Shengye/HKE 2627 2023; 杨,
   立宇/GZM 5725 2022
FU Major Program of the National Nature Science Foundation of China
   [81370981]; Outstanding Scientific Fund of Shengjing Hospital
FX The present work was supported by The Major Program of the National
   Nature Science Foundation of China (grant no. 81370981) and The
   Outstanding Scientific Fund of Shengjing Hospital.
CR Alford AI, 2013, CONNECT TISSUE RES, V54, P275, DOI 10.3109/03008207.2013.811236
   An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Baron R, 2012, J CLIN ENDOCR METAB, V97, P311, DOI 10.1210/jc.2011 2332
   Canalis E, 2018, EUR J ENDOCRINOL, V178, pR33, DOI 10.1530/EJE 17 0920
   Canalis E, 2010, J CLIN ENDOCR METAB, V95, P1496, DOI 10.1210/jc.2009 2677
   Cauley JA, 2013, J GERONTOL A BIOL, V68, P1243, DOI 10.1093/gerona/glt093
   Cosman F, 2017, J BONE MINER RES, V32, P198, DOI 10.1002/jbmr.3051
   Daoussis D, 2011, SEMIN ARTHRITIS RHEU, V41, P170, DOI 10.1016/j.semarthrit.2011.01.006
   Das S, 2013, DRUG DES DEV THER, V7, P435, DOI 10.2147/DDDT.S31504
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Genovese C, 2018, J CHEMOTHERAPY, V30, P107, DOI 10.1080/1120009X.2017.1393587
   Hernlund E., 2013, ARCH OSTEOPOROS, V8, P1, DOI DOI 10.1007/S11657 013 0136 1
   Hoeppner LH, 2009, EXPERT OPIN THER TAR, V13, P485, DOI [10.1517/14728220902841961 , 10.1517/14728220902841961]
   Jiang LY, 2018, INT J MOL MED, V41, P1048, DOI 10.3892/ijmm.2017.3256
   Jurica K, 2018, CYTOTECHNOLOGY, V70, P1261, DOI 10.1007/s10616 018 0218 4
   Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623
   Kim YJ, 2004, J BIOL CHEM, V279, P50773, DOI 10.1074/jbc.M404145200
   Kobayashi T, 2005, ENDOCRINOLOGY, V146, P1012, DOI 10.1210/en.2004 1343
   Kramer I, 2010, MOL CELL BIOL, V30, P3071, DOI 10.1128/MCB.01428 09
   Lamien Meda A, 2009, PHYTOCHEM ANALYSIS, V20, P416, DOI 10.1002/pca.1142
   Lee HJ, 2012, INFLAMM RES, V61, P817, DOI 10.1007/s00011 012 0474 2
   Lim YJ, 2009, ARCH PHARM RES, V32, P367, DOI 10.1007/s12272 009 1309 8
   Lin X, 2015, CLIN INTERV AGING, V10, P1017, DOI 10.2147/CIA.S54613
   Liu SY, 2018, INT J MOL MED, V41, P2059, DOI 10.3892/ijmm.2018.3414
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Maeda K, 1996, J PHARMACOL EXP THER, V276, P765
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   Marie PJ, 2011, EUR J ENDOCRINOL, V165, P1, DOI 10.1530/EJE 11 0132
   Nakamura T, 2012, J CLIN ENDOCR METAB, V97, P3097, DOI 10.1210/jc.2011 3479
   Neve A, 2013, J CELL PHYSIOL, V228, P1149, DOI 10.1002/jcp.24278
   Omori A, 2015, BIOMED REP, V3, P483, DOI 10.3892/br.2015.452
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Schindler G, 2002, J CLIN PHARMACOL, V42, P920, DOI 10.1177/009127002401102740
   Tang DZ, 2010, J BONE MINER RES, V25, P1234, DOI 10.1002/jbmr.21
   Taurin S, 2006, J BIOL CHEM, V281, P9971, DOI 10.1074/jbc.M508778200
   Uihlein AV, 2012, ENDOCRIN METAB CLIN, V41, P507, DOI 10.1016/j.ecl.2012.05.002
   Wang YP, 2014, FRONT BIOSCI LANDMRK, V19, P379, DOI 10.2741/4214
   WEINREB M, 1990, J BONE MINER RES, V5, P831
   Williams BO, 2009, J BONE MINER RES, V24, P171, DOI [10.1359/JBMR.081235, 10.1359/jbmr.081235]
   Wu LH, 2014, APOPTOSIS, V19, P1654, DOI 10.1007/s10495 014 1032 x
   Yun HM, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.185
NR 47
TC 22
Z9 26
U1 2
U2 15
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD JUN
PY 2019
VL 19
IS 6
BP 4637
EP 4644
DI 10.3892/mmr.2019.10125
PG 8
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA II0DC
UT WOS:000474874600014
PM 30957189
OA Green Published, Green Submitted, hybrid
DA 2025 08 17
ER

PT J
AU Cai, TW
   Chen, SY
   Wu, CH
   Lou, C
   Wang, WD
   Lin, CH
   Jiang, HY
   Xu, XX
AF Cai, Tingwen
   Chen, Siyuan
   Wu, Chenghu
   Lou, Chao
   Wang, Weidan
   Lin, Chihao
   Jiang, Hongyi
   Xu, Xinxian
TI Erythropoietin suppresses osteoblast apoptosis and ameliorates
   steroid induced necrosis of the femoral head in rats by inhibition of
   STAT1 caspase 3 signaling pathway
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
DE Erythropoietin; Apoptosis; Necrosis of the femoral head; STAT1 caspase 3
ID GLUCOCORTICOID INDUCED OSTEONECROSIS; CASPASE 3; STAT1; INFLAMMATION;
   REPERFUSION; THERAPY; CELLS; BCL 2
AB BackgroundSteroid induced avascular necrosis of the femoral head (SANFH) is characterized by osteoblast apoptosis, leading to a loss of bone structure and impaired hip joint function. It has been demonstrated that erythropoietin (EPO) performs a number of biological roles.ObjectiveWe examined the effects of EPO on SANFH and its regulation of the STAT1 caspase 3 signaling pathway.MethodIn vitro, osteoblasts were treated with dexamethasone (Dex) or EPO. We identified the cytotoxicity of EPO by CCK 8, the protein expression of P STAT1, cleaved caspase9, cleaved caspase3, Bcl 2, BAX, and cytochrome c by Western blotting, and evaluated the apoptosis of osteoblasts by flow cytometry. In vivo, we analyzed the protective effect of EPO against SANFH by hematoxylin and eosin (H&E), Immunohistochemical staining, and Micro computed tomography (CT).ResultsIn vitro, EPO had no apparent toxic effect on osteoblasts. In Dex stimulated cells, EPO therapy lowered the protein expression of BAX, cytochrome c, p STAT1, cleaved caspase9, and cleaved caspase3 while increasing the expression of Bcl 2. EPO can alleviate the apoptosis induced by Dex. In vivo, EPO can lower the percentage of empty bone lacunae in SANFH rats.ConclusionThe present study shows that EPO conferred beneficial effects in rats with SANFH by inhibiting STAT1 caspase 3 signaling, suggesting that EPO may be developed as a treatment for SANFH.
C1 [Cai, Tingwen; Chen, Siyuan; Lou, Chao; Wang, Weidan; Lin, Chihao; Jiang, Hongyi; Xu, Xinxian] Wenzhou Med Univ, Affiliated Hosp 2, Yuying Childrens Hosp, Dept Orthoped, Wenzhou, Zhejiang, Peoples R China.
   [Cai, Tingwen; Chen, Siyuan; Lou, Chao; Wang, Weidan; Lin, Chihao; Jiang, Hongyi] Key Lab Orthoped Zhejiang Prov, Wenzhou, Zhejiang, Peoples R China.
   [Cai, Tingwen; Chen, Siyuan; Lou, Chao; Wang, Weidan; Lin, Chihao; Jiang, Hongyi] Wenzhou Med Univ, Sch Med 2, Wenzhou, Zhejiang, Peoples R China.
   [Wu, Chenghu] Wenzhou Med Univ, Sch Ophthalmol & Optometry, Sch Biomed Engn, Wenzhou, Zhejiang, Peoples R China.
   [Wu, Chenghu] Wenzhou Med Univ, Eye Hosp, Wenzhou, Zhejiang, Peoples R China.
C3 Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical
   University; Wenzhou Medical University
RP Xu, XX (通讯作者)，Wenzhou Med Univ, Affiliated Hosp 2, Yuying Childrens Hosp, Dept Orthoped, Wenzhou, Zhejiang, Peoples R China.
EM a379806041@163.com
RI Lin, ChiHao/HZK 8189 2023; Lou, Chao/JPL 0980 2023; Jiang,
   Hongyi/GLR 0971 2022
FU We thank all colleagues for their support and help during the
   experiment.
FX We thank all colleagues for their support and help during the
   experiment.
CR Brennan Speranza TC, 2012, J CLIN INVEST, V122, P4172, DOI 10.1172/JCI63377
   Bullard AJ, 2005, BASIC RES CARDIOL, V100, P397, DOI 10.1007/s00395 005 0537 4
   Chang C, 2020, J AUTOIMMUN, V110, DOI 10.1016/j.jaut.2020.102460
   Chen S, 2014, INT J MOL MED, V33, P840, DOI 10.3892/ijmm.2014.1644
   Cooper MS, 2016, BONE, V82, P64, DOI 10.1016/j.bone.2015.05.038
   Dietrich JB, 1997, ARCH PHYSIOL BIOCHEM, V105, P125, DOI 10.1076/apab.105.2.125.12927
   Dodington DW, 2018, TRENDS ENDOCRIN MET, V29, P55, DOI 10.1016/j.tem.2017.11.001
   Dong YL, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891 015 0589 z
   Du Xiaoxun, 2021, Dis Markers, V2021, P6554480, DOI 10.1155/2021/6554480
   Feng ZH, 2017, APOPTOSIS, V22, P1001, DOI 10.1007/s10495 017 1383 1
   Gu QL, 2019, J ORTHOP TRANSL, V19, P29, DOI 10.1016/j.jot.2019.04.003
   Haine L, 2021, BIOMED PHARMACOTHER, V139, DOI 10.1016/j.biopha.2021.111547
   Huang FJ, 2019, EBIOMEDICINE, V48, P491, DOI 10.1016/j.ebiom.2019.09.002
   Jani A, 2004, AM J TRANSPLANT, V4, P1246, DOI 10.1111/j.1600 6143.2004.00498.x
   Jiang CJ, 2013, INT J NEUROSCI, V123, P684, DOI 10.3109/00207454.2013.817409
   Jiang LY, 2017, J INT MED RES, V45, P1324, DOI 10.1177/0300060517707076
   Kao R, 2007, CRIT CARE, V11, DOI 10.1186/cc5920
   Karabay AZ, 2014, IMMUNOPHARM IMMUNOT, V36, P379, DOI 10.3109/08923973.2014.956752
   Kerachian MA, 2009, J STEROID BIOCHEM, V114, P121, DOI 10.1016/j.jsbmb.2009.02.007
   Kirito K, 2002, BLOOD, V99, P102, DOI 10.1182/blood.V99.1.102
   Komori T, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122045
   Kostanian I A, 2010, Bioorg Khim, V36, P15
   Kuhrt D, 2015, BLOOD, V125, P3536, DOI 10.1182/blood 2014 11 575357
   Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630
   Leyland Jones B, 2003, SEMIN ONCOL, V30, P174, DOI 10.1053/j.seminoncol.2003.08.020
   Li DH, 2018, BIOMATER SCI UK, V6, P519, DOI 10.1039/c7bm00975e
   Lin J, 2019, J BIOCHEM MOL TOXIC, V33, DOI 10.1002/jbt.22265
   Liu LH, 2017, CHINESE MED J PEKING, V130, P2601, DOI 10.4103/0366 6999.217094
   Low SC, 2014, J ORTHOP RES, V32, P826, DOI 10.1002/jor.22611
   Macdougall IC, 2002, NEPHROL DIAL TRANSPL, V17, P39, DOI 10.1093/ndt/17.suppl_11.39
   Martí Rodrigo A, 2020, GUT, V69, P920, DOI 10.1136/gutjnl 2019 318372
   Mont MA, 2006, J BONE JOINT SURG AM, V88A, P1117, DOI 10.2106/JBJS.E.01041
   Mont MA, 1998, CLIN ORTHOP RELAT R, pS314
   Nairz M, 2012, MICROBES INFECT, V14, P238, DOI 10.1016/j.micinf.2011.10.005
   Nie ZG, 2019, BIOCHEM BIOPH RES CO, V511, P693, DOI 10.1016/j.bbrc.2019.02.118
   Peng B, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2276 8
   Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476
   Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722
   Sironi JJ, 2004, J BIOL CHEM, V279, P4066, DOI 10.1074/jbc.M307774200
   Sisler JD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144444
   Tajima K, 2010, J ORTHOP RES, V28, P937, DOI 10.1002/jor.21086
   Thomas M, 2004, CANCER RES, V64, P8357, DOI 10.1158/0008 5472.CAN 04 1864
   Venkatesh B, 2018, NEW ENGL J MED, V378, P797, DOI 10.1056/NEJMoa1705835
   Verhoeven Y, 2020, SEMIN CANCER BIOL, V60, P41, DOI 10.1016/j.semcancer.2019.10.002
   Wang C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096361
   Wangq XY, 2019, J ORTHOP RES, V37, P2348, DOI 10.1002/jor.24400
   Xing YW, 2021, DRUG DEVELOP RES, V82, P990, DOI 10.1002/ddr.21801
   Xu XX, 2014, J MOL HISTOL, V45, P473, DOI 10.1007/s10735 014 9571 6
   Yang B, 2011, EUR J PHARMACOL, V660, P420, DOI 10.1016/j.ejphar.2011.03.044
   Yu HC, 2020, BMC MUSCULOSKEL DIS, V21, DOI 10.1186/s12891 020 03225 1
   Zalavras C, 2003, CRIT REV EUKAR GENE, V13, P221, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i24.140
NR 51
TC 1
Z9 3
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471 2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD NOV 17
PY 2023
VL 24
IS 1
AR 894
DI 10.1186/s12891 023 07028 y
PG 15
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA Y8EH0
UT WOS:001107531000003
PM 37978375
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Jang, SA
   Lee, SJ
   Hwang, YH
   Ha, H
AF Jang, Seon A
   Lee, Sung Ju
   Hwang, Youn Hwan
   Ha, Hyunil
TI Anti Osteoporotic Potential of Water Extract of Anethum
   graveolens L. Seeds
SO NUTRIENTS
LA English
DT Article
DE Anethum graveolens L.; osteoclastogenesis; osteoporosis; RANKL;
   ovariectomy
ID OSTEOCLAST DIFFERENTIATION; GENE EXPRESSION; BONE; NFATC1; PATHOGENESIS;
   DEFICIENCY; ACID
AB Anethum graveolens L., known as European dill, is a versatile herb widely used in both traditional medicine and culinary practices. Despite its long standing history, the potential impact of the water extract of A. graveolens seeds (WEAG) on bone health remains unexplored. In this study, we investigated the influence of WEAG on osteoclast differentiation and assessed its potential as an anti osteoporotic agent. WEAG hindered osteoclast differentiation through the suppression of receptor activator of nuclear factor kappa B ligand (RANKL) expression in osteoclast supporting cells and by directly targeting osteoclast precursor cells. WEAG significantly reduced the expression of key osteoclastogenic transcription factors, namely c Fos and NFATc1, typically induced by RANKL in osteoclast precursors. This reduction was attributed to the suppression of both MAPKs and NF kappa B pathways in response to RANKL. In vivo experiments further revealed that WEAG administration effectively reduces trabecular bone loss and weight gain triggered by ovariectomy, mimicking postmenopausal osteoporosis. Furthermore, our comprehensive phytochemical analysis of WEAG identified a range of phytochemical constituents, associated with bone health and weight regulation. Notably, we discovered a specific compound, isorhamnetin 3 O glucuronide, within WEAG that exhibits anti osteoclastogenic potential. Overall, this research elucidated the beneficial effects and mechanistic basis of WEAG on osteoclast differentiation and bone loss, indicating its potential as a viable alternative to address bone loss in conditions like postmenopause.
C1 [Jang, Seon A] KT&G Corp, Future Technol Res Ctr, 30 Gajeong Ro, Daejeon 34128, South Korea.
   [Lee, Sung Ju; Hwang, Youn Hwan; Ha, Hyunil] Korea Inst Oriental Med KIOM, KM Convergence Res Div, Yuseong Daero 1672, Daejeon 34054, South Korea.
C3 Korea Institute of Oriental Medicine (KIOM)
RP Ha, H (通讯作者)，Korea Inst Oriental Med KIOM, KM Convergence Res Div, Yuseong Daero 1672, Daejeon 34054, South Korea.
EM jsa85@ktng.com; sungjulee@kiom.re.kr; hyhhwang@kiom.re.kr;
   hyunil74@kiom.re.kr
RI Hwang, Youn Hwan/AAU 9373 2021
OI Jang, Seon A/0000 0002 8548 0984; Hwang, Youn Hwan/0000 0002 4959 2436
FU This study was supported by the Korea Institute of Oriental Medicine,
   Ministry of Science and ICT, Republic of Korea [grant number:
   KSN2022332]. [KSN2022332]; Korea Institute of Oriental Medicine,
   Ministry of Science and ICT, Republic of Korea
FX This study was supported by the Korea Institute of Oriental Medicine,
   Ministry of Science and ICT, Republic of Korea [grant number:
   KSN2022332].
CR Ali E.A., 2014, International Journal of Pharmacy Pharmaceutical Sciences, Volume, V6, P11
   Boyce BF, 2015, ENDOCRINOL METAB, V30, P35, DOI 10.3803/EnM.2015.30.1.35
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Choi EB, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms232113512
   Deng Y, 2021, LIFE BASEL, V11, DOI 10.3390/life11050445
   Dong J, 2022, HUM EXP TOXICOL, V41, DOI 10.1177/09603271221119804
   Ekeuku SO, 2021, DRUG DES DEV THER, V15, P259, DOI 10.2147/DDDT.S287280
   Goodarzi MT, 2016, J TROP MED US, V2016, DOI 10.1155/2016/1098916
   Gu DR, 2022, NUTRIENTS, V14, DOI 10.3390/nu14173667
   Hennemann Alexandra, 2002, Med Monatsschr Pharm, V25, P164
   Hosseinzadeh Hossein, 2002, BMC Pharmacol, V2, P21, DOI 10.1186/1471 2210 2 21
   Huang H, 2006, BIOCHEM BIOPH RES CO, V351, P99, DOI 10.1016/j.bbrc.2006.10.011
   Huang K, 2015, J SCI FOOD AGR, V95, P1903, DOI 10.1002/jsfa.6896
   Hwang YH, 2019, NUTRIENTS, V11, DOI 10.3390/nu11081831
   Hwang YH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030912
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Jana S, 2010, Pharmacogn Rev, V4, P179, DOI 10.4103/0973 7847.70915
   Jang SA, 2022, BIOMED PHARMACOTHER, V147, DOI 10.1016/j.biopha.2022.112640
   Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014
   Khosla S, 2011, J BONE MINER RES, V26, P441, DOI 10.1002/jbmr.262
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kim K, 2007, BLOOD, V109, P3253, DOI 10.1182/blood 2006 09 048249
   Lee JH, 2010, MOL PHARMACOL, V77, P17, DOI 10.1124/mol.109.057877
   Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Mu HN, 2021, FOOD RES INT, V143, DOI 10.1016/j.foodres.2021.110240
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Nefussi J R, 1991, J Biol Buccale, V19, P75
   Park JH, 2017, MOL CELLS, V40, P706
   Park JY, 2016, DRUG DEVELOP RES, V77, P143, DOI 10.1002/ddr.21301
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Song L, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/8417814
   Syed M, 2021, J KING SAUD UNIV SCI, V33, DOI 10.1016/j.jksus.2021.101461
   Wasli H, 2018, IND CROP PROD, V126, P466, DOI 10.1016/j.indcrop.2018.10.007
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Xiong JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138189
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Yavropoulou M. P., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P204
   Zhao BH, 2009, NAT MED, V15, P1066, DOI 10.1038/nm.2007
   Zhao S, 2002, J BONE MINER RES, V17, P2068, DOI 10.1359/jbmr.2002.17.11.2068
   Zhou F, 2019, J CELL MOL MED, V23, P4395, DOI 10.1111/jcmm.14333
NR 44
TC 1
Z9 1
U1 0
U2 3
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6643
J9 NUTRIENTS
JI Nutrients
PD OCT
PY 2023
VL 15
IS 19
AR 4302
DI 10.3390/nu15194302
PG 13
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA U5BF5
UT WOS:001084942700001
PM 37836586
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Liu, D
   Kim, B
   Fu, W
   Zhu, S
   Kang, J
   Kim, O
   Kim, O
AF Liu, Danyang
   Kim, Byunggook
   Fu, Wenqi
   Zhu, Siyu
   Kang, Jaeseok
   Kim, Oksu
   Kim, Okjoon
TI Upturn Strategies for Arachidonic Acid Induced MC3T3 E1 625 nm
   Irradiation in Combination with NSAIDs: Dissipating Inflammation and
   Promoting Healing
SO PHOTONICS
LA English
DT Article
DE bone healing; inflammation; NASIDs; 625 nm irradiation
ID LEVEL LASER THERAPY; CELL MIGRATION; PROLIFERATION; METAANALYSIS;
   CADHERIN; LLLT; BONE; MANAGEMENT; EFFICACY; SURGERY
AB Oral surgery, such as tooth extractions and dental implantations, can cause inflammation in the surrounding tissue, especially in bones. Anti inflammatory drugs are crucial for pain relief and wound healing. Nonsteroidal anti inflammatory drugs (NSAIDs) and light emitting diode irradiation (LEDI) at 625 nm have been used as therapies to reduce inflammation, which ultimately promotes wound healing. The mechanism of these two methods, however, is different, which possibly makes the combined use of the two approaches effective. Therefore, the efficacy of 625 nm LEDI, NSAIDs, or a combination of both on anti inflammatory and wound healing effects were analyzed in MC3T3 E1. In this study, piroxicam, ibuprofen, indomethacin, and celecoxib were selected as the NSAIDs. The effect of LEDI at 625 nm was investigated by cell viability, prostaglandin E 2 (PGE(2)) release, and the expression of inflammation related proteins and cell migration related proteins were evaluated. Additionally, alkaline phosphatase staining with activity, cell migration assay and BrdU cell proliferation assays were performed. Both LEDI and NSAIDs reduced cyclooxygenase 2 (COX 2) and PGE(2). Additionally, LEDI promoted cell migration, proliferation, and bone formation as well, but not by NSAIDs. Thus, a combination of LEDI and NSAIDs can benefits the cells in inflammation, which provides upturn strategies for bone healing after tooth extraction.
C1 [Liu, Danyang; Fu, Wenqi; Zhu, Siyu; Kang, Jaeseok; Kim, Okjoon] Chonnam Natl Univ, Sch Dent, Dept Oral Pathol, Gwangju 61186, South Korea.
   [Kim, Byunggook] Chonnam Natl Univ, Sch Dent, Dept Oral Med, Gwangju 61186, South Korea.
   [Kim, Oksu] Chonnam Natl Univ, Sch Dent, Dept Periodontol, Gwangju 61186, South Korea.
   [Kim, Oksu] Chonnam Natl Univ, Hard Tissue Biointerface Res Ctr, Sch Dent, Gwangju 61186, South Korea.
C3 Chonnam National University; Chonnam National University; Chonnam
   National University; Chonnam National University
RP Kim, O (通讯作者)，Chonnam Natl Univ, Sch Dent, Dept Oral Pathol, Gwangju 61186, South Korea.
EM js3894@jnu.ac.kr
OI Kim, OkJoon/0000 0002 6347 1411
FU National Research Foundation of Korea (NRF)   Korea government (MSIT)
   [2022R1F1A1068614]
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korea government (MSIT) (No.
   2022R1F1A1068614).
CR Andrzejowski P, 2019, J ORTHOP TRAUMATOL, V20, DOI 10.1186/s10195 019 0528 0
   Araújo MG, 2015, PERIODONTOL 2000, V68, P122, DOI 10.1111/prd.12082
   Avci P, 2013, SEMIN CUTAN MED SURG, V32, P41
   Bai J, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02493 5
   Battaglia Rachel A, 2018, F1000Res, V7, DOI 10.12688/f1000research.15967.1
   Bergenstock M, 2005, J ORTHOP TRAUMA, V19, P717, DOI 10.1097/01.bot.0000184144.98071.5d
   Bouloux Gary F, 2007, Oral Maxillofac Surg Clin North Am, V19, P117, DOI 10.1016/j.coms.2006.11.013
   Cho H, 2022, J MOL HISTOL, V53, P75, DOI 10.1007/s10735 021 10034 w
   Conway JRW, 2019, ESSAYS BIOCHEM, V63, P535, DOI 10.1042/EBC20190012
   Dawood M.S., 2009, AL NAHRAIN J ENG SCI, V12, P80
   De Carli ML, 2013, J ORAL REHABIL, V40, P171, DOI 10.1111/joor.12022
   Carvalho RLD, 2013, PHOTOCHEM PHOTOBIOL, V89, P508, DOI 10.1111/j.1751 1097.2012.01236.x
   Decloux D, 2021, INT DENT J, V71, P87, DOI 10.1111/idj.12615
   Dima R, 2018, ALTERN THER HEALTH M, V24, P8
   Eduardo CD, 2014, LASER MED SCI, V29, P1517, DOI 10.1007/s10103 013 1311 8
   Enwemeka CS, 2004, PHOTOMED LASER SURG, V22, P323, DOI 10.1089/pho.2004.22.323
   Etikala Anusha, 2019, Compend Contin Educ Dent, V40, pe1
   Fulop AM, 2009, PHOTOMED LASER SURG, V27, P695, DOI 10.1089/pho.2009.2550
   George S, 2018, J PHOTOCH PHOTOBIO B, V188, P60, DOI 10.1016/j.jphotobiol.2018.09.004
   Ghlichloo I., 2022, StatPearls
   Haraguchi M, 2019, BIOCHEM BIOPHYS REP, V18, DOI 10.1016/j.bbrep.2019.100650
   Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779
   He MX, 2018, EUR J PEDIATR, V177, P7, DOI 10.1007/s00431 017 3043 4
   Ibikunle AA, 2016, ORAL MAXILLOFAC SURG, V20, P239, DOI 10.1007/s10006 016 0558 1
   Juríková M, 2016, ACTA HISTOCHEM, V118, P544, DOI 10.1016/j.acthis.2016.05.002
   Kang YJ, 2007, PROG LIPID RES, V46, P108, DOI 10.1016/j.plipres.2007.01.001
   Khouly I, 2021, CLIN ORAL INVEST, V25, P2511, DOI 10.1007/s00784 021 03859 y
   Kokki Hannu, 2003, Paediatr Drugs, V5, P103, DOI 10.2165/00148581 200305020 00004
   Kumchai H., 2021, J ORAL MAXIL SURG, V79, pe76, DOI [10.1016/j.joms.2021.08.106, DOI 10.1016/J.JOMS.2021.08.106]
   Lee JH, 2018, LASER MED SCI, V33, P469, DOI 10.1007/s10103 017 2376 6
   LEWIS JE, 1994, J CELL SCI, V107, P3615
   Liu XZ, 2017, INT J MOL MED, V40, P1631, DOI 10.3892/ijmm.2017.3167
   Madani AS, 2014, CRANIO, V32, P38, DOI 10.1179/0886963413Z.0000000004
   Matzelle MM, 2012, ARTHRITIS RHEUM US, V64, P1540, DOI 10.1002/art.33504
   Miller CS, 2022, J ORAL MAXIL ANESTH, V1, DOI 10.21037/joma 21 21
   Miroshnychenko A, 2023, J DENT RES, V102, P391, DOI 10.1177/00220345221139230
   Monfared GS, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 73055 7
   Murali R, 2016, RSC ADV, V6, P19252, DOI 10.1039/c5ra27571g
   Nabi Shahnaz, 2018, Indian J Dent Res, V29, P46, DOI 10.4103/ijdr.IJDR_327_15
   Ogle Orrett E, 2012, Dent Clin North Am, V56, P133, DOI 10.1016/j.cden.2011.08.003
   Ostrowska Podhorodecka Z, 2021, J CELL SCI, V134, DOI 10.1242/jcs.254359
   Pergolizzi JV, 2020, EXPERT OPIN PHARMACO, V21, P591, DOI 10.1080/14656566.2020.1718651
   Pountos I, 2008, INJURY, V39, P384, DOI 10.1016/j.injury.2007.10.035
   Rather A.M., 2021, SAUDI J ORAL DENT RE, V6, P323
   Ren C, 2016, LASER MED SCI, V31, P1493, DOI 10.1007/s10103 016 2026 4
   Sayed Nabeel, 2019, Sultan Qaboos Univ Med J, V19, pe230, DOI 10.18295/squmj.2019.19.03.009
   Schug SA, 2021, J CLIN MED, V10, DOI 10.3390/jcm10112359
   Shih WT, 2012, J CELL SCI, V125, P3661, DOI 10.1242/jcs.103861
   Silveira PCL, 2009, J PHOTOCH PHOTOBIO B, V95, P89, DOI 10.1016/j.jphotobiol.2009.01.004
   Simon AM, 2007, J BONE JOINT SURG AM, V89A, P500, DOI 10.2106/JBJS.F.00127
   Stein A, 2005, PHOTOMED LASER SURG, V23, P161, DOI 10.1089/pho.2005.23.161
   Su B, 2013, J APPL PHYSIOL, V115, P892, DOI 10.1152/japplphysiol.00053.2013
   Sun Q, 2018, J PHOTOCH PHOTOBIO B, V186, P31, DOI 10.1016/j.jphotobiol.2018.05.015
   Swift A., 2018, Nursing Times, V114, P22
   Thiel A, 2018, BIOL REV, V93, P350, DOI 10.1111/brv.12345
   Thomas MV, 2011, J DENT RES, V90, P1052, DOI 10.1177/0022034510393967
   Trepat X, 2012, COMPR PHYSIOL, V2, P2369, DOI 10.1002/cphy.c110012
   Uchida K, 2017, FREE RADICAL BIO MED, V111, P169, DOI 10.1016/j.freeradbiomed.2017.02.004
   Vimalraj S, 2020, GENE, V754, DOI 10.1016/j.gene.2020.144855
   Wheatley BM, 2019, J AM ACAD ORTHOP SUR, V27, pE330, DOI 10.5435/JAAOS D 17 00727
   Woodruff LD, 2004, PHOTOMED LASER SURG, V22, P241, DOI 10.1089/1549541041438623
   Yang TS, 2022, PHOTONICS BASEL, V9, DOI 10.3390/photonics9080591
   Zhao H, 2020, LASER MED SCI, DOI 10.1007/s10103 020 03072 5
   Zhou Y, 2016, KIDNEY BLOOD PRESS R, V41, P901, DOI 10.1159/000452591
NR 64
TC 2
Z9 2
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2304 6732
J9 PHOTONICS BASEL
JI Photonics
PD MAY 6
PY 2023
VL 10
IS 5
AR 535
DI 10.3390/photonics10050535
PG 15
WC Optics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Optics
GA L0PW5
UT WOS:001020371600001
OA gold
DA 2025 08 17
ER

PT J
AU Qin, YW
   Song, DZ
   Liao, SJ
   Chen, JC
   Xu, ML
   Su, YA
   Lian, HY
   Peng, H
   Wei, LH
   Chen, K
   Xu, JK
   Zhao, JM
   Liu, Q
AF Qin, Yiwu
   Song, Dezhi
   Liao, Shijie
   Chen, Junchun
   Xu, Minglian
   Su, Yuangang
   Lian, Haoyu
   Peng, Hui
   Wei, Linhua
   Chen, Kai
   Xu, Jiake
   Zhao, Jinmin
   Liu, Qian
TI Isosinensetin alleviates estrogen deficiency induced osteoporosis via
   suppressing ROS mediated NF ΚB/MAPK signaling pathways
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Isosinensetin; ROS; NF ?B; MAPK; Osteoporosis
ID OSTEOCLAST DIFFERENTIATION; NFATC1; KINASE; ALPHA
AB The formation of osteoclasts and their hyperactive bone resorption are related to the aggregation of intracellular reactive oxygen species (ROS). Flavonoids, derived from plant active ingredients, can alleviate the symptoms of osteoporosis (OP). Isosinensetin (Iss) is a flavonoid with antioxidant effects obtained mainly from citrus fruits, and its effect on osteoclastogenesis has not been reported. In this study, we investigated the antioxidant activity of Iss on osteoclast differentiation and function, as well as the therapeutic impact of Iss on OP. We found that Iss inhibited osteoclastogenesis and suppressed the bone resorption function of osteoclasts. Additionally, Iss reduced receptor activator of nuclear factor kappa B ligand (RANKL) induced intracellular ROS. Using quantitative real time polymerase chain reaction and western blot, we further found that Iss inhibited osteoclast specific genes and related proteins, while promoting the expression of antioxidant enzyme related genes and proteins. Mechanis tically, Iss reduces intracellular ROS by activating nuclear factor erythroid 2 related factor 2 (Nrf2) and its related antioxidant enzymes and inhibits the downstream nuclear factor kappa B (NF kappa B) and mitogen activated protein kinase (MAPK) signaling pathways of ROS, which in turn inhibits nuclear factor of activated T cells 1 (NFATc1), and ultimately inhibits osteoclastogenesis. In vivo, by micro computed tomography (Micro CT) assay and histological analyses, we found that Iss could reduce bone loss in ovariectomized (OVX) mice. Therefore, Iss has the potential as an OP preventative and therapeutic drug option.
C1 [Qin, Yiwu; Song, Dezhi; Liao, Shijie; Chen, Junchun; Xu, Minglian; Su, Yuangang; Lian, Haoyu; Peng, Hui; Wei, Linhua; Zhao, Jinmin; Liu, Qian] Guangxi Med Univ, Affiliated Hosp 1, Res Ctr Regenerat Med, Orthopaed Dept, Nanning 530021, Guangxi, Peoples R China.
   [Qin, Yiwu; Song, Dezhi; Liao, Shijie; Chen, Junchun; Xu, Minglian; Su, Yuangang; Lian, Haoyu; Peng, Hui; Wei, Linhua; Zhao, Jinmin] Guangxi Med Univ, Guangxi Key Lab Regenerat Med, Nanning 530021, Guangxi, Peoples R China.
   [Chen, Kai] Univ Western Australia, Sch Mol Sci, Perth, WA 6009, Australia.
   [Xu, Jiake] Univ Western Australia, Sch Biomed Sci, Perth, WA 6009, Australia.
C3 Guangxi Medical University; Guangxi Medical University; University of
   Western Australia; University of Western Australia
RP Zhao, JM; Liu, Q (通讯作者)，Guangxi Med Univ, Affiliated Hosp 1, Res Ctr Regenerat Med, Orthopaed Dept, Nanning 530021, Guangxi, Peoples R China.; Zhao, JM (通讯作者)，Guangxi Med Univ, Guangxi Key Lab Regenerat Med, Nanning 530021, Guangxi, Peoples R China.
EM zhaojinmin@126.com; liuqian@gxmu.edu.cn
RI ; Song, Dezhi/AAL 9799 2020; Peng, Hui/ABB 8324 2021; Lian,
   Haoyu/W 3317 2017; zhao, jin/LBH 0351 2024; Su, Yuangang/KKU 6952 2024;
   Chen, KaiJie/A 1743 2016
OI Xu, Jiake/0000 0003 2021 8309; Chen, Kai/0000 0001 6850 1723; 
FU National Natural Science Foundation of China [81960405]; Guangxi Science
   and Technology Base and Talent Special Project [GuikeAD19254003];
   Guangxi Natural Science Foundation [2021GXNSFAA196039]; Collaborative
   Innovation Centre of Regenerative Medicine and Medical Bioresource
   Development and Application; Training Program for One Thousand Young and
   Middle aged Backbone Teachers in Guangxi Colleges and Universities
FX This research was supported by the National Natural Science Foundation
   of China (Grant No. 81960405) , Guangxi Science and Technology Base and
   Talent Special Project (Grant No. GuikeAD19254003) and Guangxi Natural
   Science Foundation (2021GXNSFAA196039) . It is also partly supported by
   the open research fund from the Collaborative Innovation Centre of
   Regenerative Medicine and Medical Bioresource Development and
   Application Co  constructed by the Province and Ministry, and the
   Training Program for One Thousand Young and Middle aged Backbone
   Teachers in Guangxi Colleges and Universities. We acknowledge all the
   people who provided helpful input to this study.
CR Aliprantis AO, 2008, J CLIN INVEST, V118, P3775, DOI 10.1172/JCI35711
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Bai J, 2019, TOXICOL APPL PHARM, V369, P49, DOI 10.1016/j.taap.2019.02.010
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Burbridge K, 2021, DEVELOPMENT, V148, DOI 10.1242/dev.197343
   Cai DW, 2021, MOL MED REP, V23, DOI 10.3892/mmr.2021.11863
   Charles JF, 2014, TRENDS MOL MED, V20, P449, DOI 10.1016/j.molmed.2014.06.001
   Chen DL, 2020, PHARMACOL RES, V159, DOI 10.1016/j.phrs.2020.104944
   Chen K, 2019, THERANOSTICS, V9, P1634, DOI 10.7150/thno.30206
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Dinesh P, 2020, J CELL PHYSIOL, V235, P9497, DOI 10.1002/jcp.29757
   Duleh S, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478 016 0384 6
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Ha H, 2004, EXP CELL RES, V301, P119, DOI 10.1016/j.yexcr.2004.07.035
   Han L, 2022, FRONT NUTR, V9, DOI 10.3389/fnut.2022.897982
   He JB, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.645140
   Kang N, 2019, KOREAN J PHYSIOL PHA, V23, P411, DOI 10.4196/kjpp.2019.23.5.411
   Kanzaki H, 2013, J BIOL CHEM, V288, P23009, DOI 10.1074/jbc.M113.478545
   Kenkre JS, 2018, ANN CLIN BIOCHEM, V55, P308, DOI 10.1177/0004563218759371
   Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046
   Kim H, 2010, FOOD CHEM TOXICOL, V48, P2435, DOI 10.1016/j.fct.2010.06.006
   Kim K, 2020, MOL CELLS, V43, P34, DOI 10.14348/molcells.2019.0232
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Li J, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.829862
   Li ZK, 2018, CALCIFIED TISSUE INT, V103, P324, DOI 10.1007/s00223 018 0425 1
   Liu YH, 2020, J CELL MOL MED, V24, P3303, DOI 10.1111/jcmm.15003
   Magnani F, 2019, CURR OPIN STRUC BIOL, V59, P91, DOI 10.1016/j.sbi.2019.03.001
   Meng XY, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00189 x
   Nakajima S, 2013, FREE RADICAL BIO MED, V65, P162, DOI 10.1016/j.freeradbiomed.2013.06.020
   Nih D., 2001, JAMA J AM MED ASSOC, V285, P785, DOI [10.1001/jama.285.6.785, DOI 10.1001/JAMA.285.6.785]
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   Park JH, 2017, MOL CELLS, V40, P706
   Qiu H, 2021, J CELL PHYSIOL, V236, P2800, DOI 10.1002/jcp.30045
   Russo R., 2020, INT J MOL SCI, V21
   Salles M.B., 2018, ACM T INTEL SYST TEC, V11
   Shi JW, 2021, INT IMMUNOPHARMACOL, V94, DOI 10.1016/j.intimp.2021.107459
   Sithole C, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221910544
   Slupski W, 2021, NUTRIENTS, V13, DOI 10.3390/nu13051609
   Song SS, 2022, PHARMACOL THERAPEUT, V237, DOI 10.1016/j.pharmthera.2022.108168
   Soudani N, 2013, J PHYSIOL BIOCHEM, V69, P239, DOI 10.1007/s13105 012 0207 6
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Sun Y., 2020, TOXINS, V12
   Suzuki A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21238992
   Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200
   Tao HQ, 2020, ACTA BIOCH BIOPH SIN, V52, P1055, DOI 10.1093/abbs/gmaa098
   Wang LJ, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00190 4
   Wang L, 2019, RSC ADV, V9, P38438, DOI 10.1039/c9ra07240c
   Wang YY, 2022, COMMUN BIOL, V5, DOI 10.1038/s42003 022 03653 w
   Watts NB, 2018, J WOMENS HEALTH, V27, P1093, DOI 10.1089/jwh.2017.6706
   Wu ZX, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.793087
   Xanthis V, 2021, ANTIOXIDANTS BASEL, V10, DOI 10.3390/antiox10010127
   Xian YS, 2021, BIOCHEM PHARMACOL, V193, DOI 10.1016/j.bcp.2021.114761
   Xie D., 2021, SIGNALING PATHWAY FR, V12
   Xu Q, 2021, J CELL MOL MED, V25, P10126, DOI 10.1111/jcmm.16949
   Xu T, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9030563
   Xu Y, 2023, BIOMED PHARMACOTHER, V159, DOI 10.1016/j.biopha.2022.114101
   Yan CQ, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/5967434
   Zeng Q., SCIENCE
   Zhang JX, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/4350965
   Zhao XD, 2019, J BONE MINER RES, V34, P911, DOI 10.1002/jbmr.3655
   Zou Y, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10870
NR 61
TC 22
Z9 24
U1 2
U2 28
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD APR
PY 2023
VL 160
AR 114347
DI 10.1016/j.biopha.2023.114347
EA FEB 2023
PG 17
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 8V9YH
UT WOS:000930979500001
PM 36746095
OA gold
DA 2025 08 17
ER

PT J
AU Yumoto, H
   Hirao, K
   Tominaga, T
   Bando, N
   Takahashi, K
   Matsuo, T
AF Yumoto, Hiromichi
   Hirao, Kouji
   Tominaga, Toshihiko
   Bando, Naoki
   Takahashi, Kanako
   Matsuo, Takashi
TI Electromagnetic Wave Irradiation Promotes Osteoblastic Cell
   Proliferation and Up Regulates Growth Factors via Activation of the
   ERK1/2 and p38 MAPK Pathways
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Electromagnetic Wave Irradiation; Osteoblasts; Cell proliferation;
   Growth factors; Signaling
ID ER YAG LASER; NONSURGICAL PERIODONTAL THERAPY; BONE MORPHOGENETIC
   PROTEINS; HUMAN GINGIVAL FIBROBLASTS; KINASE SIGNALING PATHWAYS; LOW
   PULSE ENERGY; IN VITRO; ENDODONTIC INFECTIONS; NDYAG LASER; PHOTODYNAMIC
   THERAPY
AB Background/Aims: Periodontitis with bone resorption is caused by inflammatory reactions to bacterial infection. We recently reported that electromagnetic wave irradiation (EMWI) has bactericidal effects. However, the effects of EMWI on periodontal tissues remain unclear. This study was aimed to investigate the effects of EMWI on osteoblasts. Methods: Osteoblastic cells MC3T3 E1 were treated with EMWI (500 1,000 kHz, 5 times, 1 sec/time). Cell growth and cytotoxicity were determined by cell proliferation assays and measurement of lactate dehydrogenase release, respectively. Gene expression and protein production of growth factors were analyzed using real time PCR and ELSA, respectively. EMWI activated cellular signal transduction pathways were investigated by immunoblotting and blocking assay with specific inhibitors. Results: Osteoblasts proliferation was significantly enhanced 3 days after EMWI and no cytotoxicity was observed. EMWI up regulated various growth factors, such as vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF). EMWI induced ERK1/2, p38 MARK and SAPK/JNK phosphorylation within 5 min, and the production of PDGF AA and VEGF was partially reduced by MARK specific inhibitor. Conclusion: These findings demonstrated that EMWI increases osteoblastic cell activity and the expression of growth factors via ERK1/2 and p38 MAPK pathways and suggested that EMWI may be beneficial to bone tissue repair such as periodontitis. Copyright (C) 2015 S. Karger AG, Basel
C1 [Yumoto, Hiromichi; Hirao, Kouji; Tominaga, Toshihiko; Bando, Naoki; Takahashi, Kanako; Matsuo, Takashi] Univ Tokushima, Grad Sch, Dept Conservat Dent, Inst Hlth Biosci, Tokushima 7708504, Japan.
C3 Tokushima University
RP Yumoto, H (通讯作者)，Univ Tokushima, Grad Sch, Dept Conservat Dent, Inst Hlth Biosci, 3 18 15 Kuramoto Cho, Tokushima 7708504, Japan.
EM yumoto@tokushima u.ac.jp
FU Ministry of Education, Science and Culture of Japan [23390435, 21592423,
   26462885]; Grants in Aid for Scientific Research [26462885, 23390435,
   21592423] Funding Source: KAKEN
FX This work was supported in part by a Grant in Aid for Scientific
   Research (23390435, 21592423 and 26462885) from the Ministry of
   Education, Science and Culture of Japan. All authors state that they
   have no conflicts of interest.
CR Aaron RK, 2004, CLIN ORTHOP RELAT R, P30, DOI 10.1097/01.blo.0000118698.46535.83
   Aleksic V, 2010, LASER MED SCI, V25, P559, DOI 10.1007/s10103 010 0761 5
   Aoki A, 2004, PERIODONTOL 2000, V36, P59, DOI 10.1111/j.1600 0757.2004.03679.x
   Aoki Akira, 2008, General Dentistry, V56, P674
   Babic AM, 1999, MOL CELL BIOL, V19, P2958
   BOLANDER ME, 1992, P SOC EXP BIOL MED, V200, P165
   Böttcher RT, 2005, ENDOCR REV, V26, P63, DOI 10.1210/er.2003 0040
   Bouletreau PJ, 2002, PLAST RECONSTR SURG, V110, P139, DOI 10.1097/00006534 200207000 00025
   Celotti F, 2006, WOUND REPAIR REGEN, V14, P195, DOI 10.1111/j.1743 6109.2006.00110.x
   Chellini F, 2010, LASER SURG MED, V42, P527, DOI 10.1002/lsm.20861
   CIOMBOR DM, 1993, J CELL BIOCHEM, V52, P37, DOI 10.1002/jcb.240520106
   Crespi R, 2007, J PERIODONTOL, V78, P1195, DOI 10.1902/jop.2007.060460
   Denhardt DT, 2001, ANNU REV PHARMACOL, V41, P723, DOI 10.1146/annurev.pharmtox.41.1.723
   FIORELLI G, 1994, J BONE MINER RES, V9, P329
   Fouad AF, 2002, J CLIN MICROBIOL, V40, P3223, DOI 10.1128/JCM.40.9.3223 3231.2002
   Fredriksson L, 2004, CYTOKINE GROWTH F R, V15, P197, DOI 10.1016/j.cytogfr.2004.03.007
   Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955 0674(99)80028 3
   Gerstenfeld LC, 1999, J BONE MINER RES, V14, P850, DOI 10.1359/jbmr.1999.14.6.850
   Giannelli M, 2009, J PERIODONTOL, V80, P977, DOI 10.1902/jop.2009.080648
   Giannini R, 2006, CLIN ORAL IMPLAN RES, V17, P638, DOI 10.1111/j.1600 0501.2006.01278.x
   H Wlodarski Krzysztof, 2005, Ortop Traumatol Rehabil, V7, P351
   Hollinger JO, 2008, J BONE JOINT SURG AM, V90A, P48, DOI 10.2106/JBJS.G.01231
   Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682
   Kawaguchi H, 2001, J CLIN ENDOCR METAB, V86, P875, DOI 10.1210/jc.86.2.875
   Kawaki H, 2008, BIOCHEM BIOPH RES CO, V366, P450, DOI 10.1016/j.bbrc.2007.11.155
   Khan SN, 2000, ORTHOP CLIN N AM, V31, P375, DOI 10.1016/S0030 5898(05)70157 7
   Kim IS, 2006, BBA MOL CELL RES, V1763, P907, DOI 10.1016/j.bbamcr.2006.06.007
   Kömerik N, 2003, ANTIMICROB AGENTS CH, V47, P932, DOI 10.1128/AAC.47.3.932 940.2003
   Krause F, 2007, J CLIN PERIODONTOL, V34, P66, DOI 10.1111/j.1600 051X.2006.01026.x
   Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200
   Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456
   Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137
   Li CF, 2006, J BONE MINER RES, V21, P946, DOI 10.1359/JBMR.060309
   Lieberman JR, 2002, J BONE JOINT SURG AM, V84A, P1032, DOI 10.2106/00004623 200206000 00022
   LIND M, 1995, APMIS, V103, P140, DOI 10.1111/j.1699 0463.1995.tb01089.x
   Luo Q, 2004, J BIOL CHEM, V279, P55958, DOI 10.1074/jbc.M407810200
   Montero A, 2000, J CLIN INVEST, V105, P1085, DOI 10.1172/JCI8641
   MOORE MA, 1991, BIOCHEMISTRY US, V30, P2501, DOI 10.1021/bi00223a029
   Moussad EEDA, 2000, MOL GENET METAB, V71, P276, DOI 10.1006/mgme.2000.3059
   Munson MA, 2002, J DENT RES, V81, P761, DOI 10.1177/154405910208101108
   Murakami S, 2011, PERIODONTOL 2000, V56, P188, DOI 10.1111/j.1600 0757.2010.00365.x
   Nakamae A, 2004, J ORTHOP RES, V22, P509, DOI 10.1016/j.orthres.2003.10.001
   Nakamura T, 1998, J BONE MINER RES, V13, P942, DOI 10.1359/jbmr.1998.13.6.942
   Nakata E, 2002, BONE, V31, P441, DOI 10.1016/S8756 3282(02)00846 3
   Ninomiya T, 2007, BONE, V40, P140, DOI 10.1016/j.bone.2006.07.026
   Offenbacher S, 1996, Ann Periodontol, V1, P821, DOI 10.1902/annals.1996.1.1.821
   Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140 6736(05)67728 8
   Polansky R, 2009, J CLIN PERIODONTOL, V36, P575, DOI 10.1111/j.1600 051X.2009.01412.x
   Pourzarandian A, 2005, J PERIODONTAL RES, V40, P182, DOI 10.1111/j.1600 0765.2005.00789.x
   Pourzarandian A, 2005, J PERIODONTOL, V76, P187, DOI 10.1902/jop.2005.76.2.187
   Prates RA, 2007, J PHOTOCH PHOTOBIO B, V86, P70, DOI 10.1016/j.jphotobiol.2006.07.010
   Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955 0674(97)80061 0
   Rolph HJ, 2001, J CLIN MICROBIOL, V39, P3282, DOI 10.1128/JCM.39.9.3282 3289.2001
   Safadi FF, 2003, J CELL PHYSIOL, V196, P51, DOI 10.1002/jcp.10319
   Schwarz F, 2003, LASER SURG MED, V32, P359, DOI 10.1002/lsm.10179
   Schwarz F, 2003, J CLIN PERIODONTOL, V30, P26, DOI 10.1034/j.1600 051X.2003.300105.x
   Schwarz F, 2008, J CLIN PERIODONTOL, V35, P29, DOI 10.1111/j.1600 051X.2008.01259.x
   Schwarz F, 2009, PERIODONTOL 2000, V51, P79, DOI 10.1111/j.1600 0757.2009.00301.x
   Sculean A, 2004, J PERIODONTOL, V75, P966, DOI 10.1902/jop.2004.75.7.966
   Sculean A, 2004, J CLIN PERIODONTOL, V31, P604, DOI 10.1111/j.1600 051X.2004.00525.x
   Sigusch BW, 2005, J PERIODONTOL, V76, P1100, DOI 10.1902/jop.2005.76.7.1100
   Siqueira JF, 2007, ORAL MICROBIOL IMMUN, V22, P266, DOI 10.1111/j.1399 302X.2007.00355.x
   Slot DE, 2009, J PERIODONTOL, V80, P1041, DOI 10.1902/jop.2009.080571
   Smerdel Ramoya A, 2008, J BIOL CHEM, V283, P22690, DOI 10.1074/jbc.M710140200
   Spadaro JA, 1997, BIOELECTROMAGNETICS, V18, P193, DOI 10.1002/(SICI)1521 186X(1997)18:3<193::AID BEM1>3.0.CO;2 Y
   Vassalli Massimo, 2003, Italian Journal of Anatomy and Embryology, V108, P195
   Villars F, 2002, AM J PHYSIOL CELL PH, V282, pC775, DOI 10.1152/ajpcell.00310.2001
   Wang DS, 1997, ENDOCRINOLOGY, V138, P2953, DOI 10.1210/en.138.7.2953
   Wrotniak Maciej, 2007, Ortop Traumatol Rehabil, V9, P227
   Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101
   Yumoto H, 2012, J APPL MICROBIOL, V113, P181, DOI 10.1111/j.1365 2672.2012.05307.x
   Zhuang HM, 1997, BIOCHEM BIOPH RES CO, V237, P225, DOI 10.1006/bbrc.1997.7118
NR 73
TC 32
Z9 34
U1 0
U2 15
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 1015 8987
EI 1421 9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2015
VL 35
IS 2
BP 601
EP 615
DI 10.1159/000369722
PG 15
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA CA6NY
UT WOS:000349032700015
PM 25612851
OA gold
DA 2025 08 17
ER

PT J
AU Zhou, YN
   Wu, YQ
   Jiang, XQ
   Zhang, XL
   Xia, LG
   Lin, KL
   Xu, YJ
AF Zhou, Yuning
   Wu, Yuqiong
   Jiang, Xinquan
   Zhang, Xiuli
   Xia, Lunguo
   Lin, Kaili
   Xu, Yuanjin
TI The Effect of Quercetin on the Osteogenesic Differentiation and
   Angiogenic Factor Expression of Bone Marrow Derived Mesenchymal Stem
   Cells
SO PLOS ONE
LA English
DT Article
ID ENDOTHELIAL GROWTH FACTOR; ACTIVATED PROTEIN KINASE; MAPK SIGNALING
   PATHWAYS; STROMAL CELLS; IN VITRO; OSTEOBLAST DIFFERENTIATION;
   MORPHOGENETIC PROTEIN 2; PROGENITOR CELLS; BLOOD VESSELS; P38
AB Bone marrow derived mesenchymal stem cells (BMSCs) are widely used in regenerative medicine in light of their ability to differentiate along the chondrogenic and osteogenic lineages. As a type of traditional Chinese medicine, quercetin has been preliminarily reported to promote osteogenic differentiation in osteoblasts. In the present study, the effects of quercetin on the proliferation, viability, cellular morphology, osteogenic differentiation and angiogenic factor secretion of rat BMSCs (rBMSCs) were examined by MTT assay, fluorescence activated cell sorter (FACS) analysis, real time quantitative PCR (RT PCR) analysis, alkaline phosphatase (ALP) activity and calcium deposition assays, and Enzyme linked immunosorbent assay (ELISA). Moreover, whether mitogen activated protein kinase (MAPK) signaling pathways were involved in these processes was also explored. The results showed that quercetin significantly enhanced the cell proliferation, osteogenic differentiation and angiogenic factor secretion of rBMSCs in a dose dependent manner, with a concentration of 2 mu M achieving the greatest stimulatory effect. Moreover, the activation of the extracellular signal regulated protein kinases (ERK) and p38 pathways was observed in quercetin treated rBMSCs. Furthermore, these induction effects could be repressed by either the ERK inhibitor PD98059 or the p38 inhibitor SB202190, respectively. These data indicated that quercetin could promote the proliferation, osteogenic differentiation and angiogenic factor secretion of rBMSCs in vitro, partially through the ERK and p38 signaling pathways.
C1 [Zhou, Yuning; Xu, Yuanjin] Shanghai Jiao Tong Univ, Shanghai Key Lab Stomatol, Shanghai Peoples Hosp 9, Dept Oral Surg,Sch Med, Shanghai 200030, Peoples R China.
   [Zhou, Yuning; Xu, Yuanjin] Shanghai Res Inst Stomatol, Shanghai, Peoples R China.
   [Wu, Yuqiong; Jiang, Xinquan] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Prosthodont, Sch Med, Shanghai 200030, Peoples R China.
   [Wu, Yuqiong; Jiang, Xinquan; Zhang, Xiuli] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Shanghai Res Inst Stomatol, Oral Bioengn Lab,Sch Med, Shanghai 200030, Peoples R China.
   [Xia, Lunguo] Shanghai Jiao Tong Univ, Dept Oral & Craniomaxillofacial Sci, Ctr Craniofacial Orthodont, Sch Med,Shanghai Peoples Hosp 9, Shanghai 200030, Peoples R China.
   [Lin, Kaili] Chinese Acad Sci, Shanghai Inst Ceram, Biomat & Tissue Engn Res Ctr, Shanghai 200050, Peoples R China.
   [Lin, Kaili] Tongji Univ, Lab Oral Biomed Sci & Translat Med, Sch Stomatol, Shanghai 200092, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University; Shanghai Jiao Tong University; Chinese Academy of
   Sciences; Shanghai Institute of Ceramics, CAS; Tongji University
RP Xia, LG (通讯作者)，Shanghai Jiao Tong Univ, Dept Oral & Craniomaxillofacial Sci, Ctr Craniofacial Orthodont, Sch Med,Shanghai Peoples Hosp 9, Shanghai 200030, Peoples R China.
EM xialunguo@hotmail.com; lklecnu@aliyun.com; xuyuanjin@hotmail.com
FU National Natural Science Foundation of China [81171458, 81470713,
   81400554]; Specialized Research Fund for the Doctoral Program of Higher
   Education [20110073110076]; Science and Technology Committee of Shanghai
   Municipality [14140904100, 14YF1402400, 12nm0501600]; Medicine and
   Engineering Cross Project of Shanghai Jiao Tong University [YG2012SM29]
FX This work was funded by National Natural Science Foundation of China
   (81171458, 81470713 and 81400554), Specialized Research Fund for the
   Doctoral Program of Higher Education (20110073110076), Science and
   Technology Committee of Shanghai Municipality (14140904100, 14YF1402400
   and 12nm0501600), Medicine and Engineering Cross Project of Shanghai
   Jiao Tong University (YG2012SM29).
CR Abiramasundari G, 2012, J ETHNOPHARMACOL, V141, P474, DOI 10.1016/j.jep.2012.03.015
   AMBROSE ANTHONY M., 1949, JOUR NUTRITION, V38, P305
   Anand K, 2011, ASIAN PAC J CANCER P, V12, P2829
   Bai Y, 2013, BIOTECHNOL LETT, V35, P301, DOI 10.1007/s10529 012 1084 3
   Bara JJ, 2014, TISSUE ENG PT A, V20, P147, DOI [10.1089/ten.tea.2013.0196, 10.1089/ten.TEA.2013.0196]
   Bavaria MN, 2014, APOPTOSIS, V19, P467, DOI 10.1007/s10495 013 0944 1
   BIKFALVI A, 1991, J CELL PHYSIOL, V149, P50, DOI 10.1002/jcp.1041490108
   BRUDER SP, 1994, J CELL BIOCHEM, V56, P283, DOI 10.1002/jcb.240560303
   Cancedda Ranieri, 2003, Novartis Found Symp, V249, P133
   CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504
   Chen ML, 2011, INT J MOL MED, V27, P545, DOI 10.3892/ijmm.2011.619
   Clark D, 2015, J BIOMED MATER RES A, V103, P639, DOI 10.1002/jbm.a.35215
   DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275
   Feric NT, 2014, BIOMATER SCI UK, V2, P1384, DOI 10.1039/c4bm00073k
   Ferrara N, 1996, Curr Opin Nephrol Hypertens, V5, P35, DOI 10.1097/00041552 199601000 00008
   Fukuhara S, 2010, HISTOL HISTOPATHOL, V25, P387, DOI 10.14670/HH 25.387
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Glowacki J, 1998, CLIN ORTHOP RELAT R, pS82, DOI 10.1097/00003086 199810001 00010
   Guicheux J, 2003, J BONE MINER RES, V18, P2060, DOI 10.1359/jbmr.2003.18.11.2060
   Hanada K, 1997, J BONE MINER RES, V12, P1606, DOI 10.1359/jbmr.1997.12.10.1606
   Haynesworth SE, 1996, J CELL PHYSIOL, V166, P585, DOI 10.1002/(SICI)1097 4652(199603)166:3<585::AID JCP13>3.0.CO;2 6
   Ho AWY, 2008, IMMUNOBIOLOGY, V213, P533, DOI 10.1016/j.imbio.2008.01.003
   Hoch AI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035579
   Hu N, 2013, J CELL SCI, V126, P532, DOI 10.1242/jcs.114231
   Hu YY, 2003, ENDOCRINOLOGY, V144, P2068, DOI 10.1210/en.2002 220863
   Hung SC, 2007, STEM CELLS, V25, P2363, DOI 10.1634/stemcells.2006 0686
   Jadlowiec J, 2004, J BIOL CHEM, V279, P53323, DOI 10.1074/jbc.M404934200
   Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645
   Jansen RG, 2009, J ORAL PATHOL MED, V38, P630, DOI 10.1111/j.1600 0714.2009.00763.x
   Jiang XQ, 2009, BIOMATERIALS, V30, P4522, DOI 10.1016/j.biomaterials.2009.05.021
   JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955 0674(94)90141 4
   Kim KI, 2014, BIOMATERIALS, V35, P4792, DOI 10.1016/j.biomaterials.2014.02.048
   Kim YJ, 2006, BIOCHEM PHARMACOL, V72, P1268, DOI 10.1016/j.bcp.2006.08.021
   Kinnaird T, 2004, CIRC RES, V94, P678, DOI 10.1161/01.RES.0000118601.37875.AC
   Ko J, 2007, EXP MOL MED, V39, P129, DOI 10.1038/emm.2007.15
   Krane SM, 2005, J EXP MED, V201, P841, DOI 10.1084/jem.20050354
   Kuhnau J, 1976, World Rev Nutr Diet, V24, P117
   Li ZH, 2014, INT J CLIN EXP MED, V7, P540
   Lin KL, 2013, BIOMATERIALS, V34, P10028, DOI 10.1016/j.biomaterials.2013.09.056
   Lin ZW, 2014, EXP THER MED, V7, P625, DOI 10.3892/etm.2013.1464
   Liu MM, 2017, J TISSUE ENG REGEN M, V11, P276, DOI 10.1002/term.1911
   MANIATOPOULOS C, 1988, CELL TISSUE RES, V254, P317
   Marrony S, 2003, BONE, V33, P426, DOI 10.1016/S8756 3282(03)00195 9
   Matsuoka F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055082
   Mayr Wohlfart U, 2002, BONE, V30, P472, DOI 10.1016/S8756 3282(01)00690 1
   Miles SL, 2014, NUTR REV, V72, P720, DOI 10.1111/nure.12152
   Murphy WL, 2000, BIOMATERIALS, V21, P2521, DOI 10.1016/S0142 9612(00)00120 4
   Neumann T, 2003, MICROVASC RES, V66, P59, DOI 10.1016/S0026 2862(03)00040 2
   Oh SJ, 2010, FOOD CHEM TOXICOL, V48, P3227, DOI 10.1016/j.fct.2010.08.028
   Peluso I, 2015, CRIT REV FOOD SCI, V55, P383, DOI 10.1080/10408398.2012.656770
   Peng HR, 2002, J CLIN INVEST, V110, P751, DOI 10.1172/JCI200215153
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Prouillet C, 2004, BIOCHEM PHARMACOL, V67, P1307, DOI 10.1016/j.bcp.2003.11.009
   Satue M, 2013, BIOCHEM PHARMACOL, V86, P1476, DOI 10.1016/j.bcp.2013.09.009
   Schmid J, 1997, CLIN ORAL IMPLAN RES, V8, P244, DOI 10.1034/j.1600 0501.1997.080311.x
   SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337
   Suehiro F, 2011, STEM CELLS DEV, V20, P1540, DOI 10.1089/scd.2010.0279
   Suzuki A, 2006, J BONE MINER RES, V21, P674, DOI 10.1359/JBMR.020603
   Tamama K, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/795385
   Taylor SC, 2013, MOL BIOTECHNOL, V55, P217, DOI 10.1007/s12033 013 9672 6
   Utesch D, 2008, MUTAT RES GEN TOX EN, V654, P38, DOI 10.1016/j.mrgentox.2008.04.008
   Wanachewin O, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472 6882 12 71
   Wang DS, 1997, ENDOCRINOLOGY, V138, P2953, DOI 10.1210/en.138.7.2953
   Wang XT, 2006, PLAST RECONSTR SURG, V117, P129, DOI 10.1097/01.prs.0000185609.07293.3e
   Wenger A, 2005, CELLS TISSUES ORGANS, V181, P80, DOI 10.1159/000091097
   Winet H, 1996, BONE, V19, pS39, DOI 10.1016/S8756 3282(96)00133 0
   Wu BY, 2000, J NEUROSCI RES, V62, P730, DOI 10.1002/1097 4547(20001201)62:5<730::AID JNR13>3.0.CO;2 K
   Wu YQ, 2015, CELL PROLIFERAT, V48, P375, DOI 10.1111/cpr.12185
   Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453
   ZEMANKOVA KUNZOVA H, 1949, Lek List, V4, P401
   Zeng Q, 2007, BONE, V40, P374, DOI 10.1016/j.bone.2006.09.022
   Zhai YK, 2014, INT J ENDOCRINOL, V2014, DOI 10.1155/2014/921954
   Zhang LF, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0099946, 10.1371/journal.pone.0084950]
   Zhang ZT, 2010, APOPTOSIS, V15, P105, DOI 10.1007/s10495 009 0425 8
   Zhao YF, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/637415
   Zhou C, 2014, CELL PROLIFERAT, V47, P124, DOI 10.1111/cpr.12097
NR 76
TC 104
Z9 108
U1 0
U2 50
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JUN 8
PY 2015
VL 10
IS 6
AR e0129605
DI 10.1371/journal.pone.0129605
PG 21
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CK1GM
UT WOS:000355955300152
PM 26053266
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Yakupoglu, HY
   Corsenca, A
   Wahl, P
   Wüthrich, RP
   Ambühl, PM
AF Yakupoglu, Haci Y.
   Corsenca, Alf
   Wahl, Patricia
   Wuethrich, Rudolf P.
   Ambuehl, Patrice M.
TI Posttransplant acidosis and associated disorders of mineral metabolism
   in patients with a renal graft
SO TRANSPLANTATION
LA English
DT Article
DE metabolic acidosis; transplantation; mineral metabolism; bone
ID CADAVER KIDNEY HOMOTRANSPLANTATION; TUBULAR ACIDOSIS; BONE RESORPTION;
   NET BALANCE; TRANSPLANTATION; CALCIUM; DISEASE; OSTEOCLASTS; MECHANISMS;
   EXCRETION
AB Background. Persisting disturbances in acid/base homeostasis may have an impact on several metabolic aspects of individuals with a kidney graft, specifically with regard to mineral metabolism and bone.
   Methods. We undertook a cross sectional analysis among 823 unselected patients being transplanted with a functioning renal allograft who had at least one measurement of venous serum bicarbonate available within a 4 year period before May 1, 2005. As a determinate of metabolic acidosis bicarbonate was measured along with serum calcium, phosphate, parathyroid hormone, and other routine serological and epidemiological parameters. Data were assessed according to quartiles of serum bicarbonate and by univariate analysis. A multivariate regression model examined the effects of potential predictors of acidosis.
   Results. Mean serum bicarbonate was 22.5 +/  4 mmol/L, with 58. 1% of the examined renal transplant patients having metabolic acidosis as defined by a venous bicarbonate of <24 mmol/L. Bicarbonatemia was highly associated with serum parathyroid hormone, phosphate, and calcium but also with renal graft function (determined as calculated glomerular filtration rate). Multiple stepwise regression analysis revealed age, glomerular filtration rate, parathyroid hormone, and albumin to be the strongest predictors of serum bicarbonate concentration. Therapy with any calcineurin inhibitor was not associated with an increased likelihood of acidosis (odds ratio 1.04), but a significant difference was found between cyclosporine A and tacrolimus, which had an attributed odds ratio for acidosis of 0.6 and 1.8, respectively.
   Conclusions. Metabolic acidosis is highly prevalent among an unselected cohort of renal transplant patients. A clear association exists between the severity of acidosis and disturbances of mineral metabolism. Thus, persisting acid/base disorders may accentuate bone disease in a setting with other factors predisposing for posuransplant osteopathy.
C1 Univ Zurich Hosp, Dept Nephrol, CH 8091 Zurich, Switzerland.
C3 University of Zurich; University Zurich Hospital
RP Ambühl, PM (通讯作者)，City Hosp Waid, Div Nephrol, Tiechestr 99, CH 8037 Zurich, Switzerland.
EM patrice.ambuehl@waid.zuerich.ch
CR Alpern RJ, 1997, AM J KIDNEY DIS, V29, P291, DOI 10.1016/S0272 6386(97)90045 7
   Ambühl PM, 2007, CURR OPIN NEPHROL HY, V16, P379
   Ambühl PM, 1999, AM J KIDNEY DIS, V34, P875, DOI 10.1016/S0272 6386(99)70045 4
   BAILEY RR, 1985, NEW ZEAL MED J, V98, P483
   BALLMER PE, 1995, J CLIN INVEST, V95, P39, DOI 10.1172/JCI117668
   BATTLE DC, 1981, AM J MED, V70, P786
   BETTER OS, 1970, LANCET, V1, P110
   BETTER OS, 1969, ANN INTERN MED, V71, P39, DOI 10.7326/0003 4819 71 1 39
   Domrongkitchaiporn S, 2001, KIDNEY INT, V59, P1086, DOI 10.1046/j.1523 1755.2001.0590031086.x
   GOODMAN AD, 1965, J CLIN INVEST, V44, P495, DOI 10.1172/JCI105163
   Graham KA, 1997, J AM SOC NEPHROL, V8, P627
   GYORY AZ, 1969, Q J MED, V38, P231
   Heering P, 1998, CLIN TRANSPLANT, V12, P465
   Hory B, 1997, CURR OPIN NEPHROL HY, V6, P40, DOI 10.1097/00041552 199701000 00008
   JAEGER P, 1987, EUR J CLIN INVEST, V17, P415, DOI 10.1111/j.1365 2362.1987.tb01136.x
   JULIAN BA, 1991, NEW ENGL J MED, V325, P544, DOI 10.1056/NEJM199108223250804
   Komarova SV, 2005, P NATL ACAD SCI USA, V102, P2643, DOI 10.1073/pnas.0406874102
   KRAUT JA, 1986, KIDNEY INT, V30, P694, DOI 10.1038/ki.1986.242
   LANGMAN CB, 1986, AM J PHYSIOL, V251, pF911, DOI 10.1152/ajprenal.1986.251.5.F911
   LEMANN J, 1966, J CLIN INVEST, V45, P1608, DOI 10.1172/JCI105467
   LEMANN J, 1965, J CLIN INVEST, V44, P507, DOI 10.1172/JCI105164
   LEMANN J, 1967, J CLIN INVEST, V46, P1318, DOI 10.1172/JCI105624
   Lemann J Jr, 2000, KIDNEY INT, V58, P1267, DOI 10.1046/j.1523 1755.2000.00282.x
   LITZOW JR, 1967, J CLIN INVEST, V46, P280, DOI 10.1172/JCI105530
   LU KC, 1994, NEPHRON, V67, P419, DOI 10.1159/000188015
   Massry S G, 1977, Adv Exp Med Biol, V81, P301
   MASSRY SG, 1967, AM J MED, V42, P284, DOI 10.1016/0002 9343(67)90026 5
   MAY RC, 1987, J CLIN INVEST, V79, P1099, DOI 10.1172/JCI112924
   Midtvedt K, 2004, J AM SOC NEPHROL, V15, P3233, DOI 10.1097/01.ASN.0000145435.80005.1E
   MOVSOWITZ C, 1990, J ORTHOP RES, V8, P635, DOI 10.1002/jor.1100080503
   MURRILLS RJ, 1993, J CELL PHYSIOL, V154, P511, DOI 10.1002/jcp.1041540309
   Oh MS, 2000, SEMIN DIALYSIS, V13, P212, DOI 10.1046/j.1525 139x.2000.00061.x
   Schwarz C, 2006, NEPHROL DIAL TRANSPL, V21, P2615, DOI 10.1093/ndt/gfl211
   SHERRARD DJ, 1993, KIDNEY INT, V43, P436, DOI 10.1038/ki.1993.64
   SHIBUTANI T, 1993, J BONE MINER RES, V8, P331
   Van Duijnhoven EM, 2002, J AM SOC NEPHROL, V13, P213, DOI 10.1681/ASN.V131213
   Work Group, 2003, AM J KIDNEY DIS, V42, pS1
   Ziegler R, 1998, STEROIDS, V63, P344, DOI 10.1016/S0039 128X(98)00022 1
NR 38
TC 43
Z9 46
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106 3621 USA
SN 0041 1337
J9 TRANSPLANTATION
JI Transplantation
PD NOV 15
PY 2007
VL 84
IS 9
BP 1151
EP 1157
DI 10.1097/01.tp.0000287430.19960.0e
PG 7
WC Immunology; Surgery; Transplantation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Surgery; Transplantation
GA 232PC
UT WOS:000251030600014
PM 17998871
OA Bronze
DA 2025 08 17
ER

PT J
AU Staehlke, S
   Bielfeldt, M
   Zimmermann, J
   Gruening, M
   Barke, I
   Freitag, T
   Speller, S
   Van Rienen, U
   Nebe, B
AF Staehlke, Susanne
   Bielfeldt, Meike
   Zimmermann, Julius
   Gruening, Martina
   Barke, Ingo
   Freitag, Thomas
   Speller, Sylvia
   Van Rienen, Ursula
   Nebe, Barbara
TI Pulsed Electrical Stimulation Affects Osteoblast Adhesion and Calcium
   Ion Signaling
SO CELLS
LA English
DT Article
DE electrical stimulation; electric field strength; field simulation;
   AC stimulated liquid; osteoblasts adhesion; spreading; calcium ions;
   reactive oxygen species; confocal microscopy; scanning electron
   microscopy
ID CELL ADHESION; OXIDATIVE STRESS; PROLIFERATION; BONE; LINES; FIELD;
   SCAFFOLD; MODELS; MG 63
AB An extensive research field in regenerative medicine is electrical stimulation (ES) and its impact on tissue and cells. The mechanism of action of ES, particularly the role of electrical parameters like intensity, frequency, and duration of the electric field, is not yet fully understood. Human MG 63 osteoblasts were electrically stimulated for 10 min with a commercially available multi channel system (IonOptix). We generated alternating current (AC) electrical fields with a voltage of 1 or 5 V and frequencies of 7.9 or 20 Hz, respectively. To exclude liquid mediated effects, we characterized the AC stimulated culture medium. AC stimulation did not change the medium's pH, temperature, and oxygen content. The H2O2 level was comparable with the unstimulated samples except at 5 V_7.9 Hz, where a significant increase in H2O2 was found within the first 30 min. Pulsed electrical stimulation was beneficial for the process of attachment and initial adhesion of suspended osteoblasts. At the same time, the intracellular Ca2+ level was enhanced and highest for 20 Hz stimulated cells with 1 and 5 V, respectively. In addition, increased Ca2+ mobilization after an additional trigger (ATP) was detected at these parameters. New knowledge was provided on why electrical stimulation contributes to cell activation in bone tissue regeneration.
C1 [Staehlke, Susanne; Bielfeldt, Meike; Gruening, Martina; Freitag, Thomas; Nebe, Barbara] Rostock Univ, Dept Cell Biol, Med Ctr, D 18057 Rostock, Germany.
   [Zimmermann, Julius; Van Rienen, Ursula] Univ Rostock, Inst Gen Elect Engn, Dept Comp Sci & Elect Engn, D 18059 Rostock, Germany.
   [Barke, Ingo; Speller, Sylvia] Univ Rostock, Inst Phys, Phys Surfaces & Interfaces, D 18059 Rostock, Germany.
   [Speller, Sylvia; Van Rienen, Ursula; Nebe, Barbara] Univ Rostock, Interdisciplinary Fac, Dept Life Light & Matter, D 18059 Rostock, Germany.
   [Van Rienen, Ursula] Univ Rostock, Interdisciplinary Fac, Dept Aging Individuals & Soc, D 18059 Rostock, Germany.
C3 University of Rostock; University of Rostock; University of Rostock;
   University of Rostock; University of Rostock
RP Staehlke, S (通讯作者)，Rostock Univ, Dept Cell Biol, Med Ctr, D 18057 Rostock, Germany.
EM susanne.staehlke@med.uni rostock.de
RI Barke, Ingo/H 2097 2013; Zimmermann, Julius/LUZ 8690 2024; Speller,
   Sylvia/C 2596 2009
OI Barke, Ingo/0000 0002 1717 570X; van Rienen, Ursula/0000 0003 1042 2058;
   Bielfeldt, Meike/0000 0003 4200 4934; Zimmermann,
   Julius/0000 0003 1486 0426; Speller, Sylvia/0009 0002 3463 0468;
   Stahlke, Susanne/0000 0002 0251 8263
FU Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) [SFB
   ELAINE, 1270/1,2 299150580]
FX This research was funded by the Deutsche Forschungsgemeinschaft (DFG,
   German Research Foundation), grant number SFB ELAINE, 1270/1,2 299150580
   (ELAINE).
CR Aaron RK, 2006, ANN NY ACAD SCI, V1068, P513, DOI 10.1196/annals.1346.045
   Aleem IS, 2016, SCI REP UK, V6, DOI 10.1038/srep31724
   Artun FT, 2021, BIOTECH HISTOCHEM, V96, P1, DOI 10.1080/10520295.2020.1751288
   Asadi MR, 2014, ADV WOUND CARE, V3, P91, DOI 10.1089/wound.2012.0410
   Bagne L, 2021, J BIOMED MATER RES B, V109, P2104, DOI 10.1002/jbm.b.34858
   Balint R, 2013, TISSUE ENG PART B RE, V19, P48, DOI [10.1089/ten.teb.2012.0183, 10.1089/ten.TEB.2012.0183]
   BASSETT CAL, 1962, SCIENCE, V137, P1063, DOI 10.1126/science.137.3535.1063
   Bergemann C, 2020, APPL SCI BASEL, V10, DOI 10.3390/app10155024
   Bhavsar MB, 2019, PEERJ, V7, DOI 10.7717/peerj.6341
   Bodhak S, 2012, MAT SCI ENG C MATER, V32, P2163, DOI 10.1016/j.msec.2012.05.032
   Brighton CT, 2001, J BONE JOINT SURG AM, V83A, P1514, DOI 10.2106/00004623 200110000 00009
   Budde K, 2019, IEEE ENG MED BIO, P1082, DOI [10.1109/EMBC.2019.8856863, 10.1109/embc.2019.8856863]
   Bydak B, 2022, MEMBRANES BASEL, V12, DOI 10.3390/membranes12050464
   Chen C, 2019, BIOMATER RES, V23, DOI 10.1186/s40824 019 0176 8
   Chen XP, 2010, FREE RADICAL RES, V44, P587, DOI 10.3109/10715761003709802
   CLOVER J, 1994, BONE, V15, P585, DOI 10.1016/8756 3282(94)90305 0
   Contu F, 2002, J BIOMED MATER RES, V62, P412, DOI 10.1002/jbm.10329
   Czekanska EM, 2014, J BIOMED MATER RES A, V102, P2636, DOI 10.1002/jbm.a.34937
   Dauben TJ, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/5178640
   Díaz Vegas A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129882
   Dröge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001
   Dubey AK, 2011, J BIOMED MATER RES B, V98B, P18, DOI 10.1002/jbm.b.31827
   DUNN OJ, 1964, TECHNOMETRICS, V6, P241, DOI 10.2307/1266041
   Ercan B, 2010, BIOMATERIALS, V31, P3684, DOI 10.1016/j.biomaterials.2010.01.078
   Ercan B, 2008, INT J NANOMED, V3, P477
   FUKADA E, 1957, J PHYS SOC JPN, V12, P1158, DOI 10.1143/JPSJ.12.1158
   Ghiasi Mohammad S, 2017, Bone Rep, V6, P87, DOI 10.1016/j.bonr.2017.03.002
   Görlach A, 2015, REDOX BIOL, V6, P260, DOI 10.1016/j.redox.2015.08.010
   Griffin Michelle, 2011, Eplasty, V11, pe34
   Gruening M, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.01016
   Haglin JM, 2017, JBJS REV, V5, DOI 10.2106/JBJS.RVW.16.00117
   Hoentsch M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104559
   Jin G, 2015, J BIOMED MATER RES B, V103, P935, DOI 10.1002/jbm.b.33268
   Katoh K, 2022, LIFE BASEL, V12, DOI 10.3390/life12040531
   Khatib L, 2004, FASEB J, V18, P1903, DOI 10.1096/fj.04 1814fje
   Khitrin AK, 2014, CHEM PHYS LIPIDS, V184, P76, DOI 10.1016/j.chemphyslip.2014.10.005
   Kirson ED, 2007, P NATL ACAD SCI USA, V104, P10152, DOI 10.1073/pnas.0702916104
   Kloth LC, 2014, ADV WOUND CARE, V3, P81, DOI 10.1089/wound.2013.0459
   Kumar A, 2016, J BIOMATER APPL, V31, P594, DOI 10.1177/0885328216658376
   Leppik L, 2020, EUR J TRAUMA EMERG S, V46, P231, DOI 10.1007/s00068 020 01324 1
   Li YM, 2017, MAT SCI ENG C MATER, V72, P106, DOI 10.1016/j.msec.2016.11.052
   Love MR, 2018, J CELL PHYSIOL, V233, P1860, DOI 10.1002/jcp.25975
   Manolagas SC, 2007, MOL ENDOCRINOL, V21, P2605, DOI 10.1210/me.2007 0259
   Massari L, 2019, INT ORTHOP, V43, P539, DOI 10.1007/s00264 018 4274 3
   Meng S., 2011, Appl. Biomed. Eng., IntechOpen, Rijeka, DOI [10.5772/18874, DOI 10.5772/18874]
   Nicksic PJ, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.793945
   O'Hearn Sean F, 2016, Biochem Biophys Rep, V8, P249, DOI 10.1016/j.bbrep.2016.09.004
   Pangalos M, 2011, J BIOENERG BIOMEMBR, V43, P311, DOI 10.1007/s10863 011 9354 7
   Pautke C, 2004, ANTICANCER RES, V24, P3743
   Pettersen E, 2022, J NEUROENG REHABIL, V19, DOI 10.1186/s12984 022 01005 7
   Rebl H, 2016, MAT SCI ENG C MATER, V69, P1116, DOI 10.1016/j.msec.2016.08.016
   Reissis Y, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt350
   Sahm F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186944
   Schröder M, 2022, J BIOMED SEMANT, V13, DOI 10.1186/s13326 021 00257 x
   Sies H, 2017, REDOX BIOL, V11, P613, DOI 10.1016/j.redox.2016.12.035
   Sjaastad MD, 1997, BIOESSAYS, V19, P47, DOI 10.1002/bies.950190109
   Snezhkina AV, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/6175804
   Srirussamee K, 2019, BIOTECHNOL BIOENG, V116, P3421, DOI 10.1002/bit.27142
   Staehlke S, 2022, MATERIALS, V15, DOI 10.3390/ma15030732
   Staehlke Susanne, 2021, Zenodo, DOI 10.5281/ZENODO.4923173
   Staehlke S, 2019, CELL BIOL INT, V43, P22, DOI 10.1002/cbin.11073
   Staehlke S, 2015, BIOMATERIALS, V46, P48, DOI 10.1016/j.biomaterials.2014.12.016
   Stephan M, 2020, CELLS BASEL, V9, DOI 10.3390/cells9091995
   Strong AD, 2017, BMC CANCER, V17, DOI 10.1186/s12885 017 3507 y
   Sun S, 2007, FASEB J, V21, P1472, DOI 10.1096/fj.06 7153com
   Sun S, 2006, BIOELECTROCHEMISTRY, V69, P133, DOI 10.1016/j.bioelechem.2005.11.007
   Taghian T, 2015, J R SOC INTERFACE, V12, DOI 10.1098/rsif.2015.0153
   Tandon N, 2006, 2006 28TH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY, VOLS 1 15, P6409
   Thannickal VJ, 2000, AM J PHYSIOL LUNG C, V279, pL1005
   Thrivikraman G, 2018, BIOMATERIALS, V150, P60, DOI 10.1016/j.biomaterials.2017.10.003
   Verma N, 2021, ARCH TOXICOL, V95, P2007, DOI 10.1007/s00204 021 03032 0
   Wu SY, 2015, BIOMICROFLUIDICS, V9, DOI 10.1063/1.4932662
   Zhou P, 2018, BIOELECTROCHEMISTRY, V124, P7, DOI 10.1016/j.bioelechem.2018.06.009
   Zimmermann J, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.765516
NR 74
TC 24
Z9 24
U1 6
U2 46
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4409
J9 CELLS BASEL
JI Cells
PD SEP
PY 2022
VL 11
IS 17
AR 2650
DI 10.3390/cells11172650
PG 22
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 4J1VE
UT WOS:000851057500001
PM 36078058
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Gu, YQ
   Fan, WM
   Yin, GY
AF Gu, Yanqing
   Fan, Weimin
   Yin, Guoyong
TI The Study of Mechanisms of Protective Effect of Rg1 against Arthritis by
   Inhibiting Osteoclast Differentiation and Maturation in CIA Mice
SO MEDIATORS OF INFLAMMATION
LA English
DT Article
ID NF KAPPA B; COLLAGEN INDUCED ARTHRITIS; ACTIVATED PROTEIN KINASE;
   GINSENOSIDE RG1; RHEUMATOID ARTHRITIS; NUCLEAR FACTOR; IN VITRO;
   RECEPTOR ACTIVATOR; CELLS; BONE
AB Ginsenoside Rg1 is a natural product extracted from Panax ginseng C. A. Although Rg1 protects tissue structure and functions by inhibiting local inflammatory reaction, the mechanism remains poorly understood. In vitro, Rg1 dose dependently inhibited TRAP activity in receptor activator of nuclear factor kappa B ligand  (RANKL ) induced osteoclasts and decreased the number of osteoclasts and osteoclast resorption area. Rg1 also significantly inhibited the RANK signaling pathway, including suppressing the expression of Trap, cathepsin K, matrix metalloproteinase 9 (MMP9), and calcitonin receptor (CTR). In vivo, Rg1 dramatically decreased arthritis scores in CIA mice and effectively controlled symptoms of inflammatory arthritis. Pathologic analysis demonstrated that Rg1 significantly attenuated pathological changes in CIA mice. Pronounced reduction in synovial hyperplasia and inflammatory cell invasion were observed in CIA mice after Rg1 therapy. Alcian blue staining results illustrated that mice treated with Rg1 had significantly reduced destruction in the articular cartilage. TRAP and cathepsin K staining results demonstrated a significant reduction of numbers of OCs in the articular cartilage in proximal interphalangeal joints and ankle joints in Rg1 treated mice. In summary, this study revealed that Rg1 reduced the inflammatory destruction of periarticular bone by inhibiting differentiation and maturation of osteoclasts in CIA mice.
C1 [Gu, Yanqing; Fan, Weimin; Yin, Guoyong] Nanjing Med Univ, Affiliated Hosp 1, Dept Orthoped, Nanjing 210000, Jiangsu, Peoples R China.
C3 Nanjing Medical University
RP Gu, YQ (通讯作者)，Nanjing Med Univ, Affiliated Hosp 1, Dept Orthoped, 300 Guang Zhou Rd, Nanjing 210000, Jiangsu, Peoples R China.
EM guoyong_yin2005nanjing@yahoo.com
FU National Natural and Science Foundation of China [81271988]; Jiangsu
   Natural and Science Foundation [BK2012876]; National Nature Science
   Foundation of China [81271986]; Nature Science Foundation of Jiangsu
   Province [BK2011843]
FX This work was supported by National Natural and Science Foundation of
   China (81271988), Jiangsu Natural and Science Foundation (BK2012876),
   National Nature Science Foundation of China (Grant no. 81271986), and
   Nature Science Foundation of Jiangsu Province (Grant no. BK2011843).
CR Ang E, 2011, J CELL BIOCHEM, V112, P89, DOI 10.1002/jcb.22800
   Anusaksathien O, 2001, J BIOL CHEM, V276, P22663, DOI 10.1074/jbc.M007104200
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Broadhead ML, 2011, EXPERT OPIN THER TAR, V15, P169, DOI 10.1517/14728222.2011.546351
   BROMLEY M, 1984, ARTHRITIS RHEUM US, V27, P857, DOI 10.1002/art.1780270804
   Chan RYK, 2002, J CLIN ENDOCR METAB, V87, P3691, DOI 10.1210/jc.87.8.3691
   Chang SH, 2007, CLIN NUTR, V26, P785, DOI 10.1016/j.clnu.2007.07.008
   Chen FJ, 2014, J CELL BIOCHEM, V115, P651, DOI 10.1002/jcb.24700
   Choi HJ, 2010, EUR J PHARMACOL, V636, P28, DOI 10.1016/j.ejphar.2010.03.023
   Choi YS, 2013, RHEUMATOL INT, V33, P1981, DOI 10.1007/s00296 013 2664 9
   Cohen S. B., 2006, ARTHRITIS RHEUMATOLO, V54
   Du J, 2011, J IMMUNOL, V187, P942, DOI 10.4049/jimmunol.1002579
   Hirayama T, 2002, RHEUMATOLOGY, V41, P1232, DOI 10.1093/rheumatology/41.11.1232
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Ishii M, 2009, NATURE, V458, P524, DOI 10.1038/nature07713
   Jia Lin, 2010, Zhong Xi Yi Jie He Xue Bao, V8, P358, DOI [10.3736/jcim201090410, 10.3736/jcim20100410]
   Jimi E, 1996, ENDOCRINOLOGY, V137, P2187
   Kaji H, 1997, J BONE MINER RES, V12, P734, DOI 10.1359/jbmr.1997.12.5.734
   Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279
   Karmakar S, 2010, RHEUM DIS CLIN N AM, V36, P385, DOI 10.1016/j.rdc.2010.03.003
   Kim HA, 2007, INT IMMUNOPHARMACOL, V7, P1286, DOI 10.1016/j.intimp.2007.05.006
   Kim HJ, 2007, MOL PHARMACOL, V72, P418, DOI 10.1124/mol.107.034173
   Kim YJ, 2005, J BIOL CHEM, V280, P21515, DOI 10.1074/jbc.M502230200
   King TJ, 2012, AM J PATHOL, V181, P121, DOI 10.1016/j.ajpath.2012.03.037
   Lee YJ, 1997, MOL CELL ENDOCRINOL, V133, P135, DOI 10.1016/S0303 7207(97)00160 3
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Liu P, 2006, TOXICOL IN VITRO, V20, P234, DOI 10.1016/j.tiv.2005.06.029
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Monje P, 2005, J BIOL CHEM, V280, P35081, DOI 10.1074/jbc.C500353200
   Motyckova G, 2001, P NATL ACAD SCI USA, V98, P5798, DOI 10.1073/pnas.091479298
   Ngian GS, 2010, AUST FAM PHYSICIAN, V39, P626
   Novack DV, 2011, CELL RES, V21, P169, DOI 10.1038/cr.2010.159
   Okamoto K, 2011, INT IMMUNOPHARMACOL, V11, P543, DOI 10.1016/j.intimp.2010.11.010
   Peng LH, 2010, J ETHNOPHARMACOL, V131, P282, DOI 10.1016/j.jep.2010.06.039
   Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002 9440(10)63016 7
   Radad K, 2004, BRAIN RES, V1021, P41, DOI 10.1016/j.brainres.2004.06.030
   REDDY SV, 1995, J BONE MINER RES, V10, P601
   Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582
   Rhule A, 2008, J ETHNOPHARMACOL, V116, P179, DOI 10.1016/j.jep.2007.11.019
   Schett G, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2110
   Shen Y, 2010, J NAT MED TOKYO, V64, P336, DOI 10.1007/s11418 010 0416 7
   Silman AJ, 2002, ARTHRITIS RES THER, V4, pS265, DOI 10.1186/ar578
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Sun K, 2007, LIFE SCI, V81, P509, DOI 10.1016/j.lfs.2007.06.008
   Suzuki Y, 2001, RHEUMATOLOGY, V40, P673, DOI 10.1093/rheumatology/40.6.673
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Wu CF, 2007, INT IMMUNOPHARMACOL, V7, P313, DOI 10.1016/j.intimp.2006.04.021
NR 50
TC 18
Z9 19
U1 0
U2 13
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 0962 9351
EI 1466 1861
J9 MEDIAT INFLAMM
JI Mediat. Inflamm.
PY 2014
VL 2014
AR 305071
DI 10.1155/2014/305071
PG 14
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Immunology
GA AQ6RK
UT WOS:000342941300001
PM 25214714
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Pazianas, M
   Compston, J
   Huang, CLH
AF Pazianas, Michael
   Compston, Juliet
   Huang, Christopher L H
TI Atrial Fibrillation and Bisphosphonate Therapy
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE BISPHOSPHONATES; ATRIAL FIBRILLATION; CALCIUM; MAGNESIUM; ZINC;
   METALLOPROTEINASES; INFLAMMATION, STATINS
ID STERILE PERICARDITIS MODEL; CARDIAC SURGERY; ZOLEDRONIC ACID; IN VITRO;
   ORAL BISPHOSPHONATES; MEVALONATE PATHWAY; BREAST CARCINOMA;
   CONTROLLED TRIAL; VALVE SURGERY; DOUBLE BLIND
AB Bisphosphonates are the most commonly used treatment for osteoporosis and have proven efficacy in the reduction of vertebral and nonvertebral fractures. Recently, concerns have been raised about a possible association between bisphosphonate therapy and atrial fibrillation (AF) following the report of a significant increase in risk of serious AF in women treated with zoledronic acid in the HORIZON study. Subsequent studies have produced conflicting results but have not excluded the possibility of such an association. Currently there is no direct evidence that bisphosphonates exert either acute or chronic effects on cardiac electrophysiology. Nevertheless, altered intracellular electrolyte homeostasis and proinflammatory, profibrotic, and antiangiogenic effects provide potential mechanisms by which atrial conduction could be affected in patients treated with bisphosphonates. In studies in which an increase in risk of AF has been identified, there is no evidence that this translates into increased mortality or increased risk of stroke, and the risk benefit balance of bisphosphonate therapy in patients with osteoporosis and other forms of metabolic bone disease remains strongly positive. (C) 2010 American Society for Bone and Mineral Research.
C1 [Pazianas, Michael] Univ Oxford, Inst Musculoskeletal Sci, Oxford OX3 7LD, England.
   [Compston, Juliet] Univ Cambridge, Sch Clin Med, Dept Med, Cambridge CB2 0QQ, England.
   [Huang, Christopher L H] Univ Cambridge, Physiol Lab, Cambridge CB2 3EG, England.
C3 University of Oxford; University of Cambridge; University of Cambridge
RP Pazianas, M (通讯作者)，Univ Oxford, Inst Musculoskeletal Sci, Oxford OX3 7LD, England.
EM Michael.Pazianas@ndorms.ox.ac.uk
RI Pazianas, Michael/ABE 4572 2020
FU Cambridge Biomedical Research Centre; National Institutes for Health
   Research (NHIR); Wellcome Trust; Medical Research Council; British Heart
   Foundation
FX The authors are grateful to Helene Mellor for the illustration services.
   JEC acknowledges support from the Cambridge Biomedical Research Centre
   and the National Institutes for Health Research (NHIR). CLH acknowledges
   support from the Wellcome Trust, the Medical Research Council, and the
   British Heart Foundation.
CR Abdelhadi RH, 2004, AM J CARDIOL, V93, P1176, DOI 10.1016/j.amjcard.2004.01.053
   Abrahamsen B, 2009, J INTERN MED, V265, P581, DOI 10.1111/j.1365 2796.2008.02065.x
   ALBERTS AW, 1980, P NATL ACAD SCI BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957
   Ashikaga H, 2009, HEART, V95, P693, DOI 10.1136/hrt.2008.160713
   Aviles RJ, 2003, CIRCULATION, V108, P3006, DOI 10.1161/01.CIR.0000103131.70301.4F
   Beharier O, 2007, CELL CALCIUM, V42, P71, DOI 10.1016/j.ceca.2006.11.007
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Boissier S, 1997, CANCER RES, V57, P3890
   Boos CJ, 2008, HEART, V94, P133, DOI 10.1136/hrt.2007.119651
   Boos CJ, 2006, EUR HEART J, V27, P136, DOI 10.1093/eurheartj/ehi645
   Chen CL, 2008, J MOL CELL CARDIOL, V45, P742, DOI 10.1016/j.yjmcc.2008.07.007
   Christiansen CF, 2009, ARCH INTERN MED, V169, P1677, DOI 10.1001/archinternmed.2009.297
   Colucci S, 1998, CALCIFIED TISSUE INT, V63, P230, DOI 10.1007/s002239900519
   Corradi D, 2005, HUM PATHOL, V36, P1080, DOI 10.1016/j.humpath.2005.07.018
   Corradi D, 2004, VIRCHOWS ARCH, V445, P498, DOI 10.1007/s00428 004 1040 2
   Corradi D, 2008, NAT CLIN PRACT CARD, V5, P782, DOI 10.1038/ncpcardio1370
   Cummings SR, 2007, NEW ENGL J MED, V356, P1895, DOI 10.1056/NEJMc076132
   Dernellis J, 2004, EUR HEART J, V25, P1100, DOI 10.1016/j.ehj.2004.04.025
   Dhein S, 2008, N S ARCH PHARMACOL, V377, P125, DOI 10.1007/s00210 008 0265 z
   Dobrev D, 2008, J CARDIOVASC PHARM, V52, P293, DOI 10.1097/FJC.0b013e318171924d
   Dupont E, 2001, CIRCULATION, V103, P842, DOI 10.1161/01.CIR.103.6.842
   *FDA, FDA SAF INF ADV EV R
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Fournier P, 2002, CANCER RES, V62, P6538
   Frustaci A, 1997, CIRCULATION, V96, P1180, DOI 10.1161/01.CIR.96.4.1180
   Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087
   Go AS, 2001, JAMA J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370
   Goldstein RN, 2008, J CARDIOVASC ELECTR, V19, P74, DOI 10.1111/j.1540 8167.2007.00970.x
   Gollob MH, 2006, CURR OPIN CARDIOL, V21, P155, DOI 10.1097/01.hco.0000221574.95383.6f
   Grosso A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004720
   Halonen J, 2007, JAMA J AM MED ASSOC, V297, P1562, DOI 10.1001/jama.297.14.1562
   Hamma Kourbali Y, 2003, BIOCHEM BIOPH RES CO, V310, P816, DOI 10.1016/j.bbrc.2003.09.083
   Heckbert SR, 2008, ARCH INTERN MED, V168, P826, DOI 10.1001/archinte.168.8.826
   Heeringa J, 2006, EUR HEART J, V27, P949, DOI 10.1093/eurheartj/ehi825
   Hewitt RE, 2005, CLIN EXP IMMUNOL, V139, P101, DOI 10.1111/j.1365 2249.2005.02665.x
   Hirose M, 2007, AM J PHYSIOL HEART C, V292, pH1861, DOI 10.1152/ajpheart.00826.2006
   Ho KM, 2007, HEART, V93, P1433, DOI 10.1136/hrt.2006.111492
   Hove Madsen L, 2004, CIRCULATION, V110, P1358, DOI 10.1161/01.CIR.0000141296.59876.87
   Kannel WB, 2008, MED CLIN N AM, V92, P17, DOI 10.1016/j.mcna.2007.09.002
   Karam R, 2007, NEW ENGL J MED, V357, P712
   Kemeny Suss N, 2009, VASC PHARMACOL, V51, P350, DOI 10.1016/j.vph.2009.09.002
   Kostin S, 2002, CARDIOVASC RES, V54, P361, DOI 10.1016/S0008 6363(02)00273 0
   Kumagai K, 2004, CARDIOVASC RES, V62, P105, DOI 10.1016/j.cardiores.2004.01.018
   Lertsburapa K, 2008, J THORAC CARDIOV SUR, V135, P405, DOI 10.1016/j.jtcvs.2007.08.049
   Loke YK, 2009, DRUG SAFETY, V32, P219, DOI 10.2165/00002018 200932030 00004
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941
   Mak A, 2009, BMC MUSCULOSKEL DIS, V10, DOI 10.1186/1471 2474 10 113
   Marín F, 2006, AM J CARDIOL, V97, P55, DOI 10.1016/j.amjcard.2005.07.124
   Mathew JP, 2004, JAMA J AM MED ASSOC, V291, P1720, DOI 10.1001/jama.291.14.1720
   Miller S, 2005, HEART, V91, P618, DOI 10.1136/hrt.2004.033811
   MONKKONEN J, 1991, PHARMACOL TOXICOL, V68, P284
   Nakano Y, 2004, J AM COLL CARDIOL, V43, P818, DOI 10.1016/j.jacc.2003.08.060
   PASPALIARIS V, 1991, J BONE MINER RES, V6, P835
   Pellegrini CN, 2009, HEART, V95, P704, DOI 10.1136/hrt.2008.154054
   Polontchouk L, 2001, J AM COLL CARDIOL, V38, P883, DOI 10.1016/S0735 1097(01)01443 7
   Rogers MJ, 2000, NAT MED, V6, P21, DOI 10.1038/71484
   Rosen LS, 2003, CANCER AM CANCER SOC, V98, P1735, DOI 10.1002/cncr.11701
   RUDE RK, 2006, PRIMER METABOLIC BON, P230
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Savelieva I, 2008, NAT CLIN PRACT CARD, V5, P30, DOI 10.1038/ncpcardio1038
   Sebbah Louriki M, 2002, ANTICANCER RES, V22, P3925
   Severs NJ, 2004, CARDIOVASC RES, V62, P368, DOI 10.1016/j.cardiores.2003.12.007
   Shiroshita Takeshita A, 2006, CARDIOVASC RES, V69, P865, DOI 10.1016/j.cardiores.2005.11.028
   Shiroshita Takeshita A, 2004, CIRCULATION, V110, P2313, DOI 10.1161/01.CIR.0000145163.56529.D1
   Sinno H, 2003, CIRCULATION, V107, P1930, DOI 10.1161/01.CIR.0000058743.15215.03
   Skalidis EI, 2008, J AM COLL CARDIOL, V51, P2053, DOI 10.1016/j.jacc.2008.01.055
   Sorensen HT, 2008, BMJ BRIT MED J, V336, P813, DOI 10.1136/bmj.39507.551644.BE
   Tankó LB, 2005, J BONE MINER RES, V20, P1912, DOI 10.1359/JBMR.050711
   Teronen O, 1999, ANN NY ACAD SCI, V878, P453, DOI 10.1111/j.1749 6632.1999.tb07702.x
   Van Wagoner DR, 2000, J MOL CELL CARDIOL, V32, P1101, DOI 10.1006/jmcc.2000.1147
   Virani SS, 2008, AM HEART J, V155, P541, DOI 10.1016/j.ahj.2007.10.027
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
   Yared JP, 2007, J CARDIOTHOR VASC AN, V21, P68, DOI 10.1053/j.jvca.2005.10.014
   Zandbergen HR, 2009, J CARDIOVASC PHARM T, V14, P68, DOI 10.1177/1074248408329860
   Zhang YM, 2009, CLIN EXP PHARMACOL P, V36, P969, DOI 10.1111/j.1440 1681.2009.05170.x
   2006, DRUG TOPICS TOP 200
   2008, PHVWP ASSESSMENT REP
NR 78
TC 63
Z9 65
U1 2
U2 6
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0884 0431
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JAN
PY 2010
VL 25
IS 1
BP 2
EP 10
DI 10.1359/jbmr.091201
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 555NC
UT WOS:000274517600002
PM 20091928
OA Bronze
DA 2025 08 17
ER

PT J
AU Wang, JL
   Ding, HR
   Zhou, JC
   Xia, SZ
   Shi, XL
   Ren, HZ
AF Wang, Jinglin
   Ding, Haoran
   Zhou, Jingchao
   Xia, Senzhe
   Shi, Xiaolei
   Ren, Haozhen
TI Transplantation of Mesenchymal Stem Cells Attenuates Acute Liver Failure
   in Mice via an Interleukin 4 dependent Switch to the M2 Macrophage
   Anti inflammatory Phenotype
SO JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY
LA English
DT Article
DE Acute liver failure; Mesenchymal stem cells; Interleukin 4; Macrophage;
   Wnt signaling pathway
ID THERAPY
AB Background and Aims: Transplantation of mesenchymal stem cells (MSCs) derived from bone marrow (BM) is an alternative treatment of acute liver failure (ALF) mainly because of the resulting anti inflammatory activity. It is not known how MSCs regulate local immune responses and liver regeneration. This study explored the effects of MSCs on hepatic macrophages and the Wnt signaling pathway in ALF. Methods: MSCs were isolated from BM aspirates of C57BL/6J mice, and transplanted in mice with ALF induced by D galactosamine (D Gal). The proliferation of hepatocytes was assayed by immunohistochemical (IHC) staining of Ki 67 and proliferating cell nuclear antigen (PCNA). The levels of key proteins in the Wnt signaling pathway were assayed by western blotting and cytokines were determined enzyme linked immunosorbent assays (ELISAs). A macrophage polarization assay characterized the M1/M2 ratio. The potential role of interleukin 4 (IL 4) in the biological activity of MSCs was determined by silencing of IL 4. Results: Transplantation of allogeneic MSCs significantly attenuated D Gal induced hepatic inflammation and promoted liver regeneration. MSC transplantation significantly promoted a phenotypic switch from proinflamatory M1 macrophages to anti inflammatory M2 macrophages, leading to significant Wnt 3a induction and activation of the Wnt signaling pathway in mice with D Gal induced ALF. Of the paracrine factors secreted by MSCs (G CSF, IL 6, IL 1 beta, IL 4, and IL17A), IL 4 was specifically induced following transplantation in the ALF model mice. The silencing of IL 4 significantly abrogated the phenotypic switch to M2 macrophages and the protective effects of MSCs in both the ALF model mice and a co culture model in an IL 4 dependent manner. Conclusions: In vivo and in vitro studies showed that MSCs ameliorated ALF through an IL 4 dependent macrophage switch toward the M2 anti inflammatory phenotype. The findings may have clinical implications in that overexpression of IL 4 may enhance the therapeutic effects of allogeneic MSC transplantation in the treatment of ALF.
C1 [Wang, Jinglin; Ding, Haoran; Zhou, Jingchao; Shi, Xiaolei; Ren, Haozhen] Nanjing Univ Chinese Med, Nanjing Drum Tower Hosp, Clin Coll Tradit Chinese & Western Med, 321 Zhongshan Rd, Nanjing 210008, Jiangsu, Peoples R China.
   [Wang, Jinglin; Ding, Haoran; Zhou, Jingchao; Shi, Xiaolei; Ren, Haozhen] Nanjing Univ, Dept Hepatobiliary Surg, Affiliated Drum Tower Hosp, Med Sch, Nanjing, Jiangsu, Peoples R China.
   [Wang, Jinglin; Ding, Haoran; Zhou, Jingchao; Shi, Xiaolei; Ren, Haozhen] Nanjing Med Univ, Nanjing Drum Tower Hosp, Clin Coll, Dept Hepatobiliary Surg, Nanjing, Jiangsu, Peoples R China.
   [Xia, Senzhe] Jiangsu Univ, Nanjing Drum Tower Hosp, Clin Coll, Dept Hepatobiliary Surg, Nanjing, Jiangsu, Peoples R China.
C3 Nanjing University; Nanjing University of Chinese Medicine; Nanjing
   University; Nanjing Medical University; Nanjing University; Nanjing
   University; Jiangsu University
RP Shi, XL; Ren, HZ (通讯作者)，Nanjing Univ Chinese Med, Nanjing Drum Tower Hosp, Clin Coll Tradit Chinese & Western Med, 321 Zhongshan Rd, Nanjing 210008, Jiangsu, Peoples R China.
EM sxl@nju.edu.cn; renhaozhen1984@163.com
RI Ren, Haozhen/HOA 6027 2023
FU National Natural Science Foundation of China [81872359]; Jiangsu
   Provincial key research and development [BE2020752]; Natural Science
   Foundation of Jiangsu Province [BK20190114]; Nanjing Medical Science and
   Technique Development Foundation [QRX17129]; Medical Science and
   technology development Foundation, Nanjing Department of Health
   [JQX19002, YKK19070]; Nanjing Science and technology project
   [201911039]; Fundamental Research Funds for the Central Universities
   [0214YG1312037]; Project of Modern Hospital Management and Development
   Institute, Nanjing University and Aid project of Nanjing Drum Tower
   Hospital Health, Education & Research Foundation [NDYG2020047]
FX This work was funded by the National Natural Science Foundation of China
   (81872359), Jiangsu Provincial key research and development (BE2020752),
   the Natural Science Foundation of Jiangsu Province (BK20190114), the
   Nanjing Medical Science and Technique Development Foundation (QRX17129),
   Key Project supported by Medical Science and technology development
   Foundation, Nanjing Department of Health (JQX19002, YKK19070), the
   Nanjing Science and technology project (201911039), the Fundamental
   Research Funds for the Central Universities (0214YG1312037), Project of
   Modern Hospital Management and Development Institute, Nanjing University
   and Aid project of Nanjing Drum Tower Hospital Health, Education &
   Research Foundation (NDYG2020047).
CR Alfaifi M, 2018, J HEPATOL, V68, P1272, DOI 10.1016/j.jhep.2018.01.030
   Amiri Fatemeh, 2016, Iranian Biomedical Journal, V20, P135, DOI 10.7508/ibj.2016.03.002
   Chen Y, 2005, TRANSPLANTATION, V79, P1378, DOI 10.1097/01.TP.0000160813.37515.97
   Forbes SJ, 2015, J HEPATOL, V62, pS157, DOI 10.1016/j.jhep.2015.02.040
   Galipeau J, 2018, CELL STEM CELL, V22, P824, DOI 10.1016/j.stem.2018.05.004
   Higashimoto M, 2013, EUR J IMMUNOL, V43, P2956, DOI 10.1002/eji.201343531
   Kegel V, 2016, JOVE J VIS EXP, DOI 10.3791/53069
   Lee CW, 2018, GASTROENTEROLOGY, V154, P46, DOI 10.1053/j.gastro.2017.09.049
   Lee KC, 2015, J HEPATOL, V63, P1405, DOI 10.1016/j.jhep.2015.07.035
   Michalopoulos GK, 2021, NAT REV GASTRO HEPAT, V18, P40, DOI 10.1038/s41575 020 0342 4
   Perugorria MJ, 2019, NAT REV GASTRO HEPAT, V16, P121, DOI 10.1038/s41575 018 0075 9
   Russell JO, 2018, ANNU REV PATHOL MECH, V13, P351, DOI 10.1146/annurev pathol 020117 044010
   Sala E, 2015, GASTROENTEROLOGY, V149, P163, DOI 10.1053/j.gastro.2015.03.013
   Schunk SJ, 2021, NAT REV NEPHROL, V17, P172, DOI 10.1038/s41581 020 00343 w
   Shi DY, 2017, GUT, V66, P955, DOI 10.1136/gutjnl 2015 311146
   Sun LH, 2014, INT J MOL MED, V34, P987, DOI 10.3892/ijmm.2014.1890
   Yin ZL, 2018, MOL CANCER, V17, DOI 10.1186/s12943 018 0926 6
   Ylöstalo JH, 2012, STEM CELLS, V30, P2283, DOI 10.1002/stem.1191
   Zhao LD, 2019, HEPATOLOGY, V69, P2623, DOI 10.1002/hep.30563
NR 19
TC 13
Z9 16
U1 0
U2 8
PU XIA & HE PUBLISHING INC
PI SUGAR LAND
PA SECOND AFFILIATED HOSP CHONGQING MEDICAL UNIV, 14090 SOUTHWEST FREEWAY,
   STE 300, SUGAR LAND, TX 77478 USA
SN 2225 0719
EI 2310 8819
J9 J CLIN TRANSL HEPATO
JI J. Clin. Transl. Hepatol.
PD JUL AUG
PY 2022
VL 10
IS 4
BP 669
EP 679
DI 10.14218/JCTH.2021.00127
EA JAN 2022
PG 11
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Gastroenterology & Hepatology
GA 4L6OK
UT WOS:000792949800001
PM 36062289
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU De Schutter, JW
   Park, J
   Leung, CY
   Gormley, P
   Lin, YS
   Hu, ZP
   Berghuis, AM
   Poirier, J
   Tsantrizos, YS
AF De Schutter, Joris W.
   Park, Jaeok
   Leung, Chun Yuen
   Gormley, Patrick
   Lin, Yih Shyan
   Hu, Zheping
   Berghuis, Albert M.
   Poirier, Judes
   Tsantrizos, Youla S.
TI Multistage Screening Reveals Chameleon Ligands of the Human Farnesyl
   Pyrophosphate Synthase: Implications to Drug Discovery for
   Neurodegenerative Diseases
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID NITROGEN CONTAINING BISPHOSPHONATES; ALZHEIMERS DISEASE; DIPHOSPHATE
   SYNTHASE; MULTIPLE MYELOMA; ZOLEDRONIC ACID; INHIBITORS; THERAPY;
   MECHANISM; STATINS; ANALOGS
AB Human farnesyl pyrophosphate synthase (hFPPS) is the gate keeper of mammalian isoprenoids and the key target of bisphosphonate drugs. Bisphosphonates suffer from poor "drug like" properties and are mainly effective in treating skeletal diseases. Recent investigations have implicated hFPPS in various nonskeletal diseases, including Alzheimer's disease (AD). Analysis of single nudeotide polymorphisms in the hFPPS gene and mRNA levels in autopsy confirmed AD subjects was undertaken, and a genetic link between hFPPS and phosphorylated tau (P Tau) levels in the human brain was identified. Elevated P Tau levels are strongly implicated in AD progression. The development of nonbisphosphonate inhibitors can provide molecular tools for validating hFPPS as a therapeutic target for tauopathy associated neurodegeneration. A multistage screening protocol led to the identification of a new monophosphonate chemotype that bind in an allosteric pocket of hFPPS. Optimization of these compounds could lead to human therapeutics that block tau metabolism and arrest the progression of neurodegeneration.
C1 [De Schutter, Joris W.; Leung, Chun Yuen; Lin, Yih Shyan; Hu, Zheping; Tsantrizos, Youla S.] McGill Univ, Dept Chem, Montreal, PQ H3A 0B8, Canada.
   [Park, Jaeok; Berghuis, Albert M.; Tsantrizos, Youla S.] McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada.
   [Gormley, Patrick; Poirier, Judes] Douglas Mental Hlth Univ Inst, Verdun, PQ H4H 1R3, Canada.
   [Berghuis, Albert M.] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada.
   [Berghuis, Albert M.; Tsantrizos, Youla S.] McGill Univ, Grp Rech Axe Struct Prot, Montreal, PQ H3G 0B1, Canada.
C3 McGill University; McGill University; McGill University; McGill
   University
RP Tsantrizos, YS (通讯作者)，McGill Univ, Dept Chem, 801 Sherbrooke St W, Montreal, PQ H3A 0B8, Canada.
EM Youla.tsantrizos@mcgill.ca
RI ; Park, Jaeok/U 6904 2019; Berghuis, Albert/A 6495 2008
OI Berghuis, Albert/0000 0002 2663 025X; Park, Jaeok/0000 0002 8180 3950; 
FU Natural Sciences and Engineering Research Council of Canada (NSERC);
   Canada Foundation for Innovation (CFI); Quebec Ministere de la Recherche
   en Science et Technologie (FQRNT); McGill University; NSERC; FQRNT;
   Canadian Institute of Health Research (CIHR)
FX We thank Dr. Alexios Matralis for contributing to the synthesis of some
   key building blocks. <SUP>1</SUP>H NMR experiments were acquired on a
   500 MHz NMR instrument at the Quebec/Eastern Canada High Field NMR
   Facility, supported by the Natural Sciences and Engineering Research
   Council of Canada (NSERC), the Canada Foundation for Innovation (CFI),
   the Quebec Ministere de la Recherche en Science et Technologie (FQRNT),
   and McGill University. Financial support for this work was provided by
   NSERC and FQRNT (research grants to Y. S. Tsantrizos) and the Canadian
   Institute of Health Research (CIHR; research grants to A. M. Berghuis,
   J. Poirier, and Y. S. Tsantrizos).
CR Ballatore C, 2007, NAT REV NEUROSCI, V8, P663, DOI 10.1038/nrn2194
   Beffert U, 1999, BRAIN RES, V843, P87, DOI 10.1016/S0006 8993(99)01894 6
   Bugge S, 2012, TETRAHEDRON, V68, P9226, DOI 10.1016/j.tet.2012.08.090
   CIOSEK CP, 1993, J BIOL CHEM, V268, P24832
   Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195
   De Schutter JW, 2012, BIOORGAN MED CHEM, V20, P5583, DOI 10.1016/j.bmc.2012.07.019
   Dunford JE, 2008, J MED CHEM, V51, P2187, DOI 10.1021/jm7015733
   Eckert GP, 2009, NEUROBIOL DIS, V35, P251, DOI 10.1016/j.nbd.2009.05.005
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Gabelli SB, 2006, PROTEINS, V62, P80, DOI 10.1002/prot.20754
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   GRAY BD, 1987, J CHEM SOC CHEM COMM, P1329, DOI 10.1039/c39870001329
   Hesse S, 2007, TETRAHEDRON LETT, V48, P5261, DOI 10.1016/j.tetlet.2007.05.136
   Hofman A, 1997, LANCET, V349, P151, DOI 10.1016/S0140 6736(96)09328 2
   Hooff GP, 2010, BBA MOL CELL BIOL L, V1801, P896, DOI 10.1016/j.bbalip.2010.03.014
   Hooper C, 2008, J NEUROCHEM, V104, P1433, DOI 10.1111/j.1471 4159.2007.05194.x
   Hottman DA, 2014, MOL NEUROBIOL, V50, P177, DOI 10.1007/s12035 013 8627 z
   Jahnke W, 2010, NAT CHEM BIOL, V6, P660, DOI [10.1038/NCHEMBIO.421, 10.1038/nchembio.421]
   Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140 6736(00)03155 X
   Kálmán FK, 2007, INORG CHEM, V46, P5260, DOI 10.1021/ic0702926
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Lahrache H, 2005, TETRAHEDRON LETT, V46, P1635, DOI 10.1016/j.tetlet.2005.01.089
   Lambert JC, 2009, NAT GENET, V41, P1094, DOI 10.1038/ng.439
   Leduc V, 2011, J NEUROSCI METH, V200, P14, DOI 10.1016/j.jneumeth.2011.05.026
   Leung CY, 2013, J MED CHEM, V56, P7939, DOI 10.1021/jm400946f
   Leung CY, 2013, BIOORGAN MED CHEM, V21, P2229, DOI 10.1016/j.bmc.2013.02.006
   Li G, 2007, NEUROLOGY, V69, P878, DOI 10.1212/01.wnl.0000277657.95487.1c
   Lin YS, 2012, J MED CHEM, V55, P3201, DOI 10.1021/jm201657x
   Lindert S, 2013, CHEM BIOL DRUG DES, V81, P742, DOI 10.1111/cbdd.12121
   Marchant NL, 2013, JAMA NEUROL, V70, P488, DOI 10.1001/2013.jamaneurol.405
   Mashalidis EH, 2013, NAT PROTOC, V8, P2309, DOI 10.1038/nprot.2013.130
   Morgan GJ, 2012, BLOOD, V119, P5374, DOI 10.1182/blood 2011 11 392522
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   Morita CT, 2007, IMMUNOL REV, V215, P59, DOI 10.1111/j.1600 065X.2006.00479.x
   Nguyen UTT, 2009, NAT CHEM BIOL, V5, P227, DOI 10.1038/nchembio.149
   Park J, 2012, BMC STRUCT BIOL, V12, DOI 10.1186/1472 6807 12 32
   Riekse RG, 2006, J ALZHEIMERS DIS, V10, P399
   Rondeau JM, 2006, CHEMMEDCHEM, V1, P267, DOI 10.1002/cmdc.200500059
   Sheldrick GM, 2010, ACTA CRYSTALLOGR D, V66, P479, DOI 10.1107/S0907444909038360
   Skerjanec A, 2003, J CLIN PHARMACOL, V43, P154, DOI 10.1177/0091270002239824
   Thorn A, 2011, J APPL CRYSTALLOGR, V44, P1285, DOI [10.1107/S0021889811041768, 10.1107/S00218898110417681285]
   Vagin AA, 2004, ACTA CRYSTALLOGR D, V60, P2184, DOI 10.1107/S0907444904023510
   WASZKUC W, 1984, SYNTHESIS STUTTGART, P1025
   Weiss HM, 2008, DRUG METAB DISPOS, V36, P2043, DOI 10.1124/dmd.108.021071
   Winter G, 2010, J APPL CRYSTALLOGR, V43, P186, DOI 10.1107/S0021889809045701
   Wolozin B, 2007, BMC MED, V5, DOI 10.1186/1741 7015 5 20
   Wu J, 2006, ORG BIOMOL CHEM, V4, P1663, DOI 10.1039/b602536f
   Yu WS, 2004, ORG LETT, V6, P3217, DOI 10.1021/ol0400342
   Zhang YH, 2009, J AM CHEM SOC, V131, P5153, DOI 10.1021/ja808285e
NR 49
TC 28
Z9 38
U1 0
U2 21
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022 2623
EI 1520 4804
J9 J MED CHEM
JI J. Med. Chem.
PD JUL 10
PY 2014
VL 57
IS 13
BP 5764
EP 5776
DI 10.1021/jm500629e
PG 13
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA AL2TT
UT WOS:000338979100021
PM 24911527
DA 2025 08 17
ER

PT J
AU Müller, WEG
   Neufurth, M
   Wang, SF
   Ackermann, M
   Muñoz Espí, R
   Feng, QL
   Lu, Q
   Schröder, HC
   Wang, XH
AF Mueller, Werner E. G.
   Neufurth, Meik
   Wang, Shunfeng
   Ackermann, Maximilian
   Munoz Espi, Rafael
   Feng, Qingling
   Lu, Qiang
   Schroeder, Heinz C.
   Wang, Xiaohong
TI Amorphous, Smart, and Bioinspired Polyphosphate Nano/Microparticles: A
   Biomaterial for Regeneration and Repair of Osteo Articular Impairments
   In Situ
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE long bone defects; bone marrow cells; inorganic polyphosphate;
   microparticles; bisphosphonates; Runx2; Sox9; cathepsin K; tumor
   metastases; human mesenchymal stem cells
ID MESENCHYMAL STEM CELLS; PLATELET RICH PLASMA; INORGANIC POLYPHOSPHATE;
   MAMMALIAN CELLS; ZOLEDRONIC ACID; METABOLIC FUEL; SAOS 2 CELLS; BONE;
   MINERALIZATION; EXPRESSION
AB Using femur explants from mice as an in vitro model, we investigated the effect of the physiological polymer, inorganic polyphosphate (polyP), on differentiation of the cells of the bone marrow in their natural microenvironment into the osteogenic and chondrogenic lineages. In the form of amorphous Ca polyP nano/microparticles, polyP retains its function to act as both an intra  and extracellular metabolic fuel and a stimulus eliciting morphogenetic signals. The method for synthesis of the nano/microparticles with the polyanionic polyP also allowed the fabrication of hybrid particles with the bisphosphonate zoledronic acid, a drug used in therapy of bone metastases in cancer patients. The results revealed that the amorphous Ca polyP particles promote the growth/viability of mesenchymal stem cells, as well as the osteogenic and chondrogenic differentiation of the bone marrow cells in rat femur explants, as revealed by an upregulation of the expression of the transcription factors SOX9 (differentiation towards osteoblasts) and RUNX2 (chondrocyte differentiation). In parallel to this bone anabolic effect, incubation of the femur explants with these particles significantly reduced the expression of the gene encoding the osteoclast bone catabolic enzyme, cathepsin K, while the expression of the tartrate resistant acid phosphatase remained unaffected. The gene expression data were supported by the finding of an increased mineralization of the cells in the femur explants in response to the Ca polyP particles. Finally, we show that the hybrid particles of polyP complexed with zoledronic acid exhibit both the cytotoxic effect of the bisphosphonate and the morphogenetic and mineralization inducing activity of polyP. Our results suggest that the Ca polyP nano/microparticles are not only a promising scaffold material for repairing long bone osteo articular damages but can also be applied, as a hybrid with zoledronic acid, as a drug delivery system for treatment of bone metastases. The polyP particles are highlighted as genuine, smart, bioinspired nano/micro biomaterials.
C1 [Mueller, Werner E. G.; Neufurth, Meik; Wang, Shunfeng; Lu, Qiang; Schroeder, Heinz C.; Wang, Xiaohong] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Physiol Chem, ERC Adv Investigator Grant Res Grp, Duesbergweg 6, D 55128 Mainz, Germany.
   [Ackermann, Maximilian] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Funct & Clin Anat, Johann Joachim Becher Weg 13, D 55099 Mainz, Germany.
   [Munoz Espi, Rafael] Univ Valencia, Inst Mat Sci ICMUV, C Catedratic Jose Beltran 2, Valencia 46980, Spain.
   [Feng, Qingling] Tsinghua Univ, Sch Mat Sci & Engn, Key Lab Adv Mat, Minist Educ China, Beijing 100084, Peoples R China.
C3 Johannes Gutenberg University of Mainz; Johannes Gutenberg University of
   Mainz; University of Valencia; Tsinghua University
RP Müller, WEG; Wang, XH (通讯作者)，Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Physiol Chem, ERC Adv Investigator Grant Res Grp, Duesbergweg 6, D 55128 Mainz, Germany.
EM wmueller@uni mainz.de; mneufurt@uni mainz.de; shunwang@uni mainz.de;
   maximilian.ackermann@uni mainz.de; rafael.munoz@uv.es;
   biomater@mail.tsinghua.edu.cn; qianglu1@uni mainz.de;
   hschroed@uni mainz.de; wang013@uni mainz.de
RI Müller, W./AAR 8651 2020; Muñoz Espí, Rafael/C 1686 2014; Munoz Espi,
   Rafael/C 1686 2014; Neufurth, Meik/N 4297 2015
OI Wang, Prof. Dr. Xiaohong/0000 0003 1796 6314; Schroder, Heinz
   C./0000 0003 0992 6427; Muller, Werner E.G./0000 0002 8223 3689;
   Munoz Espi, Rafael/0000 0002 8146 2332; Feng,
   Qingling/0000 0003 1288 300X; Neufurth, Meik/0000 0002 2383 6412
FU ERC [268476]; ERC PoC Grants [324564, 662486, 767234]; Max Planck
   Society through the Max Planck Partner Group on Colloidal Methods for
   Multifunctional Materials (CM3) at the University of Valencia; Spanish
   Ministry of Economy, Industry, and Competitiveness through a Ramon y
   Cajal grant [RYC 2013 13451]; BMBF Grant: NanoOsMed, the International
   Human Frontier Science Program; BiomaTiCS research initiative of the
   University Medical Center, Mainz
FX We thank Maren Muller (Physics at Interfaces) and G. Glasser [ Electron
   Microscopy], Max Planck Institute for Polymer Research, Mainz (Germany),
   for continuous support. W. E. G. Muller is the holder of an ERC Advanced
   Investigator Grant (Grant No.: 268476). In addition, W. E. G. Muller
   obtained three ERC PoC Grants (Si Bone, Grant No.: 324564;
   MorphoVES PoC, Grant No.: 662486; and ArthroDUR, Grant No.: 767234).
   Rafael Munoz Espi thanks the financial support from the Max Planck
   Society through the Max Planck Partner Group on Colloidal Methods for
   Multifunctional Materials (CM3) at the University of Valencia, as well
   as the Spanish Ministry of Economy, Industry, and Competitiveness
   through a Ramon y Cajal grant (Grant No.: RYC 2013 13451). Finally, this
   work was supported by the BMBF Grant: NanoOsMed, the International Human
   Frontier Science Program and the BiomaTiCS research initiative of the
   University Medical Center, Mainz.
CR Abrams GD, 2013, SPORTS MED ARTHROSC, V21, P213, DOI 10.1097/JSA.0b013e3182999740
   Amend Sarah R, 2016, J Vis Exp, DOI 10.3791/53936
   Angelova PR, 2016, BIOCHEM SOC T, V44, P40, DOI 10.1042/BST20150223
   Blumer MJF, 2012, MECH DEVELOP, V129, P162, DOI 10.1016/j.mod.2012.04.003
   Bowles J, 2009, DEV DYNAM, V238, P2073, DOI 10.1002/dvdy.22024
   Buckwalter JA, 1996, AAOS INSTR COURS LEC, V45, P371
   Cenni E, 2010, J ORTHOP RES, V28, P792, DOI 10.1002/jor.21073
   Clezardin Philippe, 2013, Bonekey Rep, V2, P267, DOI 10.1038/bonekey.2013.1
   Cuetara BLV, 2006, IN VITRO CELL DEV AN, V42, P182, DOI 10.1290/0510075.1
   Faloni APD, 2011, CALCIFIED TISSUE INT, V88, P63, DOI 10.1007/s00223 010 9418 4
   Di Virgilio F, 2009, PURINERG SIGNAL, V5, P251, DOI 10.1007/s11302 009 9145 3
   Docampo Roberto, 2006, V1, P53, DOI 10.1007/7171_003
   Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511
   Endo T, 2010, MOL ENDOCRINOL, V24, P1267, DOI 10.1210/me.2010 0056
   Fischer V, 2013, ADV FUNCT MATER, V23, P451, DOI 10.1002/adfm.201201839
   Gradin P, 2012, CELLS TISSUES ORGANS, V196, P68, DOI 10.1159/000330806
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   He W, 2015, RSC ADV, V5, P49809, DOI 10.1039/c5ra06386h
   Herlofsen SR, 2011, TISSUE ENG PT A, V17, P1003, DOI [10.1089/ten.tea.2010.0499, 10.1089/ten.TEA.2010.0499]
   Hirsh V, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00146
   Kabiri Azadeh, 2014, Adv Biomed Res, V3, P138, DOI 10.4103/2277 9175.135156
   Khajuria DK, 2015, EUR J PHARM SCI, V66, P173, DOI 10.1016/j.ejps.2014.10.015
   Kim A, 2016, SCI REP UK, V6, DOI 10.1038/srep30881
   KULAEV I, 2004, BIOCH INORGANIC POLY
   KUMBLE KD, 1995, J BIOL CHEM, V270, P5818, DOI 10.1074/jbc.270.11.5818
   Lafage Proust MH, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.29
   LI CY, 1970, J HISTOCHEM CYTOCHEM, V18, P901, DOI 10.1177/18.12.901
   Little DG, 2007, J BONE JOINT SURG BR, V89B, P425, DOI 10.1302/0301 620X.89B4.18301
   Liu DM, 2012, CHEM COMMUN, V48, P2668, DOI 10.1039/c2cc17635a
   Liu Xiaoyu, 2015, Bio Protoc, V5
   Mithoefer K, 2009, CLIN SPORT MED, V28, P25, DOI 10.1016/j.csm.2008.09.001
   Mori K, 2007, ONCOL REP, V18, P1365
   Morrissey JH, 2012, BLOOD, V119, P5972, DOI 10.1182/blood 2012 03 306605
   Müller WEG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188977
   Müller WEG, 2017, POLYMERS BASEL, V9, DOI 10.3390/polym9070300
   Müller WEG, 2017, J CELL SCI, V130, P2747, DOI 10.1242/jcs.204941
   Müller WEG, 2017, ACTA BIOMATER, V50, P89, DOI 10.1016/j.actbio.2016.12.045
   Müller WEG, 2016, RSC ADV, V6, P88559, DOI 10.1039/c6ra17043a
   Müller WEG, 2016, FEBS J, V283, P74, DOI 10.1111/febs.13552
   Müller WEG, 2015, MACROMOL BIOSCI, V15, P1182, DOI 10.1002/mabi.201500100
   Müller WEG, 2015, MATER LETT, V148, P163, DOI 10.1016/j.matlet.2015.02.070
   Müller WEG, 2011, ACTA BIOMATER, V7, P2661, DOI 10.1016/j.actbio.2011.03.007
   Müller WEG, 2015, J CELL SCI, V128, P2202, DOI 10.1242/jcs.170605
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Murakami S, 2000, P NATL ACAD SCI USA, V97, P1113, DOI 10.1073/pnas.97.3.1113
   Neufurth M, 2014, BIOMATERIALS, V35, P8810, DOI 10.1016/j.biomaterials.2014.07.002
   Norambuena GA, 2012, PEDIATR RES, V71, P452, DOI 10.1038/pr.2011.68
   Pavlov E, 2010, J BIOL CHEM, V285, P9420, DOI 10.1074/jbc.M109.013011
   Petrie A., 2013, STAT VET ANIMAL SCI, P85, DOI ISBN: 978 0 470 67075 0
   Polascik Thomas J, 2008, Ther Clin Risk Manag, V4, P261
   Rizzo C, 2014, IMMUN AGEING, V11, DOI 10.1186/s12979 014 0021 9
   Roca Cusachs P, 2013, P NATL ACAD SCI USA, V110, pE1361, DOI 10.1073/pnas.1220723110
   Rosen LS, 2003, J CLIN ONCOL, V21, P3150, DOI 10.1200/JCO.2003.04.105
   Saeed H, 2016, J BIOMED SCI, V23, DOI 10.1186/s12929 016 0254 3
   Schröder HC, 2005, J BIOMED MATER RES B, V75B, P387, DOI 10.1002/jbm.b.30322
   Solesio ME, 2016, BBA GEN SUBJECTS, V1860, P1317, DOI 10.1016/j.bbagen.2016.03.020
   Suva LJ, 2011, NAT REV ENDOCRINOL, V7, P208, DOI 10.1038/nrendo.2010.227
   Tanaka EM, 2011, DEV CELL, V21, P172, DOI 10.1016/j.devcel.2011.06.016
   Tate MLK, 2008, INT J BIOCHEM CELL B, V40, P2720, DOI 10.1016/j.biocel.2008.05.011
   Templeton ZS, 2015, JOVE J VIS EXP, DOI 10.3791/52656
   Theriault RL, 2012, CANCER CONTROL, V19, P92, DOI 10.1177/107327481201900203
   Walsh NC, 2003, GENE, V307, P111, DOI 10.1016/S0378 1119(03)00449 9
   Wang X, 2016, EUR CELLS MATER, V32, P271, DOI 10.22203/eCM.v032a18
   Wang XH, 2016, ADV ENG MATER, V18, P1406, DOI 10.1002/adem.201600057
   Wang XH, 2016, BIOMED MATER, V11, DOI 10.1088/1748 6041/11/3/035005
   Wang XH, 2016, BIOTECHNOL J, V11, P11, DOI 10.1002/biot.201500168
   Wang XH, 2014, INT REV CEL MOL BIO, V313, P27, DOI 10.1016/B978 0 12 800177 6.00002 5
   Wang XH, 2014, TRENDS BIOTECHNOL, V32, P441, DOI 10.1016/j.tibtech.2014.05.004
   Wang XH, 2013, J TISSUE ENG REGEN M, V7, P767, DOI 10.1002/term.1465
   Wang XQ, 2017, PROG CHEM, V29, P1, DOI 10.7536/PC161235
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Weiner Steve, 2009, Frontiers of Materials Science in China, V3, P104, DOI 10.1007/s11706 009 0036 x
   Westhrin M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120374
   Wiens M, 2010, BIOMATERIALS, V31, P7716, DOI 10.1016/j.biomaterials.2010.07.002
   Yan ZP, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/8367063
   Zekri J, 2014, J BONE ONCOL, V3, P25, DOI 10.1016/j.jbo.2013.12.001
   Zhong WJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040833
   Zhou G, 2006, P NATL ACAD SCI USA, V103, P19004, DOI 10.1073/pnas.0605170103
   Zou L, 2015, STEM CELL REP, V4, P190, DOI 10.1016/j.stemcr.2015.01.008
NR 79
TC 21
Z9 23
U1 1
U2 37
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD FEB
PY 2018
VL 19
IS 2
AR 427
DI 10.3390/ijms19020427
PG 19
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA FZ3YN
UT WOS:000427527400111
PM 29385104
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Bussard, KM
   Gigliotti, CM
   Adair, BM
   Snyder, JM
   Gigliotti, NT
   Loc, WS
   Wilczynski, ZR
   Liu, ZK
   Meisel, K
   Zemanek, C
   Mastro, AM
   Shupp, AB
   McGovern, C
   Matters, GL
   Adair, JH
AF Bussard, Karen M.
   Gigliotti, Christopher M.
   Adair, Bernadette M.
   Snyder, Jenna M.
   Gigliotti, Nicholas T.
   Loc, Welley S.
   Wilczynski, Zachary R.
   Liu, Zi Kui
   Meisel, Kacey
   Zemanek, Cecilia
   Mastro, Andrea M.
   Shupp, Alison B.
   McGovern, Christopher
   Matters, Gail L.
   Adair, James H.
TI Preferential uptake of antibody targeted calcium phosphosilicate
   nanoparticles by metastatic triple negative breast cancer cells in
   co cultures of human metastatic breast cancer cells plus bone
   osteoblasts
SO NANOMEDICINE NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE Metastatic breast cancer; Bone; Osteoblast; Gemcitabine; Nanodelivery;
   Nanoparticle
ID TRANSFERRIN RECEPTOR; PHOSPHATE; COMBINATION; ENCAPSULATION;
   CHEMOTHERAPY; GEMCITABINE; CARBOPLATIN; THERAPY; SILICON; IRON
AB Calcium phosphosilicate nanoparticles (CPSNPs) are bioresorbable nanoparticles that can be bioconjugated with targeting molecules and encapsulate active agents and deliver them to tumor cells without causing damage to adjacent healthy tissue. Data obtained in this study demonstrated that an anti CD71 antibody on CPSNPs targets these nanoparticles and enhances their internalization by triple negative breast cancer cells in vitro. Caspase 3,7 activation, DNA damage, and fluorescent microscopy confirmed the apoptotic breast cancer response caused by targeted anti CD71 CPSNPs encapsulated with gemcitabine monophosphate, the active metabolite of the chemotherapeutic gemcitabine used to treat cancers including breast and ovarian. Targeted anti CD71 CPSNPs encapsulated with the fluorophore, Rhodamine WT, were preferentially internalized by breast cancer cells in co cultures with osteoblasts. While osteoblasts partially internalized anti CD71GemMP CPSNPs, their cell growth was not affected. These results suggest that CPSNPs may be used as imaging tools and selective drug delivery systems for breast cancer that has metastasized to bone. (C) 2021 Elsevier Inc. All rights reserved.
C1 [Bussard, Karen M.; Shupp, Alison B.] Thomas Jefferson Univ, Dept Canc Biol, Philadelphia, PA 19107 USA.
   [Gigliotti, Christopher M.; Wilczynski, Zachary R.; Adair, James H.] Penn State Univ, Dept Bioengn, University Pk, PA 16802 USA.
   [Adair, Bernadette M.; Gigliotti, Nicholas T.; Liu, Zi Kui; Adair, James H.] Penn State Univ, Dept Mat Sci & Engn, University Pk, PA 16802 USA.
   [Snyder, Jenna M.; Meisel, Kacey; Zemanek, Cecilia; Mastro, Andrea M.] Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.
   [Loc, Welley S.] Penn State Univ, Dept Chem, University Pk, PA USA.
   [McGovern, Christopher; Matters, Gail L.] Penn State Univ, Dept Biochem & Mol Biol, Coll Med, Hershey, PA USA.
   [Adair, James H.] Penn State Univ, Dept Pharmacol, Coll Med, Hershey, PA USA.
C3 Thomas Jefferson University; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); Pennsylvania State University; Pennsylvania State
   University   University Park; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); Pennsylvania State University; Pennsylvania State
   University   University Park; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); Pennsylvania State University; Pennsylvania State
   University   University Park; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); Pennsylvania State University; Pennsylvania State
   University   University Park; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); Pennsylvania State University; Penn State Health;
   Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Penn State Health
RP Adair, JH (通讯作者)，Penn State Univ, Mat Sci & Engn Biomed Engn & Pharmacol, University Pk, PA 16803 USA.
EM jha3@ems.psu.edu
RI ; Loc, Welley/B 9780 2012; Liu, Zi Kui/A 8196 2009
OI McGovern, Christopher/0009 0002 2058 3410; Snyder,
   Jenna/0000 0002 5628 5442; Gigliotti, Nicholas/0000 0002 7608 7291; Liu,
   Zi Kui/0000 0003 3346 3696
FU National Cancer Institute (NCI), NIH [R01CA167535, R21CA170121, NCI
   CA178177 05]; Pennsylvania Department of Health, Tobacco CURE funds SAP
   [4100072562, 4100072566]; Pennsylvania Breast Cancer Coalition; National
   Center for Advancing Translational Sciences (NCATS) [UL1 TR000127, TL1
   TR000125]
FX This study was funded in part by National Institutes of Health (NIH)
   grants R01CA167535 (GLM and JHA) and R21CA170121 (GLM) from the National
   Cancer Institute (NCI), NIH, NCI CA178177 05 (KMB); Pennsylvania
   Department of Health, Tobacco CURE funds SAP#4100072562 (GLM and JHA),
   and SAP#4100072566 (KMB); and The Pennsylvania Breast Cancer Coalition
   (KMB). CMG and WSL were supported, in part, by grants UL1 TR000127 and
   TL1 TR000125 from the National Center for Advancing Translational
   Sciences (NCATS). The Department of Materials Science and Engineering at
   Penn State disclaims responsibility for any analyses, interpretations or
   conclusions. Penn State Research Foundation has licensed CPSNP
   technology to KeystoneNano, Inc. (PA, USA). JHA is a co founder of
   PandreaBio (formerly Keystone Nano) and CSO. All other authors declare
   no conflicts of interest.
CR Abraham T, 2021, INT J NANOMED, V16, P2297, DOI 10.2147/IJN.S295740
   Abraham T, 2018, PROC SPIE, V10497, DOI 10.1117/12.2300517
   Adair JH, 2010, ACS NANO, V4, P4967, DOI 10.1021/nn102324e
   Al Mahmood S, 2018, DRUG DELIV TRANSL RE, V8, P1483, DOI 10.1007/s13346 018 0551 3
   Altinoglu EI, 2008, ACS NANO, V2, P2075, DOI 10.1021/nn800448r
   Anderson SA, 2013, CELL METAB, V17, P282, DOI 10.1016/j.cmet.2013.01.007
   Barth BM, 2013, ACS NANO, V7, P2132, DOI 10.1021/nn304862b
   Barth BM, 2011, ACS NANO, V5, P5325, DOI 10.1021/nn2005766
   Barth BM, 2010, ACS NANO, V4, P1279, DOI 10.1021/nn901297q
   Bazydlo LAL, 2014, LABMEDICINE, V45, pE44, DOI 10.1309/LMGLMZ8CIYMFNOGX
   CARLISLE EM, 1986, CIBA F SYMP, V121, P123
   CARLISLE EM, 1970, SCIENCE, V167, P279, DOI 10.1126/science.167.3916.279
   Chen XS, 2010, ANN ONCOL, V21, P961, DOI 10.1093/annonc/mdq041
   Clawson GA, 2017, NUCLEIC ACID THER, V27, P23, DOI 10.1089/nat.2016.0621
   Dammes N, 2020, THERANOSTICS, V10, P938, DOI 10.7150/thno.37443
   Fan CM, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00687
   Hecker SJ, 2008, J MED CHEM, V51, P2328, DOI 10.1021/jm701260b
   Henry KE, 2018, J NUCL MED, V59, P51, DOI 10.2967/jnumed.117.192286
   Hu Q, 2013, ASIAN PAC J CANCER P, V14, P6221, DOI 10.7314/APJCP.2013.14.11.6221
   KASAI K, 1990, ENDOCRINOLOGY, V126, P1742, DOI 10.1210/endo 126 3 1742
   Li FH, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000018513
   Libson S, 2014, INT REV PSYCHIATR, V26, P4, DOI 10.3109/09540261.2013.852971
   Loc WS, 2017, NANOMED NANOTECHNOL, V13, P2313, DOI 10.1016/j.nano.2017.06.017
   Malorni L, 2012, BREAST CANCER RES TR, V136, P795, DOI 10.1007/s10549 012 2315 y
   Matuo R, 2009, J APPL TOXICOL, V29, P308, DOI 10.1002/jat.1411
   Miller LD, 2011, CANCER RES, V71, P6728, DOI 10.1158/0008 5472.CAN 11 1870
   Morales Cruz M, 2019, DRUG DES DEV THER, V13, P3753, DOI 10.2147/DDDT.S219489
   Morgan TT, 2008, NANO LETT, V8, P4108, DOI 10.1021/nl8019888
   Muddana HS, 2009, BIOPHYS J, V96, p400A, DOI 10.1016/j.bpj.2008.12.2035
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nielsen FH, 2014, J TRACE ELEM MED BIO, V28, P379, DOI 10.1016/j.jtemb.2014.06.024
   Park JS, 2014, CANCER CHEMOTH PHARM, V74, P799, DOI 10.1007/s00280 014 2551 4
   Patra JK, 2018, J NANOBIOTECHNOL, V16, DOI 10.1186/s12951 018 0392 8
   Pentheroudakis G, 2006, MED ONCOL, V23, P147, DOI 10.1385/MO:23:2:147
   Pradere U, 2014, CHEM REV, V114, P9154, DOI 10.1021/cr5002035
   Rauner M, 2019, NAT METAB, V1, P111, DOI 10.1038/s42255 018 0005 8
   Rizvi SAA, 2018, SAUDI PHARM J, V26, P64, DOI 10.1016/j.jsps.2017.10.012
   Roy V, 2009, ANN ONCOL, V20, P449, DOI 10.1093/annonc/mdn661
   Rozeboom B, 2019, AM J CANCER RES, V9, P2821
   Shen Y, 2018, AM J CANCER RES, V8, P916
   Shupp AB, 2018, CANCERS, V10, DOI 10.3390/cancers10060182
   Siegel RL, 2020, CA CANCER J CLIN, V70, P7
   SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409
   STEIN GS, 1990, FASEB J, V4, P3111, DOI 10.1096/fasebj.4.13.2210157
   Trautvetter U, 2018, NUTRIENTS, V10, DOI 10.3390/nu10070936
   Tseng LM, 2013, NEOPLASMA, V60, P290, DOI 10.4149/neo_2013_038
   Vernieri C, 2019, CLIN BREAST CANCER, V19, pE306, DOI 10.1016/j.clbc.2018.12.004
   Yin L, 2020, BREAST CANCER RES, V22, DOI 10.1186/s13058 020 01296 5
   Zhao DY, 2020, CANCER MANAG RES, V12, P2503, DOI 10.2147/CMAR.S245949
   Zhao S, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.03.194
NR 50
TC 5
Z9 5
U1 1
U2 20
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1549 9634
EI 1549 9642
J9 NANOMED NANOTECHNOL
JI Nanomed. Nanotechnol. Biol. Med.
PD JUN
PY 2021
VL 34
AR 102383
DI 10.1016/j.nano.2021.102383
EA APR 2021
PG 10
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Research & Experimental Medicine
GA TE6MZ
UT WOS:000670126100016
PM 33722692
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Kim, MH
   Lee, H
   Ha, IJ
   Yang, WM
AF Kim, Mi Hye
   Lee, Haesu
   Ha, In Jin
   Yang, Woong Mo
TI Zanthoxylum piperitum alleviates the bone loss in osteoporosis
   via inhibition of RANKL induced c fos/NFATc1/NF κB pathway
SO PHYTOMEDICINE
LA English
DT Article
DE Zanthoxylum piperitum; Osteoporosis; Bone mineral density; Osteoclast;
   RANKL
ID POSTMENOPAUSAL WOMEN; DIFFERENTIATION; PREVENTION; QUERCITRIN; DIAGNOSIS
AB Background: The fruit of Zanthoxylum piperitum (ZP) is an herbal medicine as well as a spice agent in Asia to treat carminative, stomachic, anthelmintic and degenerative diseases. Z. piperitum was reported to have anti oxidant, anti inflammatory, anti osteoarthritic and osteosarcoma proliferation control effects.
   Purpose and Study design: This study was conducted to determine the anti osteoporotic effects and mechanisms of action of ZP.
   Methods: Female ICR mice underwent ovariectomies (OVX) and were orally administered ZP at 1, 10 and 100 mg/kg for 6 weeks. The femoral and tibial bones were assessed by dual energy X ray absorptiometry and histology to analyze the bone mineral density (BMD) and the number of osteoclasts. Raw 264.7 cells were stimulated by 100 ng/ml receptor activator of nuclear factor kappa B ligand (RANKL) for 7 days in the presence of ZP. RANKL induced signaling molecules were analyzed in osteoclasts.
   Results: The levels of femoral and tibial BMD were significantly increased by ZP administration. Serum biomarkers such as osteocalcin, calcium, alkaline phosphatase and bone specific alkaline phosphatase concentrations were markedly recovered to normal levels in ZP treated osteoporotic mice. In addition, the number of osteoclasts in the head, trochanter and body of the femur was obviously decreased in the ZP treatment groups. Moreover, ZP treated cells showed a reduction in the number of TRAP positive multinuclear cells in RANKL stimulated Raw 264.7 cells. ZP decreased the RANKL activated NFATc1 and c fos, transcription factors of osteoclast formation. The nuclear translocation of NF kappa B and phosphorylation of ERK42/44 were inhibited by the ZP treatment in RANKL induced osteoclasts.
   Conclusion: Collectively, ZP exerts its inhibitory effect against bone resorption by regulating RANKL mediated c fos/NFATcl/NF kappa B in osteoclast. ZP may prove to be a therapeutic agent for osteoporosis.
C1 [Kim, Mi Hye; Lee, Haesu; Yang, Woong Mo] Kyung Hee Univ, Coll Korean Med, Dept Convergence Korean Med Sci, Seoul, South Korea.
   [Ha, In Jin] Kyung Hee Univ, Korean Med Hosp, Korean Med Clin Trial Ctr, Seoul, South Korea.
C3 Kyung Hee University; Kyung Hee University; Kyung Hee University
   Hospital
RP Yang, WM (通讯作者)，Kyung Hee Univ, Coll Korean Med, Dept Convergence Korean Med Sci, Seoul, South Korea.
EM wmyang@khu.ac.kr
RI Yang, Woong/AAH 9185 2020
OI Ha, In Jin/0000 0002 9210 1401; Yang, Woong Mo/0000 0001 5308 2386
CR Biver E, 2012, JOINT BONE SPINE, V79, P20, DOI 10.1016/j.jbspin.2011.05.003
   Bolland Mark J, 2011, BMJ, V342, pd2040, DOI 10.1136/bmj.d2040
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Chen JJ, 2009, J NAT PROD, V72, P107, DOI 10.1021/np800689b
   Chen YQ, 2018, BIOMED PHARMACOTHER, V107, P1175, DOI 10.1016/j.biopha.2018.08.069
   Chesnut CH III, 2000, AM J MED, V109, P267, DOI 10.1016/S0002 9343(00)00490 3
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Cummings SR, 2009, JNCI J NATL CANCER I, V101, P384, DOI 10.1093/jnci/djp018
   Das S, 2013, DRUG DES DEV THER, V7, P435, DOI 10.2147/DDDT.S31504
   Diab DL, 2013, CURR OPIN ENDOCRINOL, V20, P501, DOI 10.1097/01.med.0000436194.10599.94
   Diab DL, 2012, ENDOCRIN METAB CLIN, V41, P487, DOI 10.1016/j.ecl.2012.04.007
   Epple G, 2004, PEST MANAG SCI, V60, P624, DOI 10.1002/ps.886
   Hwang KA, 2018, BIOMED PHARMACOTHER, V105, P481, DOI 10.1016/j.biopha.2018.05.109
   Kabala SI, 2019, PREP BIOCHEM BIOTECH, V49, P511, DOI 10.1080/10826068.2019.1587628
   Kalaiselvi VS, 2013, J CLIN DIAGN RES, V7, P814, DOI 10.7860/JCDR/2013/5370.2946
   Kendler D, 2011, CLIMACTERIC, V14, P604
   Kim MH, 2017, J ETHNOPHARMACOL, V195, P137, DOI 10.1016/j.jep.2016.10.057
   Kitaguchi K, 2018, BONE, V106, P1, DOI 10.1016/j.bone.2017.09.021
   Kuo TR, 2017, BIOMARK RES, V5, DOI 10.1186/s40364 017 0097 4
   Lane NE, 2006, AM J OBSTET GYNECOL, V194, pS3, DOI 10.1016/j.ajog.2005.08.047
   Lewis JR, 2011, J BONE MINER RES, V26, P35, DOI 10.1002/jbmr.176
   Mukaiyama K, 2015, AGING CLIN EXP RES, V27, P413, DOI 10.1007/s40520 014 0296 x
   PARFITT AM, 1995, J BONE MINER RES, V10, P466
   Satue M, 2013, BIOCHEM PHARMACOL, V86, P1476, DOI 10.1016/j.bcp.2013.09.009
   Singh S, 2015, J CLIN DIAGN RES, V9, pRC4, DOI 10.7860/JCDR/2015/14857.6318
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Ukon Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102557
   Vandenbroucke A, 2017, CLIN INTERV AGING, V12, P1065, DOI 10.2147/CIA.S131023
   Xing LZ, 2017, BIOMED PHARMACOTHER, V89, P1136, DOI 10.1016/j.biopha.2017.02.073
   Yang SL, 2018, PROCEEDINGS OF 2018 INTERNATIONAL CONFERENCE ON COMPUTING AND ARTIFICIAL INTELLIGENCE (ICCAI 2018), P23, DOI 10.1145/3194452.3194473
   Yao ZQ, 2008, J BIOL CHEM, V283, P9917, DOI 10.1074/jbc.M706415200
NR 32
TC 19
Z9 19
U1 0
U2 21
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0944 7113
EI 1618 095X
J9 PHYTOMEDICINE
JI Phytomedicine
PD JAN
PY 2021
VL 80
AR 153397
DI 10.1016/j.phymed.2020.153397
PG 9
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA OW5IU
UT WOS:000592920900037
PM 33130475
DA 2025 08 17
ER

PT J
AU He, LL
   Yang, NL
   Isales, CM
   Shi, XM
AF He, Linlin
   Yang, Nianlan
   Isales, Carlos M.
   Shi, Xing Ming
TI Glucocorticoid Induced Leucine Zipper (GILZ) Antagonizes TNF α
   Inhibition of Mesenchymal Stem Cell Osteogenic Differentiation
SO PLOS ONE
LA English
DT Article
ID NF KAPPA B; OSTEOBLAST DIFFERENTIATION; PROGENITOR CELLS; DEGRADATION;
   EXPRESSION; KINASE; GENE; PATHOGENESIS; ARTHRITIS; OSTERIX
AB Tumor necrosis factor alpha (TNF alpha) is a potent proinflammatory cytokine that inhibits osteoblast differentiation while stimulating osteoclast differentiation and bone resorption. TNF alpha activates MAP kinase pathway leading to inhibition of osterix (Osx) expression. TNF alpha also induces the expression of E3 ubiquitin ligase protein Smurf1 and Smurf2 and promotes degradation of Runx2, another key transcription factor regulating osteoblast differentiation and bone formation. We showed previously that overexpression of glucocorticoid (GC) induced leucine zipper (GILZ) enhances osteogenic differentiation of bone marrow mesenchymal stem cells (MSCs). We and others also showed that GILZ is a GC effecter and mediates GC anti inflammatory activity. In this study, we asked the question whether GILZ retains its osteogenic activity while functioning as an anti inflammatory mediator. To address this question, we infected mouse bone marrow MSCs with retroviruses expressing GILZ and induced them for osteogenic differentiation in the presence or absence of TNF alpha. Our results show that overexpression of GILZ antagonized the inhibitory effects of TNF alpha on MSC osteogenic differentiation and the mRNA and protein expression of Osx and Runx2, two pivotal osteogenic regulators. Further studies show that these antagonistic actions occur via mechanisms involving GILZ inhibition of TNF alpha induced ERK MAP kinase activation and protein degradation. These results suggest that GILZ may have therapeutic potential as a novel anti inflammation therapy.
C1 [He, Linlin; Yang, Nianlan; Isales, Carlos M.; Shi, Xing Ming] Georgia Hlth Sci Univ, Inst Mol Med & Genet, Augusta, GA USA.
   [He, Linlin] Northwestern Polytech Univ, Fac Life Sci, Xian 710072, Peoples R China.
   [Isales, Carlos M.] Georgia Hlth Sci Univ, Dept Orthopaed Surg, Augusta, GA USA.
   [Shi, Xing Ming] Georgia Hlth Sci Univ, Dept Pathol, Augusta, GA USA.
C3 University System of Georgia; Augusta University; Northwestern
   Polytechnical University; University System of Georgia; Augusta
   University; University System of Georgia; Augusta University
RP He, LL (通讯作者)，Georgia Hlth Sci Univ, Inst Mol Med & Genet, Augusta, GA USA.
EM xshi@georgiahealth.edu
RI He, Linlin/KVY 7272 2024; Isales, Carlos/J 9902 2013
OI Isales, Carlos/0000 0002 4480 3484
FU National Institutes of Health [DK76045]; National Institute on Aging
   [P01AG036675]; China Scholarship Council
FX This work was supported by the National Institutes of Health grant
   (DK76045 to Dr. Shi), National Institute on Aging (P01AG036675 to Dr.
   Isales), Scholarship grant from China Scholarship Council (Dr. He). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Ayroldi E, 2002, MOL CELL BIOL, V22, P7929, DOI 10.1128/MCB.22.22.7929 7941.2002
   Ayroldi E, 2001, BLOOD, V98, P743, DOI 10.1182/blood.V98.3.743
   Ayroldi E, 2007, J CLIN INVEST, V117, P1605, DOI 10.1172/JCI30724
   Ayroldi E, 2009, FASEB J, V23, P3649, DOI 10.1096/fj.09 134684
   Beaulieu E, 2010, ARTHRITIS RHEUM US, V62, P2651, DOI 10.1002/art.27566
   Cohen N, 2006, BLOOD, V107, P2037, DOI 10.1182/blood 2005 07 2760
   Conn DL, 2001, ARTHRIT RHEUM ARTHR, V45, P462, DOI 10.1002/1529 0131(200110)45:5<462::AID ART366>3.0.CO;2 V
   D'Adamio F, 1997, IMMUNITY, V7, P803, DOI 10.1016/S1074 7613(00)80398 2
   De Bari C, 2001, ARTHRITIS RHEUM US, V44, P1928, DOI 10.1002/1529 0131(200108)44:8<1928::AID ART331>3.0.CO;2 P
   Drissi H, 2002, EXP CELL RES, V274, P323, DOI 10.1006/excr.2002.5474
   Eddleston J, 2007, J ALLERGY CLIN IMMUN, V119, P115, DOI 10.1016/j.jaci.2006.08.027
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   FitzGerald GA, 2001, NEW ENGL J MED, V345, P433, DOI 10.1056/NEJM200108093450607
   Gilbert L, 2002, J BIOL CHEM, V277, P2695, DOI 10.1074/jbc.M106339200
   Goldring SR, 2000, CURR OPIN RHEUMATOL, V12, P195, DOI 10.1097/00002281 200005000 00006
   Jones EA, 2004, ARTHRITIS RHEUM US, V50, P817, DOI 10.1002/art.20203
   Jorgensen C, 2002, ANN RHEUM DIS, V61, P6, DOI 10.1136/ard.61.1.6
   Kaneki H, 2006, J BIOL CHEM, V281, P4326, DOI 10.1074/jbc.M509430200
   Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108
   Lacey DC, 2009, OSTEOARTHR CARTILAGE, V17, P735, DOI 10.1016/j.joca.2008.11.011
   Li P, 2003, SPRINGER SEMIN IMMUN, V25, P19, DOI 10.1007/s00281 003 0125 3
   Li XL, 2006, P NATL ACAD SCI USA, V103, P17432, DOI 10.1073/pnas.0607939103
   LOCASCIO V, 1990, BONE MINER, V8, P39, DOI 10.1016/0169 6009(91)90139 Q
   Lu XH, 2006, J BIOL CHEM, V281, P6297, DOI 10.1074/jbc.M507804200
   Marinova Mutafchieva L, 2000, ARTHRITIS RHEUM US, V43, P2046, DOI 10.1002/1529 0131(200009)43:9<2046::AID ANR16>3.0.CO;2 8
   Mittelstadt PR, 2001, J BIOL CHEM, V276, P29603, DOI 10.1074/jbc.M101522200
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nishimura J, 2000, J BONE MINER METAB, V18, P350, DOI 10.1007/s007740070008
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Rauch A, 2010, CELL METAB, V11, P517, DOI 10.1016/j.cmet.2010.05.005
   Yamazaki M, 2009, J BIOL CHEM, V284, P35987, DOI 10.1074/jbc.M109.070540
   Yang NL, 2008, J CELL BIOCHEM, V103, P1760, DOI 10.1002/jcb.21562
   Zhang W, 2008, J BONE MINER RES, V23, P1118, DOI [10.1359/jbmr.080304, 10.1359/JBMR.080304]
   Zhang WX, 2008, J BIOL CHEM, V283, P4723, DOI 10.1074/jbc.M704147200
   Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200
NR 36
TC 22
Z9 27
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD MAR 2
PY 2012
VL 7
IS 3
AR e31717
DI 10.1371/journal.pone.0031717
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 928TC
UT WOS:000303006500007
PM 22396737
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Asaba, Y
   Ito, M
   Fumoto, T
   Watanabe, K
   Flikuhara, R
   Takeshita, S
   Nimura, Y
   Ishida, J
   Fukamizu, A
   Ikeda, K
AF Asaba, Yutaro
   Ito, Masako
   Fumoto, Toshio
   Watanabe, Ken
   Flikuhara, Rvoji
   Takeshita, Sunao
   Nimura, Yuji
   Ishida, Junji
   Fukamizu, Akiyoshi
   Ikeda, Kyoji
TI Activation of Renin Angiotensin System Induces Osteoporosis
   Independently of Hypertension
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE osteoporosis; hypertension; renin angiotensin system; bone resorption;
   osteoclast
ID BONE MINERAL DENSITY; BLOOD PRESSURE; OSTEOBLASTIC CELLS; CONVERTING
   ENZYME; AT(2) RECEPTOR; FRACTURE RISK; IN VITRO; MICE; STROKE; WOMEN
AB Hypertension and osteoporosis are two major age related disorders however, the underlying molecular mechanism for this comorbidity is not known. The renin angiotensin system (RAS) plays a central role in the control of blood pressure and has been all important target of antihypertensive drugs. Using a chimeric RAS model of transgenic THM (Tsukuba hypertensive mouse) expressing both the human renin and human angiotensinogen genes, we showed in this study that activation of RAS induces high turnover osteoporosis with accelerated bone resorption. Transgenic mice that express only the human renin gene were normotensive and yet exhibited a low bone mass, suggesting that osteoporosis occurs independently of the development of hypertension per se. Ex vivo cultures showed that angiotensin II (AngII) acted on osteoblasts and not directly on osteoclast precursor cells and increased osteoclastogenesis supporting cytokines, RANKL and vascular endothelial growth factor (VEGF), thereby stimulating the formation of osteoclasts. Knockdown of AT2 receptor inhibited the AngII activity, whereas silencing of the AT1 receptor paradoxically enhanced it, suggesting a functional interaction between the two AngII receptors on the osteoblastic cell surface. Finally, treatment of THM mice with an ACE inhibitor, enalapril, improved osteoporosis and hypertension, whereas treatment with losartan, an angiotensin receptor blockers specific for AT1, resulted in exacerbation of the low bone mass phenotype. Thus, blocking the synthesis of AngII may be an effective treatment of osteoporosis and hypertension. especially for those afflicted with both conditions.
C1 [Asaba, Yutaro; Fumoto, Toshio; Watanabe, Ken; Flikuhara, Rvoji; Takeshita, Sunao; Ikeda, Kyoji] Natl Ctr Geriatr & Gerontol, Dept Bone & Joint Dis, Res Inst, Aichi 4748522, Japan.
   [Asaba, Yutaro; Nimura, Yuji] Nagoya Univ, Grad Sch Med, Dept Surg, Nagoya, Aichi 4648601, Japan.
   [Ito, Masako] Nagasaki Univ, Sch Med, Dept Radiol, Nagasaki 852, Japan.
   [Ishida, Junji; Fukamizu, Akiyoshi] Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 305, Japan.
   [Fukamizu, Akiyoshi] Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 305, Japan.
C3 National Center for Geriatrics & Gerontology; Nagoya University;
   Nagasaki University; University of Tsukuba; University of Tsukuba
RP Ikeda, K (通讯作者)，Natl Ctr Geriatr & Gerontol, Dept Bone & Joint Dis, Res Inst, 36 3 Gengo, Aichi 4748522, Japan.
EM kikeda@nils.go.jp
RI fumoto, toshio/F 6345 2015; Watanabe, Ken/I 3960 2013; fukamizu,
   akiyoshi/J 5350 2012
OI fumoto, toshio/0000 0002 9273 8939; 
FU Ministry of Health, Labor and Welfare of Japan; National Institute of
   Biomedical Innovation (NIBIO) of Japan [MF 14, 06 31]
FX The authors thank Kumi Tsutsumi and Mie Suzuki for technical assistance,
   members of our Department (NCC;G') for stimulating discussion, and Dr
   Shinji Fukada (National Hospital for Geriatric Medicine, NCGG) and Dr
   Toshiyuki Arai (Department of Surgery, Nagoya University School of
   Medicine) for encouragement and support throughout the study. This study
   was supported in part by a grant in aid for Longevity Science from the
   Ministry of Health, Labor and Welfare of Japan (to KI) and by a grant
   for the Promotion of Fundamental Studies in Health Sciences of the
   National Institute of Biomedical Innovation (NIBIO) of Japan (MF 14 and
   06 31 to KI). Pacific Edit reviewed the manuscript before submission.
CR Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   BRASCH H, 1993, HYPERTENSION, V22, P699, DOI 10.1161/01.HYP.22.5.699
   BROWNER WS, 1991, LANCET, V338, P355, DOI 10.1016/0140 6736(91)90489 C
   CAMPBELL DJ, 1987, J CLIN INVEST, V79, P1, DOI 10.1172/JCI112768
   Cappuccio FP, 1999, LANCET, V354, P971, DOI 10.1016/S0140 6736(99)01437 3
   Carey RM, 2003, ENDOCR REV, V24, P261, DOI 10.1210/er.2003 0001
   Casas JP, 2005, LANCET, V366, P2026, DOI 10.1016/S0140 6736(05)67814 2
   Cohn RD, 2007, NAT MED, V13, P204, DOI 10.1038/nm1536
   Dennis MS, 2002, STROKE, V33, P728, DOI 10.1161/hs0302.103621
   Dzau V, 2005, J HYPERTENS, V23, pS9, DOI 10.1097/01.hjh.0000165623.72310.dd
   FUKAMIZU A, 1993, J BIOL CHEM, V268, P11617
   Hagiwara H, 1998, J ENDOCRINOL, V156, P543, DOI 10.1677/joe.0.1560543
   Hatton R, 1997, J ENDOCRINOL, V152, P5, DOI 10.1677/joe.0.1520005
   Hiramatsu K, 2007, ENDOCRINOLOGY, V148, P2708, DOI 10.1210/en.2007 0215
   Hunyady L, 2006, MOL ENDOCRINOL, V20, P953, DOI 10.1210/me.2004 0536
   Ito M, 2005, J BONE MINER RES, V20, P1828, DOI 10.1359/JBMR.050610
   Kanis J, 2001, STROKE, V32, P702, DOI 10.1161/01.STR.32.3.702
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Lamparter S, 1998, J CELL PHYSIOL, V175, P89, DOI 10.1002/(SICI)1097 4652(199804)175:1<89::AID JCP10>3.0.CO;2 J
   Lifton RP, 1996, SCIENCE, V272, P676, DOI 10.1126/science.272.5262.676
   Lynn H, 2006, BONE, V38, P584, DOI 10.1016/j.bone.2005.09.011
   Niida S, 2005, P NATL ACAD SCI USA, V102, P14016, DOI 10.1073/pnas.0503544102
   Nouet S, 2000, TRENDS ENDOCRIN MET, V11, P1, DOI 10.1016/S1043 2760(99)00205 2
   Okumura M, 2005, HYPERTENSION, V46, P577, DOI 10.1161/01.HYP.0000178564.14464.80
   ONDETTI MA, 1977, SCIENCE, V196, P441, DOI 10.1126/science.191908
   PEACH MJ, 1977, PHYSIOL REV, V57, P313, DOI 10.1152/physrev.1977.57.2.313
   Ralston SH, 2006, GENE DEV, V20, P2492, DOI 10.1101/gad.1449506
   Ramnemark A, 1998, OSTEOPOROSIS INT, V8, P92, DOI 10.1007/s001980050053
   Shimizu H, 2008, FASEB J, V22, P2465, DOI 10.1096/fj.07 098954
   Strawn WB, 2004, BRIT J HAEMATOL, V126, P120, DOI 10.1111/j.1365 2141.2004.04998.x
   TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo 123 5 2600
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Takimoto E, 1996, SCIENCE, V274, P995, DOI 10.1126/science.274.5289.995
   Tankó LB, 2005, J BONE MINER RES, V20, P1912, DOI 10.1359/JBMR.050711
   von der Recke P, 1999, AM J MED, V106, P273, DOI 10.1016/S0002 9343(99)00028 5
   Winslow MM, 2006, DEV CELL, V10, P771, DOI 10.1016/j.devcel.2006.04.006
   Yu XF, 2003, J BONE MINER RES, V18, P1404, DOI 10.1359/jbmr.2003.18.8.1404
NR 38
TC 139
Z9 165
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD FEB
PY 2009
VL 24
IS 2
BP 241
EP 250
DI 10.1359/JBMR.081006
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 396ER
UT WOS:000262575500008
PM 18847324
OA Bronze
DA 2025 08 17
ER

PT J
AU Jin, UH
   Kim, DI
   Lee, TK
   Lee, DN
   Kim, JK
   Lee, IS
   Kim, CH
AF Jin, Un Ho
   Kim, Dong Il
   Lee, Tae Kyun
   Lee, Dong Nyung
   Kim, June Ki
   Lee, In Seon
   Kim, Cheorl Ho
TI Herbal formulation, Yukmi jihang tang Jahage, regulates bone resorption
   by inhibition of phosphorylation mediated by tyrosine kinase Src and
   cyclooxygenase expression
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Yitkmi jihang tang Jahage; bone resorption; osteoporosis; prostaglandin
   E2; IL 1 beta; osteoblast; protein tyrosinekinase inhibitor; IL 6;
   TNF alpha; TGF beta
ID NECROSIS FACTOR ALPHA; PROSTAGLANDIN E 2 PRODUCTION; VAR.
   MANTCHURICUS SWINHOE; TINCTORIUS L. SEED; GENE EXPRESSION; MOUSE
   OSTEOBLASTS; PILOSE ANTLER; TGF BETA; INTERLEUKIN 1 BETA; EXTRACTS
AB Anti bone resorption properties of the Korean herbal medicine, Yukmi jihang tang (YJ), which is comprised of seven herbs such as Rehmannia glutinosa Libosch, Dioscorea japonica THUNB, Cornus officinalis SIEB et. ZUCC, Smilax glabra ROXB, Paeonia suffruticosa ANDR, Alisma platago aquatica var. orientale SAMUELS and Hominis placenta, were investigated. Cyclooxygenase 2 (COX 2) and tyrosine kinase involve on prostaglandin E2 (PGE2) production in mouse calvarial osteoblasts stimulated by cytokine interleukin 1 beta (IL 1 beta), tumor necrosis factor alpha (TNF alpha) and/or interleukin 6 (M 6). IL 1 beta and IL 6 and to a lesser extent TNF alpha, enhanced COX 2 mRNA levels in calvarial osteoblasts. TGF beta, YJ (100 mu g/ml) and their combinations of YJ + TGF beta reduced the COX 2 mRNA level, PGE2 biosynthesis and bone resorption induced by IL 1 beta, TNF alpha, IL 6 or their combination. Finally, YJ inhibits in vitro and in vivo bone resorption by inhibition of phosphorylation of peptide substrates. The parathyroid hormone induced bone resorption in mouse fetal long bone cultures was inhibited with an IC50 of 16 mu g/ml. YJ dose dependently reduced the hypercalcemia induced in mice by IL 1 beta and partly prevented bone loss and microarchitectural changes in young ovariectomized rats, showing that the protective effect on bone was exerted via the inhibition of bone resorption. These results indicate that the synergy between IL beta, TNF alpha, IL 6 on PGE2 production is due to an enhanced gene expression of COX 2 and that tyrosine kinase(s) are involved in the signal transduction of COX 2 in mouse calvarial osteoblasts. Thus, YJ as a possible Src family kinase inhibitor may be useful for the treatment of diseases associated with elevated bone loss. This result also suggested that the YJ extracts is effective for bone resorptive action in bone cells. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
C1 Sungkyunkwan Univ, Dept Biol Sci, Suwon 440746, South Korea.
   Sungkyunkwan Univ, Natl Res Lab Glycobiol, Suwon 440746, South Korea.
   Dongguk Univ, Coll Oriental Med, Kyungbuk 780714, South Korea.
   LeeTaeKyun Hanuiwon & Hanbang Clin, Taegu, South Korea.
   Seimyung Univ, Coll Oriental Med, Dept Gynecol, Chungbuk, South Korea.
   Keimyung Univ, Ctr Tradit Microorganism Resources, Taegu 704701, South Korea.
C3 Sungkyunkwan University (SKKU); Sungkyunkwan University (SKKU); Dongguk
   University; Keimyung University
RP Kim, CH (通讯作者)，Sungkyunkwan Univ, Dept Biol Sci, Suwon 440746, South Korea.
EM chkimbio@daum.net
RI ; Kim, Cheorl Ho/T 6753 2019; Lee, Dong/I 1569 2015; Kim,
   Yoon/HSC 8333 2023
OI Kim, Cheorl Ho/0000 0002 6323 0714; 
CR BLANCO A, 1995, BIOCHEM J, V312, P419, DOI 10.1042/bj3120419
   BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032
   GUNNESSHEY M, 1984, METAB BONE DIS RELAT, V5, P177, DOI 10.1016/0221 8747(84)90026 2
   HAHN M, 1992, BONE, V13, P327, DOI 10.1016/8756 3282(92)90078 B
   Hong HT, 2002, J ETHNOPHARMACOL, V79, P143, DOI 10.1016/S0378 8741(01)00371 3
   IZBICKA E, 1994, J BONE MINER RES, V9, P127
   JAMALL IS, 1981, ANAL BIOCHEM, V112, P70, DOI 10.1016/0003 2697(81)90261 X
   Jeong JC, 2004, IMMUNOPHARM IMMUNOT, V26, P373, DOI 10.1081/IPH 200026879
   Jeong JC, 2003, INT IMMUNOPHARMACOL, V3, P1685, DOI 10.1016/j.intimp.2003.08.003
   Kang BS, 2003, IMMUNOPHARM IMMUNOT, V25, P347, DOI 10.1081/IPH 120024503
   Kim CH, 2005, INT J BIOCHEM CELL B, V37, P375, DOI 10.1016/j.biocel.2004.07.013
   Kim CH, 2003, IMMUNOL INVEST, V32, P171, DOI 10.1081/IMM 120022977
   Kim HM, 1999, PHARMACOL RES, V40, P171, DOI 10.1006/phrs.1999.0504
   Kim HS, 2002, WA SCI TECHNOL, V2, P395, DOI 10.2166/ws.2002.0196
   Kim KH, 2005, J ETHNOPHARMACOL, V96, P497, DOI 10.1016/j.jep.2004.09.039
   Kim YK, 2003, INT IMMUNOPHARMACOL, V3, P1001, DOI 10.1016/S1567 5769(03)00098 5
   KUROKI Y, 1992, BIOCHEM BIOPH RES CO, V182, P1389, DOI 10.1016/0006 291X(92)91887 V
   Lee RT, 2003, GLYCOBIOLOGY, V13, P11, DOI 10.1093/glycob/cwg002
   LERNER UH, 1991, INFLAMMATION, V15, P427, DOI 10.1007/BF00923340
   LYDON NB, 1992, BIOCHEM J, V287, P985, DOI 10.1042/bj2870985
   Park C, 1999, ARCH BIOCHEM BIOPHYS, V362, P217, DOI 10.1006/abbi.1998.1004
   Park YG, 2004, INT J BIOCHEM CELL B, V36, P2270, DOI 10.1016/j.biocel.2004.04.019
   Park YG, 2004, INT IMMUNOPHARMACOL, V4, P779, DOI 10.1016/j.intimp.2004.03.003
   Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955 0674(97)80062 2
   PHILLIPSON JD, 1989, J ETHNOPHARMACOL, V25, P61, DOI 10.1016/0378 8741(89)90045 7
   Rodan Gideon A., 1996, P979
   Ruegsegger P, 1996, CALCIFIED TISSUE INT, V58, P24, DOI 10.1007/s002239900006
   SABATINI M, 1988, P NATL ACAD SCI USA, V85, P5235, DOI 10.1073/pnas.85.14.5235
   SAMBROOK J, 1998, MOL CLONING LAB MAN
   SERBAN D, 1986, J IMMUNOL METHODS, V90, P159, DOI 10.1016/0022 1759(86)90071 2
   Shi X., 1983, Chinese English terminology of traditional Chinese medicine, P71
   SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0
   STEIN B, 1991, DRUG DISCOV TODAY, V3, P202
   STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999
   UY HL, 1995, J BONE MINER RES, V10, P295
   YONEDA T, 1993, J CLIN INVEST, V91, P2791, DOI 10.1172/JCI116521
   Yucel Lindberg T, 1999, BIOCHEM BIOPH RES CO, V257, P528, DOI 10.1006/bbrc.1999.0523
   YUCELLINDBERG T, 1995, INFLAMMATION, V19, P549, DOI 10.1007/BF01539135
   Yuk TH, 2002, AM J CHINESE MED, V30, P95, DOI 10.1142/S0192415X02000119
NR 39
TC 30
Z9 35
U1 1
U2 19
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD JUL 19
PY 2006
VL 106
IS 3
BP 333
EP 343
DI 10.1016/j.jep.2006.01.012
PG 11
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA 062SX
UT WOS:000238965900008
PM 16513308
DA 2025 08 17
ER

PT J
AU Weekes, D
   Kashima, TG
   Zandueta, C
   Perurena, N
   Thomas, DP
   Sunters, A
   Vuillier, C
   Bozec, A
   El Emir, E
   Miletich, I
   Patiño Garcia, A
   Lecanda, F
   Grigoriadis, AE
AF Weekes, D.
   Kashima, T. G.
   Zandueta, C.
   Perurena, N.
   Thomas, D. P.
   Sunters, A.
   Vuillier, C.
   Bozec, A.
   El Emir, E.
   Miletich, I.
   Patino Garcia, A.
   Lecanda, F.
   Grigoriadis, A. E.
TI Regulation of osteosarcoma cell lung metastasis by the c Fos/AP 1 target
   FGFR1
SO ONCOGENE
LA English
DT Article
ID GROWTH FACTOR RECEPTORS; C FOS PROTOONCOGENE; NUCLEAR TRANSLOCATION;
   GENE EXPRESSION; TRANSGENIC MICE; BONE; DIFFERENTIATION; CANCER;
   OVEREXPRESSION; OSTEOBLASTS
AB Osteosarcoma is the most common primary malignancy of the skeleton and is prevalent in children and adolescents. Survival rates are poor and have remained stagnant owing to chemoresistance and the high propensity to form lung metastases. In this study, we used in vivo transgenic models of c fos oncogene induced osteosarcoma and chondrosarcoma in addition to c Fos inducible systems in vitro to investigate downstream signalling pathways that regulate osteosarcoma growth and metastasis. Fgfr1 (fibroblast growth factor receptor 1) was identified as a novel c Fos/activator protein 1(AP 1) regulated gene. Induction of c Fos in vitro in osteoblasts and chondroblasts caused an increase in Fgfr1 RNA and FGFR1 protein expression levels that resulted in increased and sustained activation of mitogen activated protein kinases (MAPKs), morphological transformation and increased anchorage independent growth in response to FGF2 ligand treatment. High levels of FGFR1 protein and activated pFRS2 alpha signalling were observed in murine and human osteosarcomas. Pharmacological inhibition of FGFR1 signalling blocked MAPK activation and colony growth of osteosarcoma cells in vitro. Orthotopic injection in vivo of FGFR1 silenced osteosarcoma cells caused a marked twofold to fivefold decrease in spontaneous lung metastases. Similarly, inhibition of FGFR signalling in vivo with the small molecule inhibitor AZD4547 markedly reduced the number and size of metastatic nodules. Thus deregulated FGFR signalling has an important role in osteoblast transformation and osteosarcoma formation and regulates the development of lung metastases. Our findings support the development of anti FGFR inhibitors as potential antimetastatic therapy.
C1 [Weekes, D.; Kashima, T. G.; Thomas, D. P.; Sunters, A.; Vuillier, C.; El Emir, E.; Miletich, I.; Grigoriadis, A. E.] Kings Coll London, Dept Craniofacial Dev & Stem Cell Biol, London SE1 9RT, England.
   [Zandueta, C.; Perurena, N.; Lecanda, F.] Univ Navarra, Ctr Appl Med Res CIMA, Div Oncol, Adhes & Metastasis Lab, E 31080 Pamplona, Spain.
   [Bozec, A.] Univ Klinikum Erlangen, Dept Rheumatol & Immunol, Erlangen, Germany.
   [Patino Garcia, A.] Univ Navarra, Ctr Appl Med Res CIMA, Lab Pediat, E 31080 Pamplona, Spain.
   [Patino Garcia, A.; Lecanda, F.] Navarra Inst Hlth Res, IdiSNA, Pamplona, Spain.
   [Weekes, D.] Kings Coll London, Breakthrough Breast Canc Unit, London SE1 9RT, England.
   [Sunters, A.] Univ London Royal Vet Coll, London, England.
C3 University of London; King's College London; University of Navarra;
   University of Erlangen Nuremberg; University of Navarra; University of
   Navarra; University of London; King's College London; University of
   London; University of London Royal Veterinary College
RP Grigoriadis, AE (通讯作者)，Kings Coll London, Guys Hosp, Dept Craniofacial Dev & Stem Cell Biol, Tower Floor 27, London SE1 9RT, England.
EM agi.grigoriadis@kcl.ac.uk
RI Patino Garcia, Ana/I 4299 2012; Perurena, Naiara/IVH 3795 2023;
   Patiño Garcia, Ana/I 4299 2012; Bozec, Aline/M 6942 2015
OI Patino Garcia, Ana/0000 0002 4066 8203; Zandueta Pascual,
   Carolina/0000 0002 7931 8649; Perurena, Naiara/0000 0003 0874 3389;
   Miletich, Isabelle/0000 0003 2817 7492; Weekes,
   Daniel/0000 0001 8083 7617; 
FU Bone Cancer Research Trust, UK [BCRT04/07, BCRT09/08]; Wellcome Trust
   [059344]; Arthritis Research UK [G0538]; Medical Research Council
   [G78/4785]; 'UTE project FIMA' agreement; Cancer Research Thematic
   Network of the Health Institute Carlos III [RTICC RD06/0020/0066];
   Spanish Ministry of Science and Innovation; European Regional
   Development Fund (ERDF); AECC grant
FX This manuscript is dedicated to the memory of Dr Takeshi G Kashima,
   friend and colleague, without whom this work would not progress. We
   thank Dr M Albert Basson (KCL, London, UK), Dr Ozge Uluckan (CNIO,
   Madrid, Spain) and Dr Latifa Bakiri (CNIO, Madrid, Spain) for helpful
   comments and critical reading of the manuscript and Professor Larry J
   Suva (UAMS, Little Rock, AR, USA) for the microCT analysis. This work
   was supported in part by: Bone Cancer Research Trust, UK (BCRT04/07;
   BCRT09/08), Wellcome Trust (059344), Arthritis Research UK (G0538) and
   Medical Research Council (G78/4785) to AEG; 'UTE project FIMA'
   agreement, The Cancer Research Thematic Network of the Health Institute
   Carlos III (RTICC RD06/0020/0066), Spanish Ministry of Science and
   Innovation and European Regional Development Fund (ERDF) 'Una manera de
   hacer Europa' and AECC grant to FL. FL is an investigator from the I3
   Program.
CR Amary MF, 2014, CANCER MED US, V3, P980, DOI 10.1002/cam4.268
   Ando Kosei, 2012, Sarcoma, V2012, P523432, DOI 10.1155/2012/523432
   Behr B, 2010, BONE, V47, P281, DOI 10.1016/j.bone.2010.05.008
   Bodo M, 2002, MOL MED, V8, P393, DOI 10.1007/BF03402020
   Bozec A, 2010, J CELL BIOL, V190, P1093, DOI 10.1083/jcb.201002111
   Brooks AN, 2012, CLIN CANCER RES, V18, P1855, DOI 10.1158/1078 0432.CCR 11 0699
   Carter EP, 2015, TRENDS CELL BIOL, V25, P221, DOI 10.1016/j.tcb.2014.11.003
   Chen Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098293
   Dailey L, 2005, CYTOKINE GROWTH F R, V16, P233, DOI 10.1016/j.cytogfr.2005.01.007
   David JP, 2005, J CLIN INVEST, V115, P664, DOI 10.1172/JCI200522877
   Durchdewald M, 2008, CANCER RES, V68, P6877, DOI 10.1158/0008 5472.CAN 08 0299
   Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001
   FERRACINI R, 1995, ONCOGENE, V10, P739
   Franchi A, 1998, VIRCHOWS ARCH, V432, P515, DOI 10.1007/s004280050199
   Fujiwara M, 2011, TUMOR BIOL, V32, P611, DOI 10.1007/s13277 011 0160 y
   Gavine PR, 2012, CANCER RES, V72, P2045, DOI 10.1158/0008 5472.CAN 11 3034
   Greulich H, 2011, TRENDS MOL MED, V17, P283, DOI 10.1016/j.molmed.2011.01.012
   GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685
   Grose R, 2007, EMBO J, V26, P1268, DOI 10.1038/sj.emboj.7601583
   Guagnano V, 2012, CANCER DISCOV, V2, P1118, DOI 10.1158/2159 8290.CD 12 0210
   Hajihosseini MK, 2004, DEVELOPMENT, V131, P325, DOI 10.1242/dev.00940
   Jamil N, 2010, INT J EXP PATHOL, V91, P387, DOI 10.1111/j.1365 2613.2010.00749.x
   Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389
   Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838
   Kashima T, 2003, INT J CANCER, V104, P147, DOI 10.1002/ijc.10931
   Kashimaa TG, 2009, HUM PATHOL, V40, P226, DOI 10.1016/j.humpath.2008.07.008
   Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982
   Kunita A, 2011, AM J PATHOL, V179, P1041, DOI 10.1016/j.ajpath.2011.04.027
   LADANYI M, 1993, DIAGN MOL PATHOL, V2, P163, DOI 10.1097/00019606 199300020 00026
   Marie PJ, 2005, J CELL BIOCHEM, V96, P888, DOI 10.1002/jcb.20582
   Marshall ME, 2011, CLIN CANCER RES, V17, P5016, DOI 10.1158/1078 0432.CCR 11 0050
   Mills IG, 2012, SEMIN CELL DEV BIOL, V23, P165, DOI 10.1016/j.semcdb.2011.09.004
   Miraoui H, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3146re9
   Ng AJM, 2012, CLIN SARCOMA RES, V2, DOI 10.1186/2045 3329 2 19
   Ohbayashi N, 2002, GENE DEV, V16, P870, DOI 10.1101/gad.965702
   Ornitz DM, 2005, CYTOKINE GROWTH F R, V16, P205, DOI 10.1016/j.cytogfr.2005.02.003
   Ozanne BW, 2007, ONCOGENE, V26, P1, DOI 10.1038/sj.onc.1209759
   Raucci A, 2008, J CELL PHYSIOL, V215, P442, DOI 10.1002/jcp.21323
   Sabbieti MG, 2005, CELL TISSUE RES, V319, P267, DOI 10.1007/s00441 004 0981 8
   Shimizu T, 2010, ONCOGENE, V29, P5687, DOI 10.1038/onc.2010.312
   Shimizu T, 2012, MOL CANCER RES, V10, P454, DOI 10.1158/1541 7786.MCR 11 0347
   Sorensen V, 2006, BIOESSAYS, V28, P504, DOI 10.1002/bies.20405
   Sunters A, 2004, J BIOL CHEM, V279, P9882, DOI 10.1074/jbc.M310184200
   Sunters A, 1998, DEV GENET, V22, P386, DOI 10.1002/(SICI)1520 6408(1998)22:4<386::AID DVG8>3.0.CO;2 2
   Thomas DP, 2000, J CELL SCI, V113, P439
   Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780
   Vicent S, 2008, CANCER RES, V68, P2275, DOI 10.1158/0008 5472.CAN 07 6493
   WANG ZQ, 1995, CANCER RES, V55, P6244
   WANG ZQ, 1991, EMBO J, V10, P2437, DOI 10.1002/j.1460 2075.1991.tb07783.x
   Wilkie AOM, 2005, CYTOKINE GROWTH F R, V16, P187, DOI 10.1016/j.cytogfr.2005.03.001
   WU JX, 1990, ONCOGENE, V5, P989
   Yaguchi Y, 2009, DEV DYNAM, V238, P2058, DOI 10.1002/dvdy.22013
   Zenz R, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2338
NR 53
TC 51
Z9 52
U1 0
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950 9232
EI 1476 5594
J9 ONCOGENE
JI Oncogene
PD JUN 2
PY 2016
VL 35
IS 22
BP 2852
EP 2861
DI 10.1038/onc.2015.344
PG 10
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA DO0MT
UT WOS:000377473700005
PM 26387545
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Zeng, XZ
   Zhang, YY
   Yang, Q
   Wang, S
   Zou, BH
   Tan, YH
   Zou, M
   Liu, SW
   Li, XJ
AF Zeng, Xiang zhou
   Zhang, Yue yang
   Yang, Qin
   Wang, Song
   Zou, Bin hua
   Tan, Yan hui
   Zou, Min
   Liu, Shu wen
   Li, Xiao juan
TI Artesunate attenuates LPS induced osteoclastogenesis by suppressing
   TLR4/TRAF6 and PLCγ1 Ca<SUP>2+</SUP> NFATc1 signaling pathway
SO ACTA PHARMACOLOGICA SINICA
LA English
DT Article
DE artesunate; osteoclast; LPS; PP2B A alpha; Ca2+; NFATc1; TLR4; RAW264; 7
   cells; chronic infectious diseases
ID RANKL INDUCED OSTEOCLASTOGENESIS; TUMOR NECROSIS FACTOR; BONE LOSS;
   LIPOPOLYSACCHARIDE; EXPRESSION; DIFFERENTIATION; ACTIVATION; INHIBITION;
   RESORPTION; ALPHA
AB In chronic infectious diseases caused by gram negative bacteria, such as osteomyelitis, septic arthritis, and periodontitis, osteoclastic activity is enhanced with elevated inflammation, which disturbs the bone homeostasis and results in osteolysis. Lipopolysaccharide (LPS), as a bacteria product, plays an important role in this process. Recent evidence shows that an antimalarial drug artesunate attenuates LPS induced osteolysis independent of RANKL. In this study we evaluated the effects of artesunate on LPS induced osteoclastogenesis in vitro and femur osteolysis in vivo, and explored the mechanisms underlying the effects of artesunate on LPS induced osteoclast differentiation independent of RANKL. In preosteoclastic RAW264.7 cells, we found that artesunate (1.56 12.5 mu M) dose dependently inhibited LPS induced osteoclast formation accompanied by suppressing LPS stimulated osteoclast related gene expression (Fra 2, TRAP, Cathepsin K, beta 3 integrin, DC STAMP, and Atp6v0d2). We showed that artesunate (3.125 12.5 mu M) inhibited LPS stimulated nuclear factor of activated T cells c1 (NFATc1) but not NF kappa B transcriptional activity; artesunate (6.25, 12.5 mu M) significantly inhibited LPS stimulated NFATc1 protein expression. Furthermore, artesunate treatment markedly suppressed LPS induced Ca2+ influx, and decreased the expression of PP2B A alpha (calcineurin) and pPLC gamma 1 in the cells. In addition, artesunate treatment significantly decreased the expression of upstream signals TLR4 and TRAF6 during LPS induced osteoclastogenesis. Administration of artesunate (10 mg/kg, ip) for 8 days effectively inhibited serum TNF alpha levels and ameliorated LPS (5 mg/kg, ip) induced inflammatory bone loss in vivo. Taken together, artesunate attenuates LPS induced inflammatory osteoclastogenesis by inhibiting the expression of TLR4/TRAF6 and the downstream PLC gamma 1 Ca2+ NFATc1 signaling pathway. Artesunate is a valuable choice to treat bone loss induced by gram negative bacteria infection or inflammation in RANKL independent pathway.
C1 [Zeng, Xiang zhou; Zhang, Yue yang; Yang, Qin; Tan, Yan hui; Li, Xiao juan] Southern Med Univ, Sch Pharmaceut Sci, Lab Antiinflammatory & Immunomodulatory Pharmacol, Guangzhou 510515, Peoples R China.
   [Zeng, Xiang zhou; Zhang, Yue yang; Yang, Qin; Zou, Bin hua; Tan, Yan hui; Zou, Min; Liu, Shu wen; Li, Xiao juan] Southern Med Univ, Sch Pharmaceut Sci, Guangdong Prov Key Lab New Drug Screening, Guangzhou 510515, Peoples R China.
   [Zeng, Xiang zhou] Hainan Med Coll, Dept Pharmacol, Haikou 571199, Hainan, Peoples R China.
   [Wang, Song] Guangdong Hosp Tradit Chinese Med, Dept Surg, Guangzhou 510120, Peoples R China.
C3 Southern Medical University   China; Southern Medical University  
   China; Hainan Medical University; Guangzhou University of Chinese
   Medicine
RP Li, XJ (通讯作者)，Southern Med Univ, Sch Pharmaceut Sci, Lab Antiinflammatory & Immunomodulatory Pharmacol, Guangzhou 510515, Peoples R China.; Liu, SW; Li, XJ (通讯作者)，Southern Med Univ, Sch Pharmaceut Sci, Guangdong Prov Key Lab New Drug Screening, Guangzhou 510515, Peoples R China.
EM liusw@smu.edu.cn; lixiaoj@smu.edu.cn
RI Liu, Shuwen/D 1514 2012; Zeng, Xiangzhou/AAK 1176 2020; Yang,
   Qinfeng/GWZ 7495 2022; 邹, 斌华/CAG 5540 2022
OI Liu, Shuwen/0000 0001 6346 5006; Zou, Binhua/0000 0003 0731 1525; 
FU National Natural Science Foundation of China [81773740, 81073119,
   81611130078]; Natural Science Foundation of Guangdong Province, China
   [2015A030313287]; Natural Science Foundation of Hainan Province, China
   [817129]
FX This work was supported by the National Natural Science Foundation of
   China (81773740, 81073119, and 81611130078), the Natural Science
   Foundation of Guangdong Province, China (2015A030313287), and the
   Natural Science Foundation of Hainan Province, China (817129).
CR AbuAmer Y, 1997, J CLIN INVEST, V100, P1557, DOI 10.1172/JCI119679
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bohannon JK, 2013, SHOCK, V40, P451, DOI 10.1097/SHK.0000000000000042
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cen YY, 2016, INT IMMUNOPHARMACOL, V38, P252, DOI 10.1016/j.intimp.2016.06.007
   Guo C, 2012, CELL PHYSIOL BIOCHEM, V30, P123, DOI 10.1159/000339052
   He AQ, 2016, INFLAMMATION, V39, P172, DOI 10.1007/s10753 015 0236 8
   He LG, 2016, EUR J PHARMACOL, V779, P66, DOI 10.1016/j.ejphar.2016.03.014
   Ho WE, 2014, PHARMACOL THERAPEUT, V142, P126, DOI 10.1016/j.pharmthera.2013.12.001
   Hotokezaka H, 2007, J CELL BIOCHEM, V101, P122, DOI 10.1002/jcb.21167
   Hou GQ, 2013, INT J MOL MED, V32, P503, DOI 10.3892/ijmm.2013.1406
   Islam S, 2007, BIOCHEM BIOPH RES CO, V360, P346, DOI 10.1016/j.bbrc.2007.06.023
   Keestra JAJ, 2015, J PERIODONTAL RES, V50, P689, DOI 10.1111/jre.12252
   Khuda IIE, 2010, IMMUNOLOGY, V131, P59, DOI 10.1111/j.1365 2567.2010.03274.x
   Lee EY, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3385
   Nair SP, 1996, INFECT IMMUN, V64, P2371, DOI 10.1128/IAI.64.7.2371 2380.1996
   Park H, 2015, ANTIOXID REDOX SIGN, V22, P63, DOI 10.1089/ars.2013.5748
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rosenthal PJ, 2008, NEW ENGL J MED, V358, P1829, DOI 10.1056/NEJMct0709050
   Suda K, 2004, J IMMUNOL, V172, P2504, DOI 10.4049/jimmunol.172.4.2504
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Thummuri D, 2015, PHARMACOL RES, V99, P63, DOI 10.1016/j.phrs.2015.05.006
   Wei CM, 2018, J CELL PHYSIOL, V233, P476, DOI 10.1002/jcp.25907
   Yang M, 2017, CHIN J INTEGR MED, V23, P496, DOI 10.1007/s11655 016 2650 7
   Ye F, 2017, MOL MED REP, V16, P6228, DOI 10.3892/mmr.2017.7338
   Yoon SH, 2009, FEBS LETT, V583, P1164, DOI 10.1016/j.febslet.2009.03.005
   Zeng XZ, 2017, BIOCHEM PHARMACOL, V124, P57, DOI 10.1016/j.bcp.2016.10.007
   Zhang Y, 2016, BIOL PHARM BULL, V39, P2028, DOI 10.1248/bpb.b16 00522
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
   Zhao CJ, 2017, BIOMED PHARMACOTHER, V96, P410, DOI 10.1016/j.biopha.2017.10.018
   Zhou L, 2016, J BONE MINER RES, V31, P964, DOI 10.1002/jbmr.2771
NR 31
TC 97
Z9 106
U1 6
U2 47
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1671 4083
EI 1745 7254
J9 ACTA PHARMACOL SIN
JI Acta Pharmacol. Sin.
PD FEB
PY 2020
VL 41
IS 2
BP 229
EP 236
DI 10.1038/s41401 019 0289 6
PG 8
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA KH6NZ
UT WOS:000510769500010
PM 31431733
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Wang, QS
   Zhang, XC
   Li, RX
   Sun, JG
   Su, WH
   Guo, Y
   Li, H
   Zhang, XZ
AF Wang, Qiang Song
   Zhang, Xin Chang
   Li, Rui Xin
   Sun, Jing Gong
   Su, Wei Hua
   Guo, Yong
   Li, Hao
   Zhang, Xi Zheng
TI A comparative study of mechanical strain, icariin and combination
   stimulations on improving osteoinductive potential via NF kappaB
   activation in osteoblast like cells
SO BIOMEDICAL ENGINEERING ONLINE
LA English
DT Article
DE Mechanical strain; Icariin; BMP 2; NF kappa B; Bone remodeling
ID MESENCHYMAL STEM CELLS; IN VITRO; SIGNALING PATHWAY; B ACTIVATION; BONE;
   DIFFERENTIATION; EXPRESSION; ESTROGEN; MATRIX; MECHANOTRANSDUCTION
AB Background: The combination of drugs and exercise was the effective treatment in bone injure and rebuilding in clinic. As mechanical strain has potential in inducing the differentiation of osteoblasts in our previous study, the further research to investigate the combination of mechanical strain and icariin stimulation on inducing osteoblast proliferation, differentiation and the possible mechanism in MC3T3 E1 cell line.
   Methods: A whole cell enzyme linked immunosorbent assay that detects the bromodeoxyuridine incorporation during DNA synthesis was applied to evaluate the proliferation. The mRNA expression of alkaline phosphatase (ALP), osteocalcin (OCN), type I collagen (Col I), bone morphogenetic protein 2 (BMP 2) and BMP 4 was detected by real time reverse transcription polymerase chain reaction. The activity of ALP was analyzed by ELISA and the protein expression of OCN, Col I and BMP 2 was assessed by western blot. Moreover, the activity of nuclear transcription factor kappa B (NF kappa B) signaling pathway was investigated with the expression of inhibitor of kappa B (I kappa B) a, phosphorylation of I kappa B alpha (P I kappa B alpha), p65, P p65 by western blot.
   Results: We observed that compared to single mechanical strain or icariin stimulation, the mRNA and protein expressions of ALP (P < 0.05 or P < 0.01), OCN (P < 0.01) and Col I (P < 0.05 or P < 0.01) were increased significantly by the combination of mechanical strain and icariin stimulation. Moreover, the combination of mechanical strain and icariin stimulation could up regulate the expression of BMP 2 (P < 0.01) and BMP 4 compared to single mechanical strain or icariin stimulation. The combination of mechanical strain and icariin stimulation could activate NF kappa B signaling pathway by increasing the expression of I kappa B a, P I kappa B alpha, p65, P p65 (P < 0.01).
   Conclusion: The combination of mechanical strain and icariin stimulation could activate the NF kappa B pathway to improve the proliferation, differentiation of osteoblast like cells.
C1 [Wang, Qiang Song; Zhang, Xin Chang; Li, Rui Xin; Sun, Jing Gong; Su, Wei Hua; Guo, Yong; Li, Hao; Zhang, Xi Zheng] Acad Mil Med Sci, Tianjin Inst Med Equipment, Tianjin 300162, Peoples R China.
C3 Academy of Military Medical Sciences   China
RP Zhang, XZ (通讯作者)，Acad Mil Med Sci, Tianjin Inst Med Equipment, 106 Wandong Rd, Tianjin 300162, Peoples R China.
EM z56717@sohu.com
RI Li, Hao/HKO 5710 2023; Zhang, Xinchang/HOH 1114 2023
FU key program of the National Nature Science Foundation of China
   [11432016]; National Nature Science Foundation of China [31470935,
   11372351]; Postdoctoral Science Foundation of China [2014M552639]
FX This work was supported by Grants from the key program of the National
   Nature Science Foundation of China (No. 11432016), the National Nature
   Science Foundation of China (No. 31470935, 11372351) and the
   Postdoctoral Science Foundation of China (No. 2014M552639).
CR Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092 8674(00)81318 5
   BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.iy.12.040194.001041
   Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649
   BARBEE KA, 1994, ANN BIOMED ENG, V22, P14, DOI 10.1007/BF02368218
   Bhatt KA, 2007, J SURG RES, V143, P329, DOI 10.1016/j.jss.2007.01.023
   Bottlang M, 1997, BIOMED TECH, V42, P305, DOI 10.1515/bmte.1997.42.11.305
   BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532
   Burr DB, 1996, BONE, V18, P405, DOI 10.1016/8756 3282(96)00028 2
   Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002 0023
   Cui YL, 2003, BIOMATERIALS, V24, P3859, DOI 10.1016/S0142 9612(03)00209 6
   Duquette TL, 2010, J ORTHOP SPORT PHYS, V40, P834, DOI 10.2519/jospt.2010.0421
   Ehrlich PJ, 2002, OSTEOPOROSIS INT, V13, P688, DOI 10.1007/s001980200095
   FROST HM, 1992, BONE MINER, V19, P257, DOI 10.1016/0169 6009(92)90875 E
   Granet C, 2001, BIOCHEM BIOPH RES CO, V284, P622, DOI 10.1006/bbrc.2001.5023
   Guo Y, 2012, BIOMED ENG ONLINE, V11, DOI 10.1186/1475 925X 11 80
   Hess K, 2009, BONE, V45, P367, DOI 10.1016/j.bone.2009.04.252
   HILLAM RA, 1995, J BONE MINER RES, V10, P683
   Hsieh CP, 2010, CONNECT TISSUE RES, V51, P497, DOI 10.3109/03008201003746679
   Hughes Fulford Millie, 2004, Sci STKE, V2004, pRE12
   Kumar A, 2004, FASEB J, V18, P1524, DOI 10.1096/fj.04 2414com
   Lappas M, 2002, BIOL REPROD, V67, P668, DOI 10.1095/biolreprod67.2.668
   Liang FQ, 1999, J CLIN INVEST, V104, P1603, DOI 10.1172/JCI7362
   Martin TJ, 2006, NAT MED, V12, P612, DOI 10.1038/nm0606 612
   Miyazono K, 2005, CYTOKINE GROWTH F R, V16, P251, DOI 10.1016/j.cytogfr.2005.01.009
   Mok SK, 2010, BRIT J PHARMACOL, V159, P939, DOI 10.1111/j.1476 5381.2009.00593.x
   Mullender M, 2004, MED BIOL ENG COMPUT, V42, P14, DOI 10.1007/BF02351006
   NASA, 2012, STRONG BON FEW REN S
   Nian H, 2009, PHYTOMEDICINE, V16, P320, DOI 10.1016/j.phymed.2008.12.006
   Owan I, 1997, AM J PHYSIOL CELL PH, V273, pC810, DOI 10.1152/ajpcell.1997.273.3.C810
   Perrien DS, 2006, J CLIN ENDOCR METAB, V91, P1848, DOI 10.1210/jc.2005 2423
   RUBIN CT, 1984, J BONE JOINT SURG AM, V66A, P397, DOI 10.2106/00004623 198466030 00012
   Rubin J, 2006, GENE, V367, P1, DOI 10.1016/j.gene.2005.10.028
   Ryu B, 2010, CHEM BIOL INTERACT, V184, P413, DOI 10.1016/j.cbi.2009.12.003
   Schriefer JL, 2005, J BIOMECH, V38, P1838, DOI 10.1016/j.jbiomech.2004.08.017
   Simmons CA, 2003, J BIOMECH, V36, P1087, DOI 10.1016/S0021 9290(03)00110 6
   Song LG, 2013, EUR J PHARMACOL, V714, P15, DOI 10.1016/j.ejphar.2013.05.039
   Surh YJ, 2001, MUTAT RES FUND MOL M, V480, P243, DOI 10.1016/S0027 5107(01)00183 X
   Tang LL, 2004, J BIOMECH, V37, P157, DOI 10.1016/S0021 9290(03)00237 9
   URIST MR, 1972, CLIN ORTHOP RELAT R, P132
   Wang C, 2011, J BONE MINER METAB, V29, P466, DOI 10.1007/s00774 010 0244 6
   Wang L, 2012, ANN BIOMED ENG, V40, P1884, DOI 10.1007/s10439 012 0548 x
   Wang LA, 2010, CELL PHYSIOL BIOCHEM, V26, P1093, DOI 10.1159/000323987
   Wang QS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034122
   Wang QS, 2012, J ETHNOPHARMACOL, V141, P377, DOI 10.1016/j.jep.2012.02.049
   Wozniak M, 2000, J BONE MINER RES, V15, P1731, DOI 10.1359/jbmr.2000.15.9.1731
   Yan YX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035709
   Yoshitake F, 2008, J BIOL CHEM, V283, P11535, DOI 10.1074/jbc.M607999200
NR 47
TC 11
Z9 20
U1 0
U2 30
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1475 925X
J9 BIOMED ENG ONLINE
JI Biomed. Eng. Online
PD MAY 21
PY 2015
VL 14
AR 46
DI 10.1186/s12938 015 0039 z
PG 15
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA CI7AV
UT WOS:000354916200001
PM 25994935
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yoon, I
   Xue, LL
   Chen, QY
   Liu, JY
   Xu, JC
   Siddiqui, Z
   Kim, D
   Chen, BL
   Shi, QQ
   Han, EL
   Ruiz, MC
   Vining, KH
   Mitchell, MJ
AF Yoon, Il Chul
   Xue, Lulu
   Chen, Qinyuan
   Liu, Jingyi
   Xu, Junchao
   Siddiqui, Zain
   Kim, Dongyoon
   Chen, Bingling
   Shi, Qiangqiang
   Han, Emily Laura
   Ruiz, Mia Cherry
   Vining, Kyle H.
   Mitchell, Michael J.
TI Piperazine Derived Bisphosphonate Based Ionizable Lipid Nanoparticles
   Enhance mRNA Delivery to the Bone Microenvironment
SO ANGEWANDTE CHEMIE INTERNATIONAL EDITION
LA English
DT Article
DE Bisphosphonate; Lipid nanoparticles; mRNA delivery; Piperazine based
   ionizable lipids; Targeting bone microenvironment
ID CALCIUM PHOSPHATE MATERIALS; OSTEOBLASTS; COMPLEXES; MECHANISM; SIZE;
   MINERALIZATION; OSTEONECROSIS; SURFACTANT; CARRIERS; SIGNALS
AB Nucleic acid delivery with mRNA lipid nanoparticles are being developed for targeting a wide array of tissues and cell types. However, targeted delivery to the bone microenvironment remains a significant challenge in the field, due in part to low local blood flow and poor interactions between drug carriers and bone material. Here we report bone targeting ionizable lipids incorporating a piperazine backbone and bisphosphate moieties, which bind tightly with hydroxyapatite ([Ca5(PO4)3OH]), a key component of mineralized tissues. These lipids demonstrate biocompatibility and low toxicity in both vitro and in vivo studies. LNP formulated with these lipids facilitated efficient cellular transfection and improved binding to hydroxyapatite in vitro, and targeted delivery to the bone microenvironment in vivo following systemic administration. Overall, our findings demonstrate the critical role of the piperazine backbone in a novel ionizable lipid, which incorporates a bisphosphonate group to enable efficient bone targeted delivery, highlighting the potential of rational design of ionizable lipids for next generation bone targeting delivery systems.
C1 [Yoon, Il Chul; Xue, Lulu; Liu, Jingyi; Xu, Junchao; Siddiqui, Zain; Kim, Dongyoon; Shi, Qiangqiang; Han, Emily Laura; Mitchell, Michael J.] Univ Penn, Sch Engn & Appl Sci, Dept Bioengn, Philadelphia, PA 19104 USA.
   [Yoon, Il Chul; Vining, Kyle H.] Univ Penn, Sch Engn & Appl Sci, Dept Mat Sci & Engn, Philadelphia, PA 19104 USA.
   [Yoon, Il Chul; Chen, Qinyuan; Liu, Jingyi; Siddiqui, Zain; Chen, Bingling; Ruiz, Mia Cherry; Vining, Kyle H.] Univ Penn, Sch Dent Med, Prevent & Restorat Sci, Philadelphia, PA 19104 USA.
   [Mitchell, Michael J.] Univ Penn, Abramson Canc Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Mitchell, Michael J.] Univ Penn, Ctr Cellular Immunotherapies, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Mitchell, Michael J.] Univ Penn, Penn Inst RNA Innovat, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Mitchell, Michael J.] Univ Penn, Inst Immunol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Mitchell, Michael J.] Univ Penn, Cardiovasc Inst, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Mitchell, Michael J.] Univ Penn, Inst Regenerat Med, Perelman Sch Med, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; University of Pennsylvania; University of
   Pennsylvania; University of Pennsylvania; University of Pennsylvania;
   University of Pennsylvania; University of Pennsylvania; University of
   Pennsylvania; University of Pennsylvania
RP Mitchell, MJ (通讯作者)，Univ Penn, Sch Engn & Appl Sci, Dept Bioengn, Philadelphia, PA 19104 USA.; Vining, KH (通讯作者)，Univ Penn, Sch Engn & Appl Sci, Dept Mat Sci & Engn, Philadelphia, PA 19104 USA.; Vining, KH (通讯作者)，Univ Penn, Sch Dent Med, Prevent & Restorat Sci, Philadelphia, PA 19104 USA.; Mitchell, MJ (通讯作者)，Univ Penn, Abramson Canc Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA.; Mitchell, MJ (通讯作者)，Univ Penn, Ctr Cellular Immunotherapies, Perelman Sch Med, Philadelphia, PA 19104 USA.; Mitchell, MJ (通讯作者)，Univ Penn, Penn Inst RNA Innovat, Perelman Sch Med, Philadelphia, PA 19104 USA.; Mitchell, MJ (通讯作者)，Univ Penn, Inst Immunol, Perelman Sch Med, Philadelphia, PA 19104 USA.; Mitchell, MJ (通讯作者)，Univ Penn, Cardiovasc Inst, Perelman Sch Med, Philadelphia, PA 19104 USA.; Mitchell, MJ (通讯作者)，Univ Penn, Inst Regenerat Med, Perelman Sch Med, Philadelphia, PA 19104 USA.
EM viningk@seas.upenn.edu; mjmitch@seas.upenn.edu
RI Shi, Qiangqiang/KWU 0671 2024; Xu, Junchao/R 6796 2016; Xue,
   Lulu/IXN 2023 2023; Mitchell, Michael/K 8420 2014; Vining,
   Kyle/I 9256 2017
OI Han, Emily/0009 0008 6276 7502; Vining, Kyle/0000 0002 4009 879X
FU Foundation for the National Institutes of Health; Innovation in Dental
   Medicine and Engineering to Advance Oral Health   Center for Innovation
   & Precision Dentistry (CiPD); Penn Health Tech (PHT) at the University
   of Pennsylvania [R00DE030084]; National Institute of Dental &
   Craniofacial Research of the National Institutes of Health [DP2
   TR002776]; NIH Director's New Innovator Award; Burroughs Wellcome Fund
   Career Award at the Scientific Interface (CASI) [RSG 22 122 01 ET];
   American Cancer Society Research Scholar Grant [CBET 2145491]; NSF
   CAREER Award [HD115877]; NIH NICHD R01 Grant [1845298]; NSF Graduate
   Research Fellowship; MALDI ToF analyses at the Biological Chemistry
   Research Center at the Department of Chemistry at the University of
   Pennsylvania [NSF CHE 1827457, 3R01GM118510 03S1, 3R01GM087605 06S1];
   NSF Major Research Instrumentation Program [RRID: SCR_022375]; Vagelos
   Institute for Energy Science and Technology [ECCS 1542153]; NSF
FX This study was supported by the Innovation in Dental Medicine and
   Engineering to Advance Oral Health (IDEA) prize funded by the Center for
   Innovation & Precision Dentistry (CiPD) and Penn Health Tech (PHT) at
   the University of Pennsylvania. Research reported in this manuscript was
   supported by the National Institute of Dental & Craniofacial Research of
   the National Institutes of Health under award number R00DE030084 (K. H.
   V.). This project was also supported by the NIH Director ' s New
   Innovator Award (DP2 TR002776), the Burroughs Wellcome Fund Career Award
   at the Scientific Interface (CASI), the American Cancer Society Research
   Scholar Grant (RSG 22 122 01 ET), the NSF CAREER Award (CBET 2145491),
   and the NIH NICHD R01 Grant (HD115877) (M. J. M.), as well as an NSF
   Graduate Research Fellowship (Award 1845298) (E. L. H.). The authors
   gratefully acknowledge the support and assistance of Ryan S. Kubanoff,
   with the FT IR and MALDI ToF analyses at the Biological Chemistry
   Research Center at the Department of Chemistry at the University of
   Pennsylvania. Appreciation is extended to Dr. Jun Gu and Dr. Chad
   Lawrence for their discussions on the use of NMR instruments at the
   Department of Chemistry NMR Facility and analysis of the spectra
   results. The NSF Major Research Instrumentation Program (award NSF
   CHE 1827457), NIH supplements awards 3R01GM118510 03S1 and
   3R01GM087605 06S1, and Vagelos Institute for Energy Science and
   Technology supported the purchase of the NMRs used in this study.
   Special thanks are given to Dr. Charles W. Ross III, UPenn Chemistry
   Director   Automated Synthesis and Characterization, for his assistance
   with the use of the mass spectrometer and discussions on the analysis of
   mass spectrometry results. The authors extend their appreciation to Dr.
   Stefan Steimle, Dr. Prerana Gogoi, and Dr. Molugu Sudheer from the
   Institute of Structural Biology and Beckman Center for cryo TEM at the
   University of Pennsylvania (RRID: SCR_022375), for their contributions
   to the cryo TEM experiments. Special thanks are given to Dr. Matthew J.
   Brukman for his invaluable insights and thorough analysis of the AFM
   usage and results. AFM measurements were performed at the Singh Center
   for Nanotechnology, an NNIN member with support from NSF grant
   ECCS 1542153. The authors thank Dr. Zhi Ren for his assistance in
   confocal microscopy and valuable discussions prior to the submission.
CR Ahmad A, 2019, BIOCHIMIE, V160, P61, DOI 10.1016/j.biochi.2019.02.012
   Alameh M. G., 2022, RNA THERAPEUTICS
   Alfranca A, 2015, CELL MOL LIFE SCI, V72, P3097, DOI 10.1007/s00018 015 1918 y
   Beird HC, 2022, NAT REV DIS PRIMERS, V8, DOI 10.1038/s41572 022 00409 y
   Burdusel AC, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10123158
   Caetano Lopes J, 2007, ACTA REUMATOL PORT, V32, P103
   Cárdenas M, 2023, CURR OPIN COLLOID IN, V66, DOI 10.1016/j.cocis.2023.101705
   Carina V, 2020, CALCIFIED TISSUE INT, V107, P301, DOI 10.1007/s00223 020 00724 0
   Chabloz NG, 2020, CHEM EUR J, V26, P4552, DOI 10.1002/chem.201904757
   Chabloz NG, 2019, CHEM EUR J, V25, P10895, DOI 10.1002/chem.201901820
   Champion JA, 2007, P NATL ACAD SCI USA, V104, P11901, DOI 10.1073/pnas.0705326104
   Chang C, 2020, J AUTOIMMUN, V110, DOI 10.1016/j.jaut.2020.102460
   Chaudhary N, 2021, NAT REV DRUG DISCOV, V20, P817, DOI 10.1038/s41573 021 00283 5
   Chen KP, 2022, ADV FUNCT MATER, V32, DOI 10.1002/adfm.202204692
   Chindamo G, 2020, NANOMATERIALS BASEL, V10, DOI 10.3390/nano10050875
   Chithrani BD, 2007, NANO LETT, V7, P1542, DOI 10.1021/nl070363y
   Chithrani BD, 2006, NANO LETT, V6, P662, DOI 10.1021/nl052396o
   Cowin SC, 2015, J BIOMECH, V48, P842, DOI 10.1016/j.jbiomech.2014.12.013
   de Azevedo JWV, 2020, ONCOL LETT, V19, P1099, DOI 10.3892/ol.2019.11229
   Decuzzi P, 2009, PHARM RES DORD, V26, P235, DOI 10.1007/s11095 008 9697 x
   Dong SJ, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.201907071
   Duncan RL, 1998, SEMIN NEPHROL, V18, P178
   Dvorak MM, 2004, CELL CALCIUM, V35, P249, DOI 10.1016/j.ceca.2003.10.014
   Eisermann J, 2023, RSC CHEM BIOL, V4, P386, DOI 10.1039/d2cb00158f
   Etich J, 2020, CELL SIGNAL, V76, DOI 10.1016/j.cellsig.2020.109789
   FLEISCH H, 1993, OSTEOPOROSIS INT, V3, pS15
   Fleisch H., 2005, AGING SPINE
   Fleisch H., 1988, CALCIUM DRUG ACTIONS
   Forlino A, 2016, LANCET, V387, P1657, DOI 10.1016/S0140 6736(15)00728 X
   Forlino A, 2011, NAT REV ENDOCRINOL, V7, P540, DOI 10.1038/nrendo.2011.81
   Glimcher MJ, 2006, REV MINERAL GEOCHEM, V64, P223, DOI 10.2138/rmg.2006.64.8
   Goodman SB, 2020, J INFLAMM RES, V13, P913, DOI 10.2147/JIR.S281941
   GOTOH Y, 1990, BONE MINER, V8, P239, DOI 10.1016/0169 6009(90)90109 S
   Gratton SEA, 2008, P NATL ACAD SCI USA, V105, P11613, DOI 10.1073/pnas.0801763105
   Han YJ, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0019 6
   Hendriks M, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.602278
   Hou XC, 2021, NAT REV MATER, V6, P1078, DOI 10.1038/s41578 021 00358 0
   Hsu WL, 2005, LANGMUIR, V21, P9426, DOI 10.1021/la051863e
   Huotari J, 2011, EMBO J, V30, P3481, DOI 10.1038/emboj.2011.286
   ILLUM L, 1984, FEBS LETT, V167, P79, DOI 10.1016/0014 5793(84)80836 4
   ILLUM L, 1987, LIFE SCI, V40, P367, DOI 10.1016/0024 3205(87)90138 X
   Jeong J, 2019, BIOMATER RES, V23, DOI 10.1186/s40824 018 0149 3
   Joseph Cherian, 2005, Molecular Aspects of Medicine, V26, P181, DOI 10.1016/j.mam.2005.01.004
   Keeling GP, 2021, BIOCONJUGATE CHEM, V32, P1276, DOI 10.1021/acs.bioconjchem.0c00401
   Kenny GD, 2016, J FLUORINE CHEM, V184, P58, DOI 10.1016/j.jfluchem.2016.02.008
   Khare P, 2024, NANOSCALE ADV, V6, DOI 10.1039/d3na00699a
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   KLEIN CPAT, 1983, J BIOMED MATER RES, V17, P769, DOI 10.1002/jbm.820170505
   Kulkarni JA, 2018, NUCLEIC ACID THER, V28, P146, DOI 10.1089/nat.2018.0721
   Kunik A., 2020, EUR J PHARMACOL, V866
   Lee ES, 2023, CANCERS, V15, DOI 10.3390/cancers15225366
   LeGeros RZ, 2008, CHEM REV, V108, P4742, DOI 10.1021/cr800427g
   Love KT, 2010, P NATL ACAD SCI USA, V107, P1864, DOI 10.1073/pnas.0910603106
   Lu JC, 2023, PHARMACEUTICS, V15, DOI 10.3390/pharmaceutics15061572
   MARSH ME, 1995, J BONE MINER RES, V10, P1635
   Mbese Z, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136869
   McCarthy I, 2006, J BONE JOINT SURG AM, V88A, P4, DOI 10.2106/JBJS.F.00890
   MCLEAN FC, 1959, ANNU REV PHYSIOL, V21, P69, DOI 10.1146/annurev.ph.21.030159.000441
   Ni HZ, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 32281 5
   Nugent M, 2014, CANCER MANAG RES, V6, P15, DOI 10.2147/CMAR.S53928
   PAPAPOULOS SE, 1992, BONE, V13, pS41, DOI 10.1016/S8756 3282(09)80009 4
   Parhiz H., 2024, LANCET
   Pazianas M, 2013, THER CLIN RISK MANAG, V9, P395, DOI 10.2147/TCRM.S52291
   Percec V, 2006, SCIENCE, V313, P55, DOI 10.1126/science.1129512
   Percec V, 2024, BIOMACROMOLECULES, V25, P1353, DOI 10.1021/acs.biomac.3c01390
   Percec V, 2021, B CHEM SOC JPN, V94, P900, DOI 10.1246/bcsj.20210015
   Perry HL, 2020, INORG CHEM, V59, P10813, DOI 10.1021/acs.inorgchem.0c01318
   Peterca M, 2011, J AM CHEM SOC, V133, P20507, DOI 10.1021/ja208762u
   Pignolo RJ, 2021, JBMR PLUS, V5, DOI 10.1002/jbm4.10488
   Psimma C, 2022, GERODONTOLOGY, V39, P330, DOI 10.1111/ger.12590
   Ramasamy SK, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/5046953
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Sabnis S, 2018, MOL THER, V26, P1509, DOI 10.1016/j.ymthe.2018.03.010
   Sahoo D, 2024, J AM CHEM SOC, V146, P3627, DOI 10.1021/jacs.3c13569
   Sandiford L, 2013, ACS NANO, V7, P500, DOI 10.1021/nn3046055
   Sherwood R, 2015, INORG CHEM, V54, P4222, DOI 10.1021/ic5028527
   Sivaraj KK, 2016, DEVELOPMENT, V143, P2706, DOI 10.1242/dev.136861
   Skjodt MK, 2019, BRIT J CLIN PHARMACO, V85, P1063, DOI 10.1111/bcp.13759
   TENENBAUM HC, 1982, CALCIFIED TISSUE INT, V34, P76, DOI 10.1007/BF02411212
   Vargas Franco JW, 2018, J CELL PHYSIOL, V233, P5696, DOI 10.1002/jcp.26465
   Walkey CD, 2012, J AM CHEM SOC, V134, P2139, DOI 10.1021/ja2084338
   Wang GL, 2012, J BIOMED MATER RES A, V100A, P684, DOI 10.1002/jbm.a.34002
   Wasungu L, 2006, J CONTROL RELEASE, V116, P255, DOI 10.1016/j.jconrel.2006.06.024
   Watts NB, 2010, J CLIN ENDOCR METAB, V95, P1555, DOI 10.1210/jc.2009 1947
   Wilson B, 2022, J DRUG DELIV SCI TEC, V74, DOI 10.1016/j.jddst.2022.103553
   Winkeljann B, 2023, J CONTROL RELEASE, V353, P518, DOI 10.1016/j.jconrel.2022.12.008
   Xu YH, 1996, BIOCHEMISTRY US, V35, P5616, DOI 10.1021/bi9602019
   Xue LL, 2022, J AM CHEM SOC, V144, P9926, DOI 10.1021/jacs.2c02706
   Yang DH, 2024, MATER TODAY BIO, V26, DOI 10.1016/j.mtbio.2024.101016
   Yuan HF, 2015, EXP MOL PATHOL, V98, P158, DOI 10.1016/j.yexmp.2015.01.002
   Zayzafoon M, 2006, J CELL BIOCHEM, V97, P56, DOI 10.1002/jcb.20675
   Zelphati O, 1996, PHARMACEUT RES, V13, P1367, DOI 10.1023/A:1016026101195
   Zhang DP, 2022, J AM CHEM SOC, V144, P4746, DOI 10.1021/jacs.2c00273
   Zhang YB, 2021, CHEM REV, V121, P12181, DOI 10.1021/acs.chemrev.1c00244
NR 94
TC 5
Z9 5
U1 19
U2 41
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
EI 1521 3773
J9 ANGEW CHEM INT EDIT
JI Angew. Chem. Int. Edit.
PD JAN 15
PY 2025
VL 64
IS 3
DI 10.1002/anie.202415389
EA DEC 2024
PG 13
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA Z8P1L
UT WOS:001376099500001
PM 39379320
OA hybrid
DA 2025 08 17
ER

PT J
AU Yu, Z
   Kreitler, DF
   Chiu, YTT
   Xu, RW
   Bruchs, AT
   Bingman, CA
   Gellman, SH
AF Yu, Zhen
   Kreitler, Dale F.
   Chiu, Yin Ting T.
   Xu, Ruiwen
   Bruchs, Austin T.
   Bingman, Craig A.
   Gellman, Samuel H.
TI Harnessing Aromatic Histidine Interactions through Synergistic Backbone
   Extension and Side Chain Modification
SO ANGEWANDTE CHEMIE INTERNATIONAL EDITION
LA English
DT Article
DE Backbone Modification; G Protein Coupled Receptors; Histidine;
   Protein Peptide Interactions; & beta; Amino Acids
ID PARATHYROID HORMONE RECEPTOR; PEPTIDE PTHRP; AMINO ACIDS; IN VIVO;
   PROTEIN; SELECTION; GLUCAGON; CHALLENGES; FRAGMENTS; ANALOGS
AB Peptide engineering efforts have delivered drugs for diverse human diseases. Side chain alteration is among the most common approaches to designing new peptides for specific applications. The peptide backbone can be modified as well, but this strategy has received relatively little attention. Here we show that new and favorable contacts between a His side chain on a target protein and an aromatic side chain on a synthetic peptide ligand can be engineered by rational and coordinated side chain modification and backbone extension. Side chain modification alone was unsuccessful. Binding measurements, high resolution structural studies and pharmacological outcomes all support the synergy between backbone and side chain modification in engineered ligands of the parathyroid hormone receptor 1, which is targeted by osteoporosis drugs. These results should motivate other structure based designs featuring coordinated side chain modification and backbone extension to enhance the engagement of peptide ligands with target proteins.
C1 [Yu, Zhen; Chiu, Yin Ting T.; Xu, Ruiwen; Bruchs, Austin T.; Gellman, Samuel H.] Univ Wisconsin Madison, Dept Chem, Madison, WI 53706 USA.
   [Kreitler, Dale F.] Brookhaven Natl Lab, Natl Synchrotron Light Source 2, Upton, NY 11973 USA.
   [Bingman, Craig A.] Univ Wisconsin Madison, Dept Biochem, Madison, WI 53706 USA.
C3 University of Wisconsin System; University of Wisconsin Madison; United
   States Department of Energy (DOE); Brookhaven National Laboratory;
   University of Wisconsin System; University of Wisconsin Madison
RP Gellman, SH (通讯作者)，Univ Wisconsin Madison, Dept Chem, Madison, WI 53706 USA.
EM gellman@chem.wisc.edu
RI ; Bingman, Craig/F 1711 2019; Bingman, Craig/HLG 8162 2023; Yu,
   Zhen/S 8325 2016
OI Gellman, Samuel/0000 0001 5617 0058; Kreitler, Dale/0000 0003 4758 7913;
   Bingman, Craig/0000 0002 3073 5089; Xu, Ruiwen/0000 0001 8477 2718;
   Bruchs, Austin/0000 0003 0819 3639; Chiu, Yin Ting/0000 0001 5449 8391;
   Yu, Zhen/0000 0003 2092 9960
FU NIH [R01GM056414]; Vilas Fund [085P1000817]; U.S. Department of Energy,
   Basic Energy Sciences, Office of Science [DE AC02 06CH11357]; Michigan
   Economic Development Corporation; Michigan Technology Tri Corridor
   [085P1000817]; UW Madison Office of VCRGE; National Institutes of
   Health, National Institute of General Medical Sciences (NIGMS) through a
   Center Core P30 Grant [P30GM133893]; DOE Office of Biological and
   Environmental Research [KP1605010]; DOE Office of Science by Brookhaven
   National Laboratory [DE SC0012704]
FX This work was funded in part by the NIH grant R01GM056414. We are
   grateful to the Vilas Fund for partial support. We thank Weiting Lyu for
   help with preliminary studies. Crystal handling was performed in the
   Collaborative Crystallography Core at UW Madison. Advanced Photon Source
   supported by the U.S. Department of Energy, Basic Energy Sciences,
   Office of Science, under contract No. DE AC02 06CH11357. LS CAT Sector
   21 was supported by the Michigan Economic Development Corporation and
   the Michigan Technology Tri Corridor (Grant 085P1000817). Use of LS CAT
   was supported by the UW Madison Office of VCRGE. The Center for
   BioMolecular Structure (CBMS) is primarily supported by the National
   Institutes of Health, National Institute of General Medical Sciences
   (NIGMS) through a Center Core P30 Grant (P30GM133893), and by the DOE
   Office of Biological and Environmental Research (KP1605010). This
   research used resources 17 ID 1 or 17 ID 2 of the National Synchrotron
   Light Source II, a U.S. Department of Energy (DOE) Office of Science
   User Facility operated for the DOE Office of Science by Brookhaven
   National Laboratory under Contract No. DE SC0012704.
CR Abdulkadir S, 2022, J AM CHEM SOC, V144, P270, DOI 10.1021/jacs.1c09571
   Andrei SA, 2019, CHEM COMMUN, V55, P14809, DOI 10.1039/c9cc07982c
   Arlt H, 2020, BONE REP, V13, DOI 10.1016/j.bonr.2020.100291
   Bai XH, 2016, BIOORGAN MED CHEM, V24, P1163, DOI 10.1016/j.bmc.2016.01.036
   Ballinger MD, 1998, J BIOL CHEM, V273, P11675, DOI 10.1074/jbc.273.19.11675
   Barber C, 2022, EUR J IMMUNOL, V52, P618, DOI 10.1002/eji.202149745
   Bartus É, 2017, CHEMISTRYOPEN, V6, P236, DOI 10.1002/open.201700012
   Binkowski BF, 2011, ACS CHEM BIOL, V6, P1193, DOI 10.1021/cb200248h
   Blaskovich MAT, 2016, J MED CHEM, V59, P10807, DOI 10.1021/acs.jmedchem.6b00319
   BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014 5793(86)80730 X
   Cabalteja CC, 2022, ACS CHEM BIOL, V17, P987, DOI 10.1021/acschembio.2c00138
   Cabrele C, 2014, J MED CHEM, V57, P9718, DOI 10.1021/jm5010896
   Cary BP, 2023, STRUCTURE, V31, P668, DOI 10.1016/j.str.2023.04.002
   Cheloha RW, 2017, J MED CHEM, V60, P8816, DOI 10.1021/acs.jmedchem.7b00876
   Cheloha RW, 2015, NAT REV ENDOCRINOL, V11, P712, DOI 10.1038/nrendo.2015.139
   Chen X, 2017, J AM CHEM SOC, V139, P16688, DOI 10.1021/jacs.7b08417
   CHOREV M, 1990, BIOCHEMISTRY US, V29, P1580, DOI 10.1021/bi00458a032
   Cussol L, 2021, ANGEW CHEM INT EDIT, V60, P2296, DOI 10.1002/anie.202008992
   Eddinger GA, 2018, ANGEW CHEM INT EDIT, V57, P13829, DOI 10.1002/anie.201806909
   Fanelli R, 2020, J AM CHEM SOC, V142, P1382, DOI 10.1021/jacs.9b10861
   Fremaux J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 08793 y
   Gardella TJ, 1996, ENDOCRINOLOGY, V137, P3936, DOI 10.1210/en.137.9.3936
   Gibadullin R, 2021, J AM CHEM SOC, V143, P6470, DOI 10.1021/jacs.1c00016
   Grison CM, 2016, ANGEW CHEM INT EDIT, V55, P11096, DOI 10.1002/anie.201604517
   Hargrove DM, 2020, J PHARMACOL EXP THER, V373, P193, DOI 10.1124/jpet.119.262238
   Hetherington K, 2021, RSC CHEM BIOL, V2, P1474, DOI 10.1039/d1cb00137j
   Horne WS, 2020, NAT CHEM, V12, P331, DOI 10.1038/s41557 020 0420 9
   Horne WS, 2009, P NATL ACAD SCI USA, V106, P14751, DOI 10.1073/pnas.0902663106
   HORVATH A, 1982, PEPTIDES, V3, P969, DOI 10.1016/0196 9781(82)90066 3
   Jones ES, 2011, HYPERTENSION, V57, P570, DOI 10.1161/HYPERTENSIONAHA.110.164301
   Katoh T, 2022, J AM CHEM SOC, V144, P2069, DOI 10.1021/jacs.1c12133
   Katoh T, 2021, J AM CHEM SOC, V143, P18844, DOI 10.1021/jacs.1c09270
   Khatri B, 2021, METHOD ENZYMOL, V656, P27, DOI 10.1016/bs.mie.2021.04.018
   Kobayashi K, 2022, MOL CELL, V82, P3468, DOI 10.1016/j.molcel.2022.07.003
   Liao S, 2010, AMINO ACIDS, V38, P1595, DOI 10.1007/s00726 009 0376 y
   Makwana KM, 2021, ACS CHEM NEUROSCI, V12, P3928, DOI 10.1021/acschemneuro.1c00528
   Mbianda J, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abd9153
   Miller PD, 2016, JAMA J AM MED ASSOC, V316, P722, DOI 10.1001/jama.2016.11136
   Mundy GR, 2008, J AM SOC NEPHROL, V19, P672, DOI 10.1681/ASN.2007090981
   Noda H, 2020, JBMR PLUS, V4, DOI 10.1002/jbm4.10367
   NYGREN PA, 1994, TRENDS BIOTECHNOL, V12, P184, DOI 10.1016/0167 7799(94)90080 9
   Okazaki M, 2008, P NATL ACAD SCI USA, V105, P16525, DOI 10.1073/pnas.0808750105
   Passioura T, 2017, CHEM COMMUN, V53, P1931, DOI 10.1039/c6cc06951g
   Passioura T, 2014, ANNU REV BIOCHEM, V83, P727, DOI 10.1146/annurev biochem 060713 035456
   Peña KA, 2022, J BIOL CHEM, V298, DOI 10.1016/j.jbc.2022.102332
   Pioszak AA, 2009, J BIOL CHEM, V284, P28382, DOI 10.1074/jbc.M109.022905
   Rathman BM, 2021, METHOD ENZYMOL, V656, P271, DOI 10.1016/bs.mie.2021.04.013
   Rogers JM, 2018, NAT CHEM, V10, P405, DOI 10.1038/s41557 018 0007 x
   Sang P, 2021, J MED CHEM, V64, P13893, DOI 10.1021/acs.jmedchem.1c01289
   Sang P, 2020, ACCOUNTS CHEM RES, V53, P2425, DOI 10.1021/acs.accounts.0c00482
   Sang P, 2019, P NATL ACAD SCI USA, V116, P10757, DOI 10.1073/pnas.1819663116
   Sharma A, 2021, CELL, V184, P6052, DOI 10.1016/j.cell.2021.11.010
   Steer DL, 2001, LETT PEPT SCI, V8, P241, DOI 10.1007/BF02446523
   Tököli A, 2020, CHEM SCI, V11, P10390, DOI 10.1039/d0sc03525d
   Tsvetanova NG, 2014, NAT CHEM BIOL, V10, P1061, DOI 10.1038/nchembio.1665
   Wang LJ, 2006, BIOCHEMISTRY US, V45, P13750, DOI 10.1021/bi0615689
   Weber T, 2022, IMMUNITY, V55, P341, DOI 10.1016/j.immuni.2021.12.003
   Wilczynska D, 2009, J PEPT SCI, V15, P777, DOI 10.1002/psc.1175
   WILLIS KJ, 1994, INT J PEPT PROT RES, V43, P23
   Yang B, 2021, J MED CHEM, V64, P4697, DOI 10.1021/acs.jmedchem.0c02069
   Yu Z, 2022, ACS CHEM BIOL, V17, P3148, DOI 10.1021/acschembio.2c00595
NR 61
TC 3
Z9 3
U1 4
U2 27
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
EI 1521 3773
J9 ANGEW CHEM INT EDIT
JI Angew. Chem. Int. Edit.
PD OCT 2
PY 2023
VL 62
IS 40
AR e202308100
DI 10.1002/anie.202308100
EA AUG 2023
PG 7
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA W2RE9
UT WOS:001063811900001
PM 37587780
OA hybrid, Green Accepted
DA 2025 08 17
ER

PT J
AU Ferrari, S
   Libanati, C
   Lin, CJF
   Brown, JP
   Cosman, F
   Czerwinski, E
   de Gregorio, LH
   Malouf Sierra, J
   Reginster, JY
   Wang, A
   Wagman, RB
   Lewiecki, EM
AF Ferrari, S.
   Libanati, C.
   Lin, Celia Jow Fang
   Brown, J. P.
   Cosman, F.
   Czerwinski, E.
   de Gregorio, L. H.
   Malouf Sierra, J.
   Reginster, J Y
   Wang, A.
   Wagman, R. B.
   Lewiecki, E. M.
TI Relationship Between Bone Mineral Density T Score and
   Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE ANTIRESORPTIVES; DXA; FRACTURE RISK ASSESSMENT; OSTEOPOROSIS; TREAT TO
   TARGET
ID GOAL DIRECTED TREATMENT; POSTMENOPAUSAL WOMEN; OSTEOPOROSIS;
   ALENDRONATE; PREVENTION; EXPOSURE; THERAPY; ADULTS; MEN; AGE
AB Although treat to target strategies are being discussed in osteoporosis, there is little evidence of what the target should be to reduce fracture risk maximally. We investigated the relationship between total hip BMD T score and the incidence of nonvertebral fracture in women who received up to 10 years of continued denosumab therapy in the FREEDOM (3 years) study and its long term Extension (up to 7 years) study. We report the percentages of women who achieved a range of T scores at the total hip or femoral neck over 10 years of denosumab treatment (1343 women completed 10 years of treatment). The incidence of nonvertebral fractures was lower with higher total hip T score. This relationship plateaued at a T score between  2.0 and  1.5 and was independent of age and prevalent vertebral fractures, similar to observations in treatment naive subjects. Reaching a specific T score during denosumab treatment was dependent on the baseline T score, with higher T scores at baseline more likely to result in higher T scores at each time point during the study. Our findings highlight the importance of follow up BMD measurements in patients receiving denosumab therapy because BMD remains a robust indicator of fracture risk. These data support the notion of a specific T score threshold as a practical target for therapy in osteoporosis. (c) 2019 The Authors Journal of Bone and Mineral Research published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research (ASBMR)
C1 [Ferrari, S.] Geneva Univ Hosp, CH 1211 Geneva, Switzerland.
   [Libanati, C.] UCB Pharma, Brussels, Belgium.
   [Lin, Celia Jow Fang; Wang, A.; Wagman, R. B.] Amgen Inc, Thousand Oaks, CA 91320 USA.
   [Brown, J. P.] Laval Univ, Quebec City, PQ, Canada.
   [Brown, J. P.] CHU Quebec Res Ctr, Quebec City, PQ, Canada.
   [Cosman, F.] Columbia Univ, New York, NY 10027 USA.
   [Czerwinski, E.] Krakow Med Ctr, Krakow, Poland.
   [de Gregorio, L. H.] Ctr Clin & Basic Res Brasil, Rio De Janeiro, Brazil.
   [Malouf Sierra, J.] Univ Autonoma Barcelona, Barcelona, Spain.
   [Reginster, J Y] Univ Liege, Liege, Belgium.
   [Lewiecki, E. M.] New Mexico Clin Res & Osteoporosis Ctr, Albuquerque, NM USA.
C3 University of Geneva; UCB Pharma SA; Amgen; Laval University; Columbia
   University; Center Clinical & Basic Research; Autonomous University of
   Barcelona; University of Liege; New Mexico Clinical Research &
   Osteoporosis Center
RP Ferrari, S (通讯作者)，Geneva Univ Hosp, CH 1211 Geneva, Switzerland.
EM Serge.Ferrari@unige.ch
RI Reginster, Jean Yves/AGC 6097 2022; Libanati, Cesar/LGZ 1518 2024;
   Lewiecki, E./B 3706 2018; Ferrari, Serge/ABD 2730 2020
OI ferrari, serge/0000 0002 1372 4417; Lewiecki, E.
   Michael/0000 0003 2026 9587; Libanati, Cesar/0000 0003 1427 7839; Brown,
   Jacques/0000 0003 1910 788X
FU Amgen Inc.
FX This study was funded by Amgen Inc. Medical writing assistance was
   provided by Michelle N. Bradley, PhD, of Amgen Inc.; Jennifer Villa,
   PhD, of Oxford PharmaGenesis, Inc., funded by Amgen Inc.; and Kathryn
   Boorer, PhD, of KB Scientific Communications, LLC, funded by Amgen Inc.
   Formatting support was provided by Cactus, on behalf of Amgen Inc.
CR Adachi JD, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891 017 1520 6
   [Anonymous], 2017, Diabetes Care, V40, pS48, DOI DOI 10.2337/DC17 S009
   Austin M, 2012, J BONE MINER RES, V27, P687, DOI 10.1002/jbmr.1472
   Bone HG, 2017, LANCET DIABETES ENDO, V5, P513, DOI 10.1016/S2213 8587(17)30138 9
   Bone HG, 2013, J CLIN ENDOCR METAB, V98, P4483, DOI 10.1210/jc.2013 1597
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Cosman F, 2017, MAYO CLIN PROC, V92, P200, DOI 10.1016/j.mayocp.2016.10.009
   Cosman F, 2014, J CLIN ENDOCR METAB, V99, P4546, DOI 10.1210/jc.2014 1971
   Cummings SR, 2017, J BONE MINER RES, V32, P3, DOI 10.1002/jbmr.3039
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Ferrari S, 2015, OSTEOPOROSIS INT, V26, P2763, DOI 10.1007/s00198 015 3179 x
   Holloway KL, 2015, OSTEOPOROSIS INT, V26, P629, DOI 10.1007/s00198 014 2897 9
   Johnell O, 2005, J BONE MINER RES, V20, P1185, DOI 10.1359/JBMR.050304
   Kanis JA, 2014, OSTEOPOROSIS INT, V25, P2533, DOI 10.1007/s00198 014 2787 1
   Kopperdahl DL, 2014, J BONE MINER RES, V29, P570, DOI 10.1002/jbmr.2069
   Krege John H, 2013, Bonekey Rep, V2, P404, DOI 10.1038/bonekey.2013.138
   Leder BZ, 2015, LANCET, V386, P1147, DOI 10.1016/S0140 6736(15)61120 5
   Lewiecki EM, 2017, CURR OSTEOPOROS REP, V15, P103, DOI 10.1007/s11914 017 0350 7
   Looker AC, 1997, J BONE MINER RES, V12, P1761, DOI 10.1359/jbmr.1997.12.11.1761
   McCloskey E, 2013, J BONE MINER RES, V28, P439, DOI 10.1002/jbmr.1859
   Papapoulos S, 2015, OSTEOPOROSIS INT, V26, P2773, DOI 10.1007/s00198 015 3234 7
   Papapoulos S, 2012, J BONE MINER RES, V27, P694, DOI 10.1002/jbmr.1479
   Roux C, 2014, BONE, V58, P48, DOI 10.1016/j.bone.2013.10.006
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Schuit SCE, 2004, BONE, V34, P195, DOI 10.1016/j.bone.2003.10.001
   Singer BR, 1998, J BONE JOINT SURG BR, V80B, P243, DOI 10.1302/0301 620X.80B2.7762
   Siris ES, 2006, OSTEOPOROSIS INT, V17, P565, DOI 10.1007/s00198 005 0027 4
   Siris ES, 2004, ARCH INTERN MED, V164, P1108, DOI 10.1001/archinte.164.10.1108
   Siris ES, 2001, JAMA J AM MED ASSOC, V286, P2815, DOI 10.1001/jama.286.22.2815
   Whelton PK, 2018, HYPERTENSION, V71, pE13, DOI [10.1161/HYP.0000000000000065, 10.1161/HYP.0000000000000066]
NR 30
TC 86
Z9 86
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUN
PY 2019
VL 34
IS 6
BP 1033
EP 1040
DI 10.1002/jbmr.3722
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA IM3XF
UT WOS:000477928600006
PM 30919997
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Li, W
   Zhu, HM
   Xu, HD
   Zhang, B
   Huang, SM
AF Li, W.
   Zhu, H.  M.
   Xu, H.  D.
   Zhang, B.
   Huang, S.  M.
TI CRNDE impacts the proliferation of osteoclast by estrogen deficiency in
   postmenopausal osteoporosis
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE CRNDE; Estrogen; Postmenopausal osteoporosis
ID CELL PROLIFERATION; STEM CELLS; ACTIVATION; MIGRATION; BIOMARKER;
   INVASION
AB OBJECTIVE: Bone loss is the main reason for postmenopausal osteoporosis, caused by estrogen deficiency. ERT (estrogen replacement therapy) has been demonstrated to protect bone loss efficiently. LncRNA (long non coding RNA) has been proved to be important in different disease progression. We aimed at analyzing whether the lncRNAs influence the activity of osteoclasts and the progression of this disease.
   PATIENTS AND METHODS: RT PCR (reverse transcriptase polymerase chain reaction) was used to detect the expression of lncRNA CRNDE in OH (osteoclast from healthy people) and OP (osteoclast from patients with postmenopausal osteoporosis). MTT (methylthiazolyl tetrazolium) assay was used to detect the viability of the cells. The cell cycle and apoptosis rate in OH and OP were measured by the flow cytometry analysis. Western blot was used to analyze the possible related mechanism that CRNDE regulated the cells proliferation in postmenopausal osteoporosis.
   RESULTS: We found that the CRNDE was highly expressed in the osteoclast from patients with OP, compared with OH. We also found that overexpressing CRNDE increased the viability in OH whilst reducing CRNDE in OP decreased the viability. The cell cycle was arrested in G0/G1 phase and the apoptosis rate was improved in OP after transfection with siRNA. Moreover, CRNDE could impact the proliferation of osteoclasts by PI3K/Akt signaling pathway and estrogen could inhibit this proliferation.
   CONCLUSIONS: We found that lncRNA CRNDE was closely related to the postmenopausal osteoporosis with estrogen deficiency. CRNDE may be involved in the development and progression of postmenopausal osteoporosis in the absence of estrogen and become a potential target for treating.
C1 [Li, W.; Xu, H.  D.; Zhang, B.; Huang, S.  M.] Heilongjiang Univ Chinese Med, Inst Chinese Med, Dept Neurosci, Harbin, Heilongjiang, Peoples R China.
   [Zhu, H.  M.] Hubei Univ Arts & Sci, Xiangyang, Hubei, Peoples R China.
   [Zhu, H.  M.] Northeast Agr Univ, Coll Vet Med, Harbin, Heilongjiang, Peoples R China.
   [Xu, H.  D.] Heilongjiang Univ Chinese Med, Jiamusi Coll, Jiamusi, Heilongjiang, Peoples R China.
C3 Heilongjiang University of Chinese Medicine; Hubei University of Arts &
   Science; Northeast Agricultural University   China; Heilongjiang
   University of Chinese Medicine
RP Huang, SM (通讯作者)，Heilongjiang Univ Chinese Med, Inst Chinese Med, Dept Neurosci, Harbin, Heilongjiang, Peoples R China.
EM huangshuminghljzyy@126.com
RI zhu, huimin/JZT 6551 2024
CR Ballantyne MD, 2016, CIRCULATION, V133, P2050, DOI 10.1161/CIRCULATIONAHA.115.021019
   Bhukhai K, 2012, J BIOL CHEM, V287, P36168, DOI 10.1074/jbc.M112.344747
   Carbonare LD, 2009, ARTHRITIS RHEUM US, V60, P3356, DOI 10.1002/art.24884
   Chen ZL, 2016, AM J CANCER RES, V6, P2299
   D'Aniello C, 2018, EUR REV MED PHARMACO, V22, P1169, DOI 10.26355/eurrev_201803_14452
   Gao P, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061239
   Graham Lloyd D, 2011, Genes Cancer, V2, P829, DOI 10.1177/1947601911431081
   Hong L, 2006, TISSUE ENG, V12, P2747, DOI 10.1089/ten.2006.12.2747
   Hu CE, 2017, CELL PHYSIOL BIOCHEM, V42, P13, DOI 10.1159/000477107
   Huan JL, 2017, AM J TRANSL RES, V9, P1977
   Kiang KMY, 2017, TARGET ONCOL, V12, P353, DOI 10.1007/s11523 017 0488 3
   Luo YH, 2017, ONCOTARGET, V8, P74139, DOI 10.18632/oncotarget.18274
   Miyauchi Y, 2013, P NATL ACAD SCI USA, V110, P16568, DOI 10.1073/pnas.1308755110
   Nelson ER, 2013, BONE, V53, P42, DOI 10.1016/j.bone.2012.11.011
   Salehi S, 2017, J CELL MOL MED, V21, P3120, DOI 10.1111/jcmm.13238
   Shen S, 2016, ONCOTARGET, V7, P72833, DOI 10.18632/oncotarget.12023
   Sun HG, 2017, ONCOTARGET, V8, P110552, DOI 10.18632/oncotarget.22819
   Tong X, 2015, BIOSCI BIOTECH BIOCH, V79, P732, DOI 10.1080/09168451.2014.998617
   Wang Z, 2006, TISSUE ENG, V12, P1753, DOI 10.1089/ten.2006.12.1753
   Yang L, 2016, ONCOL LETT, V12, P3771, DOI 10.3892/ol.2016.5213
NR 20
TC 36
Z9 41
U1 1
U2 6
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186 00165, ITALY
SN 1128 3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PD SEP
PY 2018
VL 22
IS 18
BP 5815
EP 5821
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA GV6NH
UT WOS:000446228200009
PM 30280760
DA 2025 08 17
ER

PT J
AU Hagemann, UB
   Schatz, CA
   Suominen, MI
   Schlicker, A
   Knuuttila, M
   Wilson, T
   Alhoniemi, E
   Kaekoenen, SM
   Haendler, B
   Scholz, A
AF Hagemann, Urs B.
   Schatz, Christoph A.
   Suominen, Mari I.
   Schlicker, Andreas
   Knuuttila, Matias
   Wilson, Timothy
   Alhoniemi, Esa
   Kaekoenen, Sanna Maria
   Haendler, Bernard
   Scholz, Arne
TI Darolutamide in Combination with Radium 223 Exhibits Synergistic
   Antitumor Efficacy in LNCaP Prostate Cancer Models
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE radium 223; darolutamide; prostate cancer; bone metastases; CRPC
ID ENZALUTAMIDE; SURVIVAL; THERAPY
AB Despite treatment, prostate cancer commonly progresses into castration resistant prostate cancer (CRPC), which remains largely incurable, requiring the development of new interventions. Darolutamide is an orally administered second generation androgen receptor inhibitor indicated for patients with non metastatic CRPC or metastatic hormone sensitive prostate cancer. Here, we evaluated the effect of androgen receptor (AR) inhibition by darolutamide in combination with DNA double strand break inducing targeted radium 223 alpha therapy in vitro and in an intratibial LNCaP xenograft model mimicking prostate cancer metastasized to bone. The results highlight the synergistic antitumor efficacy of darolutamide in combination with radium 223 both in vitro and in vivo. This effect was most likely driven by the downregulation of genes involved in DDR signaling, which was demonstrated in vitro by a gene set enrichment analysis. The combination treatment also reduced pathological tumor induced effects in bone by decreasing the number of osteoblasts and osteoclasts and reducing abnormal bone formation in tumor bearing bone. Additionally, it was shown that darolutamide does not affect the uptake of radium 223 into bone tissue. These results support the investigation of darolutamide in combination with radium 223 for the treatment of patients with CRPC metastasized to bone.
C1 [Hagemann, Urs B.; Schatz, Christoph A.; Schlicker, Andreas; Haendler, Bernard; Scholz, Arne] Bayer AG, Res & Dev, Pharmaceut, D 13353 Berlin, Germany.
   [Suominen, Mari I.] Pharmatest Serv Ltd, FI 20520 Turku, Finland.
   [Knuuttila, Matias; Wilson, Timothy; Kaekoenen, Sanna Maria] Aurexel Life Sci Ltd, Askainen 21240, Finland.
   [Alhoniemi, Esa] Inoi Oy, Turku 20100, Finland.
   [Kaekoenen, Sanna Maria] Univ Turku, Inst Biomed, FIN 20520 Turku, Finland.
C3 Bayer AG; Pharmatest Services; University of Turku
RP Scholz, A (通讯作者)，Bayer AG, Res & Dev, Pharmaceut, D 13353 Berlin, Germany.
EM arne.scholz@bayer.com
RI ; Suominen, Mari/KHZ 4938 2024
OI Schlicker, Andreas/0000 0002 6588 7883; Kakonen,
   Sanna Maria/0000 0001 9393 6235; Knuuttila, Matias/0000 0002 9953 5755;
   Alhoniemi, Esa/0000 0003 2040 163X; Suominen, Mari/0000 0002 8760 6595
FU Bayer AG
FX This research was funded by Bayer AG.
CR Agarwal N, 2020, CLIN CANCER RES, V26, P2104, DOI 10.1158/1078 0432.CCR 19 2591
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Dempster DW, 2008, PRINCIPLES OF BONE BIOLOGY, VOL 1, 3RD EDITION, P447, DOI 10.1016/B978 0 12 373884 4.00041 0
   Erben RG, 2012, METHODS MOL BIOL, V816, P279, DOI 10.1007/978 1 61779 415 5_19
   Fizazi K, 2023, EUR J CANCER, V192, DOI 10.1016/j.ejca.2023.113258
   Germain L, 2023, NAT REV UROL, V20, P480, DOI 10.1038/s41585 023 00726 1
   Gillespie M, 2022, NUCLEIC ACIDS RES, V50, pD687, DOI 10.1093/nar/gkab1028
   Hammer S, 2021, CLIN CANCER RES, V27, P4367, DOI 10.1158/1078 0432.CCR 21 0342
   HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809
   Humm JL, 2015, INT J RADIAT ONCOL, V91, P898, DOI 10.1016/j.ijrobp.2014.12.061
   Hussain M, 2024, JAMA ONCOL, V10, P807, DOI 10.1001/jamaoncol.2024.0591
   Hussain M, 2023, J CLIN ONCOL, V41, P3595, DOI 10.1200/JCO.23.00041
   Korotkevich G., 2021, bioRxiv, DOI [DOI 10.1101/060012, DOI 10.1101/060012V3]
   Lee AR, 2023, TARGET ONCOL, V18, P793, DOI 10.1007/s11523 023 00984 4
   Leys C, 2013, J EXP SOC PSYCHOL, V49, P764, DOI 10.1016/j.jesp.2013.03.013
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260
   Maughan BL, 2021, ONCOLOGIST, V26, P1006, DOI 10.1002/onco.13949
   McDermott RS, 2021, THER ADV MED ONCOL, V13, DOI 10.1177/17588359211042691
   Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755
   Parker C, 2018, JAMA ONCOL, V4, P1765, DOI 10.1001/jamaoncol.2018.4044
   Polkinghorn WR, 2013, CANCER DISCOV, V3, P1245, DOI 10.1158/2159 8290.CD 13 0172
   R Core Team, 2016, R LANG ENV STAT COMP
   Rice MA, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00801
   Schatz CA, 2024, CANCER RES, V84, DOI 10.1158/1538 7445.AM2024 688
   Schatz CA, 2024, CLIN CANCER RES, V30, P2531, DOI 10.1158/1078 0432.CCR 23 3746
   Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506
   Shore N, 2020, PROSTATE CANCER P D, V23, P680, DOI 10.1038/s41391 020 0236 0
   Smith MR, 2022, NEW ENGL J MED, V386, P1132, DOI 10.1056/NEJMoa2119115
   Spratt DE, 2015, CANCER RES, V75, P4688, DOI 10.1158/0008 5472.CAN 15 0892
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sung H, 2021, CA CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Suominen MI, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24032189
   Suominen MI, 2020, CANCER RES, V80, DOI 10.1158/1538 7445.AM2020 6286
   Suominen MI, 2017, CLIN CANCER RES, V23, P4335, DOI 10.1158/1078 0432.CCR 16 2955
   Swami U, 2020, TRENDS CANCER, V6, P702, DOI 10.1016/j.trecan.2020.04.010
   Tombal BF, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.5007
   Triggiani L, 2018, ANTICANCER RES, V38, P3487, DOI 10.21873/anticanres.12619
   Wilson JM, 2016, EXPERT REV ANTICANC, V16, P911, DOI 10.1080/14737140.2016.1222273
NR 40
TC 0
Z9 0
U1 2
U2 2
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD DEC
PY 2024
VL 25
IS 24
AR 13672
DI 10.3390/ijms252413672
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA Q4Z5G
UT WOS:001384781000001
PM 39769434
OA gold
DA 2025 08 17
ER

PT J
AU Schönitzer, V
   Wirtz, R
   Ulrich, V
   Berger, T
   Karl, A
   Mutschler, W
   Schieker, M
   Böcker, W
AF Schoenitzer, Veronika
   Wirtz, Roman
   Ulrich, Veronika
   Berger, Tamara
   Karl, Angelika
   Mutschler, Wolf
   Schieker, Matthias
   Boecker, Wolfgang
TI Sox2 Is a Potent Inhibitor of Osteogenic and Adipogenic Differentiation
   in Human Mesenchymal Stem Cells
SO CELLULAR REPROGRAMMING
LA English
DT Article
ID MARROW STROMAL CELLS; BONE MARROW; OSTEOBLAST DIFFERENTIATION;
   SELF RENEWAL; HUMAN FIBROBLASTS; IN VITRO; WNT; OCT4; PROLIFERATION;
   PLURIPOTENCY
AB Human mesenchymal stem cells (hMSCs) are a promising target for cell based bone regeneration. However, their application for clinical use is limited because hMSCs lose their ability for cell division and differentiation during longer in vitro cultivation. The osteogenic differentiation is regulated through a complex network of molecular signal transduction pathways where the canonical Wnt pathway plays an important role. Sox2, a known key factor for maintenance of cellular pluripotency in stem cells, is supposed to influence the Wnt pathway in osteoblasts. In this study, we overexpressed Sox2 in immortalized hMSCs by lentiviral gene transfer. Sox2 overexpression significantly reduced the osteogenic and adipogenic differentiation potentials. This effect was abolished by knockdown of Sox2 overexpression. In addition, Oct4 and Nanog, other key transcription factors for pluripotency, are strongly upregulated when Sox2 is overexpressed. Furthermore, Dkk1, a target gene of the Sox2 Oct4 heterodimer and a Wnt antagonist, is downregulated. Sox2 overexpression causes higher expression levels of beta catenin, the central transcription factor of the canonical Wnt pathway. These results suggest that Sox2 keeps hMSCs in an undifferentiated state by influencing the canonical Wnt pathway. Regulated expression of Sox2 may be a promising tool to cultivate hMSCs in sufficient quantities for cell and gene therapy applications.
C1 [Schoenitzer, Veronika; Wirtz, Roman; Ulrich, Veronika; Berger, Tamara; Karl, Angelika; Mutschler, Wolf; Schieker, Matthias; Boecker, Wolfgang] Univ Munich, Dept Surg, D 80336 Munich, Germany.
   [Boecker, Wolfgang] Univ Hosp, Dept Orthopaed Trauma Surg, D 35385 Giessen, Germany.
C3 University of Munich
RP Böcker, W (通讯作者)，Univ Munich, Dept Surg, Nussbaumstr 20, D 80336 Munich, Germany.
EM Wolfgang.Boecker@med.uni muenchen.de
RI Schieker, Matthias/J 6511 2015; Schieker, Matthias/A 9583 2015
OI Schieker, Matthias/0000 0002 1230 3653
FU Friedrich Baur Foundation, LMU Munich
FX The authors thank professor Ulrich Koszinowski and professor Jurgen Haas
   (Max von Pettenkofer Institute, Virology Section, LMU) for providing us
   the S2 laboratory. The study was supported by the
   Friedrich Baur Foundation, LMU Munich.
CR Babaie Y, 2007, STEM CELLS, V25, P500, DOI 10.1634/stemcells.2006 0426
   Basu Roy U, 2010, CELL DEATH DIFFER, V17, P1345, DOI 10.1038/cdd.2010.57
   Böcker W, 2008, J CELL MOL MED, V12, P1347, DOI [10.1111/j.1582 4934.2008.0299.x, 10.1111/j.1582 4934.2008.00299.x]
   Boiani M, 2005, NAT REV MOL CELL BIO, V6, P872, DOI 10.1038/nrm1744
   Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284
   Bowles J, 2000, DEV BIOL, V227, P239, DOI 10.1006/dbio.2000.9883
   Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020
   Bruder SP, 1997, J CELL BIOCHEM, V64, P278, DOI 10.1002/(SICI)1097 4644(199702)64:2<278::AID JCB11>3.0.CO;2 F
   Chavez L, 2009, BMC GENOMICS, V10, DOI 10.1186/1471 2164 10 314
   Chen Y, 2009, J CELL BIOCHEM, V106, P353, DOI 10.1002/jcb.22020
   Chew LJ, 2009, J NEUROSCI RES, V87, P3277, DOI 10.1002/jnr.22128
   Chiodi I, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00133
   Christodoulides C, 2006, J CELL SCI, V119, P2613, DOI 10.1242/jcs.02975
   D'Ippolito G, 1999, J BONE MINER RES, V14, P1115, DOI 10.1359/jbmr.1999.14.7.1115
   Huangfu DW, 2008, NAT BIOTECHNOL, V26, P1269, DOI 10.1038/nbt.1502
   De Boer J, 2004, TISSUE ENG, V10, P393, DOI 10.1089/107632704323061753
   DiGirolamo CM, 1999, BRIT J HAEMATOL, V107, P275, DOI 10.1046/j.1365 2141.1999.01715.x
   Ding DF, 2012, INT ORTHOP, V36, P1087, DOI 10.1007/s00264 011 1368 6
   Eijken M, 2008, J CELL BIOCHEM, V104, P568, DOI 10.1002/jcb.21651
   Go MJ, 2008, EXP CELL RES, V314, P1147, DOI 10.1016/j.yexcr.2007.11.021
   Greco SJ, 2007, STEM CELLS, V25, P3143, DOI 10.1634/stemcells.2007 0351
   Gregory CA, 2005, ANN NY ACAD SCI, V1049, P97, DOI 10.1196/annals.1334.010
   Gregory CA, 2003, J BIOL CHEM, V278, P28067, DOI 10.1074/jbc.M300373200
   Holmes G, 2011, BONE, V49, P653, DOI 10.1016/j.bone.2011.06.008
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   Janderová L, 2003, OBES RES, V11, P65, DOI 10.1038/oby.2003.11
   Kang S, 2007, J BIOL CHEM, V282, P14515, DOI 10.1074/jbc.M700030200
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kim JB, 2009, CELL, V136, P411, DOI 10.1016/j.cell.2009.01.023
   Kormish JD, 2010, DEV DYNAM, V239, P56, DOI 10.1002/dvdy.22046
   Leucht P, 2008, SEMIN CELL DEV BIOL, V19, P434, DOI 10.1016/j.semcdb.2008.09.002
   Ling L, 2009, GENE, V433, P1, DOI 10.1016/j.gene.2008.12.008
   Liu GZ, 2009, J CELL BIOL, V185, P67, DOI 10.1083/jcb.200810137
   Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760
   Mansukhani A, 2005, J CELL BIOL, V168, P1065, DOI 10.1083/jcb.200409182
   Nakagawa M, 2008, NAT BIOTECHNOL, V26, P101, DOI 10.1038/nbt1374
   Nusse R, 2005, NATURE, V438, P747, DOI 10.1038/438747a
   Oreffo ROC, 1998, CLIN SCI, V94, P549, DOI 10.1042/cs0940549
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   QUARTO R, 1995, CALCIFIED TISSUE INT, V56, P123, DOI 10.1007/BF00296343
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Riekstina U, 2009, STEM CELL REV REP, V5, P378, DOI 10.1007/s12015 009 9094 9
   Rizzino A, 2009, WIRES SYST BIOL MED, V1, P228, DOI 10.1002/wsbm.12
   Shi Y, 2008, CELL STEM CELL, V3, P568, DOI 10.1016/j.stem.2008.10.004
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Taura D, 2009, FEBS LETT, V583, P1029, DOI 10.1016/j.febslet.2009.02.031
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Yoon DS, 2011, CELL PROLIFERAT, V44, P428, DOI 10.1111/j.1365 2184.2011.00770.x
NR 49
TC 17
Z9 19
U1 0
U2 13
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2152 4971
EI 2152 4998
J9 CELL REPROGRAM
JI Cell. Reprogramm.
PD OCT
PY 2014
VL 16
IS 5
BP 355
EP 365
DI 10.1089/cell.2014.0006
PG 11
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Genetics & Heredity
GA AP7ZS
UT WOS:000342298000006
PM 25127284
DA 2025 08 17
ER

PT J
AU Chaudhari, KR
   Kumar, A
   Khandelwal, VKM
   Ukawala, M
   Manjappa, AS
   Mishra, AK
   Monkkonen, J
   Murthy, RSR
AF Chaudhari, Kiran Ramanlal
   Kumar, Abhinesh
   Khandelwal, Vinoth Kumar Megraj
   Ukawala, Mukesh
   Manjappa, Arehalli S.
   Mishra, Anil Kumar
   Monkkonen, Jukka
   Murthy, Rayasa S. Ramachandra
TI Bone metastasis targeting: A novel approach to reach bone using
   Zoledronate anchored PLGA nanoparticle as carrier system loaded with
   Docetaxel
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Bisphosphonates; Zoledronic acid; Docetaxel; Nanoparticles; Bone
   targeting
ID IN VIVO; PROSTATE CANCER; CELLULAR UPTAKE; ATP ANALOG; ACID; DRUG;
   DELIVERY; CELLS; BIODISTRIBUTION; MECHANISM
AB In spite of good research in drug delivery, bone targeting remains largely unexplored. Even some of the bone diseases are seldom cured just because of poor distribution of drug at the bone site. Zoledronate (ZOL) having strong affinity towards bone and its utility in bone metastasis management makes it perfect ligand for bone targeting. Recent studies revealed that ZOL in combination with docetaxel showed significant synergism in the management of bone metastasis. From the results, it is clear that ZOL conjugated PLGA nanoparticles (NPs) showed more cellular uptake than pegylated PLGA NPs with change in cellular uptake route. In vitro studies on MCF 7 and BO2 cell line revealed that ZOL anchored PLGA PEG NPs showed enhanced cell cytotoxicity, increase in cell cycle arrest and more apoptotic activity. PLGA PEG ZOL NPs found to block mevalonate pathway and increase accumulation of apoptotic metabolites such as ApppI. In vivo animal studies using technetium 99 m radiolabeling showed prolong blood circulation half life, reduced liver uptake and significantly higher retention of ZOL tagged NPs at the bone site with enhanced tumor retention. Here, we can conclude that the targeting ability of ZOL enhanced by strong affinity to bone, enhanced endocytosis of ZOL anchored PLGA PEG NPs. (C) 2011 Elsevier B. V. All rights reserved.
C1 [Murthy, Rayasa S. Ramachandra] ISF Coll Pharm, Moga 142001, Punjab, India.
   [Chaudhari, Kiran Ramanlal; Kumar, Abhinesh; Ukawala, Mukesh; Manjappa, Arehalli S.] Maharaja Sayajirao Univ Baroda, Dept Pharm, TIFAC Ctr Relevance & Excellence New Drug Deliver, Fatehgunj 390002, Vadodara, India.
   [Chaudhari, Kiran Ramanlal; Khandelwal, Vinoth Kumar Megraj; Monkkonen, Jukka] Univ Eastern Finland, Sch Pharm, Fac Hlth Sci, Kuopio, Finland.
   [Chaudhari, Kiran Ramanlal; Mishra, Anil Kumar] Inst Nucl Med & Allied Sci INMAS, Dept Radiopharmaceut & Radiat Biol, Delhi 110054, India.
C3 ISF College of Pharmacy; Maharaja Sayajirao University Baroda;
   University of Eastern Finland; Defence Research & Development
   Organisation (DRDO); Institute of Nuclear Medicine & Allied Sciences
   (INMAS)
RP Murthy, RSR (通讯作者)，ISF Coll Pharm, Firozpur GT Rd, Moga 142001, Punjab, India.
EM m_rsr@rediffmail.com
RI Khandelwal, Vinoth/O 8443 2019; Manjappa, Arehalli/JAO 0218 2023;
   Mishra, Anil/J 9502 2013
FU All India Council of Technical Education (AICTE), India
   [1 10/RID/NDF PG/(39)2008 2009]
FX This research was supported by National Doctoral Fellowship by All India
   Council of Technical Education (AICTE) (1 10/RID/NDF PG/(39)2008 2009),
   India. The authors are thankful to Boehringer Ingelheim, Germany for
   providing free gift sample of PLGA. The authors are also thankful to Ms.
   Krishna Chuttani for her kind help in conducting animal studies and to
   Marjo Jauhiainen for her help in estimation of IPP and ApppI.
CR Acharya S, 2009, BIOMATERIALS, V30, P5737, DOI 10.1016/j.biomaterials.2009.07.008
   Alila S, 2009, CARBOHYD POLYM, V77, P553, DOI 10.1016/j.carbpol.2009.01.028
   Brubaker KD, 2006, BMC CANCER, V6, DOI 10.1186/1471 2407 6 15
   CATIZONE A, 1993, CELL MOL BIOL, V39, P155
   Chaudhari KR, 2010, J MICROENCAPSUL, V27, P303, DOI 10.3109/02652040903191818
   Chaudhari KR, 2012, PHARM RES DORDR, V29, P53, DOI 10.1007/s11095 011 0510 x
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   Chithrani BD, 2007, NANO LETT, V7, P1542, DOI 10.1021/nl070363y
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Fancis M.D., 1987, BONE SCANNING CLIN P, P7
   FESSI H, 1989, INT J PHARMACEUT, V55, pR1, DOI 10.1016/0378 5173(89)90281 0
   Gil L, 1999, BIOORGAN MED CHEM, V7, P901, DOI 10.1016/S0968 0896(99)00045 0
   Gittens SA, 2005, ADV DRUG DELIVER REV, V57, P1011, DOI 10.1016/j.addr.2004.12.015
   Hengst V, 2007, INT J PHARMACEUT, V331, P224, DOI 10.1016/j.ijpharm.2006.11.024
   Hirabayashi H, 2001, J CONTROL RELEASE, V70, P183, DOI 10.1016/S0168 3659(00)00355 2
   Hosain F, 1996, J NUCL MED, V37, P105
   Iaffaioli RV, 2007, J CLIN ONCOL, V25
   Jauhiainen M, 2009, J CHROMATOGR B, V877, P2967, DOI 10.1016/j.jchromb.2009.07.010
   Karabulut B, 2009, CELL BIOL INT, V33, P239, DOI 10.1016/j.cellbi.2008.11.011
   Khandare J, 2006, PROG POLYM SCI, V31, P359, DOI 10.1016/j.progpolymsci.2005.09.004
   Lamb HM, 1997, DRUG AGING, V11, P413, DOI 10.2165/00002512 199711050 00007
   Lipton A, 2008, CANCER TREAT REV, V34, pS25, DOI 10.1016/j.ctrv.2008.03.008
   Liu XM, 2008, BIOMATERIALS, V29, P1686, DOI 10.1016/j.biomaterials.2007.12.023
   Mönkkönen H, 2006, BRIT J PHARMACOL, V147, P437, DOI 10.1038/sj.bjp.0706628
   Mönkkönen H, 2000, J CHROMATOGR B, V738, P395, DOI 10.1016/S0378 4347(99)00559 9
   Mönkkönen H, 2007, LIFE SCI, V81, P1066, DOI 10.1016/j.lfs.2007.08.007
   Mundy GR, 1997, CANCER AM CANCER SOC, V80, P1546, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1546::AID CNCR4>3.3.CO;2 R
   Murthy N, 2003, J CONTROL RELEASE, V89, P365, DOI 10.1016/S0168 3659(03)00099 3
   Nam HY, 2009, J CONTROL RELEASE, V135, P259, DOI 10.1016/j.jconrel.2009.01.018
   Panyam J, 2003, PHARM RES DORDR, V20, P212, DOI 10.1023/A:1022219003551
   Peyruchaud O, 2001, J BONE MINER RES, V16, P2027, DOI 10.1359/jbmr.2001.16.11.2027
   Räikkönen J, 2009, BRIT J PHARMACOL, V157, P427, DOI 10.1111/j.1476 5381.2009.00160.x
   Reddy LH, 2004, AAPS J, V6
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Rupper A, 2001, BBA GEN SUBJECTS, V1525, P205, DOI 10.1016/S0304 4165(01)00106 4
   Shah N, 2009, J DRUG TARGET, V17, P533, DOI 10.1080/10611860903046628
   Shakespeare WC, 2003, CURR OPIN DRUG DISC, V6, P729
   Shane E, 2010, NEW ENGL J MED, V362, P1825, DOI 10.1056/NEJMe1003064
   Shea JE, 2005, ADV DRUG DELIVER REV, V57, P945, DOI 10.1016/j.addr.2004.12.017
   Thompson W.J., 1989, Patent No. [EP0341961, 0341961]
   Weinstein RS, 2009, NEW ENGL J MED, V360, P53, DOI 10.1056/NEJMoa0802633
NR 41
TC 142
Z9 155
U1 4
U2 98
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168 3659
EI 1873 4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD MAR 28
PY 2012
VL 158
IS 3
BP 470
EP 478
DI 10.1016/j.jconrel.2011.11.020
PG 9
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA 931QL
UT WOS:000303234300016
PM 22146683
DA 2025 08 17
ER

PT J
AU Yin, C
   Tian, Y
   Li, DJ
   Yu, Y
   Jiang, SF
   Hou, YM
   Deng, M
   Zheng, KY
   Zhang, Y
   Deng, XN
   Chen, ZH
   Miao, ZP
   Hao, Q
   Li, Y
   Qian, AR
AF Yin, Chong
   Tian, Ye
   Li, Dijie
   Yu, Yang
   Jiang, Shanfeng
   Hou, Yimei
   Deng, Meng
   Zheng, Kaiyuan
   Zhang, Yan
   Deng, Xiaoni
   Chen, Zhihao
   Miao, Zhiping
   Hao, Qiang
   Li, Yu
   Qian, Airong
TI Long noncoding RNA Lnc DIF inhibits bone formation by sequestering
   miR 489 3p
SO ISCIENCE
LA English
DT Article
ID OSTEOBLASTS; SURFACES; CELLS
AB Osteoporosis has become a high incident bone disease along with the aging of human population. Long noncoding RNAs (LncRNAs) play an important role in osteoporosis incidence. In this study, we screened out an LncRNA negatively correlated with osteoblast differentiation, which was therefore named Lnc DIF (differentiation inhibiting factor). Functional analysis proved that Lnc DIF inhibited bone formation. A special structure containing multiple 53 nucleotide repeats was found in the trailing end of Lnc DIF. Our study suggested that this repeat sequence could sequester multiple miR 489 3p and inhibit bone formation through miR 489 3p/SMAD2 axis. Moreover, siRNA of Lnc DIF would rescue bone formation in both aging and ovariectomized osteoporosis mice. This study revealed a kind of LncRNA that could function as a sponge and regulate multiple miRNAs. RNA therapy techniques that target these LncRNAs could manipulate its downstream miRNA target pathway with significantly higher efficiency and specificity. This provided potential therapeutic insight for RNA based therapy for osteoporosis.
C1 [Yin, Chong; Tian, Ye; Li, Dijie; Jiang, Shanfeng; Zhang, Yan; Deng, Xiaoni; Chen, Zhihao; Miao, Zhiping; Li, Yu; Qian, Airong] Northwestern Polytech Univ, Res Ctr Special Med & Hlth Syst Engn, Sch Life Sci,Key Lab Space Biosci & Biotechnol,NP, Lab Bone Metab,Xian Key Lab Special Med & Hlth En, 127 West Youyi Rd, Xian 710072, Shaanxi, Peoples R China.
   [Yin, Chong] North Sichuan Med Coll, Affiliated Hosp, Dept Clin Lab, Lab Epigenet & RNA Therapy,Academician Expert Wor, Nanchong, Peoples R China.
   [Yin, Chong; Hou, Yimei; Deng, Meng; Zheng, Kaiyuan] North Sichuan Med Coll, Translat Med Res Ctr, Dept Lab Med, Nanchong, Peoples R China.
   [Yu, Yang] Tianjin Med Univ, Sch Pharm, Tianjin Key Lab Technol Enabling Dev Clin Therape, Tianjin, Peoples R China.
   [Hao, Qiang] Fourth Mil Med Univ, Biotechnol Ctr, Sch Pharm, State Key Lab Canc Biol, Xian 710032, Peoples R China.
C3 Northwestern Polytechnical University; North Sichuan Medical University;
   North Sichuan Medical University; Tianjin Medical University; Air Force
   Medical University
RP Li, Y; Qian, AR (通讯作者)，Northwestern Polytech Univ, Res Ctr Special Med & Hlth Syst Engn, Sch Life Sci,Key Lab Space Biosci & Biotechnol,NP, Lab Bone Metab,Xian Key Lab Special Med & Hlth En, 127 West Youyi Rd, Xian 710072, Shaanxi, Peoples R China.
EM liyu@nwpu.edu.cn; qianair@nwpu.edu.cn
RI Li, Mengyuan/ISR 9246 2023; chen, zhihao/GXM 3816 2022; Zheng,
   Yuanlin/C 9770 2017; Hao, Qiang/MIT 6089 2025; Zhang, Yan/MTF 5312 2025;
   Yu, Yang/AAI 2652 2020; Chen, Zhihao/ACK 3514 2022; Li,
   Dijie/KVB 3667 2024
OI Zhang, Yan/0000 0001 6213 4416; Chen, Zhihao/0000 0003 0128 1409; 
FU National Natural Science Foundation of China [81801871, 81803577,
   82072106, 32000924]; China Postdoctoral Science Foundation
   [2019T120947]; Shaanxi Provincial Key RD Program [2018KWZ 10]; Special
   fund for technological innovation of Shaanxi Province [2019QYPY 207];
   Shaanxi Postdoctoral Science Foundation [2017BSHEDZZ13]; Medical Science
   and Technology Project of the Health Planning Committee of Sichuan
   [21PJ101]; Clinical Research Program of Affiliated Hospital of North
   Sichuan Medical College [2021LC008];  [BKJ17J004]
FX The authors would like to thank Dr. Hong Zhou (The University of Sydney,
   Australia) for her generous gift of the MC3T3 E1 cell line. This work
   was supported by the National Natural Science Foundation of China
   (81801871, 81803577, 82072106, 32000924), the China Postdoctoral Science
   Foundation (2019T120947), the key grant BKJ17J004 and Shaanxi Provincial
   Key R&D Program (2018KWZ 10), Special fund for technological innovation
   of Shaanxi Province (2019QYPY 207), Shaanxi Postdoctoral Science
   Foundation (2017BSHEDZZ13), Medical Science and Technology Project of
   the Health Planning Committee of Sichuan (21PJ101), and Clinical
   Research Program of Affiliated Hospital of North Sichuan Medical College
   (2021LC008).
CR Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012
   Clarke BL, 2010, RADIOL CLIN N AM, V48, P483, DOI 10.1016/j.rcl.2010.02.014
   Feng YM, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.918932
   Geisler S, 2013, NAT REV MOL CELL BIO, V14, P699, DOI 10.1038/nrm3679
   Hassan MQ, 2015, BONE, V81, P746, DOI 10.1016/j.bone.2015.05.026
   He SW, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 2148 2
   Hung T, 2011, NAT GENET, V43, P621, DOI 10.1038/ng.848
   Li B, 2017, ORTHOP SURG, V9, P319, DOI 10.1111/os.12321
   Li CJ, 2015, J CLIN INVEST, V125, P1509, DOI 10.1172/JCI77716
   Liang C, 2015, NAT MED, V21, P288, DOI 10.1038/nm.3791
   Lin YX, 2017, TRANSL ONCOL, V10, P211, DOI 10.1016/j.tranon.2017.01.010
   Liu J, 2015, BIOMATERIALS, V52, P148, DOI 10.1016/j.biomaterials.2015.02.007
   Marie PJ, 1999, HISTOL HISTOPATHOL, V14, P525, DOI 10.14670/HH 14.525
   Matsumoto Y, 2012, MOL CELL ENDOCRINOL, V350, P78, DOI 10.1016/j.mce.2011.11.023
   Meng LY, 2015, NATURE, V518, P409, DOI 10.1038/nature13975
   Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031
   Mulati M, 2020, BONE, V130, DOI 10.1016/j.bone.2019.115076
   Palmieri Annalisa, 2008, J Prosthodont, V17, P522, DOI 10.1111/j.1532 849X.2008.00331.x
   Peng SP, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/8273648
   Peng W, 2018, BIOCHEM BIOPH RES CO, V503, P815, DOI 10.1016/j.bbrc.2018.06.081
   Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Thomson DW, 2016, NAT REV GENET, V17, P272, DOI 10.1038/nrg.2016.20
   Tripathi V, 2010, MOL CELL, V39, P925, DOI 10.1016/j.molcel.2010.08.011
   Ushiku C, 2010, J ORTHOP RES, V28, P1338, DOI 10.1002/jor.21105
   Wang CG, 2019, EXP MOL PATHOL, V107, P77, DOI 10.1016/j.yexmp.2019.01.012
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Wang YX, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2325 3
   Wang YX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 1153 1
   Wu JJ, 2018, BONE, V108, P62, DOI 10.1016/j.bone.2017.12.013
   Wu QY, 2016, SCI REP UK, V6, DOI 10.1038/srep30921
   Wu Y, 2019, BMC MOL CELL BIOL, V20, DOI 10.1186/s12860 019 0230 3
   Yan K, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010132
   Yin C, 2019, J CELL PHYSIOL, V234, P11524, DOI 10.1002/jcp.27815
   Yin C, 2018, J CELL PHYSIOL, V233, P5405, DOI 10.1002/jcp.26374
   Yuan HR, 2019, CELL DEATH DIFFER, V26, P2029, DOI 10.1038/s41418 019 0296 7
   Yuan P, 2017, CANCER RES, V77, P100, DOI 10.1158/0008 5472.CAN 16 1898
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
   Zhang YZ, 2019, PATHOL RES PRACT, V215, P525, DOI 10.1016/j.prp.2018.12.034
   Zhao J, 2008, SCIENCE, V322, P750, DOI 10.1126/science.1163045
NR 40
TC 11
Z9 13
U1 0
U2 11
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
EI 2589 0042
J9 ISCIENCE
JI iScience
PD MAR 18
PY 2022
VL 25
IS 3
AR 103949
DI 10.1016/j.isci.2022.103949
EA MAR 2022
PG 26
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 2P3QL
UT WOS:000819660100009
PM 35265818
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Li, P
   Ma, YC
   Sheng, XY
   Dong, HT
   Han, H
   Wang, J
   Xia, YY
AF Li, Peng
   Ma, Yan chao
   Sheng, Xiao yun
   Dong, Hai tao
   Han, Hua
   Wang, Jing
   Xia, Ya yi
TI Cyclic fluid shear stress promotes osteoblastic cells proliferation
   through ERK5 signaling pathway
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article
DE Cyclic fluid shear stress; ERK5; Osteoblast; Proliferation
ID KINASE 1 BMK1; EXPRESSION; ACTIVATION; DIFFERENTIATION; INHIBITORS;
   INCREASES; PULSATILE; PGE(2); FLOW
AB Fluid shear stress plays an important role in bone remodeling, however, the mechanism of mechanotransduction in bone tissue remains unclear. Recently, ERK5 has been found to be involved in multiple cellular processes. This study was designed to investigate the potential involvement of ERK5 in the proliferative response of osteoblastic cells to cyclic fluid shear stress. We reported here that cyclic fluid shear stress promoted ERK5 phosphorylation in MC3T3 E1 cells. Inhibition of ERK5 phosphorylation attenuated the increased expression of AP 1 and cyclin D1 and cell proliferation induced by cyclic fluid flow, but promoted p 16 expression. Further more, we found that cyclic fluid shear stress was a better stimuli for ERK5 activation and cyclin D1 expression compared with continuous fluid shear stress. Moreover, the pharmacological ERK5 inhibitor, BIX02189, which inhibited ERK5 phosphorylation in a time dependent manner and the suppression lasted for at least 4 h. Taken together, we demonstrate that ERK5/AP 1/cyclin D1 pathway is involved in the mechanism of osteoblasts proliferation induced by cyclic fluid shear stress, which is superior in promoting cellular proliferation compared with continuous fluid shear stress.
C1 [Li, Peng; Sheng, Xiao yun; Dong, Hai tao; Wang, Jing; Xia, Ya yi] Lanzhou Univ, Hosp 2, Inst Orthopaed, Lanzhou 730030, Gansu, Peoples R China.
   [Ma, Yan chao; Han, Hua; Xia, Ya yi] Lanzhou Univ, Hosp 2, Dept Orthopaed, Lanzhou 730030, Gansu, Peoples R China.
C3 Lanzhou University; Lanzhou University
RP Xia, YY (通讯作者)，Lanzhou Univ, Hosp 2, Inst Orthopaed, Lanzhou 730030, Gansu, Peoples R China.
EM xiayy@lzu.edu.cn
RI xiaoyun, sheng/MVU 3246 2025
FU National Natural Science Foundation of China [81071478]
FX This study was supported by the National Natural Science Foundation of
   China (Grant No. 81071478). The authors are very grateful to Boehringer
   Ingelheim for their kindly providing of ERK5 inhibitors, BIX02188, and
   BIX02189.
CR Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586
   Basso N, 2002, BONE, V30, P347, DOI 10.1016/S8756 3282(01)00678 0
   BIEWENER AA, 1986, J EXP BIOL, V123, P383
   Coqueret O, 2002, GENE, V299, P35, DOI 10.1016/S0378 1119(02)01055 7
   Dinev D, 2001, EMBO REP, V2, P829, DOI 10.1093/embo reports/kve177
   FRANGOS JA, 1988, BIOTECHNOL BIOENG, V32, P1053, DOI 10.1002/bit.260320812
   Fukuno N, 2011, BIOCHEM BIOPH RES CO, V408, P202, DOI 10.1016/j.bbrc.2011.02.127
   Hsieh TP, 2011, PHYTOMEDICINE, V18, P176, DOI 10.1016/j.phymed.2010.04.003
   Huang YC, 2011, TOXICOL LETT, V200, P59, DOI 10.1016/j.toxlet.2010.10.015
   Hwang J, 2003, CIRC RES, V93, P1225, DOI 10.1161/01.RES.0000104087.29395.66
   Jacobs CR, 1998, J BIOMECH, V31, P969, DOI 10.1016/S0021 9290(98)00114 6
   Jia XW, 2011, CELL BIOL INT, V35, P697, DOI 10.1042/CBI20100298
   Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058
   Keselowsky BG, 2005, P NATL ACAD SCI USA, V102, P5953, DOI 10.1073/pnas.0407356102
   Kim IS, 2009, J BIOMECH, V42, P2721, DOI 10.1016/j.jbiomech.2009.08.006
   LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189
   Li L, 2008, BIOCHEM BIOPH RES CO, V370, P159, DOI 10.1016/j.bbrc.2008.03.051
   Liu DW, 2008, BONE, V42, P644, DOI 10.1016/j.bone.2007.09.058
   Majima T, 2000, J ORTHOPAED RES, V18, P524, DOI 10.1002/jor.1100180403
   Mehta PB, 2003, ONCOGENE, V22, P1381, DOI 10.1038/sj.onc.1206154
   Mulloy R, 2003, ONCOGENE, V22, P5387, DOI 10.1038/sj.onc.1206839
   Myers KA, 2007, BIOCHEM BIOPH RES CO, V364, P214, DOI 10.1016/j.bbrc.2007.09.109
   Nauman EA, 2001, J APPL PHYSIOL, V90, P1849, DOI 10.1152/jappl.2001.90.5.1849
   Pi XC, 2004, CIRC RES, V94, P362, DOI 10.1161/01.RES.0000112406.27800.6F
   REICH KM, 1990, J CELL PHYSIOL, V143, P100, DOI 10.1002/jcp.1041430113
   Sakai K, 1998, CALCIFIED TISSUE INT, V63, P515, DOI 10.1007/s002239900567
   Takai E, 2004, J BONE MINER RES, V19, P1403, DOI 10.1359/JBMR.040516
   Tatake RJ, 2008, BIOCHEM BIOPH RES CO, V377, P120, DOI 10.1016/j.bbrc.2008.09.087
   Yan C, 1999, J BIOL CHEM, V274, P143, DOI 10.1074/jbc.274.1.143
   Yan Lijun, 2003, BMC Dev Biol, V3, P11, DOI 10.1186/1471 213X 3 11
   Yang Q, 2011, NEUROSCI LETT, V494, P38
   Young SRL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016026
NR 32
TC 31
Z9 53
U1 0
U2 25
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300 8177
EI 1573 4919
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD MAY
PY 2012
VL 364
IS 1 2
BP 321
EP 327
DI 10.1007/s11010 012 1233 y
PG 7
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 934PY
UT WOS:000303458300034
PM 22286747
DA 2025 08 17
ER

PT J
AU Liu, J
   Leng, FF
   Gao, YH
   He, WF
   Wang, JF
   Xian, CJ
   Ma, HP
   Chen, KM
AF Liu, Jing
   Leng, Fei Fan
   Gao, Yu Hai
   He, Wen Fang
   Wang, Ju Fang
   Xian, Cory J. J.
   Ma, Hui Ping
   Chen, Ke Ming
TI Protection of primary cilia is an effective countermeasure against the
   impairment of osteoblast function induced by simulated microgravity
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE BMP 2; microgravity; miRNA 129 3p; osteoblasts; osteogenic
   differentiation; primary cilia
ID FLUID SHEAR STRESS; SPACE FLIGHT; BONE; CELLS
AB The molecular mechanism for the microgravity induced decrease in bone formation remains unclear and there is a lack of effective specific preventative therapies. We recently reported that primary cilia of osteoblasts became shorter and even disappeared when the cells were exposed to random positioning machine (RPM) simulated microgravity and that the microgravity induced loss of osteogenic potential of osteoblasts could be attenuated when the resorption of primary cilia was prevented by treatment with 0.1 mu M cytochalasin D. In the current study, it was further found that the loss of the osteogenic capacity of rat calvarial osteoblasts (ROBs) was associated with the inhibition of the BMP 2/Smad1/5/8 signalling pathway, of which most of the signalling proteins including BMP 2, BMPRII, Smad1/5/8 and p Smad1/5/8 were found localized to primary cilia. Accompanying the resorption of primary cilia following the cells being exposed to simulated microgravity, the expression levels of these signalling proteins were reduced significantly. Furthermore, the expression of miRNA 129 3p, a microRNA previously reported to control cilium biogenesis, was found to be reduced quickly and changed in a similar tendency with the length of primary cilia. Moreover, overexpression of miRNA 129 3p in ROBs significantly attenuated microgravity induced inhibition of BMP 2 signalling and loss of osteogenic differentiation and mineralization. These results indicated the important role of miRNA 129 3p in microgravity induced resorption of primary cilia of osteoblasts and the potential of replenishing the miRNA 129 3p as an effective countermeasure against microgravity induced loss of primary cilia and impairment of osteoblast function.
C1 [Liu, Jing; Gao, Yu Hai; He, Wen Fang; Chen, Ke Ming] Peoples Liberat Army, 940th Hosp Joint Logist Support Force, Fundamental Med Sci Res Labs, Lanzhou, Peoples R China.
   [Leng, Fei Fan] Lanzhou Univ Technol, Sch Life Sci & Engn, Dept Bioengn, Lanzhou, Peoples R China.
   [Wang, Ju Fang] Chinese Acad Sci, Inst Modern Phys, Gansu Key Lab Space Radiobiol, Lanzhou, Peoples R China.
   [Xian, Cory J. J.] Univ South Australia, UniSA Clin & Hlth Sci, Adelaide, SA, Australia.
   [Ma, Hui Ping] Peoples Liberat Army, 940th Hosp Joint Logist Support Force, Dept Pharm, Lanzhou, Peoples R China.
   [Chen, Ke Ming] Peoples Liberat Army, 940th Hosp Joint Logist Support Force, Fundamental Med Sci Res Labs, Lanzhou 730050, Peoples R China.
   [Ma, Hui Ping] Peoples Liberat Army, 940th Hosp Joint Logist Support Force, Dept Pharm, Lanzhou 730050, Peoples R China.
C3 Lanzhou University of Technology; Chinese Academy of Sciences; Institute
   of Modern Physics, CAS; University of South Australia
RP Chen, KM (通讯作者)，Peoples Liberat Army, 940th Hosp Joint Logist Support Force, Fundamental Med Sci Res Labs, Lanzhou 730050, Peoples R China.; Ma, HP (通讯作者)，Peoples Liberat Army, 940th Hosp Joint Logist Support Force, Dept Pharm, Lanzhou 730050, Peoples R China.
EM mahuipingcxr@aliyun.com; chenkm@lut.edu.cn
RI Gao, Yuhai/AHB 5767 2022
OI He, Wenfang/0000 0002 0032 5978; Chen, Ke Ming/0000 0002 9749 8356; Liu,
   Jing/0000 0002 7005 611X
CR Anvarian Z, 2019, NAT REV NEPHROL, V15, P199, DOI 10.1038/s41581 019 0116 9
   Arai K, 2008, CELL STRUCT FUNCT, V33, P203, DOI 10.1247/csf.08025
   Bergouignan A, 2016, NPJ MICROGRAVITY, V2, DOI 10.1038/npjmgrav.2016.29
   Cao JL, 2012, NAT CELL BIOL, V14, P697, DOI 10.1038/ncb2512
   Cao Xin sheng, 2003, Space Med Med Eng (Beijing), V16, P269
   Carmeliet G, 2001, CRIT REV EUKAR GENE, V11, P131, DOI 10.1615/CritRevEukarGeneExpr.v11.i1 3.70
   Cavanagh Peter R, 2005, Gravit Space Biol Bull, V18, P39
   Cervantes JL, 2016, INT REV IMMUNOL, V35, P67, DOI 10.3109/08830185.2015.1027821
   Choi H, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 51939 7
   Dai ZQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063661
   Delaine Smith RM, 2014, FASEB J, V28, P430, DOI 10.1096/fj.13 231894
   Demontis GC, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00547
   FEDERMAN M, 1974, CALC TISS RES, V17, P81, DOI 10.1007/BF02547216
   Geng B, 2016, EXP CELL RES, V343, P208, DOI 10.1016/j.yexcr.2016.03.014
   Grimm D, 2016, BONE, V87, P44, DOI 10.1016/j.bone.2015.12.057
   Hamamoto A, 2016, CELL SIGNAL, V28, P572, DOI 10.1016/j.cellsig.2016.02.018
   Hoey DA, 2011, BIOCHEM BIOPH RES CO, V412, P182, DOI 10.1016/j.bbrc.2011.07.072
   Hu LF, 2015, CELL BIOL INT, V39, P364, DOI 10.1002/cbin.10391
   Jirak P, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103467
   Kwon RY, 2010, FASEB J, V24, P2859, DOI 10.1096/fj.09 148007
   LeBlanc A. D., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P33
   Mahjoub MR, 2013, ORGANOGENESIS, V9, P61, DOI 10.4161/org.25144
   Markin A A, 1997, Aviakosm Ekolog Med, V31, P14
   McGlashan SR, 2010, CELL BIOL INT, V34, P441, DOI 10.1042/CBI20090094
   Nagaraja MP, 2013, J CELL BIOCHEM, V114, P1001, DOI 10.1002/jcb.24454
   Noda K, 2016, P NATL ACAD SCI USA, V113, pE2589, DOI 10.1073/pnas.1519458113
   Qian XD, 2014, CELL BIOCHEM BIOPHYS, V70, P1127, DOI 10.1007/s12013 014 0032 3
   Qin WW, 2019, ENDOCRINE, V65, P426, DOI 10.1007/s12020 019 01952 7
   Saxena R, 2007, ANN NY ACAD SCI, V1116, P494, DOI 10.1196/annals.1402.033
   Schwartz EA, 1997, AM J PHYSIOL RENAL, V272, pF132, DOI 10.1152/ajprenal.1997.272.1.F132
   Shi WG, 2020, BONE, V136, DOI 10.1016/j.bone.2020.115346
   Shi WG, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 02049 9
   Siamwala JH, 2015, VITAM HORM, V99, P249, DOI 10.1016/bs.vh.2015.05.004
   Sun Y, 2013, OSTEOPOROSIS INT, V24, P969, DOI 10.1007/s00198 012 2028 4
   Sun ZY, 2015, SCI REP UK, V5, DOI 10.1038/srep08077
   Temiyasathit S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033368
   Tian Y, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102132
   Wang Bing, 2004, Space Med Med Eng (Beijing), V17, P176
   Wang RN, 2014, GENES DIS, V1, P87, DOI 10.1016/j.gendis.2014.07.005
   White RJ, 2001, NATURE, V409, P1115, DOI 10.1038/35059243
   Zhong Z, 2013, EUR J ORTHODONT, V35, P59, DOI 10.1093/ejo/cjr016
   Zhou J, 2019, J BONE MINER RES, V34, P1336, DOI 10.1002/jbmr.3704
NR 42
TC 4
Z9 8
U1 0
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1582 1838
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD JAN
PY 2023
VL 27
IS 1
BP 36
EP 51
DI 10.1111/jcmm.17628
EA DEC 2022
PG 16
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA 7K8GF
UT WOS:000896834300001
PM 36512344
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Pepene, CE
   Seck, T
   Diel, I
   Minne, HW
   Ziegler, R
   Pfeilschifter, J
AF Pepene, C. E.
   Seck, T.
   Diel, I.
   Minne, H. W.
   Ziegler, R.
   Pfeilschifter, J.
TI Effect of Glucocorticoid , Parathyroid  and Thyroid Hormones Excess on
   Human Iliac Crest Bone Matrix Insulin like Growth Factor (IGF) I in
   Patients with Osteoporosis
SO EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
LA English
DT Article
DE glucocorticoids; hormones; thyroid; autoimmunity; thyrotropin; hormones
ID FACTOR I; IGF I; TRANSFORMING GROWTH FACTOR BETA 1; GENE EXPRESSION;
   OSTEOBLASTS; SERUM; MECHANISMS; OSTEOCYTES; INCREASES; APOPTOSIS
AB Insulin like growth factor I (IGF I) is a well documented bone active growth factor. Clinical studies reported that circulating hormones may affect serum IGF I levels, with potential consequences on bone remodeling. However, no data on bone matrix concentrations of IGF I in subjects with endocrine dysfunction is available in humans. Bone mineral density and cancellous bone matrix IGF I levels were assessed in iliac crest biopsies from 38 patients with low bone mass related to glucocorticoid  (n = 10), parathyroid  (n = 14) or thyroid (n = 14) hormones excess. Results were compared to those of sex and age matched patients with primary osteoporosis. Bone matrix extraction was performed based on a guanidine chlorhidric acid/ethylendiamine tetraacetic acid method. Long term glucocorticoid therapy (>= 24 months) led to significantly lower cancellous bone matrix IGF I levels in comparison to age matched controls (p = 0.03). Although higher trabecular bone IGF I levels were seen in hyperparathyroid subjects, the difference was not significant in comparison to controls (p = 0.24). Likewise, no difference was noticed in cancellous bone matrix IGF I concentrations between subjects with low bone mass and sub clinical or overt thyrotoxicosis and euthyroid controls. Neither parathyroid hormone (PTH) nor thyroxin (T 4) concentrations were associated with bone matrix IGF I levels. To conclude, our study documented that in vivo long term corticotherapy is associated with low trabecular human bone matrix IGF I. In contrast, no influence of increased circulating parathyroid  or thyroid hormones levels on human iliac crest skeletal IGF I concentrations was observed.
C1 [Pepene, C. E.] Univ Med & Pharm Cluj Napoca, Cluj Napoca 3400, Romania.
C3 Iuliu Hatieganu University of Medicine & Pharmacy
RP Pepene, CE (通讯作者)，Univ Med & Pharm Cluj Napoca, Louis Pasteur St 3, Cluj Napoca 3400, Romania.
EM c_e_georgescu@yahoo.com
CR BANG P, 1993, ACTA ENDOCRINOL COP, V128, P397
   Blum W F, 1994, Growth Regul, V4 Suppl 1, P11
   CO NG, 2000, J PEDIAT ENDOCRINOL, V13, P1073
   DELANY AM, 1995, ENDOCRINOLOGY, V136, P4776, DOI 10.1210/en.136.11.4776
   Delany AM, 2001, MOL ENDOCRINOL, V15, P1781, DOI 10.1210/me.15.10.1781
   DEQUEKER J, 1995, BONE, V17, P247, DOI 10.1016/8756 3282(95)00224 2
   Guicheux J, 1998, BONE, V22, P25, DOI 10.1016/S8756 3282(97)00224 X
   Iglesias P, 2001, THYROID, V11, P1043, DOI 10.1089/105072501753271734
   Jehle PM, 2000, KIDNEY INT, V57, P423, DOI 10.1046/j.1523 1755.2000.t01 1 00862.x
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017
   Koch H, 2005, STEM CELLS DEV, V14, P621, DOI 10.1089/scd.2005.14.621
   Lakatos P, 2000, THYROID, V10, P417, DOI 10.1089/thy.2000.10.417
   Langdahl BL, 1998, EUR J CLIN INVEST, V28, P176
   Maccario M, 2001, EUR J ENDOCRINOL, V144, P251, DOI 10.1530/eje.0.1440251
   McCarthy TL, 2000, ENDOCRINOLOGY, V141, P127, DOI 10.1210/en.141.1.127
   MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P1247, DOI 10.1210/endo 124 3 1247
   Nakayama Y, 2006, J CELL PHYSIOL, V208, P326, DOI 10.1002/jcp.20664
   Noda T, 2005, HORM METAB RES, V37, P270, DOI 10.1055/s 2005 861468
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   OKAZAKI R, 1994, ENDOCRINOLOGY, V134, P126, DOI 10.1210/en.134.1.126
   Pepene CE, 2004, EXP CLIN ENDOCR DIAB, V112, P38, DOI 10.1055/s 2004 815725
   Pepene CE, 2004, EUR J ENDOCRINOL, V150, P81, DOI 10.1530/eje.0.1500081
   Pepene CE, 2001, BONE, V29, P540, DOI 10.1016/S8756 3282(01)00607 X
   PFEILSCHIFTER J, 1995, J CLIN INVEST, V96, P767, DOI 10.1172/JCI118121
   Seck T, 1998, J CLIN ENDOCR METAB, V83, P2331, DOI 10.1210/jc.83.7.2331
   Wang JS, 2006, NEW CARBON MATER, V21, P9
   WATSON P, 1995, BONE, V16, P357, DOI 10.1016/8756 3282(94)00051 4
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Zimmermann Belsing T, 2004, GROWTH HORM IGF RES, V14, P235, DOI 10.1016/j.ghir.2003.12.015
NR 29
TC 3
Z9 3
U1 0
U2 4
PU JOHANN AMBROSIUS BARTH VERLAG MEDIZINVERLAGE HEIDELBERG GMBH
PI STUTTGART
PA RUEDIGERSTR 14, D 70469 STUTTGART, GERMANY
SN 0947 7349
EI 1439 3646
J9 EXP CLIN ENDOCR DIAB
JI Exp. Clin. Endocrinol. Diabet.
PD MAY
PY 2010
VL 118
IS 5
BP 310
EP 314
DI 10.1055/s 0029 1224124
PG 5
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 608BT
UT WOS:000278557200005
PM 19998242
DA 2025 08 17
ER

PT J
AU Kumar, S
   Ponnazhagan, S
AF Kumar, Sanjay
   Ponnazhagan, Selvarangan
TI Bone homing of mesenchymal stem cells by ectopic α4 integrin expression
SO FASEB JOURNAL
LA English
DT Article
DE tissue regeneration; cell therapy; bone targeting
ID ADHESION MOLECULE 1; ENGRAFTMENT; DIFFERENTIATION; MOBILIZATION;
   FIBRONECTIN; INHIBITION; DOMAIN 4; BINDING; VLA 4; STAGE
AB The pluripotent nature of mesenchymal stem cells ( MSC) widens their potential for tissue regeneration and as vehicles for cell therapy in molecular medicine. Although the MSC are relatively easier to obtain and propagate in culture, a major impediment remains in their engraftment to target tissues on autologous transfer. We report here that transient, ectopic expression of alpha 4 integrin (CD49d) on MSC greatly increases bone homing in an immunocompetent mouse model. Heterodimerization of the alpha 4 integrin with endogenous beta 1 integrin (CD29) was confirmed to influence this targeting. In addition to retaining their stem cell property, the engrafted MSC were also found to form osteoblasts and osteocytes in the growth plate of recipient mouse limb bones ( femur/ tibia) in vivo. These findings provide evidence for a novel strategy to achieve bone homing of genetically engineered MSC, which may broadly benefit in targeted therapies for osteopenic bone defects and cancer bone metastasis.
C1 Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham
RP Ponnazhagan, S (通讯作者)，Univ Alabama Birmingham, Dept Pathol, 701 19th St South, LHRB 513, Birmingham, AL 35294 USA.
EM pons@uab.edu
RI kumar, Sanjay/ITT 3680 2023
FU NCI NIH HHS [CA 98817] Funding Source: Medline; NIAMS NIH HHS [AR 50251]
   Funding Source: Medline
CR Adams GB, 2006, NATURE, V439, P599, DOI 10.1038/nature04247
   Bergstrom DE, 1998, GENOMICS, V48, P304, DOI 10.1006/geno.1997.5176
   Bonig H, 2006, BLOOD, V107, P79, DOI 10.1182/blood 2005 05 2023
   Catalina MD, 1999, BLOOD, V93, P580, DOI 10.1182/blood.V93.2.580.402k16_580_589
   Chateauvieux S, 2007, PHYSIOL GENOMICS, V29, P128, DOI 10.1152/physiolgenomics.00197.2006
   Corey E, 2005, CANCER RES, V65, P1710, DOI 10.1158/0008 5472.CAN 04 2033
   De Ugarte DA, 2003, IMMUNOL LETT, V89, P267, DOI 10.1016/S0165 2478(03)00108 1
   Feeley BT, 2006, BONE, V38, P154, DOI 10.1016/j.bone.2005.07.015
   Gao JZ, 2001, CELLS TISSUES ORGANS, V169, P12, DOI 10.1159/000047856
   GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092 8674(90)90715 Q
   Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092 8674(02)00971 6
   Jacobsen K, 1996, BLOOD, V87, P73
   Jin H, 2006, J CLIN INVEST, V116, P652, DOI 10.1172/JCI24751
   Kalajzic I, 2003, J CELL BIOCHEM, V88, P1168, DOI 10.1002/jcb.10459
   KILGER G, 1995, J BIOL CHEM, V270, P5979, DOI 10.1074/jbc.270.11.5979
   Koistinen P, 2002, J BIOL CHEM, V277, P24835, DOI 10.1074/jbc.M203149200
   Kumar S, 2005, BBA GENE STRUCT EXPR, V1731, P95, DOI 10.1016/j.bbaexp.2005.08.007
   MASUMOTO A, 1993, J BIOL CHEM, V268, P228
   MATSUSHIMA T, 1996, TRENDS CHEM PHYS, V4, P1
   MIYAKE K, 1991, J EXP MED, V173, P599, DOI 10.1084/jem.173.3.599
   Pacary E, 2006, J CELL SCI, V119, P2667, DOI 10.1242/jcs.03004
   PETERS SO, 1995, EXP HEMATOL, V23, P461
   Prockop DJ, 2003, P NATL ACAD SCI USA, V100, P11917, DOI 10.1073/pnas.1834138100
   Prosper F, 1998, J CLIN INVEST, V101, P2456, DOI 10.1172/JCI188
   QIAN F, 1994, CELL, V77, P335, DOI 10.1016/0092 8674(94)90149 X
   SCHADENDORF D, 1993, J PATHOL, V170, P429, DOI 10.1002/path.1711700405
   Schweitzer KM, 1996, AM J PATHOL, V148, P165
   Stewart FM, 1998, BLOOD, V91, P3681
   Woodside DG, 2006, J IMMUNOL, V176, P5041, DOI 10.4049/jimmunol.176.8.5041
   Zanjani ED, 1999, BLOOD, V94, P2515, DOI 10.1182/blood.V94.7.2515.419k15_2515_2522
   Zolotukhin S, 1999, GENE THER, V6, P973, DOI 10.1038/sj.gt.3300938
NR 31
TC 126
Z9 136
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD DEC
PY 2007
VL 21
IS 14
BP 3917
EP 3927
DI 10.1096/fj.07 8275com
PG 11
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA 236DP
UT WOS:000251283500017
PM 17622670
DA 2025 08 17
ER

PT J
AU Nagano, Y
   Matsui, H
   Shimokawa, O
   Hirayama, A
   Nakamura, Y
   Tamura, M
   Rai, K
   Kaneko, T
   Hyodo, I
AF Nagano, Yumiko
   Matsui, Hirofumi
   Shimokawa, Osamu
   Hirayama, Aki
   Nakamura, Yukio
   Tamura, Masato
   Rai, Kanho
   Kaneko, Tsuyoshi
   Hyodo, Ichinosuke
TI Bisphosphonate induced gastrointestinal mucosal injury is mediated by
   mitochondrial superoxide production and lipid peroxidation
SO JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION
LA English
DT Article
DE bisphosphonates; non steroidal anti inflammatory drugs (NSAIDs);
   geranylgeranylacetone; superoxide; lipid peroxidation
ID SMALL BOWEL INJURY; EPITHELIAL CELLS; CELLULAR INJURY; SMALL INTESTINE;
   GASTRIC ULCERS; RAT STOMACHS; ALENDRONATE; REBAMIPIDE; FLUORESCENCE;
   DISORDERS
AB Bisphosphonates such as alendronate and risedronate are commonly used for the treatment of postmenopausal osteoporosis. They have the gastrointestinal adverse effects such as erosions and ulcers in stomach and small intestine. However, the detailed biological mechanism remains to be elucidated. Since alendronate is suggested to increase the risk of non steroidal anti inflammatory drug related gastropathy, we hypothesized that bisphosphonates and non steroidal anti inflammatory drugs have the same pathophysiological mechanisms in gastrointestinal mucosa: Bisphosphonates may induce cellular lipid peroxidation by inducing the production of mitochondria! superoxide. We also hypothesized that geranylgeranylacetone, an antiulcer drug, may prevent lipid peroxidation by reducing superoxide production. We treated gastric RGM1 cells and small intestinal IEC6 cells with alendronate or risedronate, and examined cellular injury, lipid peroxidation and superoxide production with specific fluorescent dyes, and underwent electron paramagnetic resonance spectroscopy to detect the production of superoxide in vitro. The results indicated that bisphosphonates indeed induced cellular injury, cellular lipid peroxidation, and superoxide production. We also demonstrated that the pretreatment of geranylgeranylacetone decreased superoxide production and prevented cellular lipid peroxidation. These results suggested that bisphosphonates, like non steroidal anti inflammatory drugs, induce lipid peroxidation by producing mitochondrial superoxide, which was prevented by geranylgeranylacetone.
C1 [Nagano, Yumiko; Matsui, Hirofumi; Shimokawa, Osamu; Tamura, Masato; Rai, Kanho; Kaneko, Tsuyoshi; Hyodo, Ichinosuke] Univ Tsukuba, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 3058575, Japan.
   [Hirayama, Aki] Tsukuba Univ Technol, Ctr Integrat Med, Tsukuba, Ibaraki 3058521, Japan.
   [Nagano, Yumiko; Nakamura, Yukio] RIKEN BioResource Ctr, Cell Engn Div, Tsukuba, Ibaraki 3050074, Japan.
C3 University of Tsukuba; Tsukuba University of Technology; RIKEN
RP Matsui, H (通讯作者)，Univ Tsukuba, Grad Sch Comprehens Human Sci, 1 1 1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.
EM hmatsui@md.tsukuba.ac.jp
RI Hirayama, Aki/G 7842 2017; Nakamura, Yukio/A 5263 2016
OI Hirayama, Aki/0000 0001 5777 4208; 
FU Grants in Aid for Scientific Research [24591224, 24591024] Funding
   Source: KAKEN
CR Akamatsu T, 2010, J CLIN BIOCHEM NUTR, V47, P256, DOI 10.3164/jcbn.10 86
   Blank MA, 1997, DIGEST DIS SCI, V42, P281, DOI 10.1023/A:1018849415297
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   deGroen PC, 1996, NEW ENGL J MED, V335, P1016, DOI 10.1056/NEJM199610033351403
   Elliott SN, 1997, LIFE SCI, V62, P77, DOI 10.1016/S0024 3205(97)01040 0
   Graham DY, 1999, ALIMENT PHARM THER, V13, P515
   Graham DY, 2002, DIGEST DIS SCI, V47, P1665, DOI 10.1023/A:1016495221567
   Graham DY, 2001, ARCH INTERN MED, V161, P107, DOI 10.1001/archinte.161.1.107
   Higuchi K, 2009, J GASTROENTEROL, V44, P879, DOI 10.1007/s00535 009 0102 2
   Ikeda R, 2003, MICROBIOL IMMUNOL, V47, P271, DOI 10.1111/j.1348 0421.2003.tb03395.x
   Kamibayashi M, 2006, FREE RADICAL RES, V40, P1166, DOI 10.1080/10715760600883254
   Kanatsu K, 2004, J GASTROEN HEPATOL, V19, P512, DOI 10.1111/j.1440 1746.2003.03314.x
   Kaneko T, 2007, J GASTROENTEROL, V42, P939, DOI 10.1007/s00535 007 2116 y
   Lichtenberger LM, 2000, DIGEST DIS SCI, V45, P1792, DOI 10.1023/A:1005574009856
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Matsui H, 1998, J GASTROENTEROL, V33, P318, DOI 10.1007/s005350050090
   Matsui H, 2011, J GASTROENTEROL, V46, P1167, DOI 10.1007/s00535 011 0434 6
   Matsui H, 2011, J CLIN BIOCHEM NUTR, V48, P107, DOI 10.3164/jcbn.10 79
   Nagano Y, 2005, DIGEST DIS SCI, V50, pS76, DOI 10.1007/s10620 005 2810 7
   Ohashi Y, 2009, J PHYSIOL PHARMACOL, V60, P85
   Okimoto Y, 2000, FEBS LETT, V474, P137, DOI 10.1016/S0014 5793(00)01587 8
   Omatsu T, 2009, J GASTROENTEROL, V44, P30, DOI 10.1007/s00535 008 2293 3
   QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248
   Russell RGG, 1999, OSTEOPOROSIS INT, V9, P66, DOI 10.1007/PL00004164
   Shinohara T, 2007, AM J PHYSIOL HEART C, V293, pH1892, DOI 10.1152/ajpheart.00493.2007
   Suemasu S, 2009, J BIOL CHEM, V284, P19705, DOI 10.1074/jbc.M109.006817
   Suzuki H, 2012, J CLIN BIOCHEM NUTR, V50, P35, DOI [10.3164/jcbn.11 11SSR, 10.3164/jcbn.11 115SR]
   Ushijima H, 2005, MOL PHARMACOL, V68, P1156, DOI 10.1124/mol.105.015784
   Watanabe T, 2011, J CLIN BIOCHEM NUTR, V48, P117, DOI 10.3164/jcbn.10 73
NR 29
TC 21
Z9 23
U1 0
U2 6
PU JOURNAL CLINICAL BIOCHEMISTRY & NUTRITION
PI KYOTO
PA KYOTO PREFECTURAL UNIV MED, GRAD SCH MEDICAL SCIENCE, DEPT MOLECULAR
   GASTROENTEROLOGY & HEPATOLOGY, KYOTO, 602 8566, JAPAN
SN 0912 0009
EI 1880 5086
J9 J CLIN BIOCHEM NUTR
JI J. Clin. Biochem. Nutr.
PD NOV 1
PY 2012
VL 51
IS 3
BP 196
EP 203
DI 10.3164/jcbn.12 41
PG 8
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA 037TK
UT WOS:000311129200006
PM 23170047
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Huang, TC
   Chiu, PR
   Chang, WT
   Hsieh, BS
   Huang, YC
   Cheng, HL
   Huang, LW
   Hu, YC
   Chang, KL
AF Huang, Tzu Ching
   Chiu, Pu Rong
   Chang, Wen Tsan
   Hsieh, Bau Shan
   Huang, Yu Ci
   Cheng, Hsiao Ling
   Huang, Li Wen
   Hu, Yu Chen
   Chang, Kee Lung
TI Epirubicin induces apoptosis in osteoblasts through death receptor and
   mitochondrial pathways
SO APOPTOSIS
LA English
DT Article
DE Epirubicin; Osteoblast; Apoptosis; Bone; Mineralization
ID CANCER CELL LINE; BREAST CANCER; BONE LOSS; ALKALINE PHOSPHATASE;
   OXIDATIVE STRESS; MARROW ADIPOSITY; CHEMOTHERAPY; CYCLOPHOSPHAMIDE;
   HA22T/VGH; THERAPY
AB Epirubicin is an anthracycline and is widely used in tumor treatment, but has toxic and undesirable side effects on wide range of cells and hematopoietic stem cells (HSC). Osteoblasts play important roles in bone development and in supporting HSC differentiation and maturation. It remains unknown whether epirubicin induced bone loss and hematological toxicity are associated with its effect on osteoblasts. In primary osteoblast cell cultures, epirubicin inhibited cell growth and decreased mineralization. Moreover, epirubicin arrested osteoblasts in the G2/M phase, and this arrest was followed by apoptosis in which both the extrinsic (death receptor mediated) and intrinsic (mitochondrial mediated) apoptotic pathways were evoked. The factors involved in the extrinsic apoptotic pathway were increased FasL and FADD as well as activated caspase 8. Those involved in the intrinsic apoptotic pathway were decreased Bcl 2; increased reactive oxygen species, Bax, cytochrome c; and activated caspase 9 and caspase 3. These results demonstrate that epirubicin induced osteoblast apoptosis through the extrinsic and intrinsic apoptotic pathways, leading to the destruction of osteoblasts and consequent lessening of their functions in maintaining bone density and supporting hematopoietic stem cell differentiation and maturation.
C1 [Huang, Tzu Ching; Chang, Kee Lung] Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung 80708, Taiwan.
   [Huang, Tzu Ching; Chiu, Pu Rong; Hsieh, Bau Shan; Huang, Yu Ci; Cheng, Hsiao Ling; Hu, Yu Chen; Chang, Kee Lung] Kaohsiung Med Univ, Sch Med, Dept Biochem, Coll Med, Kaohsiung 80708, Taiwan.
   [Chang, Wen Tsan] Kaohsiung Med Univ, Sch Med, Dept Surg, Coll Med, Kaohsiung 80708, Taiwan.
   [Chang, Wen Tsan] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Div Gen & Digest & Pancreat Surg, Dept Surg, Kaohsiung 80756, Taiwan.
   [Huang, Li Wen] Kaohsiung Med Univ, Dept Med Lab Sci & Biotechnol, Coll Hlth Sci, Kaohsiung 80708, Taiwan.
   [Chang, Kee Lung] Natl Sun Yat Sen Univ, Inst Med Sci & Technol, Coll Sci, Kaohsiung 80424, Taiwan.
   [Chang, Kee Lung] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung 80756, Taiwan.
C3 Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung
   Medical University; Kaohsiung Medical University; Kaohsiung Medical
   University Hospital; Kaohsiung Medical University; National Sun Yat Sen
   University; Kaohsiung Medical University; Kaohsiung Medical University
   Hospital
RP Chang, KL (通讯作者)，Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung 80708, Taiwan.; Hu, YC; Chang, KL (通讯作者)，Kaohsiung Med Univ, Sch Med, Dept Biochem, Coll Med, Kaohsiung 80708, Taiwan.; Chang, KL (通讯作者)，Natl Sun Yat Sen Univ, Inst Med Sci & Technol, Coll Sci, Kaohsiung 80424, Taiwan.; Chang, KL (通讯作者)，Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung 80756, Taiwan.
EM chingshouhu@gmail.com; Chang.KeeLung@msa.hinet.net
RI ; Chang, Wen Tsan/G 3511 2011; Chang, Kee Lung/D 5512 2009; Hsieh,
   Bau/A 3229 2011
OI Hu, Yu Chen/0000 0002 0713 770X; Chang, Wen Tsan/0000 0001 5622 8299;
   Chang, Kee Lung/0000 0002 9801 6355; Huang,
   Tzu Ching/0000 0003 4002 5862
FU Ministry of Science and Technology, Taiwan [104 2320 B 037 024 MY3]
FX This work was partially supported by a Grant from the Ministry of
   Science and Technology, Taiwan (104 2320 B 037 024 MY3).
CR Anderson HC, 2004, AM J PATHOL, V164, P841, DOI 10.1016/S0002 9440(10)63172 0
   Azab SS, 2005, BIOCHEM PHARMACOL, V70, P725, DOI 10.1016/j.bcp.2005.03.036
   Bianco P, 2011, BLOOD, V117, P5281, DOI 10.1182/blood 2011 01 315069
   Caulfield AJ, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004252
   Chang KL, 2009, CANCER LETT, V276, P14, DOI 10.1016/j.canlet.2008.10.033
   Chang WT, 2014, SCI WORLD J, DOI 10.1155/2014/567148
   Chang WT, 2014, J SURG RES, V188, P432, DOI 10.1016/j.jss.2014.01.063
   Cheng HL, 2010, MOL CANCER, V9, DOI 10.1186/1476 4598 9 126
   Czabotar PE, 2014, NAT REV MOL CELL BIO, V15, P49, DOI 10.1038/nrm3722
   Dickinson BC, 2008, J AM CHEM SOC, V130, P9638, DOI 10.1021/ja802355u
   Du P, 2013, ASIAN PAC J CANCER P, V14, P5849, DOI 10.7314/APJCP.2013.14.10.5849
   Fan CM, 2016, J BONE MINER METAB, V34, P277, DOI 10.1007/s00774 015 0679 x
   Fogli S, 2002, ANN ONCOL, V13, P919, DOI 10.1093/annonc/mdf164
   Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608
   Garrett RW, 2009, CELL STEM CELL, V4, P503, DOI 10.1016/j.stem.2009.05.011
   Georgiou KR, 2012, AM J STEM CELLS, V1, P205
   Hsieh BS, 2011, J NUTR BIOCHEM, V22, P234, DOI 10.1016/j.jnutbio.2010.01.009
   Hu YC, 2012, BONE, V50, P1406, DOI 10.1016/j.bone.2012.03.012
   Hung TC, 2011, INT J CARDIOL, V151, P187, DOI 10.1016/j.ijcard.2010.05.015
   Jonat W, 2002, J CLIN ONCOL, V20, P4628, DOI 10.1200/JCO.2002.05.042
   Khasraw M, 2012, BREAST, V21, P142, DOI 10.1016/j.breast.2011.12.012
   Minotti G, 2004, PHARMACOL REV, V56, P185, DOI 10.1124/pr.56.2.6
   Mirzaei HR, 2013, INT J BREAST CANCER, V2013, DOI 10.1155/2013/404396
   Nurgalieva Z, 2011, MED ONCOL, V28, P716, DOI 10.1007/s12032 010 9512 5
   Olive PL, 2006, NAT PROTOC, V1, P23, DOI 10.1038/nprot.2006.5
   Orimo Hideo, 2010, Journal of Nippon Medical School, V77, P4
   Ozkan A, 2004, POL J PHARMACOL, V56, P435
   Salvatorelli E, 2006, J BIOL CHEM, V281, P10990, DOI 10.1074/jbc.M508343200
   Shapiro CL, 2001, J CLIN ONCOL, V19, P3306, DOI 10.1200/JCO.2001.19.14.3306
   TAICHMAN RS, 1994, J EXP MED, V179, P1677, DOI 10.1084/jem.179.5.1677
   Tait SWG, 2010, NAT REV MOL CELL BIO, V11, P621, DOI 10.1038/nrm2952
NR 31
TC 28
Z9 29
U1 1
U2 17
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1360 8185
EI 1573 675X
J9 APOPTOSIS
JI Apoptosis
PD APR
PY 2018
VL 23
IS 3 4
BP 226
EP 236
DI 10.1007/s10495 018 1450 2
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA FZ6LM
UT WOS:000427710300005
PM 29468482
DA 2025 08 17
ER

PT J
AU Zhang, JY
   Wang, FL
   Wu, DB
   Zhao, DW
AF Zhang, Jiaoyue
   Wang, Fanli
   Wu, Dengbin
   Zhao, Dewei
TI Revealing the mechanisms of Weishi Huogu I capsules used for treating
   osteonecrosis of the femoral head based on systems pharmacology with one
   mechanism validated with in vitro experiments
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Osteonecrosis of the femoral head; Systems pharmacology; Absorption,
   distribution, metabolism and excretion (ADME); Traditional Chinese
   medicine; Weishi Huogu I Capsule; Human umbilical mesenchymal stem cells
ID NETWORK PHARMACOLOGY; NONTRAUMATIC OSTEONECROSIS; BONE; INHIBITORS;
   DIFFERENTIATION; METABOLISM; EXPRESSION; PROMOTES; CELLS
AB Ethnopharmacological relevance: Weishi Huogu I (WH I) capsules, developed through traditional Chinese medicine, have been used to treat clinical osteonecrosis of the femoral head (ONFH) for decades. However, the mechanisms have not been systematically studied. Aim of the study: In this study, the mechanisms of WH I capsules used in treating ONFH were examined through a systems pharmacology strategy, and one mechanism was validated with in vitro experiments. Materials and methods: WH I capsules compounds were identified by screening databases; then, a database of the potential active compounds was constructed after absorption, distribution, metabolism and excretion (ADME) evaluation. The compounds were identified through a systematic approach in which the probability of an interaction of every candidate compound with each corresponding target in the DrugBank database was calculated. Gene Ontology (GO) and pathway enrichment analyses of the targets was performed with the Metascape and KEGG DISEASE databases. Then, a compound target network (C T) and target pathway network (T P) of WH I capsule components were constructed, and network characteristics and related information were used for systematically identifying WH I capsule multicomponent target interactions. Furthermore, the effects of WH I capsule compounds identified through the systematic pharmacology analysis of the osteogenic transformation of human umbilical mesenchymal stem cells (HUMSCs) were validated in vitro. Results: In total, 152 potentially important compounds and 176 associated targets were identified. Twenty two crucial GO biological process (BP) or pathways were related to ONFH, mainly in regulatory modules regulating blood circulation, modulating growth, and affecting pathological processes closely related to ONFH. Furthermore, the GO enrichment analysis showed that corydine, isorhamnetin, and bicuculline were enriched in "RUNX2 regulates osteoblast differentiation ", significantly increased alkaline phosphatase activity and calcium deposition and upregulated runt related transcription factor 2 mRNA and protein expression and osteocalcin mRNA expression in HUMSCs, suggesting that these compounds promoted the mesenchymal stem cell (MSC) osteogenic transformation. Conclusions: The study showed that the pharmacological mechanisms of WH I capsule attenuation of ONFH mainly involve three therapeutic modules: blood circulation, modulating growth, and regulating pathological processes. The crosstalk between GOBPs/pathways may constitute the basis of the synergistic effects of the compounds in WH I capsules in attenuating ONFH. One of the pharmacological mechanisms in the WH I capsule effect on ONFH involves enhancement of the osteogenic transformation of MSCs, as validated in experiments performed in vitro; however, more mechanisms should be validated in further studies.
C1 [Zhang, Jiaoyue; Zhao, Dewei] Dalian Univ, Affifiliated Zhongshan Hosp, Dept Orthoped, Dalian 116001, Peoples R China.
   [Zhang, Jiaoyue; Wang, Fanli; Wu, Dengbin] Ansteel Grp Hosp, Anshan 114002, Peoples R China.
   [Zhao, Dewei] Dalian Univ, Affiliated Zhongshan Hosp, 6 Jiefang St, Dalian 116001, Liaoning, Peoples R China.
C3 Dalian University; Dalian University
RP Zhao, DW (通讯作者)，Dalian Univ, Affifiliated Zhongshan Hosp, Dept Orthoped, Dalian 116001, Peoples R China.; Zhao, DW (通讯作者)，Dalian Univ, Affiliated Zhongshan Hosp, 6 Jiefang St, Dalian 116001, Liaoning, Peoples R China.
EM 61827011@qq.com; wangfanli_2007@aliyun.com; dengbinwu@163.com;
   zhaodewei2016@163.com
RI Zhao, Dewei/G 8369 2016
OI ZHANG, JIAOYUE/0009 0004 4621 7288
FU Affiliated Zhongshan Hospital of Dalian University
FX This study was supported by Affiliated Zhongshan Hospital of Dalian
   University.
CR Adhireksan Z, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14860
   Arduíno DM, 2010, CNS NEUROL DISORD DR, V9, P105, DOI 10.2174/187152710790966687
   Bandow K, 2010, BIOCHEM BIOPH RES CO, V402, P755, DOI 10.1016/j.bbrc.2010.10.103
   BJURHOLM A, 1991, INT ORTHOP, V15, P325
   Buerk Donald G., 2011, Critical Reviews in Biomedical Engineering, V39, P397, DOI 10.1615/CritRevBiomedEng.v39.i5.40
   Burley SK, 2018, PROTEIN SCI, V27, P316, DOI 10.1002/pro.3331
   Chen C, 2016, MOL MED REP, V14, P4209, DOI 10.3892/mmr.2016.5745
   Chen K, 2020, INT J BIOL SCI, V16, P1888, DOI 10.7150/ijbs.40917
   Cui Q, 2020, J ETHNOPHARMACOL, V257, DOI 10.1016/j.jep.2020.112891
   Neto IVD, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00190
   Diaz J, 2008, J PHARMACOL EXP THER, V325, P1031, DOI 10.1124/jpet.108.136226
   Gagala J, 2013, INT ORTHOP, V37, P1381, DOI 10.1007/s00264 013 1892 7
   Geng W, 2018, INT IMMUNOPHARMACOL, V60, P228, DOI 10.1016/j.intimp.2018.05.005
   Hines JT, 2021, J KOREAN MED SCI, V36, DOI 10.3346/jkms.2021.36.e177
   Hong ZC, 2021, J ETHNOPHARMACOL, V281, DOI 10.1016/j.jep.2021.114553
   Hua KC, 2019, J ORTHOP SURG RES, V14, DOI 10.1186/s13018 019 1359 7
   Hua YL, 2019, CHIN J NAT MEDICINES, V17, P275, DOI 10.1016/S1875 5364(19)30031 7
   Huten D., 2021, Morphologie, V105, P102, DOI 10.1016/j.morpho.2021.02.003
   Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004 0001
   Johnson MG, 2017, PHYSIOL REP, V5, DOI 10.14814/phy2.13088
   Kanehisa M, 2017, NUCLEIC ACIDS RES, V45, pD353, DOI 10.1093/nar/gkw1092
   Kim CJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010125
   Lee YK, 2019, CLIN ORTHOP SURG, V11, P137, DOI 10.4055/cios.2019.11.2.137
   Li BJ, 2019, J ETHNOPHARMACOL, V233, P158, DOI 10.1016/j.jep.2018.12.033
   Li JP, 2014, BIOELECTROMAGNETICS, V35, P170, DOI 10.1002/bem.21833
   Li WC, 2019, MOL MED REP, V20, P2073, DOI 10.3892/mmr.2019.10458
   Li Y, 2015, J ETHNOPHARMACOL, V175, P301, DOI 10.1016/j.jep.2015.09.016
   Li Y, 2015, EXP THER MED, V9, P2072, DOI 10.3892/etm.2015.2388
   Liao FK, 2021, BIOENGINEERED, V12, P11837, DOI 10.1080/21655979.2021.1999366
   Lin L, 2010, APMIS, V118, P595, DOI 10.1111/j.1600 0463.2010.02634.x
   Liu JL, 2016, EVID BASED COMPL ALT, V2016, DOI 10.1155/2016/9025036
   Liu R, 2019, PHARM BIOL, V57, P161, DOI 10.1080/13880209.2019.1577461
   Lu N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20153792
   Moorer MC, 2017, J CELL SCI, V130, P531, DOI 10.1242/jcs.197285
   Motamedi Fahimeh, 2021, Bioinformatics, DOI 10.1093/bioinformatics/btab659
   Nash LA, 2015, MOL NUTR FOOD RES, V59, P443, DOI 10.1002/mnfr.201400592
   Pan SL, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935 019 0775 4
   Panwar P, 2016, BRIT J PHARMACOL, V173, P396, DOI 10.1111/bph.13383
   Qazi SU, 2018, BIOORG CHEM, V79, P19, DOI 10.1016/j.bioorg.2018.03.029
   Rego P, 2017, J BONE JOINT SURG AM, V99, P1213, DOI 10.2106/JBJS.16.01386
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Salameh M, 2021, INT ORTHOP, V45, P2519, DOI 10.1007/s00264 021 05120 3
   Sheng SJ, 2014, J ETHNOPHARMACOL, V154, P735, DOI 10.1016/j.jep.2014.04.048
   Shi XQ, 2019, J ETHNOPHARMACOL, V235, P227, DOI 10.1016/j.jep.2019.01.027
   Sibbesen NA, 2015, ONCOTARGET, V6, P20555, DOI 10.18632/oncotarget.4111
   Singh M, 2022, J BIOMOL STRUCT DYN, V40, P8494, DOI 10.1080/07391102.2021.1913229
   Togari A, 2002, MICROSC RES TECHNIQ, V58, P77, DOI 10.1002/jemt.10121
   Taboada López MV, 2021, TALANTA, V233, DOI 10.1016/j.talanta.2021.122494
   Wang JH, 2013, MOL BIOSYST, V9, P2296, DOI 10.1039/c3mb70105k
   Wang KX, 2021, J ETHNOPHARMACOL, V274, DOI 10.1016/j.jep.2021.114043
   Wang PZ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148372
   Wang S., 2010, MODERN CHIN MED, VI
   Wang XL, 2013, J ORTHOP RES, V31, P164, DOI 10.1002/jor.22188
   Wang YS, 2008, CLIN ORTHOP RELAT R, V466, P1059, DOI 10.1007/s11999 008 0178 7
   Wang YJ, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1167 3
   Warden SJ, 2005, MOL CELL ENDOCRINOL, V242, P1, DOI 10.1016/j.mce.2005.06.005
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   White K, 2021, POLYMERS BASEL, V13, DOI 10.3390/polym13142274
   Xu YX, 2020, REGEN THER, V15, P295, DOI 10.1016/j.reth.2020.11.003
   Ye JW, 2019, MOL MED REP, V20, P3175, DOI 10.3892/mmr.2019.10553
   Yeh YA, 2019, EVID BASED COMPL ALT, V2019, DOI 10.1155/2019/5870179
   Yin H, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891 016 1199 0
   Yu HP, 2020, J CELL MOL MED, V24, P4439, DOI 10.1111/jcmm.15103
   Yu WD, 2019, J CELL PHYSIOL, V234, P1842, DOI 10.1002/jcp.27057
   Zeng HB, 2020, ACTA HISTOCHEM, V122, DOI 10.1016/j.acthis.2020.151601
   Zhang G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006419
   Zhang GX, 2018, ACTA PHARMACOL SIN, V39, P952, DOI 10.1038/aps.2017.191
   Zhang HG, 2022, CELL DEATH DIFFER, V29, P351, DOI 10.1038/s41418 021 00858 0
   Zhang L, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929 018 0418 4
   Zhang YL, 2021, J ETHNOPHARMACOL, V281, DOI 10.1016/j.jep.2021.114534
   Zhang Y, 2017, ORTHOPADE, V46, P737, DOI 10.1007/s00132 017 3408 4
   Zhao D., 2014, CHIN J JOINT SURG, V8, P563
   Zhao D., 2003, CHINA J ORTHOP TRAUM, V16, P716
   Zhao DW, 2015, CHINESE MED J PEKING, V128, P2843, DOI 10.4103/0366 6999.168017
   Zhao DW, 2020, J ORTHOP TRANSL, V21, P100, DOI 10.1016/j.jot.2019.12.004
   Zhao HY, 2021, AM J MED SCI, V362, P78, DOI 10.1016/j.amjms.2021.03.005
   Zhao WY, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 020 02159 7
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09234 6
   Zhou ZY, 2019, J CELL PHYSIOL, V234, P23448, DOI 10.1002/jcp.28914
NR 79
TC 4
Z9 4
U1 3
U2 14
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD SEP 15
PY 2022
VL 295
AR 115354
DI 10.1016/j.jep.2022.115354
EA MAY 2022
PG 12
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA 1X8QT
UT WOS:000807715800005
PM 35577160
DA 2025 08 17
ER

PT J
AU Qu, B
   Gong, K
   Yang, HS
   Li, YG
   Jiang, T
   Zeng, ZM
   Cao, ZR
   Pan, XM
AF Qu, Bo
   Gong, Kai
   Yang, Hong Sheng
   Li, Yu Gang
   Jiang, Tao
   Zeng, Zhi Mou
   Cao, Zong Rui
   Pan, Xian Ming
TI MiR 449 overexpression inhibits osteogenic differentiation of bone
   marrow mesenchymal stem cells via suppressing Sirt1/Fra 1 pathway in
   high glucose and free fatty acids microenvironment
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE miR 449; Osteogenic differentiation; Bone marrow mesenchymal stem cells;
   Diabetic osteoporosis
ID DIABETES MELLITUS; OSTEOPOROSIS; SKELETAL; EXPRESSION; SIRT1; RUNX2;
   PROLIFERATION; OSTEOBLASTS; MECHANISMS; OSTEOCYTES
AB Diabetic osteoporosis is a chronic complication caused by diabetes mellitus, and However, the exact mechanism of diabetes mellitus induced osteoporosis is still unknown. In this study, we investigate the effect of miR 449 on osteogenic differentiation and its underlying mechanism in human bone marrow derived mesenchymal stem cells (hBMSCs) with high glucose (HG) and free fatty acids (FFA) treatment. Results showed that after culturing for 14 days, high glucose (HG) and free fatty acids (FFA) treatment dramatically decreased mineralization of human bone marrow derived mesenchymal stem cells (hBMSCs) compared with cells treated with osteogenic medium (OM) alone. We also found that miR 449 expression was up regulated during osteogenic differentiation of hBMSCs with HG and FFA treatment. Moreover, during osteogenic differentiation of hBMSCs with HG and FFA treatment, miR 449 mimics notably decreased the alkaline phosphatase (ALP) activity and the mRNA and protein expression levels of runt related transcription factor 2 (Runx2), ALP, collagen I, osteocalcin (OCN), and bone sialoprotein (BSP), which was remarkably increased by miR 449 inhibitors. Furthermore, miR 449 directly targets Sirt1 by binding to its 3' UTR. Sirt1 overexpression reverses the suppressive effect of miR 449 mimics on Fra 1 mRNA and protein expression, which was also alleviated by Fra 1 overexpression. In addition, Fra 1 overexpression alleviates the inhibitory effect of miR 449 mimics on the ALP activity and the mRNA and protein of Runx2, collagen I, OCN and BSP. Taken together, our results indicated that miR 449 over expression inhibited osteogenic differentiation of HG FFA treated hBMSCs through the Sirt1/Fra 1 signal pathway. It is conceivable that modulating miR 449 might provide a new therapy for intervention in diabetic osteoporosis. (C) 2018 Published by Elsevier Inc.
C1 [Qu, Bo; Yang, Hong Sheng; Li, Yu Gang; Jiang, Tao; Zeng, Zhi Mou; Cao, Zong Rui; Pan, Xian Ming] Chengdu Med Coll, Affiliated Hosp 1, Dept Orthopaed, Chengdu, Sichuan, Peoples R China.
   [Gong, Kai] Chengdu Mil Gen Hosp, Dept Orthopaed, Chengdu, Sichuan, Peoples R China.
   [Qu, Bo] Chengdu Mil Command, Ctr Dis Control & Prevent, Chengdu, Sichuan, Peoples R China.
C3 Chengdu Medical College; Chinese Center for Disease Control & Prevention
RP Pan, XM (通讯作者)，Chengdu Med Coll, Affiliated Hosp 1, Dept Orthopaed, Chengdu, Sichuan, Peoples R China.
EM xianmingpanxj@163.com
FU China postdoctoral science foundation [2017M613425]; science and
   technology support project of sichuan science and technology department
   [2015SZ0167]; research projects of orthopedic research project of
   sichuan medical association [2016GK002]
FX This work was supported by China postdoctoral science foundation funded
   project (2017M613425), science and technology support project of sichuan
   science and technology department (2015SZ0167), and research projects of
   orthopedic research project of sichuan medical association(2016GK002).
CR Almeida MI, 2016, ONCOTARGET, V7, P7, DOI 10.18632/oncotarget.6589
   Amer Diabet Assoc, 2013, DIABETES CARE, V36, pS67, DOI [10.2337/dc14 S081, 10.2337/dc11 S011, 10.2337/dc13 S067, 10.2337/dc13 S011, 10.2337/dc11 S062, 10.2337/dc10 S062, 10.2337/dc10 S011, 10.2337/dc12 s064, 10.2337/dc12 s011]
   Baglìo SR, 2013, GENE, V527, P321, DOI 10.1016/j.gene.2013.06.021
   BarrettConnor E, 1996, DIABETES CARE, V19, P1388, DOI 10.2337/diacare.19.12.1388
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bruder SP, 1998, CLIN ORTHOP RELAT R, pS247
   Chen HY, 2014, J ENDOCRINOL, V222, pR1, DOI 10.1530/JOE 13 0544
   Cheng FF, 2016, CANCER LETT, V375, P274, DOI 10.1016/j.canlet.2016.03.010
   de Paula FJA, 2010, DIABETES METAB RES, V26, P622, DOI 10.1002/dmrr.1135
   Eskildsen T, 2011, P NATL ACAD SCI USA, V108, P6139, DOI 10.1073/pnas.1016758108
   Finkel T, 2009, NATURE, V460, P587, DOI 10.1038/nature08197
   Fung CH, 2014, ULTRASONICS, V54, P1358, DOI 10.1016/j.ultras.2014.02.003
   Gong K, 2016, BIOCHEM BIOPH RES CO, V478, P260, DOI 10.1016/j.bbrc.2016.07.057
   Grabowska W, 2017, BIOGERONTOLOGY, V18, P447, DOI 10.1007/s10522 017 9685 9
   GREGORIO F, 1994, DIABETES RES CLIN PR, V23, P43, DOI 10.1016/0168 8227(94)90126 0
   Heilmeier U, 2016, J BONE MINER RES, V31, P2173, DOI 10.1002/jbmr.2897
   Iyer S, 2014, J BIOL CHEM, V289, P24069, DOI 10.1074/jbc.M114.561803
   Jepsen KJ, 2014, J BONE MINER RES, V29, P784, DOI 10.1002/jbmr.2189
   Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676
   Kalaitzoglou E, 2016, CURR OSTEOPOROS REP, V14, P310, DOI 10.1007/s11914 016 0329 9
   Li JL, 2016, MOL MED REP, V13, P4108, DOI 10.3892/mmr.2016.4994
   Neve A, 2013, J CELL PHYSIOL, V228, P1149, DOI 10.1002/jcp.24278
   Pereira M, 2017, OSTEOPOROSIS INT, V28, P309, DOI 10.1007/s00198 016 3718 0
   Pesesse L, 2014, OSTEOARTHR CARTILAGE, V22, P547, DOI 10.1016/j.joca.2014.01.010
   Piscitelli P, 2015, CURR OPIN ENDOCRINOL, V22, P439, DOI 10.1097/MED.0000000000000203
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Roy B, 2013, WORLD J DIABETES, V4, P101, DOI 10.4239/wjd.v4.i4.101
   Schwartz AV, 2003, CALCIFIED TISSUE INT, V73, P515, DOI 10.1007/s00223 003 0023 7
   Sealand R, 2013, CURR DIABETES REP, V13, P411, DOI 10.1007/s11892 013 0376 x
   Shakibaei M, 2011, J BIOL CHEM, V286, P11492, DOI 10.1074/jbc.M110.198713
   Shukla Girish C, 2011, Mol Cell Pharmacol, V3, P83
   Stein GS, 2004, ONCOGENE, V23, P4315, DOI 10.1038/sj.onc.1207676
   Vimalraj S, 2015, INT J BIOL MACROMOL, V78, P202, DOI 10.1016/j.ijbiomac.2015.04.008
   Wang HR, 2016, SCI REP UK, V6, DOI 10.1038/srep36988
   Wongdee K, 2011, WORLD J DIABETES, V2, P41, DOI 10.4239/wjd.v2.i3.41
   Yoshizawa Tatsuya, 2012, Clin Calcium, V22, P1367, DOI CliCa120913671373
   You L, 2014, INT J CLIN EXP PATHO, V7, P7249
   Yu SH, 2013, BIOCHEM BIOPH RES CO, V430, P173, DOI 10.1016/j.bbrc.2012.11.033
   Zhang HY, 2014, INT J ONCOL, V45, P2143, DOI 10.3892/ijo.2014.2596
NR 39
TC 19
Z9 21
U1 0
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JAN 29
PY 2018
VL 496
IS 1
BP 120
EP 126
DI 10.1016/j.bbrc.2018.01.009
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA FU7YF
UT WOS:000424068000020
PM 29305863
DA 2025 08 17
ER

PT J
AU Ashley, JW
   McCoy, EM
   Clements, DA
   Shi, ZQ
   Chen, TS
   Feng, X
AF Ashley, Jason W.
   McCoy, Erin M.
   Clements, Daniel A.
   Shi, Zhenqi
   Chen, Taosheng
   Feng, Xu
TI Development of Cell Based High Throughput Assays for the Identification
   of Inhibitors of Receptor Activator of Nuclear Factor Kappa B Signaling
SO ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES
LA English
DT Article
ID TUMOR NECROSIS FACTOR; OSTEOCLAST DIFFERENTIATION; POSTMENOPAUSAL
   OSTEOPOROSIS; ANTIRESORPTIVE TREATMENT; TNF RECEPTOR; TRAF FAMILY; RANK;
   BONE; MEMBER; PATHOGENESIS
AB Bone loss due to metabolic or hormonal disorders and osteolytic tumor metastasis continues to be a costly health problem, but current therapeutics offer only modest efficacy. Unraveling of the critical role for the receptor activator of nuclear factor kappa B (RANK) and its ligand, RANK ligand (RANKL), in osteoclast biology provides an opportunity to develop more effective antiresorptive drugs. The in vivo effectiveness of RANKL inhibitors demonstrates the potency of the RANKL/RANK system as a drug target. Here, we report the development of cell based assays for high throughput screening to identify compounds that inhibit signaling from two RANK cytoplasmic motifs (PVQEET 559 564 and PVQEQG 604 609), which play potent roles in osteoclast formation and function. Inhibitors of these motifs' signaling have the potential to be developed into new antiresorptive drugs that can complement current therapies. The cell based assays consist of cell lines generated from RAW264.7 macrophages stably expressing a nuclear factor kappa B responsive luciferase reporter and a chimeric receptor containing the human Fas external domain linked to a murine RANK transmembrane and intracellular domain in which only one of the RANK motifs is functional. With these cells, specific RANK motif activation after chimeric receptor stimulation can be measured as an increase in luciferase activity. These assays demonstrated >300% increases in luciferase activity after RANK motif activation and Z' factor values over 0.55. Our assays will be used to screen compound libraries for molecules that exhibit inhibitory activity. Follow up assays will refine hits to a smaller group of more specific inhibitors of RANK signaling.
C1 [Ashley, Jason W.; McCoy, Erin M.; Clements, Daniel A.; Shi, Zhenqi; Feng, Xu] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
   [Chen, Taosheng] St Jude Childrens Res Hosp, Dept Chem Biol & Therapeut, Memphis, TN 38105 USA.
C3 University of Alabama System; University of Alabama Birmingham; St Jude
   Children's Research Hospital
RP Feng, X (通讯作者)，Univ Alabama Birmingham, Dept Pathol, 1670 Univ Blvd,Volker Hall G046B, Birmingham, AL 35294 USA.
EM xufeng@uab.edu
RI ; Ashley, Jason/S 9142 2019; Chen, Taosheng/I 6351 2013
OI Ashley, Jason/0000 0003 1064 542X; 
FU National Institute of Neurological Disorders and Stroke (NINDS)
   [NS061677]; National Institute of Arthritis and Musculoskeletal and Skin
   Diseases (NIAMS) [AR47830]; University of Alabama at Birmingham;
   University of Alabama at Birmingham's Center for Metabolic Bone Disease
   [T32 AR047512 09]
FX This work was supported by grant number NS061677 (to X.F.) from National
   Institute of Neurological Disorders and Stroke (NINDS), grant number
   AR47830 (to X.F.) from National Institute of Arthritis and
   Musculoskeletal and Skin Diseases (NIAMS), the University of Alabama at
   Birmingham Marie and Emmett Carmichael Scholarship for Graduate Studies
   in Biosciences (to E.M.M.), and a training fellowship (to J.W.A.) from
   the University of Alabama at Birmingham's Center for Metabolic Bone
   Disease (T32 AR047512 09). We would like to thank Joanne Murphy Ullrich,
   Ph.D., and Danny R. Welch, Ph.D., for use of equipment and the
   University of Alabama at Birmingham Center for AIDS Research sequencing
   core.
CR Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Battaglino R, 2002, J BONE MINER RES, V17, P763, DOI 10.1359/jbmr.2002.17.5.763
   Bodmer JL, 2002, TRENDS BIOCHEM SCI, V27, P19, DOI 10.1016/S0968 0004(01)01995 8
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen TS, 2006, ASSAY DRUG DEV TECHN, V4, P473, DOI 10.1089/adt.2006.4.473
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551
   Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724
   Fouque Aubert A, 2008, JOINT BONE SPINE, V75, P5, DOI 10.1016/j.jbspin.2007.05.004
   Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120
   Goldring SR, 2003, RHEUMATOLOGY, V42, P11, DOI 10.1093/rheumatology/keg327
   GRUBER HE, 1984, METABOLISM, V33, P295, DOI 10.1016/0026 0495(84)90187 2
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Kim HH, 1999, FEBS LETT, V443, P297, DOI 10.1016/S0014 5793(98)01731 1
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lewiecki EM, 2009, J WOMENS HEALTH, V18, P1615, DOI 10.1089/jwh.2008.1086
   Lian JB, 2008, OSTEOPOROSIS, VOLS I AND II, 3RD EDITION, P93
   Liu W, 2004, J BIOL CHEM, V279, P54759, DOI 10.1074/jbc.M404687200
   Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092 8674(01)00237 9
   Lufkin EG, 2004, CURR MED RES OPIN, V20, P351, DOI 10.1185/030079904125003071
   Marcus R, 2002, ENDOCR REV, V23, P16, DOI 10.1210/er.23.1.16
   McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905
   Miller PD, 2010, OSTEOPOROSIS IN MEN: THE EFFECTS OF GENDER ON SKELETAL HEALTH, 2ND EDITION, P453, DOI 10.1016/B978 0 12 374602 3.00038 9
   Miller Paul D, 2009, Curr Osteoporos Rep, V7, P18
   Miller PD, 2008, OSTEOPOROSIS, VOLS I AND II, 3RD EDITION, P1725
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400
   Prince R, 2008, OSTEOPOROSIS, VOLS I AND II, 3RD EDITION, P1705
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Shin HM, 2004, FEBS LETT, V571, P50, DOI 10.1016/j.febslet.2004.06.056
   Shui C, 2002, CALCIFIED TISSUE INT, V71, P437, DOI 10.1007/s00223 001 1138 3
   Stefanick ML, 2005, AM J MED, V118, P1407, DOI 10.1016/j.amjmed.2005.10.014
   Stepan J J, 2003, Endocr Regul, V37, P225
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Weldon CB, 2001, SURGERY, V130, P143, DOI 10.1067/msy.2001.115512
   Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355
   Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075
   Xu DR, 2004, BIOCHEM J, V383, P219, DOI 10.1042/BJ20040961
   Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206
NR 42
TC 7
Z9 9
U1 0
U2 7
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540 658X
EI 1557 8127
J9 ASSAY DRUG DEV TECHN
JI ASSAY DRUG DEV. TECHNOL.
PD FEB
PY 2011
VL 9
IS 1
BP 40
EP 49
DI 10.1089/adt.2010.0307
PG 10
WC Biochemical Research Methods; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 719TY
UT WOS:000287233800004
PM 21050071
OA Green Published
DA 2025 08 17
ER

PT J
AU Sochett, EB
   Mäkitie, O
AF Sochett, EB
   Mäkitie, O
TI Osteoporosis in chronically ill children
SO ANNALS OF MEDICINE
LA English
DT Article
DE bisphosphonates; bone biopsy; bone density; chronic illness; screening;
   treatment
ID BONE MINERAL DENSITY; SYSTEMIC LUPUS ERYTHEMATOSUS;
   RENAL TRANSPLANTATION; LIVER TRANSPLANTATION; PHYSICAL ACTIVITY;
   DISEASE; DETERMINANTS; ADOLESCENTS; METABOLISM; RISK
AB Gains in bone mass are very rapid during adolescence and peak bone mass, the most important determinant of osteoporosis, is attained by early adulthood. Glucocorticoids, widely used in children with chronic illness, are known to impact bone mass and quality. In addition, disease and treatment related factors, nutrient and hormone deficiencies and decreased physical activity may all negatively affect bone mass accrual. Although decreased bone density is increasingly recognized in chronically ill children, current knowledge of the epidemiology, diagnosis and optimal treatment of pediatric secondary osteoporosis is limited. In addition to bone densitometry, biochemical and radiographic tests should be used in the diagnosis of osteoporosis. Bone histomorphometry may be needed in selected situations. At risk children should be advised to ensure sufficient calcium and vitamin D intake and weight bearing physical activity. Growth and pubertal development require careful assessment because of their close correlation with bone formation. Given limited experience with bisphosphonates, it seems prudent to target antiresorptive therapy to those children who have developed symptomatic disease. Ideally this should be done in controlled settings. Early identification and adequate intervention, in selected cases with bisphosphonates, is needed in order to prevent deleterious skeletal complications of osteoporrosis in chronically ill children.
C1 Univ Toronto, Hosp Sick Children, Div Endocrinol, Toronto, ON M5G 1X8, Canada.
   Univ Helsinki, Metab Bone Clin, Hosp Children & Adolescents, Helsinki, Finland.
C3 University of Toronto; Hospital for Sick Children (SickKids); University
   of Helsinki
RP Sochett, EB (通讯作者)，Univ Toronto, Hosp Sick Children, Div Endocrinol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.
EM etienne.sochett@sickkids.ca
RI Pedersen, Ole/F 2476 2011
OI Makitie, Outi/0000 0002 4547 001X
CR Bachrach LK, 2004, J PEDIATR US, V144, P285, DOI 10.1016/j.jpeds.2003.11.019
   Bailey DA, 1999, J BONE MINER RES, V14, P1672, DOI 10.1359/jbmr.1999.14.10.1672
   Ball AM, 2002, JAMA J AM MED ASSOC, V288, P3014, DOI 10.1001/jama.288.23.3014
   Benfield MR, 2003, PEDIATR CLIN N AM, V50, P1301, DOI 10.1016/S0031 3955(03)00122 6
   Bianchi ML, 2003, OSTEOPOROSIS INT, V14, P761, DOI 10.1007/s00198 003 1443 y
   Braith RW, 2000, J HEART LUNG TRANSPL, V19, P840, DOI 10.1016/S1053 2498(00)00159 5
   Brown JP, 2002, CAN MED ASSOC J, V167, pS1
   Byers PH., 2002, CONNECTIVE TISSUE IT, P385, DOI DOI 10.1002/0471221929.CH8
   Canalis E, 1996, J CLIN ENDOCR METAB, V81, P3441, DOI 10.1210/jc.81.10.3441
   Canalis E, 1998, ENDOCRINOLOGY, V139, P3041, DOI 10.1210/en.139.7.3041
   Canalis E., 2000, CURRENT OPINION ENDO, V7, P320
   CARTER DR, 1992, J BONE MINER RES, V7, P137
   Cayco AV, 2000, TRANSPLANTATION, V70, P1722, DOI 10.1097/00007890 200012270 00011
   Cohen A, 2003, OSTEOPOROSIS INT, V14, P617, DOI 10.1007/s00198 003 1426 z
   Compston JE, 2003, LIVER TRANSPLANT, V9, P321, DOI 10.1053/jlts.2003.50044
   Cruz DN, 2001, TRANSPLANTATION, V72, P83, DOI 10.1097/00007890 200107150 00017
   Cueto Manzano AM, 1999, KIDNEY INT, V55, P2021, DOI 10.1046/j.1523 1755.1999.00445.x
   CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140 6736(93)92555 8
   Daci E, 2002, HORM RES, V58, P44, DOI 10.1159/000064758
   de Ridder Christine M., 1998, Current Opinion in Pediatrics, V10, P441, DOI 10.1097/00008480 199808000 00020
   Deal Chad, 2004, Curr Rheumatol Rep, V6, P49
   El Husseini AA, 2003, NEFROLOGIA, V23, P131
   FEBER J, 1994, J PEDIATR US, V125, P870, DOI 10.1016/S0022 3476(05)82001 3
   Golden Neville H, 2003, Adolesc Med, V14, P97
   Gronowitz E, 2003, ACTA PAEDIATR, V92, P688, DOI 10.1080/08035250310002443
   Harpavat M, 2004, J CLIN GASTROENTEROL, V38, P218, DOI 10.1097/00004836 200403000 00005
   Hartikka H, 2005, J BONE MINER RES, V20, P783, DOI 10.1359/JBMR.050101
   Henderson RC, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.1.e5
   Ilowite NT, 2002, PEDIATRICS, V109, P109, DOI 10.1542/peds.109.1.109
   Javaid MK, 2002, BEST PRACT RES CL EN, V16, P349, DOI 10.1053/beem.2002.0199
   JULIAN BA, 1991, NEW ENGL J MED, V325, P544, DOI 10.1056/NEJM199108223250804
   KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802
   Kavak US, 2003, J PEDIATR GASTR NUTR, V37, P434, DOI 10.1097/00005176 200310000 00007
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Kotaniemi A, 1997, SCAND J RHEUMATOL, V26, P14, DOI 10.3109/03009749709065658
   Kotaniemi A, 1999, SCAND J RHEUMATOL, V28, P19, DOI 10.1080/03009749950155733
   Leidig Bruckner G, 2001, LANCET, V357, P342, DOI 10.1016/S0140 6736(00)03641 2
   Leonard MB, 2003, MED PEDIATR ONCOL, V41, P198, DOI 10.1002/mpo.10337
   Leonard MB, 2001, AM J TRANSPLANT, V1, P193, DOI 10.1046/j.1600 6135.ajt10301.x
   Mäkitie O, 2005, J PEDIATR US, V146, P395, DOI 10.1016/j.jpeds.2004.10.052
   Marini JC, 2003, NEW ENGL J MED, V349, P423, DOI 10.1056/NEJMp038103
   Monegal A, 2001, OSTEOPOROSIS INT, V12, P484, DOI 10.1007/s001980170094
   Murray KJ, 2000, ARTHRITIS RHEUM, V43, pS119
   NISBETH U, 1994, TRANSPLANT P, V26, P1764
   Pepmueller PH, 1996, ARTHRITIS RHEUM, V39, P746, DOI 10.1002/art.1780390506
   Ralston SH, 1997, BMJ BRIT MED J, V315, P469, DOI 10.1136/bmj.315.7106.469
   Rauch F, 2004, LANCET, V363, P1377, DOI 10.1016/S0140 6736(04)16051 0
   Rauch F, 2002, J CLIN INVEST, V110, P1293, DOI 10.1172/JCI200215952
   Sanchez CP, 1998, KIDNEY INT, V53, P1358, DOI 10.1046/j.1523 1755.1998.00866.x
   Schönau E, 1998, PEDIATR NEPHROL, V12, P420, DOI 10.1007/s004670050479
   Shane E, 1997, J CLIN ENDOCR METAB, V82, P1497, DOI 10.1210/jc.82.5.1497
   Sheth RD, 2004, EPILEPSY BEHAV, V5, pS30, DOI 10.1016/j.yebeh.2003.11.025
   Siffledeen JS, 2004, INFLAMM BOWEL DIS, V10, P220, DOI 10.1097/00054725 200405000 00007
   Sinigaglia L, 1999, J RHEUMATOL, V26, P1280
   Soyka LA, 2000, J CLIN ENDOCR METAB, V85, P3951, DOI 10.1210/jc.85.11.3951
   Sperschneider H, 2003, NEPHROL DIAL TRANSPL, V18, P874, DOI 10.1093/ndt/gfg029
   Steelman J, 2001, Pediatr Rev, V22, P56, DOI 10.1542/pir.22 2 56
   Trapani S, 1998, RHEUMATOL INT, V18, P45, DOI 10.1007/s002960050056
   TROTTER M, 1974, ANAT REC, V179, P1, DOI 10.1002/ar.1091790102
   van Staa TP, 2004, OSTEOPOROSIS INT, V15, P785, DOI 10.1007/s00198 004 1606 5
   Van Staa TP, 2000, J BONE MINER RES, V15, P993, DOI 10.1359/jbmr.2000.15.6.993
   YOUNG MF, 2003, STEOPOROS INT, V14, pS35
   Zak M, 1999, ARTHRITIS RHEUM US, V42, P790, DOI 10.1002/1529 0131(199904)42:4<790::AID ANR24>3.0.CO;2 G
NR 63
TC 22
Z9 23
U1 0
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0785 3890
EI 1365 2060
J9 ANN MED
JI Ann. Med.
PY 2005
VL 37
IS 4
BP 286
EP 294
DI 10.1080/07853890510007250
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA 943PX
UT WOS:000230367300007
PM 16019728
OA Bronze
DA 2025 08 17
ER

PT J
AU Smeester, BA
   Slipek, NJ
   Pomeroy, EJ
   Laoharawee, K
   Osum, SH
   Larsson, AT
   Williams, KB
   Stratton, N
   Yamamoto, K
   Peterson, JJ
   Rathe, SK
   Mills, LJ
   Hudson, WA
   Crosby, MR
   Wang, MJ
   Rahrmann, EP
   Moriarity, BS
   Largaespada, DA
AF Smeester, Branden A.
   Slipek, Nicholas J.
   Pomeroy, Emily J.
   Laoharawee, Kanut
   Osum, Sara H.
   Larsson, Alex T.
   Williams, Kyle B.
   Stratton, Natalie
   Yamamoto, Kenta
   Peterson, Joseph J.
   Rathe, Susan K.
   Mills, Lauren J.
   Hudson, Wendy A.
   Crosby, Margaret R.
   Wang, Minjing
   Rahrmann, Eric P.
   Moriarity, Branden S.
   Largaespada, David A.
TI PLX3397 treatment inhibits constitutive CSF1R induced oncogenic ERK
   signaling, reduces tumor growth, and metastatic burden in osteosarcoma
SO BONE
LA English
DT Article
DE Osteosarcoma; CSF1R; PLX3397
ID STIMULATING FACTOR 1 RECEPTOR; SLEEPING BEAUTY; PROGRESSION; CSF 1; FMS
AB Osteosarcoma (OSA) is a heterogeneous and aggressive solid tumor of the bone. We recently identified the colony stimulating factor 1 receptor (Csf1r) gene as a novel driver of osteosarcomagenesis in mice using the Sleeping Beauty (SB) transposon mutagenesis system. Here, we report that a CSF1R CSF1 autocrine/paracrine signaling mechanism is constitutively activated in a subset of human OSA cases and is critical for promoting tumor growth and contributes to metastasis. We examined CSF1R and CSF1 expression in OSAs. We utilized gain of function and loss of function studies (GOF/LOF) to evaluate properties of cellular transformation, downstream signaling, and mechanisms of CSF1R CSF1 action. Genetic perturbation of CSF1R in immortalized osteoblasts and human OSA cell lines significantly altered oncogenic properties, which were dependent on the CSF1R CSF1 autocrine/paracrine signaling. These functional alterations were associated with changes in the known CSF1R downstream ERK effector pathway and mitotic cell cycle arrest. We evaluated the recently FDA approved CSF1R inhibitor Pexidartinib (PLX3397) in OSA cell lines in vitro and in vivo in cell line and patient derived xenografts. Pharmacological inhibition of CSF1R signaling recapitulated the in vitro genetic alterations. Moreover, in orthotopic OSA cell line and subcutaneous patient derived xenograft (PDX) injected mouse models, PLX3397 treatment significantly inhibited local OSA tumor growth and lessened metastatic burden. In summary, CSF1R is utilized by OSA cells to promote tumorigenesis and may represent a new molecular target for therapy.
C1 [Smeester, Branden A.; Slipek, Nicholas J.; Pomeroy, Emily J.; Laoharawee, Kanut; Osum, Sara H.; Williams, Kyle B.; Stratton, Natalie; Yamamoto, Kenta; Peterson, Joseph J.; Rathe, Susan K.; Mills, Lauren J.; Hudson, Wendy A.; Crosby, Margaret R.; Wang, Minjing; Moriarity, Branden S.; Largaespada, David A.] Univ Minnesota, Dept Pediat, Canc & Cardiovasc Res Bldg CCRB,2231 6th St SE, Minneapolis, MN 55455 USA.
   [Largaespada, David A.] Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA.
   [Smeester, Branden A.; Slipek, Nicholas J.; Pomeroy, Emily J.; Laoharawee, Kanut; Osum, Sara H.; Williams, Kyle B.; Yamamoto, Kenta; Wang, Minjing; Moriarity, Branden S.; Largaespada, David A.] Univ Minnesota, Ctr Genome Engn, Minneapolis, MN 55455 USA.
   [Smeester, Branden A.; Slipek, Nicholas J.; Pomeroy, Emily J.; Laoharawee, Kanut; Osum, Sara H.; Larsson, Alex T.; Williams, Kyle B.; Rathe, Susan K.; Hudson, Wendy A.; Crosby, Margaret R.; Wang, Minjing; Moriarity, Branden S.; Largaespada, David A.] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA.
   [Rahrmann, Eric P.] Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge, England.
   [Mills, Lauren J.] Univ Minnesota, Childhood Canc Genom Grp, Minneapolis, MN 55455 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Cambridge; CRUK Cambridge Institute; Cancer Research UK;
   University of Minnesota System; University of Minnesota Twin Cities
RP Moriarity, BS; Largaespada, DA (通讯作者)，Univ Minnesota, Dept Pediat, Canc & Cardiovasc Res Bldg CCRB,2231 6th St SE, Minneapolis, MN 55455 USA.
EM mori0164@umn.edu; larga002@umn.edu
RI ; Mills, Lauren/HTM 1052 2023; WANG, MINJING/ITV 8903 2023; Smeester,
   Branden/E 7655 2013
OI Laoharawee, Kanut/0000 0001 8216 2131; Larsson,
   Alex/0000 0002 1350 8271; Mills, Lauren/0000 0002 8914 2587; WANG,
   MINJING/0000 0003 4725 8351; Williams, Kyle/0000 0003 4333 9111; Osum,
   Sara/0000 0002 4548 5422; Yamamoto, Kenta/0000 0002 9424 1993; Smeester,
   Branden/0000 0001 9421 1711
FU NIH NIAMS [T32 AR050938]; Doctoral Dissertation Fellowship (DDF) through
   the Graduate School at the University of Minnesota; NIH NIAID [T32
   AI997313]; Children's Tumor Foundation Young Investigator Award from the
   NF Research Initiative at Boston Children's Hospital; Zach Sobiech OSA
   Fund Award; Randy Shaver Cancer Research and Community Fund; Aflac AACR
   Career Development Award; Children's Cancer Research Fund; American
   Cancer Society (ACS);  [NIHT32 OD0100993]
FX The authors would like to thank Plexxikon for their gift of PLX3397
   formulated rodent chow. The authors acknowledge the Minnesota
   Supercomputing Institute (MSI) at the University of Minnesota for
   providing resources that contributed to the research results reported
   within this paper. URL: http://www.msi.umn.edu.Author B.A.S. was
   previously supported by an NIH NIAMS T32 AR050938 Musculoskeletal
   Training Grant and is currently supported by a Doctoral Dissertation
   Fellowship (DDF) through the Graduate School at the University of
   Minnesota. Author E.J.P. is supported by an NIH NIAID T32 AI997313
   Immunology Training Grant. Author S.H.O. is supported by an NIHT32
   OD0100993 Comparative Medicine and Pathology Training Grant. Author
   K.B.W. is supported by a Children's Tumor Foundation Young Investigator
   Award from the NF Research Initiative at Boston Children's Hospital made
   possible by an anonymous gift. This work was made possible through
   funding from the Zach Sobiech OSA Fund Award, Randy Shaver Cancer
   Research and Community Fund, Aflac AACR Career Development Award, and
   the Children's Cancer Research Fund to author B.S.M. and American Cancer
   Society (ACS) Professor award to author D.A.L.
CR Azzam G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074297
   Bacci G, 2000, ONCOL REP, V7, P339
   Barbetti V, 2014, ONCOGENE, V33, P4359, DOI 10.1038/onc.2013.542
   Bencheikh L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09970 9
   Chihara T, 2010, CELL DEATH DIFFER, V17, P1917, DOI 10.1038/cdd.2010.60
   Cioce M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.136
   Coniglio SJ, 2012, MOL MED, V18, P519, DOI 10.2119/molmed.2011.00217
   Durfee RA, 2016, RHEUMATOL THER, V3, P221, DOI 10.1007/s40744 016 0046 y
   Faustino Rocha A, 2013, LAB ANIMAL, V42, P217, DOI 10.1038/laban.254
   Giustini N, 2018, CLIN SARCOMA RES, V8, DOI 10.1186/s13569 018 0101 2
   HARRIS SA, 1995, J BONE MINER RES, V10, P178
   Hung JY, 2014, LAB INVEST, V94, P371, DOI 10.1038/labinvest.2014.1
   Kuijjer ML, 2013, INT J CANCER, V133, P2512, DOI 10.1002/ijc.28124
   Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011
   Li NF, 2009, ONCOGENE, V28, P773, DOI 10.1038/onc.2008.412
   Misaghi A, 2018, SICOT J, V4, DOI 10.1051/sicotj/2017028
   Morandi A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027450
   Moriarity BS, 2015, NAT GENET, V47, P615, DOI 10.1038/ng.3293
   Murga Zamalloa C, 2020, CLIN CANCER RES, V26, P690, DOI 10.1158/1078 0432.CCR 19 1486
   Pass HI, 2016, ONCOTARGET, V7, P56408, DOI 10.18632/oncotarget.10895
   Perry J.A., 2014, P NATL ACAD SCI USA, V111
   ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0
   ROUSSEL MF, 1994, J CELL SCI, P105
   Saraf AJ, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00004
   Sayles LC, 2019, CANCER DISCOV, V9, P46, DOI 10.1158/2159 8290.CD 17 1152
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Scott MC, 2018, CANCER RES, V78, P326, DOI 10.1158/0008 5472.CAN 17 0576
   Ségaliny AI, 2015, INT J CANCER, V137, P73, DOI 10.1002/ijc.29376
   Sharma N, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.tps3127
   Smeester B.A., 2019, SEMA4C IS NOVEL TARG
   Smeester BA, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/387169
   Smeester BA, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/671386
   Stanley ER, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a021857
   Temiz NA, 2016, GENOME RES, V26, P119, DOI 10.1101/gr.188649.114
   von Tresckow B, 2015, CLIN CANCER RES, V21, P1843, DOI 10.1158/1078 0432.CCR 14 1845
   Wang D, 2019, CANCER RES, V79, P7, DOI 10.1158/0008 5472.CAN 18 1086
   Wen ZQ, 2017, AM J CANCER RES, V7, P801
   Wesolowski R., 2016, Gynecologic Oncology, V141, P121, DOI [10.1016/j.ygyno.2016.04, DOI 10.1016/J.YGYNO.2016.04]
   Wesolowski R, 2019, THER ADV MED ONCOL, V11, DOI 10.1177/1758835919854238
   Wittrant Y, 2009, ENDOCRINOLOGY, V150, P4977, DOI 10.1210/en.2009 0248
   Wrobel CN, 2004, J CELL BIOL, V165, P263, DOI 10.1083/jcb.200309102
   Yao GQ, 2002, CALCIFIED TISSUE INT, V70, P339, DOI 10.1007/s00223 001 1079 x
NR 42
TC 26
Z9 31
U1 1
U2 27
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JUL
PY 2020
VL 136
AR 115353
DI 10.1016/j.bone.2020.115353
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA LQ6SP
UT WOS:000535131500013
PM 32251854
DA 2025 08 17
ER

PT J
AU Hegewald, AB
   Breitwieser, K
   Ottinger, SM
   Mobarrez, F
   Korotkova, M
   Rethi, B
   Jakobsson, PJ
   Catrina, AI
   Wähämaa, H
   Saul, MJ
AF Hegewald, Anett B.
   Breitwieser, Kai
   Ottinger, Sarah M.
   Mobarrez, Fariborz
   Korotkova, Marina
   Rethi, Bence
   Jakobsson, Per Johan
   Catrina, Anca I.
   Wahamaa, Heidi
   Saul, Meike J.
TI Extracellular miR 574 5p Induces Osteoclast Differentiation via TLR 7/8
   in Rheumatoid Arthritis
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE TLR7; 8; miR 574 5p; extracellular vesicle (EV); osteoclast
   differentiation; rheumatoid arthritis
ID TOLL LIKE RECEPTORS; SYNOVIAL FIBROBLASTS; EXPRESSION; MICRORNAS;
   VESICLES; RNA
AB Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by synovial inflammation and joint destruction. Cell derived small extracellular vesicles (sEV) mediate cell to cell communication in the synovial microenvironment by carrying microRNAs (miRs), a class of small non coding RNAs. Herein, we report that sEV from synovial fluid promote osteoclast differentiation which is attributed to high levels of extracellular miR 574 5p. Moreover, we demonstrate for the first time that enhanced osteoclast maturation is mediated by Toll like receptor (TLR) 7/8 signaling which is activated by miR 574 5p binding. This is a novel mechanism by which sEV and miRs contribute to RA pathogenesis and indicate that pharmacological inhibition of extracellular miR 574 5p might offer new therapeutic strategies to protect osteoclast mediated bone destruction in RA.
C1 [Hegewald, Anett B.; Breitwieser, Kai; Ottinger, Sarah M.; Saul, Meike J.] Tech Univ Darmstadt, Dept Biol, Darmstadt, Germany.
   [Mobarrez, Fariborz; Korotkova, Marina; Rethi, Bence; Jakobsson, Per Johan; Catrina, Anca I.; Wahamaa, Heidi] Karolinska Univ Hosp, Karolinska Inst, Dept Med, Rheumatol Unit, Stockholm, Sweden.
   [Saul, Meike J.] Goethe Univ Frankfurt, Inst Pharmaceut Chem, Frankfurt, Germany.
C3 Technical University of Darmstadt; Karolinska Institutet; Karolinska
   University Hospital; Goethe University Frankfurt
RP Saul, MJ (通讯作者)，Tech Univ Darmstadt, Dept Biol, Darmstadt, Germany.; Saul, MJ (通讯作者)，Goethe Univ Frankfurt, Inst Pharmaceut Chem, Frankfurt, Germany.
EM saul@bio.tu darmstadt.de
RI Jakobsson, Per Johan/ABC 5594 2021; Mobarrez, Fariborz/JTS 5830 2023;
   Saul, Meike/T 6671 2019; Rethi, Bence/C 5770 2013
OI Korotkova, Marina/0000 0002 4838 3608; Jakobson,
   Per Johan/0000 0001 7665 9715; Saul, Meike/0000 0002 6893 1050; Rethi,
   Bence/0000 0001 8220 5015; Mobarrez, Fariborz/0000 0002 7106 6248
FU Else Kroner Fresenius Stiftung [2013_A265]; Boehringer Ingelheim Fond;
   Athene Young Investigator program (Technische Universitat Darmstadt);
   Dr. Ing. Wilhelm und Maria Kirmser Stiftung; LOEWE Zentrum
   Translationale Medizin und Pharmakologie (Innovationsfond); Swedish
   Rheumatism Association; German Research Foundation; Open Access
   Publishing Fund of Technical University of Darmstadt
FX This project was supported by Else Kroner Fresenius Stiftung
   (2013_A265), Boehringer Ingelheim Fond (Travel grant; grant no.: n/a),
   Athene Young Investigator program (Technische Universitat Darmstadt;
   grant no.: n/a), Dr. Ing. Wilhelm und Maria Kirmser Stiftung (grant no.:
   n/a), LOEWE Zentrum Translationale Medizin und Pharmakologie
   (Innovationsfond) and the Swedish Rheumatism Association (grant no.:
   n/a). We acknowledge support by the German Research Foundation and the
   Open Access Publishing Fund of Technical University of Darmstadt.
CR Adamopoulos IE, 2018, CURR OPIN RHEUMATOL, V30, P59, DOI 10.1097/BOR.0000000000000449
   Alexander M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8321
   Amarasekara DS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e8
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Anwar MA, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.28
   Bayraktar R, 2017, MOL ONCOL, V11, P1673, DOI 10.1002/1878 0261.12144
   Beyer C, 2010, NAT REV RHEUMATOL, V6, P21, DOI 10.1038/nrrheum.2009.229
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Dunaeva M, 2018, CLIN EXP IMMUNOL, V193, P376, DOI 10.1111/cei.13156
   Eiring AM, 2010, CELL, V140, P652, DOI 10.1016/j.cell.2010.01.007
   Ell B, 2013, CANCER CELL, V24, P542, DOI 10.1016/j.ccr.2013.09.008
   Fabbri M, 2012, P NATL ACAD SCI USA, V109, pE2110, DOI 10.1073/pnas.1209414109
   Fauth M, 2019, FASEB BIOADV, V1, P481, DOI 10.1096/fba.2019 00018
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   Foers AD, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1490145
   Fu HT, 2018, MOL IMMUNOL, V93, P125, DOI 10.1016/j.molimm.2017.11.016
   Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620
   Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758
   Huber LC, 2006, RHEUMATOLOGY, V45, P669, DOI 10.1093/rheumatology/kel065
   Jurk M, 2002, NAT IMMUNOL, V3, P499, DOI 10.1038/ni0602 499
   Karsenty G, 2009, ANNU REV CELL DEV BI, V25, P629, DOI 10.1146/annurev.cellbio.042308.113308
   Kato T, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4679
   Kim SJ, 2016, ARTHRITIS RHEUMATOL, V68, P1099, DOI 10.1002/art.39544
   Leclerc P, 2013, SCAND J IMMUNOL, V77, P350, DOI 10.1111/sji.12041
   Lefèvre S, 2015, CURR PHARM DESIGN, V21, P130
   Lehmann SM, 2012, NAT NEUROSCI, V15, P827, DOI 10.1038/nn.3113
   Lytle JR, 2007, P NATL ACAD SCI USA, V104, P9667, DOI 10.1073/pnas.0703820104
   Martinez FO, 2006, J IMMUNOL, V177, P7303, DOI 10.4049/jimmunol.177.10.7303
   Mehta A, 2016, NAT REV IMMUNOL, V16, P279, DOI 10.1038/nri.2016.40
   Miyamoto A, 2012, CYTOTECHNOLOGY, V64, P331, DOI 10.1007/s10616 012 9442 5
   Mulcahy LA, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.24641
   Pauley KM, 2011, IMMUNOTHERAPY UK, V3, P829, DOI [10.2217/imt.11.70, 10.2217/IMT.11.70]
   Penfornis P, 2016, INT J CANCER, V138, P14, DOI 10.1002/ijc.29417
   Salvi V, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98204
   Saul MJ, 2019, FASEB J, V33, P6933, DOI 10.1096/fj.201802547R
   Saul MJ, 2016, SCI REP UK, V6, DOI 10.1038/srep31995
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Scott David L, 2010, Lancet, V376, P1094, DOI 10.1016/S0140 6736(10)60826 4
   Shurtleff MJ, 2016, ELIFE, V5, DOI 10.7554/eLife.19276
   Stanczyk J, 2008, ARTHRITIS RHEUM, V58, P1001, DOI 10.1002/art.23386
   Su LC, 2017, INT J RHEUM DIS, V20, P1631, DOI 10.1111/1756 185X.13202
   Susa Mira, 2004, J Transl Med, V2, P6, DOI 10.1186/1479 5876 2 6
   Syversen SW, 2010, ANN RHEUM DIS, V69, P345, DOI 10.1136/ard.2009.113092
   Théry C, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1535750
   van Niel G, 2018, NAT REV MOL CELL BIO, V19, P213, DOI 10.1038/nrm.2017.125
   Visintin A, 2001, J IMMUNOL, V166, P249, DOI 10.4049/jimmunol.166.1.249
   Westman M, 2004, ARTHRITIS RHEUM US, V50, P1774, DOI 10.1002/art.20286
   Wienken CJ, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1093
   Withrow J, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075 016 1178 8
NR 49
TC 42
Z9 42
U1 0
U2 14
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD OCT 14
PY 2020
VL 11
AR 585282
DI 10.3389/fimmu.2020.585282
PG 14
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA OH5YU
UT WOS:000582662600001
PM 33154755
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Chen, WX
   Xie, Z
   Tang, P
   Wang, YL
   Jie, ZW
   Qin, A
   Jiang, XS
   Hu, ZJ
   Fan, SW
AF Chen, Wenxiang
   Xie, Ziang
   Tang, Pan
   Wang, Yongli
   Jie, Zhiwei
   Qin, An
   Jiang, Xuesheng
   Hu, Zhijun
   Fan, Shunwu
TI The emerging role of IMD 0354 on bone homeostasis by suppressing
   osteoclastogenesis and bone resorption, but without affecting bone
   formation
SO CELL DEATH & DISEASE
LA English
DT Article
ID NF KAPPA B; INHIBITOR; DIFFERENTIATION; INFLAMMATION; METABOLISM;
   ACTIVATION; IMD 0354
AB Osteoporosis is caused by an imbalance between bone formation and bone resorption. Receptor activator of nuclear factor kappa B ligand (RANKL) promotes the activity and differentiation of osteoclasts via activating the nuclear factor kappa B (NF kappa B) and mitogen activated protein kinase (MAPK) signaling pathways. IMD 0354 is a selective molecular inhibitor of inhibitor of NF kappa B kinase subunit beta (IKK beta) and effective for treatment of acute and subacute inflammatory diseases through the suppression of NF kappa B activation. However, the effect of IMD 0354 on bone homeostasis is unknown. In this study, we demonstrated that IMD 0354 significantly attenuated ovariectomy induced bone loss and inhibited osteoclastogenesis in mice, whereas bone formation was not affected. Additionally, IMD 0354 dramatically inhibited osteoclast differentiation and function induced by RANKL and macrophage colony stimulating factor in bone marrow monocytes as verified by tartrate resistant acid phosphatase (TRAP) staining as well as bone resorption assay in vitro. Subsequently, we found that activation of NF kappa B signaling and the ERK/c Fos axis were blunted during osteoclast formation induced by RANKL. Transcription factors nuclear factor of activated T cells c1 (NFATc1) and c Fos were suppressed with the decreased expression of osteoclast related genes by IMD 0354. Our findings suggest that IMD 0354 could be a potential preventive and therapeutic drug for osteoporosis.
C1 [Chen, Wenxiang; Tang, Pan; Wang, Yongli; Jiang, Xuesheng] Zhejiang Univ, Huzhou Hosp, Huzhou Cent Hosp, Dept Orthopaed, Huzhou, Zhejiang, Peoples R China.
   [Chen, Wenxiang; Xie, Ziang; Jie, Zhiwei; Hu, Zhijun; Fan, Shunwu] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Orthopaed, Hangzhou, Zhejiang, Peoples R China.
   [Chen, Wenxiang; Xie, Ziang; Jie, Zhiwei; Hu, Zhijun; Fan, Shunwu] Key Lab Musculoskeletal Syst Degenerat & Regenera, Hangzhou, Zhejiang, Peoples R China.
   [Qin, An] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Shanghai Key Lab Orthopaed Implant, Dept Orthopaed,Sch Med, Shanghai, Peoples R China.
C3 Huzhou University; Zhejiang University; Zhejiang University; Shanghai
   Jiao Tong University
RP Hu, ZJ; Fan, SW (通讯作者)，Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Orthopaed, Hangzhou, Zhejiang, Peoples R China.; Hu, ZJ; Fan, SW (通讯作者)，Key Lab Musculoskeletal Syst Degenerat & Regenera, Hangzhou, Zhejiang, Peoples R China.
EM hzjspine@zju.edu.cn; 0099203@zju.edu.cn
RI hu, zhijun/HLP 6607 2023; Qin, An/J 2518 2019; Tang, Pan/AIC 2118 2022;
   Chen, Wenxiang/JXW 5268 2024
OI Jie, Zhiwei/0000 0002 9469 4490; 
FU National Key R&D Program of China [2018YFC1105200]; Key Research and
   Development Plan in Zhejiang Province [2018C03060]; National Nature
   Science Fund of China [81672150, 81871797, 81874015, 81871796, 81873985,
   81802680, 81802147]; Natural Science Fund of Zhejiang Province
   [Z15H060002, LY16H060004, LY16H060002]; Zhejiang medical and health
   science and technology project [2018KY117, 2019ZD041]; fundamental
   research funds for the central universities [2019QNA7027]; New talent in
   medical field of Zhejiang Province
FX This work was supported by National Key R&D Program of China (No.
   2018YFC1105200), the Key Research and Development Plan in Zhejiang
   Province (No. 2018C03060), National Nature Science Fund of China
   (81672150, 81871797, 81874015, 81871796, 81873985, 81802680, 81802147),
   Natural Science Fund of Zhejiang Province (Z15H060002, LY16H060004.
   LY16H060002), Zhejiang medical and health science and technology project
   (2018KY117, 2019ZD041), New talent in medical field of Zhejiang
   Province, and the fundamental research funds for the central
   universities (2019QNA7027).We would like to acknowledge Editage for
   English language editing.
CR Américo Da Silva L, 2018, FASEB J, V32, P4681, DOI 10.1096/fj.201701229RR
   Bae S, 2017, J CLIN INVEST, V127, P2555, DOI 10.1172/JCI89935
   Binder NB, 2009, NAT MED, V15, P417, DOI 10.1038/nm.1945
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Chandra A, 2018, FASEB J, V32, P52, DOI 10.1096/fj.201700375R
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Chen S, 2015, SCI REP UK, V5, DOI 10.1038/srep12853
   Chen X, 2017, FASEB J, V31, P4855, DOI 10.1096/fj.201700316R
   Cho YA, 2015, J DENT RES, V94, P371, DOI 10.1177/0022034514563335
   Cunningham CC, 2016, OSTEOARTHR CARTILAGE, V24, P2141, DOI 10.1016/j.joca.2016.07.001
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Fiore A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 07654 4
   Fontalis A, 2019, EXPERT OPIN PHARMACO, V20, P1123, DOI 10.1080/14656566.2019.1594772
   Gavali S, 2019, BBA MOL BASIS DIS, V1865, P547, DOI 10.1016/j.bbadis.2018.12.016
   Gomez Cabrero A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073607
   Hemming S, 2017, FASEB J, V31, P1011, DOI 10.1096/fj.201600748R
   Hosokawa S, 2013, CARDIOVASC RES, V99, P35, DOI 10.1093/cvr/cvt105
   Ikebuchi Y, 2018, NATURE, V561, P195, DOI 10.1038/s41586 018 0482 7
   Ishii T, 2018, FASEB J, V32, P4016, DOI 10.1096/fj.201701424R
   Jie ZW, 2019, BBA MOL BASIS DIS, V1865, P115, DOI 10.1016/j.bbadis.2018.10.026
   Lennikov A, 2014, INVEST OPHTH VIS SCI, V55, P6365, DOI 10.1167/iovs.14 14671
   Li CH, 2011, J BONE MINER RES, V26, P644, DOI 10.1002/jbmr.242
   Li F, 2018, BBA MOL BASIS DIS, V1864, P3449, DOI 10.1016/j.bbadis.2018.07.034
   Li ZQ, 2019, J BONE MINER RES, V34, P752, DOI 10.1002/jbmr.3645
   Lin TH, 2014, ACTA BIOMATER, V10, P1, DOI 10.1016/j.actbio.2013.09.034
   Lotinun S, 2013, J CLIN INVEST, V123, P666, DOI 10.1172/JCI64840
   Lu D, 2018, J BONE MINER RES, V33, P1773, DOI 10.1002/jbmr.3469
   Meng JH, 2018, AM J TRANSL RES, V10, P2901
   Migliaccio S, 2007, CLIN INTERV AGING, V2, P55, DOI 10.2147/ciia.2007.2.1.55
   Murata K, 2017, IMMUNITY, V47, P66, DOI 10.1016/j.immuni.2017.06.018
   Park Min KH, 2018, CELL MOL LIFE SCI, V75, P2519, DOI 10.1007/s00018 018 2817 9
   Ping ZC, 2017, ACTA BIOMATER, V62, P362, DOI 10.1016/j.actbio.2017.08.046
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Raucci A, 2008, J CELL PHYSIOL, V215, P442, DOI 10.1002/jcp.21323
   Sapkota M, 2018, FOOD CHEM TOXICOL, V120, P418, DOI 10.1016/j.fct.2018.07.032
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Scholtysek C, 2018, J BONE MINER RES, V33, P2035, DOI 10.1002/jbmr.3533
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Vieira CS, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01189
   Watanabe R, 2013, AM J PHYSIOL HEART C, V305, pH1761, DOI 10.1152/ajpheart.00159.2013
   Yagishita N, 2001, ENDOCRINOLOGY, V142, P5332, DOI 10.1210/en.142.12.5332
   Yasui T, 2011, J BONE MINER RES, V26, P1447, DOI 10.1002/jbmr.357
   Yu B, 2018, CELL STEM CELL, V23, P615, DOI 10.1016/j.stem.2018.09.001
   Yu B, 2014, NAT MED, V20, P1009, DOI 10.1038/nm.3586
   Zhang T, 2019, FASEB J, V33, P5399, DOI 10.1096/fj.201801797R
   Zhang Z, 2020, J CELL BIOCHEM, V121, P609, DOI 10.1002/jcb.29306
NR 46
TC 8
Z9 9
U1 0
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041 4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD SEP 10
PY 2019
VL 10
AR 654
DI 10.1038/s41419 019 1914 5
PG 16
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA JK6RP
UT WOS:000494969900001
PM 31506437
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU He, Q
   Yang, JZ
   Zhang, GY
   Chen, DL
   Zhang, M
   Pan, ZF
   Wang, ZH
   Su, LJ
   Zeng, JX
   Wang, BH
   Wang, HB
   Chen, P
AF He, Qi
   Yang, Junzheng
   Zhang, Gangyu
   Chen, Delong
   Zhang, Meng
   Pan, Zhaofeng
   Wang, Zihao
   Su, Lijun
   Zeng, Jiaxu
   Wang, Baohua
   Wang, Haibin
   Chen, Peng
TI Sanhuang Jiangtang tablet protects type 2 diabetes osteoporosis via
   AKT GSK38 NFATc1 signaling pathway by integrating bioinformatics
   analysis and experimental validation
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Sanhuang jiangtang tablet; Type 2 diabetes osteoporosis; Bioinformatics;
   AKT GSK3 beta NFATc1 signaling pathway
ID BONE FORMATION; DB/DB MICE; MELLITUS; OBESITY; RISK; FRACTURE;
   OSTEOCLASTOGENESIS; MECHANISMS; INSIGHT; GLUCOSE
AB Ethnopharmacological relevance: Sanhuang Jiangtang tablet (SHJTT), has been widely used to treat type 2 diabetes mellitus (T2DM). However, the potential and mechanism of SHJTT in treating type 2 diabetes osteoporosis (T2DOP) has not been reported.
   Aim of the study: The aim of this work was to investigate the role and the underlying molecular mechanism of SHJTT in managing type 2 diabetes osteoporosis.
   Materials and methods: The target genes of each component consisting of SHJTT were obtained by searching the ETCM database. The target genes of osteoporosis and diabetes were individually acquired by analyzing the DisGeNET and OMIM disease databases. Then the potential therapeutic genes were obtained from the intersection of the herbal medicine targets and the disease targets which were imported into the R and STRING platform for the analysis of GO terms, KEGG pathways and PPI network. The key modules of PPI network were constructed by Cytoscape software. Finally, leptin receptor deficiency (db/db) mice were confirmed as an animal model of type 2 diabetic osteoporosis (T2DOP) through phenotype assessment and the key genes of SHJTT against T2DOP were validated by quantitative real time PCR (qRT PCR).
   Results: A total of 786 target genes of SHJTT were obtained from ETCM. Simultaneously, a total of 3906 osteoporosis and type 2 diabetes associated targets were acquired from DisGeNET and OMIM databases. Then, 97 common targets were found by overlapping them. On the basis of the GO and KEGG enrichment analysis and PPI network, we found that the related pathway of SHJTT in type 2 diabetes osteoporosis was AKT GSK3 beta NFATc1 pathway which is tightly associated with osteoclast differentiation. The expression of key genes including Akt1, Mapk3, Gsk3 beta, Mmp9, Nfkb1 were significantly down regulated by SHJTT in T2DOP mice (p < 0.05).
   Conclusions: SHJTT had a protective effect on T2DOP via regulating AKT GSK3 beta NFATc1 signaling pathway. This study might provide a theoretical basis for the application of SHJTT for the treatment of type 2 diabetic osteoporosis.
C1 [He, Qi; Yang, Junzheng; Zhang, Gangyu; Pan, Zhaofeng; Su, Lijun; Zeng, Jiaxu] Guangzhou Univ Chinese Med, Sch Med 1, 12 Jichang Rd, Guangzhou 510405, Peoples R China.
   [He, Qi; Yang, Junzheng; Zhang, Gangyu; Pan, Zhaofeng; Su, Lijun; Zeng, Jiaxu] Guangzhou Univ Chinese Med, Lingnan Med Res Ctr, Lab Orthopaed & Traumatol, Guangzhou 510405, Peoples R China.
   [Chen, Delong] Jinan Univ, Clifford Hosp, Dept Orthopaed Surg, Guangzhou 510006, Peoples R China.
   [Zhang, Meng] Henan Univ, Zhengzhou Univ, Peoples Hosp, Dept Orthoped,Henan Prov Peoples Hosp, Zhengzhou 450003, Henan, Peoples R China.
   [Wang, Zihao] Queens Univ Belfast, Univ Rd, Belfast BT7 1NN, Antrim, North Ireland.
   [Wang, Baohua] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Endocrinol, Guangzhou 510405, Peoples R China.
   [Wang, Haibin; Chen, Peng] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Orthopaed, 12 Jichang Rd, Guangzhou 510405, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of
   Chinese Medicine; Jinan University; Henan University; Zhengzhou
   University; Queens University Belfast; Guangzhou University of Chinese
   Medicine; Guangzhou University of Chinese Medicine
RP Wang, BH (通讯作者)，Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Endocrinol, Guangzhou 510405, Peoples R China.; Wang, HB; Chen, P (通讯作者)，Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Orthopaed, 12 Jichang Rd, Guangzhou 510405, Peoples R China.
EM wangbaohua@gzhtcm.edu.cn; hipknee@163.com; docchen777@gmail.com
RI zhang, zhizhong/KRP 4408 2024; Zeng, Jiaxu/HPH 6958 2023
OI Chen, Peng/0000 0002 3069 9997
FU National Natural Science Foundation of China [81774339, 82074462]; Major
   research project of Guangzhou University of Chinese Medicine
   [XK2019012]; Guangdong Science Province and Technology Program project
   [2017A020213030]; Guangzhou Science and Technology Planning Project
   [201707010319]
FX This research was supported by National Natural Science Foundation of
   China (No. 81774339; NO. 82074462), Major research project of Guangzhou
   University of Chinese Medicine (No. XK2019012), the Guangdong Science
   Province and Technology Program project (No. 2017A020213030) and the
   Guangzhou Science and Technology Planning Project (No. 201707010319).
CR Abdulameer SA, 2013, OSTEOPOROSIS INT, V24, P929, DOI 10.1007/s00198 012 2071 1
   Chen DL, 2020, PHARMACOL RES, V159, DOI 10.1016/j.phrs.2020.104944
   Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092 8674(00)81294 5
   Chen HL, 2013, INT J ENDOCRINOL, V2013, DOI 10.1155/2013/285729
   Cui X, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113634
   Deng Chang qing, 2004, Zhongguo Zhong Xi Yi Jie He Za Zhi, V24, P348
   Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097 4652(200009)184:3<341::AID JCP8>3.3.CO;2 Q
   Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092 8674(00)81558 5
   Ealey KN, 2006, REGUL PEPTIDES, V136, P9, DOI 10.1016/j.regpep.2006.04.013
   FRIEDMAN JM, 1991, GENOMICS, V11, P1054, DOI 10.1016/0888 7543(91)90032 A
   Giesbertz P, 2015, DIABETOLOGIA, V58, P2133, DOI 10.1007/s00125 015 3656 y
   Guo Q, 2019, MOLECULES, V24, DOI 10.3390/molecules24224050
   Hamann C, 2012, NAT REV ENDOCRINOL, V8, P297, DOI 10.1038/nrendo.2011.233
   He HB, 2004, ENDOCRINOLOGY, V145, P447, DOI 10.1210/en.2003 1239
   Hildebrand T, 1997, J MICROSC OXFORD, V185, P67, DOI 10.1046/j.1365 2818.1997.1340694.x
   Huang XJ, 2018, INT J BIOL SCI, V14, P1483, DOI 10.7150/ijbs.27173
   Janghorbani M, 2007, AM J EPIDEMIOL, V166, P495, DOI 10.1093/aje/kwm106
   Jing D, 2016, J BONE MINER RES, V31, P1713, DOI 10.1002/jbmr.2837
   Kanzaki H, 2016, REDOX BIOL, V8, P186, DOI 10.1016/j.redox.2016.01.006
   Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058
   Khan MAB, 2020, J EPIDEMIOL GLOB HEA, V10, P107, DOI 10.2991/jegh.k.191028.001
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Komori T, 2017, ADV EXP MED BIOL, V962, P83, DOI 10.1007/978 981 10 3233 2_6
   Lebedev DA, 2020, J DIABETES RES, V2020, DOI 10.1155/2020/6976153
   Lecka Czernik B, 2017, DIABETOLOGIA, V60, P1163, DOI 10.1007/s00125 017 4269 4
   Lee J, 2021, ANTIOXIDANTS BASEL, V10, DOI 10.3390/antiox10010081
   Lee SH, 2002, J BIOCHEM, V131, P161, DOI 10.1093/oxfordjournals.jbchem.a003071
   Li S, 2000, Zhongguo Zhong Xi Yi Jie He Za Zhi, V20, P438
   Lin X, 2019, MOL CELL ENDOCRINOL, V494, DOI 10.1016/j.mce.2019.110494
   Liu CY, 2017, J ETHNOPHARMACOL, V198, P351, DOI 10.1016/j.jep.2017.01.021
   Massaro Joseph, 2008, WILEY ENCY CLIN TRIA
   Miura M, 2021, HEART VESSELS, V36, P568, DOI 10.1007/s00380 020 01726 6
   Montagnani A, 2011, AGING CLIN EXP RES, V23, P84, DOI 10.1007/BF03351073
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Nakahama K, 2010, CELL MOL LIFE SCI, V67, P4001, DOI 10.1007/s00018 010 0479 3
   Napoli N, 2017, NAT REV ENDOCRINOL, V13, P208, DOI 10.1038/nrendo.2016.153
   Nie YN, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472 6882 14 148
   Portha B, 2005, DIABETES METAB RES, V21, P495, DOI 10.1002/dmrr.566
   Shan PF, 2011, J ENDOCRINOL INVEST, V34, P190, DOI [10.1007/BF03347065, 10.3275/7239]
   Shanbhogue VV, 2016, LANCET DIABETES ENDO, V4, P159, DOI 10.1016/S2213 8587(15)00283 1
   Strotmeyer ES, 2005, ARCH INTERN MED, V165, P1612, DOI 10.1001/archinte.165.14.1612
   Sugatani T, 2005, J BIOL CHEM, V280, P3583, DOI 10.1074/jbc.M410480200
   Sun L, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.553288
   Tian S, 2013, J CHEM INF MODEL, V53, P1787, DOI 10.1021/ci400146u
   Vestergaard P, 2007, OSTEOPOROSIS INT, V18, P427, DOI 10.1007/s00198 006 0253 4
   Walsh MC, 2006, ANNU REV IMMUNOL, V24, P33, DOI 10.1146/annurev.immunol.24.021605.090646
   Williams GA, 2011, J BONE MINER RES, V26, P1698, DOI 10.1002/jbmr.367
   Wu MR, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13700
   Xiao DL, 2020, J CELL BIOCHEM, V121, P4542, DOI 10.1002/jcb.29677
   Xiong M Q, 1997, Zhongguo Zhong Xi Yi Jie He Za Zhi, V17, P165
   Xu HY, 2019, NUCLEIC ACIDS RES, V47, pD976, DOI 10.1093/nar/gky987
   Yang LH, 2019, AM J CHINESE MED, V47, P1419, DOI 10.1142/S0192415X19500733
   Yeu J, 2019, LAB ANIM RES, V35, DOI 10.1186/s42826 019 0004 2
   YOON JW, 1988, DIABETES, V37, P1287, DOI 10.2337/diabetes.37.9.1287
   Yue SJ, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00694
   Zhang Y, 2016, WORLD J GASTROENTERO, V22, P2558, DOI 10.3748/wjg.v22.i8.2558
   ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0
   Zhao MD, 2019, INT J NANOMED, V14, P9453, DOI 10.2147/IJN.S224579
   Zhou SS, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00425
   Zhu Z Z, 1997, Zhongguo Zhong Xi Yi Jie He Za Zhi, V17, P590
NR 60
TC 17
Z9 22
U1 1
U2 65
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD JUN 12
PY 2021
VL 273
AR 113946
DI 10.1016/j.jep.2021.113946
EA MAR 2021
PG 11
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA RI2UB
UT WOS:000636763400004
PM 33647426
DA 2025 08 17
ER

PT J
AU Schoenecker, J
   Mignemi, N
   Stutz, C
   Liu, QX
   Edwards, J
   Lynch, C
   Holt, G
   Schwartz, H
   Mencio, G
   Hamm, H
AF Schoenecker, Jonathan
   Mignemi, Nicholas
   Stutz, Christopher
   Liu, Qixu
   Edwards, James
   Lynch, Conor
   Holt, Ginger
   Schwartz, Herbert
   Mencio, Gregory
   Hamm, Heidi
TI 2010 Young Investigator Award Winner: Therapeutic Aprotinin Stimulates
   Osteoblast Proliferation but Inhibits Differentiation and Bone Matrix
   Mineralization
SO SPINE
LA English
DT Article
DE antifibrinolytics; hemostatic agents; bleeding; tissue sealant;
   aprotinin; osteoblast; aminocaproic acid; tranexamic acid
ID PLASMINOGEN ACTIVATOR INHIBITOR 1; EPSILON AMINOCAPROIC ACID;
   CARDIAC SURGERY; RENAL DYSFUNCTION; RISK; SYSTEM; ASSOCIATION;
   EXPRESSION; RECEPTOR; GENDER
AB Study Design. Analysis of the effect of antifibrinolytics on in vitro bone formation.
   Objective. As the direct effect of antifibrinolytics on bone formation is unknown, we examined whether antifibrinolytics routinely used in spine surgery, namely, aprotinin and aminocaproic acid, affect osteoblast function in vitro.
   Summary of Background Data. Antifibrinolytics are used in spine surgery to prevent intraoperative blood loss and decrease the need for transfusion. They are either delivered systemically or included as a component of most tissue sealants. Although the role of the fibrinolytic system in wound healing is well established, reports of indirect effects on normal bone biology are emerging. This suggests that the pharmacological targeting of this system may also influence skeletal mass and integrity.
   Methods. Osteoblast progenitor cells were cultured with therapeutic doses of aprotinin and aminocaproic acid. The effect of the antifibrinolytics on osteoblast development was determined by measuring cellular viability and proliferation, quantification of matrix mineralization, and genetic analysis of osteoblast differentiation markers. Protease inhibition profiles of the antifibrinolytics were determined by amidolytic chromogenic assays.
   Results. Therapeutic concentrations of aprotinin dose dependently inhibited plasmin's proteolytic activity, stimulated osteoblast proliferation, and inhibited osteoblast differentiation and matrix mineralization. Aprotinin inhibition of osteoblast differentiation and matrix mineralization could be recovered by removing aprotinin from culture or stimulating cells with bone morphogenetic protein 2 or plasmin. Conversely, aminocaproic acid inhibited plasmin's proteolytic activity significantly less than aprotinin and had no effect on osteoblast proliferation, differentiation, or matrix mineralization in its therapeutic range.
   Conclusion. These findings demonstrate that the antifibrinolytics have drastically different effects on osteoblasts due in part to different efficacies of protease inhibition. Further, this work suggests that the fibrinolytic proteases and their inhibitors have great potential to regulate bone by affecting the processes that control osteoblast growth and differentiation.
C1 [Schoenecker, Jonathan; Mignemi, Nicholas; Stutz, Christopher; Lynch, Conor; Holt, Ginger; Schwartz, Herbert; Mencio, Gregory] Vanderbilt Univ, Dept Orthopaed, Nashville, TN USA.
   [Schoenecker, Jonathan; Mignemi, Nicholas; Liu, Qixu; Edwards, James; Hamm, Heidi] Vanderbilt Univ, Dept Pediat & Pharmacol, Nashville, TN USA.
C3 Vanderbilt University; Vanderbilt University
RP Schoenecker, J (通讯作者)，4202 Doctors Off Tower,220 Childrens Way, Nashville, TN 37232 USA.
EM jon.schoenecker@vanderbilt.edu
OI Schoenecker, Jonathan/0000 0002 3097 5496
FU the Orthopaedic Research and Education Foundation (OREF); Mid American
   Orthopaedic Association (MAOA); Vanderbilt Brooks Fund
FX This work was funded by the Orthopaedic Research and Education
   Foundation (OREF), the Mid American Orthopaedic Association (MAOA) and
   the Vanderbilt Brooks Fund.
CR Albala DM, 2003, CARDIOVASC SURG, V11, P5, DOI 10.1016/S0967 2109(03)00065 6
   ALLAN EH, 1995, CLIN ORTHOP RELAT R, P54
   AUBIN JE, 1995, BONE, V17, pS77, DOI 10.1016/8756 3282(95)00183 E
   Beath SM, 2000, ANESTH ANALG, V91, P257
   BROCKWAY WJ, 1971, J BIOL CHEM, V246, P4641
   Brown NJ, 2002, SEMIN NEPHROL, V22, P399, DOI 10.1053/snep.2002.34725
   Butterworth J, 1999, ANESTHESIOLOGY, V90, P1624, DOI 10.1097/00000542 199906000 00019
   Butterworth J, 2001, ANESTH ANALG, V92, P1384
   Castellino FJ, 2005, THROMB HAEMOSTASIS, V93, P647, DOI 10.1160/TH04 12 0842
   *CBS, 2008, 1000 LIV MONTH 60 MI
   Chan JCY, 2001, AM J PATHOL, V159, P1681, DOI 10.1016/S0002 9440(10)63015 5
   Coughlin SR, 2005, J THROMB HAEMOST, V3, P1800, DOI 10.1111/j.1538 7836.2005.01377.x
   Daci E, 1999, J BONE MINER RES, V14, P946, DOI 10.1359/jbmr.1999.14.6.946
   Daci E, 2000, J BONE MINER RES, V15, P1510, DOI 10.1359/jbmr.2000.15.8.1510
   *FDA, 2007, FDA REQ MARK SUSP TR
   Fergusson DA, 2008, NEW ENGL J MED, V358, P2319, DOI 10.1056/NEJMoa0802395
   Furlan F, 2007, J BONE MINER RES, V22, P1387, DOI 10.1359/JBMR.070516
   Gagne JJ, 2009, PHARMACOEPIDEM DR S, V18, P259, DOI 10.1002/pds.1714
   Henry DA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001886.pub2
   Henry D, 2009, CAN MED ASSOC J, V180, P183, DOI 10.1503/cmaj.081109
   Horodyski J, 1996, J SURG RES, V66, P115, DOI 10.1006/jsre.1996.0381
   Huffman NT, 2007, J BIOL CHEM, V282, P26002, DOI 10.1074/jbc.M701332200
   Jenkins G, 2008, INT J BIOCHEM CELL B, V40, P1068, DOI 10.1016/j.biocel.2007.11.026
   Keating E M, 1999, Instr Course Lect, V48, P655
   Mangano DT, 2007, JAMA J AM MED ASSOC, V297, P471, DOI 10.1001/jama.297.5.471
   Mangano DT, 2006, NEW ENGL J MED, V354, P353, DOI 10.1056/NEJMoa051379
   Mouton R, 2008, LANCET, V371, P475, DOI 10.1016/S0140 6736(08)60237 8
   Nordstrom SM, 2007, BONE, V41, P995, DOI 10.1016/j.bone.2007.08.020
   Oliver WC, 2004, J THORAC CARDIOV SUR, V127, P1670, DOI 10.1016/j.jtcvs.2003.10.029
   Peters DC, 1999, DRUGS, V57, P233, DOI 10.2165/00003495 199957020 00015
   PLOW EF, 1995, FASEB J, V9, P939, DOI 10.1096/fasebj.9.10.7615163
   Roth D, 2006, AM J PATHOL, V168, P670, DOI 10.2353/ajpath.2006.050372
   Rundle CH, 2008, CALCIFIED TISSUE INT, V83, P276, DOI 10.1007/s00223 008 9169 7
   Schneeweiss S, 2008, NEW ENGL J MED, V358, P771, DOI 10.1056/NEJMoa0707571
   Schwab W, 2001, HISTOCHEM CELL BIOL, V115, P317
   SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191
   Toriseva M, 2009, CELL MOL LIFE SCI, V66, P203, DOI 10.1007/s00018 008 8388 4
   Tumber A, 2003, J ENDOCRINOL, V178, P437, DOI 10.1677/joe.0.1780437
   Twite MD, 2008, PEDIATR ANESTH, V18, P809, DOI 10.1111/j.1460 9592.2008.02717.x
NR 39
TC 8
Z9 9
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0362 2436
EI 1528 1159
J9 SPINE
JI SPINE
PD APR 20
PY 2010
VL 35
IS 9
BP 1008
EP 1016
DI 10.1097/BRS.0b013e3181d3cffe
PG 9
WC Clinical Neurology; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology; Orthopedics
GA 590KG
UT WOS:000277223900013
PM 20407341
DA 2025 08 17
ER

PT J
AU Yang, H
   Gao, HC
   Wang, YJ
AF Yang, Hui
   Gao, Huichang
   Wang, Yingjun
TI Hollow hydroxyapatite microsphere: a promising carrier for bone tissue
   engineering
SO JOURNAL OF MICROENCAPSULATION
LA English
DT Article
DE Hydroxyapatite; mesoporous; alendronate; drug delivery; osteogenesis
ID CALCIUM PHOSPHATES; ALENDRONATE; DRUG; BISPHOSPHONATES; DIFFERENTIATION;
   OSTEOCLASTS; MECHANISMS; PARTICLES; RELEASE; FTIR
AB Hydroxyapatite (HA) microsphere with abundant ordered mesoporous and large hollow structure was prepared at hydrothermal condition with the aid of citrate. The obtained microsphere was performed as a drug delivery carrier to evaluate its drug loading/releasing behaviour using alendronate (AL) as a model drug. Results revealed that HA particles performed high AL loading capability (46.8wt % with respect to the powdered starting materials) and excellent AL releasing behaviour (sustained drug releasing profile without burst release). Besides, although a proliferation inhibition phenomenon was observed as HA and AL loading HA (HA AL) co cultured with mesenchymal stem cells (MSCs) at the initial stage, after prolonging co culture period, compared with HA and control group, HA AL promoted the cells' proliferation, meanwhile, it facilitated osteogenic differentiation of MSCs and enhanced the expression level of typical markers, all of that ensure HA microsphere is a promising carrier for bone repair.
C1 [Yang, Hui] Jiangxi Univ Sci & Technol, Sch Mat Sci & Engn, Ganzhou 341000, Peoples R China.
   [Gao, Huichang; Wang, Yingjun] South China Univ Technol, Sch Mat Sci & Engn, Guangzhou, Guangdong, Peoples R China.
C3 Jiangxi University of Science & Technology; South China University of
   Technology
RP Yang, H (通讯作者)，Jiangxi Univ Sci & Technol, Sch Mat Sci & Engn, Ganzhou 341000, Peoples R China.
EM yanghui_2521@163.com; imwangyj@163.com
RI ; yang, hui/E 8863 2018
OI Yang, Hui/0000 0001 8691 5110; 
FU Jiangxi University of Science and Technology Scientific Research
   Foundation [NSFJ2015 G11]; Scientific Research Starting Foundation
   [jxxjbs14011]; Youth Science Foundation of Jiangxi Province
   [20151BAB216007]
FX This research was supported by Jiangxi University of Science and
   Technology Scientific Research Foundation (NSFJ2015 G11), Scientific
   Research Starting Foundation (jxxjbs14011) and Youth Science Foundation
   of Jiangxi Province (20151BAB216007).
CR Allgrove J, 1997, ARCH DIS CHILD, V76, P73, DOI 10.1136/adc.76.1.73
   Boanini E, 2008, BIOMATERIALS, V29, P790, DOI 10.1016/j.biomaterials.2007.10.040
   Boanini E, 2007, ADV MATER, V19, P2499, DOI 10.1002/adma.200602497
   Cramer JA, 2007, OSTEOPOROSIS INT, V18, P1023, DOI 10.1007/s00198 006 0322 8
   Ebetino FH, 1998, REV CONTEMP PHARMACO, V9, P233
   ERIKSEN EF, 1993, J BONE MINER RES, V8, P127
   García Moreno C, 1998, BONE, V22, P233, DOI 10.1016/S8756 3282(97)00270 6
   Halvorsen YDC, 2001, TISSUE ENG, V7, P729, DOI 10.1089/107632701753337681
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Josse S, 2004, ADV MATER, V16, P1423, DOI 10.1002/adma.200306340
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   LeGeros RZ, 2002, CLIN ORTHOP RELAT R, P81
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Martins M, 2004, PREPARATION POROUS H
   Matsumoto T, 2004, BIOMATERIALS, V25, P3807, DOI 10.1016/j.biomaterials.2003.10.081
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Correia VDP, 2006, DENT TRAUMATOL, V22, P312, DOI 10.1111/j.1600 9657.2005.00434.x
   Panda RN, 2003, J PHYS CHEM SOLIDS, V64, P193, DOI 10.1016/S0022 3697(02)00257 3
   Rehman I, 1997, J MATER SCI MATER M, V8, P1, DOI 10.1023/A:1018570213546
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Shi XT, 2009, BIOMATERIALS, V30, P3996, DOI 10.1016/j.biomaterials.2009.04.021
   Shi XT, 2009, PHARM RES DORDR, V26, P422, DOI 10.1007/s11095 008 9759 0
   Slosarczyk A, 1997, CERAM INT, V23, P297, DOI 10.1016/S0272 8842(96)00016 8
   Uskokovic V, 2011, J BIOMED MATER RES B, V96B, P152, DOI 10.1002/jbm.b.31746
   Xiong Y, 2009, J INT MED RES, V37, P407, DOI 10.1177/147323000903700216
   Xue W, 2007, ACTA BIOMATER, V3, P1007, DOI 10.1016/j.actbio.2007.05.009
   Yang H, 2013, CRYSTENGCOMM, V15, P5760, DOI 10.1039/c3ce40710a
   Zhang CM, 2010, BIOMATERIALS, V31, P3374, DOI 10.1016/j.biomaterials.2010.01.044
   Zhao XY, 2013, CHEM ASIAN J, V8, P1313, DOI 10.1002/asia.201300142
   Zhu YJ, 2015, CHEM ASIAN J, V10, P284, DOI 10.1002/asia.201402715
NR 30
TC 15
Z9 15
U1 0
U2 77
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0265 2048
EI 1464 5246
J9 J MICROENCAPSUL
JI J. Microencapsul.
PD AUG
PY 2016
VL 33
IS 5
BP 421
EP 426
DI 10.1080/02652048.2016.1202347
PG 6
WC Chemistry, Applied; Engineering, Chemical; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Engineering; Pharmacology & Pharmacy
GA DX3QG
UT WOS:000384287200003
PM 27357859
DA 2025 08 17
ER

PT J
AU Neha, R
   Beulah, E
   Anusha, B
   Vasista, S
   Stephy, C
   Subeesh, V
AF Neha, Reddy
   Beulah, Elsa
   Anusha, Bellapu
   Vasista, Sharma
   Stephy, Chacko
   Subeesh, Viswam
TI Aromatase inhibitors associated osteonecrosis of jaw: signal refining to
   identify pseudo safety signals
SO INTERNATIONAL JOURNAL OF CLINICAL PHARMACY
LA English
DT Article
DE Aromatase inhibitors; Confounding factors; FDA adverse event reporting
   system; Jaw osteonecrosis; Pseudo signals; Signal detection
ID PHARMACOVIGILANCE
AB Background Signal generation through data mining algorithms is an innovative and emerging field in pharmacovigilance. Early detection of safety signals is important for public health safety. However, the possibility of generating pseudo signals should not be overlooked. Objective Our study aimed to identify potential signals of aromatase inhibitors associated Osteonecrosis of Jaw and assess the possibilities of the safety signal to be a pseudo signal/false positive in FDA Adverse Event Reporting System (FAERS). Setting Spontaneously reported data in FAERS database. Methods Data for this study were obtained from the public release of data in FAERS. OpenVigil, a pharmacovigilance analytical tool was used to access FAERS data. Reporting Odds Ratio (ROR) was used to assess the relation between the drug and adverse event. A value of ROR 1.96SE > 1, (SE standard error) was considered positive. Main outcome measure Signal strength. Results FAERS database had a total of 15,178 reports for Osteonecrosis of Jaw. Amongst which 617 reports were associated with aromatase inhibitors. Signal strength ROR (lower bound of the 95% CI) for letrozole, anastrozole and exemestane associated Osteonecrosis of Jaw without any background correction was 8.34, 6.64 and 15.14 respectively. Upon removing the reports of concomitantly administered drugs (bisphosphonates and denosumab), signal strength drastically decreased to 0.03, 0.36 and 0.47 for letrozole, anastrozole and exemestane respectively. The signal strength of bisphosphonates and denosumab associated Osteonecrosis of Jaw was not changed significantly upon removal of aromatase inhibitors. Conclusion Our study concluded that the signal generated for aromatase inhibitors associated Osteonecrosis of Jaw in FAERS database can be false positive. Careful background corrections with identification of those risk factors are imperative to exclude false positive results.
C1 [Neha, Reddy; Beulah, Elsa; Anusha, Bellapu; Vasista, Sharma; Stephy, Chacko; Subeesh, Viswam] MS Ramaiah Univ Appl Sci, Fac Pharm, Dept Pharm Practice, New BEL Rd, Bengaluru 560054, Karnataka, India.
C3 M. S. Ramaiah University of Applied Sciences
RP Subeesh, V (通讯作者)，MS Ramaiah Univ Appl Sci, Fac Pharm, Dept Pharm Practice, New BEL Rd, Bengaluru 560054, Karnataka, India.
EM subeeshkviswam@gmail.com
RI ; Viswam, Subeesh/J 5436 2019
OI Kulangara Viswam, Subeesh/0000 0002 1721 4553; Bellapu,
   Anusha/0000 0003 0605 1063
CR Ahmed I, 2010, BIOMETRICS, V66, P301, DOI 10.1111/j.1541 0420.2009.01262.x
   Almenoff J, 2005, DRUG SAFETY, V28, P981, DOI 10.2165/00002018 200528110 00002
   [Anonymous], SPONTANEOUS REPORTIN
   [Anonymous], 2002, SAFETY MED GUIDE DET
   Böhm R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157753
   Grigoriev I, 2014, PHARMACOEPIDEM DR S, V23, P795, DOI 10.1002/pds.3561
   Gupta Swati, 2013, Natl J Maxillofac Surg, V4, P151, DOI 10.4103/0975 5950.127643
   Hamadeh IS, 2015, CANCER TREAT REV, V41, P455, DOI 10.1016/j.ctrv.2015.04.007
   Härmark L, 2008, EUR J CLIN PHARMACOL, V64, P743, DOI 10.1007/s00228 008 0475 9
   Hauben M, 2003, DRUG SAFETY, V26, P159, DOI 10.2165/00002018 200326030 00003
   Hauben Manfred, 2005, Expert Opin Drug Saf, V4, P929, DOI 10.1517/14740338.4.5.929
   Lindquist M, 2000, DRUG SAFETY, V23, P533, DOI 10.2165/00002018 200023060 00004
   Meyboom RHB, 1997, DRUG SAFETY, V16, P355, DOI 10.2165/00002018 199716060 00002
   Nicolatou Galitis O, 2019, OR SURG OR MED OR PA, V127, P117, DOI 10.1016/j.oooo.2018.09.008
   Pal SN, 2013, DRUG SAFETY, V36, P75, DOI 10.1007/s40264 012 0014 6
   Poluzzi E, 2012, DATA MINING APPLICATIONS IN ENGINEERING AND MEDICINE, P265, DOI 10.5772/50095
   Pratt LA, 2009, NAT BIOTECHNOL, V27, P601, DOI 10.1038/nbt0709 601
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Subeesh V, 2017, ASIAN J PSYCHIATR, V30, P152, DOI 10.1016/j.ajp.2017.09.005
   Wilson AM, 2004, BRIT J CLIN PHARMACO, V57, P127, DOI 10.1046/j.1365 2125.2003.01968.x
NR 20
TC 13
Z9 15
U1 0
U2 12
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 2210 7703
EI 2210 7711
J9 INT J CLIN PHARM NET
JI Int. J. Clin. Phar,.
PD APR
PY 2020
VL 42
IS 2
BP 721
EP 727
DI 10.1007/s11096 020 01018 z
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA LI7XA
UT WOS:000529692500048
PM 32270377
DA 2025 08 17
ER

PT J
AU Gioia, R
   Panaroni, C
   Besio, R
   Palladini, G
   Merlini, G
   Giansanti, V
   Scovassi, IA
   Villani, S
   Villa, I
   Villa, A
   Vezzoni, P
   Tenni, R
   Rossi, A
   Marini, JC
   Forlino, A
AF Gioia, Roberta
   Panaroni, Cristina
   Besio, Roberta
   Palladini, Giovanni
   Merlini, Giampaolo
   Giansanti, Vincenzo
   Scovassi, Ivana A.
   Villani, Simona
   Villa, Isabella
   Villa, Anna
   Vezzoni, Paolo
   Tenni, Ruggero
   Rossi, Antonio
   Marini, Joan C.
   Forlino, Antonella
TI Impaired Osteoblastogenesis in a Murine Model of Dominant Osteogenesis
   Imperfecta: A New Target for Osteogenesis Imperfecta Pharmacological
   Therapy
SO STEM CELLS
LA English
DT Article
DE Osteogenesis imperfecta; Adult stem cell; Osteoblastogenesis;
   Adipogenesis; Adult stem cells differentiation; Autophagy
ID MESENCHYMAL STEM CELLS; MULTIPLE MYELOMA PATIENTS; MARROW STROMAL CELLS;
   IV MOUSE MODEL; IN VIVO; PROTEASOME INHIBITORS; TRANS DIFFERENTIATION;
   BONE; MICE; BORTEZOMIB
AB The molecular basis underlying the clinical phenotype in bone diseases is customarily associated with abnormal extracellular matrix structure and/or properties. More recently, cellular malfunction has been identified as a concomitant causative factor and increased attention has focused on stem cells differentiation. Classic osteogenesis imperfecta (OI) is a prototype for heritable bone dysplasias: it has dominant genetic transmission and is caused by mutations in the genes coding for collagen I, the most abundant protein in bone. Using the Brtl mouse, a well characterized knockin model for moderately severe dominant OI, we demonstrated an impairment in the differentiation of bone marrow progenitor cells toward osteoblasts. In mutant mesenchymal stem cells (MSCs), the expression of early (Runx2 and Sp7) and late (Col1a1 and Ibsp) osteoblastic markers was significantly reduced with respect to wild type (WT). Conversely, mutant MSCs generated more colony forming unit adipocytes compared to WT, with more adipocytes per colony, and increased number and size of triglyceride drops per cell. Autophagy upregulation was also demonstrated in mutant adult MSCs differentiating toward osteogenic lineage as consequence of endoplasmic reticulum stress due to mutant collagen retention. Treatment of the Brtl mice with the proteasome inhibitor Bortezomib ameliorated both osteoblast differentiation in vitro and bone properties in vivo as demonstrated by colony forming unit osteoblasts assay and peripheral quantitative computed tomography analysis on long bones, respectively. This is the first report of impaired MSC differentiation to osteoblasts in OI, and it identifies a new potential target for the pharmacological treatment of the disorder. STEM CELLS 2012;30:1465 1476
C1 [Gioia, Roberta; Panaroni, Cristina; Besio, Roberta; Palladini, Giovanni; Merlini, Giampaolo; Tenni, Ruggero; Rossi, Antonio; Forlino, Antonella] Univ Pavia, Dept Mol Med, Biochem Sect, I 27100 Pavia, Italy.
   [Villani, Simona] Univ Pavia, Dept Hlth Sci, Sect Med Stat & Epidemiol, I 27100 Pavia, Italy.
   [Panaroni, Cristina; Villa, Anna; Vezzoni, Paolo] CNR, Milan Unit, Ist Ric Genet & Biomed, I 20133 Milan, Italy.
   [Palladini, Giovanni; Merlini, Giampaolo] Fdn IRCCS Policlin San Matteo, Biotechnol Res Labs, Amyloidosis Res & Treatment Ctr, Pavia, Italy.
   [Giansanti, Vincenzo; Scovassi, Ivana A.] CNR, Inst Mol Genet, I 27100 Pavia, Italy.
   [Villa, Isabella] Ist Sci San Raffaele, Bone Metab Unit, I 20132 Milan, Italy.
   [Villa, Anna; Vezzoni, Paolo] Ist Clin Humanitas, Rozzano, Italy.
   [Marini, Joan C.] NICHD, Bone & Extracellular Matrix Branch, NIH, Bethesda, MD USA.
C3 University of Pavia; University of Pavia; Consiglio Nazionale delle
   Ricerche (CNR); Istituto di Ricerca Genetica e Biomedica (IRGB CNR);
   IRCCS Fondazione San Matteo; Consiglio Nazionale delle Ricerche (CNR);
   Istituto di Genetica Molecolare (IGM CNR); Vita Salute San Raffaele
   University; IRCCS Ospedale San Raffaele; IRCCS Humanitas Research
   Hospital; National Institutes of Health (NIH)   USA; NIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD)
RP Forlino, A (通讯作者)，Univ Pavia, Dept Mol Med, Biochem Sect, Via Taramelli 3 B, I 27100 Pavia, Italy.
EM aforlino@unipv.it
RI ; Besio, Roberta/AAQ 7151 2020; Vezzoni, Paolo/R 3416 2019; Merlini,
   Giampaolo/JOZ 1429 2023; Villani, Simona/HSH 3595 2023; Villa,
   Isabella/AAN 3790 2020; Scovassi, Anna/F 2458 2010; Forlino,
   Antonella/H 5385 2015; Palladini, Giovanni/G 1763 2010; Rossi,
   Antonio/E 9935 2012; Merlini, Giampaolo/A 3817 2008
OI /0000 0003 2517 6515; Villa, Anna/0000 0003 4428 9013; Scovassi, Anna
   Ivana/0000 0003 3484 9881; Palladini, Giovanni/0000 0001 5994 5138;
   Vezzoni, Paolo/0000 0002 6382 3923; Besio, Roberta/0000 0003 1430 2934;
   Merlini, Giampaolo/0000 0001 7680 3254
FU PRIN [2008XA48SC, 200999KRFW 002]; Fondazione Cariplo; Progetto Premiale
   CNR Invecchiamento; Progetto Regione Lombardia [cod. SAL/45]; Collegio
   Ghislieri, Pavia, Italy, fellowship
FX We thank Dr. Lupi A. for initial set up of MSCs culture and Dr. Vaghi P.
   (Centro Grandi Strumenti, University of Pavia, Italy) for technical
   assistance for Confocal Microscopy. This work was supported by PRIN 2008
   (2008XA48SC) to A. F., by PRIN 200999KRFW 002 to P. V., by Fondazione
   Cariplo 2007 to A. F. and P.V., by Progetto Premiale CNR Invecchiamento
   to P. V., and by Progetto Regione Lombardia (cod. SAL/45) "Dalla scienza
   dei materiali alla medicina molecolare" to A. F. G. V. was supported by
   Collegio Ghislieri, Pavia, Italy, fellowship.
CR Abdallah BM, 2012, BONE, V50, P540, DOI 10.1016/j.bone.2011.06.030
   Adams J, 2004, CANCER CELL, V5, P417, DOI 10.1016/S1535 6108(04)00120 5
   Anjos Afonso F, 2004, J CELL SCI, V117, P5655, DOI 10.1242/jcs.01488
   Baerga R, 2009, AUTOPHAGY, V5, P1118, DOI 10.4161/auto.5.8.9991
   Bamber BA, 2006, AUTOPHAGY, V2, P247, DOI 10.4161/auto.2746
   Bellantuono I, 2009, BBA MOL BASIS DIS, V1792, P364, DOI 10.1016/j.bbadis.2009.01.008
   Bi YM, 2005, J BIOL CHEM, V280, P30481, DOI 10.1074/jbc.M500573200
   Cecconi F, 2008, DEV CELL, V15, P344, DOI 10.1016/j.devcel.2008.08.012
   Chen D, 2011, CURR CANCER DRUG TAR, V11, P239, DOI 10.2174/156800911794519752
   Chen XD, 2002, J BONE MINER RES, V17, P331, DOI 10.1359/jbmr.2002.17.2.331
   Crossno JT, 2006, J CLIN INVEST, V116, P3220, DOI 10.1172/JCI28510
   Evans KD, 2003, BONE, V32, P268, DOI 10.1016/S8756 3282(02)00974 2
   Forlino A, 1999, J BIOL CHEM, V274, P37923, DOI 10.1074/jbc.274.53.37923
   Forlino A, 2007, MATRIX BIOL, V26, P604, DOI 10.1016/j.matbio.2007.06.005
   Forlino A, 2007, PROTEOMICS, V7, P1877, DOI 10.1002/pmic.200600919
   Forlino A, 2011, NAT REV ENDOCRINOL, V7, P540, DOI 10.1038/nrendo.2011.81
   Genin E, 2010, CURR TOP MED CHEM, V10, P232, DOI 10.2174/156802610790725515
   Gimble JM, 2006, J CELL BIOCHEM, V98, P251, DOI 10.1002/jcb.20777
   Giuliani N, 2007, BLOOD, V110, P334, DOI 10.1182/blood 2006 11 059188
   Harslof T, 2011, J CLIN ENDOCR METAB, V96, P1541, DOI 10.1210/jc.2010 2077
   Hausman GJ, 2006, J CLIN INVEST, V116, P3103, DOI 10.1172/JCI30666
   Heider U, 2009, EUR J HAEMATOL, V82, P31, DOI 10.1111/j.1600 0609.2008.01164.x
   Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399
   Horwitz EM, 2001, BLOOD, V97, P1227, DOI 10.1182/blood.V97.5.1227
   Ishida Y, 2011, METHOD ENZYMOL, V499, P167, DOI 10.1016/B978 0 12 386471 0.00009 2
   Ishida Y, 2009, MOL BIOL CELL, V20, P2744, DOI 10.1091/mbc.E08 11 1092
   Kassem M, 2008, ARCH BIOCHEM BIOPHYS, V473, P183, DOI 10.1016/j.abb.2008.03.028
   Kilian KA, 2010, P NATL ACAD SCI USA, V107, P4872, DOI 10.1073/pnas.0903269107
   Kim M, 2008, EMBO REP, V9, P878, DOI 10.1038/embor.2008.125
   Kozloff KM, 2004, J BONE MINER RES, V19, P614, DOI 10.1359/JBMR.040111
   Krings A, 2012, BONE, V50, P546, DOI 10.1016/j.bone.2011.06.016
   Marini JC, 2007, HUM MUTAT, V28, P209, DOI 10.1002/humu.20429
   Meirelles LD, 2003, BRIT J HAEMATOL, V123, P702, DOI 10.1046/j.1365 2141.2003.04669.x
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Mukherjee S, 2008, J CLIN INVEST, V118, P491, DOI [10.1172/JCI33102, 10.1172/JC133102]
   Ozaki S, 2007, INT J HEMATOL, V86, P180, DOI 10.1532/IJH97.07030
   Panaroni C, 2009, BLOOD, V114, P459, DOI 10.1182/blood 2008 12 195859
   Post S, 2008, BONE, V43, P32, DOI 10.1016/j.bone.2008.03.011
   Quarto N, 2006, TISSUE ENG, V12, P1405, DOI 10.1089/ten.2006.12.1405
   SANGUINETTI C, 1990, J BONE JOINT SURG BR, V72, P475, DOI 10.1302/0301 620X.72B3.2187879
   Savopoulos C, 2011, HIPPOKRATIA, V15, P18
   SILLENCE DO, 1979, J MED GENET, V16, P101, DOI 10.1136/jmg.16.2.101
   Singh R, 2009, J CLIN INVEST, V119, P3329, DOI 10.1172/JCI39228
   Sun SK, 2003, STEM CELLS, V21, P527, DOI 10.1634/stemcells.21 5 527
   Taipaleenmäki H, 2011, EXP CELL RES, V317, P745, DOI 10.1016/j.yexcr.2010.12.015
   Terpos E, 2010, ANN ONCOL, V21, P1561, DOI 10.1093/annonc/mdq259
   Terpos E, 2011, INT J CANCER, V2011, P27342, DOI [10.1002/ijc27342, DOI 10.1002/IJC27342]
   Tornvig L, 2001, CALCIFIED TISSUE INT, V69, P46, DOI 10.1007/s002230020018
   Uveges TE, 2009, J BONE MINER RES, V24, P849, DOI [10.1359/jbmr.081238, 10.1359/JBMR.081238]
   Uveges TE, 2008, J BONE MINER RES, V23, P1983, DOI 10.1359/JBMR.080804
   Vanky P, 1998, BONE, V22, P331, DOI 10.1016/S8756 3282(97)00286 X
   Vanleene M, 2011, BLOOD, V117, P1053, DOI 10.1182/blood 2010 05 287565
   Xu Y, 2008, NATURE, V453, P338, DOI 10.1038/nature07042
   Zangari M, 2012, CANC TREAT REV, DOI [10.1016/j.ctvr.2011.12.007, DOI 10.1016/J.CTVR.2011.12.007]
   Zangari M, 2011, HAEMATOL HEMATOL J, V96, P333, DOI 10.3324/haematol.2010.031302
   Zhang Y, 2009, P NATL ACAD SCI USA, V106, P19860, DOI 10.1073/pnas.0906048106
NR 56
TC 62
Z9 72
U1 0
U2 33
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1066 5099
J9 STEM CELLS
JI Stem Cells
PD JUL
PY 2012
VL 30
IS 7
BP 1465
EP 1476
DI 10.1002/stem.1107
PG 12
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA 961PB
UT WOS:000305477000015
PM 22511244
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Zheng, LW
   Lan, CN
   Kong, Y
   Liu, LH
   Fan, YM
   Zhang, CJ
AF Zheng, Li Wen
   Lan, Chun Na
   Kong, Ying
   Liu, Li Hong
   Fan, Yong Mei
   Zhang, Chang Jie
TI Exosomal miR 150 derived from BMSCs inhibits TNF α mediated osteoblast
   apoptosis in osteonecrosis of the femoral head by GREM1/NF κB signaling
SO REGENERATIVE MEDICINE
LA English
DT Article
DE exosomes; GREM1/NF kappa B; miR 150; osteonecrosis of the femoral head
ID STEROID INDUCED OSTEONECROSIS; GLUCOCORTICOID INDUCED OSTEONECROSIS;
   AUTOPHAGY; INTERPLAY; PATHWAYS; GREMLIN; INJURY
AB Aim: The purpose of this study was to investigate the functions of exosomal miR 150 derived from bone marrow mesenchymal stem cells in osteonecrosis of the femoral head (ONFH). Materials & methods: Cell viability and apoptosis were detected using 3 (4,5 dimethylthiazol 2 yl) 2,5 diphenyltetrazolium bromide assay and flow cytometry. Alizarin red staining was performed to detect calcium deposits. A rat model was established to assess the effects of exosomal miR 150 on ONFH in vivo. Results: Exosomes or exosomal miR 150 derived from bone marrow mesenchymal stem cells inhibited TNF alpha induced osteoblast apoptosis and promoted osteogenic differentiation and autophagy. Exosomal miR 150 suppressed apoptosis and induced autophagy in TNF alpha treated osteoblasts by regulating the GREM1/NF kappa B axis. Exosomal miR 150 also improved the pathological features of ONFH in vivo. Conclusion: Exosomal miR 150 alleviates ONFH by mediating the GREM1/NF kappa B axis. This study provides a potential therapeutic strategy for ONFH.
   Plain language summary: Osteonecrosis of the femoral head (ONFH) is an orthopedic disease that frequently occurs in young adults aged less than 50 years. At present, there is no widely accepted curative surgical procedure or drug therapy for this disease. Bone marrow mesenchymal stem cells (BMSCs) play a key role in the progression of ONFH. BMSC derived exosomes refer to small membrane vesicles that can transfer proteins, miRNAs and mRNAs, which are closely related to the development of ONFH. This study showed that exosomal miRNA 150 derived from BMSCs inhibited TNF alpha induced osteoblast apoptosis and promoted osteogenic differentiation and autophagy by regulating the GREM1/NF kappa B axis. In addition, exosomal miRNA 150 alleviated the symptoms of ONFH in rats.
   [GRAPHICS]
   .
C1 [Zheng, Li Wen; Lan, Chun Na; Kong, Ying; Liu, Li Hong; Fan, Yong Mei; Zhang, Chang Jie] Cent South Univ, Xiangya Hosp 2, Dept Rehabil, Changsha 410011, Hunan, Peoples R China.
C3 Central South University
RP Zheng, LW (通讯作者)，Cent South Univ, Xiangya Hosp 2, Dept Rehabil, Changsha 410011, Hunan, Peoples R China.
EM zhengliwen@csu.edu.cn
RI Lan, Chunna/T 1309 2017
CR Basal O, 2018, BOSNIAN J BASIC MED, V18, P352, DOI 10.17305/bjbms.2018.3259
   Boontanapibul K, 2021, J ARTHROPLASTY, V36, P1879, DOI 10.1016/j.arth.2021.01.075
   Chang SH, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09491 5
   Chen DL, 2021, AM J TRANSL RES, V13, P7574
   Chen XD, 2021, J CELL PHYSIOL, V236, P4273, DOI 10.1002/jcp.30051
   Church RH, 2015, BIOCHEM J, V466, P55, DOI 10.1042/BJ20140771
   Dai WY, 2021, INT J MOL MED, V47, P607, DOI 10.3892/ijmm.2020.4827
   Dong S, 2020, AM J TRANSL RES, V12, P6853
   Fang SH, 2019, DRUG DES DEV THER, V13, P45, DOI 10.2147/DDDT.S178698
   Gu CX, 2016, SCI REP UK, V6, DOI 10.1038/srep38491
   Guo YF, 2021, J CELL PHYSIOL, V236, P4152, DOI 10.1002/jcp.30111
   Huang SX, 2020, J CELL MOL MED, V24, P11512, DOI 10.1111/jcmm.15766
   Jiang SP, 2021, BIOACT MATER, V6, P2711, DOI 10.1016/j.bioactmat.2021.01.031
   Jiang YX, 2021, J BIOL CHEM, V296, DOI 10.1016/j.jbc.2021.100287
   Jie K, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02246 3
   Jin SY, 2020, J ORTHOP RES, V38, P2020, DOI 10.1002/jor.24619
   Khokha MK, 2003, NAT GENET, V34, P303, DOI 10.1038/ng1178
   Kong LC, 2020, INT J BIOL SCI, V16, P655, DOI 10.7150/ijbs.38713
   Kuroda Y, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02288 7
   Lavoz C, 2018, CLIN SCI, V132, P1097, DOI 10.1042/CS20171553
   Lavoz C, 2015, J PATHOL, V236, P407, DOI 10.1002/path.4537
   Lawrence Toby, 2009, Cold Spring Harb Perspect Biol, V1, pa001651, DOI 10.1101/cshperspect.a001651
   Lee SW, 2021, BMC MUSCULOSKEL DIS, V22, DOI 10.1186/s12891 021 04047 5
   Li DH, 2022, ADV HEALTHC MATER, V11, DOI 10.1002/adhm.202101412
   Li DH, 2018, BIOMATER SCI UK, V6, P519, DOI 10.1039/c7bm00975e
   Li L, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01991 2
   Liao W, 2019, CLIN SCI, V133, P1955, DOI 10.1042/CS20181064
   Liu HN, 2021, CONNECT TISSUE RES, V62, P325, DOI 10.1080/03008207.2020.1736054
   Mao GC, 2021, ACTA PHARMACOL SIN, V42, P2082, DOI 10.1038/s41401 021 00625 4
   Mao Z, 2021, ORTHOP SURG, V13, P573, DOI 10.1111/os.12883
   Mitsuzawa S, 2022, J ORTHOP SCI, V27, P395, DOI 10.1016/j.jos.2020.12.014
   Nan K, 2021, ANN NY ACAD SCI, V1503, P23, DOI 10.1111/nyas.14555
   Niedermair T, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.615520
   Park A, 2019, ARCH TOXICOL, V93, P1239, DOI 10.1007/s00204 019 02424 7
   Qiu F, 2020, CEREB CORTEX, V30, P2229, DOI 10.1093/cercor/bhz236
   Qiu M, 2021, HUM GENE THER, V32, P717, DOI 10.1089/hum.2020.005
   Qu Y, 2019, INFLAMMATION, V42, P1491, DOI 10.1007/s10753 019 01012 2
   Sun ZB, 2019, CURR PHARM DESIGN, V25, P4806, DOI 10.2174/1381612825666190930094019
   Tang J, 2021, CURR MOL PHARMACOL, V14, P914, DOI 10.2174/1874467214666210301121020
   Tang JS, 2021, J MOL HISTOL, V52, P279, DOI 10.1007/s10735 020 09947 9
   Tian G, 2023, J PLAST SURG HAND SU, V57, P71, DOI 10.1080/2000656X.2021.1981352
   Trocoli A, 2011, AM J CANCER RES, V1, P629
   Wang A, 2018, GENE, V671, P103, DOI 10.1016/j.gene.2018.05.091
   Wang CQ, 2021, BIOMATER SCI UK, V9, P3005, DOI 10.1039/d0bm02071k
   Wang Y, 2021, J ADV RES, V28, P231, DOI 10.1016/j.jare.2020.07.007
   Wen T, 2021, CELL CYCLE, V20, P256, DOI 10.1080/15384101.2020.1863682
   Wu XJ, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/8140595
   Xu GP, 2021, BIOL TRACE ELEM RES, V199, P3781, DOI 10.1007/s12011 020 02508 x
   Xu HJ, 2019, FASEB J, V33, P8055, DOI 10.1096/fj.201801618RRR
   Xu HX, 2021, STEM CELL TRANSL MED, V10, P781, DOI 10.1002/sctm.20 0346
   Yu HC, 2019, J CELL MOL MED, V23, P7320, DOI 10.1111/jcmm.14589
   Yuan N, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/6655225
   Zhang C, 2020, J CELL MOL MED, V24, P9605, DOI 10.1111/jcmm.15395
   Zhang SY, 2021, KAOHSIUNG J MED SCI, V37, P1089, DOI 10.1002/kjm2.12426
   Zhang YX, 2021, BIOL DIRECT, V16, DOI 10.1186/s13062 021 00294 7
   Zhang YL, 2016, INT J BIOL SCI, V12, P776, DOI 10.7150/ijbs.15248
   Zhao JQ, 2021, INT J MED SCI, V18, P1382, DOI 10.7150/ijms.50919
   Zhao J, 2020, MOL MED REP, V21, P533, DOI 10.3892/mmr.2019.10866
   Zhu D., 2021, PHYTOTHER RES
NR 59
TC 8
Z9 10
U1 1
U2 22
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1746 0751
EI 1746 076X
J9 REGEN MED
JI Regen. Med.
PD OCT
PY 2022
VL 17
IS 10
BP 739
EP 753
DI 10.2217/rme 2021 0169
EA AUG 2022
PG 15
WC Cell & Tissue Engineering; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering
GA 4L3FT
UT WOS:000837084300001
PM 35938412
DA 2025 08 17
ER

PT J
AU Richardson, KK
   Ling, W
   Krager, K
   Fu, Q
   Byrum, SD
   Pathak, R
   Aykin Burns, N
   Kim, H
AF Richardson, Kimberly K.
   Ling, Wen
   Krager, Kimberly
   Fu, Qiang
   Byrum, Stephanie D.
   Pathak, Rupak
   Aykin Burns, Nukhet
   Kim, Ha Neui
TI Ionizing Radiation Activates Mitochondrial Function in Osteoclasts and
   Causes Bone Loss in Young Adult Male Mice
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE ionizing radiation; bone loss; bone resorption; osteoclast;
   mitochondria; Sirtuin 3
ID BODY IRRADIATION; CANCELLOUS BONE; BLOOD LEAD; EXPRESSION; HEALTH;
   THERAPY; CELLS; SUPPRESSION; DEFICIENCY; LONGEVITY
AB The damaging effects of ionizing radiation (IR) on bone mass are well documented in mice and humans and are most likely due to increased osteoclast number and function. However, the mechanisms leading to inappropriate increases in osteoclastic bone resorption are only partially understood. Here, we show that exposure to multiple fractions of low doses (10 fractions of 0.4 Gy total body irradiation [TBI]/week, i.e., fractionated exposure) and/or a single exposure to the same total dose of 4 Gy TBI causes a decrease in trabecular, but not cortical, bone mass in young adult male mice. This damaging effect was associated with highly activated bone resorption. Both osteoclast differentiation and maturation increased in cultures of bone marrow derived macrophages from mice exposed to either fractionated or singular TBI. IR also increased the expression and enzymatic activity of mitochondrial deacetylase Sirtuin 3 (Sirt3) an essential protein for osteoclast mitochondrial activity and bone resorption in the development of osteoporosis. Osteoclast progenitors lacking Sirt3 exposed to IR exhibited impaired resorptive activity. Taken together, targeting impairment of osteoclast mitochondrial activity could be a novel therapeutic strategy for IR induced bone loss, and Sirt3 is likely a major mediator of this effect.
C1 [Richardson, Kimberly K.; Ling, Wen; Fu, Qiang; Kim, Ha Neui] Univ Arkansas Med Sci, Dept Internal Med, Div Endocrinol & Metab, Ctr Musculoskeletal Dis Res, Little Rock, AR 72205 USA.
   [Richardson, Kimberly K.; Ling, Wen; Fu, Qiang; Kim, Ha Neui] Univ Arkansas Med Sci, Dept Internal Med, Div Endocrinol & Metab, Ctr Osteoporosis & Metab Bone Dis, Little Rock, AR 72205 USA.
   [Krager, Kimberly; Pathak, Rupak; Aykin Burns, Nukhet] Univ Arkansas Med Sci, Dept Pharmaceut Sci, Div Radiat Hlth, Little Rock, AR 72205 USA.
   [Byrum, Stephanie D.] Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA.
C3 University of Arkansas System; University of Arkansas Medical Sciences;
   University of Arkansas System; University of Arkansas Medical Sciences;
   University of Arkansas System; University of Arkansas Medical Sciences;
   University of Arkansas System; University of Arkansas Medical Sciences
RP Kim, H (通讯作者)，Univ Arkansas Med Sci, Dept Internal Med, Div Endocrinol & Metab, Ctr Musculoskeletal Dis Res, Little Rock, AR 72205 USA.; Kim, H (通讯作者)，Univ Arkansas Med Sci, Dept Internal Med, Div Endocrinol & Metab, Ctr Osteoporosis & Metab Bone Dis, Little Rock, AR 72205 USA.
EM KKRichardson@uams.edu; WLing@uams.edu; KJKrager@uams.edu; QFu@uams.edu;
   SBYRUM@uams.edu; RPathak@uams.edu; NAykinburns@uams.edu; HKim@uams.edu
RI ; Fu, Qiang/W 5836 2019
OI Byrum, Stephanie/0000 0002 1783 3610; KIM, HA NEUI/0000 0003 2498 6700;
   Aykin Burns, Nukhet/0000 0001 8574 4102; Pathak,
   Rupak/0000 0002 6239 301X
CR Almeida M, 2017, PHYSIOL REV, V97, P135, DOI 10.1152/physrev.00033.2015
   Alwood JS, 2010, BONE, V47, P248, DOI 10.1016/j.bone.2010.05.004
   Alwood Joshua S, 2012, J Aging Res, V2012, P481983, DOI 10.1155/2012/481983
   Alwood JS, 2015, J INTERF CYTOK RES, V35, P480, DOI 10.1089/jir.2014.0152
   Bartell SM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4773
   Cantó C, 2015, CELL METAB, V22, P31, DOI 10.1016/j.cmet.2015.05.023
   Chandra A, 2019, BONE, V120, P423, DOI 10.1016/j.bone.2018.12.006
   Chandra A, 2018, FASEB J, V32, P52, DOI 10.1096/fj.201700375R
   Chandra A, 2017, J BONE MINER RES, V32, P360, DOI 10.1002/jbmr.2996
   Chandra A, 2015, J BIOL CHEM, V290, P157, DOI 10.1074/jbc.M114.608158
   Charles JF, 2014, TRENDS MOL MED, V20, P449, DOI 10.1016/j.molmed.2014.06.001
   Costa S, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00587
   Fang F, 2017, AM J EPIDEMIOL, V186, P1057, DOI 10.1093/aje/kwx176
   Fang F, 2010, AM J EPIDEMIOL, V171, P1126, DOI 10.1093/aje/kwq063
   Farr JN, 2018, J BONE MINER RES, V33, P1568, DOI 10.1002/jbmr.3564
   Hadji P, 2012, CANCER TREAT REV, V38, P798, DOI 10.1016/j.ctrv.2012.02.008
   Han KH, 2014, BONE, V61, P91, DOI 10.1016/j.bone.2013.12.032
   Higham CE, 2015, CLIN ONCOL UK, V27, P668, DOI 10.1016/j.clon.2015.07.006
   Hirschey MD, 2010, NATURE, V464, P121, DOI 10.1038/nature08778
   HOLTROP ME, 1977, CLIN ORTHOP RELAT R, P177
   Hopewell JW, 2003, MED PEDIATR ONCOL, V41, P208, DOI 10.1002/mpo.10338
   Houtkooper RH, 2013, NATURE, V497, P451, DOI 10.1038/nature12188
   Hui SK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042668
   Ishii T, 2013, J BONE MINER METAB, V31, P613, DOI 10.1007/s00774 013 0482 5
   Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037
   Khosla S, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031211
   Kim HN, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222111711
   Kim HN, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 68890 7
   Kim HN, 2017, AGING CELL, V16, P693, DOI 10.1111/acel.12597
   Kincaid B, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00048
   Kondo H, 2010, J APPL PHYSIOL, V108, P152, DOI 10.1152/japplphysiol.00294.2009
   Kondo H, 2009, RADIAT RES, V171, P283, DOI 10.1667/RR1463.1
   Li QQ, 2021, BONE, V144, DOI 10.1016/j.bone.2020.115827
   Ling W, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.146728
   Ho L, 2017, ENDOCRINOLOGY, V158, P2741, DOI 10.1210/en.2016 1739
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Manolagas SC, 2013, NAT REV ENDOCRINOL, V9, P699, DOI 10.1038/nrendo.2013.179
   Marcovici PA, 2007, PEDIATR RADIOL, V37, P301, DOI 10.1007/s00247 006 0382 0
   Martin Millan M, 2010, MOL ENDOCRINOL, V24, P323, DOI 10.1210/me.2009 0354
   Mohrin M, 2015, SCIENCE, V347, P1374, DOI 10.1126/science.aaa2361
   Mouchiroud L, 2013, CELL, V154, P430, DOI 10.1016/j.cell.2013.06.016
   Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261
   Nuttall JM, 2014, AUTOPHAGY, V10, P835, DOI 10.4161/auto.28259
   Orwoll ES, 2013, J BONE MINER RES, V28, P1243, DOI 10.1002/jbmr.1948
   Pellegrino MW, 2013, BBA MOL CELL RES, V1833, P410, DOI 10.1016/j.bbamcr.2012.02.019
   Piemontese M, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93771
   PROBERT JC, 1975, RADIOLOGY, V114, P155, DOI 10.1148/114.1.155
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Samartzis D, 2011, J BONE JOINT SURG AM, V93A, P1008, DOI 10.2106/JBJS.J.00256
   SCOTT BL, 1956, ANAT RECORD, V126, P465, DOI 10.1002/ar.1091260405
   Seo JG, 2007, AGING CELL, V6, P405, DOI 10.1111/j.1474 9726.2007.00291.x
   Szymczyk KH, 2004, BONE, V34, P148, DOI 10.1016/j.bone.2003.09.003
   Turner RT, 2013, BONE, V57, P164, DOI 10.1016/j.bone.2013.08.002
   Ucer S, 2017, J BONE MINER RES, V32, P560, DOI 10.1002/jbmr.3014
   Wallace DC, 2015, CELL, V163, P33, DOI 10.1016/j.cell.2015.08.067
   Wang YY, 2021, INT J MOL MED, V47, DOI 10.3892/ijmm.2021.4909
   Willey JS, 2008, RADIAT RES, V170, P388, DOI 10.1667/RR1388.1
   Willey JS, 2011, CLIN REV BONE MINER, V9, P54, DOI 10.1007/s12018 011 9092 8
   Willey Jeffrey S, 2011, Gravit Space Biol Bull, V25, P14
   Willey JS, 2010, BONE, V46, P101, DOI 10.1016/j.bone.2009.09.002
   Winnik S, 2015, EUR HEART J, V36, P3404, DOI 10.1093/eurheartj/ehv290
   Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/NMETH.1322, 10.1038/nmeth.1322]
   Wissing MD, 2015, CURR OSTEOPOROS REP, V13, P140, DOI 10.1007/s11914 015 0266 z
   Wright LE, 2015, J BONE MINER RES, V30, P1268, DOI 10.1002/jbmr.2458
   Yang W, 2016, CELL, V167, P985, DOI 10.1016/j.cell.2016.10.016
   Yaprak G, 2018, BMC CANCER, V18, DOI 10.1186/s12885 018 4899 z
   Yumoto K, 2010, RADIAT RES, V173, P494, DOI 10.1667/RR1754.1
   Zhang J, 2020, BIOL TRACE ELEM RES, V196, P502, DOI 10.1007/s12011 019 01929 7
   Zhang J, 2018, CONNECT TISSUE RES, V59, P509, DOI 10.1080/03008207.2018.1439482
NR 70
TC 17
Z9 18
U1 2
U2 10
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JAN
PY 2022
VL 23
IS 2
AR 675
DI 10.3390/ijms23020675
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA YL6RT
UT WOS:000746017100001
PM 35054859
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Takamatsu, A
   Ohkawara, B
   Ito, M
   Masuda, A
   Sakai, T
   Ishiguro, N
   Ohno, K
AF Takamatsu, Akira
   Ohkawara, Bisei
   Ito, Mikako
   Masuda, Akio
   Sakai, Tadahiro
   Ishiguro, Naoki
   Ohno, Kinji
TI Verapamil Protects against Cartilage Degradation in Osteoarthritis by
   Inhibiting Wnt/β Catenin Signaling
SO PLOS ONE
LA English
DT Article
ID BETA CATENIN; ARTICULAR CARTILAGE; CHONDROCYTE DIFFERENTIATION; HIP
   OSTEOARTHRITIS; JOINT DEGENERATION; HYALURONAN EXPORT; GROWTH; PATHWAY;
   SOX9; EXPRESSION
AB In past years, the canonical Wnt/beta catenin signaling pathway has emerged as a critical regulator of cartilage development and homeostasis. FRZB, a soluble antagonist of Wnt signaling, has been studied in osteoarthritis (OA) animal models and OA patients as a modulator of Wnt signaling. We screened for FDA approved drugs that induce FRZB expression and suppress Wnt/beta catenin signaling. We found that verapamil, a widely prescribed L type calcium channel blocker, elevated FRZB expression and suppressed Wnt/beta catenin signaling in human OA chondrocytes. Expression and nuclear translocation of beta catenin was attenuated by verapamil in OA chondrocytes. Lack of the verapamil effects in LiCl treated and FRZB downregulated OA chondrocytes also suggested that verpamil suppressed Wnt signaling by inducing FRZB. Verapamil enhanced gene expressions of chondrogenic markers of ACAN encoding aggrecan, COL2A1 encoding collagen type II alpha 1, and SOX9, and suppressed Wnt responsive AXIN2 and MMP3 in human OA chondrocytes. Verapamil ameliorated Wnt3A induced proteoglycan loss in chondrogenically differentiated ATDC5 cells. Verapamil inhibited hypertrophic differentiation of chondrocytes in the explant culture of mouse tibiae. Intraarticular injection of verapamil inhibited OA progression as well as nuclear localizations of b catenin in a rat OA model. We propose that verapamil holds promise as a potent therapeutic agent for OA by upregulating FRZB and subsequently downregulating Wnt/beta catenin signaling.
C1 [Takamatsu, Akira; Ohkawara, Bisei; Ito, Mikako; Masuda, Akio; Ohno, Kinji] Nagoya Univ, Grad Sch Med, Ctr Neurol Dis & Canc, Div Neurogenet, Nagoya, Aichi 4648601, Japan.
   [Takamatsu, Akira; Sakai, Tadahiro; Ishiguro, Naoki] Nagoya Univ, Grad Sch Med, Dept Orthopaed Surg, Nagoya, Aichi 4648601, Japan.
C3 Nagoya University; Nagoya University
RP Ohno, K (通讯作者)，Nagoya Univ, Grad Sch Med, Ctr Neurol Dis & Canc, Div Neurogenet, Nagoya, Aichi 4648601, Japan.
EM ohnok@med.nagoya u.ac.jp
RI Ishiguro, Naoki/I 1563 2012; Ito, Mikako/I 1941 2012; Masuda,
   Akio/H 6323 2012; Ohno, Kinji/H 4020 2012
OI Ohkawara, Bisei/0000 0002 1987 458X; Ohno, Kinji/0000 0002 1529 2750
FU Ministry of Education, Culture, Sports, Science and Technology (MEXT);
   Ministry of Health, Labor and Welfare (MHLW) of Japan; Hori Sciences &
   Arts foundation; Grants in Aid for Scientific Research [24659672,
   23710253] Funding Source: KAKEN
FX This work was supported by Grants in Aid from the Ministry of Education,
   Culture, Sports, Science and Technology (MEXT), the Ministry of Health,
   Labor and Welfare (MHLW) of Japan, and the Hori Sciences & Arts
   foundation. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Abbott A, 2002, NATURE, V417, P109, DOI 10.1038/417109a
   Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802
   Akiyama H, 2004, GENE DEV, V18, P1072, DOI 10.1101/gad.1171104
   Beck E, 2005, AM FAM PHYSICIAN, V71, P717
   Bian Y, 2009, HUM MOL GENET, V18, P1229, DOI 10.1093/hmg/ddp023
   Chan BY, 2011, OSTEOARTHR CARTILAGE, V19, P874, DOI 10.1016/j.joca.2011.04.014
   Corrêa S, 2012, BMC CANCER, V12, DOI 10.1186/1471 2407 12 303
   De Luca F, 2001, ENDOCRINOLOGY, V142, P430, DOI 10.1210/en.142.1.430
   Furman BD, 2007, J ORTHOP RES, V25, P578, DOI 10.1002/jor.20331
   HAMERMAN D, 1986, J CELL PHYSIOL, V127, P317, DOI 10.1002/jcp.1041270220
   Hens JR, 2005, J BONE MINER RES, V20, P1103, DOI 10.1359/JBMR.050210
   Hoang B, 1996, J BIOL CHEM, V271, P26131, DOI 10.1074/jbc.271.42.26131
   Hunter DJ, 2006, BMJ BRIT MED J, V332, P639, DOI 10.1136/bmj.332.7542.639
   Hwang SG, 2005, J BIOL CHEM, V280, P12758, DOI 10.1074/jbc.M413367200
   Inada M, 2004, P NATL ACAD SCI USA, V101, P17192, DOI 10.1073/pnas.0407788101
   Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172 1183.2002
   Kamekura S, 2005, OSTEOARTHR CARTILAGE, V13, P632, DOI 10.1016/j.joca.2005.03.004
   Kumar D, 2009, MOL CELL BIOL, V29, P4262, DOI 10.1128/MCB.01779 08
   Lane NE, 2007, ARTHRITIS RHEUM US, V56, P3319, DOI 10.1002/art.22867
   Lawrence RC, 2008, ARTHRITIS RHEUM, V58, P26, DOI 10.1002/art.23176
   Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718
   Leijten JCH, 2012, ARTHRITIS RHEUM US, V64, P3302, DOI 10.1002/art.34535
   Little CB, 2010, CURR DRUG TARGETS, V11, P561
   Lories RJU, 2007, ARTHRITIS RHEUM US, V56, P4095, DOI 10.1002/art.23137
   Loughlin J, 2004, P NATL ACAD SCI USA, V101, P9757, DOI 10.1073/pnas.0403456101
   MANKIN HJ, 1971, J BONE JOINT SURG AM, VA 53, P523, DOI 10.2106/00004623 197153030 00009
   Nalesso G, 2011, J CELL BIOL, V193, P551, DOI 10.1083/jcb.201011051
   Ouskova G, 2004, GLYCOBIOLOGY, V14, P931, DOI 10.1093/glycob/cwh115
   Prehm P, 2004, BIOCHEM PHARMACOL, V68, P1401, DOI 10.1016/j.bcp.2004.06.017
   Prehm P, 2005, J RHEUMATOL, V32, P690
   Ryu JH, 2002, DEVELOPMENT, V129, P5541, DOI 10.1242/dev.00110
   Saito T, 2010, NAT MED, V16, P678, DOI 10.1038/nm.2146
   Stewart AJ, 2006, J CELL PHYSIOL, V206, P435, DOI 10.1002/jcp.20481
   Strazielle N, 2013, MOL PHARMACEUT, V10, P1473, DOI 10.1021/mp300518e
   TAKIGAWA M, 1989, CANCER RES, V49, P3996
   Thomas RS, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3536
   Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613
   Weng LH, 2012, ARTHRITIS RHEUM US, V64, P3267, DOI 10.1002/art.34602
   Yan W, 2004, BONE, V35, P1273, DOI 10.1016/j.bone.2004.09.009
   Yuasa T, 2008, LAB INVEST, V88, P264, DOI 10.1038/labinvest.3700747
   Zhu M, 2008, ARTHRITIS RHEUM US, V58, P2053, DOI 10.1002/art.23614
   Zhu M, 2009, J BONE MINER RES, V24, P12, DOI [10.1359/jbmr.080901, 10.1359/JBMR.080901]
NR 42
TC 71
Z9 82
U1 2
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD MAR 21
PY 2014
VL 9
IS 3
AR e92699
DI 10.1371/journal.pone.0092699
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA AD6GL
UT WOS:000333355300118
PM 24658359
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Desiderio, V
   Tirino, V
   Papaccio, G
   Paino, F
AF Desiderio, Vincenzo
   Tirino, Virginia
   Papaccio, Gianpaolo
   Paino, Francesca
TI Bone defects: Molecular and cellular therapeutic targets
SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
LA English
DT Article
DE Bone disease; Mesenchymal stem cells; Histone deacetylases; Wnt pathway
ID MESENCHYMAL STEM CELLS; DENTAL PULP; OSTEOBLAST DIFFERENTIATION;
   SKELETOGENESIS; PROGENITORS; DISEASE; ROLES; RUNX2; LRP5; MASS
AB Bone defects are one of the most serious pathologies that need tissue regeneration therapies. Studies on mesenchymal stem cells are changing the way we treat bone diseases. MSCs have been used for the treatment of osteogenesis imperfecta, hypophosphatasia, osteonecrosis of the femoral head, osteoporosis, rheumatoid arthritis and osteoarthritis. In this context, it is becoming ever more clear that the future of therapies will be based on the use of stem cells. In this concise review, we highlight the importance of the use of MSCs in bone diseases, focusing on the role of histone deacetylases and Wnt pathways involved in osteogenesis. A better understanding of MSC biology and osteogenesis is needed in order to develop new and targeted therapeutic strategies for the treatment of bone diseases/disorders. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Desiderio, Vincenzo; Tirino, Virginia; Papaccio, Gianpaolo; Paino, Francesca] Secondo Ateneo Napoli, Sez Istol & Biotecnol, TERM Lab, Dipartimento Med Sperimentale, I 80138 Naples, Italy.
RP Tirino, V (通讯作者)，Secondo Ateneo Napoli, Sez Istol & Biotecnol, TERM Lab, Dipartimento Med Sperimentale, Via L Armanni 5, I 80138 Naples, Italy.
EM virginia.tirino@unina2.it; gianpaolo.papaccio@unina2.it
RI ; Papaccio, Gianpaolo/B 7150 2014; paino, francesca/AAC 8150 2019;
   desiderio, vincenzo/K 4244 2018
OI desiderio, vincenzo/0000 0003 1819 6083; Paino,
   Francesca/0000 0002 3186 1888; Papaccio, Gianpaolo/0000 0002 4014 5306;
   Tirino, Virginia/0000 0003 2731 5718; 
FU EU PON [01_02834]; MIUR PRIN [20102M7T8X_002]
FX This work was funded by EU PON n. 01_02834 and by MIUR PRIN n.
   20102M7T8X_002. The authors declare no financial interest in the content
   of this manuscript.
CR Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Case N, 2010, J CELL BIOCHEM, V110, P545, DOI 10.1002/jcb.22574
   Chang SR, 2006, CELL, V126, P321, DOI 10.1016/j.cell.2006.05.040
   Costa AG, 2012, CURR OSTEOPOROS REP, V10, P64, DOI 10.1007/s11914 011 0089 5
   d'Aquino R, 2007, CELL DEATH DIFFER, V14, P1162, DOI 10.1038/sj.cdd.4402121
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   De Francesco F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006537
   De Rosa A, 2009, TISSUE ENG PART C ME, V15, P659, DOI [10.1089/ten.tec.2008.0674, 10.1089/ten.TEC.2008.0674]
   Giuliani A, 2013, STEM CELL TRANSL MED, V2, P316, DOI 10.5966/sctm.2012 0136
   Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485
   Hassan MQ, 2012, J BIOL CHEM, V287, P42084, DOI 10.1074/jbc.M112.377515
   Jensen ED, 2008, J BONE MINER RES, V23, P361, DOI 10.1359/JBMR.071104
   Jeon EJ, 2006, J BIOL CHEM, V281, P16502, DOI 10.1074/jbc.M512494200
   Kapinas K, 2010, J BIOL CHEM, V285, P25221, DOI 10.1074/jbc.M110.116137
   Lee HW, 2006, MOL ENDOCRINOL, V20, P2432, DOI 10.1210/me.2006 0061
   Levasseur R, 2005, JOINT BONE SPINE, V72, P207, DOI 10.1016/j.jbspin.2004.10.008
   Li H, 2009, J CLIN INVEST, V119, P3666, DOI 10.1172/JCI39832
   Li ZY, 2009, J BIOL CHEM, V284, P15676, DOI 10.1074/jbc.M809787200
   Liu Y, 2014, CLIN EXP MED, V14, P13, DOI 10.1007/s10238 012 0218 1
   Monroe DG, 2012, GENE, V492, P1, DOI 10.1016/j.gene.2011.10.044
   Paino F, 2014, STEM CELLS, V32, P279, DOI 10.1002/stem.1544
   Paino F, 2010, EUR CELLS MATER, V20, P295
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Rao TP, 2010, CIRC RES, V106, P1798, DOI 10.1161/CIRCRESAHA.110.219840
   Riancho JA, 2011, EUR J ENDOCRINOL, V164, P123, DOI 10.1530/EJE 10 0582
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Vega RB, 2004, CELL, V119, P555, DOI 10.1016/j.cell.2004.10.024
   Zhang J, 2011, J BONE MINER RES, V26, P1953, DOI 10.1002/jbmr.377
   Zhang Y, 2004, EXP HEMATOL, V32, P657, DOI 10.1016/j.exphem.2004.04.001
   Zimmermann S, 2007, CANCER RES, V67, P9047, DOI 10.1158/0008 5472.CAN 07 0312
NR 30
TC 25
Z9 29
U1 0
U2 20
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1357 2725
EI 1878 5875
J9 INT J BIOCHEM CELL B
JI Int. J. Biochem. Cell Biol.
PD JUN
PY 2014
VL 51
BP 75
EP 78
DI 10.1016/j.biocel.2014.03.025
PG 4
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA AJ6BL
UT WOS:000337774600011
PM 24704416
DA 2025 08 17
ER

PT J
AU Luo, JQ
   Wang, XH
   Chen, ZY
   Zhou, HQ
   Xiao, YH
AF Luo, Jiaquan
   Wang, Xuhua
   Chen, Zhaoyuan
   Zhou, Huaqiang
   Xiao, Yihui
TI The role and mechanism of JAK2/STAT3 signaling pathway regulated by m6A
   methyltransferase KIAA1429 in osteosarcoma
SO JOURNAL OF BONE ONCOLOGY
LA English
DT Article
DE Osteosarcoma; m6A modification; KIAA1429; JAK2; STAT3 signal pathway
ID CANCER; SURVIVAL
AB Osteosarcoma (OS) is the most malignant bone tumor which mainly occurs in childhood or adolescence. The previous studies indicated that OS is difficult to treat. KIAA1429 is one of the components of m6A complex that regulating the process of m6A modification, which plays a crucial role in tumorigenesis. But the mechanism of KIAA1429 regulating OS cell identity was not entirely clear, which needs further investigate. RT qPCR and western blotting were applied to determine KIAA1429 expression station in OS cells and tissues. To further detect the KIAA1429 function in OS cells, the ability of proliferation, migration and invasion were analyzed by Edu, wound healing and transwell experiments respectively. Besides, RNA sequencing was also used to further find the downstream of KIAA1429 regulation and small molecule inhibitor was added to explore the specific role of signaling pathway. Our data found that KIAA1429 is up regulated in human OS cell lines compared to the human osteoblast cells. Meanwhile, the deletion of KIAA1429 significantly decreased cell proliferation, migration, and invasion. Interestingly, the JAK2/STAT3 signal pathway was involved in KIAA1429 regulation on OS cell characters. The KIAA1429 eliminated OS cells exhibited a decreased activity of JAK2/STAT3 signal. And the addition of JAK2/STAT3 stimulator (colivelin) could distinctly rescue the decreased OS cells' proliferation, migration, and invasion upon KIAA1429 knockdown. In summary, these data demonstrated that KIAA1429/ JAK2/STAT3 axis may a new target for OS therapy.
C1 [Luo, Jiaquan; Wang, Xuhua; Chen, Zhaoyuan; Zhou, Huaqiang; Xiao, Yihui] Gannan Med Univ, Affiliated Hosp 1, Dept Spine Surg, Ganzhou 341099, Jiangxi, Peoples R China.
C3 Gannan Medical University
RP Luo, JQ (通讯作者)，Gannan Med Univ, Affiliated Hosp 1, Dept Spine Surg, Ganzhou 341099, Jiangxi, Peoples R China.
EM luojiaquan666@163.com
RI Zhou, Huaqiang/MVW 4086 2025; Chen, Zhaoyuan/G 7490 2011; WANG,
   XUHUA/C 5053 2011
CR Alvarez JV, 2006, CANCER RES, V66, P3162, DOI 10.1158/0008 5472.CAN 05 3757
   Barbieri I, 2017, NATURE, V552, P126, DOI 10.1038/nature24678
   Campbell PJ, 2005, LANCET, V366, P1945, DOI 10.1016/S0140 6736(05)67785 9
   Chen MN, 2018, HEPATOLOGY, V67, P2254, DOI 10.1002/hep.29683
   Chen SJ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 02847 6
   Chen X., 2020, FRONT ENDOCRINOL, V10
   Chen XY, 2019, MOL CANCER, V18, DOI 10.1186/s12943 019 1033 z
   Huang HL, 2020, CANCER CELL, V37, P270, DOI 10.1016/j.ccell.2020.02.004
   Huang Y, 2019, CANCER CELL, V35, P677, DOI 10.1016/j.ccell.2019.03.006
   Lan T, 2019, MOL CANCER, V18, DOI 10.1186/s12943 019 1106 z
   Li FX, 2019, CANCER RES, V79, P5785, DOI 10.1158/0008 5472.CAN 18 2868
   Li JH, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00769
   Li JS, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.594125
   Li ZR, 2018, CELL RES, V28, P904, DOI 10.1038/s41422 018 0072 0
   LINK MP, 1986, NEW ENGL J MED, V314, P1600, DOI 10.1056/NEJM198606193142502
   Liu RY, 2014, INT J ONCOL, V44, P1643, DOI 10.3892/ijo.2014.2310
   Luwor RB, 2013, J CLIN NEUROSCI, V20, P907, DOI 10.1016/j.jocn.2013.03.006
   Ma JZ, 2017, HEPATOLOGY, V65, P529, DOI 10.1002/hep.28885
   Ma L, 2022, ONCOGENE, V41, P692, DOI 10.1038/s41388 021 02066 z
   Meyers PA, 2005, J CLIN ONCOL, V23, P2004, DOI 10.1200/JCO.2005.06.031
   Miao R, 2020, J CELL PHYSIOL, V235, P7420, DOI 10.1002/jcp.29645
   Miller Benjamin J, 2013, J Bone Joint Surg Am, V95, pe89, DOI 10.2106/JBJS.L.01189
   Mirabello L, 2009, CANCER AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121
   Qian JY, 2019, ONCOGENE, V38, P6123, DOI 10.1038/s41388 019 0861 z
   Roundtree IA, 2017, CELL, V169, P1187, DOI 10.1016/j.cell.2017.05.045
   Sahu RP, 2009, JNCI J NATL CANCER I, V101, P176, DOI 10.1093/jnci/djn470
   Wang Q, 2020, GUT, V69, P1193, DOI 10.1136/gutjnl 2019 319639
   Ward E, 2014, CA CANCER J CLIN, V64, P83, DOI 10.3322/caac.21219
   Yang Z, 2017, J BIOL CHEM, V292, P3614, DOI 10.1074/jbc.M116.749689
   Zhang C., CANC COMMUN LOND
   Zhang C, 2021, BIOENGINEERED, V12, P3159, DOI 10.1080/21655979.2021.1946305
   Zhang JW, 2016, GUT, V65, P1482, DOI 10.1136/gutjnl 2014 308614
   Zhang XL, 2010, BIOCHEM PHARMACOL, V79, P1398, DOI 10.1016/j.bcp.2010.01.001
   Zhang X, 2022, MOL THER NUCL ACIDS, V27, P133, DOI 10.1016/j.omtn.2021.08.009
   Zhou CL, 2020, EBIOMEDICINE, V59, DOI 10.1016/j.ebiom.2020.102955
   Zhou L, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.109964
NR 36
TC 11
Z9 12
U1 1
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 2212 1374
J9 J BONE ONCOL
JI J. Bone Oncol.
PD APR
PY 2023
VL 39
AR 100471
DI 10.1016/j.jbo.2023.100471
EA MAR 2023
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA H3QI9
UT WOS:000995142200001
PM 36915895
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wang, YC
   Cai, MT
   Chen, MH
   Tung, F
   Chen, MH
   Liu, TY
AF Wang, Yu Chi
   Cai, Meng Ting
   Chen, Ming Hong
   Tung, Fu , I
   Chen, Mei Hsiu
   Liu, Tse Ying
TI Europium Containing Nanospheres for Treating Ovariectomy Induced
   Osteoporosis: Targeted Bone Remodeling and Macrophage Polarization
   Modulation
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE osteoporosis; macrophage polarization; osteoblast; osteoclast;
   nanocrystals; poly(lactic co glycolic acid)
ID IRON OXIDE NANOPARTICLES; INDUCED INFLAMMATORY RESPONSES;
   MAGNETIC FIELD; THERAPY
AB Purpose: Osteoporosis, characterized by reduced bone mass and structural deterioration, poses a significant healthcare challenge. Traditional treatments, while effective in reducing fracture risks, are often limited by side effects. This study introduces a novel nanocomplex, europium (Eu) ions doped superparamagnetic iron oxide (SPIO) nanocrystals encapsulated in poly(lactic co glycolic acid) (PLGA) nanospheres, abbreviated as SPIO:Eu@PLGA nanospheres, as a potential therapeutic agent for osteoporosis by modulating macrophage polarization, enhancing osteoblast differentiation and inhibiting osteoclastogenesis. Methods: SPIO and SPIO:Eu nanocrystals were synthesized through pyrolysis and encapsulated in PLGA using an emulsification method. To evaluate the impact of SPIO:Eu@PLGA nanospheres on macrophage reprogramming and reactive oxygen species (ROS) production, flow cytometry analysis was conducted. Furthermore, an ovariectomized (OVX) rat model was employed to assess the therapeutic efficacy of SPIO:Eu@PLGA nanospheres in preventing the deterioration of osteoporosis. Results: In vitro, SPIO:Eu@PLGA nanospheres significantly attenuated M1 macrophage activation induced by lipopolysaccharides, promoting a shift towards the M2 phenotype. This action is linked to the modulation of ROS and the NF kappa B pathway. Unlike free Eu ions, which do not achieve similar results when not incorporated into the SPIO nanocrystals. SPIO:Eu@PLGA nanospheres enhanced osteoblast differentiation and matrix mineralization while inhibiting RANKL induced osteoclastogenesis. In vivo studies demonstrated that SPIO: Eu@PLGA nanospheres effectively targeted trabecular bone surfaces in OVX rats under magnetic guidance, preserving their structure and repairing trabecular bone loss by modulating macrophage polarization, thus restoring bone remodeling homeostasis. The study underscores the critical role of Eu doping in boosting the anti osteoporotic effects of SPIO:Eu@PLGA nanospheres, evident at both cellular and tissue levels in vitro and in vivo. Conclusion: The inclusion of Eu into SPIO matrix suggests a novel approach for developing more effective osteoporosis treatments, particularly for conditions induced by OVX. This research provides essential insights into SPIO:Eu@PLGA nanospheres as an innovative osteoporosis treatment, addressing the limitations of conventional therapies through targeted delivery and macrophage polarization modulation.
C1 [Wang, Yu Chi; Cai, Meng Ting; Liu, Tse Ying] Natl Yang Ming Chiao Tung Univ, Dept Biomed Engn, Taipei 112304, Taiwan.
   [Chen, Ming Hong] Far Eastern Mem Hosp, Dept Surg, Div Neurosurg, New Taipei City 220216, Taiwan.
   [Chen, Ming Hong] Yuan Ze Univ, Dept Elect Engn, Taoyuan City 320315, Taiwan.
   [Tung, Fu , I] Taipei City Hosp, Dept Orthopaed, Yang Ming Branch, Taipei 111024, Taiwan.
   [Tung, Fu , I] Univ Taipei, Coll City Management, Dept Hlth & Welf, Taipei 111036, Taiwan.
   [Chen, Mei Hsiu] Far Eastern Mem Hosp, Dept Internal Med, New Taipei City 220216, Taiwan.
   [Chen, Mei Hsiu] Ming Chuang Univ, Dept Biomed Engn, Taoyuan 333, Taiwan.
C3 National Yang Ming Chiao Tung University; Far Eastern Memorial Hospital;
   Yuan Ze University; Taipei City Hospital; Far Eastern Memorial Hospital
RP Liu, TY (通讯作者)，Natl Yang Ming Chiao Tung Univ, Dept Biomed Engn, Taipei 112304, Taiwan.; Chen, MH (通讯作者)，Far Eastern Mem Hosp, Dept Internal Med, New Taipei City 220216, Taiwan.; Chen, MH (通讯作者)，Ming Chuang Univ, Dept Biomed Engn, Taoyuan 333, Taiwan.
EM michelle8989@gmail.com; tyliu5@nycu.edu.tw
RI Liu, Tse Ying/HDM 1274 2022; Huang, Chen/I 2304 2019
OI Tung, Fui/0000 0002 3363 6617; Wang, Yu Chi/0000 0003 1308 324X
FU National Science and Technology Council (NSTC) [NSTC
   111 2221 E A49 051 MY2, NSTC 111 2811 E A49A 007 MY2, NSTC
   111 2314 B 038 094, NSTC 113 2314 B A49 065 MY3, NSTC
   113 2811 B A49A 029]; Far Eastern Memorial Hospital [FEMH 2024 C 013,
   FEMH 2024 C 057, FEMH 2023 C 081]; Department of Health, Taipei City
   Government [11201 62 004, 11301 62 048]
FX We are grateful to the National Science and Technology Council (NSTC
   111 2221 E A49 051 MY2, NSTC 111 2811 E A49A 007 MY2, NSTC
   111 2314 B 038 094, NSTC 113 2314 B A49 065 MY3, NSTC
   113 2811 B A49A 029) , the Far Eastern Memorial Hospital
   (FEMH 2024 C 013, FEMH 2024 C 057, FEMH 2023 C 081) , and the Department
   of Health, Taipei City Government (11201 62 004, 11301 62 048) for
   financial support.
CR Ashtar M, 2020, CANCERS, V12, DOI 10.3390/cancers12040929
   Batoon L, 2021, J BONE MINER RES, V36, P2214, DOI 10.1002/jbmr.4413
   Chen SS, 2023, HELIYON, V9, DOI 10.1016/j.heliyon.2023.e15583
   Chen YJ, 2020, J APPL TOXICOL, V40, P1067, DOI 10.1002/jat.3967
   Dou C, 2018, J BONE MINER RES, V33, P899, DOI 10.1002/jbmr.3364
   Fazeli PK, 2013, J CLIN ENDOCR METAB, V98, P935, DOI 10.1210/jc.2012 3634
   Feng P, 2018, ADV SCI, V5, DOI 10.1002/advs.201700817
   Foessl I, 2023, NAT REV ENDOCRINOL, V19, P520, DOI 10.1038/s41574 023 00866 9
   Grosse S, 2016, INT J NANOMED, V11, P4625, DOI 10.2147/IJN.S113425
   Gubernatorova EO, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201700176
   Guo XM, 2017, ACS APPL MATER INTER, V9, P16581, DOI 10.1021/acsami.6b16513
   Guo Z, 2007, FASEB J, V21, P535, DOI 10.1096/fj.06 6739com
   Iantomasi T, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24043772
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kimball JS, 2021, J BONE JOINT SURG AM, V103, P1451, DOI 10.2106/JBJS.20.00989
   Krege JH, 2022, JBMR PLUS, V6, DOI 10.1002/jbm4.10665
   Kumar A, 2009, LANGMUIR, V25, P10998, DOI 10.1021/la901298q
   Langdahl B, 2016, THER ADV MUSCULOSKEL, V8, P225, DOI 10.1177/1759720X16670154
   Lassus J, 1998, CLIN ORTHOP RELAT R, P7
   Li HX, 2021, CURR MED CHEM, V28, P1489, DOI 10.2174/0929867327666200330142432
   Li YY, 2020, BRIT J CANCER, V123, P1570, DOI 10.1038/s41416 020 01043 9
   Liang YJ, 2020, COLLOID SURFACE A, V588, DOI 10.1016/j.colsurfa.2019.124364
   Licini C, 2019, CYTOKINE GROWTH F R, V49, P59, DOI 10.1016/j.cytogfr.2019.09.001
   Liu M, 2021, NANOSCALE, V13, P1181, DOI 10.1039/d0nr05608a
   Liu YC, 2014, INT J BIOL SCI, V10, P520, DOI 10.7150/ijbs.8879
   Maeno S, 2005, BIOMATERIALS, V26, P4847, DOI 10.1016/j.biomaterials.2005.01.006
   McClung M, 2013, AM J MED, V126, P13, DOI 10.1016/j.amjmed.2012.06.023
   Morgan MJ, 2011, CELL RES, V21, P103, DOI 10.1038/cr.2010.178
   Muñoz J, 2020, NUTRIENTS, V12, DOI 10.3390/nu12102999
   Murray PJ, 2017, ANNU REV PHYSIOL, V79, P541, DOI 10.1146/annurev physiol 022516 034339
   Nicolete R, 2011, INT IMMUNOPHARMACOL, V11, P1557, DOI 10.1016/j.intimp.2011.05.014
   Orimo Hideo, 2010, Journal of Nippon Medical School, V77, P4
   Park J, 2004, NAT MATER, V3, P891, DOI 10.1038/nmat1251
   Rashki Kemmak Asma, 2020, Med J Islam Repub Iran, V34, P154, DOI 10.34171/mjiri.34.154
   RIGGS BL, 1983, AM J MED, V75, P899, DOI 10.1016/0002 9343(83)90860 4
   Saengruengrit C, 2018, J COLLOID INTERF SCI, V520, P101, DOI 10.1016/j.jcis.2018.03.008
   Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140 6736(06)68891 0
   Shuai CJ, 2024, INT J EXTREME MANUF, V6, DOI 10.1088/2631 7990/ad01fd
   Shuai CJ, 2021, BIOACT MATER, V6, P490, DOI 10.1016/j.bioactmat.2020.09.001
   Sobh MM, 2022, J CLIN MED, V11, DOI 10.3390/jcm11092382
   Song SS, 2022, PHARMACOL THERAPEUT, V237, DOI 10.1016/j.pharmthera.2022.108168
   Tan HY, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/2795090
   Thummuri D, 2017, J MOL MED, V95, P1065, DOI 10.1007/s00109 017 1553 1
   Wang WH, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/2485959
   Weivoda MM, 2023, J BONE MINER RES, V38, P359, DOI 10.1002/jbmr.4773
   Wu LK, 2023, MATER TODAY BIO, V19, DOI 10.1016/j.mtbio.2023.100595
   Wu PC, 2017, NANOMED NANOTECHNOL, V13, P1975, DOI 10.1016/j.nano.2017.05.005
   Yang DH, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092093
   Yang LJ, 2015, NANOSCALE, V7, P6843, DOI 10.1039/c5nr00774g
   Zhi DF, 2020, ACTA BIOMATER, V102, P13, DOI 10.1016/j.actbio.2019.11.027
NR 50
TC 3
Z9 3
U1 8
U2 14
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178 2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2024
VL 19
BP 10145
EP 10163
DI 10.2147/IJN.S472253
PG 19
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Pharmacology & Pharmacy
GA I6D4E
UT WOS:001331142200001
PM 39386058
OA gold
DA 2025 08 17
ER

PT J
AU Liang, WN
   Lin, MN
   Li, XH
   Li, CD
   Gao, BZ
   Gan, HJ
   Yang, ZY
   Lin, XJ
   Liao, LH
   Yang, M
AF Liang, Wenna
   Lin, Munan
   Li, Xihai
   Li, Candong
   Gao, Bizheng
   Gan, Huijuan
   Yang, Zhaoyang
   Lin, Xuejuan
   Liao, Linghong
   Yang, Min
TI Icariin promotes bone formation via the BMP 2/Smad4 signal transduction
   pathway in the hFOB 1.19 human osteoblastic cell line
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE bone formation; osteoblast; icariin; osteoporosis
ID MARROW STROMAL CELLS; IN VITRO; POSTMENOPAUSAL OSTEOPOROSIS; OSTEOGENIC
   DIFFERENTIATION; CBFA1 EXPRESSION; DEFICIENT MICE; INVOLVEMENT;
   FLAVONOIDS; RANKL
AB Icariin, the main active compound of the traditional Chinese medicine, Epimedium, is commonly used for the clinical treatment of osteoporosis. However, the precise molecular mechanism of the therapeutic effect of icariin has not been elucidated. The aim of this study was to examine the effect of icariin on cell viability, alkaline phosphatase (ALP) activity, the amount of calcified nodules, and to delineate the molecular mechanism of icariin enhanced bone formation by investigating the expression of bone morphogenic protein 2 (BMP 2), Smad4, Cbfa1/Runx2, osteoprotegerin (OPG), receptor activator of nuclear factor kappa B ligand (RANKL) and the OPG/RANKL ratio in the hFOB 1.19 human osteoblastic cell line. We found that icariin significantly increased the cell viability, the activity of ALP and the amount of calcified nodules in the hFOB 1.19 cells. Furthermore, we observed that icariin upregulated the expression of BMP 2, Smad4, Cbfa1/Runx2, OPG, RANKL and the OPG/RANKL ratio. Our results indicate that icariin can modulate the process of bone formation via the BMP 2/Smad4 signal transduction pathway in hFOB 1.19 cells.
C1 [Liang, Wenna; Li, Candong; Gao, Bizheng; Gan, Huijuan; Yang, Zhaoyang; Lin, Xuejuan; Liao, Linghong; Yang, Min] Fujian Univ Tradit Chinese Med, Res Base Tradit Chinese Med Syndrome, Fuzhou 350122, Peoples R China.
   [Lin, Munan] Fuzhou Gen Hosp Nanjing Mil Command, Dept Tradit Chinese Med, Fuzhou 350025, Peoples R China.
   [Li, Xihai] Fujian Univ Tradit Chinese Med, Acad Integrat Med, Fuzhou 350122, Peoples R China.
C3 Fujian University of Traditional Chinese Medicine; Fujian University of
   Traditional Chinese Medicine
RP Li, CD (通讯作者)，Fujian Univ Tradit Chinese Med, Res Base Tradit Chinese Med Syndrome, 1 Huatuo Rd, Fuzhou 350122, Peoples R China.
EM fjzylcd@126.com
RI Li, Xihai/NUQ 4105 2025; Ma, Guannan/JTV 2014 2023
FU National Natural Science Foundation of China [81102609]; Natural Science
   Foundation of Fujian Province [2011J05076]; Youth Foundation of Fujian
   Provincial Health Bureau [2011 2 31]
FX This study was supported by the National Natural Science Foundation of
   China (Grant no. 81102609), the Natural Science Foundation of Fujian
   Province (Grant no. 2011J05076) and the Youth Foundation of Fujian
   Provincial Health Bureau (Grant no. 2011 2 31).
CR Cao H, 2012, INT J MOL MED, V29, P435, DOI 10.3892/ijmm.2011.845
   Chen KM, 2007, PHARMAZIE, V62, P785, DOI 10.1691/ph.2007.10.7504
   Datta NS, 2011, WORLD J ORTHOP, V2, P67, DOI 10.5312/wjo.v2.i8.67
   Enjuanes A, 2010, ENDOCRINE, V37, P180, DOI 10.1007/s12020 009 9285 9
   Hsieh TP, 2011, PHYTOMEDICINE, V18, P176, DOI 10.1016/j.phymed.2010.04.003
   Hsieh TP, 2010, PHYTOMEDICINE, V17, P414, DOI 10.1016/j.phymed.2009.08.007
   Huang J, 2007, LIFE SCI, V81, P832, DOI 10.1016/j.lfs.2007.07.015
   Lee JW, 2012, J NAT MED TOKYO, V66, P8, DOI 10.1007/s11418 011 0537 7
   Ma B, 2012, ACTA PHARMACOL SIN, V33, P479, DOI 10.1038/aps.2011.177
   Ma HP, 2011, J CELL BIOCHEM, V112, P916, DOI 10.1002/jcb.23007
   Matsubara T, 2008, J BIOL CHEM, V283, P29119, DOI 10.1074/jbc.M801774200
   Mlakar SJ, 2012, MATURITAS, V71, P180, DOI 10.1016/j.maturitas.2011.11.023
   Mok SK, 2010, BRIT J PHARMACOL, V159, P939, DOI 10.1111/j.1476 5381.2009.00593.x
   Narayanan D, 2012, J BIOMED NANOTECHNOL, V8, P98, DOI 10.1166/jbn.2012.1367
   Nojima J, 2010, J BIOL CHEM, V285, P15577, DOI 10.1074/jbc.M109.028019
   Padova G, 2011, CLIN CASES MINER BON, V8, P37
   Peng SL, 2009, BONE, V45, P534, DOI 10.1016/j.bone.2009.05.022
   Przedlacki J, 2011, ENDOKRYNOL POL, V62, P65
   Qian GF, 2006, ENDOCR J, V53, P87, DOI 10.1507/endocrj.53.87
   Qin LP, 2008, J ETHNOPHARMACOL, V118, P271, DOI 10.1016/j.jep.2008.04.009
   Rodriguez JES, 2009, J BONE MINER RES, V24, P1917, DOI [10.1359/JBMR.090507, 10.1359/jbmr.090507]
   Schmidt S, 2011, J PHARMACOKINET PHAR, V38, P873, DOI 10.1007/s10928 011 9224 2
   Swarnkar G, 2011, EUR J PHARMACOL, V658, P65, DOI 10.1016/j.ejphar.2011.02.032
   Tabuchi M, 2005, CALCIFIED TISSUE INT, V77, P239, DOI 10.1007/s00223 004 0223 9
   Wang LA, 2010, CELL PHYSIOL BIOCHEM, V26, P1093, DOI 10.1159/000323987
   Xiao Qiangbing, 2005, J Huazhong Univ Sci Technolog Med Sci, V25, P690
   Xiong JH, 2012, J BONE MINER RES, V27, P499, DOI 10.1002/jbmr.1547
   Zhang JC, 2011, BIOL TRACE ELEM RES, V143, P1746, DOI 10.1007/s12011 011 8987 z
   Zhao J, 2008, BIOCHEM BIOPH RES CO, V369, P444, DOI 10.1016/j.bbrc.2008.02.054
NR 29
TC 90
Z9 109
U1 0
U2 41
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107 3756
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD OCT
PY 2012
VL 30
IS 4
BP 889
EP 895
DI 10.3892/ijmm.2012.1079
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 013IB
UT WOS:000309298000023
PM 22842877
OA Bronze
DA 2025 08 17
ER

PT J
AU Huang, YJ
   Xiao, ZH
   Guan, ZL
   Zeng, ZS
   Shen, YF
   Xu, XY
   Zhao, CS
AF Huang, Yanjuan
   Xiao, Zhanghong
   Guan, Zilin
   Zeng, Zishan
   Shen, Yifeng
   Xu, Xiaoyu
   Zhao, Chunshun
TI Bone seeking nanoplatform co delivering cisplatin and zoledronate for
   synergistic therapy of breast cancer bone metastasis and bone resorption
SO ACTA PHARMACEUTICA SINICA B
LA English
DT Article
DE Bone metastasis; Bone targeting; Osteolysis; Zoledronate; Cisplatin
ID COORDINATION POLYMER NANOPARTICLES; METAL ORGANIC FRAMEWORKS; ACID;
   NANOMEDICINE; CHEMOTHERAPY; MACROPHAGES; COMBINATION; OSTEOCLASTS;
   GENERATION; EVEROLIMUS
AB The "vicious cycle" established between tumor growth and osteolysis aggravates the process of breast cancer bone metastasis, leading to life threatening skeletal related events that severely reduce survival and quality of life. To effectively interrupt the "vicious cycle", innovative therapeutic strategies that not only reduce osteolysis but also relieve tumor burden are urgently needed. Herein, a bone seeking moiety, alendronate (ALN), functionalized coordination polymer nanoparticles (DZ@ALN) co delivering cisplatin prodrug (DSP) and antiresorptive agent zoledronate (ZOL) via Zn2+ crosslinking for combination therapy was reported. The versatile DZ@ ALN with a diameter of about 40 nm can cross the fissure in the bone marrow sinus capillaries, and possesses an excellent bone seeking ability both in vitro and in vivo. Additionally, DZ@ALN could synergistically inhibit the proliferation of cancer cells, suppress the formation of osteoclast like cells and induce the apoptosis of osteoclasts in vitro. Importantly, it could preferentially accumulate in bone affected site, remarkably inhibit the proliferation of tumor cells, relieving bone pain, and significantly inhibit the activation of osteoclasts, protecting the bone from destruction in vivo, eventually leading to the breakdown of "vicious cycle" without inducing obvious systemic toxicity. This innovative nanoagent combines chemotherapy and osteolysis inhibition, exhibiting an inspiring strategy for effective treatment of bone metastasis. (C) 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
C1 [Huang, Yanjuan; Xiao, Zhanghong; Guan, Zilin; Zeng, Zishan; Shen, Yifeng; Xu, Xiaoyu; Zhao, Chunshun] Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou 510006, Peoples R China.
C3 Sun Yat Sen University
RP Zhao, CS (通讯作者)，Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou 510006, Peoples R China.
EM zhaocs@mail.sysu.edu.cn
FU National Natural Science Foundation of China [81973256/H3008]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 81973256/H3008).
CR Au KM, 2016, BIOMATERIALS, V82, P178, DOI 10.1016/j.biomaterials.2015.12.018
   Bi HT, 2019, CHEM ENG J, V356, P543, DOI 10.1016/j.cej.2018.09.076
   Boissier S, 2000, CANCER RES, V60, P2949
   Brook N, 2018, INT J BIOCHEM CELL B, V96, P63, DOI 10.1016/j.biocel.2018.01.003
   Chu WJ, 2017, INT J PHARMACEUT, V516, P352, DOI 10.1016/j.ijpharm.2016.11.051
   Clarke B, 2008, CLIN J AM SOC NEPHRO, V3, pS131, DOI 10.2215/CJN.04151206
   Cleeland C, 2016, SUPPORT CARE CANCER, V24, P3557, DOI 10.1007/s00520 016 3154 x
   Coleman RE, 2012, NAT REV CLIN ONCOL, V9, P76, DOI 10.1038/nrclinonc.2011.198
   Dhar S, 2009, J AM CHEM SOC, V131, P14652, DOI 10.1021/ja9071282
   Ellard SL, 2009, J CLIN ONCOL, V27, P4536, DOI 10.1200/JCO.2008.21.3033
   Fujise K, 2000, J BIOL CHEM, V275, P39458, DOI 10.1074/jbc.M006626200
   Glausch A, United States Patent, Patent No. [US7932241B2, 7932241]
   He CB, 2015, CHEM REV, V115, P11079, DOI 10.1021/acs.chemrev.5b00125
   He X, 2010, BIOCHEM BIOPH RES CO, V401, P356, DOI 10.1016/j.bbrc.2010.09.053
   He YF, 2017, J CONTROL RELEASE, V264, P76, DOI 10.1016/j.jconrel.2017.08.024
   Huang YJ, 2020, J CONTROL RELEASE, V319, P119, DOI 10.1016/j.jconrel.2019.12.043
   Huang YJ, 2020, CHEM ENG J, V380, DOI 10.1016/j.cej.2019.122369
   Huang YJ, 2017, NANOSCALE, V9, P10002, DOI 10.1039/c7nr02662e
   Huang ZY, 2017, NANOSCALE, V9, P15883, DOI 10.1039/c7nr05402e
   Ibrahim T, 2013, INT J ONCOL, V42, P1263, DOI 10.3892/ijo.2013.1809
   Johnstone TC, 2016, CHEM REV, V116, P3436, DOI 10.1021/acs.chemrev.5b00597
   Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167
   Kim JH, 2016, INT J MOL MED, V37, P649, DOI 10.3892/ijmm.2016.2477
   Kohno N, 2005, J CLIN ONCOL, V23, P3314, DOI 10.1200/JCO.2005.05.116
   Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014
   Li DJ, 2018, J BIOMED NANOTECHNOL, V14, P2003, DOI 10.1166/jbn.2018.2646
   Li SL, 2017, J MATER CHEM B, V5, P9546, DOI 10.1039/c7tb02513k
   Liu JC, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201605221
   Mei D, 2019, ACTA PHARM SIN B, V9, P1061, DOI 10.1016/j.apsb.2019.03.006
   Meng FF, 2018, ACS NANO, V12, P6458, DOI 10.1021/acsnano.8b02881
   Moriceau G, 2010, CANCER RES, V70, P10329, DOI 10.1158/0008 5472.CAN 10 0578
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Peng JR, 2013, BIOMATERIALS, V34, P8726, DOI 10.1016/j.biomaterials.2013.07.092
   Räikkönen J, 2009, BRIT J PHARMACOL, V157, P427, DOI 10.1111/j.1476 5381.2009.00160.x
   Ren GW, 2015, J MOL MED, V93, P1203, DOI 10.1007/s00109 015 1329 4
   Rieter WJ, 2008, J AM CHEM SOC, V130, P11584, DOI 10.1021/ja803383k
   ROSENBERG B, 1969, NATURE, V222, P385, DOI 10.1038/222385a0
   Saad F, 2012, ANN ONCOL, V23, P1341, DOI 10.1093/annonc/mdr435
   Sarin Hemant, 2010, J Angiogenes Res, V2, P14, DOI 10.1186/2040 2384 2 14
   Shalgunov V, 2017, J CONTROL RELEASE, V261, P31, DOI 10.1016/j.jconrel.2017.06.006
   SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014 4827(88)90191 7
   Son HS, 2020, ACTA PHARM SIN B, V10, P462, DOI 10.1016/j.apsb.2019.11.004
   SUBRAMANIAN G, 1983, RADIOLOGY, V149, P823, DOI 10.1148/radiology.149.3.6316414
   Sun WT, 2019, ACS NANO, V13, P7556, DOI 10.1021/acsnano.9b00097
   Suvannasankha A, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058 014 0484 9
   Swami A, 2014, P NATL ACAD SCI USA, V111, P10287, DOI 10.1073/pnas.1401337111
   Tabrizi M, 2010, AAPS J, V12, P33, DOI 10.1208/s12248 009 9157 5
   Valkenburg KC, 2013, CHIN J CANCER, V32, P380, DOI 10.5732/cjc.012.10218
   Vincent C, 2009, J BONE MINER METAB, V27, P114, DOI 10.1007/s00774 008 0018 6
   Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691
   Wang FF, 2014, J CONTROL RELEASE, V196, P222, DOI 10.1016/j.jconrel.2014.10.012
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   WEINSTEIN JN, 1992, CANCER RES, V52, pS2747
   Yang J, 2011, BIOMATERIALS, V32, P9136, DOI 10.1016/j.biomaterials.2011.08.022
   Yerushalmi R, 2010, LANCET ONCOL, V11, P174, DOI 10.1016/S1470 2045(09)70262 1
   Yu C, 2018, BIOMATERIALS, V155, P112, DOI 10.1016/j.biomaterials.2017.11.014
   Zhao L, 2004, CLIN CANCER RES, V10, P7994, DOI 10.1158/1078 0432.CCR 04 1087
   Zhou F, 2019, ACTA PHARM SIN B, V9, P973, DOI 10.1016/j.apsb.2019.01.015
NR 58
TC 28
Z9 29
U1 4
U2 55
PU INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
PI BEIJING
PA C/O EDITORIAL BOARD OF ACTA PHARMACEUTICA SINICA, 1 XIANNONGTAN ST,
   BEIJING, 100050, PEOPLES R CHINA
SN 2211 3835
EI 2211 3843
J9 ACTA PHARMACOL SIN B
JI Acta Pharm. Sin. B
PD DEC
PY 2020
VL 10
IS 12
BP 2384
EP 2403
DI 10.1016/j.apsb.2020.06.006
PG 20
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA PG3ET
UT WOS:000599622800010
PM 33354509
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Spatz, JM
   Wein, MN
   Gooi, JH
   Qu, YL
   Garr, JL
   Liu, S
   Barry, KJ
   Uda, Y
   Lai, F
   Dedic, C
   Balcells Camps, M
   Kronenberg, HM
   Babij, P
   Pajevic, PD
AF Spatz, Jordan M.
   Wein, Marc N.
   Gooi, Jonathan H.
   Qu, Yili
   Garr, Jenna L.
   Liu, Shawn
   Barry, Kevin J.
   Uda, Yuhei
   Lai, Forest
   Dedic, Christopher
   Balcells Camps, Mercedes
   Kronenberg, Henry M.
   Babij, Philip
   Pajevic, Paola Divieti
TI The Wnt Inhibitor Sclerostin Is Up regulated by Mechanical Unloading in
   Osteocytes in Vitro
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID SOST DOWN REGULATION; SPINAL CORD INJURY; PARATHYROID HORMONE;
   BONE FORMATION; BED REST; TARGETED ABLATION; SERUM SCLEROSTIN; RANKL
   EXPRESSION; GENE EXPRESSION; SPACE FLIGHT
AB Although bone responds to its mechanical environment, the cellular and molecular mechanisms underlying the response of the skeleton to mechanical unloading are not completely understood. Osteocytes are the most abundant but least understood cells in bones and are thought to be responsible for sensing stresses and strains in bone. Sclerostin, a product of the SOST gene, is produced postnatally primarily by osteocytes and is a negative regulator of bone formation. Recent studies show that SOST is mechanically regulated at both the mRNA and protein levels. During prolonged bed rest and immobilization, circulating sclerostin increases both in humans and in animal models, and its increase is associated with a decrease in parathyroid hormone. To investigate whether SOST/sclerostin up regulation in mechanical unloading is a cell autonomous response or a hormonal response to decreased parathyroid hormone levels, we subjected osteocytes to an in vitro unloading environment achieved by the NASA rotating wall vessel system. To perform these studies, we generated a novel osteocytic cell line (Ocy454) that produces high levels of SOST/sclerostin at early time points and in the absence of differentiation factors. Importantly, these osteocytes recapitulated the in vivo response to mechanical unloading with increased expression of SOST (3.4 +/  1.9 fold, p< 0.001), sclerostin (4.7 +/  0.1 fold, p< 0.001), and the receptor activator of nuclear factor kappa B ligand (RANKL)/osteoprotegerin (OPG) (2.5 +/  0.7 fold, p < 0.001) ratio. These data demonstrate for the first time a cell autonomous increase in SOST/sclerostin and RANKL/OPG ratio in the setting of unloading. Thus, targeted osteocyte therapies could hold promise as novel osteoporosis and disuse induced bone loss treatments by directly modulating the mechanosensing cells in bone.
C1 [Spatz, Jordan M.; Wein, Marc N.; Qu, Yili; Garr, Jenna L.; Liu, Shawn; Barry, Kevin J.; Uda, Yuhei; Lai, Forest; Dedic, Christopher; Kronenberg, Henry M.; Pajevic, Paola Divieti] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
   [Spatz, Jordan M.; Wein, Marc N.; Qu, Yili; Garr, Jenna L.; Liu, Shawn; Barry, Kevin J.; Uda, Yuhei; Lai, Forest; Dedic, Christopher; Kronenberg, Henry M.; Pajevic, Paola Divieti] Harvard Univ, Sch Med, Boston, MA 02114 USA.
   [Spatz, Jordan M.; Balcells Camps, Mercedes] MIT, Harvard MIT Inst Med Engn & Sci, Cambridge, MA 02139 USA.
   [Balcells Camps, Mercedes] Ramon Llull Univ, Inst Quim Sarria, Bioengn Dept, Barcelona 08017, Spain.
   [Gooi, Jonathan H.] Univ Melbourne, NorthWest Acad Ctr, St Albans, Vic 3065, Australia.
   [Babij, Philip] Amgen Inc, Thousand Oaks, CA 91320 USA.
C3 Harvard University; Harvard University Medical Affiliates; Massachusetts
   General Hospital; Harvard University; Harvard Medical School;
   Massachusetts Institute of Technology (MIT); Universitat Ramon Llull;
   Institut Quimic de Sarria; University of Melbourne; Amgen
RP Pajevic, PD (通讯作者)，Boston Univ, Goldman Sch Dent Med, Mol & Cell Biol, 700 Albany St, Boston, MA 02118 USA.
EM pdivieti@bu.edu
RI ; Gooi, Jonathan/AAS 7982 2020; Pajevic, Paola/M 3236 2019; Uda,
   Yuhei/AAZ 4978 2021; KRONENBERG, HENRY/MXK 0923 2025
OI Spatz, Jordan/0000 0002 6732 7353; Divieti Pajevic,
   Paola/0000 0001 9853 9837; Aronson, Jenna/0000 0002 7376 8622; Uda,
   Yuhei/0000 0003 4705 6215; Gooi, Jonathan/0000 0002 8839 1602; 
FU National Institutes of Health from the NIAMS [AR059655]; National
   Institutes of Health from NIDDK [DK011794, DK100215]; Northrop Grumman
   Aerospace Systems Ph.D. training fellowship; Massachusetts Institute of
   Technology Hugh Hampton Young fellowship; National Space Biomedical
   Research Institute through NASA [NCC 9 58]; United States Army Institute
   for Environmental Medicine Oak Ridge Science Institute for Science and
   Education fellowship program; Spain's Ministerio de Economia e
   Innovacion [SAF2013 43302 R]; Posimat; Fundacio Empreses Institut Quimic
   de Sarria
FX This work was supported, in whole or in part, by National Institutes of
   Health Grants AR059655 from the NIAMS (to P. D. P.) and DK011794 (to H.
   M. K.) and DK100215 (to M. N. W.) from the NIDDK. P. Babij was employed
   by Amgen Inc. and received Amgen stock. Supported by a Northrop Grumman
   Aerospace Systems Ph.D. training fellowship, a Massachusetts Institute
   of Technology Hugh Hampton Young fellowship, the National Space
   Biomedical Research Institute through NASA Grant NCC 9 58, and the
   United States Army Institute for Environmental Medicine Oak Ridge
   Science Institute for Science and Education fellowship program.
   Supported by Spain's Ministerio de Economia e Innovacion (Grant
   SAF2013 43302 R), Posimat, and Fundacio Empreses Institut Quimic de
   Sarria.
CR Armamento Villareal R, 2012, J BONE MINER RES, V27, P1215, DOI 10.1002/jbmr.1560
   Arnold MA, 2007, DEV CELL, V12, P377, DOI 10.1016/j.devcel.2007.02.004
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   Bishop KA, 2011, J BIOL CHEM, V286, P20880, DOI 10.1074/jbc.M111.231548
   Bonewald LF, 1999, J BONE MINER METAB, V17, P61, DOI 10.1007/s007740050066
   Bonnet N, 2012, P NATL ACAD SCI USA, V109, P15048, DOI 10.1073/pnas.1203085109
   Bonnet N, 2009, J BIOL CHEM, V284, P35939, DOI 10.1074/jbc.M109.060335
   Boukhechba F, 2009, J BONE MINER RES, V24, P1927, DOI [10.1359/JBMR.090517, 10.1359/jbmr.090517]
   Capulli M, 2009, J CELL BIOCHEM, V107, P240, DOI 10.1002/jcb.22120
   Chen JH, 2010, J BIOMECH, V43, P108, DOI 10.1016/j.jbiomech.2009.09.016
   Cherian PP, 2003, J BIOL CHEM, V278, P43146, DOI 10.1074/jbc.M302993200
   Cohen Kfir E, 2011, ENDOCRINOLOGY, V152, P4514, DOI 10.1210/en.2011 1128
   Costa AG, 2011, J CLIN ENDOCR METAB, V96, P3804, DOI 10.1210/jc.2011 0566
   Fulzele K, 2013, BLOOD, V121, P930, DOI 10.1182/blood 2012 06 437160
   Galea GL, 2011, FEBS LETT, V585, P2450, DOI 10.1016/j.febslet.2011.06.019
   Gaudio A, 2010, J CLIN ENDOCR METAB, V95, P2248, DOI 10.1210/jc.2010 0067
   Genetos DC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017772
   Hammond TG, 2001, AM J PHYSIOL RENAL, V281, pF12, DOI 10.1152/ajprenal.2001.281.1.F12
   Holdsworth G, 2012, J BIOL CHEM, V287, P26464, DOI 10.1074/jbc.M112.350108
   Honma M, 2015, J BONE MINER METAB, V33, P73, DOI 10.1007/s00774 013 0555 5
   Hughes JM, 2010, J MUSCULOSKEL NEURON, V10, P128
   Hughes Fulford M, 2001, J Gravit Physiol, V8, pP1
   Igwe JC, 2011, CONNECT TISSUE RES, V52, P401, DOI 10.3109/03008207.2010.546536
   Inniss AM, 2009, AVIAT SPACE ENVIR MD, V80, pA9, DOI 10.3357/ASEM.BR04.2009
   Ito Takayasu, 1996, Environmental Medicine (Nagoya), V40, P43
   Jami A, 2013, MOL CELLS, V35, P305, DOI 10.1007/s10059 013 2310 0
   Kalajzic I, 2004, BONE, V35, P74, DOI 10.1016/j.bone.2004.03.006
   Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004
   Kramer I, 2010, J BONE MINER RES, V25, P178, DOI 10.1359/jbmr.090730
   LeBlanc A. D., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P33
   Leupin O, 2007, J BONE MINER RES, V22, P1957, DOI 10.1359/JBMR.070804
   Li J, 2012, J BIOMECH, V45, P247, DOI 10.1016/j.jbiomech.2011.10.037
   Lin CW, 2009, J BONE MINER RES, V24, P1651, DOI [10.1359/JBMR.090411, 10.1359/jbmr.090411]
   Loots GG, 2012, BONE, V50, P663, DOI 10.1016/j.bone.2011.11.016
   Macias BR, 2013, BONE, V53, P515, DOI 10.1016/j.bone.2013.01.018
   Massagli TL, 1999, ARCH PHYS MED REHAB, V80, P998, DOI 10.1016/S0003 9993(99)90050 3
   Morse LR, 2012, J BONE MINER RES, V27, P352, DOI 10.1002/jbmr.546
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Nguyen J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053813
   O'Brien CA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002942
   Paic F, 2009, BONE, V45, P682, DOI 10.1016/j.bone.2009.06.010
   Papanicolaou SE, 2009, BIORHEOLOGY, V46, P389, DOI 10.3233/BIR 2009 0550
   Paszty C, 2010, J BONE MINER RES, V25, P1897, DOI 10.1002/jbmr.161
   Powell WF, 2011, J ENDOCRINOL, V209, P21, DOI 10.1530/JOE 10 0308
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Rodionova NV, 2002, ADV SPACE RES, V30, P765, DOI 10.1016/S0273 1177(02)00393 9
   Santos A, 2009, J ORTHOP RES, V27, P1280, DOI 10.1002/jor.20888
   Semenov M., 2005, J BIOL CHEM, V280, P26770
   Sevetson B, 2004, J BIOL CHEM, V279, P13849, DOI 10.1074/jbc.M306249200
   Sinha NN, 2011, PHYS WORLD, V24, P25
   Smith SM, 2012, NUTRIENTS, V4, P2047, DOI 10.3390/nu4122047
   Song KD, 2013, CELL STRESS CHAPERON, V18, P193, DOI 10.1007/s12192 012 0370 2
   Spatz JM, 2012, J CLIN ENDOCR METAB, V97, pE1736, DOI 10.1210/jc.2012 1579
   Spatz JM, 2013, J BONE MINER RES, V28, P865, DOI 10.1002/jbmr.1807
   Spector ER, 2009, AVIAT SPACE ENVIR MD, V80, pA23, DOI 10.3357/ASEM.BR02.2009
   Stein EM, 2013, J CLIN ENDOCR METAB, V98, P541, DOI 10.1210/jc.2012 2394
   Tatsumi S, 2007, CELL METAB, V5, P464, DOI 10.1016/j.cmet.2007.05.001
   Tu XL, 2012, BONE, V50, P209, DOI 10.1016/j.bone.2011.10.025
   Vilarrasa N, 2011, OBES SURG, V21, P465, DOI 10.1007/s11695 010 0338 1
   Wein Marc N, 2015, J Bone Miner Res, V30, P400, DOI 10.1002/jbmr.2381
   Woo SM, 2011, J BONE MINER RES, V26, P2634, DOI 10.1002/jbmr.465
   Wu JY, 2011, J CLIN INVEST, V121, P3492, DOI 10.1172/JCI46406
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Yang F, 2010, BIOCHEM BIOPH RES CO, V400, P684, DOI 10.1016/j.bbrc.2010.08.128
   Yu EW, 2011, J CLIN ENDOCR METAB, V96, P2011
   Yu LC, 2011, BONE, V49, P1131, DOI 10.1016/j.bone.2011.08.016
   Zhang KQ, 2006, MOL CELL BIOL, V26, P4539, DOI 10.1128/MCB.02120 05
   Zhu J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050099
NR 68
TC 220
Z9 257
U1 2
U2 30
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUL 3
PY 2015
VL 290
IS 27
BP 16744
EP 16758
DI 10.1074/jbc.M114.628313
PG 15
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA CM3HN
UT WOS:000357572800022
PM 25953900
OA Green Published
DA 2025 08 17
ER

PT J
AU Yin, C
   Tian, Y
   Yu, Y
   Li, DJ
   Miao, ZP
   Su, PH
   Zhao, YP
   Wang, X
   Pei, JW
   Zhang, KW
   Qian, AR
AF Yin, Chong
   Tian, Ye
   Yu, Yang
   Li, Dijie
   Miao, Zhiping
   Su, Peihong
   Zhao, Yipu
   Wang, Xue
   Pei, Jiawei
   Zhang, Kewen
   Qian, Airong
TI Long noncoding RNA AK039312 and AK079370 inhibits bone formation via
   miR 199b 5p
SO PHARMACOLOGICAL RESEARCH
LA English
DT Article
DE Long non coding RNA; AK039312; AK079370; miR 199b 5p; Osteoblast
   differentiation; Bone formation
ID BETA CATENIN; DIFFERENTIATION; OSTEOBLAST; CELLS; THERAPY; SWITCH
AB Osteoporosis caused by aging and menopause had become an emerging threat to human health. The reduction of osteoblast differentiation has been considered to be an essential cause of osteoporosis. Osteoblast differentiation could be regulated by LncRNAs, and increasing evidences have proved that LncRNAs may be adopted as potential therapeutic targets for osteoporosis. However, reports on rescue effects of LncRNAs in vivo are relatively limited. In this study, two LncRNAs (AK039312 and AK079370) were screened as osteogenic related LncRNAs. Both AK039312 and AK079370 could inhibit osteoblast differentiation and bone formation through suppressing osteogenic transcription factors. This inhibitory effect was achieved via binding and sequestering miR 199b 5p, and enhanced GSK 3 beta which further inhibited wnt/beta catenin pathway. Moreover, the siRNAs of AK039312 and AK079370 significantly alleviated postmenopausal osteoporosis, and the combination of si AK039312 and si AK079370 was more efficient than applying one si LncRNA alone. This study has provided new insights for the therapy of osteoporosis.
C1 [Yin, Chong; Tian, Ye; Li, Dijie; Miao, Zhiping; Su, Peihong; Zhao, Yipu; Wang, Xue; Pei, Jiawei; Zhang, Kewen; Qian, Airong] Northwestern Polytech Univ, Res Ctr Special Med & Hlth Syst Engn,Lab Bone Met, Xian Key Lab Special Med & Hlth Engn,Sch Life Sci, Key Lab Space Biosci & Biotechnol,NPU UAB Joint L, Xian, Shaanxi, Peoples R China.
   [Yu, Yang] Tianjin Med Univ, Sch Pharm, Tianjin Key Lab Technol Enabling Dev Clin Therape, Tianjin, Peoples R China.
C3 Northwestern Polytechnical University; Tianjin Medical University
RP Qian, AR (通讯作者)，Northwestern Polytech Univ, Sch Life Sci, 127 West Youyi Rd, Xian 710072, Shaanxi, Peoples R China.
EM qianair@nwpu.edu.cn
RI zhang, kewen/KXR 4680 2024; Yu, Yang/AAI 2652 2020; Li,
   Dijie/KVB 3667 2024
FU National Natural Science Foundation of China [81801871]; China
   Postdoctoral Science Foundation [2019T120947, 2017M613210]; Shaanxi
   Postdoctoral Science Foundation [2017BSHEDZZ13]; Shaanxi Provincial Key
   RD Program [2018KWZ 10]; Special fund for technological innovation of
   Shaanxi Province [2019QYPY 207]; Tianjin Nature Science Foundation
   [16JCQNJC13100]; Nature Science Foundation of Tianjin Medical University
   [2015KYZQ05]
FX The authors would like to thank Dr. Hong Zhou (The University of Sydney,
   Australia) for her generous gift of the MC3T3 E1 cell line. This work
   was supported by the National Natural Science Foundation of China
   (81801871), the China Postdoctoral Science Foundation (2019T120947,
   2017M613210), Shaanxi Postdoctoral Science Foundation (2017BSHEDZZ13),
   Shaanxi Provincial Key R&D Program (2018KWZ 10), Special fund for
   technological innovation of Shaanxi Province (2019QYPY 207), Tianjin
   Nature Science Foundation (16JCQNJC13100) and Nature Science Foundation
   of Tianjin Medical University to young scientist (2015KYZQ05).
CR Almeida M, 2007, J BIOL CHEM, V282, P27298, DOI 10.1074/jbc.M702811200
   Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302
   Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012
   Dai FJ, 2018, MED SCI MONITOR, V24, P2700, DOI 10.12659/MSM.907441
   Deng LD, 2018, BIOCHEM BIOPH RES CO, V503, P2061, DOI 10.1016/j.bbrc.2018.07.160
   Feng YM, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.918932
   Geisler S, 2013, NAT REV MOL CELL BIO, V14, P699, DOI 10.1038/nrm3679
   Georgiou KR, 2012, AM J STEM CELLS, V1, P205
   Hendrickx G, 2015, NAT REV RHEUMATOL, V11, P462, DOI 10.1038/nrrheum.2015.48
   Hu LF, 2018, J CELL PHYSIOL, V233, P1574, DOI 10.1002/jcp.26059
   Li B, 2018, BONE, V111, P82, DOI 10.1016/j.bone.2018.03.017
   Li B, 2017, ORTHOP SURG, V9, P319, DOI 10.1111/os.12321
   Li CJ, 2015, J CLIN INVEST, V125, P1509, DOI 10.1172/JCI77716
   Li DJ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20246229
   Liu SC, 2019, EUR REV MED PHARMACO, V23, P4584, DOI 10.26355/eurrev_201906_18035
   Meng LY, 2015, NATURE, V518, P409, DOI 10.1038/nature13975
   Mulati M, 2020, BONE, V130, DOI 10.1016/j.bone.2019.115076
   Qu XC, 2017, J CELL MOL MED, V21, P1159, DOI 10.1111/jcmm.13047
   Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014
   Thomson DW, 2016, NAT REV GENET, V17, P272, DOI 10.1038/nrg.2016.20
   Ushiku C, 2010, J ORTHOP RES, V28, P1338, DOI 10.1002/jor.21105
   Wang YX, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2325 3
   Wang YX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 1153 1
   Wu Y, 2019, BMC MOL CELL BIOL, V20, DOI 10.1186/s12860 019 0230 3
   Yan K, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010132
   Yi JY, 2019, CELL TISSUE RES, V376, P113, DOI 10.1007/s00441 018 2963 2
   Yin C, 2019, J CELL PHYSIOL, V234, P11524, DOI 10.1002/jcp.27815
   Yin C, 2018, J CELL PHYSIOL, V233, P5405, DOI 10.1002/jcp.26374
   Zhao RB, 2016, BIOCHEM BIOPH RES CO, V477, P749, DOI 10.1016/j.bbrc.2016.06.130
NR 29
TC 19
Z9 23
U1 0
U2 16
PU ACADEMIC PRESS LTD  ELSEVIER SCIENCE LTD
PI LONDON
PA 24 28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043 6618
EI 1096 1186
J9 PHARMACOL RES
JI Pharmacol. Res.
PD JAN
PY 2021
VL 163
AR 105230
DI 10.1016/j.phrs.2020.105230
EA JAN 2021
PG 16
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA PU3TD
UT WOS:000609226800016
PM 33031910
DA 2025 08 17
ER

PT J
AU Xu, K
   Fei, WC
   Gao, WX
   Fan, CX
   Li, YH
   Hong, Y
   Cui, R
AF Xu, Ke
   Fei, Wenchao
   Gao, Wenxue
   Fan, Changxiu
   Li, Yinghua
   Hong, Yang
   Cui, Ran
TI SOD3 regulates FLT1 to affect bone metabolism by promoting osteogenesis
   and inhibiting adipogenesis through PI3K/AKT and MAPK pathways
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Osteoporosis; SOD3; FLT1; BMSCs; Adipogenesis; Osteogenesis
ID UP REGULATION; OSTEOPOROSIS; CELLS; DIFFERENTIATION; ANGIOGENESIS;
   INFLAMMATION; VEGFR2
AB Osteoporosis is a chronic disease that seriously affects the quality of life and longevity of the elderly, so exploring the mechanism of osteoporosis is crucial for drug development and treatment. Bone marrow mesenchymal stem cells are stem cells with multiple differentiation potentials in bone marrow, and changing their differentiation direction can change bone mass. As an extracellular superoxide dismutase, Superoxide Dismutase 3 (SOD3) has been proved to play an important role in multiple organs, but the detailed mechanism of action in bone metabolism is still unclear.In this study, the results of clinical serum samples ELISA and single cell sequencing chip analysis proved that the expression of SOD3 was positively correlated with bone mass, and SOD3 was mainly expressed in osteoblasts and adipocytes and rarely expressed in osteoblasts in BMSCs. In vitro experiments showed that SOD3 can promote osteogenesis and inhibit adipogenesis. Compared with WT mice, the mice that were knocked out of SOD3 had a significant decrease in bone mineral density and significant changes in related parameters. The results of HE and IHC staining suggested that knocking out SOD3 would lead to fat accumulation in the bone marrow cavity and weakened osteogenesis. Both in vitro and in vivo experiments indicated that SOD3 affects bone metabolism by promoting osteogenesis and inhibiting adipogenesis. The results of transcriptome sequencing and revalidation showed that SOD3 can affect the expression of FLT1. Through in vitro experiments, we proved that FLT1 can also promote osteogenesis and inhibit adipogenesis. In addition, through the repeated experiments, the interaction between the two molecules (SOD3 and FLT1) was verified again. Finally, it was verified by WB that SOD3 regulates FLT1 to affect bone metabolism through PI3K/AKT and MAPK pathways.
C1 [Xu, Ke; Fei, Wenchao; Hong, Yang] Fudan Univ, Peoples Hosp Shanghai 5, Dept Orthoped, Shanghai, Peoples R China.
   [Cui, Ran] Tongji Univ, Shanghai Peoples Hosp 10, Sch Med, Dept Endocrinol & Metab, Shanghai, Peoples R China.
   [Xu, Ke; Fei, Wenchao; Li, Yinghua; Hong, Yang] Shanghai Clin Res Ctr Aging & Med, Shanghai, Peoples R China.
   [Xu, Ke; Fei, Wenchao; Li, Yinghua; Hong, Yang] Fudan Univ, Ctr Community Based Hlth Res, Shanghai, Peoples R China.
   [Gao, Wenxue] Tongji Univ, Shanghai Peoples Hosp 10, Sch Med, Med Serv Sect, Shanghai, Peoples R China.
   [Li, Yinghua] Fudan Univ, Peoples Hosp Shanghai 5, Cent Lab, Shanghai, Peoples R China.
   [Fan, Changxiu] Fudan Univ, Peoples Hosp Shanghai 5, Dept Stomatol, Shanghai, Peoples R China.
C3 Fudan University; Tongji University; Fudan University; Tongji
   University; Fudan University; Fudan University
RP Hong, Y (通讯作者)，Fudan Univ, Peoples Hosp Shanghai 5, Dept Orthoped, Shanghai, Peoples R China.; Cui, R (通讯作者)，Tongji Univ, Shanghai Peoples Hosp 10, Sch Med, Dept Endocrinol & Metab, Shanghai, Peoples R China.; Li, YH; Hong, Y (通讯作者)，Shanghai Clin Res Ctr Aging & Med, Shanghai, Peoples R China.
EM 21111290003@m.fudan.edu.cn; feiwenchao@fudan.edu.cn; gaowx2000@163.com;
   fancx1996119@foxmail.com; zhulihan@fudan.edu.cn; hongyangcm@163.com;
   cuiran1172@163.com
RI Li, Yinghua/C 6999 2013
OI Cui, Ran/0000 0003 4386 3140
FU Shanghai Science and Technology Commission Outstanding Academic Leader
   project [20XD1402700]; Science and Technology Commission of Shanghai
   Municipality [YNCR2C001]; Clinical research project of Shanghai Tenth
   People's Hospital of Tongji University [SHDC2022CRS033]; Shanghai
   Hospital Development Center Foundation [2021 A 2]; Teaching research
   project of Shanghai Tenth People's Hospital of Tongji University; 
   [22Y11904900];  [2019WYZD01]
FX This study was supported by Shanghai Science and Technology Commission
   Outstanding Academic Leader project (20XD1402700) , Research topics in
   the hospital (2019WYZD01) , Science and Technology Commission of
   Shanghai Municipality (22Y11904900) , Clinical research project of
   Shanghai Tenth People's Hospital of Tongji University (YNCR2C001) ,
   Teaching research project of Shanghai Tenth People's Hospital of Tongji
   University (2021 A 2) and Shanghai Hospital Development Center
   Foundation (SHDC2022CRS033) .
CR Annamalai D, 2014, J CELL BIOCHEM, V115, P1308, DOI 10.1002/jcb.24785
   Arceo Mendoza R, 2021, ENDOCRIN METAB CLIN, V50, P167, DOI 10.1016/j.ecl.2021.03.009
   Armas LAG, 2012, ENDOCRIN METAB CLIN, V41, P475, DOI 10.1016/j.ecl.2012.04.006
   Azouz AA, 2022, LIFE SCI, V288, DOI 10.1016/j.lfs.2021.120154
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Blake J, 2021, MENOPAUSE, V28, P973, DOI 10.1097/GME.0000000000001831
   Charbord P, 2010, HUM GENE THER, V21, P1045, DOI 10.1089/hum.2010.115
   Cho DI, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2013.135
   Diercke K, 2011, J DENT RES, V90, P1108, DOI 10.1177/0022034511413926
   Dong BZ, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 34869 3
   Eom J, 2022, MOL CELLS, V45, P963, DOI 10.14348/molcells.2022.0123
   Fan ZM, 2017, J ETHNOPHARMACOL, V204, P132, DOI 10.1016/j.jep.2017.04.006
   Feng HR, 2021, ONCOGENE, V40, P6115, DOI 10.1038/s41388 021 01830 5
   Gao D, 2020, ANTIOXID REDOX SIGN, V32, P193, DOI 10.1089/ars.2018.7628
   Gong CX, 2022, CELL MOL NEUROBIOL, V42, P1897, DOI 10.1007/s10571 021 01071 w
   Harris R, 2018, J ALZHEIMERS DIS, V61, P741, DOI 10.3233/JAD 170745
   Hopwood B, 2009, BONE, V44, P87, DOI 10.1016/j.bone.2008.08.120
   Hu LT, 2023, NEURAL REGEN RES, V18, P560, DOI 10.4103/1673 5374.346551
   In S, 2016, MOL NEUROBIOL, V53, P777, DOI 10.1007/s12035 014 9087 9
   Jin QH, 2021, KNEE SURG SPORT TR A, V29, P1090, DOI 10.1007/s00167 020 06099 x
   Kanis JA, 2020, OSTEOPOROSIS INT, V31, P1, DOI 10.1007/s00198 019 05176 3
   Kespohl B, 2021, CYTOKINE GROWTH F R, V60, P18, DOI 10.1016/j.cytogfr.2021.04.002
   Kim J, 2014, ANTICANCER RES, V34, P2821
   Kim SM, 1997, MOL CELLS, V7, P120
   Kwon MJ, 2015, ANTIOXID REDOX SIGN, V23, P985, DOI 10.1089/ars.2014.6035
   Lamo Espinosa JM, 2021, J TRANSL MED, V19, DOI 10.1186/s12967 021 03160 2
   LeBoff MS, 2022, OSTEOPOROSIS INT, V33, P2049, DOI 10.1007/s00198 021 05900 y
   Lewandowski L, 2019, EUR J CLIN INVEST, V49, DOI 10.1111/eci.13036
   Lin ZY, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12688
   Ling MF, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222413352
   Ma BC, 2020, BIOCHEM BIOPH RES CO, V524, P163, DOI 10.1016/j.bbrc.2020.01.060
   Mai N, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.118.011801
   Matthiesen CL, 2021, FREE RADICAL BIO MED, V164, P399, DOI 10.1016/j.freeradbiomed.2021.01.027
   Mead B, 2017, STEM CELL TRANSL MED, V6, P1273, DOI 10.1002/sctm.16 0428
   Mira E, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03079 1
   Ning WL, 2021, CELL SIGNAL, V77, DOI 10.1016/j.cellsig.2020.109812
   Nishio N, 2015, SCI REP UK, V5, DOI 10.1038/srep13519
   Ohkawa Y, 2023, ANTIOXID REDOX SIGN, V38, P1201, DOI 10.1089/ars.2022.0010
   Portokallidou K, 2023, FRONT CARDIOVASC MED, V10, DOI 10.3389/fcvm.2023.1115623
   Sadremomtaz A, 2018, BBA GEN SUBJECTS, V1862, P2688, DOI 10.1016/j.bbagen.2018.08.013
   Schoppa AM, 2022, DIS MODEL MECH, V15, DOI 10.1242/dmm.049392
   Si L, 2015, OSTEOPOROSIS INT, V26, P1929, DOI 10.1007/s00198 015 3093 2
   Tao HQ, 2021, PHARMACOL RES, V174, DOI 10.1016/j.phrs.2021.105967
   Tasaki E, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/5127251
   Tompkins YH, 2022, FRONT PHYSIOL, V13, DOI 10.3389/fphys.2022.945740
   Uemura A, 2021, PROG RETIN EYE RES, V84, DOI 10.1016/j.preteyeres.2021.100954
   Wang B, 2017, J MOL CELL BIOL, V9, P338, DOI 10.1093/jmcb/mjx026
   Wang F, 2011, J BIOL CHEM, V286, P9097, DOI 10.1074/jbc.M110.165605
   Wang XD, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02224 w
   Wert KJ, 2018, FREE RADICAL BIO MED, V124, P408, DOI 10.1016/j.freeradbiomed.2018.06.024
   Xing JY, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 04453 9
   Xu RQ, 2019, J CELL MOL MED, V23, P7617, DOI 10.1111/jcmm.14635
   Xu Y, 2022, BASIC RES CARDIOL, V117, DOI 10.1007/s00395 022 00956 1
   Yang XC, 2019, AGING US, V11, P8777, DOI 10.18632/aging.102264
   Yi X, 2022, FOLIA HISTOCHEM CYTO, V60, P179, DOI 10.5603/FHC.a2022.0012
   You WJ, 2023, J CACHEXIA SARCOPENI, V14, P326, DOI 10.1002/jcsm.13134
   Zayzafoon M, 2000, J CELL BIOCHEM, V79, P301, DOI 10.1002/1097 4644(20001101)79:2<301::AID JCB130>3.0.CO;2 0
   Zhang J, 2022, EXP NEUROL, V347, DOI 10.1016/j.expneurol.2021.113895
   Zhang JY, 2020, AGING US, V12, P25138, DOI 10.18632/aging.104110
   Zhang RP, 2011, J BIOL CHEM, V286, P41083, DOI 10.1074/jbc.M111.258715
   Zhang X, 2019, FASEB J, V33, P5495, DOI 10.1096/fj.201801907R
   Zhang YQ, 2023, BBA MOL BASIS DIS, V1869, DOI 10.1016/j.bbadis.2023.166693
   Zhang YW, 2022, SCI CHINA LIFE SCI, V65, P1636, DOI 10.1007/s11427 021 2061 7
   Zhang YD, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.722646
   Zhao YY, 2022, MOL NEUROBIOL, V59, P6771, DOI 10.1007/s12035 022 03006 y
   Zheng G, 2022, J NANOBIOTECHNOL, V20, DOI 10.1186/s12951 022 01400 1
   Zhi F, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02214 y
   Zhou J, 2016, MOL MED REP, V14, P5653, DOI 10.3892/mmr.2016.5951
NR 68
TC 11
Z9 12
U1 2
U2 23
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0891 5849
EI 1873 4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD FEB 20
PY 2024
VL 212
BP 65
EP 79
DI 10.1016/j.freeradbiomed.2023.12.021
EA DEC 2023
PG 15
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA GB5Y6
UT WOS:001150223600001
PM 38141889
OA hybrid
DA 2025 08 17
ER

PT J
AU Brom, VC
   Strauss, AC
   Sieberath, A
   Salber, J
   Burger, C
   Wirtz, DC
   Schildberg, FA
AF Brom, Victoria C. C.
   Strauss, Andreas C. C.
   Sieberath, Alexander
   Salber, Jochen
   Burger, Christof
   Wirtz, Dieter C. C.
   Schildberg, Frank A. A.
TI Agonistic and antagonistic targeting of immune checkpoint molecules
   differentially regulate osteoclastogenesis
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE immune checkpoint molecules; osteoclasts; osteolysis; osteoporosis;
   endoprosthesis loosening; cancer; osteoimmunology; musculoskeletal
   immunology
ID RECEPTOR PD 1; IN VITRO; BONE; INFLAMMATION; MECHANISMS; PRECURSORS;
   BLOCKADE; TIGIT
AB IntroductionImmune checkpoint inhibitors are used in the treatment of various cancers and have been extensively researched with regard to inflammatory and autoimmune diseases. However, this revolutionary therapeutic strategy often provokes critical auto inflammatory adverse events, such as inflammatory reactions affecting the cardiovascular, gastrointestinal, nervous, and skeletal systems. Because the function of these immunomodulatory co receptors is highly cell type specific and the role of macrophages as osteoclast precursors is widely published, we aimed to analyze the effect of immune checkpoint inhibitors on these bone resorbing cells. MethodsWe established an in vitro model of osteoclastogenesis using human peripheral blood mononuclear cells, to which various immune checkpoints and corresponding antagonistic antibodies were administered. Formation of osteoclasts was quantified and cell morphology was analyzed via immunofluorescence staining, cell size measurements, and calculation of cell numbers in a multitude of samples. ResultsThese methodical approaches for osteoclast research achieved objective, comparable, and reproducible results despite the great heterogeneity in the form, size, and number of osteoclasts. In addition to the standardization of experimental analyses involving osteoclasts, our study has revealed the substantial effects of agonistic and antagonistic checkpoint modulation on osteoclastogenesis, confirming the importance of immune checkpoints in bone homeostasis. DiscussionOur work will enable more robust and reproducible investigations into the use of immune checkpoint inhibitors in conditions with diminished bone density such as osteoporosis, aseptic loosening of endoprostheses, cancer, as well as the side effects of cancer therapy, and might even pave the way for novel individualized diagnostic and therapeutic strategies.
C1 [Brom, Victoria C. C.; Strauss, Andreas C. C.; Burger, Christof; Wirtz, Dieter C. C.; Schildberg, Frank A. A.] Univ Hosp Bonn, Clin Orthoped & Trauma Surg, Bonn, Germany.
   [Sieberath, Alexander; Salber, Jochen] Ruhr Univ Bochum, Ctr Clin Res, Dept Expt Surg, Bochum, Germany.
   [Salber, Jochen] Univ klinikum Knappschaftskrankenhaus Bochum GmbH, Dept Surg, Bochum, Germany.
C3 University of Bonn; Ruhr University Bochum; Ruhr University Bochum
RP Schildberg, FA (通讯作者)，Univ Hosp Bonn, Clin Orthoped & Trauma Surg, Bonn, Germany.
EM frank.schildberg@ukbonn.de
RI ; Salber, Jochen/ABD 5182 2020; Strauss, Andreas/AFF 8005 2022;
   Sieberath, Alexander/NQF 1506 2025
OI Strauss, Andreas/0000 0001 7777 3253; Salber,
   Jochen/0000 0001 9738 2305; Sieberath, Alexander/0000 0002 6676 4164; 
CR Abdallah D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00632
   Astarita JL, 2015, NAT IMMUNOL, V16, P75, DOI 10.1038/ni.3035
   Badran Z, 2012, J MATER SCI MATER M, V23, P797, DOI 10.1007/s10856 011 4534 x
   Borggrewe M, 2020, J MOL MED, V98, P1415, DOI 10.1007/s00109 020 01968 x
   Brom VC, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.837645
   Cai JJ, 2019, J CANCER RES CLIN, V145, P1377, DOI 10.1007/s00432 019 02879 2
   Cai XP, 2020, J CLIN LAB ANAL, V34, DOI 10.1002/jcla.23223
   Cassetta L, 2018, IMMUNOLOGY, V155, P285, DOI 10.1111/imm.12976
   Chao MP, 2020, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01380
   Chauvin JM, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc 2020 000957
   Chen X, 2016, IMMUNOBIOLOGY, V221, P48, DOI 10.1016/j.imbio.2015.08.003
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Ciapetti G, 2017, ACTA BIOMATER, V50, P102, DOI 10.1016/j.actbio.2016.12.013
   Corsello SM, 2013, J CLIN ENDOCR METAB, V98, P1361, DOI 10.1210/jc.2012 4075
   Das M, 2017, IMMUNOL REV, V276, P97, DOI 10.1111/imr.12520
   De Martinis M, 2020, CURR MED CHEM, V27, P6356, DOI 10.2174/0929867326666190730113123
   Diskin B, 2020, NAT IMMUNOL, V21, P442, DOI 10.1038/s41590 020 0620 x
   Duan ZJ, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392 021 00506 6
   Dyck L, 2017, EUR J IMMUNOL, V47, P765, DOI 10.1002/eji.201646875
   Filippini DM, 2021, INT J CANCER, V149, P675, DOI 10.1002/ijc.33592
   Fu Z, 2020, J LEUKOCYTE BIOL, V107, P309, DOI 10.1002/JLB.3A0919 387RR
   Ghiotto M, 2010, INT IMMUNOL, V22, P651, DOI 10.1093/intimm/dxq049
   Gibellini L, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00490
   Greisen SR, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.773946
   Greisen SR, 2020, J TRANSL AUTOIMMUN, V3, DOI 10.1016/j.jtauto.2019.100028
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Harjunpää H, 2020, CLIN EXP IMMUNOL, V200, P108, DOI 10.1111/cei.13407
   Hiram Bab S, 2015, FASEB J, V29, P1890, DOI 10.1096/fj.14 259085
   Hobolt Pedersen AS, 2014, CALCIFIED TISSUE INT, V95, P73, DOI 10.1007/s00223 014 9864 5
   Hou AH, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00783
   Hoves S, 2018, J EXP MED, V215, P859, DOI 10.1084/jem.20171440
   Jansen IDC, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.921066
   Johnson DB, 2022, NAT REV CLIN ONCOL, V19, P254, DOI 10.1038/s41571 022 00600 w
   Jubel JM, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.687065
   Khair DO, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00453
   Khan S, 2020, SEMIN CANCER BIOL, V64, P93, DOI 10.1016/j.semcancer.2019.06.012
   Lampiasi N, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/9089610
   Larionova I, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.566511
   Lei YN, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.617335
   Liu J, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.134728
   Lukacs Kornek V, 2011, NAT IMMUNOL, V12, P1096, DOI 10.1038/ni.2112
   Lundberg P, 2007, BIOCHEM BIOPH RES CO, V352, P444, DOI 10.1016/j.bbrc.2006.11.057
   Mantovani A, 2015, J EXP MED, V212, P435, DOI 10.1084/jem.20150295
   Moriyama K, 2014, LAB INVEST, V94, P1200, DOI 10.1038/labinvest.2014.107
   Moseley KF, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425 018 0417 8
   Nagahama K, 2004, BONE, V35, P1059, DOI 10.1016/j.bone.2004.06.018
   Nakamura M, 2013, J BIOMED MATER RES A, V101, P3141, DOI 10.1002/jbm.a.34621
   Nakashima T, 2011, ANN NY ACAD SCI, V1240, pE13, DOI 10.1111/j.1749 6632.2011.06373.x
   Ocaña Guzman R, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00229
   Oomizu S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048574
   Palmieri DJ, 2018, CURR ONCOL REP, V20, DOI 10.1007/s11912 018 0718 6
   Panagopoulos V, 2017, MOL CELL ENDOCRINOL, V440, P8, DOI 10.1016/j.mce.2016.11.007
   Pathria P, 2019, TRENDS IMMUNOL, V40, P310, DOI 10.1016/j.it.2019.02.003
   Pereira M, 2018, J CELL SCI, V131, DOI 10.1242/jcs.216267
   Philips EA, 2020, J BIOL CHEM, V295, P4372, DOI 10.1074/jbc.AC119.011747
   Postow MA, 2015, NEW ENGL J MED, V372, P2006, DOI 10.1056/NEJMoa1414428
   Robert C, 2020, NAT COMMUN, V11, DOI [10.1038/s41467 020 17670 y, 10.1038/s41467 020 17608 4]
   Sacdalan DB, 2021, ONCOTARGETS THER, V14, P2053, DOI 10.2147/OTT.S278089
   Saha D, 2017, CANCER CELL, V32, P253, DOI 10.1016/j.ccell.2017.07.006
   Schildberg FA, 2016, IMMUNITY, V44, P955, DOI 10.1016/j.immuni.2016.05.002
   Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172
   Shin HH, 2006, BONE, V39, P716, DOI 10.1016/j.bone.2006.03.015
   Sun Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.778078
   Tai YT, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01822
   Takahashi S, 2018, BIOMED REP, V9, P3, DOI 10.3892/br.2018.1102
   Tas AC, 2004, J MATER RES, V19, P2742, DOI 10.1557/JMR.2004.0349
   Terashima A, 2018, CALCIFIED TISSUE INT, V102, P503, DOI 10.1007/s00223 018 0417 1
   Tian J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.588682
   Uluçkan Ö, 2009, CANCER RES, V69, P3196, DOI 10.1158/0008 5472.CAN 08 3358
   Varayathu H, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.559161
   Vivarelli S, 2021, INT J ONCOL, V58, P145, DOI 10.3892/ijo.2020.5159
   Walsh MC, 2018, NAT REV RHEUMATOL, V14, P146, DOI 10.1038/nrrheum.2017.213
   Wang KY, 2020, J CLIN INVEST, V130, P3603, DOI 10.1172/JCI133334
   Wang XG, 2021, BIOACT MATER, V6, P4517, DOI 10.1016/j.bioactmat.2021.05.003
   Winograd R, 2015, CANCER IMMUNOL RES, V3, P399, DOI 10.1158/2326 6066.CIR 14 0215
   Wykes MN, 2018, NAT REV IMMUNOL, V18, P91, DOI 10.1038/nri.2017.112
   Xiong HZ, 2019, CANCER RES, V79, P1493, DOI 10.1158/0008 5472.CAN 18 3208
   Yao Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.664871
   Zak KM, 2017, STRUCTURE, V25, P1163, DOI 10.1016/j.str.2017.06.011
   Zhang YC, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.911180
NR 80
TC 9
Z9 9
U1 0
U2 14
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD FEB 2
PY 2023
VL 14
AR 988365
DI 10.3389/fimmu.2023.988365
PG 14
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA 8V7LS
UT WOS:000930811000001
PM 36817431
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Maurin, J
   Morel, A
   Hassen Khodja, C
   Vives, V
   Jurdic, P
   Machuca Gayet, I
   Blangy, A
AF Maurin, Justine
   Morel, Anne
   Hassen Khodja, Cedric
   Vives, Virginie
   Jurdic, Pierre
   Machuca Gayet, Irma
   Blangy, Anne
TI Combined strategy of siRNA and osteoclast actin cytoskeleton automated
   imaging to identify novel regulators of bone resorption shows a
   non mitotic function for anillin
SO EUROPEAN JOURNAL OF CELL BIOLOGY
LA English
DT Article
DE Osteoclast; Cytoskeleton; Actin; Anillin; Bone resorption; Automated
   imaging
ID BINDING PROTEIN; PODOSOME ORGANIZATION; DYNAMICS; MYOSIN;
   PHOSPHORYLATION; INTEGRITY; CORTACTIN; PATHWAY; KINASE; GTP
AB Osteoclasts are the main cells responsible for the resorption of mineralized extracellular matrices. They are the major targets for anti resorptive therapies to manage osteoporosis, a major public health problem. Osteoclasts are giant multinucleated cells that can organize their a unique adhesion structure based on a belt of podosomes, which is the keystone of the bone resorption apparatus. We combined differential transcriptomics and siRNA screening approaches to get a broader view of cytoskeletal regulators that participate in the control of osteoclast cytoskeleton and identify novel regulators of bone resorption by osteoclasts. We identified 20 new candidate regulators of osteoclasts cytoskeleton including Fkbp15, Spirel, Tacc2 and RalA, for which we confirmed they are necessary for proper organization of the podosome belt. We also showed that Anillin, well known for its role during cytokinesis, is essential in osteoclasts for correct podosome patterning and efficient bone resorption. In particular, Anillin controls the levels of the GTPase RhoA, a known regulator of osteoclast cytoskeleton and resorption activity. Finally, we set up and validated an automated imaging strategy based on open  source software for automatic and objective measurement of actin cytoskeleton organization in osteoclasts. We provide these pipelines that are useful to automatically assess the effect of collections of siRNAs or chemical compounds on osteoclast cytoskeleton or differentiation.
C1 [Maurin, Justine; Morel, Anne; Vives, Virginie; Blangy, Anne] Montpellier Univ, CNRS, CRBM, Montpellier, France.
   [Hassen Khodja, Cedric] Univ Montpellier, CNRS, INSERM, MRI, Biocampus Montpellier, Montpellier, France.
   [Jurdic, Pierre; Machuca Gayet, Irma] Univ Lyon, CNRS, Ecole Normale Super Lyon, Inst Genom Fonct Lyon,UMR3444, Lyon, France.
   [Machuca Gayet, Irma] INSERM, Unit 1033, Lyon, France.
   [Machuca Gayet, Irma] Univ Claude Bernard Lyon 1, Lyon, France.
C3 Centre National de la Recherche Scientifique (CNRS); Universite de
   Montpellier; Centre National de la Recherche Scientifique (CNRS);
   Universite de Montpellier; Institut National de la Sante et de la
   Recherche Medicale (Inserm); CHU Lyon; Centre National de la Recherche
   Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON);
   Universite Claude Bernard Lyon 1; Institut National de la Sante et de la
   Recherche Medicale (Inserm); Universite Claude Bernard Lyon 1
RP Blangy, A (通讯作者)，CNRS, CRBM, UMR 5237, 1919 Route Mende, F 34293 Montpellier 5, France.
EM anne.blangy@crbm.cnrs.fr
RI VIVES, Virginie/JVZ 4304 2024
OI BLANGY, Anne/0000 0001 7043 0784; Machuca  Gayet,
   irma/0000 0002 3010 9774; HASSEN KHODJA, CEDRIC/0000 0002 7715 7167
FU French Centre National de la Recherche Scientifique (CNRS), Montpellier
   University; Fondation pour la Recherche Medicale [LEQ20151134530];
   Societe Francaise de Rhumatologie (SFR A.P. 2014 Grant) [2676]; GEFLUC
   Languedoc Roussillon (GEFLUC LR A.P. 2015 Grant) [136873 6715711];
   Fondation ARC [PJA 20151203109]
FX This work was funded by the French Centre National de la Recherche
   Scientifique (CNRS), Montpellier University and French grants from the
   Fondation pour la Recherche Medicale (Grant #LEQ20151134530), from the
   Societe Francaise de Rhumatologie (SFR A.P. 2014 Grant #2676) and from
   the GEFLUC Languedoc Roussillon (GEFLUC LR A.P. 2015 Grant
   #136873 6715711) to A.B. and a grant from the Fondation ARC (Grant #PJA
   20151203109) to V.V.
CR Badowski C, 2008, MOL BIOL CELL, V19, P633, DOI 10.1091/mbc.E06 01 0088
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Blangy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045909
   Brazier H, 2006, J BONE MINER RES, V21, P1387, DOI 10.1359/JBMR.060613
   Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324
   Cappariello A, 2014, ARCH BIOCHEM BIOPHYS, V558, P70, DOI 10.1016/j.abb.2014.06.017
   Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb 2006 7 10 r100
   Chellaiah MA, 2000, J BIOL CHEM, V275, P11993, DOI 10.1074/jbc.275.16.11993
   Coelho LFL, 2005, P NATL ACAD SCI USA, V102, P11917, DOI 10.1073/pnas.0502188102
   Croke M, 2011, J CELL SCI, V124, P3811, DOI 10.1242/jcs.086280
   Destaing O, 2005, J CELL SCI, V118, P2901, DOI 10.1242/jcs.02425
   Destaing O, 2008, MOL BIOL CELL, V19, P394, DOI 10.1091/mbc.E07 03 0227
   Duplan MB, 2014, MOL CELL BIOL, V34, P16, DOI 10.1128/MCB.00578 13
   Faccio R, 2005, NAT MED, V11, P284, DOI 10.1038/nm1194
   Fukunaga T, 2014, J BIOL CHEM, V289, P13554, DOI 10.1074/jbc.M114.550731
   Fuller K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012837
   Gallois A, 2010, J BONE MINER RES, V25, P661, DOI 10.1359/jbmr.090829
   Georgess D, 2014, CELL ADHES MIGR, V8, P192, DOI 10.4161/cam.27840
   Georgess D, 2014, MOL BIOL CELL, V25, P380, DOI 10.1091/mbc.E13 07 0363
   Ishida Kitagawa N, 2012, J BIOL CHEM, V287, P17493, DOI 10.1074/jbc.M111.324194
   Kastner M, 2018, OSTEOPOROSIS INT, V29, P5, DOI 10.1007/s00198 017 4248 0
   Knoch KP, 2004, NAT CELL BIOL, V6, P207, DOI 10.1038/ncb1099
   Lagal V, 2014, J CELL SCI, V127, P328, DOI 10.1242/jcs.130161
   Lee SR, 2016, MOL REPROD DEV, V83, P792, DOI 10.1002/mrd.22688
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Luxenburg C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000179
   McMichael BK, 2009, J BIOL CHEM, V284, P12266, DOI 10.1074/jbc.M808621200
   Ory S, 2008, EUR J CELL BIOL, V87, P469, DOI 10.1016/j.ejcb.2008.03.002
   Pan YR, 2013, J CELL SCI, V126, P5670, DOI 10.1242/jcs.134361
   Piekny AJ, 2008, CURR BIOL, V18, P30, DOI 10.1016/j.cub.2007.11.068
   Reyes CC, 2014, CURR BIOL, V24, P1263, DOI 10.1016/j.cub.2014.04.021
   Roux C, 2018, NAT REV RHEUMATOL, V14, P67, DOI 10.1038/nrrheum.2017.218
   Rutherford EL, 2016, MOL BIOL CELL, V27, P3013, DOI 10.1091/mbc.E16 03 0198
   Saltel F, 2004, MOL BIOL CELL, V15, P5231, DOI 10.1091/mbc.E04 06 0522
   Seeman E, 2003, J APPL PHYSIOL, V95, P2142, DOI 10.1152/japplphysiol.00564.2003
   Straight AF, 2005, MOL BIOL CELL, V16, P193, DOI 10.1091/mbc.E04 08 0758
   Takegahara N, 2010, FASEB J, V24, P4782, DOI 10.1096/fj.10 158212
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Tian D, 2015, CURR BIOL, V25, P1135, DOI 10.1016/j.cub.2015.02.072
   Touaitahuata H, 2016, J CELL SCI, V129, P3449, DOI 10.1242/jcs.184622
   Touaitahuata Heiani, 2014, Small GTPases, V5, pe28119, DOI 10.4161/sgtp.28119
   Triplet CV, 2014, J CELL SCI, V127, P3699, DOI 10.1242/jcs.147504
   van Dam EM, 2006, INT J BIOCHEM CELL B, V38, P1841, DOI 10.1016/j.biocel.2006.04.006
   Vives V, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7218
   Vives V, 2011, J BONE MINER RES, V26, P1099, DOI 10.1002/jbmr.282
   Wang D, 2015, CELL MOL LIFE SCI, V72, P3185, DOI 10.1007/s00018 015 1890 6
   Wang YQ, 2008, J BONE MINER RES, V23, P260, DOI 10.1359/JBMR.071013
   Zalli D, 2016, J BONE MINER RES, V31, P1701, DOI 10.1002/jbmr.2851
   ZHANG D, 1995, J CELL SCI, V108, P2285
   Zhang L, 2010, CURR BIOL, V20, pR135, DOI 10.1016/j.cub.2009.12.017
NR 50
TC 6
Z9 7
U1 1
U2 4
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0171 9335
EI 1618 1298
J9 EUR J CELL BIOL
JI Eur. J. Cell Biol.
PD NOV
PY 2018
VL 97
IS 8
BP 568
EP 579
DI 10.1016/j.ejcb.2018.10.002
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA HJ3KA
UT WOS:000457068600005
PM 30424898
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Martin, M
   Sansalone, V
   Cooper, DML
   Forwood, MR
   Pivonka, P
AF Martin, Madge
   Sansalone, Vittorio
   Cooper, David M. L.
   Forwood, Mark R.
   Pivonka, Peter
TI Assessment of romosozumab efficacy in the treatment of postmenopausal
   osteoporosis: Results from a mechanistic PK PD mechanostat model of bone
   remodeling
SO BONE
LA English
DT Article
DE Romosozumab; Bone remodeling; Frost's mechanostat; Postmenopausal
   osteoporosis; Pharmacokinetics; Pharmacodynamics; Patient specific
   therapy
ID MEDIATED DRUG DISPOSITION; MINERAL DENSITY; NITRIC OXIDE;
   MATHEMATICAL MODEL; SERUM SCLEROSTIN; WNT; EXPRESSION; OSTEOCYTES;
   MARKERS; TARGET
AB This paper introduces a theoretical framework for the study of the efficacy of romosozumab, a humanized monoclonal antibody targeting sclerostin for the treatment of osteoporosis. We developed a comprehensive mechanistic pharmacokinetic pharmacodynamic (PK PD) model of the effect of drug treatment on bone remodeling in postmenopausal osteoporosis (PMO). We utilized a one compartment PK model to represent subcutaneous injections of romosozumab and subsequent absorption into serum. The PD model is based on a recently developed bone cell population model describing the bone remodeling process at the tissue scale. The latter accounts for mechanical feedback by incorporating nitric oxide (NO) and sclerostin (Scl) as biochemical feedback molecules. Utilizing a competitive binding model, where Wnt and Scl compete for binding to LRP5/6, allows to regulate anabolic bone remodeling responses. Here, we extended this model with respect to romosozumab binding to sclerostin. For the currently approved monthly injections of 210 mg, the model predicted a 6.59%, 10.38% and 15.25% increase in BMD at the lumbar spine after 6, 12 and 24 months, respectively. These results are in good agreement with the data reported in the literature. Our model is also able to distinguish the bone site specific drug effects. For instance, at the femoral neck, our model predicts a BMD increase of 3.85% after 12 months of 210 mg injections, which is consistent with literature observations. Finally, our simulations indicate rapid bone loss after treatment discontinuation, indicating that some additional interventions such as use of bisphosphonates are required to maintain bone mass.
C1 [Martin, Madge; Pivonka, Peter] Queensland Univ Technol, Sch Chem Phys & Mech Engn, 2 George St, Brisbane, Qld 4000, Australia.
   [Martin, Madge; Sansalone, Vittorio] Univ Paris Est Creteil, Lab Modelisat & Simulat Multiechelle MSME, UMR 8208, CNRS, 61 Ave Gen Gaulle, F 94010 Creteil, France.
   [Cooper, David M. L.] Univ Saskatchewan, Dept Anat Physiol & Pharmacol, 107 Wiggins Rd, Saskatoon, SK 107, Canada.
   [Forwood, Mark R.] Griffith Univ, Sch Med Sci, Gold Goast, Qld 4222, Australia.
C3 Queensland University of Technology (QUT); Centre National de la
   Recherche Scientifique (CNRS); CNRS   Institute for Engineering &
   Systems Sciences (INSIS); Universite Paris Est Creteil Val de Marne
   (UPEC); University of Saskatchewan; Griffith University
RP Martin, M (通讯作者)，Queensland Univ Technol, Sch Chem Phys & Mech Engn, 2 George St, Brisbane, Qld 4000, Australia.
EM madgeaudreymarie.martin@hdr.qut.edu.au
RI ; Pivonka, Peter/AAL 1053 2021; Martin, Madge/MEP 6647 2025; Forwood,
   Mark/ABA 9040 2021
OI Forwood, Mark/0000 0002 9963 1616; Pivonka, Peter/0000 0001 9183 530X;
   Martin, Madge/0000 0002 7897 197X; Cooper, David/0000 0002 3175 9170; 
CR [Anonymous], EVENITY PRESCRIBING
   [Anonymous], IUPHAR BPS GUIDE PHA
   Ardawi MSM, 2011, J BONE MINER RES, V26, P2812, DOI 10.1002/jbmr.479
   Bonewald LF, 2008, BONE, V42, P606, DOI 10.1016/j.bone.2007.12.224
   Bonewald LF, 2007, ANN NY ACAD SCI, V1116, P281, DOI 10.1196/annals.1402.018
   Bourhis E, 2010, J BIOL CHEM, V285, P9172, DOI 10.1074/jbc.M109.092130
   Cao YG, 2014, J PHARMACOKINET PHAR, V41, P375, DOI 10.1007/s10928 014 9372 2
   Chow JWM, 1998, J BONE MINER RES, V13, P1039, DOI 10.1359/jbmr.1998.13.6.1039
   Dua P, 2015, CPT PHARMACOMET SYST, V4, P324, DOI 10.1002/psp4.41
   Eudy RJ, 2015, CPT PHARMACOMET SYST, V4, P527, DOI 10.1002/psp4.12013
   Fan X, 2004, ENDOCRINOLOGY, V145, P751, DOI 10.1210/en.2003 0726
   Finkelstein JS, 2002, J CLIN ENDOCR METAB, V87, P3057, DOI 10.1210/jc.87.7.3057
   FROST HM, 1987, ANAT RECORD, V219, P1, DOI 10.1002/ar.1092190104
   Gaudio A, 2010, J CLIN ENDOCR METAB, V95, P2248, DOI 10.1210/jc.2010 0067
   Ishibashi H, 2017, BONE, V103, P209, DOI 10.1016/j.bone.2017.07.005
   Jabbar S, 2011, J CLIN PATHOL, V64, P354, DOI 10.1136/jcp.2010.086595
   Jastrzebski S, 2013, J BONE MINER RES, V28, P618, DOI 10.1002/jbmr.1773
   Ke D, 2010, BONE, V46, pS15, DOI 10.1016/j.bone.2010.01.022
   Klein Nulend J, 2013, BONE, V54, P182, DOI 10.1016/j.bone.2012.10.013
   Klika V, 2010, J MUSCULOSKEL NEURON, V10, P220
   Komarova SV, 2003, BONE, V33, P206, DOI 10.1016/S8756 3282(03)00157 1
   Kruck B, 2018, J BONE MINER RES, V33, P1686, DOI 10.1002/jbmr.3454
   Langdahl B, 2016, THER ADV MUSCULOSKEL, V8, P225, DOI 10.1177/1759720X16670154
   Langdahl BL, 2017, LANCET, V390, P1585, DOI 10.1016/S0140 6736(17)31613 6
   Legrand E, 2000, J BONE MINER RES, V15, P13, DOI 10.1359/jbmr.2000.15.1.13
   Lemaire T, 2012, Comput Methods Biomech Biomed Engin, V15 Suppl 1, P331
   Lemaire V, 2004, J THEOR BIOL, V229, P293, DOI 10.1016/j.jtbi.2004.03.023
   Lerner UH, 2006, J DENT RES, V85, P584, DOI 10.1177/154405910608500703
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Maldonado S, 2006, 2006 28TH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY, VOLS 1 15, P5842
   Markham A, 2019, DRUGS, V79, P471, DOI 10.1007/s40265 019 01072 6
   Martin M, 2019, BIOMECH MODEL MECHAN, V18, P1475, DOI 10.1007/s10237 019 01158 w
   Martínez Reina J, 2019, BONE, V125, P87, DOI 10.1016/j.bone.2019.04.022
   McClung M, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2167
   McClung MR, 2018, J BONE MINER RES, V33, P1397, DOI 10.1002/jbmr.3452
   Nazarian A, 2007, J BIOMECH, V40, P2573, DOI 10.1016/j.jbiomech.2006.11.022
   NORDIN BEC, 1990, J CLIN ENDOCR METAB, V70, P83, DOI 10.1210/jcem 70 1 83
   Padhi D, 2007, J BONE MINER RES, V22, pS37
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Pastrama MI, 2018, BONE, V107, P208, DOI 10.1016/j.bone.2017.11.009
   Paton DM, 2014, DRUG FUTURE, V39, P553, DOI 10.1358/dof.2014.039.08.2164452
   Peterson MC, 2010, BONE, V46, P49, DOI 10.1016/j.bone.2009.08.053
   Pivonka P., 2012, Cell Interaction, DOI DOI 10.5772/51149
   Pivonka P, 2008, BONE, V43, P249, DOI 10.1016/j.bone.2008.03.025
   Pivonka P, 2010, J THEOR BIOL, V262, P306, DOI 10.1016/j.jtbi.2009.09.021
   Ramtani S, 2008, INT J ENG SCI, V46, P1173, DOI 10.1016/j.ijengsci.2008.06.001
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Sansalone V, 2013, BIOMECH MODEL MECHAN, V12, P533, DOI 10.1007/s10237 012 0422 7
   Scheiner S, 2016, BIOMECH MODEL MECHAN, V15, P9, DOI 10.1007/s10237 015 0704 y
   Scheiner S, 2013, COMPUT METHOD APPL M, V254, P181, DOI 10.1016/j.cma.2012.10.015
   Spatz JM, 2015, J BIOL CHEM, V290, P16744, DOI 10.1074/jbc.M114.628313
   Stolina M, 2014, BONE, V67, P305, DOI 10.1016/j.bone.2014.07.031
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   Warmington K, 2004, J BONE MINER RES, V19, pS56
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
   Yang CS, 2015, IEEE PHOTONICS J, V7, DOI 10.1109/JPHOT.2015.2504960
   Zaman G, 1999, J BONE MINER RES, V14, P1123, DOI 10.1359/jbmr.1999.14.7.1123
NR 57
TC 16
Z9 18
U1 0
U2 19
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD APR
PY 2020
VL 133
AR 115223
DI 10.1016/j.bone.2020.115223
PG 16
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA KR1BX
UT WOS:000517355400015
PM 31935526
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Battaglino, RA
   Sudhakar, S
   Lazzari, AA
   Garshick, E
   Zafonte, R
   Morse, LR
AF Battaglino, Ricardo A.
   Sudhakar, Supreetha
   Lazzari, Antonio A.
   Garshick, Eric
   Zafonte, Ross
   Morse, Leslie R.
TI Circulating sclerostin is elevated in short term and reduced in
   long term SCI
SO BONE
LA English
DT Article
DE Osteoporosis; Sclerostin; Spinal cord injury; Rehabilitation medicine
ID SPINAL CORD INJURY; BONE MINERAL DENSITY; POSTMENOPAUSAL WOMEN; SERUM
   SCLEROSTIN; OSTEOPOROSIS; CORRELATE
AB Spinal cord injury (SCI) causes profound bone loss due to muscle paralysis resulting in the inability to walk. Sclerostin, a Wnt signaling pathway antagonist produced by osteocytes, is a potent inhibitor of bone formation. Short term studies in rodent models have demonstrated increased sclerostin in response to mechanical unloading that is reversed with reloading. Although sclerostin inhibition has been proposed as a potential therapy for bone loss, it is not known if sclerostin levels vary with duration of SCI in humans. We analyzed circulating sclerostin in 155 men with varying degrees of SCI who were 1 year or more post injury. We report that sclerostin levels are greatest in subjects with short term SCI (<= 5 years post injury) and decrease significantly over the first 5 years post injury. There was no association between sclerostin and injury duration in subjects with long term SCI (>5 years post injury). In subjects with long term SCI, sclerostin levels were positively associated with lower extremity bone density and bone mineral content. These data suggest that sclerostin levels are initially increased after SCI in response to mechanical unloading. This response is time limited and as bone loss progresses, circulating sclerostin is lowest in subjects with severe osteoporosis. These findings support a dual role for sclerostin after SCI: a therapeutic target in acute SCI, and a biomarker of osteoporosis severity in chronic SCI. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Zafonte, Ross; Morse, Leslie R.] Harvard Univ, Sch Med, Dept PMR, Boston, MA 02114 USA.
   [Battaglino, Ricardo A.; Morse, Leslie R.] Forsyth Inst, Cambridge, MA USA.
   [Battaglino, Ricardo A.] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02114 USA.
   [Sudhakar, Supreetha; Zafonte, Ross; Morse, Leslie R.] Spaulding Rehabil Hosp, Spaulding Harvard SCI Model Syst, Boston, MA USA.
   [Lazzari, Antonio A.] VA Boston Healthcare Syst, Primary Care Sect, Boston, MA USA.
   [Lazzari, Antonio A.] VA Boston Healthcare Syst, Rheumatol Sect, Boston, MA USA.
   [Lazzari, Antonio A.] Boston Univ, Sch Med, Boston, MA 02118 USA.
   [Garshick, Eric] VA Boston Healthcare Syst, Med Serv, Pulm & Crit Care Med Sect, Boston, MA USA.
   [Garshick, Eric] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Channing Lab, Boston, MA 02114 USA.
C3 Harvard University; Harvard Medical School; Harvard University; Harvard
   University Medical Affiliates; Forsyth Institute; Harvard University;
   Harvard School of Dental Medicine; Harvard University; Harvard Medical
   School; Harvard University Medical Affiliates; Spaulding Rehabilitation
   Hospital; Harvard University; Harvard University Medical Affiliates; US
   Department of Veterans Affairs; Veterans Health Administration (VHA); VA
   Boston Healthcare System; Harvard University; Harvard University Medical
   Affiliates; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); VA Boston Healthcare System; Boston University;
   Harvard University; Harvard University Medical Affiliates; US Department
   of Veterans Affairs; Veterans Health Administration (VHA); VA Boston
   Healthcare System; Harvard University; Harvard Medical School; Harvard
   University Medical Affiliates; Brigham & Women's Hospital
RP Morse, LR (通讯作者)，Harvard Univ, Sch Med, Dept PMR, 125 Nashua St, Boston, MA 02114 USA.
EM lmorse4@partners.org
RI ; Garshick, Eric/Y 6509 2019; battaglino, ricardo/D 2892 2015; Morse,
   Leslie/AAU 5608 2020
OI Lazzari, Antonio/0000 0003 0256 4742; 
FU National Institute of Child Health and Human Development [R21HD057030,
   R21HD057030 02S1]; National Institute of Arthritis and Musculoskeletal
   and Skin Diseases [1R01AR059270 02]; Office of Research and Development,
   Rehabilitation Research and Development [B6618R]; Massachusetts Veterans
   Epidemiology Research and Information Center, Cooperative Studies
   Program, Department of Veterans Affairs
FX 0This study received support from: the National Institute of Child
   Health and Human Development [R21HD057030 and R21HD057030 02S1], the
   National Institute of Arthritis and Musculoskeletal and Skin Diseases
   [1R01AR059270 02], the Office of Research and Development,
   Rehabilitation Research and Development [Merit Review Grant B6618R], and
   the Massachusetts Veterans Epidemiology Research and Information Center,
   Cooperative Studies Program, Department of Veterans Affairs.
CR Ardawi MSM, 2011, J BONE MINER RES, V26, P2812, DOI 10.1002/jbmr.479
   Bauman WA, 2009, J SPINAL CORD MED, V32, P398, DOI 10.1080/10790268.2009.11754393
   Cejka D, 2012, NEPHROL DIAL TRANSPL, V27, P226, DOI 10.1093/ndt/gfr270
   Demirel G, 1998, SPINAL CORD, V36, P822, DOI 10.1038/sj.sc.3100704
   Gaudio A, 2010, J CLIN ENDOCR METAB, V95, P2248, DOI 10.1210/jc.2010 0067
   Jiang SD, 2006, OSTEOPOROSIS INT, V17, P180, DOI 10.1007/s00198 005 2028 8
   Kirshblum SC, 2002, AM J PHYS MED REHAB, V81, P502, DOI 10.1097/00002060 200207000 00006
   Kusu N, 2003, J BIOL CHEM, V278, P24113, DOI 10.1074/jbc.M301716200
   Lewiecki EM, 2011, EXPERT OPIN BIOL TH, V11, P117, DOI 10.1517/14712598.2011.540565
   Lin CW, 2009, J BONE MINER RES, V24, P1651, DOI [10.1359/JBMR.090411, 10.1359/jbmr.090411]
   Mirza FS, 2010, J CLIN ENDOCR METAB, V95, P1991, DOI 10.1210/jc.2009 2283
   Mödder UI, 2011, J BONE MINER RES, V26, P373, DOI 10.1002/jbmr.217
   Morse LR, 2009, ARCH PHYS MED REHAB, V90, P827, DOI 10.1016/j.apmr.2008.12.004
   Pederson L, 2008, P NATL ACAD SCI USA, V105, P20764, DOI 10.1073/pnas.0805133106
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Sutherland MK, 2004, BONE, V35, P448, DOI 10.1016/j.bone.2004.04.019
   Szollar SM, 1998, AM J PHYS MED REHAB, V77, P28, DOI 10.1097/00002060 199801000 00005
   Tatsumi S, 2007, CELL METAB, V5, P464, DOI 10.1016/j.cmet.2007.05.001
NR 18
TC 41
Z9 43
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
J9 BONE
JI Bone
PD SEP
PY 2012
VL 51
IS 3
BP 600
EP 605
DI 10.1016/j.bone.2012.04.019
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 990FW
UT WOS:000307617400036
PM 22575440
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Farr, JN
   Xu, M
   Weivoda, MM
   Monroe, DG
   Fraser, DG
   Onken, JL
   Negley, BA
   Sfeir, JG
   Ogrodnik, MB
   Hachfeld, CM
   LeBrasseur, NK
   Drake, MT
   Pignolo, RJ
   Pirtskhalava, T
   Tchkonia, T
   Oursler, MJ
   Kirkland, JL
   Khosla, S
AF Farr, Joshua N.
   Xu, Ming
   Weivoda, Megan M.
   Monroe, David G.
   Fraser, Daniel G.
   Onken, Jennifer L.
   Negley, Brittany A.
   Sfeir, Jad G.
   Ogrodnik, Mikolaj B.
   Hachfeld, Christine M.
   LeBrasseur, Nathan K.
   Drake, Matthew T.
   Pignolo, Robert J.
   Pirtskhalava, Tamar
   Tchkonia, Tamara
   Oursler, Merry Jo
   Kirkland, James L.
   Khosla, Sundeep
TI Targeting cellular senescence prevents age related bone loss in mice
SO NATURE MEDICINE
LA English
DT Article
ID SECRETORY PHENOTYPE; CELLS; IDENTIFICATION; MASS; OSTEOCLASTOGENESIS;
   DYSFUNCTION; FRACTURES; ACTIVATOR; ESTROGEN; MATURE
AB Aging is associated with increased cellular senescence, which is hypothesized to drive the eventual development of multiple comorbidities(1). Here we investigate a role for senescent cells in age related bone loss through multiple approaches. In particular, we used either genetic (i.e., the INK ATTAC 'suicide' transgene encoding an inducible caspase 8 expressed specifically in senescent cells(2 4)) or pharmacological (i.e., 'senolytic' compounds(5,6)) means to eliminate senescent cells. We also inhibited the production of the proinflammatory secretome of senescent cells using a JAK inhibitor (JAKi)(3,7). In aged (20  to 22 month old) mice with established bone loss, activation of the INK ATTAC caspase 8 in senescent cells or treatment with senolytics or the JAKi for 2 4 months resulted in higher bone mass and strength and better bone microarchitecture than in vehicle treated mice. The beneficial effects of targeting senescent cells were due to lower bone resorption with either maintained (trabecular) or higher (cortical) bone formation as compared to vehicle treated mice. In vitro studies demonstrated that senescent cell conditioned medium impaired osteoblast mineralization and enhanced osteoclast progenitor survival, leading to increased osteoclastogenesis. Collectively, these data establish a causal role for senescent cells in bone loss with aging, and demonstrate that targeting these cells has both anti resorptive and anabolic effects on bone. Given that eliminating senescent cells and/or inhibiting their proinflammatory secretome also improves cardiovascular function(4), enhances insulin sensitivity(3), and reduces frailty(7), targeting this fundamental mechanism to prevent age related bone loss suggests a novel treatment strategy not only for osteoporosis, but also for multiple age related comorbidities.
C1 [Farr, Joshua N.; Xu, Ming; Weivoda, Megan M.; Monroe, David G.; Fraser, Daniel G.; Onken, Jennifer L.; Negley, Brittany A.; Sfeir, Jad G.; Ogrodnik, Mikolaj B.; Hachfeld, Christine M.; LeBrasseur, Nathan K.; Drake, Matthew T.; Pignolo, Robert J.; Pirtskhalava, Tamar; Tchkonia, Tamara; Oursler, Merry Jo; Kirkland, James L.; Khosla, Sundeep] Mayo Clin, Coll Med, Robert & Arlene Kogod Ctr Aging, Rochester, MN 55905 USA.
   [Farr, Joshua N.; Xu, Ming; Weivoda, Megan M.; Monroe, David G.; Fraser, Daniel G.; Onken, Jennifer L.; Negley, Brittany A.; Sfeir, Jad G.; Ogrodnik, Mikolaj B.; Hachfeld, Christine M.; LeBrasseur, Nathan K.; Drake, Matthew T.; Pignolo, Robert J.; Pirtskhalava, Tamar; Tchkonia, Tamara; Oursler, Merry Jo; Kirkland, James L.; Khosla, Sundeep] Mayo Clin, Coll Med, Div Endocrinol, Rochester, MN 55905 USA.
C3 Mayo Clinic; Mayo Clinic
RP Kirkland, JL; Khosla, S (通讯作者)，Mayo Clin, Coll Med, Robert & Arlene Kogod Ctr Aging, Rochester, MN 55905 USA.; Kirkland, JL; Khosla, S (通讯作者)，Mayo Clin, Coll Med, Div Endocrinol, Rochester, MN 55905 USA.
EM kirkland.james@mayo.edu; khosla.sundeep@mayo.edu
RI ; Sfeir, Jad/X 4788 2018; Ogrodnik, Mikolaj/GSI 9480 2022; Farr,
   Joshua/B 3355 2011; Xu, Ming/L 4044 2019; Khosla, Sundeep/AAE 6170 2020;
   Kirkland, James/F 9159 2016; LeBrasseur, Nathan/HGD 6434 2022
OI Xu, Ming/0000 0002 4477 939X; Rowsey, Jennifer/0009 0005 0677 7907;
   Sfeir, Jad/0000 0003 1576 1534; Ogrodnik, Mikolaj/0000 0003 3137 2037;
   Tchkonia, Tamar/0000 0003 4623 7145; 
FU NIH [P01 AG004875, R01 AG048792, K01 AR070241, K01 AR070281, R01
   AR068275, R37 AG013925, AG R21 049182]; Connor Group; Noaber; Ted Nash
   Foundations; Glenn Foundation; High Risk Pilot Award; Career Development
   Awards from the Mayo Clinic Robert and Arlene Kogod Center on Aging;
   Richard F. Emslander Career Development Award in Endocrinology; James A.
   Ruppe Career Development Award in Endocrinology; Glenn/American
   Federation for Aging Research Postdoctoral Fellowship for Translational
   Research on Aging; Biotechnology and Biological Sciences Research
   Council [1369828] Funding Source: researchfish
FX This work was supported by NIH grants P01 AG004875 (S.K.), R01 AG048792
   (S.K.), K01 AR070241 (J.N.F.), K01 AR070281 (M.M.W.), R01 AR068275
   (D.G.M.), R37 AG013925 (J.L.K.), AG R21 049182 (J.L.K.), the Connor
   Group, the Noaber, and the Ted Nash Foundations (J.L.K.), the Glenn
   Foundation (J.L.K., N.K.L.), and both a High Risk Pilot Award (J.N.F.
   and S.K.) and Career Development Awards (J.N.F. and M.M.W.) from the
   Mayo Clinic Robert and Arlene Kogod Center on Aging, as well as the
   Richard F. Emslander Career Development Award in Endocrinology (J.N.F.),
   the James A. Ruppe Career Development Award in Endocrinology (M.M.W.),
   and the Glenn/American Federation for Aging Research Postdoctoral
   Fellowship for Translational Research on Aging (M.X.). We thank M. Ruan,
   G.L. Evans, B.S. Thicke, and J.M. Peterson (Mayo Clinic) for their
   technical assistance. We also thank A.R. Thoreson, A.W. Hooke (Mayo
   Clinic), and the Mayo Clinic Materials and Structural Testing Resource
   Laboratory for performing the bone biomechanical compression and
   nano indentation testing.
CR Acosta JC, 2013, NAT CELL BIOL, V15, P978, DOI 10.1038/ncb2784
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Baker DJ, 2011, NATURE, V479, P232, DOI 10.1038/nature10600
   BELLIDO T, 1995, J CLIN INVEST, V95, P2886, DOI 10.1172/JCI117995
   Bendre MS, 2003, BONE, V33, P28, DOI 10.1016/S8756 3282(03)00086 3
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003
   Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233
   Coppé JP, 2010, ANNU REV PATHOL MECH, V5, P99, DOI 10.1146/annurev pathol 121808 102144
   D'Andrea G, 2015, FITOTERAPIA, V106, P256, DOI 10.1016/j.fitote.2015.09.018
   Daci E, 2000, J BONE MINER RES, V15, P1510, DOI 10.1359/jbmr.2000.15.8.1510
   Farr JN, 2016, J BONE MINER RES, V31, P1920, DOI 10.1002/jbmr.2892
   Gingery A, 2003, J CELL BIOCHEM, V89, P165, DOI 10.1002/jcb.10503
   Glatt V, 2007, J BONE MINER RES, V22, P1197, DOI 10.1359/JBMR.070507
   Hamrick MW, 2006, BONE, V39, P845, DOI 10.1016/j.bone.2006.04.011
   Herbig U, 2006, SCIENCE, V311, P1257, DOI 10.1126/science.1122446
   Jurk D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5172
   Jurk D, 2012, AGING CELL, V11, P996, DOI 10.1111/j.1474 9726.2012.00870.x
   Khosla S, 2012, J BONE MINER RES, V27, P506, DOI 10.1002/jbmr.1541
   Kirkland JL, 2015, EXP GERONTOL, V68, P19, DOI 10.1016/j.exger.2014.10.012
   LeBrasseur NK, 2015, NESTLE NUTR WORKS SE, V83, P11, DOI 10.1159/000382054
   Lee BY, 2006, AGING CELL, V5, P187, DOI 10.1111/j.1474 9726.2006.00199.x
   Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941
   McGee Lawrence ME, 2013, BONE, V52, P296, DOI 10.1016/j.bone.2012.10.015
   Minamino T, 2009, NAT MED, V15, P1082, DOI 10.1038/nm.2014
   Mullard A, 2016, NAT REV DRUG DISCOV, V15, P669, DOI 10.1038/nrd.2016.207
   Nelson G, 2012, AGING CELL, V11, P345, DOI 10.1111/j.1474 9726.2012.00795.x
   OLIVER WC, 1992, J MATER RES, V7, P1564, DOI 10.1557/JMR.1992.1564
   Qing H, 2012, J BONE MINER RES, V27, P1018, DOI 10.1002/jbmr.1567
   Roos CM, 2016, AGING CELL, V15, P973, DOI 10.1111/acel.12458
   Silva MJ, 2004, BONE, V35, P425, DOI 10.1016/j.bone.2004.03.027
   Stern AR, 2012, BIOTECHNIQUES, V52, P361, DOI 10.2144/0000113876
   Swanson EC, 2013, J CELL BIOL, V203, P929, DOI 10.1083/jcb.201306073
   Syed FA, 2005, J BONE MINER RES, V20, P1992, DOI 10.1359/JBMR.050713
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Tchkonia T, 2005, AM J PHYSIOL ENDOC M, V288, pE267, DOI 10.1152/ajpendo.00265.2004
   Tchkonia T, 2013, J CLIN INVEST, V123, P966, DOI 10.1172/JCI64098
   WANG E, 1995, CANCER RES, V55, P2284
   Wright NC, 2014, J BONE MINER RES, V29, P2520, DOI 10.1002/jbmr.2269
   Xu M, 2015, ELIFE, V4, DOI 10.7554/eLife.12997
   Xu M, 2015, P NATL ACAD SCI USA, V112, pE6301, DOI 10.1073/pnas.1515386112
   Yi JS, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.90220
   Zhu Y, 2016, AGING CELL, V15, P428, DOI 10.1111/acel.12445
   Zhu Y, 2015, AGING CELL, V14, P644, DOI 10.1111/acel.12344
   Zhu Y, 2014, CURR OPIN CLIN NUTR, V17, P324, DOI 10.1097/MCO.0000000000000065
NR 45
TC 834
Z9 926
U1 13
U2 241
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013 1917 USA
SN 1078 8956
EI 1546 170X
J9 NAT MED
JI Nat. Med.
PD SEP
PY 2017
VL 23
IS 9
BP 1072
EP +
DI 10.1038/nm.4385
PG 15
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA FG2XO
UT WOS:000409996200014
PM 28825716
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Ndong, JD
   Makowski, AJ
   Uppuganti, S
   Vignaux, G
   Ono, K
   Perrien, DS
   Joubert, S
   Baglio, SR
   Granchi, D
   Stevenson, DA
   Rios, JJ
   Nyman, JS
   Elefteriou, F
AF Ndong, Jean de la Croix
   Makowski, Alexander J.
   Uppuganti, Sasidhar
   Vignaux, Guillaume
   Ono, Koichiro
   Perrien, Daniel S.
   Joubert, Simon
   Baglio, Serena R.
   Granchi, Donatella
   Stevenson, David A.
   Rios, Jonathan J.
   Nyman, Jeffry S.
   Elefteriou, Florent
TI Asfotase α improves bone growth, mineralization and strength in mouse
   models of neurofibromatosis type 1
SO NATURE MEDICINE
LA English
DT Article
ID SUPPRESSES OSTEOBLAST DIFFERENTIATION; CONGENITAL PSEUDOARTHROSIS;
   MORPHOGENETIC PROTEIN 7; INORGANIC PYROPHOSPHATE; ENZYME REPLACEMENT;
   TIBIAL PSEUDOARTHROSIS; DISTINCT ROLES; NF1; OSTEOPONTIN; EXPRESSION
AB Individuals with neurofibromatosis type 1 (NF1) can manifest focal skeletal dysplasias that remain extremely difficult to treat. NF1 is caused by mutations in the NF1 gene, which encodes the RAS GTPase activating protein neurofibromin. We report here that ablation of Nf1 in bone forming cells leads to supraphysiologic accumulation of pyrophosphate (PPi), a strong inhibitor of hydroxyapatite formation, and that a chronic extracellular signal regulated kinase (ERK) dependent increase in expression of genes promoting PPi synthesis and extracellular transport, namely Enpp1 and Ank, causes this phenotype. Nf1 ablation also prevents bone morphogenic protein 2 induced osteoprogenitor differentiation and, consequently, expression of alkaline phosphatase and PPi breakdown, further contributing to PPi accumulation. The short stature and impaired bone mineralization and strength in mice lacking Nf1 in osteochondroprogenitors or osteoblasts can be corrected by asfotase alpha enzyme therapy aimed at reducing PPi concentration. These results establish neurofibromin as an essential regulator of bone mineralization. They also suggest that altered PPi homeostasis contributes to the skeletal dysplasias associated with NF1 and that some of the NF1 skeletal conditions could be prevented pharmacologically.
C1 [Ndong, Jean de la Croix; Makowski, Alexander J.; Uppuganti, Sasidhar; Vignaux, Guillaume; Ono, Koichiro; Perrien, Daniel S.; Nyman, Jeffry S.; Elefteriou, Florent] Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Bone Biol, Nashville, TN 37235 USA.
   [Ndong, Jean de la Croix; Vignaux, Guillaume; Ono, Koichiro; Elefteriou, Florent] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA.
   [Makowski, Alexander J.; Nyman, Jeffry S.] Vanderbilt Univ, Dept Biomed Engn, Nashville, TN 37235 USA.
   [Makowski, Alexander J.; Uppuganti, Sasidhar; Perrien, Daniel S.; Nyman, Jeffry S.] Vanderbilt Univ, Med Ctr, Dept Orthopaed Surg & Rehabil, Nashville, TN USA.
   [Makowski, Alexander J.; Perrien, Daniel S.; Nyman, Jeffry S.] Tennessee Valley Healthcare Syst, Dept Vet Affairs, Nashville, TN USA.
   [Ono, Koichiro] Nohon Koukan Hosp, Dept Orthopaed, Kawasaki, Kanagawa, Japan.
   [Perrien, Daniel S.] Vanderbilt Univ, Med Ctr, Inst Imaging Sci, Nashville, TN USA.
   [Joubert, Simon] Alex Pharmaceut, Cheshire, CT USA.
   [Baglio, Serena R.; Granchi, Donatella] Ist Ortoped Rizzoli, Lab Orthoped Pathophysiol & Regenerat Med, Bologna, Italy.
   [Stevenson, David A.] Univ Utah, Dept Pediat, Salt Lake City, UT USA.
   [Rios, Jonathan J.] Texas Scottish Rite Hosp Children, Sarah M & Charles E Seay Ctr Musculoskeletal Res, Dallas, TX 75219 USA.
   [Rios, Jonathan J.] UT SW Med Ctr Dallas, Dept Pediat, Dallas, TX USA.
   [Rios, Jonathan J.] UT SW Med Ctr Dallas, Eugene McDermott Ctr Human Growth & Dev, Dallas, TX USA.
   [Rios, Jonathan J.] UT SW Med Ctr Dallas, Dept Orthopaed Surg, Dallas, TX USA.
   [Elefteriou, Florent] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA.
   [Elefteriou, Florent] Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN USA.
C3 Vanderbilt University; Vanderbilt University; Vanderbilt University;
   Vanderbilt University; US Department of Veterans Affairs; Veterans
   Health Administration (VHA); VA Tennessee Valley Healthcare System;
   Vanderbilt University; IRCCS Istituto Ortopedico Rizzoli; Utah System of
   Higher Education; University of Utah; Texas Scottish Rite Hospital for
   Children; University of Texas System; University of Texas Southwestern
   Medical Center; University of Texas System; University of Texas
   Southwestern Medical Center; University of Texas System; University of
   Texas Southwestern Medical Center; Vanderbilt University; Vanderbilt
   University
RP Elefteriou, F (通讯作者)，Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Bone Biol, Nashville, TN 37235 USA.
EM florent.elefteriou@vanderbilt.edu
RI ; Granchi, Donatella/J 3647 2016; Perrien, Daniel/ISV 0029 2023;
   Elefteriou, Florent/P 2586 2017; Nyman, Jeffry/L 5736 2013
OI Nyman, Jeffry/0000 0001 7403 7605; Granchi,
   Donatella/0000 0001 7225 0023; Elefteriou, Florent/0000 0002 2972 5633;
   Uppuganti, Sasidhar/0000 0002 0656 2122; Baglio, Serena
   Rubina/0000 0003 0503 8908; Perrien, Daniel/0000 0002 5488 3932; 
FU Children's Tumor Foundation [2012 01 028]; US National Institute of
   Arthritis and Musculoskeletal and Skin Diseases; National Center for
   Research Resources of the US National Institutes of Health [5R01
   AR055966, S10 RR027631]; National Center for Advancing Translational
   Sciences of the National Institutes of Health [UL1TR001105]; Pediatric
   Orthopaedic Society of North America; Texas Scottish Rite Hospital for
   Children; US Army Medical Research Acquisition Activity
   [W81XWH 11 1 0250]
FX We thank A. Bianchi and F. Cailotto for their help in establishing the
   PP<INF>1</INF> measurement protocol and K.S. Campbell for editorial
   assistance. This work was supported by a Young Investigator Award
   (2012 01 028) from the Children's Tumor Foundation (J.d.l.C.N.), the US
   National Institute of Arthritis and Musculoskeletal and Skin Diseases
   and National Center for Research Resources, part of the US National
   Institutes of Health, under award numbers 5R01 AR055966 (F.E.) and S10
   RR027631 (D.S.P.), the National Center for Advancing Translational
   Sciences of the National Institutes of Health under award number
   UL1TR001105 (J.J.R.), the Pediatric Orthopaedic Society of North America
   and Texas Scottish Rite Hospital for Children (J.J.R.) and the US Army
   Medical Research Acquisition Activity under award W81XWH 11 1 0250
   (D.A.S.). The content is solely the responsibility of the authors and
   does not necessarily represent the official views of the US National
   Institutes of Health or US government.
CR Addison WN, 2007, J BIOL CHEM, V282, P15872, DOI 10.1074/jbc.M701116200
   Alves RDAM, 2013, MOL CELL PROTEOMICS, V12, P2890, DOI 10.1074/mcp.M112.024927
   Anticevic D, 2006, J PEDIATR ORTHOP B, V15, P220, DOI 10.1097/01.bpb.0000194439.75378.ac
   Cailotto F, 2010, J BIOL CHEM, V285, P10572, DOI 10.1074/jbc.M109.050534
   Duman O, 2008, BRAIN DEV JPN, V30, P584, DOI 10.1016/j.braindev.2008.02.002
   Elefteriou F, 2006, CELL METAB, V4, P441, DOI 10.1016/j.cmet.2006.10.010
   Elefteriou F, 2009, AM J MED GENET A, V149A, P2327, DOI 10.1002/ajmg.a.33045
   Fabeck L, 2006, J BONE JOINT SURG BR, V88B, P116, DOI 10.1302/0301 620X.88B1.16619
   Harmey D, 2004, AM J PATHOL, V164, P1199, DOI 10.1016/S0002 9440(10)63208 7
   Hatch NE, 2005, CONNECT TISSUE RES, V46, P184, DOI 10.1080/03008200500237203
   HUSON SM, 1989, J MED GENET, V26, P704, DOI 10.1136/jmg.26.11.704
   Ippolito E, 2000, J PEDIATR ORTHOP B, V9, P3, DOI 10.1097/01202412 200001000 00002
   Johnson K, 2003, J BONE MINER RES, V18, P994, DOI 10.1359/jbmr.2003.18.6.994
   Kolanczyk M, 2007, HUM MOL GENET, V16, P874, DOI 10.1093/hmg/ddm032
   Kühnisch J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086115
   Kuorilehto T, 2005, OSTEOPOROSIS INT, V16, P928, DOI 10.1007/s00198 004 1801 4
   Kyono A, 2012, J BONE MINER METAB, V30, P19, DOI 10.1007/s00774 011 0288 2
   Larizza L, 2009, CURR MOL MED, V9, P634, DOI 10.2174/156652409788488801
   Le LQ, 2007, ONCOGENE, V26, P4609, DOI 10.1038/sj.onc.1210261
   Lecanda F, 1997, J CELL BIOCHEM, V67, P386, DOI 10.1002/(SICI)1097 4644(19971201)67:3<386::AID JCB10>3.3.CO;2 5
   Lee DY, 2011, CLIN ORTHOP SURG, V3, P230, DOI 10.4055/cios.2011.3.3.230
   Lee FYI, 2006, J BONE JOINT SURG AM, V88A, P627, DOI 10.2106/JBJS.D.02201
   Leskelä HV, 2009, BONE, V44, P243, DOI 10.1016/j.bone.2008.10.050
   Lian N, 2012, J BIOL CHEM, V287, P35975, DOI 10.1074/jbc.M112.372458
   Liu SG, 2007, AM J PHYSIOL ENDOC M, V293, pE1636, DOI 10.1152/ajpendo.00396.2007
   MacRae VE, 2010, BONE, V46, P1146, DOI 10.1016/j.bone.2009.12.018
   Neitzschman H R, 2001, J La State Med Soc, V153, P119
   Ono K, 2013, HUM MOL GENET, V22, P3048, DOI 10.1093/hmg/ddt162
   Rhodes SD, 2013, J BONE MINER RES, V28, P2476, DOI 10.1002/jbmr.1992
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Schindeler A, 2011, J BONE JOINT SURG BR, V93B, P1134, DOI 10.1302/0301 620X.93B8.25940
   Schindeler A, 2008, J ORTHOP RES, V26, P65, DOI 10.1002/jor.20481
   Seitz S, 2010, OSTEOPOROSIS INT, V21, P119, DOI 10.1007/s00198 009 0933 y
   Sohn P, 2002, OSTEOARTHR CARTILAGE, V10, P482, DOI 10.1053/joca.2002.0810
   Sowa H, 2002, J BIOL CHEM, V277, P36024, DOI 10.1074/jbc.M206030200
   Stevenson DA, 2006, AM J HUM GENET, V79, P143, DOI 10.1086/504441
   Stevenson DA, 1999, AM J MED GENET, V84, P413, DOI 10.1002/(SICI)1096 8628(19990611)84:5<413::AID AJMG5>3.0.CO;2 1
   Stevenson DA, 2007, J PEDIATR US, V150, P83, DOI 10.1016/j.jpeds.2006.10.048
   Stevenson DA, 2013, J PEDIATR ORTHOPED, V33, P269, DOI 10.1097/BPO.0b013e31828121b8
   Sullivan K, 2011, BONE, V49, P1311, DOI 10.1016/j.bone.2011.09.043
   Terkeltaub RA, 1998, J BONE MINER RES, V13, P931, DOI 10.1359/jbmr.1998.13.6.931
   Terkeltaub RA, 2001, AM J PHYSIOL CELL PH, V281, pC1, DOI 10.1152/ajpcell.2001.281.1.C1
   Vitale MG, 2002, CLIN ORTHOP RELAT R, P107, DOI 10.1097/01.blo.0000022199.37246.c9
   Wang H, 2008, J BONE MINER RES, V23, P939, DOI 10.1359/JBMR.080220
   Wang WX, 2011, HUM MOL GENET, V20, P3910, DOI 10.1093/hmg/ddr310
   Wang WX, 2010, J BONE MINER RES, V25, P1658, DOI 10.1002/jbmr.42
   Whyte MP, 2012, NEW ENGL J MED, V366, P904, DOI 10.1056/NEJMoa1106173
   Whyte MP, 2010, ANN NY ACAD SCI, V1192, P190, DOI 10.1111/j.1749 6632.2010.05387.x
   Wu XH, 2006, HUM MOL GENET, V15, P2837, DOI 10.1093/hmg/ddl208
   Yadav MC, 2012, J BONE MINER RES, V27, P1722, DOI 10.1002/jbmr.1619
   Yadav MC, 2011, BONE, V49, P250, DOI 10.1016/j.bone.2011.03.770
   Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200
   Zhu Y, 2001, GENE DEV, V15, P859, DOI 10.1101/gad.862101
NR 53
TC 54
Z9 73
U1 0
U2 21
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013 1917 USA
SN 1078 8956
EI 1546 170X
J9 NAT MED
JI Nat. Med.
PD AUG
PY 2014
VL 20
IS 8
BP 904
EP 910
DI 10.1038/nm.3583
PG 7
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA AM7UQ
UT WOS:000340074600022
PM 24997609
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Blazek, JD
   Abeysekera, I
   Li, JL
   Roper, RJ
AF Blazek, Joshua D.
   Abeysekera, Irushi
   Li, Jiliang
   Roper, Randall J.
TI Rescue of the abnormal skeletal phenotype in Ts65Dn Down syndrome mice
   using genetic and therapeutic modulation of trisomic Dyrk1a
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID SYNDROME MOUSE MODEL; OSTEOCLAST DIFFERENTIATION; MENTAL RETARDATION;
   BONE; EXPRESSION; OSTEOPOROSIS; PROTEIN; ADULTS;
   EPIGALLOCATECHIN 3 GALLATE; HAPLOINSUFFICIENCY
AB Trisomy 21 causes skeletal alterations in individuals with Down syndrome (DS), but the causative trisomic gene and a therapeutic approach to rescue these abnormalities are unknown. Individuals with DS display skeletal alterations including reduced bone mineral density, modified bone structure and distinctive facial features. Due to peripheral skeletal anomalies and extended longevity, individuals with DS are increasingly more susceptible to bone fractures. Understanding the genetic and developmental origin of DS skeletal abnormalities would facilitate the development of therapies to rescue these and other deficiencies associated with DS. DYRK1A is found in three copies in individuals with DS and Ts65Dn DS mice and has been hypothesized to be involved in many Trisomy 21 phenotypes including skeletal abnormalities. Return of Dyrk1a copy number to normal levels in Ts65Dn mice rescued the appendicular bone abnormalities, suggesting that appropriate levels of DYRK1A expression are critical for the development and maintenance of the DS appendicular skeleton. Therapy using the DYRK1A inhibitor epigallocatechin 3 gallate improved Ts65Dn skeletal phenotypes. These outcomes suggest that the osteopenic phenotype associated with DS may be rescued postnatally by targeting trisomic Dyrk1a.
C1 [Roper, Randall J.] Indiana Univ Purdue Univ, Dept Biol, Indianapolis, IN 46202 USA.
   Indiana Univ, Ctr Regenerat Biol & Med, Indianapolis, IN 46202 USA.
C3 Purdue University System; Purdue University; Purdue University in
   Indianapolis; Indiana University System; Indiana University Indianapolis
RP Roper, RJ (通讯作者)，Indiana Univ Purdue Univ, Dept Biol, 723 W Michigan St,SL 306, Indianapolis, IN 46202 USA.
EM rjroper@iupui.edu
OI Roper, Randall J./0000 0002 9860 5037
FU Jerome Lejuene Foundation; Blue River Community Foundation; National
   Science Foundation [DGE 07042475]; Purdue Research Foundation
FX This work was supported by grants from the Jerome Lejuene Foundation
   (R.J.R.), the Blue River Community Foundation (R.J.R.), a National
   Science Foundation GK 12 fellowship (grant number DGE 07042475 to
   J.D.B.) and the Purdue Research Foundation (J.D.B.).
CR Abekhoukh S, 2013, MOL NEUROBIOL, V47, P105, DOI 10.1007/s12035 012 8326 1
   Angelopoulou N, 2000, CALCIFIED TISSUE INT, V66, P176, DOI 10.1007/s002230010035
   Antonarakis SE, 2006, TRENDS MOL MED, V12, P473, DOI 10.1016/j.molmed.2006.08.005
   Arron JR, 2006, NATURE, V441, P595, DOI 10.1038/nature04678
   Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535
   Baptista F, 2005, OSTEOPOROSIS INT, V16, P380, DOI 10.1007/s00198 004 1687 1
   Becker W, 1998, J BIOL CHEM, V273, P25893, DOI 10.1074/jbc.273.40.25893
   Blazek JD, 2015, MECH DEVELOP, V136, P133, DOI 10.1016/j.mod.2014.12.004
   Blazek JD, 2011, BONE, V48, P275, DOI 10.1016/j.bone.2010.09.028
   Canzonetta C, 2008, AM J HUM GENET, V83, P388, DOI 10.1016/j.ajhg.2008.08.012
   Carfi A, 2014, FRONT MED, V1, DOI 10.3389/fmed.2014.00051
   Center J, 1998, AM J MENT RETARD, V103, P19, DOI 10.1352/0895 8017(1998)103<0019:PWMRHA>2.0.CO;2
   Cooper JD, 2001, P NATL ACAD SCI USA, V98, P10439, DOI 10.1073/pnas.181219298
   De la Torre R, 2014, MOL NUTR FOOD RES, V58, P278, DOI 10.1002/mnfr.201300325
   de Lagrán MM, 2004, NEUROBIOL DIS, V15, P132, DOI 10.1016/j.nbd.2003.10.002
   Erlebacher A, 1996, J CELL BIOL, V132, P195, DOI 10.1083/jcb.132.1.195
   Fotaki V, 2004, BEHAV NEUROSCI, V118, P815, DOI 10.1037/0735 7044.118.4.815
   Fotaki V, 2002, MOL CELL BIOL, V22, P6636, DOI 10.1128/MCB.22.18.6636 6647.2002
   Fowler TW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042967
   García Cerro S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106572
   Gardiner KJ, 2014, DRUG DES DEV THER, V9, P103, DOI 10.2147/DDDT.S51476
   Guijarro M, 2008, J INTELL DISABIL RES, V52, P182, DOI 10.1111/j.1365 2788.2007.00992.x
   Hämmerle B, 2011, DEVELOPMENT, V138, P2543, DOI 10.1242/dev.066167
   He YZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024780
   Hill CA, 2009, AM J MED GENET A, V149A, P2158, DOI 10.1002/ajmg.a.33012
   Korbel JO, 2009, P NATL ACAD SCI USA, V106, P12031, DOI 10.1073/pnas.0813248106
   Lee Y, 2009, J BIOL CHEM, V284, P33343, DOI 10.1074/jbc.M109.042234
   de Moraes MEL, 2008, SPEC CARE DENT, V28, P101, DOI 10.1111/j.1754 4505.2008.00020.x
   Li XY, 2013, J NUTRIGENET NUTRIGE, V6, P169, DOI 10.1159/000354402
   Lyle R, 2009, EUR J HUM GENET, V17, P454, DOI 10.1038/ejhg.2008.214
   McKelvey KD, 2013, OSTEOPOROSIS INT, V24, P1333, DOI 10.1007/s00198 012 2109 4
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Moore CS, 2006, MAMM GENOME, V17, P1005, DOI 10.1007/s00335 006 0032 8
   Neal JW, 2001, J BIOL CHEM, V276, P3666, DOI 10.1074/jbc.M004888200
   Nizetic D, 2012, NAT REV CANCER, V12, P721, DOI 10.1038/nrc3355
   Oka Y, 2012, J PHARMACOL SCI, V118, P55, DOI 10.1254/jphs.11082FP
   Papadopoulos C, 2011, J BIOL CHEM, V286, P5494, DOI 10.1074/jbc.M110.157909
   Park Joongkyu, 2013, Exp Neurobiol, V22, P244, DOI 10.5607/en.2013.22.4.244
   Park J, 2009, CELL MOL LIFE SCI, V66, P3235, DOI 10.1007/s00018 009 0123 2
   Parker SE, 2010, BIRTH DEFECTS RES A, V88, P1008, DOI 10.1002/bdra.20735
   Parsons T, 2007, ANAT REC, V290, P414, DOI 10.1002/ar.20494
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Pons Espinal M, 2013, NEUROBIOL DIS, V60, P18, DOI 10.1016/j.nbd.2013.08.008
   REEVES RH, 1995, NAT GENET, V11, P177, DOI 10.1038/ng1095 177
   Reinholdt LG, 2011, MAMM GENOME, V22, P685, DOI 10.1007/s00335 011 9357 z
   Richtsmeier JT, 2000, DEV DYNAM, V217, P137, DOI 10.1002/(SICI)1097 0177(200002)217:2<137::AID DVDY1>3.0.CO;2 N
   Sato K, 2006, NAT MED, V12, P1410, DOI 10.1038/nm1515
   Schenk RK, 1984, METHODS CALCIFIED TI, P1
   Schrager S, 2004, J WOMENS HEALTH, V13, P431, DOI 10.1089/154099904323087123
   Spellman C, 2013, GENE, V512, P219, DOI 10.1016/j.gene.2012.10.051
   TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756 3282(93)90081 K
   Van Allen MI, 1999, AM J MED GENET, V89, P100, DOI 10.1002/(SICI)1096 8628(19990625)89:2<100::AID AJMG8>3.0.CO;2 N
   Yagi H, 2013, J CELL BIOCHEM, V114, P1163, DOI 10.1002/jcb.24459
   Yang EJ, 2001, J BIOL CHEM, V276, P39819, DOI 10.1074/jbc.M104091200
NR 54
TC 39
Z9 47
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964 6906
EI 1460 2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD OCT 15
PY 2015
VL 24
IS 20
BP 5687
EP 5696
DI 10.1093/hmg/ddv284
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA CT7VM
UT WOS:000363022600003
PM 26206885
OA Bronze, Green Submitted
DA 2025 08 17
ER

PT J
AU Chen, L
   Xiong, L
   Yao, LL
   Pan, JX
   Arzola, E
   Zhu, XJ
   Mei, L
   Xiong, WC
AF Chen, Li
   Xiong, Lei
   Yao, Lingling
   Pan, Jinxiu
   Arzola, Emily
   Zhu, Xiaojuan
   Mei, Lin
   Xiong, Wen Cheng
TI Attenuation of Alzheimer's brain pathology in 5XFAD mice by
   PTH1 34, a peptide of parathyroid hormone
SO ALZHEIMERS RESEARCH & THERAPY
LA English
DT Article
DE Alzheimer's disease; PTH; A beta; Neuroinflammation; Astrocytes
ID CALCIUM SENSING RECEPTOR; CENTRAL NERVOUS SYSTEM; MOUSE MODEL; DISEASE;
   EXPRESSION; MECHANISMS; PROMOTES; DEFICITS; DENSITY; CELLS
AB BackgroundAlzheimer's disease (AD) and osteoporosis are two distinct diseases but often occur in the same patient. Their relationship remains poorly understood. Studies using Tg2576 AD animal model demonstrate bone deficits, which precede the brain phenotypes by several months, arguing for the independence of bone deficits on brain degeneration and raising a question if the bone deficits contribute to the AD development. To address this question, we investigated the effects of PTH1 34, a peptide of parathyroid hormone analog and a well recognized effective anabolic therapy drug for patients with osteoporosis, on 5XFAD animal model.Methods5XFAD mice, an early onset beta amyloid (A beta) based AD mouse model, were treated with PTH1 34 intermittently [once daily injection of hPTH(1 34) (50 mu g/Kg), 5 days/week, starting at 2 month old (MO) for 2 3 month]. Wild type mice (C57BL/6) were used as control. The bone phenotypes were examined by microCT and evaluated by measuring serum bone formation and resorption markers. The AD relevant brain pathology (e.g., A beta and glial activation) and behaviors were assessed by a combination of immunohistochemical staining analysis, western blots, and behavior tests. Additionally, systemic and brain inflammation were evaluated by serum cytokine array, real time PCR (qPCR), and RNAscope.ResultsA reduced trabecular, but not cortical, bone mass, accompanied with a decrease in bone formation and an increase in bone resorption, was detected in 5XFAD mice at age of 5/6 month old (MO). Upon PTH1 34 treatments, not only these bone deficits but also A beta associated brain pathologies, including A beta and A beta deposition levels, dystrophic neurites, glial cell activation, and brain inflammatory cytokines, were all diminished; and the cognitive function was improved. Further studies suggest that PTH1 34 acts on not only osteoblasts in the bone but also astrocytes in the brain, suppressing astrocyte senescence and expression of inflammatory cytokines in 5XFAD mice.ConclusionsThese results suggest that PTH1 34 may act as a senolytic like drug, reducing systemic and brain inflammation and improving cognitive function, and implicate PTH1 34's therapeutic potential for patients with not only osteoporosis but also AD.
C1 [Chen, Li; Xiong, Lei; Yao, Lingling; Pan, Jinxiu; Arzola, Emily; Mei, Lin; Xiong, Wen Cheng] Case Western Reserve Univ, Sch Med, Dept Neurosci, 2210 Circle Dr, Cleveland, OH 44106 USA.
   [Chen, Li; Zhu, Xiaojuan] Northeast Normal Univ, Inst Cytol & Genet, Changchun, Jilin, Peoples R China.
   [Xiong, Lei; Pan, Jinxiu; Mei, Lin; Xiong, Wen Cheng] Louis Stokes Cleveland Vet Affairs Med Ctr, Cleveland, OH 44106 USA.
C3 University System of Ohio; Case Western Reserve University; Northeast
   Normal University   China; University System of Ohio; Case Western
   Reserve University; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Louis Stokes Cleveland Veterans Affairs Medical
   Center
RP Xiong, WC (通讯作者)，Case Western Reserve Univ, Sch Med, Dept Neurosci, 2210 Circle Dr, Cleveland, OH 44106 USA.; Xiong, WC (通讯作者)，Louis Stokes Cleveland Vet Affairs Med Ctr, Cleveland, OH 44106 USA.
EM Wen Cheng.Xiong@case.edu
RI PAN, JIN XIU/O 4840 2019; yao, lingling/GZG 6776 2022; CHEN,
   LI/LDG 4369 2024
FU Case Western Reserve University, Meisel Family; InMotion at Cleveland,
   Ohio
FX This work is supported in part by start up fund from Case Western
   Reserve University, Meisel Family, and InMotion at Cleveland, Ohio.
CR Acosta C, 2017, J NEUROSCI RES, V95, P2430, DOI 10.1002/jnr.24075
   Aggarwal S, 2013, EUR J ENDOCRINOL, V168, P895, DOI 10.1530/EJE 12 0946
   Anderson MA, 2016, NATURE, V532, P195, DOI 10.1038/nature17623
   Annweiler C, 2013, J ALZHEIMERS DIS, V33, P659, DOI 10.3233/JAD 2012 121432
   Basgöz BB, 2020, TURK J PH MED REHAB, V66, P193, DOI 10.5606/tftrd.2020.3803
   Blanco Suárez E, 2017, J PHYSIOL LONDON, V595, P1903, DOI 10.1113/JP270988
   Brines ML, 1999, NEUROSCI LETT, V274, P13, DOI 10.1016/S0304 3940(99)00664 3
   Carrillo López N, 2021, CALCIFIED TISSUE INT, V108, P439, DOI 10.1007/s00223 020 00803 2
   Çermik TF, 2007, NEURORADIOLOGY, V49, P379, DOI 10.1007/s00234 006 0198 5
   Chandran M, 2022, REV ENDOCR METAB DIS, V23, P1079, DOI 10.1007/s11154 022 09750 9
   Childs BG, 2015, NAT MED, V21, P1424, DOI 10.1038/nm.4000
   Cho SW, 2013, J BIOL CHEM, V288, P6814, DOI 10.1074/jbc.M112.393363
   Cohen J, 2019, AGING CELL, V18, DOI 10.1111/acel.12937
   D'Souza DG, 2015, AIMS MED SCI, V2, P118, DOI 10.3934/medsci.2015.3.118
   Deczkowska A, 2018, CELL, V173, P1073, DOI 10.1016/j.cell.2018.05.003
   DeTure MA, 2019, MOL NEURODEGENER, V14, DOI 10.1186/s13024 019 0333 5
   Dubal DB, 2017, JAMA NEUROL, V74, P1167, DOI 10.1001/jamaneurol.2017.1470
   Forner S, 2021, SCI DATA, V8, DOI 10.1038/s41597 021 01054 y
   Frame G, 2020, CONNECT TISSUE RES, V61, P4, DOI 10.1080/03008207.2019.1624734
   Funk JL, 2001, BRAIN RES, V915, P195, DOI 10.1016/S0006 8993(01)02850 5
   Ginaldi Lia, 2005, Immun Ageing, V2, P14, DOI 10.1186/1742 4933 2 14
   Guo HH, 2021, BONE RES, V9, DOI 10.1038/s41413 021 00146 0
   Han XJ, 2020, FRONT AGING NEUROSCI, V12, DOI 10.3389/fnagi.2020.00148
   Hardy John, 2006, Current Alzheimer Research, V3, P71, DOI 10.2174/156720506775697098
   Hendy GN, 2016, SEMIN CELL DEV BIOL, V49, P37, DOI 10.1016/j.semcdb.2015.11.006
   Hernández JCC, 2019, NAT NEUROSCI, V22, P413, DOI 10.1038/s41593 018 0329 4
   Hogan BM, 2005, ENDOCRINOLOGY, V146, P547, DOI 10.1210/en.2004 0296
   Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99
   Huang JC, 2004, J BONE MINER RES, V19, P235, DOI 10.1359/JBMR.0301226
   Huang ZH, 2016, J NEUROSCI, V36, P5833, DOI 10.1523/JNEUROSCI.4487 15.2016
   Kang C, 2015, SCIENCE, V349, DOI 10.1126/science.aaa5612
   Keren Shaul H, 2017, CELL, V169, P1276, DOI 10.1016/j.cell.2017.05.018
   Kinney Jefferson W, 2018, Alzheimers Dement (N Y), V4, P575, DOI 10.1016/j.trci.2018.06.014
   Kumar K, 2018, BIOMED PHARMACOTHER, V98, P297, DOI 10.1016/j.biopha.2017.12.053
   Li SF, 2014, BONE, V61, P164, DOI 10.1016/j.bone.2014.01.010
   Li X, 2007, J BIOL CHEM, V282, P33086, DOI 10.1074/jbc.M705194200
   Lissner LJ, 2021, PHARMACOL BIOCHEM BE, V210, DOI 10.1016/j.pbb.2021.173273
   Loi F, 2016, BONE, V86, P119, DOI 10.1016/j.bone.2016.02.020
   Lourida I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127574
   Martin B, 2005, NEUROMOL MED, V7, P3, DOI 10.1385/NMM:7:1 2:003
   Milikovsky DZ, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaw8954
   Mirzayans R, 2010, J CELL PHYSIOL, V223, P57, DOI 10.1002/jcp.22002
   Musi N, 2018, AGING CELL, V17, DOI 10.1111/acel.12840
   O'Leary TP, 2018, BEHAV BRAIN RES, V337, P256, DOI 10.1016/j.bbr.2017.09.009
   O'Leary TP, 2022, GENES BRAIN BEHAV, V21, DOI 10.1111/gbb.12794
   Oakley H, 2006, J NEUROSCI, V26, P10129, DOI 10.1523/JNEUROSCI.1202 06.2006
   Pan JX, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003 021 02843 2
   Pan JX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 1123 7
   Perry VH, 2004, BRAIN BEHAV IMMUN, V18, P407, DOI 10.1016/j.bbi.2004.01.004
   Pilat D, 2022, J NEUROINFLAMM, V19, DOI 10.1186/s12974 022 02407 z
   Polyzos SA, 2015, EXPERT OPIN INV DRUG, V24, P145, DOI 10.1517/13543784.2015.973021
   Qin L, 2004, TRENDS ENDOCRIN MET, V15, P60, DOI 10.1016/j.tem.2004.01.006
   Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142
   Ren X, 2022, J NEUROINFLAMM, V19, DOI 10.1186/s12974 022 02422 0
   Schildge S, 2013, JOVE J VIS EXP, DOI 10.3791/50079
   Senatorov VV, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaw8283
   Sharoar MG, 2019, MOL PSYCHIATR, V24, P1369, DOI 10.1038/s41380 019 0396 2
   Shen XN, 2019, J NEUROL NEUROSUR PS, V90, P590, DOI 10.1136/jnnp 2018 319148
   Siddiqui JA, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115762
   Toribio RE, 2003, J MOL ENDOCRINOL, V31, P609, DOI 10.1677/jme.0.0310609
   Uda Y, 2021, AGING US, V13, P25607, DOI 10.18632/aging.203808
   van Deursen JM, 2014, NATURE, V509, P439, DOI 10.1038/nature13193
   van Gijsel Bonnello M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175369
   Xia WF, 2013, J BONE MINER RES, V28, P2122, DOI 10.1002/jbmr.1954
   Xiong L, 2017, J CELL BIOL, V216, P761, DOI 10.1083/jcb.201608002
   Xiong L, 2016, EBIOMEDICINE, V9, P45, DOI 10.1016/j.ebiom.2016.05.028
   Yamazaki Y, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091965
   Yao LL, 2020, J CLIN INVEST, V130, DOI 10.1172/JCI132372
   Young ARJ, 2009, EMBO REP, V10, P228, DOI 10.1038/embor.2009.22
   Yuan J, 2019, J ALZHEIMERS DIS, V69, P59, DOI 10.3233/JAD 181249
   Zenaro E, 2015, NAT MED, V21, P880, DOI 10.1038/nm.3913
   Zhang HS, 2020, J NEUROSCI, V40, P5347, DOI 10.1523/JNEUROSCI.0250 20.2020
   Zhang HS, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11773
   Zhang PS, 2019, NAT NEUROSCI, V22, P719, DOI 10.1038/s41593 019 0372 9
   Zhao LH, 2019, SCIENCE, V364, P148, DOI 10.1126/science.aav7942
   Zhao Y, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22168394
   Zhou R, 2014, CURR ALZHEIMER RES, V11, P706, DOI 10.2174/1567205011666140812115818
   Zhou R, 2011, J ALZHEIMERS DIS, V24, P101, DOI 10.3233/JAD 2010 101467
NR 78
TC 12
Z9 12
U1 3
U2 19
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1758 9193
J9 ALZHEIMERS RES THER
JI Alzheimers Res. Ther.
PD MAR 14
PY 2023
VL 15
IS 1
AR 53
DI 10.1186/s13195 023 01202 z
PG 20
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology
GA A1VC6
UT WOS:000953067300001
PM 36918976
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yu, LY
   Jia, D
   Feng, KM
   Sun, XL
   Xu, WM
   Ding, LY
   Xin, HL
   Qin, LP
   Han, T
AF Yu, Luyao
   Jia, Dan
   Feng, Kunmiao
   Sun, Xiaolei
   Xu, Wumu
   Ding, Luying
   Xin, Hailiang
   Qin, Luping
   Han, Ting
TI A natural compound (LCA) isolated from Litsea cubeba inhibits
   RANKL induced osteoclast differentiation by suppressing Akt and MAPK
   pathways in mouse bone marrow macrophages
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE LCA; Osteoclast differentiation; RANKL; Bone marrow macrophages; Akt;
   MAPK
ID ESSENTIAL OILS; CONSTITUENTS; ROOT
AB Ethnopharmacological relevance: Litsea cubeba (Lour.) Pers. has been traditionally used as a folk prescription for treating rheumatic diseases in China.
   Aim of the study: This study aimed to investigate the effects and underlying mechanism of LCA, a new type of dibenzyl butane lignin compound extracted from L. cubeba, on macrophage colony stimulating factor (M CSF) plus receptor activator of NF kappa B ligand (RANKL) induced osteoclast differentiation in mouse derived bone marrow macrophages (BMMs).
   Material and methods: TRAP staining, TRAP enzyme activity assay and actin ring staining were applied to identify the effects of LCA on osteoclast differentiation. Protein expression of NFATc1, c Fos and MMP 9, and phosphorylation of p65, Akt, JNK, ERK and p38 in RANKL induced osteoclasts was determined using western blotting to investigate the underlying mechanism.
   Results: LCA significantly suppressed RANKL induced osteoclast differentiation by inhibiting TRAP activity, decreasing the number of TRAP(+) multinuclear osteoclasts and reducing the formation of F actin ring without obvious cytotoxicity in BMMs. Moreover, LCA treatment strongly reduced protein expression of NFATc1, c Fos and MMP 9, and attenuated the phosphorylation of p65, Akt, JNK, ERK and p38 in RANKL stimulated BMMs.
   Conclusions: LCA ameliorated RANKL induced osteoclast differentiation via inhibition of Akt and MAPK signalings in BMMs, and may serve as a potential pro drug for bone destruction prevention.
C1 [Yu, Luyao; Jia, Dan; Feng, Kunmiao; Sun, Xiaolei; Xu, Wumu; Xin, Hailiang; Qin, Luping; Han, Ting] Second Mil Med Univ, Sch Pharm, 325 Guohe Rd, Shanghai 200433, Peoples R China.
   [Yu, Luyao] Shanghai Normal Univ, Sch Life Sci, Shanghai, Peoples R China.
   [Qin, Luping] Zhejiang Chinese Med Univ, Sch Pharm, Hangzhou, Peoples R China.
   [Ding, Luying] Second Mil Med Univ, Changhai Hosp, Dept Pharm, Shanghai, Peoples R China.
C3 Naval Medical University; Shanghai Normal University; Zhejiang Chinese
   Medical University; Naval Medical University
RP Xin, HL; Qin, LP; Han, T (通讯作者)，Second Mil Med Univ, Sch Pharm, 325 Guohe Rd, Shanghai 200433, Peoples R China.
EM Specium@163.com; speciumyiyi@163.com; hailiangxin@163.com;
   lpqin@zcmu.edu.cn
RI HAN, TINGTING/GQZ 8692 2022
OI Han, Ting/0000 0003 4365 0479
FU National Natural Science Foundation of China [81573696, 81872953]
FX This work was supported by the National Natural Science Foundation of
   China (Grant Nos., 81573696 and 81872953).
CR Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Cao HL, 2013, J BIOL CHEM, V288, P30399, DOI 10.1074/jbc.M113.469973
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   Goto H, 2011, CYTOKINE, V56, P662, DOI 10.1016/j.cyto.2011.09.005
   Ho CL, 2010, NAT PROD COMMUN, V5, P617
   Hu JP, 2008, EUR J PHARMACOL, V580, P70, DOI 10.1016/j.ejphar.2007.11.013
   Jiang ZL, 2009, J AGR FOOD CHEM, V57, P4833, DOI 10.1021/jf900274r
   Kim Jung Ha, 2016, Chonnam Med J, V52, P12, DOI 10.4068/cmj.2016.52.1.12
   Kim MH, 2008, FOOD CHEM TOXICOL, V46, P3375, DOI 10.1016/j.fct.2008.08.016
   Kwak HB, 2010, BONE, V46, P724, DOI 10.1016/j.bone.2009.10.042
   Lee K, 2016, INT J BIOL SCI, V12, P235, DOI 10.7150/ijbs.13814
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   Lin B, 2016, PHARM BIOL, V54, P1741, DOI 10.3109/13880209.2015.1126619
   Lin B, 2013, J ETHNOPHARMACOL, V147, P327, DOI 10.1016/j.jep.2013.03.011
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Peng W, 2018, MED CHEM RES, V27, P2062, DOI 10.1007/s00044 018 2215 8
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Trina B, 2010, J TROPICAL MED PLANT, V11, P179
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wang HW, 2010, CHEM BIODIVERS, V7, P229, DOI 10.1002/cbdv.200800349
   Wang YW, 2012, ADV DRUG DELIVER REV, V64, P1341, DOI 10.1016/j.addr.2011.09.002
   Weilbaecher KN, 2001, MOL CELL, V8, P749, DOI 10.1016/S1097 2765(01)00360 4
   Wright HL, 2009, CURR REV MUSCULOSKE, V2, P56, DOI 10.1007/s12178 009 9046 7
   Yamashita M, 2010, REGUL PEPTIDES, V162, P99, DOI 10.1016/j.regpep.2010.03.003
   Zavrski I, 2005, BIOCHEM BIOPH RES CO, V333, P200, DOI 10.1016/j.bbrc.2005.05.098
   Zeng GZ, 2006, BIOORG MED CHEM LETT, V16, P6178, DOI 10.1016/j.bmcl.2006.09.042
NR 28
TC 12
Z9 14
U1 2
U2 24
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD JUL 15
PY 2020
VL 257
AR 112873
DI 10.1016/j.jep.2020.112873
PG 6
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA LV0TI
UT WOS:000538156200030
PM 32298753
DA 2025 08 17
ER

PT J
AU Hua, WK
   Shiau, YH
   Lee, OK
   Lin, WJ
AF Hua, Wei Kai
   Shiau, Ya Huei
   Lee, Oscar K.
   Lin, Wey Jinq
TI Elevation of protein kinase Cα stimulates osteogenic differentiation of
   mesenchymal stem cells through the TAT mediated protein transduction
   system
SO BIOCHEMISTRY AND CELL BIOLOGY BIOCHIMIE ET BIOLOGIE CELLULAIRE
LA English
DT Article
DE protein kinase C alpha; mesenchymal stem cells; osteogenic
   differentiation; TAT mediated protein transduction
ID FIBROBLAST GROWTH FACTOR; BONE FORMATION; PARATHYROID HORMONE;
   MAMMALIAN CELLS; DELIVERY; PKC; MARROW; RATS; OSTEOBLASTS; ACTIVATION
AB Mesenchymal stem cells (MSCs) can differentiate toward various lineages, including the osteogenic lineage, and thus hold great potential for clinic purposes. By using pharmacological inhibitors, protein kinase C (PKC) signaling has been shown to either negatively or positively regulate differentiation of bone, however, due to the low transfection efficiency in MSCs, the role of individual PKC isoforms is still not fully understood. In this study, we established a TAT peptide mediated transduction system that efficiently delivered PKC alpha proteins into MSCs in a non invasive fashion. The increased PKC alpha protein levels significantly promoted osteogenic differentiation in the murine mesenchymal C3H10T1/2 cells and in primary MSCs from both human and mouse, as demonstrated by the enhanced activity of the osteoblast marker, alkaline phosphatase, and the enhanced expression of the key transcription factor runx2. Mineralization is an important functional indication for bone differentiation. Our results further showed that PKC alpha promoted expression of the important osteocalcin gene and the accumulation of calcium minerals. Taken together, this study provides direct evidence showing that PKC alpha positively regulates osteogenic differentiation and demonstrates that the TAT peptide mediated method enables functional study of specific PKC isoforms in MSCs without using viral infection. This may promote the application of PKCs in therapeutic treatment.
C1 [Hua, Wei Kai; Shiau, Ya Huei; Lin, Wey Jinq] Natl Yang Ming Univ, Inst Biopharmaceut Sci, Taipei 112, Taiwan.
   [Lee, Oscar K.] Natl Yang Ming Univ, Inst Clin Med, Taipei 112, Taiwan.
C3 National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung
   University
RP Lin, WJ (通讯作者)，Natl Yang Ming Univ, Inst Biopharmaceut Sci, 155,Sec 2,Linong St, Taipei 112, Taiwan.
EM wjlin@ym.edu.tw
RI Lee, Oscar/MEK 9750 2025
FU University System of Taiwan Grant [97DFA2200014]; Ministry of Education,
   Aim for the Top University Plan
FX We would like to thank the members of WJL's group for their helpful
   assistance. This work was supported by University System of Taiwan Grant
   97DFA2200014 (to WJL) and a grant from the Ministry of Education, Aim
   for the Top University Plan.
CR Antonawich FJ, 1999, EXP NEUROL, V156, P130, DOI 10.1006/exnr.1998.7004
   Becker Hapak M, 2001, METHODS, V24, P247, DOI 10.1006/meth.2001.1186
   Boguslawski G, 2000, J BIOL CHEM, V275, P999, DOI 10.1074/jbc.275.2.999
   Connolly JB, 2002, GENE THER, V9, P1730, DOI 10.1038/sj.gt.3301893
   Erben RG, 1997, ENDOCRINOLOGY, V138, P4629, DOI 10.1210/en.138.11.4629
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Goekjian PG, 2001, EXPERT OPIN INV DRUG, V10, P2117
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Gump JM, 2007, TRENDS MOL MED, V13, P443, DOI 10.1016/j.molmed.2007.08.002
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Jeong HM, 2012, BBA MOL CELL RES, V1823, P1225, DOI 10.1016/j.bbamcr.2012.05.018
   Kordower JH, 2000, SCIENCE, V290, P767, DOI 10.1126/science.290.5492.767
   Krosl J, 2003, NAT MED, V9, P1428, DOI 10.1038/nm951
   Kügler S, 2003, GENE THER, V10, P337, DOI 10.1038/sj.gt.3301905
   Lee KD, 2004, HEPATOLOGY, V40, P1275, DOI 10.1002/hep.20469
   Lee OKS, 2004, J CELL BIOCHEM, V93, P917, DOI 10.1002/jcb.20241
   Liu J, 2010, J TISSUE ENG REGEN M, V4, P329, DOI 10.1002/term.242
   Liu ZJ, 2009, J CELL BIOCHEM, V106, P984, DOI 10.1002/jcb.22091
   Martin I, 1997, ENDOCRINOLOGY, V138, P4456, DOI 10.1210/en.138.10.4456
   Miraoui H, 2009, J BIOL CHEM, V284, P4897, DOI 10.1074/jbc.M805432200
   Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201 1173
   NAGAI H, 1995, BONE, V16, P367, DOI 10.1016/8756 3282(94)00049 2
   Nakura A, 2011, BONE, V48, P476, DOI 10.1016/j.bone.2010.09.238
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Rosse C, 2010, NAT REV MOL CELL BIO, V11, P103, DOI 10.1038/nrm2847
   Ryoo HM, 2006, GENE, V366, P51, DOI 10.1016/j.gene.2005.10.011
   Sanders JL, 1996, J BONE MINER RES, V11, P1862
   Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962 8924(00)01771 2
   Swarthout JT, 2001, J BIOL CHEM, V276, P7586, DOI 10.1074/jbc.M007400200
   Tang CH, 2004, MOL PHARMACOL, V66, P440
   Wang SN, 2012, STEM CELL RES, V8, P346, DOI 10.1016/j.scr.2011.12.005
   Weinreb M, 1997, BONE, V20, P521, DOI 10.1016/S8756 3282(97)00033 1
   Zhu FC, 2013, STEM CELLS, V31, P1181, DOI 10.1002/stem.1353
NR 33
TC 2
Z9 3
U1 0
U2 8
PU CANADIAN SCIENCE PUBLISHING, NRC RESEARCH PRESS
PI OTTAWA
PA 1200 MONTREAL ROAD, BUILDING M 55, OTTAWA, ON K1A 0R6, CANADA
SN 0829 8211
EI 1208 6002
J9 BIOCHEM CELL BIOL
JI Biochem. Cell Biol.
PD DEC
PY 2013
VL 91
IS 6
BP 443
EP 448
DI 10.1139/bcb 2013 0035
PG 6
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 254DC
UT WOS:000327142700017
PM 24219286
DA 2025 08 17
ER

PT J
AU Shao, RY
   Wang, YB
   Li, LF
   Dong, YQ
   Zhao, JY
   Liang, WQ
AF Shao, Ruyi
   Wang, Yeben
   Li, Laifeng
   Dong, Yongqiang
   Zhao, Jiayi
   Liang, Wenqing
TI Bone tumors effective therapy through functionalized hydrogels: current
   developments and future expectations
SO DRUG DELIVERY
LA English
DT Article
DE Functionalized hydrogels; bone tumors; targeted; therapy
ID HYALURONIC ACID; DRUG RELEASE; INJECTABLE HYDROGELS; PHOTOTHERMAL
   THERAPY; CANCER STATISTICS; POLYMER NETWORKS; HYBRID HYDROGEL;
   GROWTH FACTOR; OSTEOSARCOMA; SCAFFOLDS
AB Primary bone tumors especially, sarcomas affect adolescents the most because it originates from osteoblasts cells responsible for bone growth. Chemotherapy, surgery, and radiation therapy are the most often used clinical treatments. Regrettably, surgical resection frequently fails to entirely eradicate the tumor, which is the primary cause of metastasis and postoperative recurrence, leading to a high death rate. Additionally, bone tumors frequently penetrate significant regions of bone, rendering them incapable of self repair, and impairing patients' quality of life. As a result, treating bone tumors and regenerating bone in the clinic is difficult. In recent decades, numerous sorts of alternative therapy approaches have been investigated due to a lack of approved treatments. Among the novel therapeutic approaches, hydrogel based anticancer therapy has cleared the way for the development of new targeted techniques for treating bone cancer and bone regeneration. They include strategies such as co delivery of several drug payloads, enhancing their biodistribution and transport capabilities, normalizing accumulation, and optimizing drug release profiles to decrease the limitations of current therapy. This review discusses current advances in functionalized hydrogels to develop a new technique for treating bone tumors by reducing postoperative tumor recurrence and promoting tissue repair.
C1 [Shao, Ruyi] Zhuji Peoples Hosp, Dept Orthoped, Shaoxing, Zhejiang, Peoples R China.
   [Wang, Yeben; Li, Laifeng] Jining Med Univ, Dept Traumat Orthoped, Affiliated Jinan Hosp 3, Jinan, Shandong, Peoples R China.
   [Dong, Yongqiang] Xinchang Peoples Hosp, Dept Orthopaed, Shaoxing, Zhejiang, Peoples R China.
   [Zhao, Jiayi; Liang, Wenqing] Zhejiang Chinese Med Univ, Dept Orthoped, Zhoushan Hosp Tradit Chinese Med, 355 Xingiao Rd, Zhoushan 316000, Zhejiang, Peoples R China.
C3 Jining Medical University; Zhejiang Chinese Medical University
RP Zhao, JY; Liang, WQ (通讯作者)，Zhejiang Chinese Med Univ, Dept Orthoped, Zhoushan Hosp Tradit Chinese Med, 355 Xingiao Rd, Zhoushan 316000, Zhejiang, Peoples R China.
EM zjy2038689@sina.com; liangwq@usx.edu.cn
RI Dong, Yong/G 5057 2011; Zhao, Jiayi/AAD 9716 2019
OI Liang, Wen Qing/0000 0001 9770 882X; 
FU Nature Science Foundation of Zhejiang Province [GF22H064147]; Medical
   and Health Research Project of Zhejiang Province [2020KY995, 2022KY433];
   Science and Technology Project of Shaoxing [2018C30165, 2018C30149]
FX This work was supported by the Nature Science Foundation of Zhejiang
   Province (GF22H064147), Medical and Health Research Project of Zhejiang
   Province (2020KY995, 2022KY433), Science and Technology Project of
   Shaoxing (2018C30165, 2018C30149).
CR Agrawal G, 2018, POLYMERS BASEL, V10, DOI 10.3390/polym10040418
   Ahmed EM, 2015, J ADV RES, V6, P105, DOI 10.1016/j.jare.2013.07.006
   Akhtar MF, 2016, SAUDI PHARM J, V24, P554, DOI 10.1016/j.jsps.2015.03.022
   Amini AA, 2012, BIOMED MATER, V7, DOI 10.1088/1748 6041/7/2/024105
   Badila AE, 2021, CANCERS, V13, DOI 10.3390/cancers13164229
   Bai X, 2018, BIOACT MATER, V3, P401, DOI 10.1016/j.bioactmat.2018.05.006
   Balakrishnan B, 2013, J MATER CHEM B, V1, P5564, DOI 10.1039/c3tb21056a
   Boehme KA, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010311
   Buwalda SJ, 2017, BIOMACROMOLECULES, V18, P316, DOI 10.1021/acs.biomac.6b01604
   Buwalda SJ, 2014, J CONTROL RELEASE, V190, P254, DOI 10.1016/j.jconrel.2014.03.052
   Cascone MG, 1999, J MATER SCI MATER M, V10, P431, DOI 10.1023/A:1008983215833
   Chen GY, 2016, CHEM REV, V116, P2826, DOI 10.1021/acs.chemrev.5b00148
   Chen SS, 2022, COLLOID SURFACE B, V213, DOI 10.1016/j.colsurfb.2022.112364
   Chen WJ, 2004, J BONE MINER METAB, V22, P303, DOI 10.1007/s00774 004 0487 6
   Chen YH, 2013, CHEM COMMUN, V49, P1524, DOI 10.1039/c2cc38200h
   Chen YW, 2019, J BIOMED NANOTECHNOL, V15, P1923, DOI 10.1166/jbn.2019.2821
   Chindamo G, 2020, NANOMATERIALS BASEL, V10, DOI 10.3390/nano10050875
   Chou Alexander J, 2008, Paediatr Drugs, V10, P315, DOI 10.2165/00148581 200810050 00005
   Cortini M, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00814
   Cui YX, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.563938
   Culebras M, 2021, ACS SUSTAIN CHEM ENG, V9, P2515, DOI 10.1021/acssuschemeng.0c08022
   Culver HR, 2016, BIOMACROMOLECULES, V17, P4045, DOI 10.1021/acs.biomac.6b01482
   Darge HF, 2019, INT J PHARMACEUT, V572, DOI 10.1016/j.ijpharm.2019.118799
   Davis ME, 2008, NAT REV DRUG DISCOV, V7, P771, DOI 10.1038/nrd2614
   Di Mauro PP, 2018, INT J PHARMACEUT, V553, P169, DOI 10.1016/j.ijpharm.2018.10.022
   Diehl KL, 2016, NAT CHEM, V8, P968, DOI 10.1038/NCHEM.2601
   Ding JX, 2013, J CONTROL RELEASE, V172, P444, DOI 10.1016/j.jconrel.2013.05.029
   Elkhoury K, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201900506
   Fan DY, 2019, FRONT CHEM, V7, DOI 10.3389/fchem.2019.00675
   Fedorovich NE, 2009, BIOMATERIALS, V30, P344, DOI 10.1016/j.biomaterials.2008.09.037
   Ferguson WS, 2001, CANCER INVEST, V19, P292, DOI 10.1081/CNV 100102557
   Ferracini R, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10030122
   Fitzgerald KA, 2015, BIOMATERIALS, V66, P53, DOI 10.1016/j.biomaterials.2015.07.019
   Franchi A, 2012, CLIN CASES MINER BON, V9, P92
   Fu SZ, 2012, BIOMATERIALS, V33, P4801, DOI 10.1016/j.biomaterials.2012.03.040
   Fu SY, 2019, ACS APPL MATER INTER, V11, P1841, DOI 10.1021/acsami.8b18664
   Fujiwara T, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/2603092
   Gambera S, 2021, CANCERS, V13, DOI 10.3390/cancers13092003
   Gumustas SA, 2016, CURR PHARM BIOTECHNO, V17, P866, DOI 10.2174/1389201017666160519113104
   Gurski LA, 2009, BIOMATERIALS, V30, P6076, DOI 10.1016/j.biomaterials.2009.07.054
   Hakim DN, 2015, J BONE ONCOL, V4, P37, DOI 10.1016/j.jbo.2015.02.001
   Han Y, 2013, ACTA BIOMATER, V9, P9107, DOI 10.1016/j.actbio.2013.06.022
   He QY, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201705069
   Heris HK, 2016, ADV HEALTHC MATER, V5, P255, DOI 10.1002/adhm.201500370
   Hodgson SM, 2017, BIOMACROMOLECULES, V18, P4054, DOI 10.1021/acs.biomac.7b01115
   Hosoya K, 2008, VET RADIOL ULTRASOUN, V49, P189, DOI 10.1111/j.1740 8261.2008.00349.x
   Hou QP, 2004, J MATER CHEM, V14, P1915, DOI 10.1039/b401791a
   Huang MH, 2008, INT J PHARMACEUT, V346, P38, DOI 10.1016/j.ijpharm.2007.06.021
   Huang QT, 2017, CHEM SOC REV, V46, P6255, DOI 10.1039/c6cs00052e
   Iizawa T, 2007, J APPL POLYM SCI, V104, P842, DOI 10.1002/app.25605
   Jaffe N, 2009, CANCER TREAT RES, V152, P239, DOI 10.1007/978 1 4419 0284 9_12
   Jemal A, 2005, CA CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10
   Jeznach O, 2018, J BIOMED MATER RES A, V106, P2762, DOI 10.1002/jbm.a.36449
   Kim IL, 2011, BIOMATERIALS, V32, P8771, DOI 10.1016/j.biomaterials.2011.08.073
   Kolambkar YM, 2011, BIOMATERIALS, V32, P65, DOI 10.1016/j.biomaterials.2010.08.074
   Krishna R, 2000, EUR J PHARM SCI, V11, P265, DOI 10.1016/S0928 0987(00)00114 7
   Li FY, 2018, ACTA BIOMATER, V77, P48, DOI 10.1016/j.actbio.2018.07.015
   Li XY, 2021, COMPOS PART B ENG, V222, DOI 10.1016/j.compositesb.2021.109084
   Li YC, 2015, J CONTROL RELEASE, V213, pE140, DOI 10.1016/j.jconrel.2015.05.237
   Liao JF, 2021, BONE RES, V9, DOI 10.1038/s41413 021 00139 z
   Liao JF, 2021, BIOACT MATER, V6, P2221, DOI 10.1016/j.bioactmat.2021.01.006
   Liao JF, 2020, WIRES NANOMED NANOBI, V12, DOI 10.1002/wnan.1581
   Lindsey BA, 2017, RHEUMATOL THER, V4, P25, DOI 10.1007/s40744 016 0050 2
   Links M, 1999, Expert Rev Mol Med, V1999, P1, DOI 10.1017/S1462399499001099X
   Liou GS, 2010, J MATER CHEM, V20, P531, DOI 10.1039/b916758g
   Lipatov YS, 2002, PROG POLYM SCI, V27, P1721, DOI 10.1016/S0079 6700(02)00021 7
   Liu B, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202010779
   Liu CY, 2021, ACTA BIOMATER, V131, P314, DOI 10.1016/j.actbio.2021.07.011
   Liu HT, 2019, ADV MATER, V31, DOI 10.1002/adma.201902042
   Liu WJ, 2020, CHEM ENG J, V394, DOI 10.1016/j.cej.2020.124875
   Liu YQ, 2019, NANOSCALE, V11, P13678, DOI 10.1039/c9nr02955a
   Lü SY, 2015, ACS APPL MATER INTER, V7, P13029, DOI 10.1021/acsami.5b03143
   Luetke A, 2014, CANCER TREAT REV, V40, P523, DOI 10.1016/j.ctrv.2013.11.006
   Luo SY, 2019, MACROMOL BIOSCI, V19, DOI 10.1002/mabi.201900047
   Ma HC, 2015, ACS APPL MATER INTER, V7, P27040, DOI 10.1021/acsami.5b09112
   Ma HS, 2016, ADV FUNCT MATER, V26, P1197, DOI 10.1002/adfm.201504142
   Ma PQ, 2021, MACROMOL BIOSCI, V21, DOI 10.1002/mabi.202100191
   Macedo F, 2017, ONCOL REV, V11, P43, DOI 10.4081/oncol.2017.321
   Menéndez ST, 2021, J CLIN MED, V10, DOI 10.3390/jcm10122621
   MEYERS PA, 1992, J CLIN ONCOL, V10, P5, DOI 10.1200/JCO.1992.10.1.5
   Miller KD, 2019, CA CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565
   Min Q, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11050214
   Misaghi A, 2018, SICOT J, V4, DOI 10.1051/sicotj/2017028
   Miwa S, 2021, CANCERS, V13, DOI 10.3390/cancers13081832
   Mousa Shaker A, 2011, Cancers (Basel), V3, P2888, DOI 10.3390/cancers3032888
   Murphy SV, 2014, NAT BIOTECHNOL, V32, P773, DOI 10.1038/nbt.2958
   Nagahama K, 2013, REACT FUNCT POLYM, V73, P979, DOI 10.1016/j.reactfunctpolym.2012.11.003
   Nair DP, 2014, CHEM MATER, V26, P724, DOI 10.1021/cm402180t
   NALBANDIAN RM, 1972, J BIOMED MATER RES, V6, P583, DOI 10.1002/jbm.820060610
   Park K, 2007, J CONTROL RELEASE, V120, P1, DOI 10.1016/j.jconrel.2007.05.003
   Praetorius Natalie P, 2007, Recent Pat Drug Deliv Formul, V1, P37, DOI 10.2174/187221107779814104
   Przekora A, 2019, MAT SCI ENG C MATER, V97, P1036, DOI 10.1016/j.msec.2019.01.061
   Qian J, 2013, J MATER CHEM B, V1, P3464, DOI 10.1039/c3tb20527d
   Qing GY, 2013, MINI REV MED CHEM, V13, P1369
   Qureshi MA, 2019, J SCI ADV MATER DEV, V4, P201, DOI 10.1016/j.jsamd.2019.04.004
   Rajani Rajiv, 2012, Surg Pathol Clin, V5, P301, DOI 10.1016/j.path.2011.07.015
   Ren KX, 2015, BIOMATERIALS, V51, P238, DOI 10.1016/j.biomaterials.2015.02.026
   Saber Samandari S, 2019, INT J BIOL MACROMOL, V138, P810, DOI 10.1016/j.ijbiomac.2019.07.145
   Sasaki N, 2013, J EQUINE VET SCI, V33, P210, DOI 10.1016/j.jevs.2012.06.012
   Sasaki Y, 2010, CHEM REC, V10, P366, DOI 10.1002/tcr.201000008
   Siegel RL, 2021, CA CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654
   Sisu A. M., 2012, HISTOPATHOL REV RECE, P65, DOI [10.5772/52969, DOI 10.5772/52969]
   Sood N, 2016, DRUG DELIV, V23, P758, DOI 10.3109/10717544.2014.940091
   Soundarya SP, 2018, INT J BIOL MACROMOL, V119, P1228, DOI 10.1016/j.ijbiomac.2018.08.056
   Steinbichler TB, 2018, SEMIN CANCER BIOL, V53, P156, DOI 10.1016/j.semcancer.2018.11.006
   Stevens MM, 2008, MATER TODAY, V11, P18, DOI 10.1016/S1369 7021(08)70086 5
   Svensson E, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen 2017 016022
   Tan BW, 2021, ACS APPL MATER INTER, V13, P31542, DOI 10.1021/acsami.1c08775
   Tan BW, 2021, INT J ORAL SCI, V13, DOI 10.1038/s41368 021 00113 9
   Tao J, 2020, INT J NANOMED, V15, P5855, DOI 10.2147/IJN.S247088
   Taran SJ, 2017, INDIAN J MED PAEDIAT, V38, P33, DOI 10.4103/0971 5851.203513
   Thanindratarn P, 2019, J BONE ONCOL, V15, DOI 10.1016/j.jbo.2019.100221
   Thévenin Lemoine C, 2018, J BONE JOINT SURG AM, V100, P13, DOI 10.2106/JBJS.16.01461
   Tzanakakis GN, 2021, CANCERS, V13, DOI 10.3390/cancers13102478
   Tzeng HE, 2021, CANCERS, V13, DOI 10.3390/cancers13133347
   Ullah F, 2015, MAT SCI ENG C MATER, V57, P414, DOI 10.1016/j.msec.2015.07.053
   van Nostrum CF, 2004, MACROMOLECULES, V37, P2113, DOI 10.1021/ma035534+
   Vanaei S., Engineered Regeneration, V2, P1, DOI [10.1016/j.engreg.2020.12.001, DOI 10.1016/J.ENGREG.2020.12.001]
   Wang HX, 2018, THERANOSTICS, V8, P3949, DOI 10.7150/thno.26161
   Wang JZ, 2019, MAT SCI ENG C MATER, V97, P1021, DOI 10.1016/j.msec.2019.01.057
   Wasupalli GK, 2020, MAT SCI ENG C MATER, V107, DOI 10.1016/j.msec.2019.110343
   WICHTERLE O, 1960, NATURE, V185, P117, DOI 10.1038/185117a0
   Wu DD, 2018, CHINESE CHEM LETT, V29, P1098, DOI 10.1016/j.cclet.2018.04.030
   Wu WT, 2011, ADV FUNCT MATER, V21, P2830, DOI 10.1002/adfm.201100201
   Wu YH, 2014, ACTA BIOMATER, V10, P1965, DOI 10.1016/j.actbio.2013.12.044
   Xian CH, 2020, CHINESE CHEM LETT, V31, P19, DOI 10.1016/j.cclet.2019.03.052
   Xu XW, 2021, MATER HORIZ, V8, P1173, DOI 10.1039/d0mh01514h
   Xue YM, 2020, ACS NANO, V14, P442, DOI 10.1021/acsnano.9b06145
   Yang Z, 2021, CHEM ENG J, V419, DOI 10.1016/j.cej.2021.129520
   Yang ZM, 2020, INT J ONCOL, V57, P433, DOI 10.3892/ijo.2020.5067
   Yin F, 2020, NANOMED NANOTECHNOL, V23, DOI 10.1016/j.nano.2019.102085
   Yu L, 2008, CHEM SOC REV, V37, P1473, DOI 10.1039/b713009k
   Yu QW, 2021, POLYMERS BASEL, V13, DOI 10.3390/polym13142302
   Yue S, 2020, NANOMATERIALS BASEL, V10, DOI 10.3390/nano10081511
   Zajac AE, 2021, CANCERS, V13, DOI 10.3390/cancers13102390
   Zhai ML, 2000, RADIAT PHYS CHEM, V58, P397, DOI 10.1016/S0969 806X(99)00491 0
   Zhang JT, 2009, ACTA BIOMATER, V5, P488, DOI 10.1016/j.actbio.2008.06.012
   Zhang PF, 2018, ADV MATER, V30, DOI 10.1002/adma.201705350
   Zhang W, 2020, ACTA PHARMACOL SIN B, V10, P2037, DOI 10.1016/j.apsb.2020.07.013
   Zhang WX, 2019, MAT SCI ENG C MATER, V102, P458, DOI 10.1016/j.msec.2019.04.025
   Zhang Y, 2018, NANO RES, V11, P4806, DOI 10.1007/s12274 018 2066 0
   Zhang Y, 2017, J CONTROL RELEASE, V261, P352, DOI 10.1016/j.jconrel.2017.01.047
   Zhang YS, 2017, SCIENCE, V356, DOI 10.1126/science.aaf3627
   Zhao H, 2020, BIOMATERIALS, V230, DOI 10.1016/j.biomaterials.2019.119598
   Zheng P, 2021, ADV MATER, V33, DOI 10.1002/adma.202007426
   Zhou YG, 2021, INT J ADV MANUF TECH, V112, P1211, DOI 10.1007/s00170 020 06538 6
   Zhu J, 2018, ACS APPL MATER INTER, V10, P13304, DOI 10.1021/acsami.7b18927
   Zhu SS, 2021, COMPOS SCI TECHNOL, V208, DOI 10.1016/j.compscitech.2021.108763
   zur Nieden NI, 2015, ACS APPL MATER INTER, V7, P10599, DOI 10.1021/acsami.5b02368
NR 149
TC 31
Z9 32
U1 8
U2 135
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1071 7544
EI 1521 0464
J9 DRUG DELIV
JI Drug Deliv.
PD DEC 31
PY 2022
VL 29
IS 1
BP 1631
EP 1647
DI 10.1080/10717544.2022.2075983
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 1M5SV
UT WOS:000800029800001
PM 35612368
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Annussek, T
   Kleinheinz, J
   Thomas, S
   Joos, U
   Wermker, K
AF Annussek, Tobias
   Kleinheinz, Johannes
   Thomas, Szuwart
   Joos, Ulrich
   Wermker, Kai
TI Short time administration of antirheumatic drugs   Methotrexate as a
   strong inhibitor of osteoblast's proliferation in vitro
SO HEAD & FACE MEDICINE
LA English
DT Article
DE Antirheumatic drugs; Methotrexate; Osteoblast; In vitro; Bone metabolism
ID RHEUMATOID ARTHRITIS; AMERICAN COLLEGE; DISEASE; RECOMMENDATIONS;
   MECHANISMS; CRITERIA; THERAPY; UPDATE; CELLS; BONE
AB Introduction: Due to increasing use of disease modifying antirheumatic drugs (DMARDs) as first line therapy in rheumatic diseases, dental and maxillofacial practitioner should be aware of drug related adverse events. Especially effects on bone metabolism and its cells are discussed controversially. Therefore we investigate the in vitro effect of short time administration of low dose methotrexate (MTX) on osteoblasts as essential part of bone remodelling cells.
   Methods: Primary bovine osteoblasts (OBs) were incubated with various concentrations of MTX, related to tissue concentrations, over a period of fourteen days by using a previously established standard protocol. The effect on cell proliferation as well as mitochondrial activity was assessed by using 3 (4, 5 dimethylthiazol 2 yl) 2, 5 diphenyltetrazolium bromide (MTT) assay, imaging and counting of living cells. Additionally, immunostaining of extracellular matrix proteins was used to survey osteogenic differentiation.
   Results: All methods indicate a strong inhibition of osteoblast's proliferation by short time administration of low dose MTX within therapeutically relevant concentrations of 1 to 1000nM, without affecting cell differentiation of middle stage differentiated OBs in general. More over a significant decrease of cell numbers and mitochondrial activity was found at these MTX concentrations. The most sensitive method seems to be the MTT assay. MTX concentration of 0,01nM and concentrations below had no inhibitory effects anymore.
   Conclusion: Even low dose methotrexate acts as a potent inhibitor of osteoblast's proliferation and mitochondrial metabolism in vitro, without affecting main differentiation of pre differentiated osteoblasts. These results suggest possible negative effects of DMARDs concerning bone healing and for example osseointegration of dental implants. Especially the specifics of the jaw bone with its high vascularisation and physiological high tissue metabolism, suggests possible negative effects of DMARD therapy concerning oral and cranio maxillofacial bone surgery as could be seen in a similar way in bisphosphonate related osteonecrosis of the jaw.
C1 [Annussek, Tobias; Kleinheinz, Johannes; Thomas, Szuwart; Joos, Ulrich] Univ Hosp Muenster, Dept Craniomaxillofacial Surg, Munster, Germany.
   [Wermker, Kai] Univ Munster, Fachklin Hornheide, Dept Craniomaxillofacial Surg, D 48149 Munster, Germany.
C3 University of Munster; University of Munster
RP Annussek, T (通讯作者)，Univ Hosp Muenster, Dept Craniomaxillofacial Surg, Munster, Germany.
EM tobias.annussek@ukmuenster.de
OI Wermker, Kai/0000 0001 8284 217X
CR Alamanos Y, 2005, AUTOIMMUN REV, V4, P130, DOI 10.1016/j.autrev.2004.09.002
   Alamanos Y, 2006, SEMIN ARTHRITIS RHEU, V36, P182, DOI 10.1016/j.semarthrit.2006.08.006
   Aletaha D, 2010, ARTHRITIS RHEUM US, V62, P2569, DOI 10.1002/art.27584
   Benedek TG, 2010, CLIN EXP RHEUMATOL, V28, pS3
   BOLOGNA C, 1994, ARTHRITIS RHEUM, V37, P1770, DOI 10.1002/art.1780371210
   Braun J, 2009, CURR OPIN RHEUMATOL, V21, P216, DOI 10.1097/BOR.0b013e328329c79d
   Colmegna I, 2012, CLIN PHARMACOL THER, V91, P607, DOI 10.1038/clpt.2011.325
   Detert J, 2010, Z RHEUMATOL, V69, P109, DOI 10.1007/s00393 009 0560 1
   Gaujoux Viala C, 2010, ANN RHEUM DIS, V69, P1004, DOI 10.1136/ard.2009.127225
   Heldmann F, 2010, CLIN EXP RHEUMATOL, V28, pS110
   Hider SL, 2007, RHEUMATOLOGY, V46, P1520, DOI 10.1093/rheumatology/kem147
   JONES DB, 1991, BIOMATERIALS, V12, P101, DOI 10.1016/0142 9612(91)90186 E
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   Meyer U, 2005, Eur Cell Mater, V9, P39
   Minaur NJ, 2002, RHEUMATOLOGY, V41, P735, DOI 10.1093/rheumatology/41.7.735
   O'Dell JR, 2004, NEW ENGL J MED, V350, P2591, DOI 10.1056/NEJMra040226
   Salliot C, 2009, ANN RHEUM DIS, V68, P1100, DOI 10.1136/ard.2008.093690
   SCHEVEN BAA, 1995, J BONE MINER RES, V10, P874
   Scott DL, 2010, LANCET, V376, P1094, DOI 10.1016/S0140 6736(10)60826 4
   Singh JA, 2012, ARTHRIT CARE RES, V64, P625, DOI 10.1002/acr.21641
   Tian HH, 2007, BULL HOSP JT DIS, V65, P168
   Uehara R, 2001, J RHEUMATOL, V28, P251
   Xian CJ, 2007, BONE, V41, P842, DOI 10.1016/j.bone.2007.07.021
NR 23
TC 19
Z9 19
U1 1
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1746 160X
J9 HEAD FACE MED
JI Head Face Med.
PD SEP 29
PY 2012
VL 8
AR 26
DI 10.1186/1746 160X 8 26
PG 9
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 067II
UT WOS:000313287100001
PM 23021595
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Jiang, QL
   Yang, L
   Hai, L
   Wu, Y
AF Jiang, Qinglin
   Yang, Li
   Hai, Li
   Wu, Yong
TI Synthesis of melphalan gem bisphosphonate conjugation to bone tumors and
   study of affinity to hydroxyapatite in vitro
SO LETTERS IN ORGANIC CHEMISTRY
LA English
DT Article
DE bone targeting; gem bisphosphonates; melphalan; bone tumors
AB To develop a methodology for bone specific delivery of drugs, a bone targeting gem bisphosphonate was used as a carrier of drugs. We had synthesized five compounds, which were a new class of potential bone targeting reagents for bone tumors consisting of melphalan linked to a gem bisphosphonate moiety through an amide linkage. The conjugates showed a high affinity to hydroxyapatite in vitro.
C1 [Jiang, Qinglin; Yang, Li; Hai, Li; Wu, Yong] Sichuan Univ, W China Sch Pharm, Key Lab Drug Targeting, Educ Minist, Chengdu 610041, Peoples R China.
C3 Sichuan University
RP Wu, Y (通讯作者)，Sichuan Univ, W China Sch Pharm, Key Lab Drug Targeting, Educ Minist, Chengdu 610041, Peoples R China.
EM smile.hl@hotmail.com
OI Jiang, Qinglin/0000 0002 4056 165X
CR DEGENHARDT CR, 1986, J ORG CHEM, V51, P3488, DOI 10.1021/jo00368a017
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   FLEISCH H, 1991, DRUGS, V42, P919, DOI 10.2165/00003495 199142060 00003
   FLEISCH H, 1966, NATURE, V212, P901, DOI 10.1038/212901a0
   [郭子维 Guo Ziwei], 2002, [四川大学学报. 自然科学版, Journal of Sichuan University.Natural Science edition], V39, P922
   Kantoci D, 1996, SYNTHETIC COMMUN, V26, P2037, DOI 10.1080/00397919608003560
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Willson TM, 1996, BIOORG MED CHEM LETT, V6, P1047, DOI 10.1016/0960 894X(96)00165 5
   Winckler W, 1996, PHOSPHORUS SULFUR, V112, P137, DOI 10.1080/10426509608046357
NR 9
TC 13
Z9 14
U1 2
U2 15
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1570 1786
EI 1875 6255
J9 LETT ORG CHEM
JI Lett. Org. Chem.
PD APR
PY 2008
VL 5
IS 3
BP 229
EP 233
DI 10.2174/157017808783955862
PG 5
WC Chemistry, Organic
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA 305QL
UT WOS:000256192800013
DA 2025 08 17
ER

PT J
AU Li, ZC
   Li, DD
   Chen, RC
   Gao, S
   Xu, ZW
   Li, NH
AF Li, Zhichao
   Li, Dandan
   Chen, Renchang
   Gao, Shang
   Xu, Zhanwang
   Li, Nianhu
TI Cell death regulation: A new way for natural products to treat
   osteoporosis
SO PHARMACOLOGICAL RESEARCH
LA English
DT Article
DE Natural products; Phytocompound; Osteoporosis; Bone metabolism;
   Programmed cell death
ID GLUCOCORTICOID INDUCED OSTEOPOROSIS; MESENCHYMAL STEM CELLS; NF KAPPA B;
   MIXED LINEAGE KINASE; APOPTOSIS IN VIVO; OXIDATIVE STRESS; BONE LOSS;
   OSTEOCYTE APOPTOSIS; TRABECULAR BONE; IRON OVERLOAD
AB Osteoporosis is a common metabolic bone disease that results from the imbalance of homeostasis within the bone. Intra bone homeostasis is dependent on a precise dynamic balance between bone resorption by osteoclasts and bone formation by mesenchymal lineage osteoblasts, which comprises a series of complex and highly standardized steps. Programmed cell death (PCD) (e.g., apoptosis, autophagy, ferroptosis, pyroptosis, and necroptosis) is a cell death process that involves a cascade of gene expression events with tight structures. These events play a certain role in regulating bone metabolism by determining the fate of bone cells. Moreover, existing research has suggested that natural products derived from a wide variety of dietary components and medicinal plants modulate the PCDs based on different mechanisms, which show great potential for the prevention and treatment of osteoporosis, thus revealing the emergence of more acceptable complementary and alternative drugs with lower costs, fewer side effects and more long term application. Accordingly, this review summarizes the common types of PCDs in the field of osteoporosis. Moreover, from the perspective of targeting PCDs, this review also discussed the roles of currently reported natural products in the treatment of osteoporosis and the involved mechanisms. Based on this, this review provides more insights into new molecular mechanisms of osteoporosis and provides a reference for developing more natural anti osteoporosis drugs in the future.
C1 [Li, Zhichao; Chen, Renchang; Gao, Shang; Xu, Zhanwang; Li, Nianhu] Shandong Univ Tradit Chinese Med, Coll Clin Med 1, Jinan 250014, Peoples R China.
   [Li, Dandan] Hebei Univ Chinese Med, Coll Integrated Tradit Chinese & Western Med, Shijiazhuang 050011, Peoples R China.
   [Xu, Zhanwang; Li, Nianhu] Shandong Univ Tradit Chinese Med, Affiliated Hosp, Dept Orthoped, Jinan 250014, Peoples R China.
   [Li, Nianhu] Shandong Univ Tradit Chinese Med, 16369 Jingshi Rd, Jinan, Peoples R China.
C3 Shandong University of Traditional Chinese Medicine; Hebei University of
   Chinese Medicine; Shandong University of Traditional Chinese Medicine;
   Shandong University of Traditional Chinese Medicine
RP Li, NH (通讯作者)，Shandong Univ Tradit Chinese Med, 16369 Jingshi Rd, Jinan, Peoples R China.
EM tigerlee073@126.com
RI Li, Nianhu/AAL 9779 2020; Li, Dandan/HPH 9109 2023; li,
   zhichao/HKP 0624 2023; Li, Zhichao/HKP 0624 2023
OI Li, Zhichao/0000 0002 5314 2112
FU National Natural Science Foundation of China [82174410]; Natural Science
   Foundation of Shandong Province [ZR2019MH044, ZR2020KH011]; Construction
   Project of Inheritance Studio of National Famous Old Chinese Medicine
   Experts [Chinese Medicine Education Letter];  [75]
FX This work was supported by the National Natural Science Foundation of
   China (82174410), the Natural Science Foundation of Shandong Province
   (ZR2019MH044 and ZR2020KH011), and the Construction Project of
   Inheritance Studio of National Famous Old Chinese Medicine Experts
   [Chinese Medicine Education Letter (2022) grant No. 75].
CR Aachoui Y, 2013, CURR OPIN MICROBIOL, V16, P319, DOI 10.1016/j.mib.2013.04.004
   Aglietti RA, 2016, P NATL ACAD SCI USA, V113, P7858, DOI 10.1073/pnas.1607769113
   Arai A, 2019, J BONE MINER RES, V34, P1753, DOI 10.1002/jbmr.3756
   Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305
   Bachhawat AK, 2018, IUBMB LIFE, V70, P585, DOI 10.1002/iub.1756
   Badila AE, 2022, ANTIOXIDANTS BASEL, V11, DOI 10.3390/antiox11020318
   Ballane G, 2017, OSTEOPOROSIS INT, V28, P1531, DOI 10.1007/s00198 017 3909 3
   Balogh E, 2018, PHARMACEUTICALS BASE, V11, DOI 10.3390/ph11040107
   Balogh E, 2016, BBA MOL BASIS DIS, V1862, P1640, DOI 10.1016/j.bbadis.2016.06.003
   Bedoui S, 2020, NAT REV MOL CELL BIO, V21, P678, DOI 10.1038/s41580 020 0270 8
   Bertrand RL, 2017, MED HYPOTHESES, V101, P69, DOI 10.1016/j.mehy.2017.02.017
   Cabahug Zuckerman P, 2016, J BONE MINER RES, V31, P1356, DOI 10.1002/jbmr.2807
   Cai H, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.908830
   Cardoso L, 2009, J BONE MINER RES, V24, P597, DOI 10.1359/JBMR.081210
   Ceccariglia S, 2020, AUTOPHAGY, V16, P28, DOI 10.1080/15548627.2019.1630223
   Chan FKM, 2012, CELL, V148, P17, DOI 10.1016/j.cell.2011.12.020
   Chekeni FB, 2010, NATURE, V467, P863, DOI 10.1038/nature09413
   Chen LL, 2020, BIOMED PHARMACOTHER, V126, DOI 10.1016/j.biopha.2020.110093
   Chen TY, 2022, ANN TRANSL MED, V10, DOI 10.21037/atm 21 6742
   Chen WZ, 2013, J BIOL CHEM, V288, P16247, DOI 10.1074/jbc.M112.435545
   Chen WS, 2021, BIOMATER SCI UK, V9, P4922, DOI 10.1039/d1bm00691f
   Chen X, 2021, NAT REV CANCER, V21, P71, DOI 10.1038/s41568 020 00312 2
   Chen XZ, 2022, FRONT CARDIOVASC MED, V9, DOI 10.3389/fcvm.2022.897815
   Chen YQ, 2018, LIFE SCI, V208, P305, DOI 10.1016/j.lfs.2018.07.048
   Chen ZG, 2016, CLIN EXP PHARMACOL P, V43, P268, DOI 10.1111/1440 1681.12513
   Chung YH, 2012, INT J BIOCHEM CELL B, V44, P989, DOI 10.1016/j.biocel.2012.03.007
   Coipeau P, 2009, CYTOTHERAPY, V11, P584, DOI 10.1080/14653240903079385
   Cong L, 2019, EUR J MED CHEM, V166, P11, DOI 10.1016/j.ejmech.2019.01.039
   Conrad M, 2019, NAT CHEM BIOL, V15, P1137, DOI 10.1038/s41589 019 0408 1
   Cookson BT, 2001, TRENDS MICROBIOL, V9, P113, DOI 10.1016/S0966 842X(00)01936 3
   Cornut M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218087
   Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883
   Cruz SA, 2018, NEURAL REGEN RES, V13, P252, DOI 10.4103/1673 5374.226394
   Dai PP, 2017, CELL PHYSIOL BIOCHEM, V41, P661, DOI 10.1159/000457945
   Dawodu D, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 29963 w
   Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711
   Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83
   Deng WY, 2022, NATURE, V602, P496, DOI 10.1038/s41586 021 04384 4
   DeSelm CJ, 2011, DEV CELL, V21, P966, DOI 10.1016/j.devcel.2011.08.016
   Dick MS, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11929
   Ding LZ, 2018, INT J MOL MED, V41, P2517, DOI 10.3892/ijmm.2018.3506
   Ding P, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00210 3
   Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042
   Doll S, 2019, NATURE, V575, P693, DOI 10.1038/s41586 019 1707 0
   Domazetovic V, 2019, FEBS OPEN BIO, V9, P1082, DOI 10.1002/2211 5463.12634
   Dong XL, 2020, AM J CHINESE MED, V48, P463, DOI 10.1142/S0192415X2050024X
   Dostert C, 2008, ADV DRUG DELIVER REV, V60, P830, DOI 10.1016/j.addr.2007.12.003
   Duan JY, 2021, FRONT CELL DEV BIOL, V09, DOI 10.3389/fcell.2021.701788
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Fan P, 2022, MOL CANCER RES, V20, P193, DOI 10.1158/1541 7786.MCR 21 0702
   Feng M, 2014, J STEROID BIOCHEM, V144, P455, DOI 10.1016/j.jsbmb.2014.09.005
   Feng SY, 2018, J MOL BIOL, V430, P3068, DOI 10.1016/j.jmb.2018.07.002
   Föger Samwald U, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23052701
   Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96
   Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418 017 0012 4
   Galluzzi L, 2017, ANNU REV PATHOL MECH, V12, P103, DOI 10.1146/annurev pathol 052016 100247
   Ge WW, 2022, MOL MED REP, V25, DOI 10.3892/mmr.2022.12656
   Gong W, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/5410377
   Grootjans S, 2017, CELL DEATH DIFFER, V24, P1184, DOI 10.1038/cdd.2017.65
   Guggenbuhl P, 2008, METABOLISM, V57, P903, DOI 10.1016/j.metabol.2008.02.004
   Guo C, 2017, CELL PHYSIOL BIOCHEM, V43, P1547, DOI 10.1159/000481978
   Guo M, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/3027954
   Guo YZ, 2020, RES VET SCI, V130, P237, DOI 10.1016/j.rvsc.2020.03.021
   Gutierrez KD, 2017, J IMMUNOL, V198, P2156, DOI 10.4049/jimmunol.1601757
   Han DD, 2019, FREE RADICAL BIO MED, V137, P1, DOI 10.1016/j.freeradbiomed.2019.04.014
   Harris PA, 2021, EXPERT OPIN THER PAT, V31, P137, DOI 10.1080/13543776.2021.1854729
   Hassannia B, 2019, CANCER CELL, V35, P830, DOI 10.1016/j.ccell.2019.04.002
   He B, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.790613
   He TF, 2019, MOL MED REP, V20, P1499, DOI 10.3892/mmr.2019.10396
   He Y, 2016, TRENDS BIOCHEM SCI, V41, P1012, DOI 10.1016/j.tibs.2016.09.002
   Hu XL, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.1032614
   Huang SJ, 2019, J BIOL CHEM, V294, P18726, DOI 10.1074/jbc.REV119.007036
   Inaba Nao, 2017, Biochem Biophys Rep, V11, P191, DOI 10.1016/j.bbrep.2017.04.018
   Ishii K, 2009, NAT MED, V15, P259, DOI 10.1038/nm.1910
   Jaco I, 2017, MOL CELL, V66, P698, DOI 10.1016/j.molcel.2017.05.003
   Jia P, 2012, J ORTHOP RES, V30, P1843, DOI 10.1002/jor.22133
   Jilka RL, 2007, J BONE MINER RES, V22, P1492, DOI 10.1359/JBMR.070518
   Jilka RL, 2014, J BONE MINER RES, V29, P103, DOI 10.1002/jbmr.2007
   Jilka RL, 2013, BONE, V54, P264, DOI 10.1016/j.bone.2012.11.038
   Jin ZX, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02228 6
   Jing L, 2018, MOL MED REP, V17, P2415, DOI 10.3892/mmr.2017.8128
   Jing XZ, 2019, J CELL PHYSIOL, V234, P10123, DOI 10.1002/jcp.27678
   Jing Z, 2019, J CELL PHYSIOL, V234, P4472, DOI 10.1002/jcp.27252
   Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004
   Kang S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8515
   Katsumata SI, 2009, J NUTR, V139, P238, DOI 10.3945/jn.108.093757
   Kayagaki N, 2015, NATURE, V526, P666, DOI 10.1038/nature15541
   Ke FFS, 2018, CELL, V173, P1217, DOI 10.1016/j.cell.2018.04.036
   Khoshlahni N, 2020, CELL STRESS CHAPERON, V25, P1059, DOI 10.1007/s12192 020 01142 9
   Kim CJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010125
   KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460 2075.1995.tb00245.x
   Klionsky DJ, 2013, J INNATE IMMUN, V5, P427, DOI 10.1159/000351979
   Komori T, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122045
   Korcok J, 2005, J BIOL CHEM, V280, P16909, DOI 10.1074/jbc.M410764200
   Kraya AA, 2015, AUTOPHAGY, V11, P60, DOI 10.4161/15548627.2014.984273
   Lamb CA, 2013, NAT REV MOL CELL BIO, V14, P759, DOI 10.1038/nrm3696
   Lane NE, 2006, J BONE MINER RES, V21, P466, DOI 10.1359/JBMR.051103
   Lee B, 2021, INT J MOL MED, V48, DOI 10.3892/ijmm.2021.4988
   Lemaire I, 2011, J IMMUNOL, V187, P3878, DOI 10.4049/jimmunol.1002780
   Li Bo, 2022, Phytomedicine, V102, P154198, DOI 10.1016/j.phymed.2022.154198
   Li DY, 2017, EUR REV MED PHARMACO, V21, P5548, DOI 10.26355/eurrev_201712_13991
   Li FB, 2014, BIOCHEM BIOPH RES CO, V452, P629, DOI 10.1016/j.bbrc.2014.08.117
   Li GY, 2020, DRUG DELIV, V27, P1010, DOI 10.1080/10717544.2020.1785582
   Li HX, 2018, AUTOPHAGY, V14, P1726, DOI 10.1080/15548627.2018.1483807
   Li JX, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.241
   Li QS, 2022, PHYSIOL INT, V109, P46, DOI 10.1556/2060.2022.00154
   Li XC, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9030205
   Li XC, 2018, CHEMISTRYOPEN, V7, P730, DOI 10.1002/open.201800108
   Li XC, 2018, MOLECULES, V23, DOI 10.3390/molecules23071692
   Li X, 2020, AGEING RES REV, V62, DOI 10.1016/j.arr.2020.101098
   Li Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.691013
   Liang C, 2019, ADV MATER, V31, DOI 10.1002/adma.201904197
   Liang SX, 2020, AUTOPHAGY, V16, P1453, DOI 10.1080/15548627.2019.1687214
   Liang XX, 2019, J CELL BIOCHEM, V120, P13121, DOI 10.1002/jcb.28585
   Lin H, 2015, BIOCHEM BIOPH RES CO, V460, P422, DOI 10.1016/j.bbrc.2015.03.049
   Lin H, 2014, DRUG DES DEV THER, V8, P973, DOI 10.2147/DDDT.S65410
   Lin NY, 2016, ANN RHEUM DIS, V75, P1203, DOI 10.1136/annrheumdis 2015 207240
   Lin YF, 2022, FASEB J, V36, DOI 10.1096/fj.202101610R
   Liu CH, 2022, FOOD RES INT, V151, DOI 10.1016/j.foodres.2022.111273
   Liu F, 2013, J BONE MINER RES, V28, P2414, DOI 10.1002/jbmr.1971
   Liu JS, 2020, FOOD RES INT, V138, DOI 10.1016/j.foodres.2020.109811
   Liu S, 2016, BIOCHEM PHARMACOL, V106, P82, DOI 10.1016/j.bcp.2016.03.002
   Liu SS, 2020, J MOL HISTOL, V51, P221, DOI 10.1007/s10735 020 09874 9
   Liu SY, 2018, INT J MOL MED, V41, P2059, DOI 10.3892/ijmm.2018.3414
   Liu YY, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aax7969
   Lu HD, 2015, MOL MED REP, V11, P143, DOI 10.3892/mmr.2014.2769
   Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092 8674(00)81589 5
   Ma HP, 2014, CELL PROLIFERAT, V47, P527, DOI 10.1111/cpr.12147
   Ma HD, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/9067610
   Ma Y, 2018, AGING CELL, V17, DOI 10.1111/acel.12709
   Mahmood Z, 2010, EXP CELL RES, V316, P887, DOI 10.1016/j.yexcr.2009.12.011
   Malik A, 2017, J CELL SCI, V130, P3955, DOI 10.1242/jcs.207365
   Man SM, 2017, IMMUNOL REV, V277, P61, DOI 10.1111/imr.12534
   Manolagas SC, 2010, TRENDS ENDOCRIN MET, V21, P369, DOI 10.1016/j.tem.2010.01.010
   Mao C, 2021, NATURE, V593, P586, DOI 10.1038/s41586 021 03539 7
   Mao WH, 2018, MOL MED REP, V17, P8369, DOI 10.3892/mmr.2018.8908
   Markaki M, 2020, FEBS J, V287, P5024, DOI 10.1111/febs.15573
   Meng Zhen S, 2022, HELIYON, V8, DOI 10.1016/j.heliyon.2022.e11440
   Molitor C, 2016, P NATL ACAD SCI USA, V113, pE1806, DOI 10.1073/pnas.1523575113
   Moriishi T, 2016, J BONE MINER RES, V31, P1366, DOI 10.1002/jbmr.2808
   Mullin BH, 2020, GENOME BIOL, V21, DOI 10.1186/s13059 020 01997 2
   Murphy JM, 2013, IMMUNITY, V39, P443, DOI 10.1016/j.immuni.2013.06.018
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Napolitano A, 2011, CURR MED CHEM, V18, P1832, DOI 10.2174/092986711795496863
   Newton K, 2019, NATURE, V575, P679, DOI 10.1038/s41586 019 1752 8
   Nie ZG, 2019, MOL MED REP, V20, P401, DOI 10.3892/mmr.2019.10267
   Nollet M, 2014, AUTOPHAGY, V10, P1965, DOI 10.4161/auto.36182
   Onal M, 2013, J BIOL CHEM, V288, P17432, DOI 10.1074/jbc.M112.444190
   Pan YH, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.654494
   Park JY, 2020, INT J MED SCI, V17, P1006, DOI 10.7150/ijms.39003
   Philpott CC, 2019, FREE RADICAL BIO MED, V133, P112, DOI 10.1016/j.freeradbiomed.2018.10.411
   Pushpamalar J, 2021, GELS BASEL, V7, DOI 10.3390/gels7040153
   Qu C, 2015, FASEB J, V29, P1269, DOI 10.1096/fj.14 264804
   Ran S, 2019, INT ENDOD J, V52, P44, DOI 10.1111/iej.12965
   Roodman GD, 2009, CELL METAB, V9, P405, DOI 10.1016/j.cmet.2009.04.005
   Roper PM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9102157
   Ru JY, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 03059 8
   Russell RC, 2013, NAT CELL BIOL, V15, P741, DOI 10.1038/ncb2757
   Sànchez Riera L, 2010, BEST PRACT RES CL RH, V24, P793, DOI 10.1016/j.berh.2010.10.003
   Sartoretto S, 2019, J CELL PHYSIOL, V234, P4140, DOI 10.1002/jcp.27226
   Shalini S, 2015, CELL DEATH DIFFER, V22, P526, DOI 10.1038/cdd.2014.216
   Shi G, 2019, BRAZ J MED BIOL RES, V52, DOI [10.1590/1414 431X20187844, 10.1590/1414 431x20187844]
   Shi Y, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109566
   Shibutani ST, 2014, CELL RES, V24, P58, DOI 10.1038/cr.2013.159
   Shimbara Matsubayashi S, 2019, BIOL PHARM BULL, V42, P850, DOI 10.1248/bpb.b19 00085
   Shintoku R, 2017, CANCER SCI, V108, P2187, DOI 10.1111/cas.13380
   Singh A, 2022, CELL REP MED, V3, DOI 10.1016/j.xcrm.2022.100633
   Song CJ, 2014, CYTOTHERAPY, V16, P1361, DOI 10.1016/j.jcyt.2014.04.006
   Song SS, 2022, PHARMACOL THERAPEUT, V237, DOI 10.1016/j.pharmthera.2022.108168
   Soula M, 2020, NAT CHEM BIOL, V16, P1351, DOI 10.1038/s41589 020 0613 y
   Soysa NS, 2019, BONE REP, V11, DOI 10.1016/j.bonr.2019.100225
   Stockwell BR, 2017, CELL, V171, P273, DOI 10.1016/j.cell.2017.09.021
   Stroikin Y, 2005, BIOGERONTOLOGY, V6, P39, DOI 10.1007/s10522 004 7382 y
   Sudhakaran M, 2019, ANTIOXIDANTS BASEL, V8, DOI 10.3390/antiox8040103
   Sugiyama T, 2015, OSTEOPOROSIS INT, V26, P443, DOI 10.1007/s00198 014 2923 y
   Sun LJ, 2014, FOOD FUNCT, V5, P471, DOI 10.1039/c3fo60522a
   Sun LM, 2012, CELL, V148, P213, DOI 10.1016/j.cell.2011.11.031
   Sun Q, 2022, PHARMACOL RES, V184, DOI 10.1016/j.phrs.2022.106419
   Sun X, 2020, AMB EXPRESS, V10, DOI 10.1186/s13568 020 01098 0
   Sun XL, 2022, J BONE MINER METAB, V40, P375, DOI 10.1007/s00774 021 01295 2
   Sundaram A, 2018, MOL BIOL CELL, V29, P1376, DOI 10.1091/mbc.E17 10 0594
   Tang DL, 2019, CELL RES, V29, P347, DOI 10.1038/s41422 019 0164 5
   Tang DZ, 2010, J BONE MINER RES, V25, P1234, DOI 10.1002/jbmr.21
   Tao HQ, 2021, PHARMACOL RES, V174, DOI 10.1016/j.phrs.2021.105967
   Tower J, 2015, AGEING RES REV, V23, P90, DOI 10.1016/j.arr.2015.04.002
   Trojani MC, 2022, JOINT BONE SPINE, V89, DOI 10.1016/j.jbspin.2021.105301
   Tsay J, 2010, BLOOD, V116, P2582, DOI 10.1182/blood 2009 12 260083
   Vanden Berghe T, 2016, CELL MOL LIFE SCI, V73, P2137, DOI 10.1007/s00018 016 2189 y
   Wang C, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.58
   Wang LF, 2019, J CELL PHYSIOL, V234, P3207, DOI 10.1002/jcp.27335
   Wang NN, 2021, FREE RADICAL BIO MED, V171, P112, DOI 10.1016/j.freeradbiomed.2021.05.014
   Wang SS, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.874849
   Wang TT, 2020, APOPTOSIS, V25, P157, DOI 10.1007/s10495 020 01599 0
   Wang XY, 2020, EUR J PHARMACOL, V880, DOI 10.1016/j.ejphar.2020.173212
   Wang XD, 2022, BIOL TRACE ELEM RES, V200, P298, DOI 10.1007/s12011 021 02627 z
   Wang XM, 2020, MOL MED REP, V22, P3299, DOI 10.3892/mmr.2020.11433
   Wang YQ, 2021, COMPUT STRUCT BIOTEC, V19, P4641, DOI 10.1016/j.csbj.2021.07.038
   Wang Y, 2017, BIOMED PHARMACOTHER, V96, P993, DOI 10.1016/j.biopha.2017.11.136
   Wang YP, 2017, NATURE, V547, P99, DOI 10.1038/nature22393
   Wang ZG, 2012, CELL, V148, P228, DOI 10.1016/j.cell.2011.11.030
   Weinstein RS, 2000, AM J MED, V108, P153, DOI 10.1016/S0002 9343(99)00420 9
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Weng YM, 2018, EUR REV MED PHARMACO, V22, P1224, DOI 10.26355/eurrev_201803_14462
   Wilson MI, 2014, BIOCHEM SOC T, V42, P1327, DOI 10.1042/BST20140177
   Wu XJ, 2003, ENDOCRINOLOGY, V144, P5545, DOI 10.1210/en.2003 0296
   Xia TS, 2022, J PHARM PHARMACOL, V74, P1017, DOI 10.1093/jpp/rgac007
   Xiao YS, 2022, J ETHNOPHARMACOL, V291, DOI 10.1016/j.jep.2022.115154
   Xu DH, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.938303
   Xu HY, 2022, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.782736
   Xu LJ, 2018, CALCIFIED TISSUE INT, V103, P400, DOI 10.1007/s00223 018 0428 y
   Xue WY, 2022, FRONT MOL NEUROSCI, V15, DOI 10.3389/fnmol.2022.872471
   Yang F, 2016, CELL PHYSIOL BIOCHEM, V39, P1369, DOI 10.1159/000447841
   Yang JC, 2021, CELLS BASEL, V10, DOI 10.3390/cells10123519
   Yang JC, 2020, CALCIFIED TISSUE INT, V107, P499, DOI 10.1007/s00223 020 00735 x
   Yang L, 2020, BIOCHEM BIOPH RES CO, V522, P471, DOI 10.1016/j.bbrc.2019.11.080
   Yang LY, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/6623464
   Yang R, 2016, STEM CELLS DEV, V25, P788, DOI 10.1089/scd.2015.0387
   Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010
   Yang Y, 2020, CELL DEATH DIFFER, V27, P858, DOI 10.1038/s41418 019 0480 9
   Yang YQ, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00198 w
   Yao H, 2017, EXPERT OPIN DRUG DIS, V12, P121, DOI 10.1080/17460441.2016.1272757
   Yin W, 2020, SMALL, V16, DOI 10.1002/smll.201905977
   Yin ZY, 2016, MICROB CELL, V3, P457, DOI 10.15698/mic2016.12.546
   Yoshida G, 2022, AUTOPHAGY, V18, P2323, DOI 10.1080/15548627.2021.2017587
   Yu DD, 2015, INT J MOL MED, V36, P345, DOI 10.3892/ijmm.2015.2258
   Yuan HS, 2021, BIOCHEM PHARMACOL, V186, DOI 10.1016/j.bcp.2021.114486
   Yuan H, 2016, BIOCHEM BIOPH RES CO, V478, P1338, DOI 10.1016/j.bbrc.2016.08.124
   Yue C, 2021, J CELL MOL MED, V25, P10175, DOI 10.1111/jcmm.16954
   Zacharski LR, 2000, AM HEART J, V140, P98, DOI 10.1067/mhj.2000.106646
   Zahm AM, 2011, CELLS TISSUES ORGANS, V194, P274, DOI 10.1159/000324647
   Zhang BB, 2018, REDOX BIOL, V14, P492, DOI 10.1016/j.redox.2017.10.021
   Zhang Q, 2005, ARTHRITIS RHEUM US, V52, P2708, DOI 10.1002/art.21236
   Zhang Q, 2012, STEM CELLS DEV, V21, P1321, DOI 10.1089/scd.2011.0684
   Zhang QL, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9281481
   Zhang S, 2015, CELL STRESS CHAPERON, V20, P621, DOI 10.1007/s12192 015 0585 0
   Zhang XN, 2020, DRUG DEVELOP RES, V81, P875, DOI 10.1002/ddr.21705
   Zhang YQ, 2021, EXP BIOL MED, V246, P1650, DOI 10.1177/15353702211002136
   Zhang Y, 2020, CELL SIGNAL, V67, DOI 10.1016/j.cellsig.2019.109505
   Zhang ZF, 2014, J TOXICOL SCI, V39, P803, DOI 10.2131/jts.39.803
   Zhao BK, 2022, CELLS BASEL, V11, DOI 10.3390/cells11111724
   Zhao BK, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.615191
   Zhao L, 2015, J NUTR BIOCHEM, V26, P1174, DOI 10.1016/j.jnutbio.2015.05.009
   Zhao YG, 2021, NAT REV MOL CELL BIO, V22, P733, DOI 10.1038/s41580 021 00392 4
   Zheng HY, 2020, TOXICOL APPL PHARM, V409, DOI 10.1016/j.taap.2020.115271
   Zheng LW, 2020, CELL BIOL INT, V44, P1881, DOI 10.1002/cbin.11394
   Zheng XD, 2019, EXP ANIM TOKYO, V68, P453, DOI 10.1538/expanim.18 0178
   Zhou ZW, 2020, SCIENCE, V368, P965, DOI 10.1126/science.aaz7548
   Zhu XB, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.03.40
   Zhu YS, 2010, PROTEIN CELL, V1, P468, DOI 10.1007/s13238 010 0048 4
   Zhuo Y, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.901545
NR 250
TC 102
Z9 106
U1 21
U2 133
PU ACADEMIC PRESS LTD  ELSEVIER SCIENCE LTD
PI LONDON
PA 24 28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043 6618
EI 1096 1186
J9 PHARMACOL RES
JI Pharmacol. Res.
PD JAN
PY 2023
VL 187
AR 106635
DI 10.1016/j.phrs.2022.106635
EA DEC 2022
PG 27
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 8A0LD
UT WOS:000915939200001
PM 36581167
OA hybrid
DA 2025 08 17
ER

PT J
AU Ma, YM
   Ren, YX
   Han, EQ
   Li, HW
   Chen, D
   Jacobs, JJ
   Gitelis, S
   O'Keefe, RJ
   Konttinen, YT
   Yin, GY
   Li, TF
AF Ma, Yimin
   Ren, Yongxin
   Han, Ethan Q.
   Li, Huiwu
   Chen, Di
   Jacobs, Joshua J.
   Gitelis, Steven
   O'Keefe, Regis J.
   Konttinen, Yrjo T.
   Yin, Guoyong
   Li, Tian Fang
TI Inhibition of the Wnt β catenin and Notch signaling pathways sensitizes
   osteosarcoma cells to chemotherapy
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Osteosarcoma; Catenin; Notch; Pathway; Methotrexate; Apoptosis
ID THERAPY; METASTASIS; DISEASE; MICE; CYCLOPAMINE; INVASION; FACTOR 1;
   P53; RB
AB Osteosarcoma (OS) is one of the most common malignant bone tumors in early adolescence. Multi drug chemotherapy has greatly increased the five year survival rate from 20% to 70%. However, the rate has been staggering for 30 years and the prognosis is particularly poor for patients with recurrence and metastasis. Our study aimed to investigate the role of Wnt beta catenin, Notch and Hedgehog pathway in OS development because all these pathways are involved in skeletal development, tumorigenesis and chemoresistance. Our results showed that the major components in Wnt beta catenin pathway, e.g. Wnt3a, beta catenin and Lef1, were consistently upregulated in human osteosarcoma cell line Saos2 cells compared to human fetal osteoblasts (hFOB), whereas the changes in the expression levels of Notch and Hh signaling molecules were not consistent. Knocking down beta catenin increased the Saos2 sensitivity to methotrexate (MTX) induced cell death. Consistently, the expression level of beta catenin protein correlated with the invasiveness of OS, as evidenced by more intensive beta catenin immunoreactivity in higher grade OS samples. Chemical inhibition of the Wnt beta catenin signaling enhanced MTX mediated death of Saos2 cells. A synergistic effect with MIX was observed when both inhibitors for Wnt beta catenin and Notch pathways were simultaneously used, while the addition of the Hh inhibitor did not further improve the efficacy. Our findings provide some novel insight to OS pathogenesis and lay a foundation for future application of Wnt beta catenin and Notch inhibitors together with the currently used chemotherapeutic drugs to improve the outcome of OS treatment. Published by Elsevier Inc.
C1 [Ma, Yimin; Ren, Yongxin; Yin, Guoyong] Nanjing Med Univ, Affiliated Hosp 1, Dept Orthopaed, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.
   [Han, Ethan Q.] Drexel Univ, Coll Med, Philadelphia, PA 19129 USA.
   [Li, Huiwu] Shanghai Jiao Tong Univ, Shanghai Hosp 9, Dept Orthopaed, Shanghai 200011, Peoples R China.
   [Chen, Di; Li, Tian Fang] Rush Univ, Med Ctr, Dept Biochem, Chicago, IL 60612 USA.
   [Jacobs, Joshua J.; Gitelis, Steven; Li, Tian Fang] Rush Univ, Med Ctr, Dept Orthopaed, Chicago, IL 60612 USA.
   [O'Keefe, Regis J.] Univ Rochester, Dept Orthopaed, Rochester, NY 14642 USA.
   [Konttinen, Yrjo T.] Univ Helsinki, Dept Med, FIN 00028 Helsinki, Finland.
C3 Nanjing Medical University; Drexel University; Shanghai Jiao Tong
   University; Rush University; Rush University; University of Rochester;
   University of Helsinki
RP Yin, GY (通讯作者)，Nanjing Med Univ, Affiliated Hosp 1, Dept Orthopaed, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.
EM guoyong_yin2005nanjing@yahoo.com; tianfang_li@rush.edu
RI Chen, Di/AAJ 3665 2021; Han, Ethan/MIK 3465 2025; Jacobs,
   Joshua/AGG 8284 2022
OI Jacobs, Joshua/0000 0003 3902 7334; li, huiwu/0000 0002 2084 2737
FU NIAMS NIH HHS [R01 AR055915, R01 AR054465] Funding Source: Medline
CR Adhikari AS, 2010, CANCER RES, V70, P4602, DOI 10.1158/0008 5472.CAN 09 3463
   Cai YP, 2010, J PATHOL, V220, P24, DOI 10.1002/path.2628
   Chou Alexander J, 2008, Paediatr Drugs, V10, P315, DOI 10.2165/00148581 200810050 00005
   D'Adamo DR, 2011, SEMIN ONCOL, V38, pS19, DOI 10.1053/j.seminoncol.2011.09.004
   Engin F, 2009, HUM MOL GENET, V18, P1464, DOI 10.1093/hmg/ddp057
   Federman N, 2009, CURR TREAT OPTION ON, V10, P82, DOI 10.1007/s11864 009 0087 3
   Ferrari S, 2007, CURR OPIN ONCOL, V19, P341, DOI 10.1097/CCO.0b013e328122d73f
   Geller David S, 2010, Clin Adv Hematol Oncol, V8, P705
   Grimer RJ, 2005, LANCET ONCOL, V6, P85, DOI 10.1016/S1470 2045(05)01734 1
   Hoang BH, 2004, CANCER RES, V64, P2734, DOI 10.1158/0008 5472.CAN 03 1952
   Hoang BH, 2004, INT J CANCER, V109, P106, DOI 10.1002/ijc.11677
   Iwaya K, 2003, CLIN EXP METASTAS, V20, P525, DOI 10.1023/A:1025821229013
   Janeway KA, 2010, LANCET ONCOL, V11, P670, DOI 10.1016/S1470 2045(10)70062 0
   Jeon DG, 2010, EXPERT REV ANTICANC, V10, P1313, DOI 10.1586/ERA.10.79
   Kansara M, 2009, J CLIN INVEST, V119, P837, DOI 10.1172/JCI37175
   Lin PP, 2009, CARCINOGENESIS, V30, P1789, DOI 10.1093/carcin/bgp180
   McQueen P, 2011, EXPERT REV ANTICANC, V11, P1223, DOI [10.1586/era.11.94, 10.1586/ERA.11.94]
   Messerschmitt PJ, 2009, J AM ACAD ORTHOP SUR, V17, P515, DOI 10.5435/00124635 200908000 00005
   Nagao H, 2011, J PATHOL, V224, P169, DOI 10.1002/path.2880
   Niswander LM, 2010, CURR ONCOL REP, V12, P266, DOI 10.1007/s11912 010 0106 3
   Ritter J, 2010, ANN ONCOL, V21, P320, DOI 10.1093/annonc/mdq276
   Rubin EM, 2010, MOL CANCER THER, V9, P731, DOI 10.1158/1535 7163.MCT 09 0147
   Tanaka M, 2009, BRIT J CANCER, V100, P1957, DOI 10.1038/sj.bjc.6605060
   Tao JN, 2010, ANN NY ACAD SCI, V1192, P257, DOI 10.1111/j.1749 6632.2009.05307.x
   Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808
   Walters DK, 2008, ANTICANCER RES, V28, P673
   Warzecha J, 2007, J CHEMOTHERAPY, V19, P554, DOI 10.1179/joc.2007.19.5.554
   Warzecha J, 2012, INT J MOL MED, V29, P423, DOI 10.3892/ijmm.2011.851
   Zhang P, 2010, ONCOGENE, V29, P2916, DOI 10.1038/onc.2010.62
   Zhang PY, 2008, CLIN CANCER RES, V14, P2962, DOI 10.1158/1078 0432.CCR 07 1992
NR 30
TC 105
Z9 121
U1 0
U2 19
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD FEB 8
PY 2013
VL 431
IS 2
BP 274
EP 279
DI 10.1016/j.bbrc.2012.12.118
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 095HM
UT WOS:000315325300028
PM 23291185
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Bai, JW
   Zhang, WJ
   Zhou, CW
   Zhao, GF
   Zhong, HM
   Hang, K
   Xu, JX
   Zhang, W
   Chen, ER
   Wu, JQ
   Liu, L
   Xue, DT
AF Bai, Jinwu
   Zhang, Weijun
   Zhou, Chenwei
   Zhao, Guangfeng
   Zhong, Huiming
   Hang, Kai
   Xu, Jianxiang
   Zhang, Wei
   Chen, Erman
   Wu, Jiaqi
   Liu, Ling
   Xue, Deting
TI MFG E8 promotes osteogenic differentiation of human bone marrow
   mesenchymal stem cells through GSK3β/β catenin signaling pathway
SO FASEB JOURNAL
LA English
DT Article
DE hBMSCs; MFG E8; osteogenesis; osteogenic differentiation;
   Wnt/beta catenin
ID FRACTURE HEMATOMA; STROMAL CELLS; IDENTIFICATION; OSTEOBLASTS;
   EXPRESSION; CATENIN; SCAFFOLDS; THERAPY; MASS
AB Fracture nonunion and bone defects are challenging for orthopedic surgeons. Milk fat globule epidermal growth factor 8 (MFG E8), a glycoprotein possibly secreted by macrophages in a fracture hematoma, participates in bone development. However, the role of MFG E8 in the osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) is unclear. We investigated the osteogenic effect of MFG E8 in vitro and in vivo. The CCK 8 assay was used to assess the effect of recombinant human MFG E8 (rhMFG E8) on the viability of hBMSCs. Osteogenesis was investigated using RT PCR, Western blotting, and immuno fluorescence. Alkaline phosphatase (ALP) and Alizarin red staining were used to evaluate ALP activity and mineralization, respectively. An enzyme linked immunosorbent assay was conducted to evaluate the secretory MFG E8 concentration. Knockdown and overexpression of MFG E8 in hBMSCs were established via siRNA and lentivirus vector transfection, respectively. Exogenous rhMFG E8 was used to verify the in vivo therapeutic effect in a tibia bone defect model based on radiographic analysis and histological evaluation. Endogenous and secretory MFG E8 levels increased significantly during the early osteogenic differentiation of hBMSCs. Knockdown of MFG E8 inhibited the osteogenic differentiation of hBMSCs. Overexpression of MFG E8 and rhMFG E8 protein increased the expression of osteogenesis related genes and proteins and enhanced calcium deposition. The active beta catenin to total beta catenin ratio and the p GSK3 beta protein level were increased by MFG E8. The MFG E8 induced enhanced osteogenic differentiation of hBMSCs was partially attenuated by a GSK3 beta/beta catenin signaling inhibitor. Recombinant MFG E8 accelerated bone healing in a rat tibial defect model. In conclusion, MFG E8 promotes the osteogenic differentiation of hBMSCs by regulating the GSK3 beta/beta catenin signaling pathway and so, is a potential therapeutic target.
C1 [Bai, Jinwu; Zhang, Weijun; Zhou, Chenwei; Hang, Kai; Xu, Jianxiang; Zhang, Wei; Chen, Erman; Wu, Jiaqi; Xue, Deting] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Orthopaed, 88 Jiefang Rd, Hangzhou 310009, Peoples R China.
   [Bai, Jinwu; Zhang, Weijun; Zhou, Chenwei; Hang, Kai; Xu, Jianxiang; Zhang, Wei; Chen, Erman; Wu, Jiaqi; Xue, Deting] Zhejiang Univ, Orthoped Res Inst, Hangzhou, Peoples R China.
   [Bai, Jinwu; Zhang, Weijun; Zhou, Chenwei; Hang, Kai; Xu, Jianxiang; Zhang, Wei; Chen, Erman; Wu, Jiaqi; Xue, Deting] Key Lab Motor Syst Dis Res & Precis Therapy Zhejia, Hangzhou, Zhejiang, Peoples R China.
   [Bai, Jinwu; Zhang, Weijun; Zhou, Chenwei; Hang, Kai; Xu, Jianxiang; Zhang, Wei; Chen, Erman; Wu, Jiaqi; Xue, Deting] Clin Res Ctr Motor Syst Dis Zhejiang Prov, Hangzhou, Zhejiang, Peoples R China.
   [Zhao, Guangfeng; Zhong, Huiming] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Emergency, Hangzhou, Peoples R China.
   [Liu, Ling] Zhejiang Chinese Med Univ, Hangzhou TCM Hosp, Dept Nephrol, Hangzhou, Peoples R China.
C3 Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang
   Chinese Medical University
RP Xue, DT (通讯作者)，Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Orthopaed, 88 Jiefang Rd, Hangzhou 310009, Peoples R China.
EM blueskine@zju.edu.cn
RI Bai, Jinwu/AAP 3345 2020; Weijun, Zhang/GQA 8308 2022; Zhang,
   Weijun/GQA 8308 2022
OI Bai, Jinwu/0000 0001 9485 3562; Zhang, Weijun/0000 0002 9957 0438
FU Joint Funds of the Zhejiang Provincial Natural Science Foundation of
   China [LBY21H060004]; Zhejiang Provincial Natural Science Foundation of
   China [LY18H060003]; National Natural Science Foundation of China
   [82172189, 81871759]
FX Joint Funds of the Zhejiang Provincial Natural Science Foundation of
   China, Grant/Award Number: LBY21H060004; Zhejiang Provincial Natural
   Science Foundation of China, Grant/Award Number: LY18H060003; National
   Natural Science Foundation of China, Grant/Award Number: 82172189 and
   81871759
CR Abe T, 2014, J IMMUNOL, V193, P1383, DOI 10.4049/jimmunol.1400970
   Ankrum JA, 2014, NAT BIOTECHNOL, V32, P252, DOI 10.1038/nbt.2816
   Aziz MM, 2009, J IMMUNOL, V182, P7222, DOI 10.4049/jimmunol.0803711
   Aziz M, 2012, J IMMUNOL, V189, P393, DOI 10.4049/jimmunol.1200262
   Aziz M, 2011, APOPTOSIS, V16, P1077, DOI 10.1007/s10495 011 0630 0
   Bai JW, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.607635
   Bu HF, 2007, J CLIN INVEST, V117, P3673, DOI 10.1172/JCI31841
   Busti AJ, 2005, PHARMACOTHERAPY, V25, P1566, DOI 10.1592/phco.2005.25.11.1566
   Chen EEM, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.429
   Cho TJ, 2002, J BONE MINER RES, V17, P513, DOI 10.1359/jbmr.2002.17.3.513
   Dimitriou R, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 66
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Dong CH, 2017, EUR REV MED PHARMACO, V21, P5542, DOI 10.26355/eurrev_201712_13990
   Einhorn TA, 1998, CLIN ORTHOP RELAT R, pS7
   El Rashidy AA, 2017, ACTA BIOMATER, V62, P1, DOI 10.1016/j.actbio.2017.08.030
   FROST HM, 1989, CLIN ORTHOP RELAT R, P283
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   GRUNDNES O, 1993, ACTA ORTHOP SCAND, V64, P340, DOI 10.3109/17453679308993640
   Han X, 2002, CONNECT TISSUE RES, V43, P63
   Hanayama R, 2002, NATURE, V417, P182, DOI 10.1038/417182a
   Hang K, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1286 x
   Hang K, 2018, CELL STRESS CHAPERON, V23, P1153, DOI 10.1007/s12192 018 0932 z
   Harre U, 2012, AUTOIMMUNITY, V45, P612, DOI 10.3109/08916934.2012.719950
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Hur EM, 2010, NAT REV NEUROSCI, V11, P539, DOI 10.1038/nrn2870
   Kolar P, 2010, TISSUE ENG PART B RE, V16, P427, DOI [10.1089/ten.teb.2009.0687, 10.1089/ten.TEB.2009.0687]
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Laplante P, 2017, J INVEST DERMATOL, V137, P2005, DOI 10.1016/j.jid.2017.04.030
   Li BZ, 2013, EXPERT OPIN THER TAR, V17, P1275, DOI 10.1517/14728222.2013.829455
   Lin FX, 2018, CELL PHYSIOL BIOCHEM, V47, P161, DOI 10.1159/000489763
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mbalaviele G, 2005, J CELL BIOCHEM, V94, P403, DOI 10.1002/jcb.20253
   MIZUNO K, 1990, J BONE JOINT SURG BR, V72, P822, DOI 10.1302/0301 620X.72B5.2211764
   Motegi S, 2011, ARTERIOSCL THROM VAS, V31, P2024, DOI 10.1161/ATVBAHA.111.232587
   Park JS, 2015, METHODS, V84, P3, DOI 10.1016/j.ymeth.2015.03.002
   Park SH, 2002, J ORTHOP RES, V20, P1197, DOI 10.1016/S0736 0266(02)00072 4
   Qiao Z, 2018, SHOCK, V49, P486, DOI 10.1097/SHK.0000000000001002
   Roseti L, 2017, MAT SCI ENG C MATER, V78, P1246, DOI 10.1016/j.msec.2017.05.017
   Rupp M, 2018, INT ORTHOP, V42, P247, DOI 10.1007/s00264 017 3734 5
   Silvestre JS, 2005, NAT MED, V11, P499, DOI 10.1038/nm1233
   Sinningen K, 2016, BONEKEY REP, V5, DOI 10.1038/bonekey.2016.52
   Sinningen K, 2015, BONE, V76, P107, DOI 10.1016/j.bone.2015.04.003
   Verrier S, 2016, EUR CELLS MATER, V32, P87, DOI 10.22203/eCM.v032a06
   Walters G, 2018, J TISSUE ENG REGEN M, V12, pE1662, DOI 10.1002/term.2593
   WRAY JB, 1970, SURG GYNECOL OBSTETR, V130, P847
   Wu DQ, 2010, TRENDS BIOCHEM SCI, V35, P161, DOI 10.1016/j.tibs.2009.10.002
   Yang DB, 2019, SEMIN IMMUNOPATHOL, V41, P551, DOI 10.1007/s00281 019 00754 3
   Yi YS, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/5628486
   Zhang W, 2018, FASEB J, V32, P2280, DOI 10.1096/fj.201700998RR
   Zura R, 2016, JAMA SURG, V151, DOI 10.1001/jamasurg.2016.2775
NR 50
TC 4
Z9 5
U1 2
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD JUN
PY 2023
VL 37
IS 6
DI 10.1096/fj.202201417RRR
PG 18
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA F4PR9
UT WOS:000982188700001
PM 37144883
DA 2025 08 17
ER

PT J
AU Cheon, YH
   Kim, JY
   Baek, JM
   Ahn, SJ
   So, HS
   Oh, J
AF Cheon, Yoon Hee
   Kim, Ju Young
   Baek, Jong Min
   Ahn, Sung Jun
   So, Hong Seob
   Oh, Jaemin
TI Niclosamide suppresses RANKL induced osteoclastogenesis and prevents
   LPS induced bone loss
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Niclosamide; RANKL; Osteoclast differentiation; Bone loss
ID ANTIHELMINTHIC NICLOSAMIDE; DRUG NICLOSAMIDE; GENE EXPRESSION; CRITICAL
   ROLES; DIFFERENTIATION; CELLS; ACTIVATION; NFATC1; PATHWAY; SURVIVAL
AB Niclosamide (5 chloro salicyl (2 chloro 4 nitro) anilide) is an oral anthelmintic drug used for treating intestinal infection of most tapeworms. Recently, niclosamide was shown to have considerable efficacy against some tumor cell lines, including colorectal, prostate, and breast cancers, and acute myelogenous leukemia. Specifically, the drug was identified as a potent inhibitor of signal transducer and activator of transcription 3 (STAT3), which is associated with osteoclast differentiation and function. In this study, we assessed the effect of niclosamide on osteoclastogenesis in vitro and in vivo. Our in vitro study showed that receptor activator of nuclear factor kappaB ligand (RANKL) induced osteoclast differentiation was inhibited by niclosamide, due to inhibition of serine threonine protein kinase (Akt) phosphorylation, inhibitor of nuclear factor kappaB (I kappa B), and STAT3 serine(727). Niclosamide decreased the expression of the major transcription factors c Fos and NFATc1, and thereafter abrogated the mRNA expression of osteoclast specific genes, including TRAP, OSCAR, alpha v/beta 3 integrin (integrin alpha v, integrin, beta 3), and cathepsin K (CtsK). In an in vivo model, niclosamide prevented lipopolysaccharide induced bone loss by diminishing osteoclast activity. Taken together, our results show that niclosamide is effective in suppressing osteoclastogenesis and may be considered as a new and safe therapeutic candidate for the clinical treatment of osteoclast related diseases such as osteoporosis. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Cheon, Yoon Hee; So, Hong Seob] Wonkwang Univ, Sch Med, Ctr Metab Funct Regulat, Iksan 570749, Jeonbuk, South Korea.
   [Kim, Ju Young; Oh, Jaemin] Wonkwang Univ, Sch Med, Imaging Sci Based Lung & Bone Dis Res Ctr, Iksan 570749, Jeonbuk, South Korea.
   [Baek, Jong Min; Ahn, Sung Jun; Oh, Jaemin] Wonkwang Univ, Sch Med, Dept Anat, Iksan 570749, Jeonbuk, South Korea.
   [Oh, Jaemin] Wonkwang Univ, Sch Med, Inst Skeletal Dis, Iksan 570749, Jeonbuk, South Korea.
C3 Wonkwang University; Wonkwang University; Wonkwang University; Wonkwang
   University
RP So, HS (通讯作者)，Wonkwang Univ, Sch Med, Ctr Metab Funct Regulat, Iksan 570749, Jeonbuk, South Korea.; Oh, J (通讯作者)，Wonkwang Univ, Sch Med, Dept Anat, Iksan 570749, Jeonbuk, South Korea.
EM jeanso@wku.ac.kr; jmoh@wku.ac.kr
FU National Research Foundation of Korea   Korean government (MSIP)
   [2011 0030130]
FX This work was supported by a National Research Foundation of Korea grant
   funded by the Korean government (MSIP): No. 2011 0030130.
CR Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Crotti TN, 2006, GENE, V372, P92, DOI 10.1016/j.gene.2005.12.012
   DITZEL J, 1967, ACTA MED SCAND, V182, P663
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Jin YL, 2010, CANCER RES, V70, P2516, DOI 10.1158/0008 5472.CAN 09 3950
   Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058
   Kim K, 2005, J BIOL CHEM, V280, P35209, DOI 10.1074/jbc.M505815200
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Lamothe B, 2007, BIOCHEM BIOPH RES CO, V359, P1044, DOI 10.1016/j.bbrc.2007.06.017
   Li CH, 2012, BIOCHEM BIOPH RES CO, V429, P156, DOI 10.1016/j.bbrc.2012.10.122
   Li M, 2013, J BIOL CHEM, V288, P35769, DOI 10.1074/jbc.M113.511212
   Liang LQ, 2015, INFLAMM RES, V64, P225, DOI 10.1007/s00011 015 0801 5
   Liao Z, 2015, CURR CANCER DRUG TAR, V15, P726, DOI 10.2174/1568009615666150629132157
   Liu HT, 2003, BLOOD, V102, P344, DOI 10.1182/blood 2002 11 3396
   Londoño Joshi AI, 2014, MOL CANCER THER, V13, P800, DOI 10.1158/1535 7163.MCT 13 0555
   Lu WY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029290
   Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200
   Merschiohann K, 2008, EXP PARASITOL, V118, P637, DOI 10.1016/j.exppara.2007.12.001
   Ofori Adjei D., 2008, INT J RISK SAF MED, V20, DOI [DOI 10.3233/JRS 2008 0440, 10.3233/JRS 2008 0440]
   Osada T, 2011, CANCER RES, V71, P4172, DOI 10.1158/0008 5472.CAN 10 3978
   Sack U, 2011, JNCI J NATL CANCER I, V103, P1018, DOI 10.1093/jnci/djr190
   Sugatani T, 2005, J BIOL CHEM, V280, P3583, DOI 10.1074/jbc.M410480200
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Udagawa N, 1999, BONE, V25, P517, DOI 10.1016/S8756 3282(99)00210 0
   Walsh MC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00511
   Wang AM, 2009, J CELL BIOCHEM, V106, P682, DOI 10.1002/jcb.22065
   Wei JC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049567
   Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200
   Wu CS, 2014, CELL IMMUNOL, V288, P15, DOI 10.1016/j.cellimm.2013.12.006
   Yoshida Y, 2004, J BIOL CHEM, V279, P1768, DOI 10.1074/jbc.M311498200
   You S, 2014, MOL CANCER THER, V13, P606, DOI 10.1158/1535 7163.MCT 13 0608
NR 34
TC 13
Z9 15
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD FEB 5
PY 2016
VL 470
IS 2
BP 343
EP 349
DI 10.1016/j.bbrc.2016.01.048
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA DE4EF
UT WOS:000370581300017
PM 26792726
DA 2025 08 17
ER

EF